TY - JOUR AB - The article cites a study which finds that Metipranolol HCl 0.3% (Opti-Pranolol), a new topical beta blocker for the treatment of openangle glaucoma and ocular hyper tension, may offer the additional benefit of improved patient compliance because of lower cost. Mark B. Abelson, MD, assistant clinical professor of ophthalmology, Harvard Medical School, found that metipranolol's ability to control intraocular pressure was similar to that of other beta-blockers. He recommends metipranolol as a first-line agent for elderly patients with no cardiac or respiratory problems. AN - 15817193. Language: English. Entry Date: 20120504. Revision Date: 20050623. Publication Type: Article. Journal Subset: Biomedical DB - ccm DP - EBSCOhost IS - 5 N1 - Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 2985102R. PY - 1991 SN - 0016-867X SP - 20-20 ST - New glaucoma drug may encourage compliance T2 - Geriatrics TI - New glaucoma drug may encourage compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=15817193&site=ehost-live&scope=site VL - 46 ID - 4746 ER - TY - JOUR AB - This paper is the complete protocol (Manual of Operations) used in the Central Vein Occlusion Study (CVOS). The CVOS is a randomized clinical trial and natural history study of central retinal vein occlusion supported by the National Eye Institute. The administrative structure includes a Data and Safety Monitoring Board, 9 clinical centers, a coordinating center, and a photograph reading center. The Manual of Operations describes study design, organization, policies, and procedures. Procedures described in detail include measurement of visual acuity, fundus and iris photography, fluorescein angiography, and quality control. DB - Medline KW - adult article clinical protocol clinical trial controlled clinical trial human iris ischemia laser coagulation methodology multicenter study neovascular glaucoma neovascularization (pathology) patient compliance prospective study randomized controlled trial retina artery occlusion retina macula cystoid edema vascularization visual acuity LA - English M3 - Article N1 - L24861598 1994-03-17 PY - 1993 SN - 1059-2725 SP - [32,228 words; 678 paragraphs] ST - Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group T2 - The Online journal of current clinical trials TI - Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group UR - https://www.embase.com/search/results?subaction=viewrecord&id=L24861598&from=export VL - Doc No 92 ID - 4015 ER - TY - JOUR AB - Physicians who treat patients with glaucoma say there is a serious lack of attention to screening, a deficiency that can lead to blindness for many patients with asthma, diabetes, and heart disease. Here's what your DM program can do about it. DB - Medline IS - 4 KW - article diagnostic test disease management glaucoma human patient compliance physical examination risk factor United States LA - English M3 - Article N1 - L128262484 1998-06-16 PY - 1998 SN - 1094-2521 SP - 59-61 ST - Make glaucoma screening a routine part of DM programs T2 - Healthcare demand & disease management TI - Make glaucoma screening a routine part of DM programs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L128262484&from=export VL - 4 ID - 3947 ER - TY - JOUR AB - There are over 1.5 million children blind worldwide. The prevalence of childhood cataract has been reported as 1-4 cases per 10,000 children in the developing world. Aphakic glasses and contact lenses are unsatisfactory for rehabilitation of aphakia because of various problems associated with their use. The development of improved and refined microsurgical techniques, the availability of suitable PMMA and foldable IOL designs, better methods of modern capsular surgery, and a better understanding of the growth and refractive development of eyes in children have all helped make pediatric intraocular lens implantation a most successful technique. There is presently a clear shift in favor of IOL implantation for pediatric cataract. The main advance in treatment of childhood cataract over the past decade has been with the transition from a specific form of surgery, namely varying forms of lensectomy with spectacle or contact lens correction, to a much more modern procedure based on the principles learned in adult cataract surgery. In particular, the use of modern hydrodissection and capsulorhexis techniques, better techniques for removal of lens substance, and placement of modern PC-IOL designs into the capsular bag, have brought this procedure into step with the established techniques applied in adult cataracts. As recently as the early 1990s, there was controversy as to whether or not to place implants in the eyes of children. There is no longer such a controversy; the age limit for receiving lens implants is rapidly decreasing, encroaching on the first week of life. One of the most important factors in the advancement of pediatric surgery has been the recent success in reducing the incidence of secondary cataract (chapter 7). This problem basically occurred in 100% of the cases and had been a major stumbling block in introducing successful pediatric implantation, for a half century. Primary posterior capsulotomy was almost always required. Now, with better cortical removal techniques and introduction of highly biocompatible IOL designs, such as the Alcon AcrySof design, which appears to help to retard PCO, the previously almost unavoidable problem of PCO can now be better contained. Performing primary posterior capsulotomy and anterior vitrectomy is very important in developing countries (Table 9.3). In most cases, it ensures a clear visual axis. This is very important, as follow-up PCO treatment is often limited or not possible. Early use of an IOL may be justified in selected cases in developing countries, where parental compliance and follow up may be particularly difficult to achieve and where regular spectacle or contact lens wear is difficult to maintain. However, of utmost importance, pediatric cataract surgery, as described here, especially in very young children is best performed in a referral center by ophthalmologists with advanced experience in this field. Visually significant cataracts may be successfully operated even in newborns in order to prevent amblyopia. In such cases, careful planning of the surgical procedure, selection of the IOL and use of appropriate IOL power is an obvious must. DB - Scopus DO - 10.1016/S0039-6257(00)00182-X IS - 3 SUPPL. 1 M3 - Note N1 - Cited By :9 Export Date: 19 July 2021 PY - 2000 SP - S150-S168 ST - Pediatric cataract T2 - Survey of Ophthalmology TI - Pediatric cataract UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034467445&doi=10.1016%2fS0039-6257%2800%2900182-X&partnerID=40&md5=94a645d96967b3f2afb441ed45ad7033 VL - 45 ID - 5315 ER - TY - JOUR DB - Scopus IS - 1 M3 - Conference Paper N1 - Export Date: 19 July 2021 PY - 2004 SP - 15-17 ST - Management of ocular hypertension and glaucoma T2 - Asian Journal of Ophthalmology TI - Management of ocular hypertension and glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-11244349351&partnerID=40&md5=291efda67b0df507e62be8b10d5bb40d VL - 6 ID - 5779 ER - TY - JOUR DB - Medline IS - 2 KW - eye drops article glaucoma human patient compliance polypharmacy statistics LA - English M3 - Article N1 - L43397809 2006-03-22 PY - 2006 SN - 1042-1882 SP - 6-7 ST - Keeping an eye on glaucoma treatment T2 - The Johns Hopkins medical letter health after 50 TI - Keeping an eye on glaucoma treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43397809&from=export VL - 18 ID - 3612 ER - TY - JOUR AN - 106447050. Language: English. Entry Date: 20060526. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Consumer Health DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma -- Complications Glaucoma -- Drug Therapy Hypertension -- Complications Ophthalmic Solutions -- Therapeutic Use Adrenergic Beta-Antagonists -- Therapeutic Use Glaucoma -- Prevention and Control Hypertension -- Drug Therapy Ophthalmic Solutions -- Administration and Dosage Patient Compliance N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9802902. PMID: NLM16544434. PY - 2006 SN - 1042-1882 SP - 6-7 ST - Keeping an eye on glaucoma treatment T2 - Johns Hopkins Medical Letter: Health After 50 TI - Keeping an eye on glaucoma treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106447050&site=ehost-live&scope=site VL - 18 ID - 4749 ER - TY - JOUR DB - Medline IS - 53 KW - alpha adrenergic receptor stimulating agent angiogenesis inhibitor antiinfective agent antioxidant beta adrenergic receptor blocking agent carbonate dehydratase inhibitor cholinergic receptor stimulating agent cyclosporine eye drops glucocorticoid immunosuppressive agent osmotic diuretic agent prostaglandin triamcinolone acetonide vasculotropin A zinc allergic conjunctivitis conjunctivitis drug antagonism dry eye eye disease glaucoma human patient compliance patient selection photochemotherapy macular degeneration review treatment outcome LA - English M3 - Review N1 - L45007878 2007-01-01 PY - 2007 SN - 1541-2784 SP - 1-8 ST - Drugs for some common eye disorders T2 - Treatment guidelines from the Medical Letter TI - Drugs for some common eye disorders UR - https://www.embase.com/search/results?subaction=viewrecord&id=L45007878&from=export VL - 5 ID - 3550 ER - TY - JOUR AB - OBJECTIVE: To assess the availability and affordability of medicines used to treat cardiovascular disease, diabetes, chronic respiratory disease and glaucoma and to provide palliative cancer care in six low- and middle-income countries. METHODS: A survey of the availability and price of 32 medicines was conducted in a representative sample of public and private medicine outlets in four geographically defined areas in Bangladesh, Brazil, Malawi, Nepal, Pakistan and Sri Lanka. We analysed the percentage of these medicines available, the median price versus the international reference price (expressed as the median price ratio) and affordability in terms of the number of days wages it would cost the lowest-paid government worker to purchase one month of treatment. FINDINGS: In all countries or = 40 years, CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) for 19 U.S. states for the period 2006-2008. This report summarizes the results of that analysis, which indicated that 21% of women with self-reported DR, 12% of women with self-reported glaucoma, and 8% of women with self-reported ARMD did not visit an eye-care provider in the recommended follow-up period. Women who did not have insurance coverage for eye care or who did not receive routine medical check-ups were more likely to report not having the recommended follow-up eye care. The two most commonly cited reasons for not having an eye-care visit were cost or not having insurance (range across diseases: 40%-46%) and having no reason to go for follow-up (range: 20%-29%). Compliance with obtaining eye examinations at recommended intervals among women aged > or = 40 years with eye diseases might be enhanced by improving access to health care and implementing and expanding existing educational programs to raise awareness regarding the importance of routine follow-up eye examinations. DB - Medline IS - 19 KW - adult aged article behavioral risk factor surveillance system diabetic retinopathy female glaucoma health care delivery health service human insurance middle aged patient patient compliance macular degeneration United States utilization review vision test LA - English M3 - Article N1 - L358883236 2010-06-02 PY - 2010 SN - 1545-861X SP - 588-591 ST - Eye-care utilization among women aged > or =40 years with eye diseases--19 states, 2006-2008 T2 - MMWR. Morbidity and mortality weekly report TI - Eye-care utilization among women aged > or =40 years with eye diseases--19 states, 2006-2008 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358883236&from=export VL - 59 ID - 3255 ER - TY - JOUR AN - 105100188. Language: English. Entry Date: 20101001. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost KW - Vision Aging Vision -- Physiology Presbyopia Dry Eye Syndromes Cataract Glaucoma Macular Degeneration Office Visits Diagnosis, Eye Emergencies Eyeglasses Foreign Bodies Ophthalmic Solutions Dietary Supplements Diabetes Mellitus N1 - pictorial. Supplement Title: Oct2010 Supplement. Journal Subset: Consumer Health; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8507508. PY - 2010 SN - 0741-6245 SP - 1-8 ST - Vision T2 - Mayo Clinic Health Letter TI - Vision UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105100188&site=ehost-live&scope=site ID - 4659 ER - TY - JOUR AN - 105114443. Language: English. Entry Date: 20101015. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 20 KW - Glaucoma -- Surgery Eye Surgery -- Methods Decision Making, Clinical Intraocular Pressure Patient Compliance N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 16-16 ST - Physician shares pearls, indications for laser trabeculoplasty T2 - Ocular Surgery News TI - Physician shares pearls, indications for laser trabeculoplasty UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105114443&site=ehost-live&scope=site VL - 28 ID - 4680 ER - TY - JOUR AB - The article presents questions & answers related to coding for ophthalmological diseases including the code to be used for rust ring removal through slit lamp and a burr, whether 99215 is applicable for extended office visit, and the rules for coding corneal tophography. AN - 69879674. Language: English. Entry Date: 20120104. Revision Date: 20120104. Publication Type: Article DB - ccm DP - EBSCOhost IS - 8 KW - Ophthalmology Coding Cornea -- Surgery Eye Foreign Bodies Office Visits Medicare Current Procedural Terminology Corneal Topography Visual Fields Glaucoma Hospitalization Lasers N1 - questions and answers. Journal Subset: Health Services Administration; USA. PY - 2011 SN - 1523-4843 SP - 52-55 ST - Reader Questions T2 - Ophthalmology Coding Alert TI - Reader Questions UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=69879674&site=ehost-live&scope=site VL - 14 ID - 4408 ER - TY - JOUR AN - 107991669. Language: English. Entry Date: 20130321. Revision Date: 20150712. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 8 KW - Medication Compliance Professional-Patient Relations Glaucoma -- Drug Therapy Communication Research Reminder Systems -- Evaluation N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2011 SN - 8750-3085 SP - 16-16 ST - Improved communication may increase patients' adherence to glaucoma medication T2 - Ocular Surgery News TI - Improved communication may increase patients' adherence to glaucoma medication UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107991669&site=ehost-live&scope=site VL - 29 ID - 4720 ER - TY - JOUR AN - 108239905. Language: English. Entry Date: 20110712. Revision Date: 20150712. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 7 KW - Glaucoma -- Drug Therapy Medication Compliance Physician-Patient Relations Communication N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2011 SN - 8750-3085 SP - 17-17 ST - Physician offers simple ways to improve glaucoma regimen adherence T2 - Ocular Surgery News TI - Physician offers simple ways to improve glaucoma regimen adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108239905&site=ehost-live&scope=site VL - 29 ID - 4721 ER - TY - JOUR AN - 104241555. Language: English. Entry Date: 20130305. Revision Date: 20150711. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 79/80 KW - Glaucoma -- Therapy Patient Care -- Methods Health Services Accessibility Help Seeking Behavior Patient Attitudes Health Beliefs N1 - pictorial. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 8912615. PMID: NLM23520412. PY - 2012 SN - 0953-6833 SP - 44-45 ST - Patients and glaucoma: what are the challenges? T2 - Community Eye Health Journal TI - Patients and glaucoma: what are the challenges? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104241555&site=ehost-live&scope=site VL - 25 ID - 4683 ER - TY - JOUR AB - The article discusses the challenges that need to be addressed in the ongoing development of sustained drug release devices including the limitations of extraocular delivery to small, lipophilic molecules, and adverse side effects like endopththalmitis, retinal detachment, and vitreous hemorrhage. AN - 74573224. Language: English. Entry Date: 20120509. Revision Date: 20120521. Publication Type: Article DB - ccm DP - EBSCOhost IS - 7 KW - Glaucoma -- Drug Therapy Drug Delivery Systems Problem Solving N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2012 SN - 8750-3085 SP - 16-16 ST - Obstacles remain for innovative sustained glaucoma drug delivery systems T2 - Ocular Surgery News TI - Obstacles remain for innovative sustained glaucoma drug delivery systems UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=74573224&site=ehost-live&scope=site VL - 30 ID - 4705 ER - TY - JOUR AB - The article presents arguments for and against the public health implications for optical coherence tomography (OCT) screening for glaucoma. Professor Anne L. Coleman points out the need for OCT to meet screening criteria and cites some considerations for screening with any device. Assistant professor Joshua D. Stein points out the need for improved compatibility between OCT devices and models to allow longitudinal monitoring of patients for glaucoma progression. AN - 86287304. Language: English. Entry Date: 20130401. Revision Date: 20150319. Publication Type: Article DB - ccm DP - EBSCOhost IS - 6 KW - Tomography Interferometry Glaucoma -- Diagnosis Health Screening Public Health Cost Benefit Analysis Quality of Health Care Health Services Accessibility Technology Socioeconomic Factors N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Public Health. NLM UID: 9882135. PY - 2013 SN - 8750-3085 SP - 11-11 ST - POINT/COUNTER T2 - Ocular Surgery News TI - POINT/COUNTER UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=86287304&site=ehost-live&scope=site VL - 31 ID - 4738 ER - TY - JOUR AN - 107997268. Language: English. Entry Date: 20130401. Revision Date: 20150712. Publication Type: Journal Article DB - ccm DP - EBSCOhost IS - 6 KW - Tomography Interferometry Glaucoma -- Diagnosis Health Screening Public Health Cost Benefit Analysis Quality of Health Care Health Services Accessibility Technology Socioeconomic Factors N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Perioperative Care; Public Health. NLM UID: 9882135. PY - 2013 SN - 8750-3085 SP - 11-11 ST - POINT/COUNTER T2 - Ocular Surgery News TI - POINT/COUNTER UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107997268&site=ehost-live&scope=site VL - 31 ID - 4761 ER - TY - JOUR AB - The article reports that a sustained-release version of bimatoprost is in phase 3 U.S. Food and Drug Administration trials that if proven safe and effective can be applied by anterior segment surgeons in the same way anti-VEGF solutions are injected for neovascular age-related macular degeneration. AN - 99435579. Language: English. Entry Date: 20141119. Revision Date: 20141125. Publication Type: Article DB - ccm DP - EBSCOhost IS - 21 KW - Glaucoma -- Therapy Injections Patient Compliance -- Evaluation Ophthalmology Serial Publications Administration, Topical Patient Care Intraocular Pressure Bimatoprost -- Administration and Dosage N1 - brief item; pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2014 SN - 8750-3085 SP - 18-18 ST - Injectable glaucoma medicine: a possible answer to compliance issues T2 - Ocular Surgery News TI - Injectable glaucoma medicine: a possible answer to compliance issues UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=99435579&site=ehost-live&scope=site VL - 32 ID - 4637 ER - TY - JOUR AN - 99786629. Language: English. Entry Date: 20141211. Revision Date: 20141212. Publication Type: Article DB - ccm DP - EBSCOhost IS - 11 KW - Vision Screening World Wide Web Applications -- Utilization Health Services Accessibility -- Central America Glaucoma Wireless Communications Central America N1 - brief item; pictorial. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2014 SN - 0030-4085 SP - 17-17 ST - Glaucoma Screening App May Benefit Patients Who Lack Access to Eye Care T2 - Optometric Management TI - Glaucoma Screening App May Benefit Patients Who Lack Access to Eye Care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=99786629&site=ehost-live&scope=site VL - 49 ID - 4759 ER - TY - JOUR AB - Importance: To investigate the safety, effectiveness and follow-up rates after transscleral diode laser cyclophotocoagulation as primary treatment for seeing eyes with primary open angle glaucoma in Bauchi, Nigeria. Background: There is a high prevalence of primary open angle glaucoma in Africa where adherence to medical treatment and acceptance of surgery are poor. Design: Prospective case series. Participants: New glaucoma patients where surgical intervention was recommended. Methods: A diode 810 nm laser G-probe was used under retrobulbar anaesthesia to deliver approximately 20 shots for 2000 ms, titrating the power. If both eyes were treated the first was the study eye. Repeat treatment offered if the intraocular pressure (IOP) was >21 mmHg on two consecutive visits. Main Outcome Measures: IOP < 22 mmHg, change in ≥2 lines of Snellen visual acuity (VA), and complications. Results: 201 out of 204 eyes with complete data analysed. Mean age 52 years, 17 (8.3%) eyes were re-treated. Mean pre-treatment IOP was 39 (SD 11) mmHg. 106 (53%) attended at 12 months when the mean IOP was 19 (7–45) mmHg; 77 (73%) had IOP < 22 mmHg. VAs were better in 13 (12.3%) and worse in 23 (21.7%) eyes. Postoperative complications included mild uveitis (5.5%), corneal oedema (2.5%), severe uveitis (0.5%) and transient hypotony (2.0%). No hypotony at 12 months. Conclusions and Relevance: Transscleral diode laser cyclophotocoagulation controlled IOP in almost three quarters of eyes at 12 months with short-term preservation of vision and minimal complications. Poor follow-up in this setting highlights the need for an effective, safe and acceptable treatment where regular follow-up is less critical. © 2018 The Authors Clinical & Experimental Ophthalmology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Ophthalmologists AD - Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom Directorate of Ophthalmology, Norwich and Norfolk University Hospital NHS Foundation Trust, Norwich, United Kingdom Baze University, Abuja, Nigeria AU - Abdull, M. M. AU - Broadway, D. C. AU - Evans, J. AU - Kyari, F. AU - Muazu, F. AU - Gilbert, C. DB - Scopus DO - 10.1111/ceo.13328 IS - 9 KW - Africa cyclophotocoagulation diode laser glaucoma M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2018 SP - 1041-1047 ST - Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria T2 - Clinical and Experimental Ophthalmology TI - Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058502515&doi=10.1111%2fceo.13328&partnerID=40&md5=13186387d46ce697a4bd4f4c1354be10 VL - 46 ID - 5504 ER - TY - JOUR AB - Importance To investigate the safety, effectiveness and follow-up rates after transscleral diode laser cyclophotocoagulation as primary treatment for seeing eyes with primary open angle glaucoma in Bauchi, Nigeria. Background There is a high prevalence of primary open angle glaucoma in Africa where adherence to medical treatment and acceptance of surgery are poor. Design Prospective case series. Participants New glaucoma patients where surgical intervention was recommended. Methods A diode 810 nm laser G-probe was used under retrobulbar anaesthesia to deliver approximately 20 shots for 2000 ms, titrating the power. If both eyes were treated the first was the study eye. Repeat treatment offered if the intraocular pressure (IOP) was >21 mmHg on two consecutive visits. Main Outcome Measures IOP < 22 mmHg, change in >= 2 lines of Snellen visual acuity (VA), and complications. Results 201 out of 204 eyes with complete data analysed. Mean age 52 years, 17 (8.3%) eyes were re-treated. Mean pre-treatment IOP was 39 (SD 11) mmHg. 106 (53%) attended at 12 months when the mean IOP was 19 (7-45) mmHg; 77 (73%) had IOP < 22 mmHg. VAs were better in 13 (12.3%) and worse in 23 (21.7%) eyes. Postoperative complications included mild uveitis (5.5%), corneal oedema (2.5%), severe uveitis (0.5%) and transient hypotony (2.0%). No hypotony at 12 months. Conclusions and Relevance Transscleral diode laser cyclophotocoagulation controlled IOP in almost three quarters of eyes at 12 months with short-term preservation of vision and minimal complications. Poor follow-up in this setting highlights the need for an effective, safe and acceptable treatment where regular follow-up is less critical. AN - WOS:000454302200008 AU - Abdull, M. M. AU - Broadway, D. C. AU - Evans, J. AU - Kyari, F. AU - Muazu, F. AU - Gilbert, C. DA - DEC DO - 10.1111/ceo.13328 IS - 9 PY - 2018 SN - 1442-6404 1442-9071 SP - 1041-1047 ST - Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Safety and effectiveness of primary transscleral diode laser cyclophotoablation for glaucoma in Nigeria VL - 46 ID - 5961 ER - TY - JOUR AB - METHOD: Hospital based qualitative study. Six focus group discussions were held with patients with advanced disease and who had either undergone glaucoma surgery, were receiving medical treatment, or had neither surgery nor medical treatment. Two traditional healers who treat eye conditions were interviewed. Audio files were transcribed, translated into English and recurring themes coded and categorized as the impact of vision loss, and understandings of the disease and its management. RESULTS: Visual loss impacted significantly on the lives of people with glaucoma in many ways. Many heard the term "glaucoma" for the first time during the study. Local terms to describe the symptoms included Hawan jinin ido ("hypertension of the eye"). Patients sought treatment in pharmacies, or with traditional healers who had different interpretations of glaucoma and its treatment to biomedical understandings. Cost and forgetfulness were the main reasons for low adherence to treatment while fear was a reason for not accepting surgery. Lack of money and negative staff attitudes were reasons for low follow up. CONCLUSION: Halting the progression of glaucoma is possible with treatment but the condition will remain a "silent thief of sight" in West Africa unless awareness, uptake of services and adherence to treatment improve. Understanding how glaucoma is locally conceptualised, lived with and responded to by patients is essential to aid the design of interventions to prevent glaucoma blindness in Africa. Findings have been used to adapt a motivational interviewing intervention, which is being evaluated in a clinical trial. BACKGROUND: In Nigeria, glaucoma has a high prevalence and is the second cause of blindness among adults after cataract. People with glaucoma frequently present very late with advanced disease, and acceptance of and adherence to treatment is low. The purpose of the study was to explore how patients' understand and respond to glaucoma in order develop an intervention to improve adherence to treatment. AU - Abdull, M. M. AU - Chandler, C. AU - Gilbert, C. DB - Medline DO - 10.1186/s12886-016-0220-6 KW - antihypertensive agent attitude to health female filtering operation glaucoma health behavior health care delivery human intraocular pressure male Nigeria patient patient attitude patient compliance psychology rural population visual acuity LA - English M3 - Article N1 - L616141014 2017-05-16 PY - 2016 SN - 1471-2415 SP - 44 ST - Glaucoma, "the silent thief of sight": patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria T2 - BMC ophthalmology TI - Glaucoma, "the silent thief of sight": patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616141014&from=export http://dx.doi.org/10.1186/s12886-016-0220-6 VL - 16 ID - 2745 ER - TY - JOUR AB - Background: In Nigeria, glaucoma has a high prevalence and is the second cause of blindness among adults after cataract. People with glaucoma frequently present very late with advanced disease, and acceptance of and adherence to treatment is low. The purpose of the study was to explore how patients' understand and respond to glaucoma in order develop an intervention to improve adherence to treatment.Method: Hospital based qualitative study. Six focus group discussions were held with patients with advanced disease and who had either undergone glaucoma surgery, were receiving medical treatment, or had neither surgery nor medical treatment. Two traditional healers who treat eye conditions were interviewed. Audio files were transcribed, translated into English and recurring themes coded and categorized as the impact of vision loss, and understandings of the disease and its management.Results: Visual loss impacted significantly on the lives of people with glaucoma in many ways. Many heard the term "glaucoma" for the first time during the study. Local terms to describe the symptoms included Hawan jinin ido ("hypertension of the eye"). Patients sought treatment in pharmacies, or with traditional healers who had different interpretations of glaucoma and its treatment to biomedical understandings. Cost and forgetfulness were the main reasons for low adherence to treatment while fear was a reason for not accepting surgery. Lack of money and negative staff attitudes were reasons for low follow up.Conclusion: Halting the progression of glaucoma is possible with treatment but the condition will remain a "silent thief of sight" in West Africa unless awareness, uptake of services and adherence to treatment improve. Understanding how glaucoma is locally conceptualised, lived with and responded to by patients is essential to aid the design of interventions to prevent glaucoma blindness in Africa. Findings have been used to adapt a motivational interviewing intervention, which is being evaluated in a clinical trial. AD - Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, PMB 0117, Bauchi, Bauchi State, Nigeria International Centre for Eye Health, Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK Department of Global Health and Development London School of Hygiene & Tropical Medicine, London, UK AN - 114857665. Language: English. Entry Date: 20180728. Revision Date: 20210110. Publication Type: journal article AU - Abdull, Mohammed Mahdi AU - Chandler, Clare AU - Gilbert, Clare DB - ccm DO - 10.1186/s12886-016-0220-6 DP - EBSCOhost KW - Patients -- Psychosocial Factors Glaucoma -- Psychosocial Factors Patient Attitudes Attitude to Health Health Behavior Glaucoma -- Therapy Filtering Surgery Intraocular Pressure Antihypertensive Agents -- Therapeutic Use Male Female Rural Population Health Services Accessibility Nigeria Patient Compliance Glaucoma -- Epidemiology Visual Acuity Human N1 - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: /WT_/Wellcome Trust/United Kingdom. NLM UID: 100967802. PMID: NLM27102524. PY - 2016 SN - 1471-2415 SP - 1-9 ST - Glaucoma, "the silent thief of sight": patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria T2 - BMC Ophthalmology TI - Glaucoma, "the silent thief of sight": patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=114857665&site=ehost-live&scope=site VL - 16 ID - 4301 ER - TY - JOUR AB - Background: In Nigeria, glaucoma has a high prevalence and is the second cause of blindness among adults after cataract. People with glaucoma frequently present very late with advanced disease, and acceptance of and adherence to treatment is low. The purpose of the study was to explore how patients' understand and respond to glaucoma in order develop an intervention to improve adherence to treatment. Method: Hospital based qualitative study. Six focus group discussions were held with patients with advanced disease and who had either undergone glaucoma surgery, were receiving medical treatment, or had neither surgery nor medical treatment. Two traditional healers who treat eye conditions were interviewed. Audio files were transcribed, translated into English and recurring themes coded and categorized as the impact of vision loss, and understandings of the disease and its management. Results: Visual loss impacted significantly on the lives of people with glaucoma in many ways. Many heard the term "glaucoma" for the first time during the study. Local terms to describe the symptoms included Hawan jinin ido ("hypertension of the eye"). Patients sought treatment in pharmacies, or with traditional healers who had different interpretations of glaucoma and its treatment to biomedical understandings. Cost and forgetfulness were the main reasons for low adherence to treatment while fear was a reason for not accepting surgery. Lack of money and negative staff attitudes were reasons for low follow up. Conclusion: Halting the progression of glaucoma is possible with treatment but the condition will remain a "silent thief of sight" in West Africa unless awareness, uptake of services and adherence to treatment improve. Understanding how glaucoma is locally conceptualised, lived with and responded to by patients is essential to aid the design of interventions to prevent glaucoma blindness in Africa. Findings have been used to adapt a motivational interviewing intervention, which is being evaluated in a clinical trial. © 2016 Abdull et al. AD - Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, PMB 0117, Bauchi, Bauchi State, Nigeria Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom International Centre for Eye Health, Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom AU - Abdull, M. M. AU - Chandler, C. AU - Gilbert, C. C7 - 44 DB - Scopus DO - 10.1186/s12886-016-0220-6 IS - 1 KW - Acceptance Adherence Africa Awareness Behaviour Glaucoma Traditional medicine Treatment M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2016 ST - Glaucoma, "the silent thief of sight": Patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria T2 - BMC Ophthalmology TI - Glaucoma, "the silent thief of sight": Patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84966332489&doi=10.1186%2fs12886-016-0220-6&partnerID=40&md5=a44da2585581f25912a72e07e5e182a3 VL - 16 ID - 5230 ER - TY - JOUR AB - Background: In Nigeria, glaucoma has a high prevalence and is the second cause of blindness among adults after cataract. People with glaucoma frequently present very late with advanced disease, and acceptance of and adherence to treatment is low. The purpose of the study was to explore how patients' understand and respond to glaucoma in order develop an intervention to improve adherence to treatment. Method: Hospital based qualitative study. Six focus group discussions were held with patients with advanced disease and who had either undergone glaucoma surgery, were receiving medical treatment, or had neither surgery nor medical treatment. Two traditional healers who treat eye conditions were interviewed. Audio files were transcribed, translated into English and recurring themes coded and categorized as the impact of vision loss, and understandings of the disease and its management. Results: Visual loss impacted significantly on the lives of people with glaucoma in many ways. Many heard the term "glaucoma" for the first time during the study. Local terms to describe the symptoms included Hawan jinin ido ("hypertension of the eye"). Patients sought treatment in pharmacies, or with traditional healers who had different interpretations of glaucoma and its treatment to biomedical understandings. Cost and forgetfulness were the main reasons for low adherence to treatment while fear was a reason for not accepting surgery. Lack of money and negative staff attitudes were reasons for low follow up. Conclusion: Halting the progression of glaucoma is possible with treatment but the condition will remain a "silent thief of sight" in West Africa unless awareness, uptake of services and adherence to treatment improve. Understanding how glaucoma is locally conceptualised, lived with and responded to by patients is essential to aid the design of interventions to prevent glaucoma blindness in Africa. Findings have been used to adapt a motivational interviewing intervention, which is being evaluated in a clinical trial. AN - WOS:000374440700001 AU - Abdull, M. M. AU - Chandler, C. AU - Gilbert, C. DA - APR 21 DO - 10.1186/s12886-016-0220-6 PY - 2016 SN - 1471-2415 ST - Glaucoma, "the silent thief of sight": patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria T2 - BMC OPHTHALMOLOGY TI - Glaucoma, "the silent thief of sight": patients' perspectives and health seeking behaviour in Bauchi, northern Nigeria VL - 16 ID - 6117 ER - TY - JOUR AB - Background: Glaucoma is a chronic eye disease associated with irreversible visual loss. In Africa, glaucoma patients often present late, with very advanced disease. One-off procedures, such as laser or surgery, are recommended in Africa because of lack of or poor adherence to medical treatment. However, acceptance of surgery is usually extremely low. To prevent blindness, adherence to treatment needs to improve, using acceptable, replicable and cost-effective interventions. After reviewing the literature and interviewing patients in Bauchi (Nigeria) motivational interviewing (MI) was selected as the intervention for this trial, with adaptation for glaucoma (MIG). MI is designed to strengthen personal motivation for, and commitment to a specific goal by eliciting and exploring a person's reasons for change within an atmosphere of acceptance and compassion. The aim of this study is to assess whether MIG increases the uptake of laser or surgery amongst glaucoma patients where this is the recommended treatment. The hypothesis is that MIG increases the uptake of treatment. This will be the first trial of MI in Africa.Methods: This is a hospital based, single centre, randomized controlled trial of MIG plus an information sheet on glaucoma and its treatment (the latter being " standard care" ) compared with standard care alone for glaucoma patients where the treatment recommended is surgery or laser.Those eligible for the trial are adults aged 17 years and above who live within 200 km of Bauchi with advanced glaucoma where the examining ophthalmologist recommends surgery or laser. After obtaining written informed consent, participants will be randomly allocated to MIG plus standard care, or standard care alone. Motivational interviewing will be delivered in Hausa or English by one of two MIG trained personnel. One hundred and fifty participants will be recruited to each arm. The primary outcome is the proportion of participants undergoing laser or surgery within two months of the date given to re attend for the procedure. MIG quality will be assessed using the validated MI treatment integrity scale.Discussion: Motivational interviewing may be an important tool to increase the acceptance of treatment for glaucoma. The approach is potentially scalable and may be useful for other chronic conditions in Africa.Trial registration: ISRCTN79330571 (Controlled-Trials.com). © 2014 Abdull et al.; licensee BioMed Central Ltd. AD - M.M. Abdull, Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Hospital Road, PMB 0117 Bauchi, Bauchi State, Nigeria AU - Abdull, M. M. AU - Gilbert, C. AU - McCambridge, J. AU - Evans, J. DB - Embase Medline DO - 10.1186/1745-6215-15-149 IS - 1 KW - eye drops adaptation adolescent adult article blindness clinical article controlled study cost effectiveness analysis glaucoma glaucoma surgery health care quality human informed consent intraocular pressure lifestyle modification low level laser therapy motivational interviewing Nigeria ophthalmologist outcome assessment patient compliance personnel pilot study program cost effectiveness randomized controlled trial LA - English M3 - Article N1 - L53121383 2014-05-16 2014-05-22 PY - 2014 SN - 1745-6215 ST - Adapted motivational interviewing to improve the uptake of treatment for glaucoma in Nigeria: Study protocol for a randomized controlled trial T2 - Trials TI - Adapted motivational interviewing to improve the uptake of treatment for glaucoma in Nigeria: Study protocol for a randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L53121383&from=export http://dx.doi.org/10.1186/1745-6215-15-149 VL - 15 ID - 2887 ER - TY - JOUR AB - BACKGROUND: To determine the stage of primary open angle glaucoma at presentation at a tertiary eye unit, to assess patient's knowledge of glaucoma and acceptance and subsequent adherence to treatment. METHOD: Information collected prospectively on new glaucoma patients aged 30 or more years included distance from residence and what they knew about glaucoma and its treatment. Treatment offered took account of disease severity and socioeconomic factors. Reasons for not accepting surgery were recorded. At follow up intraocular pressure (IOP) was measured and adherence to medication assessed verbally. Four categories of severity were defined based on visual acuity and visual fields defects in the worse eye. RESULTS: 131 patients were recruited (mean age 52.8 years; 62% male). Most attended because of symptoms (70%). Mean IOP in affected eyes was 31.9+/-SD 12.4 and mean vertical cup:disc ratio was 0.8. 99 eyes (47%) had a visual acuity of light perception or worse. Risk factors for advanced/end-stage disease were age >50 years, living >10 km from the hospital, some awareness of glaucoma, not being literate, being unemployed and presenting with symptoms. In multivariable analysis older age and poor knowledge of glaucoma remained independent risk factors. 75 were offered trabeculectomy: five agreed but only one underwent surgery. Reasons for rejecting surgery were fear (37%), preferred medical treatment (27 %) and cost (15 %). 32/85 (24 %) participants started on topical medication attended follow up. 72% reported excellent compliance but only 56% of glaucomatous eyes had IOPs less than 21 mmHg. CONCLUSIONS: To prevent glaucoma blindness strategies are required which promote earlier detection, with counselling to promote acceptance of and adherence to treatment. AU - Abdull, M. M. AU - Gilbert, C. C. AU - Evans, J. DB - Medline DO - 10.1186/s12886-015-0097-9 KW - adult aged attitude to health female open angle glaucoma human intraocular pressure male middle aged Nigeria patient attitude patient compliance perimetry physiology prospective study risk factor statistics and numerical data trabeculectomy very elderly visual acuity visual field LA - English M3 - Article N1 - L615751298 2017-06-19 PY - 2015 SN - 1471-2415 SP - 111 ST - Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment T2 - BMC ophthalmology TI - Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615751298&from=export http://dx.doi.org/10.1186/s12886-015-0097-9 VL - 15 ID - 2791 ER - TY - JOUR AB - Background: To determine the stage of primary open angle glaucoma at presentation at a tertiary eye unit, to assess patient's knowledge of glaucoma and acceptance and subsequent adherence to treatment.Method: Information collected prospectively on new glaucoma patients aged 30 or more years included distance from residence and what they knew about glaucoma and its treatment. Treatment offered took account of disease severity and socioeconomic factors. Reasons for not accepting surgery were recorded. At follow up intraocular pressure (IOP) was measured and adherence to medication assessed verbally. Four categories of severity were defined based on visual acuity and visual fields defects in the worse eye.Results: 131 patients were recruited (mean age 52.8 years; 62% male). Most attended because of symptoms (70%). Mean IOP in affected eyes was 31.9+/-SD 12.4 and mean vertical cup:disc ratio was 0.8. 99 eyes (47%) had a visual acuity of light perception or worse. Risk factors for advanced/end-stage disease were age >50 years, living >10 km from the hospital, some awareness of glaucoma, not being literate, being unemployed and presenting with symptoms. In multivariable analysis older age and poor knowledge of glaucoma remained independent risk factors. 75 were offered trabeculectomy: five agreed but only one underwent surgery. Reasons for rejecting surgery were fear (37%), preferred medical treatment (27 %) and cost (15 %). 32/85 (24 %) participants started on topical medication attended follow up. 72% reported excellent compliance but only 56% of glaucomatous eyes had IOPs less than 21 mmHg.Conclusions: To prevent glaucoma blindness strategies are required which promote earlier detection, with counselling to promote acceptance of and adherence to treatment. AN - 109631472. Language: English. Entry Date: 20150923. Revision Date: 20190223. Publication Type: journal article. Journal Subset: Biomedical AU - Abdull, Mohammed M. AU - Gilbert, Clare C. AU - Evans, Jennifer DB - ccm DO - 10.1186/s12886-015-0097-9 DP - EBSCOhost IS - 1 N1 - Europe; UK & Ireland. NLM UID: 100967802. PMID: NLM26296993. PY - 2015 SN - 1471-2415 SP - 111-111 ST - Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment T2 - BMC Ophthalmology TI - Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109631472&site=ehost-live&scope=site VL - 15 ID - 4577 ER - TY - JOUR AB - Background: To determine the stage of primary open angle glaucoma at presentation at a tertiary eye unit, to assess patient's knowledge of glaucoma and acceptance and subsequent adherence to treatment. Method: Information collected prospectively on new glaucoma patients aged 30 or more years included distance from residence and what they knew about glaucoma and its treatment. Treatment offered took account of disease severity and socioeconomic factors. Reasons for not accepting surgery were recorded. At follow up intraocular pressure (IOP) was measured and adherence to medication assessed verbally. Four categories of severity were defined based on visual acuity and visual fields defects in the worse eye. Results: 131 patients were recruited (mean age 52.8 years; 62 % male). Most attended because of symptoms (70 %). Mean IOP in affected eyes was 31.9+/-SD 12.4 and mean vertical cup:disc ratio was 0.8. 99 eyes (47 %) had a visual acuity of light perception or worse. Risk factors for advanced/end-stage disease were age >50 years, living >10 km from the hospital, some awareness of glaucoma, not being literate, being unemployed and presenting with symptoms. In multivariable analysis older age and poor knowledge of glaucoma remained independent risk factors. 75 were offered trabeculectomy: five agreed but only one underwent surgery. Reasons for rejecting surgery were fear (37 %), preferred medical treatment (27 %) and cost (15 %). 32/85 (24 %) participants started on topical medication attended follow up. 72 % reported excellent compliance but only 56 % of glaucomatous eyes had IOPs less than 21mmHg. Conclusions: To prevent glaucoma blindness strategies are required which promote earlier detection, with counselling to promote acceptance of and adherence to treatment. © 2015 Abdull et al. AD - Ophthalmology Department, Abubakar Tafawa Balewa University, Teaching Hospital, Bauchi, Bauchi State, Nigeria International Centre for Eye Health, Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom AU - Abdull, M. M. AU - Gilbert, C. C. AU - Evans, J. C7 - 111 DB - Scopus DO - 10.1186/s12886-015-0097-9 IS - 1 M3 - Article N1 - Cited By :32 Export Date: 19 July 2021 PY - 2015 ST - Primary open angle glaucoma in northern Nigeria: Stage at presentation and acceptance of treatment T2 - BMC Ophthalmology TI - Primary open angle glaucoma in northern Nigeria: Stage at presentation and acceptance of treatment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939623922&doi=10.1186%2fs12886-015-0097-9&partnerID=40&md5=9f9cd8ffbee678e5657a746668cfcfa9 VL - 15 ID - 5048 ER - TY - JOUR AB - Background: To determine the stage of primary open angle glaucoma at presentation at a tertiary eye unit, to assess patient's knowledge of glaucoma and acceptance and subsequent adherence to treatment. Method: Information collected prospectively on new glaucoma patients aged 30 or more years included distance from residence and what they knew about glaucoma and its treatment. Treatment offered took account of disease severity and socioeconomic factors. Reasons for not accepting surgery were recorded. At follow up intraocular pressure (IOP) was measured and adherence to medication assessed verbally. Four categories of severity were defined based on visual acuity and visual fields defects in the worse eye. Results: 131 patients were recruited (mean age 52.8 years; 62 % male). Most attended because of symptoms (70 %). Mean IOP in affected eyes was 31.9+/-SD 12.4 and mean vertical cup: disc ratio was 0.8. 99 eyes (47 %) had a visual acuity of light perception or worse. Risk factors for advanced/end-stage disease were age > 50 years, living > 10 km from the hospital, some awareness of glaucoma, not being literate, being unemployed and presenting with symptoms. In multivariable analysis older age and poor knowledge of glaucoma remained independent risk factors. 75 were offered trabeculectomy: five agreed but only one underwent surgery. Reasons for rejecting surgery were fear (37 %), preferred medical treatment (27 %) and cost (15 %). 32/85 (24 %) participants started on topical medication attended follow up. 72 % reported excellent compliance but only 56 % of glaucomatous eyes had IOPs less than 21mmHg. Conclusions: To prevent glaucoma blindness strategies are required which promote earlier detection, with counselling to promote acceptance of and adherence to treatment. AN - WOS:000359830900001 AU - Abdull, M. M. AU - Gilbert, C. C. AU - Evans, J. DA - AUG 22 DO - 10.1186/s12886-015-0097-9 PY - 2015 SN - 1471-2415 ST - Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment T2 - BMC OPHTHALMOLOGY TI - Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment VL - 15 ID - 5933 ER - TY - JOUR AB - Purpose. To study factors affecting patients' compliance to antiglaucoma medications in Egypt where there are unique factors as a developing country. Patients and Methods. A cross-sectional descriptive study on 440 Egyptian patients with open angle glaucoma (OAG) recruited for over two years. The patients were thoroughly interviewed about their age, education level, duration of glaucoma, difficulty in instilling the drops, medication regimens, a family history of glaucoma, knowledge of the disease, and the presence of medical insurance. Results. 236 (53.6%) were noncompliant compared to 204 (46.4%) who were compliant. Females had a tendency for higher compliance (P = 0.061). Patient age above 50 years and low level of education and negative family history of glaucoma were factors significantly associated with poor compliance (P < 0.0001). Polytherapy and lack of medical insurance could be contributing factors. Conclusion. Egyptian patients have a high rate of noncompliance compared to the average in literature. Great effort is needed in educating patients about the importance of medications and the risk and the prognosis of this disease. Economic factors must also be taken into consideration in developing countries with large number of poor patients. We recommend simplifying drug regimens, incorporating electronic dose monitors, and creating reminders for follow-up visits of glaucoma patients. AN - WOS:000357213800001 AU - Abu Hussein, N. B. AU - Eissa, I. AU - Abdel-Kader, A. A. DO - 10.1155/2015/234157 PY - 2015 SN - 2090-004X 2090-0058 ST - Analysis of Factors Affecting Patients' Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model T2 - JOURNAL OF OPHTHALMOLOGY TI - Analysis of Factors Affecting Patients' Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model VL - 2015 ID - 5859 ER - TY - JOUR AB - Purpose. To study factors affecting patients’ compliance to antiglaucoma medications in Egypt where there are unique factors as a developing country. Patients and Methods. A cross-sectional descriptive study on 440 Egyptian patients with open angle glaucoma (OAG) recruited for over two years. The patients were thoroughly interviewed about their age, education level, duration of glaucoma, difficulty in instilling the drops, medication regimens, a family history of glaucoma, knowledge of the disease, and the presence of medical insurance. Results. 236 (53.6%) were noncompliant compared to 204 (46.4%) who were compliant. Females had a tendency for higher compliance (p=0.061). Patient age above 50 years and low level of education and negative family history of glaucoma were factors significantly associated with poor compliance (p<0.0001). Polytherapy and lack of medical insurance could be contributing factors. Conclusion. Egyptian patients have a high rate of noncompliance compared to the average in literature. Great effort is needed in educating patients about the importance of medications and the risk and the prognosis of this disease. Economic factors must also be taken into consideration in developing countries with large number of poor patients. We recommend simplifying drug regimens, incorporating electronic dose monitors, and creating reminders for follow-up visits of glaucoma patients. AD - Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo 11562, Egypt AN - 109224571. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - Abu Hussein, Nahla B. AU - Eissa, Iman M. AU - Abdel-Kader, Ahmed A. DB - ccm DO - 10.1155/2015/234157 DP - EBSCOhost KW - Intraocular Pressure Patient Compliance Medication Compliance Descriptive Research Family -- Education Family History Developing Countries Egypt Factor Analysis Logistic Regression Female Multivariate Analysis Univariate Statistics Middle Age Chi Square Test Descriptive Statistics Clinical Trials Regression Case Studies Qualitative Studies Data Collection Cross Sectional Studies Interviews Questionnaires Surveys N1 - research; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 101524199. PY - 2015 SN - 2090-004X SP - 1-7 ST - Analysis of Factors Affecting Patients’ Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model T2 - Journal of Ophthalmology TI - Analysis of Factors Affecting Patients’ Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109224571&site=ehost-live&scope=site VL - 2015 ID - 4342 ER - TY - JOUR AB - Purpose. To study factors affecting patients' compliance to antiglaucoma medications in Egypt where there are unique factors as a developing country. Patients and Methods. A cross-sectional descriptive study on 440 Egyptian patients with open angle glaucoma (OAG) recruited for over two years. The patients were thoroughly interviewed about their age, education level, duration of glaucoma, difficulty in instilling the drops, medication regimens, a family history of glaucoma, knowledge of the disease, and the presence of medical insurance. Results. 236 (53.6%) were noncompliant compared to 204 (46.4%) who were compliant. Females had a tendency for higher compliance (p 0.061). Patient age above 50 years and low level of education and negative family history of glaucoma were factors significantly associated with poor compliance (p < 0.0001). Polytherapy and lack of medical insurance could be contributing factors. Conclusion. Egyptian patients have a high rate of noncompliance compared to the average in literature. Great effort is needed in educating patients about the importance of medications and the risk and the prognosis of this disease. Economic factors must also be taken into consideration in developing countries with large number of poor patients. We recommend simplifying drug regimens, incorporating electronic dose monitors, and creating reminders for follow-up visits of glaucoma patients. © 2015 Nahla B. Abu Hussein et al. AD - Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo, 11562, Egypt AU - Abu Hussein, N. B. AU - Eissa, I. M. AU - Abdel-Kader, A. A. C7 - 234157 DB - Scopus DO - 10.1155/2015/234157 M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2015 ST - Analysis of Factors Affecting Patients' Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model T2 - Journal of Ophthalmology TI - Analysis of Factors Affecting Patients' Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84934324352&doi=10.1155%2f2015%2f234157&partnerID=40&md5=eedd683ba2ea4e87d05aa6cceaa1a2b5 VL - 2015 ID - 5233 ER - TY - JOUR AB - Purpose: To describe clinical manifestations, diagnostic approaches, therapy, and outcomes of biopsy-proven intraocular lymphoma. Methods: Review of tertiary referral center records between 2005 and 2015. Results: A total of 51 eyes of 26 patients were included; mean age of onset was 60.42 years. Common ocular complaints included floaters (42%) and blurred vision (35%); 62% of patients had ocular and central nervous system involvement; 11% had systemic lymphoma; and 27% had only ocular involvement. Vitreous analysis was positive for malignant cells in 77% of patients on initial biopsy, and in 100% of patients on repeat biopsy. In total, 20/26 patients received systemic and topical treatment before IOL diagnosis was made; 25 patients received intravitreal methotrexate and/or rituximab; one patient received intracameral rituximab. All patients achieved remission by their final visit. Conclusions: Intraocular lymphoma often masquerades as intraocular inflammation, resulting in delayed or misdiagnosis with subsequent inappropriate management. Optimal therapy is a challenge for oncologists and ophthalmologists. © Taylor & Francis Group, LLC. AD - Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, MA, United States Ocular Immunology and Uveitis Foundation, Waltham, MA, United States Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology, Istanbul, Turkey Harvard Medical School, Boston, MA, United States AU - Abu Samra, K. AU - Oray, M. AU - Ebrahimiadib, N. AU - Lee, S. AU - Anesi, S. AU - Foster, C. S. DB - Scopus DO - 10.1080/09273948.2016.1193206 IS - 3 KW - Clinical manifestations intraocular lymphoma masquerade syndrome treatment outcomes uveitis M3 - Article N1 - Cited By :15 Export Date: 19 July 2021 PY - 2018 SP - 347-352 ST - Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes T2 - Ocular Immunology and Inflammation TI - Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979047239&doi=10.1080%2f09273948.2016.1193206&partnerID=40&md5=c1d5858e78c7c1e7de3dc3dd8b0ef00a VL - 26 ID - 5186 ER - TY - JOUR AB - Introduction As the world population ages, glaucoma is becoming an increasingly significant cause of blindness. A key component in the management of glaucoma is the use of prescribed medications and the adherence to treatment. However, there is evidence of low adherence to prescribed medication in chronic diseases, such as glaucoma. This study aims to explore the level of medication adherence, self-efficacy, social support and health literacy among the patients with glaucoma and to determine if there are any correlations between them. The ultimate aim is to use the information to develop an educational programme for patients with glaucoma at a later stage. Methods and analysis This is a mixed-methods study which includes two stages: a descriptive study (stage 1) and focus group discussions (stage 2). Sample: Patients with glaucoma or ocular hypertension, using at least one kind of drops, from two ophthalmology clinics. Selected measures include: The Glaucoma Treatment Compliance Assessment Tool, The European Health Literacy Survey Questionnaire, The Glaucoma Medication Self-Efficacy Questionnaire and The Multidimensional Scale of Perceived Social Support. Two focus groups will be used for the collection of qualitative data, aiming to enrich the study with the patients' experiences. The data will be analysed with SPSS, using descriptive and inferential statistics for stage 1 whereas content analysis will be used for the data from the focus group discussions (stage 2). Ethics and dissemination Permission to conduct the study was received from the National Bioethics Committee and the board of management of the two ophthalmology clinics. All participants will be informed fully on the purpose and methods of the study. Consent forms will be signed and at any time participants will have the right to withdraw. Confidentiality and the protection of data will be respected at all times. AD - M. Achilleos, Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus AU - Achilleos, M. AU - Merkouris, A. AU - Charalambous, A. AU - Papastavrou, E. DB - Embase Medline DO - 10.1136/bmjopen-2020-039788 IS - 1 KW - data analysis software information processing device antiglaucoma agent eye drops article assessment of humans content analysis descriptive research European health literacy survey questionnaire glaucoma glaucoma medication self efficacy questionnaire glaucoma treatment compliance assessment tool health literacy human intraocular hypertension medication compliance Multidimensional Scale of Perceived Social Support patient compliance qualitative research self concept social support structured questionnaire systematic review SPSS LA - English M3 - Article N1 - L633971000 2021-02-02 2021-03-16 PY - 2021 SN - 2044-6055 ST - Medication adherence, self-efficacy and health literacy among patients with glaucoma: A mixed-methods study protocol T2 - BMJ Open TI - Medication adherence, self-efficacy and health literacy among patients with glaucoma: A mixed-methods study protocol UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633971000&from=export http://dx.doi.org/10.1136/bmjopen-2020-039788 VL - 11 ID - 2326 ER - TY - JOUR AB - Background: Teriparatide (parathyroid hormone [1-34] [ribosomal DNA origin]) stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity. It has been found to significantly reduce vertebral fractures by 65%, and nonvertebral fragility fractures by 53% in treatment-naive postmenopausal women who have previously suffered a vertebral fracture. Objective: This study examined the compliance, acceptance, and adherance of SC teriparatide 20 pg QD. Methods: In this 18-month, multicenter, openlabel, prospective study, women with postmenopausal osteoporosis, and men >30 years of age with either idiopathic or hypogonadal osteoporosis (with low bone mass [T-score of -1 or worse] and ≥1 fragility fracture), who had experienced a treatment-related adverse event (AE) or an inadequate response while receiving antiresorptive treatment, and who were willing to receive open-label teriparatide for ≥18 months were eligible. Compliance was defined as self-reported use of ≥80% of study medication. Acceptance of the injection pen was determined by scores obtained from questionnaires and rating scales measuring patients' perception. Patients self-reported on injection discomfort, ease of use, and the overall injection administration. Acceptance was assessed at baseline, and 3, 6, and 18 months. AEs were recorded at each clinical visit from the patients' self-reports. At the 3-month visit, a serum calcium level was drawn ≥16 hours after the previous teriparatide dose. Results: In this study, 116 patients-102 women with postmenopausal osteoporosis and 14 men (12 with idiopathic osteoporosis and 2 with hypogonadal osteoporosis)-were assessed for inclusion in the study. The mean (SD) age was 68.8 (11.1) years (range, 40-89 years) and the mean (SD) weight was 60.5 (11.7) kg (range, 37-87 kg). Seventy-three percent of the patients in this study had baseline spinal T-scores ≤-2.5, and 72% had fractured during treatment with an osteoporosis medication. Reported compliance was 89% at 6 months and 82% at 18 months. At baseline, 42% of patients were concerned about injection discomfort, and 43% were somewhat concerned with daily injections, while 7% were quite concerned. At 6 months, most patients reported much less concern (49%) or no concern (42%). Patient perceptions associated with learning how to use the pen injection, attaching the needle, holding the pen, and injecting the dose, improved during the first 6 months of the study. The most commonly reported AEs were dizziness, 12 (10.3%); nausea, 12 (10.3%); back pain, 9 (7.8%); and muscle cramps, 9 (7.8%). No AEs were believed to be associated with the use of the pen injection or teriparatide. Five patients had mildly elevated serum calcium concentrations (maximum value 2.8 mmol/L) at 3 months. However, all were normal on repeat testing ~4 weeks thereafter. Conclusions: This study found that teriparatide pen injection was well accepted in these patients, and acceptance rates improved during the first 6 months of treatment and, thereafter, improved slightly for ~18 months. Reported compliance remained high throughout the study (82%-89%). Teriparatide pen injection was a viable treatment in these osteopenic or osteoporotic patients with fragility fractures. © 2007 Excerpta Medica, Inc. AD - Department of Medicine, McMaster University, Hamilton, Ont., Canada Department of Medicine, University of Calgary, Calgary, Alta., Canada 0steoporosis and Diabetes, Eli Lilly Canada Inc., Toronto, Ont., Canada AU - Adachi, J. D. AU - Hanley, D. A. AU - Lorraine, J. K. AU - Yu, M. DB - Scopus DO - 10.1016/j.clinthera.2007.09.024 IS - 9 KW - acceptance adherence compliance elderly osteoporosis teriparatide M3 - Article N1 - Cited By :28 Export Date: 19 July 2021 PY - 2007 SP - 2055-2067 ST - Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study T2 - Clinical Therapeutics TI - Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-36849048891&doi=10.1016%2fj.clinthera.2007.09.024&partnerID=40&md5=16bb58da49683f52b5f43c0313595178 VL - 29 ID - 5073 ER - TY - JOUR AB - Objectives: To determine ocular outcomes and factors associated with adherence to ophthalmic follow-up in a medically underserved population at a single health centre in Philadelphia. Design: Retrospective chart review. Participants: Patients from a community glaucoma screening program. Methods: Chart review was conducted for participants who received a complete eye examination at the Philadelphia District Health Center 5 between January 1, 2012 and May 31, 2014 within the Philadelphia Glaucoma Detection and Treatment Project. Multivariate logistic regression was used to determine factors related to ophthalmic follow-up adherence. Results: A total of 249 participants completed an eye examination (mean age = 57.7 ± 6.9 years). Most were African American (n = 220; 88.4%); female (n = 129; 51.8%). Forty-seven participants (18.9%) received glaucoma-related diagnoses, 20 (8.0%) were prescribed ocular medication, and 26 (10.4%) underwent laser therapy. Ninety (36.1%) attended their recommended follow-up eye examination at the health centre. Glaucoma-related diagnosis (p ≤ 0.001), recommendation of a 4- to 6-week follow-up period (p < 0.001), prescribed eye drops (p < 0.001), or received laser therapy (p = 0.047) were factors most predictive of ophthalmic follow-up adherence. Conclusions: The collaborative effort of eye care providers and health centres offers an important opportunity to detect, treat, and manage glaucoma and other ocular pathology in medically underserved communities. Having a glaucoma-related diagnosis, initiating treatment, and scheduling regular follow-up visits are the most important factors influencing adherence to follow-up eye appointments. AD - L.A. Hark, Professor of Ophthalmic Sciences (Ophthalmology), Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, The Edward S. Harkness Eye Institute, 635 West 165th Street, Suite 504, New York, NY, United States AU - Adeghate, J. O. AU - Hark, L. A. AU - Brown, H. AU - Henderer, J. D. AU - Waisbourd, M. AU - Molineaux, J. AU - Malik, K. AU - Maity, A. AU - Chuang, D. AU - Donches, K. AU - Heres, C. AU - Eburuoh, R. AU - Schardt, M. AU - Yu, D. AU - Ramsey, F. AU - Myers, J. S. AU - Katz, L. J. DB - Embase Medline DO - 10.1016/j.jcjo.2019.03.003 IS - 6 KW - eye drops adult African American article cataract extraction clinical outcome controlled study diabetic retinopathy eye care eye examination female follow up glaucoma health center human low level laser therapy major clinical study male medical record review medically underserved middle aged patient compliance Pennsylvania refraction error retrospective study screening LA - English M3 - Article N1 - L2002927842 2019-09-23 2019-12-31 PY - 2019 SN - 1715-3360 0008-4182 SP - 717-722 ST - Philadelphia glaucoma detection and treatment project: ocular outcomes and adherence to follow-up at a single health centre T2 - Canadian Journal of Ophthalmology TI - Philadelphia glaucoma detection and treatment project: ocular outcomes and adherence to follow-up at a single health centre UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2002927842&from=export http://dx.doi.org/10.1016/j.jcjo.2019.03.003 VL - 54 ID - 2469 ER - TY - JOUR AB - Objectives: To determine ocular outcomes and factors associated with adherence to ophthalmic follow-up in a medically underserved population at a single health centre in Philadelphia. Design: Retrospective chart review. Participants: Patients from a community glaucoma screening program. Methods: Chart review was conducted for participants who received a complete eye examination at the Philadelphia District Health Center 5 between January 1, 2012 and May 31, 2014 within the Philadelphia Glaucoma Detection and Treatment Project. Multivariate logistic regression was used to determine factors related to ophthalmic follow-up adherence. Results: A total of 249 participants completed an eye examination (mean age = 57.7 ± 6.9 years). Most were African American (n = 220; 88.4%); female (n = 129; 51.8%). Forty-seven participants (18.9%) received glaucoma-related diagnoses, 20 (8.0%) were prescribed ocular medication, and 26 (10.4%) underwent laser therapy. Ninety (36.1%) attended their recommended follow-up eye examination at the health centre. Glaucoma-related diagnosis (p ≤ 0.001), recommendation of a 4- to 6-week follow-up period (p < 0.001), prescribed eye drops (p < 0.001), or received laser therapy (p = 0.047) were factors most predictive of ophthalmic follow-up adherence. Conclusions: The collaborative effort of eye care providers and health centres offers an important opportunity to detect, treat, and manage glaucoma and other ocular pathology in medically underserved communities. Having a glaucoma-related diagnosis, initiating treatment, and scheduling regular follow-up visits are the most important factors influencing adherence to follow-up eye appointments. © 2019 Canadian Ophthalmological Society AD - Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA, United States Department of Ophthalmology, Weill Cornell Medical College, New York, NY, United States Department of Ophthalmology, Columbia University Irving Medical Center, New York, NY, United States Department of Ophthalmology, Temple University Hospital, Philadelphia, PA, United States Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States Department of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States Health District #5 Health Center, Philadelphia Department of Health, Philadelphia, PA, United States Philadelphia College of Osteopathic Medicine, Philadelphia, PA, United States AU - Adeghate, J. O. AU - Hark, L. A. AU - Brown, H. AU - Henderer, J. D. AU - Waisbourd, M. AU - Molineaux, J. AU - Malik, K. AU - Maity, A. AU - Chuang, D. AU - Donches, K. AU - Heres, C. AU - Eburuoh, R. AU - Schardt, M. AU - Yu, D. AU - Ramsey, F. AU - Myers, J. S. AU - Katz, L. J. DB - Scopus DO - 10.1016/j.jcjo.2019.03.003 IS - 6 M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2019 SP - 717-722 ST - Philadelphia glaucoma detection and treatment project: ocular outcomes and adherence to follow-up at a single health centre T2 - Canadian Journal of Ophthalmology TI - Philadelphia glaucoma detection and treatment project: ocular outcomes and adherence to follow-up at a single health centre UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072280042&doi=10.1016%2fj.jcjo.2019.03.003&partnerID=40&md5=129fefa8f1d164d2b1150b94034f9474 VL - 54 ID - 5609 ER - TY - JOUR AB - Objectives: To determine ocular outcomes and factors associated with adherence to ophthalmic follow-up in a medically underserved population at a single health centre in Philadelphia. Design: Retrospective chart review. Participants: Patients from a community glaucoma screening program. Methods: Chart review was conducted for participants who received a complete eye examination at the Philadelphia District Health Center 5 between January 1, 2012 and May 31, 2014 within the Philadelphia Glaucoma Detection and Treatment Project. Multivariate logistic regression was used to determine factors related to ophthalmic follow-up adherence. Results: A total of 249 participants completed an eye examination (mean age = 57.7 +/- 6.9 years). Most were African American (n = 220; 88.4%); female (n = 129; 51.8%). Forty-seven participants (18.9%) received glaucoma-related diagnoses, 20 (8.0%) were prescribed ocular medication, and 26 (10.4%) underwent laser therapy. Ninety (36.1%) attended their recommended follow-up eye examination at the health centre. Glaucoma-related diagnosis (p < 0.001), recommendation of a 4- to 6-week follow-up period (p < 0.001), prescribed eye drops (p < 0.001), or received laser therapy (p = 0.047) were factors most predictive of ophthalmic follow-up adherence. Conclusions: The collaborative effort of eye care providers and health centres offers an important opportunity to detect, treat, and manage glaucoma and other ocular pathology in medically underserved communities. Having a glaucoma-related diagnosis, initiating treatment, and scheduling regular follow-up visits are the most important factors influencing adherence to follow-up eye appointments. AN - WOS:000502071100037 AU - Adeghate, J. O. AU - Hark, L. A. AU - Brown, H. AU - Henderer, J. D. AU - Waisbourd, M. AU - Molineaux, J. AU - Malik, K. AU - Maity, A. AU - Chuang, D. AU - Donches, K. AU - Heres, C. AU - Eburuoh, R. AU - Schardt, M. AU - Yu, D. H. AU - Ramsey, F. AU - Myers, J. S. AU - Katz, L. J. DA - DEC DO - 10.1016/j.jcjo.2019.03.003 IS - 6 PY - 2019 SN - 0008-4182 1715-3360 SP - 717-722 ST - Philadelphia glaucoma detection and treatment project: ocular outcomes and adherence to follow-up at a single health centre T2 - CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE TI - Philadelphia glaucoma detection and treatment project: ocular outcomes and adherence to follow-up at a single health centre VL - 54 ID - 5845 ER - TY - JOUR AB - BACKGROUND: Glaucoma management is challenging to patients as well as to the eye care providers. The study is aimed at describing the challenges faced by providers using qualitative methods. METHODS: In-depth interviews were conducted with selected Ophthalmologists and resident doctors in ophthalmology at centres offering medical and surgical glaucoma services in Lagos state, Nigeria, according to established qualitative methods. This was done using semi-structured, open ended questions to explore the providers' perspective on glaucoma burden, challenges in the management, surgery for glaucoma, acceptance of glaucoma surgery by patients, and recommendations for improving glaucoma services. The discussions were recorded with the aid of a micro-cassette recorder. Familiarisation was done to identify key ideas in the data, then, the main themes and sub-themes were identified. Quotes that reflect the themes and sub-themes were then identified in the data. RESULTS: In-depth interviews were conducted with a total of 11 ophthalmologists and resident doctors in training. Majority were of the opinion that glaucoma is a significant burden constituting about 35% of outpatient visits. Identified patient related challenges include; late presentation, lack of glaucoma awareness, delay in referral from optometrists, and poor compliance with medications. Shortages in needed equipment were also identified. Availability, affordability and counterfeiting of drugs were the major challenges related to medical treatment. Majority of the participants agreed that surgery should be offered to the patients as soon as the diagnosis of glaucoma is made. However, continuous monitoring of the patient on medical treatment is another line of option for them in early cases; if they are convinced the patients will be compliant. Some respondents considered the current number of glaucoma surgeries as adequate, while some think otherwise. Reasons put forward for reluctance to offer glaucoma surgery include; late presentation, lack of patient satisfaction, complications of surgery, and negative publicity. CONCLUSION: Even though the challenges in the management of glaucoma in developing countries are many, they are not insurmountable. There is need for concerted and integrated efforts involving all cadres of eye care practitioners, patients, institutions and governments to address this important eye disease. Improved awareness, provision of adequate equipment, availability and affordability of medications, need for training and retraining of eye care providers are all important measures that can lead to better management of the glaucoma patient. AU - Adekoya, B. J. AU - Adepoju, F. G. AU - Moshood, K. F. AU - Balarabe, A. H. DB - Scopus IS - 4 M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2015 SP - 315-322 ST - CHALLENGES IN THE MANAGEMENT OF GLAUCOMA IN A DEVELOPING COUNTRY; A QUALITATIVE STUDY OF PROVIDERS' PERSPECTIVES T2 - Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria TI - CHALLENGES IN THE MANAGEMENT OF GLAUCOMA IN A DEVELOPING COUNTRY; A QUALITATIVE STUDY OF PROVIDERS' PERSPECTIVES UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84986587168&partnerID=40&md5=92f2f65207b8de37f7f7868276bda7d0 VL - 24 ID - 5381 ER - TY - JOUR AB - Background: Primary open angle glaucoma is reported to blind 150,000 people in the Nigerian population and over 7000 in Rivers State, and requires constant follow-up. Compliance is a challenge, given that most inhabitants live below the poverty line. This study was performed to determine how Nigerian patients are affected economically by the disease. Methods: Consecutive adult patients attending the eye clinic of the University of Port Harcourt Teaching Hospital, Rivers State, Nigeria, with a diagnosis of primary open angle glaucoma and on outpatient antiglaucoma treatment in the first 6 months of 2006, were recruited for the study. The lowest paid government worker was on USD50 (N7500.00) per month and the gross domestic product per capita was USD1150 for the period under review. Results: We enrolled 120 consecutive patients of mean age 52.7 ± 10.4 years, with a male to female ratio of 2:3. The most common occupations were in the civil service (n = 56, 46.7%). All participants were on topical antiglaucoma treatment. The average cost of medical antiglaucoma medication was N6000 (USD40) per month. Computed to include indirect costs, including medical laboratory tests, transportation, and care by patient escorts, an average sum of USD105.4 (N15,810) was spent by each patient per month. Most of the patients (73.3%) were responsible for their own treatment costs. No patient accepted the cheaper option of surgery (USD275.4, N41,310). Eighty of the patients (66.7%) visited our eye clinic monthly. Direct and indirect loss to the economy was USD3,064587 per annum from those already blind. This was in addition to the USD 4.1 million being spent yearly on medical treatment by those who were visually impaired by glaucoma. Conclusion: Middle-income earners spent over 50% of their monthly income and low-income earners spend all their monthly earnings on treatment for glaucoma. This situation often resulted in noncompliance with treatment and hospital follow-up visits. To reduce the economic burden of glaucoma, trabeculectomy performed by experienced surgeons should be offered as first-line treatment for glaucoma in this country, rather than medical therapy. © 2012 Adio and Onua, publisher and licensee Dove Medical Press Ltd. AD - A. O. Adio, Eye Clinic, University of Port Harcourt Teaching Hospital, Rivers State, Nigeria AU - Adio, A. O. AU - Onua, A. A. DB - Embase DO - 10.2147/OPTH.S37145 IS - 1 KW - antiglaucoma agent adult aged blindness drug cost female glaucoma glaucoma surgery health care cost health care utilization health economics human major clinical study male Nigeria occupation review visual impairment L1 - internal-pdf://0628175011/3048-Economic burden of glaucoma in River-2012.pdf LA - English M3 - Review N1 - L366222384 2012-12-17 2012-12-19 PY - 2012 SN - 1177-5467 1177-5483 SP - 2023-2031 ST - Economic burden of glaucoma in Rivers State, Nigeria T2 - Clinical Ophthalmology TI - Economic burden of glaucoma in Rivers State, Nigeria UR - https://www.embase.com/search/results?subaction=viewrecord&id=L366222384&from=export http://dx.doi.org/10.2147/OPTH.S37145 VL - 6 ID - 3048 ER - TY - JOUR AB - Background: Primary open angle glaucoma is reported to blind 150,000 people in the Nigerian population and over 7000 in Rivers State, and requires constant follow-up. Compliance is a challenge, given that most inhabitants live below the poverty line. This study was performed to determine how Nigerian patients are affected economically by the disease. Methods: Consecutive adult patients attending the eye clinic of the University of Port Harcourt Teaching Hospital, Rivers State, Nigeria, with a diagnosis of primary open angle glaucoma and on outpatient antiglaucoma treatment in the first 6 months of 2006, were recruited for the study. The lowest paid government worker was on USD50 (N7500.00) per month and the gross domestic product per capita was USD1150 for the period under review. Results: We enrolled 120 consecutive patients of mean age 52.7 ± 10.4 years, with a male to female ratio of 2:3. The most common occupations were in the civil service (n = 56, 46.7%). All participants were on topical antiglaucoma treatment. The average cost of medical antiglaucoma medication was N6000 (USD40) per month. Computed to include indirect costs, including medical laboratory tests, transportation, and care by patient escorts, an average sum of USD105.4 (N15,810) was spent by each patient per month. Most of the patients (73.3%) were responsible for their own treatment costs. No patient accepted the cheaper option of surgery (USD275.4, N41,310). Eighty of the patients (66.7%) visited our eye clinic monthly. Direct and indirect loss to the economy was USD3,064587 per annum from those already blind. This was in addition to the USD 4.1 million being spent yearly on medical treatment by those who were visually impaired by glaucoma. Conclusion: Middle-income earners spent over 50% of their monthly income and low-income earners spend all their monthly earnings on treatment for glaucoma. This situation often resulted in noncompliance with treatment and hospital follow-up visits. To reduce the economic burden of glaucoma, trabeculectomy performed by experienced surgeons should be offered as first-line treatment for glaucoma in this country, rather than medical therapy. © 2012 Adio and Onua, publisher and licensee Dove Medical Press Ltd. AD - University Of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria Braithwaite Memorial Specialist Hospital, Port Harcourt, Rivers State, Nigeria AU - Adio, A. O. AU - Onua, A. A. DB - Scopus DO - 10.2147/OPTH.S37145 IS - 1 KW - Blindness Chronic glaucoma Economic burden Nigeria Rivers State M3 - Review N1 - Cited By :28 Export Date: 19 July 2021 PY - 2012 SP - 2023-2031 ST - Economic burden of glaucoma in Rivers State, Nigeria T2 - Clinical Ophthalmology TI - Economic burden of glaucoma in Rivers State, Nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84870726844&doi=10.2147%2fOPTH.S37145&partnerID=40&md5=10f805a6be95db454a5aeba429ec0dc6 VL - 6 ID - 5071 ER - TY - JOUR AB - Colored lenses were first designed for patients with eye pathologies, such as aniridia or corneal opacity. However, in recent years they have become readily available over-the-counter as cosmetic accessories. Widespread use of these lenses has been noted among young adults. Acanthamoeba keratitis is a rare cause of corneal infection, which is associated with poor visual prognosis. Over the past ten years, improvements in the management of this infection have been documented, yet the best treatment is still primary prevention. Hence, contact lens wearers must be provided with proper instructions regarding contact lens hygiene. We present a case of unilateral Acanthamoeba keratitis in a cosmetic contact lens wearer who presented with a month history of right eye pain, photophobia, redness and blurred vision. The contact lenses were obtained over the counter, and a history of poor contact lens hygiene was found. The patient was started on empirical treatment initially. The treatment was modified once the diagnosis was confirmed via Giemsa Stain of corneal scrapings, which showed Acanthamoeba cysts. The patient improved markedly and was discharged from the hospital. The disease classically has a slowly progressive, chronic course, with frequent remission periods. Our patient was lost to follow-up due to poor compliance and failure to adhere to guidelines. AN - WOS:000416757800019 AU - Agab, A. W. AU - Albuainain, A. R. AU - Al Bin Ali, G. DA - MAR IS - 1 PY - 2017 SN - 1012-8298 SP - 69-71 ST - Unilateral Acanthamoeba Keratitis following the Use of Cosmetic Contact Lens T2 - BAHRAIN MEDICAL BULLETIN TI - Unilateral Acanthamoeba Keratitis following the Use of Cosmetic Contact Lens VL - 39 ID - 6289 ER - TY - JOUR AB - CONTEXT: Risk factors for failure of trabeculectomy may have a cumulative effect on the outcome. AIMS: To study the effect of preoperative ocular risk factors on the surgical outcome of trabeculectomy augmented with 2 commonly used doses of Mitomycin C. SETTINGS AND DESIGN: In a prospective cohort study, cases were recruited over an 18 month period. 92 eyes of 83 patients with one to three known risk factors for failure of trabeculectomy underwent Mitomycin-C (MMC) augmented trabeculectomy. METHODS AND MATERIAL: Trabeculectomy was done with a randomly chosen MMC dose of 0.2 mg/ml or 0.4 mg/ml. All cases were followed up for a period of at least 3 months. Surgical success was defined as the lowering of intraocular pressure (IOP) below 21 mmHg during the follow up period. STATISTICAL ANALYSIS USED: Chi square test, paired t test, odds ratio, effect size. RESULTS: Eyes with two or three risk factors (out of aphakic glaucoma, failed trabeculectomy, neovascular glaucoma, post uveitic glaucoma, traumatic glaucoma, adherent leucoma, juvenile glaucoma, prolonged medical therapy, steroid induced glaucoma, post penetrating keratoplasty glaucoma and developmental glaucoma) had a significantly poorer surgical success rate (88% and 78%) than eyes with one risk factor (100%). 0.4 mg/ml MMC used sub-sclerally had a statistically similar effect on lowering the IOP as 0.2 mg/ml in all groups. The rate of complications was significantly higher in the 0.4 mg/ml subgroup. CONCLUSIONS: The presence of more than one preoperative ocular risk factor, affects the surgical success of MMC augmented trabeculectomy in high-risk cases. Because of the significantly higher rate of complications with the higher dose of MMC, this should be used sparingly, only in cases with more than two risk factors. AD - RP Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi - 110 029, India. AN - 105823732. Language: English. Entry Date: 20080307. Revision Date: 20150711. Publication Type: Journal Article AU - Agarwal, H. C. AU - Sharma, T. K. AU - Sihota, R. AU - Gulati, V. DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Glaucoma -- Surgery Mitomycins -- Administration and Dosage Adult Chemotherapy, Adjuvant Clinical Trials Dose-Response Relationship, Drug Drug Administration Schedule Female Intraocular Pressure Male Middle Age Odds Ratio Postoperative Complications Preoperative Care Probability Prospective Studies Risk Factors Treatment Outcomes Human N1 - clinical trial; research. Journal Subset: Asia; Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed. NLM UID: 2985196R. PMID: NLM12215687. PY - 2002 SN - 0022-3859 SP - 92-96 ST - Cumulative effect of risk factors on short-term surgical success of mitomycin augmented trabeculectomy T2 - Journal of Postgraduate Medicine TI - Cumulative effect of risk factors on short-term surgical success of mitomycin augmented trabeculectomy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105823732&site=ehost-live&scope=site VL - 48 ID - 4604 ER - TY - JOUR AB - Context: Risk factors for failure of trabeculectomy may have a cumulative effect on the outcome. Aims: To study the effect of preoperative ocular risk factors on the surgical outcome of trabeculectomy augmented with 2 commonly used doses of Mitomycin C. Settings and Design: In a prospective cohort study, cases were recruited over an 18 month period. 92 eyes of 83 patients with one to three known risk factors for failure of trabeculectomy underwent Mitomycin-C (MMC) augmented trabeculectomy. Methods and Material: Trabeculectomy was done with a randomly chosen MMC dose of 0.2 mg/ml or 0.4 mg/ml. All cases were followed up for a period of at least 3 months. Surgical success was defined as the lowering of intraocular pressure (IOP) below 21 mmHg during the follow up period. Statistical Analysis Used: Chi square test, paired t test, odds ratio, effect size. Results: Eyes with two or three risk factors (out of aphakic glaucoma, failed trabeculectomy, neovascular glaucoma, post uveitic glaucoma, traumatic glaucoma, adherent leucoma, juvenile glaucoma, prolonged medical therapy, steroid induced glaucoma, post penetrating keratoplasty glaucoma and developmental glaucoma) had a significantly poorer surgical success rate (88% and 78%) than eyes with one risk factor (100%). 0.4 mg/ml MMC used sub-sclerally had a statistically similar effect on lowering the IOP as 0.2 mg/ml in all groups. The rate of complications was significantly higher in the 0.4 mg/ml subgroup. Conclusions: The presence of more than one preoperative ocular risk factor, affects the surgical success of MMC augmented trabeculectomy in high-risk cases. Because of the significantly higher rate of complications with the higher dose of MMC, this should be used sparingly, only in cases with more than two risk factors. AD - RP Centre for Ophthalmic Sciences, All India Inst. of Medical Sciences, Ansari Nagar, New Delhi - 110029, India AU - Agarwal, H. C. AU - Sharma, T. K. AU - Sihota, R. AU - Gulati, V. DB - Scopus IS - 2 KW - Mitomycin-C Risk factors Success rate Trabeculectomy M3 - Article N1 - Cited By :18 Export Date: 19 July 2021 PY - 2002 SP - 92-96 ST - Cumulative effect of risk factors on short-term surgical success of mitomycin augmented trabeculectomy T2 - Journal of Postgraduate Medicine TI - Cumulative effect of risk factors on short-term surgical success of mitomycin augmented trabeculectomy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036526523&partnerID=40&md5=b90e9a0c3f00a7e02a2a5578d4a12002 VL - 48 ID - 5166 ER - TY - JOUR AB - Purpose: The aim of this study was to evaluate the effect of clinical and biochemical effects of subconjunctival bevacizumab injection in eyes with corneal neovascularization (CNV) due to varied etiologies. Methods: This prospective interventional case series included 12 eyes of 12 patients with CNV after failed therapeutic penetrating keratoplasty (4 eyes), viral keratitis (4 eyes), adherent leucoma (2 eyes), and pseudophakic bullous keratopathy (2 eyes). Each eye received 3 doses of 1.25 mg (0.05 mL) of bevacizumab at 1-month intervals. Morphological changes in neovascularization were evaluated at each visit by slit-lamp examination and corneal digital photography. Corneal buttons of 4 eyes that underwent optical penetrating keratoplasty after bevacizumab injections were analyzed for vascular endothelial growth factor (VEGF) expression and were compared with untreated vascularized and normal cadaveric donor corneas. Results: Of the 12 patients, 10 were males and 2 were females. Four eyes received injections in the early phase of vascularization (<12 weeks of onset) of which 3 showed regression of vessels. Eight eyes received bevacizumab in the mature phase (>12 weeks) of which 5 showed regression. The follow-up ranged from 1 to 16 months. Five eyes underwent optical penetrating keratoplasty after receiving the last dose of bevacizumab and maintained graft clarity with no episodes of rejection over a mean follow-up of 9.8 months. Four of these 5 corneal buttons analyzed for VEGF expression revealed clinically significant lower levels of expression as compared with the vascular untreated corneas. No local or systemic adverse effects were noted in any patient. Conclusions: Subconjunctival bevacizumab helps to regress CNV due to a decrease in corneal VEGF levels and might prove beneficial for use in clinical conditions leading to CNV. Copyright © 2014 by Lippincott Williams & Wilkins. AD - C. J. Shah Department of Cornea and Refractive Surgery, Medical Research Foundation, 18, College Road, Sankara Nethralaya, Chennai, Tamil Nadu, 600 006, India R. S. Mehta Jain Department of Biochemistry and Cell Biology, Vision Research Foundation, Chennai, India AU - Agarwal, S. AU - Angayarkanni, N. AU - Iyer, G. AU - Srinivasan, B. AU - Natarajan, R. AU - Charola, S. AU - Arumugam, S. AU - Padmanabhan, P. DB - Scopus DO - 10.1097/ICO.0000000000000198 IS - 10 KW - Bevacizumab Corneal neovascularization High-risk corneal graft VEGF M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2014 SP - 1016-1021 ST - Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization T2 - Cornea TI - Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925883663&doi=10.1097%2fICO.0000000000000198&partnerID=40&md5=994806ed0dbf4ba62d99e1aa76deee78 VL - 33 ID - 5384 ER - TY - JOUR AB - Purpose: The aim of this study was to evaluate the effect of clinical and biochemical effects of subconjunctival bevacizumab injection in eyes with corneal neovascularization (CNV) due to varied etiologies. Methods: This prospective interventional case series included 12 eyes of 12 patients with CNV after failed therapeutic penetrating keratoplasty (4 eyes), viral keratitis (4 eyes), adherent leucoma (2 eyes), and pseudophakic bullous keratopathy (2 eyes). Each eye received 3 doses of 1.25 mg (0.05 mL) of bevacizumab at 1-month intervals. Morphological changes in neovascularization were evaluated at each visit by slit-lamp examination and corneal digital photography. Corneal buttons of 4 eyes that underwent optical penetrating keratoplasty after bevacizumab injections were analyzed for vascular endothelial growth factor (VEGF) expression and were compared with untreated vascularized and normal cadaveric donor corneas. Results: Of the 12 patients, 10 were males and 2 were females. Four eyes received injections in the early phase of vascularization (<12 weeks of onset) of which 3 showed regression of vessels. Eight eyes received bevacizumab in the mature phase (>12 weeks) of which 5 showed regression. The follow-up ranged from 1 to 16 months. Five eyes underwent optical penetrating keratoplasty after receiving the last dose of bevacizumab and maintained graft clarity with no episodes of rejection over a mean follow-up of 9.8 months. Four of these 5 corneal buttons analyzed for VEGF expression revealed clinically significant lower levels of expression as compared with the vascular untreated corneas. No local or systemic adverse effects were noted in any patient. Conclusions: Subconjunctival bevacizumab helps to regress CNV due to a decrease in corneal VEGF levels and might prove beneficial for use in clinical conditions leading to CNV. AN - WOS:000341863300004 AU - Agarwal, S. AU - Angayarkanni, N. AU - Iyer, G. AU - Srinivasan, B. AU - Natarajan, R. AU - Charola, S. AU - Arumugam, S. AU - Padmanabhan, P. DA - OCT DO - 10.1097/ICO.0000000000000198 IS - 10 PY - 2014 SN - 0277-3740 1536-4798 SP - 1016-1021 ST - Clinico-biochemical Correlation of the Effect of Subconjunctival Bevacizumab for Corneal Neovascularization T2 - CORNEA TI - Clinico-biochemical Correlation of the Effect of Subconjunctival Bevacizumab for Corneal Neovascularization VL - 33 ID - 6244 ER - TY - JOUR AB - Glaucoma is a group of optic neuropathies that is more prevalent among the elderly population and commonly associates with comorbidities, including mental disorders in that population. This article reviews the relationship between glaucoma and mental disorders. In it, we discuss the coexistence of glaucoma and mental illnesses, including Alzheimer's disease, depression, and personality disorder. We also focus on the proper treatment approaches for glaucoma patients with mental comorbidity and poor treatment adherence. We summarize some cautiously recommended psychotherapeutic medications, while also discussing the psychologically adverse effects of antiglaucoma medications. AD - Department of Ophthalmology and Inha Vision Science Laboratory, Inha University School of Medicine, Incheon Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul Department of Psychiatry, Inha University School of Medicine, Incheon, Korea *Department of Ophthalmology and Inha Vision Science Laboratory, Inha University School of Medicine, Incheon; †Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul; and ‡Department of Psychiatry, Inha University School of Medicine, Incheon, Korea AN - 113702501. Language: English. Entry Date: 20160708. Revision Date: 20160708. Publication Type: journal article AU - Ah Reum, Jeong AU - Chan Yun, Kim AU - Min Hee, Kang AU - Na Rae, Kim AU - Jeong, Ah Reum AU - Kim, Chan Yun AU - Kang, Min Hee AU - Kim, Na Rae DB - ccm DO - 10.1097/NMD.0000000000000467 DP - EBSCOhost IS - 3 KW - Mental Disorders -- Psychosocial Factors Comorbidity Glaucoma -- Psychosocial Factors Mental Disorders -- Epidemiology Glaucoma -- Epidemiology Glaucoma -- Drug Therapy Mental Disorders -- Chemically Induced N1 - review. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 0375402. PMID: NLM26919300. PY - 2016 SN - 0022-3018 SP - 217-220 ST - Psychological Aspects of Glaucoma T2 - Journal of Nervous & Mental Disease TI - Psychological Aspects of Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113702501&site=ehost-live&scope=site VL - 204 ID - 4523 ER - TY - JOUR AB - There is a disparity between the number of people who need healthcare and availability of medical services in rural areas. This paper describes the experience of using telemedicine technologies for ophthalmologic evaluation in diabetic and hypertensive patients presenting to a community health center in rural West Virginia. A registered nurse at a community health center in McDowell County, WV was trained to use a retinal camera to capture high-resolution digital images of the retina. Patients with diabetes or hypertension were screened during their routine primary care visits. Retinal photos were transmitted to an ophthalmologist for review and reports from the screenings were returned with instruction for follow-up care or specialist referral when indicated. A retrospective chart review of 643 patients with diabetes or hypertension who were screened for ocular problems from October 2003 to December 2009 was completed. 44.8% of patients who were screened in the primary care center were identified as having 1 of 34 types of eye pathology that were previously unknown, of which 33% of patients were recommended to seek prompt attention by a retina consultant or glaucoma specialist for suspected ocular pathology. Our review demonstrates the actual benefits of telemedicine in the effective screening of diabetic and hypertensive patients for eye pathology, and our experience suggests that using distance medicine and telemedicine technologies is valuable for screening rural populations. AD - Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, Huntington, United States AU - Ahmed, R. AU - Petrany, S. AU - Fry, R. AU - Krasnow, M. DB - Scopus IS - 1 M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2013 SP - 6-10 ST - Screening diabetic and hypertensive patients for ocular pathology using telemedicine technology in rural West Virginia: a retrospective chart review T2 - The West Virginia medical journal TI - Screening diabetic and hypertensive patients for ocular pathology using telemedicine technology in rural West Virginia: a retrospective chart review UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876337893&partnerID=40&md5=195a17bb7ae43133fb6e0f110cd98bba VL - 109 ID - 5282 ER - TY - JOUR AB - Purpose: To assess the efficacy and safety of switching from timolol 0.5% to brimonidine 0.1% in patients with glaucoma treated with a prostaglandin analog (PGA) and timolol combination. Methods: This prospective, open-label multicenter study enrolled patients with open-angle glaucoma or ocular hypertension who were being treated with a PGA and timolol. After baseline measurements, timolol was switched to brimonidine 0.1%, and patients were followed for 12 weeks. Patients visited at 4 and 12 weeks after switching. The main outcome measure was the change in intraocular pressure (IOP). For safety evaluations, hyperemia, formation of conjunctival follicles, superficial punctate keratopathy as a local side effect, blood pressure (BP), and heart rate (HR) were evaluated. Results: One hundred seven patients participated in this study. Among them, 103 patients completed the study. The IOP values at baseline, 4 weeks, and 12 weeks after the transition were 15.7±2.7, 14.3±2.8, and 14.0±2.8mmHg, respectively. IOP was significantly reduced at 4 and 12 weeks compared with baseline (p<0.001). There were no significant changes in hyperemia or follicle formation. The superficial punctate keratopathy score was significantly reduced at 12 weeks compared with baseline (p<0.05). Systolic and diastolic BP values were significantly reduced and HR significantly increased after switching (p<0.05). Conclusion: Switching from timolol 0.5% to brimonidine 0.1% may not change IOP in the combination use of timolol 0.5% and a PGA and was well tolerated by patients without severe ocular or systemic side effects. © Mary Ann Liebert, Inc. 2015. AD - Shirato Eye Clinic, 1-1-2 Yotsuya, Shinjuku, Tokyo, 160-0004, Japan Eye Rose Clinic, Tokyo, Japan Omiya Hamada Eye Clinic, Kanagawa, Japan Honda Eye Clinic, Kanagawa, Japan Koseki Eye Clinic, Saitama, Japan Matsuo Eye Clinic, Tokyo, Japan Miyata Eye Hospital, Miyazaki, Japan Kagoshima Miyata Eye Clinic, Miyazaki, Japan Unoki Eye Clinic, Kagoshima, Japan AU - Aihara, M. AU - Adachi, M. AU - Hamada, N. AU - Honda, N. AU - Koseki, N. AU - Matsuo, H. AU - Miyata, K. AU - Otani, S. I. AU - Unoki, K. DB - Scopus DO - 10.1089/jop.2014.0174 IS - 8 M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2015 SP - 482-486 ST - Effects of switching from timolol to brimonidine in prostaglandin analog and timolol combination therapy T2 - Journal of Ocular Pharmacology and Therapeutics TI - Effects of switching from timolol to brimonidine in prostaglandin analog and timolol combination therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943522979&doi=10.1089%2fjop.2014.0174&partnerID=40&md5=792b0d54374ba7ded9ec259c372b1eb0 VL - 31 ID - 5468 ER - TY - JOUR AD - [1] Manchester Royal Eye Hospital, Manchester, UK [2] University of Manchester, Manchester, UK. AN - 104915326. Language: English. Entry Date: 20110527. Revision Date: 20200708. Publication Type: Journal Article AU - Ajit, R. R. AU - Fenerty, C. H. AU - Henson, D. B. DB - ccm DO - 10.1038/eye.2010.27 DP - EBSCOhost IS - 8 KW - Antihypertensive Agents -- Administration and Dosage Prostaglandins, Synthetic -- Analogs and Derivatives Drug Monitoring -- Equipment and Supplies Glaucoma -- Drug Therapy Medication Compliance Adult Aged Aged, 80 and Over Prostaglandins, Synthetic -- Administration and Dosage Prospective Studies Female Human Male Middle Age Ophthalmic Solutions -- Administration and Dosage N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM20339390. PY - 2010 SN - 0950-222X SP - 1338-1343 ST - Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid T2 - Eye TI - Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104915326&site=ehost-live&scope=site VL - 24 ID - 4483 ER - TY - JOUR AB - Aims and purpose To identify patterns and rates of adherence with travoprost eye drops using the Travatan dosing aid (TDA) and to present a method for graphically presenting adherence data. Methods A prospective observational cohort study of patients on travoprost (prostaglandin) monotherapy. Patients were dispensed a TDA and followed up after approximately 3 months of usage. Data were downloaded from the TDA into a computer for analysis. Analysis used inter-dose intervals (the time between each dosing) to look at adherence between days 4 and 75. Results In all, 100 patients were invited to participate, 53 agreed and complete TDA data sets were obtained from 37. In total 23 of the complete data sets showed good adherence (dosing within ±4 h of the agreed dosing time on >80% of occasions), 3 patients discontinued usage before 75 days, 4 showed frequent drug holidays (no dosing for ≥8 days) and 7 frequently missed doses with adherence rates of <60%. Of the 16 patients for whom no TDA data was obtained, 5 were lost to follow-up, 4 had faulty/damaged TDAs, 3 changed medication, 3 preferred not to use the TDA, and 1 was hospitalized. Conclusions There were four easily defined patterns of adherence; (1) good adherence; (2) discontinued usage; (3) frequent drug holidays; and (4) frequent missed doses with low adherence rates. A new method for graphically presenting adherence data helps clinicians identify the pattern of usage and is a valuable aid to the overall management of patients on travoprost therapy. © 2010 Macmillan Publishers Limited All rights reserved. AD - Manchester Royal Eye Hospital, Manchester, United Kingdom University of Manchester, Manchester Royal Eye Hospital, Oxford Road, Manchester M13 9WH, United Kingdom AU - Ajit, R. R. AU - Fenerty, C. H. AU - Henson, D. B. DB - Scopus DO - 10.1038/eye.2010.27 IS - 8 KW - adherence compliance glaucoma travatan dosing aid M3 - Article N1 - Cited By :20 Export Date: 19 July 2021 PY - 2010 SP - 1338-1343 ST - Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid T2 - Eye TI - Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955615657&doi=10.1038%2feye.2010.27&partnerID=40&md5=96ccddf64e673f0f8b41ae77109ea341 VL - 24 ID - 5142 ER - TY - JOUR AB - Aims and purpose To identify patterns and rates of adherence with travoprost eye drops using the Travatan dosing aid (TDA) and to present a method for graphically presenting adherence data. Methods A prospective observational cohort study of patients on travoprost (prostaglandin) monotherapy. Patients were dispensed a TDA and followed up after approximately 3 months of usage. Data were downloaded from the TDA into a computer for analysis. Analysis used inter-dose intervals (the time between each dosing) to look at adherence between days 4 and 75. Results In all, 100 patients were invited to participate, 53 agreed and complete TDA data sets were obtained from 37. In total 23 of the complete data sets showed good adherence (dosing within +/- 4 h of the agreed dosing time on 480% of occasions), 3 patients discontinued usage before 75 days, 4 showed frequent drug holidays (no dosing for >= 8 days) and 7 frequently missed doses with adherence rates of <60%. Of the 16 patients for whom no TDA data was obtained, 5 were lost to follow-up, 4 had faulty/damaged TDAs, 3 changed medication, 3 preferred not to use the TDA, and 1 was hospitalized. Conclusions There were four easily defined patterns of adherence; (1) good adherence; (2) discontinued usage; (3) frequent drug holidays; and (4) frequent missed doses with low adherence rates. A new method for graphically presenting adherence data helps clinicians identify the pattern of usage and is a valuable aid to the overall management of patients on travoprost therapy. Eye (2010) 24, 1338-1343; doi:10.1038/eye.2010.27; published online 26 March 2010 AN - WOS:000280830800007 AU - Ajit, R. R. AU - Fenerty, C. H. AU - Henson, D. B. DA - AUG DO - 10.1038/eye.2010.27 IS - 8 PY - 2010 SN - 0950-222X SP - 1338-1343 ST - Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid T2 - EYE TI - Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid VL - 24 ID - 6060 ER - TY - JOUR AD - Manchester Royal Eye Hospital, Manchester, United Kingdom University of Manchester, Manchester, United Kingdom AU - Ajit, R. R. AU - Fenerty, C. H. AU - Henson, D. B. DB - Scopus DO - 10.1038/eye.2011.113 IS - 9 M3 - Letter N1 - Cited By :1 Export Date: 19 July 2021 PY - 2011 SP - 1238-1239 ST - Response to Cate and Broadway T2 - Eye TI - Response to Cate and Broadway UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052610707&doi=10.1038%2feye.2011.113&partnerID=40&md5=bc5e7394c477cb7d4d3b470908f6c100 VL - 25 ID - 5639 ER - TY - JOUR AB - Purpose: The aim of this study was to compare the intraocular pressure (IOP) lowering efficacy and to determine patient preference based on ocular discomfort with fixed combination brinzolamide/timolol and fixed combination dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension who required a change in therapy due to elevated IOP while receiving IOP-lowering medication. Methods: This was a 3-month, randomized, double-blinded, active-controlled, parallel-group trial. Patients had open-angle glaucoma or ocular hypertension, which could not be controlled with monotherapy and were randomized to twice daily therapy with either brinzolamide 1%/timolol 0.5% or dorzolamide 2%/timolol 0.5%. IOP assessments were taken at 8 AM, 10 AM, and 4 PM at week 2 as well as at months 1, 2, and 3. Patients completed ocular discomfort assessments (based on stinging, burning, feeling of heat or warmth, or sharp pain) on their current IOP lowering therapy at baseline. Results: Of the 114 patients enrolled, 57 received Brinz/Tim and 57 received Dorz/Tim twice daily. Both medications produced statistically relevant IOP reductions, which were similar in both groups at each visit. The IOP reductions with Brinz/Tim ranged from 6.42 to 9.74 mmHg (26.09%-37.46%), whereas Dorz/Tim produced mean IOP reductions ranging from 8.16 to 12.41 mmHg (31.19%-41.44%) (P>0.05). Brinz/Tim showed significantly less ocular irritation (0.5% vs. 15.7%, respectively; P=0.0004) than Dorz/Tim. Conclusions: Both Brinz/Tim and Dorz/Tim showed similar significant and clinically relevant IOP-lowering efficacy, whereas Brinz/Tim provided superior outcomes in terms of ocular comfort. © Copyright 2013, Mary Ann Liebert, Inc. 2013. AD - B.I.S. Akçay, Umraniye Research and Training Hospital, Ophthalmology Clinic, Elmalikent Mahallesi Adem Yavuz Cad. No:1, Ümraniye, Istanbul, 34766, Turkey AU - Akçay, B. I. S. AU - Güney, E. AU - Bozkurt, K. T. AU - Ünlü, C. AU - Akçali, G. C1 - azarga(Alcon) cosopt(msd europe,United States) C2 - Alcon msd europe(United States) DB - Embase Medline DO - 10.1089/jop.2013.0102 IS - 10 KW - brinzolamide plus timolol dorzolamide plus timolol abnormal sensation adult article blurred vision burning sensation comparative effectiveness controlled study crossover procedure double blind procedure drug efficacy drug safety drug tolerability drug withdrawal eye discomfort eye irritation eye pain female human intraocular foreign body intraocular hypertension intraocular pressure major clinical study male open angle glaucoma outcome assessment parallel design patient compliance patient preference prospective study randomized controlled trial treatment duration azarga cosopt LA - English M3 - Article N1 - L370444403 2013-12-18 2013-12-24 PY - 2013 SN - 1080-7683 1557-7732 SP - 882-886 ST - The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension T2 - Journal of Ocular Pharmacology and Therapeutics TI - The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370444403&from=export http://dx.doi.org/10.1089/jop.2013.0102 VL - 29 ID - 2948 ER - TY - JOUR AB - Purpose: The aim of this study was to compare the intraocular pressure (IOP) lowering efficacy and to determine patient preference based on ocular discomfort with fixed combination brinzolamide/timolol and fixed combination dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension who required a change in therapy due to elevated IOP while receiving IOP-lowering medication. Methods: This was a 3-month, randomized, double-blinded, active-controlled, parallel-group trial. Patients had open-angle glaucoma or ocular hypertension, which could not be controlled with monotherapy and were randomized to twice daily therapy with either brinzolamide 1%/timolol 0.5% or dorzolamide 2%/timolol 0.5%. IOP assessments were taken at 8 AM, 10 AM, and 4 PM at week 2 as well as at months 1, 2, and 3. Patients completed ocular discomfort assessments (based on stinging, burning, feeling of heat or warmth, or sharp pain) on their current IOP lowering therapy at baseline. Results: Of the 114 patients enrolled, 57 received Brinz/Tim and 57 received Dorz/Tim twice daily. Both medications produced statistically relevant IOP reductions, which were similar in both groups at each visit. The IOP reductions with Brinz/Tim ranged from 6.42 to 9.74 mmHg (26.09%-37.46%), whereas Dorz/Tim produced mean IOP reductions ranging from 8.16 to 12.41 mmHg (31.19%-41.44%) (P>0.05). Brinz/Tim showed significantly less ocular irritation (0.5% vs. 15.7%, respectively; P=0.0004) than Dorz/Tim. Conclusions: Both Brinz/Tim and Dorz/Tim showed similar significant and clinically relevant IOP-lowering efficacy, whereas Brinz/Tim provided superior outcomes in terms of ocular comfort. © Copyright 2013, Mary Ann Liebert, Inc. 2013. AD - Umraniye Research and Training Hospital, Ophthalmology Clinic, Elmalikent Mahallesi Adem Yavuz Cad. No:1, Ümraniye, Istanbul, 34766, Turkey AU - Akçay, B. I. S. AU - Güney, E. AU - Bozkurt, K. T. AU - Ünlü, C. AU - Akçali, G. DB - Scopus DO - 10.1089/jop.2013.0102 IS - 10 M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2013 SP - 882-886 ST - The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension T2 - Journal of Ocular Pharmacology and Therapeutics TI - The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890038970&doi=10.1089%2fjop.2013.0102&partnerID=40&md5=0ddc78dd02c9118a33fee49dc635c147 VL - 29 ID - 5253 ER - TY - JOUR AB - Purpose: To compare the toxicity effect of polyquaternium (PQ) and benzalkonium chloride (BAK) preservation of travoprost on the ocular surface. Methods: This prospective study included 44 eyes of 44 patients with newly diagnosed glaucoma. Twenty-two patients used PQ-preserved travoprost (PQ group) and 22 patients used BAK-preserved travoprost (BAK group). To investigate the effect on the ocular surface, conjunctival impression cytology (IC) was performed at baseline and the 1-and 6-month follow-up visits. Additionally, the ocular surface disease index (OSDI) questionnaire, Schirmer I test, and tear break-up time (TBUT) measurement were administered at baseline, and at 1-, 3-, and 6-month follow-up visits. Results: While both groups showed statistically significant IC grade increases at 1 and 6 months when compared with baseline measurements, IC grades were significantly higher for patients using PQ-preserved travoprost compared with patients using BAK-preserved travoprost. The Schirmer I test and TBUT scores were not statistically significant between group 1 and BAK group at baseline and at 1-, 3-, and 6-month visits (P>0.05). OSDI scores did not statistically differ at baseline and the 1-month measurements between the 2 groups (P>0.05), but the 3-and 6-month OSDI scores were significantly higher for BAK group (P=0.001). Differences in OSDI and Schirmer I test scores were statistically significant at 1, 3, and 6 months in both groups as compared with baseline values (P<0.05). Statistically significant differences in the TBUT scores were seen for both groups at 3 and 6 months, while BAK group, but not PQ group, had insignificant score differences at 1 month as compared with baseline values of PQ group (P=0.083). Conclusion: PQ-preserved travoprost was found to be safer and better-tolerated than BAK-preserved travoprost. PQ-preserved travoprost provided better ocular surface comfort, and therefore a better patient experience, which would likely result in higher treatment compliance. © 2014 Mary Ann Liebert, Inc. AD - Umraniye Research and Training Hospital, Eye Clinic, Elmalýkent Mahallesi Adem Yavuz Cad. No:1 Umraniye, Istanbul, 34766, Turkey Umraniye Research and Training Hospital, Pathology Clinic, Istanbul, Turkey Department of Ophthalmology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey AU - Akçay, B. I. S. AU - Güney, E. AU - Bozkurt, T. K. AU - Topal, C. S. AU - Akkan, J. C. U. AU - Ünlü, C. DB - Scopus DO - 10.1089/jop.2013.0248 IS - 7 M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2014 SP - 548-553 ST - Effects of polyquaternium-and benzalkonium-chloride-preserved travoprost on ocular surfaces: An impression cytology study T2 - Journal of Ocular Pharmacology and Therapeutics TI - Effects of polyquaternium-and benzalkonium-chloride-preserved travoprost on ocular surfaces: An impression cytology study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906963436&doi=10.1089%2fjop.2013.0248&partnerID=40&md5=dfa1cb090fb634cd798d5cfae1e63a1d VL - 30 ID - 5280 ER - TY - JOUR AB - Purpose: To compare the toxicity effect of polyquaternium (PQ) and benzalkonium chloride (BAK) preservation of travoprost on the ocular surface. Methods: This prospective study included 44 eyes of 44 patients with newly diagnosed glaucoma. Twenty-two patients used PQ-preserved travoprost (PQ group) and 22 patients used BAK-preserved travoprost (BAK group). To investigate the effect on the ocular surface, conjunctival impression cytology (IC) was performed at baseline and the 1- and 6-month follow-up visits. Additionally, the ocular surface disease index (OSDI) questionnaire, Schirmer I test, and tear break-up time (TBUT) measurement were administered at baseline, and at 1-, 3-, and 6-month follow-up visits. Results: While both groups showed statistically significant IC grade increases at 1 and 6 months when compared with baseline measurements, IC grades were significantly higher for patients using PQ-preserved travoprost compared with patients using BAK-preserved travoprost. The Schirmer I test and TBUT scores were not statistically significant between group 1 and BAK group at baseline and at 1-, 3-, and 6-month visits (P > 0.05). OSDI scores did not statistically differ at baseline and the 1-month measurements between the 2 groups (P > 0.05), but the 3- and 6-month OSDI scores were significantly higher for BAK group (P = 0.001). Differences in OSDI and Schirmer I test scores were statistically significant at 1, 3, and 6 months in both groups as compared with baseline values (P < 0.05). Statistically significant differences in the TBUT scores were seen for both groups at 3 and 6 months, while BAK group, but not PQ group, had insignificant score differences at 1 month as compared with baseline values of PQ group (P = 0.083). Conclusion: PQ-preserved travoprost was found to be safer and better-tolerated than BAK-preserved travoprost. PQ-preserved travoprost provided better ocular surface comfort, and therefore a better patient experience, which would likely result in higher treatment compliance. AN - WOS:000341737200005 AU - Akcay, B. I. S. AU - Guney, E. AU - Bozkurt, T. K. AU - Topal, C. S. AU - Akkan, J. C. U. AU - Unlu, C. DA - SEP DO - 10.1089/jop.2013.0248 IS - 7 PY - 2014 SN - 1080-7683 1557-7732 SP - 548-553 ST - Effects of Polyquaternium- and Benzalkonium-Chloride-Preserved Travoprost on Ocular Surfaces: An Impression Cytology Study T2 - JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS TI - Effects of Polyquaternium- and Benzalkonium-Chloride-Preserved Travoprost on Ocular Surfaces: An Impression Cytology Study VL - 30 ID - 6073 ER - TY - JOUR AB - Treatment for several major age-related ocular diseases has undergone a paradigm shift in recent years. Advances in basic science and clinical research have led to a more thorough understanding of the complex pathophysiology underlying common ocular diseases of aging, and to the development of highly effective new therapies for these conditions. The use of intraocular anti-angiogenic drugs, for example, has transformed the management of neovascular age-related macular degeneration and diabetic retinopathy. Many patients achieve impressive and durable gains in vision with these agents that were unattainable with older treatments. For glaucoma and dry eye disease, clinicians have a variety of pharmacologic and surgical options to choose from. However, significant challenges remain: not all patients respond to treatment, many older patients have difficulty complying with complex drug regimens, frequent office visits put a substantial strain on patients and caregivers, and therapies may cause unpleasant side effects. This article reviews the current treatment landscape for 4 major age-related ocular diseases: age-related macular degeneration, glaucoma, diabetic retinopathy, and dry eye. AD - Division of Cornea, Cataract, and External Diseases, Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD, United States AU - Akpek, E. K. AU - Smith, R. A. DB - Scopus IS - 5 SUPPL. M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2013 SP - S76-S84 ST - Current treatment strategies for age-related ocular conditions T2 - American Journal of Managed Care TI - Current treatment strategies for age-related ocular conditions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894420260&partnerID=40&md5=1942dce025db676c0ea9786ef94fda51 VL - 19 ID - 5361 ER - TY - JOUR AB - Renal transplantation is the surgical implantation of a human kidney from a compatible donor into a recipient. Renal transplantation is a means of restoring renal function to normal in most patients, thus allowing a return to a healthy lifestyle. Patients and their families often ask nurses for health information. Professional nurses must ensure that patients and families understand the transplantation and therapeutic regimen and provide health education. It should be remembered that certain physiological, psychosocial and pathological conditions might inhibit the education process. Before renal transplantation the patient's understanding of the procedure and follow-up regimen and also the patient's ability to cope with a complex medication regimen are assessed. The nurse and the patient and family should work together to set realistic, achievable goals, the aims of which are mutually agreed. The agreed goals of health education should be documented in a care plan, which will also provide reinforcement for both the nurse and patient. AD - College of Nursing, Istanbul University, Istanbul, Turkey Istanbul Univ. Hemsirel. Yuksekokulu, Abide-i Hurriyet Cad. 80270, Istanbul, Turkey AU - Akyolcu, N. DB - Scopus DO - 10.1111/j.1755-6686.2002.tb00240.x IS - 4 KW - Home care Patient education Renal transplant M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2002 SP - 176-179 ST - Patient education in renal transplantation T2 - EDTNA-ERCA Journal TI - Patient education in renal transplantation UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036826225&doi=10.1111%2fj.1755-6686.2002.tb00240.x&partnerID=40&md5=0ff3678be965b6c5e610a51b54614c4e VL - 28 ID - 5537 ER - TY - JOUR AB - Purpose: To assess the effectiveness and safety of a single iStent trabecular micro-bypass stent implantation in combination with cataract surgery in lowering the intra ocular pressure (IOP) and number of anti-glaucoma medications in Saudi patients with open-angle glaucoma (OAG). Setting: King Fahad Hospital of the University, Al Khobar, Saudi Arabia. Design: Prospective, non-comparative, uncontrolled, non-randomized interventional case series. Methods: One iStent was implanted during phacoemulsification cataract surgery for adult patients with OAG by a single surgeon over a period of 3 years. Main outcome measures include number of anti-glaucoma medications, IOP, corrected distance visual acuity (CDVA) and complications. Results: Thirty-six eyes of 33 patients with OAG underwent the surgery. The pre-operative mean IOP and mean anti-glaucoma medications were 17.47 +/- 5.44 mmHg and 2.69 +/- 0.92, respectively. At 1 year of follow-up mean, IOP decreased to 13.44 +/- 1.99 (23.1% reduction) (P<0.001) and mean anti-glaucoma medications decreased to 1.47 +/- 1.13 (45.4% reduction) (P<0.001). Conclusion: After 12-month follow-up, phacoemulsification with the implantation of a single iStent seems to be an effective and safe procedure to lower IOP and the number of anti-glaucoma medications, and to overcome the problems associated with medication nonadherence in OAG patients with cataracts. AN - WOS:000541011800001 AU - Al Habash, A. AU - Khan, O. DO - 10.2147/OPTH.S249261 PY - 2020 SN - 1177-5483 SP - 1573-1580 ST - Outcomes of Combined iStent Trabecular Micro-Bypass and Cataract Surgery for the Treatment of Open-Angle Glaucoma in a Saudi Population T2 - CLINICAL OPHTHALMOLOGY TI - Outcomes of Combined iStent Trabecular Micro-Bypass and Cataract Surgery for the Treatment of Open-Angle Glaucoma in a Saudi Population VL - 14 ID - 6014 ER - TY - JOUR AB - Introduction: Endoscopic diode cycloablation (ECP) has shown modest efficacy for the management of pediatric glaucomas. Eyes with pediatric glaucoma and corneal opacities pose obstacles to intraocular surgery. We examined the role of ECP in lowering intraocular pressure (IOP) as well as that of endoscopy in facilitating tube shunt placement in these eyes. Methods: Retrospective chart review of 12 eyes (11 patients) with glaucoma and corneal opacities from 12/99 to 9/05. ECP was performed for IOP control with success defined as postoperative IOP ≤21 mm Hg, with or without medications and without procedure-related complications. Success of ECP, repeat ECP, and endoscopically guided tube shunt placement was studied. Results: Diagnoses included the following: Peters/anterior segment dysgenesis in nine eyes and corneal scar/failed corneal graft in three. Patients included eight females and three males with median age 3 years (0.5 to 10.3) at treatment. Median number of prior surgeries was three; median time to failure was 7.8 months (0.3 to 38). Ten eyes had prior external cycloablation(s). Success of first ECP (mean 6.1 clock hours) was 2/12 (17%), with Kaplan-Meier median survival 12 months. Two treatment failures had repeat ECP, and both failed. Four treatment failures had subsequent tube shunt surgery (three with endoscopic assistance), and all were successful at median follow-up of 33 months (11 to 63). Baseline IOP was 36.8 ± 11 mm Hg before ECP versus 28.2 ± 16 mm Hg after first treatment (p = 0.07). Procedure-related complications included chorioretinal detachment in one eye. Conclusions: ECP had limited success in children with refractory glaucoma. However, with anatomic limitations, endoscopy itself was valuable in facilitating subsequent successful tube shunt surgery. © 2007 American Association for Pediatric Ophthalmology and Strabismus. AD - Duke University Eye Center, Durham, NC, United States AU - Al-Haddad, C. E. AU - Freedman, S. F. DB - Scopus DO - 10.1016/j.jaapos.2006.08.005 IS - 1 M3 - Article N1 - Cited By :28 Export Date: 19 July 2021 PY - 2007 SP - 23-28 ST - Endoscopic laser cyclophotocoagulation in pediatric glaucoma with corneal opacities T2 - Journal of AAPOS TI - Endoscopic laser cyclophotocoagulation in pediatric glaucoma with corneal opacities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33847247393&doi=10.1016%2fj.jaapos.2006.08.005&partnerID=40&md5=332f9d76e73ad01638512a7fb2dee877 VL - 11 ID - 5074 ER - TY - JOUR AB - INTRODUCTION Endoscopic diode cycloablation (ECP) has shown modest efficacy for the management of pediatric glaucomas. Eyes with pediatric glaucoma and corneal opacities pose obstacles to intraocular surgery. We examined the role of ECP in lowering intraocular pressure (IOP) as well as that of endoscopy in facilitating tube shunt placement in these eyes. METHODS Retrospective chart review of 12 eyes (11 patients) with glaucoma and corneal opacities from 12/99 to 9/05. ECP was performed for IOP control with success defined as postoperative IOP <= 21 mm Hg, with or without medications and without procedure-related complications. Success of ECP, repeat ECP, and endoscopically guided tube shunt placement was studied. RESULTS Diagnoses included the following: Peters/anterior segment dysgenesis in nine eyes and corneal scar/failed corneal graft in three. Patients included eight females and three males with median age 3 years (0.5 to 10.3) at treatment. Median number of prior surgeries was three; median time to failure was 7.8 months (0.3 to 3 8). Ten eyes had prior external cycloablation(s). Success of first ECP (mean 6.1 clock hours) was 2/12 (17%), with Kaplan-Meier median survival 12 months. Two treatment failures had repeat ECP, and both failed. Four treatment failures had subsequent tube shunt surgery (three with endoscopic assistance), and all were successful at median follow-up of 33 months (11 to 63). Baseline IOP was 36.8 +/- 11 mm Hg before ECP versus 28.2 +/- 16 mm Hg after first treatment (p = 0.07). Procedure-related complications included chorioretinal detachment in one eye. CONCLUSIONS ECP had limited success in children with refractory glaucoma. However, with anatomic limitations, endoscopy itself was valuable in facilitating subsequent successful tube shunt surgery. AN - WOS:000244587300007 AU - Al-Haddad, C. E. AU - Freedman, S. F. DA - FEB DO - 10.1016/j.jaapos.2006.08.005 IS - 1 PY - 2007 SN - 1091-8531 SP - 23-28 ST - Endoscopic laser cyclophotocoagulation in pediatric glaucoma with corneal opacities T2 - JOURNAL OF AAPOS TI - Endoscopic laser cyclophotocoagulation in pediatric glaucoma with corneal opacities VL - 11 ID - 6190 ER - TY - JOUR AB - Purpose : To define the main causes of blindness, demographic characteristics and barriers to care of blind patients attending a teaching eye hospital in Iraq. Material and Method : Successive new patients, 6 years of age and older, who attended three outpatients clinics at Ibn Al-Haetham Teaching Eye Hospital (IAHTEH), Baghdad, Iraq, from September 1 to November 30, 2007, were included in this study. Inclusion criterion was fulfillment of the World Health Organization′s definition of blindness. The cause of blindness was identified and subjects were interviewed for collection of data on demographic characteristics and barriers to treatment. Results : Of 18612 consecutive patients who attended the outpatient clinics, 497 (2.7%) patients were blind. Cataract (76.1%), diabetic retinopathy (12.9%), and glaucoma (5%) were the leading causes of blindness. The majority of blind patients had low socioeconomic status and poor educational level. In cases of cataract, the most important barrier to treatment was the waiting list at the hospital (53.7%). A lack of awareness was the most important barrier to treatment for patients with diabetic retinopathy (54.7%) and glaucoma (56%). Conclusions : The preliminary data from our study will aid in the development of blindness prevention programs in Iraq. Priorities include decreasing waiting lists for cataract surgeries at governmental hospitals. Active health promotion programs for early detection and treatment of diabetic retinopathy and glaucoma are also warranted. AD - F.I. Al-Shakarchi, Department of Ophthalmology Medical College, Ibn Al-Haetham Teaching Eye Hospital, Al-Mustanserya University, Baghdad, Iraq AU - Al-Shakarchi, F. I. DB - Embase DO - 10.4103/0974-9233.84044 IS - 3 KW - adolescent adult age aged article awareness blast injury blindness cataract child cornea dystrophy demography diabetic retinopathy educational status eye injury female glaucoma health care access hospital admission human interview Iraq keratitis major clinical study male optic nerve atrophy outpatient care pathogenesis patient care preschool child priority journal refraction error retina detachment retina dystrophy age related macular degeneration school child social status teaching hospital urban rural difference uveitis LA - English M3 - Article N1 - L362501043 2011-09-14 2011-09-19 PY - 2011 SN - 0974-9233 0975-1599 SP - 199-203 ST - Blindness in Iraq: Leading causes, target patients, and barriers to treatment T2 - Middle East African Journal of Ophthalmology TI - Blindness in Iraq: Leading causes, target patients, and barriers to treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362501043&from=export http://dx.doi.org/10.4103/0974-9233.84044 VL - 18 ID - 3163 ER - TY - JOUR AB - Purpose: To describe the variations in intraoperative technique, postoperative complications, and visual outcomes associated with Descemet stripping endothelial keratoplasty (DSEK) after Ophtec iris reconstruction lens implantation. Design: Retrospective, interventional, consecutive case series. Participants: Patients who underwent DSEK after Ophtec 311 iris reconstruction lens implantation at the Jules Stein Eye Institute, University of California, Los Angeles. Methods: Medical records were reviewed for demographic information, ophthalmic history, DSEK surgical technique, and postoperative clinical course. Main Outcome Measures: Intraoperative and postoperative complications and visual outcomes. Results: Four patients were identified (1 man and 3 women, age: 43-78). Three of the eyes had undergone prior penetrating keratoplasty (PKP), and each of the eyes had a history of glaucoma, with previous glaucoma surgery having been performed in 2 of the eyes. No intraoperative complications were encountered during the procedures, although an unplanned anterior vitrectomy was required in a previously vitrectomized eye. In each case, a complete air fill of the globe was obtained to ensure adherence of the donor button, and in 3 of the 4 cases, the donor button was sutured to the recipient cornea to prevent potential posterior dislocation. None of the cases developed donor button dislocation or primary graft failure. Corrected distance visual acuities improved to 20/40-20/160, corresponding to a mean improvement of 0.25 (range, 0.12-0.40), limited by irregular corneal astigmatism and advanced glaucomatous optic neuropathy. During a mean follow-up period of 15.6 months (range, 4.9-24.8 months), graft rejection developed in 2 of the 3 eyes with a history of endothelial rejection after PKP (0.42 episode per eye-year). Both of these eyes developed secondary graft failure, which also developed 14 months after DSEK in the other eye with a history of PKP failure before DSEK. Conclusions: DSEK can be successfully performed in eyes with partial or complete aniridia, such as those after Ophtec iris reconstruction lens implantation. Modifications to the standard DSEK technique increase the probability of successful donor adherence and decrease the risk of posterior dislocation of the donor corneal button. However, endothelial rejection may occur at an increased frequency, resulting in secondary graft failure. Copyright © 2011 by Lippincott Williams & Wilkins. AD - Jules Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095, United States AU - Aldave, A. J. AU - Baghdasaryan, E. AU - Miller, K. M. DB - Scopus DO - 10.1097/ICO.0b013e3181f237c4 IS - 4 KW - Descemet stripping endothelial keratoplasty (DSEK) Ophtec 311 iris reconstruction lens implantation M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2011 SP - 405-408 ST - Descemet stripping endothelial keratoplasty after ophtec 311 iris reconstruction lens implantation T2 - Cornea TI - Descemet stripping endothelial keratoplasty after ophtec 311 iris reconstruction lens implantation UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952994319&doi=10.1097%2fICO.0b013e3181f237c4&partnerID=40&md5=4502c8242e2dd799a69f90b59761f384 VL - 30 ID - 5578 ER - TY - JOUR AB - Purpose: To describe the variations in intraoperative technique, postoperative complications, and visual outcomes associated with Descemet stripping endothelial keratoplasty (DSEK) after Ophtec iris reconstruction lens implantation. Design: Retrospective, interventional, consecutive case series. Participants: Patients who underwent DSEK after Ophtec 311 iris reconstruction lens implantation at the Jules Stein Eye Institute, University of California, Los Angeles. Methods: Medical records were reviewed for demographic information, ophthalmic history, DSEK surgical technique, and postoperative clinical course. Main Outcome Measures: Intraoperative and postoperative complications and visual outcomes. Results: Four patients were identified (1 man and 3 women, age: 43-78). Three of the eyes had undergone prior penetrating keratoplasty (PKP), and each of the eyes had a history of glaucoma, with previous glaucoma surgery having been performed in 2 of the eyes. No intraoperative complications were encountered during the procedures, although an unplanned anterior vitrectomy was required in a previously vitrectomized eye. In each case, a complete air fill of the globe was obtained to ensure adherence of the donor button, and in 3 of the 4 cases, the donor button was sutured to the recipient cornea to prevent potential posterior dislocation. None of the cases developed donor button dislocation or primary graft failure. Corrected distance visual acuities improved to 20/40-20/160, corresponding to a mean improvement of 0.25 (range, 0.12-0.40), limited by irregular corneal astigmatism and advanced glaucomatous optic neuropathy. During a mean follow-up period of 15.6 months (range, 4.9-24.8 months), graft rejection developed in 2 of the 3 eyes with a history of endothelial rejection after PKP (0.42 episode per eye-year). Both of these eyes developed secondary graft failure, which also developed 14 months after DSEK in the other eye with a history of PKP failure before DSEK. Conclusions: DSEK can be successfully performed in eyes with partial or complete aniridia, such as those after Ophtec iris reconstruction lens implantation. Modifications to the standard DSEK technique increase the probability of successful donor adherence and decrease the risk of posterior dislocation of the donor corneal button. However, endothelial rejection may occur at an increased frequency, resulting in secondary graft failure. AN - WOS:000288196200007 AU - Aldave, A. J. AU - Baghdasaryan, E. AU - Miller, K. M. DA - APR DO - 10.1097/ICO.0b013e3181f237c4 IS - 4 PY - 2011 SN - 0277-3740 SP - 405-408 ST - Descemet Stripping Endothelial Keratoplasty After Ophtec 311 Iris Reconstruction Lens Implantation T2 - CORNEA TI - Descemet Stripping Endothelial Keratoplasty After Ophtec 311 Iris Reconstruction Lens Implantation VL - 30 ID - 6310 ER - TY - JOUR AB - Objectives: Geriatric patients can be non-adherent to ophthalmic glaucoma medications because of complex eye drops instillation techniques and forgetfulness, so pharmacists can play their part in improving the clinical outcomes of patients by acting as care providers. The purpose of the current study was to implement various pharmacist-led interventions to improve adherence to glaucoma medications and to evaluate the outcomes of interventions in the geriatric population. Methods: The Morisky Green Levine (MGL) adherence scale was used for analysis because it measures the extent of non-adherence and analyses the reasons for it. The interview-based sessions were conducted with control and interventional groups followed by educational interventions, including techniques for eye drop instillation, graphical images, precautionary measures, and individual patient counselling for the interventional group. Patients were asked to complete the adherence scale after the conclusion of every follow-up session for a duration of 6 months. Results: After 6 months of pharmacist-led interventions, a significant shift was found in the interventional group from low to high adherence according to MGL scale evaluation. Moreover, the number of patients in the interventional group whose intraocular pressure was in the safe range significantly increased and follow-up sessions significantly improved the patient's knowledge about glaucoma. Conclusion: The results of this pharmacist-led educational interventional study showed it was effective in improving adherence to glaucoma medications in the geriatric patients, who showed better adherence scores and improved intraocular pressure. © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ. AD - Lahore College for Women University, Lahore, Pakistan Department of Pharmaceutics, University of Sargodha, Sargodha, Pakistan University of Lahore, Lahore, Pakistan Department of Pharmacy, District Head Quarter Hospital, Chiniot, Pakistan AU - Aleem, A. AU - Amin, F. AU - Asim, M. H. AU - Farooq, N. AU - Arshad, S. AU - Raziq, M. DB - Scopus DO - 10.1136/ejhpharm-2021-002788 KW - continuing education geriatrics hospital pharmacy pharmacy service primary health care public health quality of health care M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 ST - Impact of pharmacist-led interventions in improving adherence to glaucoma medications in the geriatric population T2 - European Journal of Hospital Pharmacy TI - Impact of pharmacist-led interventions in improving adherence to glaucoma medications in the geriatric population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109515394&doi=10.1136%2fejhpharm-2021-002788&partnerID=40&md5=cbcaeb8dd3a7342acc1fbd020eb19c85 ID - 5668 ER - TY - JOUR AB - PURPOSE. To determine the incidence of progression of primary open-angle glaucoma at individual levels of mean intraocular pressure (IOP) in patients in Ethiopia. METHODS. A retrospective, multicenter, cohort analysis of patient records with at least 5 years of potential follow-up were evaluated for risk factors associated with progressive optic disc and visual field loss. RESULTS. There were 300 patients with the potential of 5 years of follow-up. In total, 166 patients progressed before 5 years and 134 remained stable for the full 5-year follow-up period. Of the total sample, 84% of patients with IOPs ≤19 (n=117/139), 53% of patients with IOPs of 20 (n=9/17), 14% of patients with IOPs of 21-24 (n=9/63), and 0% of the patients with IOPs of ≥25 mmHg (n=0/79) remained stable over at least 5 years. The mean IOP was 17.4±2.1 in the stable group and 25.0±5.9 mmHg in the progressed group (p<0.0001). The highest average peak IOP was 24.5±4.5 in the stable group and 29.0±6.1 mmHg in the progressed group (p<0.0001). A multivariant regression analysis to determine risk factors for progression was positive for mean IOP (p=0.0097). CONCLUSIONS. This study suggests that IOP reduction in a developing country, despite potential limitations in diagnostic techniques, follow-up, and compliance, can be effective in reducing the risk of glaucomatous progression over long-term follow-up. © 2009 Wichtig Editore. AD - W. C. Stewart, 5430 LBJ Freeway, Dallas, TX 75240, United States AU - Alemu, A. M. AU - Kristoffersen, C. J. AU - Kristoffersen, M. S. AU - Stewart, J. A. AU - Stewart, W. C. DB - Embase Medline DO - 10.1177/112067211002000209 IS - 2 KW - aged article cohort analysis controlled study developing country disease course Ethiopia female follow up human intraocular pressure major clinical study male open angle glaucoma outcome assessment priority journal religion retrospective study risk factor trabeculectomy visual acuity LA - English M3 - Article N1 - L358895097 2010-06-04 2010-11-25 2021-04-26 PY - 2010 SN - 1120-6721 SP - 310-315 ST - Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia T2 - European Journal of Ophthalmology TI - Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358895097&from=export http://dx.doi.org/10.1177/112067211002000209 VL - 20 ID - 3288 ER - TY - JOUR AB - PURPOSE. To determine the incidence of progression of primary open-angle glaucoma at individual levels of mean intraocular pressure (IOP) in patients in Ethiopia. METHODS. A retrospective, multicenter, cohort analysis of patient records with at least 5 years of potential follow-up were evaluated for risk factors associated with progressive optic disc and visual field loss. RESULTS. There were 300 patients with the potential of 5 years of follow-up. In total, 166 patients progressed before 5 years and 134 remained stable for the full 5-year follow-up period. Of the total sample, 84% of patients with IOPs ≤19 (n=117/139), 53% of patients with IOPs of 20 (n=9/17), 14% of patients with IOPs of 21-24 (n=9/63), and 0% of the patients with IOPs of ≥25 mmHg (n=0/79) remained stable over at least 5 years. The mean IOP was 17.4±2.1 in the stable group and 25.0±5.9 mmHg in the progressed group (p<0.0001). The highest average peak IOP was 24.5±4.5 in the stable group and 29.0±6.1 mmHg in the progressed group (p<0.0001). A multivariant regression analysis to determine risk factors for progression was positive for mean IOP (p=0.0097). CONCLUSIONS. This study suggests that IOP reduction in a developing country, despite potential limitations in diagnostic techniques, follow-up, and compliance, can be effective in reducing the risk of glaucomatous progression over long-term follow-up. © 2009 Wichtig Editore. AD - Ras Desta Hospital, Addis Ababa, Ethiopia Charleston Research Company, LLC, Charleston, SC, United States PRN Pharmaceutical Research Network, LLC, Dallas, TX, United States AU - Alemu, A. M. AU - Kristoffersen, C. J. AU - Kristoffersen, M. S. AU - Stewart, J. A. AU - Stewart, W. C. DB - Scopus DO - 10.1177/112067211002000209 IS - 2 KW - Africa Ethiopia Glaucoma Intraocular pressure Primary open-angle glaucoma Target pressure M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2010 SP - 310-315 ST - Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia T2 - European Journal of Ophthalmology TI - Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952863026&doi=10.1177%2f112067211002000209&partnerID=40&md5=3e2f4267e2f79a06d8d13b5a430e911e VL - 20 ID - 5581 ER - TY - JOUR AB - PURPOSE. To determine the incidence of progression of primary open-angle glaucoma at individual levels of mean intraocular pressure (IOP) in patients in Ethiopia. METHODS. A retrospective, multicenter, cohort analysis of patient records with at least 5 years of potential follow-up were evaluated for risk factors associated with progressive optic disc and visual field loss. RESULTS. There were 300 patients with the potential of 5 years of follow-up. In total, 166 patients progressed before 5 years and 134 remained stable for the full 5-year follow-up period. Of the total sample, 84% of patients with IOPs <= 19 (n = 117/139), 53% of patients with IOPs of 20 (n = 9/17), 14% of patients with IOPs of 21-24 (n = 9/63), and 0% of the patients with IOPs of >= 25 mmHg (n = 0/79) remained stable over at least 5 years. The mean IOP was 17.4 +/- 2.1 in the stable group and 25.0 +/- 5.9 mmHg in the progressed group (p < 0.0001). The highest average peak IOP was 24.5 +/- 4.5 in the stable group and 29.0 +/- 6.1 mmHg in the progressed group (p < 0.0001). A multivariant regression analysis to determine risk factors for progression was positive for mean IOP (p = 0.0097). CONCLUSIONS. This study suggests that IOP reduction in a developing country, despite potential limitations in diagnostic techniques, follow-up, and compliance, can be effective in reducing the risk of glaucomatous progression over long-term follow-up. (Eur J Ophthalmol 2010; 20: 310-5) AN - WOS:000278793200009 AU - Alemu, A. M. AU - Kristoffersen, C. J. AU - Kristoffersen, M. S. AU - Stewart, J. A. AU - Stewart, W. C. DA - MAR-APR IS - 2 PY - 2010 SN - 1120-6721 1724-6016 SP - 310-315 ST - Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia T2 - EUROPEAN JOURNAL OF OPHTHALMOLOGY TI - Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia VL - 20 ID - 6003 ER - TY - JOUR AB - Primary open-angle glaucoma offers a significant diagnostic and management challenge for primary care providers. Uncertainty clouds the definition of the disease, its prevalence, the sensitivity and accuracy of the clinical tests used for its diagnosis, the efficacy of antiglaucoma medications, the compliance of patients with these drug regimens, the appropriate use of follow-up examinations, and the use of surgical techniques in lieu of medical management. This discussion addresses these many vexing issues for the purpose of assisting primary care providers to better diagnose and manage glaucoma patients. AU - Alexander, L. J. DB - Scopus IS - 1 M3 - Review N1 - Cited By :10 Export Date: 19 July 2021 PY - 1991 SP - 19-102 ST - Diagnosis and management of primary open-angle glaucoma T2 - Optometry clinics : the official publication of the Prentice Society TI - Diagnosis and management of primary open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026280173&partnerID=40&md5=a47411e3358299b7bdbb0055adaaedfe VL - 1 ID - 5295 ER - TY - JOUR AB - Introduction: Fixed-combination glaucoma medications are commonly used to achieve target intraocular pressure (IOP) reduction in patients uncontrolled with monotherapy; however, ocular discomfort associated with eye drops can decrease adherence. This study assessed the efficacy and tolerability of twice-daily fixed-combination brinzolamide 1%/timolol 0.5% (BRINZ/TIM-FC) in Latin American patients transitioned from fixed-combination brimonidine 0.2%/timolol 0.5% (BRIM/TIM-FC) because of insufficient IOP control or treatment intolerance.Methods: This 8-week, open-label, prospective study was conducted at six sites in Argentina, Chile, and Mexico. Enrolled patients were aged ≥18 years with open-angle glaucoma (including primary, exfoliative, or pigment-dispersion glaucoma) or ocular hypertension with IOP of 19-35 mmHg in ≥1 eye at baseline (on BRIM/TIM-FC). Patients self-administered BRINZ/TIM-FC to both eyes at 8 a.m. and 8 p.m. daily for 8 weeks. The primary and secondary efficacy endpoints were mean IOP change from baseline at week 8 and percentage of patients achieving target IOP (≤18 mmHg) at week 8, respectively. Exploratory endpoints included patient and investigator preference for treatment at week 8. Adverse events (AEs) were assessed as the safety endpoint.Results: Fifty patients (mean ± SD age, 66.7 ± 11.5 years) received BRINZ/TIM-FC, and 49 were included in the intent-to-treat population. Mean ± SD IOP was significantly reduced from baseline after 8 weeks of treatment with BRINZ/TIM-FC (-3.6 ± 3.0 mmHg; P < 0.0001, Wilcoxon signed-rank test; 17.1% reduction). Overall, 55.3% of patients achieved IOP ≤18 mmHg at week 8. Significantly more patients (89.4%) and investigators (95.7%) preferred BRINZ/TIM-FC to BRIM/TIM-FC (both P < 0.0001, exact binomial test). Of the 13 AEs observed, 8 were related to BRINZ/TIM-FC; the most common treatment-related AEs were eye irritation (n = 4) and abnormal sensation in the eye (n = 2).Conclusion: BRINZ/TIM-FC provides an effective and well-tolerated treatment option for patients transitioned from BRIM/TIM-FC. AN - 109679823. Language: English. Entry Date: 20150923. Revision Date: 20200708. Publication Type: journal article AU - Alezzandrini, Arturo AU - Hubatsch, Douglas AU - Alfaro, Rene DB - ccm DO - 10.1007/s12325-014-0145-5 DP - EBSCOhost IS - 9 N1 - clinical trial; research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8611864. PMID: NLM25138224. PY - 2014 SN - 0741-238X SP - 975-985 ST - Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination T2 - Advances in Therapy TI - Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109679823&site=ehost-live&scope=site VL - 31 ID - 4290 ER - TY - JOUR AB - Background: The pterygopalatine fossa (PPF) and inferomedial orbital apex are difficult regions for open neurosurgical access. The traditional extensive anterior approach (transfacial or transmandibular) and lateral/posterolateral (transcranial) approach were used to access the PPF. The combined endonasal and sublabial transmaxillary approach is a less invasive access route for these lesions. In this study, we present the technical and clinical details of our experience with the combined endoscopic endonasal and transmaxillary approach. Methods: A retrospective analysis of our patients operated on using a combined endoscopic endonasal and transmaxillary approach was done. The preoperative, intraoperative and postoperative images and all the clinical data were evaluated. The accessibility to the area and extent of surgical resection were reviewed. The surgery-related complications and postoperative morbidities were analyzed. The main items of interest were the exposure of the target area and possibility for safe removal. Results: Five patients with pathologies located in the area of the PPF and orbital apex were operated on using the combined endoscopic sublabial and endonasal transmaxillary approach. The technique provided sufficient exposure of the area and allowed for safe removal of the preoperatively determined target in all of the patients. One patient developed dry eye and a neurotrophic corneal ulcer, and another patient developed temporary postoperative facial numbness. In the follow-up, only one patient with skull base chordoma had an asymptomatic tumor regrowth. The other patients had no recurrence or regrowth. Conclusions: The combined endoscopic sublabial and endonasal transmaxillary approach is a safe and effective method for resection of lesions in the PPF and inferomedial orbital apex. © 2015, Springer-Verlag Wien. AD - International Neuroscience Institute, Rudolf Pichlmayr Street, No. 4, Hannover, 30625, Germany Iranian International Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran AU - Alimohamadi, M. AU - Hajiabadi, M. AU - Gerganov, V. AU - Fahlbusch, R. AU - Samii, M. DB - Scopus DO - 10.1007/s00701-015-2402-z IS - 6 KW - Endoscopic Infratemporal fossa Orbital apex Pterygopalatine fossa Skull base Sublabial Transmaxillary M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2015 SP - 919-929 ST - Combined endonasal and sublabial endoscopic transmaxillary approach to the pterygopalatine fossa and orbital apex T2 - Acta Neurochirurgica TI - Combined endonasal and sublabial endoscopic transmaxillary approach to the pterygopalatine fossa and orbital apex UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929707798&doi=10.1007%2fs00701-015-2402-z&partnerID=40&md5=db2859eb283943f8b3e993950b9c7de5 VL - 157 ID - 5250 ER - TY - JOUR AB - The pterygopalatine fossa (PPF) and inferomedial orbital apex are difficult regions for open neurosurgical access. The traditional extensive anterior approach (transfacial or transmandibular) and lateral/posterolateral (transcranial) approach were used to access the PPF. The combined endonasal and sublabial transmaxillary approach is a less invasive access route for these lesions. In this study, we present the technical and clinical details of our experience with the combined endoscopic endonasal and transmaxillary approach. A retrospective analysis of our patients operated on using a combined endoscopic endonasal and transmaxillary approach was done. The preoperative, intraoperative and postoperative images and all the clinical data were evaluated. The accessibility to the area and extent of surgical resection were reviewed. The surgery-related complications and postoperative morbidities were analyzed. The main items of interest were the exposure of the target area and possibility for safe removal. Five patients with pathologies located in the area of the PPF and orbital apex were operated on using the combined endoscopic sublabial and endonasal transmaxillary approach. The technique provided sufficient exposure of the area and allowed for safe removal of the preoperatively determined target in all of the patients. One patient developed dry eye and a neurotrophic corneal ulcer, and another patient developed temporary postoperative facial numbness. In the follow-up, only one patient with skull base chordoma had an asymptomatic tumor regrowth. The other patients had no recurrence or regrowth. The combined endoscopic sublabial and endonasal transmaxillary approach is a safe and effective method for resection of lesions in the PPF and inferomedial orbital apex. AN - WOS:000354706200005 AU - Alimohamadi, M. AU - Hajiabadi, M. AU - Gerganov, V. AU - Fahlbusch, R. AU - Samii, M. DA - JUN DO - 10.1007/s00701-015-2402-z IS - 6 PY - 2015 SN - 0001-6268 0942-0940 SP - 919-929 ST - Combined endonasal and sublabial endoscopic transmaxillary approach to the pterygopalatine fossa and orbital apex T2 - ACTA NEUROCHIRURGICA TI - Combined endonasal and sublabial endoscopic transmaxillary approach to the pterygopalatine fossa and orbital apex VL - 157 ID - 5903 ER - TY - SER AB - Curcumin has been successfully applied to treat inflammatory conditions in experimental research and in clinical trials. The purpose of our study is to evaluate the efficacy of an adjunctive-to-traditional treatment with Norflo tablets (curcumin-phosphatidylcholine complex; Meriva) administered twice a day in recurrent anterior uveitis of different etiologies. The study group consisted of 106 patients who completed a 12-month follow-up therapeutic period. We divided the patients into three main groups of different uveitis origin: group 1 (autoimmune uveitis), group 2 (herpetic uveitis), and group 3 (different etiologies of uveitis). The primary end point of our work was the evaluation of relapse frequency in all treated patients, before and after Norflo treatment, followed by the number of relapses in the three etiological groups. Wilcoxon signed-rank test showed a P < 0.001 in all groups. The secondary end points were the evaluation of relapse severity and of the overall quality of life. The results showed that Norflo was well tolerated and could reduce eye discomfort symptoms and signs after a few weeks of treatment in more than 80% of patients. In conclusion, our study is the first to report the potential therapeutic role of curcumin and its efficacy in eye relapsing diseases, such as anterior uveitis, and points out other promising curcumin-related benefits in eye inflammatory and degenerative conditions, such as dry eye, maculopathy, glaucoma, and diabetic retinopathy. © 2010 Allegri et al. AD - Uveitis Center Head, Ophthalmological Department of Lavagna Hospital, Corso Valparaiso 96/3, Chiavari 16043, Genova, Italy Uveitis Unit, The Eye Clinic, Azienda Ospedaliero- Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy AU - Allegri, P. AU - Mastromarino, A. AU - Neri, P. DB - Scopus DO - 10.2147/OPTH.S13271 KW - Anterior recurrent uveitis Curcumin Phosphatidylcholine-bound-curcumin (Meriva) M3 - Article N1 - Cited By :57 Export Date: 19 July 2021 PY - 2010 SP - 1201-1206 ST - Management of chronic anterior uveitis relapses: Efficacy of oral phospholipidic curcumin treatment. Long-term follow-up T2 - Clinical Ophthalmology TI - Management of chronic anterior uveitis relapses: Efficacy of oral phospholipidic curcumin treatment. Long-term follow-up UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650689102&doi=10.2147%2fOPTH.S13271&partnerID=40&md5=2f48ec237523c1b636812c457c49cdf6 VL - 4 ID - 4977 ER - TY - JOUR AB - Inhaled corticosteroids play a pivotal role in the treatment of asthma. Inhalation permits effective delivery of the corticosteroid in high concentration to target sites within the lung while minimizing systemic exposure. Consequently, the safety profile of inhaled corticosteroids is markedly better than that of oral corticosteroid therapy. However, although it was first thought that direct delivery might eliminate systemic adverse effects, this has not been confirmed by clinical trials and experience. Inhaled corticosteroids are absorbed from the lungs into the systemic circulation, in which they can acutely decrease growth velocity in children, an effect that fortunately appears to be temporary and might have no effect on final adult height. In sufficient dosages, they also produce bone mineral loss leading to osteoporosis and might increase the risk of cataracts, glaucoma, skin atrophy, and vascular changes that increase the risk of ecchymoses. Effective evaluation of the severity and significance of these complications is challenging because highly sensitive tests do not reliably predict clinically significant events, and short-term observations do not predict long-term consequences. Also, compliance wanes with long-term treatment, and susceptibility to a particular adverse event can vary over time, even in the same individual, because of developmental or hormonal changes. This journal supplement will review what has been learned about the safety of inhaled corticosteroids during the past decade, discussing some of the questions that remain and considering the characteristics of an "ideal" inhaled corticosteroid: one with high local activity in the lung and minimal or no adverse systemic effects. AD - D.B. Allen, Univ. of WI Children's Hospital, H4/448 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792-4108, United States AU - Allen, D. B. AU - Bielory, L. AU - Derendorf, H. AU - Dluhy, R. AU - Colice, G. L. AU - Szefler, S. J. DB - Embase Medline DO - 10.1016/S0091-6749(03)01859-1 IS - 3 SUPPL. KW - beclomethasone dipropionate budesonide ciclesonide corticosteroid flunisolide fluticasone propionate mometasone furoate prednisone prodrug triamcinolone acetonide aging asthma atrophy bioavailability bone mineral cataract Cushing syndrome disease severity dose response dose time effect relation drug activity drug clearance drug conjugation drug distribution drug effect drug half life drug mechanism drug receptor binding drug safety ecchymosis glaucoma growth rate hirsutism human intraocular hypertension keratoconjunctivitis long term care obesity osteolysis osteoporosis patient compliance perioral dermatitis priority journal protein binding review risk risk factor sensitivity and specificity side effect Stevens Johnson syndrome stria systemic circulation tinea treatment outcome LA - English M3 - Review N1 - L37108545 2003-09-25 PY - 2003 SN - 0091-6749 SP - S1-S40 ST - Inhaled corticosteroids: Past lessons and future issues T2 - Journal of Allergy and Clinical Immunology TI - Inhaled corticosteroids: Past lessons and future issues UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37108545&from=export http://dx.doi.org/10.1016/S0091-6749(03)01859-1 VL - 112 ID - 3801 ER - TY - JOUR AB - Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of prostaglandin (PG) F2α, which was the first of the currently available topical PGF2α analogs to be launched for glaucoma or ocular hypertension and which still accounts for the majority of prescriptions. It is better absorbed than the parent compound through the cornea, and peak concentration of the active drug is in the aqueous humor 1–2 hours after topical dosing (15–30 ng/mL). Metabolism occurs mainly in the liver. Latanoprost (0.005%) has been very well studied in clinical trials and meta-analyses that show it to be generally as effective as the other PG analogs (bimatoprost, travoprost, and tafluprost) and more effective than timolol, dorzolamide, and brimonidine. Latanoprost has good short- and long-term safety and tolerability profiles. In common with other prostaglandins, it lacks systemic effects, but can cause ocular adverse events such as conjunctival hyperemia, pigmentation of the iris, periocular skin or eyelashes, hypertrichosis, and ocular surface effects or irritation. Latanoprost is significantly better tolerated than either bimatoprost or travoprost. Patients treated with latanoprost have better compliance and persist with therapy longer than those that are given other drugs. An improved formulation of latanoprost without the preservative benzalkonium chloride has recently been developed. It is as effective as conventional latanoprost, has a lower incidence of hyperemia, and can be stored at room temperature. In conclusion, latanoprost has the best efficacy–tolerability ratio of the PG analogs available for glaucoma treatment, and has good compliance and persistence. These factors should be improved further by the recent development of preservative-free latanoprost. AD - A. Alm, Department of Neuroscience, Ophthalmology, University Hospital, Husargarten 3, Uppsala, Sweden AU - Alm, A. C1 - monoprost(Laboratioires Thea,Germany) protriaxin(Laboratioires Thea,Germany) DB - Embase DO - 10.2147/OPTH.S59162 KW - bimatoprost brimonidine brinzolamide dorzolamide latanoprost tafluprost timolol travoprost comparative effectiveness conjunctival hyperemia dose response drug absorption drug effect drug efficacy drug half life drug indication drug mechanism drug metabolism drug safety drug tolerability eye irritation eyelash glaucoma human hypertrichosis intraocular pressure iris disease iris pigmentation meta analysis (topic) multicenter study (topic) outcome assessment patient compliance phase 2 clinical trial (topic) phase 3 clinical trial (topic) randomized controlled trial (topic) review side effect treatment duration monoprost protriaxin LA - English M3 - Review N1 - L600112541 2014-10-21 PY - 2014 SN - 1177-5483 1177-5467 SP - 1967-1985 ST - Latanoprost in the treatment of glaucoma T2 - Clinical Ophthalmology TI - Latanoprost in the treatment of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600112541&from=export http://dx.doi.org/10.2147/OPTH.S59162 VL - 8 ID - 2872 ER - TY - JOUR AB - Microbial keratitis is a major risk for corneal blindness worldwide. We aimed to study the clinical presentation and outcome of hospitalized patients having infective corneal ulcers.All patients who were diagnosed as microbial keratitis and were admitted to Al-Ain Hospital during the period July 2011-Dec 2016 were retrospectively studied. Patients' demography, predisposing factors, symptoms and signs at presentation, time to presentation after onset of symptoms, microbial isolates, hospital stay, and visual acuity (VA) outcome were studied.74 patients with corneal ulcers were hospitalized. 79.7% were males. The median (range) age was 44 years (1-91). 36.5% had trauma as a risk factor. The main presenting symptoms were pain (90.5%), red eye (79.7%), and decreased vision (63.5%). All patients had stromal infiltrate while 39.2% had hypopyon at presentation. The average time from the start of the symptoms to hospital presentation was 11 (1-90) days. The mean (range) hospital stay was 10.6 (1-60) days. Forty eyes were culture positive. Bacteria were identified in 27 eyes and fungus in 16. Pseudomonas aeruginosa (9 eyes) and Staphylococcus epidermis (5 eyes) were the most common bacterial islolates. Aspergillus (6 eyes) was the most common fungus species. 95.2% of the bacterial isolates were susceptible to the quinolone antibiotics group. Twenty eight (51.9%) patients had a vision worse than 6/60 in the affected eye.Corneal ulcer poses a significant threat to the sight of an affected eye. Trauma was the most common risk factor for corneal ulcers. Usage of eyes personal protective equipment for high risk occupations and earlier accessibility to health care may reduce the impact of corneal ulcers in our community. AD - Department of Surgery, College of Medicine and Health Sciences, Khalifa Bin Zayed Street, United Arab Emirates University Department of Ophthalmology, Al-Ain Hospital, Al Jimi District, Al-Ain, UAE AN - 143847965. Language: English. Entry Date: 20200622. Revision Date: 20200622. Publication Type: journal article. Journal Subset: Biomedical AU - AlMahmoud, Tahra AU - Elhanan, Mohamed AU - Elshamsy, Mohamed H. AU - Alshamsi, Hanan N. AU - Abu-Zidan, Fikri M. DB - ccm DO - 10.1097/MD.0000000000018243 DP - EBSCOhost IS - 51 KW - Corneal Ulcer -- Therapy Corneal Ulcer -- Diagnosis Child, Preschool Adolescence Corneal Ulcer -- Epidemiology Retrospective Design Risk Factors Female Infant Aged Developing Countries Adult Aged, 80 and Over Male Middle Age Child United Arab Emirates Young Adult Impact of Events Scale Personal Resource Questionnaire Scales N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Impact of Events Scale (IES); Personal Resource Questionnaire (PRQ). NLM UID: 2985248R. PMID: NLM31860971. PY - 2019 SN - 0025-7974 SP - 1-5 ST - Management of infective corneal ulcers in a high-income developing country T2 - Medicine TI - Management of infective corneal ulcers in a high-income developing country UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143847965&site=ehost-live&scope=site VL - 98 ID - 4204 ER - TY - JOUR AB - Purpose: To describe the results of selective laser trabeculoplasty (SLT) in eyes with angle recession glaucoma (ARG). To our knowledge, this is the first report of SLT being used as treatment modality for angle recession glaucoma. Argon laser trabeculoplasty (ALT) was used for ARG but showed a little therapeutic effect. Observations: Retrospective case series of 4 eyes of 4 patients with history of non-penetrating injury to the eye resulted in angle recession glaucoma. All eyes underwent SLT. Post-treatment, the best-corrected visual acuity (BCVA), intraocular pressure (IOP), number of glaucoma medications, additional need for intervention, and complications were recorded. Success of treatment was defined as an IOP reduction of 20% or reduction in medications and maintaining target IOP without further intervention during follow up period of more than 3 months. Mean patient age was 44 years (SD = 9) and 2 out of 4 were females. SLT treatment resulted in decreased IOP from 21 to 12 mmHg in one patient and from 26 to 20 mmHg with reduced medication burden in another patient and reduced medication burden in the third patient who stopped glaucoma medication with no significant change in IOP (from 10 to 14 mmHg) at last follow up visit at 45 months. Two SLT sessions failed in one patient who underwent tube surgery. In the 3 patients with successful treatment, IOP remained controlled for the duration of follow up ranging from 4 to 45 months. Conclusions and Importance: Predicting IOP outcomes after SLT is difficult in patients with ARG. Success was noted early in the post-treatment period and was maintained for years. Repeating SLT in a case of early failure didn't change the result and is not recommended. A larger study is required to confirm the safety and effectiveness of SLT for ARG. © 2020 AD - King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia AU - AlObaida, I. AU - Aljasim, L. A. C7 - 100835 DB - Scopus DO - 10.1016/j.ajoc.2020.100835 KW - Angle recession IOP Secondary open angle glaucoma Selective laser trabeculoplasty SLT Trauma M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 ST - Selective laser trabeculoplasty in patients with angle recession glaucoma: A small case series T2 - American Journal of Ophthalmology Case Reports TI - Selective laser trabeculoplasty in patients with angle recession glaucoma: A small case series UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088867963&doi=10.1016%2fj.ajoc.2020.100835&partnerID=40&md5=18f348e265f06a4a924706041917cc10 VL - 19 ID - 5691 ER - TY - JOUR AB - AIM: Primary open angle glaucoma (POAG) is a leading cause of permanent visual loss affecting significant numbers in Saudi Arabia. There is no cure for glaucoma but there is mounting evidence to guide ophthalmologists in diagnosing and managing this disease. The aim of this pilot project was to assess the compliance with evidence-based criteria and to implement an adapted clinical practice guideline (CPG) for the management of patients with POAG at a tertiary eye care center in Riyadh, Saudi Arabia that will lead to improving quality, consistency and optimizing patients' care. METHODS: The project consisted of three phases using audit and feedback strategy. It has utilized the Joanna Briggs Institute Practical Application of Clinical Evidence System and Getting Research into Practice audit and feedback tool. Eleven evidence-based audit criteria were developed. A baseline audit was then conducted. Barriers behind areas of noncompliance were identified and a number of strategies were implemented to overcome them. A follow-up postimplementation audit was then conducted. RESULTS: Twenty electronic medical files were randomly selected for baseline audit. The results of the audit have identified a number of possible areas to improve in the diagnosis and management of POAG in compliance with the adapted CPG with compliance rate as low as 20% (4/20) in some criteria. Multifaceted interventions were implemented targeting mainly attitude and lack of knowledge and time and resource barriers. Significant improvement occurred in most criteria audited postimplementation. CONCLUSION: The project demonstrates that audit and feedback is a feasible and effective tool to change glaucoma practice in a teaching hospital in Saudi Arabia. The success was due to multifaceted interventions including clear communication to promote awareness, an easily accessible CPG, and regular reminders to improve knowledge and change behavior. We propose our pilot implementation to be generalized to promote implementing evidence-based ophthalmology. Copyright © 2020 University of Adelaide, Joanna Briggs Institute. AD - Ophthalmology Department, College of Medicine Ophthalmology Department, King Abdul-Aziz University Hospital, King Saud University Clinical Practice Guidelines Unit, Quality Management Department, King Khalid University Hospital, King Saud University Medical City Research Chair for Evidence-Based Health Care and Knowledge Translation, King Saud University Pediatrics Department, King Khalid University Hospital, King Saud University Medical city, Riyadh, Saudi Arabia Faculty of health and medical science, Joanna Briggs Institute, University of Adelaide. South Australia, Australia AU - Alshowaeir, D. AU - Almasoud, N. AU - Aldossari, S. AU - Alsirhy, E. Y. AU - Osman, E. AU - Turjoman, A. AU - Amer, Y. AU - Munn, Z. AU - McArthur, A. DB - Scopus DO - 10.1097/XEB.0000000000000257 IS - 2 M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 208-216 ST - Primary open angle glaucoma management in a tertiary eye care center in Saudi Arabia: a best practice implementation pilot project T2 - JBI evidence implementation TI - Primary open angle glaucoma management in a tertiary eye care center in Saudi Arabia: a best practice implementation pilot project UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107428654&doi=10.1097%2fXEB.0000000000000257&partnerID=40&md5=19cd559be3b3a3b7911e6deceb8879ab VL - 19 ID - 5683 ER - TY - JOUR AB - Purpose: The objective of this study was to assess preference for fixed-combination brinzolamide 1%/timolol 0.5% (BTFC) versus fixed-combination dorzolamide 2%/timolol 0.5% (DTFC) in patients with open-angle glaucoma or ocular hypertension. Methods: In this prospective, single-masked crossover study, patients were randomized 1:1 to BTFC-DTFC or DTFC-BTFC treatment sequences. Patients self-administered each medication for 7 days, with a 48-hour washout period between treatments, and rated ocular discomfort after each treatment period. Medication preferences based on ocular comfort (primary endpoint) and anticipated adherence were assessed. Safety outcomes included adverse events and intraocular pressure. Between-group differences in treatment preference and ocular discomfort scores were analyzed using chi-square and Wilcoxon–Mann–Whitney tests, respectively. Adherence, intraocular pressure, and adverse events were summarized descriptively. Results: In total, 112 patients were enrolled (mean ± SD age, 66±11 years), and 109 patients completed the study. Numerically, more patients in the intent-to-treat dataset preferred BTFC versus DTFC (59.3% versus 40.7%); however, this result was not statistically significant (treatment difference, 18.6%; P=0.0670). Mean ocular discomfort scores (range, 0–9) were statistically significantly lower with BTFC versus DTFC (2.6 versus 3.7; P=0.0002, Wilcoxon–Mann–Whitney test). More patients who preferred BTFC over DTFC were confident that they would adhere to their preferred medication. Treatment-related adverse events included blurred vision with BTFC and eye irritation or eye pain with DTFC. Conclusion: BTFC and DTFC were preferred by approximately 60% and 40% of patients, respectively, and BTFC was associated with less patient-reported ocular discomfort. Greater ocular comfort of glaucoma medications may improve treatment adherence. AD - R. Altafini, 155, Corso Palladio, Andrea, Vicenza, Italy AU - Altafini, R. AU - Scherzer, M. L. AU - Hubatsch, D. A. AU - Frezzotti, P. DB - Embase DO - 10.2147/OPTH.S88891 KW - NCT01340014 brinzolamide plus timolol dorzolamide plus timolol abnormal sensation adult aged article blurred vision controlled study crossover procedure dizziness drug efficacy drug preference drug safety drug withdrawal eye discomfort eye irritation eye pain fatigue female human intention to treat analysis intraocular foreign body intraocular hypertension major clinical study male open angle glaucoma patient compliance patient preference phase 4 clinical trial pruritus randomized controlled trial rhinopharyngitis side effect single blind procedure tachycardia taste disorder very elderly LA - English M3 - Article N1 - L607245014 2015-12-23 2015-12-24 PY - 2015 SN - 1177-5483 1177-5467 SP - 2263-2270 ST - Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: Prospective randomized patient-preference study T2 - Clinical Ophthalmology TI - Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: Prospective randomized patient-preference study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607245014&from=export http://dx.doi.org/10.2147/OPTH.S88891 VL - 9 ID - 2778 ER - TY - JOUR AB - Objective: To assess perceived barriers to glaucoma follow-up care, including the lack of glaucoma knowledge and the lack of health care access, among participants in a community glaucoma screening program. Design: Community survey. Participants: Two hundred forty-three consecutive participants in a series of free glaucoma screenings between November 2002 and August 2003. Methods: The survey consisted of 20 questions designed to elicit knowledge of glaucoma and perception of potential barriers to follow-up care. Our aim was to find correlations between patient demographics and knowledge of glaucoma as well as perceived potential barriers to follow-up care. The data were analyzed using SPSS, v. 10.1. Results: The average age of the respondents was 70 years, and females predominated (66%). About half of the respondents knew of an eye doctor in their neighborhood, and 60% had had an eye examination in the past year. Two hundred twenty-two (91%) indicated they could get to an eye doctor if the screening examination indicated they needed a follow-up examination. Two hundred twenty (90.5%) had medical insurance. One hundred seventy-eight (73%) of the participants had heard of glaucoma; 71 (29%) identified an accurate definition of glaucoma. The level of education and the language spoken at home were correlated with both glaucoma awareness (p < 0.001; p < 0.001) and knowledge of an accurate definition of glaucoma (p < 0.001; p < 0.025). Conclusions: In this population, a lack of adequate education about glaucoma may be more significantly associated with poor follow-up rates than a lack of access to care in those identified as glaucoma suspects. AD - J. D. Henderer, Department of Ophthalmology, Temple University, Parkinson Pavilion, 3401 North Broad St., Philadelphia PA 19140, United States AU - Altangerel, U. AU - Nallamshetty, H. S. AU - Uhler, T. AU - Fontanarosa, J. AU - Steinmann, W. C. AU - Almodin, J. M. AU - Chen, B. H. AU - Henderer, J. D. DB - Embase Medline DO - 10.3129/I08-175 IS - 1 KW - aged article community program controlled study eye examination female follow up glaucoma health survey human major clinical study male patient care patient education screening test LA - English M3 - Article N1 - L354164279 2009-02-26 PY - 2009 SN - 1715-3360 0008-4182 SP - 66-69 ST - Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program T2 - Canadian Journal of Ophthalmology TI - Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354164279&from=export http://dx.doi.org/10.3129/I08-175 VL - 44 ID - 3388 ER - TY - JOUR AB - Objective: To assess perceived barriers to glaucoma follow-up care, including the lack of glaucoma knowledge and the lack of health care access, among participants in a community glaucoma screening program. Design: Community survey. Participants: Two hundred forty-three consecutive participants in a series of free glaucoma screenings between November 2002 and August 2003. Methods: The survey consisted of 20 questions designed to elicit knowledge of glaucoma and perception of potential barriers to follow-up care. Our aim was to find correlations between patient demographics and knowledge of glaucoma as well as perceived potential barriers to follow-up care. The data were analyzed using SPSS, v. 10.1. Results: The average age of the respondents was 70 years, and females predominated (66%). About half of the respondents knew of an eye doctor in their neighborhood, and 60% had had an eye examination in the past year. Two hundred twenty-two (91%) indicated they could get to an eye doctor if the screening examination indicated they needed a follow-up examination. Two hundred twenty (90.5%) had medical insurance. One hundred seventy-eight (73%) of the participants had heard of glaucoma; 71 (29%) identified an accurate definition of glaucoma. The level of education and the language spoken at home were correlated with both glaucoma awareness (p < 0.001; p < 0.001) and knowledge of an accurate definition of glaucoma (p < 0.001; p < 0.025). Conclusions: In this population, a lack of adequate education about glaucoma may be more significantly associated with poor follow-up rates than a lack of access to care in those identified as glaucoma suspects. AD - Department of Ophthalmology, Temple University, Parkinson Pavilion, 3401 North Broad St., Philadelphia PA 19140, United States AU - Altangerel, U. AU - Nallamshetty, H. S. AU - Uhler, T. AU - Fontanarosa, J. AU - Steinmann, W. C. AU - Almodin, J. M. AU - Chen, B. H. AU - Henderer, J. D. DB - Scopus DO - 10.3129/I08-175 IS - 1 KW - Community survey Glaucoma Knowledge Screening M3 - Article N1 - Cited By :33 Export Date: 19 July 2021 PY - 2009 SP - 66-69 ST - Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program T2 - Canadian Journal of Ophthalmology TI - Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-59849114221&doi=10.3129%2fI08-175&partnerID=40&md5=973542b2db07e0ee2d0155a5270eb2a0 VL - 44 ID - 5046 ER - TY - JOUR AB - Objective: To assess perceived barriers to glaucoma follow-up care, including the lack of glaucoma knowledge and the lack of health care access, among participants in a community glaucoma screening program. Design: Community survey. Participants: Two hundred forty-three consecutive participants in a series of free glaucoma screenings between November 2002 and August 2003. Methods:The survey consisted of 20 questions designed to elicit knowledge of glaucoma and perception of potential barriers to follow-up care. Our aim was to find correlations between patient demographics and knowledge of glaucoma as well as perceived potential barriers to follow-up care. The data were analyzed using SPSS, v. 10.1. Results: The average age of the respondents was 70 years, and females predominated (66%). About half of the respondents knew of an eye doctor in their neighborhood, and 60% had had an eye examination in the past year. Two hundred twenty-two (91%) indicated they could get to an eye doctor if the screening examination indicated they needed a follow-up examination. Two hundred twenty (90.5%) had medical insurance. One hundred seventy-eight (73%) of the participants had heard of glaucoma; 71 (29%) identified an accurate definition of glaucoma. The level of education and the language spoken at home were correlated with both glaucoma awareness (p<0.001; p<0.001) and knowledge of an accurate definition of glaucoma (p<0.001; p<0.025). Conclusions: In this population, a lack of adequate education about glaucoma may be more significantly associated with poor follow-up rates than a lack of access to care in those identified as glaucoma suspects. AN - WOS:000263486900012 AU - Altangerel, U. AU - Nallamshetty, H. S. AU - Uhler, T. AU - Fontanarosa, J. AU - Steinmann, W. C. AU - Almodin, J. M. AU - Chen, B. H. AU - Henderer, J. D. DA - FEB DO - 10.3129/i08-175 IS - 1 PY - 2009 SN - 0008-4182 1715-3360 SP - 66-69 ST - Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program T2 - CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE TI - Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program VL - 44 ID - 5915 ER - TY - JOUR AB - PURPOSE: To facilitate future glaucoma model development and to provide guidance for decision-makers evaluating them, we provide an overview of an innovative glaucoma model and highlight important modeling considerations. CONSIDERATIONS: The considerations that were addressed include: disease outcome that is both relevant and meaningful to current clinical practice; diversity in treatment options and practices; incorporation of therapy discontinuation; and consideration of the variability in patient response to treatment. MODEL SCOPE: A state-transition, Monte Carlo simulation model was developed to simulate the management and treatment of patients with glaucoma and/or ocular hypertension. The model examines strategies involving sequential use of up to 6 pharmacologic interventions. Transitions are based on the monthly probability that a patient is no longer "successfully maintained" on therapy, which can be a consequence of lack of intraocular pressure control, adverse events, lack of compliance, or lack of persistence. Outputs of the model include months on each treatment, frequency of therapy switches, days of intraocular pressure control, frequency of ophthalmologist visits, frequency of surgery, and glaucoma-related costs. The model allows the user to specify country-specific treatment strategies, survival on therapy, surgical rates, practice patterns, and costs. CONCEPT APPLICATION: The model presented offers insights into accommodating patient and clinician variability through the use of persistence distributions. It will facilitate future glaucoma model development and provide insight for decision-makers who must evaluate model-based analyses of the economic value of glaucoma interventions. © 2006 Lippincott Williams & Wilkins, Inc. AD - R. Althin, Pfizer Global Pharmaceuticals, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom AU - Althin, R. AU - Grima, D. T. AU - Dhawan, R. AU - Bernard, L. M. DB - Embase Medline DO - 10.1097/01.ijg.0000212296.39034.cb IS - 6 KW - beta adrenergic receptor blocking agent brimonidine carbonate dehydratase inhibitor latanoprost biodiversity clinical practice cost effectiveness analysis disease course drug cost lack of drug effect economic evaluation eye surgery glaucoma health care cost human intraocular hypertension intraocular pressure medical decision making medical specialist Monte Carlo method open angle glaucoma ophthalmology outcome assessment patient compliance priority journal probability review simulation survival treatment failure treatment outcome treatment planning treatment response treatment withdrawal LA - English M3 - Review N1 - L44760330 2006-11-30 PY - 2006 SN - 1057-0829 SP - 541-547 ST - Considerations in developing model-based economic evaluations of glaucoma treatment T2 - Journal of Glaucoma TI - Considerations in developing model-based economic evaluations of glaucoma treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44760330&from=export http://dx.doi.org/10.1097/01.ijg.0000212296.39034.cb VL - 15 ID - 3569 ER - TY - JOUR AB - PURPOSE: To facilitate future glaucoma model development and to provide guidance for decision-makers evaluating them, we provide an overview of an innovative glaucoma model and highlight important modeling considerations. CONSIDERATIONS: The considerations that were addressed include: disease outcome that is both relevant and meaningful to current clinical practice; diversity in treatment options and practices; incorporation of therapy discontinuation; and consideration of the variability in patient response to treatment. MODEL SCOPE: A state-transition, Monte Carlo simulation model was developed to simulate the management and treatment of patients with glaucoma and/or ocular hypertension. The model examines strategies involving sequential use of up to 6 pharmacologic interventions. Transitions are based on the monthly probability that a patient is no longer "successfully maintained" on therapy, which can be a consequence of lack of intraocular pressure control, adverse events, lack of compliance, or lack of persistence. Outputs of the model include months on each treatment, frequency of therapy switches, days of intraocular pressure control, frequency of ophthalmologist visits, frequency of surgery, and glaucoma-related costs. The model allows the user to specify country-specific treatment strategies, survival on therapy, surgical rates, practice patterns, and costs. CONCEPT APPLICATION: The model presented offers insights into accommodating patient and clinician variability through the use of persistence distributions. It will facilitate future glaucoma model development and provide insight for decision-makers who must evaluate model-based analyses of the economic value of glaucoma interventions. © 2006 Lippincott Williams & Wilkins, Inc. AD - Pfizer Global Pharmaceuticals, Sandwich, United Kingdom Cornerstone Research Group Inc. i3 Innovus, Burlington, Ont., Canada Pfizer Global Pharmaceuticals, Peapack, NJ, United States Pfizer Global Pharmaceuticals, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom AU - Althin, R. AU - Grima, D. T. AU - Dhawan, R. AU - Bernard, L. M. DB - Scopus DO - 10.1097/01.ijg.0000212296.39034.cb IS - 6 KW - Cost-effectiveness analysis Decision analysis Glaucoma Ocular hypertension M3 - Review N1 - Cited By :1 Export Date: 19 July 2021 PY - 2006 SP - 541-547 ST - Considerations in developing model-based economic evaluations of glaucoma treatment T2 - Journal of Glaucoma TI - Considerations in developing model-based economic evaluations of glaucoma treatment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33751049940&doi=10.1097%2f01.ijg.0000212296.39034.cb&partnerID=40&md5=5b3d36026925811d26be8d8dc608ac2e VL - 15 ID - 5648 ER - TY - JOUR AB - Purpose: To facilitate future glaucoma model development and to provide guidance for decision-makers evaluating them, we provide an overview of an innovative glaucoma model and highlight important modeling considerations. Considerations: The considerations that were addressed include: disease outcome that is both relevant and meaningful to current clinical practice; diversity in treatment options and practices; incorporation of therapy discontinuation; and consideration of the variability in patient response to treatment. Model Scope: A state-transition, Monte Carlo simulation model was developed to simulate the management and treatment of patients with glaucoma and/or ocular hypertension. The model examines strategies involving sequential use of up to 6 pharmacologic interventions. Transitions are based on the monthly probability that a patient is no longer "successfully maintained" on therapy, which can be a consequence of lack of intraocular pressure control, adverse events, lack of compliance, or lack of persistence. Outputs of the model include months on each treatment, frequency of therapy switches, days of intraocular pressure control, frequency of ophthalmologist visits, frequency of surgery, and glaucoma-related costs. The model allows the user to specify country-specific treatment strategies, survival on therapy, surgical rates, practice patterns, and costs. Concept Application: The model presented offers insights into accommodating patient and clinician variability through the use of persistence distributions. It will facilitate future glaucoma model development and provide insight for decision-makers who must evaluate model-based analyses of the economic value of glaucoma interventions. AN - WOS:000242264200012 AU - Althin, R. AU - Grima, D. T. AU - Dhawan, R. AU - Bernard, L. M. DA - DEC DO - 10.1097/01.ijg.0000212296.39034.cb IS - 6 PY - 2006 SN - 1057-0829 SP - 541-547 ST - Considerations in developing model-based economic evaluations of glaucoma treatment T2 - JOURNAL OF GLAUCOMA TI - Considerations in developing model-based economic evaluations of glaucoma treatment VL - 15 ID - 6022 ER - TY - JOUR AB - Objectives. To determine the prevalence of blindness and visual impairment in Honduras, its causes and the response by the health services to growing demand. Methods. A cross-sectional population study was conducted between June and December 2013 using the standard methodology of the Rapid Assessment of Avoidable Blindness. A random sample survey was done in 63 clusters of 50 individuals aged ≥ 50, representative of the country as a whole. Visual acuity (VA) was assessed using a Snellen eye chart, and the condition of the lens and posterior pole was examined by direct ophthalmoscopy. Cataract surgical coverage was calculated and an assessment made of its quality, the causes of VA < 20/60 and the barriers to accessing surgical treatment. Results. A total of 2 999 people were examined (95.2% of the forecast total). Blindness prevalence was 1.9% (confidence interval of 95%: 1.4-2.4%) and 82.2% of these cases were avoidable. The main causes of blindness were unoperated cataracts (59.2%) and glaucoma (21.1%). Uncorrected refraction error was the main cause of severe (19.7%) and moderate (58.6%) visual impairment. Cataract surgical coverage was 75.2%. 62.5% of the eyes operated for cataracts achieved a VA > 20/60 with available correction. The main barriers against cataract surgery were cost (27.7%) and the lack of availability or difficulty of geographical access to the treatment (24.6%). Conclusions. The prevalence of blindness and visual impairment in Honduras is similar to that of other Latin American countries. 67% of cases of blindness could be resolved by improving the response capacity of the ophthalmological services, especially of cataract surgery, improving optician services and incorporating eye care in primary health care. AD - Hospital San Felipe, Tegucigalpa, Honduras Instituto Hondureño de la Seguridad Social, Tegucigalpa, Honduras Centro de Salud Integral ZOE, Tegucigalpa, Honduras Visión 2000, Agencia Internacional para la Prevención de la Ceguera, México, D.F., México Health Information Services, Grootebroek, Países Bajos Organizacion Panamericana de la Salud, Bogotá, Colombia AN - 103748509. Language: Spanish. Entry Date: 20150128. Revision Date: 20150710. Publication Type: Journal Article AU - Alvarado, Doris AU - Rivera, Belinda AU - Lagos, Luis AU - Ochoa, Mayra AU - Starkman, Ivette AU - Castillo, Mariela AU - Flores, Eduardo AU - Lansingh, Van C. AU - Limburg, Hans AU - Silva, Juan Carlos DB - ccm DO - dx.doi.org/S1020-49892014001000003 DP - EBSCOhost IS - 5 KW - Blindness -- Epidemiology -- Honduras Vision Disorders -- Epidemiology -- Honduras Prevalence Human Honduras Descriptive Statistics Cross Sectional Studies Random Sample Visual Acuity Blindness -- Etiology -- Honduras Cataract -- Complications -- Honduras Glaucoma -- Complications -- Honduras Cataract Extraction -- Economics -- Honduras Health Services Accessibility Male Female N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; Public Health; USA. Special Interest: Public Health. NLM UID: 9705400. PMID: NLM25604099. PY - 2014 SN - 1020-4989 SP - 300-305 ST - National survey of blindness and avoidable visual impairment in Honduras T2 - Revista Panamericana de Salud Pública TI - National survey of blindness and avoidable visual impairment in Honduras UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103748509&site=ehost-live&scope=site VL - 36 ID - 4473 ER - TY - JOUR AB - In an objective test to determine compliance with acetazolamide regimens by patients with glaucoma, treated inpatients had lower carbon dioxide levels (≤ 20 mEq/L) than untreated patients (≥ 25 mEq/L). The test results may be inaccurate in some obese diabetic patients with hyperglycemia and in some patients with obstructive lung disease, such as asthma and emphysema. In an outpatient clinic population, the test showed that 35% (30/87) of the patients did not seem to be taking acetazolamide and 22% (19/87) seemed to be taking it less frequently. AD - Dept. Ophthalmol., Univ. Illinois Abraham Lincoln Sch. Med., Chicago, IL AU - Alward, P. D. AU - Wilensky, J. T. DB - Embase Medline IS - 11 KW - acetazolamide carbon dioxide asthma central nervous system diabetes mellitus emphysema endocrine system glaucoma hyperglycemia major clinical study patient compliance psychological aspect respiratory system therapy visual system LA - English M3 - Article N1 - L12228336 1982-01-12 PY - 1981 SN - 0003-9950 SP - 1973-1976 ST - Determination of acetazolamide compliance in patients with glaucoma T2 - Archives of Ophthalmology TI - Determination of acetazolamide compliance in patients with glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L12228336&from=export VL - 99 ID - 4097 ER - TY - JOUR AB - Adherence to medical treatment in primary open angle glaucoma is key to the success of the treatment. Most of the work show that glaucoma patients are poor observant. Poor adherence is multifactorial. The analysis of these factors is crucial. That is why the author wanted to exposethrough a literature review, the main determinants of adherence in glaucoma. AU - Amara, F. AU - Ben Amor, H. AU - Kaibi, I. AU - Taktak, M. AU - Taktak, J. DB - Embase Medline IS - 6 KW - article human open angle glaucoma patient compliance LA - English M3 - Article N1 - L624325675 2018-10-18 2019-09-20 PY - 2018 SN - 0041-4131 SP - 22-25 ST - The determinants of therapeutic observance in open-angle glaucoma T2 - Tunisie Medicale TI - The determinants of therapeutic observance in open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624325675&from=export VL - 96 ID - 2588 ER - TY - JOUR AB - Background: To support patient-centred care, healthcare organisations increasingly offer patients access to data stored in the institutional electronic health record (EHR). Objectives: Primary objective. 1. To assess the effects of providing adult patients with access to electronic health records (EHRs) alone or with additional functionalities on a range of patient, patient-provider, and health resource consumption outcomes, including patient knowledge and understanding, patient empowerment, patient adherence, patient satisfaction with care, adverse events, health-related quality of life, health-related outcomes, psychosocial health outcomes, health resource consumption, and patient-provider communication. Secondary objective. 1. To assess whether effects of providing adult patients with EHR access alone versus EHR access with additional functionalities differ among patient groups according to age, educational level, or different status of disease (chronic or acute). Search methods: We searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, and Scopus in June 2017 and in April 2020. Selection criteria: Randomised controlled trials and cluster-randomised trials of EHR access with or without additional functionalities for adults with any medical condition. Data collection and analysis: We used standard Cochrane methodological procedures. Main results: We included 10 studies with 78 to 4500 participants and follow-up from 3 to 24 months. Nine studies assessed the effects of EHR with additional functionalities, each addressing a subset of outcomes sought by this review. Five studies focused on patients with diabetes mellitus, four on patients with specific diseases, and one on all patients. All studies compared EHR access alone or with additional functionalities plus usual care versus usual care only. No studies assessing the effects of EHR access alone versus EHR access with additional functionalities were identified. Interventions required a variety of data within the EHR, such as patient history, problem list, medication, allergies, and lab results. In addition to EHR access, eight studies allowed patients to share self-documented data, seven offered individualised disease management functions, seven offered educational disease-related information, six supported secure communication, and one offered preventive reminders. Only two studies were at low or unclear risk of bias across domains. Meta-analysis could not be performed, as participants, interventions, and outcomes were too heterogeneous, and most studies presented results based on different adjustment methods or variables. The quality of evidence was rated as low or very low across outcomes. Overall differences between intervention and control groups, if any, were small. The relevance of any small effects remains unclear for most outcomes because in most cases, trial authors did not define a minimal clinically important difference. Overall, results suggest that the effects of EHR access alone and with additional functionalities are mostly uncertain when compared with usual care. Patient knowledge and understanding: very low-quality evidence is available from one study, so we are uncertain about effects of the intervention on patient knowledge about diabetes and blood glucose testing. Patient empowerment: low-quality evidence from three studies suggests that the intervention may have little or no effect on patient empowerment measures. Patient adherence: low-quality evidence from two studies suggests that the intervention may slightly improve adherence to the process of monitoring risk factors and preventive services. Effects on medication adherence are conflicting in two studies; this may or may not improve to a clinically relevant degree. Patient satisfaction with care: low-quality evidence from three studies suggests that the intervention may have little or no effect on patient satisfaction, with conflicting results. Adverse events: two small studies reported on mortality; one of these also reported on serious and other adverse events, but sample sizes were too small for small differences to be detected. Therefore, low-quality evidence suggests that the intervention may have little to no effect on mortality and other adverse events. Health-related quality of life: only very low-quality evidence from one study is available. We are uncertain whether the intervention improves disease-specific quality of life of patients with asthma. Health-related outcomes: low-quality evidence from eight studies suggests that the intervention may have little to no effect on asthma control, glycosylated haemoglobin (HbA1c) levels, blood pressure, low-density lipoprotein or total cholesterol levels, body mass index or weight, or 10-year Framingham risk scores. Low-quality evidence from one study suggests that the composite scores of risk factors for diabetes mellitus may improve slightly with the intervention, but there is uncertainty about effects on ophthalmic medications or intraocular pressure. Psychosocial health outcomes: no study investigated psychosocial health outcomes in a more than anecdotal way. Health resource consumption: low-quality evidence for adult patients in three studies suggests that there may be little to no effect of the intervention on different measures of healthcare use. Patient-provider communication: very low-quality evidence is available from a single small study, and we are uncertain whether the intervention improves communication measures, such as the number of messages sent. Authors' conclusions: The effects of EHR access with additional functionalities in comparison with usual care for the most part are uncertain. Only adherence to the process of monitoring risk factors and providing preventive services as well as a composite score of risk factors for diabetes mellitus may improve slightly with EHR access with additional functionalities. Due to inconsistent terminology in this area, our search may have missed relevant studies. As the overall quality of evidence is very low to low, future research is likely to change these results. Further trials should investigate the impact of EHR access in a broader range of countries and clinical settings, including more patients over a longer period of follow-up, as this may increase the likelihood of detecting effects of the intervention, should these exist. More studies should focus on assessing outcomes such as patient empowerment and behavioural outcomes, rather than concentrating on health-related outcomes alone. Future studies should distinguish between effects of EHR access only and effects of additional functionalities, and investigate the impact of mobile EHR tools. Future studies should include information on usage patterns, and consider the potential for widening health inequalities with implementation of EHR access. A taxonomy for EHR access and additional functionalities should be developed to promote consistency and comparability of outcome measures, and facilitate future reviews by better enabling cross-study comparisons. Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. AD - Department of Biomedical Informatics and Mechatronics, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria Department of Nursing Science and Gerontology, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria AU - Ammenwerth, E. AU - Neyer, S. AU - Hörbst, A. AU - Mueller, G. AU - Siebert, U. AU - Schnell-Inderst, P. C7 - Cd012707 DB - Scopus DO - 10.1002/14651858.CD012707.pub2 IS - 2 M3 - Review N1 - Cited By :1 Export Date: 19 July 2021 PY - 2021 ST - Adult patient access to electronic health records T2 - Cochrane Database of Systematic Reviews TI - Adult patient access to electronic health records UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102154431&doi=10.1002%2f14651858.CD012707.pub2&partnerID=40&md5=761065514110ee8a311089e3003d2178 VL - 2021 ID - 5595 ER - TY - JOUR AB - Expert patient programmes (EPPs) are becoming an increasingly important aspect of chronic disease management, resulting in improved health outcomes for patients. Patients with chronic open angle glaucoma (COAG) require lifelong therapy. However, to date, no EPPs have been designed specifically for patients with chronic eye conditions like COAG. This article describes the development and implementation of the Glaucoma Expert Patient Programme (GEPP), a glaucoma-specific educational self-management programme which aims to improve glaucoma patients' knowledge, self-management skills, expectations and adherence to treatment. A review of theoretical frameworks and models which underpin the design, use and conduct of EPPs was undertaken, and the GEPP was designed based on the model by Kate Lorig (2003). The result is an educational programme which offers COAG patients a different perspective on their condition and supports them with knowledge, skills and strategies to better manage their condition on a daily basis. AD - R. Amro, Accident and Emergency Department, Moorfields Eye Hospital NHS Foundation Trust, London and Doctoral Candidate City University London, London, United Kingdom AU - Amro, R. AU - Cox, C. L. AU - Waddington, K. AU - Siriwardena, D. DB - Medline DO - 10.12968/bjon.2010.19.20.79682 IS - 20 KW - article chronic disease disease management educational model health behavior human methodology motivation nonbiological model open angle glaucoma organization and management patient compliance patient education patient participation peer group program development psychological aspect self care self help LA - English M3 - Article N1 - L360093616 2011-03-07 article=BJN_19_20_1287_1292 PY - 2010 SN - 0966-0461 SP - 1287-1292 ST - Glaucoma expert patient programme and ocular hypotensive treatment T2 - British Journal of Nursing TI - Glaucoma expert patient programme and ocular hypotensive treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L360093616&from=export http://dx.doi.org/10.12968/bjon.2010.19.20.79682 http://www.internurse.com/cgi-bin/go.pl/library/article.cgi?uid=79682 VL - 19 ID - 3221 ER - TY - JOUR AB - Expert patient programmes (EPPs) are becoming an increasingly important aspect of chronic disease management, resulting in improved health outcomes for patients. Patients with chronic open angle glaucoma (COAG) require lifelong therapy. However, to date, no EPPs have been designed specifically for patients with chronic eye conditions like COAG. This article describes the development and implementation of the Glaucoma Expert Patient Programme (GEPP), a glaucoma-specific educational self-management programme which aims to improve glaucoma patients' knowledge, self-management skills, expectations and adherence to treatment. A review of theoretical frameworks and models which underpin the design, use and conduct of EPPs was undertaken, and the GEPP was designed based on the model by Kate Lorig (2003). The result is an educational programme which offers COAG patients a different perspective on their condition and supports them with knowledge, skills and strategies to better manage their condition on a daily basis. AD - Ophthalmic Nurse Practitioner, Accident and Emergency Department, Moorfields Eye Hospital NHS Foundation Trust, LondonDoctoral candidate City University London AN - 105017389. Language: English. Entry Date: 20101115. Revision Date: 20200708. Publication Type: Journal Article AU - Amro, R. AU - Cox, C. L. AU - Waddington, K. AU - Siriwardena, D. DB - ccm DO - 10.12968/bjon.2010.19.20.79682 DP - EBSCOhost IS - 20 KW - Glaucoma -- Therapy Program Development Self Care Patient Education Motivation Health Behavior Medication Compliance Models, Theoretical Health Knowledge National Health Programs Ophthalmic Solutions Motivational Interviewing Role Playing N1 - review; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Nursing; Peer Reviewed; UK & Ireland. NLM UID: 9212059. PY - 2010 SN - 0966-0461 SP - 1287-1292 ST - Glaucoma expert patient programme and ocular hypotensive treatment T2 - British Journal of Nursing TI - Glaucoma expert patient programme and ocular hypotensive treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105017389&site=ehost-live&scope=site VL - 19 ID - 4460 ER - TY - JOUR AB - Purpose: The purpose of the study was to determine proportion of adherence to topical glaucoma medications and associated factors among glaucoma patients in Gondar University Hospital Tertiary Eye Care and Training Center, northwest Ethiopia. Methods: This cross-sectional design study was conducted on 360 participants from April–May 2017. Structured questionnaire was completed and adherence was assessed by patients’ self-report survey. The data were analyzed by SPSS version 20. Multivariate logistic regression was used to identify the determinant factors. The significance was considered at p value less than 0.05. Result: More than half, 221 (61.4%) (95% confidence interval: 56.1–66.7), of the study participants were found to adhere well to glaucoma medications. Male sex (adjusted odds ratio = 1.86 (95% confidence interval: 1.13–3.06)), urban residence (adjusted odds ratio = 2.33 (95% confidence interval: 1.46–3.72)), normal visual acuity (adjusted odds ratio = 2.23 (95% confidence interval: 1.13–4.42)), low visual acuity (adjusted odds ratio = 1.74 (95% confidence interval: 1.05–2.88)), and self-sponsor for medications (adjusted odds ratio = 0.21 (95% confidence interval: 0.12–0.38)) were significantly associated with good adherence Conclusion: The level of medication adherence to topical glaucoma medications is not good enough as compared to other studies done in Ethiopia. Male sex, urban residence, normal, and low visual acuity were positive predictors, whereas self-sponsored for medications was negative predictors for good adherence to glaucoma medications. AD - D.H. Anbesse, Department of Ophthalmology, St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia AU - Anbesse, D. H. AU - Yibekal, B. T. AU - Assefa, N. L. DB - Embase Medline DO - 10.1177/1120672118772517 IS - 2 KW - antiglaucoma agent adult article blindness cross-sectional study female follow up glaucoma human major clinical study male middle aged open angle glaucoma optic nerve lesion patient compliance prevalence priority journal refraction error self report structured questionnaire visual acuity visual stimulation LA - English M3 - Article N1 - L623718773 2018-09-06 2019-04-02 PY - 2019 SN - 1120-6721 SP - 189-195 ST - Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia T2 - European Journal of Ophthalmology TI - Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623718773&from=export http://dx.doi.org/10.1177/1120672118772517 VL - 29 ID - 2521 ER - TY - JOUR AB - Purpose: The purpose of the study was to determine proportion of adherence to topical glaucoma medications and associated factors among glaucoma patients in Gondar University Hospital Tertiary Eye Care and Training Center, northwest Ethiopia. Methods: This cross-sectional design study was conducted on 360 participants from April–May 2017. Structured questionnaire was completed and adherence was assessed by patients’ self-report survey. The data were analyzed by SPSS version 20. Multivariate logistic regression was used to identify the determinant factors. The significance was considered at p value less than 0.05. Result: More than half, 221 (61.4%) (95% confidence interval: 56.1–66.7), of the study participants were found to adhere well to glaucoma medications. Male sex (adjusted odds ratio = 1.86 (95% confidence interval: 1.13–3.06)), urban residence (adjusted odds ratio = 2.33 (95% confidence interval: 1.46–3.72)), normal visual acuity (adjusted odds ratio = 2.23 (95% confidence interval: 1.13–4.42)), low visual acuity (adjusted odds ratio = 1.74 (95% confidence interval: 1.05–2.88)), and self-sponsor for medications (adjusted odds ratio = 0.21 (95% confidence interval: 0.12–0.38)) were significantly associated with good adherence Conclusion: The level of medication adherence to topical glaucoma medications is not good enough as compared to other studies done in Ethiopia. Male sex, urban residence, normal, and low visual acuity were positive predictors, whereas self-sponsored for medications was negative predictors for good adherence to glaucoma medications. © The Author(s) 2018. AD - Department of Ophthalmology, St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia Department of Optometry, School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia AU - Anbesse, D. H. AU - Yibekal, B. T. AU - Assefa, N. L. DB - Scopus DO - 10.1177/1120672118772517 IS - 2 KW - Adherence Gondar University Hospital topical glaucoma medications M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2019 SP - 189-195 ST - Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia T2 - European Journal of Ophthalmology TI - Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052589636&doi=10.1177%2f1120672118772517&partnerID=40&md5=f450dbaad788888d6261188770f6d033 VL - 29 ID - 5371 ER - TY - JOUR AB - Purpose Recent developments in electronic technology are making it possible to home monitor the sensitivity of the central visual field using portable devices. We used simulations to investigate whether the higher test frequency afforded by home monitoring improves the early detection of rapid visual field loss in glaucoma and how any benefits might be affected by imperfect compliance or increased variability in the home-monitoring test. Design Computer simulation, with parameter selection confirmed with a cohort study. Participants A total of 43 patients with treated glaucoma (both open-angle and closed-angle), ocular hypertension or glaucoma suspects (mean age, 71 years; range, 37–89 years), were followed in the cohort study. Methods We simulated series (n = 100 000) of visual fields for patients with stable glaucoma and patients with progressing glaucoma for 2 in-clinic (yearly and 6-monthly) and 3 home-monitoring (monthly, fortnightly, and weekly) schedules, each running over a 5-year period. Various percentages of home-monitored fields were omitted at random to simulate reduced compliance, and the variability of the home monitored fields also was manipulated. We used previously published variability characteristics for perimetry and confirmed their appropriateness for a home-monitoring device by measuring the device's retest variability at 2 months in a cohort of 43 patients. The criterion for flagging progression in our simulation was a significant slope of the ordinary least squares regression of a simulated patient's mean deviation (MD) data. Main Outcome Measures The sensitivity for identifying rapid visual field loss (−2 decibels [dB]/year loss of MD). Results Although a sensitivity of 0.8 for rapid field loss was achieved after 2.5 years of 6-monthly testing in the clinic, weekly home monitoring achieved this by 0.9 years despite moderate test compliance of 63%. The improved performance of weekly home monitoring over 6-monthly clinical testing was retained even when home monitoring was assumed to produce more variable test results or be associated with low patient compliance. Conclusions Detecting rapid visual field progression may be improved using a home-monitoring strategy, even when compliance is imperfect. The cost-benefit of such an approach is yet to be demonstrated, however. © 2017 American Academy of Ophthalmology AD - Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, Australia Clinical Research Department, Centre for Eye Research Australia, East Melbourne, Australia Department of Clinical Neurosciences, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom AU - Anderson, A. J. AU - Bedggood, P. A. AU - George Kong, Y. X. AU - Martin, K. R. AU - Vingrys, A. J. DB - Scopus DO - 10.1016/j.ophtha.2017.06.028 IS - 12 M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2017 SP - 1735-1742 ST - Can Home Monitoring Allow Earlier Detection of Rapid Visual Field Progression in Glaucoma? T2 - Ophthalmology TI - Can Home Monitoring Allow Earlier Detection of Rapid Visual Field Progression in Glaucoma? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026455659&doi=10.1016%2fj.ophtha.2017.06.028&partnerID=40&md5=a195ec57745d2f6e665d858d0ed4583e VL - 124 ID - 5104 ER - TY - JOUR AB - PURPOSE. To investigate the usefulness of daily-wear opaque contact lens treatment for older children with amblyopia. METHODS. A retrospective chart review of all children undergoing opaque contact lens therapy for amblyopia between 2000 and 2003 was performed. All patients were included except for those younger than 5 years of age, those undergoing maintenance treatment only, those lost to follow-up, or those unable to cooperate with Snellen visual acuity testing. RESULTS. Thirteen children were identified, and seven met the inclusion criteria. The seven patients had a mean age of 7.5 years (range, 5.7-8.7 years). The causes of amblyopia were anisometropia (five patients), cataract (one patient), and strabismus (one patient). For all seven patients, the mean logMAR improvement in visual acuity was 0.52 (range, 0.26-1.22). The average duration of opaque contact lens use was 9.3 months (range, 2-21 months). Compliance problems were encountered in three patients. No major complications occurred, but one patient had an episode of mild superficial punctate keratitis. CONCLUSIONS. Daily-wear opaque contact lens treatment is a useful occlusion method for amblyopia treatment in older children with various practical and social impediments to skin patching. Meaningful improvement in visual acuity can be obtained, even in children older than 8 years of age. © 2006 Lippincott Williams & Wilkins, Inc. AD - S.M. Mathews, Stop 7217, 3601 Fourth Street, Lubbock, TX 79430-7217, United States AU - Anderson, J. E. AU - Brown, S. M. AU - Mathews, T. A. AU - Mathews, S. M. DB - Embase Medline DO - 10.1097/01.icl.0000174758.03018.a9 IS - 2 KW - amblyopia analytic method anisometropia cataract child clinical article contact lens controlled study follow up groups by age human maintenance therapy medical record review patient compliance pediatrics priority journal punctate keratitis retrospective study review skin statistical analysis strabismus treatment duration treatment outcome visual acuity Kontur LA - English M3 - Review N1 - L44510052 2006-10-25 PY - 2006 SN - 1542-2321 SP - 84-87 ST - Opaque contact lens treatment for older children with amblyopia T2 - Eye and Contact Lens TI - Opaque contact lens treatment for older children with amblyopia UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44510052&from=export http://dx.doi.org/10.1097/01.icl.0000174758.03018.a9 VL - 32 ID - 3626 ER - TY - JOUR AB - PURPOSE. To investigate the usefulness of daily-wear opaque contact lens treatment for older children with amblyopia. METHODS. A retrospective chart review of all children undergoing opaque contact lens therapy for amblyopia between 2000 and 2003 was performed. All patients were included except for those younger than 5 years of age, those undergoing maintenance treatment only, those lost to follow-up, or those unable to cooperate with Snellen visual acuity testing. RESULTS. Thirteen children were identified, and seven met the inclusion criteria. The seven patients had a mean age of 7.5 years (range, 5.7-8.7 years). The causes of amblyopia were anisometropia (five patients), cataract (one patient), and strabismus (one patient). For all seven patients, the mean logMAR improvement in visual acuity was 0.52 (range, 0.26-1.22). The average duration of opaque contact lens use was 9.3 months (range, 2-21 months). Compliance problems were encountered in three patients. No major complications occurred, but one patient had an episode of mild superficial punctate keratitis. CONCLUSIONS. Daily-wear opaque contact lens treatment is a useful occlusion method for amblyopia treatment in older children with various practical and social impediments to skin patching. Meaningful improvement in visual acuity can be obtained, even in children older than 8 years of age. © 2006 Lippincott Williams & Wilkins, Inc. AD - Department of Ophthalmology and Visual Sciences, Texas Tech. University Health Sciences Center, Lubbock, TX, United States Cabarrus Eye Center, Concord, NC, United States Stop 7217, 3601 Fourth Street, Lubbock, TX 79430-7217, United States AU - Anderson, J. E. AU - Brown, S. M. AU - Mathews, T. A. AU - Mathews, S. M. DB - Scopus DO - 10.1097/01.icl.0000174758.03018.a9 IS - 2 KW - Amblyopia Children Occlusion Opaque contact lens Therapy M3 - Review N1 - Cited By :8 Export Date: 19 July 2021 PY - 2006 SP - 84-87 ST - Opaque contact lens treatment for older children with amblyopia T2 - Eye and Contact Lens TI - Opaque contact lens treatment for older children with amblyopia UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645800572&doi=10.1097%2f01.icl.0000174758.03018.a9&partnerID=40&md5=bc5359603b3da9c40858bdd8cef0997e VL - 32 ID - 5340 ER - TY - JOUR AB - Intraocular pressure (IOP) reduction is currently the only therapeutic approach demonstrated to preserve visual function in patients with glaucoma. The first line of glaucoma treatment consists of topical IOP-lowering medications, usually initiated as monotherapy. A significant proportion of patients require more than one medication to reach a target IOP at which optic nerve damage will not progress. As prostaglandin analogues (PGAs) are the most effective class for reducing IOP, one of the other commonly used classes (β-adrenoceptor antagonist [β-blocker], carbonic anhydrase inhibitor or α2-adrenoceptor agonist) is frequently combined with a PGA. In the last decade, the use of fixed combinations containing two medications in a single bottle has steadily increased. Fixed combinations have the potential to simplify the dosing regimen, increase patient adherence, avoid the washout effect of the second drop on the first medication instilled, decrease exposure to preservatives and, sometimes, reduce the cost of treatment. Clinical trials have evaluated PGA-based fixed combinations versus unfixed combinations (individual components administered concomitantly) or versus individual monotherapies; however, any advantage that the fixed combinations may have in terms of IOP-lowering efficacy is still debated. For these reasons, the PGA-based fixed combinations are not approved by regulatory authorities in some countries, such as the US. We review the published studies evaluating the efficacy and tolerability of the IOP-lowering unfixed and fixed combination therapies with PGAs. Regarding unfixed combinations, the review shows that α2-adrenergic agonists-PGA and carbonic anhydrase inhibitor-PGA combinations seem to be at least as effective at reducing IOP as the β-blocker-PGA combinations. As for the fixed combinations, the review shows that the three PGA-timolol fixed combinations are more effective than their component medications used separately as monotherapy and are better tolerated than the three respective prostaglandins. The three PGA-timolol fixed combinations are less effective at reducing IOP than the unfixed combinations but are better tolerated. The advantage of the fixed combinations in terms of patient adherence and persistence is supported by a very small number of studies and remains to be more accurately determined. Most studies, but not all, seem to show that PGA-timolol fixed combinations are more effective than other available β-blocker fixed combinations (dorzolamide-timolol fixed combinations) at reducing IOP and are similarly tolerated AD - Université Joseph Fourier (UJF), Grenoble, France; Department of Ophthalmology, University Hospital, CHU Grenoble, Grenoble, France AN - 108140903. Language: English. Entry Date: 20120813. Revision Date: 20200708. Publication Type: Journal Article AU - Aptel, Florent AU - Chiquet, Christophe AU - Romanet, Jean-Paul DB - ccm DO - 10.2165/11634460-000000000-00000 DP - EBSCOhost IS - 10 KW - Prostaglandins -- Analogs and Derivatives Intraocular Pressure -- Drug Effects Glaucoma -- Drug Therapy Drug Combinations Adrenergic Beta-Antagonists -- Therapeutic Use Adrenergic Alpha-Agonists -- Therapeutic Use Human France Medline Databases Meta Analysis Randomized Controlled Trials Costs and Cost Analysis Patient Compliance Quality Improvement N1 - meta analysis; research; systematic review; tables/charts. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. Special Interest: Evidence-Based Practice; Public Health. NLM UID: 7600076. PMID: NLM22686588. PY - 2012 SN - 0012-6667 SP - 1355-1371 ST - Intraocular Pressure-Lowering Combination Therapies with Prostaglandin Analogues T2 - Drugs TI - Intraocular Pressure-Lowering Combination Therapies with Prostaglandin Analogues UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108140903&site=ehost-live&scope=site VL - 72 ID - 4519 ER - TY - JOUR AB - Purpose. To evaluate the intraocular pressure (IOP)-lowering effects and tolerability of the 3 prosta-glandin-timolol fixed combinations (PG-timolol FCs). methods. Clinical trials comparing directly the PG-timolol FCs or comparing the PG-timolol FCs to their individual components were thoroughly searched. The main outcome measures were efficacy assessed by IOP (taken at 9 am, noon, 4 pm, and over the mean diurnal curve) change at 3 months (or after 1 to 6 months of treatment if no data were available at month 3) from baseline and tolerability assessed by the incidence of conjunctival hyperemia. results. Twenty trials were identified (n=4684 patients). Intraocular pressure reduction was usually greater with the 3 PG-timolol FCs than the individual PG (mean difference [MD] 0.00 mmHg to 2.59 mmHg; p>0.1 to p<0.001). The incidence of hyperemia was significantly less with latanoprost- and bi-matoprost-timolol FCs than with the individual PG (relative risk = 0.66 and 0.61; p=0.05 and p<0.001). From direct comparisons, IOP reduction was significantly greatest with bimatoprost-timolol FC, at 9 am, 4 pm, and over the mean diurnal curve compared to latanoprost-timolol FC (MD = 0.90 mmHg to 1.48 mmHg; p<0.001) and at all time points compared to travoprost-timolol FC (MD = 0.66 mmHg to 0.90 mmHg; p<0.001). The incidence of hyperemia was not significantly less with latanoprost-timolol FC than with bimatoprost-timolol FC (relative risk = 1.32; p>0.1). ConClusions. The 3 PG-timolol FCs provide a greater IOP reduction and lower incidence of hyperemia than the 3 PGs alone. The direct comparisons suggest a greater efficacy of the bimatoprost-timolol FC compared with latanoprost- and travoprost-timolol FCs. © 2011 Wichtig Editore. AD - Department of Ophthalmology, Edouard Herriot Hospital, 69437 Lyon, France TherInfo, Lyon1 University, Lyon, France Department of Ophthalmology, Croix-Rousse Hospital, Lyon, France AU - Aptel, F. AU - Cucherat, M. AU - Denis, P. DB - Scopus DO - 10.5301/ejo.5000009 IS - 1 KW - Effect size Fixed combination Glaucoma Intraocular pressure Meta-analysis Prosta-glandin-timolol M3 - Article N1 - Cited By :45 Export Date: 19 July 2021 PY - 2011 SP - 5-18 ST - Efficacy and tolerability of prostaglandin-timolol fixed combinations: A meta-analysis of randomized clinical trials T2 - European Journal of Ophthalmology TI - Efficacy and tolerability of prostaglandin-timolol fixed combinations: A meta-analysis of randomized clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-81855166777&doi=10.5301%2fejo.5000009&partnerID=40&md5=a234b5e9e852866b0be759fa81dfab6e VL - 22 ID - 5010 ER - TY - JOUR AB - Background: Lowering intraocular pressure (IOP) is currently the only therapeutic approach that preserves visual function in primary open-angle glaucoma. In making treatment decisions for first-and second-line therapy, the clinician needs to provide an appropriate balance of efficacy and tolerability. Prostaglandin analogues (PGAs) are frequently used as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Similarly, PGA-based fixed combinations are frequently used in patients who progress or fail to achieve the target IOP. Scope: We have reviewed the literature on the management of primary open-angle glaucoma with PGAs, both as monotherapies and in fixed combinations. Findings: In the clinical trial and meta-analysis data identified, bimatoprost 0.03% seems to be associated with a greater overall ability to lower IOP compared with latanoprost, travoprost or tafluprost, at the cost of a slightly higher incidence of conjunctival hyperaemia. Studies indicate that patients' adherence to treatment is generally better with PGAs than with many other monotherapies. In patients requiring more than one IOP-lowering agent, fixed combination treatments may provide improved adherence and tolerability benefits compared with concomitant use of individual treatments. Bimatoprost/timolol fixed combination appears to be slightly more efficacious than latanoprost/timolol or travoprost/timolol, and tolerability differences between the fixed combinations appear to be slight, probably because the addition of timolol to the PGA component lessens the associated hyperaemia. Surveys on EU physician attitudes appear largely in line with these clinical data. Conclusion: An appropriate balance between efficacy and tolerability ensures optimum IOP lowering and reduces the risk of non-adherence. PGAs largely fulfil this need as monotherapies and as components of combinations. © 2011 Informa UK Ltd. AD - F. Aptel, Department of Ophthalmology, Edouard Herriot Hospital, Lyon 1 University, 5 place d'Arsonval, 69437 Lyon Cedex 03, France AU - Aptel, F. AU - Denis, P. C1 - duotrav(Alcon) ganfort(Allergan) lumigan(Allergan) saflotan(Merck) taflotan(Santen) travatan(Alcon) xalacom(Pfizer) xalatan(Pfizer) C2 - Alcon Allergan Merck Pfizer Santen DB - Embase Medline DO - 10.1185/03007995.2011.613923 IS - 10 KW - bimatoprost bimatoprost plus timolol brimonidine plus timolol latanoprost latanoprost plus timolol saflotan tafluprost timolol timolol plus travoprost travoprost unclassified drug conjunctival hyperemia disease course drug cost drug efficacy drug safety drug substitution drug tolerability drug withdrawal dry eye eye burning follow up human intraocular pressure meta analysis (topic) monotherapy ocular pruritus open angle glaucoma patient compliance quality of life randomized controlled trial (topic) review single drug dose duotrav ganfort lumigan taflotan travatan xalacom xalatan LA - English M3 - Review N1 - L362599161 2011-09-28 2011-10-04 PY - 2011 SN - 0300-7995 1473-4877 SP - 1949-1958 ST - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandintimolol fixed combinations in primary open-angle glaucoma T2 - Current Medical Research and Opinion TI - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandintimolol fixed combinations in primary open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362599161&from=export http://dx.doi.org/10.1185/03007995.2011.613923 VL - 27 ID - 3139 ER - TY - JOUR AB - Background:Lowering intraocular pressure (IOP) is currently the only therapeutic approach that preserves visual function in primary open-angle glaucoma. In making treatment decisions for first- and second-line therapy, the clinician needs to provide an appropriate balance of efficacy and tolerability. Prostaglandin analogues (PGAs) are frequently used as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Similarly, PGA-based fixed combinations are frequently used in patients who progress or fail to achieve the target IOP.Scope:We have reviewed the literature on the management of primary open-angle glaucoma with PGAs, both as monotherapies and in fixed combinations.Findings:In the clinical trial and meta-analysis data identified, bimatoprost 0.03% seems to be associated with a greater overall ability to lower IOP compared with latanoprost, travoprost or tafluprost, at the cost of a slightly higher incidence of conjunctival hyperaemia. Studies indicate that patients’ adherence to treatment is generally better with PGAs than with many other monotherapies. In patients requiring more than one IOP-lowering agent, fixed combination treatments may provide improved adherence and tolerability benefits compared with concomitant use of individual treatments. Bimatoprost/timolol fixed combination appears to be slightly more efficacious than latanoprost/timolol or travoprost/timolol, and tolerability differences between the fixed combinations appear to be slight, probably because the addition of timolol to the PGA component lessens the associated hyperaemia. Surveys on EU physician attitudes appear largely in line with these clinical data.Conclusion:An appropriate balance between efficacy and tolerability ensures optimum IOP lowering and reduces the risk of non-adherence. PGAs largely fulfil this need as monotherapies and as components of combinations. AN - 65870778. Language: English. Entry Date: 20111020. Revision Date: 20181231. Publication Type: Article AU - Aptel, F. AU - Denis, P. DB - ccm DO - 10.1185/03007995.2011.613923 DP - EBSCOhost IS - 10 KW - Intraocular Pressure Glaucoma -- Drug Therapy Prostaglandins -- Administration and Dosage Human Timolol Bimatoprost Drug Therapy, Combination Meta Analysis N1 - meta analysis; research; systematic review. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 0351014. PY - 2011 SN - 0300-7995 SP - 1949-1958 ST - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin–timolol fixed combinations in primary open-angle glaucoma T2 - Current Medical Research & Opinion TI - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin–timolol fixed combinations in primary open-angle glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=65870778&site=ehost-live&scope=site VL - 27 ID - 4391 ER - TY - JOUR AB - Background: Lowering intraocular pressure (IOP) is currently the only therapeutic approach that preserves visual function in primary open-angle glaucoma. In making treatment decisions for first-and second-line therapy, the clinician needs to provide an appropriate balance of efficacy and tolerability. Prostaglandin analogues (PGAs) are frequently used as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Similarly, PGA-based fixed combinations are frequently used in patients who progress or fail to achieve the target IOP. Scope: We have reviewed the literature on the management of primary open-angle glaucoma with PGAs, both as monotherapies and in fixed combinations. Findings: In the clinical trial and meta-analysis data identified, bimatoprost 0.03% seems to be associated with a greater overall ability to lower IOP compared with latanoprost, travoprost or tafluprost, at the cost of a slightly higher incidence of conjunctival hyperaemia. Studies indicate that patients' adherence to treatment is generally better with PGAs than with many other monotherapies. In patients requiring more than one IOP-lowering agent, fixed combination treatments may provide improved adherence and tolerability benefits compared with concomitant use of individual treatments. Bimatoprost/timolol fixed combination appears to be slightly more efficacious than latanoprost/timolol or travoprost/timolol, and tolerability differences between the fixed combinations appear to be slight, probably because the addition of timolol to the PGA component lessens the associated hyperaemia. Surveys on EU physician attitudes appear largely in line with these clinical data. Conclusion: An appropriate balance between efficacy and tolerability ensures optimum IOP lowering and reduces the risk of non-adherence. PGAs largely fulfil this need as monotherapies and as components of combinations. © 2011 Informa UK Ltd. AD - Department of Ophthalmology, Edouard Herriot Hospital, Lyon 1 University, 5 place d'Arsonval, 69437 Lyon Cedex 03, France Department of Ophthalmology, Hpital de la Croix-Rousse, Lyon, France AU - Aptel, F. AU - Denis, P. DB - Scopus DO - 10.1185/03007995.2011.613923 IS - 10 KW - Bimatoprost Glaucoma Intraocular pressure Latanoprost Prostaglandins Travoprost M3 - Review N1 - Cited By :28 Export Date: 19 July 2021 PY - 2011 SP - 1949-1958 ST - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandintimolol fixed combinations in primary open-angle glaucoma T2 - Current Medical Research and Opinion TI - Balancing efficacy and tolerability of prostaglandin analogues and prostaglandintimolol fixed combinations in primary open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052996950&doi=10.1185%2f03007995.2011.613923&partnerID=40&md5=9a610d648537cde1e1b28294d1e2865f VL - 27 ID - 5072 ER - TY - JOUR AB - The side effects of glaucoma hypotensive treatments usually remain moderate and limited to local side effects - conjunctival hyperemia, itching, discomfort after instillation - but are very often a leading source of poor compliance to treatment and thereby may decrease its efficacy. Moreover, these symptoms usually reflect progressive and irreversible major ocular surface changes. These ocular surface changes induced by glaucoma eyedrops may include subconjunctival fibrosis, increasing the risk of failure of a further glaucoma surgery. All the components of the hypotensive eye drops, including the active ingredient, the preservatives, and the excipients, may be involved in the occurrence of these side effects. It is therefore important to identify the agents involved and the mechanisms of these side effects, in order to choose a treatment minimizing their risk and the discomfort felt by patients, and therefore increasing the likelihood of good compliance. When available, preservative-free solutions should be considered. © 2011 Elsevier Masson SAS. Tous droits réservés. AD - F. Aptel, Service d'Ophtalmologie, Hospices Civils de Lyon, Hôpital Édouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France AU - Aptel, F. AU - Denis, P. AU - Baudouin, C. DB - Medline DO - 10.1016/j.jfo.2010.12.005 IS - 6 KW - benzalkonium excipient eye drops preservative prostaglandin article chemically induced disorder conjunctiva disease dry eye fibrosis glaucoma human hyperemia patient compliance pruritus LA - French M3 - Article N1 - L361993700 2012-07-24 PY - 2011 SN - 0181-5512 SP - 409-412 ST - Managing treatment side effects: The respective roles of the active ingredient and the preservative T2 - Journal Francais d'Ophtalmologie TI - Managing treatment side effects: The respective roles of the active ingredient and the preservative UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361993700&from=export http://dx.doi.org/10.1016/j.jfo.2010.12.005 VL - 34 ID - 3169 ER - TY - JOUR AD - F. Aptel, Department of Ophthalmology, University Hospital of Grenoble - CHU de Grenoble, 38043 Grenoble cedex 09, France AU - Aptel, F. AU - Toren, A. DB - Embase Medline DO - 10.1016/j.ophtha.2020.02.015 IS - 5 KW - antiglaucoma agent blindness cost effectiveness analysis economic aspect editorial eye care professional glaucoma health care system human medication compliance patient compliance priority journal quality adjusted life year social aspect LA - English M3 - Editorial N1 - L2005579229 2020-04-21 2020-04-29 PY - 2020 SN - 1549-4713 0161-6420 SP - 599-600 ST - Societal and Economic Impact of Poor Glaucoma Medication Adherence T2 - Ophthalmology TI - Societal and Economic Impact of Poor Glaucoma Medication Adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005579229&from=export http://dx.doi.org/10.1016/j.ophtha.2020.02.015 VL - 127 ID - 2412 ER - TY - JOUR AB - Purpose: To evaluate the effects of topical latanoprost, travoprost, and bimatoprost on the blood-aqueous barrier and central corneal thickness (CCT) of patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Design: Prospective, randomized, masked-observer, crossover clinical trial. Methods: A total of 34 phakic patients with POAG or OHT with no previous history of intraocular surgery or uveitis completed the study. Patients were randomized to use latanoprost 0.005%, travoprost 0.004%, or bimatoprost 0.03% once daily (2000 hours) for 1 month, followed by a washout period of 4 weeks between each drug. Aqueous flare was measured with a laser flare metre. CCT was calculated as the average of five measurements using ultrasound pachymetry. All measurements were performed by a masked observer (1000 h). Results: There were no statistically significant differences between baseline mean IOP, mean CCT, and mean flare values among the groups. There was no statistically significant increase in mean flare values from baseline in all groups (P>0.05). There were no statistically significant differences between mean flare values among the groups (P>0.05). All medications significantly reduced the mean IOP from baseline (P<0.0001). IOP reduction obtained with travoprost (7.3±3.8mmHg) was significantly higher than that obtained with latanoprost (4.7±4.2mmHg) (P=0.01). A statistically significant reduction in mean CCT (0.6±1.3%) from baseline was observed when patients instilled bimatoprost (P=0.01). Conclusions: Latanoprost, travoprost, and bimatoprost had no statistically significant effect on the blood-aqueous barrier of phakic patients with POAG or OHT. Bimatoprost may be associated with a clinically irrelevant reduction in mean CCT. AD - Glaucoma Service, Department of Ophthalmology, University of Campinas, Campinas, São Paulo, Brazil Department of Ophthalmoloy, School of Medicine, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil Department of Ophthalmology, University of São Paulo, São Paulo, Brazil AU - Arcieri, E. S. AU - Pierre Filho, P. T. P. AU - Wakamatsu, T. H. AU - Costa, V. P. DB - Scopus DO - 10.1038/sj.eye.6702542 IS - 2 M3 - Article N1 - Cited By :31 Export Date: 19 July 2021 PY - 2008 SP - 179-183 ST - The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension T2 - Eye TI - The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-39449114200&doi=10.1038%2fsj.eye.6702542&partnerID=40&md5=596637b6effbb81f9fed91af51d2b3b8 VL - 22 ID - 5056 ER - TY - JOUR AB - Objectives: To investigate the effects of prostaglandin analogues on the blood-aqueous barrier and to evaluate the occurrence of cystoid macular edema in aphakic or pseudophakic patients with glaucoma. Methods: in this randomized, masked-observer, 6-month clinical trial, patients with primary open-angle, pseudophakic, or aphakic glaucoma were treated once daily with bimatoprost (n = 16), latanoprost (n = 15), or travoprost (n = 17) or twice daily with unoprostone (n = 16) or lubricant drops (control group) (n = 16). Blood-aqueous barrier status, which was assessed using a laser flare meter; intraocular pressure; the occurrence of angiographic cystoid macular edema; and conjunctival hyperemia were evaluated. Results: Mean flare values were significantly higher in the bimatoprost, latanoprost, and travoprost groups throughout follow-up (P < .02). Four latanoprost-treated eyes, 1 bimatoprost-treated eye, and 1 travoprost-treated eye developed cystoid macular edema; all cases resolved after discontinuation of the prostaglandin analogue and treatment with topical diclofenac sodium. Mean intraocular pressure reductions after 6 months were higher for the latanoprost (26%), bimatoprost (28%), and travoprost (29%) groups than for the control (3%) and unoprostone (14%) groups (P < .05). Bimatoprost induced significantly higher hyperemia scores than latanoprost, unoprostone, and placebo (P < .01). Conclusion: Bimatoprost, latanoprost, and travoprost use may lead to disruption of the blood-aqueous barrier in patients with pseudophakia and aphakia. AN - WOS:000226755000006 AU - Arcieri, E. S. AU - Santana, A. AU - Rocha, F. N. AU - Guapo, G. L. AU - Costa, V. P. DA - FEB DO - 10.1001/archopht.123.2.186 IS - 2 PY - 2005 SN - 0003-9950 1538-3601 SP - 186-192 ST - Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia - A 6-month randomized trial T2 - ARCHIVES OF OPHTHALMOLOGY TI - Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia - A 6-month randomized trial VL - 123 ID - 6200 ER - TY - JOUR AB - Uveitis in children has been reported at a much lower incidence than in adults, although with worse prognosis because at the time of diagnosis a substantial number of patients have complications that represent an important cause of ocular morbidity and visual loss. Children may be at special risk of complications, because inflammation is frequently chronic, and diagnosis is often delayed because of lack of symptoms or failure to report changes in vision. In addition, children are more difficult to examine and to treat. The evaluation and management of children with uveitis require special considerations. Medical and surgical management can be challenging owing to the unique features of clinical presentation. Therefore, early and aggressive anti-inflammatory therapy is the best means to improved long-term outcomes in children. Surgical intervention for diagnostic or therapeutic reasons may be necessary, and generally is required to address complications that are unresponsive to or not amenable to medical therapy. In addition, surgical procedures must be appropriately planned keeping in mind the risks and benefits and always under an appropriate and strict immunosuppressive (preoperative, intraoperative, and postoperative) therapy. Surgical treatment should be considered only when uveitis is controlled medically. Multistage surgery may be necessary to address each complication of uveitis using diverse strategies. Finally, a close relation should be fostered among pediatricians, pediatric rheumatologist, and ophthalmologist to more effectively diagnose and manage children with uveitis. © 2008, Lippincott Williams & Wilkins.SRSR. AU - Arevalo, J. F. AU - Garcia-Amaris, R. A. DB - Scopus DO - 10.1097/IIO.0b013e31817d7fc1 IS - 3 M3 - Review N1 - Cited By :6 Export Date: 19 July 2021 PY - 2008 SP - 153-172 ST - The role of vitreo-retinal surgery in children with uveitis T2 - International Ophthalmology Clinics TI - The role of vitreo-retinal surgery in children with uveitis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-51649083863&doi=10.1097%2fIIO.0b013e31817d7fc1&partnerID=40&md5=d9a2b284db9e588c6d0bfa5d6841ed36 VL - 48 ID - 5394 ER - TY - JOUR AB - PURPOSE: To determine the work time used for out-patients seen in the ophthalmology out-patient clinic according to treatment for each diagnosis and examination guidelines. Another objective was to discover the diagnostic related outpatient demand as well as the time spent on each technique. METHOD: We have designed a computer database system that includes examinations, treatments and medical services. Their duration was measured in a random sample of 127 ophthalmology outpatients in the General Hospital of Castellon. Sixty five of the patients had come to their first visit and 62 to the follow-up visits. RESULTS: A new patient spends a mean of 42 minutes and a follow-up patient spends a mean of 27 minutes. The most frequent diagnoses are retinal diseases (30%), cataract (18.6%), glaucoma (11.8%) and ocular motility disorders (11.8%). We present the mean times used by the physician in the ophthalmic techniques used in outpatients. CONCLUSIONS: We have modified the standard times of 30 minutes for the first visit and 15 minutes for the follow-up visit. Data on the work time used for all the ophthalmics techniques in our outpatient clinic are presented. This ophthalmology survey can be used for health care managers to establish the <> and health care plan administration to adapt the resources to the demand. AD - M.C. Arias López, Servicio de Oftalmología, Hospital General de Castellón, Castellón, España. AU - Arias López, M. C. AU - Lanuza García, A. AU - García García, N. AU - Ramos Martí, F. DB - Medline IS - 3 KW - ambulatory care article eye disease human ophthalmology outpatient department statistics time LA - Spanish M3 - Article N1 - L33465666 2001-04-02 PY - 2001 SN - 0365-6691 SP - 159-163 ST - Evaluation of the work time used in outpatient ophthalmology techniques T2 - Archivos de la Sociedad Española de Oftalmología TI - Evaluation of the work time used in outpatient ophthalmology techniques UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33465666&from=export VL - 76 ID - 3896 ER - TY - JOUR AB - Background: To compare access time and cycle time between an "in-house" teleglaucoma program and in-person glaucoma consultation. Patients and Methods: This was a prospective comparative study of 71 patients seen through the teleglaucoma program (eligible patients were glaucoma suspects or early-stage open-angle glaucoma) and 63 patients seen via a traditional in-person exam with a physician present. Access time was calculated as the time from the patient being referred to the date of a booked visit for either a teleglaucoma or in-person exam. Cycle time was defined as the time from registration until departure during the visit to the hospital; it was calculated for the subset of patients from each study group who completed activity logs on the day of their visit. Results: The mean access time was significantly shorter for patients seen through teleglaucoma compared with in-person exam: 45±22 days (range, 13-121 days) (n=68) versus 88±47 days (range, 27-214 days) (n=63), respectively (p<0.0001). The cycle time was also reduced for patients seen through teleglaucoma, compared with in-person assessment: 78±20 min (range, 40-130 min) (n=39) versus 115±44 min (range, 51-216 min) (n=39), respectively (p<0.001). The mean percentage time spent in the waiting room was also significantly reduced for patients seen through teleglaucoma versus in-person assessments: 19±13% versus 41±24% (n=39), respectively (p<0.01). Conclusions: Teleglaucoma improves access to care and is a more efficient way of managing glaucoma suspects and patients with early-stage glaucoma compared with in-person assessment. Copyright © 2014, Mary Ann Liebert, Inc. AD - Department of Ophthalmology, University of Alberta, Edmonton, AB, Canada Royal Alexandra Hospital, 2317, 10240 Kingsway Avenue, Edmonton, AB, T5H 3V9, Canada AU - Arora, S. AU - Rudnisky, C. J. AU - Damji, K. F. DB - Scopus DO - 10.1089/tmj.2013.0241 IS - 5 KW - clinical efficiency ophthalmology patient access teleglaucoma telehealth M3 - Article N1 - Cited By :18 Export Date: 19 July 2021 PY - 2014 SP - 439-445 ST - Improved access and cycle time with an "In-house" patient-centered teleglaucoma program versus traditional in-person assessment T2 - Telemedicine and e-Health TI - Improved access and cycle time with an "In-house" patient-centered teleglaucoma program versus traditional in-person assessment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84900000258&doi=10.1089%2ftmj.2013.0241&partnerID=40&md5=0001af7c63d704a5d00dfb57ad897a23 VL - 20 ID - 5159 ER - TY - JOUR AB - Background: Water exposure during contact lens wear has been associated with contact lens disease including microbial keratitis and sterile corneal infiltrates. Despite the documented risks, water exposure is common amongst lens wearers. This study aimed to determine the effect of water education in the form of “no-water” lens case stickers on water-contact behaviours and storage case contamination. Methods: In a prospective, masked, randomised controlled trial, 200 daily lens wearers were randomised to either receive a storage case with a “no-water” sticker (test) or without a “no-water” sticker (control). Both groups received written compliance information. Participants completed a self-administered lens hygiene questionnaire at baseline and after 6 weeks. Microbial analysis of used storage cases, collected at both study visits, was conducted using ATP and limulus amebocyte lysate (LAL) assays for overall microbial contamination and endotoxin levels, respectively. A one-way ANCOVA and multiple logistic regression determined the change in water-contact behaviours and storage case contamination over time. Results: A total of 188 lens wearers completed both study visits; 128 females and 60 males; average age 29 ± 13 (range 18–78 years); 95 test and 93 control participants. After 6 weeks, the overall water exposure score and endotoxin levels reduced significantly in the test group compared with the control group (p < 0.05). There were no significant changes in individual water-contact behaviours or overall storage case contamination. Conclusion: A no-water infographic on the contact lens case improved overall water-contact behaviours and reduced storage case endotoxin. Refining the messaging may be beneficial in future to improve other aspects of compliance. © 2020, The Author(s), under exclusive licence to The Royal College of Ophthalmologists. AD - School of Optometry and Vision Science, UNSW Sydney, Sydney, NSW, Australia AU - Arshad, M. AU - Carnt, N. AU - Tan, J. AU - Stapleton, F. DB - Scopus DO - 10.1038/s41433-020-1015-9 IS - 3 M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2021 SP - 988-995 ST - Compliance behaviour change in contact lens wearers: a randomised controlled trial T2 - Eye (Basingstoke) TI - Compliance behaviour change in contact lens wearers: a randomised controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089739138&doi=10.1038%2fs41433-020-1015-9&partnerID=40&md5=68d8a7ddace35533f7b3432e1bb6aa7f VL - 35 ID - 5439 ER - TY - JOUR AB - Background Water exposure during contact lens wear has been associated with contact lens disease including microbial keratitis and sterile corneal infiltrates. Despite the documented risks, water exposure is common amongst lens wearers. This study aimed to determine the effect of water education in the form of "no-water" lens case stickers on water-contact behaviours and storage case contamination. Methods In a prospective, masked, randomised controlled trial, 200 daily lens wearers were randomised to either receive a storage case with a "no-water" sticker (test) or without a "no-water" sticker (control). Both groups received written compliance information. Participants completed a self-administered lens hygiene questionnaire at baseline and after 6 weeks. Microbial analysis of used storage cases, collected at both study visits, was conducted using ATP and limulus amebocyte lysate (LAL) assays for overall microbial contamination and endotoxin levels, respectively. A one-way ANCOVA and multiple logistic regression determined the change in water-contact behaviours and storage case contamination over time. Results A total of 188 lens wearers completed both study visits; 128 females and 60 males; average age 29 +/- 13 (range 18-78 years); 95 test and 93 control participants. After 6 weeks, the overall water exposure score and endotoxin levels reduced significantly in the test group compared with the control group (p < 0.05). There were no significant changes in individual water-contact behaviours or overall storage case contamination. Conclusion A no-water infographic on the contact lens case improved overall water-contact behaviours and reduced storage case endotoxin. Refining the messaging may be beneficial in future to improve other aspects of compliance. AN - WOS:000540672500001 AU - Arshad, M. AU - Carnt, N. AU - Tan, J. E. AU - Stapleton, F. DA - MAR DO - 10.1038/s41433-020-1015-9 IS - 3 PY - 2021 SN - 0950-222X 1476-5454 SP - 988-995 ST - Compliance behaviour change in contact lens wearers: a randomised controlled trial T2 - EYE TI - Compliance behaviour change in contact lens wearers: a randomised controlled trial VL - 35 ID - 6304 ER - TY - JOUR AB - Purpose: To study the indications and variables correlating with graft survival in optical penetrating keratoplasty in a tertiary care hospital in north India. Participants: All patients who underwent optical keratoplasty, except those undergoing lamellar grafts, tectonic grafts transplants and penetrating keratoplasty done for therapeutic purposes were included in the study. Patients with follow-up less than 2 years were excluded from the study. Materials and methods: Data were obtained by reviewing the records of 101 patients who underwent optical penetrating keratoplasty from 2008 to 2013 for various indications. Results: Out of 101 patients who underwent optical penetrating keratoplasty, 71 were males and 30 were females. The mean age of the recipient was 48.53 years with range 1–82 years. The main indications were previous failed graft (29.7%), healed keratitis except HSV (15.8%), pseudophakic or aphakic bullous keratopathy (14.8%), corneal dystrophies/degenerations (12.9%), adherent leucoma (9.9%), post-HSV scars (8.9%), and others like anterior staphyloma, congenital corneal opacities, buphthalmos and keratoconus (7.9%). The graft survival rate was 67.33% at 1-year follow-up and 59.4% at 2-year follow-up. The mean survival time of the grafts was 22.42 months. The mean time for graft failure was 7.12 (±0.9) months. Conclusion: One- and 2-year survival of grafts at our center is lower as compared to western studies, probably due to higher percentage of poor prognosis indications for surgery and a relative scarcity of excellent-quality donor corneas. © 2017, Springer Science+Business Media B.V. AD - Department of Ophthalmology, D Block, Level 3, Government Medical College and Hospital, Sector 32, Chandigarh, 160030, India AU - Arya, S. K. AU - Raj, A. AU - Bamotra, R. K. AU - Bhatti, A. AU - Deswal, J. AU - Sindhu, M. DB - Scopus DO - 10.1007/s10792-017-0641-0 IS - 4 KW - Donor tissue quality Graft rejection Graft survival Herpes simplex keratitis Penetrating keratoplasty M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2018 SP - 1669-1679 ST - Indications and graft survival analysis in optical penetrating keratoplasty in a tertiary care center in North India: a 5-year study T2 - International Ophthalmology TI - Indications and graft survival analysis in optical penetrating keratoplasty in a tertiary care center in North India: a 5-year study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021866906&doi=10.1007%2fs10792-017-0641-0&partnerID=40&md5=18035ae8a38e012ae8d040186c7ba459 VL - 38 ID - 5559 ER - TY - JOUR AB - To study the indications and variables correlating with graft survival in optical penetrating keratoplasty in a tertiary care hospital in north India. All patients who underwent optical keratoplasty, except those undergoing lamellar grafts, tectonic grafts transplants and penetrating keratoplasty done for therapeutic purposes were included in the study. Patients with follow-up less than 2 years were excluded from the study. Data were obtained by reviewing the records of 101 patients who underwent optical penetrating keratoplasty from 2008 to 2013 for various indications. Out of 101 patients who underwent optical penetrating keratoplasty, 71 were males and 30 were females. The mean age of the recipient was 48.53 years with range 1-82 years. The main indications were previous failed graft (29.7%), healed keratitis except HSV (15.8%), pseudophakic or aphakic bullous keratopathy (14.8%), corneal dystrophies/degenerations (12.9%), adherent leucoma (9.9%), post-HSV scars (8.9%), and others like anterior staphyloma, congenital corneal opacities, buphthalmos and keratoconus (7.9%). The graft survival rate was 67.33% at 1-year follow-up and 59.4% at 2-year follow-up. The mean survival time of the grafts was 22.42 months. The mean time for graft failure was 7.12 (+/- 0.9) months. One- and 2-year survival of grafts at our center is lower as compared to western studies, probably due to higher percentage of poor prognosis indications for surgery and a relative scarcity of excellent-quality donor corneas. AN - WOS:000439166500038 AU - Arya, S. K. AU - Raj, A. AU - Bamotra, R. K. AU - Bhatti, A. AU - Deswal, J. AU - Sindhu, M. DA - AUG DO - 10.1007/s10792-017-0641-0 IS - 4 PY - 2018 SN - 0165-5701 1573-2630 SP - 1669-1679 ST - Indications and graft survival analysis in optical penetrating keratoplasty in a tertiary care center in North India: a 5-year study T2 - INTERNATIONAL OPHTHALMOLOGY TI - Indications and graft survival analysis in optical penetrating keratoplasty in a tertiary care center in North India: a 5-year study VL - 38 ID - 6221 ER - TY - JOUR AB - The side effects of topical antiglaucoma medications and their preservatives range from ocular discomfort to sight-threatening alterations of the ocular surface. Conjunctival hyperemia, decreased tear production and function, and superficial punctate keratitis are among the most common signs seen on routine clinical examination. Squamous cell metaplasia and changes in cell morphology have been demonstrated by impression cytology studies and evaluation of biopsy specimens, and inflammatory effects are documented by the presence of inflammatory markers. The adverse effects of topical antiglaucoma eyedrops interfere with the treatment of glaucoma on two levels: first, the discomfort produced by the eye drops discourages patient compliance; and, second, long-term treatment with eyedrops is associated with a higher failure of filtration surgery. The detailed mechanism of inflammatory response and/or direct toxicity of eye drops has yet to be determined, but it may vary with the different classes of eye drops, different preservatives, and durations of treatments. Upcoming multicenter trials for new antiglaucoma eye drops should specifically evaluate ocular surface effects. © 2005 Ethis Communications, Inc. AD - P.A. Asbell, Department of Ophthalmology, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029-5574, United States AU - Asbell, P. A. AU - Potapova, N. C1 - alphagan p(Allergan) alphagan(Allergan) azopt(Alcon) betagan(Allergan) betoptic s(Alcon) cosopt(Merck and Co) lumigan(Allergan) propine(Allergan) rescula(Ciba Vision) timoptic xe(Merck and Co) timoptic(Merck and Co) trusopt(Merck and Co) uf 021 xalatan(Pharmacia Upjohn) C2 - Alcon Allergan Ciba Vision Merck and Co Pharmacia Upjohn DB - Embase DO - 10.1016/S1542-0124(12)70120-9 IS - 1 KW - epinephrine brimonidine antiglaucoma agent betaxolol bimatoprost brinzolamide cytokine dipivefrine dorzolamide dorzolamide plus timolol drug preservative eye drops HLA DR antigen intercellular adhesion molecule 1 interleukin 4 latanoprost levobunolol major histocompatibility antigen class 2 pilocarpine prostaglandin F2 alpha timolol timolol maleate unoprostone isopropyl ester article burning sensation cell structure clinical examination clinical feature clinical trial conjunctiva disease conjunctival hyperemia cornea disease cytology disease marker drug classification drug efficacy drug hypersensitivity dry eye eye disease eye irritation filtering operation glaucoma human inflammation intraocular foreign body lacrimal duct nonhuman patient compliance protein expression pruritus punctate keratitis squamous cell metaplasia tissue culture treatment failure alphagan p alphagan azopt betagan betoptic s cosopt lumigan propine rescula timoptic xe timoptic trusopt uf 021 xalatan LA - English M3 - Article N1 - L40347578 2005-03-23 PY - 2005 SN - 1542-0124 SP - 27-40 ST - Effects of topical antiglaucoma medications on the ocular surface T2 - Ocular Surface TI - Effects of topical antiglaucoma medications on the ocular surface UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40347578&from=export http://dx.doi.org/10.1016/S1542-0124(12)70120-9 VL - 3 ID - 3705 ER - TY - JOUR AB - BACKGROUND:: The aim of this study was to characterize veterans' adherence to glaucoma medications and follow-up eye care, and to examine the influence of coexisting chronic conditions such as posttraumatic stress disorder (PTSD)/anxiety. PATIENTS AND METHODS:: A retrospective review of computerized medical records was performed for 161 veterans taking topical glaucoma medications. Medication possession ratio (MPR) was calculated using pharmacy data. Mean follow-up ratio (FUR) was calculated using the number of days between visits. RESULTS:: Among the health conditions examined, the most prevalent was hearing loss (0.34), followed by arthritis (0.29), PTSD, or other anxiety disorder (0.27), and dementia or other memory disorder (0.09). The average rates of MPR and FUR were 0.69±0.20 and 0.84±0.19, respectively.Group comparisons found that patients with hearing loss had higher MPR compared with patients without hearing loss, and patients who were white had higher FUR than African American patients. When demographic and health characteristics were examined simultaneously in multiple linear regressions, hearing loss emerged as a significant predictor of MPR, and being older was significantly related to FUR. Younger age was also associated with MPR and being white (vs. African American) or having a PTSD/other anxiety disorder was related to FUR, although these findings did not reach statistical significance. CONCLUSIONS:: FUR was better than MPR in a veteran population being treated for glaucoma.Hearing loss was significantly related to higher MPR, whereas being older was significantly associated with higher FUR. These characteristics should be taken into consideration in future programs to improve adherence to glaucoma care. © 2014 by Lippincott Williams & Wilkins. AD - B. Asefzadeh, VA Boston Health Care System, Eye Clinic, Jamaica Plain Campus, 150 South Huntington Avenue, Jamaica Plain, MA 02130, United States AU - Asefzadeh, B. AU - Rett, D. AU - Pogoda, T. K. AU - Selvin, G. AU - Cavallerano, A. DB - Embase Medline DO - 10.1097/IJG.0000000000000044 IS - 4 KW - alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor prostaglandin derivative African American aged anxiety disorder arthritis article Caucasian chronic disease clinical assessment dementia demography eye care female follow up glaucoma groups by age hearing impairment human major clinical study male mean follow up ratio medical record review medication compliance medication possession ratio memory disorder patient compliance posttraumatic stress disorder priority journal veteran LA - English M3 - Article N1 - L53006221 2014-02-24 2014-04-17 PY - 2014 SN - 1536-481X 1057-0829 SP - 240-245 ST - Glaucoma medication adherence in veterans and influence of coexisting chronic disease T2 - Journal of Glaucoma TI - Glaucoma medication adherence in veterans and influence of coexisting chronic disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L53006221&from=export http://dx.doi.org/10.1097/IJG.0000000000000044 VL - 23 ID - 2928 ER - TY - JOUR AB - BACKGROUND:: The aim of this study was to characterize veterans' adherence to glaucoma medications and follow-up eye care, and to examine the influence of coexisting chronic conditions such as posttraumatic stress disorder (PTSD)/anxiety. PATIENTS AND METHODS:: A retrospective review of computerized medical records was performed for 161 veterans taking topical glaucoma medications. Medication possession ratio (MPR) was calculated using pharmacy data. Mean follow-up ratio (FUR) was calculated using the number of days between visits. RESULTS:: Among the health conditions examined, the most prevalent was hearing loss (0.34), followed by arthritis (0.29), PTSD, or other anxiety disorder (0.27), and dementia or other memory disorder (0.09). The average rates of MPR and FUR were 0.69±0.20 and 0.84±0.19, respectively.Group comparisons found that patients with hearing loss had higher MPR compared with patients without hearing loss, and patients who were white had higher FUR than African American patients. When demographic and health characteristics were examined simultaneously in multiple linear regressions, hearing loss emerged as a significant predictor of MPR, and being older was significantly related to FUR. Younger age was also associated with MPR and being white (vs. African American) or having a PTSD/other anxiety disorder was related to FUR, although these findings did not reach statistical significance. CONCLUSIONS:: FUR was better than MPR in a veteran population being treated for glaucoma.Hearing loss was significantly related to higher MPR, whereas being older was significantly associated with higher FUR. These characteristics should be taken into consideration in future programs to improve adherence to glaucoma care. © 2014 by Lippincott Williams & Wilkins. AD - VA Boston Health Care System, Eye Clinic, Jamaica Plain Campus, 150 South Huntington Avenue, Jamaica Plain, MA 02130, United States AU - Asefzadeh, B. AU - Rett, D. AU - Pogoda, T. K. AU - Selvin, G. AU - Cavallerano, A. DB - Scopus DO - 10.1097/IJG.0000000000000044 IS - 4 KW - Adherence Glaucoma Hearing loss PTSD M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2014 SP - 240-245 ST - Glaucoma medication adherence in veterans and influence of coexisting chronic disease T2 - Journal of Glaucoma TI - Glaucoma medication adherence in veterans and influence of coexisting chronic disease UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897581048&doi=10.1097%2fIJG.0000000000000044&partnerID=40&md5=5e4b4297b9ada7eeaeb4733d7f2290ba VL - 23 ID - 5519 ER - TY - JOUR AB - Background: The aim of this study was to characterize veterans' adherence to glaucoma medications and follow-up eye care, and to examine the influence of coexisting chronic conditions such as posttraumatic stress disorder (PTSD)/anxiety. Patients and Methods: A retrospective review of computerized medical records was performed for 161 veterans taking topical glaucoma medications. Medication possession ratio (MPR) was calculated using pharmacy data. Mean follow-up ratio (FUR) was calculated using the number of days between visits. Results: Among the health conditions examined, the most prevalent was hearing loss (0.34), followed by arthritis (0.29), PTSD, or other anxiety disorder (0.27), and dementia or other memory disorder (0.09). The average rates of MPR and FUR were 0.69 +/- 0.20 and 0.84 +/- 0.19, respectively. Group comparisons found that patients with hearing loss had higher MPR compared with patients without hearing loss, and patients who were white had higher FUR than African American patients. When demographic and health characteristics were examined simultaneously in multiple linear regressions, hearing loss emerged as a significant predictor of MPR, and being older was significantly related to FUR. Younger age was also associated with MPR and being white (vs. African American) or having a PTSD/other anxiety disorder was related to FUR, although these findings did not reach statistical significance. Conclusions: FUR was better than MPR in a veteran population being treated for glaucoma. Hearing loss was significantly related to higher MPR, whereas being older was significantly associated with higher FUR. These characteristics should be taken into consideration in future programs to improve adherence to glaucoma care. AN - WOS:000334245600009 AU - Asefzadeh, B. AU - Rett, D. AU - Pogoda, T. K. AU - Selvin, G. AU - Cavallerano, A. DA - APR-MAY DO - 10.1097/IJG.0000000000000044 IS - 4 PY - 2014 SN - 1057-0829 1536-481X SP - 240-245 ST - Glaucoma Medication Adherence in Veterans and Influence of Coexisting Chronic Disease T2 - JOURNAL OF GLAUCOMA TI - Glaucoma Medication Adherence in Veterans and Influence of Coexisting Chronic Disease VL - 23 ID - 5899 ER - TY - JOUR AB - Purpose: To find the dropout rate and identify the clinical characteristics of patients who drop out in the first year of follow-up from a glaucoma clinic. Design: Descriptive hospital-based study at a tertiary hospital eye department. Methods: Clinical characteristics of consecutive patients newly diagnosed with glaucoma who dropped out (n = 452) were compared with patients who did not drop out (n = 295) within 12 months. Results: The rate of dropout from follow-up was 60.5% within 1 year; 43. 1 % of the study group dropped out after their first follow-up visit. The dropout rate was high in all age groups, but higher in the age groups 21 to 30 years, 41 to 50 years, and over 70 years. Males had a higher dropout rate than females (78.6% vs. 34.5%). Dropout rate was higher among those with mild/ moderate glaucoma than those with severe disease (88.2% vs. 37.2%); those who lived further away from the hospital than those who lived nearer to the hospital (72.5% vs. 40.8%), those who were referred from screening clinics for nonblinding eye disease compared with those referred because of a blinding eye disease (72.2% vs. 58.9%). More patients (63.8%) unsure of their family eye disease history dropped out, compared with 34.3% of those with positive family history of glaucoma and other potentially blinding diseases. More patients who had no systemic disease dropped out, than those with systemic disease (54.6% vs. 39.6%); whereas patients on 2 medications or more had a higher dropout rate than those on less than 2 medications (68.1 % vs. 52.1%). Of the study factors, those that were statistically significantly associated with dropping out of follow-up from the glaucoma clinic were age, sex, place of domicile, diagnosis at referral, severity of disease, family history, and polydrug use. Conclusions: The dropout rate from this glaucoma clinic in the first year was high (60.5%). Patients who were more likely to dropout were younger patients, male, those who travelled far distances to the clinic, those with mild to moderate glaucoma, those with no family history of blinding eye diseases, and patients taking 2 or more eyedrops. Patients who seem to perceive their problems as not serious dropped out of follow-up. These findings have great implications in planning future studies and intervention to improve the follow-up of glaucoma patients in the study area. AN - WOS:000255368700012 AU - Ashaye, A. O. AU - Adeoye, A. O. DA - APR-MAY DO - 10.1097/IJG.0b013e31815768b3 IS - 3 PY - 2008 SN - 1057-0829 SP - 227-232 ST - Characteristics of patients who dropout from a glaucoma clinic T2 - JOURNAL OF GLAUCOMA TI - Characteristics of patients who dropout from a glaucoma clinic VL - 17 ID - 5895 ER - TY - JOUR AB - Background: The degree to which ocular morbidity affects workers productivity in the developing countries has not been studied adequately. A federal government research institute based in Lagos introduced an annual health screen for all its workers, which included eye tests. This provided an opportunity to study the pattern of ocular conditions among workers who were 30 years and above, and to determine the effect of eye diseases on the workers productivity. Study design: Detailed eye examination including refraction, was done on every respondent at the institution's clinic by an ophthalmologist. A questionnaire on ocular health status and occupational history was administered independently by an ophthalmic nurse. Sickness absenteeism, use of the clinic were obtained from clinic records, and the results were analysed. Results: The common ocular conditions were uncorrected or poorly corrected refractive error, uncorrected or poorly corrected presbyopia and allergic conjunctivitis. Glaucoma, maculopathy and optic atrophy were causes of severe visual impairment or blindness in 1.9% of the subjects. Absenteeism and clinic use were more common in subjects with ocular morbidity than those with non-ocular morbidity. Subjects with ocular morbidity had more illnesses, absenteeism and used the clinic more. Conclusion: Ocular problems which reduce worker's productivity are prevalent among the staff of the institution studied. They are mostly unrecognised. AD - A.O. Ashaye, Department of Ophthalmology, College of Medicine, University of Ibadan, Ibadan, Nigeria AU - Ashaye, A. O. AU - Asuzu, M. C. DB - Embase Medline DO - 10.4314/wajm.v24i2.28175 IS - 2 KW - absenteeism adult age distribution allergic conjunctivitis anamnesis article blindness controlled study developing country disease severity eye disease eye refraction female glaucoma government health care personnel health care utilization health status human male medical record medical research medical specialist Nigeria occupational disease ophthalmology optic nerve atrophy presbyopia prevalence productivity questionnaire refraction error retina maculopathy screening test visual impairment visual system examination LA - English M3 - Article N1 - L41057361 2005-08-14 PY - 2005 SN - 0189-160X SP - 96-99 ST - Ocular findings seen among the staff of an institution in Lagos, Nigeria T2 - West African Journal of Medicine TI - Ocular findings seen among the staff of an institution in Lagos, Nigeria UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41057361&from=export http://dx.doi.org/10.4314/wajm.v24i2.28175 VL - 24 ID - 3694 ER - TY - JOUR AB - PURPOSE: To report the visual, refractive, and functional outcomes of photorefractive keratectomy (PRK) and of laser-assisted subepithelial keratectomy in a group of children with significant refractive error and underlying medical conditions or ocular pathology who were noncompliant with traditional management. SETTING: Nonhospital surgical facility and a hospital clinic. METHODS: This case series comprised 5 individual cases of anisometropic amblyopia and/or high myopia. Underlying medical and ocular conditions were as follows: upper eyelid hemangioma with oblique myopic astigmatism, Pelizaeus-Merzbacher leukodystrophy with nystagmus, Klippel-Trenaunay-Weber syndrome with glaucoma, incontinentia pigmenti with unilateral optic nerve atrophy, and Goldenhar syndrome with unilateral optic nerve hypoplasia. Photorefractive keratectomy or LASEK was performed in 6 eyes of 5 patients. Age range at the time of surgery was 1.0 to 7.0 years. All procedures were performed under general anesthesia. RESULTS: Best corrected visual acuity improved by 2 lines in 2 patients and 1 line in 2 patients by 6 months after surgery. Stereopsis and/or fusional status improved in 3 patients. Amblyopia treatment compliance improved in 1 patient. Alignment improved without strabismus surgery in 2 cases. A functional vision survey demonstrated a positive effect on the ability of all 5 children to function in their environment. CONCLUSION: During the period of visual cortical plasticity, refractive surgery, by eliminating the refractive component of amblyopia and by promoting fusional ability, provides considerable improvement in children, even those with underlying medical conditions associated with ocular pathology. © 2006 ASCRS and ESCRS. AD - W.F. Astle, Eye Clinic, Alberta Children's Hospital, 1820 Richmond Road SW, Calgary, Alta. T2T 5C7, Canada AU - Astle, W. F. AU - Papp, A. AU - Huang, P. T. AU - Ingram, A. DB - Embase Medline DO - 10.1016/j.jcrs.2005.11.028 IS - 1 KW - amblyopia anisometropia article astigmatism child clinical article controlled study female glaucoma health survey human laser epithelial keratomileusis laser surgery male myopia operation duration optic nerve atrophy optic nerve hypoplasia patient compliance photorefractive keratectomy priority journal refraction error refractive surgery spectacles treatment outcome vision test visual acuity LA - English M3 - Article N1 - L43330057 2006-03-14 PY - 2006 SN - 0886-3350 SP - 103-108 ST - Refractive laser surgery in children with coexisting medical and ocular pathology T2 - Journal of Cataract and Refractive Surgery TI - Refractive laser surgery in children with coexisting medical and ocular pathology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43330057&from=export http://dx.doi.org/10.1016/j.jcrs.2005.11.028 VL - 32 ID - 3640 ER - TY - JOUR AB - Background. The possible sequel of poorly controlled intraocular pressure (IOP) includes treatment failure, unnecessary medication use, and economic burden on patients with glaucoma. Objective. To assess the impact of adherence and instillation technique on IOP control. Methods. A cross-sectional study was conducted on 359 glaucoma patients in Menelik II Hospital from June 1 to July 31, 2015. After conducting a Q-Q analysis, multiple binary logistic analyses, linear regression analyses, and two-tailed paired t-test were conducted to compare IOP in the baseline versus current measurements. Results. Intraocular pressure was controlled in 59.6% of the patients and was relatively well controlled during the study period (mean (M) = 17.911 mmHg, standard deviation (S) = 0.323) compared to the baseline (M=20.866 mmHg, S=0.383, t (358) = −6.70, p<0.0001). A unit increase in the administration technique score resulted in a 0.272 mmHg decrease in IOP (p=0.03). Moreover, primary angle-closure glaucoma (adjusted odds ratio (AOR) = 0.347, 95% confidence interval (CI): 0.144–0.836) and two medications (AOR = 1.869, 95% CI: 1.259–9.379) were factors affecting IOP. Conclusion. Good instillation technique of the medications was correlated with a reduction in IOP. Consequently, regular assessment of the instillation technique and IOP should be done for better management of the disease. AD - Clinical Pharmacy Unit, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Tigray, Ethiopia Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia Department of Ophthalmology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia AN - 125151019. Language: English. Entry Date: 20170919. Revision Date: 20170919. Publication Type: Article AU - Atey, Tesfay Mehari AU - Shibeshi, Workineh AU - T. Giorgis, Abeba AU - Asgedom, Solomon Weldegebreal DB - ccm DO - 10.1155/2017/1683430 DP - EBSCOhost KW - Medication Compliance Instillation, Drug Administration, Topical Glaucoma -- Drug Therapy Intraocular Pressure Antihypertensive Agents -- Therapeutic Use Human Cross Sectional Studies Multiple Logistic Regression Linear Regression Paired T-Tests Glaucoma, Angle-Closure -- Drug Therapy Odds Ratio Confidence Intervals Antihypertensive Agents -- Administration and Dosage N1 - research; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 101524199. PY - 2017 SN - 2090-004X SP - 1-8 ST - The Impact of Adherence and Instillation Proficiency of Topical Glaucoma Medications on Intraocular Pressure T2 - Journal of Ophthalmology TI - The Impact of Adherence and Instillation Proficiency of Topical Glaucoma Medications on Intraocular Pressure UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=125151019&site=ehost-live&scope=site ID - 4244 ER - TY - JOUR AB - Purpose: To validate the treatment-specific Treatment Satisfaction Survey for Intraocular Pressure (TSSIOP). Methods: Item content was developed by 4 heterogeneous patient focus groups (n = 32). Instrument validation involved 250 patients on ocular hypotensive medications recruited from ophthalmology practices in the Southern USA. Participants responded to demographic and test questions during a clinic visit. Standard psychometric analyses were performed on the resulting data. Sample: Of the 412 patients screened, 253 consented to participate, and 250 provided complete datasets. The sample included 44% male (n = 109), 44% Black (n = 109) and 57% brown eyed (n = 142) participants, with a mean age of 64.6 years (SD 13.1) and a history of elevated IOP for an average of 8.4 yrs (SD 7.8). A majority was receiving monotherapy (60%, n = 151). Results: A PC Factor analysis (w/ varimax rotation) of the 31 items yielded 5 factors (Eigenvalues > 1.0) explaining 70% of the total variance. Weaker and conceptually redundant items were removed and the remaining 15 items reanalyzed. The satisfaction factors were; Eye Irritation (EI; 4 items), Convenience of Use (CofU; 3 items), Ease of Use (EofU; 3 items), Hyperemia (HYP; 3 items), and Medication Effectiveness (EFF; 2 items). Chronbach's Alphas ranged from .80 to .86. Greater distributional skew was found for less common experiences (i.e., HYP & EI with 65% & 48.4% ceilings) than for more common experiences (i.e., EofU, CofU, EFF with 10.8%, 20.8% & 15.9% ceilings). TSS-IOP scales converged with conceptually related scales on a previously validated measure of treatment satisfaction, the TSQM (r = .36 to .77). Evidence of concurrent criterion-related validity was found. Patients' symptomatic ratings of eye irritation, hyperemia and difficulties using the medication correlated with satisfaction on these dimensions (r = .30-.56, all p < .001). Clinicians' ratings of IOP control, severity of side effects and problematic medication use correlated with patients' satisfaction scores on these dimensions (r = .13-.26, all p < .01). Conclusions: This study provides initial evidence that the TSS-IOP is a reliable and valid measure, assessing patients' satisfaction with ocular hypotensive medications. © 2003 Atkinson et al; licensee BioMed Central Ltd. AD - Worldwide Outcomes Research, Pfizer, La Jolla, CA, United States Pharmaceutical Reseach Network, Univ. of S. Carolina School of Med., Charleston, SC, United States Pfizer Global Pharmaceuticals, New York, NY, United States Clinical Project Management, Pharmaceutical Research Network, Charleston, SC, United States Lohs Research Group, Palatine, IL, United States AU - Atkinson, M. J. AU - Stewart, W. C. AU - Fain, J. M. AU - Stewart, J. A. AU - Dhawan, R. AU - Mozaffari, E. AU - Lohs, J. C7 - 67 DB - Scopus DO - 10.1186/1477-7525-1-67 M3 - Article N1 - Cited By :39 Export Date: 19 July 2021 PY - 2003 ST - A new measure of patient satisfaction with ocular hypotensive medications: The Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP) T2 - Health and Quality of Life Outcomes TI - A new measure of patient satisfaction with ocular hypotensive medications: The Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-4243156209&doi=10.1186%2f1477-7525-1-67&partnerID=40&md5=e70cd9ee7c69482439883fc04d0a6578 VL - 1 ID - 5026 ER - TY - JOUR AD - J. F. Awobem, Hull and East Yorkshire Eye Hospital, East Yorkshire, United Kingdom AU - Awobem, J. F. AU - Cassels-Brown, A. AU - Buchan, J. C. AU - Hughes, K. A. DB - Embase Medline DO - 10.1038/eye.2008.42 IS - 1 KW - African Caribbean clinical study eye care glaucoma health care utilization health service human letter patient attitude primary medical care socioeconomics United Kingdom LA - English M3 - Letter N1 - L354074295 2009-02-17 PY - 2009 SN - 1476-5454 0950-222X SP - 243 ST - Exploring glaucoma awareness and the utilization of primary eye care services: Community perceived barriers among elderly African Caribbeans in Chapeltown, Leeds T2 - Eye TI - Exploring glaucoma awareness and the utilization of primary eye care services: Community perceived barriers among elderly African Caribbeans in Chapeltown, Leeds UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354074295&from=export http://dx.doi.org/10.1038/eye.2008.42 VL - 23 ID - 3386 ER - TY - JOUR AD - Hull and East Yorkshire Eye Hospital, East Yorkshire, UK. AN - 105624056. Language: English. Entry Date: 20090807. Revision Date: 20200708. Publication Type: Journal Article AU - Awobem, J. F. AU - Cassels-Brown, A. AU - Buchan, J. C. AU - Hughes, K. A. DB - ccm DO - 10.1038/eye.2008.42 DP - EBSCOhost IS - 1 KW - Black Persons Glaucoma -- Therapy Patient Attitudes -- Ethnology Aged Attitude to Health England West Indies -- Ethnology N1 - commentary; letter. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM18344962. PY - 2009 SN - 0950-222X SP - 243-243 ST - Exploring glaucoma awareness and the utilization of primary eye care services: community perceived barriers among elderly African Caribbeans in Chapeltown, Leeds...Eye. 2007 Jul;21(7):912-20 T2 - Eye TI - Exploring glaucoma awareness and the utilization of primary eye care services: community perceived barriers among elderly African Caribbeans in Chapeltown, Leeds...Eye. 2007 Jul;21(7):912-20 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105624056&site=ehost-live&scope=site VL - 23 ID - 4739 ER - TY - JOUR AB - Background: Eye care is an essential component in the management of critically ill patients. Standardized eye care can prevent corneal complications in ventilated patients. Objective: This study was designed to compare old and new practices of corneal care for reduction in corneal complications in ventilated patients. Methods: This study was done in three phases each of six month duration. Phase 1 was the ongoing practice of eye care in the unit. Before the start of phase 2, a new protocol was made for eye care. Corneal complications were observed in terms of haziness, dryness, and ulceration. All nursing staffs were educated and made compliant with the new protocol. In phase 2, a follow-up audit was done to check the effectiveness and compliance to protocol. In phase 3, a follow-up audit was started 3 months after phase 2. Results: In phase 1, total ventilated patients were 40 with 240 ventilator days. The corneal dryness rate was 40 per 1000 ventilator days while the haziness and ulceration rate was 16 per 1000 ventilator days each. In the second phase 2, total ventilated patients were 53 making 561 ventilator days. The rate of corneal haziness and dryness was 3.52 and 1.78 per 1000 ventilator days, respectively, with no case of corneal ulceration. In phase 3, the number of ventilated patients was 91 with 1114 ventilator days. The corneal dryness rate was 2.69 while the haziness and ulceration rate was 1.79 each. Conclusion: Protocolized eye care can reduce the risk of corneal complications in ventilated patients. AD - Department of Critical Care, King Khalid University Hospital, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia AU - Azfar, M. F. AU - Khan, M. F. AU - Alzeer, A. H. DB - Scopus DO - 10.4103/1658-354X.109805 IS - 1 KW - Corneal complications eye care ventilated patients M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2013 SP - 33-36 ST - Protocolized eye care prevents corneal complications in ventilated patients in a medical intensive care unit T2 - Saudi Journal of Anaesthesia TI - Protocolized eye care prevents corneal complications in ventilated patients in a medical intensive care unit UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876837877&doi=10.4103%2f1658-354X.109805&partnerID=40&md5=4ed2e31ab5201158c7254cb9b634fe12 VL - 7 ID - 5241 ER - TY - JOUR AB - Purpose: This study evaluates the influence of intraocular silicone oil on iris diabetic microangiopathy in diabetic vitrectomized eyes. Methods: The authors examined 20 eyes of 20 patients with diabetes undergoing primary vitrectomy for tractional diabetic retinal detachment, endophotocoagulation, and 1000 centistokes silicone oil tamponade. The vascular status of the iris in these eyes was examined by iris fluorescein angiography once before silicone oil injection and again when it was removed (mean follow-up, 8.3 months). Results: Iris diabetic microangiopathy, including breakdown of the blood-iris barrier and iris neovascularization, improved or remained stable in 40% of eyes. It worsened in 60% bf eyes, including all aphakic eyes. Neovascular glaucoma developed in one of them. A significant correlation was found between worsening of iris diabetic microangiopathy and both aphakia (P = 0.01) and severe immediate postvitrectomy inflammation (P = 0.02). Eyes with recurrent retinal detachment (n = 4) showed worsening of iris diabetic microangiopathy, but this was not significantly correlated. Conclusion: Aphakic vitrectomized eyes have a higher risk of iris diabetic microangiopathy developing, even after silicone oil tamponade. Immediate postoperative intraocular inflammation also is a risk factor for worsening of iris diabetic microangiopathy in phakic eyes. Recurrence of retinal detachment was not significantly correlated with worsening of iris status. AN - WOS:A1993LQ62700011 AU - Azzolini, C. AU - Brancato, R. AU - Camesasca, F. I. AU - Codenotti, M. DA - AUG IS - 8 PY - 1993 SN - 0161-6420 SP - 1152-1159 ST - INFLUENCE OF SILICONE OIL ON IRIS MICROANGIOPATHY IN DIABETIC VITRECTOMIZED EYES T2 - OPHTHALMOLOGY TI - INFLUENCE OF SILICONE OIL ON IRIS MICROANGIOPATHY IN DIABETIC VITRECTOMIZED EYES VL - 100 ID - 6272 ER - TY - JOUR AB - Aim: To assess the efficacy of Intracameral (bevacizumab) in combination with and without pan retinal photocoagulation (PRP) in regressing anterior chamber iris and angle neovascularization and stabilizing IOP and improving outcome of secondary neovascular glaucoma in patients with proliferative retinal ischemic disorders in our population. Methods: A Prospective, consecutive, interventional case series study was conducted at AFIO RWP and CMH Khuzdar on a series of patients 25 to 70 years of age. Thirty patients (30 eyes) with NVG secondary to ischemic retinal disorders were enrolled in the study design. The study group included 18(60%) males and 12 (40%) females. Cases were divided into two groups (A, B) and written informed consent was taken prior to procedure. Group A (15 patients) were managed with Intracameral bevacizumab alone While group B (15 patients) received laser pan retinal photocoagulation in addition to Intracameral bevacizumab. Majority had proliferative diabetic retinopathy (21 cases) and remaining nine cases were secondary to ischemic central retinal vein occlusion (CRVO). Baseline records were documented after carrying out complete ophthalmic evaluation in all patients. Follow up was carried out for 03 to 06 months depending on patient compliance. Results: Significantly better reduction of Iris (rubeosis) and anterior chamber angle neovascularization and stabilizing of IOP was observed in Group B who received PRP in addition to Intracameral bevacizumab as compared to group A who were managed with Intracameral bevacizumab alone. Moreover early remission of neovascularization was observed in group A receiving bevacizumab only. Conclusions: Combined procedures seems to be more effective in regressing and stabilizing iris/angle neovascularization, and lowering IOP in patients with NVG particularly in advanced cases. AD - AFPGMI, Pakistan AFIO RWP, Pakistan AU - Babar, Z. U. D. AU - Khan, T. P. DB - Scopus IS - 1 KW - Anterior chamber angle Bevacizumab Iris neovascularization Neovascularization Pan retinal photocoagulation M3 - Article N1 - Export Date: 19 July 2021 PY - 2014 SP - 75-78 ST - Role of intracameral bevacizumab in combination with and without Panretinal Photocoagulation (PRP) in neovascular glaucoma patients in our population T2 - Pakistan Journal of Medical and Health Sciences TI - Role of intracameral bevacizumab in combination with and without Panretinal Photocoagulation (PRP) in neovascular glaucoma patients in our population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899834700&partnerID=40&md5=ffc7aac63e18796abb356a2a11df4d6e VL - 8 ID - 5752 ER - TY - JOUR AB - INTRODUCTION: Combining two medications in one bottle may improve compliance by reducing the time required to administer drops and the frequency of the total number of medication bottles. OBJECTIVE: To compare the efficacy of reduced intraocular pressure (IOP) and safety of fixed combination travoprost 0.004%/timolol 0.5% vs. fixed combination dorzolamide 2%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. METHODS: Prospective randomized clinical study included 60 patients divided into 2 groups. Follow-up was done at day 14 and 45 and month 3. IOP measurements were taken at each follow-up examination at 8 am, 10 am and 4 pm. RESULTS: Both fixed combinations reduced IOP significantly compared to initial values at all follow-ups (p < 0.001). Mean pooled IOP at all visits and time points was slightly lower in the travoprost/timolol group compared with the dorzolamide/timolol group (16.13 mmHg vs. 16.15 mmHg). Mean IOP reduction from baseline ranged from -7.46 mmHg to -9.92 mmHg in the travoprost/timolol group and from -6.93 mmHg to -8.93 mmHg for the dorzolamide/timolol group. Mean (+/- standard error of the mean) reduction in diurnal LOP from baseline to 3rd month was 8.96 +/- 2.79 in the travoprost/timolol group versus 8.07 +/- 2.91 in patients receiving dorzolamide/timolol fixed combination (p = 0.196). The most frequent treatment-related adverse events were conjunctival hyperemia in the travoprost/timolol group, and dry eye and foreign body sensation in the dorzolamide/timolol group. CONCLUSION: Travoprost/timolol fixed combination was slightly more effective than dorzolamide/timolol fixed combination in reducing mean diurnal IOP. Travoprost/timolol group resulted in an IOP reduction for up to 1.07 mmHg higher than dorzolamide/timolol group. Both fixed combinations were well tolerated and safe. AU - Babić, N. AU - Andreić, V. AU - Miljković, A. AU - Grković, D. AU - Jovanović, P. DB - Medline IS - 7-8 KW - antihypertensive agent cloprostenol dorzolamide plus timolol drug combination sulfonamide thiophene derivative timolol travoprost analogs and derivatives controlled study open angle glaucoma human intraocular hypertension patient compliance prospective study randomized controlled trial LA - English M3 - Article N1 - L606763286 2015-11-10 PY - 2013 SN - 0370-8179 SP - 441-446 ST - Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension T2 - Srpski arhiv za celokupno lekarstvo TI - Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606763286&from=export VL - 141 ID - 2988 ER - TY - JOUR AB - Introduction Combining two medications in one bottle may improve compliance by reducing the time required to administer drops and the frequency of the total number of medication bottles. Objective To compare the efficacy of reduced intraocular pressure (IOP) and safety of fixed combination travoprost 0.004%/timolol 0.5% vs. fixed combination dorzolamide 2%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Methods Prospective randomized clinical study included 60 patients divided into 2 groups. Follow-up was done at day 14 and 45 and month 3. IOP measurements were taken at each follow-up examination at 8 am, 10 am and 4 pm. Results Both fixed combinations reduced IOP significantly compared to initial values at all follow-ups (p<0.001). Mean pooled IOP at all visits and time points was slightly lower in the travoprost/timolol group compared with the dorzolamide/timolol group (16.13 mmHg vs. 16.15 mmHg). Mean IOP reduction from baseline ranged from-7.46 mmHg to-9.92 mmHg in the travoprost/timolol group and from-6.93 mmHg to-8.93 mmHg for the dorzolamide/timolol group. Mean (±standard error of the mean) reduction in diurnal IOP from baseline to 3rd month was 8.96±2.79 in the travoprost/timolol group versus 8.07±2.91 in patients receiving dorzolamide/timolol fixed combination (p=0.196). The most frequent treatmentrelated adverse events were conjunctival hyperemia in the travoprost/timolol group, and dry eye and foreign body sensation in the dorzolamide/timolol group. Conclusion Travoprost/timolol fixed combination was slightly more effective than dorzolamide/timolol fixed combination in reducing mean diurnal IOP. Travoprost/timolol group resulted in an IOP reduction for up to 1.07 mmHg higher than dorzolamide/timolol group. Both fixed combinations were well tolerated and safe. AD - Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia University of Novi Sad, Novi Sad, Serbia Eye Clinic, Clinical Center, Niš, Serbia AU - Babić, N. AU - Andreić, V. AU - Miljković, A. AU - Grković, D. AU - Jovanović, P. DB - Scopus DO - 10.2298/SARH1308441B IS - 7-8 KW - Dorzolamide Ocular hypertension Primary open-angle glaucoma Timolol Travoprost M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2013 SP - 441-446 ST - Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension T2 - Srpski Arhiv za Celokupno Lekarstvo TI - Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/ timolol in patients with primary open-angle glaucoma and ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940317467&doi=10.2298%2fSARH1308441B&partnerID=40&md5=1a801f0bc83a0d1384a5dcff5bcac05d VL - 141 ID - 5523 ER - TY - JOUR AB - Introduction Combining two medications in one bottle may improve compliance by reducing the time required to administer drops and the frequency of the total number of medication bottles. Objective To compare the efficacy of reduced intraocular pressure (IOP) and safety of fixed combination travoprost 0.004%/timolol 0.5% vs. fixed combination dorzolamide 2%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Methods Prospective randomized clinical study included 60 patients divided into 2 groups. Follow-up was done at day 14 and 45 and month 3. IOP measurements were taken at each follow-up examination at 8 am, 10 am and 4 pm. Results Both fixed combinations reduced IOP significantly compared to initial values at all follow-ups (p<0.001). Mean pooled IOP at all visits and time points was slightly lower in the travoprost/timolol group compared with the dorzolamide/timolol group (16.13 mmHg vs. 16.15 mmHg). Mean IOP reduction from baseline ranged from -7.46 mmHg to -9.92 mmHg in the travoprost/timolol group and from -6.93 mmHg to -8.93 mmHg for the dorzolamide/timolol group. Mean (standard error of the mean) reduction in diurnal IOP from baseline to 3rd month was 8.96 +/- 2.79 in the travoprost/timolol group versus 8.07 +/- 2.91 in patients receiving dorzolamide/timolol fixed combination (p=0.196). The most frequent treatment-related adverse events were conjunctival hyperemia in the travoprost/timolol group, and dry eye and foreign body sensation in the dorzolamide/timolol group. Conclusion Travoprost/timolol fixed combination was slightly more effective than dorzolamide/timolol fixed combination in reducing mean diurnal IOP. Travoprost/timolol group resulted in an IOP reduction for up to 1.07 mmHg higher than dorzolamide/timolol group. Both fixed combinations were well tolerated and safe. AN - WOS:000325381500002 AU - Babic, N. AU - Andreic, V. AU - Miljkovic, A. AU - Grkovic, D. AU - Jovanovic, P. DA - JUL-AUG DO - 10.2298/SARH1308441B IS - 7-8 PY - 2013 SN - 0370-8179 SP - 441-446 ST - Comparison of the Efficacy and Safety of Fixed Combination Travoprost/Timolol and Dorzolamide/Timolol in Patients with Primary Open-Angle Glaucoma and Ocular Hypertension T2 - SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO TI - Comparison of the Efficacy and Safety of Fixed Combination Travoprost/Timolol and Dorzolamide/Timolol in Patients with Primary Open-Angle Glaucoma and Ocular Hypertension VL - 141 ID - 5974 ER - TY - JOUR AB - Purpose: To evaluate consistency in documentation of glaucoma medications in the electronic medical record and identify which regimen patients adhere to when inconsistencies exist. Factors contributing to medication nonadherence are also explored. Methods: Retrospective chart review of medication adherence encompassing 200 patients from three glaucoma physicians at a tertiary referral center over a 1-month period. Adherence was determined by the consistency between a patients stated medication regimen and either the active medication list in the electronic medical record, or the physicians planned medication regimen in the preceding clinic visit. Patient charts were also reviewed for patient sex, age, primary language, race, and total number of medications. Results: A total of 160 charts showed consistency in documentation between the physician note and electronic medication reconciliation. Of those patients, 83.1% reported adherence with their glaucoma medication schedule. When there was a discrepancy in documentation (40 charts), 72.5% patients followed the physician-stated regimen vs 20% who followed neither vs 7.5% who followed the medical record (P<0.01). No difference in adherence was observed based on sex (P=0.912) or total number of medications taken (P=0.242). Language, both English- (P=0.075) and Haitian (P=0.10) -speaking populations, as well as race, Caucasian (P=0.31), African-American (P=0.54), and Hispanic (P=0.58), had no impact on medica­tion adherence. Patients over 80 years of age were more nonadherent as compared to other decades (P=0.04). Conclusion: Inconsistent documentation between the electronic medical record physician note and medication regimen may contribute to patient medication nonadherence. Patients over 80 years of age were associated with higher rates of nonadherence, while sex, total number of medications, race, and language had no interaction with medication adherence. AD - T.S. Bacon, Department of Ophthalmology, Boston University School of Medicine, Boston Medical Center, 850 Harrison Ave, Yawkey Building, 2nd Fl, Boston, MA, United States AU - Bacon, T. S. AU - Fan, K. C. AU - Desai, M. A. DB - Embase DO - 10.2147/OPTH.S92785 KW - antiglaucoma agent adult African American age aged article Caucasian electronic medical record ethnicity female glaucoma Hispanic human major clinical study male medication compliance medication therapy management patient compliance race retrospective study very elderly LA - English M3 - Article N1 - L607940744 2016-02-05 2016-02-15 PY - 2016 SN - 1177-5483 1177-5467 SP - 221-225 ST - Electronic medical record and glaucoma medications: Connecting the medication reconciliation with adherence T2 - Clinical Ophthalmology TI - Electronic medical record and glaucoma medications: Connecting the medication reconciliation with adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607940744&from=export http://dx.doi.org/10.2147/OPTH.S92785 VL - 10 ID - 2758 ER - TY - JOUR AB - Purpose: To evaluate consistency in documentation of glaucoma medications in the electronic medical record and identify which regimen patients adhere to when inconsistencies exist. Factors contributing to medication nonadherence are also explored. Methods: Retrospective chart review of medication adherence encompassing 200 patients from three glaucoma physicians at a tertiary referral center over a 1-month period. Adherence was determined by the consistency between a patients stated medication regimen and either the active medication list in the electronic medical record, or the physicians planned medication regimen in the preceding clinic visit. Patient charts were also reviewed for patient sex, age, primary language, race, and total number of medications. Results: A total of 160 charts showed consistency in documentation between the physician note and electronic medication reconciliation. Of those patients, 83.1% reported adherence with their glaucoma medication schedule. When there was a discrepancy in documentation (40 charts), 72.5% patients followed the physician-stated regimen vs 20% who followed neither vs 7.5% who followed the medical record (P<0.01). No difference in adherence was observed based on sex (P=0.912) or total number of medications taken (P=0.242). Language, both English- (P=0.075) and Haitian (P=0.10) -speaking populations, as well as race, Caucasian (P=0.31), African-American (P=0.54), and Hispanic (P=0.58), had no impact on medica­tion adherence. Patients over 80 years of age were more nonadherent as compared to other decades (P=0.04). Conclusion: Inconsistent documentation between the electronic medical record physician note and medication regimen may contribute to patient medication nonadherence. Patients over 80 years of age were associated with higher rates of nonadherence, while sex, total number of medications, race, and language had no interaction with medication adherence. © 2016 Bacon et al. AD - Department of Ophthalmology, Boston University School of Medicine, Boston Medical Center, Boston, MA, United States AU - Bacon, T. S. AU - Fan, K. C. AU - Desai, M. A. DB - Scopus DO - 10.2147/OPTH.S92785 KW - Demographics Electronic medical record Glaucoma Medication reconciliation M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2016 SP - 221-225 ST - Electronic medical record and glaucoma medications: Connecting the medication reconciliation with adherence T2 - Clinical Ophthalmology TI - Electronic medical record and glaucoma medications: Connecting the medication reconciliation with adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970935839&doi=10.2147%2fOPTH.S92785&partnerID=40&md5=da6a9544b34c82aff458d8d32485c381 VL - 10 ID - 5515 ER - TY - JOUR AB - Purpose: To evaluate consistency in documentation of glaucoma medications in the electronic medical record and identify which regimen patients adhere to when inconsistencies exist. Factors contributing to medication nonadherence are also explored. Methods: Retrospective chart review of medication adherence encompassing 200 patients from three glaucoma physicians at a tertiary referral center over a 1-month period. Adherence was determined by the consistency between a patients stated medication regimen and either the active medication list in the electronic medical record, or the physicians planned medication regimen in the preceding clinic visit. Patient charts were also reviewed for patient sex, age, primary language, race, and total number of medications. Results: A total of 160 charts showed consistency in documentation between the physician note and electronic medication reconciliation. Of those patients, 83.1% reported adherence with their glaucoma medication schedule. When there was a discrepancy in documentation (40 charts), 72.5% patients followed the physician-stated regimen vs 20% who followed neither vs 7.5% who followed the medical record (P<0.01). No difference in adherence was observed based on sex (P=0.912) or total number of medications taken (P=0.242). Language, both English- (P=0.075) and Haitian (P=0.10) -speaking populations, as well as race, Caucasian (P=0.31), African-American (P=0.54), and Hispanic (P=0.58), had no impact on medication adherence. Patients over 80 years of age were more nonadherent as compared to other decades (P=0.04). Conclusion: Inconsistent documentation between the electronic medical record physician note and medication regimen may contribute to patient medication nonadherence. Patients over 80 years of age were associated with higher rates of nonadherence, while sex, total number of medications, race, and language had no interaction with medication adherence. AN - WOS:000371773900002 AU - Bacon, T. S. AU - Fan, K. C. AU - Desai, M. A. DO - 10.2147/OPTH.S92785 PY - 2016 SN - 1177-5483 SP - 221-225 ST - Electronic medical record and glaucoma medications: connecting the medication reconciliation with adherence T2 - CLINICAL OPHTHALMOLOGY TI - Electronic medical record and glaucoma medications: connecting the medication reconciliation with adherence VL - 10 ID - 6076 ER - TY - JOUR AB - Background: Cataract is a leading cause of childhood blindness in eastern Africa and other resource-constrained regions around the world, and high-quality surgical centers are increasingly responding to this challenge. Despite evidence concerning the ongoing risk of postoperative glaucoma after lensectomy, little is known of the incidence of glaucoma after pediatric cataract surgery in Africa. We sought to evaluate the frequency and predictors of postoperative glaucoma in this setting. Methods: The medical records of all children who underwent surgery for congenital or developmental cataract between 2003 and 2005 at the Kilimanjaro Christian Medical Centre were retrospectively reviewed to determine the incidence of postoperative glaucoma. Potential risk factors were evaluated by means of logistic regression. Results: Cumulative incidence of glaucoma at 3 years was 6.5% (95% CI, 2.5-16.0), and the annual incidence rate was 2.0 cases per 100 operated eyes (95% confidence interval, 0.74-4.37). Total time of follow-up and absence of primary intraocular lens implantation correlated with risk for postoperative glaucoma, but multivariate analysis could not confirm independent associations. Conclusions: As cataract surgical rates continue to increase and pediatric ophthalmology centers in Africa progress toward the goals of Vision 2020: The Right to Sight, renewed efforts must be directed toward the long-term postoperative care of all children undergoing operation for pediatric cataract. © 2013 by the American Association for Pediatric Ophthalmology and Strabismus. AD - University of North Carolina-Chapel Hill, Chapel Hill, NC, United States Kilimanjaro Centre for Community Ophthalmology, Good Samaritan Foundation, Moshi, Tanzania Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania AU - Baden, C. AU - Shija, F. AU - Lewallen, S. AU - Courtright, P. AU - Hall, A. DB - Scopus DO - 10.1016/j.jaapos.2012.11.009 IS - 2 M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2013 SP - 158-162 ST - Glaucoma after pediatric cataract surgery in a population with limited access to care T2 - Journal of AAPOS TI - Glaucoma after pediatric cataract surgery in a population with limited access to care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876945399&doi=10.1016%2fj.jaapos.2012.11.009&partnerID=40&md5=988bf502b97cf27b9872c2280eb7ca6e VL - 17 ID - 5239 ER - TY - JOUR AB - Introduction: The frequency of eye diseases has been suggested to start increasing around 40 years of age, with an even steeper increase beginning around 60 years of age. Health promotions and curative and rehabilitative services for the visually impaired elderly population should therefore be a priority in the coming years especially in low and middle income countries. Aim: To examine the changing pattern of ocular morbidity in the elderly population of Northern India and to determine the socioeconomic status in relation to ocular morbidities. Materials and Methods: A team from the Department of Ophthalmology and Department of Community Medicine, conducted house visits and did a complete eye examination of 450 elderly subjects. They were selected by systematic random sampling from the data base available in the Department of Community Medicine. Results: A total of 900 eyes were examined. Visual impairment and blindness was seen in 135 (30%) and 36 (8%) individuals respectively. The most common cause of blindness was cataract, followed by corneal opacity, glaucoma, refractive error, diabetic retinopathy, macular scar, age related macular degeneration, retinal detachment, retinitis pigmentosa. Visual impairment was more in individuals with low socioeconomic status. Conclusion: The results of this study suggest that though cataract remains the main cause of blindness, there is an increase in blindness and visual impairment due to corneal diseases and glaucoma which was not seen earlier. The availability and accessibility to eye care facilities particularly for corneal diseases and glaucoma should be increased to reduce blindness in Northern India. © 2017, Journal of Clinical and Diagnostic Research. All rights reserved. AD - Department of Ophthalmology, Christian Medical College and Hospital, Ludhiana, Punjab, India Department of Community Medicine, Christian Medical College and Hospital, Ludhiana, Punjab, India AU - Baldev, V. F. AU - Chopra, R. AU - Batra, N. AU - Singh, S. DB - Scopus DO - 10.7860/JCDR/2017/27056.10496 IS - 8 KW - Geriatric population Socioeconomic status Visual impairment M3 - Article N1 - Export Date: 19 July 2021 PY - 2017 SP - NC20-NC23 ST - Pattern of ocular morbidity in the elderly population of Northern India T2 - Journal of Clinical and Diagnostic Research TI - Pattern of ocular morbidity in the elderly population of Northern India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028576770&doi=10.7860%2fJCDR%2f2017%2f27056.10496&partnerID=40&md5=93b6930a67c5c1cd257f7986481c4591 VL - 11 ID - 5735 ER - TY - JOUR AB - Introduction: The frequency of eye diseases has been suggested to start increasing around 40 years of age, with an even steeper increase beginning around 60 years of age. Health promotions and curative and rehabilitative services for the visually impaired elderly population should therefore be a priority in the coming years especially in low and middle income countries. Aim: To examine the changing pattern of ocular morbidity in the elderly population of Northern India and to determine the socioeconomic status in relation to ocular morbidities. Materials and Methods: A team from the Department of Ophthalmology and Department of Community Medicine, conducted house visits and did a complete eye examination of 450 elderly subjects. They were selected by systematic random sampling from the data base available in the Department of Community Medicine. Results: A total of 900 eyes were examined. Visual impairment and blindness was seen in 135 (30%) and 36 (8%) individuals respectively. The most common cause of blindness was cataract, followed by corneal opacity, glaucoma, refractive error, diabetic retinopathy, macular scar, age related macular degeneration, retinal detachment, retinitis pigmentosa. Visual impairment was more in individuals with low socioeconomic status. Conclusion: The results of this study suggest that though cataract remains the main cause of blindness, there is an increase in blindness and visual impairment due to corneal diseases and glaucoma which was not seen earlier. The availability and accessibility to eye care facilities particularly for corneal diseases and glaucoma should be increased to reduce blindness in Northern India. AN - WOS:000412202900072 AU - Baldev, V. F. AU - Chopra, R. AU - Batra, N. AU - Singh, S. DA - AUG DO - 10.7860/JCDR/2017/27056.10496 IS - 8 PY - 2017 SN - 2249-782X 0973-709X SP - NC20-NC23 ST - Pattern of Ocular Morbidity in the Elderly Population of Northern India T2 - JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH TI - Pattern of Ocular Morbidity in the Elderly Population of Northern India VL - 11 ID - 6282 ER - TY - JOUR AB - Background: Glaucoma comprises a group of neurodegenerative diseases resulting in retinal ganglion cell death within the optic nerve head. It is projected to affect almost 80 million people worldwide by 2020. The condition’s asymptomatic nature translates to over half of glaucoma sufferers being unaware of their condition. By the time of diagnosis, irreversible blindness is likely to have occurred. Prime areas of glaucoma research therefore include identification and optimization of risk factors for the disease, accurate and early diagnostic tools and novel therapeutic methods. Methods: The goal of this review was to summarize main areas of latest glaucoma research into risk factors of glaucoma, diagnostic tools and treatments. PubMed was used to search for terms including glaucoma risk factors, glaucoma diagnostics, glaucoma treatment, glaucoma drug delivery and glaucoma IOP. Results: The evidence for risk factors of low CSF pressure, IOP, smoking, vascular risk factors and light toxicity is described. Latest diagnostic and monitoring techniques for glaucoma include SD-OCT, DARC and IOP telemetry. Current and emerging medical and surgical treatments in glaucoma are discussed. Rho kinase inhibitors have the potential to both lower IOP and also provide neuroprotection, several of which are in clinical trials. Several other new medical treatments such as calcium channel blockers and neurotrophic agents also have the capacity to provide neuroprotection. Minimally Invasive Glaucoma Surgery (MIGS) devices provide an improved safety profile compared to traditional trabeculectomy; the latest ab interno and ab externo devices are described. Novel drug delivery methods, including punctual plugs and contact lenses, help overcome the challenges with patient adherence. Conclusion: The ultimate goals are to reduce the individual patient risk factors associated with glaucoma, diagnose the condition early and to find treatments that not only reduce IOP but also reverse neurodegeneration of RGCs. The usage of combinations of novel medical and surgical treatments may help maximize IOP reduction and neuroprotection. and neuroprotection. AD - M.F. Cordeiro, Glaucoma and Retinal Neurodegeneration Group, Department of Visual Neuroscience, UCL Institute of Ophthalmology, London, United Kingdom AU - Balendra, S. I. AU - Shah, P. A. AU - Jain, M. AU - Grzybowski, A. AU - Cordeiro, M. F. DB - Embase Medline DO - 10.2174/1381612822666161129151308 IS - 4 KW - NCT02024464 calcium channel blocking agent neuroprotective agent neurotrophic factor Rho kinase inhibitor apoptosis article contact lens diagnostic procedure drug delivery system glaucoma glaucoma surgery human intraocular pressure meta analysis (topic) minimally invasive surgery multicenter study (topic) nerve degeneration neuroprotection patient compliance patient safety phase 2 clinical trial (topic) phototoxicity priority journal punctal plug randomized controlled trial (topic) retina ganglion cell risk factor risk reduction smoking spectral domain optical coherence tomography telemetry trabeculectomy LA - English M3 - Article N1 - L614951800 2017-04-26 2017-05-04 PY - 2017 SN - 1873-4286 1381-6128 SP - 596-607 ST - Glaucoma: Hot topics in pharmacology T2 - Current Pharmaceutical Design TI - Glaucoma: Hot topics in pharmacology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614951800&from=export http://dx.doi.org/10.2174/1381612822666161129151308 VL - 23 ID - 2669 ER - TY - JOUR AB - Introduction: Personalized medicine is the future goal across all specialties. Accurate prediction of optimal treatment beneficial and adverse effects could transform patient management. This is of particular importance in chronic conditions, where a 'trial and error' approach over months and years can contribute to significant morbidity. Glaucoma is a chronic irreversible progressive optic neuropathy, a leading cause of blindness worldwide. An ideal personalized approach in glaucoma clinic would be to answer the inevitable question in a patient's first visit: 'Which treatment option will work best for me so that I won't go blind?' Areas covered: This review will give an overview of the knowledge we have acquired to achieve this goal, particularly discussing using patient's individual risk factors, their genetic profile, and different treatment modalities, including therapy compliance, to personalize care. Expert opinion: Pharmacogenomics and genetic profiling are the most tangible ways in which glaucoma management can be personalized. Future challenges will include developing realistic animal models to reflect the underlying genetic patterns in glaucoma to investigate their interaction with different treatments. AN - WOS:000533876500001 AU - Balendra, S. I. AU - Zollet, P. AU - Casasca, Gcade AU - Cordeiro, M. F. DA - MAY 3 DO - 10.1080/23808993.2020.1756770 IS - 3 PY - 2020 SN - 2380-8993 SP - 145-164 ST - Personalized approaches for the management of glaucoma T2 - EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT TI - Personalized approaches for the management of glaucoma VL - 5 ID - 6075 ER - TY - JOUR AB - Introduction: Personalized medicine is the future goal across all specialties. Accurate prediction of optimal treatment beneficial and adverse effects could transform patient management. This is of particular importance in chronic conditions, where a ‘trial and error’ approach over months and years can contribute to significant morbidity. Glaucoma is a chronic irreversible progressive optic neuropathy, a leading cause of blindness worldwide. An ideal personalized approach in glaucoma clinic would be to answer the inevitable question in a patient’s first visit: ‘Which treatment option will work best for me so that I won’t go blind?’ Areas covered: This review will give an overview of the knowledge we have acquired to achieve this goal, particularly discussing using patient’s individual risk factors, their genetic profile, and different treatment modalities, including therapy compliance, to personalize care. Expert opinion: Pharmacogenomics and genetic profiling are the most tangible ways in which glaucoma management can be personalized. Future challenges will include developing realistic animal models to reflect the underlying genetic patterns in glaucoma to investigate their interaction with different treatments. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. AD - The Western Eye Hospital, Imperial College Healthcare NHS Trust (ICHNT), London, United Kingdom The Imperial College Ophthalmic Research Group (ICORG), Imperial College, London, United Kingdom Glaucoma and Retinal Neurodegeneration Group, Department of Visual Neuroscience, UCL Institute of Ophthalmology, London, United Kingdom Department of Ophthalmology, University Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy AU - Balendra, S. I. AU - Zollet, P. AU - Cisa Asinari Di Gresy E Casasca, G. AU - Cordeiro, M. F. DB - Scopus DO - 10.1080/23808993.2020.1756770 IS - 3 KW - personalization pharamacogenetics pharmacogenomics M3 - Review N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - 145-164 ST - Personalized approaches for the management of glaucoma T2 - Expert Review of Precision Medicine and Drug Development TI - Personalized approaches for the management of glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084815325&doi=10.1080%2f23808993.2020.1756770&partnerID=40&md5=a060e30a110674fea28768903310db09 VL - 5 ID - 5604 ER - TY - JOUR AB - Précis: Community-engaged research (CER) enables researchers to identify community-specific barriers and facilitators to program implementation. Broadly applicable barriers to glaucoma care, such as Cost, Transportation, and Trust, and community-specific barriers, such as Language and Convenience/Access, were identified. Purpose: The aim was to identify the facilitators and barriers to implementing glaucoma screening programs in 2 community clinics. Methods: A concurrent mixed-methods process analysis using CER. Key stakeholders - including patients, providers, and staff members - from 2 community clinics were interviewed using a semistructured interview guide. Interviews had 2 parts: (1) asking patients about community-based facilitators and barriers to implementing glaucoma screening and care and (2) eliciting feedback about a personalized coaching program. The transcripts were coded using Grounded Theory. Number of participants and number of representative citations were counted per theme. The qualitative analysis was coded using Dedoose 8.3.17 (Los Angeles, CA). Results: Thematic saturation was reached after coding 12 interviews. 30 participants were interviewed, 13 from Hamilton Clinic (Flint, MI; 8 patients, 5 providers and staff members) and 17 from Hope Clinic (Ypsilanti, MI; 6 patients, 11 providers and staff members). The most commonly cited themes were: Priorities (98 citations, 30 participants), Knowledge (73, 26) Transportation (63, 26), Cost (60, 23), and Convenience/Access (63, 22). Broadly applicable barriers to glaucoma care, such as Cost, Transportation, and Trust were identified alongside community-specific barriers such as Language and Convenience/Access. Participants rated their likelihood to follow up with an ophthalmologist after participating in the personalized coaching program at a mean of 8.83 (on a scale of 1 to 10 with 10 being the most confident). Conclusions: CER enables researchers to identify community-specific barriers and facilitators, allowing more effective program implementation. AD - P.A. Newman-Casey, Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, United States AU - Ballouz, D. AU - Cho, J. AU - Woodward, M. A. AU - Elam, A. R. AU - Musch, D. C. AU - Zhang, J. AU - Moroi, S. E. AU - Johnson, L. AU - Cederna, J. AU - Newman-Casey, P. A. DB - Embase Medline DO - 10.1097/IJG.0000000000001756 IS - 5 KW - article attitude to health clinical article follow up glaucoma grounded theory health care access health care cost health care personnel human mass screening medically underserved ophthalmologist patient care priority journal qualitative analysis semi structured interview stakeholder engagement telehealth traffic and transport LA - English M3 - Article N1 - L635014058 2021-05-19 2021-05-28 PY - 2021 SN - 1536-481X 1057-0829 SP - 402-409 ST - Facilitators and Barriers to Glaucoma Screening Identified by Key Stakeholders in Underserved Communities: A Community-engaged Research Approach T2 - Journal of Glaucoma TI - Facilitators and Barriers to Glaucoma Screening Identified by Key Stakeholders in Underserved Communities: A Community-engaged Research Approach UR - https://www.embase.com/search/results?subaction=viewrecord&id=L635014058&from=export http://dx.doi.org/10.1097/IJG.0000000000001756 VL - 30 ID - 2302 ER - TY - JOUR AB - Précis: Community-engaged research (CER) enables researchers to identify community-specific barriers and facilitators to program implementation. Broadly applicable barriers to glaucoma care, such as Cost, Transportation, and Trust, and community-specific barriers, such as Language and Convenience/Access, were identified. Purpose: The aim was to identify the facilitators and barriers to implementing glaucoma screening programs in 2 community clinics. Methods: A concurrent mixed-methods process analysis using CER. Key stakeholders - including patients, providers, and staff members - from 2 community clinics were interviewed using a semistructured interview guide. Interviews had 2 parts: (1) asking patients about community-based facilitators and barriers to implementing glaucoma screening and care and (2) eliciting feedback about a personalized coaching program. The transcripts were coded using Grounded Theory. Number of participants and number of representative citations were counted per theme. The qualitative analysis was coded using Dedoose 8.3.17 (Los Angeles, CA). Results: Thematic saturation was reached after coding 12 interviews. 30 participants were interviewed, 13 from Hamilton Clinic (Flint, MI; 8 patients, 5 providers and staff members) and 17 from Hope Clinic (Ypsilanti, MI; 6 patients, 11 providers and staff members). The most commonly cited themes were: Priorities (98 citations, 30 participants), Knowledge (73, 26) Transportation (63, 26), Cost (60, 23), and Convenience/Access (63, 22). Broadly applicable barriers to glaucoma care, such as Cost, Transportation, and Trust were identified alongside community-specific barriers such as Language and Convenience/Access. Participants rated their likelihood to follow up with an ophthalmologist after participating in the personalized coaching program at a mean of 8.83 (on a scale of 1 to 10 with 10 being the most confident). Conclusions: CER enables researchers to identify community-specific barriers and facilitators, allowing more effective program implementation. © 2021 Lippincott Williams and Wilkins. All rights reserved. AD - Department of Ophthalmology and Visual Sciences Institute for Healthcare Policy and Innovation, University of Michigan, United States Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, United States Hamilton Community Health Network, Flint, United States Hope Clinic, Ypsilanti, MI, United States Department of Ophthalmology, Ohio State University, Columbus, OH, United States AU - Ballouz, D. AU - Cho, J. AU - Woodward, M. A. AU - Elam, A. R. AU - Musch, D. C. AU - Zhang, J. AU - Moroi, S. E. AU - Johnson, L. AU - Cederna, J. AU - Newman-Casey, P. A. DB - Scopus DO - 10.1097/IJG.0000000000001756 IS - 5 KW - community-engaged research glaucoma screening telemedicine M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 402-409 ST - Facilitators and Barriers to Glaucoma Screening Identified by Key Stakeholders in Underserved Communities: A Community-engaged Research Approach T2 - Journal of Glaucoma TI - Facilitators and Barriers to Glaucoma Screening Identified by Key Stakeholders in Underserved Communities: A Community-engaged Research Approach UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105724820&doi=10.1097%2fIJG.0000000000001756&partnerID=40&md5=da68215dfb78eb461e64e63525400cbf VL - 30 ID - 5657 ER - TY - JOUR AB - Precis: Community-engaged research (CER) enables researchers to identify community-specific barriers and facilitators to program implementation. Broadly applicable barriers to glaucoma care, such as Cost, Transportation, and Trust, and community-specific barriers, such as Language and Convenience/Access, were identified. Purpose: The aim was to identify the facilitators and barriers to implementing glaucoma screening programs in 2 community clinics. Methods: A concurrent mixed-methods process analysis using CER. Key stakeholders-including patients, providers, and staff members-from 2 community clinics were interviewed using a semistructured interview guide. Interviews had 2 parts: (1) asking patients about community-based facilitators and barriers to implementing glaucoma screening and care and (2) eliciting feedback about a personalized coaching program. The transcripts were coded using Grounded Theory. Number of participants and number of representative citations were counted per theme. The qualitative analysis was coded using Dedoose 8.3.17 (Los Angeles, CA). Results: Thematic saturation was reached after coding 12 interviews. 30 participants were interviewed, 13 from Hamilton Clinic (Flint, MI; 8 patients, 5 providers and staff members) and 17 from Hope Clinic (Ypsilanti, MI; 6 patients, 11 providers and staff members). The most commonly cited themes were: Priorities (98 citations, 30 participants), Knowledge (73, 26) Transportation (63, 26), Cost (60, 23), and Convenience/Access (63, 22). Broadly applicable barriers to glaucoma care, such as Cost, Transportation, and Trust were identified alongside community-specific barriers such as Language and Convenience/Access. Participants rated their likelihood to follow up with an ophthalmologist after participating in the personalized coaching program at a mean of 8.83 (on a scale of 1 to 10 with 10 being the most confident). Conclusions: CER enables researchers to identify community-specific barriers and facilitators, allowing more effective program implementation. AN - WOS:000647978800024 AU - Ballouz, D. AU - Cho, J. AU - Woodward, M. A. AU - Elam, A. R. AU - Musch, D. C. AU - Zhang, J. AU - Moroi, S. E. AU - Johnson, L. AU - Cederna, J. AU - Newman-Casey, P. A. DA - MAY DO - 10.1097/IJG.0000000000001756 IS - 5 PY - 2021 SN - 1057-0829 1536-481X SP - 402-409 ST - Facilitators and Barriers to Glaucoma Screening Identified by Key Stakeholders in Underserved Communities: A Community-engaged Research Approach T2 - JOURNAL OF GLAUCOMA TI - Facilitators and Barriers to Glaucoma Screening Identified by Key Stakeholders in Underserved Communities: A Community-engaged Research Approach VL - 30 ID - 6114 ER - TY - JOUR AB - Purpose:To understand medication use and patient burden for treatment of bacterial keratitis (BK).Methods:A retrospective study was conducted examining medical records of adult patients with BK in an academic cornea practice. Data collected included medications used in the treatment of BK, dosing of medications, and the number and total duration of clinical encounters. Costs of medications were estimated using the average wholesale pharmacy price. Linear regression analysis was used to investigate associations of medication use with patient demographics and corneal culture results and reported with beta estimates (β) and 95% confidence intervals (95% CIs).Results:Forty-eight patients with BK (56% female) were studied. Patients were treated for a median of 54 days with 10 visits, 5 unique medications, 587 drops, and 7 prescriptions. The estimated median medication cost was $933 (interquartile range: $457-$1422) US dollars. Positive bacterial growth was significantly associated with more visits (β: 6.16, 95% CI: 1.75-10.6, P = 0.007), more days of treatment (β: 86.8, 95% CI: 10.8-163, P = 0.026), more prescribed medications (β: 2.86, 95% CI: 1.04-4.67, P = 0.003), and more doses of medications (β: 796, 95% CI: 818-1412, P = 0.012) compared with patients who did not undergo corneal scraping. Patients were prescribed 132 more drops of medication for every 10 years of older age (β: 132, 95% CI: 18.2-246, P = 0.024). Sex and income were not associated with medication burden or treatment length.Conclusions:Older patients and those with positive cultures incur the most medication burden in treatment of BK. Providers should be aware of medication usage and cost burden as it may affect compliance with treatment. © 2019 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, 1000 Wall St, Ann Arbor, MI 48105, United States Feinberg School of Medicine, Northwestern University, Chicago, IL, United States Consulting for Statistics, Computing and Analytics Research (CSCAR), University of Michigan, Ann Arbor, MI, United States Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States AU - Ballouz, D. AU - Maganti, N. AU - Tuohy, M. AU - Errickson, J. AU - Woodward, M. A. DB - Scopus DO - 10.1097/ICO.0000000000001942 IS - 8 KW - bacterial keratitis cost drops medication M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2019 SP - 933-937 ST - Medication Burden for Patients with Bacterial Keratitis T2 - Cornea TI - Medication Burden for Patients with Bacterial Keratitis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066635748&doi=10.1097%2fICO.0000000000001942&partnerID=40&md5=f99ead7af30b28694e0be1b594134698 VL - 38 ID - 5500 ER - TY - JOUR AB - Purpose: To understand medication use and patient burden for treatment of bacterial keratitis (BK). Methods: A retrospective study was conducted examining medical records of adult patients with BK in an academic cornea practice. Data collected included medications used in the treatment of BK, dosing of medications, and the number and total duration of clinical encounters. Costs of medications were estimated using the average wholesale pharmacy price. Linear regression analysis was used to investigate associations of medication use with patient demographics and corneal culture results and reported with beta estimates (beta) and 95% confidence intervals (95% CIs). Results: Forty-eight patients with BK (56% female) were studied. Patients were treated for a median of 54 days with 10 visits, 5 unique medications, 587 drops, and 7 prescriptions. The estimated median medication cost was $933 (interquartile range: $457-$1422) US dollars. Positive bacterial growth was significantly associated with more visits (beta: 6.16, 95% CI: 1.75-10.6, P = 0.007), more days of treatment (beta: 86.8, 95% CI: 10.8-163, P = 0.026), more prescribed medications (beta: 2.86, 95% CI: 1.04-4.67, P = 0.003), and more doses of medications (beta: 796, 95% CI: 818-1412, P = 0.012) compared with patients who did not undergo corneal scraping. Patients were prescribed 132 more drops of medication for every 10 years of older age (beta: 132, 95% CI: 18.2-246, P = 0.024). Sex and income were not associated with medication burden or treatment length. Conclusions: Older patients and those with positive cultures incur the most medication burden in treatment of BK. Providers should be aware of medication usage and cost burden as it may affect compliance with treatment. AN - WOS:000480682500005 AU - Ballouz, D. AU - Maganti, N. AU - Tuohy, M. AU - Errickson, J. AU - Woodward, M. A. DA - AUG DO - 10.1097/ICO.0000000000001942 IS - 8 PY - 2019 SN - 0277-3740 1536-4798 SP - 933-937 ST - Medication Burden for Patients With Bacterial Keratitis T2 - CORNEA TI - Medication Burden for Patients With Bacterial Keratitis VL - 38 ID - 6306 ER - TY - JOUR AB - Glaucoma is a chronic neurodegenerative optic nerve disease. Treatment is intended to prevent the development and progression of optic nerve damage by lowering intraocular pressure (IOP). Current therapy options include topical/systemic drugs that increase aqueous humor outflow or decrease its production, laser therapy that targets the trabecular meshwork and ciliary body, and incisional surgery. Trabeculectomy as well as glaucoma drainage devices are often performed, given their high efficacy in lowering IOP. However, the significant risk profile with potential sight-threatening complications has motivated glaucoma experts to create alternative surgeries to treat glaucoma. Minimally invasive glaucoma surgery (MIGS) is defined by: micro-invasive approach, minimal tissue trauma, high safety profile, and rapid recovery. The new devices might promote an earlier transition from medical/laser therapy to surgery, and therefore decrease the side effects associated with long-term use of topical medications as well as deal with the limited adherence of patients to their regimens. This review presents the surgical options available for glaucoma patients and their evolution over the past 25 years. AN - WOS:000440212400004 AU - Bar-David, L. AU - Blumenthal, E. Z. DA - JUL DO - 10.5041/RMMJ.10345 IS - 3 PY - 2018 SN - 2076-9172 ST - Evolution of Glaucoma Surgery in the Last 25 Years T2 - RAMBAM MAIMONIDES MEDICAL JOURNAL TI - Evolution of Glaucoma Surgery in the Last 25 Years VL - 9 ID - 6090 ER - TY - JOUR AN - 109785400. Language: English. Entry Date: 20150821. Revision Date: 20200708. Publication Type: Journal Article AU - Barker, Gordon T. AU - Cook, Paul F. AU - Schmiege, Sarah J. AU - Kahook, Malik Y. AU - Kammer, Jeffrey A. AU - Mansberger, Steven L. DB - ccm DO - 10.1016/j.ajo.2015.03.006 DP - EBSCOhost IS - 6 KW - Antihypertensive Agents -- Administration and Dosage Glaucoma -- Drug Therapy Health Behavior Medication Compliance Models, Psychological Psychometrics Questionnaires Aged Attitude to Health Clinical Assessment Tools False Positive Results Female Glaucoma -- Psychosocial Factors Human Male Middle Age Models, Statistical Ocular Hypertension -- Drug Therapy Ocular Hypertension -- Psychosocial Factors Ophthalmic Solutions Patient Attitudes Predictive Value of Tests Reproducibility of Results Scales N1 - research. Journal Subset: Biomedical; USA. Instrumentation: Glaucoma Treatment Compliance Assessment Tool. NLM UID: 0370500. PMID: NLM25794793. PY - 2015 SN - 0002-9394 SP - 1092-1099.e2 ST - Psychometric properties of the glaucoma treatment compliance assessment tool in a multicenter trial T2 - American Journal of Ophthalmology TI - Psychometric properties of the glaucoma treatment compliance assessment tool in a multicenter trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109785400&site=ehost-live&scope=site VL - 159 ID - 4629 ER - TY - JOUR AB - Background: The first topically active carbonic anhydrase inhibitor, dorzolamide, was developed to circumvent the adverse systemic effects of oral carbonic anhydrase inhibitors. However, its use has been associated with ocular discomfort. Objective: The present study examined the acceptability of brinzolamide, as measured by patients' ratings and stated preferences, in patients with glaucoma previously treated with dorzolamide in the clinical practice setting. Methods: This was a prospective, open-label, noncomparative study conducted shortly after the approval of brinzolamide. Ophthalmologists in private practice in the continental United States were asked to select patients currently using dorzolamide as their sole or combination therapy for glaucoma. Patients underwent a screening assessment in which they were asked to rate their ocular comfort with dorzolamide on a scale from 1 to 6. Brinzolamide was then substituted for dorzolamide, and patients returned for a follow-up visit ~1 to 3 months later. At this visit, patients were asked about ocular comfort, their preferred medication, and whether they thought ocular comfort influenced their adherence to treatment. Intraocular pressure (IOP) was measured at both visits. Results: Valid visit dates (ie, both baseline and follow-up dates) were available for 447 of 501 patients from 68 of 73 sites (range, 1-40 patients per site). Because not all measurements were available for all patients at each visit, the sample size varied for each measurement. Demographic data were not available. The switch to brinzolamide resulted in a mean decrease in IOP of ~0.8 mm Hg (P < 0.001, paired t test). Sixty-nine percent of patients (274/397) reported an improvement of ≥1 grade in their comfort rating with brinzolamide versus dorzolamide. The mean (± SD) improvement in comfort rating was 1.43 ± 1.48 grades (P < 0.001, Wilcoxon rank sum test). When patients were asked whether their adherence to treatment was affected by the occurrence of burning and stinging, 43% (173/399) answered affirmatively. Fifty-nine percent (251/424) preferred brinzolamide to dorzolamide. At the end of the study, based on patient preference, physician judgment, and other factors, 73% of responding patients (301/410) continued with brinzolamide therapy. Conclusions: In this study, the switch from dorzolamide to brinzolamide resulted in overall improvements in comfort and ocular hypotensive efficacy. However, studies using a more rigorous randomized, controlled, crossover design are needed to support these observations. AD - H. Barnebey, 901 Boren, Seattle, WA 98104, United States AU - Barnebey, H. AU - Kwok, S. Y. DB - Embase Medline DO - 10.1016/S0149-2918(00)83063-5 IS - 10 KW - brinzolamide dorzolamide adult aged article clinical practice drug efficacy drug tolerability female glaucoma human intraocular pressure major clinical study male osmolality patient compliance patient satisfaction rating scale screening LA - English M3 - Article N1 - L30809728 2000-11-25 PY - 2000 SN - 0149-2918 SP - 1204-1212 ST - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting T2 - Clinical Therapeutics TI - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30809728&from=export http://dx.doi.org/10.1016/S0149-2918(00)83063-5 VL - 22 ID - 3905 ER - TY - JOUR AB - BACKGROUND: The first topically active carbonic anhydrase inhibitor, dorzolamide, was developed to circumvent the adverse systemic effects of oral carbonic anhydrase inhibitors. However, its use has been associated with ocular discomfort. OBJECTIVE: The present study examined the acceptability of brinzolamide, as measured by patients' ratings and stated preferences, in patients with glaucoma previously treated with dorzolamide in the clinical practice setting. METHODS: This was a prospective, open-label, noncomparative study conducted shortly after the approval of brinzolamide. Ophthalmologists in private practice in the continental United States were asked to select patients currently using dorzolamide as their sole or combination therapy for glaucoma. Patients underwent a screening assessment in which they were asked to rate their ocular comfort with dorzolamide on a scale from 1 to 6. Brinzolamide was then substituted for dorzolamide, and patients returned for a follow-up visit approximately 1 to 3 months later. At this visit, patients were asked about ocular comfort, their preferred medication, and whether they thought ocular comfort influenced their adherence to treatment. Intraocular pressure (IOP) was measured at both visits. RESULTS: Valid visit dates (ie, both baseline and follow-up dates) were available for 447 of 501 patients from 68 of 73 sites (range, 1-40 patients per site). Because not all measurements were available for all patients at each visit, the sample size varied for each measurement. Demographic data were not available. The switch to brinzolamide resulted in a mean decrease in IOP of approximately 0.8 mm Hg (P < 0.001, paired t test). Sixty-nine percent of patients (274/397) reported an improvement of > or =1 grade in their comfort rating with brinzolamide versus dorzolamide. The mean (+/- SD) improvement in comfort rating was 1.43 +/- 1.48 grades (P < 0.001, Wilcoxon rank sum test). When patients were asked whether their adherence to treatment was affected by the occurrence of burning and stinging, 43% (173/399) answered affirmatively. Fifty-nine percent (251/424) preferred brinzolamide to dorzolamide. At the end of the study, based on patient preference, physician judgment, and other factors, 73% of responding patients (301/410) continued with brinzolamide therapy. CONCLUSIONS: In this study, the switch from dorzolamide to brinzolamide resulted in overall improvements in comfort and ocular hypotensive efficacy. However, studies using a more rigorous randomized, controlled, crossover design are needed to support these observations. AD - Department of Ophthalmology, University of Washington, Seattle, WA; barnebey@u.washington.edu AN - 106836144. Language: English. Entry Date: 20030530. Revision Date: 20150711. Publication Type: Journal Article AU - Barnebey, H. AU - Kwok, S. Y. DB - ccm DP - EBSCOhost IS - 10 KW - Glaucoma -- Drug Therapy Descriptive Statistics Intraocular Pressure -- Drug Effects Paired T-Tests Prospective Studies Scales Wilcoxon Rank Sum Test Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Alcon Laboratories, Inc., Forth Worth, Texas. NLM UID: 7706726. PMID: NLM11110231. PY - 2000 SN - 0149-2918 SP - 1204-1212 ST - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting T2 - Clinical Therapeutics TI - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106836144&site=ehost-live&scope=site VL - 22 ID - 4513 ER - TY - JOUR AB - Examined the acceptability of the oral carbonic anhydrease inhibitor brinzolamide in patients with glaucoma previously treated with dorzolamide. 397 patients reported their comfort with using brinzolamide compared with dorzolamide at baseline and at 3–184 day follow-up. Results show that 59% of Ss preferred brinzolamide to dorzolamide. 43% reported that stinging affected adherence to medication treatment regimens. 73% of Ss continued to use brinzolamide. (PsycINFO Database Record (c) 2017 APA, all rights reserved) AN - 2000-12310-001 AU - Barnebey, Howard AU - Kwok, Shiu Y. DB - psyh DO - 10.1016/S0149-2918(00)83063-5 DP - EBSCOhost IS - 10 KW - oral carbonic anhydrease inhibitor brinzolamide vs dorzolamide treatment comfort glaucoma patients 3–184 day followup Carbonic Anhydrase Inhibitors Glaucoma Humans Intraocular Pressure Patient Satisfaction Prospective Studies Sulfonamides Thiazines Thiophenes Drug Therapy Prescription Drugs Side Effects (Drug) N1 - U Washington, Dept of Ophthalmology, Seattle, WA, US. Release Date: 20010131. Correction Date: 20170615. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Glaucoma; Prescription Drugs; Side Effects (Drug). Classification: Medical Treatment of Physical Illness (3363). Population: Human (10). Methodology: Clinical Trial; Empirical Study; Followup Study. Page Count: 9. Issue Publication Date: Oct, 2000. PY - 2000 SN - 0149-2918 1879-114X SP - 1204-1212 ST - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting T2 - Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy TI - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2000-12310-001&site=ehost-live&scope=site VL - 22 ID - 4872 ER - TY - JOUR AB - Background: The first topically active carbonic anhydrase inhibitor, dorzolamide, was developed to circumvent the adverse systemic effects of oral carbonic anhydrase inhibitors. However, its use has been associated with ocular discomfort. Objective: The present study examined the acceptability of brinzolamide, as measured by patients' ratings and stated preferences, in patients with glaucoma previously treated with dorzolamide in the clinical practice setting. Methods: This was a prospective, open-label, noncomparative study conducted shortly after the approval of brinzolamide. Ophthalmologists in private practice in the continental United States were asked to select patients currently using dorzolamide as their sole or combination therapy for glaucoma. Patients underwent a screening assessment in which they were asked to rate their ocular comfort with dorzolamide on a scale from 1 to 6. Brinzolamide was then substituted for dorzolamide, and patients returned for a follow-up visit ~1 to 3 months later. At this visit, patients were asked about ocular comfort, their preferred medication, and whether they thought ocular comfort influenced their adherence to treatment. Intraocular pressure (IOP) was measured at both visits. Results: Valid visit dates (ie, both baseline and follow-up dates) were available for 447 of 501 patients from 68 of 73 sites (range, 1-40 patients per site). Because not all measurements were available for all patients at each visit, the sample size varied for each measurement. Demographic data were not available. The switch to brinzolamide resulted in a mean decrease in IOP of ~0.8 mm Hg (P < 0.001, paired t test). Sixty-nine percent of patients (274/397) reported an improvement of ≥1 grade in their comfort rating with brinzolamide versus dorzolamide. The mean (± SD) improvement in comfort rating was 1.43 ± 1.48 grades (P < 0.001, Wilcoxon rank sum test). When patients were asked whether their adherence to treatment was affected by the occurrence of burning and stinging, 43% (173/399) answered affirmatively. Fifty-nine percent (251/424) preferred brinzolamide to dorzolamide. At the end of the study, based on patient preference, physician judgment, and other factors, 73% of responding patients (301/410) continued with brinzolamide therapy. Conclusions: In this study, the switch from dorzolamide to brinzolamide resulted in overall improvements in comfort and ocular hypotensive efficacy. However, studies using a more rigorous randomized, controlled, crossover design are needed to support these observations. AD - Department of Ophthalmology, University of Washington, Seattle, WA, United States Department of Ophthalmology, University of California, San Francisco, CA, United States 901 Boren, Seattle, WA 98104, United States AU - Barnebey, H. AU - Kwok, S. Y. DB - Scopus DO - 10.1016/S0149-2918(00)83063-5 IS - 10 KW - Brinzolamide Comfort Dorzolamide Intraocular pressure M3 - Article N1 - Cited By :51 Export Date: 19 July 2021 PY - 2000 SP - 1204-1212 ST - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting T2 - Clinical Therapeutics TI - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033736217&doi=10.1016%2fS0149-2918%2800%2983063-5&partnerID=40&md5=6ef07a54cfec6376f228bc03d7c7010f VL - 22 ID - 4994 ER - TY - JOUR AB - Background: The first topically active carbonic anhydrase inhibitor, dorzolamide, was developed to circumvent the adverse systemic effects of oral carbonic anhydrase inhibitors. However, its use has been associated with ocular discomfort. Objective: The present study examined the acceptability of brinzolamide, as measured by patients' ratings and stated preferences, in patients with glaucoma previously treated with dorzolamide in the clinical practice setting. Methods: This was a prospective, open-label, noncomparative study conducted shortly after the approval of brinzolamide. Ophthalmologists in private practice in the continental United States were asked to select patients currently using dorzolamide as their sole or combination therapy for glucoma. Patients underwent a screening assessment in which they were asked to rate their ocular comfort with dorzolamide on a scale from 1 to 6. Brinzolamide was,then substituted for dorzolamide, and patients returned for a follow-up visit similar to1 to 3 months later. At this visit, patients were asked about ocular comfort, their preferred medication, and whether they thought ocular comfort influenced their adherence to treatment. Intraocular pressure (IOP) was measured at both visits. Results: Valid visit dates (ie, both baseline and follow-up dates) were available for 447 of 501 patients from 68 of 73 sites (range, 1-40 patients per site). Because not all measurements were available for all patients at each visit, the sample size varied for each measurement. Demographic data were not available. The switch to brinzolamide resulted in a mean decrease in IOP of similar to0.8 mm Hg (P < 0.001, paired t test). Sixty-nine percent of patients (274/397) reported an improvement of 1 grade in their comfort rating with brinzolamide versus dorzolamide. The mean (+/- SD) improvement in comfort rating was 1.43 +/- 1.48 grades (P < 0.001, Wilcoxon rank sum test). When patients were asked whether their adherence to treatment was affected by the occurrence of burning and stinging, 43% (173/399) answered affirmatively Fifty-nine percent (251/424) preferred brinzolamide to dorzolamide. At the end of the study, based on patient preference, physician judgment, and other factors, 73% of responding patients (301/410) continued with brinzolamide therapy. Conclusions: In this study, the switch from dorzolamide to brinzolamide resulted in overall improvements in comfort and ocular hypotensive efficacy. However, studies using a more rigorous randomized, controlled, crossover design are needed to support these observations. AN - WOS:000165688900005 AU - Barnebey, H. AU - Kwok, S. Y. DA - OCT DO - 10.1016/S0149-2918(00)83063-5 IS - 10 PY - 2000 SN - 0149-2918 1879-114X SP - 1204-1212 ST - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting T2 - CLINICAL THERAPEUTICS TI - Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting VL - 22 ID - 5986 ER - TY - JOUR AB - Purpose To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids. Design Randomized, controlled, observer-masked clinical trial. Methods SETTING: Two US clinical sites. PATIENT POPULATION: Eligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension. Patients (n = 81) were sequentially randomized 1:1 to receive TTFC or TRAV+TIM for 12 months. INTERVENTION: TTFC was administered once daily in the morning or evening with a single dosing aid. Patients randomized to TRAV+TIM administered TRAV once daily in the evening and TIM once daily in the morning using separate dosing aids. MAIN OUTCOME MEASURE: Adherence with administered medication, as recorded by the dosing aids. Results Mean ± SD patient age was 60 ± 10 years; most patients were male and white. Compared with TRAV+TIM (n = 40), patients receiving TTFC (n = 41) were consistently adherent on a greater percentage of days through month 12 (60% vs 43%). At months 1, 3, 6, and 12, 80% adherence was achieved by 71% vs 38%, 53% vs 30%, 45% vs 16%, and 32% vs 11% of patients receiving TTFC vs TRAV+TIM, respectively. Significantly more patients were adherent on ≥80% of days with TTFC compared with TRAV+TIM (P < .001 to P = .041). Both treatments reduced IOP from baseline, and no safety issues were identified in either group. Ocular hyperemia was the most common treatment-related adverse event (n = 3/group). Conclusions Patients receiving TTFC maintained better treatment adherence compared with patients receiving TRAV+TIM through 12 months of on-therapy evaluation. This suggests that, for patients requiring multiple IOP-lowering medications, a fixed combination may provide improved long-term adherence compared with unfixed therapy. AD - H.S. Barnebey, Specialty Eyecare Centre, 1920 116th Ave NE, Bellevue, WA, United States AU - Barnebey, H. S. AU - Robin, A. L. C1 - duotrav(Alcon,United States) C2 - Alcon(United States) Falcon(United States) DB - Embase Medline DO - 10.1016/j.ajo.2016.12.002 KW - NCT00465803 timolol travoprost adult alopecia anemia article controlled study evening dosage eye disease eye irritation eye pain female hip arthroplasty human hyperemia intraocular hypertension intraocular pressure major clinical study male medication compliance morning dosage open angle glaucoma outcome assessment patient compliance photophobia priority journal randomized controlled trial single drug dose treatment duration duotrav LA - English M3 - Article N1 - L614177840 2017-01-31 2017-03-03 PY - 2017 SN - 1879-1891 0002-9394 SP - 61-69 ST - Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial T2 - American Journal of Ophthalmology TI - Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614177840&from=export http://dx.doi.org/10.1016/j.ajo.2016.12.002 VL - 176 ID - 2658 ER - TY - JOUR AB - Purpose To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids. Design Randomized, controlled, observer-masked clinical trial. Methods SETTING: Two US clinical sites. PATIENT POPULATION: Eligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension. Patients (n = 81) were sequentially randomized 1:1 to receive TTFC or TRAV+TIM for 12 months. INTERVENTION: TTFC was administered once daily in the morning or evening with a single dosing aid. Patients randomized to TRAV+TIM administered TRAV once daily in the evening and TIM once daily in the morning using separate dosing aids. MAIN OUTCOME MEASURE: Adherence with administered medication, as recorded by the dosing aids. Results Mean ± SD patient age was 60 ± 10 years; most patients were male and white. Compared with TRAV+TIM (n = 40), patients receiving TTFC (n = 41) were consistently adherent on a greater percentage of days through month 12 (60% vs 43%). At months 1, 3, 6, and 12, 80% adherence was achieved by 71% vs 38%, 53% vs 30%, 45% vs 16%, and 32% vs 11% of patients receiving TTFC vs TRAV+TIM, respectively. Significantly more patients were adherent on ≥80% of days with TTFC compared with TRAV+TIM (P < .001 to P = .041). Both treatments reduced IOP from baseline, and no safety issues were identified in either group. Ocular hyperemia was the most common treatment-related adverse event (n = 3/group). Conclusions Patients receiving TTFC maintained better treatment adherence compared with patients receiving TRAV+TIM through 12 months of on-therapy evaluation. This suggests that, for patients requiring multiple IOP-lowering medications, a fixed combination may provide improved long-term adherence compared with unfixed therapy. © 2016 The Author(s) AD - Specialty Eyecare Centre, Bellevue, Washington, United States Department of Ophthalmology, Johns Hopkins University, Baltimore, Maryland, United States Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States University of Maryland, Baltimore, Maryland, United States University of Michigan, Ann Arbor, Michigan, United States AU - Barnebey, H. S. AU - Robin, A. L. DB - Scopus DO - 10.1016/j.ajo.2016.12.002 M3 - Article N1 - Cited By :33 Export Date: 19 July 2021 PY - 2017 SP - 61-69 ST - Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial T2 - American Journal of Ophthalmology TI - Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010297198&doi=10.1016%2fj.ajo.2016.12.002&partnerID=40&md5=af5d656ea95b173924eec1c8de43056f VL - 176 ID - 5043 ER - TY - JOUR AB - Purpose. This evaluation was conducted as part of a protocol entitled Evaluation of the Menicon Z Rigid Gas Permeable Contact Lens for up to 30 Days Extended Wear. The purpose of the protocol was to compare corneal endothelial morphology changes after wearing rigid gas-permeable (RGP) Menicon Z contact lenses, continuously for up to 30 days, with ACUVUE (Johnson & Johnson Vision Care) hydrogel contact lenses, worn for up to 6 nights of extended wear. Methods. Sixty patients, who were adapted to RGP daily wear and soft contact lens daily wear, were recruited at two study sites. The thirty subjects who wore RGP daily wear lenses were fitted with the Menicon Z (tisilfocon A, oxygen permeablility [Dk] = 163) RGP contact lens comprised the test group. The control group subjects (n = 30 former users of daily wear soft contact lenses) were fitted with ACUVUE (etafilcon A, Dk = 28) hydrogel contact lenses. After a 2-week adaptation period of daily wear, subjects began extended wear. Endothelial imaging was performed at the two study sites in this multicenter study (University Hospitals of Cleveland/Case Western Reserve University Department of Ophthalmology [CWRU] and The Ohio State University [OSU]). The hydrogel lens group was instructed to wear their lenses for 7 days and 6 nights before discarding the lenses and to sleep with no lenses on the seventh night. The RGP group was permitted to wear the lenses for up to 30 days and 29 consecutive nights before removing the lenses for cleaning and overnight soaking. Results. CWRU had 24 patients (12 soft contact lens and 12 rigid contact lens) and OSU had 21 patients (12 soft contact lens and 9 rigid contact lens) who completed the study and were included in the analyses. Patients who were withdrawn from the study at CWRU included one RGP patient dropped out because of pregnancy; one RGP patient developed vascularized limbal keratitis and discomfort; one could not be fitted with a bitoric RGP; two soft lens patients moved from the area, and one dropped out because of dry eyes. At OSU, four patients dropped out due to discomfort (two in each lens type); one moved from the study area; one decided not to participate soon after the consent visit; one had worries of reduced vision at 6 months; one subject's attitude changed prior to the 6 month visit; and one subject was withdrawn for reasons of poor study schedule compliance. Conclusion. The Menicon Z lens wearers in this study did not show significant endothelial cell morphology changes after 1 year of nearly continuous contact lens wear. This finding is particularly important considering the RGP wearers in this study were older by a average of 10 years (mean age approximately 40) and had worn their contact lenses an average of almost 10 years longer than the soft contact lens wearers. © 2003 Contact Lens Association of Ophthalmologists, Inc. AD - Ohio State University, College of Optometry, Columbus, OH, United States Department of Ophthalmology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, United States Foresite Regulatory Strategies, Ltd., Wilmington, MA, United States Ohio State University, College of Optometry, 248 Fry Hall, 320 W. 10th Avenue, Columbus, OH 43218-2342, United States AU - Barr, J. T. AU - Pall, B. AU - Szczotka, L. B. AU - Mitchell, G. L. AU - Gleason, W. DB - Scopus DO - 10.1097/00140068-200301000-00004 IS - 1 KW - Contact lenses Cornea Orthokeratology M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2003 SP - 14-16 ST - Corneal endothelial morphology results in the Menicon Z 30-day continuous-wear contact lens clinical trial T2 - Eye and Contact Lens TI - Corneal endothelial morphology results in the Menicon Z 30-day continuous-wear contact lens clinical trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038825097&doi=10.1097%2f00140068-200301000-00004&partnerID=40&md5=ce768be99a1fd36c175268d2bc1d0da4 VL - 29 ID - 5313 ER - TY - JOUR AB - Background: This research was designed to provide an in-depth exploration of the perceptions of optometrists relating to the challenges of glaucoma case finding in the Irish health-care system.Methods: A survey was developed, piloted and distributed for anonymous completion by optometrists registered to practise in Ireland. The survey included 10 five-level Likert items exploring potential barriers to glaucoma detection and a free-text box for participants to comment more broadly.Results: One hundred and ninety-nine optometrists (27 per cent of registrants) responded to the survey. Among the barriers identified, there was notable agreement (71 per cent) with the need for extra training on glaucoma detection. Logistic regression showed that optometrists without postgraduate qualifications were more likely to agree with the need for extra training (OR 3.2, 95 per cent CI 1.3-8.1). Respondents largely agreed (61 per cent) that patient unwillingness to pay additional fees for supplementary glaucoma-specific tests was also a barrier. Appointment times of less than 30 minutes were significantly associated with six of the 10 proposed barriers to glaucoma detection. A logistic regression analysis (n = 179) confirmed that the time allotted per appointment was a significant predictor of the agreement time of optometrists as a barrier (χ2 [1] = 13.52, p < 0.001). Multiple linear regression showed that optometrists with less experience, charging lower fees, and working in large multiples or franchised practices have the shortest appointment times.Conclusion: The strong link found between postgraduate education and the confidence of optometrists in detecting glaucoma indicates that optometrists wishing to increase their scope of practice in the new legislative environment in Ireland may more actively seek training in areas of interest. The responses also indicate a lack of funding for the level of diagnostic testing required for accurate glaucoma diagnosis. Recent increases in the state's eye examination fees look likely to address the identified time and financial barriers to glaucoma detection in Ireland. Future work should look to analyse the effects of increased funding on optometric case finding for glaucoma. AD - School of Physics and Clinical and Optometric Sciences, Dublin Institute of Technology, Dublin, Ireland Mater Misericordiae University Hospital, Dublin, Ireland School of Mathematical Sciences, Dublin Institute of Technology, Dublin, Ireland African Vision Research Institute, University of KwaZulu Natal, Durban, South Africa AN - 126723214. Language: English. Entry Date: 20180326. Revision Date: 20190101. Publication Type: journal article AU - Barrett, Catriona AU - O'Brien, Colm AU - Butler, John S. AU - Loughman, James DB - ccm DO - 10.1111/cxo.12573 DP - EBSCOhost IS - 1 KW - Attitude to Health Glaucoma -- Diagnosis Optometry -- Manpower Health Care Delivery -- Administration Diagnosis, Eye -- Statistics and Numerical Data Glaucoma -- Epidemiology Retrospective Design Ireland Morbidity -- Trends Human Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Australia & New Zealand; Biomedical. NLM UID: 8703442. PMID: NLM28718219. PY - 2018 SN - 0816-4622 SP - 90-99 ST - Barriers to glaucoma case finding as perceived by optometrists in Ireland T2 - Clinical & Experimental Optometry TI - Barriers to glaucoma case finding as perceived by optometrists in Ireland UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126723214&site=ehost-live&scope=site VL - 101 ID - 4233 ER - TY - JOUR AB - Background: This research was designed to provide an in-depth exploration of the perceptions of optometrists relating to the challenges of glaucoma case finding in the Irish health-care system. Methods: A survey was developed, piloted and distributed for anonymous completion by optometrists registered to practise in Ireland. The survey included 10 five-level Likert items exploring potential barriers to glaucoma detection and a free-text box for participants to comment more broadly. Results: One hundred and ninety-nine optometrists (27 per cent of registrants) responded to the survey. Among the barriers identified, there was notable agreement (71 per cent) with the need for extra training on glaucoma detection. Logistic regression showed that optometrists without postgraduate qualifications were more likely to agree with the need for extra training (OR 3.2, 95 per cent CI 1.3–8.1). Respondents largely agreed (61 per cent) that patient unwillingness to pay additional fees for supplementary glaucoma-specific tests was also a barrier. Appointment times of less than 30 minutes were significantly associated with six of the 10 proposed barriers to glaucoma detection. A logistic regression analysis (n = 179) confirmed that the time allotted per appointment was a significant predictor of the agreement time of optometrists as a barrier (χ2 [1] = 13.52, p < 0.001). Multiple linear regression showed that optometrists with less experience, charging lower fees, and working in large multiples or franchised practices have the shortest appointment times. Conclusion: The strong link found between postgraduate education and the confidence of optometrists in detecting glaucoma indicates that optometrists wishing to increase their scope of practice in the new legislative environment in Ireland may more actively seek training in areas of interest. The responses also indicate a lack of funding for the level of diagnostic testing required for accurate glaucoma diagnosis. Recent increases in the state's eye examination fees look likely to address the identified time and financial barriers to glaucoma detection in Ireland. Future work should look to analyse the effects of increased funding on optometric case finding for glaucoma. © 2017 Optometry Australia AD - School of Physics and Clinical and Optometric Sciences, Dublin Institute of Technology, Dublin, Ireland Mater Misericordiae University Hospital, Dublin, Ireland School of Mathematical Sciences, Dublin Institute of Technology, Dublin, Ireland African Vision Research Institute, University of KwaZulu Natal, Durban, South Africa AU - Barrett, C. AU - O'Brien, C. AU - Butler, J. S. AU - Loughman, J. DB - Scopus DO - 10.1111/cxo.12573 IS - 1 KW - barriers case finding glaucoma optometrist survey M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2018 SP - 90-99 ST - Barriers to glaucoma case finding as perceived by optometrists in Ireland T2 - Clinical and Experimental Optometry TI - Barriers to glaucoma case finding as perceived by optometrists in Ireland UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85024494822&doi=10.1111%2fcxo.12573&partnerID=40&md5=1671b6f0b9882dfdb63624892d00cd30 VL - 101 ID - 5345 ER - TY - JOUR AB - BackgroundThis research was designed to provide an in-depth exploration of the perceptions of optometrists relating to the challenges of glaucoma case finding in the Irish health-care system. MethodsA survey was developed, piloted and distributed for anonymous completion by optometrists registered to practise in Ireland. The survey included 10 five-level Likert items exploring potential barriers to glaucoma detection and a free-text box for participants to comment more broadly. ResultsOne hundred and ninety-nine optometrists (27 per cent of registrants) responded to the survey. Among the barriers identified, there was notable agreement (71 per cent) with the need for extra training on glaucoma detection. Logistic regression showed that optometrists without postgraduate qualifications were more likely to agree with the need for extra training (OR 3.2, 95 per cent CI 1.3-8.1). Respondents largely agreed (61 per cent) that patient unwillingness to pay additional fees for supplementary glaucoma-specific tests was also a barrier. Appointment times of less than 30 minutes were significantly associated with six of the 10 proposed barriers to glaucoma detection. A logistic regression analysis (n = 179) confirmed that the time allotted per appointment was a significant predictor of the agreement time of optometrists as a barrier ((2) [1] = 13.52, p < 0.001). Multiple linear regression showed that optometrists with less experience, charging lower fees, and working in large multiples or franchised practices have the shortest appointment times. ConclusionThe strong link found between postgraduate education and the confidence of optometrists in detecting glaucoma indicates that optometrists wishing to increase their scope of practice in the new legislative environment in Ireland may more actively seek training in areas of interest. The responses also indicate a lack of funding for the level of diagnostic testing required for accurate glaucoma diagnosis. Recent increases in the state's eye examination fees look likely to address the identified time and financial barriers to glaucoma detection in Ireland. Future work should look to analyse the effects of increased funding on optometric case finding for glaucoma. AN - WOS:000417934000016 AU - Barrett, C. AU - O'Brien, C. AU - Butler, J. S. AU - Loughman, J. DA - JAN DO - 10.1111/cxo.12573 IS - 1 PY - 2018 SN - 0816-4622 1444-0938 SP - 90-99 ST - Barriers to glaucoma case finding as perceived by optometrists in Ireland T2 - CLINICAL AND EXPERIMENTAL OPTOMETRY TI - Barriers to glaucoma case finding as perceived by optometrists in Ireland VL - 101 ID - 6019 ER - TY - JOUR AB - Objective: To describe the characteristics, treatment patterns, health care resource utilization (HCRU), and cost of care for members of a large United States (US) health insurance plan with lupus nephritis (LN). Methods: A retrospective observational study was conducted using a health insurance plan database to identify adult members with a diagnosis of LN. Medical and pharmacy claims were used to describe demographics, comorbidities, HCRU, and cost patterns over a 12-month follow-up period for each patient, between January 1, 2014, and December 31, 2016. All study variables were examined descriptively. Results: A total of 1039 patients were available for analysis (median age, 47 years; 83% female). The median Charlson Comorbidity Index (CCI) was 3.3. Less than half (41%) of patients received immunosuppressive therapies commonly used to treat LN. Evidence indi-cated that 58% of the study population were prescribed corticosteroid therapy, in most cases (73%) for more than 60 days. Adverse events known to be associated with corticosteroid therapy were recorded in 58% of patients. Guideline-recommended preventive therapy with hydroxychloroquine was prescribed for 54% of members with LN. Nearly half (47%) of members with LN did not see a nephrologist and more than one-third (36%) did not see a rheumatologist over 1 year of follow-up. Rates of all-cause hospitalization and emergency department (ED) use were 25% and 35%, respectively. The mean all-cause per-member-per-month (PMPM) medical cost for the study population was $2801, with LN-specific costs accounting for $1147 PMPM. Conclusion: Patients with LN who are insured through a large US health plan appeared to underutilize outpatient specialist services and guideline-recommended hydroxychloroquine therapy. Corticosteroid use and adverse events known to be associated with corticosteroids were common in this cohort. © 2020 Bartels-Peculis et al. AD - Mallinckrodt Pharmaceuticals, Inc., Bedminster, NJ, United States Healthagen LLC, New York, NY 10017, United States AU - Bartels-Peculis, L. AU - Sharma, A. AU - Edwards, A. M. AU - Sanyal, A. AU - Connolly-Strong, E. AU - Nelson, W. W. DB - Scopus DO - 10.2147/OARRR.S248750 KW - Health care costs Health care resource utilization Lupus nephritis Provider visits Real-world evidence M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 117-124 ST - Treatment patterns and health care costs of lupus nephritis in a united states payer population T2 - Open Access Rheumatology: Research and Reviews TI - Treatment patterns and health care costs of lupus nephritis in a united states payer population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086946496&doi=10.2147%2fOARRR.S248750&partnerID=40&md5=33f74fb678bbdd3292daa4ac6acc024f VL - 12 ID - 5713 ER - TY - JOUR AB - Purpose: To analyze intraocular pressure (IOP) response after 20-mg decanted intravitreal triamcinolone acetonide followed by early prophylactic IOP-lowering therapy. Method: Overall, IOP results of 120 high-dose decanted intravitreal triamcinolone acetonide injections from 58 nonglaucomatous patients with macular edema, with antiglaucoma therapy prescribed from Week 1 regardless of baseline IOP were retrospectively reviewed. Results: In cases of consistent compliance with IOP-lowering drugs (79.2%), IOP increased by 2 mmHg at 4 months (P = 0.300) and returned to baseline at 6 months. In cases of noncompliance (20.8%), IOP increased by 7 mmHg at 1 month (P < 0.001) and returned to baseline after starting treatment. Multivariate regression analysis showed that nonvitrectomized eyes and noncompliance with IOP-lowering drugs were independent predictors of increase in IOP greater than 21 mmHg (P = 0.0098 and P = 0.0019, respectively). Nonvitrectomized eyes had a 46% greater chance to experience increase in IOP compared with vitrectomized ones. Poor compliance with IOP-lowering drugs lead to a 45% greater likelihood of experiencing increase in IOP compared with compliant patients. Multiple injections were not associated with the increased risk for increase in IOP greater than 21 mmHg (P = 0.273). Of 120 cases, 2 eyes (1.7%) developed uncontrolled IOP and required glaucoma surgery by 4 months, with good final IOP outcome. Conclusion: Twenty milligram decanted intravitreal triamcinolone acetonide can be safely used to treat macular edema in nonglaucomatous patients; IOP elevation can be adequately controlled with prophylactic antiglaucoma drugs. Noncompliance with prophylactic therapy creates an early spike in IOP, and vitreous status can significantly impact increase in IOP. Compliance with IOP-lowering drugs should be stressed to patients receiving high-dose intravitreal triamcinolone acetonide especially in cases of nonvitrectomized eyes. AD - W.R. Freeman, Department of Ophthalmology, Jacobs Retina Center at the Shiley Eye Center, University of California, San Diego, 0946, 9415 Campus Point Drive, San Diego, CA, United States AU - Barteselli, G. AU - Amini, P. AU - Ezon, I. C. AU - Nezgoda, J. T. AU - Cheng, L. AU - Freeman, W. R. C1 - kenalog(Bristol Myers Squibb,United States) C2 - Bristol Myers Squibb(United States) DB - Embase Medline DO - 10.1097/IAE.0000000000000268 IS - 1 KW - brimonidine dorzolamide plus timolol triamcinolone acetonide adult aged article drug effect drug megadose female glaucoma glaucoma surgery human intraocular pressure macular edema major clinical study male patient compliance prophylaxis vitrectomy kenalog LA - English M3 - Article N1 - L53270683 2014-08-14 2015-01-22 PY - 2015 SN - 1539-2864 0275-004X SP - 75-81 ST - Impact on intraocular pressure after 20-MG decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy T2 - Retina TI - Impact on intraocular pressure after 20-MG decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L53270683&from=export http://dx.doi.org/10.1097/IAE.0000000000000268 VL - 35 ID - 2825 ER - TY - JOUR AB - Background: Lions Outback Vision has run a state-wide teleophthalmology service since 2011. In September 2015 the Australian federal government introduced a Medicare reimbursement for optometry-facilitated teleophthalmology consultations under specific circumstances. This audit demonstrates the first 12 months experience with this scheme. We aim to provide practical insights for others looking to embed a telemedicine program as part of delivering outreach clinical services.Methods: A 12-month retrospective audit was performed between September 2015 and August 2016, inclusive. A research officer used a specifically designed data extraction tool to record information from all teleophthalmology consultations performed in the time period. The primary outcome was the diagnosis at the end of the teleophthalmology consultation. Secondary outcome measures included the number of teleconsultations, cataract surgery rate, remoteness area of patients referred and imaging accompanying the referral.Results: In the 12-month period, 709 patients were referred resulting in 683 teleophthalmology teleconsultations. Cataract was the most frequent diagnosis (n = 287, 42.7 per cent), followed by glaucoma (n = 77, 11 per cent), age-related macular degeneration (n = 30, 4.4 per cent) and diabetic retinopathy (n = 26, 3.8 per cent). Of those who had teleconsultations, 98.6 per cent were from Outer Regional, Remote or Very Remote Australia. One or more accompanying images or investigations were part of 349 (49 per cent) teleconsultations, most commonly optical coherence tomography (215, 30 per cent) and fundus photography (148, 21 per cent). Face-to-face consultations were undertaken at an outreach clinic in 23 (3.4 per cent) cases, to determine the diagnosis. There were no statistically significant factors associated with attendance at teleophthalmology consultation, or for successfully undergoing cataract surgery.Conclusion: Teleophthalmology is a valuable adjunct to regional outreach ophthalmology services, providing patients with increased access to specialist care for a wide range of ophthalmic conditions, and more efficient access to surgical care. AD - Lions Outback Vision, Lions Eye Institute, Perth, Western Australia, Australia The Centre for Vision and Ophthalmic Science, The University of Western Australia, Perth, Western Australia, Australia AN - 131480572. Language: English. Entry Date: 20190617. Revision Date: 20190902. Publication Type: journal article AU - Bartnik, Stephen E. AU - Copeland, Stephen P. AU - Aicken, Angela J. AU - Turner, Angus W. DB - ccm DO - 10.1111/cxo.12658 DP - EBSCOhost IS - 5 KW - Optometry -- Statistics and Numerical Data Health Care Delivery -- Statistics and Numerical Data Audit Ophthalmology -- Statistics and Numerical Data Telemedicine -- Statistics and Numerical Data Health Services Accessibility Eye Diseases -- Diagnosis Middle Age Aged Female Referral and Consultation Adult Child, Preschool Eye Diseases -- Therapy Retrospective Design Male Rural Population Western Australia Child Aged, 80 and Over Adolescence Human N1 - research; tables/charts. Journal Subset: Australia & New Zealand; Biomedical. NLM UID: 8703442. PMID: NLM29444552. PY - 2018 SN - 0816-4622 SP - 700-703 ST - Optometry-facilitated teleophthalmology: an audit of the first year in Western Australia T2 - Clinical & Experimental Optometry TI - Optometry-facilitated teleophthalmology: an audit of the first year in Western Australia UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131480572&site=ehost-live&scope=site VL - 101 ID - 4307 ER - TY - JOUR AB - In 1987, it was estimated that over 13 million people in the world were visually impaired, and more than 27 to 35 million were classified as blind. Greater than 6 million visually impaired people live in the United States. There are many causes of visual impairment, including age-related macular degeneration, cataracts, glaucoma, diabetic retinopathy, autoimmune deficiency syndrome, and trauma. Some patients may be helped or visual loss delayed with surgery. Many may have dramatic visual improvement with optical devices, large-print publications, and improved lighting. The ophthalmic nurse may assist in accurately assessing the patient's vision and identifying his or her lifestyle and ability to function independently. Assisting the patient to overcome psychosocial and economic barriers and helping to obtain assistance is critical to enable patients to function independently. Ophthalmic nurses may be instrumental in increasing patients' awareness of community resources and services available to those who are visually impaired. AD - Department of Ophthalmology, Veteran Administration, Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA 98108 AN - 107263355. Language: English. Entry Date: 19980601. Revision Date: 20150820. Publication Type: Journal Article AU - Barton, W. DB - ccm DP - EBSCOhost IS - 1 KW - Vision Disorders -- Nursing Ophthalmic Nursing Nursing Role Vision Disorders -- Classification Rehabilitation of Vision Impaired Vision Disorders -- Etiology N1 - tables/charts. Journal Subset: Core Nursing; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9111431. PMID: NLM9866521. PY - 1998 SN - 1060-135X SP - 5-10 ST - Role of ophthalmic nurses with visually impaired patients T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - Role of ophthalmic nurses with visually impaired patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107263355&site=ehost-live&scope=site VL - 23 ID - 4640 ER - TY - JOUR AB - This study reports the short-term functional and anatomical outcome of Boston Type 1 keratoprosthesis (Boston Kpro) implantation for bilateral limbal stem cell deficiency (LCSD). Retrospective analysis was done on eight eyes of eight patients who underwent Boston Kpro implantation between July 2009 and October 2009. The best corrected visual acuity (BCVA) and slit-lamp biomicroscopy findings were assessed at 1, 3 and 6 months postoperatively. All eight eyes retained the prosthesis. BCVA of 20/40 or better was achieved in 8, 6, and 5 eyes at 1, 3, and 6 months, respectively, postoperatively. One patient each developed epithelial defect, sterile stromal melt and fungal keratitis in the late postoperative period associated with antecedent loss of the soft contact lens from the eye. Boston Kpro has good short-term visual and anatomical outcome in patients with bilateral LSCD, provided compliance with postoperative care can be ensured. AD - Cornea and Anterior Segment Service, LV Prasad Eye Institute, Kallam Anji Reddy Campus, LV Prasad Marg, Banjara Hills, Hyderabad - 500 034, India Smt. Kanuri Santhamma Retina and Vitreous Centre, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad, India VST Glaucoma Centre, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad, India AU - Basu, S. AU - Taneja, M. AU - Narayanan, R. AU - Senthil, S. AU - Sangwan, V. DB - Scopus DO - 10.4103/0301-4738.94060 IS - 2 KW - Boston keratoprosthesis limbal stem cell deficiency M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 2012 SP - 151-153 ST - Short-term outcome of Boston Type 1 keratoprosthesis for bilateral limbal stem cell deficiency T2 - Indian Journal of Ophthalmology TI - Short-term outcome of Boston Type 1 keratoprosthesis for bilateral limbal stem cell deficiency UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859524334&doi=10.4103%2f0301-4738.94060&partnerID=40&md5=1e5ce3a92920035ed5a454d34de20a4b VL - 60 ID - 5180 ER - TY - JOUR AB - Background: The National Patient Safety Agency (2009) publication advising timely follow-up of patients with established glaucoma followed several reported instances of visual loss due to postponed appointments and patients lost to follow-up. The Royal College of Ophthalmologists Quality Standards Development Group stated that all hospital appointments should occur within 15% of the intended follow-up period.Aim: To determine whether: 1. Glaucoma follow-up appointments at a teaching hospital occur within the requested time 2. Appointments are requested at appropriate intervals based on the NICE Guidelines 3. The capacity of the glaucoma service is adequate Methods: A two-part audit was undertaken of 98 and 99 consecutive patients respectively attending specialist glaucoma clinics. In the first part, the reasons for delayed appointments were recorded. In the second part the requested follow-up was compared with NICE guidelines where applicable. Based on the findings, changes were implemented and a re-audit of 100 patients was carried out.Results: The initial audit found that although clinical decisions regarding follow-up intervals were 100% compliant with NICE guidelines where applicable, 24% of appointments were delayed beyond 15% of the requested period, due to administrative errors and inadequate capacity, leading to significant clinical deterioration in two patients. Following the introduction of an electronic appointment tracker and increased clinical capacity created by extra clinics and clinicians, the re-audit found a marked decrease in the percentage of appointments being delayed (9%).Conclusions: This audit is a useful tool to evaluate glaucoma service provision, assist in resource planning for the service and bring about change in a non-confrontational way. It can be widely applied and adapted for use in other medical specialities. AD - Department of Ophthalmology, University Hospitals Birmingham, United Kingdom AN - 131859898. Language: English. Entry Date: 20180926. Revision Date: 20200424. Publication Type: journal article AU - Batra, Ruchika AU - Sharma, Hannah E. AU - Elaraoud, Ibrahim AU - Mohamed, Shabbir DB - ccm DO - 10.1080/08820538.2017.1418012 DP - EBSCOhost IS - 6 KW - Management -- Methods Glaucoma -- Therapy Academic Medical Centers -- Administration Benchmarking -- Methods Appointments and Schedules Referral and Consultation -- Standards Ophthalmology -- Standards Intraocular Pressure Patient Compliance Human Female Male Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8610759. PMID: NLM29283293. PY - 2018 SN - 0882-0538 SP - 733-738 ST - Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity T2 - Seminars in Ophthalmology TI - Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131859898&site=ehost-live&scope=site VL - 33 ID - 4217 ER - TY - JOUR AB - Background: The National Patient Safety Agency (2009) publication advising timely follow-up of patients with established glaucoma followed several reported instances of visual loss due to postponed appointments and patients lost to follow-up. The Royal College of Ophthalmologists Quality Standards Development Group stated that all hospital appointments should occur within 15% of the intended follow-up period. Aim: To determine whether: 1. Glaucoma follow-up appointments at a teaching hospital occur within the requested time 2. Appointments are requested at appropriate intervals based on the NICE Guidelines 3. The capacity of the glaucoma service is adequate Methods: A two-part audit was undertaken of 98 and 99 consecutive patients respectively attending specialist glaucoma clinics. In the first part, the reasons for delayed appointments were recorded. In the second part the requested follow-up was compared with NICE guidelines where applicable. Based on the findings, changes were implemented and a re-audit of 100 patients was carried out. Results: The initial audit found that although clinical decisions regarding follow-up intervals were 100% compliant with NICE guidelines where applicable, 24% of appointments were delayed beyond 15% of the requested period, due to administrative errors and inadequate capacity, leading to significant clinical deterioration in two patients. Following the introduction of an electronic appointment tracker and increased clinical capacity created by extra clinics and clinicians, the re-audit found a marked decrease in the percentage of appointments being delayed (9%). Conclusions: This audit is a useful tool to evaluate glaucoma service provision, assist in resource planning for the service and bring about change in a non-confrontational way. It can be widely applied and adapted for use in other medical specialities. ©, © Taylor & Francis. AD - Department of Ophthalmology, University Hospitals Birmingham, United Kingdom AU - Batra, R. AU - Sharma, H. E. AU - Elaraoud, I. AU - Mohamed, S. DB - Scopus DO - 10.1080/08820538.2017.1418012 IS - 6 KW - Audit glaucoma NICE guidelines patient safety service capacity M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2018 SP - 733-738 ST - Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity T2 - Seminars in Ophthalmology TI - Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85039557739&doi=10.1080%2f08820538.2017.1418012&partnerID=40&md5=9f48cfa095d606326b05cd05a89d371c VL - 33 ID - 5619 ER - TY - JOUR AB - Background: The National Patient Safety Agency (2009) publication advising timely follow-up of patients with established glaucoma followed several reported instances of visual loss due to postponed appointments and patients lost to follow-up. The Royal College of Ophthalmologists Quality Standards Development Group stated that all hospital appointments should occur within 15% of the intended follow-up period. Aim: To determine whether: 1. Glaucoma follow-up appointments at a teaching hospital occur within the requested time 2. Appointments are requested at appropriate intervals based on the NICE Guidelines 3. The capacity of the glaucoma service is adequate Methods: A two-part audit was undertaken of 98 and 99 consecutive patients respectively attending specialist glaucoma clinics. In the first part, the reasons for delayed appointments were recorded. In the second part the requested follow-up was compared with NICE guidelines where applicable. Based on the findings, changes were implemented and a re-audit of 100 patients was carried out. Results: The initial audit found that although clinical decisions regarding follow-up intervals were 100% compliant with NICE guidelines where applicable, 24% of appointments were delayed beyond 15% of the requested period, due to administrative errors and inadequate capacity, leading to significant clinical deterioration in two patients. Following the introduction of an electronic appointment tracker and increased clinical capacity created by extra clinics and clinicians, the re-audit found a marked decrease in the percentage of appointments being delayed (9%). Conclusions: This audit is a useful tool to evaluate glaucoma service provision, assist in resource planning for the service and bring about change in a non-confrontational way. It can be widely applied and adapted for use in other medical specialities. AN - WOS:000444817100001 AU - Batra, R. AU - Sharma, H. E. AU - Elaraoud, I. AU - Mohamed, S. DO - 10.1080/08820538.2017.1418012 IS - 6 PY - 2018 SN - 0882-0538 1744-5205 SP - 733-738 ST - Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity T2 - SEMINARS IN OPHTHALMOLOGY TI - Resource Planning in Glaucoma: A Tool to Evaluate Glaucoma Service Capacity VL - 33 ID - 5846 ER - TY - JOUR AB - Purpose: To report an unusual case of contact lens-associated pseudomonal keratitis in a compliant daily disposable contact lens wearer. Methods: A case report is presented of a compliant daily disposable contact lens wearer who developed culture-positive pseudomonal keratitis. Results: A 38-year-old woman who reported compliant and infrequent use of daily disposable contact lenses presented with rapid-onset, severe keratitis consistent with pseudomonal infection. Corneal cultures were positive for Pseudomonas aeruginosa. She had no identifiable risk factors, although notably had a remote history of contact lens-associated keratitis in the fellow eye. Conclusions: Although extremely rare, pseudomonal keratitis should still be considered in the differential diagnosis of severe keratitis in daily disposable contact lens wearers. Given the history of a previous contact lens-related bacterial keratitis in this compliant patient, it is possible that host susceptibility factors played a role in the case of pseudomonal keratitis described here. Copyright © Contact Lens Association of Ophthalmologists, Inc. AD - P. Batta, Tufts Medical Center-New England Eye Center, 260 Tremont Street, Boston, MA 02116, United States AU - Batta, P. AU - Goldstein, M. H. DB - Embase Medline DO - 10.1097/ICL.0b013e3181da2339 IS - 3 KW - gatifloxacin prednisolone acetate tobramycin vancomycin adult anamnesis article bacterium culture case report contact lens differential diagnosis disease severity eye examination female host susceptibility human keratitis patient compliance priority journal Pseudomonas aeruginosa Pseudomonas infection risk factor LA - English M3 - Article N1 - L358819458 2010-05-25 2010-06-02 PY - 2010 SN - 1542-2321 SP - 181-182 ST - Severe pseudomonal keratitis in an infrequent daily disposable contact lens wearer T2 - Eye and Contact Lens TI - Severe pseudomonal keratitis in an infrequent daily disposable contact lens wearer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358819458&from=export http://dx.doi.org/10.1097/ICL.0b013e3181da2339 VL - 36 ID - 3258 ER - TY - JOUR AB - Antiglaucoma medications are often associated with ocular adverse reactions such as dry eye, and burning or stinging sensations. These undesirable effects may lead to treatment discontinuation and reduced quality of life in patients with glaucoma. Antiglaucoma medications usually contain benzalkonium chloride (BAK) as a preservative. Animal studies, in vitro studies and in vivo experiments have demonstrated various adverse effects of BAK. Clinical studies have also shown an increased incidence of adverse events with BAK and have demonstrated that the withdrawal of preservatives reduces these effects. Collectively, these data suggest that preservative-free antiglaucoma treatments have clinically relevant benefits for patients. © 2008 The Authors Journal compilation © 2008 Acta Ophthalmol. AD - C. Baudouin, Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, 28 rue de Charenton, 75012 Paris, France AU - Baudouin, C. C1 - lumigan purite(Allergan,United States) refresh tears(Allergan) timabak(Thea,France) timoptol(Merck Sharp and Dohme Chibret,France) travatan xalatan(Pfizer) C2 - Allergan(United States) Merck Sharp and Dohme Chibret(France) Pfizer Thea(France) DB - Embase Medline DO - 10.1111/j.1755-3768.2008.01250.x IS - 7 KW - adrenergic receptor stimulating agent antiglaucoma agent artificial tear befunolol benzalkonium chloride beta adrenergic receptor blocking agent bimatoprost brimonidine dipivefrine drug preservative eye drops latanoprost miotic agent pilocarpine placebo purite refresh tears tafluprost timolol timolol maleate travoprost unclassified drug blurred vision cataract cataract extraction clinical feature clinical study clinical trial conjunctiva disease conjunctiva epithelium conjunctival hyperemia conjunctivitis cornea cell cornea disease cornea injury cost effectiveness analysis disease model drug bioavailability drug dosage form comparison drug dose increase drug efficacy drug hypersensitivity drug induced disease drug mechanism drug response drug safety drug substitution drug tolerability drug toxicity drug withdrawal dry eye eye burning eye discomfort eye disease eye pain filtering operation glaucoma goblet cell human human cell culture in vitro study in vivo study incidence intraocular foreign body intraocular pressure keratinization lacrimation lens epithelium long term care morbidity nonhuman ocular fibrosis ocular pruritus patient compliance patient satisfaction priority journal quality of life retina macula cystoid edema review side effect squamous cell metaplasia surgical risk tear film topical treatment trabecular meshwork trabeculectomy treatment duration treatment failure treatment response lumigan timabak timoptol travatan xalatan LA - English M3 - Review N1 - L352622475 2008-12-17 PY - 2008 SN - 1755-375X SP - 716-726 ST - Detrimental effect of preservatives in eyedrops: Implications for the treatment of glaucoma T2 - Acta Ophthalmologica TI - Detrimental effect of preservatives in eyedrops: Implications for the treatment of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352622475&from=export http://dx.doi.org/10.1111/j.1755-3768.2008.01250.x VL - 86 ID - 3403 ER - TY - JOUR AB - Chronic glaucoma is a severe disease that can induce blindness. Early diagnosis and symptomatic treatment reduce the risk of blindness. Treatment that will be started before the onset of clinical signs and will remain lifelong thereafter is troublesome, and therapeutic compliance is usually poor. Thus, quality of life (QOL) measurement in patients with chronic glaucoma has a particular purpose: to measure patients' perception of the disease and treatment in order to maintain good treatment compliance to ensure therapeutic management efficacy and to preserve visual function. No glaucoma-specific instrument is available in the medical and QOL literature. Various generic (SF-36, SF-20 and SIP)1 and specific (VAQ, VF-14, NEI-VFQ)1 QOL questionnaires, one glaucoma-specific symptomatic scale (GSS)1, and one treatment preference scale (COMTol)1 have been used to measure QOL in glaucoma patients. These instruments do not sufficiently measure the psychosocial dimension of the disease and the QOL impact of treatment. An instrument able to measure all dimensions needs to be developed in order to help ophthalmologists in the therapeutic management of their patients and to mesure QOL in patients in the successive stages of the disease. AD - B. Arnould, Mapi Values Le D'Aubigny, 27, rue de la Villette, 69003 Lyon, France AU - Baudouin, C. AU - Béchetoille, A. AU - Bron, A. AU - Denis, P. AU - Nordmann, J. P. AU - Renard, J. P. AU - Rouland, J. F. AU - Sellem, E. AU - Rigeade, M. C. AU - Arnould, B. DB - Embase Medline IS - 10 KW - blindness early diagnosis open angle glaucoma palliative therapy patient compliance quality of life questionnaire rating scale review social psychology vision LA - French M3 - Review N1 - L32049813 2001-01-30 PY - 2000 SN - 0181-5512 SP - 1057-1064 ST - Relevance of quality of life and treatment compliance measurement in patients with chronic open-angle glaucoma T2 - Journal Francais d'Ophtalmologie TI - Relevance of quality of life and treatment compliance measurement in patients with chronic open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32049813&from=export VL - 23 ID - 3899 ER - TY - JOUR AB - Objectives: The aim of this study was to assess the changes in intraocular pressure (IOP) and ophthalmic symptoms with the Glaucoma Symptom Scale in patients suffering from open-angle glaucoma (OAG) or ocular hypertension (OHT) after 3 months of treatment with latanoprost. Materials and methods: This multicentric open study was carried out in adult patients suffering from OAG or simple OHT (naive or previously treated with monotherapy) and needing a change or initiation of anti-glaucomatous treatment. One drop of latanoprost 0.005% was instilled every evening for 12 weeks in each affected eye. Efficacy was assessed by the variation in IOP and ophthalmic symptomatology at the end of treatment. Prognosis factors associated with a relative IOP reduction of at least 30% were sought (using a logistic regression model). Results: A total of 920 patients suffering from OAG (54%) or OHT (44%), either previously treated (69%) or naive (31%), were included. The male:female ratio was 0.78 and the mean age was 63±13 years. At inclusion, the mean IOP was 22.1 ±3.8 mmHg. After treatment, IOP was significantly decreased by 5.1±4 mmHg, corresponding to a 22% reduction. IOP reduction was 7.1±4 mmHg, corresponding to 29% in naive patients and 4.2±4 mmHg, corresponding to 19% in previously treated patients. A relative IOP reduction of at least 30% was reached by 47% of naive patients and 21% of previously treated patients. In previously treated patients, a relative IOP reduction of at least 30% had a greater chance of being reached in men with previous ophthalmic history and high IOP at inclusion (above 21 mmHg). IOP reduction was similar in patients with OAG and OHT. A significant improvement in ophthalmic symptoms was observed after treatment in previously treated patients. A total of 7% of the patients presented an adverse event affecting the visual system: eye irritation (2%), eye pain (2%), or eye hyperemia (1%). Compliance was good for 94% of the patients. Conclusion: Latanoprost given as first or second-line treatment at the recommended dose effectively decreases IOP in patients with OAG or OHT. This treatment also improves visual and nonvisual symptoms in previously treated patients and presents a good safety profile. © Masson, 2006. AD - C. Baudouin, Centre National d'Ophtalmologie, Hôpital des XV-XX, 28, rue de Charenton, 75012 Paris, France AU - Baudouin, C. AU - Rouland, J. F. AU - Nordmann, J. P. AU - Bron, A. AU - Pelen, F. C1 - xalatan DB - Embase Medline DO - 10.1016/S0181-5512(06)73821-9 IS - 6 KW - antiglaucoma agent eye drops latanoprost adult age distribution aged article clinical trial controlled clinical trial controlled study drug efficacy eye irritation eye pain female glaucoma symptom scale human hyperemia intraocular hypertension intraocular pressure logistic regression analysis major clinical study male monotherapy multicenter study open angle glaucoma open study patient compliance phase 4 clinical trial prognosis rating scale sex ratio statistical significance symptomatology treatment duration treatment outcome visual system xalatan LA - French M3 - Article N1 - L44174872 2006-08-20 PY - 2006 SN - 0181-5512 SP - 615-624 ST - Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension T2 - Journal Francais d'Ophtalmologie TI - Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44174872&from=export http://dx.doi.org/10.1016/S0181-5512(06)73821-9 VL - 29 ID - 3607 ER - TY - JOUR AB - Purpose: To describe the clinical outcome and complications of repeat Descemet membrane endothelial keratoplasty (re-DMEK). Design: Retrospective case series study at a tertiary referral center. Participants: From a series of 550 consecutive DMEK surgeries with ≥6 months follow-up, 17 eyes underwent re-DMEK for graft detachment after initial DMEK (n = 14) and/or endothelial graft failure (n = 3). The outcomes were compared with an age-matched control group of uncomplicated primary DMEK surgeries. Methods: The re-DMEK eyes were evaluated for best-corrected visual acuity (BCVA), densitometry, endothelial cell density (ECD), pachymetry, and intraoperative and postoperative complications. Main Outcome Measures: Feasibility and clinical outcome of re-DMEK. Results: In all eyes, re-DMEK was uneventful. At 12 months, 12 of 14 eyes (86%) achieved a BCVA of ≥20/40 (≥0.5); 8 of 14 eyes (57%) achieved ≥20/25 (≥0.8), 3 of 14 eyes (21%) achieved ≥20/20 (≥1.0), and 1 eye (7%) achieved 20/17 (1.2); 5 eyes were fitted with a contact lens. Average donor ECD decreased from 2580±173 cells/ mm2 before to 1390±466 cells/mm2 at 6 months after surgery, and pachymetry from 703±126 μm to 515±39 μm, respectively. No difference in densitometry could be detected between re-DMEK and control eyes (P = 0.99). Complications after re-DMEK included primary graft failure (n = 1), secondary graft failure (n = 2), graft detachment requiring rebubbling (n = 1), secondary glaucoma (n = 2), cataract (n = 1), and corneal ulcer (n = 1). One eye received tertiary DMEK. Conclusions: In the management of persistent graft detachment and graft failure after primary DMEK, re-DMEK proved a feasible procedure. Acceptable BCVA may be achieved, albeit lower than after DMEK in virgin eyes, and some cases may benefit from contact lens fitting. Complications after re-DMEK may be better anticipated than after primary DMEK because graft detachment and graft failure tended to recur, suggesting that intrinsic properties of the host eye play a role in graft adherence and graft failure. © 2015 by the American Academy of Ophthalmology. AD - Netherlands Institute for Innovative Ocular Surgery, Rotterdam, Netherlands Melles Cornea Clinic, Rotterdam, Netherlands Amnitrans EyeBank, Rotterdam, Netherlands Calderdale and Huddersfield NHS Trust, Huddersfield, West Yorkshire, United Kingdom AU - Baydoun, L. AU - Van Dijk, K. AU - Dapena, I. AU - Musa, F. U. AU - Liarakos, V. S. AU - Ham, L. AU - Melles, G. R. J. DB - Scopus DO - 10.1016/j.ophtha.2014.07.024 IS - 1 M3 - Article N1 - Cited By :45 Export Date: 19 July 2021 PY - 2015 SP - 8-16 ST - Repeat descemet membrane endothelial keratoplasty after complicated primary descemet membrane endothelial keratoplasty T2 - Ophthalmology TI - Repeat descemet membrane endothelial keratoplasty after complicated primary descemet membrane endothelial keratoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920713699&doi=10.1016%2fj.ophtha.2014.07.024&partnerID=40&md5=001208f339c438113415a17597bdd725 VL - 122 ID - 5008 ER - TY - JOUR AB - Purpose: To describe the clinical outcome and complications of repeat Descemet membrane endothelial keratoplasty (re-DMEK). Design: Retrospective case series study at a tertiary referral center. Participants: From a series of 550 consecutive DMEK surgeries with 6 months follow-up, 17 eyes underwent re-DMEK for graft detachment after initial DMEK (n = 14) and/or endothelial graft failure (n = 3). The outcomes were compared with an age-matched control group of uncomplicated primary DMEK surgeries. Methods: The re-DMEK eyes were evaluated for best-corrected visual acuity (BCVA), densitometry, endothelial cell density (ECD), pachymetry, and intraoperative and postoperative complications. Main Outcome Measures: Feasibility and clinical outcome of re-DMEK. Results: In all eyes, re-DMEK was uneventful. At 12 months, 12 of 14 eyes (86%) achieved a BCVA of >= 20/40 (>= 0.5); 8 of 14 eyes (57%) achieved >= 20/25 (>= 0.8), 3 of 14 eyes (21%) achieved >= 20/20 (>= 1.0), and 1 eye (7%) achieved 20/17 (1.2); 5 eyes were fitted with a contact lens. Average donor ECD decreased from 2580 +/- 173 cells/ mm(2) before to 1390 +/- 466 cells/mm(2) at 6 months after surgery, and pachymetry from 703 = 126 mm to 515 = 39 mm, respectively. No difference in densitometry could be detected between re-DMEK and control eyes (P = 0.99). Complications after re-DMEK included primary graft failure (n = 1), secondary graft failure (n = 2), graft detachment requiring rebubbling (n = 1), secondary glaucoma (n = 2), cataract (n = 1), and corneal ulcer (n = 1). One eye received tertiary DMEK. Conclusions: In the management of persistent graft detachment and graft failure after primary DMEK, re-DMEK proved a feasible procedure. Acceptable BCVA may be achieved, albeit lower than after DMEK in virgin eyes, and some cases may benefit from contact lens fitting. Complications after re-DMEK may be better anticipated than after primary DMEK because graft detachment and graft failure tended to recur, suggesting that intrinsic properties of the host eye play a role in graft adherence and graft failure. (C) 2015 by the American Academy of Ophthalmology. AN - WOS:000346737000013 AU - Baydoun, L. AU - van Dijk, K. AU - Dapena, I. AU - Musa, F. U. AU - Liarakos, V. S. AU - Ham, L. AU - Melles, G. R. J. DA - JAN DO - 10.1016/j.ophtha.2014.07.024 IS - 1 PY - 2015 SN - 0161-6420 1549-4713 SP - 8-16 ST - Repeat Descemet Membrane Endothelial Keratoplasty after Complicated Primary Descemet Membrane Endothelial Keratoplasty T2 - OPHTHALMOLOGY TI - Repeat Descemet Membrane Endothelial Keratoplasty after Complicated Primary Descemet Membrane Endothelial Keratoplasty VL - 122 ID - 5911 ER - TY - JOUR AB - Aim: The aim of this study was to evaluate the long-term follow-up of patients who were changed to latanoprost from previous glaucoma therapies. Methods: Primary open-angle, exfoliative or chronic angle-closure glaucoma, or ocular hypertensive patients who switched to latanoprost therapy with a 2-year follow-up, were evaluated for efficacy, safety, and continuance of therapy. Results: In 1,571 patients, the intraocular pressure (IOP) across all treatment groups of 21.3 ± 4.1 was reduced to 17.6 ± 3.2 mm Hg after switching to latanoprost. Latanoprost reduced the IOP from previous monotherapies, including nonselective beta-adrenergic blockers, topical carbonic anhydrase inhibitors, alpha-adrenergic agonists and pilocarpine (p < 0.0001) and adjunctive therapies, including the fixed combinations of dorzolamide and timolol, pilocarpine and timolol, and pilocarpine and metipranolol, and the unfixed combination of dorzolamide and timolol and dorzolamide and clonidine (p < 0.0028). Latanoprost further reduced the IOP across all diagnostic groups (p < 0.0001). The most common ocular adverse event was ocular irritation (n = 25; 1.6%), which was also the most common reason given for patients who discontinued latanoprost because of an adverse event (n = 20; 1.3%). Conclusions: The mean IOP was maintained at an acceptable level throughout the 2-year follow-up period on latanoprost. Latanoprost generally provides further reduction of IOP when switched from previous mono- and adjunctive therapies, with a low rate of side effects and discontinuations. AD - Pharmaceutical Research Network, LLC, Charleston, SC, United States Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, United States Pharmaceutical Research Network, LLC, 1639 Tatum Street, Charleston, SC 29412-2464, United States AU - Bayer, A. AU - Weiler, W. AU - Oeverhaus, U. AU - Skrotzki, F. E. AU - Stewart, W. C. DB - Scopus DO - 10.1089/jop.2004.20.470 IS - 6 M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2004 SP - 470-478 ST - Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies T2 - Journal of Ocular Pharmacology and Therapeutics TI - Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-10344224531&doi=10.1089%2fjop.2004.20.470&partnerID=40&md5=f67ff6916ec4226da80158a0a7d3f3b4 VL - 20 ID - 5115 ER - TY - JOUR AB - Background: To compare the tolerability of commonly prescribed topical glaucoma medications by determining frequency and bother of side effects, patient satisfaction with their medication, and the chance of discontinuation of eye drops. Methods: The tolerability of topical glaucoma medication was studied in glaucoma patients from nine hospitals. The frequency and severity of side effects was investigated together with patient satisfaction with the medication and the probability to change medication due to reported side effects. To register side effects of topical glaucoma medication, patients were requested to fill in a questionnaire based on "the Comparison of Ophthalmic Medications for Tolerability" (COMTOL) questionnaire supplemented with items based on the most frequently observed and severe side effects. Results: The number of patients responding was 3,333 (87%). Most patients (79%) were satisfied with their eye medication. The median score for ocular side effects was 58 on a scale ranging from 0 to 320. The probability that medication would be changed by the ophthalmologist at the next visit due to reported side effects occurring since the patients' last or last but one visit to the ophthalmologist was 9%. The most frequently prescribed drugs were timolol, latanoprost, and the fixed combinations of dorzolamide/timolol (Cosopt®) and latanoprost/ timolol (Xalcom®). Only small differences in tolerability were found between these drugs. Conclusions: The tolerability of timolol, latanoprost, and the fixed combinations of latanoprost/timolol (Xalcom®) and dorzolamide/ timolol (Cosopt®) seem to be comparable. Patients are satisfied with their glaucoma medication and have a low chance of discontinuation of eye drops due to side effects. © Springer-Verlag 2008. AD - Department of Ophthalmology, Maastricht University Hospital, P.O. Box 5800, 6202 AZ Maastricht, Netherlands Department of Epidemiology, Maastricht University, Maastricht, Netherlands AU - Beckers, H. J. M. AU - Schouten, J. S. A. G. AU - Webers, C. A. B. AU - Valk, R. AU - Hendrikse, F. DB - Scopus DO - 10.1007/s00417-008-0875-7 IS - 10 KW - Glaucoma Glaucoma medication Side effects M3 - Article N1 - Cited By :33 Export Date: 19 July 2021 PY - 2008 SP - 1485-1490 ST - Side effects of commonly used glaucoma medications: Comparison of tolerability, chance of discontinuation, and patient satisfaction T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - Side effects of commonly used glaucoma medications: Comparison of tolerability, chance of discontinuation, and patient satisfaction UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-51649104272&doi=10.1007%2fs00417-008-0875-7&partnerID=40&md5=0594ffd972f8fbdb4fdfa0f11706bbc6 VL - 246 ID - 5047 ER - TY - JOUR AB - Purpose: To study the effect of patient education and the TravAlert ®-Eyot® drop guider on intraocular pressure (IOP) and adherence in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) monitored with the TravAlert® dosing aid. Methods: Multicentre, randomized, controlled clinical trial among 18 Dutch hospitals. Patients were randomized to one of the four study arms: (1) use of the dosing aid, (2) use of the dosing aid with the drop guider, (3) use of the dosing aid together with patient education or (4) use of the dosing aid and drop guider together with patient education. IOP was recorded at baseline and after 3 and 6 months. Data on adherence generated by the dosing aid were collected and studied at the end of the study. Results: Mean IOP dropped from 20.3 ± 5.7 mmHg at baseline to 16.3 ± 4.0 mmHg (right eye) after 6 months and from 20.2 ± 5.9 mmHg to 16.4 ± 4.1 mmHg (left eye). The mean adherence rate was 0.91 ± 0.1. IOP and adherence rate were not statistically different between the study arms. Patients with 'drug holidays' had a significantly higher mean IOP after 6 months. Patients who used the drop guider were less adherent. A lower adherence level was also associated with new patients with glaucoma and patients with a lower level of knowledge on glaucoma. Conclusion: Patient education is especially useful for new patients with glaucoma. The use of a drop guider does not improve adherence. Especially patients with 'drug holidays' are at risk for developing uncontrolled IOP levels. Copyright © 2012 Acta Ophthalmologica Scandinavica Foundation. AD - H.J.M. Beckers, University Eye Clinic, Maastricht University Medical Centre, P.O. Box 5800, Maastricht, Netherlands AU - Beckers, H. J. M. AU - Webers, C. A. B. AU - Busch, M. J. W. M. AU - Brink, H. M. A. AU - Colen, T. P. AU - Schouten, J. S. A. G. C2 - Alcon DB - Embase Medline DO - 10.1111/j.1755-3768.2012.02571.x IS - 7 KW - NCT00603005 timolol plus travoprost travoprost adult age distribution aged article controlled study educational status female human intraocular hypertension intraocular pressure major clinical study male medication compliance multicenter study open angle glaucoma ophthalmological equipment patient attitude patient compliance patient education patient satisfaction priority journal questionnaire randomized controlled trial self report sex difference visual impairment Eyot TravAlert LA - English M3 - Article N1 - L52241159 2012-10-06 2013-11-21 PY - 2013 SN - 1755-375X 1755-3768 SP - 610-618 ST - Adherence improvement in Dutch glaucoma patients: A randomized controlled trial T2 - Acta Ophthalmologica TI - Adherence improvement in Dutch glaucoma patients: A randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52241159&from=export http://dx.doi.org/10.1111/j.1755-3768.2012.02571.x VL - 91 ID - 2956 ER - TY - JOUR AB - Objectives Glaucoma is a major cause of blindness, preventable by a regular therapy. Thus, a good knowledge of patients’ adherence to preventive therapy is critical to improve disease management. Early persistence to first-line glaucoma therapy is poorly documented in France. We verified to what extent first-line glaucoma therapy was interrupted within the 12 months following initiation and how this interruption varied with patients’ characteristics and drug classes. Methods Patients newly-treated with chronic glaucoma therapy (prostaglandins, beta-blockers alone or combined with another therapy, and topical carbonic anhydrase inhibitors) between 2005 and 2008 were identified in the French National Claims data (1/97th random sample). Twelve-month persistence was defined by the presence of the first-line drug class (≥ 1 dispensation) between the 12th and 24th months following initiation. Twelve-month persistence was compared between patients according to the first-line drug classes and baseline characteristics. Proportion of days covered (12 months) and number of quarters with initiated drug class (24 months) were also studied. Results Among 5331 patients initiated with chronic glaucoma therapy in monotherapy (63% aged ≥ 60 years old, 57% females), initiated therapy mainly consisted of prostaglandins (43%) and beta-blockers alone (32%). Only 45% of the patients were persistent to first-line therapy 12 months after initiation. Salient differences in persistence rates appeared between drug classes (P < 0.0001): from 59% with prostaglandins to 26% for topical carbonic anhydrase inhibitors. Better results also appeared for prostaglandins with other dimensions of adherence. Non-persistent patients were more likely younger than 40, or conversely aged ≥ 80 (P < 0.0001). They were also more likely to necessitate social assistance for therapy (P = 0.0007). No salient difference appeared as to gender. Conclusions Our findings confirm the low early persistence of first-line therapy, despite better results for prostaglandins. Education of patients and identification of barriers to adherence could contribute to improve quality of care. AD - É. Van Ganse, Lyon, France AU - Belhassen, M. AU - Laforest, L. AU - Licaj, I. AU - Van Ganse, É DB - Embase Medline DO - 10.1016/j.therap.2016.02.033 IS - 5 KW - antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor prostaglandin adult aged article female glaucoma human major clinical study male medication compliance middle aged monotherapy observational study patient compliance priority journal time to treatment topical treatment treatment interruption very elderly LA - English French M3 - Article N1 - L612775891 2016-10-21 2016-11-02 PY - 2016 SN - 1958-5578 0040-5957 SP - 491-499 ST - Early adherence to anti-glaucoma therapy: An observational study T2 - Therapie TI - Early adherence to anti-glaucoma therapy: An observational study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612775891&from=export http://dx.doi.org/10.1016/j.therap.2016.02.033 VL - 71 ID - 2699 ER - TY - JOUR AB - Purpose: To present a case of repeated graft dislocation after Descemet stripping automated endothelial keratoplasty (DSAEK) in a post-trabeculectomy eye and to suggest a simple postoperative maneuver to minimize this occurrence. Methods: A 61-year-old woman presented to our cornea clinic with pseudophakic bullous keratopathy in her left eye 13 years after a trabeculectomy had been performed. After the DSAEK was performed, repeated graft dislocations were observed. When air was seen in the filtering bleb in the immediate postoperative period, it was assumed that it had escaped from the air bubble remaining in the anterior chamber at the end of the surgery. The patient was thus placed in the Trendelenburg position immediately after performing a rebubbling procedure to retain the air bubble in the anterior chamber and away from the filtering bleb. Results: The corneal graft remained centered and clear at postoperative day 1 and remained so at the last follow-up visit 8 months after the surgery had taken place. The patientÊs intraocular pressure was well controlled with a functional filtering bleb. Conclusions: Postoperative Trendelenburg positioning is an easily applied maneuver that may promote graft adherence after performing a DSAEK in eyes that have undergone glaucoma surgery. © 2013 Lippincott Williams & Wilkins. AD - Department of Ophthalmology, Meir Medical Center, 44281 Kfar Saba, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel AU - Belkin, A. AU - Nesher, R. AU - Segev, F. DB - Scopus DO - 10.1097/ICO.0b013e31829eeafb IS - 11 KW - Descemet stripping automated endothelial keratoplasty graft dislocation Trendelenburg M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2013 SP - 1509-1511 ST - Postoperative trendelenburg position for graft adherence after descemet stripping automated endothelial keratoplasty T2 - Cornea TI - Postoperative trendelenburg position for graft adherence after descemet stripping automated endothelial keratoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886091956&doi=10.1097%2fICO.0b013e31829eeafb&partnerID=40&md5=1bf103f32fc4c7b26af932ef76290da1 VL - 32 ID - 5520 ER - TY - JOUR AB - Purpose:To present a case of repeated graft dislocation after Descemet stripping automated endothelial keratoplasty (DSAEK) in a post-trabeculectomy eye and to suggest a simple postoperative maneuver to minimize this occurrence.Methods:A 61-year-old woman presented to our cornea clinic with pseudophakic bullous keratopathy in her left eye 13 years after a trabeculectomy had been performed. After the DSAEK was performed, repeated graft dislocations were observed. When air was seen in the filtering bleb in the immediate postoperative period, it was assumed that it had escaped from the air bubble remaining in the anterior chamber at the end of the surgery. The patient was thus placed in the Trendelenburg position immediately after performing a rebubbling procedure to retain the air bubble in the anterior chamber and away from the filtering bleb.Results:The corneal graft remained centered and clear at postoperative day 1 and remained so at the last follow-up visit 8 months after the surgery had taken place. The patient's intraocular pressure was well controlled with a functional filtering bleb.Conclusions:Postoperative Trendelenburg positioning is an easily applied maneuver that may promote graft adherence after performing a DSAEK in eyes that have undergone glaucoma surgery. AN - WOS:000325921300023 AU - Belkin, A. AU - Nesher, R. AU - Segev, F. DA - NOV DO - 10.1097/ICO.0b013e31829eeafb IS - 11 PY - 2013 SN - 0277-3740 1536-4798 SP - 1509-1511 ST - Postoperative Trendelenburg Position for Graft Adherence After Descemet Stripping Automated Endothelial Keratoplasty T2 - CORNEA TI - Postoperative Trendelenburg Position for Graft Adherence After Descemet Stripping Automated Endothelial Keratoplasty VL - 32 ID - 6101 ER - TY - GEN AB - Glaucoma is a collection of diseases characterized by multifactorial progressive changes leading to visual field loss and optic neuropathy most frequently due to elevated intraocular pressure (IOP). The goal of treatment is the lowering of the IOP to prevent additional optic nerve damage. Treatment usually begins with topical pharmacological agents as monotherapy, progresses to combination therapy with agents from up to 4 different classes of IOP-lowering medications, and then proceeds to laser or incisional surgical modalities for refractory cases. The fixed combination therapy with the carbonic anhydrase inhibitor dorzolamide hydrochloride 2% and the beta blocker timolol maleate 0.5% is now available in a generic formulation for the treatment of patients who have not responded sufficiently to monotherapy with beta adrenergic blockers. In pre- and postmarketing clinical studies, the fixed combination dorzolamide-timolol has been shown to be safe and efficacious, and well tolerated by patients. The fixed combination dorzolamide-timolol is convenient for patients, reduces their dosing regimen with the goal of increasing their compliance, reduces the effects of "washout" when instilling multiple drops, and reduces the preservative burden by reducing the number of drops administered per day. © 2010 Bell et al. AD - N. P. Bell, Robert Cizik Eye Clinic, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, 6400 Fannin Street, 18th Floor, Houston, TX 77030, United States AU - Bell, N. P. AU - Ramos, J. L. AU - Feldman, R. M. C1 - alphagan p(Allergan) alphagan(Allergan) azarga cosopt(Merck,United States) lumigan(Allergan) timoptic(Merck,United States) travatan z(Alcon) travatan(Alcon) trusopt(Merck,United States) xalatan(Pfizer,United States) C2 - Alcon Allergan Merck(United States) Pfizer(United States) DB - Embase DO - 10.2147/OPTH.S14054 J2 - Clin. Ophthalmol. KW - antiglaucoma agent bimatoprost brimonidine brimonidine plus latanoprost brimonidine plus timolol brinzolamide plus timolol carbonate dehydratase inhibitor dorzolamide dorzolamide plus timolol dorzolamide plus timolol maleate latanoprost latanoprost plus timolol timolol maleate timolol plus travoprost travoprost unclassified drug abdominal pain add on therapy adjuvant therapy article backache bitter taste blepharitis blurred vision bradycardia bronchitis cataract cerebrovascular accident chemosis choroid detachment conjunctiva disease conjunctival discharge conjunctival hyperemia conjunctivitis cornea erosion coughing crystalluria depression diarrhea dizziness drug absorption drug cost drug efficacy drug eruption drug excretion drug hypersensitivity drug induced headache drug metabolism drug safety drug substitution drug tissue level drug tolerability drug withdrawal dry eye dysgeusia dyspepsia dyspnea epiphora eye burning eye discharge eye disease eye pain eyelid disease eyelid edema eyelid erythema eyelid exudate eyelid pain fatigue finger injury glaucoma health care cost heart atrium myxoma heart block heart failure heart infarction human hyperglycemia hyperoxaluria hypertension hypertrichosis hypotension incidence influenza intraocular foreign body intraocular hypertension iridocyclitis leukocytosis morning dosage nausea nose obstruction ocular pruritus ocular stinging open angle glaucoma parathyroid hyperplasia paresthesia patient compliance pharmacodynamics pharyngitis photophobia pneumonia prevalence pseudoexfoliation punctate keratitis respiratory failure respiratory tract disease side effect subcapsular cataract taste aversion thorax pain thrombocytopenia thumb injury tremor upper respiratory tract infection urinary tract infection urolithiasis visual field defect vitreous body detachment vomiting xerostomia alphagan p alphagan azarga cosopt lumigan timoptic travatan z travatan trusopt xalatan L1 - internal-pdf://2550207934/3216-Safety, tolerability, and efficacy o-2010.pdf LA - English M1 - (Bell N.P., nicholas.bell@uth.tmc.edu; Ramos J.L.; Feldman R.M.) Robert Cizik Eye Clinic, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, Houston, United States M3 - Article N1 - L361011352 2011-01-11 PY - 2010 SN - 1177-5467 1177-5483 SP - 1331-1346 ST - Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension TI - Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361011352&from=export http://dx.doi.org/10.2147/OPTH.S14054 VL - 4 ID - 3216 ER - TY - JOUR AB - Précis:A 15-year analysis of 198,843 visual field (VF) tests revealed a growing trend for their performance for nonglaucoma indications. Adherence to glaucoma management guidelines was suboptimal. Guidelines for referral to VF assessments should be established.Purpose:The purpose of this study was to identify trends in VF assessments over 15 years among patients with and without suspected or confirmed glaucoma, in a large healthcare maintenance organization.Methods:This was a population-based retrospective cohort study, conducted by means of electronic medical database analyses. Study population: Maccabi Healthcare Services is an healthcare maintenance organization that insures 2 million members constituting 25% of the population. All members who underwent at least 1 VF test between January 2000 and December 2014 were included. In addition, all members with glaucoma or suspected glaucoma diagnosis or who were prescribed with antiglaucoma medications were evaluated. Main outcome measures: VF performance rates.Results:A total of 93,617 Maccabi Healthcare Services members underwent 198,843 VF tests; of whom 47.9% involved patients without any glaucoma-related conditions. There was a growing trend over time toward more of those members to undergo VF tests and, by 2014, non-glaucoma-related members comprised 74.0% of new VF assessments. In contrast, 32.3% of glaucoma-related patients did not perform even 1 VF test throughout the entire study period. Although over 2 years (25.95±6.33 mo) passed between the first glaucoma-related diagnosis and first VF test, once a patient underwent the first VF test, an average once-a-year VF follow-up (0.95±0.37 annual tests) began.Conclusion:There is a growing trend for VF tests being apparently overused for indications other than glaucoma. Concurrently, adherence to glaucoma management guidelines on VF tests is suboptimal, leading to discernible underuse. Guidelines for VF assessments in nonglaucoma patients should be established. Adherence to existing glaucoma management guidelines should be improved. © 2019 Wolters Kluwer Health, Inc. AD - Goldschleger Eye Institute, Sheba Medical Center, Affiliated to the Sackler School of Medicine, Tel Aviv University, Hashomer 64, Ramat Gan, 52620, Israel Maccabi Healthcare Services, Tel Aviv, Israel AU - Ben-Artsi, E. AU - Goldenfeld, M. AU - Zehavi-Dorin, T. AU - Cohen, A. AU - Porath, A. AU - Levkovitch-Verbin, H. DB - Scopus DO - 10.1097/IJG.0000000000001262 IS - 7 KW - adherence epidemiology glaucoma guidelines ophthalmology visual fields M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2019 SP - 660-665 ST - Overuse and Underuse of Visual Field Testing Over 15 Years T2 - Journal of Glaucoma TI - Overuse and Underuse of Visual Field Testing Over 15 Years UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064255384&doi=10.1097%2fIJG.0000000000001262&partnerID=40&md5=cc848e38a777b0c6a430d4e03f8d3dc3 VL - 28 ID - 5612 ER - TY - JOUR AB - Precis: A 15-year analysis of 198,843 visual field (VF) tests revealed a growing trend for their performance for nonglaucoma indications. Adherence to glaucoma management guidelines was suboptimal. Guidelines for referral to VF assessments should be established. Purpose: The purpose of this study was to identify trends in VF assessments over 15 years among patients with and without suspected or confirmed glaucoma, in a large healthcare maintenance organization. Methods: This was a population-based retrospective cohort study, conducted by means of electronic medical database analyses. Study population: Maccabi Healthcare Services is an healthcare maintenance organization that insures 2 million members constituting 25% of the population. All members who underwent at least 1 VF test between January 2000 and December 2014 were included. In addition, all members with glaucoma or suspected glaucoma diagnosis or who were prescribed with antiglaucoma medications were evaluated. Main outcome measures: VF performance rates. Results: A total of 93,617 Maccabi Healthcare Services members underwent 198,843 VF tests; of whom 47.9% involved patients without any glaucoma-related conditions. There was a growing trend over time toward more of those members to undergo VF tests and, by 2014, non-glaucoma-related members comprised 74.0% of new VF assessments. In contrast, 32.3% of glaucoma-related patients did not perform even 1 VF test throughout the entire study period. Although over 2 years (25.95 +/- 6.33 mo) passed between the first glaucoma-related diagnosis and first VF test, once a patient underwent the first VF test, an average once-a-year VF follow-up (0.95 +/- 0.37 annual tests) began. Conclusion: There is a growing trend for VF tests being apparently overused for indications other than glaucoma. Concurrently, adherence to glaucoma management guidelines on VF tests is suboptimal, leading to discernible underuse. Guidelines for VF assessments in nonglaucoma patients should be established. Adherence to existing glaucoma management guidelines should be improved. AN - WOS:000475936400024 AU - Ben-Artsi, E. AU - Goldenfeld, M. AU - Zehavi-Dorin, T. AU - Cohen, A. AU - Porath, A. AU - Levkovitch-Verbin, H. DA - JUL DO - 10.1097/IJG.0000000000001262 IS - 7 PY - 2019 SN - 1057-0829 1536-481X SP - 660-665 ST - Overuse and Underuse of Visual Field Testing Over 15 Years T2 - JOURNAL OF GLAUCOMA TI - Overuse and Underuse of Visual Field Testing Over 15 Years VL - 28 ID - 6138 ER - TY - JOUR AB - Purpose: The primary objective of the ongoing Glaucoma Intensive Treatment Study (GITS) is to evaluate the effectiveness of immediate intensive treatment in comparison with the commonly recommended stepped regimen on the predicted visual field. The two treatment arms are also being compared regarding quality of life (QoL), intraocular pressure (IOP) reduction, frequency of reported side-effects, adverse events and adherence to prescribed treatment. Design: A randomized, two-centre, prospective open-labelled treatment trial for open-angle glaucoma. Participants: Individuals aged 40–78 years with previously untreated and newly diagnosed glaucoma with early to moderate visual field loss were eligible. Methods: Patients were randomized to initial treatment either using drug monotherapy in accordance with common glaucoma guidelines or using a more intensive approach including eyedrops containing drugs from three different classes combined with 360° laser trabeculoplasty. The patients are to be followed for 5 years at visits including standard automated perimetry, optical coherence tomography (OPT) and tonometry. Change of treatment is allowed and decided upon jointly with the patient as in conventional glaucoma management. Main outcome: The estimated predicted preserved visual field and QoL at end of expected lifetime. Results: A total of 242 patients, 45% females, mean age 68 years, were randomized. The median untreated IOP was 24 mm Hg, and the median visual field index (VFI), indicating the percentage of a full field, was 92%. Conclusion: Glaucoma Intensive Treatment Study is a clinical trial in which two groups of patients randomized to different initial intensities of IOP-reducing treatment are being compared with regard to rate of visual field progression and prediction of serious glaucomatous visual field loss at estimated at end of life. © 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd AD - Department of Clinical Sciences in Malmö, Ophthalmology, Lund University, Malmö, Sweden Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden AU - Bengtsson, B. AU - Heijl, A. AU - Johannesson, G. AU - Andersson-Geimer, S. AU - Aspberg, J. AU - Lindén, C. DB - Scopus DO - 10.1111/aos.13791 IS - 6 KW - drug trial glaucoma quality of life visual field M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2018 SP - 557-566 ST - The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data T2 - Acta Ophthalmologica TI - The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052842739&doi=10.1111%2faos.13791&partnerID=40&md5=ec032ad42132767e4aab4d79cbb664cb VL - 96 ID - 5372 ER - TY - JOUR AB - Purpose The primary objective of the ongoing Glaucoma Intensive Treatment Study (GITS) is to evaluate the effectiveness of immediate intensive treatment in comparison with the commonly recommended stepped regimen on the predicted visual field. The two treatment arms are also being compared regarding quality of life (QoL), intraocular pressure (IOP) reduction, frequency of reported side-effects, adverse events and adherence to prescribed treatment. DesignParticipantsA randomized, two-centre, prospective open-labelled treatment trial for open-angle glaucoma. Individuals aged 40-78years with previously untreated and newly diagnosed glaucoma with early to moderate visual field loss were eligible. MethodsResultsPatients were randomized to initial treatment either using drug monotherapy in accordance with common glaucoma guidelines or using a more intensive approach including eyedrops containing drugs from three different classes combined with 360 degrees laser trabeculoplasty. The patients are to be followed for 5years at visits including standard automated perimetry, optical coherence tomography (OPT) and tonometry. Change of treatment is allowed and decided upon jointly with the patient as in conventional glaucoma management. Main outcome: The estimated predicted preserved visual field and QoL at end of expected lifetime. A total of 242 patients, 45% females, mean age 68years, were randomized. The median untreated IOP was 24mm Hg, and the median visual field index (VFI), indicating the percentage of a full field, was 92%. ConclusionGlaucoma Intensive Treatment Study is a clinical trial in which two groups of patients randomized to different initial intensities of IOP-reducing treatment are being compared with regard to rate of visual field progression and prediction of serious glaucomatous visual field loss at estimated at end of life. AN - WOS:000447257100003 AU - Bengtsson, B. AU - Heijl, A. AU - Johannesson, G. AU - Andersson-Geimer, S. AU - Aspberg, J. AU - Linden, C. DA - SEP DO - 10.1111/aos.13791 IS - 6 PY - 2018 SN - 1755-375X 1755-3768 SP - 557-566 ST - The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data T2 - ACTA OPHTHALMOLOGICA TI - The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data VL - 96 ID - 6159 ER - TY - JOUR AB - PURPOSE: To report the outcome of epiretinal membrane (ERM) surgery in young patients. DESIGN: Interventional case series study. METHOD: A retrospective review of 20 young patients who had undergone vitrectomy and epiretinal membrane removal. All patients had a preoperative examination, including fundus biomicroscopy, red free photographs, and fluorescein angiography. RESULTS: Nine patients were males and 11 females (age: 7-26 years; mean: 16.3 years). Follow up ranged from 4-96 months (mean: 21.2 months). The 20 patients comprised 13 cases of idiopathic ERM, six cases in which ERM was associated with ocular inflammation and one case of combined hamartoma of the retina and retinal pigment epithelium (RPE). In 13 cases, the ERM was especially white, thick, and opaque, with localized constriction and severe retinal distortion. Final best-corrected visual acuity (VA) was significantly better than preoperatively (20/50 vs. 20/112), (P = 0.0002). Mean improvement in VA was 4.25 lines and 17 patients gained two or more lines. This improvement was better in secondary than idiopathic ERM (6 lines vs. 3.3). During follow up, five cases of recurrence were observed (25%). In another case, postoperative persistent ocular hypertension required filtering surgery. CONCLUSION: The characteristics of ERM in young patients are quite different in many cases from those in adults in terms of thickness and adherence. Removal of ERM in young patients is feasible and safe although the membrane may focally adhere strongly to retinal vessels. VA usually improves significantly after surgery, but recurrences are more frequent than in adults. © 2002 Elsevier Science Inc. All rights reserved. AD - Department of Ophthalmology, Hôpital Lariboisière, Université Paris 7, Paris, France 2 rue Ambroise Paré, 75475 Paris Cedex 10, France AU - Benhamou, N. AU - Massin, P. AU - Spolaore, R. AU - Paques, M. AU - Gaudric, A. DB - Scopus DO - 10.1016/S0002-9394(01)01422-2 IS - 3 M3 - Article N1 - Cited By :37 Export Date: 19 July 2021 PY - 2002 SP - 358-364 ST - Surgical management of epiretinal membrane in young patients T2 - American Journal of Ophthalmology TI - Surgical management of epiretinal membrane in young patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036183418&doi=10.1016%2fS0002-9394%2801%2901422-2&partnerID=40&md5=abb487e28e25dda61882c67603913585 VL - 133 ID - 5030 ER - TY - JOUR AB - Purpose: To report the outcome of epiretinal membrane (ERM) surgery in young patients. Design: Interventional case series study. Method: A retrospective review of 20 young patients who had undergone vitrectomy and epiretinal membrane removal. All patients had a preoperative examination, including fundus biomicroscopy, red free photographs, and fluorescein angiography. Results: Nine patients were males and 11 females (age: 7-26 years; mean: 16.3 years). Follow up ranged from 4-96 months (mean: 21.2 months). The 20 patients comprised 13 cases of idiopathic ERM, six cases in which ERM was associated with ocular inflammation and one case of combined hamartoma of the retina and retinal pigment epithelium (RPE). In 13 cases, the ERM was especially white, thick, and opaque, with localized constriction and severe retinal distortion. Final best,corrected visual acuity (VA) was significantly better than preoperatively (20/50 vs. 20/112), (P=0.0002). Mean improvement in VA was 4.25 lines and 17 patients gained two or more lines. This improvement was better in secondary than idiopathic ERM (6 lines vs. 3.3). During follow up, five cases of recurrence were observed (25%). In another case, postoperative persistent ocular hypertension required filtering surgery. Conclusion: The characteristics of ERM. in young patients are quite different in many cases from those in adults in terms of thickness and adherence. Removal of ERM in young patients is feasible and safe although the membrane may focally adhere strongly to retinal vessels. VA usually improves significantly after surgery, but recurrences are more frequent than in adults. (Am J Ophthalmol 2002;133:358-364. (C) 2002 by Elsevier Science Inc. All rights reserved.). AN - WOS:000174268600009 AU - Benhamou, N. AU - Massin, P. AU - Spolaore, R. AU - Paques, M. AU - Gaudric, A. DA - MAR DO - 10.1016/S0002-9394(01)01422-2 IS - 3 PY - 2002 SN - 0002-9394 SP - 358-364 ST - Surgical management of epiretinal membrane in young patients T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Surgical management of epiretinal membrane in young patients VL - 133 ID - 6286 ER - TY - JOUR AB - Streptococcus pneumoniae is a gram-positive, facultatively anaerobic pathogen that can cause severe infections such as pneumonia, meningitis, septicemia, and middle ear infections. It is also one of the top pathogens contributing to bacterial keratitis and conjunctivitis. Though two pneumococcal vaccines exist for the prevention of nonocular diseases, they do little to fully prevent ocular infections. This pathogen has several virulence factors that wreak havoc on the conjunctiva, cornea, and intraocular system. Polysaccharide capsule aids in the evasion of host complement system. Pneumolysin (PLY) is a cholesterol-dependent cytolysin that acts as pore-forming toxin. Neuraminidases assist in adherence and colonization by exposing cell surface receptors to the pneumococcus. Zinc metalloproteinases contribute to evasion of the immune system and disease severity. The main purpose of this review is to consolidate the multiple studies that have been conducted on several pneumococcal virulence factors and the role each plays in conjunctivitis, keratitis, and endophthalmitis. AD - Department of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216, USA AN - 132988123. Language: English. Entry Date: In Process. Revision Date: 20181121. Publication Type: Article. Journal Subset: Biomedical AU - Benton, Angela H. AU - Marquart, Mary E. DB - ccm DO - 10.1155/2018/2525173 DP - EBSCOhost N1 - USA. NLM UID: 101496545. PY - 2018 SN - 1687-708X SP - 1-9 ST - The Role of Pneumococcal Virulence Factors in Ocular Infectious Diseases T2 - Interdisciplinary Perspectives on Infectious Diseases TI - The Role of Pneumococcal Virulence Factors in Ocular Infectious Diseases UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132988123&site=ehost-live&scope=site ID - 4294 ER - TY - JOUR AB - IMPORTANCE: Familial amyloid polyneuropathy, a lethal genetic disease caused by aggregation of variant transthyretin, induces progressive peripheral nerve deficits and disability. Diflunisal, a nonsteroidal anti-inflammatory agent, stabilizes transthyretin tetramers and prevents amyloid fibril formation in vitro. OBJECTIVE: To determine the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy. DESIGN, SETTING, AND PARTICIPANTS: International randomized, double-blind, placebo-controlled study conducted among 130 patients with familial amyloid polyneuropathy exhibiting clinically detectable peripheral or autonomic neuropathy at amyloid centers in Sweden (Umeå), Italy (Pavia), Japan (Matsumoto and Kumamoto), England (London), and the United States (Boston, Massachusetts; New York, New York; and Rochester, Minnesota) from 2006 through 2012. INTERVENTION: Participants were randomly assigned to receive diflunisal, 250 mg (n=64), or placebo (n=66) twice daily for 2 years. MAIN OUTCOMES AND MEASURES: The primary end point, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurological deficits) to 270 points (no detectable peripheral nerve function). Secondary outcomes included a quality-of-life questionnaire (36-Item Short-Form Health Survey [SF-36]) and modified body mass index. Because of attrition, we used likelihood-based modeling and multiple imputation analysis of baseline to 2-year data. RESULTS: By multiple imputation, the NIS+7 score increased by 25.0 (95% CI, 18.4-31.6) points in the placebo group and by 8.7 (95% CI, 3.3-14.1) points in the diflunisal group, a difference of 16.3 points (95% CI, 8.1-24.5 points; P < .001). Mean SF-36 physical scores decreased by 4.9 (95% CI, -7.6 to -2.2) points in the placebo group and increased by 1.5 (95% CI, -0.8 to 3.7) points in the diflunisal group (P < .001). Mean SF-36 mental scores declined by 1.1 (95% CI, -4.3 to 2.0) points in the placebo group while increasing by 3.7 (95% CI, 1.0-6.4) points in the diflunisal group (P = .02). By responder analysis, 29.7% of the diflunisal group and 9.4% of the placebo group exhibited neurological stability at 2 years (<2-point increase in NIS+7 score; P = .007). CONCLUSIONS AND RELEVANCE: Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurological impairment and preserved quality of life. Although longer-term follow-up studies are needed, these findings suggest benefit of this treatment for familial amyloid polyneuropathy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00294671. Copyright 2013 American Medical Association. All rights reserved. AD - Amyloidosis Center, Departments of Medicine and Neurology, Boston University School of Medicine, Boston, MA, United States Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden Amyloidosis Research and Treatment Center, Department of Molecular Medicine, University of Pavia, Pavia, Italy Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan Departments of Medicine and Neurology, Mayo Clinic, Rochester, MN, United States Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan Institute of Liver Studies, King's College Hospital Foundation Trust, London, United Kingdom Istituto Clinico Humanitas, Rozzano, Italy C. Mondino National Institute of Neurology, Foundation IRCCS, Pavia, Italy Departments of Medicine and Neurology, Mount Sinai School of Medicine, New York, NY, United States Department of Epidemiology, Boston University School of Public Health, Boston, MA, United States Data Coordinating Center, Boston University School of Public Health, Boston, MA, United States Departments of Chemistry and Molecular and Experimental Medicine, Skaggs Institute of Chemical Biology, Scripps Research Institute, San Diego, CA, United States AU - Berk, J. L. AU - Suhr, O. B. AU - Obici, L. AU - Sekijima, Y. AU - Zeldenrust, S. R. AU - Yamashita, T. AU - Heneghan, M. A. AU - Gorevic, P. D. AU - Litchy, W. J. AU - Wiesman, J. F. AU - Nordh, E. AU - Corato, M. AU - Lozza, A. AU - Cortese, A. AU - Robinson-Papp, J. AU - Colton, T. AU - Rybin, D. V. AU - Bisbee, A. B. AU - Ando, Y. AU - Ikeda, S. I. AU - Seldin, D. C. AU - Merlini, G. AU - Skinner, M. AU - Kelly, J. W. AU - Dyck, P. J. DB - Scopus DO - 10.1001/jama.2013.283815 IS - 24 M3 - Article N1 - Cited By :372 Export Date: 19 July 2021 PY - 2013 SP - 2658-2667 ST - Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial T2 - JAMA - Journal of the American Medical Association TI - Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890954073&doi=10.1001%2fjama.2013.283815&partnerID=40&md5=8004c6c4a76c7019d7bc2237fdbe587c VL - 310 ID - 4903 ER - TY - JOUR AU - Bertram, B. AU - Gante, C. AU - Hilgers, R. D. DB - Medline DO - 10.1007/s00347-013-2966-z IS - 8 KW - adult aged ambulatory care cataract clinical practice comorbidity comparative study cross-sectional study diabetic retinopathy female Germany glaucoma health care survey human macular degeneration male middle aged ophthalmology prevalence statistics and numerical data trends utilization utilization review very elderly visual system examination LA - German M3 - Article N1 - L603713779 2015-04-17 PY - 2014 SN - 1433-0423 SP - 757-764 ST - Increase in examinations for cataracts, glaucoma, diabetic retinopathy and age-related macular degeneration : Comparative cross-sectional study between 2010 and 1997 in ophthalmological practices T2 - Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft TI - Increase in examinations for cataracts, glaucoma, diabetic retinopathy and age-related macular degeneration : Comparative cross-sectional study between 2010 and 1997 in ophthalmological practices UR - https://www.embase.com/search/results?subaction=viewrecord&id=L603713779&from=export http://dx.doi.org/10.1007/s00347-013-2966-z VL - 111 ID - 2876 ER - TY - JOUR AB - It is estimated that 2.2 million people have glaucoma in the US and 67 million people worldwide. The majority of cases are associated with elevated intraocular pressure (IOP) and decreasing IOP eliminates or greatly reduces degeneration in most cases, including cases in which the IOP is in the normal range but optic neuropathy occurs. Timolol maleate has the longest record of safety and efficacy to lower IOP and is administered via eye drops one or more times per day. Unfortunately, compliance is poor across patient populations leading to degeneration. Patients typically see their ophthalmologist once every 3-4 months. If one could administer a long-acting treatment while in the doctor's office, one might overcome the compliance issue and effectively preserve sight. The critical step is to develop a formulation for timolol maleate that leads to sustained delivery for greater than 90 days and would permit a different treatment paradigm, namely subconjunctival administration once every 3-4 months. By using a 50 : 50 blend of PLGA 502H and PLA, this study was able to fabricate microspheres that delivered timolol maleate continually over 107 days, well within the time frame needed to make subconjunctival administration feasible and permit a new approach to treating glaucoma and diseases of the eye more broadly. AD - E.B. Lavik, Department of Biomedical Engineering, Yale University, New Haven, CT, United States AU - Bertram, J. P. AU - Saluja, S. S. AU - McKain, J. AU - Lavik, E. B. DB - Embase Medline DO - 10.1080/02652040802095250 IS - 1 KW - eye drops microsphere polyglactin polylactic acid timolol maleate article controlled study drug delivery system drug efficacy drug safety encapsulation glaucoma human intraocular pressure particle size patient compliance scanning electron microscopy sustained drug release sustained release formulation LA - English M3 - Article N1 - L352858747 2009-01-22 PY - 2009 SN - 0265-2048 1464-5246 SP - 18-26 ST - Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/ poly(lactic acid) microspheres for over 3 months T2 - Journal of Microencapsulation TI - Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/ poly(lactic acid) microspheres for over 3 months UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352858747&from=export http://dx.doi.org/10.1080/02652040802095250 VL - 26 ID - 3385 ER - TY - JOUR AB - Purpose: In response to recent calls for clearer specification of behavior change interventions, the purpose of this study was to apply a system of taxonomy for behavior change techniques (BCTs) to two educational interventions to improve adherence to glaucoma eye drops. Clarification of constituent BCTs will promote easy and reliable application of the interventions in clinical settings and research. Methods: A published taxonomy of BCTs was used to code two interventions (group and individual) to increase adherence to eye drops. Intervention materials were coded by assigning a BCT label to each text unit. We noted the frequency with which each BCT occurred, compared the interventions in terms of the BCTs that were delivered, and identified whether the taxonomy was sufficient to describe the intervention components. Results: The individual intervention consisted of 94 text units. Fifty-seven were identified as targeting behavior change and coded using 18 BCTs, many coded more than once. In the group intervention, 165 units of text were identified, and 125 were coded using 22 BCTs. The most frequently coded BCT was 'provide information about behavior–health link' in the group intervention and 'prompt barrier identification' in the individual intervention. The interventions included similar BCTs. All text units targeting behavior change were codable into BCTs. Conclusion: The similarity of the two interventions may have implications for the cost-effectiveness of the interventions. The taxonomy was found sufficient to describe both interventions. This level of specification can be used to ensure that precisely the same intervention that has been pilot tested is reproducible in the clinical setting and in any further research. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Waterman, Heather, School of Nursing, Midwifery and Social Work, University of Manchester, Room 6.314a, Jean McFarlane Building, Oxford Road, Manchester, United Kingdom, M13 9PL AN - 2015-38576-001 AU - Berzins, Kathryn M. AU - Gray, Trish A. AU - Waterman, Heather AU - Francis, Jill J. DB - psyh DP - EBSCOhost KW - behavior change techniques glaucoma adherence Behavior Change Treatment Compliance Intervention N1 - School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom. Release Date: 20150907. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishConference Information: Meeting of the UK and Eire Glaucoma Society, Dec, 2013, Nottingham, United Kingdom. Conference Note: Parts of this work have previously been presented at the aforementioned conference and at the annual conference of the British Psychological Society Division of Health Psychology, Brighton, 11–13 September 2013. Major Descriptor: Behavior Change; Glaucoma; Treatment Compliance. Minor Descriptor: Intervention. Classification: Behavioral & Psychological Treatment of Physical Illness (3361). Population: Human (10). Methodology: Empirical Study; Quantitative Study. References Available: Y. ArtID: 201-209. Issue Publication Date: Jul 9, 2015. Copyright Statement: This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creative commons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Berzins et al. 2015. PY - 2015 SN - 1179-1578 ST - Specifying active components of educational interventions to promote adherence to treatment in glaucoma patients: Application of a taxonomy of behavior change techniques T2 - Psychology Research and Behavior Management TI - Specifying active components of educational interventions to promote adherence to treatment in glaucoma patients: Application of a taxonomy of behavior change techniques UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-38576-001&site=ehost-live&scope=site waterman@manchester.ac.uk VL - 8 ID - 4822 ER - TY - JOUR AD - S.J. Best, Auckland Eye, Remuera, Auckland, New Zealand AU - Best, S. J. DB - Embase Medline DO - 10.1111/j.1442-9071.2007.01600.x IS - 7 KW - antiglaucoma agent eye drops prostaglandin derivative blindness diabetic retinopathy diagnostic error drug utilization early diagnosis editorial evidence based medicine glaucoma human open angle glaucoma patient compliance patient education practice guideline prescription unspecified side effect visual impairment LA - English M3 - Editorial N1 - L47491213 2007-09-01 PY - 2007 SN - 1442-6404 1442-9071 SP - 593 ST - Does persistency truly equate to compliance? T2 - Clinical and Experimental Ophthalmology TI - Does persistency truly equate to compliance? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47491213&from=export http://dx.doi.org/10.1111/j.1442-9071.2007.01600.x VL - 35 ID - 3508 ER - TY - JOUR AB - Background: Benzalkonium chloride (BAK) is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes. This study compared the intraocular pressure (IOP)-lowering efficacy and safety of a novel once-daily, BAK-free, fixed-dose combination of latanoprost plus timolol with latanoprost or timolol administered as monotherapy or concomitantly. Methods: This was a 6-week, randomized, open-label, parallel-group, active-controlled study in patients aged > 18 years with open-angle glaucoma or ocular hypertension. A total of 227 patients were randomized to either a once-daily, BAK-free, fixed-dose combination of latanoprost 0.005%/timolol 0.5% ophthalmic solution or concomitant administration of once-daily latanoprost 0.005% plus twice-daily timolol 0.5% or once-daily latanoprost 0.005% monotherapy, or twice-daily timolol 0.5% monotherapy. Efficacy end points were assessed at three time points on visits at weeks 1, 2, 4, and 6 versus baseline. Results: The IOP-lowering efficacy of the fixed-dose combination of latanoprost/timolol was similar to that of latanoprost plus timolol administered concomitantly at all time points (mean IOP difference and 95% confidence interval within ±1.5 mmHg; P=0.4223 to P=0.9981). The fixed-dose combination of latanoprost/timolol demonstrated significantly better IOP-lowering efficacy than timolol monotherapy at all time points (P=0.001 to P<0.0001) and significantly better IOP-lowering efficacy than latanoprost monotherapy at all time points. Responder rates on at least one time point and on at least two time points with fixed-dose combination latanoprost/ timolol were similar to those with concomitant latanoprost plus timolol (85.5% versus 82.1%, P=0.6360; 78.2% versus 75%, P=0.6923), but significantly better than either latanoprost or timolol monotherapy (68.5%, P=0.0355; 55.4%, P=0.0005; 57.4%, P=0.0202; and 46.4%, P=0.0006, respectively). No significant differences in ocular and nonocular treatment-emergent adverse events were found between the treatment groups. Conclusion: A BAK-free, fixed-dose combination of latanoprost 0.005%/timolol 0.5% was as effective and well tolerated as concomitant latanoprost and timolol for treatment of elevated IOP in patients with open-angle glaucoma or ocular hypertension. © 2014 Bhagat et al. AD - Glaucoma Clinic, M and J Western regional institute of Ophthalmology, Civil Hospital, Ahmedabad, Gujarat, India Glaucoma department, PBMA's H.V. Desai eye hospital, Maharashtra, India Glaucoma Service, B B Eye Foundation, Kolkata, India Advanced Eye Centre, Postgraduate Institute Of Medical Education And Research, Chandigarh, India Glaucoma Clinic, Aravind Eye Hospital, Coimbatore, Tamilnadu, India Glaucoma Clinic, Aravind Eye Hospital, Tirunelveli, Tamilnadu, India Clinical Research Department, Sun Pharma Advanced Research Company Ltd, Mumbai, Maharashtra, India AU - Bhagat, P. AU - Sodimalla, K. AU - Paul, C. AU - Pandav, S. S. AU - Raman, G. V. AU - Ramakrishnan, R. AU - Joshi, A. AU - Raut, A. DB - Scopus DO - 10.2147/OPTH.S64584 KW - Benzalkonium chloride Latanoprost Ocular hypertension Open-angle glaucoma Pharmaceutical preservatives Timolol M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2014 SP - 1241-1252 ST - Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension T2 - Clinical Ophthalmology TI - Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903635735&doi=10.2147%2fOPTH.S64584&partnerID=40&md5=ef412e1b40f2497f35c4573da84764a7 VL - 8 ID - 5386 ER - TY - JOUR AB - Aims: To determine patients' preferences for provision of glaucoma follow-up services examining preferences for location, access and personnel for delivery of this care. Methods: 100 patient patients attending the glaucoma outpatient clinic for follow-up review underwent an interview-based assessment during which they completed the visual function questionnaire 25 and ranking of scenario options for provision of follow-up care for their glaucoma. Percentage preferences for aspects of care offered in the conjoint analysis scenario packages and generation of utility values for each of the factor levels included in the scenario design were calculated. Results: Travel time and training of health professional were the most important factors for patients (accounting for over 60%) of their preference. Utility scores were generated for each factor, with shorter travel time and examination by a doctor being the most important features to the patients. Patients who lived furthest from the hospital and had severe visual disability considered the number of visits to complete an episode to be an important feature. Conclusion: Patients ideally would like to travel a short distance and be seen by a doctor when being followed up for their glaucoma. AD - A. J. King, Department of Ophthalmology, Nottingham University NHS Trust, Queen's Medical Centre Campus, Derby Road, Nottingham NG7 2UH, United Kingdom AU - Bhargava, J. S. AU - Bhan-Bhargava, A. AU - Foss, A. J. E. AU - King, A. J. DB - Embase Medline DO - 10.1136/bjo.2008.140483 IS - 12 KW - adult aged article female follow up glaucoma health care access health care delivery health care personnel hospital human independent variable internal validity interview linear regression analysis male medical education multivariate analysis outpatient department patient assessment priority journal questionnaire trabeculectomy travel vision visual acuity LA - English M3 - Article N1 - L352772220 2009-01-09 PY - 2008 SN - 0007-1161 1468-2079 SP - 1601-1605 ST - Views of glaucoma patients on provision of follow-up care; An assessment of patient preferences by conjoint analysis T2 - British Journal of Ophthalmology TI - Views of glaucoma patients on provision of follow-up care; An assessment of patient preferences by conjoint analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352772220&from=export http://dx.doi.org/10.1136/bjo.2008.140483 VL - 92 ID - 3405 ER - TY - JOUR AB - Aims: To determine patients' preferences for provision of glaucoma follow-up services examining preferences for location, access and personnel for delivery of this care. Methods: 100 patient patients attending the glaucoma outpatient clinic for follow-up review underwent an interview-based assessment during which they completed the visual function questionnaire 25 and ranking of scenario options for provision of follow-up care for their glaucoma. Percentage preferences for aspects of care offered in the conjoint analysis scenario packages and generation of utility values for each of the factor levels included in the scenario design were calculated. Results: Travel time and training of health professional were the most important factors for patients (accounting for over 60%) of their preference. Utility scores were generated for each factor, with shorter travel time and examination by a doctor being the most important features to the patients. Patients who lived furthest from the hospital and had severe visual disability considered the number of visits to complete an episode to be an important feature. Conclusion: Patients ideally would like to travel a short distance and be seen by a doctor when being followed up for their glaucoma. AD - Department of Ophthalmology, Queen's Medical Centre, Nottingham, United Kingdom Department of Ophthalmology, Nottingham University NHS Trust, Queen's Medical Centre Campus, Derby Road, Nottingham NG7 2UH, United Kingdom AU - Bhargava, J. S. AU - Bhan-Bhargava, A. AU - Foss, A. J. E. AU - King, A. J. DB - Scopus DO - 10.1136/bjo.2008.140483 IS - 12 M3 - Article N1 - Cited By :21 Export Date: 19 July 2021 PY - 2008 SP - 1601-1605 ST - Views of glaucoma patients on provision of follow-up care; An assessment of patient preferences by conjoint analysis T2 - British Journal of Ophthalmology TI - Views of glaucoma patients on provision of follow-up care; An assessment of patient preferences by conjoint analysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-57149088695&doi=10.1136%2fbjo.2008.140483&partnerID=40&md5=9d7183e71051334e576b94a04d2981bc VL - 92 ID - 5136 ER - TY - JOUR AB - Ab s t r ac t​ The ultimate goal of glaucoma therapy, as of any other therapeutic intervention, is to achieve superior clinical outcomes, patient satisfaction, and patient adherence to treatment. In a chronic asymptomatic disease, such as, glaucoma, where diagnostic and therapeutic algorithms may have multiple acceptable treatment arms, patient centricity becomes increasingly important. Shared decision-making, patient participation, quality of life (QoL) concerns, and risk–benefit analyzes further complicate this decision-making. In addition, the ethics of research in glaucoma and also that of glaucoma screening may often be in conflict with the ethics of patient care. This article aims to highlight the ethical dilemmas that confound decision-making in current glaucoma practice, and the doctors’ fiduciary duties to the patient. © The Author(s). 2020. AD - Department of Ophthalmology, Glaucoma Services, Fortis Memorial Research Institute, Gurugram, Haryana, India AU - Bhartiya, S. DB - Scopus DO - 10.5005/jp-journals-10078-1281 IS - 2 KW - Ethics Glaucoma practice Patient centricity Quality of life Shared decision-making M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 68-71 ST - Patient centricity and the ethics of glaucoma care T2 - Journal of Current Glaucoma Practice TI - Patient centricity and the ethics of glaucoma care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095459747&doi=10.5005%2fjp-journals-10078-1281&partnerID=40&md5=8cc12d226aad4aebfb622a6a6d453039 VL - 14 ID - 5711 ER - TY - JOUR AB - This study aims to evaluate the efficacy and safety of post-trabeculectomy topical bevacizumab, in preventing bleb failure. A total of 11 females and 12 males were enrolled for the study. After a complete ophthalmic evaluation, the patients underwent trabeculectomy. Full ophthalmic examination was done the next day, which included visual acuity, intraocular pressure (IOP), and bleb morphology. Next, two drops of bevacizumab [0.25 mg (0.01 ml)] were instilled over the wound area with a tuberculin (1 ml) syringe. Pressure was applied at the medial canthus to prevent it from going into the lacrimal passage. Similar postoperative procedures were repeated at 1, 2, 3, and 4 weeks. So in all, five instillations of bevacizumab were completed. Later, the patients were followed at 1-month interval for 6 months. Target IOP was achieved in all eyes and was maintained during the study period of 6 months without any anti-glaucoma medication. Average IOP before trabeculectomy was 27.27±8.92 mmHg, which decreased postoperatively to 8.77±0.97 mmHg at 3 months and 9.27±1.16 mmHg at 6 months. This drop in IOP was statistically significant on both occasions (p=0.00). A nice low filtering bleb was formed after the surgery, and it remained the same during the study period. The other parameters like cup-to-disc ratio and visual field did not change during the 6 months of study as expected because glaucoma is a slow progressive disease. Modulating the wound at multiple sites by bevacizumab (inflammation, proliferative, and remodeling stages) can lead to success of trabeculectomy. © Springer Science+Business Media New York 2013. AD - King George's Medical University, Lucknow, Uttar Pradesh, India AU - Bhasker, S. K. AU - Saxena, S. AU - Singh, K. DB - Scopus DO - 10.1007/s12177-013-9108-3 IS - 3-4 KW - Trabeculectomy Topical bevacizumab Wound healing M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2012 SP - 89-95 ST - Post-trabeculectomy topical bevacizumab preventing bleb failure: A preliminary study T2 - Journal of Ocular Biology, Diseases, and Informatics TI - Post-trabeculectomy topical bevacizumab preventing bleb failure: A preliminary study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892819961&doi=10.1007%2fs12177-013-9108-3&partnerID=40&md5=b338382d7ce7e8ce59520a0b6de111e2 VL - 5 ID - 5574 ER - TY - JOUR AB - Abstract. Background: Latanoprost, a prostaglandin inhibitor, is inercasingly being used in the therapcutic management of glaucoma. However, there is scant literature examining the cost and outcome ramifications of latanoprost. Objectives: This study examined the medication use behavior (medication-related persistence and adherence rates) and costs associated with the introduction of latanoprost therapy in a treatment-naive older population (aged ≥65 years) enrolled in Medicare. Methods: The study employed a retrospective observational cohort design and used administrative claims data from a Medicare health maintenance organization (HMO), which offered complete coverage to enrollees, including prescription benefits. The case group consisted of patients with glaucoma who began latanoprost therapy. The control group consisted of enrollees with glaucoma who started any therapy other than latanoprost. Both groups were followed up for 1 year before and after initiation of therapy. Bivariate and multivariate techniques incorporating health care utilization in the year before the start of new therapy were used to determine the study outcomes. Results: The case group comprised 101 patients (mean age, 77.60 years), while the control group included 168 patients (mean age, 77.59 years). There were no significant differences across the 2 groups with respect to age, sex, general health scores on the 12 item Short-Form Health Survey, severity of comorbidity, or the proportion of respondents with perception of worsened health. Introduction of latanoprost therapy was associated with higher medication persistence (hazard ratio, 0.90; 95% CI, 0.68-0.98) and adherence rates (mean [SD], 0.51 [0.26] vs 0.40 [0.25]; P < 0.001) compared with patients starting other glaucoma medication. Furthermore, there were no additional increases in total health care costs in the entire population associated with the introduction of latanoprost therapy, after adjusting for group and time effects, as well as other confounders (mean [SD], $4718.24 [$8982.92] vs $4046.55 [$6505.39]). Conclusions: Latanoprost therapy offered improved medication use behavior in these older adults enrolled in a Medicare HMO. There were no significant additional increases in overall health care costs as a result of introduction of latanoprost therapy, after adjusting for group and time effects, as well as other baseline confounders in this study cohort. © 2007 Excerpta Medica. Inc. AD - R. Balkrishnan, Department of Pharmacy Practice and Administration, The Ohio State University, Columbus, OH, United States AU - Bhosle, M. J. AU - Reardon, G. AU - Camacho, F. T. AU - Anderson, R. T. AU - Balkrishnan, R. DB - Embase Medline DO - 10.1016/j.amjopharm.2007.05.004 IS - 2 KW - antiglaucoma agent apraclonidine beta adrenergic receptor blocking agent bimatoprost brimonidine brinzolamide carteolol dipivefrine dorzolamide dorzolamide plus timolol latanoprost levobunolol metipranolol timolol maleate travoprost unoprostone isopropyl ester aged article bivariate analysis cohort analysis comorbidity confidence interval controlled study drug cost drug exposure drug use elderly care female follow up hazard ratio health care utilization human major clinical study male managed care medicare multivariate analysis observational study open angle glaucoma patient compliance priority journal retrospective study statistical significance treatment outcome LA - English M3 - Article N1 - L47264113 2007-06-01 PY - 2007 SN - 1543-5946 SP - 100-111 ST - Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population T2 - American Journal Geriatric Pharmacotherapy TI - Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47264113&from=export http://dx.doi.org/10.1016/j.amjopharm.2007.05.004 VL - 5 ID - 3523 ER - TY - JOUR AB - Abstract. Background: Latanoprost, a prostaglandin inhibitor, is inercasingly being used in the therapcutic management of glaucoma. However, there is scant literature examining the cost and outcome ramifications of latanoprost. Objectives: This study examined the medication use behavior (medication-related persistence and adherence rates) and costs associated with the introduction of latanoprost therapy in a treatment-naive older population (aged ≥65 years) enrolled in Medicare. Methods: The study employed a retrospective observational cohort design and used administrative claims data from a Medicare health maintenance organization (HMO), which offered complete coverage to enrollees, including prescription benefits. The case group consisted of patients with glaucoma who began latanoprost therapy. The control group consisted of enrollees with glaucoma who started any therapy other than latanoprost. Both groups were followed up for 1 year before and after initiation of therapy. Bivariate and multivariate techniques incorporating health care utilization in the year before the start of new therapy were used to determine the study outcomes. Results: The case group comprised 101 patients (mean age, 77.60 years), while the control group included 168 patients (mean age, 77.59 years). There were no significant differences across the 2 groups with respect to age, sex, general health scores on the 12 item Short-Form Health Survey, severity of comorbidity, or the proportion of respondents with perception of worsened health. Introduction of latanoprost therapy was associated with higher medication persistence (hazard ratio, 0.90; 95% CI, 0.68-0.98) and adherence rates (mean [SD], 0.51 [0.26] vs 0.40 [0.25]; P < 0.001) compared with patients starting other glaucoma medication. Furthermore, there were no additional increases in total health care costs in the entire population associated with the introduction of latanoprost therapy, after adjusting for group and time effects, as well as other confounders (mean [SD], $4718.24 [$8982.92] vs $4046.55 [$6505.39]). Conclusions: Latanoprost therapy offered improved medication use behavior in these older adults enrolled in a Medicare HMO. There were no significant additional increases in overall health care costs as a result of introduction of latanoprost therapy, after adjusting for group and time effects, as well as other baseline confounders in this study cohort. © 2007 Excerpta Medica. Inc. AD - Department of Pharmacy Practice and Administration, The Ohio State University, Columbus, OH, United States Informagenics Inc., Worthington, OH, United States Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, United States AU - Bhosle, M. J. AU - Reardon, G. AU - Camacho, F. T. AU - Anderson, R. T. AU - Balkrishnan, R. DB - Scopus DO - 10.1016/j.amjopharm.2007.05.004 IS - 2 KW - elderly glaucoma medication adherence open-angle glaucoma M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 2007 SP - 100-111 ST - Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population T2 - American Journal Geriatric Pharmacotherapy TI - Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547932062&doi=10.1016%2fj.amjopharm.2007.05.004&partnerID=40&md5=cd27647ffe33b05b70f86ec45d94e4ee VL - 5 ID - 5184 ER - TY - JOUR AB - The aim of this review is to report the updates in the medical literature on the outcomes associated with inhaled corticosteroid use. This update finds that inhaled corticosteroids remain a frontline choice as controller therapy in the treatment of asthma. Adherence to medications, especially inhaled corticosteroids used as controller medications, is responsible for a decrease in hospital, emergency room and physician visits. All of these translate to reduced asthma-related healthcare costs and an increase in health-related quality of life. There is a need for further research on the role of inhaled corticosteroids in chronic obstructive pulmonary disease outcomes. © 2004 Future Drugs Ltd. AD - The University of Texas, Health Science Center, School of Public Health, 1200 Hermann Pressler, Houston, TX 77030, United States AU - Bhosle, M. J. AU - Shenolikar, R. A. AU - Kulkarni, A. S. AU - Balkrishnan, R. DB - Scopus DO - 10.1586/14737167.4.6.645 IS - 6 KW - Asthma Chronic obstructive pulmonary disease Clinical studies Cost analyses Health outcomes Health-related quality of life Inhaled corticosteroids M3 - Review N1 - Export Date: 19 July 2021 PY - 2004 SP - 645-656 ST - Outcomes associated with inhaled corticosteroid use in asthma and COPD: An update T2 - Expert Review of Pharmacoeconomics and Outcomes Research TI - Outcomes associated with inhaled corticosteroid use in asthma and COPD: An update UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-9944256976&doi=10.1586%2f14737167.4.6.645&partnerID=40&md5=5d2f07f1a3dbb1a09d21e385a55407bc VL - 4 ID - 5777 ER - TY - JOUR AB - Eighty nine patients with newly diagnosed asymptomatic elevations of intraocular pressure were followed up over a 12 to 20 mth interval. During this period 33 (37%) of the patients were lost to ophthalmic follow up evaluation. The majority of these patients dropped out within 1 mth following the initial diagnosis. While institution of medical therapy for the elevated ocular pressure improved patient compliance when compared to the nontreated group, the rates of noncompliance in both groups were unacceptably high in view of the disease risk. Management of the noncompliant patient requires good physician patient communication, emphasis on patient education activities, and the use of selective reminder and recall systems within the ophthalmologist's office. AD - Dept. Ophthalmol., Med. Coll. Georgia, Augusta, Ga., United States AU - Bigger, J. F. DB - Scopus IS - 2 M3 - Article N1 - Cited By :24 Export Date: 19 July 2021 PY - 1976 SP - op277-285 ST - A comparison of patient compliance in treated vs untreated ocular hypertension T2 - Transactions of the American Academy of Ophthalmology and Otolaryngology TI - A comparison of patient compliance in treated vs untreated ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0346014933&partnerID=40&md5=552837073ee0faadd34a8609bab851a0 VL - 81 ID - 5103 ER - TY - JOUR AB - Background: Many glaucoma patients do not adhere to their medication regimens because they fail to internalize the (health) costs of non-adherence, which may not occur until years or decades later. Behavioural economic theory suggests that adherence rates can be improved by offering patients a near-term benefit. Our proposed strategy is to offer adherence-contingent rebates on medication and check-up costs. This form of value pricing (VP) ensures that rebates are granted only to those most likely to benefit. Moreover, by leveraging loss aversion, rebates are expected to generate a stronger behavioural response than equivalent financial rewards.Methods/design: The main objective of the Study on Incentives for Glaucoma Medication Adherence (SIGMA) is to test the VP approach relative to usual care (UC) in improving medication adherence. SIGMA is a randomized, controlled, open-label, single-centre superiority trial with two parallel arms. A total of 100 non-adherent (Morisky Medication Adherence Scale ≤6) glaucoma patients from the Singapore National Eye Centre are block-randomized (blocking factor: single versus multiple medications users) into the VP and UC arms in a 1:1 ratio. The treatment received by VP patients will be strictly identical to that received by UC patients, with the only exception being that VP patients can earn either a 50 % or 25 % rebate on their glaucoma-related healthcare costs conditional on being adherent on at least 90 % or 75 % of days as measured by a medication event monitoring system. Masking the arm allocation will be precluded by the behavioural nature of the intervention but blocking size will not be disclosed to protect concealment. The primary outcome is the mean change from baseline in percentage of adherent days at month 6. A day will be counted as adherent when the patients take all their medication(s) within the appropriate dosing windows.Discussion: This trial will provide evidence on whether adherence-contingent rebates can improve medication adherence among non-adherent glaucoma patients, and more generally whether this approach represents a promising strategy to cost-effectively improve chronic disease management.Trial Registration: NCT02271269 . Registered on 19 October 2014. AD - Health Services & Systems Research, Duke-NUS Graduate Medical School, 8 College Road, 169857 Singapore, Singapore Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, 168751 Singapore, Singapore Duke Global Health Institute, Duke University, 310 Trent Drive, Durham, NC 27710, USA Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, 168751, Singapore, Singapore AN - 116869311. Language: English. Entry Date: 20180725. Revision Date: 20190619. Publication Type: journal article AU - Bilger, Marcel AU - Wong, Tina T. AU - Howard, Kaye L. AU - Jia Yi, Lee AU - Ai Nee, Toh AU - John, Geraldine AU - Lamoureux, Ecosse L. AU - Finkelstein, Eric A. AU - Lee, Jia Yi AU - Toh, Ai Nee DB - ccm DO - 10.1186/s13063-016-1459-1 DP - EBSCOhost KW - Motivation Office Visits -- Economics Health Care Costs Glaucoma -- Drug Therapy Insurance, Health, Reimbursement Medication Compliance Glaucoma -- Economics Glaucoma -- Diagnosis Risk Factors Treatment Outcomes Human Singapore Study Design Aged Attitude to Health Risk Assessment Middle Age Male Female Time Factors Young Adult Adult Aged, 80 and Over Glaucoma -- Psychosocial Factors Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research; tables/charts. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 101263253. PMID: NLM27422389. PY - 2016 SN - 1745-6215 SP - 1-12 ST - Study on Incentives for Glaucoma Medication Adherence (SIGMA): study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing T2 - Trials TI - Study on Incentives for Glaucoma Medication Adherence (SIGMA): study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116869311&site=ehost-live&scope=site VL - 17 ID - 4230 ER - TY - JOUR AB - Background: Many glaucoma patients do not adhere to their medication regimens because they fail to internalize the (health) costs of non-adherence, which may not occur until years or decades later. Behavioural economic theory suggests that adherence rates can be improved by offering patients a near-term benefit. Our proposed strategy is to offer adherence-contingent rebates on medication and check-up costs. This form of value pricing (VP) ensures that rebates are granted only to those most likely to benefit. Moreover, by leveraging loss aversion, rebates are expected to generate a stronger behavioural response than equivalent financial rewards. Methods/Design: The main objective of the Study on Incentives for Glaucoma Medication Adherence (SIGMA) is to test the VP approach relative to usual care (UC) in improving medication adherence. SIGMA is a randomized, controlled, open-label, single-centre superiority trial with two parallel arms. A total of 100 non-adherent (Morisky Medication Adherence Scale ≤6) glaucoma patients from the Singapore National Eye Centre are block-randomized (blocking factor: single versus multiple medications users) into the VP and UC arms in a 1:1 ratio. The treatment received by VP patients will be strictly identical to that received by UC patients, with the only exception being that VP patients can earn either a 50 % or 25 % rebate on their glaucoma-related healthcare costs conditional on being adherent on at least 90 % or 75 % of days as measured by a medication event monitoring system. Masking the arm allocation will be precluded by the behavioural nature of the intervention but blocking size will not be disclosed to protect concealment. The primary outcome is the mean change from baseline in percentage of adherent days at month 6. A day will be counted as adherent when the patients take all their medication(s) within the appropriate dosing windows. Discussion: This trial will provide evidence on whether adherence-contingent rebates can improve medication adherence among non-adherent glaucoma patients, and more generally whether this approach represents a promising strategy to cost-effectively improve chronic disease management. Trial registration:NCT02271269. Registered on 19 October 2014. AD - M. Bilger, Health Services and Systems Research, Duke-NUS Graduate Medical School, 8 College Road, Singapore, Singapore AU - Bilger, M. AU - Wong, T. T. AU - Howard, K. L. AU - Lee, J. Y. AU - Toh, A. N. AU - John, G. AU - Lamoureux, E. L. AU - Finkelstein, E. A. DB - Embase Medline DO - 10.1186/s13063-016-1459-1 IS - 1 KW - NCT02271269 antiglaucoma agent article controlled study cost effectiveness analysis glaucoma health care cost human medication compliance money open study parallel design patient compliance randomized controlled trial (topic) randomized controlled trial reward Singapore value pricing LA - English M3 - Article N1 - L611210025 2016-07-20 2016-07-26 PY - 2016 SN - 1745-6215 ST - Study on Incentives for Glaucoma Medication Adherence (SIGMA): Study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing T2 - Trials TI - Study on Incentives for Glaucoma Medication Adherence (SIGMA): Study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611210025&from=export http://dx.doi.org/10.1186/s13063-016-1459-1 VL - 17 ID - 2724 ER - TY - JOUR AB - Background: Many glaucoma patients do not adhere to their medication regimens because they fail to internalize the (health) costs of non-adherence, which may not occur until years or decades later. Behavioural economic theory suggests that adherence rates can be improved by offering patients a near-term benefit. Our proposed strategy is to offer adherence-contingent rebates on medication and check-up costs. This form of value pricing (VP) ensures that rebates are granted only to those most likely to benefit. Moreover, by leveraging loss aversion, rebates are expected to generate a stronger behavioural response than equivalent financial rewards. Methods/Design: The main objective of the Study on Incentives for Glaucoma Medication Adherence (SIGMA) is to test the VP approach relative to usual care (UC) in improving medication adherence. SIGMA is a randomized, controlled, open-label, single-centre superiority trial with two parallel arms. A total of 100 non-adherent (Morisky Medication Adherence Scale ≤6) glaucoma patients from the Singapore National Eye Centre are block-randomized (blocking factor: single versus multiple medications users) into the VP and UC arms in a 1:1 ratio. The treatment received by VP patients will be strictly identical to that received by UC patients, with the only exception being that VP patients can earn either a 50 % or 25 % rebate on their glaucoma-related healthcare costs conditional on being adherent on at least 90 % or 75 % of days as measured by a medication event monitoring system. Masking the arm allocation will be precluded by the behavioural nature of the intervention but blocking size will not be disclosed to protect concealment. The primary outcome is the mean change from baseline in percentage of adherent days at month 6. A day will be counted as adherent when the patients take all their medication(s) within the appropriate dosing windows. Discussion: This trial will provide evidence on whether adherence-contingent rebates can improve medication adherence among non-adherent glaucoma patients, and more generally whether this approach represents a promising strategy to cost-effectively improve chronic disease management. Trial registration:NCT02271269. Registered on 19 October 2014. © 2016 Bilger et al. AD - Health Services and Systems Research, Duke-NUS Graduate Medical School, 8 College Road, Singapore, 169857, Singapore Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore Duke Global Health Institute, Duke University, 310 Trent Drive, Durham, NC 27710, United States AU - Bilger, M. AU - Wong, T. T. AU - Howard, K. L. AU - Lee, J. Y. AU - Toh, A. N. AU - John, G. AU - Lamoureux, E. L. AU - Finkelstein, E. A. C7 - 316 DB - Scopus DO - 10.1186/s13063-016-1459-1 IS - 1 KW - Chronic disease Conditional cash transfer Contingent rebates Financial incentive Glaucoma Loss aversion Medication adherence Value pricing Value-based insurance M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 ST - Study on Incentives for Glaucoma Medication Adherence (SIGMA): Study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing T2 - Trials TI - Study on Incentives for Glaucoma Medication Adherence (SIGMA): Study protocol for a randomized controlled trial to increase glaucoma medication adherence using value pricing UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978216567&doi=10.1186%2fs13063-016-1459-1&partnerID=40&md5=a8e3dc2da2a90bec2228b7fd548ca072 VL - 17 ID - 5350 ER - TY - JOUR AB - Background: Poor adherence to medications is a global public health concern with substantial health and cost implications, especially for chronic conditions. In the USA, poor adherence is estimated to cause 125,000 deaths and cost $US100 billion annually. The most successful adherence-promoting strategies that have been identified so far have moderate effect, are relatively costly, and raise availability, feasibility, and/or scalability issues. Objective: The main objective of SIGMA (Study on Incentives for Glaucoma Medication Adherence) was to measure the effectiveness on medication adherence of a novel incentive strategy based on behavioral economics that we refer to as adherence-contingent rebates. These rebates offered patients a near-term benefit while leveraging loss aversion and regret and increasing the salience of adherence. Methods: SIGMA is a 6-month randomized, controlled, open-label, single-center superiority trial with two parallel arms. A total of 100 non-adherent glaucoma patients from the Singapore National Eye Centre were randomized into intervention (adherence-contingent rebates) and usual care (no rebates) arms in a 1:1 ratio. The primary outcome was the mean change from baseline in percentage of adherent days at Month 6. The trial registration number is NCT02271269 and a detailed study protocol has been published elsewhere. Findings: We found that participants who were offered adherence-contingent rebates were adherent to all their medications on 73.1% of the days after 6 months, which is 12.2 percentage points (p = 0.027) higher than in those not receiving the rebates after controlling for baseline differences. This better behavioral outcome was achieved by rebates averaging 8.07 Singapore dollars ($US5.94 as of 2 November 2017) per month during the intervention period. Conclusion: This study shows that simultaneously leveraging several insights from behavioral economics can significantly improve medication adherence rates. The relatively low cost of the rebates and significant health and cost implications of medication non-adherence suggest that this strategy has the potential to cost-effectively improve health outcomes for many conditions. AD - M. Bilger, Health Economics and Policy, Vienna University of Business and Economics, Welthandelsplatz 1, Building D4, Vienna, Austria AU - Bilger, M. AU - Wong, T. T. AU - Lee, J. Y. AU - Howard, K. L. AU - Bundoc, F. G. AU - Lamoureux, E. L. AU - Finkelstein, E. A. DB - Embase Medline DO - 10.1007/s40258-019-00497-0 IS - 6 KW - NCT02271269 antiglaucoma agent eye drops adherence contingent rebate adult aged article behavioral economics chronic disease controlled study cost effectiveness analysis female glaucoma human major clinical study male medication compliance open study parallel design patient compliance randomized controlled trial reimbursement treatment duration very elderly LA - English M3 - Article N1 - L2002308720 2019-07-26 2019-12-31 PY - 2019 SN - 1179-1896 1175-5652 SP - 841-855 ST - Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial T2 - Applied Health Economics and Health Policy TI - Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2002308720&from=export http://dx.doi.org/10.1007/s40258-019-00497-0 VL - 17 ID - 2468 ER - TY - JOUR AB - We aimed to determine true and false positives of glaucoma screening, relying solely on photos of the retina, taken with a smartphone. We performed a descriptive and analytical study on patients with type 2 diabetes at the National Obesity Centre, Yaoundé, Cameroon. Participating patients had retinal photography sessions using an iPhone 5s (iOS 10.3.3; Apple, Cupertino, CA) coupled to the Make in India Retinal Camera (MIIRetCam; MIIRetCam Inc., Coimbatore, TN, India). Obtained pictures of the retina were stored and transferred via the internet to an ophthalmologist to assess glaucoma. Selected patients were then invited to undergo a conventional ophthalmological examination to confirm the diagnosis. A total of 395 patients were screened, 39 (including 20 women) were diagnosed with suspicion of glaucoma based on retinal photos, a prevalence rate of 9.87%. The following signs were found; Cup/Disc ratio (C/D) ≥0.5 in 64.1% (25/39), asymmetric C/D >0.2 in 35.9% (14/39), papillary haemorrhage in 10.2% (4/39) and retinal nerve fibre deficiency in 2.5% (1/39). Only 14 of 39 patients with suspicion of glaucoma were examined, giving a lost-to-follow-up rate of 64.1%. Chronic open-angle glaucoma was confirmed in 8 patients (true positives) and absent in 6 patients (false positives). The prevalence of smartphone-detected glaucoma and lost-to-follow-up rates were high. So we need to improve this type of screening, with additional tests like transpalpebral applanation tonometer and the smartphone Frequency Doubling Technique visual field combined with better education of patients to increase their adherence to follow-up. AD - Y. Bilong, Department of Ophthalmology, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon AU - Bilong, Y. AU - Domngang, C. N. AU - Nwanlih, G. G. AU - Katte, J. C. AU - Afetane, T. E. AU - Kagmeni, G. AU - Mbanya, J. C. AU - Kumar, N. AU - Sharma, A. AU - Sobngwi, E. DB - Embase IS - 1 KW - iOS 10.3.3 ophthalmic camera smartphone article best corrected visual acuity female follow up glaucoma human intraocular pressure major clinical study male non insulin dependent diabetes mellitus ophthalmologist optical coherence tomography pachymetry pilot study tonometry virus genome visual acuity visual field visual system examination LA - English M3 - Article N1 - L2004133857 2020-08-27 PY - 2020 SN - 2322-3219 2322-4436 SP - 61-95 ST - Smartphone-assisted glaucoma screening in patients with type 2 diabetes: A pilot study T2 - Medical Hypothesis, Discovery, and Innovation in Ophthalmology TI - Smartphone-assisted glaucoma screening in patients with type 2 diabetes: A pilot study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004133857&from=export VL - 9 ID - 2428 ER - TY - JOUR AB - We aimed to determine true and false positives of glaucoma screening, relying solely on photos of the retina, taken with a smartphone. We performed a descriptive and analytical study on patients with type 2 diabetes at the National Obesity Centre, Yaoundé, Cameroon. Participating patients had retinal photography sessions using an iPhone 5s (iOS 10.3.3; Apple, Cupertino, CA) coupled to the Make in India Retinal Camera (MIIRetCam; MIIRetCam Inc., Coimbatore, TN, India). Obtained pictures of the retina were stored and transferred via the internet to an ophthalmologist to assess glaucoma. Selected patients were then invited to undergo a conventional ophthalmological examination to confirm the diagnosis. A total of 395 patients were screened, 39 (including 20 women) were diagnosed with suspicion of glaucoma based on retinal photos, a prevalence rate of 9.87%. The following signs were found; Cup/Disc ratio (C/D) ≥0.5 in 64.1% (25/39), asymmetric C/D >0.2 in 35.9% (14/39), papillary haemorrhage in 10.2% (4/39) and retinal nerve fibre deficiency in 2.5% (1/39). Only 14 of 39 patients with suspicion of glaucoma were examined, giving a lost-to-follow-up rate of 64.1%. Chronic open-angle glaucoma was confirmed in 8 patients (true positives) and absent in 6 patients (false positives). The prevalence of smartphone-detected glaucoma and lost-to-follow-up rates were high. So we need to improve this type of screening, with additional tests like transpalpebral applanation tonometer and the smartphone Frequency Doubling Technique visual field combined with better education of patients to increase their adherence to follow-up. © 2020, Author(s). AD - Department of Ophthalmology, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon Department of Clinical Sciences, Faculty of Health Sciences, Universite des Montagnes, Bangangte, Cameroon Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon Ophthalmo-Pediatric Unit, Magrabi ICO Cameroon Eye Institute, Okala, Cameroon Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, TN, India AU - Bilong, Y. AU - Domngang, C. N. AU - Nwanlih, G. G. AU - Katte, J. C. AU - Afetane, T. E. AU - Kagmeni, G. AU - Mbanya, J. C. AU - Kumar, N. AU - Sharma, A. AU - Sobngwi, E. DB - Scopus IS - 1 KW - Diabetes Glaucoma Make in india retinal camera (MIIRetCam) Screening Smartphone M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2020 SP - 61-95 ST - Smartphone-assisted glaucoma screening in patients with type 2 diabetes: A pilot study T2 - Medical Hypothesis, Discovery, and Innovation in Ophthalmology TI - Smartphone-assisted glaucoma screening in patients with type 2 diabetes: A pilot study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082877650&partnerID=40&md5=1298a6121880efc44489b3a46cd3c33a VL - 9 ID - 5400 ER - TY - JOUR AB - PURPOSE: To study the impact of a 2-hour information session and 3 patients' phone calls on patient persistence with glaucoma medication. PATIENTS AND METHODS: All patients with glaucoma treatment, part of a 27-year old solo glaucoma practice, were invited to attend the information session. Patients who attended the session (n=342) were contacted by phone 1, 4, 10 months later and regular use of drops was stressed. Patients were unaware of the study. We compared the persistence of the patients before and after attending the session, and their persistence to that of patients who did not attend (n=1187). Persistence with glaucoma medication was assessed by examination of data (2002 to 2007) from a provincial medical and drug insurance database. RESULTS: Patients attending the session had glaucoma for 10 years. They had a better persistence than those who did not attend (P<0.05). Their persistence remained the same 1 year after attending the session but tended to be improved in the first 180 days (P<0.076). During the study period, there was a 4% increase in overall persistence (P<0.05). This could be due to an increase in prostaglandins prescriptions and changes in β2-blockers formulation. CONCLUSIONS: The information session and patient's recalls had a limited impact on patient persistence. This could be due to the selection of a population already persistent (78.9%). The results could have been different in less persistent patients and new patients. It could be different in another practice setting. Copyright © 2012 by Lippincott Williams & Wilkins. AD - P. Blondeau, Division of Ophthalmology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 580 Bowen St., Sherbrooke, QC J1G 2E8, Canada AU - Blondeau, P. AU - Carbonneau, M. AU - Esper, P. AU - Turcotte, P. C. DB - Embase Medline DO - 10.1097/IJG.0b013e3182127a9b IS - 6 KW - beta adrenergic receptor blocking agent prostaglandin article glaucoma human major clinical study medical practice patient compliance patient information prescription priority journal recall LA - English M3 - Article N1 - L51333075 2011-03-29 2012-08-21 PY - 2012 SN - 1057-0829 1536-481X SP - 379-382 ST - A 2-hour information session and patient recall has minimal impact on glaucoma-treatment persistence in a mature practice T2 - Journal of Glaucoma TI - A 2-hour information session and patient recall has minimal impact on glaucoma-treatment persistence in a mature practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51333075&from=export http://dx.doi.org/10.1097/IJG.0b013e3182127a9b VL - 21 ID - 3073 ER - TY - JOUR AB - Background: A 2-hour information session to improve understanding and compliance was offered to glaucoma patients. Three studies are presented regarding the participants, their satisfaction with the presentation, and their retention of information. Methods: One hundred consecutive patients were invited to participate. Age, sex, race, travelling distance, type of glaucoma, number of medications, duration of glaucoma, laser trabeculoplasty, trabeculectomy, medical conditions, visual acuity, visual field mean deviation, and pattern standard deviation (PSD) were documented. At the conclusion of the session, patient satisfaction was determined using a questionnaire. Responses to 6 glaucoma-related questions were requested prior to the session and again at 1, 4, and 10 months afterwards. The effects of age, sex, duration of glaucoma, drops applied, and compliance were analysed. Results: The invitation was accepted by 65.2% of all subjects, including 93.4% of those who had been undergoing therapy for less than 1 year. Factors identified in nonparticipation were advanced age, a longer duration of glaucoma, coronary heart disease, and worse PSD in the worse eye. Transportation was the main reason for nonparticipation. Patient satisfaction was excellent, and 99% indicated that they would recommend the clinic to friends with glaucoma. Patient knowledge increased and persisted throughout the 10 months. Older participants had lower scores. Interpretation: Most patients wanted to participate in the information session. Participants subjectively felt that the session was useful. It improved their knowledge of glaucoma, and has the potential to increase patient compliance. AD - P. Blondeau, 1732 rue Denault #1, Sherbrooke, QC J1K 1E8, Canada AU - Blondeau, P. AU - Esper, P. AU - Mazerolle, É DB - Embase Medline DO - 10.3129/I07-154 IS - 6 KW - antiglaucoma agent age distribution article disease duration female glaucoma human ischemic heart disease major clinical study male patient compliance patient education patient satisfaction patient transport questionnaire race difference sex difference visual acuity visual field LA - English M3 - Article N1 - L351096448 2008-02-04 PY - 2007 SN - 1715-3360 0008-4182 SP - 816-820 ST - An information session for glaucoma patients T2 - Canadian Journal of Ophthalmology TI - An information session for glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351096448&from=export http://dx.doi.org/10.3129/I07-154 VL - 42 ID - 3548 ER - TY - JOUR AB - Importance Understanding factors that lead to nonadherence to glaucoma treatment is important to diminish glaucoma-related disability. ObjectiveS To determine whether the implementation of the Medicare Part D prescription drug benefit affected rates of cost-related nonadherence and cost-reduction strategies in Medicare beneficiaries with and without glaucoma and to evaluate associated risk factors for such nonadherence. Design, Setting, and ParticipantsSerial cross-sectional study using 2004 to 2009 Medicare Current Beneficiary Survey data linked with Medicare claims. Coding to extract data started in January 2014 and analyses were performed between September and November of 2014. Participants were all Medicare beneficiaries, including those with a glaucoma-related diagnosis in the year prior to the collection of the survey data, those with a nonglaucomatous ophthalmic diagnosis in the year prior to the collection of the survey data, and those without a recent eye care professional claim. Intervention Effect of the implementation of the Medicare Part D drug benefit. Main Outcomes and Measures The change in cost-related nonadherence and the change in cost-reduction strategies. Results Between 2004 and 2009, the number of Medicare beneficiaries with glaucoma who reported taking smaller doses and skipping doses owing to cost dropped from 9.4%and 8.2%to 2.7%(P < .001) and 2.8%, respectively (P = .001). However, reports of failure to obtain prescriptions owing to cost did not improve in the same period (3.4%in 2004 and 2.1% in 2009; P = .12). After Part D, patients with glaucoma had a decrease in several cost-reduction strategies, namely price shopping (26.2%-15.2%; P < .001), purchasing outside the United States (6.9%-1.3%; P < .001), and spending less money to save for medications (8.0%to 3.5%; P < .001). Using a multivariate analysis, the main independent risk factors common to all cost-related nonadherence measures were female sex, younger age, lower income (<30 000), self-reported visual disability, and a smaller Lawton index. Conclusions and Relevance After the implementation of Part D, there was a decrease in the rate that beneficiaries with glaucoma reported engaging in cost-saving measures. Although there was a decline in the rate of several cost-related nonadherence behaviors, patients reporting failure to fill prescriptions owing to cost remained stable. This suggests that efforts to improve cost-related nonadherence should focus both on financial hardship and medical therapy prioritization, particularly in certain high-risk sociodemographic groups. AD - D.M. Blumberg, Columbia University, Department of Ophthalmology, Harkness Eye Institute, 635W165th St, New York, NY, United States AU - Blumberg, D. M. AU - Prager, A. J. AU - Liebmann, J. M. AU - Cioffi, G. A. AU - De Moraes, C. G. DB - Embase Medline DO - 10.1001/jamaophthalmol.2015.1671 IS - 9 KW - prescription drug adult article cost control cross-sectional study drug cost eye care female glaucoma health care planning human major clinical study male medicaid medicare medication compliance patient compliance prescription priority journal self report LA - English M3 - Article N1 - L605992556 2015-09-17 2015-09-18 PY - 2015 SN - 2168-6165 SP - 985-996 ST - Cost-Related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of medicare part D T2 - JAMA Ophthalmology TI - Cost-Related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of medicare part D UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605992556&from=export http://dx.doi.org/10.1001/jamaophthalmol.2015.1671 VL - 133 ID - 2861 ER - TY - JOUR AB - Importance: Understanding factors that lead to nonadherence to glaucoma treatment is important to diminish glaucoma-related disability.Objectives: To determine whether the implementation of the Medicare Part D prescription drug benefit affected rates of cost-related nonadherence and cost-reduction strategies in Medicare beneficiaries with and without glaucoma and to evaluate associated risk factors for such nonadherence.Design, Setting, and Participants: Serial cross-sectional study using 2004 to 2009 Medicare Current Beneficiary Survey data linked with Medicare claims. Coding to extract data started in January 2014 and analyses were performed between September and November of 2014. Participants were all Medicare beneficiaries, including those with a glaucoma-related diagnosis in the year prior to the collection of the survey data, those with a nonglaucomatous ophthalmic diagnosis in the year prior to the collection of the survey data, and those without a recent eye care professional claim.Intervention: Effect of the implementation of the Medicare Part D drug benefit.Main Outcomes and Measures: The change in cost-related nonadherence and the change in cost-reduction strategies.Results: Between 2004 and 2009, the number of Medicare beneficiaries with glaucoma who reported taking smaller doses and skipping doses owing to cost dropped from 9.4% and 8.2% to 2.7% (P < .001) and 2.8%, respectively (P = .001). However, reports of failure to obtain prescriptions owing to cost did not improve in the same period (3.4% in 2004 and 2.1% in 2009; P = .12). After Part D, patients with glaucoma had a decrease in several cost-reduction strategies, namely price shopping (26.2%-15.2%; P < .001), purchasing outside the United States (6.9%-1.3%; P < .001), and spending less money to save for medications (8.0% to 3.5%; P < .001). Using a multivariate analysis, the main independent risk factors common to all cost-related nonadherence measures were female sex, younger age, lower income (<$30 000), self-reported visual disability, and a smaller Lawton index.Conclusions and Relevance: After the implementation of Part D, there was a decrease in the rate that beneficiaries with glaucoma reported engaging in cost-saving measures. Although there was a decline in the rate of several cost-related nonadherence behaviors, patients reporting failure to fill prescriptions owing to cost remained stable. This suggests that efforts to improve cost-related nonadherence should focus both on financial hardship and medical therapy prioritization, particularly in certain high-risk sociodemographic groups. AN - 109647717. Language: English. Entry Date: 20150923. Revision Date: 20200708. Publication Type: journal article AU - Blumberg, Dana M. AU - Prager, Alisa J. AU - Liebmann, Jeffrey M. AU - Cioffi, George A. AU - De Moraes, C. Gustavo DB - ccm DO - 10.1001/jamaophthalmol.2015.1671 DP - EBSCOhost IS - 9 N1 - research. Journal Subset: Biomedical; USA. Grant Information: P30 EY019007/EY/NEI NIH HHS/United States. NLM UID: 101589539. PMID: NLM26042393. PY - 2015 SN - 2168-6165 SP - 985-996 ST - Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D T2 - JAMA Ophthalmology TI - Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109647717&site=ehost-live&scope=site VL - 133 ID - 4264 ER - TY - JOUR AB - Purpose. To assess the impact on visual function of community glaucoma screening in an African American population using spectral-domain optical coherence tomography (SD-OCT). Methods. Using a Monte Carlo microsimulation model with a 10-year time horizon, we analyzed the efficacy of SD-OCT screening on visual field outcomes in a population of African Americans who are not otherwise seeking office-based care. Outcomes included classification of visual field severity, quality-adjusted life years, and direct health care costs. Results. Assuming a 60% follow-up rate, screening decreased the prevalence of undiagnosed glaucoma from 75% to 38%, and decreased the prevalence of severe visual field loss in patients with glaucoma from 29.1% to 23.9%. Conversely, screening increased the prevalence of mild visual field loss in patients with glaucoma from 9.2% to 18.7%. From initial screening through confirmatory eye examination, the screening program ("screen only") cost $98 per screened individual, and $2561 per new diagnosis of glaucoma. When considering the costs of initial screening though the resultant treatment, the screening program ("screen and treat") had an average annual cost of $79 and $2138, respectively, over a 10-year time period. The cost of one quality-adjusted life year (QALY) gained by screening, including management and treatment, in comparison with opportunistic case finding, ranged from $46,416 to $67,813. Conclusions. Our findings suggest that community SD-OCT screening in an African American population will minimize glaucoma-related visual morbidity. Ideally, strategies to maximize treatment efficacy through improved medication adherence and improved compliance with follow-up should be identified and implemented before instituting a screening program. © 2014 The Association for Research in Vision and Ophthalmology, Inc. AD - Department of Ophthalmology, Harkness Eye Institute, Columbia University, New York, NY, United States Columbia University College of Physicians and Surgeons, New York, NY, United States AU - Blumberg, D. M. AU - Vaswani, R. AU - Nong, E. AU - Al-Aswad, L. AU - Cioffi, G. A. DB - Scopus DO - 10.1167/iovs.14-14014 IS - 6 KW - Comparative effectiveness Glaucoma Markov model Screening SD-OCT M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2014 SP - 3491-3500 ST - A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SDOCT in African American communities T2 - Investigative Ophthalmology and Visual Science TI - A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SDOCT in African American communities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902278012&doi=10.1167%2fiovs.14-14014&partnerID=40&md5=b6a18cc671f379cb4a9a8f5b992d2810 VL - 55 ID - 5235 ER - TY - JOUR AB - PURPOSE. To assess the impact on visual function of community glaucoma screening in an African American population using spectral-domain optical coherence tomography (SD-OCT). METHODS. Using a Monte Carlo microsimulation model with a 10-year time horizon, we analyzed the efficacy of SD-OCT screening on visual field outcomes in a population of African Americans who are not otherwise seeking office-based care. Outcomes included classification of visual field severity, quality-adjusted life years, and direct health care costs. RESULTS. Assuming a 60% follow-up rate, screening decreased the prevalence of undiagnosed glaucoma from 75% to 38%, and decreased the prevalence of severe visual field loss in patients with glaucoma from 29.1% to 23.9%. Conversely, screening increased the prevalence of mild visual field loss in patients with glaucoma from 9.2% to 18.7%. From initial screening through confirmatory eye examination, the screening program ("screen only'') cost $98 per screened individual, and $2561 per new diagnosis of glaucoma. When considering the costs of initial screening though the resultant treatment, the screening program ("screen and treat'') had an average annual cost of $79 and $2138, respectively, over a 10-year time period. The cost of one quality-adjusted life year (QALY) gained by screening, including management and treatment, in comparison with opportunistic case finding, ranged from $46,416 to $67,813. CONCLUSIONS. Our findings suggest that community SD-OCT screening in an African American population will minimize glaucoma-related visual morbidity. Ideally, strategies to maximize treatment efficacy through improved medication adherence and improved compliance with follow-up should be identified and implemented before instituting a screening program. AN - WOS:000339485800017 AU - Blumberg, D. M. AU - Vaswani, R. AU - Nong, E. AU - Al-Aswad, L. AU - Cioffi, G. A. DA - JUN DO - 10.1167/iovs.14-14014 IS - 6 PY - 2014 SN - 0146-0404 1552-5783 SP - 3491-3500 ST - A Comparative Effectiveness Analysis of Visual Field Outcomes After Projected Glaucoma Screening Using SD-OCT in African American Communities T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - A Comparative Effectiveness Analysis of Visual Field Outcomes After Projected Glaucoma Screening Using SD-OCT in African American Communities VL - 55 ID - 5973 ER - TY - JOUR AB - Purpose: To evaluate the accuracy of a prototype electronic device for recording eye drop usage. Participants and Methods: Ten volunteers were randomly assigned to one of five usage patterns designed to mimic common patterns of use in glaucoma patients from 100% compliant to 50% compliant. All participants agreed to adhere to a pre-determined "dosing" schedule for 15 days using the monitoring/reminder device to instill artificial tears. Participants also recorded drop usage in a diary. The main outcome measures were device accuracy and reproducibility. Device accuracy was defined as the magnitude of the difference between the diary and device output for three variables: date, number of drops, and instillation time. Results: Date stamping by the device was 100% accurate. The mean ± SD time difference between the device and the diary was -2.0 ± 19.7 minutes when data from all participants was pooled. In seven of the ten participants, the device did not record at least one drop. The mean ± SD difference in the number of drops recorded by the device minus the diary was 0.16 ± 0.97 when data from all participants was pooled. Conclusions: The prototype compliance reminder/monitoring device may underestimate compliance in some patients. The date and time stamping mechanisms were generally accurate and reproducible. Copyright © 2006 by Lippincott Williams & Wilkins. AD - C. Boden, Department of Ophthalmology, University of California, San Diego, 9500 Gilman Drive, San Diego, CA 92093-0946, United States AU - Boden, C. AU - Sit, A. AU - Weinreb, R. N. DB - Embase Medline DO - 10.1097/01.ijg.0000196654.77836.61 IS - 1 KW - travoprost accuracy article clinical article devices electronics glaucoma human monitoring outcome assessment patient compliance priority journal reproducibility LA - English M3 - Article N1 - L43068417 2006-01-30 PY - 2006 SN - 1057-0829 SP - 30-34 ST - Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops T2 - Journal of Glaucoma TI - Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43068417&from=export http://dx.doi.org/10.1097/01.ijg.0000196654.77836.61 VL - 15 ID - 3628 ER - TY - JOUR AB - Purpose: To evaluate surgical outcomes and to describe a strategy for pediatric uveitic glaucoma. Design: Retrospective case series. Methods: The clinical practice of a single surgeon identified 36 patients with juvenile uveitic glaucoma (diagnosed before 18 years of age) who underwent 1 or more intraocular pressure (IOP)-lowering surgical procedures. The first eye operated on was included in the analysis. The main indication for success was IOP of less than 21 mm Hg with controlled inflammation, without further IOP-lowering surgery or devastating complication. Results: Patients with uveitic glaucoma associated with juvenile idiopathic arthritis (n = 20), idiopathic uveitis (n = 9), other (n = 6) were included. Mean age ± standard deviation at initial glaucoma surgery was 11.1 ± 4.4 years with a follow-up of 5.6 ± 4.8 years (range, 0.2 to 16.4 years). Goniotomy was the initial surgical procedure in 31 (86%) eyes. Fifteen eyes did not require further IOP-lowering surgery. Sixteen eyes had additional IOP-lowering surgery: second goniotomy (n = 9), glaucoma drainage device (n = 6), and trabeculectomy (n = 1). By Kaplan-Meier survival analysis, the first versus the first or second goniotomy were successful at 10 years in 48% (95% confidence interval, 28% to 65%) versus 69% (95% confidence interval, 47% to 84%). Goniotomy failure was noncorrelative with phakic status or presence of preoperative synechiae. Five eyes (14%) had initial glaucoma drainage device implantation because of closed angles. Visual acuity was similar between initial and final examinations (0.37 ± 0.48 logarithm of the minimal angle of resolution units [Snellen 20/47] vs 0.28 ± 0.34 logarithm of the minimal angle of resolution units [Snellen 20/38]). IOP was reduced (33.0 ± 8.0 mm Hg vs 12.6 ± 4.5 mm Hg; P <.0001), as was number of glaucoma medications (3.2 ± 1.1 vs 1.2 ± 1.3; P <.0001). Eyes undergoing cataract removal after successful glaucoma surgery maintained IOP control. Glaucoma was controlled and vision was preserved in 33 (92%) eyes. Conclusions: Refractory juvenile uveitic glaucoma was managed successfully by goniosurgery and glaucoma drainage device implantation. Cataract removal can be accomplished successfully, provided IOP and uveitis are well controlled before surgery. © 2013 Elsevier Inc. AD - Department of Ophthalmology, Duke University, School of Medicine, 2351 Erwin Road, Durham, NC 27710, United States AU - Bohnsack, B. L. AU - Freedman, S. F. DB - Scopus DO - 10.1016/j.ajo.2012.07.008 IS - 1 M3 - Article N1 - Cited By :39 Export Date: 19 July 2021 PY - 2013 SP - 134-142 ST - Surgical outcomes in childhood uveitic glaucoma T2 - American Journal of Ophthalmology TI - Surgical outcomes in childhood uveitic glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871244624&doi=10.1016%2fj.ajo.2012.07.008&partnerID=40&md5=ee1ee7835318bd17b8bf007709e9e9a4 VL - 155 ID - 5025 ER - TY - JOUR AB - IMPORTANCE: Adherence with topical glaucoma medications is low in some patients. To identify these patients, we need more information on risk factors for nonadherence. OBJECTIVE: To assess adherence with once-daily glaucoma medication. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study involving patients whowere recruited from a university-based glaucoma clinic and treated with once-daily prostaglandin eyedrops. Baseline characteristics were recorded, and each patient was provided a medication bottle to hold his or her eyedrop bottle throughout the study. An electronic cap recorded each time the larger bottle holding the eyedrops was opened. Participants were administered standardized tests of depression and mental status and answered questions about their health and their attitudes toward medication adherence. They used the electronic monitors for 3 months, during which their adherence with medications was assessed. MAIN OUTCOMES AND MEASURES: Adherence with daily glaucoma medication and factors associated with poor adherence. RESULTS: Of the 491 participants enrolled, 407 (82.9%) successfully completed the 3-month adherence assessment. Of this group, 337 (82.8%) took their medication correctly on at least 75% of days and were deemed adherent. Compared with this adherent group, the 70 participants (17.2%) who were nonadherent were slightly younger, were more likely to be of African descent, took medications for a shorter time, had a lower level of educational attainment, and had worse scores on mental status and depression scales (P < .05 for all). Nonadherent participants were less likely to be able to name their glaucoma medications, reported a lower estimate of adherence, and were more likely to admit some missed doses over the past 2 weeks or in general (P < .05 for all). Those who were nonadherent were also less likely to agree that remembering their eyedrops is easy, more likely to strongly agree with the statement that eyedrops can cause problems, and less likely to agree that they followed physicians' orders. CONCLUSIONS AND RELEVANCE: Electronic monitoring of patient adherence documented that a sizable number of patients with glaucoma do not take their medications as prescribed. Factors were identified that may prove useful in targeting those nonadherent patients for interventions. Copyright 2014 American Medical Association. All rights reserved. AD - M.V. Boland, Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 NWolfe St, Wilmer 131, Baltimore, MD 21287, United States AU - Boland, M. V. AU - Chang, D. S. AU - Frazier, T. AU - Plyler, R. AU - Friedman, D. S. DB - Embase Medline DO - 10.1001/jamaophthalmol.2014.856 IS - 7 KW - prostaglandin adult article automation cohort analysis educational status ethnicity female follow up glaucoma human major clinical study male medication compliance mental health Mini Mental State Examination patient compliance patient monitoring priority journal prospective study reminder system risk factor text messaging treatment duration LA - English M3 - Article N1 - L373517342 2014-07-22 2014-07-29 PY - 2014 SN - 2168-6165 SP - 838-844 ST - Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: The automated dosing reminder study T2 - JAMA Ophthalmology TI - Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: The automated dosing reminder study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373517342&from=export http://dx.doi.org/10.1001/jamaophthalmol.2014.856 VL - 132 ID - 2910 ER - TY - JOUR AD - Glaucoma Center of Excellence, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland2Division of Health Sciences Informatics, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Glaucoma Center of Excellence, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland3Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University, Baltimore, Maryland. Madigan Army Medical Center, Fort Lewis, Washington. Georgetown University School of Medicine, Washington, DC. AN - 103969768. Language: English. Entry Date: 20141003. Revision Date: 20150710. Publication Type: Journal Article AU - Boland, Michael V. AU - Chang, Dolly S. AU - Frazier, Travis AU - Plyler, Ryan AU - Friedman, David S. DB - ccm DO - 10.1001/jamaophthalmol.2014.856 DP - EBSCOhost IS - 7 KW - Antihypertensive Agents -- Administration and Dosage Drug Monitoring -- Methods Glaucoma -- Drug Therapy Medication Compliance Prostaglandins F, Synthetic -- Administration and Dosage Reminder Systems -- Equipment and Supplies Aged Antihypertensive Agents -- Therapeutic Use Prospective Studies Drug Monitoring -- Equipment and Supplies Female Health Behavior Attitude to Health Human Intraocular Pressure -- Drug Effects Male Ophthalmic Solutions Prostaglandins F, Synthetic -- Therapeutic Use Questionnaires Risk Factors N1 - research. Journal Subset: Biomedical; USA. NLM UID: 101589539. PMID: NLM24830878. PY - 2014 SN - 2168-6165 SP - 838-844 ST - Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study T2 - JAMA Ophthalmology TI - Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103969768&site=ehost-live&scope=site VL - 132 ID - 4346 ER - TY - JOUR AB - IMPORTANCE: Adherence with topical glaucoma medications is low in some patients. To identify these patients, we need more information on risk factors for nonadherence. OBJECTIVE: To assess adherence with once-daily glaucoma medication. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study involving patients whowere recruited from a university-based glaucoma clinic and treated with once-daily prostaglandin eyedrops. Baseline characteristics were recorded, and each patient was provided a medication bottle to hold his or her eyedrop bottle throughout the study. An electronic cap recorded each time the larger bottle holding the eyedrops was opened. Participants were administered standardized tests of depression and mental status and answered questions about their health and their attitudes toward medication adherence. They used the electronic monitors for 3 months, during which their adherence with medications was assessed. MAIN OUTCOMES AND MEASURES: Adherence with daily glaucoma medication and factors associated with poor adherence. RESULTS: Of the 491 participants enrolled, 407 (82.9%) successfully completed the 3-month adherence assessment. Of this group, 337 (82.8%) took their medication correctly on at least 75% of days and were deemed adherent. Compared with this adherent group, the 70 participants (17.2%) who were nonadherent were slightly younger, were more likely to be of African descent, took medications for a shorter time, had a lower level of educational attainment, and had worse scores on mental status and depression scales (P < .05 for all). Nonadherent participants were less likely to be able to name their glaucoma medications, reported a lower estimate of adherence, and were more likely to admit some missed doses over the past 2 weeks or in general (P < .05 for all). Those who were nonadherent were also less likely to agree that remembering their eyedrops is easy, more likely to strongly agree with the statement that eyedrops can cause problems, and less likely to agree that they followed physicians' orders. CONCLUSIONS AND RELEVANCE: Electronic monitoring of patient adherence documented that a sizable number of patients with glaucoma do not take their medications as prescribed. Factors were identified that may prove useful in targeting those nonadherent patients for interventions. Copyright 2014 American Medical Association. All rights reserved. AD - Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 NWolfe St, Wilmer 131, Baltimore, MD 21287, United States Division of Health Sciences Informatics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States Madigan Army Medical Center, Fort Lewis, WA, United States Georgetown University School of Medicine, Washington, DC, United States AU - Boland, M. V. AU - Chang, D. S. AU - Frazier, T. AU - Plyler, R. AU - Friedman, D. S. DB - Scopus DO - 10.1001/jamaophthalmol.2014.856 IS - 7 M3 - Article N1 - Cited By :31 Export Date: 19 July 2021 PY - 2014 SP - 838-844 ST - Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: The automated dosing reminder study T2 - JAMA Ophthalmology TI - Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: The automated dosing reminder study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904188219&doi=10.1001%2fjamaophthalmol.2014.856&partnerID=40&md5=cc8cd30d326341ecfbb547c32be16889 VL - 132 ID - 5052 ER - TY - JOUR AB - IMPORTANCE: Topical glaucoma medications lower intraocular pressure and alter the course of the disease. Because adherence with glaucoma medications is a known problem, interventions are needed to help those patients who do not take their medications as prescribed. OBJECTIVE: To assess the ability of an automated telecommunication-based intervention to improve adherence with glaucoma medications. DESIGN, SETTING, AND PARTICIPANTS: We performed a prospective cohort study of medication adherence, followed by a randomized intervention for those found to be nonadherent, of individuals recruited from a university-based glaucoma subspecialty clinic. A total of 491 participants were enrolled in the initial assessment of adherence. Of those, 70 were nonadherent with their medications after 3 months of electronic monitoring and randomized to intervention and control groups. INTERVENTIONS: A personal health record was used to store the list of patient medications and reminder preferences. On the basis of those data, participants randomized to the intervention received daily messages, either text or voice, reminding them to take their medication. Participants randomized to the control group received usual care. MAIN OUTCOMES AND MEASURES: Difference in adherence before and after initiation of the intervention. RESULTS: Using an intent-to-treat analysis, we found that the median adherence rate in the 38 participants randomized to the intervention increased from 53% to 64% (P < .05). There was no statistical change in 32 participants in the control group. To assess the real efficacy of the intervention, the same comparison was performed for the participants who successfully completed the study after randomization. Analyzed this way, the adherence rate in the 20 participants in the intervention group increased from 54% to 73% (P < .05), whereas there was again no statistical change in the 19 participants in the control group. Eighty-four percent of the participants who received reminders agreed they were helpful and would continue using them outside the study. CONCLUSIONS AND RELEVANCE: Automated telecommunication-based reminders linked to data in a personal health record improved adherence with once-daily glaucoma medications. This is an effectivemethod to improve adherence that could realistically be implemented in ophthalmology practices with a minimum amount of effort on the part of the practice or the patient. Copyright 2014 American Medical Association. All rights reserved. AD - M.V. Boland, Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University, 600 N Wolfe St, Wilmer 131, Baltimore, MD 21287, United States AU - Boland, M. V. AU - Chang, D. S. AU - Frazier, T. AU - Plyler, R. AU - Jefferys, J. L. AU - Friedman, D. S. DB - Embase Medline DO - 10.1001/jamaophthalmol.2014.857 IS - 7 KW - prostaglandin adult aged article automation cohort analysis controlled study electronic medical record female follow up glaucoma human intention to treat analysis interactive voice response system major clinical study male medication compliance Mini Mental State Examination patient compliance priority journal prospective study randomized controlled trial reminder system risk factor telecommunication LA - English M3 - Article N1 - L373517343 2014-07-22 2014-07-29 PY - 2014 SN - 2168-6165 SP - 845-850 ST - Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: The automated dosing reminder study T2 - JAMA Ophthalmology TI - Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: The automated dosing reminder study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373517343&from=export http://dx.doi.org/10.1001/jamaophthalmol.2014.857 VL - 132 ID - 2911 ER - TY - JOUR AD - Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland2Division of Health Sciences Informatics, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland3Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. Madigan Army Medical Center, Fort Lewis, Washington. Georgetown University School of Medicine, Washington, DC. Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. AN - 103969769. Language: English. Entry Date: 20141003. Revision Date: 20150710. Publication Type: Journal Article AU - Boland, Michael V. AU - Chang, Dolly S. AU - Frazier, Travis AU - Plyler, Ryan AU - Jefferys, Joan L. AU - Friedman, David S. DB - ccm DO - 10.1001/jamaophthalmol.2014.857 DP - EBSCOhost IS - 7 KW - Antihypertensive Agents -- Administration and Dosage Drug Monitoring Glaucoma -- Drug Therapy Medication Compliance Reminder Systems -- Equipment and Supplies Telecommunications -- Equipment and Supplies Administration, Topical Aged Prospective Studies Female Human Intraocular Pressure -- Drug Effects Male Medical Record Linkage Middle Age Ophthalmic Solutions N1 - research; randomized controlled trial. Journal Subset: Biomedical; USA. NLM UID: 101589539. PMID: NLM24831037. PY - 2014 SN - 2168-6165 SP - 845-850 ST - Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the automated dosing reminder study T2 - JAMA Ophthalmology TI - Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the automated dosing reminder study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103969769&site=ehost-live&scope=site VL - 132 ID - 4378 ER - TY - JOUR AB - IMPORTANCE: Topical glaucoma medications lower intraocular pressure and alter the course of the disease. Because adherence with glaucoma medications is a known problem, interventions are needed to help those patients who do not take their medications as prescribed. OBJECTIVE: To assess the ability of an automated telecommunication-based intervention to improve adherence with glaucoma medications. DESIGN, SETTING, AND PARTICIPANTS: We performed a prospective cohort study of medication adherence, followed by a randomized intervention for those found to be nonadherent, of individuals recruited from a university-based glaucoma subspecialty clinic. A total of 491 participants were enrolled in the initial assessment of adherence. Of those, 70 were nonadherent with their medications after 3 months of electronic monitoring and randomized to intervention and control groups. INTERVENTIONS: A personal health record was used to store the list of patient medications and reminder preferences. On the basis of those data, participants randomized to the intervention received daily messages, either text or voice, reminding them to take their medication. Participants randomized to the control group received usual care. MAIN OUTCOMES AND MEASURES: Difference in adherence before and after initiation of the intervention. RESULTS: Using an intent-to-treat analysis, we found that the median adherence rate in the 38 participants randomized to the intervention increased from 53% to 64% (P < .05). There was no statistical change in 32 participants in the control group. To assess the real efficacy of the intervention, the same comparison was performed for the participants who successfully completed the study after randomization. Analyzed this way, the adherence rate in the 20 participants in the intervention group increased from 54% to 73% (P < .05), whereas there was again no statistical change in the 19 participants in the control group. Eighty-four percent of the participants who received reminders agreed they were helpful and would continue using them outside the study. CONCLUSIONS AND RELEVANCE: Automated telecommunication-based reminders linked to data in a personal health record improved adherence with once-daily glaucoma medications. This is an effectivemethod to improve adherence that could realistically be implemented in ophthalmology practices with a minimum amount of effort on the part of the practice or the patient. Copyright 2014 American Medical Association. All rights reserved. AD - Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University, 600 N Wolfe St, Wilmer 131, Baltimore, MD 21287, United States Division of Health Sciences Informatics, Johns Hopkins University, School of Medicine, Baltimore, MD, United States Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States Madigan Army Medical Center, Fort Lewis, WA, United States Georgetown University, School of Medicine, Washington, DC, United States AU - Boland, M. V. AU - Chang, D. S. AU - Frazier, T. AU - Plyler, R. AU - Jefferys, J. L. AU - Friedman, D. S. DB - Scopus DO - 10.1001/jamaophthalmol.2014.857 IS - 7 M3 - Article N1 - Cited By :51 Export Date: 19 July 2021 PY - 2014 SP - 845-850 ST - Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: The automated dosing reminder study T2 - JAMA Ophthalmology TI - Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: The automated dosing reminder study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904213755&doi=10.1001%2fjamaophthalmol.2014.857&partnerID=40&md5=7e00b43462b6c79ff9fe07fdda6089b2 VL - 132 ID - 4992 ER - TY - JOUR AB - Importance: During the coronavirus disease 2019 (COVID-19) pandemic, eye care professionals caring for patients with sight-threatening diseases, such as glaucoma, have had to determine whether some patient appointments could safely get postponed, weighing the risk that the patient's glaucoma could worsen during the interim vs the morbidity risk of acquiring COVID-19 while seeking ophthalmic care. They also need to prioritize appointment rescheduling during the ramp-up phase (when pandemic-associated service reductions are eased).Objective: To describe a flexible and scalable scoring algorithm for patients with glaucoma that considers glaucoma severity and progression risk vs the presence of high-risk features for morbidity from COVID-19, using information from a large data repository.Design, Setting, and Participants: In this cross-sectional study, patients with upcoming clinic appointments for glaucoma from March 16, 2020, to April 16, 2020, at an academic institution enrolled in the Sight Outcomes Research Collaborative (SOURCE) Ophthalmology Electronic Health Record Data Repository were identified. A risk stratification tool was developed that calculated a glaucoma severity and progression risk score and a COVID-19 morbidity risk score. These scores were summed to determine a total score for each patient.Main Outcomes and Measures: Total scores and percentages of clinic appointments recommended for rescheduling.Results: Among the 1034 patients with upcoming clinic appointments for glaucoma, the mean (SD) age was 66.7 (14.6) years. There were 575 women (55.6%), 733 White individuals (71%), and 160 Black individuals (15.5%). The mean (SD) glaucoma severity and progression risk score was 4.0 (14.4) points, the mean (SD) COVID-19 morbidity risk score was 27.2 (16.1) points, and the mean (SD) total score was 31.2 (21.4) points. During pandemic-associated reductions in services, using total score thresholds of 0, 25, and 50 points would identify 970 appointments (93.8%), 668 appointments (64.6%), and 275 appointments (26.6%), respectively, for postponement and rescheduling. The algorithm-generated total scores also helped prioritize appointment rescheduling during the ramp-up phase.Conclusions and Relevance: A tool that considers the risk of underlying ophthalmic disease progression from delayed care receipt and the morbidity risk from COVID-19 exposure was developed and implemented, facilitating the triage of upcoming ophthalmic appointments. Comparable approaches for other ophthalmic and nonophthalmic care during the COVID-19 pandemic and similar crises may be created using this methodology. AD - W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor Center for Eye Policy and Innovation, University of Michigan, Ann Arbor Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor AN - 145694729. Corporate Author: SOURCE Consortium. Language: English. Entry Date: 20210225. Revision Date: 20201107. Publication Type: journal article. Journal Subset: Biomedical AU - Bommakanti, Nikhil K. AU - Zhou, Yunshu AU - Ehrlich, Joshua R. AU - Elam, Angela R. AU - John, Denise AU - Kamat, Shivani S. AU - Kelstrom, Jared AU - Newman-Casey, Paula Anne AU - Shah, Manjool M. AU - Weizer, Jennifer S. AU - Wood, Sarah D. AU - Zhang, Amy D. AU - Zhang, Jason AU - Lee, Paul P. AU - Stein, Joshua D. DB - ccm DO - 10.1001/jamaophthalmol.2020.2974 DP - EBSCOhost IS - 9 KW - Glaucoma -- Therapy Pneumonia, Viral -- Epidemiology Triage Appointments and Schedules Coronavirus Infections -- Epidemiology Aged Aged, 80 and Over Ambulatory Care Facilities Middle Age Ophthalmology Disease Outbreaks Female Male Cross Sectional Studies N1 - USA. Grant Information: R01 EY026641/EY/NEI NIH HHS/United States. NLM UID: 101589539. PMID: NLM32678424. PY - 2020 SN - 2168-6165 SP - 974-980 ST - Application of the Sight Outcomes Research Collaborative Ophthalmology Data Repository for Triaging Patients With Glaucoma and Clinic Appointments During Pandemics Such as COVID-19 T2 - JAMA Ophthalmology TI - Application of the Sight Outcomes Research Collaborative Ophthalmology Data Repository for Triaging Patients With Glaucoma and Clinic Appointments During Pandemics Such as COVID-19 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145694729&site=ehost-live&scope=site VL - 138 ID - 4172 ER - TY - JOUR AB - Purpose. - To evaluate the lowering of intraocular pressure (IOP) one year after SLT and to assess if differences are related to number of pre-SLT topical treatments in ocular hypertension (OHT) and primary open angle glaucoma (POAG) patients. Methods. - Retrospective review of 106 eyes of 13 OHT and 93 POAG patients treated by SLT for insufficient IOP control, allergy, discomfort or non-compliance to glaucoma medications, excluding patients with less than 1 year of follow-up after SLT. IOP was measured by applanation before and at 1, 6 and 12 months after SLT. Results. - Hundred and six eyes untreated (n = 13), or treated with one (n =25), two (n = 40) or three or more (n = 28) glaucoma medications were included. Mean IOP decreased from 19.4 +/- 3.6 mmHg preoperatively to 15.7+3.1 mmHg at 12 months, which corresponds to an average decrease of 18.8%. At 1 year, 62.2% (n = 66) were responders (IOP reduction >= 3 mmHg): 92.3% without medications (n = 12), 68% with one (n = 17), 57.5% with two (n = 23) and 50% with three or more medications (n = 14). Their average IOP decreased from 20.7 +/- 3.4 to 15.2 +/- 2.9 mmHg (26.6%), respectively from 20.8 +/- 2.6 to 15.8 +/- 3.2 (25%) without medications, 20.6+3.2 to 14.9+3.7 (27.3%) with one, 20.8 +/- 4.1 to 15.5 +/- 3.3 (25.1%) with two and 20.7 +/- 3.2 to 14.4 +/- 2.4 mmHg (29.7%) with three medications. Conclusions. - The number of responders seems to be greater in OHT and POAG patients without or with few glaucoma medications, but the IOP reduction seems to be similar regardless of the number of glaucoma medications. (C) 2016 Elsevier Masson SAS. All rights reserved. AN - WOS:000396414600015 AU - Bonnel, S. AU - Fenolland, J. R. AU - Marill, A. F. AU - Gaillard, R. AU - Rosenberg, R. AU - Theillac, V. AU - Mazharian, A. AU - Giraud, J. M. AU - Renard, J. P. DA - JAN DO - 10.1016/j.jfo.2016.11.003 IS - 1 PY - 2017 SN - 0181-5512 1773-0597 SP - 22-28 ST - Selective laser trabeculoplasty: Effect of number of preoperative topical glaucoma medications on pressure lowering and success rate T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Selective laser trabeculoplasty: Effect of number of preoperative topical glaucoma medications on pressure lowering and success rate VL - 40 ID - 5939 ER - TY - JOUR AB - Purpose: To evaluate to what extent contemporary glaucoma abstracts offer complete information and to suggest a new manner of pressure results reporting. Materials, methods, and results: Most of the 36 relevant surgical glaucoma abstracts found in one issue of International Glaucoma Review contain insufficient data-supported statements. Such abstracts cannot offer a clear picture of the study essence if economic, linguistic, or political barriers prevent access to the full text. In order to enrich abstract content and to avoid typographic space waste, a formula is suggested to provide, in one single line of symbols and figures, all the necessary data for statistical interpretation at two evolution moments: the first significative control (6 months) and the final one. Conclusion: The current manner of results reporting in surgical glaucoma abstracts is subject to too little standardization, allowing insufficiently data-supported statements. Abstracts, especially those printed in small-circulation language journals, should be conceived and standardized in such a manner that any abstract review reader is capable of grasping the essence of the study at first glance. The suggested manner of reporting results would bring satisfaction to all areas of the process. Publishers would save typographic space, readers would find all the necessary data for statistical analysis and comparison with other studies, and authors would be convinced that the essence of their work would penetrate in spite of any economic, linguistic, or political barriers. © 2012 Bordeianu and Ticu, publisher and licensee Dove Medical Press Ltd. AD - Department of Ophthalmology, Emergency Hospital, Ploiesti, Romania Provisional Candidate for PhD, Edmonton, AB, Canada AU - Bordeianu, C. D. AU - Ticu, C. E. DB - Scopus DO - 10.2147/OPTH.S13674 IS - 1 KW - Abstract construction Glaucoma IOP Reporting results Standardization formula M3 - Review N1 - Cited By :2 Export Date: 19 July 2021 PY - 2011 SP - 23-31 ST - A new manner of reporting pressure results after glaucoma surgery T2 - Clinical Ophthalmology TI - A new manner of reporting pressure results after glaucoma surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856198495&doi=10.2147%2fOPTH.S13674&partnerID=40&md5=4e082da02c1e55b8d5b87fabdcca13dc VL - 6 ID - 5576 ER - TY - JOUR AB - Objective: To assess real-world results and the impact on a hospital service corridor for screening for DR through an urban community teleophthalmology service. Methods: Retrospective analysis at the hospital service corridor of 148 diabetics referred to it following DR teleophthalmology screening of 1185 type II diabetics. Results: Of the screened diabetics, 87.4% (n = 1036) were exempted from face-to-face clinical examination (FFCE) in a traditional hospital eye care pathway and continued monitoring through teleophthalmology under a watch-and-wait attitude, while 12.5% (n = 148) were recommended for an FFCE. The FFCEs revealed that significant DR was present in 48.2% or in 5.6% of this screened diabetic population. Reasons for referral were findings of significant DR in 40.5%, of which diabetic macular edema (DME) represented 86.6%, other incidental significant sight-threatening findings represented 32.4% (4% of the screened diabetics), and insufficient image quality was obtained for the other 27.0%. Optical coherence tomography (OCT) imaging at FFCE confirmed DME in 26.4% and led to treatment. Patients referred for insufficient image quality showed significant pathology in 90.2%, of whom 63.4% underwent further monitoring or treatment. The readers requested the FFCEs for 148 patients within 1 month of the reading in 19.6%, 3 months in 26.3%, 4–12 months in 47.3%, and 12 months in 6.7% over the 34 months of the study. Compliance with FFCEs was 91.9%, absolute in 78.4% and relative in 21.5%. The availability of OCT at the imaging site would have impacted 4.5% of the screened diabetics by enabling teleophthalmology monitoring of 91.6%, identifying just-in-time interventions for DME treatments in 26.4% and reducing by 25% the need for referral of OCT-negative reader-identified DME. Conclusion: The FFCEs generated at the hospital service corridor by an urban community DR screening teleophthalmology project did not impact negatively on its services; moreover, the service corridor was exempted from providing FFCEs to 87.4% of the diabetic population it serves. This study may help provide cost-efficiency indications for a screening protocol that would include OCT availability at the imaging site and measure its positive effects. While DR of which DME was the main cause of referral for FFCE, incidental significant sight-threatening findings were significant and approached DR as a cause of referral; this supports the recommendation of continued human intervention in DR teleophthalmology screening at this time and for this population, until automatic computer-aided diagnosis systems can recognise biomarkers associated with other significant fundus diseases. As a secondary gain this project benefited individuals in need of care who were lost to the traditional eye care pathway. Good compliance with the follow-up FFCE further supports teleophthalmology in its effort to provide better access to DR screening. © 2018 Canadian Ophthalmological Society AD - Department of Ophthalmology, Université de Montréal, Canada Ophthalmology University Center, Maisonneuve-Rosemont Hospital-Rosemont Hospital, Canada Faculty of Medicine, Université de Montréal, Montréal, Qué., Canada AU - Boucher, M. C. AU - El Yamani, M. E. M. DB - Scopus DO - 10.1016/j.jcjo.2018.06.008 IS - 3 M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2019 SP - 359-366 ST - Urban diabetic retinopathy teleophthalmology screening: results and impact at the service corridor T2 - Canadian Journal of Ophthalmology TI - Urban diabetic retinopathy teleophthalmology screening: results and impact at the service corridor UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054075273&doi=10.1016%2fj.jcjo.2018.06.008&partnerID=40&md5=6cf07f6c296bed7d14ac87b1c55e8ace VL - 54 ID - 5502 ER - TY - JOUR AB - Background: Although many diabetic retinopathy (DR) tele-screening projects have shown effectiveness for DR, timely follow-up care after screening is essential to achieve the expected visual benefits of screening. Objective: To better understand the possible factors of non-compliance to follow-up care in diabetics after tele-screening for DR. Method: This cross-sectional retrospective descriptive study analyses the data of 148 diabetics referred to follow-up care following screening of 1185 diabetics through an urban community-based DR Teleophthalmology Project aimed at Type 2 diabetes. A telephone survey was conducted to assess the screening program appreciation and the sociodemographic characteristics of that population. Results: This study achieved a 91,9% (n=136) compliance rate to follow-up care. Female sex, type 2 diabetes, lower general and DR education, telephone unreachability, age less than 60 years, knowledge of a visually impaired acquaintance and more severe DR were more prevalent in non-compliant patients. Age, ethnicity, economic status, level of precariousness, distance from home to the screening/examination sites, and previous adherence to the DR screening guidelines were similar in both compliants and noncompliants. A high satisfaction score (4,8/5, n=96) to the tele-screening program was measured. Conclusion: This study is applicable to other screening programs and suggests that an increase in the number of recall letters and a greater flexibility in the organization of follow-up care appointments as well as the addition of multilingual members to the recalling team may have further improved compliance to follow-up care. It measures a high level of satisfaction provided by this model of urban teleophthalmology screening. © 2019 Canadian Ophthalmological Society AD - Department of Ophthalmology, Université de Montréal, Montreal, Que., Canada AU - Boucher, M. C. AU - Ouazani Chahdi, H. AU - El Yamani, M. E. M. DB - Scopus DO - 10.1016/j.jcjo.2019.01.001 IS - 1 M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 2-7 ST - Compliance to follow-up care after urban diabetic retinopathy tele-screening T2 - Canadian Journal of Ophthalmology TI - Compliance to follow-up care after urban diabetic retinopathy tele-screening UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061777879&doi=10.1016%2fj.jcjo.2019.01.001&partnerID=40&md5=4283061bad4c8afea89e37eade725bd0 VL - 55 ID - 5704 ER - TY - JOUR AB - Purpose. - To evaluate the efficacy of functional amblyopia treatment in children having undergone surgery for primary infantile glaucoma. Patients and method. - Parameters studied included: age at surgery, current age, visual acuity (VA) (initial and most recent acuity), refraction, alignment, adherence to amblyopia treatment, condition of the cornea (Haab striae, stromal scarring, pachymetry, cell count), condition of the optic disc (cupping, RNFL OCT) and intraocular pressure. Pearson's p-value was fixed at 5%. Results. - Retrospective study of 29 eyes; average age at surgery was four months, mean follow-up was 11.2 years. Initial VA averaged 4.5 over 10, most recent VA 7 over 10, i.e. a gain of 2.3 over 10. Refraction revealed 37.9% myopia, 10.3% emmetropia, 48.2% hyperopia and an average astigmatism of 2.14 D. A negative correlation was found between astigmatism and most recent VA (rho = -0.7; P < 0.001). A positive correlation was found between the quality of the occlusion therapy and the recovery of VA with a gain of 3.2 over 10 (P = 0.001). A strong positive correlation was found between the cylinder power and the number of Haab striae [rho 0.702, P < 0.0001]; final VA is best when the striae show no organized scar formation (P = 0.04). Conclusion. - This study underlines the necessity of prolonged treatment of functional amblyopia in primary infantile glaucoma for the best possible visual rehabilitation. (C) 2012 Elsevier Masson SAS. All rights reserved. AN - WOS:000303401200007 AU - Boulze-Pankert, M. AU - Zanin, E. AU - Matonti, F. AU - Benso, C. AU - Toesca, E. AU - Denis, D. DA - MAR DO - 10.1016/j.jfo.2011.08.008 IS - 3 PY - 2012 SN - 0181-5512 SP - 181-186 ST - Post-operative rehabilitation of functional amblyopia in primary infantile glaucoma: 11 year-follow-up T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Post-operative rehabilitation of functional amblyopia in primary infantile glaucoma: 11 year-follow-up VL - 35 ID - 6094 ER - TY - JOUR AB - PURPOSE:: Our goal is to investigate the opinion and practice pattern of Canadian ophthalmologists regarding the use of and recommendations for complementary and alternative medicine (CAM) for their glaucoma patients. METHODS:: Institutional review board approval for this prospective, cross-sectional survey was obtained from the Research Ethics Board of Sunnybrook Health Sciences Centre. The survey was sent to all ophthalmologists in Canada electronically through the e-mail lists of 4 ophthalmology associations. RESULTS:: A total of 241 ophthalmologists representing all provinces in Canada responded to the questionnaire. Twenty-two percent felt that CAM does have a role in glaucoma therapy with specialists being more likely to believe there is a role (P<0.05). Of the total respondents, 26% ask their patients if they use CAM with those in practice for <20 years more likely to encourage use (P<0.05). Of the respondents, 9% recommend CAM and if an ophthalmologist was in practice for <20 years he/she was significantly more likely to recommend CAM (P<0.01). Respondents (62%) in general do not discourage CAM with younger ophthalmologists (younger than 50 y, P<0.02) and ophthalmologists in practice for <20 years (P<0.05) being less likely to discourage CAM use. Respondents (41%) believe that CAM rarely ever affects compliance with ophthalmologists from an urban practice (P<0.01) and academic practice (P<0.05) more likely to deny effect on compliance. Respondents believe that CAM sometimes (46%) results in patient morbidity with ophthalmologists being in practice for <20 years believing that morbidity is less likely (P<0.05). CONCLUSION:: A substantial minority of respondents believe that CAM has a role in glaucoma therapy, recommend its use, and ask their patients if they use CAM. Younger doctors are more likely to encourage alternatives; those in practice for <20 years are more likely to ask about alternative medicine use, recommend its use, and believe that morbidity usually does not result from the use of alternative treatments. Copyright © 2013 by Lippincott Williams & Wilkins. AD - O. Kasner, Department of Ophthalmology, Jewish General Hospital, McGill University, 3755 Cote Ste-Catherine, Room E-008, Montreal, QC H3T 1E2, Canada AU - Bower, T. N. AU - Muhsen, S. AU - Overbury, O. AU - Birt, C. AU - Kasner, O. DB - Embase Medline DO - 10.1097/IJG.0b013e31827b139d IS - 7 KW - alpha tocopherol antioxidant antioxidant vitamin ascorbic acid cannabis cyanocobalamin retinol riboflavin thiamine unclassified drug vitamin acupuncture adult aged alternative medicine article Canada Canadian Chinese medicine chiropractic cross-sectional study demography diet Euphrasia exercise female fruit Ginkgo biloba glaucoma herbal medicine homeopathy human language low fat diet low sugar diet major clinical study male meditation morbidity ophthalmologist patient compliance physician attitude priority journal prospective study protein diet questionnaire running sodium restriction bilberry vegetable walking weight lifting LA - English M3 - Article N1 - L52456572 2013-02-26 2014-09-25 PY - 2014 SN - 1536-481X 1057-0829 SP - 430-434 ST - Canadian ophthalmologists' opinions concerning complementary and alternative medicine (CAM) use in Glaucoma T2 - Journal of Glaucoma TI - Canadian ophthalmologists' opinions concerning complementary and alternative medicine (CAM) use in Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52456572&from=export http://dx.doi.org/10.1097/IJG.0b013e31827b139d VL - 23 ID - 2922 ER - TY - JOUR AN - 55075832. Language: English. Entry Date: 20101110. Revision Date: 20101111. Publication Type: Article AU - Boyle, Erin L. AU - Bechtel, Bryan AU - Hasson, Matt AU - Master, Joe AU - Mullin, David W. DB - ccm DP - EBSCOhost IS - 22 KW - Glaucoma -- Therapy -- United States Geographic Factors Health Services Accessibility United States Health Care Costs N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 24-24 ST - Study: Regional differences appear to be costliest disparity in US glaucoma care T2 - Ocular Surgery News TI - Study: Regional differences appear to be costliest disparity in US glaucoma care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=55075832&site=ehost-live&scope=site VL - 28 ID - 4584 ER - TY - JOUR AN - 105114447. Language: English. Entry Date: 20101015. Revision Date: 20150711. Publication Type: Journal Article AU - Boyle, E. L. AU - Mullin, D. W. DB - ccm DP - EBSCOhost IS - 20 KW - Glaucoma -- Drug Therapy -- India Prostaglandins -- Economics Costs and Cost Analysis Medication Compliance Patient Attitudes India N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2010 SN - 8750-3085 SP - 17-17 ST - Glaucoma medication cost, compliance pose challenges in India T2 - Ocular Surgery News TI - Glaucoma medication cost, compliance pose challenges in India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105114447&site=ehost-live&scope=site VL - 28 ID - 4548 ER - TY - JOUR AB - Purpose Improving adherence to manage elevated intraocular pressure (IOP) remains an unmet need. A topical bimatoprost ocular insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) treated for 6 months. Design Parallel-arm, multicenter, double-masked, randomized, controlled trial. Participants One hundred thirty adult OAG or OHT patients. Methods Eligible patients were randomized 1:1 to receive a bimatoprost insert plus artificial tears twice daily or a placebo insert plus timolol (0.5% solution) twice daily for 6 months after a screening washout period. Diurnal IOP measurements (at 0, 2, and 8 hours) were obtained at baseline; weeks 2, 6, and 12; and months 4, 5, and 6. Key eligibility included washout IOP of 23 mmHg or more at time 0, IOP of 20 mmHg or more at 2 and 8 hours, and IOP of 34 mmHg or less at all time points; no prior incisional surgery for OAG or OHT; and no known nonresponders to prostaglandins. Main Outcome Measures The primary efficacy end point examined the difference in mean change from baseline in diurnal IOPs (point estimate, 95% confidence interval) across 9 coprimary end points at weeks 2, 6, and 12 comparing the bimatoprost arm with the timolol arm using a noninferiority margin of 1.5 mmHg. Secondary end points were diurnal IOP measurements at months 4, 5, and 6 and adverse events (AEs). Results A mean reduction from baseline IOP of −3.2 to −6.4 mmHg was observed for the bimatoprost group compared with −4.2 to −6.4 mmHg for the timolol group over 6 months. The study met the noninferiority definition at 2 of 9 time points but was underpowered for the observed treatment effect. Adverse events were consistent with bimatoprost or timolol exposure; no unexpected ocular AEs were observed. Primary retention rate of the insert was 88.5% of patients at 6 months. Conclusions Clinically relevant reduction in mean IOP was observed over 6 months with a bimatoprost ocular insert and seems to be safe and well tolerated. The topically applied bimatoprost insert may provide an alternative to daily eye drops to improve adherence, consistency of delivery, and reduction of elevated IOP. © 2016 American Academy of Ophthalmology AD - Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, California, United States Sall Research Medical Center, Artesia, California, United States Clayton Eye Center, Morrow, Georgia, United States Apex Eye, Cincinnati, Ohio, United States ForSight VISION5, Inc., Menlo Park, California, United States AU - Brandt, J. D. AU - Sall, K. AU - DuBiner, H. AU - Benza, R. AU - Alster, Y. AU - Walker, G. AU - Semba, C. P. DB - Scopus DO - 10.1016/j.ophtha.2016.04.026 IS - 8 M3 - Conference Paper N1 - Cited By :45 Export Date: 19 July 2021 PY - 2016 SP - 1685-1694 ST - Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study T2 - Ophthalmology TI - Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964921522&doi=10.1016%2fj.ophtha.2016.04.026&partnerID=40&md5=aa61a0ca2e2a9c97a5d9cefe5534c0d8 VL - 123 ID - 5007 ER - TY - JOUR AB - Objective: To better understand the course of glaucoma during pregnancy in women with preexisting disease. Methods: Retrospective case series of 28 eyes of 15 women with glaucoma followed up during pregnancy. Data were analyzed for age, race/ethnicity, medications, glaucoma type, intraocular pressure (IOP), and visual fields before, during, and after pregnancy. Results: In 16 (57.1%) of 28 eyes, IOP was stable during pregnancy, with no progression of visual field loss. In 5 eyes (17.9%), visual field loss progressed during pregnancy, while IOP remained stable or increased. In 5 eyes (17.9%), IOP increased during pregnancy, but there was no progression of visual field loss. In 2 eyes (7.1%), data were inconclusive because of medication noncompliance and preexisting severe visual field loss. Glaucoma medications were used by 13 of 15 patients to control glaucoma during pregnancy. The classes of medications used most frequently were β-blockers, α2-adrenergic agents, cholinergic agents, and topical carbonic anhydrase inhibitors. Conclusions: The course of glaucoma during pregnancy is variable, and women must be monitored closely during pregnancy. Medications may be necessary to control IOP and to prevent vision loss during pregnancy. ©2006 American Medical Association. All rights reserved. AD - Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles St, Boston, MA 02114, United States AU - Brauner, S. C. AU - Chen, T. C. AU - Hutchinson, B. T. AU - Chang, M. A. AU - Pasquale, L. R. AU - Grosskreutz, C. L. DB - Scopus DO - 10.1001/archopht.124.8.1089 IS - 8 M3 - Article N1 - Cited By :50 Export Date: 19 July 2021 PY - 2006 SP - 1089-1094 ST - The course of glaucoma during pregnancy: A retrospective case series T2 - Archives of Ophthalmology TI - The course of glaucoma during pregnancy: A retrospective case series UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33747184500&doi=10.1001%2farchopht.124.8.1089&partnerID=40&md5=981e417897c1f741af434c8e8caf6727 VL - 124 ID - 4996 ER - TY - JOUR AB - Background. Convenience and safety are major motivating factors in the choice of a mode of correction for refractive errors. Extended wear of contact lenses is associated with greater convenience than daily wear, but questions remain concerning the safety and risks associated with this modality. This paper investigates the hurdles that have rendered extended wear an unfavorable option thus far and seeks to identify strategies to overcome these obstacles. Method. We review the history of extended contact lens wear, focusing on soft extended wear for cosmetic use. Results of incidence and relative risk studies for the major complications are scrutinized. The factors that are associated with increased risk together with mechanisms which have been proposed on based on scientific research are analyzed to derive strategies for preventing adverse reactions in extended wear. Result. Infectious keratitis associated with extended wear of contact lenses has been identified by the community as a major issue, although the degree of concern may be disproportionate. Current perceptions of the relative risk of extended wear versus daily wear in the context of the risk for nonwearers may be misplaced, and the role of eye closure versus consistency and duration of wear remains open to debate. In the minds of practitioners and patients, other adverse reactions may be of greater significance in rejecting extended wear. Nonetheless, the potential extent of injury from infection demands attention. Studies collectively attest that corneal hypoxia during extended wear is a potential causative mechanism in infectious keratitis, suggesting that the provision of higher oxygen levels to the cornea will reduce morbidity rates from this unwanted complication. However, the issues of stagnation of the post-lens tear film during eye closure, mechanical properties of the lens, and lens movement remain unresolved and may prove to be contributing factors to adverse responses. Conclusions. Attention to oxygen permeability and mechanical properties of soft contact lenses should solve the remaining problems with extended wear. Materials currently under development promise to meet at least some of the desired properties and may lead to the long-awaited advent of safe extended wear. AD - N.A. Brennan, Brennan Consultants Pty. Ltd., Medical Centre, 517 St Kilda Rd., Melbourne 3004, Australia AU - Brennan, N. A. AU - Chantal Coles, M. L. DB - Embase Medline DO - 10.1097/00006324-199708000-00022 IS - 8 KW - poly(methyl methacrylate) silastic aphakia contact lens cornea cornea ulcer disposable equipment extended wear contact lens gas permeability human hydrogel hygiene hypoxia keratitis morbidity oxygen transport papillary conjunctivitis patient compliance priority journal refraction error review risk benefit analysis risk factor smoking tear film LA - English M3 - Review N1 - L27432770 1997-11-03 PY - 1997 SN - 1040-5488 SP - 609-623 ST - Extended wear in perspective T2 - Optometry and Vision Science TI - Extended wear in perspective UR - https://www.embase.com/search/results?subaction=viewrecord&id=L27432770&from=export http://dx.doi.org/10.1097/00006324-199708000-00022 VL - 74 ID - 3959 ER - TY - GEN AB - Objective: To assess the efficacy and tolerability of a fixed combination of bimatoprost and timolol (BTFC) in a large patient sample in a clinical setting. Methods: In this multicenter, observational, noncontrolled, open-label study, patients (n = 1862) with primary open-angle glaucoma or ocular hypertension were treated with BTFC. Assessments were made at baseline, six weeks, and three months. Results: Prior to starting BTFC, 92.3% of patients were taking other ocular hypotensive medications. In the overall group at three months, mean intraocular pressure was reduced from baseline (21.7 ± 4.5 mmHg and 21.8 ± 4.9 mmHg for the right and left eye, respectively) to 16.1 ± 3.0 mmHg for each eye (P < 0.0001). The majority of patients (92%) reported no adverse events. The most commonly reported adverse events (in >1% of patients) were eye irritation, and ocular and conjunctival hyperemia. Adherence to treatment was generally better than (35.4%) or the same as (57.5%) with prior therapy. BTFC tolerability was rated as excellent or good by 92.3% of physicians and 85.8% of patients. Conclusions: In a large group of patients with primary open-angle glaucoma or ocular hypertension, treatment with BTFC was associated with consistent reductions in IOP, improved adherence to treatment, and good tolerability. © 2010 Brief et al. AD - G. Brief, Facharzt für Augenheilkunde, Kaubomstr 7, 44388 Dortmund, Germany AU - Brief, G. AU - Lammich, T. AU - Nagel, E. AU - Pfennigsdorf, S. AU - Spraul, C. W. AU - Ho, S. C1 - alphagan arutimol azopt betamann combigan cosopt duo trav ganfort(Allergan,Ireland) lumigan nyogel tim ophtal timohexal travatan trusopt vistagan xalacom xalatan C2 - Allergan(Ireland) DB - Embase DO - 10.2147/OPTH.S13074 J2 - Clin. Ophthalmol. KW - beta adrenergic receptor blocking agent bimatoprost bimatoprost plus timolol brimonidine brimonidine plus timolol brinzolamide dorzolamide dorzolamide plus timolol latanoprost latanoprost plus timolol levobunolol metipranolol timolol timolol maleate timolol plus travoprost travoprost aged article child conjunctival hyperemia drug dose titration drug efficacy drug response drug tolerability exploratory research eye irritation female follow up human intraocular hypertension intraocular pressure major clinical study male multicenter study observational study open angle glaucoma open study patient compliance preschool child alphagan arutimol azopt betamann combigan cosopt duo trav ganfort lumigan nyogel tim ophtal timohexal travatan trusopt vistagan xalacom xalatan L1 - internal-pdf://3617318129/3219-Fixed combination of bimatoprost and-2010.pdf LA - English M1 - (Brief G., gerrett.brief@dgn.de) Facharzt für Augenheilkunde, Kaubomstr 7, 44388 Dortmund, Germany M3 - Article N1 - L361011385 2011-01-12 PY - 2010 SN - 1177-5467 1177-5483 SP - 1125-1129 ST - Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment TI - Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361011385&from=export http://dx.doi.org/10.2147/OPTH.S13074 VL - 4 ID - 3219 ER - TY - JOUR AB - Objective: To assess the efficacy and tolerability of a fixed combination of bimatoprost and timolol (BTFC) in a large patient sample in a clinical setting. Methods: In this multicenter, observational, noncontrolled, open-label study, patients (n = 1862) with primary open-angle glaucoma or ocular hypertension were treated with BTFC. Assessments were made at baseline, six weeks, and three months. Results: Prior to starting BTFC, 92.3% of patients were taking other ocular hypotensive medications. In the overall group at three months, mean intraocular pressure was reduced from baseline (21.7 ± 4.5 mmHg and 21.8 ± 4.9 mmHg for the right and left eye, respectively) to 16.1 ± 3.0 mmHg for each eye (P < 0.0001). The majority of patients (92%) reported no adverse events. The most commonly reported adverse events (in >1% of patients) were eye irritation, and ocular and conjunctival hyperemia. Adherence to treatment was generally better than (35.4%) or the same as (57.5%) with prior therapy. BTFC tolerability was rated as excellent or good by 92.3% of physicians and 85.8% of patients. Conclusions: In a large group of patients with primary open-angle glaucoma or ocular hypertension, treatment with BTFC was associated with consistent reductions in IOP, improved adherence to treatment, and good tolerability. © 2010 Brief et al. AD - Facharzt für Augenheilkunde, Kaubomstr 7, 44388 Dortmund, Germany Allergan Europe, Marlow, United Kingdom AU - Brief, G. AU - Lammich, T. AU - Nagel, E. AU - Pfennigsdorf, S. AU - Spraul, C. W. AU - Ho, S. DB - Scopus DO - 10.2147/OPTH.S13074 IS - 1 KW - Bimatoprost Fixed combination Glaucoma Intraocular pressure Timolol M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2010 SP - 1125-1129 ST - Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment T2 - Clinical Ophthalmology TI - Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650706366&doi=10.2147%2fOPTH.S13074&partnerID=40&md5=ef408587477883d151ee184f0f637a3f VL - 4 ID - 5336 ER - TY - JOUR AD - Kwale District Eye Centre, Mombasa, Kenya. AN - 105181895. Language: English. Entry Date: 20100604. Revision Date: 20200708. Publication Type: Journal Article AU - Briesen, S. AU - Geneau, R. AU - Roberts, H. AU - Opiyo, J. AU - Courtright, P. DB - ccm DO - 10.1111/j.1365-3156.2010.02486.x DP - EBSCOhost IS - 5 KW - Literature Cataract -- Psychosocial Factors Cataract Extraction -- Psychosocial Factors Treatment Refusal -- Psychosocial Factors Adult Aged Cataract -- Economics Cataract Extraction -- Economics Communication Decision Making Female Glaucoma -- Economics Glaucoma -- Therapy Attitude to Health Health Services Accessibility -- Economics Human Kenya Male Middle Age Qualitative Studies Quality of Life Treatment Refusal -- Statistics and Numerical Data Visual Acuity N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 9610576. PMID: NLM20214758. PY - 2010 SN - 1360-2276 SP - 534-539 ST - Understanding why patients with cataract refuse free surgery: the influence of rumours in Kenya T2 - Tropical Medicine & International Health TI - Understanding why patients with cataract refuse free surgery: the influence of rumours in Kenya UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105181895&site=ehost-live&scope=site VL - 15 ID - 4644 ER - TY - JOUR AB - Glaucoma is a leading cause of visual morbidity throughout the world and is an age-related condition, the prevalence of which rises significantly with increasing age. Glaucoma, a condition affecting the optic nerve, has a variety of subtypes with multiple aetiological factors, the most important of which are intraocular pressure (IOP) and increasing age. Treatment by lowering of IOP is the only current method, for which there is evidence, by which the rate of progressive visual deterioration can be slowed or halted. Although there are surgical and laser treatments that are efficacious in lowering IOP, the most common manner in which patients with glaucoma control their IOP is with administration of daily topical ocular hypotensive drugs (eye drops). The variety of topical drugs utilised in the management of glaucoma all have the potential to have adverse effects and/or interactions with concomitant medications, many of which may be used for other age-related conditions. Adherence with appropriate medicines has a major effect on the outcome of medical conditions and this aspect applies to the management of glaucoma. There are certain specific issues that relate to the administration of topical agents, with respect to both adverse effects and adherence. Although many suspect poor adherence in elderly patients with glaucoma, relative to younger patients, adequate evidence for this is lacking. Furthermore, the manner by which adherence issues could be improved remains inadequately understood and poorly addressed. The aims of this article were to review, from a clinical perspective, the medical therapies currently used for glaucoma and discuss adherence issues with respect to the population of patients with glaucoma, who tend to be relatively elderly. AN - 109820670. Language: English. Entry Date: 20150728. Revision Date: 20200708. Publication Type: Journal Article AU - Broadway, David AU - Cate, Heidi DB - ccm DO - 10.1007/s40266-015-0282-9 DP - EBSCOhost IS - 7 KW - Drug Therapy -- Evaluation Glaucoma -- Drug Therapy Medication Compliance Adrenergic Beta-Antagonists -- Classification Prostaglandins -- Analogs and Derivatives Carbonic Anhydrase Inhibitors Adrenergic Alpha-Agonists Miotics Drug Interactions Aged Intraocular Pressure Diuretics Drug Therapy, Combination Comorbidity Age Factors N1 - review; tables/charts. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. Special Interest: Gerontologic Care. NLM UID: 9102074. PMID: NLM26136215. PY - 2015 SN - 1170-229X SP - 569-581 ST - Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma T2 - Drugs & Aging TI - Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109820670&site=ehost-live&scope=site VL - 32 ID - 4510 ER - TY - JOUR AB - Purpose To report the outcome of 5-fluorouracil (5-FU)-augmented bleb needling revision of failed and failing filtration blebs and to identify risk factors for failure, indicators for success, and any complications of the procedure. Design Prospective, observational, noncomparative, interventional case series with survival analysis. Methods The results of 101 bleb needling procedures augmented with subconjunctival 5-FU injection were determined after a minimum follow-up of 9 months. Kaplan-Meier plots were constructed and a Cox proportional hazards regression analysis was performed to assess the association between study factors and time to failure. Main outcome measures Reduction in intraocular pressure (IOP) by 2 criteria (<22 mmHg, >30%), glaucoma medications, complications, and factors associated with outcome. Results At the time of their last follow-up visit, 60 eyes had an IOP <22 mmHg, mean IOP being reduced from 26.5 mmHg to 18 mmHg after a median of 1 needling procedure (mean, 1.6). The median interval between the "index" filtration surgery and the first (or only) needling procedure was 3.1 months, with a range of 10 days to 11 years. There was a reduction in mean number of topical antiglaucoma agents from 0.7 to 0.2 per successful eye and a median follow-up duration of 18.7 months (range, 9.3-52.0 months). Thus, the overall cross-sectional success rate of the procedure at the time of the last visit was 59.4%. Strong evidence was found for an association between the immediate attainment of a low IOP (<11 mmHg) and longer survival times. None of the other proposed factors that may have affected outcome were identified as having a statistically significant effect; however, this may have been the result of the low statistical power for some of the factors in this study. Conclusions These data suggest that bleb needling augmented with 5-FU is a safe and effective method by which a significant number of failed or failing filtration blebs can be rescued from failure. Attaining an immediate reduction in IOP to <11 mmHg seems to be a favorable factor with respect to reasonably long-term efficacy. © 2004 by the American Academy of Ophthalmology. AD - Norfolk and Norwich Univ. Hospital, Norwich, United Kingdom Hillingdon Hospital, Western Eye Hospital, London, United Kingdom Moorfields Eye Hospital, London, United Kingdom Norfolk and Norwich Univ. Hospital, Colney Lane, Norwich, Norfolk NR4 7UZ, United Kingdom AU - Broadway, D. C. AU - Bloom, P. A. AU - Bunce, C. AU - Thiagarajan, M. AU - Khaw, P. T. DB - Scopus DO - 10.1016/j.ophtha.2003.07.009 IS - 4 M3 - Article N1 - Cited By :120 Export Date: 19 July 2021 PY - 2004 SP - 665-673 ST - Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil: Survival analysis T2 - Ophthalmology TI - Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil: Survival analysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-1842528812&doi=10.1016%2fj.ophtha.2003.07.009&partnerID=40&md5=e8efbb29968a284d48cebf1c59eaa3b6 VL - 111 ID - 4922 ER - TY - JOUR AB - Glaucoma is a leading cause of visual morbidity throughout the world and is an age-related condition, the prevalence of which rises significantly with increasing age. Glaucoma, a condition affecting the optic nerve, has a variety of subtypes with multiple aetiological factors, the most important of which are intraocular pressure (IOP) and increasing age. Treatment by lowering of IOP is the only current method, for which there is evidence, by which the rate of progressive visual deterioration can be slowed or halted. Although there are surgical and laser treatments that are efficacious in lowering IOP, the most common manner in which patients with glaucoma control their IOP is with administration of daily topical ocular hypotensive drugs (eye drops). The variety of topical drugs utilised in the management of glaucoma all have the potential to have adverse effects and/or interactions with concomitant medications, many of which may be used for other age-related conditions. Adherence with appropriate medicines has a major effect on the outcome of medical conditions and this aspect applies to the management of glaucoma. There are certain specific issues that relate to the administration of topical agents, with respect to both adverse effects and adherence. Although many suspect poor adherence in elderly patients with glaucoma, relative to younger patients, adequate evidence for this is lacking. Furthermore, the manner by which adherence issues could be improved remains inadequately understood and poorly addressed. The aims of this article were to review, from a clinical perspective, the medical therapies currently used for glaucoma and discuss adherence issues with respect to the population of patients with glaucoma, who tend to be relatively elderly. AD - D.C. Broadway, Department of Ophthalmology, Norfolk and Norwich University Hospital, Colney Lane, Norwich, Norfolk, United Kingdom AU - Broadway, D. C. AU - Cate, H. DB - Embase Medline DO - 10.1007/s40266-015-0282-9 IS - 7 KW - acetazolamide alpha adrenergic receptor stimulating agent apraclonidine beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brinzolamide carbonate dehydratase inhibitor carteolol cholinergic receptor stimulating agent dorzolamide glycerol latanoprost levobunolol mannitol miotic agent osmotic diuretic agent pilocarpine prostaglandin derivative tafluprost timolol travoprost unoprostone aqueous humor bradycardia bronchospasm central nervous system disease circadian rhythm comorbidity dehydration drug hypersensitivity elderly care glaucoma heart disease human hyperemia intraocular pressure life expectancy miosis myopia open angle glaucoma patient compliance prescription priority journal quality of life review tachyphylaxis taste disorder xerostomia LA - English M3 - Review N1 - L605091528 2015-07-08 2015-08-12 PY - 2015 SN - 1179-1969 1170-229X SP - 569-581 ST - Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma T2 - Drugs and Aging TI - Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605091528&from=export http://dx.doi.org/10.1007/s40266-015-0282-9 VL - 32 ID - 2799 ER - TY - JOUR AB - Background/Objectives: to determine whether mass case review, carried out by glaucoma sub-specialist consultants, for patients for whom there was insufficient clinic capacity, could aid reduction of the glaucoma clinic appointment backlog. Subjects/Methods: patient hospital notes were reviewed by a glaucoma fellowship trained consultant and a decision was made as to whether the planned review was appropriate. Decisions were made with respect to timing, clinic-type and necessity for follow-up, together with an assessment as to whether visual field testing was required. Results: in a 3-year study a total of 9290 cases were included in the study. After consultant review, 5521 (59.5%) patients were kept within the hospital eye service (HES) and an additional 1350 (14.5%) had their next appointment delayed, 384 (4%) were discharged to specialist community glaucoma optometrists and 2035 (22%) were discharged to their standard community optometrists. Overall, therefore 26% of patients were discharged from the HES. Of the planned 9290 appointments, simultaneous visual field testing had been planned for 5393 patients (58%), but after consultant review only 65% (n = 3482) of these were considered necessary, reducing the number of required visual field tests by 35% (n = 1911). Conclusions: the authors suggest that ophthalmology departments experiencing significant clinic appointment backlog issues, consider utilising trained glaucoma sub-specialist consultants to review planned follow-up management of patients within a backlog deficit. © 2019, The Royal College of Ophthalmologists. AD - Directorate of Ophthalmology, Norfolk & Norwich University Hospital NHS Foundation Trust Colney Lane, Norwich, NR4 7UY, United Kingdom School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR45 7TJ, United Kingdom AU - Broadway, D. C. AU - Tibbenham, K. DB - Scopus DO - 10.1038/s41433-019-0468-1 IS - 11 M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2019 SP - 1715-1721 ST - Tackling the NHS glaucoma clinic backlog issue T2 - Eye (Basingstoke) TI - Tackling the NHS glaucoma clinic backlog issue UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066063076&doi=10.1038%2fs41433-019-0468-1&partnerID=40&md5=bab5746e4cf859844645ade688c36d6d VL - 33 ID - 5402 ER - TY - JOUR AB - Objectives: To evaluate satisfaction and compliance in glaucoma and ocular hypertensive patients receiving a fixed combination treatment. Materials and methods: After instilling a fixed combination, patients were asked to fill out a questionnaire about their satisfaction and compliance at baseline and 15 days after the onset of new therapy. Results: 1693 glaucoma patients (G) and 621 ocular hypertensive (OHT) patients were included. Mean age was 65.6±11.7 years. Onset of disease was 7.2±6.6 years and 5.2±4.9 years for G and OHT patients, respectively. Insufficient efficacy of the previous topical treatment (monotherapy in 55 % of cases) was the main cause for shifting to a fixed combination in 70 % of cases. Satisfaction was increased in 15 % of the patients and compliance was increased in 25 % of the patients. Discussion: Fixed combination provides an easier regimen and therefore encourages better compliance, a key issue in a chronic disease such as glaucoma. © 2008. Elsevier Masson SAS. AD - A. Bron, Service d'Ophtalmologie, CHU Hôpital Général, 21000 Dijon, France AU - Bron, A. AU - Baudouin, C. AU - Denis, P. AU - Nordmann, J. P. AU - Renard, J. P. AU - Rouland, J. F. AU - Sellem, E. DB - Medline DO - 10.1016/S0181-5512(08)74379-1 IS - 7 KW - beta adrenergic receptor blocking agent carbonate dehydratase inhibitor eye drops prostaglandin aged article clinical trial comparative study drug combination female human intraocular hypertension male middle aged multicenter study open angle glaucoma patient compliance patient satisfaction prospective study treatment outcome LA - French M3 - Article N1 - L352585077 2009-02-26 PY - 2008 SN - 0181-5512 SP - 659-665 ST - Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy T2 - Journal Francais d'Ophtalmologie TI - Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352585077&from=export http://dx.doi.org/10.1016/S0181-5512(08)74379-1 VL - 31 ID - 3432 ER - TY - JOUR AB - Aim: To evaluate the efficacy and safety of a single daily instillation of nonpreserved timolol in patients with chronic glaucoma or ocular hypertension previously treated with a twice-daily regimen of timolol 0.25% or 0.50%. Patients and methods: A prospective open clinical trial was undertaken by 220 ophthalmologists in 435 patients with chronic glaucoma or ocular hypertension controlled with twicedaily instillations of timolol 0.25% or 0.50%. In this population, the previous regimen was substituted with a single daily instillation of preservative-free timolol 0.25% or 0.50% for 3 months. The changes in intraocular pressure (IOP) were recorded as well as local and systemic tolerance and patient compliance. Results: It was found that 398 patients (93.6%) maintained stable IOP: in 92%, IOP increased no more than 2 mmHg. The mean IOP was 17.0 ± 2.2mmHg at DO, 16.5 ± 2.4mmHg at D28/ 42 and 16.6 ± 2.4mmHg at D84. The proportion of patients with at least one ocular symptom upon instillation or at another time decreased (p<0.0001 and p=0.03, respectively). The proportion of conjunctival hyperemia reduced from 24.4% to 14.6% (P=0.0002). The rate of folliculopapillar reactions and superficial punctate keratitis was halved (p=0.005 and p=0.02, respectively). Conclusion: During this study in daily practice, the switch from a twice-daily regimen of timolol to a once-daily application maintained stable intraocular pressure with a notable improvement in tolerance. AD - A. Bron, Service d'Ophtalmologie, CHU de Dijon, Hôpital Général, 3, rue du Faubourg Raines, 21033 Dijon Cedex, France AU - Bron, A. AU - Chiambaretta, F. AU - Pouliquen, P. AU - Rigal, D. AU - Rouland, J. F. DB - Embase Medline IS - 7 KW - timolol adult aged article clinical trial conjunctival hyperemia controlled clinical trial controlled study dose response dose time effect relation drug efficacy drug instillation drug safety drug tolerability drug tolerance eye irritation female glaucoma human intraocular hypertension intraocular pressure major clinical study male multicenter study patient compliance phase 4 clinical trial punctate keratitis treatment outcome LA - French M3 - Article N1 - L37173418 2003-10-09 PY - 2003 SN - 0181-5512 SP - 668-674 ST - Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension T2 - Journal Francais d'Ophtalmologie TI - Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37173418&from=export VL - 26 ID - 3803 ER - TY - JOUR AB - Aim: To ascertain why ophthalmologists shift therapy to a fixed-combination or non-fixed-combination drug therapy. Patients and methods: A prospective multicenter observational study was conducted among French ophthalmologists working in private or mixed practice. The study included adult patients with open-angle glaucoma or ocular hypertension, treated with monotherapy or dual therapy and needing to modify their initial treatment. The patients had to fill out a self-questionnaire 15 days after the change in therapy, evaluating the compliance and assessment of the new treatment. Results: The analysis was made on 775 questionnaires filled out by ophthalmologists between March 1 st and July 31st 2003 on 5734 patients. The mean age was 66.4±12.4 years and women represented 53.6% of the patients. The diagnosis had been made, on average, 7.5±7.3 years before. The mean initial intraocular pressure under treatment was 19.8±4.1 mmHg in both eyes. Initially, 58.2% of the patients had monotherapy, 40.4% dual therapy and 1.4% triple therapy. The main reasons for shifting therapy were "high intraocular pressure under treatment" for 63.5% of the patients and "simplification of the treatment" for 39.1% of the patients (several reasons per patient were accepted). Most of the patients were satisfied with their new therapy (71%), which in most cases was a fixed-combination therapy (95.2%). Discussion: This study has shown that the use of at least two active principles is a common practice in the treatment of glaucoma and ocular hypertension. An additive therapy is given in order to better control the intraocular pressure, mainly with a fixed combination. © Masson, 2006. AD - A. Bron, Service d'Ophtalmologie, Hôpital Général, CHU Dijon, BP1519, Dijon 21003, France AU - Bron, A. AU - Nordmann, J. P. AU - Rouland, J. F. AU - Baudouin, C. AU - Sartral, M. DB - Embase Medline DO - 10.1016/s0181-5512(06)73765-2 IS - 2 KW - adrenergic receptor stimulating agent beta adrenergic receptor blocking agent cholinergic receptor stimulating agent prostaglandin derivative adult aged article clinical trial controlled clinical trial controlled study female health survey human intraocular hypertension intraocular pressure major clinical study male monotherapy multicenter study observation open angle glaucoma ophthalmology patient compliance patient satisfaction questionnaire sclerotomy trabeculoplasty trabeculotomy LA - French M3 - Article N1 - L43357242 2006-03-21 PY - 2006 SN - 0181-5512 SP - 164-168 ST - Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment T2 - Journal Francais d'Ophtalmologie TI - Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43357242&from=export http://dx.doi.org/10.1016/s0181-5512(06)73765-2 VL - 29 ID - 3641 ER - TY - JOUR AB - Aim: To compare the efficacy and safety of a single daily instillation of nonpreserved timolol to a timolol maleate gel-forming solution in patients with chronic glaucoma or ocular hypertension already treated with latanoprost. Patients and methods: A randomized, prospective, multicenter, open, parallel-group clinical trial was undertaken with 73 patients with chronic glaucoma treated with latanoprost and a timolol maleate gel-forming solution. In 36 patients, the previous regimen was substituted by nonpreserved timolol given instead of timolol maleate gel for 3 months. The changes in intraocular pressure (IOP) were recorded as well as local and systemic tolerance and patient compliance. Results: At 3 months, both regimens were found equivalent in maintaining IOP control between DO and D84. The difference with baseline was -0.08 ±2.22mmHg and -0.38 ±2.41mmHg in the nonpreserved timolol group and in the timolol maleate gel-forming solution group, respectively (CI 95% [-0.79; 1.38]). After 84 days of treatement, blurred vision (5.9%) and eyelid deposits (5.9%) were reduced in the preservative-free timolol group compared to the other group (respectively, 33.3% and 24.2%). These differences were statistically significant for both signs (blurred vision: p<0.0001 and for eyelid deposits: p=0.03). Conclusion: This short-term study has demonstrated the equivalence of nonpreserved timolol to timolol maleate gel-forming solution in terms of IOP control. Moreover, the local tolerance of nonpreserved timolol was better. AD - A. Bron, Service d'Ophtalmologie, CHU de Dijon, Hôpital Général, 3, rue du Faubourg Raines, 21033 Dijon Cedex, France AU - Bron, A. AU - Velasque, L. AU - Rebica, H. AU - Pouliquen, P. AU - Elena, P. P. AU - Rouland, J. F. C1 - timabak timoptol xalatan DB - Embase Medline DO - 10.1016/S0181-5512(04)96251-1 IS - 9 I KW - antiglaucoma agent latanoprost timolol timolol maleate adult aged article clinical trial confidence interval controlled clinical trial controlled study drug efficacy drug safety drug tolerability eyelid disease female gel glaucoma human information processing intermethod comparison intraocular pressure major clinical study male multicenter study patient compliance phase 4 clinical trial randomized controlled trial statistical significance time treatment outcome visual impairment timabak timoptol xalatan LA - French M3 - Article N1 - L39556823 2004-12-09 PY - 2004 SN - 0181-5512 SP - 971-977 ST - Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost T2 - Journal Francais d'Ophtalmologie TI - Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39556823&from=export http://dx.doi.org/10.1016/S0181-5512(04)96251-1 VL - 27 ID - 3722 ER - TY - JOUR AU - Bruce, D. W. IS - 6792 KW - Aged Efficiency *Glaucoma/di [Diagnosis] Humans Patient Acceptance of Health Care Referral and Consultation N1 - Comment on (CON) PY - 1991 SN - 0959-8138 SP - 1607 ST - Efficiency of referral for suspected glaucoma T2 - BMJ (Clinical research ed.) T3 - Comment on: BMJ. 1991 Apr 27;302(6783):998-1000; PMID: 2039899 [https://www.ncbi.nlm.nih.gov/pubmed/2039899] TI - Efficiency of referral for suspected glaucoma UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=1855064 VL - 302 ID - 2132 ER - TY - JOUR AB - The behavior and effects of medications may be modified in the elderly. Factors contributing to such alterations may involve differences in drug pharmacokinetics and response and/or social and economic factors that affect nutrition and compliance to medications. Many studies have been devoted to such factors, but most of them have not taken into account chronopharmacologic data. Indeed, drug-administration time constitutes an additional factor of variability in drug response in the elderly. Biological rhythm-dependent differences in the kinetics and dynamics of medications seem to be diminished or altered with aging. Chronopathological (rhythmic aspects of disease) data in the elderly are of particular importance, taking into account frequently associated diseases, such as chronic obstructive pulmonary disease, cancer, diabetes, glaucoma, hypertension, and inflammatory conditions, among others. Although some chronobiological data are available, chronopharmacologic phenomena have yet to be extensively investigated in the elderly. Most of the sparse studies concern drug chronokinetics, but the data found in the literature do not reveal a clear trend in the age-related changes. Chronokinetic variations in the elderly, compared to young adults, suggest an amplification of the administration-time effects, as demonstrated for digoxin; dampening, as demonstrated for indomethacin; or detection of administration-time effects only in aged but not in young subjects, as found for others medications. Additional studies are needed to better understand the influence of age on the chronokinetics of medications. Moreover, the literature on possible administration-time differences in drug dynamics in the elderly is also very sparse. Altered receptor and/or post-receptor properties and impaired sensitivity of homeostatic mechanisms have yet to be studied from a chronopharmacological point of view. Thus, additional studies are needed to properly understand how drug responses in the elderly may vary in relation to the circadian timing of medications. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Bruguerolle, Bernard, Faculty of Medicine, Marseille, Universite de la Mediterranee, Timone AP-HM, 27 Bld J. Moulin, F-13385, Marseilles, France, Cedex 5 AN - 2008-02734-001 AU - Bruguerolle, Bernard DB - psyh DO - 10.1080/07420520801909247 DP - EBSCOhost IS - 1 KW - clinical chronopharmacology elderly medications effects Aged Chronobiology Phenomena Disease Health Humans Kinetics Pharmaceutical Preparations Clinical Psychology Drug Therapy Geriatrics Pharmacology N1 - Faculty of Medicine, Marseille, Universite de la Mediterrane, Marseilles, France. Other Publishers: Taylor & Francis. Release Date: 20080602. Correction Date: 20150921. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Clinical Psychology; Drug Therapy; Geriatrics; Pharmacology. Classification: Clinical Psychopharmacology (3340). Population: Human (10); Male (30); Female (40). Location: France. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 15. Issue Publication Date: Feb, 2008. PY - 2008 SN - 0742-0528 1525-6073 SP - 1-15 ST - Clinical chronopharmacology in the elderly T2 - Chronobiology International TI - Clinical chronopharmacology in the elderly UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-02734-001&site=ehost-live&scope=site bernard.bruguerolle@medecine.univ-mrs.fr VL - 25 ID - 4876 ER - TY - JOUR AD - J. Abbott, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, United Kingdom AU - Bruynseels, A. AU - Cross, V. AU - Sii, F. AU - Shah, P. AU - Abbott, J. DB - Embase Medline DO - 10.1038/eye.2017.115 IS - 12 KW - consultation glaucoma health care management health care system human note patient compliance self care LA - English M3 - Note N1 - L619813532 2017-12-22 2018-07-10 PY - 2017 SN - 1476-5454 0950-222X SP - 1635-1638 ST - Developing a children's glaucoma passport: Mapping innovations in healthcare T2 - Eye (Basingstoke) TI - Developing a children's glaucoma passport: Mapping innovations in healthcare UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619813532&from=export http://dx.doi.org/10.1038/eye.2017.115 VL - 31 ID - 2622 ER - TY - JOUR AB - Migraine therapeutics are pharmacological, including acute and preventive, nonpharmacological and/or both. Preventive pharmacological strategies serendipitously were discovered to be effective and include drugs from various pharmacological classes (e.g., β-adrenergic blocker, anticonvulsant, tricyclic antidepressants, serotonin receptor antagonist). Converging level I evidence and clinical experience support the use of the antidepressant amitriptyline, the anticonvulsants divalproex and topiramate, and the β-adrenergic blockers propranolol, timolol, and metoprolol in migraine prevention. Other options for migraine prophylaxis exist, but the level of evidence in support of their use is not as robust. All of these drugs have varying degrees of adverse effects, some of which can limit their use. Balancing potential efficacy with risk of adverse effects, addressing patients' expectations and desires, complying with management recommendations, adequate follow up, and accurate assessment of treatment goals are key to migraine prevention. Finally, future migraine-preventive drugs likely will target migraine mechanisms more specifically, which undoubtedly will enhance the therapeutic index. Copyright © 2006 by Thieme Medical Publishers, Inc. AD - Department of Neurology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States Department of Neurology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064, United States AU - Buchanan, T. M. AU - Ramadan, N. M. DB - Scopus DO - 10.1055/s-2006-939919 IS - 2 KW - Cortical spreading depression Hyperexcitability Mechanisms Migraine Pharmacology Prevention M3 - Review N1 - Cited By :50 Export Date: 19 July 2021 PY - 2006 SP - 188-198 ST - Prophylactic pharmacotherapy for migraine headaches T2 - Seminars in Neurology TI - Prophylactic pharmacotherapy for migraine headaches UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646231746&doi=10.1055%2fs-2006-939919&partnerID=40&md5=8350716ab3f9fed12feb898d271c40ec VL - 26 ID - 4997 ER - TY - JOUR AB - PURPOSE: To apply lessons learned in the treatment of systemic hypertension to the problem of nonadherence in glaucoma medical therapy. CLINICAL RELEVANCE: Although physicians recognize that nonadherence with glaucoma medication is a problem, most lack the skill set to identify nonadherent patients, to identify the causes of nonadherence, and to provide solutions to address nonadherence. METHODS: A PubMed search was conducted using the terms "adherence" OR "compliance" AND "hypertension," with the following limitations: title, English language, humans, from 2000 through 2009. Other studies identified outside of the PubMed search were included if relevant. RESULTS: Studies from the systemic hypertension literature suggest that simplifying medication regimens, lowering costs, and patient education about the disease and the importance of taking medications are successful strategies for improving adherence. In addition, good family or social support, frequent physician visits, and pairing medication administration with specific activities (such as meals or brushing one's teeth) can help improve adherence. CONCLUSIONS: The body of literature on adherence interventions in chronic diseases such as systemic hypertension shows that although many interventions have been tested and evaluated, only some are successful. Paradigms derived from behavioral medicine and nursing offer valuable lessons on how to motivate patients to change behavior, but these activities require skill sets not traditionally taught in medical school. Just as there are myriad causes of nonadherence, the interventions most likely will need to be multifaceted and tailored to the individual patient. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. AD - D.L. Budenz, Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Florida 33136, USA. AU - Budenz, D. L. DB - Medline IS - 11 Suppl KW - antihypertensive agent eye drops blindness doctor patient relationship glaucoma health behavior human motivation paramedical personnel patient compliance patient education practice guideline psychological aspect review LA - English M3 - Review N1 - L355507628 2009-11-04 PY - 2009 SN - 1549-4713 SP - S43-47 ST - A clinician's guide to the assessment and management of nonadherence in glaucoma T2 - Ophthalmology TI - A clinician's guide to the assessment and management of nonadherence in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355507628&from=export VL - 116 ID - 3317 ER - TY - JOUR AB - PURPOSE: To apply lessons learned in the treatment of systemic hypertension to the problem of nonadherence in glaucoma medical therapy. CLINICAL RELEVANCE: Although physicians recognize that nonadherence with glaucoma medication is a problem, most lack the skill set to identify nonadherent patients, to identify the causes of nonadherence, and to provide solutions to address nonadherence. METHODS: A PubMed search was conducted using the terms "adherence" OR "compliance" AND "hypertension," with the following limitations: title, English language, humans, from 2000 through 2009. Other studies identified outside of the PubMed search were included if relevant. RESULTS: Studies from the systemic hypertension literature suggest that simplifying medication regimens, lowering costs, and patient education about the disease and the importance of taking medications are successful strategies for improving adherence. In addition, good family or social support, frequent physician visits, and pairing medication administration with specific activities (such as meals or brushing one's teeth) can help improve adherence. CONCLUSIONS: The body of literature on adherence interventions in chronic diseases such as systemic hypertension shows that although many interventions have been tested and evaluated, only some are successful. Paradigms derived from behavioral medicine and nursing offer valuable lessons on how to motivate patients to change behavior, but these activities require skill sets not traditionally taught in medical school. Just as there are myriad causes of nonadherence, the interventions most likely will need to be multifaceted and tailored to the individual patient. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. AD - Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Florida, 33136, United States AU - Budenz, D. L. DB - Scopus DO - 10.1016/j.ophtha.2009.06.022 IS - 11 Suppl M3 - Review N1 - Cited By :30 Export Date: 19 July 2021 PY - 2009 SP - S43-47 ST - A clinician's guide to the assessment and management of nonadherence in glaucoma T2 - Ophthalmology TI - A clinician's guide to the assessment and management of nonadherence in glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350500110&doi=10.1016%2fj.ophtha.2009.06.022&partnerID=40&md5=ed1b91972d70e9f16d1239e56f117a1f VL - 116 ID - 5062 ER - TY - JOUR AB - Purpose: To apply lessons learned in the treatment of systemic hypertension to the problem of nonadherence in glaucoma medical therapy. Clinical Relevance: Although physicians recognize that nonadherence with glaucoma medication is a problem, most lack the skill set to identify nonadherent patients, to identify the causes of nonadherence, and to provide solutions to address nonadherence. Methods: A PubMed search was conducted using the terms "adherence" OR "compliance" AND "hypertension," with the following limitations: title, English language, humans, from 2000 through 2009. Other studies identified outside of the PubMed search were included if relevant. Results: Studies from the systemic hypertension literature suggest that simplifying medication regimens, lowering costs, and patient education about the disease and the importance of taking medications are successful strategies for improving adherence. In addition, good family or social support, frequent physician visits, and pairing medication administration with specific activities (such as meals or brushing one's teeth) can help improve adherence. Conclusions: The body of literature on adherence interventions in chronic diseases such as systemic hypertension shows that although many interventions have been tested and evaluated, only some are successful. Paradigms derived from behavioral medicine and nursing offer valuable lessons on how to motivate patients to change behavior, but these activities require skill sets not traditionally taught in medical school. Just as there are myriad causes of nonadherence, the interventions most likely will need to be multifaceted and tailored to the individual patient. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009; 116:S43-S47 (C) 2009 by the American Academy of Ophthalmology. AN - WOS:000271291800004 AU - Budenz, D. L. DA - NOV DO - 10.1016/j.ophtha.2009.06.022 IS - 11 PY - 2009 SN - 0161-6420 1549-4713 SP - S43-S47 ST - A Clinician's Guide to the Assessment and Management of Nonadherence in Glaucoma T2 - OPHTHALMOLOGY TI - A Clinician's Guide to the Assessment and Management of Nonadherence in Glaucoma VL - 116 ID - 5996 ER - TY - JOUR AB - Objectives: Corticosteroids (CSs) are used concomitantly with life-extending therapies (LETs) in patients with castration-resistant prostate cancer (CRPC). This study examined time to LETs, LETs and concomitant CS adherence, and monthly all-cause healthcare utilization and costs in patients with CPRC with and without CS-sensitive comorbidities in the Veterans Health Administration population. Methods: Patients had CRPC if records showed prostate cancer diagnosis, medical/surgical castration and ≥2 prostate-specific antigen increases through 1 June 2007-31 May 2012. CS-sensitive comorbidities were assessed 6 months prior to the index date. Adherence, defined as medication possession ratio (MPR) ≥0.8, among patients initiating LETs (cabazitaxel, docetaxel, or abiraterone acetate) before 30 November 2011, resource utilization and costs among patients with concomitant CS were assessed. Statistical analysis included descriptive, Cox proportional hazards, and logistic regression models. Results: Common CS-sensitive conditions among 12,128 patients with CRPC included hypertension (75.74%) and hyperlipidemia (54.69%). Those with glaucoma (hazard ratio [HR]=0.67), ischemic heart disease (HR=0.78), and peripheral vascular disease (PVD) (HR=0.78) were less likely to be prescribed LETs (all p<0.01). Duration of LET was shorter among patients with CS-sensitive comorbidities (125.02 vs 133.08 days; p=0.04) in the 6 month follow-up period. Among LET-treated patients with and without CS-sensitive comorbidities, less than half had MPR≥0.8 (LET: 48.72% vs 54.05%; concomitant CS: 42.19% vs 40.54%, respectively). Cerebrovascular disease (odds ratio=0.107; 95% confidence interval=0.012 to 0.966) and PVD (odds ratio=0.523; 95% confidence interval=0.276 to 0.991) were associated with reduced CS adherence. Among patients with concomitant CS, those with CS-sensitive comorbidities had more inpatient stays than those without (20.45% vs 12.88%; p=0.033), incurring higher monthly inpatient costs ($1157 vs $342; p<0.0001) and total costs ($5725 vs $4772; p=0.036). Conclusion: CS-sensitive conditions influence initiation and duration of LETs, concomitant CS adherence, inpatient stays, and total costs. Future efforts should focus on specific strategies for treating prostate cancer patients with CS-sensitive comorbidities to ensure that they have appropriate access to LETs and to reduce costs and inpatient stays. Study limitations include the use of retrospective claims data and the relatively restricted subpopulation of older North American males. AD - C.N. Bui, Astellas Scientific and Medical Affairs, 1 Astellas Way, Northbrook, IL, United States AU - Bui, C. N. AU - Wang, L. AU - Baser, O. DB - Embase Medline DO - 10.1185/03007995.2014.955170 IS - 11 KW - abiraterone acetate cabazitaxel corticosteroid docetaxel adult article cancer diagnosis cancer therapy castration resistant prostate cancer cerebrovascular disease clinical assessment comorbidity confidence interval controlled study corticosteroid therapy follow up glaucoma health care cost health care utilization hospital patient human hyperlipidemia hypertension ischemic heart disease major clinical study male medical record medication compliance North American peripheral vascular disease prescription proportional hazards model statistical analysis treatment duration veterans health LA - English M3 - Article N1 - L600378817 2014-11-14 2014-11-19 PY - 2014 SN - 1473-4877 0300-7995 SP - 2355-2364 ST - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities T2 - Current Medical Research and Opinion TI - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600378817&from=export http://dx.doi.org/10.1185/03007995.2014.955170 VL - 30 ID - 2934 ER - TY - JOUR AB - Objectives: Corticosteroids (CSs) are used concomitantly with life-extending therapies (LETs) in patients with castration-resistant prostate cancer (CRPC). This study examined time to LETs, LETs and concomitant CS adherence, and monthly all-cause healthcare utilization and costs in patients with CPRC with and without CS-sensitive comorbidities in the Veterans Health Administration population. METHODS: Patients had CRPC if records showed prostate cancer diagnosis, medical/surgical castration and >=2 prostate-specific antigen increases through 1 June 2007-31 May 2012. CS-sensitive comorbidities were assessed 6 months prior to the index date. Adherence, defined as medication possession ratio (MPR) >=0.8, among patients initiating LETs (cabazitaxel, docetaxel, or abiraterone acetate) before 30 November 2011, resource utilization and costs among patients with concomitant CS were assessed. Statistical analysis included descriptive, Cox proportional hazards, and logistic regression models. RESULTS: Common CS-sensitive conditions among 12,128 patients with CRPC included hypertension (75.74%) and hyperlipidemia (54.69%). Those with glaucoma (hazard ratio [HR] = 0.67), ischemic heart disease (HR = 0.78), and peripheral vascular disease (PVD) (HR = 0.78) were less likely to be prescribed LETs (all p < 0.01). Duration of LET was shorter among patients with CS-sensitive comorbidities (125.02 vs 133.08 days; p = 0.04) in the 6 month follow-up period. Among LET-treated patients with and without CS-sensitive comorbidities, less than half had MPR >= 0.8 (LET: 48.72% vs 54.05%; concomitant CS: 42.19% vs 40.54%, respectively). Cerebrovascular disease (odds ratio = 0.107; 95% confidence interval = 0.012 to 0.966) and PVD (odds ratio = 0.523; 95% confidence interval = 0.276 to 0.991) were associated with reduced CS adherence. Among patients with concomitant CS, those with CS-sensitive comorbidities had more inpatient stays than those without (20.45% vs 12.88%; p = 0.033), incurring higher monthly inpatient costs ($1157 vs $342; p < 0.0001) and total costs ($5725 vs $4772; p = 0.036). CONCLUSION: CS-sensitive conditions influence initiation and duration of LETs, concomitant CS adherence, inpatient stays, and total costs. Future efforts should focus on specific strategies for treating prostate cancer patients with CS-sensitive comorbidities to ensure that they have appropriate access to LETs and to reduce costs and inpatient stays. Study limitations include the use of retrospective claims data and the relatively restricted subpopulation of older North American males. AD - Astellas Scientific and Medical Affairs , Northbrook, IL , USA. AN - 103852623. Language: English. Entry Date: 20150605. Revision Date: 20200708. Publication Type: Journal Article AU - Bui, Cat N. AU - Wang, Li AU - Baser, Onur DB - ccm DO - 10.1185/03007995.2014.955170 DP - EBSCOhost IS - 11 KW - Glucocorticoids -- Therapeutic Use Health Care Costs Health Services -- Utilization Prostatic Neoplasms -- Complications Prostatic Neoplasms -- Drug Therapy Adult Aged Glucocorticoids -- Contraindications Human Logistic Regression Male Medication Compliance Middle Age Prostatic Neoplasms -- Pathology Retrospective Design United States N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 0351014. PMID: NLM25133961. PY - 2014 SN - 0300-7995 SP - 2355-2364 ST - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities T2 - Current Medical Research & Opinion TI - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103852623&site=ehost-live&scope=site VL - 30 ID - 4419 ER - TY - JOUR AB - Objectives: Corticosteroids (CSs) are used concomitantly with life-extending therapies (LETs) in patients with castration-resistant prostate cancer (CRPC). This study examined time to LETs, LETs and concomitant CS adherence, and monthly all-cause healthcare utilization and costs in patients with CPRC with and without CS-sensitive comorbidities in the Veterans Health Administration population. Methods: Patients had CRPC if records showed prostate cancer diagnosis, medical/surgical castration and ≥2 prostate-specific antigen increases through 1 June 2007-31 May 2012. CS-sensitive comorbidities were assessed 6 months prior to the index date. Adherence, defined as medication possession ratio (MPR) ≥0.8, among patients initiating LETs (cabazitaxel, docetaxel, or abiraterone acetate) before 30 November 2011, resource utilization and costs among patients with concomitant CS were assessed. Statistical analysis included descriptive, Cox proportional hazards, and logistic regression models. Results: Common CS-sensitive conditions among 12,128 patients with CRPC included hypertension (75.74%) and hyperlipidemia (54.69%). Those with glaucoma (hazard ratio [HR]=0.67), ischemic heart disease (HR=0.78), and peripheral vascular disease (PVD) (HR=0.78) were less likely to be prescribed LETs (all p<0.01). Duration of LET was shorter among patients with CS-sensitive comorbidities (125.02 vs 133.08 days; p=0.04) in the 6 month follow-up period. Among LET-treated patients with and without CS-sensitive comorbidities, less than half had MPR≥0.8 (LET: 48.72% vs 54.05%; concomitant CS: 42.19% vs 40.54%, respectively). Cerebrovascular disease (odds ratio=0.107; 95% confidence interval=0.012 to 0.966) and PVD (odds ratio=0.523; 95% confidence interval=0.276 to 0.991) were associated with reduced CS adherence. Among patients with concomitant CS, those with CS-sensitive comorbidities had more inpatient stays than those without (20.45% vs 12.88%; p=0.033), incurring higher monthly inpatient costs ($1157 vs $342; p<0.0001) and total costs ($5725 vs $4772; p=0.036). Conclusion: CS-sensitive conditions influence initiation and duration of LETs, concomitant CS adherence, inpatient stays, and total costs. Future efforts should focus on specific strategies for treating prostate cancer patients with CS-sensitive comorbidities to ensure that they have appropriate access to LETs and to reduce costs and inpatient stays. Study limitations include the use of retrospective claims data and the relatively restricted subpopulation of older North American males. © 2014 Informa UK Ltd. AD - Astellas Scientific and Medical Affairs, 1 Astellas Way, Northbrook, IL 60062, United States STATinMED Research, Dallas, TX, United States STATinMED Research, University of Michigan, Ann Arbor, MI, United States AU - Bui, C. N. AU - Wang, L. AU - Baser, O. DB - Scopus DO - 10.1185/03007995.2014.955170 IS - 11 KW - Corticosteroids Cost Life-extending therapy Prostate cancer Resource utilization Treatment adherence M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2014 SP - 2355-2364 ST - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities T2 - Current Medical Research and Opinion TI - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84908635300&doi=10.1185%2f03007995.2014.955170&partnerID=40&md5=fb198fd4f8a5bd4389dc9136b209caff VL - 30 ID - 5387 ER - TY - JOUR AB - Objectives: Corticosteroids (CSs) are used concomitantly with life-extending therapies (LETs) in patients with castration-resistant prostate cancer (CRPC). This study examined time to LETs, LETs and concomitant CS adherence, and monthly all-cause healthcare utilization and costs in patients with CPRC with and without CS-sensitive comorbidities in the Veterans Health Administration population. Methods: Patients had CRPC if records showed prostate cancer diagnosis, medical/surgical castration and >= 2 prostate-specific antigen increases through 1 June 2007-31 May 2012. CS-sensitive comorbidities were assessed 6 months prior to the index date. Adherence, defined as medication possession ratio (MPR) >= 0.8, among patients initiating LETs (cabazitaxel, docetaxel, or abiraterone acetate) before 30 November 2011, resource utilization and costs among patients with concomitant CS were assessed. Statistical analysis included descriptive, Cox proportional hazards, and logistic regression models. Results: Common CS-sensitive conditions among 12,128 patients with CRPC included hypertension (75.74%) and hyperlipidemia (54.69%). Those with glaucoma (hazard ratio [HR] = 0.67), ischemic heart disease (HR = 0.78), and peripheral vascular disease (PVD) (HR = 0.78) were less likely to be prescribed LETs (all p<0.01). Duration of LET was shorter among patients with CS-sensitive comorbidities (125.02 vs 133.08 days; p = 0.04) in the 6 month follow-up period. Among LET-treated patients with and without CS-sensitive comorbidities, less than half had MPR >= 0.8 (LET: 48.72% vs 54.05%; concomitant CS: 42.19% vs 40.54%, respectively). Cerebrovascular disease (odds ratio = 0.107; 95% confidence interval = 0.012 to 0.966) and PVD (odds ratio = 0.523; 95% confidence interval = 0.276 to 0.991) were associated with reduced CS adherence. Among patients with concomitant CS, those with CS-sensitive comorbidities had more inpatient stays than those without (20.45% vs 12.88%; p = 0.033), incurring higher monthly inpatient costs ($1157 vs $342; p<0.0001) and total costs ($5725 vs $4772; p = 0.036). Conclusion: CS-sensitive conditions influence initiation and duration of LETs, concomitant CS adherence, inpatient stays, and total costs. Future efforts should focus on specific strategies for treating prostate cancer patients with CS-sensitive comorbidities to ensure that they have appropriate access to LETs and to reduce costs and inpatient stays. Study limitations include the use of retrospective claims data and the relatively restricted subpopulation of older North American males. AN - WOS:000344606300021 AU - Bui, C. N. AU - Wang, L. AU - Baser, O. DA - NOV DO - 10.1185/03007995.2014.955170 IS - 11 PY - 2014 SN - 0300-7995 1473-4877 SP - 2355-2364 ST - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities T2 - CURRENT MEDICAL RESEARCH AND OPINION TI - Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities VL - 30 ID - 6328 ER - TY - JOUR AB - Objectives: Patient noncompliance with recommended hygienic practices in contact lens wear is often considered a significant risk factor for microbial keratitis and adverse contact lens-related events. Despite advancements in lens materials and care solutions, noncompliant behavior continues to hinder efforts to maximize contact lens safety. The objective of this pilot study was to assess the relationship between perceived and actual compliance with awareness of risk and behavior. Methods: One hundred sixty-two established contact lens wearers were sequentially evaluated after their routine contact lens examination at the Optometry Clinic at the University of Texas Southwestern Medical Center at Dallas, TX. Each patient was questioned by a single trained interviewer regarding his or her lens care practices and knowledge of risk factors associated with lens wear. Results: Eighty-six percent of patients believed they were compliant with lens wear and care practices; 14% identified themselves as noncompliant. Using a scoring model, 32% demonstrated good compliance, 44% exhibited average compliance, and 24% were noncompliant; age was a significant factor (P = 0.020). Only 34% of patients who perceived themselves as compliant exhibited a good level of compliance (P<0.001). Eighty percent of patients reported an awareness of risk factors, but awareness did not influence negative behavior. Replacing the lens case was the only behavior associated with a positive history for having experienced a prior contact lens-related complication (P = 0.002). Conclusions: Perceived compliance is not an indicator for appropriate patient behavior. A large proportion of patients remain noncompliant despite awareness of risk. Education alone is not a sufficient strategy to improve behavior; newer approaches aimed at improving compliance with lens care practices are urgently needed. Copyright © Contact Lens Association of Opthalmologists, Inc. AD - D. M. Robertson, Department of Ophthalmology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9057, United States AU - Bui, T. H. AU - Cavanagh, H. D. AU - Robertson, D. M. DB - Embase Medline DO - 10.1097/ICL.0b013e3181f579f7 IS - 6 KW - adolescent adult aged article awareness contact lens female human hygiene keratitis major clinical study male patient compliance priority journal risk factor LA - English M3 - Article N1 - L51102247 2010-10-13 2010-12-07 PY - 2010 SN - 1542-2321 SP - 334-339 ST - Patient compliance during contact lens wear: Perceptions, awareness, and behavior T2 - Eye and Contact Lens TI - Patient compliance during contact lens wear: Perceptions, awareness, and behavior UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51102247&from=export http://dx.doi.org/10.1097/ICL.0b013e3181f579f7 VL - 36 ID - 3224 ER - TY - JOUR AD - A. Buller, Department of Ophthalmology, Manchester Royal Eye Hospital, Oxford Road, Manchester M13 9WH, United Kingdom AU - Buller, A. AU - Hercules, B. L. DB - Embase Medline DO - 10.1111/j.1600-0420.2005.00502.x IS - 1 KW - antiglaucoma agent eye drops circadian rhythm clinical article controlled study drug bioavailability drug dose regimen drug indication drug preference glaucoma human intraocular pressure letter outpatient department patient attitude patient care patient compliance priority journal questionnaire visual analog scale LA - English M3 - Letter N1 - L43337492 2006-03-20 PY - 2006 SN - 1395-3907 1600-0420 SP - 150-151 ST - Should patients choose their own eyedrops? [3] T2 - Acta Ophthalmologica Scandinavica TI - Should patients choose their own eyedrops? [3] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43337492&from=export http://dx.doi.org/10.1111/j.1600-0420.2005.00502.x VL - 84 ID - 3633 ER - TY - JOUR AB - Background: The relationship between complexity of eye drop regime and compliance is not straightforward, i.e. fewer drops may not mean better compliance. We investigated the level of inconvenience different eye drop regimes incurred in comparison with a once-daily (OD) regime for patients experienced with using topical anti-glaucoma medication. Methods: Patients indicated the level of inconvenience from drop regimes of 1,2,3 or 4 times daily on 10-cm visual analogue scales. The score for the OD regime was then compared with the scores for the other regimes using paired t-tests with Bonferroni correction. Results: At a significance limit of p=0.05, five of six subgroups indicated once-a-day drops were significantly more convenient than other regimes. Patients who had used the OD regime considered this difference greater than those who had not. Conclusions: This study's results offer some pragmatic guidance on choice of therapy and on counselling patients about compliance. We would suggest starting patients on OD drops in preference to alternatives to promote compliance. © Springer-Verlag 2006. AD - A.J. Buller, Stepping Hill Hospital, Poplar Grove, Stockport, Cheshire, United Kingdom AU - Buller, A. J. AU - Morgan, L. H. AU - Hercules, B. L. DB - Embase Medline DO - 10.1007/s00417-006-0333-3 IS - 2 KW - antiglaucoma agent article dosage schedule comparison drug dose regimen glaucoma human major clinical study patient attitude patient compliance priority journal questionnaire statistical significance Student t test visual analog scale LA - English M3 - Article N1 - L46291461 2007-03-26 PY - 2007 SN - 0721-832X SP - 293-294 ST - Patients prefer once-daily glaucoma drops T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - Patients prefer once-daily glaucoma drops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46291461&from=export http://dx.doi.org/10.1007/s00417-006-0333-3 VL - 245 ID - 3543 ER - TY - JOUR AB - OBJECTIVES: To determine effective and efficient monitoring criteria for ocular hypertension [raised intraocular pressure (IOP)] through (i) identification and validation of glaucoma risk prediction models; and (ii) development of models to determine optimal surveillance pathways. DESIGN: A discrete event simulation economic modelling evaluation. Data from systematic reviews of risk prediction models and agreement between tonometers, secondary analyses of existing datasets (to validate identified risk models and determine optimal monitoring criteria) and public preferences were used to structure and populate the economic model. SETTING: Primary and secondary care. PARTICIPANTS: Adults with ocular hypertension (IOP > 21mmHg) and the public (surveillance preferences). INTERVENTIONS: We compared five pathways: two based on National Institute for Health and Clinical Excellence (NICE) guidelines with monitoring interval and treatment depending on initial risk stratification, 'NICE intensive' (4-monthly to annual monitoring) and 'NICE conservative' (6-monthly to biennial monitoring); two pathways, differing in location (hospital and community), with monitoring biennially and treatment initiated for a >= 6% 5-year glaucoma risk; and a 'treat all' pathway involving treatment with a prostaglandin analogue if IOP > 21 mmHg and IOP measured annually in the community. MAIN OUTCOME MEASURES: Glaucoma cases detected; tonometer agreement; public preferences; costs; willingness to pay and quality-adjusted life-years (QALYs). RESULTS: The best available glaucoma risk prediction model estimated the 5-year risk based on age and ocular predictors (IOP, central corneal thickness, optic nerve damage and index of visual field status). Taking the average of two IOP readings, by tonometry, true change was detected at two years. Sizeable measurement variability was noted between tonometers. There was a general public preference for monitoring; good communication and understanding of the process predicted service value. 'Treat all' was the least costly and 'NICE intensive' the most costly pathway. Biennial monitoring reduced the number of cases of glaucoma conversion compared with a 'treat all' pathway and provided more QALYs, but the incremental cost-effectiveness ratio (ICER) was considerably more than £30,000. The 'NICE intensive' pathway also avoided glaucoma conversion, but NICE-based pathways were either dominated (more costly and less effective) by biennial hospital monitoring or had a ICERs > £30,000. Results were not sensitive to the risk threshold for initiating surveillance but were sensitive to the risk threshold for initiating treatment, NHS costs and treatment adherence. LIMITATIONS: Optimal monitoring intervals were based on IOP data. There were insufficient data to determine the optimal frequency of measurement of the visual field or optic nerve head for identification of glaucoma. The economic modelling took a 20-year time horizon which may be insufficient to capture long-term benefits. Sensitivity analyses may not fully capture the uncertainty surrounding parameter estimates. CONCLUSIONS: For confirmed ocular hypertension, findings suggest that there is no clear benefit from intensive monitoring. Consideration of the patient experience is important. A cohort study is recommended to provide data to refine the glaucoma risk prediction model, determine the optimum type and frequency of serial glaucoma tests and estimate costs and patient preferences for monitoring and treatment. FUNDING: The National Institute for Health Research Health Technology Assessment Programme. AN - 108123990. Language: English. Entry Date: 20130628. Revision Date: 20150712. Publication Type: Journal Article AU - Burr, J. AU - Botello-Pinzon, P. AU - Takwoingi, Y. AU - Hernández, R. AU - Vazquez-Montes, M. AU - Elders, A. AU - Asaoka, R. AU - Banister, K. AU - van der Schoot, J. AU - Fraser, C. AU - King, A. AU - Lemij, H. AU - Sanders, R. AU - Vernon, S. AU - Tuulonen, A. AU - Kotecha, A. AU - Glasziou, P. AU - Garway-Heath, D. AU - Crabb, D. AU - Vale, L. DB - ccm DO - 10.3310/hta16290 DP - EBSCOhost IS - 50 KW - Antihypertensive Agents -- Economics Antihypertensive Agents -- Therapeutic Use Glaucoma -- Prevention and Control Ocular Hypertension -- Drug Therapy Ocular Hypertension -- Economics Age Factors Antihypertensive Agents -- Administration and Dosage Clinical Trials Cost Benefit Analysis Health Screening Human Intraocular Pressure Models, Theoretical Ocular Hypertension -- Epidemiology Prospective Studies Quality-Adjusted Life Years Risk Assessment Systematic Review N1 - research; systematic review. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 9706284. PMID: NLM22687263. PY - 2012 SN - 1366-5278 SP - 1-272 ST - Surveillance for ocular hypertension: an evidence synthesis and economic evaluation T2 - Health Technology Assessment TI - Surveillance for ocular hypertension: an evidence synthesis and economic evaluation UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108123990&site=ehost-live&scope=site VL - 16 ID - 4436 ER - TY - JOUR AB - A hand-held noncontact tonometer (Pulsair, Keeler Ltd., UK) was tested in 42 children, from 5 months to 12 years of age. At least 1 intraocular pressure (IOP) reading was obtained in all of the 84 eyes studied, whereas with a Goldman applanation tonometer measurements could be obtained in only 26 eyes (14 subjects). Time required for examination with the Pulsair was quite variable and related to age (p<0.0001). Compliance in children was reported as “good” in the majority of cases; it was also age-related (p<0.005). Although its reliability could not be definitely evaluated, the results of this study indicate that this instrument may be a valuable choice for screening and follow-up purposes in childhood. © 1991 American Academy of Optometry. AD - Department of Ophthalmology, University of Milan, San Raffaele Hospital, Milan, Italy AU - Buscemi, M. AU - Capoferri, C. AU - Garavaglia, A. AU - Nassivera, C. AU - Nucci, P. DB - Scopus DO - 10.1097/00006324-199106000-00009 IS - 6 KW - Childhoodt Glaucoma Intraocular pressure Tonometry M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 1991 SP - 461-464 ST - Noncontact tonometry in children T2 - Optometry and Vision Science TI - Noncontact tonometry in children UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025912284&doi=10.1097%2f00006324-199106000-00009&partnerID=40&md5=a717e8ef3f783632b1984a1ff423f001 VL - 68 ID - 5296 ER - TY - JOUR AB - A hand-held noncontact tonometer (Pulsair, Keeler Ltd., UK) was tested in 42 children, from 5 months to 12 years of age. At least 1 intraocular pressure (IOP) reading was obtained in all of the 84 eyes studied, whereas with a Goldman applanation tonometer measurements could be obtained in only 26 eyes (14 subjects). Time required for examination with the Pulsair was quite variable and related to age (p < 0.0001). Compliance in children was reported as "good" in the majority of cases; it was also age-related (p < 0.005). Although its reliability could not be definitely evaluated, the results of this study indicate that this instrument may be a valuable choice for screening and follow-up purposes in childhood. AN - WOS:A1991FQ93500009 AU - Buscemi, M. AU - Capoferri, C. AU - Garavaglia, A. AU - Nassivera, C. AU - Nucci, P. DA - JUN DO - 10.1097/00006324-199106000-00009 IS - 6 PY - 1991 SN - 1040-5488 SP - 461-464 ST - NONCONTACT TONOMETRY IN CHILDREN T2 - OPTOMETRY AND VISION SCIENCE TI - NONCONTACT TONOMETRY IN CHILDREN VL - 68 ID - 6202 ER - TY - JOUR AD - Department of Ophthalmology, University of Toronto, Toronto, ON, Canada Department of Ophthalmology, University of Sydney, Sydney, NSW, Australia Athens Institute of Ophthalmology, Athens, Greece Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY, United States AU - Buys, Y. AU - Goldberg, I. AU - Lambrou, G. N. AU - Ritch, R. DB - Scopus DO - 10.1111/j.1442-9071.2008.01677.x IS - 1 M3 - Editorial N1 - Export Date: 19 July 2021 PY - 2008 SP - 6-7 ST - World Glaucoma Day, 6 March 2008: Tackling glaucoma internationally T2 - Clinical and Experimental Ophthalmology TI - World Glaucoma Day, 6 March 2008: Tackling glaucoma internationally UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-39649109432&doi=10.1111%2fj.1442-9071.2008.01677.x&partnerID=40&md5=2d8da165b56fc7cd0571df90e9b89a63 VL - 36 ID - 5768 ER - TY - JOUR AB - Aim: To assess the utilization of eye care services by Australians most likely to benefit from eye assessment. Methods: The Melbourne Visual Impairment Project was a population-based study that collected demographic, health and vision-related information including use of eye care services. A standardized detailed ophthalmic examination was performed. Utilization of eye care services by those who might most benefit from eye care was assessed and compared to the general population. These participants include those with undiagnosed glaucoma, unoperated visually significant cataract, undercorrected refractive error, diabetes mellitus, age-related macular degeneration and visual acuity < 6/12. Sociodemographic characteristics were assessed for their influence on eye care utilization among these participants. Results: A total of 4744 urban and rural residents participated (86% of those eligible) and 4612 (83% of total eligible) of these had a complete data set for the use of eye care services and were included. There were 933 participants (20.2%) who did not report eye assessment in the previous 5 years, and 891 participants (19.3%) had one or more aforementioned conditions potentially benefiting from eye care. Of these, between 34.4% and 59.4% reported no examination in the previous year and between 9% and 25% reported no examination within the previous 5 years. These participants were more likely to seek eye care within the short term (1 year) if they had a family history of eye disease, otherwise a noticed change in vision was the main influence in the longer term (2-5 years). Male participants, younger participants and those whose main spoken language was not English were less likely to seek eye care in the longer term. Conclusions: In Victoria 19% of those >40 years of age have potentially unmanaged eye disease including glaucoma, unoperated visually significant cataract, undercorrected refractive error, age-related macular degeneration, diabetes mellitus or visual acuity < 6/12. A substantial proportion of these report no eye assessment in the previous 1, 2 or 5 years or ever before. Younger age, male sex and main language other than English make assessment less likely. Many may have these conditions despite having had a recent eye assessment. AD - G. Bylsma, 35 Broomfield Avenue, Alphington, Vic. 3078, Australia AU - Bylsma, G. W. AU - Le, A. AU - Mukesh, B. N. AU - Taylor, H. R. AU - McCarty, C. A. DB - Embase Medline DO - 10.1111/j.1442-9071.2004.00905.x IS - 6 KW - adult aged article Australia cataract demography diabetes mellitus eye disease family history female glaucoma health care utilization health service human language major clinical study male ophthalmology patient care refraction error age related macular degeneration rural area sex difference urban area visual acuity LA - English M3 - Article N1 - L40074101 2005-01-24 PY - 2004 SN - 1442-6404 SP - 573-577 ST - Utilization of eye care services by Victorians likely to benefit from eye care T2 - Clinical and Experimental Ophthalmology TI - Utilization of eye care services by Victorians likely to benefit from eye care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40074101&from=export http://dx.doi.org/10.1111/j.1442-9071.2004.00905.x VL - 32 ID - 3717 ER - TY - JOUR AB - Objective Patients with diabetic macular oedema (DME) are known to have significantly greater medical treatment burden than patients with non-DME. Frequent injections and office visits can have a substantial impact on patient adherence and quality of life. This analysis assesses the impact of the 0.19 mg fluocinolone acetonide (FAc) implant (or injection) on treatment burden and practice resource utilisation in patients with DME. Methods and analysis This study is a single-centre retrospective chart review of 30 eyes (23 patients) that received a single FAc implant. Data was collected for a 12-month period pre-injection and post-injection of the FAc implant. Primary outcomes included the frequency of injections and ophthalmology office visits. Secondary outcomes included visual acuity (VA), intraocular pressure (IOP) and central subfield thickness (CSFT). Results The injection frequency significantly decreased from one injection every 2.6 months pre-injection to one injection every 8.8 months post-injection of the FAc implant (p<0.001). Sixty-three percent of the subjects did not require additional injections post-FAc implant. The mean number of ophthalmology office visits significantly decreased from 12.7 visits pre-FAc to 9.3 visits post-FAc implant (p<0.001). The mean VA (p=0.24) and CSFT (p=0.39) showed a mild numerical improvement that was not statistically significant. Thirty-seven percent of the eyes required additional IOP lowering drops. No eyes required incisional glaucoma surgeries. Conclusions The FAc implant significantly decreased the treatment burden and improved practice resource utilisation while maintaining or improving VA and CSFT. IOP events were mostly well-controlled with drops and no eyes required incisional glaucoma surgery. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. AD - Retina, University of Illinois at Chicago, Chicago, IL, United States University Retina and Macula Associates, Oak Forest, IL, United States Retina, Cincinnati Eye Institute, Cincinnati, OH, United States Retina, University of Cincinnati, Cincinnati, OH, United States AU - Byun, M. AU - Osher, J. AU - Riemann, C. D. C7 - e000416 DB - Scopus DO - 10.1136/bmjophth-2019-000416 IS - 1 KW - macula treatment medical vision M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 ST - Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema T2 - BMJ Open Ophthalmology TI - Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083293420&doi=10.1136%2fbmjophth-2019-000416&partnerID=40&md5=659d370071b3246c90d5cce8c783287c VL - 5 ID - 5700 ER - TY - JOUR AB - Objective Patients with diabetic macular oedema (DME) are known to have significantly greater medical treatment burden than patients with non-DME. Frequent injections and office visits can have a substantial impact on patient adherence and quality of life. This analysis assesses the impact of the 0.19 mg fluocinolone acetonide (FAc) implant (or injection) on treatment burden and practice resource utilisation in patients with DME. Methods and analysis This study is a single-centre retrospective chart review of 30 eyes (23 patients) that received a single FAc implant. Data was collected for a 12-month period pre-injection and post-injection of the FAc implant. Primary outcomes included the frequency of injections and ophthalmology office visits. Secondary outcomes included visual acuity (VA), intraocular pressure (IOP) and central subfield thickness (CSFT). Results The injection frequency significantly decreased from one injection every 2.6 months pre-injection to one injection every 8.8 months post-injection of the FAc implant (p<0.001). Sixty-three percent of the subjects did not require additional injections post-FAc implant. The mean number of ophthalmology office visits significantly decreased from 12.7 visits pre-FAc to 9.3 visits post-FAc implant (p<0.001). The mean VA (p=0.24) and CSFT (p=0.39) showed a mild numerical improvement that was not statistically significant. Thirty-seven percent of the eyes required additional IOP lowering drops. No eyes required incisional glaucoma surgeries. Conclusions The FAc implant significantly decreased the treatment burden and improved practice resource utilisation while maintaining or improving VA and CSFT. IOP events were mostly well-controlled with drops and no eyes required incisional glaucoma surgery. AN - WOS:000573861800001 AU - Byun, M. AU - Osher, J. AU - Riemann, C. D. DA - APR 8 DO - 10.1136/bmjophth-2019-000416 IS - 1 PY - 2020 SN - 2397-3269 ST - Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema T2 - BMJ OPEN OPHTHALMOLOGY TI - Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema VL - 5 ID - 6233 ER - TY - JOUR AU - Cakiner-Egilmez, T. DB - Medline IS - 3 KW - antihypertensive agent glaucoma human intraocular pressure medication compliance patient compliance LA - English M3 - Review N1 - L611467491 2016-08-05 PY - 2015 SN - 1060-135X SP - 5-11 ST - Glaucoma Medications Update: How to Improve Compliance and Adherence T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - Glaucoma Medications Update: How to Improve Compliance and Adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611467491&from=export VL - 40 ID - 2806 ER - TY - JOUR AD - T. Cakiner-Egilmez, Boston VA Healthcare System, JP Campus, Ophthalmology Department, United States AU - Cakiner-Egilmez, T. AU - Lara-Smalling, A. DB - Medline IS - 2 KW - antihypertensive agent article drug effect glaucoma human intraocular pressure patient compliance LA - English M3 - Article N1 - L364821644 2012-08-31 PY - 2012 SN - 1060-135X SP - 5-9 ST - Glaucoma medications: How to improve compliance and adherence T2 - Insight - Journal of the American Society of Ophthalmic Registered Nurses TI - Glaucoma medications: How to improve compliance and adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364821644&from=export VL - 37 ID - 3070 ER - TY - JOUR AD - Ophthalmology Department, Boston VA Healthcare System, JP Campus. AN - 107997051. Language: English. Entry Date: 20130405. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Core Nursing AU - Cakiner-Egilmez, Tulay AU - Lara-Smalling, Agueda DA - 2012 Spring DB - ccm DP - EBSCOhost IS - 2 KW - Antihypertensive Agents -- Administration and Dosage Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Medication Compliance Patient Compliance N1 - Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9111431. PMID: NLM22685875. PY - 2012 SN - 1060-135X SP - 5-9; quiz 10 ST - Glaucoma medications. How to improve compliance and adherence T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - Glaucoma medications. How to improve compliance and adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107997051&site=ehost-live&scope=site VL - 37 ID - 4685 ER - TY - JOUR AB - Background: To determine the temperament and character profile of glaucoma patients.Methods: A total of 234 patients (104 with primary open angle glaucoma, and 130 control subjects without any ocular disease) were selected for this prospective, cross-sectional study. All the participants underwent a comprehensive ophthalmological examination, including the best corrected visual acuity, intraocular pressure measurement, gonioscopy, and visual field analysis. All the participants were given the Turkish version of the Temperament and Character Inventory (TCI). The TCI is a self-reported evaluate, with 240 true/false items measuring four domains of temperament; harm avoidance (HA), persistence (PS), novelty seeking (NS), reward dependence (RD), and three domains of character; self-transcendence (ST), cooperativeness (C), self-directedness (SD).Results: The glaucoma patients achieved the higher scores than the controls for the HA and SD dimensions (p < 0.001 and p = 0.033). The glaucoma patients scored lower than the controls for the NS, P and ST dimensions (p < 0.001, p < 0.001 and p = 0.002). There were no differences in the RD and C scores between the patients and the controls (p = 0.944 and p = 0.343). There was no correlation between the duration of illness and the TCI dimensions. Disease severity was positively associated with HA (r = 0,220, p = 0,025) and the anticipatory worry (r = 0.227, p = 0.021) dimension.Conclusions: Glaucoma patients had a different personality profile to healthy individuals. This may affect treatment compliance and is also important when coping with maladaptive patient attitudes. AD - Department of Ophthalmology, Adnan Menderes University Medical Faculty, Merkez Kampus Kepez Mevkii, 09100 Aytepe, Aydın, Turkey Department of Psychiatry, Adnan Menderes University Medical Faculty, Merkez Kampus Kepez Mevkii, 09100 Aytepe, Aydın, Turkey Department of Ophthalmology, Ege University Medical Faculty, Ege Universitesi Tip Fakultesi Hastanesi, 35040 Bornova, Izmir, Turkey Department of Statistic, Adnan Menderes University Medical Faculty, Merkez Kampus Kepez Mevkii, 09100 Aytepe, Aydın, Turkey Department of Ophthalmology, Balıkesir University Medical Faculty, Usak yolu uzeri Cagis yerleskesi, 10145 Balikesir, Turkey AN - 110097003. Language: English. Entry Date: 20160429. Revision Date: 20190308. Publication Type: journal article AU - Çakmak, Harun AU - Altinyazar, Vesile AU - Yilmaz, Suzan Güven AU - Ömürlü, İmran Kurt AU - Kocatürk, Tolga AU - Yazici, Alper AU - Değirmenci, Cumali AU - Dündar, Sema Oruç AU - Ates, Halil DB - ccm DO - 10.1186/s12886-015-0117-9 DP - EBSCOhost IS - 1 KW - Personality Assessment Glaucoma -- Psychosocial Factors Character Temperament Visual Acuity Male Prospective Studies Medication Compliance Female Aged Middle Age Cross Sectional Studies Intraocular Pressure Human Psychological Tests N1 - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Psychiatry/Psychology. Instrumentation: Temperament and Character Inventory (TCI) [Turkish version]. NLM UID: 100967802. PMID: NLM26427803. PY - 2015 SN - 1471-2415 SP - 1-8 ST - The temperament and character personality profile of the glaucoma patient T2 - BMC Ophthalmology TI - The temperament and character personality profile of the glaucoma patient UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110097003&site=ehost-live&scope=site VL - 15 ID - 4309 ER - TY - JOUR AB - Objective To determine the frequency of patient visits in which an unplanned treatment modification was required in chronic patients attending a glaucoma clinic for routine follow-up and to identify the treatment interventions most commonly employed. Design Prospective, cross-sectional study. Participants A total of 630 previously stable patients attending a glaucoma clinic for routine follow-up. Methods This was a single-centre survey of all eligible patients returning to an academic glaucoma clinic. Data regarding whether patients’ visit remained routine or required intervention, which clinical parameter had changed, and any alterations in treatment regimens were studied. Results The percentage of patients found to require a change in management was 20.79% (131 of 630 patients); 16.9% were found to have a cause for change because of glaucoma, and the remaining 4% required intervention because of a nonglaucomatous condition. The most common parameter that changed treatment was intraocular pressure (43.87%), followed by visual fields (21.29%). The frequency of abnormal parameters varied within each subtype of glaucoma. The frequency of treatment changes among those with primary open-angle glaucoma was 22.58% compared with 16.5% of glaucoma suspects, 14% of ocular hypertensives, 32% of pseudoexfoliative glaucoma, and 50% of normal tension glaucoma patients. The most common intervention (32.84%) was a change in antiglaucoma medications. The next most frequent interventions were laser procedures (21.90%) and surgery (16.06%). Conclusions This study suggests that a significant minority of patients attending a glaucoma clinic for a routine appointment require treatment modification. AD - C.M. Birt, M1-302a, 2075 Bayview Avenue, M4N 3M5, Toronto, Ont, Canada AU - Calafati, J. AU - Pradhan, Z. S. AU - Birt, C. M. DB - Embase Medline DO - 10.1016/j.jcjo.2016.05.003 IS - 6 KW - antiglaucoma agent article capsulotomy cataract extraction comparative study controlled study cross-sectional study eye examination follow up glaucoma glaucoma surgery health care utilization human intraocular hypertension intraocular pressure lens implantation low level laser therapy low tension glaucoma major clinical study observational study open angle glaucoma ophthalmic neodymium YAG laser patient referral pharmaceutical care prospective study pseudoexfoliation trabeculectomy treatment planning visual acuity visual field LA - English M3 - Article N1 - L613528652 2016-12-08 2017-02-15 PY - 2016 SN - 1715-3360 0008-4182 SP - 426-430 ST - Frequency of unplanned interventions in patients attending for a presumed routine glaucoma follow-up appointment T2 - Canadian Journal of Ophthalmology TI - Frequency of unplanned interventions in patients attending for a presumed routine glaucoma follow-up appointment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613528652&from=export http://dx.doi.org/10.1016/j.jcjo.2016.05.003 VL - 51 ID - 2692 ER - TY - JOUR AB - Objective: To compare patient adherence and persistence with bimatoprost 0.01%, a new formulation that offers equivalent intraocular pressure-lowering efficacy to bimatoprost 0.03% and improved tolerability, with that of the original bimatoprost 0.03% formulation. Methods: Pharmacy claims from a longitudinal database of prescription and medical claims for >115 million patients were analyzed. Patients with an initial (index) prescription for bimatoprost 0.01% or 0.03% between April and June 2011, and with no claim for ophthalmic prostaglandin or prostamide analogs during the preceding 18 months, were identified. Treatment adherence was expressed as the proportion of days covered (PDC) with study medication over the first 365 days after the index prescription. Treatment persistence over the first 12 months following the index prescription was assessed using Kaplan-Meier analyses, assuming a 30 day grace period for prescription refill. Treatment status (on/off study medication) was determined monthly for 12 months post-index. Results: In total, 6150 patients were assessed for treatment adherence and 7660 for persistence. Adherence was significantly better with bimatoprost 0.01% than bimatoprost 0.03% (mean PDC 0.540 vs. 0.438; p < 0.001). Significantly more patients had high adherence (PDC > 0.80) with bimatoprost 0.01% than 0.03% (29.1% vs. 17.3%; p < 0.001). Persistence was also significantly better with bimatoprost 0.01%, with 29.5% (95% confidence interval [CI]: 28.3%, 30.8%) versus 18.3% (95% CI: 16.8%, 19.9%) of patients remaining on continuous treatment for 12 months (p < 0.001). At 12 months, significantly more patients were 'on treatment' (continuing/restarting treatment) with bimatoprost 0.01% than 0.03% (48.8% vs. 33.9%; p < 0.001). Sensitivity analyses demonstrated similar findings in cohorts of ocular hypotensive treatment-naïve and elderly (≥65 years) patients. Conclusions: Bimatoprost 0.01% offers adherence and persistency advantages over bimatoprost 0.03% in patients requiring ocular hypotensive therapy. Study limitations included the observational design, lack of control for imbalances in patient characteristics, and assumption that prescription refill is synonymous with medication use. © 2013 Informa UK Ltd. AD - Allergan Inc., 2525 Dupont Drive, MI3-450A, Irvine, CA 92612-1599, United States Greater Baltimore Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States Principled Strategies Inc., Encinitas, CA, United States AU - Campbell, J. H. AU - Schwartz, G. AU - Labounty, B. AU - Kowalski, J. AU - Patel, V. D. DB - Scopus DO - 10.1185/03007995.2013.815160 IS - 9 KW - Adherence ocular Bimatoprost Hypotensive Persistence Prostamide agonist Treatment compliance M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2013 SP - 1201-1209 ST - Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions T2 - Current Medical Research and Opinion TI - Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882765889&doi=10.1185%2f03007995.2013.815160&partnerID=40&md5=a273c930dd3cc69b1888a58c3dbab3c3 VL - 29 ID - 5254 ER - TY - JOUR AB - Background: Effective control of intraocular pressure is predicated upon patient compliance with pharmacotherapy. We compared patient adherence and persistence with two new ocular hypotensive formulations, using real-world utilization data. Methods: This observational cohort study employed pharmacy claims data from the Source® Lx (Wolters Kluwer Pharma Solutions) database. Patients with an initial (index) prescription for topical bimatoprost 0.01% or travoprost Z (April to June 2011) and no claim for ophthalmic prostaglandin or prostamide analogs within the previous 18 months were identified. Treatment adherence was expressed as proportion of days covered with study medication during the first 365 days after the index prescription. Treatment persistence with study medication was assessed over the first 12 months using Kaplan-Meier survival analyses, allowing a maximum 30-day gap for prescription refill. Treatment status was determined monthly over this period.Results: A total of 12,985 patients were assessed for treatment adherence, and 10,470 for t{stroke}reatment persistence. Adherence was better with bimatoprost 0.01% than with travoprost Z (mean proportion of days covered 0.540 versus [vs] 0.486, P,0.001), and more patients showed high adherence (proportion of days covered.0.80) with bimatoprost 0.01% than travoprost Z (29.1% vs 22.3%, P,0.001). Continuous 12-month persistence was higher with bimatoprost 0.01% than with travoprost Z (29.5% vs 24.2%, P,0.001). At month 12, more patients were on treatment with bimatoprost 0.01% than travoprost Z (48.8% vs 45.7%, P,0.01). Similar findings were demonstrated in cohorts of ocular hypotensive treatment-naïve patients, branded latanoprost switchers, and older patients (age $65 years), and after inclusion of patient characteristics as covariates. Conclusion: For patients with glaucoma or ocular hypertension, bimatoprost 0.01% offers compliance advantages over travoprost Z. © 2014 Campbell et al. AD - J. H. Campbell, Global Health Outcomes Strategy and Research, Allergan, Inc, 2525 Dupont Drive - MI3-450A, Irvine, CA 92612-1599, United States AU - Campbell, J. H. AU - Schwartz, G. F. AU - Labounty, B. AU - Kowalski, J. W. AU - Patel, V. D. C1 - lumigan(Allergan,United States) travatan z(Alcon,United States) C2 - Alcon(United States) Allergan(United States) DB - Embase DO - 10.2147/OPTH.S49467 KW - bimatoprost latanoprost travoprost travoprost Z unclassified drug adolescent adult aged article child cross-sectional study drug substitution drug utilization drug withdrawal female follow up glaucoma human intraocular hypertension intraocular pressure major clinical study male medical procedures observational study patient attitude patient compliance prescription school child topical ocular hypotensive therapy treatment duration very elderly lumigan travatan z LA - English M3 - Article N1 - L373103632 2014-05-27 2014-06-10 PY - 2014 SN - 1177-5483 1177-5467 SP - 927-935 ST - Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: A comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions T2 - Clinical Ophthalmology TI - Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: A comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373103632&from=export http://dx.doi.org/10.2147/OPTH.S49467 VL - 8 ID - 2882 ER - TY - JOUR AB - Background: Effective control of intraocular pressure is predicated upon patient compliance with pharmacotherapy. We compared patient adherence and persistence with two new ocular hypotensive formulations, using real-world utilization data. Methods: This observational cohort study employed pharmacy claims data from the Source® Lx (Wolters Kluwer Pharma Solutions) database. Patients with an initial (index) prescription for topical bimatoprost 0.01% or travoprost Z (April to June 2011) and no claim for ophthalmic prostaglandin or prostamide analogs within the previous 18 months were identified. Treatment adherence was expressed as proportion of days covered with study medication during the first 365 days after the index prescription. Treatment persistence with study medication was assessed over the first 12 months using Kaplan-Meier survival analyses, allowing a maximum 30-day gap for prescription refill. Treatment status was determined monthly over this period.Results: A total of 12,985 patients were assessed for treatment adherence, and 10,470 for t{stroke}reatment persistence. Adherence was better with bimatoprost 0.01% than with travoprost Z (mean proportion of days covered 0.540 versus [vs] 0.486, P,0.001), and more patients showed high adherence (proportion of days covered.0.80) with bimatoprost 0.01% than travoprost Z (29.1% vs 22.3%, P,0.001). Continuous 12-month persistence was higher with bimatoprost 0.01% than with travoprost Z (29.5% vs 24.2%, P,0.001). At month 12, more patients were on treatment with bimatoprost 0.01% than travoprost Z (48.8% vs 45.7%, P,0.01). Similar findings were demonstrated in cohorts of ocular hypotensive treatment-naïve patients, branded latanoprost switchers, and older patients (age $65 years), and after inclusion of patient characteristics as covariates. Conclusion: For patients with glaucoma or ocular hypertension, bimatoprost 0.01% offers compliance advantages over travoprost Z. © 2014 Campbell et al. AD - Allergan, Inc, Irvine, CA, United States Greater Baltimore Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States Principled Strategies, Inc, Encinitas, CA, United States AU - Campbell, J. H. AU - Schwartz, G. F. AU - Labounty, B. AU - Kowalski, J. W. AU - Patel, V. D. DB - Scopus DO - 10.2147/OPTH.S49467 KW - Bimatoprost Ocular hypotensive Travoprost Treatment compliance M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2014 SP - 927-935 ST - Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: A comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions T2 - Clinical Ophthalmology TI - Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: A comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84900799739&doi=10.2147%2fOPTH.S49467&partnerID=40&md5=87e8122815f79537c15de03da757f9bb VL - 8 ID - 5234 ER - TY - JOUR AB - Purpose To evaluate the impact of surgeon practice profile on clinic-based glaucoma care. Design Population-based study of glaucoma care patterns in Ontario, Canada from 2000-2010. Methods Using comprehensive physician services data from the Ontario Health Insurance Plan database, ophthalmologists were divided into 5 surgical practice subgroups. The role of each subgroup in the provision of glaucoma care was evaluated. Consultations and office visits were used to assess nonsurgical care, while laser trabeculoplasty procedures were used to assess clinic-based procedural care. Results Between 2000 and 2010, the population rate of glaucoma consultations and follow-up visits provided by ophthalmologists who do not perform incisional glaucoma surgery increased at average annual rates of 1.6% (P <.0002) and 3.3% (P <.0001), respectively. In contrast, no significant growth in the rate of glaucoma consultations or follow-up visits provided by glaucoma surgeons was observed (0.8%/year [P =.2] for consultations; 0.2%/year [P =.6] for follow-up visits). Between 2000 and 2010, the rate of laser trabeculoplasty procedures provided by ophthalmologists who do not perform incisional glaucoma surgery increased 19.3% annually (P <.0001), while growth among glaucoma surgeons was more modest (annual growth of 9.2% [P =.0002]). Conclusions While subspecialization is a growing reality in most areas of medicine, we found that the provision of clinic-based glaucoma care remains dependent on ophthalmologists who do not perform incisional glaucoma surgery. With increasing focus on integrated care, these findings will have important implications for residency education programs and their accrediting bodies and will inform decisions of health care policymakers, hospitals, and academic departments. AD - R.J. Campbell, Department of Ophthalmology, Queen's University, Hotel Dieu Hospital, 166 Brock Street, Kingston, ON K7L 5G2, Canada AU - Campbell, R. J. AU - Bell, C. M. AU - Gill, S. S. AU - Whitehead, M. AU - Campbell, E. D. L. P. AU - Xu, K. AU - El-Defrawy, S. R. DB - Embase Medline DO - 10.1016/j.ajo.2013.11.019 IS - 3 KW - ambulatory care article Canada consultation follow up glaucoma glaucoma surgery health service human laser ophthalmologist patient care priority journal retrospective study surgeon trabeculoplasty LA - English M3 - Article N1 - L372405620 2014-02-27 2014-03-03 PY - 2014 SN - 0002-9394 1879-1891 SP - 631-639.e2 ST - Clinic-based glaucoma care in the era of surgical subspecialization T2 - American Journal of Ophthalmology TI - Clinic-based glaucoma care in the era of surgical subspecialization UR - https://www.embase.com/search/results?subaction=viewrecord&id=L372405620&from=export http://dx.doi.org/10.1016/j.ajo.2013.11.019 VL - 157 ID - 2893 ER - TY - JOUR AD - Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada; Department of Ophthalmology, Hotel Dieu and Kingston General Hospitals, Kingston, Ontario, Canada; Institute for Clinical Evaluative Sciences - Queen's University Site, Queen's University, Kingston, Ontario, Canada. Electronic address: rob.campbell@queensu.ca. Institute for Clinical Evaluative Sciences - Sunnybrook Site, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. Division of Geriatric Medicine, Queen's University, Kingston, Ontario, Canada; Institute for Clinical Evaluative Sciences - Queen's University Site, Queen's University, Kingston, Ontario, Canada; Division of Geriatric Medicine, St. Mary's of the Lake Hospital, Kingston, Ontario, Canada. Institute for Clinical Evaluative Sciences - Queen's University Site, Queen's University, Kingston, Ontario, Canada; Queen's University, Kingston, Ontario, Canada. Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada; Department of Ophthalmology, Hotel Dieu and Kingston General Hospitals, Kingston, Ontario, Canada. Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada; Department of Ophthalmology, Kensington Eye Institute, Toronto, Ontario, Canada. AN - 104026103. Language: English. Entry Date: 20140509. Revision Date: 20200708. Publication Type: Journal Article AU - Campbell, Robert J. AU - Bell, Chaim M. AU - Gill, Sudeep S. AU - Whitehead, Marlo AU - Campbell, Erica de L. P. AU - Xu, Kunyong AU - El-Defrawy, Sherif R. DB - ccm DO - 10.1016/j.ajo.2013.11.019 DP - EBSCOhost IS - 3 KW - Glaucoma -- Surgery Health Care Delivery -- Statistics and Numerical Data Ophthalmology -- Statistics and Numerical Data Practice Patterns -- Statistics and Numerical Data Eye Surgery -- Statistics and Numerical Data Antihypertensive Agents -- Therapeutic Use Human Intraocular Pressure Laser Therapy -- Statistics and Numerical Data Office Visits Ontario Referral and Consultation Retrospective Design Specialties, Surgical N1 - research. Journal Subset: Biomedical; USA. NLM UID: 0370500. PMID: NLM24321471. PY - 2014 SN - 0002-9394 SP - 631-639.e2 ST - Clinic-based glaucoma care in the era of surgical subspecialization T2 - American Journal of Ophthalmology TI - Clinic-based glaucoma care in the era of surgical subspecialization UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104026103&site=ehost-live&scope=site VL - 157 ID - 4697 ER - TY - JOUR AB - Objective. To estimate the prevalence of blindness and visual impairment among adults in Peru and to determine their causes, to evaluate the coverage and quality of the cataract surgical services and to investigate the barriers that inhibit access to these services. Methods. A cross-sectional population study with two-stage random cluster sampling of individuals of ≥ 50 years old, representative of the entire country, using the standard methodology of the Rapid Assessment of Avoidable Blindness. Visual acuity was assessed and the condition of the lens and posterior pole examined by direct ophthalmoscopy. Cataract surgical coverage was calculated. Its quality, as well as the causes of visual acuity < 20/60 and the barriers to accessing surgical treatment were assessed. Results. A total of 4 849 people were examined. Blindness prevalence was 2.0% (confidence interval of 95%: 1.5-2.5%). The main causes of blindness were cataract (58.0%), glaucoma (13.7%) and age-related macular degeneration (11.5%). Uncorrected refraction errors were the principal cause of moderate visual impairment (67.2%). Cataract surgical coverage was 66.9%. 60.5% of the eyes operated for cataracts achieved a visual acuity ≥ 20/60 with available correction. The main barriers to cataract surgery were the high cost (25.9%) and people being unaware that treatment was possible (23.8%). Conclusions. The prevalence of blindness and visual impairment in Peru is similar to that of other Latin American countries. Given the low cataract surgical coverage and the aging of the population, access to the services could be improved by increasing the population education on eye health and the response capacity of the ophthalmological and cataract surgical services, and by reducing the costs of the latter. AD - Instituto Nacional de Oftalmología, Lima, Perú Asociación Divino Niño Jesús, Lima, Perú Visión 2020, Agencia Internacional para la Prevención de la Ceguera, México, D.F., México Organización Panamericana de la Salud, Bogotá, Colombia Health Information Services, Grootebroek, Países Bajos AN - 103748507. Language: Spanish. Entry Date: 20150128. Revision Date: 20150710. Publication Type: Journal Article AU - Campos, Betty AU - Cerrate, Amelia AU - Montjoy, Enrique AU - Dulanto Gomero, Víctor AU - Gonzales, César AU - Tecse, Aldo AU - Pariamachi, Andrés AU - Lansingh, Van C. AU - Dulanto Reinoso, Víctor AU - Minaya Barba, Jean AU - Carlos Silva, Juan AU - Limburg, Hans DB - ccm DO - dx.doi.org/S1020-49892014001000001 DP - EBSCOhost IS - 5 KW - Blindness -- Epidemiology -- Peru Prevalence Blindness -- Etiology -- Peru Vision Disorders -- Epidemiology -- Peru Human Cross Sectional Studies Descriptive Statistics Peru Confidence Intervals Middle Age Visual Acuity Cataract Extraction -- Economics -- Peru Male Female Aged Aged, 80 and Over N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; Public Health; USA. Special Interest: Public Health. NLM UID: 9705400. PMID: NLM25604097. PY - 2014 SN - 1020-4989 SP - 283-289 ST - National survey on the prevalence and causes of blindness in Peru T2 - Revista Panamericana de Salud Pública TI - National survey on the prevalence and causes of blindness in Peru UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103748507&site=ehost-live&scope=site VL - 36 ID - 4474 ER - TY - JOUR AB - Purpose: To review the role of intervisit intraocular pressure (IOP) fluctuation as an independent risk factor for glaucoma.Design: Perspective after literature review.Methods: Analysis of pertinent publications in the peer-reviewed literature.Results: Disparate findings regarding the role of intervisit IOP variation have been published. IOP variation was a significant risk factor in the Advanced Glaucoma Intervention Study (AGIS), the Collaborative Initial Glaucoma Treatment Study, and other smaller studies. These studies have in common low IOPs (often after surgery) and moderately advanced disease. In the AGIS, when patients were stratified by mean IOP, only those patients with low IOPs showed the detrimental effects of IOP variation. IOP variation was not a significant risk factor in the Early Manifest Glaucoma Treatment Trial, and in 2 separate studies of ocular hypertensives. These studies have in common generally higher IOPs and an earlier stage of glaucoma (or no glaucoma at all). We believe these results are complementary rather than contradictory: existing data suggest that the effects of IOP variation depend on the characteristics of the patient, the baseline IOP, their stage of damage, the type of glaucoma, and other as-yet unknown factors.Conclusions: Practitioners should consider whether patients who are progressing at low mean IOP may benefit from having IOP variation reduced. Single elevated measures of IOP may not be an anomaly or may not be related to compliance, but may identify patients who are at high risk for progressive glaucomatous damage, and thus should be monitored more carefully and potentially treated more aggressively. AD - Jules Stein Eye Institute, The David Geffen School of Medicine, Los Angeles, California Doheny Eye Institute, University of Southern California, Los Angeles, California Jules Stein Eye Institute, The David Geffen School of Medicine, Los Angeles, California. AN - 104672884. Language: English. Entry Date: 20111021. Revision Date: 20200708. Publication Type: journal article AU - Caprioli, J. AU - Varma, R. AU - Caprioli, Joseph AU - Varma, Rohit DB - ccm DO - 10.1016/j.ajo.2011.05.029 DP - EBSCOhost IS - 3 KW - Glaucoma -- Drug Therapy Glaucoma -- Physiopathology Intraocular Pressure -- Drug Effects Antihypertensive Agents -- Therapeutic Use Intraocular Pressure -- Physiology Risk Factors Tonometry Vision Disorders -- Physiopathology Visual Acuity -- Physiology N1 - review. Journal Subset: Biomedical; USA. NLM UID: 0370500. PMID: NLM21855671. PY - 2011 SN - 0002-9394 SP - 340-344.e2 ST - Intraocular pressure: modulation as treatment for glaucoma T2 - American Journal of Ophthalmology TI - Intraocular pressure: modulation as treatment for glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104672884&site=ehost-live&scope=site VL - 152 ID - 4788 ER - TY - JOUR AB - The economic costs of age-related ocular diseases and vision loss are increasing rapidly as our society ages. In addition to the direct costs of treating age-related eye diseases, elderly persons with vision loss are at significantly increased risk for falls and fractures, experiencing social isolation, and suffering from an array of comorbid medical conditions compared with individuals with normal vision. Recent studies estimate the total economic burden (direct and indirect costs) of adult vision impairment in the United States at $51.4 billion. This figure is expected to increase as the baby boomer generation continues to age. While a number of highly effective new therapies have caused a paradigm shift in the management of several major age-related ocular diseases in recent years, these treatments come at a substantial cost. This article reviews the economic burdens and treatment-related costs of 4 major ocular diseases of aging - glaucoma, age-related macular degeneration, diabetic retinopathy, and dry eye disease - and the implications for managed care. AD - W.J. Cardarelli, Atrius Health/Harvard Vanguard Medical Associates, Watertown, MA, United States AU - Cardarelli, W. J. AU - Smith, R. A. DB - Embase Medline IS - 5 SUPPL. KW - aflibercept artificial tear bevacizumab cyclosporine latanoprost prostaglandin ranibizumab triamcinolone vasculotropin awareness baby boomer comorbidity cost control cost effectiveness analysis diabetic macular edema diabetic retinopathy diseases dry eye early intervention eye disease Food and Drug Administration glaucoma health care cost health care policy health insurance health service home health agency human intraocular pressure job performance managed care managed care organization medical care medicare medication compliance nursing home open angle glaucoma optical coherence tomography patient patient compliance photodynamic therapy prescription priority journal productivity quality adjusted life year reimbursement age related macular degeneration retrospective study review social isolation symptom United States visual acuity visual disorder visual impairment LA - English M3 - Review N1 - L373644015 2014-08-07 2014-08-15 PY - 2013 SN - 1088-0224 SP - S85-S91 ST - Managed care implications of age-related ocular conditions T2 - American Journal of Managed Care TI - Managed care implications of age-related ocular conditions UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373644015&from=export VL - 19 ID - 3040 ER - TY - JOUR AB - Chronic glucocorticoid (GC) therapy is associated with an increased risk of developing cataracts and glaucoma, and recommendations have been developed for monitoring these side effects in patients with rheumatic diseases. The aim of this study was to assess the prevalence of cataracts and glaucoma and the adherence to the existing recommendations for monitoring eye toxicity of chronic GC therapy among systemic lupus erythematosus (SLE) patients in routine clinical practice. Clinical charts of 170 patients were examined, and 34 (20 %) of them never underwent an eye assessment. The remaining 136 underwent an eye assessment with an interval of 75 ± 61.7 months. Only 45 (33 %) had received an evaluation during the previous 12 months. All these 170 patients were taking chronic CG therapy at a mean daily dose of 5.4 ± 2.4 mg prednisone and a mean cumulative dose of 27.6 ± 20.5 g. Out of the 136 patients with at least one eye assessment, cataracts were observed in 39 patients (29 %) and glaucoma in 4 patients (3 %). Cataracts were diagnosed at a mean age of 46.5 ± 10 years; the development of cataracts was associated with age, disease duration, and cumulative GC dose. Glaucoma was diagnosed at a mean age of 40.5 ± 16 years; due to the small number of patients, no correlations were made. The prevalence of cataracts and glaucoma is higher than in the general population, and these conditions occur early in the life of SLE patients. An association between GC and cataracts is confirmed. The adherence to recommendations is suboptimal as only 33 % of patients underwent an eye assessment over the previous 12 months. These data reinforce the need to improve adherence to recommendations for eye monitoring among SLE patients under chronic therapy with GC. © 2013 Clinical Rheumatology. AD - Rheumatology Unit, University of Pisa, Via Roma, 67, 56126 Pisa, Italy Clinical Immunology Unit, University of Pisa, Pisa, Italy AU - Carli, L. AU - Tani, C. AU - Querci, F. AU - Della Rossa, A. AU - Vagnani, S. AU - Baldini, C. AU - Talarico, R. AU - D'Ascanio, A. AU - Neri, R. AU - Tavoni, A. G. AU - Bombardieri, S. AU - Mosca, M. DB - Scopus DO - 10.1007/s10067-013-2214-6 IS - 7 KW - Cataracts Glaucoma Monitoring Recommendations Systemic lupus erythematosus M3 - Conference Paper N1 - Cited By :22 Export Date: 19 July 2021 PY - 2013 SP - 1071-1073 ST - Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity T2 - Clinical Rheumatology TI - Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880151347&doi=10.1007%2fs10067-013-2214-6&partnerID=40&md5=9071bd57451884eeec0ddd9fec88658e VL - 32 ID - 5123 ER - TY - JOUR AB - Purpose: Medication self-efficacy, or patients' confidence that they can perform medication-related behaviors, is associated with better glaucoma medication adherence. Little is known about how to enhance glaucoma patients' medication self-efficacy. Our purpose is to examine whether patient-provider communication increases glaucoma patients' medication self-efficacy.Methods: During an 8-month cohort study of 279 glaucoma patients and 15 providers, two office visits were videotape-recorded, transcribed, and coded for six patient-provider communication behaviors. A validated scale was used at baseline and 8-month follow-up to assess patients' confidence in overcoming adherence barriers (adherence barriers self-efficacy) and carrying out tasks to use eye drops correctly (eye drop task self-efficacy). We ran two generalized estimating equations to examine whether more frequent patient-provider communication during office visits predicted increased patient adherence barriers self-efficacy and eye drop task self-efficacy at 8-month follow-up.Results: For each additional topic providers educated about, patients reported an average increase of 0.35 in self-efficacy in overcoming adherence barriers (p < 0.001). Patients also reported an average increase of 1.01 points in eye drop task self-efficacy when providers asked about patients' views of glaucoma and its treatment versus not (p < 0.001). Patients who asked more medication questions (p < 0.001) and African-American patients (p < 0.05) reported lower adherence barriers self-efficacy by 0.30 and 2.15 points, respectively. Women had a 0.63 lower eye drop task self-efficacy than men (p < 0.05).Conclusions: When providers educate glaucoma patients and assess patient views about glaucoma and its treatment, patients report higher medication self-efficacy. Providers should be aware that patients who ask more medication questions may have less confidence in their ability to overcome barriers to adherence. AD - *PhD, MSPH †PhD, MPH ‡PharmD §MD ∥PhD Division of Pharmaceutical Outcomes and Policy (DMC), University of North Carolina at Chapel Hill, Asheville Satellite Campus, Asheville, North Carolina; Division of Pharmaceutical Outcomes and Policy (SJB, BLS), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; School of Medicine (RS), Stanford University, Stanford, California; Duke University School of Medicine & Durham VA Medical Center (KWM), Durham, North Carolina; Wilmer Institute and Bloomberg School of Public Health (ALR), Johns Hopkins University, Baltimore, Maryland; Department of Ophthalmology (ALR), University of Maryland, College Park, Maryland; John A. Moran Eye Center (MEH), University of Utah, Salt Lake City, Utah; School of Medicine (ALG), Emory University, Atlanta, Georgia; and Department of Mathematics and Statistics (GET), Husson University, Bangor, Maine AN - 116332383. Language: English. Entry Date: 20180726. Revision Date: 20191223. Publication Type: journal article AU - Carpenter, Delesha M. AU - Blalock, Susan J. AU - Sayner, Robyn AU - Muir, Kelly W. AU - Robin, Alan L. AU - Hartnett, Mary Elizabeth AU - Giangiacomo, Annette L. AU - Tudor, Gail E. AU - Sleath, Betsy L. DB - ccm DO - 10.1097/OPX.0000000000000856 DP - EBSCOhost IS - 7 KW - Patient Education -- Methods Communication -- Methods Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Physician-Patient Relations Medication Compliance Female Human Ophthalmic Solutions Self-Efficacy Male Prospective Studies Young Adult Aged Middle Age Aged, 80 and Over Adult Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: R56 EY015130/EY/NEI NIH HHS/United States. NLM UID: 8904931. PMID: NLM27003815. PY - 2016 SN - 1040-5488 SP - 731-737 ST - Communication Predicts Medication Self-Efficacy in Glaucoma Patients T2 - Optometry & Vision Science TI - Communication Predicts Medication Self-Efficacy in Glaucoma Patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116332383&site=ehost-live&scope=site VL - 93 ID - 4141 ER - TY - JOUR AB - Purpose. Medication self-efficacy, or patients' confidence that they can perform medication-related behaviors, is associated with better glaucoma medication adherence. Little is known about how to enhance glaucoma patients' medication self-efficacy. Our purpose is to examine whether patient-provider communication increases glaucoma patients' medication self-efficacy. Methods. During an 8-month cohort study of 279 glaucoma patients and 15 providers, two office visits were videotaperecorded, transcribed, and coded for six patient-provider communication behaviors. Avalidated scale was used at baseline and 8-month follow-up to assess patients' confidence in overcoming adherence barriers (adherence barriers self-efficacy) and carrying out tasks to use eye drops correctly (eye drop task self-efficacy).We ran two generalized estimating equations to examine whether more frequent patient-provider communication during office visits predicted increased patient adherence barriers self-efficacy and eye drop task self-efficacy at 8-month follow-up. Results. For each additional topic providers educated about, patients reported an average increase of 0.35 in self-efficacy in overcoming adherence barriers (p < 0.001). Patients also reported an average increase of 1.01 points in eye drop task selfefficacy when providers asked about patients' views of glaucoma and its treatment versus not (p < 0.001). Patients who asked more medication questions (p < 0.001) and African-American patients (p < 0.05) reported lower adherence barriers self-efficacy by 0.30 and 2.15 points, respectively.Women had a 0.63 lower eye drop task self-efficacy than men (p < 0.05). Conclusions. When providers educate glaucoma patients and assess patient views about glaucoma and its treatment, patients report higher medication self-efficacy. Providers should be aware that patients who ask more medication questions may have less confidence in their ability to overcome barriers to adherence. Copyright © 2016 American Academy of Optometry. AD - Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Asheville Satellite Campus, Asheville, NC, United States Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States School of Medicine, Stanford University, Stanford, CA, United States Duke University School of Medicine, Durham VA Medical Center, Durham, NC, United States Wilmer Institute, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States Department of Ophthalmology, University of Maryland, College Park, MD, United States John A. Moran Eye Center, University of Utah, Salt Lake City, UT, United States School of Medicine, Emory University, Atlanta, GA, United States Department of Mathematics and Statistics (GET), Husson University, Bangor, ME, United States AU - Carpenter, D. M. AU - Blalock, S. J. AU - Sayner, R. AU - Muir, K. W. AU - Robin, A. L. AU - Hartnett, M. E. AU - Giangiacomo, A. L. AU - Tudor, G. E. AU - Sleath, B. L. DB - Scopus DO - 10.1097/OPX.0000000000000856 IS - 7 KW - Eye drop technique Glaucoma Medication adherence Patient-provider communication Self-efficacy M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 SP - 731-737 ST - Communication predicts medication self-efficacy in glaucoma patients T2 - Optometry and Vision Science TI - Communication predicts medication self-efficacy in glaucoma patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978010258&doi=10.1097%2fOPX.0000000000000856&partnerID=40&md5=c140da865e6ec77e23d0cdc61eab46b9 VL - 93 ID - 5351 ER - TY - JOUR AB - Purpose Medication self-efficacy, or patients' confidence that they can perform medication-related behaviors, is associated with better glaucoma medication adherence. Little is known about how to enhance glaucoma patients' medication self-efficacy. Our purpose is to examine whether patient-provider communication increases glaucoma patients' medication self-efficacy. Methods During an 8-month cohort study of 279 glaucoma patients and 15 providers, two office visits were videotape-recorded, transcribed, and coded for six patient-provider communication behaviors. A validated scale was used at baseline and 8-month follow-up to assess patients' confidence in overcoming adherence barriers (adherence barriers self-efficacy) and carrying out tasks to use eye drops correctly (eye drop task self-efficacy). We ran two generalized estimating equations to examine whether more frequent patient-provider communication during office visits predicted increased patient adherence barriers self-efficacy and eye drop task self-efficacy at 8-month follow-up. Results For each additional topic providers educated about, patients reported an average increase of 0.35 in self-efficacy in overcoming adherence barriers (p < 0.001). Patients also reported an average increase of 1.01 points in eye drop task self-efficacy when providers asked about patients' views of glaucoma and its treatment versus not (p < 0.001). Patients who asked more medication questions (p < 0.001) and African-American patients (p < 0.05) reported lower adherence barriers self-efficacy by 0.30 and 2.15 points, respectively. Women had a 0.63 lower eye drop task self-efficacy than men (p < 0.05). Conclusions When providers educate glaucoma patients and assess patient views about glaucoma and its treatment, patients report higher medication self-efficacy. Providers should be aware that patients who ask more medication questions may have less confidence in their ability to overcome barriers to adherence. AN - WOS:000380241300010 AU - Carpenter, D. M. AU - Blalock, S. J. AU - Sayner, R. AU - Muir, K. W. AU - Robin, A. L. AU - Hartnett, M. E. AU - Giangiacomo, A. L. AU - Tudor, G. E. AU - Sleath, B. L. DA - JUL DO - 10.1097/OPX.0000000000000856 IS - 7 PY - 2016 SN - 1040-5488 1538-9235 SP - 731-737 ST - Communication Predicts Medication Self-Efficacy in Glaucoma Patients T2 - OPTOMETRY AND VISION SCIENCE TI - Communication Predicts Medication Self-Efficacy in Glaucoma Patients VL - 93 ID - 5876 ER - TY - JOUR AB - Education about how to administer eye drops may improve a patient’s ability to instill his or her eye drops correctly. Our objectives were to (a) document the methods providers use to educate glaucoma patients about eye drop technique; (b) determine whether eye drop technique education varies by provider and patient characteristics; and (c) evaluate whether education predicts improved patient technique. We conducted an 8-month longitudinal study of 279 glaucoma patients and 15 providers in which we recorded on videotape the content of glaucoma office visits at two time points (baseline and 4- to 6-week follow-up) and videotaped patient eye drop technique at three time points (baseline, 4- to 6-week follow-up, and 8-month follow-up). Mann–Whitney rank sum tests were used to determine whether education was associated with improved patient eye drop technique over time. Ninety-four patients (34%) received technique education at either visit; 31% received verbal education and 10% received a technique demonstration. Only 24 patients (47%) who were new to eye drops received technique education at the baseline visit. Patients who were new to drops at baseline (p = .008) and patients who asked a question about drops (p < .001) were more likely to receive technique education. Education was not associated with improved technique. Eye drop technique education occurs infrequently during glaucoma office visits. Future studies should compare the effectiveness of different educational methods, such as patient demonstration versus provider verbal instruction, to determine which method is best at improving patient eye drop technique. © 2016 Taylor & Francis. AD - Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, United States School of Medicine, Stanford University, United States School of Medicine, Duke University, United States John A. Moran Eye Center, University of Utah, United States Kittner Eye Center, University of North Carolina, United States School of Medicine, Emory University, United States Department of Mathematics and Statistics, Husson University, United States Wilmer Institute and Bloomberg School of Public Health, Johns Hopkins University, and Department of Ophthalmology, University of Maryland, United States AU - Carpenter, D. M. AU - Sayner, R. AU - Blalock, S. J. AU - Muir, K. W. AU - Hartnett, M. E. AU - Lawrence, S. D. AU - Giangiacomo, A. L. AU - Goldsmith, J. A. AU - Tudor, G. E. AU - Robin, A. L. AU - Sleath, B. L. DB - Scopus DO - 10.1080/10410236.2015.1020263 IS - 8 M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 SP - 1036-1042 ST - The Effect of Eye Drop Technique Education in Patients With Glaucoma T2 - Health Communication TI - The Effect of Eye Drop Technique Education in Patients With Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84954183117&doi=10.1080%2f10410236.2015.1020263&partnerID=40&md5=a575d7fdda1e8be6df7b1d4a13ae017b VL - 31 ID - 5349 ER - TY - JOUR AB - Education about how to administer eye drops may improve a patient's ability to instill his or her eye drops correctly. Our objectives were to (a) document the methods providers use to educate glaucoma patients about eye drop technique; (b) determine whether eye drop technique education varies by provider and patient characteristics; and (c) evaluate whether education predicts improved patient technique. We conducted an 8-month longitudinal study of 279 glaucoma patients and 15 providers in which we recorded on videotape the content of glaucoma office visits at two time points (baseline and 4- to 6-week follow-up) and videotaped patient eye drop technique at three time points (baseline, 4- to 6-week follow-up, and 8-month follow-up). Mann-Whitney rank sum tests were used to determine whether education was associated with improved patient eye drop technique over time. Ninety-four patients (34%) received technique education at either visit; 31% received verbal education and 10% received a technique demonstration. Only 24 patients (47%) who were new to eye drops received technique education at the baseline visit. Patients who were new to drops at baseline (p = .008) and patients who asked a question about drops (p < .001) were more likely to receive technique education. Education was not associated with improved technique. Eye drop technique education occurs infrequently during glaucoma office visits. Future studies should compare the effectiveness of different educational methods, such as patient demonstration versus provider verbal instruction, to determine which method is best at improving patient eye drop technique. AN - WOS:000377295600013 AU - Carpenter, D. M. AU - Sayner, R. AU - Blalock, S. J. AU - Muir, K. W. AU - Hartnett, M. E. AU - Lawrence, S. D. AU - Giangiacomo, A. L. AU - Goldsmith, J. A. AU - Tudor, G. E. AU - Robin, A. L. AU - Sleath, B. L. DA - AUG DO - 10.1080/10410236.2015.1020263 IS - 8 PY - 2016 SN - 1041-0236 1532-7027 SP - 1036-1042 ST - The Effect of Eye Drop Technique Education in Patients With Glaucoma T2 - HEALTH COMMUNICATION TI - The Effect of Eye Drop Technique Education in Patients With Glaucoma VL - 31 ID - 5858 ER - TY - JOUR AB - Objective: We examined whether six patient-provider communication behaviors directly affected the intraocular pressure (IOP) of glaucoma patients or whether patient medication adherence and eye drop technique mediated the relationship between self-efficacy, communication, and IOP.Methods: During an 8-month, longitudinal study of 279 glaucoma patients and 15 providers, two office visits were videotape-recorded, transcribed, and coded for six patient-provider communication behaviors. Medication adherence was measured electronically and IOP was extracted from medical records. We ran generalized estimating equations to examine the direct effects of communication on IOP and used bootstrapping to test whether medication adherence and eye drop technique mediated the effect of communication on IOP.Results: Provider education about medication adherence (B=-0.50, p<0.05) and inclusion of patient input into the treatment plan (B=-0.35, p<0.05) predicted improved IOP. There was no evidence of significant mediation.Conclusion: The positive effects of provider education and provider inclusion of patient input in the treatment plan were not mediated by adherence and eye drop technique.Practice Implications: Providers should educate glaucoma patients about the importance of medication adherence and include patient input into their treatment plan. AD - Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Asheville, USA Department of Mathematics and Statistics, Husson University, Bangor, USA School of Medicine, Stanford University, Stanford, CA, USA School of Medicine, Duke University, & Durham VA Medical Center, Durham, USA Wilmer Institute and Bloomberg School of Public Health; Johns Hopkins University, & University of Maryland, Baltimore, MD, USA Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, USA John A. Moran Eye Center, University of Utah, Salt Lake City, USA School of Medicine, Emory University, Atlanta, USA AN - 110942343. Language: English. Entry Date: 20180904. Revision Date: 20200308. Publication Type: journal article AU - Carpenter, Delesha M. AU - Tudor, Gail E. AU - Sayner, Robyn AU - Muir, Kelly W. AU - Robin, Alan L. AU - Blalock, Susan J. AU - Hartnett, Mary Elizabeth AU - Giangiacomo, Annette L. AU - Sleath, Betsy L. DB - ccm DO - 10.1016/j.pec.2015.07.001 DP - EBSCOhost IS - 12 KW - Physician-Patient Relations Patient Education Intraocular Pressure -- Evaluation Glaucoma Human Videorecording Communication Medication Compliance Prospective Studies Ophthalmic Solutions Funding Source N1 - research. Journal Subset: Core Nursing; Europe; Health Promotion/Education; Nursing; Peer Reviewed; UK & Ireland. Grant Information: R56 EY015130/EY/NEI NIH HHS/United States. NLM UID: 8406280. PMID: NLM26223851. PY - 2015 SN - 0738-3991 SP - 1558-1567 ST - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients T2 - Patient Education & Counseling TI - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110942343&site=ehost-live&scope=site VL - 98 ID - 4303 ER - TY - JOUR AB - Objective: We examined whether six patient-provider communication behaviors directly affected the intraocular pressure (IOP) of glaucoma patients or whether patient medication adherence and eye drop technique mediated the relationship between self-efficacy, communication, and IOP. Methods: During an 8-month, longitudinal study of 279 glaucoma patients and 15 providers, two office visits were videotape-recorded, transcribed, and coded for six patient-provider communication behaviors. Medication adherence was measured electronically and IOP was extracted from medical records. We ran generalized estimating equations to examine the direct effects of communication on IOP and used bootstrapping to test whether medication adherence and eye drop technique mediated the effect of communication on IOP. Results: Provider education about medication adherence (B = −0.50, p < 0.05) and inclusion of patient input into the treatment plan (B = −0.35, p < 0.05) predicted improved IOP. There was no evidence of significant mediation. Conclusion: The positive effects of provider education and provider inclusion of patient input in the treatment plan were not mediated by adherence and eye drop technique. Practice Implications: Providers should educate glaucoma patients about the importance of medication adherence and include patient input into their treatment plan. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Carpenter, Delesha M., Eshelman School of Pharmacy University of North Carolina, CPO 2125, Asheville, NC, US, 28804 AN - 2015-34655-001 AU - Carpenter, Delesha M. AU - Tudor, Gail E. AU - Sayner, Robyn AU - Muir, Kelly W. AU - Robin, Alan L. AU - Blalock, Susan J. AU - Hartnett, Mary Elizabeth AU - Giangiacomo, Annette L. AU - Sleath, Betsy L. DB - psyh DO - 10.1016/j.pec.2015.07.001 DP - EBSCOhost IS - 12 KW - Glaucoma Patient-provider communication Medication adherence Eye drop technique Mediation analysis Drug Therapy Physical Treatment Methods Treatment Compliance Self-Efficacy Therapeutic Processes N1 - Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Asheville, NC, US. Release Date: 20150803. Correction Date: 20201005. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Glaucoma; Physical Treatment Methods; Treatment Compliance. Minor Descriptor: Self-Efficacy; Therapeutic Processes. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Mental Status Questionnaire; Glaucoma Medication Self-Efficacy Questionnaire. Methodology: Empirical Study; Followup Study; Longitudinal Study; Interview; Mathematical Model; Quantitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Dec, 2015. Publication History: Accepted Date: Jul 1, 2015; Revised Date: May 13, 2015; First Submitted Date: Jan 12, 2015. Copyright Statement: All rights reserved. Elsevier Ireland Ltd. 2015. Sponsor: National Eye Institute, US. Grant: EY018400. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Center for Research Resources, US. Grant: 1UL1TR001111. Recipients: No recipient indicated Sponsor: National Institutes of Health, US. Grant: EY015130; EY017011. Recipients: No recipient indicated PY - 2015 SN - 0738-3991 1873-5134 SP - 1558-1567 ST - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients T2 - Patient Education and Counseling TI - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-34655-001&site=ehost-live&scope=site ORCID: 0000-0003-2025-8140 dmcarpenter@unc.edu VL - 98 ID - 4829 ER - TY - JOUR AB - Objective: We examined whether six patient-provider communication behaviors directly affected the intraocular pressure (IOP) of glaucoma patients or whether patient medication adherence and eye drop technique mediated the relationship between self-efficacy, communication, and IOP. Methods: During an 8-month, longitudinal study of 279 glaucoma patients and 15 providers, two office visits were videotape-recorded, transcribed, and coded for six patient-provider communication behaviors. Medication adherence was measured electronically and IOP was extracted from medical records. We ran generalized estimating equations to examine the direct effects of communication on IOP and used bootstrapping to test whether medication adherence and eye drop technique mediated the effect of communication on IOP. Results: Provider education about medication adherence (B = -0.50, p< 0.05) and inclusion of patient input into the treatment plan (B = -0.35, p < 0.05) predicted improved IOP. There was no evidence of significant mediation. Conclusion: The positive effects of provider education and provider inclusion of patient input in the treatment plan were not mediated by adherence and eye drop technique. Practice Implications: Providers should educate glaucoma patients about the importance of medication adherence and include patient input into their treatment plan. © 2015 Elsevier Ireland Ltd. AD - Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Asheville, United States Department of Mathematics and Statistics, Husson University, Bangor, United States School of Medicine, Stanford University, Stanford, CA, United States School of Medicine, Duke University, Durham VA Medical Center, Durham, United States Wilmer Institute and Bloomberg School of Public Health, Johns Hopkins University, University of Maryland, Baltimore, MD, United States Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States John A. Moran Eye Center, University of Utah, Salt Lake City, United States School of Medicine, Emory University, Atlanta, United States AU - Carpenter, D. M. AU - Tudor, G. E. AU - Sayner, R. AU - Muir, K. W. AU - Robin, A. L. AU - Blalock, S. J. AU - Hartnett, M. E. AU - Giangiacomo, A. L. AU - Sleath, B. L. DB - Scopus DO - 10.1016/j.pec.2015.07.001 IS - 12 KW - Eye drop technique Glaucoma Mediation analysis Medication adherence Patient-provider communication M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2015 SP - 1558-1567 ST - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients T2 - Patient Education and Counseling TI - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84947493773&doi=10.1016%2fj.pec.2015.07.001&partnerID=40&md5=b3a03900cfeb703441118429e876a36b VL - 98 ID - 5382 ER - TY - JOUR AB - Objective: We examined whether six patient-provider communication behaviors directly affected the intraocular pressure (IOP) of glaucoma patients or whether patient medication adherence and eye drop technique mediated the relationship between self-efficacy, communication, and IOP. Methods: During an 8-month, longitudinal study of 279 glaucoma patients and 15 providers, two office visits were videotape-recorded, transcribed, and coded for six patient-provider communication behaviors. Medication adherence was measured electronically and IOP was extracted from medical records. We ran generalized estimating equations to examine the direct effects of communication on IOP and used bootstrapping to test whether medication adherence and eye drop technique mediated the effect of communication on IOP. Results: Provider education about medication adherence (B = -0.50, p < 0.05) and inclusion of patient input into the treatment plan (B = -0.35, p < 0.05) predicted improved IOP. There was no evidence of significant mediation. Conclusion: The positive effects of provider education and provider inclusion of patient input in the treatment plan were not mediated by adherence and eye drop technique. Practice Implications: Providers should educate glaucoma patients about the importance of medication adherence and include patient input into their treatment plan. (C) 2015 Elsevier Ireland Ltd. All rights reserved. AN - WOS:000368332400011 AU - Carpenter, D. M. AU - Tudor, G. E. AU - Sayner, R. AU - Muir, K. W. AU - Robin, A. L. AU - Blalock, S. J. AU - Hartnett, M. E. AU - Giangiacomo, A. L. AU - Sleath, B. L. DA - DEC DO - 10.1016/j.pec.2015.07.001 IS - 12 PY - 2015 SN - 0738-3991 SP - 1558-1567 ST - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients T2 - PATIENT EDUCATION AND COUNSELING TI - Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients VL - 98 ID - 6020 ER - TY - JOUR AB - PURPOSE:: To report the beneficial properties of subconjunctival amphotericin B as an adjunctive therapy in patients with severe fungal keratitis. METHODS:: Case reports and review of medical literature. Four patients with advanced fungal keratitis were treated with repeated injections of subconjunctival amphotericin B in addition to topical and systemic antifungal treatment. RESULTS:: Two to 8 injections were given to each patient. All patients showed rapid clinical improvement after the injections. No serious adverse effects were observed. However, all patients experienced pain during the injections. CONCLUSIONS:: Subconjunctival injections of amphotericin B are useful as an adjunctive treatment of advanced fungal keratitis. This treatment assures compliance and may be an alternative to avoid a surgical intervention in an acute stage of advanced fungal keratitis. More cases are needed to validate our findings. Copyright © 2011 by Lippincott Williams & Wilkins. AD - M. A. Carrasco, Sarmiento 1326, Luzuriaga M5516BGH Mendoza, Argentina AU - Carrasco, M. A. AU - Genesoni, G. C1 - anfotericina b northia(northia,Argentina) C2 - northia(Argentina) DB - Embase Medline DO - 10.1097/ICO.0b013e3181fb826d IS - 5 KW - aciclovir amikacin amphotericin B anfotericina b northia antifungal agent ceftazidime ciprofloxacin corticosteroid dexamethasone fluconazole gatifloxacin natamycin unclassified drug vancomycin adjuvant therapy adult aged article case report disease severity female human injection site pain keratitis keratomycosis male medical literature patient compliance priority journal repeated drug dose treatment outcome visual acuity LA - English M3 - Article N1 - L51167641 2010-11-30 2011-05-06 PY - 2011 SN - 0277-3740 1536-4798 SP - 608-611 ST - Treatment of severe fungal keratitis with subconjunctival Amphotericin B T2 - Cornea TI - Treatment of severe fungal keratitis with subconjunctival Amphotericin B UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51167641&from=export http://dx.doi.org/10.1097/ICO.0b013e3181fb826d VL - 30 ID - 3178 ER - TY - JOUR AB - Purpose: To assess the ocular hypotensive effect of 15-keto fluprostenol, the oxidized metabolite of travoprost, on glaucoma patients, through a randomized double-masked placebo-controlled study. Methods: Twelve patients with ocular normal tension glaucoma (NTG) (intraocular pressure [IOP] < 22 mmHg) were enrolled. In order to ensure patient compliance to treatment, all study subjects were hospitalized. In each patient, the eye to be submitted to the treatments was randomly chosen. After hospital admission (day 1), those patients received for 5 days at 8 P.M. either one drop of 15-keto fluprostenol (35 μg/ml) or one drop of placebo. IOP evaluation was performed within 8 A.M. and 8 P.M. for 6 days. Furthermore, we performed a determination of cardiovascular parameters before and after the treatments. Results: Starting with the first IOP measurement after the first treatment (8 A.M. on day 2), IOP was reduced of about 14% in the eyes treated 15-keto fluprostenol, in comparison with baseline IOP values of 15-keto fluprostenol-treated patients. The IOP reduction in the 15-keto fluprostenol-treated group was significantly compared to placebo group (p < 0.05) starting from day 3 till day 6 of the study. Except for mild hyperemia in one 15-keto fluprostenol-treated eye, no other side effects were observed or reported by the enrolled patients. Conclusions: The travoprost metabolite 15-keto fluprostenol was effective in decrease IOP and maintained IOP reduction along 5 days of treatment. The 15-keto fluprostenol can be developed as a good candidate for once-a-day NTG patients’ treatment. AD - C. Caruso, Corneal Transplant Center, Pellegrini Hospital, Via Portamedina alla Pignasecca 41, Naples, Italy AU - Caruso, C. AU - Pacente, L. AU - Troiano, P. AU - Ostacolo, C. AU - D’Andrea, L. AU - Bartollino, S. AU - Costagliola, C. DB - Embase Medline DO - 10.1007/s10792-019-01243-0 IS - 4 KW - eye drops fluprostenol placebo adult aged article cardiovascular parameters clinical article controlled study evening dosage female hospital admission hospitalization human hyperemia intraocular pressure low tension glaucoma male patient compliance pilot study randomized controlled trial therapy effect treatment duration LA - English M3 - Article N1 - L2003785782 2019-12-12 PY - 2020 SN - 1573-2630 0165-5701 SP - 823-831 ST - Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients T2 - International Ophthalmology TI - Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003785782&from=export http://dx.doi.org/10.1007/s10792-019-01243-0 VL - 40 ID - 2416 ER - TY - JOUR AB - Aims - To determine the visual outcome and complications of lens aspiration with intraocular lens implantation in children aged 5 years and under. Methods - The hospital notes of all children aged 5 years and under, who had undergone lens aspiration with intraocular lens implantation between January 1994 and September 1998, and for whom follow up data of at least 1 year were available, were reviewed. Results - Of 50 children who underwent surgery, 45 were eligible based on the follow up criteria. 34 children had bilateral cataracts and, of these, 30 had surgery on both eyes. Cataract was unilateral in 11 cases; thus, 75 eyes of 45 children had surgery. Cataracts were congenital in 28 cases, juvenile in 16, and traumatic in one case. The median age at surgery was 39 months (range 11-70 months). Follow up ranged from 12-64 months (median 36 months). Of 34 children with bilateral disease, 25 (73.5%) had a final best corrected visual acuity of 6/12 or better, while seven (20.5%) achieved 6/18 or less; in one child the vision improved from UCUSUM to CSM but another, who had only one eye operated on, was unable to fix or follow with this eye preoperatively or 2 years postoperatively. Of 11 children with unilateral cataract, five (45.5%) had a final best corrected visual of 6/12 or better, and six (54.5%) 6/18 or less. A mild fibrinous uveitis occurred in 20 (28.2%) eyes in the immediate postoperative period, but resolved with topical steroids. One child had a vitreous wick postoperatively requiring surgical division. Glaucoma, endophthalmitis, or retinal detachment have not been observed so far in any patient postoperatively. Conclusion - From this series the authors suggest that, in children aged 5 years and under, lens aspiration with intraocular lens implantation is a safe procedure, with a good visual outcome in the short term. Further studies are needed to investigate these outcomes in the long term. AD - Department of Ophthalmology, Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3JH, United Kingdom Department of Paediatric Epidemiology, Institute of Child Health, Guilford Street, London, United Kingdom AU - Cassidy, L. AU - Rahi, J. AU - Nischal, K. AU - Russell-Eggitt, I. AU - Taylor, D. DB - Scopus DO - 10.1136/bjo.85.5.540 IS - 5 M3 - Article N1 - Cited By :22 Export Date: 19 July 2021 PY - 2001 SP - 540-542 ST - Outcome of lens aspiration and intraocular lens implantation in children aged 5 years and under T2 - British Journal of Ophthalmology TI - Outcome of lens aspiration and intraocular lens implantation in children aged 5 years and under UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035033179&doi=10.1136%2fbjo.85.5.540&partnerID=40&md5=88f6aa8c628a12a72f624311903eb442 VL - 85 ID - 5129 ER - TY - JOUR AB - To evaluate compliance with diagnostic and therapeutic recommendations of the European Glaucoma Society (EGS) for the management of glaucoma in Spain, as determined using the Achievable Benchmarks of Care approach. A panel of 3 experts extracted quality and process-of-care indicators from the EGS guidelines. Investigators from all over the country, representative of Spanish ophthalmologists, were invited to participate in the study, completing a questionnaire on quality indicators (pertaining to the center) and process-of-care indicators (pertaining to all patients) for the first, diagnostic visit (retrospective) and the study visit. A total of 495 Spanish ophthalmologists included 5,060 patients with glaucoma or intraocular hypertension. The treatment was initiated with monotherapy in 88.5% of the patients. Overall, the percentage compliance with diagnostic examinations was 84.6% for intraocular pressure measurement, 96.3% for optic nerve head evaluation, 76.6% for visual field evaluation, 29.5% for central corneal thickness evaluation, and 49.3% at the study visit. The benchmark performance was close to 100% for most examinations. Only 32.8% of the centres had a written protocol for the management of the patients with glaucoma, and in these centers the recommendations of the EGS were followed in a higher proportion (p<0.0001) than in the rest. The use of local protocols for the management of glaucoma seems to enhance compliance. Benchmark performance was close to 100% in most indicators, suggesting that EGS recommendations are attainable in Spain. The overall performance suggests that certain diagnostic procedures are, in practice, not as widely used as recommended. AD - Ophthalmology Department, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. AU - Castejón-Cervero, M. A. AU - Jiménez-Parras, R. AU - Fernandez-Arias, I. AU - Teus-Guezala, M. A. AU - Group, Imca Study DB - Scopus DO - 10.5301/ejo.2010.5973 IS - 2 M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2011 SP - 149-155 ST - Evaluation of compliance with the EGS guidelines in Spain, using Achievable Benchmarks of Care (ABC®) methodology: the IMCA Study T2 - European journal of ophthalmology TI - Evaluation of compliance with the EGS guidelines in Spain, using Achievable Benchmarks of Care (ABC®) methodology: the IMCA Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955683975&doi=10.5301%2fejo.2010.5973&partnerID=40&md5=d4a4bb4127b0571787f9c6fa05fb254e VL - 21 ID - 5334 ER - TY - JOUR AB - PURPOSE. To evaluate compliance with diagnostic and therapeutic recommendations of the European Glaucoma Society (EGS) for the management of glaucoma in Spain, as determined using the Achievable Benchmarks of Care approach. METHODS. A panel of 3 experts extracted quality and process-of-care indicators from the EGS guidelines. Investigators from all over the country, representative of Spanish ophthalmologists, were invited to participate in the study, completing a questionnaire on quality indicators (pertaining to the center) and process-of-care indicators (pertaining to all patients) for the first, diagnostic visit (retrospective) and the study visit. RESULTS. A total of 495 Spanish ophthalmologists included 5,060 patients with glaucoma or intraocular hypertension. The treatment was initiated with monotherapy in 88.5% of the patients. Overall, the percentage compliance with diagnostic examinations was 84.6% for intraocular pressure measurement, 96.3% for optic nerve head evaluation, 76.6% for visual field evaluation, 29.5% for central corneal thickness evaluation, and 49.3% at the study visit. The benchmark performance was close to 100% for most examinations. Only 32.8% of the centres had a written protocol for the management of the patients with glaucoma, and in these centers the recommendations of the EGS were followed in a higher proportion (p < 0.0001) than in the rest. CONCLUSIONS. The use of local protocols for the management of glaucoma seems to enhance compliance. Benchmark performance was close to 100% in most indicators, suggesting that EGS recommendations are attainable in Spain. The overall performance suggests that certain diagnostic procedures are, in practice, not as widely used as recommended. AN - WOS:000290347300005 AU - Castejon-Cervero, M. A. AU - Jimenez-Parras, R. AU - Fernandez-Arias, I. AU - Teus-Guezala, M. A. AU - Grp, Imca Study DA - MAR-APR DO - 10.5301/EJO.2010.5973 IS - 2 PY - 2011 SN - 1120-6721 SP - 149-155 ST - Evaluation of compliance with the EGS Guidelines in Spain, using Achievable Benchmarks of Care (ABC (R)) methodology: The IMCA Study T2 - EUROPEAN JOURNAL OF OPHTHALMOLOGY TI - Evaluation of compliance with the EGS Guidelines in Spain, using Achievable Benchmarks of Care (ABC (R)) methodology: The IMCA Study VL - 21 ID - 5997 ER - TY - JOUR AB - Background: Primary open-angle glaucoma is a leading cause of irreversible blindness. Objectives: To identify factors associated with adherence to glaucoma pharmacotherapy in the primary care setting, focusing on physicians’ role. Methods: Patients were recruited from primary care clinics and telephone-interviewed using a structured questionnaire that addressed patient-, medication-, environment- and physicians-related factors. Patients’ data on pharmacy claims were retrieved to calculate the medication possession ratio for measuring adherence. Results: Seven hundred thirty-eight glaucoma patients were interviewed. The multivariate analysis identified eight variables that were associated independently with adherence. Barriers to adherence were found to be low income, believing that ‘It makes no difference to my vision whether I take the drops or not’ and relying on someone else for drop instillation (exp(B) = 1.91, P = 0.002; exp(B) = 2.61, P < 0.0001; exp(B) = 2.17, P = 0.001, respectively). Older age, having a glaucoma patient among close acquaintances, taking a higher number of drops per day, taking a prostaglandin drug and reporting that the ophthalmologist had discussed the importance of taking eye drops as prescribed, were found to promote adherence (exp(B) = 0.96, P < 0.0001; exp(B) = 0.54, P = 0.014; exp(B) = 0.81, P = 0.001; exp(B) = 0.37, P < 0.0001; exp(B) = 0.60, P = 0.034, respectively). No association was found between the patient’s relationship with the family physician and adherence to glaucoma treatment. Conclusion: Adherence to glaucoma pharmacotherapy is associated with patient-related, medication-related, physician-related and environmental factors. Ophthalmologists have a significant role in promoting adherence. However, the potential role of family physicians is unfulfilled and unrecognized. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Castel, Orit Cohen, Division of Family Medicine, Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 4 Hasport Street, Haifa, Israel, 347402 AN - 2014-30875-011 AU - Castel, Orit Cohen AU - Keinan-Boker, Lital AU - Geyer, Orna AU - Milman, Uzi AU - Karkabi, Khaled DB - psyh DO - 10.1093/fampra/cmu031 DP - EBSCOhost IS - 4 KW - Doctor patient relationship family physicians glaucoma patient adherence primary care Drug Therapy Psychotherapeutic Processes Treatment Compliance Patients Primary Health Care N1 - Division of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel. Release Date: 20141027. Correction Date: 20190107. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Glaucoma; Psychotherapeutic Processes; Treatment Compliance. Minor Descriptor: Family Physicians; Patients; Primary Health Care. Classification: Vision & Hearing & Sensory Disorders (3299); Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: Israel. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Tests & Measures: Structured Questionnaire. Methodology: Empirical Study; Interview; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Aug, 2014. Publication History: First Posted Date: Jun 12, 2014; Accepted Date: May 7, 2014; Revised Date: Apr 25, 2014; First Submitted Date: Oct 23, 2013. Copyright Statement: Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. The Author. 2014. Sponsor: Clalit Health Services. Grant: CLALIT-HPR-21. Recipients: No recipient indicated PY - 2014 SN - 0263-2136 1460-2229 SP - 453-461 ST - Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting T2 - Family Practice TI - Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-30875-011&site=ehost-live&scope=site hforitco@gmail.com VL - 31 ID - 4823 ER - TY - JOUR AB - Background: Primary open-angle glaucoma is a leading cause of irreversible blindness. Objectives: To identify factors associated with adherence to glaucoma pharmacotherapy in the primary care setting, focusing on physicians' role. Methods: Patients were recruited from primary care clinics and telephone-interviewed using a structured questionnaire that addressed patient-, medication-, environment- and physiciansrelated factors. Patients' data on pharmacy claims were retrieved to calculate the medication possession ratio for measuring adherence. Results: Seven hundred thirty-eight glaucoma patients were interviewed. The multivariate analysis identified eight variables that were associated independently with adherence. Barriers to adherence were found to be low income, believing that 'It makes no difference to my vision whether I take the drops or not' and relying on someone else for drop instillation (exp(B) = 1.91, P = 0.002; exp(B) = 2.61, P < 0.0001; exp(B) = 2.17, P = 0.001, respectively). Older age, having a glaucoma patient among close acquaintances, taking a higher number of drops per day, taking a prostaglandin drug and reporting that the ophthalmologist had discussed the importance of taking eye drops as prescribed, were found to promote adherence (exp(B) = 0.96, P < 0.0001; exp(B) = 0.54, P = 0.014; exp(B) = 0.81, P = 0.001; exp(B) = 0.37, P < 0.0001; exp(B) = 0.60, P = 0.034, respectively). No association was found between the patient's relationship with the family physician and adherence to glaucoma treatment. Conclusion: Adherence to glaucoma pharmacotherapy is associated with patient-related, medicationrelated, physician-related and environmental factors. Ophthalmologists have a significant role in promoting adherence. However, the potential role of family physicians is unfulfilled and unrecognized. © The Author 2014. Published by Oxford University Press. AD - O.C. Castel, Division of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 4 Hasport street, Haifa 347402, Israel AU - Castel, O. C. AU - Keinan-Boker, L. AU - Geyer, O. AU - Milmana, U. AU - Karkabi, K. DB - Embase Medline DO - 10.1093/fampra/cmu031 IS - 4 KW - alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor dorzolamide plus timolol eye drops latanoprost plus timolol pilocarpine prostaglandin timolol adult aged article cross-sectional study daily life activity doctor patient relationship environmental factor female general practitioner glaucoma health status human lowest income group major clinical study male medication compliance ophthalmologist patient compliance prescription primary medical care self report social status structured questionnaire telephone interview vision LA - English M3 - Article N1 - L373610826 2014-08-01 2014-08-05 PY - 2014 SN - 1460-2229 0263-2136 ST - Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting T2 - Family Practice TI - Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373610826&from=export http://dx.doi.org/10.1093/fampra/cmu031 VL - 31 ID - 2914 ER - TY - JOUR AB - INTRODUCTION: The treatment of glaucoma is made initially with the use of eyedrops, with the purpose to decrease intraocular pressure and to minimize the damages to the optic nerve. The lack of compliance with drug therapy can be influenced by factors related to patients, doctors and medicines. PURPOSES: To estimate the rate of noncompliance with the treatment with antiglaucoma eyedrops and to verify the intervenience of possible factors for noncompliance. METHODS: A study of the transversal type was carried out, in the Ophthalmologic Clinic of the Hospital Governador Israel Pinheiro, in Belo Horizonte, Minas Gerais. Questionnaires were applied to 102 glaucoma patients to collect information about the level of noncompliance and the intervenience of possible factors for noncompliance with drug therapy. RESULTS: The rate of noncompliance was 21.5%. The factors: not using the eyedrops due to money shortage (p=0.035) and accomplishment of corrective surgery (p=0.049), significantly contributed to noncompliance. CONCLUSION: More than one fifth of the glaucoma patients does not follow the drug treatment in an adequate way. Donation of eyedrops to all the glaucoma patients without favorable economic conditions, governmental actions for the reduction of the prices of the eyedrops, information on the continuity of the use of the eyedrops after the accomplishment of corrective surgeries would help to decrease the rates of noncompliance. AD - A.N. Castro, Clínica Oftalmológica do Hospital Israel Pinheiro, Instituto de Previdência dos Servidores de Minas Gerais, Belo Horizonte, MG, Brasil. AU - Castro, A. N. AU - Mesquita, W. A. DB - Medline IS - 2 KW - eye drops timolol adult aged article cross-sectional study female glaucoma human male middle aged patient compliance psychological aspect questionnaire risk factor socioeconomics statistics LA - Portuguese M3 - Article N1 - L550080597 2009-01-16 PY - 2008 SN - 0004-2749 SP - 207-214 ST - Noncompliance with drug therapy for glaucoma T2 - Arquivos brasileiros de oftalmologia TI - Noncompliance with drug therapy for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L550080597&from=export VL - 71 ID - 3471 ER - TY - JOUR AB - Background: Improving adherence to ocular hypertension (OH)/glaucoma therapy is highly likely to prevent or reduce progression of optic nerve damage. The present study used a behaviour change counselling intervention to determine whether education and support was beneficial and cost-effective in improving adherence with glaucoma therapy.Methods: A randomised controlled trial with a 13-month recruitment and 8-month follow-up period was conducted. Patients with OH/glaucoma attending a glaucoma clinic and starting treatment with travoprost were approached. Participants were randomised into two groups and adherence was measured over 8 months, using an electronic monitoring device (Travalert® dosing aid, TDA). The control group received standard clinical care, and the intervention group received a novel glaucoma education and motivational support package using behaviour change counselling. Cost-effectiveness framework analysis was used to estimate any potential cost benefit of improving adherence.Results: Two hundred and eight patients were recruited (102 intervention, 106 control). No significant difference in mean adherence over the monitoring period was identified with 77.2% (CI, 73.0, 81.4) for the control group and 74.8% (CI, 69.7, 79.9) for the intervention group (p = 0.47). Similarly, there was no significant difference in percentage intraocular pressure reduction; 27.6% (CI, 23.5, 31.7) for the control group and 25.3% (CI, 21.06, 29.54) for the intervention group (p = 0.45). Participants in the intervention group were more satisfied with information about glaucoma medication with a mean score of 14.47/17 (CI, 13.85, 15.0) compared with control group which was 8.51 (CI, 7.72, 9.30). The mean intervention cost per patient was GB£10.35 (= 30% from baseline IOP with medication burden reduction from preoperative levels, success probability was 5.4% at 1.5 years. For success defined as medication burden reduction with an IOP reaching goal IOP as determined by the glaucoma specialist, success probabilities were 67.2% at 1.5 years and 29.4% at 2.5 years. At the last follow-up visit, eyes with two MIGS procedures with different mechanisms of action achieved successful medication reduction 68.8% of the time versus 35.7% achieved by a single MIGS procedure (p=0.052). At their last visit, visual acuity was unchanged or improved in all eyes (100%). MIGS with cataract surgery results in modest reductions in IOP and medication burden in NTG patients, which may lead to lower costs and better therapeutic compliance. A combination of two MIGS procedures with different mechanisms of action may potentially be more effective in reducing medication burden than a single MIGS procedure in NTG patients. Further research is necessary to ascertain whether MIGS for NTG patients may help decrease medication burden while helping achieve goal IOP. AN - WOS:000647144000004 AU - Chang, E. K. AU - Gupta, S. AU - Chachanidze, M. AU - Hall, N. AU - Chang, T. C. AU - Sola-Del Valle, D. DA - APR 26 DO - 10.1038/s41598-021-88358-6 IS - 1 PY - 2021 SN - 2045-2322 ST - Safety and efficacy of microinvasive glaucoma surgery with cataract extraction in patients with normal-tension glaucoma T2 - SCIENTIFIC REPORTS TI - Safety and efficacy of microinvasive glaucoma surgery with cataract extraction in patients with normal-tension glaucoma VL - 11 ID - 6025 ER - TY - JOUR AB - A multi-site, open-labeled clinical trial was conducted to evaluate the ease of use and acceptance of a newly developed medication cap with a memory aid (C Cap(TM) Compliance Cap, Allergan, Inc.) and its effect on patient compliance and intraocular pressure. One-hundred-twenty-two patients with glaucoma or ocular hypertension received their prescribed eye drops in bottles with the compliance cap. Overall, 83% of the patients found the compliance cap very easy to use. By the end of the study, significantly more patients (67%) claimed 100% compliance than prior to using the compliance cap (41%). An overall drop in intraocular pressure of 0.8 mm Hg was seen. However, in a subset of patients who reported an increase in compliance, mean intraocular pressure decreased from baseline by 1.7 mm Hg. The results of this study suggest that the compliance cap helps patients with glaucoma or ocular hypertension remember to take their medication as prescribed. AD - Jules Stein Eye Institute, UCLA School of Medicine, 100 Stein Plaza, Los Angeles, CA 90024 AU - Chang Jr, J. S. AU - Lee, D. A. AU - Petursson, G. AU - Spaeth, G. AU - Zimmerman, T. J. AU - Hoskins, H. D. AU - Mills, R. AU - Brown, R. AU - Kass, M. AU - Lue, J. DB - Embase Medline IS - 2 KW - dipivefrine levobunolol pilocarpine adolescent adult article clinical trial female glaucoma human intraocular pressure major clinical study male patient compliance LA - English M3 - Article N1 - L21283857 1991-10-24 PY - 1991 SN - 8756-3320 SP - 117-124 ST - The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure T2 - Journal of Ocular Pharmacology TI - The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure UR - https://www.embase.com/search/results?subaction=viewrecord&id=L21283857&from=export VL - 7 ID - 4035 ER - TY - JOUR AB - Background: To investigate the risk factors and probability of blindness in patients treated for glaucoma. Methods: The study design was a retrospective, hospital-based, clinical chart, review study. Medical records were reviewed from patients seen between January 2003 and December 2003 at the Kaohsiung Chang Gung Memorial Hospital eye clinic, who had been diagnosed with glaucoma in 1986 or later and who had been treated for at least 2 years for glaucoma. Results: A total of 186 charts were reviewed, which included 66 patients who were blind in at least one eye from glaucoma on presentation. A total of 172 patients and 290 eyes were followed-up for a mean duration of 10.6 ± 4.67 years. Twenty seven patients and 31 eyes developed blindness from glaucoma during follow-up. The Kaplan-Meier survival estimate at 16 years was 28.6% for glaucoma-related blindness in at least one eye. A worse visual field on presentation, older age, and poor compliance during therapy were significantly associated with the development of blindness. Glaucoma type, a gender difference, systemic disease, greater intraocular pressure fluctuation in the last year of therapy and blindness in one eye on presentation did not show a significant relationship with the rate of development of blindness. Conclusion: Blindness from treated glaucoma is considerable. Our results gave a 28.6% probability of blindness at 16 years in at least one eye. An older age, poor compliance and a worse visual field on presentation were significant risk factors. AD - M.-C. Teng, Department of Ophthalmology, Chang Gung Memorial Hospital, No. 123, Dabi Rd., Niausung Shiang, Kaohsiung 833, Taiwan AU - Chang, L. C. AU - Teng, M. C. AU - Chang, H. W. AU - Lai, I. C. AU - Lin, P. W. AU - Tsai, J. C. DB - Embase Medline IS - 7 KW - adult aged blindness controlled study female follow up glaucoma human intraocular pressure major clinical study male optic nerve lesion patient compliance probability retrospective study review risk factor sex difference survival visual acuity visual field LA - English M3 - Review N1 - L41277332 2005-10-02 PY - 2005 SN - 0255-8270 SP - 492-497 ST - The probability of blindness in patients treated for glaucoma T2 - Chang Gung Medical Journal TI - The probability of blindness in patients treated for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41277332&from=export VL - 28 ID - 3680 ER - TY - JOUR AB - Background: To investigate the risk factors and probability of blindness in patients treated for glaucoma. Methods: The study design was a retrospective, hospital-based, clinical chart, review study. Medical records were reviewed from patients seen between January 2003 and December 2003 at the Kaohsiung Chang Gung Memorial Hospital eye clinic, who had been diagnosed with glaucoma in 1986 or later and who had been treated for at least 2 years for glaucoma. Results: A total of 186 charts were reviewed, which included 66 patients who were blind in at least one eye from glaucoma on presentation. A total of 172 patients and 290 eyes were followed-up for a mean duration of 10.6 ± 4.67 years. Twenty seven patients and 31 eyes developed blindness from glaucoma during follow-up. The Kaplan-Meier survival estimate at 16 years was 28.6% for glaucoma-related blindness in at least one eye. A worse visual field on presentation, older age, and poor compliance during therapy were significantly associated with the development of blindness. Glaucoma type, a gender difference, systemic disease, greater intraocular pressure fluctuation in the last year of therapy and blindness in one eye on presentation did not show a significant relationship with the rate of development of blindness. Conclusion: Blindness from treated glaucoma is considerable. Our results gave a 28.6% probability of blindness at 16 years in at least one eye. An older age, poor compliance and a worse visual field on presentation were significant risk factors. AD - Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan Chang Gung University, Medical College, Taoyuan, Taiwan Department of Biological Science, National Sun Yat Sen University, Taiwan Department of Ophthalmology, Chang Gung Memorial Hospital, No. 123, Dabi Rd., Niausung Shiang, Kaohsiung 833, Taiwan AU - Chang, L. C. AU - Teng, M. C. AU - Chang, H. W. AU - Lai, I. C. AU - Lin, P. W. AU - Tsai, J. C. DB - Scopus IS - 7 KW - Blindness Glaucoma Intraocular pressure M3 - Review N1 - Cited By :5 Export Date: 19 July 2021 PY - 2005 SP - 492-497 ST - The probability of blindness in patients treated for glaucoma T2 - Chang Gung Medical Journal TI - The probability of blindness in patients treated for glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-24644486440&partnerID=40&md5=8bbd44bcadfb2e44c770e311b1e63a14 VL - 28 ID - 5434 ER - TY - JOUR AB - The article offers information on a video imaging device that can be used for the instillation of eye drops by patients in both clinic and at-home settings. Topics covered include the features of the device, including a video camera, recording device and light source, and the views of Dr. Alexander M. Eaton on the potential use of the device in assessing the efficiency of eye drop use of patients. AN - 101535755. Language: English. Entry Date: 20150316. Revision Date: 20190326. Publication Type: Article AU - Charters, Lynda AU - Eaton, Alexander M. DB - ccm DP - EBSCOhost IS - 4 KW - Glaucoma -- Drug Therapy Medication Compliance -- Evaluation Digital Imaging -- Equipment and Supplies Ophthalmic Solutions -- Administration and Dosage N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2015 SN - 0193-032X SP - 8-9 ST - Device helps monitor patient eye drop regimen, adherence T2 - Ophthalmology Times TI - Device helps monitor patient eye drop regimen, adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=101535755&site=ehost-live&scope=site VL - 40 ID - 4603 ER - TY - JOUR AN - 109803154. Language: English. Entry Date: 20150714. Revision Date: 20150923. Publication Type: Journal Article AU - Charters, Lynda AU - Stein, Joshua D. DB - ccm DP - EBSCOhost IS - 9 KW - Glaucoma -- Drug Therapy Medication Compliance -- Evaluation Drugs, Generic N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2015 SN - 0193-032X SP - 8-8 ST - Adherence to drug regimens may increase with generics T2 - Ophthalmology Times TI - Adherence to drug regimens may increase with generics UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109803154&site=ehost-live&scope=site VL - 40 ID - 4672 ER - TY - GEN AD - Ophthalmology, University Hospital of North Staffordshire, Stoke-on-Trent, West Midlands, UK. AU - Chaudhary, R. AU - Dhillion, N. AU - Jones, L. AU - Dhillon, N. CY - Dordrecht, DB - ccm DO - 10.1038/eye.2013.2 DP - EBSCOhost J2 - Eye KW - Glaucoma -- Diagnosis Guideline Adherence -- Standards Practice Guidelines Great Britain National Health Programs N1 - Accession Number: 104270018. Language: English. Entry Date: 20130920. Revision Date: 20200708. Publication Type: letter; letter. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM23429410. PB - Springer Nature PY - 2013 SN - 0950-222X SP - 571-572 ST - Adherence to NICE guidelines for new glaucoma referrals TI - Adherence to NICE guidelines for new glaucoma referrals UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104270018&site=ehost-live&scope=site VL - 27 ID - 4628 ER - TY - JOUR AB - PurposeTo describe the results of endothelial keratoplasty (EK) in the management of irido-corneal endothelial (ICE) syndrome.DesignRetrospective, consecutive, interventional case series.MethodsEight eyes of seven patients underwent EK for corneal edema owing to ICE syndrome. Simultaneous cataract surgery was performed in five eyes. The charts were reviewed for demographics, clinical findings, and outcomes after EK.ResultsMean age was 50.4 years (range 35-59 years). Mean follow-up was 12.5 months (range 6-24 months). Corneal clarity was restored in all eyes and was maintained till the last follow-up. Four patients had acute rise in the intraocular pressure in the post-operative period, which was well controlled on medical treatment. One patient who was non-compliant with medications and regular follow-up advice had progression of glaucomatous disc changes and visual field loss. The best-corrected visual acuity ranged from 20/50-20/30.ConclusionsEK is a viable option in ICE syndrome. Adequate control of glaucoma is the paramount factor in maintaining good visual acuity in these eyes. © 2013 Macmillan Publishers Limited All rights reserved 0950-222X/13. AD - Cornea and Anterior Segment Services, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad 560034, Andhra Pradesh, India VST Glaucoma Center, LV Prasad Eye Institute, Hyderabad, India AU - Chaurasia, S. AU - Ramappa, M. AU - Garg, P. AU - Murthy, S. I. AU - Senthil, S. AU - Sangwan, V. S. DB - Scopus DO - 10.1038/eye.2012.298 IS - 4 KW - endothelial keratoplasty glaucoma ICE syndrome M3 - Review N1 - Cited By :11 Export Date: 19 July 2021 PY - 2013 SP - 564-566 ST - Endothelial keratoplasty in the management of irido-corneal endothelial syndrome T2 - Eye (Basingstoke) TI - Endothelial keratoplasty in the management of irido-corneal endothelial syndrome UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876158343&doi=10.1038%2feye.2012.298&partnerID=40&md5=ebe26de1bdf6b78d74131e8c738b2085 VL - 27 ID - 5255 ER - TY - JOUR AB - Purpose To describe the results of endothelial keratoplasty (EK) in the management of irido-corneal endothelial (ICE) syndrome. Design Retrospective, consecutive, interventional case series. Methods Eight eyes of seven patients underwent EK for corneal edema owing to ICE syndrome. Simultaneous cataract surgery was performed in five eyes. The charts were reviewed for demographics, clinical findings, and outcomes after EK. Results Mean age was 50.4 years (range 35-59 years). Mean follow-up was 12.5 months (range 6-24 months). Corneal clarity was restored in all eyes and was maintained till the last follow-up. Four patients had acute rise in the intraocular pressure in the post-operative period, which was well controlled on medical treatment. One patient who was non-compliant with medications and regular follow-up advice had progression of glaucomatous disc changes and visual field loss. The best-corrected visual acuity ranged from 20/50-20/30. Conclusions EK is a viable option in ICE syndrome. Adequate control of glaucoma is the paramount factor in maintaining good visual acuity in these eyes. Eye (2013) 27, 564-566; doi:10.1038/eye.2012.298; published online 25 January 2013 AN - WOS:000317594000016 AU - Chaurasia, S. AU - Ramappa, M. AU - Garg, P. AU - Murthy, S. I. AU - Senthil, S. AU - Sangwan, V. S. DA - APR DO - 10.1038/eye.2012.298 IS - 4 PY - 2013 SN - 0950-222X SP - 564-566 ST - Endothelial keratoplasty in the management of irido-corneal endothelial syndrome T2 - EYE TI - Endothelial keratoplasty in the management of irido-corneal endothelial syndrome VL - 27 ID - 5966 ER - TY - JOUR AD - Division of Stomatology, School of Dentistry, Federal University of Ceará, Fortaleza, Ceará, Brazil Division of Pediatric Dentistry, Department of Clinical Dentistry, Federal University of Ceará, Fortaleza, Ceará, Brazil Division of Oral and Maxillofacial Surgery, Walter Cantídio University Hospital, Federal University of Ceará, Fortaleza, Ceará, Brazil Division of Clinical Dentistry, School of Dentistry, Federal University of Ceará, Fortaleza, Ceará, Brazil Division of Stomatology, School of Dentistry, Federal University of Ceará Campus Sobral, Sobral, Brazil AU - Chaves, F. N. AU - Fonteles, C. S. R. AU - Carvalho, F. S. R. AU - Ribeiro, T. R. AU - Pereira, K. M. A. AU - Costa, F. W. G. DB - Scopus DO - 10.1111/jdv.12460 IS - 6 M3 - Letter N1 - Export Date: 19 July 2021 PY - 2015 SP - 1235-1236 ST - An adult blind man presenting severe impairment of the right finger, ecchymosis in the thorax region, and haemorrhagic blisters on the oral mucosa T2 - Journal of the European Academy of Dermatology and Venereology TI - An adult blind man presenting severe impairment of the right finger, ecchymosis in the thorax region, and haemorrhagic blisters on the oral mucosa UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929653549&doi=10.1111%2fjdv.12460&partnerID=40&md5=de87cebab6d75238e6654f1c4936cdd8 VL - 29 ID - 5746 ER - TY - JOUR AD - A. Chawla, Royal Bolton Eye Unit, Minnerva Road, Bolton BL4 0JR, United Kingdom AU - Chawla, A. AU - McGalliard, J. N. AU - Batterbury, M. DB - Embase Medline DO - 10.1111/j.1600-0420.2007.00882.x IS - 4 KW - antiglaucoma agent eye drops blindness doctor patient relationship dosage schedule comparison family history glaucoma health survey human intraocular pressure letter major clinical study patient attitude patient compliance patient education patient participation pressure measurement priority journal treatment duration unspecified side effect LA - English M3 - Letter N1 - L46901501 2007-06-01 PY - 2007 SN - 1395-3907 1600-0420 SP - 464 ST - Use of eyedrops in glaucoma: How can we help to reduce non-compliance? [6] T2 - Acta Ophthalmologica Scandinavica TI - Use of eyedrops in glaucoma: How can we help to reduce non-compliance? [6] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46901501&from=export http://dx.doi.org/10.1111/j.1600-0420.2007.00882.x VL - 85 ID - 3520 ER - TY - JOUR AB - Purpose To assess adherence patterns to the UK National Institute of Health and Clinical Excellence (NICE) guidelines on glaucoma management (2009) in a tertiary referral centre shared care setting and in a district general hospital (DGH) setting.MethodWe performed a retrospective case note analysis of 200 patients from two centres between January and June 2010. The two centres involved were a consultant-guided teaching hospital optometry-led shared care setting (setting 1) and a consultant-led DGH clinic setting (setting 2). The main outcome measures were compliance with eight of the main NICE guidelines on glaucoma diagnosis and management (2009).ResultsBoth centres showed good adherence to the guidelines regarding the choice of initial treatment (96% vs 100%, settings 1 and 2, respectively) and arranging appropriate monitoring intervals (92% vs 86%). However, significant differences were seen when assessing whether an optic disc image was obtained at the initial visit (74% vs 10%), whether an appropriate initial assessment was performed (96% vs 58%), whether patients review interval complied with the NICE guidance regardless of hospital cancellations (92% vs 66%), and whether concordance with medication was checked (88% vs 24%) (settings 1 and 2, respectively, P0.01-Fishers exact test).ConclusionOur study provides evidence to suggest that a hospital-based shared care service with trained optometrists using assessment sheets compares favourably to non-specialist glaucoma care delivered by ophthalmologists. © 2012 Macmillan Publishers Limited All rights reserved. AD - Manchester Royal Eye Hospital, Manchester Academic and Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, United Kingdom Stepping Hill Hospital, Stockport, United Kingdom AU - Chawla, A. AU - Patel, I. AU - Yuen, C. AU - Fenerty, C. DB - Scopus DO - 10.1038/eye.2012.171 IS - 11 KW - glaucoma optometry shared care M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2012 SP - 1412-1417 ST - Patterns of adherence to NICE Glaucoma Guidance in two different service delivery models T2 - Eye (Basingstoke) TI - Patterns of adherence to NICE Glaucoma Guidance in two different service delivery models UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84869034785&doi=10.1038%2feye.2012.171&partnerID=40&md5=75c18376fee8af3c0103892128344ee7 VL - 26 ID - 5391 ER - TY - JOUR AB - Purpose To assess adherence patterns to the UK National Institute of Health and Clinical Excellence (NICE) guidelines on glaucoma management (2009) in a tertiary referral centre shared care setting and in a district general hospital (DGH) setting. Method We performed a retrospective case note analysis of 200 patients from two centres between January and June 2010. The two centres involved were a consultant-guided teaching hospital optometry-led shared care setting (setting 1) and a consultant-led DGH clinic setting (setting 2). The main outcome measures were compliance with eight of the main NICE guidelines on glaucoma diagnosis and management (2009). Results Both centres showed good adherence to the guidelines regarding the choice of initial treatment (96% vs 100%, settings 1 and 2, respectively) and arranging appropriate monitoring intervals (92% vs 86%). However, significant differences were seen when assessing whether an optic disc image was obtained at the initial visit (74% vs 10%), whether an appropriate initial assessment was performed (96% vs 58%), whether patients' review interval complied with the NICE guidance regardless of hospital cancellations (92% vs 66%), and whether concordance with medication was checked (88% vs 24%) (settings 1 and 2, respectively, P <0.01-Fisher's exact test). Conclusion Our study provides evidence to suggest that a hospital-based shared care service with trained optometrists using assessment sheets compares favourably to non-specialist glaucoma care delivered by ophthalmologists. Eye (2012) 26, 1412-1417; doi:10.1038/eye.2012.171; published online 31 August 2012 AN - WOS:000310846700004 AU - Chawla, A. AU - Patel, I. AU - Yuen, C. AU - Fenerty, C. DA - NOV DO - 10.1038/eye.2012.171 IS - 11 PY - 2012 SN - 0950-222X SP - 1412-1417 ST - Patterns of adherence to NICE Glaucoma Guidance in two different service delivery models T2 - EYE TI - Patterns of adherence to NICE Glaucoma Guidance in two different service delivery models VL - 26 ID - 6160 ER - TY - JOUR AB - Purpose: To assess adherence patterns to the UK National Institute of Health and Clinical Excellence (NICE) guidelines on glaucoma management (2009) in a tertiary referral centre shared care setting and in a district general hospital (DGH) setting. Method: We performed a retrospective case note analysis of 200 patients from two centres between January and June 2010. The two centres involved were a consultant-guided teaching hospital optometry-led shared care setting (setting 1) and a consultant-led DGH clinic setting (setting 2). The main outcome measures were compliance with eight of the main NICE guidelines on glaucoma diagnosis and management (2009). Results: Both centres showed good adherence to the guidelines regarding the choice of initial treatment (96% vs 100%, settings 1 and 2, respectively) and arranging appropriate monitoring intervals (92% vs 86%). However, significant differences were seen when assessing whether an optic disc image was obtained at the initial visit (74% vs 10%), whether an appropriate initial assessment was performed (96% vs 58%), whether patients' review interval complied with the NICE guidance regardless of hospital cancellations (92% vs 66%), and whether concordance with medication was checked (88% vs 24%) (settings 1 and 2, respectively, P<0.01-Fisher's exact test). Conclusion: Our study provides evidence to suggest that a hospital-based shared care service with trained optometrists using assessment sheets compares favourably to non-specialist glaucoma care delivered by ophthalmologists. AD - Manchester Royal Eye Hospital and Manchester Academic and Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Manchester Royal Eye Hospital and Manchester Academic and Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. AN - 104381566. Language: English. Entry Date: 20130531. Revision Date: 20200708. Publication Type: journal article AU - Chawla, A. AU - Patel, I. AU - Yuen, C. AU - Fenerty, C. AU - Chawla, A. AU - Patel, I. AU - Yuen, C. AU - Fenerty, C. DB - ccm DO - 10.1038/eye.2012.171 DP - EBSCOhost IS - 11 KW - Glaucoma -- Diagnosis Guideline Adherence -- Standards Intraocular Pressure Ophthalmology -- Standards Optometry -- Standards Multidisciplinary Care Team -- Standards Practice Guidelines -- Standards Aged Health Care Delivery -- Standards Female Diagnosis, Eye Great Britain Hospitals, Public -- Standards Academic Medical Centers -- Standards Human Male Middle Age National Health Programs -- Standards Retrospective Design Tonometry Perimetry Visual Fields N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM22935671. PY - 2012 SN - 0950-222X SP - 1412-1417 ST - Patterns of adherence to NICE glaucoma guidance in two different service delivery models T2 - Eye TI - Patterns of adherence to NICE glaucoma guidance in two different service delivery models UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104381566&site=ehost-live&scope=site VL - 26 ID - 4341 ER - TY - JOUR AB - Background: Peripheral field loss from conditions such as retinitis pigmentosa and glaucoma can cause significant disabilities by limiting activities of daily living. Severe peripheral field loss causes mobility difficulties with activities such as identifying and adapting to obstacles in the environment. It can also cause emotional strain and impair quality of life. Because this visual field loss is often slow and progressive, patients may be unaware of these functional implications. In addition to orientation and mobility training, sector Fresnel prism therapy is a complementary visual field awareness technique to help the patients obtain information from the missing field. Case Reports: Two cases are presented with the characteristic functional impairments of severe overall visual field constriction. The first case involves a 58-year-old male with advanced retinitis pigmentosa. The second case is of a 52-year-old male with advanced primary open-angle glaucoma. Conclusion: The use of sector Fresnel prism to improve mobility and spatial awareness has long been a clinically accepted tool for rehabilitating patients with overall constricted peripheral visual fields. The prism reduces the degree of eye movement needed to detect peripheral objects in the environment. With in-office training and mobility training, sector Fresnel prism can be successful in helping the patients increase their peripheral awareness of objects, improve their navigational ability, and improve their quality of life. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Chea, Christine AN - 2015-54859-002 AU - Chea, Christine AU - Marinoff, Rebecca DB - psyh DP - EBSCOhost IS - 4 KW - end-stage glaucoma Fresnel prism low vision rehabilitation retinitis pigmentosa visual field awareness visual field constriction Glaucoma Medical Treatment (General) Peripheral Vision Vision Disorders Visual Field Quality of Life N1 - State University of New York, State College of Optometry, New York, NY, US. Release Date: 20151221. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Glaucoma; Medical Treatment (General); Peripheral Vision; Vision Disorders; Visual Field. Minor Descriptor: Quality of Life. Classification: Vision & Hearing & Sensory Disorders (3299); Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30). Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Methodology: Clinical Case Study. References Available: Y. Page Count: 9. Issue Publication Date: Aug, 2015. Copyright Statement: Optometric Extension Program Foundation. 2015. PY - 2015 SN - 2325-3479 2325-3487 SP - 272-280 ST - Case reports: The use of sector Fresnel prism for increased peripheral visual field awareness for patients with end-stage retinitis pigmentosa and glaucoma T2 - Optometry & Visual Performance TI - Case reports: The use of sector Fresnel prism for increased peripheral visual field awareness for patients with end-stage retinitis pigmentosa and glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-54859-002&site=ehost-live&scope=site Christine20c@gmail.com VL - 3 ID - 4831 ER - TY - JOUR AB - Purpose: To investigate blindness in patients with treated open-angle glaucoma (OAG) and risk factors for blindness. Design: Retrospective observational case series. Participants: One hundred eighty-six patients seen between April and November 2000 at the University of Washington Medical Center Eye Clinic, diagnosed in 1975 or later, and treated for at least 2 years for OAG. Methods: Chart review with evaluation of visual acuity and visual field. Kaplan-Meier survival analysis was used to estimate the risk of blindness in one and both eyes. Variables considered to be possible risk factors for blindness were evaluated using chi-square test, t test, and Cox proportional hazards regression analysis. Main Outcome Measures: Blindness, defined as visual acuity of 20/200 or worse, and/or continuous constriction of the visual field to 20° or less in all four quadrants with a size III4e Goldmann stimulus or the equivalent on automated perimetry, allowing a higher threshold level on one point in one quadrant on automated perimetry. Results: The mean duration of disease was 10.2 ± 4.9 years. Twelve patients were blind in at least one eye from OAG at diagnosis. Nineteen other patients became blind in at least one eye from OAG, and three patients became bilaterally blind from OAG. The Kaplan-Meier estimate for blindness at 15 years in one eye was 14.6%, and in both eyes was 6.4%. Noncompliance with the treatment regimen (P = 0.016) and worse initial visual field loss (P < 0.0001) were significantly associated with development of blindness. Nonwhite race was associated with blindness (P = 0.014) when all blindness, including that found at diagnosis, was considered in the analysis. Conclusions: Bilateral blindness from chronic OAG was uncommon in this population of treated patients diagnosed in 1975 or later. Of patients with a blind eye, 39% were blind at diagnosis, and worse visual field loss at diagnosis and noncompliance were associated with development of blindness. © 2003 by the American Academy of Ophthalmology. AD - P.P. Chen, Department of Ophthalmology, Box 356485, University of Washington, Seattle, WA 98195-6485, United States AU - Chen, P. P. DB - Embase Medline DO - 10.1016/S0161-6420(02)01974-7 IS - 4 KW - adult aged article blindness chi square distribution controlled study diode laser disease course disease severity glaucoma surgery human major clinical study open angle glaucoma patient compliance perimetry postoperative complication priority journal prognosis regression analysis retrospective study risk assessment risk factor survival rate visual acuity visual field LA - English M3 - Article N1 - L36520071 2003-05-12 PY - 2003 SN - 0161-6420 SP - 726-733 ST - Blindness in patients with treated open-angle glaucoma T2 - Ophthalmology TI - Blindness in patients with treated open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36520071&from=export http://dx.doi.org/10.1016/S0161-6420(02)01974-7 VL - 110 ID - 3823 ER - TY - JOUR AB - Purpose: To investigate blindness in patients with treated open-angle glaucoma (OAG) and risk factors for blindness. Design: Retrospective observational case series. Participants: One hundred eighty-six patients seen between April and November 2000 at the University of Washington Medical Center Eye Clinic, diagnosed in 1975 or later, and treated for at least 2 years for OAG. Methods: Chart review with evaluation of visual acuity and visual field. Kaplan-Meier survival analysis was used to estimate the risk of blindness in one and both eyes. Variables considered to be possible risk factors foe blindness were evaluated using chi-square test, t test, and Cox proportional hazards regression analysis. Main Outcome Measures: Blindness, defined as visual acuity of 20/200 or worse, and/or continuous constriction of the visual field to 20degrees or less in all four quadrants with a size III4e Goldmann stimulus or the equivalent on automated perimetry, allowing a higher threshold level on one point in one quadrant on automated perimetry. Results: The mean duration of disease was 10.2 +/- 4.9 years. Twelve patients were blind in at least one eye from OAG at diagnosis. Nineteen other patients became blind in at least one eye from OAG, and three patients became bilaterally blind from OAG. The Kaplan-Meier estimate for blindness at 15 years in one eye was 14.6%, and in both eyes was 6.4%. Noncompliance with the treatment regimen (P = 0.016) and worse initial visual field loss (P < 0.0001) were significantly associated with development of blindness. Nonwhite race was associated with blindness (P = 0.014) when all blindness, including that found at diagnosis, was considered in the analysis. Conclusions: Bilateral blindness from chronic OAG was uncommon in this population of treated patients diagnosed in 1975 or later. Of patients with a blind eye, 39% were blind at diagnosis, and worse visual field loss at diagnosis and noncompliance were associated with development of blindness. (C) 2003 by the American Academy of Ophthalmology. AN - WOS:000182566600033 AU - Chen, P. P. DA - APR DO - 10.1016/S0161-6420(02)01974-7 IS - 4 PY - 2003 SN - 0161-6420 SP - 726-733 ST - Blindness in patients with treated open-angle glaucoma T2 - OPHTHALMOLOGY TI - Blindness in patients with treated open-angle glaucoma VL - 110 ID - 6257 ER - TY - JOUR AB - Purpose of review: Estimates of blindness from glaucoma and risk factors for blindness remain of interest for all ophthalmologists. Recent findings: Long-term retrospective studies of patients with open-angle glaucoma in developed countries have noted that progression to bilateral blindness among treated patients is relatively uncommon. Risk factors for development of blindness include advanced visual field loss at presentation and noncompliance with the treatment regimen. Age is a risk factor in some studies. Many of those with blindness are blind at presentation. Untreated rates of blindness are higher. Population-based studies of glaucoma in developing countries have highlighted the obstacles to prevention of blindness in such settings, with astonishingly high rates of blindness noted. Summary: The risk of blindness from glaucoma is very high among patients in developing countries, the vast majority of whom do not know they are afflicted. When considering all glaucoma worldwide, the greatest risk factor for blindness is almost certainly being an average citizen of a developing country. Among those with open-angle glaucoma in developed countries, more advanced visual field loss at presentation and noncompliance are risk factors for development of blindness, as well as advanced age. Effective public education about glaucoma and targeted screening of those most likely to have glaucoma are necessary if the number of blind from glaucoma is to be reduced worldwide. Better treatment options for those in developing countries must also be developed. AD - P.P. Chen, Department of Ophthalmology, Box 356485, University of Washington, Seattle, WA 98195-6485, United States AU - Chen, P. P. DB - Embase Medline DO - 10.1097/00055735-200404000-00009 IS - 2 KW - age blindness clinical feature developing country human medical specialist open angle glaucoma patient compliance patient education priority journal review risk risk factor screening test visual field LA - English M3 - Review N1 - L38457129 2004-05-11 PY - 2004 SN - 1040-8738 SP - 107-111 ST - Risk and risk factors for blindness from glaucoma T2 - Current Opinion in Ophthalmology TI - Risk and risk factors for blindness from glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38457129&from=export http://dx.doi.org/10.1097/00055735-200404000-00009 VL - 15 ID - 3750 ER - TY - JOUR AB - Purpose Of Review: Estimates of blindness from glaucoma and risk factors for blindness remain of interest for all ophthalmologists.Recent Findings: Long-term retrospective studies of patients with open-angle glaucoma in developed countries have noted that progression to bilateral blindness among treated patients is relatively uncommon. Risk factors for development of blindness include advanced visual field loss at presentation and noncompliance with the treatment regimen. Age is a risk factor in some studies. Many of those with blindness are blind at presentation. Untreated rates of blindness are higher. Population-based studies of glaucoma in developing countries have highlighted the obstacles to prevention of blindness in such settings, with astonishingly high rates of blindness noted.Summary: The risk of blindness from glaucoma is very high among patients in developing countries, the vast majority of whom do not know they are afflicted. When considering all glaucoma worldwide, the greatest risk factor for blindness is almost certainly being an average citizen of a developing country. Among those with open-angle glaucoma in developed countries, more advanced visual field loss at presentation and noncompliance are risk factors for development of blindness, as well as advanced age. Effective public education about glaucoma and targeted screening of those most likely to have glaucoma are necessary if the number of blind from glaucoma is to be reduced worldwide. Better treatment options for those in developing countries must also be developed. AD - Department of Ophthalmology, University of Washington, Seattle, Washington, USA AN - 139345330. Language: English. Entry Date: 20040813. Revision Date: 20210409. Publication Type: journal article AU - Chen, Philip P. DB - ccm DO - 10.1097/00055735-200404000-00009 DP - EBSCOhost IS - 2 KW - Blindness -- Etiology Blindness -- Epidemiology Glaucoma -- Complications Glaucoma -- Epidemiology Human Risk Factors Risk Assessment Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research; review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM15021221. PY - 2004 SN - 1040-8738 SP - 107-111 ST - Risk and risk factors for blindness from glaucoma T2 - Current Opinion in Ophthalmology TI - Risk and risk factors for blindness from glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139345330&site=ehost-live&scope=site VL - 15 ID - 4696 ER - TY - JOUR AB - PURPOSE: To evaluate continued visual field (VF) progression in eyes with prior VF progression from open-angle glaucoma, using event-based criteria. METHODS: Retrospective observational case series of 70 eyes (70 patients) with open-angle glaucoma, treated for at least 2 years, that had earlier shown 1 step of VF progression. Further VF progression required a worsening of 3 adjacent points at the same location on 2 consecutive VF tests. Potential risk factors for continued progression were evaluated. RESULTS: The mean follow-up was 127±43 months. Thirty-seven eyes (55%) continued to progress. At 5, 10, and 15 years after the initial VF, the Kaplan-Meier estimate of the risk of developing 2 steps of progression was 18%, 53%, and 71%. A shorter time to the first step of progression was significantly associated with further progression (P<0.001), as was slope of the VF mean deviation (P<0.001) and pattern standard deviation (P=0.041). Eyes with further progression had higher mean IOP after the first step of progression (P=0.026). Among 37 eyes with 2 steps of progression, the estimate of the risk of progressing further was 32% at 10 years after the initial VF. CONCLUSION: Eyes with a relatively shorter time to initial VF progression from open-angle glaucoma are likely to continue to progress over long-term follow-up. More aggressive treatment in such eyes might reduce the likelihood of further VF progression. Copyright © 2010 by Lippincott Williams & Wilkins. AD - Department of Ophthalmology, University of Washington, Seattle, United States AU - Chen, P. P. AU - Cady, R. S. AU - Mudumbai, R. C. AU - Ngan, R. DB - Scopus DO - 10.1097/IJG.0b013e3181d12e1e IS - 9 KW - glaucoma progression rate visual field M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2010 SP - 598-603 ST - Continued visual field progression in eyes with prior visual field progression in patients with open-angle glaucoma T2 - Journal of Glaucoma TI - Continued visual field progression in eyes with prior visual field progression in patients with open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650493562&doi=10.1097%2fIJG.0b013e3181d12e1e&partnerID=40&md5=6b0efafc7e16234f6ee7a5fb19cf90f3 VL - 19 ID - 5580 ER - TY - JOUR AB - Purpose: To assess how general glaucoma patients understand their disease compared with patients from the Shanghai Glaucoma Club and various influencing factors as well. Shanghai Glaucoma Club was further evaluated to determine its efficacy on its members' understanding and knowledge of glaucoma. Methods: A total of 301 glaucoma patients in Shanghai Glaucoma Club and 314 general glaucoma patients were investigated by a questionnaire, composed of three parts and consisting of 20 questions. The first part asked questions about 'level of cognition about glaucoma', the second part was about 'compliance of medication and follow-up', and the third part was about 'life style and habit'. Answers were graded on each question and scores were summed up separately for each part and as a total. Differences of scores and influencing effects were analysed using multivariate linear regression (stepwise) between the two groups. Results: The average total scores of the general glaucoma patients and the glaucoma club members were 19.6 ± 5.4 and 23.8 ± 4.0 (t = -11.14 P < 0.01), respectively. After multivariate linear regression adjustment for the effects of age, diagnosis and educational level glaucoma club members still had 3.73 points edge over the general patients (t = 8.14, P < 0.01). The club was shown to be the strongest positive factor influencing patients' cognition. Patients in Shanghai Glaucoma Club understood the nature and course of glaucoma significantly better than the general glaucoma patients (t = 10.97, P < 0.01) and also lived healthier lives (t = 7.55, P < 0.01). The level of background education was found to be a positive influencing factor although age was negatively correlated with total score. Primary glaucoma patients demonstrated better cognition of their diseases compared with secondary glaucoma patients, and those patients unaware of their type of glaucoma produced lower scores. Conclusions: This study demonstrated significant differences regarding the basic understanding of glaucoma between two groups: general glaucoma patients and members of the Shanghai Glaucoma Club. Club members presented with better cognition of glaucoma and self-management compared with general glaucoma patients. Therefore, the Shanghai Glaucoma Club is an effective medium to improve patients' knowledge of disease and compliance for medication. © 2009 The Authors Journal compilation © 2009 Royal Australian and New Zealand College of Ophthalmologists. AD - X. Sun, Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, 83 Fenyang Road, 200031 Shanghai, China AU - Chen, X. AU - Chen, Y. AU - Sun, X. DB - Embase Medline DO - 10.1111/j.1442-9071.2009.02101.x IS - 6 KW - adult age aged article attitude to health China cognition educational status female glaucoma habit health education human lifestyle major clinical study male patient compliance primary glaucoma questionnaire scoring system secondary glaucoma support group LA - English M3 - Article N1 - L355070905 2009-09-09 PY - 2009 SN - 1442-6404 1442-9071 SP - 590-594 ST - Notable role of glaucoma club on patients' knowledge of glaucoma T2 - Clinical and Experimental Ophthalmology TI - Notable role of glaucoma club on patients' knowledge of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355070905&from=export http://dx.doi.org/10.1111/j.1442-9071.2009.02101.x VL - 37 ID - 3335 ER - TY - JOUR AB - Purpose: To assess how general glaucoma patients understand their disease compared with patients from the Shanghai Glaucoma Club and various influencing factors as well. Shanghai Glaucoma Club was further evaluated to determine its efficacy on its members' understanding and knowledge of glaucoma. Methods: A total of 301 glaucoma patients in Shanghai Glaucoma Club and 314 general glaucoma patients were investigated by a questionnaire, composed of three parts and consisting of 20 questions. The first part asked questions about 'level of cognition about glaucoma', the second part was about 'compliance of medication and follow-up', and the third part was about 'life style and habit'. Answers were graded on each question and scores were summed up separately for each part and as a total. Differences of scores and influencing effects were analysed using multivariate linear regression (stepwise) between the two groups. Results: The average total scores of the general glaucoma patients and the glaucoma club members were 19.6 ± 5.4 and 23.8 ± 4.0 (t = -11.14 P < 0.01), respectively. After multivariate linear regression adjustment for the effects of age, diagnosis and educational level glaucoma club members still had 3.73 points edge over the general patients (t = 8.14, P < 0.01). The club was shown to be the strongest positive factor influencing patients' cognition. Patients in Shanghai Glaucoma Club understood the nature and course of glaucoma significantly better than the general glaucoma patients (t = 10.97, P < 0.01) and also lived healthier lives (t = 7.55, P < 0.01). The level of background education was found to be a positive influencing factor although age was negatively correlated with total score. Primary glaucoma patients demonstrated better cognition of their diseases compared with secondary glaucoma patients, and those patients unaware of their type of glaucoma produced lower scores. Conclusions: This study demonstrated significant differences regarding the basic understanding of glaucoma between two groups: general glaucoma patients and members of the Shanghai Glaucoma Club. Club members presented with better cognition of glaucoma and self-management compared with general glaucoma patients. Therefore, the Shanghai Glaucoma Club is an effective medium to improve patients' knowledge of disease and compliance for medication. © 2009 The Authors Journal compilation © 2009 Royal Australian and New Zealand College of Ophthalmologists. AD - Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, 83 Fenyang Road, 200031 Shanghai, China AU - Chen, X. AU - Chen, Y. AU - Sun, X. DB - Scopus DO - 10.1111/j.1442-9071.2009.02101.x IS - 6 KW - Club Glaucoma Health education Knowledge M3 - Article N1 - Cited By :22 Export Date: 19 July 2021 PY - 2009 SP - 590-594 ST - Notable role of glaucoma club on patients' knowledge of glaucoma T2 - Clinical and Experimental Ophthalmology TI - Notable role of glaucoma club on patients' knowledge of glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-68349128428&doi=10.1111%2fj.1442-9071.2009.02101.x&partnerID=40&md5=e63f0789b604eea2a96159b32946a16a VL - 37 ID - 5127 ER - TY - JOUR AB - P>Purpose: To assess how general glaucoma patients understand their disease compared with patients from the Shanghai Glaucoma Club and various influencing factors as well. Shanghai Glaucoma Club was further evaluated to determine its efficacy on its members' understanding and knowledge of glaucoma. Methods: A total of 301 glaucoma patients in Shanghai Glaucoma Club and 314 general glaucoma patients were investigated by a questionnaire, composed of three parts and consisting of 20 questions. The first part asked questions about 'level of cognition about glaucoma', the second part was about 'compliance of medication and follow-up', and the third part was about 'life style and habit'. Answers were graded on each question and scores were summed up separately for each part and as a total. Differences of scores and influencing effects were analysed using multivariate linear regression (stepwise) between the two groups. Results: The average total scores of the general glaucoma patients and the glaucoma club members were 19.6 +/- 5.4 and 23.8 +/- 4.0 (t = -11.14 P < 0.01), respectively. After multivariate linear regression adjustment for the effects of age, diagnosis and educational level glaucoma club members still had 3.73 points edge over the general patients.(t = 8.14, P < 0.01). The club was shown to be the strongest positive factor influencing patients' cognition. Patients in Shanghai Glaucoma Club understood the nature and course of glaucoma significantly better than the general glaucoma patients (t = 10.97, P < 0.01) and also lived healthier lives (t = 7.55, P < 0.01). The level of background education was found to be a positive influencing factor although age was negatively correlated with total score. Primary glaucoma patients demonstrated better cognition of their diseases compared with secondary glaucoma patients, and those patients unaware of their type of glaucoma produced lower scores. Conclusions: This study demonstrated significant differences regarding the basic understanding of glaucoma between two groups: general glaucoma patients and members of the Shanghai Glaucoma Club. Club members presented with better cognition of glaucoma and self-management compared with general glaucoma patients. Therefore, the Shanghai Glaucoma Club is an effective medium to improve patients' knowledge of disease and compliance for medication. AN - WOS:000268587600010 AU - Chen, X. L. AU - Chen, Y. H. AU - Sun, X. H. DA - AUG DO - 10.1111/j.1442-9071.2009.02101.x IS - 6 PY - 2009 SN - 1442-6404 1442-9071 SP - 590-594 ST - Notable role of glaucoma club on patients' knowledge of glaucoma T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Notable role of glaucoma club on patients' knowledge of glaucoma VL - 37 ID - 6024 ER - TY - JOUR AB - Background: To evaluate the surgical results of patients with persistent fetal vasculature (PFV), also known as persistent hyperplastic primary vitreous (PHPV). Methods: From 1991 to 2001, a retrospective, noncomparative study of 7 eyes of 7 patients diagnosed with PFV was conducted. In each case, type of anterior and/or posterior PHPV findings, preoperative testing, surgical procedures, and visual outcomes were obtained from the records. Follow-up ranged from 12 to 43 months, with a mean of 15 months. Results: Of the 7 eyes, one (14%) had strictly anterior PFV, 1 (14%) had strictly posterior PFV, and 5 (71%) had components of both anterior and posterior disease. Initial lens aspiration only was performed in 3 (43%) eyes. Initial vitrectomy only was performed in 1 eye (14%). Initial lensectomy and vitrectomy was performed in 3 (42.8%) eyes. The reoperation rate was 43% for membrane reproliferation, glaucoma, vitreous hemorrhage, and retinal detachment. Final best-corrected visual acuity ranged from light perception only to 20/70 on the Snellen chart. Conclusions: Functional vision is possible in selected patients. However, poor final visual outcome despite adequate anatomic success were noted in this study. The poor outcomes might have been due to patients delaying vitrectomy until retinal detachment developed or that the patients had poor compliance with postoperative ocular rehabilitation. AD - Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan Department of Ophthalmology, Chang Gung Memorial Hospital, 123, Dabi Road, Niaosung Shiang, Kaohsiung, 833, Taiwan AU - Cheng, L. S. AU - Kuo, H. K. AU - Lin, S. A. AU - Kuo, M. L. DB - Scopus IS - 8 KW - Persistent fetal vasculature (PFV) Persistent hyperplastic primary vitreous (PHPV) M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2004 SP - 602-608 ST - Surgical results of persistent fetal vasculature T2 - Chang Gung Medical Journal TI - Surgical results of persistent fetal vasculature UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-5644292073&partnerID=40&md5=2fcb4c6fb042ea0900ceba8429f016d2 VL - 27 ID - 5265 ER - TY - JOUR AB - There are 34,492 registered with severe or partial sight impairment in Scotland, with 75% aged over 65. With the ageing population, the proportion of those who will develop sight impairing disease will only increase. Therefore, early presentation and treatment are important. Recently, new sight saving treatments and community screening programmes for sight impairing disease have been introduced with concomitant advance in ophthalmic digital imaging. In order to assess older patients’ attendance of free eye tests, awareness of different sight impairing disease and treatments. We describe the first electronic visual healthcare system within any global public healthcare service—‘The Scottish Eyecare Integration Project’—and potential improvements along with the General Ophthalmic Service (GOS) contract. A 14-point questionnaire was devised to assess 100 patients’ awareness of free annual eye tests, and the three most common causes and treatment for severe sight impairment: age-related macular degeneration (ARMD), glaucoma, and diabetic retinopathy (DR). In all, 82% of patients were aware of the free annual eye tests; however, 31% had not attended community optometrist for over 2 years. There was good awareness of glaucoma (77%), but poor understanding of glaucoma treatment (24%), ARMD (43%) and ARMD treatment (17%). Only 39% of patients had heard of free annual DR screening, but there was a significant difference between the two groups (p = .0263), with increased awareness in the middle-aged group. More education is required to encourage the older population to use existing and new eye services. The Scottish Eyecare Integration Project along with the GOS contract is a significant step of change towards meeting the demand for a multidisciplinary approach, bringing ophthalmic care closer to home and into the community. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Cheng, Mei-Ling, Queen Margaret Hospital, Whitefield Road, Dunfermline, United Kingdom, KY12 0SU AN - 2015-41261-006 AU - Cheng, Mei-Ling AU - Henderson, Clair AU - Sinclair, Anne AU - Sanders, Roshini DB - psyh DO - 10.1177/0264619615600009 DP - EBSCOhost IS - 3 KW - Blindness older people Scottish Eyecare Integration Project teleophthalmology vision Community Services Ophthalmology Prevention Telemedicine Vision Disorders Health Care Psychology Optometry Health Awareness N1 - Queen Margaret Hospital, Dunfermline, United Kingdom. Release Date: 20151102. Correction Date: 20200713. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Community Services; Ophthalmology; Prevention; Telemedicine; Vision Disorders. Minor Descriptor: Health Care Psychology; Optometry; Health Awareness. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10). Location: United Kingdom. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Visual Health Questionnaire. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Sep, 2015. Copyright Statement: The Author(s). 2015. PY - 2015 SN - 0264-6196 1744-5809 SP - 220-226 ST - Visual health awareness, the Scottish community optometry service and Eyecare Integration Project: Breaking barriers in preventing visual impairment T2 - British Journal of Visual Impairment TI - Visual health awareness, the Scottish community optometry service and Eyecare Integration Project: Breaking barriers in preventing visual impairment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-41261-006&site=ehost-live&scope=site mcheng@doctors.org.uk VL - 33 ID - 4834 ER - TY - JOUR AB - Purpose: To report the clinical features, management, and outcomes of patients with ocular surface damage secondary to Roman candle explosion accidents. Methods: Retrospective, noncomparative, interventional case series of 11 patients with Roman candle explosion-related ocular surface injuries referred to the Cincinnati Eye Institute between 2007 and 2016. Results: Eleven patients (10 male, 1 female, mean age 22.4 years) sustained unilateral ocular surface injuries with presenting visual acuity ranging from count fingers to light perception. All patients had severe limbal stem cell deficiency with total ocular surface failure. Eight eyes received a conjunctival-limbal autograft (CLAU) with a keratolimbal allograft (KLAL), 1 eye received a living related-conjunctival limbal allograft (lr-CLAL) with a KLAL, and 2 eyes received a CLAU with lr-CLAL. Nine eyes underwent subsequent penetrating keratoplasty, and 7 eyes had reconstructive eyelid surgery. Nine eyes demonstrated improved visual acuity at last follow-up; seven eyes demonstrated a stable ocular surface at last follow-up. Nonadherence was noted in 7 patients, either with poor adherence with post-operative treatment or poor follow-up; this portended a worse visual result. Conclusions: Roman candle-related accidents can lead to severe ocular surface injury. Despite total ocular surface failure, these eyes can achieve good postoperative visual results following limbal stem cell transplantation and subsequent keratoplasty with appropriate compliance. © 2018 Elsevier Inc. AD - Cincinnati Eye Institute/University of Cincinnati, Department of Ophthalmology, Cincinnati, OH, United States Virginia Eye Consultants, Norfolk, VA, United States Grandview Medical Center, Department of Ophthalmology, Dayton, OH, United States Division of Nephrology and Hypertension, University of Cincinnati, Cincinnati, OH, United States AU - Cheung, A. Y. AU - Genereux, B. M. AU - Dautremont, B. AU - Govil, A. AU - Holland, E. J. DB - Scopus DO - 10.1016/j.jtos.2018.03.005 IS - 3 KW - Chemical/thermal injury Limbal stem cell deficiency Ocular surface stem cell transplantation Roman candle fireworks M3 - Article N1 - Export Date: 19 July 2021 PY - 2018 SP - 294-300 ST - Surgical management of severe ocular surface injury due to Roman candle explosion accidents T2 - Ocular Surface TI - Surgical management of severe ocular surface injury due to Roman candle explosion accidents UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044503743&doi=10.1016%2fj.jtos.2018.03.005&partnerID=40&md5=f1af52f5ed44bf91bca8edd9e624d675 VL - 16 ID - 5730 ER - TY - JOUR AB - Purpose: To investigate normal flora of children with and without orthokeratology (ortho-k) treatment, and the associations between carriage of Staphylococcus aureus and Gram-negative rods with contamination of contact lenses and lens cases in ortho-k subjects and with spectacles of control subjects.Methods: Twenty-three ortho-k subjects (treatment >12 months) and 20 control myopic subjects aged 7-14 years were recruited. Samples were collected from four sites surrounding the left eye (lower conjunctiva, upper and lower eyelids, and eyelashes) for all subjects, spectacles for control subjects and contact lens accessories for ortho-k subjects. Samples were cultured, total numbers enumerated, and isolates identified using chromogenic agars.Results: Ortho-k subjects had significantly less total isolates in the conjunctiva than controls (p = 0.009). Otherwise, carriage rates in normal flora levels of the peri-orbital tissues were not significantly different between the two groups (p > 0.19). The total isolates and carriage rates of normal flora on spectacles, contact lenses, and lens cases were similar to those identified on the skin tissues. Small numbers of bacteria were identified from the multipurpose solution of two ortho-k subjects. Although the association between the carriage of S. aureus with contamination of accessories was statistically significant only in control subjects (p = 0.03), ortho-k subjects not yielding S. aureus and Gram-negative rods from samples of their peri-orbital tissues tended to be less likely to have these organisms in their accessories. No Pseudomonas was isolated from any of the sites sampled and no Acinetobacter was isolated from any of the accessories.Conclusions: Ortho-k may lower the total number of bacteria in conjunctiva due to the use of solution and lenses, but the physiologic effect of this treatment on the types of normal flora in children was minimal and should not increase the risk of microbial keratitis in children with good compliance. AD - *MPhil, FAAO †DPhil ‡MD §PhD, FAAO School of Optometry (SWC, GSS, PC), and Squina Centre for Infection Control, School of Nursing (MB), The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, China AN - 124441134. Language: English. Entry Date: 20170804. Revision Date: 20180608. Publication Type: journal article AU - Cheung, Sin Wan AU - Boost, Maureen AU - Shi, Guang Sen AU - Cho, Pauline DB - ccm DO - 10.1097/OPX.0000000000000843 DP - EBSCOhost IS - 6 KW - Staphylococcus Aureus Conjunctiva -- Microbiology Eyelids -- Microbiology Equipment Contamination Contact Lenses Gram-Negative Bacteria Refractive Errors -- Therapy Myopia -- Therapy Male Child Female Adolescence Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 8904931. PMID: NLM26945175. PY - 2016 SN - 1040-5488 SP - 612-618 ST - Microbial Contamination of Periorbital Tissues and Accessories of Children T2 - Optometry & Vision Science TI - Microbial Contamination of Periorbital Tissues and Accessories of Children UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124441134&site=ehost-live&scope=site VL - 93 ID - 4402 ER - TY - JOUR AB - Background Population-based data on prevalence, causes of blindness and extent of ophthalmological coverage is required for efficient implementation and evaluation of ocular health programs. In view of the scarcity of prevalence data for visual impairment and blindness in Malaysia, this study aims to estimate the prevalence and causes of visual impairment (VI) in the elderly, using Rapid Assessment of Avoidable Blindness (RAAB) survey technique. Methods Malaysia was divided into six regions, with each region consisting of 50 clusters. Multistage cluster sampling method was used and each cluster contained 50 residents aged 50 years and above. Eligible subjects were interviewed and pertinent demographic details, barriers to cataract surgery, medical and ocular history was noted. Subjects had visual acuity assessment with tumbling ‘E’ Snellen optotypes and ocular examination with direct ophthalmoscope. The primary cause of VI was documented. Results were calculated for individual zones and weighted average was used to obtain overall prevalence for the country. Inter-regional and overall prevalence for blindness, severe VI and moderate VI were determined. Causes of VI, cataract surgical coverage and barriers to cataract surgery were assessed. Results A total of 15,000 subjects were examined with a response rate of 95.3%. The age and gender-adjusted prevalence of blindness, severe visual impairment and moderate visual impairment were 1.2% (95% Confidence Interval: 1.0–1.4%), 1.0% (95%CI: 0.8–1.2%) and 5.9% (5.3–6.5%) respectively. Untreated cataract (58.6%), diabetic retinopathy (10.4%) and glaucoma (6.6%) were the commonest causes of blindness. Overall, 86.3% of the causes of blindness were avoidable. Cataract surgical coverage (CSC) in persons for blindness, severe visual impairment and moderate visual impairment was 90%, 86% and 66% respectively. Conclusion Increased patient education and further expansion of ophthalmological services are required to reduce avoidable blindness even further in Malaysia. AD - F.L.M. Chew, Department of Ophthalmology, Hospital Selayang, Batu Caves, Selangor, Malaysia AU - Chew, F. L. M. AU - Salowi, M. A. AU - Mustari, Z. AU - Husni, M. A. AU - Hussein, E. AU - Adnan, T. H. AU - Ngah, N. F. AU - Limburg, H. AU - Goh, P. P. DB - Embase Medline DO - 10.1371/journal.pone.0198799 IS - 6 KW - Snellen chart adult aged blindness cataract extraction controlled study cross-sectional study demography diabetic retinopathy disease severity female geographic distribution glaucoma health care access health care delivery health survey human major clinical study Malaysia male medical history middle aged ophthalmoscopy patient education population research prevalence review risk factor very elderly visual acuity visual impairment LA - English M3 - Review N1 - L622712497 2018-07-05 2019-01-11 PY - 2018 SN - 1932-6203 ST - Estimates of visual impairment and its causes from the national eye survey in Malaysia (NESII) T2 - PLoS ONE TI - Estimates of visual impairment and its causes from the national eye survey in Malaysia (NESII) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622712497&from=export http://dx.doi.org/10.1371/journal.pone.0198799 VL - 13 ID - 2585 ER - TY - JOUR AB - PURPOSE: To evaluate the outcomes of the Boston Keratoprosthesis (KPro) at our institution. METHODS: A computerized database retrospectively identified all patients who received a Boston KPro from August 2005 to October 2007. RESULTS: There were 37 patients, 24 (65%) were male. Mean age was 66.3 years (median 69 years, range: 24-93 years; SD = 18.1 years). Mean follow-up was 16 months (range: 6-28 months; SD = 6.0 months). There were 36 type 1 (97%) and 1 type 2 (3%) KPros. The primary indication was failed penetrating keratoplasty in 29 patients (78%)-22 (59%) from multiple failures. Preoperative comorbidities included glaucoma [27 patients (73%)] and limbal stem cell deficiency [13 patients (35%)]. No intraoperative complications occurred. Postoperative complications included retroprosthetic membrane [24 patients (65%)], increased intraocular pressure [14 patients (38%)], glaucoma progression [5 patients (13.5%)], and endophthalmitis [4 patients (11%)-3 who discontinued prophylactic antibiotics secondary to compliance]. Thirty-six KPros (97%) were retained-1 type 2 KPro (3%) in a patient with ocular cicatricial pemphigoid extruded and was replaced. Mean best-corrected visual acuities were counting fingers preoperatively (range: light perception to 20/100) and 20/90 at last follow-up (range: light perception to 20/25). At last follow-up, 31 patients (84%) improved 2 lines or greater-3 patients (8%) had worse vision. CONCLUSIONS: Retention rates were excellent, and best-corrected visual acuities improved in the vast majority of patients. Complications can occur and require frequent follow-up to monitor and treat glaucoma progression, endophthalmitis, and inflammation. Patient compliance is of paramount importance. Despite the potential complications, the Boston KPro provides visual improvement in patients with an otherwise poor prognosis. © 2009 Lippincott Williams & Wilkins, Inc. AD - Cornea Service, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, United States Department of Ophthalmology and Vision Sciences, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada Glaucoma Service, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, United States Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada AU - Chew, H. F. AU - Ayres, B. D. AU - Hammersmith, K. M. AU - Rapuano, C. J. AU - Laibson, P. R. AU - Myers, J. S. AU - Jin, Y. P. AU - Cohen, E. J. DB - Scopus DO - 10.1097/ICO.0b013e3181a186dc IS - 9 KW - Boston Keratoprosthesis Complications Outcomes Penetrating keratoplasty M3 - Article N1 - Cited By :187 Export Date: 19 July 2021 PY - 2009 SP - 989-996 ST - Boston keratoprosthesis outcomes and complications T2 - Cornea TI - Boston keratoprosthesis outcomes and complications UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349751967&doi=10.1097%2fICO.0b013e3181a186dc&partnerID=40&md5=df06375ab1349639b13491615aa06fc8 VL - 28 ID - 4908 ER - TY - JOUR AB - Purpose: To evaluate the outcomes of the Boston Keratoprosthesis (KPro) at our institution. Methods: A computerized database retrospectively identified all patients who received a Boston KPro from August 2005 to October 2007. Results: There were 37 patients, 24 (65%) were male. Mean age was 66.3 years (median 69 years, range: 24-93 years; SD = 18.1 years). Mean follow-up was 16 months (range: 6-28 months; SD = 6.0 months). There were 36 type 1 (97%) and I type 2 (3%) KPros. The primary indication was failed penetrating keratoplasty in 29 patients (78%)-22 (59%) from multiple failures, Preoperative comorbidities included glaucoma [27 patients (73%)] and limbal stern cell deficiency [13 patients (35%)]. No intraoperative complications occurred. Postoperative complications included retroprosthetic membrane [24 patients (65%)], increased intraocular pressure [14 patients (38%)], glaucoma progression [5 patients (13.5%)], and endophthalmitis [4 patients (11%)-3 who discontinued prophylactic antibiotics secondary to compliance]. Thirty-six KPros (97%) were retained-1 type 2 KPro (3%) in a patient with ocular cicatricial pemphigoid extruded and was replaced. Mean best-corrected visual acuities were counting fingers preoperatively (range: light perception to 20/100) and 20/90 at last follow-up (range: light perception to 20/25). At last follow-up, 31 patients (84%) improved 2 lines or greater-3 patients (8%) had worse vision. Conclusions: Retention rates were excellent, and best-corrected Visual acuities improved in the vast majority of patients. Complications can occur and require frequent follow-up to monitor and treat glaucoma progression, endophthalmitis, and inflammation. Patient compliance is of paramount importance. Despite the potential complications, the Boston KPro provides visual improvement in patients with an otherwise poor prognosis. AN - WOS:000271118400008 AU - Chew, H. F. AU - Ayres, B. D. AU - Hammersmith, K. M. AU - Rapuano, C. J. AU - Laibson, P. R. AU - Myers, J. S. AU - Jin, Y. P. AU - Cohen, E. J. DA - OCT DO - 10.1097/ICO.0b013e3181a186dc IS - 9 PY - 2009 SN - 0277-3740 1536-4798 SP - 989-996 ST - Boston Keratoprosthesis Outcomes and Complications T2 - CORNEA TI - Boston Keratoprosthesis Outcomes and Complications VL - 28 ID - 6032 ER - TY - JOUR AB - Purpose: To report the first case of fungal keratitis caused by presumed Carpoligna species. Methods: A 37-year-old gardener sustained a full-thickness, stellate corneal laceration while cutting wood outdoors with a circular saw. Two months after surgical repair, he developed a severe infectious keratitis with descemetocoele at the apex of the original stellate laceration. Results: Culture results confirmed fungal elements without evidence of bacteria. Oral and topical voriconazole were initiated. Due to compliance and cost issues, voriconazole was replaced with natamycin 5% prior to discharge from hospital. The patient improved and healed without perforation. The patient was left with a central stromal scar. DNA extraction from the fungal colony allowed PCR amplification of the 28s ribosomal RNA region of the fungus that led to the diagnosis of Carpoligna pleurothecii. Corticosteroids were never used during the patient's treatment. Conclusion: This is the first reported case of infectious keratitis caused by presumed Carpoligna species. The treatment for Carpoligna pleurothecii keratitis includes voriconazole, natamycin, and possibly amphotericin B. © 2010 Lippincott Williams & Wilkins. AD - H. F. Chew, Sunnybrook Health Sciences Centre, Department of Ophthalmology and Vision Sciences, University of Toronto, 2075 Bayview Ave., Toronto, ON M4 N 3M5, Canada AU - Chew, H. F. AU - Jungkind, D. L. AU - Mah, D. Y. AU - Raber, I. M. AU - Toll, A. D. AU - Tokarczyk, M. J. AU - Cohen, E. J. DB - Embase Medline DO - 10.1097/ICO.0b013e3181af3954 IS - 4 KW - atropine bacitracin cefazolin ceftazidime doxycycline gentamicin moxifloxacin natamycin polymyxin tobramycin vancomycin voriconazole adult article aspiration biopsy B scan bacterium culture Carpoligna pleurothecii case report cornea injury disease course disease severity drug dose reduction drug substitution drug withdrawal eye inflammation eye pain follow up fungus fungus culture fungus growth glaucoma Gram staining human intraocular pressure keratomycosis lensectomy male patient compliance priority journal visual acuity vitrectomy LA - English M3 - Article N1 - L359693988 2010-10-12 2010-10-15 PY - 2010 SN - 0277-3740 SP - 449-452 ST - Post-traumatic fungal keratitis caused by carpoligna sp T2 - Cornea TI - Post-traumatic fungal keratitis caused by carpoligna sp UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359693988&from=export http://dx.doi.org/10.1097/ICO.0b013e3181af3954 VL - 29 ID - 3266 ER - TY - JOUR AB - Purpose: To report the first case of fungal keratitis caused by presumed Carpoligna species. Methods: A 37-year-old gardener sustained a full-thickness, stellate corneal laceration while cutting wood outdoors with a circular saw. Two months after surgical repair, he developed a severe infectious keratitis with descemetocoele at the apex of the original stellate laceration. Results: Culture results confirmed fungal elements without evidence of bacteria. Oral and topical voriconazole were initiated. Due to compliance and cost issues, voriconazole was replaced with natamycin 5% prior to discharge from hospital. The patient improved and healed without perforation. The patient was left with a central stromal scar. DNA extraction from the fungal colony allowed PCR amplification of the 28s ribosomal RNA region of the fungus that led to the diagnosis of Carpoligna pleurothecii. Corticosteroids were never used during the patient's treatment. Conclusion: This is the first reported case of infectious keratitis caused by presumed Carpoligna species. The treatment for Carpoligna pleurothecii keratitis includes voriconazole, natamycin, and possibly amphotericin B. © 2010 Lippincott Williams & Wilkins. AD - Cornea Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, PA, United States Sunnybrook Health Sciences Centre, Department of Ophthalmology and Vision Sciences, University of Toronto, 2075 Bayview Ave., Toronto, ON M4 N 3M5, Canada Department of Microbiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, United States Department of Pathology, Anatomy, and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, United States Department of Ophthalmology, University of Alberta, Edmonton, AB, Canada AU - Chew, H. F. AU - Jungkind, D. L. AU - Mah, D. Y. AU - Raber, I. M. AU - Toll, A. D. AU - Tokarczyk, M. J. AU - Cohen, E. J. DB - Scopus DO - 10.1097/ICO.0b013e3181af3954 IS - 4 KW - amphotericin B Carpoligna fungal keratitis natamycin trauma voriconazole M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2010 SP - 449-452 ST - Post-traumatic fungal keratitis caused by carpoligna sp T2 - Cornea TI - Post-traumatic fungal keratitis caused by carpoligna sp UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957354616&doi=10.1097%2fICO.0b013e3181af3954&partnerID=40&md5=f2bb2db248e8334ea79554b1c7ff867d VL - 29 ID - 5260 ER - TY - JOUR AB - Purpose: This study aimed to identify patient and appointment characteristics associated with no-shows to new patient appointments at a US academic ophthalmology department. Design: Cross-sectional study. Methods: This was a study of all adult patients with new patient appointments scheduled with an attending ophthalmologist at Penn State Eye Center between January 1st and December 31st of 2019. A multiple logistic regression model was used to assess the association between characteristics and no-show status. Results: Of 4,628 patients, 759 (16.4%) were no-shows. From the multiple logistic regression model, characteristics associated with no-shows were age (Odds Ratio (OR) for 18-40 years vs. >60 years: 3.41, 95% Confidence Interval (CI) 2.57, 4.51, p <0.001 and OR for 41-60 years vs. >60 years: 2.14, 95% CI 1.67, 2.74, p<0.001), median household income (OR for <$35,667 vs. >$59,445: 1.59, 95% CI 1.08, 2.34, p<0.001), insurance (OR for None vs. Medicare: 6.92, 95% CI 4.41, 10.86, p<0.001 and OR for Medicaid vs. Medicare: 1.54, 95% CI 1.18, 2.01, p=0.002), race (OR for Black vs. White: 2.62, 95% CI 2.00, 3.43, p<0.001 and OR for Other vs. White: 2.02, 95% CI 1.58, 2.59, p<0.001), and commute distance (OR for 5-10 mi vs. ≤5 mi: 1.73, 95% CI 1.17, 2.55, p=0.006). Appointments with longer lead times and scheduled with glaucoma or retina specialists were also significantly associated with greater no-shows. Conclusion: Certain patient and appointment characteristics were associated with no-show status. These findings may assist in the development of targeted interventions at the patient, practice, and health system levels to improve appointment attendance. AD - M.C. Chen, Department of Ophthalmology, Penn State College of Medicine, 500 University Drive, Hershey, PA, United States AU - Chiam, M. AU - Kunselman, A. R. AU - Chen, M. C. DB - Embase Medline DO - 10.1016/j.ajo.2021.02.020 KW - hydroxychloroquine adult article clinical assessment clinical feature clinical practice controlled study cross-sectional study diabetic retinopathy disease association female glaucoma health care hospital management household income human major clinical study male medicaid medicare ophthalmologist ophthalmology patient attendance patient identification ptosis (eyelid) race difference retrospective study United States LA - English M3 - Article N1 - L2013206649 2021-06-29 2021-07-07 PY - 2021 SN - 1879-1891 0002-9394 SP - 210-219 ST - Characteristics Associated With New Patient Appointment No-Shows at an Academic Ophthalmology Department in the United States T2 - American Journal of Ophthalmology TI - Characteristics Associated With New Patient Appointment No-Shows at an Academic Ophthalmology Department in the United States UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2013206649&from=export http://dx.doi.org/10.1016/j.ajo.2021.02.020 VL - 229 ID - 2291 ER - TY - JOUR AB - Purpose: This study aimed to identify patient and appointment characteristics associated with no-shows to new patient appointments at a US academic ophthalmology department. Design: Cross-sectional study. Methods: This was a study of all adult patients with new patient appointments scheduled with an attending ophthalmologist at Penn State Eye Center between January 1st and December 31st of 2019. A multiple logistic regression model was used to assess the association between characteristics and no-show status. Results: Of 4,628 patients, 759 (16.4%) were no-shows. From the multiple logistic regression model, characteristics associated with no-shows were age (Odds Ratio (OR) for 18-40 years vs. >60 years: 3.41, 95% Confidence Interval (CI) 2.57, 4.51, p <0.001 and OR for 41-60 years vs. >60 years: 2.14, 95% CI 1.67, 2.74, p<0.001), median household income (OR for <$35,667 vs. >$59,445: 1.59, 95% CI 1.08, 2.34, p<0.001), insurance (OR for None vs. Medicare: 6.92, 95% CI 4.41, 10.86, p<0.001 and OR for Medicaid vs. Medicare: 1.54, 95% CI 1.18, 2.01, p=0.002), race (OR for Black vs. White: 2.62, 95% CI 2.00, 3.43, p<0.001 and OR for Other vs. White: 2.02, 95% CI 1.58, 2.59, p<0.001), and commute distance (OR for 5-10 mi vs. ≤5 mi: 1.73, 95% CI 1.17, 2.55, p=0.006). Appointments with longer lead times and scheduled with glaucoma or retina specialists were also significantly associated with greater no-shows. Conclusion: Certain patient and appointment characteristics were associated with no-show status. These findings may assist in the development of targeted interventions at the patient, practice, and health system levels to improve appointment attendance. © 2021 Elsevier Inc. AD - Department of Ophthalmology (MC, MCC), Pennsylvania State College of Medicine, Hershey, PA, United States Department of Public Health Sciences (ARK), Pennsylvania State College of Medicine, Hershey, PA, United States AU - Chiam, M. AU - Kunselman, A. R. AU - Chen, M. C. DB - Scopus DO - 10.1016/j.ajo.2021.02.020 M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 210-219 ST - Characteristics Associated With New Patient Appointment No-Shows at an Academic Ophthalmology Department in the United States T2 - American Journal of Ophthalmology TI - Characteristics Associated With New Patient Appointment No-Shows at an Academic Ophthalmology Department in the United States UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108423427&doi=10.1016%2fj.ajo.2021.02.020&partnerID=40&md5=9be2a2aa2349d7eb393b3f24fa750c44 VL - 229 ID - 5655 ER - TY - JOUR AB - Purpose: In an in vitrostudy, fixed-combination fortified vancomycin and amikacin ophthalmic solutions (VA solution) had the same potency and stable physical properties as the separate components. In this retrospective clinical study, we evaluated the efficacy of the topical VA solution in the treatment of bacterial corneal ulcer and comparison with separate topical fortified vancomycin and amikacin. Methods: Separate topical fortified eye drops was used prior to January 2004 and switched to the VA solution afterwards in the treatment of bacterial corneal ulcer. The medical records of 223 patients diagnosed with bacterial corneal ulcers between January 2002 and December 2005 were reviewed retrospectively. There were 122 patients in the VA group and 101 in the separate group. Cure was defined as complete healing of the ulcer accompanied by a nonprogressive stromal infiltrate on two consecutive visits. Results: No significant difference was found between the VA and separate therapy group. The mean treatment duration was 15.4 days in the VA group and 16.1 days in the separate therapy group. The average hospital stay was 5.4 days (VA) and 7.2 days (separate antibiotics). Stromal infiltration regressed significantly without further expansion in both groups. All corneal ulcers completely re-epithelialized without complications related to drugs. Conclusion: VA solution provided similar efficacy to the conventional separate therapy in the treatment of bacterial corneal ulcers; however, it is more convenient and tolerable, promotes patient's compliance, avoids the washout effect, and reduces nurse utilization. Hence, VA solution is a good alternative to separate therapy. © 2009 Macmillan Publishers Limited All rights reserved. AD - Y.-Y. Tsai, Department of Ophthalmology, China Medical University Hospital, No. 2, Yue Der Road, Taichung, Taiwan AU - Chiang, C. C. AU - Lin, J. M. AU - Chen, W. L. AU - Chiu, Y. T. AU - Tsai, Y. Y. C1 - amikin(Bristol Myers Squibb,Italy) vancocin cp(Lilly,Japan) C2 - Bristol Myers Squibb(Italy) Lilly(Japan) DB - Embase Medline DO - 10.1038/sj.eye.6703078 IS - 2 KW - amikacin amikacin plus vancomycin unclassified drug vancomycin adolescent adult aged article bacterial infection child comparative study controlled study cornea ulcer drug efficacy drug potency epithelization female healing health care utilization hospitalization human major clinical study male medical record medical record review monotherapy patient compliance retrospective study school child time series analysis amikin vancocin cp LA - English M3 - Article N1 - L354177646 2009-03-03 PY - 2009 SN - 1476-5454 0950-222X SP - 294-298 ST - Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer T2 - Eye TI - Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354177646&from=export http://dx.doi.org/10.1038/sj.eye.6703078 VL - 23 ID - 3389 ER - TY - JOUR AB - Purpose: In an in vitrostudy, fixed-combination fortified vancomycin and amikacin ophthalmic solutions (VA solution) had the same potency and stable physical properties as the separate components. In this retrospective clinical study, we evaluated the efficacy of the topical VA solution in the treatment of bacterial corneal ulcer and comparison with separate topical fortified vancomycin and amikacin. Methods: Separate topical fortified eye drops was used prior to January 2004 and switched to the VA solution afterwards in the treatment of bacterial corneal ulcer. The medical records of 223 patients diagnosed with bacterial corneal ulcers between January 2002 and December 2005 were reviewed retrospectively. There were 122 patients in the VA group and 101 in the separate group. Cure was defined as complete healing of the ulcer accompanied by a nonprogressive stromal infiltrate on two consecutive visits. Results: No significant difference was found between the VA and separate therapy group. The mean treatment duration was 15.4 days in the VA group and 16.1 days in the separate therapy group. The average hospital stay was 5.4 days (VA) and 7.2 days (separate antibiotics). Stromal infiltration regressed significantly without further expansion in both groups. All corneal ulcers completely re-epithelialized without complications related to drugs. Conclusion: VA solution provided similar efficacy to the conventional separate therapy in the treatment of bacterial corneal ulcers; however, it is more convenient and tolerable, promotes patient's compliance, avoids the washout effect, and reduces nurse utilization. Hence, VA solution is a good alternative to separate therapy. © 2009 Macmillan Publishers Limited All rights reserved. AD - Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan Institute of Medical and Molecular Toxicology, Chung Shan Medical University, Taichung, Taiwan Department of Ophthalmology, China Medical University Hospital, No. 2, Yue Der Road, Taichung, Taiwan AU - Chiang, C. C. AU - Lin, J. M. AU - Chen, W. L. AU - Chiu, Y. T. AU - Tsai, Y. Y. DB - Scopus DO - 10.1038/sj.eye.6703078 IS - 2 KW - Amikacin Bacterial keratitis Fortified antibiotics Vancomycin M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2009 SP - 294-298 ST - Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer T2 - Eye TI - Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-60149107495&doi=10.1038%2fsj.eye.6703078&partnerID=40&md5=b92e91e4719f689ce40cedb9195eabc9 VL - 23 ID - 5533 ER - TY - JOUR AB - Purpose In an in vitro study, fixed-combination fortified vancomycin and amikacin ophthalmic solutions (VA solution) had the same potency and stable physical properties as the separate components. In this retrospective clinical study, we evaluated the efficacy of the topical VA solution in the treatment of bacterial corneal ulcer and comparison with separate topical fortified vancomycin and amikacin. Methods Separate topical fortified eye drops was used prior to January 2004 and switched to the VA solution afterwards in the treatment of bacterial corneal ulcer. The medical records of 223 patients diagnosed with bacterial corneal ulcers between January 2002 and December 2005 were reviewed retrospectively. There were 122 patients in the VA group and 101 in the separate group. Cure was defined as complete healing of the ulcer accompanied by a nonprogressive stromal infiltrate on two consecutive visits. Results No significant difference was found between the VA and separate therapy group. The mean treatment duration was 15.4 days in the VA group and 16.1 days in the separate therapy group. The average hospital stay was 5.4 days (VA) and 7.2 days (separate antibiotics). Stromal infiltration regressed significantly without further expansion in both groups. All corneal ulcers completely re-epithelialized without complications related to drugs. Conclusion VA solution provided similar efficacy to the conventional separate therapy in the treatment of bacterial corneal ulcers; however, it is more convenient and tolerable, promotes patient's compliance, avoids the washout effect, and reduces nurse utilization. Hence, VA solution is a good alternative to separate therapy. AN - WOS:000263321000009 AU - Chiang, C. C. AU - Lin, J. M. AU - Chen, W. L. AU - Chiu, Y. T. AU - Tsai, Y. Y. DA - FEB DO - 10.1038/sj.eye.6703078 IS - 2 PY - 2009 SN - 0950-222X 1476-5454 SP - 294-298 ST - Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer T2 - EYE TI - Comparison of topical fixed-combination fortified vancomycin-amikacin (VA solution) to conventional separate therapy in the treatment of bacterial corneal ulcer VL - 23 ID - 5808 ER - TY - JOUR AB - PURPOSE: To evaluate the situation of glaucoma patients' management in Romania. METHOD: A questionnaire was presented to 400 ophthalmologists with experience in glaucoma management; they have responded anonymously to 32 questions. The obtained data were subject to statistical analysis (mean, standard deviation, statistical significance). RESULTS: 327 ophthalmologists have responded; 70% have more than 10 years of practice; 50% are each managing 100 to 500 glaucoma patients. 2/3 of participants are using the Goldmann aplanotonometer, 38% are assessing visual field in automated perimetry, 61% are examining the optic discs using an direct ophthalmoscope and 80% are currently performing gonioscopy. 55% are treating ocular hypertension under special circumstances, 93% are using initial monotherapy, 3/4 are using prostaglandin derivates as initial therapy and 79% are resorting to fixed combinations when the initial monotherapy has become inefficient. Most participants desire to use modern diagnostic methods and treatments in glaucoma, to continuously improve the education in glaucoma management and to collaborate efficiently with other healthcare partners. CONCLUSIONS: The questionnaire has provided useful information on the quality of glaucoma patients care in Romania; if it is periodically repeated (with necessary updates) it will reflect the dynamic of this issue in our country AD - D. Chiseliţǎ AU - Chiseliţǎ, D. AU - Apreutesei, N. DB - Medline IS - 1 KW - article clinical competence glaucoma health care quality human patient compliance physician attitude questionnaire Romania standard LA - Romanian M3 - Article N1 - L355034888 2009-08-11 PY - 2009 SN - 1220-0875 SP - 64-70 ST - The management of glaucoma patients in Romania: analysis of an evaluation questionnaire T2 - Oftalmologia (Bucharest, Romania : 1990) TI - The management of glaucoma patients in Romania: analysis of an evaluation questionnaire UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355034888&from=export VL - 53 ID - 3341 ER - TY - JOUR AB - Medical care in Taiwan is well known for its low cost, high efficiency, high quality, excellent medical accessibility, and high equity. We investigate the trends in medication expenditures for glaucoma from 1997 to 2010. The results show that higher medical expenditures were incurred by patients who were aged ≥40 years, male patients, and patients in the highest salary population whereas lower medical expenditures were incurred by blue-collar workers. The medications with the most significant increases in expenditure were prostaglandin analogs (PGAs), α-agonists, and fixed combinations, whereas the medications with the most significant decreases in expenditure were β-blockers and cholinergic agonists. The number of trabeculectomies shows two downward break points in 1999 and 2000 when PGAs were listed and were reimbursed. These results suggest socioeconomic disparities in glaucoma care, as well as understanding of the changes in the expenditure of glaucoma medications under such universal health insurance coverage system. AD - Department of Ophthalmology, Changhua Christian Hospital, 135 Nanxiao Street, Changhua City, Changhua County 500, Taiwan Department of Healthcare Administration Management, Asia University, 500 Lioufeng Road, Wufeng, Taichung 41354, Taiwan Management Office for Health Data, China Medical University Hospital, 2 Yude Road, Taichung 40447, Taiwan Department of Orthopedics, Changhua Christian Hospital, 135 Nanxiao Street, Changhua City, Changhua County 500, Taiwan AN - 109224556. Language: English. Entry Date: 20151027. Revision Date: 20151027. Publication Type: Article AU - Chiu, Shin-Lin AU - Chu, Chiao-Lee AU - Muo, Chih-Hsin AU - Chen, Chiu-Liang AU - Lan, Shou-Jen DB - ccm DO - 10.1155/2015/243401 DP - EBSCOhost KW - Glaucoma -- Drug Therapy Drugs, Prescription -- Economics Health Care Costs -- Taiwan Insurance Coverage Government Programs Taiwan Human Prospective Studies Adult Costs and Cost Analysis Linear Regression Pearson's Correlation Coefficient Models, Statistical Data Analysis Software Male Middle Age Aged Female N1 - research; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 101524199. PY - 2015 SN - 2090-004X SP - 1-6 ST - Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan T2 - Journal of Ophthalmology TI - Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109224556&site=ehost-live&scope=site VL - 2015 ID - 4335 ER - TY - JOUR AB - Purpose: To understand the epidemiology, severity, types of pathology, clinical features, precipitating factors, and treatment outcomes of patients with allergic conjunctivitis in a tropical climate receiving corneal subspecialist intervention. A total of 33 patients with severe allergic conjunctivitis under corneal subspecialist care in National University Hospital, Singapore were studied. Design: A retrospective, noncomparative case series. Main outcome measures: epidemiological data, clinical features, complete ophthalmological examination, and treatment types. Methods: Both eyes of 33 patients seen at the cornea subspecialist clinic between May 2005 and July 2006 were examined at baseline, and followed up. Clinical features, treatment given, and outcome variables through case sheet review were analyzed. Results: Twenty-five patients (75.8%) were male, and 8 (24.2%) were female. Seventeen patients (51.5%) had concomitant allergic rhinitis, 16 patients (48.5%) had asthma, and 17 (51.5%) had associated dermatitis. Only 9 patients (27.3%) had documented precipitating factors. None of the 33 patients said that their symptoms were seasonal; 22 (66.7%) said their symptoms were perennial. Twenty-nine patients (87.9%) had punctate epithelial erosions, and 12 patients eventually progressed to have a corneal epithelial defect or shield ulcer (36.4%). Eleven out of the 33 patients (33.3%) received topical cyclosporine 0.5%. Of these, only 1 (9.1%) had documented complaints of intolerable side effects. Conclusion: Allergic conjunctivitis in a non-temperate, non-seasonal climate has different clinical presentations, and varied precipitating factors. The disease in such conditions may respond differently to the usual anti-allergy drug options used in temperate countries. Copyright © Informa Healthcare USA, Inc. AD - Department of Ophthalmology, National University Hospital, Singapore, Singapore Department of Ophthalmology, National University Hospital, Main Building, 5 Lower Kent Ridge Road, Singapore 119074, Singapore AU - Choi, H. AU - Lee, S. B. DB - Scopus DO - 10.1080/09273940802184182 IS - 4 KW - Allergic conjunctivitis Asian Atopic keratoconjunctivitis Corneal ulcer Corticosteriod Cyclosporine Olopatadine Perennial Restasis Seasonal Steroid-response glaucoma Tropical climate Vernal keratoconjunctivitis M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2008 SP - 141-145 ST - Nonseasonal allergic conjunctivitis in the tropics: Experience in a tertiary care institution T2 - Ocular Immunology and Inflammation TI - Nonseasonal allergic conjunctivitis in the tropics: Experience in a tertiary care institution UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-50049129232&doi=10.1080%2f09273940802184182&partnerID=40&md5=1879ee0adb657a9b2946b2a0d1c3b405 VL - 16 ID - 5311 ER - TY - JOUR AB - Due to the rapidly increasing life-expectancy, the prevalence of glaucoma has increased steadily in recent years. We aimed to evaluate the patterns of care and primary treatment strategy patterns in Korea according to glaucoma subtypes to assess the quality of care for glaucoma patients. In this serial cross-sectional survey, the claims data from the Korean National Health Insurance Service was used to identify and group glaucoma patients into primary open-angle glaucoma (POAG), primary angle-closure glaucoma (PACG), other types of glaucoma, and ocular hypertension from 2002 to 2013. Records for outpatient visits, hospitalizations, drug prescriptions, admissions, and surgical interventions were used to determine the patterns of care and identify primary treatment strategies. Both the prevalence (0.11% in 2002 to 0.43% in 2013) and incidence rates (0.06% in 2003 to 0.11% in 2013) for glaucoma increased over time. The mean number of outpatient visits increased (4.9-6.0 visits per year), while the proportion of hospitalized patients (2.3-1.0% of patients) and duration of hospital stay (4.5-3.4 days among hospitalized patients) decreased between 2002 and 2013 for patients with POAG. The proportion of patients not being managed by medication or surgery decreased, with POAG and PACG patients receiving medications increasing from 70.9% and 59.2% in 2002 to 88.4% and 63.3% in 2013, respectively. Finally, while the proportion of trabeculectomy decreased (22.2% to 10.0% of surgical procedures in 2002 and 2013, respectively), more patients with PACG have received iridectomy (59.3% to 86.0% of surgical procedures in 2002 and 2013, respectively). Between 2002 and 2013, the pattern of care for both patients with POAG and PACG has shifted toward management by outpatient visits and intervention with anti-glaucoma medications in Korea. AN - WOS:000449338200042 AU - Choi, S. AU - Choi, J. A. AU - Kwon, J. W. AU - Park, S. M. AU - Jee, D. DA - SEP DO - 10.1097/MD.0000000000012357 IS - 38 PY - 2018 SN - 0025-7974 1536-5964 ST - Patterns of care for glaucoma patients in Korea from 2002 to 2013 using the national health insurance service claims data T2 - MEDICINE TI - Patterns of care for glaucoma patients in Korea from 2002 to 2013 using the national health insurance service claims data VL - 97 ID - 5978 ER - TY - JOUR AB - PURPOSE:: Nonadherence to glaucoma medications may be a major cause of treatment failure. We examined the acceptance of glaucoma patients toward a possible new route of administering glaucoma medication by subconjunctival injection. PATIENTS AND METHODS:: Patients were recruited from specialist glaucoma clinics on a voluntary basis. Trained interviewers administered a 30-item questionnaire and an information sheet with details of an alternative subconjunctival injection route involving injections at 3-month intervals. Outcome measures regarding acceptance of the new procedure, social situational factors, disease factors, and treatment factors were assessed. RESULTS:: A total of 151 patients participated in this study. Of the 151 patients 112 (74.2%) were willing to have their glaucoma medication given by the new method of subconjunctival injection, 101 of 112 (90.2%) were willing to accept it at the same cost as their present medication, and 87 of 101 (86.1%) were willing to accept it even at a higher cost. These patients tended to be on a greater number of medications (P=0.006), and medicating more frequently in a day (P=0.003). Nine of 10 (90%) patients who were admitted to nonadherence were willing to accept subconjunctival injections at 3-month intervals in place of their topical medication. CONCLUSIONS:: Our study found that 74% of glaucoma patients were willing to accept an alternative form of glaucoma treatment through 3-monthly subconjunctival injections. A large proportion of patients who were admitted to nonadherence to topical medication were willing to consider this alternative method of medication. Our findings are helpful when developing patient-acceptable drug-delivery regimes, which may alleviate the need for daily medication. Copyright © 2013 by Lippincott Williams & Wilkins. AD - T.T. Wong, Singapore National Eye Centre, National University of Singapore, 11 Third Hospital Avenue, Singapore 168751, Singapore AU - Chong, R. S. AU - Su, D. H. W. AU - Tsai, A. AU - Jiang, Y. AU - Htoon, H. M. AU - Lamoureux, E. L. AU - Aung, T. AU - Wong, T. T. DB - Embase Medline DO - 10.1097/IJG.0b013e318237c6c4 IS - 3 KW - antiglaucoma agent aged article controlled study cost female glaucoma human interview major clinical study male patient attitude patient compliance priority journal questionnaire treatment outcome LA - English M3 - Article N1 - L51688564 2011-11-02 2013-03-22 PY - 2013 SN - 1057-0829 1536-481X SP - 190-194 ST - Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma T2 - Journal of Glaucoma TI - Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51688564&from=export http://dx.doi.org/10.1097/IJG.0b013e318237c6c4 VL - 22 ID - 3021 ER - TY - JOUR AB - Purpose: L. V. Prasad Eye Institute has adopted horizontal approach of eye care delivery for the past 22 years at one of its rural secondary centers. The recent implementation of a diagonal model for enhancing glaucoma care at this center and its outcomes are reported. Methods: This was a retrospective case-control study. We included newly and consecutively diagnosed adult glaucoma patients. A comprehensive ophthalmologist provided glaucoma care. During the study period, an experienced glaucoma specialist supported the care for 2 days every month in a structured format that consisted of triaging glaucoma patients for defined protocols of therapy along with hands-on and remote online guidance to the comprehensive ophthalmologist. The data from the worst or single eye were analyzed. Results: We have included 231 patients (151 study and 80 historical controls). Sixty (75%) control patients were managed at the study center and 20 (25%) were referred. The comprehensive ophthalmologist managed 70 (48.2%) study patients and co-managed 75 (51.7%) with the glaucoma specialist. The latter changed the diagnosis in 15 eyes and altered the treatment plan in 44 eyes. Six were excluded. Successful outcome was achieved in 52 (65%) eyes in the control group and 120 (84.5%) eyes in the study group (P <.01). Additionally, study group did better in terms of case detection rate, compliance to treatment and saving on expenses for patients. Conclusion: The new model has shown better clinical outcomes of glaucoma care in an under-served geographic area. The model has the potential for wider applicability. AD - N.S. Choudhari, L V Prasad Eye Institute, Dr. Kallam Anji Reddy campus, L V Prasad Marg, Banjara Hills, Hyderabad, Andhra Pradesh, India AU - Choudhari, N. S. AU - Mundhe, G. AU - Khanna, R. AU - Rathi, V. AU - Garudadri, C. S. DB - Embase Medline DO - 10.1080/09286586.2019.1646292 IS - 6 KW - adult article case control study clinical outcome closed angle glaucoma conservative treatment controlled study cost control disease severity eye care female glaucoma glaucoma surgery gonioscopy health care cost health care delivery human laser surgery major clinical study male medical specialist medically underserved open angle glaucoma ophthalmologist patient care patient compliance patient safety priority journal retrospective study rural health care rural population secondary glaucoma treatment outcome LA - English M3 - Article N1 - L628774544 2019-08-07 2020-01-07 PY - 2019 SN - 1744-5086 0928-6586 SP - 420-429 ST - Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute’s Diagonal Model of Glaucoma Care T2 - Ophthalmic Epidemiology TI - Toward Better Health Outcomes in Rural and Under-served Areas: L. V. Prasad Eye Institute’s Diagonal Model of Glaucoma Care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628774544&from=export http://dx.doi.org/10.1080/09286586.2019.1646292 VL - 26 ID - 2472 ER - TY - JOUR AB - The purpose of this systematic review and meta-analysis was to examine the availability of evidence for one of the earliest available minimally invasive glaucoma surgery (MIGS) procedures, the Trabectome. Various databases were searched up to December 20, 2016, for any published studies assessing the use of the Trabectome as a solo procedure in patients with primary open-angle glaucoma (POAG). The standardized mean differences (SMD) were calculated for the change in intraocular pressure (IOP) and number of glaucoma mediations used at 1-month, 6-month, and 12-month follow-up. After screening, three studies and one abstract with analyzable data were included. The meta-analysis showed statistically significant reductions in IOP and number of glaucoma medications used at all time points. Though the Trabectome as a solo procedure appears to lower IOP and reduces the number of glaucoma medications, more high-quality studies are required to make definitive conclusions. The difficulty of obtaining evidence may be one of the many obstacles that limit a full understanding of the potential safety and/or efficacy benefits compared to standard treatments. The time has come for a thoughtful and integrated approach with stakeholders to determine optimal access to care strategies for our patients. AD - Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada Department of Ophthalmology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada AN - 123803372. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - Chow, Jeffrey T. Y. AU - Hutnik, Cindy M. L. AU - Solo, Karla AU - Malvankar-Mehta, Monali S. DB - ccm DO - 10.1155/2017/2965725 DP - EBSCOhost KW - Intraocular Pressure Glaucoma -- Drug Therapy Glaucoma -- Surgery Minimally Invasive Procedures Glaucoma Computerized Literature Searching Health Screening Systematic Review Randomized Controlled Trials Confidence Intervals Descriptive Statistics Clinical Trials Nonexperimental Studies Case Studies Study Design Literature Review Prospective Studies Checklists N1 - research; systematic review; tables/charts. Journal Subset: Biomedical; USA. Special Interest: Evidence-Based Practice. NLM UID: 101524199. PY - 2017 SN - 2090-004X SP - 1-8 ST - When Is Evidence Enough Evidence? A Systematic Review and Meta-Analysis of the Trabectome as a Solo Procedure in Patients with Primary Open-Angle Glaucoma T2 - Journal of Ophthalmology TI - When Is Evidence Enough Evidence? A Systematic Review and Meta-Analysis of the Trabectome as a Solo Procedure in Patients with Primary Open-Angle Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123803372&site=ehost-live&scope=site ID - 4268 ER - TY - JOUR AB - The purpose of this systematic review and meta-analysis was to examine the availability of evidence for one of the earliest available minimally invasive glaucoma surgery (MIGS) procedures, the Trabectome. Various databases were searched up to December 20, 2016, for any published studies assessing the use of the Trabectome as a solo procedure in patients with primary open-angle glaucoma (POAG). The standardized mean differences (SMD) were calculated for the change in intraocular pressure (IOP) and number of glaucoma mediations used at 1-month, 6-month, and 12-month follow-up. After screening, three studies and one abstract with analyzable data were included. The meta-analysis showed statistically significant reductions in IOP and number of glaucoma medications used at all time points. Though the Trabectome as a solo procedure appears to lower IOP and reduces the number of glaucoma medications, more high-quality studies are required to make definitive conclusions. The difficulty of obtaining evidence may be one of the many obstacles that limit a full understanding of the potential safety and/or efficacy benefits compared to standard treatments. The time has come for a thoughtful and integrated approach with stakeholders to determine optimal access to care strategies for our patients. © 2017 Jeffrey T. Y. Chow et al. AD - Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada Department of Ophthalmology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada AU - Chow, J. T. Y. AU - Hutnik, C. M. L. AU - Solo, K. AU - Malvankar-Mehta, M. S. C7 - 2965725 DB - Scopus DO - 10.1155/2017/2965725 M3 - Review N1 - Cited By :6 Export Date: 19 July 2021 PY - 2017 ST - When Is Evidence Enough Evidence? A Systematic Review and Meta-Analysis of the Trabectome as a Solo Procedure in Patients with Primary Open-Angle Glaucoma T2 - Journal of Ophthalmology TI - When Is Evidence Enough Evidence? A Systematic Review and Meta-Analysis of the Trabectome as a Solo Procedure in Patients with Primary Open-Angle Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023634937&doi=10.1155%2f2017%2f2965725&partnerID=40&md5=3bc8b7dbdc2ac3549b725dd192bdefe2 VL - 2017 ID - 5376 ER - TY - JOUR AB - The purpose of this systematic review and meta-analysis was to examine the availability of evidence for one of the earliest available minimally invasive glaucoma surgery (MIGS) procedures, the Trabectome. Various databases were searched up to December 20, 2016, for any published studies assessing the use of the Trabectome as a solo procedure in patients with primary open-angle glaucoma (POAG). The standardized mean differences (SMD) were calculated for the change in intraocular pressure (IOP) and number of glaucoma mediations used at 1-month, 6-month, and 12-month follow-up. After screening, three studies and one abstract with analyzable data were included. The meta-analysis showed statistically significant reductions in IOP and number of glaucoma medications used at all time points. Though the Trabectome as a solo procedure appears to lower IOP and reduces the number of glaucoma medications, more high-quality studies are required to make definitive conclusions. The difficulty of obtaining evidence may be one of the many obstacles that limit a full understanding of the potential safety and/or efficacy benefits compared to standard treatments. The time has come for a thoughtful and integrated approach with stakeholders to determine optimal access to care strategies for our patients. AN - WOS:000405211600001 AU - Chow, J. T. Y. AU - Hutnik, C. M. L. AU - Solo, K. AU - Malvankar-Mehta, M. S. DO - 10.1155/2017/2965725 PY - 2017 SN - 2090-004X 2090-0058 ST - When Is Evidence Enough Evidence? A Systematic Review and Meta-Analysis of the Trabectome as a Solo Procedure in Patients with Primary Open-Angle Glaucoma T2 - JOURNAL OF OPHTHALMOLOGY TI - When Is Evidence Enough Evidence? A Systematic Review and Meta-Analysis of the Trabectome as a Solo Procedure in Patients with Primary Open-Angle Glaucoma VL - 2017 ID - 6143 ER - TY - JOUR AB - Purpose: To investigate differences in the utilization of healthcare services between subjects with open-angle glaucoma (OAG) and comparison subjects without OAG using Taiwan's National Health Insurance population-based database. Patients and Methods: The study comprised 2204 subjects with OAG and 2204 sex-matched and age-matched subjects without OAG. We individually followed each subject for a 1-year period to evaluate their healthcare resource utilization. Outcome variables of the healthcare resource utilization were as follows: numbers of outpatient visits and inpatient days and the mean costs of outpatient and inpatient treatment. In addition, we divided healthcare resource utilization into ophthalmologic and nonophthalmologic services. Results: As for the utilization of ophthalmologic services, OAG subjects had significantly more outpatient visits (7.4 vs. 1.3, P < 0.001) and significantly higher outpatient costs (US$272 vs. US$39, P < 0.001) than comparison subjects. For nonophthalmologic services, OAG subjects also had significantly more outpatient visits (29.4 vs. 21.8, P < 0.001) and significantly higher outpatient costs (US$1263 vs. US$847, P < 0.001) than comparison subjects. Furthermore, OAG subjects incurred significantly higher inpatient costs compared with comparison subjects (US$434 vs. US$234, P < 0.001). For all healthcare services, OAG subjects had significantly more outpatient visits (36.8 vs. 23.1, P < 0.001) and significantly higher outpatient (US$1535 vs. US$887, P < 0.001) and total (US$2245 vs. US$1122, P < 0.001) costs than comparison subjects. In other words, the total cost was about 2-fold greater for OAG subjects than comparison subjects. Conclusions: We concluded that subjects with OAG had significantly higher utilization of all healthcare services than comparison subjects. AD - M.-C. Tsai, Department of Internal Medicine, Cathay General Hospital, No. 280, Sec. 4, Ren'ai Rd., Da'an Dist., Taipei, Taiwan AU - Chung, S. D. AU - Ho, J. D. AU - Lin, H. C. AU - Kao, L. T. AU - Tsai, M. C. DB - Embase Medline DO - 10.1097/IJG.0000000000000222 IS - 5 KW - adult aged ambulatory care article controlled study cross-sectional study essential hypertension female follow up health care cost health care utilization health service hospitalization human income major clinical study male middle aged national health insurance non insulin dependent diabetes mellitus open angle glaucoma outpatient care population research priority journal senile cataract Taiwan upper respiratory tract infection urbanization very elderly LA - English M3 - Article N1 - L602056613 2015-02-11 2015-08-12 PY - 2015 SN - 1536-481X 1057-0829 SP - e116-e120 ST - Incremental Healthcare Service Utilization for Open-angle Glaucoma: A Population-Based Study T2 - Journal of Glaucoma TI - Incremental Healthcare Service Utilization for Open-angle Glaucoma: A Population-Based Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L602056613&from=export http://dx.doi.org/10.1097/IJG.0000000000000222 VL - 24 ID - 2837 ER - TY - JOUR AB - The article highlights a 1-day course undertaken by a group of physicians intended to improve communication skills in a clinical setting where a speaker indicated that learning communication skills allow physicians to improve patients' risk awareness. AN - 97373638. Language: English. Entry Date: 20140812. Revision Date: 20140815. Publication Type: Article AU - Cimberle, Michela DB - ccm DP - EBSCOhost IS - 15 KW - Medication Compliance Glaucoma -- Drug Therapy Communication -- Methods Physicians N1 - brief item; pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2014 SN - 8750-3085 SP - 14-14 ST - Simple communication techniques help physicians address glaucoma medication compliance T2 - Ocular Surgery News TI - Simple communication techniques help physicians address glaucoma medication compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=97373638&site=ehost-live&scope=site VL - 32 ID - 4639 ER - TY - JOUR AB - Because of the risk of serious complication that accompanies the extended wear of contact lenses, clinical management should emphasize adequate communication with the patient and a systematic program of examination and follow-up. Management should be in compliance with informed consent requirements, which obligate practitioners to document instructions, findings, warnings, and recall examinations. The most likely legal claim is one of negligence, and the most common causes of liability are inappropriate patient selection, improper wearing schedules, improper management of contact lens-related complications (especially corneal abrasions), and inadequate monitoring of ocular health. In determining the liability of optometrists, a medical standard of care may be applied. AD - J.G. Classé AU - Classé, J. G. DB - Medline IS - 3 KW - cornea ulcer disposable equipment extended wear contact lens human legal aspect legal liability malpractice optometry patient compliance review risk factor LA - English M3 - Review N1 - L22899730 1992-04-15 PY - 1991 SN - 1050-6918 SP - 51-62 ST - Liability for extended-wear contact lenses T2 - Optometry clinics : the official publication of the Prentice Society TI - Liability for extended-wear contact lenses UR - https://www.embase.com/search/results?subaction=viewrecord&id=L22899730&from=export VL - 1 ID - 4034 ER - TY - JOUR AB - Because of the risk of serious complication that accompanies the extended wear of contact lenses, clinical management should emphasize adequate communication with the patient and a systematic program of examination and follow-up. Management should be in compliance with informed consent requirements, which obligate practitioners to document instructions, findings, warnings, and recall examinations. The most likely legal claim is one of negligence, and the most common causes of liability are inappropriate patient selection, improper wearing schedules, improper management of contact lens-related complications (especially corneal abrasions), and inadequate monitoring of ocular health. In determining the liability of optometrists, a medical standard of care may be applied. AU - Classé, J. G. DB - Scopus IS - 3 M3 - Review N1 - Export Date: 19 July 2021 PY - 1991 SP - 51-62 ST - Liability for extended-wear contact lenses T2 - Optometry clinics : the official publication of the Prentice Society TI - Liability for extended-wear contact lenses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026295045&partnerID=40&md5=ca2ba9ba333b7caa2639002b53b35148 VL - 1 ID - 5801 ER - TY - JOUR AB - Maximal drug treatment can be absolute, using all the combinations possible if no surgery can reasonably be undertaken, or relative, with surgery as the next step. The drug treatment is chosen in collaboration with the patient, who should always receive attentive explanations, detailing the prescription and adapting it to each situation so as to achieve maximum compliance. © Masson, Paris, 2005. AD - I. Cochereau, Service d'Ophtalmologie, 4 rue Larrey, 49933 Angers Cedex 9, France AU - Cochereau, I. C1 - alphagan azopt carpilo cosopt diamox pilobloc trusopt xalacom DB - Embase Medline IS - SPEC. ISS. 2 KW - acetazolamide alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent brimonidine brinzolamide carbonate dehydratase inhibitor carpilo cholinergic receptor stimulating agent dorzolamide dorzolamide plus timolol fluorometholone hydroxymethylglutaryl coenzyme A reductase inhibitor latanoprost latanoprost plus timolol mannitol memantine pilobloc prostaglandin timolol allergy bradycardia chronic inflammation depression drug contraindication eye irritation fatigue glaucoma glaucoma surgery headache human hypokalemia hypotension iris disease kidney colic libido disorder miosis myopia neuroprotection patient compliance prescription review alphagan azopt cosopt diamox trusopt xalacom LA - French M3 - Review N1 - L41494678 2005-11-16 PY - 2005 SN - 0181-5512 SP - 2S45-2S47 ST - Medical treatments and practices. Ascertaining maximal drug treatment T2 - Journal Francais d'Ophtalmologie TI - Medical treatments and practices. Ascertaining maximal drug treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41494678&from=export VL - 28 ID - 3686 ER - TY - JOUR AB - Compliance is a major issue in glaucoma, a chronic and asymptomatic disease. The management of the disease by the patient himself is a key point in the prognosis of glaucoma. Ophthalmologists can increase glaucoma patient compliance through education and medicopsychological assistance. AD - I. Cochereau, Service d'ophtalmologie, CHU d'Angers, 4, rue Larrey, 49033 Angers cedex 01. AU - Cochereau, I. DB - Medline IS - 5 Pt 2 KW - article glaucoma human patient compliance patient education psychological aspect quality of life LA - French M3 - Article N1 - L350052918 2007-05-01 PY - 2007 SN - 1773-0597 SP - 3S79-81 ST - Increasing compliance in glaucoma patients through education T2 - Journal français d'ophtalmologie TI - Increasing compliance in glaucoma patients through education UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350052918&from=export VL - 30 ID - 3524 ER - TY - JOUR AD - Division of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, hforitco@gmail.com. Faculty of Social Welfare and Health Sciences, School of Public Health, University of Haifa, Haifa. Department of Ophthalmology, Carmel Medical Center, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa and. Division of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Department of Family Medicine and Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District, Haifa, Israel. Division of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Department of Family Medicine and. AN - 103835551. Language: English. Entry Date: 20150501. Revision Date: 20150803. Publication Type: Journal Article AU - Cohen Castel, Orit AU - Keinan-Boker, Lital AU - Geyer, Orna AU - Milman, Uzi AU - Karkabi, Khaled DB - ccm DO - fampra/cmu031 DP - EBSCOhost IS - 4 KW - Glaucoma -- Drug Therapy Medication Compliance Physician's Role Primary Health Care Aged Aged, 80 and Over Antihypertensive Agents -- Therapeutic Use Cross Sectional Studies Female Human Israel Male Ophthalmology Physicians, Family Questionnaires N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 8500875. PMID: NLM24927725. PY - 2014 SN - 0263-2136 SP - 453-461 ST - Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting T2 - Family Practice TI - Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103835551&site=ehost-live&scope=site VL - 31 ID - 4358 ER - TY - JOUR AB - Objective This article investigates the prevalence and attributes of patients with open-angle glaucoma who exhibit improvement of visual field loss in a clinical setting. Design We conducted a retrospective chart review of patients in a clinical glaucoma practice. Participants We identified 719 glaucoma patients with at least 5 SITA strategy visual field tests and a minimum continuous follow-up period of 5 years. Methods The change in the slope of the visual field index (VFI) over time was illustrated using histogram analysis for the study eye with the worst VFI at baseline. Multiple variables were analyzed to determine their impact on rates of visual field progression, including sex, age, disease staging, intraocular pressure (IOP), and incisional surgeries. Eyes with severe nonophthalmic and ophthalmic comorbidities were excluded. Results Considering 582 eligible eyes, 232 (39.9%) showed significantly positive slopes of the VFI as a function of time, 76 (13.1%) showed nonsignificant slopes, and 276 (47.4%) showed significantly negative slopes. In all, 10 eyes (1.7%) demonstrated VFI slope improvement of ≥2% per year, whereas 21 (3.6%) demonstrated VFI slope reduction ≥2% per year. More advanced disease stage was significantly associated with a negative VFI slope (p < 0.0001). Trabeculectomy and poor compliance were not associated with a negative VFI slope, whereas cataract surgery correlated with higher odds of a negative VFI slope (p = 0.048). Conclusions In a clinical setting, a significant VFI improvement over time was observed over an interval of greater than 5 years. AD - S.L. Cohen, McGill University, 1414 Drummond, Suite 322, Montreal, Que., Canada AU - Cohen, S. L. AU - Rosen, A. I. AU - Tan, X. AU - Kingdom, F. A. A. DB - Embase Medline DO - 10.1016/j.jcjo.2016.10.001 IS - 6 KW - eye drops age aged article cataract extraction comorbidity disease classification follow up histogram human incision intraocular pressure laser surgery major clinical study measurement medical record review open angle glaucoma patient compliance perimetry plots and curves sex staging time trabeculectomy trabeculoplasty visual field visual field defect visual field index LA - English M3 - Article N1 - L613627197 2016-12-14 2019-09-11 PY - 2016 SN - 1715-3360 0008-4182 SP - 445-451 ST - Improvement of the visual field index in clinical glaucoma care T2 - Canadian Journal of Ophthalmology TI - Improvement of the visual field index in clinical glaucoma care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613627197&from=export http://dx.doi.org/10.1016/j.jcjo.2016.10.001 VL - 51 ID - 2693 ER - TY - JOUR AB - Objective This article investigates the prevalence and attributes of patients with open-angle glaucoma who exhibit improvement of visual field loss in a clinical setting. Design We conducted a retrospective chart review of patients in a clinical glaucoma practice. Participants We identified 719 glaucoma patients with at least 5 SITA strategy visual field tests and a minimum continuous follow-up period of 5 years. Methods The change in the slope of the visual field index (VFI) over time was illustrated using histogram analysis for the study eye with the worst VFI at baseline. Multiple variables were analyzed to determine their impact on rates of visual field progression, including sex, age, disease staging, intraocular pressure (IOP), and incisional surgeries. Eyes with severe nonophthalmic and ophthalmic comorbidities were excluded. Results Considering 582 eligible eyes, 232 (39.9%) showed significantly positive slopes of the VFI as a function of time, 76 (13.1%) showed nonsignificant slopes, and 276 (47.4%) showed significantly negative slopes. In all, 10 eyes (1.7%) demonstrated VFI slope improvement of ≥2% per year, whereas 21 (3.6%) demonstrated VFI slope reduction ≥2% per year. More advanced disease stage was significantly associated with a negative VFI slope (p < 0.0001). Trabeculectomy and poor compliance were not associated with a negative VFI slope, whereas cataract surgery correlated with higher odds of a negative VFI slope (p = 0.048). Conclusions In a clinical setting, a significant VFI improvement over time was observed over an interval of greater than 5 years. © 2016 Canadian Ophthalmological Society AD - McGill University, Montreal, Que, Canada University of North Carolina, Chapel Hill, North Carolina, United States AU - Cohen, S. L. AU - Rosen, A. I. AU - Tan, X. AU - Kingdom, F. A. A. DB - Scopus DO - 10.1016/j.jcjo.2016.10.001 IS - 6 M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2016 SP - 445-451 ST - Improvement of the visual field index in clinical glaucoma care T2 - Canadian Journal of Ophthalmology TI - Improvement of the visual field index in clinical glaucoma care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85002730608&doi=10.1016%2fj.jcjo.2016.10.001&partnerID=40&md5=8b364553dddbfbf3b6f81dd9d6bc2ce7 VL - 51 ID - 5458 ER - TY - JOUR AB - Objective: This article investigates the prevalence and attributes of patients with open-angle glaucoma who exhibit improvement of visual field loss in a clinical setting. Design: We conducted a retrospective chart review of patients in a clinical glaucoma practice. Participants: We identified 719 glaucoma patients with at least 5 SITA strategy visual field tests and a minimum continuous follow-up period of 5 years. Methods: The change in the slope of the visual field index (VFI) over time was illustrated using histogram analysis for the study eye with the worst VFI at baseline. Multiple variables were analyzed to determine their impact on rates of visual field progression, including sex, age, disease staging, intraocular pressure (IOP), and incisional surgeries. Eyes with severe nonophthalmic and ophthalmic comorbidities were excluded. Results: Considering 582 eligible eyes, 232 (39.9%) showed significantly positive slopes of the VFI as a function of time, 76 (13.1%) showed nonsignificant slopes, and 276 (47.4%) showed significantly negative slopes. In all, 10 eyes (1.7%) demonstrated VFI slope improvement of >= 2% per year, whereas 21 (3.6%) demonstrated VFI slope reduction >= 2% per year. More advanced disease stage was significantly associated with a negative VFI slope (p < 0.0001). Trabeculectomy and poor compliance were not associated with a negative VFI slope, whereas cataract surgery correlated with higher odds of a negative VFI slope (p = 0.048). Conclusions: In a clinical setting, a significant VFI improvement over time was observed over an interval of greater than 5 years. AN - WOS:000392815000024 AU - Cohen, S. L. AU - Rosen, A. I. AU - Tan, X. M. AU - Kingdom, F. A. A. DA - DEC DO - 10.1016/j.jcjo.2016.10.001 IS - 6 PY - 2016 SN - 0008-4182 1715-3360 SP - 445-451 ST - Improvement of the visual field index in clinical glaucoma care T2 - CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE TI - Improvement of the visual field index in clinical glaucoma care VL - 51 ID - 6216 ER - TY - JOUR AB - BACKGROUND: It is known that office-hour measurements might not adequately estimate IOP mean, peaks and fluctuations in healthy subjects. The purpose of the present study is to verify whether office-hour measurements in patients in different body positions can estimate the characteristics of 24-hour intraocular pressure (IOP) in treated POAG patients. METHODS: The 24-hour IOP curves of 70 eyes of 70 caucasian patients with treated glaucoma were analyzed. Measurements were taken at 9 AM; 12, 3, 6, and 9 PM; and 12, 3, and 6 AM, both in the supine (TonoPen XL) and sitting (Goldmann tonometer) positions. The ability of five strategies to estimate IOP mean, peak and fluctuation was evaluated. Each method was analyzed both with regression of the estimate error on the real value and with "hit or miss" analysis. RESULTS: The least biased estimate of the Peak IOP was obtained using measurements from both supine and sitting positions, also yielding the highest rate of correct predictions (which was significantly different from 3 of the remaining 4 strategies proposed, p < 0.05). Strategies obtained from the combination of supine, sitting and peak measurements resulted to be least biased for the Mean IOP and the IOP Fluctuation estimate, but all strategies were not found significantly different in terms of correct prediction rate (the only significant difference being between the two strategies based on sitting or supine measurements only, with the former being the one with the highest correct prediction rate). CONCLUSIONS: The results of this study remark the concept that IOP is a dynamic parameter and that intensive measurement is helpful in determining its characteristics. All office-hour strategies showed a very poor performance of in correctly predicting the considered parameters within the thresholds used in this paper, all scoring a correct prediction rate below 52%. AU - Colombo, L. AU - Fogagnolo, P. AU - Montesano, G. AU - De Cillà, S. AU - Orzalesi, N. AU - Rossetti, L. DB - Medline DO - 10.1186/s12886-016-0191-7 KW - antihypertensive agent brimonidine drug combination latanoprost prostaglandin F timolol aged ambulatory care body position circadian rhythm drug effect female open angle glaucoma health care facility human intraocular pressure male middle aged oculoplethysmography pathophysiology physiology very elderly LA - English M3 - Article N1 - L615996153 2017-05-16 PY - 2016 SN - 1471-2415 SP - 15 ST - Strategies to estimate the characteristics of 24-hour IOP curves of treated glaucoma patients during office hours T2 - BMC ophthalmology TI - Strategies to estimate the characteristics of 24-hour IOP curves of treated glaucoma patients during office hours UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615996153&from=export http://dx.doi.org/10.1186/s12886-016-0191-7 VL - 16 ID - 2759 ER - TY - JOUR AB - Background: It is known that office-hour measurements might not adequately estimate IOP mean, peaks and fluctuations in healthy subjects. The purpose of the present study is to verify whether office-hour measurements in patients in different body positions can estimate the characteristics of 24-hour intraocular pressure (IOP) in treated POAG patients.Methods: The 24-hour IOP curves of 70 eyes of 70 caucasian patients with treated glaucoma were analyzed. Measurements were taken at 9 AM; 12, 3, 6, and 9 PM; and 12, 3, and 6 AM, both in the supine (TonoPen XL) and sitting (Goldmann tonometer) positions. The ability of five strategies to estimate IOP mean, peak and fluctuation was evaluated. Each method was analyzed both with regression of the estimate error on the real value and with "hit or miss" analysis.Results: The least biased estimate of the Peak IOP was obtained using measurements from both supine and sitting positions, also yielding the highest rate of correct predictions (which was significantly different from 3 of the remaining 4 strategies proposed, p < 0.05). Strategies obtained from the combination of supine, sitting and peak measurements resulted to be least biased for the Mean IOP and the IOP Fluctuation estimate, but all strategies were not found significantly different in terms of correct prediction rate (the only significant difference being between the two strategies based on sitting or supine measurements only, with the former being the one with the highest correct prediction rate).Conclusions: The results of this study remark the concept that IOP is a dynamic parameter and that intensive measurement is helpful in determining its characteristics. All office-hour strategies showed a very poor performance of in correctly predicting the considered parameters within the thresholds used in this paper, all scoring a correct prediction rate below 52%. AD - Eye Clinic, San Paolo Hospital, University of Milan, Via A. Di Rudinì 8, 20142 Milan, Italy AN - 112569917. Language: English. Entry Date: 20180723. Revision Date: 20191029. Publication Type: journal article AU - Colombo, Leonardo AU - Fogagnolo, Paolo AU - Montesano, Giovanni AU - De Cillà, Stefano AU - Orzalesi, Nicola AU - Rossetti, Luca DB - ccm DO - 10.1186/s12886-016-0191-7 DP - EBSCOhost KW - Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Circadian Rhythm -- Physiology Glaucoma -- Physiopathology Intraocular Pressure -- Physiology Office Visits Tonometry Male Timolol -- Therapeutic Use Posture Practitioner's Office Drug Combinations Intraocular Pressure -- Drug Effects Prostaglandins F, Synthetic -- Therapeutic Use Aged, 80 and Over Female Middle Age Aged Human N1 - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 100967802. PMID: NLM26818941. PY - 2016 SN - 1471-2415 SP - 1-12 ST - Strategies to estimate the characteristics of 24-hour IOP curves of treated glaucoma patients during office hours T2 - BMC Ophthalmology TI - Strategies to estimate the characteristics of 24-hour IOP curves of treated glaucoma patients during office hours UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112569917&site=ehost-live&scope=site VL - 16 ID - 4326 ER - TY - JOUR AB - Objectives: To assess the clinical effectiveness and cost-effectiveness of ranibizumab and pegaptanib for subfoveal choroidal neovascularisation (CNV) associated with wet age-related macular degeneration (AMD). Data sources: Electronic databases were searched from inception to September 2006. Experts in the field were consulted and manufacturers' submissions were examined. Review methods: The quality of included studies was assessed using standard methods and the clinical effectiveness data were synthesised through a narrative review with full tabulation of results. A model was developed to estimate the cost-effectiveness of ranibizumab and of pegaptanib (separately), compared with current practice or best supportive care, from the perspective of the NHS and Personal Social Services. Two time horizons were adopted for each model. The first adopted time horizons determined by the available trial data. The second analysis extrapolated effects of treatment beyond the clinical trials, adopting a time horizon of 10 years. Results: The combined analysis of two randomised controlled trials (RCTs) of pegaptanib [0.3 mg (licensed dose), 1.0 mg and 3.0 mg] versus sham injection in patients with all lesion types was reported by three publications (the VISION study). Three published RCTs of ranibizumab were identified (MARINA, ANCHOR, FOCUS), and an additional unpublished RCT was provided by the manufacturer (PIER). Significantly more patients lost less than 15 letters of visual acuity at 12 months when taking pegaptanib (0.3 mg: 70% of patients; 1.0 mg: 71% of patients; 3.0 mg: 65% of patients) or ranibizumab (0.3 mg: 94.3-94.5%; 0.5 mg: 94.6-96.4%) than sham injection patients (55% versus pegaptanib and 62.2% versus ranibizumab) or, in the case of ranibizumab, photodynamic therapy (PDT) (64.3%). The proportion of patients gaining 15 letters or more (a clinically important outcome having a significant impact on quality of life) was statistically significantly greater in the pegaptanib group for doses of 0.3 and 1.0 mg but not for 3.0 mg, and for all ranibizumab groups compared to the sham injection groups or PDT. This was also statistically significant for patients receiving 0.5 mg ranibizumab plus PDT compared with PDT plus sham injection. Pegaptanib patients lost statistically significantly fewer letters after 12 months of treatment than the sham group [mean letters lost: 7.5 (0.3 mg), 6.5 (1.0 mg) or 10 (3.0 mg) vs 14.5 (sham)]. In the MARINA and ANCHOR trials, ranibizumab patients gained letters of visual acuity at 12 months whereas patients with sham injection or PDT lost about 10 letters (p < 0.001) and in the PIER study, ranibizumab patients lost significantly fewer than the sham injection group. Significantly fewer patients receiving pegaptanib or ranibizumab deteriorated to legal blindness compared with the control groups. Adverse events were common for both pegaptanib and ranibizumab but most were mild to moderate. Drug costs for 1 year of treatment were estimated as £4626 for pegaptanib and £9134 for ranibizumab. Non-drug costs accounted for an additional £2614 for pegaptanib and £3120 for ranibizumab. Further costs are associated with the management of injection-related adverse events, from £1200 to £2100. For pegaptanib compared with usual care, the incremental cost-effectiveness ratio (ICER) ranged from £163,603 for the 2-year model to £30,986 for the 10-year model. Similarly, the ICERs for ranibizumab for patients with minimally classic and occult no classic lesions, compared with usual care, ranged from £152,464 for the 2-year model to £25,098 for the 10-year model. Conclusions: Patients with AMD of any lesion type benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. Patients who continued treatment with either drug appeared to maintain benefits after 2 years of follow-up. When comparing pegaptanib and ranibizumab, the evidence was less clear due to the lack of direct comparison through head-to-head trials and the lack of opp rtunity for indirect statistical comparison due to heterogeneity. The cost-effectiveness analysis showed that the two drugs offered additional benefit over the comparators of usual care and PDT but at increased cost. Future research should encompass trials to compare pegaptanib with ranibizumab and bevacizumab, and to investigate the role of verteporfin PDT in combination with these drugs. Studies are also needed to assess adverse events outside the proposed RCTs, to consider the optimal dosing regimes of these drugs and the benefits of re-treatment after initial treatment, and to review costing in more detail. Health state utilities and their relationship with visual acuity and contrast sensitivity, the relationship between duration of vision loss and the quality of life and functional impact of vision loss, behavioural studies of those genetically at risk are other topics requiring further research. © Queen's Printer and Controller of HMSO 2008. All rights reserved. AD - Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research and Development (WIHRD), University of Southampton, Southampton, United Kingdom AU - Colquitt, J. L. AU - Jones, J. AU - Tan, S. C. AU - Takeda, A. AU - Clegg, A. J. AU - Price, A. DB - Scopus DO - 10.3310/hta12160 IS - 16 M3 - Review N1 - Cited By :100 Export Date: 19 July 2021 PY - 2008 SP - iii-107 ST - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation T2 - Health Technology Assessment TI - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-46949111802&doi=10.3310%2fhta12160&partnerID=40&md5=47127b513c52e7749886e765cebe8f44 VL - 12 ID - 4930 ER - TY - JOUR AB - THE REMOVAL OF large acoustic tumors is associated with increased mortality and cranial nerve injury. One method for treating these difficult lesions is staged resection. Between 1972 and 1992, more than 600 acoustic tumors were resected at our institution. Of these, 83 were removed in stages. This represents the largest series of staged acoustic tumor resections reported to date. A review of available films and patient records was performed for all acoustic tumors resected in stages between 1972 and early 1993 to analyze demographic information, tumor size, operative technique, outcome, and complications. The information was collected on standardized data sheets and entered into a computer database. Virtually all tumors were large, with the average size being 4 cm in greatest diameter. The average patient age was 41 years, and there was a slight preponderance of female patients. Ten patients had neurofibromatosis Type 2. The suboccipital approach was used in most patients. Anatomic preservation of the VIIth cranial nerve was achieved in >72% of patients, with an average House-Brackmann score of Grade 3 at the longest follow-up (mean, 43 mo). Facial reanimation was performed in 19 of 23 patients with transected VIIth cranial nerves. Complications included cerebrospinal fluid fistulas in 11 patients, with 8 of 11 fistulas resolving after lumbar drainage. Six patients had meningitis (bacterial in three and aseptic in three). Two patients developed wound infections, and 10 patients developed exposure keratitis. There were two documented recurrences. There were no operative deaths. In most series, the incidence of cranial nerve deficits as well as morbidity and mortality is directly related to tumor size. Our operative strategy involved debulking the lateral aspect of large tumors during Stage I. Second stage removal is performed after the remaining tumor is shown to decompress out of the pons on computed tomographic or magnetic resonance images. During the second procedure, the residual tumor is less vascular and no longer densely adherent to the brain stem. Although staged removal is not without risk, there seems to be no apparent increase in morbidity when these results are compared with the results of series from the literature. Although there remain no absolute indications for staged resection of acoustic tumors, we think that it may represent the safest option for these difficult lesions. © by the Congress of Neurological Surgeons. AD - Department of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, United States AU - Comey, C. H. AU - Jannetta, P. J. AU - Sheptak, P. E. AU - Jho, H. D. AU - Burkhart, L. E. DB - Scopus DO - 10.1227/00006123-199511000-00010 IS - 5 KW - Acoustic neuroma Cerebellopontine angle tumor Staged resection Vestibular schwannoma M3 - Article N1 - Cited By :35 Export Date: 19 July 2021 PY - 1995 SP - 915-921 ST - Staged removal of acoustic tumors: Techniques and lessons learned from a series of 83 patients T2 - Neurosurgery TI - Staged removal of acoustic tumors: Techniques and lessons learned from a series of 83 patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028875667&doi=10.1227%2f00006123-199511000-00010&partnerID=40&md5=94fa337d7ff107cb744bfbb15c713c5e VL - 37 ID - 5038 ER - TY - JOUR AB - Background: Poor adherence hinders glaucoma treatment. Studies have identified demographic and clinical predictors of adherence but fewer psychological variables.Purpose: We examined predictors from four health behavior theories and past research.Methods: In the baseline phase of a three-site adherence study, before any intervention, 201 participants used electronic Medication Event Monitoring System (MEMS) bottles to monitor eyedrop use for 2 months, and completed questionnaires including self-reported adherence.Results: MEMS showed 79% adherence and self-report 94% (0.5-1.5 missed weekly doses), but they correlated only r(s) = 0.31. Self-efficacy, motivation, dose frequency, and nonminority race/ethnicity predicted 35% of variance in MEMS. Cues to action, self-efficacy, and intention predicted 20% of variance in self-reported adherence.Conclusions: Self-efficacy, motivation, intention, cues to action, dose frequency, and race/ethnicity each independently predicted adherence. Predictors from all theories were supported in bivariate analyses, but additional study is needed. Researchers and clinicians should consider psychological predictors of adherence. (ClinicalTrials.gov ID# NCT01409421.). AN - 109702819. Language: English. Entry Date: 20150923. Revision Date: 20200708. Publication Type: journal article AU - Cook, Paul F. AU - Schmiege, Sarah J. AU - Mansberger, Steven L. AU - Kammer, Jeffrey AU - Fitzgerald, Timothy AU - Kahook, Malik Y. DB - ccm DO - 10.1007/s12160-014-9641-8 DP - EBSCOhost IS - 1 N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Psychiatry/Psychology. Grant Information: 1UL1RR025780-01/RR/NCRR NIH HHS/United States. NLM UID: 8510246. PMID: NLM25248302. PY - 2015 SN - 0883-6612 SP - 29-39 ST - Predictors of adherence to glaucoma treatment in a multisite study T2 - Annals of Behavioral Medicine TI - Predictors of adherence to glaucoma treatment in a multisite study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109702819&site=ehost-live&scope=site VL - 49 ID - 4310 ER - TY - JOUR AB - Background: Poor adherence hinders glaucoma treatment. Studies have identified demographic and clinical predictors of adherence but fewer psychological variables. Purpose: We examined predictors from four health behavior theories and past research. Methods: In the baseline phase of a three-site adherence study, before any intervention, 201 participants used electronic Medication Event Monitoring System (MEMS) bottles to monitor eyedrop use for 2 months, and completed questionnaires including self-reported adherence. Results: MEMS showed 79 % adherence and self-report 94 % (0.5–1.5 missed weekly doses), but they correlated only rs = 0.31. Self-efficacy, motivation, dose frequency, and nonminority race/ethnicity predicted 35 % of variance in MEMS. Cues to action, self-efficacy, and intention predicted 20 % of variance in self-reported adherence. Conclusions: Self-efficacy, motivation, intention, cues to action, dose frequency, and race/ethnicity each independently predicted adherence. Predictors from all theories were supported in bivariate analyses, but additional study is needed. Researchers and clinicians should consider psychological predictors of adherence. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Cook, Paul F., University of Colorado College of Nursing, Campus Box C288-04, Aurora, CO, US, 80045 AN - 2015-08126-006 AU - Cook, Paul F. AU - Schmiege, Sarah J. AU - Mansberger, Steven L. AU - Kammer, Jeffrey AU - Fitzgerald, Timothy AU - Kahook, Malik Y. DB - psyh DO - 10.1007/s12160-014-9641-8 DP - EBSCOhost IS - 1 KW - Attitude Glaucoma Medication adherence Motivation Theory Adult Aged Aged, 80 and over Female Health Behavior Health Knowledge, Attitudes, Practice Humans Male Middle Aged Self Efficacy Self Report Young Adult Treatment Compliance Attitudes Theories N1 - University of Colorado College of Nursing, Aurora, CO, US. Other Publishers: Lawrence Erlbaum; Oxford University Press. Release Date: 20150330. Correction Date: 20180503. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Glaucoma; Motivation; Treatment Compliance. Minor Descriptor: Attitudes; Theories. Classification: Vision & Hearing & Sensory Disorders (3299); Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Visual Functioning Questionnaire; Herzog Motivation Scale; Adherence Attitude Inventory; 36-Item Short Form Health Survey DOI: 10.1037/t07023-000. Methodology: Empirical Study; Interview; Quantitative Study; Treatment Outcome. References Available: Y. Page Count: 11. Issue Publication Date: Feb, 2015. Publication History: First Posted Date: Sep 24, 2014. Copyright Statement: The Society of Behavioral Medicine. 2014. Sponsor: Merck & Co., Inc., US. Recipients: No recipient indicated Sponsor: National Institutes of Health, Colorado Clinical and Translational Science Institute, US. Grant: 1UL1RR025780-01. Recipients: No recipient indicated PY - 2015 SN - 0883-6612 1532-4796 SP - 29-39 ST - Predictors of adherence to glaucoma treatment in a multisite study T2 - Annals of Behavioral Medicine TI - Predictors of adherence to glaucoma treatment in a multisite study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-08126-006&site=ehost-live&scope=site paul.cook@ucdenver.edu VL - 49 ID - 4826 ER - TY - JOUR AB - Objective:Nonadherence reduces glaucoma treatment efficacy. Motivational interviewing (MI) is a well-studied adherence intervention, but has not been tested in glaucoma. Reminder interventions also may improve adherence. Design:201 patients with glaucoma or ocular hypertension were urn-randomised to receive MI delivered by an ophthalmic technician (OT), usual care or a minimal behavioural intervention (reminder calls). Main Outcome Measures:Outcomes included electronic monitoring with Medication Event Monitoring System (MEMS) bottles, two self-report adherence measures, patient satisfaction and clinical outcomes. Multilevel modelling was used to test differences in MEMS results by group over time; ANCOVA was used to compare groups on other measures. Results:Reminder calls increased adherence compared to usual care based on MEMS,p = .005, and self-report,p = .04. MI had a nonsignificant effect but produced higher satisfaction than reminder calls,p = .007. Treatment fidelity was high on most measures, with observable differences in behaviour between groups. All groups had high baseline adherence that limited opportunities for change. Conclusion:Reminder calls, but not MI, led to better adherence than usual care. Although a large literature supports MI, reminder calls might be a cost-effective intervention for patients with high baseline adherence. Replication is needed with less adherent participants. AD - College of Nursing, University of Colorado, Aurora, CO, USA Devers Eye Institute, Legacy Health, Portland, OR, USA Vanderbilt Eye Institute, Vanderbilt University, Nashville, TN, USA Global Health Outcomes, Merck & Co. Inc., White Horse Station, NJ, USA School of Medicine, University of Colorado, Aurora, CO, USA AN - 120431503. Language: English. Entry Date: 20170106. Revision Date: 20190213. Publication Type: Article AU - Cook, Paul F. AU - Schmiege, Sarah J. AU - Mansberger, Steven L. AU - Sheppler, Christina AU - Kammer, Jeffrey AU - Fitzgerald, Timothy AU - Kahook, Malik Y. DB - ccm DO - 10.1080/08870446.2016.1244537 DP - EBSCOhost IS - 2 KW - Motivational Interviewing -- Methods Glaucoma -- Drug Therapy Medication Compliance Reminder Systems Human Randomized Controlled Trials Self Report Patient Satisfaction Treatment Outcomes Analysis of Covariance P-Value Colorado Oregon Tennessee Aged Ocular Hypertension -- Drug Therapy Male Female Chi Square Test Comorbidity Random Assignment Prospective Studies Drug Monitoring Questionnaires Aged, 80 and Over Summated Rating Scaling Coefficient Alpha Regression Variable Pretest-Posttest Design Power Analysis Effect Size Intraclass Correlation Coefficient Coding Checklists Exploratory Research Funding Source N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Instrumentation: 31-item Adherence Attitude Inventory (AAI) (Lewis & Abell); 8-item Morisky scale (Krousel-Wood et al.); Visual Functioning Questionnaire (VFQ-25) (Mangione et al.). Grant Information: This work was funded by a grant from Merck & Co., Inc., with additional support from theColorado Clinical and Translational Science Institute, NIH [grant #1UL1RR025780-01].. NLM UID: 8807983. PY - 2017 SN - 0887-0446 SP - 145-165 ST - Motivational interviewing or reminders for glaucoma medication adherence: Results of a multi-site randomised controlled trial T2 - Psychology & Health TI - Motivational interviewing or reminders for glaucoma medication adherence: Results of a multi-site randomised controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120431503&site=ehost-live&scope=site VL - 32 ID - 4164 ER - TY - JOUR AB - Objective: Nonadherence reduces glaucoma treatment efficacy. Motivational interviewing (MI) is a well-studied adherence intervention, but has not been tested in glaucoma. Reminder interventions also may improve adherence. Design: 201 patients with glaucoma or ocular hypertension were urn-randomised to receive MI delivered by an ophthalmic technician (OT), usual care or a minimal behavioural intervention (reminder calls). Main Outcome Measures: Outcomes included electronic monitoring with Medication Event Monitoring System (MEMS) bottles, two self-report adherence measures, patient satisfaction and clinical outcomes. Multilevel modelling was used to test differences in MEMS results by group over time; ANCOVA was used to compare groups on other measures. Results: Reminder calls increased adherence compared to usual care based on MEMS, p = .005, and self-report, p = .04. MI had a nonsignificant effect but produced higher satisfaction than reminder calls, p = .007. Treatment fidelity was high on most measures, with observable differences in behaviour between groups. All groups had high baseline adherence that limited opportunities for change. Conclusion: Reminder calls, but not MI, led to better adherence than usual care. Although a large literature supports MI, reminder calls might be a cost-effective intervention for patients with high baseline adherence. Replication is needed with less adherent participants. (PsycINFO Database Record (c) 2017 APA, all rights reserved) AD - Cook, Paul F. AN - 2016-60534-002 AU - Cook, Paul F. AU - Schmiege, Sarah J. AU - Mansberger, Steven L. AU - Sheppler, Christina AU - Kammer, Jeffrey AU - Fitzgerald, Timothy AU - Kahook, Malik Y. DB - psyh DO - 10.1080/08870446.2016.1244537 DP - EBSCOhost IS - 2 KW - adherence glaucoma motivational interviewing reminder treatment satisfaction Client Satisfaction Treatment Compliance N1 - College of Nursing, University of Colorado, Aurora, CO, US. Release Date: 20170112. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Client Satisfaction; Glaucoma; Motivational Interviewing; Treatment Compliance. Classification: Health Psychology & Medicine (3360). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Clinical Trial; Empirical Study; Interview; Quantitative Study. References Available: Y. Page Count: 21. Issue Publication Date: Feb, 2017. Publication History: Accepted Date: Sep 27, 2016; First Submitted Date: Mar 14, 2016. Copyright Statement: Informa UK Limited, trading as Taylor & Francis Group. 2016. Sponsor: Merck & Co., Inc., US. Recipients: No recipient indicated Sponsor: National Institutes of Health, Colorado Clinical and Translational Science Institute, US. Grant: 1UL1RR025780-01. Recipients: No recipient indicated PY - 2017 SN - 0887-0446 1476-8321 SP - 145-165 ST - Motivational interviewing or reminders for glaucoma medication adherence: Results of a multi-site randomised controlled trial T2 - Psychology & Health TI - Motivational interviewing or reminders for glaucoma medication adherence: Results of a multi-site randomised controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-60534-002&site=ehost-live&scope=site paul.cook@ucdenver.edu VL - 32 ID - 4807 ER - TY - JOUR AB - Many older patients attending ophthalmic out-patient clinics have been prescribed eye drops for long-term use to treat glaucoma but do not continue with their treatment. This review looks at chronic simple glaucoma, the problems of compliance with long-term medical treatment in older people and the current and future treatment of glaucoma. Recommendations are made on the nurses' role in supporting these patients. AD - J. Cooper AU - Cooper, J. DB - Medline IS - 32 KW - aged human nursing open angle glaucoma patient compliance patient education review LA - English M3 - Review N1 - L126287475 1996-11-27 PY - 1996 SN - 0954-7762 SP - 36-37 ST - Improving compliance with glaucoma eye-drop treatment T2 - Nursing times TI - Improving compliance with glaucoma eye-drop treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L126287475&from=export VL - 92 ID - 3974 ER - TY - JOUR AB - Many older patients attending ophthalmic out-patient clinics have been prescribed eye drops for long-term use to treat glaucoma but do not continue with their treatment. This review looks at chronic simple glaucoma, the problems of compliance with long-term medical treatment in older people and the current and future treatment of glaucoma. Recommendations are made on the nurses' role in supporting these patients. AD - Ophthalmic Out-Patients Dept, Royal Hampshire County Hospital, Winchester AN - 107386010. Language: English. Entry Date: 19961001. Revision Date: 20150819. Publication Type: Journal Article. Supplement Title: 1996 Aug 7-13 Prof Dev. Journal Subset: Core Nursing AU - Cooper, J. DB - ccm DP - EBSCOhost IS - 32 KW - Glaucoma -- Drug Therapy Patient Compliance Administration, Intraocular -- Education Patient Education Glaucoma -- Nursing Ophthalmic Nursing N1 - Double Blind Peer Reviewed; Europe; Expert Peer Reviewed; Nursing; Peer Reviewed; UK & Ireland. NLM UID: 0423236. PMID: NLM8826416. PY - 1996 SN - 0954-7762 SP - 36-37 ST - Improving compliance with glaucoma eye-drop treatment T2 - Nursing Times TI - Improving compliance with glaucoma eye-drop treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107386010&site=ehost-live&scope=site VL - 92 ID - 4716 ER - TY - JOUR AB - Contact lenses, when worn and cared for properly, are a safe and effective form of vision correction used by an estimated 45 million Americans. However, contact lens wearers are at risk for contact lens-related eye infections, especially when wearers do not practice proper contact lens wear and care habits. These infections, affecting the cornea and known as microbial keratitis (Figure), can lead to serious adverse health outcomes. Because contact lenses are regulated by the Food and Drug Administration (FDA) as medical devices, contact lens-related corneal infections should be reported to FDA as an adverse event. To illustrate their serious health implications, six cases of contact lens-related corneal infection, in which sleeping in lenses was reported as the main risk factor, are presented. Consequences of infection reported among the identified cases included the need for frequent administration of antibiotic eye drops, multiple follow-up medical appointments, and permanent eye damage. Health education measures directed toward contact lens wearers should emphasize raising awareness of the risks of sleeping in contact lenses as well as adherence to all recommendations for the wear and care of contact lenses. Additional measures are needed to educate eye care professionals about the need to report contact lens-related corneal infections to MedWatch, the FDA Safety Information and Adverse Event Reporting program (https://www.fda.gov/MedWatch/). AD - Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC Massachusetts Eye and Ear Infirmary, Boston, Massachusetts University of Pittsburgh Medical Center Eye Center, Pittsburgh, Pennsylvania New York Eye and Ear Infirmary of Mount Sinai, New York, New York MetroHealth Medical Center, Cleveland, Ohio Case Western Reserve University School of Medicine, Cleveland, Ohio AN - 131306881. Language: English. Entry Date: In Process. Revision Date: 20190110. Publication Type: journal article AU - Cope, Jennifer R. AU - Konne, Nuadum Muriel AU - Jacobs, Deborah S. AU - Dhaliwal, Deepinder K. AU - Rhee, Michelle K. AU - Jia, Yin AU - Steinemann, Thomas L. AU - Yin, Jia DB - ccm DO - 10.15585/mmwr.mm6732a2 DP - EBSCOhost IS - 32 KW - Corneal Diseases -- Diagnosis Sleep Risk Taking Behavior Eye Infections -- Diagnosis Contact Lenses -- Adverse Effects Adolescence Female Corneal Diseases -- Epidemiology Eye Infections -- Epidemiology United States Adult Middle Age Male Contact Lenses Clinical Assessment Tools N1 - case study. Journal Subset: Biomedical; Public Health; USA. Instrumentation: Frenchay Dysarthria Assessment (FDA). Grant Information: K12 EY016335/EY/NEI NIH HHS/United States. NLM UID: 7802429. PMID: NLM30114003. PY - 2018 SN - 0149-2195 SP - 877-881 ST - Corneal Infections Associated with Sleeping in Contact Lenses - Six Cases, United States, 2016-2018 T2 - MMWR: Morbidity & Mortality Weekly Report TI - Corneal Infections Associated with Sleeping in Contact Lenses - Six Cases, United States, 2016-2018 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131306881&site=ehost-live&scope=site VL - 67 ID - 4209 ER - TY - JOUR AD - Department of Urology, Jewish General Hospital, McGill University, Montreal, QC, Canada Northern Alberta Urology Centre, Edmonton, AB, Canada Division of Urology, Department of Surgery, Ottawa Hospital, Ottawa, ON, Canada Division of Urology, Toronto Western Hospital, University of Toronto, University Health Network, Toronto, ON, Canada Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada Department of Medicine, University of Alberta, Edmonton, AB, Canada AU - Corcos, J. AU - Przydacz, M. AU - Campeau, L. AU - Gray, G. AU - Hickling, D. AU - Honeine, C. AU - Radomski, S. B. AU - Stothers, L. AU - Wagg, A. DB - Scopus DO - 10.5489/cuaj.4586 IS - 5 M3 - Review N1 - Cited By :53 Export Date: 19 July 2021 PY - 2017 SP - E142-E173 ST - CUA guideline on adult overactive bladder T2 - Canadian Urological Association Journal TI - CUA guideline on adult overactive bladder UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020713755&doi=10.5489%2fcuaj.4586&partnerID=40&md5=d48e5d48b355f0a645b07a67d3b9773e VL - 11 ID - 4987 ER - TY - JOUR AB - Purpose: To estimate the prevalence and causes of blindness and visual impairment, cataract surgical coverage (CSC), visual outcome of cataract surgery, and barriers to uptake cataract surgery in Timor-Leste. Method: In a nationwide rapid assessment of avoidable blindness (RAAB), the latest population (1,066,409) and household data were used to create a sampling frame which consists of 2,227 population units (study clusters) from all 13 districts, with populations of 450-900 per unit. The sample size of 3,350 was calculated with the assumed prevalence of blindness at 4.5% among people aged ≥50 years with a 20% tolerable error, 95% CI, and a 90% response rate. The team was trained in the survey methodology, and inter-observer variation was measured. Door-to-door visits, led by an ophthalmologist, were made in preselected study clusters, and data were collected in line with the RAAB5 survey protocol. An Android smart phone installed with mRAAB software was used for data collection. Result: The age-gender standardized prevalence of blindness, severe visual impairment, and visual impairment were 2.8%, (1.8-3.8), 1.7% (1.7-2.3), and 8.1% (6.6-9.6), respectively. Cataract was the leading cause of blindness (79.4%). Blindness was more prevalent in the older age group and in women. CSC was 41.5% in cataract blind eyes and 48.6% in cataract blind people. Good visual outcome in the cataract-operated eyes was 62% (presenting) and 75.2% (best corrected). Two important barriers to not using available cataract surgical services were accessibility (45.5%) and lack of attendants to accompany (24.8%). Conclusion: The prevalence of blindness and visual impairment in Timor-Leste remains high. CSC is unacceptably low; gender inequity in blindness and CSC exists. Lack of access is the prominent barrier to cataract surgery. © 2017 Correia et al. AD - National Eye Center, Guido Valadares National Hospital, Dili, Timor Leste International Agency for Prevention of Blindness South East Asia Regional Office, LV Prasad Eye Institute, Banjara Hills, Hyderabad, India LV Prasad Eye Institute, Hyderabad, India International Centre for Eye Health, London, United Kingdom International Agency for Prevention of Blindness, London, United Kingdom Ophthalmology Department, University of Tasmania and Sydney, Royal Hobart Hospital, North HobartTAS, Australia AU - Correia, M. AU - Das, T. AU - Magno, J. AU - Pereira, B. M. AU - Andrade, V. AU - Limburg, H. AU - Trevelyan, J. AU - Keeffe, J. AU - Verma, N. AU - Sapkota, Y. DB - Scopus DO - 10.2147/OPTH.S146901 KW - Blindness Population based survey Prevalence RAAB Timor M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2017 SP - 2125-2131 ST - Prevalence and causes of blindness, visual impairment, and cataract surgery in Timor-Leste T2 - Clinical Ophthalmology TI - Prevalence and causes of blindness, visual impairment, and cataract surgery in Timor-Leste UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044331388&doi=10.2147%2fOPTH.S146901&partnerID=40&md5=38043f5d810800d816c1bf05a51f2c14 VL - 11 ID - 5325 ER - TY - JOUR AB - Introduction: To report the case of a high hyperopic refractive shift associated with significant shortening of the ocular axial length following glaucoma filtering surgery. Methods: Case report. Patient’s records were consulted retrospectively. Results: A 57-year-old woman, highly myopic, with a history of bilateral intraocular refractive surgery in 1998 (phakic lens ZB5M) and bilensectomy in 2011 (phakic intraocular lens extraction plus cataract surgery with pseudophakic intraocular lens implantation), presented with consistently high intraocular pressure. Despite the treatment with different topical antiglaucomatous medications and good compliance, her intraocular pressure values remained consistently above 20 mmHg. In 2016, the patient was submitted for glaucoma filtering surgery and the mini shunt Ex-Press was implanted in both the eyes (3 months between surgeries). On the first postoperative day, the eyes were hypotonic (intraocular pressure of 5 mmHg) and bilateral macular edema was observed. Three days later, the intraocular pressure in both the eyes reached values higher than 6 mmHg (between 6 and 14 mmHg). Five months after the surgery the macular edema resolved and a significant shortening of the axial length and an important hyperopic refractive shift was observed. When comparing the preoperative and postoperative (18 months) measurements, the variation of the axial length was 2.49 mm in the right eye and 2.19 mm in the left eye; the patient refraction (spherical equivalent) shifted 2.50 diopters in the right eye and 1.75 diopters in the left eye. Conclusion: To the best of our knowledge, we report herein the first documented case of an axial length change of this magnitude after glaucoma filtering surgery. AD - J. Alió, Cornea, Cataract and Refractive Surgery Unit, Vissum Corporación, Alicante, Spain AU - Costa, J. C. AU - Alió, J. DB - Embase Medline DO - 10.1177/1120672118794564 IS - 1 KW - Acrysof MA60MA applanation tonometer nonvalved ophthalmic drainage device ophthalmological implant phakic intraocular lens antiglaucoma agent corticosteroid latanoprost plus timolol mitomycin nepafenac adult article best corrected visual acuity case report cataract extraction clinical article eye axis length eye refraction female glaucoma surgery high myopia human hypermetropia interferometry intraocular hypertension intraocular hypotension intraocular pressure keratometry lens implantation macular edema middle aged ophthalmoscopy optometry patient compliance priority journal refractive surgery retina degeneration retinal pigment epithelium retrospective study subretinal neovascularization tonometry visual impairment Ex-Press LA - English M3 - Article N1 - L625851008 2019-01-15 2019-02-04 PY - 2019 SN - 1120-6721 SP - NP6-NP9 ST - Significant hyperopic shift in a patient with extreme myopia following severe hypotonia caused by glaucoma filtering surgery T2 - European Journal of Ophthalmology TI - Significant hyperopic shift in a patient with extreme myopia following severe hypotonia caused by glaucoma filtering surgery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625851008&from=export http://dx.doi.org/10.1177/1120672118794564 VL - 29 ID - 2548 ER - TY - JOUR AB - Glaucoma is a pathological condition whose most important risk factor is increased intraocular pressure (IOP). The medical treatment of glaucoma essentially consists of compounds that are able to decrease the IOP. The compounds discussed in this review act in a different way, β-blockers mainly inhibit the production of aqueous humor, whereas latanoprost decreases the resistance in the outflow channels. β-Blockers are compounds with a well-known efficacy and safety profile and they are fairly inexpensive. Their systemic and local side effects are mainly cardiovascular and pulmonary adverse events, dry eye and keratopathy. Latanoprost, which has recently been introduced into the market, has been shown to be equally as effective, or better in lowering IOP in patients than timolol, although it is more expensive. Systemic reported side effects are anecdotal; local hyperaemia, keratopathy, hypertrichosis, increased pigmentation of eyelashes and iris, uveitis and cystoid macular oedema have been reported. A comparison of costs reveals that a 1-year therapy with timolol ophthalmic solution starts from €11.00 and can reach €146.00 for the most expensive preservative-free 1-day dispenser packages (∼ 13.5 times higher). For latanoprost once-daily administration, the cost for 1-years therapy is €98.55, approximately six times higher than generic or brand 0.5% timolol applied twice-daily. What are the factors influencing a change in therapy from β-blockers to latanoprost? The only good reason is represented by a further deterioration in the visual field. This may occur, despite a significant reduction in IOP, because the reached IOP is not sufficient enough to avoid further deterioration because the patient's work or social activities do not allow a correct daily dosage of the compound (bad compliance); or as a result of treatment suspension, because of the development of systemic and/or local side effects. Changes in therapy must always be related to a failing control of the disease, as any therapeutic modification leading to an increase in the number of visits and additional examinations, consequently enhances the costs. AD - C. Costagliola, Corso Giovecca 203, 44100 Ferrara, Italy AU - Costagliola, C. AU - Parmeggiani, F. AU - Sebastiani, A. C1 - betaclar(Angelini) betoptic s(Alcon) betoptic(Alcon) carteol(Societa Industria Farmaceutica Italiana) droptimol tg(Farmigea) droptimol(Farmigea) nyogel(Novartis) oftimolo(Farmila Farmaceutici Milano) timolabak(Farmila Farmaceutici Milano) timololo ciba vision(Novartis) timolux(Tubilux) timoptol xe(Merck Sharp and Dohme) timoptol(Merck Sharp and Dohme) turoptin(Novartis) vistagan(Allergan) xalatan(Pharmacia Upjohn) C2 - Alcon Allergan Angelini Farmigea Farmila Farmaceutici Milano Merck Sharp and Dohme Novartis Pharmacia Upjohn Societa Industria Farmaceutica Italiana Tubilux DB - Embase Medline DO - 10.1517/eoph.4.10.1775.22310 IS - 10 KW - acetazolamide epinephrine befunolol beta 1 adrenergic receptor blocking agent beta 2 adrenergic receptor blocking agent beta adrenergic receptor blocking agent betaclar betaxolol carteolol cyclic AMP droptimol tg eye drops latanoprost levobunolol metipranolol timolol maleate oftimolo pilocarpine pindolol prostaglandin derivative timolol timololo ciba vision timolux turoptin aqueous humor formation aqueous humor outflow cardiovascular disease clinical trial cost benefit analysis cost effectiveness analysis cost minimization analysis cost utility analysis deterioration drug clearance drug cost drug efficacy drug elimination drug half life drug inhibition drug mechanism drug safety dry eye eyelash flu like syndrome glaucoma herpes simplex human hyperemia hypertrichosis intraocular hypertension intraocular pressure iris disease keratopathy lung disease medical examination mental disease myalgia neurologic disease patient compliance rash retina macula cystoid edema review risk factor sexual dysfunction social behavior treatment failure treatment planning uveitis visual field defect betoptic s betoptic carteol droptimol nyogel timolabak timoptol xe timoptol vistagan xalatan LA - English M3 - Review N1 - L37322362 2003-11-10 PY - 2003 SN - 1465-6566 SP - 1775-1788 ST - Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension T2 - Expert Opinion on Pharmacotherapy TI - Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37322362&from=export http://dx.doi.org/10.1517/eoph.4.10.1775.22310 VL - 4 ID - 3796 ER - TY - JOUR AB - Glaucoma is a pathological condition whose most important risk factor is increased intraocular pressure (IOP). The medical treatment of glaucoma essentially consists of compounds that are able to decrease the IOP. The compounds discussed in this review act in a different way, β-blockers mainly inhibit the production of aqueous humor, whereas latanoprost decreases the resistance in the outflow channels. β-Blockers are compounds with a well-known efficacy and safety profile and they are fairly inexpensive. Their systemic and local side effects are mainly cardiovascular and pulmonary adverse events, dry eye and keratopathy. Latanoprost, which has recently been introduced into the market, has been shown to be equally as effective, or better in lowering IOP in patients than timolol, although it is more expensive. Systemic reported side effects are anecdotal; local hyperaemia, keratopathy, hypertrichosis, increased pigmentation of eyelashes and iris, uveitis and cystoid macular oedema have been reported. A comparison of costs reveals that a 1-year therapy with timolol ophthalmic solution starts from €11.00 and can reach €146.00 for the most expensive preservative-free 1-day dispenser packages (∼ 13.5 times higher). For latanoprost once-daily administration, the cost for 1-years therapy is €98.55, approximately six times higher than generic or brand 0.5% timolol applied twice-daily. What are the factors influencing a change in therapy from β-blockers to latanoprost? The only good reason is represented by a further deterioration in the visual field. This may occur, despite a significant reduction in IOP, because the reached IOP is not sufficient enough to avoid further deterioration because the patient's work or social activities do not allow a correct daily dosage of the compound (bad compliance); or as a result of treatment suspension, because of the development of systemic and/or local side effects. Changes in therapy must always be related to a failing control of the disease, as any therapeutic modification leading to an increase in the number of visits and additional examinations, consequently enhances the costs. AD - Corso Giovecca 203, 44100 Ferrara, Italy Department of Ophthalmology, University of Ferrara, Ferrara, Italy AU - Costagliola, C. AU - Parmeggiani, F. AU - Sebastiani, A. DB - Scopus DO - 10.1517/14656566.4.10.1775 IS - 10 KW - Compliance Cost Glaucoma Hypertension Latanoprost Ocular Side effects β-blockers M3 - Review N1 - Cited By :14 Export Date: 19 July 2021 PY - 2003 SP - 1775-1788 ST - Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension T2 - Expert Opinion on Pharmacotherapy TI - Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0142148155&doi=10.1517%2f14656566.4.10.1775&partnerID=40&md5=58ea49f0b303c3d0f514ab3bea1c4669 VL - 4 ID - 5208 ER - TY - JOUR AB - Glaucoma is a pathological condition whose most important risk factor is increased intraocular pressure (IOP). The medical treatment of glaucoma essentially consists of compounds that are able to decrease the IOP. The compounds discussed in this review act in a different way, beta-blockers mainly inhibit the production of aqueous humor, whereas latanoprost decreases the resistance in the outflow channels. beta-Blockers are compounds with a well-known efficacy and safety profile and they are fairly inexpensive. Their systemic and local side effects are mainly cardiovascular and pulmonary adverse events, dry eye and keratopathy. Latanoprost, which has recently been introduced into the market, has been shown to be equally as effective, or better in lowering IOP in patients than timolol, although it is more expensive. Systemic reported side effects are anecdotal; local hyperaemia, keratopathy, hypertrichosis, increased pigmentation of eyelashes and iris, uveitis and cystoid macular oedema have been reported. A comparison of costs reveals that a 1-year therapy with timolol ophthalmic solution starts from Euro11.00 and can reach Euro146.00 for the most expensive preservative-free 1-day dispenser packages (similar to 13.5 times higher). For latanoprost once-daily administration, the cost for 1-years therapy is Euro98.55, approximately six times higher than generic or brand 0.5% timolol applied twice-daily. What are the factors influencing a change in therapy from beta-blockers to latanoprost? The only good reason is represented by a further deterioration in the visual field. This may occur, despite a significant reduction in IOP, because the reached IOP is not sufficient enough to avoid further deterioration because the patient's work or social activities do not allow a correct daily dosage of the compound (bad compliance); or as a result of treatment suspension, because of the development of systemic and/or local side effects. Changes in therapy must always be related,to a failing control of the disease, as any therapeutic modification leading to an increase in the number of visits and additional examinations, consequently enhances the costs. AN - WOS:000185994400014 AU - Costagliola, C. AU - Parmeggiani, F. AU - Sebastiani, A. DA - OCT DO - 10.1517/14656566.4.10.1775 IS - 10 PY - 2003 SN - 1465-6566 1744-7666 SP - 1775-1788 ST - Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension T2 - EXPERT OPINION ON PHARMACOTHERAPY TI - Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension VL - 4 ID - 6208 ER - TY - JOUR AB - Purpose: This study contrasts the utilization of adjunctive medication associated with travoprost, bimatoprost, or latanoprost, as primary glaucoma therapies. Methods: Patients in the Medco Health database who initiated prostaglandin analog therapy on travoprost, bimatoprost or latanoprost between January 1, 2002 and July 31, 2002 were selected if they had no prostaglandin analog use in the prior 6 months. Patients were also required to have 12 months of prostaglandin therapy subsequent to the initial prescription. Data were available through July 31, 2003. The t-test and chi-square were used where appropriate to calculate p-values and assess significant differences. Results: A total of 13 171 benefit-eligible subjects were identified of which 8381 (64%), 2637 (20%), and 2153 (16%) patients were treated with latanoprost, bimatoprost, and travoprost, respectively. There were no significant differences in mean age or gender between the three study groups with the exception that latanoprost patients were statistically older than travoprost patients (69.0 vs. 68.0). This was not considered a clinically meaningful difference. Overall, patients using travoprost or bimatoprost had a significantly lower rate of adjunctive medication use compared to patients starting on latanoprast monotherapy (22.5%, 23.2%, and 30.2%, respectively). Therefore, for every 14 patients treated with latanoprost instead of travoprost or bimatoprost, one additional patient would be expected to need adjunctive therapy with another agent. The difference between travoprost and bimatoprost patients was not significant. Conclusions: The use of adjunctive medications to control intraocular pressure was significantly higher for latanoprost patients compared to travoprost and bimatoprost patients. This finding should be interpreted in the context that this study was based only on prescription claims data. It is important to simplify ophthalmic medical regimen as it is more cost effective, better for the patient, and minimizes the washout effect from administering two eye medications within 5 min. Decreasing the complexity of the patients' drug regimen may lead to increased adherence to prescribed therapy and a decreased risk of the incidence of blindness. © 2006 Librapharm Limited. AD - D. Covert, Alcon Research Ltd., 6201 S. Freeway, Fort Worth, TX, United States AU - Covert, D. AU - Robin, A. L. DB - Embase Medline DO - 10.1185/030079906X104777 IS - 5 KW - bimatoprost latanoprost prostaglandin travoprost adult aged article blindness controlled study cost effectiveness analysis female glaucoma human intraocular pressure major clinical study male monotherapy patient compliance population research prescription risk assessment risk factor Student t test LA - English M3 - Article N1 - L43875566 2006-06-28 PY - 2006 SN - 0300-7995 SP - 971-976 ST - Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost T2 - Current Medical Research and Opinion TI - Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43875566&from=export http://dx.doi.org/10.1185/030079906X104777 VL - 22 ID - 3610 ER - TY - JOUR AB - Purpose: This study contrasts the utilization of adjunctive medication associated with travoprost, bimatoprost, or latanoprost, as primary glaucoma therapies.Methods: Patients in the Medco Health database who initiated prostaglandin analog therapy on travoprost, bimatoprost or latanoprost between January 1, 2002 and July 31, 2002 were selected if they had no prostaglandin analog use in the prior 6 months. Patients were also required to have 12 months of prostaglandin therapy subsequent to the initial prescription. Data were available through July 31, 2003. The t-test and chi-square were used where appropriate to calculate p-values and assess significant differences.Results: A total of 13 171 benefit-eligible subjects were identified of which 8381 (64%), 2637 (20%), and 2153 (16%) patients were treated with latanoprost, bimatoprost, and travoprost, respectively. There were no significant differences in mean age or gender between the three study groups with the exception that latanoprost patients were statistically older than travoprost patients (69.0 vs. 68.0). This was not considered a clinically meaningful difference. Overall, patients using travoprost or bimatoprost had a significantly lower rate of adjunctive medication use compared to patients starting on latanoprost monotherapy (22.5%, 23.2%, and 30.2 %, respectively). Therefore, for every 14 patients treated with latanoprost instead of travoprost or bimatoprost, one additional patient would be expected to need adjunctive therapy with another agent. The difference between travoprost and bimatoprost patients was not significant.Conclusions: The use of adjunctive medications to control intraocular pressure was significantly higher for latanoprost patients compared to travoprost and bimatoprost patients. This finding should be interpreted in the context that this study was based only on prescription claims data. It is important to simplify ophthalmic medical regimen as it is more cost effective, better for the patient, and minimizes the washout effect from administering two eye medications within 5 min. Decreasing the complexity of the patients' drug regimen may lead to increased adherence to prescribed therapy and a decreased risk of the incidence of blindness. AD - Alcon Research Ltd., Fort Worth, TX, USA Alcon Research Ltd., Fort Worth, TX, USA. AN - 106349804. Language: English. Entry Date: 20061020. Revision Date: 20190915. Publication Type: journal article AU - Covert, D. AU - Robin, A. L. AU - Covert, David AU - Robin, Alan L. DB - ccm DP - EBSCOhost IS - 5 KW - Bimatoprost -- Therapeutic Use Glaucoma -- Drug Therapy Latanoprost -- Therapeutic Use Travoprost -- Therapeutic Use Aged Chi Square Test Confidence Intervals Data Analysis Software Descriptive Statistics Drug Therapy, Combination Female Funding Source Human Intraocular Pressure -- Drug Effects Male T-Tests N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Grant Information: Alcon Research Ltd.. NLM UID: 0351014. PMID: NLM16709319. PY - 2006 SN - 0300-7995 SP - 971-976 ST - Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost T2 - Current Medical Research & Opinion TI - Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106349804&site=ehost-live&scope=site VL - 22 ID - 4509 ER - TY - JOUR AU - Covert, D. AU - Robin, A. L. AU - Novack, G. D. DB - Embase Medline DO - 10.1016/j.ophtha.2005.07.016 IS - 10 KW - acetylsalicylic acid calcium proton pump inhibitor timolol travoprost vitamin adult age distribution aged comorbidity controlled study drug dose regimen drug efficacy drug safety female gender glaucoma human intraocular hypertension letter major clinical study male patient compliance prescription priority journal LA - English M3 - Letter N1 - L41400031 2005-10-26 PY - 2005 SN - 0161-6420 SP - 1849.e1-1849.e2 ST - Systemic medications and glaucoma patients [6] T2 - Ophthalmology TI - Systemic medications and glaucoma patients [6] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41400031&from=export http://dx.doi.org/10.1016/j.ophtha.2005.07.016 VL - 112 ID - 3660 ER - TY - JOUR AB - Aims: To evaluate the current visual status and ophthalmic history of a sample of elderly patients with fractured neck of femur and to study the relationship between visual status and demographic factors. Methods: A four-centre study of all patients admitted to hospital with fractured neck of femur. The setting was two district (Ayr, Dunfermline) and two teaching (Glasgow, Dundee) hospitals in Scotland. The study examined 537 patients aged 65 years and over admitted with acute fractured neck of femur to hospital. Results: Bilateral visual impairment (binocular visual acuity worse than 6/12) was found in 239 of 518 patients (46%). Of this group, the principal causes for visual deficit were untreated cataract (49%), macular degeneration (21%), uncorrected refractive error (17%), and glaucoma (3%). The visually impaired group were more likely to have symptomatic visual complaints (58 vs 26%), however, were less likely to be under optometric care (71 vs 85%). A higher proportion of the group with visual impairment lived in areas of social deprivation (40 vs 26%). Conclusions: Patients with fractured neck of femur represent a frail elderly group that have poorer vision than that documented in any other elderly population. The visual defect was potentially remediable in the majority of cases but this group of individuals are not generally in touch with the ophthalmic services. Social deprivation appears to be associated with this groups' inability to access ophthalmic care. © 2005 Nature Publishing Group All rights reserved. AD - A. Cox, Department of Ophthalmology, Ninewells Hospital, Dundee DD1 9SY, United Kingdom AU - Cox, A. AU - Blaikie, A. AU - MacEwen, C. J. AU - Jones, D. AU - Thompson, K. AU - Holding, D. AU - Sharma, T. AU - Miller, S. AU - Dobson, S. AU - Sanders, R. DB - Embase Medline DO - 10.1038/sj.eye.6701610 IS - 6 KW - acute disease aged anamnesis article cataract controlled study demography disease association female femoral neck fracture glaucoma health care access health status hip fracture hospital admission human major clinical study male medical documentation population research refraction error macular degeneration social isolation symptomatology teaching hospital United Kingdom visual acuity visual field defect visual impairment visual system examination LA - English M3 - Article N1 - L40895478 2005-07-11 PY - 2005 SN - 0950-222X SP - 652-656 ST - Visual impairment in elderly patients with hip fracture: Causes and associations T2 - Eye TI - Visual impairment in elderly patients with hip fracture: Causes and associations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40895478&from=export http://dx.doi.org/10.1038/sj.eye.6701610 VL - 19 ID - 3684 ER - TY - JOUR AB - Background: Keratitis due to by filamentous fungi are not easy to diagnose thus causing a delay in correct therapy. There are many descriptions of keratitis due to Candida, Fusarium and Aspergillus genera. Subramaniula genus has only recently been reported to cause human infections and there are few descriptions of eye infections due to this filamentous fungus. Diagnosis of fungal keratitis is usually based on microscopic and cultural techniques of samples obtained by corneal swabbing or scraping. Considering the amount of time required to obtain culture results it is wise to use other diagnostic methods, such as molecular analyses. Therapeutic options against these fungi are limited by low tissue penetration in the eye due to ocular barriers. We describe the first case of S. asteroides human keratitis treated with isavuconazole.Case Presentation: We describe a rare case of fungal keratitis unresponsive to antimicrobial treatment in a 65-year-old male patient without a history of diabetes or immunological diseases. He reported that the onset of symptoms occurred during a long holiday in Cape Verde Island. Initial treatment with topical antibiotics associated to steroids were ineffective, allowing a slow clinical progression of disease to corneal perforation. On admission in our Hospital, slit-lamp examination of the left eye showed conjunctival congestion and hyperemia, a large inferior corneal ulceration with brown pigment, corneal edema, about 3 mm of hypopyon and irido-lenticular synechiae. The slow clinical progression of the disease to corneal perforation and the aspect of the ulcer were consistent with a mycotic etiology. Molecular methods used on fungal colonies isolated by Sabouraud's dextrose agar cultures allowed the identification of Subramaniula asteroids from corneal scraping. Antimicrobial test showed a good susceptibility of this filamentous fungus to voriconazole and isavuconazole. Moreover, this fungal keratitis was successfully treated with isavuconazole, without side effects, observing a progressive clinical improvement.Conclusions: Molecular methods may be useful for the identification of filamentous fungal keratitis on scraping samples thus shortening the time of diagnosis. Systemic therapy by isavuconazole could be useful to treat the filamentous fungal keratitis, reducing the possible adverse effects due to the use of voriconazole by systemic administration. AD - Department of Morphology, Surgery and Experimental Medicine, Infectious Diseases Unit, University 'S. Anna' Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy Department of Biomedical and Surgical Sciences, Ophthalmology Unit, 'S. Anna' University Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy Clinical Microbiology, 'S. Anna' University Hospital of Ferrara, Via Aldo Moro 8, 44124, Ferrara, Italy Dipartimento di Scienze Biotecnologiche di base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy AN - 148189026. Language: English. Entry Date: In Process. Revision Date: 20210130. Publication Type: journal article AU - Cultrera, Rosario AU - Torelli, Riccardo AU - Sarnicola, Caterina AU - Segala, Daniela AU - Mengoli, Andrea AU - Chiaretto, Giuseppina AU - Perri, Paolo AU - Sanguinetti, Maurizio DB - ccm DO - 10.1186/s12879-021-05768-7 DP - EBSCOhost IS - 1 KW - Corneal Ulcer -- Diagnosis Fungi Eye Infections, Fungal -- Diagnosis Pyridines -- Therapeutic Use Heterocyclic Compounds -- Therapeutic Use Diagnosis, Differential Corneal Ulcer -- Microbiology Corneal Ulcer -- Drug Therapy Antifungal Agents -- Therapeutic Use Heterocyclic Compounds -- Administration and Dosage Antifungal Agents -- Administration and Dosage Organic Chemicals -- Therapeutic Use Aged Ophthalmic Solutions Organic Chemicals -- Administration and Dosage Eye Infections, Fungal -- Drug Therapy Eye Infections, Fungal -- Microbiology Male Pyridines -- Administration and Dosage Scales N1 - case study. Journal Subset: Biomedical; Europe; UK & Ireland. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). NLM UID: 100968551. PMID: NLM33461505. PY - 2021 SN - 1471-2334 SP - 1-6 ST - Identification and molecular characterization of Subramaniula asteroides causing human fungal keratitis: a case report T2 - BMC Infectious Diseases TI - Identification and molecular characterization of Subramaniula asteroides causing human fungal keratitis: a case report UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148189026&site=ehost-live&scope=site VL - 21 ID - 4162 ER - TY - JOUR AB - Ophthalmic nurses at Sydney Hospital Sydney Eye Hospital aimed to assess and evaluate the knowledge and resulting behaviours of patients using eye drop therapy for glaucoma and the effect that using interpreters or English speaking family members had on patients' understanding and compliance. Non-compliance is known to lead to progression of the disease with resulting loss of vision. The study showed that patients undergoing long-term therapy for glaucoma have areas of non-compliance that may not be apparent to staff who see them in a clinic setting. It also showed that ineffectual use or missed doses of eye drops occur in both male and female groups, young and older groups and those from non-English and English speaking backgrounds. This is in spite of the same patients' assurances that they have received clear instructions. It has been shown that the use of interpreters or English speaking family members has not affected compliance. This study has shown that even patients who have been on therapy for over 12 months are likely to benefit from continuing education and reinforcement of good technique. Poor understanding of glaucoma in the over 65 age group was not associated with a higher rate of non-compliance. AD - C. Curtis, Outpatients Department, Sydney Eye Hospital, Sydney NSW, Australia. AU - Curtis, C. AU - Lo, E. AU - Ooi, L. AU - Bennett, L. AU - Long, J. DB - Medline IS - 2 KW - eye drops adolescent adult aged ambulatory care article Australia cultural anthropology female glaucoma human male middle aged patient compliance questionnaire LA - English M3 - Article N1 - L354961425 2009-07-29 PY - 2009 SN - 1037-6178 SP - 121-128 ST - Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting T2 - Contemporary nurse : a journal for the Australian nursing profession TI - Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354961425&from=export VL - 31 ID - 3381 ER - TY - JOUR AB - Ophthalmic nurses at Sydney Hospital Sydney Eye Hospital aimed to assess and evaluate the knowledge and resulting behaviours of patients using eye drop therapy for glaucoma and the effect that using interpreters or English speaking family members had on patients' understanding and compliance. Non-compliance is known to lead to progression of the disease with resulting loss of vision. The study showed that patients undergoing long-term therapy for glaucoma have areas of non-compliance that may not be apparent to staff who see them in a clinic setting. It also showed that ineffectual use or missed doses of eye drops occur in both male and female groups, young and older groups and those from non-English and English speaking backgrounds. This is in spite of the same patients' assurances that they have received clear instructions. It has been shown that the use of interpreters or English speaking family members has not affected compliance. This study has shown that even patients who have been on therapy for over 12 months are likely to benefit from continuing education and reinforcement of good technique. Poor understanding of glaucoma in the over 65 age group was not associated with a higher rate of non-compliance. Acknowledgements The authors thank Nick Marosszeky for assistance with data analysis and staff of Sydney Hospital Sydney Eye Hospital Eye Outpatients Department for their comments. AD - Ophthalmic Nurse, Outpatients Department, Sydney Eye Hospital, Sydney NSW. AN - 105519210. Language: English. Entry Date: 20090626. Revision Date: 20200708. Publication Type: Journal Article AU - Curtis, C. AU - Lo, E. AU - Ooi, L. AU - Bennett, L. AU - Long, J. DB - ccm DO - 10.5172/conu.673.31.2.121 DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Medication Compliance Ophthalmic Solutions -- Administration and Dosage Adolescence Adult Aged Aged, 80 and Over Chi Square Test Communication Barriers Convenience Sample Female Health Knowledge Hospitals, Special Male Middle Age New South Wales Ophthalmic Nursing Outpatient Service Outpatients Patient Education Questionnaires Human N1 - research. Journal Subset: Australia & New Zealand; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed. NLM UID: 9211867. PMID: NLM19379114. PY - 2009 SN - 1037-6178 SP - 121-128 ST - Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting T2 - Contemporary Nurse: A Journal for the Australian Nursing Profession TI - Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105519210&site=ehost-live&scope=site VL - 31 ID - 4403 ER - TY - JOUR AB - Ophthalmic nurses at Sydney Hospital Sydney Eye Hospital aimed to assess and evaluate the knowledge and resulting behaviours of patients using eye drop therapy for glaucoma and the effect that using interpreters or English speaking family members had on patients’ understanding and compliance. Non-compliance is known to lead to progression of the disease with resulting loss of vision. The study showed that patients undergoing long-term therapy for glaucoma have areas of non-compliance that may not be apparent to staff who see them in a clinic setting. It also showed that ineffectual use or missed doses of eye drops occur in both male and female groups, young and older groups and those from non-English and English speaking backgrounds. This is in spite of the same patients’ assurances that they have received clear instructions. It has been shown that the use of interpreters or English speaking family members has not affected compliance. This study has shown that even patients who have been on therapy for over 12 months are likely to benefit from continuing education and reinforcement of good technique. Poor understanding of glaucoma in the over 65 age group was not associated with a higher rate of non-compliance. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 2010-17184-003 AU - Curtis, Cheryl AU - Lo, Eva AU - Ooi, Linda AU - Bennett, Lydia AU - Long, Janet DB - psyh DO - 10.5172/conu.673.31.2.121 DP - EBSCOhost IS - 2 KW - multicultural outpatients setting eye drop therapy glaucoma ophthalmic nurses treatment compliance factors English speaking family members Adolescent Adult Aged Aged, 80 and over Ambulatory Care Cultural Diversity Female Humans Male Middle Aged New South Wales Ophthalmic Solutions Patient Compliance Surveys and Questionnaires Young Adult Family Members Outpatients Treatment Compliance Treatment Nurses Ophthalmologic Examination N1 - Outpatients Department, Sydney Hospital Sydney Eye Hospital, Sydney, NSW, Australia. Other Publishers: Taylor & Francis. Release Date: 20110124. Correction Date: 20150608. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Family Members; Glaucoma; Outpatients; Treatment Compliance; Treatment. Minor Descriptor: Nurses; Ophthalmologic Examination. Classification: Outpatient Services (3371). Population: Human (10); Male (30); Female (40); Outpatient (60). Location: Australia. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Qualitative Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Feb, 2009. Publication History: Accepted Date: Dec 20, 2008; First Submitted Date: Mar 14, 2006. Copyright Statement: eContent Management Pty Ltd. PY - 2009 SN - 1037-6178 SP - 121-128 ST - Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting T2 - Contemporary Nurse TI - Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-17184-003&site=ehost-live&scope=site VL - 31 ID - 4846 ER - TY - JOUR AB - Introduction: Administrative claims data have a limited ability to identify persons with high compliance to oral bisphosphonates. We tested whether adding information on compliance with other drugs used to treat chronic, asymptomatic conditions would improve the predictive ability of administrative data to identify adherent individuals. Methods: Using data from a large, US healthcare organization, we identified new bisphosphonate users and their 1-year compliance to oral bisphosphonates, quantified by the Medication Possession Ratio (MPR). Multivariable logistic regression models evaluated the relationship between high bisphosphonate compliance (MPR ≥80%) and patient demographics, comorbidities, and health services utilization. To these logistic regression models, we evaluated the incremental change in the area under the receiver operator curve (AUC) after adding information regarding compliance with other drug classes. These included antihyperlipidemics (statins), antihypertensives, antidepressants, oral diabetes agents, and glaucoma medications. Results from the logistic regression models were evaluated in parallel using recursive partitioning trees with 10-fold cross-validation. Results: Among 101,038 new bisphosphonate users, administrative data identified numerous nonmedication factors (eg, age, gender, use of preventive services) significantly associated with high bisphosphonate compliance at 1 year. However, all these factors in aggregate had low discriminant ability to identify persons highly adherent with bisphosphonates (AUC = 0.62). For persons who were new users of ≥1 of the other asymptomatic condition drugs, MPR data on the other drugs substantially improved the prediction of high bisphosphonate compliance. The impact on prediction was largest for concomitant statin users (AUC = 0.70). Conclusions: Information on compliance with drugs used to treat chronic asymptomatic conditions improves the prediction of compliance with oral bisphosphonates. This information may help identify persons who should receive targeted interventions to promote compliance to osteoporosis medications. Copyright © 2009 by Lippincott Williams & Wilkins. AD - J.R. Curtis, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, UAB FOT 840, 510 20th Street South, Birmingham, AL 35294, United States AU - Curtis, J. R. AU - Xi, J. AU - Westfall, A. O. AU - Cheng, H. AU - Lyles, K. AU - Saag, K. G. AU - Delzell, E. DB - Embase Medline DO - 10.1097/MLR.0b013e31818afa1c IS - 3 KW - alendronic acid angiotensin receptor antagonist antidepressant agent antidiabetic agent antiglaucoma agent antihypertensive agent beta adrenergic receptor blocking agent bisphosphonic acid derivative calcitonin calcium channel blocking agent dipeptidyl carboxypeptidase inhibitor estrogen glucocorticoid hydroxymethylglutaryl coenzyme A reductase inhibitor ibandronic acid raloxifene risedronic acid serotonin uptake inhibitor thiazide diuretic agent adult aged article colonoscopy comorbidity controlled study demography depression diabetes mellitus female gender glaucoma health care utilization hip fracture human hypertension hyperthyroidism long term care major clinical study male mammography occult blood osteoporosis patient compliance prediction rheumatoid arthritis sigmoidoscopy smoking spine fracture LA - English M3 - Article N1 - L354333073 2009-04-02 PY - 2009 SN - 0025-7079 SP - 334-341 ST - Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosis T2 - Medical Care TI - Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354333073&from=export http://dx.doi.org/10.1097/MLR.0b013e31818afa1c VL - 47 ID - 3373 ER - TY - JOUR AB - Introduction: Administrative claims data have a limited ability to identify persons with high compliance to oral bisphosphonates. We tested whether adding information on compliance with other drugs used to treat chronic, asymptomatic conditions would improve the predictive ability of administrative data to identify adherent individuals.Methods: Using data from a large, US healthcare organization, we identified new bisphosphonate users and their 1-year compliance to oral bisphosphonates, quantified by the Medication Possession Ratio (MPR). Multivariable logistic regression models evaluated the relationship between high bisphosphonate compliance (MPR >or=80%) and patient demographics, comorbidities, and health services utilization. To these logistic regression models, we evaluated the incremental change in the area under the receiver operator curve (AUC) after adding information regarding compliance with other drug classes. These included antihyperlipidemics (statins), antihypertensives, antidepressants, oral diabetes agents, and glaucoma medications. Results from the logistic regression models were evaluated in parallel using recursive partitioning trees with 10-fold cross-validation.Results: Among 101,038 new bisphosphonate users, administrative data identified numerous nonmedication factors (eg, age, gender, use of preventive services) significantly associated with high bisphosphonate compliance at 1 year. However, all these factors in aggregate had low discriminant ability to identify persons highly adherent with bisphosphonates (AUC = 0.62). For persons who were new users of >or=1 of the other asymptomatic condition drugs, MPR data on the other drugs substantially improved the prediction of high bisphosphonate compliance. The impact on prediction was largest for concomitant statin users (AUC = 0.70).Conclusions: Information on compliance with drugs used to treat chronic asymptomatic conditions improves the prediction of compliance with oral bisphosphonates. This information may help identify persons who should receive targeted interventions to promote compliance to osteoporosis medications. AD - Center for Education and Research on Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA Center for Education and Research on Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. jcurtis@uab.edu AN - 105462902. Language: English. Entry Date: 20090327. Revision Date: 20161125. Publication Type: journal article AU - Curtis, J. R. AU - Xi, J. AU - Westfall, A. O. AU - Cheng, H. AU - Lyles, K. AU - Saag, K. G. AU - Delzell, E. AU - Curtis, Jeffrey R. AU - Xi, Juan AU - Westfall, Andrew O. AU - Cheng, Hong AU - Lyles, Kenneth AU - Saag, Kenneth G. AU - Delzell, Elizabeth DB - ccm DO - 10.1097/MLR.0b013e31818afa1c DP - EBSCOhost IS - 3 KW - Chronic Disease -- Drug Therapy Diphosphonates -- Therapeutic Use Medication Compliance Osteoporosis -- Drug Therapy Preventive Health Care -- Utilization Administration, Oral Age Factors Aged Antidepressive Agents -- Therapeutic Use Antihypertensive Agents -- Therapeutic Use Antilipemic Agents -- Therapeutic Use Comorbidity Diphosphonates -- Administration and Dosage Female Hypoglycemic Agents -- Therapeutic Use Insurance Insurance, Pharmaceutical Services Logistic Regression Male Middle Age Sex Factors United States Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: K24 AR052361/AR/NIAMS NIH HHS/United States. NLM UID: 0230027. PMID: NLM19194337. PY - 2009 SN - 0025-7079 SP - 334-341 ST - Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis T2 - Medical Care TI - Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105462902&site=ehost-live&scope=site VL - 47 ID - 4530 ER - TY - JOUR AB - AIM OF THE STUDY: The purpose of this study was to estimate and evaluate costs of glaucoma therapy in Poland in 1998-2000 years. MATERIAL AND METHODS: 315 patients (591 eyes) including 364 POAG eyes and 227 PACG eyes were evaluated. Progression of the disease was measured in two modes: by changes in the optical nerve disc (c/d) and by IOP level. Duration of the study was 12 months. Total costs (e.g. number of visits, amount of medications used, surgical and laser procedures performed) were calculated on 100 eyes/12 months. RESULTS: Pharmacological therapy constitutes 40-50% of the total costs in both glaucoma types. Timolol was the mostly prescribed drug in POAG, while pilocarpine led in PACG group. Dorzolamide was on the third place, but it generated the biggest part of total costs. Patients with advanced forms of the disease more frequently saw doctor on visits (average 6 visits per year); patients with elevated IOP (> 21 mm Hg) underwent surgical procedures more commonly than these with optical nerve disc changes (c/d > 0.6). The total costs of the therapy of non-advanced cases amounted 70.243 PLN on the average, while in advanced cases it reached the average of 155.230 PLN. CONCLUSION: 1. The total cost of glaucoma therapy depends on progression of the disease. 2. The most cost-generating part is the pharmacological therapy of glaucoma. AD - K. Czechowicz-Janicka, Kliniki Okulistycznej Centrum Medycznego Kształcenia Podyplomowego w Warszawie. AU - Czechowicz-Janicka, K. AU - Orlewska, E. AU - Tobota, Z. AU - Anielska, E. AU - Dyczkowska, A. DB - Medline IS - 6 KW - dorzolamide pilocarpine sulfonamide thiophene derivative timolol adult aged ambulatory care article cost disease course economics female glaucoma human intraocular pressure laser surgery male middle aged Poland LA - Polish M3 - Article N1 - L33487106 2001-06-05 PY - 2000 SN - 0023-2157 SP - 417-422 ST - Analysis of glaucoma therapy costs in Poland. I--population of the Mazovian District T2 - Klinika oczna TI - Analysis of glaucoma therapy costs in Poland. I--population of the Mazovian District UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33487106&from=export VL - 102 ID - 3902 ER - TY - JOUR AB - Background: Gefitinib is active in patients with pretreated non-small-cell lung cancer (NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced NSCLC followed by chemotherapy at disease progression. Patients and methods: In all, 63 patients with chemotherapy-naive stage IIIB/IV NSCLC received gefitinib 250 mg/day. At disease progression, gefitinib was replaced by cisplatin 80 mg/m2 on day 1 and gemcitabine 1250 mg/m2 on days 1, 8 for up to six 3-week cycles. Primary end point was the disease stabilization rate (DSR) after 12 weeks of gefitinib. Results: After 12 weeks of gefitinib, the DSR was 24% and the response rate (RR) was 8%. Median time to progression (TtP) was 2.5 months and median overall survival (OS) 11.5 months. Never smokers (n = 9) had a DSR of 56% and a median OS of 20.2 months; patients with epidermal growth factor receptor (EGFR) mutation (n = 4) had a DSR of 75% and the median OS was not reached after the follow-up of 21.6 months. In all, 41 patients received chemotherapy with an overall RR of 34%, DSR of 71% and median TtP of 6.7 months. Conclusions: First-line gefitinib monotherapy led to a DSR of 24% at 12 weeks in an unselected patients population. Never smokers and patients with EGFR mutations tend to have a better outcome; hence, further trials in selected patients are warranted. © The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. AD - Department of Oncology, Kantonsspital St.Gallen, St Gallen, Switzerland Department of Oncology, Spital Thun, Thun, Switzerland Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland Universitaetsspital Basel, Basel, Switzerland Department of Oncology, Universitaetsspital Zuerich, Zuerich, Switzerland Deaprtment of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland Department of Oncology, Kantonsspital Bruderholz, Bruderholz, Switzerland Department of Oncology, Triemlispital Zuerich, Zuerich, Switzerland Institut für Pathologie, Universitaetsspital Basel, Basel, Switzerland SAKK Coordinating Center, Bern, Switzerland Institute of Medical Oncology, Inselspital Bern, Bern, Switzerland Onkologie Schaffhausen, Rheinstrasse 17, 8200 Schaffhausen, Switzerland Kantonsspital Winterthur, Medizinische Onkologie, Kantonsspital Winterthur, Winterthur, Switzerland Hôpital Cantonal Fribourg, Department of Oncologie, Hôpital Cantonal Fribourg, Fribourg, Switzerland AU - D'Addario, G. AU - Rauch, D. AU - Stupp, R. AU - Pless, M. AU - Stahel, R. AU - Mach, N. AU - Jost, L. AU - Widmer, L. AU - Tapia, C. AU - Bihl, M. AU - Mayer, M. AU - Ribi, K. AU - Lerch, S. AU - Bubendorf, L. AU - Betticher, D. C. DB - Scopus DO - 10.1093/annonc/mdm564 IS - 4 KW - Advanced disease Chemotherapy First-line therapy Gefitinib Non-small-cell lung cancer M3 - Article N1 - Cited By :34 Export Date: 19 July 2021 PY - 2008 SP - 739-745 ST - Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03 T2 - Annals of Oncology TI - Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-41549125361&doi=10.1093%2fannonc%2fmdm564&partnerID=40&md5=657f7db6d3dd6209e92178eecb0f2d04 VL - 19 ID - 5040 ER - TY - JOUR AB - Provision of eye care services for competitors and their support teams has become an integral part of the modern Olympic Games. To describe the organisation of the eye clinic at London 2012 over a 4-week period and provide outline audit data. The clinic employed multidisciplinary eye care professionals and utilised state-of-the-art instrumentation to provide the highest level of eye care. A total of 1406 patients from 154 countries attended the clinic over the Olympic Games, of which, 276 were competitors. All individuals received a comprehensive refractive and ocular health examination. Minor ocular injuries, glaucoma, diabetic retinopathy and macular degeneration were among the conditions detected and managed. Most patients attended the clinic to have their refractive status checked: 973 spectacles and 50 pairs of contact lenses were dispensed. It is hoped that this account of the provision of eye care at London 2012 will assist with the planning of this service at future events. AD - P.J. D'Ath, Division of Optometry and Visual Science, City University London, London, UK. AU - D'Ath, P. J. AU - Thomson, W. D. AU - Wilson, C. M. DB - Medline IS - 7 KW - adolescent adult aged ambulatory care article athlete female history human male middle aged ophthalmology outpatient department patient attitude spectacles sport sports medicine statistics United Kingdom utilization review vision test visual disorder LA - English M3 - Article N1 - L370092893 2013-10-30 PY - 2013 SN - 1473-0480 SP - 463-466 ST - Seeing you through London 2012: eye care at the Olympics T2 - British journal of sports medicine TI - Seeing you through London 2012: eye care at the Olympics UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370092893&from=export VL - 47 ID - 3005 ER - TY - JOUR AB - Background: Infectious keratitis is a major global cause of visual impairment and irrever- sible blindness among the corneal diseases. Its diagnosis and management remain getting challenge. The clinical and visual outcome remains poor in developing countries. The aim of this study was to determine treatment outcome and its predictors among patients with infectious keratitis. Methods: Prospective observational study was conducted among adult patients diagnosed with infectious keratitis at the Ophthalmology Department in Jimma University Medical Center from April 1 to September 30, 2019. The primary outcome indicator was response of the ulcer to empirical treatment. Ulcers that did not heal and required surgery had a poor outcome. Variables with a p-value of <0.25 were entered into a multivariate logistic regres- sion model to determine the independent predictors of poor treatment outcome and variables with a p-value of <0.05 were considered statistically significant. Results: The research involved 131 adult patients. Eighty-seven (66.4%) were males. The mean age was 39.38 (±18.9) years. Eighty-three (63.4%) patients had poor treatment out- come. Mean length of hospital stay was 17.38 (±12.563) days. Poor visual outcome was observed among 71 (54.2%) participants. Evisceration was done for seven (5.3%) patients. Independent predictors of poor treatment outcome include perforation at admission (AOR=6.1, 95%CI: 1.5-25.1), presence of comorbidity (AOR=7.7, 95%CI: 2.16-27.3), poor adherence (AOR=5.3, 95%CI: 1.8-25.9), traditional medicine use (AOR=6.7, 95%CI: 1.8-25.4), ulcer depth >1/3 (AOR=7.6, 95%CI: 2.48-48.23) and farm workers (AOR=3.59, 95%CI: 1.09-11.77). Major complications occurred after admissions were perforation (14.5%), followed by endophthalmitis (7.63%) and corneal opacity (6.87%). Conclusion and Recommendation: Our study found high poor treatment outcomes and high poor visual outcomes. Presence of comorbidity, perforation at admission, traditional medicine use, working on a farm, poor adherence, and ulcer depth were the predictors of poor treatment outcome. This high poor outcome requires a nationwide interventional study and urgent intervention that may reach rural communities. AD - T.R. Dago, School of Pharmacy, College of Medicine and Health Science, Mizan Tepi University, Mizan-Aman, Ethiopia AU - Dago, T. R. AU - Woldemichael, D. K. AU - Daba, F. B. DB - Embase DO - 10.2147/OPTH.S291880 KW - acetazolamide aciclovir amoxicillin plus clavulanic acid ampicillin artificial tear cefepime ceftazidime ceftriaxone chloramphenicol ciprofloxacin cloxacillin cotrimoxazole dexamethasone diclofenac erythromycin eye drops fluconazole gentamicin glycerol herbaceous agent ibuprofen imipenem meropenem metronidazole piperacillin plus tazobactam sultamicillin tetracycline tobramycin tramadol tropicamide vancomycin adolescent adult agricultural worker antibiotic resistance antibiotic sensitivity article bacterial keratitis blepharitis blepharoconjunctivitis blindness cataract clinical feature comorbidity computer assisted tomography conjunctivitis controlled study cornea opacity cornea ulcer corneal scraping disease severity echooculography endophthalmitis entropion Ethiopia eye discharge eye evisceration eye pain eye redness female fever glaucoma Haemophilus influenzae hospital readmission human human tissue hypopyon image analysis incidence intraocular foreign body keratomycosis keratopathy Klebsiella length of stay major clinical study male medical history medication compliance meibomian gland dysfunction microbial keratitis coinfection nonhuman observational study patient compliance perforating eye injury photophobia predictor variable prospective study pterygium slit lamp microscopy treatment outcome upper respiratory tract infection virus keratitis visual acuity LA - English M3 - Article N1 - L2006825635 2021-03-31 2021-04-16 PY - 2021 SN - 1177-5483 1177-5467 SP - 1223-1237 ST - Medical history, clinical features, treatment outcome and its predictors among infectious keratitis patients in jimma university medical center, southwest Ethiopia: Prospective observational study T2 - Clinical Ophthalmology TI - Medical history, clinical features, treatment outcome and its predictors among infectious keratitis patients in jimma university medical center, southwest Ethiopia: Prospective observational study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2006825635&from=export http://dx.doi.org/10.2147/OPTH.S291880 VL - 15 ID - 2328 ER - TY - JOUR AB - To evaluate the perioperative complications of intraocular lens (IOL) exchange in 25 eyes of 22 patients with opacified Aqua-Sense® IOLs (Ophthalmic Innovations International). Department of Ophthalmology, University Hospital Aintree, Liverpool, United Kingdom. The study comprised 22 patients (25 eyes) who had previous phacoemulsification and implantation of Aqua-Sense single-piece hydrophilic acrylic IOLs in the capsular bag and developed severe late opacification of the IOL. All patients reported glare and deterioration in vision. The IOLs were explanted and replaced with new lenses. The perioperative complications were evaluated. The best corrected visual acuity (BCVA) before and after surgery was compared. In 24 eyes, the opacification was complete, involving the optic, haptics, and substance of the IOLs. Uneventful IOL exchange and placement of a new IOL in the bag was achieved in 13 eyes (52%). Complications occurred in the remaining 12 eyes (48%). Ten eyes (40%) developed zonular dehiscence, 4 (16%) of which were managed with anterior chamber IOL implantation. One eye (4%) developed posterior capsule rupture and 1 eye (4%), posterior capsule rupture and zonular dehiscence. The cornea decompensated in 2 eyes (8%). One eye (4%) developed Pseudomonas keratitis. The mean BCVA (decimal scale) before and after IOL exchange was 0.57 ± 0.24 and 0.60 ± 0.28, respectively. There was no significant difference in visual acuity between before and after IOL exchange (P =. 782, paired t test). Explantation of Aqua-Sense IOLs was challenging because of the tight adherence of the optic and haptics to the capsule. Long-term follow-up of patients with Aqua-Sense IOLs should be maintained. © 2004 ASCRS and ESCRS. AD - Department of Ophthalmology, University Hospital Aintree, Liverpool, United Kingdom, United Kingdom Royal Liverpool University Hospital, Ophthalmology, 8Z Link, Prescot St., Liverpool L., United Kingdom AU - Dagres, E. AU - Khan, M. A. AU - Kyle, G. M. AU - Clark, D. DB - Scopus DO - 10.1016/j.jcrs.2004.04.055 IS - 12 M3 - Article N1 - Cited By :30 Export Date: 19 July 2021 PY - 2004 SP - 2569-2573 ST - Perioperative complications of intraocular lens exchange in patients with opacified Aqua-Sense lenses T2 - Journal of Cataract and Refractive Surgery TI - Perioperative complications of intraocular lens exchange in patients with opacified Aqua-Sense lenses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-11144331045&doi=10.1016%2fj.jcrs.2004.04.055&partnerID=40&md5=b607ba1f80d45bba8fd45f0c75777ee5 VL - 30 ID - 5063 ER - TY - JOUR AB - Purpose: To evaluate the perioperative complications of intraocular lens (IOL) exchange in 25 eyes of 22 patients with opacified Aqua-Sense(R) IOLs (Ophthalmic Innovations International). Setting: Department of Ophthalmology, University Hospital Aintree, Liverpool, United Kingdom. Methods: The study comprised 22 patients (25 eyes) who had previous phacoemulsification and implantation of Aqua-Sense single-piece hydrophilic acrylic IOLs in the capsular bag and developed severe late opacification of the IOL. All patients reported glare and deterioration in vision. The IOLs were explanted and replaced with new lenses. The perioperative complications were evaluated. The best corrected visual acuity (BCVA) before and after surgery was compared. Results: In 24 eyes, the opacification was complete, involving the optic, haptics, and substance of the IOLs. Uneventful IOL exchange and placement of a new IOL in the bag was achieved in 13 eyes (52%). Complications occurred in the remaining 12 eyes (48%). Ten eyes (40%) developed zonular dehiscence, 4 (16%) of which were managed with anterior chamber IOL implantation. One eye (4%) developed posterior capsule rupture and 1 eye (4%), posterior capsule rupture and zonular dehiscence. The cornea decompensated in 2 eyes (8%). One eye (4%) developed Pseudomonas keratitis. The mean BCVA (decimal scale) before and after IOL exchange was 0.57 +/- 0.24 and 0.60 +/- 0.28, respectively. There was no significant difference in visual acuity between before and after IOL exchange (P = .782, paired t test). Conclusions: Explantation of Aqua-Sense IOLs was challenging because of the tight adherence of the optic and haptics to the capsule. Long-term follow-up of patients with Aqua-Sense IOLs should be maintained. AN - WOS:000226300500030 AU - Dagres, E. AU - Khan, M. A. AU - Kyle, G. M. AU - Clark, D. DA - DEC DO - 10.1016/j.jcrs.2004.04.055 IS - 12 PY - 2004 SN - 0886-3350 1873-4502 SP - 2569-2573 ST - Perioperative complications of intraocular lens exchange in patients with opacified Aqua-Sense lenses T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Perioperative complications of intraocular lens exchange in patients with opacified Aqua-Sense lenses VL - 30 ID - 6347 ER - TY - JOUR AB - Asthma is a complex disease of the respiratory tract associated with chronic inflammation in which an intricate network of cells and cellular factors plays a major role. Asthma is one of the most common chronic diseases, with an estimated 300 million cases worldwide, imposing a considerable burden on society in morbidity, quality of life, and healthcare costs. Inhaled corticosteroids (ICSs) form the gold standard, first-line therapy in the effective management of persistent asthma and reduce morbidity and mortality from asthma. However, long-term use of high-dose ICS therapy has potential to cause systemic side effects-impaired growth in children, decreased bone mineral density, skin thinning and bruising, and cataracts. Hypothalamic-pituitary-adrenal-axis suppression, measured by serum or urine cortisol decrease, correlates with the occurrence of systemic side effects of high-dose ICSs. Therefore, cortisol may be a relevant surrogate marker to identify the potential for adverse effects from ICS therapy. Ciclesonide is a new generation ICS with demonstrable safety and efficacy in the treatment of asthma. The unique pharmacologic characteristics of ciclesonide, such as reduced local adverse effects, lack of cortisol suppression, and the option for once-daily dosing, may improve compliance with therapy and allow long-term use of ICSs without fear of systemic adverse effects. © 2005 Elsevier Ltd. All rights reserved. AD - R. Dahl, Department of Respiratory Diseases, Aarhus University Hospital, Norrebrogade, DK 8000 Aarhus C, Denmark AU - Dahl, R. DB - Embase Medline DO - 10.1016/j.rmed.2005.11.020 IS - 8 KW - beclometasone beclomethasone dipropionate budesonide ciclesonide corticosteroid flunisolide fluticasone propionate hydrocortisone mometasone furoate nedocromil placebo prednisolone triamcinolone adrenal cortex insufficiency asthma bone disease bronchospasm cataract clinical trial correlation function coughing dose response drug absorption drug bioavailability drug efficacy drug exposure drug megadose drug metabolism drug safety dysphonia fracture glaucoma growth disorder human hydrocortisone blood level hydrocortisone urine level hypothalamus hypophysis adrenal system intraocular hypertension long term care morbidity mortality oropharynx candidiasis osteoporosis patient compliance pharyngitis priority journal review risk benefit analysis single drug dose skin contusion systemic disease LA - English M3 - Review N1 - L43942329 2006-07-17 PY - 2006 SN - 0954-6111 SP - 1307-1317 ST - Systemic side effects of inhaled corticosteroids in patients with asthma T2 - Respiratory Medicine TI - Systemic side effects of inhaled corticosteroids in patients with asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43942329&from=export http://dx.doi.org/10.1016/j.rmed.2005.11.020 VL - 100 ID - 3594 ER - TY - JOUR AB - Introduction: Development of mobile health (m-health) in China carries tremendous potential, especially for glaucoma, one of the major chronic ophthalmic diseases afflicting millions of people. However, little research has been undertaken to investigate the willingness of glaucoma patients to use m-health and the factors influencing their decisions. Subjects and Methods: This was a cross-sectional study. A self-administered or face-to-face interview survey was performed on 1,487 patients with glaucoma at the outpatient glaucoma service, Zhongshan Ophthalmic Center, Sun Yat-sen University. Questionnaires captured patients' demographic data, WeChat access, and willingness to receive m-health. The data were analyzed by single factor chi-square test. Multiple logistic regression revealed the motivators and barriers to accept m-health adoption. Results: One thousand ninety-seven valid questionnaires were obtained. Seven hundred twenty-five respondents (66.1%) were willing to participate in m-health programs. 65.4% were younger than 60 years old. 40.9% had travel time from home to hospital of > 3 h. 63.6% had more than four follow-up visits for glaucoma. 86.5% experienced trouble events during clinic visits. The overall WeChat usage rate was 61.7%. Age, travel time, number of visits, trouble events in clinic, and WeChat access in patients with glaucoma were related to the willingness to use m-health (p < 0.05). Conclusions: Most patients with glaucoma were willing to participate in m-health programs, which are essential to increasing and improving access to care. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Huang, Jingjing, State Key Laboratory of Ophthalmology, Department of Glaucoma, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 Xianlienan Road, Guangzhou, China, 510060 AN - 2017-46609-005 AU - Dai, Miaomiao AU - Xu, Jianan AU - Lin, Jialiu AU - Wang, Zhonghao AU - Huang, Wenmin AU - Huang, Jingjing DB - psyh DO - 10.1089/tmj.2016.0254 DP - EBSCOhost IS - 10 KW - mobile health m-Health e-Health telemedicine glaucoma ophthalmology chronic disease patient attitudes Adult Age Factors Aged China Cross-Sectional Studies Female Health Services Accessibility Humans Interviews as Topic Jet Lag Syndrome Male Middle Aged Patient Preference Socioeconomic Factors Transportation Client Attitudes Mobile Devices Decision Making N1 - Telemedicine Journal and e-Health. Partial author list: First Author & Affiliation: Dai, Miaomiao; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China. Release Date: 20180329. Correction Date: 20190211. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Client Attitudes; Glaucoma; Telemedicine; Mobile Devices; Mobile Health. Minor Descriptor: Decision Making. Classification: Vision & Hearing & Sensory Disorders (3299); Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40); Outpatient (60). Location: China. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Tests & Measures: Willingness to Use M-Health Questionnaire. Methodology: Empirical Study; Interview; Quantitative Study. References Available: Y. Page Count: 6. Issue Publication Date: Oct, 2017. Publication History: First Posted Date: Apr 18, 2017; Accepted Date: Feb 14, 2017; Revised Date: Feb 14, 2017; First Submitted Date: Dec 1, 2016. Copyright Statement: Mary Ann Liebert, Inc. Sponsor: National Natural Science Foundation of China, China. Grant: 81670850. Recipients: No recipient indicated Sponsor: Guangzhou Science Technology and Innovation Commission in China, China. Grant: 201607010321. Recipients: No recipient indicated PY - 2017 SN - 1530-5627 1556-3669 SP - 822-827 ST - Willingness to use mobile health in glaucoma patients T2 - Telemedicine and e-Health TI - Willingness to use mobile health in glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-46609-005&site=ehost-live&scope=site hjjing@mail.sysu.edu.cn VL - 23 ID - 4815 ER - TY - JOUR AB - Introduction: Development of mobile health (m-health) in China carries tremendous potential, especially for glaucoma, one of the major chronic ophthalmic diseases afflicting millions of people. However, little research has been undertaken to investigate the willingness of glaucoma patients to use m-health and the factors influencing their decisions. Subjects and Methods: This was a cross-sectional study. A self-administered or face-to-face interview survey was performed on 1,487 patients with glaucoma at the outpatient glaucoma service, Zhongshan Ophthalmic Center, Sun Yat-sen University. Questionnaires captured patients' demographic data, WeChat access, and willingness to receive m-health. The data were analyzed by single factor chi-square test. Multiple logistic regression revealed the motivators and barriers to accept m-health adoption. Results: One thousand ninety-seven valid questionnaires were obtained. Seven hundred twenty-five respondents (66.1%) were willing to participate in m-health programs. 65.4% were younger than 60 years old. 40.9% had travel time from home to hospital of >3 h. 63.6% had more than four follow-up visits for glaucoma. 86.5% experienced trouble events during clinic visits. The overall WeChat usage rate was 61.7%. Age, travel time, number of visits, trouble events in clinic, and WeChat access in patients with glaucoma were related to the willingness to use m-health (p < 0.05). Conclusions: Most patients with glaucoma were willing to participate in m-health programs, which are essential to increasing and improving access to care. © Copyright 2017, Mary Ann Liebert, Inc. 2017. AD - State Key Laboratory of Ophthalmology, Department of Glaucoma, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 Xianlienan Road, Guangzhou, 510060, China AU - Dai, M. AU - Xu, J. AU - Lin, J. AU - Wang, Z. AU - Huang, W. AU - Huang, J. DB - Scopus DO - 10.1089/tmj.2016.0254 IS - 10 KW - chronic disease e-Health glaucoma m-Health mobile health ophthalmology telemedicine M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2017 SP - 822-827 ST - Willingness to Use Mobile Health in Glaucoma Patients T2 - Telemedicine and e-Health TI - Willingness to Use Mobile Health in Glaucoma Patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031309670&doi=10.1089%2ftmj.2016.0254&partnerID=40&md5=193a9f00959e2b94d6b0e9278340c7c5 VL - 23 ID - 5274 ER - TY - JOUR AB - Introduction: Development of mobile health (m-health) in China carries tremendous potential, especially for glaucoma, one of the major chronic ophthalmic diseases afflicting millions of people. However, little research has been undertaken to investigate the willingness of glaucoma patients to use m-health and the factors influencing their decisions. Subjects and Methods: This was a cross-sectional study. A self-administered or face-to-face interview survey was performed on 1,487 patients with glaucoma at the outpatient glaucoma service, Zhongshan Ophthalmic Center, Sun Yatsen University. Questionnaires captured patients' demographic data, WeChat access, and willingness to receive m-health. The data were analyzed by single factor chi-square test. Multiple logistic regression revealed the motivators and barriers to accept m-health adoption. Results: One thousand ninety-seven valid questionnaires were obtained. Seven hundred twenty-five respondents (66.1%) were willing to participate in m-health programs. 65.4% were younger than 60 years old. 40.9% had travel time from home to hospital of > 3 h. 63.6% had more than four followup visits for glaucoma. 86.5% experienced trouble events during clinic visits. The overall We Chat usage rate was 61.7%. Age, travel time, number of visits, trouble events in clinic, and We Chat access in patients with glaucoma were related to the willingness to use m-health (p < 0.05). Conclusions: Most patients with glaucoma were willing to participate in m-health programs, which are essential to increasing and improving access to care. AN - WOS:000412817100005 AU - Dai, M. M. AU - Xu, J. A. AU - Lin, J. L. AU - Wang, Z. H. AU - Huang, W. M. AU - Huang, J. J. DA - OCT DO - 10.1089/tmj.2016.0254 IS - 10 PY - 2017 SN - 1530-5627 1556-3669 SP - 822-827 ST - Willingness to Use Mobile Health in Glaucoma Patients T2 - TELEMEDICINE AND E-HEALTH TI - Willingness to Use Mobile Health in Glaucoma Patients VL - 23 ID - 6070 ER - TY - JOUR AD - M.D. Dalzell AU - Dalzell, M. D. DB - Medline IS - 11 Suppl KW - adult aged ambulatory care article comparative study economics ethnology female glaucoma health service human male middle aged prevalence United States utilization review LA - English M3 - Article N1 - L39321529 2004-10-17 PY - 2002 SN - 1062-3388 SP - 10-15 ST - Glaucoma: prevalence, utilization, and economic implications T2 - Managed care (Langhorne, Pa.) TI - Glaucoma: prevalence, utilization, and economic implications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39321529&from=export VL - 11 ID - 3848 ER - TY - JOUR AB - Purpose: To determine the effect of a glaucoma team care model on resource utilization and efficiency in glaucoma management. Methods: Retrospective cohort study of 358 patients diagnosed and treated for glaucoma. Analysis included number of patient visits, diagnostic tests, and glaucoma procedures performed before (2005–2007) and after (2008–2010) implementation of a team care model in 2008. Patients not involved in the model served as controls. Results: Number of patient visits did not change significantly after model implementation (p > .05). Diagnostic tests significantly increased in comprehensive ophthalmologist and glaucoma subspecialist groups 25 months after diagnosis (p = .03 and p = .001). Procedures increased for glaucoma subspecialists but was not statistically significant (p = .06). Optometrists used billing codes with significantly lower reimbursement than other providers (p < .001). Conclusions: Team care model had neutral effect on patient visits and increased testing. Continued evaluation of this model is required to determine its effect on disease progression and outcomes. AD - G.M. Damento, Department of Ophthalmology, Mayo Clinic, 200 First Street SW, Rochester, MN, United States AU - Damento, G. M. AU - Winkler, N. S. AU - Hodge, D. O. AU - Khanna, S. S. AU - Khanna, C. L. DB - Embase Medline DO - 10.1080/08820538.2018.1514059 IS - 7-8 KW - article cataract extraction cohort analysis collaborative care team controlled study Current Procedural Terminology diagnostic test glaucoma gonioscopy health care cost health care utilization human major clinical study ophthalmologist ophthalmoscopy optical coherence tomography optometrist pachymetry patient care priority journal reimbursement retrospective study tonometry trabeculectomy trabeculoplasty trabeculotomy LA - English M3 - Article N1 - L624004390 2018-09-27 2019-01-11 PY - 2018 SN - 1744-5205 0882-0538 SP - 829-837 ST - Healthcare Utilization by Glaucoma Patients in a Team Care Model T2 - Seminars in Ophthalmology TI - Healthcare Utilization by Glaucoma Patients in a Team Care Model UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624004390&from=export http://dx.doi.org/10.1080/08820538.2018.1514059 VL - 33 ID - 2562 ER - TY - JOUR AB - Aim/background - The public health significance of corneal transplantation in dealing with corneal blindness in the developing world would depend upon the survival rate of transplants. This study was done to analyse the survival rate of corneal transplants in a large series in India, and to evaluate the influence of various risk factors on transplant survival. Methods - The records of a series of 1725 cases of corneal transplants carried out during 1987-95 at a tertiary eye care institution in India were reviewed. The Kaplan-Meier method was used to determine 5 year survival rates of corneal transplants performed for the various categories of preoperative diagnosis. Multivariate Cox proportional hazards regression was used to assess how preoperative diagnosis, socioeconomic status, age, sex, vascularisation of host cornea, quality of donor cornea, and training status of surgeon influenced transplant survival. The effect of these variables on visual outcome was assessed using multiple logistic regression. Results - The survival rates at 1, 2, and 5 years for all corneal transplants performed for the first time in 1389 cases were 79.6% (95% confidence interval = 77.3-81.9%), 68.7% (65.7-71.7%) and 46.5% (41.7-51.3%). The 5 year survival rate was highest if the corneal transplant was done for keratoconus (95.1% (84.8-100%)) and lowest if carried out for previous transplant failure (21.2% (13.8-28.6%)). The relative risk of transplant failure was higher if the preoperative diagnosis was previous transplant failure (2.04 (1.62-2.55)), aphakic bullous keratopathy (1.78 (1.38-2.28)), corneal clouding due to miscellaneous causes including congenital conditions and glaucoma (1.63 (1.21-2.19)), or adherent leucoma (1.11 (0.81-1.51)) than for the other preoperative diagnoses. Patients with lower socioeconomic status had higher relative risk of transplant failure (1.28 (1.16-1.42)), as did patients < 10 years of age (1.42 (1.23-1.64)). Higher relative risk of transplant failure was associated with vascularisation of the host cornea before transplantation (1.15 (1.04-1.27)), and with the use of fair quality donor cornea for transplantation compared with excellent, very good, or good quality donor cornea (1.26 (1.06-1.52)). Before corneal transplant 80.2% of the eyes were blind (visual acuity < 3/60),whereas at last follow up 41.8% eyes were blind. The odds of having visual acuity > 6/18 were higher if the transplant was done for keratoconus (9.99 (6.10-16.36)) or corneal dystrophies (1.77 (1.21-2.58)) than for the other preoperative diagnoses. Conclusion - Reasonable success with corneal transplantation is possible in the developing world if data from this part of the world regarding the different survival rates for the various preoperative diagnoses and the influence of risk factors on transplant survival and visual outcome are taken into account while determining priority for transplant cases in the present situation of limited availability of donor corneas. AD - Public Health Ophthalmology Service, L V Prasad Eye Institute, Hyderabad, India Cornea Service, L V Prasad Eye Institute, Hyderabad, India Public Health Ophthalmology Service, L V Prasad Eye Institute, Road No 2, Banjara Hills, Hyderabad - 500 034, India AU - Dandona, L. AU - Naduvilath, T. J. AU - Janarthanan, M. AU - Ragu, K. AU - Rao, G. N. DB - Scopus DO - 10.1136/bjo.81.9.726 IS - 9 M3 - Article N1 - Cited By :108 Export Date: 19 July 2021 PY - 1997 SP - 726-731 ST - Survival analysis and visual outcome in a large series of corneal transplants in India T2 - British Journal of Ophthalmology TI - Survival analysis and visual outcome in a large series of corneal transplants in India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030658010&doi=10.1136%2fbjo.81.9.726&partnerID=40&md5=6b0ccb75ea8e8f3e54e83c2b5a4a1d99 VL - 81 ID - 4927 ER - TY - JOUR AB - Aim/background-The public health significance of corneal transplantation in dealing with corneal blindness in the developing world would depend upon the survival rate of transplants. This study was done to analyse the survival rate of corneal transplants in a large series in India, and to evaluate the influence of various risk factors on transplant survival. Methods-The records of a series of 1725 cases of corneal transplants carried out during 1987-95 at a tertiary eye care institution in India were reviewed. The Kaplan-Meier method was used to determine 5 year survival rates of corneal transplants performed for the various categories of preoperative diagnosis. Multivariate Cox proportional hazards regression was used to assess how preoperative diagnosis, socioeconomic status, age, sex, vascularisation of host cornea, quality of donor cornea, and training status of surgeon influenced transplant survival. The effect of these variables on visual outcome was assessed using multiple logistic regression. Results-The survival rates at 1, 2, and 5 years for all corneal transplants performed for the first time in 1389 cases were 79.6% (95% confidence interval = 77.3-81.9%), 68.7% (65.7-71.7%) and 46.5% (41.7-51.3%). The 5 year survival rate was highest if the corneal transplant was done for keratoconus (95.1% (84.8-100%)) and lowest if carried out for previous transplant failure (21.2% (13.8-28.6%)). The relative risk of transplant failure was higher if the preoperative diagnosis was previous transplant failure (2.04 (1.62-2.55)), aphakic bullous keratopathy (1.78 (1.38-2.28)), corneal clouding due to miscellaneous causes including congenital conditions and glaucoma (1.63 (1.21-2.19)), or adherent leucoma (1.11 (0.81-1.51)) than for the other preoperative diagnoses. Patients with lower socioeconomic status had higher relative risk of transplant failure (1.28 (1.16-1.42)), as did patients <10 years of age (1.42 (1.23-1.64)). Higher relative risk of transplant failure was associated with vascularisation of the host cornea before transplantation (1.15 (1.04-1.27)), and with the use of fair quality donor cornea for transplantation compared with excellent, very good, or good quality donor cornea (1.26 (1.06-1.52)). Before corneal transplant 80.2% of the eyes were blind (visual acuity <3/60), whereas at last follow up 41.8% eyes were blind. The odds of having visual acuity >6/18 were higher if the transplant was done for keratoconus (9.99 (6.10-16.36)) or corneal dystrophies (1.77 (1.21-2.58)) than for the other preoperative diagnoses. Conclusion-Reasonable success with corneal transplantation is possible in the developing world if data from this part of the world regarding the different survival rates for the various preoperative diagnoses and the influence of risk factors on transplant survival and visual outcome are taken into account while determining priority for transplant cases in the present situation of limited availability of donor corneas. AN - WOS:A1997XW81500009 AU - Dandona, L. AU - Naduvilath, T. J. AU - Janarthanan, M. AU - Ragu, K. AU - Rao, G. N. DA - SEP DO - 10.1136/bjo.81.9.726 IS - 9 PY - 1997 SN - 0007-1161 SP - 726-731 ST - Survival analysis and visual outcome in a large series of corneal transplants in India T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - Survival analysis and visual outcome in a large series of corneal transplants in India VL - 81 ID - 6362 ER - TY - JOUR AB - PURPOSE. To evaluate microbial contamination in silver-impregnated contact lens (CL) storage cases while establishing the effect of "wet" and "dry" case maintenance and to determine its association with clinical signs, symptoms, and compliance. METHODS. Two noncontemporaneous prospective studies were conducted. Regular storage cases in study 1 (n = 40) and silver-impregnated cases in study 2 (n = 41) were used in conjunction with CL solution and CLs (balafilcon A). Cases were replaced monthly and collected at 1, 3, and 4 (for silver-impregnated cases only) months. Regular cases and the fourth-month silver-impregnated cases were maintained dry, and the other cases were maintained wet between uses. At collection, storage cases were sampled and cultured for microbial identification and enumeration. Ocular clinical findings, subjective responses to CL wear, and compliance were recorded at each visit. RESULTS. The percentages of microbial contamination for silver-impregnated and regular cases were 71% and 82% respectively. There were significantly (P < 0.005) fewer organisms in silver-impregnated cases (1.7 log CFU per well) than in regular cases (4.1 log CFU per well). In particular, silver-impregnated cases showed lower levels of Gram-negative bacteria (P = 0.04), Gram-positive bacilli (P = 0.03), and fungi (P = 0.006). Maintaining the silver-impregnated cases wet resulted in a lower percentage of contamination (71%; P < 0.01) than maintaining them dry (94%). There was no association between any clinical signs, symptoms, or compliance and microbial contamination of storage cases. CONCLUSIONS. More than 70% of the storage cases used in daily wear CL care for a month was contaminated irrespective of the types of cases. However, silver-impregnated cases were colonized by reduced levels of Gram-negative bacteria. (www.anzctr.org.au number, ACTRN12609000165280.) (Invest Ophthalmol Vis Sci. 2012;53:1641-1648) DOI: 10.1167/iovs.11-8197 AN - WOS:000302790700078 AU - Dantam, J. AU - Zhu, H. AU - Willcox, M. AU - Ozkan, J. AU - Naduvilath, T. AU - Thomas, V. AU - Stapleton, F. DA - MAR DO - 10.1167/iovs.11-8197 IS - 3 PY - 2012 SN - 0146-0404 1552-5783 SP - 1641-1648 ST - In Vivo Assessment of Antimicrobial Efficacy of Silver-Impregnated Contact Lens Storage Cases T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - In Vivo Assessment of Antimicrobial Efficacy of Silver-Impregnated Contact Lens Storage Cases VL - 53 ID - 5893 ER - TY - JOUR AB - India has done well in eye care delivery by recognizing visual impairment and blindness as a major medical challenge. Major contributions have come from ophthalmologists (mass cataract surgery in the early 1900s; major participation of non-government organizations), policy makers (National Program for Control of Blindness and Visual Impairment 1976; systematic development under the World Bank assisted India Cataract Project, 1995-2002), and the industry (manufacturing of affordable surgical instruments and medicines). Although the country could boast of higher cataract surgical coverage and near-total elimination of trachoma, there is increasing prevalence of diabetic retinopathy and undetected glaucoma. India is in the crossroad of adherence to old successful models of service delivery and adoption of new innovative methods of teaching and training, manpower development and skill-based training, relevant medical research and product development. In the absence of these new approaches, the initial gains in eye care could not be furthered in India. A new approach, that will combine the best of the "old" tradition of empathy and the "new" technology of analytics, is required to imagine the future of eye care in India. AD - Srimati Kanuri Santhamma Centre for Vitreoretinal Diseases, L V Prasad Eye Institute, Hyderabad, Telangana; Indian Oil Center for Rural Eye Health, L V Prasad Eye Institute, Bhubaneswar, Odisha Indian Oil Center for Rural Eye Health, L V Prasad Eye Institute, Bhubaneswar, Odisha AN - 132740626. Language: English. Entry Date: 20181124. Revision Date: 20190515. Publication Type: journal article AU - Das, Taraprasad AU - Panda, Lapam DB - ccm DO - 10.4103/ijo.IJO_872_18 DP - EBSCOhost IS - 11 KW - Diagnostic Imaging -- Methods Eye Diseases -- Diagnosis Diagnosis, Eye -- Trends Diagnostic Imaging -- Trends India N1 - review; tables/charts. Journal Subset: Asia; Biomedical; Peer Reviewed. NLM UID: 0405376. PMID: NLM30355857. PY - 2018 SN - 0301-4738 SP - 1532-1538 ST - Imagining eye care in India (2018 Lalit Prakash Agarwal lecture) T2 - Indian Journal of Ophthalmology TI - Imagining eye care in India (2018 Lalit Prakash Agarwal lecture) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132740626&site=ehost-live&scope=site VL - 66 ID - 4485 ER - TY - JOUR AB - Background: Persistency with drug therapy reflects a number of factors, including patient tolerability of adverse events resulting from therapy and clinician satisfaction with the medication's effectiveness in reducing intraocular pressure. Objective: This study assesses persistency with topical glaucoma medications administered as initial therapy by evaluating rates of discontinuation and change in therapy. Methods: A retrospective cohort study was conducted using pharmacy claims data from 3 geographically diverse healthcare plans. Newly treated glaucoma patients younger than 65 years of age were selected based on an initial glaucoma medication fill during a 12-month period. Patients were followed for persistency, defined as discontinuation or change (switch or add-on) of initial glaucoma therapy; discontinuation of therapy was also evaluated as a separate end point. Results: In all, 1330 patients (followed for 1126 person-years) met the eligibility criteria. Compared with latanoprost users, patients initiated on other topical monotherapies were more likely to discontinue or change therapy, and patients initiated on other topical monotherapies were more likely than latanoprost users to discontinue therapy. Conclusion: Population-based data indicate that latanoprost offers superior persistency compared to agents from other popular classes of topical ocular hypotensives. AU - Dasgupta, S. AU - Oates, V. AU - Bookhart, B. K. AU - Vaziri, B. AU - Schwartz, G. F. AU - Mozaffari, E. DB - Scopus IS - 10 SUPPL. M3 - Article N1 - Cited By :75 Export Date: 19 July 2021 PY - 2002 SP - S255-S261 ST - Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data T2 - American Journal of Managed Care TI - Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036677782&partnerID=40&md5=b4024905394e8f6e29f48ed8b09d5882 VL - 8 ID - 4952 ER - TY - JOUR AB - Purpose Of Review: The purpose is to provide an overview of the recent advancements in the diagnosis and treatment of microbial keratitis and endophthalmitis after keratoprosthesis implantation.Recent Findings: The addition of vancomycin daily to a fluoroquinolone in the postoperative management of keratoprosthesis patients successfully reduced the number of cases of bacterial keratitis and endophthalmitis with an increased number of fungal infections now documented both in the United States and abroad.Summary: Compliance with the regimen of a fluoroquinolone and vancomycin daily for life after keratoprosthesis implantation should be stressed with the patient. Further research is needed to investigate whether intermittent use of 5% povidone-iodine and frequent replacement of the bandage contact lens could reduce fungal infection after keratoprosthesis surgery. Future advancements in the Boston keratoprosthesis design and/or postoperative management are needed to further reduce infection after keratoprosthesis placement. AD - Cornea and External Disease Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA AN - 116120837. Language: English. Entry Date: 20161223. Revision Date: 20190708. Publication Type: journal article AU - Davies, Emma AU - Chodosh, James DB - ccm DO - 10.1097/ICU.0000000000000270 DP - EBSCOhost IS - 4 KW - Prostheses and Implants -- Adverse Effects Keratitis -- Etiology Antibiotics -- Therapeutic Use Eye Infections, Bacterial -- Etiology Eye Infections, Fungal -- Etiology Endophthalmitis -- Etiology Postoperative Complications -- Microbiology Eye Infections, Fungal -- Diagnosis Eye Infections, Bacterial -- Diagnosis Endophthalmitis -- Therapy Eye Infections, Fungal -- Therapy Keratitis -- Therapy Eye Infections, Bacterial -- Therapy Endophthalmitis -- Diagnosis Cornea -- Surgery Keratitis -- Diagnosis Artificial Organs N1 - pictorial; review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM27138637. PY - 2016 SN - 1040-8738 SP - 373-377 ST - Infections after keratoprosthesis T2 - Current Opinion in Ophthalmology TI - Infections after keratoprosthesis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116120837&site=ehost-live&scope=site VL - 27 ID - 4642 ER - TY - JOUR AB - Purpose: The aim of this study was to evaluate differences in the persistency and treatment costs for latanoprost, bimatoprost, or beta-blockers in open-angle glaucoma or ocular hypertensive patients. Methods: This study was a retrospective, multicenter, parallel, active-controlled comparison of patients who were prescribed with ocular hypotensive monotherapy between September 1996 and August 2002. Results: 1,182 patients were included. The Kaplan Meier life table analysis showed that latanoprost was continued longest among the groups for the first year of therapy (p = 0.02). A significant difference existed between groups in the final intraocular pressure for latanoprost(17.3 ± 3.9, N = 357), for bimatoprost (18.0 ± 3.6, N = 146), and for the beta-blockers (17.9 ± 3.7, N = 335) (p = < 0.0001). The average number of visits was statistically higher for beta-blockers (3.3), compared to latanoprost (2.9) and bimatoprost (3.1) (p = 0.01). Further, the mean number of medicine changes was greater for bimatoprost (0.45) and beta-blockers (0.47) than for latanoprost (0.27) (p = 0.0008). The cost of visits and medications was lowest for beta-blockers ($119.3 ± $78.9) and highest for bimatoprost ($163.8 ± $51.2) (p < 0.001). Conclusions: Patients were more persistent with latanoprost and demonstrated lower intraocular pressure, fewer visits, and fewer medicine changes when compared to bimatoprost or beta-blocker therapy. In contrast, the beta-blocker group provided lower overall cost. AD - W.C. Stewart, Pharmaceutical Research Network, LLC, 1639 Tatum Street, Charleston, SC 29412-2464, United States AU - Day, D. G. AU - Schacknow, P. N. AU - Sharpe, E. D. AU - Ellyn, J. C. AU - Kulze Iii, J. C. AU - Threlkeld, A. B. AU - Jones, E. D. AU - Brown, R. H. AU - Jenkins, J. N. AU - Stewart, W. C. DB - Embase Medline DO - 10.1089/jop.2004.20.383 IS - 5 KW - beta adrenergic receptor blocking agent betaxolol bimatoprost carteolol latanoprost levobunolol metipranolol timolol timolol maleate adult aged allergic reaction article blepharitis conjunctival hyperemia controlled study cost benefit analysis cost of illness drug safety economic aspect eye burning eye irritation female human intraocular hypertension intraocular pressure Kaplan Meier method major clinical study male monotherapy ocular pruritus open angle glaucoma parallel design patient compliance retrospective study visual impairment LA - English M3 - Article N1 - L39441778 2004-11-16 PY - 2004 SN - 1080-7683 SP - 383-392 ST - A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension T2 - Journal of Ocular Pharmacology and Therapeutics TI - A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39441778&from=export http://dx.doi.org/10.1089/jop.2004.20.383 VL - 20 ID - 3727 ER - TY - JOUR AB - Purpose: The aim of this study was to evaluate differences in the persistency and treatment costs for latanoprost, bimatoprost, or beta-blockers in open-angle glaucoma or ocular hypertensive patients. Methods: This study was a retrospective, multicenter, parallel, active-controlled comparison of patients who were prescribed with ocular hypotensive monotherapy between September 1996 and August 2002. Results: 1,182 patients were included. The Kaplan Meier life table analysis showed that latanoprost was continued longest among the groups for the first year of therapy (p = 0.02). A significant difference existed between groups in the final intraocular pressure for latanoprost(17.3 ± 3.9, N = 357), for bimatoprost (18.0 ± 3.6, N = 146), and for the beta-blockers (17.9 ± 3.7, N = 335) (p = < 0.0001). The average number of visits was statistically higher for beta-blockers (3.3), compared to latanoprost (2.9) and bimatoprost (3.1) (p = 0.01). Further, the mean number of medicine changes was greater for bimatoprost (0.45) and beta-blockers (0.47) than for latanoprost (0.27) (p = 0.0008). The cost of visits and medications was lowest for beta-blockers ($119.3 ± $78.9) and highest for bimatoprost ($163.8 ± $51.2) (p < 0.001). Conclusions: Patients were more persistent with latanoprost and demonstrated lower intraocular pressure, fewer visits, and fewer medicine changes when compared to bimatoprost or beta-blocker therapy. In contrast, the beta-blocker group provided lower overall cost. AD - Atlanta Research Company, Atlanta, GA, United States Visual Health and Surgical Center, Lake Worth, FL, United States Charleston Research Company, L.L.C., Charleston, SC, United States Marietta Eye Clinic, Marietta, GA, United States Carolina Eye Center, Charleston, SC, United States Atlanta Ophthalmology Associates, Atlanta, GA, United States Pharmaceutical Res. Network, L.L.C., Charleston, SC, United States Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, United States Pharmaceutical Research Network, LLC, 1639 Tatum Street, Charleston, SC 29412-2464, United States AU - Day, D. G. AU - Schacknow, P. N. AU - Sharpe, E. D. AU - Ellyn, J. C. AU - Kulze Iii, J. C. AU - Threlkeld, A. B. AU - Jones, E. D. AU - Brown, R. H. AU - Jenkins, J. N. AU - Stewart, W. C. DB - Scopus DO - 10.1089/jop.2004.20.383 IS - 5 M3 - Article N1 - Cited By :24 Export Date: 19 July 2021 PY - 2004 SP - 383-392 ST - A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension T2 - Journal of Ocular Pharmacology and Therapeutics TI - A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-7444250645&doi=10.1089%2fjop.2004.20.383&partnerID=40&md5=bd43333cf825fca758c7b0323d09791e VL - 20 ID - 5101 ER - TY - JOUR AB - Purpose: To provide initial validation of the Treatment Satisfaction Survey-Intraocular Pressure (TSS-IOP) quality-of-life survey that analyses specific issues related to side effects, patient satisfaction, and compliance. Methods: A prospective, observational cohort of 250 consecutive patients with primary open-angle glaucoma or ocular hypertension was administered the TSS-IOP survey. Results: Factors that correlated with patient satisfaction included perceived effectiveness of the medicine (F=7.47, P<0.001), ocular irritation (F=6.06, P<0.001), conjunctival hyperaemia (F=4.40, P<0.001), ease of use (F=8.52, P<0.001), and convenience of use (F=6.90, P<0.001). Patient compliance, acceptance of their illness, and knowledge of glaucoma were also related to perceived effectiveness of the medicine (P<0.001), ease of use (P<0.05) and convenience (P<0.001). Physician ratings of patient pressure control, side effects, and instillation problems also were significantly correlated to patient satisfaction (R=0.13=0.26, P=0.05-0.001). The physician ratings of patient compliance, however, were not significantly related to any dimension of patient satisfaction (P>0.05). Among monotherapy prostaglandin treatments, latanoprost demonstrated statistically greater satisfaction than bimatoprost or travoprost regarding conjunctival hyperaemia (P<0.05) and eye irritation (P<0.01). Conclusions: This study provides initial evidence that patient satisfaction may be related to compliance, perceived effectiveness of treatment, adverse side effects, ease and convenience of use, acceptance of illness, and knowledge of glaucoma. © 2006 Nature Publishing Group. All rights reserved. AD - W.C. Stewart, Pharmaceutical Research Network, LLC, 1 Southpark Circle, Charleston, SC 29407, United States AU - Day, D. G. AU - Sharpe, E. D. AU - Atkinson, M. J. AU - Stewart, J. A. AU - Stewart, W. C. DB - Embase Medline DO - 10.1038/sj.eye.6701932 IS - 5 KW - alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent bimatoprost carbonate dehydratase inhibitor latanoprost prostaglandin travoprost adult article attitude to illness clinical trial cohort analysis conjunctival hyperemia controlled clinical trial controlled study correlation analysis drug efficacy drug utilization eye irritation female human intraocular hypertension intraocular pressure knowledge major clinical study male monotherapy observational study open angle glaucoma patient compliance patient satisfaction physician attitude quality of life questionnaire rating scale treatment satisfaction survey intraocular pressure validity LA - English M3 - Article N1 - L43674996 2006-05-25 PY - 2006 SN - 1476-5454 0950-222X SP - 583-590 ST - The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients T2 - Eye TI - The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43674996&from=export http://dx.doi.org/10.1038/sj.eye.6701932 VL - 20 ID - 3642 ER - TY - JOUR AD - Public Health, NHS Yorkshire and Humber, Leeds, UK. AN - 104569337. Language: English. Entry Date: 20121019. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Day, F. AU - Buchan, J. C. AU - Cassells-Brown, A. AU - Fear, J. AU - Dixon, R. AU - Wood, F. DB - ccm DO - 10.1038/eye.2010.73 DP - EBSCOhost IS - 9 KW - Glaucoma -- Epidemiology Glaucoma -- Ethnology Health Services Accessibility -- Administration Health Services Needs and Demand Ophthalmology Age Factors Aged Aged, 80 and Over England Female Health Services Accessibility -- Standards Male Middle Age Public Health Socioeconomic Factors National Health Programs -- Administration N1 - Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM20508654. PY - 2010 SN - 0950-222X SP - 1478-1485 ST - A glaucoma equity profile: correlating disease distribution with service provision and uptake in a population in Northern England, UK T2 - Eye TI - A glaucoma equity profile: correlating disease distribution with service provision and uptake in a population in Northern England, UK UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104569337&site=ehost-live&scope=site VL - 24 ID - 4533 ER - TY - JOUR AB - Purpose: We examined selective laser trabeculoplasty (SLT) as a replacement therapy for medically controlled open-angle glaucoma (OAG) or ocular hypertensive patients. Methods: A prospective randomized interventional clinical trial on 143 glaucoma patients. Patients were randomized to either receiving SLT or to the control group that continued on pressure lowering medication. Data were recorded 1 hr, 1 week, 1, 3, 6, 12 and 18 months after SLT. Primary outcome was number of medications at 12 and 18 months while maintaining a predetermined target intraocular pressure (IOP). Results: Selective laser trabeculoplasty (SLT) reduced number of medications from a mean of 1.5 at baseline, to 0.35 after 12 months and 0.29 after 18 months. Meanwhile, SLT achieved more than 20% IOP lowering in 95% of eyes and more than 30% IOP lowering in 86% of eyes after 18 months. Seventy-seven per cent of our eyes no longer needed any medication after SLT at 18 months. Conclusion: Selective laser trabeculoplasty (SLT) enabled a reduction in number of medications while maintaining good IOP control. Selective laser trabeculoplasty (SLT) was able to completely replace medical therapy in 77% of eyes after 18 months. Selective laser trabeculoplasty (SLT) as replacement therapy may reduce local and systemic side-effects and prevent adherence issues. © 2017 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd AD - Department of Medicine, University of Antwerp, Antwerp, Belgium Department of Experimental Psychology, Ghent University, Ghent, Belgium Department of Ophthalmology, University Hospital Antwerp, Edegem, Belgium AU - De Keyser, M. AU - De Belder, M. AU - De Belder, J. AU - De Groot, V. DB - Scopus DO - 10.1111/aos.13509 IS - 5 KW - glaucoma ocular hypertension replacement therapy selective laser trabeculoplasty M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2018 SP - e577-e581 ST - Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients T2 - Acta Ophthalmologica TI - Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020976760&doi=10.1111%2faos.13509&partnerID=40&md5=918a19ad0cd3c3d4a7ff9284e47a5e9f VL - 96 ID - 5244 ER - TY - JOUR AD - Institute of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands. d.dekorne@oogziekenhuis.nl AN - 105332208. Language: English. Entry Date: 20091030. Revision Date: 20150711. Publication Type: Journal Article AU - de Korne, D. F. AU - Sol, K. AU - Custers, T. AU - van Sprundel, E. AU - van Ineveld, B. M. AU - Lemij, H. G. AU - Klazinga, N. S. DB - ccm DP - EBSCOhost IS - 3 KW - Glaucoma -- Therapy Health Care Delivery -- Administration Patient Satisfaction Quality of Health Care -- Administration Quality of Health Care Clinical Indicators -- Administration Costs and Cost Analysis Data Collection Health Care Costs Health Services Accessibility -- Administration Health Services Needs and Demand -- Administration Netherlands Process Assessment (Health Care) -- Administration Quality of Health Care -- Economics Reimbursement Mechanisms Retrospective Design Human N1 - case study; research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8916799. PMID: NLM19537185. PY - 2009 SN - 0952-6862 SP - 232-251 ST - Creating patient value in glaucoma care: applying quality costing and care delivery value chain approaches--a five-year case study in the Rotterdam Eye Hospital T2 - International Journal of Health Care Quality Assurance (09526862) TI - Creating patient value in glaucoma care: applying quality costing and care delivery value chain approaches--a five-year case study in the Rotterdam Eye Hospital UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105332208&site=ehost-live&scope=site VL - 22 ID - 4524 ER - TY - JOUR AB - Purpose: To determine the association of visual field (VF) progression with medication persistence in a cohort on glaucoma therapy. Patients and Methods: Pharmacy records were examined over 3 years for patients started on glaucoma monotherapy. A patient was persistent if a prescription was refilled for the same medication < 90 days after the previous prescription had lapsed; otherwise was nonpersistent. Only patients with > 5 reliable VFs within 1-year pretherapy and 6-year posttherapy were included. Progression was analyzed with pointwise linear regression and defined using 2 criteria: (A) >= 2 adjacent progressing points (slope P < 0.01) in 1 hemifield; and (B) >= 3 progressing points (slope P < 0.01). The mean number and mean slope of progressing points and the mean global slopes were determined. Results: Of 1206 patient eyes (131 persistent, 1075 nonpersistent), 941 were excluded leaving 175 (47 persistent and 128 nonpersistent) for analysis. The mean follow-up durations were 59.3 +/- 10.9 and 58.2 +/- 9.7 months (P = 0.07) for persistent and nonpersistent eyes, respectively. Overall, 2/47 (4.3%) and 10/128 (7.8%) eyes progressed among persistent and nonpersistent patients, respectively (P = 0.52) using criterion A and 1/47 (2.1%) and 12/128 (9.4%; P = 0.19) eyes using criterion B. Mean number of progressing points (0.3 +/- 0.9 vs. 0.7 +/- 1.8; P = 0.17), mean slope of progressing points (-2.2 +/- 1.1 vs. -2.8 +/- 1.3 dB/y; P = 0.27), and mean global slope (0.7 +/- 0.5 vs. -0.1 +/- 0.8 dB/y; P = 0.07) were similar for persistent and nonpersistent patients, respectively. Conclusion: There were small but appreciable differences in VF progression rates between persistent and nonpersistent patient eyes on glaucoma drops, but differences were not significant. AN - WOS:000374834000007 AU - de Leon, J. M. S. AU - Quek, D. T. AU - Htoon, H. M. AU - Perera, S. A. AU - Lamoureux, E. L. AU - Aung, T. DA - APR DO - 10.1097/IJG.0000000000000345 IS - 4 PY - 2016 SN - 1057-0829 1536-481X SP - E336-E339 ST - Persistence of Glaucoma Therapy and Visual Field Progression T2 - JOURNAL OF GLAUCOMA TI - Persistence of Glaucoma Therapy and Visual Field Progression VL - 25 ID - 6225 ER - TY - JOUR AB - Purpose: To determine the association of visual field (VF) progression with medication persistence in a cohort on glaucoma therapy. Patients and Methods: Pharmacy records were examined over 3 years for patients started on glaucoma monotherapy. A patient was persistent if a prescription was refilled for the same medication <90 days after the previous prescription had lapsed; otherwise was nonpersistent. Only patients with >5 reliable VFs within 1-year pretherapy and 6-year posttherapy were included. Progression was analyzed with pointwise linear regression and defined using 2 criteria: (A) Z2 adjacent progressing points (slope P<0.01) in 1 hemifield; and (B) Z3 progressing points (slope P<0.01). The mean number and mean slope of progressing points and the mean global slopes were determined. Results: Of 1206 patient eyes (131 persistent, 1075 nonpersistent), 941 were excluded leaving 175 (47 persistent and 128 nonpersistent) for analysis. The mean follow-up durations were 59.3±10.9 and 58.2±9.7 months (P=0.07) for persistent and nonpersistent eyes, respectively. Overall, 2/47 (4.3%) and 10/128 (7.8%) eyes progressed among persistent and nonpersistent patients, respectively (P=0.52) using criterion A and 1/47 (2.1%) and 12/128 (9.4%; P=0.19) eyes using criterion B. Mean number of progressing points (0.3±0.9 vs. 0.7±1.8; P=0.17), mean slope of progressing points (-2.2±1.1 vs.-2.8±1.3 dB/y; P=0.27), and mean global slope (0.7±0.5 vs.-0.1±0.8 dB/y; P=0.07) were similar for persistent and nonpersistent patients, respectively. Conclusion: There were small but appreciable differences in VF progression rates between persistent and nonpersistent patient eyes on glaucoma drops, but differences were not significant. © 2015 Wolters Kluwer Health, Inc. All rights reserved. AD - Singapore and Singapore National Eye Centre, Singapore Eye Research Institute, Singapore Duke-NUS Medical School, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore Cardinal Santos Medical Center, San Juan City, Metro Manila, Philippines AU - De Leon, J. M. S. AU - Quek, D. T. AU - Htoon, H. M. AU - Tun, T. A. AU - Perera, S. A. AU - Lamoureux, E. L. AU - Aung, T. DB - Scopus DO - 10.1097/IJG.0000000000000345 IS - 4 KW - Glaucoma Glaucoma progression Medication persistence Visual fields M3 - Article N1 - Export Date: 19 July 2021 PY - 2016 SP - e336-e339 ST - Persistence of glaucoma therapy and visual field progression T2 - Journal of Glaucoma TI - Persistence of glaucoma therapy and visual field progression UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946616026&doi=10.1097%2fIJG.0000000000000345&partnerID=40&md5=618c1856e060ddf71ba00e8c493a92ad VL - 25 ID - 5743 ER - TY - JOUR AB - Zika virus (ZIKV) is an arbovirus mainly transmitted to humans by mosquitoes from Aedes genus. Other ways of transmission include the perinatal and sexual routes, blood transfusion, and laboratory exposure. Although the first human cases were registered in 1952 in African countries, outbreaks were only reported since 2007, when entire Pacific islands were affected. In March 2015, the first cases of ZIKV acute infection were notified in Brazil and, to date, 48 countries and territories in the Americas have confirmed local mosquito-borne transmission of ZIKV. Until 2015, ZIKV infection was thought to only cause asymptomatic or mild exanthematous febrile infections. However, after explosive ZIKV outbreaks in Polynesia and Latin American countries, it was confirmed that ZIKV could also lead to Guillain-Barré syndrome and congenital birth abnormalities. These abnormalities, which can include neurologic, ophthalmologic, audiologic, and skeletal findings, are now considered congenital Zika syndrome (CZS). Brain abnormalities in CZS include cerebral calcifications, malformations of cortical development, ventriculomegaly, lissencephaly, hypoplasia of the cerebellum and brainstem. The ocular findings, which are present in up to 70% of infants with CZS, include iris coloboma, lens subluxation, cataract, congenital glaucoma, and especially posterior segment findings. Loss of retinal pigment epithelium, the presence of a thin choroid, a perivascular choroidal inflammatory infiltrate, and atrophic changes within the optic nerve were seen in histologic analyses of eyes from deceased fetuses. To date, there is no ZIKV licensed vaccines or antiviral therapies are available for treatment. Preventive measures include individual protection from mosquito bites, control of mosquito populations and the use of barriers measures such as condoms during sexual intercourse or sexual abstinence for couples either at risk or after confirmed infection. A literature review based on studies that analyzed ocular findings in mothers and infants with CZS, with or without microcephaly, was conducted and a theoretical pathophysiologic explanation for ZIKV-ocular abnormalities was formulated. AD - Vision Institute, Department of Ophthalmology, Paulista Medical School, Federal University of São Paulo, São Paulo, Brazil Altino Ventura Foundation, Recife, Pernambuco, Brazil HOPE Eye Hospital, Recife, Pernambuco, Brazil Department of Ophthalmology, Roberto Santos General Hospital, Salvador, Brazil Scheie Eye Institute at the Perelman Center for Advanced Medicine, Perelman School of Medicine, Department of Ophthalmology, University of Pennsylvania, Philadelphia, United States Gonçalo Moniz Research Center, Oswaldo Cruz Foundation, Salvador, Brazil Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States Clinical Research Unit, Fernandes Figueira Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil Brazilian Institute of Fight Against Blindness, Assis and Presidente Prudente, São Paulo, Brazil AN - 131795846. Corporate Author: Zika Virus Study Group. Language: English. Entry Date: In Process. Revision Date: 20190712. Publication Type: journal article AU - de Oliveira Dias, João Rafael AU - Ventura, Camila V. AU - de Paula Freitas, Bruno AU - Prazeres, Juliana AU - Ventura, Liana O. AU - Bravo-Filho, Vasco AU - Aleman, Tomas AU - Ko, Albert Icksang AU - Zin, Andréa AU - Belfort, Rubens AU - Maia, Mauricio AU - de Oliveira Dias, João Rafael AU - Zin, Andréa AU - Belfort, Rubens, Jr. DB - ccm DO - 10.1016/j.preteyeres.2018.04.004 DP - EBSCOhost KW - Pregnancy Complications, Infectious Eye Infections, Viral Craniofacial Abnormalities Pregnancy Female Eye Infections, Viral -- Complications Eye Infections, Viral -- Transmission Human Craniofacial Abnormalities -- Complications Ways of Coping Questionnaire N1 - research. Journal Subset: Biomedical; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Instrumentation: Ways of Coping Questionnaire (WCQ) (Folkman et al). NLM UID: 9431859. PMID: NLM29698814. PY - 2018 SN - 1350-9462 SP - 85-106 ST - Zika and the Eye: Pieces of a Puzzle T2 - Progress in Retinal & Eye Research TI - Zika and the Eye: Pieces of a Puzzle UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131795846&site=ehost-live&scope=site VL - 66 ID - 4296 ER - TY - JOUR AB - We describe an unusual case of acquired anterior staphyloma in a patient addicted to crack cocaine. At the beginning of his crack cocaine abuse, he noticed redness and irritation of his eyes. Over the next 4 months, the patient also noticed the onset of decreasing visual acuity in his right eye (OD). Initially, his visual acuity was light perception in OD, and slit-lamp examination revealed a corneal infiltrate with a peripheral perforation and an iris prolapse. The patient was hospitalized to ensure compliance with the prescribed treatment and was advised to undergo therapeutic keratoplasty; however, the patient left the hospital against medical advice and was lost to follow-up for the next 6 months. He returned with complaints of photophobia and the inability to close his right eyelids. At this time, his cornea had developed an anterior staphyloma and required a sclerokeratoplasty. Following surgery, the patient was again lost to follow-up. AN - WOS:000384334100017 AU - de Vasconcelos, S. B. D. AU - Guerra, F. M. AU - Morato, G. M. AU - das Neves, N. T. AU - Tzelikis, P. F. DA - JUL-AUG DO - 10.5935/0004-2749.20160076 IS - 4 PY - 2016 SN - 0004-2749 1678-2925 SP - 268-269 ST - Acquired anterior staphyloma after corneal ulcer associated with the use of crack T2 - ARQUIVOS BRASILEIROS DE OFTALMOLOGIA TI - Acquired anterior staphyloma after corneal ulcer associated with the use of crack VL - 79 ID - 5811 ER - TY - JOUR AB - We describe an unusual case of acquired anterior staphyloma in a patient addicted to crack cocaine. At the beginning of his crack cocaine abuse, he noticed redness and irritation of his eyes. Over the next 4 months, the patient also noticed the onset of decreasing visual acuity in his right eye (OD). Initially, his visual acuity was light perception in OD, and slit-lamp examination revealed a corneal infiltrate with a peripheral perforation and an iris prolapse. The patient was hospitalized to ensure compliance with the prescribed treatment and was advised to undergo therapeutic keratoplasty; however, the patient left the hospital against medical advice and was lost to follow-up for the next 6 months. He returned with complaints of photophobia and the inability to close his right eyelids. At this time, his cornea had developed an anterior staphyloma and required a sclerokeratoplasty. Following surgery, the patient was again lost to follow-up. AD - Hospital de Base do Distrito Federal, Brasilia, DF, Brazil AU - de Vasconcelos, S. B. D. AU - Guerra, F. M. AU - Morato, G. M. AU - Neves, N. T. AU - Tzelikis, P. F. DB - Scopus DO - 10.5935/0004-2749.20160076 IS - 4 KW - Corneal ulcer/complications Crack cocaine/ adverse effects Eye infection/etiology M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2016 SP - 268-269 ST - Acquired anterior staphyloma after corneal ulcer associated with the use of crack T2 - Arquivos Brasileiros de Oftalmologia TI - Acquired anterior staphyloma after corneal ulcer associated with the use of crack UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988851111&doi=10.5935%2f0004-2749.20160076&partnerID=40&md5=4730fc46c580fadeee7543d1fec36556 VL - 79 ID - 5628 ER - TY - JOUR AB - Purpose: To test whether general nurses, trained in screening for glaucoma, can increase the number of glaucoma cases seen by eye-care professionals in a rural setting in Africa. Methods: In two districts in Malawi, 87 clinic nurses and two ophthalmic clinical officers were trained in case detection and referral of patients with suspect glaucoma. Data were collected on the number of patients screened and referred over a 12-month period. The clinic nurses and ophthalmic clinical officers received supportive supervision four times during the period and interviews were used to elicit their perspectives on the training and referral procedures. Results: The 87 nurses screened 294 people (mean 3.4 per nurse) and referred 147 (50%) of them. Of the 147 referred, 56 (38%) were seen by the ophthalmic clinical officers who referred 15 (27%) to the ophthalmologist. Only two people were seen by the ophthalmologist. Testing visual acuity in people over 40 years of age was not seen as a priority by primary level clinic nurses. Nurses reported that cost and distance were barriers precluding attendance by patients at the next level. Women were two times less likely to be referred. About one quarter of patients who were offered surgery refused. Fewer than half the patients who had surgery attend for follow-up. Conclusions: Training general nurses to screen for and refer suspect glaucoma cases did not lead to increased glaucoma service delivery. Other strategies to identify high risk patients need to be tested. © 2012 Informa Healthcare USA, Inc. AD - Nkhoma Eye Hospital, PO Box 48, Nkhoma, Malawi Department of Ophthalmology, Children's Hospital Boston, Harvard Medical School, Boston, United States Kilimanjaro Centre for Community Ophthalmology, Moshi, Tanzania Department of Ophthalmology, Groote Schuur Hospital, Cape Town, South Africa AU - Dean, W. H. AU - Courtright, P. AU - Cook, C. DB - Scopus DO - 10.3109/09286586.2012.712193 IS - 5 KW - Glaucoma case detection Glaucoma referral Malawi Vision 2020 M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2012 SP - 293-296 ST - Does training clinic nurses to test pinhole visual acuity as a screen for glaucoma increase glaucoma referrals to eye care professionals a pilot study in Malawi T2 - Ophthalmic Epidemiology TI - Does training clinic nurses to test pinhole visual acuity as a screen for glaucoma increase glaucoma referrals to eye care professionals a pilot study in Malawi UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866423419&doi=10.3109%2f09286586.2012.712193&partnerID=40&md5=cdab7486c5d95b86977b9474952fd6a3 VL - 19 ID - 5474 ER - TY - JOUR AB - Purpose: To test whether general nurses, trained in screening for glaucoma, can increase the number of glaucoma cases seen by eye-care professionals in a rural setting in Africa. Methods: In two districts in Malawi, 87 clinic nurses and two ophthalmic clinical officers were trained in case detection and referral of patients with suspect glaucoma. Data were collected on the number of patients screened and referred over a 12-month period. The clinic nurses and ophthalmic clinical officers received supportive supervision four times during the period and interviews were used to elicit their perspectives on the training and referral procedures. Results: The 87 nurses screened 294 people (mean 3.4 per nurse) and referred 147 (50%) of them. Of the 147 referred, 56 (38%) were seen by the ophthalmic clinical officers who referred 15 (27%) to the ophthalmologist. Only two people were seen by the ophthalmologist. Testing visual acuity in people over 40 years of age was not seen as a priority by primary level clinic nurses. Nurses reported that cost and distance were barriers precluding attendance by patients at the next level. Women were two times less likely to be referred. About one quarter of patients who were offered surgery refused. Fewer than half the patients who had surgery attend for follow-up. Conclusions: Training general nurses to screen for and refer suspect glaucoma cases did not lead to increased glaucoma service delivery. Other strategies to identify high risk patients need to be tested. AN - WOS:000308951500006 AU - Dean, W. H. AU - Courtright, P. AU - Cook, C. DA - OCT DO - 10.3109/09286586.2012.712193 IS - 5 PY - 2012 SN - 0928-6586 1744-5086 SP - 293-296 ST - Does Training Clinic Nurses to Test Pinhole Visual Acuity as a Screen for Glaucoma Increase Glaucoma Referrals to Eye Care Professionals? A Pilot Study in Malawi T2 - OPHTHALMIC EPIDEMIOLOGY TI - Does Training Clinic Nurses to Test Pinhole Visual Acuity as a Screen for Glaucoma Increase Glaucoma Referrals to Eye Care Professionals? A Pilot Study in Malawi VL - 19 ID - 6168 ER - TY - JOUR AB - Purpose: The first objective of the present study was to estimate the prevalence of patients treated for glaucoma or ocular hypertension (OHT) with an IOP (intraocular pressure) -lowering topical medication. Subjects were 40 years old and living in continental France. The second objective was to describe the type of therapy, compliance, and the quality of life of the subjects treated.Methods: This study was a telephone survey conducted in a general population on a representative sample of 5726 subjects in 2004. Subjects treated for glaucoma or OHT were defined as those declaring use of eye drops for more than 1 month and mentioning one of the 52 registered IOP-lowering topical medications and/or stating that they were taking eye drops for glaucoma or OHT. Quality of life was measured using the GlauQOL-17 questionnaire.Results: 237 subjects (4.1%) corresponded to this definition. The prevalence increased with age, from 0.7% in subjects aged 40-44 years to 10.6% in those aged 80 years or more. The age-standardized prevalence was higher in the Paris area (5.3%), the Mediterranean (4.5%), and the Southwest (4.7%), and lower in rural areas (3.2%), and in subjects with less than high school education (2.9%). Beta-blockers (49.5%) and prostaglandins (37.4%) were the most frequent treatments, followed by carbonic anhydrase inhibitors (15.3%), sympathomimetics (5.7%), and myotics (1.3%). Compliance was not total in 39% of the patients (22% of those treated with once-a-day dosage).Discussion: The results of the present study are in line with French health authority data and with the results of the French "Glaucoma and intraocular high pressure, one day" study results. Moreover, the lower prevalence in regions with low medical density, low socioeconomic level, and rural areas, suggest that glaucoma or OHT might be underdiagnosed.Conclusion: On the basis of this first nationwide study, it can be estimated that the prevalence of subjects treated with IOP-lowering topical medications is about 1.2 million in France. The number of daily doses appears to influence compliance. © 2006. Elsevier Masson SAS. Tous droits réservés. AD - F. Levrat, Service Épidémiologie et Médico-économie, Pfizer, 23-25 Avenue du Dr. Lannelongue, 75014 Paris, France AU - Delcourt, C. AU - Bron, A. AU - Baudouin, C. AU - Denis, P. AU - Nordmann, J. P. AU - Renard, J. P. AU - Rouland, J. F. AU - Sellem, E. AU - Stephan, M. AU - Levrat, F. AU - Solesse, A. DB - Embase Medline DO - 10.1016/S0181-5512(06)73905-5 IS - 10 KW - adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor eye drops miotic agent prostaglandin academic achievement adult age distribution aged article controlled study France glaucoma health survey human intraocular hypertension intraocular pressure major clinical study patient compliance quality of life questionnaire rural area telemedicine topical treatment treatment outcome LA - French M3 - Article N1 - L46034130 2007-01-23 PY - 2006 SN - 0181-5512 SP - 1098-1106 ST - Prevalence and description of treatment with intraocular pressure-lowering topical medications in continental France T2 - Journal Francais d'Ophtalmologie TI - Prevalence and description of treatment with intraocular pressure-lowering topical medications in continental France UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46034130&from=export http://dx.doi.org/10.1016/S0181-5512(06)73905-5 VL - 29 ID - 3575 ER - TY - JOUR AD - Hopital Saint-Joseph, 7, Rue Pierre-Larousse, 75674 Paris Cedex 14 AU - Demailly, Ph AU - Zoute, C. AU - Castro, D. DB - Embase Medline IS - 8-9 KW - article female human major clinical study male open angle glaucoma patient compliance personality LA - French M3 - Article N1 - L20143362 1990-06-11 PY - 1989 SN - 0181-5512 SP - 595-601 ST - Personalities and chronic glaucoma T2 - Journal Francais d'Ophtalmologie TI - Personalities and chronic glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L20143362&from=export VL - 12 ID - 4048 ER - TY - JOUR AD - Arena Eye Surgeons, Columbus, OH AN - 93916711. Language: English. Entry Date: 20140127. Revision Date: 20200310. Publication Type: Article AU - DeNaeyer, Gregory W. DB - ccm DP - EBSCOhost IS - 1 KW - Sterilization and Disinfection -- Methods Contact Lenses Sterilization and Disinfection -- Evaluation Infection -- Prevention and Control Acanthamoeba Keratitis -- Diagnosis United States Food and Drug Administration Cleaning Compounds Patient Compliance -- Evaluation Outcomes (Health Care) N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 8610268. PY - 2014 SN - 0885-9175 SP - 49-49 ST - Topping Off Happens: Disinfection Efficacy Matters T2 - Contact Lens Spectrum TI - Topping Off Happens: Disinfection Efficacy Matters UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=93916711&site=ehost-live&scope=site VL - 29 ID - 4795 ER - TY - JOUR AB - Even if glaucoma treatment often begins with monotherapy, combined treatments are in fact frequent. However, they are associated with poorer compliance, which may lead to lower efficacy, notably if the delay between two eyedrops is too short. The main advantages of fixed combinations are better therapeutic compliance and a lesser effect of dilution of the first eyedrops by the second. Nevertheless, it is impossible to change the dosing interval of one or the other of the components and adverse side effects cannot be controlled. The fixed combinations available today or in the near future are based for the most part on the combination of timolol and a prostaglandin. Their efficacy is comparable to the efficacy of each of the components or of nonfixed combinations, but it is not strictly equivalent. This difference (on the order of 1 mmHg) could be explained by unsuitable frequency or poor timing of the instillation. © Masson, 2006. AD - P. Denis, Service d'Ophtalmologie Pavillon C, Hôpital Édouard Herriot, Place d'Arsonval, 69437 Lyon Cedex 03, France AU - Denis, P. C1 - carpilo combigan cosopt duotrav pilobloq xalacom xalatan DB - Embase Medline IS - SUPPL. 2 KW - brimonidine carpilo carteolol brimonidine plus timolol dorzolamide dorzolamide plus timolol timolol plus travoprost latanoprost latanoprost plus timolol pilobloq pilocarpine prostaglandin timolol article clinical trial dilution disease association drug efficacy glaucoma human intraocular pressure patient compliance unspecified side effect combigan cosopt duotrav xalacom xalatan LA - French M3 - Article N1 - L44652173 2006-11-22 PY - 2006 SN - 0181-5512 SP - 2S45-2S48 ST - Practical measures: Advantages of fixed combination treatments T2 - Journal Francais d'Ophtalmologie TI - Practical measures: Advantages of fixed combination treatments UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44652173&from=export VL - 29 ID - 3645 ER - TY - JOUR AB - Purpose: To study the awareness of the nature of the disease, compliance with treatment, and prevalence of systemic symptoms in a group of patients with chronic open angle glaucoma (COAG). Method: A structured questionnaire was designed and given to 260 consecutive COAG patients attending a general ophthalmology clinic. Questions related to the increased risk of COAG amongst family members, screening of family members, nature of field defects, variation in IOP, topical treatment and availability of a free eye test for a COAG patient in the UK were asked. Compliance and systemic symptoms were also assessed. Results: Forty-one per cent (107 of 260) of patients in the study group were aware of the increased risk of COAG in family members and 45.5% (118 of 260) of patient's family members had undergone screening for COAG. Seventy-three per cent (191 of 260) of the patients were aware of their own and their family members' entitlement to a free eye test. Seventy-seven per cent of patients claimed full compliance. Thirty per cent of patients were noted to have systemic symptoms. Conclusions: The awareness of the nature of COAG in this population was low and incidence of perceived drug related systemic symptoms very high. Both of these may contribute to poor compliance. © 2004 The College of Optometrists. AD - S. Shah, Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QP, United Kingdom AU - Deokule, S. AU - Sadiq, S. AU - Shah, S. DB - Embase Medline DO - 10.1046/j.1475-1313.2003.00155.x IS - 1 KW - agents acting on the eye article awareness controlled study human major clinical study open angle glaucoma patient compliance prevalence priority journal questionnaire screening test symptomatology vision test visual field defect LA - English M3 - Article N1 - L41711035 2006-01-12 PY - 2004 SN - 0275-5408 SP - 9-15 ST - Chronic open angle glaucoma: Patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms T2 - Ophthalmic and Physiological Optics TI - Chronic open angle glaucoma: Patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41711035&from=export http://dx.doi.org/10.1046/j.1475-1313.2003.00155.x VL - 24 ID - 3772 ER - TY - GEN AB - Normal-tension glaucoma (NTG) is generally defined as visual field loss and optic nerve defects consistent with glaucoma and an intraocular pressure (IOP) that does not exceed 21 mmHg (Allingham, R.R., Damji, K., Freedman, S., Moroi, S., Shafranov, G., Shields, M.B. (2005). In: Pine J. and Murphy J. (Eds.), Shields' Textbook of Glaucoma, 5th edn., Lippincott Williams & Wilkins, Philadelphia, PA, pp. 197-207, Chapter 11). If a patient has an atypical presentation (unilateral disease, decreased central visual acuity or visual field loss not consistent with optic disk appearance) then the clinician should rule out medical or neurologic etiologies. IOP-dependent and IOP-independent mechanisms play a role in NTG nerve damage. The exact mechanisms of IOP-independent damage are not currently known. Research has shown that vascular etiologies, such as vascular insufficiency and vasospasm, may be possible mechanisms for IOP-independent damage. The mainstay of glaucoma treatment remains robust IOP reduction. The chief goal of ongoing glaucoma research is to more clearly identify IOP-independent mechanisms of damage and to find neuroprotective treatment strategies to prevent retinal ganglion cell death and consequent visual loss. © 2008 Elsevier B.V. All rights reserved. AD - P.V. Desai, Jules Stein Eye Institute, UCLA, 100 Stein Plaza, Suite 2-118, Los Angeles, CA 90095, United States AU - Desai, P. V. AU - Caprioli, J. C5 - 18929110 DB - Embase Medline DO - 10.1016/S0079-6123(08)01114-X J2 - Prog. Brain Res. KW - calcium channel blocking agent dipeptidyl carboxypeptidase inhibitor memantine nifedipine nimodipine verapamil cell death clinical feature differential diagnosis disease course genetic association glaucoma glaucoma surgery high tension glaucoma human intraocular pressure nerve injury neuroprotection low tension glaucoma open angle glaucoma optic nerve optic nerve disease orthostatic hypotension patient compliance prevalence priority journal retina ganglion cell review risk factor trabeculoplasty visual impairment LA - English M1 - (Desai P.V., Desai@jsei.ucla.edu; Caprioli J.) Jules Stein Eye Institute, UCLA, 100 Stein Plaza, Suite 2-118, Los Angeles, CA 90095, United States M3 - Review N1 - L352448980 2008-11-12 PY - 2008 SN - 0079-6123 9780444532565 SP - 195-210 ST - The treatment of normal-tension glaucoma TI - The treatment of normal-tension glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352448980&from=export http://dx.doi.org/10.1016/S0079-6123(08)01114-X VL - 173 ID - 3417 ER - TY - JOUR AB - Treatment of glaucoma aims at preserving the visual function and the Quality of Life (QoL) of the patients. To slow down the progression of the disease, the IOP should be decreased to a level where the risk of further deterioration is reduced to a minimum. Rates of progression vary between patients. Detection of glaucoma progression should be based on the assessment of structure and function. When making a treatment plan, one should take into consideration the rate of progression and the impact of visual field deterioration on the QoL. Therefore, a careful and reliable baseline examination is crucial. Furthermore, yearly documentation of the optic disc and frequent examinations of the visual field, especially during the first two years of follow-up, are mandatory to evaluate how aggressive the treatment should be. Slowing down progression of the disease is closely related to a good communication with the patient, the quality of the information provided, and the tolerance of the medications, all keys to a good adherence. Other risk factors than IOP should be looked for and treated if possible, especially when worsening of glaucoma damage is observed despite apparently good IOP control and compliance. Modern monitoring of the glaucoma patient can be summarized in six keys. Current limitations of this approach will be briefly discussed. AD - M. Detry-Morel, Service d'Ophtalmologie, Cliniques Universitaires St. Luc, Université Catholique de Louvain, Bruxelles, Belgique. AU - Detry-Morel, M. DB - Medline IS - 316 KW - disease course doctor patient relationship follow up glaucoma human intraocular pressure patient compliance patient education perimetry quality of life review risk factor trabeculectomy LA - French M3 - Review N1 - L361369610 2011-03-10 PY - 2010 SN - 0081-0746 SP - 63-84 ST - [The six keys of the monitoring of the glaucoma patient] T2 - Bulletin de la Société belge d'ophtalmologie TI - [The six keys of the monitoring of the glaucoma patient] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361369610&from=export ID - 3220 ER - TY - JOUR AB - PURPOSE: To evaluate the long-term efficacy and side effects of off-label topical tacrolimus 0.03% ointment (Protopic; Fujisawa Health, Deerfield, IL) as a sole second-line immunosuppressive agent in the management of high-risk corneal grafts. METHODS: Four consecutive patients underwent high-risk penetrating keratoplasty (4 grafts) with a prior diagnosis of corneal scar secondary to herpetic keratitis, keratoconus, acanthamoeba keratitis, and Fuchs endothelial dystrophy, respectively. All 4 patients developed steroid-induced glaucoma and failed traditional immunosuppressant therapy. Patients were started on topical tacrolimus ointment 0.03%, twice daily, which was tapered to the lowest possible therapeutic dose that maintained its antirejection efficacy. Patients were monitored for adverse treatment effects. The mean follow-up was 33 months (range, 26-48 months), and the mean treatment duration was 22.6 months (range, 13-32 months). RESULTS: All 4 high-risk corneal transplant patients experienced episodes of acute rejection that was successfully reversed with topical tacrolimus treatment. During tacrolimus treatment, there were no further episodes of graft rejection and no incidents of herpes simplex virus infection or reactivation, with the longest follow-up being 4 years. Two patients have been successfully tapered off tacrolimus, and 2 patients are currently on once-daily dosing. No adverse effects were observed. CONCLUSIONS: Topical tacrolimus 0.03% ointment seems to be a promising second-line immunosuppressant in management of high-risk grafts. © 2008 Lippincott Williams & Wilkins, Inc. AD - Henry Ford Health System, Ophthalmology, Troy, MI, United States Department of Ophthalmology, University of Minnesota, Minneapolis, MN, United States University of Minnesota, Department of Ophthalmology, MMC 493, 420 Delaware Street SE, Minneapolis, MN 55455, United States AU - Dhaliwal, J. S. AU - Mason, B. F. AU - Kaufman, S. C. DB - Scopus DO - 10.1097/ICO.0b013e3181606086 IS - 4 KW - Cornea FK506 Graft Keratoplasty Protopic Tacrolimus M3 - Article N1 - Cited By :41 Export Date: 19 July 2021 PY - 2008 SP - 488-493 ST - Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty T2 - Cornea TI - Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-42549169600&doi=10.1097%2fICO.0b013e3181606086&partnerID=40&md5=cb6087d6db1191a298cc0c88418214b0 VL - 27 ID - 5016 ER - TY - JOUR AB - Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as one-third of all patients being treated for glaucoma need additional therapy to reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are three potent drugs that have been used in combination to reduce IOP. Timolol reduces the production rate of aqueous humor to achieve the IOP decrease. Latanoprost and pilocarpine both affect aqueous outflow, although by different mechanisms. The IOP efficacy of combined therapy with timolol and pilocarpine compared with timolol and latanoprost or with latanoprost alone has been investigated in three multicenter, randomized, clinical trials in Europe. This is a review of those published trials. In 2 of the 3 studies, the additional IOP lowering effect of latanoprost 0.005% administered once daily was compared with pilocarpine 2% administered 3 times daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension currently on monotherapy with timolol 0.5% twice daily. These 6-month studies found that the timolol and latanoprost combination reduced IOP more and was better tolerated with fewer side-effects than the timolol and pilocarpine combination. At 6 months, there was no evidence of long-term drift in IOP with timolol and latanoprost. This combined therapy provides an effective and safe option for lowering IOP in glaucoma patients. These results suggest that the timolol/latanoprost combination is preferable to the timolol/pilocarpine combination not only with regard to side effects but also to the magnitude of IOP reduction. Two of the 3 studies compared latanoprost monotherapy with timolol and pilocarpine combined therapy in patients with POAG, various other glaucomas, or ocular hypertension. Treatment was for 6 weeks or 6 months. In both studies, latanoprost was more effective and better tolerated than the combination of timolol and pilocarpine. These results suggest that latanoprost alone should be tried before the addition of pilocarpine to timolol therapy is considered. The convenience of daily administration of a single drop of latanoprost versus multiple drops of timolol and pilocarpine should improve patient compliance. © 2002 by Elsevier Science Inc. All rights reserved. AD - M. Diestelhorst, Department of Ophthalmology, University of Cologne, Joseph-Stelzmann-str 9, Cologne 50931, Germany AU - Diestelhorst, M. AU - Nordmann, J. P. AU - Toris, C. B. DB - Embase Medline DO - 10.1016/S0039-6257(02)00329-6 IS - 4 SUPPL. 1 KW - latanoprost pilocarpine prostaglandin derivative timolol aqueous humor flow clinical trial conjunctival hyperemia conjunctivitis drug efficacy drug indication drug potency drug safety drug tolerability eye pain human intraocular hypertension intraocular pressure miosis open angle glaucoma patient compliance priority journal review visual acuity visual impairment LA - English M3 - Review N1 - L35232230 2002-11-12 PY - 2002 SN - 0039-6257 SP - S155-S161 ST - Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy T2 - Survey of Ophthalmology TI - Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35232230&from=export http://dx.doi.org/10.1016/S0039-6257(02)00329-6 VL - 47 ID - 3860 ER - TY - JOUR AB - Background: Although interaction between doctor and patient is undoubtedly influenced by their mutual expectations, little information is available about the knowledge and expectations of glaucoma doctors concerning their patients' attitudes and treatment patterns. The aim of our prospective study was to compare the actual responses of glaucoma patients concerning various issues related to their disease and the responses the glaucoma doctors expected their patients to give. Methods: Glaucoma patients consecutively sent to our glaucoma centre were asked to complete a standardised questionnaire about their glaucoma history, treatment routines and opinions on issues related to glaucoma. Ophthalmologists at the glaucoma centre were asked to predict patients' answers. Results: One hundred and twenty-eight consecutive glaucoma patients completed the patients' questionnaire and 12 glaucoma specialists completed the corresponding questionnaire for doctors. Frequency of intraocular pressure (IOP) measurements and visual field testing, as well as the number of topical medications, were relatively accurately predicted by the glaucoma doctors. Differences between the doctors' predictions and patients' responses were found concerning discomfort after surgery and the influence of stress or environmental factors on IOP. The largest range of doctors' predictions (0-100%) was observed concerning the portion of patients claiming a 100% adherence to glaucoma medication. Conclusion: Glaucoma specialists are familiar with the treatment patterns of their patients. The knowledge of glaucoma specialists of their patients' subjective attitudes to glaucoma-related issues deserves further investigation, as discrepancies between doctors' and patients' responses were observed in this area. © Springer-Verlag 2005. AD - T.S. Dietlein, Department of Ophthalmology, University of Cologne, Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany AU - Dietlein, T. S. AU - Jordan, J. AU - Dinslage, S. AU - Krieglstein, G. K. DB - Embase Medline DO - 10.1007/s00417-005-0142-0 IS - 7 KW - topical agent accuracy adult aged article attitude to illness doctor patient relationship environmental factor glaucoma glaucoma surgery human intraocular pressure major clinical study medical specialist ophthalmology patient care patient compliance physician attitude postoperative complication prediction priority journal questionnaire physiological stress vision test visual field LA - English M3 - Article N1 - L44103334 2006-08-13 PY - 2006 SN - 0721-832X SP - 859-862 ST - What do glaucoma specialists know about their patients? T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - What do glaucoma specialists know about their patients? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44103334&from=export http://dx.doi.org/10.1007/s00417-005-0142-0 VL - 244 ID - 3600 ER - TY - JOUR AB - Purpose: To determine whether two sessions of a glaucoma educational intervention resulted in better persistence to glaucoma eye drop therapy compared to normal care.Methods: A total of 165 patients newly diagnosed with glaucoma who required eye drop therapy were recruited into a randomized clinical trial from the glaucoma clinic at Maisonneuve-Rosemont Hospital in Montreal, Canada. Patients were randomized to either an immediate intervention or normal care. The intervention consisted of two 60-90 minute sessions of education on glaucoma and its management, given in a small group format by a non-practicing ophthalmologist. Persistence to glaucoma medication was examined for 1 year by the use of Hospital medical records and by pharmacy claims records from the Régie de lassurance maladie du Québec (Quebec Health Insurance Program). A questionnaire was administered, and medication possession ratio calculated. The primary outcome was persistence, defined as having medication available at least 75% of the time. Secondary outcomes included eye drop instillation technique and perception of the importance of eye drop therapy.Results: The intervention group achieved better persistence to eye drop therapy, as 77% of controls and 89% of people receiving the intervention were persistent (p = 0.049). The intervention also resulted in better eye drop instillation technique (p < 0.001) and greater perception of the importance of eye drop therapy (p < 0.001).Conclusions: Brief instructional sessions offered to newly diagnosed glaucoma patients can result in better persistence rates over 1-year follow-up. Strategies to permanently offer these types of initiatives should be considered. © 2015 Taylor & Francis Group, LLC. AD - Research Centre, Maisonneuve-Rosemont Hospital, CSA, RC, F131, 5415 Boulevard de l'Assomption, Montreal, QC H1T 2M4, Canada Department of Ophthalmology, Université de Montréal, Montreal, QC, Canada AU - Djafari, F. AU - Lesk, M. R. AU - Giguère, C. E. AU - Siam, G. AU - Freeman, E. E. DB - Scopus DO - 10.3109/09286586.2015.1083036 IS - 6 KW - Adherence education glaucoma medication medication possession ratio persistence trial M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2015 SP - 380-386 ST - Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial T2 - Ophthalmic Epidemiology TI - Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84951267124&doi=10.3109%2f09286586.2015.1083036&partnerID=40&md5=5c49afbc26e5eab1ba2b0580832f60b4 VL - 22 ID - 5380 ER - TY - JOUR AB - Purpose: To determine whether two sessions of a glaucoma educational intervention resulted in better persistence to glaucoma eye drop therapy compared to normal care.Methods: A total of 165 patients newly diagnosed with glaucoma who required eye drop therapy were recruited into a randomized clinical trial from the glaucoma clinic at Maisonneuve-Rosemont Hospital in Montreal, Canada. Patients were randomized to either an immediate intervention or normal care. The intervention consisted of two 60-90 minute sessions of education on glaucoma and its management, given in a small group format by a non-practicing ophthalmologist. Persistence to glaucoma medication was examined for 1 year by the use of Hospital medical records and by pharmacy claims records from the Regie de l'assurance maladie du Quebec (Quebec Health Insurance Program). A questionnaire was administered, and medication possession ratio calculated. The primary outcome was persistence, defined as having medication available at least 75% of the time. Secondary outcomes included eye drop instillation technique and perception of the importance of eye drop therapy.Results: The intervention group achieved better persistence to eye drop therapy, as 77% of controls and 89% of people receiving the intervention were persistent (p=0.049). The intervention also resulted in better eye drop instillation technique (p<0.001) and greater perception of the importance of eye drop therapy (p<0.001).Conclusions: Brief instructional sessions offered to newly diagnosed glaucoma patients can result in better persistence rates over 1-year follow-up. Strategies to permanently offer these types of initiatives should be considered. AN - WOS:000366469400004 AU - Djafari, F. AU - Lesk, M. R. AU - Giguere, C. E. AU - Siam, G. AU - Freeman, E. E. DA - NOV 2 DO - 10.3109/09286586.2015.1083036 IS - 6 PY - 2015 SN - 0928-6586 1744-5086 SP - 380-386 ST - Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial T2 - OPHTHALMIC EPIDEMIOLOGY TI - Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial VL - 22 ID - 6147 ER - TY - JOUR AB - PURPOSE: Estimate patient adherence to glaucoma medications and identify potential determinants of nonadherence. DESIGN: Descriptive study. METHODS: Two hundred patients with open angle glaucoma, ocular hypertension, or glaucoma suspects were interviewed regarding their glaucoma and its treatment and their charts were reviewed. Their ophthalmologist completed a brief assessment form. Drug utilization data were extracted from the provincial drug program database. Patients were defined as adherent if they filled at least 75% of the prescribed medication necessary for their treatment. RESULTS: Data were available for 181 patients. About 62.9% were female and the mean age (±SD) was 75.1±8.8 years. The mean number of years of glaucoma treatment was 10.7±9.3. Self-reported treatment adherence was 88.3%. On the basis of the drug database, the proportion of patients who were adherent to treatment was 71.8%. According to physicians, 74.6% of patients were adherent. Among patients considered by physicians as nonadherent, 71.1% (32/45) were adherent and among patients predicted as adherent, 72.1% (98/136) were adherent. There was no significant difference in adherence according to age, sex, education, and income. However, patients using fewer agents (P=0.041), who were widowed (P=0.041), or who lived alone (P=0.042) were more adherent. Patients using prostaglandins analogs or β-blockers were more adherent than those using carbonic anhydrase inhibitors (P<0.05). CONCLUSIONS: Fewer medications, use of prostaglandin analogs or β-blockers, living alone, and being widowed were significantly associated with adherence. Physicians were unable to significantly predict which patients are adherent. © 2009 Lippincott Williams & Wilkins, Inc. AD - J. Lachaine, Faculty of Pharmacy, University of Montreal, Quebec, QC, Canada AU - Djafari, F. AU - Lesk, M. R. AU - Harasymowycz, P. J. AU - Desjardins, D. AU - Lachaine, J. DB - Embase Medline DO - 10.1097/IJG.0b013e3181815421 IS - 3 KW - adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor miotic agent prostaglandin derivative aged article controlled study female glaucoma human intraocular hypertension long term care major clinical study male open angle glaucoma patient compliance patient education priority journal self report LA - English M3 - Article N1 - L354985166 2009-08-26 PY - 2009 SN - 1057-0829 SP - 238-242 ST - Determinants of adherence to glaucoma medical therapy in a long-term patient population T2 - Journal of Glaucoma TI - Determinants of adherence to glaucoma medical therapy in a long-term patient population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354985166&from=export http://dx.doi.org/10.1097/IJG.0b013e3181815421 VL - 18 ID - 3378 ER - TY - JOUR AB - Purpose To evaluate the impact of traditional counseling and patient-centered counseling, either alone or with recorded audio counseling reinforcement, on glaucoma knowledge and clinical follow-up. Design Prospective randomized controlled trial. Methods Newly diagnosed adult glaucoma patients were randomized to 1 of 3 categories of glaucoma counseling: traditional counseling, patient-centered counseling, or patient-centered counseling with audio counseling reinforcement. Demographic and clinical information from each subject was ascertained, and all subjects completed the Glaucoma Knowledge Assessment before and after counseling sessions at the time of diagnosis and at 1-month follow-up. Patients were instructed to return to clinic for routine follow-up at 1, 3, 6, 9, and 12 months after enrollment. A multivariate logistic regression model was used to determine factors associated with appropriate clinical follow-up. Results Overall, only 13.5% of subjects had appropriate clinical follow-up at 1 year, defined as attending at least 3 follow-up visits during that interval, and there was no significant difference between counseling groups. The mean glaucoma knowledge assessment score (GKAS) improved by 77.6% with the initial counseling intervention (P <.0001), decreased by 17.4% within a 1-month period following initial counseling, and improved by 22.8% (P <.001) after the second counseling intervention. Monthly household income over 2500 rupees, GKAS greater than 5 after initial counseling, and undergoing any ocular surgical procedure were all independent predictors of appropriate follow-up. Conclusion While all 3 counseling methods resulted in transient improvement of patient knowledge regarding glaucomatous disease, follow-up rates were poor for all groups. Poor retention of glaucoma knowledge may impact the likelihood of patient follow-up, and reinforcement with repeated counseling may be beneficial with regard to both disease knowledge and follow-up. © 2016 Elsevier Inc. All rights reserved. AD - Department of Ophthalmology, Stanford University, Palo Alto, CA, United States Aravind Eye Care System, 1 Anna Nagar, Madurai, 625 020, India Wilmer Eye Institute, Baltimore, MD, United States Bascom Palmer Eye Institute, Miami, FL, United States AU - Do, A. T. AU - Pillai, M. R. AU - Balakrishnan, V. AU - Chang, R. T. AU - Robin, A. L. AU - Singh, K. AU - Lee, B. W. DB - Scopus DO - 10.1016/j.ajo.2015.12.009 M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 SP - 180-189.e4 ST - Effectiveness of Glaucoma Counseling on Rates of Follow-up and Glaucoma Knowledge in a South Indian Population T2 - American Journal of Ophthalmology TI - Effectiveness of Glaucoma Counseling on Rates of Follow-up and Glaucoma Knowledge in a South Indian Population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959206504&doi=10.1016%2fj.ajo.2015.12.009&partnerID=40&md5=6e562f8c26d3082800e5018241b7b38f VL - 163 ID - 5354 ER - TY - JOUR AB - PURPOSE: To evaluate the impact of traditional counseling, and patient-centered counseling, either alone or with recorded audio counseling reinforcement, on glaucoma knowledge and clinical follow-up. DESIGN: Prospective randomized controlled trial. METHODS: Newly diagnosed adult glaucoma patients were randomized to 1 of 3 categories of glaucoma counseling: traditional counseling, patient-centered counseling, or patient-centered counseling with audio counseling reinforcement. Demographic and clinical information from each subject was ascertained, and all subjects completed the Glaucoma Knowledge Assessment before and after counseling sessions at the time of diagnosis and at 1-month follow-up. Patients were instructed to return to clinic for routine follow-up at 1, 3, 6, 9, and 12 months after enrollment. A multivariate logistic regression model was used to determine factors associated with appropriate clinical follow-up. RESULTS: Overall, only 13.5% of subjects had appropriate clinical follow-up at 1 year, defined as attending at least 3 follow-up visits during that interval, and there was no significant difference between counseling groups. The mean glaucoma knowledge assessment score (GKAS) improved by 77.6% with the initial counseling intervention (P<.0001), decreased by 17.4% within a 1-month period following initial counseling, and improved by 22.8% (P<.001) after the second counseling intervention. Monthly household income over 2500 rupees, GKAS greater than 5 after initial counseling, and undergoing any ocular surgical procedure were all independent predictors of appropriate follow-up. CONCLUSION: While all 3 counseling methods resulted in transient improvement of patient knowledge regarding glaucomatous disease, follow-up rates were poor for all groups. Poor retention of glaucoma knowledge may impact the likelihood of patient follow-up, and reinforcement with repeated counseling may be beneficial with regard to both disease knowledge and follow-up. (C) 2016 by Elsevier Inc. All rights reserved. AN - WOS:000371447500024 AU - Do, A. T. AU - Pillai, M. R. AU - Balakrishnan, V. AU - Chang, R. T. AU - Robin, A. L. AU - Singh, K. AU - Lee, B. W. DA - MAR DO - 10.1016/j.ajo.2015.12.009 PY - 2016 SN - 0002-9394 1879-1891 SP - 180-189 ST - Effectiveness of Glaucoma Counseling on Rates of Follow-up and Glaucoma Knowledge in a South Indian Population T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Effectiveness of Glaucoma Counseling on Rates of Follow-up and Glaucoma Knowledge in a South Indian Population VL - 163 ID - 5887 ER - TY - JOUR AB - Purpose: To describe whether subconjunctival bevacizumab decreases corneal neovascularization in patients with ocular surface inflammatory diseases. Methods: The study is a retrospective case series that includes 8 eyes of 7 patients with corneal neovascularization. Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab. Morphologic changes were assessed clinically by the same investigator at each visit. Results: Subconjunctival bevacizumab was well-tolerated without obvious corneal side effects. All 8 eyes of the 7 patients showed a reduction in the neovascularized area. Conclusions: Subconjunctival bevacizumab may provide an additional strategy in improving vision or improving success of corneal grafts in these patients. © 2008 by Lippincott Williams & Wilkins. AD - Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institute, Harvard Medical School, Cambridge, MA, United States Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institute, Harvard Medical School, 5 Cambridge Center, Cambridge, MA 02142, United States AU - Doctor, P. P. AU - Bhat, P. V. AU - Foster, C. S. DB - Scopus DO - 10.1097/ICO.0b013e31817786ad IS - 9 KW - Avastin Corneal neovascularization Subconjunctival bevacizumab M3 - Article N1 - Cited By :65 Export Date: 19 July 2021 PY - 2008 SP - 992-995 ST - Subconjunctival bevacizumab for corneal neovascularization T2 - Cornea TI - Subconjunctival bevacizumab for corneal neovascularization UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-58149163501&doi=10.1097%2fICO.0b013e31817786ad&partnerID=40&md5=609cf02aad086c8dd41b83abc01506ef VL - 27 ID - 4966 ER - TY - JOUR AB - Adherence to medicines is a major determinant of their effectiveness. However, estimates of non-adherence in the older-aged (defined as those aged ≥65 years) with chronic conditions vary from 40 to 75. The problems caused by non-adherence in the older-aged include residential care and hospital admissions, progression of the disease and increased costs to society. The reasons for non-adherence in the older-aged include items related to the medicine (e.g. cost, number of medicines, adverse effects) and those related to the person (e.g. cognition, vision, depression). It is also known that there are many ways adherence can be increased (e.g. use of blister packs, cues).Although it is assumed that interventions by allied health professionals (i.e. other than the prescriberdoctor), including a discussion of adherence, will improve adherence to medicines in the older-aged, the evidence for this has not been reviewed. There is some evidence that telephone counselling concerning adherence by a nurse or pharmacist improves short-and long-term adherence. However, face-to-face intervention counselling at the pharmacy or during a home visit by a pharmacist has shown variable results, with some studies showing improved adherence and some not. Broad-based education programmes during hospital stays have not been shown to improve medication adherence following discharge, whereas education programmes specifically for subjects with hypertension have been shown to improve adherence. In combination with an education programme, both counselling and a medicine review programme have been shown to improve short-term adherence in the older-aged.Thus, there are many unanswered questions about the most effective interventions for promoting adherence. More studies are needed to determine the most appropriate interventions by allied health professionals, and such studies need to consider the disease state, demographics and socioeconomic status of the older-aged subject, and the intensity and duration of intervention required. © 2010 Adis Data Information BV. All rights reserved. AD - School of Life Sciences, Queensland University of Technology, GPO Box 2334, Brisbane, QLD 4001, Australia AU - Doggrell, S. A. DB - Scopus DO - 10.2165/11532870-000000000-00000 IS - 3 M3 - Review N1 - Cited By :80 Export Date: 19 July 2021 PY - 2010 SP - 239-254 ST - Adherence to medicines in the older-aged with chronic conditions: Does intervention by an allied health professional help? T2 - Drugs and Aging TI - Adherence to medicines in the older-aged with chronic conditions: Does intervention by an allied health professional help? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77949413479&doi=10.2165%2f11532870-000000000-00000&partnerID=40&md5=53a06c528823ef14245cce86390a643a VL - 27 ID - 4946 ER - TY - JOUR AB - PURPOSE: Glaucoma is a frequent and often severe problem in patients needing keratoprosthesis (KPro) surgery. Standard glaucoma shunts in these cases often develop a very dense capsule that obstructs flow and causes intraocular pressure elevation. Therefore, we developed shunts that deliver aqueous to distant epithelialized cavities where an obstructing capsule is less likely to form. In this retroactive study of such shunts, the risk of postoperative infection (especially endophthalmitis) has been assessed. METHODS: Ahmed shunts were connected with a tube to the lacrimal sac or ethmoid sinuses. In subsequent designs the polypropylene plate was eliminated, the valve was enclosed and a distal tube added (New World Medical Inc, Rancho Cucamonga, CA). The latter shunts were connected to the maxillary sinus or lower lid fornix. Between 2001 and 2005 the devices were implanted in 34 patients with very severe ocular disease. (31 had KPro implanted). Thus, the distal tube was led to the lacrimal sac (2 cases), to the ethmoid sinuses (6), to the maxillary sinus (16 cases), and to the lower lid fornix (10 cases). The patients were followed for cumulatively 145 shunt years, with a mean follow-up of 4 years and 3 months. They were instructed to administer low-dose topical antibiotics indefinitely. RESULTS: Only 1 case of acute bacterial endophthalmitis occurred, thus an incidence of 0.7% per shunt year. A slow-growing Mycobacterium was cultured in a disintegrating eye and 1 bacterial maxillary sinusitis occurred, both in autoimmune diseases. Three valves became exposed and had to be removed (1 replaced). Four eyes developed hypotony, probably from valve failure. CONCLUSIONS: The shunt arrangement, which connects the anterior chamber to potentially microbe-populated cavities or to the lower lid fornix and its flora, might be suspected to allow rapid retrograde invasion of infective agents, resulting in endophthalmitis. In this series of KPro patients, however, the incidence of severe infection was very low, in fact comparable to that after standard trabeculectomy. © 2010 Lippincott Williams & Wilkins, Inc. AD - Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States AU - Dohlman, C. H. AU - Grosskreutz, C. L. AU - Chen, T. C. AU - Pasquale, L. R. AU - Rubin, P. A. D. AU - Kim, E. C. AU - Durand, M. DB - Scopus DO - 10.1097/IJG.0b013e3181a2fbeb IS - 2 KW - Aqueous diversion Epithelialized cavities Glaucoma shunts M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2010 SP - 111-115 ST - Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery T2 - Journal of Glaucoma TI - Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77149172058&doi=10.1097%2fIJG.0b013e3181a2fbeb&partnerID=40&md5=9510e2d4a44ceba5ddcd4f9342bbf959 VL - 19 ID - 5111 ER - TY - JOUR AB - Purpose: To review the case of a 41-year-old woman who underwent bariatric surgery in 2000. She subsequently underwent laser in situ keratomileusis (LASIK) surgery in 2008 and complained of dry eye since the LASIK surgery. In November 2010, she was diagnosed with a corneal melt and was treated with aggressive lubrication, followed by eventual amniotic membrane placement and a tarsorrhaphy. She then presented for consultation at the Bascom Palmer Eye Institute when she developed a corneal infiltrate. She was diagnosed with fungal keratitis with corneal xerosis. At that time, vitamin A levels were measured and were less than 2 μ/dL. The patient admitted noncompliance with nutritional supplements. Methods: Case report. Results: The patient was treated with aggressive lubrication and natamycin. Vitamin supplements were restarted, and the patient experienced dramatic improvement in symptoms with resolution of the infection. A central corneal scar with corneal thinning remains. The patient underwent a penetrating keratoplasty for visual rehabilitation. Conclusions: Patient education with emphasis on compliance with nutritional supplements is essential after bariatric surgery. Consider vitamin A deficiency in the differential diagnosis of dry eye after LASIK surgery. Copyright © 2012 by Lippincott Williams and Wilkins. AD - K.E. Donaldson, Bascom Palmer Eye Institute, 1000 South Pine Island Rd, Plantation, FL 33324, United States AU - Donaldson, K. E. AU - Fishler, J. DB - Embase Medline DO - 10.1097/ICO.0b013e318243e4ac IS - 12 KW - bacitracin gentamicin natamycin retinol vancomycin adult amniotic membrane placement bandage contact lens bariatric surgery case report conjunctival biopsy consultation cornea disease cornea scar cornea ulcer corneal melt corneal thinning Curvularia diet supplementation disease severity drug dose reduction dry eye eye care female hospital admission human keratomileusis keratomycosis keratoplasty lubrication patient compliance penetrating keratoplasty postoperative period priority journal rehabilitation care retinol deficiency review tarsorhaphy vitamin blood level vitamin supplementation LA - English M3 - Review N1 - L51972017 2012-04-26 2012-12-14 PY - 2012 SN - 0277-3740 1536-4798 SP - 1497-1499 ST - Corneal ulceration in a LASIK patient due to vitamin a deficiency after bariatric surgery T2 - Cornea TI - Corneal ulceration in a LASIK patient due to vitamin a deficiency after bariatric surgery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51972017&from=export http://dx.doi.org/10.1097/ICO.0b013e318243e4ac VL - 31 ID - 3053 ER - TY - JOUR AB - Since the introduction of commercial optical coherence tomography (OCT) systems, the ophthalmic imaging modality has rapidly expanded and it has since changed the paradigm of visualization of the retina and revolutionized the management and diagnosis of neuro-retinal diseases, including glaucoma. OCT remains a dynamic and evolving imaging modality, growing from time-domain OCT to the improved spectral-domain OCT, adapting novel image analysis and processing methods, and onto the newer swept-source OCT and the implementation of adaptive optics (AO) into OCT. The incorporation of AO into ophthalmic imaging modalities has enhanced OCT by improving image resolution and quality, particularly in the posterior segment of the eye. Although OCT previously captured in-vivo cross-sectional images with unparalleled high resolution in the axial direction, monochromatic aberrations of the eye limit transverse or lateral resolution to about 15-20 μm and reduce overall image quality. In pairing AO technology with OCT, it is now possible to obtain diffraction-limited resolution images of the optic nerve head and retina in three-dimensions, increasing resolution down to a theoretical 3 μm3. It is now possible to visualize discrete structures within the posterior eye, such as photoreceptors, retinal nerve fiber layer bundles, the lamina cribrosa, and other structures relevant to glaucoma. Despite its limitations and barriers to widespread commercialization, the expanding role of AO in OCT is propelling this technology into clinical trials and onto becoming an invaluable modality in the clinician's arsenal. AD - University of Pittsburgh Medical Center (UPMC) Eye Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Ophthalmology and Visual Science Research Center, Pittsburgh, PA, United States New York University (NYU) Langone Eye Center, NYU Langone Medical Center, Department of Ophthalmology, NYU School of Medicine, New York, NY, United States Department of Electrical and Computer Engineering, New York University Tandon School of Engineering, Brooklyn, NY, United States AN - 121755744. Language: English. Entry Date: 20171209. Revision Date: 20190326. Publication Type: journal article AU - Dong, Zachary M. AU - Wollstein, Gadi AU - Wang, Bo AU - Schuman, Joel S. DB - ccm DO - 10.1016/j.preteyeres.2016.11.001 DP - EBSCOhost KW - Tomography, Optical Coherence -- Equipment and Supplies Lenses Glaucoma -- Diagnosis Equipment Design Human Funding Source N1 - research. Journal Subset: Biomedical; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. Grant Information: R01 EY013178/EY/NEI NIH HHS/United States. NLM UID: 9431859. PMID: NLM27916682. PY - 2017 SN - 1350-9462 SP - 76-88 ST - Adaptive optics optical coherence tomography in glaucoma T2 - Progress in Retinal & Eye Research TI - Adaptive optics optical coherence tomography in glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121755744&site=ehost-live&scope=site VL - 57 ID - 4273 ER - TY - JOUR AD - Massachusetts Eye and Ear Infirmary, Quincy, MA, United States AU - Dorgan, J. AU - McGoldrick, A. DB - Scopus IS - 2 M3 - Article N1 - Export Date: 19 July 2021 PY - 2013 SP - 10-11 ST - Killing the amoebae T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - Killing the amoebae UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880425740&partnerID=40&md5=4d83ea8d844777a561cde596bbc8a178 VL - 38 ID - 5756 ER - TY - JOUR AB - The goal of antihypertensive therapy is to reduce intraocular pressure (IOP). Sometimes it can only be achieved by using two or more drugs, which can lead to undesirable side effects on the ocular surface. The use of drugs that do not contain preservatives leads to fewer undesirable side effects, while also reducing the need for instillations of artificial tears, making it economically beneficial for patients. Purpose — to assess the state of ocular surface in patients with POAG when switching to preservative-free carbonic anhydrase inhibitor (ICA) containing 0.18% sodium hyaluronate in combination with prostaglandin analogues and beta-adrenergic blocking agents. Material and methods. The study was conducted in 2019; according to selection criteria, it included 46 patients (80 eyes) with POAG and a control group of healthy persons. At the start of the study and one month later, after a change of treatment to unin terrupted ICA containing 0.18% sodium hyaluronate, the patients had state of their ocular surface examined: Norn’s test (tear breakup time; TBUT), Schirmer’s test, vital staining with lissamine green and an Ocular Surface Disease Index (OSDI) survey. Results. Replacing the ICA with benzalkonium chloride in the combination therapy of glaucoma with a preservative-free ICA containing 0.18% sodium hyaluronate — Dorzolan Solo (Solopharm, Russia) — expectedly did not lead to additional decrease of IOP, but resulted in a decrease in the width of the confidence interval according to both Maklakov’s and Icare tonometers, which may be associated with increased treatment adherence. At the same time, the state of ocular surface in the observation group was statistically significantly improved according to Norn’s test — from 3.57±1.3; 3.0 (3.0; 5.0) to 4.9±2.5; 5.0 (3.0; 6.0) (V=16.5; p=0.0039). Conclusion. According to Schirmer’s test and vital staining with lissamine green, no statistically significant changes have occurred. OSDI survey did not reveal changes in the study patients during 4 weeks of the follow-up, while the control group exhibited improvement. © 2019, Media Sfera. All rights reserved. AD - Chelyabinsk City Clinical Hospital No. 2, 82 Lenina Pr., Chelyabinsk, 454080, Russian Federation South Ural State Medical University, 64 Vorovskogo St., Chelyabinsk, 454092, Russian Federation AU - Dorofeev, D. A. AU - Tur, E. V. AU - Vizgalova, L. O. AU - Tryapitsin, I. D. AU - Ciganov, A. Z. DB - Scopus DO - 10.17116/oftalma201913506152 IS - 6 KW - Antihypertensive therapy Dry eye syndrome Glaucoma Intraocular pressure Ocular surface M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2019 SP - 52-59 ST - The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (Intermediate results) T2 - Vestnik Oftalmologii TI - The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (Intermediate results) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078785037&doi=10.17116%2foftalma201913506152&partnerID=40&md5=e9a50d1b074fe1f98c8d5004a376a1b2 VL - 135 ID - 5616 ER - TY - JOUR AB - IMPORTANCE: Low-socioeconomic urban children often do not have access to ophthalmic care. OBJECTIVE: To characterize the demographic characteristics and ophthalmic conditions in children attending Give Kids Sight Day (GKSD), an outreach ophthalmic care program held annually in Philadelphia, Pennsylvania, providing vision screening and immediate treatment when needed. DESIGN, SETTING, AND PARTICIPANTS: Retrospective case-series study of children attending GKSD in 2012 (GKSD 2012) at an ophthalmology center in Philadelphia. Registration forms and records of all children attending GKSD 2012 were reviewed. MAINOUTCOMESANDMEASURES: Demographic characteristics, insurance status, spoken languages, reasons for attending, prior failure of vision screening, and attendance pattern of previous events were analyzed. The ophthalmological findings of these children were examined, including refractive errors, need for optical correction, and diagnoses for which continuous ophthalmic care was necessary. For children who needed ophthalmic follow-up, the rate of return to clinic and barriers for continuous care were analyzed. RESULTS: We studied 924 children (mean age, 9 years; age range, 0-18 years; 51% female; 25% speaking a non-English language) coming from 584 families who attended GKSD 2012, of whom 27% were uninsured and 10% were not aware of their insurance status. Forty-two percent of participants had public insurance, which covered vision care and glasses, but 35% did not know their benefits and did not realize vision care was covered. Forty-nine percent of children attended because they failed community vision screening. Provision of free glasses and failure of previous vision screening were the most common reasons families elected to attend GKSD (64% and 49%, respectively). Eighty-five percent of children attended GKSD 2012 for the first time, whereas 15% attended prior events. Glasses were provided to 61% of attendees. Ten percent of the attendees needed continuous ophthalmic care, most commonly for amblyopia. Ten children needed ocular surgery for cataract, strabismus, nystagmus, ptosis, or nasolacrimal duct obstruction. With the assistance of a social worker, 59% of children requiring continuous treatment returned to the clinic, compared with 2% in prior years before social worker intervention. CONCLUSIONS AND RELEVANCE: Programs suchas GKSD can bridge the gap between successful vision screening and ophthalmic treatment, a gap that often occurs in low-socioeconomic urban populations. Those with public insurance coverage for vision services may not realize these services are covered. Social worker intervention is useful in overcoming common barriers to follow-up care. AD - Pediatric Ophthalmology and Ocular Genetics, Wills Eye Hospital, 840 Walnut St., Philadelphia, PA 19107, United States Public Citizens for Children and Youth, Philadelphia, PA, United States Eagles Youth Partnership, Philadelphia, PA, United States Department of Ophthalmology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, United States AU - Dotan, G. AU - Truong, B. AU - Snitzer, M. AU - McCauley, C. AU - Martinez-Helfman, S. AU - Maria, K. S. AU - Levin, A. V. DB - Scopus DO - 10.1001/jamaophthalmol.2015.8 IS - 5 M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 2015 SP - 527-532 ST - OUTCOMES of an inner-city vision outreach program: Give Kids Sight Day T2 - JAMA Ophthalmology TI - OUTCOMES of an inner-city vision outreach program: Give Kids Sight Day UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929687512&doi=10.1001%2fjamaophthalmol.2015.8&partnerID=40&md5=2b0f499999790b1b97355ce6c30e5cd0 VL - 133 ID - 5178 ER - TY - JOUR AD - J. Draeger AU - Draeger, J. DB - Medline IS - 1 KW - article glaucoma human intraocular pressure oculoplethysmography patient compliance psychological aspect self care LA - German M3 - Article N1 - L128309788 1998-11-24 PY - 1998 SN - 0023-2165 SP - aA9 ST - Intraocular pressure self-monitoring in glaucoma patients T2 - Klinische Monatsblätter für Augenheilkunde TI - Intraocular pressure self-monitoring in glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L128309788&from=export VL - 213 ID - 3940 ER - TY - JOUR AB - Introduction/Purpose: To determine the associations between medical, demographic, socioeconomic, and ocular factors and adherence to topical glaucoma ocular hypotensive therapy. Methods: One hundred sixteen patients with ocular hypertension or open-angle glaucoma from 2 tertiary glaucoma services participated in this prospective study. Adherence to ocular hypotensive therapy was measured using an electronic dose monitor (Travatan Dosing Aid, Alcon Laboratories Inc., Fort Worth, TX) and collected data at 3 months after enrollment. We used 3 different definitions of adherence: 1) Definition 1: the proportion of days taking the prescribed number of drops within 3 hours of the prescribed dosing time; 2) Definition 2: the proportion of days taking any drops within 3 hours of the prescribed dosing time; and 3) Definition 3: the proportion of days taking any drops within 6 hours of the prescribed dosing time. Univariate and multivariate models were used to determine the association between the 3 adherence definitions, medical, demographic, socioeconomic, and ocular factors at 3-month follow-up. The main outcome measures for this study were risk factors for poor objective medication adherence. Results: Adherence, using Definition 1, Definition 2, and Definition 3, was 64%, 75%, and 80%, respectively. Age, total number of other eye diseases, and race were significantly associated with full treatment adherence (Definition 1), with race alone significantly predicting 11% of full treatment adherence. For Definition 2, age, income, level of education, and total number of eye diseases were significantly associated with partial adherence (3 h), again race alone significantly predicted 15% of partial adherence (any drops within 3 h). For Definition 3, race, income, level of education, and total number of other eye diseases significantly predicted partial adherence (any drops within 6 h), both race and income predicted 19% of partial treatment adherence. Significant differences for adherence rates between patients of European descent and those of African descent were found for all 3 definitions with those who were less adherent more likely to be of African descent. Conclusions: Electronic dose monitors provide important information regarding adherence to topical ocular hypotensive medications in glaucoma patients. Electronic dose monitors show low adherence in a significant number of participants. Future studies are needed to determine the reasons for these differences in health behaviors related to glaucoma treatment, which should guide treatment of poor adherence with glaucoma therapy. © 2012 by Lippincott Williams & Wilkins. AD - S.L. Mansberger, Devers Eye Institute, Legacy Health System, 1040 NW 22nd Avenue, Portland, OR 97210, United States AU - Dreer, L. E. AU - Girkin, C. AU - Mansberger, S. L. DB - Embase DO - 10.1097/IJG.0b013e31821dac86 IS - 4 KW - travoprost adult article female follow up human intraocular hypertension major clinical study male open angle glaucoma outcome assessment patient compliance priority journal prospective study risk factor socioeconomics topical glaucoma therapy topical treatment LA - English M3 - Article N1 - L51447338 2011-05-31 2012-04-13 PY - 2012 SN - 1057-0829 1536-481X SP - 234-240 ST - Determinants of medication adherence to topical glaucoma therapy T2 - Journal of Glaucoma TI - Determinants of medication adherence to topical glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51447338&from=export http://dx.doi.org/10.1097/IJG.0b013e31821dac86 VL - 21 ID - 3099 ER - TY - JOUR AB - Introduction/Purpose: To determine the associations between medical, demographic, socioeconomic, and ocular factors and adherence to topical glaucoma ocular hypotensive therapy. Methods: One hundred sixteen patients with ocular hypertension or open-angle glaucoma from 2 tertiary glaucoma services participated in this prospective study. Adherence to ocular hypotensive therapy was measured using an electronic dose monitor (Travatan Dosing Aid, Alcon Laboratories Inc., Fort Worth, TX) and collected data at 3 months after enrollment. We used 3 different definitions of adherence: 1) Definition 1: the proportion of days taking the prescribed number of drops within 3 hours of the prescribed dosing time; 2) Definition 2: the proportion of days taking any drops within 3 hours of the prescribed dosing time; and 3) Definition 3: the proportion of days taking any drops within 6 hours of the prescribed dosing time. Univariate and multivariate models were used to determine the association between the 3 adherence definitions, medical, demographic, socioeconomic, and ocular factors at 3-month follow-up. The main outcome measures for this study were risk factors for poor objective medication adherence. Results: Adherence, using Definition 1, Definition 2, and Definition 3, was 64%, 75%, and 80%, respectively. Age, total number of other eye diseases, and race were significantly associated with full treatment adherence (Definition 1), with race alone significantly predicting 11% of full treatment adherence. For Definition 2, age, income, level of education, and total number of eye diseases were significantly associated with partial adherence (3 h), again race alone significantly predicted 15% of partial adherence (any drops within 3 h). For Definition 3, race, income, level of education, and total number of other eye diseases significantly predicted partial adherence (any drops within 6 h), both race and income predicted 19% of partial treatment adherence. Significant differences for adherence rates between patients of European descent and those of African descent were found for all 3 definitions with those who were less adherent more likely to be of African descent. Conclusions: Electronic dose monitors provide important information regarding adherence to topical ocular hypotensive medications in glaucoma patients. Electronic dose monitors show low adherence in a significant number of participants. Future studies are needed to determine the reasons for these differences in health behaviors related to glaucoma treatment, which should guide treatment of poor adherence with glaucoma therapy. © 2012 by Lippincott Williams & Wilkins. AD - Department of Ophthalmology, School of Medicine, Birmingham, Alabama, United Kingdom Devers Eye Institute, Legacy Health System, 1040 NW 22nd Avenue, Portland, OR 97210, United States AU - Dreer, L. E. AU - Girkin, C. AU - Mansberger, S. L. DB - Scopus DO - 10.1097/IJG.0b013e31821dac86 IS - 4 KW - compliance electronic dosing aids glaucoma health behaviors medication adherence topical glaucoma therapy Travatan Travoprost M3 - Article N1 - Cited By :67 Export Date: 19 July 2021 PY - 2012 SP - 234-240 ST - Determinants of medication adherence to topical glaucoma therapy T2 - Journal of Glaucoma TI - Determinants of medication adherence to topical glaucoma therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859429275&doi=10.1097%2fIJG.0b013e31821dac86&partnerID=40&md5=ef97d5c43a65c37a30cb45ce631a8181 VL - 21 ID - 4960 ER - TY - JOUR AB - Introduction/Purpose: To determine the associations between medical, demographic, socioeconomic, and ocular factors and adherence to topical glaucoma ocular hypotensive therapy. Methods: One hundred sixteen patients with ocular hypertension or open-angle glaucoma from 2 tertiary glaucoma services participated in this prospective study. Adherence to ocular hypotensive therapy was measured using an electronic dose monitor (Travatan Dosing Aid, Alcon Laboratories Inc., Fort Worth, TX) and collected data at 3 months after enrollment. We used 3 different definitions of adherence: 1) Definition 1: the proportion of days taking the prescribed number of drops within 3 hours of the prescribed dosing time; 2) Definition 2: the proportion of days taking any drops within 3 hours of the prescribed dosing time; and 3) Definition 3: the proportion of days taking any drops within 6 hours of the prescribed dosing time. Univariate and multivariate models were used to determine the association between the 3 adherence definitions, medical, demographic, socioeconomic, and ocular factors at 3-month follow-up. The main outcome measures for this study were risk factors for poor objective medication adherence. Results: Adherence, using Definition 1, Definition 2, and Definition 3, was 64%, 75%, and 80%, respectively. Age, total number of other eye diseases, and race were significantly associated with full treatment adherence (Definition 1), with race alone significantly predicting 11% of full treatment adherence. For Definition 2, age, income, level of education, and total number of eye diseases were significantly associated with partial adherence (3 h), again race alone significantly predicted 15% of partial adherence (any drops within 3 h). For Definition 3, race, income, level of education, and total number of other eye diseases significantly predicted partial adherence (any drops within 6 h), both race and income predicted 19% of partial treatment adherence. Significant differences for adherence rates between patients of European descent and those of African descent were found for all 3 definitions with those who were less adherent more likely to be of African descent. Conclusions: Electronic dose monitors provide important information regarding adherence to topical ocular hypotensive medications in glaucoma patients. Electronic dose monitors show low adherence in a significant number of participants. Future studies are needed to determine the reasons for these differences in health behaviors related to glaucoma treatment, which should guide treatment of poor adherence with glaucoma therapy. AN - WOS:000302382100005 AU - Dreer, L. E. AU - Girkin, C. AU - Mansberger, S. L. DA - APR-MAY DO - 10.1097/IJG.0b013e31821dac86 IS - 4 PY - 2012 SN - 1057-0829 1536-481X SP - 234-240 ST - Determinants of Medication Adherence to Topical Glaucoma Therapy T2 - JOURNAL OF GLAUCOMA TI - Determinants of Medication Adherence to Topical Glaucoma Therapy VL - 21 ID - 5932 ER - TY - JOUR AB - Purpose: To elucidate barriers and facilitators related to glaucoma medication adherence among African Americans (AA) with glaucoma and to elicit input from a community-based participatory research team to guide the development of a culturally informed health promotion program for improving glaucoma medication adherence among AAs.Methods: The nominal group technique (NGT), a highly structured focus group methodology, was implemented with 12 separate groups of AA patients with glaucoma (N = 89) to identify barriers and facilitators related to glaucoma medication usage. Participant rank-ordering votes were summed across groups and categorized into themes. Next, an individually and culturally targeted health promotion program promoting appropriate medication adherence was developed based on focus group results and input from a community-based participatory research team.Results: The top five barriers included problems with forgetfulness, side effects, cost/affordability, eyedrop administration, and the eyedrop schedule. The most salient top five facilitators were fear or thoughts about the consequences of not taking eyedrops; use of memory aids, cues, or strategies; maintaining a regular routine or schedule for eyedrop administration; ability to afford eyedrops; and keeping eyedrops in the same area. The resulting health promotion program was based on a multicomponent empowerment framework that included glaucoma education, motivational interviewing, and problem-solving training to improve glaucoma medication adherence.Conclusions: Barriers and facilitators related to glaucoma medication adherence among AAs are multifactorial. Based on the NGT themes and input from the community-based participatory research team, a culturally informed health promotion program was designed and holds great promise for improving medication adherence among this vulnerable population. AD - PhD tMD, MSPH tBA §PhD, MSPH Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama (LED, CAG, AW, LG, CO); and Department of Psychology, East Carolina University, Greenville, North Carolina (LC). AN - 107908061. Language: English. Entry Date: 20140411. Revision Date: 20161117. Publication Type: journal article AU - Dreer, Laura E. AU - Girkin, Christopher A. AU - Campbell, Lisa AU - Wood, Andy AU - Gao, Liyan AU - Owsley, Cynthia DB - ccm DO - 10.1097/OPX.0000000000000009 DP - EBSCOhost IS - 8 KW - Black Persons -- Statistics and Numerical Data Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Medication Compliance Program Development Adult Aged Aged, 80 and Over Female Focus Groups Glaucoma -- Ethnology Health Promotion Human Male Middle Age N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: K23 EY017327/EY/NEI NIH HHS/United States. NLM UID: 8904931. PMID: NLM23873033. PY - 2013 SN - 1040-5488 SP - 883-897 ST - Glaucoma medication adherence among African Americans: program development T2 - Optometry & Vision Science TI - Glaucoma medication adherence among African Americans: program development UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107908061&site=ehost-live&scope=site VL - 90 ID - 4312 ER - TY - JOUR AB - Purpose/Aims: To examine the feasibility, patient acceptability, and preliminary effectiveness of a culturally informed, health promotion program designed to improve glaucoma medication adherence among African Americans (AAs) with glaucoma.Materials/Methods: A sample of 11 AA glaucoma patients (mean age 61 years; 73% women and 27% men) completed a culturally informed and individually tailored, health promotion program developed for AAs titled, "Glaucoma Management Optimism for African Americans Living with Glaucoma" (GOAL). The aim of the brief 4-week program is to enhance glaucoma medication adherence through a combination of education, motivational interviewing (MI), and problem-solving training (PST). Feasibility was assessed on the basis of patient satisfaction with the program, number of sessions completed, and length of sessions. Preliminary efficacy was evaluated using a pre-post design to determine whether the program improved objective glaucoma medication adherence via an electronic Travalert dosing aid as well as satisfaction with aspects of glaucoma treatment, health beliefs about medications, glaucoma symptoms, emotional well-being, and intraocular pressure.Results: Overall patient satisfaction and acceptability was high for the program, interactions with the health educator, program materials, and the length of sessions. Feasibility was also supported given the need for the program, success in recruitment/retention, and ease of implementing the program with AA glaucoma patients in clinic and/or over the telephone. In terms of preliminary efficacy, patients showed significant pre-post improvements in objective medication adherence rates by 15% (p = 0.03), self-efficacy for glaucoma management (p = 0.02), ease of use in administering eye drops (p = 0.03), glaucoma treatment satisfaction (p = 0.05), beliefs about the necessity of taking glaucoma medications (p = 0.05), and functional visual ocular symptoms (p = 0.03).Conclusions: (GOAL) holds great promise toward improving glaucoma medication adherence and beliefs among AAs with glaucoma. AD - L.E. Dreer, Department of Ophthalmology, University of Alabama at Birmingham, Psychological and Neuropsychological Clinical Research Services, Birmingham, AL, United States AU - Dreer, L. E. AU - Owsley, C. AU - Campbell, L. AU - Gao, L. AU - Wood, A. AU - Girkin, C. A. DB - Embase Medline DO - 10.3109/02713683.2014.1002045 IS - 1 KW - antiglaucoma agent eye drops adult African American article clinical article clinical effectiveness female glaucoma health belief health education health promotion human intraocular pressure male medication compliance motivational interviewing patient compliance patient satisfaction priority journal program acceptability program feasibility LA - English M3 - Article N1 - L605676909 2015-08-25 2016-01-15 PY - 2016 SN - 1460-2202 0271-3683 SP - 50-58 ST - Feasibility, Patient Acceptability, and Preliminary Efficacy of a Culturally Informed, Health Promotion Program to Improve Glaucoma Medication Adherence among African Americans: " G laucoma Management O ptimism for A frican Americans L iving with Glaucoma" (GOAL) T2 - Current Eye Research TI - Feasibility, Patient Acceptability, and Preliminary Efficacy of a Culturally Informed, Health Promotion Program to Improve Glaucoma Medication Adherence among African Americans: " G laucoma Management O ptimism for A frican Americans L iving with Glaucoma" (GOAL) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605676909&from=export http://dx.doi.org/10.3109/02713683.2014.1002045 VL - 41 ID - 2761 ER - TY - JOUR AB - Disposable soft lenses are now available for extended wear. These lenses were designed to provide a more acceptable margin of safety than conventional extended wear soft lenses. Disposable lenses, which are intended to be discarded after 1-2 weeks of continuous wearing time, do offer a number of theoretical advantages. The short wearing schedule minimizes deposit formation which has been implicated in the development of giant papillary conjunctivitis and infectious keratitis. Lens disinfection systems, which are expensive and time consuming, and may become contaminated, are rarely needed if the manufacturer's guidelines are followed. Careful longterm follow-up of disposable soft lens patients will be needed to establish actual patient compliance and the safety of these lenses. © 1989. AD - Department of Ophthalmology, University of Florida College of Medicine, Gainesville, FL, United States AU - Driebe Jr, W. T. DB - Scopus DO - 10.1016/0039-6257(89)90128-8 IS - 1 KW - disposable lenses extended wear infectious keratitis soft lenses M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 1989 SP - 44-46 ST - Disposable soft contact lenses T2 - Survey of Ophthalmology TI - Disposable soft contact lenses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024314763&doi=10.1016%2f0039-6257%2889%2990128-8&partnerID=40&md5=4b365f5b4381a4a329513efb98c1a696 VL - 34 ID - 5318 ER - TY - JOUR AB - PURPOSE: To investigate the long-term therapeutic effect of Hunan aqueous drainage (HAD) implantation with and without adjunctive intraoperative mitomycin C (MMC) for refractory glaucoma. METHODS: 154 cases (159 eyes) with refractory glaucoma underwent Hunan aqueous drainage (HAD) implantation from July 1995 to July 2001. Sixty-five eyes were combined with MMC (0.4 mg/ml, 1 to 5 mins). With success defined as the introcular pressure (IOP) greater than 6 mmHg but no greater than 21 mmHg at the last visit. RESULTS: The mean period of postoperative follow-up was 54.6 (range, 12-72) months. The IOP was lowered from preoperative (46.8 +/- 14.5) mmHg to postoperative (16.8 +/- 11.3) mmHg at the 1st year after surgery. The success rate with MMC and without MMC were 90.0%, 77.3% (P < 0.05) at the 1st year, 87.1%, 67.3% (P < 0.05) at the 2nd year, 83.3%, 61.1% (P < 0.05) at the 3rd year, 81.3%, 56.7% (P < 0.05) at the 4th year, and 75.0%, 50.0% (P < 0.05) at the 5th year using Kaplan-Meier life-table analysis. The height of the posterior bleb underwent standardized ocular echography at the 1st year was (3.8 +/- 0.9) mm and (2.1 +/- 1.4) mm, respectively. Ninty-five eyes (81.9%) with visual acuity remained or improved after the surgery (P > 0.05). The most frequent complications for long-term follow-up included elevated IOP (IOP > 22 mmHg) (19.8%), the iris adherent to the proximal orifice of the tube (15.5%), developed cataract formation (12.9%) and so on (P > 0.05). We didn't find any severe complications after using MMC. CONCLUSION: This study suggests that HAD implantation is an effective method in the management of refractory glaucoma in spite of its unneligible complications and combined with MMC can improve the prognosis. AD - Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha, 410011, China AU - Duan, X. AU - Jiang, Y. AU - Qing, G. DB - Scopus IS - 2 M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2003 SP - 81-85 ST - Long-term follow-up study on Hunan aqueous drainage implantation combined with mitomycin C for refractory glaucoma T2 - Yan ke xue bao = Eye science / "Yan ke xue bao" bian ji bu TI - Long-term follow-up study on Hunan aqueous drainage implantation combined with mitomycin C for refractory glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-3142728085&partnerID=40&md5=c1f042224d130d40add8c0ffa3a6ae99 VL - 19 ID - 5223 ER - TY - JOUR AB - Introduction: Retinal vein occlusions (RVOs) are a common cause of severe or total loss of vision. Although the disease entity has long been known, its management is still controversial. We report five patients (six eyes) who experienced RVO even though they were taking anticoagulants or antiplatelet agents. Case reports: Two patients developed a central retinal vein occlusion (two eyes), two patients a branch retinal vein occlusion (two eyes), and one patient a bilateral central retinal vein occlusion (two eyes). Three patients were treated with anticoagulants, two for hemostatic pathologies and one for cardiopathy; two patients were treated with antiplatelet agents, one for auricular fibrillation and one for a cardiac graft. Retinal photocoagulation was performed in all cases to treat retinal ischemia. Neovascular glaucoma occurred in a single eye. Discussion: Treatments for thromboembolic disorders are more and more commonly used for various indications. Nevertheless, many patients develop RVO while taking such treatments, even though the International Normalized Ratio (INR) shows good patient compliance. Many case reports and small case series illustrate the occurrence of RVO with such treatments. These examples seem to illustrate the lack of efficacy of anticoagulants and platelet aggregation inhibitors in preventing vascular complications in the retinal venous circulation. Conclusion: Anticoagulants and platelet aggregation inhibitors must only be used to treat systemic factors or thromboembolic disorders associated with RVO. These five case reports illustrate that anticoagulants and platelet aggregation inhibitors cannot guarantee that a severe RVO will not occur. A prospective study would be useful to analyze their advantages in RVO management. © 2007. Elsevier Masson SAS. AD - G. Ducos De Lahitte, Service d'Ophtalmologie, Hôpital de la Pitié-Salpétrière, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France AU - Ducos De Lahitte, G. AU - Quintyn, J. C. AU - Leparmentier, A. AU - Mathis, A. DB - Medline DO - JFO-02-2007-30-2-0181-5512-101019-200609129 IS - 2 KW - anticoagulant agent antithrombocytic agent adult aged article case report human international normalized ratio male middle aged patient compliance retina vein occlusion treatment outcome LA - French M3 - Article N1 - L46326293 2007-05-03 PY - 2007 SN - 0181-5512 SP - 145-149 ST - Retinal vein occlusions in patients treated with anticoagulant and/or platelet aggregation inhibitors. Five case studies T2 - Journal Francais d'Ophtalmologie TI - Retinal vein occlusions in patients treated with anticoagulant and/or platelet aggregation inhibitors. Five case studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46326293&from=export http://dx.doi.org/JFO-02-2007-30-2-0181-5512-101019-200609129 VL - 30 ID - 3545 ER - TY - JOUR AU - Dugast, P. AU - Thiboust, P. AU - Blumen-Ohana, E. AU - Nordmann, J. P. DB - Medline DO - 10.1016/j.jfo.2016.02.004 IS - 6 KW - eye drops adult aged blindness disease course female open angle glaucoma human knowledge male middle aged needs assessment patient compliance patient education perception questionnaire standards very elderly LA - French M3 - Article N1 - L616464930 2017-06-01 PY - 2016 SN - 1773-0597 SP - 527-534 ST - Is there a need for a therapeutic education with patients suffering with open-angle glaucoma? Preliminary inquiry regarding knowledge and patient adherence T2 - Journal francais d'ophtalmologie TI - Is there a need for a therapeutic education with patients suffering with open-angle glaucoma? Preliminary inquiry regarding knowledge and patient adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616464930&from=export http://dx.doi.org/10.1016/j.jfo.2016.02.004 VL - 39 ID - 2738 ER - TY - JOUR AB - Purpose. - To evaluate the knowledge and compliance of patients with open-angle glaucoma in order to propose an approach by therapeutic education, validated for other chronic pathologies. Methods. - A questionnaire-based interview of all patients in the waiting room of the glaucoma center is performed by the same health care professional. Results. - Out of 200 patients, 73% know they will need to be treated throughout their lives and 95% are aware of the risk of blindness in the absence of appropriate treatment. However, 16% respond that they can be cured, and 54% believe that treatment can save their eyesight. Knowledge increases with the length of follow-up of patients at the glaucoma center beyond one year, but the progress is still insufficient in their confidence that treatment can save their eyesight (36% to 57%), and in the decrease in the number of patients who forget their treatment (56% to 30%). Conclusion. - Cognitive knowledge is insufficient to encourage the patient to comply with treatment. It is necessary to consider therapeutic patient education (TPE) techniques, such as described by WHO, in group and/or individual sessions, aimed at building the patient's confidence that treatment can delay the progression of the disease and blindness, strengthening his/her capacity to properly administer the eye drops, managing his/her treatment and coping with frequent side effects. Within this framework, our knowledge of the patients' representations of their glaucoma and its treatment must improve. (C) 2016 Elsevier Masson SAS. All rights reserved. AN - WOS:000379155500014 AU - Dugast, P. AU - Thiboust, P. AU - Blumen-Ohana, E. AU - Nordmann, J. P. DA - JUN DO - 10.1016/j.jfo.2016.02.004 IS - 6 PY - 2016 SN - 0181-5512 1773-0597 SP - 527-534 ST - Is there a need for a therapeutic education with patients suffering with open-angle glaucoma? Preliminary inquiry regarding knowledge and patient adherence T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Is there a need for a therapeutic education with patients suffering with open-angle glaucoma? Preliminary inquiry regarding knowledge and patient adherence VL - 39 ID - 6074 ER - TY - JOUR AB - Purpose: To compare the surgical outcomes of trabeculectomy performed in elderly patients (above 80 y) with those of younger controls. Materials and Methods: We retrospectively reviewed the charts of patients who underwent trabeculectomy from January 1, 2009 through April 30, 2011 at the Wills Eye Hospital. Patients over 80 years of age were compared with younger controls. Outcome measures included intraocular pressure (IOP), visual acuity, number of glaucoma medications, surgical complications, and surgical failure. Surgical failure was defined as when IOP > 21 mm Hg or < 20% reduction below baseline or IOP < 5 mm Hg or reoperation for glaucoma, or loss of light perception. Results: Eighty-six eyes of patients over 80 years of age (range, 81 to 94 y) were compared with 86 eyes of younger controls (range, 22 to 79 y). Mean follow-up time was 23.9 +/- 8.0 and 25.1 +/- 8.0 months for each group, respectively. After 1 year, the failure rate was 31.3% in the elderly group, compared with 29.5% in the control group (P = 0.98). At last follow-up visit, the rate of failure between the groups was similar (P = 0.35). Postoperative complications were similar between the groups (P = 0.25). Conclusions: The surgical outcomes of trabeculectomy in patients older than 80 years were found to be similar to those of younger controls. Taking into consideration elderly glaucoma patients' general health condition and life expectancy, age alone may not be a barrier to performing glaucoma filtration surgery. AN - WOS:000374821000002 AU - Duman, F. AU - Waisbourd, M. AU - Faria, B. AU - Addis, V. AU - Hsieh, M. AU - Ekici, F. AU - Hark, L. A. AU - Spaeth, G. L. DA - MAR DO - 10.1097/IJG.0000000000000230 IS - 3 PY - 2016 SN - 1057-0829 1536-481X SP - E123-E127 ST - Trabeculectomy in Patients With Glaucoma Over 80 Years of Age: Relatively Short-term Outcomes T2 - JOURNAL OF GLAUCOMA TI - Trabeculectomy in Patients With Glaucoma Over 80 Years of Age: Relatively Short-term Outcomes VL - 25 ID - 5992 ER - TY - JOUR AB - The compliance to treatment of glaucoma patient has a big importance on the long term vision preservation, as well as on the quality of life of our patients. Unknowing and misunderstanding of disease real implications and the importance of the treatment are present in out every day practice in our patients. We want to identify and analyze these aspects in a glaucoma group of Romanian patients, knowing the implications of socio-economic aspects. AD - D.M. Dumitrica, Spitalul Clinic de Urgenta Militar Central "Dr Carol Davila". AU - Dumitrica, D. M. AU - Stefan, C. DB - Medline IS - 3 KW - antihypertensive agent aged article attitude to health doctor patient relationship drug effect female glaucoma health survey human intraocular pressure male open angle glaucoma patient compliance quality of life questionnaire reproducibility Romania statistics LA - Romanian M3 - Article N1 - L355855554 2010-01-12 PY - 2009 SN - 1220-0875 SP - 130-133 ST - Compliance and ignorance in glaucoma in Romanian patients T2 - Oftalmologia (Bucharest, Romania : 1990) TI - Compliance and ignorance in glaucoma in Romanian patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355855554&from=export VL - 53 ID - 3297 ER - TY - JOUR AB - This study was undertaken to assess tolerability, quality of life, and persistency of use and to monitor changes in intraocular pressure (IOP) during the first 6 mo after a switch to fixed combination latanoprost/timolol. In Germany, 271 general ophthalmology practices enrolled patients who were switched from previous ocular hypotensive therapies to latanoprost/timolol for medical reasons. Usual care routines were followed, and IOP was measured at baseline and approximately 6 mo later. Adverse events were recorded throughout. Immediately before switching and at follow-up, patients completed a 29-item quality-of-life questionnaire. Of 1052 patients who met analysis criteria, 748 (71%) switched from combination therapy and 304 (29%) from monotherapy. An insufficient IOP reduction with the previous therapy was a reason for switching in 71% of patients; the desire to simplify to once-daily administration was cited in 66%. Ocular adverse events were reported in 19 patients after the switch, and 97% remained on therapy throughout the follow%up period. After switching, patients were less likely to forget to instill their eyedrops or to feel that their drops had adverse effects; they found it easier to include eyedrop administration in their routine; they were more satisfied with the frequency of instillation; and they were more likely to want to continue with the drops. Across all previous therapies, mean IOP decreased from 20.6+/-3.7 mm Hg to 17.2+/-2.8 mm Hg after the switch (P<.001)-a 14.8% difference. Fixed combination latanoprost/timolol is well tolerated and effective in patients who are switched from other monotherapies or combination therapies for medical reasons. Such a switch may be associated with improved quality of life. AD - Troisdorf, Germany AN - 105921929. Corporate Author: Latanoprost/Timolol Fixed Combination Study Group. Language: English. Entry Date: 20080111. Revision Date: 20200623. Publication Type: journal article AU - Dunker, S. AU - Schmucker, A. AU - Maier, H. AU - Dunker, Stephan AU - Schmucker, Achmed AU - Maier, Hubert DB - ccm DO - 10.1007/bf02849907 DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Latanoprost -- Therapeutic Use Patient Compliance Quality of Life Timolol -- Therapeutic Use Aged Aged, 80 and Over Descriptive Statistics Drug Combinations Female Funding Source Human Intraocular Pressure -- Drug Effects Latanoprost -- Adverse Effects Male Middle Age Patient Satisfaction Prospective Studies N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Pfizer Pharma GmbH, Germany. NLM UID: 8611864. PMID: NLM17565929. PY - 2007 SN - 0741-238X SP - 376-386 ST - Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol T2 - Advances in Therapy TI - Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105921929&site=ehost-live&scope=site VL - 24 ID - 4565 ER - TY - JOUR AB - Background: Delusional infestation (DI) is characterized by the fixed belief to be infested by small creatures or inanimate particles without medical evidence for this, and abnormal cutaneous sensations explained by these imaginary pathogens. DI has been described in several diseases. As for pathophysiology and neural basis of DI, some evidence suggest a pivotal role of dopamine and published cases secondary to localized brain lesions led to a hypothetical dysfunction in a frontostriato-thalamo-parietal network. We describe a unique case of Parkinson’s Disease (PD) and ophtalmologic DI. Case History: A 62-year-old male, with a 5 year diagnosis of PD with poor treatment adherence presented a depressive episode two years before admission. He was hospitalized because he started referring pareidolias, visual and somatic hallucinations and the delirious idea of parasitosis, described as a Loa-loa nematode that moved around the right eye and sometimes exited across the lacrimal and toward the nose bones. He developed conjunctivitis and the ophtalmologic evaluation showed bilateral open angle glaucoma. He was given treatment with low dosis of clozapine with remission of the psychotic symptoms. Conclusions: The presence of psychotic symptoms in PD are considered a neuropsychiatric complication that may have many clinical presentations, being DI a rare symptom in PD. In this case we discuss the pathophysiology implications of PD, dopaminergic drugs, concomitant depressive disorder and ophtalmologic pathology in the development of a DI. AU - Durand-Arias, S. AU - De La Garza-Neme, Y. DB - Embase DO - 10.1176/appi.neuropsych.262abstract IS - 2 KW - dopamine clozapine delusional parasitosis psychosis pathophysiology depression infestation skin sensation diseases brain damage patient compliance nematode laryngeal mask male diagnosis human pathogenesis hallucination parasitosis Loa loa eye nasal bone conjunctivitis open angle glaucoma remission pathology LA - English M3 - Conference Abstract N1 - L75006333 2014-06-04 PY - 2014 SN - 0895-0172 1545-7222 SP - 13 ST - Ophtalmologic Delusional Parasitosis in Parkinson’s Disease T2 - Journal of Neuropsychiatry and Clinical Neurosciences TI - Ophtalmologic Delusional Parasitosis in Parkinson’s Disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L75006333&from=export http://dx.doi.org/10.1176/appi.neuropsych.262abstract VL - 26 ID - 2901 ER - TY - JOUR AB - Micelles have been studied in the targeting of drug substances to different tissues as a nano-sized delivery system for many years. Sustained drug release, ease of production, increased solubility, and bioavailability of drugs with low water solubility are the most important superiorites of micellar carriers. These advantages paved the way for the use of micelles as a drug delivery system in the ocular tissues. The unique anatomical structure of the eye as well as its natural barriers and physiology affect ocular bioavailability of the drugs negatively. Conventional dosage forms can only reach the anterior segment of the eye and are used for the treatment of diseases of this segment. In the treatment of posterior segment diseases, conventional dosage forms are administered sclerally, via an intravitreal injection, or systemically. However, ocular irritation, low patient compliance, and high side effects are also observed. Micellar ocular drug delivery systems have significant promise for the treatment of ocular diseases. The potential of micellar systems ocular drug delivery has been demonstrated by in vivo animal experiments and clinical studies, and they are continuing extensively. In this review, the recent research studies, in which the positive outcomes of micelles for ocular targeting of drugs for both anterior and posterior segment diseases as well as glaucoma has been demonstrated by in vitro, ex vivo, or in vivo studies, are highlighted. AD - Department of Pharmaceutical Technology, Istanbul University, Istanbul, Turkey. AN - 144803218. Language: English. Entry Date: In Process. Revision Date: 20210701. Publication Type: journal article. Journal Subset: Biomedical AU - Durgun, Meltem Ezgi AU - Güngör, Sevgi AU - Özsoy, Yıldız DB - ccm DO - 10.1089/jop.2019.0109 DP - EBSCOhost IS - 6 N1 - Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM32310723. PY - 2020 SN - 1080-7683 SP - 323-341 ST - Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases T2 - Journal of Ocular Pharmacology & Therapeutics TI - Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=144803218&site=ehost-live&scope=site VL - 36 ID - 4200 ER - TY - JOUR AB - Purpose: To assess the ability of a novel imaging device to allow physicians to personalize therapeutic regimens based on objective patient drop administration data.Methods: A novel imaging system was used to record video of the drop technique of subjects in clinic (n=25) or at home (n=17) for 1 week. Video assessment by a reading center was compared with patient reporting and their prescribed regimen with respect to how many drops were applied and how many landed in the eye.Results: Reading center assessment of both drops dispensed and drops landing in the eye was significantly different from the prescribed regimen in the clinic (Pd=0.005, Pi<0.001, respectively) and at-home arms (Pd=0.003, Pi<0.001, respectively).Conclusions: This imaging system is a powerful tool to help physicians tailor patient therapy more accurately, to help researchers evaluate new drop therapies with objective rather than subjective data, and to potentially facilitate better patient training for improved drug delivery. AD - Konowal Vision Center, Fort Myers, FL, USA Retina Health Center, Fort Myers, FL, USA AN - 110197439. Language: English. Entry Date: 20160517. Revision Date: 20190326. Publication Type: journal article AU - Eaton, A. M. AU - Gordon, G. M. AU - Konowal, A. AU - Allen, A. AU - Allen, M. AU - Sgarlata, A. AU - Gao, G. AU - Wafapoor, H. AU - Avery, R. L. DB - ccm DO - 10.1038/eye.2015.155 DP - EBSCOhost IS - 10 KW - Glaucoma -- Drug Therapy Videorecording -- Equipment and Supplies Antihypertensive Agents -- Administration and Dosage Medication Compliance Drug Delivery Systems -- Equipment and Supplies Female Adult Prospective Studies Male Self Administration Pilot Studies Aged, 80 and Over Middle Age Monitoring, Physiologic Young Adult Aged Ophthalmic Solutions Human N1 - pictorial; research; tables/charts. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM26358235. PY - 2015 SN - 0950-222X SP - 1383-1391 ST - A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study T2 - Eye TI - A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110197439&site=ehost-live&scope=site VL - 29 ID - 4405 ER - TY - JOUR AB - Background: Lack of efficacy due to bad compliance caused by intolerance issues is the main reason for a change to a better tolerated ocular treatment, such as using preservative-free (PF) eye drops. Aim: To assess the efficacy and local tolerance after 12 months and patient satisfaction regarding local treatment tolerance and handling at inclusion and after 6 months of PF latanoprost compared to preserved glaucoma eye drops. Methods: This was an international, prospective, and observational real-life study. Up to three visits, one at inclusion and two follow-up visits (one after 6 and one after 12 months) were planned. Efficacy, local tolerance, and patient satisfaction were the main evaluation criteria. Results: Data from 721 patients were available for the statistical analysis. Overall, 64.8% (467/721) of patients switched treatment before inclusion: 62.2% in the preserved and 68.9% in the PF latanoprost group. IOP values were similar between PF latanoprost and preserved eye drops and remained stable at all visits. Ocular signs and symptoms improved after switching to PF latanoprost; the prevalence of conjunctival hyperemia was significantly lower (P=0.0015) at both follow-up visits. At follow-up visit 1, 49.5% of the patients who switched to PF latanoprost decreased or stopped the use of artificial tears. Satisfaction regarding tolerance in patients using PF latanoprost improved significantly after the switch from preserved eye drops to PF latanoprost (88.9% and 42.5%, respectively, P<0.0001). Conclusion: This first real-life study showed that PF latanoprost was as efficacious but better tolerated than preserved eye drops over a sustained period of 12 months, while providing a significantly higher patient satisfaction and potentially allowing improvement in the patient’s daily life. © 2018 Economou et al. AD - Anterior Segment Department, St Erik’s Eye Hospital, Karolinska Institute, Stockholm, Sweden Department of Ophthalmology, University Hospital, Trondheim, Norway Department of Laboratory Medicine, Norwegian University of Science and Technology, Trondheim, Norway Department of Ophthalmology, Ophthalmology Clinic Postgraduate Centre of Medical Education, Warszawa, Poland Department of Ophtalmology, Claude Huriez Hospital, University Hospital, Lille, France AU - Economou, M. A. AU - Laukeland, H. K. AU - Grabska-Liberek, I. AU - Rouland, J. F. DB - Scopus DO - 10.2147/OPTH.S176605 KW - Conjunctival hyperemia Glaucoma Ocular surface diseases Patient satisfaction Preservative-free latanoprost Prostaglandins M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2018 SP - 2399-2407 ST - Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: The 12-month real-life FREE study T2 - Clinical Ophthalmology TI - Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: The 12-month real-life FREE study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057718450&doi=10.2147%2fOPTH.S176605&partnerID=40&md5=9d62028c9b56760b88b6536b6054af67 VL - 12 ID - 5344 ER - TY - JOUR AB - Background: Lack of efficacy due to bad compliance caused by intolerance issues is the main reason for a change to a better tolerated ocular treatment, such as using preservative-free (PF) eye drops. Aim: To assess the efficacy and local tolerance after 12 months and patient satisfaction regarding local treatment tolerance and handling at inclusion and after 6 months of PF latanoprost compared to preserved glaucoma eye drops. Methods: This was an international, prospective, and observational real-life study. Up to three visits, one at inclusion and two follow-up visits (one after 6 and one after 12 months) were planned. Efficacy, local tolerance, and patient satisfaction were the main evaluation criteria. Results: Data from 721 patients were available for the statistical analysis. Overall, 64.8% (467/721) of patients switched treatment before inclusion: 62.2% in the preserved and 68.9% in the PF latanoprost group. IOP values were similar between PF latanoprost and preserved eye drops and remained stable at all visits. Ocular signs and symptoms improved after switching to PF latanoprost; the prevalence of conjunctival hyperemia was significantly lower (P=0.0015) at both follow-up visits. At follow-up visit 1, 49.5% of the patients who switched to PF latanoprost decreased or stopped the use of artificial tears. Satisfaction regarding tolerance in patients using PF latanoprost improved significantly after the switch from preserved eye drops to PF latanoprost (88.9% and 42.5%, respectively, P<0.0001). Conclusion: This first real-fife study showed that PF latanoprost was as efficacious but better tolerated than preserved eye drops over a sustained period of 12 months, while providing a significantly higher patient satisfaction and potentially allowing improvement in the patient's daily life. AN - WOS:000451277400001 AU - Economou, M. A. AU - Laukeland, H. K. AU - Grabska-Liberek, I. AU - Rouland, J. F. DO - 10.2147/OPTH.S176605 PY - 2018 SN - 1177-5483 SP - 2399-2407 ST - Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study T2 - CLINICAL OPHTHALMOLOGY TI - Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study VL - 12 ID - 5888 ER - TY - JOUR AB - Background/aims: The clinical course for childhood chronic anterior uveitis can vary from mild, self limiting disease to bilateral blindness. The purpose of this study was to identify those risk factors at onset that predict disease severity. Methods: A retrospective case note review of all patients with painless anterior uveitis diagnosed from 1982 to 1998. Patients were divided into two cohorts based on route of referral, diagnosis, and compliance with treatment. The standard cohort consisted of only those diagnosed from routine screening of juvenile idiopathic arthritis. Results: Complications-cataract surgery, ocular hypertension treatment, and visual acuity <6/24. Remission: inactive uveitis on no topical treatment for >6 months. Results - 163 patients were included. 34 patients (21%) developed at least one complication. The most significant predictor of complications was severe disease at onset (p = 0.001). Other factors included uveitis at the first examination (p = 0.034), membership of the non-standard cohort (p = 0.0001), non-oligoarticular disease (p = 0.02), and late onset arthritis (p = 0.024). Male sex was associated with increased complications in the standard cohort (p = 0.001). Factors predisposing to remission included membership of the standard cohort (p = 0.003), onset after 1990 (p = 0.016), white race (p = 0.015), mild disease onset (p = 0.003), and a long gap between arthritis and uveitis onset (p = 0.015). Conclusions: It is possible to characterise the severity of those with childhood chronic anterior uveitis at the onset of disease. The majority of patients remit without visually disabling complications. It may be possible to reduce the complication rate by targeting aggressive immunosuppression on high risk patients before complications develop. AD - Medical Ophthalmology Department, Prince Charles Eye Unit, King Edward VII Hospital, Great Ormond Street Hospital, Windsor, United Kingdom AU - Edelsten, C. AU - Lee, V. AU - Bentley, C. R. AU - Kanski, J. J. AU - Graham, E. M. DB - Scopus DO - 10.1136/bjo.86.1.51 IS - 1 M3 - Article N1 - Cited By :157 Export Date: 19 July 2021 PY - 2002 SP - 51-56 ST - An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood T2 - British Journal of Ophthalmology TI - An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036145153&doi=10.1136%2fbjo.86.1.51&partnerID=40&md5=728ee27ded00db4892b77efe9c2f485a VL - 86 ID - 4911 ER - TY - JOUR AB - Objective: The objective of this article was to describe the incidence, clinical characteristics, and visual outcomes of Vogt- Koyanagi-Harada disease in First Nations and Metis individuals. Design: A retrospective chart review. Participants: Nineteen First Nation and Metis Canadian residents in Northern Alberta. Methods: Electronic records for a 17-year period (1994-2010) were reviewed. Charts were reviewed for age, sex, length of followup, location of primary residence, diagnostic criteria at presentation, disease stage at presentation, duration of symptoms before presentation, ocular and extraocular manifestations at presentation, treatments, compliance, and complications. The time to an eye reaching 20/40, 20/200, and a halving of the baseline visual angle was plotted using Kaplan-Meier methodology. Results: Of 19 First Nations and Metis individuals identified, 84.2% were female, and the average age at presentation was 30.8 years. The most common presenting symptom and sign were blurred vision (89.5%) and anterior segment inflammation (89.5%), respectively. Fifteen (78.9%) patients had extraocular manifestations, the most common being alopecia (26.3%) and cerebrospinal fluid pleocytosis (26.3%). All patients were initially treated with corticosteroids; immunomodulatory therapy was used for 2 (10.5%) patients. Twelve (63.2%) patients experienced ocular complications; 47.4% of patients had difficulty with treatment compliance and attending follow-up appointments. The median time to achieve 20/40 vision was shorter for compliant patients compared with noncompliant patients (P = 0.048). Conclusions: The features of Vogt-Koyanagi-Harada disease in First Nations and Metis Canadians are most similar to series of South Asian and Hispanic patients. Compliant patients were found to achieve 20/40 vision significantly sooner than noncompliant patients. © 2013 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. AD - Department of Ophthalmology, University of Alberta, Royal Alexandra Hospital, 10240 Kingsway Avenue NW, Edmonton, AB, Canada AU - Ehmann, D. AU - Tennant, M. T. S. AU - Somani, R. AU - Rudnisky, C. J. DB - Scopus DO - 10.1016/j.jcjo.2012.10.008 IS - 3 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2013 SP - 146-152 ST - Vogt-Koyanagi-Harada disease in first nations and metis of northern Alberta T2 - Canadian Journal of Ophthalmology TI - Vogt-Koyanagi-Harada disease in first nations and metis of northern Alberta UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880159729&doi=10.1016%2fj.jcjo.2012.10.008&partnerID=40&md5=26f787790ce630901d8c87358c05e0b4 VL - 48 ID - 5573 ER - TY - JOUR AB - Purpose Improving adherence to practice guidelines can improve patient safety and quality of care. We sought to establish a regional glaucoma physician collaborative to evaluate and improve adherence to the American Academy of Ophthalmology's Primary Open-angle Glaucoma (POAG) Preferred Practice Pattern (PPP) guidelines. Design Prospective interventional study. Methods The collaborative consisted of 13 glaucoma specialists from 3 practices in Michigan. All consecutive POAG new patient visits were reviewed from each study site to determine physician adherence to the 13 major examination elements of the PPP. In phase 1 of the study, physician adherence rates for each of the recommended examination elements were combined and averaged for all groups. Averages for the collaborative were reported to each site, and each physician received his or her individual adherence rates. Physicians discussed strategies to improve overall adherence to the PPP. Adherence rates were collected in phase 2 to determine if feedback and sharing of strategies resulted in improved adherence. Results A total of 274 new POAG patient visits from phase 1 and 280 visits from phase 2 were reviewed. After accounting for multiple comparisons, overall improvement approached statistical significance for the evaluation of visual function (91.2% to 96.1%, P <.02) and target intraocular pressure determination (73.7% to 83.2%, P <.01). Improvement for other measures that had a high rate of adherence at baseline (eg, ocular history, pupil examination, and central corneal thickness measurement) was not statistically significant. Conclusions It is feasible to establish a regional glaucoma physician collaborative to improve standardization of care for patients with newly diagnosed POAG. © 2017 Elsevier Inc. AD - Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, United States Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, United States Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan, United States Department of Health Policy and Management, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States Grand Traverse Ophthalmology Clinic, Traverse City, Michigan, United States Henry Ford Health System, Dearborn, Michigan, United States AU - Ehrlich, J. R. AU - Wentzloff, J. N. AU - Imami, N. R. AU - Blachley, T. S. AU - Stein, J. D. AU - Lee, P. P. AU - Weizer, J. S. DB - Scopus DO - 10.1016/j.ajo.2017.04.022 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2017 SP - 145-150 ST - Establishing a Regional Glaucoma Physician Collaborative to Improve Quality of Care T2 - American Journal of Ophthalmology TI - Establishing a Regional Glaucoma Physician Collaborative to Improve Quality of Care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020094892&doi=10.1016%2fj.ajo.2017.04.022&partnerID=40&md5=96b3894f55a858fc905cbe3fd18cac15 VL - 179 ID - 5562 ER - TY - JOUR AB - PURPOSE: Improving adherence to practice guidelines can improve patient safety and quality of care. We sought to establish a regional glaucoma physician collaborative to evaluate and improve adherence to the American Academy of Ophthalmology's Primary Open-angle Glaucoma (POAG) Preferred Practice Pattern (PPP) guidelines. DESIGN: Prospective interventional study. METHODS: The collaborative consisted of 13 glaucoma specialists from 3 practices in Michigan. All consecutive POAG new patient visits were reviewed from each study site to determine physician adherence to the 13 major examination elements of the PPP. In phase 1 of the study, physician adherence rates for each of the recommended examination elements were combined and averaged for all groups. Averages for the collaborative were reported to each site, and each physician received his or her individual adherence rates. Physicians discussed strategies to improve overall adherence to the PPP. Adherence rates were collected in phase 2 to determine if feedback and sharing of strategies resulted in improved adherence. RESULTS: A total of 274 new POAG patient visits from phase 1 and 280 visits from phase 2 were reviewed. After accounting for multiple comparisons, overall improvement approached statistical significance for the evaluation of visual function (91.2% to 96.1%, P <.02) and target intraocular pressure determination (73.7% to 83.2%, P <.01). Improvement for other measures that had a high rate of adherence at baseline (eg, ocular history, pupil examination, and central corneal thickness measurement) was not statistically significant. CONCLUSIONS: It is feasible to establish a regional glaucoma physician collaborative to improve standardiza-tion of care for patients with newly diagnosed POAG. (C) 2017 Elsevier Inc. All rights reserved. AN - WOS:000405163900017 AU - Ehrlich, J. R. AU - Wentzloff, J. N. AU - Imami, N. R. AU - Blachley, T. S. AU - Stein, J. D. AU - Lee, P. P. AU - Weizer, J. S. DA - JUL DO - 10.1016/j.ajo.2017.04.022 PY - 2017 SN - 0002-9394 1879-1891 SP - 145-150 ST - Establishing a Regional Glaucoma Physician Collaborative to Improve Quality of Care T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Establishing a Regional Glaucoma Physician Collaborative to Improve Quality of Care VL - 179 ID - 6067 ER - TY - JOUR AB - Background: Glaucoma is a progressive disease responsible for the second commonest cause of blindness in the UK. Identifying appropriate patients for hospital care remains an ongoing challenge for all UK hospital glaucoma services. The purpose of our study is to evaluate accuracy and outcome of community optometry referrals before and after implementation of the new general ophthalmic service contract in 2006, the Eyecare Integration Programme pilot in 2008 and the effect of NICE guidelines in glaucoma in 2009, over a 12-year periodMethods: A retrospective case analysis using a glaucoma electronic patient record was performed encompassing two six-year periods, 2000-2006 (Group A), and 2007-2012 (Group B).Results: One thousand six hundred twenty-two new patients' records were analysed. Waiting times reduced from 12.3 to 9.4 weeks. Significantly more patients kept first appointment (p = 0.0002) in group B. Glaucoma symptoms were significantly more in group A (p <0.0001) and only three patients lost Snellen' visual acuity before appointment in group B compared to 12 in group A. Documentation of intraocular pressure was made in 74.1% of Group A and 75.9% of Group B, optic disc appearance in 85.4% of Group A, and 93% of Group B and visual fields in 84.4% of Group A and 81.3% of Group B. Significantly less normal (p < 0,0001), more glaucoma suspects (p < 0.0001), more open angle glaucoma (p = 0.0006) and fewer other conditions (p = 0.0024) were present in group B, compared to group A.Conclusion: Patients were referred earlier with shorter waiting times for hospital appointments with the new Scottish general ophthalmic service and Eyecare Integration Programme. Additionally there were fewer false positive referrals with more diagnosis of glaucomatous disease. We discuss the benefits of these national screening and referral pathways together with their limitations and further refinements. AD - Department of Ophthalmology, Queen Margaret Hospital, Whitefield Road, KY12 0SU Dunfermline, Fife, UK Department of Ophthalmology, Ninewells Hospital, Dundee, UK Medical Informatics, Queen Margaret Hospital, Dunfermline, Fife, UK AN - 111507112. Language: English. Entry Date: 20180801. Revision Date: 20190711. Publication Type: journal article AU - El-Assal, Karim AU - Foulds, Jonathan AU - Dobson, Stuart AU - Sanders, Roshini DB - ccm DO - 10.1186/s12886-015-0161-5 DP - EBSCOhost KW - Health Care Delivery, Integrated -- Administration Optometry -- Standards Referral and Consultation -- Standards Practice Guidelines -- Standards Glaucoma -- Diagnosis National Health Programs -- Standards Health Facility Departments -- Standards Contracts Aged Ophthalmoscopy Glaucoma -- Epidemiology Scotland Adult Human Visual Fields Waiting Lists National Health Programs -- Administration Guideline Adherence Male Documentation -- Statistics and Numerical Data Female Tonometry Pilot Studies Retrospective Design Intraocular Pressure -- Physiology Middle Age Referral and Consultation -- Administration Perimetry Aged, 80 and Over Ophthalmology -- Standards Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - forms; research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 100967802. PMID: NLM26643710. PY - 2015 SN - 1471-2415 SP - 1-8 ST - A comparative study of glaucoma referrals in Southeast Scotland: effect of the new general ophthalmic service contract, Eyecare integration pilot programme and NICE guidelines T2 - BMC Ophthalmology TI - A comparative study of glaucoma referrals in Southeast Scotland: effect of the new general ophthalmic service contract, Eyecare integration pilot programme and NICE guidelines UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=111507112&site=ehost-live&scope=site VL - 15 ID - 4318 ER - TY - JOUR AB - Background: Glaucoma is a progressive disease responsible for the second commonest cause of blindness in the UK. Identifying appropriate patients for hospital care remains an ongoing challenge for all UK hospital glaucoma services. The purpose of our study is to evaluate accuracy and outcome of community optometry referrals before and after implementation of the new general ophthalmic service contract in 2006, the Eyecare Integration Programme pilot in 2008 and the effect of NICE guidelines in glaucoma in 2009, over a 12-year period Methods: A retrospective case analysis using a glaucoma electronic patient record was performed encompassing two six-year periods, 2000-2006 (Group A), and 2007-2012 (Group B). Results: One thousand six hundred twenty-two new patients' records were analysed. Waiting times reduced from 12.3 to 9.4 weeks. Significantly more patients kept first appointment (p = 0.0002) in group B. Glaucoma symptoms were significantly more in group A (p <0.0001) and only three patients lost Snellen' visual acuity before appointment in group B compared to 12 in group A. Documentation of intraocular pressure was made in 74.1 % of Group A and 75.9 % of Group B, optic disc appearance in 85.4 % of Group A, and 93 % of Group B and visual fields in 84.4 % of Group A and 81.3 % of Group B. Significantly less normal (p < 0,0001), more glaucoma suspects (p < 0.0001), more open angle glaucoma (p = 0.0006) and fewer other conditions (p = 0.0024) were present in group B, compared to group A. Conclusion: Patients were referred earlier with shorter waiting times for hospital appointments with the new Scottish general ophthalmic service and Eyecare Integration Programme. Additionally there were fewer false positive referrals with more diagnosis of glaucomatous disease. We discuss the benefits of these national screening and referral pathways together with their limitations and further refinements. © 2015 El-Assal et al. AD - Department of Ophthalmology, Queen Margaret Hospital, Whitefield Road, Dunfermline, Fife KY12 0SU, United Kingdom Department of Ophthalmology, Ninewells Hospital, Dundee, United Kingdom Medical Informatics, Queen Margaret Hospital, Dunfermline, Fife, United Kingdom AU - El-Assal, K. AU - Foulds, J. AU - Dobson, S. AU - Sanders, R. C7 - 172 DB - Scopus DO - 10.1186/s12886-015-0161-5 IS - 1 KW - Applanation tonometry Fundoscopy Glaucoma Optometrist Referral Visual fields M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2015 ST - A comparative study of glaucoma referrals in Southeast Scotland: Effect of the new general ophthalmic service contract, Eyecare integration pilot programme and NICE guidelines T2 - BMC Ophthalmology TI - A comparative study of glaucoma referrals in Southeast Scotland: Effect of the new general ophthalmic service contract, Eyecare integration pilot programme and NICE guidelines UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84949238414&doi=10.1186%2fs12886-015-0161-5&partnerID=40&md5=0eb15881b41340408fe3716dd8339f51 VL - 15 ID - 5215 ER - TY - JOUR AB - Background: Voriconazole (VRC) is a triazole broad spectrum antifungal drug, used in the management of versatile fungal infections, particularly fungal keratitis. The obligatory use of niosomal delivery of VRC may reduce the frequency of dosing intervals resulting from its short biological half time and consequently improve patient compliance. Methods: VRC loaded proniosomes (VRC-PNs) were set by the coacervation technique and completely characterized. The developed formula was comprehensively assessed concerning in-vitro release behavior, kinetic investigation, and its conflict against refrigerated and room temperature conditions. A selected noisomal formula was incorporated into ocusert (VRCPNs Ocu) formulated by 1% w/w hydroxypropyl methyl cellulose HPMC and 0.1% w/w carbopol940. Eventually, in vitro antifungal activity against Candida albicans and Aspergillus nidulans was assessed by the cup diffusion method. Results: The optimized VRC-PNs (Pluronic F127: cholesterol weight ratio 1:1 w/w) exhibited the highest entrapment efficiency (87.4±2.55%) with a spherical shape, proper size in nano range and a suitable Zeta potential of 209.7±8.13 nm and −33.5±1.85 mV, respectively. Assurance of drug encapsulation in nanovesicles was accomplished by several means such as attenuated total reflection Fourier-transform infrared spectroscopy, differential scanning calorimetry in addition to powder X-ray diffraction investigations. It displayed a biphasic in vitro release pattern and after 6 months of storage at a refrigerated temperature, the optimized formula preserved its stability. VRC-PNs Ocu proved a very highly significant antifungal activity matched with the free drug or nanosuspension which was extra assured by comparing its mean inhibition zone with that of 5% natamycin market eye drops. Conclusion: In conclusion, VRC-PNs Ocu could be considered as a promising stable sustained release topical ocular nanoparticulate system for the management of fungal infections. AD - G.N.S. Girgis, Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt AU - El-Emam, G. A. AU - Girgis, G. N. S. AU - El Sokkary, M. M. A. AU - El-Azeem Soliman, O. A. AU - Abd El Gawad, A. E. G. H. C2 - Pfizer(Egypt) DB - Embase Medline DO - 10.2147/IJN.S268208 KW - cholesterol gel hydroxypropylmethylcellulose proniosomal gel unclassified drug voriconazole antifungal activity article Aspergillus nidulans Candida albicans controlled study differential scanning calorimetry drug delivery system drug formulation drug release Fourier transform infrared spectroscopy in vitro study mycosis nanoencapsulation particle size patient compliance phase separation physical chemistry process optimization room temperature transmission electron microscopy X ray diffraction zeta potential LA - English M3 - Article N1 - L2005203814 2020-10-19 2020-12-15 PY - 2020 SN - 1178-2013 1176-9114 SP - 7825-7840 ST - Ocular inserts of voriconazole-loaded proniosomal gels: Formulation, evaluation and microbiological studies T2 - International Journal of Nanomedicine TI - Ocular inserts of voriconazole-loaded proniosomal gels: Formulation, evaluation and microbiological studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005203814&from=export http://dx.doi.org/10.2147/IJN.S268208 VL - 15 ID - 2444 ER - TY - JOUR AB - Much work has been done to highlight and understand the significant disparities in the use of eye care services, but they continue to exist. We review the existing literature on utilization in high-risk populations to provide a context for understanding what "high-risk" means, to understand the utilization patterns among high-risk populations, and to highlight barriers to appropriate eye care utilization. We also discuss potential approaches to reduce these disparities. © 2013 Elsevier Inc. AD - Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh,PA, United States Department of Ophthalmology, University of Michigan Kellogg Eye Center, Ann Arbor, MI, United States AU - Elam, A. R. AU - Lee, P. P. DB - Scopus DO - 10.1016/j.survophthal.2012.07.005 IS - 4 KW - Barriers Disparities Eye care utilization High-risk M3 - Article N1 - Cited By :26 Export Date: 19 July 2021 PY - 2013 SP - 348-358 ST - High-Risk Populations for Vision Loss and Eye Care Underutilization: A Review of the Literature and Ideas on Moving Forward T2 - Survey of Ophthalmology TI - High-Risk Populations for Vision Loss and Eye Care Underutilization: A Review of the Literature and Ideas on Moving Forward UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879173078&doi=10.1016%2fj.survophthal.2012.07.005&partnerID=40&md5=9cde1ba445314ae9c047bf2616f7ce10 VL - 58 ID - 5085 ER - TY - JOUR AB - AIM: To study the particularities of late post-traumatic glaucoma with irido-corneal angle injuries in black Cameroonians. MATERIAL AND METHODS: Retrospective analysis of 1343 files of glaucomatous patients was carried out from January 1991 to December 2001 at the Douala General Hospital in Cameroon in Central Africa. Fifty seven of them had post-traumatic glaucoma. Of these 28 were secondary to irido-corneal angle injuries. RESULTS: The prevalence of post-traumatic glaucoma related to irido-corneal angle injuries in our population was 2.1%. The mean patients age was 45.9 +/- 18.3 years (range, 17 to 67 years). The time from injury to diagnosis ranged from 1 year 4 months to 7 years (median: 3.7 years). The follow-up period ranged from 3 months to 5 years 6 months, with a mean of 1.7 +/- 1.9 years. The prevalence of monocular blindness was 61.9% and 81% at the first and last examination respectively. The mean intraocular pressure was 36.9 +/- 13.8 mmHg (range: 22 and 66 mmHg) at the first examination and 24.3 +/- 13 mmHg (range: 12 and 29 mmHg) at the last examination. The mean recorded cup/disc ratio was 0.8 +/- 0.2. It was equal to 1.0 in 61.9% of cases. Irido-corneal angle recession was the most common lesion (61.9%) followed by iridodialysis (38.1%) and cyclodialysis (14.3%). Normalization of the intraocular pressure was achieved with medical treatment in 23.8% and with trabelectomy in 12.3% of the cases. Neovascular glaucoma was found in 4.8% of the cases. CONCLUSION: The treatment of secondary post-traumatic open angle glaucoma is disappointing. The patients are young, the disease is advanced, and the compliance and follow-up are poor. The prevention of post-traumatic glaucoma is based on the control of ocular trauma and the periodic follow-up of patients with and history of non perforating injury of the eye. AD - A. Ellong, Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Cameroun. AU - Ellong, A. AU - Ebana Mvogo, C. AU - Nyouma Moune, E. AU - Bella-Hiag, A. AU - Ngosso, A. AU - Njoh Litumbe, C. DB - Medline IS - 298 KW - adolescent adult aged article blindness Cameroon comorbidity cornea eye injury female follow up human injury iris male middle aged open angle glaucoma prevalence retrospective study treatment outcome LA - French M3 - Article N1 - L43621937 2006-05-03 PY - 2005 SN - 0081-0746 SP - 21-28 ST - Post-traumatic glaucoma with irido-corneal angle injuries in Cameroon T2 - Bulletin de la Société belge d'ophtalmologie TI - Post-traumatic glaucoma with irido-corneal angle injuries in Cameroon UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43621937&from=export ID - 3653 ER - TY - JOUR AB - Objectives: To determine the prevalence and the various types of glaucoma in a Black urban Cameroonian population. Material and method: A retrospective analysis of 1,343 glaucomatous patients' files (757 men and 586 women) from a total of 24,462 Cameroonian patients of all ages was carried out from January 1991 to December 2001 in the Douala General Hospital in Cameroon in Central Africa. Results: The prevalence of glaucoma of all types is 5.5%. It increases with age. Of subjects with glaucoma, 79.6% had not been previously diagnosed. The mean patient's age is 533 (+/-17.1) years. The mean intraocular pressure is 29.6 (+/-12.6) mmHg. The mean vertical cup-disc ratio is 0.7 (+/-0.2). The prevalence of primary glaucoma of any type is 4.5%. The overall prevalence of primary open-angle glaucoma, primary angle-closure glaucoma and congenital glaucoma was 4.3%, 0.03% and 0.07%, respectively. The normal-tension glaucoma is rare in this study (6.3% of primary open-angle glaucoma).The most common form of primary angle closure glaucoma is chronic angle closure glaucoma (61,1%) and is usually undiagnosed due to a lack of gonioscopic evaluation. The prevalence of secondary glaucoma of any type is 1%. The most common forms of secondary angle closure glaucoma were neovascular glaucoma (47.4% of cases with the prevalence of 0.5%) and post-traumatic glaucoma (23.1% of cases with the prevalence of 0.2%). Prevalence of bilateral and monocular blindness due to glaucoma is 8% (108/1,343) and 32.9% (441/1,343) respectively of glaucoma patients. Conclusion: This study confirms the high prevalence of glaucoma in a black African population. Gonioscopy is an important diagnostic tool that should be promoted to guide more effective glaucoma treatment in our region. The very high rate of blindness among the glaucoma patients in Cameroon is due to a lack of care. The patients are young, the disease is advanced, and compliance and follow-up are poor. Glaucoma surgery therefore offers a favourable option from an economical standpoint. Glaucoma is a devastating disease and constitutes a significant public health problem. AD - A. Ellong, Université Yaoundé I, Faculté de Médecine et des Sciences Biomédicales, BP 1364, Yaoundé, Cameroon AU - Ellong, A. AU - Mvogo, C. E. AU - Bella-Hiag, A. L. AU - Mouney, E. N. AU - Ngosso, A. AU - Litumbe, C. N. DB - Embase Medline DO - 10.1684/san.2006.0018 IS - 2 KW - adult article Cameroon closed angle glaucoma controlled study female glaucoma gonioscopy hospital human intraocular pressure major clinical study male Black person open angle glaucoma prevalence LA - French M3 - Article N1 - L44914932 2007-01-05 PY - 2006 SN - 1157-5999 SP - 83-88 ST - Prevalence of glaucomas in a Black Cameroonian population T2 - Cahiers Sante TI - Prevalence of glaucomas in a Black Cameroonian population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44914932&from=export http://dx.doi.org/10.1684/san.2006.0018 VL - 16 ID - 3620 ER - TY - JOUR AB - Background: This study aims to identify interventions used to reduce medication regimen complexity and to assess their impact on medication adherence and clinical outcomes. Methods: A literature search was conducted using pre-defined search terms in three scientific databases, including ScienceDirect, ProQuest and MEDLINE. Original research articles published in English between 2009 and 2020 that assessed the impact of medication regimen simplification on medication adherence in patients with long-term medical conditions were eligible for inclusion. Review articles, meta-analysis studies and conference proceedings were excluded. Data charting was done in an iterative process using a studyspecific extraction form. Results: Of the 684 studies identified through initial searches, 17 studies were included in the review. Nine studies involved simplification of medication regimen related to HIV, while three studies focused on patients with diabetes with or without coronary artery disease. The remaining five studies included medications used among elderly patients or medications related to hypertension, psychiatric disorders, glaucoma and kidney diseases. Three medication regimen simplification strategies were identified; fixed-dose combination (n = 7), oncedaily dosing (n = 4) and the combination of both fixed-dose and once-daily dosing (n = 6). Overall, most of the regimen simplification strategies (14 out of 17) were found to be useful in improving medication adherence. There was no assessment of clinical outcomes in four out of 17 studies. Furthermore, more than half of the studies that assessed clinical outcomes did not show any additional impact on clinical outcomes. Conclusion: The findings suggest that there was an equal utilization of the three main approaches of regimen simplifications; fixed-dose combination, once-daily dosing and a combination of both. Overall, most of the regimen simplification strategies were found to be effective in improving medication adherence. However, the associated improvement in medication adherence did not extend to improvement in the clinical outcomes. AD - E. Cheema, School of Pharmacy, University of Birmingham, Edgbaston, Birmingham, United Kingdom AU - Elnaem, M. H. AU - Irwan, N. A. AU - Abubakar, U. AU - Sulaiman, S. A. S. AU - Elrggal, M. E. AU - Cheema, E. DB - Embase DO - 10.2147/PPA.S268499 KW - angiotensin receptor antagonist antiretrovirus agent atazanavir plus ritonavir corticosteroid dipeptidyl carboxypeptidase inhibitor efavirenz emtricitabine hydroxymethylglutaryl coenzyme A reductase inhibitor insulin lamivudine proteinase inhibitor rapamycin RNA directed DNA polymerase inhibitor tacrolimus tenofovir timolol travoprost antiretroviral therapy chronic disease clinical outcome coronary artery disease diabetes mellitus dosage schedule comparison drug dose regimen glaucoma human Human immunodeficiency virus infection hypertension insulin treatment intraocular hypertension kidney disease kidney transplantation medication compliance mental disease mental patient non insulin dependent diabetes mellitus open angle glaucoma patient compliance review systematic review LA - English M3 - Review N1 - L2005420589 2020-11-24 2021-02-11 PY - 2020 SN - 1177-889X SP - 2135-2145 ST - Impact of medication regimen simplification on medication adherence and clinical outcomes in patients with long-term medical conditions T2 - Patient Preference and Adherence TI - Impact of medication regimen simplification on medication adherence and clinical outcomes in patients with long-term medical conditions UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005420589&from=export http://dx.doi.org/10.2147/PPA.S268499 VL - 14 ID - 2448 ER - TY - JOUR AB - Purpose: Brimonidine is a relatively selective (x-agonist, which reduces intraocular pressure (IOP) by decreasing aqueous production and increasing uveoscleral outflow. Brimonidine passes through the blood-brain barrier, potentially causing central nervous system (CNS) toxicity. There have been reports of bradycardia, hypotension, hypothermia, hypotonia, and apnea in infants after topical brimonidine. Methods: We reviewed the IOP data and side effects of children at the Duke University Eye Center placed on brimonidine from June 1997 to October 2000. Brimonidine 0.2% was used for patients whose glaucoma was uncontrolled on maximal tolerated medical therapy. A monocular trial was performed whenever possible, and brimonidine was not prescribed for infants. Included were 32 eyes of 30 patients with uncontrolled IOP and varied glaucoma diagnoses. Results: The mean patient age was 10.5 years, with a mean follow-up on brimonidine of 10.8 months. Most patients were on other glaucoma medications. In 11 of the 32 eyes the IOP data could be interpreted, and in these eyes the IOP decreased from a mean of 22.5 +/- 4.9 mm Hg to a mean of 20.8 +/- 4.0 mm Hg (a mean decrease of 6.7% +/- 10%, P = .04) on brimonidine after a mean follow-up of 11.0 +/- 6.9 months. Two young children (ages 2.4 and 3.7 years) repeatedly were unarousable soon after the administration of brimonidine. Five other children experienced extreme fatigue after brimonidine administration. All symptoms resolved after brimonidine was discontinued. Discussion/Conclusions: Brimonidine should be used with caution in young children because of the potential for CNS depression. In selected patients, brimonidine has a substantial ocular hypotensive effect. AN - WOS:000171925700003 AU - Enyedi, L. B. AU - Freedman, S. F. DA - OCT DO - 10.1067/mpa.2001.117571 IS - 5 PY - 2001 SN - 1091-8531 1528-3933 SP - 281-284 ST - Safety and efficacy of brimonidine in children with glaucoma T2 - JOURNAL OF AAPOS TI - Safety and efficacy of brimonidine in children with glaucoma VL - 5 ID - 6050 ER - TY - JOUR AB - Background: The purpose of this register was to determine the links between glaucoma, age, concomitant disease, medication, and dry eye in a large group of glaucoma patients. Methods: A total of 20,506 patients from 900 centers across Germany were included. The first 30 consecutive glaucoma patients at each center were recruited. Epidemiological data as well as information on glaucoma, medication, concomitant diseases, dry eye, and local symptoms were elicited by means of a questionnaire. We analyzed primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PEX), and pigmentary glaucoma (PDG). Results: According to the register data, more women develop dry eye and glaucoma than men (56.9 vs. 45.7%). The most frequent concomitant systemic diseases were hypertension (48.1%), diabetes mellitus (22.5%), and dry mouth, nose, and skin (11.3%). As expected, the highest incidence of dry eye was found in those patients with dry mouth, nose, and skin. Dry eye occurred with dissimilar frequencies in association with the various glaucoma types: PEX>POAG>PDG. The incidence of dry eye increases with age. The gender difference in the occurrence of dry eye becomes apparent from the age of 50. Dry eye occurred more frequently when three or more antiglaucoma drugs were used and increased with the duration of glaucoma disease. Conclusions: We publish the first results from the German Glaucoma and Dry Eye Register. We found that the occurrence of dry eye is linked to several factors. Thus, the type of glaucoma has an impact on the risk of dry eye. The quantity of eye drops applied also plays a role in the development of the dry eye syndrome if more than three medications are used. While POAG is usually treated with one drug, PEX and PDG tend to be treated with multiple drugs. The gender difference in the occurrence of dry eye becomes apparent from the age 50 years. Because of the vicious circle of dry eye, antiglaucoma eye drops containing benzalkonium chloride compromises patient compliance. The results of the register are therefore of key relevance for the care of glaucoma patients. © Springer-Verlag 2008. AD - C. Erb, Ophthalmology Department, Schlosspark Clinic, Heubnerweg 2, Berlin 14059, Germany AU - Erb, C. AU - Gast, U. AU - Schremmer, D. DB - Embase Medline DO - 10.1007/s00417-008-0881-9 IS - 11 KW - antiglaucoma agent benzalkonium chloride adult aged aging arthritis article blurred vision comorbidity controlled study depression diabetes mellitus disease classification disease course disease duration dry eye dry nose dry skin eye pain female Germany glaucoma human hypertension hypotension incidence intraocular foreign body lipid metabolism major clinical study male migraine neoplasm obesity open angle glaucoma patient compliance photosensitivity pigment glaucoma priority journal pruritus pseudoexfoliation questionnaire register risk factor sex difference skin disease slit lamp smoking thyroid disease tinnitus xerostomia LA - English M3 - Article N1 - L50216206 2008-11-12 PY - 2008 SN - 0721-832X SP - 1593-1601 ST - German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50216206&from=export http://dx.doi.org/10.1007/s00417-008-0881-9 VL - 246 ID - 3418 ER - TY - JOUR AD - C. Erb, Universitäts-Augenklinik, Basel, Schweiz. AU - Erb, C. AU - Stübiger, N. AU - Schüller, S. AU - Rassmann, K. DB - Medline IS - 1 KW - adult aged article curriculum female Germany glaucoma human male methodology middle aged open angle glaucoma patient compliance patient education psychological aspect university hospital LA - German M3 - Article N1 - L128309787 1998-11-24 PY - 1998 SN - 0023-2165 SP - aA6-8 ST - The glaucoma work group--an initiative of the Tübingen University Eye Clinic T2 - Klinische Monatsblätter für Augenheilkunde TI - The glaucoma work group--an initiative of the Tübingen University Eye Clinic UR - https://www.embase.com/search/results?subaction=viewrecord&id=L128309787&from=export VL - 213 ID - 3939 ER - TY - JOUR AB - Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to medications may affect patients' quality of life and may cause poor compliance, which leads to poor intraocular pressure control. To minimize the side effects of long-term treatment, preparations with lower benzalkonium chloride concentrations, preservative-free preparations and alternative preservatives have been developed and reported to have a lower rate of side effects. Tafluprost, launched on the ophthalmic market in 2008, is a new 16-phenoxy analogue of prostaglandin F2α, clinically used as an ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. The safety and intraocular pressure-lowering efficacy of tafluprost has been demonstrated in various preclinical and clinical studies. © 2012 Ermiş, publisher and licensee Dove Medical Press Ltd. AD - S. S. Ermiş, Faculty of Medicine, Balikesir University, Tip Fakültesi, Çagiş Kampüsü, 10145 Balikesir, Turkey AU - Ermiş, S. S. C1 - travatan z(Alcon,Switzerland) travatan(Alcon) C2 - Alcon(Switzerland) DB - Embase DO - 10.2147/OPTH.S24248 IS - 1 KW - aciclovir antiglaucoma agent benzalkonium chloride bimatoprost dorzolamide eye drops latanoprost prostaglandin derivative prostaglandin F2 alpha derivative tafluprost timolol travoprost unoprostone abnormal sensation aphakia blurred vision clinical effectiveness conjunctival hyperemia disease control disease severity dose response drug absorption drug blood level drug cost drug distribution drug effect drug efficacy drug half life drug hypersensitivity drug marketing drug metabolism drug penetration drug safety drug tissue level drug tolerability dry eye epiphora evening dosage evidence based medicine pseudoexfoliation eye burning eye pain eyelash glaucoma herpes simplex keratitis human intraocular hypertension intraocular hypotension intraocular pressure abnormality iris disease monotherapy nonhuman ocular surface disease open angle glaucoma patient compliance photosensitivity disorder pigment disorder pseudophakia quality of life retina macula cystoid edema review side effect single drug dose systemic disease treatment duration treatment planning uveitis travatan z travatan L1 - internal-pdf://4084960732/3087-Differential pharmacology and clinic-2012.pdf LA - English M3 - Review N1 - L365167539 2012-07-11 2012-07-17 PY - 2012 SN - 1177-5467 1177-5483 SP - 673-678 ST - Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma T2 - Clinical Ophthalmology TI - Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365167539&from=export http://dx.doi.org/10.2147/OPTH.S24248 VL - 6 ID - 3087 ER - TY - JOUR AB - Background and Aims: Primary wide-angle glaucoma (the most common form of glaucoma) is a multi-factorial disease of the optic nerve marked by the preceding loss of retinal ganglion cells, eventually leading to the atrophy of the optic nerve. Intraocular pressure (IOP) makes up the most important and most treatable risk factor. Methods: The study examined the effect of acupuncture therapy on eye pressure and the compliance in patients suffering from primary wide-angle glaucoma (n = 21) and ocular hypertension (n = 13) against a group of test subjects not suffering from any eye complaint (n = 16). Before commencing therapy, corneal thickness was determined by 4Optics-Pachymeter. Before and after acupuncture treatment, an ophthalmologic determination of visual acuity according to DIN 58220 and a computer-aided visual field analysis were done. The IOP was measured before and immediately after acupuncture as well as 30 minutes after therapy. Changes in compliance were documented with a standardized questionnaire completed by each patient having received this treatment. Results: It was shown that for patients with primary wide-angle glaucoma and ocular hypertension, acupuncture is able to significantly lower intraocular pressure. According to the questionnaire analysis, a subjective improvement of quality of life and better compliance of using anti-glaucomatous medication was achieved. Conclusions: Acupuncture is an appropriate method to treat patients with primary wide-angle glaucoma in addition to lowering eye pressure by anti-glaucomatous pharmacological therapy. In patients suffering from ocular hypertension, acupuncture can significantly lower intraocular pressure and therefore reduce the rate of conversion into a manifest glaucoma. Therefore this treatment can be suggested for ocular hypertension patients with contraindications against local anti-glaucomatous medicine (e. g. beta-blocker). However, it is absolutely necessary in this treatment that patients are continuously monitored regarding visual field, retinal nerve fibre thickness and micro-morphological alterations of the disc in order to detect tissue damage of the optic nerve and functional loss caused by the onset of glaucoma. AD - H. Ewert, Facharzt für Augenheilkunde Zusatzbezeichnung Akupunktur, Trienheider Weg 21, D-19288 Ludwigslust, Germany AU - Ewert, H. AU - Schwanitz, R. DB - Embase DO - 10.1016/J.DZA.2008.04.001 IS - 2 KW - antiglaucoma agent beta adrenergic receptor blocking agent acupuncture article clinical article cornea devices drug contraindication follow up human intraocular hypertension intraocular pressure open angle glaucoma optic nerve lesion patient compliance prospective study questionnaire retina nerve cell risk factor thickness tissue injury treatment indication treatment outcome visual acuity visual field 4Optics LA - German M3 - Article N1 - L352026867 2008-08-22 PY - 2008 SN - 0415-6412 SP - 13-20 ST - Influence of acupuncture on intraocular pressure and compliance of patients with ocular hypertension or primary wide-angle glaucoma: First results of a controlled prospective follow-up study T2 - Deutsche Zeitschrift fur Akupunktur TI - Influence of acupuncture on intraocular pressure and compliance of patients with ocular hypertension or primary wide-angle glaucoma: First results of a controlled prospective follow-up study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352026867&from=export http://dx.doi.org/10.1016/J.DZA.2008.04.001 VL - 51 ID - 3483 ER - TY - JOUR AB - Introduction: The purpose of this study was to determine prescribing trends in a specialist glaucoma clinic in the UK. Specifically, the aims were to determine which drugs were prescribed as first-, second-, and third-line treatment, the persistence of first-, second-, and third-line treatment regimens, and the proportion of treatment decisions conforming to the European Glaucoma Society (EGS) guidelines.Methods: A retrospective, non-interventional, single-center, case-note review was performed on a cohort of consecutive patients presenting to a specialist glaucoma clinic for follow-up. Inclusion criteria for the study were (1) a diagnosis of primary open-angle glaucoma or ocular hypertension, (2) glaucoma management entirely within the unit, and (3) minimum of 2 years of follow-up.Results: A total of 114 case notes met the inclusion criteria. Mean age was 71 years (range 40-95 years). Mean length of follow-up was 56 months (range 24-180 months). Prostaglandin analogues (PGA) were the most popular first-line treatment in 73% of patients. As second-line treatment, PGA were again the predominant class, prescribed in 87% of cases, whereas beta-blockers (BB) were prescribed in 70% of cases. Carbonic anhydrase inhibitors (CAI) and alpha-2 agonists (AA) were more popular in third-line regimens. Second-line treatment was introduced at a mean of 28.0 months after first-line treatment (range 1-120 months, 95% CI 22.1-33.9 months). Third-line treatment was introduced at a mean of 22.9 months after second-line treatment (range 1-96 months, 95% CI 17.1-28.8 months). Breaches to EGS guidelines were most common for third-line treatment and included duplication of drug classes.Discussion: There was a clear hierarchy of PGA as first-line, BB as second-line, while CAI and AA were considered third-line choices. First-line choices were generally in line with EGS guidelines. There was a tendency to breach guidelines by escalating treatment in dual steps rather than single steps (especially in third-line treatment). Combination drops were popular. In third-line treatment there was an increased incidence of prescribing errors. This data is important in terms of informing patients of the expected treatment course, to remind clinicians about best practice, and also to guide comparisons of cost-effectiveness with other treatment modalities. AD - Maidstone and Tunbridge Wells NHS Trust , Maidstone UK AN - 124765382. Language: English. Entry Date: 20180720. Revision Date: 20191029. Publication Type: journal article AU - Fajgenbaum, Mark AU - Ansari, Ejaz DB - ccm DO - 10.1007/s12325-017-0593-9 DP - EBSCOhost IS - 8 KW - Prescriptions, Drug -- Statistics and Numerical Data Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Practice Guidelines Prostaglandins, Synthetic -- Therapeutic Use Human N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8611864. PMID: NLM28726170. PY - 2017 SN - 0741-238X SP - 2033-2042 ST - Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study T2 - Advances in Therapy TI - Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124765382&site=ehost-live&scope=site VL - 34 ID - 4243 ER - TY - JOUR AB - Introduction: The purpose of this study was to determine prescribing trends in a specialist glaucoma clinic in the UK. Specifically, the aims were to determine which drugs were prescribed as first-, second-, and third-line treatment, the persistence of first-, second-, and third-line treatment regimens, and the proportion of treatment decisions conforming to the European Glaucoma Society (EGS) guidelines. Methods: A retrospective, non-interventional, single-center, case-note review was performed on a cohort of consecutive patients presenting to a specialist glaucoma clinic for follow-up. Inclusion criteria for the study were (1) a diagnosis of primary open-angle glaucoma or ocular hypertension, (2) glaucoma management entirely within the unit, and (3) minimum of 2 years of follow-up. Results: A total of 114 case notes met the inclusion criteria. Mean age was 71 years (range 40–95 years). Mean length of follow-up was 56 months (range 24–180 months). Prostaglandin analogues (PGA) were the most popular first-line treatment in 73% of patients. As second-line treatment, PGA were again the predominant class, prescribed in 87% of cases, whereas beta-blockers (BB) were prescribed in 70% of cases. Carbonic anhydrase inhibitors (CAI) and alpha-2 agonists (AA) were more popular in third-line regimens. Second-line treatment was introduced at a mean of 28.0 months after first-line treatment (range 1–120 months, 95% CI 22.1–33.9 months). Third-line treatment was introduced at a mean of 22.9 months after second-line treatment (range 1–96 months, 95% CI 17.1–28.8 months). Breaches to EGS guidelines were most common for third-line treatment and included duplication of drug classes. Discussion: There was a clear hierarchy of PGA as first-line, BB as second-line, while CAI and AA were considered third-line choices. First-line choices were generally in line with EGS guidelines. There was a tendency to breach guidelines by escalating treatment in dual steps rather than single steps (especially in third-line treatment). Combination drops were popular. In third-line treatment there was an increased incidence of prescribing errors. This data is important in terms of informing patients of the expected treatment course, to remind clinicians about best practice, and also to guide comparisons of cost-effectiveness with other treatment modalities. © 2017, Springer Healthcare Ltd. AD - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom University of Kent at Canterbury, Canterbury, United Kingdom AU - Fajgenbaum, M. AU - Ansari, E. DB - Scopus DO - 10.1007/s12325-017-0593-9 IS - 8 KW - Adherence Alpha 2 agonists Beta blockers Carbonic anhydrase inhibitors EGS guidelines Glaucoma Ocular hypertension Ophthalmology Prostaglandins M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2017 SP - 2033-2042 ST - Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study T2 - Advances in Therapy TI - Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85025112252&doi=10.1007%2fs12325-017-0593-9&partnerID=40&md5=9b1ee5e1c29c085aa0da156f5a5399cd VL - 34 ID - 5326 ER - TY - JOUR AB - Introduction: The purpose of this study was to determine prescribing trends in a specialist glaucoma clinic in the UK. Specifically, the aims were to determine which drugs were prescribed as first-, second-, and third-line treatment, the persistence of first-, second-, and third-line treatment regimens, and the proportion of treatment decisions conforming to the European Glaucoma Society (EGS) guidelines. A retrospective, non-interventional, single-center, case-note review was performed on a cohort of consecutive patients presenting to a specialist glaucoma clinic for follow-up. Inclusion criteria for the study were (1) a diagnosis of primary open-angle glaucoma or ocular hypertension, (2) glaucoma management entirely within the unit, and (3) minimum of 2 years of follow-up. A total of 114 case notes met the inclusion criteria. Mean age was 71 years (range 40-95 years). Mean length of follow-up was 56 months (range 24-180 months). Prostaglandin analogues (PGA) were the most popular first-line treatment in 73% of patients. As second-line treatment, PGA were again the predominant class, prescribed in 87% of cases, whereas beta-blockers (BB) were prescribed in 70% of cases. Carbonic anhydrase inhibitors (CAI) and alpha-2 agonists (AA) were more popular in third-line regimens. Second-line treatment was introduced at a mean of 28.0 months after first-line treatment (range 1-120 months, 95% CI 22.1-33.9 months). Third-line treatment was introduced at a mean of 22.9 months after second-line treatment (range 1-96 months, 95% CI 17.1-28.8 months). Breaches to EGS guidelines were most common for third-line treatment and included duplication of drug classes. There was a clear hierarchy of PGA as first-line, BB as second-line, while CAI and AA were considered third-line choices. First-line choices were generally in line with EGS guidelines. There was a tendency to breach guidelines by escalating treatment in dual steps rather than single steps (especially in third-line treatment). Combination drops were popular. In third-line treatment there was an increased incidence of prescribing errors. This data is important in terms of informing patients of the expected treatment course, to remind clinicians about best practice, and also to guide comparisons of cost-effectiveness with other treatment modalities. AN - WOS:000408091800018 AU - Fajgenbaum, M. AU - Ansari, E. DA - AUG DO - 10.1007/s12325-017-0593-9 IS - 8 PY - 2017 SN - 0741-238X 1865-8652 SP - 2033-2042 ST - Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study T2 - ADVANCES IN THERAPY TI - Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study VL - 34 ID - 5955 ER - TY - JOUR AB - Glaucoma filtration surgery is regularly performed for the treatment of glaucoma and trabeculectomy is often regarded as the 'gold standard' glaucoma operation. The biggest risk of failure of the operation is bleb scarring. The advent of antifibrotic agents, such as mitomycin C (MMC) and 5-fluorouracil (5FU) has vastly prolonged the longevity of the bleb, but concerns remain regarding the potential increase in postoperative complications. More selective therapeutic targets have therefore been explored. One of these is vascular endothelial growth factor (VEGF) inhibition. VEGF inhibition has a role not only in subconjunctival angiogenesis inhibition but also it has direct anti-fibrotic properties. Newer pharmacological compounds and materials have also been developed in recent years in attempt to modulate the wound healing in different ways after glaucoma surgery. These include physical barriers to scarring and vehicles for sustained release of pharmacological agents, and early promising results have been demonstrated. This two-part review will provide a discussion of the application of anti-fibrotic agents in glaucoma filtration surgery and evaluate the newer agents that have been developed. How to cite this article: Fan Gaskin JC, Nguyen DQ, Ang GS, O'Connor J, Crowston JG. Wound Healing Modulation in Glau coma Filtration Surgery-Conventional Practices and New Pers pectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II). J Curr Glaucoma Pract 2014;8(2):46-53. AU - Fan Gaskin, Jennifer C. AU - Nguyen, Dan Q. AU - Soon Ang, Ghee AU - O'Connor, Jeremy AU - Crowston, Jonathan G. DO - https://dx.doi.org/10.5005/jp-journals-10008-1160 IS - 2 PY - 2014 SE - Fan Gaskin, Jennifer C. Glaucoma Fellow, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia. Nguyen, Dan Q. Consultant, Department of Ophthalmology, Mid Cheshire Hospitals, NHS Foundation Trust, Cheshire; Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, UK. Soon Ang, Ghee. Consultant, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia. O'Connor, Jeremy. Consultant, Glaucoma Investigation and Research Unit, University Hospital Limerick, Ireland. Crowston, Jonathan G. Professor, Glaucoma Investigation and Research Unit, Centre for Eye Research, University of Melbourne, Melbourne, Australia. SN - 0974-0333 SP - 46-53 ST - Wound Healing Modulation in Glaucoma Filtration Surgery- Conventional Practices and New Perspectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II) T2 - Journal of current glaucoma practice TI - Wound Healing Modulation in Glaucoma Filtration Surgery- Conventional Practices and New Perspectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=26997808 VL - 8 Y2 - 20140612// ID - 1073 ER - TY - JOUR AB - Glaucoma is a common eye disease that can lead to irreversible vision loss if left untreated. The early diagnosis and treatment of primary open-angle glaucoma is challenging, and visual impairment in Chinese glaucoma patients is a serious concern. Most of these patients need more than one topical antiglaucoma agent to control their intraocular pressures (IOPs). In the People’s Republic of China, the daily cost of different glaucoma medication varies greatly, and the treatment habits differ throughout the country. Prostaglandin analogs (PGAs) are recommended as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Fixed-combination drops, particularly PGA-based fixed combinations, have recently been developed and used in patients with progression or who have failed to achieve their target IOPs. Here, we reviewed the current literature on the use of bimatoprost-timolol fixed combination (BTFC) in the People’s Republic of China. BTFC has achieved good efficacy and tolerability in Chinese clinical trials. In addition, BTFC is more cost effective compared with other fixed combinations available in the People’s Republic of China. Fixed-combination drops may offer benefits, such as keeping the ocular surface healthy, convenience of administration, and improvement in long-term adherence and quality of life. Therefore, BTFC has great potential for the treatment of Chinese glaucoma patients. However, the long-term efficacy of BTFC, comparisons of BTFC with other fixed-combination drugs, and treatment adherence and persistence with treatment in Chinese patients are unknown and will require further study. AD - X. Sun, Department of Ophthalmology and Visual Science, Eye, Ear, Nose and Throat Hospital, Shanghai Medical College, Fudan University, 83 Fenyang Road, Shanghai, China AU - Fang, Y. AU - Ling, Z. AU - Sun, X. C1 - ganfort(Allergan,United States) lumigan(Allergan,United States) travatan(Alcon,United States) xalacom(Pfizer,United States) xalatan(Pfizer,United States) C2 - Wuhan Wujin(China) Alcon(United States) Allergan(United States) Pfizer(United States) DB - Embase Medline DO - 10.2147/DDDT.S80338 KW - benzalkonium chloride bimatoprost bimatoprost plus timolol eye drops latanoprost latanoprost plus timolol prostaglandin derivative timolol timolol plus travoprost travoprost Chinese conjunctival hyperemia cost effectiveness analysis deepening of the upper eyelid sulcus drug cost drug efficacy drug safety drug tolerability evening dosage eye disease eye pain eyelash bristling eyelash lengthening eyelid pigmentation glaucoma human intraocular hypertension intraocular pressure iris pigmentation low tension glaucoma medication compliance open angle glaucoma patient compliance quality of life review unspecified side effect ganfort lumigan travatan xalacom xalatan LA - English M3 - Review N1 - L604426279 2015-05-27 2015-05-29 PY - 2015 SN - 1177-8881 SP - 2617-2625 ST - Fixed-combination treatments for intraocular hypertension in Chinese patients – Focus on bimatoprost-timolol T2 - Drug Design, Development and Therapy TI - Fixed-combination treatments for intraocular hypertension in Chinese patients – Focus on bimatoprost-timolol UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604426279&from=export http://dx.doi.org/10.2147/DDDT.S80338 VL - 9 ID - 2814 ER - TY - JOUR AB - The problem associated with the prevalence of retinal diseases, and age-related macular degeneration (AMD) in particular, is un-doubtedly relevant. This aspect is based on steadily growing statistics on morbidity, a high number of randomized controlled trials (RCT) and published real world data (RWD). The analysis of RCT results being published by researchers on 15.05.19 showed 2915 studies were registered on the subject of retinal diseases; that exceeds the number of studies on glaucoma by approximately 1.38 times (2118 studies) and conjunctival lesions by 2.37 times (1230 studies). AMD is one of the leading causes of irreversible vision loss and blindness; its neovascular form leads to blindness in 80—90% of all cases. Even though the topic of nAMD therapy is widely highlighted in modern ophthalmology, today there are many aspects that require targeted solutions. The main con-troversial issues that determine the complexity of therapy and patient management include discrepancies in determination of ref-erence points (disease activity criteria) for implementation of anti-VEGF dosing regimens, patients’ compliance, prioritization issues in treatment, its continuity with potential for the increase of intervals between injections and monitoring visits. © 2021, Media Sphera Publishing Group. All rights reserved. AD - N.I. Pirogov National Medical and Surgical Center, Moscow, Russian Federation JSC Bayer, Moscow, Russian Federation Clinics of doctor Shatalov», Orekhovo-Zuevo, Russian Federation AU - Fayzrakhmanov, R. R. AU - Voropaev, V. Yu AU - Sukhanova, A. V. AU - Shatalova, E. O. DB - Scopus DO - 10.17116/oftalma202113701183 IS - 1 KW - Aflibercept Age-related macular degeneration Dosing regimen Neovascular AMD Ranibizumab T&E Treat-and-extend M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 83-93 ST - Antiangiogenic therapy of neovascular age-related macular degeneration T2 - Vestnik Oftalmologii TI - Antiangiogenic therapy of neovascular age-related macular degeneration UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102068262&doi=10.17116%2foftalma202113701183&partnerID=40&md5=3d92020881208eb73dd2e5e15cd54e26 VL - 137 ID - 5677 ER - TY - JOUR AB - Purpose:To investigate the efficacy and safety of a cross-linked gel stent (XEN45) with or without cataract surgery in the treatment of glaucoma patients.Setting:Five university hospitals.Design:Prospective multicenter clinical trial.Methods:Patients with glaucoma inadequately controlled by treatment or poor compliance or intolerance to topical therapy were included. Patients were divided into those who had an implant only (Solo Group; phakic and pseudophakic patients) and those who had an implant combined with cataract surgery (Combo Group). Differences in mean intraocular pressure (IOP) and number of medications between the baseline preoperative visit and study end (12 months), and the rate of qualified and complete success, were evaluated.Results:The Solo Group comprised 115 glaucoma patients (43 phakic and 72 pseudophakic) and the Combo Group comprised 56 patients. Compared with baseline, mean IOP (23.9 ± 7.6 to 15.5 ± 3.9) and number of medications (3.0 ± 1.1 to 0.5 ± 1.0) decreased significantly at 12-month follow-up (P <.001 for both). A >20% and >30% reduction in IOP from baseline was achieved by 72.3% and 52.6% of patients, respectively. IOP at 1 week postoperatively was a predictor of success, and the needling rate was inversely correlated with early postoperative IOP. The number of preoperative medications and patient age were not significantly associated with failure.Conclusions:Insertion of a cross-linked gel stent alone or combined with phacoemulsification might be effective and safe in the treatment of open-angle glaucoma, with a substantial reduction in IOP and number of medications. © 2020 Elsevier Inc.. All rights reserved. AD - Department of Surgical Sciences, Eye Clinic, University Hospital, Montevecchio 62, Torino, 10129, Italy Department of Ophthalmology, S. Orsola Hospital, Bologna, Italy Department of Ophthalmology, Sassuolo Hospital, Sassuolo, Italy Department of Surgical, Medical, Molecular Pathology, and Critical Area, University of Pisa, Pisa, Italy IRCCS GB Bietti Foundation, Rome, Italy Department of Ophthalmology, University Hospital, Dijon, France St Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden AU - Fea, A. M. AU - Bron, A. M. AU - Economou, M. A. AU - Laffi, G. AU - Martini, E. AU - Figus, M. AU - Oddone, F. DB - Scopus DO - 10.1097/j.jcrs.0000000000000065 IS - 3 M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2020 SP - 441-450 ST - European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma T2 - Journal of Cataract and Refractive Surgery TI - European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081531121&doi=10.1097%2fj.jcrs.0000000000000065&partnerID=40&md5=e0193068219fda3a4598a5d2b39c89b3 VL - 46 ID - 5297 ER - TY - JOUR AB - Purpose: To investigate the efficacy and safety of a cross-linked gel stent (XEN45) with or without cataract surgery in the treatment of glaucoma patients. Setting: Five university hospitals. Design: Prospective multicenter clinical trial. Methods: Patients with glaucoma inadequately controlled by treatment or poor compliance or intolerance to topical therapy were included. Patients were divided into those who had an implant only (Solo Group; phakic and pseudophakic patients) and those who had an implant combined with cataract surgery (Combo Group). Differences in mean intraocular pressure (IOP) and number of medications between the baseline preoperative visit and study end (12 months), and the rate of qualified and complete success, were evaluated. Results: The Solo Group comprised 115 glaucoma patients (43 phakic and 72 pseudophakic) and the Combo Group comprised 56 patients. Comparedwith baseline, mean IOP (23.9 +/- 7.6 to 15.5 +/- 3.9) and number of medications (3.0 +/- 1.1 to 0.5 +/- 1.0) decreased significantly at 12-month follow-up (P <.001 for both). A >20% and >30% reduction in IOP from baseline was achieved by 72.3% and 52.6% of patients, respectively. IOP at 1 week postoperatively was a predictor of success, and the needling rate was inversely correlated with early postoperative IOP. The number of preoperative medications and patient age were not significantly associated with failure. Conclusions: Insertion of a cross-linked gel stent alone or combined with phacoemulsification might be effective and safe in the treatment of open-angle glaucoma, with a substantial reduction in IOP and number of medications. Copyright (C) 2020 Published by Wolters Kluwer on behalf of ASCRS and ESCRS. AN - WOS:000579535500017 AU - Fea, A. M. AU - Bron, A. M. AU - Economou, M. A. AU - Laffi, G. AU - Martini, E. AU - Figus, M. AU - Oddone, F. DA - MAR DO - 10.1097/j.jcrs.0000000000000065 IS - 3 PY - 2020 SN - 0886-3350 1873-4502 SP - 441-450 ST - European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma VL - 46 ID - 6120 ER - TY - JOUR AB - This study determined the degree of adherence to medications for glaucoma among patients refilling prescriptions in community pharmacies. Methods: Data abstracted from the dispensing records for 3615 adult patients (18 years or older, predominantly over 45) receiving glaucoma medications from two retail pharmacy chains (64 stores in total) were analyzed. From a 24-month historic data capture period, the 12-month levels of adherence were determined using standard metrics, the proportion of days covered (PDC) and the medication possession ratio (MPR). The overall 12-month mean PDC was only 57%, and the mean MPR was 71%. Using a criterion by which 80% coverage was considered satisfactory adherence, only 30% had satisfactory overall 12-month PDC coverage, and only 37% had satisfactory overall 12-month MPR coverage. Refill adherence increased with age and was highest in the 65-and-older age group (p < 0.001). Differential adherence was found across medication classes, with the highest satisfactory coverage seen for those taking alpha2-adrenergic agonists (PDC = 36.0%; MPR = 47.6%) down to those taking direct cholinergic agonists (PDC = 25.0%; MPR = 31.2%) and combination products (PDC = 22.7%; MPR = 31.0%). Adherence to glaucoma medications in the community setting, as measured by pharmacy refill data, is very poor and represents a critical target for intervention. Community pharmacists are well positioned to monitor and reinforce adherence in this population. AD - M. Feehan, Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, United States AU - Feehan, M. AU - Munger, M. A. AU - Cooper, D. K. AU - Hess, K. T. AU - Durante, R. AU - Jones, G. J. AU - Montuoro, J. AU - Morrison, M. A. AU - Clegg, D. AU - Crandall, A. S. AU - DeAngelis, M. M. DB - Embase DO - 10.3390/jcm5090079 IS - 9 KW - alpha 2 adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor cholinergic receptor stimulating agent prostaglandin derivative adult age distribution aged article female glaucoma human major clinical study male medical record patient compliance patient satisfaction pharmacy (shop) prescription United States LA - English M3 - Article N1 - L612026526 2016-09-16 2016-09-21 PY - 2016 SN - 2077-0383 ST - Adherence to glaucoma medications over 12 months in two US community pharmacy chains T2 - Journal of Clinical Medicine TI - Adherence to glaucoma medications over 12 months in two US community pharmacy chains UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612026526&from=export http://dx.doi.org/10.3390/jcm5090079 VL - 5 ID - 2708 ER - TY - JOUR AB - Poor compliance with prescribed medications limits the effectiveness of many pharmacologic therapies and enhances their potential toxicities. Traditional methods of measuring drug-taking behavior, including direct observation, patient self-report, pill counts, and therapeutic drug level monitoring, all have well-described limitations in validity and interpretability. Electronic medication event monitoring has been used to assess compliance with therapies for hypertension, glaucoma, anemia, and epilepsy, overcoming many problems of traditional approaches. However, no published reports describe the use of electronic monitoring with immunosuppressive agents, despite their increasing use for non-life-threatening conditions and their many dose-dependent toxicities. Transplant recipients are thought to be at particular risk from noncompliance. Therefore, we undertook this study to assess the feasibility of electronically monitoring compliance with immunosuppressive drugs among renal allograft recipients. Twenty-five kidney transplant patients receiving immunosuppressive medications from a single pharmacy were enrolled. Each subject received electronic monitors with their immunosuppressive serum drug refills for cyclosporine and azathioprine. Each subject returned their monitors after the first month of this 2-month study for downloading data. The frequency distribution of interdose intervals were described. Two measures of average non-compliance were calculated for both drugs: the proportion of monitored days that had missed doses, and the proportion of missed doses. Once daily and twice daily regimens of cyclosporine were compared. Concordance in drug compliance between the two drugs was calculated for each subject and averaged over the study population. Twenty-two of 25 subjects missed one or more doses of cyclosporine or azathioprine. Seventeen (68%) subjects never missed four or more consecutive doses. Subjects were non-compliant with cyclosporine on 8.7% of monitored days, and noncompliance with azathioprine on 9.8% of monitored days. Subjects were non-compliant with 6.8% of their cyclosporine doses and 9.8% of their azathioprine doses. Patients were compliant with both drugs on 86.6% of days and were non-compliant with both drugs on 5.1% of days. Subjects were noncompliant with cyclosporine during 5% and 13.2% of monitored days for once and twice daily dosing regimens, respectively. Concordance analysis demonstrated that for 91.7% of days of monitoring, compliance information was identical for both drugs. This study demonstrated the feasibility of electronic medication event monitoring among kidney transplant patients. This methodology represents an important tool for monitoring compliance of immunosuppressive agents essential to their safe and effective use, and should be considered for use in future studies of these drugs and others with substantial dose-dependent toxicity. AD - H.I. Feldman, Department Medicine and Epidemiology, University Pennsylvania Medical Ctr., 720 Blockley Hall, 423 Service Drive, Philadelphia, PA 19104-6021, United States AU - Feldman, H. I. AU - Hackett, M. AU - Bilker, W. AU - Strom, B. L. DB - Embase DO - 10.1002/(SICI)1099-1557(199901/02)8:1<1::AID-PDS382>3.0.CO;2-4 IS - 1 KW - antianemic agent anticonvulsive agent antiglaucoma agent antihypertensive agent azathioprine cyclosporine immunosuppressive agent anemia article clinical article drug efficacy epilepsy glaucoma human hypertension kidney transplantation patient compliance patient monitoring priority journal self report MEMS LA - English M3 - Article N1 - L29090220 1999-03-02 PY - 1999 SN - 1053-8569 SP - 1-14 ST - Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents T2 - Pharmacoepidemiology and Drug Safety TI - Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunosuppressive agents UR - https://www.embase.com/search/results?subaction=viewrecord&id=L29090220&from=export http://dx.doi.org/10.1002/(SICI)1099-1557(199901/02)8:1<1::AID-PDS382>3.0.CO;2-4 VL - 8 ID - 3931 ER - TY - JOUR AB - The prostaglandin derivatives are thought to lower intraocular pressure (IOP) primarily by increasing uveoscleral outflow. The ocular side effect, hyperemia, appears to occur via a secondary, unrelated mechanism. Variations in the IOP-lowering effect and incidence of hyperemia associated with these drugs are a function of their different chemical structures. Among the currently approved prostaglandin derivatives, hyperemia occurs in as many as 50% of patients treated with travoprost and as few as 5% of patients treated with latanoprost. The side effect of hyperemia may be of concern to the ophthalmologist for at least 2 reasons: hyperemia may compromise the outcome of filtration surgery, and it may represent a cosmetic problem to the patient thereby leading to noncompliance. The extent to which hyperemia may contribute to patient noncompliance and the effect of administration of the prostaglandin derivatives on outcome of filtration surgery remain to be determined. Until more definitive data are available, when selecting a prostaglandin analogue for ocular hypotensive therapy, it seems prudent to choose an agent with a low incidence of hyperemia. AD - R.M. Feldman, Herman Eye Center, 6411 Fannin, Houston, TX 77030, United States AU - Feldman, R. M. DB - Embase Medline DO - 10.1089/108076803762718088 IS - 1 KW - bimatoprost brimonidine dorzolamide latanoprost prostaglandin derivative timolol travoprost unoprostone isopropyl ester clinical trial conjunctival hyperemia drug receptor binding drug use glaucoma human intraocular hypertension intraocular hypotension intraocular pressure patient compliance review LA - English M3 - Review N1 - L36249877 2003-03-19 PY - 2003 SN - 1080-7683 SP - 23-35 ST - Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension T2 - Journal of Ocular Pharmacology and Therapeutics TI - Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36249877&from=export http://dx.doi.org/10.1089/108076803762718088 VL - 19 ID - 3835 ER - TY - JOUR AB - Glaucoma is one of the leading causes of irreversible blindness worldwide. Although there is no cure for this chronic disease, medical treatment is aimed at reducing levels of intraocular pressure (IOP) using ocular hypotensive agents. Very often, patients require more than one IOP-reducing drug, resulting in complex medication regimens that may be difficult to maintain and that can lead to non-compliance. A fixed-combination (FC) ophthalmic solution consisting of the prostaglandin, latanoprost (0.005%), and the β-blocker, timolol (0.5%), is now available. The primary mechanism of action of latanoprost is to increase uveoscleral outflow whereas timolol lowers IOP levels by decreasing the formation of aqueous humor in the ciliary epithelium. Due to the unique mechanism of action of latanoprost, once-daily dosing of one drop of FC latanoprost/timolol results in additional IOP reduction compared with either drug administered separately. FC latanoprost/timolol is well-tolerated and has a safety profile similar to that of its individual components. This combination drug provides a safe, effective and convenient alternative for the treatment of patients with elevated IOP levels uncontrolled with monotherapy. 2004 © Ashley Publications Ltd. AD - R.M. Feldman, The Heymann Eye Center, 6411 Fannin, Houston, TX 77030, United States AU - Feldman, R. M. C1 - combigan cosopt(Merck) normoglaucon(Bausch and Lomb) timpilo(Merck) xalacom(Pfizer) C2 - Bausch and Lomb Merck Pfizer DB - Embase Medline DO - 10.1517/14656566.5.4.909 IS - 4 KW - epinephrine adrenergic receptor stimulating agent beta adrenergic receptor blocking agent bimatoprost brimonidine carbachol carbonate dehydratase inhibitor cholinergic receptor stimulating agent brimonidine plus timolol cyclic AMP dipivefrine dorzolamide dorzolamide plus timolol eye drops latanoprost latanoprost plus timolol matrix metalloproteinase normoglaucon pilocarpine prostaglandin derivative protein c fos protein c jun timolol maleate travoprost unoprostone isopropyl ester aqueous humor flow area under the curve cataract ciliary body epithelium clinical trial conjunctiva conjunctival hyperemia dose response drug absorption drug bioavailability drug blood level drug efficacy drug half life drug mechanism drug metabolism drug safety drug synthesis drug tolerability eye color eye irritation eyelash flu like syndrome hair disease headache human hyperemia hypertension hypertrichosis intraocular hypertension intraocular pressure monotherapy open angle glaucoma patient compliance review structure activity relation upper respiratory tract infection vertigo visual disorder visual field defect visual impairment combigan cosopt timpilo xalacom LA - English M3 - Review N1 - L38489513 2004-04-28 PY - 2004 SN - 1465-6566 SP - 909-921 ST - An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension T2 - Expert Opinion on Pharmacotherapy TI - An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38489513&from=export http://dx.doi.org/10.1517/14656566.5.4.909 VL - 5 ID - 3751 ER - TY - JOUR AB - Background: Rising healthcare costs motivate continued cost-reduction efforts. To help lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease with substantial direct and indirect costs, clinicians need to understand the cost-effectiveness of intraocular pressure (IOP)-lowering pharmacotherapies. There is little published information on clinicians’ knowledge and attitudes about cost-effectiveness in glaucoma treatment. Purpose: This pilot focus group study aimed to explore clinician attitudes and perspectives around the costs and cost drivers of glaucoma therapy; the implementation of cost-effectiveness decisions; the clinical utility of cost-effectiveness studies; and the cost-effectiveness of available treatments. Methods: Six US glaucoma specialists participated in two separate teleconferencing sessions (three participants each), managed by an independent, skilled moderator (also a glaucoma specialist) using a discussion guide. Participants reviewed recent publications (n=25) on health economics outcomes research in glaucoma prior to the sessions. Results: Participants demonstrated a clear understanding of the economic burden of glaucoma therapy and identified medications, diagnostics, office visits, and treatment changes as key cost drivers. They considered cost-effectiveness an appropriate component of treatment decision-making but identified the need for additional data to inform these decisions. Participants indicated that there were only a few recent studies on health economics outcomes in glaucoma which evaluate parameters important to patient care, such as quality of life and medication adherence, and that longitudinal data were scant. In addition to efficacy, participants felt patient adherence and side-effect profile should be included in economic evaluations of glaucoma pharmacotherapy. Recently approved medications were evaluated in this context. Conclusion: Clinicians deem treatment decisions based on cost-effectiveness data as clinically appropriate. Newer IOP-lowering therapies with potentially greater efficacy and favorable side-effect and adherence profiles may help optimize cost-effectiveness. Future studies should include: clinicians’ perspectives; lack of commercial bias; analysis of long-term outcomes/costs; more comprehensive parameters; real-world (including quality-of-life) data; and a robust Markov model. AD - R.M. Feldman, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, 6400 Fannin St., Ste 1800, Houston, TX, United States AU - Feldman, R. M. AU - Cioffi, G. A. AU - Liebmann, J. M. AU - Weinreb, R. N. DB - Embase DO - 10.2147/OPTH.S236030 KW - article clinical decision making cost effectiveness analysis disease burden economic evaluation glaucoma health care cost health care planning health care utilization health personnel attitude human longitudinal study patient care pilot study professional knowledge protocol compliance quality of life teleconference LA - English M3 - Article N1 - L2003982218 2020-03-17 2020-03-24 PY - 2020 SN - 1177-5483 1177-5467 SP - 729-739 ST - Current knowledge and attitudes concerning cost-effectiveness in glaucoma pharmacotherapy: A glaucoma specialists focus group study T2 - Clinical Ophthalmology TI - Current knowledge and attitudes concerning cost-effectiveness in glaucoma pharmacotherapy: A glaucoma specialists focus group study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003982218&from=export http://dx.doi.org/10.2147/OPTH.S236030 VL - 14 ID - 2439 ER - TY - JOUR AB - Background: Rising healthcare costs motivate continued cost-reduction efforts. To help lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease with substantial direct and indirect costs, clinicians need to understand the cost-effectiveness of intraocular pressure (IOP)-lowering pharmacotherapies. There is little published information on clinicians’ knowledge and attitudes about cost-effectiveness in glaucoma treatment. Purpose: This pilot focus group study aimed to explore clinician attitudes and perspectives around the costs and cost drivers of glaucoma therapy; the implementation of cost-effectiveness decisions; the clinical utility of cost-effectiveness studies; and the cost-effectiveness of available treatments. Methods: Six US glaucoma specialists participated in two separate teleconferencing sessions (three participants each), managed by an independent, skilled moderator (also a glaucoma specialist) using a discussion guide. Participants reviewed recent publications (n=25) on health economics outcomes research in glaucoma prior to the sessions. Results: Participants demonstrated a clear understanding of the economic burden of glaucoma therapy and identified medications, diagnostics, office visits, and treatment changes as key cost drivers. They considered cost-effectiveness an appropriate component of treatment decision-making but identified the need for additional data to inform these decisions. Participants indicated that there were only a few recent studies on health economics outcomes in glaucoma which evaluate parameters important to patient care, such as quality of life and medication adherence, and that longitudinal data were scant. In addition to efficacy, participants felt patient adherence and side-effect profile should be included in economic evaluations of glaucoma pharmacotherapy. Recently approved medications were evaluated in this context. Conclusion: Clinicians deem treatment decisions based on cost-effectiveness data as clinically appropriate. Newer IOP-lowering therapies with potentially greater efficacy and favorable side-effect and adherence profiles may help optimize cost-effectiveness. Future studies should include: clinicians’ perspectives; lack of commercial bias; analysis of long-term outcomes/costs; more comprehensive parameters; real-world (including quality-of-life) data; and a robust Markov model. © 2020 Feldman et al. AD - The University of Texas Medical School, Houston, TX, United States Department of Ophthalmology, NewYork Presbyterian Hospital Columbia University Irving Medical Center, New York, NY, United States Columbia University Medical Center, New York, NY, United States University of California San Diego, LaJollaCA, United States AU - Feldman, R. M. AU - Cioffi, G. A. AU - Liebmann, J. M. AU - Weinreb, R. N. DB - Scopus DO - 10.2147/OPTH.S236030 KW - Clinician knowledge and attitudes Cost-effectiveness Focus group Ocular hypertension Open-angle glaucoma Prostaglandin analogs M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2020 SP - 729-739 ST - Current knowledge and attitudes concerning cost-effectiveness in glaucoma pharmacotherapy: A glaucoma specialists focus group study T2 - Clinical Ophthalmology TI - Current knowledge and attitudes concerning cost-effectiveness in glaucoma pharmacotherapy: A glaucoma specialists focus group study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081274137&doi=10.2147%2fOPTH.S236030&partnerID=40&md5=9a6b7ef442c5fa04f553ced0ff9e43e7 VL - 14 ID - 5549 ER - TY - JOUR AB - Background: Rising healthcare costs motivate continued cost-reduction efforts. To help lower costs associated with open-angle glaucoma (OAG), a prevalent, progressive disease with substantial direct and indirect costs, clinicians need to understand the cost-effectiveness of intraocular pressure (IOP)-lowering pharmacotherapies. There is little published information on clinicians' knowledge and attitudes about cost-effectiveness in glaucoma treatment. Purpose: This pilot focus group study aimed to explore clinician attitudes and perspectives around the costs and cost drivers of glaucoma therapy; the implementation of costeffectiveness decisions; the clinical utility of cost-effectiveness studies; and the costeffectiveness of available treatments. Methods: Six US glaucoma specialists participated in two separate teleconferencing sessions (three participants each), managed by an independent, skilled moderator (also a glaucoma specialist) using a discussion guide. Participants reviewed recent publications (n=25) on health economics outcomes research in glaucoma prior to the sessions. Results: Participants demonstrated a clear understanding of the economic burden of glaucoma therapy and identified medications, diagnostics, office visits, and treatment changes as key cost drivers. They considered cost-effectiveness an appropriate component of treatment decisionmaking but identified the need for additional data to inform these decisions. Participants indicated that there were only a few recent studies on health economics outcomes in glaucoma which evaluate parameters important to patient care, such as quality of life and medication adherence, and that longitudinal data were scant. In addition to efficacy, participants felt patient adherence and side-effect profile should be included in economic evaluations of glaucoma pharmacotherapy. Recently approved medications were evaluated in this context. Conclusion: Clinicians deem treatment decisions based on cost-effectiveness data as clinically appropriate. Newer IOP-lowering therapies with potentially greater efficacy and favorable side-effect and adherence profiles may help optimize cost-effectiveness. Future studies should include: clinicians' perspectives; lack of commercial bias; analysis of long-term outcomes/costs; more comprehensive parameters; real-world (including quality-of-life) data; and a robust Markov model. AN - WOS:000520502400001 AU - Feldman, R. M. AU - Cioffi, G. A. AU - Liebmann, J. M. AU - Weinreb, R. N. DO - 10.2147/OPTH.S236030 PY - 2020 SN - 1177-5483 SP - 729-739 ST - Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study T2 - CLINICAL OPHTHALMOLOGY TI - Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study VL - 14 ID - 6078 ER - TY - JOUR AB - Glaucoma, an irreversible blinding condition affecting 3–4% adults aged above 40 years worldwide, is set to increase with a rapidly aging global population. Raised intraocular pressure (IOP) is a major risk factor for glaucoma where the treatment paradigm is focused on managing IOP using medications, laser, or surgery regimens. However, notwithstanding IOP and other clinical parameters, patient-reported outcomes, including daily functioning, emotional well-being, symptoms, mobility, and social life, remain the foremost concerns for people being treated for glaucoma. These outcomes are measured using objective patient-centered outcome measures (PCOMs) and subjective patient-reported outcome measures (PROMs). Studies using PCOMs have shown that people with glaucoma have several mobility, navigational and coordination challenges; reading and face recognition deficits; and are slower in adapting to multiple real-world situations when compared to healthy controls. Similarly, studies have consistently demonstrated, using PROMs, that glaucoma substantially and negatively impacts on peoples’ self-reported visual functioning, mobility, independence, emotional well-being, self-image, and confidence in healthcare, compared to healthy individuals, particularly in those with late-stage disease undergoing a heavy treatment regimen. The patient-centred effectiveness of current glaucoma treatment paradigms is equivocal due to a lack of well-designed randomized controlled trials; short post-treatment follow-up periods; an inappropriate selection or availability of PROMs; and/or an insensitivity of currently available PROMs to monitor changes especially in patients with newly diagnosed early-stage glaucoma. We provide a comprehensive, albeit non-systematic, critique of the psychometric properties, limitations, and recent advances of currently available glaucoma-specific PCOMs and PROMs. Finally, we propose that item banking and computerized adaptive testing methods can address the multiple limitations of paper-pencil PROMs; customize their administration; and have the potential to improve healthcare outcomes for people with glaucoma. © 2019 Elsevier Ltd AD - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore Duke-NUS Medical School, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore Glaucoma Centre of Excellence, Wilmer Eye Institute, Johns Hopkins University, United States AU - Fenwick, E. K. AU - Man, R. E. AU - Aung, T. AU - Ramulu, P. AU - Lamoureux, E. L. C7 - 100801 DB - Scopus DO - 10.1016/j.preteyeres.2019.100801 KW - Computerized adaptive testing Glaucoma Glaucoma treatments Patient-centred outcomes Patient-reported outcomes Quality of life M3 - Review N1 - Cited By :4 Export Date: 19 July 2021 PY - 2020 ST - Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma T2 - Progress in Retinal and Eye Research TI - Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075420204&doi=10.1016%2fj.preteyeres.2019.100801&partnerID=40&md5=350c159a84ec7f907dc5f9fbe315f9cd VL - 76 ID - 5441 ER - TY - JOUR AU - Ferrari, C. DB - Scopus DO - 10.1089/clm.1995.13.113 IS - 2 M3 - Short Survey N1 - Export Date: 19 July 2021 PY - 1995 SP - 113-114 ST - Laser glaucoma treatment under development T2 - Journal of Clinical Laser Medicine and Surgery TI - Laser glaucoma treatment under development UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029052958&doi=10.1089%2fclm.1995.13.113&partnerID=40&md5=386f3baa32a709a593c4983c7ce8ad71 VL - 13 ID - 5799 ER - TY - JOUR AB - Purpose:To report management of de novo vitreous amyloid opacities after previous pars plana vitrectomy in familial amyloidotic polyneuropathy transthyretin Val30Met.Methods:This work is a retrospective observational consecutive case series of five eyes of four patients. Demographic data, transthyretin mutation involved, age at the beginning of disease, duration of disease, treatment (liver transplant or tafamidis), time between vitrectomy and re-intervention, and ophthalmologic changes were evaluated. Surgical re-intervention included phacoemulsification with intraocular lens implantation in phakic eyes, re-vitrectomy as complete as possible with posterior capsulectomy, and internal limiting membrane peeling if wrinkling of internal retinal surface was present.Results:All patients had transthyretin Val30Met mutation, and three were women. Mean age of onset of the disease was 52 ± 11.0 years, and average evolution time of the disease was 8 years. Three patients had been submitted to liver transplant 4, 9, and 15 years before. Time between first vitrectomy and surgical re-intervention was longer than 2 years in all cases. Two eyes had amyloid deposits on anterior lens surface and pupillary border with scalloped pupil. Two eyes were phakic. Glaucoma was present in two eyes; one of them had previous trabeculectomy. All cases had vitreous opacities behind posterior lens capsule and at vitreous base area. After re-intervention, no further recurrence was observed (average follow-up of 10 months).Conclusion:De novo vitreous amyloid opacities may occur several years after pars plana vitrectomy. Amyloid deposition in vitreous cavity was observed only in strong vitreous adherence locations (behind posterior lens capsule and at vitreous base area). The authors expect that this procedure, an extensive re-vitrectomy associated with posterior capsulectomy, will prevent de novo vitreous amyloid opacities. Copyright © by Ophthalmic Communications Society, Inc. Unauthorized reproduction of this article is prohibited. AD - Department of Ophthalmology, Hospital Santo António, Centro Hospitalar, Universitário Do Porto, Travessa de Nossa Senhora da Saúde, n 31, Aveiro, 3810-292, Portugal Department of Ophthalmology, Hospital Pedro Hispano, Matosinhos, Portugal Unidade Corino de Andrade, Department of Neurophysiology, Hospital Santo António, Centro Hospitalar, Universitário Do Porto, Porto, Portugal AU - Ferreira, N. N. AU - Cunha Dias, D. A. AU - Afonso Carvalho, R. P. AU - Pardal Monteiro Coelho, M. T. DB - Scopus DO - 10.1097/ICB.0000000000000578 IS - 3 KW - familial amyloidotic polyneuropathy TTR Val30Met pars plana vitrectomy vitreous opacities M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2019 SP - 273-278 ST - RE-INTERVENTION in de NOVO VITREOUS OPACITIES after PARS PLANA VITRECTOMY in FAMILIAL AMYLOIDOTIC POLYNEUROPATHY TTR VAL30METPORTUGUESE PATIENTS T2 - Retinal Cases and Brief Reports TI - RE-INTERVENTION in de NOVO VITREOUS OPACITIES after PARS PLANA VITRECTOMY in FAMILIAL AMYLOIDOTIC POLYNEUROPATHY TTR VAL30METPORTUGUESE PATIENTS UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066415512&doi=10.1097%2fICB.0000000000000578&partnerID=40&md5=9399b2a2bb6495a4eb1a801267b684c2 VL - 13 ID - 5553 ER - TY - JOUR AB - PURPOSE: To determine the main causes of intrastromal corneal ring segment (ICRS) explantation and the relationship with the microscopic findings on the ICRS surface. SETTING: Vissum Corporation-Instituto Oftalmologico de Alicante, Alicante, Spain. METHODS: This study evaluated ICRS that were explanted in centers in Spain from 2000 to 2008. Clinical data (reasons for explantation, date of implantation/explantation, tunnel creation technique, ICRS type) and scanning electron microscopy findings on the ICRS surface (adherent tissue-like material, cell deposits, protein) were documented. RESULTS: Intrastromal corneal ring segments were explanted from 58 eyes (47 patients). The main cause was extrusion (48.2% of explanted segments), followed by refractive failure (ie, poor refractive outcome) (37.9%), keratitis (6.8%; 3.7% culture positive), and corneal melting and perforation (6.8%). Scanning electron microscopy showed cells and cell debris on the ICRS explanted by extrusion, a clean surface on the ICRS explanted for refractive failure, and bacteria (cocci) in the case of proven infectious keratitis. CONCLUSIONS: The main cause of explantation was extrusion of the ICRS followed by refractive failure. There was a clear correlation between the cause of explantation and the microscopic findings on the ICRS. Extrusion was accompanied by inflammatory cells and cell debris on the ICRS surface. No inflammatory reaction was observed on the ICRS explanted for refractive failure. AN - WOS:000278652600015 AU - Ferrer, C. AU - Alio, J. L. AU - Montanes, A. U. AU - Perez-Santonja, J. J. AU - del Rio, M. A. D. AU - de Toledo, J. A. AU - Teus, M. A. AU - Jayaloy, J. DA - JUN DO - 10.1016/j.jcrs.2009.12.042 IS - 6 PY - 2010 SN - 0886-3350 1873-4502 SP - 970-977 ST - Causes of intrastromal corneal ring segment explantation: Clinicopathologic correlation analysis T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Causes of intrastromal corneal ring segment explantation: Clinicopathologic correlation analysis VL - 36 ID - 6300 ER - TY - JOUR AB - Aim To evaluate goniotomy, trabeculotomy, transscleral cyclophotocoagulation (TSCPC) and trabeculectomy as initial procedures in children with primary childhood glaucoma from Northern Tanzania. Methods A retrospective analysis of consecutive interventions for primary childhood glaucoma from 2000 to 2013 was conducted at the Kilimanjaro Christian Medical Centre. Success was defined as postoperative intraocular pressure (IOP) below 22 mmHg. Success rates, IOP, visual acuity (VA), subsequent interventions and potential risk factors for failure were reported for the respective interventions. Results The study included 116 eyes of 70 children (age 4.6±5.9 years) with primary childhood glaucoma; 46 (65.7%) children were male. The preoperative IOP was 33.1±10.2 mmHg, the preoperative cup/disc (CD) ratio 0.71±0.3 and the corneal diameter 13.3±1.4 mm. As a primary intervention, 61 (52.6%) eyes underwent goniotomy, 10 (8.6%) eyes trabeculotomy, 12 (10.3%) TSCPC and 33 (28.4%) trabeculectomy. Follow-up data after 12 months were available for 63 (54.3%) eyes. Success rates at 12 months were 38% (goniotomy), 30% (trabeculotomy), 17% (TSCPC) and 64% (trabeculectomy). All interventions achieved a statistically significant IOP reduction at 3, 6 and 12 months, except for trabeculotomy after 6 months and TSCPC at all time points. Postoperative endophthalmitis occurred in one child treated with trabeculectomy. VA in 82% of all eyes was maintained or had improved after 12 months. Conclusions Based on the success rates of this retrospective analysis, goniotomy or trabeculotomy for younger and trabeculectomy for older children can be recommended in our setting to reduce IOP. Late presentation in combination with advanced glaucomatous damage as well as erratic postoperative follow-up and treatment were likely factors that compromised overall success rates. More efforts are necessary to detect the blinding disease earlier and improve adherence to follow-up. AD - A. Fieß, Department of Ophthalmology, HELIOS Dr. Horst Schmidt Kliniken, Ludwig-Erhard-Straße 100, Wiesbaden, Germany AU - Fieß, A. AU - Furahini, G. AU - Bowman, R. AU - Bauer, J. AU - Dithmar, S. AU - Philippin, H. DB - Embase Medline DO - 10.1136/bjophthalmol-2015-308137 IS - 2 KW - adolescent age cataract cataract extraction child conference paper cornea opacity endophthalmitis female follow up glaucoma glaucoma surgery goniotomy human intermethod comparison intraocular pressure keratopathy laser coagulation major clinical study male postoperative period preschool child reoperation retrospective study risk factor school child surgical technique Tanzania trabeculotomy treatment failure treatment indication treatment outcome visual acuity LA - English M3 - Conference Paper N1 - L610213998 2016-05-10 2017-02-21 PY - 2017 SN - 1468-2079 0007-1161 SP - 126-130 ST - Outcomes of surgical interventions for primary childhood glaucoma in Northern Tanzania T2 - British Journal of Ophthalmology TI - Outcomes of surgical interventions for primary childhood glaucoma in Northern Tanzania UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610213998&from=export http://dx.doi.org/10.1136/bjophthalmol-2015-308137 VL - 101 ID - 2666 ER - TY - JOUR AB - Aim To evaluate goniotomy, trabeculotomy, transscleral cyclophotocoagulation (TSCPC) and trabeculectomy as initial procedures in children with primary childhood glaucoma from Northern Tanzania. Methods A retrospective analysis of consecutive interventions for primary childhood glaucoma from 2000 to 2013 was conducted at the Kilimanjaro Christian Medical Centre. Success was defined as postoperative intraocular pressure (IOP) below 22 mmHg. Success rates, IOP, visual acuity (VA), subsequent interventions and potential risk factors for failure were reported for the respective interventions. Results The study included 116 eyes of 70 children (age 4.6±5.9 years) with primary childhood glaucoma; 46 (65.7%) children were male. The preoperative IOP was 33.1±10.2 mmHg, the preoperative cup/disc (CD) ratio 0.71±0.3 and the corneal diameter 13.3±1.4 mm. As a primary intervention, 61 (52.6%) eyes underwent goniotomy, 10 (8.6%) eyes trabeculotomy, 12 (10.3%) TSCPC and 33 (28.4%) trabeculectomy. Follow-up data after 12 months were available for 63 (54.3%) eyes. Success rates at 12 months were 38% (goniotomy), 30% (trabeculotomy), 17% (TSCPC) and 64% (trabeculectomy). All interventions achieved a statistically significant IOP reduction at 3, 6 and 12 months, except for trabeculotomy after 6 months and TSCPC at all time points. Postoperative endophthalmitis occurred in one child treated with trabeculectomy. VA in 82% of all eyes was maintained or had improved after 12 months. Conclusions Based on the success rates of this retrospective analysis, goniotomy or trabeculotomy for younger and trabeculectomy for older children can be recommended in our setting to reduce IOP. Late presentation in combination with advanced glaucomatous damage as well as erratic postoperative follow-up and treatment were likely factors that compromised overall success rates. More efforts are necessary to detect the blinding disease earlier and improve adherence to follow-up. AD - Department of Ophthalmology, HELIOS Dr. Horst Schmidt Kliniken, Ludwig-Erhard-Straße 100, Wiesbaden, 65199, Germany Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania Faculty of Infectious and Tropical Diseases, International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, United Kingdom Paediatric Department, HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany AU - Fieß, A. AU - Furahini, G. AU - Bowman, R. AU - Bauer, J. AU - Dithmar, S. AU - Philippin, H. DB - Scopus DO - 10.1136/bjophthalmol-2015-308137 IS - 2 KW - Child health (paediatrics) Glaucoma Low vision aid Optic Nerve Public health M3 - Conference Paper N1 - Cited By :2 Export Date: 19 July 2021 PY - 2017 SP - 126-130 ST - Outcomes of surgical interventions for primary childhood glaucoma in Northern Tanzania T2 - British Journal of Ophthalmology TI - Outcomes of surgical interventions for primary childhood glaucoma in Northern Tanzania UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964810314&doi=10.1136%2fbjophthalmol-2015-308137&partnerID=40&md5=eed5edc3f7cab48ad89f1855f0997938 VL - 101 ID - 5564 ER - TY - JOUR AB - Aim To evaluate goniotomy, trabeculotomy, transscleral cyclophotocoagulation (TSCPC) and trabeculectomy as initial procedures in children with primary childhood glaucoma from Northern Tanzania. Methods A retrospective analysis of consecutive interventions for primary childhood glaucoma from 2000 to 2013 was conducted at the Kilimanjaro Christian Medical Centre. Success was defined as postoperative intraocular pressure (IOP) below 22 mmHg. Success rates, IOP, visual acuity (VA), subsequent interventions and potential risk factors for failure were reported for the respective interventions. Results The study included 116 eyes of 70 children (age 4.6 +/- 5.9 years) with primary childhood glaucoma; 46 (65.7%) children were male. The preoperative IOP was 33.1 +/- 10.2 mmHg, the preoperative cup/disc (CD) ratio 0.71 +/- 0.3 and the corneal diameter 13.3 +/- 1.4 mm. As a primary intervention, 61 (52.6%) eyes underwent goniotomy, 10 (8.6%) eyes trabeculotomy, 12 (10.3%) TSCPC and 33 (28.4%) trabeculectomy. Follow-up data after 12 months were available for 63 (54.3%) eyes. Success rates at 12 months were 38% (goniotomy), 30% (trabeculotomy), 17% (TSCPC) and 64% (trabeculectomy). All interventions achieved a statistically significant IOP reduction at 3, 6 and 12 months, except for trabeculotomy after 6 months and TSCPC at all time points. Postoperative endophthalmitis occurred in one child treated with trabeculectomy. VA in 82% of all eyes was maintained or had improved after 12 months. Conclusions Based on the success rates of this retrospective analysis, goniotomy or trabeculotomy for younger and trabeculectomy for older children can be recommended in our setting to reduce IOP. Late presentation in combination with advanced glaucomatous damage as well as erratic postoperative follow-up and treatment were likely factors that compromised overall success rates. More efforts are necessary to detect the blinding disease earlier and improve adherence to follow-up. AN - WOS:000393306300008 AU - Fiess, A. AU - Furahini, G. AU - Bowman, R. AU - Bauer, J. AU - Dithmar, S. AU - Philippin, H. DA - FEB DO - 10.1136/bjophthalmol-2015-308137 IS - 2 PY - 2017 SN - 0007-1161 1468-2079 SP - 126-130 ST - Outcomes of surgical interventions for primary childhood glaucoma in Northern Tanzania T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - Outcomes of surgical interventions for primary childhood glaucoma in Northern Tanzania VL - 101 ID - 6064 ER - TY - JOUR AB - Background: After a successful trabeculectomy, a sudden intraocular pressure decrease may alter the intracranial to intraocular pressure ratio and cause decompression retinopathy. Frequent Valsalva maneuvers may also play a role in its pathogenesis. This condition may manifest as multiple retinal hemorrhages, edema of the optic disc, macular edema, or a sudden decrease in visual acuity postoperatively. Outcomes for patients are usually good, with spontaneous resolution occurring within a matter of weeks. It has been rarely reported in the literature as a bilateral condition. Case presentation: We present a case of consecutive bilateral decompression retinopathy in a 54-year-old severely obese Caucasian woman (body mass index 37 kg/m2) with open angle glaucoma and a poor history of medical therapeutic compliance, who chose surgical treatment based on her inability to consistently use ocular drops. Our patient underwent a trabeculectomy with mitomycin C in both eyes, with surgeries taking place 3 months apart. After the first surgery, 2 weeks postoperatively, she complained of decreased visual acuity. Examination of her right eye fundus revealed multiple retinal hemorrhages and disc edema. There was a similar pattern in her left eye, this time including maculopathy. Her visual acuity and fundoscopic changes resolved spontaneously over a period of a month in both cases. Currently, our patient has well-controlled bilateral intraocular pressure, ranging between 14 and 16 mmHg, without hypotensive medication. Conclusions: Decompression retinopathy is a potential complication after glaucoma surgery, but has rarely been described as a bilateral consecutive condition. A comprehensive approach could help to anticipate its occurrence and manage it. © 2016 Figueiredo et al. AD - Ophthalmology Department, Centro Hospital Do Porto, EPE - Hospital de Santo António, Largo Professor Abel Salazar, Porto, 4099-001, Portugal Wills Eye Hospital, Jefferson Medical College, 840 Walnut Street, Philadelphia, PA 19107, United States AU - Figueiredo, A. R. M. AU - Sampaio, I. C. AU - Menéres, M. J. F. D. S. AU - Spaeth, G. L. C7 - 32 DB - Scopus DO - 10.1186/s13256-016-0814-x IS - 1 KW - Decompression retinopathy Macular edema Open angle glaucoma Retinal hemorrhages Trabeculectomy M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2016 ST - Consecutive bilateral decompression retinopathy after mitomycin C trabeculectomy: A case report T2 - Journal of Medical Case Reports TI - Consecutive bilateral decompression retinopathy after mitomycin C trabeculectomy: A case report UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047597725&doi=10.1186%2fs13256-016-0814-x&partnerID=40&md5=85585ac804b442a1f705cbadff2d046a VL - 10 ID - 5461 ER - TY - JOUR AB - SIGNIFICANCE: Noncompliance is a problem affecting glaucoma patients. Approaches to improve adherence include the use of drug-delivery systems and safer forms of surgery. Minimally invasive glaucoma surgery (MIGS) has reduced complications, particularly in combination with cataract surgery, and with its good intraocular pressure (IOP) reduction may reduce or eliminate glaucoma medications.Glaucoma is a progressive disease and a leading cause of irreversible blindness. Elevated IOP is the most important risk factor, but effective medical management is dependent on patient adherence. This review summarizes the adherence problem in glaucoma and the efforts, including MIGS, to provide effective IOP control that is not dependent on patient compliance.The current understanding of patient adherence to pharmacological treatment of glaucoma is discussed including the challenges facing glaucoma patients. Historical approaches to providing IOP control in a sustained and reliable way are presented culminating in a review of the burgeoning use of MIGS devices.It is estimated that, in the United States, 27% of prescriptions written, across all medications, are not filled or are filled but not taken. For ocular hypotensive medications, even when filled, a large percentage (which varies widely by study) are not instilled as prescribed. To address this problem, methods for sustained drug delivery have been and continue to be developed, as well as surgical and laser approaches. Most recently, MIGS devices have gained popularity because of the ease of implantation during cataract surgery, favorable safety profile, and the possibility for effective and long-lasting IOP lowering, as well as the reduction or elimination of need for IOP-lowering medication.Poor adherence to treatment is relatively common among glaucoma patients and is associated with progression of disease. Recommending MIGS implantation during cataract surgery may offer optometrists a valuable treatment option in managing glaucoma patients, particularly where good adherence is in doubt. AU - Fingeret, M. AU - Dickerson, J. E. DB - Medline DO - 10.1097/OPX.0000000000001173 IS - 2 KW - cataract extraction glaucoma glaucoma drainage implant human intraocular pressure minimally invasive surgery pathophysiology patient compliance physiology LA - English M3 - Review N1 - L624966486 2019-01-11 PY - 2018 SN - 1538-9235 SP - 155-162 ST - The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624966486&from=export http://dx.doi.org/10.1097/OPX.0000000000001173 VL - 95 ID - 2605 ER - TY - JOUR AB - Significance: Noncompliance is a problem affecting glaucoma patients. Approaches to improve adherence include the use of drug-delivery systems and safer forms of surgery. Minimally invasive glaucoma surgery (MIGS) has reduced complications, particularly in combination with cataract surgery, and with its good intraocular pressure (IOP) reduction may reduce or eliminate glaucoma medications.Glaucoma is a progressive disease and a leading cause of irreversible blindness. Elevated IOP is the most important risk factor, but effective medical management is dependent on patient adherence. This review summarizes the adherence problem in glaucoma and the efforts, including MIGS, to provide effective IOP control that is not dependent on patient compliance.The current understanding of patient adherence to pharmacological treatment of glaucoma is discussed including the challenges facing glaucoma patients. Historical approaches to providing IOP control in a sustained and reliable way are presented culminating in a review of the burgeoning use of MIGS devices.It is estimated that, in the United States, 27% of prescriptions written, across all medications, are not filled or are filled but not taken. For ocular hypotensive medications, even when filled, a large percentage (which varies widely by study) are not instilled as prescribed. To address this problem, methods for sustained drug delivery have been and continue to be developed, as well as surgical and laser approaches. Most recently, MIGS devices have gained popularity because of the ease of implantation during cataract surgery, favorable safety profile, and the possibility for effective and long-lasting IOP lowering, as well as the reduction or elimination of need for IOP-lowering medication.Poor adherence to treatment is relatively common among glaucoma patients and is associated with progression of disease. Recommending MIGS implantation during cataract surgery may offer optometrists a valuable treatment option in managing glaucoma patients, particularly where good adherence is in doubt. Noncompliance is a problem affecting glaucoma patients. Approaches to improve adherence include the use of drug-delivery systems and safer forms of surgery. Minimally invasive glaucoma surgery (MIGS) has reduced complications, particularly in combination with cataract surgery, and with its good intraocular pressure (IOP) reduction may reduce or eliminate glaucoma medications.Glaucoma is a progressive disease and a leading cause of irreversible blindness. Elevated IOP is the most important risk factor, but effective medical management is dependent on patient adherence. This review summarizes the adherence problem in glaucoma and the efforts, including MIGS, to provide effective IOP control that is not dependent on patient compliance. The current understanding of patient adherence to pharmacological treatment of glaucoma is discussed including the challenges facing glaucoma patients. Historical approaches to providing IOP control in a sustained and reliable way are presented culminating in a review of the burgeoning use of MIGS devices.It is estimated that, in the United States, 27% of prescriptions written, across all medications, are not filled or are filled but not taken. For ocular hypotensive medications, even when filled, a large percentage (which varies widely by study) are not instilled as prescribed. To address this problem, methods for sustained drug delivery have been and continue to be developed, as well as surgical and laser approaches. Most recently, MIGS devices have gained popularity because of the ease of implantation during cataract surgery, favorable safety profile, and the possibility for effective and long-lasting IOP lowering, as well as the reduction or elimination of need for IOP-lowering medication.Poor adherence to treatment is relatively common among glaucoma patients and is associated with progression of disease. Recommending MIGS implantation during cataract surgery may offer optometrists a valuable treatment option in managing glaucoma patients, particularly where good adherence is in doubt. AD - New York Harbor Health Care System, Department of Veterans Affairs, Brooklyn, New York State University of New York College of Optometry, New York, New York Alcon Research, Ltd., FortWorth, Texas University of North Texas Health Science Center, Fort Worth, Texas Alcon Research, Ltd., Fort Worth, Texas University of North Texas Health Science Center, Fort Worth, Texas * AN - 127810539. Language: English. Entry Date: 20181115. Revision Date: 20181115. Publication Type: journal article AU - Fingeret, Murray AU - Dickerson, Jaime E. AU - Dickerson, Jaime E., Jr. DB - ccm DO - 10.1097/OPX.0000000000001173 DP - EBSCOhost IS - 2 KW - Intraocular Pressure -- Physiology Minimally Invasive Procedures Glaucoma -- Surgery Prostheses and Implants Cataract Extraction Patient Compliance Glaucoma -- Physiopathology N1 - review. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Profile of Mood States (POMS). NLM UID: 8904931. PMID: NLM29370021. PY - 2018 SN - 1040-5488 SP - 155-162 ST - The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma T2 - Optometry & Vision Science TI - The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=127810539&site=ehost-live&scope=site VL - 95 ID - 4365 ER - TY - JOUR AB - Open-angle glaucoma is a chronic disease usually requiring a patient to take medications for the rest of his or her life. Because of the expense and side effects of the medications and due to a lack of understanding of the condition, many patients do not take their medications properly, often leading to progressive damage. A written instruction sheet completed for each patient covering their medication dosage schedule is an aid that may subtly remind individuals to use their medications, reducing the problems associated with noncompliance. AD - M. Fingeret, St. Albans Veterans Administration, NY 11425. AU - Fingeret, M. AU - Schuettenberg, S. P. DB - Medline IS - 6 KW - adrenergic receptor blocking agent article drug administration human open angle glaucoma patient compliance LA - English M3 - Article N1 - L22924387 1992-06-14 PY - 1991 SN - 0003-0244 SP - 478-480 ST - Patient drug schedules and compliance T2 - Journal of the American Optometric Association TI - Patient drug schedules and compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L22924387&from=export VL - 62 ID - 4040 ER - TY - JOUR AB - Discusses the problem of noncompliance in managing and treating patients with glaucoma. A patient dosage schedule is presented to help improve patient compliance. The dosage schedule codes the names of the medication by bottle or cap color. By using a dosage schedule, patients benefit and doctors gain insight into successful patient management. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1991-31199-001 AU - Fingeret, Murray AU - Schuettenberg, Susan P. DB - psyh DP - EBSCOhost IS - 6 KW - drug dosage schedule treatment compliance & management glaucoma patients Drug Administration Schedule Glaucoma, Open-Angle Humans Patient Compliance Sympatholytics Drug Dosages Drug Therapy Glaucoma Treatment Compliance N1 - St Albans Veterans Administration, NY, US. Release Date: 19911101. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Dosages; Drug Therapy; Glaucoma; Treatment Compliance. Classification: Clinical Psychopharmacology (3340). Population: Human (10). Page Count: 3. Issue Publication Date: Jun, 1991. PY - 1991 SN - 0003-0244 SP - 478-480 ST - Patient drug schedules and compliance T2 - Journal of the American Optometric Association TI - Patient drug schedules and compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1991-31199-001&site=ehost-live&scope=site VL - 62 ID - 4863 ER - TY - JOUR AD - R. Fiscella AU - Fiscella, R. AU - Stewart, W. C. DB - Medline DO - 10.1089/jop.2005.21.349 IS - 4 KW - antihypertensive agent analysis of variance drug effect glaucoma human intraocular pressure note pathophysiology patient compliance statistics treatment outcome LA - English M3 - Note N1 - L41308287 2005-09-25 PY - 2005 SN - 1080-7683 SP - 349-350; author reply 350-352 ST - Letter to the editor: patient persistency with glaucoma therapy T2 - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics TI - Letter to the editor: patient persistency with glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41308287&from=export http://dx.doi.org/10.1089/jop.2005.21.349 VL - 21 ID - 3675 ER - TY - JOUR AB - Cost-of-illness studies determine the total financial burden of a disease by considering direct and indirect costs, including medication, diagnostics and surgery. Studies of resource use and costs associated with primary open-angle glaucoma have used varying methodologies. Most have focused on consumption of healthcare resources at various stages of disease to anticipate costs. The direct costs associated with the disease often continue to increase as glaucoma progresses from the earliest to most advanced stages. Determinations of the costs associated with glaucoma progression and prevention should also incorporate the chance of patient non-compliance with treatment. Since glaucoma severity most often correlates with increased costs, minimizing or halting visual field loss and increasing patient treatment compliance may all contribute to a reduction in the overall economic burden of glaucoma. AD - University of Illinois at Chicago, Chicago, Illinois 60612, USA University of Illinois at Chicago, Chicago, Illinois, USA. AN - 105524353. Language: English. Entry Date: 20090717. Revision Date: 20200708. Publication Type: journal article AU - Fiscella, R. G. AU - Lee, J. AU - Davis, E. J. AU - Walt, J. AU - Fiscella, Richard G. AU - Lee, Jeff AU - Davis, Elizabeth J. H. AU - Walt, John DB - ccm DO - 10.2165/00019053-200927030-00002 DP - EBSCOhost IS - 3 KW - Glaucoma -- Drug Therapy Glaucoma -- Economics Canada Economic Aspects of Illness Europe United States Human N1 - research; systematic review. Journal Subset: Australia & New Zealand; Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed. NLM UID: 9212404. PMID: NLM19354339. PY - 2009 SN - 1170-7690 SP - 189-198 ST - Cost of illness of glaucoma: a critical and systematic review T2 - PharmacoEconomics TI - Cost of illness of glaucoma: a critical and systematic review UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105524353&site=ehost-live&scope=site VL - 27 ID - 4455 ER - TY - JOUR AB - Cost-of-illness studies determine the total financial burden of a disease by considering direct and indirect costs, including medication, diagnostics and surgery. Studies of resource use and costs associated with primary open-angle glaucoma have used varying methodologies. Most have focused on consumption of healthcare resources at various stages of disease to anticipate costs. The direct costs associated with the disease often continue to increase as glaucoma progresses from the earliest to most advanced stages. Determinations of the costs associated with glaucoma progression and prevention should also incorporate the chance of patient non-compliance with treatment. Since glaucoma severity most often correlates with increased costs, minimizing or halting visual field loss and increasing patient treatment compliance may all contribute to a reduction in the overall economic burden of glaucoma. © 2009 Adis Data Information BV. All rights reserved. AD - R. G. Fiscella, University of Illinois at Chicago, 833 S. Wood, Chicago, IL 60612, United States AU - Fiscella, R. G. AU - Lee, J. AU - Davis, E. J. H. AU - Walt, J. DB - Embase Medline DO - 10.2165/00019053-200927030-00002 IS - 3 KW - Canada cost of illness diagnostic procedure disease course disease severity drug cost economic aspect Europe glaucoma surgery human open angle glaucoma patient compliance priority journal prophylaxis review treatment refusal United States visual field visual impairment LA - English M3 - Review N1 - L354477803 2009-04-24 PY - 2009 SN - 1170-7690 SP - 189-198 ST - Cost of illness of glaucoma: A critical and systematic review T2 - PharmacoEconomics TI - Cost of illness of glaucoma: A critical and systematic review UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354477803&from=export http://dx.doi.org/10.2165/00019053-200927030-00002 VL - 27 ID - 3359 ER - TY - JOUR AB - Background: Fungal keratitis is a fungal infection of the cornea. It is common in lower income countries, particularly in agricultural areas but relatively uncommon in higher income countries. Although there are medications available, their effectiveness is unclear.Objectives: To assess the effects of different antifungal drugs in the management of fungal keratitis.Search Methods: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 2), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to March 2015), EMBASE (January 1980 to March 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to March 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 16 March 2015.Selection Criteria: We included randomised controlled trials of medical therapy for fungal keratitis.Data Collection and Analysis: Two review authors selected studies for inclusion in the review, assessed trials for risk of bias and extracted data. The primary outcome was clinical cure at two to three months. Secondary outcomes included best-corrected visual acuity, time to clinical cure, compliance with treatment, adverse outcomes and quality of life.Main Results: We included 12 trials in this review; 10 trials were conducted in India, one in Bangladesh and one in Egypt. Seven of these trials were at high risk of bias in one or more domains, two of these studies were at low risk of bias in all domains. Participants were randomised to the following comparisons: topical 5% natamycin compared to topical 1% voriconazole; topical 5% natamycin compared to topical 2% econazole; topical 5% natamycin compared to topical chlorhexidine gluconate (0.05%, 0.1% and 0.2%); topical 1% voriconazole compared to intrastromal voriconazole 50 g/0.1 mL (both treatments combined with topical 5% natamycin); topical 1% voriconazole combined with oral voriconazole compared to both oral voriconazole and oral itraconazole (both combined with topical 5% natamycin); topical 1% itraconazole compared to topical 1% itraconazole combined with oral itraconazole; topical amphotericin B compared to topical amphotericin B combined with subconjunctival injection of fluconazole; intracameral injection of amphotericin B with conventional treatment compared to conventional treatment alone (severe fungal ulcers); topical 0.5% and 1% silver sulphadiazine compared to topical 1% miconazole. Overall the results were inconclusive because for most comparisons only one small trial was available. The exception was the comparison of topical natamycin and topical voriconazole for which three trials were available. In one of these trials clinical cure (healed ulcer) was reported in all 15 people allocated to natamycin and in 14/15 people allocated to voriconazole (risk ratio (RR) 1.07; 95% confidence interval (CI) 0.89 to 1.28, low quality evidence). In one trial people randomised to natamycin were more likely to have a microbiological cure at six days (RR 1.64; 95% CI 1.38 to 1.94, 299 participants). On average, people randomised to natamycin had better spectacle-corrected visual acuity at two to three months compared to people randomised to voriconazole but the estimate was uncertain and the 95% confidence intervals included 0 (no difference) (mean difference -0.12 logMAR, 95% CI -0.31 to 0.06, 434 participants; 3 studies, low quality evidence) and a decreased risk of corneal perforation or therapeutic penetrating keratoplasty, or both (RR 0.61; 95% CI 0.40 to 0.94, 434 participants, high quality evidence). There was inconclusive evidence on time to clinical cure. Compliance with treatment and quality of life were not reported. One trial compari g natamycin and voriconazole found the effect of treatment greater in Fusarium species, but this subgroup analysis was not prespecified by this review.Authors' Conclusions: The trials included in this review were of variable quality and were generally underpowered. There is evidence that natamycin is more effective than voriconazole in the treatment of fungal ulcers. Future research should evaluate treatment effects according to fungus species. AD - Department of Ophthalmology and Visual Sciences, University of the Phillipines-Philippine General Hospital, Taft Avenue, Manila, Philippines, 1000 AN - 105901860. Language: English. Entry Date: 20110107. Revision Date: 20151022. Publication Type: journal article AU - FlorCruz, N. V. AU - Peczon, I. V. AU - FlorCruz, Nilo Vincent AU - Evans, Jennifer R. DB - ccm DO - 10.1002/14651858.CD004241.pub4 DP - EBSCOhost IS - 4 KW - Antifungal Agents -- Therapeutic Use Keratitis -- Drug Therapy Mycoses -- Drug Therapy Chlorhexidine Clinical Effectiveness Clinical Trials Comparative Studies Developing Countries Itraconazole Keratitis -- Etiology -- Developing Countries Miconazole Ointments Silver Sulfadiazine Treatment Failure Human N1 - research; systematic review. Journal Subset: Europe; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. Grant Information: //Department of Health/United Kingdom. NLM UID: 100909747. Cochrane AN: CD004241. PMID: NLM25855311. PY - 2015 SN - 1469-493X SP - N.PAG-N.PAG ST - Medical interventions for fungal keratitis T2 - Cochrane Database of Systematic Reviews TI - Medical interventions for fungal keratitis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105901860&site=ehost-live&scope=site ID - 4745 ER - TY - JOUR AB - OBJECTIVE: This study describes patients' and physicians' perceptions of issues related to dosing adherence with topical therapies for lowering intraocular pressure before and after use of the travoprost dosing aid (Travatan Dosing Aid, Alcon Research Ltd., Fort Worth, Texas). METHODS: The study had an open-label, multicenter, single-treatment-arm design that included sequential patients with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension who were taking any prostaglandin analogue monotherapy. Ten participating physicians were chosen on the basis of factors such as their experience, qualifications, and previous clinical study participation. The study consisted of 2 visits: screening and week 4. Patients were asked to complete a survey about their medication adherence before study entry at the screening visit and at study exit during the week-4 visit. In addition, each physician was asked to complete an entry and exit survey on each patient as well as a survey to provide feedback on the travoprost dosing aid. RESULTS: Of the 87 enrolled patients, 6 did not complete the exit survey; therefore, 81 patients were included in the intent-to-treat analysis. Mean (SD) age at enrollment was 65.4 (11.6) years; 61.7% (50/81) of the patients were women and 60.5% (49/81) were white. Most patients (96.3% [78/81]) had open-angle glaucoma. Participating physicians perceived that problems involving dosing and adherence were reduced after patients used the dosing aid. Physicians indicated that they would recommend continued use of the travoprost dosing aid for 91.3% (73/80) of patients. All 10 participating physicians said that they would recommend the dosing aid to patients in the future. Of the 81 patients, the majority (68.8% [55/80]) indicated that they would like to continue using the travoprost dosing aid. For 67.5% (54/80) of patients, dosing adherence as recorded by the travoprost dosing aid was >70%. The dosing lever (39.7% [31/78]) and the visual alarm (29.5% [23/78]) were the 2 most favored features of the dosing aid reported by all evaluable patients. The majority of patients (58.8% [47/80]) indicated that they were 'relieved' or 'very relieved' that the doctor was able to monitor when they dosed their medication; few (7.5% [6/80]) were 'concerned' or 'very concerned' that the doctor was able to monitor their dosing. CONCLUSIONS: The travoprost dosing aid was perceived to be effective in reminding this group of patients to take their medication as prescribed. In this study, the device was well accepted by both patients and physicians. AD - Ophthalmology Associates, Fort Worth, Texas, USA. AN - 105928222. Corporate Author: Travatan Dosing Aid Study Group. Language: English. Entry Date: 20080118. Revision Date: 20200708. Publication Type: Journal Article AU - Flowers, B. AU - Wand, M. AU - Piltz-Seymour, J. AU - Berke, S. J. AU - Day, D. AU - Teague, J. AU - Smoot, T. M. AU - Landry, T. A. AU - Bergamini, M. V. AU - Mallick, S. DB - ccm DO - 10.1016/j.clinthera.2006.11.001 DP - EBSCOhost IS - 11 KW - Glaucoma -- Drug Therapy Medication Compliance Ocular Hypertension -- Drug Therapy Travoprost -- Administration and Dosage Blindness -- Prevention and Control Clinical Trials Funding Source Human Multicenter Studies Self Report N1 - clinical trial; pictorial; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Supported by Alcon Research Ltd.. NLM UID: 7706726. PMID: NLM17213000. PY - 2006 SN - 0149-2918 SP - 1803-1811 ST - Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension T2 - Clinical Therapeutics TI - Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105928222&site=ehost-live&scope=site VL - 28 ID - 4372 ER - TY - JOUR AB - Objective: This study describes patients' and physicians' perceptions of issues related to dosing adherence with topical therapies for lowering intraocular pressure before and after use of the travoprost dosing aid (Travatan™ Dosing Aid, Alcon Research Ltd., Fort Worth, Texas). Methods: The study had an open-label, multicenter, single-treatment-arm design that included sequential patients with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension who were taking any prostaglandin analogue monotherapy. Ten participating physicians were chosen on the basis of factors such as their experience, qualifications, and previous clinical study participation. The study consisted of 2 visits: screening and week 4. Patients were asked to complete a survey about their medication adherence before study entry at the screening visit and at study exit during the week-4 visit. In addition, each physician was asked to complete an entry and exit survey on each patient as well as a survey to provide feedback on the travoprost dosing aid. Results: Of the 87 enrolled patients, 6 did not complete the exit survey; therefore, 81 patients were included in the intent-to-treat analysis. Mean (SD) age at enrollment was 65.4 (11.6) years; 61.7% (50/81) of the patients were women and 60.5% (49/81) were white. Most patients (96.3% [78/81]) had open-angle glaucoma. Participating physicians perceived that problems involving dosing and adherence were reduced after patients used the dosing aid. Physicians indicated that they would recommend continued use of the travoprost dosing aid for 91.3% (73/80) of patients. All 10 participating physicians said that they would recommend the dosing aid to patients in the future. Of the 81 patients, the majority (68.8% [55/80]) indicated that they would like to continue using the travoprost dosing aid. For 67.5% (54/80) of patients, dosing adherence as recorded by the travoprost dosing aid was >70%. The dosing lever (39.7% [31/78]) and the visual alarm (29.5% [23/78]) were the 2 most favored features of the dosing aid reported by all evaluable patients. The majority of patients (58.8% [47/80]) indicated that they were "relieved" or "very relieved" that the doctor was able to monitor when they dosed their medication; few (7.5% [6/80]) were "concerned" or "very concerned" that the doctor was able to monitor their dosing. Conclusions: The travoprost dosing aid was perceived to be effective in reminding this group of patients to take their medication as prescribed. In this study, the device was well accepted by both patients and physicians. © 2006 Excerpta Medica, Inc. AD - S. Mallick, Alcon Research Ltd., Fort Worth, TX, United States AU - Flowers, B. AU - Wand, M. AU - Piltz-Seymour, J. AU - Berke, S. J. AU - Day, D. AU - Teague, J. AU - Smoot, T. M. AU - Landry, T. A. AU - Bergamini, M. V. W. AU - Mallick, S. C1 - travatan(Alcon,United States) C2 - Alcon(United States) DB - Embase Medline DO - 10.1016/j.clinthera.2006.11.001 IS - 11 KW - prostaglandin derivative travoprost adult aged article attitude to health clinical trial consumer attitude controlled clinical trial controlled study double blind procedure drug dose regimen drug withdrawal eye pain female health survey human intraocular hypertension major clinical study male monotherapy multicenter study open angle glaucoma patient attitude patient compliance physician rectum hemorrhage throat irritation travatan LA - English M3 - Article N1 - L46038521 2007-02-08 PY - 2006 SN - 0149-2918 1879-114X SP - 1803-1811 ST - Patients' and physicians' perceptions of the travoprost dosing aid: An open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension T2 - Clinical Therapeutics TI - Patients' and physicians' perceptions of the travoprost dosing aid: An open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46038521&from=export http://dx.doi.org/10.1016/j.clinthera.2006.11.001 VL - 28 ID - 3580 ER - TY - JOUR AB - Objective: This study describes patients' and physicians' perceptions of issues related to dosing adherence with topical therapies for lowering intraocular pressure before and after use of the travoprost dosing aid (Travatan™ Dosing Aid, Alcon Research Ltd., Fort Worth, Texas). Methods: The study had an open-label, multicenter, single-treatment-arm design that included sequential patients with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension who were taking any prostaglandin analogue monotherapy. Ten participating physicians were chosen on the basis of factors such as their experience, qualifications, and previous clinical study participation. The study consisted of 2 visits: screening and week 4. Patients were asked to complete a survey about their medication adherence before study entry at the screening visit and at study exit during the week-4 visit. In addition, each physician was asked to complete an entry and exit survey on each patient as well as a survey to provide feedback on the travoprost dosing aid. Results: Of the 87 enrolled patients, 6 did not complete the exit survey; therefore, 81 patients were included in the intent-to-treat analysis. Mean (SD) age at enrollment was 65.4 (11.6) years; 61.7% (50/81) of the patients were women and 60.5% (49/81) were white. Most patients (96.3% [78/81]) had open-angle glaucoma. Participating physicians perceived that problems involving dosing and adherence were reduced after patients used the dosing aid. Physicians indicated that they would recommend continued use of the travoprost dosing aid for 91.3% (73/80) of patients. All 10 participating physicians said that they would recommend the dosing aid to patients in the future. Of the 81 patients, the majority (68.8% [55/80]) indicated that they would like to continue using the travoprost dosing aid. For 67.5% (54/80) of patients, dosing adherence as recorded by the travoprost dosing aid was >70%. The dosing lever (39.7% [31/78]) and the visual alarm (29.5% [23/78]) were the 2 most favored features of the dosing aid reported by all evaluable patients. The majority of patients (58.8% [47/80]) indicated that they were "relieved" or "very relieved" that the doctor was able to monitor when they dosed their medication; few (7.5% [6/80]) were "concerned" or "very concerned" that the doctor was able to monitor their dosing. Conclusions: The travoprost dosing aid was perceived to be effective in reminding this group of patients to take their medication as prescribed. In this study, the device was well accepted by both patients and physicians. © 2006 Excerpta Medica, Inc. AD - Ophthalmology Associates, Fort Worth, TX, United States Consulting Ophthalmologists, Farmington, CT, United States Keystone Eye Associates, Philadelphia, PA, United States Ophthalmic Consultants of Long Island, Lynbrook, NY, United States Omni Eye Services, Atlanta, GA, United States Alcon Research Ltd., Fort Worth, TX, United States AU - Flowers, B. AU - Wand, M. AU - Piltz-Seymour, J. AU - Berke, S. J. AU - Day, D. AU - Teague, J. AU - Smoot, T. M. AU - Landry, T. A. AU - Bergamini, M. V. W. AU - Mallick, S. DB - Scopus DO - 10.1016/j.clinthera.2006.11.001 IS - 11 KW - adherence compliance glaucoma travoprost M3 - Article N1 - Cited By :18 Export Date: 19 July 2021 PY - 2006 SP - 1803-1811 ST - Patients' and physicians' perceptions of the travoprost dosing aid: An open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension T2 - Clinical Therapeutics TI - Patients' and physicians' perceptions of the travoprost dosing aid: An open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845963145&doi=10.1016%2fj.clinthera.2006.11.001&partnerID=40&md5=a2037b3a63519180c2f7acf1ab1ad0bf VL - 28 ID - 5164 ER - TY - JOUR AB - Objective: This Study describes patients' and physicians' Perceptions of issues related to dosing adherence with topical therapies for lowering Intraocular pressure before and after use of the travoprost dosing aid (Travatan (TM) Dosing Aid, Alcon Research Ltd., Fort Worth, Texas). Methods: The Study had an open-label, multicenter, single-treatment-arm design that included sequential patients with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension who were taking any prostaglandin analogue monotherapy. Ten participating physicians were chosen on the basis of factors Such as their experience, qualifications, and previous clinical study participation. The study consisted of 2 visits: screening and week 4. Patients were asked to complete a survey about their medication adherence before study entry at the screening visit and at study exit during the week-4 visit. In addition, each Physician was asked to complete an entry and exit survey on each patient as well as a survey to provide feedback on the travoprost dosing aid. Results: Of the 87 enrolled patients, 6 did not complete the exit survey; therefore, 81 patients were included in the intent-to-treat analysis. Mean (SD) age at enrollment was 65.4 (11.6) years; 61.7% (50/81) of the patients were women and 60.5% (49/81) were white. Most patients (96.3% [78/81]) had open-angle glaucoma. Participating physicians perceived that problems involving dosing and adherence were reduced after patients used the dosing aid. Physicians indicated that they would recommend Continued use of the travoprost dosing aid for 91.3% (73/80) of patients. All 10 participating physicians said that they Would recommend the dosing aid to patients in the future. Of the 81 patients, the majority (68.8% vertical bar 55/80 vertical bar) indicated that they would like to continue using the travoprost dosing aid. For 67.5'% (54/80) of patients, dosing adherence as recorded by the travoprost dosing aid was > 70%. The dosing lever (39.7%, vertical bar 31/78 vertical bar) and the visual alarm (29.5% vertical bar 23/78 vertical bar) were the 2 most favored features of the dosing aid reported by all evaluable patients. The majority of patients (58.8% vertical bar 47/80 vertical bar) indicated that they were "relieved" or "very relieved" that the doctor was able to monitor when they dosed their medication; few (7.5% [6/80]) were "concerned" or "very concerned" that the doctor was able to monitor their dosing. Conclusions: The travoprost dosing aid was perceived to be effective in reminding this group of patients to take their medication as prescribed. In this Study, the device was well accepted by both patients and physicians. (Clin Ther. 2006;28:1803-1811) Copyright (c) 2006 Excerpta Medica, Inc. AN - WOS:000243042900004 AU - Flowers, B. AU - Wand, M. AU - Piltz-Seymour, J. AU - Berke, S. J. AU - Day, D. AU - Teague, J. AU - Smoot, T. M. AU - Landry, T. A. AU - Bergamini, M. V. W. AU - Mallick, S. AU - Travatan Dosing Study, Grp DA - NOV DO - 10.1016/j.clinthera.2006.11.001 IS - 11 PY - 2006 SN - 0149-2918 SP - 1803-1811 ST - Patients' and physicians' perceptions of the travoprost dosing aid: An open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension T2 - CLINICAL THERAPEUTICS TI - Patients' and physicians' perceptions of the travoprost dosing aid: An open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension VL - 28 ID - 6029 ER - TY - JOUR AB - Lack of or inadequate hand washing is a risk factor in the development of contact lens related microbial keratitis and corneal inflammatory events. In the public health domain there is compelling evidence that proper hand washing with soap can save lives. The purpose of this review is to draw attention to some of the public health literature in support of hand washing and how education can influence patients' hand hygiene behavior. Contact lens wearers are also guilty of poor hand washing behavior but there is scant evidence that education of hand washing procedures of lens wearers alters patient non-compliance. It is well known that pathogenic microbial contamination of contact lenses, lens cases, care solutions and anterior ocular components have been found with contact lens wear. However while the originating source may be hands or water, it is most likely both of these. Besides proper hand washing this paper will include mitigating strategies for avoiding microbial contamination. AD - Centre for Ocular Research and Education, School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada AN - 135532241. Language: English. Entry Date: 20191219. Revision Date: 20200510. Publication Type: journal article AU - Fonn, Desmond AU - Jones, Lyndon DB - ccm DO - 10.1016/j.clae.2018.10.022 DP - EBSCOhost IS - 2 KW - Keratitis -- Microbiology Eye Infections, Bacterial -- Microbiology Handwashing Contact Lenses Equipment Contamination Risk Factors Patient Compliance Inflammation -- Microbiology N1 - review. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 9712714. PMID: NLM30413375. PY - 2019 SN - 1367-0484 SP - 132-135 ST - Hand hygiene is linked to microbial keratitis and corneal inflammatory events T2 - Contact Lens & Anterior Eye TI - Hand hygiene is linked to microbial keratitis and corneal inflammatory events UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135532241&site=ehost-live&scope=site VL - 42 ID - 4399 ER - TY - JOUR AB - PURPOSE:: To determine if adherence and convenience of once-daily glaucoma medication is greater in the morning or the evening. DESIGN:: Prospective, randomized crossover treatment trial. PATIENTS AND METHODS:: Thirty patients newly diagnosed with glaucoma or ocular hypertension requiring intraocular pressure (IOP) reduction were started on travoprost eye drops and randomized to either morning or evening administration for 1 month. They were then crossed over to the opposite dosing schedule for the following month. Adherence was monitored using an automated dosing aid. MAIN OUTCOME MEASURES:: Adherence was compared between morning versus evening dosing and first versus second month dosing. Demographic characteristics were obtained, treatment effect was measured, and patients completed a post-study questionnaire regarding the convenience of the 2 dosing regimens. RESULTS:: Patient adherence overall was good (89.3%). There was no statistically significant difference (P=0.07) in adherence between morning dosing (90.9%) and evening dosing (87.3%). Adherence in the first month (91.7%) was superior to the second month (86.5%). There was no significant difference in IOP response between morning and evening dosing. Patients found morning dosing more convenient than evening dosing. CONCLUSIONS:: Early adherence to treatment with a prostaglandin analogue is good, but patients prefer morning administration to evening administration. This may lead to greater adherence with morning administration, particularly among men. Adherence decreases from the first to second month after initiation of treatment. IOP response to this treatment is not significantly affected by morning versus evening administration. Copyright © 2013 by Lippincott Williams & Wilkins. AD - B.A. Ford, Department of Surgery, Division of Ophthalmology, University of Calgary, #102, 49 Richard Way SW, Calgary, AB, T3E 7M8, Canada AU - Ford, B. A. AU - Gooi, M. AU - Carlsson, A. AU - Crichton, A. C. DB - Embase DO - 10.1097/IJG.0b013e31822e622f IS - 1 KW - travoprost adult aged article automation clinical article controlled study crossover procedure drug dose regimen evening dosage female glaucoma human intraocular hypertension intraocular pressure male morning dosage patient compliance priority journal questionnaire randomized controlled trial therapy effect LA - English M3 - Article N1 - L51631172 2011-10-05 2013-01-31 PY - 2013 SN - 1057-0829 1536-481X SP - 1-4 ST - Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing T2 - Journal of Glaucoma TI - Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51631172&from=export http://dx.doi.org/10.1097/IJG.0b013e31822e622f VL - 22 ID - 3041 ER - TY - JOUR AB - Of the various undesired side effects associated with antidepressants, minor tranquilizers and mood stabilizers commonly used in psychiatry, those affecting the eye and vision are often neglected and largely ignored. This review of published data calls the clinician's attention to the need for a better understanding of such adverse affects to ensure a correct, more rational pharmacotherapy with such agents, as they are also often employed in chronic treatment. Specifically, lesser known and not infrequently rare complications are examined, including mydriasis and tricyclic-antidepressant- induced cycloplegia, which may lead to the onset of acute glaucoma and augment the risk of irreversible severe eye damage, including blindness; the undesired effects of lithium salts are frequently a sign of neurotoxicity; the effects of carbamazepine and especially those caused by topyramate, an anticonvulsant increasingly used in psychiatry because of its therapeutic efficacy in the treatment of bipolar disorders and because of its ability to induce weight loss. The ocular side effects these agents cause may sometimes be so severe that compliance is reduced and health risks are increased. Close collaboration with the oculist and accurate monitoring of the patient's ophthalmic conditions are therefore recommended. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Fornaro, P., Dipartimento di Neuroscienze, Oftalmologia e Genetica, Sezione di Psichiatria, Universita Degli Studi di Geneva, Largo Rosanna Benzi 10, 16132, Genova, Italy AN - 2006-02616-005 AU - Fornaro, P. AU - Venuti, S. AU - Fornaro, M. AU - Sartore, F. AU - Gabrielli, F. DB - psyh DP - EBSCOhost IS - 4 KW - ophthalmological side effects antidepressants anxiolytic agents mood stabilizer agents pharmacotherapy Drug Therapy Eye Disorders Ophthalmology Side Effects (Treatment) Mood Stabilizers Antidepressant Drugs Tranquilizing Drugs N1 - Sezione di Psichiatria, Dipartimento di Neuroscienze, Oftalmologia e Genetica, Università Degli Studi di Genova, Genova, Italy. Release Date: 20060619. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: ItalianMajor Descriptor: Drug Therapy; Eye Disorders; Ophthalmology; Side Effects (Treatment); Mood Stabilizers. Minor Descriptor: Antidepressant Drugs; Tranquilizing Drugs. Classification: Clinical Psychopharmacology (3340). Population: Human (10). Methodology: Literature Review. References Available: Y. Page Count: 13. Issue Publication Date: Dec, 2005. PY - 2005 SN - 0391-1772 1827-1731 SP - 301-313 ST - Effetti oftalmologici indesiderati dei farmaci antidepressivi, ansiolitici e stabilizzatori del tono dell'umore = Ophthalmological side effects of anti-depressant, anxiolytic and mood stabilizer agents T2 - Minerva Psichiatrica TI - Effetti oftalmologici indesiderati dei farmaci antidepressivi, ansiolitici e stabilizzatori del tono dell'umore = Ophthalmological side effects of anti-depressant, anxiolytic and mood stabilizer agents UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2006-02616-005&site=ehost-live&scope=site VL - 46 ID - 4878 ER - TY - JOUR AB - PURPOSE: To study how many of the patients with treated glaucoma or ocular hypertension go blind during their lifetime and which factors are associated with blindness. PATIENTS: The data on 106 consecutive patients who had died between 1991 and 2002 was retrospectively evaluated. At diagnosis 39 patients had primary open-angle glaucoma, 27 had exfoliation glaucoma, and 40 had ocular hypertension. METHODS: Clinical records and causes of death were reviewed. Visual disability at the last visit before death was evaluated. Outcome measures were visual handicap and blindness based on visual acuity and/or visual fields. RESULTS: At the last visit, 17 patients [16%, 95% confidence interval (CI) 9-23] were visually handicapped. Thirteen patients (14%) were bilaterally blind. Glaucoma was the cause of blindness in one or both eyes in 16 patients (15%, 95% CI 8-22) and in both eyes in 6 patients (6%, 95% CI 1-10). In the analysis of only 1 eye of each patient, the cumulative incidence of glaucoma-caused blindness was 6% (95% CI 2-11) at 5 years, 9% (95% CI 4-15) at 10 years, and 15% (95% CI 9-23) at 15 years. An advanced stage of glaucoma at diagnosis, fluctuation in intraocular pressure during treatment, the presence of exfoliation syndrome, and poor patient compliance increased the occurrence of blindness. Positive family history of glaucoma and vascular causes of death had no effect on visual outcome. CONCLUSIONS: Glaucoma-caused blindness was associated with an advanced stage of glaucoma at diagnosis, fluctuation of intraocular pressure during treatment, the presence of exfoliation syndrome, and poor patient compliance. The risk of going blind from glaucoma in both eyes was 6%. © 2007 Lippincott Williams & Wilkins, Inc. AD - E. Forsman, Västerbackavägen 4, 10120 Täkter, Finland AU - Forsman, E. AU - Kivelä, T. AU - Vesti, E. DB - Embase Medline DO - 10.1097/IJG.0b013e318033500f IS - 3 KW - adult aged article blindness controlled study data analysis pseudoexfoliation female human intraocular hypertension intraocular pressure lifespan major clinical study male open angle glaucoma outcome assessment patient compliance priority journal risk factor visual acuity visual disorder visual field visual impairment LA - English M3 - Article N1 - L46626058 2007-05-01 PY - 2007 SN - 1057-0829 SP - 313-319 ST - Lifetime visual disability in open-angle glaucoma and ocular hypertension T2 - Journal of Glaucoma TI - Lifetime visual disability in open-angle glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46626058&from=export http://dx.doi.org/10.1097/IJG.0b013e318033500f VL - 16 ID - 3526 ER - TY - JOUR AB - PURPOSE: To study how many of the patients with treated glaucoma or ocular hypertension go blind during their lifetime and which factors are associated with blindness. PATIENTS: The data on 106 consecutive patients who had died between 1991 and 2002 was retrospectively evaluated. At diagnosis 39 patients had primary open-angle glaucoma, 27 had exfoliation glaucoma, and 40 had ocular hypertension. METHODS: Clinical records and causes of death were reviewed. Visual disability at the last visit before death was evaluated. Outcome measures were visual handicap and blindness based on visual acuity and/or visual fields. RESULTS: At the last visit, 17 patients [16%, 95% confidence interval (CI) 9-23] were visually handicapped. Thirteen patients (14%) were bilaterally blind. Glaucoma was the cause of blindness in one or both eyes in 16 patients (15%, 95% CI 8-22) and in both eyes in 6 patients (6%, 95% CI 1-10). In the analysis of only 1 eye of each patient, the cumulative incidence of glaucoma-caused blindness was 6% (95% CI 2-11) at 5 years, 9% (95% CI 4-15) at 10 years, and 15% (95% CI 9-23) at 15 years. An advanced stage of glaucoma at diagnosis, fluctuation in intraocular pressure during treatment, the presence of exfoliation syndrome, and poor patient compliance increased the occurrence of blindness. Positive family history of glaucoma and vascular causes of death had no effect on visual outcome. CONCLUSIONS: Glaucoma-caused blindness was associated with an advanced stage of glaucoma at diagnosis, fluctuation of intraocular pressure during treatment, the presence of exfoliation syndrome, and poor patient compliance. The risk of going blind from glaucoma in both eyes was 6%. © 2007 Lippincott Williams & Wilkins, Inc. AD - Population Genetics Unit, Folkhälsan Institute of Genetics, Helsinki, Finland Department of Ophthalmology, University of Helsinki, Helsinki, Finland Västerbackavägen 4, 10120 Täkter, Finland AU - Forsman, E. AU - Kivelä, T. AU - Vesti, E. DB - Scopus DO - 10.1097/IJG.0b013e318033500f IS - 3 KW - Blindness Exfoliation glaucoma Ocular hypertension Primary open-angle glaucoma Visual disability M3 - Article N1 - Cited By :61 Export Date: 19 July 2021 PY - 2007 SP - 313-319 ST - Lifetime visual disability in open-angle glaucoma and ocular hypertension T2 - Journal of Glaucoma TI - Lifetime visual disability in open-angle glaucoma and ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247235167&doi=10.1097%2fIJG.0b013e318033500f&partnerID=40&md5=c58c8bf36ddc0822b7c1327d5e9f7c4c VL - 16 ID - 4971 ER - TY - JOUR AB - Purpose: To study how many of the patients with treated glaucoma or ocular hypertension go blind during their lifetime and which factors are associated with blindness. Patients: The data on 106 consecutive patients who had died between 1991 and 2002 was retrospectively evaluated. At diagnosis 39 patients had primary open-angle glaucoma, 27 had exfoliation glaucoma, and 40 had ocular hypertension. Methods: Clinical records and causes of death were reviewed. Visual disability at the last visit before death was evaluated. Outcome measures were visual handicap and blindness based on visual acuity and/or visual fields. Results: At the last visit, 17 patients [16%, 95% confidence interval (CI) 9-23] were visually handicapped. Thirteen patients (14%) were bilaterally blind. Glaucoma was the cause of blindness in one or both eyes in 16 patients (15%, 95% CI 8-22) and in both eyes in 6 patients (6%, 95% CI 1-10). In the analysis of only I eye of each patient, the cumulative incidence of glaucoma-caused blindness was 6% (95% CI 2-11) at 5 years, 9% (95% CI 4-15) at 10 years, and 15% (95% CI 9-23) at 15 years. An advanced stage of glaucoma at diagnosis, fluctuation in intraocular pressure during treatment, the presence of exfoliation syndrome, and poor patient compliance increased the occurrence of blindness. Positive family history of glaucoma and vascular causes of death had no effect on visual outcome. Conclusions: Glaucoma-caused blindness was associated with an advanced stage of glaucoma at diagnosis, fluctuation of intraocular pressure during treatment, the presence of exfoliation syndrome, and poor patient compliance. The risk of going blind from glaucoma in both eyes was 6%. AN - WOS:000246194400008 AU - Forsman, E. AU - Kivela, T. AU - Vesti, E. DA - MAY DO - 10.1097/IJG.0b013e318033500f IS - 3 PY - 2007 SN - 1057-0829 SP - 313-319 ST - Lifetime visual disability in open-angle glaucoma and ocular hypertension T2 - JOURNAL OF GLAUCOMA TI - Lifetime visual disability in open-angle glaucoma and ocular hypertension VL - 16 ID - 5954 ER - TY - JOUR AB - Background: A patient's perception of how their glaucoma is managed will influence both adherence to their medication and outcome measures such as quality of life.Methods: Prospective consecutive study using a Glaucoma Patient-reported Outcome and Experience Measure (POEM) modified for an Australian ophthalmic private clinical practice setting. The Australian Glaucoma POEM consists of eight items related to the patient's understanding of the diagnosis and management, acceptability of the treatment, whether they feel their glaucoma is getting worse, interfering with their daily life and concerns regarding loss of vision as well as addressing whether they feel safe under the care of their glaucoma team and how well their care is organised.Results: Two hundred and two patients (M:F 91:111) participated in the study. Mean ± standard deviation for subject age was 69 ± 13 years. Patient's overall perception of their treatment and outcome was favourable. Younger patients felt their glaucoma interfered more with their daily lives and were more worried about losing vision from glaucoma. The greater the number of medications in use, the more they felt their glaucoma was getting worse and that glaucoma interfered with their daily lives. With all other variables accounted for by the multivariate linear model, female patients more strongly agreed that they understood their glaucoma diagnosis and glaucoma management. The patients with a severe visual defect in their worse eye, reported a greater perceived understanding of their glaucoma diagnosis and management and that they felt that glaucoma had a greater interference on their daily life. They were also more concerned about losing vision from glaucoma than their fellow glaucoma patients with less severe or no visual field deficit in the worse eye.Conclusions: The modified POEM demonstrates potential to capture the concerns of a practice's glaucoma cohort with a view to enhancing the quality of glaucoma care delivered. AD - City Eye Centre, 10/135 Wickham Terrace, 4000, Brisbane, Queensland, Australia University of Queensland, Brisbane, Queensland, Australia Queensland University of Technology, Brisbane, Australia Cambridge University Hospitals, Cambridge, UK University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK Institute of Ophthalmology, University College London, London, UK Centre for Health & Social Care Improvement, University of Wolverhampton, Wolverhampton, UK AN - 138199409. Language: English. Entry Date: In Process. Revision Date: 20191001. Publication Type: Journal Article. Journal Subset: Biomedical AU - Fraenkel, Alison AU - Lee, Graham A. AU - Vincent, Stephen J. AU - Vincent, Roslyn A. AU - Bourne, Rupert R. A. AU - Shah, Peter DB - ccm DO - 10.1186/s12886-019-1198-7 DP - EBSCOhost IS - 1 KW - Visual Fields -- Physiology Intraocular Pressure -- Physiology Quality of Health Care Visual Acuity Glaucoma -- Therapy Quality of Life Glaucoma -- Physiopathology Glaucoma -- Epidemiology Female Prospective Studies Aged Morbidity -- Trends Young Adult Aged, 80 and Over Middle Age Male Activities of Daily Living Cross Sectional Studies Adult Queensland Ferrans and Powers Quality of Life Index Scales N1 - Europe; UK & Ireland. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Perceived Stress Scale (PSS) (Cohen et al); Longitudinal Interval Follow-Up Evaluation (LIFE); Ferrans and Powers Quality of Life Index. NLM UID: 100967802. PMID: NLM31438884. PY - 2019 SN - 1471-2415 SP - N.PAG-N.PAG ST - Lessons learned from the development and implementation of a patient-reported outcome and experience measure (POEM) in an Australian glaucoma practice T2 - BMC Ophthalmology TI - Lessons learned from the development and implementation of a patient-reported outcome and experience measure (POEM) in an Australian glaucoma practice UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138199409&site=ehost-live&scope=site VL - 19 ID - 4348 ER - TY - JOUR AD - B. A. Francis AU - Francis, B. A. AU - Winarko, J. DB - Embase Medline DO - 10.1097/IIO.0b013e31821e53c8 IS - 3 KW - epinephrine apraclonidine brimonidine carbonate dehydratase inhibitor collagen fiber interleukin 1 interleukin 1alpha interleukin 1beta interleukin 8 matrix metalloproteinase pilocarpine timolol timolol maleate tumor necrosis factor aqueous humor outflow argon laser trabeculoplasty article cell division cell membrane permeability cell population clinical effectiveness closed angle glaucoma DNA replication electromagnetic radiation endothelium cell extracellular matrix follow up gene expression human intraocular pressure intraocular pressure abnormality low tension glaucoma micropulse laser trabeculoplasty open angle glaucoma outcome assessment patient compliance patient positioning postoperative complication priority journal randomized controlled trial (topic) Schlemm canal selective laser trabeculoplasty tissue injury tissue reaction titanium sapphire laser trabeculoplasty trabecular meshwork trabeculoplasty treatment indication United States upregulation SOLX 790 laser LA - English M3 - Article N1 - L361902955 2011-06-15 2011-06-17 PY - 2011 SN - 0020-8167 1536-9617 SP - 165-177 ST - Laser trabeculoplasty in the treatment of open-angle glaucoma T2 - International Ophthalmology Clinics TI - Laser trabeculoplasty in the treatment of open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361902955&from=export http://dx.doi.org/10.1097/IIO.0b013e31821e53c8 VL - 51 ID - 3167 ER - TY - JOUR AU - Francis, B. A. AU - Winarko, J. DB - Scopus DO - 10.1097/IIO.0b013e31821e53c8 IS - 3 M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2011 SP - 165-177 ST - Laser trabeculoplasty in the treatment of open-angle glaucoma T2 - International Ophthalmology Clinics TI - Laser trabeculoplasty in the treatment of open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958099815&doi=10.1097%2fIIO.0b013e31821e53c8&partnerID=40&md5=c16967fa64d4e2322f4f6fd07bd50652 VL - 51 ID - 5637 ER - TY - JOUR AB - BACKGROUND: Children and patients with developmental delay frequently resist the procedure of tonometry. Intraocular pressure (IOP) readings, if obtained under stressful circumstances, may have questionable reliability because IOP is influenced by numerous factors characteristic of the uncooperative patient. These factors include possible increases in arterial blood pressure, intraocular vascular engorgement, and pressure on the globe. A study of the effect upon IOP of these factors occurring simultaneously has not been reported previously. METHODS: We measured IOP using the Tono-Pen on 40 cooperative adults under normal conditions and again under conditions simulating the resistant patient. RESULTS: Paired t-test revealed a statistically significant difference between IOP readings under the two conditions (p < 0.001), with IOP under "resistant" conditions showing more variability and averaging 6mmHg higher than under normal conditions. CONCLUSIONS: We conclude that IOP readings in resistant patients should be viewed with caution. The possibility of obtaining false high readings in these patients could lead to unnecessary glaucoma evaluations if based only on elevated IOP readings. AD - K.A. Frantz, Illinois College of Optometry, Chicago 60616. AU - Frantz, K. A. AU - Peters, R. J. AU - Maino, D. M. AU - Gunderson, G. G. DB - Medline IS - 10 KW - adult article female human intraocular pressure male oculoplethysmography patient compliance physiology reproducibility standard Valsalva maneuver LA - English M3 - Article N1 - L125006528 1995-01-19 PY - 1994 SN - 0003-0244 SP - 732-736 ST - Effect of resisting tonometry on intraocular pressure T2 - Journal of the American Optometric Association TI - Effect of resisting tonometry on intraocular pressure UR - https://www.embase.com/search/results?subaction=viewrecord&id=L125006528&from=export VL - 65 ID - 3993 ER - TY - JOUR AB - The goal of this study was to assess the adherence of primary open-angle glaucoma (POAG) patients to medication, and to determine co-factors influencing adherence, using a representative sample of members of the largest German public health insurer. The observational cohort study was based on a longitudinal data set from 2010–2013 and included 250,000 insured persons aged 50 and older with 10,120 diagnosed POAG patients. Uni- and multivariate analysis was performed to investigate several aspects of glaucoma, such as prevalence, adherence, and co-factors influencing adherence. The main outcome measured adherence with prescriptions filled within a year. Multivariate panel regression analysis was used to determine the co-factors influencing this adherence. Prevalence of POAG was 3.36% [CI: 3.28–3.43%], with 2.91% [CI: 2.81–3.01%] for males and 3.71% [CI: 3.61–3.81%] for females, increasing with age. The mean level of adherence in terms of prescriptions filled was 66.5% [CI: 65.50–67.60%]. The results of this analysis revealed a significant influence of age, duration of the disease, care need, distance to death, and multimorbidity as co-factors of non-adherence, whereas gender had no influence. The analysis provided detailed information about POAG health care aspects concerning prevalence and adherence. The most endangered risk groups for non-adherence were patients aged 50–59, patients older than 80 years, patients with a longer duration of POAG, patients with care needs, and patients with three or more severe diseases in addition to glaucoma. To know the predictors responsible for an increased risk to develop POAG is of importance for all persons involved in health care management. Therefore effective strategies to increase awareness of patients and medical care personnel about non-adherence and the importance of a regular and continuous medication to avoid further nerve fiber damage and possible blindness have to be developed. AD - S. Frech, Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany AU - Frech, S. AU - Kreft, D. AU - Guthoff, R. F. AU - Doblhammer, G. DB - Embase Medline DO - 10.1371/journal.pone.0191185 IS - 1 KW - antiglaucoma agent adult aged aging article cohort analysis death disease duration female health care need high risk population human major clinical study male medication compliance multiple chronic conditions multivariate analysis observational study open angle glaucoma outcome assessment patient compliance prescription prevalence risk factor sex difference very elderly LA - English M3 - Article N1 - L620181515 2018-01-19 2018-01-23 PY - 2018 SN - 1932-6203 ST - Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients—An observational cohort study T2 - PLoS ONE TI - Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients—An observational cohort study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620181515&from=export http://dx.doi.org/10.1371/journal.pone.0191185 VL - 13 ID - 2610 ER - TY - JOUR AB - Significance: We propose an alternative method for eye drop self-administration. Similar IOP reductions were found with this method compared with clinician instillation. The alternative method of self-administration potentially benefits patients who have trouble successfully instilling drops.Purpose: The purpose of this study was to validate the efficacy of an alternative method of drop instillation.Methods: This study is a randomized controlled crossover clinical trial. Thirty participants were recruited. A drop of 0.5% timolol maleate was instilled into subject's eye on two separate visits. On one visit, eye drop instillation was by a trained clinician, and on the other, self-instillation using an alternative method was used. The order was randomly chosen. Intraocular pressure was measured before drop instillation and 2 hours after drop instillation. The investigator was masked during measurement, and an observer recorded the IOP measurements.Results: Mean ± SD IOP measurement before 0.5% timolol maleate instillation measured 13.89 ± 2.29 mmHg. An average reduction 3.75 ± 2.36 mmHg was found with clinician administration, and an average reduction of 3.32 ± 2.31 mmHg was recorded with the new method. No significance was found in IOP reduction between two groups P < .45. Percent reduction was 25.17 ± 16.21% and 24.38 ± 16.31% in clinician instillation and alternative instillation method group, respectively. No significant difference was found. This percentage reduction was similar to previously reported studies. No reported cases of eye infection or irritation were found in any case, within a 3-month follow-up period.Conclusions: We have proposed a more reliable method for instillation that provides a larger area for instillation and lessen the risk of contamination and patient's fear for eye drops. Similar efficacy was found compared with that of having a clinician directly administer the drop. This alternative method could potentially benefit patients who require topical eye drop therapy and result in increased compliance. AD - Massachusetts College of Pharmacy and Health Sciences University, Boston, Massachusetts School of Optometry and Vision Science, University of Waterloo, Waterloo, Ontario, Canada AN - 145250163. Language: English. Entry Date: 20210619. Revision Date: 20210715. Publication Type: journal article AU - Freddo, Thomas F. AU - Ho, Derek Y. AU - Steenbakkers, Michelle AU - Furtado, Nadine DB - ccm DO - 10.1097/OPX.0000000000001535 DP - EBSCOhost IS - 7 KW - Antihypertensive Agents -- Administration and Dosage Intraocular Pressure -- Drug Effects Ocular Hypertension -- Drug Therapy Administration, Intraocular Timolol -- Administration and Dosage Crossover Design Ophthalmic Solutions -- Administration and Dosage Tonometry Double-Blind Studies Human Adult Reproducibility of Results Young Adult Female Middle Age Self Administration Male Comparative Studies Multicenter Studies Evaluation Research Validation Studies Scales N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). NLM UID: 8904931. PMID: NLM32697556. PY - 2020 SN - 1040-5488 SP - 496-502 ST - Validation of a More Reliable Method of Eye Drop Self-Administration T2 - Optometry & Vision Science TI - Validation of a More Reliable Method of Eye Drop Self-Administration UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145250163&site=ehost-live&scope=site VL - 97 ID - 4215 ER - TY - JOUR AB - SIGNIFICANCE We propose an alternative method for eye drop self-administration. Similar IOP reductions were found with this method compared with clinician instillation. The alternative method of self-administration potentially benefits patients who have trouble successfully instilling drops. PURPOSE The purpose of this study was to validate the efficacy of an alternative method of drop instillation. METHODS This study is a randomized controlled crossover clinical trial. Thirty participants were recruited. A drop of 0.5% timolol maleate was instilled into subject's eye on two separate visits. On one visit, eye drop instillation was by a trained clinician, and on the other, self-instillation using an alternative method was used. The order was randomly chosen. Intraocular pressure was measured before drop instillation and 2 hours after drop instillation. The investigator was masked during measurement, and an observer recorded the IOP measurements. RESULTS Mean ± SD IOP measurement before 0.5% timolol maleate instillation measured 13.89 ± 2.29 mmHg. An average reduction 3.75 ± 2.36 mmHg was found with clinician administration, and an average reduction of 3.32 ± 2.31 mmHg was recorded with the new method. No significance was found in IOP reduction between two groups P <.45. Percent reduction was 25.17 ± 16.21% and 24.38 ± 16.31% in clinician instillation and alternative instillation method group, respectively. No significant difference was found. This percentage reduction was similar to previously reported studies. No reported cases of eye infection or irritation were found in any case, within a 3-month follow-up period. CONCLUSIONS We have proposed a more reliable method for instillation that provides a larger area for instillation and lessen the risk of contamination and patient's fear for eye drops. Similar efficacy was found compared with that of having a clinician directly administer the drop. This alternative method could potentially benefit patients who require topical eye drop therapy and result in increased compliance. © Lippincott Williams & Wilkins. AD - Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, United States School of Optometry and Vision Science, University of Waterloo, Waterloo, ON, Canada AU - Freddo, T. F. AU - Ho, D. Y. AU - Steenbakkers, M. AU - Furtado, N. DB - Scopus DO - 10.1097/OPX.0000000000001535 IS - 7 M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 496-502 ST - Validation of a more reliable method of eye drop self-administration T2 - Optometry and Vision Science TI - Validation of a more reliable method of eye drop self-administration UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088473648&doi=10.1097%2fOPX.0000000000001535&partnerID=40&md5=5945bdbb4a84629ca27d97386204187e VL - 97 ID - 5694 ER - TY - JOUR AB - SIGNIFICANCE We propose an alternative method for eye drop self-administration. Similar IOP reductions were found with this method compared with clinician instillation. The alternative method of self-administration potentially benefits patients who have trouble successfully instilling drops. PURPOSE The purpose of this study was to validate the efficacy of an alternative method of drop instillation. METHODS This study is a randomized controlled crossover clinical trial. Thirty participants were recruited. A drop of 0.5% timolol maleate was instilled into subject's eye on two separate visits. On one visit, eye drop instillation was by a trained clinician, and on the other, self-instillation using an alternative method was used. The order was randomly chosen. Intraocular pressure was measured before drop instillation and 2 hours after drop instillation. The investigator was masked during measurement, and an observer recorded the IOP measurements. RESULTS Mean +/- SD IOP measurement before 0.5% timolol maleate instillation measured 13.89 +/- 2.29 mmHg. An average reduction 3.75 +/- 2.36 mmHg was found with clinician administration, and an average reduction of 3.32 +/- 2.31 mmHg was recorded with the new method. No significance was found in IOP reduction between two groups P < .45. Percent reduction was 25.17 +/- 16.21% and 24.38 +/- 16.31% in clinician instillation and alternative instillation method group, respectively. No significant difference was found. This percentage reduction was similar to previously reported studies. No reported cases of eye infection or irritation were found in any case, within a 3-month follow-up period. CONCLUSIONS We have proposed a more reliable method for instillation that provides a larger area for instillation and lessen the risk of contamination and patient's fear for eye drops. Similar efficacy was found compared with that of having a clinician directly administer the drop. This alternative method could potentially benefit patients who require topical eye drop therapy and result in increased compliance. AN - WOS:000584685400007 AU - Freddo, T. F. AU - Ho, D. Y. AU - Steenbakkers, M. AU - Furtado, N. DA - JUL DO - 10.1097/OPX.0000000000001535 IS - 7 PY - 2020 SN - 1040-5488 1538-9235 SP - 496-502 ST - Validation of a More Reliable Method of Eye Drop Self-Administration T2 - OPTOMETRY AND VISION SCIENCE TI - Validation of a More Reliable Method of Eye Drop Self-Administration VL - 97 ID - 6247 ER - TY - JOUR AB - Objective: To assess glaucoma medication adherence in children, hypothesizing that poor parental health literacy and eye drop instillation by the child are associated with worse adherence. Methods: This prospective, observational study enrolled pediatric patients with glaucoma who were prescribed eye drops. Parent(s) reported who was responsible for eye drop instillation (parent vs child), took the Rapid Estimate of Adult Literacy in Medicine, and were instructed on the use and purpose of the Medication Event Monitoring System. Calculations included average adherence (proportion of prescribed doses taken), dosing errors (number of overdosing or underdosing events in 24 hours), and proportion of doses taken on schedule (doses taken within2 hours of prescribed dosing interval). Results are reported as mean (SD) or median. Results: The study included 46 of the 50 enrolled children who used the Medication Event Monitoring System for 30 days or more. Adherence ranged from 43% to 107% (93%[12%]) and was not associated with age (slope, 0.09 [0.52]; P=.86) but decreased with the parent's lower health literacy (slope, 0.62 [0.24]; P=.01).The mean number of dosing errors for medications prescribed daily vs twice daily was similar (3.3 vs 2.9; P=.66). The proportion of doses taken on schedule (within2hours of prescribed dosing interval) ranged from 3% to 97% (median, 34%; mean, 41%[24%]) and was better when the parent vs the child instilled eye drops (46% [26%] vs 23% [19%]; P <.001). Conclusions: Time-dependent glaucoma medication adherence was better when the parent was responsible for eye drop instillation. Overall decreased adherence was associated with decreased parental health literacy. Children of parents with poor health literacy are vulnerable to poor medication adherence; efforts to address poor health literacy may improve outcomes. ©2012 American Medical Association. All rights reserved. AD - K.W. Muir, Duke University Medical Center, PO Box 3802, Durham, NC 27710, United States AU - Freedman, R. B. AU - Jones, S. K. AU - Lin, A. AU - Robin, A. L. AU - Muir, K. W. DB - Embase Medline DO - 10.1001/archopthalmol.2011.1788 IS - 3 KW - antiglaucoma agent adolescent article child clinical article drug dose regimen drug instillation drug monitoring drug overdose female glaucoma health literacy human male medication error observational study parental behavior patient compliance preschool child prescription priority journal prospective study Rapid Estimate of Adult Literacy in Medicine Scale school child screening test treatment outcome LA - English M3 - Article N1 - L364463849 2012-03-27 2012-03-29 PY - 2012 SN - 0003-9950 1538-3601 SP - 303-311 ST - Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherence T2 - Archives of Ophthalmology TI - Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364463849&from=export http://dx.doi.org/10.1001/archopthalmol.2011.1788 http://archopht.ama-assn.org/cgi/reprint/130/3/306 VL - 130 ID - 3105 ER - TY - JOUR AD - Duke Eye Center, Durham, North Carolina, USA. AN - 104503445. Language: English. Entry Date: 20120914. Revision Date: 20150711. Publication Type: Journal Article AU - Freedman, R. B. AU - Jones, S. K. AU - Lin, A. AU - Robin, A. L. AU - Muir, K. W. DB - ccm DP - EBSCOhost IS - 3 KW - Glaucoma -- Drug Therapy Information Literacy Medication Compliance Ophthalmic Solutions -- Administration and Dosage Parents -- Education Health Literacy Adolescence Adult Child Child, Preschool Clinical Assessment Tools Drug Monitoring -- Statistics and Numerical Data Female Human Male Medication Errors -- Prevention and Control Medication Errors -- Statistics and Numerical Data Prospective Studies Surveys N1 - research. Journal Subset: Biomedical; USA. Instrumentation: Rapid Estimate of Adult Literacy in Medicine (REALM). NLM UID: 7706534. PMID: NLM22411659. PY - 2012 SN - 0003-9950 SP - 306-311 ST - Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherence T2 - Archives of Ophthalmology TI - Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104503445&site=ehost-live&scope=site VL - 130 ID - 4442 ER - TY - JOUR AD - D.S. Friedman AU - Friedman, D. S. DB - Medline DO - 10.1016/j.ophtha.2009.06.026 IS - 11 Suppl KW - antihypertensive agent eye drops blindness editorial glaucoma human patient compliance topical drug administration LA - English M3 - Editorial N1 - L355507625 2009-11-04 PY - 2009 SN - 1549-4713 SP - S29 ST - Introduction: new insights on enhancing adherence to topical glaucoma medications T2 - Ophthalmology TI - Introduction: new insights on enhancing adherence to topical glaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355507625&from=export http://dx.doi.org/10.1016/j.ophtha.2009.06.026 VL - 116 ID - 3397 ER - TY - JOUR AD - Wilmer Eye Institute, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287, United States AU - Friedman, D. S. AU - Cramer, J. AU - Quigley, H. DB - Scopus DO - 10.1001/archopht.123.8.1134 IS - 8 M3 - Editorial N1 - Cited By :12 Export Date: 19 July 2021 PY - 2005 SP - 1134-1135 ST - A more proactive approach is needed in glaucoma care T2 - Archives of Ophthalmology TI - A more proactive approach is needed in glaucoma care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-23844552415&doi=10.1001%2farchopht.123.8.1134&partnerID=40&md5=3cab8c0d2b1df0097c25bd9e7854b4c0 VL - 123 ID - 5243 ER - TY - JOUR AB - Objective: To use multiple data sources to determine drivers of patient adherence to topical ocular hypotensive therapy. Design: Retrospective database and chart reviews in combination with prospective patient surveys. Diverse medical environments where insured patients in the research database seek care. Participants: Three hundred patients with a new claim diagnosis for open-angle glaucoma who initially were prescribed one of three prostaglandins and 103 physicians participating in the same medical plans. Methods: A structured interview addressing self-reported adherence, experiences with medication, communication with the physician, and health-related beliefs associated with adherence behavior was administered to surveyed patients. Phone interviews were conducted with participating ophthalmologists. Main Outcome Measure: Of adherence, medication possession ratio. Results: Eight variables were associated independently with a lower medication possession ratio: (1) hearing all of what you know about glaucoma from your doctor (compared with some or nothing); (2) not believing that reduced vision is a risk of not taking medication as recommended; (3) having a problem paying for medications; (4) difficulty while traveling or away from home; (5) not acknowledging stinging and burning; (6) being nonwhite; (7) receiving samples; and (8) not receiving a phone call visit reminder. The multivariate model explained 21% of the variance. Conclusions: These findings indicate that doctor-patient communications and health-related beliefs of patients contribute to patient adherence. Patient learning styles that are associated with less concern about the future effects of glaucoma and the risks of not taking medications are associated with lower adherence. Specifically, knowledge about potential vision loss from glaucoma is a critical element that tends to be missed by more passive doctor-dependent patients who tend to be poorly adherent. These findings suggest that educational efforts in the office may improve patient adherence to medical therapies. © 2008 American Academy of Ophthalmology. AD - D.S. Friedman, Wilmer Eye Institute, Baltimore, MD, United States AU - Friedman, D. S. AU - Hahn, S. R. AU - Gelb, L. AU - Tan, J. AU - Shah, S. N. AU - Kim, E. E. AU - Zimmerman, T. J. AU - Quigley, H. A. DB - Embase Medline DO - 10.1016/j.ophtha.2007.11.023 IS - 8 KW - prostaglandin timolol adult article burn comparative study controlled study data base doctor patient relationship education environment female health behavior home human hyperemia interpersonal communication knowledge learning style major clinical study male medical record review medical research multivariate analysis open angle glaucoma ophthalmology patient compliance physician planning prescription priority journal prospective study retrospective study risk sample structured interview travel vision visual impairment LA - English M3 - Article N1 - L50081783 2008-09-02 PY - 2008 SN - 0161-6420 SP - 1320-1327.e3 ST - Doctor-Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma. Results from the Glaucoma Adherence and Persistency Study T2 - Ophthalmology TI - Doctor-Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma. Results from the Glaucoma Adherence and Persistency Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50081783&from=export http://dx.doi.org/10.1016/j.ophtha.2007.11.023 VL - 115 ID - 3437 ER - TY - JOUR AB - Objective: To use multiple data sources to determine drivers of patient adherence to topical ocular hypotensive therapy. Design: Retrospective database and chart reviews in combination with prospective patient surveys. Diverse medical environments where insured patients in the research database seek care. Participants: Three hundred patients with a new claim diagnosis for open-angle glaucoma who initially were prescribed one of three prostaglandins and 103 physicians participating in the same medical plans. Methods: A structured interview addressing self-reported adherence, experiences with medication, communication with the physician, and health-related beliefs associated with adherence behavior was administered to surveyed patients. Phone interviews were conducted with participating ophthalmologists. Main Outcome Measure: Of adherence, medication possession ratio. Results: Eight variables were associated independently with a lower medication possession ratio: (1) hearing all of what you know about glaucoma from your doctor (compared with some or nothing); (2) not believing that reduced vision is a risk of not taking medication as recommended; (3) having a problem paying for medications; (4) difficulty while traveling or away from home; (5) not acknowledging stinging and burning; (6) being nonwhite; (7) receiving samples; and (8) not receiving a phone call visit reminder. The multivariate model explained 21% of the variance. Conclusions: These findings indicate that doctor-patient communications and health-related beliefs of patients contribute to patient adherence. Patient learning styles that are associated with less concern about the future effects of glaucoma and the risks of not taking medications are associated with lower adherence. Specifically, knowledge about potential vision loss from glaucoma is a critical element that tends to be missed by more passive doctor-dependent patients who tend to be poorly adherent. These findings suggest that educational efforts in the office may improve patient adherence to medical therapies. © 2008 American Academy of Ophthalmology. AD - Wilmer Eye Institute, Baltimore, MD, United States Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Departments of Medicine and Psychiatry, Albert Einstein College of Medicine, Bronx, NY, United States Medintel On-Call, Pleasantville, NY, United States HealthCore, Inc., Wilmington, DE, United States Pfizer Inc, New York, NY, United States Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, KY, United States AU - Friedman, D. S. AU - Hahn, S. R. AU - Gelb, L. AU - Tan, J. AU - Shah, S. N. AU - Kim, E. E. AU - Zimmerman, T. J. AU - Quigley, H. A. DB - Scopus DO - 10.1016/j.ophtha.2007.11.023 IS - 8 M3 - Article N1 - Cited By :183 Export Date: 19 July 2021 PY - 2008 SP - 1320-1327.e3 ST - Doctor-Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma. Results from the Glaucoma Adherence and Persistency Study T2 - Ophthalmology TI - Doctor-Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma. Results from the Glaucoma Adherence and Persistency Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-48149084617&doi=10.1016%2fj.ophtha.2007.11.023&partnerID=40&md5=855e543b24a3f9f15bdb90e5f16506eb VL - 115 ID - 4910 ER - TY - JOUR AB - Objective: To use multiple data sources to determine drivers of patient adherence to topical ocular hypotensive therapy. Design: Retrospective database and chart reviews in combination with prospective patient surveys. Diverse medical environments where insured patients in the research database seek care. Participants: Three hundred patients with a new claim diagnosis for open-angle glaucoma who initially were prescribed one of three prostaglandins and 103 physicians participating in the same medical plans. Methods: A structured interview addressing self-reported adherence, experiences with medication, communication with the physician, and health-related beliefs associated with adherence behavior was administered to surveyed patients. Phone interviews were conducted with participating ophthalmologists. Main Outcome Measure: Of adherence, medication possession ratio. Results: Eight variables were associated independently with a lower medication possession ratio: (1) hearing all of what you know about glaucoma from your doctor (compared with some or nothing); (2) not believing that reduced vision is a risk of not taking medication as recommended; (3) having a problem paying for medications; (4) difficulty while traveling or away from home; (5) not acknowledging stinging and burning; (6) being nonwhite; (7) receiving samples; and (8) not receiving a phone call visit reminder. The multivariate model explained 21% of the variance. Conclusions: These findings indicate that doctor-patient communications and health-related beliefs of patients contribute to patient adherence. Patient learning styles that are associated with less concern about the future effects of glaucoma and the risks of not taking medications are associated with lower adherence. Specifically, knowledge about potential vision loss from glaucoma is a critical element that tends to be missed by more passive doctor-dependent patients who tend to be poorly adherent. These findings suggest that educational efforts in the office may improve patient adherence to medical therapies. AN - WOS:000258237300010 AU - Friedman, D. S. AU - Hahn, S. R. AU - Gelb, L. AU - Tan, J. AU - Shah, S. N. AU - Kim, E. E. AU - Zimmerman, T. J. AU - Quigley, H. A. DA - AUG DO - 10.1016/j.ophtha.2007.11.023 IS - 8 PY - 2008 SN - 0161-6420 1549-4713 SP - 1320-1327 ST - Doctor-patient communication, health-related beliefs, and adherence in glaucoma T2 - OPHTHALMOLOGY TI - Doctor-patient communication, health-related beliefs, and adherence in glaucoma VL - 115 ID - 6144 ER - TY - JOUR AB - Purpose: To assess doctor-patient communication in patients with glaucoma. Design: Observational cohort study. Participants: Twenty-three ophthalmologists and 50 patients with glaucoma. Methods: Doctor-patient encounters were audio- and videotaped and analyzed using validated sociolinguistic approaches. After the visit, the doctor and the patient completed questionnaires, and patients were interviewed using a semistructured, patient-centered protocol. Main Outcome Measures: Summary statistics about doctor-patient encounters, assessment of alignment of attitudes between patients and doctors, and patient admission to missing doses. Results: Physicians spent an average of 8.0 (standard deviation [SD], 3.1; median, 7.8) minutes in the room with the patient and an average of 5.8 (SD, 2.4; median, 7.5) minutes talking with the patient, delivering 70% of all spoken words and asking two thirds of all questions. Glaucoma-related discussion occupied 50% of talk time and was focused primarily on examinations and treatment (25%). One third of discussions addressed ocular issues other than glaucoma. Virtually all physician questions (94%) were closed ended. Most patient questions were about intraocular pressure (20% of visits), details of the medication regimen (20%), disease status (14%), and testing (12%). Although physicians and patients were aligned in believing that the physician should control the visit agenda, physicians tended to support greater physician control of decision making than did patients. Physicians failed to identify most patients who admitted to missing doses, a surrogate for nonadherence, stating that 10 of 13 in this category were taking drops "all" or "most" of the time. Physician interviews detected 3 of the 11 patients whose postvisit questionnaire indicated missing a dose in the last week compared with 11 of the 11 detected by the postvisit research interview. Patients who stated they had missed doses recently reported being less satisfied with the doctor-patient encounter than those who did not. Conclusions: Doctor-patient dialogue was universally physician centered; physicians spoke 70% of the words and asked closed-ended questions that restricted the patient's contribution to "yes/no" or brief responses. A minority of physicians ever asked patients if they had questions. In contrast with the patient-centered research interview, doctors' physician-centered communication failed to identify most patients who had missed doses. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2009 American Academy of Ophthalmology. AD - D.S. Friedman, Wilmer Eye Institute, Baltimore, MD, United States AU - Friedman, D. S. AU - Hahn, S. R. AU - Quigley, H. A. AU - Kotak, S. AU - Kim, E. AU - Onofrey, M. AU - Eagan, C. AU - Mardekian, J. DB - Embase Medline DO - 10.1016/j.ophtha.2009.04.052 IS - 12 KW - antiglaucoma agent adult aged article clinical article clinical practice cohort analysis doctor patient relationship female glaucoma human male normal human observational study patient compliance priority journal treatment refusal LA - English M3 - Article N1 - L50635564 2009-12-30 PY - 2009 SN - 0161-6420 SP - 2277-2285.e3 ST - Doctor-Patient Communication in Glaucoma Care. Analysis of Videotaped Encounters in Community-Based Office Practice T2 - Ophthalmology TI - Doctor-Patient Communication in Glaucoma Care. Analysis of Videotaped Encounters in Community-Based Office Practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50635564&from=export http://dx.doi.org/10.1016/j.ophtha.2009.04.052 VL - 116 ID - 3309 ER - TY - JOUR AB - Purpose: To assess doctor-patient communication in patients with glaucoma. Design: Observational cohort study. Participants: Twenty-three ophthalmologists and 50 patients with glaucoma. Methods: Doctor-patient encounters were audio- and videotaped and analyzed using validated sociolinguistic approaches. After the visit, the doctor and the patient completed questionnaires, and patients were interviewed using a semistructured, patient-centered protocol. Main Outcome Measures: Summary statistics about doctor-patient encounters, assessment of alignment of attitudes between patients and doctors, and patient admission to missing doses. Results: Physicians spent an average of 8.0 (standard deviation [SD], 3.1; median, 7.8) minutes in the room with the patient and an average of 5.8 (SD, 2.4; median, 7.5) minutes talking with the patient, delivering 70% of all spoken words and asking two thirds of all questions. Glaucoma-related discussion occupied 50% of talk time and was focused primarily on examinations and treatment (25%). One third of discussions addressed ocular issues other than glaucoma. Virtually all physician questions (94%) were closed ended. Most patient questions were about intraocular pressure (20% of visits), details of the medication regimen (20%), disease status (14%), and testing (12%). Although physicians and patients were aligned in believing that the physician should control the visit agenda, physicians tended to support greater physician control of decision making than did patients. Physicians failed to identify most patients who admitted to missing doses, a surrogate for nonadherence, stating that 10 of 13 in this category were taking drops "all" or "most" of the time. Physician interviews detected 3 of the 11 patients whose postvisit questionnaire indicated missing a dose in the last week compared with 11 of the 11 detected by the postvisit research interview. Patients who stated they had missed doses recently reported being less satisfied with the doctor-patient encounter than those who did not. Conclusions: Doctor-patient dialogue was universally physician centered; physicians spoke 70% of the words and asked closed-ended questions that restricted the patient's contribution to "yes/no" or brief responses. A minority of physicians ever asked patients if they had questions. In contrast with the patient-centered research interview, doctors' physician-centered communication failed to identify most patients who had missed doses. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2009 American Academy of Ophthalmology. AD - Wilmer Eye Institute, Baltimore, MD, United States Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Albert Einstein College of Medicine, The Bronx, NY, United States Medintel On-Call, Pleasantville, NY, United States Pfizer Ophthalmics, New York, NY, United States MBS, VOX, Parsippany, NJ, United States AU - Friedman, D. S. AU - Hahn, S. R. AU - Quigley, H. A. AU - Kotak, S. AU - Kim, E. AU - Onofrey, M. AU - Eagan, C. AU - Mardekian, J. DB - Scopus DO - 10.1016/j.ophtha.2009.04.052 IS - 12 M3 - Article N1 - Cited By :29 Export Date: 19 July 2021 PY - 2009 SP - 2277-2285.e3 ST - Doctor-Patient Communication in Glaucoma Care. Analysis of Videotaped Encounters in Community-Based Office Practice T2 - Ophthalmology TI - Doctor-Patient Communication in Glaucoma Care. Analysis of Videotaped Encounters in Community-Based Office Practice UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70649085935&doi=10.1016%2fj.ophtha.2009.04.052&partnerID=40&md5=a76f00da0ff25b698a0e43b7ef53ba90 VL - 116 ID - 5065 ER - TY - JOUR AB - Purpose: To assess doctor-patient communication in patients with glaucoma. Design: Observational cohort study. Participants: Twenty-three ophthalmologists and 50 patients with glaucoma. Methods: Doctor-patient encounters were audio- and videotaped and analyzed using validated sociolinguistic approaches. After the visit, the doctor and the patient completed questionnaires, and patients were interviewed using a semistructured, patient-centered protocol. Main Outcome Measures: Summary statistics about doctor-patient encounters, assessment of alignment of attitudes between patients and doctors, and patient admission to missing doses. Results: Physicians spent an average of 8.0 (standard deviation [SD], 3.1; median, 7.8) minutes in the room with the patient and an average of 5.8 (SD, 2.4; median, 7.5) minutes talking with the patient, delivering 70% of all spoken words and asking two thirds of all questions. Glaucoma-related discussion occupied 50% of talk time and was focused primarily on examinations and treatment (25%). One third of discussions addressed ocular issues other than glaucoma. Virtually all physician questions (94%) were closed ended. Most patient questions were about intraocular pressure (20% of visits), details of the medication regimen (20%), disease status (14%), and testing (12%). Although physicians and patients were aligned in believing that the physician should control the visit agenda, physicians tended to support greater physician control of decision making than did patients. Physicians failed to identify most patients who admitted to missing doses, a surrogate for nonadherence, stating that 10 of 13 in this category were taking drops "all" or "most" of the time. Physician interviews detected 3 of the 11 patients whose postvisit questionnaire indicated missing a dose in the last week compared with 11 of the 11 detected by the postvisit research interview. Patients who stated they had missed doses recently reported being less satisfied with the doctor-patient encounter than those who did not. Conclusions: Doctor-patient dialogue was universally physician centered; physicians spoke 70% of the words and asked closed-ended questions that restricted the patient's contribution to "yes/no" or brief responses. A minority of physicians ever asked patients if they had questions. In contrast with the patient-centered research interview, doctors' physician-centered communication failed to identify most patients who had missed doses. AN - WOS:000272579200003 AU - Friedman, D. S. AU - Hahn, S. R. AU - Quigley, H. A. AU - Kotak, S. AU - Kim, E. AU - Onofrey, M. AU - Eagan, C. AU - Mardekian, J. DA - DEC DO - 10.1016/j.ophtha.2009.04.052 IS - 12 PY - 2009 SN - 0161-6420 SP - 2277-2285 ST - Doctor-Patient Communication in Glaucoma Care Analysis of Videotaped Encounters in Community-Based Office Practice T2 - OPHTHALMOLOGY TI - Doctor-Patient Communication in Glaucoma Care Analysis of Videotaped Encounters in Community-Based Office Practice VL - 116 ID - 6179 ER - TY - JOUR AB - Purpose: To identify risk factors for poor adherence to topical once daily therapy for glaucoma. Design: Prospective, observational cohort study. Participants: A total of 196 patients with glaucoma who were being treated with a prostaglandin analog in 1 or more eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. Methods: Demographics, ocular history, and responses to interview questions about glaucoma knowledge, health beliefs, and drop-taking behaviors were obtained from each patient. All patients used the Travatan Dosing Aid (DA; Alcon Laboratories Inc., Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months, and the data of drop use were downloaded using software provided with the DA. Patients taking ≤75% doses during the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit were compared with those taking >75% of doses. Main Outcome Measures: Risk factors for poor adherence. Results: Eighty-seven patients (44.4% of the 196 subjects with evaluable data at 3 months) used the DA on 75% or less of the monitored days. In univariate analysis, poorer adherers were more likely to be <50 or ≥80 years of age, to be African American, to report less than excellent health, to report higher amounts of depression, to have lower income, and to be treated at the Scheie Eye Institute. Multivariate analysis (adjusting for education and income) found that age, race/ethnicity, and less than excellent health were associated with poor adherence. Conclusions: Those who failed to take more than 75% of eyedrop doses were more likely to be African American and to report poor health. Those in the youngest and oldest age groups were less adherent, although this finding was not always statistically significant. Further research into the factors driving these associations and into developing predictive models to assist in screening for low adherence are warranted. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2009 American Academy of Ophthalmology. AD - D.S. Friedman, Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States AU - Friedman, D. S. AU - Okeke, C. O. AU - Jampel, H. D. AU - Ying, G. s AU - Plyler, R. J. AU - Jiang, Y. AU - Quigley, H. A. DB - Embase Medline DO - 10.1016/j.ophtha.2009.01.021 IS - 6 KW - travoprost adult African American aged article software controlled study depression dosing aid electronics female follow up glaucoma health belief human lowest income group major clinical study male patient compliance priority journal LA - English M3 - Article N1 - L50491504 2009-06-18 PY - 2009 SN - 0161-6420 SP - 1097-1105 ST - Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma T2 - Ophthalmology TI - Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50491504&from=export http://dx.doi.org/10.1016/j.ophtha.2009.01.021 VL - 116 ID - 3354 ER - TY - JOUR AB - Purpose: To identify risk factors for poor adherence to topical once daily therapy for glaucoma. Design: Prospective, observational cohort study. Participants: A total of 196 patients with glaucoma who were being treated with a prostaglandin analog in 1 or more eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. Methods: Demographics, ocular history, and responses to interview questions about glaucoma knowledge, health beliefs, and drop-taking behaviors were obtained from each patient. All patients used the Travatan Dosing Aid (DA; Alcon Laboratories Inc., Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months, and the data of drop use were downloaded using software provided with the DA. Patients taking ≤75% doses during the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit were compared with those taking >75% of doses. Main Outcome Measures: Risk factors for poor adherence. Results: Eighty-seven patients (44.4% of the 196 subjects with evaluable data at 3 months) used the DA on 75% or less of the monitored days. In univariate analysis, poorer adherers were more likely to be <50 or ≥80 years of age, to be African American, to report less than excellent health, to report higher amounts of depression, to have lower income, and to be treated at the Scheie Eye Institute. Multivariate analysis (adjusting for education and income) found that age, race/ethnicity, and less than excellent health were associated with poor adherence. Conclusions: Those who failed to take more than 75% of eyedrop doses were more likely to be African American and to report poor health. Those in the youngest and oldest age groups were less adherent, although this finding was not always statistically significant. Further research into the factors driving these associations and into developing predictive models to assist in screening for low adherence are warranted. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2009 American Academy of Ophthalmology. AD - Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States Department of Preventive Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China AU - Friedman, D. S. AU - Okeke, C. O. AU - Jampel, H. D. AU - Ying, G. s AU - Plyler, R. J. AU - Jiang, Y. AU - Quigley, H. A. DB - Scopus DO - 10.1016/j.ophtha.2009.01.021 IS - 6 M3 - Article N1 - Cited By :120 Export Date: 19 July 2021 PY - 2009 SP - 1097-1105 ST - Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma T2 - Ophthalmology TI - Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67349227964&doi=10.1016%2fj.ophtha.2009.01.021&partnerID=40&md5=c4f18e14203c931c2a0789c413eed9b2 VL - 116 ID - 4921 ER - TY - JOUR AB - Purpose: To identify risk factors for poor adherence to topical once daily therapy for glaucoma. Design: Prospective, observational cohort study. Participants: A total of 196 patients with glaucoma who were being treated with a prostaglandin analog in 1 or more eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. Methods: Demographics, ocular history, and responses to interview questions about glaucoma knowledge, health beliefs, and drop-taking behaviors were obtained from each patient. All patients used the Travatan Dosing Aid (DA; Alcon Laboratories Inc., Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months, and the data of drop use were downloaded using software provided with the DA. Patients taking <= 75% doses during the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit were compared with those taking >75% of doses. Main Outcome Measures: Risk factors for poor adherence. Results: Eighty-seven patients (44.4% of the 196 subjects with evaluable data at 3 months) used the DA on 75% or less of the monitored days. In univariate analysis, poorer adherers were more likely to be <50 or a >= 80 years of age, to be African American, to report less than excellent health, to report higher amounts of depression, to have lower income, and to be treated at the Scheie Eye Institute. Multivariate analysis (adjusting for education and income) found that age, race/ethnicity, and less than excellent health were associated with poor adherence. Conclusions: Those who failed to take more than 75% of eyedrop doses were more likely to be African American and to report poor health. Those in the youngest and oldest age groups were less adherent, although this finding was not always statistically significant. Further research into the factors driving these associations and into developing predictive models to assist in screening for low adherence are warranted. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009; 116:1097-1105 (C) 2009 by the American Academy of Ophthalmology. AN - WOS:000266906500011 AU - Friedman, D. S. AU - Okeke, C. O. AU - Jampel, H. D. AU - Ying, G. S. AU - Plyler, R. J. AU - Jiang, Y. Z. AU - Quigley, H. A. DA - JUN DO - 10.1016/j.ophtha.2009.01.021 IS - 6 PY - 2009 SN - 0161-6420 1549-4713 SP - 1097-1105 ST - Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma T2 - OPHTHALMOLOGY TI - Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma VL - 116 ID - 6098 ER - TY - JOUR AB - PURPOSE. To develop methods for investigating adherence to glaucoma medications by using a modified claims data-based measure of adherence, validation by chart review, and patient and physician interviews. METHODS. Data from administrative claims of 13,956 subjects receiving an initial glaucoma medication, and data from overlapping samples of 300 patients' charts, 300 interviews of patients, and 103 interviews of physicians were analyzed and compared. RESULTS. The mean medication possession ratio (MPR) was 0.64 (median 0.57) for the 13,956 subjects. Although 59% potentially had an ocular hypotensive agent at 12 months, only 10% had such medication available continuously. Chart review revealed that 31% of subjects "new to therapy" in claims data had actually been previously treated; and that 90% of the 17% who had medication added to initial monotherapy were misclassified by claims-based algorithms as medication switches or no change. Twenty percent of surveyed patients received samples on a regular basis and had lower MPR than those who did not (P < 0.05). CONCLUSIONS. Large pharmacy databases offer insight into medication usage but are vulnerable to errors from sampling (since patients who receive samples will be considered to have poor adherence), misidentification of newly treated patients, and misclassification of added versus switched medications. That a large proportion of patients stop and restart medications makes MPR a robust measure of adherence over time that reflects the resumption of medication after a gap in adherence. The data confirm that adherence to treatment with glaucoma medications is poor, similar to adherence in patients with other chronic diseases. Copyright © Association for Research in Vision and Ophthalmology. AD - D.S. Friedman, Johns Hopkins Hospital, 600 North Wolfe Street, Wilmer 120, Baltimore, MD 21287, United States AU - Friedman, D. S. AU - Quigley, H. A. AU - Gelb, L. AU - Tan, J. AU - Margolis, J. AU - Shah, S. N. AU - Kim, E. E. AU - Zimmerman, T. AU - Hahn, S. R. DB - Embase Medline DO - 10.1167/iovs.07-0290 IS - 11 KW - alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent bimatoprost carbonate dehydratase inhibitor latanoprost prostaglandin timolol travoprost adult aged algorithm article clinical pharmacy data analysis female glaucoma health survey human interview major clinical study male medical record review methodology patient compliance physician priority journal reference database validation study LA - English M3 - Article N1 - L351260915 2008-03-17 PY - 2007 SN - 0146-0404 SP - 5052-5057 ST - Using pharmacy claims data to study adherence to glaucoma medications: Methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS) T2 - Investigative Ophthalmology and Visual Science TI - Using pharmacy claims data to study adherence to glaucoma medications: Methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351260915&from=export http://dx.doi.org/10.1167/iovs.07-0290 VL - 48 ID - 3500 ER - TY - JOUR AB - This paper investigates the patient response to a medical social worker in a glaucoma clinic. The literature suggests that medical social workers are effective in a variety of health care settings, yet the efficacy of a medical social worker in an adult ophthalmic setting has not been studied. We present the results of a retrospective chart review of 50 patients with glaucoma referred to a medical social worker between January 5, 2015 and June 31, 2015 in an outpatient clinic of an urban eye hospital. Clinical and demographic data, as well as the data from a quality of care questionnaire, were collected for each patient. Patients rated their interaction with the medical social worker as highly positive (mean = 4.75, 5-point Likert scale), and nearly 90 % of patients expressed interest in future contact with the social worker. Additionally, most patients reported that the social worker resolved the issues they were facing (61.1 %), supported them in seeing their ophthalmologist (70.6 %), and helped them to manage their glaucoma (69.7 %). Reported barriers to glaucoma care were emotional distress; cost of office visits and medications; lack of medical insurance; transportation; poor medication adherence; impairment of daily activities; follow-up adherence; and language. As vision loss from glaucoma is irreversible, it is important to detect and treat patients at early stages of the disease. Therefore, it is imperative for patients to regularly visit their eye care providers and adhere to treatment and follow-up recommendations. This study suggests that a medical social worker could play a pivotal role in helping patients with glaucoma overcome barriers to treatment and facilitate disease management. AD - Glaucoma Research Center, Wills Eye Hospital, Philadelphia 19107 USA AN - 116527499. Language: English. Entry Date: 20160706. Revision Date: 20190710. Publication Type: Article AU - Fudemberg, Scott AU - Amarasekera, Dilru AU - Silverstein, Marlee AU - Linder, Kathryn AU - Heffner, Paul AU - Hark, Lisa AU - Waisbourd, Michael DB - ccm DO - 10.1007/s10900-016-0162-1 DP - EBSCOhost IS - 4 KW - Eye Care Health Services Accessibility Patient Care Glaucoma -- Prevention and Control Community Health Centers Human Social Workers Medical Practice Glaucoma -- Complications Referral and Consultation Quality of Health Care Middle Age Male Female Race Factors Glaucoma -- Diagnosis Glaucoma -- Classification N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. NLM UID: 7600747. PY - 2016 SN - 0094-5145 SP - 845-849 ST - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service T2 - Journal of Community Health TI - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116527499&site=ehost-live&scope=site VL - 41 ID - 4170 ER - TY - JOUR AB - This paper investigates the patient response to a medical social worker in a glaucoma clinic. The literature suggests that medical social workers are effective in a variety of health care settings, yet the efficacy of a medical social worker in an adult ophthalmic setting has not been studied. We present the results of a retrospective chart review of 50 patients with glaucoma referred to a medical social worker between January 5, 2015 and June 31, 2015 in an outpatient clinic of an urban eye hospital. Clinical and demographic data, as well as the data from a quality of care questionnaire, were collected for each patient. Patients rated their interaction with the medical social worker as highly positive (mean = 4.75, 5-point Likert scale), and nearly 90 % of patients expressed interest in future contact with the social worker. Additionally, most patients reported that the social worker resolved the issues they were facing (61.1 %), supported them in seeing their ophthalmologist (70.6 %), and helped them to manage their glaucoma (69.7 %). Reported barriers to glaucoma care were emotional distress; cost of office visits and medications; lack of medical insurance; transportation; poor medication adherence; impairment of daily activities; follow-up adherence; and language. As vision loss from glaucoma is irreversible, it is important to detect and treat patients at early stages of the disease. Therefore, it is imperative for patients to regularly visit their eye care providers and adhere to treatment and follow-up recommendations. This study suggests that a medical social worker could play a pivotal role in helping patients with glaucoma overcome barriers to treatment and facilitate disease management. AU - Fudemberg, S. J. AU - Amarasekera, D. C. AU - Silverstein, M. H. AU - Linder, K. M. AU - Heffner, P. AU - Hark, L. A. AU - Waisbourd, M. DB - Medline DO - 10.1007/s10900-016-0162-1 IS - 4 KW - aged female glaucoma health care delivery human male middle aged ophthalmology patient attitude social worker statistics and numerical data very elderly LA - English M3 - Article N1 - L620153836 2018-01-12 PY - 2016 SN - 1573-3610 SP - 845-849 ST - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service T2 - Journal of community health TI - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620153836&from=export http://dx.doi.org/10.1007/s10900-016-0162-1 VL - 41 ID - 2722 ER - TY - JOUR AB - This paper investigates the patient response to a medical social worker in a glaucoma clinic. The literature suggests that medical social workers are effective in a variety of health care settings, yet the efficacy of a medical social worker in an adult ophthalmic setting has not been studied. We present the results of a retrospective chart review of 50 patients with glaucoma referred to a medical social worker between January 5, 2015 and June 31, 2015 in an outpatient clinic of an urban eye hospital. Clinical and demographic data, as well as the data from a quality of care questionnaire, were collected for each patient. Patients rated their interaction with the medical social worker as highly positive (mean = 4.75, 5-point Likert scale), and nearly 90 % of patients expressed interest in future contact with the social worker. Additionally, most patients reported that the social worker resolved the issues they were facing (61.1 %), supported them in seeing their ophthalmologist (70.6 %), and helped them to manage their glaucoma (69.7 %). Reported barriers to glaucoma care were emotional distress; cost of office visits and medications; lack of medical insurance; transportation; poor medication adherence; impairment of daily activities; follow-up adherence; and language. As vision loss from glaucoma is irreversible, it is important to detect and treat patients at early stages of the disease. Therefore, it is imperative for patients to regularly visit their eye care providers and adhere to treatment and follow-up recommendations. This study suggests that a medical social worker could play a pivotal role in helping patients with glaucoma overcome barriers to treatment and facilitate disease management. © 2016, Springer Science+Business Media New York. AD - Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA 19107, United States AU - Fudemberg, S. J. AU - Amarasekera, D. C. AU - Silverstein, M. H. AU - Linder, K. M. AU - Heffner, P. AU - Hark, L. A. AU - Waisbourd, M. DB - Scopus DO - 10.1007/s10900-016-0162-1 IS - 4 KW - Barriers to care Glaucoma Medical social work Social worker M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2016 SP - 845-849 ST - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service T2 - Journal of Community Health TI - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957650967&doi=10.1007%2fs10900-016-0162-1&partnerID=40&md5=b9ed7d598c6ad549f63b53af923d16fe VL - 41 ID - 5510 ER - TY - JOUR AB - This paper investigates the patient response to a medical social worker in a glaucoma clinic. The literature suggests that medical social workers are effective in a variety of health care settings, yet the efficacy of a medical social worker in an adult ophthalmic setting has not been studied. We present the results of a retrospective chart review of 50 patients with glaucoma referred to a medical social worker between January 5, 2015 and June 31, 2015 in an outpatient clinic of an urban eye hospital. Clinical and demographic data, as well as the data from a quality of care questionnaire, were collected for each patient. Patients rated their interaction with the medical social worker as highly positive (mean = 4.75, 5-point Likert scale), and nearly 90 % of patients expressed interest in future contact with the social worker. Additionally, most patients reported that the social worker resolved the issues they were facing (61.1 %), supported them in seeing their ophthalmologist (70.6 %), and helped them to manage their glaucoma (69.7 %). Reported barriers to glaucoma care were emotional distress; cost of office visits and medications; lack of medical insurance; transportation; poor medication adherence; impairment of daily activities; follow-up adherence; and language. As vision loss from glaucoma is irreversible, it is important to detect and treat patients at early stages of the disease. Therefore, it is imperative for patients to regularly visit their eye care providers and adhere to treatment and follow-up recommendations. This study suggests that a medical social worker could play a pivotal role in helping patients with glaucoma overcome barriers to treatment and facilitate disease management. AN - WOS:000379163700020 AU - Fudemberg, S. J. AU - Amarasekera, D. C. AU - Silverstein, M. H. AU - Linder, K. M. AU - Heffner, P. AU - Hark, L. A. AU - Waisbourd, M. DA - AUG DO - 10.1007/s10900-016-0162-1 IS - 4 PY - 2016 SN - 0094-5145 1573-3610 SP - 845-849 ST - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service T2 - JOURNAL OF COMMUNITY HEALTH TI - Overcoming Barriers to Eye Care: Patient Response to a Medical Social Worker in a Glaucoma Service VL - 41 ID - 5883 ER - TY - JOUR AB - Purpose: To determine the rate of adherence to follow-up appointment recommendations in a resident glaucoma clinic with no mechanism for reminders, compared to a resident cataract and primary eye care (CPEC) clinic in which telephone reminders were used, and to identify factors that contribute to adherence in each patient group. Methods: This retrospective cohort study included subjects in the CPEC clinic who received telephone reminders and those in the glaucoma clinic who did not. Each sample was selected to have a similar proportion of follow-up recommendations for 1, 3, and 6 months. Subjects were considered adherent if they returned within a specified timeframe. Results: A total of 144 subjects from the glaucoma clinic and 151 subjects from the CPEC clinic were included. There was no significant difference between follow-up adherence rates of patients who received telephone reminders and those who did not (odds ratio [OR] =1.35, 95% confidence interval [CI] 0.79–2.32, P=0.28). Patients who were on more than two ocular medications were more likely to return for follow-up (OR=3.11, 95% CI 1.53–6.35, P=0.0018). Subjects between the ages 50 and 80 years were more likely to be adherent compared to their younger and older peers (P=0.02). Conclusion: The follow-up adherence of patients in a CPEC clinic who received telephone reminders was similar to patients in a glaucoma clinic who did not receive any intervention to increase their adherence. Younger (<50 years old) and elderly (>80 years old) subjects, as well as patients using less than two glaucoma medications, were less likely to adhere to their follow-up appointments. AD - S.J. Fudemberg, Glaucoma Research Center, Wills Eye Hospital, 840 Walnut Street, Suite 1140, Philadelphia, PA, United States AU - Fudemberg, S. J. AU - Lee, B. AU - Waisbourd, M. AU - Murphy, R. A. AU - Dai, Y. AU - Leiby, B. E. AU - Hark, L. A. DB - Embase DO - 10.2147/PPA.S89336 KW - antiglaucoma agent adult age distribution aged article cataract and primary eye care clinic controlled study drug use female follow up glaucoma glaucoma surgery hospital human insurance intraocular pressure major clinical study male optic disk optic disk cup patient attitude resident glaucoma clinic retrospective study telephone urban area very elderly visual acuity visual field LA - English M3 - Article N1 - L607820950 2016-02-02 2016-02-03 PY - 2016 SN - 1177-889X SP - 19-25 ST - Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic T2 - Patient Preference and Adherence TI - Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607820950&from=export http://dx.doi.org/10.2147/PPA.S89336 VL - 10 ID - 2760 ER - TY - JOUR AB - Purpose: To determine the rate of adherence to follow-up appointment recommendations in a resident glaucoma clinic with no mechanism for reminders, compared to a resident cataract and primary eye care (CPEC) clinic in which telephone reminders were used, and to identify factors that contribute to adherence in each patient group. Methods: This retrospective cohort study included subjects in the CPEC clinic who received telephone reminders and those in the glaucoma clinic who did not. Each sample was selected to have a similar proportion of follow-up recommendations for 1, 3, and 6 months. Subjects were considered adherent if they returned within a specified timeframe. Results: A total of 144 subjects from the glaucoma clinic and 151 subjects from the CPEC clinic were included. There was no significant difference between follow-up adherence rates of patients who received telephone reminders and those who did not (odds ratio [OR] =1.35, 95% confidence interval [CI] 0.79–2.32, P=0.28). Patients who were on more than two ocular medications were more likely to return for follow-up (OR=3.11, 95% CI 1.53–6.35, P=0.0018). Subjects between the ages 50 and 80 years were more likely to be adherent compared to their younger and older peers (P=0.02). Conclusion: The follow-up adherence of patients in a CPEC clinic who received telephone reminders was similar to patients in a glaucoma clinic who did not receive any intervention to increase their adherence. Younger (<50 years old) and elderly (>80 years old) subjects, as well as patients using less than two glaucoma medications, were less likely to adhere to their follow-up appointments. © 2016 Fudemberg et al. AD - Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, United States Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, United States AU - Fudemberg, S. J. AU - Lee, B. AU - Waisbourd, M. AU - Murphy, R. A. AU - Dai, Y. AU - Leiby, B. E. AU - Hark, L. A. DB - Scopus DO - 10.2147/PPA.S89336 KW - Age Glaucoma Medications Patient adherence Retrospective studies Telephone reminders M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2016 SP - 19-25 ST - Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic T2 - Patient Preference and Adherence TI - Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955266014&doi=10.2147%2fPPA.S89336&partnerID=40&md5=4fa8556ebf5bc9005a63fa11976de581 VL - 10 ID - 5248 ER - TY - JOUR AB - Purpose: To determine the rate of adherence to follow-up appointment recommendations in a resident glaucoma clinic with no mechanism for reminders, compared to a resident cataract and primary eye care (CPEC) clinic in which telephone reminders were used, and to identify factors that contribute to adherence in each patient group. Methods: This retrospective cohort study included subjects in the CPEC clinic who received telephone reminders and those in the glaucoma clinic who did not. Each sample was selected to have a similar proportion of follow-up recommendations for 1, 3, and 6 months. Subjects were considered adherent if they returned within a specified timeframe. Results: A total of 144 subjects from the glaucoma clinic and 151 subjects from the CPEC clinic were included. There was no significant difference between follow-up adherence rates of patients who received telephone reminders and those who did not (odds ratio [OR] = 1.35, 95% confidence interval [CI] 0.79-2.32, P=0.28). Patients who were on more than two ocular medications were more likely to return for follow-up (OR=3.11, 95% CI 1.53-6.35, P=0.0018). Subjects between the ages 50 and 80 years were more likely to be adherent compared to their younger and older peers (P=0.02). Conclusion: The follow-up adherence of patients in a CPEC clinic who received telephone reminders was similar to patients in a glaucoma clinic who did not receive any intervention to increase their adherence. Younger (<50 years old) and elderly (>80 years old) subjects, as well as patients using less than two glaucoma medications, were less likely to adhere to their follow-up appointments. AN - WOS:000367710800002 AU - Fudemberg, S. J. AU - Lee, B. AU - Waisbourd, M. AU - Murphy, R. A. AU - Dai, Y. AU - Leiby, B. E. AU - Hark, L. A. DO - 10.2147/PPA.S89336 PY - 2016 SN - 1177-889X SP - 19-25 ST - Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic T2 - PATIENT PREFERENCE AND ADHERENCE TI - Factors contributing to nonadherence to follow-up appointments in a resident glaucoma clinic versus primary eye care clinic VL - 10 ID - 5814 ER - TY - JOUR AB - Purpose: To evaluate changes in intraocular pressure before and after withdrawal of topical medications except latanoprost. Cases and Method: This study involved 7 eyes of 5 patients who had been treated by multiple topical medications including latanoprost. The series comprised primary open-angle glaucoma 4 eyes, secondary glaucoma 2 eyes and capsular glaucoma 1 eye. Tonometry was performed before withdrawal of medications except latanoprost and after 8 weeks following withdrawal. They were followed up for 61.7±6.5 weeks. Results: The intraocular pressure (OP) averaged 16.2 mmHg before withdrawal and 15.4 mmHg after withdrawal. The difference was not significant (p=0.21). Conclusion: Treatment with latanoprost alone was equally effective as multiple medications. Latanoprost monotherapy may lead to improved complicance and less damage to the cornea. AD - Dept. of Ophthalmol. and Vis. Sci., Grad. Sch. of Biomed. Sci., Nagasaki Univ., Nagasaki, Japan Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan AU - Fujikawa, A. AU - Tsuiki, E. AU - Ogawa, T. AU - Kitaoka, T. DB - Scopus IS - 9 M3 - Conference Paper N1 - Export Date: 19 July 2021 PY - 2005 SP - 1567-1569 ST - Intraocular pressure after withdrawal of hypotensive medications except latanoprost T2 - Japanese Journal of Clinical Ophthalmology TI - Intraocular pressure after withdrawal of hypotensive medications except latanoprost UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-26644474962&partnerID=40&md5=452ce687955dc2c5c746777d84290c00 VL - 59 ID - 5775 ER - TY - JOUR AB - SIGNIFICANCE: This study affirms the long-term safety and efficacy of scleral contact lens use in patients with keratoconus. PURPOSE: This study aimed to evaluate the safety and efficacy of contemporary scleral contact lenses in the visual rehabilitation of the keratoconic population. METHODS: A retrospective study of keratoconic subjects examined between 2013 and 2018 was conducted. Subjects were included regardless of age, sex, pre-existing morbidity, or scleral lens design. Only eyes fit successfully with scleral contact lenses for ≥1 year were included. Exclusion criteria were prior corneal surgery, dystrophy, degeneration, and trauma. RESULTS: A total of 157 eyes of 86 subjects met the study criteria. The mean Keratoconus Severity Score at initial fitting was 3.6 ± 1.0. Lenses were gas-permeable and nonfenestrated, with a mean overall diameter of 15.8 ± 0.6 mm and 70.1% toric scleral periphery. Physiological adverse events occurred in 9.6% of eyes, including microbial keratitis (0.6%), phlyctenulosis (0.6%), corneal abrasion (1.3%), contact lens-induced acute red eye (1.3%), corneal infiltrative events (1.3%), pingueculitis (1.3%), and hydrops (3.2%). Lens-related adverse events were documented in 55.4% of eyes. Adverse events related to surface issues included poor wetting in 1.9%, handling in 3.8%, reservoir fogging in 7.0%, lens intolerance in 7.6%, deposit in 8.9%, and broken lenses in 26.1% of eyes. The most common management strategies involved refits (54.0% of interventions), patient reeducation (29.5%), medical treatment (5.5%), surgical referral (6.8%), adjustment to wear time (2.5%), surface treatment (1.2%), and lens replacement (0.6%). Best-corrected distance logMAR visual acuity improved significantly from a mean of 0.50 in spectacles to a mean of 0.08 in scleral lenses (P < .0001). During the study period, 14.6% of eyes lost best-corrected scleral lens visual acuity, all from keratoconus progression. CONCLUSIONS: Consistent with other groups, our study demonstrates excellent safety and efficacy of scleral contact lenses in subjects with keratoconus. AU - Fuller, D. G. AU - Wang, Y. DB - Medline DO - 10.1097/OPX.0000000000001578 IS - 9 KW - adolescent adult contact lens device safety eye refraction female human keratoconus male middle aged pathophysiology patient compliance physiology prosthetic fitting retrospective study sclera treatment outcome visual acuity young adult LA - English M3 - Article N1 - L632884824 2020-09-23 2021-04-26 PY - 2020 SN - 1538-9235 SP - 741-748 ST - Safety and Efficacy of Scleral Lenses for Keratoconus T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Safety and Efficacy of Scleral Lenses for Keratoconus UR - https://www.embase.com/search/results?subaction=viewrecord&id=L632884824&from=export http://dx.doi.org/10.1097/OPX.0000000000001578 VL - 97 ID - 2390 ER - TY - JOUR AB - Significance: This study affirms the long-term safety and efficacy of scleral contact lens use in patients with keratoconus.Purpose: This study aimed to evaluate the safety and efficacy of contemporary scleral contact lenses in the visual rehabilitation of the keratoconic population.Methods: A retrospective study of keratoconic subjects examined between 2013 and 2018 was conducted. Subjects were included regardless of age, sex, pre-existing morbidity, or scleral lens design. Only eyes fit successfully with scleral contact lenses for ≥1 year were included. Exclusion criteria were prior corneal surgery, dystrophy, degeneration, and trauma.Results: A total of 157 eyes of 86 subjects met the study criteria. The mean Keratoconus Severity Score at initial fitting was 3.6 ± 1.0. Lenses were gas-permeable and nonfenestrated, with a mean overall diameter of 15.8 ± 0.6 mm and 70.1% toric scleral periphery. Physiological adverse events occurred in 9.6% of eyes, including microbial keratitis (0.6%), phlyctenulosis (0.6%), corneal abrasion (1.3%), contact lens-induced acute red eye (1.3%), corneal infiltrative events (1.3%), pingueculitis (1.3%), and hydrops (3.2%). Lens-related adverse events were documented in 55.4% of eyes. Adverse events related to surface issues included poor wetting in 1.9%, handling in 3.8%, reservoir fogging in 7.0%, lens intolerance in 7.6%, deposit in 8.9%, and broken lenses in 26.1% of eyes. The most common management strategies involved refits (54.0% of interventions), patient reeducation (29.5%), medical treatment (5.5%), surgical referral (6.8%), adjustment to wear time (2.5%), surface treatment (1.2%), and lens replacement (0.6%). Best-corrected distance logMAR visual acuity improved significantly from a mean of 0.50 in spectacles to a mean of 0.08 in scleral lenses (P < .0001). During the study period, 14.6% of eyes lost best-corrected scleral lens visual acuity, all from keratoconus progression.Conclusions: Consistent with other groups, our study demonstrates excellent safety and efficacy of scleral contact lenses in subjects with keratoconus. AD - Southern College of Optometry, Memphis, Tennessee AN - 146171593. Language: English. Entry Date: In Process. Revision Date: 20210715. Publication Type: journal article. Journal Subset: Biomedical AU - Fuller, Daniel G. AU - Wang, Yueren DB - ccm DO - 10.1097/OPX.0000000000001578 DP - EBSCOhost IS - 9 KW - Corneal Diseases -- Therapy Contact Lenses Sclera Male Refraction, Ocular Prosthetic Fitting Equipment Safety Female Retrospective Design Corneal Diseases -- Physiopathology Visual Acuity -- Physiology Adult Treatment Outcomes Adolescence Middle Age Patient Compliance Young Adult Scales N1 - Peer Reviewed; USA. Instrumentation: Global Assessment Scale (GAS). NLM UID: 8904931. PMID: NLM32932400. PY - 2020 SN - 1040-5488 SP - 741-748 ST - Safety and Efficacy of Scleral Lenses for Keratoconus T2 - Optometry & Vision Science TI - Safety and Efficacy of Scleral Lenses for Keratoconus UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=146171593&site=ehost-live&scope=site VL - 97 ID - 4202 ER - TY - JOUR AB - Précis:This study addresses the paucity of literature examining glaucoma patients' distance from clinic on postoperative follow-up outcomes. Greater distance from clinic was associated with higher likelihood of loss to follow-up and missed appointments.Purpose:To investigate the relationship of patient travel distance and interstate access to glaucoma surgery postoperative follow-up visit attendance.Methods and Participants:Retrospective longitudinal chart review of all noninstitutionalized adult glaucoma patients with initial trabeculectomies or drainage device implantations between April 4, 2014 and December 31, 2018. Patients were stratified into groups on the basis of straight-line distance from residence to University of North Carolina at Chapel Hill's Kittner Eye Center and distance from residence to interstate access. Corrective procedures, visual acuity, appointment cancellations, no-shows, and insurance data were recorded. Means were compared using 2-tailed Student t-test, Pearson χ2, analysis of variance, and multivariate logistical regression determined odds ratios for loss to follow-up.Results:In total, 199 patients met all inclusion criteria. Six-month postoperatively, patients >50 miles from clinic had greater odds of loss to follow-up compared with patients <25 miles (odds ratios, 3.47; 95% confidence interval, 1.24-4.12; P<0.05). Patients >50 miles from clinic had significantly more missed appointments than patients 25 to 50 miles away, and patients <25 miles away (P=0.008). Patients >20 miles from interstate access had greater loss to follow-up than those <10 miles (t(150)=2.05; P<0.05). Mean distance from clinic was 12.59 miles farther for patients lost to follow-up (t(197)3.29; P<0.01). Patients with Medicaid coverage had more missed appointments than those with Medicare plans (t(144)=-2.193; P<0.05).Conclusions:Increased distance from clinic and interstate access are associated with increased missed appointments and loss to follow-up. Glaucoma specialists should consider these factors when choosing surgical interventions requiring frequent postoperative evaluations. AD - D. Fleischman, University of North Carolina at Chapel Hill, 5126 Bioinformatics Building, Chapel Hill, NC, United States AU - Funk, I. T. AU - Strelow, B. A. AU - Klifto, M. R. AU - Knight, O. J. AU - Van Buren, E. AU - Lin, F. C. AU - Fleischman, D. DB - Embase Medline DO - 10.1097/IJG.0000000000001609 IS - 11 KW - adult analysis of variance article controlled study female follow up glaucoma surgery human implantation major clinical study male medicaid medical record review medicare North Carolina postoperative care retrospective study trabeculectomy travel visual acuity LA - English M3 - Article N1 - L633611318 2020-12-11 PY - 2020 SN - 1536-481X 1057-0829 SP - 1056-1064 ST - The Relationship of Travel Distance to Postoperative Follow-up Care on Glaucoma Surgery Outcomes T2 - Journal of Glaucoma TI - The Relationship of Travel Distance to Postoperative Follow-up Care on Glaucoma Surgery Outcomes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633611318&from=export http://dx.doi.org/10.1097/IJG.0000000000001609 VL - 29 ID - 2372 ER - TY - JOUR AB - Précis:This study addresses the paucity of literature examining glaucoma patients' distance from clinic on postoperative follow-up outcomes. Greater distance from clinic was associated with higher likelihood of loss to follow-up and missed appointments.Purpose:To investigate the relationship of patient travel distance and interstate access to glaucoma surgery postoperative follow-up visit attendance.Methods and Participants:Retrospective longitudinal chart review of all noninstitutionalized adult glaucoma patients with initial trabeculectomies or drainage device implantations between April 4, 2014 and December 31, 2018. Patients were stratified into groups on the basis of straight-line distance from residence to University of North Carolina at Chapel Hill's Kittner Eye Center and distance from residence to interstate access. Corrective procedures, visual acuity, appointment cancellations, no-shows, and insurance data were recorded. Means were compared using 2-tailed Student t-test, Pearson χ2, analysis of variance, and multivariate logistical regression determined odds ratios for loss to follow-up.Results:In total, 199 patients met all inclusion criteria. Six-month postoperatively, patients >50 miles from clinic had greater odds of loss to follow-up compared with patients <25 miles (odds ratios, 3.47; 95% confidence interval, 1.24-4.12; P<0.05). Patients >50 miles from clinic had significantly more missed appointments than patients 25 to 50 miles away, and patients <25 miles away (P=0.008). Patients >20 miles from interstate access had greater loss to follow-up than those <10 miles (t(150)=2.05; P<0.05). Mean distance from clinic was 12.59 miles farther for patients lost to follow-up (t(197)3.29; P<0.01). Patients with Medicaid coverage had more missed appointments than those with Medicare plans (t(144)=-2.193; P<0.05).Conclusions:Increased distance from clinic and interstate access are associated with increased missed appointments and loss to follow-up. Glaucoma specialists should consider these factors when choosing surgical interventions requiring frequent postoperative evaluations. © 2020 Wolters Kluwer Health, Inc. All rights reserved. AD - School of Medicine Departments of Ophthalmology Biostatistics and North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States AU - Funk, I. T. AU - Strelow, B. A. AU - Klifto, M. R. AU - Knight, O. J. AU - Van Buren, E. AU - Lin, F. C. AU - Fleischman, D. DB - Scopus DO - 10.1097/IJG.0000000000001609 IS - 11 KW - appointment cancellations loss to follow-up Medicaid Medicare postoperative outcomes proximity to postoperative care travel distance M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - 1056-1064 ST - The Relationship of Travel Distance to Postoperative Follow-up Care on Glaucoma Surgery Outcomes T2 - Journal of Glaucoma TI - The Relationship of Travel Distance to Postoperative Follow-up Care on Glaucoma Surgery Outcomes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095977160&doi=10.1097%2fIJG.0000000000001609&partnerID=40&md5=d98cd40164acc1a0d3a5243d1655d2c5 VL - 29 ID - 5600 ER - TY - JOUR AB - Precis: This study addresses the paucity of literature examining glaucoma patients' distance from clinic on postoperative follow-up outcomes. Greater distance from clinic was associated with higher likelihood of loss to follow-up and missed appointments. Purpose: To investigate the relationship of patient travel distance and interstate access to glaucoma surgery postoperative follow-up visit attendance. Methods and Participants: Retrospective longitudinal chart review of all noninstitutionalized adult glaucoma patients with initial trabeculectomies or drainage device implantations between April 4, 2014 and December 31, 2018. Patients were stratified into groups on the basis of straight-line distance from residence to University of North Carolina at Chapel Hill's Kittner Eye Center and distance from residence to interstate access. Corrective procedures, visual acuity, appointment cancellations, no-shows, and insurance data were recorded. Means were compared using 2-tailed Student t-test, Pearson chi(2), analysis of variance, and multivariate logistical regression determined odds ratios for loss to follow-up. Results: In total, 199 patients met all inclusion criteria. Six-month postoperatively, patients >50 miles from clinic had greater odds of loss to follow-up compared with patients <25 miles (odds ratios, 3.47; 95% confidence interval, 1.24-4.12; P<0.05). Patients >50 miles from clinic had significantly more missed appointments than patients 25 to 50 miles away, and patients <25 miles away (P=0.008). Patients >20 miles from interstate access had greater loss to follow-up than those <10 miles (t((150))=2.05; P<0.05). Mean distance from clinic was 12.59 miles farther for patients lost to follow-up (t((197))=3.29; P<0.01). Patients with Medicaid coverage had more missed appointments than those with Medicare plans (t((144))=-2.193; P<0.05). Conclusions: Increased distance from clinic and interstate access are associated with increased missed appointments and loss to follow-up. Glaucoma specialists should consider these factors when choosing surgical interventions requiring frequent postoperative evaluations. AN - WOS:000591398800011 AU - Funk, I. T. AU - Strelow, B. A. AU - Klifto, M. R. AU - Knight, O. J. AU - Van Buren, E. AU - Lin, F. C. AU - Fleischman, D. DA - NOV DO - 10.1097/IJG.0000000000001609 IS - 11 PY - 2020 SN - 1057-0829 1536-481X SP - 1056-1064 ST - The Relationship of Travel Distance to Postoperative Follow-up Care on Glaucoma Surgery Outcomes T2 - JOURNAL OF GLAUCOMA TI - The Relationship of Travel Distance to Postoperative Follow-up Care on Glaucoma Surgery Outcomes VL - 29 ID - 5820 ER - TY - JOUR AB - Importance: Corneal transplantation restores visual function when visual impairment caused by a corneal disease becomes too severe. It is considered the world's most frequent type of transplantation, but, to our knowledge, there are no exhaustive data allowing measurement of supply and demand, although such data are essential in defining local, national, and global strategies to fight corneal blindness.Objective: To describe the worldwide situation of corneal transplantation supply and demand.Design, Setting, and Participants: Data were collected between August 2012 and August 2013 from a systematic review of published literature in parallel with national and international reports on corneal transplantation and eye banking. In a second step, eye bank staff and/or corneal surgeons were interviewed on their local activities. Interviews were performed during international ophthalmology or eye-banking congresses or by telephone or email. Countries' national supply/demand status was classified using a 7-grade system. Data were collected from 148 countries.Main Outcomes and Measures: Corneal transplantation and corneal procurements per capita in each country.Results: In 2012, we identified 184,576 corneal transplants performed in 116 countries. These were procured from 283,530 corneas and stored in 742 eye banks. The top indications were Fuchs dystrophy (39% of all corneal transplants performed), a primary corneal edema mostly affecting elderly individuals; keratoconus (27%), a corneal disease that slowly deforms the cornea in young people; and sequellae of infectious keratitis (20%). The United States, with 199.10-6 corneal transplants per capita, had the highest transplantation rate, followed by Lebanon (122.10-6) and Canada (117.10-6), while the median of the 116 transplanting countries was 19.10-6. Corneas were procured in only 82 countries. Only the United States and Sri Lanka exported large numbers of donor corneas. About 53% of the world's population had no access to corneal transplantation.Conclusions and Relevance: Our survey globally quantified the considerable shortage of corneal graft tissue, with only 1 cornea available for 70 needed. Efforts to encourage cornea donation must continue in all countries, but it is also essential to develop alternative and/or complementary solutions, such as corneal bioengineering. AD - Ophthalmology Department, University Hospital, Saint-Etienne, France Federative Institute of Research in Sciences and Health Engineering, Corneal Graft Biology, Engineering, and Imaging Laboratory, Faculty of Medicine, Jean Monnet University, Saint-Etienne, France Eye Bank of Saint-Etienne, Auvergne Loire Blood Centre, Saint-Etienne, France Institut Universitaire de France, Paris, France AN - 112951398. Language: English. Entry Date: 20160615. Revision Date: 20190718. Publication Type: journal article AU - Gain, Philippe AU - Jullienne, Rémy AU - Zhiguo, He AU - Aldossary, Mansour AU - Acquart, Sophie AU - Cognasse, Fabrice AU - Thuret, Gilles AU - He, Zhiguo DB - ccm DO - 10.1001/jamaophthalmol.2015.4776 DP - EBSCOhost IS - 2 KW - Corneal Transplantation -- Statistics and Numerical Data Tissue Banks -- Statistics and Numerical Data World Health Organ Procurement -- Statistics and Numerical Data Transplant Donors Cornea Organ Procurement -- Legislation and Jurisprudence Surveys Prayer Corneal Diseases -- Rehabilitation Waiting Lists Systematic Review Human N1 - pictorial; research; systematic review; tables/charts. Journal Subset: Biomedical; USA. Special Interest: Evidence-Based Practice. NLM UID: 101589539. PMID: NLM26633035. PY - 2016 SN - 2168-6165 SP - 167-173 ST - Global Survey of Corneal Transplantation and Eye Banking T2 - JAMA Ophthalmology TI - Global Survey of Corneal Transplantation and Eye Banking UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112951398&site=ehost-live&scope=site VL - 134 ID - 4421 ER - TY - JOUR AB - PURPOSE:: To identify the type and frequency of ocular and orbital complications observed following treatment for primary rhabdomyosarcoma of the paranasal sinuses or the orbit. METHODS:: An institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective chart review was conducted to identify all patients treated at one institution from 1966 to 2005 with biopsy-proven primary paranasal sinus or orbital rhabdomyosarcoma. Pretreatment, treatment, and follow-up data were collected. RESULTS:: Forty-four patients (25 male) of a median age of 7.8 years (range 1.0-18.0 years) with primary paranasal sinus (17) or orbital (27) rhabdomyosarcoma were treated and followed for a median period of 5.3 years (range 0.6-32.0 years). The three most frequently observed ophthalmic complications were persistent eyelid erythema or cellulitis (12), epithelial keratitis (7), and conjunctival injection (6) in the paranasal sinus and epithelial keratitis (18), conjunctival injection (11), and cataract (10) in the orbit. Overall survival after treatment trended higher for the orbital rhabdomyosarcoma group (23 of 27) than the paranasal sinus group (9 of 17). CONCLUSIONS:: The most frequently observed treatment-induced ophthalmic complications in the paranasal sinus group were manageable with minimal patient morbidity, as in the patients with orbital disease. Vision-threatening complications were infrequently encountered. Despite maximal therapy, the mortality rate was higher in the paranasal sinus rhabdomyosarcoma group than in the orbital rhabdomyosarcoma group. © 2011 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc. AD - Hamilton Eye Institute, University of Tennessee, Health Science Center, Memphis, TN, United States Department of Surgery, Division of Ophthalmology and Pathology, St Jude Children's Research Hospital, Memphis, TN, United States AU - Gandhi, P. D. AU - Fleming, J. C. AU - Haik, B. G. AU - Wilson, M. W. DB - Scopus DO - 10.1097/IOP.0b013e318203d5e8 IS - 4 M3 - Review N1 - Cited By :6 Export Date: 19 July 2021 PY - 2011 SP - 241-246 ST - Ophthalmic complications following treatment of paranasal sinus rhabdomyosarcoma in comparison to orbital disease T2 - Ophthalmic Plastic and Reconstructive Surgery TI - Ophthalmic complications following treatment of paranasal sinus rhabdomyosarcoma in comparison to orbital disease UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960559671&doi=10.1097%2fIOP.0b013e318203d5e8&partnerID=40&md5=f1aa3d5ada729fbfd188c231412e2606 VL - 27 ID - 5392 ER - TY - JOUR AB - Purpose: To identify the type and frequency of ocular and orbital complications observed following treatment for primary rhabdomyosarcoma of the paranasal sinuses or the orbit. Methods: An institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective chart review was conducted to identify all patients treated at one institution from 1966 to 2005 with biopsy-proven primary paranasal sinus or orbital rhabdomyosarcoma. Pretreatment, treatment, and follow-up data were collected. Results: Forty-four patients (25 male) of a median age of 7.8 years (range 1.0-18.0 years) with primary paranasal sinus (17) or orbital (27) rhabdomyosarcoma were treated and followed for a median period of 5.3 years (range 0.6-32.0 years). The three most frequently observed ophthalmic complications were persistent eyelid erythema or cellulitis (12), epithelial keratitis (7), and conjunctival injection (6) in the paranasal sinus and epithelial keratitis (18), conjunctival injection (11), and cataract (10) in the orbit. Overall survival after treatment trended higher for the orbital rhabdomyosarcoma group (23 of 27) than the paranasal sinus group (9 of 17). Conclusions: The most frequently observed treatment-induced ophthalmic complications in the paranasal sinus group were manageable with minimal patient morbidity, as in the patients with orbital disease. Vision-threatening complications were infrequently encountered. Despite maximal therapy, the mortality rate was higher in the paranasal sinus rhabdomyosarcoma group than in the orbital rhabdomyosarcoma group. AN - WOS:000292633700018 AU - Gandhi, P. D. AU - Fleming, J. C. AU - Haik, B. G. AU - Wilson, M. W. DA - JUL-AUG DO - 10.1097/IOP.0b013e318203d5e8 IS - 4 PY - 2011 SN - 0740-9303 1537-2677 SP - 241-246 ST - Ophthalmic Complications Following Treatment of Paranasal Sinus Rhabdomyosarcoma in Comparison to Orbital Disease T2 - OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY TI - Ophthalmic Complications Following Treatment of Paranasal Sinus Rhabdomyosarcoma in Comparison to Orbital Disease VL - 27 ID - 6313 ER - TY - JOUR AB - Purpose: To evaluate the early outcomes of pediatric corneal transplantation in patients with acquired, nontraumatic corneal pathology. Methods: In this retrospective series, the records of children 15 years of age or younger who underwent optical penetrating keratoplasty for acquired nontraumatic corneal pathologies between December 2008 and June 2010 were reviewed. Demographic features, etiology of opacification, visual acuity, and other clinical findings were recorded. Results: Nineteen eyes of 19 children (10 females) were included. Mean age at time of surgery was 9.1 ± 3.01 years (range, 5-15 years). Adherent leukoma secondary to healed infectious keratitis (n = 12, 63%) and keratoconus (n = 7, 37%) were the leading indications for surgery. The mean follow-up period was 10.2 ± 3.3 months (range, 6-18 months). Postoperatively, clear grafts were seen in 15 cases (79%). Graft failure was noted in 4 eyes secondary to allograft rejection (n = 1), graft infection (n = 1), primary graft failure (n = 1), and uncontrolled glaucoma (n = 1). The most common cause of moderate or poor visual outcome was amblyopia (80%). Overall, 13 patients (68%) had postoperative visual acuity better than the preoperative vision. Conclusions: Penetrating keratoplasty can yield good anatomic results in children with acquired, nontraumatic causes of corneal scarring, but amblyopia limits the visual outcomes. Copyright © 2011 Published by Elsevier Inc. on behalf of American Association for Pediatric Ophthalmology and Strabismus. AD - Nayana Super Specialty Eye Hospital, Research Centre, Davangere, India New York Eye and Ear Infirmary, New York, NY, United States Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Hong Kong, Hong Kong Centre for Eye Research Australia, University of Melbourne, Australia AU - Ganekal, S. AU - Gangangouda, C. AU - Dorairaj, S. AU - Jhanji, V. DB - Scopus DO - 10.1016/j.jaapos.2011.05.002 IS - 4 M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2011 SP - 353-355 ST - Early outcomes of primary pediatric keratoplasty in patients with acquired, atraumatic corneal pathology T2 - Journal of AAPOS TI - Early outcomes of primary pediatric keratoplasty in patients with acquired, atraumatic corneal pathology UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052781410&doi=10.1016%2fj.jaapos.2011.05.002&partnerID=40&md5=57ac5fa90db4dc0f9f4bb3d6a7c6f988 VL - 15 ID - 5259 ER - TY - JOUR AB - PURPOSE To evaluate the early outcomes of pediatric corneal transplantation in patients with acquired, nontraumatic corneal pathology. METHODS In this retrospective series, the records of children 15 years of age or younger who underwent optical penetrating keratoplasty for acquired nontraumatic corneal pathologies between December 2008 and June 2010 were reviewed. Demographic features, etiology of opacification, visual acuity, and other clinical findings were recorded. RESULTS Nineteen eyes of 19 children (10 females) were included. Mean age at time of surgery was 9.1 +/- 3.01 years (range, 5-15 years). Adherent leukoma secondary to healed infectious keratitis (n = 12, 63%) and keratoconus (n = 7, 37%) were the leading indications for surgery. The mean follow-up period was 10.2 +/- 3.3 months (range, 6-18 months). Postoperatively, clear grafts were seen in 15 cases (79%). Graft failure was noted in 4 eyes secondary to allograft rejection (n = 1), graft infection (n = 1), primary graft failure (n = 1), and uncontrolled glaucoma (n = 1). The most common cause of moderate or poor visual outcome was amblyopia (80%). Overall, 13 patients (68%) had postoperative visual acuity better than the preoperative vision. CONCLUSIONS Penetrating keratoplasty can yield good anatomic results in children with acquired, nontraumatic causes of corneal scarring, but amblyopia limits the visual outcomes. (J AAPOS 2011; 15:353-355) AN - WOS:000295061200010 AU - Ganekal, S. AU - Gangangouda, C. AU - Dorairaj, S. AU - Jhanji, V. DA - AUG DO - 10.1016/j.jaapos.2011.05.002 IS - 4 PY - 2011 SN - 1091-8531 SP - 353-355 ST - Early outcomes of primary pediatric keratoplasty in patients with acquired, atraumatic corneal pathology T2 - JOURNAL OF AAPOS TI - Early outcomes of primary pediatric keratoplasty in patients with acquired, atraumatic corneal pathology VL - 15 ID - 6246 ER - TY - JOUR AB - PURPOSE:: Tissue adhesives have been used in ophthalmology instead of sutures to minimize the operating time. This case series investigated the effectiveness and safety of use of cyanoacrylate in Ahmed valve implantation through pars plana for refractory glaucoma. PATIENTS AND METHODS:: Seventeen eyes of 17 patients with refractory glaucoma underwent Ahmed valve scleral suture-less implantation through pars plana with a cyanoacrylate suture of the plate. Refractory glaucoma was defined as intraocular pressure (IOP) ≥21 mm Hg with antiglaucoma eye drops, good adherence to treatment, and no previous glaucoma surgery. IOP control and development of complications were evaluated during the follow-up (mean follow-up, 13.23 mo, 6 to 28 mo). RESULTS:: IOP control, defined as IOP≤21 mm Hg with or without antiglaucoma eye drops, was achieved in 82.2% of patients, and 58.8% were able to eliminate antiglaucoma eye drops. Mean surgical time was 9.76±2.60 and 6±0.81 minutes in patients with previous vitrectomy (4 cases). Postoperative complications included transiently increased IOP, transient hyphema, early postoperative hypotony (4 cases), and tube block by the vitreous (2 cases): 1 resolved by Nd:YAG and the other by second vitrectomy. No cases of tube or plate extrusion, plate migration, choroidal or retinal detachment, or vitreous hemorrhage were observed. CONCLUSIONS:: These results are promising and demonstrate a safe and effective alternative to the traditional scleral suture. Our data suggest that Ahmed valve implantation through pars plana with cyanoacrylate is a safe and effective method for refractory glaucoma. Further studies are needed to confirm our observation. Copyright © 2012 by Lippincott Williams & Wilkins. AD - E. Sanz-Marco, Ophthalmology Department, La Fe University Hospital, 21 Campanar Av., 46015 Valencia, Spain AU - García-Delpech, S. AU - Sanz-Marco, E. AU - Martinez-Castillo, S. AU - López-Prats, M. J. AU - Udaondo, P. AU - Salom, D. AU - Díaz-Llopis, M. DB - Embase Medline DO - 10.1097/IJG.0b013e318264ba4d IS - 9 KW - antiglaucoma agent bimatoprost brimonidine cyanoacrylate cyclopentolate prednisolone acetate suture material timolol tissue adhesive tobramycin adult aged Ahmed valve article ciliary disk clinical article drug dose reduction dysesthesia female glaucoma glaucoma drainage implant human hyphema intraocular hypotension intraocular pressure male operation duration patient compliance patient safety postoperative complication priority journal prosthesis complication refractory glaucoma sclera surgical approach surgical technique sutureless implantation trabeculectomy treatment outcome visual acuity vitrectomy LA - English M3 - Article N1 - L370502148 2013-12-26 2014-01-03 PY - 2013 SN - 1536-481X 1057-0829 SP - 750-756 ST - Ahmed valve, suture-less implantation: A new approach to an easier technique T2 - Journal of Glaucoma TI - Ahmed valve, suture-less implantation: A new approach to an easier technique UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370502148&from=export http://dx.doi.org/10.1097/IJG.0b013e318264ba4d VL - 22 ID - 3039 ER - TY - JOUR AB - PURPOSE:: Tissue adhesives have been used in ophthalmology instead of sutures to minimize the operating time. This case series investigated the effectiveness and safety of use of cyanoacrylate in Ahmed valve implantation through pars plana for refractory glaucoma. PATIENTS AND METHODS:: Seventeen eyes of 17 patients with refractory glaucoma underwent Ahmed valve scleral suture-less implantation through pars plana with a cyanoacrylate suture of the plate. Refractory glaucoma was defined as intraocular pressure (IOP) ≥21 mm Hg with antiglaucoma eye drops, good adherence to treatment, and no previous glaucoma surgery. IOP control and development of complications were evaluated during the follow-up (mean follow-up, 13.23 mo, 6 to 28 mo). RESULTS:: IOP control, defined as IOP≤21 mm Hg with or without antiglaucoma eye drops, was achieved in 82.2% of patients, and 58.8% were able to eliminate antiglaucoma eye drops. Mean surgical time was 9.76±2.60 and 6±0.81 minutes in patients with previous vitrectomy (4 cases). Postoperative complications included transiently increased IOP, transient hyphema, early postoperative hypotony (4 cases), and tube block by the vitreous (2 cases): 1 resolved by Nd:YAG and the other by second vitrectomy. No cases of tube or plate extrusion, plate migration, choroidal or retinal detachment, or vitreous hemorrhage were observed. CONCLUSIONS:: These results are promising and demonstrate a safe and effective alternative to the traditional scleral suture. Our data suggest that Ahmed valve implantation through pars plana with cyanoacrylate is a safe and effective method for refractory glaucoma. Further studies are needed to confirm our observation. Copyright © 2012 by Lippincott Williams & Wilkins. AD - Ophthalmology Department, La Fe University Hospital, 21 Campanar Av., 46015 Valencia, Spain Ophthalmology Department, Medicine Faculty, Catholic University of Valencia, Valencia, Spain Ophthalmology Department, Medicine Faculty, University of Valencia, Valencia, Spain Research Center for Rare Diseases (CIBERER), Valencia, Spain AU - García-Delpech, S. AU - Sanz-Marco, E. AU - Martinez-Castillo, S. AU - López-Prats, M. J. AU - Udaondo, P. AU - Salom, D. AU - Díaz-Llopis, M. DB - Scopus DO - 10.1097/IJG.0b013e318264ba4d IS - 9 KW - Ahmed valve cyanoacrylate glaucoma scleral tunnel suture less M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2013 SP - 750-756 ST - Ahmed valve, suture-less implantation: A new approach to an easier technique T2 - Journal of Glaucoma TI - Ahmed valve, suture-less implantation: A new approach to an easier technique UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890514186&doi=10.1097%2fIJG.0b013e318264ba4d&partnerID=40&md5=20f8a110f227cb6745f74bbc1f2693dd VL - 22 ID - 5389 ER - TY - JOUR AB - Purpose:Tissue adhesives have been used in ophthalmology instead of sutures to minimize the operating time. This case series investigated the effectiveness and safety of use of cyanoacrylate in Ahmed valve implantation through pars plana for refractory glaucoma.Patients and Methods:Seventeen eyes of 17 patients with refractory glaucoma underwent Ahmed valve scleral suture-less implantation through pars plana with a cyanoacrylate suture of the plate. Refractory glaucoma was defined as intraocular pressure (IOP) 21 mm Hg with antiglaucoma eye drops, good adherence to treatment, and no previous glaucoma surgery. IOP control and development of complications were evaluated during the follow-up (mean follow-up, 13.23 mo, 6 to 28 mo).Results:IOP control, defined as IOP21 mm Hg with or without antiglaucoma eye drops, was achieved in 82.2% of patients, and 58.8% were able to eliminate antiglaucoma eye drops. Mean surgical time was 9.762.60 and 6 +/- 0.81 minutes in patients with previous vitrectomy (4 cases). Postoperative complications included transiently increased IOP, transient hyphema, early postoperative hypotony (4 cases), and tube block by the vitreous (2 cases): 1 resolved by Nd:YAG and the other by second vitrectomy. No cases of tube or plate extrusion, plate migration, choroidal or retinal detachment, or vitreous hemorrhage were observed.Conclusions:These results are promising and demonstrate a safe and effective alternative to the traditional scleral suture. Our data suggest that Ahmed valve implantation through pars plana with cyanoacrylate is a safe and effective method for refractory glaucoma. Further studies are needed to confirm our observation. AN - WOS:000328455600018 AU - Garcia-Delpech, S. AU - Sanz-Marco, E. AU - Martinez-Castillo, S. AU - Lopez-Prats, M. J. AU - Udaondo, P. AU - Salom, D. AU - Diaz-Llopis, M. DA - DEC DO - 10.1097/IJG.0b013e318264ba4d IS - 9 PY - 2013 SN - 1057-0829 1536-481X SP - 750-756 ST - Ahmed Valve, Suture-less Implantation: A New Approach to an Easier Technique T2 - JOURNAL OF GLAUCOMA TI - Ahmed Valve, Suture-less Implantation: A New Approach to an Easier Technique VL - 22 ID - 6099 ER - TY - JOUR AB - Purpose To evaluate the effect of oral antioxidant supplementation (OAS) on primary open-angle glaucoma (POAG) over a 2-year follow-up period. Patients and methods In this open-label, randomized controlled trial, 117 eyes of 117 patients with mild or moderate POAG and intraocular pressure under control with topical antiglaucoma medications were recruited and randomly divided into three groups according to supplementation: (1) OAS with (ICAPS R® - Alcon Laboratories, n = 26); (2) OAS without ω-3 fatty acids (OFTAN MACULA® - Laboratorios Esteve, n = 28); and (3) a control group without OAS (n = 63). They all underwent visual field (VF) tests (Humphrey 24-2) and scans using a Fourier-domain optical coherence tomography (FD-OCT) device (RTVue-100) at the beginning of the study and 2 years later. Mean deviation (MD), standard pattern deviation (PSD), peripapillary retinal nerve fibre layer (RNFL) and macular ganglion cell complex (GCC) parameters were considered for the analysis. Patients were also classified according to MD deterioration (fast deterioration vs. slow deterioration). Results Visual field global indices, peripapillary RNFL thickness and macular GCC thickness showed no differences among the groups at the beginning and end of the follow-up. Besides all the comparisons among groups for differences before and after the follow-up of the MD, PSD, RNFL and GCC parameters were also non-significant. The proportions of patients according to MD deterioration were similar among the groups and subgroups (p > 0.05 for all the comparisons). Conclusion Oral antioxidant supplementation with or without ω-3 fatty acids does not appear useful as an adjuvant treatment of mild/moderate POAG in the short term. © 2014 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. AD - Department of Ophthalmology, Huercal Overa Hospital, Almeria, Spain Department of Ophthalmology, Reina Sofia University Hospital, Murcia, Spain Department of Ophthalmology and Optometry, School of Medicine, University of Murcia, Murcia, Spain Ophthalmology Research Unit Santiago Grisolia, Valencia, Spain Department of Ophthalmology, Torrecardenas Hospital, Almeria, Spain Head of the Andalusian Ophthalmic Research Group (GIAO), Almería, Spain Eastern Andalusian Biosanitary Research Foundation Alejandro Otero (FIBAO), Torrecardenas Hospital, Almeria, Spain School of Medicine, University of Sevilla, Sevilla, Spain Genetic and Molecular Epidemiology Unit, Department of Preventive Medicine and Public Health, School of Medicine, University of Valencia, Valencia, Spain Department of Ophthalmology, School of Medicine, University of Valencia, Valencia, Spain Department of Ophthalmology, University Hospital Reina Sofia, Avenida Intendente Jorge Palacios, 1, Murcia, 30003, Spain AU - Garcia-Medina, J. J. AU - Garcia-Medina, M. AU - Garrido-Fernandez, P. AU - Galvan-Espinosa, J. AU - Garcia-Maturana, C. AU - Zanon-Moreno, V. AU - Pinazo-Duran, M. D. DB - Scopus DO - 10.1111/aos.12629 IS - 6 KW - antioxidant ganglion cell glaucoma omega-3 fatty acids optical coherence tomography oxidative stress M3 - Conference Paper N1 - Cited By :34 Export Date: 19 July 2021 PY - 2015 SP - 546-554 ST - A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: An open-label, randomized, controlled trial T2 - Acta Ophthalmologica TI - A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: An open-label, randomized, controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84947027357&doi=10.1111%2faos.12629&partnerID=40&md5=b8fcf24fe96117637a798fa6a884cf03 VL - 93 ID - 5039 ER - TY - JOUR AB - Purpose To analyse the role of keratoplasty in reducing world blindness due to corneal diseases. Methods Review of published literature. We collected and analysed articles published in the English language literature related to the prevalence and causes of blindness in different parts of the world, causes of corneal blindness, and outcome of corneal transplantation for various corneal diseases. Results A total of 80% of the world's blind live in developing countries. Retinal diseases are the most important causes of blindness (40-54%) in established economy nations while cataract (44-60%) and corneal diseases (8-25%) are the most common causes of blindness in countries with less developed economies. Keratitis during childhood, trauma, and keratitis during adulthood resulting in a vascularized corneal scar and adherent leucoma are the most frequent causes of corneal blindness in developing countries. Corneal diseases are responsible for 20% of childhood blindness. Nearly 80% of all corneal blindness is avoidable. The outcome of keratoplasty for vascularized corneal scar and adherent leucoma is unsatisfactory, necessitating repeat surgery in a high proportion of these cases. Other barriers for keratoplasty in these nations are suboptimal eye banking, lack of trained human resources, and infrastructure. Conclusions Since the developing world carries most of the load of corneal blindness and the major causes of corneal blindness are corneal scar and active keratitis, development of corneal transplantation services need a comprehensive approach encompassing medical standards in eye banking, training of cornea specialists and eye banking personnel and exposure of ophthalmologists to care of corneal transplants for better follow-up care. However, concerted efforts should be made to develop and implement prevention strategies since most corneal blindness is preventable. AN - WOS:000232469900012 AU - Garg, P. AU - Krishna, P. V. AU - Stratis, A. AU - Gopinathan, U. DA - OCT DO - 10.1038/sj.eye.6701968 IS - 10 PY - 2005 SN - 0950-222X 1476-5454 SP - 1106-1114 ST - The value of corneal transplantation in reducing blindness T2 - EYE TI - The value of corneal transplantation in reducing blindness VL - 19 ID - 6264 ER - TY - JOUR AB - Purpose: To analyse the role of keratoplasty in reducing world blindness due to corneal diseases. Methods: Review of published literature. We collected and analysed articles published in the English language literature related to the prevalence and causes of blindness in different parts of the world, causes of corneal blindness, and outcome of corneal transplantation for various corneal diseases. Results: A total of 80% of the world's blind live in developing countries. Retinal diseases are the most important causes of blindness (40-54%) in established economy nations while cataract (44-60%) and corneal diseases (8-25%) are the most common causes of blindness in countries with less developed economies. Keratitis during childhood, trauma, and keratitis during adulthood resulting in a vascularized corneal scar and adherent leucoma are the most frequent causes of corneal blindness in developing countries. Corneal diseases are responsible for 20% of childhood blindness. Nearly 80% of all corneal blindness is avoidable. The outcome of keratoplasty for vascularized corneal scar and adherent leucoma is unsatisfactory, necessitating repeat surgery in a high proportion of these cases. Other barriers for keratoplasty in these nations are suboptimal eye banking, lack of trained human resources, and infrastructure. Conclusions: Since the developing world carries most of the load of corneal blindness and the major causes of corneal blindness are corneal scar and active keratitis, development of corneal transplantation services need a comprehensive approach encompassing medical standards in eye banking, training of cornea specialists and eye banking personnel and exposure of ophthalmologists to care of corneal transplants for better follow-up care. However, concerted efforts should be made to develop and implement prevention strategies since most corneal blindness is preventable. © 2005 Nature Publishing Group All rigths reserved. AD - Cornea Service, LV Prasad Eye Institute, LV Prasad Marg, Hyderabad 500034, India Dalhousie University, Halifax, NS, Canada Ramayamma International Eye Bank, LV Prasad Eye Institute, LV Prasad Marg, Hyderabad 500034, India AU - Garg, P. AU - Krishna, P. V. AU - Stratis, A. K. AU - Gopinathan, U. DB - Scopus DO - 10.1038/sj.eye.6701968 IS - 10 KW - Blindness Corneal blindness Keratoplasty Survival of corneal grafts M3 - Article N1 - Cited By :77 Export Date: 19 July 2021 PY - 2005 SP - 1106-1114 ST - The value of corneal transplantation in reducing blindness T2 - Eye TI - The value of corneal transplantation in reducing blindness UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-29244483389&doi=10.1038%2fsj.eye.6701968&partnerID=40&md5=5981ad695f4c25e3068f603ff95c3f27 VL - 19 ID - 4949 ER - TY - JOUR AB - Introduction: Corneal ulceration is one of the leading causes of blindness especially in low- and mid-income countries (LMICs). Surgical treatment of microbial keratitis is associated with multiple challenges that include non-availability of donor corneal tissues, lack of trained corneal surgeons, and poor compliance to follow up care. As a result, the surgery fails in 70–90% cases. Therefore, improving outcome of medical treatment and thereby avoiding the need for the surgery is an unmet need in the care of corneal ulcer cases. Areas covered: In this review article, the authors have tried to compile information on the novel drug-delivery systems that have potential to enhance success of medical management. We have discussed the following systems: cyclodextrins, gel formulations, colloidal system, nanoformulations, drug-eluting contact lens, microneedle patch, and ocular inserts. Expert opinion: The goals of corneal ulcer treatment are as follows: rapid eradication of causative microorganisms, control of damage from induced inflammation and microbial toxins, and facilitation of repair. The ocular surface anatomy poses several challenges for drug delivery using standard topical therapy. The novel drug-delivery systems mentioned above aim to enhanced tear solubility; superior stability; improved bio-availability; reduced toxicity; besides facilitating targeted drug delivery and convenience of administration. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. AD - Tej Kohli Cornea Institute, KAR campus, L. V. Prasad Eye Institute, Hyderabad, India Department of Pharmacology, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad, India Tej Kohli Cornea Institute, KVC campus, L. V. Prasad Eye Institute, Vijayawada, India AU - Garg, P. AU - Venuganti, V. V. K. AU - Roy, A. AU - Roy, G. DB - Scopus DO - 10.1080/17425247.2019.1690451 IS - 12 KW - colloidal system Corneal ulcer cyclodextrins drug-eluting contact lens gel formulation microneedle patch nanoformulations ocular inserts M3 - Review N1 - Cited By :6 Export Date: 19 July 2021 PY - 2019 SP - 1381-1391 ST - Novel drug delivery methods for the treatment of keratitis: moving away from surgical intervention T2 - Expert Opinion on Drug Delivery TI - Novel drug delivery methods for the treatment of keratitis: moving away from surgical intervention UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075078855&doi=10.1080%2f17425247.2019.1690451&partnerID=40&md5=9af0d94a0dff49f1b09ee845278faef3 VL - 16 ID - 5369 ER - TY - JOUR AB - Introduction: Corneal ulceration is one of the leading causes of blindness especially in low- and midincome countries (LMICs). Surgical treatment of microbial keratitis is associated with multiple challenges that include non-availability of donor corneal tissues, lack of trained corneal surgeons, and poor compliance to follow up care. As a result, the surgery fails in 70-90% cases. Therefore, improving outcome of medical treatment and thereby avoiding the need for the surgery is an unmet need in the care of corneal ulcer cases. Areas covered: In this review article, the authors have tried to compile information on the novel drugdelivery systems that have potential to enhance success of medical management. We have discussed the following systems: cyclodextrins, gel formulations, colloidal system, nanoformulations, drug-eluting contact lens, microneedle patch, and ocular inserts. Expert opinion: The goals of corneal ulcer treatment are as follows: rapid eradication of causative microorganisms, control of damage from induced inflammation and microbial toxins, and facilitation of repair. The ocular surface anatomy poses several challenges for drug delivery using standard topical therapy. The novel drug-delivery systems mentioned above aim to enhanced tear solubility; superior stability; improved bio-availability; reduced toxicity; besides facilitating targeted drug delivery and convenience of administration. AN - WOS:000496082200001 AU - Garg, P. AU - Venuganti, V. V. K. AU - Roy, A. AU - Roy, G. DO - 10.1080/17425247.2019.1690451 IS - 12 PY - 2019 SN - 1742-5247 1744-7593 SP - 1381-1391 ST - Novel drug delivery methods for the treatment of keratitis: moving away from surgical intervention T2 - EXPERT OPINION ON DRUG DELIVERY TI - Novel drug delivery methods for the treatment of keratitis: moving away from surgical intervention VL - 16 ID - 5809 ER - TY - JOUR AB - Objective: Elevated intraocular pressure (IOP) is a major risk factor for the deterioration of open-angle glaucoma (OAG); medical IOP reduction is the standard treatment, yet no randomized placebo-controlled study of medical IOP reduction has been undertaken previously. The United Kingdom Glaucoma Treatment Study (UKGTS) tests the hypothesis that treatment with a topical prostaglandin analog, compared with placebo, reduces the frequency of visual field (VF) deterioration events in OAG patients by 50% over a 2-year period. Design: The UKGTS is a randomized, double-masked, placebo-controlled, multicenter treatment trial for OAG. Participants: Five hundred sixteen newly diagnosed (previously untreated) patients with OAG were recruited prospectively at 10 centers between 2007 and 2010. Methods: Patients were assigned by concealed telephone allocation to treatment with a prostaglandin analog (latanoprost 0.005%) or placebo. The observation period was 2 years, with subjects monitored by VF testing, quantitative imaging, optic disc photography, and tonometry at 11 visits. Data were acquired according to novel protocols optimized for the analysis of deterioration velocity. The sample size was determined for a 2-sided error of α = 0.05 to detect the difference between 24% and 11% in incident deterioration over a 24-month follow-up at 90% power and assuming a 25% attrition rate. Main Outcome Measures: The primary outcome was time to VF deterioration within 24 months. Secondary outcomes included the deterioration velocity of VF and quantitative imaging measures and the relationship between these velocities and risk factors for deterioration. Results: The study design enabled a short trial with a 2-year observation period and provided data that can be used to assess the feasibility of further shortening trial duration with the progression velocity of VF and structural imaging measurements as outcomes. Conclusions: The UKGTS is the first randomized, placebo-controlled trial to evaluate the efficacy of medical treatment in reducing VF deterioration in OAG. The measurement of deterioration velocity and inclusion of quantitative imaging has the potential to reduce the number of patients and duration required for subsequent clinical trials. This trial also will quantify risk factors for deterioration, enabling more precise risk profiling of patients and the development of patient management protocols. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2013 American Academy of Ophthalmology. AD - D.F. Garway-Heath, NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, 162 City Road, London EC1V 2PD, United Kingdom AU - Garway-Heath, D. F. AU - Lascaratos, G. AU - Bunce, C. AU - Crabb, D. P. AU - Russell, R. A. AU - Shah, A. C2 - Pfizer DB - Embase Medline DO - 10.1016/j.ophtha.2012.07.028 IS - 1 KW - ISRCTN96423140 latanoprost placebo article controlled study disease course double blind procedure drug formulation follow up human imaging system intraocular pressure abnormality major clinical study multicenter study open angle glaucoma patient compliance patient monitoring photography priority journal randomized controlled trial risk factor sample size teleconsultation tonometry treatment outcome treatment planning United Kingdom unspecified side effect visual field LA - English M3 - Article N1 - L52210975 2012-09-18 2013-01-22 PY - 2013 SN - 0161-6420 1549-4713 SP - 68-76 ST - The United Kingdom glaucoma treatment study: A multicenter, randomized, placebo-controlled clinical trial: Design and methodology T2 - Ophthalmology TI - The United Kingdom glaucoma treatment study: A multicenter, randomized, placebo-controlled clinical trial: Design and methodology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52210975&from=export http://dx.doi.org/10.1016/j.ophtha.2012.07.028 VL - 120 ID - 3043 ER - TY - JOUR AB - Objective: Elevated intraocular pressure (IOP) is a major risk factor for the deterioration of open-angle glaucoma (OAG); medical IOP reduction is the standard treatment, yet no randomized placebo-controlled study of medical IOP reduction has been undertaken previously. The United Kingdom Glaucoma Treatment Study (UKGTS) tests the hypothesis that treatment with a topical prostaglandin analog, compared with placebo, reduces the frequency of visual field (VF) deterioration events in OAG patients by 50% over a 2-year period. Design: The UKGTS is a randomized, double-masked, placebo-controlled, multicenter treatment trial for OAG. Participants: Five hundred sixteen newly diagnosed (previously untreated) patients with OAG were recruited prospectively at 10 centers between 2007 and 2010. Methods: Patients were assigned by concealed telephone allocation to treatment with a prostaglandin analog (latanoprost 0.005%) or placebo. The observation period was 2 years, with subjects monitored by VF testing, quantitative imaging, optic disc photography, and tonometry at 11 visits. Data were acquired according to novel protocols optimized for the analysis of deterioration velocity. The sample size was determined for a 2-sided error of α = 0.05 to detect the difference between 24% and 11% in incident deterioration over a 24-month follow-up at 90% power and assuming a 25% attrition rate. Main Outcome Measures: The primary outcome was time to VF deterioration within 24 months. Secondary outcomes included the deterioration velocity of VF and quantitative imaging measures and the relationship between these velocities and risk factors for deterioration. Results: The study design enabled a short trial with a 2-year observation period and provided data that can be used to assess the feasibility of further shortening trial duration with the progression velocity of VF and structural imaging measurements as outcomes. Conclusions: The UKGTS is the first randomized, placebo-controlled trial to evaluate the efficacy of medical treatment in reducing VF deterioration in OAG. The measurement of deterioration velocity and inclusion of quantitative imaging has the potential to reduce the number of patients and duration required for subsequent clinical trials. This trial also will quantify risk factors for deterioration, enabling more precise risk profiling of patients and the development of patient management protocols. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2013 American Academy of Ophthalmology. AD - National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, University College London, London, United Kingdom Department of Optometry and Visual Science, City University London, London, United Kingdom AU - Garway-Heath, D. F. AU - Lascaratos, G. AU - Bunce, C. AU - Crabb, D. P. AU - Russell, R. A. AU - Shah, A. DB - Scopus DO - 10.1016/j.ophtha.2012.07.028 IS - 1 M3 - Article N1 - Cited By :39 Export Date: 19 July 2021 PY - 2013 SP - 68-76 ST - The United Kingdom glaucoma treatment study: A multicenter, randomized, placebo-controlled clinical trial: Design and methodology T2 - Ophthalmology TI - The United Kingdom glaucoma treatment study: A multicenter, randomized, placebo-controlled clinical trial: Design and methodology UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872040270&doi=10.1016%2fj.ophtha.2012.07.028&partnerID=40&md5=98dc3ee59a6f43d07b214ac14893bea3 VL - 120 ID - 5024 ER - TY - JOUR AB - Purpose: To compare use of topical medications between a wireless monitoring device and validated self-reported measures of glaucoma medication adherence. Patients and Methods: This study involved adults from a group ophthalmology practice diagnosed with and being medicinally treated for glaucoma who were not scheduled for a surgery during the study period. Subjects were required to use a new wireless device to dispense their glaucoma medication for 2 months, and were surveyed at baseline and immediately following the study to assess mobile phone use, glaucoma-related self-efficacy, and medication adherence. Results: Complete data (survey and accurate device recordings) were available for 23 subjects at both baseline and endpoint. Median adherence, as measured by the device, was 82% and dropped slightly between 30-day periods, from 83% to 77%. Similarly, the percent adherent (dosing at least 75% of the time) dropped significantly between months according to both the device (78.3% and 52.2%) and a self-reported measure (63% and 56%). Kappa statistics indicated low agreement between the device and self-report when classifying adherent status. A majority of subjects interviewed found the device easy to use, indicated that it did not interfere with medication-taking or normal activities, and were not bothered by their physician knowing when medication was dispensed. Conclusion: In this pilot, nearly all Kali Drop devices performed as expected, providing real-time data on medication use over a 60-day period. Data suggested that self-reported and electronic estimates of glaucoma medication use differ, but additional testing of this new device is needed to corroborate the data observed. AD - J.D. Gatwood, University of Tennessee, Health Science Center, College of Pharmacy, 193 Polk Ave. Suite 2D, Nashville, TN, United States AU - Gatwood, J. D. AU - Johnson, J. AU - Jerkins, B. DB - Embase Medline DO - 10.1097/IJG.0000000000000777 IS - 11 KW - Kali Drop mobile phone monitor antiglaucoma agent aged article clinical article cohort analysis controlled study female glaucoma human intermethod comparison male medication compliance patient compliance pilot study priority journal prospective study self concept self report wireless monitoring device LA - English M3 - Article N1 - L619161671 2017-11-14 2017-11-21 PY - 2017 SN - 1536-481X 1057-0829 SP - 1056-1061 ST - Comparisons of Self-reported Glaucoma Medication Adherence with a New Wireless Device: A Pilot Study T2 - Journal of Glaucoma TI - Comparisons of Self-reported Glaucoma Medication Adherence with a New Wireless Device: A Pilot Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619161671&from=export http://dx.doi.org/10.1097/IJG.0000000000000777 VL - 26 ID - 2686 ER - TY - JOUR AB - Background: Newly diagnosed open-angle glaucoma (OAG) and ocular hypertension (OHT) are habitually treated with intraocular pressure (IOP)-lowering eyedrops. Selective laser trabeculoplasty (SLT) is a safe alternative to drops and is rarely used as first-line treatment. Objectives: To compare health-related quality of life (HRQoL) in newly diagnosed, treatment-naive patients with OAG or OHT, treated with two treatment pathways: topical IOP-lowering medication from the outset (Medicine-1st) or primary SLT followed by topical medications as required (Laser-1st). We also compared the clinical effectiveness and cost-effectiveness of the two pathways. Design: A 36-month pragmatic, unmasked, multicentre randomised controlled trial. Settings: Six collaborating specialist glaucoma clinics across the UK. Participants: Newly diagnosed patients with OAG or OHT in one or both eyes who were aged ≥ 18 years and able to provide informed consent and read and understand English. Patients needed to qualify for treatment, be able to perform a reliable visual field (VF) test and have visual acuity of at least 6 out of 36 in the study eye. Patients with VF loss mean deviation worse than –12 dB in the better eye or –15 dB in the worse eye were excluded. Patients were also excluded if they had congenital, early childhood or secondary glaucoma or ocular comorbidities; if they had any previous ocular surgery except phacoemulsification, at least 1 year prior to recruitment or any active treatment for ophthalmic conditions; if they were pregnant; or if they were unable to use topical medical therapy or had contraindications to SLT. Interventions: SLT according to a predefined protocol compared with IOP-lowering eyedrops, as per national guidelines. Main outcome measures: The primary outcome was HRQoL at 3 years [as measured using the EuroQol-5 Dimensions, five-level version (EQ-5D-5L) questionnaire]. Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness and safety. Results: Of the 718 patients enrolled, 356 were randomised to Laser-1st (initial SLT followed by routine medical treatment) and 362 to Medicine-1st (routine medical treatment only). A total of 652 (91%) patients returned the primary outcome questionnaire at 36 months. The EQ-5D-5L score was not significantly different between the two arms [adjusted mean difference (Laser-1st – Medicine-1st) 0.01, 95% confidence interval (CI) –0.01 to 0.03; p = 0.23] at 36 months. Over 36 months, the proportion of visits at which IOP was within the target range was higher in the Laser-1st arm (93.0%, 95% CI 91.9% to 94.0%) than in the Medicine-1st arm (91.3%, 95% CI 89.9% to 92.5%), with IOP-lowering glaucoma surgery required in 0 and 11 patients, respectively. There was a 97% probability of Laser-1st being more cost-effective than Medicine-1st for the NHS, at a willingness to pay for a quality-adjusted life-year of £20,000, with a reduction in ophthalmology costs of £458 per patient (95% of bootstrap iterations between –£585 and –£345). Limitation: An unmasked design, although a limitation, was essential to capture any treatment effects on patients’ perception. The EQ-5D-5L questionnaire is a generic tool used in multiple settings and may not have been the most sensitive tool to investigate HRQoL. Conclusions: Compared with medication, SLT provided a stable, drop-free IOP control to 74.2% of patients for at least 3 years, with a reduced need for surgery, lower cost and comparable HRQoL. Based on the evidence, SLT seems to be the most cost-effective first-line treatment option for OAG and OHT, also providing better clinical outcomes. Future work: Longitudinal research into the clinical efficacy of SLT as a first-line treatment will specify the long-term differences of disease progression, treatment intensity and ocular surgery rates between the two pathways. © Queen’s Printer and Controller of HMSO 2019. AD - National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom Institute of Ophthalmology, University College London, London, United Kingdom Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London, London, United Kingdom Research Department of Primary Care and Population Health, University College London, London, United Kingdom Department of Statistical Science, University College London, London, United Kingdom School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom London School of Hygiene & Tropical Medicine, London, United Kingdom Department of Applied Health Research, Institute of Epidemiology and Health Care, University College London, London, United Kingdom AU - Gazzard, G. AU - Konstantakopoulou, E. AU - Garway-Heath, D. AU - Garg, A. AU - Vickerstaff, V. AU - Hunter, R. AU - Ambler, G. AU - Bunce, C. AU - Wormald, R. AU - Nathwani, N. AU - Barton, K. AU - Rubin, G. AU - Morris, S. AU - Buszewicz, M. AU - Li, G. H. T. Trial Study Group DB - Scopus DO - 10.3310/hta23310 IS - 31 M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2019 SP - 1-101 ST - Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: The LiGHT RCT T2 - Health Technology Assessment TI - Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: The LiGHT RCT UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069268585&doi=10.3310%2fhta23310&partnerID=40&md5=5885e41f22587abd06201925ba15a0d6 VL - 23 ID - 5298 ER - TY - JOUR AB - Introduction: Anti-inflammatory, topical therapy of severe keratitis in dry eye disease (DED) and ocular graft-versus-host disease (oGvHD) includes steroids, cyclosporine (Cs), and others. In Germany, a commercial product containing 0.1% Cs in a cationic formulation is available since 2015. Objective: The aim of this study was to present real-life data using cationic 0.1% Cs in oGvHD patients. Methods: This was a retrospective study of 26 oGvHD and 41 DED patients with corneal staining of at least Oxford grade III. Parameters analyzed were Ocular Surface Disease Index, corneal staining, intraocular pressure, tear film break-up time, Schirmer, and visual acuity. In addition, it was evaluated how different Cs formulations were tolerated. Results: Corneal staining improved significantly in 1 eye in DED but not in oGvHD. In DED, cationic 0.1% Cs was not tolerated by 32% of the patients, in contrast to 0.05% Cs in castor oil not tolerated by 47% and liposomal 0.05% Cs by 63%. In oGvHD patients, cationic 0.1% Cs was not tolerated by 62%, 0.05% Cs in castor oil by 33%, and liposomal 0.05% Cs by 39% of the patients. Conclusions: This study demonstrates differences between the tolerance of different Cs formulations depending on the underlying cause of severe keratitis. Cationic 0.1% Cs is considerably less tolerated in oGvHD, and its use should be considered with care. AD - P. Steven, Department of Ophthalmology, University of Cologne, Faculty of Medicine, University Hospital Cologne, Cologne, Germany P. Steven, Division of Dry-Eye and Ocular GvHD, University of Cologne, Department of Ophthalmology, University Hospital of Cologne, Kerpener Strasse 62, Cologne, Germany AU - Gehlsen, U. AU - Siebelmann, S. AU - Steven, P. C1 - bepanthen(Bayer) berberil n(Bausch and Lomb) corneregel(Bausch and Lomb) dexa-sine(Novartis) dexapos comod(Ursapharm) floxal(Bausch and Lomb) ikervis(Santen,Germany) monodex(Thea) monoprost(Thea) restasis(Allergan,Ireland) taflotan(Kohl) vexol(Alcon) vitapos(Ursapharm) zadithen ophtha sine(Thea) C2 - Alcon Allergan(Ireland) Bausch and Lomb Bayer Kohl Novartis Santen(Germany) Thea Ursapharm DB - Embase Medline DO - 10.1159/000509034 IS - 1 KW - contact lens punctal plug albumin artificial tear castor oil cationic surfactant cyclosporine dexa-sine dexapos comod dexpanthenol glucocorticoid latanoprost liposome monodex ofloxacin rimexolone tafluprost tetryzoline vitapos zadithen ophtha sine adult aged article burning sensation conjunctiva disease cornea drug dosage form comparison drug formulation drug tolerance drug withdrawal dry eye eye disease eye redness eyelid disease female graft versus host reaction human keratitis major clinical study male ocular graft versus host disease ocular pruritus patient compliance priority journal retrospective study staining treatment outcome very elderly bepanthen berberil n corneregel floxal ikervis monoprost restasis taflotan vexol LA - English M3 - Article N1 - L634337312 2021-03-05 2021-03-09 PY - 2021 SN - 1423-0259 0030-3747 SP - 77-84 ST - Tolerance and Adherence to Cationic 0.1% Cyclosporine in Ocular Graft-versus-Host Disease T2 - Ophthalmic Research TI - Tolerance and Adherence to Cationic 0.1% Cyclosporine in Ocular Graft-versus-Host Disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634337312&from=export http://dx.doi.org/10.1159/000509034 VL - 64 ID - 2325 ER - TY - JOUR AB - PURPOSE: Patient adherence with topical glaucoma therapy is recognized as suboptimal. Though some studies have associated physician/patient interaction with adherence, little systematic research has explored the ophthalmologist's perspective of this interaction. Telephone interviews with physicians treating glaucoma were conducted to ascertain the extent to which multivariate analysis of physician demographics, beliefs, and behaviors could reveal differences potentially relevant to future adherence with topical glaucoma therapy for primary open-angle glaucoma, in conjunction with other phases of the Glaucoma Adherence and Persistency Study (GAPS). METHODS: Structured interviews were conducted with 103 ophthalmologists treating significant numbers of primary open-angle glaucoma patients in a national managed care network. To the maximum extent possible, eligible patients of physicians interviewed were included in the other GAPS phases (claims analysis, patient surveys, and medical chart reviews). RESULTS: Physicians reported a wide range of beliefs and behaviors regarding patients' medication adherence, but beliefs and behaviors were linked. The segmentation analysis yielded 3 clusters of physicians, which we have described on the basis of their predominant beliefs as "reactives," "skeptics," and "idealists." The "idealists," though the smallest group, more often reported beliefs and behaviors that may be more positively associated with patient adherence, especially in the context of other GAPS findings. CONCLUSIONS: Physician vigilance for opportunities to detect and address nonadherence is suggested, as is interventional research on the basis of the constructs identified. Copyright © 2008 by Lippincott Williams & Wilkins. AD - L. Gelb, 902 N, Market Street, Wilmington, DE 19801 AU - Gelb, L. AU - Friedman, D. S. AU - Quigley, H. A. AU - Lyon, D. W. AU - Tan, J. AU - Kim, E. E. AU - Zimmerman, T. J. AU - Hahn, S. R. DB - Embase Medline DO - 10.1097/IJG.0b013e31816b3001 IS - 8 KW - alertness article demography glaucoma health behavior health belief managed care medical record review medical research open angle glaucoma ophthalmology patient compliance physician priority journal structured interview telephone topical treatment LA - English M3 - Article N1 - L354838842 2009-08-04 PY - 2008 SN - 1057-0829 SP - 690-698 ST - Physician beliefs and behaviors related to glaucoma treatment adherence: The glaucoma adherence and persistency study T2 - Journal of Glaucoma TI - Physician beliefs and behaviors related to glaucoma treatment adherence: The glaucoma adherence and persistency study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354838842&from=export http://dx.doi.org/10.1097/IJG.0b013e31816b3001 VL - 17 ID - 3414 ER - TY - JOUR AB - After the diagnosis of chronic open-angle glaucoma has been made, and the indications vs. contraindications of each of the potential first-line topical medications have been weighed, what medical therapy should be initiated if the most cost effective form of management is desired? We surveyed 40 pharmacies in four cities and found no statistical difference between the mean annual cost of therapy with timolol maleate (Timoptic), betaxolol (Betoptic), and pilocarpine. Statistically, both dipivefrin (Propine) and levobunolol (Betagan) were found to be more expensive. We also discovered that there are large variations in medication prices between various pharmacies. In order to enhance compliance, optometrists may want to know the pharmacies in their communities that offer antiglaucoma medications at reasonable prices. AD - J.B. Gelvin, Optometry Section, Pensacola VA Outpatient Clinic, FL 32503. AU - Gelvin, J. B. AU - Goen, T. M. DB - Medline IS - 10 KW - analysis of variance article cost economics human open angle glaucoma patient compliance pharmacy (shop) randomization LA - English M3 - Article N1 - L20781577 1990-01-11 PY - 1989 SN - 0003-0244 SP - 768-770 ST - Dosage cost analysis in glaucoma management T2 - Journal of the American Optometric Association TI - Dosage cost analysis in glaucoma management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L20781577&from=export VL - 60 ID - 4049 ER - TY - JOUR AB - Topical medications remain the mainstay of glaucoma treatment. This review will aim to cover the pharmacokinetics of topically applied drops, the ocular barriers to drug delivery, and the role of ophthalmic drug formulation in enhancing drug delivery to the target tissue while minimizing side effects and increasing patient compliance. Recent advances in surgical techniques, therapeutic approaches, and material sciences have produced exciting new therapies for ocular diseases. The development of new vehicles and drug formulations that require less patient compliance is also discussed, as are the routes of drug delivery for neuroprotection. © 2008 Lippincott Williams & Wilkins, Inc. AD - H. F. Edelhauser, Emory University Eye Center, 1365B Clifton Road, Atlanta, GA 30322, United States AU - Ghate, D. AU - Edelhauser, H. F. DB - Embase Medline DO - 10.1097/IJG.0b013e31814b990d IS - 2 KW - acetazolamide aciclovir antiglaucoma agent benzalkonium chloride beta adrenergic receptor blocking agent betaxolol bimatoprost brinzolamide carbonate dehydratase inhibitor cefazolin chitosan ciprofloxacin cyclodextrin cyclosporine dipivefrine dorzolamide drug vehicle gentamicin hydrocortisone hydroxypropylmethylcellulose inulin latanoprost ofloxacin phenylephrine pilocarpine polyvinyl alcohol timolol timolol maleate trifluoromethazolamide unindexed drug asthma blurred vision cornea epithelium dosage schedule comparison drug absorption drug binding drug bioavailability drug blood level drug delivery system drug formulation drug metabolism drug penetration drug solubility edema eye disease glaucoma human nonhuman patient compliance priority journal review LA - English M3 - Review N1 - L351412405 2008-04-11 PY - 2008 SN - 1057-0829 SP - 147-156 ST - Barriers to glaucoma drug delivery T2 - Journal of Glaucoma TI - Barriers to glaucoma drug delivery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351412405&from=export http://dx.doi.org/10.1097/IJG.0b013e31814b990d VL - 17 ID - 3466 ER - TY - JOUR AB - PURPOSE: We report 4 cases of corneal ulcers associated with drug abuse. The pathogenesis of these ulcers and management of these patients are also reviewed. METHODS: Review of all cases of corneal ulcers associated with drug abuse seen at our institution from July 2006 to December 2006. RESULTS: Four patients with corneal ulcers associated with crack cocaine use were reviewed. All corneal ulcers were cultured, and the patients were admitted to the hospital for intensive topical antibiotic treatment. Each patient received comprehensive health care, including medical and substance abuse consultations. Streptococcal organisms were found in 3 cases and Capnocytophaga and Brevibacterium casei in 1 patient. The infections responded to antibiotic treatment. Two patients needed a lateral tarsorrhaphy for persistent epithelial defects. CONCLUSIONS: Aerosolized crack cocaine use can be associated with the development of corneal ulcers. Drug abuse provides additional challenges for management. Not only treatment of their infections but also the overall poor health of the patients and increased risk of noncompliance need to be addressed. Comprehensive care may provide the patient the opportunity to discontinue their substance abuse, improve their overall health, and prevent future corneal complications. © 2007 Lippincott Williams & Wilkins, Inc. AD - Cornea Service, Wills Eye Institute, Philadelphia, PA, United States Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107, United States AU - Ghosheh, F. R. AU - Ehlers, J. P. AU - Ayres, B. D. AU - Hammersmith, K. M. AU - Rapuano, C. J. AU - Cohen, E. J. DB - Scopus DO - 10.1097/ICO.0b013e3180cfe716 IS - 8 KW - Cocaine Cornea Crack Infections Keratitis Methamphetamine Ulcers M3 - Review N1 - Cited By :17 Export Date: 19 July 2021 PY - 2007 SP - 966-969 ST - Corneal ulcers associated with aerosolized crack cocaine use T2 - Cornea TI - Corneal ulcers associated with aerosolized crack cocaine use UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548253114&doi=10.1097%2fICO.0b013e3180cfe716&partnerID=40&md5=a885e3032210e9dc40ad998e47a15a85 VL - 26 ID - 5172 ER - TY - JOUR AB - Poor adherence with medical regimens by patients with asthma and chronic obstructive pulmonary disease (COPD) is a major problem facing medical practitioners, with patients typically taking approximately half the prescribed doses of self-administered medications. Poor adherence with medication regimens results in inadequate disease control and is assumed to be associated with poor long-term outcomes and high medical and social costs. Efforts to assist patients with treatment adherence are thought to improve the benefits of prescribed medications; however, even the most effective interventions do not necessarily lead to significant improvements in adherence and treatment outcomes. Simple interventions (such as re-calling patients who miss appointments, making every effort to keep patients in care, and simplifying treatment regimens) and complex strategies (including combinations of more thorough patient instructions and counseling, reminders, close follow-up, supervised self-monitoring, family therapy, crisis intervention, and telephone follow-up) may improve adherence and treatment outcomes for both short- and long-term treatments. All these measures are highly dependent on a good physician-patient relationship, and the willingness and ability of caregivers to closely follow guidelines and recommendations. The diversity and complexity of interventions, and uncertainty about their effects, make it difficult to assess which interventions are effective and which are not. The literature regarding interventions remains surprisingly limited. There is little evidence to show that medication adherence can be improved consistently, or that interventions will inevitably lead to improvements in treatment outcomes, especially considering the resources usually available in outpatient settings. Most studies assessing successful complex interventions have not assessed the effect on clinical endpoints. Studies in COPD are sparse compared with those in asthma, leaving room for further research efforts. As all self-administered treatments are affected by low adherence, and as the number of efficacious, self-administered treatments continues to grow, detailed knowledge about this complex issue may help to ensure better management in patients with obstructive pulmonary diseases. © 2007 Adis Data Information BV. All rights reserved. AD - St. George Medical Center, Robert-Koch-Hospital, Leipzig, Germany Department of Pulmonary Medicine, University Hospital, Leipzig, Germany University Hospital Bonn, Bonn, Germany St. George Medical Center, Robert-Koch-Hospital, Nikolai-Rumjanzew-Str. 100, Leipzig, D-04702, Germany AU - Gillissen, A. AU - Wirtz, H. AU - Juergens, U. DB - Scopus DO - 10.2165/00115677-200715060-00004 IS - 6 KW - Asthma, treatment Chronic obstructive pulmonary disease, treatment Patient compliance M3 - Review N1 - Cited By :4 Export Date: 19 July 2021 PY - 2007 SP - 355-376 ST - Patient and physician factors contributing to poor outcomes in patients with asthma and COPD T2 - Disease Management and Health Outcomes TI - Patient and physician factors contributing to poor outcomes in patients with asthma and COPD UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-36949029610&doi=10.2165%2f00115677-200715060-00004&partnerID=40&md5=73ba61bb03d2ef67fade8fa5ee34fe0e VL - 15 ID - 5482 ER - TY - JOUR AU - Gilmartin, B. DB - Embase IS - 3 KW - accommodation color discrimination computer model editorial glaucoma human intraocular pressure patient compliance priority journal vision test visual field LA - English M3 - Editorial N1 - L24241434 1994-08-17 PY - 1994 SN - 0275-5408 SP - 225-226 ST - Editorial T2 - Ophthalmic and Physiological Optics TI - Editorial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L24241434&from=export VL - 14 ID - 3997 ER - TY - JOUR AB - Objective: To investigate the barriers to access to eye health services for patients with glaucoma in Tanzania with the aim of identifying key areas for improvement and further research.Design: Qualitative investigation using face-to-face semi-structured interviews with patients recruited from the Kilimanjaro Christian Medical Centre (KCMC) outpatient eye clinic. This project is part of the international strategy of the Research into Glaucoma and Ethnicity (ReGAE) programme.Methods: Interviews were conducted with the help of a translator; all data were transcribed in Swahili and then translated into English. Manual coding and qualitative analysis was used to identify major themes and relevant concepts. Data were collected during May and June 2013.Main Outcome Measures: Qualitative data on glaucoma awareness and access to healthcare.Results: 12 patients (7 men, 5 women) of mean age 67.5 years (range 53-86 years) were interviewed. All participants had a previous diagnosis of glaucoma and no other eye conditions. The understanding of glaucoma was limited and the capacity for healthcare providers to improve glaucoma knowledge seemed underused. Participants had particular difficulty in understanding the aetiology and chronicity of the disease. Socioeconomic factors also posed significant barriers to service usage.Conclusions: Among many barriers to access to health services for patients with glaucoma, knowledge of the condition was identified as a key issue. Enhancing the understanding of glaucoma may improve access by triggering earlier presentation, informing those at risk and improving adherence to treatment. This is an area for further research with potential for improving service provision. AN - 109599405. Language: English. Entry Date: 20150923. Revision Date: 20160525. Publication Type: journal article. Journal Subset: Biomedical AU - Gilmour-White, Jeremy A. AU - Shah, Peter AU - Cross, Vinette AU - Makupa, William AU - Philippin, Heiko DB - ccm DO - 10.1136/postgradmedj-2014-133094 DP - EBSCOhost IS - 1077 N1 - Europe; Peer Reviewed; UK & Ireland. NLM UID: 0234135. PMID: NLM26069217. PY - 2015 SN - 0032-5473 SP - 373-378 ST - Glaucoma awareness and access to healthcare: perceptions among glaucoma patients in Tanzania T2 - Postgraduate Medical Journal TI - Glaucoma awareness and access to healthcare: perceptions among glaucoma patients in Tanzania UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109599405&site=ehost-live&scope=site VL - 91 ID - 4316 ER - TY - JOUR AB - Announcement of a chronic disease, always, is a difficult task in the physician professional activity. For glaucoma, its possible impact on their vision and quality of life are a source of anxiety for most patients. The message should be simple and comprehensible, but accurate, to ensure long term compliance to follow-up and treatment. Announcement should be tailored to the patient personality and psychological profile. The clinician should know his own personality, but his patient's personality also, to guarantee successful information and communication and a good quality patient-clinician relationship. Simple rules to be applied are described. © 2009 Elsevier Masson SAS. All rights reserved. AD - P. Ginies, Président du Collège national des médecins, la douleur Centre d'évaluation et de traitement de la douleur, CHU de Montpellier, 191, avenue Doyen Gaston Giraud, F-34090 Montpellier cedex, France AU - Ginies, P. DB - Medline DO - 10.1016/j.jfo.2009.03.011 IS - 3 KW - adaptive behavior doctor patient relationship glaucoma human interpersonal communication ophthalmology psychological aspect short survey LA - French M3 - Short Survey N1 - L354406556 2010-02-08 PY - 2009 SN - 0181-5512 SP - 190-193 ST - Relationship with the glaucomatous patient: how to announce glaucoma to the patient? T2 - Journal Francais d'Ophtalmologie TI - Relationship with the glaucomatous patient: how to announce glaucoma to the patient? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354406556&from=export http://dx.doi.org/10.1016/j.jfo.2009.03.011 VL - 32 ID - 3376 ER - TY - JOUR AB - Announcement of a chronic disease, always, is a difficult task in the physician professional activity. For glaucoma, its possible impact on their vision and quality of life are a source of anxiety for most patients. The message should be simple and comprehensible, but accurate, to ensure tong term compliance to follow-up and treatment. Announcement should be tailored to the patient personality and psychological profile. The clinician should know his own personality, but his patient's personality also, to guarantee successful information and communication and a good quality patient-clinician relationship. Simple rules to be applied are described. (C) 2009 Elsevier Masson SAS. All rights reserved. AN - WOS:000265502900007 AU - Ginies, P. DA - MAR DO - 10.1016/j.jfo.2009.03.011 IS - 3 PY - 2009 SN - 0181-5512 1773-0597 SP - 190-193 ST - Relationship with the glaucomatous patient: how to announce glaucoma to the patient? T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Relationship with the glaucomatous patient: how to announce glaucoma to the patient? VL - 32 ID - 6068 ER - TY - JOUR AB - Objective: To determine the efficacy of an automated, interactive, telephone-based health communication intervention for improving glaucoma treatment adherence among patients in 2 hospital-based eye clinics. Method: A total of 312 patients with glaucoma (18-80 years of age) were enrolled in a randomized controlled trial at 2 eye clinics located in hospitals in the southeastern United States. These patients were considered non-adherent because they did not take their medication, refill their medication, and/or keep their appointments. The treatment group received an automated, interactive, tailored, telephone-based health communication intervention and tailored print materials. The control group received usual care. Main Outcome Measures: Adherence with medication taking, prescription refills, and appointment keeping measured by interviews, medical charts, appointment records, and pharmacy data. Results: A statistically significant increase was found for all adherence measures in both the intervention and control groups. Interactive telephone calls and tailored print materials did not significantly improve adherence measures compared with controls. Conclusions: During the study period, patient adherence to glaucoma treatment and appointment keeping improved in both study arms. Participation in the study and interviews may have contributed. Strategies that address individuals' barriers and facilitators may increase the impact of telephone calls, especially for appointment keeping and prescription refills. Application to Clinical Practice: Glaucoma patient care should include reminders about consistent use of medication and the importance of keeping appointments. More frequent, and personalized, telephone contact may be helpful to patients who are known to be non-adherent. Trial Registration: clinicaltrials.gov Identifier: NCT00794170 ©2012 American Medical Association. All rights reserved. AD - K. Glanz, Perelman School of Medicine, School of Nursing, University of Pennsylvania, 423 Guardian Dr, Philadelphia, PA 19104-6021, United States AU - Glanz, K. AU - Beck, A. D. AU - Bundy, L. AU - Primo, S. AU - Lynn, M. J. AU - Cleveland, J. AU - Wold, J. A. AU - Echt, K. V. DB - Embase Medline DO - 10.1001/archophthalmol.2012.1607 IS - 10 KW - NCT00794170 antiglaucoma agent adult aged article automation controlled study female glaucoma health communication intervention human interview major clinical study male medical information medical record multicenter study outcome assessment patient compliance pharmacy (shop) prescription priority journal randomized controlled trial telemedicine telephone United States LA - English M3 - Article N1 - L365827696 2012-10-20 PY - 2012 SN - 0003-9950 1538-3601 SP - 1252-1258 ST - Impact of a health communication intervention to improve glaucoma treatment adherence: Results of the interactive study to increase glaucoma adherence to treatment trial T2 - Archives of Ophthalmology TI - Impact of a health communication intervention to improve glaucoma treatment adherence: Results of the interactive study to increase glaucoma adherence to treatment trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365827696&from=export http://dx.doi.org/10.1001/archophthalmol.2012.1607 http://archopht.jamanetwork.com/data/Journals/OPHTH/25306/ect120002_1252_1258.pdf VL - 130 ID - 3062 ER - TY - JOUR AD - Perelman School of Medicine and School of Nursing, University of Pennsylvania, Philadelphia, USA. AN - 104240055. Language: English. Entry Date: 20130308. Revision Date: 20180402. Publication Type: Journal Article AU - Glanz, Karen AU - Beck, Allen D. AU - Bundy, Lucja AU - Primo, Susan AU - Lynn, Michael J. AU - Cleveland, Julia AU - Wold, Jessica A. AU - Echt, Katharina V. DB - ccm DP - EBSCOhost IS - 10 KW - Antihypertensive Agents -- Administration and Dosage Communication -- Methods Glaucoma -- Drug Therapy Health Promotion -- Methods Medication Compliance Patient Education Adolescence Adult Aged Aged, 80 and Over Appointments and Schedules Female Health Behavior Human Male Middle Age Ophthalmic Solutions Patient Attitudes Prescriptions, Drug -- Statistics and Numerical Data Randomized Controlled Trials Teaching Materials Telephone -- Utilization Young Adult N1 - research; randomized controlled trial. Journal Subset: Biomedical; USA. NLM UID: 7706534. PMID: NLM22688429. PY - 2012 SN - 0003-9950 SP - 1252-1258 ST - Impact of a health communication intervention to improve glaucoma treatment adherence. Results of the interactive study to increase glaucoma adherence to treatment trial T2 - Archives of Ophthalmology TI - Impact of a health communication intervention to improve glaucoma treatment adherence. Results of the interactive study to increase glaucoma adherence to treatment trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104240055&site=ehost-live&scope=site VL - 130 ID - 4413 ER - TY - JOUR AB - Objective: To determine the efficacy of an automated, interactive, telephone-based health communication intervention for improving glaucoma treatment adherence among patients in 2 hospital-based eye clinics. Method: A total of 312 patients with glaucoma (18-80 years of age) were enrolled in a randomized controlled trial at 2 eye clinics located in hospitals in the southeastern United States. These patients were considered non-adherent because they did not take their medication, refill their medication, and/or keep their appointments. The treatment group received an automated, interactive, tailored, telephone-based health communication intervention and tailored print materials. The control group received usual care. Main Outcome Measures: Adherence with medication taking, prescription refills, and appointment keeping measured by interviews, medical charts, appointment records, and pharmacy data. Results: A statistically significant increase was found for all adherence measures in both the intervention and control groups. Interactive telephone calls and tailored print materials did not significantly improve adherence measures compared with controls. Conclusions: During the study period, patient adherence to glaucoma treatment and appointment keeping improved in both study arms. Participation in the study and interviews may have contributed. Strategies that address individuals' barriers and facilitators may increase the impact of telephone calls, especially for appointment keeping and prescription refills. Application to Clinical Practice: Glaucoma patient care should include reminders about consistent use of medication and the importance of keeping appointments. More frequent, and personalized, telephone contact may be helpful to patients who are known to be non-adherent. Trial Registration: clinicaltrials.gov Identifier: NCT00794170 ©2012 American Medical Association. All rights reserved. AD - Perelman School of Medicine, School of Nursing, University of Pennsylvania, 423 Guardian Dr, Philadelphia, PA 19104-6021, United States School of Medicine, Rollins School of Public Health, Emory University, United States Atlanta Veterans Affairs Medical Center, Rehabilitation Research and Development Center of Excellence, GA, United States AU - Glanz, K. AU - Beck, A. D. AU - Bundy, L. AU - Primo, S. AU - Lynn, M. J. AU - Cleveland, J. AU - Wold, J. A. AU - Echt, K. V. DB - Scopus DO - 10.1001/archophthalmol.2012.1607 IS - 10 M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2012 SP - 1252-1258 ST - Impact of a health communication intervention to improve glaucoma treatment adherence: Results of the interactive study to increase glaucoma adherence to treatment trial T2 - Archives of Ophthalmology TI - Impact of a health communication intervention to improve glaucoma treatment adherence: Results of the interactive study to increase glaucoma adherence to treatment trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84867340542&doi=10.1001%2farchophthalmol.2012.1607&partnerID=40&md5=e1eb08151f761fe8ef5511fda10b580a VL - 130 ID - 5110 ER - TY - JOUR AB - Objective: To determine the efficacy of an automated, interactive, telephone-based health communication intervention for improving glaucoma treatment adherence among patients in 2 hospital-based eye clinics. Method: A total of 312 patients with glaucoma (18-80 years of age) were enrolled in a randomized controlled trial at 2 eye clinics located in hospitals in the southeastern United States. These patients were considered nonadherent because they did not take their medication, refill their medication, and/or keep their appointments. The treatment group received an automated, interactive, tailored, telephone-based health communication intervention and tailored print materials. The control group received usual care. Main Outcome Measures: Adherence with medication taking, prescription refills, and appointment keeping measured by interviews, medical charts, appointment records, and pharmacy data. Results: A statistically significant increase was found for all adherence measures in both the intervention and control groups. Interactive telephone calls and tailored print materials did not significantly improve adherence measures compared with controls. Conclusions: During the study period, patient adherence to glaucoma treatment and appointment keeping improved in both study arms. Participation in the study and interviews may have contributed. Strategies that address individuals' barriers and facilitators may increase the impact of telephone calls, especially for appointment keeping and prescription refills. Application to Clinical Practice: Glaucoma patient care should include reminders about consistent use of medication and the importance of keeping appointments. More frequent, and personalized, telephone contact may be helpful to patients who are known to be nonadherent. AN - WOS:000309543500001 AU - Glanz, K. AU - Beck, A. D. AU - Bundy, L. AU - Primo, S. AU - Lynn, M. J. AU - Cleveland, J. AU - Wold, J. A. AU - Echt, K. V. DA - OCT DO - 10.1001/archophthalmol.2012.1607 IS - 10 PY - 2012 SN - 0003-9950 1538-3601 SP - 1252-1258 ST - Impact of a Health Communication Intervention to Improve Glaucoma Treatment Adherence T2 - ARCHIVES OF OPHTHALMOLOGY TI - Impact of a Health Communication Intervention to Improve Glaucoma Treatment Adherence VL - 130 ID - 5841 ER - TY - JOUR AB - Objectives: To investigate the views and experiences of patients regarding their glaucoma follow-up, particularly towards the type and frequency of visual field (VF) testing. Design: A qualitative investigation using focus groups. The group discussion used broad open questions around the topics in a prompt guide relating to experiences of glaucoma follow-up, and in particular, VF monitoring. All the groups were taped, transcribed and coded using manual and computer-aided methods. Setting: Three National Health Service (NHS) hospitals in England; two focus groups took place at each hospital. Participants: 28 patients (mean (SD) age: 74 (9) years; 54% women) diagnosed with glaucoma for at least 2 years. Each focus group consisted of 3-6 patients. Primary and secondary outcomes: (1) Attitudes and experiences of patients with glaucoma regarding VF testing. (2) Patients' opinions about successful follow-up in glaucoma. Results: These patients did not enjoy the VF test but they recognised the importance of regular monitoring for preserving their vision. These patients would agree to more frequent VF testing on their clinician's recommendation. A number of themes recurred throughout the focus groups representing perceived barriers to follow-up care. The testing environment, waiting times, efficiency of appointment booking and travel to the clinic were all perceived to influence the general clinical experience and the quality of assessment data. Patients were also concerned about aspects of patient-doctor communication, and often received little to no feedback about their results. Conclusions: Patients trust the clinician to make the best decisions for their glaucoma follow-up. However, patients highlighted a number of issues that could compromise the effectiveness of VF testing. Addressing patient-perceived barriers could be an important step for devising optimal strategies for follow-up care. AD - D.P. Crabb, Division of Optometry and Visual Science, School of Health Sciences, City University London, London, United Kingdom AU - Glen, F. C. AU - Baker, H. AU - Crabb, D. P. DB - Embase Medline DO - 10.1136/bmjopen-2013-003996 IS - 1 KW - aged article clinical article clinical assessment computer aided design doctor patient relationship female follow up glaucoma hospital management human male national health service patient attitude patient monitoring perimetry personal experience qualitative research United Kingdom LA - English M3 - Article N1 - L372178199 2014-01-30 2014-02-06 PY - 2014 SN - 2044-6055 ST - A qualitative investigation into patients' views on visual field testing for glaucoma monitoring T2 - BMJ Open TI - A qualitative investigation into patients' views on visual field testing for glaucoma monitoring UR - https://www.embase.com/search/results?subaction=viewrecord&id=L372178199&from=export http://dx.doi.org/10.1136/bmjopen-2013-003996 http://bmjopen.bmj.com/content/4/1/e003996.full.pdf+html VL - 4 ID - 2896 ER - TY - JOUR AB - Objectives: To investigate the views and experiences of patients regarding their glaucoma follow-up, particularly towards the type and frequency of visual field (VF) testing. Design: A qualitative investigation using focus groups. The group discussion used broad open questions around the topics in a prompt guide relating to experiences of glaucoma follow-up, and in particular, VF monitoring. All the groups were taped, transcribed and coded using manual and computer-aided methods. Setting: Three National Health Service (NHS) hospitals in England; two focus groups took place at each hospital. Participants: 28 patients (mean (SD) age: 74 (9) years; 54% women) diagnosed with glaucoma for at least 2 years. Each focus group consisted of 3-6 patients. Primary and secondary outcomes: (1) Attitudes and experiences of patients with glaucoma regarding VF testing. (2) Patients' opinions about successful follow-up in glaucoma. Results: These patients did not enjoy the VF test but they recognised the importance of regular monitoring for preserving their vision. These patients would agree to more frequent VF testing on their clinician's recommendation. A number of themes recurred throughout the focus groups representing perceived barriers to follow-up care. The testing environment, waiting times, efficiency of appointment booking and travel to the clinic were all perceived to influence the general clinical experience and the quality of assessment data. Patients were also concerned about aspects of patient-doctor communication, and often received little to no feedback about their results. Conclusions: Patients trust the clinician to make the best decisions for their glaucoma follow-up. However, patients highlighted a number of issues that could compromise the effectiveness of VF testing. Addressing patient-perceived barriers could be an important step for devising optimal strategies for follow-up care. AD - Division of Optometry and Visual Science, School of Health Sciences, City University London, London, United Kingdom AU - Glen, F. C. AU - Baker, H. AU - Crabb, D. P. C7 - e003996 DB - Scopus DO - 10.1136/bmjopen-2013-003996 IS - 1 M3 - Article N1 - Cited By :52 Export Date: 19 July 2021 PY - 2014 ST - A qualitative investigation into patients' views on visual field testing for glaucoma monitoring T2 - BMJ Open TI - A qualitative investigation into patients' views on visual field testing for glaucoma monitoring UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892846203&doi=10.1136%2fbmjopen-2013-003996&partnerID=40&md5=66369af463b79cdea8fc57a90166f397 VL - 4 ID - 4991 ER - TY - JOUR AB - Objectives To investigate the views and experiences of patients regarding their glaucoma follow-up, particularly towards the type and frequency of visual field (VF) testing. Design A qualitative investigation using focus groups. The group discussion used broad open questions around the topics in a prompt guide relating to experiences of glaucoma follow-up, and in particular, VF monitoring. All the groups were taped, transcribed and coded using manual and computer-aided methods. Setting Three National Health Service (NHS) hospitals in England; two focus groups took place at each hospital. Participants 28 patients (mean (SD) age: 74 (9) years; 54% women) diagnosed with glaucoma for at least 2years. Each focus group consisted of 3-6 patients. Primary and secondary outcomes (1) Attitudes and experiences of patients with glaucoma regarding VF testing. (2) Patients' opinions about successful follow-up in glaucoma. Results These patients did not enjoy the VF test but they recognised the importance of regular monitoring for preserving their vision. These patients would agree to more frequent VF testing on their clinician's recommendation. A number of themes recurred throughout the focus groups representing perceived barriers to follow-up care. The testing environment, waiting times, efficiency of appointment booking and travel to the clinic were all perceived to influence the general clinical experience and the quality of assessment data. Patients were also concerned about aspects of patient-doctor communication, and often received little to no feedback about their results. Conclusions Patients trust the clinician to make the best decisions for their glaucoma follow-up. However, patients highlighted a number of issues that could compromise the effectiveness of VF testing. Addressing patient-perceived barriers could be an important step for devising optimal strategies for follow-up care. AN - WOS:000334311200031 AU - Glen, F. C. AU - Baker, H. AU - Crabb, D. P. DO - 10.1136/bmjopen-2013-003996 IS - 1 PY - 2014 SN - 2044-6055 ST - A qualitative investigation into patients' views on visual field testing for glaucoma monitoring T2 - BMJ OPEN TI - A qualitative investigation into patients' views on visual field testing for glaucoma monitoring VL - 4 ID - 5904 ER - TY - JOUR AB - Background: Sight loss from glaucoma can have a significant impact on functioning and performing everyday activities, but this varies between patients. The purpose of this study was to explore whether patients with glaucoma use different coping strategies in response to their vision loss. Methods: Audio-recorded semi-structured interviews were conducted with 16 patients (median age: 71 [interquartile range [IQR]: 68 to 77 years]; 50 % female) about their experiences of living with glaucoma. Patients had their glaucoma diagnosis for at least 5 years (range: 6 to 29 years) and had a range of disease severities (median best eye Mean Deviation was -9.1 dB [IQR: -12.9 to -4.1 dB]). A framework approach to analysis was taken whereby data was indexed using manual and computer-assisted methods, with codes applied to depict areas of functioning perceived to be impacted by glaucoma and coping behaviours used in response to these difficulties. Results: In order to maintain independence, some patients increased confidence by making practical changes such as adjusting lighting, using handrails and magnifying glasses, or actively changed aspects of their behaviour such as moving their head and eyes towards known areas of vision loss. Support from friends and family was often used, although some people worried about becoming a burden. Others imposed self-restrictions or gave up activities, thus compromising well-being and independence. Certain coping strategies were linked to time since diagnosis and location of vision loss. The type and quality of information received during clinical appointments, and the potential benefits of communication with other patients, emerged as other important themes. Conclusions: Results from this qualitative study suggest that the adoption of certain coping behaviours and techniques may help some glaucomatous patients to adapt to their condition. An awareness of coping and adaptive strategies, in addition to the usual clinical tests, may provide a better insight into the impact of disease and help inform future educational and management strategies for glaucoma. AN - WOS:000362314700001 AU - Glen, F. C. AU - Crabb, D. P. DA - OCT 6 DO - 10.1186/s12886-015-0119-7 PY - 2015 SN - 1471-2415 ST - Living with glaucoma: a qualitative study of functional implications and patients' coping behaviours T2 - BMC OPHTHALMOLOGY TI - Living with glaucoma: a qualitative study of functional implications and patients' coping behaviours VL - 15 ID - 6252 ER - TY - JOUR AB - Purpose: To describe treatment patterns, adherence, and persistence with initial therapy among glaucoma patients in the community. Materials and Methods: A population-based historical prospective cohort study, using the electronic medical databases of Maccabi Healthcare Services, a 2 million member health maintenance organization in Israel. Newly diagnosed glaucoma patients between 2003 and 2010, who purchased at least 1 antiglaucoma medication, were followed up to December 31, 2012. Outcome measures included medication adherence analyzed by proportion of days covered by drugs during follow-up time, and persistence with initial therapy measured by time until switch or discontinuation of firstline therapy. Results: A total of 5934 incident definite glaucoma patients were identified, 13% of whom were nonadherent with therapy (covered <20% of the follow-up time), and only 25% exhibited high adherence (covered at least 80% of the follow-up period). Adherence was positively associated with female sex, age, socioeconomic status, frequent follow-up visits, and higher baseline intraocular pressure. Lower median adherence (P<0.01) was observed among patients of normal tension glaucoma (52%) and angle closure (59%) as compared with open angle (65%) and exfoliation glaucoma (68%). Patients treated by glaucoma specialists had similar adherence to those treated by general ophthalmologists (proportion of days covered=65% vs. 63%, P=0.42). Persistence with initial line of therapy varied by type of medication, with prostaglandin initiators exhibiting the highest persistence (13% reduced likelihood of switch or discontinuation as compared with b-blockers, P<0.01) and a-agonists the lowest persistence (39% increased likelihood of switch or discontinuation as compared with b-blockers, P<0.01). Conclusions: This large-scale analysis of real-world use of glaucoma medications reveals that adherence to glaucoma therapy is associated with medication type, patient's sex, age, socioeconomic status, type of glaucoma, follow-up visits, and baseline intraocular pressure. AD - I. Goldshtein, Epidemiology and Database Research, Maccabi Healthcare Services, Hamered 27, Tel Aviv, Israel AU - Goldshtein, I. AU - Shalev, V. AU - Zigman, N. AU - Chodick, G. AU - Levkovitch-Verbin, H. DB - Embase Medline DO - 10.1097/IJG.0000000000000380 IS - 4 KW - alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor prostaglandin age article closed angle glaucoma cohort analysis controlled study female follow up gender health maintenance organization human hypertension intraocular pressure Israeli low tension glaucoma major clinical study male malignant neoplasm medical specialist medication compliance open angle glaucoma ophthalmologist outcome assessment patient compliance priority journal prospective study pseudoexfoliation sensitivity analysis social status telephone interview LA - English M3 - Article N1 - L608643820 2016-03-03 2016-04-29 PY - 2016 SN - 1536-481X 1057-0829 SP - e386-e391 ST - The maccabi glaucoma study: Treatment patterns and persistence with glaucoma therapy in a large israeli health maintenance organization T2 - Journal of Glaucoma TI - The maccabi glaucoma study: Treatment patterns and persistence with glaucoma therapy in a large israeli health maintenance organization UR - https://www.embase.com/search/results?subaction=viewrecord&id=L608643820&from=export http://dx.doi.org/10.1097/IJG.0000000000000380 VL - 25 ID - 2768 ER - TY - JOUR AB - Purpose: To describe treatment patterns, adherence, and persistence with initial therapy among glaucoma patients in the community. Materials and Methods: A population-based historical prospective cohort study, using the electronic medical databases of Maccabi Healthcare Services, a 2 million member health maintenance organization in Israel. Newly diagnosed glaucoma patients between 2003 and 2010, who purchased at least 1 antiglaucoma medication, were followed up to December 31, 2012. Outcome measures included medication adherence analyzed by proportion of days covered by drugs during follow-up time, and persistence with initial therapy measured by time until switch or discontinuation of firstline therapy. Results: A total of 5934 incident definite glaucoma patients were identified, 13% of whom were nonadherent with therapy (covered <20% of the follow-up time), and only 25% exhibited high adherence (covered at least 80% of the follow-up period). Adherence was positively associated with female sex, age, socioeconomic status, frequent follow-up visits, and higher baseline intraocular pressure. Lower median adherence (P<0.01) was observed among patients of normal tension glaucoma (52%) and angle closure (59%) as compared with open angle (65%) and exfoliation glaucoma (68%). Patients treated by glaucoma specialists had similar adherence to those treated by general ophthalmologists (proportion of days covered=65% vs. 63%, P=0.42). Persistence with initial line of therapy varied by type of medication, with prostaglandin initiators exhibiting the highest persistence (13% reduced likelihood of switch or discontinuation as compared with b-blockers, P<0.01) and a-agonists the lowest persistence (39% increased likelihood of switch or discontinuation as compared with b-blockers, P<0.01). Conclusions: This large-scale analysis of real-world use of glaucoma medications reveals that adherence to glaucoma therapy is associated with medication type, patient's sex, age, socioeconomic status, type of glaucoma, follow-up visits, and baseline intraocular pressure. © 2015 Wolters Kluwer Health, Inc. All rights reserved. AD - Medical Division, Maccabi Healthcare Services, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Goldschleger Eye Institute, Sheba Medical Center, Tel-Hashomer, Israel AU - Goldshtein, I. AU - Shalev, V. AU - Zigman, N. AU - Chodick, G. AU - Levkovitch-Verbin, H. DB - Scopus DO - 10.1097/IJG.0000000000000380 IS - 4 KW - Adherence Glaucoma Persistence M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2016 SP - e386-e391 ST - The maccabi glaucoma study: Treatment patterns and persistence with glaucoma therapy in a large israeli health maintenance organization T2 - Journal of Glaucoma TI - The maccabi glaucoma study: Treatment patterns and persistence with glaucoma therapy in a large israeli health maintenance organization UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959131456&doi=10.1097%2fIJG.0000000000000380&partnerID=40&md5=46b805af2dbd907512670015fcb3d0ab VL - 25 ID - 5231 ER - TY - JOUR AB - Purpose: To describe treatment patterns, adherence, and persistence with initial therapy among glaucoma patients in the community. Materials and Methods: A population-based historical prospective cohort study, using the electronic medical databases of Maccabi Healthcare Services, a 2 million member health maintenance organization in Israel. Newly diagnosed glaucoma patients between 2003 and 2010, who purchased at least 1 antiglaucoma medication, were followed up to December 31, 2012. Outcome measures included medication adherence analyzed by proportion of days covered by drugs during follow-up time, and persistence with initial therapy measured by time until switch or discontinuation of first-line therapy. Results: A total of 5934 incident definite glaucoma patients were identified, 13% of whom were nonadherent with therapy (covered <20% of the follow-up time), and only 25% exhibited high adherence (covered at least 80% of the follow-up period). Adherence was positively associated with female sex, age, socioeconomic status, frequent follow-up visits, and higher baseline intraocular pressure. Lower median adherence (P < 0.01) was observed among patients of normal tension glaucoma (52%) and angle closure (59%) as compared with open angle (65%) and exfoliation glaucoma (68%). Patients treated by glaucoma specialists had similar adherence to those treated by general ophthalmologists (proportion of days covered = 65% vs. 63%, P = 0.42). Persistence with initial line of therapy varied by type of medication, with prostaglandin initiators exhibiting the highest persistence (13% reduced likelihood of switch or discontinuation as compared with beta-blockers, P < 0.01) and alpha-agonists the lowest persistence (39% increased likelihood of switch or discontinuation as compared with beta-blockers, P < 0.01). Conclusions: This large-scale analysis of real-world use of glaucoma medications reveals that adherence to glaucoma therapy is associated with medication type, patient's sex, age, socioeconomic status, type of glaucoma, follow-up visits, and baseline intraocular pressure. AN - WOS:000374834000016 AU - Goldshtein, I. AU - Shalev, V. AU - Zigman, N. AU - Chodick, G. AU - Levkovitch-Verbin, H. DA - APR DO - 10.1097/IJG.0000000000000380 IS - 4 PY - 2016 SN - 1057-0829 1536-481X SP - E386-E391 ST - The Maccabi Glaucoma Study: Treatment Patterns and Persistence With Glaucoma Therapy in a Large Israeli Health Maintenance Organization T2 - JOURNAL OF GLAUCOMA TI - The Maccabi Glaucoma Study: Treatment Patterns and Persistence With Glaucoma Therapy in a Large Israeli Health Maintenance Organization VL - 25 ID - 5836 ER - TY - JOUR AB - Clinicians in primary care settings are well positioned to participate in the prevention and management of visual disability. They can have a significant impact on their patients' visual health by screening for vision problems, aggressively controlling known risk factors for visual loss, ensuring adherence to ophthalmologic treatment and continuity of eye care, and by timely referral of specific patient populations to qualified eye care professionals (eg, ophthalmologists and optometrists). Using their knowledge about common ophthalmic medications, clinicians can detect adverse effects of these agents, including exacerbations of heart or lung disease. They can ensure that appropriate patients are screened for common serious eye diseases, such as glaucoma, and that patients with disabilities related to vision problems are assessed for treatable conditions, such as cataracts or refractive error. Finally, clinicians can direct patients with low vision from any cause to resources designed to help enhance patient function and emotional support. AD - Greater Los Angeles Veterans Affairs Health Care System, Los Angeles, Calif 90073, USA Veterans Affairs West Los Angeles Healthcare Center, 111-G, Los Angeles, CA 90073; caroline.goldzweig@med.va.gov AN - 106770891. Language: English. Entry Date: 20040827. Revision Date: 20200708. Publication Type: journal article AU - Goldzweig, C. L. AU - Rowe, S. AU - Wenger, N. S. AU - MacLean, C. H. AU - Shekelle, P. G. AU - Goldzweig, Caroline L. AU - Rowe, Susannah AU - Wenger, Neil S. AU - MacLean, Catherine H. AU - Shekelle, Paul G. DB - ccm DO - 10.1001/jama.291.12.1497 DP - EBSCOhost IS - 12 KW - Primary Health Care Vision Disorders -- Prevention and Control Vision Screening Aged Diabetes Mellitus -- Prevention and Control Diagnosis, Eye Eye Diseases -- Therapy Family Practice Female Glaucoma -- Prevention and Control Hypertension -- Prevention and Control Macular Degeneration -- Prevention and Control Male Middle Age Ophthalmic Solutions -- Adverse Effects Ophthalmic Solutions -- Therapeutic Use N1 - case study; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 7501160. PMID: NLM15039417. PY - 2004 SN - 0098-7484 SP - 1497-1502 ST - Preventing and managing visual disability in primary care: clinical applications T2 - JAMA: Journal of the American Medical Association TI - Preventing and managing visual disability in primary care: clinical applications UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106770891&site=ehost-live&scope=site VL - 291 ID - 4571 ER - TY - JOUR AB - Purpose:: To study the technique of eye drop instillation in glaucoma patients and identify independent factors that may influence their performance. Methods:: In this cross-sectional study, 71 consecutive patients with glaucoma or ocular hypertension, self-administering topical anti-glaucoma medications for ≥6 months were evaluated. All patients instilled a tear substitute into the eye with the worst eyesight using the technique normally used at home. The following parameters were evaluated: age, number of years receiving treatment with ocular hypotensive eye drops, time spent to instill the first drop, number of drops instilled, correct location of the eye drops, contact of the bottle with the eye, closing of the eyelids or occlusion of the tear punctum, and asepsis of the hands. Results:: The mean age of the patients was 66 ± 10.8 years, and patients were on ocular hypotensive drugs for 11.3 ± 7.3 (range, 2-35) years. Only 28% of the patients were able to correctly instill the eye drops (squeeze out 1 drop and instill it into the conjunctival sac without bottle tip contact). Touching the tip of the bottle to the globe or periocular tissue occurred in 62% of the patients. In 49% of the patients, the eye drops fell on the eyelids or cheek. Two or more drops were squeezed by 27% of the patients. Conclusions:: The majority of glaucoma patients were unable to correctly instill eye drops. Age was an independent factor associated with eye drop instillation performance. AU - Gomes, B. F. AU - Paredes, A. F. AU - Madeira, N. AU - Moraes, H. V. AU - Santhiago, M. R. DB - Medline DO - 10.5935/0004-2749.20170058 IS - 4 KW - eye drops adult age aged cross-sectional study drug effect drug instillation evaluation study female glaucoma human intraocular hypertension intraocular pressure male middle aged patient compliance patient education time factor very elderly visual acuity LA - English M3 - Article N1 - L619757842 2018-01-08 PY - 2017 SN - 1678-2925 SP - 238-241 ST - Assessment of eye drop instillation technique in glaucoma patients T2 - Arquivos brasileiros de oftalmologia TI - Assessment of eye drop instillation technique in glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619757842&from=export http://dx.doi.org/10.5935/0004-2749.20170058 VL - 80 ID - 2645 ER - TY - JOUR AB - PURPOSE. To evaluate the efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID and demonstrate non-inferiority to concomitant use of brimonidine tartrate 0.2% BID and timolol 0.5% BID in glaucoma and ocular hypertension patients with intraocular pressure (IOP) uncontrolled on monotherapy. METHODS. Randomized, multicenter, double-masked, parallel-group study involving 371 patients with inadequate IOP control (IOP from 22 to 34 mmHg) after ≥3 weeks of run-in on any monotherapy. Patients were treated with fixed-combination brimonidine/timolol BID (fixed-combination group, n=188) or concomitant brimonidine BID and timolol BID (concomitant group, n=183). IOP was assessed pre-dose and 2 hours after morning dosing at weeks 2, 6, and 12. RESULTS. A total of 355 patients (96%) completed the study. Patient demographics, run-in monotherapy, and baseline mean IOP on monotherapy were comparable between treatment groups. During follow-up, the mean reduction from baseline IOP was significant (p<0.001) at all time points and ranged from 4.4 to 5.3 mmHg in each group. Brimonidine/timolol fixed combination was as effective as concomitant therapy with respect to mean IOP and mean change from baseline IOP at all time points and visits. Between-group differences were ≤0.35 mmHg for mean IOP and ≤0.30 mmHg for mean change from baseline IOP; none were significant. No unexpected side effects were associated with the fixed combination. Both treatments were well tolerated with no difference in adverse events between groups. CONCLUSIONS. Brimonidine/timolol fixed-combination therapy is as safe and effective as concomitant treatment with the individual components. Its simplified dosing regimen has the potential to improve compliance. © Wichtig Editore, 2005. AD - F.J. Goñi, Balmes 323 1 1, Barcelona 08006, Spain AU - Goñi, F. J. DB - Embase Medline DO - 10.1177/112067210501500508 IS - 5 KW - brimonidine eye drops timolol adult aged allergic conjunctivitis article asthenia clinical trial closed angle glaucoma controlled clinical trial controlled study demography dose response double blind procedure drug efficacy drug safety drug tolerability eye burning eye pain female headache human hyperemia hypertension intraocular hypertension intraocular pressure major clinical study male monotherapy multicenter study ocular pruritus open angle glaucoma patient compliance priority journal randomized controlled trial somnolence treatment outcome visual disorder xerostomia LA - English M3 - Article N1 - L41426417 2005-10-31 PY - 2005 SN - 1120-6721 SP - 581-590 ST - 12-Week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension T2 - European Journal of Ophthalmology TI - 12-Week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41426417&from=export http://dx.doi.org/10.1177/112067210501500508 VL - 15 ID - 3709 ER - TY - JOUR AB - PURPOSE. To evaluate the efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID and demonstrate non-inferiority to concomitant use of brimonidine tartrate 0.2% BID and timolol 0.5% BID in glaucoma and ocular hypertension patients with intraocular pressure (IOP) uncontrolled on monotherapy. METHODS. Randomized, multicenter, double-masked, parallel-group study involving 371 patients with inadequate IOP control (IOP from 22 to 34 mmHg) after ≥3 weeks of run-in on any monotherapy. Patients were treated with fixed-combination brimonidine/timolol BID (fixed-combination group, n=188) or concomitant brimonidine BID and timolol BID (concomitant group, n=183). IOP was assessed pre-dose and 2 hours after morning dosing at weeks 2, 6, and 12. RESULTS. A total of 355 patients (96%) completed the study. Patient demographics, run-in monotherapy, and baseline mean IOP on monotherapy were comparable between treatment groups. During follow-up, the mean reduction from baseline IOP was significant (p<0.001) at all time points and ranged from 4.4 to 5.3 mmHg in each group. Brimonidine/timolol fixed combination was as effective as concomitant therapy with respect to mean IOP and mean change from baseline IOP at all time points and visits. Between-group differences were ≤0.35 mmHg for mean IOP and ≤0.30 mmHg for mean change from baseline IOP; none were significant. No unexpected side effects were associated with the fixed combination. Both treatments were well tolerated with no difference in adverse events between groups. CONCLUSIONS. Brimonidine/timolol fixed-combination therapy is as safe and effective as concomitant treatment with the individual components. Its simplified dosing regimen has the potential to improve compliance. © Wichtig Editore, 2005. AD - Servei Integrat Oftalmologia Vallès Oriental, Hospital Granollers, Mollet, Sant Celoni, Barcelona, Spain IMO, Universitat Autònoma Barcelona, Barcelona, Spain Balmes 323 1 1, Barcelona 08006, Spain AU - Goñi, F. J. DB - Scopus DO - 10.1177/112067210501500508 IS - 5 KW - Brimonidine Fixed combination Glaucoma Intraocular pressure Timolol M3 - Article N1 - Cited By :54 Export Date: 19 July 2021 PY - 2005 SP - 581-590 ST - 12-Week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension T2 - European Journal of Ophthalmology TI - 12-Week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-26444614168&doi=10.1177%2f112067210501500508&partnerID=40&md5=833a1df8848d01a42f0c19431aef9e6d VL - 15 ID - 4984 ER - TY - JOUR AB - PURPOSE. To evaluate the efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID and demonstrate non-inferiority to concomitant use of brimonidine tartrate 0.2% BID and timolol 0.5% BID in glaucoma and ocular hypertension patients with intraocular pressure (10P) uncontrolled on monotherapy. METHODS. Randomized, multicenter, double-masked, parallel-group study involving 371 patients with inadequate IOP control (IOP from 22 to 34 mmHg) after >= 3 weeks of run-in on any monotherapy. Patients were treated with fixed-combination brimonidine/timolol BID (fixed-combination group, n=188) or concomitant brimonidine BID and timolol BID (concomitant group, n=183). IOP was assessed pre-dose and 2 hours after morning dosing at weeks 2, 6, and 12. RESULTS. A total of 355 patients (96%) completed the study. Patient demographics, run-in monotherapy, and baseline mean IOP on monotherapy were comparable between treatment groups. During follow-up, the mean reduction from baseline IOP was significant (p<0.001) at all time points and ranged from 4.4 to 5.3 mmHg in each group. Brimonidine/timolol fixed combination was as effective as concomitant therapy with respect to mean IOP and mean change from baseline IOP at all time points and visits. Between-group differences were <= 0.35 mmHg for mean IOP and <= 0.30 mmHg for, mean change from baseline IOP; none were significant. No unexpected side effects were associated with the fixed combination. Both treatments were well tolerated with no difference in adverse events between groups. CONCLUSIONS. Brimonidine/timolol fixed-combination therapy is as safe and effective as concomitant treatment with the individual components. Its simplified dosing regimen has the potential to improve compliance. AN - WOS:000232352000008 AU - Goni, F. J. AU - Brimonid Timolol Fixeed Study, Grp DA - SEP-OCT IS - 5 PY - 2005 SN - 1120-6721 SP - 581-590 ST - 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension T2 - EUROPEAN JOURNAL OF OPHTHALMOLOGY TI - 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension VL - 15 ID - 6015 ER - TY - JOUR AB - PURPOSE: To evaluate the efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID and demonstrate non-inferiority to concomitant use of brimonidine tartrate 0.2% BID and timolol 0.5% BID in glaucoma and ocular hypertension patients with intraocular pressure (IOP) uncontrolled on monotherapy., METHODS: Randomized, multicenter, double-masked, parallel-group study involving 371 patients with inadequate IOP control (IOP from 22 to 34 mmHg) after > or =3 weeks of run-in on any monotherapy. Patients were treated with fixed-combination brimonidine/timolol BID (fixed-combination group, n = 188) or concomitant brimonidine BID and timolol BID (concomitant group, n = 183). IOP was assessed pre-dose and 2 hours after morning dosing at weeks 2, 6, and 12., RESULTS: A total of 355 patients (96%) completed the study. Patient demographics, run-in monotherapy, and baseline mean IOP on monotherapy were comparable between treatment groups. During follow-up, the mean reduction from baseline IOP was significant (p < 0.001) at all time points and ranged from 4.4 to 5.3 mmHg in each group. Brimonidine/timolol fixed combination was as effective as concomitant therapy with respect to mean IOP and mean change from baseline IOP at all time points and visits. Between-group differences were < or =0.35 mmHg for mean IOP and < or 0.30 mmHg for mean change from baseline IOP; none were significant. No unexpected side effects were associated with the fixed combination. Both treatments were well tolerated with no difference in adverse events between groups., CONCLUSIONS: Brimonidine/timolol fixed-combination therapy is as safe and effective as concomitant treatment with the individual components. Its simplified dosing regimen has the potential to improve compliance. AU - Goni, F. J. AU - Brimonidine/Timolol Fixed Combination Study, Group IS - 5 KW - Antihypertensive Agents/ae [Adverse Effects] *Antihypertensive Agents/tu [Therapeutic Use] Brimonidine Tartrate Double-Blind Method Drug Combinations Drug Therapy, Combination Female Follow-Up Studies *Glaucoma/dt [Drug Therapy] Humans Intraocular Pressure/de [Drug Effects] Male Middle Aged Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions/ae [Adverse Effects] Ophthalmic Solutions/tu [Therapeutic Use] Patient Compliance Quinoxalines/ae [Adverse Effects] *Quinoxalines/tu [Therapeutic Use] Timolol/ae [Adverse Effects] *Timolol/tu [Therapeutic Use] Treatment Outcome PY - 2005 SE - Goni, F J. Servei Integrat Oftalmologia Valles Oriental, Hospital Granollers, Mollet, Sant Celoni and IMO, Universitat Autonoma Barcelona, Barcelona, Spain. francisgoni@yahoo.com SN - 1120-6721 SP - 581-90 ST - 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension T2 - European journal of ophthalmology TI - 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=16167288 VL - 15 ID - 1722 ER - TY - JOUR AB - Current glaucoma management modalities are hindered by low patient compliance and adherence. This can be due to highly complex treatment strategies or poor patient understanding. Treatments focus on the management or reduction of intraocular pressure. This is most commonly done through the use of daily topical eye drops. Unfortunately, despite effective therapies, glaucoma continues to progress, possibly due to patients not adhering to their treatments. In order to mitigate these patient compliance issues, many sustained release treatments are being researched and are entering the clinic. Conjunctival, subconjunctival, and intravitreal inserts, punctal plugs, and drug depots are currently in clinical development. Each delivery system has hurdles, yet shows promise and could potentially mitigate the current problems associated with poor patient compliance. © 2012 by the authors. AD - B. Wirostko, Moran Eye Center, University of Utah, Salt Lake City, UT, United States AU - Gooch, N. AU - Molokhia, S. A. AU - Condie, R. AU - Burr, R. M. AU - Archer, B. AU - Ambati, B. K. AU - Wirostko, B. C1 - alphagan(Allergan) lacrisert(Aton) ocusert(Alza) ozurdex xalatan C2 - Aerie Alcon Allergan Alza Aton pSivida QLT(Canada) DB - Embase DO - 10.3390/pharmaceutics4010197 IS - 1 KW - 2 hydroxyethyl methacrylate anecortave antiglaucoma agent antisense oligonucleotide benzalkonium beta adrenergic receptor blocking agent brimonidine carbonate dehydratase inhibitor dexamethasone eye drops hydroxypropylcellulose latanoprost liposome microsphere nanosphere pilocarpine polycaprolactone polyglactin prostaglandin derivative silicone small interfering RNA timolol contact lens drug absorption drug delivery system drug efficacy drug formulation drug implant drug penetration drug safety drug tolerability dry eye dyspnea eye burning fatigue gel glaucoma heart disease human hydrogel hypotension incision infusion pump intraocular foreign body intraocular hypertension low level laser therapy lung disease mean residence time nonhuman open angle glaucoma ophthalmic insert patient compliance pump design punctal plug macular edema review sustained release preparation systemic disease tachycardia uveitis alphagan lacrisert ocusert ozurdex xalatan Cylindrical Smartplug L1 - internal-pdf://2639189051/3106-Ocular drug delivery for glaucoma ma-2012.pdf LA - English M3 - Review N1 - L364505283 2012-04-02 2012-04-12 PY - 2012 SN - 1999-4923 SP - 197-211 ST - Ocular drug delivery for glaucoma management T2 - Pharmaceutics TI - Ocular drug delivery for glaucoma management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364505283&from=export http://dx.doi.org/10.3390/pharmaceutics4010197 VL - 4 ID - 3106 ER - TY - JOUR AB - We investigated the regularity with which patients with diabetic retinopathy (DR) visited the DR clinic and the relationship between stage of DR or visual acuity and regularity of visits. The subjects for this study were 1,023 outpatients who were seen in Iwate Medical University Hospital between January 1997 and December 1998. We found that 70% of patients who were scheduled for follow-up visits with us from before the start of the study period visited the clinic regularly during the study period, while only 18% of patients who were newly referred to our clinic during the study period visited the clinic regularly. About 70% of patients with DR of stages A-III to A-V visited regularly, while about 40% of patients with DR of stages B-I to B-V came irregularly or did not visit within 2 scheduled follow-up appointments. Forty percent of patients with severe ocular complications such as neovascular glaucoma, optic neuropathy, or severe proliferative retinopathy discontinued their visits. Patients whose retinopathy was treated by any means were more willing to make follow-up visits. The results suggest that it is important for patients to visit the clinic on a regular schedule and for doctors to educate patients with DR about the importance of follow-up visits in managing this complication of diabetes effectively. AD - Dept of Ophthalmol., Iwate Medical Univ. School of Med., 19-1 Uchimaru, Morioka 020-8505, Japan AU - Gotoh, Y. AU - Sugawara, T. AU - Sasaki, Y. AU - Sasaki, K. AU - Kobayashi, T. AU - Takahashi, N. AU - Tazawa, Y. DB - Scopus IS - 5 KW - Diabetic Retinopathy Patient Education Periodical Ophthalmologic Care M3 - Article N1 - Export Date: 19 July 2021 PY - 2000 SP - 489-494 ST - Current status of follow-up for diabetic retinopathy patients: The importance of periodic ophthalmologic care T2 - Folia Ophthalmologica Japonica TI - Current status of follow-up for diabetic retinopathy patients: The importance of periodic ophthalmologic care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033857001&partnerID=40&md5=bba2ce3849fc338a8b967c28508d4734 VL - 51 ID - 5787 ER - TY - JOUR AB - We designed an intricate model of the process of glaucoma screening, diagnosis, and treatment in order to evaluate the medical care costs of such efforts in relation to the benefits in terms of quality-adjusted years of vision saved, utilizing the economic principles of cost-effectiveness analysis. Although a relatively limited data base and numerous assumptions concerning the accuracy of diagnostic tests, the natural history of ocular hypertension and glaucoma, and the effectiveness of available treatment modalities, limit our ability to draw definitive conclusions concerning the cost-effectiveness of various glaucoma screening options, our analysis indicates that glaucoma screening is probably cost-effective when targeted at certain subgroups of the population. Our analysis suggests that changes in several aspects of existing screening policies may be appropriate if cost-effectiveness is to be used as one of the criteria for the efficient allocation of resources to and within screening programs. Specifically, combinations of screening tests and screening targeted at high risk populations such as blacks, diabetics, and relatives of glaucoma patients are probably more cost-effective than screening of the general population with a single test. In younger populations, the importance of detecting ocular hypertension argues for the use of tonometry. Ophthalmoscopy may be more cost-effective in older age groups in whom the higher prevalence of glaucoma outweighs the need for identifying ocular hypertensives. In the very elderly, automated perimetry becomes cost-effective since the detection of established field loss will have greater yield. In addition, it is evident that diversion of resources away from actual screening efforts and towards efforts aimed at improving follow-up and compliance would be an additional cost-effective strategy. AD - Department of Ophthalmology, New England Medical Center Hospital, Tufts University School of Medicine, Boston, MA 02111 AU - Gottlieb, L. K. AU - Schwartz, B. AU - Pauker, S. G. DB - Embase Medline IS - 3 KW - cost benefit analysis diagnosis economic aspect glaucoma human prevention screening test social aspect tonometry visual field visual search visual system LA - English M3 - Article N1 - L14180494 1984-03-22 PY - 1983 SN - 0039-6257 SP - 206-226 ST - Glaucoma screening. A cost-effectiveness analysis T2 - Survey of Ophthalmology TI - Glaucoma screening. A cost-effectiveness analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L14180494&from=export VL - 28 ID - 4084 ER - TY - JOUR AB - We designed an intricate model of the process of glaucoma screening, diagnosis, and treatment in order to evaluate the medical care costs of such efforts in relation to the benefits in terms of quality-adjusted years of vision saved, utilizing the economic principles of cost-effectiveness analysis. Although a relatively limited data base and numerous assumptions concerning the accuracy of diagnostic tests, the natural history of ocular hypertension and glaucoma, and the effectiveness of available treatment modalities, limit our ability to draw definitive conclusions concerning the cost-effectiveness of various glaucoma screening options, our analysis indicates that glaucoma screening is probably cost-effective when targeted at certain subgroups of the population. Our analysis suggests that changes in several aspects of existing screening policies may be appropriate if cost-effectiveness is to be used as one of the criteria for the efficient allocation of resources to and within screening programs. Specifically, combinations of screening tests and screening targeted at high risk populations such as blacks, diabetics, and relatives of glaucoma patients are probably more cost-effective than screening of the general population with a single test. In younger populations, the importance of detecting ocular hypertension argues for the use of tonometry. Ophthalmoscopy may be more cost-effective in older age groups in whom the higher prevalence of glaucoma outweighs the need for identifying ocular hypertensives. In the very elderly, automated perimetry becomes cost-effective since the detection of established field loss will have greater yield. In addition, it is evident that diversion of resources away from actual screening efforts and towards efforts aimed at improving follow-up and compliance would be an additional cost-effective strategy. © 1983. AD - Department of Ophthalmology, New England Medical Center Hospital, Tufts University School of Medicine, Boston, MA, United States the Division of Clinical Decision Making, Department of Medicine, New England Medical Center Hospital, Boston, MA, United States AU - Gottlieb, L. K. AU - Schwartz, B. AU - Pauker, S. G. DB - Scopus DO - 10.1016/0039-6257(83)90098-X IS - 3 KW - blacks cost effectiveness analysis diabetics first degree relatives glaucoma management ocular hypertension ophthalmoscopy perimetry screening tonometry M3 - Article N1 - Cited By :44 Export Date: 19 July 2021 PY - 1983 SP - 206-226 ST - Glaucoma screening. A cost-effectiveness analysis T2 - Survey of Ophthalmology TI - Glaucoma screening. A cost-effectiveness analysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021012607&doi=10.1016%2f0039-6257%2883%2990098-X&partnerID=40&md5=d907f1f20d306858cee773964436373a VL - 28 ID - 5012 ER - TY - JOUR AB - Ocular injuries caused by chemical and thermal burns are often unmanageable and frequently result in disfigurement, corneal haze/opacification, and vision loss. Currently, a considerable number of surgical and pharmacological approaches are available to treat such injuries at either an acute or a chronic stage. However, these existing interventions are mainly directed at (and limited to) suppressing corneal inflammation and neovascularization while promoting re-epithelialization. Reconstruction of the ocular surface represents a suitable but last-option recourse in cases where epithelial healing is severely impaired, such as due to limbal stem cell deficiency. In this concise review, we discuss how biomechanical modulation therapy (BMT) may represent a more effective approach to promoting the regeneration of ocular tissues affected by burn injuries via restoration of the limbal stem cell niche. Specifically, the scientific basis supporting this new therapeutic modality is described, along with our growing understanding of the role that tissue biomechanics plays in stem cell fate and function. The potential impact of BMT as a future treatment option for the management of injuries affecting tissue compliance is also further discussed. Copyright 2020 The Authors. AU - Gouveia, Ricardo M. AU - Connon, Che J. DO - https://dx.doi.org/10.1167/tvst.9.12.5 IS - 12 KW - *Burns, Chemical Corneal Diseases/th [Therapy] *Corneal Diseases Humans *Limbus Corneae Stem Cell Transplantation PY - 2020 SE - Gouveia, Ricardo M. Biosciences Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Newcastle upon Tyne, UK. Connon, Che J. Biosciences Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Newcastle upon Tyne, UK. SN - 2164-2591 SP - 5 ST - Biomechanical Modulation Therapy-A Stem Cell Therapy Without Stem Cells for the Treatment of Severe Ocular Burns T2 - Translational vision science & technology TI - Biomechanical Modulation Therapy-A Stem Cell Therapy Without Stem Cells for the Treatment of Severe Ocular Burns UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33240564 VL - 9 Y2 - 20201102// ID - 187 ER - TY - JOUR AB - The pattern of drug self-administration among 15 patients not compliant with their pilocarpine therapy was studied with an electronic medication monitor. Recording the data and the hour every time the medication bottle was opened, the monitor gives detailed information on the medication behaviour. The results indicate different types of medication errors: inadequate spacing of doses during day with long intervals during the night, frequently missed doses at noon, and long interruptions in the medication, sometimes lasting for several days. Improvement in their compliance was seen in patients who were given instruction and taught to relate their medication to specified events in the day. AD - Dept. Ophthalmol., Huddinge Univ. Hosp., S-14186 Huddinge AU - Granstrom, P. A. DB - Embase Medline DO - 10.1136/bjo.66.7.464 IS - 7 KW - pilocarpine aged case report glaucoma patient compliance self medication therapy topical drug administration visual system LA - English M3 - Article N1 - L12085665 1982-09-19 PY - 1982 SN - 0007-1161 SP - 464-470 ST - Glaucoma patients not compliant with their drug therapy: Clinical and behavioural aspects T2 - British Journal of Ophthalmology TI - Glaucoma patients not compliant with their drug therapy: Clinical and behavioural aspects UR - https://www.embase.com/search/results?subaction=viewrecord&id=L12085665&from=export http://dx.doi.org/10.1136/bjo.66.7.464 VL - 66 ID - 4091 ER - TY - JOUR AB - Purpose: To establish the impact of educational support on patients' knowledge of glaucoma and adherence, in preparation for an intervention study. Methods: Structured observation encapsulated the educational support provided during clinical consultations and patient interviews captured the depth of glaucoma knowledge, problems associated with glaucoma therapy, and adherence issues. Results: One hundred and thirty-eight patients completed the study. Education was didactic in nature, limited for many patients and inconsistent across clinics. Patients showed generally poor knowledge of glaucoma with a median score of 6 (range 0-16). A significant association was found between educational support and knowledge for newly prescribed patients (Kendall's tau = 0.30, P = 0.003), but no association was found for follow-up patients (Kendall's tau = 0.11, P = 0.174). Only five (6%) patients admitted to a doctor that they did not adhere to their drop regimen, yet 75 (94%) reported at interview that they missed drops. Conclusions: Although important, knowledge alone may not sufficiently improve adherence: a patient-centred approach based on ongoing support according to need may provide a more effective solution for this patient group. © 2010 Macmillan Publishers Limited All rights reserved. AD - T. A. Gray, School of Biomedicine, University of Manchester, Manchester, United Kingdom AU - Gray, T. A. AU - Fenerty, C. AU - Harper, R. AU - Lee, A. AU - Spencer, A. F. AU - Campbell, M. AU - Henson, D. B. AU - Waterman, H. DB - Embase Medline DO - 10.1038/eye.2010.121 IS - 12 KW - adult aged clinical assessment correlation analysis drug instillation female glaucoma health health education health survey human interview major clinical study male medical education observation patient attitude patient compliance review self care self report LA - English M3 - Review N1 - L360163289 2010-12-23 2011-01-04 PY - 2010 SN - 1476-5454 0950-222X SP - 1777-1786 ST - Preliminary survey of educational support for patients prescribed ocular hypotensive therapy T2 - Eye TI - Preliminary survey of educational support for patients prescribed ocular hypotensive therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L360163289&from=export http://dx.doi.org/10.1038/eye.2010.121 VL - 24 ID - 3293 ER - TY - JOUR AB - Purpose: To establish the impact of educational support on patients' knowledge of glaucoma and adherence, in preparation for an intervention study. Methods: Structured observation encapsulated the educational support provided during clinical consultations and patient interviews captured the depth of glaucoma knowledge, problems associated with glaucoma therapy, and adherence issues. Results: One hundred and thirty-eight patients completed the study. Education was didactic in nature, limited for many patients and inconsistent across clinics. Patients showed generally poor knowledge of glaucoma with a median score of 6 (range 0-16). A significant association was found between educational support and knowledge for newly prescribed patients (Kendall's tau = 0.30, P = 0.003), but no association was found for follow-up patients (Kendall's tau = 0.11, P = 0.174). Only five (6%) patients admitted to a doctor that they did not adhere to their drop regimen, yet 75 (94%) reported at interview that they missed drops. Conclusions: Although important, knowledge alone may not sufficiently improve adherence: a patient-centred approach based on ongoing support according to need may provide a more effective solution for this patient group. © 2010 Macmillan Publishers Limited All rights reserved. AD - School of Biomedicine, University of Manchester, Manchester, United Kingdom Research Department, Manchester Royal Eye Hospital, Oxford Road, Manchester M13 9WL, United Kingdom School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom AU - Gray, T. A. AU - Fenerty, C. AU - Harper, R. AU - Lee, A. AU - Spencer, A. F. AU - Campbell, M. AU - Henson, D. B. AU - Waterman, H. DB - Scopus DO - 10.1038/eye.2010.121 IS - 12 KW - glaucoma medication adherence observation ocular hypertension ocular hypotensive therapy patient education M3 - Review N1 - Cited By :19 Export Date: 19 July 2021 PY - 2010 SP - 1777-1786 ST - Preliminary survey of educational support for patients prescribed ocular hypotensive therapy T2 - Eye TI - Preliminary survey of educational support for patients prescribed ocular hypotensive therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650206367&doi=10.1038%2feye.2010.121&partnerID=40&md5=bce56335a5d1350c57dd2a2c5e8a0538 VL - 24 ID - 5151 ER - TY - JOUR AB - Purpose To establish the impact of educational support on patients' knowledge of glaucoma and adherence, in preparation for an intervention study. Methods Structured observation encapsulated the educational support provided during clinical consultations and patient interviews captured the depth of glaucoma knowledge, problems associated with glaucoma therapy, and adherence issues. Results One hundred and thirty-eight patients completed the study. Education was didactic in nature, limited for many patients and inconsistent across clinics. Patients showed generally poor knowledge of glaucoma with a median score of 6 (range 0-16). A significant association was found between educational support and knowledge for newly prescribed patients (Kendall's tau =0.30, P = 0.003), but no association was found for follow-up patients (Kendall's tau = 0.11, P = 0.174). Only five (6%) patients admitted to a doctor that they did not adhere to their drop regimen, yet 75 (94%) reported at interview that they missed drops. Conclusions Although important, knowledge alone may not sufficiently improve adherence: a patient-centred approach based on ongoing support according to need may provide a more effective solution for this patient group. Eye (2010) 24, 1777-1786; doi:10.1038/eye.2010.121; published online 10 September 2010 AN - WOS:000285138500005 AU - Gray, T. A. AU - Fenerty, C. AU - Harper, R. AU - Lee, A. AU - Spencer, A. F. AU - Campbell, M. AU - Henson, D. B. AU - Waterman, H. DA - DEC DO - 10.1038/eye.2010.121 IS - 12 PY - 2010 SN - 0950-222X 1476-5454 SP - 1777-1786 ST - Preliminary survey of educational support for patients prescribed ocular hypotensive therapy T2 - EYE TI - Preliminary survey of educational support for patients prescribed ocular hypotensive therapy VL - 24 ID - 5919 ER - TY - JOUR AB - Purpose: To evaluate the impact of individualised patient care, as an adjunct to standard care, on adherence to ocular hypotensive therapy. Methods: A two-arm, single-masked exploratory randomised controlled trial recruited patients newly prescribed ocular hypotensive therapy. The intervention involved an individual assessment of health-care needs and beliefs and a 1-year follow-up period according to need. The primary outcome was refill adherence, measured by collating prescription and dispensing data for 12 months. Secondary outcomes included self-reported adherence, glaucoma knowledge, beliefs about illness and medicines, quality of care, intraocular pressure (IOP) fluctuation, and changes in clinical management assessed at 12 months. The strength of the intervention was measured following withdrawal by reviewing clinical outcomes for a further 12 months. Results: In all, 127 patients were recruited (91% response rate). Intervention-arm patients collected significantly more prescriptions than control-arm patients. Self-report adherence was significantly better in the intervention-arm for patients who forgot drops and those who intentionally missed drops. The intervention group demonstrated significantly more glaucoma knowledge, expressed a significantly stronger belief in the necessity of eye drops and believed that they had more personal control over managing their condition. Control-arm patients had more IOP fluctuation and changes in clinical management. However, this finding only reached significance at 24 months. Conclusion: Modelling patient care according to health-care needs and beliefs about illness and medicines can have a significant impact on improving adherence to therapy for this patient group, with the potential benefit of improving clinical outcomes. © 2012 Macmillan Publishers Limited All rights reserved. AD - T.A. Gray, Research Department, Manchester Royal Eye Hospital, Oxford Road, Manchester, M13 9WL, United Kingdom AU - Gray, T. A. AU - Fenerty, C. AU - Harper, R. AU - Spencer, A. F. AU - Campbell, M. AU - Henson, D. B. AU - Waterman, H. DB - Embase Medline DO - 10.1038/eye.2011.269 IS - 3 KW - ISRCTN13706134 eye drops adult aged article attitude to health controlled study exploratory research female follow up glaucoma health belief health care need health care quality human intraocular hypertension intraocular pressure major clinical study male patient care patient compliance perception prescription randomized controlled trial self report treatment outcome LA - English M3 - Article N1 - L364417781 2012-03-20 2012-03-22 PY - 2012 SN - 1476-5454 0950-222X SP - 407-417 ST - Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: An exploratory randomised controlled trial T2 - Eye TI - Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: An exploratory randomised controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364417781&from=export http://dx.doi.org/10.1038/eye.2011.269 VL - 26 ID - 3116 ER - TY - JOUR AB - Purpose: To evaluate the impact of individualised patient care, as an adjunct to standard care, on adherence to ocular hypotensive therapy. Methods: A two-arm, single-masked exploratory randomised controlled trial recruited patients newly prescribed ocular hypotensive therapy. The intervention involved an individual assessment of health-care needs and beliefs and a 1-year follow-up period according to need. The primary outcome was refill adherence, measured by collating prescription and dispensing data for 12 months. Secondary outcomes included self-reported adherence, glaucoma knowledge, beliefs about illness and medicines, quality of care, intraocular pressure (IOP) fluctuation, and changes in clinical management assessed at 12 months. The strength of the intervention was measured following withdrawal by reviewing clinical outcomes for a further 12 months. Results: In all, 127 patients were recruited (91% response rate). Intervention-arm patients collected significantly more prescriptions than control-arm patients. Self-report adherence was significantly better in the intervention-arm for patients who forgot drops and those who intentionally missed drops. The intervention group demonstrated significantly more glaucoma knowledge, expressed a significantly stronger belief in the necessity of eye drops and believed that they had more personal control over managing their condition. Control-arm patients had more IOP fluctuation and changes in clinical management. However, this finding only reached significance at 24 months. Conclusion: Modelling patient care according to health-care needs and beliefs about illness and medicines can have a significant impact on improving adherence to therapy for this patient group, with the potential benefit of improving clinical outcomes. © 2012 Macmillan Publishers Limited All rights reserved. AD - School of Biomedicine, University of Manchester, Manchester, United Kingdom Research Department, Manchester Royal Eye Hospital, Oxford Road, Manchester, M13 9WL, United Kingdom School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom AU - Gray, T. A. AU - Fenerty, C. AU - Harper, R. AU - Spencer, A. F. AU - Campbell, M. AU - Henson, D. B. AU - Waterman, H. DB - Scopus DO - 10.1038/eye.2011.269 IS - 3 KW - adherence ocular hypertension ocular hypotensive therapy open-angle glaucoma randomised controlled trial M3 - Article N1 - Cited By :40 Export Date: 19 July 2021 PY - 2012 SP - 407-417 ST - Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: An exploratory randomised controlled trial T2 - Eye TI - Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: An exploratory randomised controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858124244&doi=10.1038%2feye.2011.269&partnerID=40&md5=50f975cbed16c3b2fda5665758258cc4 VL - 26 ID - 5018 ER - TY - JOUR AB - Purpose To evaluate the impact of individualised patient care, as an adjunct to standard care, on adherence to ocular hypotensive therapy. Methods A two-arm, single-masked exploratory randomised controlled trial recruited patients newly prescribed ocular hypotensive therapy. The intervention involved an individual assessment of health-care needs and beliefs and a 1-year follow-up period according to need. The primary outcome was refill adherence, measured by collating prescription and dispensing data for 12 months. Secondary outcomes included self-reported adherence, glaucoma knowledge, beliefs about illness and medicines, quality of care, intraocular pressure (IOP) fluctuation, and changes in clinical management assessed at 12 months. The strength of the intervention was measured following withdrawal by reviewing clinical outcomes for a further 12 months. Results In all, 127 patients were recruited (91% response rate). Intervention-arm patients collected significantly more prescriptions than control-arm patients. Self-report adherence was significantly better in the intervention-arm for patients who forgot drops and those who intentionally missed drops. The intervention group demonstrated significantly more glaucoma knowledge, expressed a significantly stronger belief in the necessity of eye drops and believed that they had more personal control over managing their condition. Control-arm patients had more IOP fluctuation and changes in clinical management. However, this finding only reached significance at 24 months. Conclusion Modelling patient care according to health-care needs and beliefs about illness and medicines can have a significant impact on improving adherence to therapy for this patient group, with the potential benefit of improving clinical outcomes. Eye (2012) 26, 407-417; doi: 10.1038/eye.2011.269; published online 18 November 2011 AN - WOS:000301428900008 AU - Gray, T. A. AU - Fenerty, C. AU - Harper, R. AU - Spencer, A. F. AU - Campbell, M. AU - Henson, D. B. AU - Waterman, H. DA - MAR DO - 10.1038/eye.2011.269 IS - 3 PY - 2012 SN - 0950-222X 1476-5454 SP - 407-417 ST - Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial T2 - EYE TI - Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial VL - 26 ID - 5963 ER - TY - JOUR AB - BACKGROUND: Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information and ongoing support according to patient need, may have a positive effect on improving adherence., OBJECTIVES: To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma., SEARCH STRATEGY: We searched CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, Web of Science, ZETOC and OpenSIGLE. In addition, we searched research registers of ongoing studies. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision and Ophthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 15 January 2009., SELECTION CRITERIA: We included randomised controlled trials (RCTs) and quasi RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma., DATA COLLECTION AND ANALYSIS: At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We calculated the mean difference for continuous data and relative risks for dichotomous data. Where appropriate, we pooled data using a fixed-effect model., MAIN RESULTS: Eight trials met the inclusion criteria. There was considerable heterogeneity of interventions and reported outcome measures and therefore, meta-analysis was limited to two studies. Overall, studies were not of high quality due to small sample sizes, missing data and short term follow-up. Three of five drug comparison studies provided evidence that reducing the frequency of drops can improve adherence. However, the study that compared the least frequent regime with one of the most complicated, showed no difference in reported adherence. A small study of thirteen patients found a reminder device beneficial to adherence levels yet only one of two studies involving education and individualised care planning was found to be successful., AUTHORS' CONCLUSIONS: Interventions involving simplified dosing regimes, reminder devices, education and individualised care planning, did show improvements in adherence rates. However, due to inadequate methodological quality and heterogeneity of study design we are unable to advocate any particular interventions at this time. AU - Gray, Trish A. AU - Orton, Lois C. AU - Henson, David AU - Harper, Robert AU - Waterman, Heather DO - https://dx.doi.org/10.1002/14651858.CD006132.pub2 IS - 2 KW - Glaucoma/dt [Drug Therapy] Humans *Medication Adherence *Ocular Hypertension/dt [Drug Therapy] Ophthalmic Solutions/ad [Administration & Dosage] Randomized Controlled Trials as Topic N1 - Update in (UIN) PY - 2009 SE - Gray, Trish A. Academic Department of Ophthalmology, Manchester Royal Eye Hospital, Oxford Road, Manchester, UK, M13 9WH. trish.gray@manchester.ac.uk SN - 1469-493X 1361-6137 SP - CD006132 ST - Interventions for improving adherence to ocular hypotensive therapy T2 - The Cochrane database of systematic reviews T3 - Update in: Cochrane Database Syst Rev. 2013;4:CD006132; PMID: 23633333 [https://www.ncbi.nlm.nih.gov/pubmed/23633333] TI - Interventions for improving adherence to ocular hypotensive therapy UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN=19370627 Y2 - 20090415// ID - 1462 ER - TY - JOUR AB - Background: Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information and ongoing support according to patient need, may have a positive effect on improving adherence. Objectives: To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma. Search strategy: We searched CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, Web of Science, ZETOC and OpenSIGLE. In addition, we searched research registers of ongoing studies. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision andOphthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 15 January 2009. Selection criteria: We included randomised controlled trials (RCTs) and quasi RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma. Data collection and analysis: At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We calculated the mean difference for continuous data and relative risks for dichotomous data. Where appropriate, we pooled data using a fixed-effect model. Main results: Eight trials met the inclusion criteria. There was considerable heterogeneity of interventions and reported outcome measures and therefore, meta-analysis was limited to two studies. Overall, studies were not of high quality due to small sample sizes, missing data and short term follow-up. Three of five drug comparison studies provided evidence that reducing the frequency of drops can improve adherence. However, the study that compared the least frequent regime with one of the most complicated, showed no difference in reported adherence. A small study of thirteen patients found a reminder device beneficial to adherence levels yet only one of two studies involving education and individualised care planning was found to be successful. Authors' conclusions: Interventions involving simplified dosing regimes, reminder devices, education and individualised care planning, did showimprovements in adherence rates. However, due to inadequate methodological quality and heterogeneity of study design we are unable to advocate any particular interventions at this time. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. AD - T. A. Gray, Academic Department of Ophthalmology, Manchester Royal Eye Hospital, Oxford Road, Manchester, M13 9WH, United Kingdom AU - Gray, T. A. AU - Orton, L. C. AU - Henson, D. AU - Harper, R. AU - Waterman, H. DB - Embase Medline DO - 10.1002/14651858.CD006132.pub2 IS - 2 KW - antihypertensive agent dorzolamide dorzolamide plus timolol latanoprost pilocarpine timolol Cinahl clinical trial closed angle glaucoma Cochrane Library data extraction Embase eye examination follow up glaucoma health education health status human intraocular hypertension intraocular pressure medical record medical society Medline meta analysis oculoplethysmography outcome assessment patient care planning patient compliance patient monitoring PsycINFO register research review systematic review visual acuity visual field defect LA - English M3 - Review N1 - L355267424 2009-10-27 PY - 2009 SN - 1469-493X ST - Interventions for improving adherence to ocular hypotensive therapy T2 - Cochrane Database of Systematic Reviews TI - Interventions for improving adherence to ocular hypotensive therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355267424&from=export http://dx.doi.org/10.1002/14651858.CD006132.pub2 http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006132/pdf_fs.html ID - 3323 ER - TY - JOUR AB - Background: Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information and ongoing support according to patient need, may have a positive effect on improving adherence. Objectives: To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma. Search strategy: We searched CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, Web of Science, ZETOC and OpenSIGLE. In addition, we searched research registers of ongoing studies. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision andOphthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 15 January 2009. Selection criteria: We included randomised controlled trials (RCTs) and quasi RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma. Data collection and analysis: At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We calculated the mean difference for continuous data and relative risks for dichotomous data. Where appropriate, we pooled data using a fixed-effect model. Main results: Eight trials met the inclusion criteria. There was considerable heterogeneity of interventions and reported outcome measures and therefore, meta-analysis was limited to two studies. Overall, studies were not of high quality due to small sample sizes, missing data and short term follow-up. Three of five drug comparison studies provided evidence that reducing the frequency of drops can improve adherence. However, the study that compared the least frequent regime with one of the most complicated, showed no difference in reported adherence. A small study of thirteen patients found a reminder device beneficial to adherence levels yet only one of two studies involving education and individualised care planning was found to be successful. Authors' conclusions: Interventions involving simplified dosing regimes, reminder devices, education and individualised care planning, did showimprovements in adherence rates. However, due to inadequate methodological quality and heterogeneity of study design we are unable to advocate any particular interventions at this time. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. AD - Academic Department of Ophthalmology, Manchester Royal Eye Hospital, Oxford Road, Manchester, M13 9WH, United Kingdom School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom Optometry Department, Central Manchester and Manchester Children's NHS Trust, Manchester, United Kingdom AU - Gray, T. A. AU - Orton, L. C. AU - Henson, D. AU - Harper, R. AU - Waterman, H. C7 - Cd006132 DB - Scopus DO - 10.1002/14651858.CD006132.pub2 IS - 2 M3 - Review N1 - Cited By :43 Export Date: 19 July 2021 PY - 2009 ST - Interventions for improving adherence to ocular hypotensive therapy T2 - Cochrane Database of Systematic Reviews TI - Interventions for improving adherence to ocular hypotensive therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349149088&doi=10.1002%2f14651858.CD006132.pub2&partnerID=40&md5=73e6d894689c7f6de1a1e11f1ce9254a ID - 5013 ER - TY - JOUR AB - Background Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information and ongoing support according to patient need, may have a positive effect on improving adherence. Objectives To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma. Search strategy We searched CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, Web of Science, ZETOC and OpenSIGLE. In addition, we searched research registers of ongoing studies. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision and Ophthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 15 January 2009. Selection criteria We included randomised controlled trials (RCTs) and quasi RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma. Data collection and analysis At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We calculated the mean difference for continuous data and relative risks for dichotomous data. Where appropriate, we pooled data using a fixed-effect model. Main results Eight trials met the inclusion criteria. There was considerable heterogeneity of interventions and reported outcome measures and therefore, meta-analysis was limited to two studies. Overall, studies were not of high quality due to small sample sizes, missing data and short term follow-up. Three of five drug comparison studies provided evidence that reducing the frequency of drops can improve adherence. However, the study that compared the least frequent regime with one of the most complicated, showed no difference in reported adherence. A small study of thirteen patients found a reminder device beneficial to adherence levels yet only one of two studies involving education and individualised care planning was found to be successful. Authors' conclusions Interventions involving simplified dosing regimes, reminder devices, education and individualised care planning, did show improvements in adherence rates. However, due to inadequate methodological quality and heterogeneity of study design we are unable to advocate any particular interventions at this time. AN - WOS:000265200000045 AU - Gray, T. A. AU - Orton, L. C. AU - Henson, D. AU - Harper, R. AU - Waterman, H. DO - 10.1002/14651858.CD006132.pub2 IS - 2 PY - 2009 SN - 1469-493X 1361-6137 ST - Interventions for improving adherence to ocular hypotensive therapy T2 - COCHRANE DATABASE OF SYSTEMATIC REVIEWS TI - Interventions for improving adherence to ocular hypotensive therapy ID - 6093 ER - TY - JOUR AB - Despite the availability of numerous treatments, glaucoma is still one of the leading causes of blindness in the UK. This article examines some of the factors that might be responsible, including poor compliance with eye drops and pressure on ophthalmology services, and discusses how these problems might be overcome. AN - 139252157. Language: English. Entry Date: 20191102. Revision Date: 20200831. Publication Type: Article AU - Greener, Mark DB - ccm DO - 10.1002/psb.1786 DP - EBSCOhost IS - 9 KW - Glaucoma -- Psychosocial Factors Glaucoma -- Drug Therapy Uvea -- Physiology Intraocular Pressure -- Physiology Intraocular Pressure -- Evaluation Drugs, Investigational Intraocular Pressure -- Psychosocial Factors N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9503766. PY - 2019 SN - 0959-6682 SP - 11-18 ST - Dealing with the pressure of glaucoma management T2 - Prescriber TI - Dealing with the pressure of glaucoma management UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139252157&site=ehost-live&scope=site VL - 30 ID - 4203 ER - TY - JOUR AB - The routine, easiest-to-treat adult patients with glaucoma utilize 1.80 office visits, 3.34 prescriptions, and 2.02 medical/surgical procedures during the course of a year. Based on data from the PTE-Registry database, this patient group did not receive any hospital admissions or professional inpatient services. Eye surgery was performed at an average rate of 0.08 times per PTE. About 53.5% of all PTEs were treated without the use of prescription drugs. When a drug was prescribed, beta blockers were used most often. In fact, 74.1% of all PTEs treated with a single drug group used a beta blocker. AD - J.A. Gricar AU - Gricar, J. A. AU - Wilson, P. R. AU - Cave, D. G. DB - Medline IS - 5 KW - adolescent adult ambulatory care article clinical practice cost of illness economics glaucoma health service hospitalization human middle aged ophthalmology patient care statistics United States utilization review LA - English M3 - Article N1 - L128288567 1998-09-01 PY - 1998 SN - 1096-5645 SP - 42-44 ST - Glaucoma T2 - Managed care interface TI - Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L128288567&from=export VL - 11 ID - 3945 ER - TY - JOUR AB - PURPOSES: The purposes of this study were to report the presentation and management of an acquired total anterior staphyloma that resulted from a fungal corneal ulcer and to discuss its pathogenesis. METHODS: Observational case report. Clinical observation and surgical intervention of a patient who developed a total anterior staphyloma after a partially treated fungal corneal ulcer. RESULTS: The patient presented with a large traumatic fungal ulcer but was poorly compliant with follow-up and medications. He subsequently presented with a large total anterior staphyloma that resulted from perforation of the ulcer with plugging of the defect with iris and formation of a pseudocornea over the iris. The anterior staphyloma measured 15 × 16 mm and progressed to a stage where the patient was unable to close his eyelids and required a sclerokeratoplasty. Currently, vision is poor from amblyopia and a cloudy graft; however, the eye is intact and comfortable. CONCLUSIONS: Anterior staphylomas usually result from untreated fungal ulcers in developing nations. Poor compliance with medications and follow-up was the cause of our patient's anterior staphyloma. Sclerokeratoplasty can restore the globe structurally but has poor visual prognosis. © 2009 by Lippincott Williams & Wilkins. AD - S. S. Tuli, Department of Ophthalmology, University of Florida, 1600 SWArcher Road, Gainesville, FL 32610-0284 AU - Grieser, E. J. AU - Tuli, S. S. AU - Chabi, A. AU - Schultz, S. AU - Downer, D. DB - Embase Medline DO - 10.1097/ICO.0b013e318183a3d1 IS - 2 KW - antifungal agent timolol adult amblyopia anamnesis article case report clinical assessment clinical feature cornea neovascularization cornea ulcer eye examination follow up fungus culture histopathology human human tissue intraocular pressure abnormality keratomycosis keratoplasty male pathogenesis patient compliance priority journal sclerokeratoplasty slit lamp staphyloma surgical technique uvea disease vision visual acuity LA - English M3 - Article N1 - L354928399 2009-08-18 PY - 2009 SN - 0277-3740 SP - 231-232 ST - Blueberry eye: Acquired total anterior staphyloma after a fungal corneal ulcer T2 - Cornea TI - Blueberry eye: Acquired total anterior staphyloma after a fungal corneal ulcer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354928399&from=export http://dx.doi.org/10.1097/ICO.0b013e318183a3d1 VL - 28 ID - 3380 ER - TY - JOUR AB - PURPOSES: The purposes of this study were to report the presentation and management of an acquired total anterior staphyloma that resulted from a fungal corneal ulcer and to discuss its pathogenesis. METHODS: Observational case report. Clinical observation and surgical intervention of a patient who developed a total anterior staphyloma after a partially treated fungal corneal ulcer. RESULTS: The patient presented with a large traumatic fungal ulcer but was poorly compliant with follow-up and medications. He subsequently presented with a large total anterior staphyloma that resulted from perforation of the ulcer with plugging of the defect with iris and formation of a pseudocornea over the iris. The anterior staphyloma measured 15 × 16 mm and progressed to a stage where the patient was unable to close his eyelids and required a sclerokeratoplasty. Currently, vision is poor from amblyopia and a cloudy graft; however, the eye is intact and comfortable. CONCLUSIONS: Anterior staphylomas usually result from untreated fungal ulcers in developing nations. Poor compliance with medications and follow-up was the cause of our patient's anterior staphyloma. Sclerokeratoplasty can restore the globe structurally but has poor visual prognosis. © 2009 by Lippincott Williams & Wilkins. AD - Department of Ophthalmology, University of Florida, 1600 SWArcher Road, Gainesville, FL 32610-0284, United States AU - Grieser, E. J. AU - Tuli, S. S. AU - Chabi, A. AU - Schultz, S. AU - Downer, D. DB - Scopus DO - 10.1097/ICO.0b013e318183a3d1 IS - 2 KW - Anterior staphyloma Fungal ulcer Sclerokeratoplasty M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2009 SP - 231-232 ST - Blueberry eye: Acquired total anterior staphyloma after a fungal corneal ulcer T2 - Cornea TI - Blueberry eye: Acquired total anterior staphyloma after a fungal corneal ulcer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67650613961&doi=10.1097%2fICO.0b013e318183a3d1&partnerID=40&md5=4a774e32a99d3764cf6b4f95c1dcab34 VL - 28 ID - 5310 ER - TY - JOUR AB - Purposes: The purposes of this study were to report the presentation and management of an acquired total anterior staphyloma that resulted from a fungal corneal ulcer and to discuss its pathogenesis. Methods: Observational case report. Clinical observation and surgical intervention of a patient who developed a total anterior staphyloma after a partially treated fungal corneal ulcer. Results: The patient presented with a large traumatic fungal ulcer but was poorly compliant with follow-up and medications. He Subsequently presented with a large total anterior staphyloma that resulted from perforation of the ulcer with plugging of the defect with iris and formation of a pseudocornea over the iris. The anterior staphyloma measured 15 X 16 mm and progressed to a stage where the patient was unable to close his eyelids and required a sclerokeratoplasm Currently, vision is poor from amblyopia and a Cloudy graft; however, the eye is intact and comfortable. Conclusions: Anterior staphylomas usually result from untreated Fungal ulcers in developing nations. Poor compliance with medications and follow-up was the cause of our patient's anterior staphyloma. Sclerokeratoplasty can restore the globe Structurally but has poor visual prognosis. AN - WOS:000262844100024 AU - Grieser, E. J. AU - Tuli, S. S. AU - Chabi, A. AU - Schultz, S. AU - Downer, D. DA - FEB DO - 10.1097/ICO.0b013e318183a3d1 IS - 2 PY - 2009 SN - 0277-3740 1536-4798 SP - 231-232 ST - Blueberry Eye: Acquired Total Anterior Staphyloma After a Fungal Corneal Ulcer T2 - CORNEA TI - Blueberry Eye: Acquired Total Anterior Staphyloma After a Fungal Corneal Ulcer VL - 28 ID - 5810 ER - TY - JOUR AB - Self-tonometry could be established as an important diagnostic tool in the early diagnosis and follow-up of glaucoma provided that a self-tonometer is precise, safe and easy to use. Furthermore, it has to comply with the legal standards for tonometer calibration. A new software-controlled detection system for the self tonometer permits the evaluation of external factors during the measurement which influence the precision of the tonometric readings. The updated version of the self-tonometer (ST) was compared to the Draeger hand-held applanation tonometer (HAT) in a clinical study with 82 patients (151 eyes). The results show a regression line characterized by a slope of 0.99, an y interception of 1.41, a correlation coefficient of 0.96 and a standard deviation for the ST readings of ±1.78 mmHg. Self-tonometry improves the IOP monitoring as well as patient compliance and therefore is a potential diagnostic tool in the management of glaucoma. © 1992 Kluwer Academic Publishers. AD - Department of Ophthalmology, University of Hamburg, Martinistrasse 52, 200, Hamburg 20, Germany AU - Groenhoff, S. AU - Draeger, J. AU - Deutsch, C. AU - Wiezorrek, R. AU - Hock, B. DB - Scopus DO - 10.1007/BF00917980 IS - 4-5 KW - error detection system optical sensor self-tonometer self-tonometry M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 1992 SP - 299-303 ST - Self-tonometry: technical aspects of calibration and clinical application T2 - International Ophthalmology TI - Self-tonometry: technical aspects of calibration and clinical application UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026761921&doi=10.1007%2fBF00917980&partnerID=40&md5=75bed3df2d1bb12444c9f7fbb5c0ff9a VL - 16 ID - 5317 ER - TY - JOUR AB - Self-tonometry could be established as an important diagnostic tool in the early diagnosis and follow-up of glaucoma provided that a self-tonometer is precise, safe and easy to use. Furthermore, it has to comply with the legal standards for tonometer calibration. A new software-controlled detection system for the self-tonometer permits the evaluation of external factors during the measurement which influence the precision of the tonometric readings. The updated version of the self-tonometer (ST) was compared to the Draeger hand-held applanation tonometer (HAT) in a clinical study with 82 patients (151 eyes). The results show a regression line characterized by a slope of 0.99, an y interception of 1.41, a correlation coefficient of 0.96 and a standard deviation for the ST readings of +/- 1.78 mmHg. Self-tonometry improves the IOP monitoring as well as patient compliance and therefore is a potential diagnostic tool in the management of glaucoma. AN - WOS:A1992JW39000020 AU - Groenhoff, S. AU - Draeger, J. AU - Deutsch, C. AU - Wiezorrek, R. AU - Hock, B. DA - SEP DO - 10.1007/BF00917980 IS - 4-5 PY - 1992 SN - 0165-5701 SP - 299-303 ST - SELF-TONOMETRY - TECHNICAL ASPECTS OF CALIBRATION AND CLINICAL-APPLICATION T2 - INTERNATIONAL OPHTHALMOLOGY TI - SELF-TONOMETRY - TECHNICAL ASPECTS OF CALIBRATION AND CLINICAL-APPLICATION VL - 16 ID - 6157 ER - TY - JOUR AD - Diplomate, American Academy of Optometry's Section on Cornea, Contact Lenses and Refractive Technologies and practices, Chevy Chase, Md. AN - 108084508. Language: English. Entry Date: 20121207. Revision Date: 20150712. Publication Type: Journal Article AU - Gromacki, Susan J. DB - ccm DP - EBSCOhost IS - 11 KW - Teaching Materials -- Evaluation Writing for Publication Patient Compliance -- Evaluation Optometry Contact Lenses Patient Education Acanthamoeba Keratitis -- Risk Factors Hygiene Access to Information -- Evaluation Internet N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 8610268. PY - 2012 SN - 0885-9175 SP - 17-17 ST - Written Educational Materials Improve Lens Compliance T2 - Contact Lens Spectrum TI - Written Educational Materials Improve Lens Compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108084508&site=ehost-live&scope=site VL - 27 ID - 4796 ER - TY - JOUR AB - Purpose: To analyse a response to the therapy switch from the concomitant application of βblocker and topical carbonic anhydrase inhibitor to the fixed combination of timolol and dorzolamide (Cosopt*) in glaucoma/ocular hypertensive patients under everyday, office-practice conditions. Patients and methods: The data source was a survey among practising ophthalmologists in Switzerland assessing their experience with glaucoma patients/ocular hypertensives put for the first time on the fixed combination of timolol and dorzolamide. A total of 98 patients underwent the therapy switch in at least one eye. The intraocular pressure (IOP) change between the baseline visit before switch to the timolol-dorzolamide fixed combination occurred, and the first follow-up control after the switch, served as an indicator of compliance. Results: The IOP decreased on average from 19.43 ± 5.64 mmHg to 17.97 ± 3.58 mmHg (p < 0.01). The time to the follow-up visit ranged from 4 to 354 days, and the magnitude of IOP change demonstrated a significant dependence on the time to the follow-up visit, also when corrected for baseline IOP level. A total of 87 (85.3%) continued on the timolol-dorzolamide fixed combination therapy after the first control visit. In 68 of these 98 patients the contralateral eyes underwent the same therapy switch, and their IOP followed an identical pattern of behaviour. Conclusion: The average IOP decrease of 1.5 mmHg upon therapy switch to the timolol-dorzolamide fixed combination suggests a better efficacy due to improved compliance. Short-term compliance benefit seems to be more pronounced. The high timolol-dorzolamide fixed combination therapy continuation rate reflects an improvement in compliance and subjectively-perceived convenience. AD - K. Gugleta, University Eye Clinic Basel, Mittlere Str. 91, Basel, Switzerland AU - Gugleta, K. AU - Orgül, S. AU - Flammer, J. C1 - cosopt DB - Embase Medline DO - 10.1185/030079903125001820 IS - 4 KW - dorzolamide dorzolamide plus timolol timolol adult aged article drug efficacy female follow up glaucoma human intraocular pressure major clinical study male patient compliance Switzerland treatment outcome cosopt LA - English M3 - Article N1 - L36827842 2003-07-27 PY - 2003 SN - 0300-7995 SP - 330-335 ST - Experience with cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices T2 - Current Medical Research and Opinion TI - Experience with cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36827842&from=export http://dx.doi.org/10.1185/030079903125001820 VL - 19 ID - 3809 ER - TY - JOUR AB - Purpose: To analyse a response to the therapy switch from the concomitant application of βblocker and topical carbonic anhydrase inhibitor to the fixed combination of timolol and dorzolamide (Cosopt*) in glaucoma/ocular hypertensive patients under everyday, office-practice conditions. Patients and methods: The data source was a survey among practising ophthalmologists in Switzerland assessing their experience with glaucoma patients/ocular hypertensives put for the first time on the fixed combination of timolol and dorzolamide. A total of 98 patients underwent the therapy switch in at least one eye. The intraocular pressure (IOP) change between the baseline visit before switch to the timolol-dorzolamide fixed combination occurred, and the first follow-up control after the switch, served as an indicator of compliance. Results: The IOP decreased on average from 19.43 ± 5.64 mmHg to 17.97 ± 3.58 mmHg (p < 0.01). The time to the follow-up visit ranged from 4 to 354 days, and the magnitude of IOP change demonstrated a significant dependence on the time to the follow-up visit, also when corrected for baseline IOP level. A total of 87 (85.3%) continued on the timolol-dorzolamide fixed combination therapy after the first control visit. In 68 of these 98 patients the contralateral eyes underwent the same therapy switch, and their IOP followed an identical pattern of behaviour. Conclusion: The average IOP decrease of 1.5 mmHg upon therapy switch to the timolol-dorzolamide fixed combination suggests a better efficacy due to improved compliance. Short-term compliance benefit seems to be more pronounced. The high timolol-dorzolamide fixed combination therapy continuation rate reflects an improvement in compliance and subjectively-perceived convenience. AD - University Eye Clinic, Basel, Switzerland University Eye Clinic Basel, Mittlere Str. 91, Basel, Switzerland AU - Gugleta, K. AU - Orgül, S. AU - Flammer, J. DB - Scopus DO - 10.1185/030079903125001820 IS - 4 KW - Compliance Dorzolamide Fixed/free combination switch Intraocular pressure, control Timolol M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2003 SP - 330-335 ST - Experience with cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices T2 - Current Medical Research and Opinion TI - Experience with cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038005107&doi=10.1185%2f030079903125001820&partnerID=40&md5=d667656ab983502ae561d82be97a863b VL - 19 ID - 5116 ER - TY - JOUR AB - Purpose: To analyse a response to the therapy switch from the concomitant application of beta-blocker and topical carbonic anhydrase inhibitor to the fixed combination of timolol and dorzolamide (Cosopt*) in glaucoma/ocular hypertensive patients under everyday, office-practice conditions. Patients and methods: The data source was a survey among practising ophthalmologists in Switzerland assessing their experience with glaucoma patients/ocular hypertensives put for the first time on the fixed combination of timolol and dorzolamide. A total of 98 patients underwent the therapy switch in at least one eye. The intraocular pressure (IOP) change between the baseline visit before switch to the timolol-dorzolamide fixed combination occurred, and the first follow-up control after the switch, served as an indicator of compliance. Results: The IOP decreased on average from 19.43+/-5.64 mmHg to 17.97+/-3.58 mmHg (p<0.01). The time to the follow-up visit ranged from 4 to 354 days, and the magnitude of IOP change demonstrated a significant dependence on the time to the follow-up visit, also when corrected for baseline 1013 level. A total of 87 (85.3%) continued on the timolol-dorzolamide fixed combination therapy after the first control visit. In 68 of these 98 patients the contralateral eyes underwent the same therapy switch, and their IOP followed an identical pattern of behaviour. Conclusion: The average IOP decrease of 1.5 mmHg upon therapy switch to the timolol-dorzolamide fixed combination suggests a better efficacy due to improved compliance. Shortterm compliance benefit seems to be more pronounced. The high timolol-dorzolamide fixed combination therapy continuation rate reflects an improvement in compliance and subjectively-perceived convenience. AN - WOS:000184074300010 AU - Gugleta, K. AU - Orgul, S. AU - Flammer, J. DO - 10.1185/030079903125001820 IS - 4 PY - 2003 SN - 0300-7995 SP - 330-335 ST - Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices T2 - CURRENT MEDICAL RESEARCH AND OPINION TI - Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices VL - 19 ID - 5922 ER - TY - GEN AU - Guillon, M. AU - Benjamin, W. J. CY - Philadelphia, Pennsylvania DB - ccm DO - 10.1016/0140-6736(91)92003-k DP - EBSCOhost J2 - Lancet KW - Corneal Ulcer -- Microbiology Contact Lenses -- Adverse Effects Patient Compliance Risk Factors N1 - Accession Number: 125317010. Language: English. Entry Date: 20161125. Revision Date: 20190917. Publication Type: commentary; letter. Original Study: Lancet. 1991 Sep 14;338(8768):650-3. Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 2985213R. PMID: NLM1682565. PB - Lancet PY - 1991 SN - 0140-6736 SP - 1146-1147 ST - Contact lenses and keratitis TI - Contact lenses and keratitis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=125317010&site=ehost-live&scope=site VL - 338 ID - 4778 ER - TY - JOUR AB - To compare the short-term effectiveness and ocular side-effects of fixed combinations of dorzolamide/timolol (DTFC) and brimonidine/timolol (BTFC) in patients with primary open-angle glaucoma (POAG). Forty-two eyes of 42 patients newly diagnosed with primary open-angle glaucoma were assessed prospectively. One of the two eyes was chosen randomly and treated with DTFC (2 × 1) for 4 weeks. The treatment was then stopped to allow a 4-week wash-out period. Following the wash-out period, the same eye was treated with BTFC (2 × 1) for 4 weeks. Intraocular pressure (IOP) values were measured before and after each treatment at 0800, 1,200 and 1,600 h. Tear function test results and ocular side-effects were also recorded. The mean baseline IOP values for DTFC and BTFC were 24.1 ± 1.8 and 24.6 ± 2.4 mmHg, respectively. The mean IOP values after 4 weeks of treatment with DTFC or BTFC were 17.1 ± 2.9 and 16.9 ± 2.5 mmHg, respectively. Both medications reduced IOP values significantly (P = 0.0000). The effectiveness of both medications was similar (P = 0.7363). Both combinations significantly reduced the amount of tear secretion and tear break-up time (P = 0.0000). Eye burning was more common with DTFC than with BTFC (P = 0.0182). Other adverse effects were observed at similar rates for both combinations. This study demonstrated that the IOP-reducing effects of DTFC and BTFC in patients with POAG are similar. The side-effect profile of BTFC is similar to that of DTFC. Lower occurrence of a burning sensation may improve patient compliance in the BTFC group. © 2011 Springer Science+Business Media B.V. AD - G. Gulkilik, Sisli Etfal Training and Research Hospital, Istanbul, Turkey AU - Gulkilik, G. AU - Oba, E. AU - Odabasi, M. DB - Embase Medline DO - 10.1007/s10792-011-9495-z KW - patient open angle glaucoma side effect human intraocular pressure eye lacrimal fluid drug therapy burning sensation patient compliance commercial phenomena adverse drug reaction eye burning lacrimation function test LA - English M3 - Article in Press N1 - L51790407 2012-01-02 PY - 2011 SN - 0165-5701 1573-2630 SP - 1-5 ST - Comparison of fixed combinations of dorzolamide/timolol and brimonidine/timolol in patients with primary open-angle glaucoma T2 - International Ophthalmology TI - Comparison of fixed combinations of dorzolamide/timolol and brimonidine/timolol in patients with primary open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51790407&from=export http://dx.doi.org/10.1007/s10792-011-9495-z ID - 3122 ER - TY - JOUR AB - Glaucoma is a set of irreversible, progressive optic neuropathies that can lead to severe visual field loss and blindness. The two most common forms of glaucoma, primary open-angle glaucoma and primary angle-closure glaucoma, affect more than 2 million Americans and are increasing in prevalence. Many patients with glaucoma are asymptomatic and do not know they have the disease. Risk factors for primary open-angle glaucoma include older age, black race, Hispanic origin, family history of glaucoma, and diabetes mellitus. Risk factors for primary angle-closure glaucoma include older age, Asian descent, and female sex. Advanced disease at initial presentation and treatment nonadherence put patients with glaucoma at risk of disease progression to blindness. The U.S. Preventive Services Task Force has concluded that the evidence is insufficient to assess the potential benefits and harms of screening for glaucoma in the primary care setting. Regular eye examinations for adults are recommended by the American Academy of Ophthalmology, with the interval depending on patient age and risk factors. Diagnosis of glaucoma requires careful optic nerve evaluation and functional studies assessing a patient's visual field. The goal of treatment with eye drops, laser therapy, or surgery is to slow visual field loss by lowering intraocular pressure. Family physicians can contribute to lowering morbidity from glaucoma through early identification of high-risk patients and by emphasizing treatment adherence in patients with glaucoma. AD - Duke University School of Medicine, Durham, North Carolina. University of Washington Medical Center, Seattle, Washington. AN - 114269748. Language: English. Entry Date: 20170411. Revision Date: 20191106. Publication Type: journal article AU - Gupta, Divakar AU - Chen, Philip P. DB - ccm DP - EBSCOhost IS - 8 KW - Cholinergic Agonists -- Therapeutic Use Adrenergic Beta-Antagonists -- Therapeutic Use Prostaglandins, Synthetic -- Therapeutic Use Glaucoma -- Drug Therapy Glaucoma, Angle-Closure -- Drug Therapy Adrenergic Alpha-Agonists -- Therapeutic Use Carbonic Anhydrase Inhibitors -- Therapeutic Use Health Screening Age Factors Practice Guidelines Glaucoma -- Physiopathology Glaucoma -- Epidemiology Risk Factors Glaucoma, Angle-Closure -- Physiopathology Diabetes Mellitus -- Epidemiology Risk Assessment Glaucoma, Angle-Closure -- Epidemiology Ethnic Groups -- Statistics and Numerical Data Glaucoma, Angle-Closure -- Diagnosis Glaucoma -- Diagnosis Clinical Assessment Tools N1 - review. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Functional Living Index: Cancer (FLIC) (Schipper et al). NLM UID: 1272646. PMID: NLM27175839. PY - 2016 SN - 0002-838X SP - 668-674 ST - Glaucoma T2 - American Family Physician TI - Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=114269748&site=ehost-live&scope=site VL - 93 ID - 4491 ER - TY - JOUR AB - Purpose: To determine the rates of cost-related nonadherence to medications among US adults with glaucoma and to determine if participants with glaucoma have more cost-related medication nonadherence than those without glaucoma. Design: Cross-sectional study. Participants: Participants in the 2016–2017 National Health Interview Survey (NHIS), a cross-sectional survey regarding health topics that is administered annually to a nationally representative sample of noninstitutionalized adults in the United States. Methods: We calculated proportions of NHIS participants with and without self-reported glaucoma who reported cost-related nonadherence over the previous 12 months. We analyzed responses to 7 survey items that dealt with medication cost-related issues to any/all of a participants’ medication: couldn't afford a prescribed medication; skipped medication doses to save money; took less medicine to save money; delayed filling a prescription to save money; asked doctor for lower cost medication to save money; bought prescription drugs from another country to save money; used alternative therapies to save money. We performed univariable and multivariable logistic regression to evaluate the association between self-reported glaucoma diagnosis and responses to these selected questions. Main Outcome Measures: Proportion of participants with and without self-reported glaucoma who reported cost-related nonadherence. Results: Participants with glaucoma reported they could not afford prescribed medication more frequently than participants without glaucoma (8.2% vs. 6.4% P = 0.024). Adjusted predicted proportions from a multivariable model demonstrated that participants with glaucoma responded that they had greater cost-related barriers to medication access. Conclusions: In this nationally representative sample of the US population, after adjustment for confounding variables, participants with glaucoma more frequently reported cost-related nonadherence to medications compared with participants without glaucoma. Providers prescribing medication to patients with glaucoma should be aware of these findings and consider the impact of medication cost on their patients’ ability to adhere to therapy. AD - D. Gupta, 2351 Erwin Road, Durham, NC, United States AU - Gupta, D. AU - Ehrlich, J. R. AU - Newman-Casey, P. A. AU - Stagg, B. DB - Embase Medline DO - 10.1016/j.ogla.2020.08.010 IS - 2 KW - antiglaucoma agent adult aged comorbidity conference paper controlled study cost effectiveness analysis cross-sectional study drug cost female glaucoma human major clinical study male medicaid medicare multivariate logistic regression analysis patient compliance prescription priority journal United States univariate analysis very elderly vision visual acuity LA - English M3 - Conference Paper N1 - L2008004075 2020-10-13 PY - 2021 SN - 2589-4196 2589-4234 SP - 126-130 ST - Cost-Related Medication Nonadherence in a Nationally Representative US Population with Self-Reported Glaucoma T2 - Ophthalmology Glaucoma TI - Cost-Related Medication Nonadherence in a Nationally Representative US Population with Self-Reported Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2008004075&from=export http://dx.doi.org/10.1016/j.ogla.2020.08.010 VL - 4 ID - 2315 ER - TY - JOUR AB - Glaucoma is a slow progressive degeneration of the retinal ganglion cells (RGCs) and the optic nerve axons, leading to irreversible blindness if left undiagnosed and untreated. Although increased intraocular pressure is a major risk factor of glaucoma, other factors include increased glutamate levels, alterations in nitric oxide (NO) metabolism, vascular alterations and oxidative damage caused by reactive oxygen species. Glaucoma is the second leading cause of blindness globally, accounting for 12.3% of the total blindness. Glaucoma has been broadly classified as primary or secondary open-angle or angle-closure glaucoma. The primary goal in management of glaucoma is to prevent the risk factor, especially elevated intraocular pressure (IOP), using medications, laser therapy or conventional surgery. The first-line treatment of glaucoma usually begins with the use of a topical selective or nonselective blocker or a prostaglandin analog. Second-line drugs of choice include alpha-agonists and topical carbonic anhydrase inhibitors. Cholinergic agonists are considered third-line treatment options. When a single therapy is not sufficient to lower the IOP, a combination therapy is indicated. To enhance the patient compliance, drug delivery systems like electronic devices, ocular inserts, tansdermal and mechanical drug delivery systems have been developed. Use of viscoelastic agents in ophthalmic formulations, emulsions and soluble ophthalmic drug inserts (SODI) enhance patience compliance and ocular drug delivery in patients in long-term glaucoma therapy. For patients who do not respond to antiglaucoma medications, laser trabeculoplasty and incisional surgery are recommended. Several nutrients and botanicals hold promise for the treatment of glaucoma, but most studies are preliminary, and larger, controlled studies are required. Future directions for the development of a novel therapy glaucoma may target glutamate inhibition, NMDA receptor blockade, exogenously applied neurotrophins, open channel blockers, antioxidants, protease inhibitors and gene therapy. AD - S. Gupta, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India AU - Gupta, S. AU - Galpalli, N. AU - Agrawal, S. AU - Srivastava, S. AU - Saxena, R. DB - Embase DO - 10.4103/0253-7613.44151 IS - 5 KW - acetazolamide epinephrine alpha adrenergic receptor stimulating agent antiglaucoma agent apraclonidine ascorbic acid beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brinzolamide cannabinoid derivative carteolol clonidine dipivefrine dorzolamide flavonoid forskolin Ginkgo biloba extract latanoprost levobunolol methazolamide metipranolol miotic agent pilocarpine thioctic acid timolol travoprost unindexed drug unoprostone isopropyl ester accommodation add on therapy agranulocytosis allergic blepharitis allergic conjunctivitis anxiety aplastic anemia aqueous humor outflow argon laser bedtime dosage blindness blurred vision bradycardia bronchospasm cardiovascular disease central nervous system disease clinical trial closed angle glaucoma combination chemotherapy conjunctival hyperemia conjunctivitis cornea edema depression diplopia dizziness drowsiness drug absorption drug delivery system drug effect drug formulation drug half life drug hypersensitivity drug induced headache drug mechanism drug penetration drug potentiation drug safety drug selectivity drug tolerability dry eye enzyme inhibition epiphora evening dosage eye burning eye discomfort eye irritation eye pain fatigue gastrointestinal symptom gene therapy glaucoma glaucoma surgery heart palpitation human hypertension hypotension intraocular hypertension intraocular pressure intraocular pressure abnormality iritis low level laser therapy micturition miosis molecular dynamics monotherapy morning dosage neodymium laser nephrolithiasis neuroprotection nonhuman ocular pruritus open angle glaucoma oxidative stress paresthesia patient compliance primary glaucoma ptosis (eyelid) punctate keratitis receptor blocking respiratory tract disease retina detachment retina macula cystoid edema macular edema review risk factor salivation secondary glaucoma side effect skin manifestation tachyphylaxis thrombocytopenia trabeculoplasty treatment outcome treatment response unspecified side effect uveitis visual disorder vitamin supplementation xerostomia LA - English M3 - Review N1 - L355698548 2010-01-05 PY - 2008 SN - 0253-7613 1998-3751 SP - 197-208 ST - Recent advances in pharmacotherapy of glaucoma T2 - Indian Journal of Pharmacology TI - Recent advances in pharmacotherapy of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355698548&from=export http://dx.doi.org/10.4103/0253-7613.44151 VL - 40 ID - 3487 ER - TY - JOUR AB - Purpose: This study aimed to evaluate the clinical efficacy of contact diode trans-scleral cyclophotocoagulation (TSCPC) for treatment of refractory glaucomas. Method: Fifty two eyes of 52 patients, (post-penetrating keratoplasty glaucoma: 16 eyes; adherent leucoma with secondary glaucoma: 8 eyes; aphakic glaucoma: 6 eyes; neovascular glaucoma: 6 eyes; narrow angle glaucoma: 6 eyes; and other secondary glaucomas: 10 eyes) were followed up from 3.5 -18 months (average 12 months) after TSCPC. The treatment parameters using the contact G probe were - energy: 3-4J; area: 40 spots spread over 360°; site: 1.2-1.5 mm posterior to limbus. Retreatments (22 eyes; 42%) were given whenever intraocular pressure (IOP) exceeded 22 mmHg despite maximum tolerable topical therapy. Results: IOP decreased from a baseline of 44.7 (±7.3) mmHg to 15 (±3.7) mmHg at first week and was 15.2 ± (8.2) mmHg at the last follow up. Successful control of IOP (<22.mmHg) occurred in 30 (58%) eyes after a single treatment and in 48 (92%) eyes following retreatment. Complications included reduction in visual acuity from light perception (LP) only to no light perception (NLP) in two eyes and phthisis bulbi in one eye. Conclusion: Contact trans-scleral diode laser cyclophotocoagulation is effective in lowering IOP in eyes with intractable glaucoma with few side effects in Indian subjects. AD - Dr. Rajendra Prasad Ctr. Ophthal. S., New Delhi, India Dr.Rajendra Prasad Ctr. Ophthal. S., All India Inst. of Medical Sciences, New Delhi - 110 029, India AU - Gupta, V. AU - Agarwal, H. C. DB - Scopus IS - 4 KW - Cyclophotocoagulation Diode laser Indian population Refractory glaucoma M3 - Article N1 - Cited By :25 Export Date: 19 July 2021 PY - 2000 SP - 295-300 ST - Contact trans-scleral diode laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population T2 - Indian Journal of Ophthalmology TI - Contact trans-scleral diode laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034570032&partnerID=40&md5=8c8e33d74e079d4fe237c11c2114575d VL - 48 ID - 5093 ER - TY - JOUR AB - Purpose: To determine the prevalence of patient dropout after glaucoma surgery and reasons for the same based on patient attitudes and beliefs. Design: A hospital-based retrospective case-control study. Methods: Clinical and demographic data of patients who failed to attend follow-up within 12 months of their last scheduled appointment after glaucoma surgery were analyzed. These patients were issued recall letters and those who returned were interviewed to establish the reasons for their dropout. A structured interview was conducted to assess the educational and socioeconomic status of the patients, their knowledge and belief regarding glaucoma, their attitude towards surgery and the specific reason for their inability to follow up post-operatively. Control subjects who were regularly followed-up post-operatively were also interviewed. Results: Of 312 patients operated on from 2004-2006, only 92 (30%) patients maintained a 5-year follow-up. Of patients who dropped out, 43 patients responded to the recall letters and were interviewed along with 45 control patients. The demographic profile of those who dropped out was statistically similar to the controls; however, the controls had a significantly better awareness of glaucoma and higher monthly income (p < 0.001 and p = 0.01, respectively). Among those who dropped out, 38 (88%) believed surgery was the cure to the disease in comparison to 12 (46%) controls (p < 0.001). Conclusions: Dropout after glaucoma surgery is high among patients from lower socioeconomic strata. Misconceptions regarding surgery as a cure to glaucoma and situational factors are the most common reasons for patient dropout in this population. AN - WOS:000314068000006 AU - Gupta, V. AU - Chandra, A. AU - Yogi, R. AU - Sihota, R. AU - Singh, D. DA - FEB DO - 10.3109/09286586.2012.741278 IS - 1 PY - 2013 SN - 0928-6586 1744-5086 SP - 40-44 ST - Prevalence and Causes of Patient Dropout After Glaucoma Surgery T2 - OPHTHALMIC EPIDEMIOLOGY TI - Prevalence and Causes of Patient Dropout After Glaucoma Surgery VL - 20 ID - 5853 ER - TY - JOUR AB - Objectives. The purpose of this study was to determine the extent of nonadherence to treatment for glaucoma among elderly patients. Methods. This was a retrospective cohort study of 2440 patients older than age 65 who were enrolled in the New Jersey Medicaid Program and who were newly initiated on a topical agent for the treatment of glaucoma. Two patient-specific measures of nonadherence were employed: (1) no filled prescription for any glaucoma medication over a 12-month period after the initiation of therapy and (2) number of days without therapy for glaucoma during this 12-month period. Results. By the first measure, 569 patients (23%) were found to be nonadherent. The mean number of days without therapy during the study year was 112. Factors associated with nonadherence included the use of glaucoma medication requiring more than 2 administrations per day and the presence of multiple other medications in the patient's drug regimen. Patients started on multiple glaucoma medications were more adherent than those started on a single agent. Age and sex were not found to be predictors of nonadherence. Conclusions. Substantial nonadherence was found to be common in this population. More attention to the issue of nonadherence could result in important benefits in the preservation of sight. AD - J.H. Gurwitz, Analysis of Clin. Strategies Prog., 221 Longwood Ave, Boston, MA 02115, United States AU - Gurwitz, J. H. AU - Glynn, R. J. AU - Monane, M. AU - Everitt, D. E. AU - Gilden, D. AU - Smith, N. AU - Avorn, J. DB - Embase Medline DO - 10.2105/AJPH.83.5.711 IS - 5 KW - adult aged article cost effectiveness analysis counseling elderly care eye protection female glaucoma human major clinical study male medicaid patient compliance priority journal topical treatment visual impairment LA - English M3 - Article N1 - L23143002 1993-05-31 PY - 1993 SN - 0090-0036 SP - 711-716 ST - Treatment for glaucoma: Adherence by the elderly T2 - American Journal of Public Health TI - Treatment for glaucoma: Adherence by the elderly UR - https://www.embase.com/search/results?subaction=viewrecord&id=L23143002&from=export http://dx.doi.org/10.2105/AJPH.83.5.711 VL - 83 ID - 4019 ER - TY - JOUR AB - Objectives: The authors identify demographic and clinical characteristics associated with noncompliance in patients beginning medical therapy for the treatment of glaucoma in a managed care setting.Methods: The authors describe a retrospective cohort study in a group-model health maintenance organization in Massachusetts. Patients were members of the health maintenance organization who were newly initiated on topical drug therapy to treat open-angle glaucoma during the period January 1, 1987 through December 31, 1990, who met eligibility requirements, and who had evidence of health services utilization for a 12-month follow-up period. For all study subjects, we determined the number of days without available therapy for glaucoma during the 12-month period. Study subjects who did not fill prescriptions adequate to provide medication to cover at least 80% of days during the study period were considered noncompliant. Logistic regression analysis was used to assess demographic and clinical factors independently associated with noncompliance among patients initiated on medical therapy for the treatment of glaucoma.Results: Of 616 subjects who met inclusion criteria, 152 (24.7%; 95% confidence interval, 21.3%-28.1%) met the study definition for noncompliance. These patients had an average number of days without therapy during the 12-month study period of 103.9 +/- 70.0 days compared with 6.8 +/- 19.5 days for those categorized as compliant. Of a variety of selected demographic and clinical characteristics, having fewer visits with an ophthalmologist during the study period (< 2) was most strongly related to noncompliance (odds ratio 2.99; 95% confidence interval 2.03, 4.40). There were no differences in average intraocular pressure between the compliant and noncompliant groups during the study period.Conclusions: Noncompliance with prescribed medical therapy for glaucoma was found to be common in a managed care setting characterized by essentially unrestricted access to health care and medications. It remains difficult to identify noncompliant patients based on demographic and clinical characteristics. The use of automated prescription data to identify noncompliant patients is feasible in large managed health care insurance programs where such data are collected routinely for administrative purposes. AD - Meyers Primary Care Institute, Fallon Healthcare System, Worcester, MA 01608, USA AN - 138239341. Language: English. Entry Date: 20190826. Revision Date: 20190826. Publication Type: journal article AU - Gurwitz, J. H. AU - Yeomans, S. M. AU - Glynn, R. J. AU - Lewis, B. E. AU - Levin, R. AU - Avorn, J. DB - ccm DP - EBSCOhost IS - 3 KW - Glaucoma -- Drug Therapy Treatment Refusal -- Statistics and Numerical Data Health Maintenance Organizations -- Statistics and Numerical Data Middle Age Aged, 80 and Over Massachusetts Aged Retrospective Design Prospective Studies Self Administration Logistic Regression Time Factors Female Human Male Adult Prescriptions, Drug -- Statistics and Numerical Data Validation Studies Comparative Studies Evaluation Research Multicenter Studies Scales N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). Grant Information: K08 AG00510/AG/NIA NIH HHS/United States. NLM UID: 0230027. PMID: NLM9520960. PY - 1998 SN - 0025-7079 SP - 357-369 ST - Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma T2 - Medical Care TI - Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138239341&site=ehost-live&scope=site VL - 36 ID - 4432 ER - TY - JOUR AB - OBJECTIVES. The authors identify demographic and clinical characteristics associated with noncompliance in patients beginning medical therapy for the treatment of glaucoma in a managed care setting. METHODS. The authors describe a retrospective cohort study in a group-model health maintenance organization in Massachusetts. Patients were members of the health maintenance organization who were newly initiated on topical drug therapy to treat open-angle glaucoma during the period January 1, 1987 through December 31,1990, who met eligibility requirements, and who had evidence of health services utilization for a 12-month follow-up period. For all study subjects, we determined the number of days without available therapy for glaucoma during the 12-month period. Study subjects who did not fill prescriptions adequate to provide medication to cover at least 80% of days during the study period were considered noncompliant. Logistic regression analysis was used to assess demographic and clinical factors independently associated with noncompliance among patients initiated on medical therapy for the treatment of glaucoma. RESULTS. Of 616 subjects who met inclusion criteria, 152 (24.7%; 95% confidence interval, 21.3%-28.1%) met the study definition for noncompliance. These patients had an average number of days without therapy during the 12-month study period of 103.9 ± 70.0 days compared with 6.8 ± 19.5 days for those categorized as compliant. Of a variety of selected demographic and clinical characteristics, having fewer visits with an ophthalmologist during the study period (<2) was most strongly related to noncompliance (odds ratio 2.99; 95% confidence interval 2.03, 4.40). There were no differences in average intraocular pressure between the compliant and noncompliant groups during the study period. CONCLUSIONS. Noncompliance with prescribed medical therapy for glaucoma was found to be common in a managed care setting characterized by essentially unrestricted access to health care and medications. It remains difficult to identify noncompliant patients based on demographic and clinical characteristics. The use of automated prescription data to identify noncompliant patients is feasible in large managed health care insurance programs where such data are collected routinely for administrative purposes. AD - Meyers Primary Care Institute, 100 Central Street, Worcester, MA 01608, United States AU - Gurwitz, J. H. AU - Yeomans, S. M. AU - Glynn, R. J. AU - Lewis, B. E. AU - Levin, R. AU - Avorn, J. DB - Scopus DO - 10.1097/00005650-199803000-00012 IS - 3 KW - Adherence Compliance Glaucoma. Health maintenance organization Managed care M3 - Article N1 - Cited By :67 Export Date: 19 July 2021 PY - 1998 SP - 357-369 ST - Patient Noncompliance in the Managed Care Setting: The Case of Medical Therapy for Glaucoma T2 - Medical Care TI - Patient Noncompliance in the Managed Care Setting: The Case of Medical Therapy for Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032013090&doi=10.1097%2f00005650-199803000-00012&partnerID=40&md5=66cbd7598d635aa0cf1eadb18e0abad6 VL - 36 ID - 4963 ER - TY - JOUR AB - OBJECTIVES. The authors identify demographic and clinical characteristics associated with noncompliance in patients beginning medical therapy for the treatment of glaucoma in a managed care setting. METHODS. The authors describe a retrospective cohort study in a group-model health maintenance organization in Massachusetts. Patients were members of the health maintenance organization who were newly initiated on topical drug therapy to treat open-angle glaucoma during the period January 1, 1987 through December 31, 1990, who met eligibility requirements, and who had evidence of health services utilization for a 12-month follow-up period. For all study subjects, we determined the number of days without available therapy for glaucoma during the 12-month period. Study subjects who did not fill prescriptions adequate to provide medication to cover at least 80% of days during the study period were considered noncompliant. Logistic regression analysis was used to assess demographic and clinical factors independently associated with noncompliance among patients initiated on medical therapy for the treatment of glaucoma. RESULTS. Of 616 subjects who met inclusion criteria, 152 (24.7%; 95% confidence interval, 21.3%-28.1%) met the study definition for noncompliance. These patients had an average number of days without therapy during the 12-month study period of 103.9 +/- 70.0 days compared with 6.8 +/- 19.5 days for those categorized as compliant. Of a variety of selected demographic and clinical characteristics, having fewer visits with an ophthalmologist during the study period (<2) was most strongly related to noncompliance (odds ratio 2.99; 95% confidence interval 2.03, 4.40). There were no differences in average intraocular pressure between the compliant and noncompliant groups during the study period. CONCLUSIONS. Noncompliance with prescribed medical therapy for glaucoma was found to be common in a managed care setting characterized by essentially unrestricted access to health care and medications. It remains difficult to identify noncompliant patients based on demographic and clinical characteristics. The use of automated prescription data to identify noncompliant patients is feasible in large managed health care insurance programs where such data are collected routinely for administrative purposes. AN - WOS:000072467300012 AU - Gurwitz, J. H. AU - Yeomans, S. M. AU - Glynn, R. J. AU - Lewis, B. E. AU - Levin, R. AU - Avorn, J. DA - MAR DO - 10.1097/00005650-199803000-00012 IS - 3 PY - 1998 SN - 0025-7079 1537-1948 SP - 357-369 ST - Patient noncompliance in the managed care setting - The case of medical therapy for glaucoma T2 - MEDICAL CARE TI - Patient noncompliance in the managed care setting - The case of medical therapy for glaucoma VL - 36 ID - 5923 ER - TY - JOUR AN - 107772733. Language: English. Entry Date: 20150212. Revision Date: 20150712. Publication Type: Journal Article AU - Guttman Krader, Cheryl AU - Schwartz, Gail F. DB - ccm DP - EBSCOhost IS - 2 KW - Latanoprost Bimatoprost Glaucoma -- Drug Therapy Guideline Adherence -- Evaluation Medication Compliance -- Evaluation N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2015 SN - 0193-032X SP - 36-36 ST - Bimatoprost adherence, persistence superior in prior latanoprost users T2 - Ophthalmology Times TI - Bimatoprost adherence, persistence superior in prior latanoprost users UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107772733&site=ehost-live&scope=site VL - 40 ID - 4673 ER - TY - JOUR AB - Purpose: To evaluate the topical glaucoma eye drops adherence prevalence and its association with beliefs and illness perceptions about glaucoma in Turkey. We also aimed to explore the factors linked to patients’ total, voluntary, and involuntary non-adherence to medication in different patient attitudes. Material and Methods: A prospective study with cross-sectional design which included a total of 317 glaucoma patients who completed questionnaires. We assessed the adherence to medication, illness perceptions, and the beliefs about the glaucoma treatment by the “Reported Adherence to Medication scale,” “the Brief Illness Perception Questionnaire,” and “the Beliefs about Medicine-Specific Questionnaire,” respectively. According to the RAM scale, voluntary and involuntary non-adherence scores were also distinguished. Different adherence categories in RAM scale were compared with perception and belief measures. Patient attitudes were assessed from the BMQ. We also performed attitudinal type comparisons with different adherence groups. Results: The full adherence prevelance to glaucoma medication was 40%. The proportion of voluntary and involuntary non-adherence was 26% and 57%, respectively. The adherence groups were similar in terms of belief measures but statistically different according to illness perceptions (consequences (p = 0.002), timeline (p = 0.008), personal control (p = 0.001), identity (p = 0.019), concerns (p = 0.003)), and attitude types (ambivalent (p = 0.030) and accepting (p = 0.029)). Conclusion: New strategies are required to improve patient adherence to glaucoma medication in Turkey. The beliefs about the glaucoma treatment and illness perceptions are also needed to be enhanced. AD - S. Guven, Department of Ophthalmology, Kayseri City Hospital, Kayseri, Turkey AU - Guven, S. AU - Koylu, M. T. AU - Mumcuoglu, T. DB - Embase Medline DO - 10.1177/1120672120901687 IS - 2 KW - eye drops adult anxiety article attitude blurred vision Brief Illness Perception Questionnaire controlled study cross-sectional study emotionality female glaucoma human major clinical study medication compliance Medicine Specific Questionnaire middle aged Mini Mental State Examination patient compliance perception prevalence prospective study questionnaire scoring system Turk (people) Turkey (republic) LA - English M3 - Article N1 - L2004213008 2020-02-13 2021-05-27 PY - 2021 SN - 1724-6016 1120-6721 SP - 469-476 ST - Adherence to glaucoma medication, illness perceptions, and beliefs about glaucoma: Attitudinal perspectives among Turkish population T2 - European Journal of Ophthalmology TI - Adherence to glaucoma medication, illness perceptions, and beliefs about glaucoma: Attitudinal perspectives among Turkish population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004213008&from=export http://dx.doi.org/10.1177/1120672120901687 VL - 31 ID - 2311 ER - TY - JOUR AB - Purpose: To evaluate variables associated with failure to access free eye care after participating in glaucoma screening. Design: Review of responses to a survey completed by participants during glaucoma screening. Participants: Two hundred seventy-three surveys completed by participants of African descent during screening. Methods: African Americans 40 years or older participated in community glaucoma screening clinics, which included a survey with demographic and social variables. Each participant was given a preliminary diagnosis and encouraged to attend a free eye clinic for a complete examination. Survey results were correlated with attendance at the follow-up examination, using Student's t test, chi-square test, and logistic regression analysis. Main Outcome Measure: Noncompliance with follow-up after glaucoma screening. Results: When adjusting for risk factors in logistic regression analysis, noncompliance was associated with living alone (P = 0.008), smoking (P = 0.0005), and lacking a car (P<0.01). Odds of noncompliance for participants living alone were 2.2 times higher than those for participants not living alone. Odds of noncompliance for participants who smoked were 3.0 times greater than those for participants who did not smoke. Odds of noncompliance for participants who did not have access to a car for their last eye examination were 2.1 times greater than those for participants who did. Conclusion: Socioeconomic factors such as smoking, lack of access to a car for eye examinations, and living alone are associated with noncompliance to follow-up after glaucoma screening clinics. Identifying persons with these variables may facilitate improved compliance. © 2006 American Academy of Ophthalmology. AD - J.A. Gwira, Department of Ophthalmology and Visual Sciences, Yale University School of Medicine, New Haven, CT, United States AU - Gwira, J. A. AU - Vistamehr, S. AU - Shelsta, H. AU - Bashford, K. AU - Forster, S. AU - Palmisano, P. AU - Shafranov, G. AU - Shields, M. B. DB - Embase Medline DO - 10.1016/j.ophtha.2006.04.017 IS - 8 KW - African American article chi square test comparative study demography evaluation study eye care glaucoma health survey human logistic regression analysis medical examination patient attitude priority journal risk assessment risk factor sample size screening test smoking social aspect socioeconomics Student t test LA - English M3 - Article N1 - L44108194 2006-08-16 PY - 2006 SN - 0161-6420 SP - 1319.e1 ST - Factors Associated with Failure to Follow Up after Glaucoma Screening. A Study in an African American Population T2 - Ophthalmology TI - Factors Associated with Failure to Follow Up after Glaucoma Screening. A Study in an African American Population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44108194&from=export http://dx.doi.org/10.1016/j.ophtha.2006.04.017 VL - 113 ID - 3596 ER - TY - JOUR AB - Purpose: To evaluate variables associated with failure to access free eye care after participating in glaucoma screening. Design: Review of responses to a survey completed by participants during glaucoma screening. Participants: Two hundred seventy-three surveys completed by participants of African descent during screening. Methods: African Americans 40 years or older participated in community glaucoma screening clinics, which included a survey with demographic and social variables. Each participant was given a preliminary diagnosis and encouraged to attend a free eye clinic for a complete examination. Survey results were correlated with attendance at the follow-up examination, using Student's t test, chi-square test, and logistic regression analysis. Main Outcome Measure: Noncompliance with follow-up after glaucoma screening. Results: When adjusting for risk factors in logistic regression analysis, noncompliance was associated with living alone (P = 0.008), smoking (P = 0.0005), and lacking a car (P<0.01). Odds of noncompliance for participants living alone were 2.2 times higher than those for participants not living alone. Odds of noncompliance for participants who smoked were 3.0 times greater than those for participants who did not smoke. Odds of noncompliance for participants who did not have access to a car for their last eye examination were 2.1 times greater than those for participants who did. Conclusion: Socioeconomic factors such as smoking, lack of access to a car for eye examinations, and living alone are associated with noncompliance to follow-up after glaucoma screening clinics. Identifying persons with these variables may facilitate improved compliance. © 2006 American Academy of Ophthalmology. AD - Department of Ophthalmology and Visual Sciences, Yale University School of Medicine, New Haven, CT, United States AU - Gwira, J. A. AU - Vistamehr, S. AU - Shelsta, H. AU - Bashford, K. AU - Forster, S. AU - Palmisano, P. AU - Shafranov, G. AU - Shields, M. B. DB - Scopus DO - 10.1016/j.ophtha.2006.04.017 IS - 8 M3 - Article N1 - Cited By :19 Export Date: 19 July 2021 PY - 2006 SP - 1315-1319.e1 ST - Factors Associated with Failure to Follow Up after Glaucoma Screening. A Study in an African American Population T2 - Ophthalmology TI - Factors Associated with Failure to Follow Up after Glaucoma Screening. A Study in an African American Population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33747135786&doi=10.1016%2fj.ophtha.2006.04.017&partnerID=40&md5=0bd9c47b5e4847184f71348ca951037b VL - 113 ID - 5153 ER - TY - JOUR AB - Purpose: To evaluate variables associated with failure to access free eye care after participating in glaucoma screening. Design: Review of responses to a survey completed by participants during glaucoma screening. Participants: Two hundred seventy-three surveys completed by participants of African descent during screening. Methods: African Americans 40 years or older participated in community glaucoma screening clinics, which included a survey with demographic and social variables. Each participant was given a preliminary diagnosis and encouraged to attend a free eye clinic for a complete examination. Survey results were correlated with attendance at the follow-up examination, using Student's t test, chi-square test, and logistic regression analysis. Main Outcome Measure: Noncompliance with follow-up after glaucoma screening. Results: When adjusting for risk factors in logistic regression analysis, noncompliance was associated with living alone (P = 0.008), smoking (P = 0.0005), and lacking a car (P < 0.01). Odds of noncompliance for participants living alone were 2.2 times higher than those for participants not living alone. Odds of noncompliance for participants who smoked were 3.0 times greater than those for participants who did not smoke. Odds of noncompliance for participants who did not have access to a car for their last eye examination were 2.1 times greater than those for participants who did. Conclusion: Socioeconomic factors such as smoking, lack of access to a car for eye examinations, and living alone are associated with noncompliance to follow-up after glaucoma screening clinics. Identifying persons with these variables may facilitate improved compliance. AN - WOS:000239531400009 AU - Gwira, J. A. AU - Vistamehr, S. AU - Shelsta, H. AU - Bashford, K. AU - Forster, S. AU - Palmisano, P. AU - Shafranov, G. AU - Shields, M. B. DA - AUG DO - 10.1016/j.ophtha.2006.04.017 IS - 8 PY - 2006 SN - 0161-6420 SP - 1315-1319 ST - Factors associated with failure to follow up after glaucoma screening - A study in an African American population T2 - OPHTHALMOLOGY TI - Factors associated with failure to follow up after glaucoma screening - A study in an African American population VL - 113 ID - 5902 ER - TY - JOUR AB - Purpose: To assess the effectiveness and safety of a single iStent trabecular micro-bypass stent implantation in combination with cataract surgery in lowering the intra ocular pressure (IOP) and number of anti-glaucoma medications in Saudi patients with open-angle glaucoma (OAG). Setting: King Fahad Hospital of the University, Al Khobar, Saudi Arabia. Design: Prospective, non-comparative, uncontrolled, non-randomized interventional case series. Methods: One iStent was implanted during phacoemulsification cataract surgery for adult patients with OAG by a single surgeon over a period of 3 years. Main outcome measures include number of anti-glaucoma medications, IOP, corrected distance visual acuity (CDVA) and complications. Results: Thirty-six eyes of 33 patients with OAG underwent the surgery. The pre-operative mean IOP and mean anti-glaucoma medications were 17.47 ± 5.44 mmHg and 2.69 ± 0.92, respectively. At 1 year of follow-up mean, IOP decreased to 13.44 ± 1.99 (23.1% reduction) (P<0.001) and mean anti-glaucoma medications decreased to 1.47±1.13 (45.4% reduction) (P<0.001). Conclusion: After 12-month follow-up, phacoemulsification with the implantation of a single iStent seems to be an effective and safe procedure to lower IOP and the number of anti-glaucoma medications, and to overcome the problems associated with medication nonadherence in OAG patients with cataracts. © 2020 Al Habash and Khan. AD - Department of Ophthalmology, College of Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia Ministry of Health, Madinah, Saudi Arabia AU - Habash, A. A. AU - Khan, O. DB - Scopus DO - 10.2147/OPTH.S249261 KW - IStent trabecular micro-bypass Minimally invasive glaucoma surgery Open-angle glaucoma Schlemm's canal M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2020 SP - 1573-1580 ST - Outcomes of combined istent trabecular micro-bypass and cataract surgery for the treatment of open-angle glaucoma in a Saudi population T2 - Clinical Ophthalmology TI - Outcomes of combined istent trabecular micro-bypass and cataract surgery for the treatment of open-angle glaucoma in a Saudi population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086669114&doi=10.2147%2fOPTH.S249261&partnerID=40&md5=67c8e7ddc3f51a164f6232810f4c055b VL - 14 ID - 5443 ER - TY - JOUR AB - Introduction: Glaucoma is a progressive optic neuropathy associated with neural rim loss of the optic disc and the retinal nerve fibre layer typically causing visual field (VF) deterioration. Generally, glaucomatous lesions in the eye and in the visual field progress slowly over the years. In population-based cross-sectional studies, the percentage of unilateral or bilateral visual impairment varied between 3-12%. In screening studies, 0.03-2.4% of patients have been found to suffer visual impairment. Glaucoma has previously been associated with substantial healthcare costs and resource consumption attributable to the treatment of the disease. The disease also causes reduction in health-related quality of life (HRQoL) in patients with glaucoma. Objective and Methods: This study compares patients with diagnosed open-angle glaucoma from two geographically different regions in Finland. A total of 168 patients were examined, 85 subjects from an area with higher per patient treatment costs (Oulu) and 83 patients from a region with lower per patient treatment costs (Turku). All patients had a history of continuous glaucoma medication use for a period of 11 years. For each patient, the total direct costs from glaucoma treatment were calculated and the total amount of resource consumption was determined from registries and patient records. Each patient underwent a clinical examination with visual field assessment and fundus photography. These data were used to determine the current stage of disease for each patient. Health-related quality of life questionnaire (15D) was used in determining each patient's subjective HRQoL score. Results: When applying the current diagnostic criteria for open-angle glaucoma, a total of 40% of patients did not to display any structural or functional damage suggesting glaucoma after 11 years of continuous medical treatment and follow-up. Patients with higher glaucoma stage (worse disease) were found to have statistically higher treatment costs compared with those at lower disease stages. Resource consumption was also greater in the patients in higher glaucoma stage. Patients in the Oulu district consumed more resources, and glaucoma treatment was more expensive than in the Turku area. The total treatment cost in Oulu and Turku was 6010 € and 4452 €, respectively, for the whole 11-year period. There was no statistically significant difference in quality-of-life scores between the two areas. No difference was noted between the higher-spending and lower-spending areas in this respect. However, when the population was analysed as a whole, patients with higher glaucoma stage were found to have lower vision-based 15D scores compared with those at lower disease stages. This observation was made also at both districts independently. Conclusions: Major cost source in open-angle glaucoma treatment is medication, up to 74% of annual costs. In addition, it seems that higher resource consumption and higher treatment costs do not increase the patients' HRQoL as assessed by the 15D instrument. © 2013 Acta Ophthalmologica Scandinavica Foundation. AD - J. Hagman, Department of Ophthalmology, Faculty of Medicine, University of Oulu, Oulu, Finland AU - Hagman, J. DB - Embase Medline DO - 10.1111/aos.12141 IS - THESIS 3 KW - antiglaucoma agent adult aged article central corneal thickness controlled study disease severity drug cost evidence based medicine eye photography female Finland follow up glaucoma staging system health care cost health care utilization human intraocular pressure major clinical study male open angle glaucoma perimetry priority journal quality of life resource allocation sclerectomy scoring system trabeculectomy visual acuity LA - English M3 - Article N1 - L368830832 2013-05-08 2020-02-26 PY - 2013 SN - 1755-3768 1755-375X SP - 1-47 ST - Comparison of resource utilization in the treatment of open-angle glaucoma between two cities in Finland: Is more better? T2 - Acta Ophthalmologica TI - Comparison of resource utilization in the treatment of open-angle glaucoma between two cities in Finland: Is more better? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368830832&from=export http://dx.doi.org/10.1111/aos.12141 VL - 91 ID - 3034 ER - TY - JOUR AB - TOPIC: Using an understanding of a patient's difficulty in revealing nonadherence and patient-centered communication skills to identify and address barriers to adherence to glaucoma medication regimens. CLINICAL RELEVANCE: In addition to cost and logistical difficulties with obtaining and administering medicine, a patient's adherence to medication is influenced by the balance between the perceived need for medication and concerns about taking medication. METHODS: This article is based on both the author's clinical experience and peer-reviewed research on effective doctor-patient communication and assessment and management of nonadherence. RESULTS: Three strategies have been identified that help physicians to detect and address problems with adherence: (1) a 4-step adherence assessment interview designed to detect nonadherence that decreases patient resistance to revealing nonadherence by applying a shared decision-making process and mitigating social undesirability; (2) asking open-ended questions in ask-tell-ask sequences; and (3) tailoring interventions to the patient's stage of readiness for change. CONCLUSIONS: Patients conceal nonadherence because they want to be thought of by their physicians as good patients. They are driven to nonadherence by an imbalance between their perceived need for medication and their concerns about taking it. Patient-centered communication techniques can engage the patient in shared decision making about medication, thereby redefining the good patient as someone who works with his or her health care provider to address adherence barriers. Those barriers can be explored with open-ended questions designed to elicit the patient's understanding and concerns, to provide information, and to assess change in the patient's understanding and attitudes. Communication will be more effective if it is based on the patient's stage of readiness to adopt adherent self-management practices. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. AD - S.R. Hahn, Department of Medicine, The Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, USA. AU - Hahn, S. R. DB - Medline IS - 11 Suppl KW - antihypertensive agent eye drops doctor patient relationship glaucoma health behavior human interpersonal communication motivation patient care patient compliance patient education psychological aspect review LA - English M3 - Review N1 - L355507627 2009-11-04 PY - 2009 SN - 1549-4713 SP - S37-42 ST - Patient-centered communication to assess and enhance patient adherence to glaucoma medication T2 - Ophthalmology TI - Patient-centered communication to assess and enhance patient adherence to glaucoma medication UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355507627&from=export VL - 116 ID - 3316 ER - TY - JOUR AB - Background: Uninterrupted use of ocular hypotensive medication by glaucoma patients is important to prevent vision loss, but medication persistence is poor. Efficacy and tolerability influence physicians decisions and patient persistence, and differences between medications may impact persistence. Objective: To examine differences in physicians decisions to continue, switch, or discontinue therapy across three prostaglandin analogs (PGAs) latanoprost, bimatoprost, and travoprost using claims data supplemented by evaluation of physicians charted therapeutic decisions. Methods: A year of pharmacy claims data for 6271 patients with a first (index) fill between 5/1/2001 and 11/30/2004 for PGA monotherapy were classified as persistent, switched, restarted, or discontinued with initial PGA use. An analysis of index therapy continuation during the first 2 years reflected chart reviews for 223 patients with PGA monotherapy as the index prescription. Results: Ten percent of patients had uninterrupted use of the initial PGA alone or in combination for a year. More than half (56) stopped and then restarted, 16 switched, and 19 discontinued the initial PGA. Patients using latanoprost were more likely to be persistent (11) compared to bimatoprost (9) or travoprost (5; p<0.0001 overall comparison). Overall, 68 of patients on latanoprost persisted or restarted after a gap compared to 61 for bimatoprost and 58 for travoprost (p<0.0001). Patient charts demonstrated a parallel pattern in physicians decisions to continue latanoprost (56), bimatoprost (45), and travoprost (40). Study limitations included the inability to establish causal links between variables, to account for sample use, or to document reasons for patient-driven changes in therapy. The study should be replicated in a more recent database including a larger population. Conclusions: Uninterrupted use of ocular hypotensive therapy for a full year is relatively rare. Differences in physicians decisions to continue, switch, or discontinue PGAs were observed in claims data, and parallel trends were observed in patient medical records. © 2010 Informa UK Ltd All rights reserved. AD - S. R. Hahn, Albert Einstein College of Medicine, Jacobi Medical Center, 1400 Pelham Parkway South, Bronx, NY 10461, United States AU - Hahn, S. R. AU - Kotak, S. AU - Tan, J. AU - Kim, E. DB - Embase Medline DO - 10.1185/03007991003659012 IS - 4 KW - bimatoprost latanoprost travoprost article controlled study drug substitution drug withdrawal glaucoma human major clinical study medical decision making monotherapy patient compliance retreatment treatment planning LA - English M3 - Article N1 - L358467737 2010-03-25 2010-04-09 PY - 2010 SN - 0300-7995 1473-4877 SP - 957-963 ST - Physicians treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma T2 - Current Medical Research and Opinion TI - Physicians treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358467737&from=export http://dx.doi.org/10.1185/03007991003659012 VL - 26 ID - 3262 ER - TY - JOUR AB - Background: Uninterrupted use of ocular hypotensive medication by glaucoma patients is important to prevent vision loss, but medication persistence is poor. Efficacy and tolerability influence physicians’ decisions and patient persistence, and differences between medications may impact persistence. Objective: To examine differences in physician’s decisions to continue, switch, or discontinue therapy across three prostaglandin analogs (PGAs) latanoprost, bimatoprost, and travoprost using claims data supplemented by evaluation of physicians’ charted therapeutic decisions. Methods: A year of pharmacy claims data for 6271 patients with a first (index) fill between 5/1/2001 and 11/30/2004 for PGA monotherapy were classified as ‘persistent’, ‘switched’, ‘restarted’, or ‘discontinued’ with initial PGA use. An analysis of index therapy continuation during the first 2 years reflected chart reviews for 223 patients with PGA monotherapy as the index prescription. Results: Ten percent of patients had uninterrupted use of the initial PGA alone or in combination for a year. More than half (56%) stopped and then restarted, 16% switched, and 19% discontinued the initial PGA. Patients using latanoprost were more likely to be persistent (11%) compared to bimatoprost (9%) or travoprost (5%; p < 0.0001 overall comparison). Overall, 68% of patients on latanoprost persisted or restarted after a gap compared to 61% for bimatoprost and 58% for travoprost (p < 0.0001). Patient charts demonstrated a parallel pattern in physicians’ decisions to continue latanoprost (56%), bimatoprost (45%), and travoprost (40%). Study limitations included the inability to establish causal links between variables, to account for sample use, or to document reasons for patient-driven changes in therapy. The study should be replicated in a more recent database including a larger population. Conclusions: Uninterrupted use of ocular hypotensive therapy for a full year is relatively rare. Differences in physicians’ decisions to continue, switch, or discontinue PGAs were observed in claims data, and parallel trends were observed in patient medical records. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Hahn, Steven R., Albert Einstein College of Medicine, Jacobi Medical Center, APCS Room 4W5B, Bldg 1, 1400 Pelham Parkway South, Bronx, NY, US, 10461 AN - 2010-05356-022 AU - Hahn, Steven R. AU - Kotak, Sameer AU - Tan, Jason AU - Kim, Elizabeth DB - psyh DO - 10.1185/03007991003659012 DP - EBSCOhost IS - 4 KW - physicians therapeutic decisions patients persistence prostaglandin therapy glaucoma Adult Amides Antihypertensive Agents Bimatoprost Cloprostenol Continuity of Patient Care Humans Medication Adherence Practice Patterns, Physicians' Prostaglandins F, Synthetic Retrospective Studies Travoprost United States Decision Making Drug Therapy Prostaglandins Treatment Compliance N1 - Albert Einstein College of Medicine, Bronx, NY, US. Other Publishers: LibraPharm; Taylor & Francis. Release Date: 20100726. Correction Date: 20150921. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Decision Making; Drug Therapy; Glaucoma; Prostaglandins; Treatment Compliance. Classification: Medical Treatment of Physical Illness (3363). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Apr, 2010. Publication History: First Posted Date: Feb 18, 2010; Accepted Date: Jan 28, 2010. Copyright Statement: Informa UK Ltd. 2010. Sponsor: Pfizer Inc., US. Recipients: No recipient indicated PY - 2010 SN - 0300-7995 1473-4877 SP - 957-963 ST - Physicians’ treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma T2 - Current Medical Research and Opinion TI - Physicians’ treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-05356-022&site=ehost-live&scope=site steveroost@aol.com VL - 26 ID - 4867 ER - TY - JOUR AB - Micro-(MPs) and nanoparticles (NPs) have been recently studied for their application in ophthalmic drug delivery. These drug delivery systems are able to circumvent the ocular barriers that currently limit the efficacy of conventional treatments, as well as provide a more sustained release of drug, reducing the frequency of administration and increasing patient compliance. This review summarizes the recent trends in ophthalmic research from conventional treatment to the utilization of MPs and NPs as drug carriers. AD - V. Sutariya, Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Boulevard, Tampa, FL, United States AU - Halasz, K. AU - Kelly, S. J. AU - Iqbal, M. T. AU - Pathak, Y. AU - Sutariya, V. DB - Embase Medline DO - 10.1089/adt.2018.911 IS - 4 KW - drug carrier nanoparticle age related macular degeneration anatomy biodegradation cataract diabetic retinopathy drug delivery system drug formulation dry eye eye disease eye infection eye inflammation Fuchs endothelial dystrophy glaucoma human intraocular drug administration myopia patient compliance retina vein occlusion review subretinal neovascularization LA - English M3 - Review N1 - L628064085 2019-06-20 2019-06-25 PY - 2019 SN - 1557-8127 1540-658X SP - 152-166 ST - Micro/Nanoparticle Delivery Systems for Ocular Diseases T2 - Assay and Drug Development Technologies TI - Micro/Nanoparticle Delivery Systems for Ocular Diseases UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628064085&from=export http://dx.doi.org/10.1089/adt.2018.911 VL - 17 ID - 2508 ER - TY - JOUR AB - Combined surgery (phacoemulsification and penetrating or nonpenetrating filtering surgery) has the advantage of treating two distinct disorders in a single operation, with the objective of improving visual acuity and controlling ocular hypertension. In addition, it improves patient comfort and compliance to treatment. It lowers intraocular pressure more than simple lens surgery and the same as surgery carried out in two steps, notably with nonpenetrating filtering surgery, whereas the incidence of complications is lower. Our personal experience with 35 patients, operated on for phacoemulsification and deep sclerectomy with external trabeculectomy in the same operation confirms that this com-bined surgery in a single operation is effective in controlling ocular pressure in glaucoma subjects (mean reduction in tension, 23%), with few complications. © Masson, Paris, 2005. AD - P. Hamard, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, 28 rue de Charenton, 75012 Paris, France AU - Hamard, P. DB - Embase Medline IS - SPEC. ISS. 2 KW - cataract clinical article filtering operation glaucoma human intraocular hypertension intraocular pressure lens implant patient compliance phacoemulsification postoperative complication review sclerectomy trabeculectomy visual acuity LA - French M3 - Review N1 - L41494679 2005-11-16 PY - 2005 SN - 0181-5512 SP - 2S48-2S51 ST - Surgical controversy. Combined surgery in one procedure T2 - Journal Francais d'Ophtalmologie TI - Surgical controversy. Combined surgery in one procedure UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41494679&from=export VL - 28 ID - 3687 ER - TY - JOUR AB - Healthcare of chronic pathologies, especially in glaucoma, which is asymptomatic for a long period of time, is based on a good, confident relationship between physicians and patients. This relationship has to be created, maintained, and reinforced throughout follow-up, The patient's information source is to a large extent the physician, who must provide all the necessary information concerning the disease, including the definition, prognosis, follow-Lip, and treatment. How the information is transmitted should be personally adapted to patients, taking into account their own and their family's psychological reactions. It is also important to keep in mind the factors influencing poor compliance when talking to our patients. AN - WOS:000258861200008 AU - Hamelin, N. DA - JUN IS - 6 PY - 2008 SN - 0181-5512 SP - 39-44 ST - The physician-patient relationship in glaucoma T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - The physician-patient relationship in glaucoma VL - 31 ID - 6026 ER - TY - JOUR AB - Purpose: Evaluate the psychological consequences of announcing the diagnosis of glaucoma. Materials and methods: Two hundred patients completed a 20-item questionnaire designed to analyze the context in which glaucoma was discovered and the patients' reaction to this diagnosis. Behavioral modification in patients and their families are specified as well as their perception of the information received. Comments: Most patients had open-angle glaucoma and showed either an anxious or a passive reaction to the announcement of the diagnosis. Severe anxiety led to prescription of minor tranquilizers or antidepressants in 11% of cases. Nearly half of the patients declared that they had modified their behavior after receiving the diagnosis, indicating a need to play an active role in disease management. A large majority of the patients were conscious of the risk of blindness related to glaucoma; however, they did not feel « ill » but rather « handicapped ». Most were dissatisfied with the information provided by their doctor and sought other sources of information. Conclusion: Announcing a diagnosis of glaucoma is a decisive step in the physician-patient relationship, known to be important in future treatment compliance. Better adapted information with regular reevaluation of the need for additional information is necessary. The psychological impact should be evaluated regularly in order to promote an active role on the part of the patient and avoid a decline in quality of life. AD - N. Hamelin, Hôpital des Quinze-Vingts, Université Paris V, 28, rue de Charenton, 75012 Paris, France AU - Hamelin, N. AU - Blatrix, C. AU - Brion, F. AU - Mathieu, C. AU - Goemaere, I. AU - Nordmann, J. P. DB - Embase Medline IS - 8 KW - antidepressant agent tranquilizer anxiety disorder article behavior modification blindness depression doctor patient relationship fear human major clinical study open angle glaucoma patient attitude patient compliance patient satisfaction perception psychological aspect quality of life questionnaire risk factor LA - French M3 - Article N1 - L35315357 2002-11-26 PY - 2002 SN - 0181-5512 SP - 795-798 ST - How patients react when glaucoma is diagnosed? T2 - Journal Francais d'Ophtalmologie TI - How patients react when glaucoma is diagnosed? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35315357&from=export VL - 25 ID - 3850 ER - TY - JOUR AB - Purpose: To assess the feasibility of automated text parsing screening of physician notes in the electronic health record (EHR) to identify glaucoma patients with poor medication compliance. Design: Cross-sectional study. Methods: An automated EHR extraction identified a cohort of patients at the University of Michigan with a diagnosis of glaucoma, ≥40 years old, taking ≥1 glaucoma medication, and having no cognitive impairment. Self-reported medication adherence was assessed with 2 validated instruments: the Chang scale and the Morisky medication adherence scale. In tandem, a text parsing tool that abstracted data from the EHR was used to search for combinations of the following words in patient visit notes: “not,” “non,” “n't,” “no,” or “poor” accompanied by “adherence,” “adherent, “adhering,” “compliance,” “compliant,” or “complying.” The proportion of patients with self-reported poor adherence was compared between the EHR extraction and text parsing identification using a Fisher exact test. Results: Among 736 participants, 20.0% (n = 147) self-reported poor adherence and 6.1% (n = 45) had EHR documentation of poor adherence (P < .0001). Using text parsing as a pre-screening tool, 22 of the 45 patients (48.9%) with non-adherence identified by text parsing also self-reported poor medication adherence compared to the 20.0% by self-report overall (P < .0001). Conclusions: Text parsing physician notes to identify patients' noncompliance to their medications identified a larger proportion of patients who then self-reported poor medication adherence than an automated EHR pull alone but was limited by the small number of patients identified. Optimizing the documentation of medication adherence would maximize the utility of this automated approach to identify medication noncompliance. AD - P.A. Newman-Casey, University of Michigan Kellogg Eye Center, 1000 Wall St, Ann Arbor, MI, United States AU - Hamid, M. S. AU - Valicevic, A. AU - Brenneman, B. AU - Niziol, L. M. AU - Stein, J. D. AU - Newman-Casey, P. A. DB - Embase Medline DO - 10.1016/j.ajo.2020.09.008 KW - NCT03159247 medication adherence monitoring system antiglaucoma agent adult aged article automated text parsing screening automation Chang scale cognitive defect cohort analysis controlled study cross-sectional study electronic health record feasibility study female Fisher exact test glaucoma human major clinical study male medical documentation Michigan Morisky Medication Adherence Scale patient assessment patient compliance priority journal rating scale self report university LA - English M3 - Article N1 - L2008607682 2020-11-30 2021-02-05 PY - 2021 SN - 1879-1891 0002-9394 SP - 54-59 ST - Text Parsing-Based Identification of Patients with Poor Glaucoma Medication Adherence in the Electronic Health Record T2 - American Journal of Ophthalmology TI - Text Parsing-Based Identification of Patients with Poor Glaucoma Medication Adherence in the Electronic Health Record UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2008607682&from=export http://dx.doi.org/10.1016/j.ajo.2020.09.008 VL - 222 ID - 2323 ER - TY - JOUR AB - Purpose: To assess the feasibility of automated text parsing screening of physician notes in the electronic health record (EHR) to identify glaucoma patients with poor medication compliance. Design: Cross-sectional study. Methods: An automated EHR extraction identified a cohort of patients at the University of Michigan with a diagnosis of glaucoma, ≥40 years old, taking ≥1 glaucoma medication, and having no cognitive impairment. Self-reported medication adherence was assessed with 2 validated instruments: the Chang scale and the Morisky medication adherence scale. In tandem, a text parsing tool that abstracted data from the EHR was used to search for combinations of the following words in patient visit notes: “not,” “non,” “n't,” “no,” or “poor” accompanied by “adherence,” “adherent, “adhering,” “compliance,” “compliant,” or “complying.” The proportion of patients with self-reported poor adherence was compared between the EHR extraction and text parsing identification using a Fisher exact test. Results: Among 736 participants, 20.0% (n = 147) self-reported poor adherence and 6.1% (n = 45) had EHR documentation of poor adherence (P < .0001). Using text parsing as a pre-screening tool, 22 of the 45 patients (48.9%) with non-adherence identified by text parsing also self-reported poor medication adherence compared to the 20.0% by self-report overall (P < .0001). Conclusions: Text parsing physician notes to identify patients' noncompliance to their medications identified a larger proportion of patients who then self-reported poor medication adherence than an automated EHR pull alone but was limited by the small number of patients identified. Optimizing the documentation of medication adherence would maximize the utility of this automated approach to identify medication noncompliance. © 2020 Elsevier Inc. AD - Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, United States Center for Eye Policy and Innovation, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, United States Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, MI, United States AU - Hamid, M. S. AU - Valicevic, A. AU - Brenneman, B. AU - Niziol, L. M. AU - Stein, J. D. AU - Newman-Casey, P. A. DB - Scopus DO - 10.1016/j.ajo.2020.09.008 M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 54-59 ST - Text Parsing-Based Identification of Patients with Poor Glaucoma Medication Adherence in the Electronic Health Record T2 - American Journal of Ophthalmology TI - Text Parsing-Based Identification of Patients with Poor Glaucoma Medication Adherence in the Electronic Health Record UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096175917&doi=10.1016%2fj.ajo.2020.09.008&partnerID=40&md5=29ef8655c744d46bf8bddfaadcb7cda8 VL - 222 ID - 5667 ER - TY - JOUR AB - center dot PURPOSE: To assess the feasibility of automated text parsing screening of physician notes in the electronic health record (EHR) to identify glaucoma patients with poor medication compliance. center dot DESIGN: Cross-sectional study. center dot METHODS: An automated EHR extraction identified a cohort of patients at the University of Michigan with a diagnosis of glaucoma, & Dagger;40 years old, taking & Dagger;1 glaucoma medication, and having no cognitive impairment. Self reported medication adherence was assessed with 2 validated instruments: the Chang scale and the Morisky medication adherence scale. In tandem, a text parsing tool that abstracted data from the EHR was used to search for combinations of the following words in patient visit notes: & ldquo;not,& rdquo;& ldquo;non,& rdquo;& ldquo;n & rsquo;t,& rdquo;& ldquo;no,& rdquo;or & ldquo;poor & rdquo;accompanied by & ldquo;adherence,& rdquo;& ldquo;adherent, & ldquo;adhering,& rdquo;& ldquo;compliance,& rdquo;& ldquo;compliant,& rdquo;or & ldquo;complying.& rdquo;The proportion of patients with self-reported poor adherence was compared between the EHR extraction and text parsing identification using a Fisher exact test. center dot RESULTS: Among 736 participants, 20.0% (n = 147) self-reported poor adherence and 6.1% (n = 45) had EHR documentation of poor adherence (P < .0001). Using text parsing as a pre-screening tool, 22 of the 45 patients (48.9%) with non-adherence identified by text parsing also self-reported poor medication adherence compared to the 20.0% by self-report overall (P < .0001). center dot CONCLUSIONS: Text parsing physician notes to identify patients & rsquo; noncompliance to their medications identified a larger proportion of patients who then self reported poor medication adherence than an automated EHR pull alone but was limited by the small number of patients identified. Optimizing the documentation of medication adherence would maximize the utility of this automated approach to identify medication noncompliance. (Am J Ophthalmol 2021;222:54 & ndash;59. (c) 2020 Elsevier Inc. All rights reserved.) AN - WOS:000625478500007 AU - Hamid, M. S. AU - Valicevic, A. AU - Brenneman, B. AU - Niziol, L. M. AU - Stein, J. D. AU - Newman-Casey, P. A. DA - FEB DO - 10.1016/j.ajo.2020.09.008 PY - 2021 SN - 0002-9394 1879-1891 SP - 54-59 ST - Text Parsing-Based Identification of Patients with Poor Glaucoma Medication Adherence in the Electronic Health Record T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Text Parsing-Based Identification of Patients with Poor Glaucoma Medication Adherence in the Electronic Health Record VL - 222 ID - 5920 ER - TY - JOUR AB - PURPOSE: We investigated chief complaints and ocular disorders in infants under one year of age and analyzed the association between complaints and disorders. METHODS: The medical records of 815 infants were reviewed. Chief complaints were grouped into the following 11 categories: eyelid drooping, epiphora (tearing), ocular discharge, lid swelling, eyelashes touching the eyeball, abnormalities of the anterior segment, abnormal eyeball movement (e.g., squint or nystagmus), red eye, trauma, poor eye contact, and miscellaneous. We performed ophthalmologic examinations at the doctors' discretion and analyzed the relationship between chief complaint and final diagnosis. RESULTS: Mean age of visiting the outpatient clinic was 6.09 ± 3.07 months. The most common complaint was ocular discharge, followed by abnormal eyeball movement, epiphora, and eye redness. Among infants with ocular discharge, most were attributed to congenital nasolacrimal duct obstruction (155 infants) and conjunctivitis (75 infants). A total of 160 guardians complained of abnormal eyeball movement and 86 of 160 infants (51.9%) suffered from pseudoesotropia. Additionally, exodeviation and esodeviation was found in 17.9% and 16.4% of infants, respectively. Eight guardian complained of poor eye contact in their infants and these infants were diagnosed with retinal disorders (3), congenital optic nerve disorders (2), cataract (1), glaucoma (1), and high hyperopia (1). CONCLUSIONS: The most common ocular symptoms in infants under one year of age included ocular discharge, epiphora, and eye redness. However, infants with poor eye contact or suspected abnormal eye movement should undergo a full ophthalmologic examination. AU - Han, S. AU - Kim, U. S. DB - Medline DO - 10.3341/kjo.2014.28.3.241 IS - 3 KW - eye disease female follow up human infant male outpatient department patient compliance retrospective study LA - English M3 - Article N1 - L609594925 2016-04-11 PY - 2014 SN - 1011-8942 SP - 241-245 ST - Symptom based diagnosis of infant under one year in outpatient clinic T2 - Korean journal of ophthalmology : KJO TI - Symptom based diagnosis of infant under one year in outpatient clinic UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609594925&from=export http://dx.doi.org/10.3341/kjo.2014.28.3.241 VL - 28 ID - 2881 ER - TY - JOUR AB - PURPOSE: We investigated chief complaints and ocular disorders in infants under one year of age and analyzed the association between complaints and disorders. METHODS: The medical records of 815 infants were reviewed. Chief complaints were grouped into the following 11 categories: eyelid drooping, epiphora (tearing), ocular discharge, lid swelling, eyelashes touching the eyeball, abnormalities of the anterior segment, abnormal eyeball movement (e.g., squint or nystagmus), red eye, trauma, poor eye contact, and miscellaneous. We performed ophthalmologic examinations at the doctors' discretion and analyzed the relationship between chief complaint and final diagnosis. RESULTS: Mean age of visiting the outpatient clinic was 6.09 ± 3.07 months. The most common complaint was ocular discharge, followed by abnormal eyeball movement, epiphora, and eye redness. Among infants with ocular discharge, most were attributed to congenital nasolacrimal duct obstruction (155 infants) and conjunctivitis (75 infants). A total of 160 guardians complained of abnormal eyeball movement and 86 of 160 infants (51.9%) suffered from pseudoesotropia. Additionally, exodeviation and esodeviation was found in 17.9% and 16.4% of infants, respectively. Eight guardian complained of poor eye contact in their infants and these infants were diagnosed with retinal disorders (3), congenital optic nerve disorders (2), cataract (1), glaucoma (1), and high hyperopia (1). CONCLUSIONS: The most common ocular symptoms in infants under one year of age included ocular discharge, epiphora, and eye redness. However, infants with poor eye contact or suspected abnormal eye movement should undergo a full ophthalmologic examination. AD - Department of Ophthalmology, Kim's Eye Hospital, Korea. ; Department of Ophthalmology, Konyang University College of Medicine, Daejeon, South Korea AU - Han, S. AU - Kim, U. S. DB - Scopus DO - 10.3341/kjo.2014.28.3.241 IS - 3 KW - Diagnosis Infant M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2014 SP - 241-245 ST - Symptom based diagnosis of infant under one year in outpatient clinic T2 - Korean journal of ophthalmology : KJO TI - Symptom based diagnosis of infant under one year in outpatient clinic UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84965091641&doi=10.3341%2fkjo.2014.28.3.241&partnerID=40&md5=6d75f32f8d74f13d70665fe5f8931369 VL - 28 ID - 5570 ER - TY - JOUR AB - Background/objectives: To assess the long-term association between low-carbohydrate dietary patterns and incident primary open-angle glaucoma (POAG), and POAG subtypes defined by highest untreated intraocular pressure (IOP) and by pattern of visual field (VF) loss at diagnosis. Subjects/methods: We followed 185,638 participants of three large US prospective cohorts biennially (1976–2016, 1986–2016 and 1991–2017). Deciles of three low-carbohydrate-diet scores were calculated to represent adherence to diets lower in carbohydrate and higher in protein and fat from any source, animal sources or plant sources. We confirmed POAG cases (n = 2112) by medical record review and used Cox proportional hazards models to estimate multivariable-adjusted relative risks (MVRRs) and 95% confidence intervals (CIs). Results: There was no association between the three types of low-carbohydrate-diet scores and POAG: the MVRR for POAG in the highest vs. lowest deciles was 1.13 (95% CI, 0.91–1.39; Ptrend = 0.40) for the overall score; 1.10 (95% CI, 0.89–1.35; Ptrend = 0.38) for the animal score and 0.96 (95% CI, 0.79–1.18; Ptrend = 0.88) for the vegetable score. No differential associations by IOP level was found (Pheterogeneity ≥ 0.06). However, the vegetable score showed a suggestive inverse association with early paracentral VF loss (highest vs. lowest decile MVRR = 0.78 [95% CI, 0.55–1.10]; Ptrend = 0.12) but not with peripheral VF loss only (MVRR = 1.09 [95% CI, 0.83–1.44]; Ptrend = 0.14; Pheterogeneity = 0.03). Conclusions: Low-carbohydrate diets were not associated with risk of POAG. Our data suggested that higher consumption of fat and protein from vegetable sources substituting for carbohydrates was associated with lower risk of the POAG subtype with initial paracentral VF loss. © 2020, The Author(s), under exclusive licence to The Royal College of Ophthalmologists. AD - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, United States Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, United States Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, United States AU - Hanyuda, A. AU - Rosner, B. A. AU - Wiggs, J. L. AU - Willett, W. C. AU - Tsubota, K. AU - Pasquale, L. R. AU - Kang, J. H. DB - Scopus DO - 10.1038/s41433-020-0820-5 IS - 8 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2020 SP - 1465-1475 ST - Low-carbohydrate-diet scores and the risk of primary open-angle glaucoma: data from three US cohorts T2 - Eye (Basingstoke) TI - Low-carbohydrate-diet scores and the risk of primary open-angle glaucoma: data from three US cohorts UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081364009&doi=10.1038%2fs41433-020-0820-5&partnerID=40&md5=16f50fd2c81df2585702f2e9c10bd02e VL - 34 ID - 5547 ER - TY - JOUR AB - INTRODUCTION: To compare the tolerability and efficacy of a preservative-containing latanoprost (PCL) to a preservative-free formulation of latanoprost (PFL) in patients with open-angle glaucoma or ocular hypertension., METHODS: A pooled analysis was performed of data from five published studies. The primary outcome was tolerability as evaluated by the severity of hyperemia. The secondary objectives were patient tolerance based on a composite ocular surface disease (OSD) score arising from ocular signs and symptoms, patient and investigator satisfaction, and a comparison of IOP-lowering efficacy., RESULTS: There were three randomized controlled trials and two observational studies included in the analysis. Conjunctival hyperemia improved significantly in 25.6% (388) of patients switched to the PFL group versus 11.7% (117) of patients switched to the PCL group (p < 0.001). PFL was two times superior to PCL in reducing ocular hyperemia (odds ratio = 1.96; p < 0.001). The mean OSD composite score decreased by 32.2% in patients switched to the PFL group and 14.1% in the PCL group (p < 0.001). At 3 months, the mean IOP was similar between groups (p = 0.312)., CONCLUSION: This post hoc pooled analysis confirmed the findings of the individual studies that PFL is as efficacious at reducing IOP as PCL but better tolerated. After switching to PFL, there was twice the improvement in the OSD composite score. PFL was twice as effective at reducing ocular hyperemia and other ocular signs. These findings suggest that PFL has features that may improve patient compliance, thereby potentially improving the IOP-lowering efficacy on a long-term basis. AU - Harasymowycz, Paul AU - Hutnik, Cindy AU - Rouland, Jean-Francois AU - Negrete, Francisco J. Munoz AU - Economou, Mario A. AU - Denis, Philippe AU - Baudouin, Christophe DO - https://dx.doi.org/10.1007/s12325-021-01731-9 IS - 6 KW - Antihypertensive Agents/tu [Therapeutic Use] Glaucoma/dt [Drug Therapy] *Glaucoma Glaucoma, Open-Angle/dt [Drug Therapy] *Glaucoma, Open-Angle Humans Intraocular Pressure Latanoprost Ocular Hypertension/dt [Drug Therapy] *Ocular Hypertension Ophthalmic Solutions Prostaglandins F, Synthetic/tu [Therapeutic Use] *Prostaglandins F, Synthetic Treatment Outcome PY - 2021 SE - Harasymowycz, Paul. University of Montreal, Montreal, Canada. pavloh@igmtl.com. Harasymowycz, Paul. Bellevue Ophthalmology Clinics and Montreal Glaucoma Institute, Montreal, Canada. pavloh@igmtl.com. Hutnik, Cindy. Ivey Eye Institute, Western University, London, ON, Canada. Rouland, Jean-Francois. Ophthalmology Department, University of Lille, Lille, France. Negrete, Francisco J Munoz. Hospital Ramon y Cajal, Universidad Alcala, Ophthalmology, Madrid, Spain. Economou, Mario A. Queen Sofia Hospital, Stockholm, Sweden. Economou, Mario A. Praktikertjanst, Stockholm, Sweden. Denis, Philippe. Department of Ophthalmology, HEH, Hospices Civils de Lyon, Lyon, France. Baudouin, Christophe. Quinze-Vingts National Ophthalmology Hospital, Paris, France. SN - 1865-8652 0741-238X SP - 3019-3031 ST - Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis T2 - Advances in therapy TI - Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33891269 VL - 38 Y2 - 20210423// ID - 155 ER - TY - JOUR AB - Introduction: To compare the tolerability and efficacy of a preservative-containing latanoprost (PCL) to a preservative-free formulation of latanoprost (PFL) in patients with open-angle glaucoma or ocular hypertension.Methods: A pooled analysis was performed of data from five published studies. The primary outcome was tolerability as evaluated by the severity of hyperemia. The secondary objectives were patient tolerance based on a composite ocular surface disease (OSD) score arising from ocular signs and symptoms, patient and investigator satisfaction, and a comparison of IOP-lowering efficacy.Results: There were three randomized controlled trials and two observational studies included in the analysis. Conjunctival hyperemia improved significantly in 25.6% (388) of patients switched to the PFL group versus 11.7% (117) of patients switched to the PCL group (p < 0.001). PFL was two times superior to PCL in reducing ocular hyperemia (odds ratio = 1.96; p < 0.001). The mean OSD composite score decreased by 32.2% in patients switched to the PFL group and 14.1% in the PCL group (p < 0.001). At 3 months, the mean IOP was similar between groups (p = 0.312).Conclusion: This post hoc pooled analysis confirmed the findings of the individual studies that PFL is as efficacious at reducing IOP as PCL but better tolerated. After switching to PFL, there was twice the improvement in the OSD composite score. PFL was twice as effective at reducing ocular hyperemia and other ocular signs. These findings suggest that PFL has features that may improve patient compliance, thereby potentially improving the IOP-lowering efficacy on a long-term basis. AD - University of Montreal, Montreal, Canada Bellevue Ophthalmology Clinics and Montreal Glaucoma Institute, Montreal, Canada Ivey Eye Institute, Western University, London, ON, Canada Ophthalmology Department, University of Lille, Lille, France Hospital Ramón y Cajal, Universidad Alcalá, Ophthalmology, Madrid, Spain Queen Sofia Hospital, Stockholm, Sweden Praktikertjänst, Stockholm, Sweden Department of Ophthalmology, HEH, Hospices Civils de Lyon, Lyon, France Quinze-Vingts National Ophthalmology Hospital, Paris, France AN - 150793936. Language: English. Entry Date: In Process. Revision Date: 20210717. Publication Type: journal article AU - Harasymowycz, Paul AU - Hutnik, Cindy AU - Rouland, Jean-François AU - Negrete, Francisco J. Muñoz AU - Economou, Mario A. AU - Denis, Philippe AU - Baudouin, Christophe DB - ccm DO - 10.1007/s12325-021-01731-9 DP - EBSCOhost IS - 6 N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8611864. PMID: NLM33891269. PY - 2021 SN - 0741-238X SP - 3019-3031 ST - Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis T2 - Advances in Therapy TI - Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150793936&site=ehost-live&scope=site VL - 38 ID - 4149 ER - TY - JOUR AB - Blindness from glaucoma can be prevented by early detection and treatment. Telemedicine improves access to treatment in high-risk populations that face barriers to receiving adequate ophthalmic care. We used a practice-based telemedicine screening model at two health centers. Telemedicine imaging of the fundus and optic nerve, followed by a complete eye exam at the same location for participants with abnormal findings, unreadable images, or ocular hypertension (OHTN), was performed. A total of 182 participants were screened, of whom 108 qualified for a complete eye exam. Of these, 62 (34.1%) had abnormal images, 12 (6.6%) had OHTN, and 34 (18.7%) had unreadable images. Eighty-nine of the 108 (82%) returned for the complete eye exam. Predominantly, participants were African American with glaucoma suspect and cataract. Screening location was an important factor for follow-up. Assessment of the fundus and optic disc using telemedicine resulted in early detection of glaucoma and other ocular pathology. © Meharry Medical College. AD - Wills Eye Hospital, Glaucoma Research Center and Columbia University, Irving Medical Center, Department of Ophthalmology, United States Lake Erie College of Osteopathic Medicine, United States Wills Eye Hospital, Glaucoma Research Center, Weill Cornell Medical College, Department of Ophthalmology, United States Lewis Katz School of Medicine at Temple University, Department of Ophthalmology, United States Sidney Kimmel Medical College, Thomas Jefferson University, United States Lewis Katz School of Medicine at Temple University, United States Wills Eye Hospital, Glaucoma Research Center, United States Philadelphia Department of Public Health, Philadelphia District Five Health Center, United States Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, United States Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA, United States Sidney KimKim Thomas Jefferson University, Philadelphia, PA, United States AU - Hark, L. AU - Acito, M. AU - Adeghate, J. AU - Henderer, J. AU - Okudolo, J. AU - Malik, K. AU - Molineaux, J. AU - Eburuoh, R. AU - Zhan, T. AU - Jay Katz, L. DB - Scopus DO - 10.1353/hpu.2018.0103 IS - 4 KW - Federally qualified health center Glaucoma Health center Ophthalmology Philadelphia Preventive medicine Primary care Telemedicine Vision screening M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2018 SP - 1400-1415 ST - Philadelphia telemedicine glaucoma detection and follow-up study: Ocular findings at two health centers T2 - Journal of Health Care for the Poor and Underserved TI - Philadelphia telemedicine glaucoma detection and follow-up study: Ocular findings at two health centers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056595390&doi=10.1353%2fhpu.2018.0103&partnerID=40&md5=bf19ce5b72169edf7dc83db9c162f9bb VL - 29 ID - 5448 ER - TY - JOUR AB - Blindness from glaucoma can be prevented by early detection and treatment. Telemedicine improves access to treatment in high-risk populations that face barriers to receiving adequate ophthalmic care. We used a practice-based telemedicine screening model at two health centers. Telemedicine imaging of the fundus and optic nerve, followed by a complete eye exam at the same location for participants with abnormal findings, unreadable images, or ocular hypertension (OHTN), was performed. A total of 182 participants were screened, of whom 108 qualified for a complete eye exam. Of these, 62 (34.1%) had abnormal images, 12 (6.6%) had OHTN, and 34 (18.7%) had unreadable images. Eighty-nine of the 108 (82%) returned for the complete eye exam. Predominantly, participants were African American with glaucoma suspect and cataract. Screening location was an important factor for follow-up. Assessment of the fundus and optic disc using telemedicine resulted in early detection of glaucoma and other ocular pathology. AN - 133120424. Language: English. Entry Date: 20181124. Revision Date: 20191101. Publication Type: Article AU - Hark, Lisa AU - Acito, Megan AU - Adeghate, Jennifer AU - Henderer, Jeffrey AU - Okudolo, Joseph AU - Malik, Kunal AU - Molineaux, Jeanne AU - Eburuoh, Rita AU - Zhan, Tingting AU - Katz, L. Jay DB - ccm DO - 10.1353/hpu.2018.0103 DP - EBSCOhost IS - 4 KW - Glaucoma -- Diagnosis Glaucoma -- Therapy Telemedicine Program Evaluation Human Randomized Controlled Trials Primary Health Care Diagnosis, Eye Ocular Hypertension Cataract Vision Screening Community Health Centers Early Diagnosis Male Female T-Tests Wilcoxon Rank Sum Test Fisher's Exact Test Data Analysis Software Middle Age Aged Funding Source Prospective Studies N1 - research; tables/charts; randomized controlled trial. Journal Subset: Health Services Administration; Peer Reviewed; Public Health; USA. Grant Information: This study was funded by the United States Centers for Disease Control and Prevention(Grant Number: U01 DP005127).. NLM UID: 9103800. PY - 2018 SN - 1049-2089 SP - 1400-1415 ST - Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Ocular Findings at Two Health Centers T2 - Journal of Health Care for the Poor & Underserved TI - Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Ocular Findings at Two Health Centers UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=133120424&site=ehost-live&scope=site VL - 29 ID - 4211 ER - TY - JOUR AB - Blindness from glaucoma can be prevented by early detection and treatment. Telemedicine improves access to treatment in high-risk populations that face barriers to receiving adequate ophthalmic care. We used a practice-based telemedicine screening model at two health centers. Telemedicine imaging of the fundus and optic nerve, followed by a complete eye exam at the same location for participants with abnormal findings, unreadable images, or ocular hypertension (OHTN), was performed. A total of 182 participants were screened, of whom 108 qualified for a complete eye exam. Of these, 62 (34.1%) had abnormal images, 12 (6.6%) had OHTN, and 34 (18.7%) had unreadable images. Eighty-nine of the 108 (82%) returned for the complete eye exam. Predominantly, participants were African American with glaucoma suspect and cataract. Screening location was an important factor for follow-up. Assessment of the fundus and optic disc using telemedicine resulted in early detection of glaucoma and other ocular pathology. AN - WOS:000449935400017 AU - Hark, L. AU - Acito, M. AU - Adeghate, J. AU - Henderer, J. AU - Okudolo, J. AU - Malik, K. AU - Molineaux, J. AU - Eburuoh, R. AU - Zhan, T. T. AU - Katz, L. J. DA - NOV DO - 10.1353/hpu.2018.0103 IS - 4 PY - 2018 SN - 1049-2089 1548-6869 SP - 1400-1415 ST - Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Ocular Findings at Two Health Centers T2 - JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED TI - Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Ocular Findings at Two Health Centers VL - 29 ID - 5924 ER - TY - JOUR AB - Purpose: The Wills Eye Glaucoma Research Center initiated a 2-year demonstration project to develop and implement a community-based intervention to improve detection and management of glaucoma in Philadelphia.Methods: The glaucoma detection examination consisted of: ocular, medical, and family history; visual acuity testing; corneal pachymetry; biomicroscopy of the anterior segment; intraocular pressure (IOP) measurement; gonioscopy; funduscopy; automated visual field testing; and fundus-color photography. Treatment included laser surgery and/or IOP-lowering medication. A cost analysis was conducted to understand resource requirements. Outcome measures included; prevalence of glaucoma-related pathology and other eye diseases among high-risk populations; the impact of educational workshops on level of knowledge about glaucoma (assessed by pre- and post-test evaluation); and patient satisfaction of the glaucoma detection examinations in the community (assessed by satisfaction survey). Treatment outcome measures were change in IOP at 4-6 weeks and 4-6 months following selective laser trabeculoplasty treatment, deepening of the anterior chamber angle following laser-peripheral iridotomy treatment, and rate of adherence to recommended follow-up examinations. Cost outcomes included total program costs, cost per case of glaucoma detected, and cost per case of ocular disease detected.Results: This project enrolled 1649 participants (African Americans aged 50+ years, adults 60+ years and individuals with a family history of glaucoma). A total of 1074 individuals attended a glaucoma educational workshop and 1508 scheduled glaucoma detection examination appointments in the community setting.Conclusions: The Philadelphia Glaucoma Detection and Treatment Project aimed to improve access and use of eye care and to provide a model for a targeted community-based glaucoma program. AD - L. Hark, Wills Eye Hospital, Glaucoma Research Center, 840 Walnut Street, Philadelphia, PA, United States AU - Hark, L. AU - Waisbourd, M. AU - Myers, J. S. AU - Henderer, J. AU - Crews, J. E. AU - Saaddine, J. B. AU - Molineaux, J. AU - Johnson, D. AU - Sembhi, H. AU - Stratford, S. AU - Suleiman, A. AU - Pizzi, L. AU - Spaeth, G. L. AU - Katz, L. J. DB - Embase Medline DO - 10.3109/09286586.2015.1099683 IS - 2 KW - adult African American anterior eye segment article biomicroscopy corneal pachymetry cost benefit analysis eye disease eye examination eye photography family history follow up fundus color photography glaucoma gonioscopy high risk patient human intraocular pressure iridotomy laser surgery major clinical study measurement ophthalmoscopy outcome assessment patient satisfaction priority journal trabeculoplasty United States visual acuity visual field LA - English M3 - Article N1 - L609149035 2016-03-30 2016-04-14 PY - 2016 SN - 1744-5086 0928-6586 SP - 122-130 ST - Improving access to eye care among persons at high-risk of glaucoma in Philadelphia - design and methodology: The Philadelphia glaucoma detection and treatment project T2 - Ophthalmic Epidemiology TI - Improving access to eye care among persons at high-risk of glaucoma in Philadelphia - design and methodology: The Philadelphia glaucoma detection and treatment project UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609149035&from=export http://dx.doi.org/10.3109/09286586.2015.1099683 VL - 23 ID - 2752 ER - TY - JOUR AB - Purpose: The Wills Eye Glaucoma Research Center initiated a 2-year demonstration project to develop and implement a community-based intervention to improve detection and management of glaucoma in Philadelphia.Methods: The glaucoma detection examination consisted of: ocular, medical, and family history; visual acuity testing; corneal pachymetry; biomicroscopy of the anterior segment; intraocular pressure (IOP) measurement; gonioscopy; funduscopy; automated visual field testing; and fundus-color photography. Treatment included laser surgery and/or IOP-lowering medication. A cost analysis was conducted to understand resource requirements. Outcome measures included; prevalence of glaucoma-related pathology and other eye diseases among high-risk populations; the impact of educational workshops on level of knowledge about glaucoma (assessed by pre- and post-test evaluation); and patient satisfaction of the glaucoma detection examinations in the community (assessed by satisfaction survey). Treatment outcome measures were change in IOP at 4-6 weeks and 4-6 months following selective laser trabeculoplasty treatment, deepening of the anterior chamber angle following laser-peripheral iridotomy treatment, and rate of adherence to recommended follow-up examinations. Cost outcomes included total program costs, cost per case of glaucoma detected, and cost per case of ocular disease detected.Results: This project enrolled 1649 participants (African Americans aged 50+ years, adults 60+ years and individuals with a family history of glaucoma). A total of 1074 individuals attended a glaucoma educational workshop and 1508 scheduled glaucoma detection examination appointments in the community setting.Conclusions: The Philadelphia Glaucoma Detection and Treatment Project aimed to improve access and use of eye care and to provide a model for a targeted community-based glaucoma program. © 2016 Taylor & Francis. AD - Wills Eye Hospital, Glaucoma Research Center, 840 Walnut Street, Philadelphia, PA 19107, United States Temple University, School of Medicine, Department of Ophthalmology, Philadelphia, PA, United States Vision Health Initiative, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA, United States Thomas Jefferson University, School of Pharmacy, Philadelphia, PA, United States AU - Hark, L. AU - Waisbourd, M. AU - Myers, J. S. AU - Henderer, J. AU - Crews, J. E. AU - Saaddine, J. B. AU - Molineaux, J. AU - Johnson, D. AU - Sembhi, H. AU - Stratford, S. AU - Suleiman, A. AU - Pizzi, L. AU - Spaeth, G. L. AU - Katz, L. J. DB - Scopus DO - 10.3109/09286586.2015.1099683 IS - 2 KW - Access to eye care community-based glaucoma detection glaucoma treatment underserved population M3 - Article N1 - Cited By :20 Export Date: 19 July 2021 PY - 2016 SP - 122-130 ST - Improving access to eye care among persons at high-risk of glaucoma in Philadelphia - design and methodology: The Philadelphia glaucoma detection and treatment project T2 - Ophthalmic Epidemiology TI - Improving access to eye care among persons at high-risk of glaucoma in Philadelphia - design and methodology: The Philadelphia glaucoma detection and treatment project UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961201537&doi=10.3109%2f09286586.2015.1099683&partnerID=40&md5=eca3b5daf07d50e84bab1f2c47faadcc VL - 23 ID - 5140 ER - TY - JOUR AB - Purpose: The Wills Eye Glaucoma Research Center initiated a 2-year demonstration project to develop and implement a community-based intervention to improve detection and management of glaucoma in Philadelphia. Methods: The glaucoma detection examination consisted of: ocular, medical, and family history; visual acuity testing; corneal pachymetry; biomicroscopy of the anterior segment; intraocular pressure (IOP) measurement; gonioscopy; funduscopy; automated visual field testing; and fundus-color photography. Treatment included laser surgery and/or IOP-lowering medication. A cost analysis was conducted to understand resource requirements. Outcome measures included; prevalence of glaucoma-related pathology and other eye diseases among high-risk populations; the impact of educational workshops on level of knowledge about glaucoma (assessed by pre- and post-test evaluation); and patient satisfaction of the glaucoma detection examinations in the community (assessed by satisfaction survey). Treatment outcome measures were change in IOP at 4-6 weeks and 4-6 months following selective laser trabeculoplasty treatment, deepening of the anterior chamber angle following laser-peripheral iridotomy treatment, and rate of adherence to recommended follow-up examinations. Cost outcomes included total program costs, cost per case of glaucoma detected, and cost per case of ocular disease detected. Results: This project enrolled 1649 participants (African Americans aged 50+ years, adults 60+ years and individuals with a family history of glaucoma). A total of 1074 individuals attended a glaucoma educational workshop and 1508 scheduled glaucoma detection examination appointments in the community setting. Conclusions: The Philadelphia Glaucoma Detection and Treatment Project aimed to improve access and use of eye care and to provide a model for a targeted community-based glaucoma program. AN - WOS:000372741700009 AU - Hark, L. AU - Waisbourd, M. AU - Myers, J. S. AU - Henderer, J. AU - Crews, J. E. AU - Saaddine, J. B. AU - Molineaux, J. AU - Johnson, D. AU - Sembhi, H. AU - Stratford, S. AU - Suleiman, A. AU - Pizzi, L. AU - Spaeth, G. L. AU - Katz, L. J. DA - MAR 3 DO - 10.3109/09286586.2015.1099683 IS - 2 PY - 2016 SN - 0928-6586 1744-5086 SP - 122-130 ST - Improving Access to Eye Care among Persons at High-Risk of Glaucoma in Philadelphia - Design and Methodology: The Philadelphia Glaucoma Detection and Treatment Project T2 - OPHTHALMIC EPIDEMIOLOGY TI - Improving Access to Eye Care among Persons at High-Risk of Glaucoma in Philadelphia - Design and Methodology: The Philadelphia Glaucoma Detection and Treatment Project VL - 23 ID - 5910 ER - TY - JOUR AB - Purpose: Patients with glaucoma who do not keep their follow-up eye care appointments are at risk for developing more severe ocular disease. The primary aim of the current study was to evaluate whether the use of a patient navigator altered adherence to follow-up eye care appointments in community-versus office-based settings. Patients and methods: Patients diagnosed with a glaucoma-related condition following a comprehensive eye examination at 43 community sites in Philadelphia, PA, USA, were enrolled in this prospective, randomized, controlled trial. Patients were randomized into three groups for a 1-year period: Group 1 (G1) received follow-up eye care in a community-based setting with assistance from a patient navigator; Group 2 (G2) received follow-up eye care in an office-based setting with assistance from a patient navigator; and Group 3 (G3) received follow-up eye care in an office-based setting without a patient navigator (usual care). Adherence rates were compared among these three groups using a chi-squared test at a significance level of 0.05. Results: A total of 155 patients with glaucoma-related diagnoses were enrolled. The mean age (±standard deviation) was 71.2 (±10.0) years. Patients were predominantly female (65.8%, n=102/155) and African-American (71.6%, n=111/155). The mean (±standard deviation) number of follow-up visits during the 1-year study period was 1.3 (±1.3) for G1, 1.6 (±1.3) for G2, and 1.3 (±1.1) for G3 (P=0.48). Appointment adherence, defined as attendance of ≥1 follow-up visit, was 69.8% (n=37/53) for G1, 82.5% (n=47/57) for G2, and 73.3% (n=33/45) for G3, (P=0.28). Sub-analysis of adherence rates for patients who attended ≥2 follow-up visits were 91.3% (n=21/23) for G1, 74.3% (n=26/35) for G2, and 66.7% (n=18/27) for G3, (P=0.11). Conclusion: Help from a patient navigator did not increase the likelihood of keeping ≥1 follow-up appointment in an office-based setting. Adherence rates for follow-up appointments reached close to 70% or above in a self-selected patient population. AD - L.A. Hark, Department of Research, Glaucoma Research Center, Wills Eye Hospital, 840 Walnut Street, Suite 802, Philadelphia, PA, United States AU - Hark, L. A. AU - Johnson, D. M. AU - Berardi, G. AU - Patel, N. S. AU - Zeng, L. AU - Dai, Y. AU - Mayro, E. L. AU - Waisbourd, M. AU - Jay Katz, L. DB - Embase DO - 10.2147/PPA.S108391 KW - African American age aged article controlled study disease severity eye examination female follow up glaucoma health care access health care management health care personnel human major clinical study male multicenter study National Eye Institute Visual Function Questionnaire patient attendance patient education patient navigator Pennsylvania program effectiveness prospective study randomized controlled trial urban area LA - English M3 - Article N1 - L612205427 2016-09-23 2016-09-27 PY - 2016 SN - 1177-889X SP - 1739-1748 ST - A randomized, controlled trial to test the effectiveness of a glaucoma patient navigator to improve appointment adherence T2 - Patient Preference and Adherence TI - A randomized, controlled trial to test the effectiveness of a glaucoma patient navigator to improve appointment adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612205427&from=export http://dx.doi.org/10.2147/PPA.S108391 VL - 10 ID - 2705 ER - TY - JOUR AB - Purpose: Patients with glaucoma who do not keep their follow-up eye care appointments are at risk for developing more severe ocular disease. The primary aim of the current study was to evaluate whether the use of a patient navigator altered adherence to follow-up eye care appointments in community-versus office-based settings. Patients and methods: Patients diagnosed with a glaucoma-related condition following a comprehensive eye examination at 43 community sites in Philadelphia, PA, USA, were enrolled in this prospective, randomized, controlled trial. Patients were randomized into three groups for a 1-year period: Group 1 (G1) received follow-up eye care in a community-based setting with assistance from a patient navigator; Group 2 (G2) received follow-up eye care in an office-based setting with assistance from a patient navigator; and Group 3 (G3) received follow-up eye care in an office-based setting without a patient navigator (usual care). Adherence rates were compared among these three groups using a chi-squared test at a significance level of 0.05. Results: A total of 155 patients with glaucoma-related diagnoses were enrolled. The mean age (±standard deviation) was 71.2 (±10.0) years. Patients were predominantly female (65.8%, n=102/155) and African-American (71.6%, n=111/155). The mean (±standard deviation) number of follow-up visits during the 1-year study period was 1.3 (±1.3) for G1, 1.6 (±1.3) for G2, and 1.3 (±1.1) for G3 (P=0.48). Appointment adherence, defined as attendance of ≥1 follow-up visit, was 69.8% (n=37/53) for G1, 82.5% (n=47/57) for G2, and 73.3% (n=33/45) for G3, (P=0.28). Sub-analysis of adherence rates for patients who attended ≥2 follow-up visits were 91.3% (n=21/23) for G1, 74.3% (n=26/35) for G2, and 66.7% (n=18/27) for G3, (P=0.11). Conclusion: Help from a patient navigator did not increase the likelihood of keeping ≥1 follow-up appointment in an office-based setting. Adherence rates for follow-up appointments reached close to 70% or above in a self-selected patient population. © 2016 Hark et al. AD - Wills Eye Hospital Glaucoma Research Center, Philadelphia, PA, United States AU - Hark, L. A. AU - Johnson, D. M. AU - Berardi, G. AU - Patel, N. S. AU - Zeng, L. AU - Dai, Y. AU - Mayro, E. L. AU - Waisbourd, M. AU - Jay Katz, L. AU - Glaucoma Research, Group DB - Scopus DO - 10.2147/PPA.S108391 KW - Access to eye care Appointment adherence Glaucoma Patient navigator Underserved population M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2016 SP - 1739-1748 ST - A randomized, controlled trial to test the effectiveness of a glaucoma patient navigator to improve appointment adherence T2 - Patient Preference and Adherence TI - A randomized, controlled trial to test the effectiveness of a glaucoma patient navigator to improve appointment adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84987905569&doi=10.2147%2fPPA.S108391&partnerID=40&md5=9a48565f0a52c8ac23e96fd40d2dca43 VL - 10 ID - 5626 ER - TY - JOUR AB - Purpose: Patients with glaucoma who do not keep their follow-up eye care appointments are at risk for developing more severe ocular disease. The primary aim of the current study was to evaluate whether the use of a patient navigator altered adherence to follow-up eye care appointments in community-versus office-based settings. Patients and methods: Patients diagnosed with a glaucoma-related condition following a comprehensive eye examination at 43 community sites in Philadelphia, PA, USA, were enrolled in this prospective, randomized, controlled trial. Patients were randomized into three groups for a 1-year period: Group 1 (G1) received follow-up eye care in a community-based setting with assistance from a patient navigator; Group 2 (G2) received follow-up eye care in an office-based setting with assistance from a patient navigator; and Group 3 (G3) received follow-up eye care in an office-based setting without a patient navigator (usual care). Adherence rates were compared among these three groups using a chi-squared test at a significance level of 0.05. Results: A total of 155 patients with glaucoma-related diagnoses were enrolled. The mean age (+/- standard deviation) was 71.2 (+/- 10.0) years. Patients were predominantly female (65.8%, n= 102/155) and African-American (71.6%, n= 111/155). The mean (+/- standard deviation) number of follow-up visits during the 1-year study period was 1.3 (+/- 1.3) for G1, 1.6 (+/- 1.3) for G2, and 1.3 (+/- 1.1) for G3 (P= 0.48). Appointment adherence, defined as attendance of >= 1 follow-up visit, was 69.8% (n= 37/53) for G1, 82.5% (n= 47/57) for G2, and 73.3% (n= 33/45) for G3, (P= 0.28). Sub-analysis of adherence rates for patients who attended >= 2 follow-up visits were 91.3% (n= 21/23) for G1, 74.3% (n= 26/35) for G2, and 66.7% (n= 18/27) for G3, (P= 0.11). Conclusion: Help from a patient navigator did not increase the likelihood of keeping >= 1 follow-up appointment in an office-based setting. Adherence rates for follow-up appointments reached close to 70% or above in a self-selected patient population. AN - WOS:000383153700001 AU - Hark, L. A. AU - Johnson, D. M. AU - Berardi, G. AU - Patel, N. S. AU - Zeng, L. C. AU - Dai, Y. AU - Mayro, E. L. AU - Waisbourd, M. AU - Katz, L. J. AU - Glaucoma Res, Grp DO - 10.2147/PPA.S108391 PY - 2016 SN - 1177-889X SP - 1739-1748 ST - A randomized, controlled trial to test the effectiveness of a glaucoma patient navigator to improve appointment adherence T2 - PATIENT PREFERENCE AND ADHERENCE TI - A randomized, controlled trial to test the effectiveness of a glaucoma patient navigator to improve appointment adherence VL - 10 ID - 5824 ER - TY - JOUR AN - WOS:000442932807276 AU - Hark, L. A. AU - Katz, L. J. AU - Myers, J. S. AU - Haller, J. A. DA - JUL IS - 9 PY - 2018 SN - 0146-0404 1552-5783 ST - Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Adherence to Community Eye Exam Appointments T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Adherence to Community Eye Exam Appointments VL - 59 ID - 5842 ER - TY - JOUR AB - Purpose: To evaluate rates of adherence to free follow-up eye exam appointments among participants in the Philadelphia Glaucoma Detection and Treatment Project. Patients and Methods: Ophthalmologists and testing equipment were brought directly to participants at risk for glaucoma at 43 community sites in Philadelphia. Those diagnosed with glaucoma-related pathology were recommended to return for follow-up to be reexamined on site. Rates of adherence and clinical and demographic risk factors for adherence were evaluated. Results: Five hundred thirty-one participants were diagnosed with glaucoma-related conditions and recommended to attend community-based follow-up exams. Follow-up adherence rate was 61.2% (n=325/531). Significant factors associated with greater eye exam appointment adherence, based on our univariable analysis, included final diagnosis of glaucoma (risk ratio [RR]=1.33; 95% confidence interval [CI], 1.13-1.57), male sex (RR=1.19; 95% CI, 1.04-1.36), white race (RR=1.26; 95% CI, 1.08-1.48), age (RR=1.17; 95% CI, 1.00-1.37) recommendation for glaucoma medication (RR=1.52; 95% CI, 1.35-1.71), recommendation for laser peripheral iridotomy (RR=1.18; 95% CI, 1.02-1.35), diagnosis of age-related macular degeneration (RR=1.42; 95% CI, 1.13-1.77) and an increased intraocular pressure (>22 mm Hg in the worse eye) (RR=1.23; 95% CI, 1.06-1.42). On the basis of our multivariable model, diagnosis, sex, and recommended glaucoma medications were significantly associated with follow-up adherence. Conclusions: This study demonstrates that individuals living in underserved urban communities would take advantage of free eye exams in community sites and return for follow-up eye exams in these same settings. Future studies could investigate interventions to improve eye exam appointment adherence in community-based settings to detect glaucoma-eye conditions. AD - L.A. Hark, Wills Eye Hospital Glaucoma Research Center, Thomas Jefferson University, 840 Walnut Street, Philadelphia, PA, United States AU - Hark, L. A. AU - Leiby, B. E. AU - Waisbourd, M. AU - Myers, J. S. AU - Fudemberg, S. J. AU - Mantravadi, A. V. AU - Dai, Y. AU - Gilligan, J. P. AU - Resende, A. F. AU - Katz, L. J. DB - Embase Medline DO - 10.1097/IJG.0000000000000716 IS - 8 KW - age age related macular degeneration aged article automated perimeter controlled study demography eye photography female follow up glaucoma human intraocular pressure iridotomy laser surgery major clinical study male ophthalmologist patient compliance Pennsylvania priority journal race retrospective study risk assessment risk factor sex difference Octopus 300 Visual Field Analyzer Volk Pictor LA - English M3 - Article N1 - L617172110 2017-07-11 2017-08-15 PY - 2017 SN - 1536-481X 1057-0829 SP - 697-701 ST - Adherence to Follow-up Recommendations among Individuals in the Philadelphia Glaucoma Detection and Treatment Project T2 - Journal of Glaucoma TI - Adherence to Follow-up Recommendations among Individuals in the Philadelphia Glaucoma Detection and Treatment Project UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617172110&from=export http://dx.doi.org/10.1097/IJG.0000000000000716 VL - 26 ID - 2682 ER - TY - JOUR AB - Purpose: To evaluate rates of adherence to free follow-up eye exam appointments among participants in the Philadelphia Glaucoma Detection and Treatment Project. Patients and Methods: Ophthalmologists and testing equipment were brought directly to participants at risk for glaucoma at 43 community sites in Philadelphia. Those diagnosed with glaucoma-related pathology were recommended to return for follow-up to be reexamined on site. Rates of adherence and clinical and demographic risk factors for adherence were evaluated. Results: Five hundred thirty-one participants were diagnosed with glaucoma-related conditions and recommended to attend community-based follow-up exams. Follow-up adherence rate was 61.2% (n=325/531). Significant factors associated with greater eye exam appointment adherence, based on our univariable analysis, included final diagnosis of glaucoma (risk ratio [RR]=1.33; 95% confidence interval [CI], 1.13-1.57), male sex (RR=1.19; 95% CI, 1.04-1.36), white race (RR=1.26; 95% CI, 1.08-1.48), age (RR=1.17; 95% CI, 1.00-1.37) recommendation for glaucoma medication (RR=1.52; 95% CI, 1.35-1.71), recommendation for laser peripheral iridotomy (RR=1.18; 95% CI, 1.02-1.35), diagnosis of age-related macular degeneration (RR=1.42; 95% CI, 1.13-1.77) and an increased intraocular pressure (>22 mm Hg in the worse eye) (RR=1.23; 95% CI, 1.06-1.42). On the basis of our multivariable model, diagnosis, sex, and recommended glaucoma medications were significantly associated with follow-up adherence. Conclusions: This study demonstrates that individuals living in underserved urban communities would take advantage of free eye exams in community sites and return for follow-up eye exams in these same settings. Future studies could investigate interventions to improve eye exam appointment adherence in community-based settings to detect glaucoma-eye conditions. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. AD - Wills Eye Hospital Glaucoma Research Center, Thomas Jefferson University, 840 Walnut Street, Philadelphia, PA 19107, United States Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States Division of Biostatistics, Thomas Jefferson University, Philadelphia, PA, United States AU - Hark, L. A. AU - Leiby, B. E. AU - Waisbourd, M. AU - Myers, J. S. AU - Fudemberg, S. J. AU - Mantravadi, A. V. AU - Dai, Y. AU - Gilligan, J. P. AU - Resende, A. F. AU - Katz, L. J. DB - Scopus DO - 10.1097/IJG.0000000000000716 IS - 8 KW - community-based follow-up adherence glaucoma Philadelphia Glaucoma Detection and Treatment Project M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2017 SP - 697-701 ST - Adherence to Follow-up Recommendations among Individuals in the Philadelphia Glaucoma Detection and Treatment Project T2 - Journal of Glaucoma TI - Adherence to Follow-up Recommendations among Individuals in the Philadelphia Glaucoma Detection and Treatment Project UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021817759&doi=10.1097%2fIJG.0000000000000716&partnerID=40&md5=78426a1a7c89c75b3d8aa2f36252f8bd VL - 26 ID - 5457 ER - TY - JOUR AB - Purpose:To evaluate rates of adherence to free follow-up eye exam appointments among participants in the Philadelphia Glaucoma Detection and Treatment Project.Patients and Methods:Ophthalmologists and testing equipment were brought directly to participants at risk for glaucoma at 43 community sites in Philadelphia. Those diagnosed with glaucoma-related pathology were recommended to return for follow-up to be reexamined on site. Rates of adherence and clinical and demographic risk factors for adherence were evaluated.Results:Five hundred thirty-one participants were diagnosed with glaucoma-related conditions and recommended to attend community-based follow-up exams. Follow-up adherence rate was 61.2% (n=325/531). Significant factors associated with greater eye exam appointment adherence, based on our univariable analysis, included final diagnosis of glaucoma (risk ratio [RR]=1.33; 95% confidence interval [CI], 1.13-1.57), male sex (RR=1.19; 95% CI, 1.04-1.36), white race (RR=1.26; 95% CI, 1.08-1.48), age (RR=1.17; 95% CI, 1.00-1.37) recommendation for glaucoma medication (RR=1.52; 95% CI, 1.35-1.71), recommendation for laser peripheral iridotomy (RR=1.18; 95% CI, 1.02-1.35), diagnosis of age-related macular degeneration (RR=1.42; 95% CI, 1.13-1.77) and an increased intraocular pressure (>22 mm Hg in the worse eye) (RR=1.23; 95% CI, 1.06-1.42). On the basis of our multivariable model, diagnosis, sex, and recommended glaucoma medications were significantly associated with follow-up adherence.Conclusions:This study demonstrates that individuals living in underserved urban communities would take advantage of free eye exams in community sites and return for follow-up eye exams in these same settings. Future studies could investigate interventions to improve eye exam appointment adherence in community-based settings to detect glaucoma-eye conditions. AN - WOS:000407108300003 AU - Hark, L. A. AU - Leiby, B. E. AU - Waisbourd, M. AU - Myers, J. S. AU - Fudemberg, S. J. AU - Mantravadi, A. V. AU - Dai, Y. AU - Gilligan, J. P. AU - Resende, A. F. AU - Katz, L. J. DA - AUG DO - 10.1097/IJG.0000000000000716 IS - 8 PY - 2017 SN - 1057-0829 1536-481X SP - 697-701 ST - Adherence to Follow-up Recommendations Among Individuals in the Philadelphia Glaucoma Detection and Treatment Project T2 - JOURNAL OF GLAUCOMA TI - Adherence to Follow-up Recommendations Among Individuals in the Philadelphia Glaucoma Detection and Treatment Project VL - 26 ID - 5834 ER - TY - JOUR AB - The purpose of this study was to evaluate the effects of a six-month social worker intervention for participants with a glaucoma-related diagnosis in an urban ophthalmic setting (N = 40). The social worker assessed common barriers to eye care, helping participants with transportation, access to low-vision resources, and supportive counseling. The Distress Thermometer, Patient Health Questionnaire–9, and a satisfaction survey were administered to determine the effect of the social worker intervention and participants' overall impressions of the social worker. The most common barrier to eye care was emotional distress (77.5 percent). There was a significant decrease in the number of participants with symptoms of major and moderate depression. Fourteen participants experienced a clinically relevant decrease in depression, 37 participants felt that the social worker's support addressed their issues, and 29 participants thought it helped them in managing their glaucoma. This study provides evidence that a social work intervention may improve care coordination and management of individuals afflicted with vision impairment due to glaucoma and other ocular diseases. AD - Lisa A. Hark, PhD, RD, is professor of ophthalmic sciences, administrative director of Jonas Children's Vision Care, and director of the Clinical Trials Unit, Irving Medical Center, Columbia University, 635 West 165th Street, Mailbox 10, New York, NY 10032; lah112@cumc.columbia.edu. Malika Madhava, BS; Anjithaa Radakrishnan, BS, are medical students, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia. Catherine Anderson-Quiñones, BM, is study coordinator, Glaucoma Research Center, Wills Eye Hospital, Philadelphia. Debra Robinson, MSS, LSW, is a medical social worker, Generations Life Care, Chadds Ford, PA. Jennifer Adeghate, MD, is resident physician, Department of Ophthalmology, Weill Cornell Medical Center, New York. Stephen Silva, MD, is orthopedic resident (surgery), Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia. Tingting Zhan, PhD, is a biostatistician, Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Thomas Jefferson University, Philadelphia. Tomilade Adepoju, MD, is medical doctor and ophthalmology resident, Department of Ophthalmology, Nassau University Medical Center, East Meadow, NY. Yatee Dave, BA, is a medical student, Robert Wood Johnson Medical School, Rutgers University, Piscataway Township, NJ. Scott J. Fudemberg, MD, is ophthalmologist and glaucoma specialist, Glaucoma Research Center, Wills Eye Hospital, Philadelphia AN - 134468518. Language: English. Entry Date: 20190207. Revision Date: 20200203. Publication Type: Article AU - Hark, Lisa A. AU - Madhava, Malika AU - Radakrishnan, Anjithaa AU - Anderson-Quiñones, Catherine AU - Robinson, Debra AU - Adeghate, Jennifer AU - Silva, Stephen AU - Zhan, Tingting AU - Adepoju, Tomilade AU - Dave, Yatee AU - Fudemberg, Scott J. DB - ccm DO - 10.1093/hsw/hly038 DP - EBSCOhost IS - 1 KW - Glaucoma -- Diagnosis Eye Care Health Services Accessibility Social Workers Patient Satisfaction -- Evaluation Human Urban Areas Ophthalmology Intervention Trials -- Evaluation Transportation Counseling Clinical Assessment Tools Questionnaires Patient Attitudes -- Evaluation Adult Middle Age Aged Aged, 80 and Over Male Female Prospective Studies Pennsylvania Data Analysis, Statistical Wilcoxon Rank Sum Test Summated Rating Scaling Logistic Regression Data Analysis Software Descriptive Statistics N1 - research; tables/charts. Journal Subset: Allied Health; Peer Reviewed; USA. Instrumentation: Patient Health Questionnaire-9 (PHQ-9); Distress Thermometer (DT). NLM UID: 7611528. PY - 2019 SN - 0360-7283 SP - 48-56 ST - Impact of a Social Worker in a Glaucoma Eye Care Service: A Prospective Study T2 - Health & Social Work TI - Impact of a Social Worker in a Glaucoma Eye Care Service: A Prospective Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134468518&site=ehost-live&scope=site VL - 44 ID - 4161 ER - TY - JOUR AB - The purpose of this study was to evaluate the effects of a six-month social worker intervention for participants with a glaucoma-related diagnosis in an urban ophthalmic setting (N = 40). The social worker assessed common barriers to eye care, helping participants with transportation, access to low-vision resources, and supportive counseling. The Distress Thermometer, Patient Health Questionnaire–9, and a satisfaction survey were administered to determine the effect of the social worker intervention and participants’ overall impressions of the social worker. The most common barrier to eye care was emotional distress (77.5 percent). There was a significant decrease in the number of participants with symptoms of major and moderate depression. Fourteen participants experienced a clinically relevant decrease in depression, 37 participants felt that the social worker’s support addressed their issues, and 29 participants thought it helped them in managing their glaucoma. This study provides evidence that a social work intervention may improve care coordination and management of individuals afflicted with vision impairment due to glaucoma and other ocular diseases. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Hark, Lisa A., Clinical Trials Unit, Irving Medical Center, Columbia University, 635 West 165th Street, Mailbox 10, New York, NY, US, 10032 AN - 2019-10401-007 AU - Hark, Lisa A. AU - Madhava, Malika AU - Radakrishnan, Anjithaa AU - Anderson-Quiñones, Catherine AU - Robinson, Debra AU - Adeghate, Jennifer AU - Silva, Stephen AU - Zhan, Tingting AU - Adepoju, Tomilade AU - Dave, Yatee AU - Fudemberg, Scott J. DB - psyh DO - 10.1093/hsw/hly038 DP - EBSCOhost IS - 1 KW - barriers to eye care depression eye care adherence glaucoma Counseling Female Health Services Accessibility Humans Male Middle Aged Prospective Studies Social Support Social Workers Surveys and Questionnaires Intervention Distress Major Depression Treatment Barriers N1 - Clinical Trials Unit, Irving Medical Center, Columbia University, New York, NY, US. Release Date: 20200622. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Glaucoma; Intervention; Social Workers. Minor Descriptor: Distress; Major Depression; Treatment Barriers. Classification: Community & Social Services (3373). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Distress Thermometer; Patient Health Questionnaire-9 DOI: 10.1037/t06165-000. Methodology: Empirical Study; Longitudinal Study; Prospective Study; Quantitative Study. Page Count: 9. Issue Publication Date: Feb, 2019. Publication History: First Posted Date: Dec 15, 2018; Accepted Date: Oct 17, 2018; Revised Date: May 23, 2018; First Submitted Date: Feb 17, 2018. Copyright Statement: National Association of Social Workers. 2018. PY - 2019 SN - 0360-7283 SP - 48-56 ST - Impact of a social worker in a glaucoma eye care service: A prospective study T2 - Health & Social Work TI - Impact of a social worker in a glaucoma eye care service: A prospective study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-10401-007&site=ehost-live&scope=site ORCID: 0000-0003-3765-9063 lah112@cumc.columbia.edu VL - 44 ID - 4809 ER - TY - JOUR AB - Purpose: The purpose of this study was to assess factors affecting follow-up eye care in participants enrolled in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study, such as awareness of ocular diagnosis, availability of transportation methods, and reasons for missing eye care appointments. Methods: The sample included 172 participants who were randomized to the intervention group and contacted by the social worker. Results: A total of 155 participants completed the assessment form, which was used as an instrument to assess factors affecting adherence to follow-up eye care. The main reasons for missing eye exam appointments were feeling ill (38.1%, n = 59) and forgetting the appointment (34.2%, n = 53). In addition, 45 (29.2%) participants were unaware of or did not comprehend the severity of their ocular diagnosis. Common methods of transportation included public transportation (31.6%, n = 49), driving (29.7%, n = 46), and being driven (27.7%, n = 43) to their appointment. Conclusion: These results suggest that individuals in need of eye care may benefit from additional assistance of a social worker regarding ongoing eye exam appointment reminders and in-depth explanation of their ocular diagnosis. AU - Hark, L. A. AU - Radakrishnan, A. AU - Madhava, M. AU - Anderson-Quiñones, C. AU - Fudemberg, S. AU - Robinson, D. AU - Myers, J. S. AU - Zhan, T. AU - Adeghate, J. AU - Hegarty, S. AU - Leite, S. AU - Leiby, B. E. AU - Stempel, S. AU - Katz, L. J. DB - Medline DO - 10.1080/00981389.2019.1614711 IS - 7 KW - adult aftercare age aged controlled study female glaucoma health care delivery hospital management human male middle aged ophthalmology organization and management patient compliance Pennsylvania randomized controlled trial risk factor severity of illness index sex factor social work socioeconomics telemedicine very elderly LA - English M3 - Article N1 - L627948773 2019-06-11 PY - 2019 SN - 1541-034X SP - 651-664 ST - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study T2 - Social work in health care TI - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627948773&from=export http://dx.doi.org/10.1080/00981389.2019.1614711 VL - 58 ID - 2492 ER - TY - JOUR AB - Purpose: The purpose of this study was to assess factors affecting follow-up eye care in participants enrolled in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study, such as awareness of ocular diagnosis, availability of transportation methods, and reasons for missing eye care appointments. Methods: The sample included 172 participants who were randomized to the intervention group and contacted by the social worker. Results: A total of 155 participants completed the assessment form, which was used as an instrument to assess factors affecting adherence to follow-up eye care. The main reasons for missing eye exam appointments were feeling ill (38.1%, n = 59) and forgetting the appointment (34.2%, n = 53). In addition, 45 (29.2%) participants were unaware of or did not comprehend the severity of their ocular diagnosis. Common methods of transportation included public transportation (31.6%, n = 49), driving (29.7%, n = 46), and being driven (27.7%, n = 43) to their appointment. Conclusion: These results suggest that individuals in need of eye care may benefit from additional assistance of a social worker regarding ongoing eye exam appointment reminders and in-depth explanation of their ocular diagnosis. AD - Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA, USA Department of Ophthalmology, Columbia University Irving Medical Center, New York, NY, USA Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Thomas Jefferson University, Philadelphia, PA, USA Department of Ophthalmology, Weill Cornell Medical College, New York, NY, USA AN - 137236045. Language: English. Entry Date: 20190703. Revision Date: 20210122. Publication Type: Article AU - Hark, Lisa A. AU - Radakrishnan, Anjithaa AU - Madhava, Malika AU - Anderson-Quiñones, Catherine AU - Fudemberg, Scott AU - Robinson, Debra AU - Myers, Jonathan S. AU - Zhan, Tingting AU - Adeghate, Jennifer AU - Hegarty, Sarah AU - Leite, Stela AU - Leiby, Benjamin E. AU - Stempel, Stella AU - Katz, L. Jay DB - ccm DO - 10.1080/00981389.2019.1614711 DP - EBSCOhost IS - 7 KW - Eye Care -- Psychosocial Factors After Care -- Psychosocial Factors Transportation -- Methods Health Knowledge Appointments and Schedules Human Randomized Controlled Trials Random Assignment Patient Compliance -- Evaluation Questionnaires Female Male Adult Middle Age Aged Aged, 80 and Over Memory Social Workers Health Status Support, Psychosocial Funding Source N1 - research; tables/charts; randomized controlled trial. Journal Subset: Allied Health; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: This work was supported by the National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Vision Health Initiative [U01DP005127].. NLM UID: 7603729. PY - 2019 SN - 0098-1389 SP - 651-664 ST - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study T2 - Social Work in Health Care TI - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137236045&site=ehost-live&scope=site VL - 58 ID - 4195 ER - TY - JOUR AB - Purpose: The purpose of this study was to assess factors affecting follow-up eye care in participants enrolled in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study, such as awareness of ocular diagnosis, availability of transportation methods, and reasons for missing eye care appointments.Methods: The sample included 172 participants who were randomized to the intervention group and contacted by the social worker.Results: A total of 155 participants completed the assessment form, which was used as an instrument to assess factors affecting adherence to follow-up eye care. The main reasons for missing eye exam appointments were feeling ill (38.1%, n = 59) and forgetting the appointment (34.2%, n = 53). In addition, 45 (29.2%) participants were unaware of or did not comprehend the severity of their ocular diagnosis. Common methods of transportation included public transportation (31.6%, n = 49), driving (29.7%, n = 46), and being driven (27.7%, n = 43) to their appointment.Conclusion: These results suggest that individuals in need of eye care may benefit from additional assistance of a social worker regarding ongoing eye exam appointment reminders and in-depth explanation of their ocular diagnosis. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Hark, Lisa A. AN - 2019-29216-001 AU - Hark, Lisa A. AU - Radakrishnan, Anjithaa AU - Madhava, Malika AU - Anderson-Quiñones, Catherine AU - Fudemberg, Scott AU - Robinson, Debra AU - Myers, Jonathan S. AU - Zhan, Tingting AU - Adeghate, Jennifer AU - Hegarty, Sarah AU - Leite, Stela AU - Leiby, Benjamin E. AU - Stempel, Stella AU - Katz, L. Jay DB - psyh DO - 10.1080/00981389.2019.1614711 DP - EBSCOhost KW - Social support social worker adherence follow-up eye care barriers No terms assigned N1 - Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA, US. Other Publishers: Haworth Press. Release Date: 20190527. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Language: EnglishMajor Descriptor: No terms assigned. Classification: Health & Mental Health Treatment & Prevention (3300). References Available: Y. Publication History: Accepted Date: Apr 22, 2019; Revised Date: Mar 15, 2019; First Submitted Date: Sep 13, 2018. Copyright Statement: Taylor & Francis. 2019. PY - 2019 SN - 0098-1389 1541-034X ST - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the philadelphia telemedicine glaucoma detection and follow-up study T2 - Social Work in Health Care TI - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the philadelphia telemedicine glaucoma detection and follow-up study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-29216-001&site=ehost-live&scope=site lah112@cumc.columbia.edu ID - 4806 ER - TY - JOUR AB - Purpose: The purpose of this study was to assess factors affecting follow-up eye care in participants enrolled in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study, such as awareness of ocular diagnosis, availability of transportation methods, and reasons for missing eye care appointments. Methods: The sample included 172 participants who were randomized to the intervention group and contacted by the social worker. Results: A total of 155 participants completed the assessment form, which was used as an instrument to assess factors affecting adherence to follow-up eye care. The main reasons for missing eye exam appointments were feeling ill (38.1%, n = 59) and forgetting the appointment (34.2%, n = 53). In addition, 45 (29.2%) participants were unaware of or did not comprehend the severity of their ocular diagnosis. Common methods of transportation included public transportation (31.6%, n = 49), driving (29.7%, n = 46), and being driven (27.7%, n = 43) to their appointment. Conclusion: These results suggest that individuals in need of eye care may benefit from additional assistance of a social worker regarding ongoing eye exam appointment reminders and in-depth explanation of their ocular diagnosis. © 2019, © 2019 Taylor & Francis. AD - Wills Eye Hospital, Glaucoma Research Center, Philadelphia, PA, United States Department of Ophthalmology, Columbia University Irving Medical Center, New York, NY, United States Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Thomas Jefferson University, Philadelphia, PA, United States Department of Ophthalmology, Weill Cornell Medical College, New York, NY, United States AU - Hark, L. A. AU - Radakrishnan, A. AU - Madhava, M. AU - Anderson-Quiñones, C. AU - Fudemberg, S. AU - Robinson, D. AU - Myers, J. S. AU - Zhan, T. AU - Adeghate, J. AU - Hegarty, S. AU - Leite, S. AU - Leiby, B. E. AU - Stempel, S. AU - Katz, L. J. DB - Scopus DO - 10.1080/00981389.2019.1614711 IS - 7 KW - adherence barriers eye care follow-up Social support social worker M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2019 SP - 651-664 ST - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study T2 - Social Work in Health Care TI - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066823040&doi=10.1080%2f00981389.2019.1614711&partnerID=40&md5=1898dbf88eb5d464e598872d94b52a90 VL - 58 ID - 5611 ER - TY - JOUR AB - Purpose: The purpose of this study was to assess factors affecting follow-up eye care in participants enrolled in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study, such as awareness of ocular diagnosis, availability of transportation methods, and reasons for missing eye care appointments. Methods: The sample included 172 participants who were randomized to the intervention group and contacted by the social worker. Results: A total of 155 participants completed the assessment form, which was used as an instrument to assess factors affecting adherence to follow-up eye care. The main reasons for missing eye exam appointments were feeling ill (38.1%, n = 59) and forgetting the appointment (34.2%, n = 53). In addition, 45 (29.2%) participants were unaware of or did not comprehend the severity of their ocular diagnosis. Common methods of transportation included public transportation (31.6%, n = 49), driving (29.7%, n = 46), and being driven (27.7%, n = 43) to their appointment. Conclusion: These results suggest that individuals in need of eye care may benefit from additional assistance of a social worker regarding ongoing eye exam appointment reminders and in-depth explanation of their ocular diagnosis. AN - WOS:000469552100001 AU - Hark, L. A. AU - Radakrishnan, A. AU - Madhava, M. AU - Anderson-Quinones, C. AU - Fudemberg, S. AU - Robinson, D. AU - Myers, J. S. AU - Zhan, T. T. AU - Adeghate, J. AU - Hegarty, S. AU - Leite, S. AU - Leiby, B. E. AU - Stempel, S. AU - Katz, L. J. DA - AUG 9 DO - 10.1080/00981389.2019.1614711 IS - 7 PY - 2019 SN - 0098-1389 1541-034X SP - 651-664 ST - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study T2 - SOCIAL WORK IN HEALTH CARE TI - Awareness of ocular diagnosis, transportation means, and barriers to ophthalmology follow-up in the Philadelphia Telemedicine Glaucoma Detection and Follow-up Study VL - 58 ID - 5838 ER - TY - JOUR AB - Purpose/Aim: In the United States, high rates of vision impairment and eye disease disproportionately impact those who lack access to eye care, specifically vulnerable populations. The objective of our study was to test instruments, implement protocols, and collect preliminary data for a larger 5-year study, which aims to improve detection of eye diseases and follow-up eye care in vulnerable populations using community health workers (CHW) and patient navigators. In the study, trained CHWs conducted vision screening and patient navigators scheduled on-site eye exams and arranged appointments for those referred to ophthalmology to improve adherence to follow-up eye care. Materials and Methods: Eligible individuals age 40-and-older were recruited from the Riverstone Senior Center in Upper Manhattan, New York City. Participants underwent on-site vision screening (visual acuity with correction, intraocular pressure measurements, and fundus photography). Individuals who failed the vision screening were scheduled with an on-site optometrist for an eye exam; those with ocular pathologies were referred to an ophthalmologist. Participants were also administered the National Eye Institute Visual Function Questionnaire-8 (NEI-VFQ-8) and Stopping Elderly Accidents, Deaths, and Injuries (STEADI) test by community health workers. Results:Participants (n = 42) were predominantly older adults, with a mean age of 70.0 +/- 9.8, female (61.9%), and Hispanic (78.6%). Most individuals (78.6%, n = 33) failed vision screening. Of those who failed, 84.8% (n = 28) attended the on-site eye exam with the optometrist. Ocular diagnoses: refractive error 13/28 (46.4%), glaucoma/glaucoma suspect 9/28 (32.1%), cataract 7/28 (25.0%), retina abnormalities 6/28 (21.4%); 13 people required eyeglasses. Conclusion: This study demonstrates the feasibility of using CHWs and patient navigators for reducing barriers to vision screening and optometrist-based eye exams in vulnerable populations, ultimately improving early detection of eye disease and linking individuals to additional eye care appointments. The full five-year study aims to further examine these outcomes. AN - WOS:000641359900001 AU - Hark, L. A. AU - Tan, C. S. AU - Kresch, Y. S. AU - De Moraes, C. G. AU - Horowitz, J. D. AU - Park, L. AU - Auran, J. D. AU - Gorroochurn, P. AU - Stempel, S. AU - Maruri, S. C. AU - Besagar, S. AU - Saaddine, J. B. AU - Lambert, B. C. AU - Pizzi, L. T. AU - Sapru, S. AU - Price, S. AU - Williams, O. A. AU - Cioffi, G. A. AU - Liebmann, J. M. DO - 10.1080/02713683.2021.1905000 SN - 0271-3683 1460-2202 ST - Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results T2 - CURRENT EYE RESEARCH TI - Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results ID - 5959 ER - TY - JOUR AB - Purpose/Aim: In the United States, high rates of vision impairment and eye disease disproportionately impact those who lack access to eye care, specifically vulnerable populations. The objective of our study was to test instruments, implement protocols, and collect preliminary data for a larger 5-year study, which aims to improve detection of eye diseases and follow-up eye care in vulnerable populations using community health workers (CHW) and patient navigators. In the study, trained CHWs conducted vision screening and patient navigators scheduled on-site eye exams and arranged appointments for those referred to ophthalmology to improve adherence to follow-up eye care. Materials and Methods: Eligible individuals age 40-and-older were recruited from the Riverstone Senior Center in Upper Manhattan, New York City. Participants underwent on-site vision screening (visual acuity with correction, intraocular pressure measurements, and fundus photography). Individuals who failed the vision screening were scheduled with an on-site optometrist for an eye exam; those with ocular pathologies were referred to an ophthalmologist. Participants were also administered the National Eye Institute Visual Function Questionnaire-8 (NEI-VFQ-8) and Stopping Elderly Accidents, Deaths, and Injuries (STEADI) test by community health workers. Results:Participants (n = 42) were predominantly older adults, with a mean age of 70.0 ± 9.8, female (61.9%), and Hispanic (78.6%). Most individuals (78.6%, n = 33) failed vision screening. Of those who failed, 84.8% (n = 28) attended the on-site eye exam with the optometrist. Ocular diagnoses: refractive error 13/28 (46.4%), glaucoma/glaucoma suspect 9/28 (32.1%), cataract 7/28 (25.0%), retina abnormalities 6/28 (21.4%); 13 people required eyeglasses. Conclusion: This study demonstrates the feasibility of using CHWs and patient navigators for reducing barriers to vision screening and optometrist-based eye exams in vulnerable populations, ultimately improving early detection of eye disease and linking individuals to additional eye care appointments. The full five-year study aims to further examine these outcomes. AD - L.A. Hark, Ophthalmic Sciences (Ophthalmology), Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Edward S. Harkness Eye Institute, 635 West 165th Street, Room 504, New York, NY, United States AU - Hark, L. A. AU - Tan, C. S. AU - Kresch, Y. S. AU - De Moraes, C. G. AU - Horowitz, J. D. AU - Park, L. AU - Auran, J. D. AU - Gorroochurn, P. AU - Stempel, S. AU - Maruri, S. C. AU - Besagar, S. AU - Saaddine, J. B. AU - Lambert, B. C. AU - Pizzi, L. T. AU - Sapru, S. AU - Price, S. AU - Williams, O. A. AU - Cioffi, G. A. AU - Liebmann, J. M. DB - Embase Medline DO - 10.1080/02713683.2021.1905000 KW - accident aged article cataract clinical article controlled study eye care feasibility study female follow up glaucoma health auxiliary Hispanic human injury intraocular pressure National Eye Institute Visual Function Questionnaire New York ophthalmologist ophthalmology optometrist photography preliminary data refraction error retina senior center spectacles vision test visual acuity visual impairment vulnerable population LA - English M3 - Article in Press N1 - L2011215595 2021-05-25 PY - 2021 SN - 1460-2202 0271-3683 ST - Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results T2 - Current Eye Research TI - Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2011215595&from=export http://dx.doi.org/10.1080/02713683.2021.1905000 ID - 2341 ER - TY - JOUR AB - Purpose/Aim: In the United States, high rates of vision impairment and eye disease disproportionately impact those who lack access to eye care, specifically vulnerable populations. The objective of our study was to test instruments, implement protocols, and collect preliminary data for a larger 5-year study, which aims to improve detection of eye diseases and follow-up eye care in vulnerable populations using community health workers (CHW) and patient navigators. In the study, trained CHWs conducted vision screening and patient navigators scheduled on-site eye exams and arranged appointments for those referred to ophthalmology to improve adherence to follow-up eye care. Materials and Methods: Eligible individuals age 40-and-older were recruited from the Riverstone Senior Center in Upper Manhattan, New York City. Participants underwent on-site vision screening (visual acuity with correction, intraocular pressure measurements, and fundus photography). Individuals who failed the vision screening were scheduled with an on-site optometrist for an eye exam; those with ocular pathologies were referred to an ophthalmologist. Participants were also administered the National Eye Institute Visual Function Questionnaire-8 (NEI-VFQ-8) and Stopping Elderly Accidents, Deaths, and Injuries (STEADI) test by community health workers. Results:Participants (n = 42) were predominantly older adults, with a mean age of 70.0 ± 9.8, female (61.9%), and Hispanic (78.6%). Most individuals (78.6%, n = 33) failed vision screening. Of those who failed, 84.8% (n = 28) attended the on-site eye exam with the optometrist. Ocular diagnoses: refractive error 13/28 (46.4%), glaucoma/glaucoma suspect 9/28 (32.1%), cataract 7/28 (25.0%), retina abnormalities 6/28 (21.4%); 13 people required eyeglasses. Conclusion: This study demonstrates the feasibility of using CHWs and patient navigators for reducing barriers to vision screening and optometrist-based eye exams in vulnerable populations, ultimately improving early detection of eye disease and linking individuals to additional eye care appointments. The full five-year study aims to further examine these outcomes. © 2021 Taylor & Francis Group, LLC. AD - Department of Ophthalmology, Columbia Univertsity, Vagelos College of Physicians and Surgeons, New York, NY, United States Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, United States Department of Health Policy and Management, Columbia University Mailman School of Public Health, New York, NY, United States Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, United States Centers for Disease Control and Prevention, Vision Health Initiative, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA, United States Department of General Surgery, Montefiore Medical Center, Bronx, NY, United States Center for Health Outcomes, Policy, and Economics, Rutgers University, New Brunswick, NJ, United States Public Health and Epidemiology Practice, Westat, Inc, Rockville, MD, United States Department of Neurology, Columbia University Irving Medical Center, New York, NY, United States AU - Hark, L. A. AU - Tan, C. S. AU - Kresch, Y. S. AU - De Moraes, C. G. AU - Horowitz, J. D. AU - Park, L. AU - Auran, J. D. AU - Gorroochurn, P. AU - Stempel, S. AU - Maruri, S. C. AU - Besagar, S. AU - Saaddine, J. B. AU - Lambert, B. C. AU - Pizzi, L. T. AU - Sapru, S. AU - Price, S. AU - Williams, O. A. AU - Cioffi, G. A. AU - Liebmann, J. M. DB - Scopus DO - 10.1080/02713683.2021.1905000 KW - access to eye care community-based Glaucoma detection vision screening vulnerable populations M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 ST - Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results T2 - Current Eye Research TI - Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104737172&doi=10.1080%2f02713683.2021.1905000&partnerID=40&md5=5e8a58925c7be0f6913cfa60a9b073d7 ID - 5673 ER - TY - JOUR AB - Peripheral ulcerative keratitis (PUK) is a sight-threatening condition characterized by an epithelial defect, crescent-shaped stromal inflammation, and progressive stromal thinning. Peripheral ulcerative keratitis as a purely inflammatory entity is most commonly associated with collagen vascular diseases, including rheumatoid arthritis, polyarteritis nodosa, Wegener granulomatosis, systemic lupus erythematosus, and relapsing polychondritis. PUK can also be associated with infectious and inflammatory conditions such as hepatitis, syphilis, herpes simplex keratitis, fungal keratitis, Mooren ulcer, and marginal keratitis. We describe a case report of PUK associated with the inflammatory condition of sarcoidosis. © 2013 British Contact Lens Association. AD - Illinois College of Optometry, United States AU - Harthan, J. S. AU - Reeder, R. E. DB - Scopus DO - 10.1016/j.clae.2013.07.013 IS - 6 KW - Collagen vascular diseases Peripheral ulcerative keratitis (PUK) Sarcoidosis M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2013 SP - 313-317 ST - Peripheral ulcerative keratitis in association with sarcoidosis T2 - Contact Lens and Anterior Eye TI - Peripheral ulcerative keratitis in association with sarcoidosis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886296814&doi=10.1016%2fj.clae.2013.07.013&partnerID=40&md5=761419d43a906dba214d2d92f4c914d0 VL - 36 ID - 5471 ER - TY - JOUR AB - We present two patients with a new finding of symmetrical corneal thinning early in the clinical course of iridocorneal endothelial syndrome. Patient 1 was evaluated for uncontrolled angle closure glaucoma of the left eye (OS) status post laser peripheral iridotomy (LPI). After placement of an Ahmed glaucomatous valve and trabeculectomy with mitomycin C were performed, the patient was diagnosed with Chandler syndrome. The patient's pachymetry at the time of diagnosis revealed stable central corneal thickness (CCT) of 481 μm of the right eye (OD) (baseline 494 μm) and central cornea thinning with CCT of 407 μm OS (baseline 486 μm). Patient 2 was evaluated for ocular hypertension and Chandler syndrome OS was diagnosed. The patient had a good short-term response to LPI and ocular hypotensive medications. This patient was also found to have thinning of his affected cornea with CCT 523 μm OD and 476 μm OS. © 2020 American Institute of Physics Inc.. All rights reserved. AD - Naval Aerospace Medical Institute, Pensacola, FL, United States Department of Ophthalmology, Naval Medical Center San Diego, San Diego, CA, United States AU - Harvey, M. M. AU - Schmitz, J. W. C7 - 236354 DB - Scopus DO - 10.1136/bcr-2020-236354 IS - 9 KW - anterior chamber glaucoma Iris ophthalmology M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 ST - Cornea thinning in two cases of ICE syndrome T2 - BMJ Case Reports TI - Cornea thinning in two cases of ICE syndrome UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092088227&doi=10.1136%2fbcr-2020-236354&partnerID=40&md5=0459e836dc92575a1254c7d8bfe64846 VL - 13 ID - 5690 ER - TY - JOUR AB - Purpose: We investigated patient adherence and factors related to a newly introduced prostaglandin analog and timolol fixed-combination eye drops (PGTFC). Patients and methods: The Glaucoma Research on Adherence to fixed-Combination Eye drops in Japan (GRACE) study group performed a nationwide prospective questionnaire survey. Participants in this study were patients with glaucoma who were scheduled to receive any type of PGTFC for the first time. The participants answered a questionnaire on the day of PGTFC introduction and again at a return visit 4–6 weeks after PGTFC introduction. The physicians in charge were asked to complete a separate questionnaire on the day of PGTFC introduction. One of two leaflets was randomly delivered to each participant before the description of the PGTFC. One leaflet explained how to correctly instill the eye drops, and the other explained the clinical meaning of intraocular pressure reduction in addition to explaining how to correctly instill the eye drops. Nonadherence was defined as forgetting to instill the eye drops one or more times during the week before the return visit. Results: In total, 3,597 patients (age, 68.4±12.2 years) met the study protocol requirements. PGTFC introduction significantly reduced the number of antiglaucoma eye drops from 1.93±0.78 to 1.34±0.54 (P<0.0001) and significantly improved adherence (P<0.00001). Factors significantly associated with nonadherence at the return visit included a history of nonadherence as reported by either the patient or their physician before introduction, acceptable instillation times as reported by the patient, and burdensome eye drop instillation as reported by the patient. No significant difference was observed between the two leaflets in terms of their effects on adherence. Conclusion: PGTFC significantly improved adherence and some of the factors that were significantly associated with adherence. Registration number: UMIN000013696. AD - K. Kashiwagi, Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, 1110 Shimokato Chuo, Yamanashi, Japan AU - Hasebe, Y. AU - Kashiwagi, K. AU - Tsumura, T. AU - Suzuki, Y. AU - Yoshikawa, K. AU - Suzumura, H. AU - Maeda, T. AU - Takeda, R. AU - Saito, H. AU - Araie, M. DB - Embase DO - 10.2147/PPA.S168921 KW - 00001369 bimatoprost plus timolol latanoprost plus timolol prostaglandin derivative tafluprost plus timolol timolol timolol plus travoprost aged article cohort analysis combination drug therapy drug instillation drug utilization female glaucoma human major clinical study male patient attitude patient compliance treatment refusal LA - English M3 - Article N1 - L625482993 2018-12-25 2018-12-28 PY - 2018 SN - 1177-889X SP - 1567-1577 ST - Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy T2 - Patient Preference and Adherence TI - Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625482993&from=export http://dx.doi.org/10.2147/PPA.S168921 VL - 12 ID - 2617 ER - TY - JOUR AB - Purpose: We investigated patient adherence and factors related to a newly introduced prostaglandin analog and timolol fixed-combination eye drops (PGTFC). Patients and methods: The Glaucoma Research on Adherence to fixed-Combination Eye drops in Japan (GRACE) study group performed a nationwide prospective questionnaire survey. Participants in this study were patients with glaucoma who were scheduled to receive any type of PGTFC for the first time. The participants answered a questionnaire on the day of PGTFC introduction and again at a return visit 4–6 weeks after PGTFC introduction. The physicians in charge were asked to complete a separate questionnaire on the day of PGTFC introduction. One of two leaflets was randomly delivered to each participant before the description of the PGTFC. One leaflet explained how to correctly instill the eye drops, and the other explained the clinical meaning of intraocular pressure reduction in addition to explaining how to correctly instill the eye drops. Nonadherence was defined as forgetting to instill the eye drops one or more times during the week before the return visit. Results: In total, 3,597 patients (age, 68.4±12.2 years) met the study protocol requirements. PGTFC introduction significantly reduced the number of antiglaucoma eye drops from 1.93±0.78 to 1.34±0.54 (P<0.0001) and significantly improved adherence (P<0.00001). Factors significantly associated with nonadherence at the return visit included a history of nonadherence as reported by either the patient or their physician before introduction, acceptable instillation times as reported by the patient, and burdensome eye drop instillation as reported by the patient. No significant difference was observed between the two leaflets in terms of their effects on adherence. Conclusion: PGTFC significantly improved adherence and some of the factors that were significantly associated with adherence. Registration number: UMIN000013696. © 2018 Hasebe et al. AD - Department of Ophthalmology, University of Yamanashi, Yamanashi, Japan Department of Ophthalmology, Fussa Hospital, Tokyo, Japan Department of Ophthalmology, Tokai University, Kanagawa, Japan Yoshikawa Eye Clinic, Tokyo, Japan Suzumura Eye Clinic, Tokyo, Japan Maeda Eye Clinic, Tokyo, Japan Faculty of Agriculture, Kinki University, Nara, Japan Department of Ophthalmology, Kanto Central Hospital of the Mutual Aid Association of Public School, Tokyo, Japan AU - Hasebe, Y. AU - Kashiwagi, K. AU - Tsumura, T. AU - Suzuki, Y. AU - Yoshikawa, K. AU - Suzumura, H. AU - Maeda, T. AU - Takeda, R. AU - Saito, H. AU - Araie, M. DB - Scopus DO - 10.2147/PPA.S168921 KW - Adherence questionnaire Fixed-combination Glaucoma Japan M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2018 SP - 1567-1577 ST - Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy T2 - Patient Preference and Adherence TI - Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058791283&doi=10.2147%2fPPA.S168921&partnerID=40&md5=ed4d2b2e6328d645cde17108a1d3f7c2 VL - 12 ID - 5411 ER - TY - JOUR AB - Purpose: We investigated patient adherence and factors related to a newly introduced prostaglandin analog and timolol fixed-combination eye drops (PGTFC). Patients and methods: The Glaucoma Research on Adherence to fixed-Combination Eye drops in Japan (GRACE) study group performed a nationwide prospective questionnaire survey. Participants in this study were patients with glaucoma who were scheduled to receive any type of PGTFC for the first time. The participants answered a questionnaire on the day of PGTFC introduction and again at a return visit 4-6 weeks after PGTFC introduction. The physicians in charge were asked to complete a separate questionnaire on the day of PGTFC introduction. One of two leaflets was randomly delivered to each participant before the description of the PGTFC. One leaflet explained how to correctly instill the eye drops, and the other explained the clinical meaning of intraocular pressure reduction in addition to explaining how to correctly instill the eye drops. Nonadherence was defined as forgetting to instill the eye drops one or more times during the week before the return visit. Results: In total, 3,597 patients (age, 68.4 +/- 12.2 years) met the study protocol requirements. PGTFC introduction significantly reduced the number of antiglaucoma eye drops from 1.93 +/- 0.78 to 1.34 +/- 0.54 (P<0.0001) and significantly improved adherence (P<0.00001). Factors significantly associated with nonadherence at the return visit included a history of nonadherence as reported by either the patient or their physician before introduction, acceptable instillation times as reported by the patient, and burdensome eye drop instillation as reported by the patient. No significant difference was observed between the two leaflets in terms of their effects on adherence. Conclusion: PGTFC significantly improved adherence and some of the factors that were significantly associated with adherence. AN - WOS:000442915000001 AU - Hasebe, Y. AU - Kashiwagi, K. AU - Tsumura, T. AU - Suzuki, Y. AU - Yoshikawa, K. AU - Suzumura, H. AU - Maeda, T. AU - Takeda, R. AU - Saito, H. AU - Araie, M. DO - 10.2147/PPA.S168921 PY - 2018 SN - 1177-889X SP - 1567-1577 ST - Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy T2 - PATIENT PREFERENCE AND ADHERENCE TI - Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy VL - 12 ID - 5951 ER - TY - JOUR AB - This study aimed to evaluate the efficacy of Ahmed glaucoma valve (AGV) implantation in treating neovascular glaucoma (NVG) and to analyze the factors influencing the surgical success rate.This is a retrospective review of 40 eyes of 40 NVG patients who underwent AGV implantation at Xiangya Hospital of Central South University, China, between January 2014 and December 2016. Pre- and postoperative intraocular pressure (IOP), visual acuity, surgical success rate, medications, and complications were observed. Surgical success criteria were defined as IOP ≤21 and >6 mm Hg with or without additional medications. Kaplan-Meier survival curves and Multivariate cox regression analysis were used to examine success rates and risk factors for surgical outcomes.The mean follow-up period was 8.88 ± 3.12 months (range: 3-17). IOP declined at each visit postoperatively and it was statistically significant (P < .001). An average of 3.55 ± 0.86 drugs was applied preoperatively, while an average of 0.64 ± 0.90 drugs was used postoperatively, with the difference being of statistical significance (P < .05). The complete surgical success rate of 3, 6, and 12 months after the operation was 85%, 75%, and 65%, respectively. Meanwhile, the qualified success rate of 3, 6, and 12 months after the operation was 85%, 80%, and 77.5%, respectively. The multivariate cox regression analysis showed that age (hazard ratio: 3.717, 7.246; 95% confidence interval: 1.149-12.048, 1.349-38.461; P = .028, .021) was influencing factors for complete success rate and qualified success rate among all NVG patients. Gender, previous operation history, primary disease, and preoperative IOP were found to be not significant.AGV implantation is an effective and safe surgical method to treat NVG. Age is an important factor influencing the surgical success rate. AD - Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical College of Xiamen University, Xiamen, Fujian, China AN - 147985255. Language: English. Entry Date: 20171021. Revision Date: 20210111. Publication Type: journal article. Journal Subset: Biomedical AU - He, Ye AU - Tian, Ying AU - Song, Weitao AU - Su, Ting AU - Jiang, Haibo AU - Xia, Xiaobo DB - ccm DO - 10.1097/MD.0000000000008350 DP - EBSCOhost IS - 40 KW - Prostheses and Implants Glaucoma -- Surgery Female Intraocular Pressure Male Adult Sex Factors Middle Age Retrospective Design Postoperative Complications -- Epidemiology Visual Acuity Aged China Age Factors Kaplan-Meier Estimator Scales N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). NLM UID: 2985248R. PMID: NLM29049253. PY - 2017 SN - 0025-7974 SP - e8350-e8350 ST - Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors: A STROBE-compliant article T2 - Medicine TI - Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors: A STROBE-compliant article UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147985255&site=ehost-live&scope=site VL - 96 ID - 4458 ER - TY - JOUR AB - This study aimed to evaluate the efficacy of Ahmed glaucoma valve (AGV) implantation in treating neovascular glaucoma (NVG) and to analyze the factors influencing the surgical success rate.This is a retrospective review of 40 eyes of 40 NVG patients who underwent AGV implantation at Xiangya Hospital of Central South University, China, between January 2014 and December 2016. Pre- and postoperative intraocular pressure (IOP), visual acuity, surgical success rate, medications, and complications were observed. Surgical success criteria were defined as IOP 21 and >6 mm Hg with or without additional medications. Kaplan-Meier survival curves and Multivariate cox regression analysis were used to examine success rates and risk factors for surgical outcomes.The mean follow-up period was 8.883.12 months (range: 3-17). IOP declined at each visit postoperatively and it was statistically significant (P<.001). An average of 3.55 +/- 0.86 drugs was applied preoperatively, while an average of 0.64 +/- 0.90 drugs was used postoperatively, with the difference being of statistical significance (P<.05). The complete surgical success rate of 3, 6, and 12 months after the operation was 85%, 75%, and 65%, respectively. Meanwhile, the qualified success rate of 3, 6, and 12 months after the operation was 85%, 80%, and 77.5%, respectively. The multivariate cox regression analysis showed that age (hazard ratio: 3.717, 7.246; 95% confidence interval: 1.149-12.048, 1.349-38.461; P=.028, .021) was influencing factors for complete success rate and qualified success rate among all NVG patients. Gender, previous operation history, primary disease, and preoperative IOP were found to be not significant.AGV implantation is an effective and safe surgical method to treat NVG. Age is an important factor influencing the surgical success rate. AN - WOS:000415100000091 AU - He, Y. AU - Tian, Y. AU - Song, W. T. AU - Su, T. AU - Jiang, H. B. AU - Xia, X. B. DA - OCT DO - 10.1097/MD.0000000000008350 IS - 42 PY - 2017 SN - 0025-7974 1536-5964 ST - Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors: A STROBE-compliant article T2 - MEDICINE TI - Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors: A STROBE-compliant article VL - 96 ID - 6002 ER - TY - JOUR AB - Background: Poor adherence to treatment is a significant problem throughout medicine and particularly in the treatment of dermatologic conditions with topical medications, which present unique barriers to adherence. Purpose: We reviewed the literature to assess whether timing of office visits can be used to improve adherence. Methods: Studies examining adherence and office visits were identified using two search engines. PubMed was searched using the terms "medication adherence" OR "medication compliance" AND "visits." A Web of Science® cited reference search was performed to identify articles referencing the paper "On White-Coat Effects and the Electronic Monitoring of Compliance" by Alvan R. Feinstein, MD. Results: Fifteen studies were identified, three of which were on dermatologic conditions. Thirteen studies found a positive correlation between adherence and office visits. Three of these studies demonstrated increased adherence with increased visit frequency. One study reported adherence was unaffected by office visits. Limitations: Our review was limited in that none of the studies identified looked at the effect timing of office visits had on adherence in the long term. Conclusions: Strategic scheduling of office visits can be a valuable tool to improve adherence, particularly in the management of dermatologic conditions, and may help spare patients unnecessary exposure to more toxic systemic therapies. © 2013 Informa Healthcare USA on behalf of Informa UK Ltd. AD - Department of Dermatology, Wake Forest University, School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071, United States Department of Pathology, Wake Forest University, School of Medicine, Winston-Salem, NC, United States Department of Public Health Sciences, Wake Forest University, School of Medicine, Winston-Salem, NC, United States AU - Heaton, E. AU - Levender, M. M. AU - Feldman, S. R. DB - Scopus DO - 10.3109/09546634.2011.588194 IS - 2 KW - adherence compliance follow-up visits return visits treatment outcomes white coat compliance M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2013 SP - 82-88 ST - Review: Timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions T2 - Journal of Dermatological Treatment TI - Review: Timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84875335854&doi=10.3109%2f09546634.2011.588194&partnerID=40&md5=85750e8a1109b2c4dd236756306c9836 VL - 24 ID - 5202 ER - TY - JOUR AB - Introduction: Several studies have shown intra-ocular pressure (IOP) reductions following lifestyle and behavior changes in primary open-angled glaucoma (POAG) in the short term. Our aim in this study was to examine the potential of such interventions as an adjunct treatment and assess their cumulative short-term effect on IOP and illness perception in patients with POAG. Methods: In this randomized, parallel-arm, single blind controlled trial, POAG patients were randomized in a 1:1 ratio to either a treatment group which received instructions on dietary and lifestyle changes in addition to their standard therapy or to a control group which continued their standard therapy. Recommendations were selected to include those previously reported to reduce IOP; including: Saffron spice supplementation, high fiber diet, avoidance of caffeine, aerobic exercise, head elevation during sleep and others. Illness perception was assessed using the Brief IPQ questionnaire. Results: 22 participants were enrolled, 3 were lost to follow-up and 19 entered analysis. Mean age was 69 ± 12 and 12 (63%) were female. Concerns about the illness, symptoms, and feelings of control were significantly improved in the treatment group compared with controls (all P < 0.05). Mean IOP reduced in the treatment group by 1.0 ± 3.1 mmHg (17.5 ± 4.3–16.5 ± 4.7) and by 0.7 ± 4.1 mmHg in the controls (16.8 ± 4.7–16.1 ± 6.2) with no significant difference between them (P = 0.866). Conclusions: Dietary and lifestyle changes may improve illness perception and patient well-being, however they do not appear to affect IOP in the short term among patients with POAG. © 2018 Elsevier GmbH AD - Department of Ophthalmology, Edith Wolfson Medical Center and Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel AU - Hecht, I. AU - Achiron, A. AU - Bartov, E. AU - Maharshak, I. AU - Mendel, L. AU - Pe'er, L. AU - Bar, A. AU - Burgansky-Eliash, Z. DB - Scopus DO - 10.1016/j.eujim.2018.12.002 KW - Diet Glaucoma Illness perception Intraocular pressure Lifestyle Randomized controlled trial Saffron M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2019 SP - 60-66 ST - Effects of dietary and lifestyle recommendations on patients with glaucoma: A randomized controlled pilot trial T2 - European Journal of Integrative Medicine TI - Effects of dietary and lifestyle recommendations on patients with glaucoma: A randomized controlled pilot trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058475447&doi=10.1016%2fj.eujim.2018.12.002&partnerID=40&md5=6bbf33f35684a670c950ca990818cefa VL - 25 ID - 5555 ER - TY - JOUR AB - Background: Despite the increasing emphasis on the role of glaucoma-specific patient-reported outcome measures (PROMs) as relevant outcome measures for the impact of glaucoma and its intervention on patients' daily lives, the feasibility of implementing PROMs in the routine clinical setting in Singapore remains undefined. We aim to evaluate the comprehensibility, acceptability, and relevance of four glaucoma-specific PROMs at healthcare professionals' and patients' level in a Singapore context.Methods: Sixteen ophthalmic healthcare professionals and 24 glaucoma patients, with average age 60 years (SD = 15), were invited from a tertiary hospital in Singapore. Semi-structured interviews were conducted to explore participants' perceptions on the content and administration of four glaucoma-specific PROMs - the Glaucoma Quality of Life-15, Glaucoma Symptom Identifier, Independent Mobility Questionnaire and Treatment Satisfaction Survey of Intra-ocular Pressure. Semi-structured interviews were hand transcribed, and analysed thematically. Each participant filled out a feasibility survey at the end of interview.Results: 79% of glaucoma patients and 94% of glaucoma healthcare professionals felt selected PROMs relevant to patients. 63% of glaucoma patients and 50% of healthcare professionals felt that selected PROMs were sufficiently comprehensive for clinical use. 46% of glaucoma patients and 56% of healthcare professionals felt selected PROMs were user-friendly.Conclusions: Using PROMs in the Singapore clinical setting receives promising support from both healthcare professionals and patients. The identified potential barriers tailored to Singapore clinical setting will help successful implementation of PROMs into routine clinical care. AD - National Healthcare Group Eye Institute, Tan Tock Seng Hospital, S308433, Singapore, Singapore Health Services Research, Singapore Eye Research Institute, Singapore, Singapore AN - 131243335. Language: English. Entry Date: In Process. Revision Date: 20190603. Publication Type: journal article. Journal Subset: Biomedical AU - Hee, Owen Kim AU - Thng, Zheng-Xian AU - Zhu, Hong-Yuan AU - Lamoureux, Ecosse Luc DB - ccm DO - 10.1186/s12886-018-0803-5 DP - EBSCOhost IS - 1 KW - Glaucoma -- Therapy Antihypertensive Agents -- Therapeutic Use Pilot Studies Glaucoma -- Physiopathology Quality of Life Male Glaucoma -- Epidemiology Female Singapore Middle Age Exercise of Self-Care Agency Scale Ferrans and Powers Quality of Life Index Impact of Events Scale Scales N1 - Europe; UK & Ireland. Instrumentation: Exercise of Self-Care Agency Scale (ESCA) (Kearney and Fleischer); Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Longitudinal Interval Follow-Up Evaluation (LIFE); Impact of Events Scale (IES); Ferrans and Powers Quality of Life Index. NLM UID: 100967802. PMID: NLM30107834. PY - 2018 SN - 1471-2415 SP - N.PAG-N.PAG ST - Usage of glaucoma-specific patient-reported outcome measures (PROMs) in the Singapore context: a qualitative scoping exercise T2 - BMC Ophthalmology TI - Usage of glaucoma-specific patient-reported outcome measures (PROMs) in the Singapore context: a qualitative scoping exercise UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131243335&site=ehost-live&scope=site VL - 18 ID - 4414 ER - TY - JOUR AB - Purpose: Many glaucoma eye drop users cannot successfully self-Administer drops, and observing patients' drop technique can be time-consuming. We sought to examine the association of patient self-reported efficacy of eye drop technique and medication possession data as potential surrogate measures for actual drop administration success. Patients and Methods: In total, 137 adults with medically treated glaucoma were enrolled from a University eye clinic (n=54) or a Veteran Affairs (VA) eye clinic (n=83). All participants were asked, "How confident are you that you can get the medication into your eye?" Medication possession ratio (MPR), defined as the amount of eye drop available divided by the amount prescribed, was calculated for VA study site participants for 6 months. The main outcome was the correct eye drop technique, defined as the ability to get drops into the eye and to put only 1 drop into the eye at a time. Results: Among 117 participants who were "very confident" they could administer eye drops correctly, 95 participants (81%) displayed the correct drop technique. Of those who reported being less than "very confident" (n=18), 11 participants (61%) displayed correct drop technique (the Fisher exact test, P=0.07). For the VA sample, 20 participants with MPR<1.2, 20 participants with MPR=1.2 to 1.8, and 23 participants with MPR>1.8 displayed correct eye drop technique (the Fisher exact test, P=0.18). Conclusions: Self-reported administration success and MPR are not strongly associated with successful eye drop administration. Thus, direct observation of patients' drop instillation may be the most effective means of determining patient efficacy. AD - K.W. Muir, Departments of Ophthalmology, 508 Fulton Street, Durham, NC, United States AU - Hein, A. M. AU - Rosdahl, J. A. AU - Bosworth, H. B. AU - Woolson, S. L. AU - Olsen, M. K. AU - Kirshner, M. A. AU - Muir, K. W. DB - Embase Medline DO - 10.1097/IJG.0000000000001136 IS - 3 KW - eye drops adult aged article cohort analysis drug efficacy female glaucoma human major clinical study male patient compliance prospective study secondary analysis self report treatment outcome university hospital LA - English M3 - Article N1 - L625415468 2018-12-17 2019-04-02 PY - 2019 SN - 1536-481X 1057-0829 SP - E46-E48 ST - The Relationship of Self-Report and Medication Possession with Glaucoma Medication Administration Success T2 - Journal of Glaucoma TI - The Relationship of Self-Report and Medication Possession with Glaucoma Medication Administration Success UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625415468&from=export http://dx.doi.org/10.1097/IJG.0000000000001136 VL - 28 ID - 2523 ER - TY - JOUR AB - Background Primary open-Angle glaucoma (POAG) is still one of the most common causes of impaired vision worldwide, despite the further development of therapy options, and can lead to blindness. Micro-invasive glaucoma surgery (MIGS) using stents aims at reducing intraocular pressure (IOP), as it is the main risk factor. With regard to adherence and adverse drug reactions it also aims at reducing the drug burden on patients. The study investigates under everyday conditions the criteria according to which ophthalmologists in Germany select patients for MIGS using stents. In addition, it will be investigated which patients (could) benefit most from the therapy. Material and Methods In this qualitative study, 11 narrative interviews were conducted between May 2017 and July 2018 with ophthalmologists working in the hospital or in a private practice. They were interviewed on their experiences in the treatment of POAG with microstents. The interviews were analysed by an interdisciplinary team using the qualitative content analysis. Results The stages of therapy escalation form the frame of reference for patient selection in MIGS using stents. Only if the IOP cannot be sufficiently reduced by drop therapy or when this causes drug-related side effects that are intolerable for the patients, stents are apparently used as the next higher escalation stage. The intensive post-operative medication and the frequent check-up appointments are perceived as barriers by the interviewees, especially for people with or without disabilities, who are dependent on external help and/or those living in rural areas. The active cooperation of the patients in the demanding aftercare seems to be indispensable for the ophthalmologists. In addition, necessary revisions are sometimes stressful for patients (physical/psychological) and doctors (work organisation/therapy). Against the background of the organisational and economic challenges in the outpatient spectrum of tasks, especially physicians in private practice seem to weigh up carefully for which patients microstent therapy would be reasonable. Conclusion In view of the therapeutic requirements, the current microstent therapy seems to be used in a selected, adherent patient group. Further qualitative and quantitative studies (in other health care regions and structures) are necessary to verify and extend the available results. © 2021 Georg Thieme Verlag. All rights reserved. AD - Institute of General Medicine, University Medicine Rostock, Germany Clinic and Polyclinic for Ophthalmology, University Medicine Rostock, Germany AU - Helbig, C. AU - Wollny, A. AU - Altiner, A. AU - Diener, A. AU - Kohlen, J. AU - Ritzke, M. AU - Frech, S. AU - Guthoff, R. F. DB - Scopus DO - 10.1055/a-1241-4489 IS - 3 KW - health services research micro-invasive glaucoma surgery microstents MIGS patient selection primary open-Angle glaucoma M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 302-309 ST - Treatment Complexity in Primary Open-Angle Glaucoma (POAG): Perspectives on Patient Selection in Micro-Invasive Glaucoma Surgery (MIGS) Using Stents T2 - Klinische Monatsblatter fur Augenheilkunde TI - Treatment Complexity in Primary Open-Angle Glaucoma (POAG): Perspectives on Patient Selection in Micro-Invasive Glaucoma Surgery (MIGS) Using Stents UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103521184&doi=10.1055%2fa-1241-4489&partnerID=40&md5=0d7af7e54b409d7e82aef71fa04f345c VL - 238 ID - 5666 ER - TY - JOUR AB - Background Primary open-angle glaucoma (POAG) is still one of the most common causes of impaired vision worldwide, despite the further development of therapy options, and can lead to blindness. Micro-invasive glaucoma surgery (MIGS) using stents aims at reducing intraocular pressure (IOP), as it is the main risk factor. With regard to adherence and adverse drug reactions it also aims at reducing the drug burden on patients. The study investigates under everyday conditions the criteria according to which ophthalmologists in Germany select patients for MIGS using stents. In addition, it will be investigated which patients (could) benefit most from the therapy. Material and Methods In this qualitative study, 11 narrative interviews were conducted between May 2017 and July 2018 with ophthalmologists working in the hospital or in a private practice. They were interviewed on their experiences in the treatment of POAG with microstents. The interviews were analysed by an interdisciplinary team using the qualitative content analysis. Results The stages of therapy escalation form the frame of reference for patient selection in MIGS using stents. Only if the IOP cannot be sufficiently reduced by drop therapy or when this causes drug-related side effects that are intolerable for the patients, stents are apparently used as the next higher escalation stage. The intensive post-operative medication and the frequent check-up appointments are perceived as barriers by the interviewees, especially for people with or without disabilities, who are dependent on external help and/or those living in rural areas. The active cooperation of the patients in the demanding aftercare seems to be indispensable for the ophthalmologists. In addition, necessary revisions are sometimes stressful for patients (physical/psychological) and doctors (work organisation/therapy). Against the background of the organisational and economic challenges in the outpatient spectrum of tasks, especially physicians in private practice seem to weigh up carefully for which patients microstent therapy would be reasonable. Conclusion In view of the therapeutic requirements, the current microstent therapy seems to be used in a selected, adherent patient group. Further qualitative and quantitative studies (in other health care regions and structures) are necessary to verify and extend the available results. AN - WOS:000594819900001 AU - Helbig, C. AU - Wollny, A. AU - Altiner, A. AU - Diener, A. AU - Kohlen, J. AU - Ritzke, M. AU - Frech, S. AU - Guthoff, R. F. DA - MAR DO - 10.1055/a-1241-4489 IS - 03 PY - 2021 SN - 0023-2165 1439-3999 SP - 302-309 ST - Treatment Complexity in Primary Open-Angle Glaucoma (POAG): Perspectives on Patient Selection in Micro-Invasive Glaucoma Surgery (MIGS) Using Stents T2 - KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE TI - Treatment Complexity in Primary Open-Angle Glaucoma (POAG): Perspectives on Patient Selection in Micro-Invasive Glaucoma Surgery (MIGS) Using Stents VL - 238 ID - 6178 ER - TY - JOUR AB - Purpose: In this longitudinal study, the cumulative incidence of patients with glaucoma and disc hemorrhages was investigated. A possible effect of glaucoma therapy on the incidence rate of disc hemorrhages was evaluated. Methods: A group consisting of 68 patients with primary open-angle glaucoma (POAG), 34 with normal-pressure glaucoma, and 125 with suspected glaucoma (mean follow-up, 7.3 ± 2.5 years; range 3–13 years) was observed closely with quarterly examinations. Results: In normal-pressure glaucoma, the cumulative incidence of patients with disc hemorrhages was 35.3%, which was significantly higher than for those with POAG (10.3%; P < 0.01) and for those with suspected glaucoma (10.4%; P < 0.001). The mean follow-up period before a first disc hemorrhage was detected was 2.5 ± 2.8 years. In the bleeders, recurrent disc hemorrhages were observed in 67% of the patients with normal-pressure glaucoma, 29% of those with POAG, and 54% of glaucoma suspects. In normal-pressure glaucoma, therapy had no effect on the incidence rate of disc hemorrhages. In glaucoma suspects, a significant reduction of the incidence rate of disc hemorrhages per year (0.11 ± 0.04) was observed during episodes with therapy compared with episodes without (0.43 ± 0.15; P < 0.05). A concept of two populations (i.e., one with disc hemorrhages and the other never having them) seems to be valid for normal-pressure glaucoma, but not for POAG and suspected glaucoma. Conclusion: The cumulative incidence of initial disc hemorrhages increases with time in POAG and suspected glaucoma, but reaches a limit in normal-pressure glaucoma. Glaucoma therapy may reduce the incidence rate of all, initial and recurrent, disc hemorrhages in patients with high pressures, but not in patients with normal-pressure glaucoma. © 1994, American Academy of Ophthalmology, Inc. All rights reserved. AD - Department of Experimental Ophthalmology, The Netherlands Ophthalmic Research Institute, Amsterdam, Netherlands Department of Visual System Analysis, The Netherlands Ophthalmic Research Institute, Amsterdam, Netherlands St. Lucas Hospital, Amsterdam, Netherlands AU - Hendrickx, K. H. AU - van den Enden, A. AU - Rasker, M. T. AU - Hoyng, P. F. J. DB - Scopus DO - 10.1016/S0161-6420(94)31192-4 IS - 7 M3 - Article N1 - Cited By :67 Export Date: 19 July 2021 PY - 1994 SP - 1165-1172 ST - Cumulative Incidence of Patients with Disc Hemorrhages in Glaucoma and the Effect of Therapy T2 - Ophthalmology TI - Cumulative Incidence of Patients with Disc Hemorrhages in Glaucoma and the Effect of Therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028122999&doi=10.1016%2fS0161-6420%2894%2931192-4&partnerID=40&md5=c6e5e1a932dbe733cc4634a682fbf1b6 VL - 101 ID - 4964 ER - TY - JOUR AB - Importance: Eye health in the homeless population is important, yet follow-up to referral appointments in this population remains low. Objective: To investigate the association of health coaching and transportation vouchers with follow-up rates at a free ophthalmology homeless shelter clinic. Design, Setting, and Participants: A prospective cohort study was conducted from January 9, 2019, to March 4, 2020, among all 71 patients evaluated at a free ophthalmology clinic at a single homeless shelter in San Francisco, California. Exposures: If indicated, patients were referred for advanced ophthalmologic care at a county hospital and free eyeglasses from a nonprofit organization. Main Outcomes and Measures: The primary outcome was follow-up rates to referral appointments. The secondary outcomes were prespecified baseline variables hypothesized to be associated with follow-up. The intervention began September 4, 2019. Follow-up rates were compared between the preintervention (n = 37) and postintervention (n = 34) groups. The hypothesis was formulated before data collection. Results: Among the 71 patients, 50 (70.4%) were men, and the mean (SD) age was 51.9 (12.4) years. A total of 28 patients (39.4%) were referred for free eyeglasses, 14 (19.7%) to the county hospital for advanced care, and 7 (9.9%) to both. Of those referred, the difference in follow-up from the postintervention to preintervention groups was 53.8% (95% CI, 39.8%-67.9%; P <.001). Compared with patients who did not follow up, those who did had a mean difference of 59 more days at the shelter (95% CI, 39-80 days; P =.003). Among patients with a visual acuity of 20/40 or worse in the better-seeing eye, the mean difference between those who did not follow up and those who did was 61% (95% CI, 44%-78%; P =.003). The mean difference in follow-up between patients who were born in the US and patients not born in the US was 89% (95% CI, 79%-98%; P =.02). Of those in the postintervention group, the difference in presentation to follow-up for patients with a high school diploma compared with those without was 59% (95% CI, 37%-81%; P =.001). Conclusions and Relevance: This study suggests that a health coaching and bus token intervention improved follow-up rates at a free ophthalmology homeless shelter clinic by at least 39.8%; this improvement supports considering implementation of this intervention when developing public assistance programs if independent corroboration is provided. Barriers to follow-up included a shorter duration of stay at the homeless shelter, visual acuity better than 20/40, not being born in the US, and lower educational level, although the size of this study does not permit determining if some or all of these are associated with one another. © 2021 American Medical Association. All rights reserved. AD - Department of Ophthalmology, University of California, San Francisco, 10 KoretWay, San Francisco, CA 94143, United States AU - Hennein, L. AU - De Alba Campomanes, A. G. DB - Scopus DO - 10.1001/jamaophthalmol.2020.6373 IS - 3 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2021 SP - 311-316 ST - Association of a Health Coaching and Transportation Assistance Intervention at a Free Ophthalmology Homeless Shelter Clinic with Follow-up Rates T2 - JAMA Ophthalmology TI - Association of a Health Coaching and Transportation Assistance Intervention at a Free Ophthalmology Homeless Shelter Clinic with Follow-up Rates UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100671113&doi=10.1001%2fjamaophthalmol.2020.6373&partnerID=40&md5=aa0e62ff1f6e12166ca32d7e67dd980a VL - 139 ID - 5545 ER - TY - JOUR AB - Ocular carteolol (Mikelan®, Teoptic®, Ocupress®) is a nonselective β-adrenoceptor antagonist with intrinsic sympathomimetic activity (ISA). Ocular carteolol effectively reduces intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). Twice-daily administration of standard carteolol has generally similar IOP-lowering efficacy to other ocular β-adrenoceptor antagonists such as timolol, betaxolol and metipranolol in patients with OAG or OH. In addition, long-term treatment with carteolol has similar efficacy to timolol and betaxolol in terms of reducing IOP and maintaining visual fields in patients with newly diagnosed primary OAG (POAG). The new long-acting formulation of once-daily carteolol has equivalent efficacy to the standard formulation of carteolol administered twice daily in patients with OAG or OH. Both the standard and long-acting formulations of ocular carteolol are generally well tolerated in terms of topical adverse effects involving the eyes or systemic adverse effects involving the cardiovascular system. Thus, twice-daily carteolol is a well established option in the treatment of glaucoma and OH, and the new oncedaily formulation of long-acting carteolol offers similar efficacy and tolerability with a potential for improved patient adherence. Pharmacological Properties: Carteolol is a nonselective β-adrenoceptor antagonist with properties unlike those of other β-adrenoceptor antagonists (i.e. ISA and minimal local anaesthetic activity). Ocular carteolol significantly reduced IOP in healthy volunteers. In addition, significant reductions in aqueous humour production were seen with carteolol in patients with POAG; it did not alter corneal sensitivity, tear secretion or pupil diameter. Unlike timolol or betaxolol, carteolol also appeared to improve perfusion of the optic nerve head. Ocular carteolol did not affect respiratory function in healthy volunteers, although bronchoconstriction was seen in patients with asthma. Although carteolol had similar cardiovascular effects to other ocular β-adrenoceptor antagonists in healthy volunteers and patients with asthma, unlike timolol, it did not have a deleterious effect on the lipid profile in patients with POAG or OH. Plasma carteolol concentrations were significantly lower with the long-acting formulation of ocular carteolol than with the standard formulation. In animal models, the precorneal residence time of carteolol was increased with the long-acting versus the standard formulation, allowing for prolonged ocular delivery. Moreover, compared with standard carteolol, a single dose of long-acting carteolol resulted in significantly higher carteolol concentrations at certain timepoints in the iris and ciliary body, indicating enhanced ocular penetration. Therapeutic Efficacy: The results of numerous trials showed that the ocular hypotensive efficacy of standard carteolol 1% or 2% twice daily was similar to that of timolol 0.25% or 0.5% twice daily, betaxolol 0.5% twice daily or metipranolol 0.3% twice daily in patients with POAG, OAG or OH after 1-12 months of treatment. However, 3 months of treatment with levobunolol 0.5% twice daily resulted in a significantly greater reduction in IOP than carteolol 2% twice daily in patients with OAG or OH. A significant reduction from baseline in IOP was seen with carteolol in most studies. Long-term treatment (for up to 7 years) with carteolol 1% twice daily had similar efficacy to timolol 0.25% twice daily and betaxolol 0.5% twice daily in terms of reducing IOP and maintaining visual fields in patients with newly diagnosed POAG. Combination therapy with carteolol plus latanoprost reduced IOP to a significantly greater extent than monotherapy with latanoprost or combination therapy with nipradilol plus latanoprost in patients with POAG or normal-tension glaucoma. The ocular hypotensive efficacy of long-acting carteolol administered once daily was equivalent to that of the standard formulation of carteolol administered twice daily in two well designed trials in patients wi h OAG or OH. In addition, data from a third trial revealed significant reductions from baseline in IOP with both the long-acting and standard formulations of carteolol in patients with PAOG or OH. Tolerability: Ocular administration of standard or long-acting carteolol was generally well tolerated in patients with POAG, OAG or OH. In general, there were no significant differences in the incidence of ocular symptoms (e.g. burning/stinging at instillation, tearing, ocular pain, blurred vision, itching, conjunctival hyperaemia) between patients receiving carteolol and those receiving comparators such as timolol, metipranolol or levobunolol. However, several studies reported better ocular tolerability of carteolol versus timolol for certain endpoints (e.g. fewer ocular symptoms overall and less burning and eye pain). The long-acting formulation of carteolol was associated with a low incidence of blurred vision (≤2% of patients). Few differences emerged between carteolol and other β-adrenoceptor antagonists in terms of cardiovascular effects (i.e. effects on heart rate and blood pressure) in patients with POAG, OAG or OH. However, one study found a significantly lower incidence of cardiovascular adverse events overall and a significantly lower incidence of bradycardia with carteolol than with timolol; in particular, carteolol seemed less likely to induce nocturnal bradycardia. © 2007 Adis Data Information BV. All rights reserved. AD - G.M. Keating, Wolters Kluwer Health Adis, 41 Centorian Drive, North Shore 0754, Auckland, New Zealand AU - Henness, S. AU - Harrison, T. S. AU - Keating, G. M. C1 - mikelan ocupress teoptic DB - Embase Medline DO - 10.2165/00002512-200724060-00007 IS - 6 KW - beta adrenergic receptor blocking agent betaxolol carteolol dorzolamide latanoprost levobunolol metipranolol nipradilol pilocarpine timolol aqueous humor asthma blurred vision bradycardia burning sensation cataract ciliary body clinical trial combination chemotherapy conjunctival hyperemia data base dosage schedule comparison drug absorption drug blood level drug delivery system drug distribution drug efficacy drug excretion drug formulation drug half life drug mechanism drug metabolism drug tolerability dry eye Embase epiphora eye pain eyelid erythema glaucoma heart rate heart rate variability human hypertension intraocular pressure iris keratitis lacrimation medical literature Medline methodology monotherapy nonhuman ocular pruritus optic nerve patient compliance priority journal Leporidae rat strain review side effect single drug dose statistical significance symptom visual field vitreous disease mikelan ocupress teoptic LA - English M3 - Review N1 - L46978242 2007-07-12 jsessionid=G4qHGH5y1jn5xv9ZJdz6v5thPKjPMdvhdx89mx8s17c38vgF4LvL!-1804036389!-949856145!8091!-1 PY - 2007 SN - 1170-229X SP - 509-528 ST - Ocular carteolol: A review of its use in the management of glaucoma and ocular hypertension T2 - Drugs and Aging TI - Ocular carteolol: A review of its use in the management of glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46978242&from=export http://dx.doi.org/10.2165/00002512-200724060-00007 http://aging.adisonline.com/pt/re/dra/pdfhandler.00002512-200724060-00007.pdf VL - 24 ID - 3515 ER - TY - JOUR AB - Ocular carteolol (Mikelan((R)), Teoptic((R)), Ocupress((R))) is a nonselective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity (ISA). Ocular carteolol effectively reduces intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). Twice-daily administration of standard carteolol has generally similar IOP-lowering efficacy to other ocular beta-adrenoceptor antagonists such as timolol, betaxolol and metipranolol in patients with OAG or OH. In addition, long-term treatment with carteolol has similar efficacy to timolol and betaxolol in terms of reducing IOP and maintaining visual fields in patients with newly diagnosed primary OAG (POAG). The new long-acting formulation of once-daily carteolol has equivalent efficacy to the standard formulation of carteolol administered twice daily in patients with OAG or OH. Both the standard and long-acting formulations of ocular carteolol are generally well tolerated in terms of topical adverse effects involving the eyes or systemic adverse effects involving the cardiovascular system. Thus, twice-daily carteolol is a well established option in the treatment of glaucoma and OH, and the new once-daily formulation of long-acting carteolol offers similar efficacy and tolerability with a potential for improved patient adherence. AN - 105995414. Language: English. Entry Date: 20080222. Revision Date: 20200708. Publication Type: Journal Article AU - Henness, S. AU - Swainston Harrison, T. AU - Keating, G. M. DB - ccm DO - 10.2165/00002512-200724060-00007 DP - EBSCOhost IS - 6 KW - Adrenergic Beta-Antagonists Glaucoma -- Drug Therapy Ocular Hypertension -- Drug Therapy Adrenergic Beta-Antagonists -- Adverse Effects Adrenergic Beta-Antagonists -- Therapeutic Use Aged Clinical Trials Glaucoma -- Physiopathology Instillation, Drug Middle Age Treatment Outcomes N1 - review. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 9102074. PMID: NLM17571916. PY - 2007 SN - 1170-229X SP - 509-528 ST - Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension T2 - Drugs & Aging TI - Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105995414&site=ehost-live&scope=site VL - 24 ID - 4428 ER - TY - JOUR AB - BACKGROUND: Prostaglandin analogs (PGAs) are considered an initial therapy to manage increased intraocular pressure (IOP) for patients with glaucoma. When the initial PGA treatment fails to lower IOP adequately, the patient may add or change medications or have surgery/laser treatment. OBJECTIVE: To compare medication adherence, duration of therapy, and treatment patterns among 3 PGAs—latanoprost, travoprost, and bimatoprost—as initial therapies for patients with glaucoma or ocular hypertension. METHODS: This was a retrospective cohort study using administrative claims data. The cohort consisted of patients newly diagnosed with glaucoma or ocular hypertension with at least 1 prescription claim for latanoprost, travoprost, or bimatoprost and enrolled in a Medicare Advantage plan between 2007 and 2012. The 24-month medication possession ratio (MPR) was used to measure medication adherence. Discontinuation of first-line PGA therapy was defined as nonpersistence (90-day gap allowance) of the index PGA or a change in therapy during the 24-month follow-up period. Types of second-line therapy (i.e., switch, addition, and surgery) were identified. The 1:1:1 propensity score matching was used. RESULTS: Patients who met the inclusion criteria were propensity score matched, resulting in 1,296 patients per PGA group. Latanoprost users showed higher adherence (50.1%) than travoprost (48.8%) and bimatoprost (43.0%) users. The latanoprost and travoprost groups had significantly higher MPRs than bimatoprost (P<0.0001). The latanoprost group showed significantly longer duration of first-line therapy (372 days) than the bimatoprost group (343 days; P=0.003) but not the travoprost group (361 days). After controlling for demographic and clinical characteristics, a Cox proportional hazards model showed that the travoprost and bimatoprost groups had a higher risk of discontinuation of first-line therapy than the latanoprost group (P<0.0001). The percentage of patients continuing on the index PGA without treatment pattern change (i.e., switches, additions, and surgery) was higher for latanoprost users (52.9%) compared with travoprost (39.0%) or bimatoprost users (42.1%; P<0.001). CONCLUSIONS: Patients who used latanoprost as their initial therapy were more likely to adhere and persist to the index PGA compared with bimatoprost users. The latanoprost group demonstrated a lower risk of discontinuing first-line therapy than the travoprost and bimatoprost groups. The results may assist ophthalmologists in determining the optimal management of this patient population with respect to treatment patterns. AD - J.H. Heo, Genesis Research, 5 Marine View Plaza, Hoboken, NJ, United States AU - Heo, J. H. AU - Rascati, K. L. AU - Wilson, J. P. AU - Lawson, K. A. AU - Richards, K. M. AU - Nair, R. DB - Embase Medline DO - 10.18553/jmcp.2019.25.9.1001 IS - 9 KW - bimatoprost latanoprost travoprost adult aged article cohort analysis comparative study drug substitution drug withdrawal female glaucoma human intraocular hypertension laser surgery major clinical study male medicare medication compliance monotherapy patient compliance prescription retrospective study treatment duration very elderly LA - English M3 - Article N1 - L629279811 2019-09-20 PY - 2019 SN - 2376-1032 2376-0540 SP - 1001-1010 ST - Comparison of prostaglandin analog treatment patterns in glaucoma and ocular hypertension T2 - Journal of Managed Care and Specialty Pharmacy TI - Comparison of prostaglandin analog treatment patterns in glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629279811&from=export http://dx.doi.org/10.18553/jmcp.2019.25.9.1001 VL - 25 ID - 2489 ER - TY - JOUR AB - BACKGROUND: Prostaglandin analogs (PGAs) are considered an initial therapy to manage increased intraocular pressure (IOP) for patients with glaucoma. When the initial PGA treatment fails to lower IOP adequately, the patient may add or change medications or have surgery/laser treatment. OBJECTIVE: To compare medication adherence, duration of therapy, and treatment patterns among 3 PGAs—latanoprost, travoprost, and bimatoprost—as initial therapies for patients with glaucoma or ocular hypertension. METHODS: This was a retrospective cohort study using administrative claims data. The cohort consisted of patients newly diagnosed with glaucoma or ocular hypertension with at least 1 prescription claim for latanoprost, travoprost, or bimatoprost and enrolled in a Medicare Advantage plan between 2007 and 2012. The 24-month medication possession ratio (MPR) was used to measure medication adherence. Discontinuation of first-line PGA therapy was defined as nonpersistence (90-day gap allowance) of the index PGA or a change in therapy during the 24-month follow-up period. Types of second-line therapy (i.e., switch, addition, and surgery) were identified. The 1:1:1 propensity score matching was used. RESULTS: Patients who met the inclusion criteria were propensity score matched, resulting in 1,296 patients per PGA group. Latanoprost users showed higher adherence (50.1%) than travoprost (48.8%) and bimatoprost (43.0%) users. The latanoprost and travoprost groups had significantly higher MPRs than bimatoprost (P<0.0001). The latanoprost group showed significantly longer duration of first-line therapy (372 days) than the bimatoprost group (343 days; P=0.003) but not the travoprost group (361 days). After controlling for demographic and clinical characteristics, a Cox proportional hazards model showed that the travoprost and bimatoprost groups had a higher risk of discontinuation of first-line therapy than the latanoprost group (P<0.0001). The percentage of patients continuing on the index PGA without treatment pattern change (i.e., switches, additions, and surgery) was higher for latanoprost users (52.9%) compared with travoprost (39.0%) or bimatoprost users (42.1%; P<0.001). CONCLUSIONS: Patients who used latanoprost as their initial therapy were more likely to adhere and persist to the index PGA compared with bimatoprost users. The latanoprost group demonstrated a lower risk of discontinuing first-line therapy than the travoprost and bimatoprost groups. The results may assist ophthalmologists in determining the optimal management of this patient population with respect to treatment patterns. Copyright © 2019, Academy of Managed Care Pharmacy. All rights reserved. AD - Health Outcomes Division, College of Pharmacy, University of Texas at Austin, United States Genesis Research, 5 Marine View Plaza, Hoboken, NJ 07030, United States Humana, Louisville, KY, United States AU - Heo, J. H. AU - Rascati, K. L. AU - Wilson, J. P. AU - Lawson, K. A. AU - Richards, K. M. AU - Nair, R. DB - Scopus DO - 10.18553/jmcp.2019.25.9.1001 IS - 9 M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2019 SP - 1001-1010 ST - Comparison of prostaglandin analog treatment patterns in glaucoma and ocular hypertension T2 - Journal of Managed Care and Specialty Pharmacy TI - Comparison of prostaglandin analog treatment patterns in glaucoma and ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071746218&doi=10.18553%2fjmcp.2019.25.9.1001&partnerID=40&md5=648344a09cc81b16d6b0f0fd62741209 VL - 25 ID - 5498 ER - TY - JOUR AB - BACKGROUND: Prostaglandin analogs (PGAs) are considered an initial therapy to manage increased intraocular pressure (10P) for patients with glaucoma. When the initial PGA treatment fails to lower 10P adequately, the patient may add or change medications or have surgery/laser treatment. OBJECTIVE: To compare medication adherence, duration of therapy, and treatment patterns among 3 PGAs-latanoprost, travoprost, and bimatoprost-as initial therapies for patients with glaucoma or ocular hypertension. METHODS: This was a retrospective cohort study using administrative claims data. The cohort consisted of patients newly diagnosed with glaucoma or ocular hypertension with at least 1 prescription claim for latanoprost, travoprost, or bimatoprost and enrolled in a Medicare Advantage plan between 2007 and 2012. The 24-month medication possession ratio (MPR) was used to measure medication adherence. Discontinuation of first line PGA therapy was defined as nonpersistence (90-day gap allowance) of the index PGA or a change in therapy during the 24-month follow-up period. Types of second-line therapy (i.e., switch, addition, and surgery) were identified. The 1:1:1 propensity score matching was used. RESULTS: Patients who met the inclusion criteria were propensity score matched, resulting in 1,296 patients per PGA group. Latanoprost users showed higher adherence (50.1%) than travoprost (48.8%) and bimatoprost (43.0%) users. The latanoprost and travoprost groups had significantly higher MPRs than bimatoprost (P< 0.0001). The latanoprost group showed significantly longer duration of first-line therapy (372 days) than the bimatoprost group (343 days; P= 0.003) but not the travoprost group (361 days). After controlling for demographic and clinical characteristics, a Cox proportional hazards model showed that the travoprost and bimatoprost groups had a higher risk of discontinuation of first-line therapy than the latanoprost group (P< 0.0001). The percentage of patients continuing on the index PGA without treatment pattern change (i.e., switches, additions, and surgery) was higher for latanoprost users (52.9%) compared with travoprost (39.0%) or bimatoprost users (42.1%; P< 0.001). CONCLUSIONS: Patients who used latanoprost as their initial therapy were more likely to adhere and persist to the index PGA compared with bimatoprost users. The latanoprost group demonstrated a lower risk of discontinuing first-line therapy than the travoprost and bimatoprost groups. The results may assist ophthalmologists in determining the optimal management of this patient population with respect to treatment patterns. Copyright (C) 2019, Academy of Managed Care Pharmacy. All rights reserved. AN - WOS:000483684200007 AU - Heo, J. H. AU - Rascati, K. L. AU - Wilson, J. P. AU - Lawson, K. A. AU - Richards, K. M. AU - Nair, R. DA - SEP DO - 10.18553/jmcp.2019.25.9.1001 IS - 9 PY - 2019 SN - 2376-0540 2376-1032 SP - 1001-+ ST - Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension T2 - JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY TI - Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension VL - 25 ID - 6044 ER - TY - JOUR AB - Background: Travoprost and timolol are topical ocular hypotensive medications that have been used in the treatment of glaucoma. The fixed combination eye drop, Duotrav (travoprost 0.004% and timolol maleate 0.5%), has recently been introduced into the market. Objective: In this paper, the results of clinical trials and existing data on the performance of travoprost/timolol are discussed and analyzed. Methods: Appropriate studies for review were identified using PubMed. Studies selected for review compared efficacy and side-effect profile of fixed combination travoprost/timolol with travoprost and timolol used concomitantly, latanoprost and timolol used concomitantly, fixed combination latanoprost/timolol, travoprost alone and timolol alone. Results/conclusion: Fixed combination eye drops such as travoprost/ timolol offer the potential benefits of increased patient adherence, reduced exposure to preservatives, and reduced cost. © 2008 Informa UK Ltd. AD - R. Noecker, University of Pittsburgh School of Medicine, UPMC Eye Center, 203 Lothrop Street, Pittsburgh, PA 15213, United States AU - Herceg, M. AU - Noecker, R. C1 - duotrav DB - Embase Medline DO - 10.1517/14656566.9.6.1059 IS - 6 KW - benzalkonium chloride beta adrenergic receptor blocking agent latanoprost latanoprost plus timolol placebo prostaglandin derivative timolol timolol plus travoprost travoprost bradycardia bronchospasm clinical trial combination chemotherapy conjunctival hyperemia cost effectiveness analysis depression dizziness dosage schedule comparison dose kidney function relation drug absorption drug cost drug efficacy drug elimination drug half life drug mechanism drug metabolism drug safety drug withdrawal dyspnea evening dosage eye burning eye irritation fatigue headache heart arrhythmia human hypercholesterolemia hypertrichosis hypesthesia hypoglycemia hypotension intraocular hypertension intraocular pressure iridocyclitis monotherapy morning dosage ocular pruritus open angle glaucoma patient compliance retina macula cystoid edema retina tear review side effect skin pigmentation somnolence duotrav LA - English M3 - Review N1 - L351593749 2008-05-08 PY - 2008 SN - 1465-6566 SP - 1059-1065 ST - Travoprost/timolol fixed combination T2 - Expert Opinion on Pharmacotherapy TI - Travoprost/timolol fixed combination UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351593749&from=export http://dx.doi.org/10.1517/14656566.9.6.1059 VL - 9 ID - 3462 ER - TY - JOUR AB - Purpose: To assess the patient adherence and behavior with brimonidine twice daily (bid) or 3 times daily (tid) in patients used to topical glaucoma medication. Patients and Methods: Seventy-five patients with glaucoma or ocular hypertension were enrolled in a prospective, observational cohort study. Consenting patients were randomly assigned to brimonidine bid or tid and received conventional brimonidine eye drops with attached electronic monitoring devices for 4 weeks. Patients were not explicitly informed on the compliance monitoring. Results: The study was completed by 67 patients (89%). In 65 patients (97%), at least 1 dosing interval exceeded 24 hours. The mean adherence rates were better in the brimonidine bid group (72±19% vs. 62±16%, P=0.04), although dosing frequency was higher in the tid group (1.9±0.5 vs. 1.4±0.4 per day; P<0.001). On average medication coverage was 70% for the bid group and 67% for the tid group; 19 patients (28%) had a coverage rate above 75%, 42 patients (63%) 50% to 75%, and 6 (9%) below 50%. Patients with normal-tension glaucoma had lower coverage rates than patients with primary open-angle glaucoma and ocular hypertension (P<0.05). Data also showed that on average 20% of the glaucoma medication was wasted owing to inefficient drug delivery by using more than 1 drop per dosing. Conclusions: Individual adherence with brimonidine was highly variable and pharmacologically insufficient for more than two-third of the patients. Special attention should be paid to compliance of patients with normal-tension glaucoma. Our findings underline the need to improve individual adherence and drug delivery in topical glaucoma therapy. Copyright © 2011 by Lippincott Williams & Wilkins. AD - M.M. Hermann, Uniklinik Köln, Zentrum für Augenheilkunde, D-50924 Cologne/Köln, Germany AU - Hermann, M. M. AU - Bron, A. M. AU - Creuzot-Garcher, C. P. AU - Diestelhorst, M. C1 - alphagan(Allergan,France) C2 - Allergan(France) DB - Embase Medline DO - 10.1097/IJG.0b013e3181f3eb4a IS - 8 KW - brimonidine eye drops prostaglandin timolol accuracy adult aged article clinical article cohort analysis devices dosage schedule comparison drug efficacy drug hypersensitivity dry eye electronic monitoring electronics erythema female glaucoma human intraocular hypertension male medical technology migraine monotherapy observational study open angle glaucoma patient compliance patient monitoring priority journal prospective study alphagan LA - English M3 - Article N1 - L51081412 2010-09-26 2011-10-19 PY - 2011 SN - 1057-0829 1536-481X SP - 502-508 ST - Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring T2 - Journal of Glaucoma TI - Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51081412&from=export http://dx.doi.org/10.1097/IJG.0b013e3181f3eb4a VL - 20 ID - 3144 ER - TY - JOUR AB - Purpose: To assess the impact of open versus masked adherence monitoring on adherence with topical brimonidine using two different dosing schedules. Methods: Thirty-seven patients with glaucoma or ocular hypertension were enroled in a prospective, observational cohort study. Patients were randomly assigned to open or masked adherence monitoring and to brimonidine twice daily (BID) or three times daily (TID). Patients received conventional brimonidine eye drops with attached electronic monitoring devices for 4 weeks with weekly intraocular pressure measurements. Adherence calculations comprised dosing intervals, adherence rate and time covered. Subgroup analysis with anova included the factors masking, regimen, diagnosis and age. Results: Among 36 individually analysed patients, 12 (33%) had adherence rates above 75%, therein two (5%)>90%. The mean adherence rate in 19 patients aware of adherence measurements was 70 ± 17% for brimonidine BID and 65 ± 14% for TID, not significantly different to the rates of 17 patients not informed about adherence measurements (77 ± 6% BID, 62 ± 9% TID, p = 0.24). On average, patients with brimonidine TID achieved significantly lower adherence rates (64 ± 12%) than patients on BID (73 ± 13%, p = 0.02). Still, patients on TID applied brimonidine more often (TID 1.9 ± 0.3, BID 1.5 ± 0.1 mean applications per day). The median coverage was 70% and showed no statistically significant difference between patients on BID and TID (p = 0.36). Conclusion: The study findings suggest that adherence measurements are not significantly altered by open adherence monitoring, which may simplify future adherence studies. Adherence with brimonidine eye drops was insufficient for most patients. These results demonstrate the necessity to develop new strategies to improve compliance in glaucoma therapy. © 2010 The Authors. Acta Ophthalmologica © 2010 Acta Ophthalmologica Scandinavica Foundation. AD - M. M. Hermann, University Eye Hospital, University of Cologne, Kerpener Str. 62, 50924 Cologne / Köln, Germany AU - Hermann, M. M. AU - Papaconstantinou, D. AU - Muether, P. S. AU - Georgopoulos, G. AU - Diestelhorst, M. C1 - allergan(Irvine,United States) alphagan(Irvine,United States) C2 - Irvine(United States) DB - Embase Medline DO - 10.1111/j.1755-3768.2010.02050.x IS - 4 KW - brimonidine promethazine adult article clinical article clinical trial cohort analysis dosage schedule comparison drug efficacy drug monitoring female human intraocular hypertension intraocular pressure male monitor observational study open angle glaucoma patient compliance priority journal prospective study visual acuity allergan alphagan LA - English M3 - Article N1 - L361899741 2011-06-15 2011-06-29 PY - 2011 SN - 1755-375X 1755-3768 SP - e300-e305 ST - Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring T2 - Acta Ophthalmologica TI - Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361899741&from=export http://dx.doi.org/10.1111/j.1755-3768.2010.02050.x VL - 89 ID - 3168 ER - TY - JOUR AB - Purpose: To assess the impact of open versus masked adherence monitoring on adherence with topical brimonidine using two different dosing schedules. Methods: Thirty-seven patients with glaucoma or ocular hypertension were enroled in a prospective, observational cohort study. Patients were randomly assigned to open or masked adherence monitoring and to brimonidine twice daily (BID) or three times daily (TID). Patients received conventional brimonidine eye drops with attached electronic monitoring devices for 4 weeks with weekly intraocular pressure measurements. Adherence calculations comprised dosing intervals, adherence rate and time covered. Subgroup analysis with anova included the factors masking, regimen, diagnosis and age. Results: Among 36 individually analysed patients, 12 (33%) had adherence rates above 75%, therein two (5%)>90%. The mean adherence rate in 19 patients aware of adherence measurements was 70 ± 17% for brimonidine BID and 65 ± 14% for TID, not significantly different to the rates of 17 patients not informed about adherence measurements (77 ± 6% BID, 62 ± 9% TID, p = 0.24). On average, patients with brimonidine TID achieved significantly lower adherence rates (64 ± 12%) than patients on BID (73 ± 13%, p = 0.02). Still, patients on TID applied brimonidine more often (TID 1.9 ± 0.3, BID 1.5 ± 0.1 mean applications per day). The median coverage was 70% and showed no statistically significant difference between patients on BID and TID (p = 0.36). Conclusion: The study findings suggest that adherence measurements are not significantly altered by open adherence monitoring, which may simplify future adherence studies. Adherence with brimonidine eye drops was insufficient for most patients. These results demonstrate the necessity to develop new strategies to improve compliance in glaucoma therapy. © 2010 The Authors. Acta Ophthalmologica © 2010 Acta Ophthalmologica Scandinavica Foundation. AD - University Eye Hospital, University of Cologne, Kerpener Str. 62, 50924 Cologne / Köln, Germany Department of Ophthalmology, Athens University Medical School, Athens, Greece AU - Hermann, M. M. AU - Papaconstantinou, D. AU - Muether, P. S. AU - Georgopoulos, G. AU - Diestelhorst, M. DB - Scopus DO - 10.1111/j.1755-3768.2010.02050.x IS - 4 KW - brimonidine compliance glaucoma medication adherence monitoring M3 - Article N1 - Cited By :21 Export Date: 19 July 2021 PY - 2011 SP - e300-e305 ST - Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring T2 - Acta Ophthalmologica TI - Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958173559&doi=10.1111%2fj.1755-3768.2010.02050.x&partnerID=40&md5=82e3134d8385f2bdbe9ce01c704ecf1d VL - 89 ID - 5134 ER - TY - JOUR AB - The success of many medical treatments is built on compliance. Electronic monitoring is the most accurate tool to quantify compliance by measuring adherence. In order to assess the efficiency of a recently introduced miniature monitoring device for eye drop application, we evaluated adherence in ophthalmic patients undergoing post-operative shortterm topical treatment. This pilot study enrolled 30 outpatients (mean age 61.8 ± 18.5 years) after cataract (n = 24) and glaucoma filtration surgery (n = 6) applying fixed-combination eye drops containing prednisolone and gentamicin five times daily for 2 weeks. Patients received eye drops in conventional bottles each equipped with a miniature monitoring device recording events of application. Two patients failed to bring back the monitoring device; therefore data collected from only 28 patients could be examined. Data showed highly variable results with a mean dose compliance of 50.2%. Dose compliance was below 25% in approximately one out of five patients. Four cataract patients, but no glaucoma patient, discontinued therapy prematurely. The observed mean dosage interval was calculated for each patient and ranged 4.6-19.7 h. Thirty percent of analysed dosage intervals exceeded 12.0 h. Different patterns of compliance behaviour-like early nonpersistence, drug holiday and low treatment frequency could be identified and illustrated using electronic data. Age or gender did not significantly influence compliance rates. Our pilot study demonstrates successful electronic compliance monitoring using a technology capable of continuous data recording over weeks of treatment. The low compliance rate for a relevant part of the patients demonstrates the necessity to study and improve compliance in ophthalmology. In future, new application methods and electronic application devices may improve treatment response in eye care. © Springer Science+Business Media B.V. 2010. AD - M. M. Hermann, University Eye Hospital, University of Cologne, 50924 Cologne, Germany AU - Hermann, M. M. AU - Stündag, C. U. AU - Diestelhorst, M. C1 - inflanegent(Allergan,United States) C2 - Allergan(United States) DB - Embase Medline DO - 10.1007/s10792-010-9362-3 IS - 4 KW - eye drops gentamicin inflanegent prednisolone unclassified drug adolescent adult aged article cataract cataract extraction clinical article devices drug withdrawal electronics eye care eye surgery female filtering operation glaucoma human information processing information technology male outpatient patient compliance patient monitoring pilot study postoperative care topical treatment treatment duration treatment response LA - English M3 - Article N1 - L50863393 2010-04-12 2010-09-24 PY - 2010 SN - 0165-5701 SP - 385-390 ST - Electronic compliance monitoring of topical treatment after ophthalmic surgery T2 - International Ophthalmology TI - Electronic compliance monitoring of topical treatment after ophthalmic surgery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50863393&from=export http://dx.doi.org/10.1007/s10792-010-9362-3 VL - 30 ID - 3294 ER - TY - GEN AB - Fixed combinations of medications that lower intraocular pressure (IOP) are increasingly used in the treatment of glaucoma and ocular hypertension and offer several potential advantages over combined use of the separate component medications including enhanced convenience, improved adherence, reduced exposure to preservatives, and possible cost savings. This review aims to examine the current role of IOP-lowering fixed combinations in disease management. The results of studies that compared the efficacy and safety of IOP-lowering fixed combinations with their component medications are summarized, including those fixed combinations that consist of a prostaglandin analog and timolol. The fixed combinations currently available for use in the United States are fixed-combination dorzolamide/timolol (FCDT) and fixed-combination brimonidine/timolol (FCBT). Both of these fixed combinations reduce IOP more effectively than their component medications used separately as monotherapy. FCBT therapy also demonstrates a more favorable safety profile and reduced ocular allergy compared to monotherapy with brimonidine, a component medication. Few studies have directly compared the efficacy and safety of FCDT and FCBT, but available evidence suggests that FCBT is at least as effective as FCDT in lowering IOP and is more comfortable and better tolerated. Additional studies are needed to further evaluate the comparative efficacy and tolerability of FCDT and FCBT in the management of glaucoma and ocular hypertension. © 2010 Higginbotham, publisher and licensee Dove Medical Press Ltd. AD - E. J. Higginbotham, Morehouse School of Medicine, 720 westview Drive Sw, Atlanta GA 30310-1495, United States AU - Higginbotham, E. J. C1 - combigan(Allergan) cosopt(Merck and Co) duotrav(Alcon) ganfort(Allergan) C2 - Alcon Allergan Merck and Co DB - Embase J2 - Clin. Ophthalmol. KW - bimatoprost bimatoprost plus timolol brimonidine brimonidine plus timolol dorzolamide dorzolamide plus timolol latanoprost latanoprost plus timolol pilocarpine timolol timolol plus travoprost travoprost allergic conjunctivitis blurred vision clinical trial comparative study conjunctival hyperemia conjunctivitis dosage schedule comparison dose response drug approval drug efficacy drug safety drug substitution drug tolerability drug withdrawal evening dosage eye allergy eye burning eye discomfort eye irritation eye pain glaucoma headache human intraocular hypertension intraocular pressure monotherapy morning dosage night vision patient care patient compliance punctate keratitis review side effect taste disorder treatment response combigan cosopt duotrav ganfort L1 - internal-pdf://3264626266/3254-Considerations in glaucoma therapy_-2010.pdf LA - English M1 - (Higginbotham E.J., ejhigginbotham@msm.edu) Morehouse School of Medicine, Atlanta GA, United States M3 - Review N1 - L358704319 2010-05-04 2010-05-26 PY - 2010 SN - 1177-5467 1177-5483 SP - 1-9 ST - Considerations in glaucoma therapy: Fixed combinations versus their component medications TI - Considerations in glaucoma therapy: Fixed combinations versus their component medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358704319&from=export VL - 4 ID - 3254 ER - TY - JOUR AB - Adjunctive therapy for the management of glaucoma is commonly used. Unfixed combinations of the prostaglandin analog latanoprost and other glaucoma medications have been demonstrated to effectively lower intraocular pressure (IOP). The range of reported additional reductions in IOP compared to a monotherapy baseline are as follows: latanoprost-timolol (13-37%), latanoprost-pilocarpine 2% (7-14%), latanoprost and carbonic anhydrase inhibitors (15-24.1%), and latanoprost and dipivefrin (15-28%). There is a fixed combination of latanoprost (0.005%) and timolol (0.5%) that has been investigated in Phase III trials in Europe and the United States. In these trials, it was noted that the efficacy of the fixed combination was superior to either of the monotherapy components. After 12 months of follow-up of patients on fixed combination, there was no evidence of long-term drift. The new formulation appears to be safe and does not demonstrate any more side effects than either of the components. The convenience of a fixed combination may enhance patient compliance. Unfixed combination therapy with latanoprost and other antiglaucoma medications and the fixed combination formulation of latanoprost and timolol provide an effective and safe option for lowering IOP in glaucoma patients. © 2002 by Elsevier Science Inc. All rights reserved. AD - E.J. Higginbotham, Department of Ophthalmology, Univ. of Maryland School of Medicine, 419 W. Redwood Street, Baltimore, MD 21201, United States AU - Higginbotham, E. J. AU - Diestelhorst, M. AU - Pfeiffer, N. AU - Rouland, J. F. AU - Alm, A. C2 - Pharmacia(United States) DB - Embase Medline DO - 10.1016/S0039-6257(02)00295-3 IS - 4 SUPPL. 1 KW - acetazolamide antiglaucoma agent apraclonidine beta adrenergic receptor blocking agent brimonidine carbonate dehydratase inhibitor dipivefrine dorzolamide latanoprost pilocarpine prostaglandin derivative timolol aqueous humor flow area under the curve cell density clinical trial conjunctiva disease cornea thickness drug absorption drug bioavailability drug blood level drug effect drug efficacy drug mechanism drug safety eye color eye irritation eyelash follow up geographic distribution glaucoma human hyperemia hypertrichosis intraocular pressure patient compliance priority journal macular edema review side effect treatment outcome visual field defect LA - English M3 - Review N1 - L35232227 2002-11-12 PY - 2002 SN - 0039-6257 SP - S133-S140 ST - The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications T2 - Survey of Ophthalmology TI - The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35232227&from=export http://dx.doi.org/10.1016/S0039-6257(02)00295-3 VL - 47 ID - 3858 ER - TY - JOUR AB - Adjunctive therapy for the management of glaucoma is commonly used. Unfixed combinations of the prostaglandin analog latanoprost and other glaucoma medications have been demonstrated to effectively lower intraocular pressure (IOP). The range of reported additional reductions in IOP compared to a monotherapy baseline are as follows: latanoprost-timolol (13-37%), latanoprost-pilocarpine 2% (7-14%), latanoprost and carbonic anhydrase inhibitors (15-24.1%), and latanoprost and dipivefrin (15-28%). There is a fixed combination of latanoprost (0.005%) and timolol (0.5%) that has been investigated in Phase III trials in Europe and the United States. In these trials, it was noted that the efficacy of the fixed combination was superior to either of the monotherapy components. After 12 months of follow-up of patients on fixed combination, there was no evidence of long-term drift. The new formulation appears to be safe and does not demonstrate any more side effects than either of the components. The convenience of a fixed combination may enhance patient compliance. Unfixed combination therapy with latanoprost and other antiglaucoma medications and the fixed combination formulation of latanoprost and timolol provide an effective and safe option for lowering IOP in glaucoma patients. © 2002 by Elsevier Science Inc. All rights reserved. AD - University of Maryland, School of Medicine, Baltimore, MD, United States University of Cologne, Cologne, Germany Mainz University, Mainz, Germany University of Lille, Lille, France Uppsala University, Uppsala, Sweden Department of Ophthalmology, University of Maryland, School of Medicine, 419 W. Redwood Street, Baltimore, MD 21201, United States AU - Higginbotham, E. J. AU - Diestelhorst, M. AU - Pfeiffer, N. AU - Rouland, J. F. AU - Alm, A. DB - Scopus DO - 10.1016/S0039-6257(02)00295-3 IS - 4 SUPPL. 1 KW - Glaucoma Intraocular pressure Latanoprost Prostaglandin analog Timolol M3 - Review N1 - Cited By :32 Export Date: 19 July 2021 PY - 2002 SP - S133-S140 ST - The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications T2 - Survey of Ophthalmology TI - The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036669663&doi=10.1016%2fS0039-6257%2802%2900295-3&partnerID=40&md5=a71c2be472b70aebc3c608e699e9aac3 VL - 47 ID - 5051 ER - TY - JOUR AB - Adjunctive therapy for the management of glaucoma is commonly used. Unfixed combinations of the prostaglandin analog latanoprost and other glaucoma medications have been demonstrated to effectively lower intraocular pressure (IOP). The range of reported additional reductions in IOP compared to a monotherapy baseline are as follows: latanoprost-timolol (13-37%), latanoprost-pilocarpine 2% (7-14%), latanoprost and carbonic anhydrase inhibitors (15-24.1%), and latanoprost and dipivefrin (15-28%). There is a fixed combination of latanoprost (0.005%) and timolol (0.5%) that has been investigated in Phase III trials in Europe and the United States. In these trials, it was noted that the efficacy of the fixed combination was superior to either of the monotherapy components. After 12 months of follow-up of patients on fixed combination, there was no evidence of long-term drift. The new formulation appears to be safe and does not demonstrate any more side effects than either of the components. The convenience of a fixed combination may enhance patient compliance. Unfixed combination therapy with latanoprost and other antiglaucoma medications and the fixed combination formulation of latanoprost and timolol provide an effective and safe option for lowering IOP in glaucoma patients. AN - WOS:000177337700016 AU - Higginbotham, E. J. AU - Diestelhorst, M. AU - Pfeiffer, N. AU - Rouland, J. F. AU - Alm, A. DA - AUG DO - 10.1016/S0039-6257(02)00295-3 PY - 2002 SN - 0039-6257 SP - S133-S140 ST - The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications T2 - SURVEY OF OPHTHALMOLOGY TI - The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications VL - 47 ID - 6058 ER - TY - JOUR AB - Objective: To determine if prescribing combination therapy versus two or three separate bottles results in greater persistence among patients with glaucoma. Methods: Using a retail pharmacy claims database, three glaucoma patient cohorts were defined and followed for 12 months (January 2004 through December 2004). Patients in cohort 1 had a prescription for a single fixed-combination therapy during the month of January 2004. Cohort 2 consisted of patients with prescriptions for a β-blocker and one other glaucoma product in the same month. Cohort 3 comprised patients with prescriptions filled for three different glaucoma therapies during the first month. A fixed-combination formulation may have been included in cohorts 2 and 3 as well, but was counted as a single bottle. Persistence rate, defined as the percentage of patients who did not discontinue their medication over the 12-month period, was calculated. Results: Cohort 1 (one bottle; n = 14 742) was more persistent than cohort 2 (two bottles; n = 18 411), with 35.3% vs. 27.2% of patients remaining on therapy at the end of the study period (p < 0.0001). Cohort 3 (n = 4826), with three separate bottles per patient, had the lowest percentage remaining on therapy (23.9%; p < 0.0001). Conclusion: Analyses of pharmacy database data are limited by the possibilities of misidentifying newly treated patients or misclassifying added versus switched medications. As the number of separate products used for glaucoma therapy increases, patient persistence decreases. A management regimen requiring as few products as possible may enhance glaucoma patient persistence. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Higginbotham, Eve J., Emory School of Medicine, 720 Westview Dr SW, Atlanta, GA, US, 30310-1458 AN - 2010-11988-023 AU - Higginbotham, Eve J. AU - Hansen, Jan AU - Davis, Elizabeth J. AU - Walt, John G. AU - Guckian, Angela DB - psyh DO - 10.1185/03007990903260129 DP - EBSCOhost IS - 10 KW - glaucoma medication combination drug therapy glaucoma patient compliance Adolescent Adult Aged Aged, 80 and over Child Child, Preschool Cohort Studies Drug Combinations Drug Therapy, Combination Female Glaucoma Humans Infant Male Middle Aged Young Adult Drug Therapy Treatment Compliance Cohort Analysis Drug Administration Methods N1 - Morehouse School of Medicine, Atlanta, GA, US. Other Publishers: LibraPharm; Taylor & Francis. Release Date: 20101206. Correction Date: 20150921. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishConference Information: Annual meeting of the American Glaucoma Society, Mar, 2007, San Francisco, CA, US. Conference Note: Preliminary reports of this study were presented at the aforementioned conference and at the 8th annual meeting of the European Glaucoma Society, June 1–6, 2008, Berlin, Germany; and at the World Ophthalmology Congress, June 28 – July 2, 2008, Hong Kong, China. Major Descriptor: Drug Therapy; Glaucoma; Treatment Compliance. Minor Descriptor: Cohort Analysis; Drug Administration Methods. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Childhood (birth-12 yrs) (100); Infancy (2-23 mo) (140); Preschool Age (2-5 yrs) (160); School Age (6-12 yrs) (180); Adolescence (13-17 yrs) (200); Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 5. Issue Publication Date: Oct, 2009. Publication History: First Posted Date: Sep 4, 2009; Accepted Date: Aug 14, 2009. Copyright Statement: Informa UK Ltd. 2009. Sponsor: Allergan, Inc., US. Recipients: No recipient indicated PY - 2009 SN - 0300-7995 1473-4877 SP - 2543-2547 ST - Glaucoma medication persistence with a fixed combination versus multiple bottles T2 - Current Medical Research and Opinion TI - Glaucoma medication persistence with a fixed combination versus multiple bottles UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-11988-023&site=ehost-live&scope=site Fcweijh6786@aol.com VL - 25 ID - 4869 ER - TY - JOUR AB - Background: Contact lens related keratitis is a frequent presentation to acute ophthalmology services. Patients often do not recall being counselled regarding the safe use of contact lenses therefore fail to comply with guidance. This study aimed to identify the content and format of advice given to patients with contact lens keratitis concerning appropriate hygiene practices, determine their compliance with this and finally characterise optometrist practices regarding contact lens advice provided to patients. Methods: All adult patients presenting with contact lens related keratitis to the acute ophthalmology clinic were asked to complete a survey. Information was collected on lens type, format of advice received and compliance. Community optometrists were asked to complete an electronic survey on their contact lens review practices and routine patient education. Results: All patients surveyed recalled counselling on initiation of contact lenses; however 12% (6/50) were given no advice on return visits. This advice was in written format for 20% (10/50) of patients on initiation increasing to 32% (16/50) on renewal. Many patients slept (22%), showered (44%) or swam (36%) in lenses. 92% cleaned their contact lenses appropriately, but cases were washed infrequently (19% of cases cleaned < monthly) or with tap water (27%). All optometrists surveyed claimed to provide advice to patients in either written or verbal format for new and returning contact lens users. 49% (16/33) of optometrists gave written advice to patients on initial contact lens fitting, but only 1/33 continued with written advice for repeat customers. Conclusion: This study identified that although most patients were informed of appropriate hygiene requirements, compliance was poor. Optometrists regularly provide verbal advice but do not routinely offer written support and there is a mismatch between patient recollection and self-reported optometrist practice. It is suggested that patient education needs greater emphasis and both verbal and written information should be regularly provided on initial review and follow up assessments. AD - J. Hind, Tennent Institute of Ophthalmology, Gartnavel General Hospital, 1053 Great Western Road, Glasgow, United Kingdom AU - Hind, J. AU - Williams, O. AU - Oladiwura, D. AU - Macdonald, E. DB - Embase Medline DO - 10.1016/j.clae.2019.07.006 IS - 2 KW - bath contact lens tap water adult article cleaning counseling experience female human hygiene keratitis major clinical study male optometrist patient compliance patient education priority journal Scotland sleep swimming university hospital LA - English M3 - Article N1 - L2002325786 2019-07-24 2020-03-26 PY - 2020 SN - 1476-5411 1367-0484 SP - 185-188 ST - The differences between patient and optometrist experiences of contact lens hygiene education from the perspective of a Scottish university teaching hospital T2 - Contact Lens and Anterior Eye TI - The differences between patient and optometrist experiences of contact lens hygiene education from the perspective of a Scottish university teaching hospital UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2002325786&from=export http://dx.doi.org/10.1016/j.clae.2019.07.006 VL - 43 ID - 2414 ER - TY - JOUR AB - Background: Contact lens related keratitis is a frequent presentation to acute ophthalmology services. Patients often do not recall being counselled regarding the safe use of contact lenses therefore fail to comply with guidance. This study aimed to identify the content and format of advice given to patients with contact lens keratitis concerning appropriate hygiene practices, determine their compliance with this and finally characterise optometrist practices regarding contact lens advice provided to patients.Methods: All adult patients presenting with contact lens related keratitis to the acute ophthalmology clinic were asked to complete a survey. Information was collected on lens type, format of advice received and compliance. Community optometrists were asked to complete an electronic survey on their contact lens review practices and routine patient education.Results: All patients surveyed recalled counselling on initiation of contact lenses; however 12% (6/50) were given no advice on return visits. This advice was in written format for 20% (10/50) of patients on initiation increasing to 32% (16/50) on renewal. Many patients slept (22%), showered (44%) or swam (36%) in lenses. 92% cleaned their contact lenses appropriately, but cases were washed infrequently (19% of cases cleaned < monthly) or with tap water (27%). All optometrists surveyed claimed to provide advice to patients in either written or verbal format for new and returning contact lens users. 49% (16/33) of optometrists gave written advice to patients on initial contact lens fitting, but only 1/33 continued with written advice for repeat customers.Conclusion: This study identified that although most patients were informed of appropriate hygiene requirements, compliance was poor. Optometrists regularly provide verbal advice but do not routinely offer written support and there is a mismatch between patient recollection and self-reported optometrist practice. It is suggested that patient education needs greater emphasis and both verbal and written information should be regularly provided on initial review and follow up assessments. AD - Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK AN - 142228934. Language: English. Entry Date: 20210712. Revision Date: 20210716. Publication Type: journal article AU - Hind, Jennifer AU - Williams, Olayinka AU - Oladiwura, Dilys AU - Macdonald, Elisabeth DB - ccm DO - 10.1016/j.clae.2019.07.006 DP - EBSCOhost IS - 2 KW - Education, Medical Academic Medical Centers Contact Lenses Self Report Hygiene -- Education Patient Compliance Prospective Studies Human Scotland Comparative Studies Multicenter Studies Evaluation Research Validation Studies N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 9712714. PMID: NLM31327578. PY - 2020 SN - 1367-0484 SP - 185-188 ST - The differences between patient and optometrist experiences of contact lens hygiene education from the perspective of a Scottish university teaching hospital T2 - Contact Lens & Anterior Eye TI - The differences between patient and optometrist experiences of contact lens hygiene education from the perspective of a Scottish university teaching hospital UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142228934&site=ehost-live&scope=site VL - 43 ID - 4216 ER - TY - JOUR AB - Background: Contact lens related keratitis is a frequent presentation to acute ophthalmology services. Patients often do not recall being counselled regarding the safe use of contact lenses therefore fail to comply with guidance. This study aimed to identify the content and format of advice given to patients with contact lens keratitis concerning appropriate hygiene practices, determine their compliance with this and finally characterise optometrist practices regarding contact lens advice provided to patients. Methods: All adult patients presenting with contact lens related keratitis to the acute ophthalmology clinic were asked to complete a survey. Information was collected on lens type, format of advice received and compliance. Community optometrists were asked to complete an electronic survey on their contact lens review practices and routine patient education. Results: All patients surveyed recalled counselling on initiation of contact lenses; however 12% (6/50) were given no advice on return visits. This advice was in written format for 20% (10/50) of patients on initiation increasing to 32% (16/50) on renewal. Many patients slept (22%), showered (44%) or swam (36%) in lenses. 92% cleaned their contact lenses appropriately, but cases were washed infrequently (19% of cases cleaned < monthly) or with tap water (27%). All optometrists surveyed claimed to provide advice to patients in either written or verbal format for new and returning contact lens users. 49% (16/33) of optometrists gave written advice to patients on initial contact lens fitting, but only 1/33 continued with written advice for repeat customers. Conclusion: This study identified that although most patients were informed of appropriate hygiene requirements, compliance was poor. Optometrists regularly provide verbal advice but do not routinely offer written support and there is a mismatch between patient recollection and self-reported optometrist practice. It is suggested that patient education needs greater emphasis and both verbal and written information should be regularly provided on initial review and follow up assessments. © 2019 British Contact Lens Association AD - Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, United Kingdom AU - Hind, J. AU - Williams, O. AU - Oladiwura, D. AU - Macdonald, E. DB - Scopus DO - 10.1016/j.clae.2019.07.006 IS - 2 KW - Compliance Contact lens Hygiene Patient education M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2020 SP - 185-188 ST - The differences between patient and optometrist experiences of contact lens hygiene education from the perspective of a Scottish university teaching hospital T2 - Contact Lens and Anterior Eye TI - The differences between patient and optometrist experiences of contact lens hygiene education from the perspective of a Scottish university teaching hospital UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069599051&doi=10.1016%2fj.clae.2019.07.006&partnerID=40&md5=4116de1bf628a6d06d3799b5fbf1bbc9 VL - 43 ID - 5495 ER - TY - JOUR AB - Background: Contact lens related keratitis is a frequent presentation to acute ophthalmology services. Patients often do not recall being counselled regarding the safe use of contact lenses therefore fail to comply with guidance. This study aimed to identify the content and format of advice given to patients with contact lens keratitis concerning appropriate hygiene practices, determine their compliance with this and finally characterise optometrist practices regarding contact lens advice provided to patients. Methods: All adult patients presenting with contact lens related keratitis to the acute ophthalmology clinic were asked to complete a survey. Information was collected on lens type, format of advice received and compliance. Community optometrists were asked to complete an electronic survey on their contact lens review practices and routine patient education. Results: All patients surveyed recalled counselling on initiation of contact lenses; however 12% (6/50) were given no advice on return visits. This advice was in written format for 20% (10/50) of patients on initiation increasing to 32% (16/50) on renewal. Many patients slept (22%), showered (44%) or swam (36%) in lenses. 92% cleaned their contact lenses appropriately, but cases were washed infrequently (19% of cases cleaned < monthly) or with tap water (27%). All optometrists surveyed claimed to provide advice to patients in either written or verbal format for new and returning contact lens users. 49% (16/33) of optometrists gave written advice to patients on initial contact lens fitting, but only 1/33 continued with written advice for repeat customers. Conclusion: This study identified that although most patients were informed of appropriate hygiene requirements, compliance was poor. Optometrists regularly provide verbal advice but do not routinely offer written support and there is a mismatch between patient recollection and self-reported optometrist practice. It is suggested that patient education needs greater emphasis and both verbal and written information should be regularly provided on initial review and follow up assessments. AN - WOS:000520027500016 AU - Hind, J. AU - Williams, O. AU - Oladiwura, D. AU - Macdonald, E. DA - APR DO - 10.1016/j.clae.2019.07.006 IS - 2 PY - 2020 SN - 1367-0484 1476-5411 SP - 185-188 ST - The differences between patient and optometrist experiences of contact lens hygiene education from the perspective of a Scottish university teaching hospital T2 - CONTACT LENS & ANTERIOR EYE TI - The differences between patient and optometrist experiences of contact lens hygiene education from the perspective of a Scottish university teaching hospital VL - 43 ID - 6234 ER - TY - JOUR AB - Recurrent isolated sleep paralysis can be very disturbing and provoke anxiety. The majority of patients can be treated conservatively with cognitive and behavioural therapies. However, some patients may benefit from a pharmacologic intervention. With only scant available evidence, there are currently no standardized pharmacologic treatment recommendations for recurrent isolated sleep paralysis. We report the first two cases of escitalopram used to successfully treat recurrent isolated sleep paralysis. Escitalopram, the most selective of the selective serotonin reuptake inhibitors, generally improves subjective sleep quality, making it an appealing treatment option. © 2020 European Sleep Research Society AD - Division of Pediatric Sleep Medicine, University of South Carolina, Prisma Health, Greenville, SC, United States AU - Hintze, J. P. AU - Gault, D. C7 - e13027 DB - Scopus DO - 10.1111/jsr.13027 IS - 6 KW - antidepressant hallucinations hypnagogic hypnopompic M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 ST - Escitalopram for recurrent isolated sleep paralysis T2 - Journal of Sleep Research TI - Escitalopram for recurrent isolated sleep paralysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080144911&doi=10.1111%2fjsr.13027&partnerID=40&md5=6af44239e360869fac4c3aa14a3bc092 VL - 29 ID - 5687 ER - TY - JOUR AB - Précis:To assess the after-visit summary (AVS) as a tool for glaucoma medication recall. Medication recall was associated with level of education and complexity of medication regimen. Receiving an AVS was not associated with better medication recall.Purpose:The purpose of this study was to determine whether patients given the AVS have better or worse glaucoma medication recall.Materials and Methods:Observational clinical study. Adults on =1 glaucoma medications examined between June 30, 2017 and August 2, 2017. Data collection: in-person questionnaire and retrospective chart review. Self-reported glaucoma medications compared with prescribed glaucoma medication regimen verified by electronic medical record. Medication recall assessed using 3-point scoring: 1 point each for; (1) name or color of bottle or cap; (2) treatment eye(s); and (3) dosing regimen. Data analysis: 2-sample Welch t test, 2-proportion z-test, analysis of variance, univariate, and multivariate regression.Results:A total of 118 patients enrolled: age 69.7±12.9 years (mean±SD), 55.9% of patients had received an AVS at the previous visit. Of these, 33.3% reported receiving an AVS, 51.2% reported not receiving one (15.1% did not recall or respond). Patients who had received AVSs had lower medication recall scores than those who did not (2.4±1.0 vs. 2.7±0.6, P=0.04). Receipt of an AVS was associated with having Nisha Chadha as their provider (P=0.01), fewer days since prior visit (P=0.0001), and medication regimen change at prior visit (P<0.0001). Multivariate analysis revealed completion of associate's degree or higher and fewer prescribed medications to be independent predictors of higher recall score (P=0.0002 and 0.002).Conclusions:AVSs were conceived to enhance patient care. This study indicates this goal is not achieved consistently. Less education and more complex medication regimens were identified as barriers to medication recall. Additional investigations should explore if modifying this document and enhanced explanation of its use will impact medication recall and health outcomes. © 2020 Lippincott Williams and Wilkins. All rights reserved. AD - School of Medicine and Health Sciences, George Washington University, Washington, DC, United States College of Medicine, SUNY Upstate Medical University, Syracuse, United States Icahn School of Medicine at Mount Sinai, New York, NY, United States AU - Hirabayashi, K. J. AU - Pomerantz, M. AU - Radell, J. E. AU - Chadha, N. AU - Thomas, S. AU - Serle, J. B. DB - Scopus DO - 10.1097/IJG.0000000000001518 IS - 7 KW - after-visit summary (AVS) barrier compliance glaucoma glaucoma medication medication recall M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 529-535 ST - The efficacy of the after-visit summary in medication recall among glaucoma patients T2 - Journal of Glaucoma TI - The efficacy of the after-visit summary in medication recall among glaucoma patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087528695&doi=10.1097%2fIJG.0000000000001518&partnerID=40&md5=1cd0b4d4be1a0cf8315466c69ef3d55c VL - 29 ID - 5697 ER - TY - JOUR AB - Precis: To assess the after-visit summary (AVS) as a tool for glaucoma medication recall. Medication recall was associated with level of education and complexity of medication regimen. Receiving an AVS was not associated with better medication recall. Purpose: The purpose of this study was to determine whether patients given the AVS have better or worse glaucoma medication recall. Materials and Methods: Observational clinical study. Adults on >= 1 glaucoma medications examined between June 30, 2017 and August 2, 2017. Data collection: in-person questionnaire and retrospective chart review. Self-reported glaucoma medications compared with prescribed glaucoma medication regimen verified by electronic medical record. Medication recall assessed using 3-point scoring: 1 point each for; (1) name or color of bottle or cap; (2) treatment eye(s); and (3) dosing regimen. Data analysis: 2-sample Welchttest, 2-proportionz-test, analysis of variance, univariate, and multivariate regression. Results: A total of 118 patients enrolled: age 69.7 +/- 12.9 years (mean +/- SD), 55.9% of patients had received an AVS at the previous visit. Of these, 33.3% reported receiving an AVS, 51.2% reported not receiving one (15.1% did not recall or respond). Patients who had received AVSs had lower medication recall scores than those who did not (2.4 +/- 1.0 vs. 2.7 +/- 0.6,P=0.04). Receipt of an AVS was associated with having Nisha Chadha as their provider (P=0.01), fewer days since prior visit (P=0.0001), and medication regimen change at prior visit (P<0.0001). Multivariate analysis revealed completion of associate's degree or higher and fewer prescribed medications to be independent predictors of higher recall score (P=0.0002 and 0.002). Conclusions: AVSs were conceived to enhance patient care. This study indicates this goal is not achieved consistently. Less education and more complex medication regimens were identified as barriers to medication recall. Additional investigations should explore if modifying this document and enhanced explanation of its use will impact medication recall and health outcomes. AN - WOS:000559090500013 AU - Hirabayashi, K. J. AU - Pomerantz, M. AU - Radell, J. E. AU - Chadha, N. AU - Thomas, S. AU - Serle, J. B. DA - JUL DO - 10.1097/IJG.0000000000001518 IS - 7 PY - 2020 SN - 1057-0829 1536-481X SP - 529-535 ST - The Efficacy of the After-visit Summary in Medication Recall Among Glaucoma Patients T2 - JOURNAL OF GLAUCOMA TI - The Efficacy of the After-visit Summary in Medication Recall Among Glaucoma Patients VL - 29 ID - 6006 ER - TY - JOUR AB - BACKGROUND: Health care systems are continually being reformed, however care improvement and intervention effectiveness are often assumed, not measured. This paper aimed to review findings from published studies about the appropriateness of eye care delivery, using existing published evidence and/or experts' practice and to describe the methods used to measure appropriateness of eye care. METHODS: A systematic search was conducted using Medline, Embase and CINAHL (2006 to September 2016). Studies reporting the processes of eye care delivery against existing published evidence and/or experts' practice were selected. Data was extracted from published reports and the methodological quality using a modified critical appraisal tool. The primary outcomes were percentage of appropriateness of eye care delivery. This study was registered with PROSPERO, reference CRD42016049974. RESULTS: Fifty-seven studies were included. Most studies assessed glaucoma and diabetic retinopathy and the overall methodological quality for most studies was moderate. The ranges of appropriateness of care delivery were 2-100% for glaucoma, 0-100% for diabetic retinopathy and 0-100% for other miscellaneous conditions. Published studies assessed a single ocular condition, a sample from a single centre or a single domain of care, but no study has attempted to measure the overall appropriateness of eye care delivery. CONCLUSIONS: These findings indicated a wide range of appropriateness of eye care delivery, for glaucoma and diabetic eye care. Future research would benefit from a comprehensive approach where appropriateness of eye care is measured across multiple conditions with a single methodology, to guide priorities within eye care delivery and monitor quality improvement initiatives. AU - Ho, K. C. AU - Stapleton, F. AU - Wiles, L. AU - Hibbert, P. AU - Alkhawajah, S. AU - White, A. AU - Jalbert, I. DB - Medline DO - 10.1186/s12913-019-4493-3 IS - 1 KW - ambulatory care eye disease female health care delivery health care quality human male meta analysis program evaluation LA - English M3 - Article N1 - L629245214 2019-09-12 2020-01-06 PY - 2019 SN - 1472-6963 SP - 646 ST - Systematic review of the appropriateness of eye care delivery in eye care practice T2 - BMC health services research TI - Systematic review of the appropriateness of eye care delivery in eye care practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629245214&from=export http://dx.doi.org/10.1186/s12913-019-4493-3 VL - 19 ID - 2478 ER - TY - JOUR AB - Background: Health care systems are continually being reformed, however care improvement and intervention effectiveness are often assumed, not measured. This paper aimed to review findings from published studies about the appropriateness of eye care delivery, using existing published evidence and/or experts' practice and to describe the methods used to measure appropriateness of eye care.Methods: A systematic search was conducted using Medline, Embase and CINAHL (2006 to September 2016). Studies reporting the processes of eye care delivery against existing published evidence and/or experts' practice were selected. Data was extracted from published reports and the methodological quality using a modified critical appraisal tool. The primary outcomes were percentage of appropriateness of eye care delivery. This study was registered with PROSPERO, reference CRD42016049974.Results: Fifty-seven studies were included. Most studies assessed glaucoma and diabetic retinopathy and the overall methodological quality for most studies was moderate. The ranges of appropriateness of care delivery were 2-100% for glaucoma, 0-100% for diabetic retinopathy and 0-100% for other miscellaneous conditions. Published studies assessed a single ocular condition, a sample from a single centre or a single domain of care, but no study has attempted to measure the overall appropriateness of eye care delivery.Conclusions: These findings indicated a wide range of appropriateness of eye care delivery, for glaucoma and diabetic eye care. Future research would benefit from a comprehensive approach where appropriateness of eye care is measured across multiple conditions with a single methodology, to guide priorities within eye care delivery and monitor quality improvement initiatives. AD - School of Optometry and Vision Science, UNSW Sydney, 2052, Sydney, NSW, Australia Eye Health, Injury Division, The George Institute for Global Health, Sydney, Australia Faculty of Medicine and Health Sciences, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia Centre for Population Health Research, School of Health Sciences, University of South Australia, Adelaide, South Australia, Australia Optometry and Vision Science Department, King Saud University, Riyadh, Saudi Arabia Save Sight Institute, University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia AN - 138477821. Language: English. Entry Date: In Process. Revision Date: 20200320. Publication Type: journal article AU - Ho, Kam Chun AU - Stapleton, Fiona AU - Wiles, Louise AU - Hibbert, Peter AU - Alkhawajah, Sally AU - White, Andrew AU - Jalbert, Isabelle DB - ccm DO - 10.1186/s12913-019-4493-3 DP - EBSCOhost IS - 1 KW - Quality of Health Care Eye Diseases -- Therapy Health Care Delivery -- Standards Office Visits -- Statistics and Numerical Data Health Care Delivery -- Statistics and Numerical Data Female Male Human Program Evaluation Meta Analysis Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - meta analysis; research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. Instrumentation: Wide Range Achievement Test (WRAT). Grant Information: Faculty of Science Research Program Grant//University of New South Wales/. NLM UID: 101088677. PMID: NLM31492128. PY - 2019 SN - 1472-6963 SP - N.PAG-N.PAG ST - Systematic review of the appropriateness of eye care delivery in eye care practice T2 - BMC Health Services Research TI - Systematic review of the appropriateness of eye care delivery in eye care practice UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138477821&site=ehost-live&scope=site VL - 19 ID - 4454 ER - TY - JOUR AB - Purpose To meet the needs of an ageing population and optimise health expenditure, delivery of care should be based on evidence. However, the level of evidence-based care delivered to patients with eye conditions is rarely assessed. This study thus aimed to determine the percentage of eyecare encounters at which a sample of adult Australians received appropriate care (i.e., eyecare in line with evidence-based or consensus-based guidelines). Methods A cross-sectional retrospective review of optometry practice records was conducted using random stratified (by state) sampling in mainland Australia. Eighty-five clinical indicators were developed from evidence-based clinical practice guideline recommendations and refined by panels of experts using a modified Delphi process. Healthcare records of patients 18 years and over were examined against these indicators, representing appropriate care for three common eye conditions (preventative eyecare, glaucoma, and diabetic eyecare). Encounters occurred in optometry practices that were selected to be representative of the socioeconomic profile of Australian practices. The primary outcome measure was percentage compliance of eyecare delivery against the clinical indicators. Results From 426 optometry practices contacted by mail or telephone, 90 (21%) replied, 46 proved eligible and 42 were included in the study and visited for data collection. From these 1260 patient records were reviewed. Appropriate eyecare was received by Australian patients at an average of 71% (95%CI 70%, 73%) of eligible encounters. The percentage of appropriateness of eyecare at the condition level for preventative, glaucoma and diabetic eyecare was 81% (95%CI 79%, 83%), 63% (95%CI 61%, 64%), and 69% (95%CI 66%, 73%), respectively. Appropriateness of eyecare delivery was lowest for the domains of history taking and physical examination for all eye conditions. Conclusions There were pockets of excellence but consistent delivery of appropriate eyecare needs improvement, and gaps in eyecare delivery should be addressed. AN - WOS:000537326400001 AU - Ho, K. C. AU - Stapleton, F. AU - Wiles, L. AU - Hibbert, P. AU - White, A. AU - Jalbert, I. DA - JUL DO - 10.1111/opo.12699 IS - 4 PY - 2020 SN - 0275-5408 1475-1313 SP - 433-441 ST - iCareTrack: measuring the appropriateness of eyecare delivery in Australia T2 - OPHTHALMIC AND PHYSIOLOGICAL OPTICS TI - iCareTrack: measuring the appropriateness of eyecare delivery in Australia VL - 40 ID - 6314 ER - TY - JOUR AB - Purpose: To identify specific items on knowledge and need for information that could be used to improve compliance with glaucoma medication. Methods: Forty-four randomly selected ophthalmologists assigned 166 consecutive glaucoma patients to complete a questionnaire. The questionnaire was developed systematically based on focus group interviews, consultation of experts and a pilot test. Items included knowledge about glaucoma and its treatment, need for information and compliance with therapy. Results: No statistically significant correlation was found between the total level of knowledge and compliance. Concerning knowledge of glaucoma, one out of 19 items had a statistically significant negative correlation with compliance. Concerning knowledge of glaucoma treatment, one out of 18 items had a statistically significant positive correlation with compliance. Regarding total need for information, no statistically significant correlation with compliance was found. Three out of 22 items had a statistically significant positive correlation with compliance. Conclusion: Given the number of related items, their direction and limited strength of correlation and the difficulty of hypothesizing a causal relation for some items, it is unlikely that further improving knowledge will greatly improve compliance with glaucoma medication. Interventions focused on attitude and discipline may be of more benefit in improving compliance with therapy. © 2008 The Authors. AD - J. S. A. G. Schouten, Department of Ophthalmology, Maastricht University Hospital, Postbus 5800, 6202 AZ Maastricht, Netherlands AU - Hoevenaars, J. G. M. M. AU - Schouten, J. S. A. G. AU - Van Den Borne, B. AU - Beckers, H. J. M. AU - Webers, C. A. B. DB - Embase Medline DO - 10.1111/j.1755-3768.2007.01161.x IS - 8 KW - antiglaucoma agent article controlled study glaucoma health behavior health survey human major clinical study medical information patient attitude patient compliance priority journal questionnaire LA - English M3 - Article N1 - L352809585 2009-01-10 PY - 2008 SN - 1755-375X SP - 849-855 ST - Will improvement of knowledge lead to improvement of compliance with glaucoma medication? T2 - Acta Ophthalmologica TI - Will improvement of knowledge lead to improvement of compliance with glaucoma medication? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352809585&from=export http://dx.doi.org/10.1111/j.1755-3768.2007.01161.x VL - 86 ID - 3406 ER - TY - JOUR AB - Purpose To determine the prevalence of follow-up and factors associated with completing an eye examination after a glaucoma public service announcement. Design Cross-sectional observational study. Participants Individuals who participated in the Glaucoma EyeCare Program by calling a toll-free telephone number and receiving referral by meeting inclusion criteria. Methods The Glaucoma EyeCare Program uses public service announcements to encourage those at increased risk for glaucoma to obtain an eye examination. The program requires interested persons to dial a toll-free telephone number to collect demographic, medical, and socioeconomic information, and refers those at higher risk of glaucoma to an ophthalmologist for a free eye examination. The ophthalmologist completes an outcome form, which indicates whether the participant obtained an eye examination and the results of this eye examination. We determined the factors associated with obtaining an eye examination. Main Outcome Measures Sociodemographic characteristics associated with obtaining an eye examination after referral through the Glaucoma EyeCare Program. Results Ophthalmologists returned outcome forms for 1514 of 6343 participants (24%). Of those with outcome forms, 671 (44.3%) had an eye examination, 756 (49.9%) did not make an appointment, and 87 (5.7%) made an appointment but did not complete the examination. A multivariate logistic regression model showed younger age, female gender, lack of health insurance, medical history of diabetes, and shorter distance to be associated with obtaining an eye examination. Conclusions Public service announcements encourage participants to have an eye examination. Multiple factors alter the success of obtaining an eye examination. Future studies are needed regarding the best method of decreasing the risk of undiagnosed glaucoma. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2011 American Academy of Ophthalmology. AD - Devers Eye Institute/Discoveries in Sight, Legacy Health System, Portland, OR, United States H. Dunbar Hoskins Jr. MD Ctr. for Qual. Eye Care and EyeCare Amer, Found. of the Amer. Acad. of Ophthalmol., San Francisco, CA, United States AU - Hoffelt, Z. AU - Fallon, S. AU - Wong, B. A. AU - Lucas, B. AU - Coleman, A. L. AU - Mills, R. P. AU - Wilson, R. AU - Mansberger, S. L. DB - Scopus DO - 10.1016/j.ophtha.2010.12.013 IS - 7 M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2011 SP - 1327-1333 ST - Glaucoma public service announcements: Factors associated with follow-up of participants with risk factors for glaucoma T2 - Ophthalmology TI - Glaucoma public service announcements: Factors associated with follow-up of participants with risk factors for glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960022895&doi=10.1016%2fj.ophtha.2010.12.013&partnerID=40&md5=7cc1a2b2469e5632f80a9867da88f21c VL - 118 ID - 5286 ER - TY - JOUR AB - PURPOSE: To review issues related to the diagnosis, examination, and treatment of children with uveitis that are important for ophthalmologists. DESIGN: Literature review. METHODS: A review was made of pertinent reports from the medical literature, with commentary based on the authors' experiences and on discussions at an international workshop. RESULTS: There are differences between children and adults in the differential diagnosis and manifestations of uveitis that should be considered during evaluation. There may be a higher risk of some ocular complications such as uveitic glaucoma, and the presence of other unique complications, such as amblyopia, in young patients during follow-up. With regard to treatment, children with uveitis may have unique dosing requirements and drug-associated risks such as growth retardation with systemic corticosteroids that must be considered. Examination and treatment may also be more difficult with children because of problems with patient cooperation. CONCLUSIONS: There are unique patient care issues associated with uveitis in children that must be considered by care providers. Attention to these issues will improve the well-being of this patient population. © 2003 by Elsevier Inc. All rights reserved. AD - Ocular Inflammatory Disease Center, Jules Stein Eye Institute, Los Angeles, CA, United States Department of Ophthalmology, Univ. of California, Los Angeles, Los Angeles, CA, United States Department of Pediatrics, David Geffen Sch. of Med. at UCLA, Univ. of California, Los Angeles, Los Angeles, CA, United States Jules Stein Eye Institute, UCLA, 100 Stein Plaza, Los Angeles, CA 90095-7003, United States AU - Holland, G. N. AU - Stiehm, E. R. DB - Scopus DO - 10.1016/S0002-9394(03)00314-3 IS - 6 M3 - Review N1 - Cited By :86 Export Date: 19 July 2021 PY - 2003 SP - 867-878 ST - Special considerations in the evaluation and management of uveitis in children T2 - American Journal of Ophthalmology TI - Special considerations in the evaluation and management of uveitis in children UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038619094&doi=10.1016%2fS0002-9394%2803%2900314-3&partnerID=40&md5=5281c977df3b47593ce4e9e2dbe924a6 VL - 135 ID - 4942 ER - TY - JOUR AB - Neovascular glaucoma develops from intraocular neovascularisation in diabetes mellitus. Neovascularisation is a consequence of hypoxia-induced production of vascular endothelial growth factor-A. Neovascular glaucoma is one of the most serious, sight-threatening late complications of diabetes. Several intraocular pressure lowering drugs, surgical and adjunctive laser treatments have been used to treat this disease, but the efficacy of the interventions is limited. The role of vascular endothelial growth factor-A blocking therapy in the treatment of neovascular glaucoma remains to be determined. Development of neovascularisation, however, can be prevented with adequate long-term glycemic and lipid control, effective treatment of arterial hypertension and optimal timing of adequate panretinal photocoagulation, in the majority of the cases. Unfortunately, in clinical practice diabetic neovascular glaucoma is more frequently experienced in Hungary than would be expected based on the variety of available therapeutic possibilities. In order to increase the success of prevention both cooperation of general practitioners, diabetologists, dietitians and ophthalmologists, and compliance of diabetic patients need to be improved. AD - G. Holló, Tömo u. 25-29, Budapest, 1083, Hungary AU - Holló, G. DB - Embase Medline DO - 10.1556/OH.2011.29042 IS - 29 KW - vasculotropin A article diabetes mellitus human Hungary hypertension laser coagulation neovascular glaucoma neovascularization (pathology) patient compliance LA - Hungarian M3 - Article N1 - L362069467 2011-07-13 2011-07-14 PY - 2011 SN - 0030-6002 1788-6120 SP - 1167-1170 ST - Diabetic neovascularisation and secondary glaucoma T2 - Orvosi Hetilap TI - Diabetic neovascularisation and secondary glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362069467&from=export http://dx.doi.org/10.1556/OH.2011.29042 VL - 152 ID - 3161 ER - TY - JOUR AB - Introduction: The preservative-free (PF) fixed combination (FC) of tafluprost 0.0015%/timolol 0.5% is the newest member of the prostaglandin analogue/timolol FC class.Areas covered: In this review, we summarize data on safety and tolerability of this FC.Expert opinion: The intraocular pressure-lowering effect of the tafluprost/timolol FC is approximately 30-35%, which is similar to that of the other members of the class. However, in contrast to most similar eye drops the tafluprost/timolol FC is manufactured in a PF, unit-dose pipette formulation. The PF nature eliminates preservative-related ocular surface changes, and improves tolerability. In clinical studies, the tafluprost/timolol FC was well tolerated. The side effects represented the typical side effects of the topical prostaglandin analogue class. The most common side effect, conjunctival hyperemia was mild, and occurred in only 6.4-8% of patients during 6 months of treatment. The figures for ocular irritation were also low (7.0-12.7%). The other side effects occurred only in very few patients. The frequency and severity of conjunctival hyperemia was lower than those published for most prostaglandin/timolol FCs. Thus, the main clinical advantage of this PF FC is improved tolerability, which may support treatment adherence of glaucoma patients. AD - G. Holló, Semmelweis University, Department of Ophthalmology, Mária u. 39, 1085 Budapest, Hungary AU - Holló, G. AU - Katsanos, A. DB - Embase Medline DO - 10.1517/14740338.2015.1010507 IS - 4 KW - antiglaucoma agent drug preservative prostaglandin derivative tafluprost tafluprost plus timolol timolol unclassified drug article asthma blepharitis bradycardia clinical feature clinical trial (topic) comparative effectiveness conjunctival hyperemia disease severity dizziness drug efficacy drug formulation drug induced headache drug manufacture drug safety drug tolerability eye injury eye irritation eye pain faintness falling glaucoma heart block heart failure herpes simplex keratitis human intraocular hypertension intraocular pressure medication compliance monotherapy multicenter study (topic) ocular pruritus ocular surface disease orthostatic hypotension patient compliance phase 3 clinical trial (topic) randomized controlled trial (topic) retina macula cystoid edema sexual dysfunction side effect topical treatment weakness LA - English M3 - Article N1 - L603090396 2015-03-24 2015-03-30 PY - 2015 SN - 1744-764X 1474-0338 SP - 609-617 ST - Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma T2 - Expert Opinion on Drug Safety TI - Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L603090396&from=export http://dx.doi.org/10.1517/14740338.2015.1010507 VL - 14 ID - 2819 ER - TY - JOUR AB - PURPOSE: To investigate the influence of personality traits, depression, and training on objectively measured adherence to once-daily prostaglandin analog medication. METHODS: Adherence was measured with the Travalert Dosing Aid on 58 consecutive, regularly followed-up glaucoma patients already on self-administered travoprost. Before the 3-month data-collection period all patients received training on use of the device. Psychologic characteristics were measured using the State-Trait Anxiety Inventory, Eysenck Personality Questionnaire, and Beck Hopeless Scale and Depression Inventory. An adherent day was defined as travoprost instillation at 9 PM ±2 hours. RESULTS: Adherence was 77% for the total period. Social desirability was higher than normal (U test, P<0.0001). Seven patients (12.1%) showed mild-to-moderate depression, which was not significantly associated with decreased adherence (Kruskal-Wallis test, P=0.071). Severity of glaucoma, number of ocular and systemic medications, satisfaction with the recording device, and socio-economic characteristics had no influence on adherence. CONCLUSIONS: Objectively measured adherence to once-daily prostaglandin analog medication was good, and not influenced by treatment characteristics or patient factors including mild-to-moderate depression. The elevated social desirability suggests that self-reported adherence is not a reliable measure of adherence in glaucoma. © 2009 Lippincott Williams & Wilkins, Inc. AD - G. Holló, Department of Ophthalmology, Semmelweis University, Budapest, Hungary AU - Holló, G. AU - Kóthy, P. AU - Géczy, A. AU - Vargha, P. C1 - travatan(Alcon,United States) C2 - Alcon(United States) DB - Embase Medline DO - 10.1097/IJG.0b013e31818456b9 IS - 4 KW - travoprost anxiety article Beck Hopelessness Scale controlled study depression depression inventory devices disease severity drug instillation drug self administration evening dosage Eysenck Personality Questionnaire female follow up glaucoma human major clinical study male patient attitude patient compliance patient education patient participation patient satisfaction personality priority journal social status socioeconomics State Trait Anxiety Inventory travert dosing aid treatment duration travatan LA - English M3 - Article N1 - L354985141 2009-08-25 PY - 2009 SN - 1057-0829 SP - 288-292 ST - Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma T2 - Journal of Glaucoma TI - Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354985141&from=export http://dx.doi.org/10.1097/IJG.0b013e31818456b9 VL - 18 ID - 3364 ER - TY - JOUR AB - PURPOSE: To investigate the influence of personality traits, depression, and training on objectively measured adherence to once-daily prostaglandin analog medication. METHODS: Adherence was measured with the Travalert Dosing Aid on 58 consecutive, regularly followed-up glaucoma patients already on self-administered travoprost. Before the 3-month data-collection period all patients received training on use of the device. Psychologic characteristics were measured using the State-Trait Anxiety Inventory, Eysenck Personality Questionnaire, and Beck Hopeless Scale and Depression Inventory. An adherent day was defined as travoprost instillation at 9 PM ±2 hours. RESULTS: Adherence was 77% for the total period. Social desirability was higher than normal (U test, P<0.0001). Seven patients (12.1%) showed mild-to-moderate depression, which was not significantly associated with decreased adherence (Kruskal-Wallis test, P=0.071). Severity of glaucoma, number of ocular and systemic medications, satisfaction with the recording device, and socio-economic characteristics had no influence on adherence. CONCLUSIONS: Objectively measured adherence to once-daily prostaglandin analog medication was good, and not influenced by treatment characteristics or patient factors including mild-to-moderate depression. The elevated social desirability suggests that self-reported adherence is not a reliable measure of adherence in glaucoma. © 2009 Lippincott Williams & Wilkins, Inc. AD - Department of Ophthalmology, Semmelweis University, Budapest, Hungary Biometry Unit, Semmelweis University, Budapest, Hungary Department of Psychology, Pázmány Péter Catholic University, Piliscsaba, Hungary AU - Holló, G. AU - Kóthy, P. AU - Géczy, A. AU - Vargha, P. DB - Scopus DO - 10.1097/IJG.0b013e31818456b9 IS - 4 KW - Adherence Compliance Depression Glaucoma Personality traits Travalert dosing aid M3 - Article N1 - Cited By :22 Export Date: 19 July 2021 PY - 2009 SP - 288-292 ST - Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma T2 - Journal of Glaucoma TI - Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67651148083&doi=10.1097%2fIJG.0b013e31818456b9&partnerID=40&md5=d80b994537321a09ff193c6e1166c36c VL - 18 ID - 5128 ER - TY - JOUR AB - Objective: To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients. Research design and methods: Multicentre, open-label, non-comparative, 12-week, phase IV study conducted at 10 academic and hospital centres in Hungary. Patients' compliance to use of the pre-study medication was confirmed at a visit 10 days before the baseline measurements, and compliance was monitored throughout the study period. Results: Of the 203 COAG patients three (1.48%) ceased travoprost medication due to ocular hyperaemia, and one subject was lost from follow-up. Self-reported compliance was optimal except for two patients. For the per-protocol analysis 197 patients were evaluable. IOP of the 37 per-protocol patients receiving additional travoprost medication decreased from 23.1 ± 3.2 mmHg (mean ± SD) to 17.3 ± 2.6 mmHg at week 12 (p < 0.001). Switching the 121 per-protocol patients from latanoprost to travoprost IOP decrease from 20.8 ± 3.5 mmHg to 17.7 ± 2.4 mmHg (p < 0.001). IOP of the 11 patients switched from topical nonselective beta-blockers to travoprost decreased from 20.1 ± 2.1 mmHg to 15.7 ± 1.5 mmHg (p < 0.001). For the whole per-protocol population (n = 197) IOP decreased from 21.0 ± 3.4 mmHg to 17.4 ± 2.4 mmHg (p < 0.001 ). Defining responders as having an IOP decrease > 2.0 mmHg or ≥ 5 mmHg at week 12, the responder rate was respectively 62.9% or 31% for the total study population; 86.5% or 54.1% when travoprost was added to the established therapy; 54.5% or 24.0% if latanoprost was switched to travoprost; and 90.9% or 36.4% for those who switched from beta-blockers. Conclusion: Travoprost provided a clinically and statistically significant IOP decrease in uncontrolled COAG patients whose self-reported compliance to their previous topical medication was optimal. Our results suggest that the IOP reduction found after switching to travoprost is not explainable by improved compliance due to the clinical study situation. © 2005 Librapharm Limited. AD - G. Holló, Department of Ophthalmology, Semmelweis University, Tömö u. 25-29, 1083 Budapest, Hungary AU - Holló, G. AU - Vargha, P. AU - Kóthy, P. DB - Embase Medline DO - 10.1185/030079905X74916 IS - 12 KW - beta adrenergic receptor blocking agent latanoprost travoprost adult aged article clinical protocol clinical trial conjunctival hyperemia controlled clinical trial controlled study drug response drug substitution dry eye dyspnea eye color eye disease eye inflammation eyelash female headache heart palpitation human intraocular foreign body intraocular hypotension intraocular pressure iris disease major clinical study male multicenter study non insulin dependent diabetes mellitus ocular pruritus open angle glaucoma patient compliance patient monitoring patient participation phase 4 clinical trial sample size skin allergy university hospital visual impairment LA - English M3 - Article N1 - L41803104 2006-01-13 PY - 2005 SN - 0300-7995 SP - 1943-1948 ST - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication T2 - Current Medical Research and Opinion TI - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41803104&from=export http://dx.doi.org/10.1185/030079905X74916 VL - 21 ID - 3648 ER - TY - JOUR AB - OBJECTIVE: To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients. RESEARCH DESIGN AND METHODS: Multicentre, open-label, non-comparative, 12-week, phase IV study conducted at 10 academic and hospital centres in Hungary. Patients' compliance to use of the pre-study medication was confirmed at a visit 10 days before the baseline measurements, and compliance was monitored throughout the study period. RESULTS: Of the 203 COAG patients three (1.48%) ceased travoprost medication due to ocular hyperaemia, and one subject was lost from follow-up. Self-reported compliance was optimal except for two patients. For the per-protocol analysis 197 patients were evaluable. IOP of the 37 per-protocol patients receiving additional travoprost medication decreased from 23.1 +/- 3.2 mmHg (mean +/- SD) to 17.3 +/- 2.6 mmHg at week 12 (p < 0.001). Switching the 121 per-protocol patients from latanoprost to travoprost IOP decrease from 20.8 +/- 3.5 mmHg to 17.7 +/- 2.4 mmHg (p < 0.001). IOP of the 11 patients switched from topical nonselective beta-blockers to travoprost decreased from 20.1 +/- 2.1 mmHg to 15.7 +/- 1.5 mmHg (p < 0.001). For the whole per-protocol population (n = 197) IOP decreased from 21.0 +/- 3.4 mmHg to 17.4 +/- 2.4 mmHg (p < 0.001). Defining responders as having an IOP decrease > 2.0 mmHg or >or= 5 mmHg at week 12, the responder rate was respectively 62.9% or 31% for the total study population; 86.5% or 54.1% when travoprost was added to the established therapy; 54.5% or 24.0% if latanoprost was switched to travoprost; and 90.9% or 36.4% for those who switched from beta-blockers. CONCLUSION: Travoprost provided a clinically and statistically significant IOP decrease in uncontrolled COAG patients whose self-reported compliance to their previous topical medication was optimal. Our results suggest that the IOP reduction found after switching to travoprost is not explainable by improved compliance due to the clinical study situation. AD - Department of Ophthalmology, Semmelweis University, 1083 Budapest, Tömö u. 25-29, Hungary; hg@szem1.sote.hu AN - 106413677. Language: English. Entry Date: 20060324. Revision Date: 20150711. Publication Type: Journal Article AU - Holló, G. AU - Vargha, P. AU - Kóthy, P. DB - ccm DP - EBSCOhost IS - 12 KW - Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Travoprost -- Therapeutic Use Adolescence Adult Aged Aged, 80 and Over Analysis of Covariance Clinical Trials Confidence Intervals Data Analysis Software Female Funding Source Human Hungary Male Middle Age Pearson's Correlation Coefficient N1 - clinical trial; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Grant Information: Supported in part by Hungarian National Health Grant 011/2003 and by an unrestricted grant by Alcon Hungary, Ltd.. NLM UID: 0351014. PMID: NLM16368044. PY - 2005 SN - 0300-7995 SP - 1943-1948 ST - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication T2 - Current Medical Research & Opinion TI - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106413677&site=ehost-live&scope=site VL - 21 ID - 4451 ER - TY - JOUR AB - Objective: To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients. Research design and methods: Multicentre, open-label, non-comparative, 12-week, phase IV study conducted at 10 academic and hospital centres in Hungary. Patients' compliance to use of the pre-study medication was confirmed at a visit 10 days before the baseline measurements, and compliance was monitored throughout the study period. Results: Of the 203 COAG patients three (1.48%) ceased travoprost medication due to ocular hyperaemia, and one subject was lost from follow-up. Self-reported compliance was optimal except for two patients. For the per-protocol analysis 197 patients were evaluable. IOP of the 37 per-protocol patients receiving additional travoprost medication decreased from 23.1 ± 3.2 mmHg (mean ± SD) to 17.3 ± 2.6 mmHg at week 12 (p < 0.001). Switching the 121 per-protocol patients from latanoprost to travoprost IOP decrease from 20.8 ± 3.5 mmHg to 17.7 ± 2.4 mmHg (p < 0.001). IOP of the 11 patients switched from topical nonselective beta-blockers to travoprost decreased from 20.1 ± 2.1 mmHg to 15.7 ± 1.5 mmHg (p < 0.001). For the whole per-protocol population (n = 197) IOP decreased from 21.0 ± 3.4 mmHg to 17.4 ± 2.4 mmHg (p < 0.001 ). Defining responders as having an IOP decrease > 2.0 mmHg or ≥ 5 mmHg at week 12, the responder rate was respectively 62.9% or 31% for the total study population; 86.5% or 54.1% when travoprost was added to the established therapy; 54.5% or 24.0% if latanoprost was switched to travoprost; and 90.9% or 36.4% for those who switched from beta-blockers. Conclusion: Travoprost provided a clinically and statistically significant IOP decrease in uncontrolled COAG patients whose self-reported compliance to their previous topical medication was optimal. Our results suggest that the IOP reduction found after switching to travoprost is not explainable by improved compliance due to the clinical study situation. © 2005 Librapharm Limited. AD - Department of Ophthalmology, Semmelweis University, Budapest, Hungary Biometry Unit, Semmelweis University, Budapest, Hungary Department of Ophthalmology, Semmelweis University, Tömö u. 25-29, 1083 Budapest, Hungary AU - Holló, G. AU - Vargha, P. AU - Kóthy, P. C7 - 3143 DB - Scopus DO - 10.1185/030079905X74916 IS - 12 KW - Compliance Intraocular pressure Travoprost M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2005 SP - 1943-1948 ST - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication T2 - Current Medical Research and Opinion TI - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-29144497065&doi=10.1185%2f030079905X74916&partnerID=40&md5=55d83f68d74e289222ed4f970314ad93 VL - 21 ID - 5288 ER - TY - JOUR AB - Objective:To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients. Research design and methods: Multicentre, open-label, non-comparative, 12-week, phase IV study conducted at 10 academic and hospital centres in Hungary. Patients' compliance to use of the pre-study medication was confirmed at a visit 10 days before the baseline measurements, and compliance was monitored throughout the study period. Results: Of the 203 COAG patients three (1.48%) ceased travoprost medication due to ocular hyperaemia, and one subject was lost from follow-up. Self-reported compliance was optimal except for two patients. For the per-protocol analysis 197 patients were evaluable. IOP of the 37 per-protocol patients receiving additional travoprost medication decreased from 23.1 +/- 3.2 mmHg (mean +/- SD) to 17.3 +/- 2.6 mmHg at week 12 (p < 0.001). Switching the 121 per-protocol patients from latanoprost to travoprost IOP decrease 20.8 +/- 3.5 mmHg to 17.7 +/- 2.4 mmHg (p < 0.001). IOP of the 11 patients switched from topical nonselective beta-blockers to travoprost decreased from 20.1 +/- 2.1 mmHg to 15.7 +/- 1.5 mmHg (p < 0.001). For the whole per-protocol population (n = 197) IOP decreased from 21.0 +/- 3.4 mmHg to 17.4 +/- 2.4 mmHg (p < 0.001). Defining responders as having an IOP decrease > 2.0 mmHg or >= 5 mmHg at week 12, the responder rate was respectively 62.9% or 31 % for the total study population; 86.5% or 54.1 % when travoprost was added to the established therapy; 54.5% or 24.0% if latanoprost was switched to travoprost; and 90.9% or 36.4% for those who switched from beta-blockers. Conclusion: Travoprost provided a clinically and statistically significant IOP decrease in uncontrolled COAG patients whose self-reported compliance to their previous topical medication was optimal. Our results suggest that the IOP reduction found after switching to travoprost is not explainable by improved compliance due to the clinical study situation. AN - WOS:000233990300008 AU - Hollo, G. AU - Vargha, P. AU - Kothy, P. DA - DEC DO - 10.1185/030079905X74916 IS - 12 PY - 2005 SN - 0300-7995 1473-4877 SP - 1943-1948 ST - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication T2 - CURRENT MEDICAL RESEARCH AND OPINION TI - Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication VL - 21 ID - 6141 ER - TY - JOUR AB - Abstract. In a controlled randomized study 15 patients (20 eyes) with chronic open angle glaucoma and visual field defects were followed for > 1 year, 12 of them were followed for 3 years. Half of the group were untreated controls, the other half treated with pressure reducing medical therapy. At least 5 consecutive computerized visual fields were recorded (COMPETER) on each eye, and the linear regression coefficient was calculated. With the reservation for uncontrolled compliance no significant difference in the line of favourable effect of pressure reduction could be spotted, in spite of an average pressure reduction in the treated group of 4 mmHg. More important than this result, which is open to criticism for the smallness of the material, uncontrolled compliance etc, is the lesson that a randomized experiment with treated and non‐treated glaucoma cases carried out in accordance with the Helsingfors convention is hardly feasible. 1988 Institution Acta Ophthalmologica Scandinavica AD - University Eye Clinic, Lund, Sweden Eye Clinic, Hudiksvall Hospital, Hudiksvall, Sweden Department of Experimental Ophthalmology, General Hospital, Malmo, Sweden AU - Holmin, C. AU - Thorburn, W. AU - Krakau, C. E. T. DB - Scopus DO - 10.1111/j.1755-3768.1988.tb04006.x IS - 2 KW - computerized perimetry non‐treatment POAG randomized experiment treatment M3 - Article N1 - Cited By :26 Export Date: 19 July 2021 PY - 1988 SP - 170-173 ST - Treatment versus no treatment in chronic open angle glaucoma T2 - Acta Ophthalmologica TI - Treatment versus no treatment in chronic open angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023887774&doi=10.1111%2fj.1755-3768.1988.tb04006.x&partnerID=40&md5=fad038997b98c7001f4dfa1396c45c5d VL - 66 ID - 5088 ER - TY - JOUR AD - Institute for Health Policy and Management/Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, the Netherlands. goor@bmg.eur.nl. AN - 104238010. Language: English. Entry Date: 20140124. Revision Date: 20150711. Publication Type: Journal Article AU - Holtzer-Goor, Kim M. AU - Plochg, Thomas AU - Lemij, Hans G. AU - van Sprundel, Esther AU - Koopmanschap, Marc A. AU - Klazinga, Niek S. DB - ccm DO - 10.1186/1748-5908-8-14 DP - EBSCOhost IS - 1 KW - Glaucoma -- Therapy Hospitalization Optometry Transfer, Discharge -- Utilization Primary Health Care -- Utilization Attitude of Health Personnel Pilot Studies Health Services Accessibility Human Netherlands Optometry -- Standards Qualitative Studies Quality of Health Care N1 - research. Journal Subset: Biomedical; Europe; Health Services Administration; UK & Ireland. NLM UID: 101258411. PMID: NLM23351180. PY - 2013 SN - 1748-5908 SP - 14-14 ST - Why a successful task substitution in glaucoma care could not be transferred from a hospital setting to a primary care setting: a qualitative study T2 - Implementation Science TI - Why a successful task substitution in glaucoma care could not be transferred from a hospital setting to a primary care setting: a qualitative study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104238010&site=ehost-live&scope=site VL - 8 ID - 4717 ER - TY - JOUR AB - Background: Healthcare systems are challenged by a demand that exceeds available resources. One policy to meet this challenge is task substitution-transferring tasks to other professions and settings. Our study aimed to explore stakeholders' perceived feasibility of transferring hospital-based monitoring of stable glaucoma patients to primary care optometrists.Methods: A case study was undertaken in the Rotterdam Eye Hospital (REH) using semi-structured interviews and document reviews. They were inductively analysed using three implementation related theoretical perspectives: sociological theories on professionalism, management theories, and applied political analysis.Results: Currently it is not feasible to use primary care optometrists as substitutes for optometrists and ophthalmic technicians working in a hospital-based glaucoma follow-up unit (GFU). Respondents' narratives revealed that: the glaucoma specialists' sense of urgency for task substitution outside the hospital diminished after establishing a GFU that satisfied their professionalization needs; the return on investments were unclear; and reluctant key stakeholders with strong power positions blocked implementation. The window of opportunity that existed for task substitution in person and setting in 1999 closed with the institutionalization of the GFU.Conclusions: Transferring the monitoring of stable glaucoma patients to primary care optometrists in Rotterdam did not seem feasible. The main reasons were the lack of agreement on professional boundaries and work domains, the institutionalization of the GFU in the REH, and the absence of an appropriate reimbursement system. Policy makers considering substituting tasks to other professionals should carefully think about the implementation process, especially in a two-step implementation process (substitution in person and in setting) such as this case. Involving the substituting professionals early on to ensure all stakeholders see the change as a normal step in the professionalization of the substituting professionals is essential, as is implementing the task substitution within the window of opportunity. © 2013 Holtzer-Goor et al.; licensee BioMed Central Ltd. AD - Institute for Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, Netherlands Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands Glaucoma service, Rotterdam Eye Hospital, Rotterdam, Netherlands Glaucoma Research Unit, Netherlands and Rotterdam Ophthalmic Institute, Rotterdam, Netherlands AU - Holtzer-Goor, K. M. AU - Plochg, T. AU - Lemij, H. G. AU - van Sprundel, E. AU - Koopmanschap, M. A. AU - Klazinga, N. S. C7 - 14 DB - Scopus DO - 10.1186/1748-5908-8-14 IS - 1 KW - Access to health care Diffusion of innovation Quality of health care M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2013 ST - Why a successful task substitution in glaucoma care could not be transferred from a hospital setting to a primary care setting: A qualitative study T2 - Implementation Science TI - Why a successful task substitution in glaucoma care could not be transferred from a hospital setting to a primary care setting: A qualitative study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872782354&doi=10.1186%2f1748-5908-8-14&partnerID=40&md5=755bdf952a6cfb125142d0b16e9c30f4 VL - 8 ID - 5331 ER - TY - JOUR AD - Institute for Medical Technology Assessment-Erasmus University Rotterdam, Rotterdam, the Netherlands. goor@bmg.eur.nl AN - 104569721. Language: English. Entry Date: 20120511. Revision Date: 20150711. Publication Type: Journal Article AU - Holtzer-Goor, Kim M. AU - van Sprundel, Esther AU - Lemij, Hans G. AU - Plochg, Thomas AU - Klazinga, Niek S. AU - Koopmanschap, Marc A. DB - ccm DP - EBSCOhost KW - Glaucoma -- Therapy Hospitals, Special -- Economics Ophthalmology -- Economics Optometry -- Economics Quality of Health Care -- Standards Aged Appointments and Schedules Cost Benefit Analysis Economic Aspects of Illness Female Glaucoma -- Economics Health Care Costs Human Intraocular Pressure Male Middle Age Netherlands Ophthalmology -- Manpower Optometry -- Manpower Patient Satisfaction Prospective Studies Randomized Controlled Trials Referral and Consultation -- Economics Travel Workload N1 - research; randomized controlled trial. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 101088677. PMID: NLM21083880. PY - 2010 SN - 1472-6963 SP - 312-312 ST - Cost-effectiveness of monitoring glaucoma patients in shared care: an economic evaluation alongside a randomized controlled trial T2 - BMC Health Services Research TI - Cost-effectiveness of monitoring glaucoma patients in shared care: an economic evaluation alongside a randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104569721&site=ehost-live&scope=site VL - 10 ID - 4751 ER - TY - JOUR AB - Background. Population aging increases the number of glaucoma patients which leads to higher workloads of glaucoma specialists. If stable glaucoma patients were monitored by optometrists and ophthalmic technicians in a glaucoma follow-up unit (GFU) rather than by glaucoma specialists, the specialists' workload and waiting lists might be reduced. We compared costs and quality of care at the GFU with those of usual care by glaucoma specialists in the Rotterdam Eye Hospital (REH) in a 30-month randomized clinical trial. Because quality of care turned out to be similar, we focus here on the costs. Methods. Stable glaucoma patients were randomized between the GFU and the glaucoma specialist group. Costs per patient year were calculated from four perspectives: those of patients, the Rotterdam Eye Hospital (REH), Dutch healthcare system, and society. The outcome measures were: compliance to the protocol; patient satisfaction; stability according to the practitioner; mean difference in IOP; results of the examinations; and number of treatment changes. Results. Baseline characteristics (such as age, intraocular pressure and target pressure) were comparable between the GFU group (n = 410) and the glaucoma specialist group (n = 405). Despite a higher number of visits per year, mean hospital costs per patient year were lower in the GFU group (€139 vs. €161). Patients' time and travel costs were similar. Healthcare costs were significantly lower for the GFU group (€230 vs. €251), as were societal costs (€310 vs. €339) (p < 0.01). Bootstrap-, sensitivity- and scenario-analyses showed that the costs were robust when varying hospital policy and the duration of visits and tests. Conclusion. We conclude that this GFU is cost-effective and deserves to be considered for implementation in other hospitals. © 2010 Holtzer-Goor et al; licensee BioMed Central Ltd. AD - Institute for Medical Technology Assessment-Erasmus University Rotterdam, Rotterdam, Netherlands Rotterdam Ophthalmic Institute, Rotterdam, Netherlands Rotterdam Eye Hospital, Rotterdam, Netherlands Department of Social Medicine, Academic Medical Center (AMC), University of Amsterdam, Netherlands AU - Holtzer-Goor, K. M. AU - Van Sprundel, E. AU - Lemij, H. G. AU - Plochg, T. AU - Klazinga, N. S. AU - Koopmanschap, M. A. C7 - 312 DB - Scopus DO - 10.1186/1472-6963-10-312 M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2010 ST - Cost-effectiveness of monitoring glaucoma patients in shared care: An economic evaluation alongside a randomized controlled trial T2 - BMC Health Services Research TI - Cost-effectiveness of monitoring glaucoma patients in shared care: An economic evaluation alongside a randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78249245735&doi=10.1186%2f1472-6963-10-312&partnerID=40&md5=cf43cd31440a0cc23a6b7252db120dca VL - 10 ID - 5309 ER - TY - JOUR AB - Background: Population aging increases the number of glaucoma patients which leads to higher workloads of glaucoma specialists. If stable glaucoma patients were monitored by optometrists and ophthalmic technicians in a glaucoma follow-up unit (GFU) rather than by glaucoma specialists, the specialists' workload and waiting lists might be reduced. We compared costs and quality of care at the GFU with those of usual care by glaucoma specialists in the Rotterdam Eye Hospital (REH) in a 30-month randomized clinical trial. Because quality of care turned out to be similar, we focus here on the costs. Methods: Stable glaucoma patients were randomized between the GFU and the glaucoma specialist group. Costs per patient year were calculated from four perspectives: those of patients, the Rotterdam Eye Hospital (REH), Dutch healthcare system, and society. The outcome measures were: compliance to the protocol; patient satisfaction; stability according to the practitioner; mean difference in IOP; results of the examinations; and number of treatment changes. Results: Baseline characteristics (such as age, intraocular pressure and target pressure) were comparable between the GFU group (n = 410) and the glaucoma specialist group (n = 405). Despite a higher number of visits per year, mean hospital costs per patient year were lower in the GFU group ((sic) 139 vs. (sic) 161). Patients' time and travel costs were similar. Healthcare costs were significantly lower for the GFU group ((sic) 230 vs. (sic) 251), as were societal costs ((sic) 310 vs. (sic) 339) (p < 0.01). Bootstrap-, sensitivity- and scenario-analyses showed that the costs were robust when varying hospital policy and the duration of visits and tests. Conclusion: We conclude that this GFU is cost-effective and deserves to be considered for implementation in other hospitals. AN - WOS:000285512800001 AU - Holtzer-Goor, K. M. AU - van Sprundel, E. AU - Lemij, H. G. AU - Plochg, T. AU - Klazinga, N. S. AU - Koopmanschap, M. A. DA - NOV 17 DO - 10.1186/1472-6963-10-312 PY - 2010 SN - 1472-6963 ST - Cost-effectiveness of monitoring glaucoma patients in shared care: an economic evaluation alongside a randomized controlled trial T2 - BMC HEALTH SERVICES RESEARCH TI - Cost-effectiveness of monitoring glaucoma patients in shared care: an economic evaluation alongside a randomized controlled trial VL - 10 ID - 5994 ER - TY - JOUR AB - Purpose: Comparing the quality of care provided by a hospitalbased shared care glaucoma follow-up unit with care as usual. Patients and Methods: This randomized controlled trial included stable glaucoma patients and patients at risk for developing glaucoma. Patients in the Usual Care group (n=410) were seen by glaucoma specialists. In the glaucoma follow-up unit group (n=405), patients visited the glaucoma follow-up unit twice followed by a visit to a glaucoma specialist. The main outcome measures were: compliance to the working protocol by glaucoma follow-up unit employees; difference in intraocular pressure between baseline and at ≥18 months; and patient satisfaction. Results: Glaucoma follow-up unit employees closely adhered to the working protocol for the measurement of intraocular pressure, visual acuity and GDx (≥97.5% of all visits). Humphrey Field Analyzer examinations were not performed as frequently as prescribed by the working protocol, but more often than in the Usual Care group. In a small minority of patients that required backreferral, the protocol was disregarded, notably when criteria were only slightly exceeded. There was no statistically significant difference in changes in intraocular pressure between the 2 treatment groups (P=0.854). Patients were slightly more satisfied with the glaucoma follow-up unit employees than with the glaucoma specialists (scores: 8.56 vs. 8.40; P=0.006). Conclusions: In general, the hospital-based shared care glaucoma follow-up closely observed its working protocol and patients preferred it slightly over the usual care provided by medical doctors. The glaucoma follow-up unit operated satisfactorily and might serve as a model for shared care strategies elsewhere. © 2015 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, DR Rotterdam, 3000, Netherlands Rotterdam Ophthalmic Institute, Rotterdam Eye Hospital, Rotterdam, Netherlands Department of Social Medicine, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands School of Public Health, KU Leuven, University of Leuven, Leuven, Belgium AU - Holtzer-Goor, K. M. AU - Van Vliet, E. J. AU - Van Sprundel, E. AU - Plochg, T. AU - Koopmanschap, M. A. AU - Klazinga, N. S. AU - Lemij, H. G. DB - Scopus DO - 10.1097/IJG.0000000000000335 IS - 4 KW - Adherence Glaucoma Patient satisfaction Quality of care Shared care M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2016 SP - e392-e400 ST - Shared care in monitoring stable glaucoma patients: A randomized controlled trial T2 - Journal of Glaucoma TI - Shared care in monitoring stable glaucoma patients: A randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946594967&doi=10.1097%2fIJG.0000000000000335&partnerID=40&md5=655ae61fbb31eaa5c90fa68af023a270 VL - 25 ID - 5516 ER - TY - JOUR AB - Purpose: Comparing the quality of care provided by a hospital-based shared care glaucoma follow-up unit with care as usual. Patients and Methods: This randomized controlled trial included stable glaucoma patients and patients at risk for developing glaucoma. Patients in the Usual Care group (n = 410) were seen by glaucoma specialists. In the glaucoma follow-up unit group (n = 405), patients visited the glaucoma follow-up unit twice followed by a visit to a glaucoma specialist. The main outcome measures were: compliance to the working protocol by glaucoma follow-up unit employees; difference in intraocular pressure between baseline and at >= 18 months; and patient satisfaction. Results: Glaucoma follow-up unit employees closely adhered to the working protocol for the measurement of intraocular pressure, visual acuity and GDx (>= 97.5% of all visits). Humphrey Field Analyzer examinations were not performed as frequently as prescribed by the working protocol, but more often than in the Usual Care group. In a small minority of patients that required back-referral, the protocol was disregarded, notably when criteria were only slightly exceeded. There was no statistically significant difference in changes in intraocular pressure between the 2 treatment groups (P = 0.854). Patients were slightly more satisfied with the glaucoma follow-up unit employees than with the glaucoma specialists (scores: 8.56 vs. 8.40; P = 0.006). Conclusions: In general, the hospital-based shared care glaucoma follow-up closely observed its working protocol and patients preferred it slightly over the usual care provided by medical doctors. The glaucoma follow-up unit operated satisfactorily and might serve as a model for shared care strategies elsewhere. AN - WOS:000374834000017 AU - Holtzer-Goor, K. M. AU - van Vliet, E. J. AU - van Sprundel, E. AU - Plochg, T. AU - Koopmanschap, M. A. AU - Klazinga, N. S. AU - Lemij, H. G. DA - APR DO - 10.1097/IJG.0000000000000335 IS - 4 PY - 2016 SN - 1057-0829 1536-481X SP - E392-E400 ST - Shared Care in Monitoring Stable Glaucoma Patients: A Randomized Controlled Trial T2 - JOURNAL OF GLAUCOMA TI - Shared Care in Monitoring Stable Glaucoma Patients: A Randomized Controlled Trial VL - 25 ID - 5854 ER - TY - JOUR AB - Glaucoma affects an increasing number of people worldwide and is the second leading cause of blindness. The aim of antiglaucoma therapy is to maintain a patient's visual function and quality of life. Prostaglandin analogues are first-line topical antiglaucoma therapy. They are effective at lowering intraocular pressure (IOP) and are generally well tolerated, with fewer systemic adverse events compared with the other classes. However, the use of prostaglandin analogues can be associated with ocular adverse effects, such as stinging/burning sensation, dry eyes, iris and periocular hyperpigmentation, and eye lash growth, which can affect patient compliance. Preservatives used in antiglaucoma preparations can have dose-dependent toxic effects, which contribute to adverse effects. The development of preservative-free preparations may reduce such adverse effects and therefore improve patient compliance. Tafluprost is a prostaglandin analogue in a preservative-free formulation that was recently approved for the reduction of elevated IOP in open-angle glaucoma and ocular hypertension. Copyright © 2010 Prous Science, S.A.U. or its licensors All rights reserved. AD - A. Hommer, Augenabteilung Hera Hospital, Lustkandlgasse 24, A-1090 Vienna, Austria AU - Hommer, A. DB - Embase Medline DO - 10.1358/dot.2010.46.6.1482107 IS - 6 KW - bimatoprost latanoprost prostaglandin derivative tafluprost travoprost add on therapy burning sensation clinical trial conjunctival hyperemia drug formulation drug hypersensitivity drug safety drug structure drug substitution drug withdrawal dry eye epiphora eyelid disease foreign body reaction human intraocular hypertension intraocular pressure iris disease open angle glaucoma patient compliance patient satisfaction quality of life review LA - English M3 - Review N1 - L359326192 2010-08-18 2010-08-27 PY - 2010 SN - 1699-4019 1699-3993 SP - 409-416 ST - A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension T2 - Drugs of Today TI - A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359326192&from=export http://dx.doi.org/10.1358/dot.2010.46.6.1482107 VL - 46 ID - 3290 ER - TY - JOUR AB - The first-line option for lowering intraocular pressure (IOP) is a single hypotensive agent, but patients frequently require additional IOP-lowering agents to reach their target pressures. Disadvantages of this multi-therapy approach include washout effect, inconvenience and poor adherence. Fixed combinations (FCs) combine two or more hypotensive agents in a single bottle, providing a convenient once-daily therapy, which tends to improve adherence. FCs generally offer equivalent efficacy to concomitant use of the individual components, with equivalent or superior tolerability. Studies also show that FCs can be more cost effective than nonfixed combinations. In terms of optimizing IOP control, minimizing visual field deterioration, preventing visual disability and minimizing associated healthcare costs, FCs are an important component of glaucoma management. © 2011 Expert Reviews Ltd. AD - A. Hommer, Krankenanstalt Sanatorium Hera, Lustkandlgasse 24, A-1090 Vienna, Austria AU - Hommer, A. C1 - azarga(Alcon) combigan(Allergan) cosopt(Merck Sharp and Dohme) duotrav(Alcon) ganfort(Allergan) thiloadren(Alcon) thilodigon(Alcon) xalacom(Pfizer) C2 - Alcon Allergan Merck Sharp and Dohme Pfizer DB - Embase Medline DO - 10.1586/erp.10.83 IS - 1 KW - alpha 2 adrenergic receptor stimulating agent antiglaucoma agent antihypertensive agent beta adrenergic receptor blocking agent betaxolol plus pilocarpine bimatoprost bimatoprost plus timolol brimonidine brimonidine plus timolol brinzolamide plus timolol carbonate dehydratase inhibitor carteolol plus pilocarpine dipifevrine plus guanethidine dipifevrine plus pilocarpine dorzolamide plus timolol eye drops latanoprost latanoprost plus timolol metipranol plus pilocarpine pilocarpine plus timolol prostaglandin derivative thiloadren thilodigon timolol timolol plus travoprost travoprost unclassified drug allergic conjunctivitis burning sensation comparative effectiveness conjunctival hyperemia cost effectiveness analysis cost of illness disease control disease severity dosage schedule comparison dose response drug cost drug effect drug efficacy drug mechanism drug mixture drug tolerability drug use evening dosage pseudoexfoliation glaucoma human hyperemia intraocular pressure abnormality medical history monotherapy morning dosage open angle glaucoma patient assessment patient compliance patient satisfaction review risk reduction social aspect taste disorder visual field defect visual impairment azarga combigan cosopt duotrav ganfort xalacom LA - English M3 - Review N1 - L361347361 2011-03-09 2011-03-22 PY - 2011 SN - 1473-7167 1744-8379 SP - 91-99 ST - Role of fixed combinations in the management of open-angle glaucoma T2 - Expert Review of Pharmacoeconomics and Outcomes Research TI - Role of fixed combinations in the management of open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361347361&from=export http://dx.doi.org/10.1586/erp.10.83 VL - 11 ID - 3192 ER - TY - JOUR AB - Objective To examine whether government-funded, low-income vision care programs improve use of eye care services by low-income individuals in Canada. Design Cross-sectional survey. Participants 27,375 white respondents to the Canadian Community Health Survey (CCHS) Healthy Aging 2008/2009. Methods Government-funded, low-income vision care programs were reviewed. The amount of assistance provided was compared with professional fee schedules for general/routine eye examinations and market prices for eyeglasses. The utilization of eye care providers was derived from the CCHS. Results To receive low-income vision care assistance, individuals must be in receipt of social assistance. Criteria for receiving social assistance are stringent. The Canadian Financial Capability Survey revealed that 7.9% of Canadians aged 45 to 64 years and 5.5% aged ≥65 years received social assistance in 2009. The CCHS found in 2008/2009 that 12.5% of citizens aged 45 to 64 years and 13.2% of those aged ≥65 years had difficulty paying for basic expenses such as food. In 5 provinces, low-income vision care assistance fully covers a general/routine eye examination. In the remainder, the assistance provided is insufficient for a general/routine eye examination. The assistance for eyeglasses is inadequate in 5 provinces, requiring out-of-pocket copayments. Among middle-aged whites who self-reported not having glaucoma, cataracts, diabetes, or vision problems not corrected by lenses, utilization of eye care providers was 28.1% among those with financial difficulty versus 41.9% among those without (p < 0.05), giving a prevalence ratio 0.68 (95% CI 0.57-0.80) adjusted for age, sex and education. Conclusions Despite government assistance, low-income individuals use vision care services less often than wealthy individuals. © 2014 Canadian Ophthalmological Society. AD - Y.-P. Jin, Department of Ophthalmology and Vision Sciences, Dalla Lana School of Public Health, University of Toronto, 340 College Street, Toronto ON, M5T 3A9, Canada AU - Hong, C. J. AU - Trope, G. E. AU - Buys, Y. M. AU - Robinson, B. E. AU - Jin, Y. P. DB - Embase Medline DO - 10.1016/j.jcjo.2014.03.006 IS - 4 KW - adult age aged article Canada Caucasian controlled study cross-sectional study eye care eye examination female financial deficit government health care survey health care utilization health program human lowest income group major clinical study male medical fee spectacles LA - English M3 - Article N1 - L53251963 2014-07-23 2014-08-23 PY - 2014 SN - 1715-3360 0008-4182 SP - 320-325 ST - Does government assistance improve utilization of eye care services by low-income individuals? T2 - Canadian Journal of Ophthalmology TI - Does government assistance improve utilization of eye care services by low-income individuals? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L53251963&from=export http://dx.doi.org/10.1016/j.jcjo.2014.03.006 VL - 49 ID - 2931 ER - TY - JOUR AB - Purpose: The purpose of this study is to assess patient attitudes towards anti-glaucoma medication and their association with adherence, visual quality of life, and personality traits. Materials and Methods: One hundred and forty-seven glaucoma patients were enrolled this study. The participants were divided into 'pharmacophobic' and 'pharmacophilic' groups according to their scores on the Modified Glaucoma Drug Attitude Inventory (MG-DAI). To establish a correlation with patient drug attitude, each group had their subjective drug adherence, visual quality of life, and personality traits examined. For personality traits, the Myers-Briggs Type Indicator (MBTI) was used to sub-classify each group. Results: Among the patients analyzed, 91 (72.80%) patients showed a 'pharmacophobic' attitude and 34 (27.20%) patients showed a 'pharmacophilic' attitude. The pharmacophobic group tended to have worse adherence than the pharmacophilic group. Personality dichotomies from the MBTI also showed different patterns for each group. Conclusion: In glaucoma patients, pharmacological adherence was influenced by their attitude towards drugs; an association might exist between drug attitude and underlying personality traits. © Copyright: Yonsei University College of Medicine 2010. AD - C. Y. Kim, Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, 250 Seongsan-ro, Seodaemun-gu, Seoul 120-752, South Korea AU - Hong, S. AU - Kang, S. Y. AU - Yoon, J. U. AU - Kang, U. AU - Seong, G. J. AU - Kim, C. Y. DB - Embase Medline DO - 10.3349/ymj.2010.51.2.261 IS - 2 KW - antiglaucoma agent adult article controlled study cross-sectional study female glaucoma human major clinical study male patient attitude patient compliance personality quality of life questionnaire L1 - internal-pdf://3138376569/3269-Drug attitude and adherence to anti--2010.pdf LA - English M3 - Article N1 - L358387825 2010-03-11 2010-03-31 PY - 2010 SN - 0513-5796 SP - 261-269 ST - Drug attitude and adherence to anti-glaucoma medication T2 - Yonsei Medical Journal TI - Drug attitude and adherence to anti-glaucoma medication UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358387825&from=export http://dx.doi.org/10.3349/ymj.2010.51.2.261 VL - 51 ID - 3269 ER - TY - JOUR AB - Purpose: To assess how glaucoma patients use their topical medications. Methods: 142 subjects were tested before an examiner as to how they used their eyedrops. Results: Fifty-six patients (39.4%) used one drop. The number of drops instilled increased with age. The tip of the bottle touched the ocular surface in 78 (54.9%). The proportion of patients whose bottle came into contact with the eye or periocular tissues increased with age. Only four patients (2.8%) closed the treated eye and compressed the medial angle after applying the medication, Conclusions: It is important that ophthalmologists instruct their patients on the correct manner of applying topical medication so that the patients can themselves administer the medicine precisely. Such instruction will improve the patients' compliance and quality of life during therapy for glaucoma. AD - S. Tsukahara, Department of Ophthalmology, Yamanashi Medical College, 1110 Shimokatou, Tamaho, Yamanashi, 409-38, Japan AU - Hosoda, M. AU - Yamabayashi, S. AU - Furuta, M. AU - Tsukahara, S. DB - Embase IS - 3 KW - eye drops adult age aged article controlled study female glaucoma human major clinical study male methodology patient compliance patient counseling priority journal quality of life topical drug administration LA - English M3 - Article N1 - L25203544 1995-07-20 PY - 1995 SN - 1057-0829 SP - 202-206 ST - Do glaucoma patients use eye drops correctly? T2 - Journal of Glaucoma TI - Do glaucoma patients use eye drops correctly? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L25203544&from=export VL - 4 ID - 3982 ER - TY - JOUR AB - Purpose. To evaluate the efficacy of a combination of intrastromal and intracameral injections of amphotericin B in the treatment of severe recalcitrant fungal keratitis. Methods. Patients with severe fungal keratitis who were resistant to conventional antifungal medical treatments and needed potential surgical intervention were recruited at the First Affiliated Hospital of Fujian Medical University between January 2012 and July 2013. The patients were treated with a combination of intrastromal and intracameral injections of amphotericin B (25 μg/mL and 50 μg/mL, resp.). Selectively repeated injections were performed as necessary. The efficacy, complications, and outcome were evaluated. Results. Nine patients (9 eyes) were involved in this study. All 9 cases responded favorably, and the clinical appearance of serious corneal damage and intraocular extension was resolved after the treatment. Four eyes required only 1 injection, and 5 eyes required repeated injections. Seven corneal ulcers healed with leucoma, and 2 healed with adherent leucoma. All of our cases had a marked increase in the anterior chamber reaction and pain immediately after the injection. There was no obvious clinical evidence of corneal or lenticular toxicity in any patient. Conclusions. A combination of intrastromal and intracameral injections of amphotericin B may be safe and effective for the treatment of severe fungal keratitis that is resistant to conventional therapy. AD - The Eye Center of the First Affiliated Hospital of Fujian Medical University, Fujian Eye Institute, 20 Chazhong Road, Fuzhou 350005, China AN - 118192135. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - Hu, Jianzhang AU - Zhang, Jingjin AU - Li, Yanling AU - Han, Xiaoli AU - Zheng, Weidong AU - Yang, Juan AU - Xu, Guoxing DB - ccm DO - 10.1155/2016/3436415 DP - EBSCOhost KW - Amphotericin B Keratitis, Fungal Corneal Transplantation Corneal Injuries Anterior Chamber Corneal Ulcer Case Studies N1 - research; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 101524199. PY - 2016 SN - 2090-004X SP - 1-7 ST - A Combination of Intrastromal and Intracameral Injections of Amphotericin B in the Treatment of Severe Fungal Keratitis T2 - Journal of Ophthalmology TI - A Combination of Intrastromal and Intracameral Injections of Amphotericin B in the Treatment of Severe Fungal Keratitis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118192135&site=ehost-live&scope=site ID - 4311 ER - TY - JOUR AN - WOS:000433205503314 AU - Hu, W. D. AU - Hu, C. X. AU - Tran, J. AU - Pequignot, E. AU - Waisbourd, M. AU - Hark, L. A. AU - Katz, L. J. DA - APR IS - 13 PY - 2014 SN - 0146-0404 1552-5783 ST - Detection of Non-Glaucomatous Ocular Pathology and Barriers to Follow-Up in a Community Glaucoma Detection Program T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - Detection of Non-Glaucomatous Ocular Pathology and Barriers to Follow-Up in a Community Glaucoma Detection Program VL - 55 ID - 6013 ER - TY - JOUR AB - The aim of this study was to investigate the effect of different ocular massage health education methods on ocular massage in glaucoma patients after trabeculectomy. Eighty-six patients with glaucoma after trabeculectomy (86 eyes) were randomly divided into two health education groups. One group was a watch video group (43 patients, 43 eyes), while the other was an orally taught health education group (43 patients, 43 eyes). Patients were followed up for 1 week, 1 month, and 3, 6, and 12 months after discharge. Records of the patient responses after health education, compliance of patients with follow-up, and intraocular pressure were determined. Measurements included intraocular pressure and differences between the watch video and orally taught health education groups. The differences between the watch video group and orally taught health education group were not statistically significant at 1 week and 1 month, while the differences were statistically significant at 3, 6, and 12 months. The results indicated that health education videos can enable glaucoma patients to have a better mastery of ocular massage after trabeculectomy. According to the needs of patients, health education video use produced good results and should be promoted. © 2014 Wolters Kluwer Health Lippincott Williams & Wilkins. AD - Tianjin Medical University, Eye Hospital, No. 251 FuKang Road, Nankai District, Tianjin 300384, China AU - Hua, L. AU - Yingjuan, L. AU - Jingshu, Z. AU - Wei, C. DB - Scopus DO - 10.1097/CIN.0000000000000062 IS - 6 KW - Health education video Intraocular pressure Ocular massage Trabeculectomy M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2014 SP - 294-298 ST - The effect of health education video on ocular massage after trabeculectomy T2 - CIN - Computers Informatics Nursing TI - The effect of health education video on ocular massage after trabeculectomy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902598435&doi=10.1097%2fCIN.0000000000000062&partnerID=40&md5=7c7cca6c95c0903821993d85c8081939 VL - 32 ID - 5388 ER - TY - JOUR AB - To investigate the indications, surgical procedure, clinical efficacy, and the prevention and management of complications of Descemet's stripping with endothelial keratoplasty (DSEK) for bullous keratopathy. Methods In the nonrandomized retrospective consecutive case series, 8 patients (8 eyes) with bullous keratopadiy at Zhongshan Ophthalmic Center between September 2006 and October 2007 underwent DSEK surgery. During the surgical procedure, the Descemet's membrane and abnormal endothelial layer were stripped from the central recipient posterior surface with 7. 75 mm diameter, and then a specially designed scraper was used to roughen the peripheral recipient posterior stroma. Other surgical techniques were the same with routine DSEK surgery. The adherence of the donor lenticule to the recipient posterior stroma and postoperative donor lenticule dislocation were monitored in the early stage after surgery. Best spectacle-corrected visual acuity (BSCVA), graft clearance, corneal astigmatism and endothelial cell density (ECD) were observed over a 3-9 months follow-up period. Results All donor lenticules were well adherent to the recipient posterior stroma and no graft dislocation occurred postoperatively. One patient had papillary block glaucoma at 1-day, and relieved after 48 hours postoperative. All grafts remained transparent, and had improved visual acuity. BSCVA was 0.3-0.7 postoperative. Six patients with preoperative pain had been pain free after DSEK procedure. Mean corneal astigmatism was (1. 90 ±0. 70) diopter(D). Mean ECD was (2014 ± 192) cells/mm2. Conclusions Compared with deep lamellar endothelial keratoplasty (DLEK), DSEK procedure is technically easier and less traumatic to recipient cornea and anterior chamber structures. The skill of roughening the peripheral recipient posterior stroma should prevent postoperative graft dislocation effectively. AD - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China AU - Huang, T. AU - Wang, Y. J. AU - Gao, N. AU - Chen, J. Q. DB - Scopus DO - 10.3760/cma.j.issn.04124081.2009.05.010 IS - 5 KW - Corneal diseases Corneal transplantation Descemet membrane Prognosis M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2009 SP - 430-435 ST - Preliminary clinical study of descemet' s stripping with endothelial keratoplasty for bullous keratopathy T2 - Chinese Journal of Ophthalmology TI - Preliminary clinical study of descemet' s stripping with endothelial keratoplasty for bullous keratopathy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67650100424&doi=10.3760%2fcma.j.issn.04124081.2009.05.010&partnerID=40&md5=a64fe55dae0f08ec8b9978be010836db VL - 45 ID - 5643 ER - TY - JOUR AB - Purpose: The primary objective of this study was to compare the intraocular pressure (IOP)-lowering efficacy of travoprost 0.004%/timolol 0.5% fixed combination to the concomitant administration of travoprost 0.004% (TRAVATAN®) and timolol 0.5% in subjects with open angle glaucoma or ocular hypertension. Methods: This was a randomized, multicenter, double-masked, active-controlled, parallel group study. Three hundred sixteen patients with open angle glaucoma or ocular hypertension were randomly assigned to travoprost 0.004%/timolol 0.5% ophthalmic solution fixed combination once daily in the morning or concomitant administration of timolol 0.5% once daily in the morning and travoprost 0.004% ophthalmic solution once daily in the evening. The efficacy and safety of the fixed combination were compared with concomitant therapy over three months. The primary efficacy outcome measure was mean intraocular pressure. Results: Both travoprost 0.004%/timolol 0.5% fixed combination and the concomitant administration of travoprost 0.004% and timolol 0.5% produced statistically significant reductions from baseline in IOP, with mean IOP ranging from 15.2 to 16.5 mm Hg in the patients using travoprost 0.004%/timolol 0.5% fixed combination compared with 14.7 to 16.1 mm Hg in the concomitant group. The upper 95.1% confidence limit for the differences in mean IOP (fixed combination minus concomitant) was ≤ 1.5 mm Hg at 7 of 9 visits, including all three 8 AM time points, 24-hours post-dose. Mean IOP reductions from baseline ranged from 7.4 to 9.4 mm Hg in the fixed combination group compared with 8.4 to 9.4 mm Hg with concomitant therapy. Safety analysis demonstrated equivalent safety between the two treatment groups. Conclusions: A fixed combination of travoprost 0.004% and timolol 0.5% produced clinically relevant TOP reductions in patients with open angle glaucoma or ocular hypertension that were comparable to concomitant therapy with its components. Safety and tolerability of the fixed combination were also equivalent to concomitant therapy. Travoprost 0.004%/timolol 0.5% fixed combination offers IOP reduction equivalent to concomitant therapy, with potential benefits that include convenience (fewer bottles and drops per day), improved compliance, cost savings (based on fewer co-payments), and elimination of potential washout effects. Copyright © 2005 by Lippincott Williams & Wilkins. AD - B.A. Hughes, Kresge Eye Institute, 4717 St. Antione, Detroit, MI 48201-1423, United States AU - Hughes, B. A. AU - Bacharach, J. AU - Craven, E. R. AU - Kaback, M. B. AU - Mallick, S. AU - Landry, T. A. AU - Bergamini, M. V. W. C1 - cosopt(Merck,United States) travatan(Alcon,United States) xalatan(Pfizer,United States) xalcom(Pfizer) C2 - Alcon(United States) Merck(United States) Pfizer(United States) DB - Embase Medline DO - 10.1097/01.ijg.0000176935.08392.14 IS - 5 KW - beta adrenergic receptor blocking agent dorzolamide dorzolamide plus timolol eye drops latanoprost latanoprost plus timolol timolol timolol plus travoprost travoprost unclassified drug adult aged article clinical trial controlled clinical trial controlled study cornea disease double blind procedure drug efficacy drug mechanism drug mixture drug safety drug tolerability dry eye female human hyperemia intraocular hypertension intraocular pressure major clinical study male multicenter study ocular pruritus open angle glaucoma patient compliance priority journal randomized controlled trial cosopt travatan xalatan xalcom LA - English M3 - Article N1 - L41383334 2005-10-26 PY - 2005 SN - 1057-0829 SP - 392-399 ST - A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension T2 - Journal of Glaucoma TI - A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41383334&from=export http://dx.doi.org/10.1097/01.ijg.0000176935.08392.14 VL - 14 ID - 3659 ER - TY - JOUR AB - Purpose: The primary objective of this study was to compare the intraocular pressure (IOP)-lowering efficacy of travoprost 0.004%/timolol 0.5% fixed combination to the concomitant administration of travoprost 0.004% (TRAVATAN®) and timolol 0.5% in subjects with open angle glaucoma or ocular hypertension. Methods: This was a randomized, multicenter, double-masked, active-controlled, parallel group study. Three hundred sixteen patients with open angle glaucoma or ocular hypertension were randomly assigned to travoprost 0.004%/timolol 0.5% ophthalmic solution fixed combination once daily in the morning or concomitant administration of timolol 0.5% once daily in the morning and travoprost 0.004% ophthalmic solution once daily in the evening. The efficacy and safety of the fixed combination were compared with concomitant therapy over three months. The primary efficacy outcome measure was mean intraocular pressure. Results: Both travoprost 0.004%/timolol 0.5% fixed combination and the concomitant administration of travoprost 0.004% and timolol 0.5% produced statistically significant reductions from baseline in IOP, with mean IOP ranging from 15.2 to 16.5 mm Hg in the patients using travoprost 0.004%/timolol 0.5% fixed combination compared with 14.7 to 16.1 mm Hg in the concomitant group. The upper 95.1% confidence limit for the differences in mean IOP (fixed combination minus concomitant) was ≤ 1.5 mm Hg at 7 of 9 visits, including all three 8 AM time points, 24-hours post-dose. Mean IOP reductions from baseline ranged from 7.4 to 9.4 mm Hg in the fixed combination group compared with 8.4 to 9.4 mm Hg with concomitant therapy. Safety analysis demonstrated equivalent safety between the two treatment groups. Conclusions: A fixed combination of travoprost 0.004% and timolol 0.5% produced clinically relevant TOP reductions in patients with open angle glaucoma or ocular hypertension that were comparable to concomitant therapy with its components. Safety and tolerability of the fixed combination were also equivalent to concomitant therapy. Travoprost 0.004%/timolol 0.5% fixed combination offers IOP reduction equivalent to concomitant therapy, with potential benefits that include convenience (fewer bottles and drops per day), improved compliance, cost savings (based on fewer co-payments), and elimination of potential washout effects. Copyright © 2005 by Lippincott Williams & Wilkins. AD - Kresge Eye Institute, Department of Opthalmology, Wayne State University School of Medicine, Detroit, MI, United States North Bay Eye Associates, Inc., Petaluma, CA, United States Glaucoma Consultants of Colorado, Littleton, CO, United States Glaucoma Consultants, Slingerlands, NY, United States Alcon Research Ltd., Forth Worth, TX, United States Kresge Eye Institute, 4717 St. Antione, Detroit, MI 48201-1423, United States AU - Hughes, B. A. AU - Bacharach, J. AU - Craven, E. R. AU - Kaback, M. B. AU - Mallick, S. AU - Landry, T. A. AU - Bergamini, M. V. W. DB - Scopus DO - 10.1097/01.ijg.0000176935.08392.14 IS - 5 KW - β-blocker Compliance Glaucoma Prostaglandin Timolol Travoprost M3 - Article N1 - Cited By :86 Export Date: 19 July 2021 PY - 2005 SP - 392-399 ST - A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension T2 - Journal of Glaucoma TI - A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-25644438390&doi=10.1097%2f01.ijg.0000176935.08392.14&partnerID=40&md5=4b0e11710c1dbe7feb4d56f959f621ee VL - 14 ID - 4941 ER - TY - JOUR AB - Purpose: The primary objective of this study was to compare the intraocular pressure (IOP)-lowering efficacy of travoprost 0.004%/timolol 0.5% fixed combination to the concomitant administration of travoprost 0.004% (TRAVATANg) and timolol 0.5% in subjects with open angle glaucoma or ocular hypertension. Methods: This was a randomized, multicenter, double-masked, active-controlled, parallel group study. Three hundred sixteen patients with open angle glaucoma or ocular hypertension were randomly assigned to travoprost 0.004%/timolol 0.5% ophthalmic solution fixed combination once daily in the morning or concomitant administration of timolol 0.5% once daily in the morning and travoprost 0.004% ophthalmic solution once daily in the evening. The efficacy and safety of the fixed combination were compared with concomitant therapy over three months. The primary efficacy outcome measure was mean intraocular pressure. Results: Both travoprost 0.004%/timolol 0.5% fixed combination and the concomitant administration of travoprost 0.004% and timolol 0.5% produced statistically significant reductions from baseline in IOP, with mean IOP ranging from 15.2 to 16.5 mm Hg in the patients using travoprost 0.004%/timolol 0.5% fixed combination compared with 14.7 to 16.1 mm Hg in the concomitant group. The upper 95.1% confidence limit for the differences in mean IOP (fixed combination minus concomitant) was <= 1.5 mm Hg at 7 of 9 visits, including all three 8 AM time points, 24-hours post-dose. Mean IOP reductions from baseline ranged from 7.4 to 9.4 mm Hg in the fixed combination group compared with 8.4 to 9.4 mm Hg with concomitant therapy. Safety analysis demonstrated equivalent safety between the two treatment groups. Conclusions: A fixed combination of travoprost 0.004% and timolol 0.5% produced clinically relevant IOP reductions in patients with open angle glaucoma or ocular hypertension that were comparable to concomitant therapy with its components. Safety and tolerability of the fixed combination were also equivalent to concomitant therapy. Travoprost 0.004%/timolol 0.5% fixed combination offers IOP reduction equivalent to concomitant therapy, with potential benefits that include convenience (fewer bottles and drops per day), improved compliance, cost savings (based on fewer co-payments), and elimination of potential washout effects. AN - WOS:000232119500012 AU - Hughes, B. A. AU - Bacharach, J. AU - Craven, E. R. AU - Kaback, M. B. AU - Mallick, S. AU - Landry, T. A. AU - Bergamini, M. V. W. DA - OCT DO - 10.1097/01.ijg.0000176935.08392.14 IS - 5 PY - 2005 SN - 1057-0829 1536-481X SP - 392-399 ST - A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension T2 - JOURNAL OF GLAUCOMA TI - A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension VL - 14 ID - 6149 ER - TY - JOUR AB - All eye drops raise problems of local tolerance, but with variable frequencies. They can induce pain on instillation, allergic reactions, delayed healing, punctate keratitis, disturbances of lacrimal secretion, disturbances of accommodation (especially the parasympathomimetics) and local pigmentation after prolonged use. Corticosteroids are associated with 2 major risks: chronic glaucoma and cataract, initially reversible if treatment is stopped. There is still a major risk of corneal herpes with corticosteroids. It is important to be aware of these local problems as they are responsible for poor patient compliance. The systemic effects essentially concern the agonists and antagonists of the autonomic nervous system. β-Blocker eye drops can cause bronchospasm, heart failure, syncope and psychiatric disorders, especially at high doses and with nonselective β-blockers. These consequences are usually related to failure to comply with the prescribing precautions. α-Adrenergic agonists, which exert dose-dependent effects, can induce hypertensive crises or angina attacks. Apart from patients at risk (children under the age of 30 months and the elderly), parasympathomimetics cause few systemic adverse effects; anticholinesterases, which have curare-like properties, are contraindicated for 6 weeks before general anaesthesia. In the very young and the very old, atropinic eye drops carry a risk of cardiovascular collapse and neuropsychiatric disturbances. Problems may also occur with other classes of drugs such as anti-infectives, antiseptics, anti-inflammatories and contact lens products. Nevertheless, it is clear that this form of treatment is generally very well tolerated in relation to the volume of eye drops prescribed by ophthalmologists each day. AD - F.-C. Hugues, Chef de Service, Service de Medecine Interne, Hopital Laennec, 42 Rue de Sevres, 75340 Paris Cedex, France AU - Hugues, F. C. AU - Le Jeunne, C. DB - Embase Medline IS - 5 KW - alpha adrenergic receptor stimulating agent antibiotic agent antivirus agent atropine derivative beta adrenergic receptor blocking agent betaxolol carteolol cholinergic receptor blocking agent cholinergic receptor stimulating agent corticosteroid eye drops local anesthetic agent metipranolol timolol accommodation allergic reaction angina pectoris article bronchospasm cataract drug tolerance glaucoma heart failure herpes simplex keratitis hypertension lacrimation mental disease pain patient compliance punctate keratitis respiratory tract disease shock faintness LA - English M3 - Article N1 - L23136528 1993-05-24 PY - 1993 SN - 0114-5916 SP - 365-380 ST - Systemic and local tolerability of ophthalmic drug formulations: An update T2 - Drug Safety TI - Systemic and local tolerability of ophthalmic drug formulations: An update UR - https://www.embase.com/search/results?subaction=viewrecord&id=L23136528&from=export VL - 8 ID - 4020 ER - TY - JOUR AD - J. Hunsaker AU - Hunsaker, J. AU - Kass, M. A. DB - Medline DO - 10.1097/00004397-198423000-00004 IS - 3 KW - aged anterior eye chamber article cataract cataract extraction follow up human open angle glaucoma patient compliance postoperative complication procedures time trabecular meshwork LA - English M3 - Article N1 - L14804649 1984-11-02 PY - 1984 SN - 0020-8167 SP - 33-42 ST - Combined procedures for cataract and glaucoma T2 - International ophthalmology clinics TI - Combined procedures for cataract and glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L14804649&from=export http://dx.doi.org/10.1097/00004397-198423000-00004 VL - 24 ID - 4080 ER - TY - JOUR AU - Hunsaker, J. AU - Kass, M. A. DB - Scopus DO - 10.1097/00004397-198423000-00004 IS - 3 M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 1984 SP - 33-42 ST - Combined procedures for cataract and glaucoma T2 - International ophthalmology clinics TI - Combined procedures for cataract and glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021488163&doi=10.1097%2f00004397-198423000-00004&partnerID=40&md5=3675bf14500bb97b015892abac49d371 VL - 24 ID - 5543 ER - TY - JOUR AB - IMPORTANCE: Medication persistence is an important factor for treatment effect in patients with glaucoma. Evaluating risk factors for refill discontinuation might be helpful for improving persistence and preventing blindness in patients with glaucoma. OBJECTIVES: To estimate the persistence rate with topical glaucoma medication 2 years after diagnosis and evaluate risk factors for nonpersistence among patients in Taiwan with open-angle glaucoma and ocular hypertension. DESIGN, SETTING, AND PARTICIPANTS: A retrospective population-based study using claims data from the National Health Insurance Research Database. One million patients were randomly selected from the registered beneficiaries of the National Health Insurance Research Database in 2000. All patients with newly diagnosed open-angle glaucoma and ocular hypertension were included and followed up until December 31, 2008. Patients were included in the analysis only if they had follow-up data for more than 2 years after diagnosis. MAIN OUTCOMES AND MEASURES: Nonpersistencewas defined as the patient not refilling any topical glaucoma medication for more than 90 days. Patient characteristics, prescription-related clinical factors, and physician and hospital characteristics were identified and considered in the analysis. The rate of persistence was estimated and risk factors for nonpersistence were investigated using Cox proportional regression models. RESULTS: A total of 3134 patients were identified and observed in the study. After a 2-year follow-up, 759 patients (24.2%) persisted with their glaucoma medications. Multivariate analysis showed that patients' living or working areas (P < .001), number of glaucoma medications (P < .001), prescription of pilocarpine hydrochloride (adjusted ratio of persistence = 0.72; 95%CI, 0.59-0.88) or prostaglandin analogs (adjusted ratio of persistence = 2.04; 95%CI, 1.82-2.33), the year in which glaucoma diagnosis was made (adjusted ratios of persistence for patients whose condition was diagnosed after 2004 = 1.18; 95%CI, 1.09-1.27), sex of the main physicians (adjusted ratios of persistence for maleophthalmologists = 0.82; 95%CI, 0.74-0.90), treatment in hospitals (P < .001), and continuity of care index (P < .001) were associated with patients' persistence with glaucoma medications. CONCLUSIONS AND RELEVANCE: The rate of persistence for glaucoma medications is low in Taiwan, although health care costs, including the cost of medication, are mostly covered by the nationwide health insurance system. This study suggests that factors other than cost, such as physician-patient relationship and patient education, may play an important role in the persistence of topical glaucoma medication. © 2014 American Medical Association. All rights reserved. AD - Department of Ophthalmology, Taichung Veterans General Hospital, Taichung, Taiwan Department of Ophthalmology, National Yang-Ming University School of Medicine, Taipei, Taiwan National Yang-Ming University School of Medicine, Taipei, Taiwan Department of Ophthalmology, Taipei Veterans General Hospital, 201 Shih-Pai Rd, Section 2, Taipei, 11217, Taiwan Department of Public Health, Institute of Public Health, National Yang-Ming University, Taipei, Taiwan Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan AU - Hwang, D. K. AU - Liu, C. J. L. AU - Pu, C. Y. AU - Chou, Y. J. AU - Chou, P. DB - Scopus DO - 10.1001/jamaophthalmol.2014.3333 IS - 12 M3 - Article N1 - Cited By :24 Export Date: 19 July 2021 PY - 2014 SP - 1446-1452 ST - Persistence of topical glaucoma medication a nationwide population-based cohort study in Taiwan T2 - JAMA Ophthalmology TI - Persistence of topical glaucoma medication a nationwide population-based cohort study in Taiwan UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84918555888&doi=10.1001%2fjamaophthalmol.2014.3333&partnerID=40&md5=92d1e6da9d63a7fb83ffed6454ab7bda VL - 132 ID - 5097 ER - TY - JOUR AB - IMPORTANCE Medication persistence is an important factor for treatment effect in patients with glaucoma. Evaluating risk factors for refill discontinuation might be helpful for improving persistence and preventing blindness in patients with glaucoma. OBJECTIVES To estimate the persistence rate with topical glaucoma medication 2 years after diagnosis and evaluate risk factors for nonpersistence among patients in Taiwan with open-angle glaucoma and ocular hypertension. DESIGN, SETTING, AND PARTICIPANTS A retrospective population-based study using claims data from the National Health Insurance Research Database. One million patients were randomly selected from the registered beneficiaries of the National Health Insurance Research Database in 2000. All patients with newly diagnosed open-angle glaucoma and ocular hypertension were included and followed up until December 31, 2008. Patients were included in the analysis only if they had follow-up data for more than 2 years after diagnosis. MAIN OUTCOMES AND MEASURES Nonpersistencewas defined as the patient not refilling any topical glaucoma medication for more than 90 days. Patient characteristics, prescription-related clinical factors, and physician and hospital characteristics were identified and considered in the analysis. The rate of persistence was estimated and risk factors for nonpersistence were investigated using Cox proportional regression models. RESULTS A total of 3134 patients were identified and observed in the study. After a 2-year follow-up, 759 patients (24.2%) persisted with their glaucoma medications. Multivariate analysis showed that patients' living or working areas (P<.001), number of glaucoma medications (P<.001), prescription of pilocarpine hydrochloride (adjusted ratio of persistence = 0.72; 95% CI, 0.59-0.88) or prostaglandin analogs (adjusted ratio of persistence = 2.04; 95% CI, 1.82-2.33), the year in which glaucoma diagnosis was made (adjusted ratios of persistence for patients whose condition was diagnosed after 2004 = 1.18; 95% CI, 1.09-1.27), sex of the main physicians (adjusted ratios of persistence for male ophthalmologists = 0.82; 95% CI, 0.74-0.90), treatment in hospitals (P<.001), and continuity of care index (P<.001) were associated with patients' persistence with glaucoma medications. CONCLUSIONS AND RELEVANCE The rate of persistence for glaucoma medications is low in Taiwan, although health care costs, including the cost of medication, are mostly covered by the nationwide health insurance system. This study suggests that factors other than cost, such as physician-patient relationship and patient education, may play an important role in the persistence of topical glaucoma medication. Copyright 2014 American Medical Association. All rights reserved. AN - WOS:000346176400012 AU - Hwang, D. K. AU - Liu, C. J. L. AU - Pu, C. Y. AU - Chou, Y. J. AU - Chou, P. DA - DEC DO - 10.1001/jamaophthalmol.2014.3333 IS - 12 PY - 2014 SN - 2168-6165 2168-6173 SP - 1446-1452 ST - Persistence of Topical Glaucoma Medication A Nationwide Population-Based Cohort Study in Taiwan T2 - JAMA OPHTHALMOLOGY TI - Persistence of Topical Glaucoma Medication A Nationwide Population-Based Cohort Study in Taiwan VL - 132 ID - 5931 ER - TY - JOUR AB - Purpose: Subjective symptoms and other eye complications were assessed and retrospectively compared in patients belonging to a proprietary membership system who switched from 2-week frequent replacement (2WFR) wear to daily disposable (DD) lens use. Methods: Questionnaire responses were completed by all patients for a 5-year interval between October 2008 and September 2013 from 83 wearers in three Japanese clinics (59 female and 24 male; average age: 33.4610.9 years). Complications were recorded for each patient at times of reexamination. Results: Over the 5-year observation period, the 83 patients wore lenses for more than 26 months. The average duration of use of 2WFR lenses was 14.562.7 days/lens (n=83) and subsequently 1.0360.12 days/lens (n=83) for DD lenses. Compliance with the duration of use was consistently good as monitored by requests for lens resupply in both wearing modalities. The subjective complaint of dryness tended to consistently show improvement by the change to DD wear: 18.1% vs. 30.1% (P=0.10, Fisher exact test). Among eye complications noted in each group, the occurrence of superficial punctate keratitis (SPK) was significantly decreased in DD wear: 9.6% vs. 26.5% (P=0.008, Fisher exact test). The main reasons given by patients for changing to DD wear were (1) "DD lens wear was more hygienic" (78.6%) and (2) "DD lens use is more convenient for travel/business trips" (64.3%). Comments after the switch in wear were (1) "easy and convenient" (95.7%) and (2) "I don't have to worry about expiration dates" on solutions (57.1%). Overall, 95.7% of wearers making the change answered as "satisfied" and "mostly satisfied." Conclusions: In the subscription membership program, which provided free lens replacement and/or reexamination, individual compliance with duration of wear in 2WFR wear cycles was good; however, these patients switching to DD wear tended to have improvement in their subjective complaints of dryness and objectively demonstrated a significant reduction of SPK at follow-up examinations. © 2015 Contact Lens Association of Ophthalmologists. AD - GPR and Research Department, Menicon Co, Ltd, 3-21-19, Aoi, Naka-ku, Nagoya, Aichi, 460-0006, Japan Marie Eye Clinic, Toyama, Japan Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United States AU - Ichijima, H. AU - Karino, S. AU - Sakata, H. AU - Cavanagh, H. D. DB - Scopus DO - 10.1097/ICL.0000000000000167 IS - 3 KW - 2-Week frequent replacement Compliance Complications Contact lens Daily disposable M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2016 SP - 190-195 ST - Improvement of subjective symptoms and eye complications when changing from 2-week frequent replacement to daily disposable contact lenses in a subscriber membership system T2 - Eye and Contact Lens TI - Improvement of subjective symptoms and eye complications when changing from 2-week frequent replacement to daily disposable contact lenses in a subscriber membership system UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84966599759&doi=10.1097%2fICL.0000000000000167&partnerID=40&md5=89f0132ee9cc7712840e098b66dc145b VL - 42 ID - 5379 ER - TY - JOUR AB - Purpose: Subjective symptoms and other eye complications were assessed and retrospectively compared in patients belonging to a proprietary membership system who switched from 2-week frequent replacement (2WFR) wear to daily disposable (DD) lens use. Methods: Questionnaire responses were completed by all patients for a 5-year interval between October 2008 and September 2013 from 83 wearers in three Japanese clinics (59 female and 24 male; average age: 33.4 +/- 10.9 years). Complications were recorded for each patient at times of reexamination. Results: Over the 5-year observation period, the 83 patients wore lenses for more than 26 months. The average duration of use of 2WFR lenses was 14.5 +/- 2.7 days/lens (n=83) and subsequently 1.03 +/- 0.12 days/lens (n=83) for DD lenses. Compliance with the duration of use was consistently good as monitored by requests for lens resupply in both wearing modalities. The subjective complaint of dryness tended to consistently show improvement by the change to DD wear: 18.1% vs. 30.1% (P=0.10, Fisher exact test). Among eye complications noted in each group, the occurrence of superficial punctate keratitis (SPK) was significantly decreased in DD wear: 9.6% vs. 26.5% (P=0.008, Fisher exact test). The main reasons given by patients for changing to DD wear were (1) "DD lens wear was more hygienic" (78.6%) and (2) "DD lens use is more convenient for travel/business trips" (64.3%). Comments after the switch in wear were (1) "easy and convenient" (95.7%) and (2) "I don't have to worry about expiration dates" on solutions (57.1%). Overall, 95.7% of wearers making the change answered as "satisfied" and "mostly satisfied." Conclusions: In the subscription membership program, which provided free lens replacement and/or reexamination, individual compliance with duration of wear in 2WFR wear cycles was good; however, these patients switching to DD wear tended to have improvement in their subjective complaints of dryness and objectively demonstrated a significant reduction of SPK at follow-up examinations. AN - WOS:000375941600009 AU - Ichijima, H. AU - Karino, S. AU - Sakata, H. AU - Cavanagh, H. D. DA - MAY DO - 10.1097/ICL.0000000000000167 IS - 3 PY - 2016 SN - 1542-2321 1542-233X SP - 190-195 ST - Improvement of Subjective Symptoms and Eye Complications When Changing From 2-Week Frequent Replacement to Daily Disposable Contact Lenses in a Subscriber Membership System T2 - EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE TI - Improvement of Subjective Symptoms and Eye Complications When Changing From 2-Week Frequent Replacement to Daily Disposable Contact Lenses in a Subscriber Membership System VL - 42 ID - 6335 ER - TY - JOUR AB - PURPOSE: To obtain useful information for the improvement of patient compliance in the medical treatment of glaucoma. SUBJECTS AND METHODS: An unsigned attitude survey on glaucoma and eye drops was conducted with 431 glaucoma patients. Correlation between compliance and individual(objective and subjective) factors was investigated. Objective factors were age, sex, number of eye drop products, duration of disease, and degree of visual field defects. Subjective factors were "stinging sensation with application of eye drops" and "worry about blindness". RESULTS: Thirty-eight percent of the glaucoma patients were compliant, instilling eye drops at the right time and with good technique. For the factor "duration of disease", patients who had glaucoma for 6-10 years had the best compliance. Compliance became poorer with an increasing number of eye drop products. In the subjective factors, less pain and worry led patients to better compliance. CONCLUSION: To improve compliance with medical treatment, we should categorize patients based on objective factors, eliminating their pain and worry, and instructing them not only in the frequency of instillation but also in the technique of administration. AD - T. Ikushima, Department of Ophthalmology, Kyoto Prefecture University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokouji, Kamigyo-ku, Kyoto 602-0841, Japan. AU - Ikushima, T. AU - Mori, K. AU - Ishibashi, T. AU - Ikeda, Y. AU - Naruse, S. AU - Hozono, Y. AU - Kinoshita, S. DB - Medline IS - 7 KW - article attitude female glaucoma human male middle aged patient patient compliance psychological aspect LA - Japanese M3 - Article N1 - L44381400 2006-09-19 PY - 2006 SN - 0029-0203 SP - 497-503 ST - Relationship between compliance and background factors of glaucoma patients T2 - Nippon Ganka Gakkai zasshi TI - Relationship between compliance and background factors of glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44381400&from=export VL - 110 ID - 3602 ER - TY - JOUR AB - Purpose: To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin®). Design: Retrospective interventional case series. Methods: Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks. Results: IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment. Conclusion: IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG. © 2006 Elsevier Inc. All rights reserved. AD - Department of Ophthalmology, University of Bern, Inselspital, Bern, Switzerland AU - Iliev, M. E. AU - Domig, D. AU - Wolf-Schnurrbursch, U. AU - Wolf, S. AU - Sarra, G. M. DB - Scopus DO - 10.1016/j.ajo.2006.06.066 IS - 6 M3 - Article N1 - Cited By :212 Export Date: 19 July 2021 PY - 2006 SP - 1054-1056 ST - Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma T2 - American Journal of Ophthalmology TI - Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845227094&doi=10.1016%2fj.ajo.2006.06.066&partnerID=40&md5=616df1137a2dcdcf94babc220e472fdc VL - 142 ID - 4906 ER - TY - JOUR AB - Purpose: To evaluate the usefulness of the krypton laser for transscleral contact cyclophotocoagulation. Methods: Transscleral contact krypton laser cyclophotocoagulation was performed in 62 eyes of 57 patients with therapy-resistant glaucoma. A minimum follow-up for 6 months was obtained for 59 eyes. The krypton laser was delivered via a fiberoptic probe with compression of the sclera by the probe. The energy used was 4 to 5 J per application at the tip of the probe with an exposure time of 10 seconds. Results: The intraocular pressure (IOP) decreased from the baseline mean of 34.8 ± 11.0 mmHg to 20.4 ± 8.3 mmHg within 10 days, to 22.6 ± 12.5 mmHg at 1 month, to 21.3 ± 11.3 mmHg at 3 months, and to 20.9 ± 9.1 mmHg at 6 months postoperatively. Intraocular pressures of 8 to 24 mmHg were obtained in 62% of the eyes at 1 month, 60% at 3 months, and 73% at 6 months postoperatively with one or more cyclophotocoagulations but no other hypotensive procedures. The corresponding success rates after 6 months were 82% for eyes in which the procedure was performed to preserve vision and 50% for eyes in which the procedure was performed to relieve pain. No clinical signs of scleral injury or cyclodestruction-related loss of vision were detected. Conclusions: Krypton laser cyclophotocoagulation appears to be an effective and well-tolerated means of lowering IOP in therapy-resistant glaucoma. An advantage of the method is that standard retinal krypton photocoagulators can be used for the procedure. © 1994, American Academy of Ophthalmology, Inc. All rights reserved. AD - Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland AU - Immonen, I. J. R. AU - Puska, P. AU - Raitta, C. DB - Scopus DO - 10.1016/S0161-6420(94)31244-9 IS - 5 M3 - Article N1 - Cited By :26 Export Date: 19 July 2021 PY - 1994 SP - 876-882 ST - Transscleral Contact Krypton Laser Cyclophotocoagulation for Treatment of Glaucoma T2 - Ophthalmology TI - Transscleral Contact Krypton Laser Cyclophotocoagulation for Treatment of Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028278161&doi=10.1016%2fS0161-6420%2894%2931244-9&partnerID=40&md5=b8e8d2be1b51d1071deffdc450019491 VL - 101 ID - 5087 ER - TY - JOUR AB - The article presents questions and answers related to the concerns of patients with glaucoma and how can they be addressed in general practice. AD - GP trainee, Princess Alexandra Eye Pavilion, Edinburgh Consultant ophthalmic surgeon, Princess Alexandra Eye Pavilion, Edinburgh AN - 114779872. Language: English. Entry Date: 20170601. Revision Date: 20190514. Publication Type: journal article. Journal Subset: Biomedical AU - Imrie, Claire AU - Tatham, Andrew J. DB - ccm DO - 10.3399/bjgp16X685165 DP - EBSCOhost IS - 646 KW - Ophthalmic Solutions -- Therapeutic Use Glaucoma -- Diagnosis Antihypertensive Agents -- Therapeutic Use Age Factors Patient Compliance Referral and Consultation Health Behavior Patient Education Glaucoma -- Physiopathology Glaucoma -- Therapy Questionnaires N1 - Europe; Peer Reviewed; UK & Ireland. Instrumentation: General Health Questionnaire (GHQ). NLM UID: 9005323. PMID: NLM27127293. PY - 2016 SN - 0960-1643 SP - e371-e373 ST - Glaucoma: the patient's perspective T2 - British Journal of General Practice TI - Glaucoma: the patient's perspective UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=114779872&site=ehost-live&scope=site VL - 66 ID - 4376 ER - TY - JOUR AB - To examine safety and efficacy of bandage soft contact lenses (BSCLs) for ocular chronic graft-versus host disease (GVHD), we conducted a phase II clinical trial. Extended-wear BSCLs were applied under daily topical antibiotic prophylaxis. Patients completed standardized symptom questionnaires at enrollment and at 2 weeks, 4 weeks, and 3 months afterward. Ophthalmologic assessment was performed at enrollment, at 2 weeks, and afterward as medically needed. Assessments at follow-up were compared with baseline by paired t-test. Nineteen patients with ocular GVHD who remained symptomatic despite conventional treatments were studied. The mean Lee eye subscale score was 75.4 at enrollment and improved significantly to 63.2 at 2 weeks (P = .01), to 61.8 at 4 weeks (P = .005), and to 56.3 at 3 months (P = .02). The ocular surface disease index score and 11-point eye symptom ratings also improved significantly. According to the Lee eye subscale, clinically meaningful improvement was observed in 9 patients (47%) at 2 weeks, in 11 patients (58%) at 4 weeks, and in 9 patients (47%) at 3 months. Visual acuity improved significantly at 2 weeks compared with enrollment values. Based on slit lamp exam at 2 weeks, punctate epithelial erosions improved in 58% of the patients, showed stability in 16%, and worsened in 5%. No corneal ulceration or ocular infection occurred. BSCLs are a widely available, safe, and effective treatment option that improves manifestations of ocular GVHD in approximately 50% of patients. This study was registered at www.clinicaltrials.gov as NCT01616056. © 2015 American Society for Blood and Marrow Transplantation. AD - Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, United States Department of Ophthalmology, University of Washington, Seattle, WA, United States Department of Bioengineering, University of Washington, Seattle, WA, United States AU - Inamoto, Y. AU - Sun, Y. C. AU - Flowers, M. E. D. AU - Carpenter, P. A. AU - Martin, P. J. AU - Li, P. AU - Wang, R. AU - Chai, X. AU - Storer, B. E. AU - Shen, T. T. AU - Lee, S. J. DB - Scopus DO - 10.1016/j.bbmt.2015.07.013 IS - 11 KW - Contact lens Dry eye disease Graft-versus-host disease Hematopoietic cell transplantation Treatment M3 - Article N1 - Cited By :18 Export Date: 19 July 2021 PY - 2015 SP - 2002-2007 ST - Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease T2 - Biology of Blood and Marrow Transplantation TI - Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943456910&doi=10.1016%2fj.bbmt.2015.07.013&partnerID=40&md5=20d74d55cb4d8450c09bf9baba4e6ec7 VL - 21 ID - 5157 ER - TY - JOUR AB - Purpose: To evaluate the efficacy and safety of tafluprost/timolol fixed combination (TTFC). Study design: A prospective clinical study. Methods: Twenty-eight patients (28 eyes) with primary open-angle glaucoma, who had used tafluprost and timolol gel for at least 3 months with good adherence, were enrolled. Concomitant administration of tafluprost and timolol was switched to TTFC without a washout period. The intraocular pressure (IOP), blood pressure, pulse rate, and ocular signs were compared between before switching (baseline), and 4 and 8 weeks after switching. A questionnaire survey was also performed 4 weeks after switching to investigate ocular comfort and patient preferences. Results: The IOP showed no significant change after switching to TTFC (14.8 ± 2.8, 14.6 ± 3.4, and 14.8 ± 3.7 mmHg at baseline, Week 4, and Week 8, respectively). The pulse rate and systolic blood pressure showed no changes, but diastolic blood pressure was significantly lower at Week 8. At baseline, fluorescein staining revealed corneal abnormalities in 3 patients, which resolved by Week 8 in 1 patient. Hyperemia was noted in 2 patients at baseline, and this also resolved by Week 8 in 1 patient. Three patients discontinued study treatment for the following reasons (1 patient each): blurred vision; ocular irritation, eyelid erythema, and asthenopia; and loss to follow-up from Week 8. The questionnaire survey revealed no significant differences between the 2 treatments, although more patients preferred TTFC. Conclusion: Among 28 patients enrolled, only 2 patients discontinued the study treatment due to adverse reactions. In patients whose adherence was considered relatively good to concomitant therapy, switching to TTFC achieved similar IOP control with good safety and a high level of patient acceptance. AD - K. Inoue, Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, Tokyo, Japan AU - Inoue, K. AU - Kawashima, T. AU - Katakura, S. AU - Shidara, K. AU - Fujimoto, T. AU - Kohmoto, H. AU - Shiokawa, M. AU - Moriyama, R. AU - Okayama, R. C1 - tapcom(Santen) tapros(Santen,Japan) timoptol(Santen) C2 - Santen Santen(Japan) DB - Embase DO - 10.2147/OPTH.S150595 KW - 000016052 fluorescein tafluprost tafluprost plus timolol tapcom timolol timolol maleate adult aged article asthenopia bedtime dosage blurred vision clinical article clinical trial conjunctival hyperemia controlled study diastolic blood pressure drug efficacy drug safety drug substitution drug withdrawal eye irritation eyelid erythema female follow up human informed consent intraocular pressure male morning dosage open angle glaucoma patient compliance patient preference prospective study pulse rate questionnaire systolic blood pressure tapros timoptol LA - English M3 - Article N1 - L621319849 2018-03-29 2018-04-06 PY - 2018 SN - 1177-5483 1177-5467 SP - 549-554 ST - Switching from concomitant therapy to tafluprost/timolol fixed combination T2 - Clinical Ophthalmology TI - Switching from concomitant therapy to tafluprost/timolol fixed combination UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621319849&from=export http://dx.doi.org/10.2147/OPTH.S150595 VL - 12 ID - 2600 ER - TY - JOUR AB - Purpose: To evaluate the efficacy and safety of tafluprost/timolol fixed combination (TTFC). Study design: A prospective clinical study. Methods: Twenty-eight patients (28 eyes) with primary open-angle glaucoma, who had used tafluprost and timolol gel for at least 3 months with good adherence, were enrolled. Concomitant administration of tafluprost and timolol was switched to TTFC without a washout period. The intraocular pressure (IOP), blood pressure, pulse rate, and ocular signs were compared between before switching (baseline), and 4 and 8 weeks after switching. A questionnaire survey was also performed 4 weeks after switching to investigate ocular comfort and patient preferences. Results: The IOP showed no significant change after switching to TTFC (14.8 ± 2.8, 14.6 ± 3.4, and 14.8 ± 3.7 mmHg at baseline, Week 4, and Week 8, respectively). The pulse rate and systolic blood pressure showed no changes, but diastolic blood pressure was significantly lower at Week 8. At baseline, fluorescein staining revealed corneal abnormalities in 3 patients, which resolved by Week 8 in 1 patient. Hyperemia was noted in 2 patients at baseline, and this also resolved by Week 8 in 1 patient. Three patients discontinued study treatment for the following reasons (1 patient each): blurred vision; ocular irritation, eyelid erythema, and asthenopia; and loss to follow-up from Week 8. The questionnaire survey revealed no significant differences between the 2 treatments, although more patients preferred TTFC. Conclusion: Among 28 patients enrolled, only 2 patients discontinued the study treatment due to adverse reactions. In patients whose adherence was considered relatively good to concomitant therapy, switching to TTFC achieved similar IOP control with good safety and a high level of patient acceptance. © 2018 Inoue et al. AD - Inouye Eye Hospital, Tokyo, Japan AU - Inoue, K. AU - Kawashima, T. AU - Katakura, S. AU - Shidara, K. AU - Fujimoto, T. AU - Kohmoto, H. AU - Shiokawa, M. AU - Moriyama, R. AU - Okayama, R. DB - Scopus DO - 10.2147/OPTH.S150595 KW - Adverse reactions Intraocular pressure Switching Tafluprost/timolol fixed combination M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2018 SP - 549-554 ST - Switching from concomitant therapy to tafluprost/timolol fixed combination T2 - Clinical Ophthalmology TI - Switching from concomitant therapy to tafluprost/timolol fixed combination UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044274587&doi=10.2147%2fOPTH.S150595&partnerID=40&md5=c878e37ba2e540e768a6eea589d72948 VL - 12 ID - 5620 ER - TY - JOUR AB - Purpose: To evaluate the efficacy and safety of tafluprost/timolol fixed combination (TTFC). Study design: A prospective clinical study. Methods: Twenty-eight patients (28 eyes) with primary open-angle glaucoma, who had used tafluprost and timolol gel for at least 3 months with good adherence, were enrolled. Concomitant administration of tafluprost and timolol was switched to TTFC without a washout period. The intraocular pressure (IOP), blood pressure, pulse rate, and ocular signs were compared between before switching (baseline), and 4 and 8 weeks after switching. A questionnaire survey was also performed 4 weeks after switching to investigate ocular comfort and patient preferences. Results: The IOP showed no significant change after switching to TTFC (14.8 +/- 2.8, 14.6 +/- 3.4, and 14.8 +/- 3.7 mmHg at baseline, Week 4, and Week 8, respectively). The pulse rate and systolic blood pressure showed no changes, but diastolic blood pressure was significantly lower at Week 8. At baseline, fluorescein staining revealed corneal abnormalities in 3 patients, which resolved by Week 8 in 1 patient. Hyperemia was noted in 2 patients at baseline, and this also resolved by Week 8 in 1 patient. Three patients discontinued study treatment for the following reasons (1 patient each): blurred vision; ocular irritation, eyelid erythema, and asthenopia; and loss to follow-up from Week 8. The questionnaire survey revealed no significant differences between the 2 treatments, although more patients preferred TTFC. Conclusion: Among 28 patients enrolled, only 2 patients discontinued the study treatment due to adverse reactions. In patients whose adherence was considered relatively good to concomitant therapy, switching to TTFC achieved similar IOP control with good safety and a high level of patient acceptance. AN - WOS:000428048000001 AU - Inoue, K. AU - Kawashima, T. AU - Katakura, S. AU - Shidara, K. AU - Fujimoto, T. AU - Kohmoto, H. AU - Shiokawa, M. AU - Moriyama, R. AU - Okayama, R. DO - 10.2147/OPTH.S150595 PY - 2018 SN - 1177-5483 SP - 549-554 ST - Switching from concomitant therapy to tafluprost/timolol fixed combination T2 - CLINICAL OPHTHALMOLOGY TI - Switching from concomitant therapy to tafluprost/timolol fixed combination VL - 12 ID - 6309 ER - TY - JOUR AB - Purpose: Latanoprost 0.005%/timolol maleate 0.5% combination eye drops are now available in Japan. The aim of the present study was to investigate the prospective intraocular pressure (IOP) reduction effects and adherence with the combination eye drops in Japanese patients. Methods: The subjects were 162 patients (162 eyes) with glaucoma or ocular hypertension concomitantly using latanoprost 0.005% and timolol maleate 0.5% eye drops. Concomitant use of the 2 eye drops was stopped, and patients were switched to the latanoprost 0.005%/timolol maleate 0.5% combination eye drops without any washout period. IOP was measured before the switch, and at 1 and 3 months after the switch, and then compared. A questionnaire survey on adherence was also conducted 1 month after the switch. Results: IOP was the same before and after the switch: 15.2±3.3 mmHg before the switch, 14.9±3.0 mmHg 1 month after the switch, and 15.1±3.2 mmHg 3 months after the switch. According to the questionnaire survey, the frequency of forgetting to administer eye drops decreased with the switch, but 45.1% of the patients experienced irritation. About 82.1% replied that they preferred the latanoprost 0.005%/timolol maleate 0.5% combination eye drops. By the third month after the switch, 13 patients (8.0%) had discontinued the eye drops due to side effects or insufficient IOP reduction. Conclusion: The switch from the concomitant use of latanoprost 0.005% and timolol maleate 0.5% eye drops to latanoprost 0.005%/timolol maleate 0.5% combination eye drops improved adherence and helped maintain IOP. © Mary Ann Liebert, Inc. AD - K. Inoue, Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan AU - Inoue, K. AU - Okayama, R. AU - Higa, R. AU - Sawada, H. AU - Wakakura, M. AU - Tomita, G. C1 - rysmon tg(Wakamoto Pharmaceutical,Japan) timoptol xe timoptol(Merck Sharp and Dohme,Japan) xalacom(Pfizer,Japan) C2 - Merck Sharp and Dohme(Japan) Pfizer(Japan) Wakamoto Pharmaceutical(Japan) DB - Embase Medline DO - 10.1089/jop.2011.0057 IS - 6 KW - brinzolamide dorzolamide latanoprost latanoprost plus timolol rysmon tg timolol maleate unclassified drug adult aged article drug effect drug safety drug substitution drug withdrawal eye irritation eye pain female human intraocular hypertension intraocular pressure major clinical study male ocular pruritus open angle glaucoma patient compliance questionnaire timoptol xe timoptol xalacom LA - English M3 - Article N1 - L363086182 2011-12-21 2011-12-23 PY - 2011 SN - 1080-7683 1557-7732 SP - 581-587 ST - Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination T2 - Journal of Ocular Pharmacology and Therapeutics TI - Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination UR - https://www.embase.com/search/results?subaction=viewrecord&id=L363086182&from=export http://dx.doi.org/10.1089/jop.2011.0057 VL - 27 ID - 3126 ER - TY - JOUR AB - Purpose: To investigate the short-term intraocular pressure-lowering efficacy and safety of switching from a fixed combination of latanoprost/timolol to a fixed combination of latano-prost/carteolol. Patients and Methods: The subjects were 30 eyes of 30 adult patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who were using a latanoprost-/timolol-fixed combination with insufficient intraocular pressure-lowering efficacy or adverse reactions. The subjects were switched from once-daily latanoprost/timolol to once-daily latanoprost/carteolol with no washout interval. Intraocular pressure, tear film break-up time, corneal epithelial defects, conjunctival hyperemia, blood pressure, and pulse rate were measured and compared before and 1 and 3 months after switching. Patients were monitored for adverse reactions at each visit, and dropouts were recorded. Results: The mean intraocular pressure at 1 month (15.9±3.1 mmHg) and 3 months (16.3 ±3.8 mmHg) was not significantly different from that at baseline (16.1±3.1 mmHg). The tear film break-up time and corneal epithelial defects were significantly improved after switching (p<0.01 and p<0.0001, respectively). There was a significant decrease in systolic blood pressure after 1 month and diastolic pressure after 3 months (p<0.05). There was no significant change in pulse rate during the study. Adverse reactions (blurred vision, blepharitis, and conjunctival hyperemia) occurred in 3 patients (10.0%). Four patients (13.3%) discontinued treatment during the 3-month study period. Conclusion: A switch from a fixed combination of latanoprost/timolol to that of latanoprost/ carteolol can maintain intraocular pressure and adherence with once-daily administration while improving tear film break-up time and corneal epithelial defects. © 2020 Inoue et al. AD - Inouye Eye Hospital, Tokyo, Japan Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan AU - Inoue, K. AU - Piao, H. AU - Iwasa, M. AU - Ishida, K. AU - Tomita, G. DB - Scopus DO - 10.2147/OPTH.S240425 KW - Adverse reactions Eye drops Glaucoma Intraocular pressure M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 1207-1214 ST - Short-term efficacy and safety of switching from a latanoprost/timolol fixed combination to a latanoprost/carteolol fixed combination T2 - Clinical Ophthalmology TI - Short-term efficacy and safety of switching from a latanoprost/timolol fixed combination to a latanoprost/carteolol fixed combination UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084348636&doi=10.2147%2fOPTH.S240425&partnerID=40&md5=606ec3c3bfd58cc5fbc2e2d996356eb7 VL - 14 ID - 5715 ER - TY - JOUR AB - Purpose: To investigate the short-term intraocular pressure-lowering efficacy and safety of switching from a fixed combination of latanoprost/timolol to a fixed combination of latanoprost/carteolol. Patients and Methods: The subjects were 30 eyes of 30 adult patients with primary openangle glaucoma, normal-tension glaucoma, or ocular hypertension who were using a latanoprost-/timolol-fixed combination with insufficient intraocular pressure-lowering efficacy or adverse reactions. The subjects were switched from once-daily latanoprost/timolol to once-daily latanoprost/carteolol with no washout interval. Intraocular pressure, tear film break-up time, corneal epithelial defects, conjunctival hyperemia, blood pressure, and pulse rate were measured and compared before and 1 and 3 months after switching. Patients were monitored for adverse reactions at each visit, and dropouts were recorded. Results: The mean intraocular pressure at 1 month (15.9 +/- 3.1 mmHg) and 3 months (16.3 +/- 3.8 mmHg) was not significantly different from that at baseline (16.1 +/- 3.1 mmHg). The tear film break-up time and corneal epithelial defects were significantly improved after switching (p<0.01 and p<0.0001, respectively). There was a significant decrease in systolic blood pressure after 1 month and diastolic pressure after 3 months (p<0.05). There was no significant change in pulse rate during the study. Adverse reactions (blurred vision, blepharitis, and conjunctival hyperemia) occurred in 3 patients (10.0%). Four patients (13.3%) discontinued treatment during the 3-month study period. Conclusion: A switch from a fixed combination of latanoprost/timolol to that of latanoprost/carteolol can maintain intraocular pressure and adherence with once-daily administration while improving tear film break-up time and corneal epithelial defects. AN - WOS:000530334000001 AU - Inoue, K. AU - Piao, H. AU - Iwasa, M. AU - Ishida, K. AU - Tomita, G. DO - 10.2147/OPTH.S240425 PY - 2020 SN - 1177-5483 SP - 1207-1214 ST - Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination T2 - CLINICAL OPHTHALMOLOGY TI - Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination VL - 14 ID - 6211 ER - TY - JOUR AB - Purpose: To evaluate the safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% fixed-combination (DTFC) eye drops to brinzolamide 1.0%/timolol maleate 0.5% fixed-combination (BTFC) eye drops in patients with primary open-angle glaucoma or ocular hypertension. Methods: A total of 35 eyes of 35 patients with primary open-angle glaucoma or ocular hypertension using DTFC eye drops were included. Participants discontinued DTFC drops and immediately began using BTFC drops. All other eye drops currently being used were continued. Intraocular pressure (IOP) 1 and 3 months after switching medications was compared with baseline IOP. One month after switching medications, participant preference and adherence were evaluated. Adverse reactions were monitored at each study visit. Results: The IOP was 17.9±2.6 mmHg at baseline and 18.3±4.1 mmHg and 17.8±3.4 mmHg 1 month and 3 months after switching medications, respectively (P=0.633). The frequency of missing a dose was not different before (6.1%) and after (6.1%) switching to BTFC. Significantly fewer participants reported stinging after switching to BTFC (15.2%) than while using DTFC (51.5%, P,0.01). Blurred vision was reported with the same frequency before (39.4%) and after (42.4%) switching to BTFC. A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively. Several patients withdrew from the study because of discomfort (n=2, 5.7%), discharge (n=1, 2.9%), dizziness (n=1, 2.9%), or increased IOP (n=2, 5.7%). Conclusion: Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence. When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option. AD - K. Inoue, Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, Tokyo, Japan AU - Inoue, K. AU - Shiokawa, M. AU - Ishida, K. AU - Tomita, G. C1 - azarga(Alcon,United States) cosopt(Merck,United States) C2 - Alcon(United States) Merck(United States) DB - Embase DO - 10.2147/OPTH.S79843 KW - brinzolamide plus timolol dorzolamide plus timolol maleate eye drops adult aged article blurred vision clinical article clinical trial dizziness drug efficacy drug preference drug safety drug substitution drug withdrawal evening dosage eye discharge eye discomfort female human intraocular hypertension intraocular pressure male medication compliance morning dosage open angle glaucoma pain patient comfort patient compliance patient preference stinging azarga cosopt LA - English M3 - Article N1 - L604437792 2015-05-27 2015-05-29 PY - 2015 SN - 1177-5483 1177-5467 SP - 619-623 ST - Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops T2 - Clinical Ophthalmology TI - Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604437792&from=export http://dx.doi.org/10.2147/OPTH.S79843 VL - 9 ID - 2817 ER - TY - JOUR AB - Purpose: To evaluate the safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% fixed-combination (DTFC) eye drops to brinzolamide 1.0%/timolol maleate 0.5% fixed-combination (BTFC) eye drops in patients with primary open-angle glaucoma or ocular hypertension. Methods: A total of 35 eyes of 35 patients with primary open-angle glaucoma or ocular hypertension using DTFC eye drops were included. Participants discontinued DTFC drops and immediately began using BTFC drops. All other eye drops currently being used were continued. Intraocular pressure (IOP) 1 and 3 months after switching medications was compared with baseline IOP. One month after switching medications, participant preference and adherence were evaluated. Adverse reactions were monitored at each study visit. Results: The IOP was 17.9±2.6 mmHg at baseline and 18.3±4.1 mmHg and 17.8±3.4 mmHg 1 month and 3 months after switching medications, respectively (P=0.633). The frequency of missing a dose was not different before (6.1%) and after (6.1%) switching to BTFC. Significantly fewer participants reported stinging after switching to BTFC (15.2%) than while using DTFC (51.5%, P,0.01). Blurred vision was reported with the same frequency before (39.4%) and after (42.4%) switching to BTFC. A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively. Several patients withdrew from the study because of discomfort (n=2, 5.7%), discharge (n=1, 2.9%), dizziness (n=1, 2.9%), or increased IOP (n=2, 5.7%). Conclusion: Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence. When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option. © 2015 Leung et al. AD - Inouye Eye Hospital, Tokyo, Japan Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan AU - Inoue, K. AU - Shiokawa, M. AU - Ishida, K. AU - Tomita, G. DB - Scopus DO - 10.2147/OPTH.S79843 KW - Brinzolamide/timolol fixed-combination Dorzolamide/timolol fixed-combination Intraocular pressure Safety Switch M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2015 SP - 619-623 ST - Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops T2 - Clinical Ophthalmology TI - Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929579875&doi=10.2147%2fOPTH.S79843&partnerID=40&md5=92fda783b523f362e70e76b2830fadfc VL - 9 ID - 5466 ER - TY - JOUR AB - Purpose: To evaluate the safety and efficacy of switching from dorzolamide 1.0%/ timolol maleate 0.5% fixed-combination (DTFC) eye drops to brinzolamide 1.0%/ timolol maleate 0.5% fixed-combination (BTFC) eye drops in patients with primary open-angle glaucoma or ocular hypertension. Methods: A total of 35 eyes of 35 patients with primary open-angle glaucoma or ocular hypertension using DTFC eye drops were included. Participants discontinued DTFC drops and immediately began using BTFC drops. All other eye drops currently being used were continued. Intraocular pressure (IOP) 1 and 3 months after switching medications was compared with baseline IOP. One month after switching medications, participant preference and adherence were evaluated. Adverse reactions were monitored at each study visit. Results: The IOP was 17.9 +/- 2.6 mmHg at baseline and 18.3 +/- 4.1 mmHg and 17.8 +/- 3.4 mmHg 1 month and 3 months after switching medications, respectively (P=0.633). The frequency of missing a dose was not different before (6.1%) and after (6.1%) switching to BTFC. Significantly fewer participants reported stinging after switching to BTFC (15.2%) than while using DTFC (51.5%, P < 0.01). Blurred vision was reported with the same frequency before (39.4%) and after (42.4%) switching to BTFC. A total of 33.3% and 27.3% of patients preferred DTFC and BTFC, respectively. Several patients withdrew from the study because of discomfort (n=2, 5.7%), discharge (n=1, 2.9%), dizziness (n=1, 2.9%), or increased IOP (n=2, 5.7%). Conclusion: Switching from DTFC to BTFC was well tolerated and did not result in IOP changes or a decreased patient adherence. When glaucoma patients complain of stinging with DTFC administration, switching to BTFC is an acceptable treatment option. AN - WOS:000366273600002 AU - Inoue, K. AU - Shiokawa, M. AU - Ishida, K. AU - Tomita, G. DO - 10.2147/OPTH.S79843 PY - 2015 SN - 1177-5483 SP - 619-623 ST - Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops T2 - CLINICAL OPHTHALMOLOGY TI - Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops VL - 9 ID - 6181 ER - TY - JOUR AB - Purpose: To investigate the ocular hypotensive effect and safety of dorzolamide hydrochloride 1 %/timolol maleate 0.5 % fixed-combination eye drops. Methods: The study cohort comprised 34 patients with either primary open-angle glaucoma or ocular hypertension who were being concomitantly treated with dorzolamide hydrochloride 1 % eye drops and timolol maleate 0.5 % eye drops. The dorzolamide hydrochloride 1 % and timolol maleate 0.5 % eye drops were replaced with dorzolamide hydrochloride 1 %/timolol maleate 0.5 % fixed-combination eye drops without any washout period. The intraocular pressure (IOP) was evaluated both before and 1 and 3 months after the treatment change. The patients were asked to complete a questionnaire on adherence to the treatment protocol 1 month after the change in treatment. Results: The IOP was 15.5 ± 2.7 mmHg at the time of treatment change, 15.2 ± 2.7 mmHg at 1 month post-change, and 15.5 ± 2.9 mmHg at 3 months post-change, which is consistent with that before the treatment change (p = 0.286). Based on the completed questionnaire, following the treatment change, 50 % of patients felt a stinging sensation following administration of the eye drops and 11.8 % experienced blurred vision. In no case were the eye drops discontinued due to adverse reactions or insufficient IOP decrease. Conclusion: The replacement of concomitant treatment with dorzolamide hydrochloride 1 % and timolol maleate 0.5 % eye drops with dorzolamide hydrochloride 1 %/timolol maleate 0.5 % fixed-combination eye drops improved protocol adherence and preserved the IOP. © Japanese Ophthalmological Society 2012. AD - K. Inoue, Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan AU - Inoue, K. AU - Shiokawa, M. AU - Sugahara, M. AU - Wakakura, M. AU - Soeda, S. AU - Tomita, G. C1 - cosopt(Santen,Japan) timoptol(Merck Sharp and Dohme,Ireland) trusopt(Merck,United States) C2 - Merck Sharp and Dohme(Ireland) Merck(United States) Santen(Japan) DB - Embase Medline DO - 10.1007/s10384-012-0186-8 IS - 6 KW - bunazosin dipivefrine dorzolamide dorzolamide plus timolol eye drops latanoprost tafluprost timolol timolol maleate travoprost adult aged antihypertensive activity article bitter taste blurred vision burning sensation clinical article clinical evaluation drug safety drug substitution drug withdrawal dry eye evening dosage eye discomfort eye irritation female human intraocular hypertension intraocular pressure low tension glaucoma male morning dosage ocular pruritus open angle glaucoma patient compliance priority journal questionnaire side effect treatment outcome cosopt timoptol trusopt LA - English M3 - Article N1 - L52221681 2012-09-25 2013-01-24 PY - 2012 SN - 0021-5155 1613-2246 SP - 559-563 ST - Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs T2 - Japanese Journal of Ophthalmology TI - Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52221681&from=export http://dx.doi.org/10.1007/s10384-012-0186-8 VL - 56 ID - 3060 ER - TY - JOUR AB - Background: The Tafluprost/Timolol Fixed Combination (TTFC) has demonstrated efficacy and safety in reducing Intraocular Pressure (IOP). However, direct comparisons of switching from tafluprost to TTFC are limited. Objective: To investigate the efficacy and safety of switching from tafluprost to TTFC in patients with Primary Open-Angle Glaucoma (POAG). Methods: Thirty-four eyes (34 patients) with POAG that did not achieve adequate IOP reduction on tafluprost were switched to TTFC with no washout period. IOP, systolic/diastolic blood pressure and pulse rate were measured 1 and 3 months later and compared with baseline values. All participants were asked about specific adverse reactions after 1 and 3 months of treatment. Patients also completed a questionnaire about preference and adherence after 1 month of treatment. Results: Mean IOP after 1 and 3 months was significantly lower than at baseline (14.2 ± 2.1 mmHg and 14.1 ± 2.3 mmHg, respectively, vs 16.0 ± 2.0 mmHg, P < 0.0001). Systolic/diastolic blood pressure and pulse rate were not significantly different from baseline after 1 and 3 months. The questionnaire indicated that the frequency of missing a dose was not different before (27.3%) or after (18.2%) switching to TTFC (P = 0.2371). There were five reports of adverse reactions (14.7%), including a corneal epithelium disorder, ocular irritation, skin irritation at the wrist, and chest pain. Two patients (5.9%) withdrew because of adverse reactions. Conclusion: Switching from tafluprost to TTFC achieved IOP control safely and was well accepted by patients. AD - K. Inoue, Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, Tokyo, Japan AU - Inoue, K. AU - Ueda, T. AU - Ishida, K. AU - Tomita, G. C1 - tapcom(Santen,Japan) tapros(Santen,Japan) C2 - Santen(Japan) DB - Embase DO - 10.2174/1874364101812010121 IS - 1 KW - tafluprost tapcom timolol adult aged article blurred vision clinical article controlled study corneal epithelium disorder drug efficacy drug safety drug substitution drug withdrawal eye discomfort eye disease eye examination eye irritation female glaucoma human intraocular pressure major clinical study male oculoplethysmography ophthalmoscopy patient compliance priority journal pulse rate randomized controlled trial skin irritation structured questionnaire thorax pain very elderly visual acuity tapros LA - English M3 - Article N1 - L2001599216 2019-03-20 2019-03-25 PY - 2018 SN - 1874-3641 SP - 121-126 ST - Efficacy and safety of switching from tafluprost to a tafluprost/timolol fixed combination in patients with primary open-angle glaucoma T2 - Open Ophthalmology Journal TI - Efficacy and safety of switching from tafluprost to a tafluprost/timolol fixed combination in patients with primary open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001599216&from=export http://dx.doi.org/10.2174/1874364101812010121 VL - 12 ID - 2606 ER - TY - JOUR AB - Elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which is a progressive optic neuropathy. Lowering IOP is currently the only therapeutic approach to the therapy of glaucoma. Since the use of pilocarpine eye drops for glaucoma treatment was reported in the late 1870s, academic researchers and pharmaceutical companies attempted to discover new drugs with more potent, prolonged, and safer IOP-reducing effects. These persistent efforts finally paid off, and prostanoids with FP-receptor agonist activity were found to be very potent IOP-lowering agents. To date, three prostanoids (latanoprost, travoprost and bimatoprost) have been launched in many countries, and now a new FP-receptor agonist, tafluprost, is entering clinical development. All of these prostanoids are superior to the β-adrenoceptor antagonists in their IOP-lowering efficacy, and no severe side effects have been reported in their long-term clinical use. In addition, tafluprost may be expected to improve ocular blood flow. Hence, prostanoids currently occupy center stage among glaucoma medications. It cannot be denied that in terms of efficacy, safety, patient compliance, and medical economy prostanoids are currently the first-line medicines among ocular antihypertensive drugs. © 2006 Blackwell Publishing, Inc. AD - N. Ishida, Research and Development Center, Santen Pharmaceutical Co. Ltd., 8916-16 Takayama-cho, Ikoma, Nara 630-0101, Japan AU - Ishida, N. AU - Odani-Kawabata, N. AU - Shimazaki, A. AU - Hara, H. C1 - lumigan travatan xalatan DB - Embase Medline DO - 10.1111/j.1527-3466.2006.00001.x IS - 1 KW - alpha 2 adrenergic receptor stimulating agent beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brinzolamide carbonate dehydratase inhibitor dorzolamide latanoprost muscarinic agent prostanoid tafluprost timolol travoprost unclassified drug antihypertensive activity blood flow clinical trial conjunctival hyperemia drug efficacy drug mechanism drug potency drug safety drug selectivity drug structure drug synthesis glaucoma human in vitro study intraocular hypertension intraocular pressure long term care monotherapy nonhuman ocular blood vessel open angle glaucoma pathogenesis patient compliance priority journal recommended drug dose review socioeconomics treatment duration lumigan travatan xalatan LA - English M3 - Review N1 - L46696782 2006-03-01 PY - 2006 SN - 0897-5957 SP - 1-10 ST - Prostanoids in the therapy of glaucoma T2 - Cardiovascular Drug Reviews TI - Prostanoids in the therapy of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46696782&from=export http://dx.doi.org/10.1111/j.1527-3466.2006.00001.x VL - 24 ID - 3627 ER - TY - JOUR AB - Background: Glaucoma is one of the leading causes of blindness and visual disability. Few studies have examined persistence and adherence with topical medications in glaucoma patients. Objective: The objective of this study was to compare patient persistence with prostaglandin agonist (PA) monotherapy versus with concomitant adjunctive therapy (AT) in Canada. Methods: Data were obtained from the Québec prescription claims database. Persistence rates were determined for previously treated naive glaucoma patients at 1 year after their index date for use of any of the three available PAs (bimatoprost, latanoprost, and travoprost). Patients who had at least 334 days on their index PA were defined as being persistent during the analysis timeframe. Patient baseline demographics and persistence rates were reported. A logistic regression was used for comparing the PA and PA+AT groups, which incorporated baseline cofounders, such as age and sex, in the analyses. Results: From an initial cohort of 28 534 patients, 14 893 were identified as naive to glaucoma therapy and had a PA as their index therapy. Of these, 11 197 (75.2%) continued to receive monotherapy and 3696 (24.8%) had an AT added to the PA; 59.0% were females, and the average age was 70.5 ± 11.3 years. Overall, at the end of the first year of therapy, 57.4% of patients were persistent on their index PA; however, a statistically significant difference was observed between the two subgroups, with 54.6% for those receiving PA monotherapy and 65.8% for those receiving PA+AT (p < 0.01) persistent with therapy. On average, 10.5 prescriptions per year were dispensed to persistent patients. Conclusions: In this Canadian population, persistence rates fall to approximately 60% at the end of the first year of therapy, with patients taking AT being more persistent. Similar persistence analyses are warranted on other populations, and would yield helpful data for conducting economic evaluations of non-persistence. © 2011 Adis Data Information BV. All rights reserved. AD - M. Iskedjian, PharmIdeas Research and Consulting Inc., 1175 North Service Road West, Oakville, ON L6M 2W1, Canada AU - Iskedjian, M. AU - Covert, D. W. AU - Walker, J. H. C1 - lumigan(Allergan,Canada) travatan(Alcon,Canada) xalatan(Pfizer,Canada) C2 - Alcon(Canada) Allergan(Canada) Pfizer(Canada) DB - Embase Medline DO - 10.2165/11539460 IS - 2 KW - antiglaucoma agent bimatoprost latanoprost travoprost add on therapy adjuvant therapy adult age aged article Canada cohort analysis controlled study drug withdrawal female gender glaucoma human major clinical study male monotherapy patient compliance population research prescription priority journal lumigan travatan xalatan LA - English M3 - Article N1 - L361694412 2011-05-11 2011-05-17 PY - 2011 SN - 1178-1653 1178-1661 SP - 133-141 ST - Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: A Canadian population-based analysis T2 - Patient TI - Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: A Canadian population-based analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361694412&from=export http://dx.doi.org/10.2165/11539460 VL - 4 ID - 3174 ER - TY - JOUR AB - Background: Glaucoma is one of the leading causes of blindness and visual disability. Few studies have examined persistence and adherence with topical medications in glaucoma patients. Objective: The objective of this study was to compare patient persistence with prostaglandin agonist (PA) monotherapy versus with concomitant adjunctive therapy (AT) in Canada. Methods: Data were obtained from the Quèbec prescription claims database. Persistence rates were determined for previously treated naive glaucoma patients at 1 year after their index date for use of any of the three available PAs (bimatoprost, latanoprost, and travoprost). Patients who had at least 334 days on their index PA were defined as being persistent during the analysis timeframe. Patient baseline demographics and persistence rates were reported. A logistic regression was used for comparing the PA and PA+AT groups, which incorporated baseline cofounders, such as age and sex, in the analyses. Results: From an initial cohort of 28 534 patients, 14 893 were identified as naive to glaucoma therapy and had a PA as their index therapy. Of these, 11 197 (75.2%) continued to receive monotherapy and 3696 (24.8%) had an AT added to the PA; 59.0% were females, and the average age was 70.5 ± 11.3 years. Overall, at the end of the first year of therapy, 57.4% of patients were persistent on their index PA; however, a statistically significant difference was observed between the two subgroups, with 54.6% for those receiving PA monotherapy and 65.8% for those receiving PA+AT (p < 0.01) persistent with therapy. On average, 10.5 prescriptions per year were dispensed to persistent patients. Conclusions: In this Canadian population, persistence rates fall to approximately 60% at the end of the first year of therapy, with patients taking AT being more persistent. Similar persistence analyses are warranted on other populations, and would yield helpful data for conducting economic evaluations of non-persistence. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Iskedjian, Michael, PharmIdeas Research and Consulting Inc., 1175 North Service Road West, Suite 211, Oakville, ON, Canada, L6M 2W1 AN - 2011-09104-007 AU - Iskedjian, Michael AU - Covert, David W. AU - Walker, John H. DB - psyh DO - 10.2165/11539460-000000000-00000 DP - EBSCOhost IS - 2 KW - prostaglandin agonists adjunctive therapy glaucoma patients Canada population Aged Aged, 80 and over Amides Antihypertensive Agents Bimatoprost Chemotherapy, Adjuvant Cloprostenol Databases, Factual Female Glaucoma Humans Insurance Logistic Models Male Medication Adherence Middle Aged Prostaglandin Antagonists Prostaglandins F, Synthetic Quebec Travoprost Persistence Prostaglandins Adjunctive Treatment Patients N1 - PharmIdeas Research and Consulting Inc., Oakville, ON, Canada. Other Publishers: Springer. Release Date: 20110912. Correction Date: 20120716. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishConference Information: International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 23rd, Aug, 2007, Quebec City, PQ, Canada. Conference Note: Preliminary results of this study were presented at the aforementioned conference. Major Descriptor: Glaucoma; Persistence; Prostaglandins; Adjunctive Treatment. Minor Descriptor: Patients; Population. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: Canada. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Jun 1, 2011. Copyright Statement: All rights reserved. Adis Data Information BV. 2011. Sponsor: Alcon Research Ltd., US. Recipients: No recipient indicated PY - 2011 SN - 1178-1653 1178-1661 SP - 133-141 ST - Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: A Canadian population-based analysis T2 - The Patient: Patient-Centered Outcomes Research TI - Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: A Canadian population-based analysis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-09104-007&site=ehost-live&scope=site miskedjian@pharmideas.com VL - 4 ID - 4853 ER - TY - JOUR AB - BACKGROUND: The prevalence of open angle glaucoma increases with age, with many patients also receiving medications for non-ocular systemic diseases. Little is known about how systemic medications impact on the need for adjunctive therapy with prostaglandin analogues (PGA). OBJECTIVES: To evaluate whether systemic medications for hypertension, cholesterol, or glucose influence the need for adjunctive intraocular pressure (IOP) lowering medications in patients using PGAs. METHODS: Pharmaceutical records from the Québec prescription database provided a sample of patients receiving prescriptions for bimatoprost, latanoprost, or travoprost, from which subjects receiving > or =1 prescription for antihypertensives, antidiabetics. diuretics, and statins were identified. Chi-square tests compared proportions using PGAs to those using PGAs + adjunctive therapy, based on the use or non-use of systemic medications; a logistic regression was performed post hoc to adjust for gender and age. RESULTS: Of the 8548 evaluated patients (all using PGAs); 2934 (34.3%) took none of the studied systemic drugs. For the 5614 patients taking systemic medications, significantly fewer (p < 0.001) required an additional IOP lowering medication if taking a systemic antihypertensive medication. The use of a statin or a diabetic medication, alone or in combination, in addition to a PGA, made no significant difference in the need for adjunct glaucoma therapy. Individual drugs associated with significantly less utilization of adjunctive glaucoma medications were calcium-channel blockers, angiotensin-converting enzyme (ACE), and combination antihypertensive therapies. DISCUSSION: A profound association between systemic antihypertensive use and a reduced need for adjunct topical IOP lowering medications in patients using the same prostaglandin analogue for at least one year was found. LIMITATIONS: The use of a prescription claims database without patient compliance or patient outcomes may not reflect actual patient medication use. In addition, these findings may not be applicable to all patients initiating prostaglandin analogues. CONCLUSIONS: In this real-world population-based evaluation, a significant association exists between using systemic antihypertensive medications and reduced use of adjunctive IOP lowering therapies. These results confirm findings from previous studies suggesting an IOP lowering effect with systemic agents or some synergy with topical therapies. AD - PharmIdeas Research and Consulting Inc., Oakville, ON L6M 2W1, Canada. miskedjian@pharmideas.com AN - 105146442. Language: English. Entry Date: 20100326. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Iskedjian, M. AU - Walker, J. H. AU - Desjardins, O. AU - Robin, A. L. AU - Covert, D. W. AU - Bergamini, M. V. AU - Einarson, T. R. DB - ccm DO - 10.1185/03007990903035083 DP - EBSCOhost IS - 8 KW - Antihypertensive Agents -- Pharmacodynamics Antilipemic Agents -- Pharmacodynamics Diuretics -- Pharmacodynamics Glaucoma -- Drug Therapy Hypoglycemic Agents -- Pharmacodynamics Prostaglandins, Synthetic -- Therapeutic Use Adult Aged Aged, 80 and Over Antihypertensive Agents -- Administration and Dosage Antihypertensive Agents -- Therapeutic Use Antilipemic Agents -- Administration and Dosage Antilipemic Agents -- Therapeutic Use Databases Diuretics -- Administration and Dosage Diuretics -- Therapeutic Use Female Hypoglycemic Agents -- Administration and Dosage Hypoglycemic Agents -- Therapeutic Use Male Middle Age Quebec Young Adult N1 - Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 0351014. PMID: NLM19530975. PY - 2009 SN - 0300-7995 SP - 1879-1888 ST - Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study T2 - Current Medical Research & Opinion TI - Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105146442&site=ehost-live&scope=site VL - 25 ID - 4477 ER - TY - JOUR AB - Purpose Of Review: Adherence to chronic use of topical intraocular pressure (IOP) lowering medications is a fundamental barrier to successful, long-term control in patients suffering from glaucoma. This has fueled innovation to create new vehicles for drug administration, new drug formulations with enhanced bioavailability, and minimally invasive glaucoma surgeries (MIGS) with improved risk-benefit profiles to enhance sustained IOP control. The present article is an overview of novel devices in the pipeline.Recent Findings: Several new devices that promise to deliver sustained drug therapy and reduce dependence on daily patient adherence are currently being vetted through clinical trials. In addition, the pipeline for new MIGS devices that target sustained IOP control continues to grow.Summary: Alternative drug delivery approaches and novel MIGS devices broaden the treatment options for patients with glaucoma. This will allow the clinician to customize treatment by selecting specific approaches based on each patient's individual needs and coexisting ocular pathologies. Additional comprehensive, large-scale, clinical studies will help define the role that these options hold in a constantly evolving treatment paradigm. AD - Glaucoma Consultants of Washington Inc., Herndon, Virginia University of Colorado School of Medicine, Aurora, Colorado, USA AN - 135751994. Language: English. Entry Date: 20190409. Revision Date: 20190524. Publication Type: journal article AU - Ittoop, Sabita M. AU - Seibold, Leonard K. AU - Kahook, Malik Y. DB - ccm DO - 10.1097/ICU.0000000000000555 DP - EBSCOhost IS - 2 KW - Drug Delivery Systems Glaucoma -- Therapy Minimally Invasive Procedures Drugs Intraocular Pressure -- Drug Effects Glaucoma -- Drug Therapy Ophthalmology Tonometry Glaucoma -- Surgery N1 - pictorial; review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM30575619. PY - 2019 SN - 1040-8738 SP - 117-124 ST - Current opinion in ophthalmology: novel glaucoma devices in the pipeline T2 - Current Opinion in Ophthalmology TI - Current opinion in ophthalmology: novel glaucoma devices in the pipeline UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135751994&site=ehost-live&scope=site VL - 30 ID - 4334 ER - TY - JOUR AB - Purpose: To compare the safety, efficacy, and cost-effectiveness of manual sutureless small-incision cataract surgery (SICS) and phacoemulsification (Phaco) as treatment options for cataract surgery with focus on intumescent, mature, and hypermature lenses (white cataracts). Methods: A systematic search of research articles was conducted to develop an internal database for the investigators' appraisal. Literature searches were conducted by using key words and MeSH terms including cataracts, phacoemulsification, small-incision cataract incision, visual acuity, costs, training, time, and barriers to cataract surgery. The final synthesis included 42 manuscripts. Results: All studies show that both Phaco and SICS are safe and effective techniques to rehabilitate cataract patients, but Phaco is costlier, with its preoperative and postoperative medicines, anesthetic agents, viscoelastic materials, disposables, instrumentation, and intraocular lens (IOLs), and had a steeper learning curve. Small-incision cataract surgery, in comparison, has been shown to be faster and more cost-effective. It is useful in intumescent white, black, brown, and lens-induced glaucoma cataracts and could incorporate recent trends like topical and sub-Tenon anesthesia and temporal incisions. Both give equal best-corrected visual acuity but unaided vision has been shown to be slightly better in Phaco due to lesser astigmatism. Conclusions: The literature points to SICS being more useful for intumescent and hard cataracts and is the preferred technique for less-resourced settings. Small-incision cataract surgery is comparable to Phaco in almost all aspects except postoperative astigmatism. © 2013 Wichtig Editore - ISSN 1120-6721. AD - African Vision Research Institute, Durban, South Africa Community Eye Care Foundation, Dr. Gogate's Eye Clinic, Pune, India Brien Holden Vision Institute, Durban, South Africa AU - Jaggernath, J. AU - Gogate, P. AU - Moodley, V. AU - Naidoo, K. S. DB - Scopus DO - 10.5301/ejo.5000413 IS - 4 KW - Cataract surgery Phacoemulsification Small-incision cataract surgery M3 - Article N1 - Cited By :19 Export Date: 19 July 2021 PY - 2013 SP - 520-526 ST - Comparison of cataract surgery techniques: Safety, efficacy, and cost-effectiveness T2 - European Journal of Ophthalmology TI - Comparison of cataract surgery techniques: Safety, efficacy, and cost-effectiveness UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903124246&doi=10.5301%2fejo.5000413&partnerID=40&md5=a679bc29ba2b3cbfeaf2543b30f35e8e VL - 24 ID - 5148 ER - TY - JOUR AB - IMPORTANCE While medication efficacy is well documented in clinical trials, less is known of medication effectiveness in real-world clinical settings. OBJECTIVE To assess the effectiveness of intraocular pressure (IOP)-lowering medications in patients with open-angle glaucoma. DESIGN, SETTING, AND PARTICIPANTS Prospective, multicenter, interventional cohort from the prerandomization phase of a randomized clinical trial at multiple ophthalmology clinics. A total of 603 patients (603 eyes) with primary open-angle glaucoma who were using up to 3 glaucoma medications were included. INTERVENTIONS One IOP measurement was made while the patient was using his or her usual medications to lower IOP (ON IOP). Eligible participants underwent washout of all IOP-lowering drops, and the diurnal IOP was measured 2 to 4 weeks later (OFF IOP). MAIN OUTCOMES AND MEASURES Difference between OFF IOP and ON IOP. The hypothesis was formulated after data collection. RESULTS The mean (SD) ON IOPs for participants using 0 (n = 102), 1 (n = 272), 2 (n = 147), or 3 (n = 82) medications were 24.2 (3.2), 17.5 (3.2), 17.2 (3.1), and 17.2 (3.1) mm Hg, respectively. Patients not using medication had a mean (SD) IOP decrease of 0.2 (2.8) mm Hg at the OFF visit. Patients using 1, 2, and 3 medications had mean (SD) IOP increases of 5.4 (3.0), 6.9 (3.3), and 9.0 (3.8) mm Hg, respectively, at the OFF visit. The percentages of patients with less than a 25% increase in IOP were 38%, 21%, and 13% for those using 1, 2, and 3 medications, respectively. CONCLUSIONS AND RELEVANCE Discontinuation of 1, 2, and 3 medications was associated with a clinically significant increase in IOP, although with smaller effects for the second and third medications compared with the first medication. A substantial proportion of patients showed only small changes in IOP after medication washout, suggesting either that they were not using the medication effectively or that the medication itself, although used properly, was not lowering the IOP. AN - WOS:000337890500004 AU - Jampel, H. D. AU - Chon, B. H. AU - Stamper, R. AU - Packer, M. AU - Han, Y. AU - Nguyen, Q. H. AU - Ianchulev, T. DA - APR DO - 10.1001/jamaophthalmol.2013.7677 IS - 4 PY - 2014 SN - 2168-6165 2168-6173 SP - 390-395 ST - Effectiveness of Intraocular Pressure-Lowering Medication Determined by Washout T2 - JAMA OPHTHALMOLOGY TI - Effectiveness of Intraocular Pressure-Lowering Medication Determined by Washout VL - 132 ID - 6198 ER - TY - JOUR AB - Objective: To determine the importance that patients place on the characteristics of topical therapy for lowering intraocular pressure. Methods: We administered a willingness-to-pay instrument to 230 patients from 4 glaucoma subspecialty practices, asking them how much they would be willing to pay to obtain particular characteristics in an eye drop. Data about the subjects' demographics, economic status, attitudes toward eye drops and systemic medications, and symptoms from eye drops were correlated with their willingness to pay using 2-part models. Results: Of our subjects, 169 (77%) were using eye drops to lower their intraocular pressure. Fatigue, blurred vision, and tearing were the most commonly reported symptoms. Eye drop medications most valued by the subjects did not produce blurring, drowsiness, or inhibition of sexual performance; 85% were willing to pay more for an eye drop that did not cause blurring, and on average they were willing to pay 40% more. Higher educational levels and income were generally associated with a willingness to pay more for eye drops with desirable attributes. Main Outcome Measure: Willingness to pay more (in dollars). Conclusions: Patient preferences for eye drop characteristics can be assessed using a willingness-to-pay instrument. Patients place differing value on various eye drop characteristics. A better understanding of patient preference could lead to better compliance. AD - H.D. Jampel, Maumenee B-117, 600 N Wolfe St, Baltimore, MD 21287-9205, United States AU - Jampel, H. D. AU - Schwartz, G. F. AU - Robin, A. L. AU - Abrams, D. A. AU - Johnson, E. AU - Miller, R. B. DB - Embase Medline DO - 10.1001/archopht.121.4.540 IS - 4 KW - alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor eye drops miotic agent prostaglandin adult aged article drowsiness fatigue female human intraocular pressure abnormality major clinical study male patient attitude patient compliance patient education priority journal prospective payment retina tear sexual dysfunction side effect symptomatology taste disorder visual impairment LA - English M3 - Article N1 - L36427641 2003-04-24 PY - 2003 SN - 0003-9950 SP - 540-546 ST - Patient preferences for eye drop characteristics: A willingness-to-pay analysis T2 - Archives of Ophthalmology TI - Patient preferences for eye drop characteristics: A willingness-to-pay analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36427641&from=export http://dx.doi.org/10.1001/archopht.121.4.540 VL - 121 ID - 3821 ER - TY - JOUR AB - Purpose: The aim of this study was to create vision standards for various tasks performed by hairdressers and to assess the spectacle compliance and its impact at work.Methods: The observational cross-sectional study enrolled hairdressers in and around Chennai, Tamil Nadu. It was done in three phases: (i) Job profiling from visual task analysis, creating vision standards for various hairdressing tasks and arriving at test protocols; (ii) Comprehensive eye examination, and (iii) Assessment of spectacle compliance and its impact on work. Descriptive analysis using Microsoft Excel and SPSS (IBM SPSS Statistics Version 21.0) was performed.Results: There were 305 participants with a mean age of 48 (SD ± 12) years. The visual acuity demand was found to be 6/18 and N15, for distance and near, respectively. Appropriate spectacles were prescribed for 203 (67%) hairdressers. Even with the best possible refractive correction, a few hairdressers did not meet the distance (13) and near (11) visual acuity standard. In all, 54 hairdressers were referred for further examination to a tertiary eye care center for lenticular changes, retinal abnormalities, and glaucoma screening. Among the subjects who were dispensed with spectacles, 181 (86%) were available for telephonic spectacle compliance assessment, and 164 (90%) were compliant with spectacle usage at work. Improved visual ability was reported by 133 (81%) hairdressers at work.Conclusion: This study provides vision standards for hairdressers. From the visual task analysis, hairdressing tasks were found to be visually demanding and hazardous. The study emphasizes that providing appropriate spectacle correction showed a clinically evident positive impact at work. AD - Department of Occupational Optometry Services, Medical Research Foundation, Chennai Department of Occupational Optometry Services, Medical Research Foundation, Chennai, India AN - 150821630. Language: English. Entry Date: 20210712. Revision Date: 20210716. Publication Type: journal article. Journal Subset: Asia AU - Janani, Suresh AU - Dhanalakshmi, Sankar AU - Rashima, Asokan AU - Krishnakumar, Ramani AU - Santanam, P. AU - Santanam, P. P. DB - ccm DO - 10.4103/ijo.IJO_2491_20 DP - EBSCOhost IS - 6 KW - Refractive Errors -- Therapy Refractive Errors -- Diagnosis Refractive Errors -- Epidemiology Visual Acuity Cross Sectional Studies Eyeglasses Middle Age India Impact of Events Scale Job Descriptive Index Scales N1 - Biomedical; Peer Reviewed. Instrumentation: Job Descriptive Index (JDI) (Smith et al); Work Environment Scale (WES) (Moos et al); Impact of Events Scale (IES). NLM UID: 0405376. PMID: NLM34011702. PY - 2021 SN - 0301-4738 SP - 1369-1374 ST - Visual demand, visual ability and vision standards for hairdressers - An observational study from Chennai, Tamil Nadu T2 - Indian Journal of Ophthalmology TI - Visual demand, visual ability and vision standards for hairdressers - An observational study from Chennai, Tamil Nadu UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150821630&site=ehost-live&scope=site VL - 69 ID - 4158 ER - TY - JOUR AB - This study aimed to analyze medication adherence and persistence among open-angle glaucoma patients in Korea. A retrospective study was conducted using the Korean National Health Insurance (NHI) claims database from 2016 to 2019. Newly diagnosed open-angle glaucoma patients who were prescribed with the intraocular pressure (IOP)-lowering eyedrops were included. Adherence was measured using the medication possession ratio (MPR), and persistence was measured using the duration of therapy during the 24 month follow-up period. During the study period, 14,648 open-angle glaucoma patients were identified, and 3118 (21.3%) and 4481 patients (30.6%) were adherent to and persistent with their glaucoma treatment, respectively. The mean MPR was 48.8%, and the mean duration of therapy was 357.2 days. Logistic regression analysis showed that patients who are older, female, using prostaglandins as the index medication, and visiting secondary or tertiary hospitals were significantly associated with greater rates of adherence (odds ratio (OR) = 1.21, 1.12, 1.27, and 1.73, respectively) and persistence (OR = 1.11, 1.17, 1.16, 1.17, and 1.36, respectively) during the study period. Patients with open-angle glaucoma in Korea had substandard medication adherence and discontinued their treatment. Ophthalmologists should pay more attention to younger, male patients to improve adherence. AD - S. Bae, College of Pharmacy, Ewha Womans University, Seoul, South Korea AU - Jang, Y. AU - Jee, D. AU - Lee, D. AU - Choi, N. K. AU - Bae, S. DB - Embase Medline DO - 10.3390/ijerph18084106 IS - 8 KW - beta adrenergic receptor blocking agent prostaglandin adult age article clinical effectiveness drug effect drug efficacy drug response female follow up gender human intraocular pressure Korea major clinical study male medication compliance monotherapy national health insurance open angle glaucoma patient compliance patient risk prescription retrospective study risk factor secondary care center tertiary care center treatment outcome LA - English M3 - Article N1 - L2006938334 2021-04-16 2021-04-23 PY - 2021 SN - 1660-4601 1661-7827 ST - Medication adherence and persistence of open-angle glaucoma patients in korea: A retrospective study using national health insurance claims data T2 - International Journal of Environmental Research and Public Health TI - Medication adherence and persistence of open-angle glaucoma patients in korea: A retrospective study using national health insurance claims data UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2006938334&from=export http://dx.doi.org/10.3390/ijerph18084106 VL - 18 ID - 2329 ER - TY - JOUR AB - This study aimed to analyze medication adherence and persistence among open-angle glaucoma patients in Korea. A retrospective study was conducted using the Korean National Health Insurance (NHI) claims database from 2016 to 2019. Newly diagnosed open-angle glaucoma patients who were prescribed with the intraocular pressure (IOP)-lowering eyedrops were included. Adherence was measured using the medication possession ratio (MPR), and persistence was measured using the duration of therapy during the 24 month follow-up period. During the study period, 14,648 open-angle glaucoma patients were identified, and 3118 (21.3%) and 4481 patients (30.6%) were adherent to and persistent with their glaucoma treatment, respectively. The mean MPR was 48.8%, and the mean duration of therapy was 357.2 days. Logistic regression analysis showed that patients who are older, female, using prostaglandins as the index medication, and visiting secondary or tertiary hospitals were significantly associated with greater rates of adherence (odds ratio (OR) = 1.21, 1.12, 1.27, and 1.73, respectively) and persistence (OR = 1.11, 1.17, 1.16, 1.17, and 1.36, respectively) during the study period. Patients with open-angle glaucoma in Korea had substandard medication adherence and discontinued their treatment. Ophthalmologists should pay more attention to younger, male patients to improve adherence. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. AD - College of Pharmacy, Ewha Womans University, Seoul, 03760, South Korea St. Vincent’s Hospital, College of Medicine, The Catholic University, Seoul, 16247, South Korea Department of Statistics, Ewha Womans University, Seoul, 03760, South Korea Department of Health Convergence, Ewha Womans University, Seoul, 03760, South Korea AU - Jang, Y. AU - Jee, D. AU - Lee, D. AU - Choi, N. K. AU - Bae, S. C7 - 4106 DB - Scopus DO - 10.3390/ijerph18084106 IS - 8 KW - Claim database Medication adherence Open-angle glaucoma Persistence M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 ST - Medication adherence and persistence of open-angle glaucoma patients in korea: A retrospective study using national health insurance claims data T2 - International Journal of Environmental Research and Public Health TI - Medication adherence and persistence of open-angle glaucoma patients in korea: A retrospective study using national health insurance claims data UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103989917&doi=10.3390%2fijerph18084106&partnerID=40&md5=faa7766dc726a1d698e4712f97215fc3 VL - 18 ID - 5674 ER - TY - JOUR AB - This study aimed to analyze medication adherence and persistence among open-angle glaucoma patients in Korea. A retrospective study was conducted using the Korean National Health Insurance (NHI) claims database from 2016 to 2019. Newly diagnosed open-angle glaucoma patients who were prescribed with the intraocular pressure (IOP)-lowering eyedrops were included. Adherence was measured using the medication possession ratio (MPR), and persistence was measured using the duration of therapy during the 24 month follow-up period. During the study period, 14,648 open-angle glaucoma patients were identified, and 3118 (21.3%) and 4481 patients (30.6%) were adherent to and persistent with their glaucoma treatment, respectively. The mean MPR was 48.8%, and the mean duration of therapy was 357.2 days. Logistic regression analysis showed that patients who are older, female, using prostaglandins as the index medication, and visiting secondary or tertiary hospitals were significantly associated with greater rates of adherence (odds ratio (OR) = 1.21, 1.12, 1.27, and 1.73, respectively) and persistence (OR = 1.11, 1.17, 1.16, 1.17, and 1.36, respectively) during the study period. Patients with open-angle glaucoma in Korea had substandard medication adherence and discontinued their treatment. Ophthalmologists should pay more attention to younger, male patients to improve adherence. AN - WOS:000644118600001 AU - Jang, Y. AU - Jee, D. AU - Lee, D. AU - Choi, N. K. AU - Bae, S. DA - APR DO - 10.3390/ijerph18084106 IS - 8 PY - 2021 SN - 1660-4601 ST - Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data T2 - INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH TI - Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data VL - 18 ID - 5929 ER - TY - JOUR AB - Purpose: To report on the efficacy and safety of CO2 laser-assisted sclerectomy surgery (CLASS) compared with trabeculectomy in primary open-angle glaucoma and exfoliative glaucoma. Methods: One hundred and thirty-one patients underwent CLASS (66 patients) or trabeculectomy (65 patients) and were followed up for 12 months. ‘Complete success’ was defined as intraocular pressure (IOP) between 10 and 18 mmHg and reduced by at least 30% from the baseline without medications, while ‘qualified success’ was compliant with the above criteria with or without the medications. Results: Comparing CLASS with trabeculectomy at 1 year, the mean IOP reduction rate was 32.6 ± 10.8% versus 40.6 ± 15.9% (p < 0.001) and the average use of medications was 1.4 ± 1.4 versus 0.7 ± 1.1 (p < 0.05). At 12 months, the complete success rate was 35% for CLASS versus 60% for trabeculectomy (p < 0.01), while the qualified success rate was 74% versus 75%, respectively, with no significant difference in qualified success rate between the groups at any time-point (p > 0.05). Compared with CLASS, patients after trabeculectomy developed a higher rate of early complications (9.1% versus 29.2%, p = 0.004), higher endothelial cell density (ECD) loss (1.4 ± 1.4% versus 6.5 ± 4.8%, p < 0.001), higher astigmatism (0.0 ± 0.1 versus 0.1 ± 0.2, p < 0.001) and significant visual acuity deterioration (0.1 ± 0.1; range 0–2 lines versus 0.4 ± 0.6; range 0–3 lines, p = 0.016). Conclusion: Although CLASS shows a less potent hypotensive effect, it is similar to trabeculectomy in the qualified success rate and offers the reduction in medications up to 12 months. With a more attractive complications profile, CLASS may be an alternative to trabeculectomy, especially at the earlier glaucoma stage and in patients with a low ECD. © 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd AD - Department of Ophthalmology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland AU - Jankowska-Szmul, J. AU - Dobrowolski, D. AU - Wylegala, E. DB - Scopus DO - 10.1111/aos.13718 IS - 5 KW - CO2 laser exfoliative glaucoma glaucoma surgery nonpenetrating deep sclerectomy primary open-angle glaucoma trabeculectomy M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2018 SP - e582-e591 ST - CO2 laser-assisted sclerectomy surgery compared with trabeculectomy in primary open-angle glaucoma and exfoliative glaucoma. A 1-year follow-up T2 - Acta Ophthalmologica TI - CO2 laser-assisted sclerectomy surgery compared with trabeculectomy in primary open-angle glaucoma and exfoliative glaucoma. A 1-year follow-up UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045380438&doi=10.1111%2faos.13718&partnerID=40&md5=bed8f821547564d5184c3d384f658c39 VL - 96 ID - 5211 ER - TY - JOUR AB - PurposeTo report on the efficacy and safety of CO2 laser-assisted sclerectomy surgery (CLASS) compared with trabeculectomy in primary open-angle glaucoma and exfoliative glaucoma. MethodsOne hundred and thirty-one patients underwent CLASS (66 patients) or trabeculectomy (65 patients) and were followed up for 12months. Complete success' was defined as intraocular pressure (IOP) between 10 and 18mmHg and reduced by at least 30% from the baseline without medications, while qualified success' was compliant with the above criteria with or without the medications. ResultsComparing CLASS with trabeculectomy at 1year, the mean IOP reduction rate was 32.610.8% versus 40.6 +/- 15.9% (p<0.001) and the average use of medications was 1.4 +/- 1.4 versus 0.7 +/- 1.1 (p<0.05). At 12months, the complete success rate was 35% for CLASS versus 60% for trabeculectomy (p<0.01), while the qualified success rate was 74% versus 75%, respectively, with no significant difference in qualified success rate between the groups at any time-point (p>0.05). Compared with CLASS, patients after trabeculectomy developed a higher rate of early complications (9.1% versus 29.2%, p=0.004), higher endothelial cell density (ECD) loss (1.4 +/- 1.4% versus 6.5 +/- 4.8%, p<0.001), higher astigmatism (0.0 +/- 0.1 versus 0.1 +/- 0.2, p<0.001) and significant visual acuity deterioration (0.1 +/- 0.1; range 0-2 lines versus 0.4 +/- 0.6; range 0-3 lines, p=0.016). ConclusionAlthough CLASS shows a less potent hypotensive effect, it is similar to trabeculectomy in the qualified success rate and offers the reduction in medications up to 12months. With a more attractive complications profile, CLASS may be an alternative to trabeculectomy, especially at the earlier glaucoma stage and in patients with a low ECD. AN - WOS:000443801700020 AU - Jankowska-Szmul, J. AU - Dobrowolski, D. AU - Wylegala, E. DA - AUG DO - 10.1111/aos.13718 IS - 5 PY - 2018 SN - 1755-375X 1755-3768 SP - E582-E591 ST - CO2 laser-assisted sclerectomy surgery compared with trabeculectomy in primary open-angle glaucoma and exfoliative glaucoma. A 1-year follow-up T2 - ACTA OPHTHALMOLOGICA TI - CO2 laser-assisted sclerectomy surgery compared with trabeculectomy in primary open-angle glaucoma and exfoliative glaucoma. A 1-year follow-up VL - 96 ID - 6128 ER - TY - JOUR AB - Objective: To provide a commentary on recent studies with the new IOP-lowering fixed-combination product brinzolamide 1% 0.5. Methods: Medline was searched for brinzolamide% fixed-combination clinical literature (up to May 18, 2010) and the current comprehensive brinzolamide% literature was reviewed. Results: Compared with another carbonic anhydrase inhibitor-containing product, dorzolamide 2% 0.5, brinzolamide% has similar IOP-lowering efficacy. Brinzolamide% also produces superior comfort ratings as assessed by patients who have tried both drugs this may be explained by the more physiologic pH of brinzolamide%. A recent study reported that brinzolamide% was preferred over dorzolamide% at a ratio of nearly 4:1 among those expressing a preference. Conclusion: These results demonstrate that brinzolamide% is equally effective and more comfortable than dorzolamide%, a fact that may positively impact patient adherence, leading to an increased likelihood of reaching target IOP goals. © 2010 Informa UK Ltd All rights reserved. AD - I. Januleviciene, Eye Clinic, Kaunas University of Medicine, Eiveniu Street 2, Kaunas 50009, Lithuania AU - Januleviciene, I. C2 - Alcon DB - Embase Medline DO - 10.1185/03007995.2010.517718 IS - 11 KW - brinzolamide brinzolamide plus timolol dorzolamide plus timolol timolol unclassified drug article blood pressure blurred vision chronic obstructive lung disease clinical trial drug choice drug efficacy drug safety dysgeusia eye discomfort eye irritation eye pain glaucoma human intraocular pressure patient compliance side effect sore throat LA - English M3 - Article N1 - L359805311 2010-10-29 2010-11-04 PY - 2010 SN - 0300-7995 1473-4877 SP - 2575-2578 ST - Brinzolamide 1/timolol 0.5: Safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma T2 - Current Medical Research and Opinion TI - Brinzolamide 1/timolol 0.5: Safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359805311&from=export http://dx.doi.org/10.1185/03007995.2010.517718 VL - 26 ID - 3222 ER - TY - JOUR AB - OBJECTIVE: To provide a commentary on recent studies with the new IOP-lowering fixed-combination product brinzolamide 1%/timolol 0.5%. METHODS: Medline was searched for brinzolamide/timolol fixed-combination clinical literature (up to May 18, 2010) and the current comprehensive brinzolamide/timolol literature was reviewed. RESULTS: Compared with another carbonic anhydrase inhibitor-containing product, dorzolamide 2%/timolol 0.5%, brinzolamide/timolol has similar IOP-lowering efficacy. Brinzolamide/timolol also produces superior comfort ratings as assessed by patients who have tried both drugs - this may be explained by the more physiologic pH of brinzolamide/timolol. A recent study reported that brinzolamide/timolol was preferred over dorzolamide/timolol at a ratio of nearly 4:1 among those expressing a preference. CONCLUSION: These results demonstrate that brinzolamide/timolol is equally effective and more comfortable than dorzolamide/timolol, a fact that may positively impact patient adherence, leading to an increased likelihood of reaching target IOP goals. AD - Eye Clinic, Kaunas University of Medicine, Kaunas, Lithuania. ingrida.januleviciene@kmuk.lt AN - 108226959. Language: English. Entry Date: 20111209. Revision Date: 20150712. Publication Type: Journal Article AU - Januleviciene, Ingrida DB - ccm DO - 10.1185/03007995.2010.517718 DP - EBSCOhost IS - 11 KW - Antihypertensive Agents -- Administration and Dosage Carbonic Anhydrase Inhibitors -- Administration and Dosage Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Sulfonamides -- Administration and Dosage Sulfur Compounds -- Administration and Dosage Timolol -- Administration and Dosage Antihypertensive Agents -- Adverse Effects Antihypertensive Agents -- Pharmacodynamics Carbonic Anhydrase Inhibitors -- Adverse Effects Carbonic Anhydrase Inhibitors -- Pharmacodynamics Drug Therapy, Combination Drug Toxicity Glaucoma -- Physiopathology Sulfonamides -- Adverse Effects Sulfonamides -- Pharmacodynamics Sulfur Compounds -- Adverse Effects Sulfur Compounds -- Pharmacodynamics Timolol -- Adverse Effects Timolol -- Pharmacodynamics Treatment Outcomes N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 0351014. PMID: NLM20868340. PY - 2010 SN - 0300-7995 SP - 2575-2578 ST - Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma T2 - Current Medical Research & Opinion TI - Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108226959&site=ehost-live&scope=site VL - 26 ID - 4508 ER - TY - JOUR AD - L. Jay Katz, Glaucoma Service, Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, United States AU - Jay Katz, L. AU - Myers, J. S. DB - Embase Medline DO - 10.1016/j.ajo.2009.03.033 IS - 2 KW - antiglaucoma agent latanoprost timolol clinical trial contact lens disease course drug effect drug efficacy editorial glaucoma hemodynamics human intraocular pressure monitor open angle glaucoma optic nerve injury patient compliance patient monitoring pressure measurement priority journal risk factor telemetry tonometry treatment response visual field defect LA - English M3 - Editorial N1 - L354915598 2009-08-25 PY - 2009 SN - 0002-9394 SP - 177-178 ST - Smoothing the Intraocular Pressure Roller Coaster: A New Goal? T2 - American Journal of Ophthalmology TI - Smoothing the Intraocular Pressure Roller Coaster: A New Goal? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354915598&from=export http://dx.doi.org/10.1016/j.ajo.2009.03.033 VL - 148 ID - 3342 ER - TY - GEN AU - Jay Katz, L. AU - Myers, J. S. AU - Jay Katz, L. AU - Myers, Jonathan S. CY - Philadelphia, Pennsylvania DB - ccm DO - 10.1016/j.ajo.2009.03.033 DP - EBSCOhost J2 - American Journal of Ophthalmology KW - Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Prostaglandins, Synthetic -- Therapeutic Use Timolol -- Therapeutic Use Patient Compliance Risk Factors Tonometry Treatment Outcomes N1 - Accession Number: 105386415. Language: English. Entry Date: 20090814. Revision Date: 20200708. Publication Type: commentary; editorial. Journal Subset: Biomedical; USA. Grant Information: IK6 RX002477/RX/RRD VA/United States. NLM UID: 0370500. PMID: NLM19619716. PB - Elsevier B.V. PY - 2009 SN - 0002-9394 SP - 177-178 ST - Smoothing the intraocular pressure roller coaster: a new goal? TI - Smoothing the intraocular pressure roller coaster: a new goal? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105386415&site=ehost-live&scope=site VL - 148 ID - 4768 ER - TY - JOUR AB - PURPOSE: Depressive symptoms may impact patients' medication use behavior and utilization of healthcare services. This study examined association between depressive symptoms and Glaucoma medication-related persistence and predictors of associated healthcare charges in older adults with primary open angle Glaucoma. METHODS: This study used a retrospective cohort of older adults with primary open angle Glaucoma who completed health status assessment, used Glaucoma medications, and were enrolled in a Medicare Health Maintenance Organization. Baseline assessment surveyed patients on demographics, healthcare service utilization in year before enrollment, lifestyle, and quality of life. Demographic, clinical, and utilization-related economic variables were retrieved from administrative claims database of patients' Health Maintenance Organization. Survival techniques were used to measure time to discontinuation (persistence) and Center for Epidemiologic Studies Depression Scale a 20-item self-reporting scale assessed depressive symptomatology on a range of 0 to 60. Associations were examined using mixed-model regression approach. Sensitivity analysis that considered log-transformed and untransformed specifications of cost variable tested model appropriateness. RESULTS: In total 268 patients were followed for 2 years (N=536). After controlling for potential confounders and temporal effects, depressive symptomatology was associated with decreased Glaucoma medication-related persistence (P<0.005). Patients who lived alone and had cardiovascular disease showed higher odds of experiencing depressive symptoms (P<0.005). Healthcare charges increased with number of comorbidities and prescriptions (P<0.005). CONCLUSIONS: Presence of depressive symptoms in patients lead to poor Glaucoma medication use behavior. Healthcare expenditures increased for patients with increase in comorbidities. Plan enrollees' risk assessment offers advantage of improving health outcomes and reduces healthcare utilization. © 2007 Lippincott Williams & Wilkins, Inc. AD - R. Balkrishnan, Ohio State University, College of Pharmacy, School of Public Health, 500 W. 12th Avenue, Columbus, OH 43210, United States AU - Jayawant, S. S. AU - Bhosle, M. J. AU - Anderson, R. T. AU - Balkrishnan, R. DB - Embase Medline DO - 10.1097/IJG.0b013e31804a5ec6 IS - 6 KW - antiglaucoma agent aged article Center for Epidemiological Studies Depression Scale comorbidity demography depression disease association elderly care female health care cost health care utilization health maintenance organization human lifestyle major clinical study male open angle glaucoma patient compliance prescription priority journal quality of life risk assessment theoretical model treatment outcome LA - English M3 - Article N1 - L47415206 2007-09-01 PY - 2007 SN - 1057-0829 SP - 513-520 ST - Depressive symptomatology, medication persistence, and associated healthcare costs in older adults with glaucoma T2 - Journal of Glaucoma TI - Depressive symptomatology, medication persistence, and associated healthcare costs in older adults with glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47415206&from=export http://dx.doi.org/10.1097/IJG.0b013e31804a5ec6 VL - 16 ID - 3507 ER - TY - JOUR AB - Ophthalmology departments face intensifying pressure to expedite sight-saving treatments and reduce the global burden of disease. The use of electronic communication systems, digital imaging, and redesigned service care models is imperative for addressing such demands. The recently developed Scottish Eyecare Integration Project involves an electronic referral system from community optometry to the hospital ophthalmology department using National Health Service (NHS) email with digital ophthalmic images attached, via a virtual private network connection. The benefits over the previous system include reduced waiting times, improved triage, e-diagnosis in 20% without the need for hospital attendance, and rapid electronic feedback to referrers. We draw on the experience of the Scottish Eyecare Integration Project and discuss the global applications of this and other advances in teleophthalmology. We focus particularly on the implications for management and screening of chronic disease, such as glaucoma and diabetic eye disease, and ophthalmic disease, such as retinopathy of prematurity where diagnosis is almost entirely and critically dependent on fundus appearance. Currently in Scotland, approximately 75% of all referrals are electronic from community to hospital. The Scottish Eyecare Integration Project is globally the first of its kind and unique in a national health service. Such speedy, safe, and efficient models of communication are geographically sensitive to service provision, especially in remote and rural regions. Along with advances in teleophthalmology, such systems promote the earlier detection of sight-threatening disease and safe follow-up of non-sight-threatening disease in the community. Copyright © 2017 by Asia Pacific Academy of Ophthalmology. AD - Kellogg Eye Center, University of Michigan, Ann Arbor, MI 48105, United States Queen Margaret Hospital, NHS Fife, Edinburgh, United Kingdom University of Edinburgh, Edinburgh, United Kingdom Princess Alexander Eye Pavillion, Edinburgh, United Kingdom AU - Jeganathan, V. S. E. AU - Hall, H. N. AU - Sanders, R. DB - Scopus DO - 10.22608/APO.2016110 IS - 1 KW - Digital imaging Electronic referrals Scottish Eyecare Integration Project Screening Telemedicine Teleophthalmology M3 - Review N1 - Cited By :3 Export Date: 19 July 2021 PY - 2017 SP - 3-7 ST - Electronic referrals and digital imaging systems in ophthalmology: A global perspective T2 - Asia-Pacific Journal of Ophthalmology TI - Electronic referrals and digital imaging systems in ophthalmology: A global perspective UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85012118464&doi=10.22608%2fAPO.2016110&partnerID=40&md5=4c0e9a8739c4a222b38020ad7990224f VL - 6 ID - 5509 ER - TY - JOUR AB - Subconjuctival 5-FU injections were used as an adjunctive therapy in trabeculectomy for high risk glaucoma patients. We injected 5 mg once a day for five to seven days as a routine treatment. For the first 10 eyes, the injections were started immediately after the operation. However, for the remaining 9 eyes, the injections began 24 to 48 hours postoperative. If the appearance of the bleb was not prominent or enriched in vascularity, the duration of the injections should be extended to 10 to 14 days. At least 8 months of follow-up were available for 19 eyes, including aphakic glaucoma, 8 eyes; neovascular glaucoma, 2 eyes; previous failed filter, 6 eyes; total collapse of the anterior chamber with leucoma adherence, 1 eye; glaucoma due to mesodermal dysgenesis, 1 eye; and juvenile glaucoma, 1 eye (whose fellow eye had received twice failed filtering procedures). The results revealed a success rate of 79% (intraocular pressure below 22mmHg with or without topical medication). The success rate for aphakic glaucoma was 63% (5/8), for neovascular glaucoma 100% (2/2) and for the failed filters 83% (5/6). We also presume that 5-FU injections would be effective in the treatment of to abnormally marked fibrous proliferations caused by age factors. The complications related to the use of 5-FU include corneal epithelial defect 4/9 (21%), conjunctival leak 3/9 (16%), subconjunctival hematoma 1/19 (5%), and conjunctival sterile ulcer 1/19 (5%). AD - Department of Ophthalmology, Chang Gung Memorial Hospital, Taipei, Taiwan AU - Jeng, S. AU - Ku, W. C. AU - Fan, D. DB - Scopus IS - 11-12 M3 - Article N1 - Export Date: 19 July 2021 PY - 1989 SP - 1171-3 ST - 5-fluorouracil in trabeculectomy: preliminary report T2 - Journal of the Formosan Medical Association TI - 5-fluorouracil in trabeculectomy: preliminary report UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024952449&partnerID=40&md5=f8c8911643cc342fb6bf8ee0a6f36660 VL - 88 ID - 5802 ER - TY - JOUR AB - Background: Treatment of local relapse in adenoid cystic carcinoma (ACC) following prior radiation remains a challenge: without the possibility of surgical salvage patients face the choice between palliative chemotherapy and re-irradiation. Chemotherapy yields response rates around 30% and application of tumouricidal doses is difficult due to proximity of critical structures. Carbon ion therapy (C12) is a promising method to minimize side-effects and maximize re-treatment dose in this indication. We describe our initial results for re-irradiation in heavily pre-treated ACC patients. Methods: Patients treated with carbon ion therapy between 04/2010 and 05/2013 (N= 52 pts, median age: 54 a) were retrospectively evaluated regarding toxicity (NCI CTC v.4), tumour response (RECIST) and control rates. 48 pts (92.3%) received carbon ions only, 4 pts received IMRT plus C12. Results: 4 pts were treated following R1-resection, 43 pts for inoperable local relapse. Most common tumour sites were paranasal sinus (36.5%), parotid (19.2%), and base of skull (17.3%). Pts received a median dose of 51 GyE C12/63 Gy BED and cumulative dose of 128 Gy BED [67-182 Gy] after a median RT-interval of 61 months. Median target volume was 93 ml [9-618 ml]. No higher-grade (>degrees II) acute reactions were observed, 7 pts showed blood-brain-barrier changes (degrees I/II: 8 pts; degrees III: 2 pts), 1 pt corneal ulceration, xerophthalmia 7 pts, degrees IV bleeding 1 pt, tissue necrosis 2 pts, otherwise no significant late reactions. Objective response rate (CR/PR) was 56.6%. With a median follow-up of 14 months [1-39 months] local control and distant control at la are 70.3% and 72.6% respectively. Of the 18 pts with local relapse, 13 pts have recurred in-field, 1 pt at the field edge, 3 pts out of field, and one in the dose gradient. Conclusion: Despite high applied doses, C12 re-irradiation shows moderate side-effects, response rates even in these heavily pre-treated patients are encouraging and present a good alternative to palliative chemotherapy. Though most local recurrences occur within the high-dose area, further dose escalation should be viewed with caution. (C) 2015 The Authors. Published by Elsevier Ireland Ltd. AN - WOS:000352922900008 AU - Jensen, A. D. AU - Poulakis, M. AU - Nikoghosyan, A. V. AU - Chaudhri, N. AU - Uhl, M. AU - Munter, M. W. AU - Herfarth, K. K. AU - Debus, J. DA - FEB DO - 10.1016/j.radonc.2015.01.002 IS - 2 PY - 2015 SN - 0167-8140 1879-0887 SP - 182-188 ST - Re-irradiation of adenoid cystic carcinoma: Analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy T2 - RADIOTHERAPY AND ONCOLOGY TI - Re-irradiation of adenoid cystic carcinoma: Analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy VL - 114 ID - 6043 ER - TY - JOUR AB - Glaucoma is a group of optic neuropathies that is more prevalent among the elderly population and commonly associates with comorbidities, including mental disorders in that population. This article reviews the relationship between glaucoma and mental disorders. In it, we discuss the coexistence of glaucoma and mental illnesses, including Alzheimer's disease, depression, and personality disorder. We also focus on the proper treatment approaches for glaucoma patients with mental comorbidity and poor treatment adherence. We summarize some cautiously recommended psychotherapeutic medications, while also discussing the psychologically adverse effects of antiglaucoma medications. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Kim, Na Rae, Department of Ophthalmology, Inha University Hospital, 7-206, 3-ga, Shinheung-dong, Jung-gu, Incheon, Korea, 400-711 AN - 2016-12935-009 AU - Jeong, Ah Reum AU - Kim, Chan Yun AU - Kang, Min Hee AU - Kim, Na Rae DB - psyh DO - 10.1097/NMD.0000000000000467 DP - EBSCOhost IS - 3 KW - Adherence Alzheimer's disease depression glaucoma retinal ganglion cell Mental Disorders Ganglion Cells (Retina) N1 - Department of Ophthalmology, Inha University School of Medicine, Incheon, Korea. Release Date: 20160324. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Glaucoma; Mental Disorders. Minor Descriptor: Ganglion Cells (Retina). Classification: Vision & Hearing & Sensory Disorders (3299). Population: Human (10). Tests & Measures: Center for Epidemiologic Studies Depression Scale. Methodology: Literature Review. References Available: Y. Page Count: 4. Issue Publication Date: Mar, 2016. Copyright Statement: All rights reserved. Wolters Kluwer Health, Inc. 2016. Sponsor: Ministry of Science, Information and Communication Technologies, National Research Foundation of Korea (NRF), Korea. Other Details: Basic Science Research Program. Recipients: No recipient indicated Sponsor: NRF, Future Planning, Korea. Grant: 2013R1A1A1010814. Recipients: No recipient indicated Sponsor: Inha University, Korea. Recipients: No recipient indicated PY - 2016 SN - 0022-3018 1539-736X SP - 217-220 ST - Psychological aspects of glaucoma T2 - Journal of Nervous and Mental Disease TI - Psychological aspects of glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-12935-009&site=ehost-live&scope=site nrkim@inha.ac.kr VL - 204 ID - 4830 ER - TY - JOUR AB - Purpose: To evaluate efficacy and safety of brinzolamide (1%)/brimonidine (0.2%) fixed combination (BBFC) in normal tension glaucoma (NTG). Methods: This retrospective study included NTG patients treated with BBFC as their primary therapy, NTG patients who had changed their medication to BBFC from brinzolamide or brimonidine, and NTG patients who had changed their medication to BBFC from concomitantly using brinzolamide and brimonidine. The intraocular pressure (IOP), mean deviation value, and adverse drug reactions were evaluated. Results: In the BBFC primary therapy group, the baseline IOP was 17.1 ± 1.4 mmHg, and the mean IOP at 18 months after using BBFC was 12.4 ± 1.8 mmHg. In the brinzolamide monotherapy group, the baseline IOP was 16.2 ± 1.4 mmHg, the mean IOP using brinzolamide was 13.4 ± 1.6 mmHg, and the mean IOP at 18 months after changing to BBFC was 12.3 ± 1.4 mmHg. In the brimonidine monotherapy group, the baseline IOP was 16.5 ± 1.5 mmHg, the mean IOP using brimonidine was 13.3 ± 1.6 mmHg, and the mean IOP at 18 months after changing to BBFC was 12.4 ± 1.4 mmHg. In the unfixed brinzolamide and brimonidine group, the baseline IOP was 17.5 ± 1.3 mmHg, the mean IOP when using unfixed brinzolamide and brimonidine was 12.4 ± 1.4 mmHg, and the mean IOP at 18 months after changing to BBFC was 12.6 ± 1.5 mmHg. There were no serious adverse drug reactions. Conclusions: BBFC provides a significant IOP reduction and is a safe antiglaucoma medication for NTG patients. © 2018, Mary Ann Liebert, Inc. AD - Department of Ophthalmology, Dong-A University College of Medicine, #26 Daesingongwon-ro, Seo-gu, Busan, 49201, South Korea AU - Jin, S. W. AU - Lee, S. M. DB - Scopus DO - 10.1089/jop.2017.0075 IS - 3 KW - brimonidine brinzolamide fixed combination glaucoma normal tension simbrinza M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2018 SP - 274-279 ST - The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study T2 - Journal of Ocular Pharmacology and Therapeutics TI - The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045144496&doi=10.1089%2fjop.2017.0075&partnerID=40&md5=6098bbad6a44d91cededb74aa8dd83e5 VL - 34 ID - 5450 ER - TY - JOUR AB - Objectives: To examine patterns in, determinants of, and barriers to eye care utilization in Canada. Design: Cross-sectional survey. Participants: All 132221 respondents to the Canadian Community Health Survey 2005. Methods: Eye care utilization was self-reported and was defined as having seen or talked on the telephone with an eye care provider (ophthalmologist or optometrist) in a 12-month period. Associations of interest were assessed by prevalence ratios (PR). Results: Forty percent (11 million) of Canadians aged 12 years or older reported utilization of eye care providers. The lowest utilization rates occurred in people aged 30-39 years and the highest in those aged 70 years and older. Utilization was not related to levels of education or household income in people with self-reported glaucoma, cataracts, or diabetes. Among Canadians without these conditions, significantly less utilization occurred in men, in those with less than a postsecondary education, and in those with annual household incomes under $30 000. Canadians residing in Newfoundland and Labrador utilized eye care providers significantly less than those residing in other provinces (adjusted PR 0.80, 95% CI 0.74-0.86). Fourteen percent of glaucoma patients, 37% of diabetic patients, and 41% of people aged 65 years or older did not access eye care providers over a 12-month period. Conclusions: Marked disparities occur in eye care utilization among Canadians without known eye diseases. A substantial proportion of people at a high risk of vision loss do not access eye care providers. Attributable factors are likely incomplete government coverage, asymptomatic ocular diseases, and lack of perceived benefits of eye care services. AD - Y.-P. Jin, Health Sciences Building, 155 College St., Toronto, ON M5T 3M7, Canada AU - Jin, Y. P. AU - Trope, G. E. DB - Embase Medline DO - 10.3129/i10-120 IS - 2 KW - adult article cataract child diabetes mellitus educational status eye care glaucoma health care system health care utilization human income school child self report LA - English M3 - Article N1 - L362613646 2011-09-30 2011-10-06 PY - 2011 SN - 1715-3360 0008-4182 SP - 133-138 ST - Eye care utilization in Canada: Disparity in the publicly funded health care system T2 - Canadian Journal of Ophthalmology TI - Eye care utilization in Canada: Disparity in the publicly funded health care system UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362613646&from=export http://dx.doi.org/10.3129/i10-120 VL - 46 ID - 3202 ER - TY - JOUR AB - Objectives Population-based screening for glaucoma has been demonstrated to be cost-effective if targeted at high-risk groups such as older adults and those with a family history of glaucoma, and through use of a technician for conducting initial assessment rather than a medical specialist. This study attempts to investigate the cost-effectiveness of a hypothetical community screening and subsequent treatment programme for glaucoma in comparison with current practice (i.e. with no screening programme but with some opportunistic case finding) in the urban areas of India. Study design A hypothetical screening programme for both primary open-angle glaucoma and angle-closure disease was built for a population aged between 40 and 69 years in the urban areas of India. Methods Screening and treatment costs were obtained from an administrator of a tertiary eye hospital in India. The probabilities for the screening pathway were derived from published literature and expert opinion. The glaucoma prevalence rates for urban areas were adapted from the Chennai Glaucoma Study findings. A decision-analytical model using TreeAge Pro 2015 was built to model events, costs and treatment pathways. One-way sensitivity analyses were conducted. Results The introduction of a community screening programme for glaucoma is likely to be cost-effective, the estimated incremental cost-effectiveness ratio (ICER) values being Image 1, 10,668.68 when compared with no screening programme and would treat an additional 4443 cases and prevent 1790 person-years of blindness over a 10-year period in the urban areas of India. Sensitivity analyses revealed that glaucoma prevalence rates across various age groups, screening uptake rate, follow-up compliance after screening, treatment costs and utility values of health states associated with medical and surgical treatment of glaucoma had an impact on the ICER values of the screening programme. Conclusions In comparison with current practice (i.e. without a screening programme but with some opportunistic case finding), the introduction of a community screening programme for glaucoma for the 40–69 years age group is likely to be relatively cost-effective if implemented in the urban areas of India. AD - D. John, Tutor-Health Economics, Peoples Open Access Education, Initiative (Peoples-uni), 34, Stafford Road, Eccles, Manchester, United Kingdom AU - John, D. AU - Parikh, R. DB - Embase Medline DO - 10.1016/j.puhe.2017.02.016 KW - adult aged article blindness closed angle glaucoma controlled study cost effectiveness analysis cost utility analysis eye protection follow up glaucoma groups by age health care cost human India open angle glaucoma prevalence quality adjusted life year screening sensitivity analysis tertiary care center urban area LA - English M3 - Article N1 - L615176209 2017-04-12 2017-04-24 PY - 2017 SN - 1476-5616 0033-3506 SP - 37-48 ST - Cost-effectiveness and cost utility of community screening for glaucoma in urban India T2 - Public Health TI - Cost-effectiveness and cost utility of community screening for glaucoma in urban India UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615176209&from=export http://dx.doi.org/10.1016/j.puhe.2017.02.016 VL - 148 ID - 2641 ER - TY - JOUR AB - Objectives: Population-based screening for glaucoma has been demonstrated to be cost-effective if targeted at high-risk groups such as older adults and those with a family history of glaucoma, and through use of a technician for conducting initial assessment rather than a medical specialist. This study attempts to investigate the cost-effectiveness of a hypothetical community screening and subsequent treatment programme for glaucoma in comparison with current practice (i.e. with no screening programme but with some opportunistic case finding) in the urban areas of India. Study design: A hypothetical screening programme for both primary open-angle glaucoma and angle-closure disease was built for a population aged between 40 and 69 years in the urban areas of India. Methods: Screening and treatment costs were obtained from an administrator of a tertiary eye hospital in India. The probabilities for the screening pathway were derived from published literature and expert opinion. The glaucoma prevalence rates for urban areas were adapted from the Chennai Glaucoma Study findings. A decision-analytical model using TreeAge Pro 2015 was built to model events, costs and treatment pathways. One-way sensitivity analyses were conducted. Results: The introduction of a community screening programme for glaucoma is likely to be cost-effective, the estimated incremental cost-effectiveness ratio (ICER) values being Image 1 10,668.68 when compared with no screening programme and would treat an additional 4443 cases and prevent 1790 person-years of blindness over a 10-year period in the urban areas of India. Sensitivity analyses revealed that glaucoma prevalence rates across various age groups, screening uptake rate, follow-up compliance after screening, treatment costs and utility values of health states associated with medical and surgical treatment of glaucoma had an impact on the ICER values of the screening programme. Conclusions: In comparison with current practice (i.e. without a screening programme but with some opportunistic case finding), the introduction of a community screening programme for glaucoma for the 40-69 years age group is likely to be relatively cost-effective if implemented in the urban areas of India. AD - Tutor-Health Economics, Peoples Open Access Education, Initiative (Peoples-uni), 34, Stafford Road, Eccles, Manchester, M30 9ED, United Kingdom Consultant & Glaucoma Specialist, Shreeji Eye Clinic & Palak's, Glaucoma Care Center, Samrat Building, M Vasanji Road, Andheri (East), Mumbai, India AN - 124008967. Language: English. Entry Date: 20180117. Revision Date: 20180118. Publication Type: Article AU - John, Denny AU - Parikh, Rajul DB - ccm DO - 10.1016/j.puhe.2017.02.016 DP - EBSCOhost KW - Cost Benefit Analysis Urban Areas Glaucoma, Angle-Closure Health Care Costs Health Screening Intraocular Pressure India Adult Middle Age N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; Public Health; UK & Ireland. NLM UID: 0376507. PY - 2017 SN - 0033-3506 SP - 37-48 ST - Cost-effectiveness and cost utility of community screening for glaucoma in urban India T2 - Public Health (Elsevier) TI - Cost-effectiveness and cost utility of community screening for glaucoma in urban India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124008967&site=ehost-live&scope=site VL - 148 ID - 4274 ER - TY - JOUR AB - Objectives Population-based screening for glaucoma has been demonstrated to be cost-effective if targeted at high-risk groups such as older adults and those with a family history of glaucoma, and through use of a technician for conducting initial assessment rather than a medical specialist. This study attempts to investigate the cost-effectiveness of a hypothetical community screening and subsequent treatment programme for glaucoma in comparison with current practice (i.e. with no screening programme but with some opportunistic case finding) in the urban areas of India. Study design A hypothetical screening programme for both primary open-angle glaucoma and angle-closure disease was built for a population aged between 40 and 69 years in the urban areas of India. Methods Screening and treatment costs were obtained from an administrator of a tertiary eye hospital in India. The probabilities for the screening pathway were derived from published literature and expert opinion. The glaucoma prevalence rates for urban areas were adapted from the Chennai Glaucoma Study findings. A decision-analytical model using TreeAge Pro 2015 was built to model events, costs and treatment pathways. One-way sensitivity analyses were conducted. Results The introduction of a community screening programme for glaucoma is likely to be cost-effective, the estimated incremental cost-effectiveness ratio (ICER) values being Image 1, 10,668.68 when compared with no screening programme and would treat an additional 4443 cases and prevent 1790 person-years of blindness over a 10-year period in the urban areas of India. Sensitivity analyses revealed that glaucoma prevalence rates across various age groups, screening uptake rate, follow-up compliance after screening, treatment costs and utility values of health states associated with medical and surgical treatment of glaucoma had an impact on the ICER values of the screening programme. Conclusions In comparison with current practice (i.e. without a screening programme but with some opportunistic case finding), the introduction of a community screening programme for glaucoma for the 40–69 years age group is likely to be relatively cost-effective if implemented in the urban areas of India. © 2017 The Royal Society for Public Health AD - Tutor-Health Economics, Peoples Open Access Education, Initiative (Peoples-uni), 34, Stafford Road, Eccles, Manchester, M30 9ED, United Kingdom Consultant & Glaucoma Specialist, Shreeji Eye Clinic & Palak's, Glaucoma Care Center, Samrat Building, M Vasanji Road, Andheri (East), Mumbai, India AU - John, D. AU - Parikh, R. DB - Scopus DO - 10.1016/j.puhe.2017.02.016 KW - Angle-closure disease Cost utility Cost-effectiveness India Primary open-angle glaucoma Urban M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2017 SP - 37-48 ST - Cost-effectiveness and cost utility of community screening for glaucoma in urban India T2 - Public Health TI - Cost-effectiveness and cost utility of community screening for glaucoma in urban India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017099015&doi=10.1016%2fj.puhe.2017.02.016&partnerID=40&md5=0fc4a246a6ff58f6befdc64ea5340ac7 VL - 148 ID - 5227 ER - TY - JOUR AB - Objectives: Population-based screening for glaucoma has been demonstrated to be cost-effective if targeted at high-risk groups such as older adults and those with a family history of glaucoma, and through use of a technician for conducting initial assessment rather than a medical specialist. This study attempts to investigate the cost-effectiveness of a hypothetical community screening and subsequent treatment programme for glaucoma in comparison with current practice (i.e. with no screening programme but with some opportunistic case finding) in the urban areas of India. Study design: A hypothetical screening programme for both primary open-angle glaucoma and angle-closure disease was built for a population aged between 40 and 69 years in the urban areas of India. Methods: Screening and treatment costs were obtained from an administrator of a tertiary eye hospital in India. The probabilities for the screening pathway were derived from published literature and expert opinion. The glaucoma prevalence rates for urban areas were adapted from the Chennai Glaucoma Study findings. A decision-analytical model using TreeAge Pro 2015 was built to model events, costs and treatment pathways. One-way sensitivity analyses were conducted. Results: The introduction of a community screening programme for glaucoma is likely to be cost-effective, the estimated incremental cost-effectiveness ratio (ICER) values being (sic)10,668.68 when compared with no screening programme and would treat an additional 4443 cases and prevent 1790 person-years of blindness over a 10-year period in the urban areas of India. Sensitivity analyses revealed that glaucoma prevalence rates across various age groups, screening uptake rate, follow-up compliance after screening, treatment costs and utility values of health states associated with medical and surgical treatment of glaucoma had an impact on the ICER values of the screening programme. Conclusions: In comparison with current practice (i.e. without a screening programme but with some opportunistic case finding), the introduction of a community screening programme for glaucoma for the 40-69 years age group is likely to be relatively cost-effective if implemented in the urban areas of India. (C) 2017 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. AN - WOS:000404205600008 AU - John, D. AU - Parikh, R. DA - JUL DO - 10.1016/j.puhe.2017.02.016 PY - 2017 SN - 0033-3506 1476-5616 SP - 37-48 ST - Cost-effectiveness and cost utility of community screening for glaucoma in urban India T2 - PUBLIC HEALTH TI - Cost-effectiveness and cost utility of community screening for glaucoma in urban India VL - 148 ID - 6192 ER - TY - JOUR AB - A positive association between topical corticosteroid use and risk of type 2 diabetes mellitus has been reported in a large European population-based study. However, the increase in risk is small and should not influence the prescribing of topical corticosteroids when clinically indicated. © 2019, Springer Nature Limited. AD - Tommy’s Centre for Maternal and Fetal Health, MRC Centre for Reproductive Health, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, United Kingdom BHF Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, United Kingdom AU - Johns, E. C. AU - Reynolds, R. M. DB - Scopus DO - 10.1038/s41574-019-0212-8 IS - 7 M3 - Note N1 - Cited By :3 Export Date: 19 July 2021 PY - 2019 SP - 379-380 ST - Topical glucocorticoids and risk of type 2 diabetes mellitus T2 - Nature Reviews Endocrinology TI - Topical glucocorticoids and risk of type 2 diabetes mellitus UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066053049&doi=10.1038%2fs41574-019-0212-8&partnerID=40&md5=19e59c52ba252249a259c670bc2c166e VL - 15 ID - 5501 ER - TY - JOUR AB - Intraocular pressure (IOP) is the only treatable risk factor in glaucoma, one of the world's leading causes of blindness. Mechanisms that maintain IOP within a normal range have been poorly understood in contrast to intrinsic mechanisms that regulate systemic blood pressure. Vessel walls experience continuous pulse-induced cyclic pressure and flow. Pressure-dependent wall stress and flow-dependent shear stress provide sensory signals that initiate mechanotransduction responses. The responses optimize vessel wall elasticity, compliance and lumen size, providing a feedback loop to maintain intrinsic pressure homeostasis. Aqueous humor is part of a vascular circulatory loop, being secreted into the anterior chamber of the eye from the vasculature, then returning to the vasculature by passing through the trabecular meshwork (TM), a uniquely modified vessel wall interposed between the anterior chamber and a vascular sinus called Schlemm's canal (SC). Since pressure in circulatory loops elsewhere is modulated by cyclic stresses, one might predict similar pressure modulation in the aqueous outflow system. Recent laboratory evidence in fact demonstrates that cyclic IOP changes alter aqueous outflow while increasing cellularity and contractility of TM cells. Cyclic changes also lead to alterations in gene expression, changes in cytoskeletal networks and modulation of signal transduction. A new technology, phase-based optical coherence tomography, demonstrates in vivo pulse-dependent TM motion like that elsewhere in the vasculature. Recognition of pulse-dependent TM motion provides a linkage to well-characterized mechanisms that provide pressure homeostasis in the systemic vasculature. The linkage may permit unifying concepts of pressure control and provide new insights into IOP homeostatic mechanisms. AD - Department of Ophthalmology, University of Washington , Seattle, Washington. AN - 103816352. Language: English. Entry Date: 20150116. Revision Date: 20190110. Publication Type: journal article. Journal Subset: Biomedical AU - Johnstone, Murray A. DB - ccm DO - 10.1089/jop.2013.0224 DP - EBSCOhost IS - 2/3 KW - Glaucoma -- Pathology Intraocular Pressure -- Physiology Anterior Eye Segment -- Pathology Anterior Chamber -- Physiology Aqueous Humor -- Physiology Homeostasis Signal Transduction Risk Factors Tomography, Optical Coherence -- Methods Anterior Eye Segment -- Physiology N1 - Peer Reviewed; USA. Grant Information: P30 EY001730/EY/NEI NIH HHS/United States. NLM UID: 9511091. PMID: NLM24359130. PY - 2014 SN - 1080-7683 SP - 88-93 ST - Intraocular pressure regulation: findings of pulse-dependent trabecular meshwork motion lead to unifying concepts of intraocular pressure homeostasis T2 - Journal of Ocular Pharmacology & Therapeutics TI - Intraocular pressure regulation: findings of pulse-dependent trabecular meshwork motion lead to unifying concepts of intraocular pressure homeostasis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103816352&site=ehost-live&scope=site VL - 30 ID - 4470 ER - TY - JOUR AB - Purpose: To describe adherence to glaucoma medications. Patients and Methods: Medication adherence was investigated using the computerized records of Kaiser Permanente Southern California, a group model health maintenance organization that provides care to 3.4 million residents of Southern California. Eligible glaucoma patients were diagnosed between 2005 and 2009 and had medical and prescription drug coverage between 2005 and 2009. Utilization and adherence parameters were calculated for each of the 5 years from the incident date. Results: A total of 17,943 newly diagnosed glaucoma patients were identified between the years 2005 and 2009. Of patients diagnosed with glaucoma in 2005, 71% were continuously eligible for 5 years. Medication adherence was calculated using a medication possession ratio. Adherence was bimodal and not normal in distribution. Overall, the mean age of the entire group was 66 years, with 56% being 65 years of age or older. The high adherence group tended to be older, more likely to be female, and more likely to be white. The low adherent group (younger) tended to have more and worse diabetes, renal disease, myocardial infarction, and stroke. Conclusions: The shape of the adherence distribution appears bimodal, so analysis based on parametric measures may not be appropriate. Investigations of adherence should probably be performed separately for the low, mid, and high groups. AD - D.S. Fong, Department of Ophthalmology, Southern California Permanente Medical Group, 1011 Baldwin Park Blvd, Baldwin Park, CA, United States AU - Jones, J. P. AU - Fong, D. S. AU - Fang, E. N. AU - Mesirov, C. A. AU - Patel, V. DB - Embase Medline DO - 10.1097/IJG.0000000000000205 IS - 1 KW - antiglaucoma agent antilipemic agent prescription drug acquired immune deficiency syndrome adult age aged American Indian article Asian Black person Caucasian cerebrovascular accident comorbidity dementia diabetes mellitus disease severity education emergency ward female follow up gender glaucoma health care utilization health insurance health maintenance organization heart failure heart infarction Hispanic human Human immunodeficiency virus infection hypertension income kidney disease liver disease major clinical study male medication compliance paralysis patient compliance peptic ulcer peripheral vascular disease priority journal race rheumatic disease United States LA - English M3 - Article N1 - L607549319 2016-01-11 2016-01-14 PY - 2016 SN - 1536-481X 1057-0829 SP - 22-26 ST - Characterization of glaucoma medication adherence in kaiser permanente Southern California T2 - Journal of Glaucoma TI - Characterization of glaucoma medication adherence in kaiser permanente Southern California UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607549319&from=export http://dx.doi.org/10.1097/IJG.0000000000000205 VL - 25 ID - 2766 ER - TY - JOUR AB - Purpose: To describe adherence to glaucoma medications. Patients and Methods: Medication adherence was investigated using the computerized records of Kaiser Permanente Southern California, a group model health maintenance organization that provides care to 3.4 million residents of Southern California. Eligible glaucoma patients were diagnosed between 2005 and 2009 and had medical and prescription drug coverage between 2005 and 2009. Utilization and adherence parameters were calculated for each of the 5 years from the incident date. Results: A total of 17,943 newly diagnosed glaucoma patients were identified between the years 2005 and 2009. Of patients diagnosed with glaucoma in 2005, 71% were continuously eligible for 5 years. Medication adherence was calculated using a medication possession ratio. Adherence was bimodal and not normal in distribution. Overall, the mean age of the entire group was 66 years, with 56% being 65 years of age or older. The high adherence group tended to be older, more likely to be female, and more likely to be white. The low adherent group (younger) tended to have more and worse diabetes, renal disease, myocardial infarction, and stroke. Conclusions: The shape of the adherence distribution appears bimodal, so analysis based on parametric measures may not be appropriate. Investigations of adherence should probably be performed separately for the low, mid, and high groups. © 2015 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, United States Department of Ophthalmology, Southern California Permanente Medical Group, 1011 Baldwin Park Blvd, Baldwin Park, CA 91706, United States Department of Ophthalmology, Southern California Permanente Medical Group, Los Angeles, United States Global Health Outcomes Strategy and Research, Irvine, CA, United States AU - Jones, J. P. AU - Fong, D. S. AU - Fang, E. N. AU - Mesirov, C. A. AU - Patel, V. DB - Scopus DO - 10.1097/IJG.0000000000000205 IS - 1 KW - Adherence Distribution Glaucoma Medication M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 SP - 22-26 ST - Characterization of glaucoma medication adherence in kaiser permanente Southern California T2 - Journal of Glaucoma TI - Characterization of glaucoma medication adherence in kaiser permanente Southern California UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84952901409&doi=10.1097%2fIJG.0000000000000205&partnerID=40&md5=76cea5448e0d899d080978d9f65e9244 VL - 25 ID - 5357 ER - TY - JOUR AB - Purpose: To assess accuracy and adherence of visual field (VF) home monitoring in a pilot sample of patients with glaucoma. Design: Prospective longitudinal feasibility and reliability study. Methods: Twenty adults (median 71 years) with an established diagnosis of glaucoma were issued a tablet perimeter (Eyecatcher) and were asked to perform 1 VF home assessment per eye, per month, for 6 months (12 tests total). Before and after home monitoring, 2 VF assessments were performed in clinic using standard automated perimetry (4 tests total, per eye). Results: All 20 participants could perform monthly home monitoring, though 1 participant stopped after 4 months (adherence: 98% of tests). There was good concordance between VFs measured at home and in the clinic (r = 0.94, P < .001). In 21 of 236 tests (9%), mean deviation deviated by more than ±3 dB from the median. Many of these anomalous tests could be identified by applying machine learning techniques to recordings from the tablets' front-facing camera (area under the receiver operating characteristic curve = 0.78). Adding home-monitoring data to 2 standard automated perimetry tests made 6 months apart reduced measurement error (between-test measurement variability) in 97% of eyes, with mean absolute error more than halving in 90% of eyes. Median test duration was 4.5 minutes (quartiles: 3.9-5.2 minutes). Substantial variations in ambient illumination had no observable effect on VF measurements (r = 0.07, P = .320). Conclusions: Home monitoring of VFs is viable for some patients and may provide clinically useful data. AD - P. Campbell, Division of Optometry and Visual Sciences, School of Health Sciences, City, University of London, Northampton Square, London, United Kingdom AU - Jones, P. R. AU - Campbell, P. AU - Callaghan, T. AU - Jones, L. AU - Asfaw, D. S. AU - Edgar, D. F. AU - Crabb, D. P. DB - Embase Medline DO - 10.1016/j.ajo.2020.08.039 KW - camera tablet computer adult aged article clinical article clinical trial diagnostic accuracy diagnostic test accuracy study feasibility study female glaucoma home monitoring human male measurement accuracy measurement error mobile application patient compliance perimetry pilot study priority journal prospective study reliability LA - English M3 - Article N1 - L2010257141 2020-12-14 2021-03-16 PY - 2021 SN - 1879-1891 0002-9394 SP - 42-52 ST - Glaucoma Home Monitoring Using a Tablet-Based Visual Field Test (Eyecatcher): An Assessment of Accuracy and Adherence Over 6 Months T2 - American Journal of Ophthalmology TI - Glaucoma Home Monitoring Using a Tablet-Based Visual Field Test (Eyecatcher): An Assessment of Accuracy and Adherence Over 6 Months UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010257141&from=export http://dx.doi.org/10.1016/j.ajo.2020.08.039 VL - 223 ID - 2317 ER - TY - JOUR AB - Purpose: To assess accuracy and adherence of visual field (VF) home monitoring in a pilot sample of patients with glaucoma. Design: Prospective longitudinal feasibility and reliability study. Methods: Twenty adults (median 71 years) with an established diagnosis of glaucoma were issued a tablet perimeter (Eyecatcher) and were asked to perform 1 VF home assessment per eye, per month, for 6 months (12 tests total). Before and after home monitoring, 2 VF assessments were performed in clinic using standard automated perimetry (4 tests total, per eye). Results: All 20 participants could perform monthly home monitoring, though 1 participant stopped after 4 months (adherence: 98% of tests). There was good concordance between VFs measured at home and in the clinic (r = 0.94, P < .001). In 21 of 236 tests (9%), mean deviation deviated by more than ±3 dB from the median. Many of these anomalous tests could be identified by applying machine learning techniques to recordings from the tablets' front-facing camera (area under the receiver operating characteristic curve = 0.78). Adding home-monitoring data to 2 standard automated perimetry tests made 6 months apart reduced measurement error (between-test measurement variability) in 97% of eyes, with mean absolute error more than halving in 90% of eyes. Median test duration was 4.5 minutes (quartiles: 3.9-5.2 minutes). Substantial variations in ambient illumination had no observable effect on VF measurements (r = 0.07, P = .320). Conclusions: Home monitoring of VFs is viable for some patients and may provide clinically useful data. © 2020 Elsevier Inc. AD - Division of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, United Kingdom Department of Ophthalmology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom AU - Jones, P. R. AU - Campbell, P. AU - Callaghan, T. AU - Jones, L. AU - Asfaw, D. S. AU - Edgar, D. F. AU - Crabb, D. P. DB - Scopus DO - 10.1016/j.ajo.2020.08.039 M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2021 SP - 42-52 ST - Glaucoma Home Monitoring Using a Tablet-Based Visual Field Test (Eyecatcher): An Assessment of Accuracy and Adherence Over 6 Months T2 - American Journal of Ophthalmology TI - Glaucoma Home Monitoring Using a Tablet-Based Visual Field Test (Eyecatcher): An Assessment of Accuracy and Adherence Over 6 Months UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097379602&doi=10.1016%2fj.ajo.2020.08.039&partnerID=40&md5=d6479ec94477669b31e10ce5e04914b9 VL - 223 ID - 5438 ER - TY - JOUR AB - Purpose: To explore the feasibility of using various easy-to-obtain biomarkers to monitor non-compliance (measurement error) during visual field assessments., Methods: Forty-two healthy adults (42 eyes) and seven glaucoma patients (14 eyes) underwent two same-day visual field assessments. An ordinary webcam was used to compute seven potential biomarkers of task compliance, based primarily on eye gaze, head pose, and facial expression. We quantified the association between each biomarker and measurement error, as defined by (1) test-retest differences in overall test scores (mean sensitivity), and (2) failures to respond to visible stimuli on individual trials (stimuli -3 dB or more brighter than threshold)., Results: In healthy eyes, three of the seven biomarkers were significantly associated with overall (test-retest) measurement error (P = 0.003-0.007), and at least two others exhibited possible trends (P = 0.052-0.060). The weighted linear sum of all seven biomarkers was associated with overall measurement error, in both healthy eyes (r = 0.51, P < 0.001) and patients (r = 0.65, P < 0.001). Five biomarkers were each associated with failures to respond to visible stimuli on individual trials (all P < 0.001)., Conclusions: Inexpensive, autonomous measures of task compliance are associated with measurement error in visual field assessments, in terms of both the overall reliability of a test and failures to respond on particular trials ("lapses"). This could be helpful for identifying low-quality assessments and for improving assessment techniques (e.g., by discounting suspect responses or by automatically triggering comfort breaks or encouragement)., Translational Relevance: This study explores a potential way of improving the reliability of visual field assessments, a crucial but notoriously unreliable clinical measure. Copyright 2020 The Authors. AU - Jones, Pete R. AU - Demaria, Giorgia AU - Tigchelaar, Iris AU - Asfaw, Daniel S. AU - Edgar, David F. AU - Campbell, Peter AU - Callaghan, Tamsin AU - Crabb, David P. DO - https://dx.doi.org/10.1167/tvst.9.8.31 IS - 8 KW - Adult Glaucoma/di [Diagnosis] *Glaucoma Humans Reproducibility of Results Touch Visual Field Tests *Visual Fields PY - 2020 SE - Jones, Pete R. Division of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, UK. Demaria, Giorgia. Department of Ophthalmology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Demaria, Giorgia. Graduate School of Medical Sciences (Research School of Behavioral and Cognitive Neurosciences), University of Groningen, Groningen, The Netherlands. Tigchelaar, Iris. Department of Ophthalmology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Tigchelaar, Iris. Ocusweep, Turku, Finland. Tigchelaar, Iris. Doctoral Program in Clinical Research, University of Turku and Turku University Hospital, Turku, Finland. Asfaw, Daniel S. Division of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, UK. Edgar, David F. Division of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, UK. Campbell, Peter. Division of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, UK. Campbell, Peter. Department of Ophthalmology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Callaghan, Tamsin. Division of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, UK. Crabb, David P. Division of Optometry and Visual Sciences, School of Health Sciences, City, University of London, London, UK. SN - 2164-2591 SP - 31 ST - The Human Touch: Using a Webcam to Autonomously Monitor Compliance During Visual Field Assessments T2 - Translational vision science & technology TI - The Human Touch: Using a Webcam to Autonomously Monitor Compliance During Visual Field Assessments UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32855877 VL - 9 Y2 - 20200720// ID - 188 ER - TY - JOUR AB - Aim: To investigate characteristics of initial immunological graft rejection after Descemet stripping with endothelial keratoplasty (DSEK). Methods: The incidence, symptoms and clinical characteristics of initial immunological graft rejection episodes were analysed retrospectively in 598 eyes treated with primary DSEK at a single tertiary referral centre. Results: Graft rejection episodes occurred in 54 eyes of 48 patients. Thirty-five per cent of the eyes were asymptomatic and were diagnosed during routine examination. Signs of immunological rejection at the initial diagnosis included keratic precipitates (69%), diffuse corneal oedema (11%) or both (20%); no endothelial rejection lines were observed. In contrast to standard full-thickness grafts, there were no epithelial immunological reactions because the epithelium and anterior stroma are not transplanted in DSEK. Most grafts cleared; four (7%) progressed to graft failure and were successfully regrafted with DSEK. Conclusions: Immunological graft rejection is an important postoperative complication after DSEK. The range of clinical findings indicative of corneal graft rejection differs in some respects between DSEK and standard penetrating keratoplasty. AD - Northeastern Eye Institute, Scranton, PA, United States Cornea Research Foundation of America, Indianapolis, IN, United States Brevard Eye Center, Melbourne, FL, United States Price Vision Group, Indianapolis, IN, United States Cornea Research Foundation of America, 9002 N. Meridian Street, Ste. 212, Indianapolis, IN 46260, United States AU - Jordan, C. S. AU - Price, M. O. AU - Trespalacios, R. AU - Price Jr, F. W. DB - Scopus DO - 10.1136/bjo.2008.140020 IS - 3 M3 - Article N1 - Cited By :64 Export Date: 19 July 2021 PY - 2009 SP - 387-390 ST - Graft rejection episodes after Descemet stripping with endothelial keratoplasty: Part one: Clinical signs and symptoms T2 - British Journal of Ophthalmology TI - Graft rejection episodes after Descemet stripping with endothelial keratoplasty: Part one: Clinical signs and symptoms UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-61749085062&doi=10.1136%2fbjo.2008.140020&partnerID=40&md5=6a532e02c52aa339f5019ced64c5c7b0 VL - 93 ID - 4967 ER - TY - JOUR AB - In most forms of open angle glaucoma, the trabecular meshwork is the main barrier for aqueous humor outflow, causing elevated intraocular pressure (IOP). The Trabectome is a minimal invasive device for the surgical treatment of open angle glaucoma, particularly eliminating the juxtacanalicular meshwork. This study was conducted to compare the effectiveness and complication profile among different glaucoma subgroups. Single center prospective observational study. There were 557 consecutive eyes of 487 patients included in this study. Trabectome surgery was performed either alone or in combination with cataract surgery. Intraoperative and postoperative complications were documented systematically. Main outcome measures were IOP reduction over time and the preoperative and postoperative number of IOP-lowering medications. Due to subgroup sizes, only data from eyes with primary open angle glaucoma and pseudoexfoliation glaucoma were processed for statistical analysis. For the 261 eyes classified as primary open angle glaucoma, preoperative IOP was 24 +/- 5.5 mmHg (mean +/- SD) under 2.1 +/- 1.3 IOP-lowering medications. After a mean follow-up of 204 +/- 238 days, IOP was reduced to 18 +/- 6.1 mmHg, and medication was reduced to 1.2 +/- 1.1. For the 173 eyes classified as pseudoexfoliation glaucoma, after a mean follow-up of 200 +/- 278 days, IOP was reduced from 25 +/- 5.9 mmHg to 18 +/- 8.2 mmHg, and medication was reduced from 2.0 +/- 1.2 to 1.1 +/- 1.1. A Cox proportional hazards model hinted forward superiority of the combined surgery cases (Trabectome + Phaco + intraocular lens) in comparison to Trabectome surgery only in phakic or pseudophakic eyes. No serious complications were observed. Minimal invasive glaucoma surgery with the Trabectome seems to be safe and effective. The subgroup analysis of different kinds of open angle glaucomas presented in this study may help in first-line patient selection. The lack of ocular surface alterations makes it a valuable addition to glaucoma surgery. AN - WOS:000328345000012 AU - Jordan, J. F. AU - Wecker, T. AU - van Oterendorp, C. AU - Anton, A. AU - Reinhard, T. AU - Boehringer, D. AU - Neuburger, M. DA - DEC DO - 10.1007/s00417-013-2500-7 IS - 12 PY - 2013 SN - 0721-832X 1435-702X SP - 2753-2760 ST - Trabectome surgery for primary and secondary open angle glaucomas T2 - GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Trabectome surgery for primary and secondary open angle glaucomas VL - 251 ID - 6018 ER - TY - JOUR AB - The treatment paradigm in glaucoma classically starts with exhausting all medical therapy prior to proceeding with laser or incisional surgery, although laser-first and surgery-first strategies have been explored in randomized clinical trials. Although glaucoma drops are proven to work well to lower intraocular pressure, slow the conversion from ocular hypertension, and slow the progression of disease in early open angle glaucoma, adherence to treatment is likely optimum in the randomized clinical trials that support these claims. In real-world scenarios, medical therapy often fails and practitioners are forced to proceed with more invasive treatment modalities to slow the progression of this blinding disease. This review aims to take an evidence-based approach to study the risk factors for poor adherence in glaucoma patients, to determine whether poor adherence is, in fact, associated with worse outcomes, and to seek potential strategies to improve adherence in these patients. AD - Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA AN - 120599666. Language: English. Entry Date: 20170228. Revision Date: 20190220. Publication Type: journal article AU - Joseph, Arun AU - Pasquale, Louis R. DB - ccm DO - 10.1080/08820538.2016.1228406 DP - EBSCOhost IS - 1 KW - Intraocular Pressure -- Drug Effects Medication Compliance Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Tonometry Patient Education Human Medical Practice, Evidence-Based Risk Factors Treatment Outcomes Reminder Systems Arthritis Impact Measurement Scales Clinical Assessment Tools Scales N1 - research. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. Instrumentation: Arthritis Impact Measurement Scale (AIMS) (Meenan); Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Work Environment Scale (WES) (Moos et al); Functional Assessment of Cancer Therapy (FACT). NLM UID: 8610759. PMID: NLM27792450. PY - 2017 SN - 0882-0538 SP - 86-90 ST - Attributes Associated with Adherence to Glaucoma Medical Therapy and its Effects on Glaucoma Outcomes: An Evidence-Based Review and Potential Strategies to Improve Adherence T2 - Seminars in Ophthalmology TI - Attributes Associated with Adherence to Glaucoma Medical Therapy and its Effects on Glaucoma Outcomes: An Evidence-Based Review and Potential Strategies to Improve Adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120599666&site=ehost-live&scope=site VL - 32 ID - 4235 ER - TY - JOUR AB - The management of glaucoma therapy to reduce intraocular pressure commonly consists of a gradual approach with local monotherapy, combined therapy, laser surgery and finally filtration surgery. The local side effects of glaucoma medications and the lack of adherence and persistence to the medical therapy as well as the complication profile of the established glaucoma surgical techniques justify the introduction of new surgical procedures. Micro-invasive glaucoma surgery (MIGS) is a promising new surgical approach. Microstents can reduce the medication burden and prolong the need for filtration surgery. This review article presents the different trabecular implants (iStent, iStent inject, Hydrus (TM) Microstent) in detail and discusses the effectiveness and safety of the procedures based on the currently available data. AN - WOS:000431778900005 AU - Junemann, A. G. M. AU - Rejdak, R. AU - Hohberger, B. DA - MAY DO - 10.1007/s00347-018-0689-x IS - 5 PY - 2018 SN - 0941-293X 1433-0423 SP - 363-369 ST - Trabecular micro-invasive glaucoma surgery. Procedures and clinical results T2 - OPHTHALMOLOGE TI - Trabecular micro-invasive glaucoma surgery. Procedures and clinical results VL - 115 ID - 6063 ER - TY - JOUR AB - Objective: To assess the relationship between health literacy and compliance, disease awareness, and disease progression in patients with glaucoma. Methods: A cross-sectional observational study of 204 English-speaking patients treated for glaucoma for at least 1 year at Kresge Eye Institute was conducted. Health literacy was assessed using the standardized Test of Functional Health Literacy in Adults (TOFHLA). An oral questionnaire assessed patients' demographic information and glaucoma understanding. A retrospective medical record review was conducted to record parameters indicating glaucoma severity. Results: One hundred two participants (50%) were categorized as having poor functional health literacy (mean [SD] TOFHLA score, 18.4 [7.5]) and 102 participants (50%) had adequate health literacy (mean [SD] TOFHLA score, 42.8 [5.1]). The poor health literacy group showed significant differences in income, education, medication compliance, glaucoma understanding, and missed appointments compared with the adequate health literacy group (P < .001). Patients with poor health literacy showed a greater visual field loss on initial presentation (mean deviation [SD], -10.58 [9.3] dB) compared with the adequate health literacy group (mean deviation [SD], -7.79 [6.9] dB; P = .02) and significantly worse visual field parameters when comparing pattern SDs on the recent and the initial visual fields (pattern SD change [SD], 0.19 [2.5] dB in the poor health literacy group vs -0.7 [2.2] dB in the adequate health literacy group; P = .02). Conclusions: Patients with poor health literacy had poorer compliance, worse disease understanding, and greater disease progression compared with the adequate health literacy group, highlighting the need to promote health literacy in patients with glaucoma. ©2008 American Medical Association. All rights reserved. AD - M. S. Juzych, Department of Ophthalmology, Kresge Eye Institute, Wayne State University School of Medicine, 4717 St Antoine St, Detroit, MI 48201, United States AU - Juzych, M. S. AU - Randhawa, S. AU - Shukairy, A. AU - Kaushal, P. AU - Gupta, A. AU - Shalauta, N. DB - Embase Medline DO - 10.1001/archopht.126.5.718 IS - 5 KW - adult aged article awareness controlled study disease course disease severity female glaucoma health education human income major clinical study male medical record review patient compliance patient education priority journal questionnaire urban area visual field LA - English M3 - Article N1 - L351679570 2008-06-19 PY - 2008 SN - 0003-9950 SP - 718-724 ST - Functional health literacy in patients with glaucoma in urban settings T2 - Archives of Ophthalmology TI - Functional health literacy in patients with glaucoma in urban settings UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351679570&from=export http://dx.doi.org/10.1001/archopht.126.5.718 http://archopht.ama-assn.org/cgi/reprint/126/5/718 VL - 126 ID - 3454 ER - TY - JOUR AB - Objective: To assess the relationship between health literacy and compliance, disease awareness, and disease progression in patients with glaucoma. Methods: A cross-sectional observational study of 204 English-speaking patients treated for glaucoma for at least 1 year at Kresge Eye Institute was conducted. Health literacy was assessed using the standardized Test of Functional Health Literacy in Adults (TOFHLA). An oral questionnaire assessed patients' demographic information and glaucoma understanding. A retrospective medical record review was conducted to record parameters indicating glaucoma severity. Results: One hundred two participants (50%) were categorized as having poor functional health literacy (mean [SD] TOFHLA score, 18.4 [7.5]) and 102 participants (50%) had adequate health literacy (mean [SD] TOFHLA score, 42.8 [5.1]). The poor health literacy group showed significant differences in income, education, medication compliance, glaucoma understanding, and missed appointments compared with the adequate health literacy group (P < .001). Patients with poor health literacy showed a greater visual field loss on initial presentation (mean deviation [SD], -10.58 [9.3] dB) compared with the adequate health literacy group (mean deviation [SD], -7.79 [6.9] dB; P = .02) and significantly worse visual field parameters when comparing pattern SDs on the recent and the initial visual fields (pattern SD change [SD], 0.19 [2.5] dB in the poor health literacy group vs -0.7 [2.2] dB in the adequate health literacy group; P = .02). Conclusions: Patients with poor health literacy had poorer compliance, worse disease understanding, and greater disease progression compared with the adequate health literacy group, highlighting the need to promote health literacy in patients with glaucoma. ©2008 American Medical Association. All rights reserved. AD - Kresge Eye Institute, Wayne State University School of Medicine, Detroit, MI, United States Michigan Public Health Institute, Okemos, MI, United States Department of Ophthalmology, Kresge Eye Institute, Wayne State University School of Medicine, 4717 St Antoine St, Detroit, MI 48201, United States AU - Juzych, M. S. AU - Randhawa, S. AU - Shukairy, A. AU - Kaushal, P. AU - Gupta, A. AU - Shalauta, N. DB - Scopus DO - 10.1001/archopht.126.5.718 IS - 5 M3 - Article N1 - Cited By :54 Export Date: 19 July 2021 PY - 2008 SP - 718-724 ST - Functional health literacy in patients with glaucoma in urban settings T2 - Archives of Ophthalmology TI - Functional health literacy in patients with glaucoma in urban settings UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-43549088115&doi=10.1001%2farchopht.126.5.718&partnerID=40&md5=b7e59af069a67388a298e764a6d39362 VL - 126 ID - 4983 ER - TY - JOUR AB - Objective: To assess the relationship between health literacy and compliance, disease awareness, and disease progression in patients with glaucoma. Methods: A cross-sectional observational study of 204 English-speaking patients treated for glaucoma for at least 1 year at Kresge Eye Institute was conducted. Health literacy was assessed using the standardized Test of Functional Health Literacy in Adults (TOFHLA). An oral questionnaire assessed patients' demographic information and glaucoma understanding. A retrospective medical record review was conducted to record parameters indicating glaucoma severity. Results: One hundred two participants (50%) were categorized as having poor functional health literacy ( mean [SD] TOFHLA score, 18.4 [7.5]) and 102 participants ( 50%) had adequate health literacy ( mean [ SD] TOFHLA score, 42.8 [5.1]). The poor health literacy group showed significant differences in income, education, medication compliance, glaucoma understanding, and missed appointments compared with the adequate health literacy group ( P <. 001). Patients with poor health literacy showed a greater visual field loss on initial presentation ( mean deviation [SD], -10.58 [9.3] dB) compared with the adequate health literacy group ( mean deviation [ SD], -7.79 [6.9] dB; P=.02) and significantly worse visual field parameters when comparing pattern SDs on the recent and the initial visual fields ( pattern SD change [ SD], 0.19 [2.5] dB in the poor health literacy group vs -0.7 [2.2] dB in the adequate health literacy group; P=.02). Conclusions: Patients with poor health literacy had poorer compliance, worse disease understanding, and greater disease progression compared with the adequate health literacy group, highlighting the need to promote health literacy in patients with glaucoma. AN - WOS:000255780700017 AU - Juzych, M. S. AU - Randhawa, S. AU - Shukairy, A. AU - Kaushal, P. AU - Gupta, A. AU - Shalauta, N. DA - MAY DO - 10.1001/archopht.126.5.718 IS - 5 PY - 2008 SN - 0003-9950 SP - 718-724 ST - Functional health literacy in patients with glaucoma in urban settings T2 - ARCHIVES OF OPHTHALMOLOGY TI - Functional health literacy in patients with glaucoma in urban settings VL - 126 ID - 6021 ER - TY - JOUR AB - Objective: To evaluate the efficacy of travoprost 0.004% monotherapy in patients unsuccessfully treated with latanoprost monotherapy.Research Design and Methods: Open-label, noncomparative study conducted at US academic and private practice clinics in adult patients with ocular hypertension or primary open-angle glaucoma who required a change in therapy (due to either inadequate efficacy or safety issues) as judged by the investigator. Intraocular pressure (IOP) was measured at entry and 30 days later.Main Outcome Measures: Mean change in intraocular pressure (mm Hg).Results: Reported here are 488 per-protocol patients from 330 centers who were using latanoprost monotherapy prior to study entry, and who received travoprost monotherapy during the study. Patients had a mean age of 69 years, were approximately two-thirds Caucasian, 60% female, predominantly brown or blue eyes, and 91% were diagnosed as having primary open-angle glaucoma. The mean days in treatment were 31.9 +/- 6.4. Mean IOP at study entry was 21.2 mm Hg. Following travoprost monotherapy, this was reduced by a mean of 3.2 mm Hg to 18 mm Hg (p < 0.0001, paired t-test). There were 21 adverse events reported in the intent-to-treat (ITT) population for an incidence of 3.5%. There were some limitations to the current study including: no washout period, no control therapy, single IOP determinations at the beginning and the end of the study; patient compliance with the initial therapy was not measured, and the study was not masked. This study reflects a real-life situation of what a clinician can expect when he changes a patient from latanoprost monotherapy to travoprost monotherapy.Conclusion: This study showed that travoprost provided a statistically and clinically significant reduction (p < 0.0001) in IOP of 3.2 mm Hg for patients who had not been successfully treated with latanoprost monotherapy. The results of this trial demonstrate the potential benefit of using travoprost as a replacement therapy in order to ensure adequate IOP control. AD - Glaucoma Consultants, Slingerlands, NY, USA Glaucoma Consultants, Singerlands, NY AN - 106558468. Corporate Author: START Study Group. Language: English. Entry Date: 20050107. Revision Date: 20190915. Publication Type: journal article AU - Kaback, M. AU - Geanon, J. AU - Katz, G. AU - Ripkin, D. AU - Przydryga, J. AU - Kaback, Martin AU - Geanon, John AU - Katz, Gregory AU - Ripkin, Douglas AU - Przydryga, Johan DB - ccm DP - EBSCOhost IS - 9 KW - Glaucoma -- Drug Therapy Ocular Hypertension -- Drug Therapy Travoprost -- Therapeutic Use Adult Aged Aged, 80 and Over Clinical Trials Data Analysis Software Descriptive Statistics Female Funding Source Human Intraocular Pressure Latanoprost Male Middle Age T-Tests Treatment Failure Treatment Outcomes United States N1 - clinical trial; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Grant Information: Alcon Laboratories, Inc.. NLM UID: 0351014. PMID: NLM15383181. PY - 2004 SN - 0300-7995 SP - 1341-1345 ST - Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost T2 - Current Medical Research & Opinion TI - Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106558468&site=ehost-live&scope=site VL - 20 ID - 4585 ER - TY - JOUR AB - Pediatric migraine is a debilitating disease that affects about 10% of school-aged children. Like other pain disorders, migraines can be accompanied with sleep, mood, and cognitive difficulties, leading to interruptions in daily tasks required at both school and home. This paper serves as a review of the most current pharmacological treatments available for managing migraine in the pediatric population. Because the management of migraine is complex, we discuss the importance of multidisciplinary care involving pharmacological and non-pharmacological measures, behavioral modifications, and a shared treatment plan between the clinician, patient, and parent/care giver. A diverse group of medications are used to prevent migraine attacks including antiepileptics, antidepressants, antihistamines, and antihypertensive agents, in addition to newer classes of medications; yet there remains a serious lack of controlled studies in the pediatric population. Further clinical research is necessary to have Food and Drug Administration (FDA)-approved medications readily available for migraine sufferers. © 2020, Springer Nature Switzerland AG. AD - Division of Neurology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, MLC 2015, Cincinnati, OH 45229-3039, United States Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, United States AU - Kacperski, J. AU - Green, A. AU - Qaiser, S. DB - Scopus DO - 10.1007/s40272-020-00418-y IS - 6 M3 - Review N1 - Cited By :3 Export Date: 19 July 2021 PY - 2020 SP - 635-643 ST - Management of Chronic Migraine in Children and Adolescents: A Brief Discussion on Preventive Therapies T2 - Pediatric Drugs TI - Management of Chronic Migraine in Children and Adolescents: A Brief Discussion on Preventive Therapies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090308931&doi=10.1007%2fs40272-020-00418-y&partnerID=40&md5=435705b601fb767925f152fadf192237 VL - 22 ID - 5493 ER - TY - JOUR AB - Open-angle glaucoma is a silent, chronic disorder which results in progressive and permanent vision loss. Designing the optimal treatment regimen can be particularly challenging in the management of high-risk patients with frequent loss to follow-up or a longstanding history of medication noncompliance. In this article we aim to review fundamental techniques in glaucoma diagnosis and treatment with emphasis on the strengths and weaknesses of selective laser trabeculoplasty, a technique in modern therapy which may mold the future of primary treatment in open angle glaucoma management. [Full article available at http://rimed.org/rimedicaljournal-2016-06.asp, free with no login]. AD - Clinical Assistant Professor of Surgery (Ophthalmology), Alpert Medical School of Brown University; Rhode Island Hospital, Providence, RI, United States AU - Kadasi, L. M. AU - Wagdi, S. AU - Miller, K. V. DB - Scopus IS - 6 KW - glaucoma laser surgery selective laser trabeculoplasty M3 - Review N1 - Cited By :5 Export Date: 19 July 2021 PY - 2016 SP - 22-25 ST - Selective Laser Trabeculoplasty as Primary Treatment for Open-Angle Glaucoma T2 - Rhode Island medical journal (2013) TI - Selective Laser Trabeculoplasty as Primary Treatment for Open-Angle Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016022313&partnerID=40&md5=bfa1ca397618b6b523878c3bde32b734 VL - 99 ID - 5417 ER - TY - JOUR AN - 109829282. Language: English. Entry Date: 20150828. Revision Date: 20150923. Publication Type: Journal Article AU - Kahl, Kristie L. DB - ccm DP - EBSCOhost IS - 13 KW - Latanoprost Medication Compliance Health Care Costs Glaucoma Minority Groups Race Factors Cost Benefit Analysis Drugs, Generic N1 - pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Perioperative Care. NLM UID: 9882135. PY - 2015 SN - 8750-3085 SP - 25-26 ST - Generic latanoprost may improve patients adherence with lower costs vs. brand-name agents T2 - Ocular Surgery News TI - Generic latanoprost may improve patients adherence with lower costs vs. brand-name agents UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109829282&site=ehost-live&scope=site VL - 33 ID - 4655 ER - TY - JOUR AB - Glaucoma is a leading cause of blindness worldwide. Currently, topical drops are the mainstay of treatment for patients who suffer from this chronic disease. Adherence to topical therapy is known to be affected by forgetfulness, frequent dosing requirements and physical limitations. Dosing and adherence aids are designed to help patients adhere to their prescribed therapeutic regimens. This review discusses commonly used dosing and adherence aids, and offers opinions on how future devices may improve on currently available technology. AD - M.Y. Kahook, Rocky Mountain Lions Eye Institute, University of Colorado at Denver, Health Sciences Center, 1675 North Ursula Street, Aurora, CO 80045, United States AU - Kahook, M. Y. C1 - ocusert pilogel travatan(Alcon,United States) xalatan(Pfizer,United States) C2 - Alcon(United States) Pfizer(United States) DB - Embase Medline DO - 10.1586/17434440.4.2.261 IS - 2 KW - antiglaucoma agent eye drops latanoprost pilocarpine timolol travoprost assistive technology device blurred vision clinical trial drug instillation electronics eye irritation glaucoma human intraocular pressure patient compliance patient education questionnaire reminder system review self report ocusert pilogel travatan xalatan Auto-drop Drop Zone Easidrop Lumigan Opticare Prescript Time-Cap Travatan Dosing Aid Xal-Ease LA - English M3 - Review N1 - L46522773 2007-03-01 PY - 2007 SN - 1743-4440 1745-2422 SP - 261-266 ST - Developments in dosing aids and adherence devices for glaucoma therapy: Current and future perspectives T2 - Expert Review of Medical Devices TI - Developments in dosing aids and adherence devices for glaucoma therapy: Current and future perspectives UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46522773&from=export http://dx.doi.org/10.1586/17434440.4.2.261 http://www.future-drugs.com/doi/pdf/10.1586/17434440.4.2.261 VL - 4 ID - 3541 ER - TY - JOUR AB - Purpose. Two of the hurdles that are facing ophthalmologists in developing countries are scarcity of resources and patient follow-up. Deep sclerectomy (DS) has proven less costly and more effective than topical therapies and has a more favorable safety profile than trabeculectomy. The main factors preventing its use in developing countries are the need to perform laser goniopuncture in 40-80% of cases to maintain filtration and the risk of postoperative iris incarceration. The purpose of this study is to assess the efficacy and safety profile in advanced open -angle glaucoma of a relatively new surgical technique designed to overcome this limitation: penetrating DS. Setting. This was an investigator -initiated, prospective, interventional study, conducted at a single ophthalmology center in Kinshasa, Congo. The study was conducted in full compliance with the Declaration of Helsinki. Methods. Fifty-one eyes (34 patients) with uncontrolled advanced primary open -angle glaucoma (visual field mean deviation < 10 dBs) were enrolled between October 2012 and June 2016. Age, gender, comorbidities (hypertension/diabetes), best -corrected visual acuity, topical medications, medicated and unmedicated intraocular pressure (10P) were recorded. All patients underwent penetrating DS, during which, following standard dissection of the scleral flaps, the anterior chamber was penetrated through the trabeculo-Descemet membrane and an iridectomy was performed. Patients attended postoperative appointments at months 1, 3, 6 and 12. Surgical success was defined as a 20% reduction of 10P from baseline in conjunction with a 12 -month unmedicated 10P < 12 mm Hg. Results. The mean age was 64.5 + 14.0 years (44.1% female, 100% African). Mean 10P decreased from 20.2 6.1 (medicated) and 30.7+9.8 mm Hg (unmedicated) preoperatively to 12.1+4.1 at 12 months. Concomitantly, the number of topical medications decreased from 1.5 0.7 to 0.0. Complete surgical success was achieved in 64.7%. Four eyes (7.8%) were considered surgical failures due to uncontrolled 10P. None of the eyes lost light perception or required additional surgery. A significant association between surgical failure and hypertension was observed (HR = 1.49; P=0.008). There were no intraoperative complications. Postoperatively, 4 bleb encapsulations (7.8%) and 1 iris incarceration (2%) were observed. Conclusions. The present study demonstrates that penetrating DS achieved similar efficacy and safety results to traditional non -penetrating DS. In addition, it showed a lower potential for intraoperative complications, which might be associated with a more benign surgical learning curve. Finally, the rates of serious postoperative complications (iris incarceration, choroidal effusion and hypotony) were significantly lower than in DS and trabeculectomy, and this technique does not require subsequent Nd: YAG laser goniopuncture to maintain filtration, making frequent follow-up visits less critical. In view of these findings, perforating deep sclerectomy could offer a viable option for glaucoma management in developing countries as well as worldwide. (C) 2020 Elsevier Masson SAS. All rights reserved. AN - WOS:000518222700015 AU - Kalala, A. AU - Gillmann, K. AU - Mermoud, A. DA - MAR DO - 10.1016/j.jfo.2019.07.024 IS - 3 PY - 2020 SN - 0181-5512 1773-0597 SP - 228-236 ST - Prospective evaluation of penetrating deep sclerectomy in advanced open-angle glaucoma: Filtration surgery adapted to resource scarcity in developing countries T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Prospective evaluation of penetrating deep sclerectomy in advanced open-angle glaucoma: Filtration surgery adapted to resource scarcity in developing countries VL - 43 ID - 6041 ER - TY - JOUR AB - Purpose: To assess the penetration of topical ciprofloxacin by a presoaked medicated disposable soft contact lens without topical drop administration. Methods: Disposable soft contact lenses were presoaked in 0.3 % topical ciprofloxacin (Ciloxan, Alcon Laboratories, Fort Worth, TX) for 10- 12 hours. Presoaked lenses were placed on the eyes of patients with senile cataracts for 3 hours in group A, 5-6 hours in group B, and 8-12 hours in group C prior to their scheduled lens extraction surgery. Aqueous humor samples were drawn by paracentesis during the operation. Ciprofloxacin concentrations were determined by high pressure liquid chromatography- fluorescence detection. Results: The mean ciprofloxacin concentration was 2.70 ±0.98 μg/mL in group A, 1.22±1.0 μg/mL in group B, and 0.5 ± 0.2μg/mL in group C. Conclusions: Penetration of topical ciprofloxacin is enhanced through a presoaked disposable soft contact lens, and at 3 hours therapeutic levels are obtained. Significant levels of ciprofloxacin are retained through 8-12 hours. This mode of treatment may increase patient compliance compared to frequent topical drop administration, and as a consequence, assure efficient treatment of keratitis, at least for the first 3 hours. AD - D. Kalayci, 39. sok. 12/6, 06500 Bahcelievler, Ankara, Turkey AU - Kalayci, D. AU - Basci, N. AU - Kortunay, S. AU - Hasiripi, H. AU - Bozkurt, A. C1 - ciloxan(Alcon,United States) C2 - Alcon(United States) DB - Embase Medline IS - 3 KW - ciprofloxacin antibiotic therapy aqueous humor article cataract extraction controlled study drug delivery system drug penetration high performance liquid chromatography human keratitis patient compliance senile cataract soft contact lens topical drug administration ciloxan Plano Focus LA - English M3 - Article N1 - L29344705 1999-08-03 PY - 1999 SN - 0733-8902 SP - 182-184 ST - Penetration of topical ciprofloxacin by presoaked medicated soft contact lenses T2 - CLAO Journal TI - Penetration of topical ciprofloxacin by presoaked medicated soft contact lenses UR - https://www.embase.com/search/results?subaction=viewrecord&id=L29344705&from=export VL - 25 ID - 3924 ER - TY - JOUR AB - Purpose: To determine what criteria are being used by glaucoma specialists to refer patients to low vision services (LVS) and to identify potential barriers to LVS referral. Methods: A survey was emailed to members of the American Glaucoma Society (AGS). The number and percentage of responses to each survey question were examined. Results: Reported criteria for referral included difficulty performing activities related to vision (78%), degree of visual field loss (63%), and difficulty with orientation and mobility (27%). Reported barriers to LVS referral included patients not expressing difficulty with activities related to vision (34%), not having enough time to counsel patients during clinic visits (32%), and perceiving that patients would not be able to afford LVS even if they were referred (31%). Conclusions: Among glaucoma specialists, patient-reported difficulties with vision-related activities were the most common criteria used for LVS referral. Reported barriers to LVS referral, including perceived patient economic restraints and insufficient time to counsel patients during clinic visits, need to be addressed through appropriate interventions. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology, University of Maryland, 419 W Redwood Street, Baltimore, MD 21201, United States Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States AU - Kaleem, M. A. AU - West, S. K. AU - Im, L. AU - Swenor, B. K. DB - Scopus DO - 10.1097/IJG.0000000000000985 IS - 7 KW - barriers glaucoma low vision services referral M3 - Article N1 - Export Date: 19 July 2021 PY - 2018 SP - 653-655 ST - Referral to Low Vision Services for Glaucoma Patients: Referral Criteria and Barriers T2 - Journal of Glaucoma TI - Referral to Low Vision Services for Glaucoma Patients: Referral Criteria and Barriers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049904338&doi=10.1097%2fIJG.0000000000000985&partnerID=40&md5=37cd4fc3948178bc524c86950f122d4c VL - 27 ID - 5729 ER - TY - JOUR AB - Purpose:To determine what criteria are being used by glaucoma specialists to refer patients to low vision services (LVS) and to identify potential barriers to LVS referral.Methods:A survey was emailed to members of the American Glaucoma Society (AGS). The number and percentage of responses to each survey question were examined.Results:Reported criteria for referral included difficulty performing activities related to vision (78%), degree of visual field loss (63%), and difficulty with orientation and mobility (27%). Reported barriers to LVS referral included patients not expressing difficulty with activities related to vision (34%), not having enough time to counsel patients during clinic visits (32%), and perceiving that patients would not be able to afford LVS even if they were referred (31%).Conclusions:Among glaucoma specialists, patient-reported difficulties with vision-related activities were the most common criteria used for LVS referral. Reported barriers to LVS referral, including perceived patient economic restraints and insufficient time to counsel patients during clinic visits, need to be addressed through appropriate interventions. AN - WOS:000438232700020 AU - Kaleem, M. A. AU - West, S. K. AU - Im, L. AU - Swenor, B. K. DA - JUL DO - 10.1097/IJG.0000000000000985 IS - 7 PY - 2018 SN - 1057-0829 1536-481X SP - 653-655 ST - Referral to Low Vision Services for Glaucoma Patients: Referral Criteria and Barriers T2 - JOURNAL OF GLAUCOMA TI - Referral to Low Vision Services for Glaucoma Patients: Referral Criteria and Barriers VL - 27 ID - 6096 ER - TY - JOUR AB - Purpose Of Review: Ophthalmic herpes simplex virus (HSV) of the anterior segment is responsible for a range of corneal complications such as scarring, thinning, neovascularization, and severe loss of vision. This review provides current guidelines for treating anterior segment disease related to HSV.Recent Findings: We first review findings from the Herpetic Eye Disease Study (HEDS) clinical trials, and then review new topical and antiviral therapies developed since the HEDS studies. The development of vaccines to prevent recurrent episodes of herpetic infection is briefly reviewed. New corneal surgical procedures, developed since HEDS, may put patients at risk for ocular HSV disease: cross-linking and excimer refractive surgery.Summary: HEDS established the standard of HSV ocular therapy and is still valid today. However, newer antivirals may provide easier compliance with improved bioavailability, efficacy, dosage, and tolerability. Further research is needed to prevent latency of HSV, decrease recurrences, and more effectively treat necrotizing keratitis associated with HSV. AD - University of Belgrade, Faculty of Medicine, Clinic for Eye Disease, Clinical Center of Serbia, Belgrade, Serbia Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, USA AN - 130211278. Language: English. Entry Date: 20180702. Revision Date: 20190313. Publication Type: journal article AU - Kalezic, Tanja AU - Mazen, Mostafa AU - Kuklinski, Eric AU - Asbell, Penny DB - ccm DO - 10.1097/ICU.0000000000000482 DP - EBSCOhost IS - 4 KW - Eye Infections, Viral -- Drug Therapy Antiviral Agents -- Therapeutic Use Keratitis, Herpetic -- Drug Therapy Eye Infections, Viral -- Prevention and Control Viral Vaccines -- Administration and Dosage Human Recurrence Herpesviruses Keratitis, Herpetic -- Prevention and Control N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. NLM UID: 9011108. PMID: NLM29846207. PY - 2018 SN - 1040-8738 SP - 340-346 ST - Herpetic eye disease study: lessons learned T2 - Current Opinion in Ophthalmology TI - Herpetic eye disease study: lessons learned UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130211278&site=ehost-live&scope=site VL - 29 ID - 4320 ER - TY - JOUR AB - Importance: Glaucoma care for prison inmates is underrepresented in the literature even though managing the treatment of such patients may provide unique challenges. Objectives: To evaluate the glaucoma profile of prison inmates treated at an academic ophthalmology center and to report on the medical and surgical management and follow-up metrics. Design, Setting, and Participants: This retrospective cohort study assessed data from 82 incarcerated patients treated at the glaucoma clinic, an academic referral center at the University of Illinois at Chicago, between January 2013 and December 2017. Main Outcomes and Measures: Diagnosis, glaucoma severity, medical and surgical interventions, and patient-reported medication adherence were recorded for each visit. Recommended and actual follow-up times were recorded and compared. Data analyses were conducted from January 2013 to December 2018. Results: In total, 82 patients (161 eyes) had 375 visits during the study period. All patients were male and ranged from 20 to 75 years of age (mean [SD] age, 50.8 [11.9] years). Most participants were black patients (65 [79.3%]). The most common diagnoses were primary open-angle glaucoma (POAG; 53 eyes [32.9%]) and POAG suspect (52 eyes [32.3%]). Glaucoma severity ranged from mild (25 of 77 eyes [32.5%]) to advanced (41 of 77 eyes [53.2%]). Overall, 59 patients (73.2%) were treated medically with up to 4 topical agents (40.0%). Of those treated, 70.0% of patients (95% CI, 57.7%-81.2%) reported medication nonadherence during at least 1 visit. Medication nonadherence was more common among those taking 4 different topical medications (21 of 24 [87.5%]) compared with others taking fewer medications (20 of 35 [57.1%]), for a difference of 30.4% (95% CI, 7.0%-53.6%; P =.02), and among those with advanced disease (22 of 26 [84.6%]) compared with glaucoma suspect (6 of 13 [46.2%]), for a difference of 38.4% (95% CI, 9.3%-67.5%; P =.02). Nineteen office procedures, including laser peripheral iridotomy and laser trabeculoplasty, were performed on 14 eyes. Seventeen incisional glaucoma procedures were performed on 15 eyes, including glaucoma drainage device implant (11 procedures [64.7%]) and trabeculectomy (3 procedures [17.6%]). Only 26.6% of return office visits (95% CI, 21.3%-32.3%) occurred within the recommended follow-up time frame. Furthermore, 93 patients (34.8%; 95% CI, 28.2%-40.0%) were seen more than 1 month after the recommended follow-up. Conclusions and Relevance: Despite incarceration in prison, where medication administration and appointment attendance are theoretically controlled, the results of this study suggested that substantial medication and follow-up nonadherence exists among inmates. AD - L.N. Kanu, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1855W Taylor St, Ste 1.145 (MC 648), Chicago, IL, United States AU - Kanu, L. N. AU - Jang, I. AU - Oh, D. J. AU - Tiwana, M. S. AU - Mehta, A. A. AU - Dikopf, M. S. AU - Vajaranant, T. S. AU - Aref, A. A. AU - Edward, D. P. DB - Embase Medline DO - 10.1001/jamaophthalmol.2020.0001 IS - 4 KW - cyclophotocoagulation laser glaucoma drainage implant acetazolamide antiglaucoma agent methazolamide topical agent adult aged article cataract extraction cohort analysis disease severity follow up human iridotomy laser surgery low tension glaucoma major clinical study male medication compliance open angle glaucoma patient compliance primary glaucoma priority journal prisoner retrospective study trabeculectomy trabeculoplasty LA - English M3 - Article N1 - L631158453 2020-03-16 2020-04-29 PY - 2020 SN - 2168-6173 2168-6165 SP - 358-364 ST - Glaucoma Care of Prison Inmates at an Academic Hospital T2 - JAMA Ophthalmology TI - Glaucoma Care of Prison Inmates at an Academic Hospital UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631158453&from=export http://dx.doi.org/10.1001/jamaophthalmol.2020.0001 VL - 138 ID - 2421 ER - TY - JOUR AB - Importance: Glaucoma care for prison inmates is underrepresented in the literature even though managing the treatment of such patients may provide unique challenges.Objectives: To evaluate the glaucoma profile of prison inmates treated at an academic ophthalmology center and to report on the medical and surgical management and follow-up metrics.Design, Setting, and Participants: This retrospective cohort study assessed data from 82 incarcerated patients treated at the glaucoma clinic, an academic referral center at the University of Illinois at Chicago, between January 2013 and December 2017.Main Outcomes and Measures: Diagnosis, glaucoma severity, medical and surgical interventions, and patient-reported medication adherence were recorded for each visit. Recommended and actual follow-up times were recorded and compared. Data analyses were conducted from January 2013 to December 2018.Results: In total, 82 patients (161 eyes) had 375 visits during the study period. All patients were male and ranged from 20 to 75 years of age (mean [SD] age, 50.8 [11.9] years). Most participants were black patients (65 [79.3%]). The most common diagnoses were primary open-angle glaucoma (POAG; 53 eyes [32.9%]) and POAG suspect (52 eyes [32.3%]). Glaucoma severity ranged from mild (25 of 77 eyes [32.5%]) to advanced (41 of 77 eyes [53.2%]). Overall, 59 patients (73.2%) were treated medically with up to 4 topical agents (40.0%). Of those treated, 70.0% of patients (95% CI, 57.7%-81.2%) reported medication nonadherence during at least 1 visit. Medication nonadherence was more common among those taking 4 different topical medications (21 of 24 [87.5%]) compared with others taking fewer medications (20 of 35 [57.1%]), for a difference of 30.4% (95% CI, 7.0%-53.6%; P = .02), and among those with advanced disease (22 of 26 [84.6%]) compared with glaucoma suspect (6 of 13 [46.2%]), for a difference of 38.4% (95% CI, 9.3%-67.5%; P = .02). Nineteen office procedures, including laser peripheral iridotomy and laser trabeculoplasty, were performed on 14 eyes. Seventeen incisional glaucoma procedures were performed on 15 eyes, including glaucoma drainage device implant (11 procedures [64.7%]) and trabeculectomy (3 procedures [17.6%]). Only 26.6% of return office visits (95% CI, 21.3%-32.3%) occurred within the recommended follow-up time frame. Furthermore, 93 patients (34.8%; 95% CI, 28.2%-40.0%) were seen more than 1 month after the recommended follow-up.Conclusions and Relevance: Despite incarceration in prison, where medication administration and appointment attendance are theoretically controlled, the results of this study suggested that substantial medication and follow-up nonadherence exists among inmates. AD - Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia AN - 142666661. Language: English. Entry Date: 20201107. Revision Date: 20210223. Publication Type: journal article. Journal Subset: Biomedical AU - Kanu, Levi N. AU - Jang, Inae AU - Oh, Daniel J. AU - Tiwana, Manpreet S. AU - Mehta, Amy A. AU - Dikopf, Mark S. AU - Vajaranant, Thasarat S. AU - Aref, Ahmad A. AU - Edward, Deepak P. DB - ccm DO - 10.1001/jamaophthalmol.2020.0001 DP - EBSCOhost IS - 4 KW - Prisoners -- Statistics and Numerical Data Academic Medical Centers -- Statistics and Numerical Data Glaucoma -- Therapy Trabeculectomy Correctional Facilities Antihypertensive Agents -- Therapeutic Use Laser Therapy Referral and Consultation Aged Adult Retrospective Design Male Illinois Glaucoma -- Epidemiology Medication Compliance Young Adult Ocular Hypertension -- Epidemiology Ocular Hypertension -- Therapy Intraocular Pressure -- Physiology Middle Age Glaucoma -- Diagnosis N1 - USA. Instrumentation: Profile of Mood States (POMS). Grant Information: P30 EY001792/EY/NEI NIH HHS/United States. NLM UID: 101589539. PMID: NLM32077908. PY - 2020 SN - 2168-6165 SP - 358-364 ST - Glaucoma Care of Prison Inmates at an Academic Hospital T2 - JAMA Ophthalmology TI - Glaucoma Care of Prison Inmates at an Academic Hospital UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142666661&site=ehost-live&scope=site VL - 138 ID - 4181 ER - TY - JOUR AB - Importance: Glaucoma care for prison inmates is underrepresented in the literature even though managing the treatment of such patients may provide unique challenges. Objectives: To evaluate the glaucoma profile of prison inmates treated at an academic ophthalmology center and to report on the medical and surgical management and follow-up metrics. Design, Setting, and Participants: This retrospective cohort study assessed data from 82 incarcerated patients treated at the glaucoma clinic, an academic referral center at the University of Illinois at Chicago, between January 2013 and December 2017. Main Outcomes and Measures: Diagnosis, glaucoma severity, medical and surgical interventions, and patient-reported medication adherence were recorded for each visit. Recommended and actual follow-up times were recorded and compared. Data analyses were conducted from January 2013 to December 2018. Results: In total, 82 patients (161 eyes) had 375 visits during the study period. All patients were male and ranged from 20 to 75 years of age (mean [SD] age, 50.8 [11.9] years). Most participants were black patients (65 [79.3%]). The most common diagnoses were primary open-angle glaucoma (POAG; 53 eyes [32.9%]) and POAG suspect (52 eyes [32.3%]). Glaucoma severity ranged from mild (25 of 77 eyes [32.5%]) to advanced (41 of 77 eyes [53.2%]). Overall, 59 patients (73.2%) were treated medically with up to 4 topical agents (40.0%). Of those treated, 70.0% of patients (95% CI, 57.7%-81.2%) reported medication nonadherence during at least 1 visit. Medication nonadherence was more common among those taking 4 different topical medications (21 of 24 [87.5%]) compared with others taking fewer medications (20 of 35 [57.1%]), for a difference of 30.4% (95% CI, 7.0%-53.6%; P =.02), and among those with advanced disease (22 of 26 [84.6%]) compared with glaucoma suspect (6 of 13 [46.2%]), for a difference of 38.4% (95% CI, 9.3%-67.5%; P =.02). Nineteen office procedures, including laser peripheral iridotomy and laser trabeculoplasty, were performed on 14 eyes. Seventeen incisional glaucoma procedures were performed on 15 eyes, including glaucoma drainage device implant (11 procedures [64.7%]) and trabeculectomy (3 procedures [17.6%]). Only 26.6% of return office visits (95% CI, 21.3%-32.3%) occurred within the recommended follow-up time frame. Furthermore, 93 patients (34.8%; 95% CI, 28.2%-40.0%) were seen more than 1 month after the recommended follow-up. Conclusions and Relevance: Despite incarceration in prison, where medication administration and appointment attendance are theoretically controlled, the results of this study suggested that substantial medication and follow-up nonadherence exists among inmates. © 2020 American Medical Association. All rights reserved. AD - Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1855W Taylor St, Ste 1.145 (MC 648), Chicago, IL 60612, United States King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia AU - Kanu, L. N. AU - Jang, I. AU - Oh, D. J. AU - Tiwana, M. S. AU - Mehta, A. A. AU - Dikopf, M. S. AU - Vajaranant, T. S. AU - Aref, A. A. AU - Edward, D. P. DB - Scopus DO - 10.1001/jamaophthalmol.2020.0001 IS - 4 M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - 358-364 ST - Glaucoma Care of Prison Inmates at an Academic Hospital T2 - JAMA Ophthalmology TI - Glaucoma Care of Prison Inmates at an Academic Hospital UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081395931&doi=10.1001%2fjamaophthalmol.2020.0001&partnerID=40&md5=785d639ba1c36cd488edff23429a45b3 VL - 138 ID - 5606 ER - TY - JOUR AB - Question What is the glaucoma profile of prison inmates referred to an academic center, and how is the treatment of those patients managed? Findings In this cohort study of 82 prison inmates, suspected and primary open-angle glaucoma were the most common diagnoses, with advanced disease present in 53.2% of patients with confirmed glaucoma. Most patients self-reported medication nonadherence, and follow-up visits often were delayed, with approximately one-quarter of visits during the recommended time frame and one-third delayed by more than 1 month. Meaning These findings suggest that glaucoma management of prison inmates requires careful consideration of barriers to care, and close communication with the referring facility may be advised. Importance Glaucoma care for prison inmates is underrepresented in the literature even though managing the treatment of such patients may provide unique challenges. Objectives To evaluate the glaucoma profile of prison inmates treated at an academic ophthalmology center and to report on the medical and surgical management and follow-up metrics. Design, Setting, and Participants This retrospective cohort study assessed data from 82 incarcerated patients treated at the glaucoma clinic, an academic referral center at the University of Illinois at Chicago, between January 2013 and December 2017. Main Outcomes and Measures Diagnosis, glaucoma severity, medical and surgical interventions, and patient-reported medication adherence were recorded for each visit. Recommended and actual follow-up times were recorded and compared. Data analyses were conducted from January 2013 to December 2018. Results In total, 82 patients (161 eyes) had 375 visits during the study period. All patients were male and ranged from 20 to 75 years of age (mean [SD] age, 50.8 [11.9] years). Most participants were black patients (65 [79.3%]). The most common diagnoses were primary open-angle glaucoma (POAG; 53 eyes [32.9%]) and POAG suspect (52 eyes [32.3%]). Glaucoma severity ranged from mild (25 of 77 eyes [32.5%]) to advanced (41 of 77 eyes [53.2%]). Overall, 59 patients (73.2%) were treated medically with up to 4 topical agents (40.0%). Of those treated, 70.0% of patients (95% CI, 57.7%-81.2%) reported medication nonadherence during at least 1 visit. Medication nonadherence was more common among those taking 4 different topical medications (21 of 24 [87.5%]) compared with others taking fewer medications (20 of 35 [57.1%]), for a difference of 30.4% (95% CI, 7.0%-53.6%; P = .02), and among those with advanced disease (22 of 26 [84.6%]) compared with glaucoma suspect (6 of 13 [46.2%]), for a difference of 38.4% (95% CI, 9.3%-67.5%; P = .02). Nineteen office procedures, including laser peripheral iridotomy and laser trabeculoplasty, were performed on 14 eyes. Seventeen incisional glaucoma procedures were performed on 15 eyes, including glaucoma drainage device implant (11 procedures [64.7%]) and trabeculectomy (3 procedures [17.6%]). Only 26.6% of return office visits (95% CI, 21.3%-32.3%) occurred within the recommended follow-up time frame. Furthermore, 93 patients (34.8%; 95% CI, 28.2%-40.0%) were seen more than 1 month after the recommended follow-up. Conclusions and Relevance Despite incarceration in prison, where medication administration and appointment attendance are theoretically controlled, the results of this study suggested that substantial medication and follow-up nonadherence exists among inmates. This cohort study conducted in an academic ophthalmology referral center assesses the glaucoma disease profile and medical and surgical glaucoma management and follow-up metrics of prison inmates. AN - WOS:000526606900006 AU - Kanu, L. N. AU - Jang, I. AU - Oh, D. J. AU - Tiwana, M. S. AU - Mehta, A. A. AU - Dikopf, M. S. AU - Vajaranant, T. S. AU - Aref, A. A. AU - Edward, D. P. DA - APR DO - 10.1001/jamaophthalmol.2020.0001 IS - 4 PY - 2020 SN - 2168-6165 2168-6173 SP - 358-364 ST - Glaucoma Care of Prison Inmates at an Academic Hospital T2 - JAMA OPHTHALMOLOGY TI - Glaucoma Care of Prison Inmates at an Academic Hospital VL - 138 ID - 5839 ER - TY - JOUR AD - Baltimore, MD, United States AU - Kashaf, M. S. AU - Jampel, H. D. DB - Scopus DO - 10.1016/j.ogla.2020.05.007 IS - 4 M3 - Editorial N1 - Export Date: 19 July 2021 PY - 2020 SP - 225-227 ST - Adherence Studies with Short Follow-up Do Not Suffice for a Chronic Disease Like Open-Angle Glaucoma T2 - Ophthalmology. Glaucoma TI - Adherence Studies with Short Follow-up Do Not Suffice for a Chronic Disease Like Open-Angle Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092679333&doi=10.1016%2fj.ogla.2020.05.007&partnerID=40&md5=b823a0a91ad4c4fa2d9576e3264b6cde VL - 3 ID - 5693 ER - TY - JOUR AN - WOS:000661198600001 AU - Kashaf, M. S. AU - Jampel, H. D. DA - JUL-AUG DO - 10.1016/j.ogla.2020.05.007 IS - 4 PY - 2020 SN - 2589-4234 2589-4196 SP - 225-227 ST - Adherence Studies with Short Follow-up Do Not Suffice for a Chronic Disease Like Open-Angle Glaucoma T2 - OPHTHALMOLOGY GLAUCOMA TI - Adherence Studies with Short Follow-up Do Not Suffice for a Chronic Disease Like Open-Angle Glaucoma VL - 3 ID - 5935 ER - TY - JOUR AB - Background: Glaucoma is one of the leading causes of blindness. Reduction of intraocular pressure is the only proven way to prevent progression of glaucomatous optic neuropathy. The majority of glaucoma patients need to use antiglaucoma ophthalmic solutions over the course of their life. Thus, good adherence and persistency of glaucoma treatment are important factors for better glaucoma care. Objective: The purpose of this study was to investigate the impact of an Internet-based glaucoma care support system on glaucoma medication use. Methods: Patients were randomly divided into two groups. The non–Internet access (NIA) group consisted of patients who had access to the Internet-based glaucoma care support system during the 4-year period only when they were examined by ophthalmologists. The Internet access (IA) group consisted of patients who had the same Internet-based glaucoma care support system access as the NIA group for the first 2 years following enrollment but who were also given free access to the glaucoma care support system for the remaining 2 years. Changes in glaucoma medication use were investigated. Results: In total, 81 patients in the IA group and 90 patients in the NIA group satisfied the study protocol. The number of antiglaucoma ophthalmic solutions used during the study period significantly increased in the NIA group (P < .03) but not in the IA group. The percentages of patients with unchanged, increased, and decreased antiglaucoma ophthalmic solution use during the study period were 61.1% (55/90), 17.8% (16/90), and 3.3% (3/90), respectively, in the NIA group, and 56.8% (46/81), 8.6% (7/81), and 13.6% (11/81), respectively, in the IA group (P < .001). Internet access significantly shifted from an increasing intraocular pressure trend to a decreasing trend in the IA group (P = .002) among the patients who did not have any medication changes. Conclusions: Allowing patients to browse their medical data may reduce the use and improve the effectiveness of glaucoma medication. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Kashiwagi, Kenji, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Japan, 409-3898 AN - 2014-12211-013 AU - Kashiwagi, Kenji AU - Tsukahara, Shigeo DB - psyh DO - 10.2196/jmir.2795 DP - EBSCOhost IS - 1 KW - Internet glaucoma care support system glaucoma medication use patient access ophthalmic solutions treatment effectiveness Drug Therapy Glaucoma Information Systems Telemedicine Treatment Effectiveness Evaluation Internet Neuropathy Client Records Computer Assisted Therapy N1 - Faculty of Medicine, University of Yamanashi, Chuo, Japan. Other Publishers: JMIR Publications. Release Date: 20140818. Correction Date: 20201012. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Glaucoma; Information Systems; Telemedicine; Treatment Effectiveness Evaluation. Minor Descriptor: Internet; Neuropathy; Client Records; Computer Assisted Therapy. Classification: Clinical Psychopharmacology (3340); Vision & Hearing & Sensory Disorders (3299). Population: Human (10); Male (30); Female (40); Outpatient (60). Location: Japan. Age Group: Adulthood (18 yrs & older) (300). Methodology: Clinical Trial; Empirical Study; Quantitative Study. Supplemental Data: Appendixes Internet. References Available: Y. Page Count: 14. Issue Publication Date: Jan, 2014. Publication History: First Posted Date: Jan 15, 2014; Accepted Date: Dec 5, 2013; Revised Date: Oct 7, 2013; First Submitted Date: Jun 27, 2013. Copyright Statement: Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 15.01.2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included. Kenji Kashiwagi, Shigeo Tsukahara PY - 2014 SN - 1439-4456 1438-8871 SP - 156-169 ST - Impact of patient access to internet health records on glaucoma medication: Randomized controlled trial T2 - Journal of Medical Internet Research TI - Impact of patient access to internet health records on glaucoma medication: Randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-12211-013&site=ehost-live&scope=site kenjik@yamanashi.ac.jp VL - 16 ID - 4840 ER - TY - JOUR AB - We determined whether clinical measurements and assessments available to ophthalmologists could be used to identify patients who default from pilocarpine treatment. The measurements and assessments included intraocular pressure, pupillary diameter, pupillary reactivity to light, the patient's report of compliance, the physician's prediction of compliance, the patient's log of pilocarpine administration, and the weight of pilocarpine eyedrops utilized. Compliance with the pilocarpine regimen was measured with an unobtrusive eyedrop medication monitor. Intraocular pressure and pupillary diameter did not correlate with compliance to the regimen as measured by the eyedrop monitor. Pupillary reaction to light, the physician's prediction of compliance, a daily log of pilocarpine administration, the weight of pilocarpine utilized, and the patient's report of compliance correlated modestly with compliance as measured by the monitor (range of correlations, 0.19 to 0.24). However, none of these measures taken by itself or combined in any manner adequately distinguished patients with lower rates of compliance from those with higher rates of compliance. At present, the eyedrop monitor is the only reliable method for detecting patients who default from treatment. AD - Department of Ophthalmology, Washington University School of Medicine, St. Louis, MO 63110 AU - Kass, M. A. AU - Gordon, M. AU - Meltzer, D. W. DB - Embase Medline IS - 5 KW - eye drops pilocarpine clinical article drug delivery system drug monitoring drug therapy glaucoma human intraocular pressure patient compliance priority journal psychological aspect pupil therapy topical drug administration visual system LA - English M3 - Article N1 - L16114196 1986-07-22 PY - 1986 SN - 0002-9394 SP - 524-530 ST - Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? T2 - American Journal of Ophthalmology TI - Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L16114196&from=export VL - 101 ID - 4070 ER - TY - JOUR AB - Using an unobtrusive eyedrop medication monitor, we measured compliance with topical pilocarpine treatment in a sample of 184 patients. The eyedrop monitor recorded electronically the date and time of each pilocarpine administration over a four- to six-week period. The subjects administered a mean ± S.D. of 76.0% ± 24.3% of the prescribed pilocarpine doses. Eleven patients (6%) took less than one quarter and 28 patients (15.2%) took less than one half of the prescribed administrations. In contrast, when the subjects were interviewed they reported taking a mean ± S.D. of 97.1% ± 5.9% of the prescribed pilocarpine doses. As determined by the monitor, 45 patients (24.5%) had at least one day per month with no administrations of pilocarpine; 56 subjects (30.4%) compressed the doses during the daytime hours, leaving an interval between the night dose and the morning dose the next day of 12 hours or more. The rate of compliance was significantly higher (P < .0001) in the 24-hour period preceding the return appointment than in the entire observation period. AD - Department of Ophthalmology, Washington University School of Medicine, St. Louis, MO 63110 AU - Kass, M. A. AU - Meltzer, D. W. AU - Gordon, M. DB - Embase Medline IS - 5 KW - pilocarpine clinical article compliance (physical) drug administration drug delivery system drug formulation drug therapy glaucoma human intraocular pressure patient compliance priority journal therapy topical drug administration visual system LA - English M3 - Article N1 - L16114195 1986-07-22 PY - 1986 SN - 0002-9394 SP - 515-523 ST - Compliance with topical pilocarpine treatment T2 - American Journal of Ophthalmology TI - Compliance with topical pilocarpine treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L16114195&from=export VL - 101 ID - 4069 ER - TY - JOUR AB - Using an unobtrusive eyedrop medication monitor, we measured compliance with topical pilocarpine treatment in a sample of 184 patients. The eyedrop monitor recorded electronically the date and time of each pilocarpine administration over a four- to six-week period. The subjects administered a mean +/- S.D. of 76.0% +/- 24.3% of the prescribed pilocarpine doses. Eleven patients (6%) took less than one quarter and 28 patients (15.2%) took less than one half of the prescribed administrations. In contrast, when the subjects were interviewed they reported taking a mean +/- S.D. of 97.1% +/- 5.9% of the prescribed pilocarpine doses. As determined by the monitor, 45 patients (24.5%) had at least one day per month with no administrations of pilocarpine; 56 subjects (30.4%) compressed the doses during the daytime hours, leaving an interval between the night dose and the morning dose the next day of 12 hours or more. The rate of compliance was significantly higher (P less than .0001) in the 24-hour period preceding the return appointment than in the entire observation period. AU - Kass, M. A. AU - Meltzer, D. W. AU - Gordon, M. AU - Cooper, D. AU - Goldberg, J. IS - 5 KW - Aged Female *Glaucoma/dt [Drug Therapy] Humans Male Middle Aged *Patient Compliance Pilocarpine/ad [Administration & Dosage] *Pilocarpine/tu [Therapeutic Use] PY - 1986 SN - 0002-9394 SP - 515-23 ST - Compliance with topical pilocarpine treatment T2 - American journal of ophthalmology TI - Compliance with topical pilocarpine treatment UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=3706455 VL - 101 ID - 2208 ER - TY - JOUR AB - Using an unobtrusive eyedrop medication monitor, we measured compliance with topical pilocarpine treatment in a sample of 184 patients. The eyedrop monitor recorded electronically the date and time of each pilocarpine administration over a four- to six-week period. The subjects administered a mean ± S.D. of 76.0% ± 24.3% of the prescribed pilocarpine doses. Eleven patients (6%) took less than one quarter and 28 patients (15.2%) took less than one half of the prescribed administrations. In contrast, when the subjects were interviewed they reported taking a mean ± S.D. of 97.1% ± 5.9% of the prescribed pilocarpine doses. As determined by the monitor, 45 patients (24.5%) had at least one day per month with no administrations of pilocarpine; 56 subjects (30.4%) compressed the doses during the daytime hours, leaving an interval between the night dose and the morning dose the next day of 12 hours or more. The rate of compliance was significantly higher (P<.0001) in the 24-hour period preceding the return appointment than in the entire observation period. © 1986. AD - Department of Ophthalmology, the Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States AU - Kass, M. A. AU - Meltzer, D. W. AU - Gordon, M. AU - Cooper, D. AU - Goldberg, J. DB - Scopus DO - 10.1016/0002-9394(86)90939-6 IS - 5 M3 - Article N1 - Cited By :278 Export Date: 19 July 2021 PY - 1986 SP - 515-523 ST - Compliance with topical pilocarpine treatment T2 - American Journal of Ophthalmology TI - Compliance with topical pilocarpine treatment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022633707&doi=10.1016%2f0002-9394%2886%2990939-6&partnerID=40&md5=d6a293082961916837f1188a68978adc VL - 101 ID - 4905 ER - TY - JOUR AB - The aim of the teleglaucoma service at the University of Alberta is to improve access for people in northern Alberta who have early-stage glaucoma or who are at risk for glaucoma. Two types of teleglaucoma service are offered: remote and in-house. A standardized approach is used to capture patient information (structured histories, examinations and fundus photographs) which is then sent to a tertiary care centre for grading and recommendations. Only one grader reads and makes management recommendations for each case. Reports are sent electronically. A total of 195 cases have been graded through the remote service since 2008. A total of 62 cases have been graded through the in-house service since 2011. The average reporting time for consultations in the in-house service was 7 days, and it was also 7 days for the remote service. We believe that the use of teleglaucoma can improve the way that patients are diagnosed and managed, both in industrialized and developing countries. Teleglaucoma is currently being used as a screening tool at the Aga Khan University Hospital in Nairobi with mobile units equipped with a fundus camera and a visual field machine. AD - Department of Ophthalmology, University of Alberta, 2317, 10240 Kingsway Avenue NW, Edmonton, AB T5H 3V9, Canada kdamji@ualberta.ca. AN - 104004457. Language: English. Entry Date: 20140131. Revision Date: 20150710. Publication Type: Journal Article. Journal Subset: Biomedical AU - Kassam, Faazil AU - Amin, Samreen AU - Sogbesan, Enitan AU - Damji, Karim F. DB - ccm DO - 10.1258/jtt.2012.120313 DP - EBSCOhost IS - 7 KW - Glaucoma -- Diagnosis Ophthalmology -- Methods Telemedicine -- Utilization Africa Alberta Blindness -- Diagnosis Blindness -- Etiology Canada Glaucoma -- Complications Health Services Accessibility Remote Consultation -- Methods Rural Population N1 - Europe; Peer Reviewed; UK & Ireland. NLM UID: 9506702. PMID: NLM22977196. PY - 2012 SN - 1357-633X SP - 367-373 ST - The use of teleglaucoma at the University of Alberta T2 - Journal of Telemedicine & Telecare TI - The use of teleglaucoma at the University of Alberta UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104004457&site=ehost-live&scope=site VL - 18 ID - 4526 ER - TY - JOUR AB - Teleglaucoma is the application of telemedicine for glaucoma. We review and present the current literature on teleglaucoma; present our experience with teleglaucoma programs in Alberta, Canada and Western Australia; and discuss the challenges and opportunities in this emerging field. Teleglaucoma is a novel area that was first explored a little over a decade ago and early studies highlighted the technical challenges of delivering glaucoma care remotely. Advanced technologies have since emerged that show great promise in providing access to underserviced populations. Additionally, these technologies can improve the efficiency of healthcare systems burdened with an increasing number of patients with glaucoma, and a limited supply of ophthalmologists. Additional benefits of teleglaucoma systems include e-learning and e-research. Further work is needed to fully validate and study the cost and comparative effectiveness of this approach relative to traditional models of healthcare. AD - K.F. Damji, Department of Ophthalmology, University of Alberta, 2319-10240 Kingsway Ave., Edmonton, AB T5H3V9, Canada AU - Kassam, F. AU - Yogesan, K. AU - Sogbesan, E. AU - Pasquale, L. R. AU - Damji, K. F. DB - Embase Medline DO - 10.4103/0974-9233.110619 IS - 2 KW - comparative effectiveness conference paper geographic distribution glaucoma health care access health care cost health care delivery health care practice health care system health program human information processing learning medical information medical research ophthalmology priority journal teleglaucoma telemedicine telemonitoring LA - English M3 - Conference Paper N1 - L368829372 2013-05-08 2013-05-16 PY - 2013 SN - 0974-9233 0975-1599 SP - 142-149 ST - Teleglaucoma: Improving access and efficiency for glaucoma care T2 - Middle East African Journal of Ophthalmology TI - Teleglaucoma: Improving access and efficiency for glaucoma care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368829372&from=export http://dx.doi.org/10.4103/0974-9233.110619 VL - 20 ID - 3015 ER - TY - JOUR AB - The treatment goals for glaucoma are lowering the intraocular pressure and preservation of vision. Topical hypotensive drops are the standard form of therapy which is often associated with some symptoms of toxicity, ocular inflammation, allergy, or ocular surface disease (OSD). OSD is a common comorbidity in glaucoma patients, and its prevalence with glaucoma increases with age. Use of topical treatment could additionally increase symptoms of OSD mostly due to preservatives added to multidose medication bottles used to reduce the risk of microbial contamination. This toxicity has been particularly associated with BAK, the most commonly used preservative which damages conjunctival and corneal epithelial cells and significantly aggravates OSD symptoms. OSD adversely affects patients' quality of life causing discomfort and problems with vision which in turn may result in noncompliance, lack of adherence, and eventually visual impairment. In the management of glaucoma patients OSD symptoms should not be overlooked. If they are present, topical glaucoma treatment should be adapted by decreasing the amount of drops instilled daily, using BAK-free or preservative-free medication and lubricants if necessary. Awareness of the presence and importance of OSD will in turn improve patients' adherence and compliance and thus ultimately the preservation of long-term vision. AD - Department of Ophthalmology, Clinical Hospital Dubrava, Avenue Gojka Suska 6, 10 000 Zagreb, Croatia. AN - 103995797. Language: English. Entry Date: 20150306. Revision Date: 20171129. Publication Type: Journal Article. Journal Subset: Biomedical AU - Kastelan, Snjezana AU - Tomic, Martina AU - Metez Soldo, Kata AU - Salopek-Rabatic, Jasminka DB - ccm DO - 2013/696328 DP - EBSCOhost KW - Eye -- Drug Effects Glaucoma -- Drug Therapy Pharmaceutical Additives Administration, Topical Aged Antihypertensive Agents -- Adverse Effects Antihypertensive Agents -- Therapeutic Use Eye -- Pathology Glaucoma -- Complications Glaucoma -- Pathology Intraocular Pressure -- Drug Effects Male Pharmaceutical Additives -- Therapeutic Use Treatment Outcomes N1 - Peer Reviewed; USA. NLM UID: 101600173. PMID: NLM24224176. PY - 2013 SN - 2314-6133 SP - 696328-696328 ST - How ocular surface disease impacts the glaucoma treatment outcome T2 - BioMed Research International TI - How ocular surface disease impacts the glaucoma treatment outcome UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103995797&site=ehost-live&scope=site VL - 2013 ID - 4394 ER - TY - JOUR AB - The treatment goals for glaucoma are lowering the intraocular pressure and preservation of vision. Topical hypotensive drops are the standard form of therapy which is often associated with some symptoms of toxicity, ocular inflammation, allergy, or ocular surface disease (OSD). OSD is a common comorbidity in glaucoma patients, and its prevalence with glaucoma increases with age. Use of topical treatment could additionally increase symptoms of OSD mostly due to preservatives added to multidose medication bottles used to reduce the risk of microbial contamination. This toxicity has been particularly associated with BAK, the most commonly used preservative which damages conjunctival and corneal epithelial cells and significantly aggravates OSD symptoms. OSD adversely affects patients' quality of life causing discomfort and problems with vision which in turn may result in noncompliance, lack of adherence, and eventually visual impairment. In the management of glaucoma patients OSD symptoms should not be overlooked. If they are present, topical glaucoma treatment should be adapted by decreasing the amount of drops instilled daily, using BAK-free or preservative-free medication and lubricants if necessary. Awareness of the presence and importance of OSD will in turn improve patients' adherence and compliance and thus ultimately the preservation of long-term vision. © 2013 Snježana Kaštelan et al. AD - Department of Ophthalmology, Clinical Hospital Dubrava, Avenue Gojka Šuška 6, 10 000 Zagreb, Croatia Department of Ophthalmology, University Clinic Vuk Vrhovac, Clinical Hospital Merkur, Zajčeva Ulica 19, 10 000 Zagreb, Croatia Department of Ophthalmology, Clinical Hospital Sveti Duh, Sveti Duh 64, 10 000 Zagreb, Croatia AU - Kaštelan, S. AU - Tomić, M. AU - Metež Soldo, K. AU - Salopek-Rabatić, J. C7 - 696328 DB - Scopus DO - 10.1155/2013/696328 M3 - Review N1 - Cited By :38 Export Date: 19 July 2021 PY - 2013 ST - How ocular surface disease impacts the glaucoma treatment outcome T2 - BioMed Research International TI - How ocular surface disease impacts the glaucoma treatment outcome UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886507076&doi=10.1155%2f2013%2f696328&partnerID=40&md5=b554b0771423599ba72d7c9e89f9f963 VL - 2013 ID - 5027 ER - TY - JOUR AB - In the last decade, selective laser trabeculoplasty (SLT) has been commonly used in the management of several different types of glaucoma, as either primary or adjunct therapy. The technique has an excellent safety profile and is at least as effective as argon laser trabeculoplasty. Although the actual mechanism of action of SLT remains unclear, evidence has shown that it does not induce morphologically evident trabecular meshwork alterations. SLT's non-disruptive mode of action offers the advantage of repeatability. Exfoliation glaucoma (XFG) is a secondary open-angle glaucoma with unfavorable intraocular pressure (IOP) characteristics, which typically carries a poorer long-term prognosis than primary open-angle glaucoma. Consequently, patients with XFG often need multiple medications to achieve IOP levels that prevent disease progression. Because complicated pharmacotherapy regimens undermine the long-term tolerability and compliance of patients with XFG, options such as SLT may decrease the burden of multiple therapies and ultimately improve prognosis. In fact, SLT may be a particularly attractive option in XFG because the pigment-laden trabecular tissue of these patients enhances the absorption of laser energy and thus augments the biologic effects induced by this treatment. The current article reviews the postulated mechanisms of action of SLT, discusses practical aspects of SLT therapy, and examines selected peer-reviewed literature pertaining to the clinical usefulness of this modality in XFG patients. AD - Department of Ophthalmology, University of Ioannina, Ioannina, Greece 1st University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece 3rd University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece Glaucoma Unit, University of Brescia, Brescia, Italy Department of Ophthalmology, Hospital Universitario “Principe de Asturias,” Universidad de Alcalá, Alcalá de Henares, Spain AN - 129703213. Language: English. Entry Date: 20190902. Revision Date: 20190902. Publication Type: journal article AU - Katsanos, Andreas AU - Konstas, Anastasios G. AU - Mikropoulos, Dimitrios G. AU - Quaranta, Luciano AU - Voudouragkaki, Irini C. AU - Athanasopoulos, Georgios P. AU - Asproudis, Ioannis AU - Teus, Miguel A. DB - ccm DO - 10.1007/s12325-018-0695-z DP - EBSCOhost IS - 5 KW - Trabeculectomy -- Equipment and Supplies Trabeculectomy -- Methods Laser Therapy -- Methods Trabeculectomy -- Adverse Effects Exfoliation Syndrome -- Surgery Treatment Outcomes Clinical Assessment Tools Scales N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Profile of Mood States (POMS); Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Functional Assessment of Cancer Therapy (FACT). NLM UID: 8611864. PMID: NLM29644538. PY - 2018 SN - 0741-238X SP - 619-630 ST - A Review of the Clinical Usefulness of Selective Laser Trabeculoplasty in Exfoliative Glaucoma T2 - Advances in Therapy TI - A Review of the Clinical Usefulness of Selective Laser Trabeculoplasty in Exfoliative Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129703213&site=ehost-live&scope=site VL - 35 ID - 4392 ER - TY - JOUR AB - Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of ophthalmic formulations of bimatoprost 0.01% and 0.0125% compared with bimatoprost 0.03%. Design: Prospective, randomized, double-masked, multicenter clinical trial. Methods: Patients with glaucoma or ocular hypertension were randomized to receive once-daily bimatoprost 0.01% (n = 186), bimatoprost 0.0125% (n = 188), or bimatoprost 0.03% (n = 187) for 12 months. The primary efficacy measure was IOP. Safety measures included adverse events and an objective assessment of conjunctival hyperemia. Results: Baseline mean IOPs were similar among treatment groups. Differences in mean IOP between the bimatoprost 0.01% or 0.0125% groups and the bimatoprost 0.03% group were less than 0.9 mm Hg throughout follow-up. Bimatoprost 0.01%, but not bimatoprost 0.0125%, was equivalent in efficacy to bimatoprost 0.03% based on predetermined criteria (limits of the 95% confidence interval of the between-group difference in mean IOP within ± 1.5 mm Hg at all time points and within ± 1 mm Hg at most time points). The overall incidence of treatment-related adverse events was reduced significantly in the bimatoprost 0.01% and bimatoprost 0.0125% groups compared with the bimatoprost 0.03% group (P ≤ .034). The percentage of patients with a moderate to severe increase from the baseline macroscopic hyperemia score was: bimatoprost 0.01%, 3.2%; bimatoprost 0.0125%, 9.0%; bimatoprost 0.03%, 9.1% (P = .019 for bimatoprost 0.01% vs 0.03%). Conclusions: Bimatoprost 0.01% was equivalent to bimatoprost 0.03% in lowering IOP throughout 12 months of treatment and demonstrated improved tolerability, including less frequent and severe conjunctival hyperemia. Bimatoprost 0.01% demonstrated a better benefit-to-risk ratio than bimatoprost 0.0125%. © 2010 Elsevier Inc. All rights reserved. AD - L.J. Katz, Wills Eye Hospital, Philadelphia, PA, United States AU - Katz, L. J. AU - Cohen, J. S. AU - Batoosingh, A. L. AU - Felix, C. AU - Shu, V. AU - Schiffman, R. M. C1 - lumigan(Allergan,United States) C2 - Allergan(United States) DB - Embase Medline DO - 10.1016/j.ajo.2009.12.003 IS - 4 KW - NCT00300443 bimatoprost abnormal sensation adult aged article clinical trial conjunctival hyperemia controlled clinical trial controlled study disease severity double blind procedure drug dosage form comparison drug efficacy drug formulation drug safety drug tolerability drug withdrawal eye irritation eyelash growth eyelid erythema female foreign body sensation glaucoma hair growth human hyperpigmentation intraocular hypertension intraocular pressure iritis major clinical study male multicenter study ocular pruritus patient compliance priority journal punctate keratitis randomized controlled trial retina macula cystoid edema risk benefit analysis side effect uveitis lumigan LA - English M3 - Article N1 - L358488186 2010-03-29 2010-04-29 PY - 2010 SN - 0002-9394 SP - 661-671.e1 ST - Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension T2 - American Journal of Ophthalmology TI - Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358488186&from=export http://dx.doi.org/10.1016/j.ajo.2009.12.003 VL - 149 ID - 3264 ER - TY - JOUR AB - Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of ophthalmic formulations of bimatoprost 0.01% and 0.0125% compared with bimatoprost 0.03%. Design: Prospective, randomized, double-masked, multicenter clinical trial. Methods: Patients with glaucoma or ocular hypertension were randomized to receive once-daily bimatoprost 0.01% (n = 186), bimatoprost 0.0125% (n = 188), or bimatoprost 0.03% (n = 187) for 12 months. The primary efficacy measure was IOP. Safety measures included adverse events and an objective assessment of conjunctival hyperemia. Results: Baseline mean IOPs were similar among treatment groups. Differences in mean IOP between the bimatoprost 0.01% or 0.0125% groups and the bimatoprost 0.03% group were less than 0.9 mm Hg throughout follow-up. Bimatoprost 0.01%, but not bimatoprost 0.0125%, was equivalent in efficacy to bimatoprost 0.03% based on predetermined criteria (limits of the 95% confidence interval of the between-group difference in mean IOP within ± 1.5 mm Hg at all time points and within ± 1 mm Hg at most time points). The overall incidence of treatment-related adverse events was reduced significantly in the bimatoprost 0.01% and bimatoprost 0.0125% groups compared with the bimatoprost 0.03% group (P ≤ .034). The percentage of patients with a moderate to severe increase from the baseline macroscopic hyperemia score was: bimatoprost 0.01%, 3.2%; bimatoprost 0.0125%, 9.0%; bimatoprost 0.03%, 9.1% (P = .019 for bimatoprost 0.01% vs 0.03%). Conclusions: Bimatoprost 0.01% was equivalent to bimatoprost 0.03% in lowering IOP throughout 12 months of treatment and demonstrated improved tolerability, including less frequent and severe conjunctival hyperemia. Bimatoprost 0.01% demonstrated a better benefit-to-risk ratio than bimatoprost 0.0125%. © 2010 Elsevier Inc. All rights reserved. AD - Wills Eye Hospital, Philadelphia, PA, United States Cincinnati Eye Institute, Cincinnati, OH, United States Allergan, Inc, Irvine, CA, United States AU - Katz, L. J. AU - Cohen, J. S. AU - Batoosingh, A. L. AU - Felix, C. AU - Shu, V. AU - Schiffman, R. M. DB - Scopus DO - 10.1016/j.ajo.2009.12.003 IS - 4 M3 - Article N1 - Cited By :61 Export Date: 19 July 2021 PY - 2010 SP - 661-671.e1 ST - Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension T2 - American Journal of Ophthalmology TI - Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77949626844&doi=10.1016%2fj.ajo.2009.12.003&partnerID=40&md5=d80fb63c72552bd9ba45e0f3a435ae25 VL - 149 ID - 4970 ER - TY - GEN AD - Departments of Ophthalmologyh, Yenepoya Medical College, Yenepoya University, Mangalore, Karnataka, India Public Health, Yenepoya Medical College, Yenepoya University, Mangalore, Karnataka, India AU - Kaup, Soujanya AU - Oomman, Sithara Sara AU - Shivalli, Siddharudha DB - ccm DO - 10.4103/ijo.IJO_80_18 DP - EBSCOhost J2 - Indian Journal of Ophthalmology KW - Hospitals, Special Intraocular Pressure Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Medication Compliance India Glaucoma -- Physiopathology N1 - Accession Number: 130879468. Language: English. Entry Date: 20180801. Revision Date: 20190514. Publication Type: letter. Journal Subset: Asia; Biomedical; Peer Reviewed. NLM UID: 0405376. PMID: NLM30038195. PB - Wolters Kluwer India Pvt Ltd PY - 2018 SN - 0301-4738 SP - 1229-1230 ST - Determinants of medication adherence to topical ocular hypotensives and application of health belief model among glaucoma patients visiting a tertiary care hospital in coastal Karnataka, India TI - Determinants of medication adherence to topical ocular hypotensives and application of health belief model among glaucoma patients visiting a tertiary care hospital in coastal Karnataka, India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130879468&site=ehost-live&scope=site VL - 66 ID - 4379 ER - TY - JOUR AN - WOS:000439924900055 AU - Kaup, S. AU - Oomman, S. S. AU - Shivalli, S. DA - AUG DO - 10.4103/ijo.IJO_80_18 IS - 8 PY - 2018 SN - 0301-4738 1998-3689 SP - 1229-+ ST - Determinants of medication adherence to topical ocular hypotensives and application of health belief model among glaucoma patients visiting a tertiary care hospital in coastal Karnataka, India T2 - INDIAN JOURNAL OF OPHTHALMOLOGY TI - Determinants of medication adherence to topical ocular hypotensives and application of health belief model among glaucoma patients visiting a tertiary care hospital in coastal Karnataka, India VL - 66 ID - 6056 ER - TY - JOUR AD - Glaucoma Unit, Westmead Hospital, Sydney, Australia Wyong Eye Surgery, Wyong, NSW, Australia Glaucoma Unit, Sydney Eye Hospital, Sydney, Australia AU - Kaushik, S. AU - Ferrier, R. AU - Clement, C. DB - Scopus DO - 10.1111/ceo.12328 IS - 9 M3 - Letter N1 - Export Date: 19 July 2021 PY - 2014 SP - 883-884 ST - Primary selective laser trabeculoplasty: A cautionary tale T2 - Clinical and Experimental Ophthalmology TI - Primary selective laser trabeculoplasty: A cautionary tale UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923257302&doi=10.1111%2fceo.12328&partnerID=40&md5=441037587069f961ad11ac94341fc3e1 VL - 42 ID - 5751 ER - TY - JOUR AB - Aim: To investigate factors related to the use of eye care services in Australia. Methods: Health, eye care service use, and socio-demographic data were collected in a structured interview of participants in a population based study. All participants had a standard eye examination. Results: Men (OR 1.3 CL 1.02, 1.7), those who spoke Greek (OR 2.1 CL 1.1, 3.8) or Italian (OR 1.9 CL 1.0, 3.3), and those without private health insurance (OR 1.59 CL 1.22, 2.04) were more likely to have not used eye care services. Ophthalmology services were utilised at lower rates in rural areas (OR 0.14 CL 0.09, 0.2). Approximately 40% of participants with undercorrected refractive error, cataract, and undiagnosed glaucoma had seen either an ophthalmologist, optometrist, or both within the last year. Conclusion: Despite the similarity in prevalence of eye disease in urban and rural areas, significant differences exist in the utilisation of eye care services. Sex, private health insurance, urban residence, and the ability to converse in English were significant factors associated with eye healthcare service use. Many participants had undiagnosed eye disease despite having seen an eye care provider in the last year. AD - J.E. Keeffe, Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, Vic. 3002, Australia AU - Keeffe, J. E. AU - Weih, L. M. AU - McCarty, C. A. AU - Taylor, H. R. DB - Embase Medline DO - 10.1136/bjo.86.1.24 IS - 1 KW - article Australia cataract eye disease female glaucoma health care utilization health insurance human major clinical study male priority journal refraction error urban rural difference LA - English M3 - Article N1 - L34074878 2002-02-02 PY - 2002 SN - 0007-1161 SP - 24-27 ST - Utilisation of eye care services by urban and rural Australians T2 - British Journal of Ophthalmology TI - Utilisation of eye care services by urban and rural Australians UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34074878&from=export http://dx.doi.org/10.1136/bjo.86.1.24 VL - 86 ID - 3879 ER - TY - JOUR AB - BACKGROUND: Glaucoma is one of the leading causes of blindness. Reduction of intraocular pressure is the only proven way to prevent progression of glaucomatous optic neuropathy. The majority of glaucoma patients need to use antiglaucoma ophthalmic solutions over the course of their life. Thus, good adherence and persistency of glaucoma treatment are important factors for better glaucoma care. OBJECTIVE: The purpose of this study was to investigate the impact of an Internet-based glaucoma care support system on glaucoma medication use. METHODS: Patients were randomly divided into two groups. The non-Internet access (NIA) group consisted of patients who had access to the Internet-based glaucoma care support system during the 4-year period only when they were examined by ophthalmologists. The Internet access (IA) group consisted of patients who had the same Internet-based glaucoma care support system access as the NIA group for the first 2 years following enrollment but who were also given free access to the glaucoma care support system for the remaining 2 years. Changes in glaucoma medication use were investigated. RESULTS: In total, 81 patients in the IA group and 90 patients in the NIA group satisfied the study protocol. The number of antiglaucoma ophthalmic solutions used during the study period significantly increased in the NIA group (P<.03) but not in the IA group. The percentages of patients with unchanged, increased, and decreased antiglaucoma ophthalmic solution use during the study period were 61.1% (55/90), 17.8% (16/90), and 3.3% (3/90), respectively, in the NIA group, and 56.8% (46/81), 8.6% (7/81), and 13.6% (11/81), respectively, in the IA group (P<.001). Internet access significantly shifted from an increasing intraocular pressure trend to a decreasing trend in the IA group (P=.002) among the patients who did not have any medication changes. CONCLUSIONS: Allowing patients to browse their medical data may reduce the use and improve the effectiveness of glaucoma medication. TRIAL REGISTRATION: UMIN-CTR Clinical Trial Number: UMIN000006982; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=bro ws&action=brows&type=summary&recptno=R000008238&language=E (Archived by WebCite at http://www.webcitation.org/6MRPQeEAv). AD - Faculty of Medicine, University of Yamanashi, Chuo, Japan Faculty of Medicine, University of Yamanashi, Chuo, Japan. kenjik@yamanashi.ac.jp. AN - 104004193. Language: English. Entry Date: 20140905. Revision Date: 20180606. Publication Type: Journal Article AU - Kenji, Kashiwagi AU - Shigeo, Tsukahara DB - ccm DO - 10.2196/jmir.2795 DP - EBSCOhost IS - 1 KW - Access to Information Glaucoma -- Drug Therapy Internet Human Ophthalmic Solutions Prospective Studies Single-Blind Studies N1 - research; randomized controlled trial. Journal Subset: Biomedical; Canada; Computer/Information Science; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed. Special Interest: Informatics. NLM UID: 100959882. PMID: NLM24429379. PY - 2014 SN - 1438-8871 SP - e15-13 ST - Impact of patient access to internet health records on glaucoma medication: randomized controlled trial T2 - Journal of Medical Internet Research TI - Impact of patient access to internet health records on glaucoma medication: randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104004193&site=ehost-live&scope=site VL - 16 ID - 4632 ER - TY - JOUR AB - Recently, many new devices and procedures have been developed to lower intraocular pressure in a less invasive and purportedly safer manner than traditional glaucoma surgery. These new devices might encourage an earlier transition to surgery and reduce the long-term commitment to topical glaucoma medications with their associated compliance and intolerance issues. Although often seen as an adjunct to cataract surgery, a growing body of evidence suggests that primary minimally invasive glaucoma surgery may be a viable initial treatment option. New studies have shown that primary ab interno trabeculectomy (Trabectome, NeoMedix Inc., Tustin, CA, USA), trabecular micro-bypass stent insertion (iStent and iStent Inject, Glaukos Corporation, Laguna Hills, CA, USA), canalicular scaffolding (Hydrus, Invantis Inc., Irvine CA, USA), the ab interno gel Implant (XEN, Allergan, Dublin, Ireland) or supraciliary stenting (CyPass Micro-Stent, Alcon, Fort Worth, TX, USA) may lower the lowering intraocular pressure and/or topical medication burden in phakic or pseudophakic patients with glaucoma. This effect seems to last at least 12months but reliable cost-effectiveness and quality of life indicators have not yet been established by investigator-initiated randomized trials of sufficient size and duration. AN - WOS:000403671200010 AU - Kerr, N. M. AU - Wang, J. AU - Barton, K. DA - MAY-JUN DO - 10.1111/ceo.12888 IS - 4 PY - 2017 SN - 1442-6404 1442-9071 SP - 393-400 ST - Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma VL - 45 ID - 6124 ER - TY - JOUR AB - Introduction: With the number of people with sight loss predicted to double to four million people in the UK by the year 2050, preventable visual loss is a significant public health issue. Sight loss is associated with an increased risk of falls, accidents and depression and evidence suggests that 50% of sight loss can be avoided. Timely diagnosis is central to the prevention of sight loss. Access to care can be a limiting factor in preventable cases. By improving referrals and access to hospital eye services it is possible to treat and minimise the number of patients with preventable sight loss and the impact this has on wider society. Clinical pilot study: In 2005, NHS Fife took part in a flagship pilot funded by the Scottish government e-health department to evaluate the feasibility, safety, clinical effectiveness, and cost of electronic referral with images of patients directly from community optometrists to Hospital Eye Service (HES). The pilot study showed that electronic referral was feasible, fast, safe, and obviated the need for outpatient appointments in 128 (37%) patients with a high patient satisfaction. Centralised ophthalmic electronic referral unit: The results of the pilot study were presented and in May 2007, the electronic referral system was rolled out regionally in southeast Scotland. Referrals were accepted at a single site with vetting by a trained team and appointments were allocated within 48hours. Following the implementation of electronic referral, waiting times were reduced from a median of 14 to 4 weeks. Significantly fewer new patients were seen (7462 vs 8714 [. p<0.001]). There were also fewer casualties (1984 vs 2671 [. p<0.001]) and 'did not arrive' (DNA) new patients (503 vs 635 [. p<0.001]). Eye care integration project (Scotland): In 2010 the Scottish Government Health Department committed £6.6 million to community and hospital ophthalmic services forming the Eyecare Integration Project in 2011. The main aim of this project was to create electronic communication between community optometry practices and hospital eye departments. Five electronic forms were specifically designed for cataract, glaucoma, macula, paediatric and general ophthalmic disease. A Virtual Private Network was created which enabled optometrists to connect to the Scottish clinical information gateway system and send referrals to hospital and receive referral status feedback. Numerous hurdles have been encountered and overcome in order to deliver this project. AD - A.A. Khan, Cataract Unit, Queen Margaret Hospital, Whitefield Road, Dunfermline, United Kingdom AU - Khan, A. A. AU - Mustafa, M. Z. AU - Sanders, R. DB - Embase Medline DO - 10.1016/j.puhe.2014.10.010 IS - 2 KW - article clinical effectiveness controlled study electronic communication system electronic referral system eye care feasibility study health care access health care planning health care system hospital department hospital service human major clinical study medical information system optometry outpatient patient satisfaction pilot study public health service social welfare United Kingdom visual impairment LA - English M3 - Article N1 - L600981803 2014-12-25 2015-03-24 PY - 2015 SN - 1476-5616 0033-3506 SP - 117-123 ST - Improving patient access to prevent sight loss: Ophthalmic electronic referrals and communication (Scotland) T2 - Public Health TI - Improving patient access to prevent sight loss: Ophthalmic electronic referrals and communication (Scotland) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600981803&from=export http://dx.doi.org/10.1016/j.puhe.2014.10.010 VL - 129 ID - 2830 ER - TY - JOUR AB - Introduction: With the number of people with sight loss predicted to double to four million people in the UK by the year 2050, preventable visual loss is a significant public health issue. Sight loss is associated with an increased risk of falls, accidents and depression and evidence suggests that 50% of sight loss can be avoided. Timely diagnosis is central to the prevention of sight loss. Access to care can be a limiting factor in preventable cases. By improving referrals and access to hospital eye services it is possible to treat and minimise the number of patients with preventable sight loss and the impact this has on wider society. Clinical pilot study: In 2005, NHS Fife took part in a flagship pilot funded by the Scottish government e-health department to evaluate the feasibility, safety, clinical effectiveness, and cost of electronic referral with images of patients directly from community optometrists to Hospital Eye Service (HES). The pilot study showed that electronic referral was feasible, fast, safe, and obviated the need for outpatient appointments in 128 (37%) patients with a high patient satisfaction. Centralised ophthalmic electronic referral unit: The results of the pilot study were presented and in May 2007, the electronic referral system was rolled out regionally in southeast Scotland. Referrals were accepted at a single site with vetting by a trained team and appointments were allocated within 48 hours. Following the implementation of electronic referral, waiting times were reduced from a median of 14 to 4 weeks. Significantly fewer new patients were seen (7462 us 8714 [p < 0.001]). There were also fewer casualties (1984 us 2671 [p < 0.001]) and 'did not arrive1 (DNA) new patients (503 us 635 [p < 0.001]). Eye care integration project (Scotland): In 2010 the Scottish Government Health Department committed £6.6 million to community and hospital ophthalmic services forming the Eyecare Integration Project in 2011. The main aim of this project was to create electronic communication between community optometry practices and hospital eye departments. Five electronic forms were specifically designed for cataract, glaucoma, macula, paediatric and general ophthalmic disease. A Virtual Private Network was created which enabled optometrists to connect to the Scottish clinical information gateway system and send referrals to hospital and receive referral status feedback. Numerous hurdles have been encountered and overcome in order to deliver this project. AD - Queen Margaret Hospital, Dunfermline, Fife, UK AN - 102041573. Language: English. Entry Date: 20150414. Revision Date: 20191120. Publication Type: Article AU - Khan, A. A. AU - Mustafa, M. Z. AU - Sanders, R. DB - ccm DO - 10.1016/j.puhe.2014.10.010 DP - EBSCOhost IS - 2 KW - Health Services Accessibility -- Evaluation Patient Care Blindness -- Prevention and Control Ophthalmology Referral and Consultation Public Health Human Technology, Medical Pilot Studies N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; Public Health; UK & Ireland. NLM UID: 0376507. PY - 2015 SN - 0033-3506 SP - 117-123 ST - Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication (Scotland) T2 - Public Health (Elsevier) TI - Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication (Scotland) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=102041573&site=ehost-live&scope=site VL - 129 ID - 4446 ER - TY - JOUR AB - Introduction: With the number of people with sight loss predicted to double to four million people in the UK by the year 2050, preventable visual loss is a significant public health issue. Sight loss is associated with an increased risk of falls, accidents and depression and evidence suggests that 50% of sight loss can be avoided. Timely diagnosis is central to the prevention of sight loss. Access to care can be a limiting factor in preventable cases. By improving referrals and access to hospital eye services it is possible to treat and minimise the number of patients with preventable sight loss and the impact this has on wider society. Clinical pilot study: In 2005, NHS Fife took part in a flagship pilot funded by the Scottish government e-health department to evaluate the feasibility, safety, clinical effectiveness, and cost of electronic referral with images of patients directly from community optometrists to Hospital Eye Service (HES). The pilot study showed that electronic referral was feasible, fast, safe, and obviated the need for outpatient appointments in 128 (37%) patients with a high patient satisfaction. Centralised ophthalmic electronic referral unit: The results of the pilot study were presented and in May 2007, the electronic referral system was rolled out regionally in southeast Scotland. Referrals were accepted at a single site with vetting by a trained team and appointments were allocated within 48hours. Following the implementation of electronic referral, waiting times were reduced from a median of 14 to 4 weeks. Significantly fewer new patients were seen (7462 vs 8714 [. p<0.001]). There were also fewer casualties (1984 vs 2671 [. p<0.001]) and 'did not arrive' (DNA) new patients (503 vs 635 [. p<0.001]). Eye care integration project (Scotland): In 2010 the Scottish Government Health Department committed £6.6 million to community and hospital ophthalmic services forming the Eyecare Integration Project in 2011. The main aim of this project was to create electronic communication between community optometry practices and hospital eye departments. Five electronic forms were specifically designed for cataract, glaucoma, macula, paediatric and general ophthalmic disease. A Virtual Private Network was created which enabled optometrists to connect to the Scottish clinical information gateway system and send referrals to hospital and receive referral status feedback. Numerous hurdles have been encountered and overcome in order to deliver this project. © 2014 The Royal Society for Public Health. AD - Queen Margaret Hospital, Dunfermline, Fife, United Kingdom AU - Khan, A. A. AU - Mustafa, M. Z. AU - Sanders, R. DB - Scopus DO - 10.1016/j.puhe.2014.10.010 IS - 2 KW - Electronic referral Imaging Telemedicine M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2015 SP - 117-123 ST - Improving patient access to prevent sight loss: Ophthalmic electronic referrals and communication (Scotland) T2 - Public Health TI - Improving patient access to prevent sight loss: Ophthalmic electronic referrals and communication (Scotland) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924605231&doi=10.1016%2fj.puhe.2014.10.010&partnerID=40&md5=8a62d2abf101d0cea18c75ab6e4e5d01 VL - 129 ID - 5328 ER - TY - JOUR AB - Background: In Canada, government insurance covers eye care services provided by ophthalmologists and other physicians. However, government coverage for services provided by optometrists, non-medical school trained primary eye care providers, varies regionally. Little is known about the impact of a funding model in which ophthalmologist services are government-insured but services provided by optometrists are not, on eye care utilization and eye disease detection and treatment. We aimed to address this question by examining geographic variations in eye care service utilization on Prince Edward Island (PEI).Methods: PEI physician-billing data from 2010 to 2012 was analyzed across five distinct geographic regions (Charlottetown, Summerside, Prince, Queens & Kings and Stratford). The residential location of patients and practice locations of eye care providers were identified using the first three digits of their respective postal code. Age-standardized rates were computed for comparisons across different regions.Results: There were six ophthalmologists practicing on PEI, five with offices in Charlottetown. Twenty optometrists practiced on the island with offices across the province. Stratford is closest and Prince farthest from Charlottetown. Age-standardized utilization rates of ophthalmologists per 100 populations were 10.44 in Charlottetown and 10.90 in Stratford, which was significantly higher than in other regions (7.74-8.92; p < 0.05). The disparities were most pronounced amongst the elderly. The prevalence of glaucoma visits was higher in Charlottetown (6.10%) and Stratford (6.38%) and lower in other regions. A similar pattern was observed for the prevalence of cataract visits. While the prevalence of diabetes visits was higher in Prince and Summerside, the utilization of ophthalmologists by people with diabetes was almost twice as high in Charlottetown (6.49%) than in Prince (3.88%).Conclusions: The observed discrepancies in vision care utilization across geographic regions were likely attributed to barriers in accessing government-insured, geographically concentrated ophthalmologists, as opposed to a reflection of the true differences in eye disease occurrence. The lower prevalence of glaucoma visits in regions farther away from ophthalmologist offices may result in delayed detection and blindness in this population. Encouraging ophthalmologists to work in other areas of the province and/or to publicly fund services provided by optometrists may mitigate the observed disparities.Trial Registration: Not applicable. AD - Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON, M5T 3M7, Canada Department of Ophthalmology and Vision Sciences, University of Toronto, 340 College Street, Suite 400, Toronto, ON, M5T 3A9, Canada Health PEI, 16 Garfield Street, Charlottetown, PEI, C1A 7N8, Canada University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada AN - 129023153. Language: English. Entry Date: 20181122. Revision Date: 20190124. Publication Type: journal article AU - Khan, A. M. AU - Trope, G. E. AU - Wedge, R. AU - Buys, Y. M. AU - El-Defrawy, S. AU - Chen, Q. AU - Jin, Y. P. DB - ccm DO - 10.1186/s12913-018-3068-z DP - EBSCOhost IS - 1 KW - Ophthalmology Glaucoma -- Diagnosis Cataract -- Diagnosis Health Services Accessibility -- Statistics and Numerical Data Optometry Female Health Services Research Cross Sectional Studies Prince Edward Island Middle Age Adult Human Male Cataract -- Therapy Glaucoma -- Therapy Aged Health Personnel Insurance Coverage Funding Source N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. Grant Information: HRA 126901//Canadian Institutes for Health Research/International. NLM UID: 101088677. PMID: NLM29636054. PY - 2018 SN - 1472-6963 SP - 273-273 ST - Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012 T2 - BMC Health Services Research TI - Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129023153&site=ehost-live&scope=site VL - 18 ID - 4562 ER - TY - JOUR AB - Background: In Canada, government insurance covers eye care services provided by ophthalmologists and other physicians. However, government coverage for services provided by optometrists, non-medical school trained primary eye care providers, varies regionally. Little is known about the impact of a funding model in which ophthalmologist services are government-insured but services provided by optometrists are not, on eye care utilization and eye disease detection and treatment. We aimed to address this question by examining geographic variations in eye care service utilization on Prince Edward Island (PEI). Methods: PEI physician-billing data from 2010 to 2012 was analyzed across five distinct geographic regions (Charlottetown, Summerside, Prince, Queens & Kings and Stratford). The residential location of patients and practice locations of eye care providers were identified using the first three digits of their respective postal code. Age-standardized rates were computed for comparisons across different regions. Results: There were six ophthalmologists practicing on PEI, five with offices in Charlottetown. Twenty optometrists practiced on the island with offices across the province. Stratford is closest and Prince farthest from Charlottetown. Age-standardized utilization rates of ophthalmologists per 100 populations were 10.44 in Charlottetown and 10.90 in Stratford, which was significantly higher than in other regions (7.74-8.92; p < 0.05). The disparities were most pronounced amongst the elderly. The prevalence of glaucoma visits was higher in Charlottetown (6.10%) and Stratford (6.38%) and lower in other regions. A similar pattern was observed for the prevalence of cataract visits. While the prevalence of diabetes visits was higher in Prince and Summerside, the utilization of ophthalmologists by people with diabetes was almost twice as high in Charlottetown (6.49%) than in Prince (3.88%). Conclusions: The observed discrepancies in vision care utilization across geographic regions were likely attributed to barriers in accessing government-insured, geographically concentrated ophthalmologists, as opposed to a reflection of the true differences in eye disease occurrence. The lower prevalence of glaucoma visits in regions farther away from ophthalmologist offices may result in delayed detection and blindness in this population. Encouraging ophthalmologists to work in other areas of the province and/or to publicly fund services provided by optometrists may mitigate the observed disparities. Trial registration: Not applicable. © 2018 The Author(s). AD - Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON M5T 3M7, Canada Department of Ophthalmology and Vision Sciences, University of Toronto, 340 College Street, Toronto, ON M5T 3A9, Canada Health PEI, 16 Garfield Street, Charlottetown, PEI C1A 7N8, Canada University of Waterloo, 200 University Ave W, Waterloo, ON N2L 3G1, Canada AU - Khan, A. M. AU - Trope, G. E. AU - Wedge, R. AU - Buys, Y. M. AU - El-Defrawy, S. AU - Chen, Q. AU - Jin, Y. P. C7 - 273 DB - Scopus DO - 10.1186/s12913-018-3068-z IS - 1 KW - Cataracts Diabetes Eye care utilization Glaucoma Vision care coverage policy M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2018 ST - Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: A repeated cross-sectional analysis, 2010-2012 T2 - BMC Health Services Research TI - Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: A repeated cross-sectional analysis, 2010-2012 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045182418&doi=10.1186%2fs12913-018-3068-z&partnerID=40&md5=8840fdbdc6c0bc6f7583d9dd7a11624e VL - 18 ID - 5507 ER - TY - JOUR AB - Background: In Canada, government insurance covers eye care services provided by ophthalmologists and other physicians. However, government coverage for services provided by optometrists, non-medical school trained primary eye care providers, varies regionally. Little is known about the impact of a funding model in which ophthalmologist services are government-insured but services provided by optometrists are not, on eye care utilization and eye disease detection and treatment. We aimed to address this question by examining geographic variations in eye care service utilization on Prince Edward Island (PEI). Methods: PEI physician-billing data from 2010 to 2012 was analyzed across five distinct geographic regions (Charlottetown, Summerside, Prince, Queens & Kings and Stratford). The residential location of patients and practice locations of eye care providers were identified using the first three digits of their respective postal code. Age-standardized rates were computed for comparisons across different regions. Results: There were six ophthalmologists practicing on PEI, five with offices in Charlottetown. Twenty optometrists practiced on the island with offices across the province. Stratford is closest and Prince farthest from Charlottetown. Age-standardized utilization rates of ophthalmologists per 100 populations were 10.44 in Charlottetown and 10.90 in Stratford, which was significantly higher than in other regions (7.74-8.92; p < 0.05). The disparities were most pronounced amongst the elderly. The prevalence of glaucoma visits was higher in Charlottetown (6.10%) and Stratford (6.38%) and lower in other regions. A similar pattern was observed for the prevalence of cataract visits. While the prevalence of diabetes visits was higher in Prince and Summerside, the utilization of ophthalmologists by people with diabetes was almost twice as high in Charlottetown (6.49%) than in Prince (3.88%). Conclusions: The observed discrepancies in vision care utilization across geographic regions were likely attributed to barriers in accessing government-insured, geographically concentrated ophthalmologists, as opposed to a reflection of the true differences in eye disease occurrence. The lower prevalence of glaucoma visits in regions farther away from ophthalmologist offices may result in delayed detection and blindness in this population. Encouraging ophthalmologists to work in other areas of the province and/or to publicly fund services provided by optometrists may mitigate the observed disparities. AN - WOS:000430259300013 AU - Khan, A. M. AU - Trope, G. E. AU - Wedge, R. AU - Buys, Y. M. AU - El-Defrawy, S. AU - Chen, Q. AU - Jin, Y. P. DA - APR 10 DO - 10.1186/s12913-018-3068-z PY - 2018 SN - 1472-6963 ST - Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012 T2 - BMC HEALTH SERVICES RESEARCH TI - Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012 VL - 18 ID - 6249 ER - TY - JOUR AD - SpR Ophthalmology, Bradford Royal Infirmary, Bradford, United Kingdom AU - Khan, R. AU - Al-Maskari, A. AU - Khan, K. DB - Scopus DO - 10.1136/bjo.2009.165241 IS - 8 M3 - Letter N1 - Export Date: 19 July 2021 PY - 2009 SP - 1126-1127 ST - Increasing the efficiency of ophthalmic care for all patients during Ramadan T2 - British Journal of Ophthalmology TI - Increasing the efficiency of ophthalmic care for all patients during Ramadan UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-68049083419&doi=10.1136%2fbjo.2009.165241&partnerID=40&md5=b39afa9bbab0ff1decad602707df7eea VL - 93 ID - 5766 ER - TY - JOUR AB - Purpose: Glaucoma is a priority eye disease in Oman. In order to revise the existing policies for eye care, a study was conducted to review the noncompliance rates among glaucoma patients. Methods: Using the random method, we selected 105 glaucoma patients from among those visiting glaucoma clinics during 2003. They were interviewed by trained health professionals. A closed-ended questionnaire with 42 questions was used to note their responses. The questions dealt with their personal characteristics along with the patients' glaucoma treatment and their knowledge of and attitudes towards different components of noncompliance with medical treatment. The field staffs also observed the 'practice' of instilling placebo eyedrops. The responses were analyzed to grade the compliance, knowledge, attitude and practice of each patient. Results: Excellent compliance was found in 26 patients. Discontinuation of medication in the past was reported by 87 patients. Missing instillation of eyedrops and irregular visits to the ophthalmologist were noted in 10 and 14 patients, respectively. Adequate knowledge about glaucoma and its complications was negatively associated with noncompliance [RR 2.05 (95% CI 1.07-3.93)]. Conclusions: The high rates of noncompliance among glaucoma patients in Oman demand a systematic programmed approach. Longitudinal studies are needed to confirm the causal association between noncompliance and Knowledge, Attitude and Practice. Health education, communication while dispensing medication, reducing the frequency of medication and using devices for the easy administration of eyedrops could further improve compliance. AN - WOS:000232465300004 AU - Khandekar, R. AU - Shama, M. E. AU - Mohammed, A. J. DA - OCT DO - 10.1080/09286580500224602 IS - 5 PY - 2005 SN - 0928-6586 1744-5086 SP - 303-309 ST - Noncompliance with medical treatment among glaucoma patients in Oman - A cross-sectional descriptive study T2 - OPHTHALMIC EPIDEMIOLOGY TI - Noncompliance with medical treatment among glaucoma patients in Oman - A cross-sectional descriptive study VL - 12 ID - 5941 ER - TY - JOUR AB - Purpose: Glaucoma is a priority eye disease in Oman. In order to revise the existing policies for eye care, a study was conducted to review the noncompliance rates among glaucoma patients. Methods: Using the random method, we selected 105 glaucoma patients from among those visiting glaucoma clinics during 2003. They were interviewed by trained health professionals. A closed-ended questionnaire with 42 questions was used to note their responses. The questions dealt with their personal characteristics along with the patients' glaucoma treatment and their knowledge of and attitudes towards different components of noncompliance with medical treatment. The field staffs also observed the 'practice' of instilling placebo eyedrops. The responses were analyzed to grade the compliance, knowledge, attitude and practice of each patient. Results: Excellent compliance was found in 26 patients. Discontinuation of medication in the past was reported by 87 patients. Missing instillation of eyedrops and irregular visits to the ophthalmologist were noted in 10 and 14 patients, respectively. Adequate knowledge about glaucoma and its complications was negatively associated with noncompliance [RR 2.05 (95% CI 1.07-3.93)]. Conclusions: The high rates of noncompliance among glaucoma patients in Oman demand a systematic programmed approach. Longitudinal studies are needed to confirm the causal association between noncompliance and Knowledge, Attitude and Practice. Health education, communication while dispensing medication, reducing the frequency of medication and using devices for the easy administration of eyedrops could further improve compliance. Copyright © Taylor & Francis Inc. AD - Eye and Ear Health Care, Ministry of Health, Oman Institute of Public Health, Ministry of Health, Oman Department of Health Affairs, Ministry of Health, Oman EHCP, NCD, MOH (HQ), POB: 393, Pin: 113, Muscat, Oman AU - Khandekar, R. AU - Shama, M. E. S. AU - Mohammed, A. J. DB - Scopus DO - 10.1080/09286580500224602 IS - 5 KW - Eyedrops Glaucoma treatment Oman Questionnaire study Treatment compliance Underdeveloped countries M3 - Article N1 - Cited By :24 Export Date: 19 July 2021 PY - 2005 SP - 303-309 ST - Noncompliance with medical treatment among glaucoma patients in Oman - A cross-sectional descriptive study T2 - Ophthalmic Epidemiology TI - Noncompliance with medical treatment among glaucoma patients in Oman - A cross-sectional descriptive study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-28244491460&doi=10.1080%2f09286580500224602&partnerID=40&md5=50df6a17a6ba3aa2f2aed932c8a4dacd VL - 12 ID - 5100 ER - TY - JOUR AB - PURPOSE: Our purpose was to evaluate the accuracy of self-reporting of the prescribed medication regimen in a glaucoma population, identify contributing factors, and assess the effect of written instructions. METHODS AND MATERIALS: All patients at an urban resident glaucoma clinic were offered participation in this prospective, case-controlled study. Two trained interviewers administered a confidential questionnaire consisting of six questions regarding the name and dosage of ophthalmic medications, education level, ability to read, and age. A verbatim response for each question was recorded on the questionnaire. At the end of the visit, patients were given a written chart describing their ophthalmic medications, frequency, and dosage. At their next scheduled visit, the same questionnaire was repeated. The patients' responses from both visits were compared with the regimen they were prescribed and with each other. This information was used to determine the accuracy of reporting medications. RESULTS: A total of 193 patients were enrolled in the study over a 10-month period; 164 patients completed both phases (85% completion rate). The study population consisted of 85 women and 79 men with a mean age of 68.40 ± 11.6 years. Eighty-four patients had attained less than 12th grade education and 80 had completed high school. At the first visit, 66 patients (40%) showed less than 100% accuracy. Forty-nine of 84 (58%) patients who had not completed high school education showed less than 100% accuracy with a mean score of 65% (P≤0.001), whereas 17 of 80 (21%) of patients who had completed high school showed less than 100% accuracy with a mean score of 87% (P≤0.001). After written instruction, the accuracy of reporting improved by 23.36 ± 30.8 percentile points in patients without completion of high school education and improved by 8.46 ± 21.7 percentile points in patients who had completed high school (P<0.001). The mean number of ophthalmic medications prescribed was 2.10 ± 0.93 (range 1 to 4). Patients on one medication had 100% accuracy in reporting 82% of the time, whereas those with four medications had 100% accuracy 21% of the time. Gender, age, and race of the patient were not correlated with the accuracy of self-reporting (P>0.05). CONCLUSION: The education level of the patient and the number of medications showed direct correlation with patients' ability to report medications accurately. Patients showed improvement in accuracy of reporting medications when given written instructions about their regimen, regardless of their level of education or number of medications. Copyright © 2006 by Lippincott Williams & Wilkins. AD - D.J. Rhee, Massachusetts Eye and Ear Infirmary, 243 Charles St., Boston, MA 02114, United States AU - Kharod, B. V. AU - Johnson, P. B. AU - Nesti, H. A. AU - Rhee, D. J. DB - Embase Medline DO - 10.1097/01.ijg.0000212213.18018.8f IS - 3 KW - agents acting on the eye academic achievement accuracy adult aged article case control study controlled study demography drug dose regimen drug information evaluation study female glaucoma human major clinical study male medical assessment patient compliance patient education patient participation prescription priority journal sample size scoring system self report sex ratio structured interview urban population LA - English M3 - Article N1 - L43916818 2006-06-29 PY - 2006 SN - 1057-0829 SP - 244-247 ST - Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients T2 - Journal of Glaucoma TI - Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43916818&from=export http://dx.doi.org/10.1097/01.ijg.0000212213.18018.8f VL - 15 ID - 3605 ER - TY - JOUR AB - PURPOSE: Our purpose was to evaluate the accuracy of self-reporting of the prescribed medication regimen in a glaucoma population, identify contributing factors, and assess the effect of written instructions. METHODS AND MATERIALS: All patients at an urban resident glaucoma clinic were offered participation in this prospective, case-controlled study. Two trained interviewers administered a confidential questionnaire consisting of six questions regarding the name and dosage of ophthalmic medications, education level, ability to read, and age. A verbatim response for each question was recorded on the questionnaire. At the end of the visit, patients were given a written chart describing their ophthalmic medications, frequency, and dosage. At their next scheduled visit, the same questionnaire was repeated. The patients' responses from both visits were compared with the regimen they were prescribed and with each other. This information was used to determine the accuracy of reporting medications. RESULTS: A total of 193 patients were enrolled in the study over a 10-month period; 164 patients completed both phases (85% completion rate). The study population consisted of 85 women and 79 men with a mean age of 68.40 ± 11.6 years. Eighty-four patients had attained less than 12th grade education and 80 had completed high school. At the first visit, 66 patients (40%) showed less than 100% accuracy. Forty-nine of 84 (58%) patients who had not completed high school education showed less than 100% accuracy with a mean score of 65% (P≤0.001), whereas 17 of 80 (21%) of patients who had completed high school showed less than 100% accuracy with a mean score of 87% (P≤0.001). After written instruction, the accuracy of reporting improved by 23.36 ± 30.8 percentile points in patients without completion of high school education and improved by 8.46 ± 21.7 percentile points in patients who had completed high school (P<0.001). The mean number of ophthalmic medications prescribed was 2.10 ± 0.93 (range 1 to 4). Patients on one medication had 100% accuracy in reporting 82% of the time, whereas those with four medications had 100% accuracy 21% of the time. Gender, age, and race of the patient were not correlated with the accuracy of self-reporting (P>0.05). CONCLUSION: The education level of the patient and the number of medications showed direct correlation with patients' ability to report medications accurately. Patients showed improvement in accuracy of reporting medications when given written instructions about their regimen, regardless of their level of education or number of medications. Copyright © 2006 by Lippincott Williams & Wilkins. AD - William and Anna Goldberg Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, United States Glaucoma Service, Massachusetts Eye and Ear Infirmary, Boston, MA, United States Massachusetts Eye and Ear Infirmary, 243 Charles St., Boston, MA 02114, United States AU - Kharod, B. V. AU - Johnson, P. B. AU - Nesti, H. A. AU - Rhee, D. J. DB - Scopus DO - 10.1097/01.ijg.0000212213.18018.8f IS - 3 KW - Glaucoma Medication compliance Medication regimen Self reporting Written instructions M3 - Article N1 - Cited By :31 Export Date: 19 July 2021 PY - 2006 SP - 244-247 ST - Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients T2 - Journal of Glaucoma TI - Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745278588&doi=10.1097%2f01.ijg.0000212213.18018.8f&partnerID=40&md5=42e680ac67760bd6a670c60aee2f4780 VL - 15 ID - 5057 ER - TY - JOUR AB - Purpose: Our purpose was to evaluate the accuracy of self-reporting of the prescribed medication regimen in a glaucoma population, identify contributing factors, and assess the effect of written instructions. Methods and Materials: All patients at an urban resident glaucoma clinic were offered participation in this prospective, case-controlled study. Two trained interviewers administered a confidential questionnaire consisting of six questions regarding the name and dosage of ophthalmic medications, education level, ability to read, and age. A verbatim response for each question was recorded on the questionnaire. At the end of the visit, patients were given a written chart describing their ophthalmic medications, frequency, and dosage. At their next scheduled visit, the same questionnaire was repeated. The patients' responses from both visits were compared with the regimen they were prescribed and with each other. This information was used to determine the accuracy of reporting medications. Results: A total of 193 patients were enrolled in the study over a 10-month period; 164 patients completed both phases (85% completion rate). The study population consisted of 85 women and 79 men with a mean age of 68.40 +/- 11.6 years. Eighty-four patients had attained less than 12th grade education and 80 had completed high school. At the first visit, 66 patients (40%) showed less than 100% accuracy. Forty-nine of 84 (58%) patients who had not completed high school education showed less than 100% accuracy with a mean score of 65% (P = 0.001), whereas 17 of 80 (21%) of patients who had completed high school showed less than 100% accuracy with a mean score of 87% (P = 0.001). After written instruction, the accuracy of reporting improved by 23.36 +/- 30.8 percentile points in patients without completion of high school education and improved by 8.46 +/- 21.7 percentile points in patients who had completed high school (P < 0.001). The mean number of ophthalmic medications prescribed was 2.10 +/- 0.93 (range 1 to 4). Patients on one medication had 100% accuracy in reporting 82% of the time, whereas those with four medications had 100% accuracy 21% of the time. Gender, age, and race of the patient were not correlated with the accuracy of self-reporting (P > 0.05). Conclusion: The education level of the patient and the number of medications showed direct correlation with patients' ability to report medications accurately. Patients showed improvement in accuracy of reporting medications when given written instructions about their regimen, regardless of their level of education or number of medications. AN - WOS:000238243200011 AU - Kharod, B. V. AU - Johnson, P. B. AU - Nesti, H. A. AU - Rhee, D. J. DA - JUN DO - 10.1097/01.ijg.0000212213.18018.8f IS - 3 PY - 2006 SN - 1057-0829 1536-481X SP - 244-247 ST - Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients T2 - JOURNAL OF GLAUCOMA TI - Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients VL - 15 ID - 6268 ER - TY - JOUR AB - A 16-y ear-old boy presented with decrease of v ision ov er a period of 2 y ears. On examination, he was diagnosed to hav e microspherophakia with lenticular my opia with secondary glaucoma in both ey es. He was treated by lens aspiration and two-point capsular support using a modif ied capsular tension ring (MCTR) and capsular tension segment (CTS) sutured to the sclera along with implantation of a f oldable intraocular lens inside the bag. Lens aspiration was perf ormed without artif icial capsular hook support of the bag, as the lens was sof t and v itreous was f ormed. Howev er, M-CTR rotation into the bag was f raught with repeated adherence of the adv ancing end of the M-CTR into the loose bag causing simultaneous rotation of the bag with the rotation of the ring resulting in transient increase in bag subluxation. Capsular hooks prov ided appropriate countertraction to the unsupported bag, thus f acilitating easy insertion and rotation of the ring into the bag. AD - Department of Ophthalmology, Dr RP Centre, AIIMS, New Delhi, Delhi, India AIIMS, New Delhi, Delhi, India Dr RP Centre, AIIMS, New Delhi, Delhi, India AU - Khokhar, S. AU - Gupta, S. AU - Nayak, B. AU - Gogia, V. C7 - 214274 DB - Scopus DO - 10.1136/bcr-2015-214274 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2016 ST - Capsular hook-assisted implantation of modified capsular tension ring T2 - BMJ Case Reports TI - Capsular hook-assisted implantation of modified capsular tension ring UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964391113&doi=10.1136%2fbcr-2015-214274&partnerID=40&md5=2538601292bacea6e8e8873d8ec94074 VL - 2016 ID - 5567 ER - TY - JOUR AB - Background: Poor compliance with medication is a major concern in the management of glaucoma. Improper administration technique can lead to contamination and inaccurate dosing. This study estimates the prevalence and predictors of noncompliance and improper administration technique among Canadian glaucoma patients. Methods: Data were collected using a standardized questionnaire. Noncompliance was defined as missing at least 1 drop of medication per week and (or) the inability to accurately describe the medication regimen. Patients were asked to indicate the most common reason for missing medication. Study personnel assessed drop administration technique as patients were applying eye drops. Physicians provided information, including measures of disease stability, regarding the patient's glaucoma. Predictors were assessed using odds ratios from a logistic regression model. Results: 500 patients from 10 centers across Canada participated in the study. Of these, 25.6% reported missing at least 1 drop of medication per week, and 4.2% were unable to accurately describe their medication regimen. The overall proportion of noncompliance was 27.9%. With regard to drop administration, 6.8% missed their eye and 28.8% contaminated the bottle tip; overall, 33.8% demonstrated improper technique. The most common reasons given for missing eye drops were "forgetfulness" and "being away from drops." Formal education limited to elementary school and treatment duration of <5 years increased patient-reported noncompliance. Factors associated with improper administration technique were age 60 years and older and formal education limited to elementary school. Interpretation: Over 50% of the patients surveyed were either noncompliant or demonstrated improper administration technique. Glaucoma patients should be educated on the importance of compliance and instructed on proper drop administration. AD - Y.M. Buys, Toronto Western Hospital, 399 Bathurst St., EW 6-405, Toronto, ON M5T 2S8, Canada AU - Kholdebarin, R. AU - Campbell, R. J. AU - Jin, Y. P. AU - Buys, Y. M. AU - Beiko, G. AU - Birt, C. AU - Damji, K. AU - Feldman, F. AU - Lajaoie, C. AU - Kulkarni, S. AU - Martow, J. AU - Sakamoto, T. AU - Spencer, J. AU - Trope, G. E. DB - Embase Medline DO - 10.3129/I08-076 IS - 4 KW - antiglaucoma agent eye drops topical agent accuracy adult aged article Canada clinical protocol clinical trial education female glaucoma human major clinical study male multicenter study patient attitude patient compliance prediction prevalence questionnaire LA - English M3 - Article N1 - L352197128 2008-08-29 PY - 2008 SN - 1715-3360 0008-4182 SP - 454-461 ST - Multicenter study of compliance and drop administration in glaucoma T2 - Canadian Journal of Ophthalmology TI - Multicenter study of compliance and drop administration in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352197128&from=export http://dx.doi.org/10.3129/I08-076 VL - 43 ID - 3484 ER - TY - JOUR AB - Glaucoma is a leading cause of irreversible visual loss. This potentially blinding disease is a progressive optic neuropathy associated with elevated intraocular pressure (IOP). Initial therapy for glaucoma typically consists of topical medications or laser treatment to lower IOP. Frequently, more than one medication is required to achieve adequate control of IOP. However, more medications means more bottles and greater complexity for the patient. There are several potential benefits of fixed combination medications compared with using the individual components separately. These include a reduction in the total number of drops and preservative instilled per day, cost savings, improved tolerability and compliance and avoiding the washout effect resulting from rapid-sequence instillation of multiple drops. Attempts to develop effective fixed combinations of glaucoma medications date back several decades. In recent years, fixed combinations of commonly paired drugs have been approved by various regulatory bodies in different countries and have gained wide acceptance. Current commercially available, fixed combination drugs include the topical β-adrenoceptor antagonist timolol 0.5% combined with a prostaglandin, a topical carbonic anhydrase inhibitor or an α-adrenoceptor agonist. Although there is no uniformity among registration trial designs, most published literature compares the efficacy of the fixed combination to the individual components and to concomitant use of both components. Various factors inherent to study design such as medication run-in, washout periods and peak and trough effects have to be taken into consideration when analysing the demonstrated efficacy of fixed combinations. Fixed combination treatments offer effective IOP control while reducing the washout effect and exposure to preservatives. They are also convenient. However, fixed combinations also remove the possibility of titrating the individual components both in terms of concentration and timing of administration. In addition, fixed combinations might not always provide the same efficacy as proper use of the individual components. The clinician must make individualised assessments when weighing the convenience of these medications against their limitations for specific patients. © 2007 Adis Data Information BV. All rights reserved. AD - R.D. Fechtner, Institute of Ophthalmology and Visual Science, 90 Bergen Street, Newark, NJ 07103, United States AU - Khouri, A. S. AU - Realini, T. AU - Fechtner, R. D. C1 - combigan(Allergan,United States) cosopt(Merck,United States) duotrav(Alcon,United States) extravan(Alcon,United States) ganfort(Allergan,United States) xalacom(Pfizer,United States) C2 - Alcon(United States) Allergan(United States) Merck(United States) Pfizer(United States) DB - Embase Medline DO - 10.2165/00002512-200724120-00004 IS - 12 KW - epinephrine antiglaucoma agent betaxolol bimatoprost bimatoprost plus timolol brimonidine brimonidine plus timolol dorzolamide dorzolamide plus timolol timolol plus travoprost eye drops latanoprost latanoprost plus timolol pilocarpine timolol travoprost unclassified drug clinical trial disease exacerbation drug efficacy drug safety drug tolerability glaucoma human intraocular pressure monotherapy patient compliance priority journal review treatment outcome United States unspecified side effect vision visual impairment combigan cosopt duotrav extravan ganfort xalacom LA - English M3 - Review N1 - L350145409 2007-12-06 PY - 2007 SN - 1170-229X SP - 1007-1016 ST - Use of fixed-dose combination drugs for the treatment of glaucoma T2 - Drugs and Aging TI - Use of fixed-dose combination drugs for the treatment of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350145409&from=export http://dx.doi.org/10.2165/00002512-200724120-00004 VL - 24 ID - 3488 ER - TY - JOUR AB - Glaucoma is a leading cause of irreversible visual loss. This potentially blinding disease is a progressive optic neuropathy associated with elevated intraocular pressure (IOP). Initial therapy for glaucoma typically consists of topical medications or laser treatment to lower IOP. Frequently, more than one medication is required to achieve adequate control of IOP. However, more medications means more bottles and greater complexity for the patient. There are several potential benefits of fixed combination medications compared with using the individual components separately. These include a reduction in the total number of drops and preservative instilled per day, cost savings, improved tolerability and compliance and avoiding the washout effect resulting from rapid-sequence instillation of multiple drops. Attempts to develop effective fixed combinations of glaucoma medications date back several decades. In recent years, fixed combinations of commonly paired drugs have been approved by various regulatory bodies in different countries and have gained wide acceptance. Current commercially available, fixed combination drugs include the topical beta-adrenoceptor antagonist timolol 0.5% combined with a prostaglandin, a topical carbonic anhydrase inhibitor or an alpha-adrenoceptor agonist. Although there is no uniformity among registration trial designs, most published literature compares the efficacy of the fixed combination to the individual components and to concomitant use of both components. Various factors inherent to study design such as medication run-in, washout periods and peak and trough effects have to be taken into consideration when analysing the demonstrated efficacy of fixed combinations. Fixed combination treatments offer effective IOP control while reducing the washout effect and exposure to preservatives. They are also convenient. However, fixed combinations also remove the possibility of titrating the individual components both in terms of concentration and timing of administration. In addition, fixed combinations might not always provide the same efficacy as proper use of the individual components. The clinician must make individualised assessments when weighing the convenience of these medications against their limitations for specific patients. AD - Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey, Newark, NJ AN - 105733678. Language: English. Entry Date: 20080606. Revision Date: 20200708. Publication Type: Journal Article AU - Khouri, A. S. AU - Realini, T. AU - Fechtner, R. D. DB - ccm DO - 10.2165/00002512-200724120-00004 DP - EBSCOhost IS - 12 KW - Drug Combinations Glaucoma Glaucoma -- Drug Therapy Drug Combinations -- Adverse Effects Medication Compliance N1 - review; tables/charts. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 9102074. PMID: NLM18020533. PY - 2007 SN - 1170-229X SP - 1007-1016 ST - Use of fixed-dose combination drugs for the treatment of glaucoma T2 - Drugs & Aging TI - Use of fixed-dose combination drugs for the treatment of glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105733678&site=ehost-live&scope=site VL - 24 ID - 4505 ER - TY - JOUR AB - Background: New fixed-dose combination drugs (FDCs) had been developed in limited numbers in Japan. Since regulatory requirements were relaxed in 2005, 73 new FDCs have been approved by PMDA since 2006. In this study, we investigate trends in new FDCs and their benefits through a questionnaire survey provided to patients and pharmacists. Methods: The new FDCs were analyzed by therapeutic categories, first approval country and drug lag (DL). Questionnaire surveys were conducted on hypertension, bronchial asthma, and glaucoma in approximately 300 patients and 700 pharmacists in 66 hospitals to investigate the benefits of new FDCs. Results: The highest number of FDCs approved by the therapeutic category was 15 cardiovascular agents. The DL (median) was less than 1 year in several therapeutic categories including cardiovascular agents. The survey results showed that patient compliance improved in 30.8% of the bronchial asthma. Regarding the time and effort required to prescribe these drugs, 32.5% of pharmacists reported “slightly decreased” in bronchial asthma, while 32.0% reported “slightly increased” in hypertension. More than one-third (70.6%) responded “recommend” in bronchial asthma. Conclusion: The number of new FDCs markedly increased since 2006, and this presented new opportunities for the Japanese pharmaceutical industry. FDCs not only increase convenience to the patient but also improve patient compliance and the efficiency of pharmacist prescription processes. However, the rapid increase in new FDCs may cause confusion in the medical field, and new FDCs should be developed not only to improve convenience but also to consider the benefits they provide to patients, pharmacists, and physicians. AD - C. Kikuchi, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, Japan AU - Kikuchi, C. AU - Ohno, M. AU - Izumo, T. AU - Takahashi, S. AU - Aoki, M. AU - Shimomura, H. AU - Kawano, Y. AU - Shimada, S. AU - Aoyama, T. DB - Embase Medline DO - 10.1007/s43441-019-00046-w IS - 1 KW - agents acting on the peripheral nervous and neuromuscular systems anti human immunodeficiency virus agent antiallergic agent antiasthmatic agent antibiotic agent antidiabetic agent antiglaucoma agent antihypertensive agent antimalarial agent antineoplastic agent antivirus agent biological product cardiovascular agent central nervous system agents dermatological agent drug hormone article asthma drug approval drug combination drug cost drug industry glaucoma hypertension Japan medication compliance patient patient compliance pharmacist physician priority journal questionnaire LA - English M3 - Article N1 - L2004314180 2020-03-02 2020-04-14 PY - 2020 SN - 2168-4804 2168-4790 SP - 200-210 ST - Investigation of Approval Trends and Benefits of New Fixed-Dose Combination Drugs in Japan T2 - Therapeutic Innovation and Regulatory Science TI - Investigation of Approval Trends and Benefits of New Fixed-Dose Combination Drugs in Japan UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004314180&from=export http://dx.doi.org/10.1007/s43441-019-00046-w VL - 54 ID - 2440 ER - TY - JOUR AB - Background: New fixed-dose combination drugs (FDCs) had been developed in limited numbers in Japan. Since regulatory requirements were relaxed in 2005, 73 new FDCs have been approved by PMDA since 2006. In this study, we investigate trends in new FDCs and their benefits through a questionnaire survey provided to patients and pharmacists. Methods: The new FDCs were analyzed by therapeutic categories, first approval country and drug lag (DL). Questionnaire surveys were conducted on hypertension, bronchial asthma, and glaucoma in approximately 300 patients and 700 pharmacists in 66 hospitals to investigate the benefits of new FDCs. Results: The highest number of FDCs approved by the therapeutic category was 15 cardiovascular agents. The DL (median) was less than 1 year in several therapeutic categories including cardiovascular agents. The survey results showed that patient compliance improved in 30.8% of the bronchial asthma. Regarding the time and effort required to prescribe these drugs, 32.5% of pharmacists reported "slightly decreased" in bronchial asthma, while 32.0% reported "slightly increased" in hypertension. More than one-third (70.6%) responded "recommend" in bronchial asthma. Conclusion: The number of new FDCs markedly increased since 2006, and this presented new opportunities for the Japanese pharmaceutical industry. FDCs not only increase convenience to the patient but also improve patient compliance and the efficiency of pharmacist prescription processes. However, the rapid increase in new FDCs may cause confusion in the medical field, and new FDCs should be developed not only to improve convenience but also to consider the benefits they provide to patients, pharmacists, and physicians. AD - Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, 278-8510, Chiba, Japan Department of Pharmacy, Chiba-Nishi General Hospital, Matsudo, Chiba, Japan Department of Pharmacy, Tokushukai General Incorporated Association, Chiyoda-ku, Tokyo, Japan Department of Pharmacy, AIN Pharmacy Chiba-Nishi, Matsudo, Chiba, Japan Department of Pharmacy, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Chiba, Japan AN - 141509245. Language: English. Entry Date: 20200205. Revision Date: 20200205. Publication Type: Article AU - Kikuchi, Chikara AU - Ohno, Mifuyu AU - Izumo, Takafumi AU - Takahashi, Satoru AU - Aoki, Masayuki AU - Shimomura, Hitoshi AU - Kawano, Yohei AU - Shimada, Shuji AU - Aoyama, Takao DB - ccm DO - 10.1007/s43441-019-00046-w DP - EBSCOhost IS - 1 KW - Drug Therapy, Combination Drug Approval -- Trends -- Japan Human Patients Pharmacists Hospitals Cardiovascular Agents Japan Questionnaires Surveys Hypertension -- Drug Therapy Asthma -- Drug Therapy Glaucoma -- Drug Therapy Pharmaceutical Companies -- Japan Medication Compliance Drugs, Prescription N1 - research; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 101597411. PY - 2020 SN - 2168-4790 SP - 200-210 ST - Investigation of Approval Trends and Benefits of New Fixed-Dose Combination Drugs in Japan T2 - Therapeutic Innovation & Regulatory Science TI - Investigation of Approval Trends and Benefits of New Fixed-Dose Combination Drugs in Japan UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141509245&site=ehost-live&scope=site VL - 54 ID - 4223 ER - TY - JOUR AB - Purpose: Data on glaucoma treatment barriers in South India is limited; improved knowledge of barriers could advance disease self-management. We aimed to understand glaucoma treatment barriers in South India. Methods: Glaucoma patients ≥18 taking ≥1 medication at the Aravind Eye Hospital were screened with a validated medication adherence tool. Patients who self-reported poor adherence and/or were >3 months late for follow-up completed semi-structured interviews on treatment barriers. Interviews were audio-recorded, transcribed, translated and back-translated to ensure accuracy. Researchers used grounded theory to code the transcripts and identify themes using NVivo 11.0. Demographic and clinical characteristics were abstracted from the medical record. Results: 70/167 (42%) had poor self-reported adherence to drops. The 45 interviewed were 62 ± 12 years and took 1.6 ± 0.7 drops. Forty-two (93%) were non-adherent to medication and 21 (47%) were late for follow-up. Top barriers to medication adherence were difficulty obtaining drops (20, 44%), being busy (18, 40%), and the expense (17, 38%). Top barriers to appointment follow-up were distance to the hospital (21, 47%), expense (20, 44%), and no escort (15, 33%). Other important barriers included mistrust in the health system, poor knowledge of glaucoma and family needs. Conclusions: Previously, 6% of glaucoma patients in South India self-reported poor medication adherence; the 42% identified in this study is in line with glaucoma medication adherence rates globally. Complex factors caused high rates of non-adherence. Societal-level interventions that address systemic barriers and counselling that supports patients’ and families’ motivation for behaviour change should be implemented. AD - P.A. Newman-Casey, Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI, United States AU - Killeen, O. J. AU - Pillai, M. R. AU - Udayakumar, B. AU - Shroff, S. AU - Vimalanathan, M. AU - Cho, J. AU - Newman-Casey, P. A. DB - Embase Medline DO - 10.1080/09286586.2019.1708121 IS - 3 KW - antiglaucoma agent eye drops adult article attitude to health clinical article drug cost female follow up glaucoma grounded theory human India male medication compliance middle aged patient compliance priority journal self report semi structured interview social responsibility social status traffic and transport LA - English M3 - Article N1 - L2004097446 2020-01-24 2020-04-07 PY - 2020 SN - 1744-5086 0928-6586 SP - 200-208 ST - Understanding Barriers to Glaucoma Treatment Adherence among Participants in South India T2 - Ophthalmic Epidemiology TI - Understanding Barriers to Glaucoma Treatment Adherence among Participants in South India UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004097446&from=export http://dx.doi.org/10.1080/09286586.2019.1708121 VL - 27 ID - 2406 ER - TY - JOUR AB - Purpose: Data on glaucoma treatment barriers in South India is limited; improved knowledge of barriers could advance disease self-management. We aimed to understand glaucoma treatment barriers in South India. Methods: Glaucoma patients ≥18 taking ≥1 medication at the Aravind Eye Hospital were screened with a validated medication adherence tool. Patients who self-reported poor adherence and/or were >3 months late for follow-up completed semi-structured interviews on treatment barriers. Interviews were audio-recorded, transcribed, translated and back-translated to ensure accuracy. Researchers used grounded theory to code the transcripts and identify themes using NVivo 11.0. Demographic and clinical characteristics were abstracted from the medical record. Results: 70/167 (42%) had poor self-reported adherence to drops. The 45 interviewed were 62 ± 12 years and took 1.6 ± 0.7 drops. Forty-two (93%) were non-adherent to medication and 21 (47%) were late for follow-up. Top barriers to medication adherence were difficulty obtaining drops (20, 44%), being busy (18, 40%), and the expense (17, 38%). Top barriers to appointment follow-up were distance to the hospital (21, 47%), expense (20, 44%), and no escort (15, 33%). Other important barriers included mistrust in the health system, poor knowledge of glaucoma and family needs. Conclusions: Previously, 6% of glaucoma patients in South India self-reported poor medication adherence; the 42% identified in this study is in line with glaucoma medication adherence rates globally. Complex factors caused high rates of non-adherence. Societal-level interventions that address systemic barriers and counselling that supports patients’ and families’ motivation for behaviour change should be implemented. © 2020, © 2020 Taylor & Francis Group, LLC. AD - Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, United States Aravind Eye Care System, Madurai, India AU - Killeen, O. J. AU - Pillai, M. R. AU - Udayakumar, B. AU - Shroff, S. AU - Vimalanathan, M. AU - Cho, J. AU - Newman-Casey, P. A. DB - Scopus DO - 10.1080/09286586.2019.1708121 IS - 3 KW - adherence Glaucoma M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2020 SP - 200-208 ST - Understanding Barriers to Glaucoma Treatment Adherence among Participants in South India T2 - Ophthalmic Epidemiology TI - Understanding Barriers to Glaucoma Treatment Adherence among Participants in South India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078589437&doi=10.1080%2f09286586.2019.1708121&partnerID=40&md5=3e028bfa3e6de71e2585e5eb47e6aab3 VL - 27 ID - 5494 ER - TY - JOUR AB - Purpose: Data on glaucoma treatment barriers in South India is limited; improved knowledge of barriers could advance disease self-management. We aimed to understand glaucoma treatment barriers in South India. Methods: Glaucoma patients >= 18 taking >= 1 medication at the Aravind Eye Hospital were screened with a validated medication adherence tool. Patients who self-reported poor adherence and/or were >3 months late for follow-up completed semi-structured interviews on treatment barriers. Interviews were audio-recorded, transcribed, translated and back-translated to ensure accuracy. Researchers used grounded theory to code the transcripts and identify themes using NVivo 11.0. Demographic and clinical characteristics were abstracted from the medical record. Results: 70/167 (42%) had poor self-reported adherence to drops. The 45 interviewed were 62 +/- 12 years and took 1.6 +/- 0.7 drops. Forty-two (93%) were non-adherent to medication and 21 (47%) were late for follow-up. Top barriers to medication adherence were difficulty obtaining drops (20, 44%), being busy (18, 40%), and the expense (17, 38%). Top barriers to appointment follow-up were distance to the hospital (21, 47%), expense (20, 44%), and no escort (15, 33%). Other important barriers included mistrust in the health system, poor knowledge of glaucoma and family needs. Conclusions: Previously, 6% of glaucoma patients in South India self-reported poor medication adherence; the 42% identified in this study is in line with glaucoma medication adherence rates globally. Complex factors caused high rates of non-adherence. Societal-level interventions that address systemic barriers and counselling that supports patients' and families' motivation for behaviour change should be implemented. AN - WOS:000507816700001 AU - Killeen, O. J. AU - Pillai, M. R. AU - Udayakumar, B. AU - Shroff, S. AU - Vimalanathan, M. AU - Cho, J. AU - Newman-Casey, P. A. DA - MAY 3 DO - 10.1080/09286586.2019.1708121 IS - 3 PY - 2020 SN - 0928-6586 1744-5086 SP - 200-208 ST - Understanding Barriers to Glaucoma Treatment Adherence among Participants in South India T2 - OPHTHALMIC EPIDEMIOLOGY TI - Understanding Barriers to Glaucoma Treatment Adherence among Participants in South India VL - 27 ID - 5816 ER - TY - JOUR AB - Précis:This observed patient-specific features and treatment-driven conditions that were significantly associated with the impairment of health-related quality of life (HRQOL) among glaucoma patients. The results suggest that more systematic strategies should be implemented to improve an HRQOL.Purpose:To determine factors contributing to an HRQOL and assess total, direct and indirect, effects that may exist between the determinants using path analysis.Materials and Methods:Data were derived from previous Korea glaucoma outcomes research. A total of 847 glaucoma outpatients with ≤2 years of eye-drop use were included in the present study. Including factors and their hypothetical pathways to an HRQOL were based on the literature review and consultation with specialists. Age, sex, comorbidities, and education levels were included as underlying conditions and treatment patterns were defined by the number of daily instillations of prescribed eye-drops. Treatment satisfaction and adherence were estimated using a Treatment Satisfaction Questionnaire for Medication, which assessed side-effects, effectiveness, convenience, global satisfaction, and pill count. An HRQOL was assessed by EQ-5D and EQ-visual analogue scale (EQ-VAS).Results:In EQ-5D analysis, male individuals showed total effects (β=0.102, P=0.0026), including both direct (β=0.076, P=0.0095) and indirect effects (β=0.0253, P=0.0020), which were mediated by treatment satisfaction in the side effects and global satisfaction categories. Higher education (β=0.197, P=0.0020) and satisfaction in the side effect (β=0.095, P=0.0076) and global satisfaction (β=0.075, P=0.0414) categories were found to have direct effects on EQ-5D. For EQ-VAS, higher education levels had significant total effects (β=0.153, P=0.0020) accounting for direct effects (β=0.131, P=0.0030) and indirect effects (β=0.0223, P=0.0531) through global satisfaction. In addition, male individuals had indirect effects (β=0.274, P=0.0165), which was indirectly mediated by satisfaction in the global satisfaction category. Comorbidity (β=-0.096, P=0.0090) and satisfaction in the effectiveness (β=0.094, P=0.0302), convenience (β=0.076, P=0.0390), and global satisfaction (β =0.144, P=0.0020) categories showed indirect effect on EQ-VAS.Conclusion:Higher education and better treatment satisfaction had positive effects on HRQOL both in direct and indirect ways whereas comorbidities indirectly showed negative associations with HRQOL. AD - K.H. Park, Department of Ophthalmology, Seoul National University Hospital, Seoul, South Korea AU - Kim, C. Y. AU - Park, K. H. AU - Ahn, J. AU - Ahn, M. D. AU - Cha, S. C. AU - Kim, H. S. AU - Kim, J. M. AU - Kim, M. J. AU - Kim, T. W. AU - Kim, Y. Y. AU - Lee, J. W. AU - Park, S. W. AU - Sohn, Y. H. AU - Sung, K. R. AU - Yoo, C. AU - Cha, J. H. AU - Kim, Y. J. AU - Lee, J. AU - Choi, J. DB - Embase Medline DO - 10.1097/IJG.0000000000001312 IS - 9 KW - eye drops adult age article comorbidity educational status European Quality of Life 5 Dimensions 5 Level questionnaire female glaucoma human Korean (people) major clinical study male outcomes research outpatient patient attitude patient compliance patient satisfaction priority journal quality of life questionnaire sex visual analog scale LA - English M3 - Article N1 - L628408672 2019-07-11 2019-09-24 PY - 2019 SN - 1536-481X 1057-0829 SP - 785-789 ST - A Path Analysis of Effects of Patients' Underlying Conditions, Treatment Satisfaction, and Adherence on Quality of Life among Korea Glaucoma Patients T2 - Journal of Glaucoma TI - A Path Analysis of Effects of Patients' Underlying Conditions, Treatment Satisfaction, and Adherence on Quality of Life among Korea Glaucoma Patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628408672&from=export http://dx.doi.org/10.1097/IJG.0000000000001312 VL - 28 ID - 2485 ER - TY - JOUR AB - Purpose: To compare the therapeutic efficacy and safety of newly developed preservative-free (PF) brimonidine/timolol fixed-combination (BTFC) ophthalmic solutions and a preservative-containing (PC) BTFC ophthalmic solution in patients with open-angle glaucoma.Methods: This study was conducted as a multicenter, randomized, open-label, parallel-group clinical trial to evaluate the efficacy and safety of PF BTFC as compared with PC BTFC in adult patients (aged ≥ 19 years) with open-angle glaucoma (OAG) and ocular hypertension (OHT). A total of the 106 patients were enrolled, with 53 patients each randomized to the two treatment groups and included in the analysis of the safety set (SS).After a washout period, patients with an IOP below 35 mmHg at 9 a.m. were enrolled. After a full ophthalmic and glaucoma examination, a total of 106 OAG and OHT patients were randomized to the PF group or PC group.All subjects were examined 4 and 12 weeks after first administration. At each follow-up visit, IOP was measured at 9 a.m. and 11 a.m. and the efficacy, safety, and compliance were evaluated. Throughout the study, all adverse events were recorded and monitored by the investigators.Results The mean IOP changes from baseline to 12 weeks at 11:00 a.m. were -3.45 ± 2.53 mmHg in the PF group and -3.65 ± 2.76 mmHg in the PC group (p < .0001 for both). The difference in mean IOP change between the two groups was 0.20 ± 2.65 mmHg, which was not significantly different. The proportion of patients with IOP reductions of ≥ 15% and ≥ 20% and IOP at all-time points in the PF group were not significantly different when compared with in the PC group. There were no specific differences between the two groups regarding the incidence of adverse events.Conclusions PF BTFC ophthalmic solution shows a similar efficacy and safety profile to that of PC BTFC. AD - Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea Department of Ophthalmology, Chungnam National University Hospital, Daejeon, Republic of Korea Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea Department of Ophthalmology, Severance Hospital Institute of Vision Research, Yonsei University College of Medicine, Seoul, Republic of Korea AN - 149843412. Language: English. Entry Date: In Process. Revision Date: 20210715. Publication Type: journal article. Journal Subset: Biomedical AU - Kim, Joon Mo AU - Kim, Tae-Woo AU - Park, Sang-Woo AU - Park, Hae-Young Lopilly AU - Hwang, Young Hoon AU - Jeoung, Jin Wook AU - Kim, Chan Yun DB - ccm DO - 10.1080/08820538.2021.1885722 DP - EBSCOhost IS - 3 N1 - Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8610759. PMID: NLM33734910. PY - 2021 SN - 0882-0538 SP - 103-109 ST - Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma T2 - Seminars in Ophthalmology TI - Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149843412&site=ehost-live&scope=site VL - 36 ID - 4150 ER - TY - JOUR AB - Purpose: To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5 % timolol ophthalmic solution in normal-tension glaucoma (NTG) patients. Methods: This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients—55 undergoing therapy with BTFC and 55 0.5 %, with timolol—participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70 %. Ultimately, a total of 95 patients—48 in the BTFC group and 47 in the 0.5 % timolol group—completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators. Results: The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 ± 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5 % timolol group. The ratio of patients whose average IOP had decreased by >20 % after 4 and 12 weeks was 50 and 56 % in the BTFC group, respectively, whereas it was 29.41 and 23.53 % in the 0.5 % timolol group, respectively (p = 0.034, <0.001). Conclusions: BTFC has a superior IOP-lowering effect than 0.5 % timolol in NTG patients. © 2015, Japanese Ophthalmological Society. AD - Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea Department of Ophthalmology, Myung-Gok Eye Research Institute, Kim’s Eye Hospital, Konyang University College of Medicine, Seoul, South Korea Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea AU - Kim, J. M. AU - Kim, T. W. AU - Kim, C. Y. AU - Kim, H. K. AU - Park, K. H. DB - Scopus DO - 10.1007/s10384-015-0420-2 IS - 1 KW - 0.5 % timolol Brimonidine/timolol fixed combination Drug efficacy Normal-tension glaucoma M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2016 SP - 20-26 ST - Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients T2 - Japanese Journal of Ophthalmology TI - Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84954398226&doi=10.1007%2fs10384-015-0420-2&partnerID=40&md5=14b0da4a83e04c99bea185f48cb12762 VL - 60 ID - 5420 ER - TY - JOUR AB - Purpose To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5 % timolol ophthalmic solution in normal-tension glaucoma (NTG) patients. Methods This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients-55 undergoing therapy with BTFC and 55 0.5 %, with timolol-participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70 %. Ultimately, a total of 95 patients-48 in the BTFC group and 47 in the 0.5 % timolol group-completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators. Results The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 +/- 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5 % timolol group. The ratio of patients whose average IOP had decreased by[20 % after 4 and 12 weeks was 50 and 56 % in the BTFC group, respectively, whereas it was 29.41 and 23.53 % in the 0.5 % timolol group, respectively (p = 0.034, <0.001). Conclusions BTFC has a superior IOP-lowering effect than 0.5 % timolol in NTG patients. AN - WOS:000371274900004 AU - Kim, J. M. AU - Kim, T. W. AU - Kim, C. Y. AU - Kim, H. K. AU - Park, K. H. DA - JAN DO - 10.1007/s10384-015-0420-2 IS - 1 PY - 2016 SN - 0021-5155 1613-2246 SP - 20-26 ST - Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients T2 - JAPANESE JOURNAL OF OPHTHALMOLOGY TI - Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients VL - 60 ID - 6017 ER - TY - JOUR AB - Purpose: To compare the therapeutic efficacy and safety of newly developed preservative-free (PF) brimonidine/timolol fixed-combination (BTFC) ophthalmic solutions and a preservative-containing (PC) BTFC ophthalmic solution in patients with open-angle glaucoma. Methods: This study was conducted as a multicenter, randomized, open-label, parallel-group clinical trial to evaluate the efficacy and safety of PF BTFC as compared with PC BTFC in adult patients (aged ≥ 19 years) with open-angle glaucoma (OAG) and ocular hypertension (OHT). A total of the 106 patients were enrolled, with 53 patients each randomized to the two treatment groups and included in the analysis of the safety set (SS). After a washout period, patients with an IOP below 35 mmHg at 9 a.m. were enrolled. After a full ophthalmic and glaucoma examination, a total of 106 OAG and OHT patients were randomized to the PF group or PC group. All subjects were examined 4 and 12 weeks after first administration. At each follow-up visit, IOP was measured at 9 a.m. and 11 a.m. and the efficacy, safety, and compliance were evaluated. Throughout the study, all adverse events were recorded and monitored by the investigators. Results The mean IOP changes from baseline to 12 weeks at 11:00 a.m. were −3.45 ± 2.53 mmHg in the PF group and −3.65 ± 2.76 mmHg in the PC group (p < .0001 for both). The difference in mean IOP change between the two groups was 0.20 ± 2.65 mmHg, which was not significantly different. The proportion of patients with IOP reductions of ≥ 15% and ≥ 20% and IOP at all-time points in the PF group were not significantly different when compared with in the PC group. There were no specific differences between the two groups regarding the incidence of adverse events. Conclusions PF BTFC ophthalmic solution shows a similar efficacy and safety profile to that of PC BTFC. © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. AD - Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital, Gwangju, South Korea Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea Department of Ophthalmology, Chungnam National University Hospital, Daejeon, South Korea Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea Department of Ophthalmology, Severance Hospital Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea AU - Kim, J. M. AU - Kim, T. W. AU - Park, S. W. AU - Park, H. Y. L. AU - Hwang, Y. H. AU - Jeoung, J. W. AU - Kim, C. Y. DB - Scopus DO - 10.1080/08820538.2021.1885722 IS - 3 KW - brimonidine/timolol fixed combination intraocular pressure normal-tension glaucoma Open-angle glaucoma preservative-free M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 103-109 ST - Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma T2 - Seminars in Ophthalmology TI - Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102870933&doi=10.1080%2f08820538.2021.1885722&partnerID=40&md5=c47eab09a549eec34820bf342eea357a VL - 36 ID - 5675 ER - TY - JOUR AB - Purpose: To compare the therapeutic efficacy and safety of newly developed preservative-free (PF) brimonidine/timolol fixed-combination (BTFC) ophthalmic solutions and a preservative-containing (PC) BTFC ophthalmic solution in patients with open-angle glaucoma. Methods: This study was conducted as a multicenter, randomized, open-label, parallel-group clinical trial to evaluate the efficacy and safety of PF BTFC as compared with PC BTFC in adult patients (aged >= 19 years) with open-angle glaucoma (OAG) and ocular hypertension (OHT). A total of the 106 patients were enrolled, with 53 patients each randomized to the two treatment groups and included in the analysis of the safety set (SS). After a washout period, patients with an IOP below 35 mmHg at 9 a.m. were enrolled. After a full ophthalmic and glaucoma examination, a total of 106 OAG and OHT patients were randomized to the PF group or PC group. All subjects were examined 4 and 12 weeks after first administration. At each follow-up visit, IOP was measured at 9 a.m. and 11 a.m. and the efficacy, safety, and compliance were evaluated. Throughout the study, all adverse events were recorded and monitored by the investigators. Results The mean IOP changes from baseline to 12 weeks at 11:00 a.m. were -3.45 +/- 2.53 mmHg in the PF group and -3.65 +/- 2.76 mmHg in the PC group (p < .0001 for both). The difference in mean IOP change between the two groups was 0.20 +/- 2.65 mmHg, which was not significantly different. The proportion of patients with IOP reductions of >= 15% and >= 20% and IOP at all-time points in the PF group were not significantly different when compared with in the PC group. There were no specific differences between the two groups regarding the incidence of adverse events. Conclusions PF BTFC ophthalmic solution shows a similar efficacy and safety profile to that of PC BTFC. AN - WOS:000630309300001 AU - Kim, J. M. AU - Kim, T. W. AU - Park, S. W. AU - Park, H. Y. L. AU - Hwang, Y. H. AU - Jeoung, J. W. AU - Kim, C. Y. DA - APR 3 DO - 10.1080/08820538.2021.1885722 IS - 3 PY - 2021 SN - 0882-0538 1744-5205 SP - 103-109 ST - Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma T2 - SEMINARS IN OPHTHALMOLOGY TI - Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma VL - 36 ID - 6057 ER - TY - JOUR AB - Purpose: To evaluate the therapeutic effect of oral steroids given to patients younger than 3 years with epidemic keratoconjunctivitis (EKC) accompanied by severe eyelid edema and inflammatory ptosis, in whom eye drops were not feasible. Methods: This study included 9 patients treated for EKC in local clinics whose condition failed to improve due to severe eyelid swelling together with difficulties in application of eye drops and pseudomembrane removal. We analyzed the extent of eyelid swelling, corneal damage, follicles, chemosis, and pseudomembrane formation in these patients before and after oral corticosteroid therapy in collaboration with the pediatrics department. Results: After a mean of 1.8 ± 0.7 days of oral steroid treatment, eyelid edema, corneal damage, conjunctival injection, follicles, and chemosis improved in all patients. Conclusions: Oral steroids are an effective adjuvant treatment for EKC in patients younger than 3 years in whom eye drops could not be administered frequently due to severe eyelid edema. Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology and Visual Science, College of Medicine, Catholic University of Korea, 271 Cheonbo-ro, Seoul, Uijeongbu-si, Gyeonggi-do, 480-717, South Korea AU - Kim, S. Y. AU - Chung, Y. K. AU - Lee, Y. C. AU - Kim, S. Y. DB - Scopus DO - 10.1097/ICO.0000000000000332 IS - 2 KW - Epidemic keratoconjunctivitis Oral steroid M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2015 SP - 182-187 ST - Oral steroid therapy as an adjuvant treatment for severe epidemic keratoconjunctivitis in patients younger than 3 years T2 - Cornea TI - Oral steroid therapy as an adjuvant treatment for severe epidemic keratoconjunctivitis in patients younger than 3 years UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925819108&doi=10.1097%2fICO.0000000000000332&partnerID=40&md5=03d38ac508d856c4a034decfadf2a766 VL - 34 ID - 5467 ER - TY - JOUR AB - Background/aims To assess the reasons and factors for discontinuation of follow-up among patients with glaucoma at a tertiary referral teaching hospital in Seoul, Korea. Methods We identified all adult patients with glaucoma (≥18years), who had visited the glaucoma clinic of Seoul National University Hospital between April 2012 and March 2014 and had missed an appointment by at least 12months. These patients were traced via cellular phone, and their true status and reasons for discontinuation of follow-up were documented. Results A total of 6848 patients with glaucoma (3512 men and 3336 women) were considered. Among them, 247 (3.61%) had missed a scheduled appointment by 12months or more. Among 230 (93.1%) who were successfully traced, 4 (1.7%) had died and 96 (41.7%) had self-transferred to another glaucoma clinic. Of the 130 patients left, 123 (94.6%) had treatment and follow-up interruptions, and 7 (5.4%) had been treated with alternative medicine. The two main reasons cited for treatment and follow-up interruptions were lack of understanding regarding the necessity of follow-up (46.3%) and unawareness of appointment schedule (30.9%). In stepwise linear regression analysis, older age (p=0.001. β=0.13), male gender (p=0.013, β=0.08) and lower baseline intraocular pressure (p=0.005, β=0.11) were independently associated with follow-up loss involving treatment interruptions. Conclusions This study's results emphasise the need for ongoing educational support and improved appointment notification, especially for the elderly, men and patients with low baseline intraocular pressure. AD - K.H. Park, Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Chongno-gu, Seoul, South Korea AU - Kim, Y. K. AU - Jeoung, J. W. AU - Park, K. H. DB - Embase Medline DO - 10.1136/bjophthalmol-2016-309103 IS - 8 KW - adult aging alternative medicine article controlled study female follow up glaucoma hospital management human intraocular pressure Korea major clinical study male mobile phone priority journal sex difference tertiary care center LA - English M3 - Article N1 - L613865702 2016-12-29 2017-07-31 PY - 2017 SN - 1468-2079 0007-1161 SP - 1059-1065 ST - Understanding the reasons for loss to follow-up in patients with glaucoma at a tertiary referral teaching hospital in Korea T2 - British Journal of Ophthalmology TI - Understanding the reasons for loss to follow-up in patients with glaucoma at a tertiary referral teaching hospital in Korea UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613865702&from=export http://dx.doi.org/10.1136/bjophthalmol-2016-309103 VL - 101 ID - 2637 ER - TY - JOUR AB - Background/aims To assess the reasons and factors for discontinuation of follow-up among patients with glaucoma at a tertiary referral teaching hospital in Seoul, Korea. Methods We identified all adult patients with glaucoma (≥18years), who had visited the glaucoma clinic of Seoul National University Hospital between April 2012 and March 2014 and had missed an appointment by at least 12months. These patients were traced via cellular phone, and their true status and reasons for discontinuation of follow-up were documented. Results A total of 6848 patients with glaucoma (3512 men and 3336 women) were considered. Among them, 247 (3.61%) had missed a scheduled appointment by 12months or more. Among 230 (93.1%) who were successfully traced, 4 (1.7%) had died and 96 (41.7%) had self-transferred to another glaucoma clinic. Of the 130 patients left, 123 (94.6%) had treatment and follow-up interruptions, and 7 (5.4%) had been treated with alternative medicine. The two main reasons cited for treatment and follow-up interruptions were lack of understanding regarding the necessity of follow-up (46.3%) and unawareness of appointment schedule (30.9%). In stepwise linear regression analysis, older age (p=0.001. β=0.13), male gender (p=0.013, β=0.08) and lower baseline intraocular pressure (p=0.005, β=0.11) were independently associated with follow-up loss involving treatment interruptions. Conclusions This study's results emphasise the need for ongoing educational support and improved appointment notification, especially for the elderly, men and patients with low baseline intraocular pressure. © 2017 Published by the BMJ Publishing Group Limited. AD - Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Chongno-gu, Seoul, 110-744, South Korea Department of Ophthalmology, Seoul National University, College of Medicine, Seoul, South Korea AU - Kim, Y. K. AU - Jeoung, J. W. AU - Park, K. H. DB - Scopus DO - 10.1136/bjophthalmol-2016-309103 IS - 8 KW - Glaucoma Public health M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2017 SP - 1059-1065 ST - Understanding the reasons for loss to follow-up in patients with glaucoma at a tertiary referral teaching hospital in Korea T2 - British Journal of Ophthalmology TI - Understanding the reasons for loss to follow-up in patients with glaucoma at a tertiary referral teaching hospital in Korea UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006999411&doi=10.1136%2fbjophthalmol-2016-309103&partnerID=40&md5=cb486d431b953ce72ddc04ea6aca9c76 VL - 101 ID - 5374 ER - TY - JOUR AB - Background/aims To assess the reasons and factors for discontinuation of follow-up among patients with glaucoma at a tertiary referral teaching hospital in Seoul, Korea. Methods We identified all adult patients with glaucoma (>= 18 years), who had visited the glaucoma clinic of Seoul National University Hospital between April 2012 and March 2014 and had missed an appointment by at least 12 months. These patients were traced via cellular phone, and their true status and reasons for discontinuation of follow-up were documented. Results A total of 6848 patients with glaucoma (3512 men and 3336 women) were considered. Among them, 247 (3.61%) had missed a scheduled appointment by 12 months or more. Among 230 (93.1%) who were successfully traced, 4 (1.7%) had died and 96 (41.7%) had self-transferred to another glaucoma clinic. Of the 130 patients left, 123 (94.6%) had treatment and follow-up interruptions, and 7 (5.4%) had been treated with alternative medicine. The two main reasons cited for treatment and follow-up interruptions were lack of understanding regarding the necessity of follow-up (46.3%) and unawareness of appointment schedule (30.9%). In stepwise linear regression analysis, older age (p=0.001. beta=0.13), male gender (p=0.013, beta=0.08) and lower baseline intraocular pressure (p=0.005, beta=0.11) were independently associated with follow-up loss involving treatment interruptions. Conclusions This study's results emphasise the need for ongoing educational support and improved appointment notification, especially for the elderly, men and patients with low baseline intraocular pressure. AN - WOS:000405672100011 AU - Kim, Y. K. AU - Jeoung, J. W. AU - Park, K. H. DA - AUG DO - 10.1136/bjophthalmol-2016-309103 IS - 8 PY - 2017 SN - 0007-1161 1468-2079 SP - 1059-1065 ST - Understanding the reasons for loss to follow-up in patients with glaucoma at a tertiary referral teaching hospital in Korea T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - Understanding the reasons for loss to follow-up in patients with glaucoma at a tertiary referral teaching hospital in Korea VL - 101 ID - 5826 ER - TY - JOUR AD - S.L. Mansberger, Devers Eye Institute, 1040 NW 22nd Ave, Suite 200, Portland, OR, United States AU - Kinast, R. M. AU - Mansberger, S. L. DB - Embase Medline DO - 10.1016/j.ajo.2018.04.002 KW - antiglaucoma agent eye drops drug approval drug cost drug delivery system editorial Food and Drug Administration glaucoma health behavior history of medicine human medical decision making oral drug administration patient attitude patient compliance patient monitoring physician priority journal LA - English M3 - Editorial N1 - L2000715806 2018-05-08 2018-07-05 PY - 2018 SN - 1879-1891 0002-9394 SP - xiii-xv ST - Glaucoma Adherence—From Theriac to the Future T2 - American Journal of Ophthalmology TI - Glaucoma Adherence—From Theriac to the Future UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2000715806&from=export http://dx.doi.org/10.1016/j.ajo.2018.04.002 VL - 191 ID - 2575 ER - TY - JOUR AD - A. King, Nottingham University Hospital, University of Nottingham, Nottingham NG7 2UH, United Kingdom AU - King, A. AU - Azuara-Blanco, A. AU - Tuulonen, A. DB - Embase Medline DO - 10.1136/bmj.f3518 IS - 7912 KW - antiglaucoma agent eye drops prostaglandin blindness cataract extraction clinical feature closed angle glaucoma cost effectiveness analysis disease classification disease course drug safety eye photography genetic association glaucoma human intraocular hypertension intraocular pressure iridectomy laser surgery low level laser therapy open angle glaucoma patient compliance priority journal review screening test trabeculectomy trabeculoplasty unspecified side effect vision test visual acuity LA - English M3 - Review N1 - L369152523 2013-06-28 2013-07-08 PY - 2013 SN - 1756-1833 ST - Glaucoma T2 - BMJ (Online) TI - Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369152523&from=export http://dx.doi.org/10.1136/bmj.f3518 http://www.bmj.com/highwire/filestream/649393/field_highwire_article_pdf/0/bmj.f3518.full.pdf VL - 346 ID - 2989 ER - TY - JOUR AD - T. Kish, Long Island University, LIU Pharmacy (Arnold and Marie Schwartz College of Pharmacy and Health Sciences), Brooklyn, NY, United States AU - Kish, T. C1 - alphagan betagan betoptic bimatoprost sr(Allergan) de 117(Santen) diamox iopidine lumigan neptazane otx tp(Ocular Therapeutix) pilopine rhopressa(Aerie) roclatan(Aerie) timoptic travatan z trusopt vyzulta xalatan zioptan C2 - Aerie Allergan Ocular Therapeutix Santen DB - Embase IS - 8 KW - acetazolamide apraclonidine betaxolol bimatoprost bimatoprost sr brimonidine dorzolamide latanoprost latanoprostene bunod levobunolol methazolamide netarsudil omidenepag isopropyl otx tp pilocarpine latanoprost plus netarsudil tafluprost timolol timolol maleate travoprost blurred vision canaliculitis conjunctival hemorrhage conjunctival hyperemia drug delivery system eye pain eyelid edema glaucoma human intraocular pressure monotherapy note patient compliance patient safety phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) randomized controlled trial (topic) trabeculoplasty alphagan betagan betoptic de 117 diamox iopidine lumigan neptazane pilopine rhopressa roclatan timoptic travatan z trusopt vyzulta xalatan zioptan LA - English M3 - Note N1 - L623428770 2018-08-15 2018-08-17 PY - 2018 SN - 1052-1372 SP - 489-502 ST - Old and new drug classes expanding to include glaucoma treatments T2 - P and T TI - Old and new drug classes expanding to include glaucoma treatments UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623428770&from=export VL - 43 ID - 2572 ER - TY - JOUR AB - Poor patient adherence is fueling keen interest in the development of drugs for glaucoma management. Several long-acting formulations of existing medications are in the early stages of development, as are new therapeutic classes such as guanylate cyclase activators. AD - Associate Professor of Pharmacy Practice at Long Island University, LIU Pharmacy (Arnold and Marie Schwartz College of Pharmacy and Health Sciences), in Brooklyn, New York. AN - 131008995. Language: English. Entry Date: 20180804. Revision Date: 20201001. Publication Type: journal article AU - Kish, Troy DB - ccm DP - EBSCOhost IS - 8 KW - Drugs, Investigational Glaucoma -- Drug Therapy United States Food and Drug Administration Ophthalmic Solutions Dose-Response Relationship, Drug Latanoprost Intraocular Pressure Patient Compliance Enzymes Bimatoprost Prostheses and Implants Eye N1 - tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9015516. PMID: NLM30100690. PY - 2018 SN - 1052-1372 SP - 489-502 ST - Old and New Drug Classes Expanding To Include Glaucoma Treatments T2 - P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management TI - Old and New Drug Classes Expanding To Include Glaucoma Treatments UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131008995&site=ehost-live&scope=site VL - 43 ID - 4169 ER - TY - JOUR AD - Y. Kiuchi AU - Kiuchi, Y. DB - Medline IS - 12 KW - doctor patient relationship drug administration editorial glaucoma human interpersonal communication patient compliance patient education psychological aspect LA - Japanese M3 - Editorial N1 - L364539615 2012-04-05 PY - 2011 SN - 0029-0203 SP - 1069-1071 ST - [Adherence] T2 - Nippon Ganka Gakkai zasshi TI - [Adherence] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364539615&from=export VL - 115 ID - 3129 ER - TY - JOUR AB - Purpose: To identify the prevalence of ophthalmologic diseases in elderly patients who had been classified as severely disabled and to identify the ophthalmologic conditions leading to visual impairment and blindness. Methods: The medical records of 2806 patients who had applied to the Health Board of the Erzurum Region Training and Research Hospital between January 2011 and December 2012 were reviewed. One hundred ninety-nine patients aged >64 years who were classified as severely disabled with disability rates of over 50%, and who were unable to care for themselves or to move and/or communicate without help were included in the study. Results: The most frequently seen disabilities were neurological (47.2%) and those resulting from eye diseases (17.1%). The most common ophthalmologic diseases were cataract, glaucoma, and age-related macular degeneration. The mean right and left eye visual acuities were 1.17 +/- 1.10 logMAR and 1.13 +/- 1.0 logMAR, respectively. Of the 60 patients with ophthalmologic diseases or conditions, 33 were blind (visual acuity worse than 20/400) and 10 were visually impaired (visual acuity worse than 20/70 but better than 20/400). Cataracts were the main cause of blindness. The mean age of the patients who were still being followed up at the time of application to the disability board was significantly lower than that of the others (p=0.015). Seventy-nine percent of the blind patients were from rural areas, and 88% of these had no regular follow-up. Among the blind and visually impaired, significantly more patients from urban areas had social security insurance (SSI) than those from rural areas (p-0.043). Nearly 64% of the blind patients were women. The follow-up rate was significantly lower in women (p=0.025). According to multinomial logistic regression analysis, the visually impaired and blind patients were more likely to have lower follow-up rates than the other types of severely disabled patients (OR: 0.231, 95% CI: 0.077-0.688, p=0.009). Conclusions: Blindness gives rise to severe disability, and the most common ophthalmologic diseases that cause severe disabilities in elderly patients are cataract, glaucoma, and age-related macular degeneration. Sociodemographic factors that may affect the accessibility of visually impaired and blind people to health services include their place of residence and gender. AN - WOS:000369656700008 AU - Kivanc, S. A. AU - Akova-Budak, B. AU - Olcaysu, O. O. AU - Cevik, S. G. DA - JAN-FEB DO - 10.5935/0004-2749.20160008 IS - 1 PY - 2016 SN - 0004-2749 1678-2925 SP - 24-29 ST - Sociodemographic status of severely disabled and visually impaired elderly people in Turkey T2 - ARQUIVOS BRASILEIROS DE OFTALMOLOGIA TI - Sociodemographic status of severely disabled and visually impaired elderly people in Turkey VL - 79 ID - 6209 ER - TY - JOUR AB - Purpose: To identify the prevalence of ophthalmologic diseases in elderly patients who had been classified as severely disabled and to identify the ophthalmologic conditions leading to visual impairment and blindness. Methods: The medical records of 2806 patients who had applied to the Health Board of the Erzurum Region Training and Research Hospital between January 2011 and December 2012 were reviewed. One hundred ninety-nine patients aged >64 years who were classified as severely disabled with disability rates of over 50%, and who were unable to care for themselves or to move and/or communicate without help were included in the study. Results: The most frequently seen disabilities were neurological (47.2%) and those resulting from eye diseases (17.1%). The most common ophthalmologic diseases were cataract, glaucoma, and age-related macular degeneration. The mean right and left eye visual acuities were 1.17 ± 1.10 logMAR and 1.13 ± 1.0 logMAR, respectively. Of the 60 patients with ophthalmologic diseases or conditions, 33 were blind (visual acuity worse than 20/400) and 10 were visually impaired (visual acuity worse than 20/70 but better than 20/400). Cataracts were the main cause of blindness. The mean age of the patients who were still being followed up at the time of application to the disability board was significantly lower than that of the others (p=0.015). Seventy-nine percent of the blind patients were from rural areas, and 88% of these had no regular follow-up. Among the blind and visually impaired, significantly more patients from urban areas had social security insurance (SSI) than those from rural areas (p=0.043). Nearly 64% of the blind patients were women. The follow-up rate was significantly lower in women (p=0.025). According to multinomial logistic regression analysis, the visually impaired and blind patients were more likely to have lower follow-up rates than the other types of severely disabled patients (OR: 0.231, 95% Cl: 0.077-0.688, p=0.009). Conclusions: Blindness gives rise to severe disability, and the most common ophthalmologic diseases that cause severe disabilities in elderly patients are cataract, glaucoma, and age-related macular degeneration. Sociodemographic factors that may affect the accessibility of visually impaired and blind people to health services include their place of residence and gender. AD - Department of Ophthalmology, Erzurum Region Training and Research Hospital, Erzurum, Turkey Department of Ophthalmology, School of Medicine, Uludag University, Bursa, Turkey Department of Ophthalmology, Sevket Yilmaz Training and Research Hospital, Bursa, Turkey AU - Kivanç, S. A. AU - Akova-Budak, B. AU - Olcaysü, O. O. AU - Görkem Çevik, S. DB - Scopus DO - 10.5935/0004-2749.20160008 IS - 1 KW - Aging Blindness Cataract Disabled people M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2016 SP - 24-29 ST - Sociodemographic status of severely disabled and visually impaired elderly people in Turkey T2 - Arquivos Brasileiros de Oftalmologia TI - Sociodemographic status of severely disabled and visually impaired elderly people in Turkey UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957894959&doi=10.5935%2f0004-2749.20160008&partnerID=40&md5=b39cdc5a803d75d5ec86cc7fb97b9cb7 VL - 79 ID - 5419 ER - TY - JOUR AB - Purpose: To determine uptake, adherence and influencing factors to follow-up care by newly diagnosed glaucoma patients from free eye screening exercise. Methods: The study was a cross-sectional survey of newly diagnosed glaucoma patients during free eye screenings carried out in March and October, 2016 in Enugu, Nigeria. Data on participants were analyzed after a minimum of 6 months from the screening for uptake and adherence to follow-up care. Qualifying patients had questionnaires administered to them by phone interview. Information requested regards awareness, knowledge on diagnosis as well as reasons for non-uptake and non-adherence. Results: 182 newly diagnosed glaucoma patients were included of which 121 (66.5%) were males, with median age of 50years.About 164 (90.1%) had at least a primary education. There were more self- employed persons 59 (32.4%) compared to other occupations. Uptake of follow up care was 17.6% (32/182). Adherence rate was 25% (8/32). Major reasons for non-uptake were lack of funds 54.9% (n = 50/91), distance 11% (n = 10/91) and receiving care from other facilities 11.0% (n = 10/91). Others include discourteous staff behavior and lack of information on diagnosis. Similarly, major reasons for non-adherence were lack of funds 44.4% (n = 8/18) and distance 22.2% (n = 4/18). Knowledge and prior awareness of glaucoma were found to be significantly associated with uptake of follow up care (p = 0.020). Conclusion: Uptake and adherence to follow-up was found to be low in this study population mainly attributed to cost, distance and poor knowledge of glaucoma natural history. Reviewing cost/out of pocket expenditure, providing care closer to patients, adequate education of staff and patients may significantly improve uptake of care after initial diagnosis. AD - N.N. Kizor-Akaraiwe, 11 Church view GRA P.O Box 400009, Enugu, Enugu State, Nigeria AU - Kizor-Akaraiwe, N. N. DB - Embase Medline DO - 10.1080/09286586.2018.1555263 IS - 2 KW - adult article awareness clinical evaluation comparative study controlled study cross-sectional study educational status employment eye examination female follow up glaucoma health survey human major clinical study male medical care medical information medication compliance Nigeria priority journal screening test treatment duration visual acuity LA - English M3 - Article N1 - L625410302 2018-12-17 2019-03-29 PY - 2019 SN - 1744-5086 0928-6586 SP - 140-146 ST - Follow-up and adherence to glaucoma care by newly diagnosed glaucoma patients in enugu, nigeria T2 - Ophthalmic Epidemiology TI - Follow-up and adherence to glaucoma care by newly diagnosed glaucoma patients in enugu, nigeria UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625410302&from=export http://dx.doi.org/10.1080/09286586.2018.1555263 VL - 26 ID - 2516 ER - TY - JOUR AB - Purpose: To determine uptake, adherence and influencing factors to follow-up care by newly diagnosed glaucoma patients from free eye screening exercise. Methods: The study was a cross-sectional survey of newly diagnosed glaucoma patients during free eye screenings carried out in March and October, 2016 in Enugu, Nigeria. Data on participants were analyzed after a minimum of 6 months from the screening for uptake and adherence to follow-up care. Qualifying patients had questionnaires administered to them by phone interview. Information requested regards awareness, knowledge on diagnosis as well as reasons for non-uptake and non-adherence. Results: 182 newly diagnosed glaucoma patients were included of which 121 (66.5%) were males, with median age of 50years.About 164 (90.1%) had at least a primary education. There were more self- employed persons 59 (32.4%) compared to other occupations. Uptake of follow up care was 17.6% (32/182). Adherence rate was 25% (8/32). Major reasons for non-uptake were lack of funds 54.9% (n = 50/91), distance 11% (n = 10/91) and receiving care from other facilities 11.0% (n = 10/91). Others include discourteous staff behavior and lack of information on diagnosis. Similarly, major reasons for non-adherence were lack of funds 44.4% (n = 8/18) and distance 22.2% (n = 4/18). Knowledge and prior awareness of glaucoma were found to be significantly associated with uptake of follow up care (p = 0.020). Conclusion: Uptake and adherence to follow-up was found to be low in this study population mainly attributed to cost, distance and poor knowledge of glaucoma natural history. Reviewing cost/out of pocket expenditure, providing care closer to patients, adequate education of staff and patients may significantly improve uptake of care after initial diagnosis. © 2018, © 2018 Taylor & Francis Group, LLC. AD - College of Medicine, Enugu State University of Technology(ESUT), Enugu State University of Science and Technology (ESUT) Teaching Hospital Parklane, The Eye Specialists Hospital (TESH), Enugu, Nigeria AU - Kizor-Akaraiwe, N. N. DB - Scopus DO - 10.1080/09286586.2018.1555263 IS - 2 KW - adherence eye screening Follow up glaucoma care M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2019 SP - 140-146 ST - Follow-up and adherence to glaucoma care by newly diagnosed glaucoma patients in enugu, nigeria T2 - Ophthalmic Epidemiology TI - Follow-up and adherence to glaucoma care by newly diagnosed glaucoma patients in enugu, nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058155877&doi=10.1080%2f09286586.2018.1555263&partnerID=40&md5=07de0c045ee62ed59a6096d4104aacc3 VL - 26 ID - 5613 ER - TY - JOUR AB - Purpose: To determine uptake, adherence and influencing factors to follow-up care by newly diagnosed glaucoma patients from free eye screening exercise. Methods: The study was a cross-sectional survey of newly diagnosed glaucoma patients during free eye screenings carried out in March and October, 2016 in Enugu, Nigeria. Data on participants were analyzed after a minimum of 6 months from the screening for uptake and adherence to follow-up care. Qualifying patients had questionnaires administered to them by phone interview. Information requested regards awareness, knowledge on diagnosis as well as reasons for non-uptake and non-adherence. Results: 182 newly diagnosed glaucoma patients were included of which 121 (66.5%) were males, with median age of 50years.About 164 (90.1%) had at least a primary education. There were more self- employed persons 59 (32.4%) compared to other occupations. Uptake of follow up care was 17.6% (32/182). Adherence rate was 25% (8/32). Major reasons for non-uptake were lack of funds 54.9% (n = 50/91), distance 11% (n = 10/91) and receiving care from other facilities 11.0% (n = 10/91). Others include discourteous staff behavior and lack of information on diagnosis. Similarly, major reasons for non-adherence were lack of funds 44.4% (n = 8/18) and distance 22.2% (n = 4/18). Knowledge and prior awareness of glaucoma were found to be significantly associated with uptake of follow up care (p = 0.020). Conclusion: Uptake and adherence to follow-up was found to be low in this study population mainly attributed to cost, distance and poor knowledge of glaucoma natural history. Reviewing cost/out of pocket expenditure, providing care closer to patients, adequate education of staff and patients may significantly improve uptake of care after initial diagnosis. AN - WOS:000461817100009 AU - Kizor-Akaraiwe, N. N. DA - MAR 4 DO - 10.1080/09286586.2018.1555263 IS - 2 PY - 2019 SN - 0928-6586 1744-5086 SP - 140-146 ST - Follow-up and adherence to glaucoma care by newly diagnosed glaucoma patients in enugu, nigeria T2 - OPHTHALMIC EPIDEMIOLOGY TI - Follow-up and adherence to glaucoma care by newly diagnosed glaucoma patients in enugu, nigeria VL - 26 ID - 5869 ER - TY - JOUR AD - T. Klein, Osler Eyecare, 210-164 Queen Street East, Brampton, Ont. L6V 1B4, Canada AU - Klein, T. C1 - alphagan betoptic s cosopt diamox lumigan timoptic xe travatan xalatan DB - Embase IS - 10 KW - acetazolamide epinephrine betaxolol bimatoprost brimonidine dorzolamide dorzolamide plus timolol latanoprost pilocarpine prostaglandin derivative timolol maleate travoprost cataract clinical trial conference paper conjunctiva disease diarrhea drug choice drug hypersensitivity electrolyte disturbance erythema eye color eye disease eye irritation eye pain fatigue follow up gastrointestinal symptom glaucoma hair growth heart disease human hyperemia hyperpigmentation impotence incidence intraocular hypertension intraocular pressure long term care metabolic disorder monotherapy myopia night vision open angle glaucoma patient compliance pigment disorder respiratory tract disease side effect taste disorder treatment outcome visual disorder xerostomia alphagan betoptic s cosopt diamox lumigan timoptic xe travatan xalatan LA - English M3 - Conference Paper N1 - L39556723 2004-12-10 PY - 2003 SN - 1705-4842 SP - 426-429 ST - Canadian study of travatan as replacement therapy (CSTART): Switching to Travatan can improve long-term care T2 - Clinical and Surgical Ophthalmology TI - Canadian study of travatan as replacement therapy (CSTART): Switching to Travatan can improve long-term care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39556723&from=export VL - 21 ID - 3800 ER - TY - JOUR AD - Osler Eyecare, 210-164 Queen Street East, Brampton, Ont. L6V 1B4, Canada AU - Klein, T. DB - Scopus IS - 10 M3 - Conference Paper N1 - Cited By :2 Export Date: 19 July 2021 PY - 2003 SP - 426-429 ST - Canadian study of travatan as replacement therapy (CSTART): Switching to Travatan can improve long-term care T2 - Clinical and Surgical Ophthalmology TI - Canadian study of travatan as replacement therapy (CSTART): Switching to Travatan can improve long-term care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-9344246837&partnerID=40&md5=50bb6459b7f71fb4b7a1170ac1461cda VL - 21 ID - 5590 ER - TY - JOUR AB - Topical ophthalmic formulations of analogues of the endogenous arachidonic acid cyclooxygenase metabolite, PGF 2α , are the standard of care treatment for the blinding disease glaucoma. These are the most potent and efficacious medical therapies for lowering intraocular pressure (IOP), the most important risk factor identified for disease progression. They have few side effects and offer the convenience of once-a-day dosing. It was initially believed that endogenous PGs raised IOP and caused substantial ocular surface adverse effects. However, carefully designed experiments demonstrated that esterification of the carboxylic acid afforded potent and efficacious topical ocular hypotensive activity. The final hurdle to be overcome was improvement of the side effect profile. A hypothesis was advanced that the IOP-lowering effect of PGF 2α isopropyl ester was due to activation of its cognate PG-FP receptor, while side effects were largely due to promiscuous interaction with other PG receptors. This hypothesis was validated by modification of the ω chain (carbons 13–20) to a phenyl group. This provided the first marketed FP-class PG agonist analogue (FP-PGA) ocular hypotensive agent, latanoprost. Since the introduction of latanoprost into clinical medicine to lower and control IOP, a number of additional FP-PGAs have been discovered, characterized and marketed, including travoprost, tafluprost, unoprostone isopropyl ester and bimatoprost (an amide). Linked Articles: This article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc. © 2018 The British Pharmacological Society AD - Novartis Pharmaceuticals Corporation, Fort Worth, TX 76134, United States Santen Incorporated, Emeryville, CA 94608, United States AU - Klimko, P. G. AU - Sharif, N. A. DB - Scopus DO - 10.1111/bph.14327 IS - 8 M3 - Review N1 - Cited By :16 Export Date: 19 July 2021 PY - 2019 SP - 1051-1058 ST - Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma T2 - British Journal of Pharmacology TI - Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063958753&doi=10.1111%2fbph.14327&partnerID=40&md5=4ef33221fdb8f7c280d4378e257a97dc VL - 176 ID - 5176 ER - TY - JOUR AB - PURPOSE OF REVIEW: This article reviews recently published studies and important clinical trials of novel drug delivery systems for glaucoma and evaluates the potential of these systems to provide sustained therapeutic benefits. RECENT FINDINGS: The efficacy of topical medications to lower intraocular pressure (IOP) is limited by poor patient adherence, low bioavailability of drug and the potential for local and systemic side effects. Recent studies highlight the potential for sustained drug delivery through innovative delivery platforms. Nanoparticle-based formulations, drug-eluting contact lenses, punctum inserts and bioadhesive matrices placed in the conjunctival sac can enhance drug delivery by increasing precorneal residence time, enhancing corneal permeation and lowering the systemic absorption of drug. Periocular injections and surgically implanted drug reservoirs could offer even greater duration of drug delivery, particularly when the drug is packaged within stable vehicles. SUMMARY: Novel platforms for providing sustained drug delivery in glaucoma continue to evolve. The ability to incorporate effective commercially available drugs into more stable compounds is an important element. Although more research is needed to establish their clinical efficacy, novel delivery systems will allow for more targeted medical therapy and for the opportunity to further explore neuroprotective and gene-based therapies. © 2014 Wolters Kluwer Health. AD - S.D. Lawrence, Department of Ophthalmology, University of North Carolina at Chapel Hill, 5101 Bioinformatics Bldg, CB 7040, Chapel Hill, NC 27599, United States AU - Knight, O. J. AU - Lawrence, S. D. DB - Embase Medline DO - 10.1097/ICU.0000000000000031 IS - 2 KW - nanoparticle polymer clinical trial (topic) contact lens drug delivery system drug formulation glaucoma human intraocular pressure patient compliance periocular drug administration priority journal review sustained drug release LA - English M3 - Review N1 - L52976582 2014-01-29 2014-02-28 PY - 2014 SN - 1040-8738 1531-7021 SP - 112-117 ST - Sustained drug delivery in glaucoma T2 - Current Opinion in Ophthalmology TI - Sustained drug delivery in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52976582&from=export http://dx.doi.org/10.1097/ICU.0000000000000031 VL - 25 ID - 2894 ER - TY - JOUR AB - PURPOSE OF REVIEW: This article reviews recently published studies and important clinical trials of novel drug delivery systems for glaucoma and evaluates the potential of these systems to provide sustained therapeutic benefits. RECENT FINDINGS: The efficacy of topical medications to lower intraocular pressure (IOP) is limited by poor patient adherence, low bioavailability of drug and the potential for local and systemic side effects. Recent studies highlight the potential for sustained drug delivery through innovative delivery platforms. Nanoparticle-based formulations, drug-eluting contact lenses, punctum inserts and bioadhesive matrices placed in the conjunctival sac can enhance drug delivery by increasing precorneal residence time, enhancing corneal permeation and lowering the systemic absorption of drug. Periocular injections and surgically implanted drug reservoirs could offer even greater duration of drug delivery, particularly when the drug is packaged within stable vehicles. SUMMARY: Novel platforms for providing sustained drug delivery in glaucoma continue to evolve. The ability to incorporate effective commercially available drugs into more stable compounds is an important element. Although more research is needed to establish their clinical efficacy, novel delivery systems will allow for more targeted medical therapy and for the opportunity to further explore neuroprotective and gene-based therapies. AD - Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. AN - 107884447. Language: English. Entry Date: 20140411. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Biomedical AU - Knight, O'Rese J. AU - Lawrence, Scott D. DB - ccm DO - 10.1097/ICU.0000000000000031 DP - EBSCOhost IS - 2 KW - Antihypertensive Agents -- Administration and Dosage Delayed-Action Preparations -- Administration and Dosage Drug Delivery Systems Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Biological Availability N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM24463419. PY - 2014 SN - 1040-8738 SP - 112-117 ST - Sustained drug delivery in glaucoma T2 - Current Opinion in Ophthalmology TI - Sustained drug delivery in glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107884447&site=ehost-live&scope=site VL - 25 ID - 4360 ER - TY - JOUR AB - Background/purpose: To investigate the knowledge and learning ability of glaucoma patients regarding their anti-glaucoma topical medications.Methods: Patients on regular follow-up at the Glaucoma Clinic at Hsin-Chu General Hospital were recruited. After detailed ocular examinations, the participants were asked to recall and identify their glaucoma eye drops. The same test was repeated 3 months later. The results of both tests, the learning ability of patients regarding their glaucoma drugs, and the relationship between learning ability and demographic variables were evaluated.Results: Two hundred eighty-seven glaucoma patients participated in this study. Of the study population, 25.8% and 57.1% could recall their topical mediation at the first and second tests, whereas 72.1% and 88.5% could identify their prescribed eye drops at the first and second tests, respectively. Approximately 34% of the participants showed improved knowledge at the repeat test, whereas 40% of the participants showed no improvement. Participants with a better learning ability were more likely to be younger, with a higher level of education, and with less visual field impairment.Conclusion: The knowledge of glaucoma patients regarding their prescribed medication was deficient in Taiwan. Physician effort could improve knowledge on the prescribed drugs. Patient-centered education should be considered, targeting elderly individuals, illiterate individuals, and those with loss of visual function to increase compliance with glaucoma medication. AD - Department of Ophthalmology, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan Department of Biomedical Engineering and Environmental Science, National Tsing Hua University, Hsinchu, Taiwan Institute of Biomedical Engineering, National Chiao Tung University, Hsinchu, Taiwan Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan AN - 134069151. Language: English. Entry Date: 20190315. Revision Date: 20190531. Publication Type: journal article AU - Ko, Mei Lan AU - Wei, Kai Lin AU - Ho, Yi-Jung AU - Peng, Pai Huei AU - Lu, Henry Horng Shing DB - ccm DO - 10.1016/j.jfma.2018.07.011 DP - EBSCOhost IS - 1 KW - Attitude to Health Medication Compliance Ophthalmic Solutions -- Administration and Dosage Glaucoma -- Drug Therapy Intraocular Pressure Logistic Regression Aged Middle Age Taiwan Adult Female Male Drug Monitoring Prospective Studies Human N1 - research; tables/charts. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 9214933. PMID: NLM30060982. PY - 2019 SN - 0929-6646 SP - 457-462 ST - Knowledge of medications among patients with glaucoma in Taiwan T2 - Journal of the Formosan Medical Association TI - Knowledge of medications among patients with glaucoma in Taiwan UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134069151&site=ehost-live&scope=site VL - 118 ID - 4218 ER - TY - JOUR AB - Background/Purpose: To investigate the knowledge and learning ability of glaucoma patients regarding their anti-glaucoma topical medications. Methods: Patients on regular follow-up at the Glaucoma Clinic at Hsin-Chu General Hospital were recruited. After detailed ocular examinations, the participants were asked to recall and identify their glaucoma eye drops. The same test was repeated 3 months later. The results of both tests, the learning ability of patients regarding their glaucoma drugs, and the relationship between learning ability and demographic variables were evaluated. Results: Two hundred eighty-seven glaucoma patients participated in this study. Of the study population, 25.8% and 57.1% could recall their topical mediation at the first and second tests, whereas 72.1% and 88.5% could identify their prescribed eye drops at the first and second tests, respectively. Approximately 34% of the participants showed improved knowledge at the repeat test, whereas 40% of the participants showed no improvement. Participants with a better learning ability were more likely to be younger, with a higher level of education, and with less visual field impairment. Conclusion: The knowledge of glaucoma patients regarding their prescribed medication was deficient in Taiwan. Physician effort could improve knowledge on the prescribed drugs. Patient-centered education should be considered, targeting elderly individuals, illiterate individuals, and those with loss of visual function to increase compliance with glaucoma medication. © 2018 AD - Department of Ophthalmology, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan Department of Biomedical Engineering and Environmental Science, National Tsing Hua University, Hsinchu, Taiwan Institute of Biomedical Engineering, National Chiao Tung University, Hsinchu, Taiwan Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan AU - Ko, M. L. AU - Wei, K. L. AU - Ho, Y. J. AU - Peng, P. H. AU - Lu, H. H. S. DB - Scopus DO - 10.1016/j.jfma.2018.07.011 IS - 1P3 KW - Glaucoma drugs Identification Knowledge Recalling M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2019 SP - 457-462 ST - Knowledge of medications among patients with glaucoma in Taiwan T2 - Journal of the Formosan Medical Association TI - Knowledge of medications among patients with glaucoma in Taiwan UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050481200&doi=10.1016%2fj.jfma.2018.07.011&partnerID=40&md5=52d8f10f95a70016c7b4b9ad6e8f2dda VL - 118 ID - 5617 ER - TY - JOUR AB - Background/Purpose: To investigate the knowledge and learning ability of glaucoma patients regarding their anti-glaucoma topical medications. Methods: Patients on regular follow-up at the Glaucoma Clinic at Hsin-Chu General Hospital were recruited. After detailed ocular examinations, the participants were asked to recall and identify their glaucoma eye drops. The same test was repeated 3 months later. The results of both tests, the learning ability of patients regarding their glaucoma drugs, and the relationship between learning ability and demographic variables were evaluated. Results: Two hundred eighty-seven glaucoma patients participated in this study. Of the study population, 25.8% and 57.1% could recall their topical mediation at the first and second tests, whereas 72.1% and 88.5% could identify their prescribed eye drops at the first and second tests, respectively. Approximately 34% of the participants showed improved knowledge at the repeat test, whereas 40% of the participants showed no improvement. Participants with a better learning ability were more likely to be younger, with a higher level of education, and with less visual field impairment. Conclusion: The knowledge of glaucoma patients regarding their prescribed medication was deficient in Taiwan. Physician effort could improve knowledge on the prescribed drugs. Patient-centered education should be considered, targeting elderly individuals, illiterate individuals, and those with loss of visual function to increase compliance with glaucoma medication. Copyright (C) 2018, Formosan Medical Association. Published by Elsevier Taiwan LLC. AN - WOS:000455476100011 AU - Ko, M. L. AU - Wei, K. L. AU - Ho, Y. J. AU - Peng, P. H. AU - Lu, H. H. S. DA - JAN DO - 10.1016/j.jfma.2018.07.011 IS - 1 PY - 2019 SN - 0929-6646 1876-0821 SP - 457-462 ST - Knowledge of medications among patients with glaucoma in Taiwan T2 - JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION TI - Knowledge of medications among patients with glaucoma in Taiwan VL - 118 ID - 6080 ER - TY - JOUR AB - To study the causes of patients' nonadherence with the instruction of glaucoma medication dosing and to analyze them based on the dosing schedules by means of systemic classification. Four hundred twenty eight patients who had been prescribed glaucoma medication for at least six months were studied. Adherence was ascertained by means of a predetermined questionnaire. Nonadherent patients were interviewed with stratified questionnaires to elicit the causes for the non-adherence, which were analyzed with cluster analysis. The total number of non-adherents (more than 3 doses missed per month) was 114 (26.6%). The non-adherence rate in the morning was 18.2% (51/280) and in the evening 24.7% (75/304); there was no significant difference. Structured interviews for the 114 non-adherents elicited 194 unique situational problems (1.7 +/- 0.6/individual), which were grouped into four major categories: 25 medication regimen factors (12.9%), 119 patients' related factors (61.3%), 6 provider-related factors (3.1%) and 44 environmental factors (22.7%). Patients' related factors showed the higher incidence compared with other factors in both dosing time (p<0.01): Sleeping and taking a bath caused 39 patients (20.1%) to miss medication in patients with eye-drops' application in the evening. Each dosing time may have its own situational problems, which may be likely to be multidimensional and must considered with each individual patient. AD - H. Kobayashi, Department of Ophthalmology, Kanmon Medical Center National Hospital Organization, Japan. AU - Kobayashi, H. DB - Medline IS - 12 KW - eye drops adolescent adult aged article child cluster analysis drug administration female glaucoma human male middle aged patient compliance psychological aspect questionnaire statistics time LA - Japanese M3 - Article N1 - L364539618 2012-04-05 PY - 2011 SN - 0029-0203 SP - 1086-1093 ST - [Causes of patients' non-adherence with glaucoma medication dosing: systemic classification based on dosing schedule] T2 - Nippon Ganka Gakkai zasshi TI - [Causes of patients' non-adherence with glaucoma medication dosing: systemic classification based on dosing schedule] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364539618&from=export VL - 115 ID - 3130 ER - TY - JOUR AB - Purpose: Contact lens (CL) practice is relatively new in Ghana; a country where the geographical location (warm climate) lends itself to harsh environmental conditions (high humidity) known to influence CL wear. Recent studies suggest an increase in CL wear (corrective and cosmetic), yet, there are no studies about CL-related complications. This study sought to determine the complications associated with CL wear in Ghana.Methods: This was a retrospective cohort study. The medical records of contact lens wearers from five CL clinics in the two largest metropolises in Ghana, Accra and Kumasi, were reviewed. Included in the study were records of individuals who visited the clinics within the period of 2013-2016. Data on patients with contact lens-related complications were analyzed.Results: The prevalence of CL complications was 29.06 %. The mean ± SD age of patients with CL complications was 35 ± 15 years. Contact lens complications were more common in females (52.90 %). The majority of complications were in soft contact lens wearers (82.35 %). Refractive error correction was the most common indication for CL wear (61.76 %) among those with complications, followed by keratoconus (14.71 %), scarred blind eye (14.71 %), corneal ulcer (5.88 %) and anterior staphyloma (2.94 %). Contact lens complications reported were giant papillary conjunctivitis (41.18 %), corneal infiltrates (23.53 %), bacterial keratitis (14.71 %), corneal abrasion (11.76 %), dry eye (5.88 %) and corneal oedema (2.94 %). The causes of CL complication were inappropriate lens cleaning (29.41 %), poor hygiene (23.53 %), overnight contact lens wear (17.64 %), poor lens fit (14.71 %) and reaction to contact lens solution (14.71 %).Conclusion: Contact lens complications were more common in soft contact lens wearers in Ghana. Giant papillary conjunctivitis was the most common contact lens complication reported. Adherence to CL wear care regimen and good personal hygiene may prevent the majority of CL complications observed in Ghana. AD - Department of Optometry and Visual Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana College of Optometry, University of Houston, Houston, TX, United States Center for Visual Science, University of Rochester, Rochester, NY, United States School of Optometry and Vision Science, University of Waterloo, Canada AN - 147910524. Language: English. Entry Date: 20210717. Revision Date: 20210717. Publication Type: journal article. Journal Subset: Biomedical AU - Kobia-Acquah, Emmanuel AU - Akowuah, Prince Kwaku AU - Antwi-Adjei, Ellen Konadu AU - Forkuo, Philip Mensah AU - Koomson, Nana Yaa AU - Odotei, Samuel Odoi AU - Alabi, Emmanuel AU - Donkor, Richard DB - ccm DO - 10.1016/j.clae.2019.11.003 DP - EBSCOhost IS - 1 N1 - Europe; UK & Ireland. NLM UID: 9712714. PMID: NLM31784334. PY - 2021 SN - 1367-0484 SP - 67-71 ST - Contact lens complications among wearers in Ghana T2 - Contact Lens & Anterior Eye TI - Contact lens complications among wearers in Ghana UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147910524&site=ehost-live&scope=site VL - 44 ID - 4166 ER - TY - JOUR AB - Purpose: Contact lens (CL) practice is relatively new in Ghana; a country where the geographical location (warm climate) lends itself to harsh environmental conditions (high humidity) known to influence CL wear. Recent studies suggest an increase in CL wear (corrective and cosmetic), yet, there are no studies about CL-related complications. This study sought to determine the complications associated with CL wear in Ghana. Methods: This was a retrospective cohort study. The medical records of contact lens wearers from five CL clinics in the two largest metropolises in Ghana, Accra and Kumasi, were reviewed. Included in the study were records of individuals who visited the clinics within the period of 2013-2016. Data on patients with contact lens-related complications were analyzed. Results: The prevalence of CL complications was 29.06 %. The mean +/- SD age of patients with CL complications was 35 +/- 15 years. Contact lens complications were more common in females (52.90 %). The majority of complications were in soft contact lens wearers (82.35 %). Refractive error correction was the most common indication for CL wear (61.76 %) among those with complications, followed by keratoconus (14.71 %), scarred blind eye (14.71 %), corneal ulcer (5.88 %) and anterior staphyloma (2.94 %). Contact lens complications reported were giant papillary conjunctivitis (41.18 %), corneal infiltrates (23.53 %), bacterial keratitis (14.71 %), corneal abrasion (11.76 %), dry eye (5.88 %) and corneal oedema (2.94 %). The causes of CL complication were inappropriate lens cleaning (29.41 %), poor hygiene (23.53 %), overnight contact lens wear (17.64 %), poor lens fit (14.71 %) and reaction to contact lens solution (14.71 %). Conclusion: Contact lens complications were more common in soft contact lens wearers in Ghana. Giant papillary conjunctivitis was the most common contact lens complication reported. Adherence to CL wear care regimen and good personal hygiene may prevent the majority of CL complications observed in Ghana. AN - WOS:000609486900012 AU - Kobia-Acquah, E. AU - Akowuah, P. K. AU - Antwi-Adjei, E. K. AU - Forkuo, P. M. AU - Koomson, N. Y. AU - Odotei, S. O. AU - Alabi, E. AU - Donkor, R. DA - FEB DO - 10.1016/j.clae.2019.11.003 IS - 1 PY - 2021 SN - 1367-0484 1476-5411 SP - 67-71 ST - Contact lens complications among wearers in Ghana T2 - CONTACT LENS & ANTERIOR EYE TI - Contact lens complications among wearers in Ghana VL - 44 ID - 5944 ER - TY - JOUR AD - Department of Medicine, Division of Nephrology, Akdeniz University School of Medicine Hospital, Antalya, Turkey Department of Medicine, Division of Nephrology, University of Toronto, Toronto, ON, Canada Toronto General Hospital, University of Health Network, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada AU - Kocak, H. AU - Ly, J. AU - Chan, C. T. DB - Scopus DO - 10.1093/ndt/gfl153 IS - 9 KW - Glaucoma Intra-ocular pressure Nocturnal haemodialysis M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2006 SP - 2647-2649 ST - Improvement in open-angle glaucoma by nocturnal home haemodialysis T2 - Nephrology Dialysis Transplantation TI - Improvement in open-angle glaucoma by nocturnal home haemodialysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750115120&doi=10.1093%2fndt%2fgfl153&partnerID=40&md5=4bd29dcbfbdf65d7393c4fea58a004e0 VL - 21 ID - 5486 ER - TY - JOUR AB - Although once daily anti-glaucoma drug therapy is a current clinical reality, most therapies require multiple dosing and there is an unmet need to develop convenient, safe, and effective sustained release drug delivery systems for long-term treatment to improve patient adherence and outcomes. One of the first sustained release drug delivery systems was approved for the reduction of intraocular pressure in glaucoma patients. It is a polymeric reservoir-type insert delivery system, Ocusert™, placed under the eyelid and on the ocular surface for zero-order drug release over one week. The insert, marketed in two strengths, released pilocarpine on the eye surface. While many clinicians appreciated this drug product, it was eventually discontinued. No similar sustained release non-invasive drug delivery system has made it to the market to date for treating glaucoma. Drug delivery systems under development include punctal plugs, ring-type systems, contact lenses, implants, microspheres, nanospheres, gels, and other depot systems placed in the extraocular, periocular, or intraocular regions including intracameral, supraciliary, and intravitreal spaces. This article discusses the advantages and disadvantages of the various routes of administration and delivery systems for sustained glaucoma therapy. It also provides the reader with some examples and discussion of drug delivery systems that could potentially be applied for glaucoma treatment. Interestingly, one intracamerally injected implant, Durysta™, was approved recently for sustained intraocular pressure reduction. However, long-term acceptance of such devices has yet to be established. The ultimate success of the delivery system will depend on efficacy relative to eye drop dosing, safety, reimbursement options, and patient acceptance. Cautious development efforts are warranted considering prior failed approaches for sustained glaucoma drug delivery. Neuroprotective approaches for glaucoma therapy including cell, gene, protein, and drug-combination therapies, mostly administered intravitreally, are also rapidly progressing towards assessment in humans. AD - Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA Department of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, CO, USA Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO, USA AN - 150851113. Language: English. Entry Date: In Process. Revision Date: 20210717. Publication Type: journal article AU - Kompella, Uday B. AU - Hartman, Rachel R. AU - Patil, Madhoosudan A. DB - ccm DO - 10.1016/j.preteyeres.2020.100901 DP - EBSCOhost N1 - review. Journal Subset: Biomedical; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 9431859. PMID: NLM32891866. PY - 2021 SN - 1350-9462 SP - N.PAG-N.PAG ST - Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma T2 - Progress in Retinal & Eye Research TI - Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150851113&site=ehost-live&scope=site VL - 82 ID - 4298 ER - TY - JOUR AD - X. Kong, Eye and ENT Hospital, Fudan University, Shanghai, China AU - Kong, X. AU - Chen, X. AU - Sun, X. AU - Xiao, M. AU - Zuo, L. AU - Guo, W. DB - Embase Medline DO - 10.1111/j.1442-9071.2009.02103.x IS - 6 KW - doctor patient relationship glaucoma health education health program letter patient compliance patient education support group symposium LA - English M3 - Letter N1 - L355070918 2009-09-09 PY - 2009 SN - 1442-6404 1442-9071 SP - 634-636 ST - Glaucoma club: A successful model to educate glaucoma patients T2 - Clinical and Experimental Ophthalmology TI - Glaucoma club: A successful model to educate glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355070918&from=export http://dx.doi.org/10.1111/j.1442-9071.2009.02103.x VL - 37 ID - 3336 ER - TY - JOUR AB - Background: The increasing prevalence of diabetes is leading to a rise of eye diseases, augmenting the risk of sight-threatening complications. The aim of this study was to evaluate prevalence, awareness and practices regarding eye diseases among patients with diabetes in the canton of Vaud, Switzerland. Methods: A cohort of 323 patients with diabetes completed a self-administered questionnaire assessing prevalence, awareness and practices regarding eye diseases, besides health status and quality of care measures. Descriptive analyses followed by exploratory subgroup analyses and linear regressions were performed to investigate factors associated with awareness and practices. Results: While diabetic retinopathy was reported by 40.9% of patients with type 1 diabetes and 9.8% of patients with type 2 diabetes, 35.8% and 12.6% of all participants reported cataract and glaucoma, respectively. Awareness that diabetes could damage the eyes was reported by almost all participants; the majority was also aware of the importance of glycemic control and regular eye examination in preventing eye diseases. In contrast, only 70.5% of participants underwent an eye examination by an ophthalmologist during the past year. Eye examination was associated with better patients' awareness. Barriers mentioned by patients revealed a lack of knowledge about screening guidelines, in particular regarding the preventive nature of eye examinations. Conclusions: Despite high levels of awareness regarding diabetic eye diseases, a significant proportion of patients with diabetes did not report annual eye examination. Both healthcare strategic efforts targeting the promotion of regular eye examination and initiatives aiming at improving knowledge of screening guidelines should be encouraged. Trial registration: ClinicalTrials.gov on 9th July 2013, identifier (retrospectively registered). AD - Jules Gonin University Eye Hospital , University of Lausanne , Avenue de France 15 - Case Postale 5143 - 1000 Lausanne 2 Lausanne Switzerland Institute of Social and Preventive Medicine (IUMSP) , Lausanne University Hospital and University of Lausanne , Lausanne Switzerland Private Practice , Morges Switzerland Public Health Service, Department of Health and Social Action, Canton of Vaud , Lausanne Switzerland AN - 125067447. Language: English. Entry Date: 20170922. Revision Date: 20190507. Publication Type: Article AU - Konstantinidis, Lazaros AU - Carron, Tania AU - de Ancos, Eva AU - Chinet, Léonie AU - Hagon-Traub, Isabelle AU - Zuercher, Emilie AU - Peytremann-Bridevaux, Isabelle DB - ccm DO - 10.1186/s12902-017-0206-2 DP - EBSCOhost IS - 1 KW - Diabetes Mellitus -- Complications Eye Diseases -- Prevention and Control Prevalence -- Evaluation Cognition -- Evaluation Health Knowledge Attitude to Health -- Evaluation Human Cross Sectional Studies Prospective Studies Switzerland Self Report Questionnaires Health Status Quality of Health Care Exploratory Research Linear Regression Descriptive Statistics Cataract Glaucoma Diagnosis, Eye Health Services Accessibility N1 - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 101088676. PY - 2017 SN - 1472-6823 SP - 1-11 ST - Awareness and practices regarding eye diseases among patients with diabetes: a cross sectional analysis of the CoDiab-VD cohort T2 - BMC Endocrine Disorders TI - Awareness and practices regarding eye diseases among patients with diabetes: a cross sectional analysis of the CoDiab-VD cohort UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=125067447&site=ehost-live&scope=site VL - 17 ID - 4340 ER - TY - JOUR AD - Glaucoma Unit, A University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece. AN - 106118817. Language: English. Entry Date: 20070713. Revision Date: 20200708. Publication Type: Journal Article AU - Konstas, A. G. DB - ccm DO - 10.2165/00002512-200623070-00006 DP - EBSCOhost IS - 7 KW - Drug Combinations -- Therapeutic Use Glaucoma -- Drug Therapy Timolol -- Therapeutic Use Travoprost -- Therapeutic Use Drug Administration Schedule Drug Combinations -- Administration and Dosage Glaucoma -- Complications Intraocular Pressure Patient Compliance Timolol -- Administration and Dosage Travoprost -- Administration and Dosage N1 - commentary; editorial. Original Study: Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. (DRUGS AGING) 2006; 23 (7): 587-597. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 9102074. PY - 2006 SN - 1170-229X SP - 598-599 ST - Travoprost/timolol: a viewpoint by Anastasios G.P. Konstas T2 - Drugs & Aging TI - Travoprost/timolol: a viewpoint by Anastasios G.P. Konstas UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106118817&site=ehost-live&scope=site VL - 23 ID - 4648 ER - TY - JOUR AB - Introduction: Preservative-free (PF) medications represent a valuable treatment strategy in the lifelong management of glaucoma. By removing preservative toxicity, PF formulations provide tangible clinical benefits to glaucoma patients worldwide. They improve tolerability and adherence, leading to a positive impact in long-term intraocular pressure (IOP) control. Areas covered: A critical review of the subject is provided, including selected evidence on the safety and tolerability of currently available topical PF formulations. Cumulative evidence confirms that topical PF medications are at least equally efficacious to their preserved equivalents. There is convincing short-term evidence for superior tolerability and safety of PF formulations compared to preserved medications. The long-term benefits and success of PF therapy requires further elucidation. Expert opinion: Successful stepwise administration of medical therapy for glaucoma remains elusive. There is a greater risk for ocular toxicity and therapy failure with preserved topical glaucoma therapy. Currently available and emerging PF therapy options potentially optimize lifelong stepwise glaucoma therapy and may enhance outcome. To avert complications from preservatives leading to poor adherence, ideally, future antiglaucoma therapy should become 100% PF. There are still key aspects of PF therapy that warrant further investigation. AD - A.G. Konstas, 1st and 3rd University Departments of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece AU - Konstas, A. G. AU - Labbé, A. AU - Katsanos, A. AU - Meier-Gibbons, F. AU - Irkec, M. AU - Boboridis, K. G. AU - Holló, G. AU - García-Feijoo, J. AU - Dutton, G. N. AU - Baudouin, C. DB - Embase Medline DO - 10.1080/14740338.2021.1873947 IS - 4 KW - antiglaucoma agent benzalkonium chloride bimatoprost plus timolol brimonidine dorzolamide plus timolol drug preservative prostaglandin derivative tafluprost tafluprost plus timolol timolol drug safety drug tolerability eye toxicity filtering operation glaucoma glaucoma surgery human intraocular hypertension intraocular pressure ocular surface disease patient compliance review topical treatment treatment failure LA - English M3 - Review N1 - L2010224072 2021-02-02 2021-07-06 PY - 2021 SN - 1744-764X 1474-0338 SP - 453-466 ST - The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability T2 - Expert Opinion on Drug Safety TI - The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010224072&from=export http://dx.doi.org/10.1080/14740338.2021.1873947 VL - 20 ID - 2335 ER - TY - JOUR AB - The key clinical attributes of preserved dorzolamide/timolol fixed combination (DTFC) and the emerging potential of preservative-free (PF) DTFC are reviewed with published evidence and clinical experience. The indications and role of DTFC in current glaucoma management are critically discussed. Preserved DTFC became the first intraocular pressure (IOP)-lowering fixed combination (FC) approved by the US Food and Drug Administration (FDA) and remains one of most commonly used medications worldwide. The pharmacological properties of DTFC reflect those of its two time-tested constituents, i.e., the carbonic anhydrase inhibitor dorzolamide and the non-selective beta-blocker timolol. In regulatory studies DTFC lowers IOP on average by 9 mmHg (32.7%) at peak and by 7.7 mmHg (27%) at trough. In trials DTFC shows equivalence to unfixed concomitant therapy, but in real-life practice it may prove superior owing to enhanced convenience, elimination of the washout effect from the second drop, improved tolerability, and better adherence. PF DTFC became the first PF FC approved, first in unit-dose pipettes, and more recently in a multidose format. Cumulative evidence has confirmed that PF DTFC is at least equivalent in efficacy to preserved DTFC and provides a tangible clinical benefit to patients with glaucoma suffering from ocular surface disease by improving tolerability and adherence. Finally, we identify areas that warrant further investigation with preserved and PF DTFC. AD - 1st and 3rd University Departments of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore, Singapore Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore SERI-NTU Advanced Ocular Engineering (STANCE), Singapore, Singapore Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria Department of Ophthalmology, Medical University of Vienna, Vienna, Austria Institute of Ophthalmology, Basel, Switzerland Ophthalmology Department, University of Ioannina, Ioannina, Greece Ivey Institute of Ophthalmology and Western University, London, ON, Canada Department of Ophthalmology, Semmelweis University, Budapest, Hungary Department of Surgical and Clinical, Diagnostic and Pediatric Sciences, Section of Ophthalmology, University of Pavia-IRCCS Fondazione Policlinico San Matteo, Pavia, Italy Ophthalmology Department, University of Alcalá, Alcalá de Henares, Madrid, Spain SILK, Department of Ophthalmology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland Tays Eye Centre, Tampere University Hospital, Tampere, Finland Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA AN - 148447569. Language: English. Entry Date: In Process. Revision Date: 20210715. Publication Type: journal article AU - Konstas, Anastasios G. AU - Schmetterer, Leopold AU - Katsanos, Andreas AU - Hutnik, Cindy M. L. AU - Holló, Gábor AU - Quaranta, Luciano AU - Teus, Miguel A. AU - Uusitalo, Hannu AU - Pfeiffer, Norbert AU - Katz, L. Jay DB - ccm DO - 10.1007/s12325-020-01525-5 DP - EBSCOhost IS - 1 KW - Ocular Hypertension -- Drug Therapy Timolol Carbonic Anhydrase Inhibitors Drug Combinations Antihypertensive Agents -- Therapeutic Use Sulfur Compounds Sulfonamides Intraocular Pressure Human Tonometry Clinical Assessment Tools Scales N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Learning and Study Strategies Inventory (LASSI); Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Frenchay Dysarthria Assessment (FDA); Longitudinal Interval Follow-Up Evaluation (LIFE). NLM UID: 8611864. PMID: NLM33108623. PY - 2021 SN - 0741-238X SP - 24-51 ST - Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future T2 - Advances in Therapy TI - Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148447569&site=ehost-live&scope=site VL - 38 ID - 4176 ER - TY - JOUR AB - Purpose: The aim of this study was to evaluate the efficacy and safety in ocular hypertensive or open-angle glaucoma patients changed to a latanoprost/timolol fixed combination (LTFC) from previous therapy. Methods: We employed a retrospective, multicenter, active-controlled study evaluating patients who had a previous therapy substituted with LTFC and had a 3-month follow-up. Results: In the 168 patients included in the trial, LTFC reduced the intraocular pressure (IOP) after switching from previous therapies: timolol (22.8 ± 3.5 to 19.0 ± 3.9 mmHg, N = 49, p < 0.001), latanoprost (21.2 ± 3.8 to 18.3 ± 2.5 mmHg, N = 54, p < 0.001), and a dorzolamide/timolol fixed combination (20.9 ± 2.4 to 20.0 ± 2.7 mmHg, N = 32, p = 0.03). In switching from a latanoprost and timolol unfixed combination, the pressure changed from 18.3 ± 3.8 to 18.9 ± 3.0 mmHg (N = 33, p = 0.38). LTFC was persistent in 131 (78%) patients within the 3-month treatment period. The most common adverse event with LTFC was conjunctival hyperemia, which occurred in patients not previously treated with latanoprost therapy (N = 16, 10%). Conclusions: LTFC generally provides reduced IOP and limited side effects when substituted for other common glaucoma therapies, while providing similar pressure when switched from its own individual components. AD - Univ. Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece Department of Ophthalmology, University of Thrace, Alexandroupolis, Greece General Hospital of Edessa, Edessa, Greece Hosp. Oftalmologico Internacional M., Madrid, Spain Pharmaceutical Res. Network, L.L.C., Charleston, SC, United States Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, United States Pharmaceutical Res. Network, L.L.C., 1639 Tatum Street, Charleston, SC 29412-2464, United States AU - Konstas, A. G. P. AU - Bányai, L. AU - Blask, K. D. AU - Väth, J. AU - Kozobolis, V. P. AU - Trüb, P. R. AU - Tsironi, S. AU - Maloutas, S. AU - Teus, M. A. AU - Stewart, W. C. DB - Scopus DO - 10.1089/jop.2004.20.375 IS - 5 M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2004 SP - 375-382 ST - Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies T2 - Journal of Ocular Pharmacology and Therapeutics TI - Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-7444242571&doi=10.1089%2fjop.2004.20.375&partnerID=40&md5=322202442f4dceafdf3781627c5ae203 VL - 20 ID - 5207 ER - TY - JOUR AD - Glaucoma Unit, University Department of Ophthalmology, AHEPA Hospital, Thessaloniki 546 36, Greece Department of Hygiene, Aristotle University of Thessaloniki, Thessaloniki, Greece Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy University Eye Clinic Maastricht, University Hospital Maastricht, Maastricht, Netherlands AU - Konstas, A. G. P. AU - Haidich, A. B. AU - Rossetti, L. AU - Webers, C. DB - Scopus DO - 10.5301/ejo.5000077 IS - 1 M3 - Editorial N1 - Cited By :13 Export Date: 19 July 2021 PY - 2011 SP - 1-4 ST - Prostaglandin-timolol fixed combinations efficacy: Myth or reality? T2 - European Journal of Ophthalmology TI - Prostaglandin-timolol fixed combinations efficacy: Myth or reality? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-81855166778&doi=10.5301%2fejo.5000077&partnerID=40&md5=a0c1ee125d284c1629dad8c456041c0f VL - 22 ID - 5220 ER - TY - JOUR AB - Purpose: To compare the 24 hour efficacy of latanoprost 0.005% given every evening with that of pilocarpine 4% given four times daily as third-line therapy in patients with exfoliation glaucoma receiving timolol 0.5% and dorzolamide 2% each given twice daily. Method: We enrolled 30 patients with exfoliation glaucoma not adequately controlled on timolol maleate 0.5% and dorzolamide 2%. Each patient underwent a baseline 24 hour intraocular pressure curve testing at 06:00, 10:00, 14:00, 18:00, 22:00 and 02:00 hours. Patients were randomised to receive either latanoprost 0.005% or pilocarpine 4% for a minimum of 8 weeks and were then crossed over to the opposite therapy. Diurnal curve testing was repeated at the end of each treatment. Results: There was a significant decrease from baseline in intraocular pressure at each timepoint for both study medicines (p<0.016). Latanoprost provided better intraocular pressure control than pilocarpine at daytime measurements (17.4 vs 19.7 mmHg at 06:00 hours, p<0.001; 17.8 vs 19.1 mmHg at 10:00 hours, p=0.04). However, pilocarpine reduced the pressure more than latanoprost at 22:00 hours (18.4 vs 19.5 mmHg, p=0.016). Overall, the diurnal intraocular pressure was reduced from a baseline of 21.5 ± 3.7 mmHg to 18.8 ± 3.1 mmHg on pilocarpine and to 18.0 ± 3.0 mmHg on latanoprost (p=0.06). In addition, mean peak pressure was similar between pilocarpine (21.0 ± 2.9 mmHg) and latanoprost (20.5 ± 3.8 mmHg) (p=0.20). Side-effects were similar with the exception of blurred vision, which was only found with pilocarpine (10%). Compliance was more difficult with pilocarpine. Conclusion: In exfoliation glaucoma, as a thirdline adjunctive therapy added to timolol and dorzolamide, latanoprost and pilocarpine have similar diurnal efficacy. However, latanoprost provides a greater morning pressure reduction. AD - A.G.P. Konstas, Univ. Department of Ophthalmology, AHEPA Hospital, 1 Kyriakidi Street, Thessaloniki 540 06, Greece AU - Konstas, A. G. P. AU - Lake, S. AU - Maltezos, A. C. AU - Holmes, K. T. AU - Stewart, W. C. C2 - Alcon(Greece) Merck Sharp and Dohme(Greece) Pharmacia Upjohn(Greece) DB - Embase Medline IS - 1 KW - dorzolamide latanoprost pilocarpine timolol maleate adult aged allergy article circadian rhythm clinical article clinical trial controlled clinical trial controlled study crossover procedure drug efficacy pseudoexfoliation female headache human intraocular pressure male patient compliance randomized controlled trial vertigo visual impairment LA - English M3 - Article N1 - L32258218 2001-04-11 PY - 2001 SN - 0950-222X SP - 59-62 ST - Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma T2 - Eye TI - Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32258218&from=export VL - 15 ID - 3895 ER - TY - JOUR AB - Purpose. To document the prevalence of non-compliance and to investigate patients' perceptions concerning glaucoma in a Greek cohort. Methods. We investigated 100 consecutive patients referred to our glaucoma clinic and already treated for chronic glaucoma. Compliance and patients' insight were ascertained by two independent observers by means of a predetermined questionnaire. All patients were subsequently assessed for their ability to instil their eyedrops accurately. Results. Fifty one per cent of our patients were not aware of the nature of glaucoma, but 80% were afraid it might lead to blindness. Clinically significant non-compliance (more than two doses missed per week) was established in 44% of our patients. Men and those using eyedrops more than 4 times a day were more likely to default. Non-compliant patients exhibited higher mean intraocular pressure (22.9 vs 18.5 mmHg; p > 0.001) and worse visual field loss (10.8 vs 7.0 dB; p = 0.008) compared with compliant patients. Involuntary non-compliance was also common in our group, with only 53% instilling their eye drops accurately. Conclusion. Non-compliance is a significant limiting factor in glaucoma therapy in Greece. AD - A.G.P. Konstas, Univ. Department of Ophthalmology, AHEPA Hospital, Kiriakidi 1, Thessaloniki, Greece AU - Konstas, A. G. P. AU - Maskaleris, G. AU - Gratsonidis, S. AU - Sardelli, C. DB - Embase Medline IS - 5 KW - beta adrenergic receptor blocking agent dipivefrine dorzolamide eye drops pilocarpine adult aged article blindness chronic disease cohort analysis controlled study eye irritation fear female follow up Greece human intraocular hypertension intraocular pressure major clinical study male observer variation open angle glaucoma patient attitude patient compliance patient monitoring prevalence sex difference statistical analysis visual impairment LA - English M3 - Article N1 - L30838323 2000-11-28 PY - 2000 SN - 0950-222X SP - 752-756 ST - Compliance and viewpoint of glaucoma patients in Greece T2 - Eye TI - Compliance and viewpoint of glaucoma patients in Greece UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30838323&from=export VL - 14 ID - 3904 ER - TY - JOUR AB - Purpose. To document the prevalence of non-compliance and to investigate patients' perceptions concerning glaucoma in a Greek cohort. Methods. We investigated 100 consecutive patients referred to our glaucoma clinic and already treated for chronic glaucoma. Compliance and patients' insight were ascertained by two independent observers by means of a predetermined questionnaire. All patients were subsequently assessed for their ability to instil their eyedrops accurately. Results. Fifty one per cent of our patients were not aware of the nature of glaucoma, but 80% were afraid it might lead to blindness. Clinically significant non-compliance (more than two doses missed per week) was established in 44% of our patients. Men and those using eyedrops more than 4 times a day were more likely to default. Non-compliant patients exhibited higher mean intraocular pressure (22.9 vs 18.5 mmHg; p > 0.001) and worse visual field loss (10.8 vs 7.0 dB; p = 0.008) compared with compliant patients. Involuntary non-compliance was also common in our group, with only 53% instilling their eye drops accurately. Conclusion. Non-compliance is a significant limiting factor in glaucoma therapy in Greece. AD - Department of Ophthalmology, Aristotle University of Thessaloniki, Greece AU - Konstas, A. G. P. AU - Maskaleris, G. AU - Gratsonidis, S. AU - Sardelli, C. DB - Scopus DO - 10.1038/eye.2000.197 IS - 5 KW - Compliance Exfoliation glaucoma Glaucoma therapy POAG M3 - Article N1 - Cited By :117 Export Date: 19 July 2021 PY - 2000 SP - 752-756 ST - Compliance and viewpoint of glaucoma patients in Greece T2 - Eye TI - Compliance and viewpoint of glaucoma patients in Greece UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033731494&doi=10.1038%2feye.2000.197&partnerID=40&md5=34c6944e9dcd274439da02d755bda6b6 VL - 14 ID - 4924 ER - TY - JOUR AB - Introduction: Glaucoma is a multifactorial optic neuropathy that can lead to progressive and irreversible loss of vision. Today there are > 60 million glaucoma patients worldwide, and this figure is rising due to aging. The aim of glaucoma therapy is to maintain the patient's visual function and quality of life by means of intraocular pressure (IOP) reduction, which currently constitutes the only evidence-based approach. Areas covered: Briefly discussed are selected, recent evidence on antiglaucoma fixed combinations. Then the efficacy and safety of the latanoprost/timolol fixed combination is comprehensively reviewed. Expert opinion: The latanoprost/timolol fixed combination can be a helpful stepwise therapeutic option in patients whose IOP is insufficiently controlled with monotherapy options. Future research is needed to better delineate the role and value of this medication in glaucoma therapy. © 2013 Informa UK, Ltd. AD - 1st University Department of Ophthalmology, AHEPA Hospital, Glaucoma Unit, Thessaloniki, Greece Hacettepe University, University Department of Ophthalmology, Ankara, Turkey University Department of Ophthalmology, Ioannina, Greece AU - Konstas, A. G. P. AU - Mocan, M. C. AU - Katsanos, A. AU - Voudouragkaki, I. C. AU - Irkec, M. DB - Scopus DO - 10.1517/14656566.2013.813482 IS - 13 KW - Fixed combinations Intraocular pressure Latanoprost/timolol fixed combination Prostaglandin analog Xalacom M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2013 SP - 1815-1827 ST - Latanoprost/timolol fixed combination for the treatment of glaucoma T2 - Expert Opinion on Pharmacotherapy TI - Latanoprost/timolol fixed combination for the treatment of glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881638650&doi=10.1517%2f14656566.2013.813482&partnerID=40&md5=f1d1514d92dde723f6b9473f01e5180c VL - 14 ID - 5306 ER - TY - JOUR AB - Purpose: To describe and compare the preoperative characteristics of Greek patients with exfoliation glaucoma (EXG) and primary open-angle glaucoma (POAG). Methods: We prospectively investigated the preoperative features of 100 consecutive patients undergoing filtration surgery for either EXG, or POAG. We compared 74 patients with EXG and 26 with POAG. Results: EXG patients were older (68.2 vs 62.4 years; p < 0.05) and more often from the countryside (73%). Both glaucomas showed a preponderance for males, similar frequencies of positive family history and systemic disorders, with the exception of diabetes which was more common in POAG (19.2% vs 5.4%). The first IOP measurement, before treatment, was significantly higher in EXG (40.4 mm Hg) compared with POAG (33.9 mm Hg). Despite a shorter duration of medical therapy (25 vs 65 months) and more topical drugs EXG patients exhibited higher mean preoperative IOP (36 vs 27.8 mm Hg for POAG; p < 0.05). EXG patients had significantly worse visual acuity than POAG (0.4 vs 0.6; p < 0.05) and worse compliance to medical therapy (48%) compared to POAG (33%). AD - A.G.P. Konstas, University Department Ophthalmology, AHEPA Hospital, Kiriakidi 1, Thessaloniki, Greece AU - Konstas, A. G. P. AU - Tsatsos, I. AU - Kardasopoulos, A. AU - Bufidis, T. AU - Maskaleris, G. DB - Embase Medline DO - 10.1034/j.1600-0420.1998.760217.x IS - 2 KW - antiglaucoma agent adult age aged article clinical feature controlled study diabetes mellitus pseudoexfoliation family history female filtering operation geographic distribution human intraocular pressure major clinical study male open angle glaucoma patient compliance preoperative evaluation priority journal sex difference topical drug administration visual acuity LA - English M3 - Article N1 - L28177212 1998-05-04 PY - 1998 SN - 1395-3907 SP - 208-212 ST - Preoperative features of patients with exfoliation glaucoma and primary open-angle glaucoma. The AHEPA study T2 - Acta Ophthalmologica Scandinavica TI - Preoperative features of patients with exfoliation glaucoma and primary open-angle glaucoma. The AHEPA study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L28177212&from=export http://dx.doi.org/10.1034/j.1600-0420.1998.760217.x VL - 76 ID - 3948 ER - TY - JOUR AD - K.S. Kooner AU - Kooner, K. S. AU - Zimmerman, T. J. DB - Medline IS - 2 KW - eye drops drug administration editorial glaucoma human methodology patient compliance patient education LA - English M3 - Editorial N1 - L17718023 1987-04-28 PY - 1987 SN - 0003-4886 SP - 43-44 ST - A glaucoma medication time-table card T2 - Annals of ophthalmology TI - A glaucoma medication time-table card UR - https://www.embase.com/search/results?subaction=viewrecord&id=L17718023&from=export VL - 19 ID - 4066 ER - TY - JOUR AB - Purpose: To describe a technique to manage corneal perforations between 3 and 6 mm in size using autologous Tenons tissue with cyanoacrylate glue and a bandage contact lens. Methods: A thin layer of Tenons capsule harvested from the patient's own eye is used to seal the perforation and act as a scaffold. The Tenons patch graft is spread over the perforation and held in place by the application of cyanoacrylate glue. A bandage contact lens is then placed on the eye. Results: A 6-year retrospective review of 28 patients who underwent this procedure was performed. One patient was lost to follow-up. Of the 27 patients who were followed up, 20 healed completely, with an adherent leucoma and preservation of the anterior chamber. The condition of one patient (with a perforated Pseudomonas corneal ulcer) progressively worsened despite maximum medical therapy and had to undergo evisceration. Conclusions: This procedure makes use of easily available autologous Tenons tissue in patients with corneal perforations too large to be managed with cyanoacrylate glue alone, to preserve eyeball morphology. A corneal transplant can then be done when the cornea has healed. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology, Christian Medical College and Hospital, Vellore, 632001, India Narayana Nethralaya, Bangalore, India AU - Korah, S. AU - Selvin, S. S. T. AU - Pradhan, Z. S. AU - Jacob, P. AU - Kuriakose, T. DB - Scopus DO - 10.1097/ICO.0000000000000808 IS - 5 KW - corneal perforation cyanoacrylate glue Tenons capsule Tenons patch graft M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2016 SP - 696-699 ST - Tenons Patch Graft in the Management of Large Corneal Perforations T2 - Cornea TI - Tenons Patch Graft in the Management of Large Corneal Perforations UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961226503&doi=10.1097%2fICO.0000000000000808&partnerID=40&md5=6f68e44be47a30137a0dfb1983b4b432 VL - 35 ID - 5199 ER - TY - JOUR AB - Purpose:To describe a technique to manage corneal perforations between 3 and 6 mm in size using autologous Tenons tissue with cyanoacrylate glue and a bandage contact lens.Methods:A thin layer of Tenons capsule harvested from the patient's own eye is used to seal the perforation and act as a scaffold. The Tenons patch graft is spread over the perforation and held in place by the application of cyanoacrylate glue. A bandage contact lens is then placed on the eye.Results:A 6-year retrospective review of 28 patients who underwent this procedure was performed. One patient was lost to follow-up. Of the 27 patients who were followed up, 20 healed completely, with an adherent leucoma and preservation of the anterior chamber. The condition of one patient (with a perforated Pseudomonas corneal ulcer) progressively worsened despite maximum medical therapy and had to undergo evisceration.Conclusions:This procedure makes use of easily available autologous Tenons tissue in patients with corneal perforations too large to be managed with cyanoacrylate glue alone, to preserve eyeball morphology. A corneal transplant can then be done when the cornea has healed. AN - WOS:000374781900024 AU - Korah, S. AU - Selvin, S. S. T. AU - Pradhan, Z. S. AU - Jacob, P. AU - Kuriakose, T. DA - MAY DO - 10.1097/ICO.0000000000000808 IS - 5 PY - 2016 SN - 0277-3740 1536-4798 SP - 696-699 ST - Tenons Patch Graft in the Management of Large Corneal Perforations T2 - CORNEA TI - Tenons Patch Graft in the Management of Large Corneal Perforations VL - 35 ID - 5828 ER - TY - JOUR AB - Objective: This study aimed to identify factors associated with compliance with glaucoma follow-up visits. Design: Computer records of a university residents' eye clinic were reviewed to identify a random sample of all persons who had an examination with International Classification of Disease (ICD) 9 coding (ICD9) for glaucoma suspect or glaucoma during a 2- year period (1991-1993) to undergo telephone interview. Participants: Those who were seen at least every 6 months regardless of earlier return instructions were defined as compliant with follow-up (controls, n = 362). Those who had any lapse between visits of longer than 6 months were defined as noncompliant (cases, n = 362). Results: Interviews were completed for 196 cases and 242 controls. Noncompliant persons were significantly more likely to be suspects for glaucoma rather than to have definite glaucoma and to be dissatisfied with waiting time in the clinic (29.1% vs. 17.8%, P < 0.005) and to state that they did not take their glaucoma medications as prescribed (25.4% vs. 13.4%, P < 0.004). They also were less likely to have been prescribed eyedrop medication. A high percentage of both patients and controls knew that glaucoma can lead to blindness (85.2% and 88.4%, respectively). The most common reasons patients gave for not keeping follow- up visits were the perception that their eye problem was 'not serious enough,' the cost of examinations, and that the doctor did not tell them to come back. Conclusion: Compliance with follow-up visits for glaucoma is associated with markers for early disease attempts to improve compliance might focus on improved communication of the seriousness of the disease and improvements in clinic waiting time. AD - O. Kosoko, Howard University Hospital, 2041 Georgia Avenue, NW, Washington, DC 20060, United States AU - Kosoko, O. AU - Quigley, H. A. AU - Vitale, S. AU - Enger, C. AU - Kerrigan, L. AU - Tielsch, J. M. DB - Embase Medline DO - 10.1016/S0161-6420(98)91134-4 IS - 11 KW - adult aged article controlled study female follow up glaucoma health care cost human major clinical study male patient care patient compliance priority journal risk factor LA - English M3 - Article N1 - L30211781 2000-05-01 PY - 1998 SN - 0161-6420 SP - 2105-2111 ST - Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic T2 - Ophthalmology TI - Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30211781&from=export http://dx.doi.org/10.1016/S0161-6420(98)91134-4 VL - 105 ID - 3936 ER - TY - JOUR AB - Objective: This study aimed to identify factors associated with compliance with glaucoma follow-up visits. Design: Computer records of a university residents' eye clinic were reviewed to identify a random sample of all persons who had an examination with International Classification of Disease (ICD) 9 coding (ICD9) for glaucoma suspect or glaucoma during a 2- year period (1991-1993) to undergo telephone interview. Participants: Those who were seen at least every 6 months regardless of earlier return instructions were defined as compliant with follow-up (controls, n = 362). Those who had any lapse between visits of longer than 6 months were defined as noncompliant (cases, n = 362). Results: Interviews were completed for 196 cases and 242 controls. Noncompliant persons were significantly more likely to be suspects for glaucoma rather than to have definite glaucoma and to be dissatisfied with waiting time in the clinic (29.1% vs. 17.8%, P < 0.005) and to state that they did not take their glaucoma medications as prescribed (25.4% vs. 13.4%, P < 0.004). They also were less likely to have been prescribed eyedrop medication. A high percentage of both patients and controls knew that glaucoma can lead to blindness (85.2% and 88.4%, respectively). The most common reasons patients gave for not keeping follow- up visits were the perception that their eye problem was 'not serious enough,' the cost of examinations, and that the doctor did not tell them to come back. Conclusion: Compliance with follow-up visits for glaucoma is associated with markers for early disease attempts to improve compliance might focus on improved communication of the seriousness of the disease and improvements in clinic waiting time. AD - Division of Ophthalmology, Howard University, School of Medicine, Washington, DC, United States Dana Ctr. for Prev. Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States Glaucoma Service, Johns Hopkins University, School of Medicine, Baltimore, MD, United States Department of International Health, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, United States Howard University Hospital, 2041 Georgia Avenue, NW, Washington, DC 20060, United States AU - Kosoko, O. AU - Quigley, H. A. AU - Vitale, S. AU - Enger, C. AU - Kerrigan, L. AU - Tielsch, J. M. DB - Scopus DO - 10.1016/S0161-6420(98)91134-4 IS - 11 M3 - Article N1 - Cited By :94 Export Date: 19 July 2021 PY - 1998 SP - 2105-2111 ST - Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic T2 - Ophthalmology TI - Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032471254&doi=10.1016%2fS0161-6420%2898%2991134-4&partnerID=40&md5=ad34dbd7c45528690b6c8209bdbce79b VL - 105 ID - 4934 ER - TY - JOUR AB - Objective: This study aimed to identify factors associated with compliance with glaucoma follow-up visits. Design: Computer records of a university residents' eye clinic were reviewed to identify a random sample of all persons who had an examination with International Classification of Disease (ICD) 9 coding (ICD9) for glaucoma suspect or glaucoma during a 2-year period (1991-1993) to undergo telephone interview. Participants: Those who were seen at least every 6 months regardless of earlier return instructions were defined as compliant with follow-up (controls n = 362). Those who had any lapse between visits of longer than 6 months were defined as noncompliant (cases, n = 362). Results: Interviews were completed for 196 cases and 242 controls. Noncompliant persons were significantly more likely to be suspects for glaucoma rather than have definite glaucoma and to be dissatisfied with waiting time in the clinic (29.1% vs. 17.8%, P < 0.005) and to state that they did not take their glaucoma medications as prescribed (25.4% vs. 13.4%, P < 0.004). They also were less likely to have been prescribed eyedrop medication. A high percentage of both patients and controls knew that glaucoma can lead to blindness (85.2% and 88.4%, respectively). The most common reasons patients gave for not keeping follow-up visits were the perception that their eye problem was 'not serious enough', the cost of examinations, and that the doctor did not tell them to come back. Conclusion: Compliance with follow-up visits for glaucoma is associated with markers for early disease. Attempts to improve compliance might focus on improved communication of the seriousness of the disease and improvements in clinic waiting time. AU - Kosoko, O. AU - Quigley, H. A. AU - Vitale, S. AU - Enger, C. AU - Kerrigan, L. AU - Tielsch, J. M. DB - Scopus IS - 28 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 1998 SP - 62 ST - Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic T2 - Community Eye Health Journal TI - Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-54749135460&partnerID=40&md5=dab6d4643800244858143a03169b6cd8 VL - 11 ID - 5593 ER - TY - JOUR AB - Objective: This study aimed to identify factors associated with compliance with glaucoma follow-up visits. Design: Computer records of a university residents' eye clinic were reviewed to identify a random sample of all persons who had an examination with International Classification of Disease (ICD) 9 coding (ICD9) for glaucoma suspect or glaucoma during a 2-year period (1991-1993) to undergo telephone interview. Participants: Those who were seen at least every 6 months regardless of earlier return instructions were defined as compliant with follow-up (controls, n 362). Those who had any lapse between visits of longer than 6 months were defined as noncompliant (cases, n = 362). Results: Interviews were completed for 196 cases and 242 controls. Noncompliant persons were significantly more likely to be suspects for glaucoma rather than to have definite glaucoma and to be dissatisfied with waiting time in the clinic (29.1% vs. 17.8%, P < 0.005) and to state that they did not take their glaucoma medications as prescribed (25.4% vs. 13.4%, P < 0.004). They also were less likely to have been prescribed eyedrop medication. A high percentage of both patients and controls knew that glaucoma can lead to blindness (85.2% and 88.4%, respectively). The most common reasons patients gave for not keeping follow-up visits were the perception that their eye problem was "not serious enough," the cost of examinations, and that the doctor did not tell them to come back. Conclusion: Compliance with follow-up visits for glaucoma is associated with markers for early disease. Attempts to improve compliance might focus on improved communication of the seriousness of the disease and improvements in clinic waiting time. AN - WOS:000076831500033 AU - Kosoko, O. AU - Quigley, H. A. AU - Vitale, S. AU - Enger, C. AU - Kerrigan, L. AU - Tielsch, J. M. DA - NOV DO - 10.1016/S0161-6420(98)91134-4 IS - 11 PY - 1998 SN - 0161-6420 1549-4713 SP - 2105-2111 ST - Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic T2 - OPHTHALMOLOGY TI - Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic VL - 105 ID - 5837 ER - TY - JOUR AD - O. Kosoko-Lasaki, Department of Surgery, Creighton University, 2500 California Plaza, Omaha, NE 68178, United States AU - Kosoko-Lasaki, O. AU - Olivier, M. M. G. DB - Embase Medline DO - 10.1097/00004397-200343040-00012 IS - 4 KW - alpha adrenergic receptor blocking agent antimetabolite beta adrenergic receptor blocking agent carvedilol dipeptidyl carboxypeptidase inhibitor enalapril latanoprost prostaglandin derivative timolol travoprost argon laser blindness budget clinical trial cornea thickness drug response epidemiological data ethnic difference glaucoma health care delivery health care quality health service human laser surgery medicare open angle glaucoma optic nerve patient compliance patient education population genetics prevalence priority journal race difference review tonometer trabeculectomy treatment failure LA - English M3 - Review N1 - L37305517 2003-11-05 PY - 2003 SN - 0020-8167 SP - 123-131 ST - African American Health Disparities: Glaucoma as a Case Study T2 - International Ophthalmology Clinics TI - African American Health Disparities: Glaucoma as a Case Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37305517&from=export http://dx.doi.org/10.1097/00004397-200343040-00012 VL - 43 ID - 3805 ER - TY - JOUR AB - A prospective, cross-sectional and randomized cross-over study was conducted to study the clinical features and treatment outcome among Thai patients with vernal keratoconjunctivitis (VKC). History-taking and eye examinations were performed. Mild cases of VKC were given topical antihistamine four times daily. Moderate and severe cases of VKC were treated with topical lodoxamide four times a day. Severe cases of VKC were given topical corticosteroids. Moderate and severe cases of VKC, which were refractory to treatment with either corticosteroids or a mast cell stabilizer had topical cyclosporine 0.5 % instilled four times daily. Five patients were exposed to two different treatment regimens in sequence. As main outcome measures, itching, foreign body sensation, photophobia, conjunctival injection, papillae and chemosis were evaluated weekly. The patients with the palpebral type of VKC had daily symptoms, which were more severe and triggered by house-dust with a significant difference among the groups. Limbal VKC was associated with allergic rhinitis more commonly than palpebral VKC. Positive results of skin prick testing to acacia, careless weed, mold, Johnson grass and cow's milk were significantly more common in patients with palpebral VKC. The most common symptoms and signs were found in the mixed type of VKC. Purulent discharge, pannus and lid erythema were found in the palpebral type. Levocabastine hydrochloride was sufficient for mild cases of limbal VKC; lodoxamide for the limbal and mixed types. Prednisolone acetate was the drug of choice in severe cases of any type but only for a short period of time. The success rate of topical cyclosporine in the palpebral type was lower than in the limbal type due to an intolerable burning sensation. Topical cyclosporine used in 4 patients with limbal and palpebral type had a success rate of 100% which was greater than in the lodoxamide group. (66.7%, 0%). Compared with topical corticosteroid-treated eyes in one patient, the success rate in topical cyclosporine-treated eyes was not success. Grading the severity of each type of VKC is crucial to obtain good response of any medication and compliance. Topical cyclosporine 0.5% can be an alternative drug to relieve symptoms and signs of VKC in order to avoid steroid-induced glaucoma. AD - P. Kosrirukvongs, Department of Ophthalmology, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand AU - Kosrirukvongs, P. AU - Vichyanond, P. AU - Wongsawad, W. DB - Embase Medline IS - 1 KW - antibiotic agent antihistaminic agent corticosteroid cyclosporine histamine H1 receptor antagonist levocabastine lodoxamide histamine release inhibitor prednisolone acetate stabilizing agent steroid unclassified drug Acacia adolescent adult allergic rhinitis anamnesis article burning sensation chemosis child clinical article clinical examination clinical feature clinical trial controlled clinical trial controlled study crossover procedure disease association disease severity drug choice drug efficacy drug exposure drug hypersensitivity drug induced disease erythema female glaucoma grass house dust human infant intraocular foreign body male mast cell milk mold optic nerve lesion outcomes research palpebral fissure pannus papillary conjunctivitis patient compliance photophobia prevalence prick test prospective study pruritus pus randomized controlled trial symptomatology Thailand treatment outcome vernal conjunctivitis weed LA - English M3 - Article N1 - L36958136 2003-08-18 PY - 2003 SN - 0125-877X SP - 25-30 ST - Vernal keratoconjunctivitis in Thailand T2 - Asian Pacific Journal of Allergy and Immunology TI - Vernal keratoconjunctivitis in Thailand UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36958136&from=export VL - 21 ID - 3830 ER - TY - JOUR AB - Aims: To review the characteristics of patients attending a tertiary ophthalmic referral centre certified as sight impaired (SI) or severely sight impaired (SSI) from glaucoma. Methods: One hundred consecutive patients certified SI/SSI from the Glaucoma Service at Moorfields Eye Hospital, London, from January 2007 were identified from the England and Wales certification of visual impairment database. Clinical and demographic data were collected from hospital case records. Results: The median (IQR) age of patients at presentation was 66.3 (55.6 to 75.3) years; median (IQR) interval to certification was 62.2 (22.5 to 129.3) months. Fifty-seven patients presented with bilateral SSI (median (IQR) age 70.4 (59.0 to 76.9) years); interval to certification was 35.4 (5.6 to 78.1) months. Seventeen patients presented with a bilateral SI (median (IQR) age 62.1 (58.7 to 68.4) years; median (IQR) interval to certification: 137.4 (64.4 to 190.4) months). Twentyeight patients showed disease progression while under National Health Service hospital eye service care, five of whom had no certifiable visual impairment in either eye at presentation. This was attributed to inadequate intraocular pressure control; five of these patients (18%) were deemed poorly compliant to topical hypotensive medication. Conclusions: Over 80% patients on the certification of visual impairment register from Moorfields Eye Hospital with glaucoma as the primary cause had a significant visual disability at presentation, with almost two-thirds of patients presenting bilaterally 'blind'. There appear to be delays to certification. Despite being under the hospital eye service, a number of glaucoma patients still progress to certifiable visual impairment. AD - W.A. Franks, Glaucoma Service Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, United Kingdom AU - Kotecha, A. AU - Fernandes, S. AU - Bunce, C. AU - Franks, W. A. DB - Embase Medline DO - 10.1136/bjophthalmol-2012-301499 IS - 6 KW - antihypertensive agent adult aged article certification disease course disease registry eye care female human intraocular pressure major clinical study male national health service open angle glaucoma patient compliance priority journal retrospective study tertiary health care United Kingdom visual impairment LA - English M3 - Article N1 - L51947018 2012-04-08 2012-06-07 PY - 2012 SN - 0007-1161 1468-2079 SP - 816-820 ST - Avoidable sight loss from glaucoma: Is it unavoidable? T2 - British Journal of Ophthalmology TI - Avoidable sight loss from glaucoma: Is it unavoidable? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51947018&from=export http://dx.doi.org/10.1136/bjophthalmol-2012-301499 http://bjo.bmj.com/content/96/6/816.full.pdf+html VL - 96 ID - 3084 ER - TY - JOUR AB - PURPOSE: Aim of the study was to identify obstacles to medication adherence (compliance) for patients with glaucoma. MATERIAL AND METHODS: A prospective case series of structured interviews were conducted in 150 patients with glaucoma. (75 patients treated in the glaucoma out-patient clinic of the Department of Ophthalmology, Medical University, Lublin, Poland and 75 patients treated in regional out-patient clinics). Questionnaire of an anonymous survey, formulated on the basis of the publication: Tsai J.C. et al. "Compliance barriers in glaucoma: a systematic classification", J. Glaucoma. 2003, 12, 393-398. RESULTS: The results of the survey showed omissions of particular doses of medications in 62.7% of patients from regional outpatient clinics and in 35.3% of patients treated at the Department of Ophthalmology. It was shown that 32.7% of respondents from regional outpatient clinics and 8.7% from the Department of Ophthalmology Glaucoma Clinic declared remaining without antiglaucoma drops for more than one day. As reasons for omissions of single doses of the medications: forgetfulness (54.7%), too many doses of medications (10%) and little knowledge about the disease (10%) were usually pointed. According to the respondents: little knowledge (32%) and financial factors (22%) are the main causes of medications withdrawal for longer time. CONCLUSIONS: The most common obstacles to medication compliance for patients with glaucoma include: forgetfulness, low level of knowledge about the disease, financial factors and too many doses of the medications. Fewer doses and the presence of a supporting person have a positive influence on compliance. AD - M. Kowal, Katedry i Kliniki Okulistyki Uniwersytetu Medycznego w Lublinie. AU - Kowal, M. AU - Choragiewicz, T. AU - Mietlicka, K. AU - Wyszyńska, A. AU - Zarnowski, T. DB - Medline IS - 10-12 KW - antihypertensive agent aged article attitude to health female follow up glaucoma health behavior human male middle aged patient compliance Poland questionnaire statistics treatment refusal LA - Polish M3 - Article N1 - L354300148 2009-03-20 PY - 2008 SN - 0023-2157 SP - 347-351 ST - Obstacles to medication compliance for patients with glaucoma T2 - Klinika oczna TI - Obstacles to medication compliance for patients with glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354300148&from=export VL - 110 ID - 3413 ER - TY - JOUR AD - D. Kowing, Daytona Beach VA Outpatient Clinic, Daytona Beach, FL, USA. AU - Kowing, D. AU - Kester, E. DB - Medline DO - 10.1097/01.NPR.0000279566.70700.09 IS - 7 KW - antihypertensive agent eye drops glaucoma human pathophysiology patient compliance review LA - English M3 - Review N1 - L47419633 2007-07-01 PY - 2007 SN - 0361-1817 SP - 18-23; quiz 23-24 ST - Keep an eye out for glaucoma T2 - The Nurse practitioner TI - Keep an eye out for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47419633&from=export http://dx.doi.org/10.1097/01.NPR.0000279566.70700.09 VL - 32 ID - 3517 ER - TY - JOUR AB - Purpose: This study was designed to raise awareness of the materials, devices, and Internet resources available to improve adherence to use of medications for the treatment of glaucoma and to review new devices under development. Methods: A review of current indexed literature and Internet resources was conducted. Results: A variety of educational brochures, pamphlets, and fact sheets promoting adherence to ocular hypotensive medications are available through multiple organizations and are easily accessed and ordered on the Internet. Video and Web-based patient educational tools have been designed to support patient adherence to glaucoma management plans and promote open dialogue between patients and providers. Reminder and recall systems that integrate with office software can be sent to cell phones as well as e-mails and personal digital assistant (PDAs), alerting patients to upcoming appointments and reminding them to instill their drops. Bottle devices with dosing support (timers with audible and visual signals and dispensing aids) and electronic monitoring have been shown to promote adherence. New products currently under development to improve the delivery of medications include nanoparticles, punctal plugs, and contact lenses that release glaucoma medications. Conclusions: Many educational materials, services, Internet resources, and devices are available to optometrists to encourage patient adherence to glaucoma treatment and management. AD - D. Kowing, William Chappell Veterans Affairs Outpatient Clinic, Daytona Beach, FL, United States AU - Kowing, D. AU - Messer, D. AU - Slagle, S. AU - Wasik, A. DB - Medline DO - 10.1016/j.optm.2009.09.021 IS - 7 KW - eye drops article drug delivery system equipment design glaucoma human devices Internet methodology optometry patient compliance patient education reminder system videorecording LA - English M3 - Article N1 - L359021101 2011-04-08 PY - 2010 SN - 1529-1839 SP - 339-350 ST - Programs to optimize adherence in glaucoma T2 - Optometry TI - Programs to optimize adherence in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359021101&from=export http://dx.doi.org/10.1016/j.optm.2009.09.021 VL - 81 ID - 3242 ER - TY - JOUR AD - William Chappell Veterans Affairs Outpatient Clinic, Daytona Beach, Florida; Nova Southeastern University College of Optometry, Ft. Lauderdale, Florida. AN - 105061198. Corporate Author: V-POAG Study Group. Language: English. Entry Date: 20101126. Revision Date: 20200708. Publication Type: Journal Article AU - Kowing, D. AU - Messer, D. AU - Slagle, S. AU - Wasik, A. DB - ccm DO - 10.1016/j.optm.2009.09.021 DP - EBSCOhost IS - 7 KW - Glaucoma -- Drug Therapy Patient Compliance Drug Delivery Systems Equipment Design Human Internet Ophthalmic Solutions -- Administration and Dosage Optometry -- Equipment and Supplies Optometry -- Methods Patient Education -- Methods Reminder Systems Videorecording N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 100912421. PMID: NLM20630372. PY - 2010 SN - 1529-1839 SP - 339-350 ST - Programs to optimize adherence in glaucoma T2 - Optometry -- Journal of the American Optometric Association TI - Programs to optimize adherence in glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105061198&site=ehost-live&scope=site VL - 81 ID - 4504 ER - TY - JOUR AB - Purpose: This study was designed to raise awareness of the materials, devices, and Internet resources available to improve adherence to use of medications for the treatment of glaucoma and to review new devices under development. Methods: A review of current indexed literature and Internet resources was conducted. Results: A variety of educational brochures, pamphlets, and fact sheets promoting adherence to ocular hypotensive medications are available through multiple organizations and are easily accessed and ordered on the Internet. Video and Web-based patient educational tools have been designed to support patient adherence to glaucoma management plans and promote open dialogue between patients and providers. Reminder and recall systems that integrate with office software can be sent to cell phones as well as e-mails and personal digital assistant (PDAs), alerting patients to upcoming appointments and reminding them to instill their drops. Bottle devices with dosing support (timers with audible and visual signals and dispensing aids) and electronic monitoring have been shown to promote adherence. New products currently under development to improve the delivery of medications include nanoparticles, punctal plugs, and contact lenses that release glaucoma medications. Conclusions: Many educational materials, services, Internet resources, and devices are available to optometrists to encourage patient adherence to glaucoma treatment and management. AD - William Chappell Veterans Affairs Outpatient Clinic, Daytona Beach, FL, United States Nova Southeastern University College of Optometry, Ft. Lauderdale, FL, United States Department of Ophthalmology and Vision Science, The University of Arizona, Tucson, AZ, United States Southern Arizona Veterans Affairs Health Care System, Tucson, AZ, United States Salem Veterans Affairs Medical Center, Salem, VA, United States Edward Via Virginia College of Osteopathic Medicine, Blacksburg, VA, United States Southern Arizona Veterans Affairs, Tucson, AZ, United States Southern California College of Optometry, Fullerton, CA, United States AU - Kowing, D. AU - Messer, D. AU - Slagle, S. AU - Wasik, A. DB - Scopus DO - 10.1016/j.optm.2009.09.021 IS - 7 KW - Adherence Dosing aids and devices Education Electronic monitoring Glaucoma M3 - Article N1 - Cited By :15 Export Date: 19 July 2021 PY - 2010 SP - 339-350 ST - Programs to optimize adherence in glaucoma T2 - Optometry TI - Programs to optimize adherence in glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953670624&doi=10.1016%2fj.optm.2009.09.021&partnerID=40&md5=c9de7296ec8348ca95abf9f950ca2800 VL - 81 ID - 5196 ER - TY - JOUR AB - PURPOSE: This study was designed to raise awareness of the materials, devices, and Internet resources available to improve adherence to use of medications for the treatment of glaucoma and to review new devices under development. METHODS: A review of current indexed literature and Internet resources was conducted. RESULTS: A variety of educational brochures, pamphlets, and fact sheets promoting adherence to ocular hypotensive medications are available through multiple organizations and are easily accessed and ordered on the Internet. Video and Web-based patient educational tools have been designed to support patient adherence to glaucoma management plans and promote open dialogue between patients and providers. Reminder and recall systems that integrate with office software can be sent to cell phones as well as e-mails and personal digital assistant (PDAs), alerting patients to upcoming appointments and reminding them to instill their drops. Bottle devices with dosing support (timers with audible and visual signals and dispensing aids) and electronic monitoring have been shown to promote adherence. New products currently under development to improve the delivery of medications include nanoparticles, punctal plugs, and contact lenses that release glaucoma medications. CONCLUSIONS: Many educational materials, services, Internet resources, and devices are available to optometrists to encourage patient adherence to glaucoma treatment and management. Optometry 2010;81:339-350 AN - WOS:000293364300003 AU - Kowing, D. AU - Messer, D. AU - Slagle, S. AU - Wasik, A. AU - Grp, V. Poag Study DA - JUL DO - 10.1016/j.optm.2009.09.021 IS - 7 PY - 2010 SN - 1529-1839 1558-1527 SP - 339-350 ST - Programs to optimize adherence in glaucoma T2 - OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION TI - Programs to optimize adherence in glaucoma VL - 81 ID - 6105 ER - TY - JOUR AB - PURPOSE: To report 2 cases of keratomycosis caused by Aspergillus tubingensis. METHODS: The therapeutic courses were recorded for 2 male patients, 52 and 78 years old, with fungal keratitis caused by black Aspergillus strains. Morphological examination of the isolates was carried out on malt extract agar plates. A segment of the β-tubulin gene was used for molecular identification. Antifungal susceptibilities were determined by the E test method for molds and the broth microdilution technique National Committee for Clinical Laboratory Standards M38-A. RESULTS: A 52-year-old man presented with complaints of pain and redness in the right eye. The patient was successfully treated with natamycin and econazole eyedrops, itraconazole eye ointment, and oral ketoconazole. A 78-year-old man presented with total corneal necrosis in the right eye. A therapeutic keratoplasty was performed, and topical natamycin and econazole were applied. At the postoperative visit after 3 weeks, almost the full corneal graft was clear with formed anterior chamber. Black Aspergillus strains were isolated from the corneal scrapings of both cases and initially identified as Aspergillus niger based on culture characteristics. Sequence analysis of a segment of the β-tubulin gene revealed that the isolates are representatives of A. tubingensis. CONCLUSIONS: Aspergillus tubingensis is closely related with A. niger, the differentiation of these 2 species is difficult by classical morphological criteria. To our knowledge, the presented cases of fungal keratitis are the first reports on ocular infection caused by A. tubingensis. © 2009 Lippincott Williams & Wilkins, Inc. AD - Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary Applied and Industrial Mycology Department, CBS Fungal Biodiversity Centre, Utrecht, Netherlands Department of Microbiology, Aravind Eye Hospital, Postgraduate Institute of Ophthalmology, Avinashi Road, Coimbatore 641 014, Tamil Nadu, India Department of Clinical Microbiology and Diagnostics, Faculty of Medicine, University of Szeged, Szeged, Hungary Department of Microbiology, Coimbatore Medical College, Coimbatore, Tamil Nadu, India Department of Botany and Microbiology, A.V.V.M. Sri Pushpam College, Thanjavur, Tamil Nadu, India AU - Kredics, L. AU - Varga, J. AU - Kocsubé, S. AU - Rajaraman, R. AU - Raghavan, A. AU - Dóczi, I. AU - Bhaskar, M. AU - Németh, T. M. AU - Antal, Z. AU - Venkatapathy, N. AU - Vágvölgyi, C. AU - Samson, R. A. AU - Chockaiya, M. AU - Palanisamy, M. DB - Scopus DO - 10.1097/ICO.0b013e3181967098 IS - 8 KW - Aspergillus tubingensis Corneal ulcer Fungal keratitis Keratomycosis M3 - Article N1 - Cited By :33 Export Date: 19 July 2021 PY - 2009 SP - 951-954 ST - Infectious keratitis caused by Aspergillus tubingensis T2 - Cornea TI - Infectious keratitis caused by Aspergillus tubingensis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-69749100146&doi=10.1097%2fICO.0b013e3181967098&partnerID=40&md5=d6d95d5b21cda4ac6649c1a55b138c4e VL - 28 ID - 5045 ER - TY - JOUR AB - The monocular trial has been proposed as a test to help control for diurnal fluctuations in eye pressure when assessing medication effectiveness. We undertook a prospective study to determine the sensitivity and specificity of the monocular trial as a test for determining the effectiveness of a glaucoma medication. The efficacy of the monocular trial was compared to the diagnostic paradigm of repeated pre- and post-treatment measurements in determining whether an intraocular pressure (IOP)-lowering drug is effective. Forty-two patients with newly diagnosed open-angle glaucoma completed five visits: visit 1 for determining eligibility, obtaining consent, and measuring IOP, visit 2 for a second pressure measurement, and visit 3 for a third pressure reading. The new medication was then started in one eye. IOP measurements were made at weeks 4 and 6. The gold standard IOP change was defined as the difference in mean between the pre- and post-medication visits. A medication was deemed effective if this difference was at least 15%. The monocular trial pressure change was defined as the IOP change in the treated eye between the visit immediately before and immediately after the medication addition, corrected by subtracting the pressure change in the untreated eye. All 42 patients completed the full protocol with good compliance. Twenty-five of 42 (60%) medication additions were considered effective by the gold standard method, and 25/42 (60%) by the monocular trial method. However, the two methods agreed in only 26 patients (17 Yes/Yes, 9 No/No). The calculated sensitivity was low (0.68), with a specificity of 0.53. The monocular trial can give useful clues as to whether a medication is effective, but should not be the only information used in making this determination. To obtain the most valid results, multiple pressure checks should be done before and after starting a new medication. © 2012 Krishna et al, publisher and licensee Dove Medical Press Ltd. AD - Vision Research Center, Department of Ophthalmology, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, United States AU - Krishna, R. AU - DeBry, P. W. AU - Waldman, C. W. AU - Koulen, P. DB - Scopus DO - 10.2147/OPTH.S29858 IS - 1 KW - Applanation tonometry Eye Glaucoma Pharmacology Vision Visual field M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2012 SP - 491-496 ST - Comparing the efficacy of the monocular trial treatment paradigm with multiple measurements of intraocular pressure before and after treatment initiation in primary open-angle glaucoma T2 - Clinical Ophthalmology TI - Comparing the efficacy of the monocular trial treatment paradigm with multiple measurements of intraocular pressure before and after treatment initiation in primary open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930473301&doi=10.2147%2fOPTH.S29858&partnerID=40&md5=e7e5c5ae2a26a234df549be3317e709e VL - 6 ID - 5525 ER - TY - JOUR AN - 108110022. Language: English. Entry Date: 20121115. Revision Date: 20150712. Publication Type: Journal Article AU - Kronemyer, Bob DB - ccm DP - EBSCOhost IS - 18 KW - Glaucoma -- Complications -- In Old Age Dementia -- Risk Factors -- In Old Age Depression -- Risk Factors -- In Old Age Aged Patient Compliance N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Gerontologic Care; Perioperative Care; Psychiatry/Psychology. NLM UID: 9882135. PY - 2012 SN - 8750-3085 SP - 8-8 ST - Older adults with glaucoma more prone to cognitive impairment, depression T2 - Ocular Surgery News TI - Older adults with glaucoma more prone to cognitive impairment, depression UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108110022&site=ehost-live&scope=site VL - 30 ID - 4719 ER - TY - JOUR AB - The article discusses a study by L.Jay Katz and colleagues, which evaluated patients with open angle glaucoma or ocular hypertension, and found that the mean intra-ocular pressure (IOP) did not differ between selective laser trabeculopaslty (SLT) or medical therapy. AN - 84384562. Language: English. Entry Date: 20121226. Revision Date: 20130122. Publication Type: Article AU - Kronemyer, Bob DB - ccm DP - EBSCOhost IS - 23 KW - Treatment Outcomes Intraocular Pressure Keratectomy, Laser Glaucoma -- Therapy Ocular Hypertension -- Therapy Glaucoma -- Drug Therapy Ocular Hypertension -- Drug Therapy Patient Compliance N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9882135. PY - 2012 SN - 8750-3085 SP - 17-17 ST - Study yields no difference in IOP between SLT, drugs as initial therapy T2 - Ocular Surgery News TI - Study yields no difference in IOP between SLT, drugs as initial therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=84384562&site=ehost-live&scope=site VL - 30 ID - 4737 ER - TY - JOUR AN - 108085919. Language: English. Entry Date: 20121226. Revision Date: 20150712. Publication Type: Journal Article AU - Kronemyer, Bob DB - ccm DP - EBSCOhost IS - 23 KW - Treatment Outcomes Intraocular Pressure Keratectomy, Laser Glaucoma -- Therapy Ocular Hypertension -- Therapy Glaucoma -- Drug Therapy Ocular Hypertension -- Drug Therapy Patient Compliance N1 - brief item. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Perioperative Care. NLM UID: 9882135. PY - 2012 SN - 8750-3085 SP - 17-17 ST - Study yields no difference in IOP between SLT, drugs as initial therapy T2 - Ocular Surgery News TI - Study yields no difference in IOP between SLT, drugs as initial therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108085919&site=ehost-live&scope=site VL - 30 ID - 4762 ER - TY - JOUR AB - Aim/background-The pseudoexfoliation (PEX) syndrome is frequently associated with impairment of the blood-aqueous barrier. This study analysed if this might stimulate secondary cataract following cataract extraction. Methods-This historical cohort study included 197 eyes of 197 patients (99 with and 98 without PEX) that underwent extracapsular cataract extraction with posterior chamber lens implantation (PMMA optic) between 1985 and 1991. Secondary cataract was defined as opacification of the axial posterior capsule and decrease of visual acuity by two or more lines. Mean follow up was 23.8 months. For statistical analysis, the Kaplan-Meier method and multivariate Cox regression analysis were used. Results-Secondary cataract was observed within 24 months in 35% (SD 7%) of all eyes, and was significantly more frequent in eyes with PEX (45 (11)%) than in eyes without PEX (24 (9)%, p<0.03). Eyes with diabetes mellitus (n=32) showed a significantly lower frequency of secondary cataract (11 (11)%) than eyes without diabetes mellitus (39 (8)%, p<0.01). The influences of sex, open angle glaucoma, type of cataract, surgeon, positioning of IOL, and phacoemulsification versus nuclear expression on secondary cataract did not reach statistical significance. Conclusion-The higher frequency of secondary cataract could be considered as another potential complication of cataract surgery in eyes with PEX. AN - WOS:A1997YA15600014 AU - Kuchle, M. AU - Amberg, A. AU - Martus, P. AU - Nguyen, N. X. AU - Naumann, G. O. H. DA - OCT DO - 10.1136/bjo.81.10.862 IS - 10 PY - 1997 SN - 0007-1161 SP - 862-866 ST - Pseudoexfoliation syndrome and secondary cataract T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - Pseudoexfoliation syndrome and secondary cataract VL - 81 ID - 6271 ER - TY - JOUR AB - In a phenomenological study of glaucoma as an illness, 31 patients were interviewed. The goal of the study was an explication of the meanings of the experience of glaucoma, in a twofold sense: (1) the face, the role, or the self of the patient that responds to the illness; (2) the visage that the illness presents to the patient. This twofold explication was achieved by generating a classification of the interviews in terms of the dominant metaphor that emerged in each interview. The following basic metaphors are presented through case material: glaucoma as an accompaniment of aging, as blindness, as pressure, as an abstraction (and a weapon), and as fate. Variations on these themes demonstrate the necessity, in such work and for enhanced communication with patients, of paying attention to both the face that the illness presents and to the self that responds. AD - R. Kugelmann AU - Kugelmann, R. AU - Bensinger, R. E. DB - Medline IS - 3 KW - adaptive behavior adult aged article blindness case report doctor patient relationship female glaucoma human male middle aged patient attitude patient compliance psychological aspect social isolation LA - English M3 - Article N1 - L14709167 1984-03-14 PY - 1983 SN - 0165-005X SP - 313-328 ST - Metaphors of glaucoma T2 - Culture, medicine and psychiatry TI - Metaphors of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L14709167&from=export VL - 7 ID - 4087 ER - TY - JOUR AB - Purpose: To compare the efficacy and safety profile of Timolol maleate 0.5% versus Timolol gel forming solution (GFS) 0.5% in open angle glaucoma in Indian eyes. Methods: In a prospective crossover study 52 patients of open angle glaucoma, well controlled intraocular pressure (IOP) on 0.5% timolol maleate solution were switched over to timolol GFS once a day, after a washout period of one month. A diurnal IOP measurement was done after 6 weeks and compared with patients on timolol maleate 0.5% twice a day. In addition, side effects reported or observed were compared. Results: Statistically significant difference was not observed in ocular hypotensive effect of the two treatments. The side-effects in both the treatment groups were similar except for higher incidence of blurring of vision in patients on timolol GFS. The compliance was better with timolol GFS, but was not statistically significant. Conclusion: The results of this study suggest that the more convenient 0.5% timolol in gel forming solution can be offered as an equally efficacious and well-tolerated alternative to twice daily 0.5% timolol solution in open angle glaucoma. AD - R. Sudan, All India Inst. of Medical Sciences, Hostel No. 7, Ansari Nagar, New Delhi - 110 029, India AU - Kumar, H. AU - Sudan, R. AU - Sethi, H. S. AU - Sony, P. C1 - timolet gfs(milmet,India) C2 - milmet(India) DB - Embase Medline IS - 1 KW - timolet gfs timolol maleate adult aged article blepharitis circadian rhythm clinical trial controlled clinical trial controlled study crossover procedure drug efficacy drug formulation drug safety drug tolerability fatigue female foreign body gel headache human hyperemia insomnia intraocular hypotension intraocular pressure major clinical study male open angle glaucoma patient compliance preliminary communication prospective study pruritus tear flow tonometry treatment outcome visual impairment LA - English M3 - Article N1 - L34229345 2002-03-28 PY - 2002 SN - 0301-4738 SP - 21-23 ST - Timolol maleate 0.5% versus timolol maleate in gel forming solution 0.5% (Timolol GFS) in open angle glaucoma in India. Preliminary safety and efficacy study T2 - Indian Journal of Ophthalmology TI - Timolol maleate 0.5% versus timolol maleate in gel forming solution 0.5% (Timolol GFS) in open angle glaucoma in India. Preliminary safety and efficacy study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34229345&from=export VL - 50 ID - 3875 ER - TY - JOUR AB - Purpose: Glaucoma medications reduce the risk of progressive visual field loss, but adherence to these medications is often poor. A better understanding of the appropriate metrics for quantifying glaucoma medication adherence is needed. We describe and compare different means of quantifying glaucoma medication adherence. Methods: Adults with glaucoma were enrolled in a prospective 2-site study. Participants completed a selfreport instrument and received electronic medication monitors to use for ∗3 months. Pharmacy records were queried regarding requested refills over the monitoring period; medication possession ratio (MPR) was calculated. Results: Of the 137 total participants, those who answered "Very confident" to the question, "How confident are you that you always remember to use your glaucoma medications?" and "No" to the question, "In the past 4 weeks, did you ever forget to take your medicine?" were more likely [odds ratio (OR) 2.78, 95% confidence interval (CI) 1.19-6.52] to take ≥80% of the prescribed doses according to electronic medication monitors. Mean MPR was 1.49, standard deviation (SD) 0.82, range 0.1-5.31. The proportion of participants taking greater than or equal to 80% of the prescribed doses according to the electronic monitors was 59% for participants with MPR <1.2 (n = 27), 63% for participants with MPR 1.2-1.8 (n = 27), and 88% for MPR >1.8 (n = 25). Conclusions: Asking about confidence may be a good method of screening for poor adherence for glaucoma medication. MPR may be an inadequate representation of glaucoma medication adherence. AD - K.W. Muir, Health Services Research and Development, Durham VA Medical Center, 508 Fulton Street, Durham, NC, United States AU - Kumar, J. B. AU - Bosworth, H. B. AU - Sleath, B. AU - Woolson, S. AU - Olsen, M. AU - Danus, S. AU - Muir, K. W. DB - Embase Medline DO - 10.1089/jop.2015.0102 IS - 6 KW - antiglaucoma agent eye drops timolol adult aged article drug monitoring drug use female glaucoma health literacy human interpersonal communication major clinical study male medication compliance medication possession ratio patient compliance pharmaceutical care pharmacy (shop) prescription prospective study self concept self report treatment refusal visual analog scale LA - English M3 - Article N1 - L611357575 2016-07-28 2016-08-08 PY - 2016 SN - 1557-7732 1080-7683 SP - 346-354 ST - Quantifying glaucoma medication adherence: The relationship between self-report, electronic monitoring, and pharmacy refill T2 - Journal of Ocular Pharmacology and Therapeutics TI - Quantifying glaucoma medication adherence: The relationship between self-report, electronic monitoring, and pharmacy refill UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611357575&from=export http://dx.doi.org/10.1089/jop.2015.0102 VL - 32 ID - 2732 ER - TY - JOUR AB - Purpose: Glaucoma medications reduce the risk of progressive visual field loss, but adherence to these medications is often poor. A better understanding of the appropriate metrics for quantifying glaucoma medication adherence is needed. We describe and compare different means of quantifying glaucoma medication adherence.Methods: Adults with glaucoma were enrolled in a prospective 2-site study. Participants completed a self-report instrument and received electronic medication monitors to use for ∼3 months. Pharmacy records were queried regarding requested refills over the monitoring period; medication possession ratio (MPR) was calculated.Results: Of the 137 total participants, those who answered "Very confident" to the question, "How confident are you that you always remember to use your glaucoma medications?" and "No" to the question, "In the past 4 weeks, did you ever forget to take your medicine?" were more likely [odds ratio (OR) 2.78, 95% confidence interval (CI) 1.19-6.52] to take ≥80% of the prescribed doses according to electronic medication monitors. Mean MPR was 1.49, standard deviation (SD) 0.82, range 0.1-5.31. The proportion of participants taking greater than or equal to 80% of the prescribed doses according to the electronic monitors was 59% for participants with MPR <1.2 (n = 27), 63% for participants with MPR 1.2-1.8 (n = 27), and 88% for MPR >1.8 (n = 25).Conclusions: Asking about confidence may be a good method of screening for poor adherence for glaucoma medication. MPR may be an inadequate representation of glaucoma medication adherence. AD - Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina. Department of Medicine, Durham VA Medical Center, Duke University School of Medicine, Durham, North Carolina. Health Services Research & Development, Durham VA Medical Center, Durham, North Carolina. Eshelman School of Pharmacy, Pharmaceutical Outcomes and Policy, University of North Carolina Chapel Hill, North Carolina. Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina. AN - 116856808. Language: English. Entry Date: 20171104. Revision Date: 20191106. Publication Type: journal article AU - Kumar, Jaya B. AU - Bosworth, Hayden B. AU - Sleath, Betsy AU - Woolson, Sandra AU - Olsen, Maren AU - Danus, Susanne AU - Muir, Kelly W. DB - ccm DO - 10.1089/jop.2015.0102 DP - EBSCOhost IS - 6 KW - Pharmacy Service -- Statistics and Numerical Data Self Report Medication Compliance Glaucoma -- Drug Therapy Prescriptions, Drug -- Statistics and Numerical Data Aged Aged, 80 and Over Middle Age Adult Drug Monitoring Male Female Human N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM27058842. PY - 2016 SN - 1080-7683 SP - 346-354 ST - Quantifying Glaucoma Medication Adherence: The Relationship Between Self-Report, Electronic Monitoring, and Pharmacy Refill T2 - Journal of Ocular Pharmacology & Therapeutics TI - Quantifying Glaucoma Medication Adherence: The Relationship Between Self-Report, Electronic Monitoring, and Pharmacy Refill UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116856808&site=ehost-live&scope=site VL - 32 ID - 4267 ER - TY - JOUR AB - Congenital ectropion uveae (CEU) is a rare anomaly characterized by ectropion uveae, iris hypoplasia, iridotrabecular dysgenesis and glaucoma. The apparent ectropion uveae results from the spread of iris pigment epithelium beyond the iris ruff and onto the anterior surface of the iris. Conclusion Open-angle glaucoma results due to angle dysgenesis, so patients should be carefully examined periodically for its early detection. © 2017, Springer Science+Business Media B.V. AD - Regional Institute of Ophthalmology (RIO), Indira Gandhi Institute of Medical Science (IGIMS), Patna, India All India Institute of Medical Sciences, Patna, India AU - Kumari, R. AU - Saha, B. C. DB - Scopus DO - 10.1007/s10792-017-0727-8 IS - 6 KW - Congenital glaucoma Intractable glaucoma Iridotrabecular dysgenesis M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2018 SP - 2623-2626 ST - Congenital ectropion uveae with glaucoma: a case report T2 - International Ophthalmology TI - Congenital ectropion uveae with glaucoma: a case report UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031429183&doi=10.1007%2fs10792-017-0727-8&partnerID=40&md5=e72f111a3ab12c678092a9b8a0617600 VL - 38 ID - 5556 ER - TY - JOUR AB - Background: Glaucoma is second cause of blindness in the world. The financial burden on the patient during long-term treatment is immense and affects the compliance to medications, thus visual morbidity. Objective: To analyse economic impact of three commonly used drug combinations (Dorzolamide + Timolol = DT; Brimonidine + Timolol = BT; Latanoprost+Timolol = LT) in primary open angle glaucoma. Materials and Methods: This observational, prospective study was undertaken at M & J Institute of Ophthalmology, Civil Hospital, Ahmedabad, a western regional institute of Ophthalmology. A total of 257 patients were included in the study. Only101 patients could complete the 6 month follow-up, of which 35, 34 and 32 patients belonged to DT, BT and LT group respectively. Cost of drug, details of the transportation were noted at every visit. Total cost incurred per patient/eye was calculated. Cost effectiveness was calculated by cost per mm Hg IOP (Intra-Ocular Pressure) reduction. Results: Treatment with DT, BT & LT group consumed 8.6%, 4.6% and 7.7% of the per annum income of the family, respectively. Cost of medications per annum (in INR)/eye for DT, BT & LT group were 2562 ± 15.74, 1544 ± 32.06, 3876 ± 73.68 (Mean±SEM) respectively. Additional cost of travelling was different for patients coming from Ahmedabad (Locals) and outsiders (patients coming outside Ahmedabad, India). Outsiders has to bear the brunt of higher transport charges, where they spent an average of Rs. 914, 856 & 933 per annum (5 follow-ups), whereas, Locals spent an average of Rs. 104, 112, 100 for DT, BT & LT group respectively. Conclusion: Treatment with BT was found to be most cost-effective among three groups. Drug therapy takes substantial amount from per annum income of family and was an important compliance factor in the treatment of POAG. © 2015, Journal of Clinical and Diagnostic Research. All rights reserved. AD - Department of Pharmacology, BLDE University’s Shri B. M. Patil Medical College, Vijayapura (Bijapur), Karnataka, India AU - Kumbar, S. K. AU - Mirje, M. AU - Moharir, G. AU - Bharatha, A. DB - Scopus DO - 10.7860/JCDR/2015/12491.5966 IS - 5 KW - Cost-effectiveness Drug combinations Economics Intra-ocular pressure M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2015 SP - FC05-FC08 ST - Cost analysis of commonly used combination of drugs in primary open angle Glaucoma T2 - Journal of Clinical and Diagnostic Research TI - Cost analysis of commonly used combination of drugs in primary open angle Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928996564&doi=10.7860%2fJCDR%2f2015%2f12491.5966&partnerID=40&md5=20589831b1ec34f3dc357ca98ec036fc VL - 9 ID - 5358 ER - TY - JOUR AB - Background: Glaucoma is second cause of blindness in the world. The financial burden on the patient during long-term treatment is immense and affects the compliance to medications, thus visual morbidity. Objective: To analyse economic impact of three commonly used drug combinations (Dorzolamide + Timolol = DT; Brimonidine + Timolol = BT; Latanoprost+ Timolol = LT) in primary open angle glaucoma. Materials and Methods: This observational, prospective study was undertaken at M & J Institute of Ophthalmology, Civil Hospital, Ahmedabad, a western regional institute of Ophthalmology. A total of 257 patients were included in the study. Only101 patients could complete the 6 month follow-up, of which 35, 34 and 32 patients belonged to DT, BT and LT group respectively. Cost of drug, details of the transportation were noted at every visit. Total cost incurred per patient/eye was calculated. Cost effectiveness was calculated by cost per mm Hg IOP (Intra-Ocular Pressure) reduction. Results: Treatment with DT, BT & LT group consumed 8.6%, 4.6% and 7.7% of the per annum income of the family, respectively. Cost of medications per annum (in INR)/eye for DT, BT & LT group were 2562 +/- 15.74, 1544 +/- 32.06, 3876 +/- 73.68 (Mean +/- SEM) respectively. Additional cost of travelling was different for patients coming from Ahmedabad (Locals) and outsiders (patients coming outside Ahmedabad, India). Outsiders has to bear the brunt of higher transport charges, where they spent an average of Rs. 914, 856 & 933 per annum (5 follow-ups), whereas, Locals spent an average of Rs. 104, 112, 100 for DT, BT & LT group respectively. Conclusion: Treatment with BT was found to be most cost-effective among three groups. Drug therapy takes substantial amount from per annum income of family and was an important compliance factor in the treatment of POAG. AN - WOS:000409678000025 AU - Kumbar, S. K. AU - Mirje, M. AU - Moharir, G. AU - Bharatha, A. DA - MAY DO - 10.7860/JCDR/2015/12491.5966 IS - 5 PY - 2015 SN - 2249-782X 0973-709X SP - FC5-FC8 ST - Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma T2 - JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH TI - Cost Analysis of Commonly used Combination of Drugs in Primary Open Angle Glaucoma VL - 9 ID - 6167 ER - TY - JOUR AB - Clinical course of different stages of primary open-angle glaucoma (POAG) is studied in 216 patients (432 eyes) who followed monitoring and treatment instructions during 13 years and in those who didn't. In patients who did not follow recommendations glaucoma progression was found in 99,4% of patients with initial disease, in 48,7% of cases with advanced stage and in 50% of patients with the end stage of the disease. Patients who followed recommendations of general ophthalmologists and glaucomatologists showed stable course of glaucoma process in 1 patient (0,6%) with initial stage, in 51,3% of patients with advanced stage and in 50% of patients with the end stage of the disease. AD - V.D. Kunin AU - Kunin, V. D. AU - Redid, A. A. DB - Medline IS - 2 KW - antihypertensive agent article attitude to health disease course drug effect female health care human intraocular pressure male methodology middle aged open angle glaucoma organization and management outcome assessment pathophysiology patient compliance physiologic monitoring psychological aspect risk factor statistics visual system examination LA - Russian M3 - Article N1 - L369466272 2013-08-09 PY - 2013 SN - 0042-465X SP - 63-68 ST - [Glaucoma dynamics in patients who followed monitoring and treatment instructions and in those who didn't] T2 - Vestnik oftalmologii TI - [Glaucoma dynamics in patients who followed monitoring and treatment instructions and in those who didn't] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369466272&from=export VL - 129 ID - 3020 ER - TY - JOUR AB - We evaluated the efficacy and safety of latanoprost eye drops once-weekly, compared to once-daily for improving patient compliance. Twenty (20) patients (11 women and 9 men), 12 with ocular hypertension and 8 with early glaucoma, were studied after washout of the antiglaucoma treatment. One (1) group was treated with latanoprost once-daily (control). The other group was treated once-weekly (study group). Intraocular pressure (IOP) was measured at baseline and on the 2nd, 4th, 6th, and 9th day after the last drop in the study group, and for 3 months on the same schedule thereafter. The mean baseline IOP was 24.3 ± 3.9 mmHg in the study group (range, 18-29) and 24.4 ± 4.4 mmHg in the control group (range, 17-32). The average IOP at all time points of post-treatment was 17.7 ± 1.5 mmHg (range, 14-23) and 16.9 ± 2.30 mmHg (range, 13-21), respectively. Latanoprost significantly lowered IOP in both groups (study group, p = 0.005; controls, p = 0.0019). The difference between post-treatment IOP was insignificant in both groups at each time point. The study group had fewer minor side effects than the control group (1/10 versus 6/10, respectively). Latanoprost treatment once-weekly was as effective, and bore fewer minor side effects, as once-daily treatment after 3 months of follow-up. AD - S. Kurtz, Department of Ophthalmology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel AU - Kurtz, S. AU - Shemesh, G. C1 - xalatan(premedico pharmacia upjohn,Sweden) C2 - premedico pharmacia upjohn(Sweden) DB - Embase Medline DO - 10.1089/1080768041725353 IS - 4 KW - eye drops latanoprost adult aged article clinical article controlled study drug dose regimen drug efficacy drug safety eye burning female follow up foreign body glaucoma human intraocular hypertension intraocular pressure male ocular pruritus patient compliance patient satisfaction xalatan LA - English M3 - Article N1 - L39108896 2004-09-09 PY - 2004 SN - 1080-7683 SP - 321-327 ST - The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure T2 - Journal of Ocular Pharmacology and Therapeutics TI - The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39108896&from=export http://dx.doi.org/10.1089/1080768041725353 VL - 20 ID - 3736 ER - TY - JOUR AB - We evaluated the efficacy and safety of latanoprost eye drops once-weekly, compared to once-daily for improving patient compliance. Twenty (20) patients (11 women and 9 men), 12 with ocular hypertension and 8 with early glaucoma, were studied after washout of the antiglaucoma treatment. One (1) group was treated with latanoprost once-daily (control). The other group was treated once-weekly (study group). Intraocular pressure (IOP) was measured at baseline and on the 2nd, 4th, 6th, and 9th day after the last drop in the study group, and for 3 months on the same schedule thereafter. The mean baseline IOP was 24.3 ± 3.9 mmHg in the study group (range, 18-29) and 24.4 ± 4.4 mmHg in the control group (range, 17-32). The average IOP at all time points of post-treatment was 17.7 ± 1.5 mmHg (range, 14-23) and 16.9 ± 2.30 mmHg (range, 13-21), respectively. Latanoprost significantly lowered IOP in both groups (study group, p = 0.005; controls, p = 0.0019). The difference between post-treatment IOP was insignificant in both groups at each time point. The study group had fewer minor side effects than the control group (1/10 versus 6/10, respectively). Latanoprost treatment once-weekly was as effective, and bore fewer minor side effects, as once-daily treatment after 3 months of follow-up. AD - Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel Department of Ophthalmology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel AU - Kurtz, S. AU - Shemesh, G. DB - Scopus DO - 10.1089/1080768041725353 IS - 4 M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2004 SP - 321-327 ST - The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure T2 - Journal of Ocular Pharmacology and Therapeutics TI - The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-4243061716&doi=10.1089%2f1080768041725353&partnerID=40&md5=e3a5b619c1139aa868b3aa5477b8979f VL - 20 ID - 5266 ER - TY - JOUR AB - We evaluated the efficacy and safety of latanoprost eye drops once-weekly, compared to once-daily for improving patient compliance. Twenty (20) patients (11 women and 9 men), 12 with ocular hypertension and 8 with early glaucoma, were studied after washout of the antiglaucoma treatment. One (1) group was treated with latanoprost once-daily (control). The other group was treated once-weekly (study group). Intraocular pressure (IOP) was measured at baseline and on the 2nd, 4th, 6th, and 9th day after the last drop in the study group, and for 3 months on the same schedule thereafter. The mean baseline IOP was 24.3 +/- 3.9 mmHg in the study group (range, 18-29) and 24.4 +/- 4.4 mmHg in the control group (range, 17-32). The average IOP at all time points of post-treatment was 17.7 +/- 1.5 mmHg (range, 14-23) and 16.9 +/- 2.30 mmHg (range, 13-21), respectively. Latanoprost significantly lowered IOP in both groups (study group, p = 0.005; controls, p = 0.0019). The difference between post-treatment IOP was insignificant in both groups at each time point. The study group had fewer minor side effects than the control group (1/10 versus 6/10, respectively). Latanoprost treatment once-weekly was as effective, and bore fewer minor side effects, as once-daily treatment after 3 months of follow-up. AN - WOS:000223527800005 AU - Kurtz, S. AU - Shemesh, G. DA - AUG DO - 10.1089/1080768041725353 IS - 4 PY - 2004 SN - 1080-7683 1557-7732 SP - 321-327 ST - The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased Intraocular pressure T2 - JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS TI - The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased Intraocular pressure VL - 20 ID - 6235 ER - TY - JOUR AD - Ophthalmologist, Department of Ophthalmology, College of Health Sciences, University of Abuja, Nigeria Ophthalmology Department, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Bauchi State, Nigeria Head of Ophthalmology, Aga Khan University Hospital, Kenya Consultant Ophthalmologist and Glaucoma Specialist, James Standefer Glaucoma Institute, Lagos, Nigeria AN - 104241572. Language: English. Entry Date: 20130305. Revision Date: 20150711. Publication Type: Journal Article AU - Kyari, Fatima AU - Abdull, Mohammad AU - Kiage, Dan AU - Ogunro, Adunola DB - ccm DP - EBSCOhost IS - 79/80 KW - Glaucoma -- Drug Therapy Prostaglandins -- Therapeutic Use Prostaglandins -- Adverse Effects Costs and Cost Analysis Health Services Accessibility Adrenergic Beta-Antagonists Adrenergic Alpha-Antagonists Parasympathomimetics Carbonic Anhydrase Inhibitors Counterfeit Drugs -- Adverse Effects N1 - pictorial. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 8912615. PMID: NLM23520427. PY - 2012 SN - 0953-6833 SP - 77-78 ST - Medical treatment of open-angle glaucoma T2 - Community Eye Health Journal TI - Medical treatment of open-angle glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104241572&site=ehost-live&scope=site VL - 25 ID - 4681 ER - TY - JOUR AB - Background: Blindness from glaucoma is associated with socio-economic deprivation, presumed to reflect poor access to care and poor adherence to treatment. Objectives: To determine why people with glaucoma are presenting late for treatment and to understand access to glaucoma care. Additionally, we sought to identify what patients and the community know, do and think about the condition and why the poor are the most affected with glaucoma blindness. Design: Study participants were from four communities and two hospitals in Abuja-FCT and Kaduna State, Nigeria. A total of 120 participants were involved, including 8 focus group discussions, 7 in-depth interviews with blind/visually impaired glaucoma patients, 5 rapid direct observation visits with these patients and 13 exit interviews of glaucoma patients in the hospital. The data were analysed using content analysis, interpreting participant experiences in terms of three key steps conceptualised as important in the care pathway: what it takes to know glaucoma, to reach a diagnosis and to access continued care. Results: This article presents multiple narratives of accessing and maintaining glaucoma care and how people manage and cope with the disease. People may be presenting late due to structural barriers, which include lack of knowledge and awareness about glaucoma and not finding an appropriately equipped health care facility. What keeps glaucoma patients within the care pathway are a good hospital experience; a support structure involving family, counselling and shared patients' experiences; and an informed choice of treatment, as well as agency. The high cost of purchasing care is a major factor for patients dropping out of treatment. Conclusion: The findings suggest the need to address economic and social structural drivers as glaucoma presents another case study to demonstrate that poverty is a strong driver for blindness. There is also a need for clear glaucoma care pathways with early case finding in the community, two-way referral/feedback systems, well-equipped glaucoma care hospitals and better eye health care financing. © 2016 Fatima Kyari et al. AD - International Centre for Eye Health, Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom Department of Ophthalmology, College of Health Sciences, University of Abuja, Abuja, Nigeria Department of Global Health and Development, Faculty of Public Health Nigeriaand Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom Initiative for Community and Rural Eye Care, Kaduna, Nigeria AU - Kyari, F. AU - Chandler, C. I. AU - Martin, M. AU - Gilbert, C. E. C7 - 31886 DB - Scopus DO - 10.3402/GHA.V9.31886 IS - 1 KW - Blindness Care pathway Early detection Glaucoma Late diagnosis Nigeria Vision loss M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 ST - So let me find my way, whatever it will cost me, rather than leaving myself in darkness: Experiences of glaucoma in Nigeria T2 - Global Health Action TI - So let me find my way, whatever it will cost me, rather than leaving myself in darkness: Experiences of glaucoma in Nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015766665&doi=10.3402%2fGHA.V9.31886&partnerID=40&md5=0790ca5eb2c8475af71cd3f4ae9233a5 VL - 9 ID - 5355 ER - TY - JOUR AB - Background: Blindness from glaucoma is associated with socio-economic deprivation, presumed to reflect poor access to care and poor adherence to treatment. Objectives: To determine why people with glaucoma are presenting late for treatment and to understand access to glaucoma care. Additionally, we sought to identify what patients and the community know, do and think about the condition and why the poor are the most affected with glaucoma blindness. Design: Study participants were from four communities and two hospitals in Abuja-FCT and Kaduna State, Nigeria. A total of 120 participants were involved, including 8 focus group discussions, 7 in-depth interviews with blind/visually impaired glaucoma patients, 5 rapid direct observation visits with these patients and 13 exit interviews of glaucoma patients in the hospital. The data were analysed using content analysis, interpreting participant experiences in terms of three key steps conceptualised as important in the care pathway: what it takes to know glaucoma, to reach a diagnosis and to access continued care. Results: This article presents multiple narratives of accessing and maintaining glaucoma care and how people manage and cope with the disease. People may be presenting late due to structural barriers, which include lack of knowledge and awareness about glaucoma and not finding an appropriately equipped health care facility. What keeps glaucoma patients within the care pathway are a good hospital experience; a support structure involving family, counselling and shared patients' experiences; and an informed choice of treatment, as well as agency. The high cost of purchasing care is a major factor for patients dropping out of treatment. Conclusion: The findings suggest the need to address economic and social structural drivers as glaucoma presents another case study to demonstrate that poverty is a strong driver for blindness. There is also a need for clear glaucoma care pathways with early case finding in the community, two-way referral/feedback systems, well-equipped glaucoma care hospitals and better eye health care financing. AN - WOS:000390857800001 AU - Kyari, F. AU - Chandler, C. I. AU - Martin, M. AU - Gilbert, C. E. DO - 10.3402/gha.v9.31886 PY - 2016 SN - 1654-9880 SP - 1-11 ST - So let me find my way, whatever it will cost me, rather than leaving myself in darkness: experiences of glaucoma in Nigeria T2 - GLOBAL HEALTH ACTION TI - So let me find my way, whatever it will cost me, rather than leaving myself in darkness: experiences of glaucoma in Nigeria VL - 9 ID - 6186 ER - TY - JOUR AB - We evaluated the quality of medical services delivered to remote glaucoma patients from a mobile unit. A four-wheel-drive vehicle containing the necessary equipment visited five different remote locations in Greece. During a three-year prospective study, 1205 patients were examined, of whom 230 had glaucoma. The majority of the subjects were examined by the unit's medical staff using the available instrumentation (e.g. slit-lamp and tonometer), while 56 glaucoma subjects were telemedically examined by consultants at the Patissia General Hospital, in Athens. Control data were obtained from a random sample of 260 urban glaucoma patients. A significantly greater proportion of the remote patients had an inadequate awareness of glaucoma (77%) compared with the urban patients (20%). Significantly more remote patients had poorer compliance (68%) in comparison with urban patients (23%). A significantly larger proportion of the remote patients had high intra-ocular pressure (21%) compared with the urban patients (5%). Technical difficulties occurred in the 13 of the 56 telemedical examinations. Mobile medical units can enhance access to medical services and contribute to the health-care of under-served populations. AD - G. Labiris, Intermedico Network, Division of Medical Informatics, Athens, Greece. AU - Labiris, G. AU - Fanariotis, M. AU - Christoulakis, C. AU - Petounis, A. AU - Kitsos, G. AU - Aspiotis, M. AU - Psillas, K. DB - Medline IS - 5 KW - adult aged article female glaucoma Greece human intraocular pressure male methodology middle aged organization and management patient compliance patient education physiology preventive health service psychological aspect rural health care telemedicine LA - English M3 - Article N1 - L137588298 2004-03-19 PY - 2003 SN - 1357-633X SP - 296-299 ST - Tele-ophthalmology and conventional ophthalmology using a mobile medical unit in remote Greece T2 - Journal of telemedicine and telecare TI - Tele-ophthalmology and conventional ophthalmology using a mobile medical unit in remote Greece UR - https://www.embase.com/search/results?subaction=viewrecord&id=L137588298&from=export VL - 9 ID - 3774 ER - TY - JOUR AB - We evaluated the quality of medical services delivered to remote glaucoma patients from a mobile unit. A four-wheel-drive vehicle containing the necessary equipment visited five different remote locations in Greece. During a three-year prospective study, 1205 patients were examined, of whom 230 had glaucoma. The majority of the subjects were examined by the unit's medical staff using the available instrumentation (e.g. slit-lamp and tonometer), while 56 glaucoma subjects were telemedically examined by consultants at the Patissia General Hospital, in Athens. Control data were obtained from a random sample of 260 urban glaucoma patients. A significantly greater proportion of the remote patients had an inadequate awareness of glaucoma (77%) compared with the urban patients (20%). Significantly more remote patients had poorer compliance (68%) in comparison with urban patients (23%). A significantly larger proportion of the remote patients had high intra-ocular pressure (21%) compared with the urban patients (5%). Technical difficulties occurred in the 13 of the 56 telemedical examinations. Mobile medical units can enhance access to medical services and contribute to the health-care of under-served populations. AD - Dept of Ophthalmology, Patissia General Hospital, Calkidos 15-17, 11143 Athens, Greece; labiris@usa.net AN - 106682117. Language: English. Entry Date: 20040820. Revision Date: 20200708. Publication Type: Journal Article AU - Labiris, G. AU - Fanariotis, M. AU - Christoulakis, C. AU - Petounis, A. AU - Kitsos, G. AU - Aspiotis, M. AU - Psillas, K. DB - ccm DO - 10.1258/135763303769211337 DP - EBSCOhost IS - 5 KW - Ophthalmology Telemedicine -- Methods -- Greece Adult Aged Aged, 80 and Over Female Glaucoma Greece Health Knowledge Male Middle Age Random Sample Rural Health Services Human N1 - pictorial; research; tables/charts. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 9506702. PMID: NLM14599335. PY - 2003 SN - 1357-633X SP - 296-299 ST - Tele-ophthalmology and conventional ophthalmology using a mobile medical unit in remote Greece T2 - Journal of Telemedicine & Telecare TI - Tele-ophthalmology and conventional ophthalmology using a mobile medical unit in remote Greece UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106682117&site=ehost-live&scope=site VL - 9 ID - 4605 ER - TY - JOUR AB - We evaluated the quality of medical services delivered to remote glaucoma patients from a mobile unit. A four-wheel-drive vehicle containing the necessary equipment visited five different remote locations in Greece. During a three-year prospective study, 1205 patients were examined, of whom 230 had glaucoma. The majority of the subjects were examined by the unit's medical staff using the available instrumentation (e.g. slit-lamp and tonometer), while 56 glaucoma subjects were telemedically examined by consultants at the Patissia General Hospital, in Athens. Control data were obtained from a random sample of 260 urban glaucoma patients. A significantly greater proportion of the remote patients had an inadequate awareness of glaucoma (77%) compared with the urban patients (20%). Significantly more remote patients had poorer compliance (68%) in comparison with urban patients (23%). A significantly larger proportion of the remote patients had high intra-ocular pressure (21%) compared with the urban patients (5%). Technical difficulties occurred in the 13 of the 56 telemedical examinations. Mobile medical units can enhance access to medical services and contribute to the health-care of under-served populations. AN - WOS:000185882500010 AU - Labiris, G. AU - Fanariotis, M. AU - Christoulakis, C. AU - Petounis, A. AU - Kitsos, G. AU - Aspiotis, M. AU - Psillas, K. DO - 10.1258/135763303769211337 IS - 5 PY - 2003 SN - 1357-633X 1758-1109 SP - 296-299 ST - Tele-ophthalmology and conventional ophthalmology using in remote Greece a mobile medical unit T2 - JOURNAL OF TELEMEDICINE AND TELECARE TI - Tele-ophthalmology and conventional ophthalmology using in remote Greece a mobile medical unit VL - 9 ID - 6188 ER - TY - JOUR AB - Purpose Glaucoma is initially asymptomatic, but untreated can result in progressive visual field loss and eventual blindness. With adequate therapy progression can be halted, but poor adherence with medical therapy is a significant issue requiring further research. The aim of the present study was to gain a better understanding of the obstacles to, and the motivations for, adherence with glaucoma medication and explore potential methods to improve adherence.MethodsParticipants had moderate/severe glaucoma diagnosed for >1 year, had seen ≥2 NHS ophthalmologists, and were prescribed ≥2 topical medications. Qualitative methodology was utilized to investigate aspects of adherence. Recruited patients either attended a focus group or had a home-based semi-structured interview. The transcripts were member-checked and the resulting data were analysed using 'Framework' analysis. The analysis was verified by a co-investigator and NVIVO Software was used to check data reliability. ResultsMultiple obstacles to adherence were identified, including poor education, lack of motivation, forgetfulness, drop application, and other practical issues, together with specific individual and age differences. Motivation for adherence was determined by fear of blindness and a faith in drop efficacy.ConclusionsSpecific obstacles to adherence with anti-glaucomatous therapy should be identified as early as possible after diagnosis. A tailored approach to patient care with initial education about the consequences of non-adherence and longer-term feedback about drop efficacy may improve patients' motivations for adherence. Future research should focus on investigating methods by which initial education about glaucoma and its management should best be delivered to patients. © 2009 Macmillan Publishers Limited All rights reserved. AD - J. Lacey, Department of Ophthalmology, Glaucoma Research Unit, Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom AU - Lacey, J. AU - Cate, H. AU - Broadway, D. C. DB - Embase Medline DO - 10.1038/eye.2008.103 IS - 4 KW - adult article clinical article controlled study disease severity drug efficacy drug safety female glaucoma human male patient care patient compliance patient education patient satisfaction semi structured interview LA - English M3 - Article N1 - L354534783 2009-05-18 PY - 2009 SN - 1476-5454 0950-222X SP - 924-932 ST - Barriers to adherence with glaucoma medications: A qualitative research study T2 - Eye TI - Barriers to adherence with glaucoma medications: A qualitative research study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354534783&from=export http://dx.doi.org/10.1038/eye.2008.103 VL - 23 ID - 3391 ER - TY - JOUR AD - Department of Ophthalmology, Glaucoma Research Unit, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK. AN - 104906432. Language: English. Entry Date: 20110211. Revision Date: 20200708. Publication Type: Journal Article AU - Lacey, J. AU - Cate, H. AU - Broadway, D. C. DB - ccm DO - 10.1038/eye.2008.103 DP - EBSCOhost IS - 4 KW - Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Attitude to Health Medication Compliance Aged Blindness -- Prevention and Control Female Focus Groups Human Male Middle Age Motivation Qualitative Studies Questionnaires N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM18437182. PY - 2009 SN - 0950-222X SP - 924-932 ST - Barriers to adherence with glaucoma medications: a qualitative research study T2 - Eye TI - Barriers to adherence with glaucoma medications: a qualitative research study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104906432&site=ehost-live&scope=site VL - 23 ID - 4469 ER - TY - JOUR AB - Fixed combinations are indicated in the treatment of glaucoma and ocular hypertension when monotherapy does not sufficiently reduce IOP. Fixed combinations show better efficacy than the instillation of each separate component and are at least equivalent to the administration of both components in a separate association. They simplify treatment, increase compliance and quality of life, and decrease exposure to preservatives. Although they are less aggressive for patients when a new drug needs to be added, the use of fixed combinations should not decrease the follow-up. AN - WOS:000258861200018 AU - Lachkar, Y. DA - JUN IS - 6 PY - 2008 SN - 0181-5512 SP - 85-89 ST - Advantages of fixed combinations T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Advantages of fixed combinations VL - 31 ID - 5900 ER - TY - JOUR AB - Purpose: To determine the improvement in patient adherence to topical ocular hypotensive therapy by introducing a personalized illustrated medication reference chart and telereminder. Design: Prospective randomized controlled clinical trial. Participants: Fifty-nine patients with glaucoma who were using at least 3 or more eye drops were recruited from the ophthalmology clinic at the National University Hospital of Singapore. Methods: Participants were randomized into 3 groups: control, reference chart only, and reference chart with telereminder. They completed a survey on demographics, barriers to glaucoma medication adherence, and self-adherence (measured by the Morisky adherence scale) before and 6 weeks after intervention. Logistic regression analysis was performed on the barriers that contribute to nonadherence and paired t tests were conducted for the preimplementation and postimplementation effects of intervention on adherence score. Main Outcome Measures: Changes in mean adherence score based on the Morisky adherence scale before and after intervention in participants from all 3 groups. Results: In our study, 71% of participants who were nonadherent to medications had multiple barriers to adherence, with lack of self-efficacy and forgetfulness being the most common factors. Only the reference chart with telereminder group showed a statistically significant increase in mean adherence score, from 7.18 to 7.69 (P = 0.047). Conclusions: Adherence to medication in chronic diseases like glaucoma is an important healthcare issue to address. Most of these patients have poor adherence because of multiple factors, and hence interventions aimed at improving adherence should be multifaceted to target these barriers. AD - Y. Lai, Department of Ophthalmology, National University Health System, 1E Kent Ridge Road, Singapore, Singapore AU - Lai, Y. AU - Wu, Y. AU - Chai, C. AU - Yen, C. C. AU - Ho, Y. AU - Eng, T. C. AU - Jain, P. AU - Koh, V. C1 - alphagan(Allergan) azopt(Novartis,United Kingdom) cravit(Daiichi Sankyo) lumigan(Allergan) predforte(Allergan) C2 - Allergan Daiichi Sankyo Novartis(United Kingdom) DB - Embase Medline DO - 10.1016/j.ogla.2020.05.005 IS - 5 KW - antiglaucoma agent bimatoprost brimonidine brinzolamide eye drops levofloxacin prednisolone acetate adult aged article cognition communication skill controlled study demography doctor patient relationship female follow up forgetfulness glaucoma health survey human major clinical study male medication compliance Morisky Medication Adherence Scale patient compliance patient education personalized medicine priority journal prospective study randomized controlled trial reminder system self concept Singapore telemedicine treatment duration university hospital alphagan azopt cravit lumigan predforte LA - English M3 - Article N1 - L2007063791 2020-07-23 2020-10-02 PY - 2020 SN - 2589-4196 SP - 369-376 ST - The Effect of Patient Education and Telemedicine Reminders on Adherence to Eye Drops for Glaucoma T2 - Ophthalmology Glaucoma TI - The Effect of Patient Education and Telemedicine Reminders on Adherence to Eye Drops for Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2007063791&from=export http://dx.doi.org/10.1016/j.ogla.2020.05.005 VL - 3 ID - 2387 ER - TY - JOUR AB - Importance: Very little is known about health-care professional related prescribing errors within the glaucoma setting. Background: This study aims to quantify these errors and to explore where they occur along the prescribing pathway. Design: Cross-sectional study of patients attending a specialty glaucoma clinic over a 5-month period. Participants: Data was collected for 109 patients. Methods: We compared glaucoma drop regimes from four different sources: As documented in the hospital notes for the last appointment, the letter sent to the General Practitioner (GP), patient's self-reporting and bottles/prescriptions brought to the clinic appointment. Main Outcome Measures: Discrepancies were identified and errors were grouped into one of four categories depending on where in the prescribing pathway they occurred: Incorrect prescribing of the drops by the clinician, incorrect prescribing of the drops by the GP/failure to provide a repeat prescription, incorrect dispensing of the drops by the pharmacist and possible non-adherence by the patient. Results: There was a total of 217 individual prescription items involving 266 active ingredients. Seventy-one prescription items out of 217 (33%) had an error, of this 53 (75%) were due to possible patient non-adherence and 18 (25%) were process related errors made by health-care professionals. Conclusions and Relevance: An error was identified in 33% of prescriptions. About 8.3% of prescriptions had a health-care professional related process error. These errors are preventable and recognition of these is important to maximize drop adherence and minimize disease progression, requiring increased consultations and interventions with quality of life and health economic consequences. AD - B.K. Lakhani, Department of Ophthalmology, Nottingham University Hospital, Nottingham, United Kingdom AU - Lakhani, B. K. AU - King, A. J. DB - Embase Medline DO - 10.1111/ceo.13156 IS - 6 KW - adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor miotic agent prostaglandin derivative adult aged article consultation controlled study cross-sectional study disease course female general practitioner glaucoma health care personnel health economics human major clinical study male medical error medical record review middle aged patient compliance patient-reported outcome pharmacist prescription quality of life very elderly LA - English M3 - Article N1 - L621117042 2018-03-13 2018-08-17 PY - 2018 SN - 1442-9071 1442-6404 SP - 616-623 ST - Exploring the frequency and location of prescribing errors in the use of topical glaucoma medications T2 - Clinical and Experimental Ophthalmology TI - Exploring the frequency and location of prescribing errors in the use of topical glaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621117042&from=export http://dx.doi.org/10.1111/ceo.13156 VL - 46 ID - 2570 ER - TY - JOUR AB - Importance: Very little is known about health-care professional related prescribing errors within the glaucoma setting. Background: This study aims to quantify these errors and to explore where they occur along the prescribing pathway. Design: Cross-sectional study of patients attending a specialty glaucoma clinic over a 5-month period. Participants: Data was collected for 109 patients. Methods: We compared glaucoma drop regimes from four different sources: As documented in the hospital notes for the last appointment, the letter sent to the General Practitioner (GP), patient's self-reporting and bottles/prescriptions brought to the clinic appointment. Main Outcome Measures: Discrepancies were identified and errors were grouped into one of four categories depending on where in the prescribing pathway they occurred: Incorrect prescribing of the drops by the clinician, incorrect prescribing of the drops by the GP/failure to provide a repeat prescription, incorrect dispensing of the drops by the pharmacist and possible non-adherence by the patient. Results: There was a total of 217 individual prescription items involving 266 active ingredients. Seventy-one prescription items out of 217 (33%) had an error, of this 53 (75%) were due to possible patient non-adherence and 18 (25%) were process related errors made by health-care professionals. Conclusions and Relevance: An error was identified in 33% of prescriptions. About 8.3% of prescriptions had a health-care professional related process error. These errors are preventable and recognition of these is important to maximize drop adherence and minimize disease progression, requiring increased consultations and interventions with quality of life and health economic consequences. © 2018 Royal Australian and New Zealand College of Ophthalmologists AD - Department of Ophthalmology, Nottingham University Hospital, Nottingham, United Kingdom AU - Lakhani, B. K. AU - King, A. J. DB - Scopus DO - 10.1111/ceo.13156 IS - 6 KW - beta-blockers carbonic anhydrase inhibitors glaucoma glaucoma medical therapies glaucoma medications M3 - Article N1 - Export Date: 19 July 2021 PY - 2018 SP - 616-623 ST - Exploring the frequency and location of prescribing errors in the use of topical glaucoma medications T2 - Clinical and Experimental Ophthalmology TI - Exploring the frequency and location of prescribing errors in the use of topical glaucoma medications UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043289564&doi=10.1111%2fceo.13156&partnerID=40&md5=14f10b4fd5194075beb5509d6900cca5 VL - 46 ID - 5728 ER - TY - JOUR AB - ImportanceVery little is known about health-care professional related prescribing errors within the glaucoma setting. BackgroundThis study aims to quantify these errors and to explore where they occur along the prescribing pathway. DesignCross-sectional study of patients attending a specialty glaucoma clinic over a 5-month period. ParticipantsData was collected for 109 patients. MethodsWe compared glaucoma drop regimes from four different sources: As documented in the hospital notes for the last appointment, the letter sent to the General Practitioner (GP), patient's self-reporting and bottles/prescriptions brought to the clinic appointment. Main Outcome MeasuresDiscrepancies were identified and errors were grouped into one of four categories depending on where in the prescribing pathway they occurred: Incorrect prescribing of the drops by the clinician, incorrect prescribing of the drops by the GP/failure to provide a repeat prescription, incorrect dispensing of the drops by the pharmacist and possible non-adherence by the patient. ResultsThere was a total of 217 individual prescription items involving 266 active ingredients. Seventy-one prescription items out of 217 (33%) had an error, of this 53 (75%) were due to possible patient non-adherence and 18 (25%) were process related errors made by health-care professionals. Conclusions and RelevanceAn error was identified in 33% of prescriptions. About 8.3% of prescriptions had a health-care professional related process error. These errors are preventable and recognition of these is important to maximize drop adherence and minimize disease progression, requiring increased consultations and interventions with quality of life and health economic consequences. AN - WOS:000440911000005 AU - Lakhani, B. K. AU - King, A. J. DA - AUG DO - 10.1111/ceo.13156 IS - 6 PY - 2018 SN - 1442-6404 1442-9071 SP - 616-623 ST - Exploring the frequency and location of prescribing errors in the use of topical glaucoma medications T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Exploring the frequency and location of prescribing errors in the use of topical glaucoma medications VL - 46 ID - 5965 ER - TY - JOUR AB - PURPOSE OF REVIEW: Drooling is the involuntary spillage of saliva from the mouth. It is a major morbidity associated with cerebral palsy and other neurodegenerative disorders. The consequences of drooling are not restricted to medical issues but can cause major social handicaps. Severe psycho-social consequences, such as social stigmatization and emotional devastation for the patients and their families, may result. This paper reviews recent developments in the management of drooling. RECENT FINDINGS: Recent publications report encouraging results with botulinum toxin A. Several surgeons report on their long-term results. Reviews analyze anticholinergic drugs, surgical options, biofeedback, behavioral and speech therapy, and a multidisciplinary team approach. SUMMARY: A team approach is the key to successful rehabilitation. Oromotor therapy is the most useful nonsurgical option. Drugs are unsuitable for long-term use due to adverse effects causing serious medical complications or noncompliance. Botulinum toxin A injection is promising, but no data exists on optimal dosage, duration of action and frequency of repeat injections. Bilateral submandibular duct relocation with bilateral sublingual gland excision has been shown to be effective and safe in long-term follow-up of the largest series of patients. At present, it is the best available surgical option. © 2006 Lippincott Williams & Wilkins, Inc. AD - Department of Otolaryngology - Head and Neck Surgery, Loyola University Medical Center, Maywood, IL, United States Department of Otolaryngology - Head and Neck Surgery, Loyola University Medical Center, Building 105, 2160 South First Avenue, Maywood, IL 60153-5500, United States AU - Lal, D. AU - Hotaling, A. J. DB - Scopus DO - 10.1097/MOO.0b013e328011014a IS - 6 KW - Drooling Excessive salivation Sialorrhea M3 - Review N1 - Cited By :36 Export Date: 19 July 2021 PY - 2006 SP - 381-386 ST - Drooling T2 - Current Opinion in Otolaryngology and Head and Neck Surgery TI - Drooling UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750947184&doi=10.1097%2fMOO.0b013e328011014a&partnerID=40&md5=19e1f30845bf4fdaef9ed8def303e949 VL - 14 ID - 5033 ER - TY - JOUR AB - Evidence has shown that psychopharmacotherapy for patients with depression in primary care is effective. Inappropriate choice of medications and medication non-adherence are common in everyday practice. Nowadays, remission is considered as the treatment goal for depression and accurate diagnostic formulation, involving patient in management planning and rational choice of medications at different phases of treatment are pertinent. Medication adherence can be optimized through measures at drug, patient, doctor, family and community levels. Difficult cases should warrant referral and a collaborative care approach should be implemented into our primary care system. AD - Belcher's Street, Kenndey Town, Hong Kong, Hong Kong AU - Lam, E. W. W. DB - Scopus IS - 1 M3 - Article N1 - Export Date: 19 July 2021 PY - 2007 SP - 16-23 ST - Optimizing the psychopharmacotherapy of depression and medication adherence in primary care T2 - Hong Kong Practitioner TI - Optimizing the psychopharmacotherapy of depression and medication adherence in primary care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34147160731&partnerID=40&md5=8481ab7461378637c5c16418b5c9b2d4 VL - 29 ID - 5771 ER - TY - JOUR AB - INTRODUCTION: This study aims to identify the demographics and hygiene behaviours associated with contact lens (CL)-related microbial keratitis in Singapore. MATERIALS AND METHODS: The hygiene and social behaviours of lens wearers presenting with infectious keratitis in Singapore were examined using an externally validated questionnaire. Fifty-eight consecutive lens wearers who presented with infectious keratitis at Singapore National Eye Centre were surveyed using a self-administered questionnaire. Patients' demographics, CL-related behaviour, attitude to aftercare visits and microbial study results were collected and analysed. RESULTS: More than half (55%) of the patients surveyed were female, and the average age of the participants was 25.7 ± 6.4 years. Ninety-six percent of participants used soft CL, with the majority wearing monthly disposable lenses (74.1%). Myopia was the commonest reason for use of CL. CL overwear (81%), sleeping (50.9%) and swimming (33%) with their CL were the major non-compliant behaviours discovered. When encountered with eye discomfort as a result of lens-related infective keratitis, 83% of patients sought the advice of general medical practitioners prior to presentation at the hospital. Many (59%) patients have encountered media coverage but only 24% had any behavioural change as a result. Many patients relied on the recommendations of eyecare practitioners when purchasing disinfecting solutions (26%) and other hygiene practices. Pseudomonas Aeruginosa was the most common organism grown in 22.4% of patients while 47% of patients were culture-negative. CONCLUSION: Inadequate lens cleaning, poor aftercare, sleeping and swimming with CL were the major non-compliant behaviours among participants, and these are significant factors when assessing risks in acquiring CL-related infectious keratitis. General eyecare practitioners are the first-line of contact in patients presenting with keratitis symptoms and play an important role in emphasising the need for regular aftercare and good hygiene practices to CL wearers. AD - Singapore Eye Research Institute, Singapore AU - Lam, J. S. AU - Tan, G. AU - Tan, D. T. AU - Mehta, J. S. DB - Scopus IS - 10 M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2013 SP - 499-506 ST - Demographics and behaviour of patients with contact lens-related infectious keratitis in singapore T2 - Annals of the Academy of Medicine, Singapore TI - Demographics and behaviour of patients with contact lens-related infectious keratitis in singapore UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979859261&partnerID=40&md5=fa3b86e2d18c4cd5f5dda6a2e29872c4 VL - 42 ID - 5330 ER - TY - JOUR AB - Introduction: This study aims to identify the demographics and hygiene behaviours associated with contact lens (CL)-related microbial keratitis in Singapore. Materials and Methods: The hygiene and social behaviours of lens wearers presenting with infectious keratitis in Singapore were examined using an externally validated questionnaire. Fifty-eight consecutive lens wearers who presented with infectious keratitis at Singapore National Eye Centre were surveyed using a self-administered questionnaire. Patients' demographics, CL-related behaviour, attitude to aftercare visits and microbial study results were collected and analysed. Results: More than half (55%) of the patients surveyed were female, and the average age of the participants was 25.7 +/- 6.4 years. Ninety-six percent of participants used soft CL, with the majority wearing monthly disposable lenses (74.1%). Myopia was the commonest reason for use of CL. CL overwear (81%), sleeping (50.9%) and swimming (33%) with their CL were the major non-compliant behaviours discovered. When encountered with eye discomfort as a result of lens-related infective keratitis, 83% of patients sought the advice of general medical practitioners prior to presentation at the hospital. Many (59%) patients have encountered media coverage but only 24% had any behavioural change as a result. Many patients relied on the recommendations of eyecare practitioners when purchasing disinfecting solutions (26%) and other hygiene practices. Pseudomonas Aeruginosa was the most common organism grown in 22.4% of patients while 47% of patients were culture-negative. Conclusion: Inadequate lens cleaning, poor aftercare, sleeping and swimming with CL were the major non-compliant behaviours among participants, and these are significant factors when assessing risks in acquiring CL-related infectious keratitis. General eyecare practitioners are the first-line of contact in patients presenting with keratitis symptoms and play an important role in emphasising the need for regular aftercare and good hygiene practices to CL wearers. AN - WOS:000327577500003 AU - Lam, J. S. H. AU - Tan, G. AU - Tan, D. T. H. AU - Mehta, J. S. DA - OCT IS - 10 PY - 2013 SN - 0304-4602 SP - 499-506 ST - Demographics and Behaviour of Patients with Contact Lens-Related Infectious Keratitis in Singapore T2 - ANNALS ACADEMY OF MEDICINE SINGAPORE TI - Demographics and Behaviour of Patients with Contact Lens-Related Infectious Keratitis in Singapore VL - 42 ID - 5852 ER - TY - JOUR AB - Background: To determine whether a randomized clinical trial, the Infant Aphakia Treatment Study, comparing intraocular lens (IOL) implantation with contact lens (CL) correction for infants with a unilateral congenital cataract (UCC), is feasible by (1) ascertaining whether American Association for Pediatric Ophthalmology and Strabismus (AAPOS) members have equipoise regarding these two treatments and (2) evaluating the willingness of parents to agree to randomization. Methods: All AAPOS members were surveyed in August 1997 and again in June 2001 regarding their use of CLs and IOL implants to correct infants vision after unilateral cataract surgery. In addition, a pilot study was begun in March 2002 to evaluate the safety of IOL implantation during infancy and the willingness of parents to randomize their children with a UCC to either IOL implantation or CL correction. Results: In 1997, 89% of the 260 respondents reported that in the previous year they had treated at least one infant with a UCC, but only 4% had implanted an IOL in an infant <7 months old. Silsoft (Bausch & Lomb, Rochester, NY) CL correction was the preferred treatment choice for 84% of the respondents. In 2001, 21% of the 279 respondents had implanted an IOL in an infant. On a scale from 1 to 10 with 1 strongly favoring an IOL implant and 10 strongly favoring a CL, the median score was 7.5. Sixty-one percent of the respondents indicated that they would be willing to randomize children with a UCC to one of these two treatments. The main concerns about IOL implantation were poor predictability of power changes, postoperative complications, inflammation, and technical difficulty of surgery. The main concerns about CL correction were poor compliance, high lens loss rate, high cost, and keratitis. In our pilot study, 30 infants <7 months of age were evaluated at nine clinical centers for a visually significant UCC. Of 24 infants eligible for randomization, the parents of 17 (71%) agreed to randomization. Conclusions: Although most AAPOS members still favor CL correction after cataract surgery for a UCC, five times as many had implanted an IOL in an infant in 2001 compared with the number in 1997. Parents were almost equally divided in their preference for IOL implant versus CL correction. Given the relative equipoise of AAPOS members regarding these treatments and the willingness of more than two thirds of parents to agree to randomization, it seems likely that a randomized clinical trial comparing these two treatments could indeed be conducted. AD - S.R. Lambert, Emory Eye Center, 1365-B Clifton Rd NE, Atlanta, GA 30322, United States AU - Lambert, S. R. AU - Lynn, M. AU - Drews-Botsch, C. AU - DuBois, L. AU - Wilson, M. E. AU - Plager, D. A. AU - Wheeler, D. T. AU - Christiansen, S. P. AU - Crouch, E. R. AU - Buckley, E. G. AU - Stager Jr, D. AU - Donahue, S. P. DB - Embase Medline DO - 10.1016/j.jaapos.2003.08.004 IS - 6 KW - adolescent adult article cataract extraction child clinical trial comparative study congenital cataract contact lens controlled clinical trial controlled study health survey human infancy infant inflammation keratitis lens implant major clinical study organization parent patient compliance perception postoperative complication priority journal randomized controlled trial visual impairment LA - English M3 - Article N1 - L37532743 2004-01-20 PY - 2003 SN - 1091-8531 SP - 400-405 ST - Intraocular lens implantation during infancy: Perceptions of parents and the American Association for Pediatric Ophthalmology and Strabismus members T2 - Journal of AAPOS TI - Intraocular lens implantation during infancy: Perceptions of parents and the American Association for Pediatric Ophthalmology and Strabismus members UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37532743&from=export http://dx.doi.org/10.1016/j.jaapos.2003.08.004 VL - 7 ID - 3777 ER - TY - JOUR AB - Background. Close supervision of intraocular pressure (IOP) means monitoring an important risk factor for glaucoma. Method. After instruction in its use, patients measure their own IOP several times a day with the Dräger self-tonometer. The measurements are subsequently transmitted to a server via the telephone keypad and recorded separately for each patient. The software enables statistical evaluation of the pressure levels collected. Results. Up to now 30 of 35 patients transmit measurements or had done so for at least 6 months. Registration of measurement levels covering months and years provides the opportunity for optimizing treatment and hence can be considered a start toward quality assurance in the treatment of glaucoma patients. Conclusion. TAS is a cost-efficient method for obtaining long-term profiles of eye pressure. Thus, the possibility exists for early therapeutic intervention in patients at risk. The compliance gained by the close relationship between the physician and the patient represents a positive prognostic factor. AD - R. Lämmer, Augenklinik mit Poliklinik, F.-Alexander-Univ. Erlangen-Nurnberg, Schwabachanlage 6, 91054 Erlangen, Germany AU - Lämmer, R. AU - Groh, M. E. M. AU - Michelson, G. DB - Embase Medline IS - 8 KW - article software cost effectiveness analysis glaucoma health care quality human intraocular pressure patient compliance patient monitoring prognosis quality control registration self evaluation statistical analysis telecommunication telematic assisted self tonometry telephone tonometer tonometry Ocuton S LA - German M3 - Article N1 - L39108228 2004-09-07 PY - 2004 SN - 0941-293X SP - 813-818 ST - Telematic-assisted self-tonometry (TAS) T2 - Ophthalmologe TI - Telematic-assisted self-tonometry (TAS) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39108228&from=export VL - 101 ID - 3735 ER - TY - JOUR AB - Background: Glaucoma is the leading cause of irreversible blindness in the world. Estimated to affect 60 million people worldwide, this figure is expected to rise to 80 million by 2020. Untreated, glaucoma leads to visual decay and eventually to blindness, and can significantly reduce quality of life. First-line treatment in patients with primary open-angle glaucoma and exfoliative glaucoma is topical medical therapy with ocular hypotensives as eye drops. However, eye drops have several disadvantages including cost, possible local and systemic side effects, and adherence and perseverance issues. Randomised controlled trials have demonstrated that selective laser trabeculoplasty is equally as effective in lowering intraocular pressure as eye drops. However, the impact of these two treatment modalities from the patient and economic perspectives has not been adequately determined. Thus, it remains unclear whether topical medical therapy or selective laser trabeculoplasty should be recommended as first-line treatment for glaucoma.Methods/design: This protocol describes an international, multi-centre, randomised controlled trial to determine the optimum first-line therapy for people with primary open-angle glaucoma and exfoliative glaucoma. This study will compare the effect of selective laser trabeculoplasty and topical medication with respect to patients' generic and glaucoma-specific quality of life. The trial will also provide a detailed cost-effectiveness analysis and compare the clinical effectiveness with respect to the degree of intraocular pressure lowering and rates of treatment failure. Research coordinators in each centre will identify and recruit previously untreated patients with primary open-angle glaucoma and exfoliative glaucoma. Those who meet the eligibility criteria will be invited to enter a randomised controlled trial with either selective laser trabeculoplasty or topical ocular hypotensive therapy, according to a stepped regimen. Outcome assessment will be measured at 6 weeks and at 6, 12, and 24 months post-treatment. Regular clinic follow-ups will continue as clinically indicated between study outcome visits.Discussion: The Glaucoma Initial Treatment Study is the first multi-centred RCT to determine the optimum first-line therapy for people with glaucoma. Our trial will have an unprecedented capacity to meaningfully transform the treatment and management of glaucoma in Australia and overseas.Trial Registration: ACTRN12611000720910; Date registered: 11 July 2011. AD - Centre for Eye Research Australia, University of Melbourne, the Royal Victorian Eye and Ear Hospital, Melbourne 3002, Australia Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore Duke, Graduate Medical School, Singapore, Singapore University of Adelaide, North Terrace, Adelaide, South Australia, Australia Discipline of Ophthalmology, University of Sydney, Sydney, New South Wales, Australia Glaucoma Unit, Sydney Eye Hospital, Sydney, New South Wales, Australia Eye Associates, Sydney, New South Wales, Australia Centre for Vision Research, Department of Ophthalmology and Westmead Millennium Institute, University of Sydney, Sydney, NSW, Australia Queensland Eye Institute, 149 Melbourne Street, South Brisbane, Queensland, Australia University of Queensland, Brisbane, Queensland, Australia Royal Victorian Eye and Ear Hospital, Victoria, Australia NH&MRC Centre for Clinical Eye Research, Discipline of Optometry and Vision Science, Flinders University and Flinders Medical Centre-Australia, Adelaide, Australia Centre for Eye Research Australia, University of Melbourne, the Royal Victorian Eye and Ear Hospital, Melbourne, 3002, Australia AN - 109491281. Language: English. Entry Date: 20180802. Revision Date: 20210114. Publication Type: journal article AU - Lamoureux, Ecosse L. AU - McIntosh, Rachel AU - Constantinou, Marios AU - Fenwick, Eva K. AU - Jing, Xie AU - Casson, Robert AU - Finkelstein, Eric AU - Goldberg, Ivan AU - Healey, Paul AU - Thomas, Ravi AU - Ghee Soon, Ang AU - Pesudovs, Konrad AU - Crowston, Jonathan AU - Xie, Jing AU - Ang, Ghee Soon DB - ccm DO - 10.1186/s13063-015-0924-6 DP - EBSCOhost IS - 1 KW - Intraocular Pressure -- Drug Effects Glaucoma -- Surgery Laser Therapy -- Methods Glaucoma -- Drug Therapy Trabeculectomy -- Methods Antihypertensive Agents -- Administration and Dosage Vision -- Drug Effects Laser Therapy -- Economics Glaucoma -- Diagnosis Time Factors Administration, Intraocular Trabeculectomy -- Adverse Effects Study Design Laser Therapy -- Adverse Effects Laser Therapy -- Equipment and Supplies Human Ophthalmic Solutions Trabeculectomy -- Economics Antihypertensive Agents -- Economics Cost Benefit Analysis Trabeculectomy -- Equipment and Supplies Antihypertensive Agents -- Adverse Effects Health Care Costs Glaucoma -- Physiopathology Treatment Outcomes Glaucoma -- Economics Protocols Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Random Assignment N1 - research; randomized controlled trial. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 101263253. PMID: NLM26362541. PY - 2015 SN - 1745-6215 SP - 1-10 ST - Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial T2 - Trials TI - Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109491281&site=ehost-live&scope=site VL - 16 ID - 4308 ER - TY - JOUR AB - Background: Glaucoma is the leading cause of irreversible blindness in the world. Estimated to affect 60 million people worldwide, this figure is expected to rise to 80 million by 2020. Untreated, glaucoma leads to visual decay and eventually to blindness, and can significantly reduce quality of life. First-line treatment in patients with primary open-angle glaucoma and exfoliative glaucoma is topical medical therapy with ocular hypotensives as eye drops. However, eye drops have several disadvantages including cost, possible local and systemic side effects, and adherence and perseverance issues. Randomised controlled trials have demonstrated that selective laser trabeculoplasty is equally as effective in lowering intraocular pressure as eye drops. However, the impact of these two treatment modalities from the patient and economic perspectives has not been adequately determined. Thus, it remains unclear whether topical medical therapy or selective laser trabeculoplasty should be recommended as first-line treatment for glaucoma. Methods/Design: This protocol describes an international, multi-centre, randomised controlled trial to determine the optimum first-line therapy for people with primary open-angle glaucoma and exfoliative glaucoma. This study will compare the effect of selective laser trabeculoplasty and topical medication with respect to patients' generic and glaucoma-specific quality of life. The trial will also provide a detailed cost-effectiveness analysis and compare the clinical effectiveness with respect to the degree of intraocular pressure lowering and rates of treatment failure. Research coordinators in each centre will identify and recruit previously untreated patients with primary open-angle glaucoma and exfoliative glaucoma. Those who meet the eligibility criteria will be invited to enter a randomised controlled trial with either selective laser trabeculoplasty or topical ocular hypotensive therapy, according to a stepped regimen. Outcome assessment will be measured at 6 weeks and at 6, 12, and 24 months post-treatment. Regular clinic follow-ups will continue as clinically indicated between study outcome visits. Discussion: The Glaucoma Initial Treatment Study is the first multi-centred RCT to determine the optimum first-line therapy for people with glaucoma. Our trial will have an unprecedented capacity to meaningfully transform the treatment and management of glaucoma in Australia and overseas. Trial registration:ACTRN12611000720910 ; Date registered: 11 July 2011 © 2015 Lamoureux et al. AD - University of Melbourne, Royal Victorian Eye and Ear Hospital, Centre for Eye Research Australia, Melbourne, 3002, Australia Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore Duke, Graduate Medical School, Singapore, Singapore University of Adelaide, North Terrace, AdelaideSA, Australia University of Sydney, Discipline of Ophthalmology, Sydney, NSW, Australia Glaucoma Unit, Sydney Eye Hospital, Sydney, NSW, Australia Eye Associates, Sydney, NSW, Australia University of Sydney, Centre for Vision Research, Department of Ophthalmology and Westmead Millennium Institute, Sydney, NSW, Australia Queensland Eye Institute, 149 Melbourne Street, South Brisbane, QLD, Australia University of Queensland, Brisbane, QLD, Australia Royal Victorian Eye and Ear Hospital, VIC, Australia Flinders University and Flinders Medical Centre-Australia, NH and MRC Centre for Clinical Eye Research, Discipline of Optometry and Vision Science, Adelaide, Australia AU - Lamoureux, E. L. AU - McIntosh, R. AU - Constantinou, M. AU - Fenwick, E. K. AU - Xie, J. AU - Casson, R. AU - Finkelstein, E. AU - Goldberg, I. AU - Healey, P. AU - Thomas, R. AU - Ang, G. S. AU - Pesudovs, K. AU - Crowston, J. C7 - 406 DB - Scopus DO - 10.1186/s13063-015-0924-6 IS - 1 KW - cost-effectiveness eye drops Glaucoma quality of life randomised clinical trial selective laser trabeculoplasty M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2015 ST - Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): Study protocol for a randomised controlled trial T2 - Trials TI - Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): Study protocol for a randomised controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941267045&doi=10.1186%2fs13063-015-0924-6&partnerID=40&md5=9ed1f81df8b59917ceecc1016527a394 VL - 16 ID - 5232 ER - TY - JOUR AB - Background: Glaucoma is the leading cause of irreversible blindness in the world. Estimated to affect 60 million people worldwide, this figure is expected to rise to 80 million by 2020. Untreated, glaucoma leads to visual decay and eventually to blindness, and can significantly reduce quality of life. First-line treatment in patients with primary open-angle glaucoma and exfoliative glaucoma is topical medical therapy with ocular hypotensives as eye drops. However, eye drops have several disadvantages including cost, possible local and systemic side effects, and adherence and perseverance issues. Randomised controlled trials have demonstrated that selective laser trabeculoplasty is equally as effective in lowering intraocular pressure as eye drops. However, the impact of these two treatment modalities from the patient and economic perspectives has not been adequately determined. Thus, it remains unclear whether topical medical therapy or selective laser trabeculoplasty should be recommended as first-line treatment for glaucoma. Methods/Design: This protocol describes an international, multi-centre, randomised controlled trial to determine the optimum first-line therapy for people with primary open-angle glaucoma and exfoliative glaucoma. This study will compare the effect of selective laser trabeculoplasty and topical medication with respect to patients' generic and glaucoma-specific quality of life. The trial will also provide a detailed cost-effectiveness analysis and compare the clinical effectiveness with respect to the degree of intraocular pressure lowering and rates of treatment failure. Research coordinators in each centre will identify and recruit previously untreated patients with primary open-angle glaucoma and exfoliative glaucoma. Those who meet the eligibility criteria will be invited to enter a randomised controlled trial with either selective laser trabeculoplasty or topical ocular hypotensive therapy, according to a stepped regimen. Outcome assessment will be measured at 6 weeks and at 6, 12, and 24 months post-treatment. Regular clinic follow-ups will continue as clinically indicated between study outcome visits. Discussion: The Glaucoma Initial Treatment Study is the first multi-centred RCT to determine the optimum first-line therapy for people with glaucoma. Our trial will have an unprecedented capacity to meaningfully transform the treatment and management of glaucoma in Australia and overseas. AN - WOS:000361029000001 AU - Lamoureux, E. L. AU - McIntosh, R. AU - Constantinou, M. AU - Fenwick, E. K. AU - Xie, J. AU - Casson, R. AU - Finkelstein, E. AU - Goldberg, I. AU - Healey, P. AU - Thomas, R. AU - Ang, G. S. AU - Pesudovs, K. AU - Crowston, J. DA - SEP 11 DO - 10.1186/s13063-015-0924-6 PY - 2015 SN - 1745-6215 ST - Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial T2 - TRIALS TI - Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial VL - 16 ID - 6230 ER - TY - JOUR AB - Purpose. This case series presents the first documented cases of infectious ulcers associated with overnight orthokeratology in North America and other less serious complications associated with overnight corneal reshaping. Case Reports. Five cases of adverse corneal events associated with corneal refractive therapy are described: two cases of microbial keratitis, one case of infiltrates, one case of toxic keratitis, and one corneal abrasion. Conclusions. Corneal compromise and poor compliance can cause adverse events with corneal reshaping. The need for ongoing patient education is important not only for pediatric contact lens patients, but also for adults. © 2004 Contact Lens Association of Ophthalmologists, Inc. AD - J. Lang, New England College of Optometry, Boston, MA, United States AU - Lang, J. AU - Rah, M. J. C1 - polytrim tobradex DB - Embase Medline DO - 10.1097/01.ICL.0000140230.56008.EF IS - 4 KW - artificial tear ciprofloxacin cyclopentolate dexamethasone plus tobramycin gatifloxacin moxifloxacin ofloxacin polytrim adult article case report cell infiltration contact lens cornea disease cornea edema cornea refractive therapy eye refraction female human keratitis male patient compliance priority journal prosthesis infection school child tobradex Focus Paragon LA - English M3 - Article N1 - L43196943 2006-02-20 PY - 2004 SN - 1542-2321 SP - 231-233 ST - Adverse corneal events associated with corneal reshaping: A case series T2 - Eye and Contact Lens TI - Adverse corneal events associated with corneal reshaping: A case series UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43196943&from=export http://dx.doi.org/10.1097/01.ICL.0000140230.56008.EF VL - 30 ID - 3730 ER - TY - JOUR AB - Penetrating keratoplasty in children is associated with very specific difficulties for the surgeon as well as for the patient and the parents. Special features are specific pediatric indications, which do not occur in adults, a more difficult examination and treatment adherence depending on the parents. Diseases with a favorable prognosis include keratoconus and herpetic keratitis. Especially sclerocornea and the Peters' anomaly often have a limited prognosis regarding vision and graft survival due to secondary malformations of the eye. In addition, younger age represents a risk factor. This is most likely due to the impaired examination during follow-up and reduced compliance. For successful penetrating keratoplasty in children the timing for the operation, in which the risk for the graft is weighed up against the risk for amblyopia, is crucial. AN - WOS:000495682400003 AU - Lang, S. J. AU - Bohringer, D. AU - Reinhard, T. DA - MAR DO - 10.1007/s00347-019-01006-3 IS - 3 PY - 2020 SN - 0941-293X 1433-0423 SP - 215-217 ST - Keratoplasty in children Indications and results T2 - OPHTHALMOLOGE TI - Keratoplasty in children Indications and results VL - 117 ID - 6224 ER - TY - JOUR AB - Purpose: Evaluate outcomes from severe ocular complications of juvenile idiopathic arthritis following surgery. Methods: Eleven eyes of 7 patients underwent complete vitrectomy and peeling of the inner limiting membrane. Inclusion criteria were: anteroposterior segment involvement, hypotony, inflammation control of less than 3 months, compliance issues, rapidly progressive disease. Phacoemulsification was allowed if the patient was >6 years old and inflammation free >3 months. The alternative was a complete lensectomy. Results: Visual acuity improved from a logMAR of 1.48 to 0.37 (p < 0.0001), and 0.20 at 6 and 12 months (p < 0.0001). No flare-up was observed within the first 6 months. Five eyes developed inflammation between 7 and 19 months. Glaucoma developed in 5 eyes at a median of 16 months. No patient developed cystoid macular edema. Conclusion: Extensive pars plana vitrectomy and cataract extraction can lead to significant improvement in visual acuity. Patients continue to require long-term immunosuppression and adequate follow-up. © 2014 S. Karger AG, Basel. AD - Department of Ophthalmology, Medical University of Graz, Graz, Austria Retina and Inflammation, MIOS SA, Specialized Eye Center in Uveitis and Retina, Avenue du Léman 32, Lausanne, CH-1005, Switzerland Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands AU - Langner-Wegscheider, B. J. AU - De Smet, M. D. DB - Scopus DO - 10.1159/000365230 IS - 3 KW - Anterior vitrectomy Complications Juvenile idiopathic arthritis Ocular hypotony Posterior vitrectomy Surgical management Uveitis M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2014 SP - 179-186 ST - Surgical management of severe complications arising from uveitis in juvenile idiopathic arthritis T2 - Ophthalmologica TI - Surgical management of severe complications arising from uveitis in juvenile idiopathic arthritis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84927963523&doi=10.1159%2f000365230&partnerID=40&md5=b2e03ab3ca9bbc43a3b47fb1447542e6 VL - 232 ID - 5422 ER - TY - JOUR AB - Purpose: Evaluate outcomes from severe ocular complications of juvenile idiopathic arthritis following surgery. Methods: Eleven eyes of 7 patients underwent complete vitrectomy and peeling of the inner limiting membrane. Inclusion criteria were: anteroposterior segment involvement, hypotony, inflammation control of less than 3 months, compliance issues, rapidly progressive disease. Phacoemulsification was allowed if the patient was >6 years old and inflammation free >3 months. The alternative was a complete lensectomy. Results: Visual acuity improved from a logMAR of 1.48 to 0.37 (p < 0.0001), and 0.20 at 6 and 12 months (p < 0.0001). No flare-up was observed within the first 6 months. Five eyes developed inflammation between 7 and 19 months. Glaucoma developed in 5 eyes at a median of 16 months. No patient developed cystoid macular edema. Conclusion: Extensive pars plana vitrectomy and cataract extraction can lead to significant improvement in visual acuity. Patients continue to require long-term immunosuppression and adequate follow-up. (C) 2014 S. Karger AG, Basel AN - WOS:000345255400008 AU - Langner-Wegscheider, B. J. AU - de Smet, M. D. DO - 10.1159/000365230 IS - 3 PY - 2014 SN - 0030-3755 1423-0267 SP - 179-186 ST - Surgical Management of Severe Complications Arising from Uveitis in Juvenile Idiopathic Arthritis T2 - OPHTHALMOLOGICA TI - Surgical Management of Severe Complications Arising from Uveitis in Juvenile Idiopathic Arthritis VL - 232 ID - 6207 ER - TY - JOUR AB - Failure of glaucoma filtration surgery usually results from scarring at the surgical site. Studies have shown that fibroblast proliferation plays an important role in scar formation which results in a mechanical barrier to filtration (Gressel, Parris, & Folberg, 1984). Fibroblasts are immature collagen-producing cells which proliferate at the site of chronic inflammation. The antimetabolite 5-fluorouracil (5-FU) can inhibit fibroblast activity. Over the past ten years, the adjunctive use of 5-FU in filtration surgery has met with increased success and is particularly indicated in those patients at greatest risk of filtration failure. AU - Langseth, F. G. DB - Scopus IS - 2 M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 1993 SP - 12-13 ST - The use of 5-fluorouracil in glaucoma filtration surgery T2 - Insight (American Society of Ophthalmic Registered Nurses) TI - The use of 5-fluorouracil in glaucoma filtration surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027605537&partnerID=40&md5=7f414bd95a2dfa2c43d5d3cbd92750d5 VL - 18 ID - 5651 ER - TY - JOUR AB - Chronic eye diseases, such as glaucoma or dry eye syndrome, require long-term drug application to the eyes. Good adherence is required to achieve the therapeutic goal and patient needs and requirements have to be taken into account. This distinguishes adherence to drug therapy from the former compliance which implies only following medical instructions. Adherence is influenced by socioeconomic, health system-related, disease-related, treatment-related and patient-related factors. It can be measured by tedious procedures, such as electronic monitoring, self-assessment, drop counting and laboratory findings of systemic drug levels. Non-adherence is a growing medical problem worldwide. An increase in adherence means an increased degree of therapeutic safety for the patient and long-term cost savings for the individual as well as society. Non-adherence in chronic diseases, such as glaucoma and dry eye syndrome is increased by eye drops that cause side effects. Often these side effects are caused by agents such as the preservative benzalkonium chloride. To achieve a good adherence preservative-free eye drops are advised. © 2012 Springer-Verlag Berlin Heidelberg. AD - I. Lanzl, Augenklinik, TU München, Ismaninger Str. 22, 81675 München, Germany AU - Lanzl, I. AU - Kaercher, T. DB - Medline DO - 10.1007/s00347-012-2641-9 IS - 11 KW - eye drops preservative article human ophthalmology patient compliance practice guideline standard LA - English German M3 - Article N1 - L366164880 2013-11-21 PY - 2012 SN - 0941-293X SP - 1087-1092 ST - Preservative-containing eye drops and adherence in ophthalmological practice T2 - Ophthalmologe TI - Preservative-containing eye drops and adherence in ophthalmological practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L366164880&from=export http://dx.doi.org/10.1007/s00347-012-2641-9 VL - 109 ID - 3058 ER - TY - JOUR AU - Lanzl, I. M. AU - Poimenidou, M. AU - Spaeth, G. L. DB - Medline IS - 10 KW - delayed release formulation eye drops administration and dosage dose response evidence based medicine Germany open angle glaucoma human intraocular drug administration patient compliance treatment outcome LA - German M3 - Review N1 - L618152541 2017-09-08 PY - 2016 SN - 1433-0423 SP - 824-832 ST - Possibilities and limitations of eye drops for glaucoma therapy T2 - Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft TI - Possibilities and limitations of eye drops for glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L618152541&from=export VL - 113 ID - 2702 ER - TY - JOUR AB - BACKGROUND: This study was performed to investigate the use of an electronic medication alarm device (Prescript TimeCap) to enhance compliance in glaucoma patients taking pilocarpine. METHODS: Thirteen subjects were selected who had been diagnosed with open-angle glaucoma and were receiving 1 drop of pilocarpine solution 4 times a day in both eyes. For each subject, the study was divided into 2 30-day phases, one with the medication alarm device and the other without. Thus, each subject served as his or her own control. Compliance was measured based on the amount of pilocarpine used and by patient questionnaire. In addition, the subjects completed a post-study questionnaire regarding the ease of use of the TimeCap and whether it helped them remember to take their medication. RESULTS: When subjects used the TimeCap, they administered an average of 2.867 g (P < 0.0001) more pilocarpine over the 30 days than during the period without it. Subjects also estimated a significant difference in compliance level, 95.8 percent with the alarm device versus 83.1 percent without it (p < 0.01). All subjects reported no difficulty using the TimeCap, and all reported that it helped them remember to take their medication. CONCLUSIONS: These results are highly suggestive that the TimeCap is an effective compliance aid for glaucoma patients on pilocarpine. AD - S.F. Laster AU - Laster, S. F. AU - Martin, J. L. AU - Fleming, J. B. DB - Medline IS - 11 KW - eye drops muscarinic agent pilocarpine devices article clinical trial controlled clinical trial controlled study drug administration drug packaging female human male open angle glaucoma patient compliance phase 1 clinical trial phase 2 clinical trial questionnaire randomized controlled trial topical drug administration LA - English M3 - Article N1 - L127211316 1997-01-13 PY - 1996 SN - 0003-0244 SP - 654-658 ST - The effect of a medication alarm device on patient compliance with topical pilocarpine T2 - Journal of the American Optometric Association TI - The effect of a medication alarm device on patient compliance with topical pilocarpine UR - https://www.embase.com/search/results?subaction=viewrecord&id=L127211316&from=export VL - 67 ID - 3966 ER - TY - JOUR AB - Investigated the effectiveness of the electronic medication alarm device, the Prescript TimeCap, in improving compliance in 13 open-angle glaucoma patients taking 1 drop of pilocarpine solution 4 times a day. For each S, the study was divided into 2 30-day phases, 1 with the medication alarm device and the other without. Compliance was measured based on the amount of pilocarpine used and by patient questionnaire. Ss also completed a poststudy questionnaire. Results showed that when Ss used the TimeCap, they administered an average of 2.867 g more pilocarpine than during the period without it. Ss also estimated a significant difference in compliance level, 95.8% with the alarm device vs 83.1% without it. All Ss reported no difficulty using the TimeCap, and all reported that it helped them remember to take their medication. These results are highly suggestive that the TimeCap is an effective compliance aid for glaucoma patients on pilocarpine. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1997-02657-001 AU - Laster, Shane F. AU - Martin, Jerry L. AU - Fleming, Joseph B. DB - psyh DP - EBSCOhost IS - 11 KW - electronic medication alarm device Prescript TimeCap compliance with topical pilocarpine open-angle glaucoma patients Administration, Topical Drug Administration Schedule Drug Packaging Equipment and Supplies Female Glaucoma, Open-Angle Humans Male Muscarinic Agonists Ophthalmic Solutions Patient Compliance Pilocarpine Surveys and Questionnaires Apparatus Drug Therapy Glaucoma Treatment Compliance Self-Medication N1 - Northeastern State U, Coll of Optometry, Tahlequah, OK, US. Release Date: 19980201. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: EnglishMajor Descriptor: Apparatus; Drug Therapy; Glaucoma; Pilocarpine; Treatment Compliance. Minor Descriptor: Self-Medication. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study. Page Count: 5. Issue Publication Date: Nov, 1996. PY - 1996 SN - 0003-0244 SP - 654-658 ST - The effect of a medication alarm device on patient compliance with topical pilocarpine T2 - Journal of the American Optometric Association TI - The effect of a medication alarm device on patient compliance with topical pilocarpine UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1997-02657-001&site=ehost-live&scope=site VL - 67 ID - 4865 ER - TY - JOUR AB - Reduction of intraocular pressure (IOP) by pharmaceutical or surgical means has long been the standard treatment for glaucoma. A number of excellent drugs are available that are effective in reducing IOP. These drugs are typically applied as eye drops. However, patient adherence can be poor, thus reducing the clinical efficacy of the drugs. Several novel delivery systems designed to address the issue of adherence and to ensure consistent reduction of IOP are currently under development. These delivery systems include contact lenses-releasing glaucoma medications, injectables such as biodegradable micro- and nanoparticles, and surgically implanted systems. These new technologies are aimed at increasing clinical efficacy by offering multiple delivery options and are capable of managing IOP for several months. There is also a desire to have complementary neuroprotective approaches for those who continue to show progression, despite IOP reduction. Many potential neuroprotective agents are not suitable for traditional oral or drop formulations. Their potential is dependent on developing suitable delivery systems that can provide the drugs in a sustained, local manner to the retina and optic nerve. Drug delivery systems have the potential to improve patient adherence, reduce side effects, increase efficacy, and ultimately, preserve sight for glaucoma patients. In this review, we discuss benefits and limitations of the current systems of delivery and application, as well as those on the horizon. © 2011 Macmillan Publishers Limited All rights reserved. AD - E. Lavik, Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave, Wickenden 309, Cleveland, OH 44106, United States AU - Lavik, E. AU - Kuehn, M. H. AU - Kwon, Y. H. C1 - nyogel(Novartis,Switzerland) timoptic xe(Merck,United States) C2 - Novartis(Switzerland) Merck(United States) DB - Embase Medline DO - 10.1038/eye.2011.82 IS - 5 KW - antiglaucoma agent bimatoprost brain derived neurotrophic factor carbonate dehydratase inhibitor ciliary neurotrophic factor drug carrier glial cell line derived neurotrophic factor latanoprost liposome nanosphere neuroprotective agent ocular insert pilocarpine polymer timolol timolol maleate travoprost unclassified drug application site discoloration aqueous humor biomedical microelectromechanical system blood retina barrier blurred vision cell transplantation conjunctival hyperemia coughing diarrhea disease course diuresis drug bioavailability drug delivery system drug dosage form comparison drug efficacy drug formulation drug implant drug induced headache electrolyte disturbance fatigue glaucoma human hydrophobicity intraocular hypertension intraocular pressure nausea neuroprotection patient attitude patient compliance retina detachment review side effect skin discoloration soft contact lens vomiting body weight loss nyogel timoptic xe LA - English M3 - Review N1 - L361768461 2011-05-24 2011-05-30 PY - 2011 SN - 1476-5454 0950-222X SP - 578-586 ST - Novel drug delivery systems for glaucoma T2 - Eye TI - Novel drug delivery systems for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361768461&from=export http://dx.doi.org/10.1038/eye.2011.82 VL - 25 ID - 3201 ER - TY - JOUR AB - Reduction of intraocular pressure (IOP) by pharmaceutical or surgical means has long been the standard treatment for glaucoma. A number of excellent drugs are available that are effective in reducing IOP. These drugs are typically applied as eye drops. However, patient adherence can be poor, thus reducing the clinical efficacy of the drugs. Several novel delivery systems designed to address the issue of adherence and to ensure consistent reduction of IOP are currently under development. These delivery systems include contact lenses-releasing glaucoma medications, injectables such as biodegradable micro- and nanoparticles, and surgically implanted systems. These new technologies are aimed at increasing clinical efficacy by offering multiple delivery options and are capable of managing IOP for several months. There is also a desire to have complementary neuroprotective approaches for those who continue to show progression, despite IOP reduction. Many potential neuroprotective agents are not suitable for traditional oral or drop formulations. Their potential is dependent on developing suitable delivery systems that can provide the drugs in a sustained, local manner to the retina and optic nerve. Drug delivery systems have the potential to improve patient adherence, reduce side effects, increase efficacy, and ultimately, preserve sight for glaucoma patients. In this review, we discuss benefits and limitations of the current systems of delivery and application, as well as those on the horizon. AD - Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. AN - 104900385. Language: English. Entry Date: 20110909. Revision Date: 20200708. Publication Type: journal article AU - Lavik, E. AU - Kuehn, M. H. AU - Kwon, Y. H. AU - Lavik, E. AU - Kuehn, M. H. AU - Kwon, Y. H. DB - ccm DO - 10.1038/eye.2011.82 DP - EBSCOhost IS - 5 KW - Drug Delivery Systems -- Methods Glaucoma -- Drug Therapy Ophthalmic Solutions -- Administration and Dosage Intraocular Pressure -- Drug Effects Medication Compliance Neuroprotective Agents -- Administration and Dosage N1 - research; review. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. Grant Information: EY017142/EY/NEI NIH HHS/United States. NLM UID: 8703986. PMID: NLM21475311. PY - 2011 SN - 0950-222X SP - 578-586 ST - Novel drug delivery systems for glaucoma T2 - Eye TI - Novel drug delivery systems for glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104900385&site=ehost-live&scope=site VL - 25 ID - 4678 ER - TY - JOUR AB - Purposes: Microbial keratitis is commonly diagnosed worldwide, and continues to cause significant ocular morbidity, requiring prompt and appropriate treatment. The objective of this study is to describe the clinical characteristics and outcomes of patients with presumed microbial keratitis admitted to The Goldschleger Eye Institute, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel. Methods: A cross-sectional study was conducted, in which the medical records of patients with presumed microbial keratitis admitted during a period of 3 years were reviewed. Results: Keratitis was diagnosed in 276 patients (51% males and 48.9% females). The mean age was 39.29 ± 22.30 years. The hospital length of stay ranged from 1 to 65 days (mean 5.69 ± 5.508). Fortified antibiotics were still used at discharge in 72% of the cases. Overall visual acuity improved significantly from the time of admission to the 1st-week follow up visit showing a p<0.001 on the Wilcoxon signed ranks test. Contact lens wearing was present in 36.1% of the patients, although there was no significant relation with severity of the presentation and visual outcome (p>0.05). The degree of hypopyon and cells in the anterior chamber was significantly related to the hospital length of stay (r Spearman=0.31; p<0.001 and r Spearman=0.21; p<.001, respectively) as well as to a worse visual outcome (r Spearman=0.32; p<0.01 and r Spearman=0.18; p=0.01, respectively). Of all patients, 2.3% required an urgent therapeutic penetrating keratoplasty, and 1% underwent evisceration. There was no enucleation. Conclusion: Treating keratitis aggressively and assuring patient compliance is imperative for a good final visual outcome. Inpatient treatment may have a positive impact on this outcome. AD - Goldschleger Eye Institute, Sheba Medical Center, Tel Aviv University Sackler, Faculty of Medicine, Tel Hashomer, Israel AU - Lavinsky, F. AU - Avni-Zauberman, N. AU - Barequet, I. S. DB - Scopus DO - 10.1590/S0004-27492013000300009 IS - 3 KW - Cornea Cross-sectional studies Eye infection, bacterial Eye infection, fungal Israel Keratitis/diagnosis Prognosis Tertiary healthcare M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2013 SP - 175-179 ST - Clinical characteristics and outcomes of patients admitted with presumed microbial keratitis to a tertiary medical center in israel T2 - Arquivos Brasileiros de Oftalmologia TI - Clinical characteristics and outcomes of patients admitted with presumed microbial keratitis to a tertiary medical center in israel UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883660610&doi=10.1590%2fS0004-27492013000300009&partnerID=40&md5=ab66300dff866486e61eaec62888e49f VL - 76 ID - 5424 ER - TY - JOUR AB - Purposes: Microbial keratitis is commonly diagnosed worldwide, and continues to cause significant ocular morbidity, requiring prompt and appropriate treatment. The objective of this study is to describe the clinical characteristics and outcomes of patients with presumed microbial keratitis admitted to The Goldschleger Eye Institute, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel. Methods: A cross-sectional study was conducted, in which the medical records of patients with presumed microbial keratitis admitted during a period of 3 years were reviewed. Results: Keratitis was diagnosed in 276 patients (51% males and 48.9% females). The mean age was 39.29 +/- 22.30 years. The hospital length of stay ranged from 1 to 65 days (mean 5.69 +/- 5.508). Fortified antibiotics were still used at discharge in 72% of the cases. Overall visual acuity improved significantly from the time of admission to the 1st-week follow up visit showing a p<0.001 on the Wilcoxon signed ranks test. Contact lens wearing was present in 36.1% of the patients, although there was no significant relation with severity of the presentation and visual outcome (p>0.05). The degree of hypopyon and cells in the anterior chamber was significantly related to the hospital length of stay (r Spearman=0.31; p<0.001 and r Spearman=0.21; p<.001, respectively) as well as to a worse visual outcome (r Spearman=0.32; p<0.01 and r Spearman=0.18; p=0.01, respectively). Of all patients, 2.3% required an urgent therapeutic penetrating keratoplasty, and 1% underwent evisceration. There was no enucleation. Conclusion: Treating keratitis aggressively and assuring patient compliance is imperative for a good final visual outcome. Inpatient treatment may have a positive impact on this outcome. AN - WOS:000323010700009 AU - Lavinsky, F. AU - Avni-Zauberman, N. AU - Barequet, I. S. DA - MAR-JUN DO - 10.1590/S0004-27492013000300009 IS - 3 PY - 2013 SN - 0004-2749 1678-2925 SP - 175-179 ST - Clinical characteristics and outcomes of patients admitted with presumed microbial keratitis to a tertiary medical center in Israel T2 - ARQUIVOS BRASILEIROS DE OFTALMOLOGIA TI - Clinical characteristics and outcomes of patients admitted with presumed microbial keratitis to a tertiary medical center in Israel VL - 76 ID - 5855 ER - TY - JOUR AB - Certain ethnic subgroups of Asian-Americans appear to have a higher rate of occludable angle and PACG than do whites and blacks. It is important to recognize the different contribution of nonpupillary block mechanism of angle closure, such as anteriorly positioned ciliary processes (as in plateau iris configuration) and lens-induced decrease of anterior chamber angle width. The difference in the combination of mechanisms of angle closure in the Asian-American population would be better understood with wider application of ultrasonic biomicroscopy in evaluating the angular configuration. Because the majority of angle-closure glaucoma in Asian-Americans may be asymptomatic and laser peripheral iridotomy is proven to be an effective prophylactic treatment, examination of the peripheral angle with gonioscopy is crucial for early diagnosis and appropriate treatment. Application of public resources to the at-risk population is considered to be cost-effective in glaucoma care. For angle-closure glaucoma in Asian Americans, the at-risk population is patients older than 40 years, women, hypermetropia, family history of angle closure, and patients of certain ethnic subgroups, such as Chinese, patients from Indochina, and Asian Indians. As eye care professionals, we need to be aware that certain ethnic groups of Asian-Americans may have a lower average IOP than that of whites and blacks. Applying the average IOP for whites or blacks to Asian-Americans in diagnosing glaucoma will miss a significant proportion of Asian-American patients with glaucoma. Glaucoma is defined by the presence of glaucomatous optic neuropathy. Careful evaluation of the optic disc with dilated fundus examination and stereoscopic optic disc photography is a sensitive method of evaluation. Our understanding of primary glaucoma in Asia-Americans is limited. The prevalence and presentation of diseases in U.S. Asians may be different from that in Asians in the East because of the difference in health care structure in terms of accessibility, ophthalmic practice in terms of wider use of laser therapy, and cataract extraction in the United States; possibly such environmental factors as life-style, nutrition, and geographical location; and genetic variation from interracial marriage. Although the multicultural social environment of the United States is certainly different from that in Asia, it may provide a unique opportunity for studying glaucoma among different ethnic groups in a single setting. AD - Jules Stein Eye Institute, 100 Stein Plaza 2-235, Los Angeles, CA 90095, United States AU - Law, S. K. DB - Scopus DO - 10.1097/00004397-200343040-00013 IS - 4 M3 - Review N1 - Cited By :2 Export Date: 19 July 2021 PY - 2003 SP - 133-149 ST - Asian Americans: Glaucoma T2 - International Ophthalmology Clinics TI - Asian Americans: Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0142152482&doi=10.1097%2f00004397-200343040-00013&partnerID=40&md5=b80b8887d8f437375db21afdb8f74727 VL - 43 ID - 5591 ER - TY - JOUR AB - Purpose of review In the current medical care environment, switching within class is often demanded by cost consideration, medical insurance coverage, or formulary restriction. With many choices of drugs available within a glaucoma medication class, questions exist whether switching within class is beneficial. The purpose of this article is to provide a clinical update on the feasibility of switching among the frequently used drugs within glaucoma medication class. Recent findings Although efficacies of medications within a therapeutic class are similar and significant differences are generally not observed in clinical trials, response to medication often varies among individual patients in a clinical practice. Such variation may be secondary to differences in drug-receptor interactions, patient's compliance and tolerability to medical treatment, or bioavailability of the medication in individual ocular condition. In addition, switching within class is often necessary to minimize the systemic or local adverse reactions from the active or inactive ingredients of the medication. Summary In addition to keeping up-to-date with the efficacy and safety profiles of drugs within each glaucoma medication class, clinicians should familiarize themselves with the different formulations available, preservative systems used, generics availability and compatibility, and the local insurance formulary restriction to deliver an effective glaucoma management. © 2009 Wolters Kluwer Health|Lippincott Williams & Wilkins. AD - S.K. Law, Jules Stein Eye Institute, 100 Stein Plaza #2-235, Los Angeles, CA 90095, United States AU - Law, S. K. C1 - alphagan p(Allergan,United States) istalol(Merck,United States) ocusert timolol gfs(Alcon,United States) timoptic xe(Merck,United States) C2 - Alcon(United States) Allergan(United States) Merck(United States) DB - Embase Medline DO - 10.1097/ICU.0b013e32831d1fc7 IS - 2 KW - acetazolamide epinephrine alpha adrenergic receptor stimulating agent brimonidine apraclonidine benzalkonium chloride beta adrenergic receptor blocking agent betaxolol bimatoprost brinzolamide carbachol carbonate dehydratase inhibitor carteolol cholinergic receptor stimulating agent dipivefrine dorzolamide ecothiopate iodide latanoprost levobunolol methazolamide metipranolol pilocarpine prostaglandin derivative timolol timolol gfs timolol maleate travoprost unclassified drug unoprostone isopropyl ester bedtime dosage blurred vision bronchospasm cardiovascular disease conjunctival hyperemia drug efficacy drug formulary drug hypersensitivity drug indication drug safety drug substitution drug tolerability drug withdrawal epiphora eye color eye toxicity eyelash feasibility study glaucoma heart arrhythmia human hypertension intraocular pressure open angle glaucoma patient compliance priority journal review sedation side effect tachycardia treatment response unspecified side effect alphagan p istalol ocusert timoptic xe LA - English M3 - Review N1 - L354355311 2009-04-07 PY - 2009 SN - 1040-8738 SP - 110-115 ST - Switching within glaucoma medication class T2 - Current Opinion in Ophthalmology TI - Switching within glaucoma medication class UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354355311&from=export http://dx.doi.org/10.1097/ICU.0b013e32831d1fc7 VL - 20 ID - 3375 ER - TY - JOUR AB - PURPOSE OF REVIEW: In the current medical care environment, switching within class is often demanded by cost consideration, medical insurance coverage, or formulary restriction. With many choices of drugs available within a glaucoma medication class, questions exist whether switching within class is beneficial. The purpose of this article is to provide a clinical update on the feasibility of switching among the frequently used drugs within glaucoma medication class. RECENT FINDINGS: Although efficacies of medications within a therapeutic class are similar and significant differences are generally not observed in clinical trials, response to medication often varies among individual patients in a clinical practice. Such variation may be secondary to differences in drug-receptor interactions, patient's compliance and tolerability to medical treatment, or bioavailability of the medication in individual ocular condition. In addition, switching within class is often necessary to minimize the systemic or local adverse reactions from the active or inactive ingredients of the medication. SUMMARY: In addition to keeping up-to-date with the efficacy and safety profiles of drugs within each glaucoma medication class, clinicians should familiarize themselves with the different formulations available, preservative systems used, generics availability and compatibility, and the local insurance formulary restriction to deliver an effective glaucoma management. AD - Jules Stein Eye Institute, University of California, Los Angeles, California 90095, USA. law@jsei.ucla.edu AN - 105482558. Language: English. Entry Date: 20090501. Revision Date: 20210406. Publication Type: Journal Article AU - Law, S. K. DB - ccm DO - 10.1097/icu.0b013e32831d1fc7 DP - EBSCOhost IS - 2 KW - Drugs -- Therapeutic Use Glaucoma -- Therapy Adrenergic Antagonists -- Therapeutic Use Carbonic Anhydrase Inhibitors -- Therapeutic Use Ophthalmology Prostaglandins -- Therapeutic Use N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM19240542. PY - 2009 SN - 1040-8738 SP - 110-115 ST - Switching within glaucoma medication class T2 - Current Opinion in Ophthalmology TI - Switching within glaucoma medication class UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105482558&site=ehost-live&scope=site VL - 20 ID - 4701 ER - TY - JOUR AB - Purpose To evaluate acupuncture as treatment for glaucoma. Design Prospective double-masked randomized crossover study. Methods setting: Clinical practice. population: One eye per patient with primary open-angle glaucoma and stable intraocular pressure (IOP). intervention: Patients were randomized to receive 1 acupuncture series (12 sessions with either eye-related [eye-points] or non-eye-related [non-eye-points] acupoints) and then crossed over to receive the other series. outcome measures: IOP, blood pressure (BP), heart rate (HR), best-corrected visual acuity (BCVA), visual field (VF), optic disc and peripapillary retinal nerve fiber layer (RNFL) measurements, compliance, and adverse reactions. Probability to detect 3 mm Hg IOP difference between series was 90%. Results Twenty-two patients volunteered and 11 (50.0%) completed the study; 8 (36.4%) did not complete treatment owing to changes of health, moving away, lack of transportation, or family crisis; and 3(13.6%) were withdrawn owing to needle sensitivity or IOP elevation (8 mm Hg) in the contralateral eye. After an acupuncture session, mean IOP increased slightly with both eye-points (from 12.9 ± 1.8 mm Hg to 13.6 ± 2.0 mm Hg, P =.019) and non-eye-points (from 13.0 ± 1.5 mm Hg to 13.5 ± 1.7 mm Hg, P =.073) series. HR, diurnal IOP, and BCVA showed no statistically significant changes after 12 sessions of either series. Systolic and diastolic BP were reduced after 12 sessions of non-eye-points series (P =.040, P =.002, respectively). Optic disc, RNFL, and VF showed no statistically significant changes. Conclusions Acupuncture has no overall effect on diurnal IOP or BCVA but may temporally increase the IOP immediately after a treatment session. BP is lowered by acupuncture with non-eye-points, but not with eye-points. Compliance and adverse event rates were low. AD - S.K. Law, Stein Eye Institute, 100 Stein Plaza #2-235, Los Angeles, CA, United States AU - Law, S. K. AU - Lowe, S. AU - Law, S. M. AU - Giaconi, J. A. AU - Coleman, A. L. AU - Caprioli, J. DB - Embase Medline DO - 10.1016/j.ajo.2015.04.033 IS - 2 KW - acupuncture needle disposable equipment stainless steel acupuncture adult aged article best corrected visual acuity clinical article clinical evaluation clinical practice controlled study crossover procedure diastolic blood pressure double blind procedure family stress female heart rate human intraocular hypertension intraocular pressure male medical device complication open angle glaucoma optic disk patient compliance priority journal prospective study randomized controlled trial retinal nerve fiber layer thickness spectral domain optical coherence tomography systolic blood pressure visual acuity visual acuity chart visual field vital sign LA - English M3 - Article N1 - L604470040 2015-05-27 2015-07-30 PY - 2015 SN - 1879-1891 0002-9394 SP - 256-265 ST - Prospective Evaluation of Acupuncture as Treatment for Glaucoma T2 - American Journal of Ophthalmology TI - Prospective Evaluation of Acupuncture as Treatment for Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604470040&from=export http://dx.doi.org/10.1016/j.ajo.2015.04.033 VL - 160 ID - 2844 ER - TY - JOUR AB - Purpose: To evaluate acupuncture as treatment for glaucoma.Design: Prospective double-masked randomized crossover study.Methods: setting: Clinical practice.Population: One eye per patient with primary open-angle glaucoma and stable intraocular pressure (IOP).Intervention: Patients were randomized to receive 1 acupuncture series (12 sessions with either eye-related [eye-points] or non-eye-related [non-eye-points] acupoints) and then crossed over to receive the other series.Outcome Measures: IOP, blood pressure (BP), heart rate (HR), best-corrected visual acuity (BCVA), visual field (VF), optic disc and peripapillary retinal nerve fiber layer (RNFL) measurements, compliance, and adverse reactions. Probability to detect 3 mm Hg IOP difference between series was 90%.Results: Twenty-two patients volunteered and 11 (50.0%) completed the study; 8 (36.4%) did not complete treatment owing to changes of health, moving away, lack of transportation, or family crisis; and 3(13.6%) were withdrawn owing to needle sensitivity or IOP elevation (8 mm Hg) in the contralateral eye. After an acupuncture session, mean IOP increased slightly with both eye-points (from 12.9 ± 1.8 mm Hg to 13.6 ± 2.0 mm Hg, P = .019) and non-eye-points (from 13.0 ± 1.5 mm Hg to 13.5 ± 1.7 mm Hg, P = .073) series. HR, diurnal IOP, and BCVA showed no statistically significant changes after 12 sessions of either series. Systolic and diastolic BP were reduced after 12 sessions of non-eye-points series (P = .040, P = .002, respectively). Optic disc, RNFL, and VF showed no statistically significant changes.Conclusions: Acupuncture has no overall effect on diurnal IOP or BCVA but may temporally increase the IOP immediately after a treatment session. BP is lowered by acupuncture with non-eye-points, but not with eye-points. Compliance and adverse event rates were low. AN - 109599230. Language: English. Entry Date: 20150923. Revision Date: 20190223. Publication Type: journal article AU - Law, Simon K. AU - Lowe, Starrie AU - Law, Samuel M. AU - Giaconi, JoAnn A. AU - Coleman, Anne L. AU - Caprioli, Joseph DB - ccm DO - 10.1016/j.ajo.2015.04.033 DP - EBSCOhost N1 - research; randomized controlled trial. Journal Subset: Biomedical; USA. NLM UID: 0370500. PMID: NLM25935101. PY - 2015 SN - 0002-9394 SP - 256-265 ST - Prospective Evaluation of Acupuncture as Treatment for Glaucoma T2 - American Journal of Ophthalmology TI - Prospective Evaluation of Acupuncture as Treatment for Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109599230&site=ehost-live&scope=site ID - 4314 ER - TY - JOUR AB - Purpose To evaluate acupuncture as treatment for glaucoma. Design Prospective double-masked randomized crossover study. Methods setting: Clinical practice. population: One eye per patient with primary open-angle glaucoma and stable intraocular pressure (IOP). intervention: Patients were randomized to receive 1 acupuncture series (12 sessions with either eye-related [eye-points] or non-eye-related [non-eye-points] acupoints) and then crossed over to receive the other series. outcome measures: IOP, blood pressure (BP), heart rate (HR), best-corrected visual acuity (BCVA), visual field (VF), optic disc and peripapillary retinal nerve fiber layer (RNFL) measurements, compliance, and adverse reactions. Probability to detect 3 mm Hg IOP difference between series was 90%. Results Twenty-two patients volunteered and 11 (50.0%) completed the study; 8 (36.4%) did not complete treatment owing to changes of health, moving away, lack of transportation, or family crisis; and 3(13.6%) were withdrawn owing to needle sensitivity or IOP elevation (8 mm Hg) in the contralateral eye. After an acupuncture session, mean IOP increased slightly with both eye-points (from 12.9 ± 1.8 mm Hg to 13.6 ± 2.0 mm Hg, P =.019) and non-eye-points (from 13.0 ± 1.5 mm Hg to 13.5 ± 1.7 mm Hg, P =.073) series. HR, diurnal IOP, and BCVA showed no statistically significant changes after 12 sessions of either series. Systolic and diastolic BP were reduced after 12 sessions of non-eye-points series (P =.040, P =.002, respectively). Optic disc, RNFL, and VF showed no statistically significant changes. Conclusions Acupuncture has no overall effect on diurnal IOP or BCVA but may temporally increase the IOP immediately after a treatment session. BP is lowered by acupuncture with non-eye-points, but not with eye-points. Compliance and adverse event rates were low. © 2015 Elsevier Inc. All rights reserved. AD - Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States AU - Law, S. K. AU - Lowe, S. AU - Law, S. M. AU - Giaconi, J. A. AU - Coleman, A. L. AU - Caprioli, J. DB - Scopus DO - 10.1016/j.ajo.2015.04.033 IS - 2 M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2015 SP - 256-265 ST - Prospective Evaluation of Acupuncture as Treatment for Glaucoma T2 - American Journal of Ophthalmology TI - Prospective Evaluation of Acupuncture as Treatment for Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937517627&doi=10.1016%2fj.ajo.2015.04.033&partnerID=40&md5=eaa2bfddb275e1d168682e3b8f995b3e VL - 160 ID - 5359 ER - TY - JOUR AB - Introduction: Cataracts and glaucoma are 2 of the most common ocular diseases and they frequently coexist as the prevalence of each increases with age.1,2 The treatment of a patient's glaucoma may also increase the severity of his/her cataract. For instance, patients with glaucoma randomized to receive betaxolol and argon laser trabeculoplasty in the Early Manifested Glaucoma Treatment Trial had a significantly higher rapid development of nuclear opacities.3 In the Collaborated Intervention Glaucoma Treatment Study, initial surgical treatment resulted in the development of more cataracts that required removal than initial medical treatment. The crude proportion of cataract extraction in the surgical group (17.3%) was almost 3 times greater than the proportion in the medicine group (6.2%).4 As a result of the interaction of these 2 diseases, different surgical treatment options are available and ophthalmologists often find it difficult to determine the best recommendation for a patient. © 2011, Lippincott Williams & Wilkins. AU - Law, S. K. AU - Riddle, J. DB - Scopus DO - 10.1097/IIO.0b013e31821e58aa IS - 3 M3 - Article N1 - Cited By :15 Export Date: 19 July 2021 PY - 2011 SP - 1-18 ST - Management of cataracts in patients with glaucoma T2 - International Ophthalmology Clinics TI - Management of cataracts in patients with glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958136947&doi=10.1097%2fIIO.0b013e31821e58aa&partnerID=40&md5=89c4ee22c158d6b91acd56cac22f4cfe VL - 51 ID - 5194 ER - TY - JOUR AB - Aim: To determine the glaucoma specialists’ preferences for the different brands of topical glaucoma medications available in Mexico. Materials and methods: A web-based survey was sent to 150 board-certified glaucoma specialists in Mexico, with 14 questions related to brand preferences for all glaucoma medications available in Mexico. Participants were asked to select each glaucoma medication class by brand and to state the factors leading to their choice. Results: Data from 111 (74%) glaucoma specialists were collected. Imot (timolol 0.5%; Sophia, Mexico) was the preferred brand for the beta-blockers (BB) class by 71% (n = 79) of the participants. Azopt (brinzolamide 1%; Alcon Lab, US) was the preferred carbonic anhydrase inhibitor (CAI) by 54% (n = 60) of the glaucoma specialists. Lumigan (bimatoprost 0.01% and 0.03%; Allergan Inc., U.S.) was the first choice for the prostaglandin analogues (PGAs) in 62% (n = 70) of the answers. The most frequently prescribed alpha-agonist (AA) was Agglad (brimonidine 0.2%; Sophia Lab, Mexico) in 44% (n = 49) of the answers. Medication accessibility (31%), cost (29%), and recommended dose (23%) were the three main factors influencing the glaucoma specialists’ preferences. Conclusion: Medication cost and accessibility, as well as posology, remain the main factors influencing brand preferences among glaucoma doctors. In our professional opinion, the therapeutic effect must be the leading factor when prescribing topical medications in the daily practice, so that patients receive the best treatment option. Clinical significance: This survey provides an understanding of the decision-making process when prescribing glaucoma medications by glaucoma specialists in a Latin American developing country. Ideally, patient treatment should be individualized and aimed to achieve the best results possible for their specific condition. AD - D. Alvarez-Ascencio, Alfredo de Musset 310-208, Polanco, Miguel Hidalgo, Mexico City, Mexico AU - Lazcano-Gomez, G. AU - Alvarez-Ascencio, D. AU - Haro-Zuno, C. AU - Turati-Acosta, M. AU - Garcia-Huerta, M. AU - Jimenez-Arroyo, J. AU - Castañeda-Diez, R. AU - Castillejos-Chevez, A. AU - Gonzalez-Salinas, R. AU - Dominguez-Dueñas, F. AU - Jimenez-Roman, J. C1 - agglad(Sophia,Mexico) azopt(Alcon,United States) combigan d(Allergan,United States) imot(Sophia,Mexico) krytantek(Sophia,Mexico) lumigan(Allergan,United States) C2 - Sophia(Mexico) Alcon(United States) Allergan(United States) DB - Embase DO - 10.5005/jp-journals-10028-1232 IS - 3 KW - agglad bimatoprost brimonidine brinzolamide combigan d imot krytantek timolol article cross-sectional study drug cost drug preference glaucoma health care access health care cost health insurance health survey human major clinical study medical specialist Mexico prescription questionnaire recommended drug dose azopt lumigan LA - English M3 - Article N1 - L621927152 2018-05-04 2018-05-08 PY - 2017 SN - 0975-1947 0974-0333 SP - 97-100 ST - Glaucoma medication preferences among glaucoma specialists in Mexico T2 - Journal of Current Glaucoma Practice TI - Glaucoma medication preferences among glaucoma specialists in Mexico UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621927152&from=export http://dx.doi.org/10.5005/jp-journals-10028-1232 VL - 11 ID - 2636 ER - TY - JOUR AB - The aim of the study was to disclose a realistic estimate of primary open-angle glaucoma treatment, follow-up costs, and patients' monthly glaucoma-economic burden in an ophthalmology hospital in Mexico City. Prospective survey of 462 primary open-angle glaucoma patients from 2007 to 2012 was carried out. Costs from visits, glaucoma follow-up studies, laser, and glaucoma surgical procedures were obtained from hospital pricings. Education, employment, and monthly income were interrogated. Total cost was divided into hypotensive treatment cost, nonpharmacologic treatment cost (laser and surgeries), and follow-up studies and consults. Average wholesale price for drugs analyzed was obtained from IMS Health data; monthly cost was calculated using: Monthly cost =([average wholesale price/number of drops per eye dropper]-number of daily applications)-30 days. Patients were classified according to their glaucoma severity, and data were analyzed based on monthly income (average annual exchange rate: 12.85 Mexican pesos=1 USD). The mean age was 70±10 years, women=81%, elementary school=39%, and unemployed=53%. Low-income group=266 patients (57%), 146 with mild glaucoma; moderate-income group=176 patients (38%), 81 with mild glaucoma; high-income group= 20 patients (4.3%), 10 with mild glaucoma. Patients' monthly average economic burden in glaucoma treatment: low-income patients=61.5%, moderate-income patients=19.5%, and high-income patients=7.9%. Glaucoma-economic burden is substantial not only for health systems, but for the family and the patient. Therefore, screening plans for earlier diagnosis, and health policies that lessen the cost of disease management and increase adherence to treatment, and reduce the prevalence of blindness attributed to glaucoma are essential. These would improve quality of life, reduce personal and national expenditure, and help increase national economy. Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. AD - Glaucoma Department, Asociación para Evitar la Ceguera en México, Mexico and NYU Langone Medical Center, Department of Ophthalmology, 462 First Avenue NBV 5N18, New York, NY 10016, United States Endocrinology Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico AU - Lazcano-Gomez, G. AU - De Los Angeles Ramos-Cadena, M. AU - Torres-Tamayo, M. AU - De Oteyza, A. H. AU - Turati-Acosta, M. AU - Jimenez-Román, J. C7 - e5341 DB - Scopus DO - 10.1097/MD.0000000000005341 IS - 47 KW - Cost of glaucoma treatment Economic impact of glaucoma treatment Glaucoma economic burden in Mexico M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2016 ST - Cost of glaucoma treatment in a developing country over a 5-year period T2 - Medicine (United States) TI - Cost of glaucoma treatment in a developing country over a 5-year period UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85005991832&doi=10.1097%2fMD.0000000000005341&partnerID=40&md5=6bf90af29679315d9535dfffcb4edf2b VL - 95 ID - 5198 ER - TY - JOUR AB - The aim of the study was to disclose a realistic estimate of primary open-angle glaucoma treatment, follow-up costs, and patients' monthly glaucoma-economic burden in an ophthalmology hospital in Mexico City. Prospective survey of 462 primary open-angle glaucoma patients from 2007 to 2012 was carried out. Costs from visits, glaucoma follow-up studies, laser, and glaucoma surgical procedures were obtained from hospital pricings. Education, employment, and monthly income were interrogated. Total cost was divided into hypotensive treatment cost, nonpharmacologic treatment cost (laser and surgeries), and follow-up studies and consults. Average wholesale price for drugs analyzed was obtained from IMS Health data; monthly cost was calculated using: Monthly cost =([average wholesale price/number of drops per eye dropper] x number of daily applications) x 30 days. Patients were classified according to their glaucoma severity, and data were analyzed based on monthly income (average annual exchange rate: 12.85 Mexican pesos = 1 USD). The mean age was 70 +/- 10 years, women = 81%, elementary school = 39%, and unemployed = 53%. Low-income group = 266 patients (57%), 146 with mild glaucoma; moderate-income group = 176 patients (38%), 81 with mild glaucoma; high-income group = 20 patients (4.3%), 10 with mild glaucoma. Patients' monthly average economic burden in glaucoma treatment: low-income patients = 61.5%, moderate-income patients = 19.5%, and high-income patients = 7.9%. Glaucoma-economic burden is substantial not only for health systems, but for the family and the patient. Therefore, screening plans for earlier diagnosis, and health policies that lessen the cost of disease management and increase adherence to treatment, and reduce the prevalence of blindness attributed to glaucoma are essential. These would improve quality of life, reduce personal and national expenditure, and help increase national economy. AN - WOS:000389591000019 AU - Lazcano-Gomez, G. AU - Ramos-Cadena, M. D. AU - Torres-Tamayo, M. AU - de Oteyza, A. H. AU - Turati-Acosta, M. AU - Jimenez-Roman, J. DA - NOV DO - 10.1097/MD.0000000000005341 IS - 47 PY - 2016 SN - 0025-7974 1536-5964 ST - Cost of glaucoma treatment in a developing country over a 5-year period T2 - MEDICINE TI - Cost of glaucoma treatment in a developing country over a 5-year period VL - 95 ID - 5927 ER - TY - JOUR AB - The aim of the study was to disclose a realistic estimate of primary open-angle glaucoma treatment, follow-up costs, and patients' monthly glaucoma-economic burden in an ophthalmology hospital in Mexico City.Prospective survey of 462 primary open-angle glaucoma patients from 2007 to 2012 was carried out. Costs from visits, glaucoma follow-up studies, laser, and glaucoma surgical procedures were obtained from hospital pricings. Education, employment, and monthly income were interrogated. Total cost was divided into hypotensive treatment cost, nonpharmacologic treatment cost (laser and surgeries), and follow-up studies and consults. Average wholesale price for drugs analyzed was obtained from IMS Health data; monthly cost was calculated using: Monthly cost  = ([average wholesale price/number of drops per eye dropper] × number of daily applications) × 30 days.Patients were classified according to their glaucoma severity, and data were analyzed based on monthly income (average annual exchange rate: 12.85 Mexican pesos = 1 USD).The mean age was 70 ± 10 years, women = 81%, elementary school = 39%, and unemployed = 53%. Low-income group = 266 patients (57%), 146 with mild glaucoma; moderate-income group = 176 patients (38%), 81 with mild glaucoma; high-income group = 20 patients (4.3%), 10 with mild glaucoma. Patients' monthly average economic burden in glaucoma treatment: low-income patients = 61.5%, moderate-income patients = 19.5%, and high-income patients = 7.9%.Glaucoma-economic burden is substantial not only for health systems, but for the family and the patient. Therefore, screening plans for earlier diagnosis, and health policies that lessen the cost of disease management and increase adherence to treatment, and reduce the prevalence of blindness attributed to glaucoma are essential. These would improve quality of life, reduce personal and national expenditure, and help increase national economy. AD - aGlaucoma Department, Asociación para Evitar la Ceguera en México bEndocrinology Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico AN - 119808338. Language: English. Entry Date: 20170210. Revision Date: 20210110. Publication Type: journal article AU - Lazcano-Gomez, Gabriel AU - Ramos-Cadena, María de Los Angeles AU - Torres-Tamayo, Margarita AU - Hernandez de Oteyza, Alejandra AU - Turati-Acosta, Mauricio AU - Jimenez-Román, Jesús DB - ccm DO - 10.1097/MD.0000000000005341 DP - EBSCOhost IS - 44 KW - Glaucoma -- Economics Health Care Costs Glaucoma -- Therapy Severity of Illness Indices Male Developing Countries Female Prospective Studies Aged Mexico Human N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 2985248R. PMID: NLM27893669. PY - 2016 SN - 0025-7974 SP - e5341-e5341 ST - Cost of glaucoma treatment in a developing country over a 5-year period T2 - Medicine TI - Cost of glaucoma treatment in a developing country over a 5-year period UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119808338&site=ehost-live&scope=site VL - 95 ID - 4516 ER - TY - JOUR AB - Introduction: Glaucoma is a prevalent ocular disease with characteristic optic disc and visual field changes. Globally, it is the second most common cause of visual disability, and the most common cause of irreversible and preventable blindness. Ocular hypertension (OH) occurs where intraocular pressure elevation occurs in the absence of glaucomatous disc and visual field changes. OH is a strong risk factor for glaucoma. Ocular hypotensive medications are the mainstay of glaucoma and OH treatment, and their use modifies the course of the disease by preventing onset and progression of damage. Areas covered: Prostaglandin analogs, β-blockers, α-agonists, carbonic anhydrase inhibitors and parasympathomimetics are available in our glaucoma armamentarium and are reviewed. Novel agents have evolved as our understanding of the complex mechanisms involved in aqueous humor production and obstacles to aqueous outflow increases. Potential future candidates appear to act on enhancing trabecular meshwork outflow: the Rho-kinase inhibitors, ion-channel modulators and chelating agents. Further work is needed on other promising agents: serotonergics, melatonins, cannabinoids, adenosine agonists, components of the actomyosin system, nucleotide analogs and gene silencing. Methods to improve side effect profiles or efficacy of currently available therapies are also being developed. As glaucoma treatment adherence is poor, novel drug delivery methods might address this challenge. Expert opinion: Although there are good intraocular pressure-lowering medications available, novel mechanisms and drug delivery modes may provide more effective glaucoma control in future. © 2011 Informa UK, Ltd. AD - I. Goldberg, Eye Associates, 187 Macquarie Street, Sydney, NSW 2000, Australia AU - Lee, A. J. AU - Goldberg, I. C1 - agn 210699(Allergan) al 37807(Alcon) alphagan p alphagan ar 102(Aerie) ar 12286(Aerie) azarga(Alcon) azopt beta ophtiole betagan betoptic s betoptic carteol combigan(Allergan) cosopt(Merck Sharp and Dohme) de 104(Santen) de 104(Ube) dnb 001(Danube) doutrav(Alcon) ganfort(Allergan) h 1152 ino 8875(Inotek) iopidine isopto carbachol isopto carpine k 115(Kowa) lumigan(Allergan,United States) ncx 116(Nicox) nyogel ocupress optipranolol ot 705 ot 730(Othera) pf 4217329(Pfizer) phospholine iodide pilopine hs purite(Allergan,United States) rescula(Ciba Vision,Switzerland) saflutan st 802(Sirion) timolol la timoptic xe timoptic timoptol timpilo(Merck Sharp and Dohme) travatan z travatan(Alcon,United States) trusopt xalacom(Pfizer) xalatan(Pfizer,United States) y 27632 y 39983(Novartis) y 39983(Senju) C2 - Aerie Alcon(United States) Allergan(United States) Chakshu Ciba Vision(Switzerland) Danube Inotek Kowa Merck Sharp and Dohme Nicox Novartis Othera Pfizer(United States) QLT Santen Senju Sirion Ube DB - Embase Medline DO - 10.1517/14728214.2011.521631 IS - 1 KW - NCT00465621 NCT00523250 NCT00533962 NCT00572455 NCT00705770 NCT00753168 NCT00809848 NCT00820300 NCT00821002 NCT00824720 NCT00848536 NCT00868894 NCT00884039 NCT00892762 NCT00934089 NCT00947661 NCT00967811 NCT01037036 4 (1 aminoethyl) n (4 pyridyl)cyclohexanecarboxamide adenosine receptor stimulating agent agn 210699 al 37807 alpha 2 adrenergic receptor stimulating agent alpha adrenergic receptor stimulating agent antiglaucoma agent apraclonidine ar 102 verosudil benzalkonium chloride beta adrenergic receptor blocking agent beta adrenergic receptor stimulating agent betaxolol bimatoprost bimatoprost plus timolol brimonidine brimonidine plus timolol brinzolamide brinzolamide plus timolol cannabinoid carbachol carbonate dehydratase inhibitor carteolol chelating agent cholinergic receptor stimulating agent de 104 dnb 001 dorzolamide dorzolamide plus timolol doutrav ecothiopate iodide h 1152 ino 8875 k 115 latanoprost latanoprost plus timolol levobunolol melatonin metipranolol latanoprostene bunod nucleotide derivative ot 705 ot 730 taprenepag isopropyl ester pilocarpine prostaglandin derivative prostaglandin F2 alpha derivative purite Rho kinase inhibitor tafluprost serotonin agonist st 802 timolol timolol la timolol maleate travoprost unclassified drug unindexed drug unoprostone isopropyl ester y 39983 aqueous humor aqueous humor outflow backache bitter taste blepharoconjunctivitis blurred vision bradycardia bronchus hyperreactivity clinical trial (topic) conjunctival hyperemia disease control disease course drug absorption drug cost drug delivery system drug efficacy drug eruption drug hypersensitivity drug induced headache drug potency drug safety drug tolerability dyspnea eye allergy eye irritation eye tearing fatigue follicular conjunctivitis gene silencing glaucoma glaucoma drainage implant glaucoma filtration surgery glaucoma surgery granulomatous anterior uveitis granulomatous uveitis health care cost health care utilization herpes simplex herpes simplex keratitis human hyperpigmentation intraocular hypertension intraocular pressure iridocyclitis iris cyst iris darkening laser trabeculoplasty lung edema medicare monotherapy myalgia nonhuman open angle glaucoma paresthesia patient compliance retina macula cystoid edema review risk reduction side effect stinging thorax pain trabecular meshwork trabeculoplasty treatment indication treatment outcome treatment response upper respiratory tract infection urolithiasis vision alphagan p alphagan ar 12286 azarga azopt beta ophtiole betagan betoptic s betoptic carteol combigan cosopt ganfort iopidine isopto carbachol isopto carpine lumigan ncx 116 nyogel ocupress optipranolol pf 4217329 phospholine iodide pilopine hs rescula saflutan timoptic xe timoptic timoptol timpilo travatan z travatan trusopt xalacom xalatan y 27632 LA - English M3 - Review N1 - L361347403 2011-03-09 2011-03-21 PY - 2011 SN - 1472-8214 SP - 137-161 ST - Emerging drugs for ocular hypertension T2 - Expert Opinion on Emerging Drugs TI - Emerging drugs for ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361347403&from=export http://dx.doi.org/10.1517/14728214.2011.521631 VL - 16 ID - 3188 ER - TY - GEN AB - Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents availablefor the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004%are prodrugs and analogs of prostaglandin F2〈. Bimatoprost 0.03% is regarded as a prostamide,and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP byenhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation andremodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-loweringsuperiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOPloweringcompared with latanoprost, with weighted mean difference in IOP reduction documentedin one meta-analysis of 2.59% to 5.60% from 1- to 6-months study duration. PGAs reduce IOPfurther when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprostformulated with timolol 0.5% and administered once daily are superior to monotherapyof its constituent parts. PGA have near absence of systemic side effects, although do have othercommonly encountered ocular adverse effects. The adverse effects of PGA, and also those foundmore frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocularpigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administrationand near absence of systemic side effects enhances tolerance and compliance. PGAs are oftenprescribed as first-line treatment for ocular hypertension and open-angle glaucoma. © 2010 Lee and McCluskey, publisher and licensee Dove Medical Press Ltd. AD - P. McCluskey, Sydney Eye Hospital, 8 MacQuarie Street, Sydney NSW 2000, Australia AU - Lee, A. J. AU - McCluskey, P. C1 - duotrav(Alcon,United States) ganfort(Allergan,United States) lumigan(Allergan,United States) travatan(Alcon,United States) travatanz(Alcon,United States) xalacom(Pfizer,United States) xalatan(Pfizer,United States) C2 - Alcon(United States) Allergan(United States) Pfizer(United States) DB - Embase J2 - Clin. Ophthalmol. KW - alpha tocopherol betaxolol bimatoprost bimatoprost plus timolol brimonidine brinzolamide dorzolamide dorzolamide plus timolol latanoprost latanoprost plus timolol pilocarpine prostaglandin F2 alpha tafluprost timolol timolol plus travoprost travatanz travoprost unclassified drug unoprostone isopropyl ester angina pectoris apnea aqueous humor flow area under the curve arthralgia article asthma backache bronchospasm cataract clinical trial congestive heart failure conjunctival hyperemia conjunctivitis cornea erosion cyst dermatitis dosage schedule comparison drug efficacy drug elimination drug eruption drug excretion drug induced headache drug metabolism drug storage drug tolerability drug withdrawal dyspnea evening dosage extracellular matrix eye blood flow eye discomfort eye disease eye inflammation eye irritation face edema forced expiratory volume heart arrhythmia herpes simplex keratitis human hypertension hypertrichosis intraocular hypertension iridocyclitis iris cyst iris disease iris hyperpigmentation iritis maximum plasma concentration migraine morning dosage myalgia nonhuman ocular pruritus ocular stinging open angle glaucoma patient compliance patient satisfaction periocular skin discoloration peripheral edema pharmacodynamics plasma half life quality of life recommended drug dose respiratory tract disease retina macula cystoid edema macular degeneration macular edema rhinopharyngitis side effect skin allergy skin discoloration tachycardia thorax pain unspecified side effect upper respiratory tract infection uveitis visual field defect duotrav ganfort lumigan travatan xalacom xalatan L1 - internal-pdf://0352406219/3234-Clinical utility and differential ef-2010.pdf LA - English M1 - (Lee A.J.) Manchester Royal Eye Hospital, Manchester, United Kingdom M3 - Article N1 - L359443937 2010-09-07 2010-09-13 PY - 2010 SN - 1177-5467 1177-5483 SP - 741-764 ST - Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension TI - Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359443937&from=export VL - 4 ID - 3234 ER - TY - JOUR AN - WOS:000362891101331 AU - Lee, B. AU - Fudemberg, S. AU - Murphy, R. AU - Hark, L. A. AU - Waisbourd, M. AU - Dai, Y. AU - Leiby, B. DA - JUN IS - 7 PY - 2015 SN - 0146-0404 1552-5783 ST - Adherence to Follow-Up Appointments in a Resident Glaucoma Clinic vs. Primary Eye Care Clinic: A Retrospective Analysis T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - Adherence to Follow-Up Appointments in a Resident Glaucoma Clinic vs. Primary Eye Care Clinic: A Retrospective Analysis VL - 56 ID - 5847 ER - TY - JOUR AB - Purpose. To identify the barriers to glaucoma follow-up and to assess how ethnicity influences the effect of such barriers among patients in a county hospital population. Methods. This cross-sectional study included 152 patients, 76 with poor clinic follow-up and 76 with good clinic follow-up, who were recruited at the San Francisco General Hospital glaucoma clinic as part of a case-control study. All subjects were required to be established patients with glaucoma initially seen and diagnosed in the clinic at least 1 year before enrollment. An oral questionnaire pertaining to the barriers to follow-up for glaucoma, as well as patient ethnicity, was administered to all participating subjects. The main outcome measure was the prevalence of significant barriers to follow-up, both overall and stratified by ethnicity. Results. The most prevalent barriers to follow-up included long clinic waiting times (75%), appointment scheduling difficulties (38%), the effect of other medical or physical comorbidities (29%), and difficulties related to medical interpretation (23%). While several barriers were cited as being important across different ethnicities, Latinos and Asian-Pacific Islanders were particularly affected by difficulties related to medical interpretation (P = 0.0001) and long waiting times in the clinic (P = 0.048). Conclusions. Understanding patient-reported barriers to glaucoma follow-up and their variation based on ethnicity may give providers insight as to why patients do not adhere to follow-up recommendations. Strategies to improve follow-up may include reduced clinic wait times, simplified appointment scheduling, and provision of appropriate education and counseling regardless of the patient's native language and ethnicity. © 2013 The Association for Research in Vision and Ophthalmology, Inc. AD - S. Lin, University of California, 10 Koret Way, San Francisco, CA 94143-0730, United States AU - Lee, B. W. AU - Murakami, Y. AU - Duncan, M. T. AU - Kao, A. A. AU - Huang, J. Y. AU - Lin, S. AU - Singh, K. DB - Embase Medline DO - 10.1167/iovs.13-12108 IS - 10 KW - adult aged article comorbidity controlled study cross-sectional study disease control disease severity ethnicity female follow up glaucoma health care access health care cost human major clinical study male patient attitude pilot study prevalence priority journal questionnaire treatment outcome LA - English M3 - Article N1 - L369964841 2013-10-15 2013-10-18 PY - 2013 SN - 0146-0404 1552-5783 SP - 6542-6548 ST - Patient-related and system-related barriers to glaucoma follow-up in a county hospital population T2 - Investigative Ophthalmology and Visual Science TI - Patient-related and system-related barriers to glaucoma follow-up in a county hospital population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369964841&from=export http://dx.doi.org/10.1167/iovs.13-12108 http://www.iovs.org/content/54/10/6542.full.pdf VL - 54 ID - 2960 ER - TY - JOUR AB - Purpose. To identify the barriers to glaucoma follow-up and to assess how ethnicity influences the effect of such barriers among patients in a county hospital population. Methods. This cross-sectional study included 152 patients, 76 with poor clinic follow-up and 76 with good clinic follow-up, who were recruited at the San Francisco General Hospital glaucoma clinic as part of a case-control study. All subjects were required to be established patients with glaucoma initially seen and diagnosed in the clinic at least 1 year before enrollment. An oral questionnaire pertaining to the barriers to follow-up for glaucoma, as well as patient ethnicity, was administered to all participating subjects. The main outcome measure was the prevalence of significant barriers to follow-up, both overall and stratified by ethnicity. Results. The most prevalent barriers to follow-up included long clinic waiting times (75%), appointment scheduling difficulties (38%), the effect of other medical or physical comorbidities (29%), and difficulties related to medical interpretation (23%). While several barriers were cited as being important across different ethnicities, Latinos and Asian-Pacific Islanders were particularly affected by difficulties related to medical interpretation (P = 0.0001) and long waiting times in the clinic (P = 0.048). Conclusions. Understanding patient-reported barriers to glaucoma follow-up and their variation based on ethnicity may give providers insight as to why patients do not adhere to follow-up recommendations. Strategies to improve follow-up may include reduced clinic wait times, simplified appointment scheduling, and provision of appropriate education and counseling regardless of the patient's native language and ethnicity. © 2013 The Association for Research in Vision and Ophthalmology, Inc. AD - Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, United States Department of Ophthalmology, University of California, San Francisco, CA, United States AU - Lee, B. W. AU - Murakami, Y. AU - Duncan, M. T. AU - Kao, A. A. AU - Huang, J. Y. AU - Lin, S. AU - Singh, K. DB - Scopus DO - 10.1167/iovs.13-12108 IS - 10 KW - Barriers to follow-up Clinical follow-up Compliance Ethnicity M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2013 SP - 6542-6548 ST - Patient-related and system-related barriers to glaucoma follow-up in a county hospital population T2 - Investigative Ophthalmology and Visual Science TI - Patient-related and system-related barriers to glaucoma follow-up in a county hospital population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885061934&doi=10.1167%2fiovs.13-12108&partnerID=40&md5=65627d48b4f0ba5986867932523fd771 VL - 54 ID - 5218 ER - TY - JOUR AB - PURPOSE. To identify the barriers to glaucoma follow-up and to assess how ethnicity influences the effect of such barriers among patients in a county hospital population. METHODS. This cross-sectional study included 152 patients, 76 with poor clinic follow-up and 76 with good clinic follow-up, who were recruited at the San Francisco General Hospital glaucoma clinic as part of a case-control study. All subjects were required to be established patients with glaucoma initially seen and diagnosed in the clinic at least 1 year before enrollment. An oral questionnaire pertaining to the barriers to follow-up for glaucoma, as well as patient ethnicity, was administered to all participating subjects. The main outcome measure was the prevalence of significant barriers to follow-up, both overall and stratified by ethnicity. RESULTS. The most prevalent barriers to follow-up included long clinic waiting times (75%), appointment scheduling difficulties (38%), the effect of other medical or physical comorbidities (29%), and difficulties related to medical interpretation (23%). While several barriers were cited as being important across different ethnicities, Latinos and Asian-Pacific Islanders were particularly affected by difficulties related to medical interpretation (P = 0.0001) and long waiting times in the clinic (P = 0.048). CONCLUSIONS. Understanding patient-reported barriers to glaucoma follow-up and their variation based on ethnicity may give providers insight as to why patients do not adhere to follow-up recommendations. Strategies to improve follow-up may include reduced clinic wait times, simplified appointment scheduling, and provision of appropriate education and counseling regardless of the patient's native language and ethnicity. AN - WOS:000326567700011 AU - Lee, B. W. AU - Murakami, Y. AU - Duncan, M. T. AU - Kao, A. A. AU - Huang, J. Y. AU - Lin, S. AU - Singh, K. DA - OCT DO - 10.1167/iovs.13-12108 IS - 10 PY - 2013 SN - 0146-0404 1552-5783 SP - 6542-6548 ST - Patient-Related and System-Related Barriers to Glaucoma Follow-up in a County Hospital Population T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - Patient-Related and System-Related Barriers to Glaucoma Follow-up in a County Hospital Population VL - 54 ID - 5819 ER - TY - JOUR AB - Objectives: To determine predictors of and reasons for poor longitudinal glaucoma follow-up in South India. Methods: This 1-to-1, matched, case-control study enrolled 300 patients with established glaucoma. We defined cases (poor follow-up) and controls (good follow-up) based on number of and maximum interval between glaucoma follow-up Visits attended in the preceding year. We collected data by oral questionnaire and used step-wise multivariate logistic regression to calculate odds ratios (ORs) for poor follow-up. Results: Adjusting for age and sex, independent predictors of poor follow-up included lack of formal education (adjusted OR, 4.13; 95% confidence interval [CI], 1.44-11.90), no use of prescribed glaucoma medications (adjusted OR, 2.17; 95% CI, 1.06-4.43), and belief that follow-up is less important if one uses glaucoma medications and has no noticeable visual changes (adjusted OR, 10-59; 95% CI, 3.74-29.97). Age, sex, and disease severity were not significant predictors. The most prevalent barriers to follow-up were belief that there was no problem with one's eyes (44.4%) and lack of escort (19.7%). Conclusions: Knowing predictors of poor follow-up can help identify patients who need individualized strategies to improve follow-up. Because believing one's eyes are problem-free and lacking escorts are significant barriers to follow-up, novel strategies in patient education (eg, intensive counseling, audiovisual aides, and patient support groups) and escort provision may improve longitudinal glaucoma follow-tip and disease management. AN - WOS:000259900700017 AU - Lee, B. W. AU - Sathyam, P. AU - John, R. K. AU - Singh, K. AU - Robin, A. L. DA - OCT DO - 10.1001/archopht.126.10.1448 IS - 10 PY - 2008 SN - 0003-9950 SP - 1448-1454 ST - Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India T2 - ARCHIVES OF OPHTHALMOLOGY TI - Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India VL - 126 ID - 5866 ER - TY - JOUR AB - Objectives: To determine predictors of and reasons for poor longitudinal glaucoma follow-up in South India. Methods: This 1-to-1, matched, case-control study enrolled 300 patients with established glaucoma. We defined cases (poor follow-up) and controls (good follow-up) based on number of and maximum interval between glaucoma follow-up visits attended in the preceding year. We collected data by oral questionnaire and used step-wise multivariate logistic regression to calculate odds ratios (ORs) for poor follow-up. Results: Adjusting for age and sex, independent predictors of poor follow-up included lack of formal education (adjusted OR, 4.13; 95% confidence interval [CI], 1.44-11.90), no use of prescribed glaucoma medications (adjusted OR, 2.17; 95% CI, 1.06-4.43), and belief that follow-up is less important if one uses glaucoma medications and has no noticeable visual changes (adjusted OR, 10.59; 95% CI, 3.74-29.97). Age, sex, and disease severity were not significant predictors. The most prevalent barriers to follow-up were belief that there was no problem with one's eyes (44.4%) and lack of escort (19.7%). Conclusions: Knowing predictors of poor follow-up can help identify patients who need individualized strategies to improve follow-up. Because believing one's eyes are problem-free and lacking escorts are significant barriers to follow-up, novel strategies in patient education (eg, intensive counseling, audiovisual aides, and patient support groups) and escort provision may improve longitudinal glaucoma follow-up and disease management. ©2008 American Medical Association. All rights reserved. AD - B. W. Lee, Department of Ophthalmology, Stanford University, 804 Los Robles Ave, Palo Alto, CA 94306, United States AU - Lee, B. W. AU - Sathyan, P. AU - John, R. K. AU - Singh, K. AU - Robin, A. L. DB - Embase Medline DO - 10.1001/archopht.126.10.1448 IS - 10 KW - adult aged article controlled study educational status female follow up general aspects of disease glaucoma human major clinical study male priority journal questionnaire vision LA - English M3 - Article N1 - L352516636 2008-11-14 PY - 2008 SN - 0003-9950 SP - 1448-1454 ST - Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India T2 - Archives of Ophthalmology TI - Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352516636&from=export http://dx.doi.org/10.1001/archopht.126.10.1448 http://archopht.ama-assn.org/cgi/reprint/126/10/1448 VL - 126 ID - 3423 ER - TY - JOUR AB - Objectives: To determine predictors of and reasons for poor longitudinal glaucoma follow-up in South India. Methods: This 1-to-1, matched, case-control study enrolled 300 patients with established glaucoma. We defined cases (poor follow-up) and controls (good follow-up) based on number of and maximum interval between glaucoma follow-up visits attended in the preceding year. We collected data by oral questionnaire and used step-wise multivariate logistic regression to calculate odds ratios (ORs) for poor follow-up. Results: Adjusting for age and sex, independent predictors of poor follow-up included lack of formal education (adjusted OR, 4.13; 95% confidence interval [CI], 1.44-11.90), no use of prescribed glaucoma medications (adjusted OR, 2.17; 95% CI, 1.06-4.43), and belief that follow-up is less important if one uses glaucoma medications and has no noticeable visual changes (adjusted OR, 10.59; 95% CI, 3.74-29.97). Age, sex, and disease severity were not significant predictors. The most prevalent barriers to follow-up were belief that there was no problem with one's eyes (44.4%) and lack of escort (19.7%). Conclusions: Knowing predictors of poor follow-up can help identify patients who need individualized strategies to improve follow-up. Because believing one's eyes are problem-free and lacking escorts are significant barriers to follow-up, novel strategies in patient education (eg, intensive counseling, audiovisual aides, and patient support groups) and escort provision may improve longitudinal glaucoma follow-up and disease management. ©2008 American Medical Association. All rights reserved. AD - Stanford University, Stanford, CA, United States Aravind Eye Care System, Coimbatore, India Delve Data Systems, Coimbatore, India Johns Hopkins University, Baltimore, MD, United States Department of Ophthalmology, Stanford University, 804 Los Robles Ave, Palo Alto, CA 94306, United States AU - Lee, B. W. AU - Sathyan, P. AU - John, R. K. AU - Singh, K. AU - Robin, A. L. DB - Scopus DO - 10.1001/archopht.126.10.1448 IS - 10 M3 - Article N1 - Cited By :43 Export Date: 19 July 2021 PY - 2008 SP - 1448-1454 ST - Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India T2 - Archives of Ophthalmology TI - Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-54049155123&doi=10.1001%2farchopht.126.10.1448&partnerID=40&md5=2ce21fde3df11119c82a5c59351d5eeb VL - 126 ID - 5014 ER - TY - JOUR AB - PURPOSE: To present emerging perspectives on open-angle glaucoma related to patient compliance, current drug therapy, and treatment options. METHODS: Roundtable discussion. RESULTS: The panel discussion identified the following issues about patient compliance: 1. It is a common problem in clinical practice and is often underappreciated by physicians. 2. It is difficult for clinicians to detect. 3. There are several risk factors that increase the probability of noncompliance. 4. Compliance can be improved through education, communication, improvement of the doctor-patient relationship, compliance aids, and simplifying the treatment regimen. CONCLUSION: Patients' compliance with the therapeutic regimen for open-angle glaucoma is very important to the eventual outcome of their disease treatment. Physicians can improve their patients' compliance by a few simple, cost-effective interventions in the clinical setting. When considering different agents as first-line therapies, once-a-day dosing would be optimal for enhancing compliance. (C) 2000 by Elsevier Science Inc. AD - D.A. Lee, Department of Ophthalmology, Penn State College of Medicine, Milton S. Hershey Medical Center, P.O. Box 850, Hershey, PA 17033-0850, United States AU - Lee, D. A. AU - Fechtner, R. D. AU - Fiscella, R. G. AU - Singh, K. AU - Stewart, W. C. C1 - alphagan(Allergan,United States) azopt(Alcon,United States) betagan(Allergan,United States) betopic s(Alcon,United States) carbastat(Ciba Geigy,United States) cartrol(Abbott,United States) cosopt(Merck and Co,United States) diamox(Wyeth Ayerst,United States) epifrin(Allergan,United States) humorsol(Merck and Co,United States) lopidine(Alcon,United States) mam(Ciba Geigy,United States) optipranolol(Bausch and Lomb,United States) pilocar(Ciba Geigy,United States) propine(Allergan,United States) timoptic(Merck and Co,United States) trusopt(Merck and Co,United States) xalatan(Pharmacia Corporation,United States) xalcom(Pharmacia Corporation,United States) C2 - Abbott(United States) Alcon(United States) Allergan(United States) Bausch and Lomb(United States) Ciba Geigy(United States) Merck and Co(United States) Pharmacia Corporation(United States) Wyeth Ayerst(United States) DB - Embase Medline DO - 10.1016/s0002-9394(00)00635-8 IS - 4 SUPPL. 1 KW - acetazolamide epinephrine adrenergic receptor stimulating agent apraclonidine beta adrenergic receptor blocking agent betaxolol betopic s brimonidine brinzolamide carbachol carteolol demecarium dipivefrine dorzolamide dorzolamide plus timolol ecothiopate iodide latanoprost latanoprost plus timolol levobunolol lopidine mam methazolamide metipranolol miotic agent pilocarpine prostaglandin timolol timolol maleate unclassified drug cost effectiveness analysis doctor patient relationship glaucoma intraocular pressure open angle glaucoma patient compliance patient education priority journal review risk factor treatment outcome alphagan azopt betagan carbastat cartrol cosopt diamox epifrin humorsol optipranolol pilocar propine timoptic trusopt xalatan xalcom LA - English M3 - Review N1 - L30750641 2000-11-07 PY - 2000 SN - 0002-9394 SP - S1-S11 ST - Emerging perspectives on glaucoma: Highlights of a roundtable discussion T2 - American Journal of Ophthalmology TI - Emerging perspectives on glaucoma: Highlights of a roundtable discussion UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30750641&from=export http://dx.doi.org/10.1016/s0002-9394(00)00635-8 VL - 130 ID - 3914 ER - TY - JOUR AB - Objective: Our prior study revealed significantly lower use of eye care providers in Newfoundland and Labrador (NFLD). This study reports factors associated with this low use and related vision health outcomes. Design: Cross-sectional survey. Participants: A total of 14 925 Caucasian respondents to the Canadian Community Health Survey − Healthy Aging 2008/2009 aged ≥65 years. Methods: Univariate and multivariate analyses were performed using self-reported survey data. Results: NFLD, along with 3 other provinces, does not insure seniors for routine eye examinations. Among seniors without self-reported glaucoma, cataracts, and diabetes, the use of eye care providers in NFLD (36.3%) is the lowest compared with provinces with (50.7%, p < 0.05) and without (42.2%, p > 0.05) government-insured eye examinations. Among seniors with known eye disease insured for eye care in all provinces, eye care utilisation in NFLD (63.1%) is still the lowest across all provinces (69.4%−71.3%, p > 0.05). Compared with the national average, NFLD seniors have significantly higher proportions of low income (61.7% vs 47.4%), no postsecondary education (53.6% vs 42.2%), and rural residency (40.6% vs 18.9%). These factors are all associated with low levels of eye care utilisation. Compared with insured provinces, NFLD has a significantly lower prevalence of self-reported cataracts (16.7% vs 23.1) and glaucoma (3.8% vs 7.0%), and a slightly higher prevalence of presenting visual impairment (4.0% vs 3.5%). Conclusions: Lack of government insurance, low socioeconomic status, and living in nonurbanised areas all contribute to the underutilisation of eye care providers in NFLD. This underutilisation appears to be associated with reduced detection of eye diseases. AD - Y.-P. Jin, Department of Ophthalmology and Vision Sciences, University of Toronto, 340 College Street, Suite 400, Toronto, Ont., Canada AU - Lee, E. Y. AU - Cui, K. AU - Trope, G. E. AU - Buys, Y. M. AU - Chan, C. H. AU - Thavorn, K. AU - Jin, Y. P. DB - Embase Medline DO - 10.1016/j.jcjo.2017.11.012 IS - 4 KW - adult aged article cataract Caucasian cross-sectional study diabetes mellitus eye care eye examination glaucoma health care access health care utilization health insurance health literacy healthy aging human lowest income group Newfoundland and Labrador outcome assessment rural area social status LA - English M3 - Article N1 - L620569691 2018-02-13 2018-08-21 PY - 2018 SN - 1715-3360 0008-4182 SP - 342-348 ST - Eye care utilisation in Newfoundland and Labrador: access barriers and vision health outcomes T2 - Canadian Journal of Ophthalmology TI - Eye care utilisation in Newfoundland and Labrador: access barriers and vision health outcomes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620569691&from=export http://dx.doi.org/10.1016/j.jcjo.2017.11.012 VL - 53 ID - 2569 ER - TY - JOUR AB - Glaucoma is a leading cause of vision loss and blindness worldwide, especially among the elderly. While there are many forms of glaucoma, there are 2 major groups: 'open-angle' (OAG) and 'angle closure'. The latter is now successfully treated by laser iridotomy. The former, OAG, is a chronic condition that accounts for the majority of glaucomas in developed countries. For both major groups of glaucoma, different management guidelines exist. Both the American Academy of Ophthalmology (AAO) and the American Optometric Association (AOA) have guidelines which cover both groups of glaucoma. Comparison of these guidelines reveals striking similarity, suggesting relative uniformity of professional opinion regarding 'best practice' care of patients with glaucoma. However, there are a few important differences between the 2 guidelines promulgated by the 2 organisations. For OAG, the most important and striking difference is in the criteria for case identification and case severity classification. The AAO uses, essentially, an optic nerve head criteria for case identification and then classifies severity according to visual field criteria only. In contrast, the AOA uses both optic nerve and visual field criterion to both make a diagnosis and to classify the severity of disease. Related to this, early glaucoma in the AAO classification is explicitly glaucoma without any visual field loss, whereas the AOA classification of early glaucoma is already equivalent to at least moderate glaucoma in the AAO scheme. Additional differences between both guidelines centre mostly on more intensive use of services and testing in the optometric guidelines. Little data have been published to date on whether or not care provided to patients conforms to these guidelines. What has been described indicates relatively good compliance with most elements of care, but with major deficiencies in some important aspects of care i.e. the content of care and the follow-up nature of care. As such, significantly more work needs to be undertaken to better provide care to patients with glaucoma. AD - Duke University Medical Center, Department of Ophthalmology, Glaucoma Service, Durham, NC 27710, United States AU - Lee, P. DB - Scopus DO - 10.2165/00115677-199905040-00001 IS - 4 M3 - Review N1 - Cited By :6 Export Date: 19 July 2021 PY - 1999 SP - 187-195 ST - Use of guidelines in the management of patients with glaucoma T2 - Disease Management and Health Outcomes TI - Use of guidelines in the management of patients with glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032933502&doi=10.2165%2f00115677-199905040-00001&partnerID=40&md5=504b99cc4042c274dd30cb56f929d4c9 VL - 5 ID - 5397 ER - TY - JOUR AD - P.P. Lee, Duke University Eye Center, Durham, NC 27710, United States AU - Lee, P. P. DB - Embase Medline DO - 10.1016/j.ajo.2005.08.061 IS - 1 SUPPL. KW - antiglaucoma agent prostaglandin chronic disease doctor patient relationship drug cost editorial expectation glaucoma human interpersonal communication intraocular pressure long term care open angle glaucoma patient care patient compliance patient education patient satisfaction prescription priority journal quality of life role playing vision visual impairment LA - English M3 - Editorial N1 - L43028473 2006-01-30 PY - 2006 SN - 0002-9394 SP - S1-S2 ST - Patient perspectives in glaucoma care: Introduction to the American Journal of Ophthalmology supplement T2 - American Journal of Ophthalmology TI - Patient perspectives in glaucoma care: Introduction to the American Journal of Ophthalmology supplement UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43028473&from=export http://dx.doi.org/10.1016/j.ajo.2005.08.061 VL - 141 ID - 3635 ER - TY - JOUR AB - Objective: To assess the rate of annual eye examinations over time among older Americans with diabetes and chronic eye diseases. Design: Longitudinal analysis of Medicare claims data. Participants: Random sample of Medicare beneficiaries aged 65 years or older. Methods: Beneficiaries were followed between 1991 and 1999, unless mortality or enrollment in a health maintenance organization for > 6 months in a given 12-month period intervened. All claims data (both physician and facility) during this time were analyzed for the presence of International Classification of Diseases 9 codes consistent with 1 of the 3 study conditions and the performance of eye examinations. Main Outcome Measures: Claims submitted by optometrists, ophthalmologists, or other providers of eye care for subjects with diabetes, glaucoma, or age-related macular degeneration (ARMD). Rates were calculated on the basis of a 15-month time window for annual examinations rather than for 12 months to allow for less than full compliance with the guidelines for various reasons (e.g., bad weather). Results: Among those with diabetes in this population, 50% to 60% had annual eye examinations in a 15-month period. Of those followed for at least 75 months after diagnosis, about three quarters had one or more 15-month gaps between visits. For subjects diagnosed with glaucoma, most visit rates were in the 70% to 90% range per 15-month period. The percentage of subjects with at least one 15-month period with no visits was considerably lower than for diabetes. The patterns for those with ARMD were in between those for diabetes and glaucoma. Over a nine-year period, only slightly over half of persons with at least one of the study conditions complied with practice guidelines. Conclusions: Annual eye examinations for persons diagnosed with diabetes, glaucoma, and ARMD are important for detecting potentially treatable vision loss among those already diagnosed with these conditions. Currently, actual rates of eye examinations for persons diagnosed with the study conditions fall far short of recommended rates. As such, approaches to enhancing longitudinal follow-up of those already in the eye care system are needed. © 2003 by the American Academy of Ophthalmology. AD - Department of Ophthalmology, Duke University School of Medicine, Durham, NC, United States Department of Economics, Duke University, Durham, NC, United States Ctr. for Hlth. Policy, Law and Mgmt., Duke University, Durham, NC, United States Ctr. for Hlth. Policy, Law and Mgmt., Box 90253, Duke University, Durham, NC 27708, United States AU - Lee, P. P. AU - Feldman, Z. W. AU - Ostermann, J. AU - Brown, D. S. AU - Sloan, F. A. DB - Scopus DO - 10.1016/S0161-6420(03)00817-0 IS - 10 M3 - Article N1 - Cited By :123 Export Date: 19 July 2021 PY - 2003 SP - 1952-1959 ST - Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases T2 - Ophthalmology TI - Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141524139&doi=10.1016%2fS0161-6420%2803%2900817-0&partnerID=40&md5=ff77bac661b4b8b64dbbefaa25edc639 VL - 110 ID - 4919 ER - TY - JOUR AB - Objective: To assess the rate of annual eye examinations over time among older Americans with diabetes and chronic eye diseases. Design: Longitudinal analysis of Medicare claims data. Participants: Random sample of Medicare beneficiaries aged 65 years or older. Methods: Beneficiaries were followed between 1991 and 1999, unless mortality or enrollment in a health maintenance organization for > 6 months in a given 12-month period intervened. All claims data (both physician and facility) during this time were analyzed for the presence of International Classification of Diseases 9 codes consistent with 1 of the 3 study conditions and the performance of eye examinations. Main Outcome Measures. Claims submitted by optometrists, ophthalmologists, or other providers of eye care for subjects with diabetes, glaucoma, or age-related macular degeneration (ARMD). Rates were calculated on the basis of a 15-month time window for annual examinations rather than for 12 months to allow for less than full compliance with the guidelines for various reasons (e.g., bad weather). Results: Among those with diabetes in this population, 50% to 60% had annual eye examinations in a 15-month period. Of those followed for at least 75 months after diagnosis, about three quarters had one or more 15-month gaps between visits. For subjects diagnosed with glaucoma, most visit rates were in the 70% to 90% range per 15-month period. The percentage of subjects with at least one 15-month period with no visits was considerably lower than for diabetes. The patterns for those with ARMD were in between those for diabetes and glaucoma. Over a nine-year period, only slightly over half of persons with at least one of the study conditions complied with practice guidelines. Conclusions: Annual eye examinations for persons diagnosed with diabetes, glaucoma, and ARMD are important for detecting potentially treatable vision loss among those already diagnosed with these conditions. Currently, actual rates of eye examinations for persons diagnosed with the study conditions fall far short of recommended rates. As such, approaches to enhancing longitudinal follow-up of those already in the eye care system are needed. (C) 2003 by the American Academy of Ophthalmology. AN - WOS:000185615400016 AU - Lee, P. P. AU - Feldman, Z. W. AU - Ostermann, J. AU - Brown, D. S. AU - Sloan, F. A. DA - OCT DO - 10.1016/S0161-6420(03)00817-0 IS - 10 PY - 2003 SN - 0161-6420 SP - 1952-1959 ST - Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases T2 - OPHTHALMOLOGY TI - Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases VL - 110 ID - 6103 ER - TY - JOUR AB - Access to health care has been traditionally viewed as the ability to see a physician or to be hospitalized if necessary in the presence of a health state that may benefit from care in prevention, treatment, amelioration, or palliation. Information from national databases such as the National Ambulatory Care Medical Survey reporting on samples of visits from physician offices around the United States1,2 or from the Medicare claims data3 provides valuable insight about the status of eye care use in the United States, particularly for adults. National Ambulatory Care Medical Survey data from 2004 (the most recent year available) show that there were 47.3 million visits (SE of estimate, ±7.0 million visits) across all age groups to ophthalmologists' nonhospital-based offices, constituting 5.2% of all such visits and a rate of 16.4 visits per 100 persons in 2004.1 There were a total of 43.6 million visits for eye and ear symptoms, with 11.1 million (SE, ±2.2 million) referable to vision dysfunction symptoms. As might be expected, visit rates are traditionally higher for elderly persons, with nearly 50% of those aged 65 years and older having at least 1 eye visit in any given year in Medicare.3 In comparison, annual rates of eye care use have been estimated from the National Health Interview Survey to be 7.3% (95% confidence interval, 6.0%-8.6%) of those aged 0 to 5 years and 24.8% (95% confidence interval, 23.5%-26.2%) among those aged 6 to 17 years.4 Across all age groups,1-4 female sex was associated with greater use or likelihood of use of eye care services. ©2007 American Medical Association. All rights reserved. AD - Department of Ophthalmology, Duke University, Durham, NC, United States American Academy of Ophthalmology, San Francisco, CA, United States Foundation of the American Academy of Ophthalmology, San Francisco, CA, United States EyeCare America, San Francisco, CA, United States Department of Ophthalmology, Doheny Eye Institute, University of Southern California Keck School of Medicine, Los Angeles, CA, United States Ophthalmic Consultants of Boston, Boston, MA, United States Department of Ophthalmology, Duke University Eye Center, Duke University Medical Center, 3802 Erwin Rd, Durham, NC 27710, United States AU - Lee, P. P. AU - Hoskins Jr, H. D. AU - Smith, R. E. AU - Hutchinson, B. T. AU - Wong, B. A. DB - Scopus DO - 10.1001/archopht.125.3.403 IS - 3 M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2007 SP - 403-405 ST - Access to eye care: Response of the American Academy of Ophthalmology and its members to societal needs now and in the future T2 - Archives of Ophthalmology TI - Access to eye care: Response of the American Academy of Ophthalmology and its members to societal needs now and in the future UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33947231059&doi=10.1001%2farchopht.125.3.403&partnerID=40&md5=00e6d70d1ed7432122127e3379dd3ea4 VL - 125 ID - 5263 ER - TY - JOUR AB - PURPOSE: To develop an alternative method for analysis of patient persistence with prescribed medications using the prostaglandin class of intraocular pressure (IOP)-lowering drugs as a model. DESIGN: A retrospective study of prescription refill patterns. METHODS: Patients with a pharmacy claim for a 2.5 ml bottle of latanoprost, travoprost, or bimatoprost between September 1, 2002 and December 31, 2002 were identified from a retail pharmacy database and were followed up for 12 months. Three separate analyses defined gaps in therapy as spans in excess of 45, 60, or 120 days without a refill for the same medication. Patients were categorized by the number of gaps in therapy and the Cumulative length of gaps. A Kaplan-Meier analysis was conducted using a 120-day allowable refill period. RESULTS: For refill periods of 45, 60, and 120 days, 10.6%, 28.6%, and 77.5% of patients, respectively, had no gaps in therapy, and 32.6%, 53.4%, and 86.5%, respectively, had 30 days or fewer off therapy annually. According to the 45-day threshold analysis, 50.7% of patients had three or more gaps vs 18.5% in the 60-day analysis and none in the 120,day analysis. The KaplanMeier curve shows 88.6% and 76.1% of patients were persistent for 120 days and one year, respectively. CONCLUSIONS: Compared with Kaplan-Meier survival curves, the gap analysis approach may better parallel clinical experience with patient persistence, in which patients stop and restart medications for a variety of reasons over time. This method also may help to identify avenues for investigation of lack of persistency among many patients. AN - WOS:000249937400006 AU - Lee, P. P. AU - Walt, J. G. AU - Chiang, T. H. AU - Guckian, A. AU - Keener, J. DA - OCT DO - 10.1016/j.ajo.2007.06.023 IS - 4 PY - 2007 SN - 0002-9394 SP - 520-524 ST - A gap analysis approach to assess patient persistence with glaucoma medication T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - A gap analysis approach to assess patient persistence with glaucoma medication VL - 144 ID - 6145 ER - TY - JOUR AU - Lee, R. M. H. AU - Oleszczuk, J. D. AU - Hyer, J. N. AU - Gazzard, G. DB - Embase Medline DO - 10.1038/eye.2014.22 IS - 4 KW - eye drops disease course follow up glaucoma health care cost health care quality human letter mobile application mobile phone outcome assessment patient attitude patient compliance patient education patient monitoring treatment refusal visual field defect LA - English M3 - Letter N1 - L372827162 2014-04-23 2014-05-01 PY - 2014 SN - 1476-5454 0950-222X SP - 496 ST - Patient acceptance to smartphone technology to monitor and improve glaucoma health-care outcomes T2 - Eye (Basingstoke) TI - Patient acceptance to smartphone technology to monitor and improve glaucoma health-care outcomes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L372827162&from=export http://dx.doi.org/10.1038/eye.2014.22 VL - 28 ID - 2904 ER - TY - JOUR AD - Department of Ophthalmology, Kings College Hospital, London, United Kingdom Department of Ophthalmology, Moorfields Eye Hospital, London, United Kingdom Department of Ophthalmology, Western Eye Hospital, London, United Kingdom NIHR Biomedical Research Centre in Ophthalmology, Moorfields Eye Hospital, UCL Institute of Ophthalmology, London, United Kingdom AU - Lee, R. M. H. AU - Oleszczuk, J. D. AU - Hyer, J. N. AU - Gazzard, G. DB - Scopus DO - 10.1038/eye.2014.22 IS - 4 M3 - Letter N1 - Cited By :4 Export Date: 19 July 2021 PY - 2014 SP - 496 ST - Patient acceptance to smartphone technology to monitor and improve glaucoma health-care outcomes T2 - Eye (Basingstoke) TI - Patient acceptance to smartphone technology to monitor and improve glaucoma health-care outcomes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898438365&doi=10.1038%2feye.2014.22&partnerID=40&md5=80e4883f04a2ce5e34b32ba28ed43773 VL - 28 ID - 5470 ER - TY - JOUR AB - Purpose: We report a case of conjunctival pyogenic granuloma that developed after sub-Tenon's block at the inferotemporal conjunctival quadrant during cataract surgery. Case summary: A 74-year-old male patient with senile cataract, diabetic retinopathy and open-angle glaucoma, who was using a combination of timolol/tafluprost and brimonidine eyedrops, underwent uneventful cataract surgery after sub-Tenon's block at the inferotemporal conjunctival quadrant of his right eye. Moxifloxacin, 1% prednisolone acetate and 0.1% bromfenac sodium hydrate were administered daily for 1 month post-surgery, by which time a pink-colored, oval-shaped granulomatous mass had developed on the inferotemporal conjunctiva, at the site of the sub-Tenon's block. Dexamethasone and antibiotic combination eye drops were administered without resection of the mass, which had markedly regressed after 2 weeks and disappeared completely 6 weeks after treatment. Conclusions: Patients should be informed of the possibility of conjunctival pyogenic granuloma prior to cataract surgery using sub-Tenon's block, and it is important to carefully check the block site and compliance with eyedrops at follow-up visits. Conjunctival pyogenic granuloma can be successfully treated with topical steroids. AN - WOS:000643001500018 AU - Lee, S. H. AU - Kim, K. W. AU - Chun, Y. S. DA - APR DO - 10.3341/jkos.2021.62.4.566 IS - 4 PY - 2021 SN - 0378-6471 2092-9374 SP - 566-570 ST - Conjunctival Pyogenic Granuloma after Sub-tenon's Block T2 - JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY TI - Conjunctival Pyogenic Granuloma after Sub-tenon's Block VL - 62 ID - 6169 ER - TY - JOUR AB - Objectives: This is a prospective study in an urgent-care ophthalmic setting to investigate contact lens (CL) complications and their association with extended wear (EW). Methods: Data on CL designs, care system(s), and ocular complications were collected over a 6-month period. Results: One thousand three hundred and sixty-nine patients presented to the Jules Stein Eye Institute urgent care with symptoms of eye problems. Of these, 56 were identified with diagnoses etiologically associated with CL wear, and 49 were studied. The five most common ocular diagnoses found in our study were in the following order: epithelial staining or abrasion/epithelial defect, conjunctival injection, papillae, corneal neovascularization, and presumed microbial keratitis (PMK). Fifteen of 49 patients were diagnosed with PMK. The mean number of complications was 3.43 per eye. Most of the patients (65%) reported some form of EW. Analysis of the patients with PMK showed an association with EW. There seemed to be no statistical difference in the number of complications per symptomatic eye with hydrogel and silicone hydrogel lenses although 13 of the15 patients with PMK were silicone hydrogel wearers. Conclusions: We studied various aspects of care and compliance in an urgent-care population and found that most of our urgent-care patients slept with CLs on their eyes. Symptomatic CL wear-related complications, and specifically MK, strongly correlate with EW with less relation to lens design, material, and wear modality. We therefore conclude that CL EW is a risk factor leading to urgent-care visits. © 2012 Lippincott Williams & Wilkins. AD - S.Y. Lee, 100 Stein Plaza, Los Angeles, CA 90095, United States AU - Lee, S. Y. AU - Kim, Y. H. AU - Johnson, D. AU - Mondino, B. J. AU - Weissman, B. A. DB - Embase Medline DO - 10.1097/ICL.0b013e31823ff20e IS - 1 KW - adult aged article conjunctivitis contact lens cornea epithelium cornea injury cornea lesion cornea neovascularization corneal epithelial staining emergency care extended wear contact lens human keratitis major clinical study patient compliance presumed microbial keratitis priority journal symptom United States LA - English M3 - Article N1 - L51766292 2011-12-16 2012-01-13 PY - 2012 SN - 1542-2321 1542-233X SP - 49-52 ST - Contact lens complications in an urgent-care population: The university of california, los angeles, contact lens study T2 - Eye and Contact Lens TI - Contact lens complications in an urgent-care population: The university of california, los angeles, contact lens study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51766292&from=export http://dx.doi.org/10.1097/ICL.0b013e31823ff20e VL - 38 ID - 3121 ER - TY - JOUR AB - Objectives: This is a prospective study in an urgent-care ophthalmic setting to investigate contact lens (CL) complications and their association with extended wear (EW). Methods: Data on CL designs, care system(s), and ocular complications were collected over a 6-month period. Results: One thousand three hundred and sixty-nine patients presented to the Jules Stein Eye Institute urgent care with symptoms of eye problems. Of these, 56 were identified with diagnoses etiologically associated with CL wear, and 49 were studied. The five most common ocular diagnoses found in our study were in the following order: epithelial staining or abrasion/epithelial defect, conjunctival injection, papillae, corneal neovascularization, and presumed microbial keratitis (PMK). Fifteen of 49 patients were diagnosed with PMK. The mean number of complications was 3.43 per eye. Most of the patients (65%) reported some form of EW. Analysis of the patients with PMK showed an association with EW. There seemed to be no statistical difference in the number of complications per symptomatic eye with hydrogel and silicone hydrogel lenses although 13 of the15 patients with PMK were silicone hydrogel wearers. Conclusions: We studied various aspects of care and compliance in an urgent-care population and found that most of our urgent-care patients slept with CLs on their eyes. Symptomatic CL wear-related complications, and specifically MK, strongly correlate with EW with less relation to lens design, material, and wear modality. We therefore conclude that CL EW is a risk factor leading to urgent-care visits. © 2012 Lippincott Williams & Wilkins. AD - Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, United States AU - Lee, S. Y. AU - Kim, Y. H. AU - Johnson, D. AU - Mondino, B. J. AU - Weissman, B. A. DB - Scopus DO - 10.1097/ICL.0b013e31823ff20e IS - 1 KW - Complications Contact lenses Cornea Extended wear Microbial keratitis M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2012 SP - 49-52 ST - Contact lens complications in an urgent-care population: The university of california, los angeles, contact lens study T2 - Eye and Contact Lens TI - Contact lens complications in an urgent-care population: The university of california, los angeles, contact lens study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855347067&doi=10.1097%2fICL.0b013e31823ff20e&partnerID=40&md5=4985310b7f81ee0c0750e695f2b4af2a VL - 38 ID - 5285 ER - TY - JOUR AB - Objectives: This is a prospective study in an urgent-care ophthalmic setting to investigate contact lens (CL) complications and their association with extended wear (EW). Methods: Data on CL designs, care system(s), and ocular complications were collected over a 6-month period. Results: One thousand three hundred and sixty-nine patients presented to the Jules Stein Eye Institute urgent care with symptoms of eye problems. Of these, 56 were identified with diagnoses etiologically associated with CL wear, and 49 were studied. The five most common ocular diagnoses found in our study were in the following order: epithelial staining or abrasion/epithelial defect, conjunctival injection, papillae, corneal neovascularization, and presumed microbial keratitis (PMK). Fifteen of 49 patients were diagnosed with PMK. The mean number of complications was 3.43 per eye. Most of the patients (65%) reported some form of EW. Analysis of the patients with PMK showed an association with EW. There seemed to be no statistical difference in the number of complications per symptomatic eye with hydrogel and silicone hydrogel lenses although 13 of the15 patients with PMK were silicone hydrogel wearers. Conclusions: We studied various aspects of care and compliance in an urgent-care population and found that most of our urgent-care patients slept with CLs on their eyes. Symptomatic CL wear-related complications, and specifically MK, strongly correlate with EW with less relation to lens design, material, and wear modality. We therefore conclude that CL EW is a risk factor leading to urgent-care visits. AN - WOS:000298664900008 AU - Lee, S. Y. AU - Kim, Y. H. AU - Johnson, D. AU - Mondino, B. J. AU - Weissman, B. A. DA - JAN DO - 10.1097/ICL.0b013e31823ff20e IS - 1 PY - 2012 SN - 1542-2321 SP - 49-52 ST - Contact Lens Complications in an Urgent-Care Population: The University of California, Los Angeles, Contact Lens Study T2 - EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE TI - Contact Lens Complications in an Urgent-Care Population: The University of California, Los Angeles, Contact Lens Study VL - 38 ID - 6339 ER - TY - JOUR AB - Purpose The aim of this study was to investigate the association between tear film and meibomian gland parameters in patients with normal tension glaucoma (NTG), who underwent topical prostaglandin analog (PGA) monotherapy, and medication compliance. Methods Ocular surface disease index (OSDI), Schirmer’s test, tear film break-up time (TBUT), keratoepitheliopathy (KEP) score with fluorescein, and meibomian gland parameters were assessed in 45 eyes of 45 patients with NTG (NTG group), who received topical PGA monotherapy for more than 1 year. The results were compared to those of 40 eyes of 40 normal subjects (control group). Medication compliance was assessed by an 8-item Morisky Medication Adherence Scale (MMAS-8). Multiple logistic regression analysis was used to identify the factors associated with medication compliance. Results There was a significant difference in OSDI (P = 0.043), Schirmer’s test (P < 0.001), TBUT (P < 0.001), KEP score (P = 0.015) and all meibomian gland parameters (all P < 0.001) between two groups. When the NTG group was divided into compliant and non-compliant groups based on the scores of MMAS-8, 30 (75%) patients were classified into the compliant group. Multiple logistic regression analysis revealed that the lid margin score (OR, 0.256; 95% CI, 0.072–0.908, P = 0.035), meibum score (OR, 0.144; 95% CI, 0.023–0.915, P = 0.04), and meibo score (OR, 0.344; 95% CI, 0.140–0.845, P = 0.02) were significant factors associated with compliance in patients with NTG. The meibomian gland parameters showed a negative correlation with medication compliance (all P < 0.005). Conclusions Malfunction of the meibomian glands can be an important clinical finding associated with compliance of PGA monotherapy in patients with NTG. AD - S.W. Park, Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, South Korea AU - Lee, T. H. AU - Sung, M. S. AU - Heo, H. AU - Park, S. W. C1 - lumigan(Allergan,United States) taflotan(Santen,Japan) xalatan(Pfizer,United States) C2 - Santen(Japan) Allergan(United States) Pfizer(United States) DB - Embase Medline DO - 10.1371/journal.pone.0191398 IS - 1 KW - bimatoprost fluorescein latanoprost prostaglandin derivative tafluprost 8 item morisky medication adherence scale adult article clinical article controlled study correlational study cross-sectional study disease assessment female human keratoepitheliopathy score low tension glaucoma male medication compliance meibomian gland dysfunction middle aged monotherapy multivariate logistic regression analysis Ocular Surface Disease Index parameters patient coding patient compliance Schirmer test scoring system tear film tear break-up time lumigan taflotan xalatan LA - English M3 - Article N1 - L620393508 2018-02-05 2018-02-07 PY - 2018 SN - 1932-6203 ST - Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma T2 - PLoS ONE TI - Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620393508&from=export http://dx.doi.org/10.1371/journal.pone.0191398 VL - 13 ID - 2612 ER - TY - JOUR AB - A series of 35 patients with pigmentary glaucoma were asked to report possible side effects of topical glaucoma medication using a multiple-choice questionnaire. Of the 31 patients (89%) returning the forms, 22 (71%) were men and 9 (29%) women with a mean age of 45.1 years, range 23 to 72 years. The mean follow-up time of their glaucoma was 10.7 years, range 2 to 30 years. A mild burning feeling (in 50% in all treatment groups) and redness of the eyes (in 42% treated with timolol alone and in 50% with timolol combined with dipivephrine, pilocarpine or both) were the main complaints, followed by a slight reduction of vision (in 17% in the timolol group and in 56% with combined treatment) and mild watering of the eyes (in 42% of the timolol and in 31% of the combined treatment groups). Twenty-three percent of the patients did not have any side effects from their topical medication. Patients who admitted defaulting their topical treatment once a month amounted to 43% and once a week to 17%. Patients who admitted to never having missed a drop amounted to 40% of the sample; forgetfulness and haste were the main reasons for not applying the drops. AD - I. Lehto, Dept. of Ophthalmology, University Hospital, Helsinki, Haartmaninkatu 4 C, SF-00290 Helsinki, Finland AU - Lehto, I. DB - Embase Medline IS - 2 KW - epinephrine dipivefrine pilocarpine timolol adult aged article burn clinical article drug tolerance dyspnea eye inflammation female headache human male muscle hypotonia mydriasis open angle glaucoma patient compliance pigment disorder priority journal questionnaire topical drug administration topical treatment vertigo visual impairment LA - English M3 - Article N1 - L22149104 1992-05-21 PY - 1992 SN - 0001-639X SP - 225-227 ST - Side effects of topical treatment in pigmentary glaucoma T2 - Acta Ophthalmologica TI - Side effects of topical treatment in pigmentary glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L22149104&from=export VL - 70 ID - 4027 ER - TY - JOUR AB - Abstract. A series of 35 patients with pigmentary glaucoma were asked to report possible side effects of topical glaucoma medication using a multiple‐choice questionnaire. Of the 31 patients (89%) returning the forms, 22 (71%) were men and 9 (29%) women with a mean age of 45.1 years, range 23 to 72 years. The mean follow‐up time of their glaucoma was 10.7 years, range 2 to 30 years. A mild burning feeling (in 50% in all treatment groups) and redness of the eyes (in 42% treated with timolol alone and in 50% with timolol combined with dipivephrine, pilo‐carpine or both) were the main complaints, followed by a slight reduction of vision (in 17% in the timolol group and in 56% with combined treatment) and mild watering of the eyes (in 42% of the timolol and in 31% of the combined treatment groups). Twenty‐three percent of the patients did not have any side effects from their topical medication. Patients who admitted defaulting their topical treatment once a month amounted to 43% and once a week to 17%. Patients who admitted to never having missed a drop amounted to 40% of the sample; forgetful‐ness and haste were the main reasons for not applying the drops. 1992 Institution Acta Ophthalmologica Scandinavica AD - Department of Ophthalmology, University of Helsinki, Helsinki, Finland AU - Lehto, I. DB - Scopus DO - 10.1111/j.1755-3768.1992.tb04128.x IS - 2 KW - drug tolerance glaucoma patient compliance pigmentary M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 1992 SP - 225-227 ST - Side effects of topical treatment in pigmentary glaucoma T2 - Acta Ophthalmologica TI - Side effects of topical treatment in pigmentary glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026520146&doi=10.1111%2fj.1755-3768.1992.tb04128.x&partnerID=40&md5=26051f7b8ba1a5ef56b29a469fdd172d VL - 70 ID - 5341 ER - TY - JOUR AB - A series of 35 patients with pigmentary glaucoma were asked to report possible side effects of topical glaucoma medication using a multiple-choice questionnaire. Of the 31 patients (89%) returning the forms, 22 (71%) were men and 9 (29%) women with a mean age of 45.1 years, range 23 to 72 years. The mean follow-up time of their glaucoma was 10.7 years, range 2 to 30 years. A mild burning feeling (in 50% in all treatment groups) and redness of the eyes (in 42% treated with timolol alone and in 50% with timolol combined with dipivephrine, pilocarpine or both) were the main complaints, followed by a slight reduction of vision (in 17% in the timolol group and in 56% with combined treatment) and mild watering of the eyes (in 42% of the timolol and in 31% of the combined treatment groups). Twenty-three percent of the patients did not have any side effects from their topical medication. Patients who admitted defaulting their topical treatment once a month amounted to 43% and once a week to 17%. Patients who admitted to never having missed a drop amounted to 40% of the sample; forgetfulness and haste were the main reasons for not applying the drops. AN - WOS:A1992HT66800011 AU - Lehto, I. DA - APR IS - 2 PY - 1992 SN - 0001-639X SP - 225-227 ST - SIDE-EFFECTS OF TOPICAL TREATMENT IN PIGMENTARY GLAUCOMA T2 - ACTA OPHTHALMOLOGICA TI - SIDE-EFFECTS OF TOPICAL TREATMENT IN PIGMENTARY GLAUCOMA VL - 70 ID - 6165 ER - TY - JOUR AB - Introduction: Appointment nonadherence is common among people with glaucoma, making it difficult for eye care providers to monitor glaucoma progression. Our objective was to determine whether the use of patient navigators, in conjunction with social worker support, could increase adherence to recommended follow-up eye appointments.Methods: A randomized, controlled trial evaluated the effectiveness of an intervention that used patient navigators and social workers to improve patient adherence to follow-up eye care compared with usual care. Participants with glaucoma and other eye diseases (N = 344) were identified at primary care clinics in community settings through telemedicine screening of imaging and then randomized to enhanced intervention (EI) or usual care (UC). Data on participants' visits with local ophthalmologists were collected for up to 3 years from randomization. Groups were compared for timely attendance at the first visit with the local ophthalmologist and adherence to recommended follow-up visits.Results: Timely attendance at the first visit was higher for EI than UC (74.4% vs 39.0%; average relative risk [aRR] = 1.85; 95% CI, 1.51-2.28; P < .001). Rates of adherence to recommended annual follow-up during year 1 were 18.6% in the EI group and 8.1% in the usual care group (aRR = 2.08; 95% CI, 1.14-3.76; P = .02). The aRR across years 2 and 3 was 3.92 (95% CI, 1.24-12.43; P = .02).Conclusion: An intervention using patient navigators and social workers doubled the rate of adherence to annual recommended follow-up eye care compared with usual care in community settings, and was effective at increasing connections with local ophthalmologists. Interventions to further improve long-term adherence are needed. AD - Thomas Jefferson University, Sidney Kimmel Medical College, Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Philadelphia, Pennsylvania Wills Eye Hospital, Glaucoma Research Center, Philadelphia, Pennsylvania Thomas Jefferson University, Sidney Kimmel Medical College, Department of Ophthalmology, Philadelphia, Pennsylvania Wills Eye Hospital, Office of the Ophthalmologist-in-Chief, Philadelphia, Pennsylvania Department of Ophthalmology, Tel Aviv Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Israel Temple University School of Medicine, Department of Ophthalmology, Philadelphia, Pennsylvania Columbia University Irving Medical Center, Department of Ophthalmology, New York, New York AN - 150421961. Language: English. Entry Date: In Process. Revision Date: 20210716. Publication Type: journal article. Journal Subset: Blind Peer Reviewed AU - Leiby, Benjamin E. AU - Hegarty, Sarah E. AU - Tingting, Zhan AU - Myers, Jonathan S. AU - Katz, L. Jay AU - Haller, Julia A. AU - Waisbourd, Michael AU - Burns, Christine AU - Divers, Meskerem AU - Molineaux, Jeanne AU - Henderer, Jeffrey AU - Brodowski, Charles AU - Hark, Lisa A. AU - Zhan, Tingting DB - ccm DO - 10.5888/pcd18.200567 DP - EBSCOhost N1 - Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; Public Health; USA. NLM UID: 101205018. PMID: NLM34014814. PY - 2021 SN - 1545-1151 SP - 1-12 ST - A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma T2 - Preventing Chronic Disease TI - A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150421961&site=ehost-live&scope=site VL - 18 ID - 4144 ER - TY - JOUR AB - Introduction Appointment nonadherence is common among people with glauc- oma, making it difficult for eye care providers to monitor glauc- oma progression. Our objective was to determine whether the use of patient navigators, in conjunction with social worker support, could increase adherence to recommended follow-up eye appoint- ments. Methods A randomized, controlled trial evaluated the effectiveness of an in- tervention that used patient navigators and social workers to im- prove patient adherence to follow-up eye care compared with usu- al care. Participants with glaucoma and other eye diseases (N = 344) were identified at primary care clinics in community settings through telemedicine screening of imaging and then randomized to enhanced intervention (EI) or usual care (UC). Data on parti- cipants’ visits with local ophthalmologists were collected for up to 3 years from randomization. Groups were compared for timely at- tendance at the first visit with the local ophthalmologist and adher- ence to recommended follow-up visits. Results Timely attendance at the first visit was higher for EI than UC (74.4% vs 39.0%; average relative risk [aRR] = 1.85; 95% CI, 1.51–2.28; P <.001). Rates of adherence to recommended annual follow-up during year 1 were 18.6% in the EI group and 8.1% in the usual care group (aRR = 2.08; 95% CI, 1.14–3.76; P =.02). The aRR across years 2 and 3 was 3.92 (95% CI, 1.24–12.43; P =.02). Conclusion An intervention using patient navigators and social workers doubled the rate of adherence to annual recommended follow-up eye care compared with usual care in community settings, and was effective at increasing connections with local ophthalmologists. Interventions to further improve long-term adherence are needed. © 2021. All Rights Reserved. AD - Thomas Jefferson University, Sidney Kimmel Medical College, Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Philadelphia, Pennsylvania, United States Wills Eye Hospital, Glaucoma Research Center, Philadelphia, Pennsylvania, United States Thomas Jefferson University, Sidney Kimmel Medical College, Department of Ophthalmology, Philadelphia, Pennsylvania, United States Wills Eye Hospital, Office of the Ophthalmologist-in-Chief, Philadelphia, Pennsylvania, United States Department of Ophthalmology, Tel Aviv Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Israel Temple University School of Medicine, Department of Ophthalmology, Philadelphia, Pennsylvania, United States Columbia University Irving Medical Center, Department of Ophthalmology, New York, New York, United States AU - Leiby, B. E. AU - Hegarty, S. E. AU - Zhan, T. AU - Myers, J. S. AU - Jay Katz, L. AU - Haller, J. A. AU - Waisbourd, M. AU - Burns, C. AU - Divers, M. AU - Molineaux, J. AU - Henderer, J. AU - Brodowski, C. AU - Hark, L. A. DB - Scopus DO - 10.5888/PCD18.200567 M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 1-12 ST - A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma T2 - Preventing Chronic Disease TI - A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106597124&doi=10.5888%2fPCD18.200567&partnerID=40&md5=268c20befe0bce5aaa9012d4a0b949c7 VL - 18 ID - 5671 ER - TY - JOUR AB - INTRODUCTION: Appointment nonadherence is common among people with glaucoma, making it difficult for eye care providers to monitor glaucoma progression. Our objective was to determine whether the use of patient navigators, in conjunction with social worker support, could increase adherence to recommended follow-up eye appointments. METHODS: A randomized, controlled trial evaluated the effectiveness of an intervention that used patient navigators and social workers to improve patient adherence to follow-up eye care compared with usual care. Participants with glaucoma and other eye diseases (N = 344) were identified at primary care clinics in community settings through telemedicine screening of imaging and then randomized to enhanced intervention (EI) or usual care (UC). Data on participants' visits with local ophthalmologists were collected for up to 3 years from randomization. Groups were compared for timely attendance at the first visit with the local ophthalmologist and adherence to recommended follow-up visits. RESULTS: Timely attendance at the first visit was higher for EI than UC (74.4% vs 39.0%; average relative risk [aRR] = 1.85; 95% CI, 1.51-2.28; P < .001). Rates of adherence to recommended annual follow-up during year 1 were 18.6% in the EI group and 8.1% in the usual care group (aRR = 2.08; 95% CI, 1.14-3.76; P = .02). The aRR across years 2 and 3 was 3.92 (95% CI, 1.24-12.43; P = .02). CONCLUSION: An intervention using patient navigators and social workers doubled the rate of adherence to annual recommended follow-up eye care compared with usual care in community settings, and was effective at increasing connections with local ophthalmologists. Interventions to further improve long-term adherence are needed. AU - Leiby, B. E. AU - Hegarty, S. E. AU - Zhan, T. AU - Myers, J. S. AU - Katz, L. J. AU - Haller, J. A. AU - Waisbourd, M. AU - Burns, C. AU - Divers, M. AU - Molineaux, J. AU - Henderer, J. AU - Brodowski, C. AU - Hark, L. A. DB - Medline DO - 10.5888/pcd18.200567 KW - adult article comparative effectiveness eye care eye examination female follow up glaucoma human major clinical study male ophthalmologist primary medical care randomization randomized controlled trial risk factor social worker telemedicine LA - English M3 - Article N1 - L635132978 2021-06-02 PY - 2021 SN - 1545-1151 SP - E52 ST - A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma T2 - Preventing chronic disease TI - A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L635132978&from=export http://dx.doi.org/10.5888/pcd18.200567 VL - 18 ID - 2295 ER - TY - JOUR AB - Aim The aim of this study is to examine the attitudes of patients, who presented with advanced glaucoma in at least one eye, to participation in a randomised prospective trial comparing primary medical treatment with primary surgical treatment for advanced glaucoma. Methods Patients who had presented with advanced glaucoma (>15 dB loss mean deviation on Humphrey visual field testing) in at least one eye were asked to participate. Five focus groups comprising of 4-8 patients and consisting of 29 patients in total were undertaken. The group interviews were conducted by two experienced qualitative researchers, an ophthalmic clinician was present to clarify technical issues. The focus group discussions were taped and transcribed in full, and analysed through a process of familiarisation, open (inductive) coding, theme generation, theme refinement, and thematic mapping. Results Three overarching themes were identified: (1) the extent of patients' knowledge, (2) anxieties about surgery, and (3) concerns about compromised care due to trial involvement; these themes were further classified into eight sub-themes. Conclusion sPatients willingness to participate in randomised clinical studies is significantly connected to their level of comprehension and insight about the medical condition, its treatment, and the research process; misunderstandings about any of these aspects may act as a significant barrier to trial recruitment. Recruitment rates for future randomised trials may be enhanced by ensuring that patients have full and accurate information about the treatment alternatives, and that uncertainty exists for best patient outcomes between treatment options, and reassuring potential participants that the research process, in particular randomisation, will not compromise clinical care. © 2012 Macmillan Publishers Limited All rights reserved. AD - P. Leighton, Division of Primary Care, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom AU - Leighton, P. AU - Lonsdale, A. J. AU - Tildsley, J. AU - King, A. J. DB - Embase Medline DO - 10.1038/eye.2011.279 IS - 2 KW - anxiety clinical article controlled study female glaucoma glaucoma surgery human interview male patient attitude patient compliance patient education primary medical care randomized controlled trial review treatment planning LA - English M3 - Review N1 - L364196123 2012-02-13 2012-02-15 PY - 2012 SN - 1476-5454 0950-222X SP - 300-306 ST - The willingness of patients presenting with advanced glaucoma to participate in a trial comparing primary medical vs primary surgical treatment T2 - Eye TI - The willingness of patients presenting with advanced glaucoma to participate in a trial comparing primary medical vs primary surgical treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364196123&from=export http://dx.doi.org/10.1038/eye.2011.279 VL - 26 ID - 3115 ER - TY - JOUR AB - Since 2005, at least 38 face transplantations have been performed worldwide. Available recommendations on psychological management are based on isolated cases or small case series, either not focused on mental health or with a short follow-up. We propose herein a clinical commentary on psychological and psychiatric outcomes from the follow-up of a prospective single-center cohort of six patients over a period of 3.5 to 9 years. Seven patients received a face transplant between January 2007 and April 2011: two patients with neurofibromatosis, four with self-inflicted ballistic trauma, one with self-immolation. One patient died at 63 days of cerebral sequelae from cardiac arrest in the setting of bacterial infection. The six other patients were routinely evaluated with unstructured psychological interviews up to May 2016 and with the Short Form 36-item health survey and the Mini-International Neuropsychiatric Interview at one year and at the end of the follow-up. Clinically meaningful observations were the following: a history of mental disorders before disfigurement was associated with poor physical and mental outcomes, including poor adherence and one suicide; untreated depression was associated with poor adherence; acceptance of the new face occurred rapidly and without significant distress in all of the patients; fear of transplant rejection was present to some degree in all of the patients and did not substantially differ from other transplantation settings; media exposure may be disturbing but may also have had positive psychological effects on some of the patients. Mental health issues related to chronic rejection and re-transplantation remain to be explored. © 2019 Elsevier Inc. AD - Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France AP-HP, Hôpitaux Universitaires Paris Ouest, Service de Psychiatrie et d'Addictologie de l'adulte et du sujet âgé, Paris, France Inserm, U1266, Institut de Psychiatrie et Neurosciences de Paris, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France AP-HP, Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand-Widal, Pôle de Psychiatrie et de Médecine Addictologique, Paris, France Inserm, UMR-S1144, Paris, France Fondation FondaMental, Créteil, France Centre de Recherche en Neurosciences de Lyon (CRNL) Inserm U1028, CNRS UMR5292, Université Lyon 1 – Jean Monnet, Lyon, France Department of Psychiatry, University Hospital of Saint-Etienne, Saint-Etienne, France AP-HP, Hôpitaux Universitaires Henri-Mondor, Pôle de Psychiatrie et d'Addictologie, Créteil, France AP-HP, Hôpitaux Universitaires Paris Ouest, Service de Chirurgie Plastique, Reconstructrice et Esthétique, Paris, France Institut Cochin, Inserm U1016, UMR-S 1016, CNRS UMR 8104, Génomique et épigénétique des tumeurs rares, Université Paris Descartes, Paris, France AU - Lemogne, C. AU - Bellivier, F. AU - Fakra, E. AU - Yon, L. AU - Limosin, F. AU - Consoli, S. M. AU - Lantieri, L. AU - Hivelin, M. DB - Scopus DO - 10.1016/j.jpsychores.2019.02.006 M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2019 SP - 42-49 ST - Psychological and psychiatric aspects of face transplantation: Lessons learned from the long-term follow-up of six patients T2 - Journal of Psychosomatic Research TI - Psychological and psychiatric aspects of face transplantation: Lessons learned from the long-term follow-up of six patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061548562&doi=10.1016%2fj.jpsychores.2019.02.006&partnerID=40&md5=49c24deb1d35d8a994d4988d58caeeb2 VL - 119 ID - 5405 ER - TY - JOUR AB - Background: Asthma affects one in eight children in the UK. National management guidelines have been available for many years but, unlike in adults, studies in children have been few, with their methodologies often based on inappropriate adult models. Sound medical evidence in support of the national guidelines for asthma management in children is lacking. The MASCOT study has been developed to address this need. Objectives: To determine whether adding salmeterol or montelukast to low-dose inhaled corticosteroids (ICSs) can reduce the number of exacerbations requiring treatment with oral corticosteroids in children with uncontrolled asthma. Design: A randomised, double-blind, placebo-controlled trial with a 4-week run-in period on a fluticasone propionate inhaler (100 μg twice daily) with inhaler technique correction. Patients who met the post run-in period eligibility criteria were randomised in the ratio of 1: 1: 1 and were followed for 48 weeks. Setting: Secondary care hospitals based in England and Scotland with recruitment from primary and secondary care. Participants: Children aged 6-14 years with asthma requiring frequent short-acting beta-2 agonist relief, with symptoms of asthma resulting in nocturnal wakening and/or asthma that has interfered with usual activities. Interventions: Three groups were compared: (1) inhaled fluticasone propionate 100 μg twice daily plus placebo tablet once daily; (2) inhaled fluticasone propionate 100 μg and salmeterol 50 μg twice daily (combination inhaler) plus placebo tablet once daily; and (3) inhaled fluticasone propionate 100 μg twice daily plus montelukast 5-mg tablet once daily. Main outcome measures: The primary outcome was the number of exacerbations requiring treatment with oral corticosteroids over 48 weeks. Secondary outcome measures included quality of life as measured by the Paediatric Asthma Quality of Life Questionnaire with Standardised Activities [PAQLQ(S)] and the Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ); time from randomisation to first exacerbation requiring treatment with a short course of oral corticosteroids; school attendance; hospital admissions; amount of rescue beta-2 agonist therapy prescribed; time from randomisation to treatment withdrawal (because of lack of efficacy or side effects); lung function at 48 weeks (as assessed by spirometry); cost-effectiveness; adverse events. Results: The study was closed prematurely because of poor recruitment and the target sample size of 450 was not achieved. In total, 898 children were screened to enter the trial, 166 were registered for the 4-week run-in period and 63 were randomised (group 1: 19, group 2: 23, group 3: 21), with 38 contributing data for the primary outcome analysis. There were no significant differences between groups for any of the outcomes. Adverse events were similar between the groups except for nervous system disorders, which were more frequently reported on fluticasone plus montelukast. Conclusions: Based on the results of the MASCOT study it is not possible to conclude whether adding salmeterol or montelukast to ICSs can reduce the number of exacerbations requiring treatment with oral corticosteroids in children with uncontrolled asthma. © Queen's Printer and Controller of HMSO 2013. AD - Development Department, University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom University of Nottingham, Nottingham, United Kingdom Department of General Practice and Primary Care, University of Aberdeen, Aberdeen, United Kingdom AU - Lenney, W. AU - McKay, A. J. AU - Tudur Smith, C. AU - Williamson, P. R. AU - James, M. AU - Price, D. DB - Scopus DO - 10.3310/hta17040 IS - 4 M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 2013 SP - 1-238 ST - Management of asthma in school age children on therapy (MASCOT): A randomised, double-blind, placebocontrolled, parallel study of efficacy and safety T2 - Health Technology Assessment TI - Management of asthma in school age children on therapy (MASCOT): A randomised, double-blind, placebocontrolled, parallel study of efficacy and safety UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874054132&doi=10.3310%2fhta17040&partnerID=40&md5=7ce93d95d258ba06baff1180a0e56f99 VL - 17 ID - 5179 ER - TY - JOUR AB - Purpose: Despite advances in glaucoma treatment options, patient adherence and compliance remain very low. The EyePhone© App is a free non-commercial reminder application designed specifically for the needs of glaucoma patients. In this study, we evaluated its usefulness in improving adherence to medical treatment among glaucoma patients. Methods: This is a prospective multicenter interventional study. Glaucoma patients were recruited from a tertiary center and a large community glaucoma service center. After a short explanation, the EyePhone© App was installed on their smartphone device, and the notifications for the current medical treatment were entered. After enrollment and at 1-month follow-up, subjects completed the Morisky Medication Adherence Scale (MMAS-8) and the Quality of Life and Glaucoma 17-item (GlauQOL-17) questionnaires for evaluation of adherence and QOL, respectively. Results: In the study, 133 patients (71 men and 62 women) aged 62±15.5 years and using 2.0±0.9 IOP-lowering drugs participated. The proportion of highly adherent subjects improved from 29.3% (39/133) at baseline to 42.1% (56/133) at follow-up (P < 0.001), and the proportion of poorly adherent subjects decreased from 29.3 (39/133) to 20.3% (27/133) at follow-up (P = 0.012). QOL also improved, as evidenced by a significant increase in the GlauQOL-17 score (P < 0.05). In a subgroup of patients for whom IOP measurements were available, IOP reduced by 0.92 mmHg (P = 0.069). Conclusions: Significant improvements in glaucoma adherence and QOL were achieved among poorly adherent glaucoma patients after 1 month of using the EyePhone© App. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature. AD - The Sam Rothberg Glaucoma Center, Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel Glaucoma Institute, “Clalit” Healthcare Services, Century Tower, Tel Aviv, Israel AU - Leshno, A. AU - Gaton, D. AU - Singer, R. AU - Eliasi, E. AU - Vorobichik-Berar, O. AU - Madgar, S. AU - Stern, O. AU - Jaber, W. AU - Kapelushnik, N. AU - Skaat, A. DB - Scopus DO - 10.1007/s00417-021-05091-6 IS - 5 KW - Adherence Application Glaucoma Quality of life Smartphone M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 1253-1262 ST - A novel EyePhone© App for improving adherence to glaucoma therapy T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - A novel EyePhone© App for improving adherence to glaucoma therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100334390&doi=10.1007%2fs00417-021-05091-6&partnerID=40&md5=9fce27d747cf734495889317b665de70 VL - 259 ID - 5661 ER - TY - JOUR AB - Purpose Despite advances in glaucoma treatment options, patient adherence and compliance remain very low. The EyePhone (c) App is a free non-commercial reminder application designed specifically for the needs of glaucoma patients. In this study, we evaluated its usefulness in improving adherence to medical treatment among glaucoma patients. Methods This is a prospective multicenter interventional study. Glaucoma patients were recruited from a tertiary center and a large community glaucoma service center. After a short explanation, the EyePhone (c) App was installed on their smartphone device, and the notifications for the current medical treatment were entered. After enrollment and at 1-month follow-up, subjects completed the Morisky Medication Adherence Scale (MMAS-8) and the Quality of Life and Glaucoma 17-item (GlauQOL-17) questionnaires for evaluation of adherence and QOL, respectively. Results In the study, 133 patients (71 men and 62 women) aged 62 +/- 15.5 years and using 2.0 +/- 0.9 IOP-lowering drugs participated. The proportion of highly adherent subjects improved from 29.3% (39/133) at baseline to 42.1% (56/133) at follow-up (P < 0.001), and the proportion of poorly adherent subjects decreased from 29.3 (39/133) to 20.3% (27/133) at follow-up (P = 0.012). QOL also improved, as evidenced by a significant increase in the GlauQOL-17 score (P < 0.05). In a subgroup of patients for whom IOP measurements were available, IOP reduced by 0.92 mmHg (P = 0.069). Conclusions Significant improvements in glaucoma adherence and QOL were achieved among poorly adherent glaucoma patients after 1 month of using the EyePhone (c) App. AN - WOS:000613999100008 AU - Leshno, A. AU - Gaton, D. AU - Singer, R. AU - Eliasi, E. AU - Vorobichik-Berar, O. AU - Madgar, S. AU - Stern, O. AU - Jaber, W. AU - Kapelushnik, N. AU - Skaat, A. DA - MAY DO - 10.1007/s00417-021-05091-6 IS - 5 PY - 2021 SN - 0721-832X 1435-702X SP - 1253-1262 ST - A novel EyePhone (c) App for improving adherence to glaucoma therapy T2 - GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - A novel EyePhone (c) App for improving adherence to glaucoma therapy VL - 259 ID - 5880 ER - TY - JOUR AB - Purpose: To describe the care-seeking behavior of a representative sample of rural Africans blind from glaucoma. Patients and Methods: Patients blind from posterior segment diseases (including diseases affecting the retina or optic nerve) were identified though a population-based survey in Kilimanjaro Region, Tanzania in 2007. A year later they were traced to their homes to detail the diagnoses with more thorough examination. In-depth interviews were conducted to determine healthcare sought and received and symptoms which prompted this. Data were analyzed by framework analysis. Results: Of 30 patients previously identified, 20 were found and interviewed, 4 had died, 2 had moved, 2 lived too far to trace, and 2 could not be located. The average age was 77 years. Few patients could give a clear temporal history of how their vision failed or a sequential description of visits made to healthcare facilities over the years. However, every patient had sought eye care and most made numerous visits. Understanding of the disease and treatment was uniformly limited. Most received topical medicines and the histories of nonglaucoma and glaucoma blind were similar except that 5 glaucoma patients had received surgery. Patients described obstacles to care including poverty and other lack of support. Conclusions: These findings contrast to previous which showed that most rural Africans blind from glaucoma have not sought or received treatment. It is likely that this is partly the result of widely accessible services offered in Kilimanjaro Region. However, the challenges in treating this chronic disease are highlighted. Copyright © 2011 by Lippincott Williams & Wilkins. AD - Kilimanjaro Centre for Community Ophthalmology, Good Samaritan Foundation, Post Box 2254, Moshi, Tanzania Department of Ophthalmology, Kilimanjaro Christian Medical Center Hospital, Tumaini University, Moshi, Tanzania AU - Lewallen, S. AU - Hassan, H. G. AU - Al Attas, A. H. AU - Courtright, P. DB - Scopus DO - 10.1097/IJG.0b013e3181eda983 IS - 6 KW - glaucoma health-seeking behavior population based Tanzania M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2011 SP - 361-365 ST - A population-based study of care-seeking behavior in rural tanzanians with glaucoma blindness T2 - Journal of Glaucoma TI - A population-based study of care-seeking behavior in rural tanzanians with glaucoma blindness UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80051794575&doi=10.1097%2fIJG.0b013e3181eda983&partnerID=40&md5=d6c5eedb97ccfacde1ab9b7f238c7a88 VL - 20 ID - 5308 ER - TY - JOUR AB - Purpose: To describe the care-seeking behavior of a representative sample of rural Africans blind from glaucoma. Patients and Methods: Patients blind from posterior segment diseases (including diseases affecting the retina or optic nerve) were identified though a population-based survey in Kilimanjaro Region, Tanzania in 2007. A year later they were traced to their homes to detail the diagnoses with more thorough examination. In-depth interviews were conducted to determine healthcare sought and received and symptoms which prompted this. Data were analyzed by framework analysis. Results: Of 30 patients previously identified, 20 were found and interviewed, 4 had died, 2 had moved, 2 lived too far to trace, and 2 could not be located. The average age was 77 years. Few patients could give a clear temporal history of how their vision failed or a sequential description of visits made to healthcare facilities over the years. However, every patient had sought eye care and most made numerous visits. Understanding of the disease and treatment was uniformly limited. Most received topical medicines and the histories of nonglaucoma and glaucoma blind were similar except that 5 glaucoma patients had received surgery. Patients described obstacles to care including poverty and other lack of support. Conclusions: These findings contrast to previous which showed that most rural Africans blind from glaucoma have not sought or received treatment. It is likely that this is partly the result of widely accessible services offered in Kilimanjaro Region. However, the challenges in treating this chronic disease are highlighted. AN - WOS:000293446400006 AU - Lewallen, S. AU - Hassan, H. G. AU - Al Attas, A. H. AU - Courtright, P. DA - AUG DO - 10.1097/IJG.0b013e3181eda983 IS - 6 PY - 2011 SN - 1057-0829 SP - 361-365 ST - A Population-based Study of Care-seeking Behavior in Rural Tanzanians With Glaucoma Blindness T2 - JOURNAL OF GLAUCOMA TI - A Population-based Study of Care-seeking Behavior in Rural Tanzanians With Glaucoma Blindness VL - 20 ID - 6199 ER - TY - JOUR AB - Objectives: To compare rates of eye care visits and vision impairment among working-age adults with vision insurance vs without, among the total sample of Behavioral Risk Factor Surveillance Survey respondents and among a subsample of respondents who had diagnoses of glaucoma, age-related macular degeneration (ARMD), and/or cataract.Design: Using the Behavioral Risk Factor Surveillance Survey 2008 vision module data, we examined the likelihood of an eye care visit within the past year and of self reported visual impairment among 27 152 adults aged 40 to 65 years and among a subset of 3158 persons (11.6%) with glaucoma, ARMD, and/or cataract. Multivariate logistic regression models were used.Results: About 40% of both the study population and the subsample with glaucoma, ARMD, and/or cataract had no vision insurance. Respondents with vision insurance were more likely than those without to have had eye care visits (general population adjusted odds ratio [AOR], 1.90 [95% CI, 1.89-1.90]; glaucoma-ARMD-cataract subsample AOR, 2.15 [95% CI, 2.13-2.17]), to have no difficulty recognizing friends across the street (general population AOR, 1.24 [95% CI, 1.22-1.26]; eye-disease subsample AOR, 1.45 [95% CI, 1.42-1.49]), and to have no difficulty reading printed matter (general population AOR, 1.34 [95% CI, 1.33-1.35]; eye-disease subsample AOR, 1.37 [95% CI, 1.34-1.39]). Respondents from the total sample who had an eye care visit were better able to recognize friends across the street (AOR, 1.07) and had no difficulty reading printed matter (AOR, 1.70), and respondents from the eye-disease subsample who had an eye care visit also were better able to recognize friends across the street (AOR, 1.71) and had no difficulty reading printed matter (AOR, 1.45).Conclusions: Lack of vision insurance impedes eye care utilization, which, in turn, may irrevocably affect vision. Vision insurance for preventive eye care should cease to be a separate insurance benefit and should be mandatory in all health plans. AD - Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, USA. AN - 104171702. Language: English. Entry Date: 20130621. Revision Date: 20191030. Publication Type: journal article AU - Li, Yi-Jhen AU - Xirasagar, Sudha AU - Pumkam, Chaiporn AU - Krishnaswamy, Malavika AU - Bennett, Charles L. DB - ccm DP - EBSCOhost IS - 4 KW - Health Services -- Utilization Insurance Coverage -- Statistics and Numerical Data Office Visits -- Statistics and Numerical Data Ophthalmology -- Statistics and Numerical Data Vision Disorders -- Diagnosis Disabled -- Statistics and Numerical Data Adult Aged Cataract -- Diagnosis Cataract -- Epidemiology Cataract -- Prevention and Control Educational Status Female Glaucoma -- Diagnosis Glaucoma -- Epidemiology Glaucoma -- Prevention and Control Health Services Research Human Insurance, Health -- Statistics and Numerical Data Macular Degeneration -- Diagnosis Macular Degeneration -- Epidemiology Macular Degeneration -- Prevention and Control Male Medically Uninsured Middle Age Preventive Health Care United States Vision Disorders -- Epidemiology N1 - research. Journal Subset: Biomedical; USA. NLM UID: 101589539. PMID: NLM23710504. PY - 2013 SN - 2168-6165 SP - 499-506 ST - Vision insurance, eye care visits, and vision impairment among working-age adults in the United States T2 - JAMA Ophthalmology TI - Vision insurance, eye care visits, and vision impairment among working-age adults in the United States UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104171702&site=ehost-live&scope=site VL - 131 ID - 4517 ER - TY - JOUR AB - Background: Vision health is recognized as a critical unmet need in North America. The ocular morbidity associated with glaucoma results from increased intraocular pressure (IOP) and early detection is crucial for the management of glaucoma. Our objective was to find a diagnostically accurate screening tool for intraocular hypertension that can be used in rural communities. We sought to validate the diagnostic accuracy of the iCare rebound tonometer against the gold standard Perkins applanation tonometer (PAT) in measuring IOP. Methods: Patients from two rural communities in Ontario, Canada visiting their optometrists for routine appointments had their IOP measured by a non-contact tonometer (NCT), an iCare rebound tonometer, and a Perkins applanation tonometer (PAT). Values of sensitivity, specificity, and likelihood ratios for a positive and negative result were calculated for the iCare and the NCT. Results: Complete data was collected from 209 patients. Overall, the iCare tonometer had high levels of validity, as compared to the gold standard PAT. The iCare tonometer displayed excellent sensitivity of 98.3% (90-99%, 95% CI) and excellent negative likelihood ratio of 0.024 (0.0088-0.066, 95% CI) which is useful for ruling out intraocular hypertension. Conclusions: The iCare tonometer is a reasonably valid tool for detecting elevated IOP. Its ease of use, simplicity, and accessibility makes it a good screening tool to improve eye health in rural areas. AN - WOS:000369100600005 AU - Li, Y. F. AU - Carpenter, C. R. AU - Nicholson, K. AU - Milne, W. K. DA - DEC DO - 10.1515/dx-2015-0026 IS - 4 PY - 2015 SN - 2194-8011 2194-802X SP - 227-234 ST - Diagnostic accuracy of the iCare rebound tonometer compared to the Perkins applanation tonometer in assessing intraocular pressure in rural patients T2 - DIAGNOSIS TI - Diagnostic accuracy of the iCare rebound tonometer compared to the Perkins applanation tonometer in assessing intraocular pressure in rural patients VL - 2 ID - 6031 ER - TY - JOUR AB - Background: To assess the utilization of and satisfaction with ophthalmic healthcare provided by integrated delivery system (IDS) since 2000 and vision-related quality of life (VRQoL) for residents of an offshore island of Taiwan.Methods: Facilitators interviewed residents (age ≥ 50 years) with the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) for VRQoL and a questionnaire on clinical information, ophthalmic care utilization and satisfaction.Results: A total of 841 participants (response rate 93.4 %, 841/900) completed the questionnaire survey. Mean age was 63.7 (±10. 7) years. The common eye diseases were cataract (44.7 %), dry eye (15.5 %), and glaucoma (8.7 %). Among the participants, 61.0 % sought ophthalmic care under the IDS in the past year and 17.6 % experienced unmet ophthalmic needs in the past 6 months. Satisfaction with ophthalmic care under the IDS was 88.1 %. Determinants of dissatisfaction under the IDS were distance to healthcare facility and VRQoL. Predictors of VRQoL included age, residential area, marital status, occupation, comorbid condition, commercial insurance, household income, cataracts and glaucoma.Conclusions: The implementation of IDS improves accessibility of ophthalmic care for residents of an offshore island. Geographic proximity to avail healthcare facility and VRQoL affect satisfaction with the IDS. AD - Institute of Health Policy and Management, College of Public Health, National Taiwan University, Room 637, No 17, Hsu-Chow Road, Taipei 10055, Taiwan Department of Ophthalmology, Heping Branch, Taipei City Hospital, Taipei, Taiwan Department of General Surgery, National Taiwan University Hospital, Taipei, Taiwan Department of General Surgery, Zhongxing branch, Taipei City Hospital, Taipei, Taiwan Public Health Bureau, Lienchiang County, Matsu, Taiwan Institute of Health Policy and Management, College of Public Health, National Taiwan University, Room 637, No 17, Hsu-Chow Road, Taipei, 10055, Taiwan AN - 116873791. Language: English. Entry Date: 20180718. Revision Date: 20190711. Publication Type: journal article AU - Li-Ju, Chen AU - Yun-Jau, Chang AU - Chun-Fu, Shieh AU - Jy-Haw, Yu AU - Ming-Chin, Yang AU - Chen, Li-Ju AU - Chang, Yun-Jau AU - Shieh, Chun-Fu AU - Yu, Jy-Haw AU - Yang, Ming-Chin DB - ccm DO - 10.1186/s12913-016-1501-8 DP - EBSCOhost KW - Patient Satisfaction Vision Health Services Accessibility -- Statistics and Numerical Data Quality of Life National Health Programs Ophthalmology Aged, 80 and Over Eye Diseases -- Therapy Aged Female Male Diagnosis, Eye Health Care Delivery, Integrated -- Utilization Middle Age Taiwan Regression N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 101088677. PMID: NLM27412399. PY - 2016 SN - 1472-6963 SP - 1-10 ST - Accessibility of ophthalmic healthcare for residents of an offshore island-an example of integrated delivery system T2 - BMC Health Services Research TI - Accessibility of ophthalmic healthcare for residents of an offshore island-an example of integrated delivery system UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116873791&site=ehost-live&scope=site VL - 16 ID - 4354 ER - TY - JOUR AB - Glaucoma is the first leading cause of irreversible blindness worldwide with increasing importance in public health. Indicators of glaucoma care quality as well as efficiency would benefit public health assessments, but are lacking. We propose three such indicators. First, the glaucoma coverage rate (GCR), which is the number of people known to have glaucoma divided by the total number of people with glaucoma as estimated from population-based studies multiplied by 100%. Second, the glaucoma detection rate (GDR), which is number of newly diagnosed glaucoma patients in one year divided by the population in a defined area in millions. Third, the glaucoma follow-up adherence rate (GFAR), calculated as the number of patients with glaucoma who visit eye care provider(s) at least once a year over the total number of patients with glaucoma in given eye care provider(s) in a specific period. Regularly tracking and reporting these three indicators may help to improve the healthcare system performance at national or regional levels. AN - WOS:000457299700006 AU - Liang, Y. B. AU - Zhang, Y. AU - Musch, D. C. AU - Congdon, N. DO - 10.1186/s40662-017-0071-0 PY - 2017 SN - 2326-0254 ST - Proposing new indicators for glaucoma healthcare service T2 - EYE AND VISION TI - Proposing new indicators for glaucoma healthcare service VL - 4 ID - 5851 ER - TY - JOUR AB - To evaluate with criticism the available evidence shown in the literature about the efficacy of pneumotrabeculoplasty (PNT) as a treatment for primary open angle glaucoma. PNT is a recent non-surgical and noninvasive technique to safely reduce the intraocular pressure (IOP) in eyes suffering from ocular hypertension or primary open angle glaucoma. The technique consists in the application on the ocular surface of a disposable suction ring that induces a temporary trabecular meshwork stretching, increasing outflow of aqueous humor in the Schlemm's canal. In our study, we compared the results on the efficacy and safety of this treatment published to date in the literature. During follow-up, Authors have observed significant reductions in IOP in about 70% of treated eyes. The first treatment consists in 3 applications at day 0, 7 and 90, repeatable every 90 days. Immediately after suction ring application there is a significant elevation of IOP, however, of short duration and without demonstrable visual field worsening. Side effects observed are of little clinical significance and spontaneously resolving in a short time. The PNT is a safe and effective technique to reduce IOP in patients with ocular hypertension or open-angle glaucoma. It is repeatable, but can not replace drug treatment in patients already receiving topical therapy for glaucoma; however, it has proven effectiveness in maintaining an IOP target over time if accompanied with only a single topical drug, favoring a reduction of antiglaucoma drugs in polytherapy and increasing the compliance with treatment. AD - Department of Ophthalmology, Sapienza University of Rome, Rome, Italy AU - Librando, A. AU - Migliorini, R. AU - Pacella, F. AU - Turchetti, P. AU - Cerutti, F. AU - Mazzeo, G. AU - Mazzeo, F. DB - Scopus IS - 5 M3 - Review N1 - Export Date: 19 July 2021 PY - 2012 SP - e269-277 ST - Pneumotrabeculoplasty as treatment for primary open angle glaucoma: critical review of the literature T2 - La Clinica terapeutica TI - Pneumotrabeculoplasty as treatment for primary open angle glaucoma: critical review of the literature UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891399444&partnerID=40&md5=acc181f0e5eb54ef93a1bcab1521e0d8 VL - 163 ID - 5758 ER - TY - JOUR AB - The literature is reviewed concerning the pathophysiologic effects of contact-lens wear, the microbiology of contact lens wear, the change in microflora with contact-lens wear. The contamination of contact lenses and contact-lens products, patient compliance, and corneal interaction with the contact lens. Hypoxia and hypercapnia are the most significant changes in the cornea as a result of contact-lens wear. Changes take place in the conjunctival flora in patients with contact lenses. Compliance of patients and contamination of contact lenses and contact-lens products are significant risk factors. The corneal interaction with the contact lens can overwhelm the protective mechanisms of the cornea, increasing the ability of microbes to adhere to the cornea and progress to microbial keratitis. Some of the factors associated with microbial keratitis are modifiable and should stimulate the contact-lens industry to develop better contact lenses and contact lens products and also permit ophthalmologists to obtain better informed consent from their patients. AD - T.J. Liesegang, 4500 San Pablo Road, Jacksonville, FL 32224, United States AU - Liesegang, T. J. DB - Embase Medline IS - 3 KW - contact lens solution bacterium contamination conjunctiva contact lens cornea human keratitis microbiology microflora patient compliance priority journal review risk factor LA - English M3 - Review N1 - L27190791 1997-05-21 PY - 1997 SN - 0277-3740 SP - 265-273 ST - Contact lens-related microbial keratitis: Part II: Pathophysiology T2 - Cornea TI - Contact lens-related microbial keratitis: Part II: Pathophysiology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L27190791&from=export VL - 16 ID - 3963 ER - TY - JOUR AB - AIM: To evaluate changes in patient compliance with medical treatment while using the Proview Eye Pressure Monitor. METHODS: A crossover study design was used to compare the compliance of patients with established use of topical medication to lower intraocular pressure in the treatment of primary open-angle glaucoma. Thirty-two patients currently managed with latanoprost 0.005%, brimonidine 0.15%, travoprost 0.004% or bimatoprost 0.03% as monotherapy or in combination were randomly assigned to two study groups. Group 1 was instructed in the use of Proview Eye Pressure Monitor three times daily for 30 days as an adjunct to the glaucoma regimen. Group 2 was observed with no change in the patients' treatment regimen during this phase of study. A crossover occurred at 30 days. Compliance was monitored by assigning new bottles of topical medication during each phase of study. Bottles were weighed with a Mettler balance (Mettler Toledo Co.) at the initiation and completion of each phase. The changes in bottle-weight determined the amount of medication consumed by each patient for each phase of the study. The weights were analysed to estimate changes in compliance. RESULTS: A paired samples Student t-test compared the consumed bottle weights with and without Proview Eye Pressure Monitor usage. No statistical significance or trend was identifiable (p = 0.98). Use of the Proview Eye Pressure Monitor did not significantly change compliance with adjunct eye drop medication. CONCLUSION: The use of the Proview Eye Pressure Monitor use did not improve but appeared to hinder compliance with glaucoma treatment in this study. AD - C.W. Lievens, Southern College of Optometry, Memphis, Tennessee, USA. AU - Lievens, C. W. AU - Gunvant, P. AU - Newman, J. AU - Gerstner, M. AU - Simpson, C. DB - Medline IS - 6 KW - antihypertensive agent eye drops adult aged article clinical trial controlled clinical trial controlled study crossover procedure follow up human intraocular pressure methodology middle aged oculoplethysmography open angle glaucoma pathophysiology patient compliance physiology prognosis prospective study randomized controlled trial LA - English M3 - Article N1 - L44978727 2006-11-01 PY - 2006 SN - 0816-4622 SP - 381-385 ST - Effect of Proview self-tonometry on pharmaceutical compliance T2 - Clinical & experimental optometry : journal of the Australian Optometrical Association TI - Effect of Proview self-tonometry on pharmaceutical compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44978727&from=export VL - 89 ID - 3579 ER - TY - JOUR AB - Background: Published audits have demonstrated that corneal abrasions are a common presenting eye complaint. Eye patches are often recommended for treating corneal abrasions despite the lack of evidence for their use. This systematic review was conducted to determine the effects of the eye patch when used to treat corneal abrasions. Objectives: The objective of this review was to assess the effects of patching for corneal abrasion on healing and pain relief. Search methods: We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 4), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to May 2016), EMBASE (January 1980 to May 2016), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to May 2016), System for Information on Grey Literature in Europe (OpenGrey) (January 1995 to May 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 9 May 2016. We also searched the reference lists of included studies, unpublished 'grey' literature and conference proceedings and contacted pharmaceutical companies for details of unpublished trials. Selection criteria: We included randomised and quasi-randomised controlled trials that compared patching the eye with no patching to treat simple corneal abrasions. Data collection and analysis: Two authors independently assessed the risk of bias and extracted data. Investigators were contacted for further information regarding the quality of trials. The primary outcome was healing at 24, 48 and 72 hours while secondary outcomes included measures of pain, quality of life and adverse effects. We graded the certainty of the evidence using GRADE. Main results: We included 12 trials which randomised a total of 1080 participants in the review. Four trials were conducted in the United Kingdom, another four in the United States of America, two in Canada, one in Brazil and one in Switzerland. Seven trials were at high risk of bias in one or more domains and one trial was judged to be low risk of bias in all domains. The rest were a combination of low risk or unclear. People receiving a patch may be less likely to have a healed corneal abrasion after 24 hours compared to those not receiving a patch (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.79 to 1.00, 7 trials, 531 participants, low certainty evidence). Similar numbers of people in the patch and no-patch groups were healed by 48 hours (RR 0.97, 95% CI 0.91 to 1.02, 6 trials, 497 participants, moderate certainty evidence) and 72 hours (RR 1.01, 95% CI 0.97 to 1.05, 4 trials, 430 participants, moderate certainty evidence). Participants receiving a patch took slightly longer to heal but the difference was small and probably unimportant (mean difference (MD) 0.14 days longer, 95% CI 0 to 0.27 days longer, 6 trials, 642 participants, moderate certainty evidence). Ten trials reported pain scores. Most studies reported pain on a visual analogue scale (VAS). It was not possible to pool the data because it was skewed. In general, similar pain ratings were seen between patch and no-patch groups. Data from two trials reporting presence or absence of pain at 24 hours was inconclusive. There was a higher risk of reported pain in the patch group but wide confidence intervals compatible with higher or lower risk of pain (RR 1.51, 95% CI 0.86 to 2.65, 2 trials, 193 participants, low certainty evidence). Five trials compared analgesic use between the patch and no-patch groups. Data from three of these trials could be combined and suggested similar analgesic use in the patch and no-patch groups but with some uncertainty (RR 0.95, 95% CI 0.69 to 1.32, 256 participants, low certainty evidence). Frequently re orted symptoms included photophobia, lacrimation, foreign body sensation and blurred vision but there was little evidence to suggest any difference in these symptoms in people with or without a patch. Activities of daily living (ADL) were assessed in one study involving children. There was little difference in ADL with the exception of walking which was reported to be more difficult with a patch on: VAS 1.7 cm (SD 2.1) versus 0.3 cm (SD 0.7). Complication rates were low across studies and there is uncertainty about the relative effects of patching or not patching with respect to these (RR 3.24, 95% CI 0.87 to 12.05, 8 trials, 660 participants, low certainty evidence). Three trials reporting rates of compliance to treatment found that 22% of participants did not have their eye patches during follow-up. No-patch groups generally received more adjuvant treatment with antibiotics or cycloplegics, or both, than the patch group. There were limited data on the effect of patching on abrasions greater than 10mm2 in size. Authors' conclusions: Trials included in this review suggest that treating simple corneal abrasions with a patch may not improve healing or reduce pain. It must be noted that, in these trials, participants who did not receive a patch were more likely to receive additional treatment, for example with antibiotics. Overall we judged the certainty of evidence to be moderate to low. Further research should focus on designing and implementing better quality trials and examining the effectiveness of patching for large abrasions. © 2016 The Cochrane Collaboration. AD - The Royal Melbourne Hospital, Melbourne, VIC, Australia Royal Victorian Eye and Ear Hospital, 32 Gisborne St, East Melbourne, VIC 3002, Australia National University Health System/Jurong General Health Services, Department of Ophthalmology, Singapore, Singapore AU - Lim, C. H. L. AU - Turner, A. AU - Lim, B. X. C7 - Cd004764 DB - Scopus DO - 10.1002/14651858.CD004764.pub3 IS - 7 M3 - Review N1 - Cited By :22 Export Date: 19 July 2021 PY - 2016 ST - Patching for corneal abrasion T2 - Cochrane Database of Systematic Reviews TI - Patching for corneal abrasion UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979659153&doi=10.1002%2f14651858.CD004764.pub3&partnerID=40&md5=df385392aaaa32a46127666b021bb07c VL - 2016 ID - 5121 ER - TY - JOUR AB - PURPOSE: To determine whether multiple interventions influence adherence to glaucoma medication and to study the relationship between personality type and adherence. METHODS: Eighty patients with glaucoma using prostaglandin monotherapy were prospectively randomized to an intervention or a nonintervention group. Over a 5-month period, the intervention group received monthly automated telephone calls reminding them to take their glaucoma medications. At month 3, the intervention group had an office visit with their physician and received education regarding their disease and treatment. The nonintervention group returned at the end of the study period. Adherence was directly measured with an electronic monitoring cap. Outcome measures were adherence rate and therapeutic coverage. Patients completed the Minnesota Multiphasic Personality Inventory-2. RESULTS: Thirty-eight patients were randomized to the intervention group and 42 were randomized to the nonintervention group. Mean adherence rate for the intervention group over 5 months was 76% and for the nonintervention group, 81%. For the intervention group, adherence did not change significantly after the midstudy visit (P=0.233). No difference existed between the intervention and nonintervention groups before (P=0.456) or after (P=0.134) the midstudy intervention visit. The Minnesota Multiphasic Personality Inventory-2 personality scales for depression (P=0.01) and hypochondriasis (P>0.0001) were significantly associated with poorer adherence. CONCLUSIONS: Monthly automated telephone reminders, a 1-time educational session, and increased contact with a physician did not improve adherence rate with glaucoma medications. Depression and hypochondriasis personality types were related to poor adherence and highlight the role of psychosocial factors in medication adherence. Copyright © 2013 by Lippincott Williams & Wilkins. AD - Davis Health System Eye Center, University of California, 4860 Y Street, Sacramento, CA 95817, United States Department of Statistics and Biostatistics, California State University East Bay, Hayward, CA, United States AU - Lim, M. C. AU - Watnik, M. R. AU - Imson, K. R. AU - Porter, S. M. AU - Granier, A. M. DB - Scopus DO - 10.1097/IJG.0b013e31824cd0ae IS - 6 KW - Adherence Automated telephone calls Depression Electronic monitor Glaucoma Hypochondriasis Personality type M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2013 SP - 439-446 ST - Adherence to glaucoma medication: The effect of interventions and association with personality type T2 - Journal of Glaucoma TI - Adherence to glaucoma medication: The effect of interventions and association with personality type UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881665333&doi=10.1097%2fIJG.0b013e31824cd0ae&partnerID=40&md5=70ccb78e599246c47f6545c5c0d1f017 VL - 22 ID - 5106 ER - TY - JOUR AB - Purpose: To determine whether multiple interventions influence adherence to glaucoma medication and to study the relationship between personality type and adherence.Methods: Eighty patients with glaucoma using prostaglandin monotherapy were prospectively randomized to an intervention or a nonintervention group. Over a 5-month period, the intervention group received monthly automated telephone calls reminding them to take their glaucoma medications. At month 3, the intervention group had an office visit with their physician and received education regarding their disease and treatment. The nonintervention group returned at the end of the study period. Adherence was directly measured with an electronic monitoring cap. Outcome measures were adherence rate and therapeutic coverage. Patients completed the Minnesota Multiphasic Personality Inventory-2.Results: Thirty-eight patients were randomized to the intervention group and 42 were randomized to the nonintervention group. Mean adherence rate for the intervention group over 5 months was 76% and for the nonintervention group, 81%. For the intervention group, adherence did not change significantly after the midstudy visit (P=0.233). No difference existed between the intervention and nonintervention groups before (P=0.456) or after (P=0.134) the midstudy intervention visit. The Minnesota Multiphasic Personality Inventory-2 personality scales for depression (P=0.01) and hypochondriasis (P>0.0001) were significantly associated with poorer adherence.Conclusions: Monthly automated telephone reminders, a 1-time educational session, and increased contact with a physician did not improve adherence rate with glaucoma medications. Depression and hypochondriasis personality types were related to poor adherence and highlight the role of psychosocial factors in medication adherence. AN - WOS:000323221100003 AU - Lim, M. C. AU - Watnik, M. R. AU - Imson, K. R. AU - Porter, S. M. AU - Granier, A. M. DA - AUG DO - 10.1097/IJG.0b013e31824cd0ae IS - 6 PY - 2013 SN - 1057-0829 1536-481X SP - 439-446 ST - Adherence to Glaucoma Medication: The Effect of Interventions and Association With Personality Type T2 - JOURNAL OF GLAUCOMA TI - Adherence to Glaucoma Medication: The Effect of Interventions and Association With Personality Type VL - 22 ID - 5906 ER - TY - JOUR AB - Objective: Regular follow-up is essential to successful management of childhood cataract. We sought to assess whether a mobile phone short message service (SMS) for parents of children with cataract could improve follow-up adherence and the proportion of procedures performed in timely fashion. Design: Randomized, controlled trial. This trial is registered with ClinicalTrials.gov, NCT01417819. Participants: We included 258 parent-child pairs involved in the Childhood Cataract Program of the Chinese Ministry of Health. Methods: Participants were randomized (1:1) to a mobile phone SMS intervention or standard follow-up appointments. All participants were scheduled to attend <4 follow-up appointments according to the protocol. Parents in the intervention group received SMS automated reminders before scheduled appointments. The control group parents did not receive SMSs or any alternative reminder of scheduled appointments. Regular ocular examinations and analyses were performed by investigators masked to group allocation; however, study participants and the manager in charge of randomization and sending SMSs were not masked. Main Outcome Measures: Number of follow-up appointments attended, additional surgeries, laser treatments, changes in eyeglasses prescription, and occurrence of secondary ocular hypertension. Results: Among parent-child participants, 135 were randomly assigned to the SMS intervention and 123 to standard appointments. Attendance rates for the SMS group (first visit, 97.8%; second, 91.9%; third, 92.6%; fourth, 83%) were significantly higher than those for the control group (first visit, 87.8%; second, 69.9%; third, 56.9%; fourth, 33.3%). The increase in attendance rate for total number of follow-up visits with SMS reminders was 47.2% (relative risk [RR] for attendance, 1.47; 95% confidence interval [CI], 1.16-1.78; P = 0.003). The number needed to remind (NNR) to gain 1 additional visit by 1 child was 3 (95% CI, 1.8-4.2). A total of 247 clinical interventions were carried out in the SMS group and 134 in the control group (RR, 1.68; 95% CI, 1.37-1.99; P = 0.007). The NNR to result in 1 additional clinical intervention was 5 (95% CI, 3.5-6.5). Conclusions: The SMS reminders significantly improved follow-up adherence in pediatric cataract treatment. Using readily available mobile phone resources may be an effective and economic strategy to improve management of childhood cataract in China. Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. © 2012 American Academy of Ophthalmology. AD - Y. Liu, Zhongshan Ophthalmic Center, Xian Lie Nan South Road 54#, Guangzhou, Guangdong Province, 510060, China AU - Lin, H. AU - Chen, W. AU - Luo, L. AU - Congdon, N. AU - Zhang, X. AU - Zhong, X. AU - Liu, Z. AU - Chen, W. AU - Wu, C. AU - Zheng, D. AU - Deng, D. AU - Ye, S. AU - Lin, Z. AU - Zou, X. AU - Liu, Y. DB - Embase Medline DO - 10.1016/j.ophtha.2012.06.046 IS - 12 KW - NCT01417819 adult article cataract clinical effectiveness controlled study eye examination female follow up human intraocular hypertension low level laser therapy major clinical study male mobile phone patient compliance priority journal randomized controlled trial reminder system short message service reminder spectacles LA - English M3 - Article N1 - L52175115 2012-08-27 2012-12-19 PY - 2012 SN - 0161-6420 1549-4713 SP - 2463-2470 ST - Effectiveness of a short message reminder in increasing compliance with pediatric cataract treatment: A randomized trial T2 - Ophthalmology TI - Effectiveness of a short message reminder in increasing compliance with pediatric cataract treatment: A randomized trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52175115&from=export http://dx.doi.org/10.1016/j.ophtha.2012.06.046 VL - 119 ID - 3054 ER - TY - JOUR AB - Objective: Regular follow-up is essential to successful management of childhood cataract. We sought to assess whether a mobile phone short message service (SMS) for parents of children with cataract could improve follow-up adherence and the proportion of procedures performed in timely fashion. Design: Randomized, controlled trial. This trial is registered with ClinicalTrials.gov, NCT01417819. Participants: We included 258 parent-child pairs involved in the Childhood Cataract Program of the Chinese Ministry of Health. Methods: Participants were randomized (1:1) to a mobile phone SMS intervention or standard follow-up appointments. All participants were scheduled to attend <4 follow-up appointments according to the protocol. Parents in the intervention group received SMS automated reminders before scheduled appointments. The control group parents did not receive SMSs or any alternative reminder of scheduled appointments. Regular ocular examinations and analyses were performed by investigators masked to group allocation; however, study participants and the manager in charge of randomization and sending SMSs were not masked. Main Outcome Measures: Number of follow-up appointments attended, additional surgeries, laser treatments, changes in eyeglasses prescription, and occurrence of secondary ocular hypertension. Results: Among parent-child participants, 135 were randomly assigned to the SMS intervention and 123 to standard appointments. Attendance rates for the SMS group (first visit, 97.8%; second, 91.9%; third, 92.6%; fourth, 83%) were significantly higher than those for the control group (first visit, 87.8%; second, 69.9%; third, 56.9%; fourth, 33.3%). The increase in attendance rate for total number of follow-up visits with SMS reminders was 47.2% (relative risk [RR] for attendance, 1.47; 95% confidence interval [CI], 1.16-1.78; P = 0.003). The number needed to remind (NNR) to gain 1 additional visit by 1 child was 3 (95% CI, 1.8-4.2). A total of 247 clinical interventions were carried out in the SMS group and 134 in the control group (RR, 1.68; 95% CI, 1.37-1.99; P = 0.007). The NNR to result in 1 additional clinical intervention was 5 (95% CI, 3.5-6.5). Conclusions: The SMS reminders significantly improved follow-up adherence in pediatric cataract treatment. Using readily available mobile phone resources may be an effective and economic strategy to improve management of childhood cataract in China. Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. © 2012 American Academy of Ophthalmology. AD - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China School of Public Health, Sun Yat-sen University, Guangzhou, China AU - Lin, H. AU - Chen, W. AU - Luo, L. AU - Congdon, N. AU - Zhang, X. AU - Zhong, X. AU - Liu, Z. AU - Chen, W. AU - Wu, C. AU - Zheng, D. AU - Deng, D. AU - Ye, S. AU - Lin, Z. AU - Zou, X. AU - Liu, Y. DB - Scopus DO - 10.1016/j.ophtha.2012.06.046 IS - 12 M3 - Article N1 - Cited By :69 Export Date: 19 July 2021 PY - 2012 SP - 2463-2470 ST - Effectiveness of a short message reminder in increasing compliance with pediatric cataract treatment: A randomized trial T2 - Ophthalmology TI - Effectiveness of a short message reminder in increasing compliance with pediatric cataract treatment: A randomized trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84870704375&doi=10.1016%2fj.ophtha.2012.06.046&partnerID=40&md5=be9b4eb5dca91667016500f8a8b88cfe VL - 119 ID - 4958 ER - TY - JOUR AB - Monitoring intraocular pressure (IOP) is essential for pediatric cataract treatment but always difficult due to lack of cooperation in young children. We present the baseline characteristics and the first-year results of a long-term prospective cohort study, which are aimed to determine the relationship of the incidence of ocular hypertension (OH) in children after cataract surgery during the first-year period and the risk of developing late-onset glaucoma. Children were included with the following criteria: they were≤10 years old and scheduled to undergo cataract surgery with/without intraocular lens implantation; they were compliant with our follow-up protocol, which included monitoring IOP using a Tono-Pen under sedation or anesthesia. Incidence of OH, peak OH value, OH onset time and OH duration within a 12-month period following surgery were measured. In brief, 206 patients (379 eyes) were included and OH developed in 66 of 379 (17.4%) eyes. The mean follow-up period was 14.0±3.2 months (median, 12 months; range, 10-16 months). Moreover, 33 of 196 (16.8%) aphakic eyes and 33 of 183 (18.0%) IOL eyes were diagnosed with OH. The peak OH onset times were at 1-week (34/66, 51.5%) and 1-month (14/66, 21.2%) appointments postsurgery. The peak IOP value in the OH eyes was 29.9±7.5 mmHg (median, 29 mmHg; range, 21-48 mmHg). The duration of OH was 30.9±31.2 days (median, 30 days; range, 3-150 days). OH recurred in 13 eyes with a history of OH diagnosed within 1 month postsurgery (13/54, 24.1%), which needed temporary or long term use of antiglaucoma medications. In conclusion, the incidence of OH in children after cataract surgery was 17.4% during the first-year period. Children who have suffered elevated IOP in the first year after cataract surgery should be followed closely to determine if there is an increased risk of developing late-onset glaucoma. © 2013 Lin et al. AD - Y. Liu, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China AU - Lin, H. AU - Chen, W. AU - Luo, L. AU - Zhang, X. AU - Chen, J. AU - Lin, Z. AU - Qu, B. AU - Zhan, J. AU - Zheng, D. AU - Zhong, X. AU - Tian, Z. AU - Liu, Y. DB - Embase Medline DO - 10.1371/journal.pone.0069867 IS - 7 KW - antiglaucoma agent brimonidine brinzolamide carteolol eye drops pranoprofen steroid article cataract extraction child cohort analysis disease duration drug withdrawal female follow up glaucoma human incidence intraocular hypertension intraocular pressure lens implant major clinical study male patient compliance pediatric surgery postoperative period preschool child prospective study risk assessment school child LA - English M3 - Article N1 - L369442759 2013-08-06 2013-08-09 jsessionid=469F87063D065393A13FCB203CCAFF3A?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0069867&representation=PDF2292 PY - 2013 SN - 1932-6203 ST - Ocular Hypertension after Pediatric Cataract Surgery: Baseline Characteristics and First-Year Report T2 - PLoS ONE TI - Ocular Hypertension after Pediatric Cataract Surgery: Baseline Characteristics and First-Year Report UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369442759&from=export http://dx.doi.org/10.1371/journal.pone.0069867 http://www.plosone.org/article/fetchObjectAttachment.action VL - 8 ID - 2983 ER - TY - JOUR AB - Monitoring intraocular pressure (IOP) is essential for pediatric cataract treatment but always difficult due to lack of cooperation in young children. We present the baseline characteristics and the first-year results of a long-term prospective cohort study, which are aimed to determine the relationship of the incidence of ocular hypertension (OH) in children after cataract surgery during the first-year period and the risk of developing late-onset glaucoma. Children were included with the following criteria: they were≤10 years old and scheduled to undergo cataract surgery with/without intraocular lens implantation; they were compliant with our follow-up protocol, which included monitoring IOP using a Tono-Pen under sedation or anesthesia. Incidence of OH, peak OH value, OH onset time and OH duration within a 12-month period following surgery were measured. In brief, 206 patients (379 eyes) were included and OH developed in 66 of 379 (17.4%) eyes. The mean follow-up period was 14.0±3.2 months (median, 12 months; range, 10-16 months). Moreover, 33 of 196 (16.8%) aphakic eyes and 33 of 183 (18.0%) IOL eyes were diagnosed with OH. The peak OH onset times were at 1-week (34/66, 51.5%) and 1-month (14/66, 21.2%) appointments postsurgery. The peak IOP value in the OH eyes was 29.9±7.5 mmHg (median, 29 mmHg; range, 21-48 mmHg). The duration of OH was 30.9±31.2 days (median, 30 days; range, 3-150 days). OH recurred in 13 eyes with a history of OH diagnosed within 1 month postsurgery (13/54, 24.1%), which needed temporary or long term use of antiglaucoma medications. In conclusion, the incidence of OH in children after cataract surgery was 17.4% during the first-year period. Children who have suffered elevated IOP in the first year after cataract surgery should be followed closely to determine if there is an increased risk of developing late-onset glaucoma. © 2013 Lin et al. AD - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China AU - Lin, H. AU - Chen, W. AU - Luo, L. AU - Zhang, X. AU - Chen, J. AU - Lin, Z. AU - Qu, B. AU - Zhan, J. AU - Zheng, D. AU - Zhong, X. AU - Tian, Z. AU - Liu, Y. C7 - e69867 DB - Scopus DO - 10.1371/journal.pone.0069867 IS - 7 M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2013 ST - Ocular Hypertension after Pediatric Cataract Surgery: Baseline Characteristics and First-Year Report T2 - PLoS ONE TI - Ocular Hypertension after Pediatric Cataract Surgery: Baseline Characteristics and First-Year Report UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880819152&doi=10.1371%2fjournal.pone.0069867&partnerID=40&md5=1a077e7115ed7c28352ddf6cc3f4bb68 VL - 8 ID - 5108 ER - TY - JOUR AB - Objective: Regular follow-up is essential to successful management of childhood cataract. We sought to assess whether a mobile phone short message service (SMS) for parents of children with cataract could improve follow-up adherence and the proportion of procedures performed in timely fashion. Design: Randomized, controlled trial. This trial is registered with ClinicalTrials.gov, NCT01417819. Participants: We included 258 parent-child pairs involved in the Childhood Cataract Program of the Chinese Ministry of Health. Methods: Participants were randomized (1: 1) to a mobile phone SMS intervention or standard follow-up appointments. All participants were scheduled to attend >4 follow-up appointments according to the protocol. Parents in the intervention group received SMS automated reminders before scheduled appointments. The control group parents did not receive SMSs or any alternative reminder of scheduled appointments. Regular ocular examinations and analyses were performed by investigators masked to group allocation; however, study participants and the manager in charge of randomization and sending SMSs were not masked. Main Outcome Measures: Number of follow-up appointments attended, additional surgeries, laser treatments, changes in eyeglasses prescription, and occurrence of secondary ocular hypertension. Results: Among parent-child participants, 135 were randomly assigned to the SMS intervention and 123 to standard appointments. Attendance rates for the SMS group (first visit, 97.8%; second, 91.9%; third, 92.6%; fourth, 83%) were significantly higher than those for the control group (first visit, 87.8%; second, 69.9%; third, 56.9%; fourth, 33.3%). The increase in attendance rate for total number of follow-up visits with SMS reminders was 47.2% (relative risk [RR] for attendance, 1.47; 95% confidence interval [CI], 1.16-1.78; P = 0.003). The number needed to remind (NNR) to gain 1 additional visit by 1 child was 3 (95% CI, 1.8-4.2). A total of 247 clinical interventions were carried out in the SMS group and 134 in the control group (RR, 1.68; 95% CI, 1.37-1.99; P = 0.007). The NNR to result in 1 additional clinical intervention was 5 (95% CI, 3.5-6.5). Conclusions: The SMS reminders significantly improved follow-up adherence in pediatric cataract treatment. Using readily available mobile phone resources may be an effective and economic strategy to improve management of childhood cataract in China. Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2012;119:2463-2470 (C) 2012 by the American Academy of Ophthalmology. AN - WOS:000311954300007 AU - Lin, H. T. AU - Chen, W. R. AU - Luo, L. X. AU - Congdon, N. AU - Zhang, X. Y. AU - Zhong, X. J. AU - Liu, Z. C. AU - Chen, W. AU - Wu, C. R. AU - Zheng, D. Y. AU - Deng, D. M. AU - Ye, S. B. AU - Lin, Z. L. AU - Zou, X. AU - Liu, Y. Z. DA - DEC DO - 10.1016/j.ophtha.2012.06.046 IS - 12 PY - 2012 SN - 0161-6420 1549-4713 SP - 2463-2470 ST - Effectiveness of a Short Message Reminder in Increasing Compliance with Pediatric Cataract Treatment A Randomized Trial T2 - OPHTHALMOLOGY TI - Effectiveness of a Short Message Reminder in Increasing Compliance with Pediatric Cataract Treatment A Randomized Trial VL - 119 ID - 5860 ER - TY - JOUR AB - Monitoring intraocular pressure (IOP) is essential for pediatric cataract treatment but always difficult due to lack of cooperation in young children. We present the baseline characteristics and the first-year results of a long-term prospective cohort study, which are aimed to determine the relationship of the incidence of ocular hypertension (OH) in children after cataract surgery during the first-year period and the risk of developing late-onset glaucoma. Children were included with the following criteria: they were <= 10 years old and scheduled to undergo cataract surgery with/without intraocular lens implantation; they were compliant with our follow-up protocol, which included monitoring IOP using a Tono-Pen under sedation or anesthesia. Incidence of OH, peak OH value, OH onset time and OH duration within a 12-month period following surgery were measured. In brief, 206 patients (379 eyes) were included and OH developed in 66 of 379 (17.4%) eyes. The mean follow-up period was 14.0 +/- 3.2 months (median, 12 months; range, 10-16 months). Moreover, 33 of 196 (16.8%) aphakic eyes and 33 of 183 (18.0%) IOL eyes were diagnosed with OH. The peak OH onset times were at 1-week (34/66, 51.5%) and 1-month (14/66, 21.2%) appointments postsurgery. The peak IOP value in the OH eyes was 29.9 +/- 7.5 mmHg (median, 29 mmHg; range, 21-48 mmHg). The duration of OH was 30.9 +/- 31.2 days (median, 30 days; range, 3-150 days). OH recurred in 13 eyes with a history of OH diagnosed within 1 month postsurgery (13/54, 24.1%), which needed temporary or long term use of antiglaucoma medications. In conclusion, the incidence of OH in children after cataract surgery was 17.4% during the first-year period. Children who have suffered elevated IOP in the first year after cataract surgery should be followed closely to determine if there is an increased risk of developing late-onset glaucoma. AN - WOS:000323369700091 AU - Lin, H. T. AU - Chen, W. R. AU - Luo, L. X. AU - Zhang, X. Y. AU - Chen, J. J. AU - Lin, Z. L. AU - Qu, B. AU - Zhan, J. AU - Zheng, D. Y. AU - Zhong, X. J. AU - Tian, Z. AU - Liu, Y. AU - Study Grp, Ccpmoh DA - JUL 29 DO - 10.1371/journal.pone.0069867 IS - 7 PY - 2013 SN - 1932-6203 ST - Ocular Hypertension after Pediatric Cataract Surgery: Baseline Characteristics and First-Year Report T2 - PLOS ONE TI - Ocular Hypertension after Pediatric Cataract Surgery: Baseline Characteristics and First-Year Report VL - 8 ID - 5972 ER - TY - JOUR AB - Objectives The purpose of this study was to assess visual impairment and quality of life (QOL), the relationship between visual function and health-related and vision-related QOL, and to identify factors significantly impacting QOL for glaucoma patients. Methods One-on-one interviews of 280 glaucoma patients at a regional hospital in Taiwan from 1 April 2005 to 30 September 2005. Data collected included demographics, clinical examinations and treatment status. QOL data collected utilized the Chinese (Taiwanese) version of the Medical Outcomes Study Short-Form 36 Health Survey (SF-36) and the National Eye Institute Visual Function-25 (NEIVFQ-25). Results The majority of study participants had open-angle glaucoma (54.3%) and were classified as moderate stage (33.6%). The higher the health-related QOL scores for both questionnaires, the fewer difficulties experienced by the patients. Moderate correlation was found between the SF-36 and NEIVFQ-25 subscales and visual function. Significant predicting factors for the SF-36 were gender, age, employment status, presence of systemic disease, better-eye visual acuity and better-eye mean defect. For the NEIVFQ-25, these were general vision, near and distance activities, colour vision and peripheral vision scores. Conclusions A combination of demographic data, clinical examination and QOL questionnaires may help clinicians better ascertain the impact of disease severity on glaucoma patients' QOL. This information may help in patient education, treatment compliance and selection of treatment options. AD - Consultant Physician, Department of Ophthalmology, Taipei City Hospital, Ho-PingBranch, Taipei, Taiwan AN - 105121871. Language: English. Entry Date: 20100326. Revision Date: 20200708. Publication Type: Journal Article AU - Lin, J. AU - Yang, M. DB - ccm DO - 10.1111/j.1365-2753.2009.01135.x DP - EBSCOhost IS - 1 KW - Glaucoma -- Psychosocial Factors Glaucoma -- Symptoms Quality of Life Adult Aged Coefficient Alpha Convenience Sample Data Analysis Software Descriptive Statistics Female Glaucoma -- Classification Health Status Hospitals Human Interviews Male Middle Age One-Way Analysis of Variance Pearson's Correlation Coefficient Questionnaires Severity of Illness Severity of Illness Indices Short Form-36 Health Survey (SF-36) Step-Wise Multiple Regression Taiwan Vision N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; Public Health; UK & Ireland. Instrumentation: Short Form-36 Health Survey (SF-36) [Taiwanese]; National Eye Institute Visual Function-25 (NEIVFQ-25) [Taiwanese]. NLM UID: 9609066. PMID: NLM19558459. PY - 2010 SN - 1356-1294 SP - 134-140 ST - Correlation of visual function with health-related quality of life in glaucoma patients T2 - Journal of Evaluation in Clinical Practice TI - Correlation of visual function with health-related quality of life in glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105121871&site=ehost-live&scope=site VL - 16 ID - 4472 ER - TY - JOUR AB - Objectives: The purpose of this study was to assess visual impairment and quality of life (QOL), the relationship between visual function and health-related and vision-related QOL, and to identify factors significantly impacting QOL for glaucoma patients. Methods: One-on-one interviews of 280 glaucoma patients at a regional hospital in Taiwan from 1 April 2005 to 30 September 2005. Data collected included demographics, clinical examinations and treatment status. QOL data collected utilized the Chinese (Taiwanese) version of the Medical Outcomes Study Short-Form 36 Health Survey (SF-36) and the National Eye Institute Visual Function-25 (NEIVFQ-25). Results: The majority of study participants had open-angle glaucoma (54.3%) and were classified as moderate stage (33.6%). The higher the health-related QOL scores for both questionnaires, the fewer difficulties experienced by the patients. Moderate correlation was found between the SF-36 and NEIVFQ-25 subscales and visual function. Significant predicting factors for the SF-36 were gender, age, employment status, presence of systemic disease, better-eye visual acuity and better-eye mean defect. For the NEIVFQ-25, these were general vision, near and distance activities, color vision and peripheral vision scores. Conclusions: A combination of demographic data, clinical examination and QOL questionnaires may help clinicians better ascertain the impact of disease severity on glaucoma patients' QOL. This information may help in patient education, treatment compliance and selection of treatment options. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Lin, Jen-Chieh, Department of Ophthalmology, Taipei City Hospital, Ho-Pin Branch, No. 33, Sec 2, Chung-Hwa Road, Taipei, Taiwan, 10065 AN - 2010-03071-022 AU - Lin, Jen-Chieh AU - Yang, Ming-Chin DB - psyh DO - 10.1111/j.1365-2753.2009.01135.x DP - EBSCOhost IS - 1 KW - glaucoma health-related quality of life vision-related quality of life visual function visual impairment Adult Aged Female Humans Linear Models Male Middle Aged Multivariate Analysis Quality of Life Taiwan Visual Acuity Health Health Related Quality of Life Vision Disorders N1 - Department of Ophthalmology, Taipei City Hospital, Ho-Pin Branch, Taipei, Taiwan. Other Publishers: Blackwell Publishing. Release Date: 20100329. Correction Date: 20190211. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Glaucoma; Health; Quality of Life; Health Related Quality of Life. Minor Descriptor: Vision Disorders. Classification: Vision & Hearing & Sensory Disorders (3299). Population: Human (10); Male (30); Female (40). Location: Taiwan. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Medical Outcomes Study Short-Form 36 Health Survey. Methodology: Empirical Study. References Available: Y. Page Count: 7. Issue Publication Date: Feb, 2010. Publication History: Accepted Date: Sep 17, 2008. PY - 2010 SN - 1356-1294 1365-2753 SP - 134-140 ST - Correlation of visual function with health-related quality of life in glaucoma patients T2 - Journal of Evaluation in Clinical Practice TI - Correlation of visual function with health-related quality of life in glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-03071-022&site=ehost-live&scope=site ORCID: 0000-0001-7326-8671 jclin54@yahoo.com.tw VL - 16 ID - 4858 ER - TY - JOUR AB - Fixed-dose combinations (FDCs) are one of the options for improving blood pressure (BP) goal attainment. We enrolled 141 patients and evaluated the efficacy and safety between a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating mild to moderate hypertension after amlodipine monotherapy failure. After at least 2 weeks of monotherapy failure, the patients were randomized to receive either OA or DA for 8 weeks. We compared the systolic blood pressure (SBP)-lowering efficacy of the OA and DA using both an office BP and an ambulatory blood pressure monitoring (ABPM) device. The intent-to-treat analysis found that the early (2nd week) and final visit (8th week) SBP reductions were significantly greater in those patients receiving OA (n = 70) than DA (n = 71) (17.57 ± 15.49 vs. 10.46 ± 13.36 and 24.89 ± 14.09 vs. 17.03 ± 13.27 mmHg, p = 0.002 and 0.001, respectively). Among those using ABPM, the patients with 8-week OA had a greater SBP-lowering effect in comparison with those on DA (14.08 ± 10.74 vs. 6.32 ± 10.21, p = 0.018). Both treatment strategies were well tolerated. This study showed that an OA FDC is more effective than DA in reducing SBP for mild to moderate hypertension after the failure of amlodipine monotherapy.Copyright © 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved. AD - Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Taiwan Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung 80708, Taiwan Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taiwan Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Division of Cardiology, Department of Internal Medicine Mackay Medicine, Nursing, and Management College, Taipei, Taiwan Department of Internal Medicine, Faculty of Medicine, Kaohsiung Medical University, Taiwan AU - Lin, T. H. AU - Tsai, C. D. AU - Pan, J. P. AU - Hou, C. J. Y. AU - Hsia, C. H. AU - Tsai, J. P. AU - Lai, W. T. DB - Scopus DO - 10.1016/j.kjms.2012.09.005 IS - 5 KW - Ambulatory blood pressure monitoring Amlodipine Fixed-dose combination Hypertension Olmesartan M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2013 SP - 265-270 ST - Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension T2 - Kaohsiung Journal of Medical Sciences TI - Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876956841&doi=10.1016%2fj.kjms.2012.09.005&partnerID=40&md5=9e457dc220c3a39e656f2785df8d0078 VL - 29 ID - 5473 ER - TY - JOUR AB - One of the most recent contributions to the therapeutic arsenal available for the treatment of glaucoma is the prostaglandin (PG) analogues. They represent a new class of ocular hypotensive drugs, targeting the uveoscleral outflow of ocular aqueous humour. Two drugs, latanoprost and unoprostone, are presently commercially available. In terms of intraocular pressure (IOP) reduction, latanoprost is the most powerful drug in clinical use today. The once daily dosing promotes compliance. Additional effect is achieved in combination with other hypotensive drugs, including those that increase trabecular outflow facility. The most frequent side effect is increased iris pigmentation that seems to be irreversible. A low frequency of cystoid macular oedema has been reported, predominantly in patients whose blood-retinal barrier (BRB) is compromised. Systemic side effects are rare. The experience with unoprostone is still much less than that with latanoprost. The ocular hypotensive mechanism of action of unoprostone is not well documented but an increase in uveoscleral outflow may be at least a part of its mode of action. Systemic side effects are rare and the ocular side effects seem to be mild. The ocular hypotensive effect is less than that of latanoprost and may not be suitable for monotherapy. It is widely accepted that the IOP alone is not responsible for the development of glaucomatous visual defects. It remains to be seen if this class of drugs will preserve vision in glaucoma patients better than other classes. More PG analogues are under development for potential clinical use. AD - C. Lindén, Department of Clinical Science, Opthalmology, Umeå University, SE-901 85 Umeå, Sweden AU - Lindén, C. C1 - diamox depot rescula(Ueno,Japan) uf 201(Ueno,Japan) xalatan(Pharmacia,United States) C2 - Pharmacia(United States) Ueno(Japan) DB - Embase Medline DO - 10.1517/13543784.10.4.679 IS - 4 KW - acetazolamide adrenergic receptor stimulating agent alpha 2 adrenergic receptor stimulating agent antiglaucoma agent arachidonic acid autacoid benzalkonium chloride beta adrenergic receptor blocking agent brimonidine carbonate dehydratase inhibitor cholinergic receptor stimulating agent diamox depot diclofenac dipivefrine dorzolamide fluorometholone latanoprost physostigmine pilocarpine placebo prodrug prostaglandin derivative prostaglandin F2 alpha prostaglandin F2 alpha isopropyl ester timolol travopost uf 201 unclassified drug unoprostone isopropyl ester allergy aqueous humor outflow blood eye barrier blood retina barrier cardiovascular disease clinical trial conjunctivitis controlled clinical trial controlled study cornea erosion dose response double blind procedure drug effect drug mechanism drug metabolism drug potentiation drug selectivity drug synthesis headache herpes simplex keratitis human hyperemia intraocular pressure keratopathy monotherapy open angle glaucoma pain patient compliance pigmentation preservation randomized controlled trial respiratory tract disease retina macula cystoid edema review sclera systemic disease uvea uveitis vision rescula xalatan LA - English M3 - Review N1 - L32288186 2001-04-24 PY - 2001 SN - 1354-3784 SP - 679-694 ST - Therapeutic potential of prostaglandin analogues in glaucoma T2 - Expert Opinion on Investigational Drugs TI - Therapeutic potential of prostaglandin analogues in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32288186&from=export http://dx.doi.org/10.1517/13543784.10.4.679 VL - 10 ID - 3894 ER - TY - JOUR AB - Purpose: To report the results from a nationwide survey on glaucoma management in Sweden, performed as a part of an Open Angle Glaucoma project conducted by the Swedish Council on Health Technology Assessment 2004-2008. Methods: In 2005, a survey was distributed to all providers of glaucoma care in Sweden: public eye departments, public outpatient departments and private practices. The questionnaire included questions on number of examined patients, types of examinations during one defined week, internal organization and access to diagnostic equipment. The questionnaire was endorsed by the Swedish Ophthalmological Society. Reminders were sent out to nonresponders. Results: Response rate was high; 97% (33/34) of eye departments, 85% (39/46) of outpatient departments and 55% (69/125) of private practices. Out of 29 282 visits in ophthalmic care during the study week, 7737 (26%) were related to glaucoma. Diagnostic equipment was generally available; all public eye facilities and 92% of private practices had at least one computerized perimeter, while equipment for fundus photography/imaging was available at 100% of eye departments, 82% of outpatient departments and 62% of private practices. The number of visual field tests and fundus images was rather low. Survey results indicate that patients on the average underwent bilateral field testing every 2nd year and fundus imaging every 8th year. Conclusion: Glaucoma care generated about a quarter of all patient visits in Swedish ophthalmic care. Access to diagnostic facilities was good. To meet modern standards of glaucoma care, glaucoma damage must be measured and followed more closely than at the time of the survey. © 2011 The Authors. Acta Ophthalmologica © 2011 Acta Ophthalmologica Scandinavica Foundation. AD - Department of Clinical Sciences, Ophthalmology, Umeå University, SE-901 85 Umeå, Sweden Department of Clinical Sciences Malmö, Ophthalmology, Skåne University Hospital, Lund University, Malmö, Sweden Department of Neurosciences, Ophthalmology, Uppsala University, Uppsala, Sweden Department of Clinical Neuroscience, Ophthalmology, St. Erik Eye Hospital, Stockholm, Sweden SBU - the Swedish Council on Health Technology Assessment, Stockholm, Sweden AU - Lindén, C. AU - Bengtsson, B. AU - Alm, A. AU - Calissendorff, B. AU - Eckerlund, I. AU - Heijl, A. DB - Scopus DO - 10.1111/j.1755-3768.2011.02273.x IS - 1 KW - equipment fundus photograph glaucoma management visits visual field M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2013 SP - 20-24 ST - Glaucoma management in Sweden - Results from a nationwide survey T2 - Acta Ophthalmologica TI - Glaucoma management in Sweden - Results from a nationwide survey UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873056478&doi=10.1111%2fj.1755-3768.2011.02273.x&partnerID=40&md5=599a58012425d34653f735830c39859e VL - 91 ID - 5426 ER - TY - JOUR AB - Aims - To evaluate whether long term treatment with the prostaglandin analogue latanoprost has a deleterious effect on the blood-aqueous barrier (BAB) and to determine the duration of the effect on intraocular pressure (IOP) after withdrawal of treatment. Methods - Patients with ocular hypertension or glaucoma were topically treated with latanoprost 50 mu g/ml once daily for 6-12 months. In 26 patients IOP was followed for 14 days after withdrawal of treatment. Aqueous flare was measured with a laser hare meter during 6-12 months' treatment in 16 patients. Results - On the last day of treatment IOP was 6.9 mm Hg (95% CI 5.3-8.5) lower than before treatment. It increased slowly during the follow up period but was still 1.3 mm Hg (95% CI 0.2-2.5) lower than pretreatment IOP 14 days after cessation of treatment. No change in aqueous flare was seen throughout the study. Conclusion - Latanoprost has no clinically significant effect on the permeability of the BAB and IOP will return to pretreatment levels within a few weeks, indicating that latanoprost is safe for long term treatment. AN - WOS:A1997XC28500013 AU - Linden, C. AU - Nuija, E. AU - Alm, A. DA - MAY DO - 10.1136/bjo.81.5.370 IS - 5 PY - 1997 SN - 0007-1161 1468-2079 SP - 370-372 ST - Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension VL - 81 ID - 6054 ER - TY - JOUR AB - The aim of this study was to investigate the effect of different ocular massage health education methods on ocular massage in glaucoma patients after trabeculectomy. Eighty-six patients with glaucoma after trabeculectomy (86 eyes) were randomly divided into two health education groups. One group was a watch video group (43 patients, 43 eyes), while the other was an orally taught health education group (43 patients, 43 eyes). Patients were followed up for 1 week, 1 month, and 3,6, and 12 months after discharge. Records of the patient responses after health education, compliance of patients with follow-up, and intraocular pressure were determined. Measurements included intraocular pressure and differences between the watch video and orally taught health education groups. The differences between the watch video group and orally taught health education group were not statistically significant at 1 week and 1 month, while the differences were statistically significant at 3, 6, and 12 months. The results indicated that health education videos can enable glaucoma patients to have a better mastery of ocular massage after trabeculectomy. According to the needs of patients, health education video use produced good results and should be promoted. AD - Tianjin Medical University Eye Hospital, Tianjin, China AN - 109798292. Language: English. Entry Date: 20150626. Revision Date: 20200708. Publication Type: Journal Article AU - Liu, Hua AU - Lv, Yingjuan AU - Zhao, Jingshu AU - Cao, Wei DB - ccm DO - 10.1097/CIN.0000000000000062 DP - EBSCOhost IS - 6 KW - Trabeculectomy Health Education -- Methods Eye Care Massage -- Methods Motion Pictures Glaucoma -- Therapy Human Intraocular Pressure After Care Patient Compliance Descriptive Statistics Self Care Male Female Middle Age Aged Chi Square Test Data Analysis Software T-Tests Funding Source N1 - research; tables/charts. Journal Subset: Computer/Information Science; Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Informatics. Grant Information: This work was supported by the Tianjin Municipal Health Bureau Item of China (grant number 2013KZ115).. NLM UID: 101141667. PMID: NLM24937652. PY - 2014 SN - 1538-2931 SP - 294-298 ST - The Effect of Health Education Video on Ocular Massage After Trabeculectomy T2 - CIN: Computers, Informatics, Nursing TI - The Effect of Health Education Video on Ocular Massage After Trabeculectomy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109798292&site=ehost-live&scope=site VL - 32 ID - 4452 ER - TY - JOUR AB - The aim of this study was to investigate the effect of different ocular massage health education methods on ocular massage in glaucoma patients after trabeculectomy. Eighty-six patients with glaucoma after trabeculectomy (86 eyes) were randomly divided into two health education groups. One group was a watch video group (43 patients, 43 eyes), while the other was an orally taught health education group (43 patients, 43 eyes). Patients were followed up for 1 week, 1 month, and 3, 6, and 12 months after discharge. Records of the patient responses after health education, compliance of patients with follow-up, and intraocular pressure were determined. Measurements included intraocular pressure and differences between the watch video and orally taught health education groups. The differences between the watch video group and orally taught health education group were not statistically significant at 1 week and 1 month, while the differences were statistically significant at 3, 6, and 12 months. The results indicated that health education videos can enable glaucoma patients to have a better mastery of ocular massage after trabeculectomy. According to the needs of patients, health education video use produced good results and should be promoted. AN - WOS:000338987000006 AU - Liu, H. AU - Lv, Y. J. AU - Zhao, J. S. AU - Cao, W. DA - JUN DO - 10.1097/CIN.0000000000000062 IS - 6 PY - 2014 SN - 1538-2931 1538-9774 SP - 294-298 ST - The Effect of Health Education Video on Ocular Massage After Trabeculectomy T2 - CIN-COMPUTERS INFORMATICS NURSING TI - The Effect of Health Education Video on Ocular Massage After Trabeculectomy VL - 32 ID - 6088 ER - TY - JOUR AB - Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma. © 2013 Liu and Mao, publisher and licensee Dove Medical Press Ltd. AD - W. Mao, CBH449, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, United States AU - Liu, Y. AU - Mao, W. C1 - afp 168 C2 - Santen DB - Embase IS - 1 KW - bimatoprost dorzolamide latanoprost prostaglandin derivative prostaglandin F2 alpha derivative tafluprost timolol travoprost unoprostone adipose tissue application site irritation blood pressure cell survival clinical effectiveness concentration response conjunctiva disease cornea disease cytotoxicity test dose response drug absorption drug effect drug efficacy drug metabolism drug penetration drug potency drug potentiation drug safety drug substitution drug tolerability drug withdrawal eye blood flow eye disease eye toxicity heart rate human hyperemia intraocular hypertension intraocular pressure abnormality iris disease neuroprotection nonhuman open angle glaucoma orbit patient compliance pruritus retina ganglion cell review side effect single drug dose treatment duration trend study unspecified side effect afp 168 L1 - internal-pdf://3516616717/3047-Tafluprost once daily for treatment-2012.pdf LA - English M3 - Review N1 - L368002603 2013-01-03 2013-01-09 PY - 2012 SN - 1177-5467 1177-5483 SP - 7-14 ST - Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma T2 - Clinical Ophthalmology TI - Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368002603&from=export VL - 7 ID - 3047 ER - TY - JOUR AB - Purpose: (i) To evaluate the medication adherence rate of glaucoma patients in Singapore. (ii) To evaluate patients' quality of life status. (iii) To explore the factors related to patients' nonadherence to medication. Patients and Methods: A cross-sectional, prospective study, using interviewer-administered survey questionnaires. A total of 314 patients were interviewed altogether, of which 175 (55.7%) were male and 139 (44.3%) were female. (i) Patients' medication adherence was assessed using the Reported Adherence to Medication scale. (ii) Patients' beliefs about glaucoma and treatment were evaluated using the Brief Illness Perception Questionnaire and the Beliefs about Medicine-Specific Questionnaire. (iii) Patients' quality of life was evaluated using Glaucoma Symptom Scale and The Glaucoma Quality of Life-15 questionnaire. Results: Sixty-two (19.7%) patients reported themselves to be adherent to their medication. Male patients (P = 0.044) and smokers (P = 0.002) were more likely to be nonadherent to their medication regimen. Nonadherent patients were more likely to have (i) more concerns about their glaucoma medications (P = 0.000); (ii) less belief in the effects of their medications (P = 0.026); (iii) a lower quality of life (higher score of GQOL-15, P = 0.014); (iv) less symptoms from their glaucoma (lower score of Glaucoma Symptom Scale, P = 0.026); and (v) more effect on their lives from glaucoma (P = 0.01). Conclusions: The full-adherence rate is low among glaucoma patients. Having less belief in the need for and more concerns about their medication are the 2 factors associated with nonadherence. In the future, effective strategies should be explored to improve patients' beliefs. Nonadherence has an association with decreased quality of life. Strategies to improve adherence will need to deal with these areas. Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Level 7, Singapore, 119228, Singapore Centre for Infectious Disease Epidemiology and Research (CIDER), Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore AU - Loon, S. C. AU - Jin, J. AU - Jin Goh, M. DB - Scopus DO - 10.1097/IJG.0000000000000007 IS - 5 KW - adherence compliance glaucoma quality of life M3 - Article N1 - Cited By :25 Export Date: 19 July 2021 PY - 2015 SP - e36-e42 ST - The Relationship Between Quality of Life and Adherence to Medication in Glaucoma Patients in Singapore T2 - Journal of Glaucoma TI - The Relationship Between Quality of Life and Adherence to Medication in Glaucoma Patients in Singapore UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931570433&doi=10.1097%2fIJG.0000000000000007&partnerID=40&md5=e66088fc5511dd8eaaa21c728cc53fc8 VL - 24 ID - 5089 ER - TY - JOUR AB - Background: Prostaglandin analogs reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; however, these medications may affect the ocular surface and elicit ocular discomfort when preserved with benzalkonium chloride (BAK).Methods: This was an open-label, single-arm study conducted in Latin America from February 2012 to May 2013. Patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost 0.005 % were transitioned to receive once-daily BAK-free travoprost 0.004 % containing polyquaternium-1 (Travatan® preserved with POLYQUAD® [PQ], Alcon Laboratories, Inc; Fort Worth, TX) for 12 weeks. Mean change in IOP from baseline (primary efficacy endpoint) and the percentage of patients who achieved a target IOP of ≤18 mmHg were evaluated at all on-therapy visits. Ocular hyperemia, patient preference, and self-projected adherence were assessed at week 12. Adverse events (AEs) were monitored throughout the study.Results: All enrolled patients were included in the analysis (n = 191); the majority of patients (90.6 %, n = 173/191) completed the study. Mean (SD) patient age was 67.5 (11.3) years, and mean baseline IOP was 14.8 mmHg. Mean IOP was reduced by 0.94 mmHg at week 6 and by 1.09 mmHg at week 12 (P < 0.001 for both). A greater percentage of patients achieved a target IOP of ≤18 mmHg at week 6 (93.1 %; n = 163/175) and week 12 (93.3 %; n = 166/178) compared with baseline (89.5 %; n = 171/191). There was a 10.5 % increase in the percentage of patients with "none/trace" amounts of hyperemia. Most patients preferred the study medication (81.5 %; n = 141/173) and were confident that they would adhere to their preferred medication (90.8 %; n = 157/173). No serious AEs were reported, and eye irritation (3.7 %; n = 7/191) was the most common treatment-related AE.Conclusions: Transitioning from BAK-containing latanoprost 0.005 % to BAK-free travoprost 0.004 % preserved with PQ reduced IOP in patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost. BAK-free travoprost 0.004 % is a viable alternative for patients who require switching their IOP-lowering medications because of tolerability issues.Trial Registration: ClinicalTrials.gov identifier, NCT01510145. AD - Clinica Oftalmológica Pasteur, Luis Pasteur 5917-Vitacura, Santiago, Chile Alcon Laboratories, Inc., Fort Worth, TX, USA Clínica Oftalmológica del Caribe, Barranquilla, Colombia AN - 110923831. Language: English. Entry Date: In Process. Revision Date: 20190710. Publication Type: journal article AU - Lopes, Joao F. AU - Hubatsch, Douglas A. AU - Amaris, Patricia DB - ccm DO - 10.1186/s12886-015-0151-7 DP - EBSCOhost KW - Intraocular Pressure -- Drug Effects Pharmaceutical Additives Glaucoma -- Drug Therapy Antihypertensive Agents -- Therapeutic Use Prostaglandins F, Synthetic -- Therapeutic Use Benzalkonium Compounds Male Adult Prescriptions, Drug Middle Age Hyperemia -- Chemically Induced Antihypertensive Agents -- Adverse Effects Tonometry Female Corneal Diseases -- Chemically Induced Human Young Adult Ocular Hypertension -- Drug Therapy Aged Conjunctival Diseases -- Chemically Induced Aged, 80 and Over Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - clinical trial; research. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 100967802. PMID: NLM26563363. PY - 2015 SN - 1471-2415 SP - 1-6 ST - Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study T2 - BMC Ophthalmology TI - Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110923831&site=ehost-live&scope=site VL - 15 ID - 4289 ER - TY - JOUR AB - Background: Prostaglandin analogs reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; however, these medications may affect the ocular surface and elicit ocular discomfort when preserved with benzalkonium chloride (BAK). Methods: This was an open-label, single-arm study conducted in Latin America from February 2012 to May 2013. Patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost 0.005 % were transitioned to receive once-daily BAK-free travoprost 0.004 % containing polyquaternium-1 (Travatan® preserved with POLYQUAD® [PQ], Alcon Laboratories, Inc; Fort Worth, TX) for 12 weeks. Mean change in IOP from baseline (primary efficacy endpoint) and the percentage of patients who achieved a target IOP of ≤18 mmHg were evaluated at all on-therapy visits. Ocular hyperemia, patient preference, and self-projected adherence were assessed at week 12. Adverse events (AEs) were monitored throughout the study. Results: All enrolled patients were included in the analysis (n = 191); the majority of patients (90.6 %, n = 173/191) completed the study. Mean (SD) patient age was 67.5 (11.3) years, and mean baseline IOP was 14.8 mmHg. Mean IOP was reduced by 0.94 mmHg at week 6 and by 1.09 mmHg at week 12 (P ;lt 0.001 for both). A greater percentage of patients achieved a target IOP of ≤18 mmHg at week 6 (93.1 %; n = 163/175) and week 12 (93.3 %; n = 166/178) compared with baseline (89.5 %; n = 171/191). There was a 10.5 % increase in the percentage of patients with "none/trace" amounts of hyperemia. Most patients preferred the study medication (81.5 %; n = 141/173) and were confident that they would adhere to their preferred medication (90.8 %; n = 157/173). No serious AEs were reported, and eye irritation (3.7 %; n = 7/191) was the most common treatment-related AE. Conclusions: Transitioning from BAK-containing latanoprost 0.005 % to BAK-free travoprost 0.004 % preserved with PQ reduced IOP in patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost. BAK-free travoprost 0.004 % is a viable alternative for patients who require switching their IOP-lowering medications because of tolerability issues. Trial registration: ClinicalTrials.gov identifier, NCT01510145 © 2015 Lopes et al. AD - Clinica Oftalmológica Pasteur, Luis Pasteur - Vitacura, Santiago, 5917, Chile Alcon Laboratories, Inc., Fort Worth, TX, United States Clínica Oftalmológica Del Caribe, Barranquilla, Colombia AU - Lopes, J. F. AU - Hubatsch, D. A. AU - Amaris, P. C7 - 166 DB - Scopus DO - 10.1186/s12886-015-0151-7 IS - 1 KW - Benzalkonium chloride Efficacy Glaucoma Prostaglandin analog Safety Travoprost M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2015 ST - Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: An open-label study Glaucoma T2 - BMC Ophthalmology TI - Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: An open-label study Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946918323&doi=10.1186%2fs12886-015-0151-7&partnerID=40&md5=d51bbedbe7543f2ea942cd0b508e60d1 VL - 15 ID - 5277 ER - TY - JOUR AB - Background: Prostaglandin analogs reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; however, these medications may affect the ocular surface and elicit ocular discomfort when preserved with benzalkonium chloride (BAK). Methods: This was an open-label, single-arm study conducted in Latin America from February 2012 to May 2013. Patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost 0.005 % were transitioned to receive once-daily BAK-free travoprost 0.004 % containing polyquaternium-1 (Travatan (R) preserved with POLYQUAD (R) [PQ], Alcon Laboratories, Inc; Fort Worth, TX) for 12 weeks. Mean change in IOP from baseline (primary efficacy endpoint) and the percentage of patients who achieved a target IOP of <= 18 mmHg were evaluated at all on-therapy visits. Ocular hyperemia, patient preference, and self-projected adherence were assessed at week 12. Adverse events (AEs) were monitored throughout the study. Results: All enrolled patients were included in the analysis (n = 191); the majority of patients (90.6 %, n = 173/191) completed the study. Mean (SD) patient age was 67.5 (11.3) years, and mean baseline IOP was 14.8 mmHg. Mean IOP was reduced by 0.94 mmHg at week 6 and by 1.09 mmHg at week 12 (P < 0.001 for both). A greater percentage of patients achieved a target IOP of <= 18 mmHg at week 6 (93.1 %; n = 163/175) and week 12 (93.3 %; n = 166/178) compared with baseline (89.5 %; n = 171/191). There was a 10.5 % increase in the percentage of patients with "none/trace" amounts of hyperemia. Most patients preferred the study medication (81.5 %; n = 141/173) and were confident that they would adhere to their preferred medication (90.8 %; n = 157/173). No serious AEs were reported, and eye irritation (3.7 %; n = 7/191) was the most common treatment-related AE. Conclusions: Transitioning from BAK-containing latanoprost 0.005 % to BAK-free travoprost 0.004 % preserved with PQ reduced IOP in patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost. BAK-free travoprost 0.004 % is a viable alternative for patients who require switching their IOP-lowering medications because of tolerability issues. AN - WOS:000364541900001 AU - Lopes, J. F. AU - Hubatsch, D. A. AU - Amaris, P. DA - NOV 12 DO - 10.1186/s12886-015-0151-7 PY - 2015 SN - 1471-2415 ST - Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study T2 - BMC OPHTHALMOLOGY TI - Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study VL - 15 ID - 6174 ER - TY - JOUR AB - Objective. Determine prevalence of blindness and visual impairment in adults aged ≥ 50 years in Panama, identify their main causes, and characterize eye health services. Methods. Cross-sectional population study using standard Rapid Assessment of Avoidable Blindness methodology. Fifty people aged ≥ 50 years were selected from each of 84 clusters chosen through representative random sampling of the entire country . Visual acuity was assessed using a Snellen chart; lens and posterior pole status were assessed by direct ophthalmoscopy. Cataract surgery coverage was calculated and its quality assessed, along with causes of visual acuity < 20/60 and barriers to access to surgical treatment. Results. A total of 4 125 people were examined (98.2% of the calculated sample). Age- and sex-adjusted prevalence of blindness was 3.0% (95% CI: 2.3-3.6). The main cause of blindness was cataract (66.4%), followed by glaucoma (10.2%). Cataract (69.2%) was the main cause of severe visual impairment and uncorrected refractive errors were the main cause of moderate visual impairment (60.7%). Surgical cataract coverage in individuals was 76.3%. Of all eyes operated for cataract, 58.0% achieved visual acuity ≤ 20/60 with available correction. Conclusions. Prevalence of blindness in Panama is in line with average prevalence found in other countries of the Region. This problem can be reduced, since 76.2% of cases of blindness and 85.0% of cases of severe visual impairment result from avoidable causes. AD - Comité Nacional VISION 2020, Ciudad de Panamá, Panama Hospital Santo Tomás, Ciudad de Panamá, Panamá Caja de Seguro Social, Ciudad de Panamá, Panamá Ministerio de Salud, Ciudad de Panamá, Panamá Health Information Services, Grootebroek, los Países Bajos Organización Panamericana de la Salud, Bogotá, Colombia AN - 103766189. Language: Spanish. Entry Date: 20150309. Revision Date: 20150710. Publication Type: Journal Article AU - López, Maritza AU - Brea, Ileana AU - Yee, Rita AU - Yi, Rodolfo AU - Carles, Víctor AU - Broce, Alberto AU - Limburg, Hans AU - Silva, Juan Carlos DB - ccm DO - dx.doi.org/S1020-49892014001100001 DP - EBSCOhost IS - 6 KW - Blindness -- Epidemiology -- Panama Eye Care -- Evaluation Health Services -- Evaluation Vision Disorders -- Epidemiology -- Panama Panama Blindness -- Etiology Cross Sectional Studies Random Sample Confidence Intervals Vision Disorders -- Etiology Middle Age Aged Aged, 80 and Over Human N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; Public Health; USA. Special Interest: Public Health. NLM UID: 9705400. PMID: NLM25711745. PY - 2014 SN - 1020-4989 SP - 355-360 ST - Survey on avoidable blindness and visual impairment in Panama T2 - Revista Panamericana de Salud Pública TI - Survey on avoidable blindness and visual impairment in Panama UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103766189&site=ehost-live&scope=site VL - 36 ID - 4481 ER - TY - JOUR AB - Importance: Patient perspectives are crucial in informing design of acceptable services. Background: This study determined patient preferences in glaucoma care. Design: A discrete choice experiment was used to evaluate the relative importance of out-of-pocket costs, waiting time, continuity of care, service location and expertise. Participants: Ninety-eight glaucoma suspects or glaucoma patients were recruited from one public and two private clinics in Sydney. Methods: Twelve choice-tasks were presented in random order and forced-choice preferences were elicited. Choice data were analysed using a multinominal logit model (NLOGIT 4.0). Main Outcome Measures: The relative importance and the likelihood of choosing services with each attribute were determined. Willingness-to-pay and willingness-to-wait were calculated. Analyses were stratified by whether the patient attended a public or private glaucoma clinic and other demographic features. Results: Choice was influenced by four or five attributes: greater clinician expertise, the same clinician each visit, lower out-of-pocket costs and shorter wait times (all P <.05). Respondents were willing to pay an additional (Australian dollars) $325 (95% confidence interval [CI] 188-389) to see a senior eye doctor, and $87 (95% CI 60-116) to see the same clinician each visit. Respondents were willing to wait for these attributes; however, the estimates had wide confidence intervals and were beyond the range tested. Private patients had a stronger preference for expertise and continuity of care compared to public patients. Conclusions and Relevance: Expertise and continuity of care were important to glaucoma patients in this setting, and they were willing to pay out-of-pocket and concede longer waiting times to secure these preferences. AD - T.C. Lu, The George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia AU - Lu, T. C. AU - Angell, B. AU - Dunn, H. AU - Ford, B. AU - White, A. AU - Keay, L. DB - Embase Medline DO - 10.1111/ceo.13606 IS - 9 KW - adult aged article Australia demography female glaucoma health care cost health care personnel health service hospital admission human major clinical study male medical expert medical fee middle aged ophthalmologist patient attendance patient preference pilot study private hospital public hospital Willingness To Pay work experience LA - English M3 - Article N1 - L2003915404 2019-12-31 2020-01-03 PY - 2019 SN - 1442-9071 1442-6404 SP - 1146-1155 ST - Determining patient preferences in a glaucoma service: A discrete choice experiment T2 - Clinical and Experimental Ophthalmology TI - Determining patient preferences in a glaucoma service: A discrete choice experiment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003915404&from=export http://dx.doi.org/10.1111/ceo.13606 VL - 47 ID - 2470 ER - TY - JOUR AB - Purpose: To summarize observational studies that focus on the use of glaucoma medications and to identify gaps in knowledge to guide future investigation. Design: Literature study. Methods: We searched the electronic databases MEDLINE, EMBASE, and PubMed for English language articles published through December 2009 using the search terms physician's practice patterns, drug prescriptions, pharmaceutical services, medication adherence, ophthalmology, glaucoma, and ophthalmic solutions. We categorized studies by areas of focus and extracted and summarized key features: study population, data sources, and main findings. Results: We identified 2224 articles by the search. Fifty-five described glaucoma medication use using large databases. Predominant areas of focus were: trends in prescription choices (n = 13); adherence, persistence, or both (n = 31); rational use of medications (n = 9); and policy-related issues (n = 2). Over the last decade, use of β-blockers and miotics has decreased substantially, whereas new agents, particularly prostaglandin analogs, have become more popular. Nonadherence was an issue in more than 25% of patients. A significant proportion of patients with comorbidities, contraindications, or both had received topical β-blockers. Conclusions: To date, most studies have focused on adherence to glaucoma medications and changes in treatment choices. Major gaps in knowledge include prescribing patterns by prescriber specialty (ophthalmologists, primary care physicians, and optometrists), medication-related problems, and subsequent adverse health outcomes. Well-designed longitudinal observational studies addressing these gaps are warranted to improve patient safety. © 2010 Elsevier Inc. All Rights Reserved. AD - V. H. Lu, Sydney Eye Hospital, 187 Macquarie Street, Sydney NSW 2000, Australia AU - Lu, V. H. AU - Goldberg, I. AU - Lu, C. Y. DB - Embase Medline DO - 10.1016/j.ajo.2010.05.005 IS - 4 KW - beta adrenergic receptor blocking agent bimatoprost brimonidine carbonate dehydratase inhibitor dorzolamide plus timolol latanoprost latanoprost plus timolol miotic agent prostaglandin derivative travoprost article comorbidity data base drug contraindication drug cost drug substitution drug withdrawal electronic medical record glaucoma health care policy human medical literature medical research monotherapy observational study patient compliance prescription priority journal treatment duration LA - English M3 - Article N1 - L51011062 2010-08-11 2010-10-14 PY - 2010 SN - 0002-9394 SP - 569-574.e1-e9 ST - Use of glaucoma medications: State of the science and directions for observational research T2 - American Journal of Ophthalmology TI - Use of glaucoma medications: State of the science and directions for observational research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51011062&from=export http://dx.doi.org/10.1016/j.ajo.2010.05.005 VL - 150 ID - 3230 ER - TY - JOUR AB - Medical cannabis research has become quite extensive, with indications ranging from glaucoma to chemotherapy-induced nausea. Despite increased interest in cannabis' potential medical uses, research barriers, cannabis legislation, stigma, and lack of dissemination of data contribute to low adoption for some medical populations. Of interest, cannabis use appears low in palliative care settings, with few guidelines available to palliative care providers. The present study sought to examine the attitudes, beliefs, and practices of palliative care providers regarding the use of cannabis for terminally ill patients. Palliative care providers (N = 426) completed a one-time online survey assessing these attitudes, beliefs, and practices. Results demonstrated that palliative care providers endorse cannabis for a wide range of palliative care symptoms, end-of-life care generally, and as an adjuvant medication. Nevertheless, the gap between these beliefs and actual recommendation or prescription appears vast. Many who support the use of cannabis in palliative care do not recommend it as a treatment. These data suggest recommendations for healthcare providers and palliative care organizations. AD - Department of Psychology, University at Albany, State University of New York, Albany, NY, USA AN - 132433000. Language: English. Entry Date: In Process. Revision Date: 20200224. Publication Type: journal article. Journal Subset: Biomedical AU - Luba, Rachel AU - Earleywine, Mitch AU - Farmer, Stacey AU - Slavin, Melissa DB - ccm DO - 10.1080/02791072.2018.1462543 DP - EBSCOhost IS - 4 KW - Health Personnel -- Statistics and Numerical Data Medical Marijuana -- Therapeutic Use Palliative Care -- Methods Terminal Care -- Methods Middle Age Attitude of Health Personnel Female Surveys Male Attitude to Health Adult N1 - USA. Instrumentation: Wide Range Achievement Test (WRAT). NLM UID: 8113536. PMID: NLM29714640. PY - 2018 SN - 0279-1072 SP - 348-354 ST - Cannabis in End-of-Life Care: Examining Attitudes and Practices of Palliative Care Providers T2 - Journal of Psychoactive Drugs TI - Cannabis in End-of-Life Care: Examining Attitudes and Practices of Palliative Care Providers UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132433000&site=ehost-live&scope=site VL - 50 ID - 4295 ER - TY - JOUR AB - Medical cannabis research has become quite extensive, with indications ranging from glaucoma to chemotherapy-induced nausea. Despite increased interest in cannabis’ potential medical uses, research barriers, cannabis legislation, stigma, and lack of dissemination of data contribute to low adoption for some medical populations. Of interest, cannabis use appears low in palliative care settings, with few guidelines available to palliative care providers. The present study sought to examine the attitudes, beliefs, and practices of palliative care providers regarding the use of cannabis for terminally ill patients. Palliative care providers (N = 426) completed a one-time online survey assessing these attitudes, beliefs, and practices. Results demonstrated that palliative care providers endorse cannabis for a wide range of palliative care symptoms, end-of-life care generally, and as an adjuvant medication. Nevertheless, the gap between these beliefs and actual recommendation or prescription appears vast. Many who support the use of cannabis in palliative care do not recommend it as a treatment. These data suggest recommendations for healthcare providers and palliative care organizations. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Luba, Rachel, 1400 Washington Avenue, SS 399, Albany, NY, US, 12206 AN - 2018-20791-001 AU - Luba, Rachel AU - Earleywine, Mitch AU - Farmer, Stacey AU - Slavin, Melissa DB - psyh DO - 10.1080/02791072.2018.1462543 DP - EBSCOhost IS - 4 KW - cannabis end-of-life care palliative care Adult Attitude of Health Personnel Female Health Care Surveys Health Knowledge, Attitudes, Practice Health Personnel Humans Male Medical Marijuana Middle Aged Terminal Care Drug Therapy Health Personnel Attitudes N1 - Department of Psychology, University at Albany, State University of New York, Albany, NY, US. Other Publishers: Haight-Ashbury Publications. Release Date: 20180503. Correction Date: 20200601. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Cannabis; Drug Therapy; Health Personnel Attitudes; Palliative Care. Classification: Health & Mental Health Services (3370); Professional Personnel Attitudes & Characteristics (3430). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Sep-Oct, 2018. Publication History: Accepted Date: Jan 20, 2018; First Submitted Date: Oct 24, 2017. Copyright Statement: Taylor & Francis Group, LLC. 2018. PY - 2018 SN - 0279-1072 2159-9777 SP - 348-354 ST - Cannabis in end-of-life care: Examining attitudes and practices of palliative care providers T2 - Journal of Psychoactive Drugs TI - Cannabis in end-of-life care: Examining attitudes and practices of palliative care providers UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-20791-001&site=ehost-live&scope=site RLuba@albany.edu VL - 50 ID - 4817 ER - TY - JOUR AB - PURPOSE:: To determine acceptability and efficacy of hydroxypropyl cellulose ophthalmic inserts in patients with dry eye syndrome (DES) and additional comorbidities. DESIGN:: A multicenter, 2-visit, open-label, 4-week registry study. PARTICIPANTS:: Five hundred twenty patients were recruited to the intent-to-treat group. Four hundred eighteen patients completed the study including 86 contact lens wearers, 79 with cataract diagnosis, 52 with prior cataract surgery, 22 with prior laser-assisted in situ keratomileusis, and 15 with glaucoma. METHODS:: Patient questionnaires were completed at baseline and after 4 weeks of treatment to assess mean change in severity of DES symptoms, ocular surface disease index (OSDI) scores, frequency of occurrence of DES symptoms, occurrence of difficulty when performing activities of daily living (ADLs), and frequency of discomfort in various environmental conditions. Mean change was measured from visit 1 to visit 2. MAIN OUTCOME MEASURES:: Symptoms, OSDI scores, and measure of degree of difficulty when performing ADLs. RESULTS:: Four hundred eighteen patients completed the study. Compared with baseline, this population of patients demonstrated statistically significant improvements in mean OSDI scores (P = 0.0215) and symptoms of discomfort, burning, dryness, grittiness, stinging, and light sensitivity (P < 0.05). Mean improvement in OSDI scores of patients in the 5 identified subsets of patients with comorbid conditions were significant for patients using contact lenses (P < 0.025), who had undergone prior cataract surgery (P < 0.04), and with prior laser-assisted in situ keratomileusis surgery (P < 0.05). Patients diagnosed with cataracts or glaucoma did not show significant changes in any measures in this study. Patients with DES and comorbid conditions experienced relief of symptoms and benefit to ADLs and quality of life similar to patients without comorbid conditions. CONCLUSIONS:: In subsets of patients with moderate to severe DES and comorbid conditions, hydroxypropyl cellulose ophthalmic inserts improve the symptoms of DES, ability to perform ADLs, and quality of life. The reported benefits may be additive to those seen with patients existing therapies. Copyright © 2010 by Lippincott Williams & Wilkins. AD - South Shore Eye Care, 2185 Wantagh Avenue, Wantagh, NY 11566, United States InterQuest Medical and Scientific, LLC, Parsippany, NJ, United States Macy Eye Center, Los Angeles, CA, United States AU - Luchs, J. I. AU - Nelinson, D. S. AU - Macy, J. I. DB - Scopus DO - 10.1097/ICO.0b013e3181e3f05b IS - 12 KW - dry eye syndrome LACRISERT OSDI patient registry quality of life M3 - Article N1 - Cited By :36 Export Date: 19 July 2021 PY - 2010 SP - 1417-1427 ST - Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: Findings from a patient registry T2 - Cornea TI - Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: Findings from a patient registry UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650512958&doi=10.1097%2fICO.0b013e3181e3f05b&partnerID=40&md5=e6b3e5caaa211d8ae4ca17841ca7812f VL - 29 ID - 5032 ER - TY - JOUR AB - Purpose: To evaluate long-term functional outcome after treatment of congenital unilateral cataract. Methods: The records of 30 consecutive children operated on before the age of 12 months at St. Erik's Eye Hospital over a 5-year period (1991-96) were reviewed retrospectively. The patients were followed until 4-9.5 years of age. Linear Snellen visual acuity (VA), occlusion therapy compliance, and the presence of nystagmus, strabismus and other complications are reported. Results: Six children achieved VA of 0.1 or better. They were all operated on before 3 months of age. Of the 12 infants operated on before 6 weeks of age, four have VA between 0.3 and 0.4 and eight have VA of finger counting or less. Four developed severe secondary glaucoma within 6 months of cataract extraction. Two of these had persistent fetal vasculature. Three eyes developing glaucoma became amaurotic. Occlusion therapy was abandoned before the age of 2.5 years in 21 children. Conclusion: Good levels of VA were achieved only in children who underwent cataract surgery before 3 months of age and who adhered to the occlusion therapy schedule. Severe secondary glaucoma developed in four out of 12 children operated on within 6 weeks. Full compliance with the occlusion therapy programme was uncommon. AD - A. Lundvall, St. Erik's Eye Hospital, Karolinska Institute, Polhemsgatan 50, SE-112 82 Stockholm, Sweden AU - Lundvall, A. AU - Kugelberg, U. DB - Embase Medline DO - 10.1034/j.1600-0420.2002.800606.x IS - 6 KW - aphakia article blindness child clinical article congenital cataract controlled study disease severity female follow up functional assessment glaucoma human male nystagmus patient compliance priority journal retrospective study strabismus trabeculectomy treatment outcome vision test visual acuity vitrectomy LA - English M3 - Article N1 - L36024469 2003-01-16 PY - 2002 SN - 1395-3907 SP - 588-592 ST - Outcome after treatment of congenital unilateral cataract T2 - Acta Ophthalmologica Scandinavica TI - Outcome after treatment of congenital unilateral cataract UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36024469&from=export http://dx.doi.org/10.1034/j.1600-0420.2002.800606.x VL - 80 ID - 3840 ER - TY - JOUR AB - Purpose: To evaluate long-term functional outcome after treatment of congenital unilateral cataract. Methods: The records of 30 consecutive children operated on before the age of 12 months at St. Erik's Eye Hospital over a 5-year period (1991-96) were reviewed retrospectively. The patients were followed until 4-9.5 years of age. Linear Snellen visual acuity (VA), occlusion therapy compliance, and the presence of nystagmus, strabismus and other complications are reported. Results: Six children achieved VA of 0.1 or better. They were all operated on before 3 months of age. Of the 12 infants operated on before 6 weeks of age, four have VA between 0.3 and 0.4 and eight have VA of finger counting or less. Four developed severe secondary glaucoma within 6 months of cataract extraction. Two of these had persistent fetal vasculature. Three eyes developing glaucoma became amaurotic. Occlusion therapy was abandoned before the age of 2.5 years in 21 children. Conclusion: Good levels of VA were achieved only in children who underwent cataract surgery before 3 months of age and who adhered to the occlusion therapy schedule. Severe secondary glaucoma developed in four out of 12 children operated on within 6 weeks. Full compliance with the occlusion therapy programme was uncommon. AD - Department of Paediatric Ophthalmol., St. Erik's Eye Hospital, Karolinska Institute, Stockholm, Sweden AU - Lundvall, A. AU - Kugelberg, U. DB - Scopus DO - 10.1034/j.1600-0420.2002.800606.x IS - 6 KW - Congenital unilateral cataract Infant Outcome Surgery M3 - Article N1 - Cited By :40 Export Date: 19 July 2021 PY - 2002 SP - 588-592 ST - Outcome after treatment of congenital unilateral cataract T2 - Acta Ophthalmologica Scandinavica TI - Outcome after treatment of congenital unilateral cataract UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036914960&doi=10.1034%2fj.1600-0420.2002.800606.x&partnerID=40&md5=eb4401440e6e96d65a677321739ab5ff VL - 80 ID - 5021 ER - TY - JOUR AB - The purpose of this study was to describe the views of compliant glaucoma patients with good compliance on patient education and social support they received during their illness. The aim was to gain knowledge for developing patient compliance by means of promoting education and support methods. Twelve glaucoma patients with good compliance were interviewed, and the transcripts based on those interviews were analysed using content analysis. In the data, the participants described education and social support they had received from healthcare personnel, relatives and partly from their peers. Patient education emerged as the content, timing and methods of education. Social support emerged as emotional, informational and instrumental support, lack of support as well as patients' activity. Consequently, patients need education and support from healthcare personnel as well as from their relatives to cope with glaucoma. The need for education and support is individual but the most important time for education and support is at the initial stages of the illness. The need for education and support is also evident when the patient's treatment is changed or an operative procedure is performed. To conclude, the individual, patient-centred and properly timed education and support is a huge challenge for healthcare personnel because of the decrease in individual time for each patient. Therefore, new and timesaving methods of education and support should be developed. © 2010 The Authors. Journal compilation © 2010 Nordic College of Caring Science. AD - J. Lunnela, Department of Ophthalmology, Helsinki University Central Hospital, PB 220, 00029 HUCH, Finland AU - Lunnela, J. AU - Kääriäinen, M. AU - Kyngäs, H. DB - Medline DO - 10.1111/j.1471-6712.2009.00739.x IS - 3 KW - adaptive behavior article counseling glaucoma human patient compliance patient education psychological aspect social support LA - English M3 - Article N1 - L359376330 2011-04-08 PY - 2010 SN - 0283-9318 1471-6712 SP - 490-498 ST - The views of compliant glaucoma patients on counselling and social support T2 - Scandinavian Journal of Caring Sciences TI - The views of compliant glaucoma patients on counselling and social support UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359376330&from=export http://dx.doi.org/10.1111/j.1471-6712.2009.00739.x VL - 24 ID - 3236 ER - TY - JOUR AB - Scand J Caring Sci; 2010; 24; 490–498 The views of compliant glaucoma patients on counselling and social support The purpose of this study was to describe the views of compliant glaucoma patients with good compliance on patient education and social support they received during their illness. The aim was to gain knowledge for developing patient compliance by means of promoting education and support methods. Twelve glaucoma patients with good compliance were interviewed, and the transcripts based on those interviews were analysed using content analysis. In the data, the participants described education and social support they had received from healthcare personnel, relatives and partly from their peers. Patient education emerged as the content, timing and methods of education. Social support emerged as emotional, informational and instrumental support, lack of support as well as patients’ activity. Consequently, patients need education and support from healthcare personnel as well as from their relatives to cope with glaucoma. The need for education and support is individual but the most important time for education and support is at the initial stages of the illness. The need for education and support is also evident when the patient’s treatment is changed or an operative procedure is performed. To conclude, the individual, patient-centred and properly timed education and support is a huge challenge for healthcare personnel because of the decrease in individual time for each patient. Therefore, new and timesaving methods of education and support should be developed. AN - 105089291. Language: English. Entry Date: 20101029. Revision Date: 20200708. Publication Type: Journal Article AU - Lunnela, J. AU - Kääriäinen, M. AU - Kyngäs, H. DB - ccm DO - 10.1111/j.1471-6712.2009.00739.x DP - EBSCOhost IS - 3 KW - Patient Attitudes Patient Compliance Glaucoma -- Therapy Support, Psychosocial Patient Education Human Male Female Semi-Structured Interview Qualitative Studies Audiorecording Adult Middle Age Aged Content Analysis Early Intervention Patient Education -- Methods Psychosocial Aspects of Illness Physicians Nurses Self Care -- Education Funding Source N1 - research; tables/charts. Journal Subset: Continental Europe; Core Nursing; Europe; Nursing; Peer Reviewed. Grant Information: Funding from Tehy (the Union of Health and Social Care Professionals, Finland). NLM UID: 8804206. PY - 2010 SN - 0283-9318 SP - 490-498 ST - The views of compliant glaucoma patients on counselling and social support T2 - Scandinavian Journal of Caring Sciences TI - The views of compliant glaucoma patients on counselling and social support UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105089291&site=ehost-live&scope=site VL - 24 ID - 4225 ER - TY - JOUR AB - The purpose of this study was to describe the views of compliant glaucoma patients with good compliance on patient education and social support they received during their illness. The aim was to gain knowledge for developing patient compliance by means of promoting education and support methods. Twelve glaucoma patients with good compliance were interviewed, and the transcripts based on those interviews were analysed using content analysis. In the data, the participants described education and social support they had received from healthcare personnel, relatives and partly from their peers. Patient education emerged as the content, timing and methods of education. Social support emerged as emotional, informational and instrumental support, lack of support as well as patients’ activity. Consequently, patients need education and support from healthcare personnel as well as from their relatives to cope with glaucoma. The need for education and support is individual but the most important time for education and support is at the initial stages of the illness. The need for education and support is also evident when the patient’s treatment is changed or an operative procedure is performed. To conclude, the individual, patient-centred and properly timed education and support is a huge challenge for healthcare personnel because of the decrease in individual time for each patient. Therefore, new and timesaving methods of education and support should be developed. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Lunnela, Jaana, Department of Ophthalmology, Helsinki University Central Hospital, P. B. 220, HUCH, 00029, Helsinki, Finland AN - 2010-17286-009 AU - Lunnela, Jaana AU - Kääriäinen, Maria AU - Kyngäs, Helvi DB - psyh DO - 10.1111/j.1471-6712.2009.00739.x DP - EBSCOhost IS - 3 KW - patient compliants glaucoma patients counselling social support patient education patient compliance Adaptation, Psychological Counseling Glaucoma Humans Patient Education as Topic Client Education Treatment Compliance N1 - Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland. Other Publishers: Blackwell Publishing. Release Date: 20101011. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishGrant Information: Lunnela, Jaana. Major Descriptor: Client Education; Glaucoma; Social Support; Treatment Compliance. Minor Descriptor: Counseling. Classification: Behavioral & Psychological Treatment of Physical Illness (3361). Population: Human (10); Male (30); Female (40). Location: Finland. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Interview; Qualitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Sep, 2010. Publication History: Accepted Date: Jul 7, 2009; First Submitted Date: Feb 10, 2008. Copyright Statement: The Authors. Journal compilation—Nordic College of Caring Science. 2010. Sponsor: Union of Health and Social Care Professionals, Finland. Recipients: Lunnela, Jaana; Kääriäinen, Maria; Kyngäs, Helvi PY - 2010 SN - 0283-9318 1471-6712 SP - 490-498 ST - The views of compliant glaucoma patients on counselling and social support T2 - Scandinavian Journal of Caring Sciences TI - The views of compliant glaucoma patients on counselling and social support UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-17286-009&site=ehost-live&scope=site jaana.lunnela@netti.fi VL - 24 ID - 4839 ER - TY - JOUR AB - Objectives. The aim of the study was to describe the adherence of Finnish people with glaucoma to prescribed treatment plans, the factors connected to adherence and to produce knowledge for developing effective interventions to improve adherence to treatment plans. Study design. This was a cross-sectional study. Methods. The data (n=249) were collected at one point in time from Finnish adults diagnosed with glaucoma with a questionnaire covering adherence to treatment. These patients used glaucoma medication and had follow-up appointments with ophthalmologists. Results. Sixty-seven percent (n=166) of the patients with glaucoma were very adherent to the prescribed treatment plan in terms of self-care, treatment and follow-up visits. Almost all were very adherent to medical care (97%, n=242). More than half of those who had received information from physicians and nurses were very adherent to treatment (66%, n=163). Two factors, support from physicians and nurses (p<0.001) and being informed of the consequences of treatments (p=0.003), had a statistically significant connection to treatment adherence. Conclusions. This study indicates that people with glaucoma in Finland adhere well to care and exceptionally well to medical care. Support and patient education from health care personnel is crucial to maintain patient adherence to treatment. These results indicate that nurses play a very important role in patient education and support. In practice, it is crucial to maintain this level of patient engagement by developing more tailored and time-saving education and support methods. The results of this study could be helpful for developing new patient education and support approaches for people with glaucoma. AD - J. Lunnela, Arhipanpolku 9 A, 00420 Helsinki, Finland AU - Lunnela, J. AU - Kääriäinen, M. AU - Kyngäs, H. DB - Medline IS - 1 KW - antihypertensive agent adult aged ambulatory care article cross-sectional study drug utilization female Finland glaucoma human male middle aged patient compliance patient education questionnaire self care LA - English M3 - Article N1 - L361374485 2011-07-06 PY - 2011 SN - 1239-9744 SP - 79-89 ST - Adherence of Finnish people with glaucoma to treatment plans and connected factors T2 - International Journal of Circumpolar Health TI - Adherence of Finnish people with glaucoma to treatment plans and connected factors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361374485&from=export http://www.ijch.fi/download.php?abstract_id=1051&file_nro=1 VL - 70 ID - 3159 ER - TY - JOUR AB - Objectives. The aim of the study was to describe the adherence of Finnish people with glaucoma to prescribed treatment plans, the factors connected to adherence and to produce knowledge for developing effective interventions to improve adherence to treatment plans. Study design. This was a cross-sectional study. Methods. The data (n=249) were collected at one point in time from Finnish adults diagnosed with glaucoma with a questionnaire covering adherence to treatment. These patients used glaucoma medication and had follow-up appointments with ophthalmologists. Results. Sixty-seven percent (n=166) of the patients with glaucoma were very adherent to the prescribed treatment plan in terms of self-care, treatment and follow-up visits. Almost all were very adherent to medical care (97%, n=242). More than half of those who had received information from physicians and nurses were very adherent to treatment (66%, n=163). Two factors, support from physicians and nurses (p<0.001) and being informed of the consequences of treatments (p=0.003), had a statistically significant connection to treatment adherence. Conclusions. This study indicates that people with glaucoma in Finland adhere well to care and exceptionally well to medical care. Support and patient education from health care personnel is crucial to maintain patient adherence to treatment. These results indicate that nurses play a very important role in patient education and support. In practice, it is crucial to maintain this level of patient engagement by developing more tailored and time-saving education and support methods. The results of this study could be helpful for developing new patient education and support approaches for people with glaucoma. AD - Department of Ophthalmology, Hospital District of Helsinki and Uusimaa, Helsinki, Finland Institute of Health Sciences, University of Oulu, Oulu, Finland AU - Lunnela, J. AU - Kääriäinen, M. AU - Kyngäs, H. DB - Scopus DO - 10.3402/ijch.v70i1.17796 IS - 1 KW - Adherence Glaucoma Medical care Patient education Support M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2011 SP - 79-89 ST - Adherence of Finnish people with glaucoma to treatment plans and connected factors T2 - International Journal of Circumpolar Health TI - Adherence of Finnish people with glaucoma to treatment plans and connected factors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952275969&doi=10.3402%2fijch.v70i1.17796&partnerID=40&md5=91e04f99bda1e2ca5498b83908c8dc18 VL - 70 ID - 5335 ER - TY - JOUR AB - Objectives. The aim of the study was to describe the adherence of Finnish people with glaucoma to prescribed treatment plans, the factors connected to adherence and to produce knowledge for developing effective interventions to improve adherence to treatment plans. Study design. This was a cross-sectional study. Methods. The data (n=249) were collected at one point in time from Finnish adults diagnosed with glaucoma with a questionnaire covering adherence to treatment. These patients used glaucoma medication and had follow-up appointments with ophthalmologists. Results. Sixty-seven percent (n=166) of the patients with glaucoma were very adherent to the prescribed treatment plan in terms of self-care, treatment and follow-up visits. Almost all were very adherent to medical care (97%, n=242). More than half of those who had received information from physicians and nurses were very adherent to treatment (66%, n=163). Two factors, support from physicians and nurses (p<0.001) and being informed of the consequences of treatments (p=0.003), had a statistically significant connection to treatment adherence. Conclusions. This study indicates that people with glaucoma in Finland adhere well to care and exceptionally well to medical care. Support and patient education from health care personnel is crucial to maintain patient adherence to treatment. These results indicate that nurses play a very important role in patient education and support. In practice, it is crucial to maintain this level of patient engagement by developing more tailored and time-saving education and support methods. The results of this study could be helpful for developing new patient education and support approaches for people with glaucoma. (Int J Circumpolar Health 2011; 70(1):79-89) AN - WOS:000289010200010 AU - Lunnela, J. AU - Kaariainen, M. AU - Kyngas, H. DA - FEB DO - 10.3402/ijch.v70i1.17796 IS - 1 PY - 2011 SN - 1239-9736 SP - 79-89 ST - Adherence of Finnish people with glaucoma to treatment plans and connected factors T2 - INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH TI - Adherence of Finnish people with glaucoma to treatment plans and connected factors VL - 70 ID - 5849 ER - TY - JOUR AB - Glaucoma is an irreversible progressive optic neuropathy, for which the major proven treatment is to lower the intraocular pressure (IOP). Five groups of IOP-lowering eye drops have varying mechanisms of action. Some drops, such as β-blockers and α-2 agonists, have potentially serious systemic side effects. Acetazolamide is the only available oral agent; it is effective at lowering IOP, but significant side effects relegate its use usually to refractory glaucoma. Two new eye drops, netarsudil and latanoprostene bunod, have recently been approved by the United States Food and Drug Administration. Both have novel IOP-lowering mechanisms and target the conventional aqueous outflow system. Selective laser trabeculoplasty is a gentle treatment that enhances conventional aqueous outflow. It may be used as an initial treatment, as a substitute for eye drops, or to delay glaucoma drainage surgery. Recent advancements in glaucoma surgery have seen an influx of minimally invasive glaucoma surgery devices, which are being used more frequently and earlier on in the treatment paradigm. As limited long term data are available, trabeculectomy remains the gold standard IOP-lowering procedure. Improvements in drug delivery are on the horizon. Drug-eluting devices and implants are able to deliver the drug closer to the receptors for an extended period of time. This will improve treatment adherence and efficacy, which are major limitations with current medical therapy. AD - I. Goldberg, University of Sydney, Sydney, NSW, Australia AU - Lusthaus, J. AU - Goldberg, I. DB - Embase Medline DO - 10.5694/mja2.50020 IS - 4 KW - glaucoma drainage implant microcatheter nonvalved ophthalmic drainage device acetazolamide alpha 2 adrenergic receptor stimulating agent antiglaucoma agent apraclonidine beta adrenergic receptor blocking agent betaxolol bimatoprost bimatoprost plus timolol brimonidine brinzolamide carbonate dehydratase inhibitor cholinergic receptor stimulating agent dorzolamide latanoprost latanoprostene bunod muscarinic agent netarsudil nitric oxide pilocarpine prostaglandin derivative tafluprost timolol travoprost allergy anorexia blepharoconjunctivitis blurred vision bradycardia bronchoconstriction bronchospasm closed angle glaucoma conjunctival hyperemia diarrhea drowsiness drug delivery system drug effect drug efficacy drug mechanism drug safety drug tolerability drug withdrawal dysgeusia electrolyte disturbance eye irritation glaucoma glaucoma surgery human hyperemia hypertrichosis hypotension intraocular hypotension intraocular pressure kidney failure low level laser therapy medication compliance metabolic acidosis miosis myopia nausea nephrolithiasis nonhuman open angle glaucoma orbit disease patient compliance polyuria prevalence retina detachment retina tear review side effect skin pigmentation skin tingling Stevens Johnson syndrome tachycardia topical treatment trabeculectomy trabeculoplasty vitreous floaters vomiting weakness xerostomia CyPass Micro-Stent iStent iStent inject iTrack XEN Gel Stent LA - English M3 - Review N1 - L627239627 2019-05-14 2019-11-01 PY - 2019 SN - 1326-5377 0025-729X SP - 180-187 ST - Current management of glaucoma T2 - Medical Journal of Australia TI - Current management of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627239627&from=export http://dx.doi.org/10.5694/mja2.50020 VL - 210 ID - 2525 ER - TY - JOUR AB - Glaucoma is an irreversible progressive optic neuropathy, for which the major proven treatment is to lower the intraocular pressure (IOP). Five groups of IOP-lowering eye drops have varying mechanisms of action. Some drops, such as β-blockers and α-2 agonists, have potentially serious systemic side effects. Acetazolamide is the only available oral agent; it is effective at lowering IOP, but significant side effects relegate its use usually to refractory glaucoma. Two new eye drops, netarsudil and latanoprostene bunod, have recently been approved by the United States Food and Drug Administration. Both have novel IOP-lowering mechanisms and target the conventional aqueous outflow system. Selective laser trabeculoplasty is a gentle treatment that enhances conventional aqueous outflow. It may be used as an initial treatment, as a substitute for eye drops, or to delay glaucoma drainage surgery. Recent advancements in glaucoma surgery have seen an influx of minimally invasive glaucoma surgery devices, which are being used more frequently and earlier on in the treatment paradigm. As limited long term data are available, trabeculectomy remains the gold standard IOP-lowering procedure. Improvements in drug delivery are on the horizon. Drug-eluting devices and implants are able to deliver the drug closer to the receptors for an extended period of time. This will improve treatment adherence and efficacy, which are major limitations with current medical therapy. AD - University of Sydney, Sydney NSW Sydney Hospital and Sydney Eye Hospital, Sydney NSW AN - 135077995. Language: English. Entry Date: 20191024. Revision Date: 20200403. Publication Type: journal article AU - Lusthaus, Jed AU - Goldberg, Ivan DB - ccm DO - 10.5694/mja2.50020 DP - EBSCOhost IS - 4 KW - Drug Delivery Systems -- Trends Glaucoma -- Therapy Laser Therapy -- Trends Trabeculectomy -- Trends Ophthalmic Solutions -- Therapeutic Use N1 - review. Journal Subset: Australia & New Zealand; Biomedical; Double Blind Peer Reviewed; Peer Reviewed. NLM UID: 0400714. PMID: NLM30767238. PY - 2019 SN - 0025-729X SP - 180-187 ST - Current management of glaucoma T2 - Medical Journal of Australia TI - Current management of glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135077995&site=ehost-live&scope=site VL - 210 ID - 4349 ER - TY - JOUR AB - Background: Telemedicine can improve access to care, especially for rural patients, and ophthalmology is a field that lends itself readily to telemedicine because interpretation of photographs is a routine part of diagnosing eye disease and patient care. We developed a novel tele-eye protocol based on diabetic teleretinal screening. We performed a feasibility study to see if our tele-eye program was comparable to the gold standard face-to-face eye exam. Materials and Methods: Fifty-two subjects underwent the tele-eye protocol and then received a face-to-face exam. A masked reader reviewed the tele-eye data remotely and developed an impression and plan for the patient. The provider assessments from the face-to-face exams and the tele-eye exams were compared. Sensitivity, specificity, and percentage agreement were calculated for the tele-eye protocol, focusing on the most common age-related eye diseases: cataract, macular degeneration, and glaucoma. The difference between the autorefraction and manifest eyeglass prescription was calculated. Results: The pilot study showed excellent percentage agreement between the screening protocol and the face-to-face exam. The percentage agreement for cataract was 100%, that for macular degeneration was 96%, and that for glaucoma suspect was 87%. The difference between the autorefraction’s eyeglass prescription and the final manifest refraction was within American National Standards Institute for lens manufacturing guidelines. Conclusions: The initial data suggest that the tele-eye program is feasible to execute and appears fairly accurate when compared with the gold standard face-to-face eye exam. However, the study is significantly limited by the small sample size. This pilot provides justification of a much larger study of a similar design. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Maa, April Y., Ophthalmology Section, Atlanta Veteran Affairs Medical Center, 1670 Clairmont Road, MC 112E, Decatur, GA, US, 30033 AN - 2014-12689-004 AU - Maa, April Y. AU - Evans, Centrael AU - De Laune, WilliamR AU - Patel, Purnima S. AU - Lynch, Mary G. DB - psyh DO - 10.1089/tmj.2013.0185 DP - EBSCOhost IS - 4 KW - e-health telehealth telemedicine ophthalmology Eye Diseases Feasibility Studies Female Health Services Accessibility Humans Male Pilot Projects Sensitivity and Specificity Vision Screening Health Care Services Health Care Utilization Health Screening N1 - Telemedicine Journal and e-Health. Partial author list: First Author & Affiliation: Maa, April Y.; Department of Ophthalmology, Emory Eye Center, Atlanta, GA, US. Release Date: 20141201. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Health Care Services; Health Care Utilization; Health Screening; Ophthalmology; Telemedicine. Classification: Health & Mental Health Services (3370). Population: Human (10); Outpatient (60). Location: US. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 6. Issue Publication Date: Apr, 2014. Publication History: Accepted Date: Aug 8, 2013; Revised Date: Aug 1, 2013; First Submitted Date: May 28, 2013. Copyright Statement: Mary Ann Liebert, Inc. Sponsor: Research to Prevent Blindness. Other Details: Unrestricted educational grant. Recipients: No recipient indicated PY - 2014 SN - 1530-5627 1556-3669 SP - 318-323 ST - A novel tele-eye protocol for ocular disease detection and access to eye care services T2 - Telemedicine and e-Health TI - A novel tele-eye protocol for ocular disease detection and access to eye care services UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-12689-004&site=ehost-live&scope=site amaa@emory.edu VL - 20 ID - 4851 ER - TY - JOUR AB - Context: Veterans are at high risk for eye disease because of age and comorbid conditions. Access to eye care is challenging within the entire Veterans Hospital Administration's network of hospitals and clinics in the USA because it is the third busiest outpatient clinical service and growing at a rate of 9% per year. Issue: Rural and highly rural veterans face many more barriers to accessing eye care because of distance, cost to travel, and difficulty finding care in the community as many live in medically underserved areas. Also, rural veterans may be diagnosed in later stages of eye disease than their non-rural counterparts due to lack of access to specialty care. In March 2015, Technology-based Eye Care Services (TECS) was launched from the Atlanta Veterans Affairs (VA) as a quality improvement project to provide eye screening services for rural veterans. Lessons learned: By tracking multiple measures including demographic and access to care metrics, data shows that TECS significantly improved access to care, with 33% of veterans receiving same-day access and >98% of veterans receiving an appointment within 30 days of request. TECS also provided care to a significant percentage of homeless veterans, 10.6% of the patients screened. Finally, TECS reduced healthcare costs, saving the VA up to US$ 148 per visit and approximately US$ 52 per patient in round trip travel reimbursements when compared to completing a face-to-face exam at the medical center. Overall savings to the VA system in this early phase of TECS totaled US$ 288,400, about US$ 41,200 per month. Other healthcare facilities may be able to use a similar protocol to extend care to at-risk patients. AN - WOS:000401945200020 AU - Maa, A. Y. AU - Wojciechowski, B. AU - Hunt, K. AU - Dismuke, C. AU - Janjua, R. AU - Lynch, M. G. DA - JAN-MAR IS - 1 PY - 2017 SN - 1445-6354 ST - Remote eye care screening for rural veterans with Technology-based Eye Care Services: a quality improvement project T2 - RURAL AND REMOTE HEALTH TI - Remote eye care screening for rural veterans with Technology-based Eye Care Services: a quality improvement project VL - 17 ID - 6265 ER - TY - JOUR AB - Purpose The aging population is at risk of common eye diseases, and routine eye examinations are recommended to prevent visual impairment. Unfortunately, patients are less likely to seek care as they age, which may be the result of significant travel and time burdens associated with going to an eye clinic in person. A new method of eye-care delivery that mitigates distance barriers and improves access was developed to improve screening for potentially blinding conditions. We present the quality data from the early experience (first 13 months) of Technology-Based Eye Care Services (TECS), a novel ophthalmologic telemedicine program. Design With TECS, a trained ophthalmology technician is stationed in a primary care clinic away from the main hospital. The ophthalmology technician follows a detailed protocol that collects information about the patient's eyes. The information then is interpreted remotely. Patients with possible abnormal findings are scheduled for a face-to-face examination in the eye clinic. Participants Any patient with no known ocular disease who desires a routine eye screening examination is eligible. Methods Technology-Based Eye Care Services was established in 5 primary care clinics in Georgia surrounding the Atlanta Veterans Affairs hospital. Main Outcome Measures Four program operation metrics (patient satisfaction, eyeglass remakes, disease detection, and visit length) and 2 access-to-care metrics (appointment wait time and no-show rate) were tracked. Results Care was rendered to 2690 patients over the first 13 months of TECS. The program has been met with high patient satisfaction (4.95 of 5). Eyeglass remake rate was 0.59%. Abnormal findings were noted in 36.8% of patients and there was >90% agreement between the TECS reading and the face-to-face findings of the physician. TECS saved both patient (25% less) and physician time (50% less), and access to care substantially improved with 99% of patients seen within 14 days of contacting the eye clinic, with a TECS no-show rate of 5.2%. Conclusions The early experience with TECS has been promising. Tele-ophthalmology has the potential to improve operational efficiency, reduce cost, and significantly improve access to care. Although further study is necessary, TECS shows potential to help prevent avoidable vision loss. © 2017 AD - Ophthalmology Division, Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States Emory University School of Medicine, Atlanta, Georgia, United States Charleston Health Equity and Rural Outreach Innovation Center (HEROIC), Ralph A. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina, United States AU - Maa, A. Y. AU - Wojciechowski, B. AU - Hunt, K. J. AU - Dismuke, C. AU - Shyu, J. AU - Janjua, R. AU - Lu, X. AU - Medert, C. M. AU - Lynch, M. G. DB - Scopus DO - 10.1016/j.ophtha.2016.11.037 IS - 4 M3 - Conference Paper N1 - Cited By :26 Export Date: 19 July 2021 PY - 2017 SP - 539-546 ST - Early Experience with Technology-Based Eye Care Services (TECS): A Novel Ophthalmologic Telemedicine Initiative T2 - Ophthalmology TI - Early Experience with Technology-Based Eye Care Services (TECS): A Novel Ophthalmologic Telemedicine Initiative UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009174463&doi=10.1016%2fj.ophtha.2016.11.037&partnerID=40&md5=f051ebfeda6f6a8d5e86d23c858a1402 VL - 124 ID - 5084 ER - TY - JOUR AD - Francis I. Proctor Foundation and Department of Ophthalmology, University of California, San Francisco. Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Department of Bioengineering and Biophysics Program, University of California, Berkeley. AN - 103969779. Language: English. Entry Date: 20141003. Revision Date: 20200723. Publication Type: journal article AU - Maamari, Robi N. AU - Ausayakhun, Somsanguan AU - Margolis, Todd P. AU - Fletcher, Daniel A. AU - Keenan, Jeremy D. DB - ccm DO - 10.1001/jamaophthalmol.2014.335 DP - EBSCOhost IS - 7 KW - Wireless Communications -- Equipment and Supplies Corneal Ulcer -- Diagnosis Epithelium -- Pathology Health Services Accessibility Photography -- Equipment and Supplies Telemedicine -- Equipment and Supplies Developing Countries Fluorophotometry Health Resource Utilization Human Sensitivity and Specificity Telemedicine -- Methods Thailand N1 - research. Journal Subset: Biomedical; USA. Grant Information: K23 EY010971/EY/NEI NIH HHS/United States. NLM UID: 101589539. PMID: NLM25010172. PY - 2014 SN - 2168-6165 SP - 894-895 ST - Novel telemedicine device for diagnosis of corneal abrasions and ulcers in resource-poor settings T2 - JAMA Ophthalmology TI - Novel telemedicine device for diagnosis of corneal abrasions and ulcers in resource-poor settings UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103969779&site=ehost-live&scope=site VL - 132 ID - 4686 ER - TY - JOUR AB - Introduction: Fixed-combination glaucoma medications have altered the paradigm of ocular hypertension and glaucoma treatment and are in widespread use today. A comprehensive review of fixed-combination medications will help educate and inform providers for optimal patient care. Areas covered: In this review, the authors describe the composition, mechanism of action, efficacy, side effects, and safety profile of fixed-combination agents for the treatment of ocular hypertension and glaucoma as well as comparisons between the most frequently prescribed medications. Expert opinion: Fixed-combination therapeutics provide an effective and efficient means of lowering intraocular pressure with comparable side effects and outcomes to constituent parts with lower patient exposure to preservatives and improvement in compliance. AD - L. Machen, Glaucoma Service, Wills Eye Hospital, 840 Walnut Street, Suite 1110, Philadelphia, PA, United States AU - Machen, L. AU - Razeghinejad, R. AU - Myers, J. S. C1 - azarga(Alcon,United Kingdom) combigan(Allergan,United States) cosopt(Merck and Co,United States) duotrav(Alcon,United States) fotil(Santen,Finland) ganfort(Allergan,United States) krytantek ofteno mikeluna(Otsuka,Japan) rocklatan(Aerie,United States) simbrinza(Alcon,United States) tapticom(Santen,Finland) tim brim dor(imprimis,United States) vyzulta(Valeant,United States) xalacom(Pfizer,United States) C2 - Santen(Finland) Alcon(United Kingdom) Otsuka(Japan) Aerie(United States) Alcon(United States) Allergan(United States) imprimis(United States) Merck and Co(United States) Pfizer(United States) Valeant(United States) DB - Embase Medline DO - 10.1080/14656566.2020.1743264 IS - 10 KW - alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent bimatoprost bimatoprost plus timolol brimonidine brimonidine plus brinzolamide brimonidine plus dorzolamide plus timolol brimonidine plus timolol brinzolamide plus timolol carbonate dehydratase inhibitor carteolol carteolol plus latanoprost carteolol plus pilocarpine dorzolamide dorzolamide plus timolol krytantek ofteno latanoprost latanoprost plus netarsudil latanoprost plus timolol latanoprostene bunod mikeluna netarsudil pilocarpine pilocarpine plus timolol prostaglandin derivative tafluprost plus timolol tapticom tim brim dor timolol timolol plus travoprost travoprost unclassified drug allergic conjunctivitis application site pain asthma blurred vision bradycardia bronchospasm burn burning sensation cardiovascular disease cataract chemical composition chronic obstructive lung disease clinical trial (topic) comparative study conjunctival hemorrhage conjunctival hyperemia conjunctivitis depression dizziness drug efficacy drug mechanism drug safety drug tolerability dry eye dysgeusia eye discharge eye discomfort eye irritation eye pain foreign body glaucoma headache heart block human hyperemia hypertrichosis hypotension intraocular hypertension intraocular pressure lung disease meta analysis (topic) multicenter study (topic) nausea outcome assessment patient care patient compliance phase 2 clinical trial (topic) phase 3 clinical trial (topic) photophobia pruritus punctate keratitis randomized controlled trial (topic) review side effect taste disorder topical treatment visual disorder visual field defect xerostomia azarga combigan cosopt duotrav fotil ganfort rocklatan simbrinza vyzulta xalacom LA - English M3 - Review N1 - L2004515269 2020-04-08 PY - 2020 SN - 1744-7666 1465-6566 SP - 1269-1282 ST - Fixed-combination topical anti-hypertensive ophthalmic agents T2 - Expert Opinion on Pharmacotherapy TI - Fixed-combination topical anti-hypertensive ophthalmic agents UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004515269&from=export http://dx.doi.org/10.1080/14656566.2020.1743264 VL - 21 ID - 2395 ER - TY - JOUR AB - Glaucoma is the most common form of irreversible blindness in the world. Lowering intraocular pressure (IOP) remains the only clinically established method of treatment to slow the progression of glaucoma. Primary open angle glaucoma is a disease of the optic nerve head and often is associated with changes to the trabecular meshwork that cause a reduction to aqueous humour outflow and an increase in intraocular pressure. Until recently, topical IOP lowering medication has been limited to the mechanisms of action of decreasing aqueous production and/or redirecting outflow to the unconventional uveoscleral outflow pathway. Both of these mechanisms neglect to treat or act on tissue that becomes altered from glaucoma. Latanoprostene-bunod 0.024%, a nitric-oxide donating prostanoid, netarsudil 0.02%, a potent Rho-associated protein kinase (ROCK) inhibitor and norepinephrine transporter inhibitor, and a once daily dosed fixed combination medication with netarsudil 0.02% and latanoprost 0.005% have recently come on the market. This paper will discuss and review the limitations to traditional IOP lowering glaucoma medications as well as the mechanism of actions and clinical efficacy of the new glaucoma medications. It will also discuss how the new class of glaucoma medications might help to overcome some known limitations in treatment and barriers to patient adherence. AD - School of Optometry and Vision Science, University of Waterloo, Waterloo, Ontario, Canada Oklahoma College of Optometry, Northeastern State University, Tahlequah, OK, USA AN - 149730635. Language: English. Entry Date: In Process. Revision Date: 20210715. Publication Type: journal article. Journal Subset: Australia & New Zealand AU - MacIver, Sarah AU - Stout, Nicole AU - Ricci, Olivia DB - ccm DO - 10.1080/08164622.2021.1877529 DP - EBSCOhost IS - 3 N1 - Biomedical. NLM UID: 8703442. PMID: NLM33725467. PY - 2021 SN - 0816-4622 SP - 350-366 ST - New considerations for the clinical efficacy of old and new topical glaucoma medications T2 - Clinical & Experimental Optometry TI - New considerations for the clinical efficacy of old and new topical glaucoma medications UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149730635&site=ehost-live&scope=site VL - 104 ID - 4151 ER - TY - JOUR AB - The compliance with treatment of 168 patients with chronic open-angle glaucoma was studied. 42% of the patients missed at least some of their medication. Patients were more likely to miss doses in the middle of the day than in the morning or evening. Two factors found to improve compliance were the knowledge of the name of their eye disease and the possible ill effects of having no treatment. Patients were more likely to be poor compliers if they had been prescribed medication to be used 3 or 4 times a day than if they had been told to use treatment only twice a day. AD - Univ. Surg. Unit, Univ. Southampton, Southampton AU - MacKean, J. M. AU - Elkington, A. R. DB - Embase Medline DO - 10.1136/bjo.67.1.46 IS - 1 KW - acetazolamide epinephrine beta adrenergic receptor blocking agent pilocarpine case report glaucoma human open angle glaucoma patient compliance therapy visual system LA - English M3 - Article N1 - L13172509 1983-03-03 PY - 1983 SN - 0007-1161 SP - 46-49 ST - Compliance with treatment of patients with chronic open-angle glaucoma T2 - British Journal of Ophthalmology TI - Compliance with treatment of patients with chronic open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L13172509&from=export http://dx.doi.org/10.1136/bjo.67.1.46 VL - 67 ID - 4088 ER - TY - JOUR AB - Purpose: To compare the efficacy of bimatoprost and travoprost on intraocular pressure (IOP) reduction in an Egyptian population. Methods: Patients with primary open-angle glaucoma or ocular hypertension were randomized to receive either bimatoprost 0.03% or travoprost 0.004% once daily. IOPs were measured at baseline; 2 weeks; and 1, 2, 4, and 6 months using Goldman applanation tonometery. Results: Seventy-two patients were included: 34 and 38 (P=0.142) with a baseline mean IOP=26.52±5.185 and 26.36±1.605mm Hg (P=0.629) for bimatoprost and travoprost, respectively. Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001). Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit. Mean IOP reductions was 8.77mm Hg (33.39%) and 8.42mm Hg (31.54%) at 2 weeks (P=0.703), and 8.47mm Hg (31.61%) and 7.84mm Hg (29.50%) at 6 months (P=0.536) for bimatoprost and travoprost, respectively. IOPs at 2 weeks were ≤18mm Hg in 20 (58.8%) versus 19 (50%) eyes (P=0.603), and ≤16mm Hg in 12 (35%) versus 12 (32%) eyes (P=0.456); and at 6 months ≤18mm Hg in 22 (65%) versus 14 (37%) eyes (P=0.045), and ≤16mm Hg in 12 (35%) versus 7 (18%) eyes (P=0.037) for bimatoprost and travoprost, respectively. Ocular adverse and clinical success occurred equally with both drops. Conclusion: Both drops lowered IOP effectively but bimatoprost showed a greater non-significant reductions in mean IOP from baseline. © 2010, Mary Ann Liebert, Inc. AD - Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, 29th, 13th St., Apt. No. 11, Maadi, Cairo 11431, Egypt Al Nour Eye Hospital, Cairo, Egypt AU - MacKy, T. A. DB - Scopus DO - 10.1089/jop.2010.0068 IS - 6 M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2010 SP - 605-610 ST - Bimatoprost versus travoprost in an egyptian population: A Hospital-based prospective, randomized study T2 - Journal of Ocular Pharmacology and Therapeutics TI - Bimatoprost versus travoprost in an egyptian population: A Hospital-based prospective, randomized study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649719512&doi=10.1089%2fjop.2010.0068&partnerID=40&md5=1adde308f60a27fca57587eddc537a92 VL - 26 ID - 5477 ER - TY - JOUR AB - Adherence to prescribed medication regimens is difficult for all patients and particularly challenging for the elderly. Medication adherence demands a working relationship between a patient or caregiver and prescriber that values open, honest discussion about medications, i.e. the administration schedule, intended benefits, adverse effects and costs.Although nonadherence to medications may be common among the elderly, fundamental reasons leading to nonadherence vary among patients. Demographic characteristics may help to identify elderly patients who are at risk for nonadherence. Inadequate or marginal health literacy among the elderly is common and warrants assessment. The number of co-morbid conditions and presence of cognitive, vision and/or hearing impairment may predispose the elderly to nonadherence. Similarly, medications themselves may contribute to nonadherence secondary to adverse effects or costs. Especially worrisome is nonadherence to 'less forgiving' drugs that, when missed, may lead to an adverse event (e.g. withdrawal symptoms) or disease exacerbation.Traditional methods for assessing medication adherence are unreliable. Direct questioning at the patient interview may not provide accurate assessments, especially if closed-ended, judgmental questions are posed. Prescription refill records and pill counts often overestimate true adherence rates. However, if elders are asked to describe how they take their medicines (using the Drug Regimen Unassisted Grading Scale or MedTake test tools), adherence problems can be identified in a nonthreatening manner.Medication nonadherence should be suspected in elders who experience a decline in functional abilities. Predictors of medication nonadherence include specific disease states, such as cardiovascular diseases and depression. Technological aids to assessing medication adherence are available, but their utility is, thus far, primarily limited to a few research studies. These computerised devices, which assess adherence to oral and inhaled medications, may offer insight into difficult medication management problems. The most practical method of medication adherence assessment for most elderly patients may be through patient or caregiver interview using open-ended, nonthreatening and nonjudgmental questions. AD - Department of Pharmacy Practice at Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, Texas AN - 106400837. Language: English. Entry Date: 20060224. Revision Date: 20200708. Publication Type: Journal Article AU - MacLaughlin, E. J. AU - Raehl, C. L. AU - Treadway, A. K. AU - Sterling, T. L. AU - Zoller, D. P. AU - Bond, C. A. DB - ccm DO - 10.2165/00002512-200522030-00005 DP - EBSCOhost IS - 3 KW - Medication Compliance -- Evaluation -- In Old Age Prescriptions, Drug Program Evaluation Aged Aged, 80 and Over Breast Neoplasms -- Drug Therapy Cardiovascular Diseases -- Drug Therapy Clinical Trials Glaucoma -- Drug Therapy Lung Diseases, Obstructive -- Drug Therapy N1 - pictorial; review; tables/charts. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 9102074. PMID: NLM15813656. PY - 2005 SN - 1170-229X SP - 231-255 ST - Assessing medication adherence in the elderly: which tools to use in clinical practice? T2 - Drugs & Aging TI - Assessing medication adherence in the elderly: which tools to use in clinical practice? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106400837&site=ehost-live&scope=site VL - 22 ID - 4590 ER - TY - JOUR AB - Purpose Of Review: The management of pediatric glaucoma poses a unique challenge in terms of maintaining lifelong vision and combating an aggressive scarring response from surgery. Contemporary literature regarding the surgical management of children with pediatric glaucoma who fail, or are at a high risk of failure, from conventional surgery is limited. The aim of this review is to highlight recent developments in relation to the current opinion regarding the management of children with refractory pediatric glaucoma.Recent Findings: Some studies have reported impressive success rates with circumferential trabeculotomy, even in eyes with previous failed surgery. Early results of deep sclerectomy in populations which may not respond well to conventional angle surgery are encouraging but data is limited for the pediatric age group. In compliant patients in whom multiple postoperative examinations under anesthesia are possible, trabeculectomy remains an effective procedure. Multiple recent studies have demonstrated that glaucoma drainage device (GDD) surgery is associated with 5-year success rates of over 70% in primary childhood glaucomas.Summary: Glaucoma drainage device surgery is likely to remain a mainstay of surgical management for refractory glaucoma in older children. More prospective data are needed on the success of circumferential trabeculotomy, deep sclerectomy and micropulse laser in pediatric eyes with previous failed surgery. VIDEO ABSTRACT: http://links.lww.com/COOP/A34. AD - Glaucoma Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia Department of Ophthalmology, College of Medicine, Prince Sattam Bin Abdulaziz University, AlKharj, Saudi Arabia Department of Ophthalmology and Visual Sciences, University of Illinois College of Medicine, Chicago, Illinois, USA AN - 143888195. Language: English. Entry Date: In Process. Revision Date: 20210207. Publication Type: journal article AU - Malik, Rizwan AU - AlDarrab, Abdulrahman AU - Edward, Deepak P. DB - ccm DO - 10.1097/ICU.0000000000000642 DP - EBSCOhost IS - 2 KW - Trabeculectomy -- Methods Prostheses and Implants Child Intraocular Pressure -- Physiology N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM31895153. PY - 2020 SN - 1040-8738 SP - 123-131 ST - Contemporary management of refractory pediatric glaucoma T2 - Current Opinion in Ophthalmology TI - Contemporary management of refractory pediatric glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143888195&site=ehost-live&scope=site VL - 31 ID - 4279 ER - TY - JOUR AB - Objectives: To establish the attitudes of glaucoma specialists to the frequency of visual field (VF) testing in the UK, using the NICE recommendations as a standard for ideal practice. Design: Interview and postal survey. Setting: UK and Eire Glaucoma Society national meeting 2011 in Manchester, UK, with a second round of surveys administered by post. Participants: All consultant glaucoma specialists in England and Wales were invited to complete the survey. Primary and secondary outcome measures: (1) Compliance of assigned follow-up VF intervals with NICE guidelines for three hypothetical patient scenarios, with satisfactory treated intraocular pressure and (a) no evidence of VF progression; (b) evidence of VF progression and (c) uncertainty about VF progression, and respondents were asked to provide typical follow-up intervals representative of their practice; (2) attitudes to research recommendations for six VF in the first 2 years for newly diagnosed patients with glaucoma. Results: 70 glaucoma specialists completed the survey. For each of the clinical scenarios a, b and c, 14 (20%), 33 (47%) and 28 (40%) responses, respectively, fell outside the follow-up interval recommended by NICE. Nearly half of the specialists (46%) agreed that 6 VF tests in the first 2 years was ideal practice, while 16 (28%) said this was practice 'not possible', with many giving resources within the NHS setting as a limiting factor. Conclusions: The results from this survey suggest that there is a large variation in attitudes to follow-up intervals for patients with glaucoma in the UK, with assigned intervals for VF testing which are, in many cases, inconsistent with the guidelines from NICE. AD - D.P. Crabb, Division of Optometry and Visual Science, School of Health Science, City University London, London, United Kingdom AU - Malik, R. AU - Baker, H. AU - Russell, R. A. AU - Crabb, D. P. DB - Embase DO - 10.1136/bmjopen-2012-002067 IS - 5 KW - follow up glaucoma health care survey health personnel attitude human interview intraocular pressure medical specialist outcome assessment postal mail practice guideline protocol compliance review United Kingdom visual field LA - English M3 - Review N1 - L369023137 2013-06-07 2013-06-12 PY - 2013 SN - 2044-6055 ST - A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines T2 - BMJ Open TI - A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369023137&from=export http://dx.doi.org/10.1136/bmjopen-2012-002067 http://bmjopen.bmj.com/content/3/5/e002067.full.pdf+html VL - 3 ID - 2991 ER - TY - JOUR AB - Objectives: To establish the attitudes of glaucoma specialists to the frequency of visual field (VF) testing in the UK, using the NICE recommendations as a standard for ideal practice. Design: Interview and postal survey. Setting: UK and Eire Glaucoma Society national meeting 2011 in Manchester, UK, with a second round of surveys administered by post. Participants: All consultant glaucoma specialists in England and Wales were invited to complete the survey. Primary and secondary outcome measures: (1) Compliance of assigned follow-up VF intervals with NICE guidelines for three hypothetical patient scenarios, with satisfactory treated intraocular pressure and (a) no evidence of VF progression; (b) evidence of VF progression and (c) uncertainty about VF progression, and respondents were asked to provide typical follow-up intervals representative of their practice; (2) attitudes to research recommendations for six VF in the first 2 years for newly diagnosed patients with glaucoma. Results: 70 glaucoma specialists completed the survey. For each of the clinical scenarios a, b and c, 14 (20%), 33 (47%) and 28 (40%) responses, respectively, fell outside the follow-up interval recommended by NICE. Nearly half of the specialists (46%) agreed that 6 VF tests in the first 2 years was ideal practice, while 16 (28%) said this was practice 'not possible', with many giving resources within the NHS setting as a limiting factor. Conclusions: The results from this survey suggest that there is a large variation in attitudes to follow-up intervals for patients with glaucoma in the UK, with assigned intervals for VF testing which are, in many cases, inconsistent with the guidelines from NICE. AD - Glaucoma Research Unit, NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital Foundation NHS Trust, London, United Kingdom Division of Optometry and Visual Science, School of Health Science, City University London, London, United Kingdom AU - Malik, R. AU - Baker, H. AU - Russell, R. A. AU - Crabb, D. P. C7 - e002067 DB - Scopus DO - 10.1136/bmjopen-2012-002067 IS - 5 M3 - Review N1 - Cited By :31 Export Date: 19 July 2021 PY - 2013 ST - A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines T2 - BMJ Open TI - A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878415829&doi=10.1136%2fbmjopen-2012-002067&partnerID=40&md5=aabba52dbfcef76dadba83e2b8f02183 VL - 3 ID - 5053 ER - TY - JOUR AB - Objectives: To establish the attitudes of glaucoma specialists to the frequency of visual field (VF) testing in the UK, using the NICE recommendations as a standard for ideal practice. Design: Interview and postal survey. Setting: UK and Eire Glaucoma Society national meeting 2011 in Manchester, UK, with a second round of surveys administered by post. Participants: All consultant glaucoma specialists in England and Wales were invited to complete the survey. Primary and secondary outcome measures: (1) Compliance of assigned follow-up VF intervals with NICE guidelines for three hypothetical patient scenarios, with satisfactory treated intraocular pressure and (a) no evidence of VF progression; (b) evidence of VF progression and (c) uncertainty about VF progression, and respondents were asked to provide typical follow-up intervals representative of their practice; (2) attitudes to research recommendations for six VF in the first 2 years for newly diagnosed patients with glaucoma. Results: 70 glaucoma specialists completed the survey. For each of the clinical scenarios a, b and c, 14 (20%), 33 (47%) and 28 (40%) responses, respectively, fell outside the follow-up interval recommended by NICE. Nearly half of the specialists (46%) agreed that 6 VF tests in the first 2 years was ideal practice, while 16 (28%) said this was practice 'not possible', with many giving resources within the NHS setting as a limiting factor. Conclusions: The results from this survey suggest that there is a large variation in attitudes to follow-up intervals for patients with glaucoma in the UK, with assigned intervals for VF testing which are, in many cases, inconsistent with the guidelines from NICE. AN - WOS:000330538300006 AU - Malik, R. AU - Baker, H. AU - Russell, R. A. AU - Crabb, D. P. DO - 10.1136/bmjopen-2012-002067 IS - 5 PY - 2013 SN - 2044-6055 ST - A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines T2 - BMJ OPEN TI - A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines VL - 3 ID - 5991 ER - TY - JOUR AB - Purpose: To assess the inpatient adherence rate and factors associated with adherence to topical glaucoma medications (TGMs) at a single academic institution throughout hospitalization before and after an educational intervention. Design: Nonrandomized, comparative, retrospective study. Participants: Inpatients 18 years of age and older admitted to a single academic hospital from January 2014 through June 2019 with a diagnosis of glaucoma who also received TGMs. Methods: The medication administration record during admission was examined closely to determine if the TGMs were reconciled and administered correctly before and after an educational intervention with inpatient providers. A simple intervention reached various health care providers through an educational e-mail, communication in a weekly newsletter, and a morning report presentation. Adherence was defined as administration of more than 75% of recommended doses during the inpatient stay. Other collected variables included length of stay and primary diagnosis on admission. Main Outcome Measures: Adherence rate to inpatient administration of TGMs. Results: One hundred eighty-four patients (n = 142 before intervention; n = 42 after intervention) were included. The preintervention group had a total of 275 TGMs, of which 207 (75.3%) were administered in accordance with the adherence definition of this study. After the intervention phase, 49 of 56 (87.5%) TGMs were administered with appropriate adherence (P = 0.047). Adherence was associated significantly with a known outpatient medication regimen (P = 0.006) and correct admission reconciliation (P < 0.001). Conclusions: When glaucoma patients requiring topical treatment are admitted, approximately one quarter of patients seem to not receive their medications appropriately. In this study, a simple educational intervention was able to improve adherence. To prevent daily fluctuations in intraocular pressure for vulnerable glaucoma patients, inpatient adherence to appropriate medication administration should be stressed continuously. While in the care of health care providers, inpatients should be afforded at least the opportunity to maintain adequate adherence, just as is carried out for other medications related to other chronic medical conditions. AD - D.A. Mammo, Department of Ophthalmology, University of Minnesota, Phillips Wangensteen Building, 9th Floor, 516 Delaware Street SE, Minneapolis, MN, United States AU - Mammo, D. A. AU - Strampe, M. AU - Naravane, A. AU - Mallory, P. W. AU - Boysen, J. AU - Wright, M. M. DB - Embase Medline DO - 10.1016/j.ogla.2020.04.007 IS - 5 KW - alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor muscarinic receptor blocking agent prostaglandin adult aged comparative study conference paper controlled study e-mail female glaucoma hospital admission hospital patient hospitalization human interpersonal communication length of stay major clinical study male medication compliance outcome assessment patient compliance patient education priority journal retrospective study risk factor total quality management LA - English M3 - Conference Paper N1 - L2006057563 2020-06-05 2020-10-01 PY - 2020 SN - 2589-4196 SP - 339-342 ST - Inpatient Adherence to Topical Glaucoma Medications before and after an Educational Intervention T2 - Ophthalmology Glaucoma TI - Inpatient Adherence to Topical Glaucoma Medications before and after an Educational Intervention UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2006057563&from=export http://dx.doi.org/10.1016/j.ogla.2020.04.007 VL - 3 ID - 2385 ER - TY - JOUR AB - Aims The Community and Hospital Allied Network Glaucoma Evaluation Scheme (CHANGES) used accredited community-based optometrists with a special interest (OSIs) in glaucoma to monitor ocular hypertensive (OHT) patients under virtual supervision of the Hospital Glaucoma Service (HGS). The purpose of this paper was to report the outcomes of the first completed community-based visit. Methods Eligible patients underwent a glaucoma consultant-led clinical examination before transfer to CHANGES. Individualised intraocular pressure (IOP) and follow-up time interval targets were set for each patient. OSIs used applanation tonometry, slit-lamp biomicroscopy, automated visual field testing and digital optic disc photography. The hospital-based glaucoma team evaluated the data virtually. Patients were referred back to the HGS according to specific criteria. Results One hundred and sixty eight OHT patients were invited to attend their first OSI appointment. Of these, 144 attended their appointment (attendance rate 85.7%). Outcomes of 130 patients with complete data sets are reported. Sixteen patients (12.3%) were referred back to the HGS due to IOP above target, new visual field defects and/or optic nerve changes. The glaucoma consultant retained eight patients (6.1%) within the HGS on the basis of definite or probable glaucomatous conversion. Conclusions CHANGES freed up capacity within a busy HGS. However, improvements need to be made regarding non-attendance rates in the community. The relatively high one-year definite or probable conversion rate emphasises the importance of the comprehensive review of OHT patients and of hospital-led virtual supervision to maintain patient safety. © 2012 Macmillan Publishers Limited All rights reserved. AD - Glaucoma Service, Department of Ophthalmology, Hinchingbrooke Hospital, Hinchingbrooke Park, PE29 6NT Huntingdon, Cambridgeshire, United Kingdom Glaucoma Service, Bedford, Moorfields Eye Hospital, London, United Kingdom Vision and Eye Research Unit, Postgraduate Medical Institute, Anglia Ruskin University, Cambridge, United Kingdom AU - Mandalos, A. AU - Bourne, R. AU - French, K. AU - Newsom, W. AU - Chang, L. DB - Scopus DO - 10.1038/eye.2011.350 IS - 4 KW - community glaucoma monitoring ocular hypertension shared care M3 - Review N1 - Cited By :10 Export Date: 19 July 2021 PY - 2012 SP - 564-567 ST - Shared care of patients with ocular hypertension in the Community and Hospital Allied Network Glaucoma Evaluation Scheme (CHANGES) T2 - Eye TI - Shared care of patients with ocular hypertension in the Community and Hospital Allied Network Glaucoma Evaluation Scheme (CHANGES) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859760452&doi=10.1038%2feye.2011.350&partnerID=40&md5=1f8830a4fc55b9d3d003ac88df2ed524 VL - 26 ID - 5284 ER - TY - JOUR AB - Aims The Community and Hospital Allied Network Glaucoma Evaluation Scheme (CHANGES) used accredited community-based optometrists with a special interest (OSIs) in glaucoma to monitor ocular hypertensive (OHT) patients under virtual supervision of the Hospital Glaucoma Service (HGS). The purpose of this paper was to report the outcomes of the first completed community-based visit. Methods Eligible patients underwent a glaucoma consultant-led clinical examination before transfer to CHANGES. Individualised intraocular pressure (IOP) and follow-up time interval targets were set for each patient. OSIs used applanation tonometry, slit-lamp biomicroscopy, automated visual field testing and digital optic disc photography. The hospital-based glaucoma team evaluated the data virtually. Patients were referred back to the HGS according to specific criteria. Results One hundred and sixty eight OHT patients were invited to attend their first OSI appointment. Of these, 144 attended their appointment (attendance rate 85.7%). Outcomes of 130 patients with complete data sets are reported. Sixteen patients (12.3%) were referred back to the HGS due to IOP above target, new visual field defects and/or optic nerve changes. The glaucoma consultant retained eight patients (6.1%) within the HGS on the basis of definite or probable glaucomatous conversion. Conclusions CHANGES freed up capacity within a busy HGS. However, improvements need to be made regarding non-attendance rates in the community. The relatively high one-year definite or probable conversion rate emphasises the importance of the comprehensive review of OHT patients and of hospital-led virtual supervision to maintain patient safety. Eye (2012) 26, 564-567; doi:10.1038/eye.2011.350; published online 6 January 2012 AN - WOS:000302938500012 AU - Mandalos, A. AU - Bourne, R. AU - French, K. AU - Newsom, W. AU - Chang, L. DA - APR DO - 10.1038/eye.2011.350 IS - 4 PY - 2012 SN - 0950-222X SP - 564-567 ST - Shared care of patients with ocular hypertension in the Community and Hospital Allied Network Glaucoma Evaluation Scheme (CHANGES) T2 - EYE TI - Shared care of patients with ocular hypertension in the Community and Hospital Allied Network Glaucoma Evaluation Scheme (CHANGES) VL - 26 ID - 5850 ER - TY - JOUR AB - We report the first known case of fungal keratitis caused by Aspergillus nomius. Ocular injury was known as a predisposing factor. The patient was treated with natamycin and econazole eye drops, itraconazole eye ointment, and oral ketoconazole. A therapeutic penetrating keratoplasty was performed 16 days after presentation. A sequence-based approach was used to assign the isolate to a species. Copyright © 2009, American Society for Microbiology. All Rights Reserved. AD - Aravind Eye Hospital, Postgraduate Institute of Ophthalmology, Avinashi Road, Coimbatore 641 014, Tamilnadu, India Department of Botany and Microbiology, A. V. V. M. Sri Pushpam College, Poondi 613503, Tanjavur, India Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, H-6726 Szeged, Hungary CBS Fungal Biodiversity Centre, Uppsalalaan 8, 3584 CT Utrecht, Netherlands Department of Clinical Microbiology, Faculty of Medicine, University of Szeged, Somogyi Béla tér 1, H-6725 Szeged, Hungary AU - Manikandan, P. AU - Varga, J. AU - Kocsubé, S. AU - Samson, R. A. AU - Anita, R. AU - Revathi, R. AU - Dóczi, I. AU - Németh, T. M. AU - Narendran, V. AU - Vágvölgyi, C. AU - Manoharan, C. AU - Kredics, L. DB - Scopus DO - 10.1128/JCM.01051-09 IS - 10 M3 - Article N1 - Cited By :30 Export Date: 19 July 2021 PY - 2009 SP - 3382-3385 ST - Mycotic keratitis due to Aspergillus nomius T2 - Journal of Clinical Microbiology TI - Mycotic keratitis due to Aspergillus nomius UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349649222&doi=10.1128%2fJCM.01051-09&partnerID=40&md5=c7e44dbea2c3d34b3bde5bd2852276a9 VL - 47 ID - 5061 ER - TY - JOUR AB - PURPOSE: This study compared the intraocular pressure (IOP)-lowering efficacy of 2 fixed combination products, brinzolamide 1%/timolol 0.5% suspension (Azarga, Brinz/Tim) and dorzolamide 2%/timolol 0.5% solution (Dorz/Tim), in patients with open-angle glaucoma or ocular hypertension who required a change in therapy due to elevated IOP while receiving IOP-lowering medication. METHODS: This was a one-year, multicenter, randomized, double-masked, active-controlled, parallel-group trial of Brinz/Tim and Dorz/Tim. IOP assessments were taken at 8 and 10 AM at week 2 and months 3 and 9, and at 8 AM, 10 AM, and 4 PM at months 6 and 12. Primary efficacy was a noninferiority comparison of mean IOP at the three month 6 time points. RESULTS: Of the 437 patients enrolled, 220 dosed Brinz/Tim whereas 217 dosed Dorz/Tim twice daily. Brinz/Tim produced IOP-lowering efficacy comparable to Dorz/Tim, with the upper 95% confidence limits for the differences between groups within +1.5 mm Hg at all assessment times, including the month 6 primary efficacy time points, establishing noninferiority. Differences in means numerically favored Brinz/Tim at 9 of 12 study visits and times. The IOP reductions ranged from 7.2 to 9.2 mm Hg for Brinz/Tim and from 7.4 to 8.9 mm Hg for Dorz/Tim. Although a similar overall safety profile was observed between the 2 treatment groups, Brinz/Tim showed significantly less ocular irritation (2.7% vs. 10.6%; P=0.0009) than Dorz/Tim. CONCLUSIONS: Brinz/Tim suspension provides statistically significant and clinically relevant IOP-lowering efficacy that is noninferior to Dorz/Tim. Additionally, Brinz/Tim affords an ocular comfort advantage compared with Dorz/Tim. © 2009 Lippincott Williams & Wilkins, Inc. AD - University of Rome, Tor Vergata, Bietti Foundation IRCSS, Rome, Italy Alcon Italia S.p.A, Milan, Italy Ophthalmology Department, Hopital Edouard Herriot, Lyon, France National University Hospital, Singapore, Singapore Singapore National Eye Centre, Singapore, Singapore Glaucoma Consultants and Center for Eye Research, Mount Mount, SC, United States Baylor College of Medicine, Houston, TX, United States Alcon Research Ltd., Fort Worth, TX, United States Royal Victorian Eye and Ear Hospital, Centre for Eye Research, VIC, Australia Department of Ophthalmology, P. Stradins Clinical University Hospital, Riga, Latvia Glaucoma Service Outpatient Department, Clinical Hospital Gailezers, Riga, Latvia Ophthalmology Department, University Hospital, Leuven, Belgium Ophthalmology Department, University of Roma, Tor Vergata, V.le Oxford 81, Rome, Italy AU - Manni, G. AU - Denis, P. AU - Chew, P. AU - Sharpe, E. D. AU - Orengo-Nania, S. AU - Coote, M. A. AU - Laganovska, G. AU - Volksone, L. AU - Zeyen, T. AU - Filatori, I. AU - James, J. AU - Aung, T. DB - Scopus DO - 10.1097/IJG.0b013e31818fb434 IS - 4 KW - Brinzolamide Dorzolamide Fixed combination Glaucoma IOP Timolol M3 - Article N1 - Cited By :58 Export Date: 19 July 2021 PY - 2009 SP - 293-300 ST - The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension T2 - Journal of Glaucoma TI - The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67651183720&doi=10.1097%2fIJG.0b013e31818fb434&partnerID=40&md5=d38455df9d09850cac96f129af18f839 VL - 18 ID - 4975 ER - TY - JOUR AB - Purpose: This study compared the intraocular pressure (IOP)lowering efficacy of 2 fixed combination products, brinzolamide 1%/timolol 0.5% suspension (Azarga, Brinz/Tim) and dorzolamide 2%/timolol 0.5% solution (Dorz/Tim), in patients with open-angle glaucoma or ocular hypertension who required a change in therapy due to elevated IOP while receiving IOP-lowering medication. Methods: This was a one-year, multicenter, randomized, double-masked. active-controlled, parallel-group trial of Brinz/Tim and Dorz/Tim. IOP assessments were taken at 8 and 10 Ant at week 2 and months 3 and 9, and at 8 AM, 10 AM, and 4 PM at months 6 and 12. Primary efficacy was a noninferiority comparison of mean IOP at the three month 6 time points. Results: Of the 437 patients enrolled. 220 dosed Brinz/Tim whereas 217 dosed Dorz/Tim twice daily. Brinz/Tim produced IOP-lowering efficacy comparable to Dorz/Tim, with the upper 95% confidence limits for the differences between groups within + 1.5 mm Hg at all assessment times, including the month 6 primary efficacy time points, establishing noninferiority. Differences in means numerically favored Brinz/Tim at 9 of 12 study visits and times. The IOP reductions ranged from 7.2 to 9.2 mm Hg for Brinz/Tim and from 7.4 to 8.9 mm Hg for Dorz/Tim. Although a similar overall safety profile was observed between the 2 treatment groups, Brinz/Tim showed significantly less ocular irritation (2.7% vs. 10.6%; P = 0.0009) than Dorz/Tim. Conclusions: Brinz/Tim suspension provides statistically significant and clinically relevant IOP-lowering efficacy that is noninferior to Dorz/Tim. Additionally, Brinz/Tim affords an ocular comfort advantage compared with Dorz/Tim. AN - WOS:000265270900006 AU - Manni, G. AU - Denis, P. AU - Chew, P. AU - Sharpe, E. D. AU - Orengo-Nania, S. AU - Coote, M. A. AU - Laganovska, G. AU - Volksone, L. AU - Zeyen, T. AU - Filatori, I. AU - James, J. AU - Aung, T. DA - APR-MAY DO - 10.1097/IJG.0b013e31818fb434 IS - 4 PY - 2009 SN - 1057-0829 1536-481X SP - 293-300 ST - The Safety and Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 2%/Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension T2 - JOURNAL OF GLAUCOMA TI - The Safety and Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 2%/Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension VL - 18 ID - 6214 ER - TY - JOUR AD - S.L. Mansberger, Devers Eye Institute, Portland, OR, United States AU - Mansberger, S. L. DB - Embase Medline DO - 10.1016/j.ajo.2009.08.011 IS - 1 KW - antiglaucoma agent eye drops accuracy blindness cataract extraction disease course disease severity doctor patient relationship drug cost drug monitoring editorial eye care glaucoma health behavior Health Belief Model health care cost health care personnel hospitalization human intraocular hypertension intraocular pressure patient compliance patient education pharmacy (shop) priority journal productivity travel visual impairment LA - English M3 - Editorial N1 - L355794542 2010-01-08 PY - 2010 SN - 0002-9394 SP - 1-3 ST - Are You Compliant With Addressing Glaucoma Adherence? T2 - American Journal of Ophthalmology TI - Are You Compliant With Addressing Glaucoma Adherence? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355794542&from=export http://dx.doi.org/10.1016/j.ajo.2009.08.011 VL - 149 ID - 3278 ER - TY - JOUR AD - Devers Eye Institute, Portland, Oregon. AN - 105298910. Language: English. Entry Date: 20100226. Revision Date: 20200708. Publication Type: editorial AU - Mansberger, S. L. AU - Mansberger, Steven L. DB - ccm DO - 10.1016/j.ajo.2009.08.011 DP - EBSCOhost IS - 1 KW - Antihypertensive Agents -- Administration and Dosage Glaucoma -- Drug Therapy Medication Compliance Patient Compliance Antihypertensive Agents -- Economics Economic Aspects of Illness Glaucoma -- Psychosocial Factors Patients -- Psychosocial Factors N1 - editorial. Journal Subset: Biomedical; USA. Grant Information: K23 EY015501/EY/NEI NIH HHS/United States. NLM UID: 0370500. PMID: NLM20103035. PY - 2010 SN - 0002-9394 SP - 1-3 ST - Are you compliant with addressing glaucoma adherence? T2 - American Journal of Ophthalmology TI - Are you compliant with addressing glaucoma adherence? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105298910&site=ehost-live&scope=site VL - 149 ID - 4531 ER - TY - JOUR AB - Purpose: To report the psychometrics of the Glaucoma Treatment Compliance Assessment Tool (GTCAT), a new questionnaire designed to assess adherence with glaucoma therapy. Methods: We developed the questionnaire according to the constructs of the Health Belief Model. We evaluated the questionnaire using data from a cross-sectional study with focus groups (n = 20) and a prospective observational case series (n=58). Principal components analysis provided assessment of construct validity. We repeated the questionnaire after 3 months for test-retest reliability. We evaluated predictive validity using an electronic dosing monitor as an objective measure of adherence. Results: Focus group participants provided 931 statements related to adherence, of which 88.7% (826/931) could be categorized into the constructs of the Health Belief Model. Perceived barriers accounted for 31% (288/931) of statements, cues-to-action 14% (131/931), susceptibility 12% (116/931), benefits 12% (115/931), severity 10% (91/931), and self-efficacy 9% (85/931). The principal components analysis explained 77% of the variance with five components representing Health Belief Model constructs. Reliability analyses showed acceptable Cronbach's alphas (>.70) for four of the seven components (severity, susceptibility, barriers [eye drop administration], and barriers [discomfort]). Predictive validity was high, with several Health Belief Model questions significantly associated (P <.05) with adherence and a correlation coefficient (R2) of.40. Test-retest reliability was 90%. Conclusion: The GTCAT shows excellent repeatability, content, construct, and predictive validity for glaucoma adherence. A multisite trial is needed to determine whether the results can be generalized and whether the questionnaire accurately measures the effect of interventions to increase adherence. AD - Devers Eye Institute/Discoveries In Sight, Legacy Health, Portland, OR, United States AU - Mansberger, S. L. AU - Sheppler, C. R. AU - McClure, T. M. AU - VanAlstine, C. L. AU - Swanson, I. L. AU - Stoumbos, Z. AU - Lambert, W. E. C1 - travatan(Alcon,United States) C2 - Alcon(United States) DB - Embase Medline KW - eye drops travoprost adult aged article clinical assessment tool content validity correlation coefficient drug efficacy eye pain female follow up glaucoma Glaucoma Treatment Compliance Assessment Tool Health Belief Model human instrument validation intraocular pressure major clinical study male medication compliance patient compliance predictive validity priority journal prospective study psychometry questionnaire reproducibility risk benefit analysis self concept test retest reliability treatment outcome unspecified side effect travatan LA - English M3 - Article N1 - L369566730 2013-08-22 2013-09-10 PY - 2013 SN - 1545-6110 SP - 1-16 ST - Psychometrics of a new questionnaire to assess Glaucoma adherence: The Glaucoma treatment compliance assessment tool T2 - Transactions of the American Ophthalmological Society TI - Psychometrics of a new questionnaire to assess Glaucoma adherence: The Glaucoma treatment compliance assessment tool UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369566730&from=export http://www.aosonline.org/xactions/2013/1545-6110_v111_p001.pdf VL - 111 ID - 2969 ER - TY - JOUR AB - Purpose: To report the psychometrics of the Glaucoma Treatment Compliance Assessment Tool (GTCAT), a new questionnaire designed to assess adherence with glaucoma therapy. Methods: We developed the questionnaire according to the constructs of the Health Belief Model. We evaluated the questionnaire using data from a cross-sectional study with focus groups (n = 20) and a prospective observational case series (n=58). Principal components analysis provided assessment of construct validity. We repeated the questionnaire after 3 months for test-retest reliability. We evaluated predictive validity using an electronic dosing monitor as an objective measure of adherence. Results: Focus group participants provided 931 statements related to adherence, of which 88.7% (826/931) could be categorized into the constructs of the Health Belief Model. Perceived barriers accounted for 31% (288/931) of statements, cues-to-action 14% (131/931), susceptibility 12% (116/931), benefits 12% (115/931), severity 10% (91/931), and self-efficacy 9% (85/931). The principal components analysis explained 77% of the variance with five components representing Health Belief Model constructs. Reliability analyses showed acceptable Cronbach's alphas (>.70) for four of the seven components (severity, susceptibility, barriers [eye drop administration], and barriers [discomfort]). Predictive validity was high, with several Health Belief Model questions significantly associated (P <.05) with adherence and a correlation coefficient (R2) of.40. Test-retest reliability was 90%. Conclusion: The GTCAT shows excellent repeatability, content, construct, and predictive validity for glaucoma adherence. A multisite trial is needed to determine whether the results can be generalized and whether the questionnaire accurately measures the effect of interventions to increase adherence. AD - Devers Eye Institute/Discoveries In Sight, Legacy Health, Portland, OR, United States Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, United States AU - Mansberger, S. L. AU - Sheppler, C. R. AU - McClure, T. M. AU - VanAlstine, C. L. AU - Swanson, I. L. AU - Stoumbos, Z. AU - Lambert, W. E. DB - Scopus M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2013 SP - 1-16 ST - Psychometrics of a new questionnaire to assess Glaucoma adherence: The Glaucoma treatment compliance assessment tool T2 - Transactions of the American Ophthalmological Society TI - Psychometrics of a new questionnaire to assess Glaucoma adherence: The Glaucoma treatment compliance assessment tool UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881511264&partnerID=40&md5=2a9b5a6770d18e63a1b17d45437a3615 VL - 111 ID - 5201 ER - TY - JOUR AD - K. Mansouri, Glaucoma Research Center, Montchoisi Clinic, Swiss Visio Network, Avenue du Servan 38, Lausanne, Switzerland AU - Mansouri, K. AU - Gillmann, K. AU - Bravetti, G. E. DB - Embase Medline DO - 10.1001/jamaophthalmol.2019.2337 IS - 9 KW - developed country developing country disease burden glaucoma glaucoma surgery health care access health care cost human letter priority journal visual impairment LA - English M3 - Letter N1 - L628433262 2019-07-12 2019-09-25 PY - 2019 SN - 2168-6165 SP - 1090-1091 ST - A Metric to Consider on the Global Accessibility of Glaucoma Surgery T2 - JAMA Ophthalmology TI - A Metric to Consider on the Global Accessibility of Glaucoma Surgery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628433262&from=export http://dx.doi.org/10.1001/jamaophthalmol.2019.2337 VL - 137 ID - 2486 ER - TY - JOUR AD - Glaucoma Research Center, Montchoisi Clinic, Swiss Visio Network, Lausanne, Switzerland Department of Ophthalmology, University of Colorado School of Medicine, Denver AN - 138617575. Language: English. Entry Date: 20200614. Revision Date: 20191001. Publication Type: journal article. Journal Subset: Biomedical AU - Mansouri, Kaweh AU - Gillmann, Kevin AU - Bravetti, Giorgio Enrico DB - ccm DO - 10.1001/jamaophthalmol.2019.2337 DP - EBSCOhost IS - 9 N1 - USA. NLM UID: 101589539. PMID: NLM31268509. PY - 2019 SN - 2168-6165 SP - 1090-1091 ST - A Metric to Consider on the Global Accessibility of Glaucoma Surgery T2 - JAMA Ophthalmology TI - A Metric to Consider on the Global Accessibility of Glaucoma Surgery UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138617575&site=ehost-live&scope=site VL - 137 ID - 4322 ER - TY - JOUR AB - To document the rate of self-reported compliance and glaucoma-related knowledge in Swiss patients and to identify risk factors for their poor compliance. This was an observational study, including a total of 200 consecutive patients already under glaucoma medication in two Swiss tertiary glaucoma clinics (Geneva and Bern). Personal characteristics, presence of systemic disease, compliance with glaucoma medication, attitude to the ophthalmologist, and glaucoma-related attitudes were ascertained by means of a predetermined questionnaire with 40 questions. Patients were subsequently assessed for the ability to correctly instil placebo eye drops. Non-compliance with glaucoma medication was defined as omitting more than two doses a week as reported by the patient. Logistic regression was used to evaluate how patient characteristics and knowledge about the disease were related to compliance. Overall, 81% (n = 162) of patients reported to be compliant. Forgetfulness was the most frequently cited reason for non-compliance with dosing regimen (63%). Although 90.5% (n = 181) of patients believed glaucoma medication to be efficient, only 28% (n = 56) could correctly define glaucoma. Factors positively associated with compliance were 'knowledge of glaucoma' [adjusted odds ratio (OR) 4.77 (95% CI 1.36-16.70)] and 'getting help for administration of drops' [OR 2.95 (1.25-6.94)]. These findings indicate that despite the comparatively high compliance rate among glaucoma patients, knowledge of glaucoma remains poor in long-term glaucoma sufferers. Improving knowledge about the disease is important since it is positively associated with compliance in our study. © 2011 Springer Science+Business Media B.V. AD - K. Mansouri, Division of Ophthalmology, University of Geneva, Glaucoma Sector, 22, Rue Alcide Jentzer, Genève 1211, Switzerland AU - Mansouri, K. AU - Iliev, M. E. AU - Rohrer, K. AU - Shaarawy, T. DB - Embase Medline DO - 10.1007/s10792-011-9468-2 IS - 5 KW - alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor prostaglandin derivative adult aged article controlled study female glaucoma human knowledge major clinical study male observational study open angle glaucoma patient attitude patient compliance questionnaire risk factor self report Switzerland systemic disease LA - English M3 - Article N1 - L51659331 2011-10-14 2011-12-22 PY - 2011 SN - 0165-5701 1573-2630 SP - 369-376 ST - Compliance and knowledge about glaucoma in patients at tertiary glaucoma units T2 - International Ophthalmology TI - Compliance and knowledge about glaucoma in patients at tertiary glaucoma units UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51659331&from=export http://dx.doi.org/10.1007/s10792-011-9468-2 VL - 31 ID - 3147 ER - TY - JOUR AD - K. Mansouri, Jules Gonin Eye Hospital, University of Lausanne, 15 Avenue de France, 1007 Lausanne, Switzerland AU - Mansouri, K. AU - Shaarawy, T. DB - Embase Medline DO - 10.1111/j.1755-3768.2009.01513.x IS - 4 KW - antiglaucoma agent glaucoma human letter patient compliance patient education priority journal risk reduction treatment refusal LA - English M3 - Letter N1 - L354662569 2009-06-25 PY - 2009 SN - 1755-375X SP - 468-469 ST - Will improvement of knowledge lead to improvement of compliance with glaucoma medication? T2 - Acta Ophthalmologica TI - Will improvement of knowledge lead to improvement of compliance with glaucoma medication? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354662569&from=export http://dx.doi.org/10.1111/j.1755-3768.2009.01513.x VL - 87 ID - 3351 ER - TY - JOUR AB - Compliance with glaucoma therapy is relatively poor. Because glaucoma progresses slowly, long-term adherence is crucial to improving clinical and financial outcomes of treatment. Physicians must consider several factors before steps can be taken to promote correct use of medications. AD - S.S. Mansukani AU - Mansukani, S. S. DB - Medline IS - 11 Suppl KW - article clinical practice doctor patient relationship glaucoma human patient compliance patient education prescription United States LA - English M3 - Article N1 - L39321535 2004-10-17 PY - 2002 SN - 1062-3388 SP - 49-53 ST - Improving adherence to drug-treatment regimens for glaucoma T2 - Managed care (Langhorne, Pa.) TI - Improving adherence to drug-treatment regimens for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39321535&from=export VL - 11 ID - 3849 ER - TY - JOUR AD - M.Y. Kahook, Mail Stop F-731, 1675 Aurora Court, Aurora, CO, United States AU - Marando, C. M. AU - Seibold, L. K. AU - Soohoo, J. R. AU - Pantcheva, M. B. AU - Ramulu, P. Y. AU - Kahook, M. Y. DB - Embase Medline DO - 10.1016/j.ophtha.2015.04.039 IS - 12 KW - adult aged color drug packaging female glaucoma human intraocular pressure major clinical study male packaging material patient compliance patient satisfaction priority journal short survey topical treatment very elderly LA - English M3 - Short Survey N1 - L604804482 2015-06-16 2015-12-03 PY - 2015 SN - 1549-4713 0161-6420 SP - 2577-2578 ST - The utility of cap color and bottle characteristics for topical glaucoma therapy T2 - Ophthalmology TI - The utility of cap color and bottle characteristics for topical glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604804482&from=export http://dx.doi.org/10.1016/j.ophtha.2015.04.039 VL - 122 ID - 2849 ER - TY - JOUR AB - PURPOSE: Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects. Brinzolamide 1.0%, a new topical ocular carbonic anhydrase inhibitor, is effective apparently without significant systemic side effects. This study was performed to establish the long-term safety and efficacy of brinzolamide 1.0% two and three times daily for primary open-angle glaucoma and ocular hypertension. METHODS: An 18-month, multicenter, double-masked, parallel, controlled study was conducted. Patients were randomized to brinzolamide two or three times daily or timolol 0.5% twice daily in a 2:2:1 ratio (n = 150, 153, and 75, respectively). Intraocular pressure was measured at 8:00 AM at eligibility and months 1, 3, 6, 9, 12, 15, and 18. Efficacy was based on intraocular pressure reduction from baseline. Safety was also evaluated. RESULTS: All regimens produced clinically relevant and statistically significant (P < .05) intraocular pressure reductions from baseline. Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice- daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with - 4.7 to -5.6 mm Hg with timolol. The intraocular pressure reductions with brinzolamide two and three times daily were clinically and statistically equivalent. One hundred forty-four patients were discontinued from the study after randomization with the most common reasons being the occurrence of an adverse event (46), inadequate intraocular pressure control (23), patient decision unrelated to study medication (11), lost to follow-up (16), and noncompliance (9). Adverse events were nonserious and resolved without sequelae. There were no clinically relevant changes in safety parameters. Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects. CONCLUSION: Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months. Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort. (C) 2000 by Elsevier Science Inc. AD - W.F. March, Dept. of Ophthalmol./Visual Sciences, University of Texas Medical Branch, 700 University Blvd, Galveston, TX 77550, United States AU - March, W. F. AU - Ochsner, K. I. C1 - azopt(Alcon,United States) timoptic(Merck) C2 - Alcon(United States) Merck DB - Embase Medline DO - 10.1016/S0002-9394(99)00343-8 IS - 2 KW - brinzolamide carbonate dehydratase inhibitor timolol timolol maleate adult aged article clinical trial controlled clinical trial controlled study dose response drug efficacy drug safety female human human cell human tissue intraocular hypertension intraocular pressure abnormality long term exposure major clinical study male multicenter study open angle glaucoma priority journal randomized controlled trial single blind procedure taste disorder visual impairment azopt timoptic LA - English M3 - Article N1 - L30089271 2000-02-24 PY - 2000 SN - 0002-9394 SP - 136-143 ST - The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension T2 - American Journal of Ophthalmology TI - The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30089271&from=export http://dx.doi.org/10.1016/S0002-9394(99)00343-8 VL - 129 ID - 3912 ER - TY - JOUR AB - PURPOSE: Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects. Brinzolamide 1.0%, a new topical ocular carbonic anhydrase inhibitor, is effective apparently without significant systemic side effects. This study was performed to establish the long-term safety and efficacy of brinzolamide 1.0% two and three times daily for primary open-angle glaucoma and ocular hypertension. METHODS: An 18-month, multicenter, double-masked, parallel, controlled study was conducted. Patients were randomized to brinzolamide two or three times daily or timolol 0.5% twice daily in a 2:2:1 ratio (n = 150, 153, and 75, respectively). Intraocular pressure was measured at 8:00 AM at eligibility and months 1, 3, 6, 9, 12, 15, and 18. Efficacy was based on intraocular pressure reduction from baseline. Safety was also evaluated. RESULTS: All regimens produced clinically relevant and statistically significant (P < .05) intraocular pressure reductions from baseline. Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol. The intraocular pressure reductions with brinzolamide two and three times daily were clinically and statistically equivalent. One hundred forty-four patients were discontinued from the study after randomization with the most common reasons being the occurrence of an adverse event (46), inadequate intraocular pressure control (23), patient decision unrelated to study medication (11), lost to follow-up (16), and noncompliance (9). Adverse events were nonserious and resolved without sequelae. There were no clinically relevant changes in safety parameters. Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects. CONCLUSION: Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months. Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort. (Am J Ophthalmol 2000;129:136-143. (C) 2000 by Elsevier Science Inc. All rights reserved.) AN - WOS:000085230800002 AU - March, W. F. AU - Ochsner, K. I. AU - Brinzolamide Long-Term Therapy, Stu DA - FEB DO - 10.1016/S0002-9394(99)00343-8 IS - 2 PY - 2000 SN - 0002-9394 1879-1891 SP - 136-143 ST - The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension VL - 129 ID - 6164 ER - TY - JOUR AB - PURPOSE: Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects. Brinzolamide 1.0%, a new topical ocular carbonic anhydrase inhibitor, is effective apparently without significant systemic side effects. This study was performed to establish the long-term safety and efficacy of brinzolamide 1.0% two and three times daily for primary open-angle glaucoma and ocular hypertension. METHODS: An 18-month, multicenter, double-masked, parallel, controlled study was conducted. Patients were randomized to brinzolamide two or three times daily or timolol 0.5% twice daily in a 2:2:1 ratio (n = 150, 153, and 75, respectively). Intraocular pressure was measured at 8:00 AM at eligibility and months 1, 3, 6, 9, 12, 15, and 18. Efficacy was based on intraocular pressure reduction from baseline. Safety was also evaluated. RESULTS: All regimens produced clinically relevant and statistically significant (P <. 05) intraocular pressure reductions from baseline. Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice- daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with - 4.7 to -5.6 mm Hg with timolol. The intraocular pressure reductions with brinzolamide two and three times daily were clinically and statistically equivalent. One hundred forty-four patients were discontinued from the study after randomization with the most common reasons being the occurrence of an adverse event (46), inadequate intraocular pressure control (23), patient decision unrelated to study medication (11), lost to follow-up (16), and noncompliance (9). Adverse events were nonserious and resolved without sequelae. There were no clinically relevant changes in safety parameters. Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects. CONCLUSION: Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months. Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort. © 2000 by Elsevier Science Inc. AD - University of Texas Medical Branch, Galveston, TX, United States AU - March, W. F. AU - Ochsner, K. I. AU - The Brinzolamide Long-term Therapy Study, Group DB - Scopus DO - 10.1016/S0002-9394(99)00343-8 IS - 2 M3 - Article N1 - Cited By :71 Export Date: 19 July 2021 PY - 2000 SP - 136-143 ST - The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension T2 - American Journal of Ophthalmology TI - The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033975428&doi=10.1016%2fS0002-9394%2899%2900343-8&partnerID=40&md5=9667dc9eb48cf31b3d4300486f6b4e00 VL - 129 ID - 4956 ER - TY - JOUR AB - Background: After a successful trabeculectomy, a sudden intraocular pressure decrease may alter the intracranial to intraocular pressure ratio and cause decompression retinopathy. Frequent Valsalva maneuvers may also play a role in its pathogenesis. This condition may manifest as multiple retinal hemorrhages, edema of the optic disc, macular edema, or a sudden decrease in visual acuity postoperatively. Outcomes for patients are usually good, with spontaneous resolution occurring within a matter of weeks. It has been rarely reported in the literature as a bilateral condition.Case Presentation: We present a case of consecutive bilateral decompression retinopathy in a 54-year-old severely obese Caucasian woman (body mass index 37 kg/m(2)) with open angle glaucoma and a poor history of medical therapeutic compliance, who chose surgical treatment based on her inability to consistently use ocular drops. Our patient underwent a trabeculectomy with mitomycin C in both eyes, with surgeries taking place 3 months apart. After the first surgery, 2 weeks postoperatively, she complained of decreased visual acuity. Examination of her right eye fundus revealed multiple retinal hemorrhages and disc edema. There was a similar pattern in her left eye, this time including maculopathy. Her visual acuity and fundoscopic changes resolved spontaneously over a period of a month in both cases. Currently, our patient has well-controlled bilateral intraocular pressure, ranging between 14 and 16 mmHg, without hypotensive medication.Conclusions: Decompression retinopathy is a potential complication after glaucoma surgery, but has rarely been described as a bilateral consecutive condition. A comprehensive approach could help to anticipate its occurrence and manage it. AD - Ophthalmology Department - Centro Hospital do Porto, EPE -- Hospital de Santo António, Largo Professor Abel Salazar, 4099-001 Porto, Portugal Wills Eye Hospital, Jefferson Medical College, 840 Walnut Street, Philadelphia, PA 19107, USA Ophthalmology Department - Centro Hospital do Porto, EPE - Hospital de Santo António, Largo Professor Abel Salazar, 4099-001, Porto, Portugal AN - 112821038. Language: English. Entry Date: In Process. Revision Date: 20190516. Publication Type: journal article AU - Marcos Figueiredo, Ana Raquel AU - Coutinho Sampaio, Isabel AU - dos Santos Menéres, Maria João Fernandes AU - Spaeth, George L. AU - Figueiredo, Ana Raquel Marcos AU - Sampaio, Isabel Coutinho AU - Menéres, Maria João Fernandes Dos Santos AU - Fernandes dos Santos Menéres, Maria João DB - ccm DO - 10.1186/s13256-016-0814-x DP - EBSCOhost KW - Retinal Diseases -- Etiology Trabeculectomy -- Adverse Effects Middle Age Mitomycins -- Therapeutic Use Indicators and Reagents -- Therapeutic Use Decompression Sickness -- Prevention and Control Eye Hemorrhage -- Etiology Female Glaucoma -- Surgery Optic Nerve Diseases -- Etiology Interview Guides N1 - case study. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. Instrumentation: Diagnostic Interview Schedule for Children (DISC). NLM UID: 101293382. PMID: NLM26846338. PY - 2016 SN - 1752-1947 SP - 1-6 ST - Consecutive bilateral decompression retinopathy after mitomycin C trabeculectomy: a case report T2 - Journal of Medical Case Reports TI - Consecutive bilateral decompression retinopathy after mitomycin C trabeculectomy: a case report UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112821038&site=ehost-live&scope=site VL - 10 ID - 4344 ER - TY - JOUR AB - Background: Panophthalmitis is a severe inflammation of the globe that can result as a rare complication of ophthalmic surgery. In severe cases, it may also be associated with orbital inflammation and cavernous sinus thrombosis. Purpose: This case demonstrates a rare and life-threatening post-operative complication of cataract surgery. We also hope to highlight the importance of considering the relevant risk factors associated with developing potential infections after cataract surgery, including the use of corneal sutures, high-risk behaviours such as excessive eye-rubbing, and noncompliance with appointments and post-operative medications. Case Report: We report the case of a 35-year-old female with severe autism and developmental delay who developed panophthalmitis, orbital inflammation and cavernous sinus thrombosis 6 weeks post cataract surgery. The likely cause was corneal suture-related microbial keratitis, and the patient required enucleation due to sepsis. Conclusion: Post-surgical panophalmitis is a rapidly progressive disease that is not only sight-but life-threatening and demands urgent and intensive treatment. Consideration of early enucleation may be required to prevent deterioration in such patients. AD - E. Marinos, Ophthalmology Department, Westmead Hospital, Sydney, NSW, Australia AU - Marinos, E. AU - McCall, D. AU - Tumuluri, K. AU - Rowe, N. AU - Do, H. DB - Embase DO - 10.2147/IMCRJ.S274140 KW - suture abscess adult article autism case report cataract cataract extraction cavernous sinus thrombosis clinical article developmental delay eye enucleation female high risk behavior human infection risk microbial keratitis orbit inflammation panophthalmitis postoperative complication rare disease sepsis treatment refusal LA - English M3 - Article N1 - L2005465570 2020-11-23 2021-02-05 PY - 2020 SN - 1179-142X SP - 569-572 ST - Panophthalmitis and orbital inflammation with cavernous sinus thrombosis following cataract surgery T2 - International Medical Case Reports Journal TI - Panophthalmitis and orbital inflammation with cavernous sinus thrombosis following cataract surgery UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005465570&from=export http://dx.doi.org/10.2147/IMCRJ.S274140 VL - 13 ID - 2449 ER - TY - JOUR AB - Background: Panophthalmitis is a severe inflammation of the globe that can result as a rare complication of ophthalmic surgery. In severe cases, it may also be associated with orbital inflammation and cavernous sinus thrombosis. Purpose: This case demonstrates a rare and life-threatening post-operative complication of cataract surgery. We also hope to highlight the importance of considering the relevant risk factors associated with developing potential infections after cataract surgery, including the use of corneal sutures, high-risk behaviours such as excessive eye-rubbing, and noncompliance with appointments and post-operative medications. Case Report: We report the case of a 35-year-old female with severe autism and developmental delay who developed panophthalmitis, orbital inflammation and cavernous sinus thrombosis 6 weeks post cataract surgery. The likely cause was corneal suture-related microbial keratitis, and the patient required enucleation due to sepsis. Conclusion: Post-surgical panophalmitis is a rapidly progressive disease that is not only sight-but life-threatening and demands urgent and intensive treatment. Consideration of early enucleation may be required to prevent deterioration in such patients. © 2020 Marinos et al. AD - Ophthalmology Department, Westmead Hospital, Sydney, NSW, Australia AU - Marinos, E. AU - McCall, D. AU - Tumuluri, K. AU - Rowe, N. AU - Do, H. DB - Scopus DO - 10.2147/IMCRJ.S274140 KW - Cavernous sinus thrombosis Enucleation Orbital cellulitis Panophthalmitis Suture abscess M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - 569-572 ST - Panophthalmitis and orbital inflammation with cavernous sinus thrombosis following cataract surgery T2 - International Medical Case Reports Journal TI - Panophthalmitis and orbital inflammation with cavernous sinus thrombosis following cataract surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096186412&doi=10.2147%2fIMCRJ.S274140&partnerID=40&md5=10f8433b9c89d54b39f8d0fd1a49ae23 VL - 13 ID - 5608 ER - TY - JOUR AB - Background: Panophthalmitis is a severe inflammation of the globe that can result as a rare complication of ophthalmic surgery. In severe cases, it may also be associated with orbital inflammation and cavernous sinus thrombosis. Purpose: This case demonstrates a rare and life-threatening post-operative complication of cataract surgery. We also hope to highlight the importance of considering the relevant risk factors associated with developing potential infections after cataract surgery, including the use of corneal sutures, high-risk behaviours such as excessive eye-rubbing, and noncompliance with appointments and post-operative medications. Case Report: We report the case of a 35-year-old female with severe autism and developmental delay who developed panophthalmitis, orbital inflammation and cavernous sinus thrombosis 6 weeks post cataract surgery. The likely cause was corneal suture-related microbial keratitis, and the patient required enucleation due to sepsis. Conclusion: Post-surgical panophalmitis is a rapidly progressive disease that is not only sight- but life-threatening and demands urgent and intensive treatment. Consideration of early enucleation may be required to prevent deterioration in such patients. AN - WOS:000587476900001 AU - Marinos, E. AU - McCall, D. AU - Tumuluri, K. AU - Rowe, N. AU - Do, H. DO - 10.2147/IMCRJ.S274140 PY - 2020 SN - 1179-142X SP - 569-572 ST - Panophthalmitis and Orbital Inflammation with Cavernous Sinus Thrombosis Following Cataract Surgery T2 - INTERNATIONAL MEDICAL CASE REPORTS JOURNAL TI - Panophthalmitis and Orbital Inflammation with Cavernous Sinus Thrombosis Following Cataract Surgery VL - 13 ID - 6311 ER - TY - JOUR AB - Purpose To evaluate topical tacrolimus ointment for treating Thygeson's superficial punctate keratitis (Thygeson SPK). Design Retrospective interventional case series. Methods setting: Institutional practice. patient population: The medical records of 14 patients (9 women; age range, 9-65 years) with Thygeson SPK were reviewed retrospectively. Diagnosis was based on the history and clinical examination. intervention: Patients were treated with tacrolimus 0.03% eye ointment instilled into the lower fornix twice daily for the first 2 weeks, followed by nocturnal application. The clinical signs and symptoms were assessed after 1 month of treatment. The drug was tapered with disease improvement. main outcome measure(s): Treatment efficacy and side effects. Results All patients had bilateral disease (average duration, 6 years). All patients, except 2 who used the medication irregularly, had improved visual acuity (VA), symptoms, and signs as long as the medication was applied. Before treatment 28.57% of patients had VA between 20/30 and 20/50, with improvement after treatment to 20/25 or 20/20. Attempts to withdraw the medication resulted in recurrent disease, and, therefore, treatment was not curative during the study period. No significant local medication side effects were reported. Conclusion Tacrolimus eye ointment 0.03% was effective for controlling Thygeson SPK for a long period with good patient tolerance and no noticeable local or systemic side effects. During the average 6-year follow-up, treatment was not curative. Randomized studies are difficult to conduct because of the disease rarity. © 2015 Elsevier Inc. AD - Department of Ophthalmology and Visual Sciences, Paulista School of Medicine, São Paulo Hospital, Federal University of São Paulo, São Paulo, Brazil Department of Ophthalmology and Visual Sciences, Paulista School of Medicine, Federal University of São Paulo, Rua Botucatu, 821, São Paulo, SP, CEP 04023-062, Brazil AU - Marquezan, M. C. AU - Nascimento, H. AU - Vieira, L. A. AU - Serapião, M. AU - Ghanem, R. C. AU - Belfort, R., Jr. AU - Freitas, D. DB - Scopus DO - 10.1016/j.ajo.2015.06.019 IS - 4 M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2015 SP - 663-668 ST - Effect of Topical Tacrolimus in the Treatment of Thygeson's Superficial Punctate Keratitis T2 - American Journal of Ophthalmology TI - Effect of Topical Tacrolimus in the Treatment of Thygeson's Superficial Punctate Keratitis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941423535&doi=10.1016%2fj.ajo.2015.06.019&partnerID=40&md5=1af001bbcbab5ad007ee74302cb48158 VL - 160 ID - 5517 ER - TY - JOUR AB - Glaucoma represents a major cause of vision loss throughout the world. Primary open-angle glaucoma, the most common form of glaucoma, is a chronic, progressive disease often, though not always, accompanied by elevated intraocular pressure (IOP). In this disorder, retinal ganglion cell loss and excavation of the optic nerve head produce characteristic peripheral visual field deficits. Patients with normal-tension glaucoma present with typical visual field and optic nerve head changes, without a documented history of elevated IOP. A variety of secondary causes, such as pigment dispersion syndrome and ocular trauma, can result in glaucoma as well. Treatment of all forms of glaucoma consists of reducing IOP. With proper treatment, progression of this disease can often be delayed or prevented. Treatment options for glaucoma include medications, laser therapy and incisional surgery. Laser techniques for the reduction of IOP include argon laser trabeculoplasty and selective laser trabeculoplasty. Both techniques work by increasing outflow of aqueous humour through the trabecular meshwork. Surgical options for glaucoma treatment include trabeculectomy, glaucoma drainage tube implantation and ciliary body cyclodestruction. While each of these types of procedures is effective at lowering IOP, therapy usually begins with medications. Medications lower IOP either by reducing the production or by increasing the rate of outflow of aqueous humour within the eye. Currently, there are five major classes of drugs used for the treatment of glaucoma: (i) cholinergics (acetylcholine receptor agonists); (ii) adrenoceptor agonists; (iii) carbonic anhydrase inhibitors (CAIs); (iv) β-adrenoceptor antagonists; and (v) prostaglandin analogues (PGAs). Treatment typically begins with the selection of an agent for IOP reduction. Although β-adrenoceptor antagonists are still commonly used by many clinicians, the PGAs are playing an increasingly important role in the first-line therapy of glaucoma. Adjunctive agents, such as α-adrenoceptor agonists and CAIs are often effective at providing additional reduction in IOP for patients not controlled on monotherapy. As with any chronic disease, effective treatment depends on minimising the adverse effects of therapy and maximising patient compliance. The introduction of a variety of well tolerated and potent medications over the past few years now allows the clinician to choose a treatment regimen on an individual patient basis and thereby treat this disorder more effectively. AD - J.T. Whitson, Department of Ophthalmology, UT Southwestern Medical Center, 5323 Harry Mines Blvd., Dallas, TX 75390-9057, United States AU - Marquis, R. E. AU - Whitson, J. T. C1 - combigan(Allergan,United States) cosopt(Merck and Co,United States) extravan(Alcon,United States) normoglaucon(Bausch and Lomb,United States) timolol maleate gel forming solution(Alcon,United States) timoptic xe(Merck and Co,United States) timpilo(Merck and Co,United States) xalacom(Pfizer,United States) C2 - Alcon(United States) Allergan(United States) Bausch and Lomb(United States) Merck and Co(United States) Pfizer(United States) DB - Embase Medline DO - 10.2165/00002512-200522010-00001 IS - 1 KW - acetazolamide epinephrine adrenergic receptor stimulating agent antiglaucoma agent apraclonidine beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brinzolamide carbachol carbonate dehydratase inhibitor carteolol cholinergic receptor stimulating agent brimonidine plus timolol dipivefrine dorzolamide dorzolamide plus timolol ecothiopate iodide timolol plus travoprost latanoprost latanoprost plus timolol levobunolol mannitol methazolamide metipranolol normoglaucon pilocarpine prostaglandin derivative timolol timolol maleate timolol maleate gel forming solution travoprost unindexed drug unoprostone isopropyl ester urea acidosis agranulocytosis allergic blepharoconjunctivitis allergic conjunctivitis anxiety disorder aplastic anemia aqueous humor outflow argon laser bitter taste blepharitis bone marrow depression bradycardia browache central nervous system depression ciliary body ciliary body cyclodestruction clinical feature clinical trial congestive heart failure conjunctival hyperemia cornea decompensation cornea disease diarrhea disease exacerbation drug choice drug efficacy drug tolerability dry nose eye burning eye disease eye foreign body sensation eye injury eye irritation eye stinging sensation eye surgery eyelid retraction fatigue glaucoma glaucoma drainage implant glaucoma surgery headache heart palpitation human hyperhidrosis hypersalivation hypertension hypokalemia hyponatremia hypotension intraocular pressure lacrimation low level laser therapy monotherapy mydriasis nausea nephrolithiasis low tension glaucoma ocular pruritus open angle glaucoma optic nerve paresthesia patient compliance pigment dispersion syndrome pigment epithelium priority journal punctate keratitis respiration depression retina detachment retina ganglion cell retina macula cystoid edema review risk factor side effect Stevens Johnson syndrome syndrome tachycardia thrombocytopenia trabecular meshwork trabeculectomy trabeculoplasty visual field defect visual impairment vomiting body weight loss xerostomia combigan cosopt extravan timoptic xe timpilo xalacom LA - English M3 - Review N1 - L40188902 2005-02-17 PY - 2005 SN - 1170-229X SP - 1-21 ST - Management of glaucoma: Focus on pharmacological therapy T2 - Drugs and Aging TI - Management of glaucoma: Focus on pharmacological therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40188902&from=export http://dx.doi.org/10.2165/00002512-200522010-00001 VL - 22 ID - 3698 ER - TY - JOUR AB - Glaucoma represents a major cause of vision loss throughout the world. Primary open-angle glaucoma, the most common form of glaucoma, is a chronic, progressive disease often, though not always, accompanied by elevated intraocular pressure (IOP). In this disorder, retinal ganglion cell loss and excavation of the optic nerve head produce characteristic peripheral visual field deficits. Patients with normal-tension glaucoma present with typical visual field and optic nerve head changes, without a documented history of elevated IOP. A variety of secondary causes, such as pigment dispersion syndrome and ocular trauma, can result in glaucoma as well. Treatment of all forms of glaucoma consists of reducing IOP. With proper treatment, progression of this disease can often be delayed or prevented. Treatment options for glaucoma include medications, laser therapy and incisional surgery. Laser techniques for the reduction of IOP include argon laser trabeculoplasty and selective laser trabeculoplasty. Both techniques work by increasing outflow of aqueous humour through the trabecular meshwork. Surgical options for glaucoma treatment include trabeculectomy, glaucoma drainage tube implantation and ciliary body cyclodestruction. While each of these types of procedures is effective at lowering IOP, therapy usually begins with medications. Medications lower IOP either by reducing the production or by increasing the rate of outflow of aqueous humour within the eye. Currently, there are five major classes of drugs used for the treatment of glaucoma: (i) cholinergics (acetylcholine receptor agonists); (ii) adrenoceptor agonists; (iii) carbonic anhydrase inhibitors (CAIs); (iv) beta-adrenoceptor antagonists; and (v) prostaglandin analogues (PGAs). Treatment typically begins with the selection of an agent for IOP reduction. Although beta-adrenoceptor antagonists are still commonly used by many clinicians, the PGAs are playing an increasingly important role in the first-line therapy of glaucoma. Adjunctive agents, such as alpha-adrenoceptor agonists and CAIs are often effective at providing additional reduction in IOP for patients not controlled on monotherapy. As with any chronic disease, effective treatment depends on minimising the adverse effects of therapy and maximising patient compliance. The introduction of a variety of well tolerated and potent medications over the past few years now allows the clinician to choose a treatment regimen on an individual patient basis and thereby treat this disorder more effectively. AD - Dept of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX AN - 106375017. Language: English. Entry Date: 20070101. Revision Date: 20200708. Publication Type: Journal Article AU - Marquis, R. E. AU - Whitson, J. T. DB - ccm DO - 10.2165/00002512-200522010-00001 DP - EBSCOhost IS - 1 KW - Glaucoma -- Drug Therapy Adrenergic Beta-Antagonists -- Therapeutic Use Cholinergic Agents Clinical Trials Intraocular Pressure -- Drug Effects Lasers -- Therapeutic Use Prostaglandins -- Analogs and Derivatives Surgery, Operative N1 - review; tables/charts. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 9102074. PMID: NLM15663346. PY - 2005 SN - 1170-229X SP - 1-21 ST - Management of glaucoma: focus on pharmacological therapy T2 - Drugs & Aging TI - Management of glaucoma: focus on pharmacological therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106375017&site=ehost-live&scope=site VL - 22 ID - 4518 ER - TY - JOUR AB - Glaucoma represents a major cause of vision loss throughout the world. Primary open-angle glaucoma, the most common form of glaucoma, is a chronic, progressive disease often, though not always, accompanied by elevated intraocular pressure (IOP). In this disorder, retinal ganglion cell loss and excavation of the optic nerve head produce characteristic peripheral visual field deficits. Patients with normal-tension glaucoma present with typical visual field and optic nerve head changes, without a documented history of elevated IOP. A variety of secondary causes, such as pigment dispersion syndrome and ocular trauma, can result in glaucoma as well. Treatment of all forms of glaucoma consists of reducing IOP. With proper treatment, progression of this disease can often be delayed or prevented. Treatment options for glaucoma include medications, laser therapy and incisional surgery. Laser techniques for the reduction of IOP include argon laser trabeculoplasty and selective laser trabeculoplasty. Both techniques work by increasing outflow of aqueous humour through the trabecular meshwork. Surgical options for glaucoma treatment include trabeculectomy, glaucoma drainage tube implantation and ciliary body cyclodestruction. While each of these types of procedures is effective at lowering IOP, therapy usually begins with medications. Medications lower IOP either by reducing the production or by increasing the rate of outflow of aqueous humour within the eye. Currently, there are five major classes of drugs used for the treatment of glaucoma: (i) cholinergics (acetylcholine receptor agonists); (ii) adrenoceptor agonists; (iii) carbonic anhydrase inhibitors (CAIs); (iv) β-adrenoceptor antagonists; and (v) prostaglandin analogues (PGAs). Treatment typically begins with the selection of an agent for IOP reduction. Although β-adrenoceptor antagonists are still commonly used by many clinicians, the PGAs are playing an increasingly important role in the first-line therapy of glaucoma. Adjunctive agents, such as alpha-adrenoceptor agonists and CAIs are often effective at providing additional reduction in IOP for patients not controlled on monotherapy. As with any chronic disease, effective treatment depends on minimising the adverse effects of therapy and maximising patient compliance. The introduction of a variety of well tolerated and potent medications over the past few years now allows the clinician to choose a treatment regimen on an individual patient basis and thereby treat this disorder more effectively. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Whitson, Jess T., Department of Ophthalmology, UT Southwestern Medical Center, 5323 Harry Mines Blvd., Dallas, TX, US, 75390-9057 AN - 2007-03137-001 AU - Marquis, Robert E. AU - Whitson, Jess T. DB - psyh DO - 10.2165/00002512-200522010-00001 DP - EBSCOhost IS - 1 KW - glaucoma management pharmacological therapy intraocular pressure treatment compliance medications Adrenergic Agonists Adrenergic beta-Antagonists Aqueous Humor Carbonic Anhydrase Inhibitors Cholinergic Agonists Drug Combinations Glaucoma Humans Prostaglandins Drug Therapy Pharmacology N1 - Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, US. Other Publishers: Springer. Release Date: 20070604. Correction Date: 20120806. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Glaucoma; Pharmacology; Treatment Compliance. Classification: Clinical Psychopharmacology (3340). Population: Human (10). References Available: Y. Page Count: 21. Issue Publication Date: 2005. Sponsor: Research to Prevent Blindness, Inc., US. Other Details: Research grant. Recipients: No recipient indicated PY - 2005 SN - 1170-229X 1179-1969 SP - 1-21 ST - Management of glaucoma: Focus on pharmacological therapy T2 - Drugs & Aging TI - Management of glaucoma: Focus on pharmacological therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2007-03137-001&site=ehost-live&scope=site Jess.Whitson@UTSouthwestern.edu VL - 22 ID - 4866 ER - TY - JOUR AB - OBJECTIVE: Review the clinical manifestations and treatment of primary open-angle glaucoma (POAG). DATA SOURCES: Articles indexed in PubMed, Scopus, and Cochrane Library in the last 10 years using the key words “glaucoma,” “open-angle glaucoma,” and “‘open-angle glaucoma’ AND ‘treatment.’” Primary sources were used to locate additional resources. ClinicalTrials.gov was used to locate unpublished studies. STUDY SELECTION AND DATA EXTRACTION: Eighty-one publications were reviewed and criteria supporting the primary objective were used to identify useful resources. DATA SYNTHESIS: The literature included practice guidelines, review articles, original research articles, and product prescribing information for POAG. CONCLUSION: The POAG optic neuropathies result in optic disk damage and visual field loss. Ophthalmic medication therapy retards glaucoma progression, but many older patients require multiple medications to preserve vision and quality of life. An agent from the ophthalmic prostaglandin analog class is used as initial therapy in current practice because of the convenience of once-a-day administration and lower incidence of systemic side effects and slightly increased efficacy compared with other available ophthalmic medication classes. The other ophthalmic medication classes used in clinical practice include the beta-adrenergic blocking agents, the alpha-2 adrenergic agonists, and the carbonic anhydrase inhibitors. Proper ophthalmic eye-drop administration and medication adherence are imperative for preserving vision in POAG. Selective laser trabeculoplasty is a viable alternative to ophthalmic medications either initially or if a patient experiences ocular or systemic side effects from medication therapy. A modified prostaglandin analog was approved by the Food and Drug Administration in November 2017; its role in clinical practice is still evolving. AD - L.L. Marshall, Mercer University College of Pharmacy, Mercer Health Sciences Center, 3001 Mercer University Drive, Atlanta, GA, United States AU - Marshall, L. L. AU - Hayslett, R. L. AU - Stevens, G. A. DB - Embase Medline DO - 10.4140/TCP.n.2018.432 IS - 8 KW - adenosine receptor stimulating agent alpha 2 adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor latanoprostene bunod prostaglandin derivative Rho kinase inhibitor clinical feature clinical practice glaucoma human intraocular pressure medication compliance nonhuman open angle glaucoma optic disk pathophysiology patient compliance practice guideline primary glaucoma quality of life review visual field LA - English M3 - Review N1 - L623354561 2018-08-09 2018-09-25 PY - 2018 SN - 0888-5109 SP - 432-445 ST - Therapy for open-angle glaucoma T2 - Consultant Pharmacist TI - Therapy for open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623354561&from=export http://dx.doi.org/10.4140/TCP.n.2018.432 VL - 33 ID - 2571 ER - TY - JOUR AB - Objective: Review the clinical manifestations and treatment of primary open-angle glaucoma (POAG).Data Sources: Articles indexed in PubMed, Scopus, and Cochrane Library in the last 10 years using the key words "glaucoma," "open-angle glaucoma," and "'open-angle glaucoma' AND 'treatment.'" Primary sources were used to locate additional resources. ClinicalTrials. gov was used to locate unpublished studies.Study Selection and Data Extraction: Eighty-one publications were reviewed and criteria supporting the primary objective were used to identify useful resources.Data Synthesis: The literature included practice guidelines, review articles, original research articles, and product prescribing information for POAG.Conclusion: The POAG optic neuropathies result in optic disk damage and visual field loss. Ophthalmic medication therapy retards glaucoma progression, but many older patients require multiple medications to preserve vision and quality of life. An agent from the ophthalmic prostaglandin analog class is used as initial therapy in current practice because of the convenience of once-a-day administration and lower incidence of systemic side effects and slightly increased efficacy compared with other available ophthalmic medication classes. The other ophthalmic medication classes used in clinical practice include the beta-adrenergic blocking agents, the alpha-2 adrenergic agonists, and the carbonic anhydrase inhibitors. Proper ophthalmic eye-drop administration and medication adherence are imperative for preserving vision in POAG. Selective laser trabeculoplasty is a viable alternative to ophthalmic medications either initially or if a patient experiences ocular or systemic side effects from medication therapy. A modified prostaglandin analog was approved by the Food and Drug Administration in November 2017; its role in clinical practice is still evolving. AN - 131160388. Language: English. Entry Date: 20180923. Revision Date: 20191029. Publication Type: journal article AU - Marshall, Leisa L. AU - Hayslett, Renée L. AU - Stevens, Gregg A. DB - ccm DO - 10.4140/TCP.n.2018.432 DP - EBSCOhost IS - 8 KW - Ophthalmic Solutions -- Therapeutic Use Glaucoma -- Drug Therapy Trabeculectomy Glaucoma -- Surgery Intraocular Pressure -- Drug Effects Glaucoma -- Physiopathology Systematic Review N1 - research; systematic review. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. NLM UID: 9013983. PMID: NLM30068436. PY - 2018 SN - 0888-5109 SP - 432-445 ST - Therapy for Open-Angle Glaucoma T2 - Consultant Pharmacist TI - Therapy for Open-Angle Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131160388&site=ehost-live&scope=site VL - 33 ID - 4228 ER - TY - JOUR AB - Importance: The coronavirus disease 2019 (COVID-19) pandemic has made alcohol-based hand sanitizers (ABHS) widely available in public places. This may warrant determining whether cases of unintentional ocular exposure are increasing, especially in children. Objective: To describe the epidemiologic trend of pediatric eye exposures to ABHS and to report the severity of the ocular lesions. Design, Setting, and Participants: Retrospective case series conducted from April 1, 2020, to August 24, 2020. Cases were retrieved from the national database of the French Poison Control Centers (PCC) and from a pediatric ophthalmology referral hospital in Paris, France. Cases of ocular exposure to chemical agents in children younger than 18 years during the study period were reviewed. Cases of ABHS exposure were included. Exposures: The following data were collected: age, sex, circumstances of exposure, symptoms, size of the epithelial defect at first examination, time between the incident and re-epithelialization, and medical and/or surgical management. Main Outcomes and Measures: Comparison of the number of eye exposures to ABHS in children between April to August 2020 and April to August 2019. Results: Between April 1 and August 24, 2020, there were 7 times more pediatric cases of ABHS eye exposures reported in the PCC database compared with the same period in 2019 (9.9% of pediatric eye exposures in 2020 vs 1.3% in 2019; difference, 8.6%; 95% CI, 7.4-9.9; P <.001). The number of cases occurring in public places increased in 2020 (from 16.4% in May to 52.4% in August). Similarly, admissions to the eye hospital for ABHS exposure increased at the same period (16 children in 2020 including 10 boys; mean [SD] age, 3.5 [1.4] years vs 1 boy aged 16 months in 2019). Eight of them presented with a corneal and/or conjunctival ulcer, involving more than 50% of the corneal surface for 6 of them. Two cases required amniotic membrane transplant. Conclusions and Relevance: These data support the likelihood of an increasing number of unintentional ocular exposures to ABHS in the pediatric population. To maintain good public compliance with hand disinfection, these findings support that health authorities should ensure the safe use of these devices and warn the parents and caregivers about their potential danger for children. © 2021 American Medical Association. All rights reserved. AD - Rothschild Foundation Hospital, Ophthalmology Department, 25-29 Rue Manin, Paris, 75019, France CHU Angers, Poison Control Center of West France, Angers, France UNIV Angers, CHU Angers, Univ Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail, Angers, France Paris University, Paris, France Cornouailles Hospital, Ophthalmology Department, Quimper, France Centre Antipoison et de Toxicovigilance de Paris, Assistance Publique des Hôpitaux de Paris, Hôpital Fernand Widal, Paris, France Université de Paris, UFR de Médecine, Paris, France INSERM UMRS 1144, Faculté de Pharmacie de Paris, Paris, France AU - Martin, G. C. AU - Le Roux, G. AU - Guindolet, D. AU - Boulanger, E. AU - Hasle, D. AU - Morin, E. AU - Vodovar, D. AU - Vignal, C. AU - Gabison, E. AU - Descatha, A. DB - Scopus DO - 10.1001/jamaophthalmol.2020.6346 IS - 3 M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2021 SP - 348-351 ST - Pediatric Eye Injuries by Hydroalcoholic Gel in the Context of the Coronavirus Disease 2019 Pandemic T2 - JAMA Ophthalmology TI - Pediatric Eye Injuries by Hydroalcoholic Gel in the Context of the Coronavirus Disease 2019 Pandemic UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099927776&doi=10.1001%2fjamaophthalmol.2020.6346&partnerID=40&md5=ded278b54645bd4e8ad8bdeb69977490 VL - 139 ID - 5492 ER - TY - JOUR AB - When a single medication does not adequately control intraocular pressure, additional intraocular hypotensive agents are often added to the therapeutic regime. However, regimen complexity has been associated with reduced patient compliance. Treatment with a fixed combination may, therefore, increase compliance as a result of simplifying the dosage regimen. Bimatoprost/timolol fixed combination (BTFC) combines two clinically effective agents that decrease elevated intraocular pressure by independent mechanisms. In two clinical studies, BTFC was more effective than its individual components. Furthermore, in a non-inferiority study BTFC has been shown to be as effective as the association of its individual components. BTFC was clinically effective and generally well tolerated, with no unexpected adverse reactions reported for the BTFC compared with those reported for bimatoprost or timolol monotherapies. © 2008 Informa UK Ltd. AD - A. Martinez, C/Rosalia de Castro, No 80 50 C, 15895 Ames, La Coruña, Spain AU - Martinez, A. AU - Sanchez, M. DB - Embase Medline DO - 10.1517/14656566.9.1.137 IS - 1 KW - antiglaucoma agent beta adrenergic receptor blocking agent bimatoprost bimatoprost plus timolol latanoprost latanoprost plus timolol prostaglandin derivative prostamide derivative timolol unclassified drug aqueous humor flow article clinical effectiveness clinical examination clinical trial combination chemotherapy conjunctival hyperemia dizziness drug absorption drug contraindication drug distribution drug efficacy drug elimination drug excretion drug half life drug induced headache drug mechanism drug metabolism drug penetration drug response drug safety drug tissue level drug tolerability evening dosage eye burning eye pain eye toxicity eyelid edema follow up glaucoma human intraocular foreign body intraocular hypertension maximum plasma concentration monotherapy morning dosage outcome assessment patient compliance pruritus time to maximum plasma concentration treatment duration visual disorder LA - English M3 - Article N1 - L351233755 2008-02-21 PY - 2008 SN - 1465-6566 SP - 137-143 ST - Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension T2 - Expert Opinion on Pharmacotherapy TI - Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351233755&from=export http://dx.doi.org/10.1517/14656566.9.1.137 VL - 9 ID - 3480 ER - TY - JOUR AB - When a single medication does not adequately control intraocular pressure, additional intraocular hypotensive agents are often added to the therapeutic regime. However, regimen complexity has been associated with reduced patient compliance. Treatment with a fixed combination may, therefore, increase compliance as a result of simplifying the dosage regimen. Bimatoprost/timolol fixed combination (BTFC) combines two clinically effective agents that decrease elevated intraocular pressure by independent mechanisms. In two clinical studies, BTFC was more effective than its individual components. Furthermore, in a non-inferiority study BTFC has been shown to be as effective as the association of its individual components. BTFC was clinically effective and generally well tolerated, with no unexpected adverse reactions reported for the BTFC compared with those reported for bimatoprost or timolol monotherapies. © 2008 Informa UK Ltd. AD - Instituto Gallego de Oftalmologia, C/Ramón Baltar Sn, 15706 Santiago de Compostela, La Coruña, Spain C/Rosalia de Castro, No 80 50 C, 15895 Ames, La Coruña, Spain AU - Martinez, A. AU - Sanchez, M. DB - Scopus DO - 10.1517/14656566.9.1.137 IS - 1 KW - β-blocker Bimatoprost/timolol fixed combination Intraocular pressure Ocular hypertension Open-angle glaucoma Prostaglandin analogue M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2008 SP - 137-143 ST - Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension T2 - Expert Opinion on Pharmacotherapy TI - Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-39049138325&doi=10.1517%2f14656566.9.1.137&partnerID=40&md5=21628d10d4a11be14cae1fa107d3d344 VL - 9 ID - 5339 ER - TY - JOUR AB - Introduction: Glaucoma is a leading cause of blindness and represents a significant global health and economic concern. Prostaglandin analogs such as latanoprost - which act to reduce intraocular pressure by enhancing uveoscleral flow and slow the development and progression of glaucoma - are recommended as a first-line monotherapy. Areas covered: We review recent efficacy and safety data for latanoprost, both alone and in combination therapy, and vs. other prostaglandin analogs, focusing on the tolerability and adherence to the drug and the subsequent impact on patient-perceived quality of life. Relevant studies were identified by an electronic literature search using MEDLINE PubMed, and current global glaucoma guidelines were reviewed. Expert commentary: Prostaglandin analogs represent the cornerstone in glaucoma therapy. Individual studies demonstrate differences in efficacy between prostaglandin analogs, but within-class differences are generally small - and, on balance, latanoprost presents a good efficacy-safety profile. Low adverse event rates result in greater persistence and improved quality of life for patients. Further, a latanoprost/β-blocker combination represents an efficacious therapeutic alternative where monotherapy does not sufficiently reduce intraocular pressure. However, high-quality randomized controlled trials are required to provide further information regarding fixed-dose combination vs. unfixed combination treatment regimens. AD - Ophthalmology, Universidad Complutense de Madrid, Madrid, Spain Global Medical Affairs, Pfizer Essential Health, Tadworth, UK Department of Ophthalmology, Military Institute of Medicine, Warsaw, Poland AN - 134433868. Language: English. Entry Date: 20190205. Revision Date: 20190205. Publication Type: Article AU - Martinez-de-la-Casa, Jose M. AU - Donde, Shaantanu AU - Wierzbowska, Joanna DB - ccm DO - 10.1080/17469899.2019.1567331 DP - EBSCOhost IS - 1 KW - Latanoprost -- Administration and Dosage Prostaglandins -- Analogs and Derivatives Human Systematic Review Medline PubMed Intraocular Pressure -- Drug Effects Glaucoma -- Drug Therapy Quality of Life N1 - research; systematic review; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 101278197. PY - 2019 SN - 1746-9899 SP - 61-72 ST - Latanoprost, a balanced prostaglandin T2 - Expert Review of Ophthalmology TI - Latanoprost, a balanced prostaglandin UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134433868&site=ehost-live&scope=site VL - 14 ID - 4253 ER - TY - JOUR AD - Department of Ophthalmology, Ziv Medical Center, P.O. Box 1008, 13100 Zefat, Israel Department of Ophthalmology, Ziv Medical Center, P.O. Box 1008, 13100 Zefat, Israel; Faculty of Medicine, Bar Ilan University, 13101 Zefat, Israel AN - 104033847. Language: English. Entry Date: 20140303. Revision Date: 20200708. Publication Type: Journal Article AU - Masoud, Muhannad AU - Sharabi-Nov, Adi AU - Pikkel, Joseph DB - ccm DO - 10.1155/2013/405130 DP - EBSCOhost KW - Glaucoma -- Drug Therapy -- Israel Medication Compliance Arabs Antihypertensive Agents -- Therapeutic Use Israel Human Cross Sectional Studies Questionnaires Interviews Male Female Middle Age Aged Descriptive Statistics Multiple Logistic Regression T-Tests Chi Square Test N1 - research; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 101524199. PY - 2013 SN - 2090-004X SP - 1-6 ST - Noncompliance with Ocular Hypertensive Treatment in Patients with Primary Open Angle Glaucoma among the Arab Population in Israel: A Cross-Sectional Descriptive Study T2 - Journal of Ophthalmology TI - Noncompliance with Ocular Hypertensive Treatment in Patients with Primary Open Angle Glaucoma among the Arab Population in Israel: A Cross-Sectional Descriptive Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104033847&site=ehost-live&scope=site ID - 4410 ER - TY - JOUR AB - Objective To determine the range and burden of health services utilization among Iraqi refugees receiving health assistance in Jordan, a country of first asylum. Methods Medical conditions, diagnosed in accordance with the tenth revision of the International classification of diseases, were actively monitored from 1January to 31December 2010 using a pilot centralized database in Jordan called the Refugee Assistance Information System. Findings There were 27 166 medical visits by 7642 Iraqi refugees (mean age: 37.4 years; 49% male; 70% from Baghdad; 6% disabled; 3% with a history of torture). Chronic diseases were common, including essential hypertension (22% of refugees), visual disturbances (12%), joint disorders (11%) and type II diabetes mellitus (11%). The most common reasons for seeking acute care were upper respiratory tract infection (11%), supervision of normal pregnancy (4%) and urinary disorders (3%). The conditions requiring the highest number of visits per refugee were cerebrovascular disease (1.46 visits), senile cataract (1.46) and glaucoma (1.44). Sponsored care included 31 747 referrals or consultations to a specialty service, 18 432 drug dispensations, 2307 laboratory studies and 1090 X-rays. The specialties most commonly required were ophthalmology, dentistry, gynaecology and orthopaedic surgery. Conclusion Iraqi refugees in countries of first asylum and resettlement require targeted health services, health education and sustainable prevention and control strategies for predominantly chronic diseases. AD - F. J. Mateen, Department of Neurology, Room 627 Pathology Building, Johns Hopkins Hospital, The Johns Hopkins University, 600 North Wolfe Street, Baltimore, MD 21287, United States AU - Mateen, F. J. AU - Carone, M. AU - Al-Saedy, H. AU - Nyce, S. AU - Ghosn, J. AU - Mutuerandu, T. AU - Black, R. E. DB - Embase Medline DO - 10.2471/BLT.11.097048 IS - 6 KW - adolescent adult aged arthropathy article cerebrovascular disease child chronic disease essential hypertension female glaucoma health care utilization help seeking behavior human Jordan major clinical study male medical information system non insulin dependent diabetes mellitus patient referral population risk pregnancy preschool child refugee respiratory tract infection school child senile cataract urinary tract disease visual disorder L1 - internal-pdf://2953234494/3090-Medical conditions among Iraqi refug-2012.pdf LA - English French M3 - Article N1 - L365220608 2012-07-18 2012-07-20 PY - 2012 SN - 0042-9686 1564-0604 SP - 444-451 ST - Medical conditions among Iraqi refugees in Jordan: Data from the United Nations refugee assistance information system T2 - Bulletin of the World Health Organization TI - Medical conditions among Iraqi refugees in Jordan: Data from the United Nations refugee assistance information system UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365220608&from=export http://dx.doi.org/10.2471/BLT.11.097048 VL - 90 ID - 3090 ER - TY - JOUR AB - PURPOSE: To determine how well microinvasive glaucoma surgical (MIGS) trials conform to the World Glaucoma Association (WGA) guidelines. Lack of well-designed MIGS studies hinders meaningful evaluation of these technologies. DESIGN: Cross-sectional literature survey. METHODS: Using a predefined search strategy, the following databases were searched for comparative trials involving MIGS in the English peer-reviewed literature from January 1, 2000, through June 21, 2018: Medline, EMBASE, BIOSIS, Cochrane, and Web of Science. From the WGA guidelines, 53 outcomes were selected for evaluation: methodology (n = 31), definition of success (n = 7), ethics (n = 10), postoperative complications (n = 1), economic evaluation (n = 1), and statistical reporting (n = 3). Each article was assessed by 2 reviewers; differences were resolved by consensus. RESULTS: Twenty-five eligible publications were identified: 10 randomized controlled trials (RCTs) and 15 nonrandomized comparative trials (non-RCTs). The mean follow-up was 19.9±11.6 months (range, 6-48 months). The mean number of outcomes adhering to the WGA guidelines of the 53 evaluated was 24.2±6.1 (45.6% compliance): 28.0±6.2 (52.8%) and 21.6±4.7 (40.8%) for RCTs and non-RCTs, respectively (P = 0.01). Mean percent compliance for each subsection were: methodology, 48.8%; definition of success, 21.1%; ethics, 55.6%; postoperative complications, 88%; economic evaluation, 0%; and statistical reporting, 37.3%. In 16 studies (64%), at least 1 author reported an association with the industry. Thirty-two percent of studies reported an author being a shareholder. Twenty-four percent of studies had an industry employee author. The primary intraocular pressure (IOP) end point was defined as both an upper limit and percentage reduction in only 4 studies (16%; 1 RCT, 3 non-RCTs). An IOP-based survival curve was provided in 7 studies (28%; none of the RCTs). Two studies (8%) included an IOP scatterplot. Twelve studies (48%) reported 95% confidence intervals. Only 4 studies (16%) used the mean of 3 diurnal IOP readings as the baseline IOP. CONCLUSIONS: Published comparative MIGS trials show low adherence (45.6%) to the WGA guidelines. Development of standardized methodology and outcomes could enhance interpretation and transparency of study results and facilitate comparisons between trials. Authors and journals should be encouraged to follow the WGA guidelines. Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. AD - Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada AU - Mathew, D. J. AU - McKay, B. R. AU - Basilious, A. AU - Belkin, A. AU - Trope, G. E. AU - Buys, Y. M. DB - Scopus DO - 10.1016/j.ogla.2019.01.007 IS - 2 M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2019 SP - 78-85 ST - Adherence to World Glaucoma Association Guidelines for Surgical Trials in the Era of Microinvasive Glaucoma Surgeries T2 - Ophthalmology. Glaucoma TI - Adherence to World Glaucoma Association Guidelines for Surgical Trials in the Era of Microinvasive Glaucoma Surgeries UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078802376&doi=10.1016%2fj.ogla.2019.01.007&partnerID=40&md5=4cfa8a33d32b9a080bdaa22d7cf66946 VL - 2 ID - 5320 ER - TY - JOUR AB - Purpose: To determine how well microinvasive glaucoma surgical (MIGS) trials conform to the World Glaucoma Association (WGA) guidelines. Lack of well-designed MIGS studies hinders meaningful evaluation of these technologies. Design: Cross-sectional literature survey. Methods: Using a predefined search strategy, the following databases were searched for comparative trials involving MIGS in the English peer-reviewed literature from January 1, 2000, through June 21, 2018: Medline, EMBASE, BIOSIS, Cochrane, and Web of Science. From the WGA guidelines, 53 outcomes were selected for evaluation: methodology (n = 31), definition of success (n = 7), ethics (n = 10), postoperative complications (n = 1), economic evaluation (n = 1), and statistical reporting (n = 3). Each article was assessed by 2 reviewers; differences were resolved by consensus. Results: Twenty-five eligible publications were identified: 10 randomized controlled trials (RCTs) and 15 nonrandomized comparative trials (non-RCTs). The mean follow-up was 19.9 +/- 11.6 months (range, 6-48 months). The mean number of outcomes adhering to the WGA guidelines of the 53 evaluated was 24.2 +/- 6.1 (45.6% compliance): 28.0 +/- 6.2 (52.8%) and 21.6 +/- 4.7 (40.8%) for RCTs and non-RCTs, respectively (P = 0.01). Mean percent compliance for each subsection were: methodology, 48.8%; definition of success, 21.1 %; ethics, 55.6%; postoperative complications, 88%; economic evaluation, 0%; and statistical reporting, 37.3%. In 16 studies (64%), at least 1 author reported an association with the industry. Thirty-two percent of studies reported an author being a shareholder. Twenty-four percent of studies had an industry employee author. The primary intraocular pressure (IOP) end point was defined as both an upper limit and percentage reduction in only 4 studies (16%; 1 RCT, 3 non-RCTs). An IOP-based survival curve was provided in 7 studies (28%; none of the RCTs). Two studies (8%) included an IOP scatterplot. Twelve studies (48%) reported 95% confidence intervals. Only 4 studies (16%) used the mean of 3 diurnal IOP readings as the baseline IOP. Conclusions: Published comparative MIGS trials show low adherence (45.6%) to the WGA guidelines. Development of standardized methodology and outcomes could enhance interpretation and transparency of study results and facilitate comparisons between trials. Authors and journals should be encouraged to follow the WGA guidelines. (C) 2019 by the American Academy of Ophthalmology AN - WOS:000660578400003 AU - Mathew, D. J. AU - McKay, B. R. AU - Basilious, A. AU - Belkin, A. AU - Trope, G. E. AU - Buys, Y. M. DA - MAR-APR DO - 10.1016/j.ogla.2019.01.007 IS - 2 PY - 2019 SN - 2589-4234 2589-4196 SP - 78-85 ST - Adherence to World Glaucoma Association Guidelines for Surgical Trials in the Era of Microinvasive Glaucoma Surgeries T2 - OPHTHALMOLOGY GLAUCOMA TI - Adherence to World Glaucoma Association Guidelines for Surgical Trials in the Era of Microinvasive Glaucoma Surgeries VL - 2 ID - 6218 ER - TY - JOUR AB - Purpose: To describe current practices related to the management of diabetic retinopathy by Australian optometrists. Setting and Methods: A two-page self-administered questionnaire was mailed to a random sample of 504 Australian optometrists. The survey included questions about the practice (such as size and location); current practice with regard to management of patients with diabetic retinopathy; barriers to use of dilating drops; and a number of patient, scenarios related to screening, follow-up and treatment of diabetic retinopathy, Results: Completed questionnaires were returned by 407 of the 473 eligible optometrists (86%). They had been practising optometry between 1 and 50 years (median 14). Of the 243 optometrists who provided details about the location of their practices, 145 (37%) had at least one of their practices in a rural area The estimated percentage of patients with diagnosed diabetes ranged from 0.5 to 40% (median = 5.0%). Three-hundred and twenty-two optometrists (79%) reported that they would often or almost always ask new patients over the age of 40 whether they have diabetes. The majority of optometrists (n = 387, 95%) would often or almost always ask their new patients with diabetes about their control of blood glucose levels and the majority of optometrists (n = 330, 81%) would often or almost always tell their patients with diabetes about the importance of strict glucose control in delaying retinopathy. The most common barrier to dilated ophthalmoscopy was patients not wanting to be dilated, with 38.1% of optometrists reporting this to be a moderate or major barrier. The next most common barrier was fear of precipitating angle closure glaucoma; 17.1% of optometrists reported this to be a moderate or major barrier. Conclusion: The National Health and Medical Research Council (NHMRC) guidelines for the management of diabetic retinopathy are timely in relation to the expressed desire of Australian optometrists to learn more about management of diabetic retinopathy. These data will be used prospectively to assess changes in management of patients with diabetic retinopathy as a result of the release of the NHMRC guidelines. AN - WOS:000084660900007 AU - McCarty, C. A. AU - McKay, R. AU - Keeffe, J. E. AU - Working Grp Evaluation, Nhmrc Retin DA - DEC IS - 6 PY - 1999 SN - 0814-9763 SP - 404-409 ST - Management of diabetic retinopathy by Australian optometrists T2 - AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY TI - Management of diabetic retinopathy by Australian optometrists VL - 27 ID - 6319 ER - TY - JOUR AB - Purpose: Long-term treatment adherence for a chronic asymptomatic condition is a demanding task for many patients. Treating progressive glaucoma can also be confounding for physicians, particularly when management relies on assumption of adherence. This study investigated associations between self-reported adherence and frequency of medication changes due to glaucoma progression. Methods: A total of 128 participants with primary open angle glaucoma were recruited from glaucoma clinics in Flinders Eye Center, South Australia, and completed confidential questionnaires. Information was obtained regarding beliefs about glaucoma and their treatment. Adherence was assessed using the four-item Morisky, Green and Levine Medication Adherence Questionnaire (MGL). Medical records were analyzed for the number of medication changes, due to glaucoma progression. Results: Adherence to topical glaucoma medication was categorized as ‘high’ in 41.4% (Morisky, Green and Levine (MGL). Data were analyzed for behaviors affecting adherence, history of adherence, and reasons for changed adherence. Chi-squared test demonstrated that there was no significant association noted between adherence and changes in medication regime (χ2 (2,128)=0.968, P=0.915); however, a significantly lower adherence was detected if participants had difficulties with their drop regime (χ2 (2,128)=7.24, P=0.027) or had help with drop insertion (χ2 (1,128)=9.77, P=0.008). Conclusion: This study revealed a higher rate of non-adherence than has previously been demonstrated in other studies. This may be attributed to the unique design of the confidential questionnaire and the independent and sympathetic questioning techniques used. Further work to develop a specific glaucoma medication adherence questionnaire would be valuable to enhance glaucoma management. AD - J.F. McClelland, Vision Science Research Group, Biomedical Sciences Research Institute, Ulster University, Cromore Road, Coleraine, United Kingdom AU - McClelland, J. F. AU - Bodle, L. AU - Little, J. A. DB - Embase DO - 10.2147/PPA.S176412 KW - antiglaucoma agent eye drops adult aged article attitude to health Australia controlled study disease course employment family history female human long term care major clinical study male medication compliance Morisky Medication Adherence Scale open angle glaucoma optical coherence tomography patient attitude patient compliance patient satisfaction self report LA - English M3 - Article N1 - L628876933 2019-08-22 2019-08-23 PY - 2019 SN - 1177-889X SP - 431-439 ST - Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes T2 - Patient Preference and Adherence TI - Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628876933&from=export http://dx.doi.org/10.2147/PPA.S176412 VL - 13 ID - 2552 ER - TY - JOUR AB - A consecutive series of 14 patients with trigeminal schwannoma managed surgically at the Neurological Institute of New York since 1970 is reported. Nine women and five men (mean age 40 years) were diagnosed following a mean symptom duration of 33 months. Abnormalities of trigeminal nerve function were present in 11 patients on admission examination. Facial pain was a prominent feature in eight patients. Two patients, both with schwannomas arising from the trigeminal root, presented initially with typical trigeminal neuralgia. Additional cranial nerve palsies or cerebellar or pyramidal tract signs were noted in eight patients. The surgical approach to these tumors depends on their anatomical location. Four patients had tumors confined to the middle fossa, three patients had tumors limited to the posterior fossa, and seven patients had both supratentorial and infratentorial components of their tumors. Twenty operative procedures were performed on these patients, resulting in complete extirpation in six patients, nearly complete removal in seven patients, and partial removal in one patient. Adherence of the tumor to the lateral wall of the cavernous sinus or the brain stem precluded total removal. There was one postoperative death. In the immediate postoperative period, abnormalities of cranial nerves controlling the extraocular muscles were common. In general, these deficits were transient; however, some permanent loss of trigeminal nerve function occurred in nine patients. Two patients required tarsorrhaphy for neurotropic keratitis, and two patients underwent cerebrospinal fluid (CSF) shunting procedures for hydrocephalus or for a persistent CSF leak. The follow-up period ranged from 4 to 177 months (mean 47 months). The clinical features, anatomical considerations, and surgical approach to these rare tumors are discussed. A clinical review of 106 additional cases of trigeminal schwannoma, reported in the English literature since 1935, is also presented. AD - Department of Neurological Surgery, Columbia-Presbyterian Medical Center, New York, NY 10032, United States AU - McCormick, P. C. AU - Bello, J. A. AU - Post, K. D. DB - Scopus DO - 10.3171/jns.1988.69.6.0850 IS - 6 M3 - Review N1 - Cited By :136 Export Date: 19 July 2021 PY - 1988 SP - 850-860 ST - Trigeminal schwannoma. Surgical series of 14 cases with review of the literature T2 - Journal of Neurosurgery TI - Trigeminal schwannoma. Surgical series of 14 cases with review of the literature UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023696820&doi=10.3171%2fjns.1988.69.6.0850&partnerID=40&md5=40d0ac4b57097771aba02bc7d9ca6333 VL - 69 ID - 4914 ER - TY - JOUR AB - Pharmacy data reveal that 70% of patients were missing one or more days worth of drops out of five. Adopting approaches to behavior change and management skills used for people with diabetes may provide insight to improve self-management of glaucoma. Every person who is diagnosed with a chronic health condition such as glaucoma has unique life circumstances that may present barriers to behavior change. An accurate diagnosis and a treatment plan are useless if patients do not use their prescribed eye drops. Active listening and effective communication can result in persons who are more engaged in their self-care behaviors. Collaborative communication using person-centered and strengths-based messages could help eye care providers identify challenges and concerns for people with glaucoma who are experiencing inconsistencies with their eye drops. In an atmosphere where patients can discuss their challenges with treatment recommendations without judgment or fear, they are more likely to trust their provider and therefore share their situation openly and honestly. This is accomplished by choosing language that communicates mutually-agreed-upon self-management goals and addresses and strengthens individual and clinical outcomes. The eye care professional is then seen by the patient as a resource who can empathize when setbacks occur and reinforce the patient's self-management goals. Open-ended questions and tell-ask-tell approaches for identifying barriers to care are keys to more effective communication and trusting relationships. This includes recognizing that glaucoma is associated with increased rates of anxiety or depression that may be an overlooked barrier to self-management. By adopting language recommendations from diabetes care and education, eye care practitioners may be better equipped to help people with glaucoma improve their self-care. AD - Private Practice, Chico, California Diabetes Education and Management, Teachers College Columbia University, New York, New York * AN - 136182832. Language: English. Entry Date: 20191220. Revision Date: 20200119. Publication Type: journal article AU - McDonald, John E. AU - Dickinson, Jane K. DB - ccm DO - 10.1097/OPX.0000000000001366 DP - EBSCOhost IS - 5 KW - Antihypertensive Agents -- Administration and Dosage Ophthalmic Solutions -- Administration and Dosage Communication Glaucoma -- Drug Therapy Language Patient Education -- Methods Self Administration Medication Compliance Physician-Patient Relations Administration, Intraocular Patient Centered Care Scales N1 - review. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Longitudinal Interval Follow-Up Evaluation (LIFE). NLM UID: 8904931. PMID: NLM31046015. PY - 2019 SN - 1040-5488 SP - 331-334 ST - A Novel Approach to Helping People with Glaucoma Use Their Drops Routinely T2 - Optometry & Vision Science TI - A Novel Approach to Helping People with Glaucoma Use Their Drops Routinely UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136182832&site=ehost-live&scope=site VL - 96 ID - 4332 ER - TY - JOUR AB - Purpose: A multicenter, 2-visit, open-label, 4-week study was conducted to determine the acceptability of hydroxypropyl cellulose ophthalmic inserts in adult patients with a history of dry eye syndrome (DES). Methods: At visit 1, patients (N = 520) were evaluated, screened by slit-lamp biomicroscopy, and completed the Ocular Surface Disease Index (OSDI), a validated measure of quality of life. Patients were trained in the proper placement and use of hydroxypropyl cellulose ophthalmic inserts and were contacted by telephone on day 3 of the study. At week 4, patients were given a clinical evaluation and completed a second questionnaire. Answers determined changes in symptoms and quality of life. Adverse events were monitored throughout the study. Results: Four hundred eighteen patients completed the study and reported significant improvements in discomfort, burning, dryness, grittiness, stinging, and light sensitivity (P = .05) after 4 weeks use of hydroxypropyl cellulose ophthalmic inserts. Significant improvements in clinical signs (keratitis, conjunctival staining, and tear volume) were reported. Contact lens wearers reported significant improvements similar to nonwearers, with a strong trend toward improvement in light sensitivity. Mean OSDI total scores, measuring quality of life, significantly improved by 21.3% (from 41.8 ± 22.38 to 32.9 ± 21.97, P ≤ .0215). The most commonly reported adverse event leading to discontinuation was blurred vision, observed in 8.7% of patients (n = 45). Compliance during the study was good; 41.5% of subjects were fully compliant. Of the 58.5% of subjects who missed doses, the majority (69.4%) missed only one to five. Conclusions: Hydroxypropyl cellulose ophthalmic inserts significantly reduced symptoms and clinical signs of moderate to severe DES. They also significantly improved DES in patients wearing contact lenses. Patients experienced a statistically significant improvement in quality of life, as measured by the OSDI, of 21.3%. AD - M. McDonald, Ophthalmic Consultants of Long Island, Long Island, NY, United States AU - McDonald, M. AU - D'Aversa, G. AU - Perry, H. D. AU - Wittpenn, J. R. AU - Donnenfeld, E. D. AU - Nelinson, D. S. C1 - lacrisert(Aton,United States) C2 - Aton(United States) DB - Embase Medline KW - hydroxypropylcellulose adult article blurred vision clinical evaluation clinical trial drug packaging drug withdrawal dry eye eye discomfort eye examination eye infection eye irritation eye pain eyelash human intraocular foreign body keratomileusis major clinical study multicenter study patient compliance priority journal quality of life questionnaire side effect slit lamp treatment outcome visual acuity visual analog scale lacrisert LA - English M3 - Article N1 - L358430996 2010-03-18 2010-04-27 PY - 2009 SN - 1545-6110 SP - 214-221 ST - Hydroxypropyl cellulose ophthalmic inserts (Lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life T2 - Transactions of the American Ophthalmological Society TI - Hydroxypropyl cellulose ophthalmic inserts (Lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358430996&from=export http://www.aosonline.org/xactions/2009/1545-6110_v107_p214.pdf VL - 107 ID - 3305 ER - TY - JOUR AB - Purpose: A multicenter, 2-visit, open-label, 4-week study was conducted to determine the acceptability of hydroxypropyl cellulose ophthalmic inserts in adult patients with a history of dry eye syndrome (DES). Methods: At visit 1, patients (N = 520) were evaluated, screened by slit-lamp biomicroscopy, and completed the Ocular Surface Disease Index (OSDI), a validated measure of quality of life. Patients were trained in the proper placement and use of hydroxypropyl cellulose ophthalmic inserts and were contacted by telephone on day 3 of the study. At week 4, patients were given a clinical evaluation and completed a second questionnaire. Answers determined changes in symptoms and quality of life. Adverse events were monitored throughout the study. Results: Four hundred eighteen patients completed the study and reported significant improvements in discomfort, burning, dryness, grittiness, stinging, and light sensitivity (P = .05) after 4 weeks use of hydroxypropyl cellulose ophthalmic inserts. Significant improvements in clinical signs (keratitis, conjunctival staining, and tear volume) were reported. Contact lens wearers reported significant improvements similar to nonwearers, with a strong trend toward improvement in light sensitivity. Mean OSDI total scores, measuring quality of life, significantly improved by 21.3% (from 41.8 ± 22.38 to 32.9 ± 21.97, P ≤ .0215). The most commonly reported adverse event leading to discontinuation was blurred vision, observed in 8.7% of patients (n = 45). Compliance during the study was good; 41.5% of subjects were fully compliant. Of the 58.5% of subjects who missed doses, the majority (69.4%) missed only one to five. Conclusions: Hydroxypropyl cellulose ophthalmic inserts significantly reduced symptoms and clinical signs of moderate to severe DES. They also significantly improved DES in patients wearing contact lenses. Patients experienced a statistically significant improvement in quality of life, as measured by the OSDI, of 21.3%. AD - Ophthalmic Consultants of Long Island, Long Island, NY, United States InterQuest Medical, Mountain Lakes, NJ, United States AU - McDonald, M. AU - D'Aversa, G. AU - Perry, H. D. AU - Wittpenn, J. R. AU - Donnenfeld, E. D. AU - Nelinson, D. S. DB - Scopus M3 - Article N1 - Cited By :17 Export Date: 19 July 2021 PY - 2009 SP - 214-221 ST - Hydroxypropyl cellulose ophthalmic inserts (Lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life T2 - Transactions of the American Ophthalmological Society TI - Hydroxypropyl cellulose ophthalmic inserts (Lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77949298778&partnerID=40&md5=1fbd6ebe2302bbebfac79d3dec4be03d VL - 107 ID - 5171 ER - TY - JOUR AB - Purpose: Investigating patients’ perceptions of their illness can provide important insights into the experience and management of the illness and associated treatment, and enhance understanding of variations in adherence to prescribed medication. The Common-Sense Model of Self-Regulation (CSM) provides a theoretical framework for the study of illness cognitions, health behavior, and adherence to health recommendations. The aim of this study was to use the CSM to investigate the experience of glaucoma and its treatment from the patients’ perspective, and to apply these insights to classify and clarify issues related to nonadherence with treatment. Patients and methods: A qualitative investigation using semi-structured interviews took place in two outpatient glaucoma clinics. Thirty-three patients with primary open-angle glaucoma using hypotensive eye drops participated in the study. Deductive content analysis was used to analyze the interview data. Results: Issues relating to nonadherence with hypotensive eye drops and patients’ experience with their glaucoma and treatment were identified. Treatment schedule and patient factors were classified as common barriers to adherence. Further themes include experienced symptoms of glaucoma, illness coherence, and the emotional and practical consequences of the illness. Conclusion: Findings provide important insights into the emotional and practical outcomes of glaucoma for patients, perceived symptoms of the illness, and insights into patient memory and cognition. These findings provide supporting evidence for the importance of conducting theoretically driven qualitative investigations of patients’ experience with glaucoma and their treatment, and provide suggestions on key issues that need to be addressed in future multidimensional interventions aimed at improving adherence and patient quality of life. AD - S. McDonald, School of Psychology, University of Nottingham, University Park, Nottingham, United Kingdom AU - McDonald, S. AU - Ferguson, E. AU - Hagger, M. S. AU - Foss, A. J. E. AU - King, A. J. DB - Embase DO - 10.2147/PPA.S174922 KW - antiglaucoma agent adult aged article attitude to illness clinical article emotion female human male open angle glaucoma patient attitude patient compliance qualitative research self regulation model symptom treatment refusal very elderly LA - English M3 - Article N1 - L2001981147 2019-06-25 2019-07-01 PY - 2019 SN - 1177-889X SP - 819-828 ST - A theory-driven qualitative study exploring issues relating to adherence to topical glaucoma medications T2 - Patient Preference and Adherence TI - A theory-driven qualitative study exploring issues relating to adherence to topical glaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001981147&from=export http://dx.doi.org/10.2147/PPA.S174922 VL - 13 ID - 2541 ER - TY - JOUR AB - Introduction: While previous research has explored the meaning of positive aging discourses from the perspective of older adults, the perspective of older adults aging with a disability has not been studied. In fact the intersection of aging and disability has been largely underexplored in both social gerontology and disability studies. Method: This critical ethnography engaged ten older adults aging with vision loss in narrative interviews, participant observation sessions, and semi-structured in-depth interviews. The overarching objective was to understand those attributes that older adults with age-related vision loss perceive as being the markers of a ‘good old age.’ The authors critically examined how these markers, and their disabling effects, are situated in ageist and disablist social assumptions regarding what it means to ‘age well’. Results: The participants' descriptions of the markers of a ‘good old age’ were organized into five main themes: 1) maintaining independence while negotiating help; 2) responding positively to vision loss; 3) remaining active while managing risk; 4) managing expectations to be compliant, complicit, and cooperative and; 5) striving to maintain efficiency. Conclusion: The study findings have provided helpful insights into how the ideas and assumptions that operate in relation to disability and impairment in late life are re-produced among older adults with age-related vision loss and how older adults take on an identity that is consistent with socially embedded norms regarding what it means to ‘age well’. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - McGrath, Colleen, University of Western Ontario, School of Occupational Therapy, Elborn College, London, ON, Canada, N6G 1H1 AN - 2016-60508-003 AU - McGrath, Colleen AU - Laliberte Rudman, Debbie AU - Polgar, Jan AU - Spafford, Marlee M. AU - Trentham, Barry DB - psyh DO - 10.1016/j.jaging.2016.08.002 DP - EBSCOhost KW - Older adults Age-related vision loss Disability Positive aging Critical ethnography Adaptation, Psychological Aged Aged, 80 and over Aging Anthropology, Cultural Attitude to Health Diabetic Retinopathy Female Glaucoma Help-Seeking Behavior Humans Macular Degeneration Male Narration Qualitative Research Vision Disorders Adult Attitudes Disabilities N1 - University of Western Ontario, School of Occupational Therapy, Elborn College, London, ON, Canada. Release Date: 20170123. Correction Date: 20200903. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Adult Attitudes; Aging; Disabilities; Vision Disorders. Classification: Gerontology (2860). Population: Human (10); Male (30); Female (40). Location: Canada. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Interview; Qualitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Dec, 2016. Publication History: First Posted Date: Sep 2, 2016; Accepted Date: Aug 13, 2016; Revised Date: Jun 15, 2016; First Submitted Date: Mar 21, 2016. Copyright Statement: All rights reserved. Elsevier Inc. 2016. Sponsor: Social Sciences and Humanities Research Council of Canada, Canada. Grant: 752-2013-2249. Recipients: No recipient indicated PY - 2016 SN - 0890-4065 1879-193X SP - 1-10 ST - Negotiating ‘positive’ aging in the presence of age-related vision loss (ARVL): The shaping and perpetuation of disability T2 - Journal of Aging Studies TI - Negotiating ‘positive’ aging in the presence of age-related vision loss (ARVL): The shaping and perpetuation of disability UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-60508-003&site=ehost-live&scope=site b.trentham@utoronto.ca marlee.spafford@uwaterloo.ca jpolgar@uwo.ca drudman@uwo.ca mcgrathc@ontarioshores.ca VL - 39 ID - 4828 ER - TY - JOUR AB - Objective-To compare the effects of 2 preoperative anti-inflammatory regimens on intraocular inflammation following phacoemulsification. Design-Randomized controlled trial Animals-21 dogs with immature cataracts. Procedures-All dogs had cataract surgery via phacoemulsification, and most received prosthetic intraocular lenses. Dogs were randomly divided into 2 groups. Group A dogs were treated topically with prednisolone acetate for 7 days prior to surgery, whereas prednisolone acetate treatment commenced the evening prior to surgery in group B dogs. Postoperative care was identical for both groups. Blood-aqueous barrier breakdown was quantified by use of anterior chamber fluorophotometry, with fluorescein entry into the anterior chamber measured 2 and 9 days after surgery compared with baseline scans obtained prior to surgery. Ophthalmic examinations were performed before surgery and 1 day, 9 days, 3 weeks, 7 weeks, 3 months, and 6 months after surgery. A subjective inflammation score was established at each examination. Intraocular pressures were measured 4 and 8 hours after surgery and at each follow-up examination. Results-There was no difference in the extent of blood-aqueous barrier disruption between the groups at 2 or 9 days after surgery. Subjective inflammation scores were also similar at most time points. Dogs in group A developed postoperative ocular hypertension at a higher frequency (60%) than did those in group B (18%). Conclusions and Clinical Relevance-In dogs that underwent cataract surgery via phacoemulsification, a full week of topical prednisolone acetate treatment prior to surgery did not decrease postoperative inflammation, compared with commencement of topical prednisolone acetate treatment the evening prior to surgery, and was associated with a greater incidence of postoperative ocular hypertension. (J Am Vet Med Assoc 2012;240:563-569) AN - WOS:000300652400032 AU - McLean, N. J. AU - Ward, D. A. AU - Hendrix, D. V. H. AU - Vaughn, R. K. DA - MAR 1 DO - 10.2460/javma.240.5.563 IS - 5 PY - 2012 SN - 0003-1488 1943-569X SP - 563-569 ST - Effects of one-week versus one-day preoperative treatment with topical 1% prednisolone acetate in dogs undergoing phacoemulsification T2 - JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION TI - Effects of one-week versus one-day preoperative treatment with topical 1% prednisolone acetate in dogs undergoing phacoemulsification VL - 240 ID - 6285 ER - TY - JOUR AB - Purpose To compare the intraocular pressure (IOP)-lowering effect of latanoprostene bunod (LBN) 0.024% with timolol maleate 0.5% in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT). Design Prospective, randomized, double-masked, parallel-group, noninferiority clinical trial. Methods Adults with OAG or OHT from 46 clinical sites (United States and European Union) were randomized 2:1 to LBN instilled once daily (QD) in the evening and vehicle in the morning or timolol instilled twice a day (BID) for 3 months. IOP was measured at week 2, week 6, and month 3 (8 AM, 12 PM, and 4 PM each visit). Results A total of 387 subjects (LBN, n = 259; timolol, n = 128) completed the study. Analysis of covariance showed that mean IOP reduction with LBN was not only noninferior to timolol but significantly greater (P ≤ .025) than timolol at all but the first time point in this study (week 2, 8 AM). Of LBN- and timolol-treated subjects, respectively, 31.0% and 18.5% (P = .007) had their IOP reduced ≥25% from baseline, and 17.7% and 11.1% (P = .084) had their IOP reduced to ≤18 mm Hg over all time points/visits in this study. Ocular treatment-emergent adverse events, while uncommon, appeared more frequently in the LBN group (all mild-moderate except 1 case of severe hyperemia). Conclusions LBN 0.024% QD in the evening was noninferior to timolol 0.5% BID over 3 months of treatment, with significantly greater IOP lowering in subjects with OAG or OHT at all but the earliest time point evaluated, and demonstrated a good safety profile. © 2016 The Authors AD - Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California San Diego, La Jolla, California, United States Eye Department, Addenbrooke's Hospital, Cambridge NIHR Biomedical Research Centre, Cambridge, United Kingdom United Medical Research Institute, Inglewood, California, United States Medical Affairs, Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States Clinical Affairs, Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States AU - Medeiros, F. A. AU - Martin, K. R. AU - Peace, J. AU - Scassellati Sforzolini, B. AU - Vittitow, J. L. AU - Weinreb, R. N. DB - Scopus DO - 10.1016/j.ajo.2016.05.012 M3 - Article N1 - Cited By :52 Export Date: 19 July 2021 PY - 2016 SP - 250-259 ST - Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study T2 - American Journal of Ophthalmology TI - Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979072533&doi=10.1016%2fj.ajo.2016.05.012&partnerID=40&md5=4056acf6b16434545ea3ebd5ba6279c8 VL - 168 ID - 4990 ER - TY - JOUR AB - Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10- and 15-μg bimatoprost implant in subjects with open-angle glaucoma (OAG) and ocular hypertension (OHT) after initial and repeated administrations. Design: Randomized, 20-month, multicenter, subject- and efficacy evaluator-masked, parallel-group, phase 3 clinical study. Participants: Adults with OAG or OHT in each eye, open iridocorneal angle inferiorly in the study eye, and study eye baseline IOP (hour 0; 8 AM) of 22–32 mmHg after washout. Methods: Study eyes received bimatoprost implant 10 μg (n = 198) or 15 μg (n = 198) on day 1 with readministration at weeks 16 and 32, or twice-daily topical timolol maleate 0.5% (n = 198). Intraocular pressure was measured at hours 0 and 2 at each visit. Main Outcome Measures: Primary end points were IOP and change from baseline IOP through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD). Results: Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each administration. Mean diurnal IOP was 24.0, 24.2, and 23.9 mmHg at baseline and from 16.5–17.2, 16.5–17.0, and 17.1–17.5 mmHg through week 12 in the 10-μg implant, 15-μg implant, and timolol groups, respectively. The incidence of corneal and inflammatory TEAEs of interest (e.g., corneal endothelial cell loss, iritis) was higher with bimatoprost implant than timolol and highest with the 15-μg dose strength. Incidence of corneal TEAEs increased after repeated treatment; with 3 administrations at fixed 16-week intervals, incidence of ≥20% CECD loss was 10.2% (10-μg implant) and 21.8% (15-μg implant). Mean best-corrected visual acuity (BCVA) was stable; 3 implant-treated subjects with corneal TEAEs had >2-line BCVA loss at their last visit. Conclusions: Both dose strengths of bimatoprost implant met the primary end point of noninferiority to timolol through week 12. One year after 3 administrations, IOP was controlled in most subjects without additional treatment. The risk-benefit assessment favored the 10-μg implant over the 15-μg implant. Ongoing studies are evaluating other administration regimens to reduce the potential for CECD loss. The bimatoprost implant has potential to improve adherence and reduce treatment burden in glaucoma. © 2020 American Academy of Ophthalmology AD - Department of Ophthalmology, Duke University, Durham, NC, United States Keystone Research, Ltd., Austin, TX, United States Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup, Denmark Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia Allergan plc, Irvine, CA, United States Allergan plc, Madison, NJ, United States Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California, San Diego, CA, United States AU - Medeiros, F. A. AU - Walters, T. R. AU - Kolko, M. AU - Coote, M. AU - Bejanian, M. AU - Goodkin, M. L. AU - Guo, Q. AU - Zhang, J. AU - Robinson, M. R. AU - Weinreb, R. N. AU - Agar, A. AU - Bathijia, R. AU - Liu, L. AU - Roberts, T. AU - Faschinger, C. AU - Vass, C. AU - Collignon, N. AU - Alves Pereira, A. C. AU - Belfort de Mattos, R., Jr. AU - Dantas, F. J. AU - Lopes da Silva, M. J. AU - Kanadani, F. AU - Magacho dos Santos Silva, L. AU - Prata, T. AU - Bach-Holm, D. AU - Lai, J. AU - Tham, C. AU - Bátor, G. AU - Szalczer, L. AU - Varsányi, B. AU - Blumenthal, E. AU - Geyer, O. AU - Lavartovsky, S. AU - Pedut-Kloizman, T. AU - Shoham-Hazon, N. AU - Lujan, S. AU - Abela, B. AU - Ang, R. E. AU - Leuenberger, E. U. AU - Uy, H. AU - Yap-Veloso, M. I. AU - Fryczkowski, P. AU - Jurowski, P. AU - Kalużny, B. AU - Kalużny, J. AU - Misiuk-Hojlo, M. AU - Raczynska, K. AU - Tomczyk-Dorozynska, W. AU - Wasyluk, J. AU - Zalewski, S. AU - Zarnowski, T. AU - Feijoó, J. G. AU - Giménez-Gómez, R. AU - Griño, E. M. AU - López, A. A. AU - Miralles, M. G. AU - Moreno, J. M. AU - Polo, V. AU - Taulet, E. C. AU - Zúñiga, B. P. AU - Chen, Y. Y. AU - Lee, Y. C. AU - Alpern, L. AU - Berlin, M. S. AU - Brubaker, J. AU - Caldwell, D. AU - Camp, A. AU - Cantor, L. B. AU - Caronia, R. AU - Crane, C. J. AU - Day, D. AU - Duzman, E. AU - Elfervig, J. AU - El-Harazi, S. AU - Evans, R. AU - Fisher, A. C. AU - Flynn, W. J. AU - Foster, C. S. AU - Frenkel, R. AU - Goyal, R. AU - Gross, R. AU - Hartman, P. J. AU - Haynes, W. L. AU - Jerkins, G. AU - Kim, J. AU - Kim, M. AU - Kwapiszeski, B. AU - Lambright, B. AU - Larsen, C. AU - Lehmann, J. AU - Levenson, J. H. AU - Logan, D. AU - McMillan, B. AU - Martel, J. R. AU - Mayer, H. AU - Medeiros, F. AU - Moroi, S. AU - Moyes, A. AU - Myers, J. AU - Nairn, J. AU - Nielsen, S. AU - Ortiz, D. P. AU - Paauw, J. AU - Pai, V. AU - Panarelli, J. AU - Park, A. AU - Qazi, M. A. AU - Ragusa, N. AU - Rhee, D. J. AU - Rothman, R. AU - Sampson, R. AU - Seltzer, S. AU - Shrivastava, A. AU - Simmons, S. T. AU - Sims, A. AU - Slabaugh, M. A. AU - Smetana, S. AU - Smith, O. AU - So, S. C. AU - Stalmans, I. AU - Swarup, J. AU - Wallshein, J. AU - Zaman, F. AU - Zhang, R. AU - Group, Artemis Study DB - Scopus DO - 10.1016/j.ophtha.2020.06.018 IS - 12 M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2020 SP - 1627-1641 ST - Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) T2 - Ophthalmology TI - Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089012127&doi=10.1016%2fj.ophtha.2020.06.018&partnerID=40&md5=7c0a51d5b13d234c1b961a4432fb3853 VL - 127 ID - 5368 ER - TY - JOUR AB - PURPOSE: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10- and 15-mug bimatoprost implant in subjects with open-angle glaucoma (OAG) and ocular hypertension (OHT) after initial and repeated administrations., DESIGN: Randomized, 20-month, multicenter, subject- and efficacy evaluator-masked, parallel-group, phase 3 clinical study., PARTICIPANTS: Adults with OAG or OHT in each eye, open iridocorneal angle inferiorly in the study eye, and study eye baseline IOP (hour 0; 8 am) of 22-32 mmHg after washout., METHODS: Study eyes received bimatoprost implant 10 mug (n = 198) or 15 mug (n = 198) on day 1 with readministration at weeks 16 and 32, or twice-daily topical timolol maleate 0.5% (n = 198). Intraocular pressure was measured at hours 0 and 2 at each visit., MAIN OUTCOME MEASURES: Primary end points were IOP and change from baseline IOP through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD)., RESULTS: Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each administration. Mean diurnal IOP was 24.0, 24.2, and 23.9 mmHg at baseline and from 16.5-17.2, 16.5-17.0, and 17.1-17.5 mmHg through week 12 in the 10-mug implant, 15-mug implant, and timolol groups, respectively. The incidence of corneal and inflammatory TEAEs of interest (e.g., corneal endothelial cell loss, iritis) was higher with bimatoprost implant than timolol and highest with the 15-mug dose strength. Incidence of corneal TEAEs increased after repeated treatment; with 3 administrations at fixed 16-week intervals, incidence of >=20% CECD loss was 10.2% (10-mug implant) and 21.8% (15-mug implant). Mean best-corrected visual acuity (BCVA) was stable; 3 implant-treated subjects with corneal TEAEs had >2-line BCVA loss at their last visit., CONCLUSIONS: Both dose strengths of bimatoprost implant met the primary end point of noninferiority to timolol through week 12. One year after 3 administrations, IOP was controlled in most subjects without additional treatment. The risk-benefit assessment favored the 10-mug implant over the 15-mug implant. Ongoing studies are evaluating other administration regimens to reduce the potential for CECD loss. The bimatoprost implant has potential to improve adherence and reduce treatment burden in glaucoma. Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. AU - Medeiros, Felipe A. AU - Walters, Thomas R. AU - Kolko, Miriam AU - Coote, Michael AU - Bejanian, Marina AU - Goodkin, Margot L. AU - Guo, Qiang AU - Zhang, Jane AU - Robinson, Michael R. AU - Weinreb, Robert N. AU - Group, Artemis Study DO - https://dx.doi.org/10.1016/j.ophtha.2020.06.018 IS - 12 KW - Adult Aged Aged, 80 and over *Antihypertensive Agents/ad [Administration & Dosage] *Bimatoprost/ad [Administration & Dosage] Double-Blind Method Drug Implants Female Glaucoma, Open-Angle/di [Diagnosis] *Glaucoma, Open-Angle/dt [Drug Therapy] Glaucoma, Open-Angle/pp [Physiopathology] Humans *Intraocular Pressure/de [Drug Effects] Male Middle Aged Ocular Hypertension/di [Diagnosis] Ocular Hypertension/dt [Drug Therapy] Ocular Hypertension/pp [Physiopathology] Timolol/tu [Therapeutic Use] Tonometry, Ocular Vitreous Body/de [Drug Effects] Young Adult PY - 2020 SE - Medeiros, Felipe A. Department of Ophthalmology, Duke University, Durham, North Carolina. Walters, Thomas R. Keystone Research, Ltd., Austin, Texas. Kolko, Miriam. Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup, Denmark; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark. Coote, Michael. Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia. Bejanian, Marina. Allergan plc, Irvine, California. Goodkin, Margot L. Allergan plc, Irvine, California. Guo, Qiang. Allergan plc, Irvine, California. Zhang, Jane. Allergan plc, Madison, New Jersey. Robinson, Michael R. Allergan plc, Irvine, California. Electronic address: Robinson_Michael@Allergan.com. Weinreb, Robert N. Hamilton Glaucoma Center, Shiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California, San Diego, California. SN - 1549-4713 0161-6420 SP - 1627-1641 ST - Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) T2 - Ophthalmology TI - Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32544560 VL - 127 Y2 - 20200613// ID - 231 ER - TY - JOUR AB - Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10- and 15-mg bimatoprost implant in subjects with open-angle glaucoma (OAG) and ocular hypertension (OHT) after initial and repeated administrations. Design: Randomized, 20-month, multicenter, subject- and efficacy evaluator-masked, parallel-group, phase 3 clinical study. Participants: Adults with OAG or OHT in each eye, open iridocorneal angle inferiorly in the study eye, and study eye baseline IOP (hour 0; 8 AM) of 22-32 mmHg after washout. Methods: Study eyes received bimatoprost implant 10 mg (n = 198) or 15 mg (n = 198) on day 1 with readministration at weeks 16 and 32, or twice-daily topical timolol maleate 0.5% (n = 198). Intraocular pressure was measured at hours 0 and 2 at each visit. Main Outcome Measures: Primary end points were IOP and change from baseline IOP through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD). Results: Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each administration. Mean diurnal IOP was 24.0, 24.2, and 23.9 mmHg at baseline and from 16.5-17.2, 16.5-17.0, and 17.1-17.5 mmHg through week 12 in the 10-mg implant, 15-mg implant, and timolol groups, respectively. The incidence of corneal and inflammatory TEAEs of interest (e.g., corneal endothelial cell loss, iritis) was higher with bimatoprost implant than timolol and highest with the 15-mg dose strength. Incidence of corneal TEAEs increased after repeated treatment; with 3 administrations at fixed 16-week intervals, incidence of >= 20% CECD loss was 10.2% (10-mg implant) and 21.8% (15-mg implant). Mean best-corrected visual acuity (BCVA) was stable; 3 implant-treated subjects with corneal TEAEs had >2-line BCVA loss at their last visit. Conclusions: Both dose strengths of bimatoprost implant met the primary end point of noninferiority to timolol through week 12. One year after 3 administrations, IOP was controlled in most subjects without additional treatment. The risk-benefit assessment favored the 10-mg implant over the 15-mg implant. Ongoing studies are evaluating other administration regimens to reduce the potential for CECD loss. The bimatoprost implant has potential to improve adherence and reduce treatment burden in glaucoma. (C) 2020 by the American Academy of Ophthalmology. AN - WOS:000600742900014 AU - Medeiros, F. A. AU - Walters, T. R. AU - Kolko, M. AU - Coote, M. AU - Bejanian, M. AU - Goodkin, M. L. AU - Guo, Q. AU - Zhang, J. AU - Robinson, M. R. AU - Weinreb, R. N. AU - Grp, Artemis Study DA - DEC DO - 10.1016/j.ophtha.2020.06.018 IS - 12 PY - 2020 SN - 0161-6420 1549-4713 SP - 1627-1641 ST - Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) T2 - OPHTHALMOLOGY TI - Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1) VL - 127 ID - 6205 ER - TY - JOUR AB - Background: Good adherence to ocular hypotensive agents is important to control intraocular pressure and hence to prevent progressive glaucomatous optic nerve head damage. Periodic investigation of adherence is crucial in glaucoma treatment. The purpose of this study was to assess level of adherence to ocular hypotensive agents and to identify factors affecting adherence among glaucoma patients at a tertiary public eye care center.Methods: The study was a hospital-based cross-sectional study that was conducted in Menelik II Referral Hospital from June 1, 2015 to July 31, 2015. A systematic random sampling technique was used to select 359 study participants from the source population. The study patients were interviewed and their medical charts were reviewed using a pretested structured questionnaire. Adherence was assessed using Morisky Medication Adherence Scale - 8 and adherence determinant factors were identified using multivariate binary logistic regression analysis. The association was declared statistically significant at p < 0.05.Results: Among the 359 study glaucoma patients, 42.6 % were adherent to their prescribed hypotensive agents. Higher educational level (AOR = 4.60, 95 % CI: 1.01-21.03, p < 0.049), being self - employed (AOR = 6.14, 95 % CI: 1.37-27.50, p < 0.018) and taking lesser frequency of drops (AOR = 2.89, 95 % CI: 1.25-6.66, p < 0.013) were significantly associated with adherence, whereas being a farmer (AOR = 0.07, 95 % CI: 0.01-0.75, p < 0.028), having very low monthly family income (AOR = 0.22, 95 % CI: 0.06-0.77, p < 0.019) and self - purchasing of medications (AOR = 0.30, 95 % CI: 0.10-0.93, p < 0.036) were significantly associated with non-adherence.Conclusions: The study has identified the adherence level to the prescribed ocular hypotensive agents to be sub-optimal and is influenced by different factors among glaucoma patients of the public tertiary center. We recommend glaucoma care providers to pay due attention on the importance of adherence. AD - Department of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia Department of Ophthalmology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia AN - 117182992. Language: English. Entry Date: 20180719. Revision Date: 20191029. Publication Type: journal article AU - Mehari, Tesfay AU - Giorgis, Abeba T. AU - Shibeshi, Workineh DB - ccm DO - 10.1186/s12886-016-0316-z DP - EBSCOhost KW - Glaucoma -- Drug Therapy Medication Compliance Antihypertensive Agents -- Therapeutic Use Intraocular Pressure Aged Employment Middle Age Educational Status Adult Cross Sectional Studies Ophthalmic Solutions -- Therapeutic Use Aged, 80 and Over Socioeconomic Factors Risk Factors Ethiopia Female Young Adult Multivariate Analysis Male Attitude to Health Human N1 - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 100967802. PMID: NLM27485739. PY - 2016 SN - 1471-2415 SP - 1-8 ST - Level of adherence to ocular hypotensive agents and its determinant factors among glaucoma patients in Menelik II Referral Hospital, Ethiopia T2 - BMC Ophthalmology TI - Level of adherence to ocular hypotensive agents and its determinant factors among glaucoma patients in Menelik II Referral Hospital, Ethiopia UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=117182992&site=ehost-live&scope=site VL - 16 ID - 4238 ER - TY - JOUR AB - Background: Combined anterior and posterior segment injuries in children require special attention to the unique characteristics of children's eyes, including a pronounced tendency to scar formation and proliferation, adherence of the posterior vitreous, as well as the danger of amblyopia. Methods: This article reviews the current body of literature documenting the main aspects of surgical management, complications, and prognosis of combined anterior and posterior segment injuries in children. Results: For optimal treatment success, special strategies are necessary with regard to: 1) comprehensive secondary operation for internal reconstruction, 2) encircling buckle surgery, 3) management of the lens, 4) use of a temporary keratoprosthesis, 5) endophthalmitis, and 6) late complications, e.g., secondary glaucoma, secondary strabismus, leukoma cornea, and phthisis bulbi. Further crucial prognostic factors were analyzed. Conclusion: Combined anterior and posterior segment injuries in children require optimal surgical treatment management that varies from adult treatment with regard to several essential aspects. Care should be provided by pediatric ophthalmology specialists with orthoptic follow-up as necessary, over many years. © 2010 Springer-Verlag. AD - University Eye Hospital, University of Leipzig, Liebigstrasse 10-14, Leipzig 04103, Germany AU - Meier, P. DB - Scopus DO - 10.1007/s00417-010-1414-x IS - 9 KW - Anterior segment Children Posterior segment Trauma M3 - Review N1 - Cited By :16 Export Date: 19 July 2021 PY - 2010 SP - 1207-1219 ST - Combined anterior and posterior segment injuries in children: A review T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - Combined anterior and posterior segment injuries in children: A review UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955560664&doi=10.1007%2fs00417-010-1414-x&partnerID=40&md5=cfd326f939b3dbd795ad28d6b769f8d5 VL - 248 ID - 5182 ER - TY - JOUR AB - Combined anterior and posterior segment injuries in children require special attention to the unique characteristics of children's eyes, including a pronounced tendency to scar formation and proliferation, adherence of the posterior vitreous, as well as the danger of amblyopia. This article reviews the current body of literature documenting the main aspects of surgical management, complications, and prognosis of combined anterior and posterior segment injuries in children. For optimal treatment success, special strategies are necessary with regard to: 1) comprehensive secondary operation for internal reconstruction, 2) encircling buckle surgery, 3) management of the lens, 4) use of a temporary keratoprosthesis, 5) endophthalmitis, and 6) late complications, e.g., secondary glaucoma, secondary strabismus, leukoma cornea, and phthisis bulbi. Further crucial prognostic factors were analyzed. Combined anterior and posterior segment injuries in children require optimal surgical treatment management that varies from adult treatment with regard to several essential aspects. Care should be provided by pediatric ophthalmology specialists with orthoptic follow-up as necessary, over many years. AN - WOS:000280391200001 AU - Meier, P. DA - SEP DO - 10.1007/s00417-010-1414-x IS - 9 PY - 2010 SN - 0721-832X 1435-702X SP - 1207-1219 ST - Combined anterior and posterior segment injuries in children: a review T2 - GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Combined anterior and posterior segment injuries in children: a review VL - 248 ID - 6284 ER - TY - JOUR AB - Purpose of reviewIt is well known that glaucoma patients are not adherent to their therapeutic regimens. The issue of nonadherence is multifactorial and includes inadequate communication between doctors and patients, resulting in significant costs associated with enhanced disease progression. Therapeutic regimens are risk factors which often influences adherence rates. Thus, alternative treatment modalities, especially those risk factors that do not rely on patients' cooperation, may enable improvements in long-term outcomes of glaucoma in patient.Recent findingsThe studies selected for this review were divided into new medications, especially advancements in pharmaceutical approaches to treat glaucoma and new ways of delivering the medication, new surgical methods, especially minimally invasive surgery methods for glaucoma, and new studies about adherence in glaucoma.SummarySurprisingly, a very few studies on glaucoma medication or surgery addressed the concept of adherence. However, adherence is discussed in studies which consider psychological aspects of patients or communication issues between doctors and patients. Although these studies were performed in clinical settings, the issue of adherence is not addressed; despite it has significant effect on long-term outpatient care. A combination of both aspects, adherence and miscommunication, should be considered in studies. AD - F. Meier-Gibbons, Eye Center Rapperswil, Merkurstrasse 50, Rapperswil, Switzerland AU - Meier-Gibbons, F. AU - Berlin, M. S. AU - Töteberg-Harms, M. DB - Embase Medline DO - 10.1097/ICU.0000000000000551 IS - 2 KW - trabeculotome butanediol fasudil latanoprost latanoprostene bunod netarsudil norephedrine ripasudil aqueous humor formation aqueous humor outflow glaucoma glaucoma surgery gonioscopy human minimally invasive surgery patient compliance priority journal review risk factor surgical approach trabecular meshwork trabeculotomy ultrasound LA - English M3 - Review N1 - L629170122 2019-09-06 2019-09-12 PY - 2019 SN - 1531-7021 1040-8738 SP - 104-109 ST - Influence of new treatment modalities on adherence in glaucoma T2 - Current Opinion in Ophthalmology TI - Influence of new treatment modalities on adherence in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629170122&from=export http://dx.doi.org/10.1097/ICU.0000000000000551 VL - 30 ID - 2526 ER - TY - JOUR AB - Purpose Of Review: It is well known that glaucoma patients are not adherent to their therapeutic regimens. The issue of nonadherence is multifactorial and includes inadequate communication between doctors and patients, resulting in significant costs associated with enhanced disease progression. Therapeutic regimens are risk factors which often influences adherence rates. Thus, alternative treatment modalities, especially those risk factors that do not rely on patients' cooperation, may enable improvements in long-term outcomes of glaucoma in patient.Recent Findings: The studies selected for this review were divided into new medications, especially advancements in pharmaceutical approaches to treat glaucoma and new ways of delivering the medication, new surgical methods, especially minimally invasive surgery methods for glaucoma, and new studies about adherence in glaucoma.Summary: Surprisingly, a very few studies on glaucoma medication or surgery addressed the concept of adherence. However, adherence is discussed in studies which consider psychological aspects of patients or communication issues between doctors and patients. Although these studies were performed in clinical settings, the issue of adherence is not addressed; despite it has significant effect on long-term outpatient care. A combination of both aspects, adherence and miscommunication, should be considered in studies. AD - Eye Center Rapperswil, Merkurstrasse, Rapperswil, Switzerland Glaucoma Institute of Beverly Hills, Professor of Clinical Ophthalmology University of California Los Angeles, Stein Eye Institute, Los Angeles, California, USA Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland AN - 135751992. Language: English. Entry Date: 20190409. Revision Date: 20190708. Publication Type: journal article AU - Meier-Gibbons, Frances AU - Berlin, Michael S. AU - Töteberg-Harms, Marc DB - ccm DO - 10.1097/ICU.0000000000000551 DP - EBSCOhost IS - 2 KW - Glaucoma -- Therapy Drugs Patient Compliance Drug Delivery Systems Antihypertensive Agents -- Therapeutic Use Glaucoma -- Diagnosis Minimally Invasive Procedures N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM30562239. PY - 2019 SN - 1040-8738 SP - 104-109 ST - Influence of new treatment modalities on adherence in glaucoma T2 - Current Opinion in Ophthalmology TI - Influence of new treatment modalities on adherence in glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135751992&site=ehost-live&scope=site VL - 30 ID - 4285 ER - TY - JOUR AB - The costs for glaucoma care are rising worldwide. The main reason is the increase of life expectancy and the increasing variety of diagnostic tests and therapeutically options by implants and devices. How can we influence the increase in costs? Does a relationship exist between the rising costs and the behavior of patients especially in regard to adherence of patients to the prescribed therapy? Are there ways to improve adherence? The costs of a disease can be estimated by adding the direct costs and the indirect costs deriving from the disease. Many studies have been looking at the direct costs, for example, the costs of diagnostic tests and treatment modalities. Unfortunately, not many studies investigated the indirect costs, i.e., costs related to the need of a person to accompany the patient during his or her outpatient visits or the costs deriving from loss of work capacity because of the disease itself or the outpatient visits. Adherence or the synonym compliance has been discussed since many years, and it seems that it remains a major problem in the management of many chronic diseases. Despite all efforts to improve adherence, the adherence rate in chronic diseases such as glaucoma or arterial hypertension remains considerably low. One of the main factors in improving adherence is raising patient's awareness of the disease by providing general understanding of their disease. Other important factors are simplified therapeutic regimens, e.g., fixed combination drops, sustained drug release techniques, or new glaucoma surgical procedures with a more favorable risk profile. AD - Eye Center Rapperswil, Merkurstr. 50, Rapperswil-Jona 8640, Switzerland UniversityHospital Zurich, Department of Ophthalmology, Frauenklinikstr. 24, Zurich 8091, Switzerland AN - 142633609. Language: English. Entry Date: 20200411. Revision Date: 20200411. Publication Type: Article AU - Meier-Gibbons, Frances AU - Töteberg-Harms, Marc DB - ccm DO - 10.1155/2020/5901537 DP - EBSCOhost KW - Glaucoma -- Economics Glaucoma -- Diagnosis Glaucoma -- Therapy Health Care Costs Patient Compliance Economic Aspects of Illness Disease Management Life Expectancy Outpatient Service -- Economics Chronic Disease -- Economics Delayed-Action Preparations Ophthalmic Solutions -- Therapeutic Use Eye Surgery -- Methods Risk Assessment N1 - review. Journal Subset: Biomedical; USA. NLM UID: 101524199. PY - 2020 SN - 2090-004X SP - 1-5 ST - Influence of Cost of Care and Adherence in Glaucoma Management: An Update T2 - Journal of Ophthalmology TI - Influence of Cost of Care and Adherence in Glaucoma Management: An Update UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142633609&site=ehost-live&scope=site ID - 4246 ER - TY - JOUR AB - The costs for glaucoma care are rising worldwide. The main reason is the increase of life expectancy and the increasing variety of diagnostic tests and therapeutically options by implants and devices. How can we influence the increase in costs? Does a relationship exist between the rising costs and the behavior of patients especially in regard to adherence of patients to the prescribed therapy? Are there ways to improve adherence? The costs of a disease can be estimated by adding the direct costs and the indirect costs deriving from the disease. Many studies have been looking at the direct costs, for example, the costs of diagnostic tests and treatment modalities. Unfortunately, not many studies investigated the indirect costs, i.e., costs related to the need of a person to accompany the patient during his or her outpatient visits or the costs deriving from loss of work capacity because of the disease itself or the outpatient visits. Adherence or the synonym compliance has been discussed since many years, and it seems that it remains a major problem in the management of many chronic diseases. Despite all efforts to improve adherence, the adherence rate in chronic diseases such as glaucoma or arterial hypertension remains considerably low. One of the main factors in improving adherence is raising patient's awareness of the disease by providing general understanding of their disease. Other important factors are simplified therapeutic regimens, e.g., fixed combination drops, sustained drug release techniques, or new glaucoma surgical procedures with a more favorable risk profile. © 2020 Frances Meier-Gibbons and Marc Töteberg-Harms. AD - Eye Center Rapperswil, Merkurstr. 50, Rapperswil-Jona, 8640, Switzerland UniversityHospital Zurich, Department of Ophthalmology, Frauenklinikstr. 24, Zurich, 8091, Switzerland AU - Meier-Gibbons, F. AU - Töteberg-Harms, M. C7 - 5901537 DB - Scopus DO - 10.1155/2020/5901537 M3 - Review N1 - Cited By :3 Export Date: 19 July 2021 PY - 2020 ST - Influence of Cost of Care and Adherence in Glaucoma Management: An Update T2 - Journal of Ophthalmology TI - Influence of Cost of Care and Adherence in Glaucoma Management: An Update UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084064301&doi=10.1155%2f2020%2f5901537&partnerID=40&md5=ee1b204fb95aa5749e4f6a7b9ab21f51 VL - 2020 ID - 5497 ER - TY - JOUR AB - The costs for glaucoma care are rising worldwide. The main reason is the increase of life expectancy and the increasing variety of diagnostic tests and therapeutically options by implants and devices. How can we influence the increase in costs? Does a relationship exist between the rising costs and the behavior of patients especially in regard to adherence of patients to the prescribed therapy? Are there ways to improve adherence? The costs of a disease can be estimated by adding the direct costs and the indirect costs deriving from the disease. Many studies have been looking at the direct costs, for example, the costs of diagnostic tests and treatment modalities. Unfortunately, not many studies investigated the indirect costs, i.e., costs related to the need of a person to accompany the patient during his or her outpatient visits or the costs deriving from loss of work capacity because of the disease itself or the outpatient visits. Adherence or the synonym compliance has been discussed since many years, and it seems that it remains a major problem in the management of many chronic diseases. Despite all efforts to improve adherence, the adherence rate in chronic diseases such as glaucoma or arterial hypertension remains considerably low. One of the main factors in improving adherence is raising patient's awareness of the disease by providing general understanding of their disease. Other important factors are simplified therapeutic regimens, e.g., fixed combination drops, sustained drug release techniques, or new glaucoma surgical procedures with a more favorable risk profile. AN - WOS:000528853700001 AU - Meier-Gibbons, F. AU - Toteberg-Harms, M. DA - APR 8 DO - 10.1155/2020/5901537 PY - 2020 SN - 2090-004X 2090-0058 ST - Influence of Cost of Care and Adherence in Glaucoma Management: An Update T2 - JOURNAL OF OPHTHALMOLOGY TI - Influence of Cost of Care and Adherence in Glaucoma Management: An Update VL - 2020 ID - 6037 ER - TY - JOUR AB - Background: Asymptomatic in its early stages, glaucoma is the second leading cause of blindness worldwide. While psychosocial factors are taken into consideration for a host of diseases such as cancer, heart disease and autoimmune conditions, to date, psychological issues have been ignored in the clinical management of glaucoma. Objective: This work reviews the most relevant contributions from a health psychology perspective for the assessment and treatment of glaucoma, which is emerging in the field of psycho-ophthalmology. Method: To provide scientific evidence regarding contributions of psychology to the comprehension of glaucoma, a bibliographic review of three databases (Psicodoc, PsycInfo and Medline) was conducted, spanning the period between 1940 and 2016. Results: This review yielded a total of 66 studies published in the period analysed and identified three areas where health psychology has made substantive contributions to glaucoma screening, monitoring and treatment: the emotional impact on patients suffering from glaucoma, the adherence to treatment and the effects of stress on intraocular pressure. Conclusions: A health psychology approach for research and therapy of glaucoma must focus on the management of the negative affect associated with the diagnosis, the optimisation of treatment adherence and the stress management of the intraocular pressure measurements. AD - Faculty of Psychology, Research Group on Stress and Health, Department of Basic, Developmental and Educational Psychology, Universitat Autònoma de Barcelona, Catalonia, Spain AN - 120781690. Language: English. Entry Date: 20170124. Revision Date: 20190715. Publication Type: Article AU - Méndez-Ulrich, Jorge Luis AU - Sanz, Antoni DB - ccm DO - 10.1080/08870446.2016.1268690 DP - EBSCOhost IS - 3 KW - Glaucoma -- Diagnosis Glaucoma -- Drug Therapy Health Psychology Ophthalmology Human Systematic Review Medline Psycinfo Reference Databases, Health Patient Compliance Stress, Psychological Intraocular Pressure Vision Disorders -- Risk Factors Glaucoma -- Complications Anxiety Disorders Depression Chi Square Test Ophthalmic Solutions P-Value Ocular Hypertension Funding Source N1 - research; systematic review; tables/charts. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. Grant Information: This work was supported by the Ministry of Education, Culture and Sport, Government of Spain[grant number SEJ2006-12418/PSIC].. NLM UID: 8807983. PY - 2017 SN - 0887-0446 SP - 330-342 ST - Psycho-ophthalmology: Contributions of Health psychology to the assessment and treatment of glaucoma T2 - Psychology & Health TI - Psycho-ophthalmology: Contributions of Health psychology to the assessment and treatment of glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120781690&site=ehost-live&scope=site VL - 32 ID - 4188 ER - TY - JOUR AB - Background: Asymptomatic in its early stages, glaucoma is the second leading cause of blindness worldwide. While psychosocial factors are taken into consideration for a host of diseases such as cancer, heart disease and autoimmune conditions, to date, psychological issues have been ignored in the clinical management of glaucoma. Objective: This work reviews the most relevant contributions from a health psychology perspective for the assessment and treatment of glaucoma, which is emerging in the field of psycho-ophthalmology. Method: To provide scientific evidence regarding contributions of psychology to the comprehension of glaucoma, a bibliographic review of three databases (Psicodoc, PsycInfo and Medline) was conducted, spanning the period between 1940 and 2016. Results: This review yielded a total of 66 studies published in the period analysed and identified three areas where health psychology has made substantive contributions to glaucoma screening, monitoring and treatment: the emotional impact on patients suffering from glaucoma, the adherence to treatment and the effects of stress on intraocular pressure. Conclusions: A health psychology approach for research and therapy of glaucoma must focus on the management of the negative affect associated with the diagnosis, the optimisation of treatment adherence and the stress management of the intraocular pressure measurements. (PsycINFO Database Record (c) 2017 APA, all rights reserved) AD - Sanz, Antoni AN - 2017-02632-004 AU - Méndez-Ulrich, Jorge Luis AU - Sanz, Antoni DB - psyh DO - 10.1080/08870446.2016.1268690 DP - EBSCOhost IS - 3 KW - intraocular pressure glaucoma stress adherence anxiety depression Health Care Psychology N1 - Faculty of Psychology, Research Group on Stress and Health, Department of Basic, Developmental and Educational Psychology, Universitat Autonoma de Barcelona, Catalonia, Spain. Release Date: 20170223. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Anxiety; Health Care Psychology; Stress. Minor Descriptor: Glaucoma. Classification: Health Psychology & Medicine (3360). Population: Human (10). Methodology: Literature Review. References Available: Y. Page Count: 13. Issue Publication Date: Mar, 2017. Publication History: Accepted Date: Nov 17, 2016; First Submitted Date: Mar 24, 2016. Copyright Statement: Informa UK Limited, trading as Taylor & Francis Group. 2016. Sponsor: Government of Spain, Ministry of Education, Culture and Sport, Spain. Grant: SEJ2006-12418/PSIC. Recipients: No recipient indicated PY - 2017 SN - 0887-0446 1476-8321 SP - 330-342 ST - Psycho-ophthalmology: Contributions of Health psychology to the assessment and treatment of glaucoma T2 - Psychology & Health TI - Psycho-ophthalmology: Contributions of Health psychology to the assessment and treatment of glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-02632-004&site=ehost-live&scope=site antonio.sanz@uab.cat VL - 32 ID - 4821 ER - TY - JOUR AB - PURPOSE: To compare the visual outcome and refractive status of children with primary congenital glaucoma who underwent 360 degrees trabeculotomy or goniotomy as an initial surgical procedure. METHODS: This retrospective study describes 24 eyes (15 patients) with primary congenital glaucoma that underwent 360 degrees trabeculotomy as the initial procedure and 40 eyes (23 patients) that underwent goniotomy as the initial procedure. Inclusion criteria were: (1) diagnosis of primary congenital glaucoma and initial angle surgery before 1 year of age, (2) no other ocular or systemic diseases, (3) 360 degrees trabeculotomy or goniotomy as the first surgical procedure, and (4) ability to obtain an Allen or Snellen visual acuity. A postoperative vision of 20/50 or better was considered good. Surgical success was defined as an intraocular pressure (IOP) less than 22 mm Hg with or without medication and without evidence of a progressive optic neuropathy. RESULTS: The IOP was successfully controlled in 92% of eyes in the trabeculotomy group and in 58% of eyes in the goniotomy group (P =.004). Of eyes in the trabeculotomy group, 79% had vision of 20/50 or better compared with 53% in the goniotomy group (P =.03). High myopia was more prevalent in the goniotomy group, but this difference was not statistically significant (P =.16). A poor visual outcome was associated with failure of the angle surgery or poor compliance with follow-up and amblyopia therapy. CONCLUSION: For primary congenital glaucoma, 360 degrees trabeculotomy is a highly effective procedure that results in excellent pressure control and is at least as successful as multiple standard procedures. In this study, 360 degrees trabeculotomy resulted in better vision than what is reported in the literature for standard angle procedures. AD - M.E. Mendicino, Department of Ophthalmology, Emory University School of Medicine, Rollins School of Public Health, Emory University, Atlanta, GA30322, USA. AU - Mendicino, M. E. AU - Lynch, M. G. AU - Drack, A. AU - Beck, A. D. AU - Harbin, T. AU - Pollard, Z. AU - Vela, M. A. AU - Lynn, M. J. DB - Medline IS - 4 KW - anterior eye chamber article comparative study female follow up glaucoma human infant intraocular pressure male methodology newborn pathology retrospective study trabeculectomy treatment outcome visual acuity LA - English M3 - Article N1 - L31356628 2000-09-17 PY - 2000 SN - 1091-8531 SP - 205-210 ST - Long-term surgical and visual outcomes in primary congenital glaucoma: 360 degrees trabeculotomy versus goniotomy T2 - Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus / American Association for Pediatric Ophthalmology and Strabismus TI - Long-term surgical and visual outcomes in primary congenital glaucoma: 360 degrees trabeculotomy versus goniotomy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L31356628&from=export VL - 4 ID - 3909 ER - TY - JOUR AB - Purpose: To compare the visual outcome and refractive status of children with primary congenital glaucoma who underwent 360 degrees trabeculotomy or goniotomy as an initial surgical procedure. Methods: This retrospective study describes 24 eyes (15 patients) with primary congenital glaucoma that underwent 360 degrees trabeculotomy as the initial procedure and 40 eyes (23 patients) that underwent goniotomy as the initial procedure. Inclusion criteria were. (1) diagnosis of primary congenital glaucoma and initial angle surgery before 1 year of age, (2) no other ocular or systemic diseases, (3) 360 degrees trabeculotomy or goniotomy as the first surgical procedure, and (4) ability to obtain an Alien or Snellen visual acuity. A postoperative vision of 20/50 or better was considered good. Surgical success was defined as an intraocular pressure (IOP) less than 22 mm Hg with or without medication and without evidence of a progressive optic neuropathy. Results: The IOP was successfully controlled in 92% of eyes in the trabeculotomy group and in 58% of eyes in the goniotomy group (P = .004). Of eyes in the trabeculotomy group, 79% had vision of 20/50 or better compared with 53% in the goniotomy group (P = .03). High myopia was more prevalent in the goniotomy group, but this difference was not statistically significant (P = .16). A poor visual outcome was associated with failure of the angle surgery or poor compliance with follow-up and amblyopia therapy. Conclusion: For primary congenital glaucoma, 360 degrees trabeculotomy is a highly effective procedure that results in excellent pressure control and is at least as successful as multiple standard procedures. In this study, 360 degrees trabeculotomy resulted in better vision than what is reported in the literature for standard angle procedures. AN - WOS:000089022200004 AU - Mendicino, M. E. AU - Lynch, M. G. AU - Drack, A. AU - Beck, A. D. AU - Harbin, T. AU - Pollard, Z. AU - Vela, M. A. AU - Lynn, M. J. DA - AUG DO - 10.1067/mpa.2000.106201 IS - 4 PY - 2000 SN - 1091-8531 1528-3933 SP - 205-210 ST - Long-term surgical and visual outcomes in primary congenital glaucoma: 360 degrees trabeculotomy versus goniotomy T2 - JOURNAL OF AAPOS TI - Long-term surgical and visual outcomes in primary congenital glaucoma: 360 degrees trabeculotomy versus goniotomy VL - 4 ID - 6203 ER - TY - JOUR AB - PurposeTo compare the safety and efficacy of a single subconjunctival injection of methylprednisolone and a standard postoperative steroid regimen in terms of intraocular inflammation and intraocular pressure (IOP) after uncomplicated phacoemulsification surgery. MethodsTwo groups of 25 patients each were included in this prospective randomized controlled trial. Patients in the injection group were given a subconjunctival injection of 20mg methylprednisolone and the topical group received the conventional postoperative care with steroid eye drops (dexamethasone 1mg/ml). The patients were examined 1week and 1month after surgery. Slit-lamp evaluation of anterior chamber inflammation and IOP were performed. Changes in IOP of 2.4mmHg were considered clinically relevant. ResultsIn the injection group, mean IOP decreased from 15.42.2mmHg (baseline) to 14.1 +/- 3.2mmHg at 1week (p=0.03). The topical group had a stable IOP at 1week (16.3 +/- 2.6mmHg) compared to baseline (16.1 +/- 2.7mmHg; p=0.74). At 1month, mean IOP was 14.3 +/- 2.6mmHg (p=0.03) in the injection group and 15.6 +/- 2.3mmHg (p=0.2) in the topical group. The intragroup changes were neither statistically significant nor clinically relevant at any postoperative visit. Both groups had the highest values of intraocular inflammation at the 1-week postoperative visit, followed by a decline to barely traceable levels at 1month. The difference was not clinically relevant at any postoperative visit. ConclusionsThe subconjunctival injection of methylprednisolone appears to be as safe and effective as the conventional treatment, and it might therefore be considered for treatment of individuals with compliance issues. AN - WOS:000344162700025 AU - Merkoudis, N. AU - Matsson, A. W. AU - Granstam, E. DA - NOV DO - 10.1111/aos.12358 IS - 7 PY - 2014 SN - 1755-375X 1755-3768 SP - 623-628 ST - Comparison of peroperative subconjunctival injection of methylprednisolone and standard postoperative steroid drops after uneventful cataract surgery T2 - ACTA OPHTHALMOLOGICA TI - Comparison of peroperative subconjunctival injection of methylprednisolone and standard postoperative steroid drops after uneventful cataract surgery VL - 92 ID - 6303 ER - TY - JOUR AB - Purpose To compare the safety and efficacy of a single subconjunctival injection of methylprednisolone and a standard postoperative steroid regimen in terms of intraocular inflammation and intraocular pressure (IOP) after uncomplicated phacoemulsification surgery. Methods Two groups of 25 patients each were included in this prospective randomized controlled trial. Patients in the injection group were given a subconjunctival injection of 20 mg methylprednisolone and the topical group received the conventional postoperative care with steroid eye drops (dexamethasone 1 mg/ml). The patients were examined 1 week and 1 month after surgery. Slit-lamp evaluation of anterior chamber inflammation and IOP were performed. Changes in IOP of ≥2.4 mmHg were considered clinically relevant. Results In the injection group, mean IOP decreased from 15.4 ± 2.2 mmHg (baseline) to 14.1 ± 3.2 mmHg at 1 week (p = 0.03). The topical group had a stable IOP at 1 week (16.3 ± 2.6 mmHg) compared to baseline (16.1 ± 2.7 mmHg; p = 0.74). At 1 month, mean IOP was 14.3 ± 2.6 mmHg (p = 0.03) in the injection group and 15.6 ± 2.3 mmHg (p = 0.2) in the topical group. The intragroup changes were neither statistically significant nor clinically relevant at any postoperative visit. Both groups had the highest values of intraocular inflammation at the 1-week postoperative visit, followed by a decline to barely traceable levels at 1 month. The difference was not clinically relevant at any postoperative visit. Conclusions The subconjunctival injection of methylprednisolone appears to be as safe and effective as the conventional treatment, and it might therefore be considered for treatment of individuals with compliance issues. © 2014 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. AD - Department of Neuroscience/Ophthalmology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden Centre for Clinical Research, Uppsala University County Council of Västmanland, Västmanland County Hospital, Västerås, Sweden AU - Merkoudis, N. AU - Wikberg Matsson, A. AU - Granstam, E. DB - Scopus DO - 10.1111/aos.12358 IS - 7 KW - cataract intraocular pressure methylprednisolone phacoemulsification M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2014 SP - 623-628 ST - Comparison of peroperative subconjunctival injection of methylprednisolone and standard postoperative steroid drops after uneventful cataract surgery T2 - Acta Ophthalmologica TI - Comparison of peroperative subconjunctival injection of methylprednisolone and standard postoperative steroid drops after uneventful cataract surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84927172298&doi=10.1111%2faos.12358&partnerID=40&md5=2636b638ebaa34ebf3d2733193043c59 VL - 92 ID - 5236 ER - TY - JOUR AB - Background: Preventive service use among older adults is suboptimal. Unhealthy drinking may constitute a risk factor for failure to receive these services. Objectives: To determine the relationship between unhealthy drinking and receipt of recommended preventive services among elderly Medicare beneficiaries, applying the framework of current alcohol consumption guidelines. Design/Methods: The data source is the nationally representative 2003 Medicare Current Beneficiary Survey. The sample included community-dwelling, fee-for-service Medicare beneficiaries 65 years and older (N = 10,523). Based on self-reported drinking, respondents were categorized as nondrinkers, within-guidelines drinkers, exceeding monthly but not daily limits, or heavy episodic drinkers. Using survey and claims data, influenza vaccination, pneumonia vaccination, glaucoma screening, and mammogram receipt were determined. Bivariate and logistic regression analyses were conducted. Results: Overall, 70.3% received flu vaccination and 49% received glaucoma screening during the year, 66.8% received pneumonia vaccination, and 56.2% of women received a mammogram over 2 years. In logistic regression, heavy episodic drinking was associated with lower likelihood of service receipt compared to drinking within guidelines: flu vaccination (OR 0.75, CI 0.59–0.96), glaucoma screening (OR 0.74, CI 0.58–0.95), and pneumonia vaccination (OR 0.75, CI 0.59–0.96). Nondrinkers when compared with those reporting drinking within guidelines were less likely to receive a mammogram (OR 0.83, CI 0.69–1.00). Conclusions: Heavy episodic drinking is associated with lower likelihood of receiving several preventive services. Practitioners should be encouraged to screen all elders regarding alcohol intake and in addition to appropriate intervention, consider elders reporting heavy episodic drinking at higher risk for non-receipt of preventive services. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Merrick, Elizabeth L., Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, Mail stop 035, 415 South St., Waltham, MA, US, 02454 AN - 2008-17049-003 AU - Merrick, Elizabeth L. AU - Hodgkin, Dominic AU - Garnick, Deborah W. AU - Horgan, Constance M. AU - Panas, Lee AU - Ryan, Marian AU - Saitz, Richard AU - Blow, Frederic C. DB - psyh DO - 10.1007/s11606-008-0753-3 DP - EBSCOhost IS - 11 KW - unhealthy drinking patterns preventive medical services older adults Aged Aged, 80 and over Alcoholism Cross-Sectional Studies Female Glaucoma Humans Influenza Vaccines Male Medicare Odds Ratio Patient Acceptance of Health Care Pneumococcal Vaccines Preventive Health Services United States Alcohol Abuse Geriatrics Health Care Utilization Substance Use Prevention N1 - Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, Waltham, MA, US. Other Publishers: Blackwell Publishing. Release Date: 20091005. Correction Date: 20200713. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishConference Information: Annual conference of the American Public Health Association, Nov, 2007. Conference Note: Preliminary findings from the study were presented at the aforementioned conference. Major Descriptor: Alcohol Abuse; Geriatrics; Health Care Utilization; Substance Use Prevention. Classification: Drug & Alcohol Rehabilitation (3383). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Nov, 2008. Publication History: First Posted Date: Aug 21, 2008; Revised Date: Jul 1, 2008; Jun 11, 2008; First Submitted Date: Dec 11, 2007. Copyright Statement: Society of General Internal Medicine. 2008. Sponsor: National Institute on Alcohol Abuse and Alcoholism, US. Grant: 5R21AA015746. Recipients: No recipient indicated PY - 2008 SN - 0884-8734 1525-1497 SP - 1741-1748 ST - Unhealthy drinking patterns and receipt of preventive medical services by older adults T2 - Journal of General Internal Medicine TI - Unhealthy drinking patterns and receipt of preventive medical services by older adults UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-17049-003&site=ehost-live&scope=site merrick@brandeis.edu VL - 23 ID - 4875 ER - TY - JOUR AB - The article reports that only 25 to 50 percent of Americans are aware that they are suffering from glaucoma, which was revealed by a large prevalence survey. Topics discussed include the importance of proper treatment to individuals diagnosed with glaucoma, the state of treatment compliance among patients with glaucoma and the importance of disease identification and surveillance in managing glaucoma. AN - 97746848. Language: English. Entry Date: 20140918. Revision Date: 20140918. Publication Type: Article AU - Meszaros, Liz DB - ccm DP - EBSCOhost IS - 11 KW - Glaucoma -- Therapy Eye Care Patient Compliance N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2014 SN - 0193-032X SP - 14-16 ST - Big picture of glaucoma care presents with shades of gray T2 - Ophthalmology Times TI - Big picture of glaucoma care presents with shades of gray UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=97746848&site=ehost-live&scope=site VL - 39 ID - 4515 ER - TY - JOUR AB - Background : Globally, and in Africa, after adjusting for age, women are about 1.4 times more likely to be blind than men. While women generally live longer than men, the lack of accessibility to and use of services is likely the most important reason for excess blindness in women in Africa. Aim : We sought to review the literature on vision loss in Africa and summarize the findings related to gender equity. Materials and Methods : Information from across sub-Saharan Africa was collected on the evidence of gender inequity and reasons for this inequity. Finally, the results were used to generate suggestions on how gender equity could be improved. Results : In all published surveys (except one), cataract surgical coverage among women was lower than cataract surgical coverage among men. Although data available are limited, similar findings appeared in the use of services for other disease conditions, notably, childhood cataract and glaucoma. Evidence suggests that a variety of approaches are needed to improve the use of eye care services. Three main strategies are needed to address gender inequity in vision loss in Africa. First, it is important to address transport needs. Second, counseling of patients and family members is required. Finally, programs need to put in place pricing systems that make the services affordable the population. Conclusions : VISION 2020 can be achieved in Africa, but investment is needed in a variety of strategies that will ensure that eye care services are affordable, accessible, and acceptable to women and girls. AD - P. Courtright, Kilimanjaro Centre for Community Ophthalmology, Good Samaritan Foundation, P.O. Box 2254, Moshi, Tanzania AU - Mganga, H. AU - Lewallen, S. AU - Courtright, P. DB - Embase DO - 10.4103/0974-9233.80695 IS - 2 KW - Africa article blindness cataract cataract extraction childhood cataract congenital cataract eye care family counseling family decision making gender bias glaucoma health care access health care cost health care utilization health service human open angle glaucoma patient counseling patient transport priority journal sex difference trachoma visual impairment LA - English M3 - Article N1 - L361792628 2011-05-27 2011-06-07 PY - 2011 SN - 0974-9233 0975-1599 SP - 98-101 ST - Overcoming gender inequity in prevention of blindness and visual impairment in Africa T2 - Middle East African Journal of Ophthalmology TI - Overcoming gender inequity in prevention of blindness and visual impairment in Africa UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361792628&from=export http://dx.doi.org/10.4103/0974-9233.80695 VL - 18 ID - 3182 ER - TY - JOUR AB - Purpose: To study resident compliance with the American Academy of Ophthalmology (AAO) Preferred Practice Patterns (PPPs) for primary open-angle glaucoma suspect (POAGS) in a resident ophthalmology clinic. Patients and Methods: Two hundred charts were selected for analysis of adult patients with the International Classification of Diseases diagnosis code for POAGS during their initial visit between November 2, 2010 and May 6, 2014 at the Kresge Eye Institute resident clinic. Electronic medical records of clinic visits for POAGS patients were evaluated for documentation and compliance with 17 elements of AAO PPPs. Results: The overall mean compliance was 73.8% for all charts (n=200), 74.4% for first-year residents (n=53), 74.5% for second-year residents (n=38), and 73.3% for third-year residents (n=109). Documentation rates were high (>90%) for 9 elements, which included most elements of physical examination and history. Documentation of ocular history, central corneal thickness, gonioscopy, optic nerve head and retinal nerve fiber layer analysis, and visual field ranged from 40% to 80%. Documentation was lowest for patient education elements which ranged from 0% to 10%. Compliance was not significantly different (P>0.05) between residents or between different resident years for any element. Conclusions: Residents' compliance was high for most elements of the PPPs for POAGS. We identified elements with poor compliance especially regarding patient education. Adherence to AAO PPPs can be a helpful method of assessing resident performance. © Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology, Kresge Eye Institute, School of Medicine, Wayne State University, 4717 St Antoine Blvd, Detroit, MI 48201, United States Detroit Medical Center, Detroit Education and Research, Detroit, MI, United States Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States AU - Mihlstin, M. AU - Juzych, M. S. AU - Kromrei, H. T. AU - Hwang, F. S. AU - Yin, J. DB - Scopus DO - 10.1097/IJG.0000000000000548 IS - 12 KW - American Academy of Ophthalmology Preferred Practice Patterns Primary open-angle glaucoma suspect Resident compliance M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2016 SP - 963-967 ST - Resident compliance with the American Academy of Ophthalmology Preferred Practice Patterns for primary open-angle glaucoma suspect T2 - Journal of Glaucoma TI - Resident compliance with the American Academy of Ophthalmology Preferred Practice Patterns for primary open-angle glaucoma suspect UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991447069&doi=10.1097%2fIJG.0000000000000548&partnerID=40&md5=afec3827b00bd36b00206a15746bff25 VL - 25 ID - 5627 ER - TY - JOUR AB - Purpose:To study resident compliance with the American Academy of Ophthalmology (AAO) Preferred Practice Patterns (PPPs) for primary open-angle glaucoma suspect (POAGS) in a resident ophthalmology clinic.Patients and Methods:Two hundred charts were selected for analysis of adult patients with the International Classification of Diseases diagnosis code for POAGS during their initial visit between November 2, 2010 and May 6, 2014 at the Kresge Eye Institute resident clinic. Electronic medical records of clinic visits for POAGS patients were evaluated for documentation and compliance with 17 elements of AAO PPPs.Results:The overall mean compliance was 73.8% for all charts (n=200), 74.4% for first-year residents (n=53), 74.5% for second-year residents (n=38), and 73.3% for third-year residents (n=109). Documentation rates were high (>90%) for 9 elements, which included most elements of physical examination and history. Documentation of ocular history, central corneal thickness, gonioscopy, optic nerve head and retinal nerve fiber layer analysis, and visual field ranged from 40% to 80%. Documentation was lowest for patient education elements which ranged from 0% to 10%. Compliance was not significantly different (P>0.05) between residents or between different resident years for any element.Conclusions:Residents' compliance was high for most elements of the PPPs for POAGS. We identified elements with poor compliance especially regarding patient education. Adherence to AAO PPPs can be a helpful method of assessing resident performance. AN - WOS:000390777600009 AU - Mihlstin, M. AU - Juzych, M. S. AU - Kromrei, H. T. AU - Hwang, F. S. AU - Yin, J. DA - DEC DO - 10.1097/IJG.0000000000000548 IS - 12 PY - 2016 SN - 1057-0829 1536-481X SP - 963-967 ST - Resident Compliance With the American Academy of Ophthalmology Preferred Practice Patterns for Primary Open-Angle Glaucoma Suspect T2 - JOURNAL OF GLAUCOMA TI - Resident Compliance With the American Academy of Ophthalmology Preferred Practice Patterns for Primary Open-Angle Glaucoma Suspect VL - 25 ID - 6131 ER - TY - JOUR AB - Purpose: To determine the percent adherence to follow-up for patients with pediatric glaucomas seen at a tertiary care center and to elucidate risk factors. Design: Retrospective cohort study. Methods: Patients with pediatric glaucomas seen at the University of Minnesota over 8.5 years were classified as adherent, nonadherent, or lost to tertiary follow-up if they followed up within 0-30 days, between 31 and 180 days, or later than 180 days of the recommended appointment time or never, respectively. Results: Of 176 patients analyzed, 95 (54%) were adherent (51% male; mean [standard deviation (SD)] age: 56.1 [59.8] months), 5 (3%) were nonadherent (20% male; mean [SD] age: 25.0 [35.8] months), and 76 (43%) were lost to tertiary follow-up (55% male; mean [SD] age: 58.9 [53.1] months). Multiple logistic regression analysis of variables that were significant in isolation revealed that only race (white: odds ratio, 3.58; 95% confidence interval, 1.42-9.05; P = .007) and distance from the eye clinic (per 50 miles: odds ratio, 0.79; 95% confidence interval, 0.67-0.92; P = .003) significantly impacted adherence. Conclusions: This is the first study of adherence to follow-up recommendations for patients with pediatric glaucomas. Percent adherence to follow-up appointments was alarmingly low, and decreased adherence was observed with non-white race and increased distance to the eye clinic. Physicians should consider these risk factors when risk-stratifying patients with pediatric glaucomas for nonadherence to follow-up. Additional studies to improve adherence through interventions that reduce biases and barriers to follow-up are needed. AD - R.G. Areaux, Ophthalmology Clinic, Park Plaza Building, 3rd Floor, 701 25th Ave Street, Minneapolis, MN, United States AU - Mikolajczyk, B. AU - Greenberg, E. R. AU - Fuher, H. AU - Berres, M. AU - May, L. L. AU - Areaux, R. G. DB - Embase Medline DO - 10.1016/j.ajo.2020.08.033 KW - article best corrected visual acuity Caucasian child controlled study dependent variable female follow up glaucoma Hispanic household income human logistic regression analysis major clinical study male patient care prediction priority journal risk factor tertiary care center LA - English M3 - Article N1 - L2008478972 2020-11-10 2021-01-26 PY - 2021 SN - 1879-1891 0002-9394 SP - 48-54 ST - Follow-up Adherence and Barriers to Care for Pediatric Glaucomas at a Tertiary Care Center T2 - American Journal of Ophthalmology TI - Follow-up Adherence and Barriers to Care for Pediatric Glaucomas at a Tertiary Care Center UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2008478972&from=export http://dx.doi.org/10.1016/j.ajo.2020.08.033 VL - 221 ID - 2334 ER - TY - JOUR AB - Purpose: To determine the percent adherence to follow-up for patients with pediatric glaucomas seen at a tertiary care center and to elucidate risk factors. Design: Retrospective cohort study. Methods: Patients with pediatric glaucomas seen at the University of Minnesota over 8.5 years were classified as adherent, nonadherent, or lost to tertiary follow-up if they followed up within 0-30 days, between 31 and 180 days, or later than 180 days of the recommended appointment time or never, respectively. Results: Of 176 patients analyzed, 95 (54%) were adherent (51% male; mean [standard deviation (SD)] age: 56.1 [59.8] months), 5 (3%) were nonadherent (20% male; mean [SD] age: 25.0 [35.8] months), and 76 (43%) were lost to tertiary follow-up (55% male; mean [SD] age: 58.9 [53.1] months). Multiple logistic regression analysis of variables that were significant in isolation revealed that only race (white: odds ratio, 3.58; 95% confidence interval, 1.42-9.05; P = .007) and distance from the eye clinic (per 50 miles: odds ratio, 0.79; 95% confidence interval, 0.67-0.92; P = .003) significantly impacted adherence. Conclusions: This is the first study of adherence to follow-up recommendations for patients with pediatric glaucomas. Percent adherence to follow-up appointments was alarmingly low, and decreased adherence was observed with non-white race and increased distance to the eye clinic. Physicians should consider these risk factors when risk-stratifying patients with pediatric glaucomas for nonadherence to follow-up. Additional studies to improve adherence through interventions that reduce biases and barriers to follow-up are needed. © 2020 Elsevier Inc. AD - Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN, United States AU - Mikolajczyk, B. AU - Greenberg, E. R. AU - Fuher, H. AU - Berres, M. AU - May, L. L. AU - Areaux, R. G., Jr. DB - Scopus DO - 10.1016/j.ajo.2020.08.033 M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 48-54 ST - Follow-up Adherence and Barriers to Care for Pediatric Glaucomas at a Tertiary Care Center T2 - American Journal of Ophthalmology TI - Follow-up Adherence and Barriers to Care for Pediatric Glaucomas at a Tertiary Care Center UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095459151&doi=10.1016%2fj.ajo.2020.08.033&partnerID=40&md5=bba94ad1049beaf93265179ecfb771f6 VL - 221 ID - 5681 ER - TY - JOUR AB - PURPOSE: To determine the percent adherence to follow-up for patients with pediatric glaucomas seen at a tertiary care center and to elucidate risk factors. DESIGN: Retrospective cohort study. METHODS: Patients with pediatric glaucomas seen at the University of Minnesota over 8.5 years were classified as adherent, nonadherent, or lost to tertiary follow-up if they followed up within 0-30 days, between 31 and 180 days, or later than 180 days of the recommended appointment time or never, respectively. RESULTS: Of 176 patients analyzed, 95 (54%) were adherent (51% male; mean [standard deviation (SD)] age: 56.1 [59.8] months), 5 (3%) were nonadherent (20% male; mean [SD] age: 25.0 [35.8] months), and 76 (43%) were lost to tertiary follow-up (55% male; mean [SD] age: 58.9 [53.1] months). Multiple logistic regression analysis of variables that were significant in isolation revealed that only race (white: odds ratio, 3.58; 95% confidence interval, 1.42-9.05; P = .007) and distance from the eye clinic (per 50 miles: odds ratio, 0.79; 95% confidence interval, 0.67-0.92; P = .003) significantly impacted adherence. CONCLUSIONS: This is the first study of adherence to follow-up recommendations for patients with pediatric glaucomas. Percent adherence to follow-up appointments was alarmingly low, and decreased adherence was observed with non-white race and increased distance to the eye clinic. Physicians should consider these risk factors when risk-stratifying patients with pediatric glaucomas for nonadherence to follow-up. Additional studies to improve adherence through interventions that reduce biases and barriers to follow-up are needed. ((C) 2020 Elsevier Inc. All rights reserved.) AN - WOS:000599616500006 AU - Mikolajczyk, B. AU - Greenberg, E. R. AU - Fuher, H. AU - Berres, M. AU - May, L. L. AU - Areaux, R. G. DA - JAN DO - 10.1016/j.ajo.2020.08.033 PY - 2021 SN - 0002-9394 1879-1891 SP - 48-54 ST - Follow-up Adherence and Barriers to Care for Pediatric Glaucomas at a Tertiary Care Center T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Follow-up Adherence and Barriers to Care for Pediatric Glaucomas at a Tertiary Care Center VL - 221 ID - 5817 ER - TY - JOUR AB - Purpose: To investigate whether demographic, clinical, or psychosocial factors act as moderators of change in medication adherence in the Support, Educate, Empower (SEE) program. Design: Prospective, single-arm pilot study with a pre–post design. Participants: Patients with glaucoma aged ≥ 40 years and taking ≥ 1 glaucoma medication were recruited from the University of Michigan Kellogg Eye Center. Those who had electronically measured adherence ≤ 80% in the 3-month eligibility monitoring period were enrolled in the SEE program. Methods: Medication adherence was monitored electronically during the 7-month intervention and calculated as the percentage of doses taken correctly. Change in adherence at different points in the SEE program and cumulative change in adherence were modeled with linear regression, and baseline demographic, clinical, and psychosocial factors were investigated for significant associations. Main Outcome Measures: Demographic, clinical, and psychosocial variables associated with change in medication adherence in the SEE program. Results: Thirty-nine participants completed the SEE program. These participants were on average 63.9 years old (standard deviation [SD], 10.7 years), 56% (n = 22) were male, 44% (n = 17) were White, and 49% (n = 19) were Black. Medication adherence improved from an average of 59.9% (SD, 18.5%) at baseline to 83.6% (SD, 17.5%) after the final SEE session, for an increase of 23.7% (SD, 17.5%). Although participants with lower income (< $25 000 and $25 000–50 000 vs. >$50 000) had lower baseline adherence (48.4% and 64.1% vs. 70.4%), these individuals had greater increases in adherence during the first month of medication reminders (19.6% and 21.6% vs. 10.2%; P = 0.05 and P = 0.007, respectively). Participants taking fewer glaucoma medications also had significantly greater increases in adherence with medication reminders (P < 0.001). Those with higher levels of glaucoma-related distress (GD) had lower baseline adherence and greater increases in adherence with glaucoma coaching (P = 0.06). Conclusions: Patient-level factors associated with relatively greater improvements in medication adherence through the SEE Program included lower income, fewer glaucoma medications, and increased GD. These findings demonstrate that the SEE program can improve glaucoma self-management even among participants with social and psychological barriers to medication adherence. AD - P.A. Newman-Casey, University of Michigan, Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI, United States AU - Miller, D. J. AU - Niziol, L. M. AU - Elam, A. R. AU - Heisler, M. AU - Lee, P. P. AU - Resnicow, K. AU - Musch, D. C. AU - Darnley-Fisch, D. AU - Mitchell, J. AU - Newman-Casey, P. A. DB - Embase Medline DO - 10.1016/j.ogla.2021.06.001 KW - adult clinical article conference paper controlled study demography distress syndrome education eligibility female glaucoma human linear regression analysis male medication compliance Michigan middle aged motivational interviewing outcome assessment pilot study prospective study self care LA - English M3 - Article in Press N1 - L2013342033 2021-07-06 PY - 2021 SN - 2589-4196 2589-4234 ST - Demographic, Clinical, and Psychosocial Predictors of Change in Medication Adherence in the Support, Educate, Empower Program T2 - Ophthalmology Glaucoma TI - Demographic, Clinical, and Psychosocial Predictors of Change in Medication Adherence in the Support, Educate, Empower Program UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2013342033&from=export http://dx.doi.org/10.1016/j.ogla.2021.06.001 ID - 2347 ER - TY - JOUR AD - ADJUNCT FACULTY MEMBER, OHIO STATE UNIVERSITY COLLEGE OF OPTOMETRY AN - 96291330. Language: English. Entry Date: 20140605. Revision Date: 20191101. Publication Type: Article AU - Miller, Jason R. DB - ccm DP - EBSCOhost IS - 5 KW - Contact Lens Fitting -- Education Patient Education Corneal Ulcer -- Prevention and Control Patient Compliance Patient Satisfaction Professional-Patient Relations N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2014 SN - 0030-4085 SP - 46-46 ST - A Fitting Discussion T2 - Optometric Management TI - A Fitting Discussion UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=96291330&site=ehost-live&scope=site VL - 49 ID - 4793 ER - TY - JOUR AD - Associate professor and chair, Clinical Sciences Department, University of Houston College of Optometry Consultant or advisor, Alcon and Oasis Medical AN - 103562848. Language: English. Entry Date: 20150701. Revision Date: 20191121. Publication Type: Article AU - Miller, William L. DB - ccm DP - EBSCOhost IS - 5 KW - Corneal Diseases -- Therapy Neovascularization, Pathologic -- Therapy Neovascularization, Pathologic -- Complications Cornea -- Anatomy and Histology Neovascularization, Pathologic -- Risk Factors Neovascularization, Pathologic -- Etiology Keratitis, Herpetic -- Diagnosis Keratitis, Herpetic -- Complications Trachoma -- Diagnosis Trachoma -- Complications Blood Vessels -- Anatomy and Histology Patient Compliance Contact Lenses -- Evaluation Hyperemia -- Diagnosis Contact Lens Fitting Steroids -- Administration and Dosage Steroids -- Adverse Effects Vascular Endothelial Growth Factors -- Therapeutic Use N1 - pictorial. Journal Subset: Biomedical; USA. NLM UID: 8610268. PY - 2015 SN - 0885-9175 SP - 49-49 ST - Treatment Plan. Managing Corneal Neovascularization T2 - Contact Lens Spectrum TI - Treatment Plan. Managing Corneal Neovascularization UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103562848&site=ehost-live&scope=site VL - 30 ID - 4790 ER - TY - JOUR AB - A presumed case of fungal keratitis is presented. Confocal images highlight the advantage of using such technology to follow therapeutic progress, particularly when standard laboratory testing is inconclusive. This case also demonstrates the importance of continued patient education regarding overall compliance and lens care. © 2008 British Contact Lens Association. AD - W.L. Miller, University of Houston, College of Optometry, 505 J. Davis Armistead Building, Houston, TX 77204-2020, United States AU - Miller, W. L. AU - Giannoni, A. G. AU - Perrigin, J. C1 - vicodin vigamox DB - Embase Medline DO - 10.1016/j.clae.2008.03.008 IS - 4 KW - artificial tear bacitracin hydrocodone bitartrate plus paracetamol moxifloxacin natamycin scopolamine tobramycin adult article biomicroscopy blepharitis case report clinical assessment confocal microscopy conjunctival hyperemia contact lens cornea edema cornea ulcer drug dose reduction drug eruption drug withdrawal dry eye evening dosage eye care eye irritation eye pain follow up fungus growth fungus hyphae Fusarium human keratomycosis male nonhuman pain patient compliance patient education priority journal scar visual acuity vicodin vigamox LA - English M3 - Article N1 - L50194422 2008-08-01 PY - 2008 SN - 1367-0484 1476-5411 SP - 201-206 ST - A case of fungal keratitis: A clinical and in vivo confocal microscopy assessment T2 - Contact Lens and Anterior Eye TI - A case of fungal keratitis: A clinical and in vivo confocal microscopy assessment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50194422&from=export http://dx.doi.org/10.1016/j.clae.2008.03.008 VL - 31 ID - 3438 ER - TY - JOUR AB - A presumed case of fungal keratitis is presented. Confocal images highlight the advantage of using such technology to follow therapeutic progress, particularly when standard laboratory testing is inconclusive. This case also demonstrates the importance of continued patient education regarding overall compliance and lens care. © 2008 British Contact Lens Association. AD - University of Houston, College of Optometry, 505 J. Davis Armistead Building, Houston, TX 77204-2020, United States AU - Miller, W. L. AU - Giannoni, A. G. AU - Perrigin, J. DB - Scopus DO - 10.1016/j.clae.2008.03.008 IS - 4 KW - Confocal microscopy Contact lens solution Contact lenses Fungal keratitis M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2008 SP - 201-206 ST - A case of fungal keratitis: A clinical and in vivo confocal microscopy assessment T2 - Contact Lens and Anterior Eye TI - A case of fungal keratitis: A clinical and in vivo confocal microscopy assessment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-48949115077&doi=10.1016%2fj.clae.2008.03.008&partnerID=40&md5=8b9603372041ffcd262de3f022ef9f4e VL - 31 ID - 5430 ER - TY - GEN AB - The medical treatment of glaucoma has evolved significantly over the past several decades. The main driving forces behind this evolution are the safety profiles and efficacy of these medications. Prostaglandin (PG) analogues are shown to be superior to older drugs in both efficacy and tolerability. Though there are much fewer side effects that manifest after using PG analogues, the adherence and compliance to medication regimens are surprisingly lower than expected. A commonly sited reason is the ocular irritation and inflammation with these medications. Much of this inflammation can be attributed to the preservative, benzalkonium chloride (BAK). The chronic clinical and subclinical inflammation becomes increasingly detrimental when filtration surgery fails from bleb fibrosis secondary to this hypercellularity. A BAK-free formulation of a PG analogues recently became available. BAK-free travoprost is reviewed here. It has demonstrated equal efficacy and less ocular surface toxicity than its preserved counterparts. It is expected to serve as an instrumental resource in managing ocular hypertension and glaucoma in patients who demonstrate significant sensitivity to BAK. More randomized, controlled, double-blind studies are encouraged to evaluate its improved safety and tolerability. © 2010 Mirza and Johnson. AD - S. K. Mirza, 1812 Sugar Maple Terrace, Charlottesville, VA 22903, United States AU - Mirza, S. K. AU - Johnson, S. M. C1 - alphagan(Allergan,United States) purite travatan z C2 - Allergan(United States) DB - Embase J2 - Clin. Ophthalmol. KW - alpha adrenergic receptor stimulating agent antiglaucoma agent artificial tear benzalkonium chloride beta adrenergic receptor blocking agent bimatoprost brimonidine buffer carbonate dehydratase inhibitor drug preservative eye drops latanoprost miotic agent olopatadine phosphate buffered saline prostaglandin derivative prostaglandin F2 alpha purite quaternary ammonium derivative reactive oxygen metabolite stabilized oxychloro complex timolol travoprost tumor necrosis factor unclassified drug abnormal sensation African American apoptosis bioaccumulation burning sensation Caucasian cell death cell viability chronic inflammation clinical trial conjunctival hyperemia cornea epithelium cornea thickness drug contamination drug cost drug cytotoxicity drug efficacy drug formulation drug half life drug mechanism drug solution drug tolerability dry eye emulsion eye inflammation eye irritation eye stinging filtering operation foreign body sensation health care cost human hyperemia inflammation inflammatory cell intraocular hypertension intraocular pressure microvillus nonhuman ocular hyperemia open angle glaucoma oxidative stress patient compliance prevalence review side effect single drug dose unspecified side effect visual acuity visual analog scale xerostomia alphagan travatan z L1 - internal-pdf://0631704567/3232-Efficacy and patient tolerability of-2010.pdf LA - English M1 - (Mirza S.K., sophia.mirza@gmail.com; Johnson S.M., SMJ3A@hscmail.mcc.virginia.edu) Department of Ophthalmology, University of Virginia, Charlottesville, VA, United States M3 - Review N1 - L359443916 2010-09-07 2010-09-15 PY - 2010 SN - 1177-5467 1177-5483 SP - 877-888 ST - Efficacy and patient tolerability of travoprost bak-free solution in patients with open-angle glaucoma and ocular hypertension TI - Efficacy and patient tolerability of travoprost bak-free solution in patients with open-angle glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359443916&from=export VL - 4 ID - 3232 ER - TY - JOUR AD - L. V. Prasad Eye Institute, Kallam Anji Reddy Campus, Hyderabad, Andhra Pradesh, India, mshoba@lvpei.org L. V. Prasad Eye Institute, Kallam Anji Reddy Campus, Hyderabad, Andhra Pradesh, India Brien Holden Vision Institute, University of New South Wales, Sydney, Australia AN - 104827566. Language: English. Entry Date: 20110531. Revision Date: 20200708. Publication Type: Journal Article AU - Mocherla, Shobha AU - Raman, Usha AU - Holden, Brien DB - ccm DO - 10.1177/1049732310386050 DP - EBSCOhost IS - 3 KW - Professional-Patient Relations Communication Glaucoma Patient Compliance India Academic Medical Centers Grounded Theory Thematic Analysis Constant Comparative Method Multimethod Studies Human Semi-Structured Interview N1 - research; tables/charts. Journal Subset: Core Nursing; Nursing; Peer Reviewed; USA. NLM UID: 9202144. PMID: NLM21041519. PY - 2011 SN - 1049-7323 SP - 429-440 ST - Clinician-Patient Communication in a Glaucoma Clinic in India T2 - Qualitative Health Research TI - Clinician-Patient Communication in a Glaucoma Clinic in India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104827566&site=ehost-live&scope=site VL - 21 ID - 4529 ER - TY - JOUR AB - We compiled data from nonparticipant observations of clinician–patient communication in clinical interactions in a tertiary care eye hospital in India. Applying elements of the French philosopher Michel Foucault’s concept of power and knowledge, we deconstructed the structuring and moderating influences on the expert/nonexpert dyad. We found that clinicians enforce their 'disciplining power' through varying degrees of communicativeness to bring about compliance in the patient. Clinicians appear to classify the patient as 'participant' or 'deviant' based on the patient’s 'internalization' of instructions, and then communicate in predictable ways with the patient. Patients can also wield power, communicating it by understanding and following or not understanding and not clarifying/verifying instructions in the clinic, and thereafter failing to comply with the clinician’s advice. We suggest that clinicians need to hone their communication skills both to optimally utilize interactions in the clinic and to encourage patient compliance, thereby making possible better treatment outcomes. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Mocherla, Shobha, CAVU, L. V. Prasad Eye Institute, Kallam Anji Reddy Campus, L. V. Prasad Marg, Banjara Hills, Andhra Pradesh, Hyderabad, India, 500 034 AN - 2011-04489-013 AU - Mocherla, Shobha AU - Raman, Usha AU - Holden, Brien DB - psyh DO - 10.1177/1049732310386050 DP - EBSCOhost IS - 3 KW - client doctor interaction glaucoma therapeutic processes clinicians India Adult Ambulatory Care Facilities Chronic Disease Communication Female Humans Interview, Psychological Male Patient Education as Topic Physician-Patient Relations Power (Psychology) Qualitative Research Vision, Ocular Young Adult Patients South Asian Cultural Groups N1 - Central Audio-Visual Unit, L. V. Prasad Eye Institute, Hyderabad, India. Release Date: 20110912. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Clinicians; Glaucoma; Patients; South Asian Cultural Groups; Therapeutic Processes. Classification: Inpatient & Hospital Services (3379). Population: Human (10); Male (30); Female (40). Location: India. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Interview; Qualitative Study. References Available: Y. Page Count: 12. Issue Publication Date: Mar, 2011. Copyright Statement: The Author(s). 2011. Sponsor: Vision Cooperative Research Centres, Australia. Recipients: No recipient indicated Sponsor: L. V. Prasad Eye Institute, India. Recipients: No recipient indicated Sponsor: University of New South Wales, Brien Holden Vision Institute, Australia. Recipients: No recipient indicated PY - 2011 SN - 1049-7323 1552-7557 SP - 429-440 ST - Clinician-patient communication in a glaucoma clinic in India T2 - Qualitative Health Research TI - Clinician-patient communication in a glaucoma clinic in India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-04489-013&site=ehost-live&scope=site mshoba@lvpei.org VL - 21 ID - 4852 ER - TY - JOUR AB - PURPOSE: To evaluate once-daily nepafenac 0.3% to prevent and treat ocular pain and inflammation after cataract surgery. SETTING: Sixty-five centers in the United States and Europe. DESIGN: Randomized double-masked vehicle- and active-controlled phase 3 study. METHODS: Patients received nepafenac 0.3% once daily, nepafenac 0.1% 3 times daily, or their respective vehicles from day 1 to day 14 after cataract extraction. An additional drop of study drug was administered 30 to 120 minutes preoperatively. The primary endpoint was the percentage of patients with a cure for inflammation (score of 0 for both aqueous cells and flare) at day 14. RESULTS: Of randomized patients, 817 received nepafenac 0.3%, 819 received nepafenac 0.1%, and 200 and 206 received the respective vehicles. Significantly more nepafenac 0.3% patients had no inflammation (68.4% versus 34.0%) and were pain free (91.0% versus 49.7%) at day 14 than vehicle patients (both P<.0001). Nepafenac 0.3% was noninferior to nepafenac 0.1% for inflammation (95% confidence interval [Cl], -5.73% to 3.17%) and pain-free rates (95% Cl, -3.08% to 2.70%). At all postoperative visits, fewer treatment failures (P <=.0012) and more clinical successes (P <=.0264) were observed with nepafenac 0.3% versus vehicle. Nepafenac 0.3% was well tolerated and had a safety profile comparable to that of nepafenac 0.1%. CONCLUSIONS: Once-daily nepafenac 0.3% was noninferior to nepafenac 0.1% 3 times daily for prevention and treatment of ocular inflammation and pain following cataract surgery. The safety of nepafenac 0.3% was comparable to that of nepafenac 0.1%, with the added convenience of once-daily dosing. (C) 2013 ASCRS and ESCRS AN - WOS:000331772600007 AU - Modi, S. S. AU - Lehmann, R. P. AU - Walters, T. R. AU - Fong, R. AU - Christie, W. C. AU - Roel, L. AU - Nethery, D. AU - Sager, D. AU - Tsorbatzoglou, A. AU - Philipson, B. AU - Traverso, C. E. AU - Reiser, H. DA - FEB DO - 10.1016/j.jcrs.2013.07.042 IS - 2 PY - 2014 SN - 0886-3350 1873-4502 SP - 203-211 ST - Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: Phase 3 study VL - 40 ID - 6359 ER - TY - JOUR AD - Eye Monitoring Center, Kaiser Permanente Southern California, Baldwin Park, California, United States Department of Ophthalmology, Southern California Permanente Medical Group, Baldwin Park, California, United States National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States Department of Ophthalmology, Harvard Medical School and the Department of Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, California, United States AU - Modjtahedi, B. S. AU - Ferris, F. L., III AU - Hunter, D. G. AU - Fong, D. S. DB - Scopus DO - 10.1016/j.ophtha.2018.01.033 IS - 5 M3 - Editorial N1 - Cited By :19 Export Date: 19 July 2021 PY - 2018 SP - 628-630 ST - Public Health Burden and Potential Interventions for Myopia T2 - Ophthalmology TI - Public Health Burden and Potential Interventions for Myopia UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045380955&doi=10.1016%2fj.ophtha.2018.01.033&partnerID=40&md5=ca9f820031d70e5474845ef25adbcbfb VL - 125 ID - 5146 ER - TY - JOUR AB - Purpose: Glaucoma patients are still at risk of becoming blind. It is of clinical significance to determine the risk of blindness and its causes to prevent its occurrence. This systematic review estimates the number of treated glaucoma patients with end-of-life visual impairment (VI) and blindness and the factors that are associated with this. Methods: A systematic literature search in relevant databases was conducted in August 2014 on end-of-life VI. A total of 2574 articles were identified, of which 5 on end-of-life VI. Several data items were extracted from the reports and presented in tables. Results: All studies had a retrospective design. A considerable number of glaucoma patients were found to be blind at the end of their life; with up to 24% unilateral and 10% bilateral blindness. The following factors were associated with blindness: (1) baseline severity of visual field loss: advanced stage of glaucoma or substantial visual field loss at the initial visit; (2) factors influencing progression: fluctuation of intraocular pressure (IOP) during treatment, presence of pseudoexfoliation, poor patient compliance, higher IOP; (3) longer time period: longer duration of disease and older age at death because of a longer life expectancy; and (4) coexistence of other ocular pathology. Conclusions: Further prevention of blindness in glaucoma patients is needed. To reach this goal, it is important to address the risk factors for blindness identified in this review, especially those that can be modified, such as advanced disease at diagnosis, high and fluctuating IOP, and poor compliance. AN - WOS:000379585100035 AU - Mokhles, P. AU - Schouten, Jsag AU - Beckers, H. J. M. AU - Azuara-Blanco, A. AU - Tuulonen, A. AU - Webers, C. A. B. DA - JUL DO - 10.1097/IJG.0000000000000389 IS - 7 PY - 2016 SN - 1057-0829 1536-481X SP - 623-628 ST - A Systematic Review of End-of-Life Visual Impairment in Open-Angle Glaucoma: An Epidemiological Autopsy T2 - JOURNAL OF GLAUCOMA TI - A Systematic Review of End-of-Life Visual Impairment in Open-Angle Glaucoma: An Epidemiological Autopsy VL - 25 ID - 6219 ER - TY - JOUR AB - Purpose: Glaucoma patients are still at risk of becoming blind. It is of clinical significance to determine the risk of blindness and its causes to prevent its occurrence. This systematic review estimates the number of treated glaucoma patients with end-of-life visual impairment (VI) and blindness and the factors that are associated with this. Methods: A systematic literature search in relevant databases was conducted in August 2014 on end-of-life VI. A total of 2574 articles were identified, of which 5 on end-of-life VI. Several data items were extracted from the reports and presented in tables. Results: All studies had a retrospective design. A considerable number of glaucoma patients were found to be blind at the end of their life; with up to 24% unilateral and 10% bilateral blindness. The following factors were associated with blindness: (1) baseline severity of visual field loss: advanced stage of glaucoma or substantial visual field loss at the initial visit; (2) factors influencing progression: fluctuation of intraocular pressure (IOP) during treatment, presence of pseudoexfoliation, poor patient compliance, higher IOP; (3) longer time period: longer duration of disease and older age at death because of a longer life expectancy; and (4) coexistence of other ocular pathology. Conclusions: Further prevention of blindness in glaucoma patients is needed. To reach this goal, it is important to address the risk factors for blindness identified in this review, especially those that can be modified, such as advanced disease at diagnosis, high and fluctuating IOP, and poor compliance. AD - P. Mokhles, Department of Ophthalmology, University Eye Clinic Maastricht, Postbus 5800, Maastricht, Netherlands AU - Mokhles, P. AU - Schouten, J. S. A. G. AU - Beckers, H. J. M. AU - Azuara-Blanco, A. AU - Tuulonen, A. AU - Webers, C. A. B. DB - Embase Medline DO - 10.1097/IJG.0000000000000389 IS - 7 KW - adverse outcome age age related macular degeneration blindness cataract comorbidity disease course disease duration follow up human intraocular hypertension intraocular pressure life expectancy open angle glaucoma patient compliance priority journal pseudoexfoliation review systematic review unilateral blindness visual field defect visual impairment LA - English M3 - Review N1 - L608643818 2016-03-03 2016-08-05 PY - 2016 SN - 1536-481X 1057-0829 SP - 623-628 ST - A Systematic Review of End-of-Life Visual Impairment in Open-Angle Glaucoma: An Epidemiological Autopsy T2 - Journal of Glaucoma TI - A Systematic Review of End-of-Life Visual Impairment in Open-Angle Glaucoma: An Epidemiological Autopsy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L608643818&from=export http://dx.doi.org/10.1097/IJG.0000000000000389 VL - 25 ID - 2727 ER - TY - JOUR AB - Purpose: Glaucoma patients are still at risk of becoming blind. It is of clinical significance to determine the risk of blindness and its causes to prevent its occurrence. This systematic review estimates the number of treated glaucoma patients with end-of-life visual impairment (VI) and blindness and the factors that are associated with this. Methods: A systematic literature search in relevant databases was conducted in August 2014 on end-of-life VI. A total of 2574 articles were identified, of which 5 on end-of-life VI. Several data items were extracted from the reports and presented in tables. Results: All studies had a retrospective design. A considerable number of glaucoma patients were found to be blind at the end of their life; with up to 24% unilateral and 10% bilateral blindness. The following factors were associated with blindness: (1) baseline severity of visual field loss: advanced stage of glaucoma or substantial visual field loss at the initial visit; (2) factors influencing progression: fluctuation of intraocular pressure (IOP) during treatment, presence of pseudoexfoliation, poor patient compliance, higher IOP; (3) longer time period: longer duration of disease and older age at death because of a longer life expectancy; and (4) coexistence of other ocular pathology. Conclusions: Further prevention of blindness in glaucoma patients is needed. To reach this goal, it is important to address the risk factors for blindness identified in this review, especially those that can be modified, such as advanced disease at diagnosis, high and fluctuating IOP, and poor compliance. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology, University Eye Clinic Maastricht, Postbus 5800, Maastricht, 6202 AZ, Netherlands Queen's University Belfast, Belfast, United Kingdom Department of Ophthalmology, University of Tampere, Tampere, Finland AU - Mokhles, P. AU - Schouten, J. S. A. G. AU - Beckers, H. J. M. AU - Azuara-Blanco, A. AU - Tuulonen, A. AU - Webers, C. A. B. DB - Scopus DO - 10.1097/IJG.0000000000000389 IS - 7 KW - blindness glaucoma intraocular pressure lifetime outcome visual impairment M3 - Review N1 - Cited By :12 Export Date: 19 July 2021 PY - 2016 SP - 623-628 ST - A Systematic Review of End-of-Life Visual Impairment in Open-Angle Glaucoma: An Epidemiological Autopsy T2 - Journal of Glaucoma TI - A Systematic Review of End-of-Life Visual Impairment in Open-Angle Glaucoma: An Epidemiological Autopsy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959109057&doi=10.1097%2fIJG.0000000000000389&partnerID=40&md5=9d11add7e1d8cbacd7f3cfdd14132f36 VL - 25 ID - 5229 ER - TY - JOUR AB - Purpose: Globally, particularly in Africa, poor compliance with medication is a major problem in glaucoma management but little is known about follow-up rates among African glaucoma patients. The aim of this study was to determine rates of follow-up among glaucoma patients attending a tertiary hospital in southern Nigeria and investigate predictors of poor follow-up. Methods: Data were extracted from medical records of new glaucoma patients who attended the hospital between June 2011 and May 2013. Socio-demographic and clinical parameters (visual acuity; stage of glaucoma) recorded at diagnosis were extracted using a pre-tested form. Follow-up was defined as good if they had attended within 9 months of the study date, inadequate when the last follow-up was more than 9 months and failed if they did not attend any follow-up or the most recent visit was more than 14 months from the study date. Univariate and multivariable analyses were undertaken to explore predictors of poor follow-up (inadequate plus failed). Results: Three hundred forty-eight patients were recruited, 54% were male and the mean age was 52.7 (range 16–88) years. Follow-up was as follows: good 28.4%, inadequate 46.6%, failed 25%. Overall, 71.6% had poor follow-up. Independent predictors of poor follow-up were poorer visual acuity (OR 3.85, 95% confidence interval (CI) 1.25–11.80 for visual impairment; OR 4.11, 95% CI 1.32–12.81 for blind) and end-stage glaucoma (OR 3.55 (1.31–9.62), p = 0.01). Conclusion: Enhanced counselling of patients with moderate to advanced glaucoma and visual impairment is required to improve follow-up and hence glaucoma management. © 2018 Taylor & Francis. AD - Department of Ophthalmology, University of Benin Teaching Hospital, Benin City, Nigeria Department of Primary Care & Public Health, Kings College London, London, United Kingdom Department of Community Health, University of Benin Teaching Hospital, Benin City, Nigeria London School of Hygiene & Tropical Medicine, International Centre for Eye Health (ICEH), London, United Kingdom AU - Momoh, R. O. AU - Bunce, C. AU - Oko-oboh, G. A. AU - Gilbert, C. E. DB - Scopus DO - 10.1080/09286586.2018.1424345 IS - 3 KW - Advanced glaucoma follow-up Nigeria predictors rates M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2018 SP - 266-272 ST - Advanced glaucoma at presentation is associated with poor follow-up among glaucoma patients attending a tertiary eye facility in Southern Nigeria T2 - Ophthalmic Epidemiology TI - Advanced glaucoma at presentation is associated with poor follow-up among glaucoma patients attending a tertiary eye facility in Southern Nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044173730&doi=10.1080%2f09286586.2018.1424345&partnerID=40&md5=d32762aba8979a397c39527e1dc80410 VL - 25 ID - 5410 ER - TY - JOUR AB - Purpose: Globally, particularly in Africa, poor compliance with medication is a major problem in glaucoma management but little is known about follow-up rates among African glaucoma patients. The aim of this study was to determine rates of follow-up among glaucoma patients attending a tertiary hospital in southern Nigeria and investigate predictors of poor follow-up.Methods: Data were extracted from medical records of new glaucoma patients who attended the hospital between June 2011 and May 2013. Socio-demographic and clinical parameters (visual acuity; stage of glaucoma) recorded at diagnosis were extracted using a pre-tested form. Follow-up was defined as good if they had attended within 9months of the study date, inadequate when the last follow-up was more than 9months and failed if they did not attend any follow-up or the most recent visit was more than 14months from the study date. Univariate and multivariable analyses were undertaken to explore predictors of poor follow-up (inadequate plus failed).Results: Three hundred forty-eight patients were recruited, 54% were male and the mean age was 52.7 (range 16-88) years. Follow-up was as follows: good 28.4%, inadequate 46.6%, failed 25%. Overall, 71.6% had poor follow-up. Independent predictors of poor follow-up were poorer visual acuity (OR 3.85, 95% confidence interval (CI) 1.25-11.80 for visual impairment; OR 4.11, 95% CI 1.32-12.81 for blind) and end-stage glaucoma (OR 3.55 (1.31-9.62), p=0.01).Conclusion: Enhanced counselling of patients with moderate to advanced glaucoma and visual impairment is required to improve follow-up and hence glaucoma management. AN - WOS:000427742200013 AU - Momoh, R. O. AU - Bunce, C. AU - Oko-oboh, G. A. AU - Gilbert, C. E. DO - 10.1080/09286586.2018.1424345 IS - 3 PY - 2018 SN - 0928-6586 1744-5086 SP - 266-272 ST - Advanced glaucoma at presentation is associated with poor follow-up among glaucoma patients attending a tertiary eye facility in Southern Nigeria T2 - OPHTHALMIC EPIDEMIOLOGY TI - Advanced glaucoma at presentation is associated with poor follow-up among glaucoma patients attending a tertiary eye facility in Southern Nigeria VL - 25 ID - 5874 ER - TY - JOUR AB - Background: One barrier to patient adherence with chronic topical glaucoma treatment is an inadequate amount of medication available between prescription refills. We examined the self-reported prevalence of early exhaustion of glaucoma eye drops prior to a scheduled refill, and associated risk factors. Methods. This cross-sectional survey was performed at a University-based clinical practice. Glaucoma patients at the University of Washington who were experienced with eye drop application and were on a steady regimen of self-administered glaucoma drops in both eyes took a survey at the time of clinic examination. The main outcome measure was self-reported early eye drop bottle exhaustion. Results: 236 patients were eligible and chose to participate. In general, patients included were relatively healthy (mean 2.3 comorbid medical conditions). Sixty patients (25.4%) reported any problem with early exhaustion of eye drop bottles, and this was associated with visual acuity ≤ 20/70 in the better eye (P =.049). Twelve patients (5.1%) reported that they "often" (5-7 times per year), "usually" (8-11 times per year) or "always" ran out of eye drops prior to a scheduled refill. Patients affected by this higher level (≥5 times yearly) of eye drop bottle exhaustion were more likely to have poor visual acuity in their worse eye ≤ 20/70 (P =.015) and had significantly lower worse-eye logMAR (P =.043). Conclusions: Self-reported early glaucoma bottle exhaustion regularly affected 5% of patients in our population and 25% reported early exhaustion at least once; the main risk factor was poor vision in at least one eye. These results may not be generalizable to a broad patient population, or to those inexperienced with eye drop self-administration. However, this pilot study compels further evaluation and consideration of early eye drop bottle exhaustion in glaucoma patients. © 2014 Moore et al.; licensee BioMed Central Ltd. AD - Department of Ophthalmology, University of Washington, 325 Ninth Ave, Seattle, WA 98104-2499, United States Seattle University, Seattle, WA, United States AU - Moore, D. B. AU - Walton, C. AU - Moeller, K. L. AU - Slabaugh, M. A. AU - Mudumbai, R. C. AU - Chen, P. P. C7 - 79 DB - Scopus DO - 10.1186/1471-2415-14-79 IS - 1 KW - Adherence Blindness Compliance Eyedrop Glaucoma Low vision Medication Treatment Visual impairment M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2014 ST - Prevalence of self-reported early glaucoma eye drop bottle exhaustion and associated risk factors: A patient survey T2 - BMC Ophthalmology TI - Prevalence of self-reported early glaucoma eye drop bottle exhaustion and associated risk factors: A patient survey UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902042190&doi=10.1186%2f1471-2415-14-79&partnerID=40&md5=322baf70cf86f3415049b6999e28ff92 VL - 14 ID - 5305 ER - TY - JOUR AB - Introduction: To simplify the medical treatment of glaucoma for patients on multiple drops by introducing brinzolamide/brimonidine tartrate fixed combination (BBFC) ophthalmic suspension 1%/0.2% (SIMBRINZA®; Alcon Laboratories, Inc., Fort Worth, TX, USA) to the drop regimen and to establish its efficacy. To demonstrate that fixed combination (FC) therapies are associated with improvements in treatment adherence and persistence with reduced exposure to preservative-related ocular surface problems. Methods: Retrospective study: 76 patients were identified as taking BBFC following a switch in treatment regimen. Intraocular pressure (IOP) prior to and 2–17.5 months (average 5.4 months) after the introduction of BBFC was measured. The change in the average number of bottles used per eye was recorded. The rate of adverse effects (AEs) of BBFC was recorded. A two-tailed paired sample t test was used to compare IOP prior to and after the introduction of BBFC for each eye. Results: Mean change in IOP after BBFC introduction BBFC: − 2.76 mmHg (p < 0.0001). BBFC intolerance: 13%. On average there was a 0.24 reduction in the number of bottles of IOP-lowering medication used per eye (p < 0.0064). Conclusion: A switch to BBFC in the drop regimen is associated with a significant drop in IOP with reduced drop burden. Instead of a third IOP-lowering medication and bottle, a practitioner should consider using BBFC + prostaglandin analogue/FC drop for effective IOP control, reduced drop burden, reduced preservative load and increased likelihood of adherence. This study promotes the concept that any treatment should principally be assessed from the patients’ perspective and quality of life. AD - R. Moosavi, Eye Ear and Mouth Unit, Maidstone and Tunbridge Wells NHS Trust, Maidstone Hospital, Maidstone, United Kingdom AU - Moosavi, R. AU - Ansari, E. C1 - simbrinza(Alcon,United States) C2 - Alcon(United States) DB - Embase DO - 10.1007/s40123-018-0150-x IS - 2 KW - Goldmann applanation tonometer brimonidine plus brinzolamide adult aged article drug efficacy drug tolerability electronic patient record follow up human intraocular hypertension intraocular pressure major clinical study open angle glaucoma outcome assessment patient compliance patient identification priority journal pseudoexfoliation quality of life retrospective study very elderly simbrinza LA - English M3 - Article N1 - L625186075 2018-12-05 2018-12-06 PY - 2018 SN - 2193-6528 2193-8245 SP - 397-403 ST - Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens T2 - Ophthalmology and Therapy TI - Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625186075&from=export http://dx.doi.org/10.1007/s40123-018-0150-x VL - 7 ID - 2560 ER - TY - JOUR AB - Introduction: To simplify the medical treatment of glaucoma for patients on multiple drops by introducing brinzolamide/brimonidine tartrate fixed combination (BBFC) ophthalmic suspension 1%/0.2% (SIMBRINZA®; Alcon Laboratories, Inc., Fort Worth, TX, USA) to the drop regimen and to establish its efficacy. To demonstrate that fixed combination (FC) therapies are associated with improvements in treatment adherence and persistence with reduced exposure to preservative-related ocular surface problems. Methods: Retrospective study: 76 patients were identified as taking BBFC following a switch in treatment regimen. Intraocular pressure (IOP) prior to and 2–17.5 months (average 5.4 months) after the introduction of BBFC was measured. The change in the average number of bottles used per eye was recorded. The rate of adverse effects (AEs) of BBFC was recorded. A two-tailed paired sample t test was used to compare IOP prior to and after the introduction of BBFC for each eye. Results: Mean change in IOP after BBFC introduction BBFC: − 2.76 mmHg (p < 0.0001). BBFC intolerance: 13%. On average there was a 0.24 reduction in the number of bottles of IOP-lowering medication used per eye (p < 0.0064). Conclusion: A switch to BBFC in the drop regimen is associated with a significant drop in IOP with reduced drop burden. Instead of a third IOP-lowering medication and bottle, a practitioner should consider using BBFC + prostaglandin analogue/FC drop for effective IOP control, reduced drop burden, reduced preservative load and increased likelihood of adherence. This study promotes the concept that any treatment should principally be assessed from the patients’ perspective and quality of life. © 2018, The Author(s). AD - Eye Ear and Mouth Unit, Maidstone and Tunbridge Wells NHS Trust, Maidstone Hospital, Maidstone, United Kingdom AU - Moosavi, R. AU - Ansari, E. DB - Scopus DO - 10.1007/s40123-018-0150-x IS - 2 KW - Brinzolamide–brimonidine fixed combination Ophthalmology Simbrinza M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2018 SP - 397-403 ST - Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens T2 - Ophthalmology and Therapy TI - Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066415870&doi=10.1007%2fs40123-018-0150-x&partnerID=40&md5=43d0e7b49b47c3b2e15c09f12a0d4828 VL - 7 ID - 5408 ER - TY - JOUR AB - Local fungal infections with Candida, Fusarium, Curvularia and Aspergillus can lead to serious ulceration of the cornea and must be treated rapidly. The current treatment consists of 0.15% (w/v) amphotericin B eye drops prepared from Fungizone®, containing deoxycholate, irritant for the cornea, which reduces patient compliance. Eye drops based on liposomal amphotericin B (AmBisome®) would be a convenient alternative; however, according to the manufacturer's instructions, AmBisome® can only be kept refrigerated for 1 week after reconstitution. A longer shelf-life at ambient temperature would be preferable for a preparation made in a hospital pharmacy and delivered to patients. Thus, the possibility of storing an ophthalmic preparation of 0.5% (w/v) liposomal amphotericin B after reconstitution was investigated. After 6 months at room temperature or at +2-8 °C, the hydrodynamic diameter measured by quasi-elastic light scattering remained constant at 108 ± 30 nm with a polydispersity index lower than 0.15. Amphotericin B content, checked by a validated HPLC method, was maintained between 94 and 107%. Amphotericin B and soy phosphatidylcholine proportions remained constant, indicating that the liposomes remained intact and retained the drug. These results show the feasibility of an ophthalmic preparation based on liposomal amphotericin B developed in hospital pharmacies. © 2007. AD - A. Bochot, Univ Paris-Sud, CNRS UMR8612, Physico-chimie - Pharmacotechnie - Biopharmacie. Faculté de Pharmacie., 5 rue JB Clément, Châtenay-Malabry, F-92296, France AU - Morand, K. AU - Bartoletti, A. C. AU - Bochot, A. AU - Barratt, G. AU - Brandely, M. L. AU - Chast, F. C1 - ambisome fungizone DB - Embase Medline DO - 10.1016/j.ijpharm.2007.04.028 IS - 1-2 KW - amphotericin B deoxycholate amphotericin B lipid complex deoxycholic acid liposome phosphatidylcholine article cornea drug stability environmental temperature freezing high performance liquid chromatography hospital pharmacy human keratomycosis light scattering patient compliance priority journal room temperature shelf life ambisome fungizone LA - English M3 - Article N1 - L47464817 2007-11-01 PY - 2007 SN - 0378-5173 SP - 150-153 ST - Liposomal amphotericin B eye drops to treat fungal keratitis: Physico-chemical and formulation stability T2 - International Journal of Pharmaceutics TI - Liposomal amphotericin B eye drops to treat fungal keratitis: Physico-chemical and formulation stability UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47464817&from=export http://dx.doi.org/10.1016/j.ijpharm.2007.04.028 VL - 344 ID - 3501 ER - TY - JOUR AB - To evaluate compliance to contact lens use in 14 countries, and to identify wearer attributes which indicate lower compliance levels. Methods: A web-based survey was undertaken by 4021 contact lens wearers, revealing information about demographics, and lens and solution information including daily handling details, case care and aftercare frequency. Particular attention was paid to eight modifiable compliance-related behaviours which are associated with an increased risk of microbial keratitis. Results: Full compliance was very rare for most lens users, although better (15% of wearers) for daily disposable lenses. Reduced compliance was demonstrated in South Korea, and for young male full-time contact lens users, especially those who have not consulted their eyecare practitioner for some time. The behaviours associated with the lowest levels of compliance were rubbing and rinsing, handwashing, correct lens replacement and case cleaning. Conclusions: Given other recent literature, which suggests improved contact lens compliance with regular self-review exercises, we encourage clinical colleagues to particularly examine case cleaning, handwashing and rubbing and rinsing at aftercare examinations, especially in young male wearers. © 2011 British Contact Lens Association. AD - Eurolens Research, The University of Manchester, Carys Bannister Building, Dover Street, Manchester M13 9PL, United Kingdom Institute of Health and Biomedical Innovation, School of Optometry, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4059, Australia Juntendo University Shizuoka Hospital, Department of Ophthalmology, Shizuoka, Japan The University of Houston College of Optometry, Houston, TX, United States AU - Morgan, P. B. AU - Efron, N. AU - Toshida, H. AU - Nichols, J. J. DB - Scopus DO - 10.1016/j.clae.2011.08.001 IS - 5 KW - Case care Compliance Contact lens Microbial keratitis M3 - Article N1 - Cited By :61 Export Date: 19 July 2021 PY - 2011 SP - 223-228 ST - An international analysis of contact lens compliance T2 - Contact Lens and Anterior Eye TI - An international analysis of contact lens compliance UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860390224&doi=10.1016%2fj.clae.2011.08.001&partnerID=40&md5=a51f6d1203d51f5926cbd570e2aa7f53 VL - 34 ID - 4969 ER - TY - JOUR AB - The transplant patient's therapeutic regimen consists of a lifelong drug therapy, including immunosuppressive drugs, prophylactic antimicrobials and often medications for the treatment of hypertension, diabetes mellitus and other comorbid diseases. Regular clinic appointments are required to monitor for signs and symptoms of immunological injury, recurrent disease and adverse drug effects. Patients are instructed to avoid risk factors for cardiovascular disease and cancer (e.g. diet, exercise, sun protection and not smoking). Noncompliance with all aspects of this regimen is substantial. Medication noncompliance leads to an increased incidence of acute rejection, chronic rejection and graft loss. Undoubtedly, many practitioners fail to appreciate the extent of noncompliance as the signs are often subtle and most patients are unwilling to disclose deliberate or widespread disregard for medication use. Newer immunosuppressive agents, particularly once-daily medications and long-acting antibody preparations offer convenience and monitoring that may improve compliance. This review focuses on the prevalence, correlates and consequences of medication nonadherence after organ transplantation. Current recommendations to enhance adherence are discussed. © 2007 Adis Data Information BV. All rights reserved. AD - Brown Medical School, Rhode Island Hospital, Providence, RI, United States University of Rhode Island, Kingston, RI, United States Division of Organ Transplantation, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, United States AU - Morrissey, P. E. AU - Flynn, M. L. AU - Lin, S. DB - Scopus DO - 10.2165/00003495-200767100-00007 IS - 10 M3 - Review N1 - Cited By :92 Export Date: 19 July 2021 PY - 2007 SP - 1463-1481 ST - Medication noncompliance and its implications in transplant recipients T2 - Drugs TI - Medication noncompliance and its implications in transplant recipients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34347392312&doi=10.2165%2f00003495-200767100-00007&partnerID=40&md5=37f721c05c27e7d97ffdfb11c9083cfd VL - 67 ID - 4936 ER - TY - JOUR AB - Adherence to medication treatment protocols and active participation by individuals in their medical care are important for all patients, but especially for those with chronic conditions such as vision loss. Adherence is crucial for decreasing avoidable vision loss. Failure to take medications as prescribed and keep scheduled appointments reduces treatment effectiveness, increases complications and results in poorer outcomes. Reasons for nonad-herence vary by diagnosis and include not understanding the importance of adherence, low health literacy, lack of adequate self-efficacy, low level of activation and behavioral issues including depression. Patients may lack information about their condition and its prognosis, available treatment alternatives, and other essential information such as how to monitor their eye condition, what to do if vision deteriorates and how to get needed community-based help. Each of these factors impedes patients’ ability to engage with their physician and participate in their own care. The ability of individuals with vision loss to actively and effectively manage their health care, ie, activation, has been understudied. When patients are involved with their own care, their care experience, and most importantly, their outcomes, are improved. Identifying antecedents of adherence may help provide disease-and patient-specific pathways to reduce avoidable vision loss. © 2020 Morse and Seiple. AD - Lighthouse Guild, New York, NY, United States Harkness Eye Institute, Columbia University, New York, NY, United States Department of Ophthalmology, New York University School of Medicine, New York, NY, United States AU - Morse, A. R. AU - Seiple, W. H. DB - Scopus DO - 10.2147/OPTH.S278627 KW - Activation Adherence AMD Avoidable vision loss Diabetic eye disease Engagement Glaucoma Patient activation Patient engagement M3 - Note N1 - Export Date: 19 July 2021 PY - 2020 SP - 3735-3739 ST - Decreasing avoidable vision loss: Identifying antecedents of adherence T2 - Clinical Ophthalmology TI - Decreasing avoidable vision loss: Identifying antecedents of adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094930812&doi=10.2147%2fOPTH.S278627&partnerID=40&md5=e832c5d2c41164a6320034c07ccb96f3 VL - 14 ID - 5712 ER - TY - JOUR AB - Adherence to medication treatment protocols and active participation by individuals in their medical care are important for all patients, but especially for those with chronic conditions such as vision loss. Adherence is crucial for decreasing avoidable vision loss. Failure to take medications as prescribed and keep scheduled appointments reduces treatment effectiveness, increases complications and results in poorer outcomes. Reasons for nonadherence vary by diagnosis and include not understanding the importance of adherence, low health literacy, lack of adequate self-efficacy, low level of activation and behavioral issues including depression. Patients may lack information about their condition and its prognosis, available treatment alternatives, and other essential information such as how to monitor their eye condition, what to do if vision deteriorates and how to get needed community-based help. Each of these factors impedes patients' ability to engage with their physician and participate in their own care. The ability of individuals with vision loss to actively and effectively manage their health care, ie, activation, has been understudied. When patients are involved with their own care, their care experience, and most importantly, their outcomes, are improved. Identifying antecedents of adherence may help provide disease- and patient-specific pathways to reduce avoidable vision loss. AN - WOS:000586853300004 AU - Morse, A. R. AU - Seiple, W. H. DO - 10.2147/OPTH.S278627 PY - 2020 SN - 1177-5483 SP - 3735-3739 ST - Decreasing Avoidable Vision Loss: Identifying Antecedents of Adherence T2 - CLINICAL OPHTHALMOLOGY TI - Decreasing Avoidable Vision Loss: Identifying Antecedents of Adherence VL - 14 ID - 6091 ER - TY - JOUR AB - Background/Aim: Glaucoma is a chronic and progressive optic neuropathy which leads to deterioration of visual function. It is estimated to be the second leading cause of severe vision loss and blindness worldwide. Failure of anti-glaucoma medication to sufficiently reduce intraocular pressure (IOP) and poor compliance with medication are indications for glaucoma surgery, for example using glaucoma drainage devices. Our aim was to compare the surgical outcomes following the implantation of Ahmed FP7 and Baerveldt 350 drainage devices. Patients and Methods: Five hundred and fifty-two patients with primary or secondary glaucoma were enrolled in the study. All patients had a history of failed trabeculectomy or other intraocular surgery, and IOP ≥18 mm Hg. The implantation of Ahmed (266 patients) or Baerveldt (286 patients) devices was randomly performed in the patients, who were subsequently examined for a period of 5 years. Follow-up visits were scheduled 1 day; 1 week; 1, 3 and 6 months; and 1, 1.5, 2, 3, 4 and 5 years postoperatively. Results: Significant reduction of IOP was achieved in both groups. Ahmed valve (28.3±9.3, 13.4±6.9, 14.2±6 and 12.7±4.5 mmHg at baseline, 1, 3, and 5 years postoperatively, respectively) resulted in significantly greater IOP reduction compared to Baerveldt implant (29.6±10.1, 15.4±5.5, 14.5±5.5 and 14.7±4.4 mmHg at baseline, 1, 3, and 5 years postoperatively, respectively). © 2019 International Institute of Anticancer Research. All rights reserved. AD - First Department of Ophthalmology, University of Athens Medical School, G. Genimmatas General Hospital Athens, Athens, Greece Department of Ophthalmology, Medical School, University of Thessaly, Larissa, Greece Second Department of Propedeutic Surgery, Laiko General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece Department of Ophthalmology, Medical School of University of Ioannina, Ioannina, Greece Ikarias 6, Ekali, Athens, 14578, Greece AU - Moschos, M. M. AU - Nitoda, E. AU - Gouliopoulos, N. AU - Androudi, S. AU - Damaskos, C. AU - Laios, K. AU - Bagkli, E. AU - Garmpis, N. AU - Kitsos, G. DB - Scopus DO - 10.21873/invivo.11558 IS - 3 KW - Ahmed Baerveldt Drainage Glaucoma Implant Valve M3 - Article N1 - Export Date: 19 July 2021 PY - 2019 SP - 911-916 ST - The choice of drainage device in complicated glaucomas: Comparing Ahmed and Baerveldt implants T2 - In Vivo TI - The choice of drainage device in complicated glaucomas: Comparing Ahmed and Baerveldt implants UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065309611&doi=10.21873%2finvivo.11558&partnerID=40&md5=12ef4de578093d5e1077ecbcce515957 VL - 33 ID - 5722 ER - TY - JOUR AB - Background/Aim: Glaucoma is a chronic and progressive optic neuropathy which leads to deterioration of visual function. It is estimated to be the second leading cause of severe vision loss and blindness worldwide. Failure of anti-glaucoma medication to sufficiently reduce intraocular pressure (IOP) and poor compliance with medication are indications for glaucoma surgery, for example using glaucoma drainage devices. Our aim was to compare the surgical outcomes following the implantation of Ahmed FP7 and Baerveldt 350 drainage devices. Patients and Methods: Five hundred and fifty-two patients with primary or secondary glaucoma were enrolled in the study. All patients had a history of failed trabeculectomy or other intraocular surgery, and IOP >= 18 mm Hg. The implantation of Ahmed (266 patients) or Baerveldt (286 patients) devices was randomly performed in the patients, who were subsequently examined for a period of 5 years. Follow-up visits were scheduled 1 day; 1 week; 1, 3 and 6 months; and 1, 1.5, 2, 3, 4 and 5 years postoperatively. Results: Significant reduction of IOP was achieved in both groups. Ahmed valve (28.3 +/- 9.3 ,13.4 +/- 6.9,14.2 +/- 6 and 12.7 +/- 4.5 mmHg at baseline, 1, 3, and 5 years postoperatively, respectively) resulted in significantly greater IOP reduction compared to Baerveldt implant (29.6 +/- 10.1, 15.4 +/- 5 .5, 14.5 +/- 5 .5 and 14.7 +/- 4.4 mmHg at baseline, 1, 3, and 5 years postoperatively, respectively). A significantly lower number of medications was required in the Ahmed group in comparison to the Baerveldt one (Ahmed group: 1.5 +/- 1.4, 1.4 +/- 1.5 and 1.8 +/- 1.5; Baerveldt group: 1.9 +/- 1.3, 1.9 +/- 1.3 and 2.2 +/- 1.4, respectively). The incidence of treatment failure and the rate of glaucoma reoperation were significantly higher in the Baerveldt group (40%) compared to the Ahmed group (17%). Conclusion: Ahmed drainage implantation seemed to outclass that using the Baerveldt device in our study, in terms of efficacy and success rate. AN - WOS:000465969100035 AU - Moschos, M. M. AU - Nitoda, E. AU - Gouliopoulos, N. AU - Androudi, S. AU - Damaskos, C. AU - Laios, K. AU - Bagkli, E. AU - Garmpis, N. AU - Kitsos, G. DA - MAY-JUN DO - 10.21873/invivo.11558 IS - 3 PY - 2019 SN - 0258-851X 1791-7549 SP - 911-916 ST - The Choice of Drainage Device in Complicated Glaucomas: Comparing Ahmed and Baerveldt Implants T2 - IN VIVO TI - The Choice of Drainage Device in Complicated Glaucomas: Comparing Ahmed and Baerveldt Implants VL - 33 ID - 6125 ER - TY - JOUR AB - Purpose: The purpose of this study was to determine the risk of a steroid pressure response from inhaled corticosteroids. Patients and Methods: This randomized, double-masked, placebo-controlled trial included 22 adults with well-controlled open-angle glaucoma or ocular hypertension. Consenting participants were randomized to a 6-week course of twice-daily fluticasone propionate 250-μg metered-dose inhaler or saline placebo metered-dose inhaler. Biweekly clinic visits included masked Goldmann applanation tonometry and assessment to identify adverse effects. Primary outcome was mean intraocular pressure (IOP) at week 6. Secondary outcomes included IOP elevation of >20% at 2 consecutive visits, adherence, side effects, and logMAR visual acuity. Results: A total of 10 patients in each arm completed the study. There were no statistically significant differences in IOP between groups at baseline (14.3±3.0 and 15.6±3.6 mm Hg in steroid and placebo groups, respectively, P=0.39) or at week 6 (14.7±2.4 and 14.8±3.8 mm Hg in steroid and placebo groups, respectively, P=0.92). Adherence was >80% for all participants. There were no statistically significant differences between groups in any secondary measures. One patient in the steroid group met the secondary end point of >20% elevation in IOP (IOP increased from baseline of 9 to 11 mm Hg at weeks 2 and 4). Conclusions: We found no clinically significant increase in mean IOP in patients with well-controlled open-angle glaucoma and ocular hypertension after 6 weeks of twice-daily inhaled fluticasone propionate compared with inhaled placebo. No participants exceeded their individualized target IOP. There were no differences in secondary outcomes. AD - Y.M. Buys, Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada AU - Moss, E. B. AU - Buys, Y. M. AU - Low, S. A. AU - Yuen, D. AU - Jin, Y. P. AU - Chapman, K. R. AU - Trope, G. E. DB - Embase Medline DO - 10.1097/IJG.0000000000000429 IS - 2 KW - NCT02338362 fluticasone propionate placebo adult aged clinical article clinical study conference paper controlled study disease association drug efficacy drug response female Goldmann applanation tonometer human intraocular hypertension intraocular pressure male metered dose inhaler oculoplethysmography open angle glaucoma patient compliance randomized controlled trial risk factor treatment duration very elderly visual acuity LA - English M3 - Conference Paper N1 - L610067755 2016-04-29 2017-03-14 PY - 2017 SN - 1536-481X 1057-0829 SP - 182-186 ST - A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study T2 - Journal of Glaucoma TI - A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610067755&from=export http://dx.doi.org/10.1097/IJG.0000000000000429 VL - 26 ID - 2671 ER - TY - JOUR AB - Purpose: The purpose of this study was to determine the risk of a steroid pressure response from inhaled corticosteroids. Patients and Methods: This randomized, double-masked, placebo-controlled trial included 22 adults with well-controlled open-angle glaucoma or ocular hypertension. Consenting participants were randomized to a 6-week course of twice-daily fluticasone propionate 250-μg metered-dose inhaler or saline placebo metered-dose inhaler. Biweekly clinic visits included masked Goldmann applanation tonometry and assessment to identify adverse effects. Primary outcome was mean intraocular pressure (IOP) at week 6. Secondary outcomes included IOP elevation of >20% at 2 consecutive visits, adherence, side effects, and logMAR visual acuity. Results: A total of 10 patients in each arm completed the study. There were no statistically significant differences in IOP between groups at baseline (14.3±3.0 and 15.6±3.6 mm Hg in steroid and placebo groups, respectively, P=0.39) or at week 6 (14.7±2.4 and 14.8±3.8 mm Hg in steroid and placebo groups, respectively, P=0.92). Adherence was >80% for all participants. There were no statistically significant differences between groups in any secondary measures. One patient in the steroid group met the secondary end point of >20% elevation in IOP (IOP increased from baseline of 9 to 11 mm Hg at weeks 2 and 4). Conclusions: We found no clinically significant increase in mean IOP in patients with well-controlled open-angle glaucoma and ocular hypertension after 6 weeks of twice-daily inhaled fluticasone propionate compared with inhaled placebo. No participants exceeded their individualized target IOP. There were no differences in secondary outcomes. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON M5T 2S8, Canada Division of Respiratory Medicine, University of Toronto, Toronto, ON, Canada AU - Moss, E. B. AU - Buys, Y. M. AU - Low, S. A. AU - Yuen, D. AU - Jin, Y. P. AU - Chapman, K. R. AU - Trope, G. E. DB - Scopus DO - 10.1097/IJG.0000000000000429 IS - 2 KW - corticosteroids/glucocorticoids fluticasone propionate glaucoma intraocular pressure ocular hypertension M3 - Conference Paper N1 - Cited By :9 Export Date: 19 July 2021 PY - 2017 SP - 182-186 ST - A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study T2 - Journal of Glaucoma TI - A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964355594&doi=10.1097%2fIJG.0000000000000429&partnerID=40&md5=6c4ac2d5ec7e51c3b5460ebe1a86490c VL - 26 ID - 5302 ER - TY - JOUR AB - Purpose: The purpose of this study was to determine the risk of a steroid pressure response from inhaled corticosteroids. Patients and Methods: This randomized, double-masked, placebo-controlled trial included 22 adults with well-controlled open-angle glaucoma or ocular hypertension. Consenting participants were randomized to a 6-week course of twice-daily fluticasone propionate 250-mu g metered-dose inhaler or saline placebo metered-dose inhaler. Biweekly clinic visits included masked Goldmann applanation tonometry and assessment to identify adverse effects. Primary outcome was mean intraocular pressure (IOP) at week 6. Secondary outcomes included IOP elevation of >20% at 2 consecutive visits, adherence, side effects, and logMAR visual acuity. Results: A total of 10 patients in each arm completed the study. There were no statistically significant differences in IOP between groups at baseline (14.3 +/- 3.0 and 15.6 +/- 3.6mm Hg in steroid and placebo groups, respectively, P=0.39) or at week 6 (14.7 +/- 2.4 and 14.8 +/- 3.8mm Hg in steroid and placebo groups, respectively, P=0.92). Adherence was >80% for all participants. There were no statistically significant differences between groups in any secondary measures. One patient in the steroid group met the secondary end point of >20% elevation in IOP (IOP increased from baseline of 9 to 11mm Hg at weeks 2 and 4). Conclusions: We found no clinically significant increase in mean IOP in patients with well-controlled open-angle glaucoma and ocular hypertension after 6 weeks of twice-daily inhaled fluticasone propionate compared with inhaled placebo. No participants exceeded their individualized target IOP. There were no differences in secondary outcomes. AN - WOS:000395514100043 AU - Moss, E. B. AU - Buys, Y. M. AU - Low, S. A. AU - Yuen, D. AU - Jin, Y. P. AU - Chapman, K. R. AU - Trope, G. E. DA - FEB DO - 10.1097/IJG.0000000000000429 IS - 2 PY - 2017 SN - 1057-0829 1536-481X SP - 182-186 ST - A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study T2 - JOURNAL OF GLAUCOMA TI - A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study VL - 26 ID - 6028 ER - TY - JOUR AB - Objective: To investigate the level of compliance with glaucoma medications in a clinic setting and the factors associated with failed compliance. Method: This was a prospective study done at the Glaucoma Clinic, University Hospital of the West Indies, between April and June 2005. Consecutive patients in the clinic were administered a questionnaire by the doctor. Statistical analysis was done using cross-tabulations, Chi-square (X2) tests and odds ratio using SPSS version 11.0. Results: One hundred glaucoma patients were recruited: 63% were female; 57% of the total group was in the 61-80 year age group. Forty-seven per cent had been attending the glaucoma clinic for over 10 years. Eighty-five per cent knew their diagnosis, although only 22% understood their diagnosis. Patients who did not have a full understanding of glaucoma were more likely to be non compliant (odds ratio 0.771 (95% CI 0.298, 1.995, p = 0.591)). Females were more likely to be compliant than males (odds ratio was 1.64 (95% CI 0.72, 3.75, p = 0.24)). Patients who were clinic attendees for less than five years duration were less compliant than those attending the glaucoma clinic for 6-10 years. The reasons for reduced compliance were financial in 44%, forgetfulness in 20% and eye-drops being unimportant in 12% of cases. The educational level of patients was not related to compliance. Conclusion: The level of full compliance was 50% and partial compliance 43%. There was a 7% level of non-compliance. Higher levels of compliance were seen in females, patients who understood their diagnosis and those who had no co-morbid disease. AD - L. Mowatt, University Hospital of the West Indies, Kingston 7, Jamaica AU - Mowatt, L. AU - Nelson-Imoru, J. AU - Gordon-Strachan, G. DB - Embase Medline IS - 5 KW - antiglaucoma agent eye drops adult aged article chi square test controlled study data analysis software educational status female finance glaucoma human Jamaica major clinical study male patient compliance prospective study questionnaire risk statistical analysis university hospital LA - English M3 - Article N1 - L365592341 2012-09-14 2012-09-18 PY - 2011 SN - 0043-3144 SP - 541-547 ST - Glaucoma medication compliance issues in a Jamaican Hospital eye clinic T2 - West Indian Medical Journal TI - Glaucoma medication compliance issues in a Jamaican Hospital eye clinic UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365592341&from=export http://ojs.mona.uwi.edu/index.php/wimj/article/viewFile/2916/2676 VL - 60 ID - 3143 ER - TY - JOUR AB - PURPOSE: To investigate the effect of posterior subtenon injections of corticosteroids on intraocular pressure in a variety of ocular diseases. METHODS: We retrospectively analyzed 202 consecutive posterior subtenon corticosteroid injections (148 of methylprednisolone acetate, 80 mg, and 54 of triamcinolone acetonide, 40 mg) in 63 eyes of 55 patients (26 male, 29 female; mean age ± SD, 60.17 ± 26.55 years). All patients had received topical or systemic corticosteroids before the injection, and no rise in intraocular pressure had been noted. Preinjection and postinjection intraocular pressure measurements were compared by two-tailed paired t test. Statistical analysis was performed separately by patient (first injection of first injected eye), by eye (first injection of each eye), and by all injections. To detect increase in intraocular pressure during follow-up, statistical analysis was performed separately 14 to 90 days, 91 to 150 days, and 151 to 270 days after injection. RESULTS: No statistically significant difference was found between preinjection and postinjection intraocular pressure measurements. A power calculation in the most stringent subanalysis (by patient) proved that there is only a 3.87% chance to statistically miss a clinically significant rise in intraocular pressure from 15 to 21 mm Hg. CONCLUSIONS: Posterior subtenon injection of corticosteroids does not cause an increase in intraocular pressure. All patients in our study had been treated previously with topical or systemic corticosteroids and did not react with an excessive increase in intraocular pressure. This safety of repository corticosteroids may therefore not apply to patients whose status in responding to corticosteroids is not known. AD - Department of Ophthalmology, Shiley Eye Center, University of California San Diego, San Diego, CA, United States Depts. of Pharmacy and Pediatrics, University of California San Diego, San Diego, CA, United States Department of Ophthalmology, Shiley Eye Center, University of California, San Diego, 9415 Campus Point Dr 0946, San Diego, CA 92093-0946, United States AU - Mueller, A. J. AU - Jian, G. AU - Banker, A. S. AU - Rahhal, F. M. AU - Capparelli, E. AU - Freeman, W. R. DB - Scopus DO - 10.1016/S0002-9394(99)80085-3 IS - 2 M3 - Article N1 - Cited By :57 Export Date: 19 July 2021 PY - 1998 SP - 158-163 ST - The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure T2 - American Journal of Ophthalmology TI - The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032007330&doi=10.1016%2fS0002-9394%2899%2980085-3&partnerID=40&md5=2036baf39d00eecad39a43bbec7fa49e VL - 125 ID - 4979 ER - TY - JOUR AB - Purpose : To estimate the prevalence of low vision and blindness, identify the causes, and suggest policies for an effective eye care program based on 2005 data from Sokoto State, Nigeria. Materials and Methods : A stratified two-stage cluster sampling method was used to quantify the prevalence of blindness and the causes from 4 health zones in Sokoto State. Subjects were evaluated using a magnifying loupe, direct ophthalmoscope and torchlight. Data were collected based on the World Health Organization prevention of blindness coding for an eye examination. Prevalences with 95% confidence intervals (CI) were calculated and surgical coverage for causes of blindness was also analyzed. Results : The response rate was 91%. The prevalence of bilateral blindness was 1.9% (95% CI: 1.5-2.3%) ranging from 1.6% to 2.0% across the four health zones. The prevalence was 2.1% (95% CI: 1.6-2.6%) in males and 1.6% (95% CI: 1.1-2.1%) in females. The leading cause of bilateral blindness was cataract (51.6%), followed by uncorrected aphakia (20.9%) and glaucoma (11%). The prevalence of bilateral operable cataract was 1.9% (95% CI: 1.5-2.3%). The cataract surgical coverage (individuals with visual acuity <6/60) for the study was lower than the couching coverage (4.4% vs. 14.9%, respectively). Surgical coverage for trichiasis was 4.4%. The major barrier to cataract and glaucoma management was cost. Conclusions : The prevalence of blindness in Sokoto State is high yet the main causes are largely avoidable. Barriers can be reduced by appropriate health education regarding the eye care program and the provision of integrated, sustainable, affordable and equitable services. AD - N. Muhammad, College of Heath Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria AU - Muhammad, N. AU - Mansur, R. AU - Dantani, A. AU - Elhassan, E. AU - Isiyaku, S. DB - Embase DO - 10.4103/0974-9233.80700 IS - 2 KW - adolescent adult aged aphakia article blindness cataract cataract extraction child cornea opacity diabetic retinopathy eye examination eye surgery eyelid eyelid surgery female glaucoma groups by age health care cost health care utilization human injury keratitis major clinical study male measles Nigeria ophthalmoscope optic nerve atrophy prevalence priority journal refraction error refusal to participate macular degeneration sex difference spectacles trachoma trichiasis visual impairment xerophthalmia LA - English M3 - Article N1 - L361792632 2011-05-27 2011-06-07 PY - 2011 SN - 0974-9233 0975-1599 SP - 123-128 ST - Prevalence and causes of blindness and visual impairment in Sokoto State, Nigeria: Baseline data for Vision 2020: The right to sight eye care programme T2 - Middle East African Journal of Ophthalmology TI - Prevalence and causes of blindness and visual impairment in Sokoto State, Nigeria: Baseline data for Vision 2020: The right to sight eye care programme UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361792632&from=export http://dx.doi.org/10.4103/0974-9233.80700 VL - 18 ID - 3184 ER - TY - JOUR AB - Purpose of review This review discusses the concept and measurement of health literacy, with a focus on the care of patients with glaucoma. Recent findings Nearly one-fourth of adults in the USA lack the skills needed to fully comprehend and act on verbal or written information in the healthcare environment. This problem, referred to as poor health literacy, is associated with worse health-related outcomes in many chronic diseases, including glaucoma. Patients with glaucoma and poor literacy skills are less likely to refill their prescribed medications and miss more scheduled appointments than their more literate peers. Moreover, ophthalmic educational materials are often written at a level of readability that surpasses the skills of many patients with glaucoma. Summary Patients with chronic eye diseases such as glaucoma and limited health literacy skills are vulnerable to poor visual outcomes. Attention to health literacy may improve the care and outcomes of these patients. AN - WOS:000317039900005 AU - Muir, K. W. AU - Christensen, L. AU - Bosworth, H. B. DA - MAR DO - 10.1097/ICU.0b013e32835c8b0e IS - 2 PY - 2013 SN - 1040-8738 SP - 119-124 ST - Health literacy and glaucoma T2 - CURRENT OPINION IN OPHTHALMOLOGY TI - Health literacy and glaucoma VL - 24 ID - 6129 ER - TY - JOUR AD - K. W. Muir, Duke University Medical Center, Box 3802, Durham, NC 27710, United States AU - Muir, K. W. AU - Lee, P. P. DB - Embase Medline DO - 10.1001/archophthalmol.2010.351 IS - 2 KW - antiglaucoma agent eye drops clinical observation drug monitoring editorial follow up glaucoma health care system human intraocular pressure abnormality medical record patient compliance pharmacy (shop) prescription priority journal self report visual field defect LA - English M3 - Editorial N1 - L361277507 2011-02-24 2011-02-28 PY - 2011 SN - 0003-9950 1538-3601 SP - 243-245 ST - Glaucoma medication adherence: Room for improvement in both performance and measurement T2 - Archives of Ophthalmology TI - Glaucoma medication adherence: Room for improvement in both performance and measurement UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361277507&from=export http://dx.doi.org/10.1001/archophthalmol.2010.351 http://archopht.ama-assn.org/cgi/reprint/129/2/243 VL - 129 ID - 3191 ER - TY - JOUR AD - Duke University Eye Center, Durham, NC, United States AU - Muir, K. W. AU - Lee, P. P. DB - Scopus DO - 10.1001/archophthalmol.2010.351 IS - 2 M3 - Editorial N1 - Cited By :26 Export Date: 19 July 2021 PY - 2011 SP - 243-245 ST - Glaucoma medication adherence: Room for improvement in both performance and measurement T2 - Archives of Ophthalmology TI - Glaucoma medication adherence: Room for improvement in both performance and measurement UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951602702&doi=10.1001%2farchophthalmol.2010.351&partnerID=40&md5=65812e72bb05ccd8faaebac77f09d93b VL - 129 ID - 5086 ER - TY - JOUR AB - Purpose: To describe the health literacy of subjects with open angle glaucoma and to investigate the hypothesis that low health literacy is associated with poor glaucoma medication adherence. Design: Cross-sectional patient survey and concomitant chart review. Methods: One hundred and ninety-seven subjects with open angle glaucoma participated in a survey which included basic demographic information such as age, gender, ethnicity, and level of education completed, and a test of heath literacy, the Rapid Assessment of Adult Literacy in Medicine. Information was collected regarding visual field tests and prescribed medication. The subjects' pharmacies were contacted to ascertain the number of refills requested over the previous six months. Results: Although 146 subjects (74%) reported completing high school, only 94 subjects (48.0%) read at or above a ninth grade level; 23 (11.7%) read at a level of third grade or below. The mean number of refills requested by a subject in the preceding six months was not predicted by race (P = .27,) gender (P = .31), age (P = .92), mean deviation of the visual field (P = .36), or level of education (P = .58). There was a positive relationship between health literacy and the number of refills obtained (P = .003). Conclusions: Many patients with open angle glaucoma may have poor health literacy. The subjects in our study with low literacy were less adherent with their glaucoma medications than those with a higher level of literacy. Interventions specifically targeting patients with low literacy may improve medication adherence. © 2006 Elsevier Inc. All rights reserved. AD - P.P. Lee, Duke University Eye Center, Durham, NC, United States AU - Muir, K. W. AU - Santiago-Turla, C. AU - Stinnett, S. S. AU - Herndon, L. W. AU - Allingham, R. R. AU - Challa, P. AU - Lee, P. P. DB - Embase Medline DO - 10.1016/j.ajo.2006.03.018 IS - 2 KW - antiglaucoma agent academic achievement age distribution aged article controlled study demography ethnology female health education human male medical record review open angle glaucoma patient compliance prescription priority journal sex ratio vision test visual field LA - English M3 - Article N1 - L44107280 2006-08-14 PY - 2006 SN - 0002-9394 SP - 223-226.e2 ST - Health Literacy and Adherence to Glaucoma Therapy T2 - American Journal of Ophthalmology TI - Health Literacy and Adherence to Glaucoma Therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44107280&from=export http://dx.doi.org/10.1016/j.ajo.2006.03.018 VL - 142 ID - 3595 ER - TY - JOUR AB - Objective: To test an educational intervention targeted to health literacy level with the goal of improving glaucoma medication adherence. Methods: One hundred and twenty-seven veterans with glaucoma were randomized to glaucoma education or standard care. The intervention included a video scripted at a 4th, 7th, or 10th grade level, depending on the subject's literacy level. After six months, the number of days without glaucoma medicine (DWM) according to pharmacy records for the intervention and control groups was compared. Results: The number of DWM in the six months following enrollment was similar for control and intervention groups (intervention, n= 67, DWM = 63 ± 198; standard care, n= 60, DWM = 65 ± 198; p= 0.708). For each subgroup of literacy (adequate, marginal, inadequate), subjects in the intervention group experienced less mean DWM than subjects in the control group and the effect size (ES) increased as literacy decreased: adequate literacy, ES 0.069; marginal, ES 0.183, inadequate, ES 0.363. Decreasing health literacy skills were associated with decreasing self-reported satisfaction with care (slope = 0.017, SE = 0.005, p= 0.002). Conclusions: Patients with decreased health literacy skills may benefit from educational efforts tailored to address their health literacy level and learning style. Practice implications: Providers should consider health literacy skills when engaging in glaucoma education. © 2011. AD - K.W. Muir, Duke University Medical Center, Box 3802, Durham, NC 27710, United States AU - Muir, K. W. AU - Ventura, A. AU - Stinnett, S. S. AU - Enfiedjian, A. AU - Allingham, R. R. AU - Lee, P. P. DB - Embase Medline DO - 10.1016/j.pec.2011.09.009 IS - 2 KW - adult aged article comparative effectiveness controlled study educational model educational status female glaucoma health literacy human intervention study learning style major clinical study male outcome assessment patient care patient compliance patient education patient satisfaction priority journal randomized controlled trial scoring system self report LA - English M3 - Article N1 - L51663314 2011-10-15 2012-05-10 PY - 2012 SN - 0738-3991 1873-5134 SP - 160-164 ST - The influence of health literacy level on an educational intervention to improve glaucoma medication adherence T2 - Patient Education and Counseling TI - The influence of health literacy level on an educational intervention to improve glaucoma medication adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51663314&from=export http://dx.doi.org/10.1016/j.pec.2011.09.009 VL - 87 ID - 3091 ER - TY - JOUR AB - Objective: To test an educational intervention targeted to health literacy level with the goal of improving glaucoma medication adherence. Methods: One hundred and twenty-seven veterans with glaucoma were randomized to glaucoma education or standard care. The intervention included a video scripted at a 4th, 7th, or 10th grade level, depending on the subject's literacy level. After six months, the number of days without glaucoma medicine (DWM) according to pharmacy records for the intervention and control groups was compared. Results: The number of DWM in the six months following enrollment was similar for control and intervention groups (intervention, n = 67, DWM=63±198; standard care, n = 60, DWM = 65 ± 198; p = 0.708). For each subgroup of literacy (adequate, marginal, inadequate), subjects in the intervention group experienced less mean DWM than subjects in the control group and the effect size (ES) increased as literacy decreased: adequate literacy, ES 0.069; marginal, ES 0.183, inadequate, ES 0.363. Decreasing health literacy skills were associated with decreasing self-reported satisfaction with care (slope = 0.017, SE = 0.005, p = 0.002). Conclusions: Patients with decreased health literacy skills may benefit from educational efforts tailored to address their health literacy level and learning style. Practice implications: Providers should consider health literacy skills when engaging in glaucoma education. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Muir, Kelly W., Duke University Medical Center, Box 3802, Durham, NC, US, 27710 AN - 2012-11596-005 AU - Muir, Kelly W. AU - Ventura, Alice AU - Stinnett, Sandra S. AU - Enfiedjian, Abraham AU - Allingham, R. Rand AU - Lee, Paul P. DB - psyh DO - 10.1016/j.pec.2011.09.009 DP - EBSCOhost IS - 2 KW - health literacy level educational intervention glaucoma medication adherence Adult Aged Aged, 80 and over Educational Status Female Glaucoma Health Knowledge, Attitudes, Practice Health Literacy Health Surveys Humans Male Medication Adherence Middle Aged North Carolina Patient Education as Topic Patient Satisfaction Pharmaceutical Preparations Surveys and Questionnaires Tape Recording Veterans Drug Therapy School Based Intervention N1 - Duke University, Eye Center, Durham, NC, US. Release Date: 20120611. Correction Date: 20201005. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Glaucoma; School Based Intervention; Health Literacy. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Test of Functional Health Literacy in Adults DOI: 10.1037/t10545-000; Mini Mental State Examination. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 5. Issue Publication Date: May, 2012. Publication History: Accepted Date: Sep 17, 2011; Revised Date: Aug 15, 2011; First Submitted Date: Feb 24, 2011. Sponsor: National Institutes of Health, National Eye Institute, US. Grant: 5K12 EY016333-05. Recipients: No recipient indicated Sponsor: Prevent Blindness America, US. Recipients: No recipient indicated PY - 2012 SN - 0738-3991 1873-5134 SP - 160-164 ST - The influence of health literacy level on an educational intervention to improve glaucoma medication adherence T2 - Patient Education and Counseling TI - The influence of health literacy level on an educational intervention to improve glaucoma medication adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2012-11596-005&site=ehost-live&scope=site ORCID: 0000-0002-3338-136X kelly.muir@duke.edu VL - 87 ID - 4841 ER - TY - JOUR AB - Objective: To test an educational intervention targeted to health literacy level with the goal of improving glaucoma medication adherence.Methods: One hundred and twenty-seven veterans with glaucoma were randomized to glaucoma education or standard care. The intervention included a video scripted at a 4th, 7th, or 10th grade level, depending on the subject's literacy level. After six months, the number of days without glaucoma medicine (DWM) according to pharmacy records for the intervention and control groups was compared.Results: The number of DWM in the six months following enrollment was similar for control and intervention groups (intervention, n=67, DWM=63 ± 198; standard care, n=60, DWM=65 ± 198; p=0.708). For each subgroup of literacy (adequate, marginal, inadequate), subjects in the intervention group experienced less mean DWM than subjects in the control group and the effect size (ES) increased as literacy decreased: adequate literacy, ES 0.069; marginal, ES 0.183, inadequate, ES 0.363. Decreasing health literacy skills were associated with decreasing self-reported satisfaction with care (slope=0.017, SE=0.005, p=0.002).Conclusions: Patients with decreased health literacy skills may benefit from educational efforts tailored to address their health literacy level and learning style.Practice Implications: Providers should consider health literacy skills when engaging in glaucoma education. AD - Duke University Eye Center, Durham, USA Duke University Eye Center, Durham, USA; Durham VA Medical Center, Durham, USA. AN - 104562295. Language: English. Entry Date: 20120817. Revision Date: 20200708. Publication Type: journal article AU - Muir, K. W. AU - Ventura, A. AU - Stinnett, S. S. AU - Enfiedjian, A. AU - Allingham, R. R. AU - Lee, P. P. AU - Muir, Kelly W. AU - Ventura, Alice AU - Stinnett, Sandra S. AU - Enfiedjian, Abraham AU - Allingham, R. Rand AU - Lee, Paul P. DB - ccm DO - 10.1016/j.pec.2011.09.009 DP - EBSCOhost IS - 2 KW - Drug Administration Educational Status Glaucoma -- Drug Therapy Information Literacy Medication Compliance Patient Education -- Methods Health Literacy Adult Aged Aged, 80 and Over Attitude to Health Audiorecording Female Human Male Middle Age North Carolina Patient Satisfaction Questionnaires Randomized Controlled Trials Veterans N1 - research; randomized controlled trial. Journal Subset: Core Nursing; Europe; Health Promotion/Education; Nursing; Peer Reviewed; UK & Ireland. Grant Information: K12 EY016333/EY/NEI NIH HHS/United States. NLM UID: 8406280. PMID: NLM22000272. PY - 2012 SN - 0738-3991 SP - 160-164 ST - The influence of health literacy level on an educational intervention to improve glaucoma medication adherence T2 - Patient Education & Counseling TI - The influence of health literacy level on an educational intervention to improve glaucoma medication adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104562295&site=ehost-live&scope=site VL - 87 ID - 4385 ER - TY - JOUR AB - Purpose: To determine baseline eye care utilization by older Victorians in order to assess change in 2 years after an eye health promotion campaign. Methods: A letter of invitation to participate was sent to all people aged 70-79 years in randomly selected Melbourne postcode areas. A questionnaire was designed to allow gathering of eye health-related information. Eye exams included autorefraction, frequency doubling technology and non-mydriatic fundus photography. Results were compared with the Melbourne Vision Impairment Project. Results: A total of 1695 people with a mean age of 74 years were recruited. The overall proportion with visual impairment was 8% (134/ 1695), of which 27% (36/134) was due to non-refractive causes. Only 31% (11/36) of visually impaired people knew about low-vision services, of whom 20% (7/36) had used them. Of all people with diabetes, only 52% (96/ 184) had a dilated eye exam within the recommended 2 years (Melbourne Vision Impairment Project 44%). Conclusions: Compliance rates with recommendations for 2-yearly eye exams for people with diabetes have not improved since the last major eye health study in Victoria 10 years ago. The same is true for the rate of undiagnosed glaucoma, suggesting that messages about eye examinations need to be promoted for older people at high risk of vision loss, for example, those with diabetes and at risk of vision loss from glaucoma. © 2006 Royal Australian and New Zealand College of Ophthalmologists. AD - A. Müller, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, Vic. 3002, Australia AU - Müller, A. AU - Vu, H. T. AU - Ferraro, J. G. AU - Keeffe, J. E. AU - Taylor, H. R. DB - Embase Medline DO - 10.1111/j.1442-9071.2006.01234.x IS - 5 KW - aged article Australia cataract clinical feature controlled study diabetes mellitus diabetic retinopathy eye care eye photography female follow up geriatric care glaucoma health care utilization health promotion health service human information processing major clinical study male patient compliance quality of life questionnaire randomization refraction error risk assessment visual impairment visual system examination LA - English M3 - Article N1 - L44027232 2006-08-06 PY - 2006 SN - 1442-6404 1442-9071 SP - 445-448 ST - Utilization of eye care services in Victoria T2 - Clinical and Experimental Ophthalmology TI - Utilization of eye care services in Victoria UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44027232&from=export http://dx.doi.org/10.1111/j.1442-9071.2006.01234.x VL - 34 ID - 3599 ER - TY - JOUR AB - Purpose: To determine baseline eye care utilization by older Victorians in order to assess change in 2 years after an eye health promotion campaign. Methods: A letter of invitation to participate was sent to all people aged 70-79 years in randomly selected Melbourne postcode areas. A questionnaire was designed to allow gathering of eye health-related information. Eye exams included autorefraction, frequency doubling technology and non-mydriatic fundus photography. Results were compared with the Melbourne Vision Impairment Project. Results: A total of 1695 people with a mean age of 74 years were recruited. The overall proportion with visual impairment was 8% (134/ 1695), of which 27% (36/134) was due to non-refractive causes. Only 31% (11/36) of visually impaired people knew about low-vision services, of whom 20% (7/36) had used them. Of all people with diabetes, only 52% (96/ 184) had a dilated eye exam within the recommended 2 years (Melbourne Vision Impairment Project 44%). Conclusions: Compliance rates with recommendations for 2-yearly eye exams for people with diabetes have not improved since the last major eye health study in Victoria 10 years ago. The same is true for the rate of undiagnosed glaucoma, suggesting that messages about eye examinations need to be promoted for older people at high risk of vision loss, for example, those with diabetes and at risk of vision loss from glaucoma. © 2006 Royal Australian and New Zealand College of Ophthalmologists. AD - Centre for Eye Research Australia, University of Melbourne, Vision Cooperative Research Centre, 32 Gisborne Street, East Melbourne, Vic. 3002, Australia AU - Müller, A. AU - Vu, H. T. AU - Ferraro, J. G. AU - Keeffe, J. E. AU - Taylor, H. R. DB - Scopus DO - 10.1111/j.1442-9071.2006.01234.x IS - 5 KW - Ageing Eye examination Service utilization M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2006 SP - 445-448 ST - Utilization of eye care services in Victoria T2 - Clinical and Experimental Ophthalmology TI - Utilization of eye care services in Victoria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745859331&doi=10.1111%2fj.1442-9071.2006.01234.x&partnerID=40&md5=0f9491a4533097ea912346cf68a834db VL - 34 ID - 5287 ER - TY - JOUR AB - Purpose: To assess the efficacy of monotherapy using tacrolimus eye drops versus sodium cromoglycate for the treatment of vernal keratoconjunctivitis (VKC). Methods: Randomized double-masked controlled trial comparing the efficacy of tacrolimus 0.03% eye drops t.i.d. (Group 1) with sodium cromoglycate 4% eye drops t.i.d. (Group 2) for the symptomatic control of VKC at days 0, 15, 30, 45, and 90 of follow-up. Visual acuity, intraocular pressure, and other complications were evaluated to assess safety and side effects. Results: In total, 16 patients were included, with 8 enrolled in each group. Two patients from Group 2 were excluded from the analysis at days 45 and 90 because of corticosteroid use. Most patients were male (81.8%) and presented with limbal VKC (56.3%). There were statistically significant differences in favor of tacrolimus in the following severity scores: itching at day 90 (p = 0.001); foreign body sensation at day 15 (p = 0.042); photophobia at day 30 (p = 0.041); keratitis at day 30 (p = 0.048); and limbal activity at days 15 (p = 0.011), 30 (p = 0.007), and 45 (p = 0.015). No relevant adverse effects were reported, except for a burning sensation with tacrolimus, though this did not compromise treatment compliance. Conclusion: Treatment with tacrolimus was superior to sodium cromoglycate when comparing severity scores for symptoms of itching, foreign body sensation, and photophobia, as well as for signs of limbal inflammatory activity and keratitis. AN - WOS:000408254100004 AU - Muller, E. G. AU - dos Santos, M. S. AU - Freitas, D. AU - Gomes, J. A. P. AU - Belfort, R. DA - MAY-JUN DO - 10.5935/0004-2749.20170038 IS - 3 PY - 2017 SN - 0004-2749 1678-2925 SP - 154-158 ST - Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial T2 - ARQUIVOS BRASILEIROS DE OFTALMOLOGIA TI - Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial VL - 80 ID - 6334 ER - TY - JOUR AB - Purpose: To assess the efficacy of monotherapy using tacrolimus eye drops versus sodium cromoglycate for the treatment of vernal keratoconjunctivitis (VKC). Methods: Randomized double-masked controlled trial comparing the efficacy of tacrolimus 0.03% eye drops t.i.d. (Group 1) with sodium cromoglycate 4% eye drops t.i.d. (Group 2) for the symptomatic control of VKC at days 0, 15, 30, 45, and 90 of follow-up. Visual acuity, intraocular pressure, and other complications were evaluated to assess safety and side effects. Results: In total, 16 patients were included, with 8 enrolled in each group. Two patients from Group 2 were excluded from the analysis at days 45 and 90 because of corticosteroid use. Most patients were male (81.8%) and presented with limbal VKC (56.3%). There were statistically significant differences in favor of tacrolimus in the following severity scores: itching at day 90 (p=0.001); foreign body sensation at day 15 (p=0.042); photophobia at day 30 (p=0.041); keratitis at day 30 (p=0.048); and limbal activity at days 15 (p=0.011), 30 (p=0.007), and 45 (p=0.015). No relevant adverse effects were reported, except for a burning sensation with tacrolimus, though this did not compromise treatment compliance. Conclusion: Treatment with tacrolimus was superior to sodium cromoglycate when comparing severity scores for symptoms of itching, foreign body sensation, and photophobia, as well as for signs of limbal inflammatory activity and keratitis. AD - Department of Ophthalmology and Visual Sciences, Universidade Federal de São Paulo, São Paulo, Brazil AU - Müller, E. G. AU - dos Santos, M. S. AU - Freitas, D. AU - Gomes, J. P. AU - Belfort, R., Jr. DB - Scopus DO - 10.5935/0004-2749.20170038 IS - 3 KW - Allergic Anti-allergic agents Conjunctivitis Cromolyn sodium Ophthalmic solutions Tacrolimus M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2017 SP - 154-158 ST - Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: A randomized controlled trial T2 - Arquivos Brasileiros de Oftalmologia TI - Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: A randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027445595&doi=10.5935%2f0004-2749.20170038&partnerID=40&md5=e349f80ea56027661714bfc95aebab48 VL - 80 ID - 5228 ER - TY - JOUR AB - Objective: To determine the best approach to examine first-degree relatives (FDR) of glaucoma patients in a rural African setting. Methods: Randomized controlled trial of FDR aged 40 years and older of (index) open angle glaucoma patients who presented to KCMC Hospital. Two strategies of uptake were tested. The main outcome measure was FDR presentation for examination for glaucoma. Results: From 182 index cases, 484 FDR were enrolled in the study, 256 randomized to free examination, and 228 randomized to standard (pay) examination. Overall, 8.1% (95% CI: 5.7-10.5) came for examination. FDR who were offered examination free of charge were 1.87 times (95% CI: 0.94-3.73) more likely to present than those offered standard examination. Among those offered free examination, living near the hospital was associated with presentation (OR = 2.85; 95% CI: 1.10-7.36) whereas among those offered standard examination the association with residence was weak (OR = 2.27; 95% CI: 0.72-7.15). Conclusions: Providing good quality counseling of index cases and offering glaucoma examination free of charge is not sufficient to reach those at risk of glaucoma, suggesting that the indirect costs of accessing services are significant barriers to use of examination services. Other means of encouraging FDR to come for glaucoma examination should be investigated. Copyright © 2007 Informa Healthcare. AD - P. Courtright, Kilimanjaro Centre for Community Ophthalmology, Tumaini University/KCMC, PO Box 2254, Moshi, Tanzania AU - Munachonga, E. M. AU - Hall, A. B. AU - Courtright, P. DB - Embase Medline DO - 10.1080/09286580701257633 IS - 3 KW - adult Africa aged article confidence interval controlled study cost eye care eye examination female health care access health care utilization high risk population hospital human major clinical study male open angle glaucoma priority journal randomization relative rural area standard LA - English M3 - Article N1 - L47026990 2007-05-01 PY - 2007 SN - 0928-6586 1744-5086 SP - 155-159 ST - Examination of first-degree relatives of patients with glaucoma: A randomized trial of strategies to increase use in an eye hospital in Africa T2 - Ophthalmic Epidemiology TI - Examination of first-degree relatives of patients with glaucoma: A randomized trial of strategies to increase use in an eye hospital in Africa UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47026990&from=export http://dx.doi.org/10.1080/09286580701257633 VL - 14 ID - 3528 ER - TY - JOUR AB - The tolerability of brimonidine tartrate 0.15%-referred to as bromonidine-Purite® 0.15% in this study-was compared with brimonidine tartrate 0.2% in irritated eyes of healthy volunteers as well as patients with glaucoma or ocular hypertension (N=20) in a 2-week, single-center, randomized, double-masked, crossover study. Participants were evaluated at days 0, 7, 11, and 15. At day 0, they were exposed to a controlled adverse environment (CAE), in which humidity, temperature, and airflow was regulated, for up to 90 minutes. Participants who reported a sufficient level of bilateral ocular discomfort during exposure to the CAE were enrolled in this study and received 1 drop of brimonidine-Purite 0.15% in 1 eye and 1 drop of brimonidine tartrate 0.2% in the contralateral eye. Immediately following instillation, participants were asked to indicate their preference for either study medication. The study medications were not used between days 0 and 7. From day 7 to 10, participants administered either drug bilaterally. On day 11, the treatment was crossed over, and participants were asked to compare the preferred medication with their previous regimen. They continued to administer the drug bilaterally twice daily until day 15, when the preferred medication was again compared with the previous regimen. Following CAE exposure at visit 1, 70.6% of the participants preferred brimonidine-Purite 0.15% over brimonidine tartrate 0.2% and indicated that it was significantly more comfortable than brimonidine tartrate 0.2% (P=.009). When given brimonidine-Purite 0.15% first before switching to brimonidine tartrate 0.2%, 80% of participants preferred brimonidine-Purite 0.15% (P=.012). When given brimonidine tartrate 0.2% first before switching to brimonidine-Purite 0.15%, 85% preferred brimonidine-Purite 0.15% (P=.O01). The results of this study suggest that brimonidine-Purite 0.15% is significantly more comfortable than brimonidine tartrate 0.2% in patients with irritated eyes. AD - Mundorf Eye Center, Charlotte, NC, United States Ophthalmic Research Associates, North Andover, MA, United States Schepens Eye Research Institute, Boston, MA, United States Harvard Medical School, Boston, MA, United States 863 Turnpike Street, North Andover, MA 01845, United States AU - Mundorf, T. AU - Wilcox, K. A. AU - Ousler Iii, G. W. AU - Welch, D. AU - Abelson, M. B. DB - Scopus DO - 10.1007/BF02849799 IS - 6 KW - Alphagan® P Brimonidine Brimonidine-Purite 0.15% Glaucoma Ocular irritation Purite® M3 - Article N1 - Cited By :21 Export Date: 19 July 2021 PY - 2003 SP - 329-336 ST - Evaluation of the Comfort of Alphagan® P Compared with Alphagan® in Irritated Eyes T2 - Advances in Therapy TI - Evaluation of the Comfort of Alphagan® P Compared with Alphagan® in Irritated Eyes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-1542618573&doi=10.1007%2fBF02849799&partnerID=40&md5=c90015cd647cd7354e0c7280f3c75410 VL - 20 ID - 5139 ER - TY - JOUR AB - Objectives: To identify predictors of inconsistent attendance at glaucoma follow-up visits in a county hospital population. Methods: Prospective recruitment from August 1, 2008, through January 31, 2009, of 152 individuals with glaucoma, with 1-to-1 matching of patients (those with inconsistent follow-up) and controls (those with consistent follow-up). Data were collected via oral questionnaire. Survey results were correlated with attendance at follow-up examinations, using the t test, χ2 test, and multivariate stepwise logistic regression analysis to calculate the odds ratios (ORs) and 95% confidence intervals. Results: After adjusting for covariates in the logistic regression analysis, factors independently associated with inconsistent follow-up included black race (adjusted OR, 7.16; 95% confidence interval, 1.64-31.24), Latino ethnicity (adjusted OR, 4.77; 1.12-20.29), unfamiliarity with necessary treatment duration (adjusted OR, 3.54; 1.26-9.94), lack of knowledge of the permanency of glaucoma-induced vision loss (adjusted OR, 3.09; 1.18-8.04), and perception that it is not important to attend all follow-up visits (adjusted OR, 3.54; 1.26-9.94). Conclusions: Demographic factors, including race and ethnicity, may directly or indirectly affect adherence to recommended glaucoma follow-up visits. Lack of information regarding irreversible vision loss from glaucoma, need for lifelong treatment, and lack of visual symptoms may be significant barriers to follow-up in this population. Targeted glaucoma education by physicians may improve follow-up, thereby decreasing the morbidity associated with glaucomatous disease. ©2011 American Medical Association. All rights reserved. AD - S. C. Lin, University of California, San Francisco, 10 Koret Way, San Francisco, CA 94143-0730, United States AU - Murakami, Y. AU - Lee, B. W. AU - Duncan, M. AU - Kao, A. AU - Huang, J. Y. AU - Singh, K. AU - Lin, S. C. DB - Embase Medline DO - 10.1001/archophthalmol.2011.163 IS - 7 KW - adult aged article confidence interval controlled study correlation analysis data collection method demography disease association ethnic difference female follow up glaucoma health service health survey Hispanic hospital human major clinical study male medical education multivariate logistic regression analysis physician population predictor variable priority journal prospective study questionnaire race difference symptom treatment duration visual impairment LA - English M3 - Article N1 - L362116757 2011-07-19 2011-07-21 PY - 2011 SN - 0003-9950 1538-3601 SP - 872-878 ST - Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population T2 - Archives of Ophthalmology TI - Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362116757&from=export http://dx.doi.org/10.1001/archophthalmol.2011.163 http://archopht.ama-assn.org/cgi/reprint/129/7/872 VL - 129 ID - 3162 ER - TY - JOUR AB - Objectives: To identify predictors of inconsistent attendance at glaucoma follow-up visits in a county hospital population. Methods: Prospective recruitment from August 1, 2008, through January 31, 2009, of 152 individuals with glaucoma, with 1-to-1 matching of patients (those with inconsistent follow-up) and controls (those with consistent follow-up). Data were collected via oral questionnaire. Survey results were correlated with attendance at follow-up examinations, using the t test, χ2 test, and multivariate stepwise logistic regression analysis to calculate the odds ratios (ORs) and 95% confidence intervals. Results: After adjusting for covariates in the logistic regression analysis, factors independently associated with inconsistent follow-up included black race (adjusted OR, 7.16; 95% confidence interval, 1.64-31.24), Latino ethnicity (adjusted OR, 4.77; 1.12-20.29), unfamiliarity with necessary treatment duration (adjusted OR, 3.54; 1.26-9.94), lack of knowledge of the permanency of glaucoma-induced vision loss (adjusted OR, 3.09; 1.18-8.04), and perception that it is not important to attend all follow-up visits (adjusted OR, 3.54; 1.26-9.94). Conclusions: Demographic factors, including race and ethnicity, may directly or indirectly affect adherence to recommended glaucoma follow-up visits. Lack of information regarding irreversible vision loss from glaucoma, need for lifelong treatment, and lack of visual symptoms may be significant barriers to follow-up in this population. Targeted glaucoma education by physicians may improve follow-up, thereby decreasing the morbidity associated with glaucomatous disease. ©2011 American Medical Association. All rights reserved. AD - Departments of Ophthalmology, Stanford University, Stanford, CA, United States University of California, San Francisco, 10 Koret Way, San Francisco, CA 94143-0730, United States National Taiwan University Hospital, Taipei, Taiwan AU - Murakami, Y. AU - Lee, B. W. AU - Duncan, M. AU - Kao, A. AU - Huang, J. Y. AU - Singh, K. AU - Lin, S. C. DB - Scopus DO - 10.1001/archophthalmol.2011.163 IS - 7 M3 - Article N1 - Cited By :48 Export Date: 19 July 2021 PY - 2011 SP - 872-878 ST - Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population T2 - Archives of Ophthalmology TI - Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960189229&doi=10.1001%2farchophthalmol.2011.163&partnerID=40&md5=5ffe02f963078af4e920e4fde6ec8da7 VL - 129 ID - 5001 ER - TY - JOUR AB - Objectives: To identify predictors of inconsistent attendance at glaucoma follow-up visits in a county hospital population. Methods: Prospective recruitment from August 1, 2008, through January 31, 2009, of 152 individuals with glaucoma, with 1-to-1 matching of patients (those with inconsistent follow-up) and controls (those with consistent follow-up). Data were collected via oral questionnaire. Survey results were correlated with attendance at follow- up examinations, using the t test, chi(2) test, and multivariate stepwise logistic regression analysis to calculate the odds ratios (ORs) and 95% confidence intervals. Results: After adjusting for covariates in the logistic regression analysis, factors independently associated with inconsistent follow-up included black race (adjusted OR, 7.16; 95% confidence interval, 1.64-31.24), Latino eth-nicity (adjusted OR, 4.77; 1.12-20.29), unfamiliarity with necessary treatment duration (adjusted OR, 3.54; 1.26-9.94), lack of knowledge of the permanency of glaucomainduced vision loss (adjusted OR, 3.09; 1.18-8.04), and perception that it is not important to attend all follow- up visits (adjusted OR, 3.54; 1.26-9.94). Conclusions: Demographic factors, including race and ethnicity, may directly or indirectly affect adherence to recommended glaucoma follow-up visits. Lack of information regarding irreversible vision loss from glaucoma, need for lifelong treatment, and lack of visual symptoms may be significant barriers to follow-up in this population. Targeted glaucoma education by physicians may improve follow-up, thereby decreasing the morbidity associated with glaucomatous disease. AN - WOS:000292604000005 AU - Murakami, Y. AU - Lee, B. W. AU - Duncan, M. AU - Kao, A. AU - Huang, J. Y. AU - Singh, K. AU - Lin, S. C. DA - JUL DO - 10.1001/archophthalmol.2011.163 IS - 7 PY - 2011 SN - 0003-9950 1538-3601 SP - 872-878 ST - Racial and Ethnic Disparities in Adherence to Glaucoma Follow-up Visits in a County Hospital Population T2 - ARCHIVES OF OPHTHALMOLOGY TI - Racial and Ethnic Disparities in Adherence to Glaucoma Follow-up Visits in a County Hospital Population VL - 129 ID - 5831 ER - TY - JOUR AB - Objective Evaluate individual factors that impact adherence to eye care follow-up in patients with diabetes. Design and methods A 4-year retrospective chart review was conducted for 1968 patients with diabetes over age 40 from an urban academic center. Data collected included demographics, insurance, visual acuity, smoking status, medications, dates of dilated fundus examinations (DFE), and reported hemoglobin A1C and blood glucose levels. The primary outcome was timely DFE follow-up adherence following the initial eye exam visit. Results Overall, 41.6% of patients adhered to initial follow-up eye care recommendations. Multivariable analysis demonstrated that patients with severe diabetic retinopathy (DR) were more adherent than patients with mild DR (OR 1.86). Other variables associated with increased adherence were visual impairment and reported A1C or blood glucose. Smoking was associated with decreased adherence. Ethnicity and insurance were also significantly associated with adherence. Longitudinal follow-up rates were influenced by additional factors, including ethnicity and neighborhood deprivation index. Conclusions Patients with moderate to severe DR and/ or visual impairment were more likely to adhere to timely DFE follow-up. This could relate to the presence of visual symptoms and/or other systemic manifestations of diabetes. Smokers were less likely to adhere to timely DFE follow-up. One hypothesis is patients who smoke have other symptomatic health problems which patients prioritize over asymptomatic ocular disorders. In order to reduce vision loss from DR, practitioners should be aware that patients with mild and moderate DR, patients with normal vision, and smokers are at greater risk for poor follow-up eye care adherence. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. AD - Department of Research, Wills Eye Hospital, Philadelphia, PA, United States Thomas Jefferson University, Philadelphia, PA, United States AU - Murchison, A. P. AU - Hark, L. AU - Pizzi, L. T. AU - Dai, Y. AU - Mayro, E. L. AU - Storey, P. P. AU - Leiby, B. E. AU - Haller, J. A. C7 - e000333 DB - Scopus DO - 10.1136/bmjdrc-2016-000333 IS - 1 M3 - Article N1 - Cited By :22 Export Date: 19 July 2021 PY - 2017 ST - Non-adherence to eye care in people with diabetes T2 - BMJ Open Diabetes Research and Care TI - Non-adherence to eye care in people with diabetes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026807786&doi=10.1136%2fbmjdrc-2016-000333&partnerID=40&md5=fc42c80f4b7644624b4d0501f6c5ddd4 VL - 5 ID - 5120 ER - TY - JOUR AB - Background/Objectives: Adherence is a major challenge in topical glaucoma therapy, particularly in an African context. We report a pilot study assessing adherence independently for the first time in an African context. Subjects/Methods: Participants with newly diagnosed open-angle glaucoma received a weighed bottle of Lumigan 0.01% with counselling on therapy. The bottles were returned monthly for renewal and weighed on return to estimate drops taken during the period. Data collection was for one year with a short compliance questionnaire. Results: 11 patients participated. 5 (45%) failed to complete one full year of topical therapy. The overall mean number of drops per eye per day was 1.74 (SD 0.69) for the 6 with one year of monthly returned bottles and controlled IOPs at each visit. Self-perception of compliance in these patients was good. Conclusion: The signs of poor adherence based on both self-report (previous literature), and in this small-scale study of an objective measure suggest medication may not be the first-line treatment of choice in this environment. Our report does, however, raise the possibility that those patients who return for repeat prescriptions and review are indeed adhering to their treatment regimens. AD - I. Murdoch, Institute of Ophthalmology, Bath Street, London, United Kingdom AU - Murdoch, I. AU - Nyakundi, D. AU - Baker, H. AU - Dulku, S. AU - Kiage, D. DB - Embase DO - 10.2147/PPA.S236468 KW - bimatoprost eye drops article clinical article clinical assessment counseling human intraocular pressure Kenya medication compliance open angle glaucoma outcome assessment patient compliance pilot study prescription questionnaire self concept self report LA - English M3 - Article N1 - L2003771011 2020-02-25 2020-03-03 PY - 2020 SN - 1177-889X SP - 221-225 ST - Adherence with medical therapy for primary open-angle glaucoma in Kenya – a pilot study T2 - Patient Preference and Adherence TI - Adherence with medical therapy for primary open-angle glaucoma in Kenya – a pilot study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003771011&from=export http://dx.doi.org/10.2147/PPA.S236468 VL - 14 ID - 2438 ER - TY - JOUR AB - Background/Objectives: Adherence is a major challenge in topical glaucoma therapy, particularly in an African context. We report a pilot study assessing adherence independently for the first time in an African context. Subjects/Methods: Participants with newly diagnosed open-angle glaucoma received a weighed bottle of Lumigan 0.01% with counselling on therapy. The bottles were returned monthly for renewal and weighed on return to estimate drops taken during the period. Data collection was for one year with a short compliance questionnaire. Results: 11 patients participated. 5 (45%) failed to complete one full year of topical therapy. The overall mean number of drops per eye per day was 1.74 (SD 0.69) for the 6 with one year of monthly returned bottles and controlled IOPs at each visit. Self-perception of compliance in these patients was good. Conclusion: The signs of poor adherence based on both self-report (previous literature), and in this small-scale study of an objective measure suggest medication may not be the first-line treatment of choice in this environment. Our report does, however, raise the possibility that those patients who return for repeat prescriptions and review are indeed adhering to their treatment regimens. © 2020 Murdoch et al. AD - Institute of Ophthalmology, London, EC1V 9EL, United Kingdom Innovation Eye Centre Ltd, Kisii, Kenya University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2WB, United Kingdom AU - Murdoch, I. AU - Nyakundi, D. AU - Baker, H. AU - Dulku, S. AU - Kiage, D. DB - Scopus DO - 10.2147/PPA.S236468 KW - Adherence Africa Glaucoma Medical treatment M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 221-225 ST - Adherence with medical therapy for primary open-angle glaucoma in Kenya – a pilot study T2 - Patient Preference and Adherence TI - Adherence with medical therapy for primary open-angle glaucoma in Kenya – a pilot study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079665343&doi=10.2147%2fPPA.S236468&partnerID=40&md5=e94f36ee133b4d1ffbd8eb036b555cf5 VL - 14 ID - 5717 ER - TY - JOUR AB - Background/Objectives: Adherence is a major challenge in topical glaucoma therapy, particularly in an African context. We report a pilot study assessing adherence independently for the first time in an African context. Subjects/Methods: Participants with newly diagnosed open-angle glaucoma received a weighed bottle of Lumigan 0.01% with counselling on therapy. The bottles were returned monthly for renewal and weighed on return to estimate drops taken during the period. Data collection was for one year with a short compliance questionnaire. Results: 11 patients participated. 5 (45%) failed to complete one full year of topical therapy. The overall mean number of drops per eye per day was 1.74 (SD 0.69) for the 6 with one year of monthly returned bottles and controlled IOPs at each visit. Self-perception of compliance in these patients was good. Conclusion: The signs of poor adherence based on both self-report (previous literature), and in this small-scale study of an objective measure suggest medication may not be the first-line treatment of choice in this environment. Our report does, however, raise the possibility that those patients who return for repeat prescriptions and review are indeed adhering to their treatment regimens. AN - WOS:000519292100001 AU - Murdoch, I. AU - Nyakundi, D. AU - Baker, H. AU - Dulku, S. AU - Kiage, D. DO - 10.2147/PPA.S236468 PY - 2020 SN - 1177-889X SP - 221-225 ST - Adherence with Medical Therapy for Primary Open-Angle Glaucoma in Kenya - A Pilot Study T2 - PATIENT PREFERENCE AND ADHERENCE TI - Adherence with Medical Therapy for Primary Open-Angle Glaucoma in Kenya - A Pilot Study VL - 14 ID - 5984 ER - TY - JOUR AD - Department of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, United States Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, United States AU - Musch, D. C. DB - Scopus DO - 10.1001/jamaophthalmol.2018.3595 IS - 11 M3 - Note N1 - Cited By :2 Export Date: 19 July 2021 PY - 2018 SP - 1260-1261 ST - Anti-VEGF Neovascular Age-Related Macular Degeneration Treatment Adherence Requires Attention and Action T2 - JAMA Ophthalmology TI - Anti-VEGF Neovascular Age-Related Macular Degeneration Treatment Adherence Requires Attention and Action UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052911003&doi=10.1001%2fjamaophthalmol.2018.3595&partnerID=40&md5=28cbf793f3b406c1c50e9edfb1627f8d VL - 136 ID - 5557 ER - TY - JOUR AB - Purpose: To evaluate, both at initial glaucoma diagnosis and during treatment, the role of demographic and clinical factors on intraocular pressure (IOP). Design: Cohort study of patients enrolled in a randomized clinical trial. Participants: Six hundred seven patients with newly diagnosed open-angle glaucoma (OAG) were enrolled at 14 centers in the United States. Methods: After randomization to initial surgery or medications, patients were followed at 6-month intervals. Intraocular pressure was measured by Goldmann applanation tonometry. Predictive factors for IOP at baseline and during follow-up were analyzed using linear mixed models. Main Outcome Measure: Intraocular pressure at baseline and during follow-up. Results: The mean baseline IOP was 27.5 mmHg (standard deviation, 5.6 mmHg). Predictive factors for higher baseline IOP included younger age (0.7 mmHg per 10 years), male gender (2.4 mmHg higher than females), pseudoexfoliative glaucoma (5.4 mmHg higher than primary OAG), and pupillary defect (2.2 mmHg higher than those without a defect). During 9 years of follow-up, both surgery and medications dramatically reduced IOP from baseline levels, but the extent of IOP reduction was consistently greater in the surgery group. Over follow-up years 2 through 9, mean IOP was 15.0 versus 17.2 mmHg for surgery versus medicine, respectively. Predictive associations with higher IOP during follow-up included higher baseline IOP (P<0.0001), worse baseline visual field (mean deviation; P<0.0001), and lower level of education (P = 0.0019). Treatment effect was modified by smoking status: nonsmokers treated surgically had lower IOP than smokers treated surgically (14.6 vs. 16.7 mmHg, respectively; P = 0.0013). Clinical center effects were significant (P<0.0001) in both the baseline and follow-up models. Conclusions: In this large cohort of newly diagnosed glaucoma patients, predictors of pretreatment IOP and IOP measurements over 9 years of follow-up were identified. Our findings lend credence to the postulate that sociodemographic, economic, compliance, or other environmental influences play a role in IOP control during treatment. AN - WOS:000256282800002 AU - Musch, D. C. AU - Gillespie, B. W. AU - Niziol, L. M. AU - Cashwell, F. AU - Lichter, P. R. AU - Collaborative Initial Glaucoma, Tre DA - JUN DO - 10.1016/j.ophtha.2007.08.010 IS - 6 PY - 2008 SN - 0161-6420 1549-4713 SP - 927-933 ST - Factors associated with intraocular pressure before and during 9 years of treatment in the collaborative initial glaucoma treatment study T2 - OPHTHALMOLOGY TI - Factors associated with intraocular pressure before and during 9 years of treatment in the collaborative initial glaucoma treatment study VL - 115 ID - 5993 ER - TY - JOUR AB - Purpose: To evaluate, both at initial glaucoma diagnosis and during treatment, the role of demographic and clinical factors on intraocular pressure (IOP). Design: Cohort study of patients enrolled in a randomized clinical trial. Participants: Six hundred seven patients with newly diagnosed open-angle glaucoma (OAG) were enrolled at 14 centers in the United States. Methods: After randomization to initial surgery or medications, patients were followed at 6-month intervals. Intraocular pressure was measured by Goldmann applanation tonometry. Predictive factors for IOP at baseline and during follow-up were analyzed using linear mixed models. Main Outcome Measure: Intraocular pressure at baseline and during follow-up. Results: The mean baseline IOP was 27.5 mmHg (standard deviation, 5.6 mmHg). Predictive factors for higher baseline IOP included younger age (0.7 mmHg per 10 years), male gender (2.4 mmHg higher than females), pseudoexfoliative glaucoma (5.4 mmHg higher than primary OAG), and pupillary defect (2.2 mmHg higher than those without a defect). During 9 years of follow-up, both surgery and medications dramatically reduced IOP from baseline levels, but the extent of IOP reduction was consistently greater in the surgery group. Over follow-up years 2 through 9, mean IOP was 15.0 versus 17.2 mmHg for surgery versus medicine, respectively. Predictive associations with higher IOP during follow-up included higher baseline IOP (P<0.0001), worse baseline visual field (mean deviation; P<0.0001), and lower level of education (P = 0.0019). Treatment effect was modified by smoking status: nonsmokers treated surgically had lower IOP than smokers treated surgically (14.6 vs. 16.7 mmHg, respectively; P = 0.0013). Clinical center effects were significant (P<0.0001) in both the baseline and follow-up models. Conclusions: In this large cohort of newly diagnosed glaucoma patients, predictors of pretreatment IOP and IOP measurements over 9 years of follow-up were identified. Our findings lend credence to the postulate that sociodemographic, economic, compliance, or other environmental influences play a role in IOP control during treatment. © 2008 American Academy of Ophthalmology. AD - Department of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, MI, United States Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, United States Department of Ophthalmology, Wake Forest University Baptist Medical Center, Winston-Salem, NC, United States Greensboro Ophthalmology Associates, Greensboro, NC, United States AU - Musch, D. C. AU - Gillespie, B. W. AU - Niziol, L. M. AU - Cashwell, L. F. AU - Lichter, P. R. DB - Scopus DO - 10.1016/j.ophtha.2007.08.010 IS - 6 M3 - Article N1 - Cited By :47 Export Date: 19 July 2021 PY - 2008 SP - 927-933 ST - Factors Associated with Intraocular Pressure before and during 9 Years of Treatment in the Collaborative Initial Glaucoma Treatment Study T2 - Ophthalmology TI - Factors Associated with Intraocular Pressure before and during 9 Years of Treatment in the Collaborative Initial Glaucoma Treatment Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-44349123837&doi=10.1016%2fj.ophtha.2007.08.010&partnerID=40&md5=8f3ab546e6bf4c956ae63da8125d714e VL - 115 ID - 5003 ER - TY - JOUR AB - Purpose: To characterize longitudinal trends and factors predictive of depressive symptoms following glaucoma diagnosis in Collaborative Initial Glaucoma Treatment Study (CIGTS) participants. Design: Cohort study using follow-up data from a clinical trial. Methods: A total of 607 participants with newly diagnosed open-angle glaucoma were enrolled at 14 clinical centers in the United States from October 1993 through April 1997, randomized to treatment with medication or surgery, and followed every 6 months through 2004. The 8-item Center for Epidemiologic Studies Depression Scale (CES-D) was administered at baseline and follow-up visits. Three outcome measures were investigated: overall CES-D depression score, presence of mild or worse depression (CES-D score ≥ 7), and number of depressive symptoms endorsed. Results: The average baseline CES-D score was 2.4 (SD = 3.8), 12.5% of subjects reported symptoms associated with mild or worse depression, and 55.3% reported at least 1 depressive symptom. By 1 year posttreatment, depression measures decreased (1.5, 6.7%, and 38.4%, respectively), with modest decreases thereafter. Baseline factors predictive of mild or worse depression included worse vision-related quality of life (VRQOL) (odds ratio [OR] = 2.41), female sex (OR = 1.42), younger age (OR per 10 years younger = 1.24), and less than high school education (OR = 2.93); other outcomes showed similar results. Conclusions: Depressive symptoms decreased considerably during the first year after treatment initiation, but were elevated in those with impaired VRQOL. Given the potential of depression to reduce treatment adherence and thus increase the risk of glaucoma progression, eye care providers should ask patients about depressive symptoms, provide reassurance when appropriate, and make referrals as necessary. AD - D.C. Musch, Kellogg Eye Center, University of Michigan, 1000 Wall St, Ann Arbor, MI, United States AU - Musch, D. C. AU - Niziol, L. M. AU - Janz, N. K. AU - Gillespie, B. W. DB - Embase Medline DO - 10.1016/j.ajo.2018.09.015 KW - adult age article Center for Epidemiologic Studies Depression Scale cohort analysis controlled study depression depression assessment disease association disease exacerbation disease severity educational status eye care professional female follow up human longitudinal study major clinical study male middle aged open angle glaucoma outcome assessment patient compliance patient-reported outcome predictor variable priority journal quality of life reassurance risk factor sex difference therapy effect treatment duration trend study United States LA - English M3 - Article N1 - L2001260546 2018-11-14 2018-11-20 PY - 2019 SN - 1879-1891 0002-9394 SP - 128-135 ST - Trends in and Predictors of Depression Among Participants in the Collaborative Initial Glaucoma Treatment Study (CIGTS) T2 - American Journal of Ophthalmology TI - Trends in and Predictors of Depression Among Participants in the Collaborative Initial Glaucoma Treatment Study (CIGTS) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001260546&from=export http://dx.doi.org/10.1016/j.ajo.2018.09.015 VL - 197 ID - 2537 ER - TY - JOUR AB - Purpose: To characterize longitudinal trends and factors predictive of depressive symptoms following glaucoma diagnosis in Collaborative Initial Glaucoma Treatment Study (CIGTS) participants. Design: Cohort study using follow-up data from a clinical trial. Methods: A total of 607 participants with newly diagnosed open-angle glaucoma were enrolled at 14 clinical centers in the United States from October 1993 through April 1997, randomized to treatment with medication or surgery, and followed every 6 months through 2004. The 8-item Center for Epidemiologic Studies Depression Scale (CES-D) was administered at baseline and follow-up visits. Three outcome measures were investigated: overall CES-D depression score, presence of mild or worse depression (CES-D score ≥ 7), and number of depressive symptoms endorsed. Results: The average baseline CES-D score was 2.4 (SD = 3.8), 12.5% of subjects reported symptoms associated with mild or worse depression, and 55.3% reported at least 1 depressive symptom. By 1 year posttreatment, depression measures decreased (1.5, 6.7%, and 38.4%, respectively), with modest decreases thereafter. Baseline factors predictive of mild or worse depression included worse vision-related quality of life (VRQOL) (odds ratio [OR] = 2.41), female sex (OR = 1.42), younger age (OR per 10 years younger = 1.24), and less than high school education (OR = 2.93); other outcomes showed similar results. Conclusions: Depressive symptoms decreased considerably during the first year after treatment initiation, but were elevated in those with impaired VRQOL. Given the potential of depression to reduce treatment adherence and thus increase the risk of glaucoma progression, eye care providers should ask patients about depressive symptoms, provide reassurance when appropriate, and make referrals as necessary. © 2018 Elsevier Inc. AD - Department of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, MI, United States Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, United States Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, United States AU - Musch, D. C. AU - Niziol, L. M. AU - Janz, N. K. AU - Gillespie, B. W. DB - Scopus DO - 10.1016/j.ajo.2018.09.015 M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2019 SP - 128-135 ST - Trends in and Predictors of Depression Among Participants in the Collaborative Initial Glaucoma Treatment Study (CIGTS) T2 - American Journal of Ophthalmology TI - Trends in and Predictors of Depression Among Participants in the Collaborative Initial Glaucoma Treatment Study (CIGTS) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056220530&doi=10.1016%2fj.ajo.2018.09.015&partnerID=40&md5=3a1520a152e960f95c73168a01364a3f VL - 197 ID - 5270 ER - TY - JOUR AB - PURPOSE: To characterize longitudinal trends and factors predictive of depressive symptoms following glaucoma diagnosis in Collaborative Initial Glaucoma Treatment Study (CIGTS) participants. DESIGN: Cohort study using follow-up data from a clinical trial. METHODS: A total of 607 participants with newly diagnosed open-angle glaucoma were enrolled at 14 clinical centers in the United States from October 1993 through April 1997, randomized to treatment with medication or surgery, and followed every 6 months through 2004. The 8-item Center for Epidemiologic Studies Depression Scale (CESD) was administered at baseline and follow-up visits. Three outcome measures were investigated: overall CES-D depression score, presence of mild or worse depression (CES-D score Z 7), and number of depressive symptoms endorsed. RESULTS: The average baseline CES-D score was 2.4 (SD = 3.8), 12.5% of subjects reported symptoms associated with mild or worse depression, and 55.3% reported at least 1 depressive symptom. By 1 year posttreatment, depression measures decreased (1.5, 6.7%, and 38.4%, respectively), with modest decreases thereafter. Baseline factors predictive of mild or worse depression included worse vision-related quality of life (VRQOL) (odds ratio [OR] = 2.41), female sex (OR = 1.42), younger age (OR per 10 years younger = 1.24), and less than high school education (OR = 2.93); other outcomes showed similar results. CONCLUSIONS: Depressive symptoms decreased considerably during the first year after treatment initiation, but were elevated in those with impaired VRQOL. Given the potential of depression to reduce treatment adherence and thus increase the risk of glaucoma progression, eye care providers should ask patients about depressive symptoms, provide reassurance when appropriate, and make referrals as necessary. (C) 2018 Elsevier Inc. All rights reserved. AN - WOS:000454373600016 AU - Musch, D. C. AU - Niziol, L. M. AU - Janz, N. K. AU - Gillespie, B. W. DA - JAN DO - 10.1016/j.ajo.2018.09.015 PY - 2019 SN - 0002-9394 1879-1891 SP - 128-135 ST - Trends in and Predictors of Depression Among Participants in the Collaborative Initial Glaucoma Treatment Study (CIGTS) T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Trends in and Predictors of Depression Among Participants in the Collaborative Initial Glaucoma Treatment Study (CIGTS) VL - 197 ID - 6045 ER - TY - JOUR AB - Purpose: To determine whether the consumption of topical glaucoma medication is influenced by the type of eye drop dispenser. Design: Retrospective cohort study. Methods: We examined 366 patients with open-angle glaucoma or ocular hypertension who were bilaterally treated with 0.0015% tafluprost or 2% dorzolamide/0.5% timolol fixed combination (DTFC). The patients were grouped by the type of dispenser and content of eye drops used: (1) tafluprost in bottles (T-Bottle group); (2) tafluprost in unit-dose pipettes (T-Unit group); (3) DTFC in bottles (C-Bottle group); and (4) DTFC in unit-dose pipettes (C-Unit group). We evaluated the medication possession ratio (MPR) among groups, and factors associated with over-consumption (MPR > 1.2) or under-consumption (MPR < 0.8) in multinomial logistic regression. Results: The mean MPR was 1.49 (range, 0.69-2.91) in the T-Bottle group, 0.91 (range, 0.32-1.27) in the T-Unit group, 1.25 (range, 0.51-2.60) in the C-Bottle group, and 0.96 (range, 0.36-1.60) in the C-Unit group. The Bottle groups demonstrated higher mean values and wider ranges of MPR compared to the Unit groups. The MPR interval at which the largest number of patients were found was 1.0-1.4 in the Bottle groups and 0.8-1.2 in the Unit groups. Bottle-type dispenser (odds ratio [OR] 64.02), tafluprost medication (OR 2.84), and older age (OR 1.03) were associated with over-consumption, whereas no factor was correlated with under-consumption. Conclusions: The type of eye drop dispenser affects the consumption of glaucoma medication. Physicians should consider the type of eye drop dispenser when assessing glaucoma medication adherence. AD - C. Yoo, Department of Ophthalmology, Korea University College of Medicine, 126-1 Anam-dong 5-ga, Sungbuk-gu, Seoul, South Korea AU - Na, K. H. AU - Yoo, C. AU - Park, J. H. AU - Kim, Y. Y. C1 - cosopt taflotan(Santen,Japan) C2 - Santen(Japan) DB - Embase Medline DO - 10.1016/j.ajo.2018.01.011 KW - eye drop delivery aid dorzolamide plus timolol tafluprost tafluprost plus timolol adult article cohort analysis controlled study drug use female human intraocular hypertension logistic regression analysis major clinical study male open angle glaucoma patient compliance priority journal retrospective study cosopt taflotan LA - English M3 - Article N1 - L620589034 2018-02-14 2018-02-20 PY - 2018 SN - 1879-1891 0002-9394 SP - 9-18 ST - Eye Drop Dispenser Type and Medication Possession Ratio in Patients With Glaucoma: Single-Use Containers Versus Multiple-Use Bottles T2 - American Journal of Ophthalmology TI - Eye Drop Dispenser Type and Medication Possession Ratio in Patients With Glaucoma: Single-Use Containers Versus Multiple-Use Bottles UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620589034&from=export http://dx.doi.org/10.1016/j.ajo.2018.01.011 VL - 188 ID - 2595 ER - TY - JOUR AB - Aims: To evaluate the effect of selective laser trabeculoplasty (SLT) on intraocular pressure (IOP) control and diurnal tension curves of patients with open-angle glaucoma (OAG) and ocular hypertension (OHT), and to compare this effect with that of latanoprost. Methods: Forty patients were randomised to receive either SLT or latanoprost. IOP control was evaluated by comparing pretreatment values with post-treatment measurements on day 3, week 1, month 1 and 4-6 months; success was defined as 20% decrease in IOP. Tension curves were plotted prior to treatment and 4-6 months afterwards; success was 50% reduction in fluctuation. Results: SLT decreased pressure by 4.7 mm Hg on average (95% CI 3.6 to 5.7 mm Hg; p. 0.01). The reduction was similar for latanoprost at all follow-ups except month 1; 75% of SLT patients and 73% of latanoprost patients achieved success in IOP control (p = 0.4). SLT significantly reduced IOP fluctuation, but latanoprost was more effective (3.6 mm Hg, 95% CI 3.2 to 3.9 mm Hg vs 2.5 mm Hg, 95% CI 2.2 to 2.9 mm Hg for SLT; p = 0.04). Success in fluctuation reduction was 50% for SLT and 83% for latanoprost (p = 0.045). Conclusions: Both SLT and latanoprost had a significant impact on IOP control and fluctuation. While latanoprost may be more likely to reduce IOP fluctuation, SLT has the benefit of being a one-time intervention not requiring ongoing patient compliance. AD - M. Nagar, Clayton Hospital, Mid Yorkshire Hospitals NHS Trust, 1 Woodthorpe Park Drive, Sandal, Northgate, Wakefield WF2 6HY, United Kingdom AU - Nagar, M. AU - Luhishi, E. AU - Shah, N. DB - Embase Medline DO - 10.1136/bjo.2008.148510 IS - 4 KW - latanoprost adult aged article clinical article female human intermethod comparison intracranial pressure monitoring intraocular hypertension intraocular pressure laser surgery male open angle glaucoma patient compliance priority journal trabeculoplasty LA - English M3 - Article N1 - L354485368 2009-05-12 PY - 2009 SN - 0007-1161 1468-2079 SP - 497-501 ST - Intraocular pressure control and fluctuation: The effect of treatment with selective laser trabeculoplasty T2 - British Journal of Ophthalmology TI - Intraocular pressure control and fluctuation: The effect of treatment with selective laser trabeculoplasty UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354485368&from=export http://dx.doi.org/10.1136/bjo.2008.148510 http://bjo.bmj.com/cgi/reprint/93/4/497 VL - 93 ID - 3361 ER - TY - JOUR AB - Aims: To evaluate the effect of selective laser trabeculoplasty (SLT) on intraocular pressure (IOP) control and diurnal tension curves of patients with open-angle glaucoma (OAG) and ocular hypertension (OHT), and to compare this effect with that of latanoprost. Methods: Forty patients were randomised to receive either SLT or latanoprost. IOP control was evaluated by comparing pretreatment values with post-treatment measurements on day 3, week 1, month 1 and 4-6 months; success was defined as 20% decrease in IOP. Tension curves were plotted prior to treatment and 4-6 months afterwards; success was 50% reduction in fluctuation. Results: SLT decreased pressure by 4.7 mm Hg on average (95% CI 3.6 to 5.7 mm Hg; p. 0.01). The reduction was similar for latanoprost at all follow-ups except month 1; 75% of SLT patients and 73% of latanoprost patients achieved success in IOP control (p = 0.4). SLT significantly reduced IOP fluctuation, but latanoprost was more effective (3.6 mm Hg, 95% CI 3.2 to 3.9 mm Hg vs 2.5 mm Hg, 95% CI 2.2 to 2.9 mm Hg for SLT; p = 0.04). Success in fluctuation reduction was 50% for SLT and 83% for latanoprost (p = 0.045). Conclusions: Both SLT and latanoprost had a significant impact on IOP control and fluctuation. While latanoprost may be more likely to reduce IOP fluctuation, SLT has the benefit of being a one-time intervention not requiring ongoing patient compliance. AD - Clayton Hospital, Mid Yorkshire Hospitals NHS Trust, Northgate, Wakefield, United Kingdom Clayton Hospital, Mid Yorkshire Hospitals NHS Trust, 1 Woodthorpe Park Drive, Sandal, Northgate, Wakefield WF2 6HY, United Kingdom AU - Nagar, M. AU - Luhishi, E. AU - Shah, N. DB - Scopus DO - 10.1136/bjo.2008.148510 IS - 4 M3 - Article N1 - Cited By :69 Export Date: 19 July 2021 PY - 2009 SP - 497-501 ST - Intraocular pressure control and fluctuation: The effect of treatment with selective laser trabeculoplasty T2 - British Journal of Ophthalmology TI - Intraocular pressure control and fluctuation: The effect of treatment with selective laser trabeculoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-64849107038&doi=10.1136%2fbjo.2008.148510&partnerID=40&md5=8e35134d4cfc900308342e2a520b9cc0 VL - 93 ID - 4959 ER - TY - JOUR AB - PURPOSE: To report a case series of contact lens-related corneal ulcers in compliant patients with no apparent predisposing factors. DESIGN: Retrospective case series. METHODS: Charts of 70 patients with contact lens-related corneal ulcers from July 1999 to June 2002 were reviewed. Lens care hygiene and method of disinfection, as well as frequency of lens replacement, were recorded. Only patients who followed recommended guidelines for contact lens wear were included in the study. RESULTS: Of the 70 patients, 21 (30%) developed corneal ulcers despite being compliant with the guidelines for contact lens wear. All patients used multipurpose solutions for cleaning, disinfecting, and storing daily wear soft contact lenses. CONCLUSION: Standard lens care hygiene does not seem to be sufficient in preventing the development of corneal ulcers in patients using conventional and frequent replacement daily wear soft contact lenses. © 2004 by Elsevier Inc. All rights reserved. AD - E.J. Cohen, Cornea Service, Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA 19107, United States AU - Najjar, D. M. AU - Aktan, S. G. AU - Rapuano, C. J. AU - Laibson, P. R. AU - Cohen, E. J. DB - Embase Medline DO - 10.1016/S0002-9394(03)00722-0 IS - 1 KW - antibiotic agent contact lens solution quinoline derived antiinfective agent adolescent adult aged article cleaning cornea ulcer disinfection female human hygiene major clinical study male patient compliance priority journal soft contact lens AcuToric Acuvue Focus LA - English M3 - Article N1 - L38045203 2004-01-28 PY - 2004 SN - 0002-9394 SP - 170-172 ST - Contact lens-related corneal ulcers in compliant patients T2 - American Journal of Ophthalmology TI - Contact lens-related corneal ulcers in compliant patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38045203&from=export http://dx.doi.org/10.1016/S0002-9394(03)00722-0 VL - 137 ID - 3760 ER - TY - JOUR AB - Objectives We evaluated early medication persistence with new topical antiglaucoma eyedrops, omidenepag isopropyl 0.002% (a selective prostaglandin EP2 agonist). Design and setting Retrospective two-institute study in Himeji and Akashi in Japan. Participants We analysed patients with glaucoma who were prescribed topical omidenepag isopropyl from November 2018 to December 2019. From the last outpatient visit of patients until February 2020, 235 patients were prescribed a new solution of omidenepag isopropyl (129 patients in the initial monotherapy group, 85 in the switching group (switched from another topical antiglaucoma eyedrops), 19 added to another topical antiglaucoma eyedrops group, and 2 were lost to follow-up)). Additionally, we recruited 98 patients (3 were lost to follow-up) who received initial latanoprost 0.005% monotherapy during the same period as a control group. Outcomes Medication persistence failure was defined as drug discontinuation due to any adverse effects or change of therapy. Kaplan-Meier survival analysis was performed with a Cox regression analysis. Results Among 233 patients, 48 (20%) showed failure of treatment; the median persistence time of all patients was 165 days, and the median time until discontinuation of omidenepag isopropyl was 45 days. The total persistence rates were 85%, 80% and 70% at 3, 6 and 12 months, respectively. Risk factors for failure were male gender (HR: 1.45, p=0.023) and monotherapy/switching (HR: 1.715, p=0.002). Comparison between latanoprost and omidenepag isopropyl monotherapy, only male gender (HR: 1.43, p=0.016) was a significant risk factor. Failures associated with omidenepag isopropyl were due to insufficient intraocular pressure-lowering efficiency (n=26, observed during all the period), followed by conjunctival hyperaemia (n=10) and visual acuity disturbance (n=5) in patients who were observed until 3 months. Conclusion Medication persistence with omidenepag isopropyl is mostly positive; however, clinicians should also be cautious of early failure. © 2021 BMJ Publishing Group. All rights reserved. AD - Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan Ophthalmology, Division of Surgery, Kobe, Japan Kanamori Eye Clinic, Akashi, Japan AU - Nakakura, S. AU - Kanamori, A. AU - Fukuma, Y. AU - Wakabayashi, S. AU - Nagata, Y. AU - Adachi, M. C7 - 40301 DB - Scopus DO - 10.1136/bmjopen-2020-040301 IS - 1 KW - glaucoma medical ophthalmology ophthalmology pharmacology M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2021 ST - Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: A retrospective two-institute study T2 - BMJ Open TI - Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: A retrospective two-institute study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100560405&doi=10.1136%2fbmjopen-2020-040301&partnerID=40&md5=9e12eb0779872cc0d564c8f7a40da889 VL - 11 ID - 5596 ER - TY - JOUR AB - Introduction: Neuroticism is a personality trait often described in individuals with glaucoma (GLC), but is not necessarily representative of the total population of patients. There is a population of patients with GLC who are invisible to clinical ophthalmologists; in other words, those who once have been diagnosed with GLC, but spontaneously stop visiting an ophthalmologist. Little is known about their neuroticism personality trait. In the present study, the authors compared the level of neuroticism between patients no longer visiting an ophthalmologist and those who continue visit them regularly. Methods: Patients were assigned to two groups according to the duration of their last visit to an ophthalmologist: the Discontinued group included those patients who had not visited an ophthalmologist for the last 6 months, and the Regular Visitor group included those patients who continued to make regular visits to an ophthalmologist. The Japanese version of Ten Items Personality Inventory (TIPI-J), a questionnaire specifically used to assess the Big Five personality traits (extraversion, agreeableness, conscientiousness, neuroticism, and openness), was completed by patients through a dedicated website. Results: Three-hundred and seventy-three patients with GLC were recruited. The neuroticism score from the TIPI-J in the Discontinued group was significantly lower than that in the Regular Visitor group (7.63 ± 2.23 vs. 8.23 ± 2.21, respectively; P = 0.01). No significant difference was found in the other TIPI-J sub-item scores between the Discontinued and the Regular Visitor groups. Conclusion: In this study, the authors showed that neuroticism trait in patients with GLC who have discontinued visiting their ophthalmologists was lower than that in patients who regularly visited them, on the basis of the Big Five personality traits as measured by the TIPT-J. Funding: Santen Pharmaceutical Co., Ltd. AD - T. Nakano, Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan AU - Nakano, T. AU - Kodaka, F. AU - Tsuneoka, H. DB - Embase DO - 10.1007/s40123-016-0059-1 IS - 2 KW - adult agreeableness article comparative study conscientiousness consultation data analysis extraversion female glaucoma human Japanese version of the ten item personality inventory major clinical study male neurosis openness ophthalmologist patient compliance personality personality test priority journal questionnaire LA - English M3 - Article N1 - L613451323 2016-12-05 2016-12-08 PY - 2016 SN - 2193-6528 2193-8245 SP - 207-214 ST - Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications T2 - Ophthalmology and Therapy TI - Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613451323&from=export http://dx.doi.org/10.1007/s40123-016-0059-1 VL - 5 ID - 2690 ER - TY - JOUR AB - Introduction: Neuroticism is a personality trait often described in individuals with glaucoma (GLC), but is not necessarily representative of the total population of patients. There is a population of patients with GLC who are invisible to clinical ophthalmologists; in other words, those who once have been diagnosed with GLC, but spontaneously stop visiting an ophthalmologist. Little is known about their neuroticism personality trait. In the present study, the authors compared the level of neuroticism between patients no longer visiting an ophthalmologist and those who continue visit them regularly. Methods: Patients were assigned to two groups according to the duration of their last visit to an ophthalmologist: the Discontinued group included those patients who had not visited an ophthalmologist for the last 6 months, and the Regular Visitor group included those patients who continued to make regular visits to an ophthalmologist. The Japanese version of Ten Items Personality Inventory (TIPI-J), a questionnaire specifically used to assess the Big Five personality traits (extraversion, agreeableness, conscientiousness, neuroticism, and openness), was completed by patients through a dedicated website. Results: Three-hundred and seventy-three patients with GLC were recruited. The neuroticism score from the TIPI-J in the Discontinued group was significantly lower than that in the Regular Visitor group (7.63 ± 2.23 vs. 8.23 ± 2.21, respectively; P = 0.01). No significant difference was found in the other TIPI-J sub-item scores between the Discontinued and the Regular Visitor groups. Conclusion: In this study, the authors showed that neuroticism trait in patients with GLC who have discontinued visiting their ophthalmologists was lower than that in patients who regularly visited them, on the basis of the Big Five personality traits as measured by the TIPT-J. Funding: Santen Pharmaceutical Co., Ltd. © 2016, The Author(s). AD - Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan AU - Nakano, T. AU - Kodaka, F. AU - Tsuneoka, H. DB - Scopus DO - 10.1007/s40123-016-0059-1 IS - 2 KW - Five-factor model of personality Glaucoma Neuroticism The Big Five personality traits M3 - Article N1 - Export Date: 19 July 2021 PY - 2016 SP - 207-214 ST - Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications T2 - Ophthalmology and Therapy TI - Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066350584&doi=10.1007%2fs40123-016-0059-1&partnerID=40&md5=5e09a8c182c6fae84670e76eb29b5fb8 VL - 5 ID - 5740 ER - TY - JOUR AB - Neuroticism is a personality trait often described in individuals with glaucoma (GLC), but is not necessarily representative of the total population of patients. There is a population of patients with GLC who are invisible to clinical ophthalmologists; in other words, those who once have been diagnosed with GLC, but spontaneously stop visiting an ophthalmologist. Little is known about their neuroticism personality trait. In the present study, the authors compared the level of neuroticism between patients no longer visiting an ophthalmologist and those who continue visit them regularly. Patients were assigned to two groups according to the duration of their last visit to an ophthalmologist: the Discontinued group included those patients who had not visited an ophthalmologist for the last 6 months, and the Regular Visitor group included those patients who continued to make regular visits to an ophthalmologist. The Japanese version of Ten Items Personality Inventory (TIPI-J), a questionnaire specifically used to assess the Big Five personality traits (extraversion, agreeableness, conscientiousness, neuroticism, and openness), was completed by patients through a dedicated website. Three-hundred and seventy-three patients with GLC were recruited. The neuroticism score from the TIPI-J in the Discontinued group was significantly lower than that in the Regular Visitor group (7.63 +/- 2.23 vs. 8.23 +/- 2.21, respectively; P = 0.01). No significant difference was found in the other TIPI-J sub-item scores between the Discontinued and the Regular Visitor groups. In this study, the authors showed that neuroticism trait in patients with GLC who have discontinued visiting their ophthalmologists was lower than that in patients who regularly visited them, on the basis of the Big Five personality traits as measured by the TIPT-J. Santen Pharmaceutical Co., Ltd. AN - WOS:000389469600009 AU - Nakano, T. AU - Kodaka, F. AU - Tsuneoka, H. DA - DEC DO - 10.1007/s40123-016-0059-1 IS - 2 PY - 2016 SN - 2193-8245 2193-6528 SP - 207-214 ST - Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications T2 - OPHTHALMOLOGY AND THERAPY TI - Differences in Neuroticism Between Patients with Glaucoma Who Have Discontinued Visits to Ophthalmologists and Those Who Make Regular Visits: Implications for Adherence to Topical Glaucoma Medications VL - 5 ID - 6136 ER - TY - JOUR AB - Purpose: Systemic absorption and central nervous system (CNS) penetration of timolol drops are a well-studied phenomenon, resulting in common side effects such as bradycardia, bronchospasm, fatigue, and confusion. More serious CNS side effects, such as psychosis and depression, however, are rarely attributed to eye drops. We report a case series in which patients developed visual hallucinations secondary to topical ocular timolol use. Methods: This study is a case series and review of the literature. Results: Four patients with glaucoma developed visual hallucinations while using topical timolol. The patients were all elderly, caucasian females with associated CNS pathology. All patients had resolution of symptoms upon discontinuation and a positive retrial test to confirm the association. Conclusions: The rarity of this side effect and its anecdotal predilection for elderly, caucasian females with underlying neurological dysfunction, may involve a yet unknown predisposition or hypersensitivity to beta blocker action, such as blood brain barrier disruption leading to increased susceptibility to the medication. This case series highlights an important, although rare, side effect of this medication which clinicians should be aware of especially when using it in elderly patients who may have coexisting CNS pathology. It is important that this side effect be recognized and appropriately managed to prevent otherwise unnecessary investigations and treatment. © 2017 Wolters Kluwer Health, Inc. All rights reserved. AD - Columbia University College of Physicians and Surge., United States Harkness Eye Institute, Columbia University Medical Center, 635 W 165th Street, New York, NY 10032, United States Department of Ophthalmology, University of California at San Francisco, San Francisco, CA, United States AU - Nanda, T. AU - Rasool, N. AU - Callahan, A. B. AU - Stamper, R. L. AU - Odel, J. G. DB - Scopus DO - 10.1097/IJG.0000000000000712 IS - 9 KW - beta blocker hallucinations timolol M3 - Review N1 - Cited By :7 Export Date: 19 July 2021 PY - 2017 SP - e214-e216 ST - Ophthalmic Timolol Hallucinations: A Case Series and Review of the Literature T2 - Journal of Glaucoma TI - Ophthalmic Timolol Hallucinations: A Case Series and Review of the Literature UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021820108&doi=10.1097%2fIJG.0000000000000712&partnerID=40&md5=eaf566795a1d6934ee80801f611cb6b1 VL - 26 ID - 5348 ER - TY - JOUR AB - Purpose: To compare efficacy and safety of EX-PRESS mini glaucoma shunt (Alcon) and trabeculectomy with mitomycin-C (MMC) in the management of pediatric glaucoma. Methods: The authors retrospectively reviewed patients from a single pediatric ophthalmology practice with either congenital or juvenile glaucoma who underwent surgical treatment with either trabeculectomy or EX-PRESS shunt insertion with MMC. Postoperative intraocular pressure at 6, 18, and 36 months, medication requirements, visual acuities, postoperative interventions, complications, and noncompliance with medications or follow-up was reviewed. Results: A total of 42 cases of glaucoma with either trabeculectomy or EX-PRESS shunt were identified for review (n trabeculectomy=25, n EX-PRESS=17). At 6 months, 62.5% of trabeculectomies and 94.1% of EX-PRESS shunts met criteria for success (P=0.0281). At 18 months, 38.1% of trabeculectomies and 81.3% of EX-PRESS shunts met criteria for success (P=0.0178). At 36 months, trabeculectomies had a success rate of 33.3% versus 66.7% for EX-PRESS shunts (P=0.321). The average decrease in medications postoperatively was 0.375 and 1.63 for trabeculectomy and EX-PRESS shunt, respectively (P=0.06). Preoperative visual acuities compared with postoperative best-corrected visual acuities before additional surgery demonstrated a slight average worsening of 0.11 logMAR in trabeculectomy patients and an average improvement of 0.56 logMAR in EX-PRESS shunt patients (P=0.0037). Conclusions: In this review, patients with pediatric glaucoma managed with EX-PRESS shunt with MMC compared with trabeculectomy with MMC appear to have better intraocular pressure control, better visual acuities, and fewer complications and reoperations. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. AD - Mayo Clinic, Rochester, MN, United States Eastern Virginia Medical School, 880 Kempsville Road, Norfolk, VA 23502, United States AU - Nash, D. L. AU - Crouch, E. R. AU - Crouch, E. R. DB - Scopus DO - 10.1097/IJG.0000000000000547 IS - 2 KW - congenital glaucoma EX-PRESS shunt pediatric glaucoma trabeculectomy M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2017 SP - e58-e63 ST - Comparison of EX-PRESS Shunt and Trabeculectomy with Mitomycin-C in Congenital and Juvenile Glaucoma T2 - Journal of Glaucoma TI - Comparison of EX-PRESS Shunt and Trabeculectomy with Mitomycin-C in Congenital and Juvenile Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991497413&doi=10.1097%2fIJG.0000000000000547&partnerID=40&md5=84089f27ab33f1bcca694840f3e663e5 VL - 26 ID - 5377 ER - TY - JOUR AB -) Purpose: To compare efficacy and safety of EX-PRESS mini glaucoma shunt (Alcon) and trabeculectomy with mitomycin-C (MMC) in the management of pediatric glaucoma. Methods: The authors retrospectively reviewed patients from a single pediatric ophthalmology practice with either congenital or juvenile glaucoma who underwent surgical treatment with either trabeculectomy or EX-PRESS shunt insertion with MMC. Postoperative intraocular pressure at 6, 18, and 36 months, medication requirements, visual acuities, postoperative interventions, complications, and noncompliance with medications or follow-up was reviewed. Results: A total of 42 cases of glaucoma with either trabeculectomy or EX-PRESS shunt were identified for review (n trabeculectomy = 25, n EX-PRESS = 17). At 6 months, 62.5% of trabeculectomies and 94.1% of EX-PRESS shunts met criteria for success (P = 0.0281). At 18 months, 38.1% of trabeculectomies and 81.3% of EX-PRESS shunts met criteria for success (P = 0.0178). At 36 months, trabeculectomies had a success rate of 33.3% versus 66.7% for EX-PRESS shunts (P = 0.321). The average decrease in medications postoperatively was 0.375 and 1.63 for trabeculectomy and EX-PRESS shunt, respectively (P = 0.06). Preoperative visual acuities compared with postoperative best-corrected visual acuities before additional surgery demonstrated a slight average worsening of 0.11 logMAR in trabeculectomy patients and an average improvement of 0.56 logMAR in EX-PRESS shunt patients (P = 0.0037). Conclusions: In this review, patients with pediatric glaucoma managed with EX-PRESS shunt with MMC compared with trabeculectomy with MMC appear to have better intraocular pressure control, better visual acuities, and fewer complications and reoperations. AN - WOS:000395514100007 AU - Nash, D. L. AU - Crouch, E. R. AU - Crouch, E. R. DA - FEB DO - 10.1097/IJG.0000000000000547 IS - 2 PY - 2017 SN - 1057-0829 1536-481X SP - E58-E63 ST - Comparison of EX- PRESS Shunt and Trabeculectomy With Mitomycin- C in Congenital and Juvenile Glaucoma T2 - JOURNAL OF GLAUCOMA TI - Comparison of EX- PRESS Shunt and Trabeculectomy With Mitomycin- C in Congenital and Juvenile Glaucoma VL - 26 ID - 6152 ER - TY - JOUR AB - Glaucoma is an age-related disease and the second cause of blindness in the world. The measurement of intraocular pressure (IOP) is the cornerstone of glaucoma treatment because elevated IOP is the only risk factor that can be modified. Clinical evidences proved that single measurements obtained during office visits are neither sufficient to capture the circadian rhythm of IOP nor valid to demonstrate the effect of medication or patients’ compliance to a given therapy. As such, patients would benefit from a device that they can self-administer to gage the IOP multiple times a day. In this paper, we present a numerical study on a new approach to measure IOP noninvasively using engineering principles never explored in ophthalmology. The method relies on the dynamical interaction between the solitary waves propagating within a chain of particles and the eye to be evaluated that is in contact with the end of the chain. In the study presented in this paper, a numerical model of such interaction was implemented to demonstrate the sensitivity of the proposed approach to the variation of IOP. The findings show that some features of the waves are monotonically dependent on the IOP. These findings may pave the way to the development of a new kind of tonometer that will enable millions of glaucoma patients to perform routine self-measurements of the eye pressure without clinical visits. © 2019 Elsevier Ltd AD - Laboratory for Nondestructive Evaluation and Structural Health Monitoring Studies, Department of Civil and Environmental Engineering, University of Pittsburgh, 3700 O'Hara Street, Pittsburgh, PA 15261, United States AU - Nasrollahi, A. AU - Rizzo, P. C7 - 103534 DB - Scopus DO - 10.1016/j.jmbbm.2019.103534 KW - Finite element method Highly nonlinear solitary waves Intraocular pressure M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2020 ST - Modeling a new dynamic approach to measure intraocular pressure with solitary waves T2 - Journal of the Mechanical Behavior of Biomedical Materials TI - Modeling a new dynamic approach to measure intraocular pressure with solitary waves UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075709324&doi=10.1016%2fj.jmbbm.2019.103534&partnerID=40&md5=9e739ff8eb18786110e7c8f5262cb79b VL - 103 ID - 5496 ER - TY - JOUR AB - Glaucoma is an age-related disease and the second cause of blindness in the world. The measurement of intraocular pressure (IOP) is the cornerstone of glaucoma treatment because elevated IOP is the only risk factor that can be modified. Clinical evidences proved that single measurements obtained during office visits are neither sufficient to capture the circadian rhythm of IOP nor valid to demonstrate the effect of medication or patients' compliance to a given therapy. As such, patients would benefit from a device that they can self-administer to gage the IOP multiple times a day. In this paper, we present a numerical study on a new approach to measure IOP noninvasively using engineering principles never explored in ophthalmology. The method relies on the dynamical interaction between the solitary waves propagating within a chain of particles and the eye to be evaluated that is in contact with the end of the chain. In the study presented in this paper, a numerical model of such interaction was implemented to demonstrate the sensitivity of the proposed approach to the variation of IOP. The findings show that some features of the waves are monotonically dependent on the IOP. These findings may pave the way to the development of a new kind of tonometer that will enable millions of glaucoma patients to perform routine self-measurements of the eye pressure without clinical visits. AN - WOS:000517856400027 AU - Nasrollahi, A. AU - Rizzo, P. DA - MAR DO - 10.1016/j.jmbbm.2019.103534 PY - 2020 SN - 1751-6161 1878-0180 ST - Modeling a new dynamic approach to measure intraocular pressure with solitary waves T2 - JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS TI - Modeling a new dynamic approach to measure intraocular pressure with solitary waves VL - 103 ID - 6220 ER - TY - JOUR AB - Introduction: Glucocorticoids have been used since 1948 for their anti-inflammatory and structural effects in various inflammatory diseases. The optimal use of glucocorticoids remains controversial. Patients may have a number of concerns about the effects of glucocorticoids. Many factors can adversely affect treatment adherence. Objectives: To evaluate the main adverse effects reported by patients and physicians, and to assess representations associated with glucocorticoid therapy and the underlying disease, via measurements of treatment adherence, with the goal of optimizing treatment strategies and improving patient information. Methods: From December 2011 to May 2012, we conducted two surveys in 125 patients receiving long-term glucocorticoid therapy and followed-up at the rheumatology department of the teaching hospital in Casablanca, Morocco, and in 85 hospital physicians in various specialties, respectively. Results: Mean glucocorticoid therapy duration was 6. years, mean maximal prescribed dosage was 44.87. mg/d, and 50.4% of the patients had inflammatory joint disease. Adverse neuropsychiatric effects were reported by 70 out of 125 (56%) patients. Weight gain was the adverse effect deemed most bothersome by the physicians, who significantly underestimated the occurrence of neuropsychiatric adverse effects (27% vs 56%, P= 0.034). Adherence was poor in 80 out of 125 (64%) patients, and 22 out of 125 (18%) patients reported episodes of treatment discontinuation. Conclusion: Prescribers underestimate the frequency of neuropsychiatric adverse effects of long-term systemic glucocorticoid therapy. Regular follow-up visits during treatment, with collection of systemic adverse effects might improve treatment adherence. AD - K. Nassar, 33, avenue du 2 Mars, residence Youssef, Casablanca, Morocco AU - Nassar, K. AU - Janani, S. AU - Roux, C. AU - Rachidi, W. AU - Etaouil, N. AU - Mkinsi, O. DB - Embase DO - 10.1016/j.jbspin.2013.07.001 IS - 1 KW - glucocorticoid acne adult amenorrhea anxiety disorder article asthenia cataract connective tissue disease corticosteroid therapy cross-sectional study depression dermatomyositis diabetes mellitus drowsiness dyslipidemia eating habit female follow up fracture glaucoma headache health care survey heartburn hirsutism hospital physician human hyperhidrosis insomnia irritability leg edema lipodystrophy major clinical study male medical specialist medication compliance middle aged Morocco myopathy osteoporosis overlap syndrome patient compliance patient information persecutory delusion physician attitude recurrent infection rheumatoid arthritis sarcoidosis scleroderma side effect skin contusion stomach pain stria suicide attempt systemic lupus erythematosus systemic therapy teaching hospital treatment duration tremor vasculitis body weight gain xerostomia LA - English M3 - Article N1 - L605195150 2015-07-20 2015-07-21 PY - 2014 SN - 1778-7254 1297-319X SP - 64-68 ST - Long-term systemic glucocorticoid therapy: Patients' representations, prescribers' perceptions, and treatment adherence T2 - Joint Bone Spine TI - Long-term systemic glucocorticoid therapy: Patients' representations, prescribers' perceptions, and treatment adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605195150&from=export http://dx.doi.org/10.1016/j.jbspin.2013.07.001 VL - 81 ID - 2941 ER - TY - JOUR AB - Introduction: Glucocorticoids have been used since 1948 for their anti-inflammatory and structural effects in various inflammatory diseases. The optimal use of glucocorticoids remains controversial. Patients may have a number of concerns about the effects of glucocorticoids. Many factors can adversely affect treatment adherence. Objectives: To evaluate the main adverse effects reported by patients and physicians, and to assess representations associated with glucocorticoid therapy and the underlying disease, via measurements of treatment adherence, with the goal of optimizing treatment strategies and improving patient information. Methods: From December 2011 to May 2012, we conducted two surveys in 125 patients receiving long-term glucocorticoid therapy and followed-up at the rheumatology department of the teaching hospital in Casablanca, Morocco, and in 85 hospital physicians in various specialties, respectively. Results: Mean glucocorticoid therapy duration was 6. years, mean maximal prescribed dosage was 44.87. mg/d, and 50.4% of the patients had inflammatory joint disease. Adverse neuropsychiatric effects were reported by 70 out of 125 (56%) patients. Weight gain was the adverse effect deemed most bothersome by the physicians, who significantly underestimated the occurrence of neuropsychiatric adverse effects (27% vs 56%, P=0.034). Adherence was poor in 80 out of 125 (64%) patients, and 22 out of 125 (18%) patients reported episodes of treatment discontinuation. Conclusion: Prescribers underestimate the frequency of neuropsychiatric adverse effects of long-term systemic glucocorticoid therapy. Regular follow-up visits during treatment, with collection of systemic adverse effects might improve treatment adherence. © 2013 Société française de rhumatologie. AD - Service de rhumatologie, Centre hospitalier universitaire Ibn Rochd, Faculté de médecine et de pharmacie, Casablanca, Morocco Service de rhumatologie B, HÔpital Cochin, Université Paris-Descartes, Paris, France AU - Nassar, K. AU - Janani, S. AU - Roux, C. AU - Rachidi, W. AU - Etaouil, N. AU - Mkinsi, O. DB - Scopus DO - 10.1016/j.jbspin.2013.07.001 IS - 1 KW - Adverse effects Glucocorticoids Inflammatory disease Treatment adherence M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2014 SP - 64-68 ST - Long-term systemic glucocorticoid therapy: Patients' representations, prescribers' perceptions, and treatment adherence T2 - Joint Bone Spine TI - Long-term systemic glucocorticoid therapy: Patients' representations, prescribers' perceptions, and treatment adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893727533&doi=10.1016%2fj.jbspin.2013.07.001&partnerID=40&md5=2869a4d9fe270f478f80cb539a0ceb37 VL - 81 ID - 5281 ER - TY - JOUR AB - The Hispanic population is the United States’ largest minority and one of the fastest growing as well. In the next 30 to 40 years, the proportion of open-angle glaucoma patients represented by Hispanics is expected to dramatically rise. Here we examine the unique considerations and challenges of glaucoma care in this population, from demographics to risk factors to treatments and outcomes. Currently, access to care and the under-diagnosis of glaucoma in this population are significant issues that look only to grow in significance as the glaucoma burden continues to grow. Additionally, utilization of medical and surgical therapy remains lower in Hispanics than in many other ethnic groups. Understanding and proactively addressing the unique challenges in the screening and treatment of Hispanics will be of utmost importance to providing effective care to this population. AD - Department of Ophthalmology, Vanderbilt University, Nashville, TN, USA AN - 118941197. Language: English. Entry Date: 20170212. Revision Date: 20190514. Publication Type: journal article AU - Nathan, Niraj AU - Joos, Karen M. DB - ccm DO - 10.3109/08820538.2016.1154165 DP - EBSCOhost IS - 4 KW - Hispanic Americans -- Statistics and Numerical Data Health Status Disparities Glaucoma -- Ethnology Health Services Accessibility -- Statistics and Numerical Data Glaucoma -- Therapy Risk Factors Health Services -- Utilization N1 - review. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8610759. PMID: NLM27128326. PY - 2016 SN - 0882-0538 SP - 394-399 ST - Glaucoma Disparities in the Hispanic Population T2 - Seminars in Ophthalmology TI - Glaucoma Disparities in the Hispanic Population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118941197&site=ehost-live&scope=site VL - 31 ID - 4543 ER - TY - JOUR AB - PURPOSE: To determine the socioeconomic impact of long-term glaucoma therapy. MATERIALS AND METHODS: One hundred and fifty consecutive glaucoma patients on medical therapy, following up at our glaucoma service for at least 6 months were recruited. A questionnaire regarding monthly income, cost of glaucoma medications prescribed, availability of medications, travel time, time spent in review clinics, compliance, education status, medical insurance and systemic or local side-effects was administered. RESULTS: The patients seen at the tertiary government hospital had an average monthly income of Rs. 10,912/- (range: Rs. 500/- to Rs. 50,000/-) with approximately 56% of the patients having an income of less than Rs. 5000/month. The expenditure on anti-glaucoma medications ranged from 0.3% in high income group to 123% of their monthly gross income in low income group (P < 0.0001). The total expenditure including travel, stay, and loss of wages of patients and accompanying persons ranged from 1.6% in high income group to 137% of the monthly income in low income group (P < 0.0001). Mean time required for a glaucoma clinic visit was 15.66 h, (range: 6-96 h/month). About 2.7% experienced systemic side-effects and 21.3% had complaints of ocular adverse effects. About 90% of the patients were compliant. 92% were not covered by any insurance plan/government reimbursement for their treatment. CONCLUSIONS: Medical therapy for glaucoma is an economic burden to many patients and should be individualized, according to the socioeconomic status, availability of drugs and the required distance to travel to reach the specialist clinics. AU - Nayak, B. AU - Gupta, S. AU - Kumar, G. AU - Dada, T. AU - Gupta, V. AU - Sihota, R. DB - Medline DO - 10.4103/0301-4738.151458 IS - 1 KW - antihypertensive agent adult aged economics follow up glaucoma health care cost human incidence income India middle aged patient compliance physiology poverty prognosis questionnaire socioeconomics statistics and numerical data time factor trends very elderly visual acuity young adult LA - English M3 - Article N1 - L615364485 2017-04-19 PY - 2015 SN - 1998-3689 SP - 20-24 ST - Socioeconomics of long-term glaucoma therapy in India T2 - Indian journal of ophthalmology TI - Socioeconomics of long-term glaucoma therapy in India UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615364485&from=export http://dx.doi.org/10.4103/0301-4738.151458 VL - 63 ID - 2866 ER - TY - JOUR AB - Purpose: To determine the socioeconomic impact of long-term glaucoma therapy.Materials and Methods: One hundred and fifty consecutive glaucoma patients on medical therapy, following up at our glaucoma service for at least 6 months were recruited. A questionnaire regarding monthly income, cost of glaucoma medications prescribed, availability of medications, travel time, time spent in review clinics, compliance, education status, medical insurance and systemic or local side-effects was administered.Results: The patients seen at the tertiary government hospital had an average monthly income of Rs. 10,912/- (range: Rs. 500/- to Rs. 50,000/-) with approximately 56% of the patients having an income of less than Rs. 5000/month. The expenditure on anti-glaucoma medications ranged from 0.3% in high income group to 123% of their monthly gross income in low income group (P < 0.0001). The total expenditure including travel, stay, and loss of wages of patients and accompanying persons ranged from 1.6% in high income group to 137% of the monthly income in low income group (P < 0.0001). Mean time required for a glaucoma clinic visit was 15.66 h, (range: 6-96 h/month). About 2.7% experienced systemic side-effects and 21.3% had complaints of ocular adverse effects. About 90% of the patients were compliant. 92% were not covered by any insurance plan/government reimbursement for their treatment.Conclusions: Medical therapy for glaucoma is an economic burden to many patients and should be individualized, according to the socioeconomic status, availability of drugs and the required distance to travel to reach the specialist clinics. AN - 109701880. Language: English. Entry Date: 20150923. Revision Date: 20170104. Publication Type: journal article. Journal Subset: Asia AU - Nayak, Bhagabat AU - Gupta, Shikha AU - Kumar, Guresh AU - Dada, Tanuj AU - Gupta, Viney AU - Sihota, Ramanjit DB - ccm DO - 10.4103/0301-4738.151458 DP - EBSCOhost IS - 1 N1 - Biomedical; Peer Reviewed. NLM UID: 0405376. PMID: NLM25686057. PY - 2015 SN - 0301-4738 SP - 20-24 ST - Socioeconomics of long-term glaucoma therapy in India T2 - Indian Journal of Ophthalmology TI - Socioeconomics of long-term glaucoma therapy in India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109701880&site=ehost-live&scope=site VL - 63 ID - 4319 ER - TY - JOUR AB - Purpose: To determine the socioeconomic impact of long-term glaucoma therapy. Materials and Methods: One hundred and fifty consecutive glaucoma patients on medical therapy, following up at our glaucoma service for at least 6 months were recruited. A questionnaire regarding monthly income, cost of glaucoma medications prescribed, availability of medications, travel time, time spent in review clinics, compliance, education status, medical insurance and systemic or local side-effects was administered. Results: The patients seen at the tertiary government hospital had an average monthly income of Rs. 10,912/- (range: Rs. 500/- to Rs. 50,000/-) with approximately 56% of the patients having an income of less than Rs. 5000/month. The expenditure on anti-glaucoma medications ranged from 0.3% in high income group to 123% of their monthly gross income in low income group (P < 0.0001). The total expenditure including travel, stay, and loss of wages of patients and accompanying persons ranged from 1.6% in high income group to 137% of the monthly income in low income group (P < 0.0001). Mean time required for a glaucoma clinic visit was 15.66 h, (range: 6-96 h/month). About 2.7% experienced systemic side-effects and 21.3% had complaints of ocular adverse effects. About 90% of the patients were compliant. 92% were not covered by any insurance plan/government reimbursement for their treatment. Conclusions: Medical therapy for glaucoma is an economic burden to many patients and should be individualized, according to the socioeconomic status, availability of drugs and the required distance to travel to reach the specialist clinics. © 2015, MEDKNOW. All rights reserved. AD - Glaucoma Research Facility and Clinical Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India Department of Biostatistics, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India AU - Nayak, B. AU - Gupta, S. AU - Kumar, G. AU - Dada, T. AU - Gupta, V. AU - Sihota, R. DB - Scopus DO - 10.4103/0301-4738.151458 IS - 1 KW - Chronic glaucoma patients economic burden socioeconomic profile M3 - Article N1 - Cited By :15 Export Date: 19 July 2021 PY - 2015 SP - 20-24 ST - Socioeconomics of long-term glaucoma therapy in India T2 - Indian Journal of Ophthalmology TI - Socioeconomics of long-term glaucoma therapy in India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923517168&doi=10.4103%2f0301-4738.151458&partnerID=40&md5=54f34e7a33841389935b094e8eb84271 VL - 63 ID - 5189 ER - TY - JOUR AB - Purpose: To determine the socioeconomic impact of long-term glaucoma therapy. Materials and Methods: One hundred and fifty consecutive glaucoma patients on medical therapy, following up at our glaucoma service for at least 6 months were recruited. A questionnaire regarding monthly income, cost of glaucoma medications prescribed, availability of medications, travel time, time spent in review clinics, compliance, education status, medical insurance and systemic or local side-effects was administered. Results: The patients seen at the tertiary government hospital had an average monthly income of Rs. 10,912/- (range: Rs. 500/- to Rs. 50,000/-) with approximately 56% of the patients having an income of less than Rs. 5000/month. The expenditure on anti-glaucoma medications ranged from 0.3% in high income group to 123% of their monthly gross income in low income group (P < 0.0001). The total expenditure including travel, stay, and loss of wages of patients and accompanying persons ranged from 1.6% in high income group to 137% of the monthly income in low income group (P < 0.0001). Mean time required for a glaucoma clinic visit was 15.66 h, (range: 6-96 h/month). About 2.7% experienced systemic side-effects and 21.3% had complaints of ocular adverse effects. About 90% of the patients were compliant. 92% were not covered by any insurance plan/government reimbursement for their treatment. Conclusions: Medical therapy for glaucoma is an economic burden to many patients and should be individualized, according to the socioeconomic status, availability of drugs and the required distance to travel to reach the specialist clinics. AN - WOS:000350110500005 AU - Nayak, B. AU - Gupta, S. AU - Kumar, G. AU - Dada, T. AU - Gupta, V. AU - Sihota, R. DA - JAN DO - 10.4103/0301-4738.151458 IS - 1 PY - 2015 SN - 0301-4738 1998-3689 SP - 20-24 ST - Socioeconomics of long-term glaucoma therapy in India T2 - INDIAN JOURNAL OF OPHTHALMOLOGY TI - Socioeconomics of long-term glaucoma therapy in India VL - 63 ID - 5942 ER - TY - JOUR AB - Purpose of review: Glaucoma is one of the leading causes of irreversible blindness worldwide. Early glaucoma detection and treatment are currently the only known methods for preventing blindness and low vision resulting from this frequently asymptomatic disease. Recent findings: New technologies for detecting early glaucomatous damage are important in diagnosing optic nerve disease, not only in community screening settings but also in clinics. Imaging of the optic nerve head and macula and retinal nerve fiber layer analysis can provide quick, automated, and quantitative measurements in agreement with clinical estimates of optic disc structure and visual function. In the area of perimetry, frequency-doubling technology is a promising and feasible mass-screening method with reasonable sensitivity for detecting visual field loss. Central corneal thickness has emerged as a new risk factor for the development and progression of glaucoma, thereby complicating the role of tonometry and measurement of intraocular pressure as screening parameters for glaucoma. Along with technological advances, strides are also being made with public policy and legislative efforts to bring glaucoma onto the national and global health care agenda. These initiatives incorporate vision-screening goals into national disease prevention programs emphasizing the need for early glaucoma detection and treatment. Summary: Glaucoma awareness needs to be increased through better education, and compliance with follow-up care needs to be improved to decrease the economic and social costs from glaucoma. In addition, screening models need to be developed that will be effective in developing countries where the risk of blindness from glaucoma is highest. © 2006 Lippincott Williams & Wilkins. AD - R.K. Lee, Department of Ophthalmology, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136, United States AU - Nduaguba, C. AU - Lee, R. K. DB - Embase Medline DO - 10.1097/01.icu.0000193088.75432.c9 IS - 2 KW - automation awareness clinical assessment closed angle glaucoma cornea cornea thickness disease course disease model early diagnosis early intervention economic aspect feasibility study follow up frequency analysis functional assessment genetic screening glaucoma health care health care cost health care policy health center health education human imaging intraocular pressure law mass screening measurement nerve fiber optic disk optic nerve disease parameters pathogenesis patient compliance perimetry practice guideline prevalence priority journal prophylaxis public health quantitative analysis retina macula lutea retina nerve cell review risk assessment risk factor sensitivity analysis social aspect technology tonometry vision visual field visual impairment LA - English M3 - Review N1 - L43790810 2006-06-07 PY - 2006 SN - 1040-8738 SP - 142-152 ST - Glaucoma screening: Current trends, economic issues, technology, and challenges T2 - Current Opinion in Ophthalmology TI - Glaucoma screening: Current trends, economic issues, technology, and challenges UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43790810&from=export http://dx.doi.org/10.1097/01.icu.0000193088.75432.c9 VL - 17 ID - 3618 ER - TY - JOUR AB - PURPOSE OF REVIEW: Glaucoma is one of the leading causes of irreversible blindness worldwide. Early glaucoma detection and treatment are currently the only known methods for preventing blindness and low vision resulting from this frequently asymptomatic disease. RECENT FINDINGS: New technologies for detecting early glaucomatous damage are important in diagnosing optic nerve disease, not only in community screening settings but also in clinics. Imaging of the optic nerve head and macula and retinal nerve fiber layer analysis can provide quick, automated, and quantitative measurements in agreement with clinical estimates of optic disc structure and visual function. In the area of perimetry, frequency-doubling technology is a promising and feasible mass-screening method with reasonable sensitivity for detecting visual field loss. Central corneal thickness has emerged as a new risk factor for the development and progression of glaucoma, thereby complicating the role of tonometry and measurement of intraocular pressure as screening parameters for glaucoma. Along with technological advances, strides are also being made with public policy and legislative efforts to bring glaucoma onto the national and global health care agenda. These initiatives incorporate vision-screening goals into national disease prevention programs emphasizing the need for early glaucoma detection and treatment. SUMMARY: Glaucoma awareness needs to be increased through better education, and compliance with follow-up care needs to be improved to decrease the economic and social costs from glaucoma. In addition, screening models need to be developed that will be effective in developing countries where the risk of blindness from glaucoma is highest. AD - Scheie Eye Institute, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA. AN - 104987708. Language: English. Entry Date: 20110218. Revision Date: 20150711. Publication Type: Journal Article AU - Nduaguba, Constance AU - Lee, Richard K. DB - ccm DO - 10.1097/01.icu.0000193088.75432.c9 DP - EBSCOhost IS - 2 KW - Glaucoma -- Diagnosis Technology, Medical Vision Screening -- Economics Vision Screening -- Methods Blindness -- Prevention and Control Corneal Diseases -- Diagnosis Glaucoma -- Complications Glaucoma -- Education Glaucoma -- Prevention and Control Ophthalmology Optic Nerve Diseases -- Diagnosis Patient Education Perimetry -- Methods Retina -- Anatomy and Histology Vision Tests -- Methods N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM16552249. PY - 2006 SN - 1040-8738 SP - 142-152 ST - Glaucoma screening: current trends, economic issues, technology, and challenges T2 - Current Opinion in Ophthalmology TI - Glaucoma screening: current trends, economic issues, technology, and challenges UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104987708&site=ehost-live&scope=site VL - 17 ID - 4706 ER - TY - JOUR AB - Purpose of review: Glaucoma is one of the leading causes of irreversible blindness worldwide. Early glaucoma detection and treatment are currently the only known methods for preventing blindness and low vision resulting from this frequently asymptomatic disease. Recent findings: New technologies for detecting early glaucomatous damage are important in diagnosing optic nerve disease, not only in community screening settings but also in clinics. Imaging of the optic nerve head and macula and retinal nerve fiber layer analysis can provide quick, automated, and quantitative measurements in agreement with clinical estimates of optic disc structure and visual function. In the area of perimetry, frequency-doubling technology is a promising and feasible mass-screening method with reasonable sensitivity for detecting visual field loss. Central corneal thickness has emerged as a new risk factor for the development and progression of glaucoma, thereby complicating the role of tonometry and measurement of intraocular pressure as screening parameters for glaucoma. Along with technological advances, strides are also being made with public policy and legislative efforts to bring glaucoma onto the national and global health care agenda. These initiatives incorporate vision-screening goals into national disease prevention programs emphasizing the need for early glaucoma detection and treatment. Summary: Glaucoma awareness needs to be increased through better education, and compliance with follow-up care needs to be improved to decrease the economic and social costs from glaucoma. In addition, screening models need to be developed that will be effective in developing countries where the risk of blindness from glaucoma is highest. © 2006 Lippincott Williams & Wilkins. AD - Scheie Eye Institute, University of Pennsylvania Health System, Philadelphia, PA, United States Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, United States Department of Ophthalmology, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136, United States AU - Nduaguba, C. AU - Lee, R. K. DB - Scopus DO - 10.1097/01.icu.0000193088.75432.c9 IS - 2 KW - Blindness Glaucoma screening Vision loss Vision screening M3 - Review N1 - Cited By :28 Export Date: 19 July 2021 PY - 2006 SP - 142-152 ST - Glaucoma screening: Current trends, economic issues, technology, and challenges T2 - Current Opinion in Ophthalmology TI - Glaucoma screening: Current trends, economic issues, technology, and challenges UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646902382&doi=10.1097%2f01.icu.0000193088.75432.c9&partnerID=40&md5=f59b373f0675338ec1ebf1a324144fc8 VL - 17 ID - 5075 ER - TY - JOUR AB - Purpose of review Glaucoma is one of the leading causes of irreversible blindness worldwide. Early glaucoma detection and treatment are currently the only known methods for preventing blindness and low vision resulting from this frequently asymptomatic disease. Recent findings New technologies for detecting early glaucomatous damage are important in diagnosing optic nerve disease, not only in community screening settings but also in clinics. Imaging of the optic nerve head and macula and retinal nerve fiber layer analysis can provide quick, automated, and quantitative measurements in agreement with clinical estimates of optic disc structure and visual function. In the area of perimetry, frequency-doubling. technology is a promising and feasible mass-screening method with reasonable sensitivity for detecting visual field loss. Central corneal thickness has emerged as a new risk factor for the development and progression of glaucoma, thereby complicating the role of tonometry and measurement of intraocular pressure as screening parameters for glaucoma. Along with technological advances, strides are also, being made with public policy and legislative efforts to bring glaucoma onto the national and global health care agenda. These initiatives incorporate vision-screening goals into national disease prevention programs emphasizing the need for early glaucoma detection and treatment. Summary Glaucoma awareness needs to be increased through better education, and compliance with follow-up care needs to be improved to decrease the economic and social costs from glaucoma. In addition, screening models need to be developed that will be effective in developing countries where the risk of blindness from glaucoma is highest. AN - WOS:000237895800006 AU - Nduaguba, C. AU - Lee, R. K. DA - APR DO - 10.1097/01.icu.0000193088.75432.c9 IS - 2 PY - 2006 SN - 1040-8738 1531-7021 SP - 142-152 ST - Glaucoma screening: current trends, economic issues, technology, and challenges T2 - CURRENT OPINION IN OPHTHALMOLOGY TI - Glaucoma screening: current trends, economic issues, technology, and challenges VL - 17 ID - 6046 ER - TY - JOUR AB - Glaucoma is a progressive, chronic optic neuropathy characterized by a typical visual field defects. Four main classes of topical medication are actually available on the market: beta-blockers, prostaglandins, alpha2-agonists, and topical carbonic anhydrase inhibitor to treat intraocular pressure (IOP). The aim of this review is to outline the efficacy of timolol and to evaluate the impact of this treatment on patients' quality of life. Among beta-blockers, timolol is most used at three different concentrations: 0.1%, 0.25%, and 0.5%. While the first one is a gel, the other two products are solution. Timolol has few topical side effects, while it has some important systemic side effects on the cardiac and respiratory systems. The balance between efficacy and safety is always the main aspect to care patients. Because of the less efficacy of timolol 0.1% solution, the possibility to use carbomers as vehicle in the gel drops helped timolol 0.1 to be used in clinics, extending the time contact between the active ingredient and the surface of the cornea. Using preservative-free timolol 0.1 for treatment, IOP was at the same level of the other beta-blockers at higher concentration, but it was better tolerated. Preservative-free treatment improved the quality of life reducing dry-eye like symptoms; furthermore, the presence of an artificial tear in the medication bottle could help adherence. The once daily dosing improves compliance. AD - Anatomical-Clinical Laboratory for Functional Diagnosis and Treatment of Glaucoma and Neuro-ophthalmology, Eye Clinic, DiNOGMI, University of Genoa, Genoa, Italy Department of Ophthalmology, IIS-Aragon, Miguel Servet University Hospital, University of Zaragoza, Zaragoza, Spain AN - 136199416. Language: English. Entry Date: 20190507. Revision Date: 20191029. Publication Type: Article AU - Negri, Letizia AU - Ferreras, Antonio AU - Iester, Michele DB - ccm DO - 10.1155/2019/4146124 DP - EBSCOhost KW - Glaucoma -- Drug Therapy Timolol -- Therapeutic Use Quality of Life -- Evaluation Drug Tolerance -- Evaluation Timolol -- Administration and Dosage Patient Safety Intraocular Pressure -- Evaluation Medication Compliance N1 - review. Journal Subset: Biomedical; USA. NLM UID: 101524199. PY - 2019 SN - 2090-004X SP - 1-12 ST - Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life T2 - Journal of Ophthalmology TI - Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136199416&site=ehost-live&scope=site ID - 4406 ER - TY - JOUR AB - Medial canthus sinonasal fistula is associated with troublesome aesthetic and functional issues. Corneal irritation and drying results from escape of both air and secretions from the nasal cavity across the ocular surface as well as misting of spectacles if worn. Reconstruction of such fistulae is associated with a high rate of recurrence and thus presents a difficult surgical challenge. Methods: This paper describes the senior author's surgical approach to manage medial canthus sinonasal fistulae utilizing an interpolated forehead flap combined with extended galeafrontalis and pericranial flap for stepped closure. The technique of flap elevation and inset is discussed, with emphasis on key manoeuvres to prevent sinus recurrence. A retrospective review of consecutive cases is presented. Results: Four patients were treated using this technique over 12 months. In all cases, fistulae developed following adjuvant radiotherapy for tumour resection. Flap elevation was performed in combination with a bicoronal approach in 2 patients and via direct forehead approach in 2 patients. No post-operative complications or recurrence of fistula have occurred over 12 months follow-up. Conclusion: The success of this technique is attributed to inclusion of a galeafrontalis and pericranial extension to the forehead flap. In addition, the fistula site must be prepared to accommodate the flap by dissection of a wide subcutaneous pocket. This stepped method of closure provides an effective barrier to air and nasal secretions and also achieves an excellent aesthetic outcome. (C) 2014 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved. AN - WOS:000339354900009 AU - Nelson, L. AU - Burke-Smith, A. AU - Kirkpatrick, N. DA - JUL DO - 10.1016/j.bjps.2014.03.015 IS - 7 PY - 2014 SN - 1748-6815 1878-0539 SP - 910-915 ST - A novel approach for successful closure of sinonasal fistulae T2 - JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY TI - A novel approach for successful closure of sinonasal fistulae VL - 67 ID - 5891 ER - TY - JOUR AU - Neroev, V. V. AU - Zolotarev, A. V. AU - Karlova, E. V. AU - Kiseleva, O. A. AU - Shishkin, M. M. AU - Germanova, V. N. DB - Medline DO - 10.17116/oftalma201913506142 IS - 6 KW - antihypertensive agent preservative human intraocular pressure open angle glaucoma patient compliance prospective study LA - Russian M3 - Article N1 - L630815038 2020-02-10 2020-02-18 PY - 2019 SN - 0042-465X SP - 42-51 ST - Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting T2 - Vestnik oftalmologii TI - Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630815038&from=export http://dx.doi.org/10.17116/oftalma201913506142 VL - 135 ID - 2554 ER - TY - JOUR AB - Background: The frequent systemic side effects associated with the use of systemic carbonic anhydrase inhibitors have adversely affected the compliance to treatment in glaucoma patients, obviating their long-term use. The introduction of the topical CAI dorzolamide has further reduced their use. However, the tolerability of dorzolamide in patients who have been intolerant to systemic CAIs has not been evaluated prospectively. Objectives: To study the tolerability and efficacy of dorzolamide (a topical CAI) in a selected group of glaucoma and ocular hypertensive patients who have been intolerant to systemic CAI. Methods: A 3 month prospective study was conducted in 39 patients. Following recruitment, patients were evaluated on the day of switching from systemic CAI to dorzolamide and for five more visits. The SF-36 health assessment questionnaire was used to evaluate changes in well-being and quality of life, and the intraocular pressure was measured periodically. Results: Within 4 weeks of switching from systemic CAI to dorzolamide, the mean health assessment scores improved significantly in seven of the eight categories of the SF-36, and remained generally unchanged for the rest of the study. No significant differences were noted between the mean IOP on day 0 and the following measurements throughout the 84 days of dorzolamide therapy. Conclusion: In glaucoma patients who were intolerant to systemic CAI, topical CAI dorzolamide offers a similar efficacy and better tolerability. AD - Glaucoma Service, Dept. of Ophthalmology, Sapir Medical Center, Kfar Saba 44281, Israel Glaucoma Service, Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel Hebrew University, Hadassah Medical School, Jerusalem, Israel AU - Nesher, R. AU - Ticho, U. DB - Scopus IS - 4 KW - Carbonic anhydrase inhibitors Dorzolamide Glaucoma Health assessment questionnaire Quality of life M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2003 SP - 260-263 ST - Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: Effect on the quality of life of glaucoma patients with drug-related side effects T2 - Israel Medical Association Journal TI - Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: Effect on the quality of life of glaucoma patients with drug-related side effects UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038134974&partnerID=40&md5=db76c96e01a710f74923a624212b34d0 VL - 5 ID - 5267 ER - TY - JOUR AB - Background: The frequent systemic side effects associated with the use of systemic carbonic anhydrase inhibitors have adversely affected the compliance to treatment in glaucoma patients, obviating their long-term use. The introduction of the topical CAI dorzolamide has further reduced their use. However, the tolerability of dorzolamide in patients who have been intolerant to systemic CAIs has not been evaluated prospectively. Objectives: To study the tolerability and efficacy of dorzolamide (a topical CAI) in a selected group of glaucoma and ocular hypertensive patients who have been intolerant to systemic CAI. Methods: A 3 month prospective study was conducted in 39 patients. Following recruitment, patients were evaluated on the day of switching from systemic CAI to dorzolamide and for five more visits. The SF-36 health assessment questionnaire was used to evaluate changes in well-being and quality of life, and the intraocular pressure was measured periodically. Results: Within 4 weeks of switching from systemic CAI to dorzolamide, the mean health assessment scores improved significantly in seven of the eight categories of the SF-36, and remained generally unchanged for the rest of the study. No significant differences were noted between the mean IOP on day 0 and the following measurements throughout the 84 days of dorzolamide therapy. Conclusion: In glaucoma patients who were intolerant to systemic CAI, topical CAI dorzolamide offers a similar efficacy and better tolerability. AN - WOS:000183080800006 AU - Nesher, R. AU - Ticho, U. DA - APR IS - 4 PY - 2003 SN - 1565-1088 SP - 260-263 ST - Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: Effect on the quality of life of glaucoma patients with drug-related side effects T2 - ISRAEL MEDICAL ASSOCIATION JOURNAL TI - Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: Effect on the quality of life of glaucoma patients with drug-related side effects VL - 5 ID - 6267 ER - TY - JOUR AB - With the increasing success of liver transplantation in children, a growing number of children are reaching an age when it is no longer appropriate for them to be followed by paediatricians. Clinicians looking after these liver allograft recipients need to be aware of the additional problems and needs in this group of young patients.While life after transplantation is usually near normal, a proportion of adolescents suffer from physical and psychological stresses that may result in social and behavioural problems. Non-compliance can have a major adverse impact on graft function. Immunosuppression needs to be adjusted to maintain good graft function, but also to keep to a minimum the adverse effects including renal failure and malignancy. The adverse cosmetic effects of some immunosuppressive drugs can be particularly troublesome at this stage in life.Overall, adolescent liver allograft recipients can have an excellent quality of life. Health care professionals need to be aware of the additional problems that this group of patients may have and they will need to adapt the follow-up in response to these issues. AD - Department of Medicine, Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, United Kingdom AU - Neuberger, J. M. DB - Scopus DO - 10.1016/S1521-6918(02)00144-0 IS - 2 KW - Adolescents Liver transplantation Non-compliance Quality of life M3 - Review N1 - Cited By :5 Export Date: 19 July 2021 PY - 2003 SP - 277-289 ST - Liver transplantation T2 - Bailliere's Best Practice and Research in Clinical Gastroenterology TI - Liver transplantation UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0347353497&doi=10.1016%2fS1521-6918%2802%2900144-0&partnerID=40&md5=2997e45197f9d3c9175b23b1ac84458f VL - 17 ID - 5436 ER - TY - JOUR AB - Purpose To assess longer-term patterns of glaucoma medication adherence and identify whether patterns established during the first year of medication use persist during 3 subsequent years of follow-up. Design Retrospective, longitudinal cohort analysis. Participants Beneficiaries aged 40 years who were enrolled in a United States (US)-managed care plan for 7 years between 2001 and 2012 and newly diagnosed and treated for open-angle glaucoma. Methods For each enrollee, we quantified medication adherence using the medication possession ratio. Group-based trajectory modeling (GBTM) was applied to identify patterns of adherence for 1 and 4 years of follow-up. The percent of beneficiaries who remained in the same trajectory group in the 1- and 4-year models was tabulated to evaluate group stability. Factors impacting adherence at 1 and 4 years were identified using regression analyses. Main Outcome Measures Patterns of glaucoma medication adherence. Results Of the 1234 eligible beneficiaries, GBTM identified 5 distinct glaucoma medication adherence patterns in both the 1-year and 4-year follow-up periods. These groups were as follows: (1) never adherent after their index prescription fill (7.5% and 15.6% of persons in the 1- and 4-year models, respectively); (2) persistently very poor adherence (14.9% and 23.4% of persons in the 1- and 4-year models, respectively); (3) declining adherence (9.5% and 9.1% of persons in the 1- and 4-year models, respectively); (4) persistently moderate adherence (48.1% and 37.0% of persons in the 1- and 4-year models, respectively); and (5) persistently good adherence (20.0% and 15.0% of persons in the 1- and 4-year models, respectively). More than 90% of beneficiaries in the 4 groups with the worst and best adherence patterns (groups 1, 2, 3, 5) maintained their patterns from their first year throughout their 4 years of follow-up. Those with persistently moderate adherence (group 4), the largest group, were most likely to change groups from 1 to 4 years of follow-up. Persons with the best adherence over 4 years were more likely to be white, to be older, to earn >$60 000/year, and to have more eye care visits (P < 0.05 for all comparisons). Those with a higher initial copayment cost had lower adherence rates (β = -0.06/dollar, P = 0.03). Conclusions For most patients who were newly prescribed glaucoma medications, adherence patterns observed in the first year of treatment reflect adherence patterns over the subsequent 3 years. Investing resources in both identifying and helping patients with suboptimal adherence patterns over the first year may have a large impact on longer-term adherence. AD - P.A. Newman-Casey, Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, W.K. Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Blachley, T. AU - Lee, P. P. AU - Heisler, M. AU - Farris, K. B. AU - Stein, J. D. DB - Embase Medline DO - 10.1016/j.ophtha.2015.06.039 IS - 10 KW - alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor miotic agent prostaglandin derivative adult article Black person cohort analysis drug cost eye care female follow up glaucoma group based trajectory modeling health care cost human income longitudinal study major clinical study male managed care medication compliance model open angle glaucoma patient attitude patient compliance prescription priority journal quantitative analysis United States LA - English M3 - Article N1 - L605790362 2015-09-02 2015-10-19 PY - 2015 SN - 1549-4713 0161-6420 SP - 2010-2021 ST - Patterns of glaucoma medication adherence over four years of follow-up T2 - Ophthalmology TI - Patterns of glaucoma medication adherence over four years of follow-up UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605790362&from=export http://dx.doi.org/10.1016/j.ophtha.2015.06.039 VL - 122 ID - 2856 ER - TY - JOUR AB - Purpose To assess longer-term patterns of glaucoma medication adherence and identify whether patterns established during the first year of medication use persist during 3 subsequent years of follow-up. Design Retrospective, longitudinal cohort analysis. Participants Beneficiaries aged 40 years who were enrolled in a United States (US)-managed care plan for 7 years between 2001 and 2012 and newly diagnosed and treated for open-angle glaucoma. Methods For each enrollee, we quantified medication adherence using the medication possession ratio. Group-based trajectory modeling (GBTM) was applied to identify patterns of adherence for 1 and 4 years of follow-up. The percent of beneficiaries who remained in the same trajectory group in the 1- and 4-year models was tabulated to evaluate group stability. Factors impacting adherence at 1 and 4 years were identified using regression analyses. Main Outcome Measures Patterns of glaucoma medication adherence. Results Of the 1234 eligible beneficiaries, GBTM identified 5 distinct glaucoma medication adherence patterns in both the 1-year and 4-year follow-up periods. These groups were as follows: (1) never adherent after their index prescription fill (7.5% and 15.6% of persons in the 1- and 4-year models, respectively); (2) persistently very poor adherence (14.9% and 23.4% of persons in the 1- and 4-year models, respectively); (3) declining adherence (9.5% and 9.1% of persons in the 1- and 4-year models, respectively); (4) persistently moderate adherence (48.1% and 37.0% of persons in the 1- and 4-year models, respectively); and (5) persistently good adherence (20.0% and 15.0% of persons in the 1- and 4-year models, respectively). More than 90% of beneficiaries in the 4 groups with the worst and best adherence patterns (groups 1, 2, 3, 5) maintained their patterns from their first year throughout their 4 years of follow-up. Those with persistently moderate adherence (group 4), the largest group, were most likely to change groups from 1 to 4 years of follow-up. Persons with the best adherence over 4 years were more likely to be white, to be older, to earn >$60 000/year, and to have more eye care visits (P < 0.05 for all comparisons). Those with a higher initial copayment cost had lower adherence rates (β = -0.06/dollar, P = 0.03). Conclusions For most patients who were newly prescribed glaucoma medications, adherence patterns observed in the first year of treatment reflect adherence patterns over the subsequent 3 years. Investing resources in both identifying and helping patients with suboptimal adherence patterns over the first year may have a large impact on longer-term adherence. © 2015 American Academy of Ophthalmology. AD - Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, W.K. Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI 48105, United States University of Michigan, Institute for Health Care Policy and Innovation, Ann Arbor, MI, United States Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States School of Pharmacy, University of Michigan, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Blachley, T. AU - Lee, P. P. AU - Heisler, M. AU - Farris, K. B. AU - Stein, J. D. DB - Scopus DO - 10.1016/j.ophtha.2015.06.039 IS - 10 M3 - Article N1 - Cited By :46 Export Date: 19 July 2021 PY - 2015 SP - 2010-2021 ST - Patterns of glaucoma medication adherence over four years of follow-up T2 - Ophthalmology TI - Patterns of glaucoma medication adherence over four years of follow-up UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943449095&doi=10.1016%2fj.ophtha.2015.06.039&partnerID=40&md5=4030cf4ef4b28d740a1220ebc0d93ac6 VL - 122 ID - 5005 ER - TY - JOUR AB - Purpose: To assess longer-term patterns of glaucoma medication adherence and identify whether patterns established during the first year of medication use persist during 3 subsequent years of follow-up. Design: Retrospective, longitudinal cohort analysis. Participants: Beneficiaries aged >= 40 years who were enrolled in a United States (US)-managed care plan for >= 7 years between 2001 and 2012 and newly diagnosed and treated for open-angle glaucoma. Methods: For each enrollee, we quantified medication adherence using the medication possession ratio. Group-based trajectory modeling (GBTM) was applied to identify patterns of adherence for 1 and 4 years of follow-up. The percent of beneficiaries who remained in the same trajectory group in the 1- and 4-year models was tabulated to evaluate group stability. Factors impacting adherence at 1 and 4 years were identified using regression analyses. Main Outcome Measures: Patterns of glaucoma medication adherence. Results: Of the 1234 eligible beneficiaries, GBTM identified 5 distinct glaucoma medication adherence patterns in both the 1-year and 4-year follow-up periods. These groups were as follows: (1) never adherent after their index prescription fill (7.5% and 15.6% of persons in the 1- and 4-year models, respectively); (2) persistently very poor adherence (14.9% and 23.4% of persons in the 1- and 4-year models, respectively); (3) declining adherence (9.5% and 9.1% of persons in the 1- and 4-year models, respectively); (4) persistently moderate adherence (48.1% and 37.0% of persons in the 1- and 4-year models, respectively); and (5) persistently good adherence (20.0% and 15.0% of persons in the 1- and 4-year models, respectively). More than 90% of beneficiaries in the 4 groups with the worst and best adherence patterns (groups 1, 2, 3, 5) maintained their patterns from their first year throughout their 4 years of follow-up. Those with persistently moderate adherence (group 4), the largest group, were most likely to change groups from 1 to 4 years of follow-up. Persons with the best adherence over 4 years were more likely to be white, to be older, to earn >$60 000/year, and to have more eye care visits (P < 0.05 for all comparisons). Those with a higher initial copayment cost had lower adherence rates (beta = -0.06/dollar, P = 0.03). Conclusions: For most patients who were newly prescribed glaucoma medications, adherence patterns observed in the first year of treatment reflect adherence patterns over the subsequent 3 years. Investing resources in both identifying and helping patients with suboptimal adherence patterns over the first year may have a large impact on longer-term adherence. (C) 2015 by the American Academy of Ophthalmology. AN - WOS:000363491500017 AU - Newman-Casey, P. A. AU - Blachley, T. AU - Lee, P. P. AU - Heisler, M. AU - Farris, K. B. AU - Stein, J. D. DA - OCT DO - 10.1016/j.ophtha.2015.06.039 IS - 10 PY - 2015 SN - 0161-6420 1549-4713 SP - 2010-2021 ST - Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up T2 - OPHTHALMOLOGY TI - Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up VL - 122 ID - 5877 ER - TY - JOUR AB - Purpose: To evaluate the current state of the research on educational interventions whose aim is to improve glaucoma medication adherence. Methods: A systematic review of Pubmed, Embase and CINAHL was conducted to identify research studies evaluating educational interventions to improve glaucoma medication adherence. Studies were included if the intervention was described, the outcomes assessed glaucoma medication adherence and the focus of the research was on adults with glaucoma. The search was conducted on June 2, 2015. Results: Seventeen studies were identified that met the inclusion criteria. These included nine randomized controlled trials and eight observational studies. Eight of the studies demonstrated an impact on glaucoma medication adherence, though their outcome measures were too heterogeneous to estimate a pooled effect size. Conclusion: The interventions that successfully improved glaucoma medication adherence used an adequate dose of face-to-face counseling to overcome barriers to health behavior change alongside education about glaucoma. AD - Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA Department of Ophthalmology, University of Maryland, Baltimore, MD, USA Ophthalmology & International Health, Johns Hopkins, Baltimore, MD, USA AN - 112813150. Language: English. Entry Date: 20160220. Revision Date: 20181206. Publication Type: Article AU - Newman-Casey, Paula Anne AU - Dayno, Megan AU - Robin, Alan L. DB - ccm DO - 10.1586/17469899.2016.1134318 DP - EBSCOhost IS - 1 KW - Glaucoma -- Drug Therapy Medication Compliance -- Education Patient Education -- Evaluation Systematic Review Human PubMed Embase CINAHL Database Randomized Controlled Trials Nonexperimental Studies Effect Size Health Belief Model Quality Assessment Outcome Assessment Patient Education -- Methods Patient Education -- Trends Counseling Glaucoma -- Education Funding Source N1 - research; systematic review; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Evidence-Based Practice. Grant Information: This work was supported by the Michigan Vision Clinician-Scientist Development Program K12EY022299 (PANC).. NLM UID: 101278197. PY - 2016 SN - 1746-9899 SP - 5-20 ST - Systematic review of educational interventions to improve glaucoma medication adherence: an update in 2015 T2 - Expert Review of Ophthalmology TI - Systematic review of educational interventions to improve glaucoma medication adherence: an update in 2015 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112813150&site=ehost-live&scope=site VL - 11 ID - 4256 ER - TY - JOUR AB - Our objective was to test the feasibility of, fidelity to, and initial impact of a brief, glaucoma-specific motivational interviewing (MI) training program for ophthalmic para-professionals. This prospective, mixed-methods study had two components, one for staff and one for patients. Staff fidelity to MI principles was graded through audio-recorded encounters after initial and final training sessions. After training, patients graded staff for adherence to autonomy supportive care. Semi-structured interviews with para-professionals elicited feedback about the training and about their ability to implement MI in the clinic. The impact on patient satisfaction with staff communication, eye drop instillation self-efficacy, and overall health activation was assessed using a survey pre- and post-training. Para-professionals met two of three program goals for MI skills and improved in their overall scores for MI fidelity. Para-professionals noted lack of time in the clinic as a significant barrier to implementing counseling. Patient satisfaction with staff communication increased after the training (p = 0.04) among patients who rated their staff above the mean for providing autonomy supportive care. The intervention did not improve patients' eye drop instillation self-efficacy or overall health activation. Training para-professional staff in brief, glaucoma-specific MI techniques is feasible and may improve patient satisfaction, though dedicated time in clinic is needed to implement MI counseling into glaucoma practice. AD - Department of Ophthalmology and Visual Sciences, University of Michigan Medical School Department of Health Behavior and Health Education, University of Michigan School of Public Health Department of Family Medicine, University of Michigan Medical School College of Nursing, University of Colorado Denver Department of Internal Medicine, University of Michigan Medical School AN - 140918509. Language: English. Entry Date: 20191231. Revision Date: 20200104. Publication Type: Article AU - Newman-Casey, Paula Anne AU - Killeen, Olivia AU - Miller, Sarah AU - MacKenzie, Chamisa AU - Niziol, Leslie M. AU - Resnicow, Ken AU - Creswell, John W. AU - Cook, Paul AU - Heisler, Michele DB - ccm DO - 10.1080/10410236.2018.1557357 DP - EBSCOhost IS - 2 KW - Health Personnel, Unlicensed -- Education Motivational Interviewing -- Education Instillation, Drug -- Education Ophthalmic Solutions -- Therapeutic Use Glaucoma -- Therapy Patient Satisfaction Professional-Patient Relations Medication Compliance Outcomes of Education Human Prospective Studies Multimethod Studies Nonexperimental Studies Semi-Structured Interview Audiorecording Program Evaluation Pretest-Posttest Design Communication Self-Efficacy Professional Compliance Patient Autonomy Clinical Trials Program Development Questionnaires Professional Knowledge Health Personnel, Unlicensed -- Psychosocial Factors Scales Summated Rating Scaling Descriptive Statistics Linear Regression Models, Statistical Convenience Sample Midwestern United States Health Knowledge Confidence Unpaired T-Tests Wilcoxon Rank Sum Test Chi Square Test Fisher's Exact Test Paired T-Tests Adult Ophthalmology Open-Ended Questionnaires Structured Questionnaires Funding Source N1 - clinical trial; research; tables/charts. Journal Subset: Blind Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Instrumentation: Patient Activation Measure (PAM); Health Care Climate Questionnaire (HCCQ); Clinician and Group Survey of the Consumer Assessment of Healthcare Providers and Systems (CG-CAHPS); Eye Drop Instillation Self-efficacy Scale (EDISE). Grant Information: This research was supported in part by, the Blue Cross Blue Shield Foundation of Michigan, the American Glaucoma Society Young Clinician Scientist Award, Research to Prevent Blindness Career Development Award, the David L. Epstein, MD Chandler Grant Society Clinician-Scientist Award, and the National Eye Institute 1K23EY025320.. NLM UID: 8908762. PY - 2020 SN - 1041-0236 SP - 233-241 ST - A Glaucoma-Specific Brief Motivational Interviewing Training Program for Ophthalmology Para-professionals: Assessment of Feasibility and Initial Patient Impact T2 - Health Communication TI - A Glaucoma-Specific Brief Motivational Interviewing Training Program for Ophthalmology Para-professionals: Assessment of Feasibility and Initial Patient Impact UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=140918509&site=ehost-live&scope=site VL - 35 ID - 4183 ER - TY - JOUR AB - Our objective was to test the feasibility of, fidelity to, and initial impact of a brief, glaucoma-specific motivational interviewing (MI) training program for ophthalmic para-professionals. This prospective, mixed-methods study had two components, one for staff and one for patients. Staff fidelity to MI principles was graded through audio-recorded encounters after initial and final training sessions. After training, patients graded staff for adherence to autonomy supportive care. Semi-structured interviews with para-professionals elicited feedback about the training and about their ability to implement MI in the clinic. The impact on patient satisfaction with staff communication, eye drop instillation self-efficacy, and overall health activation was assessed using a survey pre- and post-training. Para-professionals met two of three program goals for MI skills and improved in their overall scores for MI fidelity. Para-professionals noted lack of time in the clinic as a significant barrier to implementing counseling. Patient satisfaction with staff communication increased after the training (p = 0.04) among patients who rated their staff above the mean for providing autonomy supportive care. The intervention did not improve patients’ eye drop instillation self-efficacy or overall health activation. Training para-professional staff in brief, glaucoma-specific MI techniques is feasible and may improve patient satisfaction, though dedicated time in clinic is needed to implement MI counseling into glaucoma practice. (PsycINFO Database Record (c) 2020 APA, all rights reserved) AD - Newman-Casey, Paula Anne, Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, US, 48105 AN - 2018-66171-001 AU - Newman-Casey, Paula Anne AU - Killeen, Olivia AU - Miller, Sarah AU - MacKenzie, Chamisa AU - Niziol, Leslie M. AU - Resnicow, Ken AU - Creswell, John W. AU - Cook, Paul AU - Heisler, Michele DB - psyh DO - 10.1080/10410236.2018.1557357 DP - EBSCOhost IS - 2 KW - motivational interviewing training program ophthalmology para-professionals glaucoma feasibility program adherence initial impact Eye Disorders Paraprofessional Education Paraprofessional Personnel N1 - Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, US. Other Publishers: Lawrence Erlbaum. Release Date: 20181227. Correction Date: 20200217. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Eye Disorders; Motivational Interviewing; Ophthalmology; Paraprofessional Education; Paraprofessional Personnel. Classification: Professional Education & Training (3410). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Knowledge, Attitudes, and Behavior Scale; Eye Drop Instillation Self-efficacy Scale; Patient Activation Measure; Clinician and Group Survey of the Consumer Assessment of Healthcare Providers and Systems; Health Care Climate Questionnaire DOI: 10.1037/t68628-000. Methodology: Empirical Study; Longitudinal Study; Prospective Study; Qualitative Study; Quantitative Study. Supplemental Data: Tables and Figures Internet. References Available: Y. Page Count: 9. Issue Publication Date: Feb, 2020. Copyright Statement: Taylor & Francis Group, LLC. 2018. Sponsor: Blue Cross Blue Shield Foundation of Michigan, US. Recipients: No recipient indicated Sponsor: American Glaucoma Society, US. Other Details: Young Clinician Scientist Award. Recipients: No recipient indicated Sponsor: Research to Prevent Blindness. Other Details: Career Development Award. Recipients: No recipient indicated Sponsor: David L. Epstein, MD Chandler Grant Society. Other Details: Clinician-Scientist Award. Recipients: No recipient indicated Sponsor: National Eye Institute, US. Grant: 1K23EY025320. Recipients: No recipient indicated PY - 2020 SN - 1041-0236 1532-7027 SP - 233-241 ST - A glaucoma-specific brief motivational interviewing training program for ophthalmology para-professionals: Assessment of feasibility and initial patient impact T2 - Health Communication TI - A glaucoma-specific brief motivational interviewing training program for ophthalmology para-professionals: Assessment of feasibility and initial patient impact UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-66171-001&site=ehost-live&scope=site ORCID: 0000-0002-0847-1929 panewman@med.umich.edu VL - 35 ID - 4803 ER - TY - JOUR AB - Background: As online health information becomes common, it is important to assess patients' access to and experiences with online resources. Introduction: We examined whether glaucoma patients' technology usage differs by medication adherence and whether adherence is associated with online education experiences. Materials and Methods: We included 164 adults with glaucoma taking ≥ 1 glaucoma medication. Participants completed a survey including demographic and health information, the Morisky Adherence Scale, and questions about online glaucoma resource usage. Differences in technology access, adherence, and age were compared with chi-squared, Fisher exact, and two-sample t-tests. Results: Mean age was 66 years. Twenty-six percent reported poor adherence. Eighty percent had good technology access. Seventy-three percent of subjects with greater technology access wanted online glaucoma information and yet only 14% of patients had been directed to online resources by physicians. There was no relationship between technological connectivity and adherence (p = 0.51). Nonadherent patients were younger (mean age 58 years vs. 66 years for adherent patients, p = 0.002). Nonadherence was associated with negative feelings about online searches (68% vs. 42%, p = 0.06). Discussion: Younger, poorly adherent patients navigate online glaucoma resources without physician input. These online searches are often unsatisfying. Technology should be leveraged to create high quality, online glaucoma resources that physicians can recommend to provide guidance for disease self-management. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Newman-Casey, Paula Anne, Department of Ophthalmology & Visual Sciences, University of Michigan, Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI, US, 48105 AN - 2018-62431-011 AU - Newman-Casey, Paula Anne AU - Killeen, Olivia J. AU - Renner, Morgan AU - Robin, Alan L. AU - Lee, Paul AU - Heisler, Michele DB - psyh DO - 10.1089/tmj.2017.0324 DP - EBSCOhost IS - 12 KW - glaucoma medication adherence e-health education self-management Drug Therapy Telemedicine Treatment Compliance Electronic Health Services N1 - Telemedicine Journal and e-Health. Partial author list: First Author & Affiliation: Newman-Casey, Paula Anne; Department of Ophthalmology & Visual Sciences, Kellogg Eye Center, University ofMichigan Medical School, Ann Arbor, MI, US. Release Date: 20190411. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Glaucoma; Telemedicine; Treatment Compliance; Electronic Health Services. Minor Descriptor: Self-Management. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Morisky Adherence Scale. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Dec, 2018. Publication History: First Posted Date: Apr 23, 2018; Accepted Date: Jan 9, 2018; Revised Date: Jan 9, 2018; First Submitted Date: Dec 15, 2017. Copyright Statement: MARY ANN LIEBERT, INC. Sponsor: National Eye Institute, US. Grant: 1K23EY025320-01A1. Recipients: No recipient indicated Sponsor: Research to Prevent Blindness. Other Details: Caree Development Award. Recipients: No recipient indicated PY - 2018 SN - 1530-5627 1556-3669 SP - 1026-1035 ST - Access to and experiences with, e-health technology among glaucoma patients and their relationship with medication adherence T2 - Telemedicine and e-Health TI - Access to and experiences with, e-health technology among glaucoma patients and their relationship with medication adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-62431-011&site=ehost-live&scope=site panewman@med.umich.edu VL - 24 ID - 4804 ER - TY - JOUR AB - Precis: The Michigan Screening and Intervention for Glaucoma and eye Health through Telemedicine (MI-SIGHT) program leverages community-engaged research, telemedicine, and health coaching to overcome key logistical and psychosocial barriers to improve glaucoma screening in underserved communities. Purpose: To describe the methodology of the implementation and evaluation of the MI-SIGHT Program. Methods: The MI-SIGHT Program uses community engagement, telemedicine, and health coaching to overcome key logistical and psychosocial barriers to glaucoma identification and care among underserved populations. The MI-SIGHT Program will be evaluated in 2 community clinics: Hamilton Community Health Network, a federally qualified health center in Flint, Michigan, and the Hope Clinic, a free clinic in Ypsilanti, Michigan. A Community Advisory Board including the research team and health care providers, administrators, and patients from both clinics will guide program implementation. An ophthalmic technician at the community clinics will conduct screening tests for glaucoma and eye disease. The data will be transmitted through electronic health record to be reviewed by an ophthalmologist who will make recommendations for follow-up care. The ophthalmic technician will conduct a return visit to fit low-or no-cost glasses, help arrange follow-up with an ophthalmologist, and provide education. Those diagnosed with glaucoma or suspected glaucoma will be randomized to standard education or personalized glaucoma education and coaching. Costs will be assessed. Results: The authors hypothesize that the MI-SIGHT Program will detect a higher prevalence rate of glaucoma than that found in the general population, improve upon presenting visual acuity, enhance vision-related quality of life, and demonstrate that personalized glaucoma education and coaching improve adherence to follow-up care. Conclusion: The MI-SIGHT Program may serve as a model for glaucoma screening and care in high-risk communities. AD - P.A. Newman-Casey, University of Michigan, Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Musch, D. C. AU - Niziol, L. M. AU - Elam, A. R. AU - Zhang, J. AU - Moroi, S. E. AU - Johnson, L. AU - Kershaw, M. AU - Saadine, J. AU - Winter, S. AU - Woodward, M. A. DB - Embase Medline DO - 10.1097/IJG.0000000000001812 IS - 5 KW - article community care electronic health record follow up glaucoma health care cost human intervention study mass screening Michigan prevalence priority journal quality of life risk factor telemedicine visual acuity LA - English M3 - Article N1 - L634921202 2021-05-10 2021-05-28 PY - 2021 SN - 1536-481X 1057-0829 SP - 380-387 ST - Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine (MI-SIGHT): Baseline Methodology for Implementing and Assessing a Community-based Program T2 - Journal of Glaucoma TI - Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine (MI-SIGHT): Baseline Methodology for Implementing and Assessing a Community-based Program UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634921202&from=export http://dx.doi.org/10.1097/IJG.0000000000001812 VL - 30 ID - 2301 ER - TY - JOUR AB - Precis: The Michigan Screening and Intervention for Glaucoma and eye Health through Telemedicine (MI-SIGHT) program leverages community-engaged research, telemedicine, and health coaching to overcome key logistical and psychosocial barriers to improve glaucoma screening in underserved communities. Purpose: To describe the methodology of the implementation and evaluation of the MI-SIGHT Program. Methods: The MI-SIGHT Program uses community engagement, telemedicine, and health coaching to overcome key logistical and psychosocial barriers to glaucoma identification and care among underserved populations. The MI-SIGHT Program will be evaluated in 2 community clinics: Hamilton Community Health Network, a federally qualified health center in Flint, Michigan, and the Hope Clinic, a free clinic in Ypsilanti, Michigan. A Community Advisory Board including the research team and health care providers, administrators, and patients from both clinics will guide program implementation. An ophthalmic technician at the community clinics will conduct screening tests for glaucoma and eye disease. The data will be transmitted through electronic health record to be reviewed by an ophthalmologist who will make recommendations for follow-up care. The ophthalmic technician will conduct a return visit to fit low-or no-cost glasses, help arrange follow-up with an ophthalmologist, and provide education. Those diagnosed with glaucoma or suspected glaucoma will be randomized to standard education or personalized glaucoma education and coaching. Costs will be assessed. Results: The authors hypothesize that the MI-SIGHT Program will detect a higher prevalence rate of glaucoma than that found in the general population, improve upon presenting visual acuity, enhance vision-related quality of life, and demonstrate that personalized glaucoma education and coaching improve adherence to follow-up care. Conclusion: The MI-SIGHT Program may serve as a model for glaucoma screening and care in high-risk communities. © 2021 Lippincott Williams and Wilkins. All rights reserved. AD - Department of Ophthalmology and Visual Sciences Institute for Healthcare Policy and Innovation, University of Michigan, United States Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, United States Hamilton Community Health Network, Flint, United States Hope Clinic, Ypsilanti, MI, United States Department of Ophthalmology, Ohio State University, Columbus, OH, United States Centers for Disease Control and Prevention, Atlanta, GA, United States AU - Newman-Casey, P. A. AU - Musch, D. C. AU - Niziol, L. M. AU - Elam, A. R. AU - Zhang, J. AU - Moroi, S. E. AU - Johnson, L. AU - Kershaw, M. AU - Saadine, J. AU - Winter, S. AU - Woodward, M. A. DB - Scopus DO - 10.1097/IJG.0000000000001812 IS - 5 KW - community-engaged research glaucoma screening telemedicine M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 380-387 ST - Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine (MI-SIGHT): Baseline Methodology for Implementing and Assessing a Community-based Program T2 - Journal of Glaucoma TI - Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine (MI-SIGHT): Baseline Methodology for Implementing and Assessing a Community-based Program UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105230831&doi=10.1097%2fIJG.0000000000001812&partnerID=40&md5=bf8d768f2fa05ec87a9e9bf5dbf502c9 VL - 30 ID - 5658 ER - TY - JOUR AB - Precis: The Michigan Screening and Intervention for Glaucoma and eye Health through Telemedicine (MI-SIGHT) program leverages community-engaged research, telemedicine, and health coaching to overcome key logistical and psychosocial barriers to improve glaucoma screening in underserved communities. Purpose: To describe the methodology of the implementation and evaluation of the MI-SIGHT Program. Methods: The MI-SIGHT Program uses community engagement, telemedicine, and health coaching to overcome key logistical and psychosocial barriers to glaucoma identification and care among underserved populations. The MI-SIGHT Program will be evaluated in 2 community clinics: Hamilton Community Health Network, a federally qualified health center in Flint, Michigan, and the Hope Clinic, a free clinic in Ypsilanti, Michigan. A Community Advisory Board including the research team and health care providers, administrators, and patients from both clinics will guide program implementation. An ophthalmic technician at the community clinics will conduct screening tests for glaucoma and eye disease. The data will be transmitted through electronic health record to be reviewed by an ophthalmologist who will make recommendations for follow-up care. The ophthalmic technician will conduct a return visit to fit low-or no-cost glasses, help arrange follow-up with an ophthalmologist, and provide education. Those diagnosed with glaucoma or suspected glaucoma will be randomized to standard education or personalized glaucoma education and coaching. Costs will be assessed. Results: The authors hypothesize that the MI-SIGHT Program will detect a higher prevalence rate of glaucoma than that found in the general population, improve upon presenting visual acuity, enhance vision-related quality of life, and demonstrate that personalized glaucoma education and coaching improve adherence to follow-up care. Conclusion: The MI-SIGHT Program may serve as a model for glaucoma screening and care in high-risk communities. AN - WOS:000647978800021 AU - Newman-Casey, P. A. AU - Musch, D. C. AU - Niziol, L. M. AU - Elam, A. R. AU - Zhang, J. AU - Moroi, S. E. AU - Johnson, L. AU - Kershaw, M. AU - Saadine, J. AU - Winter, S. AU - Woodward, M. A. DA - MAY DO - 10.1097/IJG.0000000000001812 IS - 5 PY - 2021 SN - 1057-0829 1536-481X SP - 380-387 ST - Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (MI-SIGHT): Baseline Methodology for Implementing and Assessing a Community-based Program T2 - JOURNAL OF GLAUCOMA TI - Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (MI-SIGHT): Baseline Methodology for Implementing and Assessing a Community-based Program VL - 30 ID - 5918 ER - TY - JOUR AB - Purpose: The main purpose of this study was to use Lean analysis to identify how often and when wait times occur during a glaucoma visit to identify opportunities for additional patient engagement. Methods: This prospective observational time-motion study measured process and wait times for 77 patient visits from 12 ophthalmologists at an academic glaucoma clinic over a 3-month period. Value stream maps visually diagramed the process of a clinical visit from the patient's perspective. Descriptive statistics were calculated for process times, wait times, and the frequency of 10+ minute wait times during each part of the visit. Key stakeholders participated in a root cause analysis to identify reasons for long wait times. The main outcome measure was average times (hours: minutes: seconds) for process times and wait times. Results: Twenty-nine new visit (NV) patients and 48 return visit (RV) patients were included. Total time in clinic was 187.1 +/- 44.5 (mean +/- SD) minutes for NV patients and 102.0 +/- 44.7 minutes for RV patients. Wait time for NV patients was 63.7 +/- 33.4 minutes (33.1% of total appointment time) and for RV patients was 52.6 +/- 31.6 minutes (49.4% of the total appointment time). All NV patients and 87.5% of RV patients had at least one 10+ minute wait time during their clinic visit and the majority (75.9% NV, 60.4% RV) had >1. Conclusions: Currently, sufficient wait time exists during the visit for key portions of glaucoma education such as teaching eye drop instillation. AN - WOS:000467740200019 AU - Newman-Casey, P. A. AU - Musser, J. A. AU - Niziol, L. M. AU - Heisler, M. M. AU - Kamat, S. S. AU - Shah, M. M. AU - Patel, N. AU - Cohn, A. M. DA - MAY DO - 10.1097/IJG.0000000000001192 IS - 5 PY - 2019 SN - 1057-0829 1536-481X SP - 415-422 ST - Integrating Patient Education Into the Glaucoma Clinical Encounter: A Lean Analysis T2 - JOURNAL OF GLAUCOMA TI - Integrating Patient Education Into the Glaucoma Clinical Encounter: A Lean Analysis VL - 28 ID - 5905 ER - TY - JOUR AD - J.S. Myers, Wills Eye Hospital, Thomas Jefferson University, 840Walnut St, Ste 1110, Philadelphia, PA, United States AU - Newman-Casey, P. A. AU - Myers, J. S. DB - Embase Medline DO - 10.1001/jamaophthalmol.2018.6074 IS - 3 KW - antiglaucoma agent glaucoma human medication compliance note patient compliance priority journal reminder system risk reduction visual impairment LA - English M3 - Note N1 - L625495548 2018-12-21 2019-05-14 PY - 2019 SN - 2168-6165 SP - 246-247 ST - Preliminary Steps to Address Glaucoma Medication Adherence: Beginning to Tackle the Elephant in the Room T2 - JAMA Ophthalmology TI - Preliminary Steps to Address Glaucoma Medication Adherence: Beginning to Tackle the Elephant in the Room UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625495548&from=export http://dx.doi.org/10.1001/jamaophthalmol.2018.6074 VL - 137 ID - 2524 ER - TY - JOUR AD - W. K. Kellogg Eye Center, University of Michigan, Ann Arbor Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania AN - 135358715. Language: English. Entry Date: 20191121. Revision Date: 20191121. Publication Type: journal article AU - Newman-Casey, Paula Anne AU - Myers, Jonathan S. DB - ccm DO - 10.1001/jamaophthalmol.2018.6074 DP - EBSCOhost IS - 3 KW - Medication Compliance Glaucoma Antihypertensive Agents Patient Satisfaction N1 - commentary. Journal Subset: Biomedical; USA. NLM UID: 101589539. PMID: NLM30543366. PY - 2019 SN - 2168-6165 SP - 246-247 ST - Preliminary Steps to Address Glaucoma Medication Adherence: Beginning to Tackle the Elephant in the Room T2 - JAMA Ophthalmology TI - Preliminary Steps to Address Glaucoma Medication Adherence: Beginning to Tackle the Elephant in the Room UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135358715&site=ehost-live&scope=site VL - 137 ID - 4353 ER - TY - JOUR AB - Purpose: To evaluate the relationship between medication adherence and visual field progression in participants randomized to the medication arm of the Collaborative Initial Glaucoma Treatment Study (CIGTS). Design: The CIGTS was a randomized, multicenter clinical trial comparing initial treatment with topical medications to trabeculectomy for 607 participants with newly diagnosed glaucoma. Participants: Three hundred seven participants randomized to the medication arm of the CIGTS. Methods: Participants were followed up at 6-month intervals for up to 10 years. Self-reported medication adherence and visual fields were measured. Medication adherence was assessed by telephone from responses to the question, “Did you happen to miss any dose of your medication yesterday?” The impact of medication adherence on mean deviation (MD) over time was assessed with a linear mixed regression model adjusting for the effects of baseline MD and age, cataract extraction, interactions, and time (through year 8, excluding time after crossover to surgery). Medication adherence was modeled as a cumulative sum of the number of prior visits where a missed dose of medication was reported. Main Outcome Measure: Mean deviation over time. Results: Three hundred seven subjects (306 with adherence data) were randomized to treatment with topical medications and followed up for an average of 7.3 years (standard deviation, 2.3 years). One hundred forty-two subjects (46%) reported never missing a dose of medication over all available follow-up, 112 patients (37%) reported missing medication at up to one third of visits, 31 patients (10%) reported missing medication at one third to two thirds of visits, and 21 patients (7%) reported missing medication at more than two thirds of visits. Worse medication adherence was associated with loss of MD over time (P = 0.005). For subjects who reported never missing a dose of medication, the average predicted MD loss over 8 years was 0.62 dB, consistent with age-related loss (95% confidence interval [CI], 0.17–1.06; P = 0.007); subjects who reported missing medication doses at one third of visits had a loss of 1.42 dB (95% CI, 0.86–1.98; P < 0.0001); and subjects who reported missing medication doses at two thirds of visits showed a loss of 2.23 dB (95% CI, 1.19–3.26; P < 0.0001). Conclusions: This longitudinal assessment demonstrated a statistically and clinically significant association between medication nonadherence and glaucomatous vision loss. AD - P.A. Newman-Casey, Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Niziol, L. M. AU - Gillespie, B. W. AU - Janz, N. K. AU - Lichter, P. R. AU - Musch, D. C. DB - Embase Medline DO - 10.1016/j.ophtha.2019.10.022 IS - 4 KW - NCT00000149 antiglaucoma agent adult age aged cataract extraction clinical evaluation conference paper disease exacerbation female follow up human longitudinal study major clinical study male medication compliance multicenter study (topic) open angle glaucoma patient compliance priority journal randomized controlled trial (topic) self report telephone interview time topical treatment trabeculectomy treatment refusal visual field visual impairment LA - English M3 - Conference Paper N1 - L2004566946 2020-01-15 PY - 2020 SN - 1549-4713 0161-6420 SP - 477-483 ST - The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study T2 - Ophthalmology TI - The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004566946&from=export http://dx.doi.org/10.1016/j.ophtha.2019.10.022 VL - 127 ID - 2420 ER - TY - JOUR AB - Purpose: To evaluate the relationship between medication adherence and visual field progression in participants randomized to the medication arm of the Collaborative Initial Glaucoma Treatment Study (CIGTS). Design: The CIGTS was a randomized, multicenter clinical trial comparing initial treatment with topical medications to trabeculectomy for 607 participants with newly diagnosed glaucoma. Participants: Three hundred seven participants randomized to the medication arm of the CIGTS. Methods: Participants were followed up at 6-month intervals for up to 10 years. Self-reported medication adherence and visual fields were measured. Medication adherence was assessed by telephone from responses to the question, “Did you happen to miss any dose of your medication yesterday?” The impact of medication adherence on mean deviation (MD) over time was assessed with a linear mixed regression model adjusting for the effects of baseline MD and age, cataract extraction, interactions, and time (through year 8, excluding time after crossover to surgery). Medication adherence was modeled as a cumulative sum of the number of prior visits where a missed dose of medication was reported. Main Outcome Measure: Mean deviation over time. Results: Three hundred seven subjects (306 with adherence data) were randomized to treatment with topical medications and followed up for an average of 7.3 years (standard deviation, 2.3 years). One hundred forty-two subjects (46%) reported never missing a dose of medication over all available follow-up, 112 patients (37%) reported missing medication at up to one third of visits, 31 patients (10%) reported missing medication at one third to two thirds of visits, and 21 patients (7%) reported missing medication at more than two thirds of visits. Worse medication adherence was associated with loss of MD over time (P = 0.005). For subjects who reported never missing a dose of medication, the average predicted MD loss over 8 years was 0.62 dB, consistent with age-related loss (95% confidence interval [CI], 0.17–1.06; P = 0.007); subjects who reported missing medication doses at one third of visits had a loss of 1.42 dB (95% CI, 0.86–1.98; P < 0.0001); and subjects who reported missing medication doses at two thirds of visits showed a loss of 2.23 dB (95% CI, 1.19–3.26; P < 0.0001). Conclusions: This longitudinal assessment demonstrated a statistically and clinically significant association between medication nonadherence and glaucomatous vision loss. © 2019 American Academy of Ophthalmology AD - Department of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, MI, United States Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, United States Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, United States Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Niziol, L. M. AU - Gillespie, B. W. AU - Janz, N. K. AU - Lichter, P. R. AU - Musch, D. C. DB - Scopus DO - 10.1016/j.ophtha.2019.10.022 IS - 4 M3 - Conference Paper N1 - Cited By :18 Export Date: 19 July 2021 PY - 2020 SP - 477-483 ST - The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study T2 - Ophthalmology TI - The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077685553&doi=10.1016%2fj.ophtha.2019.10.022&partnerID=40&md5=8f8251457191718029c1ccb8ab4af4f4 VL - 127 ID - 5155 ER - TY - JOUR AB - Purpose: To evaluate the relationship between medication adherence and visual field progression in participants randomized to the medication arm of the Collaborative Initial Glaucoma Treatment Study (CIGTS). Design: The CIGTS was a randomized, multicenter clinical trial comparing initial treatment with topical medications to trabeculectomy for 607 participants with newly diagnosed glaucoma. Participants: Three hundred seven participants randomized to the medication arm of the CIGTS. Methods: Participants were followed up at 6-month intervals for up to 10 years. Self-reported medication adherence and visual fields were measured. Medication adherence was assessed by telephone from responses to the question, "Did you happen to miss any dose of your medication yesterday?" The impact of medication adherence on mean deviation (MD) over time was assessed with a linear mixed regression model adjusting for the effects of baseline MD and age, cataract extraction, interactions, and time (through year 8, excluding time after crossover to surgery). Medication adherence was modeled as a cumulative sum of the number of prior visits where a missed dose of medication was reported. Main Outcome Measure: Mean deviation over time. Results: Three hundred seven subjects (306 with adherence data) were randomized to treatment with topical medications and followed up for an average of 7.3 years (standard deviation, 2.3 years). One hundred forty-two subjects (46%) reported never missing a dose of medication over all available follow-up, 112 patients (37%) reported missing medication at up to one third of visits, 31 patients (10%) reported missing medication at one third to two thirds of visits, and 21 patients (7%) reported missing medication at more than two thirds of visits. Worse medication adherence was associated with loss of MD over time (P = 0.005). For subjects who reported never missing a dose of medication, the average predicted MD loss over 8 years was 0.62 dB, consistent with age-related loss (95% confidence interval [CI], 0.17-1.06; P = 0.007); subjects who reported missing medication doses at one third of visits had a loss of 1.42 dB (95% CI, 0.86-1.98; P < 0.0001); and subjects who reported missing medication doses at two thirds of visits showed a loss of 2.23 dB (95% CI, 1.19-3.26; P < 0.0001). Conclusions: This longitudinal assessment demonstrated a statistically and clinically significant association between medication nonadherence and glaucomatous vision loss. (C) 2019 by the American Academy of Ophthalmology AN - WOS:000520890400016 AU - Newman-Casey, P. A. AU - Niziol, L. M. AU - Gillespie, B. W. AU - Janz, N. K. AU - Lichter, P. R. AU - Musch, D. C. DA - APR DO - 10.1016/j.ophtha.2019.10.022 IS - 4 PY - 2020 SN - 0161-6420 1549-4713 SP - 477-483 ST - The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study T2 - OPHTHALMOLOGY TI - The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study VL - 127 ID - 5896 ER - TY - JOUR AB - Purpose: To assess the efficacy of the Support, Educate, Empower (SEE) glaucoma coaching program on medication adherence among glaucoma patients with low adherence. Design: Uncontrolled intervention study with a pre–post design. Participants: Glaucoma patients ≥ age 40, taking ≥1 medication, who self-reported poor adherence were recruited from the University of Michigan Kellogg Eye Center. Adherence was monitored electronically for a 3-month baseline period; participants with median adherence of ≤80% were enrolled in the SEE program. Methods: Participants’ adherence was monitored electronically (AdhereTech, New York, NY) during the 7-month program. Adherence was calculated as the percentage of doses taken on time of those prescribed. The SEE program included (1) automated medication reminders, (2) 3 in-person counseling sessions with a glaucoma coach who had training in motivational interviewing (MI), and (3) 5 phone calls with the same coach for between-session support. The coach used a web-based tool to generate an education plan tailored to the patient's glaucoma diagnosis, test results, and ophthalmologist's recommendations (www.glaucomaeyeguide.org). The tool guided an MI-based conversation between coach and patient to identify barriers to adherence and possible solutions. Descriptive statistics were used to summarize baseline patient characteristics, and differences between those who did and did not complete the SEE program were tested with 2-sample t tests, chi-square tests, and Fisher exact tests. Adherence was compared before and after the SEE program with paired t tests. Main Outcome Measure: Change in electronically monitored medication adherence. Results: A total of 48 participants were enrolled. The participants were 54% male, 46% white, and on average 64 years of age (standard deviation [SD], 10.8 years), with an average worse-eye mean deviation (MD) of –7.9 dB (SD, 8.8 dB). Those completing the SEE program (n = 39) did not differ significantly from those who dropped out (n = 9) on gender, race, age, MD, or baseline adherence. Medication adherence improved from 59.9% at baseline to 81.3% (P < 0.0001) after completing the SEE program. Ninety-five percent of participants showed an improvement in adherence (mean relative improvement, 21.4%; SD, 16.5%; range, –3.2% to 74.4%; median, 20.1%). Fifty-nine percent of participants showed adherence of >80% on completing the SEE program. Conclusions: The SEE program participants showed clinically meaningful, statistically significant improvement in glaucoma medication adherence. AD - P.A. Newman-Casey, Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Niziol, L. M. AU - Lee, P. P. AU - Musch, D. C. AU - Resnicow, K. AU - Heisler, M. DB - Embase Medline DO - 10.1016/j.ogla.2020.04.013 IS - 4 KW - adult Caucasian clinical article clinical effectiveness conference paper counseling female gender glaucoma groups by age health care planning health center health education health program human male motivational interviewing ophthalmologist patient compliance patient monitoring personalized medicine pilot study prescription pretest posttest design priority journal race self report LA - English M3 - Conference Paper N1 - L2006789244 2020-07-06 2020-08-11 PY - 2020 SN - 2589-4196 2589-4234 SP - 228-237 ST - The Impact of the Support, Educate, Empower Personalized Glaucoma Coaching Pilot Study on Glaucoma Medication Adherence T2 - Ophthalmology Glaucoma TI - The Impact of the Support, Educate, Empower Personalized Glaucoma Coaching Pilot Study on Glaucoma Medication Adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2006789244&from=export http://dx.doi.org/10.1016/j.ogla.2020.04.013 VL - 3 ID - 2399 ER - TY - JOUR AB - Purpose To evaluate the frequency of 11 commonly cited barriers to optimal glaucoma medication adherence among glaucoma patients and to identify barriers contributing to poor adherence. Design Prospective, cross-sectional survey. Participants One hundred ninety adults with glaucoma taking 1 or more glaucoma medication who received care in glaucoma clinics in Ann Arbor, Michigan, and Baltimore, Maryland. Methods Participants completed a survey on demographic and disease characteristics, barriers to optimal glaucoma medication adherence, interest in an eye drop aid, and self-reported adherence (measured by the Morisky Adherence Scale). Descriptive statistics and logistic regression analyses were performed. Main Outcome Measures Frequency and number of barriers to adherence among both adherent and nonadherent patients. Odds ratios (ORs) with 95% confidence intervals (CIs) identifying barriers associated with poor adherence. Results Twenty-seven percent of the sample reported poor adherence. Sixty-one percent of all participants cited multiple barriers and 10% cited a single barrier as impediments to optimal adherence. Twenty-nine percent of subjects cited no barriers, although only 13% of patients who cited no barriers were nonadherent. Among nonadherent patients, 31% or more cited each of the 11 barriers as important. Logistic regression analysis, adjusted for age, revealed that the following barriers were associated with higher odds of nonadherence: decreased self-efficacy (OR, 4.7; 95% CI, 2.2-9.7; P ≤ 0.0001), difficulty instilling drops (OR, 2.3; 95% CI, 1.1-4.9; P = 0.03), forgetfulness (OR, 5.6; 95% CI, 2.6-12.1; P ≤ 0.0001), and difficulties with the medication schedule (OR, 2.9; 95% CI, 1.4-6.0; P = 0.006). For each additional barrier cited as important, there was a 10% increased odds of being nonadherent (OR, 1.1; 95% CI, 1.0-1.2; P = 0.01). Conclusions Each of the 11 barriers was important to at least 30% of surveyed patients with poor adherence, with most identifying multiple barriers to adherence. Low self-efficacy, forgetfulness, and difficulty with drop administration and the medication schedule were barriers associated with poor adherence. Interventions to improve medication adherence must address each patient's unique set of barriers. AD - P.A. Newman-Casey, Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, 1000 Wall Street, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Robin, A. L. AU - Blachley, T. AU - Farris, K. AU - Heisler, M. AU - Resnicow, K. AU - Lee, P. P. DB - Embase Medline DO - 10.1016/j.ophtha.2015.03.026 IS - 7 KW - eye drops adult article confidence interval controlled study cross-sectional study female glaucoma human logistic regression analysis major clinical study male medication compliance patient compliance priority journal prospective study self concept self report visual analog scale LA - English M3 - Article N1 - L603967817 2015-04-28 2015-08-03 PY - 2015 SN - 1549-4713 0161-6420 SP - 1308-1316 ST - The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey T2 - Ophthalmology TI - The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey UR - https://www.embase.com/search/results?subaction=viewrecord&id=L603967817&from=export http://dx.doi.org/10.1016/j.ophtha.2015.03.026 VL - 122 ID - 2801 ER - TY - JOUR AB - Purpose: The majority of patients with glaucoma do not take their medications as prescribed. Estimates of the cost-utility value of adherence to prescribed glaucoma medication are vital to implement potentially effective interventions. Design: Cost-utility analysis using Monte Carlo microsimulations incorporating a series of Markov cycles (10 000 iterations per strategy). Participants: Patients with glaucoma aged ≥40 years with a full lifetime horizon (up to 60 years). Methods: The analysis estimated glaucomatous progression on the basis of data from the United Kingdom Glaucoma Treatment Study. Participants with glaucoma entered the model at age 40 years with a mean deviation in the better-seeing eye of −1.4±−1.9 decibels (dB) and −4.3±−3.4 dB in the worse-seeing eye. Participants whose glaucoma worsened each year accumulate −0.8 dB loss compared with −0.1 dB loss for those who remained stable. Data from the Glaucoma Laser Trial and the Tube versus Trabeculectomy Studies were used to assign probabilities of worsening disease among treated patients. Claims data estimating rates of glaucoma medication adherence over 4 years were used to assign probability of adherence. Those with poor adherence were modeled as having outcomes similar to the placebo arm of the clinical trials. As patients’ mean deviation deteriorated, they transitioned between health states from mild (≥−6 dB), to moderate (<−6 to ≥−12 dB), to severe glaucoma (<−12 to ≥23 dB), to unilateral (<−20 dB) and bilateral blindness. At each health state, patients incurred the costs of treatment and established health utilities; ultimately, societal costs of low vision and blindness were included. Main Outcome Measures: Cost and quality-adjusted life year (QALY) of glaucoma medication adherence. Results: Beginning at an initial glaucoma diagnosis at age 40 years, patients proceeded to single-eye blindness as early as 19 years among those who were nonadherent and 23 years for those remaining adherent. Total healthcare costs for adherent patients averaged $62 782 (standard deviation [SD], 34 107), and those for nonadherent patients averaged $52 722 (SD, 38 868). Nonadherent patients had a mean loss of 0.34 QALYs, resulting in a cost-effectiveness ratio of $29 600 per QALY gained. Conclusion: At a conservative willingness to pay of $50 000/QALY, there is room to expand services to improve patient adherence. AD - P.A. Newman-Casey, University of Michigan, Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Salman, M. AU - Lee, P. P. AU - Gatwood, J. D. C1 - xalatan(Pfizer,United States) C2 - Pfizer(United States) DB - Embase Medline DO - 10.1016/j.ophtha.2019.09.041 IS - 5 KW - latanoprost placebo adult aged conference paper cost utility analysis female glaucoma health care cost health status human lifespan low vision major clinical study male medication compliance middle aged patient compliance prescription priority journal quality adjusted life year trabeculectomy unilateral blindness xalatan LA - English M3 - Conference Paper N1 - L2003905319 2019-12-12 PY - 2020 SN - 1549-4713 0161-6420 SP - 589-598 ST - Cost-Utility Analysis of Glaucoma Medication Adherence T2 - Ophthalmology TI - Cost-Utility Analysis of Glaucoma Medication Adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003905319&from=export http://dx.doi.org/10.1016/j.ophtha.2019.09.041 VL - 127 ID - 2410 ER - TY - JOUR AB - Purpose: To explore why glaucoma patients believe that glaucoma continues to cause vision loss despite the availability of effective treatment. Methods: Nine focus groups were conducted in 3 geographically and ethnically diverse areas of the United States (Los Angeles, CA; Rochester, MN; Durham, NC) that included 56 participants, 31 with poor vision and 25 with good vision. Content analysis was used to identify important themes. Semiquantitative analysis was used to measure the frequency of each theme. Results: A total of 474 relevant comments were made in the 9 focus groups. Focus groups elicited 305 comments about barriers to glaucoma management including issues with adherence (30%), the doctor-patient relationship (21%), knowledge about glaucoma (19%), personal support systems (19%), and barriers to health care delivery such as cost and insurance (11%). A total of 101 comments were made regarding feelings about glaucoma and 58 comments were made regarding beliefs about disease and treatment. Conclusions: These focus groups brought up many issues surrounding barriers to glaucoma treatment, perceived susceptibility to glaucoma, perceived benefits to treatment, and the emotional response to living with glaucoma. There is a need to create a more comprehensive chronic disease management approach for patients with glaucoma to address both the concrete and emotional issues identified in these focus group discussions. AD - P.A. Newman-Casey, Department of Ophthalmology and Visual Sciences, University of Michigan, School of Medicine, Kellogg Eye Center, 1000 Wall St, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Shtein, R. M. AU - Coleman, A. L. AU - Herndon, L. AU - Lee, P. P. DB - Embase Medline DO - 10.1097/IJG.0000000000000320 IS - 7 KW - antiglaucoma agent adult aged article attitude to illness blindness content analysis doctor patient relationship emotion female glaucoma health belief health care cost health care delivery health insurance human independence information processing major clinical study male medication compliance patient compliance priority journal social support United States unspecified side effect visual impairment LA - English M3 - Article N1 - L611319866 2016-07-26 2016-08-05 PY - 2016 SN - 1536-481X 1057-0829 SP - e668-e675 ST - Why Patients with Glaucoma Lose Vision: The Patient Perspective T2 - Journal of Glaucoma TI - Why Patients with Glaucoma Lose Vision: The Patient Perspective UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611319866&from=export http://dx.doi.org/10.1097/IJG.0000000000000320 VL - 25 ID - 2731 ER - TY - JOUR AB - Adherence to prescribed glaucoma medications is often poor, and proper adherence can be challenging for patients. We systematically reviewed the literature and identified eight studies using educational interventions to improve glaucoma medication adherence. Overall, five of the eight studies found that educational interventions lead to a significant improvement in medication adherence, and two additional studies found a trend towards improvement. Using information from this systematic review and Health Behavior Theory, we constructed a conceptual framework to illustrate how counseling and education can improve glaucoma medication adherence. More rigorous studies grounded in Health Behavior Theory with adequately powered samples and longer follow-up are needed. AD - Department of Ophthalmology & Visual Sciences, University of Michigan Medical School , Ann Arbor, Michigan , USA . AN - 104171344. Language: English. Entry Date: 20131108. Revision Date: 20200708. Publication Type: journal article AU - Newman-Casey, Paula Anne AU - Weizer, Jennifer S. AU - Heisler, Michele AU - Lee, Paul P. AU - Stein, Joshua D. DB - ccm DO - 10.3109/08820538.2013.771198 DP - EBSCOhost IS - 3 KW - Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Medication Compliance Patient Education Human Patient Attitudes Scales Systematic Review N1 - research; systematic review. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. Grant Information: EY00703/EY/NEI NIH HHS/United States. NLM UID: 8610759. PMID: NLM23697623. PY - 2013 SN - 0882-0538 SP - 191-201 ST - Systematic review of educational interventions to improve glaucoma medication adherence T2 - Seminars in Ophthalmology TI - Systematic review of educational interventions to improve glaucoma medication adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104171344&site=ehost-live&scope=site VL - 28 ID - 4351 ER - TY - JOUR AB - Adherence to prescribed glaucoma medications is often poor, and proper adherence can be challenging for patients. We systematically reviewed the literature and identified eight studies using educational interventions to improve glaucoma medication adherence. Overall, five of the eight studies found that educational interventions lead to a significant improvement in medication adherence, and two additional studies found a trend towards improvement. Using information from this systematic review and Health Behavior Theory, we constructed a conceptual framework to illustrate how counseling and education can improve glaucoma medication adherence. More rigorous studies grounded in Health Behavior Theory with adequately powered samples and longer follow-up are needed. © 2013 Informa Healthcare USA, Inc. AD - Department of Ophthalmology and Visual Sciences, University of Michigan, Medical School, 1000 Wall Street, Ann Arbor, MI 48105, United States Department of Internal Medicine, University of Michigan, Medical School, Ann Arbor, MI, United States Department of Health Behavior and Health Education, University of Michigan, School of Public Health, Ann Arbor, MI, United States AU - Newman-Casey, P. A. AU - Weizer, J. S. AU - Heisler, M. AU - Lee, P. P. AU - Stein, J. D. DB - Scopus DO - 10.3109/08820538.2013.771198 IS - 3 KW - Adherence Attitude Barriers Behavior Belief Compliance Education Glaucoma Medications Persistence M3 - Review N1 - Cited By :22 Export Date: 19 July 2021 PY - 2013 SP - 191-201 ST - Systematic review of educational interventions to improve glaucoma medication adherence T2 - Seminars in Ophthalmology TI - Systematic review of educational interventions to improve glaucoma medication adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878317197&doi=10.3109%2f08820538.2013.771198&partnerID=40&md5=7210208cc3ad5d02cb15a30eb5cea3dc VL - 28 ID - 5124 ER - TY - JOUR AB - Adherence to prescribed glaucoma medications is often poor, and proper adherence can be challenging for patients. We systematically reviewed the literature and identified eight studies using educational interventions to improve glaucoma medication adherence. Overall, five of the eight studies found that educational interventions lead to a significant improvement in medication adherence, and two additional studies found a trend towards improvement. Using information from this systematic review and Health Behavior Theory, we constructed a conceptual framework to illustrate how counseling and education can improve glaucoma medication adherence. More rigorous studies grounded in Health Behavior Theory with adequately powered samples and longer follow-up are needed. AN - WOS:000319402400010 AU - Newman-Casey, P. A. AU - Weizer, J. S. AU - Heisler, M. AU - Lee, P. P. AU - Stein, J. D. DA - MAY DO - 10.3109/08820538.2013.771198 IS - 3 PY - 2013 SN - 0882-0538 1744-5205 SP - 191-201 ST - Systematic Review of Educational Interventions to Improve Glaucoma Medication Adherence T2 - SEMINARS IN OPHTHALMOLOGY TI - Systematic Review of Educational Interventions to Improve Glaucoma Medication Adherence VL - 28 ID - 5848 ER - TY - JOUR AB - Purpose: To evaluate noncompliance with follow-up in normal-tension glaucoma (NTG) suspects. Design: Retrospective cohort study. Methods: We reviewed 203 patient charts at a university eye clinic, identified as NTG suspects from a database of optic disk photographs. Noncompliance was defined as less than one year of follow-up and/or fewer than two completed visual field (VF) tests. Results: Twenty-two patients (11%) were excluded because at least two VF tests were not ordered. The 181 patients analyzed included 45 (25%) non-Whites and 16 (9%) non-English speakers. Eighty-three patients (46%) were noncompliant. These patients were significantly younger (50.5 ± 15.0 years vs 55.1 ± 12.8 years; P = .028), were more likely to speak English (P = .023), and were more likely to have no or unknown health insurance (P < .001). Conclusions: Almost half of NTG suspects lacked appropriate follow-up. Lack of health insurance may be a significant barrier to compliance with follow-up in this population. © 2007 Elsevier Inc. All rights reserved. AD - P.P. Chen, Department of Ophthalmology, University of Washington, Seattle, WA, United States AU - Ngan, R. AU - Lam, D. L. AU - Mudumbai, R. C. AU - Chen, P. P. DB - Embase Medline DO - 10.1016/j.ajo.2007.04.005 IS - 2 KW - adult article controlled study female follow up glaucoma health insurance human intraocular pressure major clinical study male medical record review optic disk photography priority journal retrospective study risk factor visual field LA - English M3 - Article N1 - L47094724 2007-08-01 PY - 2007 SN - 0002-9394 SP - 310-311 ST - Risk Factors for Noncompliance With Follow-up Among Normal-tension Glaucoma Suspects T2 - American Journal of Ophthalmology TI - Risk Factors for Noncompliance With Follow-up Among Normal-tension Glaucoma Suspects UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47094724&from=export http://dx.doi.org/10.1016/j.ajo.2007.04.005 VL - 144 ID - 3510 ER - TY - JOUR AB - Purpose: To evaluate noncompliance with follow-up in normal-tension glaucoma (NTG) suspects. Design: Retrospective cohort study. Methods: We reviewed 203 patient charts at a university eye clinic, identified as NTG suspects from a database of optic disk photographs. Noncompliance was defined as less than one year of follow-up and/or fewer than two completed visual field (VF) tests. Results: Twenty-two patients (11%) were excluded because at least two VF tests were not ordered. The 181 patients analyzed included 45 (25%) non-Whites and 16 (9%) non-English speakers. Eighty-three patients (46%) were noncompliant. These patients were significantly younger (50.5 ± 15.0 years vs 55.1 ± 12.8 years; P = .028), were more likely to speak English (P = .023), and were more likely to have no or unknown health insurance (P < .001). Conclusions: Almost half of NTG suspects lacked appropriate follow-up. Lack of health insurance may be a significant barrier to compliance with follow-up in this population. © 2007 Elsevier Inc. All rights reserved. AD - Department of Ophthalmology, University of Washington, Seattle, WA, United States AU - Ngan, R. AU - Lam, D. L. AU - Mudumbai, R. C. AU - Chen, P. P. DB - Scopus DO - 10.1016/j.ajo.2007.04.005 IS - 2 M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2007 SP - 310-311 ST - Risk Factors for Noncompliance With Follow-up Among Normal-tension Glaucoma Suspects T2 - American Journal of Ophthalmology TI - Risk Factors for Noncompliance With Follow-up Among Normal-tension Glaucoma Suspects UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447627005&doi=10.1016%2fj.ajo.2007.04.005&partnerID=40&md5=1a7e5b208a52fce7d1dfda65231f9ec3 VL - 144 ID - 5114 ER - TY - JOUR AB - PURPOSE: To evaluate noncompliance with follow-up in normal-tension glaucoma (NTG) suspects. DESIGN: Retrospective cohort study. METHODS: We reviewed 203 patient charts at a university eye clinic, identified as NTG suspects from a database of optic disk photographs. Noncompliance was defined as less than one year of follow-up and/or fewer than two completed visual field (VF) tests. RESULTS: Twenty-two patients (11%) were excluded be cause at least two VF tests were not ordered. The 181 patients analyzed included 45 (25%) non-Whites and 16 (9%) non-English speakers. Eighty-three patients (46%) were noncompliant. These patients were significantly younger (50.5 +/- 15.0 years vs 55.1 +/- 12.8 years; P =.028), were more likely to speak English (P =.023), and were more likely to have no or unknown health insurance (P < .001). CONCLUSIONS: Almost half of NTG suspects lacked appropriate follow-up. Lack of health insurance may be a significant barrier to compliance with follow-up in this population. AN - WOS:000248521800030 AU - Ngan, R. AU - Lam, D. L. AU - Mudumbai, R. C. AU - Chen, P. P. DA - AUG DO - 10.1016/j.ajo.2007.04.005 IS - 2 PY - 2007 SN - 0002-9394 SP - 310-311 ST - Risk factors for noncompliance with follow-up among normal-tension glaucoma suspects T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Risk factors for noncompliance with follow-up among normal-tension glaucoma suspects VL - 144 ID - 5875 ER - TY - JOUR AB - Purpose. Three-dimensional (3D) computer-automated threshold Amsler grid testing was used to identify and characterize scotomas typical of glaucoma. Methods. The 3D test exhibits a grid on a computer screen at a preselected grayscale and angular resolution, and allows patients to trace those areas on the grid that are missing in their visual field using a touch screen. Eleven eyes in patients with an established diagnosis of glaucoma were examined according to the above protocol. A total of 23 eyes from normal subjects were used as controls. The 5-minute test required that patients repeatedly outline scotomas on a touch screen with varied displays of contrast while maintaining their gaze on a central fixation marker. A 3D depiction of the visual field defects was then obtained that was further characterized by the location, shape, extent, depth, and slope of the scotomas. Results. In this pilot study, the 3D depiction of visual field loss demonstrated paracentral, superior and inferior altitudinal, and nasal step defects consistent with glaucomatous damage. The 3D depiction showed a shape, extent, depth, and slope that are consistent with the severity of damage. Conclusions. The 3D test identified and characterized scotomas typical of glaucoma. The test provides several advantages over conventional perimetry including additional information through 3D depiction of scotomas with the addition of contrast sensitivity and a higher angular/ spatial resolution. Improved patient compliance and reliability through shorter testing time and potential interactive accessibility and distribution over the Internet further characterize the test. © Wichtig Editore, 2009. AD - A.A. Sadun, Doheny Eye Institute, Keck School of Medicine at the University of Southern California, 1450 San Pablo St., Los Angeles, CA 90033, United States AU - Nguyen, D. T. AU - Fahimi, A. AU - Fink, W. AU - Nazemi, P. P. AU - Kim, J. K. AU - Sadun, A. A. DB - Embase Medline DO - 10.1177/112067210901900515 IS - 5 KW - adult aged article clinical article clinical protocol computer aided design controlled study disease association disease classification disease severity female gaze human Internet male open angle glaucoma patient compliance perimetry pilot study priority journal reliability scotoma sensitivity analysis three-dimensional imaging visual field visual field defect Amsler grid LA - English M3 - Article N1 - L355706755 2010-01-08 PY - 2009 SN - 1120-6721 SP - 776-782 ST - Novel 3D computer-automated threshold Amsler grid visual field testing of scotomas in patients with glaucoma T2 - European Journal of Ophthalmology TI - Novel 3D computer-automated threshold Amsler grid visual field testing of scotomas in patients with glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355706755&from=export http://dx.doi.org/10.1177/112067210901900515 VL - 19 ID - 3399 ER - TY - JOUR AB - Purpose: Impairment of the blood-aqueous barrier in unoperated eyes with pseudoexfoliation syndrome has been demonstrated by fluorescein angiography, fluorophotometry, measurement of aqueous flare, and determination of aqueous protein. We performed noninvasive quantification of aqueous flare using the laser flare-cell meter to compare blood-aqueous barrier breakdown after trabeculectomy in eyes with primary open-angle glaucoma (POAG) and in eyes with pseudoexfoliative glaucoma (PEX). Methods: Twenty eyes with PEX and 20 eyes with POAG were included in the study. Trabeculectomy was performed by two surgeons according to a standard trabeculectomy technique. Intra- and postoperative treatments were identical in both groups. Aqueous flare was quantitatively determined using the laser flare-cell meter FC-1000 (Kowa, Tokyo, Japan) before and 3, 5, 7, and 9 days after trabeculectomy. Absolute flare and difference between post- and preoperative flare values were statistically analyzed using the Mann-Whitney U-Test for independent samples. Results: Before surgery, aqueous flare values were significantly higher in PEX than in POAG. On days 3, 5, 7 and 9 after surgery, flare values were significantly higher in eyes with PEX than in eyes with POAG. Absolute differences between post- and preoperative flare values also were significantly higher in eyes with PEX, but this was not true for percentage values. Conclusion: These results show that substantial blood-aqueous barrier breakdown occurs in eyes with PEX after trabeculectomy. These alterations may contribute to early or late complications of trabeculectomy and indicate the need for close postoperative follow-up evaluation in eyes with PEX. AN - WOS:000078869400006 AU - Nguyen, N. X. AU - Kuchle, M. AU - Martus, P. AU - Naumann, G. O. H. DA - FEB IS - 1 PY - 1999 SN - 1057-0829 SP - 18-23 ST - Quantification of blood-aqueous barrier breakdown after trabeculectomy: Pseudoexfoliation versus primary open-angle glaucoma T2 - JOURNAL OF GLAUCOMA TI - Quantification of blood-aqueous barrier breakdown after trabeculectomy: Pseudoexfoliation versus primary open-angle glaucoma VL - 8 ID - 6222 ER - TY - JOUR AB - Glaucoma is one of the leading causes of blindness and is characterized by optic nerve damage that results in visual field loss. Elevated intraocular pressure (IOP) has been associated with glaucoma progression; thus, IOP-lowering medications are the standard of care for glaucoma. Guidelines suggest monotherapy with IOP-lowering agents such as β-blockers (eg, timolol), prostaglandin analogs, carbonic anhydrase inhibitors (eg, brinzolamide), and α2-receptor agonists (eg, brimonidine). However, monotherapy may provide insufficient IOP reduction in some patients, thereby necessitating the use of multiple IOP-lowering medications. Multidrug regimens may be complex, may increase the risk of preservative-related ocular symptoms, and may potentially reduce overall drug exposure as a consequence of drug washout during closely timed sequential administrations; these difficulties may reduce overall drug efficacy and decrease patient persistence and adherence with multidrug treatment regimens. Fixed-combination medications that provide two IOP-lowering therapies within a single solution are available and may overcome some of these challenges. However, all currently available fixed combinations combine timolol with another IOP-lowering agent, indicating that additional fixed-combination alternatives would be beneficial. To meet this demand, a novel fixed combination of brinzolamide 1% and brimonidine 0.2% (BBFC) has recently been developed. In two randomized, double-masked, multinational clinical trials, BBFC had greater IOP-lowering efficacy than brinzolamide or brimonidine monotherapy after 3 months of treatment in patients with open-angle glaucoma or ocular hypertension. In both studies, the overall safety profile of BBFC was consistent with that of brinzolamide and brimonidine. Comparative studies with BBFC versus other IOP-lowering monotherapy and fixed-combination medications are not available, but the IOP reductions observed with BBFC are similar to or greater than those reported in the literature for other glaucoma treatments; thus, BBFC provides an additional fixed-combination therapeutic option for patients who require further efficacious IOP reduction and improved convenience and tolerability versus concomitant administration of two separate medications. © 2014 Nguyen. AD - Q. H. Nguyen, Division of Ophthalmology, Scripps Clinic, 10666 North Torrey Pines Rd, MS 214, La Jolla, CA 92037, United States AU - Nguyen, Q. H. C1 - simbrinza(Alcon,United States) C2 - Alcon(United States) DB - Embase DO - 10.2147/PPA.S53162 KW - bimatoprost plus timolol brimonidine brimonidine plus brinzolamide brimonidine plus timolol brinzolamide brinzolamide plus timolol dorzolamide plus timolol latanoprost plus timolol allergic conjunctivitis blurred vision comparative effectiveness conjunctival follicle conjunctival hyperemia conjunctivitis drug efficacy drug safety drug tolerability dry eye dysgeusia eye allergy eye irritation eye pain fatigue glaucoma human hyperemia intraocular hypertension intraocular pressure lacrimation disorder medication compliance monotherapy ocular pruritus patient comfort patient compliance patient preference phase 3 clinical trial (topic) punctate keratitis randomized controlled trial (topic) review treatment duration xerostomia simbrinza LA - English M3 - Review N1 - L373303215 2014-06-25 2014-06-27 PY - 2014 SN - 1177-889X SP - 853-864 ST - Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: Critical appraisal and patient focus T2 - Patient Preference and Adherence TI - Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: Critical appraisal and patient focus UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373303215&from=export http://dx.doi.org/10.2147/PPA.S53162 VL - 8 ID - 2879 ER - TY - JOUR AB - Purpose: To report the results of penetrating keratoplasty (PK) in active Acanthamoeba keratitis (AK). Methods: Nine patients with deep stromal infiltrates because of AK were treated with intensive antiamoebic medical therapy followed by PK during the acute infectious phase because of poor clinical response or poor compliance. Antiamoebic therapy was tapered after PK. Results: Visual acuity ranged from 20/15 to 20/50 after an average of 17 months after PK with no signs of recurrences. Patients had rapid resolution of symptoms. Conclusion: PK is a viable option for active AK not responding to maximum medical treatment. © 2010 by Lippincott Williams & Wilkins. AD - T. H. Nguyen, SUNY Upstate Medical University, Department of Ophthalmology, 550 Harrison Street, Syracuse, NY 13202, United States AU - Nguyen, T. H. AU - Weisenthal, R. W. AU - Florakis, G. J. AU - Reidy, J. J. AU - Gaster, R. N. AU - Tom, D. DB - Embase Medline DO - 10.1097/ICO.0b013e3181cc79a1 IS - 9 KW - chlorhexidine clotrimazole fluconazole itraconazole ketoconazole neomycin poly(hexamethylenebiguanide) propamidine Acanthamoeba keratitis adolescent adult article clinical article drug dose reduction female human male patient compliance penetrating keratoplasty priority journal treatment response visual acuity LA - English M3 - Article N1 - L50951735 2010-06-19 2010-09-17 PY - 2010 SN - 0277-3740 SP - 1000-1004 ST - Penetrating keratoplasty in active acanthamoeba keratitis T2 - Cornea TI - Penetrating keratoplasty in active acanthamoeba keratitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50951735&from=export http://dx.doi.org/10.1097/ICO.0b013e3181cc79a1 VL - 29 ID - 3295 ER - TY - JOUR AB - Purpose: To examine whether automated visual field (VF) testing may exert a short-term influence on subsequent intraocular pressure (IOP) measurement during the same visit. Methods: We reviewed patients with primary open-angle glaucoma whose most recent visit occurred at a major academic institution from July to December 2009 and who had 3 visits without intervening changes in glaucoma management within the previous 5 years. Exclusion criteria were patient admittance of nonadherence with medical therapy and documented difficulty of IOP measurement. One hundred nine right eyes from 109 patients were included. IOP obtained within 30 minutes after VF testing was compared with IOP from the previous and next visits without VF testing. Subgroup analyses included the role of reliability of VF test performance, surgical versus medical IOP control, and different topical medications. Results: The average IOP measured after VF testing was 14.9±4.7 mm Hg, higher than both the previous (13.7±4.4 mm Hg, P<0.001) and next visits without VF examination (13.8±4.4 mm Hg, P<0.001). A total of 22.9% of patients experienced a more than 20% increase of IOP. Eyes with surgical control had less IOP elevation than eyes with medical control (3.1%±15.9% vs. 11.7%±17.4%, P=0.009). Users of β-blockers or α-2-agonists had less IOP elevation than eyes controlled with prostaglandins or carbonic anhydrase inhibitors (0.9%±15.1% vs. 9.0%±12.3%, P=0.030). Conclusions: This retrospective study suggests that patients with primary open-angle glaucoma experience a small and transient increase in IOP after VF testing and that this effect may be lower after surgical pressure control. © 2012 by Lippincott Williams & Wilkins. AD - Department of Ophthalmology and Visual Science, Yale University School of Medicine, 40 Temple Street, New Haven, CT 06510-2715, United States AU - Ni, N. AU - Tsai, J. C. AU - Bruce Shields, M. AU - Loewen, N. A. DB - Scopus DO - 10.1097/IJG.0b013e318220db03 IS - 9 KW - automated visual field testing glaucoma intraocular pressure M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2012 SP - 590-595 ST - Elevation of intraocular pressure in glaucoma patients after automated visual field testing T2 - Journal of Glaucoma TI - Elevation of intraocular pressure in glaucoma patients after automated visual field testing UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871078585&doi=10.1097%2fIJG.0b013e318220db03&partnerID=40&md5=b94fc46cd8378a0992873827854e0e0b VL - 21 ID - 5332 ER - TY - JOUR AB - Purpose: To examine whether automated visual field (VF) testing may exert a short-term influence on subsequent intraocular pressure (IOP) measurement during the same visit. Methods: We reviewed patients with primary open-angle glaucoma whose most recent visit occurred at a major academic institution from July to December 2009 and who had 3 visits without intervening changes in glaucoma management within the previous 5 years. Exclusion criteria were patient admittance of nonadherence with medical therapy and documented difficulty of IOP measurement. One hundred nine right eyes from 109 patients were included. IOP obtained within 30 minutes after VF testing was compared with IOP from the previous and next visits without VF testing. Subgroup analyses included the role of reliability of VF test performance, surgical versus medical IOP control, and different topical medications. Results: The average IOP measured after VF testing was 14.9 +/- 4.7 mm Hg, higher than both the previous (13.7 +/- 4.4 mm Hg, P < 0.001) and next visits without VF examination (13.8 +/- 4.4 mm Hg, P < 0.001). A total of 22.9% of patients experienced a more than 20% increase of IOP. Eyes with surgical control had less IOP elevation than eyes with medical control (3.1% +/- 15.9% vs. 11.7% +/- 17.4%, P = 0.009). Users of beta-blockers or alpha-2-agonists had less IOP elevation than eyes controlled with prostaglandins or carbonic anhydrase inhibitors (0.9% +/- 15.1% vs. 9.0% +/- 12.3%, P = 0.030). Conclusions: This retrospective study suggests that patients with primary open-angle glaucoma experience a small and transient increase in IOP after VF testing and that this effect may be lower after surgical pressure control. AN - WOS:000311898700004 AU - Ni, N. N. AU - Tsai, J. C. AU - Shields, M. B. AU - Loewen, N. A. DA - DEC DO - 10.1097/IJG.0b013e318220db03 IS - 9 PY - 2012 SN - 1057-0829 SP - 590-595 ST - Elevation of Intraocular Pressure in Glaucoma Patients After Automated Visual Field Testing T2 - JOURNAL OF GLAUCOMA TI - Elevation of Intraocular Pressure in Glaucoma Patients After Automated Visual Field Testing VL - 21 ID - 6123 ER - TY - JOUR AB - BACKGROUND: This study was conducted to compare the effects on intraocular pressure and side effects of monotherapy with either latanoprost or dorzolamide in patients with open angle glaucoma, pseudoexfoliation glaucoma or ocular hypertension. METHODS: Sixty patients with open angle glaucoma or ocular hypertension were recruited to a 3-month study. Previous glaucoma medications were washed out and the patients were randomised to receive either latanoprost 0.005% once daily or dorzolamide 2% three times daily. The follow-up visits were conducted at two weeks, one months and three months of study and intraocular pressures and slit lamp examinations were carried out to look for response of therapy and detect complications. RESULTS: After 3 months, latanoprost reduced mean baseline intraocular pressure from 27.2 +/- 3.0 mm Hg by 8.5 +/- 3.3 mm Hg. The corresponding figures for dorzolamide were 27.2 +/- 3.4 and 5.6 +/- 2.6 mm Hg. The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p < 0.001). Both drugs were well tolerated systemically and locally. CONCLUSION: Latanoprost was superior to dorzolamide in reducing the intraocular pressure, judged from the effect on mean intraocular pressure. The once daily dose in the evening ensures better compliance and the problem of hyperpigmentation of the iris were not encountered. AD - Eye Department, Military Hospital, Rawalpindi, Pakistan AU - Niazi, M. K. AU - Raja, N. DB - Scopus IS - 1 M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2004 SP - 50-53 ST - Comparison of latanoprost and dorzolamide in the treatment of patients with open angle glaucoma T2 - Journal of Ayub Medical College, Abbottabad : JAMC TI - Comparison of latanoprost and dorzolamide in the treatment of patients with open angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-2442650524&partnerID=40&md5=940f423eed8b308c04c4d67c7990698f VL - 16 ID - 5365 ER - TY - JOUR AB - Aim: To determine utilisation of eye care services in a rural population of southern India aged 40 years or older. Methods: 5150 subjects aged 40 years and older selected through a random cluster sampling technique from three districts in southern India underwent detailed ocular examinations for vision impairment, blindness, and ocular morbidity. Information regarding previous use of eye care services was collected from this population through a questionnaire administered by trained social workers before ocular examinations. Results: 3476 (72.7%) of 5150 subjects examined required eye care examinations. 1827 (35.5%) people gave a history of previous eye examinations, primarily from a general hospital (n = 1073, 58.7%). Increasing age and education were associated with increased utilisation of eye care services. Among the 3323 people who had never sought eye care, 912 (27.4%) had felt the need to have an eye examination but did not do so. Only one third of individuals with vision impairment, cataracts, refractive errors, and glaucoma had previously utilised services. Conclusions: A large proportion of people in a rural population of southern India who require eye care are currently not utilising existing eye care services. Improved strategies to improve uptake of services is required to reduce the huge burden of vision impairment in India. AD - A.L. Robin, Lake Falls Professional Building, 6115, Falls Road, Baltimore, MD 21209-2226, United States AU - Nirmalan, P. K. AU - Katz, J. AU - Robin, A. L. AU - Krishnadas, R. AU - Ramakrishnan, R. AU - Thulasiraj, R. D. AU - Tielsch, J. DB - Embase Medline DO - 10.1136/bjo.2004.042606 IS - 10 KW - adult age aged aging anamnesis article blindness cataract clinical examination cluster analysis eye female general hospital glaucoma health care utilization health survey human India major clinical study male morbidity priority journal questionnaire randomization refraction error rural health care rural population social worker visual impairment LA - English M3 - Article N1 - L39312962 2004-10-17 PY - 2004 SN - 0007-1161 SP - 1237-1241 ST - Utilisation of eye care services in rural south India: The Aravind Comprehensive Eye Survey T2 - British Journal of Ophthalmology TI - Utilisation of eye care services in rural south India: The Aravind Comprehensive Eye Survey UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39312962&from=export http://dx.doi.org/10.1136/bjo.2004.042606 VL - 88 ID - 3724 ER - TY - JOUR AB - Purpose: We developed and evaluated an eye dropper bottle sensor system comprising motion sensor with automatic motion waveform analysis using deep learning (DL) to accurately measure adherence of patients with antiglaucoma ophthalmic solution therapy. Methods: We enrolled 20 patients with open-angle glaucoma who were treated with either latanoprost ophthalmic solution 0.005% or latanoprost-timolol maleate fixed combination ophthalmic solution in both eyes. An eye dropper bottle sensor was installed at patients’ homes, and they were asked to instill the medication and manually record each instillation time for 3 days. Waveform data were automatically collected from the eye dropper bottle sensor and judged as a complete instillation by the DL instillation assessment model. We compared the instillation times captured on the waveform data with those on each patient’s record form. In addition, we also calculated instillation movement duration from Waveform data. Results: The developed eye bottle sensor detected all 60 instillation events (100%). Mean difference between patient and eye bottle sensor recorded time was 1 ± 1.22 (range, 0-3) minutes. Additionally, mean instillation movement duration was 16.1 ± 14.4 (range, 4-43) seconds. Two-way ANOVA revealed a significant difference in instillation movement duration among patients (P < 0.001) and across days (P < 0.001). Conclusion: The eye dropper bottle sensor system developed by us can be used for automatic monitoring of instillation adherence in patients with glaucoma. Translational Relevance: We believe that our eye dropper bottle sensor system will accurately measure adherence of all glaucoma patients as well as help glaucoma treatment. AD - K. Nishimura, Department of Ophthalmology, Saneikai Tsukazaki Hospital, 68-1, Aboshi Waku, Himeji, Japan AU - Nishimura, K. AU - Tabuchi, H. AU - Nakakura, S. AU - Nakatani, Y. AU - Yorihiro, A. AU - Hasegawa, S. AU - Tanabe, H. AU - Noguchi, A. AU - Aoki, R. AU - Kiuchi, Y. DB - Embase DO - 10.1167/tvst.8.3.55 IS - 3 KW - electric battery eye drop delivery aid light emitting diode eye drops latanoprost plus timolol acceleration adult article clinical article drug instillation female glaucoma human learning machine learning male middle aged monitoring open angle glaucoma patient compliance perimetry prevalence questionnaire sensory system visual field LA - English M3 - Article N1 - L2002347946 2019-08-19 2019-08-21 PY - 2019 SN - 2164-2591 ST - Evaluation of automatic monitoring of instillation adherence using eye dropper bottle sensor and deep learning in patients with glaucoma T2 - Translational Vision Science and Technology TI - Evaluation of automatic monitoring of instillation adherence using eye dropper bottle sensor and deep learning in patients with glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2002347946&from=export http://dx.doi.org/10.1167/tvst.8.3.55 VL - 8 ID - 2543 ER - TY - JOUR AB - Introduction: Glaucoma is principally a disease that affects the elderly population. Although the same treatments are available for the elderly as the young, there are special considerations that have to be made for older patients. Areas covered: This review will discuss the current management options for glaucoma highlighting the factors that particularly apply to the elderly population. The published literature on treatments for glaucoma with the terms ‘age’, ‘aging’, ‘older’ and ‘elderly’ were searched using PubMed. Expert commentary: Topical medication may not be appropriate for all elderly patients due to particular side-effects and other intraocular pressure lowering treatments, including cataract surgery should be considered for these patients. Low target intraocular pressures are not always required in this age group and over-treatment of elderly patients should be avoided. AD - Department of Ophthalmology, Norfolk and Norwich University Hospital, Norwich, UK AN - 116262603. Language: English. Entry Date: 20160818. Revision Date: 20160818. Publication Type: Article AU - Niyadurupola, Nuwan AU - Broadway, David C. DB - ccm DO - 10.1080/17469899.2016.1190643 DP - EBSCOhost IS - 3 KW - Glaucoma -- Therapy Disease Management Gerontologic Care Glaucoma -- Surgery Glaucoma -- Drug Therapy Administration, Topical Intraocular Pressure Antihypertensive Agents -- Therapeutic Use Cataract Extraction Laser Therapy Patient Compliance N1 - review; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Gerontologic Care. NLM UID: 101278197. PY - 2016 SN - 1746-9899 SP - 181-189 ST - Special considerations for glaucoma management in the elderly T2 - Expert Review of Ophthalmology TI - Special considerations for glaucoma management in the elderly UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116262603&site=ehost-live&scope=site VL - 11 ID - 4544 ER - TY - JOUR AD - UPMC Eye Center, Eye & Ear Institute, Pittsburgh, Pennsylvania, USA. AN - 106118818. Language: English. Entry Date: 20070713. Revision Date: 20200624. Publication Type: Journal Article AU - Noecker, R. J. DB - ccm DO - 10.2165/00002512-200623070-00007 DP - EBSCOhost IS - 7 KW - Drug Combinations -- Therapeutic Use Glaucoma -- Drug Therapy Timolol -- Therapeutic Use Travoprost -- Therapeutic Use Patient Compliance N1 - commentary; editorial. Original Study: Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. (DRUGS AGING) 2006; 23 (7): 587-597. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 9102074. PY - 2006 SN - 1170-229X SP - 598-599 ST - Travoprost/timolol : a viewpoint by Robert J. Noecker T2 - Drugs & Aging TI - Travoprost/timolol : a viewpoint by Robert J. Noecker UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106118818&site=ehost-live&scope=site VL - 23 ID - 4647 ER - TY - JOUR AB - The fixed combination eye drop Duotrav is a combination of travoprost 0.004% and timolol maleate 0.5%. Both travoprost and timolol have been used separately for the treatment of glaucoma by lowering intraocular pressure. Multiple studies have demonstrated the efficacy and safety of the fixed combination travoprost/timolol for the treatment of open-angle glaucoma and ocular hypertension. The once daily dosing of this combination offers multiple potential advantages such as patient adherence, potential cost advantages, and reduction in exposure to preservatives. This article discusses the benefits of fixed combination medications and summarizes past and recent studies listed on the online resource PubMed of the fixed combination travoprost/timolol with comparison to both monotherapy and other similar fixed combination ocular hypotensive preparations. AD - UPMC Eye Center, Eye and Ear Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; noeckerrj@upmc.edu UPMC Eye Center, Eye and Ear Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA AN - 104989430. Language: English. Entry Date: 20110415. Revision Date: 20180301. Publication Type: Journal Article AU - Noecker, Robert J. AU - Pokabla, Michael J. DB - ccm DO - 10.4137/CMT.S2030 DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Timolol -- Therapeutic Use Travoprost -- Therapeutic Use Glaucoma -- Epidemiology Intraocular Pressure Timolol -- Adverse Effects Timolol -- Pharmacokinetics Travoprost -- Adverse Effects Travoprost -- Pharmacokinetics N1 - review. Journal Subset: Australia & New Zealand; Biomedical. PY - 2010 SN - 1179-559X SP - 417-425 ST - Safety and efficacy of fixed combination travoprost-timolol in the lowering of intraocular pressure T2 - Clinical Medicine Insights: Therapeutics TI - Safety and efficacy of fixed combination travoprost-timolol in the lowering of intraocular pressure UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104989430&site=ehost-live&scope=site ID - 4566 ER - TY - JOUR AB - Background:With regard to penetrating keratoplasty methods to culture corneal donor tissues, microsurgical techniques, HLA typing and understanding of basic mechanisms in inflammation and especially graft rejection,and postoperative treatment schedules have been improved in recent years. This now enables successful penetrating keratoplasty in many more patients than previously performed. However, in rare cases relevant problems in wound closure may appear. Patients and methods:A standardized treatment protocol was applied to 1,253 penetrating keratoplasties performed in a single center. Patients were continously followed up. Simple leakage after corneal grafting was not further analyzed if conservative treatment or additional sutures achieved sufficient wound closure. In 21 cases, however, the causes of large wound dehiscence after corneal grafting were analyzed. Results: During the first week early problems in suturing penetrating keratoplasty in five patients were associated with the instability of the recipients' cornea I stroma (stromal thinning in keratoconus or corneal herpes, suture problems in keratomalacia,active herpes keratitis, corneal burns, or rheumatic diseases). Long-term complications in 16 patients were associated with alcoholism, herpes keratitis, rheumatic disorders or traumatic suture defects. Overall, nine patients lost functionally or even anatomically one eye because of wound dehiscence after corneal grafting. Conclusions: When penetrating keratoplasty is indicated,special attention should be given to (1) the compliance of the patient, (2) sufficient treatment of herpes keratitis or other infections, (3) adequate immunosuppression in autoimmune corneal inflammation,(4) double running continuous sutures as primary suture with sometimes additonal single sutures to stabilize the graft, and (5) surgery in time. AN - WOS:000085269900003 AU - Nolle, B. AU - Halene, M. A. AU - Grutters, G. AU - Duncker, G. I. W. DA - JAN DO - 10.1007/s003470050003 IS - 1 PY - 2000 SN - 0941-293X SP - 12-16 ST - Wound or suture insufficiency complicating penetrating keratoplasty T2 - OPHTHALMOLOGE TI - Wound or suture insufficiency complicating penetrating keratoplasty VL - 97 ID - 5861 ER - TY - JOUR AB - When glaucoma worsens with elevated ocular pressure despite an initial treatment, an additional reduction of pressure is needed. It is necessary to evaluate the cause of the therapeutic failure which could be the consequence of a low compliance from the patient, a poor efficacy of the topical drug or a short or long term drift of this efficacy. Depending on the aetiology, another monotherapy or a combination of treatments should be initiated. The evaluation of the target pressure and the comparison between this pressure and the current pressure of the eye allows to evaluate the likeliness of reaching the target through medical treatment alone or through surgical approach. When medical treatment is possible, it is usual to combine two drugs, one acting on the aqueous humor inflow and the other one on the uveoscleral outflow pathway. If target pressure is lower than what can be expected to be reached with topical treatment, surgery should be proposed to the patient. Laser Argon trabeculoplasty keeps still some indications, like pigmentary or exfoliative glaucoma. Long term stability of the visual field in glaucoma depends more on the reduction of pressure and on its stability than on the choice of medical or surgical approach. AD - J.-P. Nordmann, Centre du Glaucome, Hôpital des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France AU - Nordmann, J. P. DB - Embase Medline IS - SPEC. ISS. 2 KW - alpha 2 adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor aqueous humor flow argon laser conference paper disease exacerbation pseudoexfoliation glaucoma intraocular hypertension laser surgery monotherapy patient compliance sclera surgical approach trabeculoplasty treatment failure treatment indication uvea visual field LA - French M3 - Conference Paper N1 - L37351493 2003-11-13 PY - 2003 SN - 0181-5512 SP - 2S53-2S55 ST - How to conduct glaucoma therapy when pressure stays high despite topical treatment? T2 - Journal Francais d'Ophtalmologie TI - How to conduct glaucoma therapy when pressure stays high despite topical treatment? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37351493&from=export VL - 26 ID - 3797 ER - TY - JOUR AB - Adherence to treatment through observance and persistence is mandatory to treat any glaucoma patient. Identifying the factors related to nonadherence is therefore crucial. Factors responsible for poor adherence could be related to the patients (doubt, forgetfulness, denial), environmental factors (cost, competing activities, travel, etc.), the treatment regimen (refill, side effects, complexity), and finally the relation with the physician. Physicians should presume that patients have low adherence to their treatment and give clear and precise information about the expected benefits of the treatment, the disease, and its risks of progression. Combined fixed treatments and preservative-free topical treatments should improve adherence and quality of life by simplifying instillation and tolerance of eye drops. © 2011 Elsevier Masson SAS. Tous droits réservés. AD - J. Akesbi, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France AU - Nordmann, J. P. AU - Akesbi, J. DB - Medline DO - 10.1016/j.jfo.2011.04.003 IS - 6 KW - eye drops article attitude to health cost of illness disease course doctor patient relationship economics glaucoma human lifestyle patient compliance patient education quality of life risk assessment LA - French M3 - Article N1 - L51461471 2012-07-24 PY - 2011 SN - 0181-5512 SP - 403-408 ST - Improve adherence in glaucoma patients: A doctor's duty T2 - Journal Francais d'Ophtalmologie TI - Improve adherence in glaucoma patients: A doctor's duty UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51461471&from=export http://dx.doi.org/10.1016/j.jfo.2011.04.003 VL - 34 ID - 3172 ER - TY - GEN AB - Objective: To identify and characterize treatment compliance profiles of glaucoma patients and evaluate the association with intraocular pressure (IOP). Methods: A computerized device (Travalert®) that recorded daily instillation times and eye-drop counts was given for 3 months. Patients were declared compliant when at least 2 drops were instilled per day. Compliance rates were calculated for weekdays and weekends, separately, over 8 consecutive weeks. A principal components analysis (PCA) was followed by an ascendant hierarchical classification (AHC) to identify compliance groups. Results: 140 patients were recruited (mean age 65.5 years; 51.8% female) of whom 83.6% had primary open-angle glaucoma with mean IOP 23.9 mmHg before Travalert® use. 60.7% were treated with DuoTrav® (travoprost timolol fixed combination) and 39.3% with travoprost. The PCA identified two axes (compliance and treatment weeks). The AHC identified 3 compliance groups: 'high' (56.6%, approx. 80% compliance), 'medium' (21.2%, approx. 50% compliance), and 'low' (22.1%, approx. 20% compliance). Demographics and glaucoma parameters did not predict low compliance. Final mean IOP was 16.1 mmHg, but higher in the low compliance group (17.7 mmHg, P = 0.02). Conclusions: Compliance measurement by a medical device showed compliance rates <80% by 50% (approx.) of patients, significantly impacting IOP control. No demographic or glaucoma variable was associated with low compliance. © 2010 Nordmann et al. AD - G. Berdeaux, Alcon France, 4 rue Henri Sainte-Claire Deville, F-92563 Rueil-Malmaison, France AU - Nordmann, J. P. AU - Baudouin, C. AU - Renard, J. P. AU - Denis, P. AU - Lafuma, A. AU - Laurendeau, C. AU - Jeanbat, V. AU - Berdeaux, G. C1 - duotrav(Alcon,United States) travatan(Alcon,United States) C2 - Alcon(United States) C3 - Travalert(Alcon,United States) C4 - Alcon(United States) DB - Embase J2 - Clin. Ophthalmol. KW - eye drops timolol plus travoprost travoprost age aged article cataract comorbidity computer system computerized bottle holder diabetic retinopathy drug dose regimen drug instillation female gender bias glaucoma surgery human intraocular pressure low level laser therapy major clinical study male medical device open angle glaucoma patient compliance reminder system retina detachment risk factor uveitis duotrav travatan Travalert L1 - internal-pdf://2474738234/3233-Measurement of treatment compliance-2010.pdf LA - English M1 - (Nordmann J.-P.; Baudouin C.) Hôpital des Quinzes-Vingt, Paris, France M3 - Article N1 - L359443925 2010-09-07 2010-09-15 PY - 2010 SN - 1177-5467 1177-5483 SP - 731-739 ST - Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: A survey TI - Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: A survey UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359443925&from=export VL - 4 ID - 3233 ER - TY - GEN AB - Objective: To identify poorly compliant glaucoma patients, using the Eye-Drop Satisfaction Questionnaire (EDSQ). Methods: This was an observational cross-sectional study with compliance data collected by an electronic monitoring device. Patients with primary open-angle glaucoma or ocular hypertension completed the EDSQ, a six-dimension self-reported questionnaire addressing "treatment concern", "disease concern", "patient-clinician relationship", "positive beliefs", "treatment convenience", and "self-declared compliance". A Bayesian network (BN) was applied to explore compliance associations with EDSQ. Results: Among 169 patients who completed the EDSQ, 113 had valid Travalert® data, of whom 25 (22.1%) demonstrated low compliance. All six EDSQ dimensions were associated directly, or indirectly, with compliance. Two profiles exhibited low compliance, ie, patients aged younger than 77.5 years with a poor patient-physician relationship and self-declared poor compliance and patients aged older than 77.5 years with a poor patient-physician relationship and self-declared good compliance. The third profile showed high compliance, ie, patients aged younger than 77.5 years with a good patient-physician relationship and self-declared good compliance. Conclusion: Our results confirm a central role for the patient-physician relationship in the compliance process. Age, self-declared compliance, and patient satisfaction with the patient- physician relationship are all dimensions worth exploring before glaucoma medication is switched or proceeding to laser treatment or surgery. © 2010 Nordmann et al. AD - G. Berdeaux, Alcon France, 4 rue Henri Sainte-Claire Deville, 92563 Rueil-Malmaison, Cedex, France AU - Nordmann, J. P. AU - Baudouin, C. AU - Renard, J. P. AU - Denis, P. AU - Regnault, A. AU - Berdeaux, G. C3 - Travalert DB - Embase DO - 10.2147/OPTH.S11818 J2 - Clin. Ophthalmol. KW - eye drops adult age aged article Bayes theorem classification algorithm computer system cross-sectional study disease concern score doctor patient relationship drug instillation Eye Drop Satisfaction Questionniare female gender health belief human intraocular hypertension major clinical study male observational study open angle glaucoma patient attitude patient compliance patient satisfaction questionnaire reminder system scoring system self report treatment concern score Travalert L1 - internal-pdf://1687926652/3215-Identification of noncompliant glauc-2010.pdf LA - English M1 - (Nordmann J.-P.; Baudouin C.) Hôpital des Quinzes-Vingt, Paris, France M3 - Article N1 - L361011329 2011-02-04 PY - 2010 SN - 1177-5467 1177-5483 SP - 1489-1496 ST - Identification of noncompliant glaucoma patients using Bayesian networks and the Eye-Drop Satisfaction Questionnaire TI - Identification of noncompliant glaucoma patients using Bayesian networks and the Eye-Drop Satisfaction Questionnaire UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361011329&from=export http://dx.doi.org/10.2147/OPTH.S11818 VL - 4 ID - 3215 ER - TY - JOUR AB - • PURPOSE: The present study describes the patterns and predictors of treatment persistence and adherence among patients who are diagnosed with glaucoma or as glaucoma suspects (based on claims codes). • DESIGN: A retrospective cohort study using health insurance claims data. • METHODS: Newly treated individuals with diagnosed glaucoma (n = 3623) and suspect glaucoma (n = 1677) were obtained from healthcare claims data in the Ingenix Research Database. For each of these two diagnostic groups, we calculated the duration of continuous treatment with the initially prescribed medication (persistence) and the prevalence of use of the initial medication at various time points (adherence). Four drug classes were included: β-blockers, α-agonists, carbonic anhydrase inhibitors, and prostaglandin analogs. • RESULTS: Nearly one half of the individuals who had filled a glaucoma prescription discontinued all topical ocular hypotensive therapy within six months, and just 37% of these individuals recently had refilled their initial medication at three years after the first dispensing. Prostaglandins were associated with better persistence than any other drug class, which was indicated by hazard ratios for discontinuation of prostaglandins compared with β-blockers of 0.40 (95% confidence interval, 0.35-0.44) for diagnosed patients and 0.44 (95% confidence interval, 0.37-0.52) for patients with suspect glaucoma. Prostaglandins showed a similar advantage in adherence. Furthermore, patients with diagnosed glaucoma were more likely to adhere to therapy than patients with suspect glaucoma (relative risk = 1.11; 95% confidence interval, 1.05-1.18). • CONCLUSION: Persistence and adherence were substantially better with prostaglandins than with other drug classes, and patients with diagnosed open-angle glaucoma were more likely to adhere to treatment than suspected glaucoma. © 2005 by Elsevier Inc. All rights reserved. AD - B.L. Nordstrom, Ingenix Epidemiology, Riverside Center, 275 Grove St, Auburndale, MA 02466, United States AU - Nordstrom, B. L. AU - Friedman, D. S. AU - Mozaffari, E. AU - Quigley, H. A. AU - Walker, A. M. DB - Embase Medline DO - 10.1016/j.ajo.2005.04.051 IS - 4 KW - alpha adrenergic receptor stimulating agent apraclonidine beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brinzolamide carbonate dehydratase inhibitor carteolol dipivefrine dorzolamide dorzolamide plus timolol ecothiopate latanoprost levobunolol metipranolol miotic agent pilocarpine prostaglandin timolol travoprost unoprostone isopropyl ester adult aged article cohort analysis comparative study confidence interval controlled study female glaucoma health insurance human major clinical study male patient compliance prescription prevalence priority journal treatment withdrawal LA - English M3 - Article N1 - L41455298 2005-10-25 PY - 2005 SN - 0002-9394 SP - 598.e1-598.e11 ST - Persistence and adherence with topical glaucoma therapy T2 - American Journal of Ophthalmology TI - Persistence and adherence with topical glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41455298&from=export http://dx.doi.org/10.1016/j.ajo.2005.04.051 VL - 140 ID - 3661 ER - TY - JOUR AD - S. Norell AU - Norell, S. DB - Medline IS - 143 KW - diagnostic agent eye drops fluorescein derivative pilocarpine article drug self administration glaucoma human information processing medical ethics medication error methodology patient compliance patient education patient participation psychological aspect self medication LA - English M3 - Article N1 - L11564137 1981-03-17 PY - 1980 SN - 0065-1451 SP - 1-28 ST - Medication behaviour. A study of outpatients treated with pilocarpine eye drops for primary open-angle glaucoma T2 - Acta ophthalmologica. Supplementum TI - Medication behaviour. A study of outpatients treated with pilocarpine eye drops for primary open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L11564137&from=export ID - 4100 ER - TY - JOUR AB - A medication monitor which recorded the date and hour each time a medicine bottle was opened was used to evaluate a programme for improving patients' compliance with their treatment. Eighty-two patients with glaucoma who had been prescribed pilocarpine eye drops three times daily to prevent visual loss were randomised into two groups. Both groups used the medication monitor during two 20-day periods, but before the second period the experimental group were given an education and tailoring programme in an attempt to improve their compliance. Nine patients missed the second treatment period and were excluded from the analysis. The patients in the experimental group showed significantly improved compliance when compared with the control group. The numbers of missed doses were reduced by about half, as was the proportion of time that exceeded the eight-hour dose intervals. Follow-up studies are needed to determine how long the improved compliance persists, but anyone considering setting up an education and tailoring programme should recognise the extent to which therapeutic efforts are wasted because of non-compliance. AD - Dept. Social Med., Karolinska Inst., Huddinge Univ. Hosp., Huddinge AU - Norell, S. E. DB - Embase Medline IS - 6197 KW - clinical trial controlled study drug therapy geographic distribution human methodology monitoring patient compliance psychological aspect randomized controlled trial short survey therapy LA - English M3 - Article N1 - L10249394 1980-02-07 PY - 1979 SN - 0959-8146 SP - 1031-1033 ST - Improving medication compliance: a randomised clinical trial T2 - British Medical Journal TI - Improving medication compliance: a randomised clinical trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L10249394&from=export VL - 2 ID - 4106 ER - TY - JOUR AB - A medication monitor which recorded the date and hour each time a medicine bottle was opened was used to evaluate a programme for improving patients’ compliance with their treatment. Eighty-two patients with glaucoma who had been prescribed pilocarpine eye drops three times daily to prevent visual loss were randomised into two groups. Both groups used the medication monitor during two 20-day periods, but before the second period the experimental group were given an education and tailoring programme in an attempt to improve their compliance. Nine patients missed the second treatment period and were excluded from the analysis. The patients in the experimental group showed significantly improved compliance when compared with the control group. The numbers of missed doses were reduced by about half, as was the proportion of time that exceeded the eight-hour dose intervals. Follow-up studies are needed to determine how long the improved compliance persists, but anyone considering setting up an education and tailoring programme should recognise the extent to which therapeutic efforts are wasted because of non-compliance. © 1979, British Medical Journal Publishing Group. All rights reserved. AD - Department of Social Medicine, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden AU - Norell, S. E. DB - Scopus DO - 10.1136/bmj.2.6197.1031 IS - 6197 M3 - Article N1 - Cited By :78 Export Date: 19 July 2021 PY - 1979 SP - 1031-1033 ST - Improving medication compliance: A randomised clinical trial T2 - British Medical Journal TI - Improving medication compliance: A randomised clinical trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018715186&doi=10.1136%2fbmj.2.6197.1031&partnerID=40&md5=e891cf0c55b02a399de15f132bca30e6 VL - 2 ID - 4948 ER - TY - JOUR AB - I used a recording medication monitor to obtain objective information on self-medication by date and hour from a group of 82 patients using pilocarpine three times daily to prevent visual loss from glaucoma. Doses meant to be taken during the day were missed more than twice as often as morning or evening doses. Of the missed doses, 272 (54%) were noon doses, but only 98 (19%) were morning doses. Medication compliance may be substantially improved by choosing a drug that needs to be taken less often than three times daily. The number of missed doses per day increased significantly during a 20-day period between clinic visits. This suggested that shorter intervals between clinic visits may improve adherence to the drug regimen prescribed. AD - Dept. Soc. Med., Huddinge Univ. Hosp., S-141 86 Huddinge AU - Norell, S. E. DB - Embase Medline DO - 10.1016/S0002-9394(14)74670-7 IS - 5 KW - pilocarpine central nervous system dose response drug response glaucoma major clinical study outpatient patient compliance psychological aspect therapy visual system LA - English M3 - Article N1 - L11031750 1982-01-12 PY - 1981 SN - 0002-9394 SP - 727-731 ST - Monitoring compliance with pilocarpine therapy T2 - American Journal of Ophthalmology TI - Monitoring compliance with pilocarpine therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L11031750&from=export http://dx.doi.org/10.1016/S0002-9394(14)74670-7 VL - 92 ID - 4095 ER - TY - JOUR AB - In research, as well as in daily practice, patient interviews and estimates by clinical staff are used to determine patients' adherence to drug regimens. The present study was undertaken to evaluate the accuracy of these methods in determining medication compliance among patients treated with pilocarpine to prevent visual loss from glaucoma. This was done by comparisons with objective and detailed information on self-medication behaviour obtained with a recording medication monitor. Results indicated that estimates by clinical staff were not useful in determining medication compliance. Patient interviews indentified 7 out of 16 patients who missed doses at least once a week. However, underreporting of missed doses was a major problem in determining medication compliance by interview. Of 73 patients interviewed, only 4% reported two or more missed doses during the past 7 days, whereas monitor records showed that 33% of the patients missed at least 2 doses, and 16% missed at least 6 doses, during the past week. AD - Dept. Soc. Med., Karolinska Inst., Huddinge Univ. Hosp., Huddinge AU - Norell, S. E. DB - Embase Medline IS - 1 KW - pilocarpine adult article central nervous system glaucoma major clinical study patient compliance therapy visual system LA - English M3 - Article N1 - L11157936 1981-06-28 PY - 1981 SP - 57-61 ST - Accuracy of patient interviews and estimates by clinical staff in determining medication compliance T2 - Social Science and Medicine - Part E Medical Psychology TI - Accuracy of patient interviews and estimates by clinical staff in determining medication compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L11157936&from=export VL - 15 ID - 4099 ER - TY - JOUR AB - I used a recording medication monitor to obtain objective information on self-medication by date and hour from a group of 82 patients using pilocarpine three times daily to prevent visual loss from glaucoma. Doses meant to be taken during the day were missed more than twice as often as morning or evening doses. Of the missed doses, 272 (54%) were noon doses, but only 98 (19%) were morning doses. Medication compliance may be substantially improved by choosing a drug that needs to be taken less often than three times daily. The number of missed doses per day increased significantly during a 20-day period between clinic visits. This suggested that shorter intervals between clinic visits may improve adherence to the drug regimen prescribed. AD - Dept. Soc. Med., Huddinge Univ. Hosp., S-141 86 Huddinge, Sweden AU - Norell, S. E. DB - Scopus DO - 10.1016/S0002-9394(14)74670-7 IS - 5 M3 - Article N1 - Cited By :49 Export Date: 19 July 2021 PY - 1981 SP - 727-731 ST - Monitoring compliance with pilocarpine therapy T2 - American Journal of Ophthalmology TI - Monitoring compliance with pilocarpine therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019796841&doi=10.1016%2fS0002-9394%2814%2974670-7&partnerID=40&md5=4937a37f7062955b03747c1377e1310b VL - 92 ID - 5000 ER - TY - JOUR AB - Methods were developed to study medication behaviour, in order to obtain accurate and detailed information on the patterns of drug-taking in medication with eye drops. A medication monitor was designed, which recorded the data and hour each time the medication bottle was opened. A fluorescein technique was designed to study the ability of patients to administer the eye drops in the conjunctival sac. Some problems in the measurement of medication behaviour are discussed. In a group of patients with open-angle glaucoma, for whom pilocarpine eye drops three times daily had been prescribed, 18% of dose intervals had a duration of 12 h or more and 11% had a duration of 4 h or less. Fluorescein tests indicated that the patients were usually able to administer the eye drops correctly. AD - Dept. Soc. Med., Huddinge Univ. Hosp., Karolinska Inst., S-141 86 Huddinge AU - Norell, S. E. AU - Granstrom, P. A. AU - Wassen, R. DB - Embase Medline IS - 3 KW - eye drops fluorescein pilocarpine drug monitoring drug therapy fluorescence angiography glaucoma monitoring patient compliance therapy topical drug administration visual system LA - English M3 - Article N1 - L10082886 1980-09-18 PY - 1980 SN - 0001-639X SP - 459-467 ST - A medication monitor and fluorescein technique designed to study medication behaviour T2 - Acta Ophthalmologica TI - A medication monitor and fluorescein technique designed to study medication behaviour UR - https://www.embase.com/search/results?subaction=viewrecord&id=L10082886&from=export VL - 58 ID - 4103 ER - TY - JOUR AB - Objective: To investigate the association between socioeconomic position (SEP) and poor eye health among women. Materials and Methods: We included the 7,708 women aged ≥40 years who participated in the 2008 National Health Interview Survey. We defined poor eye health as self-reported age-related eye diseases (AREDs; cataract, glaucoma, macular degeneration, or diabetic retinopathy) or visual impairment (VI). We identified diagnosed diabetes by self-report. We measured SEP by education attained and annual household income. We conducted logistic regression analyses while controlling for demographic, clinical, behavioral, and healthcare access variables. Results: The age-standardized prevalence of VI and ARED was significantly higher among women with diagnosed diabetes than among those without diagnosed diabetes, 29.8% versus 14.4% and 34.1% versus 20.8%, respectively (p < 0.05 for both). The prevalence of VI and ARED increased with decreasing SEP, but the trends were only significant among women without diabetes. After multivariable adjustment, education and income were significantly associated with VI but not with ARED. We found no interaction with diagnosed diabetes. Conclusions: SEP was inversely associated with VI but not with ARED. We found no interaction with diagnosed diabetes. AD - G.L. Beckles, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy. NE, Atlanta, GA, United States AU - Norris, K. L. AU - Beckles, G. L. AU - Chou, C. F. AU - Zhang, X. AU - Saaddine, J. DB - Embase Medline DO - 10.1089/jwh.2015.5255 IS - 3 KW - adult article cataract demography diabetes mellitus diabetic retinopathy educational status eye eye disease female glaucoma health care access health survey human income logistic regression analysis macular degeneration major clinical study prevalence priority journal self report social status visual impairment LA - English M3 - Article N1 - L609195759 2016-03-30 2016-04-07 PY - 2016 SN - 1931-843X 1540-9996 SP - 321-326 ST - Association of socioeconomic status with eye health among women with and without diabetes T2 - Journal of Women's Health TI - Association of socioeconomic status with eye health among women with and without diabetes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609195759&from=export http://dx.doi.org/10.1089/jwh.2015.5255 VL - 25 ID - 2754 ER - TY - JOUR AD - G. D. Novack AU - Novack, G. D. C1 - depakote(Abbott,United States) xalatan(Pfizer,United States) C2 - Abbott(United States) Alcon(United States) Pfizer(United States) DB - Embase Medline DO - 10.1016/S1542-0124(12)70073-3 IS - 2 KW - antihypertensive agent antilipemic agent azithromycin eye drops latanoprost pilocarpine pirenzepine prostaglandin timolol travoprost valproate semisodium article glaucoma health care cost intraocular pressure myopia ophthalmology patient compliance pharmacist physics pill prescription depakote xalatan Travalert Xal-Ease LA - English M3 - Article N1 - L358742926 2010-05-11 2010-06-10 PY - 2010 SN - 1542-0124 SP - 91-95 ST - Treatment adherence in ophthalmology and astrophysics T2 - Ocular Surface TI - Treatment adherence in ophthalmology and astrophysics UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358742926&from=export http://dx.doi.org/10.1016/S1542-0124(12)70073-3 http://docserver.ingentaconnect.com/deliver/connect/ethis/15420124/v8n2/s6.pdf?expires=1272631996&id=56513692&titleid=72010012&accname=Elsevier+Science&checksum=B46BB13102CC9619F0E95EC741DC88FD VL - 8 ID - 3273 ER - TY - JOUR AB - When glaucoma medication fails to adequately control intraocular pressure (IOP), a second medication is frequently added. Before adding a second drug to patients whose IOP was no longer controlled by 0.5% timolol, we tested the effect of switching to another beta blocker, levobunolol (0.5 or 1%). We also evaluated the effect of study participation on compliance in the control group continuing to receive 0.5% timolol. In each treatment group, the IOP of approximately 30-40% of the patients was successfully controlled for the 3-month study period. The remaining patients did not exhibit significant pressure reductions and were dropped from the study within 2 weeks. We concluded that (1) the results of 'switch' studies without a control group must be interpreted carefully, and (2) the initiation of a 'new regimen' with an equieffective beta blocker may be sufficient to increase compliance and thereby control IOP. AD - Allergan Pharmaceuticals Incorporation, Irvine, CA 92715 AU - Novack, G. D. AU - David, R. AU - Lee, P. F. AU - Freeman, M. I. AU - Duzman, E. AU - Batoosingh, A. L. C2 - Allergan(United States) DB - Embase Medline IS - 1 KW - levobunolol timolol clinical article glaucoma human intraocular pressure patient compliance topical drug administration LA - English M3 - Article N1 - L18041341 1988-03-02 PY - 1988 SN - 0030-3755 SP - 23-28 ST - Effect of changing medication regimens in glaucoma patients T2 - Ophthalmologica TI - Effect of changing medication regimens in glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L18041341&from=export VL - 196 ID - 4058 ER - TY - JOUR AB - Purpose: This retrospective study aimed to evaluate the safety and efficacy of MIGS (Xen (R) and Cypass (R)) compared to trabeculectomy and Baerveldr implants. Patients and Methods: This single-center study included patients from the Ophthalmic Hospital of Turin between January 2015 and 2018. Efficacy was assessed based on the intraocular pressure and the number of medications necessary to control IOP at 1, 3, 6, 12, 24, and 36 months and the potential complications. Complete surgical success was defined as IOP <= 21 mmHg, with no medication or additional glaucoma surgery. Qualified success was defined as IOP <= 21 mmHg with the reintroduction of topical medications. Our third measure of success was a delta IOP reduction greater than 20% compared to baseline. Results: The delta IOP compared to the baseline was significant at every instance, except in the Xen (R) implant group. The average IOP distribution at different time points was significant, except at 1 and 12 months. The delta of the medication number compared to the baseline was significant at every instant. All three methods of success were analyzed using a Kaplan-Meier survival curve that identified a significant difference on the success rates of Xen (R)-trabeculectomy, Xen (R)-Baerveldt (R), and Cypass (R) Baerveldt (R). Conclusion: MIGS can reduce the number of medication classes, thus increasing patient compliance and reducing topical ocular toxicity and general costs. Trabeculectomy remains the most effective option but still presents a percentage of failures that might increase during follow-up. AN - WOS:000658212900001 AU - Nuzzi, R. AU - Gremmo, G. AU - Toja, F. AU - Marolo, P. DO - 10.1080/08820538.2021.1931356 SN - 0882-0538 1744-5205 ST - A Retrospective Comparison of Trabeculectomy, Baerveldt Glaucoma Implant, and Microinvasive Glaucoma Surgeries in a Three-Year Follow-Up T2 - SEMINARS IN OPHTHALMOLOGY TI - A Retrospective Comparison of Trabeculectomy, Baerveldt Glaucoma Implant, and Microinvasive Glaucoma Surgeries in a Three-Year Follow-Up ID - 6116 ER - TY - JOUR AB - Purpose: This retrospective study aimed to evaluate the safety and efficacy of MIGS (Xen® and Cypass®) compared to trabeculectomy and Baerveldt® implants. Patients and Methods: This single-center study included patients from the Ophthalmic Hospital of Turin between January 2015 and 2018. Efficacy was assessed based on the intraocular pressure and the number of medications necessary to control IOP at 1, 3, 6, 12, 24, and 36 months and the potential complications. Complete surgical success was defined as IOP ≤ 21 mmHg, with no medication or additional glaucoma surgery. Qualified success was defined as IOP ≤ 21 mmHg with the reintroduction of topical medications. Our third measure of success was a delta IOP reduction greater than 20% compared to baseline. Results: The delta IOP compared to the baseline was significant at every instance, except in the Xen® implant group. The average IOP distribution at different time points was significant, except at 1 and 12 months. The delta of the medication number compared to the baseline was significant at every instant. All three methods of success were analyzed using a Kaplan-Meier survival curve that identified a significant difference on the success rates of Xen®-trabeculectomy, Xen®-Baerveldt®, and Cypass®-Baerveldt®. Conclusion: MIGS can reduce the number of medication classes, thus increasing patient compliance and reducing topical ocular toxicity and general costs. Trabeculectomy remains the most effective option but still presents a percentage of failures that might increase during follow-up. © 2021 Taylor & Francis. AD - S.C.U. Ophthalmology Unit, “City of Health and Science” University Hospital, Turin, Italy Department of Surgical Sciences, University of Turin, Turin, Italy Eye Clinic, Sapienza University of Rome, Rome, Italy AU - Nuzzi, R. AU - Gremmo, G. AU - Toja, F. AU - Marolo, P. DB - Scopus DO - 10.1080/08820538.2021.1931356 KW - Baerveldt® implant Glaucoma MIGS trabeculectomy M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 ST - A Retrospective Comparison of Trabeculectomy, Baerveldt Glaucoma Implant, and Microinvasive Glaucoma Surgeries in a Three-Year Follow-Up T2 - Seminars in Ophthalmology TI - A Retrospective Comparison of Trabeculectomy, Baerveldt Glaucoma Implant, and Microinvasive Glaucoma Surgeries in a Three-Year Follow-Up UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107512487&doi=10.1080%2f08820538.2021.1931356&partnerID=40&md5=3ec6ec1fcd1591d29f5589efc239899e ID - 5670 ER - TY - JOUR AB - We describe the case of an 86-year-old patient, pseudophakic in both eyes and with high myopia, who had previously had a 25-G vitrectomy with 20% C3F8 used as a tamponade due to a total retinal detachment with choroidal hemorrhages and macular hole. At the postoperative 4-month follow-up, we found 360° iridocorneal synechiae with elevated intraocular pressure due to angle closure in all sectors, with an adherent retina and in the absence of choroidal hemorrhage/detachment and of corneal edema or endothelial damage. The patient was, therefore, hospitalized to receive 360° anterior synechiolysis with a single opening to the corneal limbus, like in paracentesis, with topical anesthesia. We have tried to study the possible causes of this case history. However, it should be recognized that the development of iridocorneal synechiae and the rise of intraocular pressure can be a possible complication of air/C3F8 vitrectomy, which cannot be managed with medical therapy. It will be essential to monitor the situation and to hospitalize the patient for surgical synechiolysis to restore the normal anatomy and physiology and to correct the ocular hypertension. During the vitrectomy, we will have to introduce in advance an adequate amount of viscoelastic material in the anterior chamber and to perform a preventive surgical iridectomy, even if the iridocorneal angle is open in all sectors. © 2017 The Author(s) Published by S. Karger AG. AD - Eye Clinic Section, University of Turin, Ophthalmic Hospital, Turin, Italy Ospedale Oftalmico di Torino, Clinica Oculistica Universitaria, Via Juvarra 19, Torino, IT-10121, Italy AU - Nuzzi, R. AU - Monteu, F. DB - Scopus DO - 10.1159/000461573 IS - 1 KW - Iridocorneal synechiae Synechiolysis Vitrectomy M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2017 SP - 170-172 ST - Anterior 360° Synechiolysis in a Case of Late Iridocorneal Adhesions after 25-G Vitrectomy: Surgical and Physiopathogenetic Aspects T2 - Case Reports in Ophthalmology TI - Anterior 360° Synechiolysis in a Case of Late Iridocorneal Adhesions after 25-G Vitrectomy: Surgical and Physiopathogenetic Aspects UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015624581&doi=10.1159%2f000461573&partnerID=40&md5=54f7912406e6bd74a6f3549764cb3f3d VL - 8 ID - 5624 ER - TY - JOUR AB - We describe the case of an 86-year-old patient, pseudophakic in both eyes and with high myopia, who had previously had a 25-G vitrectomy with 20% C3F8 used as a tamponade due to a total retinal detachment with choroidal hemorrhages and macular hole. At the postoperative 4-month follow-up, we found 360 degrees iridocorneal synechiae with elevated intraocular pressure due to angle closure in all sectors, with an adherent retina and in the absence of choroidal hemorrhage/detachment and of corneal edema or endothelial damage. The patient was, therefore, hospitalized to receive 360 degrees anterior synechiolysis with a single opening to the corneal limbus, like in paracentesis, with topical anesthesia. We have tried to study the possible causes of this case history. However, it should be recognized that the development of iridocorneal synechiae and the rise of intraocular pressure can be a possible complication of air/C3F8 vitrectomy, which cannot be managed with medical therapy. It will be essential to monitor the situation and to hospitalize the patient for surgical synechiolysis to restore the normal anatomy and physiology and to correct the ocular hypertension. During the vitrectomy, we will have to introduce in advance an adequate amount of viscoelastic material in the anterior chamber and to perform a preventive surgical iridectomy, even if the iridocorneal angle is open in all sectors. (C) 2017 The Author(s) Published by S. Karger AG, Basel AN - WOS:000399133300029 AU - Nuzzi, R. AU - Monteu, F. DA - JAN-APR DO - 10.1159/000461573 IS - 1 PY - 2017 SN - 1663-2699 SP - 170-172 ST - Anterior 360 degrees Synechiolysis in a Case of Late Iridocorneal Adhesions after 25-G Vitrectomy: Surgical and Physiopathogenetic Aspects T2 - CASE REPORTS IN OPHTHALMOLOGY TI - Anterior 360 degrees Synechiolysis in a Case of Late Iridocorneal Adhesions after 25-G Vitrectomy: Surgical and Physiopathogenetic Aspects VL - 8 ID - 6317 ER - TY - JOUR AB - Introduction The majority of blindness worldwide could be prevented or reversed with early diagnosis and treatment, yet identifying at-risk and prevalent cases of eye disease and linking them with care remain important obstacles to addressing this burden. Leading causes of blindness like glaucoma, diabetic retinopathy and age-related macular degeneration have detectable early asymptomatic phases and can cause irreversible vision loss. Mass screening for such diseases could reduce visual impairment at the population level. Methods and analysis This protocol describes a parallel-group cluster-randomised trial designed to determine whether community-based screening for glaucoma, diabetic retinopathy and age-related macular degeneration reduces population-level visual impairment in Nepal. A door-to-door population census is conducted in all study communities. All adults aged ≥60 years have visual acuity tested at the census visit, and those meeting referral criteria are referred to a local eye care facility for further diagnosis and management. Communities are subsequently randomised to a community-based screening programme or to no additional intervention. The intervention consists of a single round of screening including intraocular pressure and optical coherence tomography assessment of all adults ≥60 years old with enhanced linkage to care for participants meeting referral criteria. Four years after implementation of the intervention, masked outcome assessors conduct a repeat census to collect data on the primary outcome, visual acuity. Individuals with incident visual impairment receive a comprehensive ophthalmological examination to determine the cause of visual impairment. Outcomes are compared by treatment arm according to the originally assigned intervention. Ethics and dissemination The trial has received ethical approval from the University of California San Francisco Institutional Review Board, Nepal Netra Jyoti Sangh and the Nepal Health Research Council. Results of this trial will be disseminated through publication in peer-reviewed journals and presentation at local and international meetings. Trial registration number NCT03752840. © AD - Francis i Proctor Foundation, University of California San Francisco, San Francisco, CA, United States Bharatpur Eye Hospital, Bharatpur, Nepal Seva Foundation, Bharatpur, Nepal Department of Ophthalmology, University of California San Francisco, San Francisco, CA, United States AU - O'Brien, K. S. AU - Stevens, V. M. AU - Byanju, R. AU - Kandel, R. P. AU - Bhandari, G. AU - Bhandari, S. AU - Melo, J. S. AU - Porco, T. C. AU - Lietman, T. M. AU - Keenan, J. D. C7 - 040219 DB - Scopus DO - 10.1136/bmjopen-2020-040219 IS - 10 KW - age-related macular degeneration diabetic retinopathy glaucoma mass screening randomised controlled trial M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 ST - Cluster-randomised trial of community-based screening for eye disease in adults in Nepal: The Village-Integrated Eye Worker Trial II (VIEW II) trial protocol T2 - BMJ Open TI - Cluster-randomised trial of community-based screening for eye disease in adults in Nepal: The Village-Integrated Eye Worker Trial II (VIEW II) trial protocol UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85093482024&doi=10.1136%2fbmjopen-2020-040219&partnerID=40&md5=a2185d434b5b0f07b72f40a0dab9c93c VL - 10 ID - 5689 ER - TY - JOUR AB - Introduction The majority of blindness worldwide could be prevented or reversed with early diagnosis and treatment, yet identifying at-risk and prevalent cases of eye disease and linking them with care remain important obstacles to addressing this burden. Leading causes of blindness like glaucoma, diabetic retinopathy and age-related macular degeneration have detectable early asymptomatic phases and can cause irreversible vision loss. Mass screening for such diseases could reduce visual impairment at the population level. Methods and analysis This protocol describes a parallel-group cluster-randomised trial designed to determine whether community-based screening for glaucoma, diabetic retinopathy and age-related macular degeneration reduces population-level visual impairment in Nepal. A door-to-door population census is conducted in all study communities. All adults aged >= 60 years have visual acuity tested at the census visit, and those meeting referral criteria are referred to a local eye care facility for further diagnosis and management. Communities are subsequently randomised to a community-based screening programme or to no additional intervention. The intervention consists of a single round of screening including intraocular pressure and optical coherence tomography assessment of all adults >= 60 years old with enhanced linkage to care for participants meeting referral criteria. Four years after implementation of the intervention, masked outcome assessors conduct a repeat census to collect data on the primary outcome, visual acuity. Individuals with incident visual impairment receive a comprehensive ophthalmological examination to determine the cause of visual impairment. Outcomes are compared by treatment arm according to the originally assigned intervention. Ethics and dissemination The trial has received ethical approval from the University of California San Francisco Institutional Review Board, Nepal Netra Jyoti Sangh and the Nepal Health Research Council. Results of this trial will be disseminated through publication in peer-reviewed journals and presentation at local and international meetings. AN - WOS:000583362600015 AU - O'Brien, K. S. AU - Stevens, V. M. AU - Byanju, R. AU - Kandel, R. P. AU - Bhandari, G. AU - Bhandari, S. AU - Melo, J. S. AU - Porco, T. C. AU - Lietman, T. M. AU - Keenan, J. D. AU - Grp Information, View DO - 10.1136/bmjopen-2020-040219 IS - 10 PY - 2020 SN - 2044-6055 ST - Cluster-randomised trial of community-based screening for eye disease in adults in Nepal: the Village-Integrated Eye Worker Trial II (VIEW II) trial protocol T2 - BMJ OPEN TI - Cluster-randomised trial of community-based screening for eye disease in adults in Nepal: the Village-Integrated Eye Worker Trial II (VIEW II) trial protocol VL - 10 ID - 6318 ER - TY - JOUR AB - Objective: To report the perspectives of optometrists, ophthalmologists and patients on a model of shared care for patients with chronic eye diseases. Design, setting and participants: Qualitative study of a model of shared care between optometrists and ophthalmologists for patients with stable agerelated macular degeneration, diabetic retinopathy and glaucoma, trialled by the Royal Victorian Eye and Ear Hospital in Melbourne during 2007-2009. Semistructured interviews were conducted with optometrists, ophthalmologists and patients at completion of the project to obtain their perspectives on this model. Results: Seventeen optometrists submitted expressions of interest to participate, and 12 completed web-based training modules and clinical observerships and adhered to specified examination and reporting protocols. All five participating ophthalmologists and 11 of the optometrists were interviewed. Ninety-eight patients participated and 37 were interviewed. Optometrists not only met ophthalmologists' expectations but exceeded them, appropriately detecting and referring patients with additional, previously undetected conditions. Patients reported savings in travel time and were satisfied with the quality of care they received. Optometrists, ophthalmologists and patients indicated a general acceptance of shared care arrangements, although there were some issues relating to interprofessional trust. Conclusions: Shared care between local optometrists and hospital-based ophthalmologists can help to reduce patient waiting time for review and offers an opportunity for these two groups of eye care professionals to collaborate in providing localised care for the benefit of patients. However, trust and relationship building need to be further developed. AD - P. M. O'Connor, Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia AU - O'Connor, P. M. AU - Alex Harper, C. AU - Brunton, C. L. AU - Clews, S. J. AU - Haymes, S. A. AU - Keeffe, J. E. DB - Embase Medline DO - 10.5694/mja11.10856 IS - 10 KW - adult aged article Australia cataract extraction chronic disease community care controlled study diabetic retinopathy disease course doctor patient relationship eye care eye disease female glaucoma health care health care access health care quality human intraocular hypertension intraocular pressure major clinical study male ophthalmologist optometrist patient care patient satisfaction personal experience physician pigment epithelium practice guideline qualitative research age related macular degeneration rural area semi structured interview trust urban area visual acuity L1 - internal-pdf://4059243604/3081-Shared care for chronic eye diseases-2012.pdf LA - English M3 - Article N1 - L368427024 2013-03-08 2013-03-18 PY - 2012 SN - 0025-729X 1326-5377 SP - 646-650 ST - Shared care for chronic eye diseases: Perspectives of ophthalmologists, optometrists and patients T2 - Medical Journal of Australia TI - Shared care for chronic eye diseases: Perspectives of ophthalmologists, optometrists and patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368427024&from=export http://dx.doi.org/10.5694/mja11.10856 VL - 196 ID - 3081 ER - TY - JOUR AB - Objective: To report the perspectives of optometrists, ophthalmologists and patients on a model of shared care for patients with chronic eye diseases.Design, Setting and Participants: Qualitative study of a model of shared care between optometrists and ophthalmologists for patients with stable age-related macular degeneration, diabetic retinopathy and glaucoma, trialled by the Royal Victorian Eye and Ear Hospital in Melbourne during 2007–2009. Semi-structured interviews were conducted with optometrists, ophthalmologists and patients at completion of the project to obtain their perspectives on this model.Results: Seventeen optometrists submitted expressions of interest to participate, and 12 completed web-based training modules and clinical observerships and adhered to specified examination and reporting protocols. All five participating ophthalmologists and 11 of the optometrists were interviewed. Ninety-eight patients participated and 37 were interviewed. Optometrists not only met ophthalmologists’ expectations but exceeded them, appropriately detecting and referring patients with additional, previously undetected conditions. Patients reported savings in travel time and were satisfied with the quality of care they received. Optometrists, ophthalmologists and patients indicated a general acceptance of shared care arrangements, although there were some issues relating to interprofessional trust.Conclusions: Shared care between local optometrists and hospital-based ophthalmologists can help to reduce patient waiting time for review and offers an opportunity for these two groups of eye care professionals to collaborate in providing localised care for the benefit of patients. However, trust and relationship building need to be further developed. AD - Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia. jillek@unimelb.edu.au. AN - 108121489. Language: English. Entry Date: 20120831. Revision Date: 20200708. Publication Type: journal article AU - O'Connor, P. M. AU - Harper, C. A. AU - Brunton, C. L. AU - Clews, S. J. AU - Haymes, S. A. AU - Keeffe, J. E. AU - O'Connor, Patricia M. AU - Harper, C. Alex AU - Brunton, Cathy L. AU - Clews, Sandra J. AU - Haymes, Sharon A. AU - Keeffe, Jill E. DB - ccm DO - 10.5694/mja11.10856 DP - EBSCOhost IS - 10 KW - Attitude to Health Diagnosis, Eye Eye Diseases -- Therapy Multidisciplinary Care Team Ophthalmology Optometry Adult Aged Aged, 80 and Over Attitude of Health Personnel Chronic Disease Diabetic Retinopathy -- Diagnosis Diabetic Retinopathy -- Therapy Female Glaucoma -- Diagnosis Glaucoma -- Therapy Human Interprofessional Relations Macular Degeneration -- Diagnosis Macular Degeneration -- Therapy Male Middle Age Patient Satisfaction Qualitative Studies Referral and Consultation Surveys Waiting Lists N1 - research. Journal Subset: Australia & New Zealand; Biomedical; Double Blind Peer Reviewed; Peer Reviewed. NLM UID: 0400714. PMID: NLM22676881. PY - 2012 SN - 0025-729X SP - 646-650 ST - Shared care for chronic eye diseases: perspectives of ophthalmologists, optometrists and patients T2 - Medical Journal of Australia TI - Shared care for chronic eye diseases: perspectives of ophthalmologists, optometrists and patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108121489&site=ehost-live&scope=site VL - 196 ID - 4551 ER - TY - JOUR AB - Purpose: To evaluate readability of eye drop labels and accurate recall of prescription instructions in a glaucoma population. Methods: A hospital-based, cross-sectional study. A trained, interviewer examined patient ability to read standard and larger font medication labels. A questionnaire was administered to ascertain accurate recall of prescribed eye drops. Clinical information was obtained through independent chart review. Glaucoma severity was classified according to a glaucoma staging system. The setting for the study was the glaucoma outpatient clinic, Royal Victorian Eye and Ear Hospital (Melbourne, Australia), a major tertiary referral centre. A total of 200 glaucoma patients (96.2% response), aged 45-90 years, on eye drops took part in the study. Non-English-speaking patients were excluded. The main outcome measure was the ability to read prescribed medication labels and accurately recall treatment regime was compared with glaucoma severity and the number of eye drops. Results: Of the glaucoma patients, 12% were unable to read standard pharmacy labels. Only 5.5% were unable to read the larger font labels. Of the patients, 32% were not able to accurately recall the type of drops or prescribed frequency of instillation. An inability to read standard labels was associated with a threefold reduction in the likelihood of accurate medication recall (95% confidence intervals, 1.40-7.66, P < 0.05). Patients with three or more types of eye drops were five times less likely to recall their medications (95% confidence interval, 0.07-0.57, P < 0.05). Conclusions: Inability to read or recall prescribed eye drops was associated with glaucoma severity and the number of prescribed eye drops. These factors may impact significantly on patients' adherence to glaucoma medications. © 2009 The Authors. Journal compilation © 2009 Royal Australian and New Zealand College of Ophthalmologists. AD - J.G. Crowston, Glaucoma Investigation and Research Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Vic. 3002, Australia AU - O'Hare, F. AU - Jeganathan, V. S. E. AU - Rokahr, C. G. AU - Rogers, S. L. AU - Crowston, J. G. C1 - xalacom DB - Embase Medline DO - 10.1111/j.1442-9071.2009.02184.x IS - 9 KW - eye drops latanoprost plus timolol prostaglandin derivative aged article disease severity drug information drug labeling female glaucoma human intraocular hypertension intraocular pressure major clinical study male medication error patient compliance prescription recall tertiary health care visual acuity xalacom LA - English M3 - Article N1 - L358075299 2010-02-22 PY - 2009 SN - 1442-6404 1442-9071 SP - 849-854 ST - Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients T2 - Clinical and Experimental Ophthalmology TI - Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358075299&from=export http://dx.doi.org/10.1111/j.1442-9071.2009.02184.x VL - 37 ID - 3302 ER - TY - JOUR AB - Background: Over the past decade, several new medical therapies have become available for the treatment of primary open-angle glaucoma (POAG). A systematic evidence-based approach for identifying an optimal therapeutic agent is lacking. Objectives: The aims of this review were to critically evaluate published treatment recommendations for POAG and, based on a systematic review of the literature, to develop criteria that would define a "gold standard" medical therapy that reflects new treatment advances and established therapeutic goals. Methods: A MEDLINE search spanning the years 1966 to 2002 and using the search terms gold standard, drug of choice, agent of choice, benchmark, ophthalmology, eye, and glaucoma was conducted and the results reviewed by a panel of 15 experts in the field of glaucoma. Published treatment recommendations for POAG were discussed. Criteria, anchored to medical evidence, for distinguishing a standard of medical therapy for POAG were defined. Results: The terms connoting a gold standard therapy were found in only 258 of ∼368,000 ophthalmology-related citations and 53 of almost 23,000 glaucoma citations, validating the need to define therapeutic standards. The lack of recommendations for the use of new classes of ocular hypotensive agents was acknowledged. Criteria identified to evaluate intraocular pressure (IOP)--lowering agents as gold standards included the following: efficacy in reducing IOP consistently over a 24-hour period to a level that will preserve the visual field and protect the optic nerve without inducing tachyphylaxis and tolerance, paucity of local and systemic adverse effects, promotion of patient compliance, and applicability in diverse patient populations. Conclusions: These criteria should be employed as measures for evidence-based analyses to evaluate available and future IOP-lowering medical therapies for POAG. The conceptual framework presented may be applicable to other therapeutic areas. Copyright © 2004 Excerpta Medica, Inc. AD - S.A. Obstbaum, 115 East 39th Street, New York, NY 10016, United States AU - Obstbaum, S. A. AU - Cioffi, G. A. AU - Krieglstein, G. K. AU - Fennerty, M. B. AU - Alm, A. AU - Araie, M. AU - Carassa, R. G. AU - Greve, E. L. AU - Hitchings, R. A. AU - Kaufman, P. L. AU - Kitazawa, Y. AU - Pongpun, P. R. AU - Susanna Jr, R. AU - Wax, M. B. AU - Zimmerman, T. J. C1 - aspirin DB - Embase Medline DO - 10.1016/j.clintera.2004.12.007 IS - 12 KW - acetylsalicylic acid aciclovir epinephrine adrenergic receptor stimulating agent alpha adrenergic receptor stimulating agent alteplase amphotericin B antiglaucoma agent antihypertensive agent apraclonidine beta adrenergic receptor blocking agent botulinum toxin brinzolamide carbachol carbonate dehydratase inhibitor cholinergic receptor stimulating agent dipivefrine high density lipoprotein cholesterol levodopa methotrexate nifedipine omeprazole pilocarpine prostaglandin derivative proton pump inhibitor sumatriptan tamoxifen timolol artery thrombosis blood clot lysis bradycardia breast cancer cholesterol blood level chronic disease clinical trial cost effectiveness analysis drug contraindication drug efficacy drug hypersensitivity drug safety epidemiological data evidence based medicine face disorder gastroesophageal reflux genital herpes glaucoma health economics human intraocular pressure juvenile rheumatoid arthritis lung function medical decision making medical literature Medline mental disease migraine open angle glaucoma ophthalmology optic nerve Parkinson disease patient compliance patient education practice guideline publication quality of life review risk benefit analysis risk factor scleroderma side effect standardization systematic review tachyphylaxis thorax pain validation process visual field aspirin LA - English M3 - Review N1 - L40353620 2005-04-18 PY - 2004 SN - 0149-2918 SP - 2102-2120 ST - Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis T2 - Clinical Therapeutics TI - Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40353620&from=export http://dx.doi.org/10.1016/j.clintera.2004.12.007 VL - 26 ID - 3720 ER - TY - JOUR AB - BACKGROUND: Over the past decade, several new medical therapies have become available for the treatment of primary open-angle glaucoma (POAG). A systematic evidence-based approach for identifying an optimal therapeutic agent is lacking. OBJECTIVES: The aims of this review were to critically evaluate published treatment recommendations for POAG and, based on a systematic review of the literature, to develop criteria that would define a 'gold standard' medical therapy that reflects new treatment advances and established therapeutic goals. METHODS: A MEDLINE search spanning the years 1966 to 2002 and using the search terms gold standard, drug of choice, agent of choice, benchmark, ophthalmology, eye, and glaucoma was conducted and the results reviewed by a panel of 15 experts in the field of glaucoma. Published treatment recommendations for POAG were discussed. Criteria, anchored to medical evidence, for distinguishing a standard of medical therapy for POAG were defined. RESULTS: The terms connoting a gold standard therapy were found in only 258 of approximately 368,000 ophthalmology-related citations and 53 of almost 23,000 glaucoma citations, validating the need to define therapeutic standards. The lack of recommendations for the use of new classes of ocular hypotensive agents was acknowledged. Criteria identified to evaluate intraocular pressure (IOP)-lowering agents as gold standards included the following: efficacy in reducing IOP consistently over a 24-hour period to a level that will preserve the visual field and protect the optic nerve without inducing tachyphylaxis and tolerance, paucity of local and systemic adverse effects, promotion of patient compliance, and applicability in diverse patient populations. CONCLUSIONS: These criteria should be employed as measures for evidence-based analyses to evaluate available and future IOP-lowering medical therapies for POAG. The conceptual framework presented may be applicable to other therapeutic areas. AD - Department of Ophthalmology, New York University School of Medicine and Lenox Hill Hospital, New York, NY; saobstbaum@aol.com AN - 106532908. Language: English. Entry Date: 20051028. Revision Date: 20200708. Publication Type: Journal Article AU - Obstbaum, S. A. AU - Cioffi, G. A. AU - Krieglstein, G. K. AU - Fennerty, M. B. AU - Alm, A. AU - Araie, M. AU - Carassa, R. G. AU - Greve, E. L. AU - Hitchings, R. A. AU - Kaufman, P. L. AU - Kitazawa, Y. AU - Pongpun, P. R. AU - Susanna, R., Jr. AU - Wax, M. B. AU - Zimmerman, T. J. DB - ccm DO - 10.1016/j.clintera.2004.12.007 DP - EBSCOhost IS - 12 KW - Glaucoma -- Drug Therapy Professional Practice, Evidence-Based Descriptive Statistics Drug Tolerance Economics, Pharmaceutical Medication Compliance Quality of Life Human N1 - research; systematic review; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 7706726. PMID: NLM15823774. PY - 2004 SN - 0149-2918 SP - 2102-2120 ST - Gold standard medical therapy for glaucoma: defining the criteria identifying measures for an evidence-based analysis T2 - Clinical Therapeutics TI - Gold standard medical therapy for glaucoma: defining the criteria identifying measures for an evidence-based analysis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106532908&site=ehost-live&scope=site VL - 26 ID - 4501 ER - TY - JOUR AB - Background: Glaucoma is the leading cause of irreversible blindness globally, and treatment involves considerable cost to stakeholders in healthcare. However, there is infrequent availability of cost information and patterns of management, especially in developing countries. This study determined the cost of the medical management of POAG, adherence, and pattern of medication prescription in Ghana. Methods: A retrospective cross-sectional study involving 891 Primary Open Angle Glaucoma (POAG) cases seen in the year 2012 at three referral facilities. Demographics, ocular history, resource consumption, medication, test, surgery and other related cost were extracted from 84 patients who had fully complied with their treatment to calculate total cost (TC) based on 2012 estimates. Glaucoma drugs prescribed to patients who had adhered to all their review visits within the period evident from case folders were recorded and analysed for the prescription pattern. Results: Out of 891 POAG cases seen in 2012, 351(39.4 %) attended all the required review visits, but only 84 (9.4) had fully and continually adhered to all their treatment regimes. They comprised 41(48.8 %) males and 43(51.2 %) females with a mean age of 65 ± 14.8. Majority of the respondents were elderly above 60 year of age (65.5 %). The total estimated cost for the 84 cases in the year was GH¢ 81,237 ($40,619), comprising GH¢ 72,193 ($36,097) direct medication cost and GH¢9,045 ($4,523) direct non-medication cost (surgery and test cost), and an average of GH¢ 967 ($484) for a mean visit of 5.6 ± 1.1 in the year. A total of 673 glaucoma medications had been prescribed for 351 patients for the year, with timolol being the most prescribed (64.19 %) and monotherapy as the most adopted form of therapy (61.06 %). Age and income showed concurrent increase with cost (P ≤ 0.05). Conclusions: Cost of managing glaucoma constitutes a substantial financial burden and influenced the pattern of medication prescription. © 2016 The Author(s). AD - Department of Vision and Hearing Sciences, Faculty of Science and Technology, Anglia Ruskin University, Cambridge, United Kingdom Department of Optometry, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana Department of Economics, Faculty of Social Sciences, College of Humanities and Legal Studies, University of Cape Coast, Cape Coast, Ghana AU - Ocansey, S. AU - Kyei, S. AU - Diafo, A. AU - Darfor, K. N. AU - Boadi-Kusi, S. B. AU - Aglobitse, P. B. C7 - 282 DB - Scopus DO - 10.1186/s12913-016-1528-x IS - 1 KW - Compliance Cost Ghana Glaucoma Medication M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2016 ST - Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities T2 - BMC Health Services Research TI - Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978722254&doi=10.1186%2fs12913-016-1528-x&partnerID=40&md5=89e43a1ba6b9b6998bc05ab7b7d9eed8 VL - 16 ID - 5275 ER - TY - JOUR AB - Background: Glaucoma is the leading cause of irreversible blindness globally, and treatment involves considerable cost to stakeholders in healthcare. However, there is infrequent availability of cost information and patterns of management, especially in developing countries. This study determined the cost of the medical management of POAG, adherence, and pattern of medication prescription in Ghana. Methods: A retrospective cross-sectional study involving 891 Primary Open Angle Glaucoma (POAG) cases seen in the year 2012 at three referral facilities. Demographics, ocular history, resource consumption, medication, test, surgery and other related cost were extracted from 84 patients who had fully complied with their treatment to calculate total cost (TC) based on 2012 estimates. Glaucoma drugs prescribed to patients who had adhered to all their review visits within the period evident from case folders were recorded and analysed for the prescription pattern. Results: Out of 891 POAG cases seen in 2012, 351(39.4 %) attended all the required review visits, but only 84 (9.4) had fully and continually adhered to all their treatment regimes. They comprised 41(48.8 %) males and 43(51.2 %) females with a mean age of 65 +/- 14.8. Majority of the respondents were elderly above 60 year of age (65.5 %). The total estimated cost for the 84 cases in the year was GH cent 81,237 ($ 40,619), comprising GH cent 72,193 ($ 36,097) direct medication cost and GH cent 9,045 ($ 4,523) direct non-medication cost (surgery and test cost), and an average of GH cent 967 ($ 484) for a mean visit of 5.6 +/- 1.1 in the year. A total of 673 glaucoma medications had been prescribed for 351 patients for the year, with timolol being the most prescribed (64.19 %) and monotherapy as the most adopted form of therapy (61.06 %). Age and income showed concurrent increase with cost (P <= 0.05). Conclusions: Cost of managing glaucoma constitutes a substantial financial burden and influenced the pattern of medication prescription. AN - WOS:000380098800004 AU - Ocansey, S. AU - Kyei, S. AU - Diafo, A. AU - Darfor, K. N. AU - Boadi-Kusi, S. B. AU - Aglobitse, P. B. DA - JUL 19 DO - 10.1186/s12913-016-1528-x PY - 2016 SN - 1472-6963 ST - Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities T2 - BMC HEALTH SERVICES RESEARCH TI - Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities VL - 16 ID - 6155 ER - TY - JOUR AB - Background: Glaucoma is the leading cause of irreversible blindness globally, and treatment involves considerable cost to stakeholders in healthcare. However, there is infrequent availability of cost information and patterns of management, especially in developing countries. This study determined the cost of the medical management of POAG, adherence, and pattern of medication prescription in Ghana.Methods: A retrospective cross-sectional study involving 891 Primary Open Angle Glaucoma (POAG) cases seen in the year 2012 at three referral facilities. Demographics, ocular history, resource consumption, medication, test, surgery and other related cost were extracted from 84 patients who had fully complied with their treatment to calculate total cost (TC) based on 2012 estimates. Glaucoma drugs prescribed to patients who had adhered to all their review visits within the period evident from case folders were recorded and analysed for the prescription pattern.Results: Out of 891 POAG cases seen in 2012, 351(39.4 %) attended all the required review visits, but only 84 (9.4) had fully and continually adhered to all their treatment regimes. They comprised 41(48.8 %) males and 43(51.2 %) females with a mean age of 65 ± 14.8. Majority of the respondents were elderly above 60 year of age (65.5 %). The total estimated cost for the 84 cases in the year was GH¢ 81,237 ($40,619), comprising GH¢ 72,193 ($36,097) direct medication cost and GH¢9,045 ($4,523) direct non-medication cost (surgery and test cost), and an average of GH¢ 967 ($484) for a mean visit of 5.6 ± 1.1 in the year. A total of 673 glaucoma medications had been prescribed for 351 patients for the year, with timolol being the most prescribed (64.19 %) and monotherapy as the most adopted form of therapy (61.06 %). Age and income showed concurrent increase with cost (P ≤ 0.05).Conclusions: Cost of managing glaucoma constitutes a substantial financial burden and influenced the pattern of medication prescription. AD - Department of Vision and Hearing Sciences, Faculty of Science and Technology, Anglia Ruskin University, Cambridge, UK Department of Optometry, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana Department of Economics, Faculty of Social Sciences, College of Humanities and Legal Studies, University of Cape Coast, Cape Coast, Ghana AN - 116923763. Language: English. Entry Date: 20180718. Revision Date: 20191120. Publication Type: journal article AU - Ocansey, Stephen AU - Kyei, Samuel AU - Diafo, Ama AU - Nkansah Darfor, Kwabena AU - Boadi-Kusi, Samuel Bert AU - Aglobitse, Peter B. AU - Darfor, Kwabena Nkansah DB - ccm DO - 10.1186/s12913-016-1528-x DP - EBSCOhost KW - Health Care Costs Glaucoma -- Drug Therapy Middle Age Intraocular Pressure Referral and Consultation Costs and Cost Analysis Health Resource Utilization -- Utilization Blindness -- Prevention and Control Cross Sectional Studies Aged Female Ghana Retrospective Design Male Human N1 - research; tables/charts. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 101088677. PMID: NLM27430262. PY - 2016 SN - 1472-6963 SP - 1-8 ST - Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities T2 - BMC Health Services Research TI - Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116923763&site=ehost-live&scope=site VL - 16 ID - 4306 ER - TY - JOUR AB - Glaucoma is the second leading cause of blindness worldwide. Even though significant advances have been made in its management, currently available antiglaucoma therapies suffer from considerable drawbacks. Typically, the success and efficacy of glaucoma medications are undermined by their limited bioavailability to target tissues and the inadequate adherence demonstrated by patients with glaucoma. The latter is due to a gradual decrease in tolerability of lifelong topical therapies and the significant burden to patients of prescribed stepwise antiglaucoma regimens with frequent dosing which impact quality of life. On the other hand, glaucoma surgery is restricted by the inability of antifibrotic agents to efficiently control the wound healing process without causing severe collateral damage and long-term complications. Evolution of the treatment paradigm for patients with glaucoma will ideally include prevention of retinal ganglion cell degeneration by the successful delivery of neurotrophic factors, anti-inflammatory drugs, and gene therapies. Nanotechnology-based treatments may surpass the limitations of currently available glaucoma therapies through optimized targeted drug delivery, increased bioavailability, and controlled release. This review addresses the recent advances in glaucoma treatment strategies employing nanotechnology, including medical and surgical management, neuroregeneration, and neuroprotection. AD - Department of Ophthalmology, University of Campinas (UNICAMP), Campinas, Brazil Laboratory of Metabolism and Lipids, Heart Institute (InCor), Medical School Hospital, University of São Paulo, São Paulo, Brazil Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil 1st and 3rd University Departments of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece AN - 141252962. Language: English. Entry Date: 20200929. Revision Date: 20201231. Publication Type: journal article AU - Occhiutto, Marcelo Luís AU - Maranhão, Raul C. AU - Costa, Vital Paulino AU - Konstas, Anastasios G. DB - ccm DO - 10.1007/s12325-019-01163-6 DP - EBSCOhost IS - 1 KW - Nanotechnology -- Methods Glaucoma -- Drug Therapy Nanoparticles Nanomedicine -- Methods Biological Availability Glaucoma -- Therapy Nanomedicine -- Trends Quality of Life Ferrans and Powers Quality of Life Index Impact of Events Scale N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Longitudinal Interval Follow-Up Evaluation (LIFE); Impact of Events Scale (IES); Ferrans and Powers Quality of Life Index. NLM UID: 8611864. PMID: NLM31823205. PY - 2020 SN - 0741-238X SP - 155-199 ST - Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review T2 - Advances in Therapy TI - Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141252962&site=ehost-live&scope=site VL - 37 ID - 4300 ER - TY - JOUR AB - Introduction: A non-interventional, multicenter, European, prospective evaluation of the effectiveness, tolerability, and safety of a topical preservative-free tafluprost (0.0015%) and timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in adults with open-angle glaucoma (OAG) and ocular hypertension (OHT) demonstrating insufficient response to topical beta-receptor blockers or prostaglandin analogue (PGA) monotherapy. Methods: Mean intraocular pressure (IOP) change from baseline was measured at study visits following a switch to PF tafluprost/timolol FC. Primary endpoint was absolute mean IOP change at month 6. Change from baseline concerning ocular signs and symptoms was also explored. Results: Analyses included 577 patients (59.6% female). Mean age (SD) was 67.8 (11.67) years. Mean (SD) IOP reduction from baseline was significant at all study visits; 5.4 (3.76) mmHg (23.7%) at week 4, 5.9 (3.90) mmHg (25.6%) at week 12, and 5.7 (4.11) mmHg (24.9%) at month 6 (p < 0.0001 for all visits). At month 6, 69.2%, 53.6%, 40.0%, and 25.8% were responders based on ≥ 20%, ≥ 25%, ≥ 30%, and ≥ 35% cutoff values for mean IOP, respectively. Significant reductions were observed concerning corneal fluorescein staining (p < 0.0001), dry eye symptoms, irritation, itching, and foreign body sensation (p < 0.001 for each parameter). Conjunctival hyperemia was significantly reduced at all study visits (p < 0.0001 at each visit). Overall, 69 treatment-related adverse events (AEs) were reported, one of which was serious (status asthmaticus). Most AEs were mild to moderate in severity, and the majority had resolved or were resolving at the end of the study period. Conclusion: In clinical practice, PF tafluprost/timolol FC provided statistically and clinically significant IOP reductions in patients with OAG and OHT insufficiently controlled on or intolerant to PGA or beta-receptor blocker monotherapy. The full IOP reduction appeared at week 4 and was maintained over the 6-month study period. Key symptoms of ocular surface health improved. Trial Registration: European Union electronic Register of Post-Authorisation Studies (EU PAS) register number, EUPAS22204. © 2020, The Author(s). AD - IRCSS-Fondazione Bietti, Rome, Italy Department of Ophthalmology, Semmelweis University, Budapest, Hungary AU - Oddone, F. AU - Tanga, L. AU - Kóthy, P. AU - Holló, G. AU - Faschinger, C. AU - Chen, E. AU - Holló, G. AU - Nemeth, G. AU - Bator, G. AU - Tsorbatzoglou, A. AU - Acs, T. AU - Ferencz, M. AU - Sohajda, Z. AU - Toth, J. AU - Volner, V. AU - Vogt, G. AU - Biro, Z. AU - Facskó, A. AU - Nemes, J. AU - Berta, A. AU - Elek, I. AU - Ng, E. AU - Oddone, F. AU - Rossi, G. AU - Rossetti, L. AU - Vetrugno, M. AU - Iester, M. AU - Marchini, G. AU - Scorcia, V. AU - Staurenghi, G. AU - Cagini, C. AU - Salgarello, T. AU - Bettin, P. AU - Figus, M. AU - Scuderi, G. L. AU - De Cilla, S. AU - Grundmane, I. AU - Linavska, N. AU - Volksone, L. AU - Laganovska, G. AU - Baumane, K. AU - Lemij, H. AU - Gundersen, K. G. AU - Zimina, M. AU - Erichev, V. AU - Karlova, E. AU - Zakharova, E. AU - Panova, I. AU - Malyugin, B. AU - Aguirrec, I. R. AU - Lopez–Lopez, F. AU - Valladares, A. M. AU - del Castillo, J. B. AU - Gimenez, R. AU - Vallejo, M. P. AU - Medina, J. G. AU - Lopez, A. A. AU - Torregrosa, S. AU - Loscos, J. AU - Kolko, M. AU - Ansari, E. AU - Broadway, D. AU - Claridge, K. AU - Ruben, S. AU - Kirwan, J. AU - Nita, A. AU - Smith, M. AU - Moosavi, A. AU - King, A. J. W. AU - Kinsella, M. AU - The, Visionary Study Group DB - Scopus DO - 10.1007/s12325-020-01239-8 IS - 4 KW - Fixed-dose combination Ocular hypertension Open-angle glaucoma Ophthalmology Preservative-free topical medication Tafluprost Timolol M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2020 SP - 1436-1451 ST - Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study T2 - Advances in Therapy TI - Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079762426&doi=10.1007%2fs12325-020-01239-8&partnerID=40&md5=4c16239962e3ef4969cd62f7abbf2bd5 VL - 37 ID - 5442 ER - TY - JOUR AB - In newly diagnosed multiple myeloma (MM), three/four-drug combinations as induction therapy seem to be more effective compared with two-drug associations in terms of response rate and duration of remission. Moreover, there is an emergent body of evidences that consolidation/maintenance therapy improves the quality of response and remission duration. However, the impact of these strategies in relapsed/refractory MM (r-rMM) is still unknown. This phase II study explored the four-drug combination of thalidomide, dexamethasone, pegylated liposomal doxorubicin (pLD), and bortezomib (ThaDD-V) as induction followed by consolidation therapy based on bortezomib-dexamethasone and thalidomide-dexamethasone and maintenance therapy with thalidomide in r-rMM patients. The primary end points of this study were best response and toxicity of the planned therapy. Forty-six patients were enrolled. At the end of therapy, the best response was as follows: 37% complete response (CR), 34.5% VGPR, and 4.5% PR with an ORR of 76%. Patients receiving ≤2 prior regimens had a CR rate significantly higher than those heavily treated (41% vs 0%; p = 0.010). With a median follow-up of 31 months, median time to progression (TTP) and OS were 18.5 months and 40 months, respectively. By a 6-month landmark analysis, patients who completed the protocol had a significantly longer TTP compared with those who did not because of toxicity (not reached vs 7 months; p < 0.0001). After the dose intensity of bortezomib was reduced due to an excess of peripheral neuropathy (PN), grade 3 PN occurred in 7.5% of patients. ThaDD-V followed by consolidation-maintenance therapy seems to be very effective in patients with r-rMM provided that this procedure is used early on relapse when very deep responses seem to be the rule. © 2011 Springer-Verlag. AD - Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Via Conca, 71, Ancona 60020, Italy Marche Myeloma Network (GEMaMM), Ancona, Italy Sezione di Ematologia, Dipartimento di Patologia Ed Ematologia, Università di Bari, Bari, Italy AU - Offidani, M. AU - Corvatta, L. AU - Polloni, C. AU - Gentili, S. AU - Mele, A. AU - Rizzi, R. AU - Catarini, M. AU - Caraffa, P. AU - Samori, A. AU - Blasi, N. AU - Ferranti, M. AU - Malerba, L. AU - Brunori, M. AU - Leoni, P. DB - Scopus DO - 10.1007/s00277-011-1217-0 IS - 12 KW - Bortezomib Multiple myeloma Pegylated liposomal doxorubicin Thalidomide M3 - Article N1 - Cited By :19 Export Date: 19 July 2021 PY - 2011 SP - 1449-1456 ST - Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma T2 - Annals of Hematology TI - Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84355161833&doi=10.1007%2fs00277-011-1217-0&partnerID=40&md5=1ae248aef948267467e6b57346068879 VL - 90 ID - 5149 ER - TY - JOUR AB - Purpose: To evaluate intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion (CRVO). Design: Randomized, double-masked, phase 3 study. Methods: A total of 177 patients with macular edema secondary to CRVO were randomized to receive 2 mg intravitreal aflibercept (n[106) or sham (n[71) every 4 weeks for 20 weeks. From weeks 24 to 48, patients were monitored every 4 weeks; the former group received intravitreal aflibercept as needed (PRN), and the sham group received sham. From weeks 52 to 76, patients were monitored every 8 weeks, and both groups received intravitreal aflibercept PRN. The primary endpoint (proportion of patients who gained ≥15 letters) was at week 24. This study reports exploratory outcomes at week 76. Results: The proportion of patients who gained ≥15 letters in the intravitreal aflibercept and sham groups was 60.2%vs 22.1%at week 24 (patients discontinued before week 24 were considered nonresponders; P < .0001), 60.2% vs 32.4% at week 52 (last observation carried forward, P <.001), and 57.3% vs 29.4% at week 76 (last observation carried forward; P < .001). Mean mm change from baseline central retinal thickness was L448.6 vs L169.3 at week 24 (P < .0001), L423.5 vs L219.3 at week 52 (P < .0001), and L389.4 vs L306.4 at week 76 (P = .1122). Over 76 weeks, the most common ocular serious adverse event in the intravitreal aflibercept group was macular edema (3.8%). Conclusion: The visual and anatomic improvements seen after fixed, monthly dosing at week 24 were largely maintained when treatment intervals were extended. Patients with macular edema following CRVO benefited from early treatment with intravitreal aflibercept. © 2014 by Elsevier Inc. All rights reserved. AD - Department of Ophthalmology and Visual Science, Nagoya City University, Graduate School of Medical Science, Nagoya, Japan Department of Ophthalmology, University of Kiel, Kiel, Germany Service d'Ophtalmologie, Hopital Pellegrin - CHU de Bordeaux, Bordeaux, France Université Bordeaux Segalen, Bordeaux, France INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France Department of Ophthalmology, University of Bonn, Bonn, Germany Department of Ophthalmology, Medical University of Vienna, Vienna, Austria Regeneron Pharmaceuticals, Inc, Tarrytown, NY, United States Bayer HealthCare AG, Berlin, Germany Department of Neurology, University of Erlangen-Nürnberg, Germany Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany Department of Neurology, Heinrich-Heine-Universität, Düsseldorf, Germany AU - Ogura, Y. AU - Roider, J. AU - Korobelnik, J. F. AU - Holz, F. G. AU - Simader, C. AU - Schmidt-Erfurth, U. AU - Vitti, R. AU - Berliner, A. J. AU - Hiemeyer, F. AU - Stemper, B. AU - Zeitz, O. AU - Sandbrink, R. DB - Scopus DO - 10.1016/j.ajo.2014.07.027 IS - 5 M3 - Article N1 - Cited By :118 Export Date: 19 July 2021 PY - 2014 SP - 1032-1038.e2 ST - Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study T2 - American Journal of Ophthalmology TI - Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84908658307&doi=10.1016%2fj.ajo.2014.07.027&partnerID=40&md5=922caefc171905ea58f035e97f410421 VL - 158 ID - 4923 ER - TY - JOUR AB - Purpose: To investigate the impact of an intervention program to improve adherence with topical, once daily therapy for glaucoma. Design: Randomized controlled clinical trial. Participants: Sixty-six patients with glaucoma being treated with a prostaglandin analog in 1 or both eyes at the Scheie Eye Institute or Wilmer Eye Institute between November 2006 and June 2007. Methods: In an observational study, participants who took 75% or fewer doses (as measured using the travoprost Dosing Aid [DA]) during an initial 3-month period were randomized into 2 groups. The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices. The control group was told to take drops as prescribed and received no additional intervention. Main Outcome Measures: Change in drop use adherence as determined by the DA device. Results: In the 3-month observation period before randomization, intervention group patients had used a mean of 54±17% of scheduled doses, and this increased to 73±22% during the following 3-month period (P<0.001, n = 35). The control mean adherence rate of 46±23% at baseline was statistically unchanged during the follow-up observation period (51±30%, P = 0.16, n = 31). In a multivariate analysis, intervention, baseline compliance rate of <50%, and white ethnicity were predictors of improved adherence during the 3 months of intervention. The intraocular pressure (IOP) of the intervention and control groups did not change between months 3 and 6 after intervention (P = 0.96, 0.34, respectively), and there was no correlation of IOP change with adherence rate change between both groups (Pearson correlation r = 0.06, P = 0.51). Conclusions: A multifaceted intervention significantly increased adherence with glaucoma medications. Those with improved adherence were in the intervention group, had very low adherence rates at baseline, and were white. IOP did not correlate with adherence. Further research is needed to determine which components of this intervention were most effective. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2009 American Academy of Ophthalmology. AD - C.O. Okeke, Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States AU - Okeke, C. O. AU - Quigley, H. A. AU - Jampel, H. D. AU - Ying, G. s AU - Plyler, R. J. AU - Jiang, Y. AU - Friedman, D. S. DB - Embase Medline DO - 10.1016/j.ophtha.2009.05.026 IS - 12 KW - travoprost adult aged article clinical trial controlled clinical trial controlled study drug monitoring electronics European American female glaucoma human intraocular pressure major clinical study male patient compliance patient monitoring predictor variable priority journal randomized controlled trial treatment refusal Dosing Aid LA - English M3 - Article N1 - L50663290 2009-10-13 2009-12-30 PY - 2009 SN - 0161-6420 SP - 2286-2293 ST - Interventions Improve Poor Adherence with Once Daily Glaucoma Medications in Electronically Monitored Patients T2 - Ophthalmology TI - Interventions Improve Poor Adherence with Once Daily Glaucoma Medications in Electronically Monitored Patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50663290&from=export http://dx.doi.org/10.1016/j.ophtha.2009.05.026 VL - 116 ID - 3310 ER - TY - JOUR AB - Purpose: To assess patient adherence and behaviors with topical once-daily therapy for glaucoma. Design: Prospective, observational cohort study. Participants: One hundred ninety-six patients with glaucoma who were being treated with a prostaglandin analog in 1 or both eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. Methods: Detailed medical history was obtained from each patient. All subjects used the Travatan Dosing Aid (DA; Alcon, Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months and the data of drop usage was downloaded using software provided with the dosing aid. Data were analyzed for the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit. Main Outcome Measures: Assessment of adherence and patterns of drop usage as indicated by the DA. Results: A total of 282 subjects consented to be in the study and 86 (30%) withdrew before study completion or had device errors, leaving 196 subjects (70%) with evaluable data at 3 months. The overall mean (±standard deviation) adherence rate was 0.71 (±0.24), ranging from 0.02 to 0.97. One hundred nine of these patients (55.6%) took greater than 75% of the expected doses. Those with adherence of less than 50% of expected doses showed substantially increased dose taking immediately after the office visit and just before the return visit at 3 months (P = 0.03). The mean adherence rate estimates of the physician and patient self-report were 0.77 and 0.95, respectively. The agreement between the physician assessment and DA-recorded adherence rate showed poor correlation for individual cases (intraclass correlation coefficient, 0.09; 95% confidence interval, 0.00-0.19). Conclusions: Nearly 45% of patients using an electronic monitoring device who knew they were being monitored and were provided free medication used their drops less than 75% of the time. Patients reported far higher medication use than their actual behavior. The ability of the physician to identify which persons are poorly adherent from their self-report or from other subjective clues is poor. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2009 American Academy of Ophthalmology. AD - C.O. Okeke, Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States AU - Okeke, C. O. AU - Quigley, H. A. AU - Jampel, H. D. AU - Ying, G. s AU - Plyler, R. J. AU - Jiang, Y. AU - Friedman, D. S. C1 - travatan(Alcon,United States) C2 - Alcon(United States) DB - Embase Medline DO - 10.1016/j.ophtha.2008.09.004 IS - 2 KW - travoprost adult aged anamnesis article clinical assessment clinical trial cohort analysis software controlled clinical trial controlled study dosing aid drug monitoring drug use electronics female glaucoma health behavior human major clinical study male medical record observational study patient attitude patient compliance patient monitoring physician priority journal prospective study randomized controlled trial self report single blind procedure technical aid treatment outcome unspecified side effect travatan Travatan dosing aid LA - English M3 - Article N1 - L50359983 2009-02-16 PY - 2009 SN - 0161-6420 SP - 191-199 ST - Adherence with Topical Glaucoma Medication Monitored Electronically. The Travatan Dosing Aid Study T2 - Ophthalmology TI - Adherence with Topical Glaucoma Medication Monitored Electronically. The Travatan Dosing Aid Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50359983&from=export http://dx.doi.org/10.1016/j.ophtha.2008.09.004 VL - 116 ID - 3382 ER - TY - JOUR AB - Purpose: To assess patient adherence and behaviors with topical once-daily therapy for glaucoma. Design: Prospective, observational cohort study. Participants: One hundred ninety-six patients with glaucoma who were being treated with a prostaglandin analog in 1 or both eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. Methods: Detailed medical history was obtained from each patient. All subjects used the Travatan Dosing Aid (DA; Alcon, Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months and the data of drop usage was downloaded using software provided with the dosing aid. Data were analyzed for the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit. Main Outcome Measures: Assessment of adherence and patterns of drop usage as indicated by the DA. Results: A total of 282 subjects consented to be in the study and 86 (30%) withdrew before study completion or had device errors, leaving 196 subjects (70%) with evaluable data at 3 months. The overall mean (±standard deviation) adherence rate was 0.71 (±0.24), ranging from 0.02 to 0.97. One hundred nine of these patients (55.6%) took greater than 75% of the expected doses. Those with adherence of less than 50% of expected doses showed substantially increased dose taking immediately after the office visit and just before the return visit at 3 months (P = 0.03). The mean adherence rate estimates of the physician and patient self-report were 0.77 and 0.95, respectively. The agreement between the physician assessment and DA-recorded adherence rate showed poor correlation for individual cases (intraclass correlation coefficient, 0.09; 95% confidence interval, 0.00-0.19). Conclusions: Nearly 45% of patients using an electronic monitoring device who knew they were being monitored and were provided free medication used their drops less than 75% of the time. Patients reported far higher medication use than their actual behavior. The ability of the physician to identify which persons are poorly adherent from their self-report or from other subjective clues is poor. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2009 American Academy of Ophthalmology. AD - Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Department of Preventive Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China AU - Okeke, C. O. AU - Quigley, H. A. AU - Jampel, H. D. AU - Ying, G. s AU - Plyler, R. J. AU - Jiang, Y. AU - Friedman, D. S. DB - Scopus DO - 10.1016/j.ophtha.2008.09.004 IS - 2 M3 - Article N1 - Cited By :197 Export Date: 19 July 2021 PY - 2009 SP - 191-199 ST - Adherence with Topical Glaucoma Medication Monitored Electronically. The Travatan Dosing Aid Study T2 - Ophthalmology TI - Adherence with Topical Glaucoma Medication Monitored Electronically. The Travatan Dosing Aid Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-58849131406&doi=10.1016%2fj.ophtha.2008.09.004&partnerID=40&md5=189bced73101e15198ea9ba7c5cfe204 VL - 116 ID - 4907 ER - TY - JOUR AB - Purpose: To investigate the impact of an intervention program to improve adherence with topical, once daily therapy for glaucoma. Design: Randomized controlled clinical trial. Participants: Sixty-six patients with glaucoma being treated with a prostaglandin analog in 1 or both eyes at the Scheie Eye Institute or Wilmer Eye Institute between November 2006 and June 2007. Methods: In an observational study, participants who took 75% or fewer doses (as measured using the travoprost Dosing Aid [DA]) during an initial 3-month period were randomized into 2 groups. The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices. The control group was told to take drops as prescribed and received no additional intervention. Main Outcome Measures: Change in drop use adherence as determined by the DA device. Results: In the 3-month observation period before randomization, intervention group patients had used a mean of 54±17% of scheduled doses, and this increased to 73±22% during the following 3-month period (P<0.001, n = 35). The control mean adherence rate of 46±23% at baseline was statistically unchanged during the follow-up observation period (51±30%, P = 0.16, n = 31). In a multivariate analysis, intervention, baseline compliance rate of <50%, and white ethnicity were predictors of improved adherence during the 3 months of intervention. The intraocular pressure (IOP) of the intervention and control groups did not change between months 3 and 6 after intervention (P = 0.96, 0.34, respectively), and there was no correlation of IOP change with adherence rate change between both groups (Pearson correlation r = 0.06, P = 0.51). Conclusions: A multifaceted intervention significantly increased adherence with glaucoma medications. Those with improved adherence were in the intervention group, had very low adherence rates at baseline, and were white. IOP did not correlate with adherence. Further research is needed to determine which components of this intervention were most effective. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2009 American Academy of Ophthalmology. AD - Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Department of Preventive Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China AU - Okeke, C. O. AU - Quigley, H. A. AU - Jampel, H. D. AU - Ying, G. s AU - Plyler, R. J. AU - Jiang, Y. AU - Friedman, D. S. DB - Scopus DO - 10.1016/j.ophtha.2009.05.026 IS - 12 M3 - Article N1 - Cited By :101 Export Date: 19 July 2021 PY - 2009 SP - 2286-2293 ST - Interventions Improve Poor Adherence with Once Daily Glaucoma Medications in Electronically Monitored Patients T2 - Ophthalmology TI - Interventions Improve Poor Adherence with Once Daily Glaucoma Medications in Electronically Monitored Patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70649107816&doi=10.1016%2fj.ophtha.2009.05.026&partnerID=40&md5=3b84172947737c97a7b14e3296a73cd0 VL - 116 ID - 4929 ER - TY - JOUR AB - Purpose: To assess patient adherence and behaviors with topical once-daily therapy for glaucoma. Design: Prospective, observational cohort study. Participants: One hundred ninety-six patients with glaucoma who were being treated with a prostaglandin analog in 1 or both eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. Methods: Detailed medical history was obtained from each patient. All subjects used the Travatan Dosing Aid (DA; Alcon, Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months and the data of drop usage was downloaded using software provided with the dosing aid. Data were analyzed for the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit. Main Outcome Measures: Assessment: of adherence and patterns of drop usage as indicated by the DA. Results: A total of 282 subjects consented to be in the study and 86 (30%) withdrew before study completion or had device errors, leaving 196 subjects (70%) with evaluable data at 3 months. The overall mean (+/- standard deviation) adherence rate was 0.71 (+/- 0.24), ranging from 0.02 to 0.97. One hundred nine of these patients (55.6%) took greater than 75% of the expected doses. Those with adherence of less than 50% of expected doses showed substantially increarsed dose taking immediately after the office visit and just before the return visit at 3 months (P = 0.03). The mean adherence rate estimates of the physician and patient self-report were 0.77 and 0.95, respectively. The agreement between the physician assessment and DA-recorded adherence rate showed poor correlation for individual cases (intraclass correlation coefficient, 0.09; 95% confidence interval, 0.00-0.19). Conclusions: Nearly 45% of patients using art electronic monitoring device who knew they were being monitored and were provided free medication used their drops less than 75% of the time. Patients reported far higher medication use than their actual behavior. The ability of the physician to identify which persons are poorly adherent from their self-report or from other subjective clues is poor. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009;116:191-199 (C) 2009 by the American Academy of Ophthalmology. AN - WOS:000263098100005 AU - Okeke, C. O. AU - Quigley, H. A. AU - Jampel, H. D. AU - Ying, G. S. AU - Plyler, R. J. AU - Jiang, Y. AU - Friedman, D. S. DA - FEB DO - 10.1016/j.ophtha.2008.09.004 IS - 2 PY - 2009 SN - 0161-6420 1549-4713 SP - 191-199 ST - Adherence with Topical Glaucoma Medication Monitored Electronically The Travatan Dosing Aid Study T2 - OPHTHALMOLOGY TI - Adherence with Topical Glaucoma Medication Monitored Electronically The Travatan Dosing Aid Study VL - 116 ID - 5975 ER - TY - JOUR AB - Purpose: To investigate the impact of an intervention program to improve adherence with topical, once daily therapy for glaucoma. Design: Randomized controlled clinical trial. Participants: Sixty-six patients with glaucoma being treated with a prostaglandin analog in 1 or both eyes at the Scheie Eye Institute or Wilmer Eye Institute between November 2006 and June 2007. Methods: In an observational study, participants who took 75% or fewer doses (as measured using the travoprost Dosing Aid [DA]) during an initial 3-month period were randomized into 2 groups. The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices. The control group was told to take drops as prescribed and received no additional intervention. Main Outcome Measures: Change in drop use adherence as determined by the DA device. Results: In the 3-month observation period before randomization, intervention group patients had used a mean of 54 +/- 17% of scheduled doses, and this increased to 73 +/- 22% during the following 3-month period (P<0.001, n = 35). The control mean adherence rate of 46 +/- 23% at baseline was statistically unchanged during the follow-up observation period (51 +/- 30%, P = 0.16, n = 31). In a multivariate analysis, intervention, baseline compliance rate of <50%, and white ethnicity were predictors of improved adherence during the 3 months of intervention. The intraocular pressure (IOP) of the intervention and control groups did not change between months 3 and 6 after intervention (P = 0.96, 0.34, respectively), and there was no correlation of IOP change with adherence rate change between both groups (Pearson correlation r = 0.06, P = 0.51). Conclusions: A multifaceted intervention significantly increased adherence with glaucoma medications. Those with improved adherence were in the intervention group, had very low adherence rates at baseline, and were white. IOP did not correlate with adherence. Further research is needed to determine which components of this intervention were most effective. AN - WOS:000272579200004 AU - Okeke, C. O. AU - Quigley, H. A. AU - Jampel, H. D. AU - Ying, G. S. AU - Plyler, R. J. AU - Jiang, Y. Z. AU - Friedman, D. S. DA - DEC DO - 10.1016/j.ophtha.2009.05.026 IS - 12 PY - 2009 SN - 0161-6420 1549-4713 SP - 2286-2293 ST - Interventions Improve Poor Adherence with Once Daily Glaucoma Medications in Electronically Monitored Patients T2 - OPHTHALMOLOGY TI - Interventions Improve Poor Adherence with Once Daily Glaucoma Medications in Electronically Monitored Patients VL - 116 ID - 6082 ER - TY - JOUR AB - Purpose: To evaluate the safety and efficacy of timolol 0.5%/travoprost 0.004% combination (duotrav) as observed in primary open-angle glaucoma (POAG), ocular hypertension (OHT) and normal tension glaucoma (NTG) in real-life conditions. Materials and Methods: Patients with uncontrolled intraocular pressure (IOP) on other medication and no contraindication to beta-blockers were switched to duotrav in 56 eyes of 28 patients. The drop in IOP was the primary outcome measured. Results: Switch to duotrav provided an additional IOP reduction after 3-month follow-up that was statistically significant for those on latanoprost (P=0.02857), bimatoprost (P=0.0497 8) and travoprost (P=0.0078). Patients on latanotrost had an additional 25.9% drop 3 months after switching to duotrav while those on bimatoprost and travatan had 18.04% and 17.59% drop, respectively, after the switch. It was effective in lowering the IOP to clinically significant levels of <= 18.5 mmHg in POAG, NTG and OHT (12.5-17.9% drop), but not in chronic angle closure glaucoma. Conclusion: Duotrav was well-tolerated and produced significant additional IOP reduction when switched from other anti-glaucoma drugs in patients with uncontrolled glaucoma. It also achieved IOP of <= 18.5 mmHg in glaucoma patients. AN - WOS:000289845500007 AU - Olali, C. AU - Malietzis, G. AU - Ahmed, S. AU - Samaila, E. AU - Gupta, M. DA - JAN-MAR DO - 10.4103/1119-3077.79236 IS - 1 PY - 2011 SN - 1119-3077 SP - 29-33 ST - Real-life experience study of the safety and efficacy of travoprost 0.004%/timoptol 0.50% fixed combination ophthalmic solution in intraocular pressure control T2 - NIGERIAN JOURNAL OF CLINICAL PRACTICE TI - Real-life experience study of the safety and efficacy of travoprost 0.004%/timoptol 0.50% fixed combination ophthalmic solution in intraocular pressure control VL - 14 ID - 5985 ER - TY - JOUR AB - BACKGROUND: Approximately 40% of patients with glaucoma are concomitantly prescribed >or=2 different intraocular pressure (IOP)-lowering medications. An effective and well-tolerated fixed combination of agents requiring once-daily instillation may improve patient compliance. OBJECTIVE: The purpose of this study was to compare the efficacy and safety profile of the fixed combination latanoprost 0.005% + timolol maleate 0.5% QD with those of latanoprost 0.005% monotherapy QD in patients whose elevated IOP (>or=21 mm Hg) was inadequately controlled by latanoprost. METHODS: This 21-day, randomized, double-masked, active-control study was conducted at 49 study sites in Argentina, Brazil, Colombia, Mexico, Peru, the United States, and Venezuela. Adults with glaucoma or ocular hypertension who had failed to reach an IOP of <21 mm Hg while receiving latanoprost for at least 28 days were enrolled. After an additional 28 days of latanoprost run-in, patients were randomly assigned to continue latanoprost monotherapy or to switch to the fixed combination for 21 days. The intent-to-treat (ITT) population included all patients who received at least 1 dose of double-masked study medication; the per-protocol (PP) analysis included patients who completed the study without a major protocol violation and who had IOP measurements both at baseline and at day 21. The primary end point was the proportion of patients whose IOP was decreased >or=2 mm Hg from the baseline level on day 21. Proportions of patients demonstrating IOP decreases >or=3, >or=4, or >or=5 mm Hg from the baseline level and of patients reaching an 10P or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001). Both treatments were well tolerated. Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively). CONCLUSION: In this selected population of patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy. AD - Maryville Eye Center, 622 Smithview Drive, Maryville, TN 37803; kwolaser7@aol.com AN - 106519494. Corporate Author: Xalacom/Latanoprost Study Group. Language: English. Entry Date: 20050930. Revision Date: 20200624. Publication Type: Journal Article AU - Olander, K. AU - Zimmerman, T. J. AU - Downes, N. AU - Schoenfelder, J. DB - ccm DO - 10.1016/j.clinthera.2004.10.009 DP - EBSCOhost IS - 10 KW - Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Latanoprost -- Therapeutic Use Ocular Hypertension -- Drug Therapy Timolol -- Therapeutic Use Aged Data Analysis, Statistical Descriptive Statistics Double-Blind Studies Female Human Male Middle Age Random Assignment Tennessee United Kingdom N1 - clinical trial; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 7706726. PMID: NLM15598478. PY - 2004 SN - 0149-2918 SP - 1619-1629 ST - Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension T2 - Clinical Therapeutics TI - Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106519494&site=ehost-live&scope=site VL - 26 ID - 4426 ER - TY - JOUR AD - K.W. Olander AU - Olander, K. W. AU - Zimmerman, T. J. DB - Medline IS - 5 KW - ambulatory care article glaucoma human LA - English M3 - Article N1 - L14775113 1984-07-31 PY - 1984 SN - 0003-4886 SP - 403-404 ST - The office visit and the glaucoma patient T2 - Annals of ophthalmology TI - The office visit and the glaucoma patient UR - https://www.embase.com/search/results?subaction=viewrecord&id=L14775113&from=export VL - 16 ID - 4081 ER - TY - JOUR AB - Introduction: Glaucoma surgical practice patterns are not well described in the United States (US). This study aims to evaluate the indications for and potential barriers to glaucoma surgery in the Veterans Health Administration (VHA).Materials and Methods: An anonymous 10-question survey using REDCap (Nashville, TN) software was sent by mail (with web link) and email to ophthalmology chiefs at the 86 academically affiliated Veterans Affairs Medical Centers (VAMCs). Academic-affiliated VAMCs were selected because of their patient range and role in ophthalmic education. Non-responders received two reminder e-mails and two phone calls; the survey was closed after 6 weeks. The data were analyzed using descriptive statistics.Results: The response rate was 45% (39/86). Most respondents (92%) worked in an integrated eye clinic with both ophthalmology and optometry services. Almost half of the respondents (49%; 19/39) believed that laser trabeculoplasty (LTP) was an option for initial glaucoma therapy. Noncompliance was a commonly reported indication for LTP (95%), tube shunt procedures (65%), micro-invasive glaucoma surgery (59%), and trabeculectomy (48.7%). One third of the respondents believed that there were delays in glaucoma care. The respondents noted that significant barriers in access to surgery included lack of transportation (69%), scheduling challenges (62%), and delayed referral (62%).Conclusion: This survey of glaucoma surgery practice patterns highlights the growing role of LTP and suggests that non-compliance and access remain significant barriers to glaucoma surgical care within the VHA. AD - Section of Ophthalmology , Providence VA Medical Center, Providence, RI 02908 Division of Ophthalmology , Alpert Medical School, Brown University, Providence, RI 02903 Section of Ophthalmology , Atlanta VA Medical Center, Atlanta, GA 30033 Department of Ophthalmology , Emory University School of Medicine, Atlanta, GA 30322 Section of Ophthalmology , Palo Alto VA Medical Center, Palo Alto, CA 94304 National Program Director , VHA Ophthalmology Service, VA Central Office 10P11, Washington, D.C. 20420 Department of Ophthalmology , Stanford University School of Medicine, Stanford, CA 94305 AN - 145173248. Language: English. Entry Date: 20200927. Revision Date: 20210715. Publication Type: journal article. Journal Subset: Biomedical AU - Olivieri, Daniel J. AU - Lynch, Mary G. AU - Cockerham, Glenn C. AU - Greenberg, Paul B. DB - ccm DO - 10.1093/milmed/usaa033 DP - EBSCOhost IS - 7/8 KW - Trabeculectomy Glaucoma -- Surgery Veterans United States Ophthalmology Arthritis Impact Measurement Scales N1 - Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Arthritis Impact Measurement Scale (AIMS) (Meenan). NLM UID: 2984771R. PMID: NLM32412083. PY - 2020 SN - 0026-4075 SP - e972-e976 ST - A Survey of Glaucoma Surgery Practice Patterns in the Veterans Health Administration T2 - Military Medicine TI - A Survey of Glaucoma Surgery Practice Patterns in the Veterans Health Administration UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145173248&site=ehost-live&scope=site VL - 185 ID - 4145 ER - TY - JOUR AB - Background: To assess the prevalence and determinants of non-adherence to topical hypotensive treatment in glaucoma patients in order to support interventions targeting enhancement of patient adherence. Methods: One-hundred and sixty-six glaucoma patients, recruited by nationwide multi-stage sampling, filled in an extensive and carefully developed questionnaire covering various theoretically relevant determinants of patient adherence which were categorized as psychosocial aspects, barriers and skills. Results: Prevalence of self-reported non-adherence was 27.3%. Younger patients (<55 years of age) had a higher risk of being non-adherent. Forgetfulness, unavailability of eye drops and difficulties with holding the bottle above the eye when applying the eye drops were the most cited reasons for non-adherence. Fifty percent of the patients indicated that they required more information on the correct administration of eye drops. There was no association between non-adherence and sex, level of education, type of insurance, duration of disease or family history of glaucoma. Conclusions: Non-adherence to topical glaucoma medication is fairly common. Aids that minimize forgetfulness and delivery systems facilitating the delivery of medications to the eye could be considered to enhance patient adherence before advancing to other therapies with additional risks and costs. © The Author(s) 2008. AD - J.S.A.G. Schouten, Department of Ophthalmology, Maastricht University Hospital, P.O. Box 5800, 6202 AZ Maastricht, Netherlands AU - Olthoff, C. M. G. AU - Hoevenaars, J. G. M. M. AU - van den Borne, B. W. AU - Webers, C. A. B. AU - Schouten, J. S. A. G. DB - Embase Medline DO - 10.1007/s00417-008-0944-y IS - 2 KW - aceclidine agents acting on the eye antiglaucoma agent befunolol betaxolol brimonidine brinzolamide carteolol dipivefrine dorzolamide dorzolamide plus timolol epinephrine plus guanethidine eye drops latanoprost levobunolol metipranolol metoprolol plus pilocarpine timolol unclassified drug adult article disease duration educational status family history female health insurance health survey high risk population human major clinical study male open angle glaucoma patient attitude patient compliance patient education priority journal self report sex difference social psychology LA - English M3 - Article N1 - L50275945 2009-01-23 PY - 2009 SN - 0721-832X SP - 235-243 ST - Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients T2 - Graefe's Archive for Clinical and Experimental Ophthalmology TI - Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50275945&from=export http://dx.doi.org/10.1007/s00417-008-0944-y VL - 247 ID - 3384 ER - TY - JOUR AB - Objective: To summarize the available scientific evidence to support clinical decisions on how to deal with noncompliance in glaucoma patients. Clinical Relevance: Insufficient reduction of intraocular pressure and progression of visual field (VF) loss in glaucoma patients due to noncompliance with topical treatment may result in unnecessary therapy, with additional risks and costs. Methods/Literature Reviewed: We conducted a literature search in the databases MEDLINE, EMBASE, CINAHL, PsychInfo, and Cochrane and reference lists. Thirty-four articles describing 29 original quantitative studies, in English, German, French, or Dutch, were included. Studies on noncompliance in drug trials were excluded. Two investigators independently selected the articles and abstracted their content, before negotiating their inclusion or exclusion. Results: The proportions of patients who deviate from their prescribed medication regimen ranged from 5% to 80%. The impact of noncompliance on clinical outcome has not yet been established. There are no determinants sensitive and specific enough to identify potential noncompliers accurately. Patient knowledge and dose frequency can be used as starting points to improve compliance. A combination of patient education and prevention of forgetting doses seems to be successful in enhancing patient compliance. Conclusion: Noncompliance with hypotensive treatment is common among glaucoma patients. However, there is no strong evidence supporting a relation between noncompliance and progression of VF loss. Only a few guidelines for clinicians can be derived from the currently available literature. Future research should be guided by clinically relevant questions. © 2005 by the American Academy of Ophthalmology. AD - J.S.A.G. Schouten, Department of Ophthalmology, Maastricht University Hospital, P.O. Box 5800, 6202 AZ Maastricht, Netherlands AU - Olthoff, C. M. G. AU - Schouten, J. S. A. G. AU - Van De Borne, B. W. AU - Webers, C. A. B. DB - Embase Medline DO - 10.1016/j.ophtha.2004.12.035 IS - 6 KW - pilocarpine timolol accuracy awareness clinical trial Cochrane Library data base disease course drug exposure Embase glaucoma human intraocular hypertension intraocular pressure Medline patient compliance patient education practice guideline prescription prevalence priority journal PsycINFO quantitative analysis rating scale review sensitivity and specificity technical aid treatment outcome visual impairment Prescript Time Cap LA - English M3 - Review N1 - L40797446 2005-06-26 PY - 2005 SN - 0161-6420 SP - 953-961 ST - Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: An evidence-based review T2 - Ophthalmology TI - Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: An evidence-based review UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40797446&from=export http://dx.doi.org/10.1016/j.ophtha.2004.12.035 VL - 112 ID - 3683 ER - TY - JOUR AB - OBJECTIVES: To determine the problems encountered in the management of primary congenital glaucoma in developing countries. METHODS: A prospective study of new patients with a diagnosis of primary congenital glaucoma attending the eye clinic of the University of Benin Teaching hospital, Benin City, Nigeria over a 5 year period, from July 2001 to June 2006. The age, sex, presenting complaints and duration were recorded. They were examined by the aid of a pen torch, hand-held slit lamp and direct ophthalmoscope. Intraocular pressure and corneal diameter were measured under anaesthesia. The patients were followed up till June 2006 and the problems encountered in management were recorded. RESULTS: Eight children comprising 5 males (62.5%) and 3 females (37.5%) with primary congenital glaucoma were seen. All the patients (100%) presented with buphthalmos and 7 (87.5%) had corneal opacity. Four (50%) accepted surgery but only 2 (25%) eventually had surgery. Maximum follow-up was 7 months. CONCLUSION: Presentation with features of advanced disease, poor acceptability of surgery, poor follow-up and low surgical rate are problems associated with the management of congenital glaucoma in Benin City, Nigeria. AD - Department of Ophthalmology, U. B. T. H., Benin-City.P. M. B. 1111, Nigeria AU - Omoti, A. E. AU - Uhumwangho, O. M. DB - Scopus IS - 4 M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2007 SP - 310-313 ST - Problems of management of primary congenital glaucoma in Benin City, Nigeria T2 - The Nigerian postgraduate medical journal TI - Problems of management of primary congenital glaucoma in Benin City, Nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-44449085530&partnerID=40&md5=fc4edf4d63df62fd81e01186629e33c6 VL - 14 ID - 5483 ER - TY - JOUR AB - Purpose: To examine resident adherence to preferred practice pattern (PPP) guidelines set up by the American Academy of Ophthalmology for follow-up care of primary open-angle glaucoma (POAG) patients. Design: Retrospective chart review. Participants: One hundred three charts were selected for analysis from all patients with an International Classification of Diseases, Ninth Revision, code of open-angle glaucoma or its related entities who underwent a follow-up evaluation between July 2, 2003, and December 15, 2004, at the resident ophthalmology clinic in the Durham Veteran Affairs Medical Center. Methods: Follow-up visits of POAG patients were evaluated for documentation of 19 elements in accordance to PPP guidelines. Main Outcome Measures: Compliance rates for the 19 elements of PPP guidelines first were averaged in all charts, and then were averaged per resident and were compared among 8 residents between their first and second years of residency. Results: The overall mean compliance rate for all 19 elements was 82.6% for all charts (n = 103), 78.8% for first-year residents, and 81.7% for second-year residents. The increase from first to second year of residency was not significant (P > 0.05). Documentation rates were high (>90%) for 14 elements, including all components of the physical examination and follow-up as well as most components of the examination history and management plan. Residents documented adjusting target intraocular pressure downward, local or systemic problems with medications, and impact of visual function on daily living approximately 50% to 80% of the time. Documentation rates for components of patient education were the lowest, between 5% and 16% in all charts. Conclusions: Residents' compliance with PPP guidelines for a POAG follow-up visit was very high for most elements, but documentation rates for components of patient education were poor. Adherence rates to PPP guidelines can be used as a tool to evaluate and improve resident performance during training. However, further studies are needed to establish the advantages of using PPP guidelines for resident education and to determine if such assessments can lead to improved patient care. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2013 by the American Academy of Ophthalmology Published by Elsevier Inc. AD - Duke Eye Center, Duke University School of Medicine, 2351 Erwin Road, Durham, NC 27710, United States Duke-NUS Graduate Medical School, Singapore, Singapore Eye Centers of Racine and Kenosha, Racine, WI, United States Brosnan Eye Associates, Asheville, NC, United States W. K. Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, MI, United States AU - Ong, S. S. AU - Sanka, K. AU - Mettu, P. S. AU - Brosnan, T. M. AU - Stinnett, S. S. AU - Lee, P. P. AU - Challa, P. DB - Scopus DO - 10.1016/j.ophtha.2013.05.019 IS - 12 M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2013 SP - 2462-2469 ST - Resident compliance with the american academy of ophthalmology preferred practice pattern guidelines for primary open-angle glaucoma T2 - Ophthalmology TI - Resident compliance with the american academy of ophthalmology preferred practice pattern guidelines for primary open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84888014869&doi=10.1016%2fj.ophtha.2013.05.019&partnerID=40&md5=df43db7345c29ee497d8f684b7a301dc VL - 120 ID - 5329 ER - TY - JOUR AB - Purpose: To examine resident adherence to preferred practice pattern (PPP) guidelines set up by the American Academy of Ophthalmology for follow-up care of primary open-angle glaucoma (POAG) patients. Design: Retrospective chart review. Participants: One hundred three charts were selected for analysis from all patients with an International Classification of Diseases, Ninth Revision, code of open-angle glaucoma or its related entities who underwent a follow-up evaluation between July 2, 2003, and December 15, 2004, at the resident ophthalmology clinic in the Durham Veteran Affairs Medical Center. Methods: Follow-up visits of POAG patients were evaluated for documentation of 19 elements in accordance to PPP guidelines. Main Outcome Measures: Compliance rates for the 19 elements of PPP guidelines first were averaged in all charts, and then were averaged per resident and were compared among 8 residents between their first and second years of residency. Results: The overall mean compliance rate for all 19 elements was 82.6% for all charts (n = 103), 78.8% for first-year residents, and 81.7% for second-year residents. The increase from first to second year of residency was not significant (P>0.05). Documentation rates were high (>90%) for 14 elements, including all components of the physical examination and follow-up as well as most components of the examination history and management plan. Residents documented adjusting target intraocular pressure downward, local or systemic problems with medications, and impact of visual function on daily living approximately 50% to 80% of the time. Documentation rates for components of patient education were the lowest, between 5% and 16% in all charts. Conclusions: Residents' compliance with PPP guidelines for a POAG follow-up visit was very high for most elements, but documentation rates for components of patient education were poor. Adherence rates to PPP guidelines can be used as a tool to evaluate and improve resident performance during training. However, further studies are needed to establish the advantages of using PPP guidelines for resident education and to determine if such assessments can lead to improved patient care. (C) 2013 by the American Academy of Ophthalmology. AN - WOS:000327249600027 AU - Ong, S. S. AU - Sanka, K. AU - Mettu, P. S. AU - Brosnan, T. M. AU - Stinnett, S. S. AU - Lee, P. P. AU - Challa, P. DA - DEC DO - 10.1016/j.ophtha.2013.05.019 IS - 12 PY - 2013 SN - 0161-6420 1549-4713 SP - 2462-2469 ST - Resident Compliance with the American Academy of Ophthalmology Preferred Practice Pattern Guidelines for Primary Open-Angle Glaucoma T2 - OPHTHALMOLOGY TI - Resident Compliance with the American Academy of Ophthalmology Preferred Practice Pattern Guidelines for Primary Open-Angle Glaucoma VL - 120 ID - 5882 ER - TY - JOUR AB - RESULTS: The total tear production in POAG patients under betaxolol therapy was 19.1 ± 10.6 mm. After the 2 months of preservative-free betaxolol use there were no statistically significant changes in Schirmer's test results (p = 0.248). Tear film break-up time (Norn test) improved from 7.8 ± 0.5 secto 9.8 ± 0.8 sec (p = 0.067) as well as the results of lissamine green staining (W = 90.0, p < 0.022). In the Morisky-Green Test betaxolol patients scored only 2.6 ± 0.05 points on average, thus showing non-compliance. After the 2 months of preservative-free betaxolol instillations the scores increased up to 3.1 ± 0.07 (p = 0.04). According to Dunnett's test, used for multiple comparisons, intraocular pressure did not change significantly in either of the study periods (baseline and follow-up measurements at weeks 2, 4, and 8 were taken into account). CONCLUSION: The study proves Xonef BK safe, effective, and appropriate in all types of glaucoma. AIM: To evaluate ocular surface changes in patients with primary open-angle glaucoma (POAG) as well as the hypotensive effect of preservative-free betaxolol eye drops. MATERIAL AND METHODS: A total of 22 patients (42 eyes) aged 55-83 with POAG stage I-II were examined. All of them were switched from betaxolol b.i.d. to its preservative-free analogue (Xonef BK). The baseline examination included visual acuity measurement, Morisky-Green test (questionnaire), Norn test, Schirmer's test, lissamine green staining, and ocular tonometry. The latter was repeated 2 and 4 weeks after the drug had been switched, while the whole complex--2 months after the beginning of the study. AU - Onischenko, A. L. AU - Dimaksyan, M. V. AU - Kolbasko, A. V. AU - Zilina, N. M. DB - Scopus DO - 10.17116/oftalma2015131276-80 IS - 2 M3 - Article N1 - Export Date: 19 July 2021 PY - 2015 SP - 76-80 ST - Preservative-free betaxolol for POAG patients: evaluation of hypotensive effect and ocular surface safety T2 - Vestnik oftalmologii TI - Preservative-free betaxolol for POAG patients: evaluation of hypotensive effect and ocular surface safety UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964697701&doi=10.17116%2foftalma2015131276-80&partnerID=40&md5=97785d125e95d54fee82e8302e48533d VL - 131 ID - 5744 ER - TY - JOUR AU - Onishchenko, A. L. AU - Kolbasko, A. V. AU - Safronova, M. A. AU - Isakov, I. N. DB - Medline IS - 3 KW - antihypertensive agent aged drug effect drug resistance female glaucoma human intraocular pressure male middle aged oculoplethysmography pathophysiology patient compliance procedures psychology statistics and numerical data treatment outcome LA - Russian M3 - Article N1 - L616505394 2017-06-02 PY - 2016 SN - 0042-465X SP - 49-51 ST - Reasons for intraocular pressure to resist hypotensive therapy in glaucoma patients T2 - Vestnik oftalmologii TI - Reasons for intraocular pressure to resist hypotensive therapy in glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616505394&from=export VL - 132 ID - 2743 ER - TY - JOUR AB - Background. Patient adherence with glaucoma medical therapy remains a global challenge. Objectives. To determine the prevalence of non-adherence and identify the determinants and deterrents to glaucoma medications in Enugu, southeast Nigeria. Material and methods. This study adopted a cross-sectional, descriptive, hospital-based survey involving 114 glaucoma patients on topical medications. They were recruited from the ophthalmic clinic of the University of Nigeria Teaching Hospital, Enugu. Information on their socio-demographic characteristics, clinical profile and issues of adherence with glaucoma medications were collected using a pre-tested, close-ended, interviewer–administered questionnaire. The data collected was analysed using SPSS version 21. Bivariate analysis was done to identify the associations of different factors of adherence with glaucoma medications. The level of significance was set at p < 0.05. Results. The participants were comprised of 58 males (50.9%) and 56 females (49.1%), with a mean age of 60.0 ± 14.8 years. Most were mainly on two or less glaucoma medications (92 (80.7%)) and were diagnosed with glaucoma for less than 5 years (73 (64.0%)). 42 (36.8%) participants were non-adherent with their glaucoma medications. Assisted administration of glaucoma medication was the most important determinant of non-adherence to medication. Gender, good/fair vision, distance from the pharmacy, knowledge of the disease and educational status also contributed. Cost was the major deterrent (59 (51.7%)) to adherence with glaucoma medications. Conclusions. The prevalence of non-adherence with medications among glaucoma patients in Enugu was high. Assisted drug administration was the most significant determinant, while the cost of drugs was a major deterrent to non-adherence with glaucoma medication. AD - Department of Ophthalmology, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria. AN - 148290284. Language: English. Entry Date: 20210130. Revision Date: 20210130. Publication Type: Article AU - Onwubiko, Stella Ngozi AU - Nwachukwu, Nkiru Zuada AU - Eze, Boniface Ikenna DB - ccm DO - 10.5114/fmpcr.2020.100436 DP - EBSCOhost IS - 4 KW - Glaucoma -- Drug Therapy -- Nigeria Medication Compliance -- Nigeria Tertiary Health Care -- Nigeria Human Nigeria Prevalence Cross Sectional Studies Descriptive Research Questionnaires Data Analysis Software Bivariate Statistics Male Female Middle Age Aged N1 - equations & formulas; research; tables/charts. Journal Subset: Biomedical. PY - 2020 SN - 1734-3402 SP - 302-306 ST - Glaucoma medications: issues with adherence in a tertiary hospital in Nigeria T2 - Family Medicine & Primary Care Review TI - Glaucoma medications: issues with adherence in a tertiary hospital in Nigeria UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148290284&site=ehost-live&scope=site VL - 22 ID - 4156 ER - TY - JOUR AB - Background: Primary open-angle glaucoma is a progressive optic neuropathy that can cause an irreversible loss of vision. A reduction in intraocular pressure (IOP) is beneficial in slowing or halting its progression. Once-per-day monotherapy glaucoma medications, such as prostaglandin analogues, are effective in lowering IOP while maintaining patients' adherence. Achieving the desired target IOP often requires multiple medications. The present study evaluates punctal occlusion of both the inferior and superior puncta as an adjunctive therapy to travoprost ophthalmic solution 0.004% for patients with primary open-angle glaucoma or ocular hypertension in order to reduce IOP. Methods: Thirteen patients who were using travoprost 0.004% ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension received silicone punctal plugs in the superior and inferior puncta of one eye. After one month, the IOP was remeasured. The percentage change of the IOP from the baseline was analysed by using a paired sample t-test. Results: The mean baseline IOP was 19.82 ± 1.19mmHg in the test eyes and 18.32 ± 1.11mmHg in the control eyes. The mean IOP at the one-month visit was 18.23 ± 1.17mmHg in the test eyes and 18.45 ± 1.04mmHg in the control eyes. The test eyes demonstrated a decrease in IOP of 1.59 (± 0.95) mmHg from the baseline, or a 6.82 per cent decrease in the IOP from the baseline. The control eyes had an increase in IOP of 0.14 ± 0.77mmHg from the baseline, or a 1.91 per cent increase in the IOP. The relative difference in the IOP between the test eyes and the control eyes at the one-month visit was 1.73mmHg, or 8.74 per cent. Conclusion: Based on the results of this study, punctal occlusion offers a statistically and clinically significant decrease in IOP when it is used as an adjunctive therapy to travoprost 0.004% for patients who are suffering from open-angle glaucoma or ocular hypertension. © 2011 Optometrists Association Australia. AD - Illinois College of Optometry, Chicago, IL, United States Midwest Eye Professionals, Palos Heights, IL, United States AU - Opitz, D. L. AU - Tung, S. AU - Jang, U. S. AU - Park, J. J. DB - Scopus DO - 10.1111/j.1444-0938.2010.00587.x IS - 5 KW - Disease management Glaucoma Ocular hypertension Patient compliance Punctal plugs Travoprost M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2011 SP - 438-442 ST - Silicone punctal plugs as an adjunctive therapy for open-angle glaucoma and ocular hypertension T2 - Clinical and Experimental Optometry TI - Silicone punctal plugs as an adjunctive therapy for open-angle glaucoma and ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052023798&doi=10.1111%2fj.1444-0938.2010.00587.x&partnerID=40&md5=796aaf498cc171ed42706303fe5b1810 VL - 94 ID - 5333 ER - TY - JOUR AB - Background: Primary open-angle glaucoma is a progressive optic neuropathy that can cause an irreversible loss of vision. A reduction in intraocular pressure (IOP) is beneficial in slowing or halting its progression. Once-per-day monotherapy glaucoma medications, such as prostaglandin analogues, are effective in lowering IOP while maintaining patients' adherence. Achieving the desired target IOP often requires multiple medications. The present study evaluates punctal occlusion of both the inferior and superior puncta as an adjunctive therapy to travoprost ophthalmic solution 0.004% for patients with primary open-angle glaucoma or ocular hypertension in order to reduce IOP. Methods: Thirteen patients who were using travoprost 0.004% ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension received silicone punctal plugs in the superior and inferior puncta of one eye. After one month, the IOP was remeasured. The percentage change of the IOP from the baseline was analysed by using a paired sample t-test. Results: The mean baseline IOP was 19.82 +/- 1.19 mmHg in the test eyes and 18.32 +/- 1.11 mmHg in the control eyes. The mean IOP at the one-month visit was 18.23 +/- 1.17 mmHg in the test eyes and 18.45 +/- 1.04 mmHg in the control eyes. The test eyes demonstrated a decrease in IOP of 1.59 (+/- 0.95) mmHg from the baseline, or a 6.82 per cent decrease in the IOP from the baseline. The control eyes had an increase in IOP of 0.14 +/- 0.77 mmHg from the baseline, or a 1.91 per cent increase in the IOP. The relative difference in the IOP between the test eyes and the control eyes at the one-month visit was 1.73 mmHg, or 8.74 per cent. Conclusion: Based on the results of this study, punctal occlusion offers a statistically and clinically significant decrease in IOP when it is used as an adjunctive therapy to travoprost 0.004% for patients who are suffering from open-angle glaucoma or ocular hypertension. AN - WOS:000294220000006 AU - Opitz, D. L. AU - Tung, S. AU - Jang, U. S. AU - Park, J. J. DA - SEP DO - 10.1111/j.1444-0938.2010.00587.x IS - 5 PY - 2011 SN - 0816-4622 1444-0938 SP - 438-442 ST - Silicone punctal plugs as an adjunctive therapy for open-angle glaucoma and ocular hypertension T2 - CLINICAL AND EXPERIMENTAL OPTOMETRY TI - Silicone punctal plugs as an adjunctive therapy for open-angle glaucoma and ocular hypertension VL - 94 ID - 5952 ER - TY - JOUR AB - We conducted a systematic review of economic studies of prostaglandin analogues for the treatment of glaucoma to assess the scope of current cost-effectiveness evidence and its relevance to decision-makers. The literature search retrieved 102 studies published before July 2005; after additional hand searching of conference proceedings, 13 full-text articles and 13 abstracts met the inclusion criteria. The reviewers extracted the key characteristics of each of the economic evaluations, and all studies received a grade in five categories to summarise the quality of the study: methodology, transparency, sensitivity, relevance and overall score. The current economic literature is predominantly focused on identifying the short-term direct cost of glaucoma treatment, particularly the precise quantification of glaucoma drug costs. Using the European and US treatment guidelines as a benchmark, it is evident that the current body of literature does not satisfy the needs of decision-makers, although certain studies provide some valuable information, which is a step towards reaching this goal. The main methodological issue in the economic models is an absence of a clinically relevant long-term effectiveness measure, or where this measure is produced, there is a lack of transparency and validation of the methods used. More attention needs to be given to modelling the consequences of treatment, and those consequences should include patient compliance, control of intraocular pressure and progression of visual field deficit, since these drive both the costs and the overall outcomes. We recognise that constructing the 'ideal' clinical outcome measure represents a major challenge to researchers. As such, we have outlined a modelling framework that could be used to produce the required level of economic evidence, and ongoing clinical research (such as the Early Manifest Glaucoma Trial) could provide the validated link between intraocular pressure and disease progression, which forms an essential part of such models. © 2006 Adis Data Information BV. All rights reserved. AD - M. Orme, Heron Evidence Development Ltd., Spirella Building, Bridge Road, Herts, SG6 4ET, United Kingdom AU - Orme, M. AU - Boler, A. C1 - lumigan rescula travatan xalacom xalatan DB - Embase Medline DO - 10.2165/00019053-200624080-00002 IS - 8 KW - bimatoprost latanoprost latanoprost plus timolol prostaglandin derivative timolol travoprost unoprostone isopropyl ester clinical research cost effectiveness analysis disease course economic aspect human intraocular hypertension intraocular pressure long term care medical assessment medical decision making medical information medical literature methodology open angle glaucoma patient compliance practice guideline priority journal quality control review systematic review treatment outcome visual field defect lumigan rescula travatan xalacom xalatan LA - English M3 - Review N1 - L44232103 2006-08-27 jsessionid=GdFJvtf7n2NYhnztn8KyHSqGQQwkn8xBVSJfhX41snxF0Dj7Fy0Y!869285401!-949856145!8091!-1 PY - 2006 SN - 1170-7690 SP - 743-750 ST - Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: A systematic review of economic evidence T2 - PharmacoEconomics TI - Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: A systematic review of economic evidence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44232103&from=export http://dx.doi.org/10.2165/00019053-200624080-00002 http://pharmacoeconomics.adisonline.com/pt/re/phe/pdfhandler.00019053-200624080-00002.pdf VL - 24 ID - 3592 ER - TY - JOUR AB - PURPOSE: The objective was to assess the long-term economic consequences of the medical management of glaucoma in the UK. METHODS: The economic evaluation was conducted using the results from a 10-year Markov model based around 3 key triggers for a switch in medical therapy for glaucoma, namely: lack of tolerance (using hyperemia as a proxy); intraocular pressure (IOP) not meeting treatment benchmark; and glaucoma progression. Clinical data from a comprehensive systematic literature review and meta-analysis were used. Direct costs associated with glaucoma treatment are considered (at 2008/9 prices) from the perspective of the UK NHS as payer (outpatient/secondary care setting). Using this model, the economic consequences of 3 prostaglandin-based treatment sequences were compared. RESULTS: Drug acquisition costs account for around 8% to 13% of the total cost of glaucoma and, if ophthalmologist visits are included, amount to approximately £0.80 to £0.90 per day of medical therapy. The total long-term costs of all prostaglandin strategies are similar because of a shift in resources: increased drug costs are offset by fewer clinic visits to instigate treatment switches, and by avoiding surgery or costs associated with managing low vision. Under the latanoprost-based strategy, patients would have longer intervals between the need to switch therapies, which is largely due to a reduction in hyperemia, seen as a proxy for tolerance. This leads to a delay in glaucoma progression of 12 to 13 months. For every 1000 clinic appointments, 719 patients can be managed for 1 year with a latanoprost-based strategy compared with 586 or 568 with a bimatoprost or travoprost-based strategy. CONCLUSIONS: Drug acquisition costs are not a key driver of the total cost of glaucoma management and the cost of medical therapy is offset by avoiding the cost of managing low vision. Economic models of glaucoma should include the long-term consequences of treatment as these will affect cost-effectiveness. This analysis supports the hypothesis that the economic and clinical benefits can be optimized by minimizing therapy switches. Copyright © 2012 by Lippincott Williams & Wilkins. AD - Abacus International, 6 Talisman Business Centre, Talisman Road, Bicester, Oxfordshire, OX26 6HR, United Kingdom Pfizer Ltd, Walton on the Hill, Surrey, United Kingdom AU - Orme, M. AU - Collins, S. AU - Loftus, J. DB - Scopus DO - 10.1097/IJG.0b013e31821dac2a IS - 7 KW - economic model ocular hypertension open-angle glaucoma prostaglandin analogs M3 - Review N1 - Cited By :11 Export Date: 19 July 2021 PY - 2012 SP - 433-449 ST - Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: Optimizing cost-effectiveness and clinic resources by minimizing therapy switches T2 - Journal of Glaucoma TI - Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: Optimizing cost-effectiveness and clinic resources by minimizing therapy switches UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866001389&doi=10.1097%2fIJG.0b013e31821dac2a&partnerID=40&md5=1df7d14bfc8111819213f42d4fabacf3 VL - 21 ID - 5256 ER - TY - JOUR AB - The nonselective β-blocker timolol and the carbonic anhydrase inhibitor dorzolamide both lower intraocular pressure (IOP). Timolol and dorzolamide have different mechanisms of action and their effects are additive when administered together. Therefore, the 2 drugs are frequently used concomitantly to treat patients with open-angle glaucoma who have not adequately responded to first-line therapy. A barrier to good compliance with concomitant therapy is the need to administer 5 or 6 drops of medication on 2 or 4 occasions during the day. Timolol 0.5% and dorzolamide 2.0% have therefore been combined in a single formulation, reducing the number of administrations required to 2 per day. Clinical trials in patients with glaucoma have demonstrated that dorzolamide 2%/timolol 0.5% (dorzolamide/timolol) is superior to monotherapy with the individual components. When dorzolamide/timolol administered twice daily was compared with concomitant treatment with dorzolamide 2% and timolol 0.5%, each administered twice daily for 90 days, both regimens resulted in marked lowering of trough IOP (measured just before the morning dose) compared with baseline (reduction in IOP = 4.2mm Hg). The effect of the 2 regimens on IOP at all time points, both before treatment and at peak effect (2 hours after treatment), were virtually indistinguishable. When the combined formulation was compared with a concomitant regimen that included dorzolamide 2% 3 times daily and timolol 0.5% twice daily the concomitant regimen was slightly more efficacious than the combined regimen at trough after 90 days: IOP was lowered by 3.6mm Hg in the combined group versus 4.1mm Hg in the concomitant group. Dorzolamide/timolol has been compared with concomitant administration of timolol 0.5% and the IOP lowering miotic drug, pilocarpine 2.0%. This non-blind patient-preference study found that both regimens reduced IOP. However, the dorzolamide/timolol combination was preferred by the patients because of reduced frequency and severity of adverse effects and less frequent administration. Dorzolamide/timolol was well tolerated in clinical trials, the adverse effects reflected those of the individual components, and no additional tolerability issues were identified. However, the potential for timolol to cause cardiorespiratory effects must be considered when prescribing this combination. Furthermore, dorzolamide is a sulfonamide and can cause allergic reactions in those who are hypersensitive to this class of drug. Conclusions: Dorzolamide/timolol is a well tolerated and effective fixed combination for lowering IOP in the treatment of open-angle glaucoma and is likely to be useful in those patients who do not respond adequately to first-line monotherapy. Compared with concomitant therapy with the same 2 drugs the primary advantage is convenience, which may lead to improved compliance. Studies of compliance and comparisons with other currently available combination therapies would be useful to fully define the value of the formulation. Nonetheless, dorzolamide combined with timolol in a single applicator system will be a useful addition to the treatment options for glaucoma, a leading cause of preventable blindness. AD - D. Ormrod, Adis International Limited, 41 Centorian Drive, Mairangi Bay, Aukland 10, New Zealand AU - Ormrod, D. AU - McClellan, K. DB - Embase Medline DO - 10.2165/00002512-200017060-00005 IS - 6 KW - beta adrenergic receptor blocking agent carbonate dehydratase inhibitor dorzolamide dorzolamide plus timolol pilocarpine timolol allergic reaction blindness dose response drug absorption drug distribution drug excretion drug metabolism drug mixture drug tolerability eye blood flow headache human intraocular hypertension intraocular pressure monotherapy nausea open angle glaucoma patient compliance priority journal review LA - English M3 - Review N1 - L32102730 2001-02-14 PY - 2000 SN - 1170-229X SP - 477-496 ST - Topical dorzolamide 2%/timolol 0.5%: A review of its use in the treatment of open-angle glaucoma T2 - Drugs and Aging TI - Topical dorzolamide 2%/timolol 0.5%: A review of its use in the treatment of open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32102730&from=export http://dx.doi.org/10.2165/00002512-200017060-00005 VL - 17 ID - 3900 ER - TY - JOUR AB - The nonselective [beta]-blocker timolol and the carbonic anhydrase inhibitor dorzolamide both lower intraocular pressure (IOP). Timolol and dorzolamide have different mechanisms of action and their effects are additive when administered together. Therefore, the 2 drugs are frequently used concomitantly to treat patients with open-angle glaucoma who have not adequately responded to first-line therapy. A barrier to good compliance with concomitant therapy is the need to administer 5 or 6 drops of medication on 2 or 4 occasions during the day. Timolol 0.5% and dorzolamide 2.0% have therefore been combined in a single formulation, reducing the number of administrations required to 2 per day. Clinical trials in patients with glaucoma have demonstrated that dorzolamide 2%/timolol 0.5% (dorzolamide/timolol) is superior to monotherapy with the individual components. When dorzolamide/timolol administered twice daily was compared with concomitant treatment with dorzolamide 2% and timolol 0.5%, each administered twice daily for 90 days, both regimens resulted in marked lowering of trough IOP (measured just before the morning dose) compared with baseline (reduction in IOP = 4.2mm Hg). The effect of the 2 regimens on IOP at all time points, both before treatment and at peak effect (2 hours after treatment), were virtually indistinguishable. When the combined formulation was compared with a concomitant regimen that included dorzolamide 2% 3 times daily and timolol 0.5% twice daily the concomitant regimen was slightly more efficacious than the combined regimen at trough after 90 days: IOP was lowered by 3.6mm Hg in the combined group versus 4.1mm Hg in the concomitant group. Dorzolamide/timolol has been compared with concomitant administration of timolol 0.5% and the IOP lowering miotic drug, pilocarpine 2.0%. This non-blind patient-preference study found that both regimens reduced IOP. However, the dorzolamide/timolol combination was preferred by the patients because of reduced frequency and severity of adverse effects and less frequent administration. Dorzolamide/timolol was well tolerated in clinical trials, the adverse effects reflected those of the individual components, and no additional tolerability issues were identified. However, the potential for timolol to cause cardiorespiratory effects must be considered when prescribing this combination. Furthermore, dorzolamide is a sulfonamide and can cause allergic reactions in those who are hypersensitive to this class of drug. Conclusions: Dorzolamide/timolol is a well tolerated and effective fixed combination for lowering IOP in the treatment of open-angle glaucoma and is likely to be useful in those patients who do not respond adequately to first-line monotherapy. Compared with concomitant therapy with the same 2 drugs the primary advantage is convenience, which may lead to improved compliance. Studies of compliance and comparisons with other currently available combination therapies would be useful to fully define the value of the formulation. Nonetheless, dorzolamide combined with timolol in a single applicator system will be a useful addition to the treatment options for glaucoma, a leading cause of preventable blindness. AN - 106100636. Language: English. Entry Date: 20070101. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Australia & New Zealand AU - Ormrod, D. AU - McClellan, K. DB - ccm DP - EBSCOhost IS - 6 KW - Adrenergic Beta-Antagonists -- Therapeutic Use Carbonic Anhydrase Inhibitors -- Therapeutic Use Glaucoma -- Drug Therapy Sulfonamides -- Therapeutic Use Sulfur Compounds -- Therapeutic Use Timolol -- Therapeutic Use Adrenergic Beta-Antagonists -- Pharmacokinetics Carbonic Anhydrase Inhibitors -- Pharmacokinetics Drug Combinations Drug Therapy, Combination Female Glaucoma -- Metabolism Intraocular Pressure -- Drug Effects Intraocular Pressure -- Physiology Male Sulfonamides -- Pharmacokinetics Sulfur Compounds -- Pharmacokinetics Timolol -- Pharmacokinetics N1 - Biomedical; Peer Reviewed. NLM UID: 9102074. PMID: NLM11200308. PY - 2000 SN - 1170-229X SP - 477-496 ST - Topical Dorzolamide 2%/Timolol 0.5%: A Review of its Use in the Treatment of Open-Angle Glaucoma T2 - Drugs & Aging TI - Topical Dorzolamide 2%/Timolol 0.5%: A Review of its Use in the Treatment of Open-Angle Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106100636&site=ehost-live&scope=site VL - 17 ID - 4302 ER - TY - JOUR AB - Silicone oil intraocular tamponade is a widely accepted procedure in the management of complex retinal detachments caused by proliferative diabetic vitreoretinopathy. Silicone oil has a high surface tension that mechanically limits fibrovascular reproliferation resulting in successful retinal reattachments. However, postoperative secondary glaucoma is a relatively frequent complication that may require intensive nursing management focused at intraocular pressure monitoring, positioning compliance, pain management, fluid and electrolyte balance, and glucose control. This article presents the postoperative clinical course of a 51-year-old man with diabetes and recurrent proliferative diabetic vitreoretinopathy who developed secondary glaucoma after silicone oil injection with a dramatic rise in intraocular pressure on the first postoperative day. Nursing management concurrent with medical and surgical management is discussed and the necessary nursing plan of care is identified. AD - Nurse Manager/Nurse Administrative Supervisor, Bascom Palmer Eye Institute, Anne Bates Leach Eye Hospital, 900 NW 17th St, Miami, FL AN - 107125665. Language: English. Entry Date: 20000801. Revision Date: 20150820. Publication Type: Journal Article AU - Orticio, L. P. DB - ccm DP - EBSCOhost IS - 2 KW - Diabetic Retinopathy -- Surgery Silicones -- Adverse Effects Glaucoma -- Etiology Eye Surgery -- Adverse Effects Case Studies Middle Age Male Oils -- Adverse Effects Ophthalmic Nursing Postoperative Complications N1 - case study; tables/charts. Journal Subset: Core Nursing; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9111431. PMID: NLM11907906. PY - 2000 SN - 1060-135X SP - 44-49 ST - Silicone oil-induced secondary glaucoma: a case study T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - Silicone oil-induced secondary glaucoma: a case study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107125665&site=ehost-live&scope=site VL - 25 ID - 4476 ER - TY - JOUR AB - Purpose: To assess the impact of medPlan®, a medication reminder mobile application in glaucoma patients in Benin City, Nigeria. Methods: In a randomized control trial with 2 months follow-up period, 200 patients receiving drug therapy for glaucoma were randomized into either into a control or study group. The study group comprised participants who made use of a medication reminder mobile application, medPlan®, while the control group consisted of those patients who did not use the application. Adherence to medication was measured for all the patients in both groups. Data was collected using a carefully designed questionnaire and statistically analyzed. Results: This study recorded 100 % response rate from the participants. In the study group, 56 % were very adherent while 18 % were moderately adherent, and 26 % were non-adherent respondents as against 45 % very adherent, 13 % moderately adherent and 42 % non-adherent respondents from the control group. In addition, 78 % of those in the study group agreed that there was improvement in their medication adherence since they started using the medication reminder application. This showed a significant positive impact of the medication reminder application (p = 0.0110) on adherence to medication. Conclusion: Medication adherence was improved in glaucoma patients who used medPlan®, a smartphone medication reminder application. This study lays a foundation for further research on medication reminder mobile applications. © 2020 The authors. AD - Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, University of Benin, Benin City, 300001, Nigeria AU - Osahon, P. T. AU - Mote, L. A. AU - Ntaji, V. I. DB - Scopus DO - 10.4314/tjpr.v19i12.28 IS - 12 KW - Glaucoma Impact Medication adherence Medication reminder MedPlan® Smartphone M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 2677-2682 ST - Assessment of the impact of medPlan®, a medication reminder mobile application, in glaucoma patients in Benin City, Nigeria T2 - Tropical Journal of Pharmaceutical Research TI - Assessment of the impact of medPlan®, a medication reminder mobile application, in glaucoma patients in Benin City, Nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099355595&doi=10.4314%2ftjpr.v19i12.28&partnerID=40&md5=25eb0594a9796d722843c769cfaffc4f VL - 19 ID - 5685 ER - TY - JOUR AB - Purpose: To assess the impact of medPlan (R), a medication reminder mobile application in glaucoma patients in Benin City, Nigeria. Methods: In a randomized control trial with 2 months follow-up period, 200 patients receiving drug therapy for glaucoma were randomized into either into a control or study group. The study group comprised participants who made use of a medication reminder mobile application, medPlan (R), while the control group consisted of those patients who did not use the application. Adherence to medication was measured for all the patients in both groups. Data was collected using a carefully designed questionnaire and statistically analyzed. Results: This study recorded 100 % response rate from the participants. In the study group, 56 % were very adherent while 18 % were moderately adherent, and 26 % were non-adherent respondents as against 45 % very adherent, 13 % moderately adherent and 42 % non-adherent respondents from the control group. In addition, 78 % of those in the study group agreed that there was improvement in their medication adherence since they started using the medication reminder application. This showed a significant positive impact of the medication reminder application (p = 0.0110) on adherence to medication. Conclusion: Medication adherence was improved in glaucoma patients who used medPlan (R), a smartphone medication reminder application. This study lays a foundation for further research on medication reminder mobile applications. AN - WOS:000604435700028 AU - Osahon, P. T. AU - Mote, L. A. AU - Ntaji, V. I. DA - DEC DO - 10.4314/tjpr.v19i12.28 IS - 12 PY - 2020 SN - 1596-5996 SP - 2677-2682 ST - Assessment of the impact of medPlan (R), a medication reminder mobile application, in glaucoma patients in Benin City, Nigeria T2 - TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH TI - Assessment of the impact of medPlan (R), a medication reminder mobile application, in glaucoma patients in Benin City, Nigeria VL - 19 ID - 5865 ER - TY - JOUR AB - The effect of different formulations of interferon on therapeutic response in patients coinfected with HIV and HCV is unclear. In this study, the safety, tolerability, viral kinetics (VK) modeling and host responses among HIV/HCV coinfected patients treated with pegylated-IFN or albinterferon alfa-2b (AlbIFN) with weight-based ribavirin were compared. Three trials treated 57 HIV/HCV coinfected genotype-1 patients with PegIFN alfa-2b (1.5μg/kg/week) (n=30), PegIFN alfa-2a (180μg/week) (n=10), and AlbIFN (900μg/q2week) (n=17) in combination with weight-based ribavirin (RBV). HCV RNA, safety labs, and interferon stimulated gene expression (ISG) was evaluated. Adverse events were documented at all study visits. HCV viral kinetics using a full pharmacokinetic/pharmacodynamic model was also evaluated. Baseline patient characteristics were similar across the three studies. All three formulations exhibited comparable safety and tolerability profiles and efficacy. VK/PK/PD parameters for all three studies as measured by mean efficiency and rate of infected cell loss were similar between the three groups. Host responses (ISG expression and immune activation markers) were similar among the three groups. All three regimens induced significant ISG at week 4 (P<0.05) and ISG expression strongly correlated with therapeutic response (r=0.65; P<0.01). In summary, a comprehensive analysis of responses to three different interferon formulations in HIV/HCV coinfected patients demonstrated similar effects. Notably, interferon-based therapy results in a blunted host response followed by modest antiviral effect in HIV/HCV coinfected patients. This suggests that future treatment options that do not rely on host immune responses such as direct antiviral agents would be particularly beneficial in these difficult to treat patients. © 2013 Wiley Periodicals, Inc. AD - LIR, NIAID, NIH, Maryland, United States Clinical Research Directorate/CMRP, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD, United States Department of Medicine, Institute of Biostatistics and Mathematical Modeling, Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany Division of Radiology, Radiology and Imaging Sciences, NIH, Bethesda, MD, United States Erasmus Medical Center, Rotterdam, Netherlands CCMD, CC, NIH, Maryland, United States AU - Osinusi, A. AU - Bon, D. AU - Nelson, A. AU - Lee, Y. J. AU - Poonia, S. AU - Shivakumar, B. AU - Cai, S. Y. AU - Wood, B. AU - Haagmans, B. AU - Lempicki, R. AU - Herrmann, E. AU - Sneller, M. AU - Polis, M. AU - Masur, H. AU - Kottilil, S. DB - Scopus DO - 10.1002/jmv.23773 IS - 2 KW - HCV HIV IFN-activity ISGs Pharmacokinetic/pharmacodynamic M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2014 SP - 177-185 ST - Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients T2 - Journal of Medical Virology TI - Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890146079&doi=10.1002%2fjmv.23773&partnerID=40&md5=409ed5ce199a516de0cc86a67fc84b04 VL - 86 ID - 5469 ER - TY - JOUR AB - Purpose: To evaluate the compliance of glaucoma patients to medical treatment and its impact on the intraocular pressure (IOP) and to verify the associated risk factors for noncompliance. Methods: All recruited patients were examined at the ophthalmology clinics of King Abdulaziz University Hospital, Riyadh, Saudi Arabia between May and August 2012. Patients were interviewed and subjected to answer a questionnaire that was developed based on a pilot test. Collected data included age, gender, number of prescribed drugs, and different reasons for noncompliance to the prescribed drugs. Results: Noncompliance was detected in 18 (19.4%) of the recruited patients. Factors associated with noncompliance demonstrated a trend toward older patients, males, patients with lower IOP at presentation, higher cup to disc ratio, and drug self-administering patients. However, the only statistically significant characteristic was being under lifelong medications (P = 0.005). Conclusion: Noncompliance was detected in around one-fifth of our glaucoma patients, particularly, the older group. Awareness programs, maintaining good patient-physician relationship, and personalizing treatment can lead to better adherence to treatment. AD - E.A. Osman, Department of Ophthalmology, College of Medicine, King Saud University, PO Box 245, Riyadh, Saudi Arabia AU - Osman, E. A. AU - Alqarni, B. A. M. AU - Alhasani, S. S. H. AU - Al Harbi, S. S. S. AU - Gikandi, P. W. AU - Mousa, A. DB - Embase Medline DO - 10.1089/jop.2015.0052 IS - 1 KW - antiglaucoma agent adult aged article closed angle glaucoma female glaucoma glaucoma surgery human intraocular pressure iridectomy laser coagulation major clinical study male open angle glaucoma patient compliance risk factor Saudi Saudi Arabia sclerectomy self report trabeculectomy LA - English M3 - Article N1 - L607901342 2016-01-29 2016-02-04 PY - 2016 SN - 1557-7732 1080-7683 SP - 50-54 ST - Compliance of glaucoma patients to ocular hypotensive medications among the saudi population T2 - Journal of Ocular Pharmacology and Therapeutics TI - Compliance of glaucoma patients to ocular hypotensive medications among the saudi population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607901342&from=export http://dx.doi.org/10.1089/jop.2015.0052 VL - 32 ID - 2767 ER - TY - JOUR AB - Purpose: To evaluate the compliance of glaucoma patients to medical treatment and its impact on the intraocular pressure (IOP) and to verify the associated risk factors for noncompliance.Methods: All recruited patients were examined at the ophthalmology clinics of King Abdulaziz University Hospital, Riyadh, Saudi Arabia between May and August 2012. Patients were interviewed and subjected to answer a questionnaire that was developed based on a pilot test. Collected data included age, gender, number of prescribed drugs, and different reasons for noncompliance to the prescribed drugs.Results: Noncompliance was detected in 18 (19.4%) of the recruited patients. Factors associated with noncompliance demonstrated a trend toward older patients, males, patients with lower IOP at presentation, higher cup to disc ratio, and drug self-administering patients. However, the only statistically significant characteristic was being under lifelong medications (P = 0.005).Conclusion: Noncompliance was detected in around one-fifth of our glaucoma patients, particularly, the older group. Awareness programs, maintaining good patient-physician relationship, and personalizing treatment can lead to better adherence to treatment. AD - Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. College of Medicine, King Saud University, Riyadh, Saudi Arabia. AN - 112333329. Language: English. Entry Date: 20161111. Revision Date: 20190619. Publication Type: journal article. Journal Subset: Biomedical AU - Osman, Essam A. AU - Alqarni, Bader Ahmed Mousa AU - AlHasani, Sara Salem Humaid AU - Al Harbi, Shatha Saleh Suliman AU - Gikandi, Priscilla Wairimu AU - Mousa, Ahmed DB - ccm DO - 10.1089/jop.2015.0052 DP - EBSCOhost IS - 1 KW - Patient Compliance Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Ocular Hypertension -- Drug Therapy Adult Adolescence Risk Factors Intraocular Pressure -- Drug Effects Cross Sectional Studies Antihypertensive Agents -- Pharmacodynamics Male Aged, 80 and Over Saudi Arabia Aged Young Adult Antihypertensive Agents -- Administration and Dosage Female Middle Age Impact of Events Scale Interview Guides N1 - Peer Reviewed; USA. Instrumentation: Diagnostic Interview Schedule for Children (DISC); Impact of Events Scale (IES). NLM UID: 9511091. PMID: NLM26600401. PY - 2016 SN - 1080-7683 SP - 50-54 ST - Compliance of Glaucoma Patients to Ocular Hypotensive Medications Among the Saudi Population T2 - Journal of Ocular Pharmacology & Therapeutics TI - Compliance of Glaucoma Patients to Ocular Hypotensive Medications Among the Saudi Population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112333329&site=ehost-live&scope=site VL - 32 ID - 4249 ER - TY - JOUR AB - Purpose: To evaluate anxiety felt by glaucoma patients. Patients and Methods: In total, 472 glaucoma patients responded to a questionnaire on anxiety, subjective symptoms, and vision-related quality of life (VR-QOL) associated with glaucoma. Anxiety was evaluated using the State-Trait Anxiety Inventory (STAI), state anxiety (STAI-State) subscale along with our novel questionnaire, assessing visual function and subjective symptoms, specialized for glaucoma. VR-QOL was evaluated using 5 subitems from the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). Adherence to ophthalmic antiglaucoma agents was confirmed. As indexes of visual function, corrected visual acuity (measured by eye chart), mean deviation (MD) score (measured with static perimetry), and 4 thresholds at the center of vision were determined. Stages were classified according to the Aulhorn Classification. From the STAI-State scores, the prevalence of anxiety in glaucoma patients was evaluated. We analyzed the correlation between the STAI-State and VFQ-25, anxiety, subjective symptoms, adherence, and visual function indexes. Results: In total, 78% of glaucoma patients experienced at least an intermediate level of anxiety. The STAI-State correlated significantly with anxiety and subjective symptoms as measured by our novel questionnaire, particularly for questions "current anxiety about loss of vision" and "current anxiety in life" (r=0.468 and 0.500; both P<0.0001). However, STAI-State correlated weakly with VFQ-25, and not at all with visual function indexes and adherence. Conclusions: Many glaucoma patients feel anxiety. The STAI-State is correlated with the VR-QOL and anxiety in glaucoma patients, making it useful for understanding the anxiety present in glaucoma patients. AD - Y. Otori, Department of Ophthalmology, National Hospital Organization, Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, Japan AU - Otori, Y. AU - Takahashi, G. AU - Urashima, M. AU - Kuwayama, Y. DB - Embase Medline DO - 10.1097/IJG.0000000000000761 IS - 11 KW - antiglaucoma agent adult aged anxiety article closed angle glaucoma female glaucoma human Japanese (people) major clinical study male medication compliance National Eye Institute Visual Function Questionnaire open angle glaucoma patient compliance prevalence priority journal quality of life secondary glaucoma State Trait Anxiety Inventory visual acuity LA - English M3 - Article N1 - L619161628 2017-11-14 2017-11-21 PY - 2017 SN - 1536-481X 1057-0829 SP - 1025-1029 ST - Evaluating the Quality of Life of Glaucoma Patients Using the State-Trait Anxiety Inventory T2 - Journal of Glaucoma TI - Evaluating the Quality of Life of Glaucoma Patients Using the State-Trait Anxiety Inventory UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619161628&from=export http://dx.doi.org/10.1097/IJG.0000000000000761 VL - 26 ID - 2685 ER - TY - JOUR AB - Background: Primary open angle glaucoma is a chronic, progressive eye disease that is the leading cause of blindness among African Americans. Glaucoma progresses more rapidly and appears about 10 years earlier in African Americans as compared to whites. African Americans are also less likely to receive comprehensive eye care when glaucoma could be detected before irreversible blindness. Screening and follow-up protocols for managing glaucoma recommended by eye-care professional organizations are often not followed by primary eye-care providers, both ophthalmologists and optometrists. There is a pressing need to improve both the accessibility and quality of glaucoma care for African Americans. Telemedicine may be an effective solution for improving management and diagnosis of glaucoma because it depends on ocular imaging and tests that can be electronically transmitted to remote reading centers where tertiary care specialists can examine the results. We describe the Eye Care Quality and Accessibility Improvement in the Community project (EQUALITY), set to evaluate a teleglaucoma program deployed in retail-based primary eye care practices serving communities with a large percentage of African Americans. Methods/Design: We conducted an observational, 1-year prospective study based in two Walmart Vision Centers in Alabama staffed by primary care optometrists. EQUALITY focuses on new or existing adult patients who are at-risk for glaucoma or already diagnosed with glaucoma. Patients receive dilated comprehensive examinations and diagnostic testing for glaucoma, followed by the optometrist's diagnosis and a preliminary management plan. Results are transmitted to a glaucoma reading center where ophthalmologists who completed fellowship training in glaucoma review results and provide feedback to the optometrist, who manages the care of the patient. Patients also receive eye health education about glaucoma and comprehensive eye care. Research questions include diagnostic and management agreement between providers, the impact of eye health education on patients' knowledge and adherence to follow-up and medication, patient satisfaction, program cost-effectiveness, and EQUALITY's impact on Walmart pharmacy prescription rates. Discussion: As eye-care delivery systems in the US strive to improve quality while reducing costs, telemedicine programs including teleglaucoma initiatives such as EQUALITY could contribute toward reaching this goal, particularly among underserved populations at-risk for chronic blinding diseases. AD - C. Owsley, Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, 700 S. 18th St, Birmingham, AL, United States AU - Owsley, C. AU - Rhodes, L. A. AU - McGwin, G. AU - Mennemeyer, S. T. AU - Bregantini, M. AU - Patel, N. AU - Wiley, D. M. AU - LaRussa, F. AU - Box, D. AU - Saaddine, J. AU - Crews, J. E. AU - Girkin, C. A. DB - Embase Medline DO - 10.1186/s12939-015-0213-8 IS - 1 KW - antiglaucoma agent adult article cost effectiveness analysis diagnostic test drug cost eye care female glaucoma health care access health care cost health care delivery health care quality health education health program high risk population human major clinical study male observational study ophthalmologist optometrist paramedical personnel patient attitude patient care patient compliance patient satisfaction prescription priority journal prospective study questionnaire telemedicine United States visual system examination LA - English M3 - Article N1 - L606952917 2015-11-24 2016-03-22 PY - 2015 SN - 1475-9276 ST - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design T2 - International Journal for Equity in Health TI - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606952917&from=export http://dx.doi.org/10.1186/s12939-015-0213-8 VL - 14 ID - 2781 ER - TY - JOUR AB - Background: Primary open angle glaucoma is a chronic, progressive eye disease that is the leading cause of blindness among African Americans. Glaucoma progresses more rapidly and appears about 10 years earlier in African Americans as compared to whites. African Americans are also less likely to receive comprehensive eye care when glaucoma could be detected before irreversible blindness. Screening and follow-up protocols for managing glaucoma recommended by eye-care professional organizations are often not followed by primary eye-care providers, both ophthalmologists and optometrists. There is a pressing need to improve both the accessibility and quality of glaucoma care for African Americans. Telemedicine may be an effective solution for improving management and diagnosis of glaucoma because it depends on ocular imaging and tests that can be electronically transmitted to remote reading centers where tertiary care specialists can examine the results. We describe the Eye Care Quality and Accessibility Improvement in the Community project (EQUALITY), set to evaluate a teleglaucoma program deployed in retail-based primary eye care practices serving communities with a large percentage of African Americans. Methods/Design: We conducted an observational, 1-year prospective study based in two Walmart Vision Centers in Alabama staffed by primary care optometrists. EQUALITY focuses on new or existing adult patients who are at-risk for glaucoma or already diagnosed with glaucoma. Patients receive dilated comprehensive examinations and diagnostic testing for glaucoma, followed by the optometrist's diagnosis and a preliminary management plan. Results are transmitted to a glaucoma reading center where ophthalmologists who completed fellowship training in glaucoma review results and provide feedback to the optometrist, who manages the care of the patient. Patients also receive eye health education about glaucoma and comprehensive eye care. Research questions include diagnostic and management agreement between providers, the impact of eye health education on patients' knowledge and adherence to follow-up and medication, patient satisfaction, program cost-effectiveness, and EQUALITY's impact on Walmart pharmacy prescription rates. Discussion: As eye-care delivery systems in the US strive to improve quality while reducing costs, telemedicine programs including teleglaucoma initiatives such as EQUALITY could contribute toward reaching this goal, particularly among underserved populations at-risk for chronic blinding diseases. © 2015 Owsley et al. AD - Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, 700 S. 18th St, Birmingham, AL 35294-0009, United States Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 1655 University Blvd, Birmingham, AL 35294-0022, United States Department of Health Care Organization and Policy, School of Public Health, 1655 University Blvd, Birmingham, 35294-0022, United States Prevent Blindness, 211 West Wacker Drive, Suite 1700, Chicago, Il 60606, United States Walmart Vision Center #1481, Birmingham, AL 35209, United States Walmart Vision Center #715 and Global Eye Care PC, Tuscaloosa, AL 35405, United States Vision Health Initiative, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA 30341-3727, United States AU - Owsley, C. AU - Rhodes, L. A. AU - McGwin, G., Jr. AU - Mennemeyer, S. T. AU - Bregantini, M. AU - Patel, N. AU - Wiley, D. M. AU - LaRussa, F. AU - Box, D. AU - Saaddine, J. AU - Crews, J. E. AU - Girkin, C. A. C7 - 213 DB - Scopus DO - 10.1186/s12939-015-0213-8 IS - 1 KW - Eye care utilization Eye health education Glaucoma suspect Health disparities Ocular hypertension Primary open angle glaucoma Spectral domain optical coherence tomography Telemedicine Vision impairment M3 - Article N1 - Cited By :18 Export Date: 19 July 2021 PY - 2015 ST - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design T2 - International Journal for Equity in Health TI - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960319004&doi=10.1186%2fs12939-015-0213-8&partnerID=40&md5=c1e4ad37a03f890f7ddda116b1ab436b VL - 14 ID - 5156 ER - TY - JOUR AB - Background: Primary open angle glaucoma is a chronic, progressive eye disease that is the leading cause of blindness among African Americans. Glaucoma progresses more rapidly and appears about 10 years earlier in African Americans as compared to whites. African Americans are also less likely to receive comprehensive eye care when glaucoma could be detected before irreversible blindness. Screening and follow-up protocols for managing glaucoma recommended by eye-care professional organizations are often not followed by primary eye-care providers, both ophthalmologists and optometrists. There is a pressing need to improve both the accessibility and quality of glaucoma care for African Americans. Telemedicine may be an effective solution for improving management and diagnosis of glaucoma because it depends on ocular imaging and tests that can be electronically transmitted to remote reading centers where tertiary care specialists can examine the results. We describe the Eye Care Quality and Accessibility Improvement in the Community project (EQUALITY), set to evaluate a teleglaucoma program deployed in retail-based primary eye care practices serving communities with a large percentage of African Americans. Methods/ Design: We conducted an observational, 1-year prospective study based in two Walmart Vision Centers in Alabama staffed by primary care optometrists. EQUALITY focuses on new or existing adult patients who are at-risk for glaucoma or already diagnosed with glaucoma. Patients receive dilated comprehensive examinations and diagnostic testing for glaucoma, followed by the optometrist's diagnosis and a preliminary management plan. Results are transmitted to a glaucoma reading center where ophthalmologists who completed fellowship training in glaucoma review results and provide feedback to the optometrist, who manages the care of the patient. Patients also receive eye health education about glaucoma and comprehensive eye care. Research questions include diagnostic and management agreement between providers, the impact of eye health education on patients' knowledge and adherence to follow-up and medication, patient satisfaction, program cost-effectiveness, and EQUALITY's impact on Walmart pharmacy prescription rates. Discussion: As eye-care delivery systems in the US strive to improve quality while reducing costs, telemedicine programs including teleglaucoma initiatives such as EQUALITY could contribute toward reaching this goal, particularly among underserved populations at-risk for chronic blinding diseases. AN - WOS:000365172500001 AU - Owsley, C. AU - Rhodes, L. A. AU - McGwin, G. AU - Mennemeyer, S. T. AU - Bregantini, M. AU - Patel, N. AU - Wiley, D. M. AU - LaRussa, F. AU - Box, D. AU - Saaddine, J. AU - Crews, J. E. AU - Girkin, C. A. DA - NOV 18 DO - 10.1186/s12939-015-0213-8 PY - 2015 SN - 1475-9276 ST - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design T2 - INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH TI - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design VL - 14 ID - 5967 ER - TY - JOUR AB - Background: Primary open angle glaucoma is a chronic, progressive eye disease that is the leading cause of blindness among African Americans. Glaucoma progresses more rapidly and appears about 10 years earlier in African Americans as compared to whites. African Americans are also less likely to receive comprehensive eye care when glaucoma could be detected before irreversible blindness. Screening and follow-up protocols for managing glaucoma recommended by eye-care professional organizations are often not followed by primary eye-care providers, both ophthalmologists and optometrists. There is a pressing need to improve both the accessibility and quality of glaucoma care for African Americans. Telemedicine may be an effective solution for improving management and diagnosis of glaucoma because it depends on ocular imaging and tests that can be electronically transmitted to remote reading centers where tertiary care specialists can examine the results. We describe the Eye Care Quality and Accessibility Improvement in the Community project (EQUALITY), set to evaluate a teleglaucoma program deployed in retail-based primary eye care practices serving communities with a large percentage of African Americans. Methods/Design: We conducted an observational, 1-year prospective study based in two Walmart Vision Centers in Alabama staffed by primary care optometrists. EQUALITY focuses on new or existing adult patients who are at-risk for glaucoma or already diagnosed with glaucoma. Patients receive dilated comprehensive examinations and diagnostic testing for glaucoma, followed by the optometrist's diagnosis and a preliminary management plan. Results are transmitted to a glaucoma reading center where ophthalmologists who completed fellowship training in glaucoma review results and provide feedback to the optometrist, who manages the care of the patient. Patients also receive eye health education about glaucoma and comprehensive eye care. Research questions include diagnostic and management agreement between providers, the impact of eye health education on patients' knowledge and adherence to follow-up and medication, patient satisfaction, program cost-effectiveness, and EQUALITY's impact on Walmart pharmacy prescription rates. Discussion: As eye-care delivery systems in the US strive to improve quality while reducing costs, telemedicine programs including teleglaucoma initiatives such as EQUALITY could contribute toward reaching this goal, particularly among underserved populations at-risk for chronic blinding diseases. AD - Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, 700 S. 18th St, Birmingham, AL 35294-0009, USA Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 1655 University Blvd, Birmingham, AL 35294-0022, USA Department of Health Care Organization and Policy, School of Public Health, 1655 University Blvd, Birmingham 35294-0022, USA Prevent Blindness, 211 West Wacker Drive, Suite 1700, Chicago, Il 60606, USA Walmart Vision Center #1481, Birmingham, AL 35209, USA Walmart Vision Center #715 and Global Eye Care PC, Tuscaloosa, AL 35405, USA Vision Health Initiative, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA 30341-3727, USA AN - 111080999. Language: English. Entry Date: 20180117. Revision Date: 20190201. Publication Type: Article AU - Owsley, Cynthia AU - Rhodes, Lindsay A. AU - McGwin Jr, Gerald AU - Mennemeyer, Stephen T. AU - Bregantini, Mary AU - Patel, Nita AU - Wiley, Demond M. AU - LaRussa, Frank AU - Box, Dan AU - Saaddine, Jinan AU - Crews, John E. AU - Girkin, Christopher A. DB - ccm DO - 10.1186/s12939-015-0213-8 DP - EBSCOhost KW - Intraocular Pressure Glaucoma -- Drug Therapy Eye Care Tertiary Health Care Glaucoma -- Diagnosis Black Persons Primary Health Care Human Nonexperimental Studies Prospective Studies Alabama Quality Improvement Telemedicine N1 - research; tables/charts. Journal Subset: Biomedical; Europe; Health Services Administration; UK & Ireland. NLM UID: 101147692. PY - 2015 SN - 1475-9276 SP - 1-14 ST - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design T2 - International Journal for Equity in Health TI - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=111080999&site=ehost-live&scope=site VL - 14 ID - 4258 ER - TY - JOUR AB - Sustained-release drug delivery systems that replace the need for daily glaucoma medications will improve outcomes for those who are nonadherent and reduce the inconvenience of having to take medications on a recurring basis.The objective is to estimate uptake (i.e., demand) for a new technology that delivers sustained-release glaucoma medication and to investigate how uptake varies by product attributes, physician recommendations, peer adoption (i.e., percentage of patients seen in a clinic using the new technology), and patient characteristics.In a web-enabled discrete-choice experiment survey, glaucoma patients in the United States were asked to choose between continuing eye drop use or purchasing the new delivery system. In a cross-sectional web-enabled survey, ophthalmologists were asked their likelihood of recommending the new technology based on product and patient characteristics.Study participants were 500 glaucoma patients who were on topical administration of daily eye drops and 155 ophthalmologists who practice in the US.Main outcomes were predicted uptake for patients and likelihood of recommending a new drug delivery system for ophthalmologists. Logistic models were used to analyze the choice data.Uptake was estimated to be 18% at an annual cost of $1000 and to be 24% when the cost was $500. A physician's recommendation increased uptake by 6% to 12%, whereas an increase in peer adoption from 5% to 50% increased uptake by 3% to 7%. Patients aged ≥ 65 and those with lower income were more likely to remain on eye drops. Physicians were more likely to recommend a product if the interval between administrations is 6 months or longer and when long-term safety and efficacy data are available. They were less likely to recommend it to patients with lower income and no adherence problems.Results suggest a significant interest in an injectable solution or other sustained-release alternatives to daily eye drops. However, in this survey, patient uptake was greatly influenced by out-of-pocket cost and the interval between treatment administrations. Few physicians were willing to recommend sustained-release technology if the treatment interval was less than 3 months. AD - Health Services and Systems Research Programme, Duke-NUS Medical School, Singapore Glaucoma Department, Singapore National Eye Centre, Singapore School of Medicine, Duke University, Durham, NC AN - 122595980. Language: English. Entry Date: 20170430. Revision Date: 20210110. Publication Type: journal article AU - Ozdemir, Semra AU - Wong, Tina T. AU - Allingham, Robert Rand AU - Finkelstein, Eric A. DB - ccm DO - 10.1097/MD.0000000000006626 DP - EBSCOhost IS - 15 KW - Patient Satisfaction -- Statistics and Numerical Data Forecasting Health Services Needs and Demand -- Trends Ophthalmic Solutions -- Administration and Dosage Glaucoma -- Psychosocial Factors Human Male Female Drug Delivery Systems Administration, Topical Logistic Regression Aged Medication Compliance Adult Delayed-Action Preparations United States Cross Sectional Studies Glaucoma -- Drug Therapy Middle Age N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 2985248R. PMID: NLM28403115. PY - 2017 SN - 0025-7974 SP - 1-5 ST - Predicted patient demand for a new delivery system for glaucoma medicine T2 - Medicine TI - Predicted patient demand for a new delivery system for glaucoma medicine UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122595980&site=ehost-live&scope=site VL - 96 ID - 4272 ER - TY - JOUR AD - New Delhi, India AU - Panda, A. AU - Bajaj, M. S. AU - Balasubramanya, R. AU - Prakash, G. DB - Scopus DO - 10.1016/S0002-9394(02)01861-5 IS - 1 M3 - Letter N1 - Cited By :7 Export Date: 19 July 2021 PY - 2003 SP - 122-123 ST - Topical mitomycin C for conjunctival-corneal squamous cell carcinoma [1] (multiple letters) T2 - American Journal of Ophthalmology TI - Topical mitomycin C for conjunctival-corneal squamous cell carcinoma [1] (multiple letters) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037216719&doi=10.1016%2fS0002-9394%2802%2901861-5&partnerID=40&md5=3a26e2a811520e0e56c17f457ff32e7e VL - 135 ID - 5366 ER - TY - JOUR AB - Purpose: Frequent steroid drops represent a challenge in patient compliance. This study evaluated the safety and efficacy of 5 minute topical dexamethasone sodium phosphate-Visulex (DSP-Visulex) treatment regimen (two applications on the first week then weekly after) compared to daily prednisolone acetate 1% (PA) for noninfectious anterior uveitis. Materials and Methods: Forty-four patients were randomized to 8% DSP-Visulex with placebo eye drops (8% group, n = 14), 15% DSP-Visulex with placebo eye drops (15% group, n = 15), or Vehicle-Visulex with PA eye drops (PA group, n = 15). Patients received daily eye drops and Visulex treatments on days 1, 3, 8, and 15 with an optional treatment on day 22. Efficacy measures were change in anterior chamber cell (ACC) count from baseline and proportion of patients with zero ACC count at days 8, 15, and 29. Safety measures were adverse events (AEs), visual acuity, ocular symptoms, and intraocular pressure (IOP). Results: ACC resolution over time was similar among the three groups. The percentage of patients with clear ACC was 18%, 22%, and 15% on day 8; 27%, 56%, and 54% on day 15; and 90%, 88%, and 77% on day 29 for the 8%, 15%, and PA groups, respectively. The numbers of reported AEs were 10, 36, and 12 for the 8%, 15%, and PA groups, respectively. Ten patients among all groups experienced treatment-related AEs, which included headache, eye pain, corneal abrasion, conjunctival/corneal staining, conjunctivitis, visual acuity reduction, and keratitis all of which were resolved during the timeframe of patients’ participation in the study. IOP elevation was noted in the PA group throughout the study, whereas IOP elevation in the DSP-Visulex groups was observed at day 3 but not thereafter. Conclusions: The efficacy of the DSP-Visulex applications was comparable to the daily PA drops in the treatment of noninfectious anterior uveitis. Both 8% and 15% DSP-Visulex treatments were safe and well tolerated. AD - K. Papangkorn, Aciont Inc, 615 Arapeen Drive, Suite 302, Salt Lake City, UT, United States AU - Papangkorn, K. AU - Truett, K. R. AU - Vitale, A. T. AU - Jhaveri, C. AU - Scales, D. K. AU - Foster, C. S. AU - Montieth, A. AU - Higuchi, J. W. AU - Brar, B. AU - Higuchi, W. I. DB - Embase Medline DO - 10.1080/02713683.2018.1540707 IS - 2 KW - NCT02309385 ophthalmic drug delivery device dexamethasone sodium phosphate placebo abrasion adult anterior eye chamber article best corrected visual acuity chemosis clinical article conjunctival hemorrhage conjunctivitis controlled study dermatitis diabetic ketoacidosis drug dose reduction drug efficacy drug safety drug tolerability eye pain eyelid pain female glaucoma headache human hyperemia intraocular pressure iridocyclitis keratitis male multicenter study patient compliance phase 1 clinical trial phase 2 clinical trial priority journal randomized controlled trial retina detachment retina hemorrhage slit lamp microscopy surgical patient treatment duration uveitis viral conjunctivitis visual acuity visual analog scale Visulex LA - English M3 - Article N1 - L625192368 2018-12-03 2019-02-19 PY - 2019 SN - 1460-2202 0271-3683 SP - 185-193 ST - Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial T2 - Current Eye Research TI - Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625192368&from=export http://dx.doi.org/10.1080/02713683.2018.1540707 VL - 44 ID - 2533 ER - TY - JOUR AB - Purpose: Frequent steroid drops represent a challenge in patient compliance. This study evaluated the safety and efficacy of 5 minute topical dexamethasone sodium phosphate-Visulex (DSP-Visulex) treatment regimen (two applications on the first week then weekly after) compared to daily prednisolone acetate 1% (PA) for noninfectious anterior uveitis. Materials and Methods: Forty-four patients were randomized to 8% DSP-Visulex with placebo eye drops (8% group, n = 14), 15% DSP-Visulex with placebo eye drops (15% group, n = 15), or Vehicle-Visulex with PA eye drops (PA group, n = 15). Patients received daily eye drops and Visulex treatments on days 1, 3, 8, and 15 with an optional treatment on day 22. Efficacy measures were change in anterior chamber cell (ACC) count from baseline and proportion of patients with zero ACC count at days 8, 15, and 29. Safety measures were adverse events (AEs), visual acuity, ocular symptoms, and intraocular pressure (IOP). Results: ACC resolution over time was similar among the three groups. The percentage of patients with clear ACC was 18%, 22%, and 15% on day 8; 27%, 56%, and 54% on day 15; and 90%, 88%, and 77% on day 29 for the 8%, 15%, and PA groups, respectively. The numbers of reported AEs were 10, 36, and 12 for the 8%, 15%, and PA groups, respectively. Ten patients among all groups experienced treatment-related AEs, which included headache, eye pain, corneal abrasion, conjunctival/corneal staining, conjunctivitis, visual acuity reduction, and keratitis all of which were resolved during the timeframe of patients’ participation in the study. IOP elevation was noted in the PA group throughout the study, whereas IOP elevation in the DSP-Visulex groups was observed at day 3 but not thereafter. Conclusions: The efficacy of the DSP-Visulex applications was comparable to the daily PA drops in the treatment of noninfectious anterior uveitis. Both 8% and 15% DSP-Visulex treatments were safe and well tolerated. © 2018, © 2018 Taylor & Francis Group, LLC. AD - Aciont Inc, Salt Lake City, UT, United States KCT Data Inc, Alpharetta, GA, United States John A Moran Eye Center, Salt Lake City, UT, United States Retina Consultants of Austin, Austin, TX, United States Retina & Uveitis Consultants of Texas, San Antonio, TX, United States Massachusetts Eye Research and Surgery Institution, Waltham, MA, United States AU - Papangkorn, K. AU - Truett, K. R. AU - Vitale, A. T. AU - Jhaveri, C. AU - Scales, D. K. AU - Foster, C. S. AU - Montieth, A. AU - Higuchi, J. W. AU - Brar, B. AU - Higuchi, W. I. DB - Scopus DO - 10.1080/02713683.2018.1540707 IS - 2 KW - clinical trial dexamethasone Ocular drug delivery safety and efficacy uveitis M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2019 SP - 185-193 ST - Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial T2 - Current Eye Research TI - Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057248343&doi=10.1080%2f02713683.2018.1540707&partnerID=40&md5=f1e3dcbbb57e14aa46705e4811290426 VL - 44 ID - 5447 ER - TY - JOUR AB - Background: The health risks associated with poor medication practices in the home suggest that patients would benefit from home-based medication reviews that could detect and resolve these issues. However, remuneration for home visits often excludes ambulatory, nonhomebound patients. A subset of these patients have issues that cannot be adequately identified and resolved during the course of a typical pharmacy-based medication review. Purpose: This study aims to characterize the prevalence and nature of “hidden in the home” medication management issues in nonhomebound patients. Methods: Pharmacists facilitated subject enrollment among patients at 6 community pharmacies in Toronto over a 15-month period, from January 2016 to March 2017. Patients taking 5 or more chronic medications who were ambulatory (able to visit the pharmacy) and scored 3 points or higher on a prescreening questionnaire were invited to participate. Visits included a standard medication review, the identification of drug therapy problems and an assessment of the patient’s medication and organization/storage practices, followed by a medication cabinet cleanup. Results: One hundred patients were recruited, with a mean age of 76.9 years and taking on average 10 chronic medications. Pharmacists identified a total of 275 drug therapy problems (2.75 per patient). The most common issues reported additional therapy required (23.6%), nonadherence (23.3%) and adverse drug reactions (17.8%). For those patients 65 years or older (87%), 32% were found to be using at least 1 medication on the Beers Criteria list, while 6% were using 3 or more. Sulfonylureas, non-steroidal anti-inflammatory drugs and short-acting benzodiazepines were the most commonly implicated drugs. Medications were removed from the homes of 67% of the patients, with expiry of medication being the most common reason for removal (54.2%). The mean duration of a home visit was 49.5 minutes. Conclusion: Pharmacist-directed home medication reviews offer an effective mechanism to address the pharmacotherapy issues of patients taking multiple medications. These findings highlight the frequency of medication management issues in this group and suggest that home medication reviews could serve to minimize inappropriate use of medication and maximize health care cost savings in this unique patient population. Can Pharm J (Ott) 2019;152:xx-xx. © The Author(s) 2019. AD - Shoppers Drug Mart, Toronto, Canada Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada Sint Maartenskliniek, Nijmegen, Netherlands School of Pharmacy, University of Waterloo, Waterloo, ON, Canada AU - Papastergiou, J. AU - Luen, M. AU - Tencaliuc, S. AU - Li, W. AU - van den Bemt, B. AU - Houle, S. DB - Scopus DO - 10.1177/1715163519861420 IS - 5 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2019 SP - 334-342 ST - Medication management issues identified during home medication reviews for ambulatory community pharmacy patients T2 - Canadian Pharmacists Journal TI - Medication management issues identified during home medication reviews for ambulatory community pharmacy patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070280077&doi=10.1177%2f1715163519861420&partnerID=40&md5=1bd32e148af9fe0a04850b2e3d09e3ae VL - 152 ID - 5550 ER - TY - JOUR AB - Objective: The aim of this study was to assess the impact of psychological distress and personality traits on self-rated compliance with glaucoma treatment. Methods: One hundred patients with primary open-angle glaucoma participated in the study. General Health Questionnaire, Symptom Distress Checklist, Center for Epidemiological Studies Depression Scale, Defense Style Questionnaire, and Hostility and Direction of Hostility Questionnaire were used. Results: Forty-two percent of patients with glaucoma classified as "noncompliers," those who omitted more than two doses per week. Noncompliers presented more severe symptoms of glaucoma. Depression was found to be associated with poor compliance, whereas adoption of immature defensive style further increased the risk for noncompliance with glaucoma treatment. Conclusions: Depression is associated with self-reported noncompliance with glaucoma treatment, whereas certain personality traits are involved in the increased risk for noncompliance. Further assessment of the depressive feelings by an ophthalmologist and treatment of depression as well as proper psychotherapeutic approaches for maladaptive personality features could be an essential strategy to diminish compliance problems. © 2006 Elsevier Inc. All rights reserved. AD - T. Hyphantis, Department of Psychiatry, Medical School, University of Ioannina, Ioannina, Greece AU - Pappa, C. AU - Hyphantis, T. AU - Pappa, S. AU - Aspiotis, M. AU - Stefaniotou, M. AU - Kitsos, G. AU - Psilas, K. AU - Mavreas, V. DB - Embase Medline DO - 10.1016/j.jpsychores.2006.03.050 IS - 5 KW - adult aged article Center for Epidemiological Studies Depression Scale controlled study defense mechanism depression disease severity female General Health Questionnaire glaucoma high risk patient hostility human major clinical study male mental stress patient compliance personality questionnaire risk factor self concept Symptom Distress Scale treatment outcome LA - English M3 - Article N1 - L44647259 2006-11-15 PY - 2006 SN - 0022-3999 SP - 609-617 ST - Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment T2 - Journal of Psychosomatic Research TI - Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44647259&from=export http://dx.doi.org/10.1016/j.jpsychores.2006.03.050 VL - 61 ID - 3578 ER - TY - JOUR AB - Objective: The aim of this study was to assess the impact of psychological distress and personality traits on self-rated compliance with glaucoma treatment. Methods: One hundred patients with primary open-angle glaucoma participated in the study. General Health Questionnaire, Symptom Distress Checklist, Center for Epidemiological Studies Depression Scale, Defense Style Questionnaire, and Hostility and Direction of Hostility Questionnaire were used. Results: Forty-two percent of patients with glaucoma classified as 'noncompliers,' those who omitted more than two doses per week. Noncompliers presented more severe symptoms of glaucoma. Depression was found to be associated with poor compliance, whereas adoption of immature defensive style further increased the risk for noncompliance with glaucoma treatment. Conclusions: Depression is associated with self-reported noncompliance with glaucoma treatment, whereas certain personality traits are involved in the increased risk for noncompliance. Further assessment of the depressive feelings by an ophthalmologist and treatment of depression as well as proper psychotherapeutic approaches for maladaptive personality features could be an essential strategy to diminish compliance problems. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Hyphantis, Thomas, Department of Psychiatry, Medical School, University of Ioannina, 45110, Ioannina, Greece AN - 2006-21171-008 AU - Pappa, Chrisavgi AU - Hyphantis, Thomas AU - Pappa, Sofia AU - Aspiotis, Miltiadis AU - Stefaniotou, Maria AU - Kitsos, Georgios AU - Psilas, Konstantinos AU - Mavreas, Venetsanos DB - psyh DO - 10.1016/j.jpsychores.2006.03.050 DP - EBSCOhost IS - 5 KW - personality traits psychological distress glaucoma treatment treatment compliance depression Adaptation, Psychological Adult Aged Aged, 80 and over Antihypertensive Agents Character Cross-Sectional Studies Defense Mechanisms Exfoliation Syndrome Female Glaucoma, Open-Angle Health Knowledge, Attitudes, Practice Hostility Humans Intraocular Pressure Male Middle Aged Personality Inventory Sick Role Treatment Refusal Distress Glaucoma Major Depression N1 - Department of Ophthalmology, Medical School, University of Ioannina, Ioannina, Greece. Release Date: 20061204. Correction Date: 20200806. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Distress; Glaucoma; Major Depression; Personality Traits; Treatment Compliance. Classification: Vision & Hearing & Sensory Disorders (3299); Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30); Female (40). Location: Greece. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Symptom Distress Checklist-90-R; Hostility and Direction of Hostility Questionnaire; General Health Questionnaire; Defense Style Questionnaire DOI: 10.1037/t45555-000; Center for Epidemiologic Studies Depression Scale. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Nov, 2006. PY - 2006 SN - 0022-3999 1879-1360 SP - 609-617 ST - Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment T2 - Journal of Psychosomatic Research TI - Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2006-21171-008&site=ehost-live&scope=site tyfantis@cc.uoi.gr VL - 61 ID - 4849 ER - TY - JOUR AB - Chronic glaucoma is one of the main causes of blindness in France. The incidence of the disease increases with age and forms an ever greater public health problem as the population ages. It is therefore important to be aware of the disabilities related to glaucoma in order to optimise the treatment of elderly patients suffering from the disease. AD - C. Parc, Hôpital Foch, Suresnes. AU - Parc, C. DB - Medline IS - 87 KW - age distribution aged article blindness chronic disease disease course France geriatric nursing glaucoma human incidence mass screening methodology patient patient compliance LA - French M3 - Article N1 - L361534844 2011-04-07 PY - 2011 SN - 1268-6034 SP - 12-14 ST - [Specific problems linked to glaucoma in elderly patients] T2 - Soins. Gérontologie TI - [Specific problems linked to glaucoma in elderly patients] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361534844&from=export ID - 3199 ER - TY - JOUR AU - Park, K. H. AU - Cha, J. H. DO - https://dx.doi.org/10.1016/j.jval.2014.08.2136 IS - 7 PY - 2014 SE - Park, K H. Seoul National University College of Medicine, Seoul, South Korea. Cha, J H. Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea. SN - 1524-4733 1098-3015 SP - A610 ST - Medication Adherence and Discontinuation Predicted by Disease Duration in Glaucoma Patients: Findings From A Cross-Sectional Study in Korea T2 - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research TI - Medication Adherence and Discontinuation Predicted by Disease Duration in Glaucoma Patients: Findings From A Cross-Sectional Study in Korea UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm3&NEWS=N&AN=27202125 VL - 17 Y2 - 20141026// ID - 1070 ER - TY - JOUR AD - Seoul National University College of Medicine, Seoul, South Korea Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea AN - 99103616. Language: English. Entry Date: In Process. Revision Date: 20190514. Publication Type: journal article. Journal Subset: Biomedical AU - Park, K. H. AU - Cha, J. H. DB - ccm DO - 10.1016/j.jval.2014.08.387 DP - EBSCOhost IS - 7 N1 - Peer Reviewed; USA. NLM UID: 100883818. PMID: NLM27202907. PY - 2014 SN - 1098-3015 SP - A783-A783 ST - Adherence, Predicting Factors and Satisfaction of Patients on Glaucoma Therapy: Findings From a Cross-Sectional Study in Korea T2 - Value in Health TI - Adherence, Predicting Factors and Satisfaction of Patients on Glaucoma Therapy: Findings From a Cross-Sectional Study in Korea UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=99103616&site=ehost-live&scope=site VL - 17 ID - 4625 ER - TY - JOUR AB - Purpose: To investigate the common side effects of topical antiglaucoma medication, factors affecting compliance, and the utilization of herbal medicine for glaucoma treatment in South Korea. Patients and methods: A cross-sectional multicenter hospital-based study. In-depth interviews using a structured questionnaire were conducted with 581 individuals diagnosed with glaucoma. Additional eligibility requirements were: all participants were diagnosed with glaucoma in one or both eyes and prescribed eye drops at least one month before the start of the study, and were in a suitable condition for an interview. The frequency of response for each category in the interview questionnaire was analyzed. Results: Conjunctival injection, a stinging sensation, and blurred vision were the most frequently reported side effects, among which blurred vision was the most unbearable. Patient knowledge of glaucoma was the only factor associated with the patient's self-evaluation of compliance. Forgetfulness was the most common reason for nonadherence. Only 2.9 % of patients were taking herbal medicine. Conclusions: Physicians should address a patient's complaint of blurred vision resulting from medication. Complete initial explanation of the consequences of nonadherence and of the potential vision loss from glaucoma are critical elements in improving patient adherence in Asian populations. © 2012 Japanese Ophthalmological Society. AD - J. Moon, Department of Ophthalmology, Yeouido St. Mary's Hospital, #62 Yeouido-dong, Yeoungdeungpo-gu, Seoul 150-713, South Korea AU - Park, M. H. AU - Kang, K. D. AU - Moon, J. DB - Embase Medline DO - 10.1007/s10384-012-0188-6 IS - 1 KW - antiglaucoma agent ginseng extract herbaceous agent abnormal sensation adult article blurred vision conjunctiva disease conjunctival drug administration cross-sectional study drug cost drug induced disease drug induced headache drug self administration drug utilization dyspnea ethnic group eye disease eyelash overgrowth eyelid skin darkening eyewax female glaucoma heart palpitation herbal medicine human injection site stinging interview itchy sensation Korean major clinical study male multicenter study patient attitude patient compliance prescription priority journal self evaluation side effect skin manifestation social status South Korea structured questionnaire taste work schedule LA - English M3 - Article N1 - L368147470 2013-01-28 2013-02-01 PY - 2013 SN - 0021-5155 1613-2246 SP - 47-56 ST - Noncompliance with glaucoma medication in Korean patients: A multicenter qualitative study T2 - Japanese Journal of Ophthalmology TI - Noncompliance with glaucoma medication in Korean patients: A multicenter qualitative study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368147470&from=export http://dx.doi.org/10.1007/s10384-012-0188-6 VL - 57 ID - 3029 ER - TY - JOUR AB - Purpose: To investigate the common side effects of topical antiglaucoma medication, factors affecting compliance, and the utilization of herbal medicine for glaucoma treatment in South Korea. Patients and methods: A cross-sectional multicenter hospital-based study. In-depth interviews using a structured questionnaire were conducted with 581 individuals diagnosed with glaucoma. Additional eligibility requirements were: all participants were diagnosed with glaucoma in one or both eyes and prescribed eye drops at least one month before the start of the study, and were in a suitable condition for an interview. The frequency of response for each category in the interview questionnaire was analyzed. Results: Conjunctival injection, a stinging sensation, and blurred vision were the most frequently reported side effects, among which blurred vision was the most unbearable. Patient knowledge of glaucoma was the only factor associated with the patient's self-evaluation of compliance. Forgetfulness was the most common reason for nonadherence. Only 2.9 % of patients were taking herbal medicine. Conclusions: Physicians should address a patient's complaint of blurred vision resulting from medication. Complete initial explanation of the consequences of nonadherence and of the potential vision loss from glaucoma are critical elements in improving patient adherence in Asian populations. © 2012 Japanese Ophthalmological Society. AD - Department of Ophthalmology, Yeouido St. Mary's Hospital, #62 Yeouido-dong, Yeoungdeungpo-gu, Seoul 150-713, South Korea Incheon St. Mary's Hospital, Incheon, South Korea School of Medicine, Catholic University of Korea, Seoul, South Korea AU - Park, M. H. AU - Kang, K. D. AU - Moon, J. DB - Scopus DO - 10.1007/s10384-012-0188-6 IS - 1 KW - Blurred vision Conjunctival injection Noncompliance Topical antiglaucoma medication M3 - Article N1 - Cited By :15 Export Date: 19 July 2021 PY - 2013 SP - 47-56 ST - Noncompliance with glaucoma medication in Korean patients: A multicenter qualitative study T2 - Japanese Journal of Ophthalmology TI - Noncompliance with glaucoma medication in Korean patients: A multicenter qualitative study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872591246&doi=10.1007%2fs10384-012-0188-6&partnerID=40&md5=f34c92364add68f89fedd2a4b5fbe479 VL - 57 ID - 5193 ER - TY - JOUR AD - P. Parker AU - Parker, P. DB - Medline IS - 3 KW - aged article bacterial infection case report cornea ulcer human male middle aged Moraxella nursing pathology patient compliance LA - English M3 - Article N1 - L18749503 1988-06-29 PY - 1988 SN - 0744-7132 SP - 87-89 ST - Moraxella corneal ulcer T2 - Journal of ophthalmic nursing & technology TI - Moraxella corneal ulcer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L18749503&from=export VL - 7 ID - 4056 ER - TY - JOUR AB - Objective: To evaluate the role of in vivo corneal tandem scanning confocal microscopy (TSCM) in the definitive diagnosis of suspected Acanthamoeba keratitis (AK). Design: Noncomparative interventional single-institution case series. Method: A retrospective case review of patients consecutively referred with suspected AK and undergoing corneal TSCM was performed. Results: A total of 63 cases that met the inclusion criteria for the study were referred for diagnostic evaluation. Tandem scanning confocal microscopy demonstrated Acanthamoeba cysts/trophozoites in 54 cases and fungal hyphae in 2, whereas 1 case was positive for both Acanthamoeba and fungus. Culture of the cornea or contact lenses was carried out in 35 cases, 9 of which were positive for Acanthamoeba. Six of the TSCM-positive cases also underwent corneal biopsy, being positive for Acanthamoeba in only 2. Six patients were negative for Acanthamoeba on TSCM, the etiology being fungal in 1 case, as shown by subsequent culture. One patient was positive on culture for Acanthamoeba but falsely negative by TSCM, which was limited by poor cooperation during the examination. Two cases initially masqueraded as Acanthamoeba keratitis but showed fungus on TSCM. Mean follow-up was 14 months. Conclusion: In vivo corneal TSCM can establish the diagnosis of Acanthamoeba keratitis rapidly and noninvasively, particularly when conventional microbiology is inconclusive. © 2006 American Academy of Ophthalmology. AD - Division of Cornea, External Disease and Refractive Surgery, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, United States AU - Parmar, D. N. AU - Awwad, S. T. AU - Petroll, W. M. AU - Bowman, R. W. AU - McCulley, J. P. AU - Cavanagh, H. D. DB - Scopus DO - 10.1016/j.ophtha.2005.12.022 IS - 4 M3 - Article N1 - Cited By :111 Export Date: 19 July 2021 PY - 2006 SP - 538-547 ST - Tandem Scanning Confocal Corneal Microscopy in the Diagnosis of Suspected Acanthamoeba Keratitis T2 - Ophthalmology TI - Tandem Scanning Confocal Corneal Microscopy in the Diagnosis of Suspected Acanthamoeba Keratitis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645336030&doi=10.1016%2fj.ophtha.2005.12.022&partnerID=40&md5=b807b339e36facce50a0862ff7242825 VL - 113 ID - 4925 ER - TY - JOUR AB - The authors performed a study of intraocular pressure-dependent changes in optic disc cupping in 17 adults with chronic open-angle glaucoma. Analyses with the Rodenstock Optic Nerve Head Analyzer were performed at baseline low intraocular pressure during therapy, after elevation of intraocular pressure (from therapeutic failure or noncompliance), and after reduction of intraocular pressure with successful therapy. Optic disc cupping increased significantly upon short-term increase of intraocular pressure from baseline of 20.4 ± 2.5 mmHg to 31.1 ± 5.9 mmHg. Optic disc cupping reverted to baseline after persistent intraocular pressure reduction to 19.3 ± 4.8 mmHg. These data demonstrate intraocular pressure-dependent dynamic changes of optic disc cupping in patients with demonstrable glaucomatous optic nerve damage. They underscore the detrimental effect of elevated intraocular pressure and the beneficial effect of intraocular pressure reduction on optic disc cup changes. © 1992, American Academy of Ophthalmology, Inc.. All rights reserved. AD - Kresge Eye Institute, Wayne State University School of Medicine, Detroit, Michigan, 48201, United States AU - Parrow, K. A. AU - Shin, D. H. AU - Tsai, C. S. AU - Hong, Y. J. AU - Juzych, M. S. AU - Shi, D. X. DB - Scopus DO - 10.1016/S0161-6420(92)32015-9 IS - 1 M3 - Article N1 - Cited By :24 Export Date: 19 July 2021 PY - 1992 SP - 36-40 ST - Intraocular Pressure-dependent Dynamic Changes of Optic Disc Cupping in Adult Glaucoma Patients T2 - Ophthalmology TI - Intraocular Pressure-dependent Dynamic Changes of Optic Disc Cupping in Adult Glaucoma Patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026631564&doi=10.1016%2fS0161-6420%2892%2932015-9&partnerID=40&md5=8b7837aa7f344bb7eb20ee951c7c0f00 VL - 99 ID - 5102 ER - TY - JOUR AD - S. Pastor, Eye Consultants of Atlanta, USA. AU - Pastor, S. AU - Harbin, T. DB - Medline IS - 1 KW - eye drops article glaucoma human devices mobile phone patient compliance reminder system LA - English M3 - Article N1 - L368626491 2013-04-08 PY - 2013 SN - 0026-6620 SP - 52 ST - Improving compliance with eye drop medications T2 - Missouri medicine TI - Improving compliance with eye drop medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368626491&from=export VL - 110 ID - 3032 ER - TY - JOUR AB - Members of the large G protein-coupled receptor (GPCR) clan are implicated in many physiological and disease processes, making them important therapeutic drug targets. In the present study, we follow up on results of a pilot study suggesting a functional relationship between glucocorticoid (GC)-induced ocular hypertension and GPR158, one of three orphan members of the GPCR Family C. GC treatment increases levels of GPR158 mRNA and protein through transcriptional mechanisms, in cultured trabecular meshwork (TBM) cells derived from the eye's aqueous outflow pathway. Like treatment with GCs, transient overexpression of GPR158 stimulates cell proliferation, while siRNA knockdown of endogenous GPR158 has the opposite effect. Both endogenous and overexpressed GPR158 show an unusual subcellular localization pattern, being found almost entirely in the nucleus. However, when cells are treated with inhibitors of clathrin-mediated endocytosis, GPR158 is shifted to the plasma membrane. Mutation of a bipartite nuclear localization signal (NLS) in the 8th helix also shifts GPR158 out of the nucleus, but in this case the protein is found in vesicles localized in the cytoplasm. These results suggest that newly synthesized GPR158 first traffics to the plasma membrane, where it rapidly undergoes endocytosis and translocation to the nucleus. Significantly, mutation of the NLS abrogates GPR158-mediated enhancement of cell proliferation, indicating a functional requirement for nuclear localization. GPR158 overexpression upregulates levels of the cell cycle regulator cyclin D1, but mutation of the NLS reverses this. Overexpression of GPR158 enhances the barrier function of a TBM cell monolayer, which is associated with an increase in the levels of tight junction proteins ZO-1 and occludin, similar to reported studies on GC treatment. Regulated paracellular permeability controls aqueous outflow facility in vivo. Since GCs stimulate GPR158 expression, the result is consistent with a role for elevation of GPR158 expression in GC-induced ocular hypertension. AN - WOS:000316849500138 AU - Patel, N. AU - Itakura, T. AU - Gonzalez, J. M. AU - Schwartz, S. G. AU - Fini, M. E. DA - FEB 25 DO - 10.1371/journal.pone.0057843 IS - 2 PY - 2013 SN - 1932-6203 ST - GPR158, an Orphan Member of G Protein-Coupled Receptor Family C: Glucocorticoid-Stimulated Expression and Novel Nuclear Role T2 - PLOS ONE TI - GPR158, an Orphan Member of G Protein-Coupled Receptor Family C: Glucocorticoid-Stimulated Expression and Novel Nuclear Role VL - 8 ID - 6326 ER - TY - JOUR AB - We studied the rate of failure to use eyedrops as prescribed for glaucoma and some of the factors possibly associated with that noncompliance by interviewing 100 patients being followed in a setting emphasizing correct usage. Fifty-nine reported they had not used their eyedrops precisely as prescribed. Factors significantly influencing compliance included daily dose frequency, forgetfulness, inconvenience, and unaffordability. Gender and race were marginally significant factors, with men and blacks reporting somewhat higher rates of missed doses than women and white. Side effects and age were not significant causes of noncompliance. AD - G.L. Spaeth, William/Anna Goldberg Glaucoma Svc., Wills Eye Hospital, 900 Walnut St, Philadelphia, PA 19107-5598, United States AU - Patel, S. C. AU - Spaeth, G. L. DB - Embase Medline IS - 3 KW - antiglaucoma agent eye drops adult aged article drug cost female glaucoma human major clinical study male patient compliance priority journal race difference risk factor side effect topical drug administration treatment failure LA - English M3 - Article N1 - L25165417 1995-06-13 PY - 1995 SN - 0022-023X SP - 233-236 ST - Compliance in patients prescribed eyedrops for glaucoma T2 - Ophthalmic Surgery TI - Compliance in patients prescribed eyedrops for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L25165417&from=export VL - 26 ID - 3983 ER - TY - JOUR AB - Coronavirus disease 2019 (COVID-19) spurred a rapid rise in telemedicine, but it is unclear how use has varied by clinical and patient factors during the pandemic. We examined the variation in total outpatient visits and telemedicine use across patient demographics, specialties, and conditions in a database of 16.7 million commercially insured and Medicare Advantage enrollees from January to June 2020. During the pandemic, 30.1 percent of all visits were provided via telemedicine, and the weekly number of visits increased twenty-three-fold compared with the prepandemic period. Telemedicine use was lower in communities with higher rates of poverty (31.9 percent versus 27.9 percent for the lowest and highest quartiles of poverty rate, respectively). Across specialties, the use of any telemedicine during the pandemic ranged from 68 percent of endocrinologists to 9 percent of ophthalmologists. Across common conditions, the percentage of visits provided during the pandemic via telemedicine ranged from 53 percent for depression to 3 percent for glaucoma. Higher rates of telemedicine use for common conditions were associated with smaller decreases in total weekly visits during the pandemic. © 2021, Project HOPE. All rights reserved. AD - National Institute of Mental Health, Department of Health Care Policy, Harvard Medical School, Boston, MA, United States Department of Health Care Policy, Harvard Medical School, United States The RAND Corporation, Arlington, VA, United States Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital and Harvard Medical School, Boston, United States Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, United States AU - Patel, S. Y. AU - Mehrotra, A. AU - Huskamp, H. A. AU - Uscher-Pines, L. AU - Ganguli, I. AU - Barnett, M. L. DB - Scopus DO - 10.1377/hlthaff.2020.01786 IS - 2 M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2021 SP - 349-358 ST - Variation in telemedicine use and outpatient care during the covid-19 pandemic in the United States T2 - Health Affairs TI - Variation in telemedicine use and outpatient care during the covid-19 pandemic in the United States UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101016704&doi=10.1377%2fhlthaff.2020.01786&partnerID=40&md5=f8238414b31af4002d1d9216f5e5437b VL - 40 ID - 5342 ER - TY - JOUR AD - C.J. Patorgis AU - Patorgis, C. J. AU - Magnus, D. DB - Medline IS - 12 KW - betaxolol nadolol propanolamine derivative timolol article drug therapy human open angle glaucoma patient compliance LA - English M3 - Article N1 - L17669300 1987-02-19 PY - 1986 SN - 0003-0244 SP - 932-935 ST - New drug therapy in open-angle glaucoma T2 - Journal of the American Optometric Association TI - New drug therapy in open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L17669300&from=export VL - 57 ID - 4068 ER - TY - JOUR AB - Vision loss affects 37 million Americans older than 50 years and one in four who are older than 80 years. The U.S. Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in adults older than 65 years. However, family physicians play a critical role in identifying persons who are at risk of vision loss, counseling patients, and referring patients for disease-specific treatment. The conditions that cause most cases of vision loss in older patients are age-related macular degeneration, glaucoma, ocular complications of diabetes mellitus, and age-related cataracts. Vitamin supplements can delay the progression of age-related macular degeneration. Intravitreal injection of a vascular endothelial growth factor inhibitor can preserve vision in the neovascular form of macular degeneration. Medicated eye drops reduce intraocular pressure and can delay the progression of vision loss in patients with glaucoma, but adherence to treatment is poor. Laser trabeculoplasty also lowers intraocular pressure and preserves vision in patients with primary open-angle glaucoma, but long-term studies are needed to identify who is most likely to benefit from surgery. Tight glycemic control in adults with diabetes slows the progression of diabetic retinopathy, but must be balanced against the risks of hypoglycemia and death in older adults. Fenofibrate also slows progression of diabetic retinopathy. Panretinal photocoagulation is the mainstay of treatment for diabetic retinopathy, whereas vascular endothelial growth factor inhibitors slow vision loss resulting from diabetic macular edema. Preoperative testing before cataract surgery does not improve outcomes and is not recommended. AD - Medical College of Georgia at Augusta University, Augusta, Georgia. AN - 116861589. Language: English. Entry Date: 20170411. Revision Date: 20170820. Publication Type: journal article AU - Pelletier, Allen L. AU - Rojas-Roldan, Ledy AU - Coffin, Janis DB - ccm DP - EBSCOhost IS - 3 KW - Cataract -- Therapy Macular Degeneration -- Therapy Glaucoma -- Therapy Diabetic Retinopathy -- Therapy Vision Disorders -- Therapy Injections Antihypertensive Agents -- Therapeutic Use Vitamins -- Therapeutic Use Blindness -- Diagnosis Blindness -- Therapy Vision, Subnormal -- Etiology Vision, Subnormal -- Diagnosis Vision Disorders -- Diagnosis Vitamin E -- Therapeutic Use Macular Degeneration -- Complications Ascorbic Acid -- Therapeutic Use Practice Guidelines Blindness -- Etiology Aged Diabetic Retinopathy -- Complications Antilipemic Agents -- Therapeutic Use Glaucoma -- Complications Angiogenesis Inhibitors -- Therapeutic Use Aged, 80 and Over Vision, Subnormal -- Therapy Fenofibrate -- Therapeutic Use Diabetic Retinopathy -- Diagnosis Glaucoma -- Diagnosis Cataract -- Complications Cataract Extraction Health Screening Cataract -- Diagnosis Macular Degeneration -- Diagnosis Eye Surgery Vision Disorders -- Etiology N1 - review. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 1272646. PMID: NLM27479624. PY - 2016 SN - 0002-838X SP - 219-226 ST - Vision Loss in Older Adults T2 - American Family Physician TI - Vision Loss in Older Adults UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116861589&site=ehost-live&scope=site VL - 94 ID - 4570 ER - TY - JOUR AB - Vision loss affects 37 million Americans older than 50 years and one in four who are older than 80 years. The U.S. Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in adults older than 65 years. However, family physicians play a critical role in identifying persons who are at risk of vision loss, counseling patients, and referring patients for disease-specific treatment. The conditions that cause most cases of vision loss in older patients are age-related macular degeneration, glaucoma, ocular complications of diabetes mellitus, and age-related cataracts. Vitamin supplements can delay the progression of age-related macular degeneration. Intravitreal injection of a vascular endothelial growth factor inhibitor can preserve vision in the neovascular form of macular degeneration. Medicated eye drops reduce intraocular pressure and can delay the progression of vision loss in patients with glincoma, but adherence to treatment is poor. Laser trabeculoplasty also lowers intraocular pressure and preserves vision in patients with primary open-angle glaucoma, but long-term studies are needed to identify who is most likely to benefit from surgery. Tight glycemic control in adults with diabetes slows the progression of diabetic retinopathy, but must be balanced against the risks of hypoglycemia and death in older adults. Fenofibrate also slows progression of diabetic retinopathy. Panretinal photocoagulation is the mainstay of treatment for diabetic retinopathy, whereas vascular endothelial growth factor inhibitors slow vision loss resulting from diabetic macular edema. Preoperative testing before cataract surgery does not improve outcomes and is not recommended. Copyright (C) 2016 American Academy of Family Physicians. AN - WOS:000381064200010 AU - Pelletier, A. L. AU - Rojas-Roldan, L. AU - Coffin, J. DA - AUG 1 IS - 3 PY - 2016 SN - 0002-838X 1532-0650 SP - 219-226 ST - Vision Loss in Older Adults T2 - AMERICAN FAMILY PHYSICIAN TI - Vision Loss in Older Adults VL - 94 ID - 6290 ER - TY - JOUR AB - The study examined the rate of patients, who do not follow recommendations for routine screening, do not visit physicians for eye-symptoms and when suffering from diabetes or glaucoma do not adhere to follow-up. To what extent can primary care physicians impact on these deficits of ophthalmologic care? 4918 consecutive, ≥ 40 old patients of 107 primary care physicians of 9 networks participated. Of these patients 15% had never, 43% not within the last 3 years, consulted an ophthalmologist. 16% were diabetics, 7% had glaucoma and 46% had observed subjective eye symptoms. A quarter of these patients turn to their primary care physician, when having eye problems. Primary care physicians do not frequently suggest routine ophthalmologic controls nor do they use diagnostic tools like the Amsler-grid or the Swinging-Flash-Light Test. AD - M. Peltenburg, H.-Z. Praxisorientierte Forsch./W., Bolleystrasse 40, 8091 Zürich, Switzerland AU - Peltenburg, M. AU - Kiener, M. AU - Iseli, H. P. AU - Trüb, P. AU - Christen, P. AU - Hurni, R. AU - Aebi, B. AU - Steurer, J. AU - Gloor, B. DB - Embase Medline IS - 1-2 KW - adult aged Amsler grid test consultation diabetes mellitus diagnostic test elderly care eye disease general practice glaucoma health care quality health care utilization human major clinical study ophthalmology patient compliance primary medical care review screening swinging flash light test symptom vision LA - German M3 - Review N1 - L38220302 2004-03-03 PY - 2004 SN - 1013-2058 SP - 9-14 ST - Preserving Vision in the Elderly: A Survey to Start a Quality Development Program in General Practice T2 - Schweizerische Rundschau fur Medizin - Praxis TI - Preserving Vision in the Elderly: A Survey to Start a Quality Development Program in General Practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38220302&from=export VL - 93 ID - 3758 ER - TY - JOUR AB - Background: Ophthalmopathy is a rare extra-thyroid manifestation of Graves’ disease, in paediatrics. Intravenous corticosteroids are the main treatment of moderate-to-severe Graves’ orbitopathy. In this paper, we describe a moderate-to-severe active Graves’ ophthalmopathy in a child and the response to oral therapy with prednisone. Case presentation: A nine-year-old male child suffering for a few months, from palpitations, tremors, and paresthesia was hospitalized in our Pediatric Clinic. At admission, the thyroid function laboratory tests showed hyperthyroidism with elevated free thyroxine (FT4) and free triiodothyronine (FT3) levels and suppressed thyroid-stimulating hormone (TSH) levels. These findings, combined with the clinical conditions—an ophthalmologic evaluation (that showed the presence of exophthalmos without lagophthalmos and visual acuity deficiency), thyroid ultrasound, and TSH receptor antibody positivity—led to a diagnosis of Graves’ disease. Therefore, methimazole was administered at a dose of 0.4|mg/kg/day. After 4 months, thyroid function was clearly improved, with normal FT3 and FT4 values and increasing TSH values, without adverse effects. Nevertheless, an eye examination showed ophthalmopathy with signs of activity, an increase in the exophthalmos of the right eye with palpebral retraction, soft tissue involvement (succulent and oedematous eyelids, caruncle and conjunctival hyperaemia and oedema) and keratopathy, resulting from exposure. We began steroid therapy with oral administration of prednisone (1 mg/kg/day) for four weeks, followed by gradual tapering. After one week of therapy with prednisone, an eye assessment showed reduced retraction of the upper eyelid of the right eye, improvement of right eye exophthalmometry and reduction of conjunctival hyperaemia. After four weeks of therapy with prednisone, an eye assessment showed reduction of the right palpebral retraction without conjunctival hyperaemia and no other signs of inflammation of the anterior segment; after twelve weeks, an eye assessment showed a notable decrease in the right palpebral retraction and the absence of keratitis, despite persisting moderate conjunctival hyperaemia. No adverse event associated with steroid use was observed during the treatment period and no problem in compliance was reported. Conclusion: Prednisone seems a better choice than intravenous corticosteroids, for treating moderate-to-severe and active Graves’ ophthalmopathy, keeping in mind the importance of quality of life in pediatric patients. AD - S. Esposito, Paediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy AU - Penta, L. AU - Muzi, G. AU - Cofini, M. AU - Leonardi, A. AU - Lanciotti, L. AU - Esposito, S. DB - Embase Medline DO - 10.3390/ijerph16010155 IS - 1 KW - liothyronine prednisone thiamazole thyroglobulin antibody thyroid peroxidase antibody thyrotropin thyrotropin receptor antibody thyroxine anterior eye segment antibody detection article case report child clinical article conjunctival hyperemia corticosteroid therapy disease duration disease severity drug choice drug dose reduction drug efficacy drug safety dry skin echography electrocardiography endocrine ophthalmopathy exophthalmos eye examination eye movement disorder eyelid edema eyelid retraction follow up free liothyronine index free thyroxine index Graves disease heart palpitation human hyperthyroidism keratopathy male paresthesia patient compliance quality of life school child sinus tachycardia thyroid function thyroid function test thyroid weight thyrotropin blood level treatment duration treatment response tremor visual acuity vital sign LA - English M3 - Article N1 - L2001814055 2019-05-14 2019-05-23 PY - 2019 SN - 1660-4601 1661-7827 ST - Corticosteroids in moderate-to-severe graves’ ophthalmopathy: Oral or intravenous therapy? T2 - International Journal of Environmental Research and Public Health TI - Corticosteroids in moderate-to-severe graves’ ophthalmopathy: Oral or intravenous therapy? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001814055&from=export http://dx.doi.org/10.3390/ijerph16010155 VL - 16 ID - 2540 ER - TY - JOUR AB - Background: Ophthalmopathy is a rare extra-thyroid manifestation of Graves’ disease, in paediatrics. Intravenous corticosteroids are the main treatment of moderate-to-severe Graves’ orbitopathy. In this paper, we describe a moderate-to-severe active Graves’ ophthalmopathy in a child and the response to oral therapy with prednisone. Case presentation: A nine-year-old male child suffering for a few months, from palpitations, tremors, and paresthesia was hospitalized in our Pediatric Clinic. At admission, the thyroid function laboratory tests showed hyperthyroidism with elevated free thyroxine (FT4) and free triiodothyronine (FT3) levels and suppressed thyroid-stimulating hormone (TSH) levels. These findings, combined with the clinical conditions—an ophthalmologic evaluation (that showed the presence of exophthalmos without lagophthalmos and visual acuity deficiency), thyroid ultrasound, and TSH receptor antibody positivity—led to a diagnosis of Graves’ disease. Therefore, methimazole was administered at a dose of 0.4|mg/kg/day. After 4 months, thyroid function was clearly improved, with normal FT3 and FT4 values and increasing TSH values, without adverse effects. Nevertheless, an eye examination showed ophthalmopathy with signs of activity, an increase in the exophthalmos of the right eye with palpebral retraction, soft tissue involvement (succulent and oedematous eyelids, caruncle and conjunctival hyperaemia and oedema) and keratopathy, resulting from exposure. We began steroid therapy with oral administration of prednisone (1 mg/kg/day) for four weeks, followed by gradual tapering. After one week of therapy with prednisone, an eye assessment showed reduced retraction of the upper eyelid of the right eye, improvement of right eye exophthalmometry and reduction of conjunctival hyperaemia. After four weeks of therapy with prednisone, an eye assessment showed reduction of the right palpebral retraction without conjunctival hyperaemia and no other signs of inflammation of the anterior segment; after twelve weeks, an eye assessment showed a notable decrease in the right palpebral retraction and the absence of keratitis, despite persisting moderate conjunctival hyperaemia. No adverse event associated with steroid use was observed during the treatment period and no problem in compliance was reported. Conclusion: Prednisone seems a better choice than intravenous corticosteroids, for treating moderate-to-severe and active Graves’ ophthalmopathy, keeping in mind the importance of quality of life in pediatric patients. © 2019 by the authors. Licensee MDPI, Basel, Switzerland. AD - Paediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, 06129, Italy AU - Penta, L. AU - Muzi, G. AU - Cofini, M. AU - Leonardi, A. AU - Lanciotti, L. AU - Esposito, S. C7 - 155 DB - Scopus DO - 10.3390/ijerph16010155 IS - 1 KW - Corticosteroids Graves’ orbitopathy Hyperthyroidism Ophthalmopathy Prednisone M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2019 ST - Corticosteroids in moderate-to-severe graves’ ophthalmopathy: Oral or intravenous therapy? T2 - International Journal of Environmental Research and Public Health TI - Corticosteroids in moderate-to-severe graves’ ophthalmopathy: Oral or intravenous therapy? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059794878&doi=10.3390%2fijerph16010155&partnerID=40&md5=b453f19d0fc4c98bd4e2bbfe1a46fe23 VL - 16 ID - 5554 ER - TY - JOUR AB - Glaucoma is a chronic eye disease affecting millions of people worldwide; it is frequently treated with daily eyedrop medications when patients are asymptomatic. Patient education is an essential feature for adherence to treatments. Developing useful patient education interventions is predicated on understanding what glaucoma patients know about their disease and identifying gaps in their knowledge. Thirteen studies that have measured and described glaucoma patient knowledge using questionnaires were identified from the literature, including cross-sectional studies of disease knowledge and studies evaluating the efficacy of an educational intervention, both randomized controlled and observational. All studies found significant knowledge gaps in glaucoma patients. Both the controlled studies and the observational studies supported the efficacy of various educational interventions for improving glaucoma knowledge. AD - Duke University, Durham, NC, USA AN - 129571460. Language: English. Entry Date: 20180529. Revision Date: 20191023. Publication Type: journal article AU - Peralta, Esteban AU - Muir, Kelly W. AU - Rosdahl, Jullia A. DB - ccm DO - 10.1080/08820538.2016.1247180 DP - EBSCOhost IS - 3 KW - Glaucoma -- Etiology Medication Compliance Glaucoma -- Drug Therapy Attitude to Health Human Cross Sectional Studies Quality of Life Patient Satisfaction Patient Education -- Methods Systematic Review N1 - research; systematic review. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. NLM UID: 8610759. PMID: NLM27960573. PY - 2018 SN - 0882-0538 SP - 377-388 ST - Systematic Review of Knowledge Assessments for Glaucoma Patients T2 - Seminars in Ophthalmology TI - Systematic Review of Knowledge Assessments for Glaucoma Patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129571460&site=ehost-live&scope=site VL - 33 ID - 4240 ER - TY - JOUR AB - Purpose: To investigate the efficacy and safety of a punctum plug-based sustained drug release system for a prostaglandin analog, travoprost (OTX-TP), for intraocular pressure (IOP) reduction in an Asian population. Methods: This is an initial feasibility, prospective, single-arm study involving 26 eyes and a bioresorbable punctum plug containing OTX-TP. An OTX-TP was placed in the vertical portion of the superior or inferior canaliculus of patients with primary open-angle glaucoma or ocular hypertension. The main outcome measure was the IOP-lowering efficacy of OTX-TP at 3 (8 am) and 10, 20, and 30 days (8 am, 10 am, and 4 pm), compared to baseline. Results: A total of 26 OTX-TP were inserted for 17 subjects. The mean (standard deviation) age was 57.2 (13.8) years. At 10 days, all plugs were still present, and the IOP reduction from baseline was 6.2 (23%), 5.4 (21%), and 7.5 mmHg (28%) at 8 am, 10 am, and 4 pm, respectively. At 10 days, the mean IOP (standard error of mean) was 21.2 (1.2), 20.4 (0.8), and 19.7 (1.0) at 8 am, 10 am, and 4 pm, respectively, showing no discernible IOP trend during the course of the day. At 30 days, plug retention had declined to 42%, and the overall IOP reduction had decreased to 16%. Conclusion: The sustained-release OTX-TP is able to reduce IOP by 24% (day 10) and 15.6% (day 30), respectively. It is a potentially well-tolerable ocular hypotensive for glaucoma patients with a history of poor compliance. AD - S.A. Perera, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, Singapore AU - Perera, S. A. AU - Ting, D. S. W. AU - Nongpiur, M. E. AU - Chew, P. T. AU - Aquino, M. C. D. AU - Sng, C. C. A. AU - Ho, S. W. AU - Aung, T. DB - Embase DO - 10.2147/OPTH.S102181 KW - travoprost adult aged article Asian clinical article controlled clinical trial controlled study drug efficacy drug safety drug tolerability drug withdrawal epiphora evening dosage eye pain feasibility study female foreign body reaction human intraocular hypertension intraocular pressure male medication compliance morning dosage multicenter study ocular pruritus open angle glaucoma patient compliance prospective study pruritus punctal plug sustained release formulation LA - English M3 - Article N1 - L610090563 2016-05-09 2016-05-19 PY - 2016 SN - 1177-5483 1177-5467 SP - 757-764 ST - Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population T2 - Clinical Ophthalmology TI - Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610090563&from=export http://dx.doi.org/10.2147/OPTH.S102181 VL - 10 ID - 2744 ER - TY - JOUR AB - All general ophthalmic services forms (GOS18) received by one practice over an 18 month period were analysed and the patient outcome after two years noted from the practice records. Sixty one forms were collected. Fifty patients (82%) were referred by the general practitioners to the local eye hospital. Among the 45 patients that have so far been seen by an ophthalmologist, 22 (49%) were diagnosed as having cataracts, eight (18%) macular degeneration and two (4%) glaucoma. Thirteen patients (29%) were found to have normal eyes. Nine of the 61 patients (15%) were not referred to an ophthalmologist and two patients (3%) were already under review at the eye hospital. It is concluded that some referrals to ophthalmologists might be avoided if general practitioners received improved training in ophthalmology, However, general practitioners remain an effective filter in the referral system between optometrists and ophthalmologists. AD - P. Perkins AU - Perkins, P. DB - Medline IS - 331 KW - adolescent adult aged ambulatory care article child eye disease female general practice human infant male middle aged optometry patient attitude patient referral preschool child prognosis United Kingdom LA - English M3 - Article N1 - L20822758 1990-05-07 PY - 1990 SN - 0960-1643 SP - 59-61 ST - Outcome of referrals by optometrists to general practitioners: an 18 month study in one practice T2 - The British journal of general practice : the journal of the Royal College of General Practitioners TI - Outcome of referrals by optometrists to general practitioners: an 18 month study in one practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L20822758&from=export VL - 40 ID - 4045 ER - TY - JOUR AB - Objective: To examine the relationship between age, gender, socioeconomic status, and 3 chronic conditions (glaucoma, cataracts, and diabetes) and corrected and uncorrected vision problems, and to document the prevalence of visual problems in Canada across the adult age range. Design: Cross-sectional, representative, population-based study. Participants: Health survey respondents (n = 113 212, aged ≥20 years). Methods: Data are from a 2000-2001 Canadian health survey. Self-reported data included sociodemographic/economic characteristics, vision problems, eye care professional consultations, and medical conditions. Prevalence estimates were calculated; multinomial logistic regression examined the relationship between indicated variables and vision problems, generally and by type. Results: Fifty-seven percent of adults reported some form of vision problem, the majority corrected by lenses. Blindness was reported by 0.09% of adults. Increasing age, being female, and having a low income and lower educational attainment were significantly associated with reported vision problems. However, age and gender were not significant determinants of the type of vision problem. Cataracts, diabetes, and glaucoma in particular, were significantly associated with reported vision problems. Conclusions: Socioeconomic characteristics may underscore the socioeconomic burden of visual impairments in the population and highlight obstacles to eye service utilization among subgroups. This information is essential to establishing the need for treatment and management services, developing targeted screening programmes, and identifying priority areas of research. AD - A. V. Perruccio, Toronto Western Research Institute, MP10-322, 399 Bathurst St., Toronto, ON M5T 2S8, Canada AU - Perruccio, A. V. AU - Badley, E. M. AU - Trope, G. E. DB - Embase Medline DO - 10.3129/i10-061 IS - 5 KW - adult aged article blindness Canada cataract consultation cross-sectional study diabetes mellitus disease association educational status eye care female gender glaucoma health care utilization health survey human lowest income group major clinical study male optical instrumentation population research self report social status visual disorder LA - English M3 - Article N1 - L359695356 2010-10-12 2010-10-20 PY - 2010 SN - 1715-3360 0008-4182 SP - 477-483 ST - A Canadian population-based study of vision problems: Assessing the significance of socioeconomic status T2 - Canadian Journal of Ophthalmology TI - A Canadian population-based study of vision problems: Assessing the significance of socioeconomic status UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359695356&from=export http://dx.doi.org/10.3129/i10-061 VL - 45 ID - 3292 ER - TY - JOUR AB - Background: The purpose of this study was to determine the factors associated with glaucoma patients’ satisfaction with their medical care by fellowship-trained glaucoma specialists in an urban tertiary referral clinic in the US. Methods: A total of 110 established patients aged ≥ 60 years with a diagnosis of either primary open angle glaucoma, glaucoma suspect, or ocular hypertension monitored by an ophthalmologist with fellowship training in glaucoma were enrolled at an academic, urban, tertiary referral eye clinic. Enrolled patients were administered a general demographics questionnaire along with a Patient Satisfaction Questionnaire-18 (PSQ-18), a Likert scale validated tool. The seven dimensions of patient satisfaction from the PSQ-18 were summarized for the sample overall and by the patients’ age, race, employment status, education level, distance travelled from home address to clinic, and glaucoma therapy type. Two-sample t-tests were used to compare group means. Spearman correlation coefficients were used to correlate satisfaction scores with peripheral vision and visual acuity function. Results: Overall, the general satisfaction scores were high (mean 4.62). Patients ≥ 70 years of age had lower general satisfaction with their care (mean 4.5 vs 4.8, p=0.03), the interpersonal manner of their appointment (mean 4.7 vs 4.9, p=0.009), and with their time spent with their doctor (mean 4.4 vs 4.7, p=0.03) than patients aged 60–69 years. Non-European descent patients (47% African descent and 1% other of sample) were more satisfied with the time they spent with the doctor (mean 4.7 vs 4.4, p=0.04) and with the communication during the appointment (mean 4.8 vs 4.6, p=0.04) than European descent patients (52% of sample). Patients with a higher level of education (>high school degree) were less satisfied with the accessibility and convenience of the appointment (mean 4.3 vs ≤ high school, 4.6, p=0.02). There were no statistically significant differences in patient satisfaction based upon employment status, distance travelled to clinic, prior glaucoma therapy, or visual function. Conclusion: Overall, across all dimensions of the PSQ-18, patients were highly satisfied with the care they received at the urban tertiary care glaucoma clinic. AD - L.A. Rhodes, Department of Ophthalmology, University of Alabama at Birmingham, EFH 601, 1720 2nd Avenue South, Birmingham, AL, United States AU - Peterson, K. M. AU - Huisingh, C. E. AU - Girkin, C. AU - Owsley, C. AU - Rhodes, L. A. DB - Embase DO - 10.2147/PPA.S162439 KW - adult African aged article cross-sectional study educational status employment status ethnic difference European female glaucoma groups by age health care access human intraocular hypertension major clinical study male medical care open angle glaucoma patient satisfaction Patient Satisfaction Questionnaire 18 peripheral vision questionnaire tertiary care center United States visual acuity LA - English M3 - Article N1 - L622304116 2018-06-05 2018-06-11 PY - 2018 SN - 1177-889X SP - 775-781 ST - Patient satisfaction with care in an urban tertiary referral academic glaucoma clinic in the us T2 - Patient Preference and Adherence TI - Patient satisfaction with care in an urban tertiary referral academic glaucoma clinic in the us UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622304116&from=export http://dx.doi.org/10.2147/PPA.S162439 VL - 12 ID - 2589 ER - TY - JOUR AB - Background: The purpose of this study was to determine the factors associated with glaucoma patients’ satisfaction with their medical care by fellowship-trained glaucoma specialists in an urban tertiary referral clinic in the US. Methods: A total of 110 established patients aged ≥ 60 years with a diagnosis of either primary open angle glaucoma, glaucoma suspect, or ocular hypertension monitored by an ophthalmologist with fellowship training in glaucoma were enrolled at an academic, urban, tertiary referral eye clinic. Enrolled patients were administered a general demographics questionnaire along with a Patient Satisfaction Questionnaire-18 (PSQ-18), a Likert scale validated tool. The seven dimensions of patient satisfaction from the PSQ-18 were summarized for the sample overall and by the patients’ age, race, employment status, education level, distance travelled from home address to clinic, and glaucoma therapy type. Two-sample t-tests were used to compare group means. Spearman correlation coefficients were used to correlate satisfaction scores with peripheral vision and visual acuity function. Results: Overall, the general satisfaction scores were high (mean 4.62). Patients ≥ 70 years of age had lower general satisfaction with their care (mean 4.5 vs 4.8, p=0.03), the interpersonal manner of their appointment (mean 4.7 vs 4.9, p=0.009), and with their time spent with their doctor (mean 4.4 vs 4.7, p=0.03) than patients aged 60–69 years. Non-European descent patients (47% African descent and 1% other of sample) were more satisfied with the time they spent with the doctor (mean 4.7 vs 4.4, p=0.04) and with the communication during the appointment (mean 4.8 vs 4.6, p=0.04) than European descent patients (52% of sample). Patients with a higher level of education (>high school degree) were less satisfied with the accessibility and convenience of the appointment (mean 4.3 vs ≤ high school, 4.6, p=0.02). There were no statistically significant differences in patient satisfaction based upon employment status, distance travelled to clinic, prior glaucoma therapy, or visual function. Conclusion: Overall, across all dimensions of the PSQ-18, patients were highly satisfied with the care they received at the urban tertiary care glaucoma clinic. © 2018 Peterson et al. AD - Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States AU - Peterson, K. M. AU - Huisingh, C. E. AU - Girkin, C. AU - Owsley, C. AU - Rhodes, L. A. DB - Scopus DO - 10.2147/PPA.S162439 KW - Access to care Adherence Barriers to care Glaucoma Patient satisfaction Tertiary care M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2018 SP - 775-781 ST - Patient satisfaction with care in an urban tertiary referral academic glaucoma clinic in the us T2 - Patient Preference and Adherence TI - Patient satisfaction with care in an urban tertiary referral academic glaucoma clinic in the us UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047767208&doi=10.2147%2fPPA.S162439&partnerID=40&md5=a5c6a53f02eae105797375984acce8b9 VL - 12 ID - 5506 ER - TY - JOUR AB - Background: The purpose of this study was to determine the factors associated with glaucoma patients' satisfaction with their medical care by fellowship-trained glaucoma specialists in an urban tertiary referral clinic in the US. Methods: A total of 110 established patients aged ?60 years with a diagnosis of either primary open angle glaucoma, glaucoma suspect, or ocular hypertension monitored by an ophthalmologist with fellowship training in glaucoma were enrolled at an academic, urban, tertiary referral eye clinic. Enrolled patients were administered a general demographics questionnaire along with a Patient Satisfaction Questionnaire-18 (PSQ-18), a Likert scale validated tool. The seven dimensions of patient satisfaction from the PSQ-18 were summarized for the sample overall and by the patients' age, race, employment status, education level, distance travelled from home address to clinic, and glaucoma therapy type. Two-sample t-tests were used to compare group means. Spearman correlation coefficients were used to correlate satisfaction scores with peripheral vision and visual acuity function. Results: Overall, the general satisfaction scores were high (mean 4.62). Patients >= 70 years of age had lower general satisfaction with their care (mean 4.5 vs 4.8, p=0.03), the interpersonal manner of their appointment (mean 4.7 vs 4.9, p=0.009), and with their time spent with their doctor (mean 4.4 vs 4.7, p=0.03) than patients aged 60-69 years. Non-European descent patients (47% African descent and 1% other of sample) were more satisfied with the time they spent with the doctor (mean 4.7 vs 4.4, p=0.04) and with the communication during the appointment (mean 4.8 vs 4.6, p=0.04) than European descent patients (52% of sample). Patients with a higher level of education (>high school degree) were less satisfied with the accessibility and convenience of the appointment (mean 4.3 vs <= high school, 4.6, p=0.02). There were no statistically significant differences in patient satisfaction based upon employment status, distance travelled to clinic, prior glaucoma therapy, or visual function. Conclusion: Overall, across all dimensions of the PSQ-18, patients were highly satisfied with the care they received at the urban tertiary care glaucoma clinic. AN - WOS:000432062200001 AU - Peterson, K. M. AU - Huisingh, C. E. AU - Girkin, C. AU - Owsley, C. AU - Rhodes, L. A. DO - 10.2147/PPA.S162439 PY - 2018 SN - 1177-889X SP - 775-781 ST - Patient satisfaction with care in an urban tertiary referral academic glaucoma clinic in the US T2 - PATIENT PREFERENCE AND ADHERENCE TI - Patient satisfaction with care in an urban tertiary referral academic glaucoma clinic in the US VL - 12 ID - 5989 ER - TY - JOUR AB - Inhaled corticosteroids (ICS) are the guideline-preferred preventative therapy for persistent asthma of all severity levels and for all ages, including children. While these drugs are unquestionably efficacious, concerns of adverse systemic effects limit patient compliance with treatment regimens and thus the attainable benefits. Suppression of bone growth, bone density, and HPA axis function, in addition to cataract formation and elevated intraocular pressure/glaucoma, have been associated with ICS use. This review will focus on recent developments in the safety and efficacy of ICS as compared to oral CS corticosteroids and the achievement of a balance between risk and benefit in optimizing ICS therapy. Copyright © 2008 Informa Healthcare USA, Inc. AD - D. P. Skoner, Allegheny General Hospital, Allergy, Asthma and Immunology, 320 East North Avenue, Pittsburgh, PA 15212, United States AU - Petrisko, M. A. AU - Skoner, J. D. AU - Skoner, D. P. DB - Embase Medline DO - 10.1080/02770900802631361 IS - SUPPL. 1 KW - beclomethasone dipropionate budesonide chlorofluorocarbon ciclesonide corticosteroid derivative cromoglycate disodium fluorinated hydrocarbon fluticasone propionate mometasone furoate montelukast nedocromil placebo prednisolone salbutamol salmeterol theophylline triamcinolone acetonide adrenal suppression age distribution asthma bone density suppression bone disease bone growth suppression cataract childhood disease clinical trial controlled clinical trial Cushing syndrome dermal thinning diabetes mellitus disease severity dose response drug absorption drug bioavailability drug dose comparison drug dose reduction drug efficacy drug elimination drug formulation drug megadose drug metabolism drug protein binding drug safety endocrine disease environmental factor glaucoma growth retardation heredity human hypothalamo pituitary adrenal function suppression hypothalamus hypophysis adrenal system inhaler intraocular hypertension low drug dose muscle weakness patient compliance prophylaxis randomized controlled trial review sex difference skin disease subcapsular cataract treatment duration treatment response LA - English M3 - Review N1 - L354017273 2009-02-16 PY - 2008 SN - 0277-0903 1532-4303 SP - 1-9 ST - Safety and efficacy of inhaled corticosteroids (ICS) in children with asthma T2 - Journal of Asthma TI - Safety and efficacy of inhaled corticosteroids (ICS) in children with asthma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354017273&from=export http://dx.doi.org/10.1080/02770900802631361 VL - 45 ID - 3408 ER - TY - JOUR AD - Division of Rheumatology, Department of Pediatrics, University of British Columbia, 4480 Oak Street, Vancouver, BC V6H 3V4, Canada Department of Rheumatology Immunology and Allergy, Children’s Hospital, Zhejiang University School of Medicine, 57# Zhu Gan Road Zhejiang Province, Hangzhou, 310000, China AU - Petty, R. E. AU - Zheng, Q. DB - Scopus DO - 10.1007/s12519-019-00331-6 IS - 6 M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - 562-565 ST - Uveitis in juvenile idiopathic arthritis T2 - World Journal of Pediatrics TI - Uveitis in juvenile idiopathic arthritis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078080144&doi=10.1007%2fs12519-019-00331-6&partnerID=40&md5=5c54ffc4d52b0169e5cd29a71b76c1a1 VL - 16 ID - 5598 ER - TY - JOUR AB - Purpose: To compare topical cyclosporine-A 2% eye drop (Cs-A) with prednisolone acetate 1% eye drop for treatment of herpetic stromal keratitis (HSK). Methods: In this randomized clinical trial, 38 eyes of 33 patients with HSK were randomly assigned to receive either 2% Cs-A or 1% prednisolone acetate eye drops. All subjects received oral acyclovir 400 mg twice a day. Slit-lamp examination, Scheimpflug tomography corneal optical densitometry (Pentacam®, Oculus Inc., Wetzlar, Germany), best-corrected visual acuity (BCVA), and intra-ocular pressure (IOP) were evaluated at the first visit, and 14 and 30 days after the treatment. Results: Within-group analysis revealed significant improvement of total cornea optical density after 30 days of treatment in both groups (30.3 ± 10.5 to 28.3 ± 9.8, p < 0.001 for prednisolone group, and 30.5 ± 8.8 to 28.8 ± 8.3 p < 0.001 for Cs-A group, mean ± SD). We were not able to disclose any significant difference between the two groups regarding the improvement of cornea optical density (p = 0.66). Best-corrected visual acuity (BCVA) logMAR significantly improved in both groups after 30 days of treatment (0.20 ± 0.52, p = 0.002 in prednisolone group, and 0.24 ± 0.31, p < 0.001 in Cs-A group, mean ± SD). Analysis between groups did not show a significant difference of BCVA improvement (p = 0.45). We did not observe any severe side effect attributable to drugs. Conclusions: Cs-A 2% and prednisolone acetate 1% topical eye drops are effective for treatment of HSK. © 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd AD - Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran Parsian Vision Science Research Institute, Isfahan, Iran Shiley Eye Institute, University of California San Diego, La Jolla, CA, United States AU - Peyman, A. AU - Nayebzadeh, M. AU - Peyman, M. AU - Afshari, N. A. AU - Pourazizi, M. DB - Scopus DO - 10.1111/aos.13913 IS - 2 KW - cyclosporine-A herpes simplex virus herpetic stromal keratitis prednisolone M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2019 SP - e194-e198 ST - Topical cyclosporine-A versus prednisolone for herpetic stromal keratitis: a randomized controlled trial T2 - Acta Ophthalmologica TI - Topical cyclosporine-A versus prednisolone for herpetic stromal keratitis: a randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054367376&doi=10.1111%2faos.13913&partnerID=40&md5=173f2f45bb13ba54a8d73b926e6c675d VL - 97 ID - 5446 ER - TY - JOUR AB - Current ocular GvHD (oGvHD) treatments are suboptimal. We investigated the safety and efficacy of long-term continuous treatment with autologous platelet lysate (PL) drops in patients with oGvHD Dry Eye Syndrome (DES) score 2-3 refractory to topical conventional therapy. Ophthalmic evaluation was performed at 6 month intervals. Symptoms were assessed using the Glaucoma Symptom Scale (GSS). Patients were defined 'responders' when showing a reduction at least one grade on National Institutes of Health Eye Score from baseline at the 6 month visit. Thirty-one patients were included, and 16 (51%) completed 36 months of follow-up (range 6.5-72.7). At 6 months all patients were classified as responders: median GSS symptom score decreased from 70 to 41 (33 at 36 months), median GSS function score reduced from 68 to 46 (33 at 36 months) (all P<0.001). Median Tear Break Up Time improved from 3 to 6 s after 6 months and was maintained over time. All signs improved at 6 and 36 months (clinical and statistical significance). No severe adverse events occurred. Long-term treatment with PL drops is secure and effective for oGvHD and can be an efficient therapy option from initial stages of oGvHD to prevent permanent ocular impairment and improving quality of life. © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. AD - Department of Ophthalmology, University Eye Clinic of Pavia, IRCCS Policlinico S Matteo Foundation, V.le Golgi 19, Pavia, 27100, Italy Immunohaematology and Transfusion Service, Apheresis Unit, IRCCS Policlinico S Matteo Foundation, Pavia, Italy Biostatistic and Clinical Epidemiology Unit, Scientific Direction, IRCCS Policlinic San Matteo Foundation, Pavia, Italy AU - Pezzotta, S. AU - Del Fante, C. AU - Scudeller, L. AU - Rossi, G. C. AU - Perotti, C. AU - Bianchi, P. E. AU - Antoniazzi, E. DB - Scopus DO - 10.1038/bmt.2016.221 IS - 1 M3 - Article N1 - Cited By :19 Export Date: 19 July 2021 PY - 2017 SP - 101-106 ST - Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD T2 - Bone Marrow Transplantation TI - Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991035781&doi=10.1038%2fbmt.2016.221&partnerID=40&md5=33fd07b114885d59e2eb0c7a2e3c8bf5 VL - 52 ID - 5147 ER - TY - JOUR AB - Purpose: The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting. Patients and methods: This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies. IOP was measured at baseline and at ~12 weeks. Tolerability and continuation of therapy were also assessed. Results: A total of 1,553 patients were included in the study, and the per-protocol population comprised 1,391 patients. There were some minor deviations from protocol: some patients with no prior therapy and some who switched for reasons other than insufficient IOP control were included in the analysis. The mean IOP was reduced by 27.4%, from 22.2 mmHg to 16.1 mmHg. In subgroup analyses, the mean IOP was significantly reduced from baseline, irrespective of whether previous treatment was monotherapy or combination therapy, and preserved or PF therapy. Physicians mostly (88.1%) reported the IOP-lowering efficacy of PF FC bimatoprost 0.03%/timolol 0.5% to be as expected or better than expected. Switching to PF FC bimatoprost 0.03%/timolol 0.5% resulted in reductions from baseline in the number of patients reporting ocular symptoms. Adverse events were reported by 6.2% of patients, the most common being eye irritation (1.6%) and eye pruritus (1.0%). Physicians reported treatment compliance as better or unchanged compared with prior treatment in almost all patients (93.9%). Most patients were expected to continue PF FC bimatoprost 0.03%/timolol 0.5% after the end of the study. Conclusion: Switching to PF FC bimatoprost 0.03%/timolol 0.5% was associated with significant IOP reductions from baseline over 12 weeks. Adverse events were uncommon, and compliance was high compared with previous therapy. PF FC bimatoprost 0.03%/timolol 0.5% may be a suitable treatment for patients with inadequately controlled IOP or who are sensitive to preservatives. AD - S. Pfennigsdorf, Marktplatz 13, Polch, Germany AU - Pfennigsdorf, S. AU - Eschstruth, P. AU - Häsemeyer, S. AU - Feuerhake, C. AU - Brief, G. AU - Grobeiu, I. AU - Shirlaw, A. C1 - ganfort(Allergan,United States) C2 - Allergan(United States) DB - Embase DO - 10.2147/OPTH.S106159 KW - NCT01999348 bimatoprost plus timolol preservative aged article conjunctival hyperemia controlled study drug efficacy drug hypersensitivity drug safety drug tolerability dry eye eye irritation eye pain eyelid erythema female foreign body sensation human informed consent intraocular foreign body intraocular hypertension intraocular pressure lacrimation major clinical study male observational study ocular pruritus open angle glaucoma open study patient compliance population research prospective study punctate keratitis randomized controlled trial side effect treatment duration ganfort LA - English M3 - Article N1 - L612301811 2016-10-03 2016-10-05 PY - 2016 SN - 1177-5483 1177-5467 SP - 1837-1846 ST - Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice T2 - Clinical Ophthalmology TI - Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612301811&from=export http://dx.doi.org/10.2147/OPTH.S106159 VL - 10 ID - 2703 ER - TY - JOUR AB - Background: Bimatoprost 0.01% was developed for improved tolerability over bimatoprost 0.03%, while maintaining efficacy in lowering intraocular pressure (IOP). This multicenter, prospective, open-label, observational study was designed to investigate the efficacy and tolerability of bimatoprost 0.01% in routine clinical practice. Methods: Data were collected from 10,337 patients with primary open-angle glaucoma or ocular hypertension attending 1334 centers in Germany. The primary efficacy outcome was mean change in IOP in each eye from baseline to 10-14 weeks after initiation of bimatoprost 0.01%. Target IOP, prior therapies, additional treatments, and adverse events were also assessed. All treatment decisions were at the physicians' discretion. Results: Bimatoprost 0.01% significantly lowered mean IOP from baseline by -4.1 mmHg (P < 0.0001) in all patients after a mean of 10.45 weeks. In patients without previous treatment, bimatoprost 0.01% reduced mean IOP from baseline by -6.5 mmHg (P<, 0.0001). Bimatoprost 0.01% also significantly reduced IOP in patients previously treated with monotherapy of β-blockers, prostaglandin analogs, carbonic anhydrase inhibitors or bimatoprost 0.03%. No adverse events were reported by 93.9% of patients during treatment with bimatoprost 0.01%; the most commonly reported adverse events were eye irritation (2.0%), ocular hyperemia (1.4%), and conjunctival hyperemia (1.2%). Physicians and patients rated tolerability and adherence as high, and most patients said they would continue with bimatoprost 0.01% treatment. Conclusion: Bimatoprost 0.01% can produce additional IOP-lowering effects when used in routine clinical practice in patients who have received prior therapy, in addition to lowering IOP in previously untreated patients. A high rate of continuation of therapy with bimatoprost 0.01% was observed in patients who switched from a variety of different medications. The results suggest that bimatoprost 0.01% is a suitable first-choice therapy in patients with primary open-angle glaucoma or ocular hypertension. © 2012 Pfennigsdorf et al, publisher and licensee Dove Medical Press Ltd. AD - S. Pfennigsdorf, Polch Ophthalmology Practice, Marktplatz 13, 56751 Polch, Germany AU - Pfennigsdorf, S. AU - Ramez, O. AU - von Kistowski, G. AU - Mäder, B. AU - Eschstruth, P. AU - Froböse, M. AU - Thelen, U. AU - Spraul, C. AU - Schnober, D. AU - Cooper, H. AU - Laube, T. DB - Embase DO - 10.2147/OPTH.S31330 IS - 1 KW - beta adrenergic receptor blocking agent bimatoprost brinzolamide carbonate dehydratase inhibitor dorzolamide prostaglandin derivative timolol abnormal sensation adult adverse outcome article asthma blurred vision chronic obstructive lung disease clinical decision making clinical practice conjunctival hyperemia controlled clinical trial controlled study dose response drug efficacy drug research drug safety drug substitution drug tolerability drug use drug withdrawal dyspnea evening dosage eye irritation eye pain eyelid disease eyelid erythema female Germany headache human hyperemia hyperpigmentation intraocular hypertension intraocular pressure lacrimation disorder major clinical study male monotherapy multicenter study observational study ocular pruritus open angle glaucoma outcome assessment patient compliance prospective study treatment duration L1 - internal-pdf://3130390644/3086-Multicenter, prospective, open-label-2012.pdf LA - English M3 - Article N1 - L365167530 2012-07-11 2012-07-18 PY - 2012 SN - 1177-5467 1177-5483 SP - 739-746 ST - Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension T2 - Clinical Ophthalmology TI - Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365167530&from=export http://dx.doi.org/10.2147/OPTH.S31330 VL - 6 ID - 3086 ER - TY - JOUR AD - Head of Postgraduate Training and Glaucoma Specialist, Kilimanjaro Christian Medical Centre, Moshi, Tanzania Ophthalmologist and Glaucoma Specialist, NHS Foundation Trust Birmingham, UK; Centre for Health and Social Care Improvement, University of Wolverhampton, School of Health and Wellbeing, UK Senior Lecturer, International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, UK AN - 104241560. Language: English. Entry Date: 20130305. Revision Date: 20150711. Publication Type: Journal Article AU - Philippin, Heiko AU - Shah, Peter AU - Burton, Matthew DB - ccm DP - EBSCOhost IS - 79/80 KW - Glaucoma -- Diagnosis Diagnosis, Eye -- Equipment and Supplies Health Services Accessibility Patient History Taking Visual Acuity Lighting Visual Fields Patient Education Cataract -- Diagnosis N1 - pictorial. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 8912615. PMID: NLM23520415. PY - 2012 SN - 0953-6833 SP - 48-49 ST - Detecting possible glaucoma with only limited equipment: a crucial first step T2 - Community Eye Health Journal TI - Detecting possible glaucoma with only limited equipment: a crucial first step UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104241560&site=ehost-live&scope=site VL - 25 ID - 4682 ER - TY - JOUR AB - Background: Indolent corneal ulcers have been described as superficial ulcers with an associated rim of loose peripheral epithelium Treatment for indolent ulcers include debridement, grid keratotomy, multiple punctate keratotomy, third eyelid flaps, application of cyanoacrylate tissue adhesives, superficial keratectomy, and a debridement with a diamond burr. Case: A 2-month-old female American Quarter Horse was referred to the Ophthalmology Veterinary Section of the Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil, presenting epiphora and blepharospasm. A local veterinarian doctor had prescribed broad spectrum topical antibiotic and anti-inflammatory drops, although there was no positive response to the treatment for the past two weeks. Ophthalmic examination reveals and moderate discomfort in the left eye, epiphora, and mild corneal edema in the area of the defect. Slit lamp biomicroscopy revealed a superficial corneal ulcer with about 6 mm. Corneal epithelium did not adhere to underlying corneal stroma. The remainder of the ophthalmic examination of the left eye was unremarkable. The diagnosis of a corneal ulcer was made based on these clinical signs and fluorescein staining of the cornea where the stain dissects under the unattached epithelial lip. A handheld battery-operated motorized diamond burr, with a 3.5 mm medium grit tip, was utilized to remove the epithelium. The medical treatment included tobramycin eye drops, and flurbiprofen sodium ophthalmic solution, being applied six times daily, after the procedure, during two weeks, and atropine sulphate 1% was applied once a day, during three days. The foal was hospitalized until healing the corneal ulcer. For two weeks, the foal was assessed daily, and, after that, follow-up visits were scheduled weekly for four months. Healing was defined as the point at which the cornea no longer retained fluorescein. Discussion: Ulcers localized to the corneal epithelium, do not heal within the expected time frame, and have been characterized by epithelial border poorly adherent corneal and being commonly referred as indolent corneal ulcers. In this case, corneal ulcers are chronic and have not responded to an appropriate therapy for 14 days. The corneal ulcer was diagnosed based on history, clinical signs and fluorescein staining of the cornea. Usually, medical treatments provide disappointing results. Surgical treatment aims to remove the loosened epithelium in order to facilitate the growth of new epithelial cells, with stronger adhesion complexes. The utilization of a diamond burr, for the treatment of an indolent corneal ulcer, has been previously reported in humans, and dogs. In the present case, the debridement with a diamond burr was chosen on account of excellent results obtained in previous studies in humans and dogs, when treating indolent corneal ulcers. In the current case, the corneal ulcer healed in ten days, while in a study comparing the outcome in 23 horses treated by debridement, grid keratotomy, or superficial keratectomy, the mean times until complete healing were 15, 16 and 23 days, respectively. In the present case, debridement with diamond burr was effective in the treatment of a recurrent corneal ulcer in a foal. AN - WOS:000424144900018 AU - Pigatto, J. A. T. AU - de Albuquerque, L. AU - Bacchin, A. B. D. AU - da Silva, G. M. R. AU - Petersen, M. B. AU - Reiter, G. G. PY - 2017 SN - 1678-0345 1679-9216 ST - Diamond Burr for the Treatment of an Indolent Corneal Ulcer in a Foal T2 - ACTA SCIENTIAE VETERINARIAE TI - Diamond Burr for the Treatment of an Indolent Corneal Ulcer in a Foal VL - 45 ID - 5806 ER - TY - JOUR AB - Background: Efficacy, tolerability and safety of the novel preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% (Taptiqom®) were investigated in an observational study in Germany. Objective: To assess efficacy, tolerability and safety of the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% in a real-life setting. Methods: Intraocular pressure (IOP) was recorded for each eye at baseline (any previous therapy or untreated) and 4–16 weeks after changing medical treatment to or initiating treatment with the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5%. Change in IOP was evaluated over the study period for all patients and for specific pretreatment subgroups. Clinical signs such as conjunctival hyperemia and lid-parallel conjunctival folds (LIPCOF) were recorded using standardized comparative photographs. Corneal staining, subjective symptoms and local comfort were measured using a four-step scale. All adverse events were recorded. Results: Among 1,157 patients enrolled, 1,075 patients were treated with the preservative-free fixed combination as the only medication at the final visit. Medical treatment was initiated in 741 patients because of an insufficient IOP-lowering effect of the prior medication. In 343 patients, medication was changed because of tolerability issues. The preservative-free fixed combination lowered IOP significantly in the subgroup of naïve patients, all subgroups with prior monotherapy and patients with prior fixed combinations: naïve patients: −8.9 mmHg, alpha-2-agonists: −6.4 mmHg, beta-blockers: −5.7 mmHg, carbonic anhydrase inhibitors: −5.2 mmHg, prostaglandins: −4.7 mmHg, fixed-combination prostaglandins/timolol: −2.4 mmHg. At the final visit, clinical signs and subjective symptoms were improved in patients with prior medical therapy. Local comfort was rated as “very good” or “good” by 89.1% of patients at the final visit. Only few adverse events occurred during the treatment period. Conclusion: The preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% was effective, well tolerated and showed a good safety profile. © 2017 Pillunat et al. AD - Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, Germany Augenklinik am Wittenbergplatz, Berlin, Germany Santen Europe, Helsinki, Finland Eyecons, Pfinztal, Germany Department of Ophthalmology, Mainz University Medical Center, Mainz, Germany AU - Pillunat, L. E. AU - Erb, C. AU - Ropo, A. AU - Kimmich, F. AU - Pfeiffer, N. DB - Scopus DO - 10.2147/OPTH.S128453 KW - Fixed combination Glaucoma Preservative-free medication Preservatives Tafluprost Timolol M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2017 SP - 1051-1064 ST - Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: Results of an open-label observational study T2 - Clinical Ophthalmology TI - Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: Results of an open-label observational study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020456240&doi=10.2147%2fOPTH.S128453&partnerID=40&md5=9f6150738d7cb6745a6304301ad5eb20 VL - 11 ID - 5454 ER - TY - JOUR AB - Background: Efficacy, tolerability and safety of the novel preservative-free fixed combination of tafluprost 0.0015%/ timolol 0.5% (Taptiqom (R)) were investigated in an observational study in Germany. Objective: To assess efficacy, tolerability and safety of the preservative-free fixed combination of tafluprost 0.0015%/ timolol 0.5% in a real-life setting. Methods: Intraocular pressure (IOP) was recorded for each eye at baseline (any previous therapy or untreated) and 4-16 weeks after changing medical treatment to or initiating treatment with the preservative-free fixed combination of tafluprost 0.0015%/ timolol 0.5%. Change in IOP was evaluated over the study period for all patients and for specific pretreatment subgroups. Clinical signs such as conjunctival hyperemia and lid-parallel conjunctival folds (LIPCOF) were recorded using standardized comparative photographs. Corneal staining, subjective symptoms and local comfort were measured using a four-step scale. All adverse events were recorded. Results: Among 1,157 patients enrolled, 1,075 patients were treated with the preservative-free fixed combination as the only medication at the final visit. Medical treatment was initiated in 741 patients because of an insufficient IOP-lowering effect of the prior medication. In 343 patients, medication was changed because of tolerability issues. The preservative-free fixed combination lowered IOP significantly in the subgroup of naive patients, all subgroups with prior monotherapy and patients with prior fixed combinations: naive patients: -8.9 mmHg, alpha-2-agonists: -6.4 mmHg, beta-blockers: -5.7 mmHg, carbonic anhydrase inhibitors: -5.2 mmHg, prostaglandins: -4.7 mmHg, fixed-combination prostaglandins/timolol: -2.4 mmHg. At the final visit, clinical signs and subjective symptoms were improved in patients with prior medical therapy. Local comfort was rated as "very good" or "good" by 89.1% of patients at the final visit. Only few adverse events occurred during the treatment period. Conclusion: The preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% was effective, well tolerated and showed a good safety profile. AN - WOS:000402980000002 AU - Pillunat, L. E. AU - Erb, C. AU - Ropo, A. AU - Kimmich, F. AU - Pfeiffer, N. DO - 10.2147/OPTH.S128453 PY - 2017 SN - 1177-5483 SP - 1051-1064 ST - Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study T2 - CLINICAL OPHTHALMOLOGY TI - Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study VL - 11 ID - 6258 ER - TY - JOUR AB - Background: Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary openangle glaucoma or ocular hypertension (IOP ≥18 mmHg) in a clinical practice setting. Methods: This open-label study observed patients who were switched to PF bimatoprost 0.03% for medical reasons. IOP was measured at baseline and ~12 weeks later at the final visit, and the change in IOP was calculated. Tolerability and continuation of therapy were assessed at two follow-up visits. Results: A total of 1,830 patients were included in the study, and complete IOP data were available for 1,543 patients. Mean IOP was reduced by 23% from 21.64 mmHg to 16.59 mmHg (P<0.0001). In subgroup analyses, the mean IOP was significantly reduced compared with baseline, regardless of prior therapy, including those previously treated with PF monotherapy. A total of 85.7% of physicians reported the IOP-lowering efficacy of PF bimatoprost 0.03% to be as expected or better than expected. Adverse events (AEs) were experienced by 5.7% of patients, and there were no serious AEs reported. The most common AEs were eye irritation (1.7%) and hyperemia (1.4%). Physician-reported treatment compliance was reported as better than (48.7%) or equal to (43.6%) prior treatment in most patients. Most patients (82%) were expected to continue PF bimatoprost 0.03% after the end of the study. Conclusion: This observational study showed that, in clinical practice, switching to PF bimatoprost 0.03% was associated with a significant IOP reduction from baseline. There was a low AE rate. PF bimatoprost 0.03% may, therefore, be an effective treatment option for patients who are intolerant of preservatives or have an inadequate response to prior IOP-lowering treatments. AD - L.E. Pillunat, Department of Ophthalmology, University Hospital Carl Gustav Carus, Fetscherstrasse 74, Dresden, Germany AU - Pillunat, L. E. AU - Eschstruth, P. AU - Häsemeyer, S. AU - Thelen, U. AU - Foja, C. AU - Leaback, R. AU - Pfennigsdorf, S. C1 - lumigan(Allergan,United States) C2 - Allergan(United States) DB - Embase DO - 10.2147/OPTH.S103084 KW - NCT01853085 bimatoprost preservative absence of side effects adult aged article controlled clinical trial controlled study coronary artery disease drug efficacy drug safety drug tolerability eye irritation female follow up human hyperemia hypertension intraocular hypertension intraocular pressure major clinical study male observational study open angle glaucoma open study patient compliance prospective study treatment outcome lumigan LA - English M3 - Article N1 - L612301889 2016-10-03 2016-10-05 PY - 2016 SN - 1177-5483 1177-5467 SP - 1759-1765 ST - Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice T2 - Clinical Ophthalmology TI - Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612301889&from=export http://dx.doi.org/10.2147/OPTH.S103084 VL - 10 ID - 2704 ER - TY - JOUR AB - Background: Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary openangle glaucoma or ocular hypertension (IOP ≥18 mmHg) in a clinical practice setting. Methods: This open-label study observed patients who were switched to PF bimatoprost 0.03% for medical reasons. IOP was measured at baseline and ~12 weeks later at the final visit, and the change in IOP was calculated. Tolerability and continuation of therapy were assessed at two follow-up visits. Results: A total of 1,830 patients were included in the study, and complete IOP data were available for 1,543 patients. Mean IOP was reduced by 23% from 21.64 mmHg to 16.59 mmHg (P<0.0001). In subgroup analyses, the mean IOP was significantly reduced compared with baseline, regardless of prior therapy, including those previously treated with PF monotherapy. A total of 85.7% of physicians reported the IOP-lowering efficacy of PF bimatoprost 0.03% to be as expected or better than expected. Adverse events (AEs) were experienced by 5.7% of patients, and there were no serious AEs reported. The most common AEs were eye irritation (1.7%) and hyperemia (1.4%). Physician-reported treatment compliance was reported as better than (48.7%) or equal to (43.6%) prior treatment in most patients. Most patients (82%) were expected to continue PF bimatoprost 0.03% after the end of the study. Conclusion: This observational study showed that, in clinical practice, switching to PF bimatoprost 0.03% was associated with a significant IOP reduction from baseline. There was a low AE rate. PF bimatoprost 0.03% may, therefore, be an effective treatment option for patients who are intolerant of preservatives or have an inadequate response to prior IOP-lowering treatments. © 2016 Pillunat et al. AD - Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, Germany Ophthalmology Practice, Kiel, Germany Eye Center, Kraichgau, Wiesloch, Germany Department of Ophthalmology, University of Münster, Münster, Germany Ophthalmology Practice, Leipzig, Germany Allergan Holdings Ltd, Marlow, United Kingdom Ophthalmology Practice, Polch, Germany AU - Pillunat, L. E. AU - Eschstruth, P. AU - Häsemeyer, S. AU - Thelen, U. AU - Foja, C. AU - Leaback, R. AU - Pfennigsdorf, S. DB - Scopus DO - 10.2147/OPTH.S103084 KW - Benzalkonium chloride free Intraocular pressure Preservative free Prostaglandin Sbimatoprost 0.03% M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2016 SP - 1759-1765 ST - Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice T2 - Clinical Ophthalmology TI - Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988734867&doi=10.2147%2fOPTH.S103084&partnerID=40&md5=06875a81be19536da0658b7dc51b4bad VL - 10 ID - 5416 ER - TY - JOUR AB - Background: Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension (IOP >= 18 mmHg) in a clinical practice setting. Methods: This open-label study observed patients who were switched to PF bimatoprost 0.03% for medical reasons. IOP was measured at baseline and similar to 12 weeks later at the final visit, and the change in IOP was calculated. Tolerability and continuation of therapy were assessed at two follow-up visits. Results: A total of 1,830 patients were included in the study, and complete IOP data were available for 1,543 patients. Mean IOP was reduced by 23% from 21.64 mmHg to 16.59 mmHg (P<0.0001). In subgroup analyses, the mean IOP was significantly reduced compared with baseline, regardless of prior therapy, including those previously treated with PF monotherapy. A total of 85.7% of physicians reported the IOP-lowering efficacy of PF bimatoprost 0.03% to be as expected or better than expected. Adverse events (AEs) were experienced by 5.7% of patients, and there were no serious AEs reported. The most common AEs were eye irritation (1.7%) and hyperemia (1.4%). Physician-reported treatment compliance was reported as better than (48.7%) or equal to (43.6%) prior treatment in most patients. Most patients (82%) were expected to continue PF bimatoprost 0.03% after the end of the study. Conclusion: This observational study showed that, in clinical practice, switching to PF bimatoprost 0.03% was associated with a significant IOP reduction from baseline. There was a low AE rate. PF bimatoprost 0.03% may, therefore, be an effective treatment option for patients who are intolerant of preservatives or have an inadequate response to prior IOP-lowering treatments. AN - WOS:000383396000001 AU - Pillunat, L. E. AU - Eschstruth, P. AU - Hasemeyer, S. AU - Thelen, U. AU - Foja, C. AU - Leaback, R. AU - Pfennigsdorf, S. DO - 10.2147/OPTH.S103084 PY - 2016 SN - 1177-5483 SP - 1759-1765 ST - Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice T2 - CLINICAL OPHTHALMOLOGY TI - Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice VL - 10 ID - 5977 ER - TY - JOUR AB - Introduction: Estimation of the prevalence of vision impairment in a population can be performed using epidemiological research. The purpose of this study was to measure, using spatial statistics, the prevalence of ophthalmologic disease identified at visits of the Mobile Ophthalmologic Unit (MOU) of the Vardinogiannion Eye Institute of Crete (VEIC) to villages in Crete. The study also aimed to estimate increased 'risk' of ophthalmological disease according to demographic and location factors and, thus, use the present findings as a basis for planning future services. Methods: Estimation of risks for cataract, glaucoma, and refractive errors were assessed by multiple logistic regression models in order to measure the effect of demographic (age, sex) and location (province, distance from nearest ophthalmologist) parameters. Spatial analysis was applied in order to produce a density and probability density map of ophthalmologic disorders using kriging interpolation methods. Results: Newly diagnosed cataracts and refractive errors were found more frequently in locations greater than 70 km from the nearest ophthalmologist (respectively, OR = 6.0 [95% CI = 1.637-9.482]; OR = 27.4 [20.038-39.028] p-value = 0.004). Those aged >60 years had higher risk for all eye abnormalities: cataracts (OR = 0.7; 95% CI = 0.238-0.938), glaucoma (OR = 1.6; 95% CI = 1.227-2.037), and refractive errors (OR = 0.5; 95% CI = 0.183-0.829). Conclusion: The present study supports the use of local policies and preventive measures in rural areas of Crete in order to improve rural health standards. Some insights concerning the effectiveness of future visits of MOUs are provided, guided by spatial analysis. © G Pistolla, MK Tsilimparis, P Prastacos, D Sifaki-Pistolla, A Philalithis, IG Pallikaris, 2013. AD - University of Crete, Heraklion, Crete, Greece Institute of Optics and Vision, University Eye Clinic, Heraklion, Crete, Greece Institute of Applied and Computational Mathematics, Foundation for Research and Technology-Hellas, Heraklion, Crete, Greece AU - Pistolla, G. AU - Tsilimparis, M. K. AU - Prastacos, P. AU - Sifaki-Pistolla, D. AU - Philalithis, A. AU - Pallikaris, I. G. C7 - 2020 DB - Scopus IS - 1 KW - Cataracts Glaucoma Greece Ophthalmologic disorders Refractive errors Spatial analysis M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2013 ST - Ophthalmological disorders in rural areas of crete: A geospatial analysis T2 - Rural and Remote Health TI - Ophthalmological disorders in rural areas of crete: A geospatial analysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84877904488&partnerID=40&md5=fce6dba8c7e1316d4d85d24c9140f979 VL - 13 ID - 5524 ER - TY - JOUR AB - We review the recent advances in nanoparticle-based glaucoma therapy with a focus on drug delivery to the eye, as well as novel applications including gene therapy. © 2013 Wolters Kluwer Health. AD - J.L. Goldberg, Bascom Palmer Eye Institute, Interdisciplinary Stem Cell Institute, University of Miami, 10th Avenue, Miami, FL 33136, United States AU - Pita-Thomas, D. W. AU - Goldberg, J. L. DB - Embase Medline DO - 10.1097/ICU.0b013e32835cfe92 IS - 2 KW - alginic acid alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor chitosan eye drops gold nanoparticle heat shock protein microsphere nanoparticle anterior eye segment aqueous humor bronchospasm central corneal thickness clinical trial (topic) cornea epithelium disease course drug bioavailability drug half life endocytosis epithelium fatigue gene mutation gene therapy glaucoma human hypotension intraocular pressure nanotechnology nerve fiber degeneration optic nerve patient compliance pigment epithelium posterior eye segment priority journal retina ganglion cell retina ischemia review subretinal neovascularization tight junction viral gene delivery system visual impairment xerostomia LA - English M3 - Review N1 - L52379684 2013-01-09 2013-04-26 PY - 2013 SN - 1040-8738 1531-7021 SP - 130-135 ST - Nanotechnology and glaucoma: Little particles for a big disease T2 - Current Opinion in Ophthalmology TI - Nanotechnology and glaucoma: Little particles for a big disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52379684&from=export http://dx.doi.org/10.1097/ICU.0b013e32835cfe92 VL - 24 ID - 3023 ER - TY - JOUR AB - PURPOSE OF REVIEW: Current medical treatments designed to halt the progressive loss of retinal ganglion cells (RGCs) in glaucoma are limited by low bioavailability to target tissues and lack of patient adherence to frequent dosing regimens. For a certain percentage of patients with glaucoma, reducing intraocular pressure (IOP) does not stop disease progression, motivating the search for new therapeutic targets and delivery systems. RECENT FINDINGS: The emerging science of nanoparticles has the potential to address the current limitations of glaucoma therapy by improving drug bioavailability, exploiting IOP-independent targets such as RGC neuroprotection, and optimizing gene therapy as a more permanent treatment for glaucoma. SUMMARY: We review the recent advances in nanoparticle-based glaucoma therapy with a focus on drug delivery to the eye, as well as novel applications including gene therapy. AD - Bascom Palmer Eye Institute, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. AN - 107999131. Language: English. Entry Date: 20130524. Revision Date: 20150712. Publication Type: Journal Article. Journal Subset: Biomedical AU - Pita-Thomas, Daniel W. AU - Goldberg, Jeffrey L. DB - ccm DO - 10.1097/ICU.0b013e32835cfe92 DP - EBSCOhost IS - 2 KW - Antihypertensive Agents Drug Delivery Systems Glaucoma -- Drug Therapy Nanotechnology Nanotechnology -- Methods Intraocular Pressure N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM23287105. PY - 2013 SN - 1040-8738 SP - 130-135 ST - Nanotechnology and glaucoma: little particles for a big disease T2 - Current Opinion in Ophthalmology TI - Nanotechnology and glaucoma: little particles for a big disease UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107999131&site=ehost-live&scope=site VL - 24 ID - 4382 ER - TY - JOUR AB - Background: Glaucoma is the leading cause of irreversible blindness in the USA. Glaucomatous vision loss is preventable with proper eye care, including appointment adherence. Therefore, interventions that improve appointment adherence can reduce the number of patients with more severe glaucoma. Objectives: The primary study aim was to determine the efficacy and cost-effectiveness of a multifaceted personal reminder intervention, which included a customized letter and personal telephone outreach, in improving appointment adherence of patients with glaucoma. A secondary study aim was to identify patient characteristics that were associated with non-adherence. Methods: This prospective, randomized, controlled study included a cost-effectiveness analysis completed using a decision analytic model. The subjects included 256 patients with glaucoma. Study measures included appointment adherence and incremental cost effectiveness ratios. Results: Patients in the intervention group were more likely to adhere to appointments (82.31 vs. 69.05 %; RR 1.23; 95 % CI 1.04–1.37, p < 0.012) than patients in the usual care group. Patients in the intervention group were 23 % more likely to adhere to appointments (RR 1.23; 95 % CI 1.08–1.41, p < 0.0021) than patients in the usual care group, when adjusting for age, secondary insurance, primary open angle glaucoma diagnosis, number of previous visits at Wills Eye Hospital, and follow-up recommendation using Poisson regression. Per-patient cost of the program was US$11.32, and cost per follow-up attended within the adherence window was US$73.56. Conclusions: A low cost reminder intervention consisting of a personalized letter and telephone outreach significantly improved appointment adherence of patients with glaucoma. AD - L.T. Pizzi, Thomas Jefferson University, 901 Walnut Street, 911, Philadelphia, PA, United States AU - Pizzi, L. T. AU - Tran, J. AU - Shafa, A. AU - Waisbourd, M. AU - Hark, L. AU - Murchison, A. P. AU - Dai, Y. AU - Mayro, E. L. AU - Haller, J. A. DB - Embase Medline DO - 10.1007/s40258-016-0231-8 IS - 2 KW - aged article controlled study cost benefit analysis cost effectiveness analysis disease severity female follow up health insurance human major clinical study male medication compliance open angle glaucoma outcome assessment prospective study randomized controlled trial sample size LA - English M3 - Article N1 - L608720463 2016-03-08 2016-04-06 PY - 2016 SN - 1179-1896 1175-5652 SP - 229-240 ST - Effectiveness and Cost of a Personalized Reminder Intervention to Improve Adherence to Glaucoma Care T2 - Applied Health Economics and Health Policy TI - Effectiveness and Cost of a Personalized Reminder Intervention to Improve Adherence to Glaucoma Care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L608720463&from=export http://dx.doi.org/10.1007/s40258-016-0231-8 VL - 14 ID - 2747 ER - TY - JOUR AB - Background: Glaucoma is the leading cause of irreversible blindness in the USA. Glaucomatous vision loss is preventable with proper eye care, including appointment adherence. Therefore, interventions that improve appointment adherence can reduce the number of patients with more severe glaucoma. Objectives: The primary study aim was to determine the efficacy and cost-effectiveness of a multifaceted personal reminder intervention, which included a customized letter and personal telephone outreach, in improving appointment adherence of patients with glaucoma. A secondary study aim was to identify patient characteristics that were associated with non-adherence. Methods: This prospective, randomized, controlled study included a cost-effectiveness analysis completed using a decision analytic model. The subjects included 256 patients with glaucoma. Study measures included appointment adherence and incremental cost effectiveness ratios. Results: Patients in the intervention group were more likely to adhere to appointments (82.31 vs. 69.05 %; RR 1.23; 95 % CI 1.04–1.37, p < 0.012) than patients in the usual care group. Patients in the intervention group were 23 % more likely to adhere to appointments (RR 1.23; 95 % CI 1.08–1.41, p < 0.0021) than patients in the usual care group, when adjusting for age, secondary insurance, primary open angle glaucoma diagnosis, number of previous visits at Wills Eye Hospital, and follow-up recommendation using Poisson regression. Per-patient cost of the program was US$11.32, and cost per follow-up attended within the adherence window was US$73.56. Conclusions: A low cost reminder intervention consisting of a personalized letter and telephone outreach significantly improved appointment adherence of patients with glaucoma. © 2016, Springer International Publishing Switzerland. AD - Thomas Jefferson University, 901 Walnut Street, 911, Philadelphia, PA 19107, United States Wills Eye Hospital Glaucoma Research Center, 840 Walnut Street Suite 1140, Philadelphia, PA, United States Wills Eye Hospital, 840 Walnut Street Suite 1500, Philadelphia, PA, United States AU - Pizzi, L. T. AU - Tran, J. AU - Shafa, A. AU - Waisbourd, M. AU - Hark, L. AU - Murchison, A. P. AU - Dai, Y. AU - Mayro, E. L. AU - Haller, J. A. DB - Scopus DO - 10.1007/s40258-016-0231-8 IS - 2 M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2016 SP - 229-240 ST - Effectiveness and Cost of a Personalized Reminder Intervention to Improve Adherence to Glaucoma Care T2 - Applied Health Economics and Health Policy TI - Effectiveness and Cost of a Personalized Reminder Intervention to Improve Adherence to Glaucoma Care UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961060999&doi=10.1007%2fs40258-016-0231-8&partnerID=40&md5=83c08307dbb194d57c5d211be21652ec VL - 14 ID - 5418 ER - TY - JOUR AB - Background Glaucoma is the leading cause of irreversible blindness in the USA. Glaucomatous vision loss is preventable with proper eye care, including appointment adherence. Therefore, interventions that improve appointment adherence can reduce the number of patients with more severe glaucoma. Objectives The primary study aim was to determine the efficacy and cost-effectiveness of a multifaceted personal reminder intervention, which included a customized letter and personal telephone outreach, in improving appointment adherence of patients with glaucoma. A secondary study aim was to identify patient characteristics that were associated with non-adherence. Methods This prospective, randomized, controlled study included a cost-effectiveness analysis completed using a decision analytic model. The subjects included 256 patients with glaucoma. Study measures included appointment adherence and incremental cost effectiveness ratios. Results Patients in the intervention group were more likely to adhere to appointments (82.31 vs. 69.05 %; RR 1.23; 95 % CI 1.04-1.37, p< 0.012) than patients in the usual care group. Patients in the intervention group were 23 % more likely to adhere to appointments (RR 1.23; 95 % CI 1.08-1.41, p< 0.0021) than patients in the usual care group, when adjusting for age, secondary insurance, primary open angle glaucoma diagnosis, number of previous visits at Wills Eye Hospital, and follow-up recommendation using Poisson regression. Per-patient cost of the program was US$11.32, and cost per follow-up attended within the adherence window was US$73.56. Conclusions A low cost reminder intervention consisting of a personalized letter and telephone outreach significantly improved appointment adherence of patients with glaucoma. AN - WOS:000372441300010 AU - Pizzi, L. T. AU - Tran, J. AU - Shafa, A. AU - Waisbourd, M. AU - Hark, L. AU - Murchison, A. P. AU - Dai, Y. AU - Mayro, E. L. AU - Haller, J. A. DA - APR DO - 10.1007/s40258-016-0231-8 IS - 2 PY - 2016 SN - 1175-5652 1179-1896 SP - 229-240 ST - Effectiveness and Cost of a Personalized Reminder Intervention to Improve Adherence to Glaucoma Care T2 - APPLIED HEALTH ECONOMICS AND HEALTH POLICY TI - Effectiveness and Cost of a Personalized Reminder Intervention to Improve Adherence to Glaucoma Care VL - 14 ID - 5822 ER - TY - JOUR AB - PURPOSE: To describe prescription refill patterns of ocular hypotensive therapies and to measure differences among refill rates across bottle sizes. DESIGN: Retrospective, population-based, cohort study. METHODS: This study included patients dispensed bimatoprost, brimonidine, dorzolamide/timolol, latanoprost, timolol gel (XE) 0.5%, or travoprost between January 1, 1996, and March 30, 2002. The initial fill date was identified for the cohort-defining ocular hypotensive, and the number of days between each subsequent refill was calculated. The analysis was repeated in patients with at least four refills to evaluate potential bias. Descriptive and survival analyses evaluated differences in refill rates across bottle sizes. RESULTS: In the 27,387 patients contributing up to four evaluable refill sequences, the amount of drug contained in bottles did not predict the number of days between fills. Patients dispensed larger bottles typically refilled sooner than drop-count studies would predict; results for patients with at least four refills (n = 12,976) confirmed these findings. Survival analysis demonstrated that the bottle size trend held across classes of therapy. Compared with 5.0-ml bottles, patients dispensed 10.0-ml and 15.0-ml bottles returned for refills at approximately 1.5 times the expected rate. When average wholesale prices were applied to refill intervals for selected agents, a 45% excess cost per month was found for the larger bottle sizes (10.0 ml vs 5.0 ml or 5.0 ml vs 2.5 ml). CONCLUSIONS: Expected refill patterns predicted by bottle size and mean number of drops do not reflect observed refill patterns. Patients dispensed larger bottle sizes return for refills much sooner than expected, regardless of the class of therapy. © 2004 by Elsevier Inc. All rights reserved. AD - R. Platt, Montreal Children's Hosp. Res. Inst., 4060 Ste Catherine W #205, Westmount, Que. H3Z 2Z3, Canada AU - Platt, R. AU - Reardon, G. AU - Mozaffari, E. DB - Embase Medline DO - 10.1016/j.ajo.2003.10.033 IS - SUPPL. KW - antihypertensive agent bimatoprost brimonidine dorzolamide latanoprost timolol travoprost aged article calculation cohort analysis container controlled study drug cost drug use female human intraocular hypertension major clinical study male open angle glaucoma patient compliance population research prediction prescription priority journal retrospective study survival LA - English M3 - Article N1 - L38091631 2004-02-03 PY - 2004 SN - 0002-9394 SP - S17-S23 ST - Observed time between prescription refills for newer ocular hypotensive agents: The effect of bottle size T2 - American Journal of Ophthalmology TI - Observed time between prescription refills for newer ocular hypotensive agents: The effect of bottle size UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38091631&from=export http://dx.doi.org/10.1016/j.ajo.2003.10.033 VL - 137 ID - 3764 ER - TY - JOUR AB - Purpose: To determine the risk factors associated with progression to blindness from primary open-angle glaucoma (POAG) in an African-American population. Methods: This study examined 2119 patients enrolled in the Primary Open-Angle African-American Glaucoma Genetics (POAAGG) study. A total of 59 eyes were identified as legally blind as a result of POAG (cases) and were age-and sex-matched to 59 non-blind eyes with glaucoma (controls). Chart reviews were performed to record known and suspected risk factors. Results: Cases were diagnosed with POAG at an earlier age than controls (p = 0.005). Of the 59 eyes of cases, 16 eyes (27.1%) presented with blindness at diagnosis. Cases had worse visual acuity (VA) at diagnosis (p < 0.0001), with VA worse than 20/40 conferring a 27 times higher risk of progression to blindness (p = 0.0005). Blind eyes also demonstrated more visual field defects (p = 0.01), higher pre-treatment intraocular pressure (IOP; p < 0.0001), and higher cup-to-disc ratio (p = 0.006) at diagnosis. IOP was less controlled in cases, and those with IOP ≥21 mmHg at more than 20% of follow-up visits were 73 times more likely to become blind (p < 0.0001). Cases missed a greater number of appointments per year (p = 0.003) and had non-adherence issues noted in their charts more often than controls (p = 0.03). However, other compliance data did not significantly differ between groups. Conclusion: Access to care, initial VA worse than 20/40, and poor control of IOP were the major risk factors associated with blindness from POAG. Future studies should examine earlier, more effective approaches to glaucoma screening as well as the role of genetics in these significantly younger patients who progress to blindness. © 2016 Taylor & Francis. AD - Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, United States AU - Pleet, A. AU - Sulewski, M. AU - Salowe, R. J. AU - Fertig, R. AU - Salinas, J. AU - Rhodes, A. AU - Merritt Iii, W. AU - Natesh, V. AU - Huang, J. AU - Gudiseva, H. V. AU - Collins, D. W. AU - Chavali, V. R. M. AU - Tapino, P. AU - Lehman, A. AU - Regina-Gigiliotti, M. AU - Miller-Ellis, E. AU - Sankar, P. AU - Ying, G. S. AU - O’Brien, J. M. DB - Scopus DO - 10.1080/09286586.2016.1193207 IS - 4 KW - African African-Americans blindness glaucoma minority research primary open-angle glaucoma M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2016 SP - 248-256 ST - Risk Factors Associated with Progression to Blindness from Primary Open-Angle Glaucoma in an African-American Population T2 - Ophthalmic Epidemiology TI - Risk Factors Associated with Progression to Blindness from Primary Open-Angle Glaucoma in an African-American Population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84976288769&doi=10.1080%2f09286586.2016.1193207&partnerID=40&md5=291e53219c5fde5121ebbebf67eaaacf VL - 23 ID - 5214 ER - TY - JOUR AB - Purpose: To determine the risk factors associated with progression to blindness from primary open-angle glaucoma (POAG) in an African-American population. Methods: This study examined 2119 patients enrolled in the Primary Open-Angle African-American Glaucoma Genetics (POAAGG) study. A total of 59 eyes were identified as legally blind as a result of POAG (cases) and were age-and sex-matched to 59 non-blind eyes with glaucoma (controls). Chart reviews were performed to record known and suspected risk factors. Results: Cases were diagnosed with POAG at an earlier age than controls (p = 0.005). Of the 59 eyes of cases, 16 eyes (27.1%) presented with blindness at diagnosis. Cases had worse visual acuity (VA) at diagnosis (p < 0.0001), with VA worse than 20/40 conferring a 27 times higher risk of progression to blindness (p = 0.0005). Blind eyes also demonstrated more visual field defects (p = 0.01), higher pre-treatment intraocular pressure (IOP; p < 0.0001), and higher cup-to-disc ratio (p = 0.006) at diagnosis. IOP was less controlled in cases, and those with IOP 21 mmHg at more than 20% of follow-up visits were 73 times more likely to become blind (p < 0.0001). Cases missed a greater number of appointments per year (p = 0.003) and had non-adherence issues noted in their charts more often than controls (p = 0.03). However, other compliance data did not significantly differ between groups. Conclusion: Access to care, initial VA worse than 20/40, and poor control of IOP were the major risk factors associated with blindness from POAG. Future studies should examine earlier, more effective approaches to glaucoma screening as well as the role of genetics in these significantly younger patients who progress to blindness. AN - WOS:000380248500005 AU - Pleet, A. AU - Sulewski, M. AU - Salowe, R. J. AU - Fertig, R. AU - Salinas, J. AU - Rhodes, A. AU - Merritt, W. AU - Natesh, V. AU - Huang, J. Y. AU - Gudiseva, H. V. AU - Collins, D. W. AU - Chavali, V. R. M. AU - Tapino, P. AU - Lehman, A. AU - Regina-Gigiliotti, M. AU - Miller-Ellis, E. AU - Sankar, P. AU - Ying, G. S. AU - O'Brien, J. M. DO - 10.1080/09286586.2016.1193207 IS - 4 PY - 2016 SN - 0928-6586 1744-5086 SP - 248-256 ST - Risk Factors Associated with Progression to Blindness from Primary Open-Angle Glaucoma in an African-American Population T2 - OPHTHALMIC EPIDEMIOLOGY TI - Risk Factors Associated with Progression to Blindness from Primary Open-Angle Glaucoma in an African-American Population VL - 23 ID - 5925 ER - TY - JOUR AB - Glaucoma is a worldwide disease and the second leading cause of blindness. Current treatments are associated with a number of side-effects and poor compliance, due to the requirement for treatment administration several times a day. These treatments typically aim to lower intraocular pressure (IOP); however, they are unable to protect retinal ganglion cells (RGCs) from undergoing apoptosis, which is the main cause of vision loss. A 3adenosine receptor (A3AR) agonists have been found to protect normal cells from undergoing apoptosis via the downregulation of death signals. Furthermore, A3AR agonists have been reported to have several ophthalmological effects, including the prevention of ganglion cell apoptosis in vitro and in vivo and anti-inflammatory effects in experimental models of autoimmune uveitis. CF101, an orally bioavailable A3AR agonist, has been analyzed in dry eye syndrome phase II clinical trials and was identified to be safe and well tolerated. The anti-inflammatory effect of CF101 was shown to significantly improve corneal staining, tear meniscus and tear break-up time in dry eye patients. In addition, CF101 was found to decrease IOP in patients. The safety and efficacy of CF101, together with its suitability for oral administration, indicates that it has potential as a candidate drug for the treatment of glaucoma. Copyright © 2013 Spandidos Publications Ltd. All rights reserved. AD - F. Pnina, Can-Fite BioPharma, 10 Bareket Street, Petach-Tikva 49170, Israel AU - Pnina, F. AU - Shira, C. AU - Bar-Yehuda, S. DB - Embase Medline DO - 10.3892/mmr.2013.1413 IS - 6 KW - piclidenoson adenosine A3 receptor adenosine A3 receptor agonist apoptosis inducing factor caspase 3 caspase 9 cytochrome c nitric oxide timolol tumor necrosis factor tumor necrosis factor alpha receptor antiinflammatory activity apoptosis aqueous humor flow article autoimmune uveitis drug efficacy drug safety drug tolerability dry eye glaucoma human in vitro study intraocular pressure membrane permeability nerve cell neuroprotection nonhuman oxidative stress pathogenesis patient compliance phase 2 clinical trial (topic) protein expression pseudoexfoliation retina ganglion cell visual impairment Wnt signaling LA - English M3 - Article N1 - L368865721 2013-05-15 2013-05-22 PY - 2013 SN - 1791-2997 1791-3004 SP - 1723-1725 ST - Targeting the A3adenosine receptor for glaucoma treatment (Review) T2 - Molecular Medicine Reports TI - Targeting the A3adenosine receptor for glaucoma treatment (Review) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368865721&from=export http://dx.doi.org/10.3892/mmr.2013.1413 http://www.spandidos-publications.com/serveFile/mmr_7_6_1723_PDF.pdf?type=article&article_id=mmr_7_6_1723&item=PDF VL - 7 ID - 2992 ER - TY - JOUR AB - Thirty-five myopic subjects were fitted with rigid gas-permeable lenses for 6 months of extended wear (EW). These lenses had an average oxygen transmissibility of 37 x 10-9 (cm x ml x O2)/(s x ml x mm Hg). For six monthly morning visits subjects reported with one eye patched; corneal thickness, corneal curvature, refractive error, endothelial photomicroscopy, and slitlamp examinations were done on both eyes. The average morning corneal swelling was 5.9 ± 3.3%. Corneal curvature showed 0.24 ± 0.44 D flattening in the steep meridian and 0.20 D steepening in the flat meridian. Spectacle refraction and corrected visual acuity changes were small in the spherical and cylindrical components. Complications that were important clinically included 10% lens adherence syndrome, 20% superficial limbal keratitis, 6.5% epithelial microcysts, and some increase in endothelial polymegath-ism. No infections, red eye responses, or infiltrative keratitis were observed during the 6-month follow-up period. These results suggest that hard-lens EW is feasible and that lenses with this Dk/L value will meet oxygen requirements for many patients; however, some patients will require lenses of higher oxygen transmissibility to avoid undesirable complications. © 1988 American Academy of Optometry. AD - School of Optometry, University of California, Berkeley, CA, United States AU - Polse, K. A. AU - Rivera, R. K. AU - Bonanno, J. DB - Scopus DO - 10.1097/00006324-198805000-00009 IS - 5 KW - Contact lenses Corneal swelling Extended wear Rigid gas permeable lenses M3 - Article N1 - Cited By :20 Export Date: 19 July 2021 PY - 1988 SP - 358-364 ST - Ocular effects of hard gas-permeable-lens extended wear T2 - Optometry and Vision Science TI - Ocular effects of hard gas-permeable-lens extended wear UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023882315&doi=10.1097%2f00006324-198805000-00009&partnerID=40&md5=bc71a0bdfdf1d6059ebf24a9ff4bbf6d VL - 65 ID - 5145 ER - TY - JOUR AD - J. Pong, Department of Ophthalmology, United Christian Hospital, Kowloon, Hong Kong AU - Pong, J. AU - Lai, J. DB - Embase Medline DO - 10.1111/j.1755-3768.2007.01162.x IS - 3 KW - eye drops follow up glaucoma Hong Kong human letter long term care patient compliance priority journal questionnaire LA - English M3 - Letter N1 - L354534693 2009-05-16 PY - 2009 SN - 1755-375X SP - 353 ST - Non-compliance in glaucoma treatment: A Hong Kong perspective T2 - Acta Ophthalmologica TI - Non-compliance in glaucoma treatment: A Hong Kong perspective UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354534693&from=export http://dx.doi.org/10.1111/j.1755-3768.2007.01162.x VL - 87 ID - 3355 ER - TY - JOUR AD - Department of Ophthalmology, United Christian Hospital, New Kowloon, Hong Kong Department of Ophthalmology, United Christian Hospital, Kowloon, Hong Kong AU - Pong, J. AU - Lai, J. DB - Scopus DO - 10.1111/j.1755-3768.2007.01162.x IS - 3 M3 - Letter N1 - Cited By :2 Export Date: 19 July 2021 PY - 2009 SP - 353 ST - Non-compliance in glaucoma treatment: A Hong Kong perspective T2 - Acta Ophthalmologica TI - Non-compliance in glaucoma treatment: A Hong Kong perspective UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-65349189625&doi=10.1111%2fj.1755-3768.2007.01162.x&partnerID=40&md5=eeecf515ffc9bd632fa29ae5b2dcb2e0 VL - 87 ID - 5582 ER - TY - JOUR AB - Purpose: To evaluate the sterility of topical glaucoma medications among chronic glaucoma medication users in the community. Setting: Glaucoma service, Sanz Medical Center, Laniado Hospital, Netanya. Research mode: Cross-sectional laboratory and clinical study, Patients and Methods: Chronic glaucoma patients were asked to submit their topical glaucoma preparations to the microbiology laboratory at Laniado hospital, Samples taken from the interior of the bottle and the tip were cultured using MacConkey agar, blood agar, and chocolate agar plates. Results: Sixty-two bottles of topical glaucoma medications used by 27 patients were tested. Bacterial growth was detected in eight (12.9%) preparations, three of which revealed Pseudomonas aeruginosa, three Staphylococcus epidermidis, one Streptococcus viridans, and one Klebsiella. During the study, acute conjunctivitis was found in one patient, possibly due to the use of infected drops. In another case, two identical medications, which had been used simultaneously for more than 6 weeks by the same patient, were found to be infected. Conclusions: Glaucoma topical preparations are generally found safe in terms of sterility, though bacterial growth may be found in a small percentage. In most cases, the cause of the loss of sterility could not be determined. However, in two preparations, contamination was related to the noncompliance of the patient who continued using the same preparation longer than instructed. It is imperative to increase the awareness of glaucoma patients to the fact that improper use can lead to eye-drop contamination. AD - Y. Porges, 5b Yahalom Street, Zichron Yaakov 30900, Israel AU - Porges, Y. AU - Rothkoff, L. AU - Glick, J. AU - Cohen, S. C1 - alphagan(Allergan,Ireland) azopt(Alcon Couvreur,Belgium) betoptic(Alcon Couvreur,Belgium) cosopt(Merck Sharp and Dohme,France) pilocarpine(Taro,Israel) propine(Promedica,Israel) trusopt(Merck Sharp and Dohme,Netherlands) vioptic(Vitamed,Israel) xalatan(Pharmacia Upjohn,United States) C2 - Alcon Couvreur(Belgium) Allergan(Ireland) Ciba Vision(Switzerland) Merck Sharp and Dohme(France) Merck Sharp and Dohme(Netherlands) Pharmacia Upjohn(United States) Promedica(Israel) Taro(Israel) Vitamed(Israel) DB - Embase Medline DO - 10.1089/108076804773710795 IS - 2 KW - agar antiglaucoma agent beta adrenergic receptor blocking agent betaxolol brimonidine brinzolamide dipivefrine dorzolamide dorzolamide plus timolol latanoprost timolol maleate pilocarpine unclassified drug vioptic adult aged alpha hemolytic Streptococcus article bacterial growth bacterium culture chronic patient clinical article conjunctivitis culture medium drug contamination drug safety drug sterility drug use female glaucoma human Israel Klebsiella long term care male microbiology patient compliance Pseudomonas aeruginosa Staphylococcus epidermidis alphagan azopt betoptic cosopt propine trusopt xalatan LA - English M3 - Article N1 - L38456585 2004-05-06 PY - 2004 SN - 1080-7683 SP - 123-128 ST - Sterility of Glaucoma Medications among Chronic Users in the Community T2 - Journal of Ocular Pharmacology and Therapeutics TI - Sterility of Glaucoma Medications among Chronic Users in the Community UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38456585&from=export http://dx.doi.org/10.1089/108076804773710795 VL - 20 ID - 3749 ER - TY - JOUR AD - A.R. Potter, Eye Clinic, Hôpital St Jean de Dieu, Boko, Parakou, Benin AU - Potter, A. R. DB - Embase Medline IS - 1 KW - adolescent adult aged article Benin cataract cataract extraction child controlled study entropion female glaucoma glaucoma surgery health care utilization human major clinical study male rural health care World Health Organization LA - English M3 - Article N1 - L34073007 2002-01-30 PY - 2002 SN - 0049-4755 SP - 17-19 ST - A study of patients attending for eye surgery at a rural hospital in the Republic of Benin T2 - Tropical Doctor TI - A study of patients attending for eye surgery at a rural hospital in the Republic of Benin UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34073007&from=export VL - 32 ID - 3880 ER - TY - JOUR AB - Importance The effect of glaucoma on nonglaucomatous medical conditions and resultant secondary health care costs is not well understood. OBJECTIVE To assess self-reported medical conditions, the use of medical services, and total health care costs among Medicare beneficiaries with glaucoma. DESIGN, SETTING, AND PARTICIPANTS Longitudinal observational study of 72 587 Medicare beneficiaries in the general community using the Medicare Current Beneficiary Survey (2004-2009). Coding to extract data started in January 2015, and analyses were performed between May and July 2015. MAIN OUTCOMES AND MEASURES Self-reported health, the use of health care services, adjusted mean annual total health care costs per person, and adjusted mean annual nonoutpatient costs per person. RESULTS Participants were 72 587 Medicare beneficiaries 65 years or older with (n = 4441) and without (n = 68 146) a glaucoma diagnosis in the year before collection of survey data. Their mean age was 76.9 years, and 43.2%were male. Patients with glaucoma who responded to survey questions on visual disability were stratified into those with (n = 1748) and without (n = 2639) self-reported visual disability. Medicare beneficiaries with glaucoma had higher adjusted odds of inpatient hospitalizations (odds ratio [OR], 1.27; 95%CI, 1.17-1.39; P <.001) and home health aide visits (OR, 1.27; 95%CI, 1.13-1.43; P <.001) compared with Medicare beneficiaries without glaucoma. Furthermore, patients with glaucoma with self-reported visual disability were more likely to report depression (OR, 1.47; 95%CI, 1.26-1.71; P <.001), falls (OR, 1.34; 95%CI, 1.09-1.66; P =.006), and difficulty walking (OR, 1.22; 95%CI, 1.02-1.45; P =.03) compared with those without self-reported visual disability. In the risk-adjusted model, Medicare beneficiaries with glaucoma incurred an additional $2903 (95%CI, $2247-$3558; P <.001) annual total health care costs and $2599 (95%CI, $1985-$3212; P <.001) higher costs for nonoutpatient services compared with Medicare beneficiaries without glaucoma. CONCLUSIONS AND RELEVANCE Glaucoma is associated with greater use of inpatient and home health aide services and with higher annual total and nonoutpatient medical costs. Perception of vision loss among patients with glaucoma may be associated with depression, falls, and difficulty walking. Reducing the prevalence and severity of glaucoma may result in improvements in associated nonglaucomatous medical conditions and resultant reduction in health care costs. AD - D.M. Blumberg, Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, 635W165th St, New York, NY, United States AU - Prager, A. J. AU - Liebmann, J. M. AU - Cioffi, G. A. AU - Blumberg, D. M. DB - Embase Medline DO - 10.1001/jamaophthalmol.2015.5479 IS - 4 KW - aged article controlled study depression female glaucoma health care cost health care utilization hip fracture human insurance longitudinal study major clinical study male medicare observational study outcome assessment prescription priority journal risk assessment self report socioeconomics very elderly walking difficulty LA - English M3 - Article N1 - L609941199 2016-04-22 2016-05-06 PY - 2016 SN - 2168-6165 SP - 357-365 ST - Self-reported function, health resource use, and total health care costs among medicare beneficiaries with glaucoma T2 - JAMA Ophthalmology TI - Self-reported function, health resource use, and total health care costs among medicare beneficiaries with glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609941199&from=export http://dx.doi.org/10.1001/jamaophthalmol.2015.5479 VL - 134 ID - 2749 ER - TY - JOUR AB - Purpose: This study examines the short-term uptake, compliance, and performance of a tablet device used for home monitoring of visual field (VF-Home) by glaucoma patients. Design: Single-center, observational, longitudinal, compliance study. Methods: Participants who were glaucoma suspects or had stable glaucoma in at least one eye were recruited during a regular clinic review. Baseline in-clinic visual field (VF) was recorded with the Humphrey Field Analyser (HFA, SITA standard) and repeated at 6 months. Participants were tasked with performing 6 VF examinations from home, at weekly intervals, using a loaned iPad tablet. Uptake was defined as returning at least 1 test from home. Reliability and global indices from VF-Home were compared to in-clinic outcomes. Data are shown as either mean ± [standard deviation] or median [quartile 1-3 range], and group comparisons were achieved with bootstrap. Results: We recruited 186 eyes of 101 participants. VF-Home uptake was excellent, with 88% of participants successfully completing ≥1 home examination and 69% completing all 6 examinations. The median duration between tests was 7.0 [7.0-8.0] days. Barriers to uptake and compliance involved information technology (IT) logistical reasons, lack of motivation, or competing life demands. VF-Home gave greater fixation loss but a similar level of False Positives (FP) as the HFA. A high correlation was found for the mean defect between in-clinic and at-home outcomes (R = 0.85). Conclusions: VF-Home can return a high level of short-term compliance and results comparable to those found by in-clinic testing. IT logistical reasons and lack of motivation are barriers to uptake and compliance. AD - A.J. Vingrys, Department of Optometry and Vision Sciences, University of Melbourne, 200 Berkeley St, Carlton, Victoria, Australia AU - Prea, S. M. AU - Kong, G. Y. X. AU - Guymer, R. H. AU - Vingrys, A. J. DB - Embase Medline DO - 10.1016/j.ajo.2020.10.023 KW - Humphrey perimeter tablet computer adult aged article bootstrapping clinical outcome cohort analysis correlational study female glaucoma home monitoring human information technology longitudinal study major clinical study male observational study patient compliance perimetry priority journal text messaging visual field iPad LA - English M3 - Article N1 - L2010440162 2020-12-28 2021-01-07 PY - 2021 SN - 1879-1891 0002-9394 SP - 286-295 ST - Uptake, Persistence, and Performance of Weekly Home Monitoring of Visual Field in a Large Cohort of Patients With Glaucoma T2 - American Journal of Ophthalmology TI - Uptake, Persistence, and Performance of Weekly Home Monitoring of Visual Field in a Large Cohort of Patients With Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010440162&from=export http://dx.doi.org/10.1016/j.ajo.2020.10.023 VL - 223 ID - 2318 ER - TY - JOUR AB - PURPOSE: To describe early challenges and techniques to promote donor tissue adherence in Descemet's stripping with endothelial keratoplasty (DSEK). SETTING: Price Vision Group, Indianapolis, Indiana, USA. METHODS: The first 200 consecutive cases of DSEK performed by a single surgeon were analyzed retrospectively. Follow-up was 7 to 20 months for 124 eyes and 2 to 6 months for 76 eyes. The surgical technique consisted of stripping Descemet's membrane and endothelium from the recipient's central cornea and transplanting an 8.0 to 9.0 mm disc of donor endothelium and posterior stroma through a 5.0 mm incision, with sutures used only to close the incision. RESULTS: The most frequent challenge was inadequate donor attachment. Using techniques to remove fluid from the donor-recipient graft interface, the donor detachment rate in the last 64 cases was 6%, with half attributable to patient eye rubbing. Detached grafts were reattached by injecting an air bubble to press the donor against the recipient cornea. There were 7 primary graft failures, with only I occurring in the second 100 cases, which primarily used microkeratome-dissected donor tissue. Other complications were infrequent and included pupillary block glaucoma (1), aqueous misdirection syndrome (1), and cataract development in 2 of 27 phakic eyes. The DSEK procedure was performed safely before and after laser in situ keratomileusis (1 each). CONCLUSIONS: Early outcomes in the initial 200 consecutive DSEK procedures suggest the technique provides significant advantages over penetrating keratoplasty, including more rapid healing, more predictable refractive outcomes, and better retention of corneal strength and integrity. Although donor adherence was more challenging, DSEK was technically easier and should be less traumatic to anterior chamber structures than earlier posterior grafting techniques. AN - WOS:000236979800015 AU - Price, F. W. AU - Price, M. O. DA - MAR DO - 10.1016/j.jcrs.2005.12.078 IS - 3 PY - 2006 SN - 0886-3350 SP - 411-418 ST - Descemet's stripping with endothelial keratoplasty in 200 eyes - Early challenges and techniques to enhance donor adherence T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Descemet's stripping with endothelial keratoplasty in 200 eyes - Early challenges and techniques to enhance donor adherence VL - 32 ID - 6298 ER - TY - JOUR AB - Purpose: To describe early challenges and techniques to promote donor tissue adherence in Descemet's stripping with endothelial keratoplasty (DSEK). Setting: Price Vision Group, Indianapolis, Indiana, USA. Methods: The first 200 consecutive cases of DSEK performed by a single surgeon were analyzed retrospectively. Follow-up was 7 to 20 months for 124 eyes and 2 to 6 months for 76 eyes. The surgical technique consisted of stripping Descemet's membrane and endothelium from the recipient's central cornea and transplanting an 8.0 to 9.0 mm disc of donor endothelium and posterior stroma through a 5.0 mm incision, with sutures used only to close the incision. Results: The most frequent challenge was inadequate donor attachment. Using techniques to remove fluid from the donor-recipient graft interface, the donor detachment rate in the last 64 cases was 6%, with half attributable to patient eye rubbing. Detached grafts were reattached by injecting an air bubble to press the donor against the recipient cornea. There were 7 primary graft failures, with only 1 occurring in the second 100 cases, which primarily used microkeratome-dissected donor tissue. Other complications were infrequent and included pupillary block glaucoma (1), aqueous misdirection syndrome (1), and cataract development in 2 of 27 phakic eyes. The DSEK procedure was performed safely before and after laser in situ keratomileusis (1 each). Conclusions: Early outcomes in the initial 200 consecutive DSEK procedures suggest the technique provides significant advantages over penetrating keratoplasty, including more rapid healing, more predictable refractive outcomes, and better retention of corneal strength and integrity. Although donor adherence was more challenging, DSEK was technically easier and should be less traumatic to anterior chamber structures than earlier posterior grafting techniques. © 2006 ASCRS and ESCRS. AD - Price Vision Group (F.W. Price), the Cornea Research Foundation of America (M.O. Price), Indianapolis, IN, United States AU - Price Jr, F. W. AU - Price, M. O. DB - Scopus DO - 10.1016/j.jcrs.2005.12.078 IS - 3 M3 - Article N1 - Cited By :556 Export Date: 19 July 2021 PY - 2006 SP - 411-418 ST - Descemet's stripping with endothelial keratoplasty in 200 eyes. Early challenges and techniques to enhance donor adherence T2 - Journal of Cataract and Refractive Surgery TI - Descemet's stripping with endothelial keratoplasty in 200 eyes. Early challenges and techniques to enhance donor adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646036099&doi=10.1016%2fj.jcrs.2005.12.078&partnerID=40&md5=6cd9b4044df62aeb567c64924a4542c4 VL - 32 ID - 4901 ER - TY - JOUR AB - Background: To develop patient-reported outcome instruments, statistical techniques (e.g., principal components analysis; PCA) are used to examine correlations among items and identify interrelated item subsets (empirical factors). However, interpretation and labelling of empirical factors is a subjective process, lacking precision or conceptual basis. We report a novel and reproducible method for mapping between theoretical and empirical factor structures. We illustrate the method using the pilot Aberdeen Glaucoma Questionnaire (AGQ), a new measure of glaucoma-related disability developed using the International Classification of Functioning and Disability (ICF) as a theoretical framework and tested in a sample representing the spectrum of glaucoma severity.Methods: We used the ICF to code AGQ item content before mailing the AGQ to a UK sample (N = 1349) selected to represent people with a risk factor for glaucoma and people with glaucoma across a range of severity. Reflecting uncertainty in the theoretical framework (items with multiple ICF codes), an exploratory PCA was conducted. The theoretical structure informed our interpretation of the empirical structure and guided the selection of theoretically-derived factor labels. We also explored the discrimination of the AGQ across glaucoma severity groups.Results: 656 (49%) completed questionnaires were returned. The data yielded a 7-factor solution with a simple structure (using cut-off point of a loading of 0.5) that together accounted for 63% of variance in the scores. The mapping process resulted in allocation of the following theoretically-derived factor labels: 1) Seeing Functions: Participation; 2) Moving Around & Communication; 3) Emotional Functions; 4) Walking Around Obstacles; 5) Light; 6) Seeing Functions: Domestic & Social Life; 7) Mobility. Using the seven factor scores as independent variables in a discriminant function analysis, the AGQ scores resulted in correct glaucoma severity grading of 32.5% of participants (p < 0.001).Conclusions: This paper addresses a methodological gap in the application of classical test theory (CTT) techniques, such as PCA, in instrument development. Labels for empirically-derived factors are often selected intuitively whereas they can inform existing bodies of knowledge if selected on the basis of theoretical construct labels, which are more explicitly defined and which relate to each other in ways that are evidence based. AD - Health Services Research Unit, University of Aberdeen, Aberdeen, UK. m.e.prior@abdn.ac.uk. AN - 104120824. Language: English. Entry Date: 20150220. Revision Date: 20210716. Publication Type: journal article AU - Prior, Maria AU - Ramsay, Craig R. AU - Burr, Jennifer M. AU - Campbell, Susan E. AU - Jenkinson, David J. AU - Asoaka, Ryo AU - Francis, Jillian J. DB - ccm DO - 10.1186/1471-2415-13-72 DP - EBSCOhost IS - 1 KW - Disability Evaluation Glaucoma -- Diagnosis Questionnaires Self Report -- Standards Aged Cross Sectional Studies Empirical Research Female Health Status Human Male Middle Age Pilot Studies Factor Analysis Reproducibility of Results Severity of Illness Indices N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: 04/08/02/DH_/Department of Health/United Kingdom. NLM UID: 100967802. PMID: NLM24268026. PY - 2013 SN - 1471-2415 SP - 72-72 ST - Theoretical and empirical dimensions of the Aberdeen Glaucoma Questionnaire: a cross sectional survey and principal component analysis T2 - BMC Ophthalmology TI - Theoretical and empirical dimensions of the Aberdeen Glaucoma Questionnaire: a cross sectional survey and principal component analysis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104120824&site=ehost-live&scope=site VL - 13 ID - 4668 ER - TY - JOUR AB - Introduction Fusarium keratitis is a severe corneal infection that is usually seen in tropical and subtropical countries after a corneal trauma. In 2005-2006, an epidemic of Fusarium keratitis, occurring predominantly among contact lens wearers, was observed in several countries. Case report We describe the clinical course of a Fusarium keratitis which failed to respond to systemic and local voriconazole treatment, and experienced a progression to a severe keratitis with endophthalmitis, requiring early therapeutic keratoplasty ("à chaud"). After 8 months of follow up, the vision recovered to 20/50. Discussion After the 2005-2006 worldwide epidemics, case-control studies pointed out that a new lens care solution, ReNu with MoistureLoc ® (Bausch & Lomb™), was likely responsible of numerous cases. Complementary studies underlined that this infection mostly concerned non-compliant patients, i.e., those reusing the solution several times, since this results in a decrease of the antifungal activity due to the uptake of the biguanides into the lens. Conclusion Fusarium endophtalmitis can result in a devastating disease with a poor visual outcome. An initial antifungal dual therapy may control the infection. In case of failure, an early keratoplasty may be mandatory. For contact lens wearers, education on sanitary good practice is necessary to avoid new epidemics in the future. © 2009 Springer Science+Business Media B.V. AD - Department of Ophthalmology, Bicêtre University Hospital, University Paris XI, Le Kremlin Bicêtre, Paris, France Ophthalmology Department, Strasbourg University Hospital, Strasbourg, France Department of Pathology, Bicêtre University Hospital, University Paris XI, Le Kremlin Bicêtre, Paris, France CHU de Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre Cedex, Paris 94275, France AU - Proença-Pina, J. AU - Ssi Yan Kai, I. AU - Bourcier, T. AU - Fabre, M. AU - Offret, H. AU - Labetoulle, M. DB - Scopus DO - 10.1007/s10792-008-9290-7 IS - 1 KW - Amphotericin B Endophthalmitis Fusarium solani Multipurpose lens care solution ReNu with MoistureLoc® Voriconazole M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2010 SP - 103-107 ST - Fusarium keratitis and endophthalmitis associated with lens contact wear T2 - International Ophthalmology TI - Fusarium keratitis and endophthalmitis associated with lens contact wear UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-76449114990&doi=10.1007%2fs10792-008-9290-7&partnerID=40&md5=b53c4df885c1e177c570bb0f474deef3 VL - 30 ID - 5112 ER - TY - JOUR AB - Background and Objective: Patients affected by glaucoma refractory to medical or surgical treatment are difficult to treat. The aim of this study was to evaluate the long-term effect of contact transscleral diode laser cyclophotocoagulation (DLPC) on intraocular pressure (IOP) and on visual acuity of these patients. Patients and Methods: One hundred and twenty eyes of 107 patients suffering from refractory glaucoma and treated with DLPC were followed at the Eye Clinic of Verona University for an average of 26 ± 8 months. Mean age was 57 ± 26 years. IOP, visual acuity, and ocular complications were analyzed. Results: A total of 207 treatments were given. More than one treatment was given in 55 eyes (45.8%). Mean pretreatment IOP was 30.4 ± 3.1 mm Hg. At the last follow-up, mean IOP was 20.3 ± 1.8 mm Hg. Mean total medications were reduced from 4.5 ± 0.5 to 2.3 ± 0.3. No serious complications occurred in the 207 treatments. Visual acuity remained stable in 66 eyes (55%),improved in 25 eyes (20.8%), and decreased in 29 eyes (24.2%). Conclusions: DLPC was effective in lowering IOP in eyes with refractory glaucoma. It also served to reduce the number of antiglaucoma medications, thus improving both the quality of life of the patients and their compliance to therapy. This procedure is relatively safe, very fast and easy to learn. However, careful attention is required to determine the exact position of the ciliary body in malformative glaucoma. Multiple treatments may be required to control IOP. Copyright © 2003 S. Karger AG, Basel. AD - Department of Ophthalmology, Verona Hospital, Verona, Italy Eye Clinic, University of Verona, Verona, Italy Clinica Oculistica, O.C. Borgo Trento, Piazzale Stefani 1, I-37126 Verona, Italy AU - Pucci, V. AU - Tappainer, F. AU - Borin, S. AU - Bellucci, R. DB - Scopus DO - 10.1159/000070635 IS - 4 KW - Diode laser cyclophotocoagulation Long-term follow-up Refractory glaucoma M3 - Article N1 - Cited By :34 Export Date: 19 July 2021 PY - 2003 SP - 279-283 ST - Long-term follow-up after transscleral diode laser photocoagulation in refractory glaucoma T2 - Ophthalmologica TI - Long-term follow-up after transscleral diode laser photocoagulation in refractory glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037603519&doi=10.1159%2f000070635&partnerID=40&md5=23d1e4e528fb9d318f9e75893315350f VL - 217 ID - 5041 ER - TY - JOUR AB - Background and Objective: Patients affected by glaucoma refractory to medical or surgical treatment are difficult to treat. The aim of this study was to evaluate the long-term effect of contact transscleral diode laser cyclo-photocoagulation (DLPC) on intraocular pressure (IOP) and on visual acuity of these patients. Patients and Methods: One hundred and twenty eyes of 107 patients suffering from refractory glaucoma and treated with DLPC were followed at the Eye Clinic of Verona University for an average of 26 8 months. Mean age was 57 26 years. IOP, visual acuity, and ocular complications were analyzed. Results: A total of 207 treatments were given. More than one treatment was given in 55 eyes (45.8%). Mean pretreatment IOP was 30.4 +/- 3.1 mm Hg. At the last follow-up, mean IOP was 20.3 +/- 1.8 mm Hg. Mean total medications were reduced from 4.5 +/- 0.5 to 2.3 +/- 0.3. No serious complications occurred in the 207 treatments. Visual acuity remained stable in 66 eyes (55%), improved in 25 eyes (20.8%), and decreased in 29 eyes (24.2%). Conclusions: DLPC was effective in lowering IOP in eyes with refractory glaucoma. It also served to reduce the number of antiglaucoma medications, thus improving both the quality of life of the patients and their compliance to therapy. This procedure is relatively safe, very fast and easy to learn. However, careful attention is required to determine the exact position of the ciliary body in malformative glaucoma. Multiple treatments may be required to control IOP. Copyright (C) 2003 S. Karger AG, Basel. AN - WOS:000183889300005 AU - Pucci, V. AU - Tappainer, F. AU - Borin, S. AU - Bellucci, R. DA - JUL-AUG DO - 10.1159/000070635 IS - 4 PY - 2003 SN - 0030-3755 1423-0267 SP - 279-283 ST - Long-term follow-up after transscleral diode laser photocoagulation in refractory glaucoma T2 - OPHTHALMOLOGICA TI - Long-term follow-up after transscleral diode laser photocoagulation in refractory glaucoma VL - 217 ID - 6036 ER - TY - JOUR AB - The ultimate goal of glaucoma management is the preservation of patients' visual function and quality of life (QoL). The disease itself as well as the medical or surgical treatment can have an enormous impact on a patient's QoL. Even the mere diagnosis of a chronic, irreversible, potentially blinding disorder can adversely affect the patient's sense of well-being and QoL by eliciting significant anxiety. Patients with primary open-angle glaucoma rarely present with visual symptoms, at least early in the course of the disease. A better understanding of patient-reported QoL can improve patient-physician interaction and enhance treatment adherence by customizing treatment options based on individual patient profile, thus optimizing long-term prognosis. These aspects are summarized and critically appraised in this article. AD - Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia Italy IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan Italy IRCCS-Fondazione G.B. Bietti, Rome Italy 1st and 3rd University Departments of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki Greece 1st and 3rd University Departments of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy AN - 116397319. Language: English. Entry Date: 20170831. Revision Date: 20180825. Publication Type: journal article AU - Quaranta, Luciano AU - Riva, Ivano AU - Gerardi, Chiara AU - Oddone, Francesco AU - Floriano, Irene AU - Konstas, Anastasios AU - Konstas, Anastasios G. P. AU - Floriani, Irene DB - ccm DO - 10.1007/s12325-016-0333-6 DP - EBSCOhost IS - 6 KW - Patient Care Plans Glaucoma -- Diagnosis Glaucoma -- Therapy Glaucoma -- Psychosocial Factors Quality of Life Perimetry Prognosis Disease Management N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Disease Activity Score (DAS). NLM UID: 8611864. PMID: NLM27138604. PY - 2016 SN - 0741-238X SP - 959-981 ST - Quality of Life in Glaucoma: A Review of the Literature T2 - Advances in Therapy TI - Quality of Life in Glaucoma: A Review of the Literature UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116397319&site=ehost-live&scope=site VL - 33 ID - 4521 ER - TY - JOUR AB - The ultimate goal of glaucoma management is the preservation of patients’ visual function and quality of life (QoL). The disease itself as well as the medical or surgical treatment can have an enormous impact on a patient’s QoL. Even the mere diagnosis of a chronic, irreversible, potentially blinding disorder can adversely affect the patient’s sense of well-being and QoL by eliciting significant anxiety. Patients with primary open-angle glaucoma rarely present with visual symptoms, at least early in the course of the disease. A better understanding of patient-reported QoL can improve patient–physician interaction and enhance treatment adherence by customizing treatment options based on individual patient profile, thus optimizing long-term prognosis. These aspects are summarized and critically appraised in this article. AD - L. Quaranta, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy AU - Quaranta, L. AU - Riva, I. AU - Gerardi, C. AU - Oddone, F. AU - Floriano, I. AU - Konstas, A. G. P. DB - Embase Medline DO - 10.1007/s12325-016-0333-6 IS - 6 KW - antiglaucoma agent anxiety disorder binocular visual field loss daily life activity doctor patient relationship glaucoma human intraocular hypertension mental health monocular visual field loss ocular surface disease open angle glaucoma patient compliance patient satisfaction quality of life questionnaire review Short Form 36 social interaction systematic review visual impairment LA - English M3 - Review N1 - L610259646 2016-05-12 2019-05-24 PY - 2016 SN - 1865-8652 0741-238X SP - 959-981 ST - Quality of Life in Glaucoma: A Review of the Literature T2 - Advances in Therapy TI - Quality of Life in Glaucoma: A Review of the Literature UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610259646&from=export http://dx.doi.org/10.1007/s12325-016-0333-6 VL - 33 ID - 2736 ER - TY - JOUR AB - Purpose: To evaluate the accuracy of the intraocular pressure (IOP) measured by healthy subjects with icare® Home and to observe the IOP fluctuation and pattern of IOP fluctuation in healthy subjects over three consecutive days. Methods: Sixty healthy subjects were recruited to the study. IOP was measured by the subjects themselves and by study staff using icare® Home tonometers on visits 1 and 2, as well as by study staff using Goldmann applanation tonometry (GAT). Furthermore, the subjects measured their IOP at home for three consecutive days. Results: Twenty-three per cent of the study eyes were excluded in the statistical analysis due to dropout or non-compliance to the schedule. Approximately 70% of the icare® Home measurements were within 3 mmHg of the GAT measurements. Ten to 16% of the study eyes had IOP peaks outside office hours. Sixty-three per cent of the study eyes had different IOP patterns on consecutive days. Conclusion: Rebound self-tonometry appears to be accurate and could be used to monitor short- and long-term IOP variations. The difference between IOP patterns on consecutive days raises questions as to the certainty of a single IOP measurement as a measure of treatment effect. © 2017 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd AD - Department of Clinical Neurosciences, Department of Anterior Segment Disorders, Glaucoma, Neuro-Ophthalmology and Oculoplastics (Clinic 1), St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden AU - Quérat, L. AU - Chen, E. DB - Scopus DO - 10.1111/aos.13389 IS - 5 KW - healthy subjects iCare® Home IOP fluctuations pattern of IOP fluctuations rebound self-tonometry M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2017 SP - 525-529 ST - Monitoring daily intraocular pressure fluctuations with self-tonometry in healthy subjects T2 - Acta Ophthalmologica TI - Monitoring daily intraocular pressure fluctuations with self-tonometry in healthy subjects UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015346839&doi=10.1111%2faos.13389&partnerID=40&md5=f7753fc85a1c115bef3779ce3fe251e3 VL - 95 ID - 5226 ER - TY - JOUR AB - PurposeTo evaluate the accuracy of the intraocular pressure (IOP) measured by healthy subjects with icare((R)) Home and to observe the IOP fluctuation and pattern of IOP fluctuation in healthy subjects over three consecutive days. MethodsSixty healthy subjects were recruited to the study. IOP was measured by the subjects themselves and by study staff using icare((R)) Home tonometers on visits 1 and 2, as well as by study staff using Goldmann applanation tonometry (GAT). Furthermore, the subjects measured their IOP at home for three consecutive days. ResultsTwenty-three per cent of the study eyes were excluded in the statistical analysis due to dropout or non-compliance to the schedule. Approximately 70% of the icare((R)) Home measurements were within 3mmHg of the GAT measurements. Ten to 16% of the study eyes had IOP peaks outside office hours. Sixty-three per cent of the study eyes had different IOP patterns on consecutive days. ConclusionRebound self-tonometry appears to be accurate and could be used to monitor short- and long-term IOP variations. The difference between IOP patterns on consecutive days raises questions as to the certainty of a single IOP measurement as a measure of treatment effect. AN - WOS:000405388500031 AU - Querat, L. AU - Chen, E. DA - AUG DO - 10.1111/aos.13389 IS - 5 PY - 2017 SN - 1755-375X 1755-3768 SP - 525-529 ST - Monitoring daily intraocular pressure fluctuations with self-tonometry in healthy subjects T2 - ACTA OPHTHALMOLOGICA TI - Monitoring daily intraocular pressure fluctuations with self-tonometry in healthy subjects VL - 95 ID - 6307 ER - TY - JOUR AD - H.A. Quigley AU - Quigley, H. A. DB - Medline IS - 3 KW - acetazolamide epinephrine pilocarpine timolol article cataract cost drug effect drug therapy endophthalmitis glaucoma human middle aged patient compliance postoperative complication tachyphylaxis time trabecular meshwork visual acuity LA - English M3 - Article N1 - L14804644 1984-11-02 PY - 1984 SN - 0020-8167 SP - 1-11 ST - A reevaluation of glaucoma management T2 - International ophthalmology clinics TI - A reevaluation of glaucoma management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L14804644&from=export VL - 24 ID - 4079 ER - TY - JOUR AD - H. A. Quigley, Glaucoma Services, Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, MD AU - Quigley, H. A. DB - Embase Medline DO - 10.1097/OPX.0b013e318177ec17 IS - 6 KW - eye drops article cognition comorbidity drug use drug withdrawal educational status family relation glaucoma health belief health care access health care cost human intraocular pressure patient compliance priority journal social status treatment withdrawal LA - English M3 - Article N1 - L354894611 2009-08-11 PY - 2008 SN - 1040-5488 SP - 374-375 ST - Improving eye drop treatment for glaucoma through better adherence T2 - Optometry and Vision Science TI - Improving eye drop treatment for glaucoma through better adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354894611&from=export http://dx.doi.org/10.1097/OPX.0b013e318177ec17 VL - 85 ID - 3450 ER - TY - JOUR AD - Glaucoma Services, Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. AN - 105815426. Language: English. Entry Date: 20080912. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Quigley, H. A. DB - ccm DP - EBSCOhost IS - 6 KW - Glaucoma -- Drug Therapy Ophthalmic Solutions -- Therapeutic Use Patient Compliance Blindness -- Prevention and Control Glaucoma -- Psychosocial Factors Patient Dropouts N1 - Peer Reviewed; USA. NLM UID: 8904931. PMID: NLM18521018. PY - 2008 SN - 1040-5488 SP - 374-375 ST - Improving Eye Drop Treatment for Glaucoma through Better Adherence T2 - Optometry & Vision Science TI - Improving Eye Drop Treatment for Glaucoma through Better Adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105815426&site=ehost-live&scope=site VL - 85 ID - 4703 ER - TY - JOUR AN - 109702815. Language: English. Entry Date: 20150923. Revision Date: 20200708. Publication Type: journal article AU - Quigley, Harry A. DB - ccm DO - 10.1007/s12160-014-9644-5 DP - EBSCOhost IS - 1 N1 - commentary. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Psychiatry/Psychology. Grant Information: P30 EY001765/EY/NEI NIH HHS/United States. NLM UID: 8510246. PMID: NLM25212508. PY - 2015 SN - 0883-6612 SP - 5-6 ST - Reminder systems, not education, improve glaucoma adherence: a comment on Cook et al T2 - Annals of Behavioral Medicine TI - Reminder systems, not education, improve glaucoma adherence: a comment on Cook et al UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109702815&site=ehost-live&scope=site VL - 49 ID - 4560 ER - TY - JOUR AB - Comments on an article by P. F. Cook et al. (see record [rid]2015-08126-006[/rid]). Cook et al. plan a controlled interventional trial to improve adherence, for which the present report is the baseline data prior to randomization. Cook et al. data show a similar rate. Self-reported adherence is dramatically higher than either device-measured or pharmacy data and indicates that patients are unaware of how poor their adherence is. Cook et al. base some of their conclusions on a substantial number of patients monitored with MEMS cap, which is much more useful than basing models of adherence behavior on self-report, which dramatically overestimates true adherence. They found that 35 % of variance in MEMS cap measurements of adherence was predicted by defined responses in areas of self-efficacy and motivation, along with dose frequency and race/ethnicity. Unfortunately, most of the variability in adherence remained unexplained. The authors report that those who were prescribed more complicated eyedrop regimens were more adherent, a finding that contradicts past publications. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Quigley, Harry A., Glaucoma Center of Excellence, Wilmer Institute, Johns Hopkins School of Medicine, Baltimore, MD, US AN - 2015-08126-003 AU - Quigley, Harry A. DB - psyh DO - 10.1007/s12160-014-9644-5 DP - EBSCOhost IS - 1 KW - Attitude Glaucoma Medication adherence Motivation Theory Female Health Behavior Health Knowledge, Attitudes, Practice Humans Male Treatment Compliance Attitudes Theories N1 - Glaucoma Center of Excellence, Wilmer Institute, Johns Hopkins School of Medicine, Baltimore, MD, US. Other Publishers: Lawrence Erlbaum; Oxford University Press. Release Date: 20150330. Correction Date: 20180503. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Comment/Reply. Language: EnglishMajor Descriptor: Glaucoma; Motivation; Treatment Compliance. Minor Descriptor: Attitudes; Theories. Classification: Vision & Hearing & Sensory Disorders (3299); Medical Treatment of Physical Illness (3363). Population: Human (10). References Available: Y. Page Count: 2. Issue Publication Date: Feb, 2015. Publication History: First Posted Date: Sep 12, 2014. Copyright Statement: The Society of Behavioral Medicine. 2014. PY - 2015 SN - 0883-6612 1532-4796 SP - 5-6 ST - Reminder systems, not education, improve glaucoma adherence: A comment on Cook et al T2 - Annals of Behavioral Medicine TI - Reminder systems, not education, improve glaucoma adherence: A comment on Cook et al UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-08126-003&site=ehost-live&scope=site hquigley@jhmi.edu VL - 49 ID - 4833 ER - TY - JOUR AB - Glaucoma care has evolved dramatically over the past generation, with changes that have incorporated new technology and improved understanding of the disease process. A major need is to construct a useful definition of glaucomatous optic neuropathy that can be used to compare data across clinical research studies. The treatment of glaucoma should now be based on achievement of a goal target for intraocular pressure, unique to each patient. Adherence with eye drop treatment is far from ideal and can be improved using reminder systems. Sustained delivery of glaucoma medication is on the horizon. New surgical approaches to glaucoma are being actively studied but have not as yet found their place in its care, with rigorous testing against present treatments needed. AD - H.A. Quigley, Department of Ophthalmology, Wilmer Institute, Johns Hopkins School of Medicine, Baltimore, MD, United States AU - Quigley, H. A. DB - Embase Medline DO - 10.1038/s41433-018-0227-8 IS - 2 KW - antiglaucoma agent eye drops cell phone use diagnostic accuracy drug delivery system glaucoma glaucoma surgery human intraocular pressure iridotomy nerve injury nonhuman optical coherence tomography patient compliance review tonometry trabeculoplasty visual field visual system examination LA - English M3 - Review N1 - L624322054 2018-10-18 2019-07-25 PY - 2019 SN - 1476-5454 0950-222X SP - 254-260 ST - 21st century glaucoma care T2 - Eye (Basingstoke) TI - 21st century glaucoma care UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624322054&from=export http://dx.doi.org/10.1038/s41433-018-0227-8 VL - 33 ID - 2531 ER - TY - JOUR AB - Objective: To perform a chart review to measure the validity of large claims databases in estimating patient cooperation with eyedrop therapy and to assess physician adherence with guidelines for a preferred practice pattern (PPP) using a new metric. Design: Claims database analysis, chart review, and telephone survey. Participants: From 10 260 persons who were recently prescribed a prostaglandin eyedrop for open-angle glaucoma (OAG), a sample of 300 charts (3650 visits) was selected for detailed abstraction. Methods: Database review of pharmacy refill, diagnostic testing, and visit information, with chart review of a sample of patients from the database and interviews with an overlapping sample of patients and physicians. Main Outcome Measures: The individual patient medication possession ratio (MPR), an index estimating the proportion of time that patients have prescribed drug available for use, frequency of examination findings present in charts, and associations between MPR and physician adherence to a PPP. Results: Chart data confirm that the claims database accurately identified the specific glaucoma eyedrop prescribed, but often identified long-term OAG patients as being new to treatment. Physicians frequently used billing codes for OAG in patients with normal visual field tests. Physicians varied dramatically in their adherence to the PPP, performing intraocular pressure measurements, disc evaluations and imaging, and visual field tests on 90% of OAG patients, but carrying out gonioscopy, central corneal thickness measurement, and setting of target intraocular pressure (IOP) on half of patients. Conclusions: Large claims databases permit conclusions regarding patient cooperation with glaucoma eyedrop therapy, but they should be used cautiously in imputing severity of disease and prior treatment history. Physician adherence to practice guidelines varied substantially; thus, scoring systems for physician behavior have promise in measuring outcome improvements related to better care. © 2007 American Academy of Ophthalmology. AD - Glaucoma Service, Dana Center for Preventive Ophthalmology, Wilmer Ophthalmological Institute, Baltimore, MD, United States Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Albert Einstein College of Medicine, Bronx, NY, United States AU - Quigley, H. A. AU - Friedman, D. S. AU - Hahn, S. R. DB - Scopus DO - 10.1016/j.ophtha.2007.03.042 IS - 9 M3 - Article N1 - Cited By :108 Export Date: 19 July 2021 PY - 2007 SP - 1599-1606 ST - Evaluation of Practice Patterns for the Care of Open-angle Glaucoma Compared with Claims Data. The Glaucoma Adherence and Persistency Study T2 - Ophthalmology TI - Evaluation of Practice Patterns for the Care of Open-angle Glaucoma Compared with Claims Data. The Glaucoma Adherence and Persistency Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548276017&doi=10.1016%2fj.ophtha.2007.03.042&partnerID=40&md5=c11cd389e3bac65d09cadcc8b5758fd0 VL - 114 ID - 4926 ER - TY - JOUR AB - Objective: To perform a chart review to measure the validity of large claims databases in estimating patient cooperation with eyedrop therapy and to assess physician adherence with guidelines for a preferred practice pattern (PPP) using a new metric. Design: Claims database analysis, chart review, and telephone survey. Participants: From 10 260 persons who were recently prescribed a prostaglandin eyedrop for open-angle glaucoma (OAG), a sample of 300 charts (3650 visits) was selected for detailed abstraction. Methods: Database review of pharmacy refill, diagnostic testing, and visit information, with chart review of a sample of patients from the database and interviews with an overlapping sample of patients and physicians. Main Outcome Measures: The individual patient medication possession ratio (MPR), an index estimating the proportion of time that patients have prescribed drug available for use, frequency of examination findings present in charts, and associations between MPR and physician adherence to a PPP. Results: Chart data confirm that the claims database accurately identified the specific glaucoma eyedrop prescribed, but often identified long-term OAG patients as being new to treatment. Physicians frequently used billing codes for OAG in patients with normal visual field tests. Physicians varied dramatically in their adherence to the PPP, performing intraocular pressure measurements, disc evaluations and imaging, and visual field tests on 90% of OAG patients, but carrying out gonioscopy, central corneal thickness measurement, and setting of target intraocular pressure (IOP) on half of patients. Conclusions: Large claims databases permit conclusions regarding patient cooperation with glaucoma eyedrop therapy, but they should be used cautiously in imputing severity of disease and prior treatment history. Physician adherence to practice guidelines varied substantially; thus, scoring systems for physician behavior have promise in measuring outcome improvements related to better care. AN - WOS:000249183700003 AU - Quigley, H. A. AU - Friedman, D. S. AU - Hahn, S. R. DA - SEP DO - 10.1016/j.ophtha.2007.03.042 IS - 9 PY - 2007 SN - 0161-6420 1549-4713 SP - 1599-1606 ST - Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data - The glaucoma adherence and persistency study T2 - OPHTHALMOLOGY TI - Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data - The glaucoma adherence and persistency study VL - 114 ID - 6007 ER - TY - JOUR AB - PURPOSE: To describe the results of a community-based eye screening program in Baltimore. DESIGN: Cross-sectional study. METHODS: This was a retrospective study of the results of screening both eyes of 5352 persons who presented at multiple community sites. The screening examination had eight risk factor questions, visual acuity measurement, and a screening field test and was carried out by technicians and lay volunteers. Screened persons (screenees) received a definitive eye examination at no out-of-pocket cost, transportation was offered, and inexpensive eyeglasses were provided if needed. The main outcome measures were the rate of appointment keeping and the eye diseases identified. Telephone interviews were used to assess reasons for missing appointments and satisfaction with visits. RESULTS: Screenees had a median age of 45 years, were 71% black, 59% female, and had estimated median annual family income of $24,000. Among 1331 screenees who scheduled a definitive examination appointment, 552 (41%) completed the visit. Data on definitive diagnosis was available in 480 out of 552 persons (87%). Reasons given for failing to come for definitive examination were: no appointment given (26%), forgot (20%), lack of transportation (9%), and lack of insurance coverage (6%). Of those who accepted a second visit date after defaulting, only 25% (41/167) appeared. Of 17 persons identified with glaucoma at screening, 4 had previously been diagnosed, but had ceased active care. CONCLUSION: After community screening for eye disease, efforts to provide definitive ophthalmic examination were only modestly effective. Failure of screenees to come for examination and loss to follow up were identified as serious problems. © 2002 by Elsevier Science Inc. All rights reserved. AD - H.A. Quigley, Wilmer 122, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287, United States AU - Quigley, H. A. AU - Park, C. K. AU - Tracey, P. A. AU - Pollack, I. P. DB - Embase Medline DO - 10.1016/S0002-9394(01)01380-0 IS - 3 KW - adult article community care controlled study cost eye disease female follow up glaucoma health care need health care personnel health insurance human interview major clinical study male mass screening outcomes research patient compliance patient transport priority journal risk factor spectacles telephone visual acuity volunteer LA - English M3 - Article N1 - L34171589 2002-03-09 PY - 2002 SN - 0002-9394 SP - 386-392 ST - Community screening for eye disease by laypersons: The Hoffberger program T2 - American Journal of Ophthalmology TI - Community screening for eye disease by laypersons: The Hoffberger program UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34171589&from=export http://dx.doi.org/10.1016/S0002-9394(01)01380-0 VL - 133 ID - 3874 ER - TY - JOUR AB - PURPOSE: To describe the results of a community-based eye screening program in Baltimore. DESIGN: Cross-sectional study. METHODS: This was a retrospective study of the results of screening both eyes of 5352 persons who presented at multiple community sites. The screening examination had eight risk factor questions, visual acuity measurement, and a screening field test and was carried out by technicians and lay volunteers. Screened persons (screenees) received a definitive eye examination at no out-of-pocket cost, transportation was offered, and inexpensive eyeglasses were provided if needed. The main outcome measures were the rate of appointment keeping and the eye diseases identified. Telephone interviews were used to assess reasons for missing appointments and satisfaction with visits. RESULTS: Screenees had a median age of 45 years, were 71% black, 59% female, and had estimated median annual family income of $24,000. Among 1331 screenees who scheduled a definitive examination appointment, 552 (41%) completed the visit. Data on definitive diagnosis was available in 480 out of 552 persons (87%). Reasons given for failing to come for definitive examination were: no appointment given (26%), forgot (20%), lack of transportation (9%), and lack of insurance coverage (6%). Of those who accepted a second visit date after defaulting, only 25% (41/167) appeared. Of 17 persons identified with glaucoma at screening, 4 had previously been diagnosed, but had ceased active care. CONCLUSION: After community screening for eye disease, efforts to provide definitive ophthalmic examination were only modestly effective. Failure of screenees to come for examination and loss to follow up were identified as serious problems. © 2002 by Elsevier Science Inc. All rights reserved. AD - Glaucoma Service, Dana Center for Preventive Ophthalmology, Baltimore, MD, United States Departments of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States Sinai Hospital of Baltimore, Baltimore, MD, United States Wilmer 122, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287, United States AU - Quigley, H. A. AU - Park, C. K. AU - Tracey, P. A. AU - Pollack, I. P. DB - Scopus DO - 10.1016/S0002-9394(01)01380-0 IS - 3 M3 - Article N1 - Cited By :76 Export Date: 19 July 2021 PY - 2002 SP - 386-392 ST - Community screening for eye disease by laypersons: The Hoffberger program T2 - American Journal of Ophthalmology TI - Community screening for eye disease by laypersons: The Hoffberger program UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036181055&doi=10.1016%2fS0002-9394%2801%2901380-0&partnerID=40&md5=7f0dd94e9e4389f9d4f907354850e9e6 VL - 133 ID - 4950 ER - TY - JOUR AB - Purpose: To describe the results of a community, based eye screening program in Baltimore. Design: Cross-sectional study. Methods: This was a retrospective study of the results of screening both eyes of 5352 persons who presented at multiple community sites. The screening examination had eight risk factor questions, visual acuity measurement, and a screening field test and was carried out by technicians and lay volunteers. Screened persons (screenees) received a definitive eye examination at no out,of,pocket cost, transportation was offered, and inexpensive eyeglasses were provided if needed. The main outcome measures were the rate of appointment keeping and the eye diseases identified. Telephone interviews were used to assess reasons for missing appointments and satisfaction with visits. Results: Screenees had a median age of 45 years, were 71% black, 59% female, and had estimated median annual family income of $24,000. Among 1331 screenees who scheduled a definitive examination appointment, 552 (41%) completed the visit. Data on definitive diagnosis was available in 480 out of 552 persons (87%). Reasons given for failing to come for definitive examination were: no appointment given (26%), forgot (20%), lack of transportation (9%), and lack of insurance coverage (6%). Of those who accepted a second visit date after defaulting, only 25% (41/167) appeared. Of 17 persons identified with glaucoma at screening, 4 had previously been diagnosed, but had ceased active care. Conclusion: After community screening for eye disease, efforts to provide definitive ophthalmic examination were only modestly effective. Failure of screenees to come for examination and loss to follow up were identified as serious problems. (Am J Ophtlialmol 2002; 133: 386-392. (C) 2002 by Elsevier Science Inc. All rights reserved.). AN - WOS:000174268600012 AU - Quigley, H. A. AU - Park, C. K. AU - Tracey, P. A. AU - Pollack, I. P. DA - MAR DO - 10.1016/S0002-9394(01)01380-0 IS - 3 PY - 2002 SN - 0002-9394 SP - 386-392 ST - Community screening for eye disease by laypersons: The Hoffberger program T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Community screening for eye disease by laypersons: The Hoffberger program VL - 133 ID - 5889 ER - TY - JOUR AB - Purpose Of Review: To discuss issues that affect development of new glaucoma treatments known as neuroprotection.Recent Findings: There are barriers to neuroprotection trials for glaucoma.Summary: With design features discussed in the review, neuroprotection trials can be effectively carried out. AD - Glaucoma Services and Dana Center for Preventive Ophthalmology, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Glaucoma Services and Dana Center for Preventive Ophthalmology, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. AN - 108161227. Language: English. Entry Date: 20120323. Revision Date: 20190313. Publication Type: journal article AU - Quigley, H. A. AU - Quigley, Harry A. DB - ccm DO - 10.1097/ICU.0b013e32834ff490 DP - EBSCOhost IS - 2 KW - Glaucoma -- Therapy Neuroprotective Agents Clinical Trials -- Evaluation Glaucoma -- Diagnosis Glaucoma -- Physiopathology Ophthalmology Outcomes (Health Care) Retina -- Anatomy and Histology Visual Fields -- Evaluation N1 - review; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: P30 EY001765/EY/NEI NIH HHS/United States. NLM UID: 9011108. PMID: NLM22249238. PY - 2012 SN - 1040-8738 SP - 144-154 ST - Clinical trials for glaucoma neuroprotection are not impossible T2 - Current Opinion in Ophthalmology TI - Clinical trials for glaucoma neuroprotection are not impossible UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108161227&site=ehost-live&scope=site VL - 23 ID - 4667 ER - TY - JOUR AB - The authors reflect on the prevalence of primary open-angle glaucoma (POAG) among people of African descent compared with people of European descent. They state that POAG could result in irreversible blindness which appears 10 years earlier in people of African descent. They relate that health disparities was defined by the U.S. National Institutes of Health (NIH) as the difference in the incidence, prevalence, mortality, and burden of diseases among specific population groups in the U.S. AD - Department of Ophthalmology, School of Medicine, Eugene and Marilyn Glick Eye Institute, Indiana University, 1160 W Michigan Street, Indianapolis, IN 46202, USA AN - 86457730. Language: English. Entry Date: 20130405. Revision Date: 20190102. Publication Type: Editorial AU - Racette, Lyne AU - Ozobu Jr, Lawrence DB - ccm DO - 10.1586/eop.13.5 DP - EBSCOhost IS - 2 KW - Glaucoma -- Ethnology Health Status Disparities Black Persons Patient Protection and Affordable Care Act Health Services Accessibility Social Justice N1 - editorial. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Public Health. NLM UID: 101278197. PY - 2013 SN - 1746-9899 SP - 107-109 ST - Racial differences in primary open-angle glaucoma: more than meets the eye T2 - Expert Review of Ophthalmology TI - Racial differences in primary open-angle glaucoma: more than meets the eye UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=86457730&site=ehost-live&scope=site VL - 8 ID - 4496 ER - TY - JOUR AD - Department of Ophthalmology, School of Medicine, Eugene and Marilyn Glick Eye Institute, Indiana University, 1160 W Michigan Street, Indianapolis, IN 46202, USA AN - 104261847. Language: English. Entry Date: 20130405. Revision Date: 20150711. Publication Type: Journal Article AU - Racette, Lyne AU - Ozobu Jr, Lawrence DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma -- Ethnology Health Status Disparities Black Persons Patient Protection and Affordable Care Act Health Services Accessibility Social Justice N1 - editorial. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Public Health. NLM UID: 101278197. PY - 2013 SN - 1746-9899 SP - 107-109 ST - Racial differences in primary open-angle glaucoma: more than meets the eye T2 - Expert Review of Ophthalmology TI - Racial differences in primary open-angle glaucoma: more than meets the eye UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104261847&site=ehost-live&scope=site VL - 8 ID - 4547 ER - TY - JOUR AB - Purpose: To report 2 patients with colonization of therapeutic contact lens with dematiaceous fungi. Methods: Case report. Results: The first patient had a retained soft contact lens on an opaque cornea for 4 years with brownish black multiple colonies on the soft contact lens and culture grew Bipolaris spp. The second patient was on therapeutic contact lens for pseudophakic bullous keratopathy for 4 months and developed a brownish colonization of contact lens with unidentified dematiaceous fungi. Both the patients had conjunctivitis but did not develop fungal keratitis. Conclusion: Judicious use of therapeutic contact lens is required in agrarian countries with adequate emphasis on strict adherence to the standard protocols and frequent replacement of the lens. © 2019 British Contact Lens Association AD - Department of Cornea and Refractive Services, Aravind Eye Hospital 1, Anna Nagar, Madurai, Tamil Nadu 625020, India AU - Radhakrishnan, N. AU - Panigrahi, A. K. AU - Balasubramanium, A. AU - Das, M. AU - Prajna, N. V. DB - Scopus DO - 10.1016/j.clae.2019.04.008 IS - 4 KW - Dematiaceous fungi Retained contact lens Therapeutic contact lens M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2019 SP - 470-472 ST - Colonization of therapeutic contact lens by dematiaceous fungi T2 - Contact Lens and Anterior Eye TI - Colonization of therapeutic contact lens by dematiaceous fungi UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064074973&doi=10.1016%2fj.clae.2019.04.008&partnerID=40&md5=5e365881a535d676f60154e19baddd86 VL - 42 ID - 5552 ER - TY - JOUR AB - Glaucoma drainage devices are commonly used for management of glaucoma in adults and children. With time, the position of the tube can change and cause damage such as corneal scarring, iris or lens contact, and uveitis. Most of these problems can be improved with tube shortening and/or excision of adherent iris or fibrous tissue. We describe a surgical technique that uses a single clear corneal incision to externalize and trim the shunt in pediatric patients. The technique has a short surgical. We review the indications and outcomes for this procedure in 13 eyes of 12 children who required shunt revision. © 2016 American Association for Pediatric Ophthalmology and Strabismus. AD - Department of Ophthalmology, University of Minnesota, Minneapolis, United States Department of Ophthalmology, Mayo Clinic, Rochester, MN, United States Department of Ophthalmology, Bascom Palmer Eye Institute, 900 N.W. 17th Street, Miami, FL 33136, United States AU - Radke, P. M. AU - Bitrian, E. AU - Grajewski, A. L. DB - Scopus DO - 10.1016/j.jaapos.2016.02.007 IS - 3 M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2016 SP - 274-276 ST - Single clear corneal incision for glaucoma drainage device shortening in pediatric glaucoma T2 - Journal of AAPOS TI - Single clear corneal incision for glaucoma drainage device shortening in pediatric glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975463785&doi=10.1016%2fj.jaapos.2016.02.007&partnerID=40&md5=e15673e391a6c92e786d6dbbf25635fb VL - 20 ID - 5566 ER - TY - JOUR AB - Biomechanical properties of the cornea have recently emerged as clinically useful in risk assessment of diagnosing glaucoma and predicting disease progression. Corneal hysteresis (CH) is a dynamic tool, which measures viscoelasticity of the cornea. It represents the overall deformability of the cornea, and reduces significantly with age. Low CH has also been associated with optic nerve damage and progression of visual field loss in glaucoma. The extracellular matrix (ECM) constituents of the cornea, trabecular meshwork (TM), sclera, and lamina cribrosa (LC) are similar, as they are predominantly made of fibrillar collagen. This suggests that biomechanical changes in the cornea may also reflect optic nerve compliance in glaucomatous optic neuropathy, and in the known increase of TM tissue stiffness in glaucoma. Increased collagen cross-linking contributes to tissue stiffening throughout the body, which is observed in normal aging and occurs at an accelerated rate in systemic conditions such as fibrotic and cardiovascular diseases, cancer, and glaucoma. We reviewed 3 ECM cross-linking proteins that may have a potential role in the disease process of increased tissue stiffness in glaucoma, including lysyl oxidase (LOX)/lysyl oxidase-like 1 (LOXL1), tissue transglutaminase (TG2), and advanced glycation end products. We also report elevated messenger RNA (mRNA) levels of LOX and TG2 in glaucoma LC cells to support our proposed theory that increased levels of cross-linking proteins in glaucoma play a role in LC tissue stiffness. We highlight areas of research that are needed to better understand the role of cross-linking in glaucoma pathogenesis, leading potentially to a novel therapeutic strategy. AD - UCD Department of Ophthalmology, Mater Misericordiae University Hospital, Dublin, Ireland. UCD Clinical Research, Catherine Mcauley Centre, Dublin, Ireland. AN - 146316747. Language: English. Entry Date: In Process. Revision Date: 20201114. Publication Type: journal article. Journal Subset: Biomedical AU - Rahman, Najiha AU - O'Neill, Evelyn AU - Irnaten, Mustapha AU - Wallace, Deborah AU - O'Brien, Colm DB - ccm DO - 10.1089/jop.2019.0118 DP - EBSCOhost IS - 8 N1 - Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM32667842. PY - 2020 SN - 1080-7683 SP - 582-594 ST - Corneal Stiffness and Collagen Cross-Linking Proteins in Glaucoma: Potential for Novel Therapeutic Strategy T2 - Journal of Ocular Pharmacology & Therapeutics TI - Corneal Stiffness and Collagen Cross-Linking Proteins in Glaucoma: Potential for Novel Therapeutic Strategy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=146316747&site=ehost-live&scope=site VL - 36 ID - 4165 ER - TY - JOUR AB - Purpose: To determine what metrics might impact satisfaction survey responses. Methods: A 37-question survey was administered to 249 participants. Responses were correlated to demographics, clinical factors, weather conditions, and examination timing. Results: Sample consists of 55.4% female and 73.9% white, and mean age was 65.1 years. Participants were assigned to: completely satisfied (77.9%) or not completely satisfied (22.1%) groups based on their rating of glaucoma specialist on a scale of 1-10, while 10 considered "completely satisfied" and less than 10 "not completely satisfied." Complete satisfaction was associated with ability to schedule appointments early, phone calls answered/returned same day, shorter perceived wait time, and better communication skills of ophthalmologist (p < 0.05). Completely satisfied participants reported their ophthalmologist spent enough time with them, listened carefully, and communicated in an understandable way (p < 0.05). Conclusions: The majority of factors found to be associated with patient satisfaction were related to characteristics of the ophthalmologists and their office. AN - WOS:000444817100004 AU - Rahmatnejad, K. AU - Myers, J. S. AU - Falls, M. E. AU - Myers, S. R. AU - Waisbourd, M. AU - Hark, L. A. DO - 10.1080/08820538.2018.1427768 IS - 6 PY - 2018 SN - 0882-0538 1744-5205 SP - 757-765 ST - Factors Associated with Patient Satisfaction in an Outpatient Glaucoma Population T2 - SEMINARS IN OPHTHALMOLOGY TI - Factors Associated with Patient Satisfaction in an Outpatient Glaucoma Population VL - 33 ID - 6254 ER - TY - JOUR AB - Purpose: To review the management of keratitis after corneal bee stings and to report a case of deep stromal corneal infiltrate secondary to a retained bee stinger managed conservatively in a patient who presented three days after unsanitary manipulation of the stinger apparatus.Methods: Case report and review of literature.Results: A 57-year-old male beekeeper was evaluated for pain, blurry vision, and photosensitivity after a corneal bee sting. Of note, the venom sac had been removed with dirty tweezers three days prior to his visit. On exam, a focal infiltrate with diffuse edema was seen surrounding a retained bee stinger in the peripheral cornea. Trace cells in the anterior chamber were also noted. Based on a high suspicion for infectious keratitis, a conservative treatment strategy was elected. Administration of broad-spectrum topical antibiotics with concomitant abstention of corticosteroids led to rapid resolution of the symptoms. Over 16 months of follow-up, the stinger has remained in situ without migration and the patient has maintained 20/20 visual acuity without complications. There is debate on the preferred method for the management of corneal injury secondary to bee stings, especially when it is associated with a retained stinger. We herein present our findings in our appraisal of reported cases.Conclusion: In the aftermath of an ocular bee sting, close surveillance for inflammation and infection is essential. Individual manifestations of these injuries vary in timing, type, and severity; therefore, the accessibility of the stinger and the evolving clinical picture should guide therapeutic decisions. AD - Veterans Affairs Boston Healthcare System, Boston, MA, USA Department of Ophthalmology, Boston University School of Medicine, Boston, MA, USA Department of Ophthalmology, Harvard Medical School, Boston, MA, USA Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA AN - 121078761. Language: English. Entry Date: 20170316. Revision Date: 20190628. Publication Type: journal article AU - Rai, Ruju R. AU - Gonzalez-Gonzalez, Luis A. AU - Papakostas, Thanos D. AU - Siracuse-Lee, Donna AU - Dunphy, Robert AU - Fanciullo, Lisa AU - Cakiner-Egilmez, Tulay AU - Daly, Mary K. DB - ccm DO - 10.3109/08820538.2015.1045301 DP - EBSCOhost IS - 2 KW - Corneal Injuries -- Therapy Cornea Insect Bites and Stings -- Therapy Eye Foreign Bodies -- Therapy Glucocorticoids -- Administration and Dosage Antibiotics -- Administration and Dosage Insect Bites and Stings -- Diagnosis Corneal Injuries -- Diagnosis Diagnosis, Eye Prospective Studies Visual Acuity Tomography, Optical Coherence Eye Foreign Bodies -- Diagnosis Drug Therapy, Combination Middle Age Male Administration, Topical Scales N1 - case study. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Appraisal of Self-Care Agency Scale; Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Standardized Assessment of Concussion (SAC). NLM UID: 8610759. PMID: NLM26161915. PY - 2017 SN - 0882-0538 SP - 177-181 ST - Management of Corneal Bee Sting Injuries T2 - Seminars in Ophthalmology TI - Management of Corneal Bee Sting Injuries UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121078761&site=ehost-live&scope=site VL - 32 ID - 4331 ER - TY - JOUR AB - Purpose: To review the management of keratitis after corneal bee stings and to report a case of deep stromal corneal infiltrate secondary to a retained bee stinger managed conservatively in a patient who presented three days after unsanitary manipulation of the stinger apparatus. Methods: Case report and review of literature. Results: A 57-year-old male beekeeper was evaluated for pain, blurry vision, and photosensitivity after a corneal bee sting. Of note, the venom sac had been removed with dirty tweezers three days prior to his visit. On exam, a focal infiltrate with diffuse edema was seen surrounding a retained bee stinger in the peripheral cornea. Trace cells in the anterior chamber were also noted. Based on a high suspicion for infectious keratitis, a conservative treatment strategy was elected. Administration of broad-spectrum topical antibiotics with concomitant abstention of corticosteroids led to rapid resolution of the symptoms. Over 16 months of follow-up, the stinger has remained in situ without migration and the patient has maintained 20/20 visual acuity without complications. There is debate on the preferred method for the management of corneal injury secondary to bee stings, especially when it is associated with a retained stinger. We herein present our findings in our appraisal of reported cases. Conclusion: In the aftermath of an ocular bee sting, close surveillance for inflammation and infection is essential. Individual manifestations of these injuries vary in timing, type, and severity; therefore, the accessibility of the stinger and the evolving clinical picture should guide therapeutic decisions. © Taylor & Francis. AD - Veterans Affairs Boston Healthcare System, Boston, MA, United States Department of Ophthalmology, Boston University School of Medicine, Boston, MA, United States Department of Ophthalmology, Harvard Medical School, Boston, MA, United States Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, United States AU - Rai, R. R. AU - Gonzalez-Gonzalez, L. A. AU - Papakostas, T. D. AU - Siracuse-Lee, D. AU - Dunphy, R. AU - Fanciullo, L. AU - Cakiner-Egilmez, T. AU - Daly, M. K. DB - Scopus DO - 10.3109/08820538.2015.1045301 IS - 2 KW - Bee sting cornea endothelial cell hymenoptera keratitis specular microscopy stinger removal trauma venom M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2017 SP - 177-181 ST - Management of Corneal Bee Sting Injuries T2 - Seminars in Ophthalmology TI - Management of Corneal Bee Sting Injuries UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011878129&doi=10.3109%2f08820538.2015.1045301&partnerID=40&md5=b19112895031fa1e8581003f0275a1af VL - 32 ID - 5375 ER - TY - JOUR AB - Purpose: To review the management of keratitis after corneal bee stings and to report a case of deep stromal corneal infiltrate secondary to a retained bee stinger managed conservatively in a patient who presented three days after unsanitary manipulation of the stinger apparatus. Methods: Case report and review of literature. Results: A 57-year-old male beekeeper was evaluated for pain, blurry vision, and photosensitivity after a corneal bee sting. Of note, the venom sac had been removed with dirty tweezers three days prior to his visit. On exam, a focal infiltrate with diffuse edema was seen surrounding a retained bee stinger in the peripheral cornea. Trace cells in the anterior chamber were also noted. Based on a high suspicion for infectious keratitis, a conservative treatment strategy was elected. Administration of broad-spectrum topical antibiotics with concomitant abstention of corticosteroids led to rapid resolution of the symptoms. Over 16 months of follow-up, the stinger has remained in situ without migration and the patient has maintained 20/20 visual acuity without complications. There is debate on the preferred method for the management of corneal injury secondary to bee stings, especially when it is associated with a retained stinger. We herein present our findings in our appraisal of reported cases. Conclusion: In the aftermath of an ocular bee sting, close surveillance for inflammation and infection is essential. Individual manifestations of these injuries vary in timing, type, and severity; therefore, the accessibility of the stinger and the evolving clinical picture should guide therapeutic decisions. AN - WOS:000394725400005 AU - Rai, R. R. AU - Gonzalez-Gonzalez, L. A. AU - Papakostas, T. D. AU - Siracuse-Lee, D. AU - Dunphy, R. AU - Fanciullo, L. AU - Cakiner-Egilmez, T. AU - Daly, M. K. DA - MAR DO - 10.3109/08820538.2015.1045301 IS - 2 PY - 2017 SN - 0882-0538 1744-5205 SP - 177-181 ST - Management of Corneal Bee Sting Injuries T2 - SEMINARS IN OPHTHALMOLOGY TI - Management of Corneal Bee Sting Injuries VL - 32 ID - 6241 ER - TY - JOUR AB - Background: Effective management of ocular hypertension requires patients to be persistent with their treatment regimen. We evaluated patients' persistency with hypotensive eyedrops commonly used to treat glaucoma and ocular hypertension. Methods: This large, population-based, retrospective, cohort study used pharmacy claims data for concessional patients from the Australian Pharmaceutical Benefits Scheme (July 1999-June 2005). Resupply rates for prostaglandins, beta-blockers, alpha-agonists and carbonic anhydrase inhibitors were analysed using life tables and Cox regression. Two populations, based on patients' supply histories, were examined: (i) 'new to this eyedrop'-patients who had used other hypotensive eyedrops before (presumably, previously diagnosed with glaucoma or ocular hypertension); and (ii) 'new to any eyedrop'-patients who were using their first hypotensive eyedrop (presumably, newly diagnosed with glaucoma or ocular hypertension). Results: Data were obtained for 14 359 618 supplies of commonly used hypotensive eyedrops to 357 099 concessional patients. For both populations, resupply rates were highest for prostaglandins or the dorzolamide-timolol combination eyedrops, compared with beta-blockers, alpha-agonists or carbonic anhydrase inhibitors. Among the prostaglandins, there was no significant difference in the risk of ceasing supply between latanoprost and bimatoprost, but the risk was significantly higher for travoprost. Conclusions: Based on resupply rates from a national pharmacy claims database, patients supplied with ocular hypotensive eyedrops were most persistent with prostaglandin (bimatoprost, latanoprost and travoprost) and dorzolamide-timolol combination eyedrops. Among the prostaglandins, persistency was highest with, and similar between, bimatoprost and latanoprost. Persistency should be taken into account when selecting the most appropriate eyedrop to treat glaucoma and ocular hypertension. © 2007 The Authors; Journal compilation © 2007 Royal Australian and New Zealand College of Ophthalmologists. AD - J.L. Rait, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Locked Bag 8, East Melbourne, VIC 3002, Australia AU - Rait, J. L. AU - Adena, M. A. DB - Embase Medline DO - 10.1111/j.1442-9071.2007.01564.x IS - 7 KW - alpha adrenergic receptor stimulating agent antihypertensive agent beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine carbonate dehydratase inhibitor dorzolamide dorzolamide plus timolol eye drops latanoprost levobunolol prostaglandin derivative timolol travoprost article Australia cohort analysis controlled study drug cost glaucoma human intraocular hypertension life table patient compliance population research retrospective study LA - English M3 - Article N1 - L47491216 2007-09-01 PY - 2007 SN - 1442-6404 1442-9071 SP - 602-611 ST - Persistency rates for prostaglandin and other hypotensive eyedrops: Population-based study using pharmacy claims data T2 - Clinical and Experimental Ophthalmology TI - Persistency rates for prostaglandin and other hypotensive eyedrops: Population-based study using pharmacy claims data UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47491216&from=export http://dx.doi.org/10.1111/j.1442-9071.2007.01564.x VL - 35 ID - 3509 ER - TY - JOUR AB - Aim: To find out and compare various predictors of glaucoma-related visual impairments in primary and secondary glaucoma. Methods: A prospective observational study of patients, who were above 30 years of age. They were diagnosed as primary/secondary glaucoma with visual acuity <20/200 Snellen’s/visual field showing less than 20° isopter in at least one eye, with a minimum follow-up of one year at a tertiary center. Patients were classified into advanced and end-stage glaucoma and outcome was assessed according to visual acuity and visual fields to see predictors of visual impairments. Results: There were 169 (99 primary/70 secondary) glaucoma patients with mean age of 62.67 ± 11.9 and 54.65 ± 15.26 years, respectively. Trauma (21.4%), complicated cataract surgery (15.7%), and silicon oil tamponade (14.3%) were common causes of secondary glaucoma. There was significant delay in diagnosis in primary compared to secondary glaucoma (57.57% vs 32.85%) and non-compliance was significantly higher in primary glaucoma (34.3% vs 17.1%, p = 0.01). In univariate analysis, literacy, income status, locality, and delayed or missed diagnosis were found to be significant (p < 0.05) according to visual acuity criteria. Out of the 33 patients who had undergone glaucoma filtration surgery, 18 (54.5%) were in the end-stage group. While 105 (77.2%) of 136 patients who were not subjected to any glaucoma filtration surgery reached end-stage glaucoma as per visual fields criteria (p = 0.011). Conclusion: Lack of awareness, delayed diagnosis, low literacy, and income were associated with poor visual outcome. Patients who underwent glaucoma filtration surgery had significantly better visual outcome in comparison to patients managed medically. © The Author(s) 2019. AD - Advanced Eye Centre, Postgraduate Institute of Medical Education Research, Chandigarh, India AU - Raj, S. AU - Savla, L. P. AU - Thattaruthody, F. AU - Seth, N. G. AU - Kaushik, S. AU - Pandav, S. S. DB - Scopus DO - 10.1177/1120672118823135 IS - 1 KW - glaucoma India Visual impairment M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 175-180 ST - Predictors of visual impairment in primary and secondary glaucoma in a tertiary institute in North India T2 - European Journal of Ophthalmology TI - Predictors of visual impairment in primary and secondary glaucoma in a tertiary institute in North India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060610404&doi=10.1177%2f1120672118823135&partnerID=40&md5=4f536267a951decc4bf4a30069638716 VL - 30 ID - 5718 ER - TY - JOUR AB - Aim: To find out and compare various predictors of glaucoma-related visual impairments in primary and secondary glaucoma. Methods: A prospective observational study of patients, who were above 30 years of age. They were diagnosed as primary/secondary glaucoma with visual acuity <20/200 Snellen's/visual field showing less than 20 degrees isopter in at least one eye, with a minimum follow-up of one year at a tertiary center. Patients were classified into advanced and end-stage glaucoma and outcome was assessed according to visual acuity and visual fields to see predictors of visual impairments. Results: There were 169 (99 primary/70 secondary) glaucoma patients with mean age of 62.67 +/- 11.9 and 54.65 +/- 15.26 years, respectively. Trauma (21.4%), complicated cataract surgery (15.7%), and silicon oil tamponade (14.3%) were common causes of secondary glaucoma. There was significant delay in diagnosis in primary compared to secondary glaucoma (57.57% vs 32.85%) and non-compliance was significantly higher in primary glaucoma (34.3% vs 17.1%, p = 0.01). In univariate analysis, literacy, income status, locality, and delayed or missed diagnosis were found to be significant (p < 0.05) according to visual acuity criteria. Out of the 33 patients who had undergone glaucoma filtration surgery, 18 (54.5%) were in the end-stage group. While 105 (77.2%) of 136 patients who were not subjected to any glaucoma filtration surgery reached end-stage glaucoma as per visual fields criteria (p = 0.011). Conclusion: Lack of awareness, delayed diagnosis, low literacy, and income were associated with poor visual outcome. Patients who underwent glaucoma filtration surgery had significantly better visual outcome in comparison to patients managed medically. AN - WOS:000503083900033 AU - Raj, S. AU - Savla, L. P. AU - Thattaruthody, F. AU - Seth, N. G. AU - Kaushik, S. AU - Pandav, S. S. DA - JAN DO - 10.1177/1120672118823135 IS - 1 PY - 2020 SN - 1120-6721 1724-6016 SP - 175-180 ST - Predictors of visual impairment in primary and secondary glaucoma in a tertiary institute in North India T2 - EUROPEAN JOURNAL OF OPHTHALMOLOGY TI - Predictors of visual impairment in primary and secondary glaucoma in a tertiary institute in North India VL - 30 ID - 6055 ER - TY - JOUR AB - Purpose: To assess the long-term visual acuity (VA) outcome after congenital cataract surgery at Imam Hossein Medical Center (Tertiary Referral Center) (2004-2014). Methods: In this descriptive study, records of 120 patients with a history of congenital cataract surgery were studied. Those with traumatic, metabolic cataract, aged <5 years at the last visit who were not able to respond VA testing accurately and follow-up < 6 months were excluded. Cases with incomplete files were recalled and reexamined. Finally, the records of 42 patients (71 eyes) were included. Results: In this study, 20 males and 22 females with a mean age of 11.80 ± 6 years at their last visit were studied. Bilateral and unilateral cataract was seen in 69% and 31% of cases, respectively. Posterior and anterior subcapsular opacity was the most common (53.70%) and rarest (1.90%) type of congenital cataract, respectively. The mean age at the time of operation and surgical interval was 65 ± 66.6 (range: 1-200) and 12.9 ± 23.5 (range: 0-96) months, respectively. The most common method of refractive error correction was pseudophakia plus glasses (56.3%) with the mean best corrected visual acuity (BCVA) of 0.29 ± 0.28 LogMAR., The mean BCVA was 0.7 ± 0.53 LogMAR for aphakic patients correcting by glasses. In our study, amblyopia (56%), glaucoma (23.90%), and posterior capsular opacity (16.40%) were observed during their follow-ups on an average of 76 ± 65 months (median: 60, range: 6-240). Unilateral cataract, aphakia, nystagmus, female gender, and strabismus were risk factors of VA loss. Conclusion: Based on our results, 56% of cases showed amblyopia. It could be due to late operation (especially in unilateral cases), longer surgical interval between two eyes, and no compliance of amblyopia therapy. Early detection through screening may reduce the rate of amblyopia. Refractive errors, visual acuity, amblyopia, glaucoma, posterior capsular opacity, and compliance of amblyopia therapy should be checked regularly at follow-up visits. © 2015 Iranian Society of Ophthalmology. AD - Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Optometry, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran AU - Rajavi, Z. AU - Mokhtari, S. AU - Sabbaghi, H. AU - Yaseri, M. DB - Scopus DO - 10.1016/j.joco.2015.11.001 IS - 3-4 KW - Best corrected visual acuity (BCVA) Complications Congenital cataract surgery M3 - Article N1 - Cited By :15 Export Date: 19 July 2021 PY - 2015 SP - 103-109 ST - Long-term visual outcome of congenital cataract at a Tertiary Referral Center from 2004 to 2014 T2 - Journal of Current Ophthalmology TI - Long-term visual outcome of congenital cataract at a Tertiary Referral Center from 2004 to 2014 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983207074&doi=10.1016%2fj.joco.2015.11.001&partnerID=40&md5=0ab78de4acc1ae53c00f9657f47c05d6 VL - 27 ID - 5187 ER - TY - JOUR AB - Purpose: To assess the long-term visual acuity (VA) outcome after congenital cataract surgery at Imam Hossein Medical Center (Tertiary Referral Center) (2004-2014). Methods: In this descriptive study, records of 120 patients with a history of congenital cataract surgery were studied. Those with traumatic, metabolic cataract, aged <5 years at the last visit who were not able to respond VA testing accurately and follow-up <6 months were excluded. Cases with incomplete files were recalled and reexamined. Finally, the records of 42 patients (71 eyes) were included. Results: In this study, 20 males and 22 females with a mean age of 11.80 +/- 6 years at their last visit were studied. Bilateral and unilateral cataract was seen in 69% and 31% of cases, respectively. Posterior and anterior subcapsular opacity was the most common (53.70%) and rarest (1.90%) type of congenital cataract, respectively. The mean age at the time of operation and surgical interval was 65 +/- 66.6 (range: 1-200) and 12.9 +/- 23.5 (range: 0-96) months, respectively. The most common method of refractive error correction was pseudophakia plus glasses (56.3%) with the mean best corrected visual acuity (BCVA) of 0.29 +/- 0.28 LogMAR., The mean BCVA was 0.7 +/- 0.53 LogMAR for aphakic patients correcting by glasses. In our study, amblyopia (56%), glaucoma (23.90%), and posterior capsular opacity (16.40%) were observed during their follow-ups on an average of 76 +/- 65 months (median: 60, range: 6-240). Unilateral cataract, aphakia, nystagmus, female gender, and strabismus were risk factors of VA loss. Conclusion: Based on our results, 56% of cases showed amblyopia. It could be due to late operation (especially in unilateral cases), longer surgical interval between two eyes, and no compliance of amblyopia therapy. Early detection through screening may reduce the rate of amblyopia. Refractive errors, visual acuity, amblyopia, glaucoma, posterior capsular opacity, and compliance of amblyopia therapy should be checked regularly at follow-up visits. Copyright (C) 2015, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. AN - WOS:000442762000008 AU - Rajavi, Z. AU - Mokhtari, S. AU - Sabbaghi, H. AU - Yaseri, M. DA - SEP-DEC DO - 10.1016/j.joco.2015.11.001 IS - 3-4 PY - 2015 SN - 2452-2325 SP - 103-109 ST - Long-term visual outcome of congenital cataract at a Tertiary Referral Center from 2004 to 2014 T2 - JOURNAL OF CURRENT OPHTHALMOLOGY TI - Long-term visual outcome of congenital cataract at a Tertiary Referral Center from 2004 to 2014 VL - 27 ID - 6049 ER - TY - JOUR AB - Purpose: To report the results of screening first degree relatives of persons identified with primary open angle glaucoma in a tertiary eye hospital glaucoma services. Design: A cross-sectional study of first degree relatives of persons with primary open angle glaucoma. Materials and methods: First degree relatives of patients identified with primary open angle glaucoma were invited to participate in a screening evaluation in the base hospital to detect glaucoma. All participating individuals had comprehensive eye examination including vision screening, refraction, slit-lamp biomicroscopy, applanation tonometry, gonioscopy, frequency doubling perimetry and dilated fundus examination. Persons with definite and suspected glaucoma were subject to full threshold automated perimetry. Results: A 514 first degree relatives of 346 persons with primary open angle glaucoma, of 4972 individuals who were invited to participate attended the screening examination (Response Rate 7%). Fifty-five percent of those who attended were males and mean age of participants was 56.8 years. Sixty-eight relatives (13.3% of those screened) were detected to have definite glaucoma. Sixty percent of those detected with definite glaucoma were siblings. Fifteen percent of siblings, 4% of off-springs and 20% of parents who attended the screening examination had definite open angle glaucoma. Conclusion: Prevalence of open angle glaucoma amongst first degree relatives of persons with glaucoma is higher than in the general population as reported in previous studies. Significant barriers, however, exist in the uptake of eye care services among relatives of persons known to have primary open angle glaucoma. © 2014, Jaypee Brothers Medical Publishers (P) Ltd. All rights reserved. AD - Department of Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu, India Aravind Eye Care System, Madurai, Tamil Nadu, India Department of Glaucoma Services, Aravind Eye Care System, Madurai, Tamil Nadu, India AU - Rajendrababu, S. AU - Gupta, N. AU - Vijayakumar, B. AU - Kumaragurupari, R. AU - Krishnadas, S. R. DB - Scopus DO - 10.5005/jp-journals-10008-1172 IS - 3 KW - Family glaucoma Family history First degree relatives Heredity Heredity history Primary open angle glaucoma Risk factor Targeted factor Targeted screening M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2014 SP - 107-112 ST - Screening first degree relatives of persons with primary open angle glaucoma in India T2 - Journal of Current Glaucoma Practice TI - Screening first degree relatives of persons with primary open angle glaucoma in India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046758849&doi=10.5005%2fjp-journals-10008-1172&partnerID=40&md5=38ef7b3630d7d6ad533518ffa04df339 VL - 8 ID - 5385 ER - TY - JOUR AB - Purpose: The present study aims to estimate the prevalence of non-compliance and improper drop administration technique among glaucoma patients and describe common obstacles to medication compliance. Methods: A hospital-based cross-sectional study, using standardized questionnaire and direct observation by study personnel was conducted among glaucoma patients aged 18 years and above at a tertiary care charitable eye hospital in North India. 151 consecutive glaucoma patients on medical therapy following up at the glaucoma clinics for at least 6 months were recruited. Non-compliance was defined as missing at-least one drop of medication per week and (or) the inability to accurately describe the medication regimen. Study personnel also assessed drop administration technique during application of eye drops by patients treating ophthalmologist-provided information, including measures of disease stability. Factors such as socioeconomic status, presence of caregiver, and number of medications with their effect on compliance were studied using chi-square statistics. Results: Among 151 patients interviewed, around 49% of patients reported problems in using glaucoma medications, with 16% of them reporting total non-compliance. 35% of patients demonstrated improper drop administration technique. Forgetfulness was cited as the main reason for being non-compliant and had a significant association with non-compliance (P = 0.00). Paying patients were more compliant as compared to subsidized patients (P = 0.05). Disease was more stable in compliant patients compared to non-compliant patients (P = 0.05). No other factor had significant association with compliance (P > 0.05). Conclusions: Over 50% of the patients surveyed were non-compliant, and 35% demonstrated improper administration technique. Glaucoma patients should be educated on the importance of compliance and aids that minimize forgetfulness, and delivery systems facilitating the delivery of medications to the eye could be considered to enhance patient adherence. AD - K. Rajurkar, Department of Glaucoma, Dr. Shroff's Charity Eye Hospital, 5027, Kedarnath Road, Daryaganj, New Delhi, India AU - Rajurkar, K. AU - Dubey, S. AU - Gupta, P. P. AU - John, D. AU - Chauhan, L. DB - Embase DO - 10.1016/j.joco.2017.09.002 IS - 2 KW - antiglaucoma agent eye drops adult aged article caregiver cross-sectional study female follow up glaucoma health survey human India major clinical study male medication compliance medication therapy management middle aged observational study patient compliance questionnaire social status tertiary care center LA - English M3 - Article N1 - L619252964 2017-11-20 2018-06-20 PY - 2018 SN - 2452-2325 SP - 125-129 ST - Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India T2 - Journal of Current Ophthalmology TI - Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619252964&from=export http://dx.doi.org/10.1016/j.joco.2017.09.002 VL - 30 ID - 2582 ER - TY - JOUR AB - Purpose: The present study aims to estimate the prevalence of non-compliance and improper drop administration technique among glaucoma patients and describe common obstacles to medication compliance. Methods: A hospital-based cross-sectional study, using standardized questionnaire and direct observation by study personnel was conducted among glaucoma patients aged 18 years and above at a tertiary care charitable eye hospital in North India. 151 consecutive glaucoma patients on medical therapy following up at the glaucoma clinics for at least 6 months were recruited. Non-compliance was defined as missing at-least one drop of medication per week and (or) the inability to accurately describe the medication regimen. Study personnel also assessed drop administration technique during application of eye drops by patients treating ophthalmologist-provided information, including measures of disease stability. Factors such as socioeconomic status, presence of caregiver, and number of medications with their effect on compliance were studied using chi-square statistics. Results: Among 151 patients interviewed, around 49% of patients reported problems in using glaucoma medications, with 16% of them reporting total non-compliance. 35% of patients demonstrated improper drop administration technique. Forgetfulness was cited as the main reason for being non-compliant and had a significant association with non-compliance (P = 0.00). Paying patients were more compliant as compared to subsidized patients (P = 0.05). Disease was more stable in compliant patients compared to non-compliant patients (P = 0.05). No other factor had significant association with compliance (P > 0.05). Conclusions: Over 50% of the patients surveyed were non-compliant, and 35% demonstrated improper administration technique. Glaucoma patients should be educated on the importance of compliance and aids that minimize forgetfulness, and delivery systems facilitating the delivery of medications to the eye could be considered to enhance patient adherence. © 2017 Iranian Society of Ophthalmology AD - Dr. Shroff's Charity Eye Hospital, New Delhi, India Campbell Collaboration, New Delhi, India Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Netherlands AU - Rajurkar, K. AU - Dubey, S. AU - Gupta, P. P. AU - John, D. AU - Chauhan, L. DB - Scopus DO - 10.1016/j.joco.2017.09.002 IS - 2 KW - Adherence Glaucoma Medication North India M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2018 SP - 125-129 ST - Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India T2 - Journal of Current Ophthalmology TI - Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033727149&doi=10.1016%2fj.joco.2017.09.002&partnerID=40&md5=80387520cc022f65547fc450dba13d56 VL - 30 ID - 5272 ER - TY - JOUR AB - Purpose: The present study aims to estimate the prevalence of non-compliance and improper drop administration technique among glaucoma patients and describe common obstacles to medication compliance. Methods: A hospital-based cross-sectional study, using standardized questionnaire and direct observation by study personnel was conducted among glaucoma patients aged 18 years and above at a tertiary care charitable eye hospital in North India. 151 consecutive glaucoma patients on medical therapy following up at the glaucoma clinics for at least 6 months were recruited. Non-compliance was defined as missing at-least one drop of medication per week and (or) the inability to accurately describe the medication regimen. Study personnel also assessed drop administration technique during application of eye drops by patients treating ophthalmologist-provided information, including measures of disease stability. Factors such as socioeconomic status, presence of caregiver, and number of medications with their effect on compliance were studied using chi-square statistics. Results: Among 151 patients interviewed, around 49% of patients reported problems in using glaucoma medications, with 16% of them reporting total non-compliance. 35% of patients demonstrated improper drop administration technique. Forgetfulness was cited as the main reason for being non-compliant and had a significant association with non-compliance (P = 0.00). Paying patients were more compliant as compared to subsidized patients (P = 0.05). Disease was more stable in compliant patients compared to non-compliant patients (P = 0.05). No other factor had significant association with compliance (P > 0.05). Conclusions: Over 50% of the patients surveyed were non-compliant, and 35% demonstrated improper administration technique. Glaucoma patients should be educated on the importance of compliance and aids that minimize forgetfulness, and delivery systems facilitating the delivery of medications to the eye could be considered to enhance patient adherence. Copyright (C) 2017, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. AN - WOS:000437411200004 AU - Rajurkar, K. AU - Dubey, S. AU - Gupta, P. P. AU - John, D. AU - Chauhan, L. DA - JUN DO - 10.1016/j.joco.2017.09.002 IS - 2 PY - 2018 SN - 2452-2325 SP - 125-129 ST - Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India T2 - JOURNAL OF CURRENT OPHTHALMOLOGY TI - Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India VL - 30 ID - 5830 ER - TY - JOUR AD - P.L. Rakow AU - Rakow, P. L. DB - Medline IS - 3 KW - Acanthamoeba keratitis allergic conjunctivitis article contact lens human patient compliance LA - English M3 - Article N1 - L20852818 1990-08-15 PY - 1990 SN - 0744-7132 SP - 112-113 ST - Maintaining a healthy eye T2 - Journal of ophthalmic nursing & technology TI - Maintaining a healthy eye UR - https://www.embase.com/search/results?subaction=viewrecord&id=L20852818&from=export VL - 9 ID - 4044 ER - TY - JOUR AB - Purpose: This study was undertaken to determine the extent of adhesion of cysts and trophozoites of Acanthamoeba to worn disposable hydrogel lenses and to study the effect of time, lens material, and washing on the adhesion. Methods: Etefilcon A (58% water content) and Polymacon (38% water content) lenses worn on a 6 night extended wear basis and collected aseptically in PBS pH 7.2, were used for the study. Unworn lenses of the same materials were used as controls. Segments of lenses were incubated in Acanthamoeba suspension (cysts and trophozoites) and examined at 0, 5, and 24 hours, either washed or unwashed, for adherent Acanthamoeba. The amoebae adherent per square mm surface of the lens were enumerated. Levels of adhesion in various groups were compared using Wilcoxon sign rank test. Results: At 0 hours, unwashed worn Polymacon lenses showed significantly greater adherence than Etafilcon A lenses compared to the controls (P=0.0469). However, there was no difference at 5 and 24 hours exposure time between the lenses. At 24 hours the adhesion of Acanthamoeba was greater for washed worn lenses of both types compared to washed lenses of controls (P=0.002, 0.012). Conclusions: Amoebae adhered with equal affinity to both types of lenses but adhered with greater affinity to worn lenses than unworn lenses. Adhesion of Acanthamoebe to worn disposable lenses may be a factor in the pathogenesis of Acanthamoeba keretitis in disposable lens wearers. AD - Bausch and Lomb Contact Lens Centre, India Devchand Nagardas Jhaveri M., India L.V. Prasad Eye Institute, Hyderabad, India L.V. Prasad Eye Institute, Road No.2, Banjara Hills, Hyderabad 500 034, India AU - Ramachandran, L. AU - Janakiraman, D. AU - Sharma, S. AU - Rao, G. N. DB - Scopus IS - 2 M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 1997 SP - 113-116 ST - Effect of time and washing on the adhesion of Acanthamoeba to extended wear disposable hydrogel contact lenses T2 - CLAO Journal TI - Effect of time and washing on the adhesion of Acanthamoeba to extended wear disposable hydrogel contact lenses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030938593&partnerID=40&md5=d4a5d1579e919a8fbfb56c8ed491f011 VL - 23 ID - 5316 ER - TY - JOUR AD - Eye Unit, Royal Bournemouth Hospital NHS Foundation Trust, Bournemouth, Dorset BH7 7DW, United Kingdom AU - Ramchandani, M. DB - Scopus DO - 10.1136/bmj.39016.626771.80 IS - 7575 M3 - Editorial N1 - Cited By :5 Export Date: 19 July 2021 PY - 2006 SP - 932 ST - Glaucoma in the developing world T2 - British Medical Journal TI - Glaucoma in the developing world UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750902442&doi=10.1136%2fbmj.39016.626771.80&partnerID=40&md5=cd6a3d688c5d3af803bc7235e0a37035 VL - 333 ID - 5433 ER - TY - JOUR AB - Purpose: To understand the factors that explain compliance to anti-glaucoma medication (AGM) in terms of application,purchase, stocking and compliance behaviour.Methods: This was a cross-sectional study conducted in the outpatient department of an urban tertiary eye care center in South India. Interviews were completed with consenting, consecutive, literate primary glaucoma patients. The components of the questionnaire included duration, application, purchase, stocking and caregiver's role. Self-reported compliance in medication taking was tested for association with rest of the components by Chi-square test and discriminant analysis.Results: A total of 101 patients, aged 34-87 years, were interviewed. Majority (64.4%) were on AGM for more than two years. Early purchase was reported among 44.3% and stocking among 41.2%. Cost was high for income among 28.7%. Majority (91.1%) of them were not aware of side-effects. Fear of blindness was the major factor (68.1%) encouraging regular usage. Half (50.5%) of the patients though, still reported missing medication in the past month. Major reasons cited were relative priority (45.1%) and forgetfulness (35.3%). Self-reported compliance was not different by demographic variables or with responses to questions regarding duration (P = 0.070), application (0.825), time of purchase (0.272), stocking (0.598), and cost perception (0.415).Conclusion: Self-reporting of AGM compliance behaviour did not reflect with responses regarding application, purchase, stocking behaviour or cost perception. Awareness and knowledge of the above factors, with an aim of improving compliance by regulating counselling for even literate patients using AGM is called for. AD - Medical Officer, Department of Glaucoma and Research, Mahathma Eye Hospital Private Limited, Trichy, Tamil Nadu Director, Sathyan Eye Care Hospital and Coimbatore Glaucoma Foundation, Coimbatore, Tamil Nadu Biostatistician, Sathyan Eye Care Hospital and Coimbatore Glaucoma Foundation, Coimbatore, Tamil Nadu Medical Officer, Department of Glaucoma and Research, Mahathma Eye Hospital Private Limited, Trichy, Tamil Nadu, India Biostatistician, Sathyan Eye Care Hospital and Coimbatore Glaucoma Foundation, Coimbatore, Tamil Nadu, India AN - 150821640. Language: English. Entry Date: 20210712. Revision Date: 20210716. Publication Type: journal article. Journal Subset: Asia AU - Ramesh, Prasanna AU - Parthasarathi, Sathyan AU - John, Rajesh AU - Ramesh, Prasanna Venkatesh AU - John, Rajesh Kumar DB - ccm DO - 10.4103/ijo.IJO_2008_20 DP - EBSCOhost IS - 6 KW - Glaucoma -- Epidemiology Glaucoma -- Drug Therapy Middle Age Adult Medication Compliance Aged Aged, 80 and Over India Cross Sectional Studies Caregiver Strain Index N1 - Biomedical; Peer Reviewed. Instrumentation: Caregiver Strain Index; Defining Issues Test (DIT) (Rest). NLM UID: 0405376. PMID: NLM34011712. PY - 2021 SN - 0301-4738 SP - 1418-1424 ST - An exploratory study of compliance to anti-glaucoma medications among literate primary glaucoma patients at an urban tertiary eye care center in South India T2 - Indian Journal of Ophthalmology TI - An exploratory study of compliance to anti-glaucoma medications among literate primary glaucoma patients at an urban tertiary eye care center in South India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150821640&site=ehost-live&scope=site VL - 69 ID - 4148 ER - TY - JOUR AB - Purpose: To study the perceptions, attitude, knowledge of the disease, and impediments to seeking early eye care in caregivers of children with childhood glaucoma.Methods: The study included new and old children diagnosed with childhood glaucoma (which included congenital glaucoma and developmental glaucoma) at a tertiary hospital of east India. The caregivers were administered a video-based questionnaire through open-ended questions intended to collect demographic and other personal details such as caregiver's socioeconomic status, knowledge, attitude towards eye health, and other social barriers. The responses were analyzed using thematic analysis technique into different buckets such as social status, knowledge/attitude, and sociocultural beliefs while individual responses in each bucket were analyzed.Results: Of a total of 43 patients included,> 75% of patients came from places> 200 km from the eye care centre with> 50% coming from> 300 km. Most patients presented either <1 year (42%, n = 18) or> 3 years (52%, n = 22) with only 2% (n = 3) presenting between 1-3 years of age. The mother was the first person of contact to diagnose the eye abnormality in> 45% of patients. Comparing differences among children who presented within 1 year of first diagnosis and those that presented later, caregivers hailing from long-distance> 200 km from an eye care center, monthly income <5000 INR, and those with social/cultural taboos (like children's eyes should not be operated) were more likely to seek delayed eye care for congenital glaucoma, P < 0.001.Conclusion: Impediments in seeking early eye care for blinding diseases in children (including distance from the nearest hospital, low socioeconomic constraints, and sociocultural beliefs/taboos) mandate serious policies towards improving education about eye disease and eye health among caregivers. AD - Glaucoma Services, MTC Campus, LV Prasad Eye Institute, KIIT School for Biotechnology, Patia, Bhubaneswar, Odisha Glaucoma Services, MTC Campus, LV Prasad Eye Institute, Odisha Glaucoma Services, MTC Campus, LV Prasad Eye Institute, Odisha, India AN - 143097876. Language: English. Entry Date: 20200927. Revision Date: 20210716. Publication Type: journal article. Journal Subset: Asia AU - Rao, Aparna AU - Raj, Niranjan AU - Padhy, Debananda AU - Sarangi, Sarada AU - Sarangi, Sarada Prasanna DB - ccm DO - 10.4103/ijo.IJO_753_19 DP - EBSCOhost IS - 5 KW - Attitude to Health Eye Diseases Health Services Accessibility Female Child Mothers Caregivers Caregiver Strain Index Personal Resource Questionnaire Social Readjustment Rating Scale N1 - Biomedical; Peer Reviewed. Instrumentation: Caregiver Strain Index; Personal Resource Questionnaire (PRQ); Social Readjustment Rating Scale (SRRS) (Holmes and Rahe). NLM UID: 0405376. PMID: NLM32317449. PY - 2020 SN - 0301-4738 SP - 798-804 ST - Perspectives and impediment to eye care in caregivers of children with childhood glaucoma T2 - Indian Journal of Ophthalmology TI - Perspectives and impediment to eye care in caregivers of children with childhood glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143097876&site=ehost-live&scope=site VL - 68 ID - 4179 ER - TY - JOUR AB - To develop metrics to identify knowledge deficits and barriers to learning in glaucoma patients, this study seeks to validate a glaucoma knowledge assessment to use in the evaluation of knowledge in glaucoma patients. Purpose: Glaucoma treatment adherence appears to improve when patients demonstrate a greater knowledge of the disease and its treatment. This study seeks to validate a glaucoma knowledge assessment in a glaucoma patient population to assist in patient educational assessments and interventions. Patients and methods: The National Eye Health Education Program’s (NEHEP) glaucoma knowledge assessment has previously been suggested as a useful measure to assess glaucoma patient’s knowledge. This questionnaire was administered in glaucoma patients along with a more comprehensive 49-question examination. Demographic data and health literacy were assessed. Statistical analyses were performed to assess the validity of the assessments. Results: A total of 12 glaucoma patients completed the knowledge assessments. The mean ± standard deviation age of the patients was 69±14 years, and the duration of glaucoma was 14±13 years. The participants’ mean score on the NEHEP assessment was 7.3±0.8 (of 10, 73% correct) vs 29.3±7.3 (of 49, 60% correct) on the comprehensive assessment. The value of coefficient α was 0.592 for NEHEP and 0.872 for the cumulative assessment. The P-value (proportion of examinees answering correctly) ranged from 0 to 1 for individual questions. Item point–biserial correlation values for each question ranged from -0.402 to 0.813. Discussion: The NEHEP quiz may be a good starting point for the development of a reliable knowledge assessment tool to measure and monitor glaucoma knowledge, due to its concise nature and reasonable level of difficulty. This study suggests that questions included in the currently available questionnaires vary widely in difficulty and ability to differentiate knowledge level, which may ultimately compromise reliability and utility of existing examinations. Further examination of individual questions and teaching points included in the current assessments may help to construct increasingly reliable and useful knowledge assessments in the future. AD - J.A. Rosdahl, Department of Ophthalmology, Duke University, 2351 Erwin Road, DUMC 3802, Durham, NC, United States AU - Rao, V. S. AU - Peralta, E. A. AU - Rosdahl, J. A. DB - Embase DO - 10.2147/OPTH.S117704 KW - antiglaucoma agent adult aged article clinical article descriptive research disease duration educational status female glaucoma health literacy human knowledge management male medical information patient compliance patient education prospective study statistical analysis validation study LA - English M3 - Article N1 - L612819463 2016-10-27 2016-11-09 PY - 2016 SN - 1177-5483 1177-5467 SP - 1913-1918 ST - Validation of a glaucoma knowledge assessment in glaucoma patients T2 - Clinical Ophthalmology TI - Validation of a glaucoma knowledge assessment in glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612819463&from=export http://dx.doi.org/10.2147/OPTH.S117704 VL - 10 ID - 2697 ER - TY - JOUR AB - Purpose: To characterize differences in resource utilization and cost of managing enrollees with exfoliation glaucoma (XFG) compared to primary open-angle glaucoma (POAG). Design: Retrospective utilization and cost comparison using Medicare claims data. Methods: We identified Medicare beneficiaries with XFG or POAG and ≥5 years of continuous enrollment from January 2008 to December 2014. We distinguished newly diagnosed cases from those with preexisting disease. We compared ophthalmic resource utilization and costs over 2 years of follow-up for persons with newly diagnosed and preexisting XFG vs those with POAG. Main outcome measures were number of clinic visits, diagnostic procedures, medication fills, laser and incisional surgery, and mean eye care costs per beneficiary. Results: Among 192 eligible enrollees (median age 77.6 years) with newly diagnosed XFG and 7339 enrollees (median age 77.3 years) with newly diagnosed POAG, those with XFG had more office visits (mean, 9.1 vs 7.9; P =.001), cataract surgery (34.9% vs 19.0%; P <.0001), and glaucoma surgery (28.7% vs 19.7%, P =.002). They also experienced 27% higher mean total eye care costs ($3260 vs $2562, P =.0001) over 2 years of follow-up. Among 2745 enrollees (median age 80.5 years) with preexisting XFG and 89 036 persons (median age 79.5) with preexisting POAG, persons with XFG had more office visits (mean 9.3 vs 7.3; P <.0001), perimetry (85.3% vs 79.8%; P <.0001), cataract surgery (23.4% vs 12.3%; P <.0001), laser trabeculoplasty (18.6% vs 9.6%; P <.0001), and trabeculectomy (8.1 vs 1.8%; P <.0001) and experienced 37% higher total mean eye care costs ($3764 vs $2739; P <.0001). Conclusions: Healthcare resource utilization and costs are substantially higher for managing patients with XFG compared to POAG. AD - J.D. Stein, Department of Ophthalmology and Visual Sciences, University of Michigan, 1000 Wall St, Ann Arbor, MI, United States AU - Rathi, S. AU - Andrews, C. AU - Greenfield, D. S. AU - Stein, J. D. DB - Embase Medline DO - 10.1016/j.ajo.2018.12.024 KW - aged article cataract extraction cost benefit analysis disease severity eye care female follow up glaucoma surgery health care cost health care utilization health insurance health service human incidence intermethod comparison major clinical study male open angle glaucoma outcome assessment perimetry priority journal pseudoexfoliation retrospective study trabeculectomy trabeculoplasty LA - English M3 - Article N1 - L2001546801 2019-02-12 2019-02-19 PY - 2019 SN - 1879-1891 0002-9394 SP - 100-109 ST - A Comparison of Resource Use and Costs of Caring for Patients With Exfoliation Syndrome Glaucoma Versus Primary Open-Angle Glaucoma T2 - American Journal of Ophthalmology TI - A Comparison of Resource Use and Costs of Caring for Patients With Exfoliation Syndrome Glaucoma Versus Primary Open-Angle Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001546801&from=export http://dx.doi.org/10.1016/j.ajo.2018.12.024 VL - 200 ID - 2511 ER - TY - JOUR AB - Telemedicine services facilitate the evaluation, diagnosis, and management of the remote patient. Telemedicine has rapidly flourished in the United States and has improved access to care, outcomes, and patient satisfaction. However, the use of telemedicine in ophthalmology is currently in its infancy and has yet to gain wide acceptance. Current models of telemedicine in ophthalmology are largely performed via “store and forward” methods, but remote monitoring and interactive modalities exist. Although studies have examined the effects of telemedicine, few reports have characterized its current status. We perform a descriptive analysis of the current state of teleophthalmology in the United States. We describe the use of teleophthalmology in the hospital and outpatient settings. We also review the applications to retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and glaucoma, as well as anticipated barriers and hurdles for the future adoption of teleophthalmology. With ongoing advances in teleophthalmology, these models may provide earlier detection and more reliable monitoring of vision-threatening diseases. AD - J.S. Schuman, NYU Langone Eye Center, Department of Ophthalmology, New York University School of Medicine, 462 First Avenue, NBV 5N3, New York, NY, United States AU - Rathi, S. AU - Tsui, E. AU - Mehta, N. AU - Zahid, S. AU - Schuman, J. S. DB - Embase Medline DO - 10.1016/j.ophtha.2017.05.026 IS - 12 KW - age related macular degeneration diabetic retinopathy emergency care glaucoma health care access human ophthalmology outpatient care priority journal remote sensing retrolental fibroplasia review teleconsultation telemedicine teleophthalmology United States LA - English M3 - Review N1 - L616896038 2017-06-28 2017-12-11 PY - 2017 SN - 1549-4713 0161-6420 SP - 1729-1734 ST - The Current State of Teleophthalmology in the United States T2 - Ophthalmology TI - The Current State of Teleophthalmology in the United States UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616896038&from=export http://dx.doi.org/10.1016/j.ophtha.2017.05.026 VL - 124 ID - 2620 ER - TY - JOUR AB - Importance: Methotrexate and mycophenolate mofetil are commonly used immunomodulatory therapies for achieving corticosteroid-sparing control of noninfectious uveitis, but there is uncertainty about which drug is more effective. Objective: To compare the effect of methotrexate and mycophenolate for achieving corticosteroid-sparing control of noninfectious intermediate uveitis, posterior uveitis, and panuveitis. Design, Setting, and Participants: The First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial screened 265 adults with noninfectious uveitis requiring corticosteroid-sparing immunosuppressive therapy from 9 referral eye centers in India, the United States, Australia, Saudi Arabia, and Mexico between August 22, 2013, and August 16, 2017. Follow-up ended on August 20, 2018. Interventions: Patients were randomized to receive oral methotrexate, 25 mg weekly (n = 107), or oral mycophenolate mofetil, 3 g daily (n = 109). Main Outcomes and Measures: The primary outcome was treatment success at 6 months, which was defined as having control of inflammation in both eyes, no more than 7.5 mg prednisone daily and less than or equal to 2 drops of prednisolone acetate 1%, and no treatment failure due to safety or intolerability. Patients underwent follow-up to 12 months while receiving the same treatment or switched to the other antimetabolite, depending on their 6-month outcome. Results: Among 216 patients who were randomized (median age, 38 years; 135 (62.5%) women), 194 (89.8%) completed follow-up through 6 months. Treatment success occurred in 64 (66.7%) patients in the methotrexate group vs 56 (57.1%) in the mycophenolate group (difference, 9.5% [95% CI, -5.3% to 21.8%]; odds ratio [OR], 1.50 [95% CI, 0.81 to 2.81]; P =.20). Among patients with posterior uveitis or panuveitis, treatment success was achieved in 58 (74.4%) in the methotrexate group vs 42 (55.3%) in the mycophenolate group (difference, 19.1% [95% CI, 3.6% to 30.6%]; OR, 2.35 [95% CI, 1.16 to 4.90]; P =.02); whereas among patients with intermediate uveitis treatment success occurred in 6 (33.3%) in the methotrexate group vs 14 (63.6%) in the mycophenolate group (difference, -30.3% [95% CI, -51.6% to 1.1%]; OR, 0.29 [95% CI, 0.08 to 1.05]; P =.07; P for interaction =.004). Elevated liver enzymes were the most common nonserious laboratory adverse event, occurring in 14 patients (13.0%) in the methotrexate group and 8 patients (7.4%) in the mycophenolate group. Conclusions and Relevance: Among adults with noninfectious uveitis, the use of mycophenolate mofetil compared with methotrexate as first-line corticosteroid-sparing treatment did not result in superior control of inflammation. Further research is needed to determine if either drug is more effective based on the anatomical subtype of uveitis. © 2019 American Medical Association. All rights reserved. AD - Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India F. I. Proctor Foundation, University of California, 513 Parnassus Ave, S309, San Francisco, CA 94143, United States Department of Ophthalmology, University of California, San Francisco, United States Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia Casey Eye Institute, Portland, OR, United States Oregon Health and Science University, Portland, United States OHSU-PSU School of Public Health, VA Portland Health Care System, Portland, OR, United States Division of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia Department of Epidemiology and Biostatistics, University of California, San Francisco, United States AU - Rathinam, S. R. AU - Gonzales, J. A. AU - Thundikandy, R. AU - Kanakath, A. AU - Murugan, S. B. AU - Vedhanayaki, R. AU - Lim, L. L. AU - Suhler, E. B. AU - Al-Dhibi, H. A. AU - Doan, T. AU - Keenan, J. D. AU - Rao, M. M. AU - Ebert, C. D. AU - Nguyen, H. H. AU - Kim, E. AU - Porco, T. C. AU - Acharya, N. R. DB - Scopus DO - 10.1001/jama.2019.12618 IS - 10 M3 - Article N1 - Cited By :24 Export Date: 19 July 2021 PY - 2019 SP - 936-945 ST - Effect of Corticosteroid-Sparing Treatment with Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients with Uveitis: A Randomized Clinical Trial T2 - JAMA - Journal of the American Medical Association TI - Effect of Corticosteroid-Sparing Treatment with Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients with Uveitis: A Randomized Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071985058&doi=10.1001%2fjama.2019.12618&partnerID=40&md5=feb59bfcc88435b9444ed7d4706c6f88 VL - 322 ID - 5094 ER - TY - JOUR AB - Purpose: To assess the impact of referral refinement criteria on the number of patients referred to, and first-visit discharges from, the Hospital Eye Service (HES) in relation to the National Institute for Health & Clinical Excellence (NICE) Glaucoma Guidelines, Joint College Group Guidance (JCG) and the NICE commissioning guidance. Methods: All low-risk (one risk factor: suspicious optic disc, abnormal visual field (VF), raised intra-ocular pressure (IOP) (22-28 mmHg) or IOP asymmetry (>5 mmHg) and high-risk (more than one risk factor, shallow anterior chamber or IOP >28 mmHg) referrals to the HES from 2006 to 2011 were analysed. Low-risk referrals were seen by Optometrists with a specialist interest in glaucoma and high-risk referrals were referred directly to the HES. Results: Two thousand nine hundred and twelve patient records were analysed. The highest Consultant first-visit discharge rates were for referrals based on IOP alone (45% for IOP 22-28 mmHg) and IOP asymmetry (53%), VF defect alone (46%) and for abnormal IOP and VF (54%). The lowest first-visit discharge rates were for referrals for suspicious optic disc (19%) and IOP >28 mmHg (22%). 73% of patients aged 65-80 and 60% of patients aged >80 who were referred by the OSI due to an IOP between 22-28 mmHg would have satisfied the JCG criteria for non-referral. For patients referred with an IOP >28 mmHg and an otherwise normal examination, adherence to the NICE commissioning guidance would have resulted in 6% fewer referrals. In 2010 this scheme reduced the number of patients attending the HES by 15%, which resulted in a saving of £16 258 (13%). Conclusion: The results support that referrals for a raised IOP alone or in combination with an abnormal VF be classified as low-risk and undergo referral refinement. Adherence to the JCG and the NICE commissioning guidance as onward referral criteria for specialist optometrists in this referral refinement scheme would result in fewer referrals. © 2013 The College of Optometrists. AD - North Central London, Essex Health Innovation Education Cluster, London, North East, United Kingdom Vision and Eye Research Unit, Postgraduate Medical Institute, Anglia Ruskin University, Cambridge, United Kingdom UCL Institute of Ophthalmology, London, United Kingdom Huntingdon Glaucoma Diagnostic and Research Centre, Hinchingbrooke Hospital, Huntingdon, United Kingdom NIHR Biomedical Research Centre, Moorfields Eye Hospital, NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom Postgraduate Medical Institute, Anglia Ruskin University, Cambridge, United Kingdom AU - Ratnarajan, G. AU - Newsom, W. AU - French, K. AU - Kean, J. AU - Chang, L. AU - Parker, M. AU - Garway-Heath, D. F. AU - Bourne, R. R. DB - Scopus DO - 10.1111/opo.12029 IS - 2 KW - First-visit discharge rate Glaucoma National Institute for Health & Clinical Excellence Glaucoma Guidelines Optometrists with specialist interest in glaucoma Referral refinement M3 - Article N1 - Cited By :18 Export Date: 19 July 2021 PY - 2013 SP - 183-189 ST - The impact of glaucoma referral refinement criteria on referral to, and first-visit discharge rates from, the hospital eye service: The Health Innovation & Education Cluster (HIEC) Glaucoma Pathways project T2 - Ophthalmic and Physiological Optics TI - The impact of glaucoma referral refinement criteria on referral to, and first-visit discharge rates from, the hospital eye service: The Health Innovation & Education Cluster (HIEC) Glaucoma Pathways project UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873905423&doi=10.1111%2fopo.12029&partnerID=40&md5=7b04a826c5921fbb0b042bde501ff6fa VL - 33 ID - 5162 ER - TY - JOUR AB - Purpose To assess the impact of referral refinement criteria on the number of patients referred to, and first-visit discharges from, the Hospital Eye Service (HES) in relation to the National Institute for Health & Clinical Excellence (NICE) Glaucoma Guidelines, Joint College Group Guidance (JCG) and the NICE commissioning guidance. Methods All low-risk (one risk factor: suspicious optic disc, abnormal visual field (VF), raised intra-ocular pressure (IOP) (2228mmHg) or IOP asymmetry (>5mmHg) and high-risk (more than one risk factor, shallow anterior chamber or IOP >28mmHg) referrals to the HES from 2006 to 2011 were analysed. Low-risk referrals were seen by Optometrists with a specialist interest in glaucoma and high-risk referrals were referred directly to the HES. Results Two thousand nine hundred and twelve patient records were analysed. The highest Consultant first-visit discharge rates were for referrals based on IOP alone (45% for IOP 2228mmHg) and IOP asymmetry (53%), VF defect alone (46%) and for abnormal IOP and VF (54%). The lowest first-visit discharge rates were for referrals for suspicious optic disc (19%) and IOP >28mmHg (22%). 73% of patients aged 6580 and 60% of patients aged >80 who were referred by the OSI due to an IOP between 2228mmHg would have satisfied the JCG criteria for non-referral. For patients referred with an IOP >28mmHg and an otherwise normal examination, adherence to the NICE commissioning guidance would have resulted in 6% fewer referrals. In 2010 this scheme reduced the number of patients attending the HES by 15%, which resulted in a saving of 16258 pound (13%). Conclusion The results support that referrals for a raised IOP alone or in combination with an abnormal VF be classified as low-risk and undergo referral refinement. Adherence to the JCG and the NICE commissioning guidance as onward referral criteria for specialist optometrists in this referral refinement scheme would result in fewer referrals. AN - WOS:000315032400014 AU - Ratnarajan, G. AU - Newsom, W. AU - French, K. AU - Kean, J. AU - Chang, L. AU - Parker, M. AU - Garway-Heath, D. F. AU - Bourne, R. R. A. DA - MAR DO - 10.1111/opo.12029 IS - 2 PY - 2013 SN - 0275-5408 SP - 183-189 ST - The impact of glaucoma referral refinement criteria on referral to, and first-visit discharge rates from, the hospital eye service: the Health Innovation & Education Cluster (HIEC) Glaucoma Pathways project T2 - OPHTHALMIC AND PHYSIOLOGICAL OPTICS TI - The impact of glaucoma referral refinement criteria on referral to, and first-visit discharge rates from, the hospital eye service: the Health Innovation & Education Cluster (HIEC) Glaucoma Pathways project VL - 33 ID - 6126 ER - TY - JOUR AB - Background: Asians from the Indian Subcontinent form the largest ethnic minority in the United Kingdom. Data on the prevalence of visually-impairing eye conditions in this population are vital for planning eye health care services. Materials and Methods: This survey was based in the two London boroughs with the largest Asian populations. Subjects originating from the Indian Subcontinent were identified from GP practice records. All subjects were asked about demographic details and were given a full ophthalmological examination. The severity of cataract, glaucoma, diabetic retinopathy, and age-related maculopathy was recorded. Blindness was defined as logMAR visual acuity of 0.99 (Snellen equivalence 20/200 in the better eye) or worse, 'low vision' was defined as Snellen equivalence of 20/63 or worse (logMAR 0.5 or higher), and visual impairment was defined as visual acuity worse than 20/40. Results: The median age was 56 years. Two hundred and eighty four subjects did not attend for eye examination. Of the 922 examined, 128 subjects (13.9%) were 'visually impaired,' 39 (4.2%) had 'low vision,' and 6 (0.7%) were bilaterally blind. The overall prevalence of cataract, open-angle glaucoma, age-related macular degeneration, and diabetic retinopathy were 77%, 1.0%, 8.7%, and 8.8%, respectively. Conclusion: Visual impairment rates amongst Asians seem to be similar to Caucasian populations in the UK. The prevalence of cataract and diabetic retinopathy is higher, while the risk of ARMD and OAG are comparable. In view of the high cataract prevalence, a more detailed assessment of the visual profile and factors limiting healthcare accessibility in this community are needed. AD - Glaucoma Research Unit, NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital Foundation NHS Trust and UCL Institute of Ophthalmology, London, United Kingdom. AN - 109867517. Language: English. Entry Date: 20150724. Revision Date: 20200708. Publication Type: journal article AU - Rauf, Abdul AU - Malik, Rizwan AU - Bunce, Catey AU - Wormald, Richard DB - ccm DO - 10.4103/0301-4738.107191 DP - EBSCOhost IS - 2 KW - Asians White Persons Eye Diseases -- Ethnology Population Surveillance Adult Demography Aged Cross Sectional Studies Female Great Britain Human India -- Ethnology Male Middle Age Prevalence N1 - research. Journal Subset: Asia; Biomedical; Peer Reviewed. NLM UID: 0405376. PMID: NLM23412521. PY - 2013 SN - 0301-4738 SP - 53-58 ST - The British Asian community eye study: outline of results on the prevalence of eye disease in British Asians with origins from the Indian subcontinent T2 - Indian Journal of Ophthalmology TI - The British Asian community eye study: outline of results on the prevalence of eye disease in British Asians with origins from the Indian subcontinent UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109867517&site=ehost-live&scope=site VL - 61 ID - 4493 ER - TY - JOUR AB - Purpose: The purpose of this study was to report the early outcomes in terms of efficacy and safety of a new, indigenously manufactured, low-cost nonvalved drainage device [AADI (Aurolab Aqueous Drainage Implant)] in the management of refractory glaucoma in the Indian population. Methods: Retrospective review of consecutive patients older than 12 years, who underwent glaucoma drainage device surgery (GDD) using AADI, by a single fellowship-trained surgeon, between January 2014 and December 2016, who had at least 3 months of documented post-op follow-up. Outcome measures: Primary-intraocular pressure (IOP). Secondary-number of antiglaucoma medication (AGM), LogMAR best corrected visual acuity (BCVA), and complications. Complete success was defined as IOP >= 5 mm Hg and <= 21 mm Hg or reduction of IOP by >= 20% from baseline without AGM; qualified success with use of AGM. Failure was defined as inability to meet IOP criteria, loss of perception of light, explantation or any additional glaucoma surgery. Results: A total of 54 eyes of 51 patients were included. Mean follow up was 12.1 +/- 6.3 months. The IOP and number of AGM required was significantly lower at every visit postoperatively (P<0.001). Median LogMAR BCVA remained unchanged (P=0.5). Complications occurred in 22 patients (40.7%). Complete success was seen in 66.6%; overall success was 92.6%. Conclusions: New nonvalved GDD (AADI) surgery is effective in reducing IOP and need for AGM with a safety profile similar to published reports of prevailing GDDs. It thus has the ability to breach the cost barrier in low-to-middle income countries; further follow-up is required to determine sustainability over time. AN - WOS:000431515400013 AU - Ray, V. P. AU - Rao, D. P. DA - MAY DO - 10.1097/IJG.0000000000000930 IS - 5 PY - 2018 SN - 1057-0829 1536-481X SP - 433-439 ST - Surgical Outcomes of a New Low-Cost Nonvalved Glaucoma Drainage Device in Refractory Glaucoma: Results at 1 Year T2 - JOURNAL OF GLAUCOMA TI - Surgical Outcomes of a New Low-Cost Nonvalved Glaucoma Drainage Device in Refractory Glaucoma: Results at 1 Year VL - 27 ID - 5948 ER - TY - JOUR AB - Purpose: This study aimed to report the 2-year surgical outcomes in terms of efficacy and safety of the relatively new, indigenously manufactured, low-cost nonvalved drainage device Aurolab Aqueous Drainage Implant (AADI) in the management of refractory glaucomas in the Indian population. Methods: A retrospective review of consecutive patients older than 12 years, who underwent nonvalved glaucoma drainage device surgery via AADI, was performed by a single fellowship-trained surgeon, between January 2014 and January 2018, who had at least 12 months of documented postoperative follow-up. Outcome Measures: Primary-intraocular pressure (IOP). Secondary-number of antiglaucoma medication (AGM), LogMAR best-corrected visual acuity and complications. Complete success was defined as IOP >= 5 and <= 21 mm Hg; qualified success was defined as fulfilling the above criteria with the use of AGM. Failure was defined as the inability to fulfill the IOP criteria, loss of perception of light, explantation, or any additional glaucoma surgery. Results: A total of 48 eyes of 46 patients were included with a median follow-up of 24 months (quartile 1=16, quartile 3=31.25; interquartile range=15.25) (mean=24.9 mo; SD=10.1). The IOP and number of AGM required was significantly lower at every timepoint postoperatively (P<0.001). The median LogMAR best-corrected visual acuity remained unchanged (P=0.307). Complications occurred in 21 patients (43.7%); some eyes had >1 complication. Complete success was seen in 56.3%; overall success was 87.5%. Conclusions: The safety and efficacy of the new nonvalved glaucoma drainage device, AADI, remain in its second year after implantation. Still further follow-up is recommended, as it has the ability to breach the cost barrier in newly industrialized nations worldwide AN - WOS:000570246800013 AU - Ray, V. P. AU - Rao, D. P. DA - SEP DO - 10.1097/IJG.0000000000001532 IS - 9 PY - 2020 SN - 1057-0829 1536-481X SP - 767-772 ST - Two-Year Outcomes of the New Low-cost Nonvalved Aurolab Aqueous Drainage Implant in Refractory Glaucoma T2 - JOURNAL OF GLAUCOMA TI - Two-Year Outcomes of the New Low-cost Nonvalved Aurolab Aqueous Drainage Implant in Refractory Glaucoma VL - 29 ID - 6072 ER - TY - JOUR AB - Purpose: To evaluate current delivery of glaucoma care in Botswana; in particular, the service infrastructure available and glaucoma-related workload.Methods: A multi-center cross-sectional study was undertaken comprising government eye care institutions and ophthalmic personnel across Botswana. Data on human resources, equipment types and numbers, diagnostic criteria routinely used, treatments routinely provided, and new and repeat glaucoma consultations were obtained through quantitative and qualitative surveys.Results: In 27 government eye care institutions there were two general ophthalmologists, neither of whom had a subspecialty interest in glaucoma, 64 ophthalmic nurses, two optometrists, one low vision therapist, one refractionist, and two equipment technicians. Only 8.5% of available ophthalmic human resources were taken up with provision of glaucoma care. About 1/3 of hospitals did not have tonometers, most primary hospitals lacked slit lamp biomicroscopes and most hospitals lacked sensitive diagnostic equipment. A diagnosis of glaucoma was made by either an ophthalmic nurse or an ophthalmologist, but only 10% of institutions could meet recommendations for follow-up assessment. Topical glaucoma medications were prescribed by almost all hospital clinics, usually by ophthalmic nurses. Drug choices were largely determined by local availability. Glaucoma surgery accounted for 0.8% of total eye operations. Glaucoma patients took up 8.5% of total clinic visits. The total number of glaucoma visits was highest in the two hospitals with ophthalmologists. New glaucoma cases took up 10.3% of total glaucoma visits.Conclusion: This study highlights the challenges faced in caring for glaucoma patients in Botswana; in particular, lack of professional human resources, equipment and availability of effective treatments. © 2015 Taylor & Francis Group, LLC. AD - University of Cambridge School of Clinical Medicine, Addenbrookes Hospital, St Edmund's College, Mount Pleasant, Cambridge, CB3 0BN, United Kingdom University of Botswana School of Medicine, Gaborone, Botswana Department of Public Health, Ministry of Health, Gaborone, Botswana Addenbrookes Abroad, Addenbrookes Hospital, Cambridge, United Kingdom Department of Ophthalmology, Addenbrookes Hospital, Cambridge, United Kingdom University of Cambridge, Cambridge NIHR Biomedical Research Centre, Cambridge, United Kingdom Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom AU - Razai, M. S. AU - Jackson, D. J. AU - Falama, R. AU - Mongwa, M. AU - Mutapanduwa, M. G. AU - Baemisi, C. AU - Josiah, E. AU - Nkomazana, O. AU - Lehasa, A. AU - Brealey, E. AU - Jankowski, D. AU - White, A. J. R. AU - Kerr Muir, M. G. AU - Martin, K. R. AU - Ngondi, J. M. DB - Scopus DO - 10.3109/09286586.2015.1010689 IS - 6 KW - Botswana glaucoma care glaucoma-related workload institutional capacity public health service infrastructure M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2015 SP - 403-408 ST - The capacity of eye care services for patients with glaucoma in Botswana T2 - Ophthalmic Epidemiology TI - The capacity of eye care services for patients with glaucoma in Botswana UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84952873373&doi=10.3109%2f09286586.2015.1010689&partnerID=40&md5=8b62ee8095bf912b2d2ec130137e4eeb VL - 22 ID - 5464 ER - TY - JOUR AB - There is debate concerning whether the use of Latanoprost in early postoperative period of cataract surgery and in glaucoma patients with uveitis as it may aggravate the inflammation and results in macular edema (ME), because of blood-ocular barrier disruption. However, there is no solid evidence for disruption of blood-ocular barrier with Latanoprost and aggravation of uveitis or ME formation. Similar to pseudophakic ME, the imaging ME in cases claimed to be secondary to Latanoprost is greater than clinical ME, happens mostly in complicated surgeries, and the vast majority resolve within weeks to months with using a non-steroidal anti-inflammatory drug. The current literature suggests that Latanoprost can be used in patients with uveitis and early after cataract surgery with or without concomitant topical non-steroidal anti-inflammatory drugs that are currently used by many ophthalmologists as a preventive measure for ME even in non-glaucoma uncomplicated cataract surgeries. © 2019, © 2019 Taylor & Francis Group, LLC. AD - Glaucoma Service, Wills Eye Institute, Philadelphia, PA, United States AU - Razeghinejad, M. R. DB - Scopus DO - 10.1080/09273948.2017.1372485 IS - 2 KW - Intraocular inflammation Iritis Latanoprost Macular edema Prostaglandin analogs M3 - Review N1 - Cited By :9 Export Date: 19 July 2021 PY - 2019 SP - 181-188 ST - The Effect of Latanaprost on Intraocular Inflammation and Macular Edema T2 - Ocular Immunology and Inflammation TI - The Effect of Latanaprost on Intraocular Inflammation and Macular Edema UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049882367&doi=10.1080%2f09273948.2017.1372485&partnerID=40&md5=cf39fe2f0cb558299191f1f6731bc8f2 VL - 27 ID - 5299 ER - TY - JOUR AB - BACKGROUND AND OBJECTIVE: To determine whether the use of postoperative topical anti-inflammatory therapy affects the intraocular pressure (IOP)-lowering efficacy of selective laser trabeculoplasty in eyes with primary open-angle glaucoma. PATIENTS AND METHODS: In this prospective, randomized, observer-masked study, 25 participants with primary open-angle glaucoma following bilateral 360° selective laser trabeculoplasty used prednisolone acetate 1% four times daily in one randomly selected eye for 1 week. IOP was assessed at baseline and 1 week, 1 month, and 3 months after selective laser trabeculoplasty. RESULTS: Baseline IOP and selective laser trabeculoplasty treatment parameters were comparable in both groups. Mean IOP was similar in eyes that did and did not receive steroid therapy at 1 week (17.0 vs 16.3 mm Hg, respectively, P = .613), 1 month (16.8 vs 16.2 mm Hg, respectively; P = .571), and 3 months (16.0 vs 15.8 mm Hg, respectively; P = .819). CONCLUSION: A 1-week course of topical prednisolone acetate 1% four times daily did not affect the IOP-lowering effect of selective laser trabeculoplasty in eyes with primary open-angle glaucoma. Copyright ©SLACK Incorporated. AD - West Virginia University Eye Institute, Morgantown, WV, United States Marshall University School of Medicine, Huntington, WV, United States AU - Realini, T. AU - Charlton, J. AU - Hettlinger, M. DB - Scopus DO - 10.3928/15428877-20091230-18 IS - 1 M3 - Article N1 - Cited By :19 Export Date: 19 July 2021 PY - 2010 SP - 100-103 ST - The impact of anti-inflammatory therapy on intraocular pressure reduction following selective laser trabeculoplasty T2 - Ophthalmic Surgery Lasers and Imaging TI - The impact of anti-inflammatory therapy on intraocular pressure reduction following selective laser trabeculoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-76149124843&doi=10.3928%2f15428877-20091230-18&partnerID=40&md5=2e3dc375f40741a0bb26f36d2990db0b VL - 41 ID - 5152 ER - TY - JOUR AB - Glaucoma is the leading cause of irreversible blindness in Africa. The condition is treatable but not curable. There are numerous obstacles to glaucoma care in Africa, including availability, accessibility and affordability of treatments, as well as medication nonadherence among patients. Medical therapy is costly relative to the average income in Africa and it requires daily self-dosing by patients. Surgery is of limited availability in many regions in Africa, and a high proportion of patients refuse surgery because it is expensive. Selective laser trabecu-loplasty (SLT) proves to be a favorable alternative to medical or surgical care, as it is highly effective and safe in people of African descent, more cost-effective than medical therapy, quick and easy to perform, and portable. The procedure also requires no postoperative care, thus obviates the issue of nonadherence. In uncontrolled studies, SLT has a high response rate and it lowers intraocular pressure by 30% to 40%, which exceeds the goal in international guidelines for initial therapies. The African Glaucoma Consortium (AGC), a member-driven stakeholder collective, has been formed in part to develop the infrastructure for continent-wide improvements in glaucoma care. It embraces SLT as a potential key tool in their development plans. The mission of AGC includes improving clinical care by educating existing and new health care professionals to expand the provider network, by conducting trials to identify optimal care strategies for glaucoma in Africa, and by facilitating the development of an integrated network of Centers of Excellence to bring SLT and other crucial glaucoma therapies to communities throughout Africa. AN - WOS:000457162600004 AU - Realini, T. AU - Olawoye, O. AU - Kizor-Akaraiwe, N. AU - Manji, S. AU - Sit, A. DA - NOV-DEC DO - 10.22608/APO.2018271 IS - 6 PY - 2018 SN - 2162-0989 SP - 387-393 ST - The Rationale for Selective Laser Trabeculoplasty in Africa T2 - ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY TI - The Rationale for Selective Laser Trabeculoplasty in Africa VL - 7 ID - 5998 ER - TY - JOUR AB - Purpose: This study summarizes findings from objective assessments of compliance (or adherence) and persistence with ocular hypotensive agents in patients with glaucoma and ocular hypertension. Design: Systematic literature review. Methods: A PubMed and reference list search was conducted across publication years 1970-2010, using these terms and variants: "compliance," the equivalent term "adherence," and "persistence" in patients with these conditions and therapies. Summaries of selected studies were stratified by measurement method (electronic monitor, prescription fills review, medical chart review). Measures of central tendency across studies were calculated for commonly-reported compliance or persistence measures. Results: Fifty-eight articles met all inclusion/exclusion criteria: measurement of compliance- electronic monitoring (seven studies reported in 14 articles), measurement of compliance/ persistence-prescription records (36 studies in 38 articles), and measurement of persistence- medical chart review (six studies in six articles). From electronic monitoring, most therapyexperienced patients took medication consistently, but ≥20% met criteria for poor compliance. From prescription records, only 56% (range 37%-92%) of the days in the first therapy year could be dosed with the medication supply dispensed over this period. At 12 months from therapy start, only 31% (range 10%-68%) of new therapy users had not discontinued, and 40% (range 14%-67%) had not discontinued or changed the initial therapy. From medical chart review, only 67% (range 62%-78%) of patients remained persistent 12 months after starting therapy. Conclusions: Evidence provided by this review suggests that poor compliance and persistence has been and remains a common problem for many glaucoma patients, and is especially problematic for patients new to therapy. The direction of empirical research should shift toward a greater emphasis on understanding of root causes and identification and testing of solutions for this problem. © 2011 Reardon et al, publisher and licensee Dove Medical Press Ltd. AD - Informagenics, LLC, 450 W. Wilson Bridge Rd, Suite 340, Worthington, OH, United States Pfizer Inc, New York, NY, United States Glaucoma Consultants, Greater Baltimore Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States The Ohio State University College of Pharmacy, Columbus, OH, United States AU - Reardon, G. AU - Kotak, S. AU - Schwartz, G. F. DB - Scopus DO - 10.2147/PPA.S23780 KW - Adherence Glaucoma Ocular hypertension Persistence Review M3 - Review N1 - Cited By :93 Export Date: 19 July 2021 PY - 2011 SP - 441-463 ST - Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: A systematic review T2 - Patient Preference and Adherence TI - Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: A systematic review UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863196283&doi=10.2147%2fPPA.S23780&partnerID=40&md5=16e38c356bdcf276c1f5adab294c0ff9 VL - 5 ID - 4935 ER - TY - JOUR AB - BACKGROUND: Prior research has demonstrated that medication persistence (continued acquisition of therapy over time) is far from optimal among patients with glaucoma. The purpose of the present study was to evaluate persistence with prostaglandin analogs among glaucoma patients in the first therapy year using a modification of a previously published technique. METHODS: This retrospective analysis of medical and pharmacy claims database included treatment-naive patients dispensed bimatoprost, latanoprost, or travoprost between 1/1/04-12/31/04. "Index agent" was defined as the first agent filled; "index date" was defined as the fill date. Follow-up continued for 358 days. Persistence measures for first therapy year were: (1) whether last fill had sufficient days supply to achieve medication possession at year's end, and (2) number of days for which the index agent was available (days covered). Associations between index agent and medication possession (logistic regression) and days covered (linear regression) were evaluated. Models were adjusted for gender, age, and previous ocular hypertension diagnosis. RESULTS: 7873 patients met inclusion criteria (bimatoprost, n = 1464; latanoprost, n = 4994; travoprost, n = 1415). Medication possession was 28% and days covered was 131 when using the unadjusted (pharmacy-reported) days supply estimates and rose to 47-48% and days covered to 228-236 days when days supply was imputed. Compared to latanoprost, odds of achieving medication possession at first year's end were 26-34% lower for bimatoprost and 34-36% lower for travoprost (p 21 mm Hg in individuals with no evidence of optic nerve damage is termed ocular hypertension, a risk factor for glaucoma that has been estimated to affect as many as 10% of individuals 40 years of age or older. OBJECTIVE: The purpose of this research was to assess persistency (time on therapy) with prostaglandin analogues in the treatment of glaucoma or ocular hypertension. METHODS: This population-based, retrospective cohort study used the Protocare Sciences managed care database, which includes prescription and medical claims data from multiple managed care organizations. Patients 20 years of age or older who initiated therapy with latanoprost, bimatoprost, or travoprost (index drugs) between April 2001 and June 2002 were included. Patients were required to be continuously enrolled in the same plan for the 180 days preceding index prescription fill. Follow-up continued through June 30, 2002. Two outcome measures were analyzed: (1) discontinuation of the index prostaglandin and (2) either discontinuation or change in the index prostaglandin regimen. Changing therapy was defined as switching to or adding another ocular hypotensive agent. Cox regression models were used to compare rate ratios of discontinuation and discontinuation/change. Patient data were censored on termination of insurance coverage or at the end of the study period. RESULTS: Overall, 7527 patients were prescribed a prostaglandin analogue; 4356 patients met the inclusion criteria (n = 2376, 993, and 987 for latanoprost, bimatoprost, and travoprost, respectively). A total of 58% of patients were women, and 74% were 65 years of age or older. Compared with latanoprost, those treated with bimatoprost were 38% more likely to discontinue and 31% more likely to discontinue/change therapy, and patients treated with travoprost were 36% more likely to discontinue and 29% more likely to discontinue/change therapy (P < 0.001 for each comparison). CONCLUSION: Latanoprost-treated patients demonstrated significantly (P < 0.001) greater persistency than did those treated with either bimatoprost or travoprost. AD - Informagenics, LLC, 500 W Wilson Bridge Road, Suite 115, Worthington, OH 43085; greardon@informagenics.com AN - 106884891. Language: English. Entry Date: 20031114. Revision Date: 20200701. Publication Type: Journal Article AU - Reardon, G. AU - Schwartz, G. F. AU - Mozaffari, E. DB - ccm DO - 10.1016/s0149-2918(03)80074-7 DP - EBSCOhost IS - 4 KW - Medication Compliance Prostaglandins -- Analysis Prostaglandins -- Therapeutic Use Adult Aged Billing and Claims Chi Square Test Comparative Studies Cox Proportional Hazards Model Female Glaucoma -- Drug Therapy Male Middle Age Patient Compliance Retrospective Design Survival Analysis Treatment Outcomes -- Evaluation Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 7706726. PMID: NLM12809964. PY - 2003 SN - 0149-2918 SP - 1172-1185 ST - Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study T2 - Clinical Therapeutics TI - Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106884891&site=ehost-live&scope=site VL - 25 ID - 4595 ER - TY - JOUR AB - PURPOSE: To evaluate persistency with monotherapy in the treatment of glaucoma in patients new to pharmacological management. METHODS: This population-based, retrospective cohort study, using managed care administrative claims data, included patients who were 20 years of age and older and who initiated monotherapy with betaxolol, brimonidine, dorzolamide, latanoprost, or timolol between May 1999 and January 2001. Follow-up continued through January 31, 2001, and prescription refill records for all ocular hypotensive medications were extracted for the full 21-month study period. The primary outcome measures were discontinuation and change (switching/adding on) of the index ocular hypotensive medication. Rates of discontinuation and discontinuation/change were compared using Cox regression methods; survival curves were generated. RESULTS: In all, 14,539 patients were prescribed any ocular hypotensive drug during the study period, and 2850 patients met all inclusion criteria. Patients treated with betaxolol, brimonidine, dorzolamide, or timolol were significantly (p < 0.05) more likely to discontinue and to discontinue/change the index therapy than were those treated with latanoprost. Results were confirmed in analyses adjusted for age and sex. CONCLUSIONS: Patients initially treated with latanoprost monotherapy are more persistent than those who begin treatment with beta-blockers, brimonidine, or the carbonic anhydrase inhibitor dorzolamide. Greater persistency with an initial ocular hypotensive therapy may improve health outcomes and reduce long-term costs to patients and health plans by limiting the increased resource use associated with discontinuations or changes in therapy. AD - Informagenics, LLC, Worthington, OH 43085, United States AU - Reardon, G. AU - Schwartz, G. F. AU - Mozaffari, E. DB - Scopus DO - 10.1177/112067210301304s05 M3 - Article N1 - Cited By :44 Export Date: 19 July 2021 PY - 2003 SP - S44-52 ST - Patient persistency with pharmacotherapy in the management of glaucoma T2 - European journal of ophthalmology TI - Patient persistency with pharmacotherapy in the management of glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0642343075&doi=10.1177%2f112067210301304s05&partnerID=40&md5=6a8c9161e1a4c252d9bfdc1993f85c7d VL - 13 Suppl 4 ID - 5011 ER - TY - JOUR AB - PURPOSE: To evaluate persistency with topical ocular hypotensive therapies in patients new to pharmacological management of elevated intraocular pressure (IOP). DESIGN: Retrospective, cohort study; Protocare Sciences managed care database; approximately 3 million members in commercial health maintenance organizations and preferred provider organizations and in Medicare risk plans. METHODS: Patients were at least 20 years of age initiating therapy between July 1, 1996, and June 30, 2002, with betaxolol, bimatoprost, brimonidine, dorzolamide, latanoprost, timolol, or travoprost as monotherapy. Patients must have been continuously enrolled and not have received glaucoma surgery in the 180 days before the index prescription fill. Prescription refill records for all ocular hypotensive drugs were extracted through June 30, 2002. Outcome measures were (1) discontinuation of index drug, and (2) either discontinuation or change in index drug. Changing therapy was defined as switching to or adding another ocular hypotensive. Rates of discontinuation and discontinuation/change were compared using Cox regression models. RESULTS: In all, 28,741 patients met the inclusion criteria. Compared with latanoprost, those treated with other drugs were from 37% (timolol) to 72% (bimatoprost) more likely to discontinue and from 20% (timolol) to 58% (dorzolamide) more likely to discontinue/change therapy (P < .001 for all comparisons). At 12 months, 33% of patients treated with latanoprost and 19% of those receiving other ocular hypotensives had not discontinued therapy; 23% and 13%, respectively, had not discontinued or changed therapy. Compared with latanoprost, significantly higher percentages of patients treated with each alternate agent had only one fill of their index drugs (P < .001). CONCLUSIONS: Although persistency rates were low across agents, latanoprost-treated patients demonstrated significantly greater persistency than did those treated with other topical ocular hypotensive therapies. © 2004 by Elsevier Inc. All rights reserved. AD - G. Reardon, Informagenics, LLC, 500 W. Wilson Bridge Rd, Worthington, OH 43085, United States AU - Reardon, G. AU - Schwartz, G. F. AU - Mozaffari, E. DB - Embase Medline DO - 10.1016/j.ajo.2003.10.035 IS - SUPPL. KW - antihypertensive agent betaxolol bimatoprost brimonidine dorzolamide hydroxymethylglutaryl coenzyme A reductase inhibitor latanoprost timolol travoprost adult aged article cohort analysis controlled study data base drug use drug withdrawal female glaucoma health maintenance organization human intraocular hypertension major clinical study male managed care medical record medicare monotherapy outcomes research patient compliance population research prescription priority journal regression analysis retrospective study topical treatment LA - English M3 - Article N1 - L38091629 2004-02-03 PY - 2004 SN - 0002-9394 SP - S3-S12 ST - Patient persistency with topical ocular hypotensive therapy in a managed care population T2 - American Journal of Ophthalmology TI - Patient persistency with topical ocular hypotensive therapy in a managed care population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38091629&from=export http://dx.doi.org/10.1016/j.ajo.2003.10.035 VL - 137 ID - 3762 ER - TY - JOUR AB - Background: Inhaled corticosteroids and oral theophylline are effective treatments for moderate asthma. Objective: We sought to compare the benefits and adverse reactions of theophylline and aerosol beclomethasone spray. Methods: A multicenter, double-blind, double-placebo, randomized, controlled trial of 1-year duration was performed. Seven hundred forty-seven patients with asthma received either beclomethasone dipropionate aerosol spray (84 μg four times per day) or sustained-release theophylline twice per day in doses adjusted for optimum control of the disease. The main outcome measures were daily diary of symptoms and peak flow rates (recorded on a mark-sense computer-readable form); supplemental bronchodilator use; doctor's office or hospital visits and absence from work or school; spirometry; methacholine testing; adverse experiences; and cortisol blood measurements. Results: Both treatment strategies reduced symptoms promptly and achieved low absenteeism from work or school and low rates of emergency treatment for asthma. Both maintained nearly normal pulmonary function. Beclomethasone was statistically significantly more effective in reducing symptoms, supplemental bronchodilator and systemic glucocorticoid doses, bronchial hyperresponsiveness, and eosinophilia. However, the magnitude of these differences was small. Theophylline caused more headache, nervousness, insomnia, and gastrointestinal distress, and more patients discontinued treatment because of side effects. Beclomethasone caused more oropharyngeal candidiases and hoarseness and reduced morning plasma cortisol levels before and after cosyntropin. It reduced the rate of growth in children. No new cataracts or glaucoma developed. Conclusion: Theophylline effectively controlled symptoms at lower than the customarily recommended blood level. The risk/benefit profiles of these agents suggest that inhaled corticosteroids may be the preferred agent for most adult patients and for some children. AD - Department of Allergy Research, Rochester, MN, United States Department of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, MN, United States National Jewish Center for Immunology and Respiratory Medicine, Mayo Clinic and Mayo Foundation, Denver, CO, United States Department of Allergy, Mayo Clinic and Mayo Foundation, Rochester, MN, United States Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States AU - Reed, C. E. AU - Offord, K. P. AU - Nelson, H. S. AU - Li, J. T. AU - Tinkelman, D. G. DB - Scopus DO - 10.1016/S0091-6749(98)70187-3 IS - 1 KW - Asthma Beclomethasone Theophylline M3 - Article N1 - Cited By :67 Export Date: 19 July 2021 PY - 1998 SP - 14-23 ST - Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma T2 - Journal of Allergy and Clinical Immunology TI - Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-6844265571&doi=10.1016%2fS0091-6749%2898%2970187-3&partnerID=40&md5=8273ff2fb4c9d0e3ab366af2e34e2fb0 VL - 101 ID - 4962 ER - TY - JOUR AB - Background: Inhaled corticosteroids and oral theophylline are effective treatments for moderate asthma. Objective: We sought to compare the benefits and adverse reactions of theophylline and aerosol beclomethasone spray. Methods: A multicenter, double-blind, double-placebo, randomized, controlled trial of 1-year duration was performed. Seven hundred forty-seven patients with asthma received either beclomethasone dipropionate aerosol spray (84 mu g four times per day) or sustained-release theophylline twice per day in doses adjusted for optimum control of the disease. The main outcome measures were daily diary of symptoms and peak flow rates (recorded on a mark-sense computer-readable form); supplemental bronchodilator use; doctor's office or hospital visits and absence from work or school; spirometry; methacholine testing; adverse experiences; and cortisol blood measurements. Results: Both treatment strategies reduced symptoms promptly and achieved low absenteeism from work or school and low rates of emergency treatment for asthma. Both maintained nearly normal pulmonary function. Beclomethasone was statistically significantly more effective in reducing symptoms, supplemental bronchodilator and systemic glucocorticoid doses, bronchial hyperresponsiveness, and eosinophilia. However, the magnitude of these differences was small. Theophylline caused more headache, nervousness, insomnia, and gastrointestinal distress, and more patients discontinued treatment because of side effects. Beclomethasone caused more oropharyngeal candidiases and hoarseness and reduced morning plasma cortisol levels before and after cosyntropin. It reduced the rate of growth in children, No new cataracts or glaucoma developed. Conclusion: Theophylline effectively controlled symptoms at lower than the customarily recommended blood level. The risk/benefit profiles of these agents suggest that inhaled corticosteroids may be the preferred agent for most adult patients and for some children. AN - WOS:000071539800003 AU - Reed, C. E. AU - Offord, K. P. AU - Nelson, H. S. AU - Li, J. T. AU - Tinkelman, D. G. AU - Amer Acad Allergy Asthma Immunology, Beclometha DA - JAN DO - 10.1016/S0091-6749(98)70187-3 IS - 1 PY - 1998 SN - 0091-6749 1097-6825 SP - 14-23 ST - Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma T2 - JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY TI - Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma VL - 101 ID - 6344 ER - TY - JOUR AB - Changes in the healthcare system, population demographics, and treatment alternatives have contributed to an emerging awareness of glaucoma among managed care organizations. Early diagnosis and treatment are essential to thwarting the personal and economic consequences of end-stage glaucoma. Despite recognition of the need for early intervention and therapy, the literature suggests a great need still exists for improvements in lowering intraocular pressure, managing appropriate follow-up, and improving adherence to current glaucoma medication regimens. As the elderly population continues to increase, these issues will intensify and present further problems for the healthcare system. The purpose of this introductory manuscript is to highlight the literature on the clinical and economic impact of glaucoma and its importance to the managed care community. The remainder of the supplement will focus on the current management of glaucoma and the potential role of neuroprotection in this patient population. AD - C. E. Reeder, Xcenda, 3270 Girardeau Ave, Columbia, SC 29204, United States AU - Reeder, C. E. AU - Franklin, M. AU - Bramley, T. J. DB - Embase Medline IS - SUPPL. 1 KW - bimatoprost dorzolamide plus timolol latanoprost timolol drug cost follow up glaucoma health care system human intraocular pressure managed care organization medical care neuroprotection prevalence priority journal review trabeculoplasty LA - English M3 - Review N1 - L351341922 2008-03-28 PY - 2008 SN - 1088-0224 SP - S5-S10 ST - Managed care and the impact of glaucoma T2 - American Journal of Managed Care TI - Managed care and the impact of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351341922&from=export VL - 14 ID - 3465 ER - TY - JOUR AB - Changes in the healthcare system, population demographics, and treatment alternatives have contributed to an emerging awareness of glaucoma among managed care organizations. Early diagnosis and treatment are essential to thwarting the personal and economic consequences of end-stage glaucoma. Despite recognition of the need for early intervention and therapy, the literature suggests a great need still exists for improvements in lowering intraocular pressure, managing appropriate follow-up, and improving adherence to current glaucoma medication regimens. As the elderly population continues to increase, these issues will intensify and present further problems for the healthcare system. The purpose of this introductory manuscript is to highlight the literature on the clinical and economic impact of glaucoma and its importance to the managed care community. The remainder of the supplement will focus on the current management of glaucoma and the potential role of neuroprotection in this patient population. AD - Xcenda, 3270 Girardeau Ave, Columbia, SC 29204, United States AU - Reeder, C. E. AU - Franklin, M. AU - Bramley, T. J. DB - Scopus IS - SUPPL. 1 M3 - Review N1 - Cited By :8 Export Date: 19 July 2021 PY - 2008 SP - S5-S10 ST - Managed care and the impact of glaucoma T2 - American Journal of Managed Care TI - Managed care and the impact of glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-40349108274&partnerID=40&md5=7cab4b523dc082c1bb99f498063f4a86 VL - 14 ID - 5338 ER - TY - JOUR AB - PURPOSE:: To determine adherence rates and beliefs about glaucoma and its treatment in white Americans, African Americans, white Australians, and Singaporeans of Chinese descent. PATIENTS AND METHODS:: Cross-sectional study of 475 glaucoma patients using topical eye drops for at least 6 months. The sample consisted of white Americans (n=133), African Americans (n=58), white Australians (n=107), and Singaporeans of Chinese descent (n=117). Self-reported adherence and beliefs about glaucoma and its treatment were assessed using the Reported Adherence to Medication scale, the Brief Illness Perception Questionnaire, and the Beliefs about Medicines-Specific Questionnaire. RESULTS:: Accounting for sociodemographic differences, significant differences in self-reported adherence rates were identified (P<0.001). White Americans and Australians reported significantly higher adherence (65.4%, 67.7% reported complete adherence) than African Americans or Singaporeans (56.9%, 47.5%, respectively; P<0.05). Beliefs about glaucoma treatment were predictive of adherence only in the Australian and white American samples (P<0.05). CONCLUSIONS:: In western cultures, attempts to improve adherence may benefit from greater examination of individual's concerns about, and perceived need, for glaucoma treatment. Further studies are needed to identify the critical predictors of adherence in nonwestern cultures and to validate measures in these populations. Copyright © 2012 by Lippincott Williams & Wilkins. AD - G. Rees, Department of Ophthalmology, Centre for Eye Research Australia, University of Melbourne, Locked Bag 8, East Melbourne, VIC 8002, Australia AU - Rees, G. AU - Chong, X. L. AU - Cheung, C. Y. AU - Aung, T. AU - Friedman, D. S. AU - Crowston, J. G. AU - Lamoureux, E. L. DB - Embase Medline DO - 10.1097/IJG.0b013e3182741f1c IS - 5 KW - African American aged article attitude to illness Chinese comparative study cross-sectional study cultural anthropology educational status European American female glaucoma human major clinical study male medication compliance patient attitude patient compliance priority journal self report treatment duration LA - English M3 - Article N1 - L52421300 2013-02-06 2014-06-26 PY - 2014 SN - 1536-481X 1057-0829 SP - 293-298 ST - Beliefs and adherence to glaucoma treatment: A comparison of patients from diverse cultures T2 - Journal of Glaucoma TI - Beliefs and adherence to glaucoma treatment: A comparison of patients from diverse cultures UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52421300&from=export http://dx.doi.org/10.1097/IJG.0b013e3182741f1c VL - 23 ID - 2920 ER - TY - JOUR AB - Objective: To determine the rate of intentional and unintentional nonadherence in glaucoma patients and to identify associations between adherence behavior and patients' beliefs. Design: Cross-sectional study. Participants: One hundred thirty-one glaucoma patients using topical eye drops for at least 6 months. Methods: Interviewer-administered surveys. Main Outcome Measures: Self-reported adherence and beliefs about glaucoma and its treatment were assessed using the Reported Adherence to Medication scale, the Brief Illness Perception Questionnaire, and the Beliefs about Medicines-Specific Questionnaire. Results: Overall, 59 (45%) participants reported some degree of nonadherence, among whom 39 (66.1%) reported unintentional nonadherence (e.g., forgetting), 10 (16.9%) reported intentional nonadherence (deliberate nonadherence), and 10 (16.9%) reported both forms of nonadherence. Compared with adherers, nonadherers were significantly younger, were less likely to have other nonocular health conditions or to use medicines other than their eye drops, and reported lower belief in the necessity of eye drops for glaucoma (P<0.05). Degree of unintentional nonadherence was associated with lower belief in necessity of eye drops, whereas degree of intentional nonadherence was associated with concerns about eye drops. Conclusions: Strategies aimed at improving adherence in glaucoma patients need to address both intentional and unintentional dimensions. Interventions focused on eliciting and addressing patients' beliefs and concerns about their eye drops require evaluation. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2010 American Academy of Ophthalmology. AD - G. Rees, Centre for Eye Research Australia, the Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia AU - Rees, G. AU - Leong, O. AU - Crowston, J. G. AU - Lamoureux, E. L. DB - Embase Medline DO - 10.1016/j.ophtha.2009.10.038 IS - 5 KW - antihypertensive agent adolescent adult age aged article controlled study cross-sectional study female glaucoma health belief human interview major clinical study male patient attitude patient compliance priority journal questionnaire self report LA - English M3 - Article N1 - L50799370 2010-03-02 2010-05-18 PY - 2010 SN - 0161-6420 SP - 903-908 ST - Intentional and Unintentional Nonadherence to Ocular Hypotensive Treatment in Patients with Glaucoma T2 - Ophthalmology TI - Intentional and Unintentional Nonadherence to Ocular Hypotensive Treatment in Patients with Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50799370&from=export http://dx.doi.org/10.1016/j.ophtha.2009.10.038 VL - 117 ID - 3260 ER - TY - JOUR AB - BACKGROUND: The objective of this study was to ascertain the scoring and assess the psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), a 43-item Patient-Reported Outcome instrument developed to assess patients' satisfaction and compliance with glaucoma treatment. METHODS: The EDSQ was administered during an observational, retrospective study to 184 French patients treated for glaucoma. The hypothesized structure, including six dimensions (patient-clinician relationship; patient experience; patient-treatment interaction; apprehension; patient knowledge; travel), was tested by assessing the internal consistency reliability (Cronbach's alpha) and construct-related validity (item convergent and discriminant validity). As unsatisfactory results were demonstrated, another structure was defined using a principal component analysis (PCA) combined with content of items. Psychometric properties of this new structure were assessed. Scores were compared between low, moderate and high compliance profile groups defined using data collected with the Travalert electronic device. RESULTS: Analyses were performed with the 169 patients who completed at least half of the EDSQ items. The hypothesized structure showed a Cronbach's alpha lower than 0.70 for four dimensions out of six and an overall poor construct-related validity (range of item-scale correlations: 0.00-0.68). The new structure obtained with the PCA included six dimensions: concern about treatment (five items); concern about disease (two items); satisfaction with patient-clinician relationship (five items); positive beliefs (three items); treatment convenience (three items); and self-declared compliance (three items). A score ranging from 0 to 100 was calculated for each dimension, with higher scores indicating more of the attribute referred to in the dimension. Internal consistency reliability was good (Cronbach's alpha greater than 0.70 for five dimensions). The structure offered good construct-related validity (range of item-scale correlations: 0.36-0.82). Ceiling effects of 21% and 49%, were observed for the satisfaction with patient-clinician relationship and self-declared compliance scores. Patients in low compliance profile group reported the lowest score for the satisfaction with patient-clinician relationship, positive beliefs, treatment convenience and self-declared compliance dimensions, and the highest score for the concern about treatment dimension. CONCLUSIONS: The scoring of the EDSQ was developed and the questionnaire proved to have satisfactory psychometric properties. EDSQ scores showed a promising relationship to compliance profiles. The EDSQ could be used in future studies. AD - A. Regnault, Mapi Values, Lyon, France. AU - Regnault, A. AU - Viala-Danten, M. AU - Gilet, H. AU - Berdeaux, G. DB - Medline DO - 10.1186/1471-2415-10-1 KW - eye drops adolescent adult aged article clinical trial cross-sectional study doctor patient relationship drug delivery system female human devices male methodology middle aged multicenter study open angle glaucoma patient compliance patient satisfaction principal component analysis psychometry questionnaire reproducibility retrospective study statistics LA - English M3 - Article N1 - L358929638 2010-06-10 PY - 2010 SN - 1471-2415 SP - 1 ST - Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment T2 - BMC ophthalmology TI - Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358929638&from=export http://dx.doi.org/10.1186/1471-2415-10-1 VL - 10 ID - 3248 ER - TY - JOUR AN - 105148166. Language: English. Entry Date: 20110218. Revision Date: 20200708. Publication Type: Journal Article AU - Regnault, A. AU - Viala-Danten, M. AU - Gilet, H. AU - Berdeaux, G. DB - ccm DO - 10.1186/1471-2415-10-1 DP - EBSCOhost KW - Glaucoma -- Drug Therapy Patient Compliance Patient Satisfaction -- Statistics and Numerical Data Psychometrics -- Methods Questionnaires Adolescence Adult Aged Aged, 80 and Over Cross Sectional Studies Drug Delivery Systems -- Equipment and Supplies Female Human Male Middle Age Ophthalmic Solutions -- Administration and Dosage Physician-Patient Relations Factor Analysis Reproducibility of Results Retrospective Design Young Adult N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 100967802. PMID: NLM20122146. PY - 2010 SN - 1471-2415 SP - 1-1 ST - Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment T2 - BMC Ophthalmology TI - Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105148166&site=ehost-live&scope=site VL - 10 ID - 4733 ER - TY - JOUR AB - BACKGROUND: With the increasing age of our population many of the causes of vision loss are becoming more frequent. Not all gradual loss of vision can be considered non urgent and those patients requiring early attention are highlighted. OBJECTIVE: This article discusses the tools available to the general practitioner for the assessment of visual loss as well as the common causes. DISCUSSION: Advances in cataract surgery with improved visual outcome, minimally invasive surgery and a reduction in surgical risk have made this operation the commonest performed in Australia. Blindness from chronic open angle glaucoma and diabetes can be mostly prevented by early diagnosis and compliance with treatment. Age related macular degeneration apart from a small subgroup, is still largely untreatable. AD - Head, General Clinic, Royal Victorian Eye and Ear Hospital AN - 106988489. Language: English. Entry Date: 20010105. Revision Date: 20150711. Publication Type: Journal Article AU - Reich, J. DB - ccm DP - EBSCOhost IS - 3 KW - Vision Disorders -- Etiology Refractive Errors Vision Disorders -- Diagnosis Vision Tests Ophthalmoscopy Myopia Astigmatism Amblyopia Diabetic Retinopathy Cataract Glaucoma Macular Degeneration N1 - pictorial; tables/charts. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 0326701. PMID: NLM9529700. PY - 1998 SN - 0300-8495 SP - 143-147 ST - Gradual loss of vision T2 - Australian Family Physician TI - Gradual loss of vision UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106988489&site=ehost-live&scope=site VL - 27 ID - 4641 ER - TY - JOUR AB - Background: Topical corticosteroids are the only effective measure in serious inflammatory corneal and conjunctival diseases. Although results obtained with topical cyclosporin A are encuraging it is not effective in all patients. The mode of action of Fk506 is similar to that of cyclosporin A, i.e. it exerts an inhibitory effect on transcription of interleukin 2 in T lymphocytes. The immunosuppressive potential of Fk506, however, is much larger. Furthermore, it penetrates more easily into cornea and conjunctiva. To find out whether the theoretical advantages of topical Fk506 can be translated into clinical practice, a selected group of patients refractory to conventional therapy was treated in this pilot study. Patients and methods: Fk506 0.06% was administered initially three times daily in 15 patients with atopic blepharokeratoconjunctivitis, Mooren's ulcer, ocular pemphigoid, Thygeson's superficial punctate keratitis, nummular adenoviral keratitis, graft-versus-host reaction of the conjunctiva and steroid response glaucoma after penetrating keratoplasty. Results: Within a follow-up of 26 ± 15 weeks improvement was recorded in 5/15 patients and stabilization in 5/15 patients. In two patients progression of the disease was noted (one patient with progression of ocular pemphigoid, another patient with suspected automutilation). Premature withdrawal the drug was judged to be necessary in two patients with ocular surface disorders and in one patient with non-compliance. Conclusions: Topical Fk506 seems to be a promising new immunosuppressive drug for patients with atopic blepharokeratoconjunctivitis, Thygeson's superficial punctate keratitis and nummular adenoviral keratitis. Exact efficacy in these and other corneal and conjunctival inflammatory diseases has to be determined in randomised clinical studies. Before these studies may start the risk of side-effects must be reduced via an improvement of the drops. AD - T. Reinhard, Augenklin. der Heinrich-Heine-Univ., Moornstraße 5, 50225 Düsseldorf, Germany AU - Reinhard, T. AU - Reis, A. AU - Mayweg, S. AU - Oberhuber, H. AU - Mathis, G. AU - Sundmacher, R. C1 - fk 506 DB - Embase Medline DO - 10.1055/s-2002-26727 IS - 3 KW - cyclosporine interleukin 2 tacrolimus adult aged article clinical article conjunctiva disease cornea disease drug effect drug efficacy female human immunosuppressive treatment keratitis male patient compliance penetrating keratoplasty pilot study side effect T lymphocyte activation fk 506 LA - German M3 - Article N1 - L34625138 2002-06-24 PY - 2002 SN - 0023-2165 SP - 125-131 ST - Topical Fk506 in inflammatory corneal and conjunctival diseases: A pilot study T2 - Klinische Monatsblatter fur Augenheilkunde TI - Topical Fk506 in inflammatory corneal and conjunctival diseases: A pilot study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34625138&from=export http://dx.doi.org/10.1055/s-2002-26727 VL - 219 ID - 3865 ER - TY - JOUR AB - Background: Topical corticosteroids are the only effective measure in serious inflammatory corneal and conjunctival diseases. Although results obtained with topical cyclosporin A are encuraging it is not effective in all patients. The mode of action of Fk506 is similar to that of cyclosporin A, i.e. it exerts an inhibitory effect on transcription of interleukin 2 in T lymphocytes. The immunosuppressive potential of Fk506, however, is much larger. Furthermore, it penetrates more easily into cornea and conjunctiva. To find out whether the theoretical advantages of topical Fk506 can be translated into clinical practice, a selected group of patients refractory to conventional therapy was treated in this pilot study. Patients and methods: Fk506 0.06% was administered initially three times daily in 15 patients with atopic blepharokeratoconjunctivitis, Mooren's ulcer, ocular pemphigoid, Thygeson's superficial punctate keratitis, nummular adenoviral keratitis, graft-versus-host reaction of the conjunctiva and steroid response glaucoma after penetrating keratoplasty. Results: Within a follow-up of 26 15 weeks improvement was recorded in 5/15 patients and stabilization in 5/15 patients. In two patients progression of the disease was noted (one patient with progression of ocular pemphigoid, another patient with suspected automutilation). Premature withdrawal the drug was judged to be necessary in two patients with ocular surface disorders and in one patient with non-compliance. Conclusions: Topical Fk506 seems to be a promising new immunosuppressive drug for patients with atopic blepharokeratoconjunctivitis, Thygeson's superficial punctate keratitis and nummular adenoviral keratitis. Exact efficacy in these and other corneal and conjunctival inflammatory diseases has to be determined in randomised clinical studies. Before these studies may start the risk of side-effects must be reduced via an improvement of the drops. AN - WOS:000175555200006 AU - Reinhard, T. AU - Reis, A. AU - Mayweg, S. AU - Oberhuber, H. AU - Mathis, G. AU - Sundmacher, R. DA - MAR DO - 10.1055/s-2002-26727 IS - 3 PY - 2002 SN - 0023-2165 SP - 125-131 ST - Topical Fk506 in inflammatory corneal and conjunctival diseases - A pilot study T2 - KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE TI - Topical Fk506 in inflammatory corneal and conjunctival diseases - A pilot study VL - 219 ID - 6163 ER - TY - JOUR AB - Adherence to glaucoma therapy is a major factor of therapeutic efficacy. It reflects the patient's perception of the glaucoma disease and its treatment. Evaluation of adherence, often underestimated, is simple with a four-step strategy underscoring the importance of informing and educating the patient. The quality of the physician-patient relationship is essential for a good adapted assessment with every patient and at all stages of the disease so as to enhance adherence to glaucoma treatment and help patients. © 2010 Elsevier Masson SAS. All rights reserved. AD - J.P. Renard, Service d'ophtalmologie, HIA du Val-de-Grâce, Paris, France AU - Renard, J. P. AU - Giraud, J. M. AU - Fenolland, J. R. AU - May, F. DB - Medline DO - 10.1016/j.jfo.2010.02.004 IS - 4 KW - article attitude to health doctor patient relationship glaucoma human motivation motor performance patient compliance patient education social environment treatment outcome LA - French M3 - Article N1 - L50839127 2010-07-26 PY - 2010 SN - 0181-5512 SP - 291-295 ST - Adherence to glaucoma therapy T2 - Journal Francais d'Ophtalmologie TI - Adherence to glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50839127&from=export http://dx.doi.org/10.1016/j.jfo.2010.02.004 VL - 33 ID - 3267 ER - TY - JOUR AB - A pretest-posttest control group experimental design (n = 100) was used to determine the effectiveness of an interactive patient education program compared with a didactic approach for persons with primary open angle glaucoma at a major specialist eye hospital in England. This study used a questionnaire with a knowledge test to explore patients' glaucoma knowledge, a series of vignettes to explore understanding of compliance and health motivation, and health locus of control scales to assess the effect of these variables. The improved posttest results (P = .000) suggest that patients benefit from education programs and that the ophthalmic nurse is an effective patient teacher. The interactive program had no statistically significant difference from the didactic presentation. Other types of interactive programs may prove to be more beneficial. (Insight 2000;25:1 12-8.). AD - J. Rendell, 74 Rogers Road, London El6 1lLR, United Kingdom AU - Rendell, J. DB - Medline DO - 10.1067/min.2000.104919 IS - 4 KW - adult aged article attitude to health female health education human male methodology middle aged open angle glaucoma patient compliance psychological aspect questionnaire LA - English M3 - Article N1 - L31228362 2002-03-22 PY - 2000 SN - 1060-135X SP - 112-118 ST - Effect of health education on patients' beliefs about glaucoma and compliance T2 - Insight - Journal of the American Society of Ophthalmic Registered Nurses TI - Effect of health education on patients' beliefs about glaucoma and compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L31228362&from=export http://dx.doi.org/10.1067/min.2000.104919 VL - 25 ID - 3907 ER - TY - JOUR AB - A pretest-posttest control group experimental design (n = 100) was used to determine the effectiveness of an interactive patient education program compared with a didactic approach for persons with primary open angle glaucoma at a major specialist eye hospital in England. This study used a questionnaire with a knowledge test to explore patients' glaucoma knowledge, a series of vignettes to explore understanding of compliance and health motivation, and health locus of control scales to assess the effect of these variables. The improved posttest results (P = .000) suggest that patients benefit from education programs and that the ophthalmic nurse is an effective patient teacher. The interactive program had no statistically significant difference from the didactic presentation. Other types of interactive programs may prove to be more beneficial. AN - 107000124. Language: English. Entry Date: 20010223. Revision Date: 20150820. Publication Type: Journal Article AU - Rendell, J. DB - ccm DP - EBSCOhost IS - 4 KW - Patient Education Glaucoma -- Education Patient Compliance Pretest-Posttest Design Experimental Studies Comparative Studies Lecture Consumer Participation Questionnaires Descriptive Statistics T-Tests Chi Square Test Health Beliefs Teaching Methods Human N1 - research; tables/charts. Journal Subset: Core Nursing; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9111431. PMID: NLM11908028. PY - 2000 SN - 1060-135X SP - 112-118 ST - Effect of health education on patients' beliefs about glaucoma and compliance T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - Effect of health education on patients' beliefs about glaucoma and compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107000124&site=ehost-live&scope=site VL - 25 ID - 4478 ER - TY - JOUR AB - Introduction: Intravitreal injections (IVI) of slow-release dexamethasone (DEX) are generally well tolerated. Ocular hypertension (OHT) and cataracts are the most common adverse effects of DEX-implant (DEX-I). Material and Methods: The cases reported concern 5 eyes in four DEX-I IVI high-responder patients whose intraocular pressure (IOP) returned to normal after administration of a XEN gel stent with mitomycin subconjunctival injection, thus allowing the continued use of DEX-I which was the only therapeutic option for these patients. All patients were pure steroid responders with normal optic nerves. Results: No hypertension was observed in any of the eyes after DEX-implant intravitreal reinjection following XEN-surgery. All patients were successfully treated with XEN surgery and were retreated with DEX-implant with no further increase in IOP. The mean duration of follow-up after the MIGS procedure was 5 months (min-max, 2-12). None of the patients required needling. Conclusions: XEN gel stent would seem to represent a safe and effective solution for treating steroid-induced hypertension. It allows for the medium and long-term use of DEX-I in high responders. It could be of clinical interest to study this combination in a prospective trial with a large number of patients and long-term follow-up. © 2018 Wolters Kluwer Health, Inc. AD - Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon, 103, Grande Rue de la Croix-Rousse, Lyon Cedex 04, 69317, France UMR-CNRS 5510 Matéis, University of Medicine Lyon, Lyon, France AU - Rezkallah, A. AU - Mathis, T. AU - Denis, P. AU - Kodjikian, L. DB - Scopus DO - 10.1097/IJG.0000000000001092 IS - 1 KW - corticosteroid-induced ocular hypertension dexamethasone implant minimally invasive glaucoma surgery XEN gel stent M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2019 SP - E5-E9 ST - XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases T2 - Journal of Glaucoma TI - XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053854364&doi=10.1097%2fIJG.0000000000001092&partnerID=40&md5=d92f3901944e4c0167255646d39ff534 VL - 28 ID - 5322 ER - TY - JOUR AB - Objective: To investigate the effect of selective laser trabeculoplasty (SLT) on the intraocular pressure (IOP) of untreated fellow eyes in patients with open-angle glaucoma. Study design: Retrospective chart review. Patients and methods: Charts of all patients who underwent SLT at the University of Texas Southwestern Medical Center at Dallas between September 2003 and May 2006 were reviewed. Each patient had IOP measurements by Goldmann applanation tonometry in both eyes preoperatively, and at 1 hour, 2 weeks, 3 months, and 6 months postoperatively. Patient age, gender, diagnosis, central corneal thickness (CCT), previous intraocular surgeries, and degrees of laser treatment were tabulated for each patient. Patients with a history of previous glaucoma surgery in either eye were excluded as were those who underwent any change in glaucoma medications or further laser or surgical intervention in either eye within 6 months of SLT. Data were analyzed using a paired two-tailed t-test, an unpaired two-tailed t-test, ANOVA, and linear regression. Results: A total of 43 patients were included through 6 months of follow-up. Mean reduction in IOP in the treated eye was 3.9 ± 0.6 mmHg or 18.8% (p < 0.001) at final exam. Mean IOP reduction in the fellow untreated eye was 2.1 ± 0.5 mmHg or 11.2% (p < 0.01). Patients with higher preoperative IOPs had a greater reduction in IOP in both eyes (p < 0.001 for treated eyes, and p = 0.02 for untreated eyes). Patients who were on a larger number of glaucoma medications preoperatively had a greater response in both eyes (treated eye p = 0.002, untreated eye p = 0.008). There was no significant difference in IOP response in either eye based on age, gender, CCT, degrees of treatment, or phakic status. Conclusions: SLT produces a sustained and statistically significant IOP reduction in the fellow untreated eyes of patients with open-angle glaucoma. The results of our study support a biological mechanism of action for SLT. Limitations of this study include its retrospective design, relatively small sample size, a possible effect of increased compliance with medical therapy following SLT, and an inherent bias of excluding patients who underwent a change in medications or further laser or surgical therapy during the period under review. © 2009 Informa UK Ltd. All rights reserved. AD - J. T. Whitson, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9057, United States AU - Rhodes, K. M. AU - Weinstein, R. AU - Saltzmann, R. M. AU - Aggarwal, N. AU - Kooner, K. S. AU - Petroll, W. M. AU - Whitson, J. T. DB - Embase Medline DO - 10.1185/03007990902728316 IS - 3 KW - adult age distribution aged analysis of variance article cornea thickness female follow up glaucoma surgery human intraocular pressure abnormality laser surgery linear regression analysis low tension glaucoma major clinical study male medical record review oculoplethysmography open angle glaucoma patient compliance phakic intraocular lens postoperative period preoperative period retrospective study sample size sex difference trabeculoplasty two tailed test LA - English M3 - Article N1 - L354797390 2009-07-28 PY - 2009 SN - 1473-4877 0300-7995 SP - 787-796 ST - Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty T2 - Current Medical Research and Opinion TI - Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354797390&from=export http://dx.doi.org/10.1185/03007990902728316 VL - 25 ID - 3392 ER - TY - JOUR AB - Objective: To investigate the effect of selective laser trabeculoplasty (SLT) on the intraocular pressure (IOP) of untreated fellow eyes in patients with open-angle glaucoma. Study design: Retrospective chart review. Patients and methods: Charts of all patients who underwent SLT at the University of Texas Southwestern Medical Center at Dallas between September 2003 and May 2006 were reviewed. Each patient had IOP measurements by Goldmann applanation tonometry in both eyes preoperatively, and at 1 hour, 2 weeks, 3 months, and 6 months postoperatively. Patient age, gender, diagnosis, central corneal thickness (CCT), previous intraocular surgeries, and degrees of laser treatment were tabulated for each patient. Patients with a history of previous glaucoma surgery in either eye were excluded as were those who underwent any change in glaucoma medications or further laser or surgical intervention in either eye within 6 months of SLT. Data were analyzed using a paired two-tailed t-test, an unpaired two-tailed t-test, ANOVA, and linear regression. Results: A total of 43 patients were included through 6 months of follow-up. Mean reduction in IOP in the treated eye was 3.9 ± 0.6 mmHg or 18.8% (p < 0.001) at final exam. Mean IOP reduction in the fellow untreated eye was 2.1 ± 0.5 mmHg or 11.2% (p < 0.01). Patients with higher preoperative IOPs had a greater reduction in IOP in both eyes (p < 0.001 for treated eyes, and p = 0.02 for untreated eyes). Patients who were on a larger number of glaucoma medications preoperatively had a greater response in both eyes (treated eye p = 0.002, untreated eye p = 0.008). There was no significant difference in IOP response in either eye based on age, gender, CCT, degrees of treatment, or phakic status. Conclusions: SLT produces a sustained and statistically significant IOP reduction in the fellow untreated eyes of patients with open-angle glaucoma. The results of our study support a biological mechanism of action for SLT. Limitations of this study include its retrospective design, relatively small sample size, a possible effect of increased compliance with medical therapy following SLT, and an inherent bias of excluding patients who underwent a change in medications or further laser or surgical therapy during the period under review. © 2009 Informa UK Ltd. All rights reserved. AD - University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9057, United States AU - Rhodes, K. M. AU - Weinstein, R. AU - Saltzmann, R. M. AU - Aggarwal, N. AU - Kooner, K. S. AU - Petroll, W. M. AU - Whitson, J. T. DB - Scopus DO - 10.1185/03007990902728316 IS - 3 KW - Contralateral eye Fellow eye Intraocular pressure Selective laser trabeculoplasty M3 - Article N1 - Cited By :31 Export Date: 19 July 2021 PY - 2009 SP - 787-796 ST - Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty T2 - Current Medical Research and Opinion TI - Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649359893&doi=10.1185%2f03007990902728316&partnerID=40&md5=ed0a8cdf4c88edddfceeec7e62b0d0d7 VL - 25 ID - 5055 ER - TY - JOUR AB - Objective: To investigate the effect of selective laser trabeculoplasty (SLT) on the intraocular pressure (IOP) of untreated fellow eyes in patients with open-angle glaucoma. Study design: Retrospective chart review. Patients and methods: Charts of all patients who underwent SLT at the University of Texas Southwestern Medical Center at Dallas between September 2003 and May 2006 were reviewed. Each patient had IOP measurements by Goldmann applanation tonometry in both eyes preoperatively, and at 1 hour, 2 weeks, 3 months, and 6 months postoperatively. Patient age, gender, diagnosis, central corneal thickness (CCT), previous intraocular surgeries, and degrees of laser treatment were tabulated for each patient. Patients with a history of previous glaucoma surgery in either eye were excluded as were those who underwent any change in glaucoma medications or further laser or surgical intervention in either eye within 6 months of SLT. Data were analyzed using a paired two-tailed t-test, an unpaired two-tailed t-test, ANOVA, and linear regression. Results: A total of 43 patients were included through 6 months of follow-up. Mean reduction in IOP in the treated eye was 3.9 +/- 0.6 mmHg or 18.8% (p<0.001) at final exam. Mean IOP reduction in the fellow untreated eye was 2.1 +/- 0.5 mmHg or 11.2% (p<0.01). Patients with higher preoperative IOPs had a greater reduction in IOP in both eyes (p<0.001 for treated eyes, and p=0.02 for untreated eyes). Patients who were on a larger number of glaucoma medications preoperatively had a greater response in both eyes (treated eye p=0.002, untreated eye p=0.008). There was no significant difference in IOP response in either eye based on age, gender, CCT, degrees of treatment, or phakic status. Conclusions: SLT produces a sustained and statistically significant IOP reduction in the fellow untreated eyes of patients with open-angle glaucoma. The results of our study support a biological mechanism of action for SLT. Limitations of this study include its retrospective design, relatively small sample size, a possible effect of increased compliance with medical therapy following SLT, and an inherent bias of excluding patients who underwent a change in medications or further laser or surgical therapy during the period under review. AN - WOS:000263720900024 AU - Rhodes, K. M. AU - Weinstein, R. AU - Saltzmann, R. M. AU - Aggarwal, N. AU - Kooner, K. S. AU - Petroll, W. M. AU - Whitson, J. T. DA - MAR DO - 10.1185/03007990902728316 IS - 3 PY - 2009 SN - 0300-7995 1473-4877 SP - 787-796 ST - Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty T2 - CURRENT MEDICAL RESEARCH AND OPINION TI - Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty VL - 25 ID - 6197 ER - TY - JOUR AB - Objective: To investigate the effect of selective laser trabeculoplasty (SLT) on the intraocular pressure (IOP) of untreated fellow eyes in patients with open-angle glaucoma.Study Design: Retrospective chart review.Patients and Methods: Charts of all patients who underwent SLT at the University of Texas Southwestern Medical Center at Dallas between September 2003 and May 2006 were reviewed. Each patient had IOP measurements by Goldmann applanation tonometry in both eyes preoperatively, and at 1 hour, 2 weeks, 3 months, and 6 months postoperatively. Patient age, gender, diagnosis, central corneal thickness (CCT), previous intraocular surgeries, and degrees of laser treatment were tabulated for each patient. Patients with a history of previous glaucoma surgery in either eye were excluded as were those who underwent any change in glaucoma medications or further laser or surgical intervention in either eye within 6 months of SLT. Data were analyzed using a paired two-tailed t-test, an unpaired two-tailed t-test, ANOVA, and linear regression.Results: A total of 43 patients were included through 6 months of follow-up. Mean reduction in IOP in the treated eye was 3.9 +/- 0.6 mmHg or 18.8% (p < 0.001) at final exam. Mean IOP reduction in the fellow untreated eye was 2.1 +/- 0.5 mmHg or 11.2% (p < 0.01). Patients with higher preoperative IOPs had a greater reduction in IOP in both eyes (p < 0.001 for treated eyes, and p = 0.02 for untreated eyes). Patients who were on a larger number of glaucoma medications preoperatively had a greater response in both eyes (treated eye p = 0.002, untreated eye p = 0.008). There was no significant difference in IOP response in either eye based on age, gender, CCT, degrees of treatment, or phakic status.Conclusions: SLT produces a sustained and statistically significant IOP reduction in the fellow untreated eyes of patients with open-angle glaucoma. The results of our study support a biological mechanism of action for SLT. Limitations of this study include its retrospective design, relatively small sample size, a possible effect of increased compliance with medical therapy following SLT, and an inherent bias of excluding patients who underwent a change in medications or further laser or surgical therapy during the period under review. AD - University of Texas Southwestern Medical Center at Dallas, TX 75390-9057, USA University of Texas Southwestern Medical Center at Dallas, Dallas, TX AN - 105509330. Language: English. Entry Date: 20090619. Revision Date: 20200708. Publication Type: journal article AU - Rhodes, K. M. AU - Weinstein, R. AU - Saltzmann, R. M. AU - Aggarwal, N. AU - Kooner, K. S. AU - Petroll, W. M. AU - Whitson, J. T. AU - Rhodes, Kyle M. AU - Weinstein, Rebecca AU - Saltzmann, Robert M. AU - Aggarwal, Nalini AU - Kooner, Karanjit S. AU - Petroll, W. Matthew AU - Whitson, Jess T. DB - ccm DO - 10.1185/03007990902728316 DP - EBSCOhost IS - 3 KW - Eye -- Physiology Glaucoma -- Surgery Intraocular Pressure Laser Therapy -- Methods Eye Surgery -- Methods Academic Medical Centers Aged Aged, 80 and Over Descriptive Statistics Female Funding Source Linear Regression Male Middle Age Paired T-Tests Record Review Retrospective Design Texas Two-Way Analysis of Variance Unpaired T-Tests Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Grant Information: Supported in part by Research to Prevent Blindness, New York, NY, USA. NLM UID: 0351014. PMID: NLM19203300. PY - 2009 SN - 0300-7995 SP - 787-796 ST - Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty T2 - Current Medical Research & Opinion TI - Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105509330&site=ehost-live&scope=site VL - 25 ID - 4587 ER - TY - JOUR AB - Purpose: To assess the impact of the education program of the Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) telemedicine program on at-risk patients' knowledge about glaucoma and attitudes about eye care as well as to assess patient satisfaction with EQUALITY. Patients and methods: New or existing patients presenting for a comprehensive eye exam (CEE) at one of two retail-based primary eye clinics were enrolled based on >= 1 of the following at-risk criteria for glaucoma: African Americans >= 40 years of age, Whites >= 50 years of age, diabetes, family history of glaucoma, and/or preexisting diagnosis of glaucoma. A total of 651 patients were enrolled. A questionnaire was administered prior to the patients' CEE and prior to the patients receiving any of the evidence-based eye health education program; a follow-up questionnaire was administered 2-4 weeks later by phone. Baseline and follow-up patient responses regarding knowledge about glaucoma and attitudes about eye care were compared using McNemar's test. Logistic regression models were used to assess the association of patient-level characteristics with improvement in knowledge and attitudes. Overall patient satisfaction was summarized. Results: At follow-up, all patient responses in the knowledge and attitude domains significantly improved from baseline (P<0.01 for all questions). Those who were unemployed (odds ratio =0.63, 95% confidence interval =0.42-0.95, P=0.026) or had lower education (odds ratio =0.55, 95% confidence interval =0.29-1.02, P=0.058) were less likely to improve their knowledge after adjusting for age, sex, race, and prior glaucoma diagnosis. This association was attenuated after further adjustment for other patient-level characteristics. Ninety-eight percent (n=501) of patients reported being likely to have a CEE within the next 2 years, whereas 63% (n=326) had a CEE in the previous 2 years. Patient satisfaction with EQUALITY was high (99%). Conclusion: Improved knowledge about glaucoma and a high intent to pursue eye care may lead to improved detection of early disease, thus lowering the risk of blindness. AN - WOS:000382877900001 AU - Rhodes, L. A. AU - Huisingh, C. E. AU - McGwin, G. AU - Mennemeyer, S. T. AU - Bregantini, M. AU - Patel, N. AU - Saaddine, J. AU - Crews, J. E. AU - Girkin, C. A. AU - Owsley, C. DO - 10.2147/PROM.S98686 PY - 2016 SN - 1179-271X SP - 37-48 ST - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY): impact of an eye health education program on patient knowledge about glaucoma and attitudes about eye care T2 - PATIENT-RELATED OUTCOME MEASURES TI - Eye Care Quality and Accessibility Improvement in the Community (EQUALITY): impact of an eye health education program on patient knowledge about glaucoma and attitudes about eye care VL - 7 ID - 6042 ER - TY - JOUR AB - Precis: This paper presents the methods and protocol of a community-based telemedicine program to identify glaucoma and other eye diseases. Purpose: To describe the study rationale and design of the Alabama Screening and Intervention for Glaucoma and eye Health through Telemedicine project. Methods: The study will implement and evaluate a telemedicine-based detection strategy for glaucoma, diabetic retinopathy, and other eye diseases in at-risk patients seen at federally qualified health centers located in rural Alabama. The study will compare the effectiveness of the remote use of structural and functional ocular imaging devices to an in-person examination. Study participants will receive a remote ocular assessment consisting of visual acuity, intraocular pressure, visual field testing, and imaging of the retina and optic nerve with spectral-domain optical coherence tomography, and the data will be reviewed by an ophthalmologist and optometrist. It will also compare the effectiveness of financial incentives along with a validated patient education program versus a validated patient education program alone in improving follow-up adherence. Finally, cost and cost-effectiveness analyses will be performed on the telemedicine program compared with standard in-person care using effectiveness measured in numbers of detected eye disease cases. Conclusions: The study aims to develop a model eye health system using telemedicine to prevent vision loss and address eye health among underserved and at-risk populations. AN - WOS:000647978800020 AU - Rhodes, L. A. AU - Register, S. AU - Asif, I. AU - McGwin, G. AU - Saaddine, J. AU - Nghiem, V. H. AU - Owsley, C. AU - Girkin, C. A. DA - MAY DO - 10.1097/IJG.0000000000001794 IS - 5 PY - 2021 SN - 1057-0829 1536-481X SP - 371-379 ST - Alabama Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (AL-SIGHT): Study Design and Methodology T2 - JOURNAL OF GLAUCOMA TI - Alabama Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (AL-SIGHT): Study Design and Methodology VL - 30 ID - 6153 ER - TY - JOUR AB - Précis: This paper presents the methods and protocol of a community-based telemedicine program to identify glaucoma and other eye diseases. Purpose: To describe the study rationale and design of the Alabama Screening and Intervention for Glaucoma and eye Health through Telemedicine project. Methods: The study will implement and evaluate a telemedicine-based detection strategy for glaucoma, diabetic retinopathy, and other eye diseases in at-risk patients seen at federally qualified health centers located in rural Alabama. The study will compare the effectiveness of the remote use of structural and functional ocular imaging devices to an in-person examination. Study participants will receive a remote ocular assessment consisting of visual acuity, intraocular pressure, visual field testing, and imaging of the retina and optic nerve with spectral-domain optical coherence tomography, and the data will be reviewed by an ophthalmologist and optometrist. It will also compare the effectiveness of financial incentives along with a validated patient education program versus a validated patient education program alone in improving follow-up adherence. Finally, cost and cost-effectiveness analyses will be performed on the telemedicine program compared with standard in-person care using effectiveness measured in numbers of detected eye disease cases. Conclusions: The study aims to develop a model eye health system using telemedicine to prevent vision loss and address eye health among underserved and at-risk populations. AD - L.A. Rhodes, Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, 1720 University Blvd, Suite 601, Birmingham, AL, United States AU - Rhodes, L. A. AU - Register, S. AU - Asif, I. AU - McGwin, G. AU - Saaddine, J. AU - Nghiem, V. T. H. AU - Owsley, C. AU - Girkin, C. A. DB - Embase Medline DO - 10.1097/IJG.0000000000001794 IS - 5 KW - imaging system Alabama article cataract clinical examination controlled study cost effectiveness analysis diabetic retinopathy economic incentive eye disease assessment follow up glaucoma health disparity human intraocular pressure optic nerve patient compliance patient education perimetry priority journal retina rural area screening spectral domain optical coherence tomography study design telediagnosis visual acuity visual impairment LA - English M3 - Article N1 - L634474219 2021-03-19 2021-05-28 PY - 2021 SN - 1536-481X 1057-0829 SP - 371-379 ST - Alabama Screening and Intervention for Glaucoma and Eye Health through Telemedicine (AL-SIGHT): Study Design and Methodology T2 - Journal of Glaucoma TI - Alabama Screening and Intervention for Glaucoma and Eye Health through Telemedicine (AL-SIGHT): Study Design and Methodology UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634474219&from=export http://dx.doi.org/10.1097/IJG.0000000000001794 VL - 30 ID - 2299 ER - TY - JOUR AB - Précis: This paper presents the methods and protocol of a community-based telemedicine program to identify glaucoma and other eye diseases. Purpose: To describe the study rationale and design of the Alabama Screening and Intervention for Glaucoma and eye Health through Telemedicine project. Methods: The study will implement and evaluate a telemedicine-based detection strategy for glaucoma, diabetic retinopathy, and other eye diseases in at-risk patients seen at federally qualified health centers located in rural Alabama. The study will compare the effectiveness of the remote use of structural and functional ocular imaging devices to an in-person examination. Study participants will receive a remote ocular assessment consisting of visual acuity, intraocular pressure, visual field testing, and imaging of the retina and optic nerve with spectral-domain optical coherence tomography, and the data will be reviewed by an ophthalmologist and optometrist. It will also compare the effectiveness of financial incentives along with a validated patient education program versus a validated patient education program alone in improving follow-up adherence. Finally, cost and cost-effectiveness analyses will be performed on the telemedicine program compared with standard in-person care using effectiveness measured in numbers of detected eye disease cases. Conclusions: The study aims to develop a model eye health system using telemedicine to prevent vision loss and address eye health among underserved and at-risk populations. © 2021 Lippincott Williams and Wilkins. All rights reserved. AD - Department of Ophthalmology and Visual Sciences Department of Family and Community Medicine, School of Medicine Department of Epidemiology Department of Health Care Organization and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States Vision Health Initiative, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, United States AU - Rhodes, L. A. AU - Register, S. AU - Asif, I. AU - McGwin, G. AU - Saaddine, J. AU - Nghiem, V. T. H. AU - Owsley, C. AU - Girkin, C. A. DB - Scopus DO - 10.1097/IJG.0000000000001794 IS - 5 KW - cataract diabetic retinopathy eye health education financial incentives glaucoma health disparities telemedicine teleophthalmology vision impairment M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 371-379 ST - Alabama Screening and Intervention for Glaucoma and Eye Health through Telemedicine (AL-SIGHT): Study Design and Methodology T2 - Journal of Glaucoma TI - Alabama Screening and Intervention for Glaucoma and Eye Health through Telemedicine (AL-SIGHT): Study Design and Methodology UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102461469&doi=10.1097%2fIJG.0000000000001794&partnerID=40&md5=044aa23a4e0d7875d47c309aba760c1a VL - 30 ID - 5660 ER - TY - JOUR AB - Background: Adherence with therapy could influence the progression of glaucoma and ultimately affect the onset of visual impairment in some individuals. This feasibility study evaluated the measures to be used for a future randomized controlled trial assessing the effects of group-based education on adherence with eye drops. Methods: People diagnosed with glaucoma within the previous 12months attending a regional ophthalmology clinic in the North West of England were recruited. A two-session education program delivered one week apart had been devised as part of a previous project. A combined adult learning and health needs approach to education was taken. Outcomes measured were knowledge of glaucoma, self-report of adherence, illness perception, beliefs about medicines, patient enablement, and general health (Short Form-12). Adherence was also measured objectively using a Medical Events Monitoring System device. Results: Twenty-six participants consented to undertake the educational program and 19 produced analyzable data. Knowledge of glaucoma, illness perception, beliefs about medicine, and patient enablement all showed statistically significant improvements after education. Mean adherence with eye drops was maintained above 85% before and for 3 months after attendance at the educational program. Self-report exaggerated adherence by at least 10% when compared with the objective Medical Events Monitoring System data, and in fact the kappa agreement was zero. Conclusion: All questionnaires other than the Short Form-12 were considered to be valuable measures and use of a Medical Events Monitoring System device was considered to be an objective surrogate measure for adherence with eye drops. A multicenter, randomized, controlled equivalence trial of group versus individualized education using adherence as the primary outcome is the next step. © 2013 Richardson et al. AD - H. Waterman, School of Nursing, Midwifery and Social Work, Jean McFarlane Building, Oxford Road, Manchester M13 9PL, United Kingdom AU - Richardson, C. AU - Brunton, L. AU - Olleveant, N. AU - Henson, D. B. AU - Pilling, M. AU - Mottershead, J. AU - Fenerty, C. H. AU - Spencer, A. F. AU - Waterman, H. DB - Embase DO - 10.2147/PPA.S47785 KW - antihypertensive agent eye drops adult aged article controlled study feasibility study female glaucoma health belief health care delivery health care need health care practice health education health program health status human intraocular hypotension major clinical study male medication compliance patient compliance patient education randomized controlled trial (topic) self report Short Form 12 study design treatment outcome United Kingdom L1 - internal-pdf://1101513929/3038-A study to assess the feasibility of-2013.pdf LA - English M3 - Article N1 - L369982283 2013-10-17 2013-11-08 PY - 2013 SN - 1177-889X SP - 1025-1039 ST - A study to assess the feasibility of undertaking a randomized controlled trial of adherence with eye drops in glaucoma patients T2 - Patient Preference and Adherence TI - A study to assess the feasibility of undertaking a randomized controlled trial of adherence with eye drops in glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369982283&from=export http://dx.doi.org/10.2147/PPA.S47785 VL - 7 ID - 3038 ER - TY - JOUR AB - Objectives: This was a secondary analysis of an existing dataset of soft contact lens wearers age 8-33 years, who received eye care outside of a clinical trial. The aim was to identify geographical and temporal factors associated with interruptions to contact lens wear. Methods: Data from six academic centers in North America captured 522 events in 3549 patients. Cases were analyzed overall and in subcategories of allergic, and serious and significant adverse events. General estimating equations were used to model the effect of geographic (Northwest, West, Central, Northeast, Southeast) and temporal (season, month, day of the week) factors, along with previously identified risk factors associated with interruptions in lens wear (patient age, contact lens material, overnight wear, lens care system, replacement schedule, and years of contact lens wear). Results: After controlling for established risk factors, both region and temporal factors disrupted the patients' ability to maintain contact lens wear. About 4% of all visits had complications that led to an interruption in wear. Allergic events were highest in the Central region. Serious and significant adverse events peaked in the Southeast during the Autumn and Winter months (September, October, December). Day of the week was not significant in any model. Conclusions: This study provides evidence of seasonal and regional challenges to contact lens wear. As the use of soft contact lenses expands for both cosmetic and medical reasons, practitioners must examine ways to maintain continuous, safe, and healthy use of contact lenses across all patients. © 2013. AD - State University of New York College of Optometry, New York, NY, United States Southern California College of Optometry, Fullerton, CA, United States Ohio State University College of Optometry, Columbus, Ohio, United States Clinical Trials Consultant, Atlanta, GA, United States Indiana University School of Optometry, Bloomington, IN, United States Pacific University College of Optometry, Forest Grove, OR, United States University of Waterloo School of Optometry and Vision Science, Waterloo, ON, Canada Nova Southeastern University College of Optometry, Fort Lauderdale, Fl, United States AU - Richdale, K. AU - Lam, D. Y. AU - Mitchell, G. L. AU - Chalmers, R. L. AU - Jansen, M. E. AU - Kinoshita, B. T. AU - Sorbara, L. AU - Wagner, H. DB - Scopus DO - 10.1016/j.clae.2013.02.002 IS - 5 KW - Complications Corneal inflammatory events Region Season Soft contact lenses M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2013 SP - 253-258 ST - Geographic and temporal risk factors for interruptions to soft contact lens wear in young wearers T2 - Contact Lens and Anterior Eye TI - Geographic and temporal risk factors for interruptions to soft contact lens wear in young wearers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882238925&doi=10.1016%2fj.clae.2013.02.002&partnerID=40&md5=092b2f7c779a27a056b47d492f9de92c VL - 36 ID - 5521 ER - TY - JOUR AB - Background and Objective: This study compares outcomes of patients who were examined on postoperative (PO) day 0 and PO day 1 following retina surgery.Patients and Methods: A nonrandomized, comparative, retrospective series of one vitreoretinal surgeon was conducted on 166 patients with a PO day 0 visit (approximately 5 hours following surgery) and 428 patients with a PO day 1 visit.Results: Among patients examined at PO day 0, 4.6% had hypotony (intraocular pressure [IOP] ≤ 5 mm Hg) and 1.8% needed intervention for elevated IOP (IOP ≥ 30 mm Hg) compared with 1.6% and 4.0% of patients, respectively, examined on PO day 1.Conclusion: Following retina surgery, there is a similar percentage of patients with abnormal IOP when patients are examined on PO day 0 when compared with PO day 1. However, the rate of hypotony was statistically higher on PO day 0, and there was a trend toward more elevated IOP on PO day 1. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:e52-e56.]. AD - VitreoRetinal Surgery PA, Minneapolis, Minnesota AN - 131827043. Language: English. Entry Date: 20190313. Revision Date: 20190318. Publication Type: journal article AU - Ringeisen, Alexander L. AU - Parke Iii, David Wilkin AU - Parke, David Wilkin, 3rd DB - ccm DO - 10.3928/23258160-20180907-07 DP - EBSCOhost IS - 9 KW - Retinal Diseases -- Surgery Ocular Hypertension -- Diagnosis Office Visits -- Statistics and Numerical Data Eye Diseases -- Diagnosis Postoperative Complications Male United States Eye Diseases -- Epidemiology Time Factors Prospective Studies Middle Age Ocular Hypertension -- Epidemiology Eye Diseases -- Physiopathology Ocular Hypertension -- Physiopathology Retrospective Design Postoperative Period Human Intraocular Pressure -- Physiology Female Incidence Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Biomedical; USA. NLM UID: 101599215. PMID: NLM30222819. PY - 2018 SN - 2325-8160 SP - e52-e56 ST - Reconsidering the Postoperative Day 0 Visit for Retina Surgery T2 - Ophthalmic Surgery, Lasers & Imaging Retina TI - Reconsidering the Postoperative Day 0 Visit for Retina Surgery UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131827043&site=ehost-live&scope=site VL - 49 ID - 4339 ER - TY - JOUR AB - Objectives: This study aims to report our experience with photosensitive autoimmune diseases including lupus erythematosus and dermatomyositis (DM) treated with quinacrine (Qn) as either monotherapy or combination with other antimalarials, steroids, and immunosuppressive therapy in an add-on regimen in light of a review of the relevant literature. Patients and methods: The study included 38 patients (6 males, 32 females; mean age 45±8 years; range, 23 to 72 years) with systemic lupus erythematosus (SLE), cutaneous lupus or DM who had been treated with Qn. The following data were obtained from the records of each patient: sex, age, diagnosis, duration of the disease, duration of treatment, smoking behavior, antimalarial treatment, concomitant treatment, and clinical indications, as well as Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity before initiation, at the last visit, or when Qn treatment was completed. We carried out a MEDLINE search for previously reported cases that, together with our patients, served as the basis of this report. Results: Of the 38 patients, 34 were suffering from SLE or cutaneous lupus and four from DM. Qn was dosed at 50 or 100 mg in most of the patients. Twenty-seven patients received Qn as an add-on regimen therapy. Clinical response was analyzed in patients with SLE or cutaneous lupus. Of the patients, 25 responded (68.4%), 13 (52%) had improved CLASI activity and 12 (48%) had improved SLEDAI score. Fifty percent of the patients with DM responded. A total of 188 cases were identified from the literature. The most frequent diagnosis was cutaneous lupus (68.6%), followed by SLE (32.6%). Only 7.4% of the patients had DM. The majority of the patients received concomitant immunosuppressive medications. Treatment response was 73% in patients with SLE and/or cutaneous lupus and 35.7% in patients with DM. Side effects were scarce and the most frequent was yellow skin discoloration. Conclusion: Quinacrine may be an alternative for patients with poor response or those who are intolerant to other antimalarials. Thus, Qn may aid in controlling the activity of photosensitive autoimmune diseases. © 2019 Turkish League Against Rheumatism. All rights reserved. AD - Hospital San Cecilio, Autoimmune Diseases Unit, Granada, Spain AU - Rios-Fernández, R. AU - Callejas-Rubio, J. L. AU - Ortego-Centeno, N. DB - Scopus DO - 10.5606/ArchRheumatol.2019.6965 IS - 1 KW - Antimalarials Cutaneous lupus erythematosus Dermatomyositis Mepacrine Quinacrine Systemic lupus erythematosus M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2019 SP - 34-43 ST - Effectiveness of quinacrine (mepacrine) in photosensitive autoimmune diseases, lupus erythematosus, and dermatomyositis: Report on 38 cases and literature review T2 - Archives of Rheumatology TI - Effectiveness of quinacrine (mepacrine) in photosensitive autoimmune diseases, lupus erythematosus, and dermatomyositis: Report on 38 cases and literature review UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064159087&doi=10.5606%2fArchRheumatol.2019.6965&partnerID=40&md5=b70555387f4c72b46ca1b23f567d3f8e VL - 34 ID - 5614 ER - TY - JOUR AB - The decision to use a compliance aid will depend on the motivation of the patient, their specific medication regimen, and their physical and cognitive ability. The administration of oral medicines may be facilitated through the appropriate use of 'organisers' which act as aides memoire. 'Medidos' and 'Dosett' are the most frequently studied compliance aids and both have been shown to be beneficial to the elderly and to community-based psychiatric patients. Adherence to a medication regimen may be improved without the use of proprietary compliance aids by ensuring that the most appropriate traditional container is used and by paying attention to the highest standard of labelling on the medicine container. Gadgets that are designed to improve physical dexterity can be useful when applying topical preparations, administering insulin injections, operating pressurised inhalers or administering eyedrops. The accurate administration of eyedrops is particularly important when treating glaucoma and may be facilitated by using devices that are designed to help with aiming of the eyedrops ('Easidrop', 'Mumford Auto-drop,' 'Opticare'). If squeezing the eyedrop container is a problem the 'Opticare' device may be particularly suitable. There may be value in the use of the compliance aids to provide assistance to carers who become involved with preparing medication for patients. Selection of an appropriate compliance aid is not likely to be the total solution to inadequate adherence and most patients will require a combination of strategies to facilitate adherence to treatment with medicines. AD - P.H. Rivers, Medicines Research Unit, Derbyshire Institute of Health and Community Studies, Derby, England. AU - Rivers, P. H. DB - Medline IS - 2 KW - drug eye drops adolescent adult aged drug packaging female human male middle aged oral drug administration patient compliance patient education review self help LA - English M3 - Review N1 - L22922201 1992-07-06 PY - 1992 SN - 1170-229X SP - 103-111 ST - Compliance aids--do they work? T2 - Drugs & aging TI - Compliance aids--do they work? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L22922201&from=export VL - 2 ID - 4030 ER - TY - JOUR AB - Purpose. This review article examines recent studies pertaining to contact lens - associated corneal infiltrates (CLACI) that occur in the absence of culture-proven microbial infection. Methods. The literature was reviewed in regard to the clinical appearance, incidence and risk, etiology, pathophysiology, differential diagnosis, and management of CLACI. Recent insights are presented in the context of future directions for prevention of CLACI. Results. Contact lens - associated comeal infiltrates may manifest in various forms that require careful observational skills to ensure proper diagnosis. Although the reported incidence of CLACI varies widely, even a low percentage of contact lens wearers would constitute a substantial number of affected individuals. Any one or a combination of multiple mechanical, hypoxic, or toxic stimuli associated with contact lens use can induce proinflammatory responses that lead to infiltration of inflammatory cells into the cornea. A number of candidate cytokines, chemokines, adhesion molecules, and so forth have been identified. In addition to differentiation from microbial keratitis, CLACI also should be differentiated from ocular disorders not associated with contact lenses but involving corneal infiltrates and from contact lens - associated disorders that may resemble infiltrates. Management of CLACI can range from simple monitoring of the patient to the use of pharmacologic intervention. Conclusions. The small percentage of affected lens wearers translates into a notable number of individuals who, although not experiencing a vision-threatening event, are inconvenienced by the development of infiltrates. Design of preventive measures for CLACI should focus on the elimination of various mechanical, hypoxic, and toxic stimuli that can induce infiltrates and on the approaches for molecular intervention of the inflammatory cascade initiated by the stimuli. © 2003 Contact Lens Association of Ophthalmologists, Inc. AD - Bausch and Lomb, Inc., Rochester, NY, United States Ocular Research Services, Mendon, NY, United States 1400 North Goodman Street, Rochester, NY 14609, United States AU - Robboy, M. W. AU - Comstock, T. L. AU - Kalsow, C. M. DB - Scopus DO - 10.1097/01.ICL.0000072830.41886.1E IS - 3 KW - CLARE CLPU Contact lens Cornea Infiltrate Microbial keratitis Sterile M3 - Review N1 - Cited By :23 Export Date: 19 July 2021 PY - 2003 SP - 146-154 ST - Contact lens - Associated corneal infiltrates T2 - Eye and Contact Lens TI - Contact lens - Associated corneal infiltrates UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0142089780&doi=10.1097%2f01.ICL.0000072830.41886.1E&partnerID=40&md5=bb943ca2957b91ab34c0cf653668c1fc VL - 29 ID - 5117 ER - TY - JOUR AB - Purpose: The goal of this study was to determine the changes in surgical techniques and leading indications for corneal transplantations performed in the last decade. The impact of administrative changes of corneal banking in Quebec was also evaluated. Methods: The records of all corneal transplantations performed between January 2000 and December 2011 in the territory subserved by the Quebec Eye Bank and Héma-Québec (Quebec, Canada) were retrospectively reviewed. Results: A total of 3459 corneal transplantations were performed between 2000 and 2011. The rate of corneal transplantation more than doubled from 234 grafts per year in 2000 to 592 grafts per year in 2011. Imported tissue represented 40% of grafted corneas. Increases in tissue importation were seen in 2003 and 2009 to address local tissue shortage and peaks in wait time. The average wait time decreased from 434 ± 456 days (2000-2008) to 418 ± 551 days (2009-2011) (P 0.01). The leading surgical indications were Fuchs endothelial corneal dystrophy (27%), pseudophakic corneal edema (26%), keratoconus (13%), and viral keratitis (8%). Regrafts represented 25% of procedures. Descemet stripping automated endothelial keratoplasty became the preferred technique for endothelial diseases, surpassing penetrating keratoplasty in 2011. Conclusions: The surgical indications and techniques used for corneal transplantation in Quebec reflected those of the literature. However, long wait times and corneal tissue shortages mandated significant changes in the organization of the Quebec Eye Bank. Partnering with a larger agency responsible for tissue and blood donation coordination (Héma-Québec) had a positive impact on yearly transplantation rates and wait times. AD - I. Brunette, Department of Ophthalmology, Maisonneuve-Rosemont Hospital, 5415 de l'Assomption blvd, Montreal, QC, Canada AU - Robert, M. C. AU - Choronzey, M. E. AU - Lapointe, J. AU - Gauvin Meunier, L. P. AU - Harissi-Dagher, M. AU - Germain, M. AU - Mabon, M. AU - Brunette, I. DB - Embase Medline DO - 10.1097/ICO.0000000000000481 IS - 8 KW - adolescent adult aged article Canada cell count comparative study hereditary corneal dystrophy controlled study cornea donor cornea edema cornea transplantation deep lamellar endothelial keratoplasty Descemet stripping endothelial keratoplasty endothelium cell eye bank female health care access hospital admission human infant keratoconus major clinical study male organ donor penetrating keratoplasty priority journal pseudophakic corneal edema retrospective study selection bias surgical technique treatment indication virus keratitis LA - English M3 - Article N1 - L605325344 2015-07-29 2015-08-04 PY - 2015 SN - 1536-4798 0277-3740 SP - 880-887 ST - Evolution of Corneal Transplantation in the Province of Quebec from 2000 to 2011 T2 - Cornea TI - Evolution of Corneal Transplantation in the Province of Quebec from 2000 to 2011 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605325344&from=export http://dx.doi.org/10.1097/ICO.0000000000000481 VL - 34 ID - 2803 ER - TY - JOUR AB - Penetrating corneal grafts were performed on 15 eyes with keratopathy due to implantation of iris‐supported intraocular lenses, on one eye with keratopathy due to an anterior chamber lens, and one eye with keratopathy due to a posterior chamber lens. A systematic meticulous surgical technique, with a softened eye, the use of a Flieringa ring, anterior vitrectomy and sodium hyaluronate (Healon) have resulted in clear grafts in all except in four eyes. Although most grafts have remained clear, the visual results are poor mainly due to glaucoma and/or maculopathy. Every effort was made to retain the implants and some were repositioned and sutured to the iris. Long‐term postoperative follow‐up, with good patient compliance and the judicious use of topical corticosteroids and timolol, is essential to maintain clear grafts. Copyright © 1985, Wiley Blackwell. All rights reserved AD - Royal Victorian Eye and Ear Hospital, Melbourne, Australia AU - Robertson, I. F. AU - Stasiuk, R. M. AU - Campbell, W. G. DB - Scopus DO - 10.1111/j.1442-9071.1985.tb00448.x IS - 4 KW - patient compliance Penetrating keratoplasty poor visual prognosis pseudophakic keratopathy retention of intraocular lens vitrectomy M3 - Article N1 - Export Date: 19 July 2021 PY - 1985 SP - 359-364 ST - KERATOPLASTY FOR PSEUDOPHAKIC KERATOPATHY T2 - Australian and New Zealand Journal of Ophthalmology TI - KERATOPLASTY FOR PSEUDOPHAKIC KERATOPATHY UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022372666&doi=10.1111%2fj.1442-9071.1985.tb00448.x&partnerID=40&md5=4133088ce856e7a1c028ac420f6975db VL - 13 ID - 5803 ER - TY - JOUR AB - Glaucoma is a preventable cause of blindness if timely effective and successful treatment is provided. Patient adherence to the medication is a constant challenge that is now recognized as an essential component to treatment. Several studies have demonstrated that patients are more likely to be adherent to their medication if they understand the disease and the rationale for treatment and if their treatment regimen is simplified. Additionally, using eye drops has its own set of challenges that must be recognized and addressed at the clinical level. Although numerous socioeconomic factors are associated with poor adherence, these factors must be addressed at the societal level. Maximizing patient adherence to medication has the potential to reduce the number of surgical interventions required to treat glaucoma, prevent unnecessary vision loss, and save the overall healthcare system money in the long run. AD - A. Robin, University of Maryland, Johns Hopkins University, 6115 Falls Road, Baltimore, MD, United States AU - Robin, A. AU - Grover, D. DB - Medline DO - 10.4103/0301-4738.73693 IS - SUPPL. 1 KW - antihypertensive agent eye drops blindness conference paper glaucoma human patient compliance socioeconomics LA - English M3 - Conference Paper N1 - L361030577 2011-04-07 PY - 2011 SN - 0301-4738 1998-3689 SP - S93-S96 ST - Compliance and adherence in glaucoma management T2 - Indian Journal of Ophthalmology TI - Compliance and adherence in glaucoma management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361030577&from=export http://dx.doi.org/10.4103/0301-4738.73693 VL - 59 ID - 3197 ER - TY - JOUR AD - Department of Glaucoma, University of Maryland, and Johns Hopkins University, 6115 Falls Road, Suite 333, Baltimore, MD, USA. AN - 105000014. Language: English. Entry Date: 20110415. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Asia AU - Robin, Alan AU - Grover, Davinder S. DB - ccm DO - 10.4103/0301-4738.73693 DP - EBSCOhost IS - 1 KW - Antihypertensive Agents -- Administration and Dosage Glaucoma -- Drug Therapy Patient Compliance Blindness -- Prevention and Control Ophthalmic Solutions Socioeconomic Factors N1 - Biomedical; Peer Reviewed. NLM UID: 0405376. PMID: NLM21150041. PY - 2011 SN - 0301-4738 SP - S93-6 ST - Compliance and adherence in glaucoma management T2 - Indian Journal of Ophthalmology TI - Compliance and adherence in glaucoma management UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105000014&site=ehost-live&scope=site VL - 59 ID - 4700 ER - TY - JOUR AB - Introduction: Nonadherence to medication is a challenge to effective treatment of many chronic diseases, including glaucoma, and persists even with interventions aimed at improving adherence. The reported rates of nonadherence to topical glaucoma medication vary widely from 16% to 67%, and it is estimated that less than a third of patients remained on their initial therapy after 12 months. Nonadherence can lead to disease progression and increased economic burden. Areas covered: This review examines factors that contribute to nonadherence in patients with glaucoma, including the severity of the disease, complexity of treatment, lack of knowledge in patients, poor communications between physician and patient, difficulty with self-administration of drops, side-effects, and medication costs. We discuss the unique challenges in identifying nonadherence in glaucoma patients and investigate the current approaches to improving adherence. Expert opinion: Strategies for improving adherence should combine new treatment methods with enhanced patient education. New pharmaceuticals may comprise multiple medications in a single bottle, making dosing regimens simpler. Novel drug delivery systems are in development, such as injectable products and implants releasing IOP-lowering medication without the need for self-administration. A comprehensive approach involving these new methods and more effective patient-physician communication may lead to improved adherence. AD - Department of Ophthalmology, Johns Hopkins School of Medicine and Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA Department of Ophthalmology, The University of Michigan, Ann Arbor, MI, USA Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA AN - 139193843. Language: English. Entry Date: 20191102. Revision Date: 20191102. Publication Type: Article AU - Robin, Alan L. AU - Muir, Kelly W. DB - ccm DO - 10.1080/17469899.2019.1635456 DP - EBSCOhost IS - 4/5 KW - Medication Compliance Ocular Hypertension -- Drug Therapy Glaucoma -- Drug Therapy Disease Progression Health Care Costs Severity of Illness Health Knowledge Physician-Patient Relations Patient Education Infusion Pumps, Implantable Drug Delivery Systems N1 - review; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 101278197. PY - 2019 SN - 1746-9899 SP - 199-210 ST - Medication adherence in patients with ocular hypertension or glaucoma T2 - Expert Review of Ophthalmology TI - Medication adherence in patients with ocular hypertension or glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139193843&site=ehost-live&scope=site VL - 14 ID - 4247 ER - TY - JOUR AB - To analyze the intraocular pressure reduction, number of anti-glaucoma medications needed, and post-operative complications of trans-scleral diode laser cyclophotocoagulation (DCPC) in patients with high-risk penetrating keratoplasty (PKP) and secondary refractory glaucoma. Prospective interventional, longitudinal, non-comparative series of cases, including 16 eyes of 15 patient’s post-PKP on maximal anti-glaucoma medical therapy with intraocular pressures above 22 mmHg. All patients received 18 shots, 360° peri-limbal (avoiding the long posterior ciliary nerves and arteries at 3 and 9 o’clock positions) of trans-scleral DCPC (2000 mW, time: 2.0 s/shot). There was a 55.5 % reduction (total of 14.0 mmHg) of the mean pre-operative IOP (31.5 mmHg) after the first diode laser application (p = 0.0020). Re-treatment was required in 31.2 % of eyes over a mean period of 10.7 months. In these five eyes, the mean pre-operative IOP was 40.4 mmHg, which decreased to 15.0 mmHg post-therapy, and a mean IOP reduction of 25.4 mmHg (p = 0.0218). There was a 51.0 % reduction in the mean number of medications used after the first, and a 57.1 % reduction after a second laser application. The incidence of failure (IOP ≥ 22 mmHg or need of additional medical therapy) from initial intervention to loss of follow-up was 1.3 % per person-month. DCPC effectively reduces the intraocular pressure and the number of anti-glaucoma medications with few complications in patients after high-risk PKP and secondary glaucoma. Only, one-third of the eyes needed a second intervention to control the intraocular pressure. Post-DCPC complications were limited to phthisis bulbi and endothelial dysfunction, one eye each. Please check and confirm the author names and initials are correct. Also, kindly confirm the details in the metadata are correct. © 2015, Springer Science+Business Media Dordrecht. AD - Cornea & External Disease Service, Instituto de Oftalmología y Ciencias Visuales, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey, Mexico Instituto de Oftalmología y Ciencias Visuales, Centro Médico Zambrano-Hellion (1er Piso Ote.), Av. Batallón de San Patricio No. 112, Col. Real de San Agustín, San Pedro Garza García, NL CP 66278, Mexico AU - Rodríguez-García, A. AU - González-González, L. A. AU - Carlos Alvarez-Guzmán, J. DB - Scopus DO - 10.1007/s10792-015-0130-2 IS - 3 KW - Ciliary body Penetrating keratoplasty Secondary glaucoma Trans-scleral cyclophotocoagulation Trans-scleral diode laser M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 SP - 373-383 ST - Trans-scleral diode laser cyclophotocoagulation for refractory glaucoma after high-risk penetrating keratoplasty T2 - International Ophthalmology TI - Trans-scleral diode laser cyclophotocoagulation for refractory glaucoma after high-risk penetrating keratoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944707418&doi=10.1007%2fs10792-015-0130-2&partnerID=40&md5=895cfc98d06233c5bc7ce23bbff55a13 VL - 36 ID - 5352 ER - TY - JOUR AB - Purpose. To evaluate the efficacy, safety, and tolerability of Timogel ® preservative-free once daily compared to timolol 0.5% ophthalmic solution bid in patients with ocular hypertension (OHT) and patients with primary open-angle glaucoma (POAG). methods. A total of 75 patients with OHT and patients with POAG treated with timolol 0.5% bid with intraocular pressure (IOP) ≤21 mmHg were enrolled. They underwent complete ophthalmologic examination, IOP measurements (at trough and daytime curve), evaluation of side effects, Schirmer test, break-up time [BUT], blood pressure, heart rate, ocular diastolic perfusion pressure measurements, and acceptance (Comparison of Ophthalmic Medications for Tolerability). Patients switched to Timo-gel ® and were re-evaluated 3 months later. The analysis of variance and the Pearson χ 2 tests were used to test differences between the treatments results. Intraocular pressure reduction at trough was 23.6% with timolol 0.5% and 22.3% with Ti-mogel ®. No statistical differences were observed in IOP values at trough and in the daytime curve between the 2 treatments. Local and systemic side effects were less frequent with Timogel ® (hazard ratio: p<0.05). Patients demonstrated a significant improvement of Schirmer test and BUT (p<0.05) and a reduction of dryness and foreign body sensation (42.6% vs 15.4%; p<0.01) after switching to Timogel ®. Mild and short-lasting blurred vision after Timogel ® instillation occurred in about 18.5% of patients. A total of 82% of patients were satisfied or very satisfied with Timogel ® vs 61% with previous treatment (p<0.01). ConClusions. Timogel ® preservative-free dosed once every morning has a 24-hour hypotensive effect with a better safety profile than timolol 0.5% bid and it is well-accepted by patients. The once-daily dosing improved acceptance and compliance. © 2011 Wichtig Editore. AD - Department of Clinical Physiopathology, Section of Ophthalmology, Eye Clinic, University of Torino, Torino, Italy AU - Rolle, T. AU - Curto, D. AU - Alovisi, C. AU - Franzone, M. AU - Brogliatti, B. AU - Grignolo, F. M. DB - Scopus DO - 10.5301/ejo.5000006 IS - 1 KW - Acceptance Glaucoma Preservative-free Safety Timolol M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2011 SP - 28-33 ST - Timogel ® vs timolol 0.5% ophthalmic solution: Efficacy, safety, and acceptance T2 - European Journal of Ophthalmology TI - Timogel ® vs timolol 0.5% ophthalmic solution: Efficacy, safety, and acceptance UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-81855184550&doi=10.5301%2fejo.5000006&partnerID=40&md5=7e247bec85ad6d864bb809e17279c023 VL - 22 ID - 5219 ER - TY - JOUR AB - A 2-year-old domestic shorthair cat was examined for severe keratitis of 10 months duration, non-responsive to 0.1% dexamethasone q8-12h. Patient and owner compliance were poor given ocular discomfort and hiding behavior. On presentation, both eyes (OU) had severe ulcerative keratitis that masked examination of deeper structures and resulted in absent menace response OU. Corneal cytology was consistent with eosinophilic keratitis (EK) OU. Initial therapy included subcutaneous triamcinolone acetonide injection (0.2 mg/kg), 0.3% ciprofloxacin OU q12h, and two compounded drugs started 5 days later upon receipt: 0.5% tacrolimus OU q6h, 0.5% cidofovir OU q12h. Visual behavior and ocular comfort were reportedly much improved within 24 h. At the first recheck (Day 11), patient and owner compliance were reported to be excellent, menace response was positive OU, and keratitis was dramatically reduced OU with absent fluorescein uptake. Subcutaneous triamcinolone acetonide was repeated (0.2 mg/kg), ciprofloxacin was discontinued, cidofovir was continued q12h, and tacrolimus was slowly tapered (q8h × 3 weeks then q12h). Keratitis was nearly 100% resolved at the second recheck (Day 38); cidofovir was discontinued and tacrolimus was slowly tapered (q12h × 1 week, q24h × 4 weeks, q48h × 4 weeks) then discontinued. A third recheck (Day 101) confirmed clinical remission OU, and disease did not reoccur within a 1 year follow up period (photographic documentation by owner). In sum, adjunct use of triamcinolone acetonide greatly improved therapeutic compliance and helped control severe EK in a rapid and effective manner. © Copyright © 2021 Romaneck and Sebbag. AD - Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel AU - Romaneck, A. K. AU - Sebbag, L. C7 - 580396 DB - Scopus DO - 10.3389/fvets.2021.580396 KW - antiviral drugs compliance corticosteroids eosinophilic keratitis eosinophilic keratoconjunctivitis immunomodulation triamcinolone acetonide M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 ST - Case Report: Clinical Remission in a Cat With Severe Bilateral Eosinophilic Keratitis Receiving Combined Immunosuppressive Therapy (Triamcinolone Acetonide and Tacrolimus) T2 - Frontiers in Veterinary Science TI - Case Report: Clinical Remission in a Cat With Severe Bilateral Eosinophilic Keratitis Receiving Combined Immunosuppressive Therapy (Triamcinolone Acetonide and Tacrolimus) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105965758&doi=10.3389%2ffvets.2021.580396&partnerID=40&md5=b5bd49ae74fc7b2163b1329c8cc7de19 VL - 8 ID - 5662 ER - TY - JOUR AB - A 2-year-old domestic shorthair cat was examined for severe keratitis of 10 months duration, non-responsive to 0.1% dexamethasone q8-12h. Patient and owner compliance were poor given ocular discomfort and hiding behavior. On presentation, both eyes (OU) had severe ulcerative keratitis that masked examination of deeper structures and resulted in absent menace response OU. Corneal cytology was consistent with eosinophilic keratitis (EK) OU. Initial therapy included subcutaneous triamcinolone acetonide injection (0.2 mg/kg), 0.3% ciprofloxacin OU q12h, and two compounded drugs started 5 days later upon receipt: 0.5% tacrolimus OU q6h, 0.5% cidofovir OU q12h. Visual behavior and ocular comfort were reportedly much improved within 24 h. At the first recheck (Day 11), patient and owner compliance were reported to be excellent, menace response was positive OU, and keratitis was dramatically reduced OU with absent fluorescein uptake. Subcutaneous triamcinolone acetonide was repeated (0.2 mg/kg), ciprofloxacin was discontinued, cidofovir was continued q12h, and tacrolimus was slowly tapered (q8h x 3 weeks then q12h). Keratitis was nearly 100% resolved at the second recheck (Day 38); cidofovir was discontinued and tacrolimus was slowly tapered (q12h x 1 week, q24h x 4 weeks, q48h x 4 weeks) then discontinued. A third recheck (Day 101) confirmed clinical remission OU, and disease did not reoccur within a 1 year follow up period (photographic documentation by owner). In sum, adjunct use of triamcinolone acetonide greatly improved therapeutic compliance and helped control severe EK in a rapid and effective manner. AN - WOS:000650015700001 AU - Romaneck, A. K. AU - Sebbag, L. DA - APR 30 DO - 10.3389/fvets.2021.580396 PY - 2021 SN - 2297-1769 ST - Case Report: Clinical Remission in a Cat With Severe Bilateral Eosinophilic Keratitis Receiving Combined Immunosuppressive Therapy (Triamcinolone Acetonide and Tacrolimus) T2 - FRONTIERS IN VETERINARY SCIENCE TI - Case Report: Clinical Remission in a Cat With Severe Bilateral Eosinophilic Keratitis Receiving Combined Immunosuppressive Therapy (Triamcinolone Acetonide and Tacrolimus) VL - 8 ID - 6256 ER - TY - JOUR AB - Aim: The aim of this study was to evaluate the long-term visual outcomes and factors affecting visual results in children undergoing secondary intraocular lens (IOL) implantation following primary congenital cataract extraction. Methods: Children with congenital cataracts who underwent secondary IOL implantation for aphakia at the Eye and ENT Hospital of Fudan University between January 1, 2001, and December 31, 2007, were retrospectively reviewed. One eye was randomly selected in children with bilateral cataracts. Laterality, type of cataract (total or partial opacity), sex, age at primary and secondary surgeries, visual axis opacity (VAO), compliance with amblyopia therapy, postoperative ocular complications, refractive error, ocular alignment, and best corrected visual acuity (BCVA) at last follow-up were recorded; potential factors that might have affected the visual results were evaluated. Results: Seventy-six bilateral and 34 unilateral congenital cataract cases were analyzed; the mean ages of the children were 12.70 ± 5.06 and 12.50 ± 2.71 years at final follow-up, the mean follow- up periods from IOL implantation were 94.93 ± 24.22 and 109.09 ± 18.89 months, and the mean BCVA (Log MAR) values were 0.51 ± 0.37 and 1.05 ± 0.46, respectively. Final BCVA after secondary IOL implantation was significantly associated with laterality, type of cataract, age at primary cataract extraction, compliance with amblyopia therapy, and refractive correction after surgery. No significant associations were found between BCVA and sex, age at secondary IOL implantation, VAO, or other ocular complications. The most common ocular complications were VAO and elevated intraocular pressure after surgery. There were no other complications, with the exception of one eye with IOL dislocation. Conclusions: The results indicate that the important determinants of long-term visual outcomes in children with congenital cataracts undergoing secondary IOL implantation are laterality, cataract type, age at initial cataract extraction, compliance with amblyopia therapy, and refractive error. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Lu, Yi AN - 2015-36745-001 AU - Rong, Xianfang AU - Ji, Yinghong AU - Fang, Yanwen AU - Jiang, Yongxiang AU - Lu, Yi DB - psyh DO - 10.1371/journal.pone.0134864 DP - EBSCOhost IS - 7 KW - refractive error congenital cataract extraction secondary surgeries visual acuity Adolescent Cataract Cataract Extraction Child Female Humans Lens Implantation, Intraocular Male Retrospective Studies Cataracts Surgery Treatment Outcomes Sequelae Eye Disorders Refraction Errors N1 - Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China. Release Date: 20150907. Correction Date: 20200622. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Cataracts; Surgery; Treatment Outcomes; Visual Acuity; Sequelae. Minor Descriptor: Eye Disorders; Refraction Errors. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: China. Age Group: Childhood (birth-12 yrs) (100); Infancy (2-23 mo) (140); Preschool Age (2-5 yrs) (160). Tests & Measures: Best Corrected Visual Acuity Scores Measure. Methodology: Empirical Study; Followup Study; Longitudinal Study; Retrospective Study; Quantitative Study. References Available: Y. ArtID: e0134864. Issue Publication Date: Jul 31, 2015. Publication History: First Posted Date: Jul 31, 2015; Accepted Date: Jul 14, 2015; First Submitted Date: Feb 10, 2015. Copyright Statement: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Rong et al. 2015. Sponsor: National Natural Science Foundation of China, China. Grant: 81300806; 81300745. Recipients: No recipient indicated Sponsor: Shanghai Shen Kang Hospital, Development Centre Program, China. Grant: SHDC12012104. Other Details: Cutting-Edge Technology Combined PR Project. Recipients: No recipient indicated Sponsor: Health Bureau of Pudong New Area, China. Grant: PW2011D-7. Other Details: Key-Collabotative Project. Recipients: No recipient indicated Sponsor: Program of Science and Technology Commission of Shanghai Municipality, China. Grant: 124119a9900. Recipients: No recipient indicated Sponsor: Shanghai Municipal Health Bureau, China. Grant: 20124y041. Other Details: Youth Foundation Project. Recipients: No recipient indicated PY - 2015 SN - 1932-6203 ST - Long-term visual outcomes of secondary intraocular lens implantation in children with congenital cataracts T2 - PLoS ONE TI - Long-term visual outcomes of secondary intraocular lens implantation in children with congenital cataracts UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-36745-001&site=ehost-live&scope=site luyiox@163.com VL - 10 ID - 4854 ER - TY - JOUR AB - Aim The aim of this study was to evaluate the long-term visual outcomes and factors affecting visual results in children undergoing secondary intraocular lens (IOL) implantation following primary congenital cataract extraction. Methods Children with congenital cataracts who underwent secondary IOL implantation for aphakia at the Eye and ENT Hospital of Fudan University between January 1, 2001, and December 31, 2007, were retrospectively reviewed. One eye was randomly selected in children with bilateral cataracts. Laterality, type of cataract (total or partial opacity), sex, age at primary and secondary surgeries, visual axis opacity (VAO), compliance with amblyopia therapy, postoperative ocular complications, refractive error, ocular alignment, and best corrected visual acuity (BCVA) at last follow-up were recorded; potential factors that might have affected the visual results were evaluated. Results Seventy-six bilateral and 34 unilateral congenital cataract cases were analyzed; the mean ages of the children were 12.70 +/- 5.06 and 12.50 +/- 2.71 years at final follow-up, the mean follow-up periods from IOL implantation were 94.93 +/- 24.22 and 109.09 +/- 18.89 months, and the mean BCVA (Log MAR) values were 0.51 +/- 0.37 and 1.05 +/- 0.46, respectively. Final BCVA after secondary IOL implantation was significantly associated with laterality, type of cataract, age at primary cataract extraction, compliance with amblyopia therapy, and refractive correction after surgery. No significant associations were found between BCVA and sex, age at secondary IOL implantation, VAO, or other ocular complications. The most common ocular complications were VAO and elevated intraocular pressure after surgery. There were no other complications, with the exception of one eye with IOL dislocation. Conclusions The results indicate that the important determinants of long-term visual outcomes in children with congenital cataracts undergoing secondary IOL implantation are laterality, cataract type, age at initial cataract extraction, compliance with amblyopia therapy, and refractive error. AN - WOS:000358838400179 AU - Rong, X. F. AU - Ji, Y. H. AU - Fang, Y. W. AU - Jiang, Y. X. AU - Lu, Y. DA - JUL 31 DO - 10.1371/journal.pone.0134864 IS - 7 PY - 2015 SN - 1932-6203 ST - Long-Term Visual Outcomes of Secondary Intraocular Lens Implantation in Children with Congenital Cataracts T2 - PLOS ONE TI - Long-Term Visual Outcomes of Secondary Intraocular Lens Implantation in Children with Congenital Cataracts VL - 10 ID - 6206 ER - TY - JOUR AB - Background: Eye care provision is currently insufficient to meet the population’s eye health needs in Kenya. Many people remain unnecessarily visually impaired or at risk of becoming so due to treatable or preventable conditions. A lack of access and awareness of services are key barriers, in large part due to their being too few eye care providers in the health system for this unmet need. Methods: A hospital-based, retrospective analysis of patients who attended Kitale eye unit, Trans Nzoia County, Kenya from 1st January 2013 to 31st December 2015. Age and sex standardized hospital attendance rates by residence, age group, and sex were calculated for Trans Nzoia county and each subcounty. The changing trends in attendance rates were estimated by calculating the difference between base year and last year. Incidence rate ratios for attendance for each age-group, sex, and residence were estimated using a multivariable regression model. Results: 20,695 patients from the county were seen in Kitale Eye Unit in 2013, 2014 and 2015. In that period, 8.3% had either uncorrected refractive error, cataracts or glaucoma, the priority VISION2020 diseases, and 61.0% had allergic or other conjunctivitis or normal eyes, which could potentially be managed at primary eye care. During the study period, overall average annual attendance rate increased from 609 to 792 per 100, 000 population, incidence rate ratio (IRR) 1.30 (95% confidence interval (CI) 1.26–1.35). Attendance rates increased more in females than males (34.7% vs. 25.1%, respectively), IRR 1.07 (1.04–1.10). Attendance rates increased with increasing age, (highest among the elderly compared to the young). We found that in extreme age groups (>75 years and <15years) females were less likely to attend than males and there was reduced utilization from those based furthest from the hospital. Conclusion: Specialist eye services are heavily utilized by people with conditions that could be managed at the primary health care level. Barriers to accessing eye services were distance and gender, especially among the most vulnerable groups (young and the elderly). Integration of primary and secondary eye care services could lower barriers to essential eye care services to the population whilst lowering pressure on the limited specialist services by ensuring more appropriate utilization. AD - H.K. Rono Mmed, International Centre for Eye Health, Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom AU - Rono Mmed, H. K. AU - Macleod, D. AU - Bastawrous, A. AU - Wanjala, E. AU - Gichangi, M. AU - Burton, M. J. DB - Embase Medline DO - 10.3390/ijerph16183371 IS - 18 KW - adolescent adult aged allergic conjunctivitis article cataract chalazion child conjunctivitis cornea disease eye allergy eye care eye injury female glaucoma health care utilization human incidence infant Kenya major clinical study male newborn patient attendance presbyopia refraction error regression analysis retina disease retrospective study sex ratio uveitis very elderly LA - English M3 - Article N1 - L2002669177 2019-10-22 2019-10-25 PY - 2019 SN - 1660-4601 1661-7827 ST - Utilization of secondary eye care services in western Kenya T2 - International Journal of Environmental Research and Public Health TI - Utilization of secondary eye care services in western Kenya UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2002669177&from=export http://dx.doi.org/10.3390/ijerph16183371 VL - 16 ID - 2480 ER - TY - JOUR AB - Background: Glaucoma treatment requires patients to follow daily, often times complex, eye drop regimens, but adherence is poor for many patients, putting them at risk for irreversible vision loss. A comprehensive approach is needed to address the challenges in the self-management of glaucoma. The purpose of this study is to improve glaucoma medication adherence in Veterans with medically treated glaucoma using an education-based intervention. Methods/design: This study is a single-site randomized controlled trial enrolling 200 Veterans and their companions, if companions are involved in their care. It has two arms: an intervention group and a control group. Participants in the intervention group receive an educational session with a non-physician interventionist and are provided with an AdhereTech smart bottle with the reminder functions activated. The control group is designed as an attention control such that they have a session on general eye health and are provided with a smart bottle but without the reminder functions activated. The primary outcome is the proportion of prescribed doses taken on schedule over 6 months following randomization according to the smart bottle. Secondary outcomes include intensification of glaucoma treatment, cost of intervention delivery, and cost-effectiveness of the intervention over 12 months. Discussion: The education-based intervention that we are testing is comprehensive in scope, to encompass a variety of barriers to adherence that glaucoma patients encounter, but personalized to address issues facing individual patients. Particular attention was given to feasibility in the real-world setting, as the high throughput of patients and lack of reimbursement for educational encounters in ophthalmology would limit implementation of a resource-intensive intervention. AD - Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA Department of Medicine, Duke University School of Medicine, Durham, NC, USA Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA Durham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA AN - 150676257. Language: English. Entry Date: 20210609. Revision Date: 20210609. Publication Type: Article AU - Rosdahl, Jullia A. AU - Hein, Aaron M. AU - Bosworth, Hayden B. AU - Woolson, Sandra AU - Olsen, Maren AU - Kirshner, Miriam AU - Hung, Anna AU - Muir, Kelly W. DB - ccm DO - 10.1177/1740774520988291 DP - EBSCOhost IS - 3 KW - Medication Compliance Glaucoma -- Therapy Patient Education Veterans Health Education Quality Improvement Self Care Randomized Controlled Trials Treatment Outcomes Ocular Hypertension Descriptive Statistics Confidence Intervals Odds Ratio Human N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 101285473. PY - 2021 SN - 1740-7745 SP - 343-350 ST - Randomized controlled trial of an education-based intervention to improve medication adherence: Design considerations in the medication adherence in glaucoma to improve care study T2 - Clinical Trials TI - Randomized controlled trial of an education-based intervention to improve medication adherence: Design considerations in the medication adherence in glaucoma to improve care study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150676257&site=ehost-live&scope=site VL - 18 ID - 4146 ER - TY - JOUR AU - Rosenbaum, L. J. DB - Scopus DO - 10.1016/j.ajo.2006.10.001 IS - 1 M3 - Letter N1 - Cited By :1 Export Date: 19 July 2021 PY - 2007 SP - 191-192 ST - Management of Patients With Ocular Hypertension: A Cost-Effectiveness Approach From the Ocular Hypertension Treatment Study T2 - American Journal of Ophthalmology TI - Management of Patients With Ocular Hypertension: A Cost-Effectiveness Approach From the Ocular Hypertension Treatment Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845488353&doi=10.1016%2fj.ajo.2006.10.001&partnerID=40&md5=01aa85fb984e496be49b13324a951926 VL - 143 ID - 5646 ER - TY - JOUR AB - Timolol (generic name) is a frequently used medication for the control of glaucoma. Benzalkonium chloride (BAK) is a commonly used preservative in ophthalmic solutions with a broad range of antimicrobial activity; however, this nonspecificity can result in toxicity. Adverse effects attributed to BAK, including conjunctival inflammation and fibrosis, tear film instability, corneal cytotoxicity, anterior chamber inflammation, trabecular meshwork cell apoptosis, cataract development, macular edema, and even systemic effects, have been well documented. These effects can lead to ocular discomfort, poor intraocular pressure control, glaucoma surgery failure, and decreased patient compliance. BAK use in topical medications has decreased recently as newer and less toxic preservatives have become available. Yet these preservatives still exert some toxic effects, especially in patients with chronic eye disease who use multiple drops over extended periods of time. Thus, attempts to reduce overall preservative loads for patients are important, whether it be decreasing the amount of preservative, decreasing the total number of drops patients use, or eliminating preservatives entirely. A preservative-free formulation of timolol, TIMOPTIC® in OCUDOSE®, is available in unit-dose vials. Preservative-free unit-dose vials minimize toxic adverse effects and are a good option for patients with ocular surface disease, on long-term multidrop therapy, or who simply do not tolerate the effects of preservatives due to discomfort. © 2013 Rosin and Bell. AD - N. P. Bell, Robert Cizik Eye Clinic, 6400 Fannin St, Suite 1800, Houston, TX 77030, United States AU - Rosin, L. M. AU - Bell, N. P. C1 - timoptic in ocudose(Valeant,United States) C2 - Merck and Co(United States) Valeant(United States) DB - Embase DO - 10.2147/OPTH.S41358 KW - antiglaucoma agent benzalkonium chloride timolol maleate anterior eye chamber cataract cataract extraction conjunctiva disease cornea disease cytotoxicity drug choice drug efficacy drug hypersensitivity drug packaging drug penetration drug safety dry eye eye discomfort eye irritation eye toxicity filtering operation glaucoma human intraocular hypertension nonhuman ocular surface disease pathogenesis patient comfort patient compliance physical chemistry randomized controlled trial (topic) review risk benefit analysis tear film toxicity testing timoptic in ocudose L1 - internal-pdf://2044897763/2959-Preservative toxicity in glaucoma me-2013.pdf LA - English M3 - Review N1 - L370170411 2013-12-03 PY - 2013 SN - 1177-5467 1177-5483 SP - 2131-2135 ST - Preservative toxicity in glaucoma medication: Clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops T2 - Clinical Ophthalmology TI - Preservative toxicity in glaucoma medication: Clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370170411&from=export http://dx.doi.org/10.2147/OPTH.S41358 VL - 7 ID - 2959 ER - TY - JOUR AB - Inhaled corticosteroids (ICS) are the standard of care in asthma and are widely used in the treatment of patients with chronic obstructive pulmonary disease. High-dose regimens and long-term use of ICS in predisposed individuals may be associated with a variety of side effects, similar to those observed with systemic corticosteroid therapy. Side effects associated with long-term ICS use include reduction in growth velocity, cataracts, glaucoma, osteoporosis, and fractures. Fear of unwanted complications may be of concern in all patients using ICS, particularly in age- and gender-specific populations that are more prone to develop side effects or to reduce treatment adherence because of physical, behavioral, or psychological problems. In addition to concerns about ICS safety, dosing regimens that are difficult to follow may further reduce a patient's ability to comply with treatment. Ciclesonide, a new-generation ICS with unique pharmacokinetic properties, was developed to provide effective anti-inflammatory control for asthma with once-daily administration to improve patient adherence and a high safety profile to reduce the occurrence of local and systemic side effects. © 2005 Elsevier Ltd. All rights reserved. AD - M. Cazzola, Unit of Pneumology and Allergology, Centre for Respiratory Clinical Pharmacology, Department of Respiratory Medicine, Via del Parco Margherita 24, 80121 Naples, Italy AU - Rossi, G. A. AU - Cerasoli, F. AU - Cazzola, M. DB - Embase Medline DO - 10.1016/j.pupt.2005.10.008 IS - 1 KW - beclomethasone dipropionate budesonide ciclesonide corticosteroid flunisolide fluticasone propionate influenza vaccine mometasone furoate nedocromil triamcinolone adrenal cortex insufficiency antiinflammatory activity article aspergillosis asthma bone density cataract chronic obstructive lung disease clinical trial corticosteroid therapy drug absorption drug megadose drug safety fracture glaucoma growth retardation high risk patient hoarseness human hypothalamus hypophysis adrenal system lung aspergillosis lung infection mycosis osteoporosis particle size patient compliance pharyngitis physical chemistry priority journal skin contusion skin manifestation skin thinning skinfold thickness thrush LA - English M3 - Article N1 - L44648798 2006-11-21 PY - 2007 SN - 1094-5539 1522-9629 SP - 23-35 ST - Safety of inhaled corticosteroids: Room for improvement T2 - Pulmonary Pharmacology and Therapeutics TI - Safety of inhaled corticosteroids: Room for improvement UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44648798&from=export http://dx.doi.org/10.1016/j.pupt.2005.10.008 VL - 20 ID - 3542 ER - TY - JOUR AB - Purpose: To record the impact of preservative-free Tafluprost on corneal status examined by in vivo confocal microscopy. Methods: A prospective cohort study on consecutive naïve or previously treated patients with a new prescription of preservative-free Tafluprost. All subjects underwent a complete ophthalmic examination [comprehensive of intraocular pressure (IOP) and central corneal thickness (CCT) measurements], and an in vivo corneal confocal microscopy evaluation, at baseline and 12 months later. A healthy control group was selected and examined at the same time. Results: Seventy-five subjects (16 controls, 20 naïve, and 39 treated) were enrolled. At baseline, IOP was 16 (13.8-18.6), 21.5 (18-23.7), and 18 (16-22) mmHg, (P=0.01); and CCT did not differ among the groups (P=0.25). Epithelial cells, keratocyte activation, a number of sub-basal nerves, and the grade of nerve tortuosity were similar (P=0.233, 0.11, 0.417, and 0.05, respectively), in naïve and controls, while previously treated patients had significantly less epithelial cells and sub-basal corneal nerves (P<0.0001), keratocyte activation, increased number of bead-like formations, and nerve tortuosity (P<0.0001). At month 12, IOP decreased in both patient groups (P<0.001); CCT did not change. Previously treated patients showed an improvement in confocal parameters: increased epithelial cells (P=0.0006), reduced keratocyte activation (P=0.003), increased number of corneal nerves (P=0.0004), decreased number of bead-like formations (P=0.0013), and nerve tortuosity (P=0.0008). Naïve patients did not show significant changes. Conclusion: The study confirmed the efficacy of preservative-free Tafluprost in reducing IOP, and underlined the drug's safety in naïve glaucoma patients with regard to corneal status. In the balance between efficacy and tolerability, formulations with low cytotoxicity may ensure fewer side effects, with higher tolerability and better compliance. © Mary Ann Liebert, Inc. AD - University Eye Clinic, IRCCS Policlinico San Matteo Foundation, P.le Golgi 19, Pavia 27100, Italy University Eye Clinic, Ospedale L. Sacco, Milano, Italy Clinical Epidemiology, Biometric Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy Eye Unit, Istituto B. Palazzolo, Bergamo, Italy AU - Rossi, G. C. M. AU - Blini, M. AU - Scudeller, L. AU - Ricciardelli, G. AU - Depolo, L. AU - Amisano, A. AU - Bossolesi, L. AU - Pasinetti, G. M. AU - Bianchi, P. E. DB - Scopus DO - 10.1089/jop.2013.0069 IS - 9 M3 - Article N1 - Cited By :15 Export Date: 19 July 2021 PY - 2013 SP - 821-825 ST - Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: A single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group T2 - Journal of Ocular Pharmacology and Therapeutics TI - Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: A single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887033433&doi=10.1089%2fjop.2013.0069&partnerID=40&md5=0a97149f3168a8c4d79c269d5717bbf1 VL - 29 ID - 5191 ER - TY - JOUR AB - Purpose. To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid® (TDA). Methods. In this 36-month retrospective study, 35 patients with primary open-angle glaucoma on travoprost or travoprost/timolol fixed combination monotherapy were submitted to ophthalmic examination and to visual field (VF) test from 2007 to 2009. Adherence was recorded with TDA. The association between VF progression (from 2007 to the end of the follow-up period) and a number of predictors (adherence rates at 12 months) was tested by means of chi-square test (or Fisher exact test) or Mann-Whitney test as appropriate. Results. The mean (±SD) adherence rates were 71.9%±27.8% after 1 month of follow-up and 76.8%±20.9% at 12 months. A total of 25 (71.4%) patients with stable VF had a median adherence rate (IQR) of 85% (75%-97%); patients who worsened (n=10; 28.6%) recorded a median (IQR) adherence of 21% (9%-45%) (p<0.001). No association was found between VF progression and any of the other variables (age, sex, schooling, visual acuity, intraocular pressure (IOP) at baseline and over time, other ocular diseases, time since diagnosis and actual therapy, number of concomitant systemic therapies). Patients who were at least 90% adherent did not progress, while 43.5% of the patients with lower adherence worsened (p=0.01). Conclusions. Our data suggest that adherence rate may play a role in glaucomatous damage and/or progression; the target IOP therefore should be adjusted by adherence rates. Monitoring tools, educational programs, use of videos, a better doctor-patient relationship, or other means to improve adherence are desirable and necessary to preserve visual function. © 2010 Wichtig Editore. AD - G. C. M. Rossi, IRCCS Policlinico San Matteo Foundation, Piazzale Golgi 2, 27100 Pavia, Italy AU - Rossi, G. C. M. AU - Pasinetti, G. M. AU - Scudeller, L. AU - Radaelli, R. AU - Bianchi, P. E. DB - Embase Medline DO - 10.5301/EJO.2010.6112 IS - 4 KW - timolol plus travoprost travoprost aged article clinical article clinical assessment controlled study devices drug monitoring human intraocular pressure open angle glaucoma patient attitude patient compliance priority journal retrospective study visual field visual system function Travatan Dosing Aid LA - English M3 - Article N1 - L361862127 2011-06-08 2011-06-17 PY - 2011 SN - 1120-6721 SP - 410-414 ST - Do adherence rates and glaucomatous visual field progression correlate? T2 - European Journal of Ophthalmology TI - Do adherence rates and glaucomatous visual field progression correlate? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361862127&from=export http://dx.doi.org/10.5301/EJO.2010.6112 http://www.eur-j-ophthalmol.com/public/EJO/Article/Attach.action?cmd=Download&uid=B470D69A-0E48-40E3-A2BC-9EF0E71A7A6F VL - 21 ID - 3160 ER - TY - JOUR AB - Purpose. To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid® (TDA). Methods. In this 36-month retrospective study, 35 patients with primary open-angle glaucoma on travoprost or travoprost/timolol fixed combination monotherapy were submitted to ophthalmic examination and to visual field (VF) test from 2007 to 2009. Adherence was recorded with TDA. The association between VF progression (from 2007 to the end of the follow-up period) and a number of predictors (adherence rates at 12 months) was tested by means of chi-square test (or Fisher exact test) or Mann-Whitney test as appropriate. Results. The mean (±SD) adherence rates were 71.9%±27.8% after 1 month of follow-up and 76.8%±20.9% at 12 months. A total of 25 (71.4%) patients with stable VF had a median adherence rate (IQR) of 85% (75%-97%); patients who worsened (n=10; 28.6%) recorded a median (IQR) adherence of 21% (9%-45%) (p<0.001). No association was found between VF progression and any of the other variables (age, sex, schooling, visual acuity, intraocular pressure (IOP) at baseline and over time, other ocular diseases, time since diagnosis and actual therapy, number of concomitant systemic therapies). Patients who were at least 90% adherent did not progress, while 43.5% of the patients with lower adherence worsened (p=0.01). Conclusions. Our data suggest that adherence rate may play a role in glaucomatous damage and/or progression; the target IOP therefore should be adjusted by adherence rates. Monitoring tools, educational programs, use of videos, a better doctor-patient relationship, or other means to improve adherence are desirable and necessary to preserve visual function. © 2010 Wichtig Editore. AD - University Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy Eye Unit, Istituto Beato Palazzolo, Bergamo, Italy Laboratory Epidemiologia e Statistica, IRCCS Policlinico San Matteo Foundation, Pavia, Italy Eye Unit, AO Bolognini, Bergamo, Italy AU - Rossi, G. C. M. AU - Pasinetti, G. M. AU - Scudeller, L. AU - Radaelli, R. AU - Bianchi, P. E. DB - Scopus DO - 10.5301/EJO.2010.6112 IS - 4 KW - Adherence Glaucoma Monitoring tools Monotherapy Travatan dosing aid® Visual field progression M3 - Article N1 - Cited By :66 Export Date: 19 July 2021 PY - 2011 SP - 410-414 ST - Do adherence rates and glaucomatous visual field progression correlate? T2 - European Journal of Ophthalmology TI - Do adherence rates and glaucomatous visual field progression correlate? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957871972&doi=10.5301%2fEJO.2010.6112&partnerID=40&md5=72dd033061ab8fffff1c5f5ba5a122e4 VL - 21 ID - 4965 ER - TY - JOUR AB - PURPOSE. To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid (R) (TDA). METHODS. In this 36-month retrospective. study, 35 patients with primary open-angle glaucoma on travoprost or travoprost/timolol fixed combination monotherapy were submitted to ophthalmic examination and to visual field (VF) test from 2007 to 2009. Adherence was recorded with TDA. The association between VF progression (from 2007 to the end of the follow-up period) and a number of predictors (adherence rates at 12 months) was tested by means of chi-square test (or Fisher exact test) or Mann-Whitney test as appropriate. RESULTS. The mean (+/- SD) adherence rates were 71.9%+/- 27.8% after 1 month of follow-up and 76.8%+/- 20.9% at 12 months. A total of 25 (71.4%) patients with stable VF had a median adherence rate (IQR) of 85% (75%-97%); patients who worsened (n=10; 28.6%) recorded a median (IQR) adherence of 21% (9%-45%) (p < 0.001). No association was found between VF progression and any of the other variables (age, sex, schooling, visual acuity, intraocular pressure (IOP) at baseline and over time, other ocular diseases, time since diagnosis and actual therapy, number of concomitant systemic therapies). Patients who were at least 90% adherent did not progress, while 43.5% of the patients with lower adherence worsened (p=0.01). CONCLUSIONS. Our data suggest that adherence rate may play a role in glaucomatous damage and/or progression; the target IOP therefore should be adjusted by adherence rates. Monitoring tools, educational programs, use of videos, a better doctor-patient relationship, or other means to improve adherence are desirable and necessary to preserve visual function. AN - WOS:000293866400010 AU - Rossi, G. C. M. AU - Pasinetti, G. M. AU - Scudeller, L. AU - Radaelli, R. AU - Bianchi, P. E. DA - JUL-AUG DO - 10.5301/EJO.2010.6112 IS - 4 PY - 2011 SN - 1120-6721 1724-6016 SP - 410-414 ST - Do adherence rates and glaucomatous visual field progression correlate? T2 - EUROPEAN JOURNAL OF OPHTHALMOLOGY TI - Do adherence rates and glaucomatous visual field progression correlate? VL - 21 ID - 6008 ER - TY - JOUR AB - Objective: To assess adherence in glaucoma patients using the Travatan Dosing Aid (TDA); to record differences in adherence by age, sex, therapy, systemic therapies, years from diagnosis, type of therapy and intraocular pressure (IOP). Research Design and Methods: Sixth-month cohort study; fifty-six Caucasian, primary open-angle glaucoma patients on travoprost (T) or travoprost/timolol fixed combination (TTFC) monotherapy were submitted to four visits: at baseline and months 1, 3 and 6 (M1, M3, M6). Adherence was recorded with TDA and classified as 'high' if greater than 90%. Self-reported and physician-presumed adherence data were collected. Kruskall-Wallis and Fisher's exact tests were applied. Results: Thirty-two patients (54.2%) were treated with T. Age, sex, level of schooling, presence of systemic comorbidities, duration of current therapy and IOP were similar between T and TTFC. Seventeen subjects (30.3%) recorded high adherence at every visit, 13 (23.2%) at two visits, 26 (46.4%) otherwise. Adherence was maintained over time with a slight decrease from month 1 to month 6 without statistical differences within and between groups. Adherence was statistically influenced by age (p Combining double low line 0.007) and duration of therapy (p Combining double low line 0.004). Conclusion: The typical nonadherent patient is elderly. TDA records indicate that only a minority of patients are really adherent: predictive models to screen for poor adherence are needed. © 2010 Informa UK Ltd. AD - G. C. M. Rossi, University Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, 27100, Italy AU - Rossi, G. C. M. AU - Pasinetti, G. M. AU - Scudeller, L. AU - Tinelli, C. AU - Milano, G. AU - Bianchi, P. E. DB - Embase Medline DO - 10.1517/14656561003601994 IS - 4 KW - timolol plus travoprost travoprost academic achievement adult aged article clinical article controlled study female groups by age human intraocular pressure male medical record monotherapy open angle glaucoma patient compliance self report sex difference systemic therapy treatment duration LA - English M3 - Article N1 - L358345764 2010-03-03 2010-06-07 PY - 2010 SN - 1465-6566 SP - 499-504 ST - Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination T2 - Expert Opinion on Pharmacotherapy TI - Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358345764&from=export http://dx.doi.org/10.1517/14656561003601994 VL - 11 ID - 3268 ER - TY - JOUR AB - Objective: To assess adherence in glaucoma patients using the Travatan Dosing Aid (TDA); to record differences in adherence by age, sex, therapy, systemic therapies, years from diagnosis, type of therapy and intraocular pressure (IOP). Research Design and Methods: Sixth-month cohort study; fifty-six Caucasian, primary open-angle glaucoma patients on travoprost (T) or travoprost/timolol fixed combination (TTFC) monotherapy were submitted to four visits: at baseline and months 1, 3 and 6 (M1, M3, M6). Adherence was recorded with TDA and classified as 'high' if greater than 90%. Self-reported and physician-presumed adherence data were collected. Kruskall-Wallis and Fisher's exact tests were applied. Results: Thirty-two patients (54.2%) were treated with T. Age, sex, level of schooling, presence of systemic comorbidities, duration of current therapy and IOP were similar between T and TTFC. Seventeen subjects (30.3%) recorded high adherence at every visit, 13 (23.2%) at two visits, 26 (46.4%) otherwise. Adherence was maintained over time with a slight decrease from month 1 to month 6 without statistical differences within and between groups. Adherence was statistically influenced by age (p Combining double low line 0.007) and duration of therapy (p Combining double low line 0.004). Conclusion: The typical nonadherent patient is elderly. TDA records indicate that only a minority of patients are really adherent: predictive models to screen for poor adherence are needed. © 2010 Informa UK Ltd. AD - University Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, 27100, Italy UO Oculistica, Istituto Beato Palazzolo, Bergamo, 24100, Italy Clinical Epidemiology and Biometric Unit, IRCCS Policlinico San Matteo Foundation, Pavia, 27100, Italy AU - Rossi, G. C. M. AU - Pasinetti, G. M. AU - Scudeller, L. AU - Tinelli, C. AU - Milano, G. AU - Bianchi, P. E. DB - Scopus DO - 10.1517/14656561003601994 IS - 4 KW - Adherence Glaucoma Travatan dosing aid Travoprost Travoprost/timolol fixed combination M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2010 SP - 499-504 ST - Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination T2 - Expert Opinion on Pharmacotherapy TI - Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77249148998&doi=10.1517%2f14656561003601994&partnerID=40&md5=41c4cb2c127432e84485d69ac2204ca7 VL - 11 ID - 5203 ER - TY - JOUR AB - Research Design and Methods: Sixth-month cohort study; fifty-six Caucasian, primary open-angle glaucoma patients on travoprost (T) or travoprost/timolol fixed combination (TTFC) monotherapy were submitted to four visits: at baseline and months 1, 3 and 6 (M1, M3, M6). Adherence was recorded with TDA and classified as 'high' if greater than 90%. Self-reported and physician-presumed adherence data were collected. Kruskall-Wallis and Fisher's exact tests were applied. Results: Thirty-two patients (54.2%) were treated with T. Age, sex, level of schooling, presence of systemic comorbidities, duration of current therapy and IOP were similar between T and TTFC. Seventeen subjects (30.3%) recorded high adherence at every visit, 13 (23.2%) at two visits, 26 (46.4%) otherwise. Adherence was maintained over time with a slight decrease from month 1 to month 6 without statistical differences within and between groups. Adherence was statistically influenced by age (p = 0.007) and duration of therapy (p = 0.004). Conclusion: The typical nonadherent patient is elderly. TDA records indicate that only a minority of patients are really adherent: predictive models to screen for poor adherence are needed. AN - WOS:000274885400002 AU - Rossi, G. C. M. AU - Pasinetti, G. M. AU - Scudeller, L. AU - Tinelli, C. AU - Milano, G. AU - Bianchi, P. E. DA - MAR DO - 10.1517/14656561003601994 IS - 4 PY - 2010 SN - 1465-6566 1744-7666 SP - 499-504 ST - Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination T2 - EXPERT OPINION ON PHARMACOTHERAPY TI - Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination VL - 11 ID - 5945 ER - TY - JOUR AB - Introduction: Glaucoma is an asymptomatic disease, which can cause irreversible blindness, with a worldwide prevalence around 64.3 million people. Adherence to glaucoma treatment is crucial to control the disease and to prevent its complications. Low medication adherence results in a visual loss, which can leads to irreversible blindness. In this sense it is important to know and evaluate adherence to pharmacological therapy among patients with glaucoma. Areas covered: A scoping review was conducted, according to the methodology proposed by Arksey and O'Malley. The databases used were Medical Literature Analysis and Retrieval System Online (MEDLINE) and the Biblioteca do Conhecimento Online (B-on). Our research used as primary sources articles in Portuguese and English. Expert opinion: The identified adherence rates were very different, and the conditions how under medication adherence was assessed were highly variable. These conditions impossibilities a proper comparative study. Further efforts are needed to increase health literacy and thus identify and support patients with low medication adherence rates. It is important that health care personnel could improve patients' knowledge about the importance of medication adherence, glaucoma disease, and the consequences that result from the lack of treatment. AD - Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal ESTeSL- Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal AN - 149380922. Language: English. Entry Date: 20210401. Revision Date: 20210407. Publication Type: Article AU - Rosu, Amalia Mihaela AU - Coelho, André AU - Camacho, Pedro DB - ccm DO - 10.1080/17469899.2020.1842197 DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Medication Compliance -- Evaluation Human Systematic Review Medline Support, Psychosocial N1 - research; systematic review; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 101278197. PY - 2021 SN - 1746-9899 SP - 113-124 ST - Assessment of medication therapy adherence in glaucoma: scoping review T2 - Expert Review of Ophthalmology TI - Assessment of medication therapy adherence in glaucoma: scoping review UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149380922&site=ehost-live&scope=site VL - 16 ID - 4153 ER - TY - JOUR AB - Purpose. To assess levels of compliance in elderly patients on timolol eyedrops for glaucoma. Methods. A postal questionnaire was sent from the general practitioner to 86 patients over 55 years of age on repeat prescriptions for timolol eyedrops. The questionnaire asked details about the duration of treatment, family history, the level of understanding of the disease and the importance of treatment, other regular medication, side-effects attributed to the drops and how often patients omitted their drops. A search of practice and local hospital dispensing data was carried out to assess how frequently monthly repeat prescriptions for timolol eyedrops were actually dispensed over a 12 month period. This allowed a total volume to be calculated for each patient. Results. Twenty-four per cent of patients admitted to omitting eyedrops either occasionally or frequently. Fifty-one per cent were found to have had insufficient drops dispensed to comply with treatment as prescribed. In non-compliant patients the mean period without drops was 85 days of the year, with a maximum of 165 days. Conclusion. Compliance with treatment is poor and patients underestimate their level of defaulting when questioned. AD - A.P. Rotchford, Hlabisa Hospital, Private Bag X5001, Hlabisa KwaZulu-Natal, South Africa AU - Rotchford, A. P. AU - Murphy, K. M. DB - Embase Medline DO - 10.1038/eye.1998.56 IS - 2 KW - timolol adult aged article comprehension family history female general practitioner geriatric patient glaucoma human major clinical study male patient compliance questionnaire topical drug administration LA - English M3 - Article N1 - L28263862 1998-06-21 PY - 1998 SN - 0950-222X SP - 234-236 ST - Compliance with timolol treatment in glaucoma T2 - Eye TI - Compliance with timolol treatment in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L28263862&from=export http://dx.doi.org/10.1038/eye.1998.56 VL - 12 ID - 3949 ER - TY - JOUR AB - Precis:Approximately 1 in 9 Florida residents over the age of 65 years (438,642 people) live more than an hour away from a glaucoma specialist, which represents a significant barrier to care.Purpose:To describe access to glaucoma care for Florida's elderly population using travel time to American Glaucoma Society (AGS) member offices.Methods:For this cross-sectional service coverage analysis, a list of AGS member locations was extracted from the AGS website, and addresses were geocoded using ArcGIS Online. Driving time regions were created using the service area tool in ArcGIS Pro 2.4 and overlaid with 2010 United States Census and 2016 American Community Survey data for all Florida residents age 65 or older.Results:Fifty-eight AGS member providers with 65 locations were identified and geocoded. There were 3,797,625 individuals aged over 65 years in Florida, of which 1,153,320 (30.4%) lived within 15 minutes of driving time from an AGS provider's office, 2,586,825 (68.1%) within 30 minutes, 3,358,983 (88.4%) within 60 minutes, and 3,491,815 (91.9%) within 120 minutes. The areas with the lowest access include rural areas near Lake Okeechobee and the Florida Panhandle. The population living beyond a 60-minute drive was more likely to be White, non-Hispanic and older, but less likely to be living below the federal poverty level or receiving public assistance than the population living within a 60-minute drive.Conclusions:There is a significant travel burden for the elderly community of Florida to reach AGS providers. Additional studies could help identify other social barriers to accessing glaucoma providers in Florida and beyond in an effort to improve patient compliance and, ultimately, vision outcomes. AD - A.L. Rothman, 900 NW 17th Street, Miami, FL, United States AU - Rothman, A. L. AU - Stoler, J. B. AU - Vu, D. M. AU - Chang, T. C. DB - Embase Medline DO - 10.1097/IJG.0000000000001648 IS - 12 KW - aged aging article Caucasian community living controlled study cross-sectional study Florida glaucoma health care access human medical specialist patient care pilot study poverty priority journal rural area social care social determinants of health time travel LA - English M3 - Article N1 - L633757768 2020-12-30 2021-04-13 PY - 2020 SN - 1536-481X 1057-0829 SP - 1147-1151 ST - A geodemographic service coverage analysis of travel time to glaucoma specialists in Florida T2 - Journal of Glaucoma TI - A geodemographic service coverage analysis of travel time to glaucoma specialists in Florida UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633757768&from=export http://dx.doi.org/10.1097/IJG.0000000000001648 VL - 29 ID - 2366 ER - TY - JOUR AB - Precis: Approximately 1 in 9 Florida residents over the age of 65 years (438,642 people) live more than an hour away from a glaucoma specialist, which represents a significant barrier to care. Purpose: To describe access to glaucoma care for Florida's elderly population using travel time to American Glaucoma Society (AGS) member offices. Methods: For this cross-sectional service coverage analysis, a list of AGS member locations was extracted from the AGS website, and addresses were geocoded using ArcGIS Online. Driving time regions were created using the service area tool in ArcGIS Pro 2.4 and overlaid with 2010 United States Census and 2016 American Community Survey data for all Florida residents age 65 or older. Results: Fifty-eight AGS member providers with 65 locations were identified and geocoded. There were 3,797,625 individuals aged over 65 years in Florida, of which 1,153,320 (30.4%) lived within 15 minutes of driving time from an AGS provider's office, 2,586,825 (68.1%) within 30 minutes, 3,358,983 (88.4%) within 60 minutes, and 3,491,815 (91.9%) within 120 minutes. The areas with the lowest access include rural areas near Lake Okeechobee and the Florida Panhandle. The population living beyond a 60-minute drive was more likely to be White, non-Hispanic and older, but less likely to be living below the federal poverty level or receiving public assistance than the population living within a 60-minute drive. Conclusions: There is a significant travel burden for the elderly community of Florida to reach AGS providers. Additional studies could help identify other social barriers to accessing glaucoma providers in Florida and beyond in an effort to improve patient compliance and, ultimately, vision outcomes. AN - WOS:000599709400017 AU - Rothman, A. L. AU - Stoler, J. B. AU - Vu, D. M. AU - Chang, T. C. DA - DEC DO - 10.1097/IJG.0000000000001648 IS - 12 PY - 2020 SN - 1057-0829 1536-481X SP - 1147-1151 ST - A Geodemographic Service Coverage Analysis of Travel Time to Glaucoma Specialists in Florida T2 - JOURNAL OF GLAUCOMA TI - A Geodemographic Service Coverage Analysis of Travel Time to Glaucoma Specialists in Florida VL - 29 ID - 6154 ER - TY - JOUR AB - Background: Glaucoma is a leading cause of blindness. The participation of primary care physicians (PCPs) in glaucoma care may improve health outcomes for glaucoma patients. Objectives: To investigate PCPs' attitudes towards their role in glaucoma care, perceived barriers, and self-reported performance in glaucoma management. Methods: PCPs working in the Haifa and Western Galilee District of Clalit Health Services, Israel's largest Health Maintenance Organization (HMO) were asked to complete a self-administered structured questionnaire. Physicians were asked to rate their agreement with statements describing the PCP's role in glaucoma care, and to state how often they behave accordingly in their practice. In addition, physicians were asked to rate the extent that factors such as time constraints and knowledge gaps impede their performance in glaucoma care. Results: Eighty-two physicians completed the questionnaire. The majority thought that PCPs have a major role in early detection of glaucoma (99 %), discussing the importance of adherence to treatment (93 %), and encouraging patients to make regular visits to their ophthalmologist (99 %). However, only 30 % reported asking patients about family history of glaucoma, 64 % reported discussing adherence to treatment, and only 35 % stated that they explain how to use eye drops, while most of respondents (87 %) regularly provide refill prescriptions for glaucoma medications. Sixty percent claimed that during their residency they had not acquired adequate knowledge and competence to allow them to take proper care of glaucoma patients. The main barriers reported were lack of time (43 %), lack of knowledge regarding treatment options and recommended follow-up (46 %), and not being familiar with glaucoma medications' side effects (54 %). Conclusions: There is a gap between PCPs' perceptions of their role in glaucoma care and their report on actual performance in early detection and management of glaucoma. Further research is needed to develop and assess interventions that aim at closing this gap. © 2015 Rotshtein et al. AD - Department of Family Medicine, Clalit Health Services, Haifa and Western Galilee, Israel Division of Family Medicine, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel Cheryl Spencer Department of Nursing, University of Haifa Israel, Haifa, Israel Department of Ophthalmology, Rappaport Faculty of Medicine, Carmel Medical Center, Technion-Israel Institute of Technology, Haifa, Israel AU - Rotshtein, A. AU - Karkabi, K. AU - Geyer, O. AU - Cohen Castel, O. C7 - 776 DB - Scopus DO - 10.1186/s13104-015-1770-z IS - 1 KW - Glaucoma Physicians' performance Primary care physicians Role perception M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2015 ST - Primary care physicians' role perception and self-reported performance in glaucoma care: A survey study T2 - BMC Research Notes TI - Primary care physicians' role perception and self-reported performance in glaucoma care: A survey study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84949895541&doi=10.1186%2fs13104-015-1770-z&partnerID=40&md5=f583c793b5f84cc83839eaa3ab919e4c VL - 8 ID - 5463 ER - TY - JOUR AB - Recurrent herpes simplex keratitis (HSK) is a leading infectious cause of blindness in industrialized countries. Antiviral prophylaxis (AVP) may fail to prevent recurrence of HSK due to viral resistance, inadequate dosing, or poor patient compliance. In this prospective multicenter study, we enrolled immunocompetent patients with recurrent HSK despite AVP. Ocular samples were tested by PCR for herpes simplex virus 1 (HSV-1). HSV-1 drug resistance was assessed with a genotypic assay based on UL23 and UL30 gene sequencing. After curative full dose valacyclovir (VACV) treatment was started, peak and trough acyclovir (ACV) plasma concentrations were measured, and patient compliance to AVP was assessed with a questionnaire. The study sample was comprised of 43 patients. Six (14%) patients were positive for HSV-1 using PCR, of whom 5 (83%) harbored genotypically ACV-resistant (ACVR) virus, due to mutations in UL23 (n = 4) or UL30 (n = 1). Disease duration was statistically significantly longer in patients with viral resistance compared to other HSK patients [35.5 ± 23.4 years (range, 6.8–68.4 years) versus 11.1 ± 12.3 years (range, 0.8–56.3 year) respectively; Mann-Whitney p = 0.01)]. While patients were treated with full dose VACV, trough ACV plasma concentrations were below the threshold for ACV sensitivity in 9.5% of cases, and compliance was poor in 5.3% of cases. To summarize, HSV-1 resistance to ACV seems to be a significant cause of failure of prophylaxis in patients with HSK and is associated with longer disease duration. Most PCR-positive samples contained genotypically ACVR virus and identification may aid in adapting treatment. Incomplete 24-h drug coverage may also explain some cases of failure of prophylaxis. AD - M. Labetoulle, Service d'ophtalmologie, Hôpital de Bicêtre, 78, rue du Général Leclerc, France AU - Rousseau, A. AU - Boutolleau, D. AU - Titier, K. AU - Bourcier, T. AU - Chiquet, C. AU - Weber, M. AU - Colin, J. AU - Gueudry, J. AU - M'Garrech, M. AU - Bodaghi, B. AU - Burrel, S. AU - Agut, H. AU - Deback, C. AU - Berrod, J. P. AU - Bodaghi, B. AU - Bourcier, T. AU - Boutolleau, D. AU - Burrel, S. AU - Chiquet, C. AU - Colin, J. AU - Deback, C. AU - Gueudry, J. AU - Gabison, E. AU - Hoffart, L. AU - Labetoulle, M. AU - Muraine, M. AU - Rousseau, A. AU - Touboul, D. AU - Weber, M. AU - Schweitzerr, C. AU - Labetoulle, M. DB - Embase Medline DO - 10.1016/j.antiviral.2017.09.013 KW - aciclovir valaciclovir adult aged article clinical article disease duration drug blood level drug megadose lack of drug effect female gene sequence genotyping technique herpes simplex keratitis human Human alphaherpesvirus 1 infection prevention male medication compliance middle aged multicenter study patient compliance polymerase chain reaction priority journal prospective study recurrent infection very elderly virus mutation virus resistance young adult LA - English M3 - Article N1 - L618423435 2017-09-29 2020-10-07 PY - 2017 SN - 1872-9096 0166-3542 SP - 205-212 ST - Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study T2 - Antiviral Research TI - Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L618423435&from=export http://dx.doi.org/10.1016/j.antiviral.2017.09.013 VL - 146 ID - 2630 ER - TY - JOUR AB - Ambulatory treatment of hypertension depends largely on long-term oral medications to lower blood pressure and delay or prevent cardiovascular morbidity and mortality. Failure to achieve the therapeutic goal may reflect biologic, pharmacologic, or behavioral factors. Ignoring behavioral factors may result in unnecessary or even dangerous regimen escalation. More than half of patients with insufficient reductions in blood pressure display suboptimal medication compliance as assessed by pill count or bioassay. Once-daily dosing may be an important part of enhancing compliance, patient convenience, and regimen simplification; however, drug concentrations may be subtherapeutic when dosing delays or omissions occur. Electronic monitoring data in hypertension, glaucoma, seizure disorders, and other diseases indicate that 50% to 60% of patients adhere well to prescribed regimens, that 5% to 10% adhere poorly, and that the 30% to 45% adhere to an intermediate but markedly variable degree. A growing body of literature offers empirical support for focused and personalized interventions. AD - P. Rudd, Stanford University Medical Center, Department of Medicine, Stanford, CA 94305-5475, United States AU - Rudd, P. DB - Embase Medline DO - 10.1016/0002-8703(95)90368-2 IS - 3 I KW - antihypertensive agent calcium antagonist debrisoquine nifedipine human hypertension outpatient care patient compliance priority journal review LA - English M3 - Review N1 - L25278161 1995-10-01 PY - 1995 SN - 0002-8703 SP - 572-579 ST - Clinicians and patients with hypertension: Unsettled issues about compliance T2 - American Heart Journal TI - Clinicians and patients with hypertension: Unsettled issues about compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L25278161&from=export http://dx.doi.org/10.1016/0002-8703(95)90368-2 VL - 130 ID - 3981 ER - TY - JOUR AB - Objective: Patient satisfaction with glaucoma therapy is one of the aspects that affects adequate adherence to treatment; therefore, it would be interesting to measure the satisfaction properly. We present the development process and psychometric properties of a new instrument for measuring patient satisfaction with glaucoma treatment. Material and methods: After collection and discussion of contents, a 38-item questionnaire was proposed and arranged into seven theoretical domains. The questionnaire was applied to a sample of 194 patients and its length was reduced using an exploratory factor analysis. Psychometric properties were assessed under classic theory. Results: The final questionnaire is formed by 22 items grouped into seven dimensions: expectations and beliefs about treatment, ease of use, efficacy, undesired effects, impact on health-related quality of life, medical care, and general satisfaction with treatment. Some dimensions correlated slightly. The reliability of the dimensions ranged from 0.77 to 0.93. Confirmatory factor analysis revealed an additional support of the proposed structure (χ2 (188)217, P=0.073). Glausat scores were proven to correlate with patients' self rating on medication tolerability, and with clinicians' assessment of tolerability, effectiveness and compliance. Conclusions: The Glausat questionnaire has proven to be reliable and structurally valid. This instrument may be used to assess patients' satisfaction with glaucoma treatment. © 2010 Informa UK Ltd. AD - J. Soto, Pfizer, Health Outcome Research, Medical Unit, Avenida de Europa 20 B, Madrid, 28108, Spain AU - Ruiz, M. A. AU - Pardo, A. AU - Martinez De La Casa, J. M. AU - Polo, V. AU - Esquiro, J. AU - Soto, J. DB - Embase Medline DO - 10.3109/09286581003734852 IS - 3 KW - adult article clinical effectiveness controlled study expectation glaucoma Glausat questionnaire health belief human major clinical study medical care patient compliance patient satisfaction priority journal psychometry quality of life questionnaire reliability self concept LA - English M3 - Article N1 - L358810363 2010-05-21 2010-06-22 PY - 2010 SN - 1744-5086 0928-6586 SP - 131-143 ST - Development of a specific questionnaire measuring patient satisfaction with glaucoma treatment: Glausat T2 - Ophthalmic Epidemiology TI - Development of a specific questionnaire measuring patient satisfaction with glaucoma treatment: Glausat UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358810363&from=export http://dx.doi.org/10.3109/09286581003734852 VL - 17 ID - 3285 ER - TY - JOUR AB - Background and objective: To describe the process of the cultural and psychometric adaptation (validation) into Spanish of the Glaucoma Symptom Scale (GSS) in order to measure the impact of glaucoma symptoms, and inform about the psychometric properties. Material and method: The study was supervised by a 6-member expert panel. After forward and backward translations in duplicate, a Spanish version was obtained which was administered to three samples: a 16-patient sample to check comprehenssion and face validity, a 100-patient sample to check structural validity (factor analysis and reliability) and, finally, a 387-patient sample for assessing construct and discrimination validity. Results: The questionnaire yielded 2 dimensions, which are not exactly the same as the ones in the original study. Reliability was high (alpha=0.82), and correlation between even-odd items was high too (r=0.92). The scale discriminated between lower and upper quartile groups (p<0.001). The average on non visual symptoms was higher than on visual ones (p=0.001), showing more inconvenience of the former. There were differences between compliant and non-compliant patients (p=0.004), but a lack of agreement between self-reported measures was also found. We found differences between patients with one or 2 drops treatments (p=0.0014). Conclusions: The results showed acceptable psychometric properties and they make available to health professionals a new instrument to assess glaucoma symptoms, taking into account the patient perspective. © 2008 Elsevier España, S.L. All rights reserved. AD - M.A. Ruiz, Facultad de Psicología. Universidad Autónoma de Madrid., Madrid, Spain AU - Ruiz, M. A. AU - Pardo, A. AU - Martínez de la Casa, J. M. AU - Polo, V. AU - Esquirol, J. AU - Soto, J. DB - Embase Medline DO - 10.1016/j.medcli.2008.06.005 IS - 3 KW - article comprehension construct validity correlation analysis cultural factor discriminant validity face validity factor analysis glaucoma Glaucoma Symptom Scale human instrument validation language language processing major clinical study patient compliance patient participation psychometry questionnaire rating scale reliability sample (statistics) self report Spain symptom validation process LA - Spanish M3 - Article N1 - L354158236 2009-02-26 PY - 2009 SN - 0025-7753 1578-8989 SP - 89-97 ST - Cultural adaptation and validation into Spanish of the Glaucoma Symptom Scale (GSS) T2 - Medicina Clinica TI - Cultural adaptation and validation into Spanish of the Glaucoma Symptom Scale (GSS) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354158236&from=export http://dx.doi.org/10.1016/j.medcli.2008.06.005 VL - 132 ID - 3383 ER - TY - JOUR AB - The prognosis of going blind is very stressful for patients diagnosed with "glaucoma". Worries and fear of losing independence is a constant mental burden, with secondary risks of depression and social isolation. But stress is not only a result of glaucoma but also a possible cause (risk factor). This should not be surprising, given that chronic stress can trigger "psychosomatic" organ dysfunctions anywhere in the body. Why should the organ "eye" be an exception? Indeed, glaucoma patients often suspect that severe emotional stress caused their visual field loss or "foggy vision". The hypothesis that stress is a possible cause of glaucoma is supported by different observations: (i) acute and chronic stress increases intraocular pressure and (ii) long-term stress can lead to vascular dysregulation of the microcirculation in the eye and brain ("Flammer's syndrome"), leading to partial hypoxia and hypoglycaemia (hypo-metabolism). Even if nerve cells do not die, they may then become inactive ("silent" neurons). (iii) Degenerative changes have been reported in the brain of glaucoma patients, affecting not only anterograde or transsynaptic areas of the central visual pathway, but degeneration is also found (iv) in brain areas involved in emotional appraisal and the physiological regulation of stress hormones. There are also psychological hints indicating that stress is a cause of glaucoma: (v) Glaucoma patients with Flammer's syndrome show typical personality traits that are associated with low stress resilience: they often have cold hands or feet, are ambitious (professionally successful), perfectionistic, obsessive, brooding and worrying a lot. (vi) If stress hormone levels and inflammation parameters are reduced in glaucoma patients by relaxation with meditation, this correlates with normalisation of intraocular pressure, and yet another clue is that (vii) visual field improvements after non-invasive current stimulation therapy, that are known to improve circulation and neuronal synchronisation, are much most effective in patients with stress resilient personalities. An appreciation of stress as a "cause" of glaucoma suggests that in addition to standard therapy (i) stress reduction through relaxation techniques should be recommended (e.g. meditation), and (ii) self-medication compliance should not be induced by kindling anxiety and worries with negative communication ("You will go blind!"), but communication should be positive ("The prognosis is optimistic"). Copyright Thieme. All rights reserved. AU - Sabel, Bernhard A. AU - Lehnigk, Luisa DO - https://dx.doi.org/10.1055/a-1303-8025 IS - 2 KW - *Glaucoma Humans Intraocular Pressure Tonometry, Ocular Visual Field Tests Visual Pathways PY - 2021 SE - Sabel, Bernhard A. Otto-von-Guericke Universitat Magdeburg, Institut fur Medizinische Psychologie, Deutschland. Lehnigk, Luisa. Otto-von-Guericke Universitat Magdeburg, Institut fur Medizinische Psychologie, Deutschland. SN - 1439-3999 0023-2165 SP - 132-145 ST - Is Mental Stress the Primary Cause of Glaucoma? T2 - Ist Stress die primare Ursache von Glaukom? TI - Is Mental Stress the Primary Cause of Glaucoma? UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=33578436 VL - 238 Y2 - 20210212// ID - 232 ER - TY - JOUR AB - Purpose To assess trends in prevalence of diagnosed ocular disease and use of eye care services in the Veterans Affairs (VA) health care system. Design Prevalence study. Methods We performed a retrospective study of all eligible veterans in the VA Capitol Health Care Network from 2007 to 2011. The VA database was used to abstract demographic and socioeconomic variables, including age, race, sex, marital status, service connection, prescription copay, homelessness, and VA facility. Primary outcome measures were the prevalence of diagnosed ocular disease and use of eye care. Ocular diagnoses were determined by International Classification of Diseases, 9th revision codes and use by prescription medication fills, visits to eye care clinics, and cataract surgery frequency. Results The average age of veterans ranged from 59.8–60.9, most veterans were male (88.1–89.8%), and there was a high proportion of African Americans (29.5–30%). The prevalence of all ocular diagnoses increased from 20.5% in 2007 to 23.3% in 2011 (P < .01), a 13.7% increase. Similarly, the prevalence of diagnosed cataract increased by 35.7% (P = .02) from 7.1% in 2007 to 9.6% in 2011. Diagnosed glaucoma prevalence increased by 9.4% (P = .03) from 6.7 to 7.4%. The percent of patients seen in eye clinics increased 11.6%% in the 5-year study period to 24.0% in fiscal year 2011 (P = .05). The use of ophthalmic medications increased 20% (P < .01). The rate of cataract surgery did not change significantly during the study period. Conclusions The prevalence of diagnosed eye conditions among American Veterans is increasing, as is the use of eye care services. Cataract surgery rates did not increase, which may indicate a need to increase availability of these services. AD - O. Saeedi, Department of Ophthalmology and Visual Sciences, 419 W Redwood St, Ste 470, Baltimore, MD, United States AU - Saeedi, O. AU - Ashraf, H. AU - Slade, E. P. AU - Medoff, D. R. AU - Li, L. AU - Friedman, D. S. AU - Kreyenbuhl, J. DB - Embase Medline DO - 10.1016/j.ajo.2016.09.030 KW - adult African American American article cataract cataract extraction eye care eye disease female glaucoma health care utilization human ICD-9 major clinical study male outcome assessment prevalence priority journal trend study veteran LA - English M3 - Article N1 - L613252149 2016-11-30 2016-12-14 PY - 2017 SN - 1879-1891 0002-9394 SP - 70-75 ST - Trends in Prevalence of Diagnosed Ocular Disease and Utilization of Eye Care Services in American Veterans T2 - American Journal of Ophthalmology TI - Trends in Prevalence of Diagnosed Ocular Disease and Utilization of Eye Care Services in American Veterans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613252149&from=export http://dx.doi.org/10.1016/j.ajo.2016.09.030 VL - 173 ID - 2674 ER - TY - JOUR AB - Purpose: To determine how receptive patients are to the use of e-mail and text message reminders for appointments and medications. Methods: We conducted a consecutive cross-sectional survey of eligible patients with glaucoma or ocular hypertension at a private glaucoma subspecialty practice with 3 locations from February 2011 to January 2012. Main outcome measures were answers to survey questions regarding how receptive patients are to e-mail and text messaging reminders for appointments and medications. Results: Of 989 patients, 404 (40.8%) patients reported that e-mail reminders would help remember appointments and 185 (18.7%) reported that they would help for medications. Among those with access to text messaging, 280 (68.9%) reported text messaging would help them remember appointments and 193 (47.5%) reported it would help with medications. Patients who reported e-mail would help them remember medications were more likely to live in an urban location [P = 0.05, odds ratio (OR) = 1.84], check the internet at least daily (P ≤ 0.001, OR = 1.04), check e-mail when not at home or the office (P = 0.02, OR = 1.62), and know how to open attachments (P = 0.03, OR = 1.87). Patients who reported that text messaging would help them remember their medications were more likely to be 40 or less (P ≤ 0.001, OR = 8.54) and African American (P < 0.001, OR = 2.59). Conclusions: E-mail and text messaging reminders currently may have a limited utility in improving adherence in the general glaucoma population but may be useful in younger patients with glaucoma. AD - O.J. Saeedi, Department of Ophthalmology and Visual Sciences, University of Maryland, 419 W. Redwood Street, Suite 479, Baltimore, MD, United States AU - Saeedi, O. J. AU - Luzuriaga, C. AU - Ellish, N. AU - Robin, A. DB - Embase Medline DO - 10.1097/IJG.0000000000000150 IS - 5 KW - adult African American age aged article cross-sectional study e-mail female follow up glaucoma health care survey human Internet intraocular hypertension knowledge major clinical study male medication therapy management outcome assessment patient compliance priority journal reminder system text messaging urban area LA - English M3 - Article N1 - L600711395 2014-12-15 2015-08-12 PY - 2015 SN - 1536-481X 1057-0829 SP - e95-e102 ST - Potential Limitations of E-mail and Text Messaging in Improving Adherence in Glaucoma and Ocular Hypertension T2 - Journal of Glaucoma TI - Potential Limitations of E-mail and Text Messaging in Improving Adherence in Glaucoma and Ocular Hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600711395&from=export http://dx.doi.org/10.1097/IJG.0000000000000150 VL - 24 ID - 2828 ER - TY - JOUR AB - Purpose: To determine how receptive patients are to the use of e-mail and text message reminders for appointments and medications. Methods: We conducted a consecutive cross-sectional survey of eligible patients with glaucoma or ocular hypertension at a private glaucoma subspecialty practice with 3 locations from February 2011 to January 2012. Main outcome measures were answers to survey questions regarding how receptive patients are to e-mail and text messaging reminders for appointments and medications. Results: Of 989 patients, 404 (40.8%) patients reported that e-mail reminders would help remember appointments and 185 (18.7%) reported that they would help for medications. Among those with access to text messaging, 280 (68.9%) reported text messaging would help them remember appointments and 193 (47.5%) reported it would help with medications. Patients who reported e-mail would help them remember medications were more likely to live in an urban location [P = 0.05, odds ratio (OR) = 1.84], check the internet at least daily (P ≤ 0.001, OR = 1.04), check e-mail when not at home or the office (P = 0.02, OR = 1.62), and know how to open attachments (P = 0.03, OR = 1.87). Patients who reported that text messaging would help them remember their medications were more likely to be 40 or less (P ≤ 0.001, OR = 8.54) and African American (P < 0.001, OR = 2.59). Conclusions: E-mail and text messaging reminders currently may have a limited utility in improving adherence in the general glaucoma population but may be useful in younger patients with glaucoma. Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology and Visual Sciences, University of Maryland, 419 W. Redwood Street, Suite 479, Baltimore, MD 21201, United States Department of Ophthalmology and International Health, Johns Hopkins University, Baltimore, MD, United States Eyes of York, York, PA, United States AU - Saeedi, O. J. AU - Luzuriaga, C. AU - Ellish, N. AU - Robin, A. DB - Scopus DO - 10.1097/IJG.0000000000000150 IS - 5 KW - adherence e-mail electronic messaging text messaging M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2015 SP - e95-e102 ST - Potential Limitations of E-mail and Text Messaging in Improving Adherence in Glaucoma and Ocular Hypertension T2 - Journal of Glaucoma TI - Potential Limitations of E-mail and Text Messaging in Improving Adherence in Glaucoma and Ocular Hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931563060&doi=10.1097%2fIJG.0000000000000150&partnerID=40&md5=007a9155b8f72f5c96cbe0efb1640a3a VL - 24 ID - 5216 ER - TY - JOUR AB - Purpose:To determine how receptive patients are to the use of e-mail and text message reminders for appointments and medications.Methods:We conducted a consecutive cross-sectional survey of eligible patients with glaucoma or ocular hypertension at a private glaucoma subspecialty practice with 3 locations from February 2011 to January 2012. Main outcome measures were answers to survey questions regarding how receptive patients are to e-mail and text messaging reminders for appointments and medications.Results:Of 989 patients, 404 (40.8%) patients reported that e-mail reminders would help remember appointments and 185 (18.7%) reported that they would help for medications. Among those with access to text messaging, 280 (68.9%) reported text messaging would help them remember appointments and 193 (47.5%) reported it would help with medications. Patients who reported e-mail would help them remember medications were more likely to live in an urban location [P=0.05, odds ratio (OR)=1.84], check the internet at least daily (P0.001, OR=1.04), check e-mail when not at home or the office (P=0.02, OR=1.62), and know how to open attachments (P=0.03, OR=1.87). Patients who reported that text messaging would help them remember their medications were more likely to be 40 or less (P0.001, OR=8.54) and African American (P<0.001, OR=2.59).Conclusions:E-mail and text messaging reminders currently may have a limited utility in improving adherence in the general glaucoma population but may be useful in younger patients with glaucoma. AN - WOS:000356375700012 AU - Saeedi, O. J. AU - Luzuriaga, C. AU - Ellish, N. AU - Robin, A. DA - JUN-JUL DO - 10.1097/IJG.0000000000000150 IS - 5 PY - 2015 SN - 1057-0829 1536-481X SP - e95-e102 ST - Potential Limitations of E-mail and Text Messaging in Improving Adherence in Glaucoma and Ocular Hypertension T2 - JOURNAL OF GLAUCOMA TI - Potential Limitations of E-mail and Text Messaging in Improving Adherence in Glaucoma and Ocular Hypertension VL - 24 ID - 5930 ER - TY - JOUR AB - To compare the efficacy, adverse effects, and patient compliance of latanoprost monotherapy with unfixed combination therapy with 0.5% timolol maleate and 1% dorzolamide in the treatment of chronic primary angle-closure glaucoma (CACG), 36 Japanese patients with CACG following laser iridotomy (LPI) were treated for 12 weeks with instillation of latanoprost alone or with unfixed combination therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride. After 12 weeks of treatment, latanoprost reduced intraocular pressure (IOP) from 22.2 ± 2.0 mmHg to 14.8 ± 1.9 mmHg (33% reduction); timolol maleate and dorzolamide hydrochloride also reduced IOP from 22.5 ± 2.2 mmHg to 17.1 ± 2.7 mmHg (24% reduction). Latanoprost monotherapy significantly lowered IOP compared with unfixed combination therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride. Furthermore, a systemic adverse effect of bradycardia was not observed in the latanoprost monotherapy group. Concerning compliance, no significant difference was observed between the two groups. Thus, latanoprost monotherapy is more effective than unfixed combination therapy with 0.5% timolol maleate and 1% dorzolamide in the treatment of CACG following relief of pupillary block in Japanese patients. © Mary Ann Liebert, Inc. AD - H. Sakai, Department of Ophthalmology, University of the Ryukyus, Faculty of Medicine, 207 Uehara, Nishihara-cho, Okinawa 903-0215, Japan AU - Sakai, H. AU - Shinjyo, S. AU - Nakamura, Y. AU - Nakamura, Y. AU - Ishikawa, S. AU - Sawaguchi, S. DB - Embase Medline DO - 10.1089/jop.2005.21.483 IS - 6 KW - acetazolamide betaxolol dorzolamide plus timolol latanoprost pilocarpine timolol adult aged article bradycardia clinical article clinical trial closed angle glaucoma controlled clinical trial controlled study drug efficacy drug mechanism female human iridotomy Japan male patient compliance randomized controlled trial LA - English M3 - Article N1 - L43083340 2006-02-08 PY - 2005 SN - 1080-7683 SP - 483-489 ST - Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients T2 - Journal of Ocular Pharmacology and Therapeutics TI - Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43083340&from=export http://dx.doi.org/10.1089/jop.2005.21.483 VL - 21 ID - 3650 ER - TY - JOUR AB - Purpose: To determine the characteristics of the patients who preferred using the eye drop guide (EDG) regularly and their opinions toward the guide in order to select the patients for prescribing the EDG appropriately. Patients and Methods: Fifty-seven glaucoma patients who completed the primary study, “The effect of ‘eye drop guide’ on the success rate of eye drop self-instillation in glaucoma patients”, were included. Patients’ instillation techniques, routine instillation or using the EDG, were chosen independently. After 4–6 months, they were interviewed about the frequency of EDG use and their rating scores toward the guide in 4 aspects including aiming aids, contamination prevention, reduction of drop waste, and ease of use. The differences in opinion scores between each frequency group and the factors associated with the regularity of EDG use were statistically analyzed. Results: Of fifty-seven patients completing the interview, 19.3% used the EDG everyday, while 45.6% had never used the EDG. The nonusers rated significantly lower scores in all aspects (p-value < 0.005). From multivariate analysis, the factors associated with the preference not to use the EDG were administering in supine position (p-value < 0.001, adjusted OR 34.866, 95% CI 4.974–244.412) and more than one eye drop use (p-value = 0.048, adjusted OR 5.280, 95% CI 1.018–27.396). Conclusion: The EDG should be selectively prescribed for the particular patients who had one medication and performed instillation in sitting or standing position. Although the regular EDG users tended to have positive opinions on the EDG, their long-term compliance with the guide was underinvestigated. Keywords:. AD - D. Sakiyalak, Department of Ophthalmology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 14th Floor, Syamindra Building, 2 Wanglang Road, Bangkoknoi, Bangkok, Thailand AU - Sakiyalak, D. AU - Kobwanthanakun, S. DB - Embase DO - 10.2147/OPTH.S271673 KW - drug delivery device eye drop guide antiglaucoma agent eye drops polystyrene aged article best corrected visual acuity contamination prevention drug instillation drug self administration female glaucoma human long term care major clinical study male medication compliance patient compliance patient preference patient selection personal experience prescription prevention sitting standing supine position telephone interview LA - English M3 - Article N1 - L2005372081 2020-11-06 2020-11-23 PY - 2020 SN - 1177-5483 1177-5467 SP - 3781-3788 ST - Patients’ experience of using eye drop guide device to aid self-administration of glaucoma medications T2 - Clinical Ophthalmology TI - Patients’ experience of using eye drop guide device to aid self-administration of glaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005372081&from=export http://dx.doi.org/10.2147/OPTH.S271673 VL - 14 ID - 2445 ER - TY - JOUR AB - Importance: Patient care should be informed by clinical practice guidelines, which in turn should be informed by evidence from reliable systematic reviews. The American Academy of Ophthalmology is updating its Preferred Practice Patterns (PPPs) for the management of the following 6 corneal diseases: bacterial keratitis, blepharitis, conjunctivitis, corneal ectasia, corneal edema and opacification, and dry eye syndrome.Objective: To summarize the reliability of the existing systematic reviews addressing interventions for corneal diseases.Data Source: The Cochrane Eyes and Vision US Satellite database.Study Selection: In this study of published systematic reviews from 1997 to 2017 (median, 2014), the Cochrane Eyes and Vision US Satellite database was searched for systematic reviews evaluating interventions for the management of any corneal disease, combining eyes and vision keywords and controlled vocabulary terms with a validated search filter.Data Extraction and Synthesis: The study classified systematic reviews as reliable when each of the following 5 criteria were met: the systematic review specified eligibility criteria for inclusion of studies, conducted a comprehensive literature search for studies, assessed risk of bias of the individual included studies, used appropriate methods for quantitative syntheses (meta-analysis) (only assessed if meta-analysis was performed), and had conclusions that were supported by the results of the systematic review. They were classified as unreliable if at least 1 criterion was not met.Main Outcomes and Measures: The proportion of systematic reviews that were reliable and the reasons for unreliability.Results: This study identified 98 systematic reviews that addressed interventions for 15 corneal diseases. Thirty-three of 98 systematic reviews (34%) were classified as unreliable. The most frequent reasons for unreliability were that the systematic review did not conduct a comprehensive literature search for studies (22 of 33 [67%]), did not assess risk of bias of the individual included studies (13 of 33 [39%]), and did not use appropriate methods for quantitative syntheses (meta-analysis) (12 of 17 systematic reviews that conducted a quantitative synthesis [71%]). Sixty-five of 98 systematic reviews (66%) were classified as reliable. Forty-two of the 65 reliable systematic reviews (65%) addressed corneal diseases relevant to the 2018 American Academy of Ophthalmology PPPs; 33 of these 42 systematic reviews (79%) are cited in the 2018 PPPs.Conclusions and Relevance: One in 3 systematic reviews addressing interventions for corneal diseases are unreliable and thus were not used to inform PPP recommendations. Careful adherence by systematic reviewers and journal editors to well-established best practices regarding systematic review conduct and reporting might help make future systematic reviews in eyes and vision more reliable. AD - Center for Evidence Synthesis in Health, Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands American Academy of Ophthalmology, San Francisco, California Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland AN - 137455554. Language: English. Entry Date: 20200208. Revision Date: 20200510. Publication Type: journal article AU - Saldanha, Ian J. AU - Lindsley, Kristina B. AU - Lum, Flora AU - Dickersin, Kay AU - Li, Tianjing DB - ccm DO - 10.1001/jamaophthalmol.2019.1063 DP - EBSCOhost IS - 7 KW - Corneal Diseases -- Therapy Resource Databases Practice Guidelines -- Standards Human Reproducibility of Results Meta Analysis Validation Studies Comparative Studies Evaluation Research Multicenter Studies Scales N1 - research. Journal Subset: Biomedical; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). Grant Information: UG1 EY020522/EY/NEI NIH HHS/United States. NLM UID: 101589539. PMID: NLM31070698. PY - 2019 SN - 2168-6165 SP - 775-785 ST - Reliability of the Evidence Addressing Treatment of Corneal Diseases: A Summary of Systematic Reviews T2 - JAMA Ophthalmology TI - Reliability of the Evidence Addressing Treatment of Corneal Diseases: A Summary of Systematic Reviews UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137455554&site=ehost-live&scope=site VL - 137 ID - 4262 ER - TY - JOUR AB - The purpose of this study was to determine the role of a reminder short message service (SMS) on the uptake of glaucoma screening by first-degree relatives (FDRs) of patients with primary open-angle glaucoma (POAG) in North-central Nigeria following a telephone invitation for screening. MATERIALS AND METHODS: A randomized controlled trial was conducted in the eye clinic of a tertiary hospital in Jos, North-central Nigeria. Two hundred FDRs of patients with POAG were invited through phone for free glaucoma screening and randomly allocated into two groups. The intervention group received a reminder SMS, whereas the control group did not receive a reminder. Those who failed to turn up for screening were contacted through phone to determine the reasons for their nonattendance. Chi-square test and bivariate analysis were used to compare attendance rate between the two groups. RESULTS: Sending a reminder SMS following a telephone invitation had no effect on the uptake of glaucoma screening. The response rate was lower in the phone call plus reminder SMS group (43.0% vs. 53.0%) though the difference was not statistically significant (P = 0.157). Competing needs such as work and lack of transport fare were the most common reasons given for not attending the screening. CONCLUSION: A reminder text message is not an effective tool for increasing the uptake of glaucoma screening in at-risk individuals in North-central Nigeria. Existing barriers to health care in the country need to be addressed before mobile phone technology can be effectively used in increasing the utilization of any free eye screening service. AD - D. Salihu, Tulsi Chanrai Foundation, Abuja, Nigeria AU - Salihu, D. AU - Adenuga, O. AU - Wade, P. DB - Embase Medline DO - 10.4103/meajo.MEAJO_98_19 IS - 4 KW - adult aged article cell phone use controlled study fear female first-degree relative human major clinical study male mass screening money Nigeria open angle glaucoma patient attendance priority journal randomized controlled trial short message service tertiary care center text messaging time travel work LA - English M3 - Article N1 - L630958766 2020-02-24 2020-04-07 PY - 2019 SN - 0975-1599 0974-9233 SP - 196-202 ST - The effect of a reminder short message service on the uptake of glaucoma screening by first-degree relatives of glaucoma patients: A randomized controlled trial T2 - Middle East African Journal of Ophthalmology TI - The effect of a reminder short message service on the uptake of glaucoma screening by first-degree relatives of glaucoma patients: A randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630958766&from=export http://dx.doi.org/10.4103/meajo.MEAJO_98_19 VL - 26 ID - 2555 ER - TY - JOUR AB - The purpose of this study was to determine the role of a reminder short message service (SMS) on the uptake of glaucoma screening by first-degree relatives (FDRs) of patients with primary open-angle glaucoma (POAG) in North-central Nigeria following a telephone invitation for screening. MATERIALS AND METHODS: A randomized controlled trial was conducted in the eye clinic of a tertiary hospital in Jos, North-central Nigeria. Two hundred FDRs of patients with POAG were invited through phone for free glaucoma screening and randomly allocated into two groups. The intervention group received a reminder SMS, whereas the control group did not receive a reminder. Those who failed to turn up for screening were contacted through phone to determine the reasons for their nonattendance. Chi-square test and bivariate analysis were used to compare attendance rate between the two groups. RESULTS: Sending a reminder SMS following a telephone invitation had no effect on the uptake of glaucoma screening. The response rate was lower in the phone call plus reminder SMS group (43.0% vs. 53.0%) though the difference was not statistically significant (P = 0.157). Competing needs such as work and lack of transport fare were the most common reasons given for not attending the screening. CONCLUSION: A reminder text message is not an effective tool for increasing the uptake of glaucoma screening in at-risk individuals in North-central Nigeria. Existing barriers to health care in the country need to be addressed before mobile phone technology can be effectively used in increasing the utilization of any free eye screening service. © 2020 Middle East African Journal of Ophthalmology | Published by Wolters Kluwer - Medknow. AD - Tulsi Chanrai Foundation, Abuja, Nigeria Department of Ophthalmology, Jos University Teaching Hospital, Jos, Plateau State, Nigeria AU - Salihu, D. AU - Adenuga, O. AU - Wade, P. DB - Scopus DO - 10.4103/meajo.MEAJO_98_19 IS - 4 KW - First-degree relative glaucoma screening short message service M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2019 SP - 196-202 ST - The effect of a reminder short message service on the uptake of glaucoma screening by first-degree relatives of glaucoma patients: A randomized controlled trial T2 - Middle East African Journal of Ophthalmology TI - The effect of a reminder short message service on the uptake of glaucoma screening by first-degree relatives of glaucoma patients: A randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079506708&doi=10.4103%2fmeajo.MEAJO_98_19&partnerID=40&md5=8e7296b93e3d42f7a3bf7c3a49db35ff VL - 26 ID - 5615 ER - TY - JOUR AB - PURPOSE: The purpose of this study was to determine the role of a reminder short message service (SMS) on the uptake of glaucoma screening by first-degree relatives (FDRs) of patients with primary open-angle glaucoma (POAG) in North-central Nigeria following a telephone invitation for screening. MATERIALS AND METHODS: A randomized controlled trial was conducted in the eye clinic of a tertiary hospital in Jos, North-central Nigeria. Two hundred FDRs of patients with POAG were invited through phone for free glaucoma screening and randomly allocated into two groups. The intervention group received a reminder SMS, whereas the control group did not receive a reminder. Those who failed to turn up for screening were contacted through phone to determine the reasons for their nonattendance. Chi-square test and bivariate analysis were used to compare attendance rate between the two groups. RESULTS: Sending a reminder SMS following a telephone invitation had no effect on the uptake of glaucoma screening. The response rate was lower in the phone call plus reminder SMS group (43.0% vs. 53.0%) though the difference was not statistically significant (P = 0.157). Competing needs such as work and lack of transport fare were the most common reasons given for not attending the screening. CONCLUSION: A reminder text message is not an effective tool for increasing the uptake of glaucoma screening in at-risk individuals in North-central Nigeria. Existing barriers to health care in the country need to be addressed before mobile phone technology can be effectively used in increasing the utilization of any free eye screening service. AN - WOS:000511846700003 AU - Salihu, D. K. AU - Adenuga, O. O. AU - Wade, P. D. DA - OCT-DEC DO - 10.4103/meajo.MEAJO_98_19 IS - 4 PY - 2019 SN - 0974-9233 0975-1599 SP - 196-202 ST - The effect of a reminder short message service on the uptake of glaucoma screening by first-degree relatives of glaucoma patients: A randomized controlled trial T2 - MIDDLE EAST AFRICAN JOURNAL OF OPHTHALMOLOGY TI - The effect of a reminder short message service on the uptake of glaucoma screening by first-degree relatives of glaucoma patients: A randomized controlled trial VL - 26 ID - 6111 ER - TY - JOUR AB - Background: Methods to improve patient compliance with prescribed topical use of glaucoma medication are sorely needed. A guide for the topical administration of ocular medication was suggested as such a tool. We investigated whether eye drop self-administration would be improved with use of the guide. Methods: An eye drop guide, a funnel-shaped device designed to fit within the contour of the orbital margins, was offered to 114 patients for use at home with their glaucoma medication. A questionnaire asking about the ease of eye drop self-administration was administered before and after 1 week's use of the device. Results: Of the 111 patients who accepted the guide, 93 returned a usable completed questionnaire. Seventy-four percent said that they found it easier to administer their eye drops without the guide and preferred to do so (χ2 = 21.77, p < 0.01). Patients using more doses per day found it more difficult to administer their drops using the guide (r = -0.233, p < 0.05), and those who had been using drops longer preferred not to continue using the guide (r = -0.222, p < 0.05). Patients who found the written instructions clearer found it easier to administer their drops using the guide (r = 0.329, p < 0.05). Interpretation: Although intended to ease the administration of eye drops, the guide proved to be counterproductive. Further work is necessary to investigate other methods of improving patient compliance with prescribed topical use of ocular medications. AD - C. Birt, Sunnybrook and Women's College Health Sciences Centre, 2075 Bayview Ave., Toronto, Ont. M4N 3M5, Canada AU - Salyani, A. AU - Birt, C. DB - Embase Medline DO - 10.1016/S0008-4182(05)80028-6 IS - 2 KW - antiglaucoma agent eye drops adult aged article cataract closed angle glaucoma controlled study devices drug delivery system drug self administration eye drop guide female follow up glaucoma human intraocular hypertension intraocular pressure low tension glaucoma major clinical study male open angle glaucoma patient compliance questionnaire secondary glaucoma visual acuity visual field LA - English M3 - Article N1 - L40676437 2005-05-30 PY - 2005 SN - 1715-3360 0008-4182 SP - 170-174 ST - Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication T2 - Canadian Journal of Ophthalmology TI - Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40676437&from=export http://dx.doi.org/10.1016/S0008-4182(05)80028-6 VL - 40 ID - 3708 ER - TY - JOUR AB - Background: Methods to improve patient compliance with prescribed topical use of glaucoma medication are sorely needed. A guide for the topical administration of ocular medication was suggested as such a tool. We investigated whether eye drop self-administration would be improved with use of the guide. Methods: An eye drop guide, a funnel-shaped device designed to fit within the contour of the orbital margins, was offered to 114 patients for use at home with their glaucoma medication. A questionnaire asking about the ease of eye drop self-administration was administered before and after 1 week's use of the device. Results: Of the 111 patients who accepted the guide, 93 returned a usable completed questionnaire. Seventy-four percent said that they found it easier to administer their eye drops without the guide and preferred to do so (χ2 = 21.77, p < 0.01). Patients using more doses per day found it more difficult to administer their drops using the guide (r = -0.233, p < 0.05), and those who had been using drops longer preferred not to continue using the guide (r = -0.222, p < 0.05). Patients who found the written instructions clearer found it easier to administer their drops using the guide (r = 0.329, p < 0.05). Interpretation: Although intended to ease the administration of eye drops, the guide proved to be counterproductive. Further work is necessary to investigate other methods of improving patient compliance with prescribed topical use of ocular medications. AD - Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont., Canada Sunnybrook and Women's College Health Sciences Centre, Toronto, Ont., Canada Sunnybrook and Women's College Health Sciences Centre, 2075 Bayview Ave., Toronto, Ont. M4N 3M5, Canada AU - Salyani, A. AU - Birt, C. DB - Scopus DO - 10.1016/S0008-4182(05)80028-6 IS - 2 KW - Aids Devices Eye drops Glaucoma Medication errors Ophthalmic solutions Patient compliance Topical administration M3 - Article N1 - Cited By :21 Export Date: 19 July 2021 PY - 2005 SP - 170-174 ST - Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication T2 - Canadian Journal of Ophthalmology TI - Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-18744409096&doi=10.1016%2fS0008-4182%2805%2980028-6&partnerID=40&md5=4f4fa2261f8c3568a914447b0337936f VL - 40 ID - 5137 ER - TY - JOUR AB - Précis:Univariate and multivariable models using the Glaucoma Treatment Compliance Assessment Tool (GTCAT) statements identified multiple, patient-specific factors associated with adherence that could be used to inform personalized interventions to optimize glaucoma adherence.Purpose:The purpose of this study was to determine the health behavior factors related to glaucoma adherence in patients with self-reported poor adherence.Methods:A research coordinator used the Chang Adherence Measure and the Morisky Medication Adherence Scale to identify subjects with poor self-reported glaucoma medication adherence and enrolled them in a 3-month study to electronically monitor medication adherence. At enrollment, the coordinator administered the GTCAT. We calculated the percentage of prescribed doses taken over a 3-month period using an electronic dose monitor (AdhereTech). We used Rasch analysis, and univariate and multivariable regression to determine the GTCAT statements that predicted electronically monitored adherence.Results:The mean adherence was 73.8% (SD=21.04%, range: 13% to 100%). Rasch analysis showed that the GTCAT had a good overall fit and no differential bias (Anderson likelihood ratio test >0.05). Multiple GTCAT statements were associated with adherence, which represented increased knowledge, increased cues-to-action, decreased barriers, less depression, and increased self-efficacy (P<0.09 for each). The full GTCAT or a subset of statements had a high association with adherence (R2 range: 0.44 to 0.51, P<0.005 for all). The GTCAT identified >50% of patients who wanted more education about glaucoma; >68% who did not use reminders; and >40% who reported having difficulty using the eye drops.Conclusions:The GTCAT identified multiple factors associated with adherence. Clinicians and researchers could use this tool to identify specific barriers to adherence and develop potential interventions to improve adherence. AD - S.L. Mansberger, Legacy Devers Eye Institute, 1040 Northwest 22nd Avenue, Portland, OR, United States AU - Sanchez, F. G. AU - Mansberger, S. L. AU - Newman-Casey, P. A. DB - Embase Medline DO - 10.1097/IJG.0000000000001616 IS - 11 KW - NCT03159247 patient monitor antiglaucoma agent eye drops adult aged Anderson likelihood ratio test article behavior assessment best corrected visual acuity Chang Adherence Measure construct validity controlled study cues to action depression electronic dose monitor female glaucoma Glaucoma Treatment Compliance Assessment Tool health behavior human knowledge major clinical study male medication compliance Morisky Medication Adherence Scale multiple regression multivariate analysis patient patient attitude patient compliance patient education Patient Health Questionnaire 9 patient identification personalized medicine prediction predictive validity prescription priority journal Rasch analysis self concept self report statistical analysis univariate analysis LA - English M3 - Article N1 - L633610360 2020-12-11 2020-12-22 PY - 2020 SN - 1536-481X 1057-0829 SP - 1017-1024 ST - Predicting Adherence with the Glaucoma Treatment Compliance Assessment Tool T2 - Journal of Glaucoma TI - Predicting Adherence with the Glaucoma Treatment Compliance Assessment Tool UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633610360&from=export http://dx.doi.org/10.1097/IJG.0000000000001616 VL - 29 ID - 2371 ER - TY - JOUR AB - Purpose: To evaluate the efficacy and safety of plasma rich in growth factors (PRGF) eye drops in patients with glaucoma with secondary ocular surface disorders (OSDs) due to surgeries and topical hypotensive drugs use. Materials and methods: A retrospective case-series study design was used including six patients (eight eyes) diagnosed with glaucoma who received surgical (nonpenetrating deep sclerectomy and/or trabeculectomy) and medical treatments (hypotensive eye drops) to control intraocular pressure (IOP) and who developed secondary OSDs, unresponsive to conventional treatments. Patients were treated with PRGF eye drops (four times a day). Outcome measures were ocular surface disease index (OSDI), best-corrected visual acuity (BCVA, in logarithm of the minimum angle of resolution), visual analog scale (VAS), frequency and severity of symptoms, and IOP. The safety of the treatment was also evaluated. Results: Six patients (seven eyes with open-angle glaucoma and one eye with uveitic glau-coma) treated with PRGF eye drops were evaluated. Mean age was 71 years (SD=7.2, range 58–79 years). Five were female and one was male. The mean treatment time was 21.8 weeks (SD=9.0, range 12–36 weeks). The mean time to reach closure of the corneal ulcer was 14.5 (SD=5.5) weeks. A statistical significant reduction in OSDI scale (50.6%), VAS frequency (53.1%), VAS severity (42.0%), and a 41.8% improvement in BCVA were observed (p<0.05). IOP also decreased by 16.6% (p=0.010). Only one of the six patients reported itching in both eyes as an adverse event (AE); however, the patient continued with the PRGF eye drops until the end of therapy; the remaining patients did not report any AEs during the follow-up period. Conclusions: In patients with glaucoma and secondary OSDs refractive to conventional treatments, the treatment with PRGF eye drops could be considered a possible therapeutic option, because it demonstrates an improvement in the signs and symptoms of the ocular surface, as well as a better control of the IOP. This is an initial research work that can open doors for future research to confirm these findings. © 2018 Sánchez-Avila et al. AD - University Institute Fernández-Vega, Ophthalmological Research Foundation, University of Oviedo, Oviedo, Spain Quilmes Eye Center, Buenos Aires, Argentina University Institute for Regenerative Medicine and Oral Implantology (UIRMI), University of the Basque Country, Eduardo Anitua Foundation, Vitoria, Spain Biotechnology Institute (BTI), Vitoria, Spain Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Vitoria, Spain AU - Sánchez-Avila, R. M. AU - Merayo-Lloves, J. AU - Fernández, M. L. AU - Rodríguez-Gutiérrez, L. A. AU - Rodríguez-Calvo, P. P. AU - Fernández-Vega Cueto, A. AU - Muruzabal, F. AU - Orive, G. AU - Anitua, E. DB - Scopus DO - 10.2147/IMCRJ.S153918 KW - Glaucoma Ocular surface disorders Plasma rich in growth factors Platelet-rich plasma PRGF PRP M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 2018 SP - 97-103 ST - Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma T2 - International Medical Case Reports Journal TI - Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049215735&doi=10.2147%2fIMCRJ.S153918&partnerID=40&md5=98ebd767a58449164b1255d8ec762927 VL - 11 ID - 5273 ER - TY - JOUR AB - Purpose: To evaluate the incidence, clinical and microbiological characteristics and risk factors of infectious keratitis in patients with limbal stem cell deficiency (LSCD). Methods: Retrospective comparative case series of 35 patients with severe LSCD. Results: The mean follow-up time was 46 months. Infectious keratitis were mainly caused by Gram positive bacteria (94%). Only 7 infections (37%) healed under fortified adapted antibiotics. In 8 cases (42%), amniotic membrane transplantation was required and in 4 cases (21%) "a chaud" keratoplasty was performed. Significant risk factors associated with infectious keratitis were: soft contact lens extended wear, history of persistent epithelial defects, number of quadrants of corneal vascularization, re-epithelialization time after amniotic membrane or corneal transplantation, and use of corticosteroid or cyclosporin eye drops. Conclusion: Infectious keratitis in LSCD is frequent and severe. The restoration of the epithelial barrier integrity and a careful use of therapeutic contact lenses may help to prevent infection. AN - WOS:000303446400005 AU - Sandali, O. AU - Gaujoux, T. AU - Goldschmidt, P. AU - Ghoubay-Benallaoua, D. AU - Laroche, L. AU - Borderie, V. M. DA - JUN DO - 10.3109/09273948.2012.672617 IS - 3 PY - 2012 SN - 0927-3948 SP - 182-189 ST - Infectious Keratitis in Severe Limbal Stem Cell Deficiency: Characteristics and Risk Factors T2 - OCULAR IMMUNOLOGY AND INFLAMMATION TI - Infectious Keratitis in Severe Limbal Stem Cell Deficiency: Characteristics and Risk Factors VL - 20 ID - 6250 ER - TY - JOUR AB - Background: The aim of this study is to examine the relationship between sociodemographic factors and utilization of eye care services in patients presenting in acute angle-closure (AAC). Design: A hospital-based retrospective, case-control study. Participants: Fifty-five patients consecutively presenting to the emergency department of the Royal Victorian Eye and Ear Hospital with AAC (cases), and 43 patients consecutively referred to the outpatient department for prophylactic laser peripheral iridotomy (controls) over a 3-year period. Methods: Standardized telephone questionnaires. Main Outcome Measures: Comparisons were made for sociodemographic factors, utilization of eye care services and provision of information on glaucoma and premonitory symptoms of AAC. Results: No significant differences across a range of socioeconomic and demographic factors were found. Fewer cases reported having attended an eye care professional ever (P=0.02), or in the 12months preceding their acute hospital attendance (P=0.002), and had less awareness of angle closure glaucoma (P=0.001). Logistic regression modelling demonstrated premonitory symptoms of AAC (odds ratio 3.96, [95% confidence interval 1.52-10.32], P<0.001) and a period of greater than 12months since the last eye examination (odds ratio 3.89, [95% confidence interval 1.64-9.21]) were significantly associated with the risk of AAC. Conclusions: No significant differences in socioeconomic or demographic parameters between cases and controls were identified. Control subjects had a history of more frequent and recent access to eye care services than cases. The finding that more than one-third of patients presenting with AAC had consulted an eye care provider in the preceding year suggests that a significant proportion of individuals at risk of AAC remain undetected. © 2012 The Authors Clinical and Experimental Ophthalmology © 2012 Royal Australian and New Zealand College of Ophthalmologists. AD - J.G. Crowston, Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, VIC 3002, Australia AU - Sandhu, S. AU - Van Wijngaarden, P. AU - Nguyen, D. Q. AU - O'Hare, F. AU - Sandhu, N. AU - Wang, J. J. AU - Crowston, J. G. DB - Embase Medline DO - 10.1111/j.1442-9071.2012.02820.x IS - 1 KW - acute angle closure glaucoma adult article awareness closed angle glaucoma controlled study emergency ward eye care eye examination female health care utilization hospital based case control study human major clinical study male outpatient department questionnaire retrospective study social status symptomatology telemonitoring tertiary health care LA - English M3 - Article N1 - L52110253 2012-07-18 2013-02-15 PY - 2013 SN - 1442-6404 1442-9071 SP - 56-62 ST - Sociodemographic factors and utilization of eye care services: Is there an association with patients presenting to a tertiary referral hospital in acute angle-closure? T2 - Clinical and Experimental Ophthalmology TI - Sociodemographic factors and utilization of eye care services: Is there an association with patients presenting to a tertiary referral hospital in acute angle-closure? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52110253&from=export http://dx.doi.org/10.1111/j.1442-9071.2012.02820.x VL - 41 ID - 3042 ER - TY - JOUR AB - Objective: To evaluate the type and incidence of adverse events seen with daily disposable hydrogel contact lens wear compared with a control (spectacle) group over 12 months. Design: Prospective, randomized, observer-masked, comparative clinical trial. Participants: Two hundred eighty-one myopes with no prior contact lens wear experience were enrolled from August to December 1996. Subjects were 16 to 35 years old and had refractive errors ranging from a -0.75-diopter (D) sphere to a -6.00-D sphere with a cylinder less than -1.00 D. Intervention: Each subject was randomly assigned to wear either bilateral disposable hydrogels on a daily disposable wear schedule or spectacles. Main Outcome Measure: Type and incidence of adverse events from each group. Adverse events were categorized as serious, significant, and nonsignificant based on the potential to cause vision impairment, severity at event, and level of clinical concern. Results: At baseline, 1.6% of eyes had asymptomatic infiltrates that were nonsignificant. During the study, asymptomatic infiltrates were seen in both contact lens and spectacle groups at 20.5 events versus 11.3 events per 100 eyes per year of wear. No significant events were seen with the spectacle group. With the contact lens group, the type and incidence of significant events per 100 eyes per year of lens wear were corneal peripheral ulcer, 2.5 events; infiltrative keratitis, 1.5 events; and papillary conjunctivitis, 1 event. The incidence of both significant and nonsignificant events was greater with the contact lens group (P<0.05). No serious events (i.e., microbial keratitis) were seen in either group. A greater number of subjects were lost to follow-up or permanently discontinued from the contact lens group relative to the spectacle group (33% vs. 17%, P = 0.002). Lens-related problems such as dryness, discomfort, and difficulty with insertion and removal accounted for 27% of discontinuations from the contact lens group. Poor compliance (40%) was the greatest reason for discontinuations from the spectacle group. Conclusions: No clinically serious events were seen with either group. Only a small percentage of contact lens-wearing eyes presented with significant events, which is promising for daily disposable lens wear. Far more contact lens subjects were lost to follow-up or discontinued. Small, asymptomatic, subepithelial corneal infiltrates of unknown significance were seen in both contact lens-and spectacle-wearing eyes. © 2003 by the American Academy of Ophthalmology. AD - P.R. Sankaridurg, Coop. Ctr. for Eye Res. and Technol., University of New South Wales, Kensington, NSW 2052, Australia AU - Sankaridurg, P. R. AU - Sweeney, D. F. AU - Holden, B. A. AU - Naduvilath, T. AU - Velala, I. AU - Gora, R. AU - Krishnamachary, M. AU - Rao, G. N. DB - Embase Medline DO - 10.1016/S0161-6420(03)00795-4 IS - 12 KW - adolescent adult article clinical trial contact lens controlled clinical trial controlled study cornea ulcer dry eye eye disease female follow up human hydrogel keratitis major clinical study male myopia papillary conjunctivitis patient compliance priority journal randomized controlled trial refraction error retina detachment spectacles visual impairment etafilcon A LA - English M3 - Article N1 - L37485162 2003-12-31 PY - 2003 SN - 0161-6420 SP - 2327-2334 ST - Comparison of Adverse Events with Daily Disposable Hydrogels and Spectacle Wear: Results from a 12-Month Prospective Clinical Trial T2 - Ophthalmology TI - Comparison of Adverse Events with Daily Disposable Hydrogels and Spectacle Wear: Results from a 12-Month Prospective Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37485162&from=export http://dx.doi.org/10.1016/S0161-6420(03)00795-4 VL - 110 ID - 3775 ER - TY - JOUR AB - Objective: To evaluate the type and incidence of adverse events seen with daily disposable hydrogel contact lens wear compared with a control (spectacle) group over 12 months. Design: Prospective, randomized, observer-masked, comparative clinical trial. Participants: Two hundred eighty-one myopes with no prior contact lens wear experience were enrolled from August to December 1996. Subjects were 16 to 35 years old and had refractive errors ranging from a -0.75-diopter (D) sphere to a -6.00-D sphere with a cylinder less than -1.00 D. Intervention: Each subject was randomly assigned to wear either bilateral disposable hydrogels on a daily disposable wear schedule or spectacles. Main Outcome Measure: Type and incidence of adverse events from each group. Adverse events were categorized as serious, significant, and nonsignificant based on the potential to cause vision impairment, severity at event, and level of clinical concern. Results: At baseline, 1.6% of eyes had asymptomatic infiltrates that were nonsignificant. During the study, asymptomatic infiltrates were seen in both contact lens and spectacle groups at 20.5 events versus 11.3 events per 100 eyes per year of wear. No significant events were seen with the spectacle group. With the contact lens group, the type and incidence of significant events per 100 eyes per year of lens wear were corneal peripheral ulcer, 2.5 events; infiltrative keratitis, 1.5 events; and papillary conjunctivitis, 1 event. The incidence of both significant and nonsignificant events was greater with the contact lens group (P<0.05). No serious events (i.e., microbial keratitis) were seen in either group. A greater number of subjects were lost to follow-up or permanently discontinued from the contact lens group relative to the spectacle group (33% vs. 17%, P = 0.002). Lens-related problems such as dryness, discomfort, and difficulty with insertion and removal accounted for 27% of discontinuations from the contact lens group. Poor compliance (40%) was the greatest reason for discontinuations from the spectacle group. Conclusions: No clinically serious events were seen with either group. Only a small percentage of contact lens-wearing eyes presented with significant events, which is promising for daily disposable lens wear. Far more contact lens subjects were lost to follow-up or discontinued. Small, asymptomatic, subepithelial corneal infiltrates of unknown significance were seen in both contact lens-and spectacle-wearing eyes. © 2003 by the American Academy of Ophthalmology. AD - Cornea and Contact Lens Res. Unit, Sch. of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia L. V. Prasad Eye Institute, Hyderabad, India Coop. Ctr. for Eye Res. and Technol., University of New South Wales, Kensington, NSW 2052, Australia AU - Sankaridurg, P. R. AU - Sweeney, D. F. AU - Holden, B. A. AU - Naduvilath, T. AU - Velala, I. AU - Gora, R. AU - Krishnamachary, M. AU - Rao, G. N. DB - Scopus DO - 10.1016/S0161-6420(03)00795-4 IS - 12 M3 - Article N1 - Cited By :36 Export Date: 19 July 2021 PY - 2003 SP - 2327-2334 ST - Comparison of Adverse Events with Daily Disposable Hydrogels and Spectacle Wear: Results from a 12-Month Prospective Clinical Trial T2 - Ophthalmology TI - Comparison of Adverse Events with Daily Disposable Hydrogels and Spectacle Wear: Results from a 12-Month Prospective Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0344442788&doi=10.1016%2fS0161-6420%2803%2900795-4&partnerID=40&md5=9213f6a1318ff2be9c686ea5707f5c42 VL - 110 ID - 5034 ER - TY - JOUR AB - Objective: To evaluate the type and incidence of adverse events seen with daily disposable hydrogel contact lens wear compared with a control (spectacle) group over 12 months. Design: Prospective, randomized, observer-masked, comparative clinical trial. Participants: Two hundred eighty-one myopes with no prior contact lens wear experience were enrolled from August to December 1996. Subjects were 16 to 35 years old and had refractive errors ranging from a -0.75-diopter (D) sphere to a -6.00-D sphere with a cylinder less than -1.00 D. Intervention: Each subject was randomly assigned to wear either bilateral disposable hydrogels on a daily disposable wear schedule or spectacles. Main Outcome Measure: Type and incidence of adverse events from each group. Adverse events were categorized as serious, significant, and nonsignificant based on the potential to cause vision impairment, severity at event, and level of clinical concern. Results: At baseline, 1.6% of eyes had asymptomatic infiltrates that were nonsignificant. During the study, asymptomatic infiltrates were seen in both contact lens and spectacle groups at 20.5 events versus 11.3 events per 100 eyes per year of wear. No significant events were seen with the spectacle group. With the contact lens group, the type and incidence of significant events per 100 eyes per year of lens wear were corneal peripheral ulcer, 2.5 events; infiltrative keratitis, 1.5 events; and papillary conjunctivitis, 1 event. The incidence of both significant and nonsignificant events was greater with the contact lens group (P<0.05). No serious events (i.e., microbial keratitis) were seen in either group. A greater number of subjects were lost to follow-up or permanently discontinued from the contact lens group relative to the spectacle group (33% vs. 17%, P = 0.002). Lens-related problems such as dryness, discomfort, and difficulty with insertion and removal accounted for 27% of discontinuations from the contact lens group. Poor compliance (40%) was the greatest reason for discontinuations from the spectacle group. Conclusions: No clinically serious events were seen with either group. Only a small percentage of contact lens-wearing eyes presented with significant events, which is promising for daily disposable lens wear. Far more contact lens subjects were lost to follow-up or discontinued. Small, asymptomatic, subepithelial corneal infiltrates of unknown significance were seen in both contact lens- and spectacle-wearing eyes. (C) 2003 by the American Academy of Ophthalmology. AN - WOS:000186875400007 AU - Sankaridurg, P. R. AU - Sweeney, D. F. AU - Holden, B. A. AU - Naduvilath, T. AU - Velala, I. AU - Gora, R. AU - Krishnamachary, M. AU - Rao, G. N. DA - DEC DO - 10.1016/S0161-6420(03)00795-4 IS - 12 PY - 2003 SN - 0161-6420 SP - 2327-2334 ST - Comparison of adverse events with daily disposable hydrogels and spectacle wear - Results from a 12-month prospective clinical trial T2 - OPHTHALMOLOGY TI - Comparison of adverse events with daily disposable hydrogels and spectacle wear - Results from a 12-month prospective clinical trial VL - 110 ID - 5971 ER - TY - JOUR AB - Objective Despite medical ad varices over the last decades, cancer is still a major cause of death worldwide. This paper explores whether laser photobiomodulation, alone and/or combined with other therapies, may be developed into a safe, effective treatment for various forms of cancer (solid tumors). Methods A literature search of English-language articles in five databases (Medline, ISI Web of Knowledge, Cochrane, Google Scholar, Scirus) was conducted using search terms relating to cancer (neoplasm, advanced cancer, palliative) in combination with photobiomodulation and/or low-level laser therapy (LLLT) in the period from January 1990 to December 2010. Controlled clinical trials with at least 1 year of follow up and minimum compliance of 90% were included. Clinical studies evaluating linfaoedema, mucositis or pain were also included to illustrate post-LLLT responses to adverse effects of chemo-radiotherapy. Uro and in studies were further considered as preliminary data for clinical trials. Results Retrieved articles suggest that photobiomodulation can modulate anti-tumor effects and reduce adverse effects of chemo-radiotherapy. Results are discussed giving particular attention to two mechanistic proposals with potential anticancer applications, photo-m-frared pulsed biomodulation (PIPBM) and water oscillator (WO). Other topics include cancer proliferation, Warburg effect, classic photobiomodulation hypothesis and ATP signaling. Conclusion Translational research with laser photobiomodulation appears warranted. AD - Fundalas, Foundation for Interdisciplinary Research and Development, MUN 1262 Calle Las Flores, C. C. Carabel PB, Estado Anzoátegui 6023-1, Venezuela AU - Santana-Blank, L. AU - Rodríguez-Santana, E. AU - Santana-Rodríguez, K. E. DB - Scopus IS - 3 KW - Anticancer effects Low level light therapy Photo infrared pulsed biomodulation Quality of life Solid tumors Water oscillator M3 - Review N1 - Cited By :3 Export Date: 19 July 2021 PY - 2011 SP - 147-158 ST - Cancer, Warburg effect and laser photobiomodulation-progress beyond skepticism review T2 - Journal of Chinese Clinical Medicine TI - Cancer, Warburg effect and laser photobiomodulation-progress beyond skepticism review UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958048311&partnerID=40&md5=f9edf86dcf998e4fb836b78b0d06cdcf VL - 6 ID - 5527 ER - TY - JOUR AB - Objective. To assess the compliance rate among glaucoma patients with medical treatment, to investigate the factors influencing their attitude and survey their expectations vis-vis the doctor. Patients and methods. This is a prospective descriptive study conducted in four eye clinics in Lome from January 2013 to July 201]. It included all glaucoma patients aged 40 years and above who have been under medical treatment for at least 6 months, with no history of surgical treatment of glaucoma. The evaluation was performed on the basis of a questionnaire. Compliance was rated good, fair or poor according to the regularity of treatment, compliance with the prescribed dosage and schedule of instillations, good instillation technique and compliance with follow-up visits. Patients consented to participate in the survey. Results. A total of 107 patients responded to our questionnaire. There were 43 men and 64 women with a sex ratio (M/F) of 0.67. The mean age was 52.40 +/- 11.03 years. In total, 7.5% of patients were illiterate. Compliance rate was estimated good in 10.3% of cases, fair in 65.4% of cases, and poor in 24.3% of cases. Only the regularity of treatment, schedule adherence and good instillation technique, as well as compliance with monitoring visits were found as significant factors (P<0.05). Concerning patients' expectations vis-vis the doctor, 49.5% said they expected nothing from the doctor, 12.1% were hoping for advice and moral support, and 11.2% were hoping for the prescription of effective but less expensive eye drops. Conclusion. A good compliance rate was very low. The improvement of this compliance rate requires better information, education and communication for behavior change, and it also requires a higher quality of care and accessibility of anti-glaucoma drugs. (C) 2016 Elsevier Masson SAS. All rights reserved. AN - WOS:000377988600015 AU - Santos, M. A. K. AU - Ayena, D. K. AU - Kuaovi, K. R. AU - Vonor, K. AU - Djagnikpo, A. AU - Balo, K. P. DA - MAY DO - 10.1016/j.jfo.2015.10.013 IS - 5 PY - 2016 SN - 0181-5512 1773-0597 SP - 459-466 ST - Compliance with medical treatment in primary open-angle glaucoma in Lome T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Compliance with medical treatment in primary open-angle glaucoma in Lome VL - 39 ID - 5917 ER - TY - JOUR AB - Introduction: Glaucoma is a leading cause of vision loss and blindness in the U.S. Risk factors include African American race, older age, family history of glaucoma, and diabetes. This paper describes the evaluation of a mobile eye health and a telemedicine program designed to improve access to eye care among people at high-risk for glaucoma. Methods: The RE-AIM (reach, efficacy, adoption, implementation, and maintenance) evaluation framework was used to harmonize indicators. Both programs provided community-based eye health education and eye services related to glaucoma detection and care. Each program reported data on participants and community partners. An external evaluator conducted site visit interviews with program staff and community partners. Quantitative and qualitative data were integrated and analyzed using the RE-AIM dimensions. Discussion: By targeting high-risk populations and providing comprehensive eye exams, both programs detected a large proportion of new glaucoma-related cases (17–19%)—a much larger proportion than that found in the general population (< 2%). The educational intervention increased glaucoma knowledge; evidence that it led people to seek eye care was inconclusive. Conclusions: Evaluation findings from the mobile eye health program and the telemedicine program may provide useful information for wider implementation in public health clinics and in optometrist clinics located in retail outlets. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Sapru, Saloni, Westat, 1600 Research Boulevard, Rockville, MD, US, 20850 AN - 2017-42634-006 AU - Sapru, Saloni AU - Berktold, Jennifer AU - Crews, John E. AU - Katz, L. Jay AU - Hark, Lisa AU - Girkin, Christopher A. AU - Owsley, Cynthia AU - Francis, Brittney AU - Saaddine, Jinan B. DB - psyh DO - 10.1016/j.evalprogplan.2017.06.006 DP - EBSCOhost KW - Glaucoma Eye health Community-based intervention Evaluation methods RE–AIM Mobile health Telemedicine Adult Community Networks Female Health Promotion Health Services Accessibility Humans Male Middle Aged Program Evaluation At Risk Populations Community Services Health Care Utilization N1 - Westat, Rockville, MD, US. Release Date: 20171009. Correction Date: 20200803. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: At Risk Populations; Community Services; Glaucoma; Health Care Utilization; Program Evaluation. Minor Descriptor: Mobile Health. Classification: Health & Mental Health Services (3370). Population: Human (10). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Tests & Measures: Interview Guide DOI: 10.1037/t25467-000. Methodology: Interview; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Dec, 2017. Publication History: First Posted Date: Jun 21, 2017; Accepted Date: Jun 19, 2017; Revised Date: May 23, 2017; First Submitted Date: Jan 25, 2017. Copyright Statement: All rights reserved. Elsevier Ltd. 2017. Sponsor: Centers for Disease Control and Prevention. Grant: GS-23F-8144H. Other Details: Westat. Recipients: No recipient indicated PY - 2017 SN - 0149-7189 1873-7870 SP - 40-46 ST - Applying RE-AIM to evaluate two community-based programs designed to improve access to eye care for those at high-risk for glaucoma T2 - Evaluation and Program Planning TI - Applying RE-AIM to evaluate two community-based programs designed to improve access to eye care for those at high-risk for glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-42634-006&site=ehost-live&scope=site salonisapru@westat.com VL - 65 ID - 4820 ER - TY - JOUR AB - Introduction: Glaucoma is a leading cause of vision loss and blindness in the U.S. Risk factors include African American race, older age, family history of glaucoma, and diabetes. This paper describes the evaluation of a mobile eye health and a telemedicine program designed to improve access to eye care among people at high-risk for glaucoma. Methods: The RE-AIM (reach, efficacy, adoption, implementation, and maintenance) evaluation framework was used to harmonize indicators. Both programs provided community-based eye health education and eye services related to glaucoma detection and care. Each program reported data on participants and community partners. An external evaluator conducted site visit interviews with program staff and community partners. Quantitative and qualitative data were integrated and analyzed using the RE-AIM dimensions. Discussion: By targeting high-risk populations and providing comprehensive eye exams, both programs detected a large proportion of new glaucoma-related cases (17-19%) a much larger proportion than that found in the general population ( < 2%). The educational intervention increased glaucoma knowledge; evidence that it led people to seek eye care was inconclusive. Conclusions: Evaluation findings from the mobile eye health program and the telemedicine program may provide useful information for wider implementation in public health clinics and in optometrist clinics located in retail outlets. AN - WOS:000412378200005 AU - Sapru, S. AU - Berktold, J. AU - Crews, J. E. AU - Katz, L. J. AU - Hark, L. AU - Girkin, C. A. AU - Owsley, C. AU - Francis, B. AU - Saaddine, J. B. DA - DEC DO - 10.1016/j.evalprogplan.2017.06.006 PY - 2017 SN - 0149-7189 1873-7870 SP - 40-46 ST - Applying RE-AIM to evaluate two community-based programs designed to improve access to eye care for those at high-risk for glaucoma T2 - EVALUATION AND PROGRAM PLANNING TI - Applying RE-AIM to evaluate two community-based programs designed to improve access to eye care for those at high-risk for glaucoma VL - 65 ID - 6172 ER - TY - JOUR AB - Introduction Glaucoma is a leading cause of vision loss and blindness in the U.S. Risk factors include African American race, older age, family history of glaucoma, and diabetes. This paper describes the evaluation of a mobile eye health and a telemedicine program designed to improve access to eye care among people at high-risk for glaucoma. Methods The RE-AIM (reach, efficacy, adoption, implementation, and maintenance) evaluation framework was used to harmonize indicators. Both programs provided community-based eye health education and eye services related to glaucoma detection and care. Each program reported data on participants and community partners. An external evaluator conducted site visit interviews with program staff and community partners. Quantitative and qualitative data were integrated and analyzed using the RE-AIM dimensions. Discussion By targeting high-risk populations and providing comprehensive eye exams, both programs detected a large proportion of new glaucoma-related cases (17–19%) – a much larger proportion than that found in the general population (<2%). The educational intervention increased glaucoma knowledge; evidence that it led people to seek eye care was inconclusive. Conclusions Evaluation findings from the mobile eye health program and the telemedicine program may provide useful information for wider implementation in public health clinics and in optometrist clinics located in retail outlets. © 2017 Elsevier Ltd AD - Health Studies, Westat, 1600 Research Boulevard, Rockville, MD, United States Vision Health Initiative, Division of Diabetes Translation, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, Atlanta, GA 30341-3717, United States Glaucoma Research Center, Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA 19107, United States Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, 700 S. 18th St, Birmingham, AL 35294-0009, United States The Center for Perinatal Research, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, United States AU - Sapru, S. AU - Berktold, J. AU - Francis, B. AU - Crews, J. E. AU - Saaddine, J. B. AU - Katz, L. J. AU - Hark, L. AU - Girkin, C. A. AU - Owsley, C. DB - Scopus DO - 10.1016/j.evalprogplan.2017.06.006 KW - Community-based intervention Evaluation methods Eye health Glaucoma Mobile health RE–AIM Telemedicine M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2017 SP - 40-46 ST - Applying RE-AIM to evaluate two community-based programs designed to improve access to eye care for those at high-risk for glaucoma T2 - Evaluation and Program Planning TI - Applying RE-AIM to evaluate two community-based programs designed to improve access to eye care for those at high-risk for glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021730248&doi=10.1016%2fj.evalprogplan.2017.06.006&partnerID=40&md5=d0420c1061868de3cdf1ffad3ae0984a VL - 65 ID - 5508 ER - TY - JOUR AB - Treatment of migraine presents special problems in the elderly. Co-morbid diseases may prohibit the use of some medications. Moreover, even when these contraindications do not exist, older patients are more likely than younger ones to develop adverse events. Managing older migraine patients, therefore, necessitates particular caution, including taking into account possible pharmacological interactions associated with the greater use of drugs for concomitant diseases in the elderly. Paracetamol (acetaminophen) is the safest drug for symptomatic treatment of migraine in the elderly. Use of selective serotonin 5-HT(1B/1D) receptor agonists ('triptans') is not recommended, even in the absence of cardiovascular or cerebrovascular risk, and NSAID use should be limited because of potential gastrointestinal adverse effects. Prophylactic treatments include antidepressants, beta-adrenoceptor antagonists, calcium channel antagonists and antiepileptics. Selection of a drug from one of these classes should be dictated by the patient's co-morbidities. Beta-adrenoceptor antagonists are appropriate in patients with hypertension but are contraindicated in those with chronic obstructive pulmonary disease, diabetes mellitus, heart failure and peripheral vascular disease. Use of antidepressants in low doses is, in general, well tolerated by elderly people and as effective, overall, as in young adults. This approach is preferred in patients with concomitant mood disorders. However, prostatism, glaucoma and heart disease make the use of tricyclic antidepressants more difficult. Fewer efficacy data in the elderly are available for selective serotonin reuptake inhibitors, which can be tried in particular cases because of their good tolerability profile. Calcium channel antagonists are contraindicated in patients with hypotension, heart failure, atrioventricular block, Parkinson's disease or depression (flunarizine), and in those taking beta-adrenoceptor antagonists and monoamine oxidase inhibitors (verapamil). Antiepileptic drug use should be limited to migraine with high frequency of attacks and refractoriness to other treatments. Promising additional strategies include ACE inhibitors and angiotensin II type 1 receptor antagonists because of their effectiveness and good tolerability in patients with migraine, particularly in those with hypertension. Because of its favourable compliance and safety profile, botulinum toxin type A can be considered an alternative treatment in elderly migraine patients who have not responded to other currently available migraine prophylactic agents. Pharmacological treatment of migraine poses special problems in regard to both symptomatic and prophylactic treatment. Contraindications to triptan use, adverse effects of NSAIDs, and unwanted reactions to some antiemetics reduce the list of drugs available for the treatment of migraine attacks in elderly patients. The choice of prophylactic treatment (beta-adrenoceptor antagonists, calcium channel antagonists, antiepileptics, and more recently, some antihypertensive drugs) is influenced by co-morbidities and should be directed at those drugs that are believed to have fewer adverse effects and a better safety profile. Unfortunately, for most of these drugs, efficacy studies are lacking in the elderly. AD - Department of Medical and Surgical Specialties and Public Health, Neurologic Clinic, University of Perugia, Perugia, Italy AN - 106118821. Language: English. Entry Date: 20070713. Revision Date: 20200708. Publication Type: Journal Article AU - Sarchielli, P. AU - Mancini, M. L. AU - Calabresi, P. DB - ccm DO - 10.2165/00002512-200623060-00003 DP - EBSCOhost IS - 6 KW - Migraine -- Drug Therapy Adrenergic Beta-Antagonists -- Administration and Dosage Analgesics -- Administration and Dosage Anticonvulsants -- Administration and Dosage Antidepressive Agents -- Administration and Dosage Antiemetics -- Administration and Dosage Antiinflammatory Agents, Non-Steroidal -- Administration and Dosage Calcium Channel Blockers -- Administration and Dosage Drug Interactions Migraine -- Prevention and Control N1 - review; tables/charts. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 9102074. PMID: NLM16872231. PY - 2006 SN - 1170-229X SP - 461-489 ST - Practical considerations for the treatment of elderly patients with migraine T2 - Drugs & Aging TI - Practical considerations for the treatment of elderly patients with migraine UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106118821&site=ehost-live&scope=site VL - 23 ID - 4615 ER - TY - JOUR AD - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina Department of Ophthalmology and Visual Sciences, University of Maryland, Baltimore, Maryland Department of Ophthalmology and Department of International Health, Johns Hopkins University, Baltimore, Maryland Department of Ophthalmology, School of Medicine, Duke University, Durham, North Carolina Durham VA Medical Center, Health Services Research and Development, Durham, North Carolina Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah Ophthalmology Department, Emory University School of Medicine, Atlanta, Georgia Department of Science and Mathematics, Husson University, Bangor, Maine Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina AN - 115262519. Language: English. Entry Date: In Process. Revision Date: 20160512. Publication Type: Article. Journal Subset: Biomedical AU - Sayner, Robyn AU - Carpenter, Delesha M. AU - Blalock, Susan J. AU - Robin, Alan L. AU - Muir, Kelly W. AU - Hartnett, Mary Elizabeth AU - Giangiacomo, Annette L. AU - Tudor, Gail AU - Sleath, Betsy DB - ccm DO - 10.1016/j.clinthera.2015.06.008 DP - EBSCOhost IS - 9 N1 - Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 7706726. PY - 2015 SN - 0149-2918 SP - 1975-1985 ST - Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors T2 - Clinical Therapeutics TI - Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115262519&site=ehost-live&scope=site VL - 37 ID - 4329 ER - TY - JOUR AB - Purpose Glaucoma medications can improve clinical outcomes when patients adhere to their medication regimen. Providers often ask patients with glaucoma to self-report their adherence, but the accuracy of self-reporting has received little scientific attention. The purpose of this article was to compare a self-reported medication adherence measure with adherence data collected from Medication Event Monitoring Systems (MEMS) electronic monitors. An additional goal was to identify which patient characteristics were associated with overreporting adherence on the self-reported measure. Methods English-speaking adult patients with glaucoma were recruited from 6 ophthalmology practices for this observational cohort study. Patients were interviewed after their initial visit and were given MEMS contains, which recorded adherence over a 60-day period. MEMS percent adherence measured the percentage of the prescribed number of doses taken. MEMS-measured timing adherence assessed the percent doses taken on time. Patients self-reported adherence to their glaucoma medications on a visual analog scale (VAS) ∼60 days after the baseline visit. Bivariate analyses and logistic regressions were used to analyze the data. Self-reported medication adherence on the VAS was plotted against MEMS adherence to illustrate the discrepancy between self-reported and electronically monitored adherence. Findings The analyses included 240 patients who returned their MEMS containers and self-reported medication adherence at the 60-day follow-up visit. Compared with MEMS-measured percent adherence, 31% of patients (n = 75) overestimated their adherence on the VAS. Compared with MEMS-measured timing adherence, 74% (n = 177) of patients overestimated their adherence. For the MEMS-measured percent adherence, logistic regression revealed that patients who were newly prescribed glaucoma medications were significantly more likely to overreport adherence on the VAS (odds ratio, 3.07 [95% CI, 1.22-7.75]). For the MEMS-measured timing adherence, being male (χ2 test, 6.78; P = 0.009) and being prescribed glaucoma medications dosed multiple times daily (χ2 test, 4.02; P = 0.045) were significantly associated with patients overreporting adherence. However, only male sex remained a significant predictor of overreporting adherence in the logistic regression (odds ratio, 4.05 [95% CI, 1.73-9.47]). Implications Many patients with glaucoma, especially those newly diagnosed, overestimated their medication adherence. Because patients were likely to overreport the percent doses taken and timing adherence, providers may want to ask patients additional questions about when they take their glaucoma medications to potentially detect issues with taking these medications on time. © 2015 Elsevier HS Journals, Inc. AD - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, NC, United States Department of Ophthalmology and Visual Sciences, University of Maryland, Baltimore, MD, United States Department of Ophthalmology, Department of International Health, Johns Hopkins University, Baltimore, MD, United States Department of Ophthalmology, School of Medicine, Duke University, Durham, NC, United States Durham VA Medical Center, Health Services Research and Development, Durham, NC, United States Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, United States Ophthalmology Department, Emory University School of Medicine, Atlanta, GA, United States Department of Science and Mathematics, Husson University, Bangor, ME, United States Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States AU - Sayner, R. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Robin, A. L. AU - Muir, K. W. AU - Hartnett, M. E. AU - Giangiacomo, A. L. AU - Tudor, G. AU - Sleath, B. C7 - 2618 DB - Scopus DO - 10.1016/j.clinthera.2015.06.008 IS - 9 KW - adherence electronically monitored medication adherence glaucoma self-reported medication M3 - Article N1 - Cited By :20 Export Date: 19 July 2021 PY - 2015 SP - 1975-1985 ST - Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared with Electronic Monitors T2 - Clinical Therapeutics TI - Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared with Electronic Monitors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941170150&doi=10.1016%2fj.clinthera.2015.06.008&partnerID=40&md5=f64b6fbf79ef9ef14d5be41c294ac7ad VL - 37 ID - 5141 ER - TY - JOUR AB - Purpose: Glaucoma medications can improve clinical outcomes when patients adhere to their medication regimen. Providers often ask patients with glaucoma to self-report their adherence, but the accuracy of self-reporting has received little scientific attention. The purpose of this article was to compare a self-reported medication adherence measure with adherence data collected from Medication Event Monitoring Systems (MEMS) electronic monitors. An additional goal was to identify which patient characteristics were associated with overreporting adherence on the self-reported measure. Methods: English-speaking adult patients with glaucoma were recruited from 6 ophthalmology practices for this observational cohort study. Patients were interviewed after their initial visit and were given MEMS contains, which recorded adherence over a 60-day period. MEMS percent adherence measured the percentage of the prescribed number of doses taken. MEMS-measured timing adherence assessed the percent doses taken on time. Patients self-reported adherence to their glaucoma medications on a visual analog scale (VAS) 60 days after the baseline visit. Bivariate analyses and logistic regressions were used to analyze the data. Self-reported medication adherence on the VAS was plotted against MEMS adherence to illustrate the discrepancy between self-reported and electronically monitored adherence. Findings: The analyses included 240 patients who returned their MEMS containers and self-reported medication adherence at the 60-day follow-up visit. Compared with MEMS-measured percent adherence, 31% of patients (n = 75) overestimated their adherence on the VAS. Compared with MEMS-measured timing adherence, 74% (n = 177) of patients overestimated their adherence. For the MEMS-measured percent adherence, logistic regression revealed that patients who were newly prescribed glaucoma medications were significantly more likely to overreport adherence on the VAS (odds ratio, 3.07 [95% CI, 1.22-7.75]). For the MEMS-measured timing adherence, being male (chi(2) test, 6.78; P = 0.009) and being prescribed glaucoma medications dosed multiple times daily (chi(2) test, 4.02; P = 0.045) were significantly associated with patients overreporting adherence. However, only male sex remained a significant predictor of overreporting adherence in the logistic regression (odds ratio, 4.05 [95% CI, 1.73-9.47]). (C) 2015 Elsevier HS Journals, Inc. All rights reserved. AN - WOS:000361780200011 AU - Sayner, R. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Robin, A. L. AU - Muir, K. W. AU - Hartnett, M. E. AU - Giangiacomo, A. L. AU - Tudor, G. AU - Sleath, B. DA - SEP DO - 10.1016/j.clinthera.2015.06.008 IS - 9 PY - 2015 SN - 0149-2918 1879-114X SP - 1975-1985 ST - Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors T2 - CLINICAL THERAPEUTICS TI - Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors VL - 37 ID - 5901 ER - TY - JOUR AB - The diagnosis and management of patients with epilepsy is often undertaken by pediatricians, internists, and geriatricians (primary care physicians [PCPs]). Although referral to a neurologist may be necessary if the diagnosis of epilepsy is unclear or if the patient does not respond to initial therapy with antiepileptic drugs, PCPs may subsequently follow-up with patients to implement the recommendations of the neurologist. To maximize the likelihood of treatment success, PCPs should supplement antiepileptic drug therapy with patient education and referrals for psychosocial and vocational support when needed. Special considerations are warranted for women of childbearing potential and elderly patients. © 2009 Elsevier Inc. All rights reserved. AD - Department of Neurology, Harvard Medical School, MA, United States Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Room K-478, Boston, MA 02215, United States AU - Schachter, S. C. DB - Scopus DO - 10.1016/j.mcna.2008.10.001 IS - 2 KW - Antiepileptic drug Convulsion Diagnosis Epilepsy Seizure M3 - Review N1 - Cited By :20 Export Date: 19 July 2021 PY - 2009 SP - 343-351 ST - Seizure Disorders T2 - Medical Clinics of North America TI - Seizure Disorders UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-61449199477&doi=10.1016%2fj.mcna.2008.10.001&partnerID=40&md5=d862cbaf2574943f7563948cddf14cd2 VL - 93 ID - 5143 ER - TY - JOUR AB - Glaucoma clinicians have numerous medications from which to select initial therapy for their patients. What are the preferred characteristics for such a drug? Consider these two factors when evaluating glaucoma medications: 1) a drug should prove efficacious in preserving visual function (i.e., it works) and 2) the drug should be "patient friendly" to ensure good compliance (i.e., patients will use it). AD - P.N. Schacknow, Department of Glaucoma Services, Visual Health and Surgical Center, 2889 10th Avenue North, Lake Worth, FL 33461, United States AU - Schacknow, P. N. C1 - lumigan namenda travatan xalatan DB - Embase IS - 11 KW - acetazolamide epinephrine alpha adrenergic receptor blocking agent alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brinzolamide carbonate dehydratase inhibitor dorzolamide latanoprost memantine methazolamide miotic agent pilocarpine prostaglandin derivative timolol travoprost allergy breathing disorder cardiovascular disease conference paper conjunctival hyperemia erythema evidence based medicine eye burning eye irritation fatigue gastrointestinal disease glaucoma hallucination human hyperpigmentation impotence intraocular pressure malaise metabolic disorder myopia ocular pruritus patient compliance respiratory tract disease taste disorder vision lumigan namenda travatan xalatan LA - English M3 - Conference Paper N1 - L39556716 2004-12-10 PY - 2003 SN - 1705-4842 SP - 448-454 ST - The medical management of glaucoma: What we have learned from clinical research trials to aid us in choosing first-line therapy T2 - Clinical and Surgical Ophthalmology TI - The medical management of glaucoma: What we have learned from clinical research trials to aid us in choosing first-line therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39556716&from=export VL - 21 ID - 3790 ER - TY - JOUR AD - S.M. Schappert, Division of Health Care Statistics, National Center for Health Statistics, USA. AU - Schappert, S. M. DB - Medline IS - 262 KW - adult African American age aged ambulatory care article Caucasian female glaucoma health service health survey human information processing male middle aged ophthalmology statistics United States utilization review LA - English M3 - Article N1 - L125063806 1995-06-05 PY - 1995 SN - 0147-3956 SP - 1-14 ST - Office visits for glaucoma: United States, 1991-92 T2 - Advance data TI - Office visits for glaucoma: United States, 1991-92 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L125063806&from=export ID - 3986 ER - TY - JOUR AB - Introduction: The advent of Microinvasive Glaucoma Surgery (MIGS) offers a novel approach in the treatment of glaucoma with the number of procedures developing at an exciting pace. MIGS procedures aim to lower intraocular pressure (IOP) via: (1) increasing trabecular outflow, (2) increasing outflow via suprachoroidal shunts, (3) reducing aqueous production, and (4) subconjunctival filtration. Areas covered: A comprehensive search for published studies for Microinvasive Glaucoma Surgery (MIGS) devices or procedure was undertaken using PubMed. Search terms included ‘minimally invasive glaucoma surgery’, ‘microincisional glaucoma surgery’, and ‘microinvasive glaucoma surgery’. A manual search for each device or procedure was also performed. After review, randomized control trials and prospective studies were preferentially included. Expert commentary: These procedures offer several benefits: an improved safety profile allowing for intervention in earlier stages of glaucoma, combination with cataract surgery, and decreased dependence on patient compliance with topical agents. Established MIGS procedures have proven efficacy and more recent devices and procedures show promising results. Despite this, further study is needed to assess the long term IOP-lowering effectiveness of these procedures. Particularly, rigorous study with more randomized control trials and head-to-head comparisons would allow for better informed clinical and surgical decision-making. MIGS offers new solutions for glaucoma treatment. AD - Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA AN - 124023275. Language: English. Entry Date: 20180117. Revision Date: 20190209. Publication Type: Article AU - Schehlein, Emily M. AU - Kaleem, Mona A. AU - Swamy, Ramya AU - Saeedi, Osamah J. DB - ccm DO - 10.1080/17469899.2017.1335597 DP - EBSCOhost IS - 4 KW - Intraocular Pressure Glaucoma -- Surgery Glaucoma -- Drug Therapy Minimally Invasive Procedures Decision Making, Clinical Cataract Extraction Patient Compliance Systematic Review Human PubMed N1 - pictorial; research; systematic review; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 101278197. PY - 2017 SN - 1746-9899 SP - 331-343 ST - Microinvasive glaucoma surgery: an evidence-based assessment T2 - Expert Review of Ophthalmology TI - Microinvasive glaucoma surgery: an evidence-based assessment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124023275&site=ehost-live&scope=site VL - 12 ID - 4259 ER - TY - JOUR AB - Purpose of review To discuss recent advances in the medical management of glaucoma and to highlight future medical therapies currently in development. Recent findings In 1996, latanoprost (Xalatan) was approved in the United States as a new chemical entity and new class (prostaglandin analogs) for the topical treatment of ocular hypertension and glaucoma. In the period from the late 1990s-2010s, while there were additional new chemical entities, fixed dose combinations, and formulation improvements, there were no new classes of ocular hypotensive medications approved worldwide. We summarize new pharmacological treatments that are currently in clinical trials-new classes, new molecules and new delivery systems. Summary Although challenges in medical treatment of glaucoma exist, particularly in patient adherence, medical therapy remains the first line treatment for almost all glaucoma patients. Few new medications for glaucoma therapy are currently available for our patients, but multiple drugs with novel mechanisms of action, new formulations, and new delivery mechanisms are currently in development. AD - A.L. Robin, University of Maryland School of Medicine, Department of Ophthalmology and Visual Sciences, 6115 Falls Road, Baltimore, MD, United States AU - Schehlein, E. M. AU - Novack, G. D. AU - Robin, A. L. C1 - ar 13324(Aerie,United States) de 117(Santen,Japan) glanatec(Kowa,Japan) ino 8875(Inotek,United States) ono 9054(Ono,Japan) syl 040012(Sylentis,Spain) xalatan C2 - Sylentis(Spain) Kowa(Japan) Ono(Japan) Santen(Japan) Aerie(United States) Bausch and Lomb(United States) Inotek(United States) DB - Embase Medline DO - 10.1097/ICU.0000000000000346 IS - 2 KW - antiglaucoma agent bamosiran cannabinoid derivative drug preservative latanoprost latanoprost plus netarsudil latanoprostene bunod netarsudil omidenepag isopropyl ripasudil trabodenoson unclassified drug drug approval drug classification drug delivery system drug mechanism glaucoma human intraocular hypertension medication compliance nonhuman patient compliance phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) priority journal randomized controlled trial (topic) review topical treatment ar 13324 de 117 glanatec ino 8875 ono 9054 syl 040012 xalatan LA - English M3 - Review N1 - L613158987 2016-11-15 2017-03-02 PY - 2017 SN - 1531-7021 1040-8738 SP - 161-168 ST - New classes of glaucoma medications T2 - Current Opinion in Ophthalmology TI - New classes of glaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613158987&from=export http://dx.doi.org/10.1097/ICU.0000000000000346 VL - 28 ID - 2661 ER - TY - JOUR AB - Purpose Of Review: To discuss recent advances in the medical management of glaucoma and to highlight future medical therapies currently in development.Recent Findings: In 1996, latanoprost (Xalatan) was approved in the United States as a new chemical entity and new class (prostaglandin analogs) for the topical treatment of ocular hypertension and glaucoma. In the period from the late 1990s-2010s, while there were additional new chemical entities, fixed dose combinations, and formulation improvements, there were no new classes of ocular hypotensive medications approved worldwide. We summarize new pharmacological treatments that are currently in clinical trials - new classes, new molecules and new delivery systems.Summary: Although challenges in medical treatment of glaucoma exist, particularly in patient adherence, medical therapy remains the first line treatment for almost all glaucoma patients. Few new medications for glaucoma therapy are currently available for our patients, but multiple drugs with novel mechanisms of action, new formulations, and new delivery mechanisms are currently in development. AD - University of Maryland School of Medicine, Department of Ophthalmology and Visual Sciences, Baltimore, Maryland, USA. PharmaLogic Development Inc., San Rafael, California, USA. Departments of Pharmacology and Ophthalmology, University of California, Davis, School of Medicine, California, USA. University of Michigan, Department of Ophthalmology and Visual Sciences, Ann Arbor, Michigan, USA. Johns Hopkins University Department of Ophthalmology and School of Public Health, Baltimore, Maryland, USA. AN - 121395278. Language: English. Entry Date: 20170320. Revision Date: 20170320. Publication Type: journal article AU - Schehlein, Emily M. AU - Novack, Gary D. AU - Robin, Alan L. DB - ccm DO - 10.1097/ICU.0000000000000346 DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Antihypertensive Agents -- Therapeutic Use Intraocular Pressure -- Drug Effects Drug Combinations Neurotransmitter Agents -- Therapeutic Use Human Receptors, Cell Surface Drug Delivery Systems RNA -- Therapeutic Use Phosphotransferases -- Antagonists and Inhibitors Prostaglandins F, Synthetic -- Therapeutic Use Scales N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). NLM UID: 9011108. PMID: NLM27828896. PY - 2017 SN - 1040-8738 SP - 161-168 ST - New classes of glaucoma medications T2 - Current Opinion in Ophthalmology TI - New classes of glaucoma medications UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121395278&site=ehost-live&scope=site VL - 28 ID - 4255 ER - TY - JOUR AB - This study was designed to compare timolol maleate ophthalmic gel- forming solution 0.5% (timolol gel) once daily with timolol maleate ophthalmic solution 0.5% (timolol solution) twice daily with respect to patient preference, intraocular pressure (IOP)-lowering effect, and tolerability. A total of 202 patients with ocular hypertension or open-angle glaucoma and an IOP ≥22 mm Hg were enrolled in this 12-week, randomized, observer-masked, two-period crossover study. Significantly more patients preferred timolol gel to timolol solution (P < 0.001). Ninety-two percent of patients preferring timolol gel strongly agreed or agreed that once-daily dosing was a reason for their preference. Those who preferred timolol solution did so because of fewer side effects. The mean IOP-lowering effects of the 2 treatments were similar at both morning trough and peak time points. The incidence of drug-related adverse experiences was similar (timolol gel 11.4% vs timolol solution 10.9%). Because both treatments were well tolerated and effective in lowering IOP, timolol gel, with its once-daily dosing regimen, should be considered in patients who are candidates for therapy with an ophthalmic beta-blocking agent. AD - D. Hartenbaum, 1600 Whitehouse Road, Maple Glen, PA 19002, United States AU - Schenker, H. AU - Maloney, S. AU - Liss, C. AU - Gormley, G. AU - Hartenbaum, D. C1 - gelrite(Monsanto,United States) timoptic(Merck and Co,United States) C2 - Merck and Co(United States) Monsanto(United States) DB - Embase Medline DO - 10.1016/S0149-2918(00)88274-0 IS - 1 KW - beta adrenergic receptor blocking agent eye drops gellan timolol maleate article beta adrenergic receptor blocking blood pressure burn clinical trial controlled clinical trial controlled study crossover procedure dose response drug efficacy drug formulation drug tolerability eye inflammation gel heart rate human intraocular hypertension intraocular pressure abnormality major clinical study open angle glaucoma patient compliance patient satisfaction questionnaire randomized controlled trial single blind procedure topical drug administration treatment outcome upper respiratory tract infection visual impairment gelrite timoptic LA - English M3 - Article N1 - L29106696 1999-03-25 PY - 1999 SN - 0149-2918 SP - 138-147 ST - Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma T2 - Clinical Therapeutics TI - Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L29106696&from=export http://dx.doi.org/10.1016/S0149-2918(00)88274-0 VL - 21 ID - 3928 ER - TY - JOUR AB - Glaucoma is a group of diseases involving the optic nerve and associated structures, which is characterized by progressive visual field loss and typical changes of the optic nerve head (ONH). The only known treatment of the disease is reduction of intraocular pressure (IOP), which has been shown to reduce glaucoma progression in a variety of large-scale clinical trials. Nowadays, a relatively wide array of topical antiglaucoma drugs is available, including prostaglandin analogues, carbonic anhydrase inhibitors, beta-receptor antagonists, adrenergic agonists, and parasympathomimetics. In clinical routine, this allows for individualized treatment taking risk factors, efficacy, and safety into account. A major challenge is related to adherence to therapy. Sustained release devices may help minimize this problem but are not yet available for clinical routine use. Another hope arises from non-IOP-related treatment concepts. In recent years, much knowledge has been gained regarding the molecular mechanisms that underlie the disease process in glaucoma. This also strengthens the hope that glaucoma therapy beyond IOP lowering will become available. Implementing this concept with clinical trials remains, however, a challenge. AN - 109704499. Language: English. Entry Date: 20150923. Revision Date: 20200708. Publication Type: journal article AU - Schmidl, Doreen AU - Schmetterer, Leopold AU - Garhöfer, Gerhard AU - Popa-Cherecheanu, Alina DB - ccm DO - 10.1089/jop.2014.0067 DP - EBSCOhost IS - 2 N1 - research; review. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM25587905. PY - 2015 SN - 1080-7683 SP - 63-77 ST - Pharmacotherapy of glaucoma T2 - Journal of Ocular Pharmacology & Therapeutics TI - Pharmacotherapy of glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109704499&site=ehost-live&scope=site VL - 31 ID - 4555 ER - TY - JOUR AB - Objective: To evaluate costs associated with prostaglandin analogs among newly-diagnosed glaucoma patients in a managed-care population. Research design and methods: A cost minimization model compared annual costs for patients initiating therapy with one of the three prostaglandin analogs (bimatoprost, latanoprost, travoprost). The study cohort was identified from pharmacy claims and eligibility files of patients who met study inclusion criteria. Annual costs were estimated for patients initiating therapy with each prostaglandin based on treatment patterns and medication use over the year. Costs for outpatient physician visits and medications were estimated from standard sources. Results: A total of 4444 patients met study criteria: 674 received travoprost, 729 received bimatoprost, and 3041 received latanoprost. More than 80% stayed on monotherapy for 1 year (82.9% of travoprost patients, 82.8% of bimatoprost patients, and 80.5% of latanoprost patients). Of those who required adjunctive therapy, the average number of days until starting adjunctive therapy was 130 days for travoprost patients, 94 days for bimatoprost patients, and 104 days for latanoprost patients. Average annual costs were $1198, $1290, and $1217 for patients treated with travoprost, bimatoprost, and latanoprost, respectively. Conclusions: The use of adjunctive therapy in glaucoma is an important driver of glaucoma management costs. This study demonstrates that the longer duration of monotherapy and the likelihood to use single rather than combination adjunctive agents contribute to lower annual costs among patients starting on travoprost compared with the other available prostaglandin analogs. Study limitations include the lack of clinical indicators in the study database; further, results may not be generalizable to patients who discontinue prostaglandin analogs or to the population of patients with glaucoma as a whole. Future studies with clinical and compliance indicators would further identity distinctions among treatment regimens. © 2007 Librapharm Limited. AD - Exponent Inc., Alexandria, VA, United States Alcon Research Ltd., Ft. Worth, TX, United States University of Maryland, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States Exponent Inc., 1800 Diagonal Rd., Alexandria, VA 22314, United States AU - Schmier, J. K. AU - Covert, D. W. AU - Robin, A. L. DB - Scopus DO - 10.1185/030079907X233287 IS - 11 KW - Costs and cost analysis Drug therapy Glaucoma Prostaglandins M3 - Review N1 - Cited By :9 Export Date: 19 July 2021 PY - 2007 SP - 2867-2875 ST - Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: A United States perspective T2 - Current Medical Research and Opinion TI - Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: A United States perspective UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-36348939280&doi=10.1185%2f030079907X233287&partnerID=40&md5=e9bf5731ccce968e6f2ecbd6d1143d94 VL - 23 ID - 5312 ER - TY - JOUR AB - Objective: To evaluate costs associated with prostaglandin analogs among newly-diagnosed glaucoma patients in a managed-care population. Research design and methods: A cost minimization model compared annual costs for patients initiating therapy with one of the three prostaglandin analogs (bimatoprost, latanoprost, travoprost). The study cohort was identified from pharmacy claims and eligibility files of patients who met study inclusion criteria. Annual costs were estimated for patients initiating therapy with each prostaglandin based on treatment patterns and medication use over the year. Costs for outpatient physician visits and medications were estimated from standard sources. Results: A total of 4444 patients met study criteria: 674 received travoprost, 729 received bimatoprost, and 3041 received latanoprost. More than 80% stayed on monotherapy for 1 year (82.9% of travoprost patients, 82.8% of bimatoprost patients, and 80.5% of latanoprost patients). Of those who required adjunctive therapy, the average number of days until starting adjunctive therapy was 130 days for travoprost patients, 94 days for bimatoprost patients, and 104 days for latanoprost patients. Average annual costs were $1198, $1290, and $1217 for patients treated with travoprost, bimatoprost, and latanoprost, respectively. Conclusions: The use of adjunctive therapy in glaucoma is an important driver of glaucoma management costs. This study demonstrates that the longer duration of monotherapy and the likelihood to use single rather than combination adjunctive agents contribute to lower annual costs among patients starting on travoprost compared with the other available prostaglandin analogs. Study limitations include the lack of clinical indicators in the study database; further, results may not be generalizable to patients who discontinue prostaglandin analogs or to the population of patients with glaucoma as a whole. Future studies with clinical and compliance indicators would further identify distinctions among treatment regimens. AN - WOS:000251245700030 AU - Schmier, J. K. AU - Covert, D. W. AU - Robin, A. L. DA - NOV DO - 10.1185/030079907X233287 IS - 11 PY - 2007 SN - 0300-7995 SP - 2867-2875 ST - Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective T2 - CURRENT MEDICAL RESEARCH AND OPINION TI - Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective VL - 23 ID - 6180 ER - TY - JOUR AB - Objective: To evaluate treatment patterns and costs among new initiators of topical prostaglandin analogs in a managed-care population. Research design and methods: Annual costs were modeled using multiple inputs. A retrospective cohort design was used to identify treatment patterns for pharmacotherapy. The study population was identified from pharmacy claims for patients who met study inclusion criteria (patients initiating prostaglandin analog monotherapy). Published studies were used to estimate visit-related resource use and costs were obtained from published and standard sources. Results: In the cohort analysis, a total of 12 202 patients met study criteria: 2275 received bimatoprost, 7347 received latanoprost and 2580 received travoprost (1808 used the original formulation and 772 used the newer preservative formulation). Of patients meeting study criteria, 50% stopped all glaucoma therapy, 6% switched from their initial prostaglandin therapy, and the remaining 44% stayed on their initial prostaglandin for 1 year. Of patients remaining on prostaglandin analog monotherapy for 1 year, 22.7% of bimatoprost patients, 19.8% of latanoprost patients and 17.9% of travoprost patients (19.7% for the original formulation and 13.7% for the new formulation) required adjunctive therapy. Of those requiring adjunctive therapy, the median number of days until starting adjunctive therapy was 53 days for bimatoprost patients, 63 days for latanoprost patients and 83 days for travoprost patients (70.5 days for the original formulation and 109 days for the new formulation). The resources used at each visit were estimated at $424 for an initial visit and $70 for follow-up visits. Estimated first-year costs were $1294, $1199, and $1186 for patients initiating therapy with bimatoprost, latanoprost, and travoprost, respectively. Estimated travoprost costs were higher for the original formulation ($1203) than for the new formulation ($1160). Sensitivity analyses suggested that the cost estimates are robust to changes in costs and use of adjunctive therapies. Limitations: The use of a claims database without compliance data or clinical outcomes and the selection of new initiators of topical prostaglandin analogs limits the findings and does not allow projecting outcomes to all glaucoma patients. Conclusions: Use of adjunctive therapy in glaucoma is an important driver of glaucoma management costs. Based on the results of this study, it is possible that longer duration of monotherapy with prostaglandin analogs may be associated with lower annual costs. Further study should be conducted to validate these findings. © 2009 Informa UK Ltd. All rights reserved. AD - Exponent Inc., 1800 Diagonal Road, Alexandria, VA 22314, United States Alcon Research Ltd., Ft. Worth, TX, United States University of Maryland, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States AU - Schmier, J. K. AU - Covert, D. W. AU - Robin, A. L. DB - Scopus DO - 10.1185/03007990902791132 IS - 4 KW - Combination Costs and cost analysis Drug therapy Glaucoma Prostaglandins M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 2009 SP - 851-858 ST - First-year treatment patterns among new initiators of topical prostaglandin analogs T2 - Current Medical Research and Opinion TI - First-year treatment patterns among new initiators of topical prostaglandin analogs UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649379079&doi=10.1185%2f03007990902791132&partnerID=40&md5=b4f24fec2e5b2834794d368d53020fee VL - 25 ID - 5183 ER - TY - JOUR AB - Objective: To evaluate treatment patterns and costs among new initiators of topical prostaglandin analogs in a managed-care population. Research design and methods: Annual costs were modeled using multiple inputs. A retrospective cohort design was used to identify treatment patterns for pharmacotherapy. The study population was identified from pharmacy claims for patients who met study inclusion criteria (patients initiating prostaglandin analog monotherapy). Published studies were used to estimate visit-related resource use and costs were obtained from published and standard sources. Results: In the cohort analysis, a total of 12202 patients met study criteria: 2275 received bimatoprost, 7347 received latanoprost and 2580 received travoprost (1808 used the original formulation and 772 used the newer preservative formulation). Of patients meeting study criteria, 50% stopped all glaucoma therapy, 6% switched from their initial prostaglandin therapy, and the remaining 44% stayed on their initial prostaglandin for 1 year. Of patients remaining on prostaglandin analog monotherapy for 1 year, 22.7% of bimatoprost patients, 19.8% of latanoprost patients and 17.9% of travoprost patients (19.7% for the original formulation and 13.7% for the new formulation) required adjunctive therapy. Of those requiring adjunctive therapy, the median number of days until starting adjunctive therapy was 53 days for bimatoprost patients, 63 days for latanoprost patients and 83 days for travoprost patients (70.5 days for the original formulation and 109 days for the new formulation). The resources used at each visit were estimated at $424 for an initial visit and $70 for follow-up visits. Estimated first-year costs were $1294, $1199, and $1186 for patients initiating therapy with bimatoprost, latanoprost, and travoprost, respectively. Estimated travoprost costs were higher for the original formulation ($1203) than for the new formulation ($1160). Sensitivity analyses suggested that the cost estimates are robust to changes in costs and use of adjunctive therapies. Limitations: The use of a claims database without compliance data or clinical outcomes and the selection of new initiators of topical prostaglandin analogs limits the findings and does not allow projecting outcomes to all glaucoma patients. Conclusions: Use of adjunctive therapy in glaucoma is an important driver of glaucoma management costs. Based on the results of this study, it is possible that longer duration of monotherapy with prostaglandin analogs may be associated with lower annual costs. Further study should be conducted to validate these findings. AN - WOS:000265970300005 AU - Schmier, J. K. AU - Covert, D. W. AU - Robin, A. L. DA - APR DO - 10.1185/03007990902791132 IS - 4 PY - 2009 SN - 0300-7995 1473-4877 SP - 851-858 ST - First-year treatment patterns among new initiators of topical prostaglandin analogs T2 - CURRENT MEDICAL RESEARCH AND OPINION TI - First-year treatment patterns among new initiators of topical prostaglandin analogs VL - 25 ID - 6030 ER - TY - JOUR AB - Objective: Ocular surface disease (OSD) is a common side effect of ophthalmic medications containing the preservative benzalkonium chloride (BAK). Little is known whether and how glaucoma treatment patterns and annual costs vary based on the presence of BAK. The objective of this analysis was to estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care population. Research design and methods: A model was developed to estimate first-year direct medical costs associated with glaucoma prescriptions and outpatient ophthalmic care. Patients were identified from a pharmacy claims database, covering more than 75 million individuals, if they initiated therapy with one of three prostaglandin analog products between November 1, 2007 and April 30, 2008. Patients needed to have at least 6 months of prior claims data in which there were no glaucoma therapy claims and at least 12 months of follow-up data available after the initial claim. Patients were excluded if they were not continuously eligible for pharmacy benefits throughout this 18-month period. Published studies were used to estimate outpatient visit-related health care resource use, and costs for prescription medications and health care resource use were derived from standard, published benchmarks. Results: The database analysis identified 9398 patients meeting study criteria, 45% (n = 4230) of whom remained on their initial prostaglandin therapy for 12 months after initiation. Adjunctive intraocular pressure lowering therapy was needed in 23.6%, 18.5%, and 13.3% of bimatoprost, latanoprost, and BAK-free travoprost patients, respectively. Median numbers of days to the first prescription filled for adjunctive therapy (if required) were 72.5, 74.0, and 125.0 for patients initiating on bimatoprost, latanoprost, and BAK-free travoprost. Total estimated first-year costs were $1973, $1807, and $1739 for patients initiating therapy with bimatoprost, latanoprost, and BAK-free travoprost. Findings were consistent through sensitivity analysis. Conclusions: A BAK-free prostaglandin analog may permit longer duration of monotherapy and be associated with lower first-year direct treatment costs. Use of a claims database and the selection of new initiators of prostaglandin analogs limit projecting findings to all glaucoma patients. AN - WOS:000284220000008 AU - Schmier, J. K. AU - Covert, D. W. AU - Robin, A. L. DA - DEC DO - 10.1185/03007995.2010.531254 IS - 12 PY - 2010 SN - 0300-7995 SP - 2769-2777 ST - First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008 T2 - CURRENT MEDICAL RESEARCH AND OPINION TI - First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008 VL - 26 ID - 6175 ER - TY - JOUR AB - Objective: To evaluate costs associated with prostaglandin analogs among newly-diagnosed glaucoma patients in a managed-care population.Research Design and Methods: A cost minimization model compared annual costs for patients initiating therapy with one of the three prostaglandin analogs (bimatoprost, latanoprost, travoprost). The study cohort was identified from pharmacy claims and eligibility files of patients who met study inclusion criteria. Annual costs were estimated for patients initiating therapy with each prostaglandin based on treatment patterns and medication use over the year. Costs for outpatient physician visits and medications were estimated from standard sources.Results: A total of 4444 patients met study criteria: 674 received travoprost, 729 received bimatoprost, and 3041 received latanoprost. More than 80% stayed on monotherapy for 1 year (82.9% of travoprost patients, 82.8% of bimatoprost patients, and 80.5% of latanoprost patients). Of those who required adjunctive therapy, the average number of days until starting adjunctive therapy was 130 days for travoprost patients, 94 days for bimatoprost patients, and 104 days for latanoprost patients. Average annual costs were $1198, $1290, and $1217 for patients treated with travoprost, bimatoprost, and latanoprost, respectively.Conclusions: The use of adjunctive therapy in glaucoma is an important driver of glaucoma management costs. This study demonstrates that the longer duration of monotherapy and the likelihood to use single rather than combination adjunctive agents contribute to lower annual costs among patients starting on travoprost compared with the other available prostaglandin analogs. Study limitations include the lack of clinical indicators in the study database; further, results may not be generalizable to patients who discontinue prostaglandin analogs or to the population of patients with glaucoma as a whole. Future studies with clinical and compliance indicators would further identify distinctions among treatment regimens. AD - Exponent Inc., Alexandria, VA 22314, USA Exponent Inc., Alexandria, VA 22314, USA. jschmier@exponent.com AN - 105833892. Language: English. Entry Date: 20080307. Revision Date: 20200518. Publication Type: journal article AU - Schmier, J. K. AU - Covert, D. W. AU - Robin, A. L. AU - Schmier, Jordana K. AU - Covert, David W. AU - Robin, Alan L. DB - ccm DO - 10.1185/030079907x233287 DP - EBSCOhost IS - 11 KW - Glaucoma -- Drug Therapy Health Care Costs Prostaglandins -- Economics Insurance Prospective Studies Prostaglandins -- Therapeutic Use United States Human N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 0351014. PMID: NLM17922980. PY - 2007 SN - 0300-7995 SP - 2867-2875 ST - Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective T2 - Current Medical Research & Opinion TI - Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105833892&site=ehost-live&scope=site VL - 23 ID - 4490 ER - TY - JOUR AB - Objective: To evaluate treatment patterns and costs among new initiators of topical prostaglandin analogs in a managed-care population.Research Design and Methods: Annual costs were modeled using multiple inputs. A retrospective cohort design was used to identify treatment patterns for pharmacotherapy. The study population was identified from pharmacy claims for patients who met study inclusion criteria (patients initiating prostaglandin analog monotherapy). Published studies were used to estimate visit-related resource use and costs were obtained from published and standard sources.Results: In the cohort analysis, a total of 12 202 patients met study criteria: 2275 received bimatoprost, 7347 received latanoprost and 2580 received travoprost (1808 used the original formulation and 772 used the newer preservative formulation). Of patients meeting study criteria, 50% stopped all glaucoma therapy, 6% switched from their initial prostaglandin therapy, and the remaining 44% stayed on their initial prostaglandin for 1 year. Of patients remaining on prostaglandin analog monotherapy for 1 year, 22.7% of bimatoprost patients, 19.8% of latanoprost patients and 17.9% of travoprost patients (19.7% for the original formulation and 13.7% for the new formulation) required adjunctive therapy. Of those requiring adjunctive therapy, the median number of days until starting adjunctive therapy was 53 days for bimatoprost patients, 63 days for latanoprost patients and 83 days for travoprost patients (70.5 days for the original formulation and 109 days for the new formulation). The resources used at each visit were estimated at $424 for an initial visit and $70 for follow-up visits. Estimated first-year costs were $1294, $1199, and $1186 for patients initiating therapy with bimatoprost, latanoprost, and travoprost, respectively. Estimated travoprost costs were higher for the original formulation ($1203) than for the new formulation ($1160). Sensitivity analyses suggested that the cost estimates are robust to changes in costs and use of adjunctive therapies.Limitations: The use of a claims database without compliance data or clinical outcomes and the selection of new initiators of topical prostaglandin analogs limits the findings and does not allow projecting outcomes to all glaucoma patients.Conclusions: Use of adjunctive therapy in glaucoma is an important driver of glaucoma management costs. Based on the results of this study, it is possible that longer duration of monotherapy with prostaglandin analogs may be associated with lower annual costs. Further study should be conducted to validate these findings. AD - Exponent Inc., 1800 Diagonal Road, Alexandria, VA 22314, USA Exponent Inc., 1800 Diagonal Road, Alexandria, VA 22314, USA. jschmier@exponent.com AN - 105532482. Language: English. Entry Date: 20090619. Revision Date: 20200708. Publication Type: journal article AU - Schmier, J. K. AU - Covert, D. W. AU - Robin, A. L. AU - Schmier, Jordana K. AU - Covert, David W. AU - Robin, Alan L. DB - ccm DO - 10.1185/03007990902791132 DP - EBSCOhost IS - 4 KW - Administration, Topical Glaucoma -- Drug Therapy Glaucoma -- Economics Health Care Costs Prostaglandins -- Administration and Dosage Prostaglandins -- Analogs and Derivatives Prostaglandins -- Economics Aged Billing and Claims Comparative Studies Female Funding Source Male Middle Age Prospective Studies Record Review Retrospective Design Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Grant Information: Funded by Alcon. NLM UID: 0351014. PMID: NLM19231912. PY - 2009 SN - 0300-7995 SP - 851-858 ST - First-year treatment patterns among new initiators of topical prostaglandin analogs T2 - Current Medical Research & Opinion TI - First-year treatment patterns among new initiators of topical prostaglandin analogs UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105532482&site=ehost-live&scope=site VL - 25 ID - 4586 ER - TY - JOUR AB - Purpose: To analyze patterns of use of adjunctive therapies among new initiators of topical prostaglandin analogs (PGAs) in a managed care population. Methods: The study cohort included patients in a claims database who initiated PGA therapy between June 2007 and April 2011. Patients who had one or more adjunctive therapy prescriptions during 24 months of follow-up were included. Patterns of adjunctive therapy use were identified and compared between patients who had one or two fills of the initial adjunctive therapy and those who had three or more. Results: There were 16,486 eligible beneficiaries. Of these, 5,933 (36%) had one or more adjunctive therapies within 24 months from the start of the PGA, 82% of whom started adjunctive therapy within 12 months. About 28% of patients started adjunctive therapy with a fixed-combination product; 45% of these patients started within the first 30 days. Overall, a large number of patients (42%) required adjunctive therapy within 30 days. Twenty-five percent of patients had only one or two prescriptions of their initial adjunctive therapy; of these patients, 74% discontinued adjunctive therapy altogether. Conclusion: Approximately 30% of patients starting glaucoma therapy will require adjunctive therapy within 1 year, and many receive a fixed-combination product as initial adjunctive therapy shortly after starting glaucoma therapy. This suggests a prescribing trend toward earlier, more aggressive drug therapy to control pressure and minimize disease progression. We found that compliance with adjunctive therapy continues to be a problem for patients, which could be attributed to a number of treatment burden and economic factors. © 2014 Schmier et al. This work is published by Dove Medical Press Limited. AD - J. K. Schmier, Exponent, 1800 Diagonal Road, Alexandria, VA 22314, United States AU - Schmier, J. K. AU - Hulme-Lowe, C. K. AU - Covert, D. W. DB - Embase DO - 10.2147/OPTH.S63760 KW - alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent bimatoprost carbonate dehydratase inhibitor latanoprost travoprost aged article cohort analysis controlled study disease course female follow up human major clinical study male monotherapy open angle glaucoma patient compliance patient selection prescription retrospective study LA - English M3 - Article N1 - L373302733 2014-06-25 2014-06-26 PY - 2014 SN - 1177-5483 1177-5467 SP - 1097-1104 ST - Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs T2 - Clinical Ophthalmology TI - Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373302733&from=export http://dx.doi.org/10.2147/OPTH.S63760 VL - 8 ID - 2880 ER - TY - JOUR AB - Purpose: To analyze patterns of use of adjunctive therapies among new initiators of topical prostaglandin analogs (PGAs) in a managed care population. Methods: The study cohort included patients in a claims database who initiated PGA therapy between June 2007 and April 2011. Patients who had one or more adjunctive therapy prescriptions during 24 months of follow-up were included. Patterns of adjunctive therapy use were identified and compared between patients who had one or two fills of the initial adjunctive therapy and those who had three or more. Results: There were 16,486 eligible beneficiaries. Of these, 5,933 (36%) had one or more adjunctive therapies within 24 months from the start of the PGA, 82% of whom started adjunctive therapy within 12 months. About 28% of patients started adjunctive therapy with a fixed-combination product; 45% of these patients started within the first 30 days. Overall, a large number of patients (42%) required adjunctive therapy within 30 days. Twenty-five percent of patients had only one or two prescriptions of their initial adjunctive therapy; of these patients, 74% discontinued adjunctive therapy altogether. Conclusion: Approximately 30% of patients starting glaucoma therapy will require adjunctive therapy within 1 year, and many receive a fixed-combination product as initial adjunctive therapy shortly after starting glaucoma therapy. This suggests a prescribing trend toward earlier, more aggressive drug therapy to control pressure and minimize disease progression. We found that compliance with adjunctive therapy continues to be a problem for patients, which could be attributed to a number of treatment burden and economic factors. © 2014 Schmier et al. This work is published by Dove Medical Press Limited. AD - Exponent, Alexandria, VA, United States Alcon Research Ltd, Fort Worth, TX, United States AU - Schmier, J. K. AU - Hulme-Lowe, C. K. AU - Covert, D. W. DB - Scopus DO - 10.2147/OPTH.S63760 KW - Combination Costs and cost analysis Drug therapy Polypharmacy M3 - Article N1 - Cited By :18 Export Date: 19 July 2021 PY - 2014 SP - 1097-1104 ST - Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs T2 - Clinical Ophthalmology TI - Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902303448&doi=10.2147%2fOPTH.S63760&partnerID=40&md5=27ccbc4632b5bdae9c8f489236bd7f5d VL - 8 ID - 5158 ER - TY - JOUR AB - Purpose Adjunctive laser trabeculoplasty (LT) is an alternative to topical medications for open-angle glaucoma (OAG). The purpose was to: (1) identify predictors of LT vs glaucoma medication treatment; and (2) estimate the resource utilization and short-term costs associated with LT vs medication management. Design Retrospective administrative claims analysis. Methods Medical and pharmacy claims data between 2007 and 2012 were analyzed to identify prostaglandin analogue monotherapy OAG patients with an index date LT claim or second medication class claim. Patients were followed for 12 months pre-index and 24 months post-index. Predictive LT attributes included age, sex, employment status, medication adherence, comorbidity status, and geographic region. Short-term costs included glaucoma-specific and comprehensive healthcare encounters. Cohort comparisons were analyzed using χ2 and Student t tests, logistic regression (predictive), and generalized linear models (cost). Results The study included 4743 LT and 16 484 medication patients. Baseline demographics were similar but significant differences were identified for comorbidities, adherence, and geography. Younger age (odds ratio [OR]: 1.21; P <.001), low adherence (OR: 1.18; P =.001), high comorbidities (OR: 1.12; P =.006), and region (OR: 1.50; P <.001) significantly predicted LT receipt. Within LT patients, 60% did not have a pharmacy claim 45 days post-index; by 2 years, this reduced to 20%. LT attributed significantly higher medical ($2684 vs $1980; P <.0001), lower pharmacy ($807 vs $1467; P <.0001), and greater overall costs ($3441 vs $3408; P =.325). Conclusions Poor adherence, younger age, and more comorbidities were predictors of receiving LT. Despite the potential for LT to address adherence, most patients had a medication claim within 2 years. Overall, LT does not provide glaucoma-specific cost savings. AD - D.C. Malone, Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, 1295 N Martin Ave, Tucson, AZ, United States AU - Schultz, N. M. AU - Wong, W. B. AU - Coleman, A. L. AU - Malone, D. C. DB - Embase Medline DO - 10.1016/j.ajo.2016.05.001 KW - prostaglandin derivative adult age aged article cohort analysis comorbidity cost control female health care cost health care utilization human major clinical study male monotherapy open angle glaucoma patient compliance pharmacy (shop) priority journal retrospective study trabeculoplasty treatment outcome LA - English M3 - Article N1 - L610551200 2016-06-08 2016-06-16 PY - 2016 SN - 1879-1891 0002-9394 SP - 78-85 ST - Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma T2 - American Journal of Ophthalmology TI - Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610551200&from=export http://dx.doi.org/10.1016/j.ajo.2016.05.001 VL - 168 ID - 2716 ER - TY - JOUR AD - G.F. Schwartz, Greater Baltimore Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, USA. AU - Schwartz, G. F. DB - Medline IS - 1 Suppl KW - antihypertensive agent eye drops article drug effect glaucoma human intraocular pressure patient compliance safety LA - English M3 - Article N1 - L137618587 2007-02-21 PY - 2004 SN - 0002-9394 SP - S1-2 ST - Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma T2 - American journal of ophthalmology TI - Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L137618587&from=export VL - 137 ID - 3759 ER - TY - JOUR AB - Purpose of review: To summarize research published between 1980 and October 2004 regarding compliance (the extent to which patients' behaviors correspond with providers' recommendations) and persistency (total time on therapy) in patients diagnosed with open-angle glaucoma or ocular hypertension; to suggest approaches ophthalmologists might consider to improve compliance and persistency; and to identify areas warranting future research. Recent findings: Medication compliance, the focus of most compliance-related research, has been measured using a variety of methods including patient self-reports, the medication possession ratio, and electronic monitoring. Noncompliance rates of at least 25% commonly have been reported. The primary obstacles to medication compliance appear to be situational/environmental (e.g., being away from home or a change in routine) or related to the medication regimen (e.g., side effects or complexity). Persistency with ocular hypotensive therapies has been found to be poor. Retrospective cohort studies using survival analyses have reported that fewer than 25% of patients are persistent over 12 months. Summary: Accurately assessing patient compliance and persistency is important to optimizing patient care. Physicians may mistake either medication noncompliance or lack of persistency with poor efficacy. Such errors would likely increase health care costs if they result in unnecessary changes to a patient's therapeutic regimen or in surgery. © 2005 Lippincott Williams & Wilkins. AD - G.F. Schwartz, Glaucoma Consultants, 6565 N Charles Street, Baltimore, MD 21204, United States AU - Schwartz, G. F. DB - Embase Medline DO - 10.1097/01.icu.0000156139.05323.26 IS - 2 KW - antihypertensive agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor cholinergic receptor stimulating agent prostaglandin accuracy cohort analysis disease course environmental factor follow up glaucoma health care cost human intraocular hypotension medical research patient care patient compliance priority journal retrospective study review self report survival LA - English M3 - Review N1 - L43790804 2006-06-07 PY - 2005 SN - 1040-8738 SP - 114-121 ST - Compliance and persistency in glaucoma follow-up treatment T2 - Current Opinion in Ophthalmology TI - Compliance and persistency in glaucoma follow-up treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43790804&from=export http://dx.doi.org/10.1097/01.icu.0000156139.05323.26 VL - 16 ID - 3695 ER - TY - JOUR AB - Purpose Of Review: To summarize research published between 1980 and October 2004 regarding compliance (the extent to which patients' behaviors correspond with providers' recommendations) and persistency (total time on therapy) in patients diagnosed with open-angle glaucoma or ocular hypertension; to suggest approaches ophthalmologists might consider to improve compliance and persistency; and to identify areas warranting future research.Recent Findings: Medication compliance, the focus of most compliance-related research, has been measured using a variety of methods including patient self-reports, the medication possession ratio, and electronic monitoring. Noncompliance rates of at least 25% commonly have been reported. The primary obstacles to medication compliance appear to be situational/environmental (e.g., being away from home or a change in routine) or related to the medication regimen (e.g., side effects or complexity). Persistency with ocular hypotensive therapies has been found to be poor. Retrospective cohort studies using survival analyses have reported that fewer than 25% of patients are persistent over 12 months.Summary: Accurately assessing patient compliance and persistency is important to optimizing patient care. Physicians may mistake either medication noncompliance or lack of persistency with poor efficacy. Such errors would likely increase health care costs if they result in unnecessary changes to a patient's therapeutic regimen or in surgery. AD - Glaucoma Consultants, Greater Baltimore Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland 21204, USA AN - 139345908. Language: English. Entry Date: 20050819. Revision Date: 20210409. Publication Type: journal article AU - Schwartz, Gail F. DB - ccm DO - 10.1097/01.icu.0000156139.05323.26 DP - EBSCOhost IS - 2 KW - Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Patient Compliance Patient Dropouts -- Statistics and Numerical Data Treatment Outcomes Physician-Patient Relations Retrospective Design Health Care Delivery -- Standards Prospective Studies Health Care Delivery -- Methods N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Home Observation for Measurement of the Environment (HOME) (Bradley and Caldwell). NLM UID: 9011108. PMID: NLM15744142. PY - 2005 SN - 1040-8738 SP - 114-121 ST - Compliance and persistency in glaucoma follow-up treatment T2 - Current Opinion in Ophthalmology TI - Compliance and persistency in glaucoma follow-up treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139345908&site=ehost-live&scope=site VL - 16 ID - 4630 ER - TY - JOUR AB - Purpose of review: To summarize research published between 1980 and October 2004 regarding compliance (the extent to which patients' behaviors correspond with providers' recommendations) and persistency (total time on therapy) in patients diagnosed with open-angle glaucoma or ocular hypertension; to suggest approaches ophthalmologists might consider to improve compliance and persistency; and to identify areas warranting future research. Recent findings: Medication compliance, the focus of most compliance-related research, has been measured using a variety of methods including patient self-reports, the medication possession ratio, and electronic monitoring. Noncompliance rates of at least 25% commonly have been reported. The primary obstacles to medication compliance appear to be situational/environmental (e.g., being away from home or a change in routine) or related to the medication regimen (e.g., side effects or complexity). Persistency with ocular hypotensive therapies has been found to be poor. Retrospective cohort studies using survival analyses have reported that fewer than 25% of patients are persistent over 12 months. Summary: Accurately assessing patient compliance and persistency is important to optimizing patient care. Physicians may mistake either medication noncompliance or lack of persistency with poor efficacy. Such errors would likely increase health care costs if they result in unnecessary changes to a patient's therapeutic regimen or in surgery. © 2005 Lippincott Williams & Wilkins. AD - Glaucoma Consultants, Johns Hopkins University, University of Maryland, Baltimore, MD, United States Glaucoma Consultants, 6565 N Charles Street, Baltimore, MD 21204, United States AU - Schwartz, G. F. DB - Scopus DO - 10.1097/01.icu.0000156139.05323.26 IS - 2 KW - Compliance Glaucoma Ocular hypertension Persistency M3 - Review N1 - Cited By :103 Export Date: 19 July 2021 PY - 2005 SP - 114-121 ST - Compliance and persistency in glaucoma follow-up treatment T2 - Current Opinion in Ophthalmology TI - Compliance and persistency in glaucoma follow-up treatment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-18944393185&doi=10.1097%2f01.icu.0000156139.05323.26&partnerID=40&md5=da945748397d22e6ece62059e813458c VL - 16 ID - 4928 ER - TY - JOUR AB - Objective: To evaluate eye drop administration by patients at multiple visits in the setting of a randomized controlled trial. Study design and methods: Patients with glaucoma or ocular hypertension were randomized to 12 weeks of treatment with topical ocular hypotensive medication in a multicenter, investigator-masked trial. At baseline, patients were given a questionnaire for self-assessment of difficulty with drop administration. At baseline and 12 weeks, patients demonstrated drop instillation using a bottle of artificial tears. Main outcome measures: Patient self-assessment of difficulty with drop administration and observed patient difficulty with drop administration, defined as bottle touching eye/adnexa, drop missing the ocular surface, or administering more than 1 drop. Results: Of 164 enrolled patients, 50% had previously been treated with ocular hypotensive medication for 3 years. Only 11.4% of patients reported difficulty with eye drop administration at study entry. At baseline, 18.2% of patients touched their eye/adnexa with the bottle and 10.3% missed the eye. At 12 weeks, 18.5% and 8.6% of patients, respectively, had similar difficulties. Overall, difficulty with drop instillation was observed in 42.1% of patients. Difficulty at both visits was seen in 35.3% of patients who reported difficulty at entry and in 17.2% of patients who denied difficulty. The relative risk of demonstrating difficulty at either visit was 2.0 times greater for patients who self-reported difficulty at study entry (P = 0.004). The relative risk of demonstrating difficulty at week 12 was 3.8 times greater for patients with observed difficulty at baseline (P < 0.001). Limitations of the study design included self-administration of drops to the eye of the patient's choice and observation in an office setting. Conclusions: Patients with experience instilling topical glaucoma medications continue to have difficulties with eye drop administration, including patients who do not self-report difficulty. The risk of difficulty with eye drop administration is increased in patients who self-report difficulty and in patients who have been previously observed to have difficulty. Clinical trial registry number: NCT01253902. © 2013 Informa UK Ltd. AD - Greater Baltimore Medical Center and Wilmer Eye Institute, Johns Hopkins University, East Suite 302, Baltimore, MD 21204, United States Allergan Inc, Irvine, CA, United States AU - Schwartz, G. F. AU - Hollander, D. A. AU - Williams, J. M. DB - Scopus DO - 10.1185/03007995.2013.833898 IS - 11 KW - Adherence Compliance Eyedrops Glaucoma Ocular hypertension Ophthalmic solutions M3 - Article N1 - Cited By :32 Export Date: 19 July 2021 PY - 2013 SP - 1515-1522 ST - Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension T2 - Current Medical Research and Opinion TI - Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885816125&doi=10.1185%2f03007995.2013.833898&partnerID=40&md5=31bc20711c9161b2628e75e8e55c5538 VL - 29 ID - 5050 ER - TY - JOUR AB - Objective: To evaluate eye drop administration by patients at multiple visits in the setting of a randomized controlled trial. Study design and methods: Patients with glaucoma or ocular hypertension were randomized to 12 weeks of treatment with topical ocular hypotensive medication in a multicenter, investigator-masked trial. At baseline, patients were given a questionnaire for self-assessment of difficulty with drop administration. At baseline and 12 weeks, patients demonstrated drop instillation using a bottle of artificial tears. Main outcome measures: Patient self-assessment of difficulty with drop administration and observed patient difficulty with drop administration, defined as bottle touching eye/adnexa, drop missing the ocular surface, or administering more than 1 drop. Results: Of 164 enrolled patients, 50% had previously been treated with ocular hypotensive medication for >= 3 years. Only 11.4% of patients reported difficulty with eye drop administration at study entry. At baseline, 18.2% of patients touched their eye/adnexa with the bottle and 10.3% missed the eye. At 12 weeks, 18.5% and 8.6% of patients, respectively, had similar difficulties. Overall, difficulty with drop instillation was observed in 42.1% of patients. Difficulty at both visits was seen in 35.3% of patients who reported difficulty at entry and in 17.2% of patients who denied difficulty. The relative risk of demonstrating difficulty at either visit was 2.0 times greater for patients who self-reported difficulty at study entry (P 0.004). The relative risk of demonstrating difficulty at week 12 was 3.8 times greater for patients with observed difficulty at baseline (P<0.001). Limitations of the study design included self-administration of drops to the eye of the patient's choice and observation in an office setting. Conclusions: Patients with experience instilling topical glaucoma medications continue to have difficulties with eye drop administration, including patients who do not self-report difficulty. The risk of difficulty with eye drop administration is increased in patients who self-report difficulty and in patients who have been previously observed to have difficulty. AN - WOS:000325853100013 AU - Schwartz, G. F. AU - Hollander, D. A. AU - Williams, J. M. DA - NOV DO - 10.1185/03007995.2013.833898 IS - 11 PY - 2013 SN - 0300-7995 1473-4877 SP - 1515-1522 ST - Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension T2 - CURRENT MEDICAL RESEARCH AND OPINION TI - Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension VL - 29 ID - 5980 ER - TY - JOUR AB - Objectives: To compare responses in two patient populations with a questionnaire developed to identify those prescribed ocular hypotensive medication whose adherence may need improvement and who may be ready to change. Methods: The content/face validity of a 62-item, self-administered questionnaire was confirmed by nine glaucoma specialists. Questions concerned demographics, health and medications, use of/problems with medications, and visual function. The questionnaire was administered anonymously to 102 consecutive patients in a glaucoma referral practice ('glaucoma practice') and 100 from a multispecialty ophthalmology practice ('multispecialty practice'). All participants were prescribed ≥1 ocular hypotensive medication and had no previous trabeculectomy. Results: Patients in the glaucoma practice were more likely to be younger, African-American, and better educated (P<0.05 for each). In both, >80% had glaucoma with >60% diagnosed ≥3 years previously. Most (glaucoma, multispecialty: 87, 93%) reported administering drops every day, but more in the multispecialty practice reported administering drops at the same time every day (79, 92%; P<0.05). Number of adherence problems (mean, 1/patient) and adherence scores (mean, 24; possible scale range, 0-25) were similar. Common adherence barriers were falling asleep and forgetting when the regular schedule changed or when travelling. In the glaucoma practice, the number of adherence problems was correlated with adherence score (r=-0.611; P<0.0001) and number of side effects (r=0.349; P<0.0001). Conclusions: Similarities between patient populations limited our ability to compare responses between groups or to propose adherence counselling tailored to specific demographics. Until such recommendations are possible, physicians should incorporate adherence counselling broadly into their practices. © 2009 Macmillan Publishers Limited All rights reserved. AD - G. F. Schwartz, Greater Baltimore Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States AU - Schwartz, G. F. AU - Plake, K. S. AU - Mychaskiw, M. A. DB - Embase Medline DO - 10.1038/eye.2008.337 IS - 8 KW - antiglaucoma agent adult aged article behavior change blurred vision eye disease face validity female glaucoma human intraocular hypotension major clinical study male patient attitude patient compliance prescription questionnaire scoring system LA - English M3 - Article N1 - L355135749 2009-09-22 PY - 2009 SN - 1476-5454 0950-222X SP - 1668-1674 ST - An assessment of readiness for behaviour change in patients prescribed ocular hypotensive therapy T2 - Eye TI - An assessment of readiness for behaviour change in patients prescribed ocular hypotensive therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355135749&from=export http://dx.doi.org/10.1038/eye.2008.337 VL - 23 ID - 3396 ER - TY - JOUR AB - Adherence and persistence with chronic therapies is crucial to prevent disease progression, such as in glaucoma. Patients report high rates of adherence, which are not supported by pharmacy claims analysis. This article reviews the literature regarding methods to assess adherence and persistence and the patient behaviors that pose challenges to proper treatment. Rates for persistence are generally below 50% at 1 year. Differentiating efficacy of eyedrops from lack of adherence presently confounds ophthalmic treatment. Additionally, as intraocular pressure (IOP) can appear controlled by short-term adherence, the physician can be fooled into believing the patient's glaucoma is well-controlled. Likewise, when progressive worsening is noted despite good IOP control, it can be problematic whether the patient's target pressure needs to be lowered or adherence needs to be improved. White-coat adherence is common, in which patient adherence rises sharply 1 week before the appointment with the physician, then declines rapidly following the appointment. White-coat adherence may make it difficult to assess IOP control over the longer term; cycling behavior with medication use is well-documented. Adherence and persistence rates differ by class of drug, with higher rates associated with prostaglandin use. We review findings from The Glaucoma Adherence and Persistency Study that identified behaviors associated with poor adherence. Greater physician awareness of adherence and persistence issues is necessary in order to help the patient become more adherent. © 2008 Elsevier Inc. All rights reserved. AD - G.F. Schwartz, Greater Baltimore Medical Center, Baltimore, MD, United States AU - Schwartz, G. F. AU - Quigley, H. A. DB - Embase Medline DO - 10.1016/j.survophthal.2008.08.002 IS - 6 SUPPL. KW - alpha adrenergic receptor blocking agent alpha adrenergic receptor stimulating agent antihypertensive agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor cholinergic receptor stimulating agent latanoprost prostaglandin derivative article clinical trial disease course drug efficacy follow up glaucoma human intraocular pressure patient compliance patient participation priority journal questionnaire risk assessment self report survival rate treatment outcome unspecified side effect LA - English M3 - Article N1 - L352713571 2009-01-05 PY - 2008 SN - 0039-6257 SP - S57-S68 ST - Adherence and Persistence with Glaucoma Therapy T2 - Survey of Ophthalmology TI - Adherence and Persistence with Glaucoma Therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352713571&from=export http://dx.doi.org/10.1016/j.survophthal.2008.08.002 VL - 53 ID - 3419 ER - TY - JOUR AB - Adherence and persistence with chronic therapies is crucial to prevent disease progression, such as in glaucoma. Patients report high rates of adherence, which are not supported by pharmacy claims analysis. This article reviews the literature regarding methods to assess adherence and persistence and the patient behaviors that pose challenges to proper treatment. Rates for persistence are generally below 50% at 1 year. Differentiating efficacy of eyedrops from lack of adherence presently confounds ophthalmic treatment. Additionally, as intraocular pressure (IOP) can appear controlled by short-term adherence, the physician can be fooled into believing the patient's glaucoma is well-controlled. Likewise, when progressive worsening is noted despite good IOP control, it can be problematic whether the patient's target pressure needs to be lowered or adherence needs to be improved. White-coat adherence is common, in which patient adherence rises sharply 1 week before the appointment with the physician, then declines rapidly following the appointment. White-coat adherence may make it difficult to assess IOP control over the longer term; cycling behavior with medication use is well-documented. Adherence and persistence rates differ by class of drug, with higher rates associated with prostaglandin use. We review findings from The Glaucoma Adherence and Persistency Study that identified behaviors associated with poor adherence. Greater physician awareness of adherence and persistence issues is necessary in order to help the patient become more adherent. © 2008 Elsevier Inc. All rights reserved. AD - Greater Baltimore Medical Center, Baltimore, MD, United States Wilmer Eye Institute, Baltimore, MD, United States AU - Schwartz, G. F. AU - Quigley, H. A. DB - Scopus DO - 10.1016/j.survophthal.2008.08.002 IS - 6 SUPPL. KW - adherence compliance glaucoma persistence M3 - Article N1 - Cited By :184 Export Date: 19 July 2021 PY - 2008 SP - S57-S68 ST - Adherence and Persistence with Glaucoma Therapy T2 - Survey of Ophthalmology TI - Adherence and Persistence with Glaucoma Therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-56449094936&doi=10.1016%2fj.survophthal.2008.08.002&partnerID=40&md5=3f15331aa8e5d0b6fbb9592ff25f77a1 VL - 53 ID - 4909 ER - TY - JOUR AB - PURPOSE: To evaluate persistency of pharmacotherapy in primary open-angle glaucoma suspects (glaucoma suspects) treated with latanoprost and timolol. DESIGN: Retrospective, cohort study using the Protocare Sciences managed care database; approximately 3 million members in commercial health maintenance organizations and preferred provider organizations and in Medicare risk plans. METHODS: Patients 20 years of age or older beginning therapy between January 1, 1997, and June 30, 2002, with latanoprost or timolol monotherapy were included. Patients must have been continuously enrolled and not undergone glaucoma surgery in the year preceding the index prescription fill and had glaucoma suspect diagnoses before and after the index date. Prescription refill records for all ocular hypotensives were extracted through June 30, 2002. The two outcome measures were (1) discontinuation of index drug, and (2) either discontinuation or change in index drug. Changing therapy was defined as switching to or adding another ocular hypotensive. Rates of discontinuation and discontinuation/change were compared using Cox regression models. RESULTS: In all, 1,474 patients met the inclusion criteria. Latanoprost was prescribed for 583 patients (40%) and timolol for 891 (60%). Compared with latanoprost, those treated with timolol were 39% more likely to discontinue and 27% more likely to discontinue/change therapy (P < .001 for both comparisons). At 12 months, 39% of patients receiving latanoprost and 25% of those treated with timolol had not discontinued therapy; no discontinuation or change in therapy was seen in 30% and 18%, respectively. CONCLUSIONS: Latanoprost-treated glaucoma suspects demonstrated significantly greater persistency than did patients treated with timolol. The reasons for this difference and its impact on intraocular pressure control and disease progression require further research. © 2004 by Elsevier Inc. All rights reserved. AD - G.F. Schwartz, 6565 N Charles St, Baltimore, MD 21204, United States AU - Schwartz, G. F. AU - Reardon, G. AU - Mozaffari, E. DB - Embase Medline DO - 10.1016/j.ajo.2003.10.034 IS - SUPPL. KW - betaxolol bimatoprost brimonidine dorzolamide latanoprost timolol travoprost adult aged article cohort analysis controlled study data base drug use drug withdrawal female glaucoma health maintenance organization human intraocular pressure major clinical study male managed care medicare monotherapy open angle glaucoma outcomes research patient compliance prescription priority journal regression analysis retrospective study LA - English M3 - Article N1 - L38091630 2004-02-03 PY - 2004 SN - 0002-9394 SP - S13-S16 ST - Persistency with latanoprost or timolol in primary open-angle glaucoma suspects T2 - American Journal of Ophthalmology TI - Persistency with latanoprost or timolol in primary open-angle glaucoma suspects UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38091630&from=export http://dx.doi.org/10.1016/j.ajo.2003.10.034 VL - 137 ID - 3763 ER - TY - JOUR AB - Aims: To develop a model to estimate and compare the cost of changing therapy due to hyperemia in glaucoma patients treated initially either with latanoprost, bimatoprost, or travoprost monotherapy. Methods: Data collected from the HealthCore Integrated Research Database, as part of the Glaucoma Adherence and Persistency Study (GAPS), were used to populate the model. Patients with a documented diagnosis of glaucoma who were newly treated (no ocular hypotensive medication and no glaucoma-related procedure during 6 months before first prescription) with latanoprost, bimatoprost, or travoprost monotherapy were identified. The time horizon for the base-case model was the duration of chart abstraction (mean = 4.1 years); a 3-month model also was developed. Physician-reported rates of hyperemia were obtained from chart reviews of 300 patients. Transition rates reflected events related to reports of hyperemia where a physician-driven change (switch or discontinuation) in therapy was documented. The per-patient direct cost (2008) due to hyperemia-driven change in therapy was calculated as the sum of the cost of the initial prescription plus the cost of the office visit where the patient was evaluated and the decision to change therapy was made. Costs were stratified by whether patients were hyperemia free or discontinued the initial therapy due to hyperemia. Results: From the sample of 13,977 newly treated patients, 8,743 patients were started on a prostaglandin monotherapy only. Of these, 5,726 received latanoprost, 1,633 were treated with bimatoprost, and 1,384 received travoprost index monotherapy. Across all treatment groups, costs among hyperemia-free patients were US$73.67 versus US$140.02 for those who discontinued the initial prostaglandin due to hyperemia. Per-patient costs were lowest in the group treated initially with latanoprost. For the base-case model, with latanoprost as the reference, total per-patient incremental costs due to hyperemia-driven change in therapy were US$5.92 for bimatoprost and US$5.43 for travoprost. Results were not highly sensitive to increases either in the incidence of hyperemia among latanoprost-treated patients or in the cost of latanoprost. Conclusions: Hyperemia results in increased overall costs in patients treated with latanoprost, bimatoprost, and travoprost. Treatment with latanoprost is associated with lower hyperemia-related costs than treatment with bimatoprost or travoprost. © Mary Ann Liebert, Inc. 2009. AD - Glaucoma Consultants, 6565 N. Charles Street, Baltimore, MD 21204, United States HealthCore, Inc., Wilmington, DE, United States Pfizer, Inc., New York, NY, United States AU - Schwartz, G. F. AU - Tan, J. AU - Kotak, S. DB - Scopus DO - 10.1089/jop.2009.0057 IS - 6 M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2009 SP - 555-561 ST - Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs T2 - Journal of Ocular Pharmacology and Therapeutics TI - Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77149177955&doi=10.1089%2fjop.2009.0057&partnerID=40&md5=6bbd0fe14bdded3df5a588e568786178 VL - 25 ID - 5205 ER - TY - JOUR AB - Aims: To develop a model to estimate and compare the cost of changing therapy due to hyperemia in glaucoma patients treated initially either with latanoprost, bimatoprost, or travoprost monotherapy. Methods: Data collected from the HealthCore Integrated Research Database, as part of the Glaucoma Adherence and Persistency Study (GAPS), were used to populate the model. Patients with a documented diagnosis of glaucoma who were newly treated (no ocular hypotensive medication and no glaucoma-related procedure during 6 months before first prescription) with latanoprost, bimatoprost, or travoprost monotherapy were identified. The time horizon for the base-case model was the duration of chart abstraction (mean = 4.1 years); a 3-month model also was developed. Physician-reported rates of hyperemia were obtained from chart reviews of 300 patients. Transition rates reflected events related to reports of hyperemia where a physician-driven change (switch or discontinuation) in therapy was documented. The per-patient direct cost (2008) due to hyperemia-driven change in therapy was calculated as the sum of the cost of the initial prescription plus the cost of the office visit where the patient was evaluated and the decision to change therapy was made. Costs were stratified by whether patients were hyperemia free or discontinued the initial therapy due to hyperemia. Results: From the sample of 13,977 newly treated patients, 8,743 patients were started on a prostaglandin monotherapy only. Of these, 5,726 received latanoprost, 1,633 were treated with bimatoprost, and 1,384 received travoprost index monotherapy. Across all treatment groups, costs among hyperemia-free patients were US$73.67 versus US$140.02 for those who discontinued the initial prostaglandin due to hyperemia. Per-patient costs were lowest in the group treated initially with latanoprost. For the base-case model, with latanoprost as the reference, total per-patient incremental costs due to hyperemia-driven change in therapy were US$5.92 for bimatoprost and US$5.43 for travoprost. Results were not highly sensitive to increases either in the incidence of hyperemia among latanoprost-treated patients or in the cost of latanoprost. Conclusions: Hyperemia results in increased overall costs in patients treated with latanoprost, bimatoprost, and travoprost. Treatment with latanoprost is associated with lower hyperemia-related costs than treatment with bimatoprost or travoprost. AN - WOS:000272994600013 AU - Schwartz, G. F. AU - Tan, J. AU - Kotak, S. DA - DEC DO - 10.1089/jop.2009.0057 IS - 6 PY - 2009 SN - 1080-7683 1557-7732 SP - 555-561 ST - Hyperemia-Associated Costs of Medication Changes in Glaucoma Patients Treated Initially With Prostaglandin Analogs T2 - JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS TI - Hyperemia-Associated Costs of Medication Changes in Glaucoma Patients Treated Initially With Prostaglandin Analogs VL - 25 ID - 6217 ER - TY - JOUR AB - Adherence and persistence with chronic therapies is crucial to prevent disease progression, such as in glaucoma. Patients report high rates of adherence, which are not supported by pharmacy claims analysis. This article reviews the literature regarding methods to assess adherence and persistence and the patient behaviors that pose challenges to proper treatment. Rates for persistence are generally below 50% at 1 year. Differentiating efficacy of eyedrops from lack of adherence presently confounds ophthalmic treatment. Additionally, as intraocular pressure (IOP) can appear controlled by short-term adherence, the physician can be fooled into believing the patient's glaucoma is well-controlled. Likewise, when progressive worsening is noted despite good IOP control, it can be problematic whether the patient's target pressure needs to be lowered or adherence needs to be improved. White-coat adherence is common, in which patient adherence rises sharply 1 week before the appointment with the physician, then declines rapidly following the appointment. White-coat adherence may make it difficult to assess IOP control over the longer term; cycling behavior with medication use is well-documented. Adherence and persistence rates differ by class of drug, with higher rates associated with prostaglandin use. We review findings from The Glaucoma Adherence and Persistency Study that. identified behaviors associated with poor adherence. Greater physician awareness of adherence and persistence issues is necessary in order to help the patient become more adherent. (Surv Ophthalmol 53:S57-S68, 2008. (C) 2008 Elsevier Inc. All rights reserved.) AN - WOS:000261587400008 AU - Schwartz, G. R. AU - Quigley, H. A. DA - NOV DO - 10.1016/j.survophthal.2008.08.002 PY - 2008 SN - 0039-6257 SP - S57-S68 ST - Adherence and Persistence with Glaucoma Therapy T2 - SURVEY OF OPHTHALMOLOGY TI - Adherence and Persistence with Glaucoma Therapy VL - 53 ID - 5907 ER - TY - JOUR AD - Member, AOA Vance Thompson Vision, Sioux Falls, S.D. AN - 97815446. Language: English. Entry Date: 20140904. Revision Date: 20140904. Publication Type: Article AU - Schweitzer, Justin DB - ccm DP - EBSCOhost IS - 8 KW - Glaucoma -- Surgery Minimally Invasive Procedures Stents Patient Safety Eye Hemorrhage Patient Compliance Coding Disease Progression -- Prevention and Control N1 - pictorial; tables/charts. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2014 SN - 0030-4085 SP - 34-71 ST - Lowering IOP With Stents...IntraOcular Pressure T2 - Optometric Management TI - Lowering IOP With Stents...IntraOcular Pressure UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=97815446&site=ehost-live&scope=site VL - 49 ID - 4710 ER - TY - JOUR AB - Background. Prospective, observational studies that enroll large numbers of patients with few exclusion criteria may better reflect actual ongoing clinical experience than randomized clinical trials. Our purpose was to obtain efficacy and safety information from a cohort of subjects exposed to latanoprost/timolol fixed combination (FC) for 18 months using a prospective, observational design. Methods. In all, 577 office-based ophthalmologists in Germany switched 2339 patients with glaucoma or ocular hypertension to latanoprost/timolol FC for medical reasons. Follow-up visits were scheduled for every 6 months over 24 months; physicians followed usual care routines. Intraocular pressure (IOP), visual field status, optic nerve head findings, and adverse events were recorded. Efficacy parameters were evaluated for the per protocol (PP) population; the safety population included subjects receiving 1 drop of FC. Physicians rated efficacy, tolerability, and subject compliance at month 24. Results. Of the 2339 subjects switched to latanoprost/timolol FC (safety population), the primary reasons for switching were inadequate IOP reduction (78.2%) and desire to simplify treatment with once-daily dosing (29.4%; multiple reasons possible). In all, 1317 (56.3%) subjects completed the study, and 1028 (44.0%) were included in the PP population. Most discontinuations were due to loss to follow-up. Change in mean IOP from baseline to month 6 was -4.0 4.31 mmHg, a reduction that was maintained throughout (P < 0.05 for change at all time points). By investigator assessments, optic disc parameters and visual field were stable over 24 months, and there was no relationship between IOP reduction over 24 months and development of a visual field defect. More than 90% of physicians rated latanoprost/timolol FC as "very good" or "good" for efficacy (PP population), tolerability, and compliance. The FC was safe and well tolerated. No change in iris color was reported by most subjects (83.1%) at month 24. Conclusions. Over 24 months, latanoprost/timolol FC effectively lowers IOP levels and is well tolerated in patients with glaucoma or ocular hypertension who change from their previous ocular hypotensive therapy for medical reasons. Investigator assessments found optic disc parameters and visual field to be stable throughout 24 months of follow-up. © 2010 Schwenn et al; licensee BioMed Central Ltd. AD - Bürgerhospital Frankfurt Am Main, Augenklinik, Frankfurt am Main, Germany Private Practice, Bruchsal, Germany Pfizer Pharma GmbH, Berlin, Germany Pfizer Limited, UK Specialty Care, Sandwich, Kent, United Kingdom AU - Schwenn, O. AU - Heckmann, B. AU - Guzy, C. AU - Miller, P. J. C7 - 21 DB - Scopus DO - 10.1186/1471-2415-10-21 IS - 1 M3 - Article N1 - Cited By :15 Export Date: 19 July 2021 PY - 2010 ST - Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: A prospective, observational, noninterventional study T2 - BMC Ophthalmology TI - Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: A prospective, observational, noninterventional study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77956477158&doi=10.1186%2f1471-2415-10-21&partnerID=40&md5=36b186b2d0e5318d7f68e7a7e229c124 VL - 10 ID - 5195 ER - TY - JOUR AB - Background: Prospective, observational studies that enroll large numbers of patients with few exclusion criteria may better reflect actual ongoing clinical experience than randomized clinical trials. Our purpose was to obtain efficacy and safety information from a cohort of subjects exposed to latanoprost/timolol fixed combination (FC) for >= 18 months using a prospective, observational design. Methods: In all, 577 office-based ophthalmologists in Germany switched 2339 patients with glaucoma or ocular hypertension to latanoprost/timolol FC for medical reasons. Follow-up visits were scheduled for every 6 months over 24 months; physicians followed usual care routines. Intraocular pressure (IOP), visual field status, optic nerve head findings, and adverse events were recorded. Efficacy parameters were evaluated for the per protocol (PP) population; the safety population included subjects receiving >= 1 drop of FC. Physicians rated efficacy, tolerability, and subject compliance at month 24. Results: Of the 2339 subjects switched to latanoprost/timolol FC (safety population), the primary reasons for switching were inadequate IOP reduction (78.2%) and desire to simplify treatment with once-daily dosing (29.4%; multiple reasons possible). In all, 1317 (56.3%) subjects completed the study, and 1028 (44.0%) were included in the PP population. Most discontinuations were due to loss to follow-up. Change in mean IOP from baseline to month 6 was -4.0 +/- 4.31 mmHg, a reduction that was maintained throughout (P < 0.05 for change at all time points). By investigator assessments, optic disc parameters and visual field were stable over 24 months, and there was no relationship between IOP reduction over 24 months and development of a visual field defect. More than 90% of physicians rated latanoprost/timolol FC as "very good" or "good" for efficacy (PP population), tolerability, and compliance. The FC was safe and well tolerated. No change in iris color was reported by most subjects (83.1%) at month 24. Conclusions: Over 24 months, latanoprost/timolol FC effectively lowers IOP levels and is well tolerated in patients with glaucoma or ocular hypertension who change from their previous ocular hypotensive therapy for medical reasons. Investigator assessments found optic disc parameters and visual field to be stable throughout 24 months of follow-up. AN - WOS:000284013700001 AU - Schwenn, O. AU - Heckmann, B. AU - Guzy, C. AU - Miller, P. J. DA - SEP 8 DO - 10.1186/1471-2415-10-21 PY - 2010 SN - 1471-2415 ST - Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: A prospective, observational, noninterventional study T2 - BMC OPHTHALMOLOGY TI - Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: A prospective, observational, noninterventional study VL - 10 ID - 5912 ER - TY - JOUR AB - In an attempt to increase patient compliance with a dosing regimen, prescriptions for topical solutions of glaucoma medication were refilled using the C Cap(TM), a memory aid designed to help patients to remember to instill the medication as prescribed. A comparison of the number of prescription refills requested by 121 patients with glaucoma showed that patients who received the C Cap requested significantly more refills in the six months after receiving the C Cap than before and requested significantly more refills than did patients who did not receive the C Cap. AD - John Stauffer Pharmaceutical Science Center, School of Pharmacy, University of Southern California, Los Angeles, CA AU - Sclar, D. A. AU - Skaer, T. L. AU - Chin, A. AU - Okamoto, M. P. AU - Nakahiro, R. K. AU - Gill, M. A. C1 - betagan(Allergan,United States) propine(Allergan,United States) timoptic(Merck Sharp and Dohme,United States) C2 - Allergan(United States) Merck Sharp and Dohme(United States) DB - Embase Medline IS - 3 KW - dipivefrine levobunolol timolol timolol maleate adult article drug delivery system female glaucoma human major clinical study male patient compliance priority journal topical drug administration betagan propine timoptic LA - English M3 - Article N1 - L21232465 1991-08-29 PY - 1991 SN - 0149-2918 SP - 396-400 ST - Effectiveness of the C Cap(TM) in promoting prescription refill compliance among patients with glaucoma T2 - Clinical Therapeutics TI - Effectiveness of the C Cap(TM) in promoting prescription refill compliance among patients with glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L21232465&from=export VL - 13 ID - 4037 ER - TY - JOUR AB - Aims: To determine the prevalence of physical illness in patients admitted to a challenging behaviour unit and to assess whether they were physically examined and investigated. Method: Retrospective case note analysis of patients admitted to the challenging behaviour unit during the period of July 1997 to July 2003. Results: All patients were suffering from serious and enduring mental illness and challenged the ordinary mental health services by behaviour such as assault, fire setting, aggression, self harm, multiple substance misuse and non-compliance at least for six months. On admission 76% of patients had examination of the cardiovascular, respiratory and gastro intestinal system and 69% of the central nervous system. During the hospital stay, all the patients had cardio vascular, respiratory and gastrointestinal system examination and 83% had central nervous system examination. All patients had base line investigations including full blood count, ESR, liver function test, urea and electrolytes, random glucose, thyroid function test and follow up investigations. 51(73%) patients were found to be suffering from some physical illness during their hospital stay. The physical illness spanned all the systems. There were newly detected cases of systemic lupus erythematosus, diabetes mellitus, glaucoma, hypertension, seizure disorder, male urinary tract infection, severe incontinence and haematological problems. Conclusion: There is a high prevalence of physical health problems among patients admitted to a challenging behaviour unit. Some problems were associated with the mental illness, some as a complication of the mental health problem and others secondary to psychotropic medication. This study highlights the importance of a proper medical history, physical examination, base line investigations and regular monitoring of the physical health of mentally ill patients. © 2005, NAPICU. All rights reserved. AD - Bracton Centre, Oxleas NHS Trust, Dartford, United Kingdom FRC Psych, Consultant Psychiatrist, Challenging Behaviour Psychiatry, Institute of Psychiatry, Bracton Centre, Oxleas NHS Trust, Bracton Lane, Dartford, Kent DA2 7AF, United Kingdom AU - Sebastian, C. AU - Beer, D. AU - Beer, M. D. DB - Scopus DO - 10.1017/S1742646406000136 IS - 2 KW - low secure unit Mental health challenging behaviour unit physical health problems M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2005 SP - 77-83 ST - Physical health of psychiatric patients admitted to a low secure challenging behaviour unit T2 - Journal of Psychiatric Intensive Care TI - Physical health of psychiatric patients admitted to a low secure challenging behaviour unit UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011510882&doi=10.1017%2fS1742646406000136&partnerID=40&md5=6b49459af9cc0f2e507d806e8644eb2f VL - 1 ID - 5435 ER - TY - JOUR AB - Purpose: To describe a case of progressive glaucomatous optic neuropathy using scanning laser polarimetry with fixed (SLP-FCC) and variable corneal compensation (SLP-VCC) and optical coherence tomography (OCT). Design: Observational case report. Methods: A 21-year-old male with juvenile primary open-angle glaucoma developed progression because of noncompliance with therapy. The patient underwent dilated stereoscopic examination and photography of the optic disk, standard automated perimetry (SAP), OCT, and SLP imaging with FCC and VCC at the baseline examination and after four years of follow-up. Results: Optic disk, retinal nerve fiber layer (RNFL) atrophy, and SAP progression was observed. Reduction in mean RNFL thickness (average, superior, inferior) was 18, 18, and 27 microns (OCT); 22, 40, and 17 microns (SLP-FCC); and 6, 12, and 12 microns (SLP-VCC), respectively. Conclusions: This case demonstrates that digital imaging of the peripapillary RNFL is capable of documentation and measurement of progressive glaucomatous RNFL atrophy. © 2006 Elsevier Inc. All rights reserved. AD - Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Palm Beach Gardens, FL, United States AU - Sehi, M. AU - Greenfield, D. S. DB - Scopus DO - 10.1016/j.ajo.2006.07.043 IS - 6 M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2006 SP - 1056-1059 ST - Assessment of Retinal Nerve Fiber Layer Using Optical Coherence Tomography and Scanning Laser Polarimetry in Progressive Glaucomatous Optic Neuropathy T2 - American Journal of Ophthalmology TI - Assessment of Retinal Nerve Fiber Layer Using Optical Coherence Tomography and Scanning Laser Polarimetry in Progressive Glaucomatous Optic Neuropathy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845190328&doi=10.1016%2fj.ajo.2006.07.043&partnerID=40&md5=fbd45e701442face81943530bd2b6da1 VL - 142 ID - 5221 ER - TY - JOUR AB - PURPOSE: To describe a case of progressive glaucomatous optic neuropathy using scanning laser polarimetry with fixed (SLP-FCC) and variable corneal compensation (SLP-VCC) and optical coherence tomography (OCT). DESIGN: Observational case report. METHODS: A 21 year-old male with juvenile primary open,angle glaucoma developed progression because of noncompliance with therapy. The patient underwent dilated stereoscopic examination and photography of the optic disk, standard automated perimetry (SAP), OCT, and SLP imaging with FCC and VCC at the baseline examination and after four years of follow-up. RESULTS: Optic disk, retinal nerve fiber layer (RNFL) atrophy, and SAP progression was observed. Reduction in mean RNFL thickness (average, superior, inferior) was 18, 18, and 27 microns (OCT); 22, 40, and 17 microns (SLP-FCC); and 6, 12, and 12 microns (SLP-VCC), respectively. CONCLUSIONS: This case demonstrates that digital imaging of the peripapillary RNFL is capable of documentation and measurement of progressive glaucomatous RNFL atrophy. AN - WOS:000242671100023 AU - Sehi, M. AU - Greenfield, D. S. DA - DEC DO - 10.1016/j.ajo.2006.07.043 IS - 6 PY - 2006 SN - 0002-9394 SP - 1056-1059 ST - Assessment of retinal nerve fiber layer using optical coherence tomography and scanning laser polarimetry in progressive glaucomatous optic neuropathy T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Assessment of retinal nerve fiber layer using optical coherence tomography and scanning laser polarimetry in progressive glaucomatous optic neuropathy VL - 142 ID - 6237 ER - TY - JOUR AB - Besides routine postoperative follow-up the prophylaxis of complications in penetrating keratoplasty (PKP) includes special preoperative and intraoperative aspects. Preoperative prophylaxis consists of the therapy of systemic diseases and eyelid abnormalities, determining individual optimal graft size, avoiding PKP in cases of uncontrolled intraocular pressure, avoiding PKP in cases of corneal hydrops, pretreatment of vascularized cornea, amniotic membrane transplantation before PKP in cases of ulcerative keratitis, quality controlled organ-cultured transplants and preoperative counselling by the surgeon to ensure patient compliance. Intraoperative prophylaxis consists of controlled arterial hypotension and complete relaxation during general anesthesia, avoidance of decentration, horizontal torsion and vertical tilt using a non-contact trephination technique (preferably excimer laser) with double-running cross-stitch sutures and application of Flieringa rings in aphakic vitrectomized eyes. Postoperatively, periodical control examinations using fluorescein and blue light are indispensable. All loose sutures have to be removed as early as possible. In cases of herpetic eye disease 2 x 400 mg of oral acyclovir should be administered for at least 1 year. In cases of therapy-resistant epithelial defects 100 % autologous serum eyedrops or amniotic membrane patches are valid options. Immune reactions must be diagnosed and treated immediately with high doses of corticosteroids. AN - WOS:000322014000002 AU - Seitz, B. AU - El-Husseiny, M. AU - Langenbucher, A. AU - Szentmary, N. DA - JUL DO - 10.1007/s00347-012-2678-9 IS - 7 PY - 2013 SN - 0941-293X SP - 605-613 ST - Prophylaxis and management of complications in penetrating keratoplasty T2 - OPHTHALMOLOGE TI - Prophylaxis and management of complications in penetrating keratoplasty VL - 110 ID - 6127 ER - TY - JOUR AB - Purpose: To evaluate the safety and efficacy of preservative-free (PF) latanoprost in glaucoma patients. Methods: In this prospective, open-label, observational study, a total of 27 primary open-Angle glaucoma patients who used benzalkonium chloride-preserved prostaglandin analogues for at least 6 months were enrolled. After changing the eye drops to PF lataprost, the intraocular pressure (IOP) and ocular surface symptoms and signs were evaluated in all patients on days 0 (first visit, D0), 45 (D45), and 90 (D90). Results: Mean IOP remained stable during the study period (14.0 ± 2.4 mmHg at D0, 13.9 ± 2.0 mmHg at D45, 13.7 ± 2.2 mmHg at D90; p = 0.603). Mean deviation, pattern standard deviation, and best-corrected visual acuity were similar before and after eye drops replacement. Bulbar conjunctival hyperemia, corneal staining, and conjunctival staining were significantly decreased over 90 days (p = 0.025, p 0.001, p = 0.020, respectively). The ocular surface disease index score showed a statistically significant improvement from 26.4 ± 18.5 at D0 to 19.8 ± 17.0 at D45 and 15.7 ± 15.6 at D90 (p 0.001). In the evaluation of ocular tolerability, burning symptoms and dryness were significantly decreased (p = 0.001, p = 0.040). Conclusions: The effects of PF latanoprost on reducing IOP were comparable with those of benzalkonium chloride-preserved prostaglandin analogues, but side effects on the ocular surface were much less pronounced when PF latanoprost was used. With this efficacy, PF latanoprost could slow the progression of glaucoma by increasing patient compliance. © 2021 Korean Ophthalmological Society (KOS). All rights reserved. AD - Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea Department of Ophthalmology, National Health Insurance Service Ilsan Hospital, Goyang, South Korea Siloam Eye Hospital, Seoul, South Korea AU - Seong, H. J. AU - Lee, K. AU - Lee, S. J. AU - Kim, S. AU - Park, J. W. DB - Scopus DO - 10.3341/KJO.2021.0010 IS - 3 KW - Glaucoma Pharmaceutical preservatives Synthetic prostaglandins M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 235-241 ST - Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-Angle Glaucoma T2 - Korean Journal of Ophthalmology TI - Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-Angle Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108710972&doi=10.3341%2fKJO.2021.0010&partnerID=40&md5=1150435eaa8f9cc0073ee94df56991e5 VL - 35 ID - 5656 ER - TY - JOUR AB - BACKGROUND: Glaucoma is a collection of eye diseases that damage the eye's optic nerve resulting in vision loss and blindness. Treatment for glaucoma is primarily pharmacologic; however, studies have shown patients have difficulty adhering to topical regimens. The reasons for potentially poor adherence are numerous, including influence from a myriad of either physical or mental comorbid conditions faced by many glaucoma patients. Neither adherence nor associated outcomes have been estimated in these 2 groups of glaucoma patients. OBJECTIVES: To (a) characterize glaucoma patients with and without select physical or mental comorbidities and (b) estimate differences between the 2 groups for 3 types of outcomes: health care resource use (HCRU; office-based/outpatient-based provider visits, emergency room visits, inpatient stays, home health provider days, prescription fills); health care expenditures; and health-related quality of life (HRQoL) as measured by the physical and mental component scores of the Short Form-12. METHODS: We used first-year data from each glaucoma patient's 2-year panel survey in the Medical Expenditure Panel Survey (MEPS) database, 2003-2014. Two groups were created using ICD-9-CM codes collected by MEPS to compare glaucoma patients with and without at least 1 selected physical or mental comorbid condition. Between-group comparisons in the outcomes of interest (HCRU, expenditure, HRQoL) were estimated using multivariable regression analyses while adjusting for socio-demographic and clinical characteristics at baseline. RESULTS: We identified 2,928 unique glaucoma patients during the 11 years of collected data, including 1,539 (53%) who had at least 1 physical or mental comorbid condition of interest. Comparing those with at least 1 select physical or mental comorbidity to those without (n=1,389), unadjusted HCRU and expenditures were greater in patients with a physical or mental comorbidity (all P<0.05). After adjustment, significant associations with increased HCRU remained for office-based provider visits and home health provider days (each P<0.01). Average total expenditures were $12,324 in those with comorbidities and $8,590 for those without. HRQoL (unadjusted and adjusted) was lower in those with a physical or mental comorbid condition (all P<0.05). CONCLUSIONS: Some differences in HCRU and expenditures were accounted for by differences in baseline characteristics between those with and those without 1 or more physical or mental comorbid conditions, but differences remained after adjustment. Results suggest that glaucoma patients with physical and mental comorbidities may experience greater HCRU and associated expenditures, and lower HRQoL, when compared with glaucoma patients without these comorbidities With this knowledge, future work may include estimating the effect of the number of these comorbid conditions on each of the 3 types of outcomes. AD - B. Devine, CHOICE Institute, University of Washington Department of Pharmacy, Box 357630, Seattle, WA, United States AU - Serbin, M. AU - Devine, B. AU - Campbell, J. AU - Basu, A. DB - Embase Medline DO - 10.18553/jmcp.2020.26.3.325 IS - 3 KW - prescription drug adolescent adult aged article child comorbidity controlled study cross-sectional study disease burden emergency ward female glaucoma health care health care cost health care utilization human ICD-9-CM major clinical study male prescription quality of life Short Form 12 LA - English M3 - Article N1 - L631373027 2020-04-07 2020-04-10 PY - 2020 SN - 2376-1032 2376-0540 SP - 325-331B ST - Assessing health care burden in glaucoma patients with and without physical or mental comorbidities T2 - Journal of Managed Care and Specialty Pharmacy TI - Assessing health care burden in glaucoma patients with and without physical or mental comorbidities UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631373027&from=export http://dx.doi.org/10.18553/jmcp.2020.26.3.325 VL - 26 ID - 2431 ER - TY - JOUR AB - BACKGROUND: Glaucoma is a collection of eye diseases that damage the eye's optic nerve resulting in vision loss and blindness. Treatment for glaucoma is primarily pharmacologic; however, studies have shown patients have difficulty adhering to topical regimens. The reasons for potentially poor adherence are numerous, including influence from a myriad of either physical or mental comorbid conditions faced by many glaucoma patients. Neither adherence nor associated outcomes have been estimated in these 2 groups of glaucoma patients. OBJECTIVES: To (a) characterize glaucoma patients with and without select physical or mental comorbidities and (b) estimate differences between the 2 groups for 3 types of outcomes: health care resource use (HCRU; office-based/outpatient-based provider visits, emergency room visits, inpatient stays, home health provider days, prescription fills); health care expenditures; and health-related quality of life (HRQoL) as measured by the physical and mental component scores of the Short Form-12. METHODS: We used first-year data from each glaucoma patient's 2-year panel survey in the Medical Expenditure Panel Survey (MEPS) database, 2003-2014. Two groups were created using ICD-9-CM codes collected by MEPS to compare glaucoma patients with and without at least 1 selected physical or mental comorbid condition. Between-group comparisons in the outcomes of interest (HCRU, expenditure, HRQoL) were estimated using multivariable regression analyses while adjusting for socio-demographic and clinical characteristics at baseline. RESULTS: We identified 2,928 unique glaucoma patients during the 11 years of collected data, including 1,539 (53%) who had at least 1 physical or mental comorbid condition of interest. Comparing those with at least 1 select physical or mental comorbidity to those without (n=1,389), unadjusted HCRU and expenditures were greater in patients with a physical or mental comorbidity (all P<0.05). After adjustment, significant associations with increased HCRU remained for office-based provider visits and home health provider days (each P<0.01). Average total expenditures were $12,324 in those with comorbidities and $8,590 for those without. HRQoL (unadjusted and adjusted) was lower in those with a physical or mental comorbid condition (all P<0.05). CONCLUSIONS: Some differences in HCRU and expenditures were accounted for by differences in baseline characteristics between those with and those without 1 or more physical or mental comorbid conditions, but differences remained after adjustment. Results suggest that glaucoma patients with physical and mental comorbidities may experience greater HCRU and associated expenditures, and lower HRQoL, when compared with glaucoma patients without these comorbidities With this knowledge, future work may include estimating the effect of the number of these comorbid conditions on each of the 3 types of outcomes. Copyright © 2020, Academy of Managed Care Pharmacy. All rights reserved. AD - Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, Departments of Health Services and Economics, University of Washington, Seattle, United States Allergan, Irvine, CA, United States Neurocrine Biosciences, San Diego, CA, United States AU - Serbin, M. AU - Devine, B. AU - Campbell, J. AU - Basu, A. DB - Scopus DO - 10.18553/jmcp.2020.26.3.325 IS - 3 M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - 325-331B ST - Assessing health care burden in glaucoma patients with and without physical or mental comorbidities T2 - Journal of Managed Care and Specialty Pharmacy TI - Assessing health care burden in glaucoma patients with and without physical or mental comorbidities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080828953&doi=10.18553%2fjmcp.2020.26.3.325&partnerID=40&md5=84285f50b45d6d41af4ee0cf37a37ed5 VL - 26 ID - 5607 ER - TY - JOUR AB - BACKGROUND: Glaucoma is a collection of eye diseases that damage the eye's optic nerve resulting in vision loss and blindness. Treatment for glaucoma is primarily pharmacologic; however, studies have shown patients have difficulty adhering to topical regimens. The reasons for potentially poor adherence are numerous, including influence from a myriad of either physical or mental comorbid conditions faced by many glaucoma patients. Neither adherence nor associated outcomes have been estimated in these 2 groups of glaucoma patients. OBJECTIVES: To (a) characterize glaucoma patients with and without select physical or mental comorbidities and (b) estimate differences between the 2 groups for 3 types of outcomes: health care resource use (HCRU; office-based/outpatient-based provider visits, emergency room visits, inpatient stays, home health provider days, prescription fills); health care expenditures; and health-related quality of life (HRGIoL) as measured by the physical and mental component scores of the Short Form-12. METHODS: We used first-year data from each glaucoma patient's 2-year panel survey in the Medical Expenditure Panel Survey (MEPS) database, 2003-2014. Two groups were created using ICD-9-CM codes collected by MEPS to compare glaucoma patients with and without at least 1 selected physical or mental comorbid condition. Between-group comparisons in the outcomes of interest (HCRU, expenditure, HROoL) were estimated using multivariable regression analyses while adjusting for socio-demographic and clinical characteristics at baseline. RESULTS: We identified 2,928 unique glaucoma patients during the 11 years of collected data, including 1,539 (53%) who had at least 1 physical or mental comorbid condition of interest. Comparing those with at least 1 select physical or mental comorbidity to those without (n =1,389), unadjusted HCRU and expenditures were greater in patients with a physical or mental comorbidity (all P < 0.05). After adjustment, significant associations with increased HCRU remained for office-based provider visits and home health provider days (each P < 0.01). Average total expenditures were $12,324 in those with comorbidities and $8,590 for those without. HRQoL (unadjusted and adjusted) was lower in those with a physical or mental comorbid condition (all P < 0.05). CONCLUSIONS: Some differences in HCRU and expenditures were accounted for by differences in baseline characteristics between those with and those without 1 or more physical or mental comorbid conditions, but differences remained after adjustment. Results suggest that glaucoma patients with physical and mental comorbidities may experience greater HCRU and associated expenditures, and lower HROoL, when compared with glaucoma patients without these comorbidities With this knowledge, future work may include estimating the effect of the number of these comorbid conditions on each of the 3 types of outcomes. Copyright (C) 2020, Academy of Managed Care Pharmacy. All rights reserved. AN - WOS:000518154200015 AU - Serbin, M. AU - Devine, B. AU - Campbell, J. AU - Basu, A. DA - MAR DO - 10.18553/jmcp.2020.26.3.325 IS - 3 PY - 2020 SN - 2376-0540 2376-1032 SP - 325-331b ST - Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities T2 - JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY TI - Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities VL - 26 ID - 6176 ER - TY - JOUR AB - Glaucoma affects millions of people around the world. With the baby boom generation aging, the number of people affected by primary open-angle glaucoma in the US is expected to reach 3.3 million by 2020, and about half may not know they have the disease. The treatment of most forms of glaucoma includes the use of topical agents that enhance aqueous humour outflow, reduce aqueous production, or both. Topical intraocular pressure-lowering drugs must penetrate across the tissues of the eye to reach their therapeutic targets. Often, these tissues show the first signs and symptoms of drug toxicity and adverse effects. These include eyelid dermatitis, malpositions, lacrimal system scarring, ocular discomfort upon instillation, tear film instability, conjunctival inflammation, subconjunctival fibrosis, conjunctival epithelium changes, and corneal surface and endothelial impairment. For these reasons, ophthalmologists should evaluate the risks and benefits of ophthalmic medications before initiating therapy, identify the minimum dosages necessary to achieve a therapeutic benefit, and monitor patients for local and systemic adverse effects. Adverse events may be reduced by changing to a different class of topical medication, using corticosteroids, lubricating the eyes frequently, and reducing exposure to preservatives. This in turn can lead to higher levels of adherence to antiglaucoma therapy, improved outcomes and a reduction in the costs associated with long-term glaucoma complications. This article reviews the ocular adverse effects associated with the various classes of topical antiglaucoma drugs, with a particular focus on the ocular surface, eyelids and periorbital tissue. AD - William Beaumont Eye Institute/Consultants in Ophthalmic and Facial Plastic Surgery, Royal Oak, Michigan, USA. Vantage Eye Center, Monterey, California, USA. AN - 104713651. Language: English. Entry Date: 20110622. Revision Date: 20200708. Publication Type: Journal Article AU - Servat, J. Javier AU - Bernardino, C. Robert DB - ccm DO - 10.2165/11588830-000000000-00000 DP - EBSCOhost IS - 4 KW - Administration, Topical Glaucoma -- Drug Therapy Eyelids -- Drug Effects Eye -- Anatomy and Histology Human PubMed Medline Receptors, Adrenergic, Beta -- Antagonists and Inhibitors Lacrimal Apparatus -- Drug Effects Receptors, Adrenergic, Alpha N1 - research; systematic review. Journal Subset: Australia & New Zealand; Biomedical; Peer Reviewed. NLM UID: 9102074. PMID: NLM21428462. PY - 2011 SN - 1170-229X SP - 267-282 ST - Effects of Common Topical Antiglaucoma Medications on the Ocular Surface, Eyelids and Periorbital Tissue T2 - Drugs & Aging TI - Effects of Common Topical Antiglaucoma Medications on the Ocular Surface, Eyelids and Periorbital Tissue UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104713651&site=ehost-live&scope=site VL - 28 ID - 4337 ER - TY - JOUR AB - BACKGROUND - Although most randomized trials and meta-analyses suggest a slight or no increase in the risk of cancer in statin users, results from observational studies have been conflicting, and some have even suggested a large protective effect of statins on certain cancers. Long-term statin users tend to be healthier, less frail, and more adherent to therapy than nonusers, however. This could explain such apparent "protective" effects. METHODS AND RESULTS - We conducted the present cohort study by linking data from a large state drug benefit program with cancer registry data and Medicare healthcare utilization data. We identified all initiators of statins; initiators of glaucoma medications, another preventive drug, served as a comparison group. Outcomes included all registry-identified cases of colorectal, lung, and breast cancer. Multivariable Cox proportional models were used to adjust for confounding. Patient characteristics were similar in both groups, but statin initiators (n=24 439) were slightly younger and used some services more frequently than glaucoma drug initiators (n=7284). The mean follow-up was 2.9 years, with the longest follow-up being 8.4 years. Incidence rates of colorectal, lung, and breast cancers in both groups were very similar to rates in the general population. Adjusted hazard ratios were 0.96 (95% CI, 0.70 to 1.31) for colorectal cancer, 1.11 (95% CI, 0.77 to 1.60) for lung cancer, and 0.99 (95% CI, 0.74 to 1.33) for breast cancer. CONCLUSIONS - These data from a large population of typical older patients who began using statins indicate that it is unlikely that statins confer a clinically important decrease or increase in the risk of colorectal, lung, or breast cancer over the durations studied. © 2007 American Heart Association, Inc. AD - S. Setoguchi, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont St, Boston, MA 02130, United States AU - Setoguchi, S. AU - Glynn, R. J. AU - Avorn, J. AU - Mogun, H. AU - Schneeweiss, S. C1 - aspirin DB - Embase Medline DO - 10.1161/CIRCULATIONAHA.106.650176 IS - 1 KW - acetylsalicylic acid antiglaucoma agent atorvastatin estrogen fluindostatin hydroxymethylglutaryl coenzyme A reductase inhibitor mevinolin nonsteroid antiinflammatory agent pravastatin simvastatin aged aging article breast cancer cancer incidence cancer prevention cancer registry cancer risk cohort analysis colorectal cancer comparative study confidence interval control group controlled study drug effect female follow up glaucoma groups by age hazard ratio health care utilization human lung cancer major clinical study male medicare multivariate analysis priority journal proportional hazards model side effect aspirin LA - English M3 - Article N1 - L46058608 2007-01-29 PY - 2007 SN - 0009-7322 SP - 27-33 ST - Statins and the risk of lung, breast, and colorectal cancer in the elderly T2 - Circulation TI - Statins and the risk of lung, breast, and colorectal cancer in the elderly UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46058608&from=export http://dx.doi.org/10.1161/CIRCULATIONAHA.106.650176 VL - 115 ID - 3552 ER - TY - JOUR AB - BACKGROUND: Although most randomized trials and meta-analyses suggest a slight or no increase in the risk of cancer in statin users, results from observational studies have been conflicting, and some have even suggested a large protective effect of statins on certain cancers. Long-term statin users tend to be healthier, less frail, and more adherent to therapy than nonusers, however. This could explain such apparent 'protective' effects. METHODS AND RESULTS: We conducted the present cohort study by linking data from a large state drug benefit program with cancer registry data and Medicare healthcare utilization data. We identified all initiators of statins; initiators of glaucoma medications, another preventive drug, served as a comparison group. Outcomes included all registry-identified cases of colorectal, lung, and breast cancer. Multivariable Cox proportional models were used to adjust for confounding. Patient characteristics were similar in both groups, but statin initiators (n=24,439) were slightly younger and used some services more frequently than glaucoma drug initiators (n=7284). The mean follow-up was 2.9 years, with the longest follow-up being 8.4 years. Incidence rates of colorectal, lung, and breast cancers in both groups were very similar to rates in the general population. Adjusted hazard ratios were 0.96 (95% CI, 0.70 to 1.31) for colorectal cancer, 1.11 (95% CI, 0.77 to 1.60) for lung cancer, and 0.99 (95% CI, 0.74 to 1.33) for breast cancer. CONCLUSIONS: These data from a large population of typical older patients who began using statins indicate that it is unlikely that statins confer a clinically important decrease or increase in the risk of colorectal, lung, or breast cancer over the durations studied. AD - Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02130, USA. ssetoguchi@partners.org AN - 106162162. Language: English. Entry Date: 20071005. Revision Date: 20150711. Publication Type: Journal Article AU - Setoguchi, S. AU - Glynn, R. J. AU - Avorn, J. AU - Mogun, H. AU - Schneeweiss, S. DB - ccm DP - EBSCOhost IS - 1 KW - Antilipemic Agents -- Adverse Effects Breast Neoplasms -- Epidemiology Colorectal Neoplasms -- Epidemiology Lung Neoplasms -- Epidemiology Aged Aged, 80 and Over Breast Neoplasms -- Chemically Induced Colorectal Neoplasms -- Chemically Induced Comparative Studies Confidence Intervals Female Lung Neoplasms -- Chemically Induced Male Medicare Prospective Studies Registries, Disease Risk Factors Human N1 - research; tables/charts. Commentary: Rubenfire M. [Commentary on] Statins and the risk of lung, breast, and colorectal cancer in the elderly. (ACC CARDIOSOURCE REV J) 2007 Mar; 16 (3): 18-18. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 0147763. PMID: NLM17179016. PY - 2007 SN - 0009-7322 SP - 27-33 ST - Statins and the risk of lung, breast, and colorectal cancer in the elderly T2 - Circulation TI - Statins and the risk of lung, breast, and colorectal cancer in the elderly UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106162162&site=ehost-live&scope=site VL - 115 ID - 4588 ER - TY - JOUR AB - BACKGROUND - Although most randomized trials and meta-analyses suggest a slight or no increase in the risk of cancer in statin users, results from observational studies have been conflicting, and some have even suggested a large protective effect of statins on certain cancers. Long-term statin users tend to be healthier, less frail, and more adherent to therapy than nonusers, however. This could explain such apparent "protective" effects. METHODS AND RESULTS - We conducted the present cohort study by linking data from a large state drug benefit program with cancer registry data and Medicare healthcare utilization data. We identified all initiators of statins; initiators of glaucoma medications, another preventive drug, served as a comparison group. Outcomes included all registry-identified cases of colorectal, lung, and breast cancer. Multivariable Cox proportional models were used to adjust for confounding. Patient characteristics were similar in both groups, but statin initiators (n=24 439) were slightly younger and used some services more frequently than glaucoma drug initiators (n=7284). The mean follow-up was 2.9 years, with the longest follow-up being 8.4 years. Incidence rates of colorectal, lung, and breast cancers in both groups were very similar to rates in the general population. Adjusted hazard ratios were 0.96 (95% CI, 0.70 to 1.31) for colorectal cancer, 1.11 (95% CI, 0.77 to 1.60) for lung cancer, and 0.99 (95% CI, 0.74 to 1.33) for breast cancer. CONCLUSIONS - These data from a large population of typical older patients who began using statins indicate that it is unlikely that statins confer a clinically important decrease or increase in the risk of colorectal, lung, or breast cancer over the durations studied. © 2007 American Heart Association, Inc. AD - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont St, Boston, MA 02130, United States AU - Setoguchi, S. AU - Glynn, R. J. AU - Avorn, J. AU - Mogun, H. AU - Schneeweiss, S. DB - Scopus DO - 10.1161/CIRCULATIONAHA.106.650176 IS - 1 KW - Age Cancer Morbidity Statins M3 - Article N1 - Cited By :121 Export Date: 19 July 2021 PY - 2007 SP - 27-33 ST - Statins and the risk of lung, breast, and colorectal cancer in the elderly T2 - Circulation TI - Statins and the risk of lung, breast, and colorectal cancer in the elderly UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846111227&doi=10.1161%2fCIRCULATIONAHA.106.650176&partnerID=40&md5=e71a5d27561901f7ff9afb0d39457115 VL - 115 ID - 4920 ER - TY - JOUR AB - Background - Although most randomized trials and meta-analyses suggest a slight or no increase in the risk of cancer in statin users, results from observational studies have been conflicting, and some have even suggested a large protective effect of statins on certain cancers. Long-term statin users tend to be healthier, less frail, and more adherent to therapy than nonusers, however. This could explain such apparent "protective" effects. Methods and Results - We conducted the present cohort study by linking data from a large state drug benefit program with cancer registry data and Medicare healthcare utilization data. We identified all initiators of statins; initiators of glaucoma medications, another preventive drug, served as a comparison group. Outcomes included all registry-identified cases of colorectal, lung, and breast cancer. Multivariable Cox proportional models were used to adjust for confounding. Patient characteristics were similar in both groups, but statin initiators (n = 24 439) were slightly younger and used some services more frequently than glaucoma drug initiators (n = 7284). The mean follow-up was 2.9 years, with the longest follow- up being 8.4 years. Incidence rates of colorectal, lung, and breast cancers in both groups were very similar to rates in the general population. Adjusted hazard ratios were 0.96 (95% CI, 0.70 to 1.31) for colorectal cancer, 1.11 (95% CI, 0.77 to 1.60) for lung cancer, and 0.99 (95% CI, 0.74 to 1.33) for breast cancer. Conclusions - These data from a large population of typical older patients who began using statins indicate that it is unlikely that statins confer a clinically important decrease or increase in the risk of colorectal, lung, or breast cancer over the durations studied. AN - WOS:000243522400007 AU - Setoguchi, S. AU - Glynn, R. J. AU - Avorn, J. AU - Mogun, H. AU - Schneeweiss, S. DA - JAN 2 DO - 10.1161/CIRCULATIONAHA.106.650176 IS - 1 PY - 2007 SN - 0009-7322 1524-4539 SP - 27-33 ST - Statins and the risk of lung, breast, and colorectal cancer in the elderly T2 - CIRCULATION TI - Statins and the risk of lung, breast, and colorectal cancer in the elderly VL - 115 ID - 6238 ER - TY - JOUR AB - Due to the rapidly increasing life-expectancy, the prevalence of glaucoma has increased steadily in recent years. We aimed to evaluate the patterns of care and primary treatment strategy patterns in Korea according to glaucoma subtypes to assess the quality of care for glaucoma patients.In this serial cross-sectional survey, the claims data from the Korean National Health Insurance Service was used to identify and group glaucoma patients into primary open-angle glaucoma (POAG), primary angle-closure glaucoma (PACG), other types of glaucoma, and ocular hypertension from 2002 to 2013. Records for outpatient visits, hospitalizations, drug prescriptions, admissions, and surgical interventions were used to determine the patterns of care and identify primary treatment strategies.Both the prevalence (0.11% in 2002 to 0.43% in 2013) and incidence rates (0.06% in 2003 to 0.11% in 2013) for glaucoma increased over time. The mean number of outpatient visits increased (4.9-6.0 visits per year), while the proportion of hospitalized patients (2.3-1.0% of patients) and duration of hospital stay (4.5-3.4 days among hospitalized patients) decreased between 2002 and 2013 for patients with POAG. The proportion of patients not being managed by medication or surgery decreased, with POAG and PACG patients receiving medications increasing from 70.9% and 59.2% in 2002 to 88.4% and 63.3% in 2013, respectively. Finally, while the proportion of trabeculectomy decreased (22.2% to 10.0% of surgical procedures in 2002 and 2013, respectively), more patients with PACG have received iridectomy (59.3% to 86.0% of surgical procedures in 2002 and 2013, respectively).Between 2002 and 2013, the pattern of care for both patients with POAG and PACG has shifted toward management by outpatient visits and intervention with anti-glaucoma medications in Korea. AD - Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea. Division of Vitreous and Retina, Department of Ophthalmology, St Vincent's Hospital, College of Medicine, Catholic University of Korea, Suwon, Republic of Korea. Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Department of Biomedical Sciences, Seoul National University Graduate School, Seoul Division of Vitreous and Retina, Department of Ophthalmology, St Vincent's Hospital, College of Medicine, Catholic University of Korea, Suwon Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea AN - 132185935. Language: English. Entry Date: 20181009. Revision Date: 20210113. Publication Type: journal article. Journal Subset: Biomedical AU - Seulggie, Choi AU - Jin, A. Choi AU - Jin Woo, Kwon AU - Sang Min, Park AU - Donghyun, Jee AU - Choi, Seulggie AU - Choi, Jin A. AU - Kwon, Jin Woo AU - Park, Sang Min AU - Jee, Donghyun DB - ccm DO - 10.1097/MD.0000000000012357 DP - EBSCOhost IS - 38 KW - Glaucoma -- Epidemiology Glaucoma, Angle-Closure -- Epidemiology Trabeculectomy -- Trends Hospitalization -- Trends Office Visits -- Trends Infant Child, Preschool Child Infant, Newborn South Korea Female Aged, 80 and Over Cross Sectional Studies Glaucoma -- Therapy Insurance, Health -- Statistics and Numerical Data Aged Adolescence Prevalence Male Adult Young Adult National Health Programs -- Statistics and Numerical Data Glaucoma, Angle-Closure -- Therapy Incidence Middle Age Ferrans and Powers Quality of Life Index N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Longitudinal Interval Follow-Up Evaluation (LIFE); Ferrans and Powers Quality of Life Index. NLM UID: 2985248R. PMID: NLM30235694. PY - 2018 SN - 0025-7974 SP - 1-9 ST - Patterns of care for glaucoma patients in Korea from 2002 to 2013 using the national health insurance service claims data T2 - Medicine TI - Patterns of care for glaucoma patients in Korea from 2002 to 2013 using the national health insurance service claims data UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132185935&site=ehost-live&scope=site VL - 97 ID - 4226 ER - TY - JOUR AB - Objective: To describe the clinical findings of a patient with tyrosinemia type I with noncompliance to a protein-restricted diet, treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). Methods: Clinical findings at the initial examination and after strict compliance to a protein-restricted diet after 4 weeks follow-up are described in a patient with tyrosinemia type I on NTBC treatment, who had been treated with presumed herpetic keratitis. Results: A 10-year-old girl diagnosed with hereditary tyrosinemia type I and on NTBC treatment presented with photophobia and ocular discomfort in both eyes. An ophthalmologic examination demonstrated bilateral dendritiform epithelial lesions in the central cornea, staining faintly with fluorescein. These lesions were subsequently intermittently treated with topical antivirals for presumed herpes simplex virus keratitis and lubricant eye drops for 9 months without resolution; however, when strict compliance with a protein-restricted diet was instituted, nearly a complete resolution of the lesions was noted at the 4-week follow-up. Conclusions: Although type II tyrosinemia is known to have corneal involvement, the natural course of tyrosinemia type I has not been shown to have corneal involvement. Corneal involvement in type I tyrosinemia may be an indicator of dietary noncompliance and may show complete resolution with a strict compliance to protein-restricted diet only. © Copyright 2017 Contact Lens Association of Opthalmologists, Inc. AD - Department of Ophthalmology, Erciyes University School of Medicine, Kayseri, 38039, Turkey Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX, United States AU - Sevim, D. G. AU - Gumus, K. AU - Cavanagh, H. D. DB - Scopus DO - 10.1097/ICL.0000000000000187 IS - 3 KW - Corneal crystals NTBC Pseudodendrite Tyrosinemia type I M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2017 SP - e7-e9 ST - Corneal pseudodendritic lesions masquerading as herpetic keratitis in a patient with tyrosinemia type I T2 - Eye and Contact Lens TI - Corneal pseudodendritic lesions masquerading as herpetic keratitis in a patient with tyrosinemia type I UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018243208&doi=10.1097%2fICL.0000000000000187&partnerID=40&md5=899e3f6d192038d3a7aa8c9656ee96ae VL - 43 ID - 5414 ER - TY - JOUR AB - Objective: To describe the clinical findings of a patient with tyrosinemia type I with noncompliance to a protein-restricted diet, treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). Methods: Clinical findings at the initial examination and after strict compliance to a protein-restricted diet after 4 weeks follow-up are described in a patient with tyrosinemia type I on NTBC treatment, who had been treated with presumed herpetic keratitis. Results: A 10-year-old girl diagnosed with hereditary tyrosinemia type I and on NTBC treatment presented with photophobia and ocular discomfort in both eyes. An ophthalmologic examination demonstrated bilateral dendritiform epithelial lesions in the central cornea, staining faintly with fluorescein. These lesions were subsequently intermittently treated with topical antivirals for presumed herpes simplex virus keratitis and lubricant eye drops for 9 months without resolution; however, when strict compliance with a protein-restricted diet was instituted, nearly a complete resolution of the lesions was noted at the 4-week follow-up. Conclusions: Although type II tyrosinemia is known to have corneal involvement, the natural course of tyrosinemia type I has not been shown to have corneal involvement. Corneal involvement in type I tyrosinemia may be an indicator of dietary noncompliance and may show complete resolution with a strict compliance to protein-restricted diet only. AN - WOS:000404146000001 AU - Sevim, D. G. AU - Gumus, K. AU - Cavanagh, H. D. DA - MAY DO - 10.1097/ICL.0000000000000187 IS - 3 PY - 2017 SN - 1542-2321 1542-233X SP - E7-E9 ST - Corneal Pseudodendritic Lesions Masquerading as Herpetic Keratitis in a Patient With Tyrosinemia Type I T2 - EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE TI - Corneal Pseudodendritic Lesions Masquerading as Herpetic Keratitis in a Patient With Tyrosinemia Type I VL - 43 ID - 6038 ER - TY - JOUR AB - Background Glaucoma in adults is a leading eye disease that causes blindness. Its management is life long and both surgical and medical treatment options are available to manage this ailment. Patients and their caregiver's cooperation in instilling timely eye drops is crucial for the effective reduction of intraocular pressure (IOP) and by halting/delaying the progression of visual disabilities due to glaucoma. Periodic assessment and strict adherence to medical treatment has been found to be less than desired. It is influenced by the severity of the disease, the duration of the ailment, the number of eye drops being used, the literacy level, and the cost of medication. We present the adherence rate of topical medications and its determinants among adult Saudi glaucoma patients getting treated in 2017 in a tertiary eye center in Saudi Arabia. Methodology This cross-sectional survey was carried out from January to March 2017 at a tertiary eye hospital in Riyadh, Saudi Arabia. To undertake a cross-sectional study, we assumed that among 1300 patients visiting the eye department of a tertiary eye hospital, the level of non-adherence to glaucoma medication would be in 27% of glaucoma patients. To achieve a 95% confidence interval and an acceptable error margin of 5% for a survey, we needed to interview at least 253 participants. Results We interviewed 263 randomly selected glaucoma patients among 1236 patients visiting the eye department of the tertiary eye hospital in Riyadh, Saudi Arabia. Two-thirds of participants were school graduates, Saudi nationals, and had undergone surgery for glaucoma in the past; perhaps only YAG laser peripheral iridotomy (PI). Less than half of the participants (43%) had less than a one-year duration of glaucoma. The client-perceived subjective adherence rate to glaucoma medication was noted in 191/263 = 72.6% (95% Confidence Interval 67.2 -78.0). Of the 263 glaucoma patients, 229 judiciously abided with their follow-up appointments with ophthalmologists. Thus, the compliance to follow-up for glaucoma treatment was 87.1% (95% CI 83.0 - 91.1). Conclusion Our study with a large sample is perhaps the first one to assess compliance with medical treatment among adult Saudi glaucoma patients. The adherence rate for topical glaucoma medication measured using the subjective method was 72% among adult glaucoma patients. Adherence with the follow-up appointment with the glaucoma specialist was as high as 87%. Adherence with medical treatment found in the present study versus the literature review suggested that despite different sets of barriers, the adherence rate in Saudi adult glaucoma patients noted in our study was high. Knowledge, beliefs, and attitude are known to affect the adherence rate. In our study, education level and relatives having glaucoma were not associated with the adherence rate. This indirectly suggests that knowledge about the use of medication in the treatment of glaucoma that is gained by patients had a limited influence on adherence in our glaucoma patients. Modes of dispersing knowledge to elderly glaucoma patients and their impact on the adherence rates of medications for glaucoma management need to be further studied. AN - WOS:000510402700002 AU - Shadid, A. AU - Alrashed, W. AU - Bin Shihah, A. AU - Alhomoud, A. AU - Alghamdi, M. AU - Alturki, A. AU - Shadid, A. AU - Osman, E. AU - Alfaris, A. AU - Khandekar, R. DA - FEB 2 DO - 10.7759/cureus.6847 IS - 2 PY - 2020 SN - 2168-8184 ST - Adherence to Medical Treatment and Its Determinants Among Adult Saudi Glaucoma Patients in Riyadh City T2 - CUREUS TI - Adherence to Medical Treatment and Its Determinants Among Adult Saudi Glaucoma Patients in Riyadh City VL - 12 ID - 5843 ER - TY - JOUR AB - Purpose: To understand demographic and socioeconomic barriers and treatment-seeking behaviors of patients with infectious keratitis requiring therapeutic penetrating keratoplasty (TPK) in a developing country.Methods: This prospective non-comparative questionnaire- based study included all patients presenting to Aravind Eye Hospital, Madurai with infectious keratitis that eventuated to TPK between November 2015 and October 2016. A structured questionnaire was administered on post-operative day 3 to collect data on the demographic details, predisposing factors, prior treatment received, and treatment expenditures.Results: In total, 227 patients underwent TPK between November 2015 and October 2016 for infectious keratitis. The majority of patients were males (n = 132, 58.1%), illiterate (n = 129, 56.8%), and had a family monthly income of less than INR 6000 (n = 142, 62.5%). Most of the patients (n = 163, 71.8%) had prior treatment with an ophthalmologist before presenting to our hospital. The mean distance travelled to reach our centre was 269.2 ± 298.5 km. The mean duration of disease before the presentation was 20.3 ± 21.1 days. Corneal smear was positive for fungus in 163 (88.1%) and Aspergillus was the most commonly isolated fungi in 55 (41.3%) cultures. The mean total cost of treatment was INR 8752.87 ± 7615.39 per patient. There was a positive correlation between the duration of the disease (rho 0.19, P = 0.0034) and the costs of treatment (rho 0.2, P = 0.0024) with the distance travelled by the patient.Conclusion: Patients who travelled a farther distance had a delayed onset of presentation and spent significantly more than their respective counterparts. AD - Department of Cornea and Refractive Services, Aravind Eye Hospital, Madurai, Tamil Nadu London School of Hygiene and Tropical Medicine, London Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA Lions Aravind Institute of Community Ophthalmology, Madurai, Tamil Nadu Francis I. Proctor Foundation, University of California-San Francisco, San Francisco, CA Department of Cornea and Refractive Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India AN - 138790956. Language: English. Entry Date: 20191111. Revision Date: 20200524. Publication Type: journal article. Journal Subset: Asia AU - Shah, Hem AU - Radhakrishnan, Naveen AU - Ramsewak, Shivaa AU - Chiu, Stephan AU - Joseph, Sanil AU - Rose-Nussbaumer, Jennifer AU - Prajna, N. AU - Prajna, N. Venkatesh DB - ccm DO - 10.4103/ijo.IJO_1821_18 DP - EBSCOhost IS - 10 KW - Eye Infections, Fungal -- Epidemiology Acanthamoeba Keratitis -- Epidemiology Patient Attitudes Corneal Ulcer -- Epidemiology Socioeconomic Factors Eye Infections, Bacterial -- Epidemiology Corneal Transplantation Male Acanthamoeba Keratitis -- Surgery Visual Acuity Eye Infections, Fungal -- Surgery Eye Infections, Bacterial -- Microbiology Graft Survival Female Corneal Ulcer -- Surgery Eye Infections, Bacterial -- Surgery Adult Corneal Ulcer -- Microbiology Acanthamoeba Keratitis Eye Infections, Fungal -- Microbiology Prospective Studies Middle Age N1 - Biomedical; Peer Reviewed. NLM UID: 0405376. PMID: NLM31546487. PY - 2019 SN - 0301-4738 SP - 1593-1598 ST - Demographic and socioeconomic barriers and treatment seeking behaviors of patients with infectious keratitis requiring therapeutic penetrating keratoplasty T2 - Indian Journal of Ophthalmology TI - Demographic and socioeconomic barriers and treatment seeking behaviors of patients with infectious keratitis requiring therapeutic penetrating keratoplasty UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138790956&site=ehost-live&scope=site VL - 67 ID - 4208 ER - TY - JOUR AB - Literature describing the trends and utilization of pediatric eye-related emergency department (ED) visits is limited. We performed a retrospective cohort study of 311 pediatric patients visiting Bascom Palmer Eye Institute (BPEI) ED between March and May 2020 to quantify the effect of the coronavirus (COVID-19) on ophthalmology care utilization. In our study, pediatric ED visits declined by half at the onset of the pandemic in March. The number of visits reached the lowest point in early April and increased to 48% of the pre-COVID volume by the end of May. Despite changes in volume, patient demographics and clinical diagnoses were relatively consistent throughout the pandemic. © 2020 American Association for Pediatric Ophthalmology and Strabismus AD - University of Miami Miller School of Medicine, Miami, FL, United States Bascom Palmer Eye Institute, Miami, FL, United States AU - Shah, K. AU - Camhi, S. S. AU - Sridhar, J. AU - Cavuoto, K. M. DB - Scopus DO - 10.1016/j.jaapos.2020.09.001 IS - 6 M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 367-369 ST - Impact of the coronavirus pandemic on pediatric eye-related emergency department services T2 - Journal of AAPOS TI - Impact of the coronavirus pandemic on pediatric eye-related emergency department services UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100678608&doi=10.1016%2fj.jaapos.2020.09.001&partnerID=40&md5=0cb857951917e1fb851448a8dd1a3530 VL - 24 ID - 5684 ER - TY - JOUR AB - Retinal ganglion cells and other central nervous system neurons fail to regenerate after injury. Understanding the obstacles to survival and regeneration, and overcoming them, is key to preserving and restoring function. While comparisons in the cellular changes seen in these non‐regenerative cells with those that do have intrinsic regenerative ability has yielded many candidate genes for regenerative therapies, complete visual recovery has not yet been achieved. Insights gained from neurodegenerative diseases, like glaucoma, underscore the importance of axonal transport of organelles, mRNA, and effector proteins in injury and disease. Targeting molecular motor networks, and their cargoes, may be necessary for realizing complete axonal regeneration and vision restoration. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Shah, Sahil H. AN - 2018-42857-001 AU - Shah, Sahil H. AU - Goldberg, Jeffrey L. DB - psyh DO - 10.1002/dneu.22630 DP - EBSCOhost IS - 10 KW - CNS regeneration axon transport optic nerve neuroprotection glaucoma Axons Animal Models N1 - Byers Eye Institute, Stanford University, Palo Alto, CA, US. Other Publishers: Wiley-Blackwell Publishing Ltd. Release Date: 20180830. Correction Date: 20181115. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Axons; Neuroprotection. Minor Descriptor: Animal Models. Classification: Neuropsychology & Neurology (2520). Population: Human (10); Animal (20). References Available: Y. Page Count: 13. Issue Publication Date: Oct, 2018. Copyright Statement: Wiley Periodicals, Inc. 2018. Sponsor: Research to Prevent Blindness. Grant: NEI R01EY026766. Recipients: No recipient indicated PY - 2018 SN - 1932-8451 1932-846X SP - 998-1010 ST - The role of axon transport in neuroprotection and regeneration T2 - Developmental Neurobiology TI - The role of axon transport in neuroprotection and regeneration UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-42857-001&site=ehost-live&scope=site sahilshah90@gmail.com VL - 78 ID - 4814 ER - TY - JOUR AB - Approximately 25% of school-aged children in the United States have vision abnormalities, most commonly refractive error that can be corrected with spectacles. Limited follow-up adherence after failed school-based vision screening led to an increase in school-based eye care programs that provide screening, eye examinations, and spectacle prescription at the school. These programs address the access barrier and often provide the first point of contact between children and eye care. Nevertheless, several lower prevalence conditions, such as amblyopia, strabismus, and glaucoma, cannot be adequately treated in the school setting, and some require frequent and long-term follow-up, necessitating referral to eye care providers in the community. We conducted a literature review and identified 10 programs that provided school-based screening, examinations, and spectacle prescription and reviewed their referral rates, criteria, mechanisms, adherence, ocular findings at referral, and long-term care plans. Most programs referred 1% to 5% of screened children. Most communicated with parents or guardians through referral letters and used various strategies to incentivize adherence. Referral adherence was 20-50% in the four programs that reported these data. School-based eye care programs rarely referred children for long-term follow-up care needs, such as updating spectacle prescriptions annually. AD - M.E. Collins, The Wilmer Eye Institute Johns Hopkins School of Medicine, 600 North Wolfe Street, Wilmer 222, Baltimore, MD, United States AU - Shakarchi, A. F. AU - Collins, M. E. DB - Embase Medline DO - 10.1016/j.survophthal.2019.04.003 IS - 6 KW - community care eye care eye examination follow up health care access health care delivery human long term care mass screening patient compliance patient referral priority journal review risk factor school United States vision test LA - English M3 - Review N1 - L2002101379 2019-06-18 2019-10-31 PY - 2019 SN - 1879-3304 0039-6257 SP - 858-867 ST - Referral to community care from school-based eye care programs in the United States T2 - Survey of Ophthalmology TI - Referral to community care from school-based eye care programs in the United States UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2002101379&from=export http://dx.doi.org/10.1016/j.survophthal.2019.04.003 VL - 64 ID - 2473 ER - TY - JOUR AB - Approximately 25% of school-aged children in the United States have vision abnormalities, most commonly refractive error that can be corrected with spectacles. Limited follow-up adherence after failed school-based vision screening led to an increase in school-based eye care programs that provide screening, eye examinations, and spectacle prescription at the school. These programs address the access barrier and often provide the first point of contact between children and eye care. Nevertheless, several lower prevalence conditions, such as amblyopia, strabismus, and glaucoma, cannot be adequately treated in the school setting, and some require frequent and long-term follow-up, necessitating referral to eye care providers in the community. We conducted a literature review and identified 10 programs that provided school-based screening, examinations, and spectacle prescription and reviewed their referral rates, criteria, mechanisms, adherence, ocular findings at referral, and long-term care plans. Most programs referred 1% to 5% of screened children. Most communicated with parents or guardians through referral letters and used various strategies to incentivize adherence. Referral adherence was 20-50% in the four programs that reported these data. School-based eye care programs rarely referred children for long-term follow-up care needs, such as updating spectacle prescriptions annually. © 2019 Elsevier Inc. AD - Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States Dana Center for Preventive Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, United States AU - Shakarchi, A. F. AU - Collins, M. E. DB - Scopus DO - 10.1016/j.survophthal.2019.04.003 IS - 6 KW - child and adolescent health mobile vision clinics school-based eye care school-based health vision screening M3 - Review N1 - Cited By :5 Export Date: 19 July 2021 PY - 2019 SP - 858-867 ST - Referral to community care from school-based eye care programs in the United States T2 - Survey of Ophthalmology TI - Referral to community care from school-based eye care programs in the United States UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067102453&doi=10.1016%2fj.survophthal.2019.04.003&partnerID=40&md5=548c51b57313fcef42a092986e9a3336 VL - 64 ID - 5401 ER - TY - JOUR AB - Approximately 25% of school-aged children in the United States have vision abnormalities, most commonly refractive error that can be corrected with spectacles. Limited follow-up adherence after failed school-based vision screening led to an increase in school-based eye care programs that provide screening, eye examinations, and spectacle prescription at the school. These programs address the access barrier and often provide the first point of contact between children and eye care. Nevertheless, several lower prevalence conditions, such as amblyopia, strabismus, and glaucoma, cannot be adequately treated in the school setting, and some require frequent and long-term follow-up, necessitating referral to eye care providers in the community. We conducted a literature review and identified 10 programs that provided school-based screening, examinations, and spectacle prescription and reviewed their referral rates, criteria, mechanisms, adherence, ocular findings at referral, and long-term care plans. Most programs referred 1% to 5% of screened children. Most communicated with parents or guardians through referral letters and used various strategies to incentivize adherence. Referral adherence was 20-50% in the four programs that reported these data. School-based eye care programs rarely referred children for long-term follow-up care needs, such as updating spectacle prescriptions annually. (C) 2019 Elsevier Inc. All rights reserved. AN - WOS:000493417900009 AU - Shakarchi, A. F. AU - Collins, M. E. DA - NOV-DEC DO - 10.1016/j.survophthal.2019.04.003 IS - 6 PY - 2019 SN - 0039-6257 1879-3304 SP - 858-867 ST - Referral to community care from school-based eye care programs in the United States T2 - SURVEY OF OPHTHALMOLOGY TI - Referral to community care from school-based eye care programs in the United States VL - 64 ID - 6083 ER - TY - JOUR AB - Introduction: Glaucoma is the leading cause of irreversible blindness worldwide. Medical therapy is the main line of treatment of open-angle glaucoma (OAG) and ocular hypertension. Despite the expansion of the glaucoma lineup with the newly approved medication classes, many barriers and issues still exist with topical therapy. Novel non-topical drug delivery may address such issues, adding more options to glaucoma pharmacotherapy. Areas Covered: This review outlines current topical therapies for glaucoma, in addition to new medications under trials. The issues with topical therapy, in general, are discussed, as well as the new non-topical drug delivery systems. The authors performed a comprehensive search for published studies on glaucoma medical therapy using the electronic database of PubMed and manual search for each medication and non-topical delivery options. The extra- and intraocular delivery methods and the new topical glaucoma medications under research are covered. Expert opinion: Medical management of glaucoma represents a challenge for both patients and clinicians. Noncompliance (e.g. difficulty with administering the eye drops), cost, side effects, and intraocular pressure fluctuation are the major problems with topical therapy. To overcome such barriers, research should continue in developing new medications and innovation of non-topical drug delivery systems. AD - R. Razeghinejad, Glaucoma Research Center, Wills Eye Hospital, Philadelphia, United States AU - Shalaby, W. S. AU - Shankar, V. AU - Razeghinejad, R. AU - Katz, L. J. C1 - de 117 ono 9054 DB - Embase Medline DO - 10.1080/14656566.2020.1795130 IS - 16 KW - biodegradable implant contact lens bimatoprost Evolute GB-401 IBI-60089 iDose implant delivery device injectable implant intravitreal implant microinjector ophthalmic drug delivery device Ophthalmic MicroPump OTX-TP punctal plug Travoprost XR adenosine receptor stimulating agent adrenalin hydrogen tartrate alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor cholinergic receptor stimulating agent eye drops oligonucleotide omidenepag isopropyl ono 9054 prostaglandin prostaglandin derivative Rho kinase inhibitor unclassified drug drug approval drug cost drug delivery system glaucoma human medication compliance nonhuman patient compliance pharmaceutical care phase 2 clinical trial (topic) phase 3 clinical trial (topic) review topical treatment de 117 Durasert DURYSTA NOVADUR LA - English M3 - Review N1 - L2005708614 2020-08-06 2021-04-13 PY - 2020 SN - 1744-7666 1465-6566 SP - 2027-2040 ST - Current and new pharmacotherapeutic approaches for glaucoma T2 - Expert Opinion on Pharmacotherapy TI - Current and new pharmacotherapeutic approaches for glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005708614&from=export http://dx.doi.org/10.1080/14656566.2020.1795130 VL - 21 ID - 2369 ER - TY - JOUR AB - Background/aims Teleophthalmology is well positioned to play a key role in screening of major chronic eye diseases. Economic evaluation of cost-effectiveness of teleophthalmology, however, is lacking. This study provides a systematic review of economic studies of teleophthalmology screening for diabetic retinopathy (DR), glaucoma and macular degeneration. Methods Structured search of electronic databases and full article review yielded 20 cost-related articles. Sixteen articles fulfilled the inclusion criteria and were retained for a narrative review: 12 on DR, 2 on glaucoma and 2 on chronic eye disease. Results Teleophthalmology for DR yielded the most cost savings when compared with traditional clinic examination. The study settings varied among urban, rural and remote settings, community, hospital and health mobile units. The most important determinant of cost-effectiveness of teleophthalmology was the prevalence of DR among patients screened, indicating an increase of cost savings with the increase of screening rates. The required patient pool size to be screened varied from 110 to 3500 patients. Other factors potentially influencing cost-effectiveness of teleophthalmology were older patient age, regular screening and full utilisation of the equipment. Teleophthalmology for glaucoma was more cost-effective compared with in-person examination. Similarly, increasing number of glaucoma patients targeted for screening yielded more cost savings. Conclusions This economic review provides supportive evidence of cost-effectiveness of teleophthalmology for DR and glaucoma screening potentially increasing screening accessibility especially for rural and remote populations. Special selection of the targeted screening population will optimise the cost-effectiveness of teleophthalmology. AD - K.F. Damji, Department of Ophthalmology and Visual Sciences, University of Alberta, Faculty of Medicine, Edmonton, AB, Canada AU - Sharafeldin, N. AU - Kawaguchi, A. AU - Sundaram, A. AU - Campbell, S. AU - Rudnisky, C. AU - Weis, E. AU - Tennant, M. T. S. AU - Damji, K. F. DB - Embase Medline DO - 10.1136/bjophthalmol-2017-311452 IS - 11 KW - age article clinical examination cost control cost effectiveness analysis diabetic retinopathy eye care glaucoma health care utilization human intermethod comparison macular degeneration prevalence priority journal rural area screening systematic review telemedicine teleophthalmology urban area LA - English M3 - Article N1 - L624635491 2018-11-02 2019-06-17 PY - 2018 SN - 1468-2079 0007-1161 SP - 1485-1491 ST - Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults T2 - British Journal of Ophthalmology TI - Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624635491&from=export http://dx.doi.org/10.1136/bjophthalmol-2017-311452 VL - 102 ID - 2565 ER - TY - JOUR AB - PURPOSE: To analyze the indications and outcomes of pediatric corneal transplantation surgery in a tertiary eye care center in the developing world. METHODS: In this longitudinal, retrospective study involving continuous cases, the records of 168 eyes of 154 children undergoing keratoplasty at a tertiary care center's specialized keratoplasty clinic during a 7-year period (1998-2004) were reviewed. The demography, etiology of opacification, visual acuity, and other findings were recorded. Intraoperative and postoperative details were reviewed. Major postoperative outcomes analyzed were visual acuity, graft survival, causes of graft failure, and follow-up duration. RESULTS: Infectious keratitis (43%) was the most common indication for keratoplasty, followed by congenital glaucoma (16.6%) and corneal trauma (11.2%). Overall 77% graft survival was seen at 36 months, and better graft outcome was associated with younger age and longer regular follow-up. Postoperatively, a best-corrected visual acuity (BCVA) > 20/200 could be achieved in only 30.1% of eyes at the last follow-up. Graft failure was seen in 18.4% of eyes, with graft infection being the most frequent cause (50%). Moreover, graft infection was the most common cause of graft failure in all age groups. CONCLUSIONS: In the developing world, infectious keratitis is the most common indication for pediatric keratoplasty and the most frequent cause of its failure. © 2007 Lippincott Williams & Wilkins, Inc. AD - Cornea and Refractive Surgery Services, Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India Centre for Eye Research Australia, University of Melbourne, East Melbourne, Vic., Australia Corneal and Cataract Surgery, Centre for Eye Research Australia, University of Melbourne, 32, Gisborne Street, East Melbourne, Vic. 3002, Australia AU - Sharma, N. AU - Prakash, G. AU - Titiyal, J. S. AU - Tandon, R. AU - Vajpayee, R. B. DB - Scopus DO - 10.1097/ICO.0b013e318074ce2e IS - 7 KW - Developing world Infectious keratitis Pediatric keratoplasty M3 - Article N1 - Cited By :40 Export Date: 19 July 2021 PY - 2007 SP - 810-813 ST - Pediatric keratoplasty in India: Indications and outcomes T2 - Cornea TI - Pediatric keratoplasty in India: Indications and outcomes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547653861&doi=10.1097%2fICO.0b013e318074ce2e&partnerID=40&md5=46db8f4a7c7454c3329cbdca4f29d0ad VL - 26 ID - 5019 ER - TY - JOUR AB - Successful management of primary open-angle glaucoma (POAG) depends heavily on patient compliance with the treatment plan. Studies have clearly shown that early treatment will slow the progress of the POAG. Despite this fact, and even when treatment plans are negotiated with the patient, patient behavior may not be conducive to conserving vision in later life. Poor compliance results from a variety of causes, including lack of understanding of the diagnosis and the progress of POAG. As POAG is a "silent" condition, unless they are aware of visual loss at the point of presentation, POAG patients need to be convinced that there is actually something wrong with them. This paper explores how health care professionals can better understand their patients' response to a diagnosis of POAG. AD - M.E. Shaw, University of Manchester, Manchester, United Kingdom AU - Shaw, M. E. DB - Medline IS - 3 KW - article female human male nursing open angle glaucoma patient care planning patient compliance LA - English M3 - Article N1 - L41569011 2006-03-15 PY - 2005 SN - 1060-135X SP - 7-9 ST - Increasing compliance with glaucoma therapy: "So, convince me I have something wrong with my eyes." T2 - Insight - Journal of the American Society of Ophthalmic Registered Nurses TI - Increasing compliance with glaucoma therapy: "So, convince me I have something wrong with my eyes." UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41569011&from=export VL - 30 ID - 3681 ER - TY - JOUR AB - Successful management of primary open-angle glaucoma (POAG) depends heavily on patient compliance with the treatment plan. Studies have clearly shown that early treatment will slow the progress of the POAG.Despite this fact, and even when treatment plans are negotiated with the patient, patient behavior may not be conducive to con-serving vision in later life. Poor compliance results from a variety of causes, including lack of understanding of the diagnosis and the progress of POAG.As POAG is a 'silent' condition, unless they are aware of visual loss at the point of presentation, POAG patients need to be convinced that there is actually something wrong with them. This paper explores how health care professionals can better understand their patients' response to a diagnosis of POAG. AD - Lecturer Practitioner, University of Manchester; Mary.e.shaw@manchester-ac.uk AN - 106384807. Language: English. Entry Date: 20060127. Revision Date: 20150820. Publication Type: Journal Article. Journal Subset: Core Nursing AU - Shaw, M. E. DB - ccm DP - EBSCOhost IS - 3 KW - Attitude to Illness Glaucoma -- Therapy Patient Compliance Patient Attitudes N1 - Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9111431. PMID: NLM16350354. PY - 2005 SN - 1060-135X SP - 7-9 ST - Increasing compliance with glaucoma therapy: 'So, convince me I have something wrong with my eyes.' T2 - Insight: The Journal of the American Society of Ophthalmic Registered Nurses TI - Increasing compliance with glaucoma therapy: 'So, convince me I have something wrong with my eyes.' UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106384807&site=ehost-live&scope=site VL - 30 ID - 4546 ER - TY - JOUR AB - Compliance with medication regimens is critical in assessing the effectiveness of treatments. As new drugs are approved for marketing and prescribed to diverse patient populations, the FDA now recommends further observational studies to continuously monitor unforeseen side effects or efficacy. More research is needed to develop valid and reliable tools to assess adherence of patients to treatment recommendations and adherence of physicians to treatment guidelines, when applicable. Information on adherence is as relevant to physicians and their patients as it is to insurers and payers, who need to implement cost-effective disease management programs. This review also has highlighted examples in the adherence literature specific to glaucoma medications and based on longitudinal survival analyses of claims data. Such results may be best complemented by primary, survey-based data collected from patients in observational studies. © 2005 Elsevier Inc. All rights reserved. AD - F.T. Shaya, Department of Pharmaceutical Health Services Research, Center on Drugs and Public Policy, University of Maryland School of Pharmacy, 515 West Lombard Street, Baltimore, MD 21201, United States AU - Shaya, F. T. DB - Embase Medline DO - 10.1016/j.ohc.2005.07.005 IS - 4 KW - beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine dorzolamide latanoprost timolol travoprost clinical practice doctor patient relationship drug cost drug efficacy drug safety drug screening drug withdrawal glaucoma human hyperemia information intraocular pressure ophthalmology patient attitude patient compliance patient monitoring priority journal review side effect LA - English M3 - Review N1 - L41728027 2005-12-29 PY - 2005 SN - 0896-1549 SP - 611-617 ST - Compliance with medicine T2 - Ophthalmology Clinics of North America TI - Compliance with medicine UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41728027&from=export http://dx.doi.org/10.1016/j.ohc.2005.07.005 VL - 18 ID - 3646 ER - TY - JOUR AB - Compliance with medication regimens is critical in assessing the effectiveness of treatments. As new drugs are approved for marketing and prescribed to diverse patient populations, the FDA now recommends further observational studies to continuously monitor unforeseen side effects or efficacy. More research is needed to develop valid and reliable tools to assess adherence of patients to treatment recommendations and adherence of patients to treatment guidelines, when applicable. Information on adherence is a relevant to physicians and their patients as it is to insurers and payers, who need to implement cost-effective disease management programs. This review also has highlighted examples in the adherence literature specific to glaucoma medications and based on longitudinal survival analyses of claims data. Such results may be best complemented by primary, survey-based data collected from patients in observational studies. Copyright © 2005 by Elsevier Inc. AD - Department of Pharmaceuticals Health Services Research, Center on Drugs and Public Policy, University of Maryland School of Pharmacy, 515 West Lombard Street, Room #256, Baltimore, MD 21201; fshaya@rx.umaryland.edu AN - 106341018. Language: English. Entry Date: 20060929. Revision Date: 20150711. Publication Type: Journal Article AU - Shaya, F. T. DB - ccm DP - EBSCOhost IS - 4 KW - Disease Management Drug Approval Medication Compliance Glaucoma United States United States Food and Drug Administration N1 - equations & formulas. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 8905383. PMID: NLM16314223. PY - 2005 SN - 0896-1549 SP - 611-617 ST - Compliance with medicine T2 - Ophthalmology Clinics of North America TI - Compliance with medicine UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106341018&site=ehost-live&scope=site VL - 18 ID - 4589 ER - TY - JOUR AB - Background: Rates of medication discontinuation reflect factors including effectiveness, tolerability, cost, and dosing frequency. Discontinuation data can be useful to physicians and health plan managers as they compare various glaucoma medications. Objective: To compare rates of discontinuation of therapy in patients initially prescribed monotherapy with a topical glaucoma medication. Methods: Members of a managed care plan who filled at least 1 prescription for latanoprost, timolol, or brimonidine during a 30-month period were eligible to participate in this study. Prescription refill records for all glaucoma agents used in the plan were extracted for the study period. Rates of discontinuation of initial glaucoma therapy were compared using Cox regression methods; Kaplan-Meier survival curves were generated. Results: A total of 72,744 prescriptions were eligible, of which 48,491 were for study drugs. Latanoprost was the most frequently dispensed therapy (accounting for 49.7% of study drugs), followed by timolol (30.6%), and brimonidine (19.6%). After inclusion and exclusion criteria were applied, 2283 patients were included in analyses. Latanoprost-treated patients were significantly less likely to discontinue medication than were those treated with timolol or brimonidine. Kaplan-Meier survival curves confirmed that latanoprost-treated patients exhibited the greatest persistency with therapy. Conclusion: In this managed care setting, rates of discontinuation in patients initially treated with latanoprost were lower than those of patients receiving comparator drugs. AU - Shaya, F. T. AU - Mullins, C. D. AU - Wong, W. AU - Cho, J. DB - Embase Medline IS - 10 SUPPL. KW - antiglaucoma agent betaxolol bimatoprost brimonidine brinzolamide carteolol dorzolamide ecothiopate iodide latanoprost levobunolol pilocarpine timolol timolol maleate travoprost unoprostone isopropyl ester adult article comparative study controlled study drug choice drug cost drug efficacy drug exposure drug tolerability drug withdrawal female glaucoma health care planning health insurance human Kaplan Meier method major clinical study male managed care manager medical decision making monotherapy patient compliance prescription priority journal regression analysis retrospective study survival rate LA - English M3 - Article N1 - L34918728 2002-09-02 PY - 2002 SN - 1088-0224 SP - S271-S277 ST - Discontinuation rates of topical glaucoma medications in a managed care population T2 - American Journal of Managed Care TI - Discontinuation rates of topical glaucoma medications in a managed care population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34918728&from=export VL - 8 ID - 3856 ER - TY - JOUR AB - PURPOSE: Glaucoma drainage devices, on rare occasions, need repositioned and the intraocular portion of the implant tube is found to be "too short" to do so. Previously, a technique was described for "extending" the tube with angiocatheter material (rather than replacing the entire apparatus), and had been performed successfully without complication for 7 years. This case describes the first known complication: trauma causing anterior chamber migration of the tube extension requiring retrieval and reconstruction of the tube extension apparatus. PATIENT AND METHODS: One eye of 1 patient (age 8) with a prior glaucoma drainage device and tube extension with angiocatheter material with elevated intraocular pressure after direct trauma to the eye from a pencil. Office examination revealed inferior corneal edema and no tube segment visible in the anterior chamber on limited examination due to age-related compliance. Gonioscopy under anesthesia revealed the tube extender in the inferior anterior chamber. The tube extender was retrieved from the anterior chamber. The glaucoma drainage device was surgically exposed and the tube extension was reconstructed, including securing the tube extension with a suture placed through the lumens of both the angiocatheter extender and the tube extension. RESULTS: The reconstructed tube extension maintained good draining function with the secured extension and no further migration of the tube extension into the anterior chamber was seen. CONCLUSIONS: Tube extension using angiocatheter material continues to be a viable, cost-effective option in difficult cases. Placing a securing suture in patients prone to eye trauma can be considered. © 2006 Lippincott Williams & Wilkins, Inc. AD - J.W. Doyle, Department of Ophthalmology, University of Florida, College of Medicine, 1600 SW Archer Road, Gainesville, FL 32610, United States AU - Sheets, C. W. AU - Ramjattan, T. K. AU - Smith, M. F. AU - Doyle, J. W. DB - Embase Medline DO - 10.1097/01.ijg.0000212272.65477.7f IS - 6 KW - anesthesia anterior eye chamber article case report clinical examination cornea edema drain eye injury glaucoma glaucoma drainage implant gonioscopy human intraocular pressure abnormality intravenous catheter male migration patient compliance priority journal school child Baerveldt LA - English M3 - Article N1 - L44760333 2006-11-30 PY - 2006 SN - 1057-0829 SP - 559-561 ST - Migration of glaucoma drainage device extender into anterior chamber after trauma T2 - Journal of Glaucoma TI - Migration of glaucoma drainage device extender into anterior chamber after trauma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44760333&from=export http://dx.doi.org/10.1097/01.ijg.0000212272.65477.7f VL - 15 ID - 3570 ER - TY - JOUR AB - Background: As a part of the Yunnan Minority Eye Studies, the purpose of this study was to determine the prevalence, barriers and visual acuity outcomes of cataract surgery in a multiethnic adult population in rural areas of southwestern China.Methods: A population-based cross-sectional survey was conducted with participants of Bai, Yi, and Han ethnicity aged ≥50 years in Yunnan. A detailed eye examination was performed. Information on the date, setting, type, and complications of cataract surgery were recorded in the examination of cataract-operated eyes.Results: Of 6546 subjects (2133 Bai ethnicity, 2208 Yi ethnicity and 2205 Han ethnicity), the prevalence of cataract surgery was 6.0%, with 4.6% in Bai, 7.0% in Yi, and 6.4% in Han ethnicity. Cataract Surgical coverage (CSC) among those with presenting visual acuity (PVA) < 20/200 in both eyes because of cataract was 53.3%, with 52.8% in Bai, 64.4% in Yi, and 45.3% in Han ethnicity. CSC was associated with Yi ethnicity, younger age, and higher education level, while unoperated cataract was associated with Han ethnicity, older age, and illiterate. The main barrier to cataract surgery was lack of awareness and knowledge, cost, and fear. Among the 525 cataract-operated eyes, PVA and best-corrected visual acuity (BCVA) of 20/63 or better was 44.5 and 67.2%, respectively, with 48.1 and 65.9% in Bai, 47.8 and 75.4% in Yi, 39.1 and 59.9% in Han ethnicity. Han ethnicity, aphakia, earlier year of surgery, lower-level surgical hospital and illiterate were associated with postoperative visual impairment defined by PVA, while Han ethnicity, aphakia, and illiterate were associated with that defined by BCVA. The principal causes of postoperative visual impairment were retinal disorders (26.8%), posterior capsule opacification (25.1%), refractive error(22.7%), and glaucoma (9.3%).Conclusions: Han ethnicity had a lower CSC and relatively poor visual outcomes compared with ethnic minorities. Further effective effort to remove barriers and provide sight restoration is warranted. AD - Department of Ophthalmology, the Fourth Affiliated Hospital of Kunming Medical University (the Second People's Hospital of Yunnan Province), Yunnan Eye Institute, Key Laboratory of Yunnan Province for the Prevention and Treatment of Ophthalmology, Kunming, 650032, People's Republic of China Department of Ophthalmology, the First Affiliated Hospital of Kunming Medical University, Kunming, China School of Public Health, Medical College of Soochow University, Suzhou, China Department of Ophthalmology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, People's Republic of China AN - 143692939. Language: English. Entry Date: In Process. Revision Date: 20201101. Publication Type: journal article. Journal Subset: Biomedical AU - Shen, Wei AU - Cun, Qing AU - Zhong, Hua AU - Pan, Chen-Wei AU - Li, Jun AU - Chen, Qin DB - ccm DO - 10.1186/s12889-020-09009-5 DP - EBSCOhost IS - 1 KW - Rural Population Cataract Extraction -- Statistics and Numerical Data Cataract -- Therapy Visual Acuity Healthcare Disparities Minority Groups -- Statistics and Numerical Data Ethnic Groups -- Statistics and Numerical Data Vision Disorders -- Etiology Aged, 80 and Over Cataract -- Epidemiology Cross Sectional Studies Refractive Errors -- Epidemiology Male China Treatment Outcomes Aged Prevalence Cataract -- Ethnology Postoperative Period Female Self Report Middle Age Eye Diseases -- Epidemiology Psychological Tests N1 - Europe; Public Health; UK & Ireland. Instrumentation: Beck Anxiety Inventory (BAI). Grant Information: 2017IC064//Expert Workstation of Yao Ke/. NLM UID: 100968562. PMID: NLM32517668. PY - 2020 SN - 1471-2458 SP - 893-893 ST - Ethnic variation in prevalence, self-reported barriers and outcome of cataract surgery in a rural population in southwestern China: the Yunnan minority eye study T2 - BMC Public Health TI - Ethnic variation in prevalence, self-reported barriers and outcome of cataract surgery in a rural population in southwestern China: the Yunnan minority eye study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143692939&site=ehost-live&scope=site VL - 20 ID - 4327 ER - TY - JOUR AB - Purpose: With the increasing use of minimally invasive surgical techniques for intraocular pressure (IOP) lowering in glaucoma patients, there is a need to examine best practices regarding the postoperative management of these patients. Corticosteroids, though effective in controlling postoperative ocular pain and inflammation, present distinct challenges in glaucoma surgery patients, as their use can be associated with IOP elevation. Loteprednol etabonate (LE) is an ocular corticosteroid designed to have an improved safety profile relative to other corticosteroids. Methods: We report here a representative selection of cases in which patients were successfully treated with LE ophthalmic gel 0.5% (LE gel) following a variety of minimally invasive glaucoma surgery (MIGS) procedures. Cases included patients undergoing various procedures including a Trabectome combined with cataract surgery; micro-stent surgery (iStent) combined with cataract surgery; supraciliary CyPass Micro-Stent placement combined with cataract surgery; Kahook Dual Blade goniotomy; and ab interno canaloplasty using the iTrack catheter. Observations: In all cases, use of LE gel during the postoperative period appeared effective and safe in reducing inflammation and controlling pain. No adverse events or IOP elevations were noted, even in those patients continuing use of LE gel past the postoperative period for longer than six months with documented follow-up. In two cases, patients with elevated IOP using either prednisolone or difluprednate postoperatively were switched to LE gel, with a subsequent reduction in IOP. Conclusions: This selection of cases involving patients undergoing MIGS suggests that LE gel may be an effective and safe option for treating postoperative inflammation and pain following such procedures with minimal to no effect on IOP or other negative sequalae. © 2019 Sheppard and Singh. AD - Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, VA, United States Department of Glaucoma, The Eye Centers of Racine & Kenosha, Racine, WI, United States AU - Sheppard, J. D. AU - Singh, I. P. DB - Scopus DO - 10.2147/OPTH.S206424 KW - Intraocular pressure Loteprednol etabonate Minimally invasive glaucoma surgery Postoperative pain and inflammation Safety M3 - Article N1 - Export Date: 19 July 2021 PY - 2019 SP - 1279-1288 ST - Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery T2 - Clinical Ophthalmology TI - Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073397147&doi=10.2147%2fOPTH.S206424&partnerID=40&md5=1329a1870cbfd9e28169c63a06958e01 VL - 13 ID - 5727 ER - TY - JOUR AB - Purpose: Supplementation with gamma-linolenic acid (GLA) and omega-3 (n-3) polyunsaturated fatty acids (PUFAs) has been found to decrease the production of disease-relevant inflammatory mediators that are implicated in the pathogenesis of chronic dry eye. This study evaluated the effect of a supplement containing both GLA and n-3 PUFAs on signs and symptoms of moderate-to-severe keratoconjunctivitis sicca in postmenopausal patients. Methods: This multicenter, double-masked placebo-controlled clinical trial enrolled 38 patients (both eyes) with tear dysfunction who were randomized to supplemental GLA + n-3 PUFAs or placebo for 6 months. Disease parameters, including Ocular Surface Disease Index, Schirmer test, tear breakup time, conjunctival fluorescein and lissamine green staining, and topographic corneal smoothness indexes (surface asymmetry index and surface regularity index), were assessed at baseline and at 4, 12, and 24 weeks. The intensity of dendritic cell CD11c integrin and HLA-DR expression was measured in conjunctival impression cytologies. Results: The Ocular Surface Disease Index score improved with supplementation and was significantly lower than placebo (21 ± 4 vs. 34 ± 5) after 24 weeks (P = 0.05, n = 19 per group). The surface asymmetry index was significantly lower in supplement-treated subjects (0.37 ± 0.03, n = 15) than placebo (0.51 ± 0.03, n = 16) at 24 weeks (P = 0.005). Placebo treatment also significantly increased HLA-DR intensity by 36% 6 9% and CD11c by 34% 6 7% when compared with supplement treatment (n = 19 per group, P = 0.001, 24 weeks). Neither treatment had any effect on tear production, tear breakup time, or corneal or conjunctival staining. Conclusions: Supplemental GLA and n-3 PUFAs for 6 months improved ocular irritation symptoms, maintained corneal surface smoothness, and inhibited conjunctival dendritic cell maturation in patients with postmenopausal keratoconjunctivitis sicca. Copyrigt © 2013 Lippincott Williams & Wilkins. AD - J.D. Sheppard Jr., Department of Ophthalmology, Eastern Virginia Medical School, 241 Corporate Blvd, Norfolk, VA 23502, United States AU - Sheppard Jr, J. D. AU - Singh, R. AU - McClellan, A. J. AU - Weikert, M. P. AU - Scoper, S. V. AU - Joly, T. J. AU - Whitley, W. O. AU - Kakkar, E. AU - Pflugfelder, S. C. DB - Embase Medline DO - 10.1097/ICO.0b013e318299549c IS - 10 KW - NCT00883649 gamma linolenic acid HLA DR antigen omega 3 fatty acid placebo adult anorexia antigen expression article clinical article constipation controlled study dendritic cell diarrhea diet supplementation disease severity double blind procedure drug withdrawal dysgeusia dyspepsia facial expression female human impression cytology infection keratoconjunctivitis sicca keratometry long term care multicenter study nausea patient compliance physical disease by body function postmenopause priority journal randomized controlled trial rash Schirmer test skin contusion slit lamp staining treatment duration visual acuity vomiting LA - English M3 - Article N1 - L52696311 2013-07-26 2013-10-30 PY - 2013 SN - 0277-3740 1536-4798 SP - 1297-1304 ST - Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: A randomized double-blind clinical trial T2 - Cornea TI - Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: A randomized double-blind clinical trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52696311&from=export http://dx.doi.org/10.1097/ICO.0b013e318299549c VL - 32 ID - 2967 ER - TY - JOUR AB - Purpose: To compare two gel-forming timolol maleate ophthalmic solutions, Timoptol XE® and Lizmon TG®, in regard to efficacy and tolerability in patients with glaucoma or ocular hypertension by means of a patient-masked prospective randomized crossover study. Subjects and Methods: A total of 37 patients with glaucoma or ocular hypertension under treatment with antiglaucoma ophthalmic solutions including 0.5% twice-daily timolol maleate participated in this study. Only timolol maleate was withdrawn and either Timoptol XE or Lizmon TG was randomly allocated. After instillation for 1 month, the other ophthalmic solution was subsequently instilled for another month. Routine ophthalmic examination including slit-lamp examination and intraocular pressure (IOP) monitoring was conducted before instillation of gel-forming ophthalmic solutions and just after completing the instillation of each ophthalmic solution. Patient questionnaire surveys were also performed just after completing the instillation of each ophthalmic solution. Results: Mean IOP, just before the withdrawal of timolol ophthalmic solution, was 16.4 ± 2.9 mm Hg. At the end of Timoptol XE or Lizmon TG instillation, mean IOPs were 16.3 ± 2.5 or 16.3 ± 3.0 mm Hg, respectively. The results of the questionnaire survey showed no significant difference between Timoptol XE and Lizmon TG in regard to all survey items. Twenty-nine patients (78.4%) preferred to use gel-forming timolol solutions rather than twice-daily timolol ophthalmic solution. The presence of concurrently used ophthalmic solutions did not effect the incidences of subjective symptoms. The incidences of objective adverse effects were not significantly different between two gel-forming timolol ophthalmic solutions. Conclusion: Both gel-forming timolol ophthalmic solutions could be good choices for glaucoma treatment. Copyright © 2003 S. Karger AG, Basel. AD - K. Kashiwagi, Department of Ophthalmology, University of Yamanashi, Faculty of Medicine, 1110 Shimokato, Tamaho Yamanashi 409-3898, Japan AU - Shibuya, T. AU - Kashiwagi, K. AU - Tsukahara, S. C1 - lizmon tg timoptol xe DB - Embase Medline DO - 10.1159/000068248 IS - 1 KW - antiglaucoma agent dipivefrine dorzolamide latanoprost lizmon tg pilocarpine timolol maleate unoprostone isopropyl ester adult aged article clinical article clinical trial conjunctiva disease conjunctival congestion controlled clinical trial controlled study drug efficacy drug instillation drug tolerability drug withdrawal eye irritation female health survey human intraocular foreign body intraocular hypertension intraocular pressure male ocular pruritus open angle glaucoma patient compliance questionnaire randomization randomized controlled trial secondary glaucoma slit lamp symptom visual impairment timoptol xe LA - English M3 - Article N1 - L36173452 2003-02-15 PY - 2003 SN - 0030-3755 SP - 31-38 ST - Comparison of efficacy and tolerability between two gel-forming timolol maleate ophthalmic solutions in patients with glaucoma or ocular hypertension T2 - Ophthalmologica TI - Comparison of efficacy and tolerability between two gel-forming timolol maleate ophthalmic solutions in patients with glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36173452&from=export http://dx.doi.org/10.1159/000068248 VL - 217 ID - 3832 ER - TY - JOUR AB - Objectives: Poor knowledge of eye health, concerns about the cost of spectacles, mistrust of optometrists and limited geographical access in socio-economically deprived areas are barriers to accessing regular eye examinations and result in low uptake and subsequent late presentation to ophthalmology clinics. Personal Medical Services (PMS) were introduced in the late 1990s to provide locally negotiated solutions to problems associated with inequalities in access to primary care. An equivalent approach to delivery of optometric services could address inequalities in the uptake of eye examinations. Study design: One-way and multiway sensitivity analyses. Methods: Variations in assumptions were included in the models for equipment and accommodation costs, uptake and length of appointments. The sensitivity analyses thresholds were cost-per-person tested below the GOS1 fee paid by the NHS and achieving break-even between income and expenditure, assuming no cross-subsidy from profits from sales of optical appliances. Results: Cost per test ranged from £24.01 to £64.80 and subsidy required varied from £14,490 to £108,046. Unused capacity utilised for local enhanced service schemes such as glaucoma referral refinement reduced the subsidy needed. Conclusions: In order to support the financial viability of primary eye care in socio-economically deprived communities, income is required from additional subsidies or from sources other than eye examinations, such as ophthalmic or other optometric community services. This would require a significant shift of activity from secondary to primary care locations. The subsidy required could also be justified by the utility gain from earlier detection of preventable sight loss. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Shickle, Darren, Academic Unit of Public Health, University of Leeds, Charles Thackrah Building, 101 Clarendon Road, Leeds, United Kingdom, LS2 9LJ AN - 2015-10021-008 AU - Shickle, Darren AU - Todkill, Daniel AU - Chisholm, Catharine AU - Rughani, Sonal AU - Griffin, Marcus AU - Cassels-Brown, Andy AU - May, Helen AU - Slade, Sarah V. AU - Davey, Christopher J. DB - psyh DO - 10.1016/j.puhe.2014.07.010 DP - EBSCOhost IS - 2 KW - Eye disorders Health services Screening Health economics Sensitivity analysis Aged Female Financing, Government Health Expenditures Health Services Accessibility Health Status Disparities Humans Income Male Middle Aged Ophthalmology Poverty Areas Primary Health Care Socioeconomic Factors State Medicine Eye (Anatomy) Health Ophthalmologic Examination Public Health Services Clinics Optometrists N1 - University of Leeds, Leeds, United Kingdom. Release Date: 20150420. Correction Date: 20200921. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Eye (Anatomy); Health; Ophthalmologic Examination; Ophthalmology; Public Health Services. Minor Descriptor: Clinics; Optometrists. Classification: Health & Mental Health Services (3370). Population: Human (10); Male (30); Female (40). Location: United Kingdom. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. Supplemental Data: Other Internet. References Available: Y. Page Count: 7. Issue Publication Date: Feb, 2015. Publication History: First Posted Date: Nov 7, 2014; Accepted Date: Jul 22, 2014; Revised Date: Jun 30, 2014; First Submitted Date: Apr 23, 2014. Copyright Statement: Published by Elsevier Ltd. All rights reserved. The Royal Society for Public Health. 2014. Sponsor: Yorkshire Eye Research, United Kingdom. Recipients: No recipient indicated Sponsor: NHS Leeds, United Kingdom. Recipients: No recipient indicated Sponsor: RNIB. Recipients: No recipient indicated PY - 2015 SN - 0033-3506 1476-5616 SP - 131-137 ST - Addressing inequalities in eye health with subsidies and increased fees for General Ophthalmic Services in socio-economically deprived communities: A sensitivity analysis T2 - Public Health TI - Addressing inequalities in eye health with subsidies and increased fees for General Ophthalmic Services in socio-economically deprived communities: A sensitivity analysis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-10021-008&site=ehost-live&scope=site ORCID: 0000-0002-9050-379X d.shickle@leeds.ac.uk VL - 129 ID - 4843 ER - TY - JOUR AB - Objectives: Poor knowledge of eye health, concerns about the cost of spectacles, mistrust of optometrists and limited geographical access in socio-economically deprived areas are barriers to accessing regular eye examinations and result in low uptake and subsequent late presentation to ophthalmology clinics. Personal Medical Services (PMS) were introduced in the late 1990s to provide locally negotiated solutions to problems associated with inequalities in access to primary care. An equivalent approach to delivery of optometric services could address inequalities in the uptake of eye examinations. Study design: One-way and multiway sensitivity analyses. Methods: Variations in assumptions were included in the models for equipment and accommodation costs, uptake and length of appointments. The sensitivity analyses thresholds were cost-per-person tested below the GOS1 fee paid by the NHS and achieving break-even between income and expenditure, assuming no cross-subsidy from profits from sales of optical appliances. Results: Cost per test ranged from £24.01 to £64.80 and subsidy required varied from £14,490 to £108,046. Unused capacity utilised for local enhanced service schemes such as glaucoma referral refinement reduced the subsidy needed. © 2014 The Royal Society for Public Health. AD - University of Leeds, United Kingdom University of Bradford, United Kingdom Royal National Institute of Blind People, United Kingdom Leeds Teaching Hospital Trust, United Kingdom AU - Shickle, D. AU - Todkill, D. AU - Chisholm, C. AU - Rughani, S. AU - Griffin, M. AU - Cassels-Brown, A. AU - May, H. AU - Slade, S. V. AU - Davey, C. J. DB - Scopus DO - 10.1016/j.puhe.2014.07.010 IS - 2 KW - Eye disorders Health economics Health services Screening Sensitivity analysis M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2015 SP - 131-137 ST - Addressing inequalities in eye health with subsidies and increased fees for General Ophthalmic Services in socio-economically deprived communities: A sensitivity analysis T2 - Public Health TI - Addressing inequalities in eye health with subsidies and increased fees for General Ophthalmic Services in socio-economically deprived communities: A sensitivity analysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924577231&doi=10.1016%2fj.puhe.2014.07.010&partnerID=40&md5=1abefc3b626106fd793d886f11da853d VL - 129 ID - 5360 ER - TY - JOUR AB - Objectives: Poor knowledge of eye health, concerns about the cost of spectacles, mistrust of optometrists and limited geographical access in socio-economically deprived areas are barriers to accessing regular eye examinations and result in low uptake and subsequent late presentation to ophthalmology clinics. Personal Medical Services (PMS) were introduced in the late 1990s to provide locally negotiated solutions to problems associated with inequalities in access to primary care. An equivalent approach to delivery of optometric services could address inequalities in the uptake of eye examinations. Study design: One-way and multiway sensitivity analyses. Methods: Variations in assumptions were included in the models for equipment and accommodation costs, uptake and length of appointments. The sensitivity analyses thresholds were cost-per-person tested below the GOS1 fee paid by the NHS and achieving break-even between income and expenditure, assuming no cross-subsidy from profits from sales of optical appliances. Results: Cost per test ranged from 24.01 pound to 64.80 pound and subsidy required varied from 14,490 pound to 108,046 pound. Unused capacity utilised for local enhanced service schemes such as glaucoma referral refinement reduced the subsidy needed. Conclusions: In order to support the financial viability of primary eye care in socio-economically deprived communities, income is required from additional subsidies or from sources other than eye examinations, such as ophthalmic or other optometric community services. This would require a significant shift of activity from secondary to primary care locations. The subsidy required could also be justified by the utility gain from earlier detection of preventable sight loss. (C) 2014 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. AN - WOS:000351300500008 AU - Shickle, D. AU - Todkill, D. AU - Chisholm, C. AU - Rughani, S. AU - Griffin, M. AU - Cassels-Brown, A. AU - May, H. AU - Slade, S. V. AU - Davey, C. J. DA - FEB DO - 10.1016/j.puhe.2014.07.010 IS - 2 PY - 2015 SN - 0033-3506 1476-5616 SP - 131-137 ST - Addressing inequalities in eye health with subsidies and increased fees for General Ophthalmic Services in socio-economically deprived communities: a sensitivity analysis T2 - PUBLIC HEALTH TI - Addressing inequalities in eye health with subsidies and increased fees for General Ophthalmic Services in socio-economically deprived communities: a sensitivity analysis VL - 129 ID - 6342 ER - TY - JOUR AB - PURPOSE: We investigated the effect of antiinflammatory treatment on the outcome of argon laser trabeculoplasty. METHODS: In this multicenter, double- masked, randomized, placebo-controlled, parallel comparison study, 140 chronic open-angle glaucoma patients received either 0.25% fluorometholone or vehicle four times a day unilaterally, beginning 24 hours before and continuing one week after argon laser trabeculoplasty. The laser surgeon placed 50 to 60 burns over the inferior 180 degrees of the trabecular meshwork. The patients were followed up frequently for five weeks after the procedure. RESULTS: Following argon laser trabeculoplasty, signs of anterior chamber inflammation were significantly lower in the fluorometholone group. However, there was no significant difference between the fluorometholone and the vehicle groups in the incidence of increased intraocular pressure in the immediate post-argon laser trabeculoplasty period. Intraocular pressure decreased significantly in both groups from day 1 throughout the follow-up period. A significant between-group difference in intraocular pressure decrease was found only at week 5 (7.83 ± 6.27 [S.D.] mm Hg for the fluorometholone group vs 6.63 ± 5.79 mm Hg for the vehicle group, P = .046). No drug-related clinically significant adverse events were observed. CONCLUSIONS: Use of fluorometholone is effective in attenuating inflammation and has no clinically significant impact on the outcome of argon laser trabeculoplasty or on the incidence of intraocular pressure spikes during the immediate post-argon laser trabeculoplasty period. AD - Kresge Eye Institute, 4717 St. Antoine Blvd., Detroit, MI 48201-1423, United States AU - Shin, D. H. AU - Frenkel, R. E. P. AU - David, R. AU - Cheetham, J. K. AU - Ahn, B. H. AU - Chan, R. Y. AU - Chen, K. AU - Hong, Y. J. AU - Lamping, K. A. AU - Latina, M. A. AU - Macy, J. AU - Rakofsky, S. AU - Samples, J. R. AU - Shani, L. DB - Scopus DO - 10.1016/S0002-9394(14)72061-6 IS - 3 M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 1996 SP - 349-354 ST - Effect of topical anti-inflammatory treatment on the outcome of laser trabeculoplasty T2 - American Journal of Ophthalmology TI - Effect of topical anti-inflammatory treatment on the outcome of laser trabeculoplasty UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-9544235156&doi=10.1016%2fS0002-9394%2814%2972061-6&partnerID=40&md5=9c3b5e4eaccb2a24c1863189b88701f5 VL - 122 ID - 5209 ER - TY - JOUR AU - Shingleton, B. J. DB - Scopus DO - 10.1016/j.jcrs.2008.11.056 IS - 3 M3 - Letter N1 - Export Date: 19 July 2021 PY - 2009 SP - 407 ST - Reply: Routine reduction of glaucoma medication following phacoemulsification T2 - Journal of Cataract and Refractive Surgery TI - Reply: Routine reduction of glaucoma medication following phacoemulsification UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-61349122206&doi=10.1016%2fj.jcrs.2008.11.056&partnerID=40&md5=7c8cf4ff051b9f8969062b5e9b2e65ab VL - 35 ID - 5767 ER - TY - JOUR AB - Purpose: This study evaluated Japanese patients' adherence to first-line therapy and physicians' compliance with the guidelines (GLs) for glaucoma in daily practice. Methods: This retrospective, noninterventional cohort study used a Japanese health care/pharmacy claims database from 2011 to 2016. We compared adherence based on the primary outcomes assessed as proportion of days covered (PDC) and persistence between patients who received first-line monotherapy followed by second-line fixed-combination therapy (GL-compliant cohort) and those who received first-line fixed-combination therapy (GL-noncompliant cohort). Furthermore, we explored treatment patterns, glaucoma consultation, and key factors associated with GL noncompliance. Results: Among 11,666 patients who received first-line therapy, 1,183 (10.1%) and 542 (4.6%) were in the GL-compliant and GL-noncompliant cohorts, respectively. Prostaglandin (70.7%) and subsequent prostaglandin/β blocker (BB) (20.9%) within 12 months were most used by the GL-compliant cohort. Prostaglandin/BB (48.9%) and carbonic anhydrase inhibitor/BB (51.1%) were prescribed for the GL-noncompliant cohort. The mean PDC [standard deviation (SD)], persistence rate (95% confidence interval), and consultation (SD) over 12 months were 60.9% (34.0), 16.0% (14.0-18.1), and 5.23 (3.21) times, respectively, in the GL-compliant cohort and 59.7% (35.8), 22.0% (18.6-25.5), and 4.76 (3.19) times, respectively, in the GL-noncompliant cohort. No significant differences were observed between the 2 cohorts. No clinically relevant factor associated with GL noncompliance was found. Conclusions: Around 5% of patients were prescribed a fixed-combination eye drop as first-line therapy not in accordance with GLs. The similarity of adherence and persistence between the 2 cohorts indicates that first-line fixed-combination therapy could be considered for glaucoma treatment. AD - T. Nakazawa, Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku Sendai, Japan AU - Shirai, C. AU - Matsuoka, N. AU - Nakazawa, T. DB - Embase Medline DO - 10.1089/jop.2020.0096 IS - 1 KW - alpha 1 adrenergic receptor blocking agent alpha 2 adrenergic receptor blocking agent alpha 2 adrenergic receptor stimulating agent antiglaucoma agent antihypertensive agent beta adrenergic receptor blocking agent brinzolamide plus timolol carbonate dehydratase inhibitor carteolol cholinergic receptor stimulating agent dorzolamide plus timolol latanoprost latanoprost plus timolol muscarinic agent prostaglandin derivative Rho kinase inhibitor tafluprost timolol timolol plus travoprost travoprost adult article cohort analysis consultation controlled study female glaucoma human Japanese (people) major clinical study male monotherapy observational study patient compliance protocol compliance reference database retrospective study topical treatment treatment duration treatment planning LA - English M3 - Article N1 - L633993687 2021-01-29 2021-02-17 PY - 2021 SN - 1557-7732 1080-7683 SP - 35-44 ST - Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database T2 - Journal of Ocular Pharmacology and Therapeutics TI - Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633993687&from=export http://dx.doi.org/10.1089/jop.2020.0096 VL - 37 ID - 2349 ER - TY - JOUR AB - Purpose: This study evaluated Japanese patients' adherence to first-line therapy and physicians' compliance with the guidelines (GLs) for glaucoma in daily practice. Methods: This retrospective, noninterventional cohort study used a Japanese health care/pharmacy claims database from 2011 to 2016. We compared adherence based on the primary outcomes assessed as proportion of days covered (PDC) and persistence between patients who received first-line monotherapy followed by second-line fixed-combination therapy (GL-compliant cohort) and those who received first-line fixed-combination therapy (GL-noncompliant cohort). Furthermore, we explored treatment patterns, glaucoma consultation, and key factors associated with GL noncompliance. Results: Among 11,666 patients who received first-line therapy, 1,183 (10.1%) and 542 (4.6%) were in the GL-compliant and GL-noncompliant cohorts, respectively. Prostaglandin (70.7%) and subsequent prostaglandin/β blocker (BB) (20.9%) within 12 months were most used by the GL-compliant cohort. Prostaglandin/BB (48.9%) and carbonic anhydrase inhibitor/BB (51.1%) were prescribed for the GL-noncompliant cohort. The mean PDC [standard deviation (SD)], persistence rate (95% confidence interval), and consultation (SD) over 12 months were 60.9% (34.0), 16.0% (14.0-18.1), and 5.23 (3.21) times, respectively, in the GL-compliant cohort and 59.7% (35.8), 22.0% (18.6-25.5), and 4.76 (3.19) times, respectively, in the GL-noncompliant cohort. No significant differences were observed between the 2 cohorts. No clinically relevant factor associated with GL noncompliance was found. Conclusions: Around 5% of patients were prescribed a fixed-combination eye drop as first-line therapy not in accordance with GLs. The similarity of adherence and persistence between the 2 cohorts indicates that first-line fixed-combination therapy could be considered for glaucoma treatment. AD - Medical Affairs, Pfizer Japan, Inc., Tokyo, Japan. Biometrics & Data Management, Pfizer R&D Japan G.K., Tokyo, Japan. Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan. AN - 148109827. Language: English. Entry Date: In Process. Revision Date: 20210715. Publication Type: journal article AU - Shirai, Chikako AU - Matsuoka, Nobushige AU - Nakazawa, Toru DB - ccm DO - 10.1089/jop.2020.0096 DP - EBSCOhost IS - 1 N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM33370214. PY - 2021 SN - 1080-7683 SP - 35-44 ST - Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database T2 - Journal of Ocular Pharmacology & Therapeutics TI - Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148109827&site=ehost-live&scope=site VL - 37 ID - 4147 ER - TY - JOUR AB - Background: Adherence to chronic therapies is crucial to prevent the progression of disease, such as glaucoma. However, only a limited number of studies have investigated them using real-world data in Japan. This study aimed to evaluate Japanese patients' adherence to fixed- and unfixed-combination eye drops as a second-line therapy for glaucoma in real-world practice.Methods: This retrospective, non-interventional cohort study utilized a commercially available Japanese healthcare database (MinaCare database). Medical/pharmacy claims data were collected from 2011 to 2016. The primary endpoint was adherence to medications, assessed by proportion of days covered (PDC) with medication during a 12-month post-index period. Meanwhile, the secondary endpoints included the persistence rate.Results: A total of 738 patients were included in this study: 309 and 329 in the fixed- and unfixed-combination cohorts, respectively. Prostaglandin analog (PG)/β-blocker (BB) was most commonly claimed in 241/309 (78.0%) patients in the fixed-combination cohort. In the unfixed-combination cohort, PG and BB were claimed in 130/329 (39.5%) patients, whereas PG and α2-agonist were claimed in 87/329 (26.4%) patients. Patients were more adherent to the fixed-combination than the unfixed-combinations (mean PDCs [SD], 79.1% [32.1] vs. 62.2% [38.0]; P < 0.0001). The proportion of patients with good adherence (PDC ≥ 80%) was also higher in the fixed-combination cohort (69.6%) than in the unfixed-combination cohort (48.6%) (P < 0.0001). During the 12-month post-index period, the persistence rate was higher in the fixed-combination cohort than in the unfixed-combination cohort (47.6% [95% confidence intervals (CI): 41.9-53.0] vs. 24.9% [95% CI: 20.4-29.7], P < 0.0001).Conclusions: Japanese patients with glaucoma preferred the fixed-combination therapies over the unfixed-combination therapies. Hence, fixed-combination therapies would contribute to the improvement of adherence. AD - Medical Affairs, Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, 151-8589, Tokyo, Japan Biometrics & Data Management, Pfizer R&D Japan G.K, 3-22-7 Yoyogi, Shibuya-ku, 151-8589, Tokyo, Japan Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, 980-8574, Sendai, Miyagi, Japan AN - 148230532. Language: English. Entry Date: 20210711. Revision Date: 20210716. Publication Type: journal article. Journal Subset: Biomedical AU - Shirai, Chikako AU - Matsuoka, Nobushige AU - Nakazawa, Toru DB - ccm DO - 10.1186/s12886-021-01813-w DP - EBSCOhost IS - 1 KW - Pharmacy and Pharmacology Glaucoma -- Drug Therapy Japan Antihypertensive Agents -- Therapeutic Use Retrospective Design Prospective Studies Medication Compliance N1 - Europe; UK & Ireland. NLM UID: 100967802. PMID: NLM33478408. PY - 2021 SN - 1471-2415 SP - 1-12 ST - Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study T2 - BMC Ophthalmology TI - Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148230532&site=ehost-live&scope=site VL - 21 ID - 4155 ER - TY - JOUR AB - Purpose: To investigate the role of the family/friends support system for patients with glaucoma and their perspective on barriers to effective glaucoma management. Methods: Six focus groups were conducted in 3 geographically and ethnically diverse areas of the United States (Los Angeles, CA; Rochester, MN; Durham, NC) that included 31 participants; 68% (21/31) were family members and friends of glaucoma patients with poor vision and 32% (10/31) were support system individuals of patients with good vision. Content analysis was used to identify important themes. Semiquantitative analysis was used to measure the frequency of each theme. Results: A total of 134 relevant comments were made in the 6 focus groups and 72% of relevant comments were made by individuals providing support for patients with poor vision. Family members and friends mentioned the following areas of concern regarding patients' glaucoma care: patient education (19.4%), doctor-patient relationship (17.9%), their own lack of involvement in the patient's medical care (17.2%), frustration with glaucoma and with the patient (14.9%), patient dependency on caregivers (14.9%), patient frustration with the disease (10.4%), and sex differences in coping mechanisms (5.2%). Conclusions: Support system individuals tend to be minimally involved in the patient's glaucoma status and care. This is especially true for support system members of patients with glaucoma who maintain good vision and those who do not have any other personal experiences with difficulties from glaucoma. Many of these family members express an interest in acquiring more education about glaucoma and becoming more involved in the patient's glaucoma care. AN - WOS:000379585100008 AU - Shtein, R. M. AU - Newman-Casey, P. A. AU - Herndon, L. AU - Coleman, A. L. AU - Lee, P. P. DA - JUL DO - 10.1097/IJG.0000000000000332 IS - 7 PY - 2016 SN - 1057-0829 1536-481X SP - E676-E680 ST - Assessing the Role of the Family/Support System Perspective in Patients With Glaucoma T2 - JOURNAL OF GLAUCOMA TI - Assessing the Role of the Family/Support System Perspective in Patients With Glaucoma VL - 25 ID - 6061 ER - TY - JOUR AB - Background A patient decision aid (PDA) is a tool for shared decision making (SDM), which emphasises patient empowerment. It is useful in chronic diseases and when there are multiple, no best single treatment option. Although SDM is prevalent in Western countries, its use is limited in Chinese societies, where the adoption of a paternalistic approach is strong. Here, we report the development, acceptance and pilot test results of a PDA targeted at Chinese patients with primary open-angle glaucoma (POAG). Methods We developed a PDA designed for use in Chinese patients with POAG. Recruited subjects were given our PDA. Baseline evaluation included decision conflict scale (DCS), validated glaucoma adherence questionnaires and glaucoma knowledge questionnaire. Subjects were briefed through the PDA and instructed to read it that day. Three to four weeks later, follow-up questionnaire as described above were conducted with the addition of acceptance questionnaires. Results Data from 65 subjects were available. The PDA was well received among subjects. DCS improved from 48.9±20.4 at baseline to 34.3±20.3 during follow-up, with P<0.01. Validated medication adherence questionnaires and knowledge showed improvement from baseline, which was statistically significant. Conclusions The use of PDA among Chinese subjects with POAG demonstrated positive reception and acceptance. Evaluation of its initial effects shows improvement in DCS, medication adherence and glaucoma knowledge. The implementation of SDM and PDA among Chinese subjects with POAG is encouraged. Future studies with randomised design and later evaluation time points can further reveal the impacts of PDA among Chinese subjects with POAG. © 2017 Article author(s) (or their employer(s) unless otherwise stated in the text of the article). All rights reserved. No commercial use is permitted unless otherwise expressly granted. AD - Department of Ophthalmology, University of Hong Kong, Hong Kong, Hong Kong School of Public Health, University of Hong Kong, Hong Kong, Hong Kong Department of Ophthalmology, Queen Mary Hospital, Hong Kong, Hong Kong AU - Shum, J. W. H. AU - Lam, W. W. T. AU - Choy, B. N. K. AU - Chan, J. C. H. AU - Ho, W. L. AU - Lai, J. S. M. C7 - e000100 DB - Scopus DO - 10.1136/bmjophth-2017-000100 IS - 1 KW - glaucoma public health M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2017 ST - Development and pilot-testing of patient decision aid for use among Chinese patients with primary open-angle glaucoma T2 - BMJ Open Ophthalmology TI - Development and pilot-testing of patient decision aid for use among Chinese patients with primary open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067422861&doi=10.1136%2fbmjophth-2017-000100&partnerID=40&md5=7dbc7f5315428367ecb632cdfba552b8 VL - 2 ID - 5561 ER - TY - JOUR AB - Background A patient decision aid (PDA) is a tool for shared decision making (SDM), which emphasises patient empowerment. It is useful in chronic diseases and when there are multiple, no best single treatment option. Although SDM is prevalent in Western countries, its use is limited in Chinese societies, where the adoption of a paternalistic approach is strong. Here, we report the development, acceptance and pilot test results of a PDA targeted at Chinese patients with primary open-angle glaucoma (POAG). Methods We developed a PDA designed for use in Chinese patients with POAG. Recruited subjects were given our PDA. Baseline evaluation included decision conflict scale (DCS), validated glaucoma adherence questionnaires and glaucoma knowledge questionnaire. Subjects were briefed through the PDA and instructed to read it that day. Three to four weeks later, follow-up questionnaire as described above were conducted with the addition of acceptance questionnaires. Results Data from 65 subjects were available. The PDA was well received among subjects. DCS improved from 48.9 +/- 20.4 at baseline to 34.3 +/- 20.3 during follow-up, with P<0.01. Validated medication adherence questionnaires and knowledge showed improvement from baseline, which was statistically significant. Conclusions The use of PDA among Chinese subjects with POAG demonstrated positive reception and acceptance. Evaluation of its initial effects shows improvement in DCS, medication adherence and glaucoma knowledge. The implementation of SDM and PDA among Chinese subjects with POAG is encouraged. Future studies with randomised design and later evaluation time points can further reveal the impacts of PDA among Chinese subjects with POAG. AN - WOS:000441775400003 AU - Shum, J. W. H. AU - Lam, W. W. T. AU - Choy, B. N. K. AU - Chan, J. C. H. AU - Ho, W. L. AU - Lai, J. S. M. DA - AUG DO - 10.1136/bmjophth-2017-000100 IS - 1 PY - 2017 SN - 2397-3269 ST - Development and pilot-testing of patient decision aid for use among Chinese patients with primary open-angle glaucoma T2 - BMJ OPEN OPHTHALMOLOGY TI - Development and pilot-testing of patient decision aid for use among Chinese patients with primary open-angle glaucoma VL - 2 ID - 6069 ER - TY - JOUR AB - Background: To evaluate the long-term effects of combined endoscopic cyclophotocoagulation and phacoemulsification (phaco) versus phacoemulsification alone on intraocular pressure control and medication reliance in the treatment of mild to moderate glaucoma. Design: Retrospective chart review in private practice setting by glaucoma fellowship trained surgeons. Participants: A total of 261 eyes in the combined phaco-endoscopic cyclophotocoagulation group with 52 eyes in the phaco-alone group. Methods: Comparison of phaco-endoscopic cyclophotocoagulation with phaco alone over 36 months. Main Outcome Measures: Full and qualified success cumulative survival, intraocular pressure and medication reliance 6-36 months compared with baseline. Full success was defined as minimum 20% intraocular pressure reduction with a decrease of at least one ocular hypertensive medication. Qualified success was defined as intraocular pressure no higher than baseline with a decrease of at least one ocular hypertensive medication. Results: At 36 months, mean intraocular pressure in the combined phaco-endoscopic cyclophotocoagulation group was 14.6mmHg, whereas the phaco-alone group was 15.5mmHg (P=0.34). Mean medication reliance in the combined phaco-endoscopic cyclophotocoagulation group was 0.2 medications, whereas the phaco-alone group was 1.2 (P<0.001). Full success in the phaco-endoscopic cyclophotocoagulation group was 61.4%; the phaco-alone group was 23.3% (P<0.001). Qualified success survival was 72.6% in the phaco-endoscopic cyclophotocoagulation group and 23.3% in the phaco-alone group (P<0.001). Conclusions: Combined phaco-endoscopic cyclophotocoagulation effectively lowers or maintains intraocular pressure and results in ocular hypertensive medication reduction up to 36 months when compared with phaco alone. Therefore, phaco-endoscopic cyclophotocoagulation may help to increase medication compliance and reduce glaucoma progression in mild to moderate glaucoma. AD - M.J. Siegel, Glaucoma Center of Michigan, 29201 Telegraph Road, Suite 301, Southfield, MI, United States AU - Siegel, M. J. AU - Boling, W. S. AU - Faridi, O. S. AU - Gupta, C. K. AU - Kim, C. AU - Boling, R. C. AU - Citron, M. E. AU - Siegel, M. J. AU - Siegel, L. I. DB - Embase Medline DO - 10.1111/ceo.12510 IS - 6 KW - antiglaucoma agent hyaluronic acid ketorolac prednisolone acetate quinoline derived antiinfective agent aged article closed angle glaucoma controlled study diode laser endoscope endoscopic cyclophotocoagulation female human intermethod comparison intraocular pressure laser coagulation lens implantation low tension glaucoma major clinical study male medical record review open angle glaucoma ophthalmic viscosurgical device patient compliance phacoemulsification postoperative infection postoperative inflammation postoperative pain private practice surgeon surgical technique survival rate treatment outcome OcuLight LA - English M3 - Article N1 - L605409604 2015-08-04 2015-08-07 PY - 2015 SN - 1442-9071 1442-6404 SP - 531-539 ST - Combined endoscopic cyclophotocoagulation and phacoemulsification versus phacoemulsification alone in the treatment of mild to moderate glaucoma T2 - Clinical and Experimental Ophthalmology TI - Combined endoscopic cyclophotocoagulation and phacoemulsification versus phacoemulsification alone in the treatment of mild to moderate glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605409604&from=export http://dx.doi.org/10.1111/ceo.12510 VL - 43 ID - 2793 ER - TY - JOUR AB - Purpose: Evaluation of the intraocular pressure (IOP) lowering efficacy of trabeculectomies over > 10 years and their ability to stabilize glaucomatous optic neuropathy. Methods: In total, 181 eyes (136 patients), which underwent trabeculectomy (10 min surgery) at least 10 years prior and were on regular follow-up, were evaluated. Qualified/complete success was taken as criteria A: IOP ≤ 12 mmHg, B: IOP ≤ 15 mmHg and C: IOP ≤ 18 mmHg, with all > 5 mmHg, with/without medications. Target IOP in advanced glaucoma is about 10 mmHg, therefore trabeculectomy 10-10-10 challenge! Results: The mean age of patients was 46.32 ± 11.50 years. Absolute success was 50.27%, 54.14% and 59.66% according to criteria A, B and C at last follow-up, while qualified success was 70.11%, 81.77% and 96.13%. An IOP of ≤ 12 mmHg was noted in 34, 64.15%, PACG eyes, 14, 73.68%, POAG, 15, 65.22%, JOAG and 64, 74.42%, secondary glaucoma eyes. The reduction in IOP overall was 64.83 ± 16.80% at last review and was 59.47 ± 16.07% in PACG, 62.40 ± 17.72% in POAG, 71.89 ± 8.50% in JOAG and 67.74 ± 18.10% in secondary glaucoma eyes. “Target” IOP was achieved in 97.29% of early glaucoma, 85.71% moderate glaucoma and 70% severe glaucoma eyes. 97.24% of patients were perimetrically stable. 2.21% of eyes post-trabeculectomy had a shallow anterior chamber needing surgical intervention. Visual acuity was maintained or better in 93.92% of patients, with a cataract surgery performed in 6.63% eyes. A repeat trabeculectomy was performed in 3.31% of eyes. Conclusion: Trabeculectomy 10-10-10 is achievable in the long term, with few complications or repeat surgical interventions in the majority of POAG, PACG, JOAG and secondary glaucomas. Therefore, trabeculectomy should not be relegated to a last resort, but should be undertaken as soon as possible, if medical therapy is inadequate, unaffordable or compliance is an issue. © 2020, Springer Nature B.V. AD - Glaucoma Service, Glaucoma Research and Clinical Facility, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Room No. 475, Fourth Floor, Ansari Nagar, New Delhi, 110029, India Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 110029, India AU - Sihota, R. AU - Shakrawal, J. AU - Sidhu, T. AU - Sharma, A. K. AU - Dada, T. AU - Pandey, V. DB - Scopus DO - 10.1007/s10792-020-01289-5 IS - 5 KW - IOP reduction Target IOP Trabeculectomy 10-10-10 M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 1233-1243 ST - Does TRABECULECTOMY meet the 10-10-10 challenge in PACG, POAG, JOAG and Secondary glaucomas? T2 - International Ophthalmology TI - Does TRABECULECTOMY meet the 10-10-10 challenge in PACG, POAG, JOAG and Secondary glaucomas? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078623484&doi=10.1007%2fs10792-020-01289-5&partnerID=40&md5=db7f9a6c2a08a04337ba9bf561605276 VL - 40 ID - 5699 ER - TY - JOUR AB - Purpose Evaluation of the intraocular pressure (IOP) lowering efficacy of trabeculectomies over > 10 years and their ability to stabilize glaucomatous optic neuropathy. Methods In total, 181 eyes (136 patients), which underwent trabeculectomy (10 min surgery) at least 10 years prior and were on regular follow-up, were evaluated. Qualified/complete success was taken as criteria A: IOP <= 12 mmHg, B: IOP <= 15 mmHg and C: IOP <= 18 mmHg, with all > 5 mmHg, with/without medications. Target IOP in advanced glaucoma is about 10 mmHg, therefore trabeculectomy 10-10-10 challenge! Results The mean age of patients was 46.32 +/- 11.50 years. Absolute success was 50.27%, 54.14% and 59.66% according to criteria A, B and C at last follow-up, while qualified success was 70.11%, 81.77% and 96.13%. An IOP of <= 12 mmHg was noted in 34, 64.15%, PACG eyes, 14, 73.68%, POAG, 15, 65.22%, JOAG and 64, 74.42%, secondary glaucoma eyes. The reduction in IOP overall was 64.83 +/- 16.80% at last review and was 59.47 +/- 16.07% in PACG, 62.40 +/- 17.72% in POAG, 71.89 +/- 8.50% in JOAG and 67.74 +/- 18.10% in secondary glaucoma eyes. "Target" IOP was achieved in 97.29% of early glaucoma, 85.71% moderate glaucoma and 70% severe glaucoma eyes. 97.24% of patients were perimetrically stable. 2.21% of eyes post-trabeculectomy had a shallow anterior chamber needing surgical intervention. Visual acuity was maintained or better in 93.92% of patients, with a cataract surgery performed in 6.63% eyes. A repeat trabeculectomy was performed in 3.31% of eyes. Conclusion Trabeculectomy 10-10-10 is achievable in the long term, with few complications or repeat surgical interventions in the majority of POAG, PACG, JOAG and secondary glaucomas. Therefore, trabeculectomy should not be relegated to a last resort, but should be undertaken as soon as possible, if medical therapy is inadequate, unaffordable or compliance is an issue. AN - WOS:000507346800001 AU - Sihota, R. AU - Shakrawal, J. AU - Sidhu, T. AU - Sharma, A. K. AU - Dada, T. AU - Pandey, V. DA - MAY DO - 10.1007/s10792-020-01289-5 IS - 5 PY - 2020 SN - 0165-5701 1573-2630 SP - 1233-1243 ST - Does TRABECULECTOMY meet the 10-10-10 challenge in PACG, POAG, JOAG and Secondary glaucomas? T2 - INTERNATIONAL OPHTHALMOLOGY TI - Does TRABECULECTOMY meet the 10-10-10 challenge in PACG, POAG, JOAG and Secondary glaucomas? VL - 40 ID - 6139 ER - TY - JOUR AB - Background Since the introduction of National Institute for Health and Care Excellence glaucoma guidelines 2009, the number of referrals from community optometrists to hospital eye services has increased across the UK, resulting in increase in first visit discharge rates (FVDRs). Aim To assess the impact of Scottish Intercollegiate Guidelines Network (SIGN) 144 on quality of referrals from community optometrists. Methodology A retrospective study of patient records who attended as new adult glaucoma referrals to clinics in Princess Alexandra Eye Pavilion, Edinburgh, and in Greater Glasgow and Clyde, was carried out across October-November 2014 (group 1) and September-October 2016 (group 2), before and after the introduction of SIGN 144. The primary outcome of this study is FVDRs. A secondary outcome is the extent of compliance to referral recommendations by SIGN guidelines. Results Three hundred and twelve and 325 patients were included in groups 1 and 2, respectively. There was a significant decline in FVDRs between these two periods from 29.2% to 19.2%. (p=0.004) (OR 0.58 (95%CI 0.40 to 0.84)). Post-SIGN guidelines, 87% of referrals were compliant to SIGN referral criteria while 13% remained non-compliant. The main reasons for non-compliance were no repeatable visual field defects (42.0%) and referrals due to high intraocular pressure were either not repeated or not interpreted in the context of age and central corneal thickness (36.8%). Conclusion Patients referred after the introduction of SIGN guidelines were 33.5% less likely to be discharged at the first visit. Although compliance to most recommendations in SIGN guidelines has improved, there is still a need to improve adherence to referral criteria. AD - S. Sii, Department of Ophthalmology, Belfast Health and Social Care Trust, Belfast, United Kingdom AU - Sii, S. AU - Nasser, A. AU - Loo, C. Y. AU - Croghan, C. AU - Rotchford, A. AU - Agarwal, P. K. DB - Embase Medline DO - 10.1136/bjophthalmol-2017-311429 IS - 3 KW - adult aged article cornea thickness false positive result female glaucoma health care quality health impact assessment hospital discharge human intraocular pressure major clinical study male optometrist patient referral practice guideline priority journal retrospective study Scotland treatment outcome treatment refusal visual field defect LA - English M3 - Article N1 - L622486663 2018-06-12 2019-11-01 PY - 2019 SN - 1468-2079 0007-1161 SP - 369-373 ST - The impact of SIGN glaucoma guidelines on false-positive referrals from community optometrists in Central Scotland T2 - British Journal of Ophthalmology TI - The impact of SIGN glaucoma guidelines on false-positive referrals from community optometrists in Central Scotland UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622486663&from=export http://dx.doi.org/10.1136/bjophthalmol-2017-311429 VL - 103 ID - 2520 ER - TY - JOUR AB - Background Since the introduction of National Institute for Health and Care Excellence glaucoma guidelines 2009, the number of referrals from community optometrists to hospital eye services has increased across the UK, resulting in increase in first visit discharge rates (FVDRs). Aim To assess the impact of Scottish Intercollegiate Guidelines Network (SIGN) 144 on quality of referrals from community optometrists. Methodology A retrospective study of patient records who attended as new adult glaucoma referrals to clinics in Princess Alexandra Eye Pavilion, Edinburgh, and in Greater Glasgow and Clyde, was carried out across October-November 2014 (group 1) and September-October 2016 (group 2), before and after the introduction of SIGN 144. The primary outcome of this study is FVDRs. A secondary outcome is the extent of compliance to referral recommendations by SIGN guidelines. Results Three hundred and twelve and 325 patients were included in groups 1 and 2, respectively. There was a significant decline in FVDRs between these two periods from 29.2% to 19.2%. (p=0.004) (OR 0.58 (95%CI 0.40 to 0.84)). Post-SIGN guidelines, 87% of referrals were compliant to SIGN referral criteria while 13% remained non-compliant. The main reasons for non-compliance were no repeatable visual field defects (42.0%) and referrals due to high intraocular pressure were either not repeated or not interpreted in the context of age and central corneal thickness (36.8%). Conclusion Patients referred after the introduction of SIGN guidelines were 33.5% less likely to be discharged at the first visit. Although compliance to most recommendations in SIGN guidelines has improved, there is still a need to improve adherence to referral criteria. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. AD - Department of Ophthalmology, Belfast Health and Social Care Trust, Belfast, BT9 7BW, United Kingdom NHS West Lothian Foundation Programme, St. Johns Hospital, United Kingdom Department of Ophthalmology, University of Edinburgh Medical School, United Kingdom Department of Ophthalmology, Tennent Institute of Ophthalmology, Glasgow, United Kingdom Department of Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom AU - Sii, S. AU - Nasser, A. AU - Loo, C. Y. AU - Croghan, C. AU - Rotchford, A. AU - Agarwal, P. K. DB - Scopus DO - 10.1136/bjophthalmol-2017-311429 IS - 3 KW - glaucoma M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2019 SP - 369-373 ST - The impact of SIGN glaucoma guidelines on false-positive referrals from community optometrists in Central Scotland T2 - British Journal of Ophthalmology TI - The impact of SIGN glaucoma guidelines on false-positive referrals from community optometrists in Central Scotland UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048097146&doi=10.1136%2fbjophthalmol-2017-311429&partnerID=40&md5=aaf18e5701ab45411fa0ab0ca6acd65d VL - 103 ID - 5407 ER - TY - JOUR AB - Background Since the introduction of National Institute for Health and Care Excellence glaucoma guidelines 2009, the number of referrals from community optometrists to hospital eye services has increased across the UK, resulting in increase in first visit discharge rates (FVDRs). Aim To assess the impact of Scottish Intercollegiate Guidelines Network (SIGN) 144 on quality of referrals from community optometrists. Methodology A retrospective study of patient records who attended as new adult glaucoma referrals to clinics in Princess Alexandra Eye Pavilion, Edinburgh, and in Greater Glasgow and Clyde, was carried out across October-November 2014 (group 1) and September-October 2016 (group 2), before and after the introduction of SIGN 144. The primary outcome of this study is FVDRs. A secondary outcome is the extent of compliance to referral recommendations by SIGN guidelines. Results Three hundred and twelve and 325 patients were included in groups 1 and 2, respectively. There was a significant decline in FVDRs between these two periods from 29.2% to 19.2%. (p= 0.004) (OR 0.58 (95% CI 0.40 to 0.84)). Post-SIGN guidelines, 87% of referrals were compliant to SIGN referral criteria while 13% remained non-compliant. The main reasons for non-compliance were no repeatable visual field defects (42.0%) and referrals due to high intraocular pressure were either not repeated or not interpreted in the context of age and central corneal thickness (36.8%). Conclusion Patients referred after the introduction of SIGN guidelines were 33.5% less likely to be discharged at the first visit. Although compliance to most recommendations in SIGN guidelines has improved, there is still a need to improve adherence to referral criteria AN - WOS:000471869500013 AU - Sii, S. AU - Nasser, A. AU - Loo, C. Y. AU - Croghan, C. AU - Rotchford, A. AU - Agarwal, P. K. DA - MAR DO - 10.1136/bjophthalmol-2017-311429 IS - 3 PY - 2019 SN - 0007-1161 1468-2079 SP - 369-373 ST - The impact of SIGN glaucoma guidelines on false-positive referrals from community optometrists in Central Scotland T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - The impact of SIGN glaucoma guidelines on false-positive referrals from community optometrists in Central Scotland VL - 103 ID - 5956 ER - TY - JOUR AB - Purpose: Considering that noncompliance to glaucoma treatment is one of the risk factors associated with diseasés progression, the purpose of the present study was to evaluate: 1) knowledge and feelings about the disease; 2) self-reported noncompliance to treatment and related factors; and 3) influence of disease in lifestyle. Methods: Interviews, with application of a semi-structured questionnaire, of 50 patients with primary open-angle glaucoma. The analysis was performed using Lefèvre's technique (Collective Subject Speech - CSS, qualitative/quantitative research). Results: Thirty-eight percent of patients did not consider themselves well informed about glaucoma. The percentage of patients that reported noncompliance was 20%. The main causes of noncompliance are: side effects of antiglaucomatous drugs (24%); lack of information about the disease (22%); difficulty in understanding information and communication problems with the physician (14%); difficulties in administering the eye drops (14%); poverty, with impossibility to pay for the eye drops (10%); patientś attitudes and beliefs (10%). Eighteen percent of the participants informed that the disease affected their life quality. Conclusion: In the studied population, most of the problems related to noncompliance to glaucoma treatment pointed out different factors that may decrease with education about POAG, interventions on attitudes and behavior, improvement of doctor-patient relationship and anti-glaucoma drugs supply. AD - M.L.V. Rodrigues, Av. Bandeirantes, 3.900, Ribeirão Preto (SP) CEP 14049-900, Brazil AU - Silva, L. R. AU - de Paula, J. S. AU - Rocha, E. M. AU - Rodrigues, M. L. V. DB - Medline DO - 10.1590/S0004-27492010000200003 IS - 2 KW - aged article attitude to health doctor patient relationship female human male middle aged open angle glaucoma patient compliance psychological aspect quality of life questionnaire statistics university hospital L1 - internal-pdf://0111537764/3274-Factors related to glaucoma treatmen-2010.pdf LA - Portuguese M3 - Article N1 - L359319608 2011-03-07 PY - 2010 SN - 0004-2749 1678-2925 SP - 116-119 ST - Factors related to glaucoma treatment compliance: Patients' opinions from a university hospital T2 - Arquivos Brasileiros de Oftalmologia TI - Factors related to glaucoma treatment compliance: Patients' opinions from a university hospital UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359319608&from=export http://dx.doi.org/10.1590/S0004-27492010000200003 VL - 73 ID - 3274 ER - TY - JOUR AB - The aim of this study was to determine the characteristics of the patients in Fife who were registered as blind with a main diagnosis of glaucoma between 1990 and 1999. The case notes of 87 people were studied. The average age at registration was 78 years (S.D. = 14). By the time of first referral to hospital, more than half were already aware of visual loss. Forty-five per cent of referrals had no optometry input. Compliance with treatment was poor in at least 26% of patients. Only 44% had glaucoma surgery. There were significant findings with regard to mental health, particularly dementia, which was eventually present in 24%. At least one-third of patients had a hearing impairment. One-third of those registered as blind could have been registered earlier. However, staff from the local provider of rehabilitation and social work services for the blind were shown to have provided prompt and helpful support to 95% of those registered. Consideration should be given to the way in which elderly patients with advanced glaucoma are managed, with awareness of mental health and hearing problems and emphasis on early referral to rehabilitation services. AD - A. Sinclair, Department of Ophthalmology, Queen Margaret Hospital, Whitefield Road, Dunfermline, Fife KY12 0SU, UK. AU - Sinclair, A. AU - Hinds, A. AU - Sanders, R. DB - Medline DO - 10.1111/j.1475-1313.2004.00200.x IS - 4 KW - aged article blindness dementia glaucoma health service hearing disorder human nurse ophthalmology optometry organization and management patient compliance social support United Kingdom LA - English M3 - Article N1 - L39680622 2005-02-24 PY - 2004 SN - 0275-5408 SP - 313-318 ST - Ten years of glaucoma blindness in Fife 1990-99 and the implications for ophthalmology, optometry and rehabilitation services T2 - Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) TI - Ten years of glaucoma blindness in Fife 1990-99 and the implications for ophthalmology, optometry and rehabilitation services UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39680622&from=export http://dx.doi.org/10.1111/j.1475-1313.2004.00200.x VL - 24 ID - 3741 ER - TY - JOUR AB - Glaucoma care is more an art than science. The introduction of several new classes of glaucoma medications and the completion of many large randomized clinical trials have not changed this fact. While we now have better choices when initiating glaucoma therapy relative to our predecessors, the principles of glaucoma therapy have not changed much during this period. Debates continue regarding the utility of concepts such as "the monocular therapeutic trial," "target intraocular pressure (IOP)," and "maximal medical therapy." Our tools for detecting and following glaucomatous disease have improved but are not precise enough for us to prospectively predict which patients will do better or worse than others. Much attention has been given to disease stage, rate of progression, and compliance with medications but regular patient follow-up, an area that has received little attention, may be among the most important predictors of patient outcomes. AD - Glaucoma Service, Stanford University, School of Medicine, 900 Blake Wilbur Drive, Palo Alto, CA 94305, United States Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, United States AU - Singh, K. AU - Shrivastava, A. DB - Scopus DO - 10.4103/0301-4738.73691 IS - SUPPL. 1 KW - Glaucoma maximal medical therapy medical management target intraocular pressure M3 - Conference Paper N1 - Cited By :17 Export Date: 19 July 2021 PY - 2011 SP - S88-S92 ST - Medical management of glaucoma: Principles and practice T2 - Indian Journal of Ophthalmology TI - Medical management of glaucoma: Principles and practice UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650810597&doi=10.4103%2f0301-4738.73691&partnerID=40&md5=807eb03e55b85186b38150a73944e654 VL - 59 ID - 5170 ER - TY - JOUR AB - Glaucoma care is more an art than science. The introduction of several new classes of glaucoma medications and the completion of many large randomized clinical trials have not changed this fact. While we now have better choices when initiating glaucoma therapy relative to our predecessors, the principles of glaucoma therapy have not changed much during this period. Debates continue regarding the utility of concepts such as "the monocular therapeutic trial," "target intraocular pressure (IOP)," and "maximal medical therapy." Our tools for detecting and following glaucomatous disease have improved but are not precise enough for us to prospectively predict which patients will do better or worse than others. Much attention has been given to disease stage, rate of progression, and compliance with medications but regular patient follow-up, an area that has received little attention, may be among the most important predictors of patient outcomes. AN - WOS:000208741900014 AU - Singh, K. AU - Shrivastava, A. DA - JAN DO - 10.4103/0301-4738.73691 PY - 2011 SN - 0301-4738 1998-3689 SP - S88-S92 ST - Medical management of glaucoma: Principles and practice T2 - INDIAN JOURNAL OF OPHTHALMOLOGY TI - Medical management of glaucoma: Principles and practice VL - 59 ID - 6092 ER - TY - JOUR AB - The delivery of ophthalmic drugs is challenging despite easy accessibility via the ocular surface. Topical instillation of eye drops is a relatively easy and most commonly used as a conduit for drug delivery for treating a myriad of ocular morbidities, particularly involving the anterior segment, and has an additional benefit of avoiding the first-pass metabolism while passing through the systemic circulation. The primary challenges of drug administration through traditional methods include—inadequate patient education for proper drug instillation technique, compliance, adherence, and persistence. Various dynamic (choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution) and static (namely, different layers of cornea, sclera, and retina including blood aqueous and blood–retinal barriers) ocular barriers limit drug delivery to the target ocular tissues. The maintenance of the therapeutic drug levels on the ocular surface for a prolonged duration is an added challenge, thus preventing persistent delivery for longer durations. These factors result in inadequate management, leading to poor prognosis in vision loss in as many as 27% of the patients diagnosed with glaucoma. We have reviewed the research and advancements in the development of novel and well-tolerated drug delivery systems with the common goal of overcoming the factors limiting adequate drug delivery to the target tissues in glaucomatous patients with traditional techniques. In the recent past, multiple research groups have successfully designed noninvasive, sustained drug delivery systems, promoting the efficacy as well as the feasibility of delivering topical drugs to the anterior segment. AD - Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA Department of Ophthalmology, Government Medical College & Hospital, Chandigarh, Chandigarh, India Department of Ophthalmology Virginia Commonwealth University School of Medicine Richmond, VA, USA AN - 142247708. Language: English. Entry Date: 20200320. Revision Date: 20200320. Publication Type: Article AU - Singh, Rohan B. AU - Ichhpujani, Parul AU - Thakur, Sahil AU - Jindal, Sumeet DB - ccm DO - 10.1177/2515841420905740 DP - EBSCOhost KW - Drug Delivery Systems Glaucoma -- Drug Therapy Treatment Outcomes Medication Compliance Morbidity Patient Education Instillation, Drug Glaucoma -- Prognosis Survival N1 - pictorial; review; tables/charts. Journal Subset: Biomedical; USA. PY - 2020 SN - 2515-8414 SP - 1-17 ST - Promising therapeutic drug delivery systems for glaucoma: a comprehensive review T2 - Therapeutic Advances in Ophthalmology TI - Promising therapeutic drug delivery systems for glaucoma: a comprehensive review UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142247708&site=ehost-live&scope=site VL - 12 ID - 4180 ER - TY - JOUR AB - The delivery of ophthalmic drugs is challenging despite easy accessibility via the ocular surface. Topical instillation of eye drops is a relatively easy and most commonly used as a conduit for drug delivery for treating a myriad of ocular morbidities, particularly involving the anterior segment, and has an additional benefit of avoiding the first-pass metabolism while passing through the systemic circulation. The primary challenges of drug administration through traditional methods include--inadequate patient education for proper drug instillation technique, compliance, adherence, and persistence. Various dynamic (choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution) and static (namely, different layers of cornea, sclera, and retina including blood aqueous and blood--retinal barriers) ocular barriers limit drug delivery to the target ocular tissues. The maintenance of the therapeutic drug levels on the ocular surface for a prolonged duration is an added challenge, thus preventing persistent delivery for longer durations. These factors result in inadequate management, leading to poor prognosis in vision loss in as many as 27% of the patients diagnosed with glaucoma. We have reviewed the research and advancements in the development of novel and well-tolerated drug delivery systems with the common goal of overcoming the factors limiting adequate drug delivery to the target tissues in glaucomatous patients with traditional techniques. In the recent past, multiple research groups have successfully designed noninvasive, sustained drug delivery systems, promoting the efficacy as well as the feasibility of delivering topical drugs to the anterior segment. AD - Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA Department of Ophthalmology, Government Medical College & Hospital, Chandigarh, Chandigarh, India Department of Ophthalmology, Government Medical College & Hospital, Chandigarh, Chandigarh, India; Singapore Eye Research Institute, Singapore Department of Ophthalmology Virginia Commonwealth University School of Medicine Richmond, VA, USA AN - 149913697. Language: English. Entry Date: 20210427. Revision Date: 20210427. Publication Type: Article AU - Singh, Rohan B. AU - Ichhpujani, Parul AU - Thakur, Sahil AU - Jindal, Sumeet DB - ccm DO - 10.1177/2515841420905740 DP - EBSCOhost KW - Glaucoma -- Drug Therapy Ophthalmic Solutions -- Therapeutic Use Drug Delivery Systems Technology, Medical Noninvasive Procedures Medication Compliance Patient Education Nanoparticles Diffusion of Innovation Contact Lenses Glaucoma -- Prognosis Drug Efficacy N1 - pictorial; review; tables/charts. Journal Subset: Biomedical; USA. PY - 2020 SN - 2515-8414 SP - 1-17 ST - Promising therapeutic drug delivery systems for glaucoma: a comprehensive review T2 - Therapeutic Advances in Ophthalmology TI - Promising therapeutic drug delivery systems for glaucoma: a comprehensive review UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149913697&site=ehost-live&scope=site VL - 12 ID - 4187 ER - TY - JOUR AB - Importance: Convenient outpatient access for ophthalmology patients seeking urgent care could offer savings compared with an emergency department (ED) visit. Objective: To evaluate the costs and visit durations of same-day access (SDA) in an ophthalmology department at an academic medical center vs ED care. Design, Setting, and Participants: This single-center study was a retrospective quality improvement analysis of an institutional electronic medical record system at the Wilmer Eye Institute clinics and the Johns Hopkins Hospital ED. On June 1, 2015, the Wilmer Eye Institute and Johns Hopkins Hospital initiated an official policy of providing SDA to patients calling for appointments (ie, the same-day project). All ophthalmology clinic locations created same-day appointment slots for at least 1 practitioner. In recognition of seasonal variations in patient visit volumes, the 10 months before implementation (August 1, 2014, to May 31, 2015) were compared with complementary periods in 2015 to 2016 and 2016 to 2017. Main Outcomes and Measures: The study tabulated encounters, charges, and visit length for outpatients seen on the same day or by previously scheduled appointments. For the ED patients, volume, diagnoses, charges, and length of stay data were collected. The numbers of SDA patients who indicated urgency were tabulated. Results: The number of SDA patients increased from 22 781 to 26 579 for the first year after SDA implementation. The mean charge was $258 (95% CI, $250-$266; median, $184; interquartile range [IQR], $175-$320), and the mean clinic transit time was 1.55 hours (95% CI, 1.54-1.57 hours; median, 1.28 hours). For patients seeking eye care in the ED, the mean professional fee was $401 (95% CI, $390-$411; median, $360; IQR, $255-$500), the mean (SD) total hospital charge was $1040 ($999) (95% CI, $729-$1079; median, $1002; IQR, $334-$1429), and the mean length of stay was 7.30 hours (95% CI, 7.01-7.57 hours; median, 7.20 hours). The top 4 ophthalmic diagnoses for ED patients were conjunctivitis, cornea abrasion, iritis, and visual loss, which were unchanged after SDA implementation. In calendar year 2017, a total of 4062 SDA patients reported urgency; their estimated savings in charges compared with an ED visit were $580866 in professional fees and $3176484 in hospital charges. Conclusions and Relevance: Same-day access appears to be less expensive and to require less time in the health care system than a visit to the ED for an ophthalmic diagnosis. Substantial savings in time and money might be achieved if urgent eye care is delivered in the clinic rather than the ED. © 2019 American Medical Association. All rights reserved. AD - Wilmer General Eye Services, Wilmer B-29 at the Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287, United States Wilmer Eye Institute, Baltimore, MD, United States Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD, United States Administrations Department, Johns Hopkins Hospital, Baltimore, MD, United States Division of Health Sciences Informatics, Johns Hopkins School of Medicine, Baltimore, MD, United States Wilmer Eye Institute at Odenton, Odenton, MD, United States Department of Health Policy and Management, Johns Hopkins Carey Business School, Baltimore, MD, United States Ophthalmology Registration, Johns Hopkins School of Medicine, Baltimore, MD, United States Biostatistics Consulting Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States AU - Singman, E. L. AU - Smith, K. AU - Mehta, R. AU - Boland, M. V. AU - Srikumaran, D. AU - Frick, K. AU - Young, L. AU - Locco, G. AU - Tian, J. AU - Kowalewski, C. AU - McDonnell, P. DB - Scopus DO - 10.1001/jamaophthalmol.2019.0864 IS - 7 M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2019 SP - 729-735 ST - Cost and Visit Duration of Same-Day Access at an Academic Ophthalmology Department vs Emergency Department T2 - JAMA Ophthalmology TI - Cost and Visit Duration of Same-Day Access at an Academic Ophthalmology Department vs Emergency Department UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064868551&doi=10.1001%2fjamaophthalmol.2019.0864&partnerID=40&md5=bd922bcf12e757710d8b2144d71b1c5e VL - 137 ID - 5370 ER - TY - JOUR AB - Normal tension glaucoma (NTG) is a disease associated with normal intraocular pressure (10 mmHg - 21 mmHg) that may lead to irreversible blindness if misdiagnosed or left untreated over a period of time. The author observed a patient with NTG over a period of 5 years (from 2013 to 2017). The initial visual field analysis results (2014) showed mild visual field defects because of NTG at the start of the 5-year period. Although the patient was also diagnosed with hydrocephalus, a condition associated with optic nerve head damage, following years of noncompliance to treatment of NTG and follow-up eye examination schedules, the patient's visual field defects were found to have progressed by the year 2017. It is therefore important for optometrists to apply due diligence when examining patients with NTG in order to expedite intervention and prevention of visual impairment and blindness. AN - WOS:000416387000001 AU - Sithole, H. L. DA - NOV 22 DO - 10.4102/aveh.v76i1.408 IS - 1 PY - 2017 SN - 0378-9411 2410-3039 ST - A longitudinal observation of a patient with normal tension glaucoma T2 - AFRICAN VISION AND EYE HEALTH JOURNAL TI - A longitudinal observation of a patient with normal tension glaucoma VL - 76 ID - 6097 ER - TY - JOUR AB - Glaucoma screening is a standard procedure at many health fairs. Information on correct screening techniques, instrumentation, and target populations has been available. However, a scarcity of information exists concerning the success of efforts to follow up on abnormal results. This study reports on the findings of a long-term (6-month) follow-up of all individuals with abnormal tonometric results screened at an inner-city osteopathic hospital. Of the 218 subjects screened, 15 were found to have abnormal tonometric results. Seven of the 15 subjects were actually reached at the 6-month follow-up interval. Four of the seven had not sought any further eye care; two had sought nonmedical evaluation; only one had sought medical ocular care, and that subject was later found to have glaucoma. The results presented in this article indicate that compliance by this population is inadequate. Inner-city participants require more education. We encourage physicians to promptly refer such patients for appropriate medical ocular care. AD - Medical Arts Center, 1620 Sauk Rd, Dixon, IL 61021, United States AU - Skorin Jr, L. AU - Multack, R. F. AU - Holtzman, J. N. DB - Scopus IS - 7 KW - Glaucoma screening health fairs intraocular pressure tonometry M3 - Conference Paper N1 - Cited By :3 Export Date: 19 July 2021 PY - 1991 SP - 671-674 ST - Health fair glaucoma screening: Follow-up evaluation T2 - Journal of the American Osteopathic Association TI - Health fair glaucoma screening: Follow-up evaluation UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026324799&partnerID=40&md5=cf4b0bf24e8c9d232ebecf382551eaeb VL - 91 ID - 5542 ER - TY - JOUR AB - Purpose. We report three atypical infiltrative keratitis events in patients that had successfully worn highly oxygen permeable (Dk) soft contact lenses on an extended wear (EW) schedule for at least 15 months. These cases highlight the role of patient/practitioner education, patient compliance, examination, and appropriate referrals that are required to reduce the risk of complications during lens wear. Methods and Results. Each patient had been wearing high Dk soft lenses on an EW schedule with monthly replacement for at least 15 months and presented with severe pain, redness, and photophobia. The events were characterized by focal infiltrate(s) with an overlying epithelial defect in the superior periphery to mid-periphery of the cornea and extensive diffuse infiltration. Conclusions. The signs and symptoms of each case were more severe than is typically associated with contact lens-related infiltrative keratitis. Because of the slow progression of signs and relatively fast resolution, the cases were not found to be microbial keratitis. Although high Dk soft contact lenses overcome hypoxia-associated complications associated with extended wear, patients and practitioners must be vigilant as adverse events can still occur and in rare instances can be severe. Education and patient compliance are a crucial part of successful management of patients on EW schedules. Constant reinforcement is necessary to ensure patient compliance. AD - D.F. Sweeney, Coop. Res. Ctr. for Eye Res./Tech., University of New South Wales, Sydney 2052, Australia AU - Skotnitsky, C. AU - Jalbert, I. AU - O'Hare, N. AU - Sweeney, D. F. AU - Holden, B. A. DB - Embase Medline DO - 10.1097/00003226-200204000-00017 IS - 3 KW - oxygen adult article case report disease course female human hydrogel hypoxia keratitis pain patient compliance patient education patient referral permeability photophobia priority journal soft contact lens staining LA - English M3 - Article N1 - L34250614 2002-04-15 PY - 2002 SN - 0277-3740 SP - 318-324 ST - Case reports of three atypical infiltrative keratitis events with high Dk soft contact lens wear T2 - Cornea TI - Case reports of three atypical infiltrative keratitis events with high Dk soft contact lens wear UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34250614&from=export http://dx.doi.org/10.1097/00003226-200204000-00017 VL - 21 ID - 3872 ER - TY - JOUR AB - This study deals with the problem of attendances in patients with pseudo‐exfoliation of the lens capsule with and without glaucoma. While 640 patients attended the controls, 321 patients did not return for re‐examination in 2 years. This represents 1/6 of the capsular glaucoma patients and 1/3 of the non‐glaucoma patients. The analysis of influencing factors revealed that the glaucoma patients who failed to return had a higher mean age than the non‐glaucoma group (P < 0.001) or the group of glaucoma patients that attended the controls (P < 0.001). Persons with pseudoexfoliation without glaucoma who did not meet for control were younger than those who met (P < 0.001). The sex or travelling distance of the patients seemed to be of no influence. Interviewing the glaucoma patients disclosed a resigned attitude towards treatment among those who failed to come. More information and/or communication seem to be the most important factors to achieve better follow‐up in persons with pseudoexfoliation without glaucoma. 1984 Institution Acta Ophthalmologica Scandinavica AD - Department of Ophthalmology, Fylkessjukehuset I Aust-Agder, Arendal, Norway AU - Slagsvold, J. E. DB - Scopus DO - 10.1111/j.1755-3768.1984.tb08391.x IS - 2 KW - follow up glaucoma patients attendance pseudoexfoliation M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 1984 SP - 177-182 ST - THE FOLLOW‐UP IN PATIENTS WITH PSEUDOEXFOLIATION OF THE LENS CAPSULE WITH AND WITHOUT GLAUCOMA: 1. Factors influencing the patients attendance in eye‐controls T2 - Acta Ophthalmologica TI - THE FOLLOW‐UP IN PATIENTS WITH PSEUDOEXFOLIATION OF THE LENS CAPSULE WITH AND WITHOUT GLAUCOMA: 1. Factors influencing the patients attendance in eye‐controls UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021345677&doi=10.1111%2fj.1755-3768.1984.tb08391.x&partnerID=40&md5=c223478ee427c27dd223ac7b5c1e7647 VL - 62 ID - 5367 ER - TY - JOUR AB - Objective: The purpose of the current study was to determine the self-reported prevalence of and factors associated with nonadherence with glaucoma medications in veteran outpatients. Methods: This survey study was conducted at a Veterans Affairs (VA) clinic. A survey was administered to patients with glaucoma. We calculated the percentage of self-reported adherence with glaucoma medications in each patient. Logistic regression was used to assess whether patient characteristics and difficulties with using glaucoma medications were related to patients' reporting that they were <100% adherent with their glaucoma medications in the previous week. Results: The survey was completed by 141 patients (men, 91.5%; mean [SD] age, 70.22 [11.60] years [range, 37-93 years]; black race, 45.4%; white race, 44.0%; "other" or data unavailable, 10.6%). Nonwhite patients were significantly less adherent in the previous week than were white patients (27.0% vs 11.3%; P < 0.05). A total of 67.4% patients reported ≥1 difficulty in using their glaucoma medications. The 3 most commonly reported difficulties were "drops fall on cheek" (29.1%), "too many drops come out" (20.6%), and "hard to read print" (17.0%). A total of 19.1% of patients self-reported using <100% of their glaucoma medications in the previous week. The number of difficulties reported was significantly associated with reporting being <100% adherent in the previous week (P<0.05). Conclusion: In this small sample of VA patients with glaucoma, adherence to glaucoma medications could be improved, especially among those who reported difficulties using their medications and those who were nonwhite. © 2009 Excerpta Medica Inc. All rights reserved. AD - B. Sleath, Division of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, Chapel Hill, NC, United States AU - Sleath, B. AU - Ballinger, R. AU - Covert, D. AU - Robin, A. L. AU - Byrd, J. E. AU - Tudor, G. DB - Embase Medline DO - 10.1016/j.amjopharm.2009.04.001 IS - 2 KW - antiglaucoma agent eye drops adult African American aged article Caucasian drug self administration female glaucoma health survey human major clinical study male outpatient outpatient care patient attitude patient compliance priority journal race difference self report veteran LA - English M3 - Article N1 - L354572504 2009-06-05 PY - 2009 SN - 1543-5946 SP - 67-73 ST - Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients T2 - American Journal Geriatric Pharmacotherapy TI - Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354572504&from=export http://dx.doi.org/10.1016/j.amjopharm.2009.04.001 VL - 7 ID - 3362 ER - TY - JOUR AB - Objective: The purpose of the current study was to determine the self-reported prevalence of and factors associated with nonadherence with glaucoma medications in veteran outpatients. Methods: This survey study was conducted at a Veterans Affairs (VA) clinic. A survey was administered to patients with glaucoma. We calculated the percentage of self-reported adherence with glaucoma medications in each patient. Logistic regression was used to assess whether patient characteristics and difficulties with using glaucoma medications were related to patients' reporting that they were <100% adherent with their glaucoma medications in the previous week. Results: The survey was completed by 141 patients (men, 91.5%; mean [SD] age, 70.22 [11.60] years [range, 37-93 years]; black race, 45.4%; white race, 44.0%; 'other' or data unavailable, 10.6%). Nonwhite patients were significantly less adherent in the previous week than were white patients (27.0% vs 11.3%; P < 0.05). A total of 67.4% patients reported >/=1 difficulty in using their glaucoma medications. The 3 most commonly reported difficulties were 'drops fall on cheek' (29.1%), 'too many drops come out' (20.6%), and 'hard to read print' (17.0%). A total of 19.1% of patients self-reported using <100% of their glaucoma medications in the previous week. The number of difficulties reported was significantly associated with reporting being <100% adherent in the previous week (P<0.05). Conclusion: In this small sample of VA patients with glaucoma, adherence to glaucoma medications could be improved, especially among those who reported difficulties using their medications and those who were nonwhite. AD - Division of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, Chapel Hill, North Carolina; Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. AN - 105533682. Language: English. Entry Date: 20090717. Revision Date: 20200708. Publication Type: Journal Article AU - Sleath, B. AU - Ballinger, R. AU - Covert, D. AU - Robin, A. L. AU - Byrd, J. E. AU - Tudor, G. DB - ccm DO - 10.1016/j.amjopharm.2009.04.001 DP - EBSCOhost IS - 2 KW - Glaucoma -- Drug Therapy Medication Compliance Outpatients -- Statistics and Numerical Data Veterans -- Statistics and Numerical Data Aged Aged, 80 and Over Black Persons -- Statistics and Numerical Data Female Glaucoma -- Ethnology Logistic Regression Male Middle Age Odds Ratio Questionnaires Risk Assessment Risk Factors Surveys United States White Persons -- Statistics and Numerical Data Human N1 - research. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 101190325. PMID: NLM19447359. PY - 2009 SN - 1543-5946 SP - 67-73 ST - Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients T2 - American Journal of Geriatric Pharmacotherapy TI - Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105533682&site=ehost-live&scope=site VL - 7 ID - 4373 ER - TY - JOUR AB - Objective: The purpose of the current study was to determine the self-reported prevalence of and factors associated with nonadherence with glaucoma medications in veteran outpatients. Methods: This survey study was conducted at a Veterans Affairs (VA) clinic. A survey was administered to patients with glaucoma. We calculated the percentage of self-reported adherence with glaucoma medications in each patient. Logistic regression was used to assess whether patient characteristics and difficulties with using glaucoma medications were related to patients' reporting that they were <100% adherent with their glaucoma medications in the previous week. Results: The survey was completed by 141 patients (men, 91.5%; mean [SD] age, 70.22 [11.60] years [range, 37–93 years]; black race, 45.4%; white race, 44.0%; 'other' or data unavailable, 10.6%). Nonwhite patients were significantly less adherent in the previous week than were white patients (27.0% vs 11.3%; P < 0.05). A total of 67.4% patients reported ≥1 difficulty in using their glaucoma medications. The 3 most commonly reported difficulties were 'drops fall on cheek' (29.1%), 'too many drops come out' (20.6%), and 'hard to read print' (17.0%). A total of 19.1% of patients self-reported using <100% of their glaucoma medications in the previous week. The number of difficulties reported was significantly associated with reporting being <100% adherent in the previous week (P < 0.05). Conclusion: In this small sample of VA patients with glaucoma, adherence to glaucoma medications could be improved, especially among those who reported difficulties using their medications and those who were nonwhite. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Sleath, Betsy, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, CB # 7590, Chapel Hill, NC, US, 27599-7590 AN - 2009-07715-001 AU - Sleath, Betsy AU - Ballinger, Rex AU - Covert, David AU - Robin, Alan L. AU - Byrd, John E. AU - Tudor, Gail DB - psyh DO - 10.1016/j.amjopharm.2009.04.001 DP - EBSCOhost IS - 2 KW - self report prevalence glaucoma medication veteran outpatients African Americans Aged Aged, 80 and over European Continental Ancestry Group Female Glaucoma Health Care Surveys Humans Logistic Models Male Medication Adherence Middle Aged Odds Ratio Outpatients Risk Assessment Risk Factors Surveys and Questionnaires United States Veterans Drug Therapy Epidemiology Self-Report N1 - Division of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, Chapel Hill, NC, US. Release Date: 20091116. Correction Date: 20091123. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Epidemiology; Glaucoma. Minor Descriptor: Outpatients; Self-Report. Classification: Physical & Somatoform & Psychogenic Disorders (3290); Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40); Outpatient (60). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Brief Medication Questionnaire. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Apr, 2009. Publication History: Accepted Date: Jan 26, 2009. Copyright Statement: All rights reserved. Excerpta Medica Inc. 2009. Sponsor: US Department of Veterans Affairs, US. Recipients: No recipient indicated PY - 2009 SN - 1543-5946 SP - 67-73 ST - Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients T2 - American Journal of Geriatric Pharmacotherapy (AJGP) TI - Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-07715-001&site=ehost-live&scope=site ORCID: 0000-0003-1959-8770 Betsy_Sleath@unc.edu VL - 7 ID - 4838 ER - TY - JOUR AB - Objective: The purpose of the study was to examine (1) how patient adherence and eye drop technique were associated with visual field defect severity and (2) how general glaucoma adherence self-efficacy and eye drop technique self-efficacy were related to visual field defect severity. Design: Cross-sectional study conducted at a single private practice site. Participants: Patients using eye drops for their glaucoma. Methods: Subject adherence to glaucoma medications through Medication Events Monitoring System (MEMS) devices were measured, and eye drop instillation technique was assessed by video recording. General glaucoma medication adherence self-efficacy was measured using a 10-item scale, and eye drop technique self-efficacy was measured using a 6-item scale. Multivariate logistic regression was used to analyze the data. Main Outcome Measures: Visual field defect severity. Results: Patients who were less than 80% adherent according to the MEMS devices were significantly more likely to have worse defect severity. Patients with lower scores on the general glaucoma medication adherence self-efficacy scale also were significantly more likely to have worse defect severity. Eye drop technique and eye drop technique self-efficacy were not related significantly to visual field defect severity. Conclusions: Eye care providers need to assess patient adherence and to work with those patients with poor adherence to find ways to improve their ability and self-efficacy in using their glaucoma medications. © 2011 by the American Academy of Ophthalmology. AD - B. Sleath, Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7590, United States AU - Sleath, B. AU - Blalock, S. AU - Covert, D. AU - Stone, J. L. AU - Skinner, A. C. AU - Muir, K. AU - Robin, A. L. DB - Embase Medline DO - 10.1016/j.ophtha.2011.05.013 IS - 12 KW - antiglaucoma agent eye drops adult aged article clinical effectiveness cross-sectional study disease severity drug instillation drug monitoring drug self administration ethnicity female glaucoma human major clinical study male outcome assessment patient compliance priority journal rating scale scoring system self concept videorecording visual field defect LA - English M3 - Article N1 - L51576987 2011-08-20 2011-12-16 PY - 2011 SN - 0161-6420 1549-4713 SP - 2398-2402 ST - The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity T2 - Ophthalmology TI - The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51576987&from=export http://dx.doi.org/10.1016/j.ophtha.2011.05.013 VL - 118 ID - 3133 ER - TY - JOUR AD - UNC Eshelman School of Pharmacy and Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, CB No. 7590, Chapel Hill, NC 27599-7590, USA Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University ofNorth Carolina at Chapel Hill, Chapel Hill, NC 27599, USA Department of Ophthalmology, School of Medicine, Duke University, Durham, NC 27710, USA; Health Services Research and Development, Durham VA Medical Center, Durham, NC 27710, USA Glaucoma Service and Research Center, UNC Kittner Eye Center, University ofNorth Carolina at Chapel Hill, Chapel Hill, NC 27599, USA Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA 30322, USA Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, UT 84132, USA Department of Science and Mathematics, Institutional Research, Husson University, Bangor, ME 04401, USA Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21209, USA; Department of Ophthalmology, School of Medicine, Johns Hopkins University, Baltimore, MD 21209, USA AN - 103877076. Language: English. Entry Date: 20150129. Revision Date: 20150710. Publication Type: Journal Article AU - Sleath, Betsy AU - Blalock, Susan J. AU - Carpenter, Delesha M. AU - Muir, Kelly W. AU - Sayner, Robyn AU - Lawrence, Scott AU - Giangiacomo, Annette L. AU - Hartnett, Mary Elizabeth AU - Tudor, Gail AU - Goldsmith, Jason AU - Robin, Alan L. DB - ccm DO - 2014/238939 DP - EBSCOhost KW - Glaucoma -- Drug Therapy Physician-Patient Relations Patient Education Physicians Patients Glaucoma -- Education Office Visits Cross Sectional Studies United States Questionnaires Videorecording Interviews Clinical Assessment Tools Interrater Reliability Descriptive Statistics Bivariate Statistics Pearson's Correlation Coefficient Chi Square Test T-Tests Human Male Female Aged Middle Age Multivariate Analysis Adult Odds Ratio Confidence Intervals Funding Source N1 - research; tables/charts. Journal Subset: Biomedical; USA. Instrumentation: Rapid Estimate of Adult Literacy in Medicine (REALM). Grant Information: This work was supported by Grant EY018400 from the National Eye Institute (Betsy Sleath, PI) and by Grant UL 1RR02574 7 from the National Center of Research Resources, NIH.. NLM UID: 101524199. PY - 2014 SN - 2090-004X SP - 1-7 ST - Provider Education about Glaucoma and Glaucoma Medications during Videotaped Medical Visits T2 - Journal of Ophthalmology TI - Provider Education about Glaucoma and Glaucoma Medications during Videotaped Medical Visits UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103877076&site=ehost-live&scope=site ID - 4422 ER - TY - JOUR AB - Objective. The purpose of this study was to examine how patient, physician, and situational factors are associated with the extent to which providers educate patients about glaucoma and glaucoma medications, and which patient and provider characteristics are associated with whether providers educate patients about glaucoma and glaucoma medications. Methods. Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited and a cross-sectional study was conducted at six ophthalmology clinics. Patients' visits were videotape recorded and patients were interviewed after visits. Generalized estimating equations were used to analyze the data. Results. Two hundred and seventy-nine patients participated. Providers were significantly more likely to educate patients about glaucoma and glaucoma medications if they were newly prescribed glaucoma medications. Providers were significantly less likely to educate African American patients about glaucoma. Providers were significantly less likely to educate patients of lower health literacy about glaucoma medications. Conclusion. Eye care providers did not always educate patients about glaucoma or glaucoma medications. Practice Implications. Providers should consider educating more patients about what glaucoma is and how it is treated so that glaucoma patients can better understand their disease. Even if a patient has already been educated once, it is important to reinforce what has been taught before. AN - WOS:000335311700001 AU - Sleath, B. AU - Blalock, S. J. AU - Carpenter, D. M. AU - Muir, K. W. AU - Sayner, R. AU - Lawrence, S. AU - Giangiacomo, A. L. AU - Hartnett, M. E. AU - Tudor, G. AU - Goldsmith, J. AU - Robin, A. L. DO - 10.1155/2014/238939 PY - 2014 SN - 2090-004X 2090-0058 ST - Provider Education about Glaucoma and Glaucoma Medications during Videotaped Medical Visits T2 - JOURNAL OF OPHTHALMOLOGY TI - Provider Education about Glaucoma and Glaucoma Medications during Videotaped Medical Visits VL - 2014 ID - 6051 ER - TY - JOUR AB - Objective To examine the associations of provider-patient communication, glaucoma medication adherence self-efficacy, and outcome expectations with glaucoma medication adherence. Design Prospective, observational cohort study. Participants Two hundred seventy-nine patients with glaucoma who were newly prescribed or taking glaucoma medications were recruited at 6 ophthalmology clinics. Methods Patients' visits were video recorded and communication variables were coded using a detailed coding tool developed by the authors. Adherence was measured using Medication Event Monitoring Systems for 60 days after their visits. Main Outcome Measures The following adherence variables were measured for the 60-day period after their visits: whether the patient took 80% or more of the prescribed doses, percentage of the correct number of prescribed doses taken each day, and percentage of the prescribed doses taken on time. Results Higher glaucoma medication adherence self-efficacy was associated positively with better adherence with all 3 measures. Black race was associated negatively with percentage of the correct number of doses taken each day (β = -0.16; P < 0.05) and whether the patient took 80% or more of the prescribed doses (odds ratio, 0.37; 95% confidence interval, 0.16-0.86). Physician education about how to administer drops was associated positively with percentage of the correct number of doses taken each day (β = 0.18; P < 0.01) and percentage of the prescribed doses taken on time (β = 0.15; P < 0.05). Conclusions These findings indicate that provider education about how to administer glaucoma drops and patient glaucoma medication adherence self-efficacy are associated positively with adherence. © 2015 American Academy of Ophthalmology. AD - Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Department of Ophthalmology, School of Medicine, Duke University, Durham, NC, United States Glaucoma Service, Kittner Eye Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, United States Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, United States Department of Science and Mathematics, Husson University, Bangor, ME, United States Department of Ophthalmology, University of Maryland, Baltimore, MD, United States Department of Ophthalmology, University of Michigan, Ann Arbor, MI, United States Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States AU - Sleath, B. AU - Blalock, S. J. AU - Carpenter, D. M. AU - Sayner, R. AU - Muir, K. W. AU - Slota, C. AU - Lawrence, S. D. AU - Giangiacomo, A. L. AU - Hartnett, M. E. AU - Tudor, G. AU - Goldsmith, J. A. AU - Robin, A. L. DB - Scopus DO - 10.1016/j.ophtha.2014.11.001 IS - 4 M3 - Article N1 - Cited By :53 Export Date: 19 July 2021 PY - 2015 SP - 748-754 ST - Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence T2 - Ophthalmology TI - Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925310713&doi=10.1016%2fj.ophtha.2014.11.001&partnerID=40&md5=9f6730bb8617b65e6010590475008b05 VL - 122 ID - 4988 ER - TY - JOUR AB - Objective: To examine the associations of providerepatient communication, glaucoma medication adherence self-efficacy, and outcome expectations with glaucoma medication adherence. Design: Prospective, observational cohort study. Participants: Two hundred seventy-nine patients with glaucoma who were newly prescribed or taking glaucoma medications were recruited at 6 ophthalmology clinics. Methods: Patients' visits were video recorded and communication variables were coded using a detailed coding tool developed by the authors. Adherence was measured using Medication Event Monitoring Systems for 60 days after their visits. Main Outcome Measures: The following adherence variables were measured for the 60-day period after their visits: whether the patient took 80% or more of the prescribed doses, percentage of the correct number of prescribed doses taken each day, and percentage of the prescribed doses taken on time. Results: Higher glaucoma medication adherence self-efficacy was associated positively with better adherence with all 3 measures. Black race was associated negatively with percentage of the correct number of doses taken each day (beta = -0.16; P < 0.05) and whether the patient took 80% or more of the prescribed doses (odds ratio, 0.37; 95% confidence interval, 0.16-0.86). Physician education about how to administer drops was associated positively with percentage of the correct number of doses taken each day (beta = 0.18; P < 0.01) and percentage of the prescribed doses taken on time (beta = 0.15; P < 0.05). Conclusions: These findings indicate that provider education about how to administer glaucoma drops and patient glaucoma medication adherence self-efficacy are associated positively with adherence. (C) 2015 by the American Academy of Ophthalmology. AN - WOS:000351710100021 AU - Sleath, B. AU - Blalock, S. J. AU - Carpenter, D. M. AU - Sayner, R. AU - Muir, K. W. AU - Slota, C. AU - Lawrence, S. D. AU - Giangiacomo, A. L. AU - Hartnett, M. E. AU - Tudor, G. AU - Goldsmith, J. A. AU - Robin, A. L. DA - APR DO - 10.1016/j.ophtha.2014.11.001 IS - 4 PY - 2015 SN - 0161-6420 1549-4713 SP - 748-754 ST - Ophthalmologist-Patient Communication, Self-efficacy, and Glaucoma Medication Adherence T2 - OPHTHALMOLOGY TI - Ophthalmologist-Patient Communication, Self-efficacy, and Glaucoma Medication Adherence VL - 122 ID - 6001 ER - TY - JOUR AB - Purpose The Purpose of this study was to develop and evaluate the psychometric properties of (a) a glaucoma medication self-efficacy scale and (b) a glaucoma outcome expectations scale.Patients and MethodsTwo instruments were developed: a glaucoma medication self-efficacy scale and a glaucoma outcome expectations scale. Packets containing (a) the instruments and patient demographic questions and (b) a letter explaining the study were distributed to 225 glaucoma patients from three ophthalmology practices between August and December 2007. The instrument was completed by 191 patients for a response rate of 85%. Principal components factor analysis with a varimax rotation and Cronbach's α reliability were used to analyse the data. To assess discriminant validity, we administered the scales and two self-reported measures of adherence in a separate sample of 43 glaucoma patients who were currently using at least one glaucoma medication.Results Our results yielded a 21-item self-efficacy in overcoming barriers that might interfere with the use of glaucoma medications scale, a 14-item self-efficacy in carrying out specific tasks required to use eye drops correctly scale, and a four-item glaucoma outcome expectations scale. Results of the Cronbach's α reliability indicated that the scales are internally consistent. The self-efficacy scales were both significantly associated with two patient self-reported measures of glaucoma medication adherence, which show discriminant validity.Conclusion sEye care providers and researchers can use these scales to identify patients with low self-efficacy in using their glaucoma medications and patients who do not believe that following their eye care providers advice can help their vision. © 2010 Macmillan Publishers Limited All rights reserved. © 2010 Macmillan Publishers Limited All rights reserved. AD - B. Sleath, Division of Pharmaceutical Outcomes and Policy, University of North Carolina, CB #7590, Chapel Hill, NC 27599-7590, United States AU - Sleath, B. AU - Blalock, S. J. AU - Robin, A. AU - Hartnett, M. E. AU - Covert, D. AU - Devellis, B. AU - Giangiacomo, A. DB - Embase Medline DO - 10.1038/eye.2009.174 IS - 4 KW - antiglaucoma agent eye drops adult aged article controlled study discriminant validity drug use expectation female glaucoma glaucoma medication self efficacy scale glaucoma outcome expectation scale human internal consistency major clinical study male patient compliance psychometry questionnaire reliability self concept self report treatment outcome LA - English M3 - Article N1 - L358662961 2010-04-28 2010-06-01 PY - 2010 SN - 1476-5454 0950-222X SP - 624-631 ST - Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations T2 - Eye TI - Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358662961&from=export http://dx.doi.org/10.1038/eye.2009.174 VL - 24 ID - 3284 ER - TY - JOUR AB - Aims: The aims of this study were: (1) to examine whether the original glaucoma medication adherence and eye drop technique self-efficacy scales could be shortened for easier use in practice settings; and (2) to validate these scales against objective medication adherence measures. Methods: Prospective study conducted at a single private practice site. We measured subjects' adherence to glaucoma medications through Medication Event Monitoring System (MEMS) devices and assessed eye drop instillation technique by video-recording. Principal components factor analysis and logistic and linear regression were used to analyse the data. Results: Our results yielded a 10-item Glaucoma Medication Adherence Self-Efficacy Scale that was strongly associated with subject adherence measured using MEMS (b coefficient 8.52, 95% CI 1.94 to 15.1). In addition, the six-item Eye Drop Technique Self-Efficacy Scale was strongly associated with video-recorded subject eye drop installation technique (OR 10.47, 95% CI 1.78 to 61.63). Conclusions: Eye care providers and researchers could use these shorter scales to identify subjects with either poor glaucoma medication adherence and/or eye drop instillation technique. This could help to identify those who may benefit most from education and training on both adherence and eye drop instillation. AD - B. Sleath, Cecil G. Sheps Center for Health Services Research, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7590, United States AU - Sleath, B. AU - Blalock, S. J. AU - Stone, J. L. AU - Skinner, A. C. AU - Covert, D. AU - Muir, K. AU - Robin, A. L. DB - Embase Medline DO - 10.1136/bjo.2010.199851 IS - 2 KW - eye drops adult aged article clinical practice controlled study disease classification disease severity drug instillation drug monitoring drug self administration Eye Drop Technique Self Efficacy Scale female glaucoma Glaucoma Medication Adherence Self Efficacy Scale human major clinical study male medication adherence monitoring system patient compliance patient monitoring priority journal prospective study questionnaire rating scale self report validation study videorecording visual field defect LA - English M3 - Article N1 - L51446746 2011-05-31 2012-02-13 PY - 2012 SN - 0007-1161 1468-2079 SP - 258-262 ST - Validation of a short version of the glaucoma medication self-efficacy questionnaire T2 - British Journal of Ophthalmology TI - Validation of a short version of the glaucoma medication self-efficacy questionnaire UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51446746&from=export http://dx.doi.org/10.1136/bjo.2010.199851 http://bjo.bmj.com/content/96/2/258.full.pdf+html VL - 96 ID - 3113 ER - TY - JOUR AB - Little is known about how ophthalmologist-patient communication over time is associated with glaucoma patient long-term adherence. The purpose of our study was to examine the association between provider use of components of the resources and supports in self-management model when communicating with patients and adherence to glaucoma medications measured electronically over an 8-month period. In this longitudinal prospective cohort study, the main variables studied were ophthalmologist communication-individualized assessment, collaborative goal setting and skills enhancement. Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited from six ophthalmology clinics. Patients' baseline and next follow-up visits were videotape-recorded. Patients were interviewed after their visits. Patients used medication event monitoring systems (MEMS) for 8 months after enrollment into the study, and adherence was measured electronically using MEMS for 240 days after their visits. Two hundred and seventy-nine patients participated. Patient race and regimen complexity were negatively associated with glaucoma medication adherence over an 8-month period. Provider communication behaviors, including providing education and positive reinforcement, can improve patient adherence to glaucoma medications over an 8-month period. © 2015 The Author. Published by Oxford University Press. All rights reserved. AD - UNC Eshelman School of Pharmacy, Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC 27599, United States Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States Department of Ophthalmology, School of Medicine, Duke University, United States Durham VA Medical Center, Health Services Research and Development, Durham, NC, United States Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA 30322, United States Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, UT 84132, United States Department of Science and Mathematics, Dirct. of Institutional Research, Husson University, Bangor, ME 04401, United States Department of Ophthalmology, University of Maryland, Baltimore, MD, United States Department of Ophthalmology, University of Michigan, Ann Arbor, MI, United States Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD 21215, United States AU - Sleath, B. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Sayner, R. AU - Muir, K. W. AU - Slota, C. AU - Giangiacomo, A. L. AU - Hartnett, M. E. AU - Tudor, G. AU - Robin, A. L. DB - Scopus DO - 10.1093/her/cyv034 IS - 5 M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2014 SP - 693-705 ST - Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence T2 - Health Education Research TI - Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943616214&doi=10.1093%2fher%2fcyv034&partnerID=40&md5=b2417529501a175a3f403c8444b241c9 VL - 30 ID - 5252 ER - TY - JOUR AB - Little is known about how ophthalmologist-patient communication over time is associated with glaucoma patient long-term adherence. The purpose of our study was to examine the association between provider use of components of the resources and supports in self-management model when communicating with patients and adherence to glaucoma medications measured electronically over an 8-month period. In this longitudinal prospective cohort study, the main variables studied were ophthalmologist communication-individualized assessment, collaborative goal setting and skills enhancement. Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited from six ophthalmology clinics. Patients' baseline and next follow-up visits were videotape-recorded. Patients were interviewed after their visits. Patients used medication event monitoring systems (MEMS) for 8 months after enrollment into the study, and adherence was measured electronically using MEMS for 240 days after their visits. Two hundred and seventy-nine patients participated. Patient race and regimen complexity were negatively associated with glaucoma medication adherence over an 8-month period. Provider communication behaviors, including providing education and positive reinforcement, can improve patient adherence to glaucoma medications over an 8-month period. AD - UNC Eshelman School of Pharmacy & Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC 27599, USA Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA Department of Ophthalmology, School of Medicine, Duke University Durham VA Medical Center, Health Services Research and Development, Durham, NC, USA Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA 30322, USA Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, UT 84132, USA Department of Science and Mathematics, Director of Institutional Research, Husson University, Bangor, ME 04401, USA Department of Ophthalmology, University of Maryland, Baltimore, MD, USA Department of Ophthalmology, University of Michigan, Ann Arbor, MI, USA Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD 21215, USA AN - 109512502. Language: English. Entry Date: 20150924. Revision Date: 20190710. Publication Type: Article AU - Sleath, B. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Sayner, R. AU - Muir, K. W. AU - Slota, C. AU - Giangiacomo, A. L. AU - Hartnett, M. E. AU - Tudor, G. AU - Robin, A. L. DB - ccm DO - 10.1093/her/cyv034 DP - EBSCOhost IS - 5 KW - Glaucoma -- Prevention and Control Physician-Patient Relations Communication -- Standards Medication Compliance -- Evaluation Self Care Goal-Setting Collaboration Patient Education Reinforcement (Psychology) Human Prospective Studies Videorecording Descriptive Statistics Questionnaires Coefficient Alpha Chi Square Test T-Tests Pearson's Correlation Coefficient Female Male Aged Aged, 80 and Over Middle Age Black Persons Odds Ratio Confidence Intervals Race Factors Funding Source N1 - research; tables/charts. Journal Subset: Europe; Health Promotion/Education; Peer Reviewed; UK & Ireland. Instrumentation: Rapid Estimate of Adult Literacy in Medicine (REALM). Grant Information: This work was supported by the National Eye Institute at the National Institutes of Health (EY018400); and the National Center of Research Resources at the National Institutes of Health (1UL1TR001111).. NLM UID: 8608459. PMID: NLM26338986. PY - 2015 SN - 0268-1153 SP - 693-705 ST - Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence T2 - Health Education Research TI - Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109512502&site=ehost-live&scope=site VL - 30 ID - 4190 ER - TY - JOUR AB - Little is known about how ophthalmologist-patient communication over time is associated with glaucoma patient long-term adherence. The purpose of our study was to examine the association between provider use of components of the resources and supports in self-management model when communicating with patients and adherence to glaucoma medications measured electronically over an 8-month period. In this longitudinal prospective cohort study, the main variables studied were ophthalmologist communication-individualized assessment, collaborative goal setting and skills enhancement. Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited from six ophthalmology clinics. Patients’ baseline and next follow-up visits were videotape-recorded. Patients were interviewed after their visits. Patients used medication event monitoring systems (MEMS) for 8 months after enrollment into the study, and adherence was measured electronically using MEMS for 240 days after their visits. Two hundred and seventy-nine patients participated. Patient race and regimen complexity were negatively associated with glaucoma medication adherence over an 8-month period. Provider communication behaviors, including providing education and positive reinforcement, can improve patient adherence to glaucoma medications over an 8-month period. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Sleath, B., UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, US, 27599 AN - 2015-42729-002 AU - Sleath, B. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Sayner, R. AU - Muir, K. W. AU - Slota, C. AU - Giangiacomo, A. L. AU - Hartnett, M. E. AU - Tudor, G. AU - Robin, A. L. DB - psyh DO - 10.1093/her/cyv034 DP - EBSCOhost IS - 5 KW - glaucoma medication adherence ophthalmologist-patient communication self-management medication event monitoring system Adult Aged Communication Female Humans Male Middle Aged Physician-Patient Relations Surveys and Questionnaires Videotape Recording Drug Therapy Self-Monitoring Treatment Compliance Patients N1 - UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, US. Release Date: 20160414. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Drug Therapy; Glaucoma; Self-Management; Self-Monitoring; Treatment Compliance. Minor Descriptor: Patients. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Self-Efficacy Scale. Methodology: Empirical Study; Followup Study; Longitudinal Study; Prospective Study; Interview; Quantitative Study. References Available: Y. Page Count: 13. Issue Publication Date: Oct, 2015. Publication History: First Posted Date: Sep 2, 2015; Accepted Date: Aug 6, 2015; First Submitted Date: Feb 9, 2015. Copyright Statement: Published by Oxford University Press. All rights reserved. The Author. 2015. Sponsor: National Institutes of Health, National Eye Institute, US. Grant: EY018400. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Center of Research Resources, US. Grant: 1UL1TR001111. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Eye Institute, US. Grant: EY015130; EY017011. Recipients: No recipient indicated PY - 2015 SN - 0268-1153 1465-3648 SP - 693-705 ST - Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence T2 - Health Education Research TI - Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-42729-002&site=ehost-live&scope=site betsy_sleath@unc.edu VL - 30 ID - 4818 ER - TY - JOUR AB - Little is known about how ophthalmologist-patient communication over time is associated with glaucoma patient long-term adherence. The purpose of our study was to examine the association between provider use of components of the resources and supports in self-management model when communicating with patients and adherence to glaucoma medications measured electronically over an 8-month period. In this longitudinal prospective cohort study, the main variables studied were ophthalmologist communication-individualized assessment, collaborative goal setting and skills enhancement. Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited from six ophthalmology clinics. Patients' baseline and next follow-up visits were videotape-recorded. Patients were interviewed after their visits. Patients used medication event monitoring systems (MEMS) for 8 months after enrollment into the study, and adherence was measured electronically using MEMS for 240 days after their visits. Two hundred and seventy-nine patients participated. Patient race and regimen complexity were negatively associated with glaucoma medication adherence over an 8-month period. Provider communication behaviors, including providing education and positive reinforcement, can improve patient adherence to glaucoma medications over an 8-month period. AN - WOS:000362992600002 AU - Sleath, B. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Sayner, R. AU - Muir, K. W. AU - Slota, C. AU - Giangiacomo, A. L. AU - Hartnett, M. E. AU - Tudor, G. AU - Robin, A. L. DA - OCT DO - 10.1093/her/cyv034 IS - 5 PY - 2015 SN - 0268-1153 1465-3648 SP - 693-705 ST - Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence T2 - HEALTH EDUCATION RESEARCH TI - Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence VL - 30 ID - 5890 ER - TY - JOUR AB - SIGNIFICANCE: The developed video can be accessed by African American patients with glaucoma from across the United States on YouTube to learn why it is important to ask eye care providers any questions they might have about glaucoma and/or its treatment. PURPOSE: Our objective was to develop an educational video for African Americans with glaucoma to watch before their ophthalmology office visits to help motivate them to be actively involved in their care. METHODS: The Social Cognitive Theory guided the development of the video. We conducted three focus groups with African American patients with glaucoma and three focus groups with providers who care for African American patients with glaucoma. The research team reviewed the transcripts of the focus groups and then developed a plan for video production. RESULTS: The themes that both patients and providers felt should be covered in the video to motivate patient question-asking included the following: what is glaucoma, glaucoma treatment, glaucoma testing, and treatment adherence. Based on focus group results, the resulting video had one male African American physician and four African American patients covering the themes that emerged. CONCLUSIONS: Ophthalmologists and African Americans with glaucoma gave us excellent insight into developing videos to increase patient involvement during their visits. AU - Sleath, B. AU - Davis, S. A. AU - Carpenter, D. M. AU - Robin, A. L. AU - Muir, K. W. AU - Lee, C. AU - Garcia, N. AU - Budenz, D. L. DB - Medline DO - 10.1097/OPX.0000000000001530 IS - 7 KW - African American aged ambulatory care doctor patient relationship ethnology female glaucoma human information processing interpersonal communication male middle aged ophthalmologist patient education patient participation procedures United States videorecording LA - English M3 - Article N1 - L632423407 2020-07-30 2021-05-11 PY - 2020 SN - 1538-9235 SP - 503-508 ST - Increasing Engagement of African American Patients with Glaucoma during Medical Encounters: Creation of a Pre-visit Video T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Increasing Engagement of African American Patients with Glaucoma during Medical Encounters: Creation of a Pre-visit Video UR - https://www.embase.com/search/results?subaction=viewrecord&id=L632423407&from=export http://dx.doi.org/10.1097/OPX.0000000000001530 VL - 97 ID - 2402 ER - TY - JOUR AB - Significance: The developed video can be accessed by African American patients with glaucoma from across the United States on YouTube to learn why it is important to ask eye care providers any questions they might have about glaucoma and/or its treatment.Purpose: Our objective was to develop an educational video for African Americans with glaucoma to watch before their ophthalmology office visits to help motivate them to be actively involved in their care.Methods: The Social Cognitive Theory guided the development of the video. We conducted three focus groups with African American patients with glaucoma and three focus groups with providers who care for African American patients with glaucoma. The research team reviewed the transcripts of the focus groups and then developed a plan for video production.Results: The themes that both patients and providers felt should be covered in the video to motivate patient question-asking included the following: what is glaucoma, glaucoma treatment, glaucoma testing, and treatment adherence. Based on focus group results, the resulting video had one male African American physician and four African American patients covering the themes that emerged.Conclusions: Ophthalmologists and African Americans with glaucoma gave us excellent insight into developing videos to increase patient involvement during their visits. AD - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Johns Hopkins University Wilmer Eye Institute, Baltimore, Maryland Department of Ophthalmology, School of Medicine, Duke University, and Health Services Research and Development, Durham VA Medical Center, Durham, North Carolina Alexor, LLC, Durham, North Carolina Division of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina AN - 145250164. Language: English. Entry Date: 20210619. Revision Date: 20210715. Publication Type: journal article. Journal Subset: Biomedical AU - Sleath, Betsy AU - Davis, Scott A. AU - Carpenter, Delesha M. AU - Robin, Alan L. AU - Muir, Kelly W. AU - Lee, Charles AU - Garcia, Nacire AU - Budenz, Donald L. DB - ccm DO - 10.1097/OPX.0000000000001530 DP - EBSCOhost IS - 7 KW - Consumer Participation Videorecording Patient Education -- Methods Glaucoma -- Ethnology Focus Groups Female Male Aged Communication Office Visits Middle Age Physician-Patient Relations United States Social Readjustment Rating Scale N1 - Peer Reviewed; USA. Instrumentation: Social Readjustment Rating Scale (SRRS) (Holmes and Rahe). Grant Information: UL1 TR001111/TR/NCATS NIH HHS/United States. NLM UID: 8904931. PMID: NLM32697557. PY - 2020 SN - 1040-5488 SP - 503-508 ST - Increasing Engagement of African American Patients with Glaucoma during Medical Encounters: Creation of a Pre-visit Video T2 - Optometry & Vision Science TI - Increasing Engagement of African American Patients with Glaucoma during Medical Encounters: Creation of a Pre-visit Video UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145250164&site=ehost-live&scope=site VL - 97 ID - 4177 ER - TY - JOUR AB - SIGNIFICANCE The developed video can be accessed by African American patients with glaucoma from across the United States on YouTube to learn why it is important to ask eye care providers any questions they might have about glaucoma and/or its treatment. PURPOSE Our objective was to develop an educational video for African Americans with glaucoma to watch before their ophthalmology office visits to help motivate them to be actively involved in their care. METHODS The Social Cognitive Theory guided the development of the video. We conducted three focus groups with African American patients with glaucoma and three focus groups with providers who care for African American patients with glaucoma. The research team reviewed the transcripts of the focus groups and then developed a plan for video production. RESULTS The themes that both patients and providers felt should be covered in the video to motivate patient question-asking included the following: what is glaucoma, glaucoma treatment, glaucoma testing, and treatment adherence. Based on focus group results, the resulting video had one male African American physician and four African American patients covering the themes that emerged. CONCLUSIONS Ophthalmologists and African Americans with glaucoma gave us excellent insight into developing videos to increase patient involvement during their visits. © Lippincott Williams & Wilkins. AD - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Johns Hopkins University Wilmer Eye Institute, Baltimore, MD, United States Department of Ophthalmology, School of Medicine, Duke University, Health Services Research and Development, Durham VA Medical Center, Durham, NC, United States Alexor, LLC, Durham, NC, United States Division of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States AU - Sleath, B. AU - Davis, S. A. AU - Carpenter, D. M. AU - Robin, A. L. AU - Muir, K. W. AU - Lee, C. AU - Garcia, N. AU - Budenz, D. L. DB - Scopus DO - 10.1097/OPX.0000000000001530 IS - 7 M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 503-508 ST - Increasing engagement of African American patients with glaucoma during medical encounters: Creation of a pre-visit video T2 - Optometry and Vision Science TI - Increasing engagement of African American patients with glaucoma during medical encounters: Creation of a pre-visit video UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088430466&doi=10.1097%2fOPX.0000000000001530&partnerID=40&md5=7cceb429114c320b1ed1d9a880de58ee VL - 97 ID - 5695 ER - TY - JOUR AB - SIGNIFICANCE The developed video can be accessed by African American patients with glaucoma from across the United States on YouTube to learn why it is important to ask eye care providers any questions they might have about glaucoma and/or its treatment. PURPOSE Our objective was to develop an educational video for African Americans with glaucoma to watch before their ophthalmology office visits to help motivate them to be actively involved in their care. METHODS The Social Cognitive Theory guided the development of the video. We conducted three focus groups with African American patients with glaucoma and three focus groups with providers who care for African American patients with glaucoma. The research team reviewed the transcripts of the focus groups and then developed a plan for video production. RESULTS The themes that both patients and providers felt should be covered in the video to motivate patient question-asking included the following: what is glaucoma, glaucoma treatment, glaucoma testing, and treatment adherence. Based on focus group results, the resulting video had one male African American physician and four African American patients covering the themes that emerged. CONCLUSIONS Ophthalmologists and African Americans with glaucoma gave us excellent insight into developing videos to increase patient involvement during their visits. AN - WOS:000584685400008 AU - Sleath, B. AU - Davis, S. A. AU - Carpenter, D. M. AU - Robin, A. L. AU - Muir, K. W. AU - Lee, C. AU - Garcia, N. AU - Budenz, D. L. DA - JUL DO - 10.1097/OPX.0000000000001530 IS - 7 PY - 2020 SN - 1040-5488 1538-9235 SP - 503-508 ST - Increasing Engagement of African American Patients with Glaucoma during Medical Encounters: Creation of a Pre-visit Video T2 - OPTOMETRY AND VISION SCIENCE TI - Increasing Engagement of African American Patients with Glaucoma during Medical Encounters: Creation of a Pre-visit Video VL - 97 ID - 6053 ER - TY - JOUR AB - Objective: The objectives of the current study were to describe the different types of problems patients receiving adjunctive therapy reported having when taking their glaucoma medications and to examine the relationship between patient-reported problems in taking their glaucoma medications and patient adherence. Design: Cross-sectional survey. Participants: A survey was distributed to glaucoma patients in 4 geographically distinct ophthalmology practices. We excluded patients using only 1 glaucoma medication. The survey was completed by 324 patients. Methods: For each patient, average percent adherence to his or her glaucoma medication regimen was calculated. Logistic regression was used to examine how patient characteristics and problems in using glaucoma medications were related to reported adherence. Main Outcome Measure: Whether patients were less than 100% adherent in the previous week. Results: We found that 60% of patients reported 1 or more problems with taking their glaucoma medications. Fourteen percent of patients reported being less than 100% adherent to their glaucoma regimen medications during the previous week. Patients who had difficulty remembering to take their glaucoma medications and those who reported that they had other problems or concerns with their glaucoma medications were significantly less likely to be 100% adherent. Conclusions: Patient adherence to a glaucoma medication regimen could be improved among patients receiving adjunctive therapy. Ophthalmologists and their clinical colleagues should make sure to discuss the problems and concerns that patients may have in taking their glaucoma medications in an effort to improve adherence. © 2006 by the American Academy of Ophthalmology. AD - B. Sleath, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, CB No. 7590, Chapel Hill, NC 27599-7590, United States AU - Sleath, B. AU - Robin, A. L. AU - Covert, D. AU - Byrd, J. E. AU - Tudor, G. AU - Svarstad, B. DB - Embase Medline DO - 10.1016/j.ophtha.2005.10.034 IS - 3 KW - antiglaucoma agent adult aged article behavior controlled study female glaucoma human major clinical study male patient compliance priority journal self report LA - English M3 - Article N1 - L43296984 2006-03-13 PY - 2006 SN - 0161-6420 SP - 431-436 ST - Patient-reported behavior and problems in using glaucoma medications T2 - Ophthalmology TI - Patient-reported behavior and problems in using glaucoma medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43296984&from=export http://dx.doi.org/10.1016/j.ophtha.2005.10.034 VL - 113 ID - 3624 ER - TY - JOUR AB - We applied the ecologic model of communication in medical consultations to examine how patient, physician, and situational/contextual factors are associated with whether patients ask one or more questions about glaucoma and glaucoma medications during visits to ophthalmologists. Patients with glaucoma who were newly prescribed or already on glaucoma medications were recruited at six ophthalmology clinics. Patients' visits with their doctors were video-recorded and patients were interviewed after visits. Generalized estimating equations were used to analyze the data. Two hundred and seventy-nine patients participated. Patients asked one or more questions about glaucoma during 59% of visits and about glaucoma medications during 48% of visits. Patients who were newly prescribed glaucoma medications were significantly more likely to ask one or more questions about glaucoma and glaucoma medications. Whether providers asked patients if they had questions was not significantly associated with patient question-asking. Patients were significantly more likely to ask older providers questions about glaucoma medications and female providers questions about glaucoma. Eye care providers should encourage glaucoma patients to ask questions during their medical visits. AU - Sleath, B. AU - Sayner, R. AU - Blalock, S. J. AU - Carpenter, D. M. AU - Muir, K. W. AU - Hartnett, M. E. AU - Tudor, G. AU - Lawrence, S. AU - Giangiacomo, A. L. AU - Robin, A. L. DB - Medline DO - 10.1080/10410236.2014.888387 IS - 7 KW - adult aged ambulatory care doctor patient relationship female glaucoma human interpersonal communication male middle aged patient physician psychology statistics and numerical data very elderly videorecording young adult LA - English M3 - Article N1 - L615277256 2017-06-28 PY - 2015 SN - 1532-7027 SP - 660-668 ST - Patient question-asking about glaucoma and glaucoma medications during videotaped medical visits T2 - Health communication TI - Patient question-asking about glaucoma and glaucoma medications during videotaped medical visits UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615277256&from=export http://dx.doi.org/10.1080/10410236.2014.888387 VL - 30 ID - 2865 ER - TY - JOUR AB - We applied the ecologic model of communication in medical consultations to examine how patient, physician, and situational/contextual factors are associated with whether patients ask one or more questions about glaucoma and glaucoma medications during visits to ophthalmologists. Patients with glaucoma who were newly prescribed or already on glaucoma medications were recruited at six ophthalmology clinics. Patients’ visits with their doctors were video-recorded and patients were interviewed after visits. Generalized estimating equations were used to analyze the data. Two hundred and seventy-nine patients participated. Patients asked one or more questions about glaucoma during 59% of visits and about glaucoma medications during 48% of visits. Patients who were newly prescribed glaucoma medications were significantly more likely to ask one or more questions about glaucoma and glaucoma medications. Whether providers asked patients if they had questions was not significantly associated with patient question-asking. Patients were significantly more likely to ask older providers questions about glaucoma medications and female providers questions about glaucoma. Eye care providers should encourage glaucoma patients to ask questions during their medical visits. AD - Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy; Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy Department of Ophthalmology, School of Medicine, Duke University and Durham VA Medical Center Department of Ophthalmology and Visual Sciences, University of Utah Department of Science and Mathematics, Husson University University of North Carolina Kittner Eye Center; Department of Ophthalmology, University of North Carolina at Chapel Hill Department of Ophthalmology, Emory University School of Medicine Department of International Health, Bloomberg School of Public Health, Johns Hopkins University School of Medicine; Department of Ophthalmology, Johns Hopkins University School of Medicine AN - 103790988. Language: English. Entry Date: 20150423. Revision Date: 20200708. Publication Type: Journal Article AU - Sleath, Betsy AU - Sayner, Robyn AU - Blalock, Susan J. AU - Carpenter, Delesha M. AU - Muir, Kelly W. AU - Hartnett, Mary E. AU - Tudor, Gail AU - Lawrence, Scott AU - Giangiacomo, Annette L. AU - Robin, Alan L. DB - ccm DO - 10.1080/10410236.2014.888387 DP - EBSCOhost IS - 7 KW - Physician-Patient Relations Glaucoma Patient Education Office Visits Communication Information Seeking Behavior Human Videorecording United States Multicenter Studies Scales Communication -- Evaluation Literacy -- Evaluation Kappa Statistic T-Tests Chi Square Test Male Female Adult Middle Age Odds Ratio Confidence Intervals Descriptive Statistics Qualitative Studies Descriptive Research Age Factors Sex Factors Funding Source N1 - research; tables/charts. Journal Subset: Blind Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Instrumentation: Rapid Estimate of Adult Literacy in Medicine (REALM). Grant Information: grant EY018400 from the National Eye Institute and by grant UL 1RR02574 7 from the National Center of Research Resources, National Institutes of Health (NIH).. NLM UID: 8908762. PMID: NLM25061778. PY - 2015 SN - 1041-0236 SP - 660-668 ST - Patient Question-Asking About Glaucoma and Glaucoma Medications During Videotaped Medical Visits T2 - Health Communication TI - Patient Question-Asking About Glaucoma and Glaucoma Medications During Videotaped Medical Visits UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103790988&site=ehost-live&scope=site VL - 30 ID - 4345 ER - TY - JOUR AB - We applied the ecologic model of communication in medical consultations to examine how patient, physician, and situational/contextual factors are associated with whether patients ask one or more questions about glaucoma and glaucoma medications during visits to ophthalmologists. Patients with glaucoma who were newly prescribed or already on glaucoma medications were recruited at six ophthalmology clinics. Patients' visits with their doctors were video-recorded and patients were interviewed after visits. Generalized estimating equations were used to analyze the data. Two hundred and seventy-nine patients participated. Patients asked one or more questions about glaucoma during 59% of visits and about glaucoma medications during 48% of visits. Patients who were newly prescribed glaucoma medications were significantly more likely to ask one or more questions about glaucoma and glaucoma medications. Whether providers asked patients if they had questions was not significantly associated with patient question-asking. Patients were significantly more likely to ask older providers questions about glaucoma medications and female providers questions about glaucoma. Eye care providers should encourage glaucoma patients to ask questions during their medical visits. AN - WOS:000353396100003 AU - Sleath, B. AU - Sayner, R. AU - Blalock, S. J. AU - Carpenter, D. M. AU - Muir, K. W. AU - Hartnett, M. E. AU - Tudor, G. AU - Lawrence, S. AU - Giangiacomo, A. L. AU - Robin, A. L. DA - JUL 3 DO - 10.1080/10410236.2014.888387 IS - 7 PY - 2015 SN - 1041-0236 1532-7027 SP - 660-668 ST - Patient Question-Asking About Glaucoma and Glaucoma Medications During Videotaped Medical Visits T2 - HEALTH COMMUNICATION TI - Patient Question-Asking About Glaucoma and Glaucoma Medications During Videotaped Medical Visits VL - 30 ID - 5940 ER - TY - JOUR AB - Objective: The purpose of this study was to: (a) describe the extent to which ophthalmologists and glaucoma patients discuss vision quality-of-life during office visits, and (b) examine the association between patient and ophthalmologist characteristics and provider-patient communication about vision quality-of-life.Methods: Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited at six ophthalmology clinics. Patients' visits were video-tape recorded and quality-of-life communication variables were coded. Generalized estimating equations were used to analyze the data.Results: Two hundred and seventy-nine patients participated. Specific glaucoma quality-of-life domains were discussed during only 13% of visits. Older patients were significantly more likely to discuss one or more vision quality-of-life domains than younger patients. African American patients were significantly less likely to make statements about their vision quality-of-life and providers were less likely to ask them one or more vision quality-of-life questions than non-African American patients.Conclusion: Eye care providers and patients infrequently discussed the patient's vision quality-of-life during glaucoma visits. African American patients were less likely to communicate about vision quality-of-life than non-African American patients.Practice Implications: Eye care providers should make sure to discuss vision quality-of-life with glaucoma patients. AD - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7573, Chapel Hill, NC 27599-7573, USA Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, CB # 7590, Chapel Hill, NC 27599-7590, USA Department of Ophthalmology, School of Medicine, Duke University and Durham VA Medical Center, Health Services Research and Development, 2351 Erwin Rd #3802, Durham, NC 27705, USA Ophthalmology, Emory University School of Medicine, 1365B Clifton Rd, Atlanta, GA 30322, USA Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center University of Utah, 65 N Mario Capecchi, Salt Lake City, UT 84132, USA Ophthalmology and International Health, Johns Hopkins School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA Department of Ophthalmology, University of Maryland, 419 West Redwood St., Suite 420, Baltimore, MD 21201, USA Department of Ophthalmology, University of Michigan, 1000 Wall St., Ann Arbor, MI 48105, USA AN - 122328470. Language: English. Entry Date: 20180108. Revision Date: 20190308. Publication Type: journal article AU - Sleath, Betsy AU - Sayner, Robyn AU - Vitko, Michelle AU - Carpenter, Delesha M. AU - Blalock, Susan J. AU - Muir, Kelly W. AU - Giangiacomo, Annette L. AU - Hartnett, Mary Elizabeth AU - Robin, Alan L. DB - ccm DO - 10.1016/j.pec.2016.11.018 DP - EBSCOhost IS - 4 KW - Patient Centered Care -- Methods Quality of Life Communication Glaucoma -- Psychosocial Factors Aged Aged, 80 and Over Middle Age Socioeconomic Factors Young Adult Office Visits Physician-Patient Relations Videorecording Glaucoma -- Drug Therapy Adult Funding Source Human N1 - research. Journal Subset: Core Nursing; Europe; Health Promotion/Education; Nursing; Peer Reviewed; UK & Ireland. Grant Information: R56 EY015130/EY/NEI NIH HHS/United States. NLM UID: 8406280. PMID: NLM27916461. PY - 2017 SN - 0738-3991 SP - 703-709 ST - Glaucoma patient-provider communication about vision quality-of-life T2 - Patient Education & Counseling TI - Glaucoma patient-provider communication about vision quality-of-life UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122328470&site=ehost-live&scope=site VL - 100 ID - 4284 ER - TY - JOUR AB - Objective: The purpose of this study was to: (a) describe the extent to which ophthalmologists and glaucoma patients discuss vision quality-of-life during office visits, and (b) examine the association between patient and ophthalmologist characteristics and provider-patient communication about vision quality-of-life. Methods: Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited at six ophthalmology clinics. Patients' visits were video-tape recorded and quality-of-life communication variables were coded. Generalized estimating equations were used to analyze the data. Results: Two hundred and seventy-nine patients participated. Specific glaucoma quality-of-life domains were discussed during only 13% of visits. Older patients were significantly more likely to discuss one or more vision quality-of-life domains than younger patients. African American patients were significantly less likely to make statements about their vision quality-of-life and providers were less likely to ask them one or more vision quality-of-life questions than non-African American patients. Conclusion: Eye care providers and patients infrequently discussed the patient's vision quality-of-life during glaucoma visits. African American patients were less likely to communicate about vision quality-of-life than non-African American patients. Practice implications: Eye care providers should make sure to discuss vision quality-of-life with glaucoma patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved. AN - WOS:000401084700012 AU - Sleath, B. AU - Sayner, R. AU - Vitko, M. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Muir, K. W. AU - Giangiacomo, A. L. AU - Hartnett, M. E. AU - Robin, A. L. DA - APR DO - 10.1016/j.pec.2016.11.018 IS - 4 PY - 2017 SN - 0738-3991 SP - 703-709 ST - Glaucoma patient-provider communication about vision quality-of-life T2 - PATIENT EDUCATION AND COUNSELING TI - Glaucoma patient-provider communication about vision quality-of-life VL - 100 ID - 6095 ER - TY - JOUR AB - Purpose The purpose of this preliminary study was to describe the extent to which providers used collaborative goal setting and individualized assessment with patients who were newly prescribed glaucoma medications. Methods English-speaking glaucoma suspect patients from six ophthalmology clinics who were newly prescribed glaucoma medications had their medical visits videotaped and were interviewed after the visits. The videotapes were transcribed and coded to examine provider use of collaborative goal setting and individualized assessment. Results Fifty-one patients seeing 12 ophthalmologists participated. Providers gave patients glaucoma treatment options during 37% of the visits; only five providers gave patients treatment options Providers asked for patient treatment preferences in less than 20% of the visits; only two providers asked for patient treatment preferences. Providers were significantly more likely to ask African American patients for their preferences or ideas concerning treatment than non-African American patients (Pearson (2) = 4.1, p = 0.04). Providers were also significantly more likely to ask African American patients about their confidence in using glaucoma medication regularly than non-African American patients (Pearson (2) = 8.2, p = 0.004). Providers asked about patient views about glaucoma in less than 20% of the visits; five providers asked patients their views on glaucoma and its treatment. Providers were significantly more likely to ask African American patients about their views on glaucoma than non-African American patients (Pearson (2) = 5.62, p = 0.02). Conclusions Eye care providers often did not use collaborative goal setting or conduct individualized assessments of patient views on glaucoma when prescribing treatment for the first time. AN - WOS:000335511300014 AU - Sleath, B. AU - Slota, C. AU - Blalock, S. J. AU - Sayner, R. AU - Carpenter, D. M. AU - Muir, K. W. AU - Hartnett, M. E. AU - Robin, A. L. DA - MAY DO - 10.1097/OPX.0000000000000244 IS - 5 PY - 2014 SN - 1040-5488 1538-9235 SP - 549-555 ST - Provider Use of Collaborative Goal Setting with Glaucoma Patients T2 - OPTOMETRY AND VISION SCIENCE TI - Provider Use of Collaborative Goal Setting with Glaucoma Patients VL - 91 ID - 6065 ER - TY - JOUR AB - Background: Many factors influence glaucoma medication adherence. A better understanding of the relationships between health literacy, depressive symptoms, and patient-reported problems in using glaucoma medications may reveal opportunities for intervention that could improve patients' clinical outcomes.Objective: To examine the relationship between patient characteristics (demographics, health literacy, and depressive symptoms) and patient-reported problems in using glaucoma medications and to assess factors related to patients' self-reported adherence to glaucoma medications.Methods: Patients diagnosed with primary open-angle glaucoma (n = 228) currently taking intraocular pressure-lowering medications were recruited at 6 ophthalmology clinics. Patients were interviewed to identify problems using glaucoma medications, and self-reported medication adherence was determined using a Visual Analog Scale. Questionnaires were administered to assess health literacy, depressive symptoms, outcome expectations, and medication self-efficacy.Results: Younger patients (P = 0.03), patients with depressive symptoms (P = 0.02), and patients who reported more medication problems (P = 0.005) were significantly less adherent to their glaucoma medications. Patients with higher glaucoma medication self-efficacy adherence scores (P = 0.003) and higher outcome expectations (P = 0.03) were significantly more adherent.Conclusions: Providers should consider using tools to screen glaucoma patients for depressive symptoms and for problems in using medications to identify patients who are at higher risk of nonadherence to treatment and who might benefit from follow-up with primary care providers. AD - University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA University of North Carolina at Chapel Hill, NC, USA Duke University, Durham, NC, USA Emory University School of Medicine, Atlanta, GA, USA John A. Moran Eye Center University of Utah, Salt Lake City, UT, USA Johns Hopkins University, Baltimore, MD, USA AN - 96737791. Language: English. Entry Date: In Process. Revision Date: 20191122. Publication Type: journal article. Journal Subset: Biomedical AU - Sleath, Betsy L. AU - Blalock, Susan J. AU - Muir, Kelly W. AU - Carpenter, Delesha M. AU - Lawrence, Scott D. AU - Giangiacomo, Annette L. AU - Goldsmith, Jason A. AU - Hartnett, Mary Elizabeth AU - Slota, Catherine AU - Robin, Alan L. DB - ccm DO - 10.1177/1060028014529413 DP - EBSCOhost IS - 7 N1 - Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9203131. PMID: NLM24692604. PY - 2014 SN - 1060-0280 SP - 856-862 ST - Determinants of Self-Reported Barriers to Glaucoma Medicine Administration and Adherence: A Multisite Study T2 - Annals of Pharmacotherapy TI - Determinants of Self-Reported Barriers to Glaucoma Medicine Administration and Adherence: A Multisite Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=96737791&site=ehost-live&scope=site VL - 48 ID - 4263 ER - TY - JOUR AB - Background: Many factors influence glaucoma medication adherence. A better understanding of the relationships between health literacy, depressive symptoms, and patient-reported problems in using glaucoma medications may reveal opportunities for intervention that could improve patients' clinical outcomes. Objective: To examine the relationship between patient characteristics (demographics, health literacy, and depressive symptoms) and patient-reported problems in using glaucoma medications and to assess factors related to patients' self-reported adherence to glaucoma medications. Methods: Patients diagnosed with primary open-angle glaucoma (n = 228) currently taking intraocular pressure-lowering medications were recruited at 6 ophthalmology clinics. Patients were interviewed to identify problems using glaucoma medications, and self-reported medication adherence was determined using a Visual Analog Scale. Questionnaires were administered to assess health literacy, depressive symptoms, outcome expectations, and medication self-efficacy. Results: Younger patients (P = 0.03), patients with depressive symptoms (P = 0.02), and patients who reported more medication problems (P = 0.005) were significantly less adherent to their glaucoma medications. Patients with higher glaucoma medication self-efficacy adherence scores (P = 0.003) and higher outcome expectations (P = 0.03) were significantly more adherent. Conclusions: Providers should consider using tools to screen glaucoma patients for depressive symptoms and for problems in using medications to identify patients who are at higher risk of nonadherence to treatment and who might benefit from follow-up with primary care providers. © The Author(s) 2014. AD - University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, United States University of North Carolina, Chapel Hill, NC, United States Duke University, Durham, NC, United States Emory University School of Medicine, Atlanta, GA, United States John A. Moran Eye Center University of Utah, Salt Lake City, UT, United States Johns Hopkins University, Baltimore, MD, United States AU - Sleath, B. L. AU - Blalock, S. J. AU - Muir, K. W. AU - Carpenter, D. M. AU - Lawrence, S. D. AU - Giangiacomo, A. L. AU - Goldsmith, J. A. AU - Hartnett, M. E. AU - Slota, C. AU - Robin, A. L. DB - Scopus DO - 10.1177/1060028014529413 IS - 7 KW - Depression Glaucoma Health literacy Medication adherence Self-efficacy M3 - Article N1 - Cited By :22 Export Date: 19 July 2021 PY - 2014 SP - 856-862 ST - Determinants of Self-Reported Barriers to Glaucoma Medicine Administration and Adherence: A Multisite Study T2 - Annals of Pharmacotherapy TI - Determinants of Self-Reported Barriers to Glaucoma Medicine Administration and Adherence: A Multisite Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905023037&doi=10.1177%2f1060028014529413&partnerID=40&md5=df7a5f8f2391869ad50257328c2d18d0 VL - 48 ID - 5122 ER - TY - JOUR AB - Background: Many factors influence glaucoma medication adherence. A better understanding of the relationships between health literacy, depressive symptoms, and patient-reported problems in using glaucoma medications may reveal opportunities for intervention that could improve patients' clinical outcomes. Objective: To examine the relationship between patient characteristics (demographics, health literacy, and depressive symptoms) and patient-reported problems in using glaucoma medications and to assess factors related to patients' self-reported adherence to glaucoma medications. Methods: Patients diagnosed with primary open-angle glaucoma (n = 228) currently taking intraocular pressure lowering medications were recruited at 6 ophthalmology clinics. Patients were interviewed to identify problems using glaucoma medications, and self-reported medication adherence was determined using a Visual Analog Scale. Questionnaires were administered to assess health literacy, depressive symptoms, outcome expectations, and medication self-efficacy. Results: Younger patients (P = 0.03), patients with depressive symptoms (P = 0.02), and patients who reported more medication problems (P = 0.005) were significantly less adherent to their glaucoma medications. Patients with higher glaucoma medication self-efficacy adherence scores (P = 0.003) and higher outcome expectations (P = 0.03) were significantly more adherent. Conclusions: Providers should consider using tools to screen glaucoma patients for depressive symptoms and for problems in using medications to identify patients who are at higher risk of nonadherence to treatment and who might benefit from follow-up with primary care providers. AN - WOS:000337650600004 AU - Sleath, B. L. AU - Blalock, S. J. AU - Muir, K. W. AU - Carpenter, D. M. AU - Lawrence, S. D. AU - Giangiacomo, A. L. AU - Goldsmith, J. A. AU - Hartnett, M. E. AU - Slota, C. AU - Robin, A. L. DA - JUL DO - 10.1177/1060028014529413 IS - 7 PY - 2014 SN - 1060-0280 1542-6270 SP - 856-862 ST - Determinants of Self-Reported Barriers to Glaucoma Medicine Administration and Adherence: A Multisite Study T2 - ANNALS OF PHARMACOTHERAPY TI - Determinants of Self-Reported Barriers to Glaucoma Medicine Administration and Adherence: A Multisite Study VL - 48 ID - 5884 ER - TY - JOUR AB - The objectives of the study were to (a) describe the different types of problems that patients in southern India reported having when taking their glaucoma medications and (b) examine the relationship between patient reported-problems in taking their glaucoma medications and the self-reported patient adherence. A survey was conducted by clinical staff on 243 glaucoma patients who were on at least one glaucoma medication in an eye clinic in southern India. We found that 42% of patients reported one or more problems in using their glaucoma medications. Approximately 6% of patients reported being less than 100% adherent in the past week. Unmarried patients and patients who reported difficulty squeezing the bottle and difficulty opening the bottle were significantly more likely to report nonadherence. AD - B. L. Sleath, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, CB # 7360, Chapel Hill, NC 27599-7360, United States AU - Sleath, B. L. AU - Krishnadas, R. AU - Cho, M. AU - Robin, A. L. AU - Mehta, R. AU - Covert, D. AU - Tudor, G. DB - Medline DO - 10.4103/0301-4738.44495 IS - 1 KW - antihypertensive agent article attitude to health drug utilization female glaucoma health care delivery health services research human India male medication error patient compliance questionnaire statistics urban population LA - English M3 - Article N1 - L354008853 2009-02-26 PY - 2009 SN - 0301-4738 1998-3689 SP - 63-68 ST - Patient-reported barriers to glaucoma medication access, use, and adherence in southern India T2 - Indian Journal of Ophthalmology TI - Patient-reported barriers to glaucoma medication access, use, and adherence in southern India UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354008853&from=export http://dx.doi.org/10.4103/0301-4738.44495 VL - 57 ID - 3367 ER - TY - JOUR AB - The objectives of the study were to (a) describe the different types of problems that patients in southern India reported having when taking their glaucoma medications and (b) examine the relationship between patient reported-problems in taking their glaucoma medications and the self-reported patient adherence. A survey was conducted by clinical staff on 243 glaucoma patients who were on at least one glaucoma medication in an eye clinic in southern India. We found that 42% of patients reported one or more problems in using their glaucoma medications. Approximately 6% of patients reported being less than 100% adherent in the past week. Unmarried patients and patients who reported difficulty squeezing the bottle and difficulty opening the bottle were significantly more likely to report nonadherence. AD - University of North Carolina, Chapel Hill, North Carolina, USA University of North Carolina and Research Associate, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. betsy_sleath@unc.edu. AN - 105619224. Language: English. Entry Date: 20090306. Revision Date: 20200708. Publication Type: journal article AU - Sleath, B. L. AU - Krishnadas, R. AU - Cho, M. AU - Robin, A. L. AU - Mehta, R. AU - Covert, D. AU - Tudor, G. AU - Sleath, Betsy L. AU - Krishnadas, R. AU - Cho, Minhee AU - Robin, Alan L. AU - Mehta, Rakhi AU - Covert, David AU - Tudor, Gail DB - ccm DO - 10.4103/0301-4738.44495 DP - EBSCOhost IS - 1 KW - Antihypertensive Agents -- Therapeutic Use Attitude to Health Drug Utilization -- Statistics and Numerical Data Glaucoma -- Drug Therapy Health Services Accessibility -- Statistics and Numerical Data Medication Errors -- Statistics and Numerical Data Patient Compliance Female Health Services Research India Male Questionnaires Urban Population Human N1 - research. Journal Subset: Asia; Biomedical; Peer Reviewed. NLM UID: 0405376. PMID: NLM19075417. PY - 2009 SN - 0301-4738 SP - 63-68 ST - Patient-reported barriers to glaucoma medication access, use, and adherence in southern India T2 - Indian Journal of Ophthalmology TI - Patient-reported barriers to glaucoma medication access, use, and adherence in southern India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105619224&site=ehost-live&scope=site VL - 57 ID - 4357 ER - TY - JOUR AB - Over the last two decades there has been an increasing demand on health care services. This has led to increased waiting lists and waiting times to access public hospital services. In ophthalmic practice an aging population and technological advances have been major contributors to this situation. The challenge for health care providers is how to manage waiting lists within the resources provided and targets set by Elective Services, a department of the Ministry of Health (MoH). The Ministerial Taskforce on Nursing (1998) highlighted that nurses are an underutilised resource. Subsequent to the Ministerial Taskforce, the availability of interim funding from Elective Services and a skilled speciality nursing workforce the Ophthalmology Department at a large metropolitan hospital was able to implement an advanced nursing role with respect to glaucoma management. Early diagnosis is important in reducing the risk of permanent visual impairment from primary open angle glaucoma; therefore the length of time to diagnosis can have long term implications for the patient. Patients for the 'nurse-led' glaucoma clinic were recruited from specific categories of glaucoma patients on the waiting list. An audit of the impact on the waiting list was undertaken periodically over a two year first specialist assessment for glaucoma. The implementation of this role proved to be successful and has subsequently become a permanent nurse specialist position in the ophthalmology department. AD - Opthalmology Department, Auckland District Health Board AN - 105532095. Language: English. Entry Date: 20090626. Revision Date: 20150820. Publication Type: Journal Article AU - Slight, C. AU - Marsden, J. AU - Raynel, S. DB - ccm DP - EBSCOhost IS - 1 KW - Clinical Nurse Specialists Glaucoma -- Diagnosis Ophthalmic Nursing Waiting Lists Audit Clinical Competence New Zealand Nurse-Managed Centers Nursing Role Outcomes (Health Care) Patient Selection Prospective Studies Referral and Consultation Triage Human N1 - research; tables/charts. Journal Subset: Australia & New Zealand; Blind Peer Reviewed; Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed. NLM UID: 9212162. PMID: NLM19558053. PY - 2009 SN - 0112-7438 SP - 38-47 ST - The impact of a glaucoma nurse specialist role on glaucoma waiting lists T2 - Nursing Praxis in New Zealand TI - The impact of a glaucoma nurse specialist role on glaucoma waiting lists UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105532095&site=ehost-live&scope=site VL - 25 ID - 4305 ER - TY - JOUR AB - Objective. To determine factors affecting compliance with guidelines for annual eye examinations for persons diagnosed with diabetes mellitus (DM) or age-related macular degeneration (ARMD). Data Sources/Study Setting. Nationally representative, longitudinal sample of individuals 65+ drawn from the National Long-Term Care Survey (NLTCS) with linked Medicare claims records from 1991 to 1999. Study Design. Medicare beneficiaries were followed from 1991 to 1999, unless mortality intervened. All claims data were analyzed for presence of ICD-9 codes indicating diagnosis of DM or ARMD and the performance of eye exams. The dependent variable was a binary indicator for whether a person had an eye exam or not during a 15-month period. Independent variables for demographics, living conditions, supplemental insurance, income, and other factors affecting the marginal cost and benefit of an eye exam were assessed to determine reasons for noncompliance. Data Collection/Extraction Methods. Panel data were created from claims files, 1991-1999, merged with data from the NLTCS. Principal Findings. The probability of having an exam reflected perceived benefits, which vary by patient characteristics (e.g., education, no dementia), and factors associated with the ease of visit. African Americans were much less likely to be examined than were whites. Conclusions. Having an exam reflects multiple factors. However, much of the variation in the probability of an exam remained unexplained as were reasons for the racial differences in use. AD - Department of Economics, Box 90097, Duke University, Durham, NC 27708, United States Ctr. for Hlth. Plcy., Law, and Mgmt., Duke University, United States Research Triangle Institute, Durham, NC, United States School of Medicine, Johns Hopkins University, Baltimore, MD, United States Department of Economics, University of South Florida, Tampa, FL, United States Department of Ophthalmology, Duke University Medical Center, United States AU - Sloan, F. A. AU - Brown, D. S. AU - Carlisle, E. S. AU - Picone, G. A. AU - Lee, P. P. DB - Scopus DO - 10.1111/j.1475-6773.2004.00297.x IS - 5 KW - Age-related macular degeneration Compliance Diabetes mellitus Eye care Practice guidelines M3 - Article N1 - Cited By :57 Export Date: 19 July 2021 PY - 2004 SP - 1429-1448 ST - Monitoring visual status: Why patients do or do not comply with practice guidelines T2 - Health Services Research TI - Monitoring visual status: Why patients do or do not comply with practice guidelines UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-4844229526&doi=10.1111%2fj.1475-6773.2004.00297.x&partnerID=40&md5=5d4d2da986be1c1ee768b9c7185c6e02 VL - 39 ID - 4978 ER - TY - JOUR AB - Objective: To determine factors affecting compliance with guidelines for annual eye examinations for persons diagnosed with diabetes mellitus (DM) or age-related macular degeneration (ARMD).Data Sources/study Setting: Nationally representative, longitudinal sample of individuals 65+ drawn from the National Long-Term Care Survey (NLTCS) with linked Medicare claims records from 1991 to 1999.Study Design: Medicare beneficiaries were followed from 1991 to 1999, unless mortality intervened. All claims data were analyzed for presence of ICD-9 codes indicating diagnosis of DM or ARMD and the performance of eye exams. The dependent variable was a binary indicator for whether a person had an eye exam or not during a 15-month period. Independent variables for demographics, living conditions, supplemental insurance, income, and other factors affecting the marginal cost and benefit of an eye exam were assessed to determine reasons for noncompliance.Data Collection/extraction Methods: Panel data were created from claims files, 1991-1999, merged with data from the NLTCS.Principal Findings: The probability of having an exam reflected perceived benefits, which vary by patient characteristics (e.g., education, no dementia), and factors associated with the ease of visit. African Americans were much less likely to be examined than were whites.Conclusions: Having an exam reflects multiple factors. However, much of the variation in the probability of an exam remained unexplained as were reasons for the racial differences in use. AD - Department of Economics, Box 90097, Duke University, Durham, North Carolina, 27708, USA Department of Economics, Box 90097, Duke University, Durham, NC 27708 AN - 106601206. Language: English. Entry Date: 20050401. Revision Date: 20200708. Publication Type: journal article AU - Sloan, F. A. AU - Brown, D. S. AU - Carlisle, E. S. AU - Picone, G. A. AU - Lee, P. P. AU - Sloan, Frank A. AU - Brown, Derek S. AU - Carlisle, Emily Streyer AU - Picone, Gabriel A. AU - Lee, Paul P. DB - ccm DO - 10.1111/j.1475-6773.2004.00297.x DP - EBSCOhost IS - 5 KW - Diabetic Retinopathy -- Prevention and Control -- In Old Age Macular Degeneration -- Prevention and Control -- In Old Age Patient Compliance -- In Old Age Vision Screening -- Utilization -- In Old Age Aged Comorbidity Confidence Intervals Descriptive Statistics Diabetes Mellitus -- Complications Diabetic Retinopathy -- Epidemiology Diagnosis, Eye Eye Diseases -- Prevention and Control Funding Source Glaucoma -- Prevention and Control Macular Degeneration -- Epidemiology Medicare Odds Ratio Practice Guidelines Probability Prospective Studies Regression Socioeconomic Factors Vision Tests Human N1 - research; tables/charts. Journal Subset: Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Services Administration; Peer Reviewed; USA. Grant Information: 1R01-AG-17473/AG/NIA NIH HHS/United States. NLM UID: 0053006. PMID: NLM15333116. PY - 2004 SN - 0017-9124 SP - 1429-1448 ST - Monitoring visual status: why patients do or do not comply with practice guidelines T2 - Health Services Research TI - Monitoring visual status: why patients do or do not comply with practice guidelines UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106601206&site=ehost-live&scope=site VL - 39 ID - 4654 ER - TY - JOUR AB - SIGNIFICANCE: This article is the first to investigate the nature of medication cost discussions between ophthalmologists and glaucoma patients. Only 87 of the 275 office visits analyzed had a discussion of medication cost. Providers should consider discussing medication cost with patients to identify potential cost-related barriers to medication use. PURPOSE: Glaucoma is an incurable chronic eye disease affecting a growing portion of the aging population. Some of the most commonly utilized treatments require lifelong use, requiring high patient adherence to ensure effectiveness. There are numerous barriers to glaucoma treatment adherence in the literature, including cost. The aim of this secondary analysis was to describe the frequency and nature of patient-physician communication regarding medication cost during glaucoma office visits. METHODS: This was a mixed-methods secondary analysis of video-recorded participant office visits (n = 275) from a larger observational study of glaucoma communication. We analyzed medical information, demographic characteristics, and interviewer-administrated questionnaires, as well as verbatim transcripts of interviews. RESULTS: Only 87 participants discussed medication cost during their glaucoma office visit. The majority of the subjects who discussed cost had mild disease severity (51%), took one glaucoma medication (63%), and had Medicare (49%) as well as a form of prescription insurance (78%). The majority of glaucoma office visits did not discuss medication cost, and providers often did not ask about cost problems. Of the few conversations related to cost, most focused on providers offering potential solutions (n = 50), medical and prescription service coverage (n = 41), and brand or generic medication choices (n = 41). CONCLUSIONS: Our findings are similar to previous studies showing few patients have conversations with providers about the cost of glaucoma medications. Providers should consider bringing up medication cost during glaucoma office visits to prompt a discussion of potential cost-related barriers to medication use. AU - Slota, C. AU - Davis, S. A. AU - Blalock, S. J. AU - Carpenter, D. M. AU - Muir, K. W. AU - Robin, A. L. AU - Sleath, B. DB - Medline DO - 10.1097/OPX.0000000000001139 IS - 12 KW - antihypertensive agent adult aged ambulatory care doctor patient relationship drug cost economics female glaucoma human interpersonal communication male middle aged ophthalmologist patient compliance patient participation statistics and numerical data very elderly LA - English M3 - Article N1 - L619808575 2017-12-22 PY - 2017 SN - 1538-9235 SP - 1095-1101 ST - Patient-Physician Communication on Medication Cost during Glaucoma Visits T2 - Optometry and vision science : official publication of the American Academy of Optometry TI - Patient-Physician Communication on Medication Cost during Glaucoma Visits UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619808575&from=export http://dx.doi.org/10.1097/OPX.0000000000001139 VL - 94 ID - 2621 ER - TY - JOUR AB - Significance: This article is the first to investigate the nature of medication cost discussions between ophthalmologists and glaucoma patients. Only 87 of the 275 office visits analyzed had a discussion of medication cost. Providers should consider discussing medication cost with patients to identify potential cost-related barriers to medication use.Purpose: Glaucoma is an incurable chronic eye disease affecting a growing portion of the aging population. Some of the most commonly utilized treatments require lifelong use, requiring high patient adherence to ensure effectiveness. There are numerous barriers to glaucoma treatment adherence in the literature, including cost. The aim of this secondary analysis was to describe the frequency and nature of patient-physician communication regarding medication cost during glaucoma office visits.Methods: This was a mixed-methods secondary analysis of video-recorded participant office visits (n = 275) from a larger observational study of glaucoma communication. We analyzed medical information, demographic characteristics, and interviewer-administrated questionnaires, as well as verbatim transcripts of interviews.Results: Only 87 participants discussed medication cost during their glaucoma office visit. The majority of the subjects who discussed cost had mild disease severity (51%), took one glaucoma medication (63%), and had Medicare (49%) as well as a form of prescription insurance (78%). The majority of glaucoma office visits did not discuss medication cost, and providers often did not ask about cost problems. Of the few conversations related to cost, most focused on providers offering potential solutions (n = 50), medical and prescription service coverage (n = 41), and brand or generic medication choices (n = 41).Conclusions: Our findings are similar to previous studies showing few patients have conversations with providers about the cost of glaucoma medications. Providers should consider bringing up medication cost during glaucoma office visits to prompt a discussion of potential cost-related barriers to medication use. AD - RTI International, Research Triangle Park, North Carolina Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina Health Services Research & Development, Durham VA Medical Center, Durham, North Carolina Department of Ophthalmology, University of Maryland, Baltimore, Maryland Department of Ophthalmology, University of Michigan, Ann Arbor, Michigan Department of International Health, Bloomberg School of Public Health, and Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, Maryland AN - 126502593. Language: English. Entry Date: 20171211. Revision Date: 20181223. Publication Type: journal article AU - Slota, Catherine AU - Davis, Scott A. AU - Blalock, Susan J. AU - Carpenter, Delesha M. AU - Muir, Kelly W. AU - Robin, Alan L. AU - Sleath, Betsy DB - ccm DO - 10.1097/OPX.0000000000001139 DP - EBSCOhost IS - 12 KW - Antihypertensive Agents -- Economics Communication Consumer Participation -- Statistics and Numerical Data Glaucoma -- Economics Health Care Costs Physician-Patient Relations Glaucoma -- Drug Therapy Female Aged Aged, 80 and Over Office Visits Adult Male Patient Compliance Middle Age Funding Source Human N1 - pictorial; research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: R36 HS023054/HS/AHRQ HHS/United States. NLM UID: 8904931. PMID: NLM29194229. PY - 2017 SN - 1040-5488 SP - 1095-1101 ST - Patient-Physician Communication on Medication Cost during Glaucoma Visits T2 - Optometry & Vision Science TI - Patient-Physician Communication on Medication Cost during Glaucoma Visits UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126502593&site=ehost-live&scope=site VL - 94 ID - 4245 ER - TY - JOUR AB - SIGNIFICANCE This article is the first to investigate the nature of medication cost discussions between ophthalmologists and glaucoma patients. Only 87 of the 275 office visits analyzed had a discussion of medication cost. Providers should consider discussing medication cost with patients to identify potential cost-related barriers to medication use. PURPOSE Glaucoma is an incurable chronic eye disease affecting a growing portion of the aging population. Some of the most commonly utilized treatments require lifelong use, requiring high patient adherence to ensure effectiveness. There are numerous barriers to glaucoma treatment adherence in the literature, including cost. The aim of this secondary analysis was to describe the frequency and nature of patient-physician communication regarding medication cost during glaucoma office visits. METHODS This was a mixed-methods secondary analysis of video-recorded participant office visits (n = 275) from a larger observational study of glaucoma communication. We analyzed medical information, demographic characteristics, and interviewer-administrated questionnaires, as well as verbatim transcripts of interviews. RESULTS Only 87 participants discussed medication cost during their glaucoma office visit. The majority of the subjects who discussed cost had mild disease severity (51%), took one glaucoma medication (63%), and had Medicare (49%) as well as a form of prescription insurance (78%). The majority of glaucoma office visits did not discuss medication cost, and providers often did not ask about cost problems. Of the few conversations related to cost, most focused on providers offering potential solutions (n = 50), medical and prescription service coverage (n = 41), and brand or generic medication choices (n = 41). CONCLUSIONS Our findings are similar to previous studies showing few patients have conversations with providers about the cost of glaucoma medications. Providers should consider bringing up medication cost during glaucoma office visits to prompt a discussion of potential cost-related barriers to medication use. © Copyright 2017 American Academy of Optometry. AD - RTI International, Research Triangle Park, Durham, NC, United States Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, NC, United States Department of Ophthalmology, Duke University School of Medicine, Durham, NC, United States Health Services Research and Development, Durham VA Medical Center, Durham, NC, United States Department of Ophthalmology, University of Maryland, Baltimore, MD, United States Department of Ophthalmology, University of Michigan, Ann Arbor, MI, United States Department of International Health, Bloomberg School of Public Health, Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD, United States AU - Slota, C. AU - Davis, S. A. AU - Blalock, S. J. AU - Carpenter, D. M. AU - Muir, K. W. AU - Robin, A. L. AU - Sleath, B. DB - Scopus DO - 10.1097/OPX.0000000000001139 IS - 12 M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2017 SP - 1095-1101 ST - Patient-Physician Communication on Medication Cost during Glaucoma Visits T2 - Optometry and Vision Science TI - Patient-Physician Communication on Medication Cost during Glaucoma Visits UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85036453232&doi=10.1097%2fOPX.0000000000001139&partnerID=40&md5=574eda205bd502d2b89177dc88c68bbf VL - 94 ID - 5346 ER - TY - JOUR AB - SIGNIFICANCE This article is the first to investigate the nature of medication cost discussions between ophthalmologists and glaucoma patients. Only 87 of the 275 office visits analyzed had a discussion of medication cost. Providers should consider discussing medication cost with patients to identify potential cost-related barriers to medication use. PURPOSE Glaucoma is an incurable chronic eye disease affecting a growing portion of the aging population. Some of the most commonly utilized treatments require lifelong use, requiring high patient adherence to ensure effectiveness. There are numerous barriers to glaucoma treatment adherence in the literature, including cost. The aim of this secondary analysis was to describe the frequency and nature of patient-physician communication regarding medication cost during glaucoma office visits. METHODS This was a mixed-methods secondary analysis of video-recorded participant office visits (n = 275) from a larger observational study of glaucoma communication. We analyzed medical information, demographic characteristics, and interviewer-administrated questionnaires, as well as verbatim transcripts of interviews. RESULTS Only 87 participants discussed medication cost during their glaucoma office visit. The majority of the subjects who discussed cost had mild disease severity (51%), took one glaucoma medication (63%), and had Medicare (49%) as well as a form of prescription insurance (78%). The majority of glaucoma office visits did not discuss medication cost, and providers often did not ask about cost problems. Of the few conversations related to cost, most focused on providers offering potential solutions (n = 50), medical and prescription service coverage (n = 41), and brand or generic medication choices (n = 41). CONCLUSIONS Our findings are similar to previous studies showing few patients have conversations with providers about the cost of glaucoma medications. Providers should consider bringing up medication cost during glaucoma office visits to prompt a discussion of potential cost-related barriers to medication use. AN - WOS:000416836000005 AU - Slota, C. AU - Davis, S. A. AU - Blalock, S. J. AU - Carpenter, D. M. AU - Muir, K. W. AU - Robin, A. L. AU - Sleath, B. DA - DEC DO - 10.1097/OPX.0000000000001139 IS - 12 PY - 2017 SN - 1040-5488 1538-9235 SP - 1095-1101 ST - Patient-Physician Communication on Medication Cost during Glaucoma Visits T2 - OPTOMETRY AND VISION SCIENCE TI - Patient-Physician Communication on Medication Cost during Glaucoma Visits VL - 94 ID - 5957 ER - TY - JOUR AB - Purpose: The purpose of this study was to examine if patient demographic factors influenced self-reporting of medication side effects, difficulty with drop instillation, and nonadherence to glaucoma therapy.Methods: English-speaking adult glaucoma patients (n = 279) from six ophthalmology clinics were enrolled. Patients' medical visits were videotaped and patients were interviewed immediately afterward by research assistants. The videotapes were transcribed verbatim and coded to identify patients who expressed problems with medication side effects, eye drop administration, and nonadherence during the glaucoma office visits. Generalized estimating equations were performed to identify whether patient characteristics were associated with expression of problems with glaucoma medication and medication nonadherence during the office visit.Results: Patients with lower health literacy were significantly less likely to express problems with side effects (odds ratio [OR], 0.47; 95% confidence interval [CI], 0.25 to 0.88) and eye drop administration (OR, 0.26; 95% CI, 0.11 to 0.63) during the visit. Patients who reported eye drop administration and side effect problems during the interview were significantly more likely to express these problems to their ophthalmologist (OR, 3.13; 95% CI, 1.82 to 5.37 and OR, 1.86; 95% CI, 1.12 to 3.08, respectively). Patients who expressed a problem with eye drop administration and with side effects were significantly more likely to express medication nonadherence to their ophthalmologist (OR, 2.89; 95% CI, 1.44 to 5.80 and OR, 2.03; 95% CI, 1.16 to 3.54, respectively). Patients who reported greater than 80% medication adherence during the interview were significantly less likely to express nonadherence to their ophthalmologist (OR, 0.22; 95% CI, 0.12 to 0.40).Conclusions: Eye care providers should be aware that glaucoma patients with lower health literacy are less likely to express problems with side effects and eye drop administration. Providers should work with patients to assess medication-related problems to mitigate potential barriers to medication adherence because patients who expressed medication problems were also more likely to express nonadherence. AN - 109783085. Language: English. Entry Date: 20150821. Revision Date: 20191223. Publication Type: journal article AU - Slota, Catherine AU - Sayner, Robyn AU - Vitko, Michelle AU - Carpenter, Delesha M. AU - Blalock, Susan J. AU - Robin, Alan L. AU - Muir, Kelly W. AU - Hartnett, Mary Elizabeth AU - Sleath, Betsy DB - ccm DO - 10.1097/OPX.0000000000000574 DP - EBSCOhost IS - 5 KW - Antihypertensive Agents -- Adverse Effects Glaucoma -- Drug Therapy Information Literacy Medication Compliance Patients -- Psychosocial Factors Adult Black Persons Aged Aged, 80 and Over Antihypertensive Agents -- Administration and Dosage White Persons Female Glaucoma -- Ethnology Human Intraocular Pressure -- Drug Effects Male Middle Age Ophthalmic Solutions -- Administration and Dosage Ophthalmic Solutions -- Adverse Effects Questionnaires Young Adult N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: R56 EY015130/EY/NEI NIH HHS/United States. NLM UID: 8904931. PMID: NLM25875690. PY - 2015 SN - 1040-5488 SP - 537-543 ST - Glaucoma patient expression of medication problems and nonadherence T2 - Optometry & Vision Science TI - Glaucoma patient expression of medication problems and nonadherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109783085&site=ehost-live&scope=site VL - 92 ID - 4261 ER - TY - JOUR AB - Purpose. The purpose of this study was to examine if patient demographic factors influenced self-reporting of medication side effects, difficulty with drop instillation, and nonadherence to glaucoma therapy. Methods. English-speaking adult glaucoma patients (n = 279) from six ophthalmology clinics were enrolled. Patients' medical visits were videotaped and patients were interviewed immediately afterward by research assistants. The videotapes were transcribed verbatim and coded to identify patients who expressed problems with medication side effects, eye drop administration, and nonadherence during the glaucoma office visits. Generalized estimating equations were performed to identify whether patient characteristics were associated with expression of problems with glaucoma medication and medication nonadherence during the office visit. Results. Patients with lower health literacy were significantly less likely to express problems with side effects (odds ratio [OR], 0.47; 95% confidence interval [CI], 0.25 to 0.88) and eye drop administration (OR, 0.26; 95% CI, 0.11 to 0.63) during the visit. Patients who reported eye drop administration and side effect problems during the interview were significantly more likely to express these problems to their ophthalmologist (OR, 3.13; 95% CI, 1.82 to 5.37 and OR, 1.86; 95% CI, 1.12 to 3.08, respectively). Patients who expressed a problem with eye drop administration and with side effects were significantly more likely to express medication nonadherence to their ophthalmologist (OR, 2.89; 95% CI, 1.44 to 5.80 and OR, 2.03; 95% CI, 1.16 to 3.54, respectively). Patients who reported greater than 80% medication adherence during the interview were significantly less likely to express nonadherence to their ophthalmologist (OR, 0.22; 95% CI, 0.12 to 0.40). Conclusions. Eye care providers should be aware that glaucoma patients with lower health literacy are less likely to express problems with side effects and eye drop administration. Providers should work with patients to assess medication-related problems to mitigate potential barriers to medication adherence because patients who expressed medication problems were also more likely to express nonadherence. © 2015 American Academy of Optometry. AD - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB #7573, Kerr Hall, Chapel Hill, NC 27599, United States Department of Ophthalmology, University of Maryland, Baltimore, MD, United States Department of Ophthalmology, University of Michigan, Ann Arbor, MI, United States Department of International Health, Bloomberg School of Public Health, Baltimore, MD, United States Department of Ophthalmology, School of Medicine, Johns Hopkins University, Baltimore, MD, United States Department of Ophthalmology, School of Medicine, Duke University, Durham, NC, United States Durham VA Medical Center, Health Services Research and Development, Durham, NC, United States Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center University of Utah, Salt Lake City, UT, United States Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States AU - Slota, C. AU - Sayner, R. AU - Vitko, M. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Robin, A. L. AU - Muir, K. W. AU - Hartnett, M. E. AU - Sleath, B. DB - Scopus DO - 10.1097/OPX.0000000000000574 IS - 5 KW - adherence glaucoma health literacy medications patient expression M3 - Article N1 - Cited By :13 Export Date: 19 July 2021 PY - 2015 SP - 537-543 ST - Glaucoma patient expression of medication problems and nonadherence T2 - Optometry and Vision Science TI - Glaucoma patient expression of medication problems and nonadherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929453377&doi=10.1097%2fOPX.0000000000000574&partnerID=40&md5=03c84c8cb931ed67161d1ffc2a8f651b VL - 92 ID - 5217 ER - TY - JOUR AB - Purpose. The purpose of this study was to examine if patient demographic factors influenced self-reporting of medication side effects, difficulty with drop instillation, and nonadherence to glaucoma therapy. Methods. English-speaking adult glaucoma patients (n = 279) from six ophthalmology clinics were enrolled. Patients' medical visits were videotaped and patients were interviewed immediately afterward by research assistants. The videotapes were transcribed verbatim and coded to identify patients who expressed problems with medication side effects, eye drop administration, and nonadherence during the glaucoma office visits. Generalized estimating equations were performed to identify whether patient characteristics were associated with expression of problems with glaucoma medication and medication nonadherence during the office visit. Results. Patients with lower health literacy were significantly less likely to express problems with side effects (odds ratio [OR], 0.47; 95% confidence interval [CI], 0.25 to 0.88) and eye drop administration (OR, 0.26; 95% CI, 0.11 to 0.63) during the visit. Patients who reported eye drop administration and side effect problems during the interview were significantly more likely to express these problems to their ophthalmologist (OR, 3.13; 95% CI, 1.82 to 5.37 and OR, 1.86; 95% CI, 1.12 to 3.08, respectively). Patients who expressed a problem with eye drop administration and with side effects were significantly more likely to express medication nonadherence to their ophthalmologist (OR, 2.89; 95% CI, 1.44 to 5.80 and OR, 2.03; 95% CI, 1.16 to 3.54, respectively). Patients who reported greater than 80% medication adherence during the interview were significantly less likely to express nonadherence to their ophthalmologist (OR, 0.22; 95% CI, 0.12 to 0.40). Conclusions. Eye care providers should be aware that glaucoma patients with lower health literacy are less likely to express problems with side effects and eye drop administration. Providers should work with patients to assess medication-related problems to mitigate potential barriers to medication adherence because patients who expressed medication problems were also more likely to express nonadherence. AN - WOS:000353421500007 AU - Slota, C. AU - Sayner, R. AU - Vitko, M. AU - Carpenter, D. M. AU - Blalock, S. J. AU - Robin, A. L. AU - Muir, K. W. AU - Hartnett, M. E. AU - Sleath, B. DA - MAY DO - 10.1097/OPX.0000000000000574 IS - 5 PY - 2015 SN - 1040-5488 1538-9235 SP - 537-543 ST - Glaucoma Patient Expression of Medication Problems and Nonadherence T2 - OPTOMETRY AND VISION SCIENCE TI - Glaucoma Patient Expression of Medication Problems and Nonadherence VL - 92 ID - 5898 ER - TY - JOUR AD - S.D. Smith, Glaucoma Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, United States AU - Smith, S. D. AU - Netland, P. A. DB - Embase Medline DO - 10.1097/00004397-199403430-00014 IS - 3 KW - acetazolamide epinephrine antiglaucoma agent beta adrenergic receptor blocking agent betaxolol calcium channel blocking agent carbachol carbonate dehydratase inhibitor cholinergic receptor stimulating agent demecarium dipivefrine ecothiopate iodide levobunolol metipranolol pilocarpine timolol timolol maleate uric acid aplastic anemia bronchospasm cardiovascular disease drug cost gastrointestinal symptom human intraocular hypertension iritis lacrimal duct occlusion laser laser surgery open angle glaucoma patient compliance priority journal retina detachment retina macula cystoid edema review trabeculoplasty visual field defect visual impairment LA - English M3 - Review N1 - L24268686 1994-09-12 PY - 1994 SN - 0020-8167 SP - 149-161 ST - The role of laser trabeculoplasty as primary therapy for open-angle glaucoma T2 - International Ophthalmology Clinics TI - The role of laser trabeculoplasty as primary therapy for open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L24268686&from=export http://dx.doi.org/10.1097/00004397-199403430-00014 VL - 34 ID - 3994 ER - TY - JOUR AB - BACKGROUND: Corneal ulcers related to contact lens wear are four to 15 times more likely to occur with extended wear lenses versus daily wear lenses. The introduction of disposable contact lenses raised hopes that this product would reduce complications related to contact lens wear. Such has proven not to be the case, especially when patients are noncompliant with the prescribed wear and care regimen. METHODS: The ordering patterns of a group of 145 patients wearing disposable contact lenses were monitored for a period of one year, 5 months in an attempt to identify those individuals who were potentially noncompliant in their wearing schedules. RESULTS: Up to 69 percent of the patients studied were identified as potentially noncompliant. A program to counsel and re-educate these patients about proper disposable contact lens wear was proposed. CONCLUSIONS: Eye care professionals have a legal and ethical responsibility to provide appropriate follow-up care for patients. The ability to track ordering patterns of patients who wear disposable contact lenses provides a valuable tool to use in identifying patients who could be putting themselves at risk to develop complications related to contact lens wear. AU - Smith, S. K. DB - Scopus IS - 3 M3 - Article N1 - Cited By :10 Export Date: 19 July 2021 PY - 1996 SP - 160-164 ST - Patient noncompliance with wearing and replacement schedules of disposable contact lenses T2 - Journal of the American Optometric Association TI - Patient noncompliance with wearing and replacement schedules of disposable contact lenses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030093510&partnerID=40&md5=6294781d33f8761060fac2c95c05a684 VL - 67 ID - 5292 ER - TY - JOUR AB - Purpose: To determine how often glaucoma specialists set a target intraocular pressure (IOP) and how they respond when the target is not achieved. Methods: We reviewed 250 randomly selected charts of glaucoma patients seen by 5 glaucoma specialists to identify whether a target IOP was specifically set and to detail the plan of action when the target was exceeded. Results: A target IOP was present for at least 1 eye in 66% of patients (165/250). Among the patients of 5 physicians, the percentage with a target IOP for both eyes ranged from 90% to 34%. Half of eyes with no target had an explaining feature, whereas the other half did not. The study visit IOP exceeded the target in at least 1 eye in 29% (50/173) of patients. When the target was not met, 66% (33/50) had a notation of action taken, with no significant difference among physicians in whether any action was taken (P=0.64). The significant differences among the 5 physicians in the use of target IOP were potentially associated with patient demographic and clinical features, such as age, race, treatment intensity, and visual field damage, which differed among the 5 practices (all P<0.05). Conclusions: Target IOP was recorded in the large majority of patient charts, but its use varied by physician and patient characteristics. On nearly one third of visits, IOP exceeded the target, indicating the need for active decision-making and management changes. © 2015 Wolters Kluwer Health, Inc. All rights reserved. AD - Glaucoma Center of Excellence, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States AU - Solano-Moncada, F. AU - Dymerska, M. AU - Jefferys, J. L. AU - Quigley, H. A. DB - Scopus DO - 10.1097/IJG.0000000000000339 IS - 4 KW - Glaucoma Intraocular pressure Management Practice pattern M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2016 SP - e424-e432 ST - Adherence with the use of target intraocular pressure for glaucoma patients in a large university practice T2 - Journal of Glaucoma TI - Adherence with the use of target intraocular pressure for glaucoma patients in a large university practice UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946593943&doi=10.1097%2fIJG.0000000000000339&partnerID=40&md5=da6799bf5fef3278845659cf70d66be0 VL - 25 ID - 5462 ER - TY - JOUR AB - Purpose: To determine how often glaucoma specialists set a target intraocular pressure (IOP) and how they respond when the target is not achieved. Methods: We reviewed 250 randomly selected charts of glaucoma patients seen by 5 glaucoma specialists to identify whether a target IOP was specifically set and to detail the plan of action when the target was exceeded. Results: A target IOP was present for at least 1 eye in 66% of patients (165/250). Among the patients of 5 physicians, the percentage with a target IOP for both eyes ranged from 90% to 34%. Half of eyes with no target had an explaining feature, whereas the other half did not. The study visit IOP exceeded the target in at least 1 eye in 29% (50/173) of patients. When the target was not met, 66% (33/50) had a notation of action taken, with no significant difference among physicians in whether any action was taken (P = 0.64). The significant differences among the 5 physicians in the use of target IOP were potentially associated with patient demographic and clinical features, such as age, race, treatment intensity, and visual field damage, which differed among the 5 practices (all P < 0.05). Conclusions: Target IOP was recorded in the large majority of patient charts, but its use varied by physician and patient characteristics. On nearly one third of visits, IOP exceeded the target, indicating the need for active decision-making and management changes. AN - WOS:000374834000022 AU - Solano-Moncada, F. AU - Dymerska, M. AU - Jefferys, J. L. AU - Quigley, H. A. DA - APR DO - 10.1097/IJG.0000000000000339 IS - 4 PY - 2016 SN - 1057-0829 1536-481X SP - E424-E432 ST - Adherence With the Use of Target Intraocular Pressure for Glaucoma Patients in a Large University Practice T2 - JOURNAL OF GLAUCOMA TI - Adherence With the Use of Target Intraocular Pressure for Glaucoma Patients in a Large University Practice VL - 25 ID - 6100 ER - TY - JOUR AB - Purpose: We aimed to investigate the safety and efficacy of dorzolamide/ timolol fixed combination (DTFC) in timolol responders with ocular hypertension or open-angle glaucoma who switched to DTFC because of insufficient control on latanoprost. Methods: We carried out a prospective, open-label cohort study with an active-historical control in which qualifying patients must have been treated with latanoprost monotherapy for at least 4weeks, must have demonstrated insufficiently controlled intraocular pressure (IOP) (≥ 19 mmHg at 08.00 hours), and must have shown a decrease in IOP at 2 hours after timolol instillation of ≥ 3 mmHg or ≥ 15%. Patients then began DTFC dosed at 08.00 hours and 20.00 hours and discontinued latanoprost. Patients were evaluated again after 4 and 12 weeks. Results: In 57 patients IOP was further reduced by 2.4 ± 3.3 mmHg at 08.00 hours (p < 0.0001) and by 3.5 ± 3.3 mmHg at 10.00 hours (p < 0.0001) after switching to DTFC. Responses to the Comparison of Ophthalmic Medications for Tolerability (COMTol) questionnaire showed no difference between DTFC and latanoprost for in terms of overall preference, typical daily activities, limitation of activities, compliance, satisfaction or quality of life (p > 0.05). However, greater frequency in burning and/or stinging (p < 0.0001) and bitter taste (p < 0.0001) were observed with DTFC, whereas unusual taste (p = 0.02) and itchy eyes (p = 0.05) were associated with latanoprost. Conclusions: This study suggests that patients who are insufficiently controlled on latanoprost monotherapy, and who are timolol responders, can generally achieve further IOP reduction and similar tolerance levels when changed to DTFC. © 2007 The Authors Journal compilation © 2007 Acta Ophthalmol. AD - W.C. Stewart, 1 Southpark Circle, Charleston, SC 29407, United States AU - Sonty, S. AU - Henry, J. C. AU - Sharpe, E. D. AU - Weiss, M. J. AU - Stewart, J. A. AU - Nelson, L. A. AU - Stewart, W. C. C1 - cosopt(Merck and Co,United States) xalatan(Pfizer,United States) C2 - Merck and Co(United States) Pfizer(United States) DB - Embase Medline DO - 10.1111/j.1600-0420.2007.01073.x IS - 4 KW - dorzolamide plus timolol latanoprost timolol adult aged article bitter taste blurred vision clinical trial cohort analysis conjunctival hyperemia controlled clinical trial controlled study daily life activity drug efficacy drug preference drug response drug safety drug substitution drug tolerability drug withdrawal dry eye eye burning female human intraocular hypertension intraocular pressure major clinical study male monotherapy ocular pruritus open angle glaucoma open study patient compliance patient satisfaction priority journal prospective study quality of life questionnaire side effect statistical significance systemic disease taste disorder cosopt xalatan LA - English M3 - Article N1 - L352093834 2008-08-12 PY - 2008 SN - 1755-375X SP - 419-423 ST - Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy T2 - Acta Ophthalmologica TI - Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352093834&from=export http://dx.doi.org/10.1111/j.1600-0420.2007.01073.x VL - 86 ID - 3448 ER - TY - JOUR AB - Purpose: This study assesses the practice patterns of diagnosing ophthalmologists, as reported by glaucoma patients attending specialty glaucoma clinics in urban and rural areas of North India, for a second opinion. Methods: Prospective cross-sectional study using a structured interview-based survey was conducted from 1 November 2011 to 31 October 2012 on patients attending two specialty glaucoma care facilities in North India. Both clinics were in North India; however, one was rural (Kaithal) and one was urban (Delhi). Patients were asked through descriptions of machines and processes, regarding practice patterns of their glaucoma diagnosing ophthalmologists. The interview was conducted by ophthalmic assistants in tune with the vernacular of the region, in a language understood by the interviewee. Results: A total of 1506 patients consented to participate in the survey. The majority of patients reported undergoing tests for intraocular pressure measurement; however, 56–60% of these tests were carried out by the non-contact tonometer. More than 90% of patients reported no knowledge regarding the type and severity of the glaucoma they suffered from, and even less reported undergoing gonioscopy (3.6% Karnal and 16% Delhi). 84–86% patients who underwent perimetry reported undergoing at least some digital imaging of the optic disc. Conclusions: Better counselling of, and communication with, the patient would help increase their awareness regarding their condition and the care required. This has the potential to enable better compliance with and adherence to treatment. Standardized training of ophthalmologists to improve clinical diagnosis of glaucoma would also go a long way. AD - I. Sood, SK Glaucoma Care Foundation, B-2/46, Safdarjung Enclave, New Delhi, India AU - Sood, D. AU - Sood, I. AU - Sood, S. AU - Kumar, D. AU - Sood, R. AU - Sood, N. N. DB - Embase Medline DO - 10.1007/s10792-020-01349-w IS - 7 KW - non contact tonometer article clinical practice cross-sectional study diagnostic procedure digital imaging disease severity disease surveillance glaucoma gonioscopy human India intraocular pressure ophthalmologist optic disk patient attitude patient compliance perimetry pressure measurement prospective study structured interview LA - English M3 - Article N1 - L2004582702 2020-04-14 2020-07-14 PY - 2020 SN - 1573-2630 0165-5701 SP - 1797-1805 ST - Patients’ perception of glaucoma diagnosis practice: Results from a survey of glaucoma patients in North India T2 - International Ophthalmology TI - Patients’ perception of glaucoma diagnosis practice: Results from a survey of glaucoma patients in North India UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004582702&from=export http://dx.doi.org/10.1007/s10792-020-01349-w VL - 40 ID - 2396 ER - TY - JOUR AD - N.N. Sood AU - Sood, N. N. AU - Grover, A. K. AU - Agarwal, H. C. DB - Medline KW - antihypertensive agent article economics human intraocular hypertension patient compliance psychology tachyphylaxis LA - English M3 - Article N1 - L15739980 1985-12-20 PY - 1983 SN - 0301-4738 SP - 866-868 ST - Therapeutic problems in ocular hypertension T2 - Indian journal of ophthalmology TI - Therapeutic problems in ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L15739980&from=export VL - 31 Suppl ID - 4086 ER - TY - JOUR AB - In recent times, the use of computer aided diagnosis for detection of Glaucoma from fundus images has been prevalent. In the proposed work, a cloud based system is proposed for automatic and real-time screening of Glaucoma with the use of automatic image processing techniques. The proposed system offers scalability to the developers and easy accessibility to the consumers. The proposed system is device and location independent. The input digital image is analyzed and a comprehensive diagnostic report is generated consisting of detailed analysis of indicative medical parameters like optic-cup-to-disc ratio, optic neuro-retinal rim, ISNT rules making the report informative and clinically significant. With recent advances in the field of communication technologies, the internet facilities are available that make the proposed system an efficient and economical method for initial screening and offer preventive and diagnostic steps in early disease intervention and management. The proposed system can perform an initial screening test in an average time of 6 s on high resolution fundus images. The proposed system has been tested on a fundus database and an average sensitivity of 93.7% has been achieved for Glaucoma cases. In places where there is scarcity of trained ophthalmologists and lack of awareness of such diseases, the cloud based system can be used as an effective diagnostic assistive tool. AD - Department of Computer Science and Engineering, Amity University, Noida, India Department of Electronics and Communication Engineering, Amity University, Noida, India Center for Advanced Studies, Dr. A.P.J. Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India AN - 136129222. Language: English. Entry Date: 20190502. Revision Date: 20200430. Publication Type: Article AU - Soorya, M. AU - Issac, Ashish AU - Dutta, Malay Kishore DB - ccm DO - 10.1007/s10916-019-1260-2 DP - EBSCOhost IS - 5 KW - Cloud Computing -- Utilization Glaucoma -- Diagnosis Health Screening -- Methods Image Processing, Computer Assisted -- Methods Automation Human Diagnosis, Computer Assisted Image Interpretation, Computer Assisted Information Technology Glaucoma -- Prevention and Control Disease Management Sensitivity and Specificity World Wide Web Applications Software Algorithms Decision Making, Clinical Funding Source N1 - computer program; equations & formulas; pictorial; research; tables/charts. Journal Subset: Computer/Information Science; Continental Europe; Europe; Peer Reviewed. Grant Information: This work was supported in part by the Grants from Department of Science and Technology, No. DST/TSG/ICT/2013/37.. NLM UID: 7806056. PY - 2019 SN - 0148-5598 SP - N.PAG-N.PAG ST - Automated Framework for Screening of Glaucoma Through Cloud Computing T2 - Journal of Medical Systems TI - Automated Framework for Screening of Glaucoma Through Cloud Computing UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136129222&site=ehost-live&scope=site VL - 43 ID - 4224 ER - TY - JOUR AB - • PURPOSE: To understand the impact of glaucoma on ability to function and on quality of life to guide therapeutic choices and strategies for improved adherence to therapeutic regimens and to suggest alterations to environments to help the patient to cope better with the effects of the disease. • DESIGN: Review of the published literature on quality-of-life assessments of patients with glaucoma. • METHODS: The published literature on quality-of-life impacts of glaucoma was reviewed with a focus on the design and evolution of quality-of-life instruments, correlations of responses with objective measures of disease progression, and insights that were gained from the analyses of results. • RESULTS: Information about the impact of glaucoma has been derived from responses to general health-related questionnaires, vision-specific questionnaires, and questionnaires that were designed to be glaucoma specific. Responses to glaucoma-specific instruments tend to correlate best with visual field measurements and other objective measures of disease progression, which suggests that such responses reflect the effects of glaucoma rather than the effects of other health-related issues in this patient population. Recent advances in the design of glaucoma-specific instruments and in analysis of the responses to them have provided some interesting insights. For example, patients who have experienced significant (peripheral) visual field loss attach greater importance to their central vision than do patients with less-advanced disease, but these patients seem to have accepted or adapted to their difficulties with outdoor mobility. • CONCLUSION: Continued improvements in the collection and analysis of quality-of-life data should assist health care providers with the effective delivery of therapies to patients with glaucoma. © 2006 by Elsevier Inc. All rights reserved. AD - G. Spaeth, Wills Eye Hospital, 840 Walnut St, Philadelphia, PA 19107, United States AU - Spaeth, G. AU - Walt, J. AU - Keener, J. DB - Embase Medline DO - 10.1016/j.ajo.2005.07.075 IS - 1 SUPPL. KW - coping behavior correlation analysis data analysis disease course evaluation study functional assessment glaucoma human devices measurement methodology patient compliance priority journal quality of life questionnaire rating scale review Short Form 36 Sickness Impact Profile validation study vision visual field visual field defect visual impairment LA - English M3 - Review N1 - L43028474 2006-01-30 PY - 2006 SN - 0002-9394 SP - S3-S14 ST - Evaluation of quality of life for patients with glaucoma T2 - American Journal of Ophthalmology TI - Evaluation of quality of life for patients with glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43028474&from=export http://dx.doi.org/10.1016/j.ajo.2005.07.075 VL - 141 ID - 3636 ER - TY - JOUR AB - Purpose: To assess which factors in the lives and disease of patients with glaucoma affect their adherence to topical glaucoma therapy and the quantitative significance of this effect. To assess qualitatively the most influential barriers to adherence from the perspective of the patient. Design: Multicenter, prospective, cross-sectional pilot study. Participants: A total of 145 patients, attending outpatient metropolitan glaucoma clinics in Sydney, Australia, who were prescribed topical glaucoma medications. Methods: A structured interview-based questionnaire was conducted with 145 individuals using glaucoma eye drops that had been prescribed at least 2 weeks previously. The questionnaire involved 2 novel questions on adherence, 29 questions on factors identified or postulated in the literature as affecting adherence for quantitative analysis, and 1 open-response question on patient-identified causes of nonadherence for qualitative analysis. This questionnaire represents the broadest coverage of factors hypothesized to affect adherence in a single study in the glaucoma medication adherence literature to date. Main Outcome Measures: Adherence rate, risk factors for poor adherence, and patient-identified barriers to adherence. Results: In response to the question “How many days have you missed a drop in the last 2 weeks,” 69.7% of patients reported total adherence. Four factors were significantly related to an increased likelihood of reporting having missed drops in the last 2 weeks. These were difficulty applying drops (odds ratio [OR], 2.35; 95% confidence interval [CI], 1.02–5.44; P < 0.05), a past or current diagnosis of depression (OR, 3.61; 95% CI, 1.53–8.52; P < 0.01), patient self-rating of own memory ≤ 7 of 10 (OR, 3.15; 95% CI, 1.36–7.30; P < 0.01), and self-reported motivation score ≤ 6 of 10 (OR, 10.94; 95% CI, 3.00–39.81; P < 0.01). Patient understanding of glaucoma, ethnicity, and socioeconomic status were among the 25 factors found not to have a statistically significant correlation with adherence. Conclusions: There is a significant proportion of patients taking their topical glaucoma medications less often than prescribed. Adherence to topical glaucoma therapies is negatively correlated to several factors: difficulty applying drops, a past or current diagnosis of depression, poor self-rating of own memory, and poor self-rating of own motivation. These may prove useful in designing interventions to improve adherence in these patients. AD - A. Agar, Department of Ophthalmology, Prince of Wales Hospital, Level 4 High Street, Randwick, NSW, Australia AU - Spencer, S. K. R. AU - Shulruf, B. AU - McPherson, Z. E. AU - Zhang, H. AU - Lee, M. B. AU - Francis, I. C. AU - Bank, A. AU - Coroneo, M. T. AU - Agar, A. DB - Embase Medline DO - 10.1016/j.ogla.2019.01.006 IS - 2 KW - antiglaucoma agent eye drops article Australia cross-sectional study depression ethnicity factor analysis feasibility study glaucoma human motivation outpatient department patient compliance pilot study prescription priority journal prospective study qualitative analysis qualitative research quantitative analysis quantitative study questionnaire risk assessment risk factor scoring system self concept self report social status structured interview systematic review LA - English M3 - Article N1 - L2001687929 2019-06-24 2019-06-26 PY - 2019 SN - 2589-4196 2589-4234 SP - 86-93 ST - Factors Affecting Adherence to Topical Glaucoma Therapy: A Quantitative and Qualitative Pilot Study Analysis in Sydney, Australia T2 - Ophthalmology Glaucoma TI - Factors Affecting Adherence to Topical Glaucoma Therapy: A Quantitative and Qualitative Pilot Study Analysis in Sydney, Australia UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001687929&from=export http://dx.doi.org/10.1016/j.ogla.2019.01.006 VL - 2 ID - 2517 ER - TY - JOUR AB - Proliferative feline eosinophilic keratitis is a chronic keratopathy caused by a suspected immune mediated response to an unknown antigenic stimulus. The purpose of this study is to demonstrate the efficacy of topical 1.5% cyclosporine solution in proliferative feline eosinophilic keratitis. Thirty-five cats were treated topically with 1.5% cyclosporine A between 1997 and 2007. Eosinophilic keratitis was diagnosed by clinical appearance and evidence of eosinophils and/or mast cells in corneal cytology. The patients were treated with topical cyclosporine (1.5%) twice (26 of 35, 74.3%) and three times (9 of 35, 25.7%) daily. The minimum period for follow-up was 5 months. The age of the patients ranged from 2 to 13 years with a mean age of 6.0 years. Twenty-two were neutered males, and 13 were females. The represented breeds were 30 DSH, 3 DLH, one Siamese and one Maine Coon. Cytologic examination of a corneal scrape revealed the presence of eosinophils in 34 of 35 specimens, and mast cells in 25 of 35 specimens. Improvement in the treated eyes was seen in 31 cats (88.6%). Four animals (11.4%) did not respond to the treatment with topical cyclosporine. Recurrences were seen in seven (22.6%) cases. Blepharitis was noted as an infrequent side effect. Based on our findings, topical cyclosporine (1.5%) is an effective treatment of proliferative feline eosinophilic keratitis in the vast majority of cases. Recurrences were mainly associated with poor owner compliance. Chronic, often lifelong therapy with medications is thus recommended. AN - WOS:000263860100011 AU - Spiess, A. K. AU - Sapienza, J. S. AU - Mayordomo, A. DA - MAR-APR DO - 10.1111/j.1463-5224.2008.00679.x IS - 2 PY - 2009 SN - 1463-5216 1463-5224 SP - 132-137 ST - Treatment of proliferative feline eosinophilic keratitis with topical 1.5% cyclosporine: 35 cases T2 - VETERINARY OPHTHALMOLOGY TI - Treatment of proliferative feline eosinophilic keratitis with topical 1.5% cyclosporine: 35 cases VL - 12 ID - 6294 ER - TY - JOUR AB - A total of 533 diabetic individuals using the Marshall, Minn, medical care system were identified as potential subjects for a study of unrecognized eye disease. Of these, 172 (32%) stated they had never had an ophthalmologic eye examination and subsequently were defined as being at high risk for unrecognized diabetic eye disease. Ophthalmic examination was performed on 145 (84%) of these high-risk individuals and revealed that 61% had clinical characteristics consistent with diabetic retinopathy, glaucoma, cataract, or other eye abnormalities. Twenty-five (17%) of these subjects presented with eye disease that required immediate treatment, referral, or accelerated follow-up. Of those indicating they had an ophthalmologist, approximately 35% reported a time since last visit of 2 years or greater. These findings indicate a high prevalence of ocular morbidity among diabetic individuals who are not under routine ophthalmic surveillance and suggest that improvements in patient and professional compliance with recommended guidelines for eye care are warranted. AD - Division of Epidemiology, School of Public Health, University of Minnesota, 611 Beacon St. SE, Minneapolis, MN 55455, United States AU - Sprafka, J. M. AU - Fritsche, T. L. AU - Baker, R. AU - Kurth, D. AU - Whipple, D. DB - Scopus DO - 10.1001/archinte.150.4.857 IS - 4 M3 - Article N1 - Cited By :60 Export Date: 19 July 2021 PY - 1990 SP - 857-861 ST - Prevalence of undiagnosed eye disease in high-risk diabetic individuals T2 - Archives of Internal Medicine TI - Prevalence of undiagnosed eye disease in high-risk diabetic individuals UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025317696&doi=10.1001%2farchinte.150.4.857&partnerID=40&md5=b6c7a9d074a671742bea894bc8d4e265 VL - 150 ID - 4972 ER - TY - JOUR AB - Purpose: To understand the treatment burden experienced by patients receiving care for primary open-angle glaucoma. Design: Semistructured, one-on-one, qualitative interviews. Participants: Patients with primary open-angle glaucoma and age ≥40 years who were scheduled for a follow-up glaucoma appointment at the Kellogg Eye Center. Researchers used purposeful sampling to ensure that there was representation of a range of ages, disease stages, total number of medical conditions, distance traveled to clinic, history of glaucoma surgery, employment, and education. Interviews were conducted until thematic saturation was obtained. Methods: Participants were interviewed using a semi-structured interview guide that addressed aspects of glaucoma care that give them burden, how this burden impacts their lives, and factors that influence the burden and its impact. Researchers analyzed the transcripts using inductive thematic analysis and grounded theory to generate themes that emerged from the interviews and to map these themes into a conceptual model of glaucoma treatment burden. Main Outcome Measures: Themes related to glaucoma treatment burden generated by qualitative analysis. Results: A total of 22 patients participated in the study. Study participants described 10 categories of glaucoma care activities that cause treatment burden, 8 themes for consequences of glaucoma treatment burden, and 25 themes of factors that influenced the workload created by the various glaucoma care activities and the consequences that they experienced because of these activities. Conclusions: Participants expressed that the treatment of glaucoma creates a burden for patients that is distinct from the burden of the disease process itself and that this burden negatively affects their quality of life and can potentially cause vision-threatening issues with medication and appointment adherence. We observed considerable variation in the extent to which participants experienced this burden and its consequences, much of which was explained by the influencing factors the participants described. Understanding glaucoma treatment burden and its influencing factors is important as we work to deliver patient-centered care and prevent vision loss. AD - B.C. Stagg, 65 Mario Capecchi Drive, Salt Lake City, UT, United States AU - Stagg, B. C. AU - Granger, A. AU - Guetterman, T. C. AU - Hess, R. AU - Lee, P. P. DB - Embase Medline DO - 10.1016/j.ogla.2021.04.011 KW - adult article blindness care behavior case report clinical article conceptual model education employment female follow up genetic transcription glaucoma surgery grounded theory human male medication compliance open angle glaucoma outcome assessment patient care prevention qualitative analysis qualitative research quality of life semi structured interview thematic analysis vision workload LA - English M3 - Article in Press N1 - L2012934933 2021-06-17 PY - 2021 SN - 2589-4196 2589-4234 ST - The Burden of Caring for and Treating Glaucoma: The Patient Perspective T2 - Ophthalmology Glaucoma TI - The Burden of Caring for and Treating Glaucoma: The Patient Perspective UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2012934933&from=export http://dx.doi.org/10.1016/j.ogla.2021.04.011 ID - 2346 ER - TY - JOUR AB - Ocular Surface Disease (OSD) and hyperemia are the most common adverse events of topical ocular medications. While active compounds may cause allergic reactions or irritation, preservatives, which are intended to prevent bacterial growth, are toxic as well. Therefore, the most recent glaucoma medications no longer contain preservatives. Despite this, local tolerability may still impact treatment compliance and patient quality of life. We conducted an observational, multi-center, international, cross-sectional study in 793 treated and stabilized glaucoma patients to assess patient satisfaction and local tolerability of their treatment. The vast majority (93.7%) of patients was satisfied or very satisfied with their treatment in terms of tolerability and only 6.3% were dissatisfied. However, ophthalmologi-cal examination showed a high frequency of ocular signs: conjunctival hyperemia (32%), OSD (42.5%) and positive conjunctival fluorescein staining (10.3%). Additionally, patients reported symptoms upon instillation (31.4%) and between instillations (57.3%); 25.1% of patients were using tear substitutes. All signs and symptoms were significantly (p<0.001) associated with patient dissatisfaction. A logistic regression model indicated that dissatisfaction was higher in patients with symptoms upon instillation and in those using tear substitutes (OR: 3.03 and 4.63, respectively). The mean patient tolerability score to treatment was 82.7 ±16.1 on a 100-point visual analogue scale. In conclusion, even if patients may be highly satisfied with their current treatment, most of them present ocular signs and symptoms. A treatment change should be considered in case of clinical signs or patient-reported symptoms. AD - C. Baudouin, Ophthalmology Unit, Quinze-Vingts National Hospital and Vision Institute, IHU ForeSight, Sorbonne University, Paris, France AU - Stalmans, I. AU - Lemij, H. AU - Clarke, J. AU - Baudouin, C. DB - Embase DO - 10.2147/OPTH.S269586 KW - artificial tear eye drops fluorescein adult aged article Belgium blurred vision conjunctival hyperemia cross-sectional study disease association dry eye epiphora eye burning eye examination eye pain eye redness female glaucoma human major clinical study male monotherapy multicenter study Netherlands observational study ocular pruritus ocular surface disease patient compliance patient satisfaction photophobia physical disease by body function prevalence staining tear break-up time United Kingdom visual analog scale LA - English M3 - Article N1 - L2005384679 2020-11-06 2020-11-18 PY - 2020 SN - 1177-5483 1177-5467 SP - 3675-3680 ST - Signs and symptoms of ocular surface disease: The reasons for patient dissatisfaction with glaucoma treatments T2 - Clinical Ophthalmology TI - Signs and symptoms of ocular surface disease: The reasons for patient dissatisfaction with glaucoma treatments UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005384679&from=export http://dx.doi.org/10.2147/OPTH.S269586 VL - 14 ID - 2447 ER - TY - JOUR AB - This set of Viewpoints articles examines the merits of beta-blockers versus other medications as the primary drug treatment for glaucoma. Ophthalmologists must balance issues such as efficacy, compliance, cost, and side effects when deciding on the appropriate medication to prescribe. Dr. Stamper stresses the advantages of tailoring the choice of medication to the needs of the individual patient. Drs. Wigginton and Higginbotham review the benefits of beta-blockers and present some of the disadvantages of the non-beta-blocker class of medications. © 2002 by Elsevier Science Inc. All rights reserved. AD - R.L. Stamper, UCSF, Department of Ophthalmology, 10 Kirkham Street, San Francisco, CA 94121, United States AU - Stamper, R. L. C1 - alphagan(Allergan,United States) azopt(Alcon,United States) cosopt(Merck and Co,United States) iopidine(Alcon,United States) lumigan(Allergan,United States) rescula(Ciba Vision,United States) travatan(Alcon,United States) trusopt(Merck and Co,United States) xalatan(Pharmacia Upjohn,United States) C2 - Alcon(United States) Allergan(United States) Ciba Vision(United States) Merck and Co(United States) Pharmacia Upjohn(United States) DB - Embase Medline DO - 10.1016/S0039-6257(01)00286-7 IS - 1 KW - alpha adrenergic receptor stimulating agent apraclonidine beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine brinzolamide carbonate dehydratase inhibitor dorzolamide dorzolamide plus timolol drug preservative latanoprost levobunolol prostaglandin derivative purite quinidine timolol travoprost unclassified drug unoprostone isopropyl ester bradycardia bronchospasm dose response drug choice drug contraindication drug cost drug effect drug efficacy drug formulation drug mechanism glaucoma human intraocular pressure patient compliance priority journal review side effect treatment indication treatment outcome alphagan azopt cosopt iopidine lumigan rescula travatan trusopt xalatan LA - English M3 - Review N1 - L34099000 2002-02-07 PY - 2002 SN - 0039-6257 SP - 63-67 ST - Primary drug treatment for glaucoma: Beta-blockers versus other medications T2 - Survey of Ophthalmology TI - Primary drug treatment for glaucoma: Beta-blockers versus other medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34099000&from=export http://dx.doi.org/10.1016/S0039-6257(01)00286-7 VL - 47 ID - 3877 ER - TY - JOUR AN - 108030003. Language: English. Entry Date: 20130218. Revision Date: 20150712. Publication Type: Journal Article AU - Stamper, Robert L. AU - Krader, Cheryl Guttman DB - ccm DP - EBSCOhost IS - 2 KW - Glaucoma -- Therapy Intraocular Pressure Glaucoma -- Trends Vision Disorders -- Prevention and Control Medication Compliance N1 - brief item. Journal Subset: Biomedical; USA. NLM UID: 9880041. PY - 2013 SN - 0193-032X SP - 20-20 ST - Simple regimen aids adherence T2 - Ophthalmology Times TI - Simple regimen aids adherence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108030003&site=ehost-live&scope=site VL - 38 ID - 4718 ER - TY - JOUR AB - Purpose: To determine the level of adherence to the American Academy of Ophthalmology preferred practice pattern (PPP) guidelines for quality primary open-angle glaucoma (POAG) and POAG suspect (POAGS) care among retail-based optometrists. Methods: Patients with a diagnosis of POAG or POAGS who participated in a telemedicine pilot project were included. Patients' charts were evaluated for 15 elements of PPP guidelines for glaucoma care. Results were further stratified by number of follow-up visits and diagnosis. Results: Of 360 identified patients, 10 elements were documented in over 98%. Documentation of the remaining 5 components was as follows: dilated fundus examination 91.1%, central corneal thickness (CCT) 88.6%, visual field 78.9%, gonioscopy 47.5%, and target intraocular pressure (IOP) 15.6%. in total, 32.8% of patients were seen once, whereas the remaining 67.2% had multiple visits. In patients with multiple visits, providers were more likely to document systemic history (100.0% vs. 97.5%; P=0.0346), review of systems (100.0% vs. 97.5%; P=0.0346), gonioscopy (60.0% vs. 22.0%; P<0.001), CCT (94.2% vs. 77.1%; P<0.001), visual field (97.5% vs. 40.7%; P<0.001), and target IOP (22.4% vs. 1.7%; P<0.001) compared with single visit patients. In stratifying results by diagnosis, POAG patients more often received visual field testing (92.7% vs. 68.9%; P<0.001) and had an established target IOP (35.1% vs. 1.4%; P<0.001) compared with POAGS patients. Conclusions: Compliance with PPP guidelines for glaucoma care was very high for most elements but lower for performing dilated fundus examination, CCT, visual field, gonioscopy, and target IOP. This study highlights deficiencies in care likely to hamper the detection of glaucoma progression. AD - L.A. Rhodes, Department of Ophthalmology and Visual Sciences, School of Medicine, University of Alabama at Birmingham, 1720 University Boulevard, Suite 601, Birmingham, AL, United States AU - Stanley, J. AU - Huisingh, C. E. AU - Swain, T. A. AU - McGwin, G. AU - Owsley, C. AU - Girkin, C. A. AU - Rhodes, L. A. DB - Embase Medline DO - 10.1097/IJG.0000000000001093 IS - 12 KW - African American article central corneal thickness clinical practice controlled study eye fundus female follow up gonioscopy human intraocular pressure major clinical study male medical documentation open angle glaucoma optometrist patient compliance perimetry pilot study practice guideline priority journal telemedicine visual field LA - English M3 - Article N1 - L624053966 2018-10-02 2019-10-23 PY - 2018 SN - 1536-481X 1057-0829 SP - 1068-1072 ST - Compliance with primary open-angle glaucoma and primary open-angle glaucoma suspect preferred practice patterns in a retail-based eye clinic T2 - Journal of Glaucoma TI - Compliance with primary open-angle glaucoma and primary open-angle glaucoma suspect preferred practice patterns in a retail-based eye clinic UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624053966&from=export http://dx.doi.org/10.1097/IJG.0000000000001093 VL - 27 ID - 2559 ER - TY - JOUR AB - Purpose: To determine the level of adherence to the American Academy of Ophthalmology preferred practice pattern (PPP) guidelines for quality primary open-angle glaucoma (POAG) and POAG suspect (POAGS) care among retail-based optometrists. Methods: Patients with a diagnosis of POAG or POAGS who participated in a telemedicine pilot project were included. Patients' charts were evaluated for 15 elements of PPP guidelines for glaucoma care. Results were further stratified by number of follow-up visits and diagnosis. Results: Of 360 identified patients, 10 elements were documented in over 98%. Documentation of the remaining 5 components was as follows: dilated fundus examination 91.1%, central corneal thickness (CCT) 88.6%, visual field 78.9%, gonioscopy 47.5%, and target intraocular pressure (IOP) 15.6%. in total, 32.8% of patients were seen once, whereas the remaining 67.2% had multiple visits. In patients with multiple visits, providers were more likely to document systemic history (100.0% vs. 97.5%; P=0.0346), review of systems (100.0% vs. 97.5%; P=0.0346), gonioscopy (60.0% vs. 22.0%; P<0.001), CCT (94.2% vs. 77.1%; P<0.001), visual field (97.5% vs. 40.7%; P<0.001), and target IOP (22.4% vs. 1.7%; P<0.001) compared with single visit patients. In stratifying results by diagnosis, POAG patients more often received visual field testing (92.7% vs. 68.9%; P<0.001) and had an established target IOP (35.1% vs. 1.4%; P<0.001) compared with POAGS patients. Conclusions: Compliance with PPP guidelines for glaucoma care was very high for most elements but lower for performing dilated fundus examination, CCT, visual field, gonioscopy, and target IOP. This study highlights deficiencies in care likely to hamper the detection of glaucoma progression. © 2018 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Ophthalmology and Visual Sciences, School of Medicine, University of Alabama at Birmingham, 1720 University Boulevard, Suite 601, Birmingham, AL 35233, United States Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States AU - Stanley, J. AU - Huisingh, C. E. AU - Swain, T. A. AU - McGwin, G., Jr. AU - Owsley, C. AU - Girkin, C. A. AU - Rhodes, L. A. DB - Scopus DO - 10.1097/IJG.0000000000001093 IS - 12 KW - optometry preferred practice pattern primary open-angle glaucoma primary open-angle glaucoma suspect retail-based eye clinic M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2018 SP - 1068-1072 ST - Compliance with primary open-angle glaucoma and primary open-angle glaucoma suspect preferred practice patterns in a retail-based eye clinic T2 - Journal of Glaucoma TI - Compliance with primary open-angle glaucoma and primary open-angle glaucoma suspect preferred practice patterns in a retail-based eye clinic UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053819411&doi=10.1097%2fIJG.0000000000001093&partnerID=40&md5=1d269df7d4bc0ea910287c0c8d5720c9 VL - 27 ID - 5618 ER - TY - JOUR AB - Purpose: To determine the level of adherence to the American Academy of Ophthalmology preferred practice pattern (PPP) guidelines for quality primary open-angle glaucoma (POAG) and POAG suspect (POAGS) care among retail-based optometrists. Methods: Patients with a diagnosis of POAG or POAGS who participated in a telemedicine pilot project were included. Patients' charts were evaluated for 15 elements of PPP guidelines for glaucoma care. Results were further stratified by number of follow-up visits and diagnosis. Results: Of 360 identified patients, 10 elements were documented in over 98%. Documentation of the remaining 5 components was as follows: dilated fundus examination 91.1%, central corneal thickness (CCT) 88.6%, visual field 78.9%, gonioscopy 47.5%, and target intraocular pressure (IOP) 15.6%. in total, 32.8% of patients were seen once, whereas the remaining 67.2% had multiple visits. In patients with multiple visits, providers were more likely to document systemic history (100.0% vs. 97.5%; P=0.0346), review of systems (100.0% vs. 97.5%; P=0.0346), gonioscopy (60.0% vs. 22.0%; P<0.001), CCT (94.2% vs. 77.1%; P<0.001), visual field (97.5% vs. 40.7%; P<0.001), and target IOP (22.4% vs. 1.7%; P<0.001) compared with single visit patients. In stratifying results by diagnosis, POAG patients more often received visual field testing (92.7% vs. 68.9%; P<0.001) and had an established target IOP (35.1% vs. 1.4%; P<0.001) compared with POAGS patients. Conclusions: Compliance with PPP guidelines for glaucoma care was very high for most elements but lower for performing dilated fundus examination, CCT, visual field, gonioscopy, and target IOP. This study highlights deficiencies in care likely to hamper the detection of glaucoma progression. AN - WOS:000453564300011 AU - Stanley, J. AU - Huisingh, C. E. AU - Swain, T. A. AU - McGwin, G. AU - Owsley, C. AU - Girkin, C. A. AU - Rhodes, L. A. DA - DEC DO - 10.1097/IJG.0000000000001093 IS - 12 PY - 2018 SN - 1057-0829 1536-481X SP - 1068-1072 ST - Compliance With Primary Open-angle Glaucoma and Primary Open-angle Glaucoma Suspect Preferred Practice Patterns in a Retail-based Eye Clinic T2 - JOURNAL OF GLAUCOMA TI - Compliance With Primary Open-angle Glaucoma and Primary Open-angle Glaucoma Suspect Preferred Practice Patterns in a Retail-based Eye Clinic VL - 27 ID - 5946 ER - TY - JOUR AB - OBJECTIVESTo determine the effect of 1% brinzolamide, 2% dorzolamide hydrochloride or combination 2% dorzolamide hydrochloride/0 5% timolol to delay the elevation of the intraocular pressure in second eyes of dogs with primary closed-angle glaucoma. METHODSAnalysis of retrospectively collated data from 40 dogs with primary closed-angle glaucoma, where the non-affected eye was treated prophylactically with brinzolamide (n = 10), dorzolamide (n = 18) or combination dorzolamide/timolol therapy (n = 12). RESULTSThe 40 treated dogs (median age of 76 2 months) comprised 25 females/15 males, 19 entire/21 neutered. Twenty dogs developed glaucoma in the contralateral eye (median time of 9 2 months). No statistically significant difference was identified during treatment failure between the treatment groups (P = 0 66). The second eye remained normotensive in 20 dogs; four dogs until the conclusion of the study (median: 27 0 months), three dogs until death (median: 15 4 months), seven dogs until lost to follow-up (median: 11 6 months). Out of these 20 dogs, treatment was discontinued because of lack of owner compliance in two dogs and following a local drug reaction in four dogs (median: 8 9 months). CLINICAL SIGNIFICANCEThere was no evidence that the tested drugs delayed elevation of intraocular pressure in contralateral eyes of dogs with primary closed-angle glaucoma. AN - WOS:000363902800006 AU - Stavinohova, R. AU - Newton, J. R. AU - Busse, C. DA - NOV DO - 10.1111/jsap.12393 IS - 11 PY - 2015 SN - 0022-4510 1748-5827 SP - 662-666 ST - The effect of prophylactic topical carbonic anhydrase inhibitors in canine primary closed-angle glaucoma T2 - JOURNAL OF SMALL ANIMAL PRACTICE TI - The effect of prophylactic topical carbonic anhydrase inhibitors in canine primary closed-angle glaucoma VL - 56 ID - 6059 ER - TY - JOUR AB - Background: The etiology of aphakic glaucoma is unclear. It has been suggested that remaining lens epithelium releases cytokines transducing trabecular meshwork cells. Therefore, we compared two cohorts of children undergoing lensectomy. In cohort 1, the entire lens including its capsule was removed, in cohort 2 the peripheral lens capsule was left intact, also to facilitate secondary intraocular lens implantation later on. Methods: We included children with uni- or bilateral congenital cataract who underwent lensectomy during the first year of life with subsequent contact lenses fitting. Group 1 comprised 41 eyes, group 2 comprised 33 eyes. In group 1, the median age at surgery was 4.0 months in unilateral and 3.0 months in bilateral cases 1, in group 2, 8.1 months and 2.4 months, respectively. The mean follow-up was 12.8 years in group 1 and 9.3 years in group 2. All cases were analyzed for the prevalence of aphakic glaucoma, for visual acuity and for compliance in visual rehabilitation (contact lens/occlusion therapy). Results: We found no significant difference in glaucoma prevalence between group 1 and group 2 (p = 0.68). The overall glaucoma rate was 26% after the mean follow-up of 11 years in both groups. In unilateral cases, the median visual acuity was logMAR 0.7 in both groups. In bilateral cases it was logMAR 0.4 in group 1 and logMAR 0.2 in group 2 (p = 0.05). Conclusions: Leaving the peripheral lens capsule intact had no negative effect on the incidence of glaucoma and on resulting visual acuity. © 2019, The Royal College of Ophthalmologists. AD - Eye Center, Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany AU - Stech, M. AU - Grundel, B. AU - Daniel, M. AU - Böhringer, D. AU - Joachimsen, L. AU - Gross, N. AU - Wolf, C. AU - Link, H. AU - Gilles, U. AU - Lagrèze, W. A. DB - Scopus DO - 10.1038/s41433-019-0435-x IS - 9 M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2019 SP - 1472-1477 ST - Risk of aphakic glaucoma after pars plana-lensectomy with and without removal of the peripheral lens capsule T2 - Eye (Basingstoke) TI - Risk of aphakic glaucoma after pars plana-lensectomy with and without removal of the peripheral lens capsule UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064083030&doi=10.1038%2fs41433-019-0435-x&partnerID=40&md5=2afa371d57255b96d9abc2ab239d4c39 VL - 33 ID - 5499 ER - TY - JOUR AB - Background The etiology of aphakic glaucoma is unclear. It has been suggested that remaining lens epithelium releases cytokines transducing trabecular meshwork cells. Therefore, we compared two cohorts of children undergoing lensectomy. In cohort 1, the entire lens including its capsule was removed, in cohort 2 the peripheral lens capsule was left intact, also to facilitate secondary intraocular lens implantation later on. Methods We included children with uni- or bilateral congenital cataract who underwent lensectomy during the first year of life with subsequent contact lenses fitting. Group 1 comprised 41 eyes, group 2 comprised 33 eyes. In group 1, the median age at surgery was 4.0 months in unilateral and 3.0 months in bilateral cases 1, in group 2, 8.1 months and 2.4 months, respectively. The mean follow-up was 12.8 years in group 1 and 9.3 years in group 2. All cases were analyzed for the prevalence of aphakic glaucoma, for visual acuity and for compliance in visual rehabilitation (contact lens/occlusion therapy). Results We found no significant difference in glaucoma prevalence between group 1 and group 2 (p = 0.68). The overall glaucoma rate was 26% after the mean follow-up of 11 years in both groups. In unilateral cases, the median visual acuity was logMAR 0.7 in both groups. In bilateral cases it was logMAR 0.4 in group 1 and logMAR 0.2 in group 2 (p = 0.05). Conclusions Leaving the peripheral lens capsule intact had no negative effect on the incidence of glaucoma and on resulting visual acuity. AN - WOS:000485778400016 AU - Stech, M. AU - Grundel, B. AU - Daniel, M. AU - Bohringer, D. AU - Joachimsen, L. AU - Gross, N. AU - Wolf, C. AU - Link, H. AU - Gilles, U. AU - Lagreze, W. A. DA - SEP DO - 10.1038/s41433-019-0435-x IS - 9 PY - 2019 SN - 0950-222X 1476-5454 SP - 1472-1477 ST - Risk of aphakic glaucoma after pars plana-lensectomy with and without removal of the peripheral lens capsule T2 - EYE TI - Risk of aphakic glaucoma after pars plana-lensectomy with and without removal of the peripheral lens capsule VL - 33 ID - 6110 ER - TY - JOUR AD - C. Stefan, Spitalul Clinic de Urgenţǎ Militar Central Bucureşti, Sectia de Oftalmologie. AU - Stefan, C. AU - Dumitricǎ, D. M. DB - Medline IS - 3 KW - antihypertensive agent eye drops drug effect glaucoma human intraocular pressure pathophysiology patient compliance patient education practice guideline quality of life review LA - Romanian M3 - Review N1 - L354256225 2009-03-11 PY - 2008 SN - 1220-0875 SP - 7-9 ST - Compliance in glaucoma T2 - Oftalmologia (Bucharest, Romania : 1990) TI - Compliance in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354256225&from=export VL - 52 ID - 3412 ER - TY - JOUR AB - Purpose: To study the clinical effectiveness of viscocanalostomy in a population of black African patients with open-angle glaucoma that was uncontrolled on medical treatment. Setting: Department of Ophthalmology, Medical University of Southern Africa, MEDUNSA, South Africa. Methods: In this prospective study, viscocanalostomy was performed in 214 eyes of 157 black African patients with open-angle glaucoma that was poorly controlled by medical therapy. The procedure involves the production of superficial and deep scleral flaps. The deep flap is dissected to the plane of Schlemm's canal. From this plane, an intact window in Descemet's membrane is created by gentle pressure at the level of Schwalbe's line using a cellulose sponge. Aqueous humor diffuses through this window into a subscleral space (lake). Reflection of the inner flap unroofs Schlemm's canal, creating a trough leading to 2 entrances into Schlemm's canal (surgical ostia). A delicate cannula is introduced into the entrance of Schlemm's canal left and right, and high-viscosity sodium hyaluronate is gently injected into the canal for 4 to 6 mm. The deeper scleral flap is excised (deep sclerectomy) and the superficial flap is sutured securely using 5, 11-0 polyester fiber (Mersilene(R)) sutures. High-viscosity sodium hyaluronate is then injected into the subscleral lake to act as a physical barrier to fibrinogen migration postoperatively. Results: Postoperative intraocular pressure (IOP) of 22 mm Hg or less was achieved without medical therapy in 82.7% of eyes. If a beta blocker was added to the cases not achieving 22 mm Hg or less postoperatively, the success rate increased to 89.0%. The average follow-up was 35 months (range 6 to 64 months). Conclusion: Viscocanalostomy produced an encouraging long-term reduction in the IOP of black African patients with glaucoma who would otherwise have had a poor prognosis. AN - WOS:000078960500013 AU - Stegmann, R. AU - Pienaar, A. AU - Miller, D. DA - MAR DO - 10.1016/S0886-3350(99)80078-9 IS - 3 PY - 1999 SN - 0886-3350 SP - 316-322 ST - Viscocanalostomy for open-angle glaucoma in black African patients T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Viscocanalostomy for open-angle glaucoma in black African patients VL - 25 ID - 6266 ER - TY - JOUR AB - Importance: Glaucoma is the most common cause of irreversible blindness worldwide. Many patients with glaucoma are asymptomatic early in the disease course. Primary care clinicians should know which patients to refer to an eye care professional for a complete eye examination to check for signs of glaucoma and to determine what systemic conditions or medications can increase a patient's risk of glaucoma. Open-angle and narrow-angle forms of glaucoma are reviewed, including a description of the pathophysiology, risk factors, screening, disease monitoring, and treatment options.Observations: Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision. Intraocular pressure is the only known modifiable risk factor. Other important risk factors include older age, nonwhite race, and a family history of glaucoma. Several systemic medical conditions and medications including corticosteroids, anticholinergics, certain antidepressants, and topiramate may predispose patients to glaucoma. There are 2 broad categories of glaucoma, open-angle and angle-closure glaucoma. Diagnostic testing to assess for glaucoma and to monitor for disease progression includes measurement of intraocular pressure, perimetry, and optical coherence tomography. Treatment of glaucoma involves lowering intraocular pressure. This can be achieved with various classes of glaucoma medications as well as laser and incisional surgical procedures.Conclusions and Relevance: Vision loss from glaucoma can be minimized by recognizing systemic conditions and medications that increase a patient's risk of glaucoma and referring high-risk patients for a complete ophthalmologic examination. Clinicians should ensure that patients remain adherent with taking glaucoma medications and should monitor for adverse events from medical or surgical interventions used to treat glaucoma. AD - W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor Center for Eye Policy and Innovation, University of Michigan, Ann Arbor Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom AN - 148105771. Language: English. Entry Date: 20210120. Revision Date: 20210211. Publication Type: journal article AU - Stein, Joshua D. AU - Khawaja, Anthony P. AU - Weizer, Jennifer S. DB - ccm DO - 10.1001/jama.2020.21899 DP - EBSCOhost IS - 2 KW - Glaucoma -- Physiopathology Glaucoma -- Therapy Intraocular Pressure Glaucoma -- Diagnosis Glaucoma -- Complications Health Screening Human Disease Progression Prognosis Vision Disorders -- Etiology Vision Disorders -- Prevention and Control Adult Risk Factors Eye -- Anatomy and Histology Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: R01 EY026641/EY/NEI NIH HHS/United States. NLM UID: 7501160. PMID: NLM33433580. PY - 2021 SN - 0098-7484 SP - 164-174 ST - Glaucoma in Adults-Screening, Diagnosis, and Management: A Review T2 - JAMA: Journal of the American Medical Association TI - Glaucoma in Adults-Screening, Diagnosis, and Management: A Review UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148105771&site=ehost-live&scope=site VL - 325 ID - 4160 ER - TY - JOUR AB - Objective: To determine the most cost-effective treatment option for patients with newly diagnosed mild openangle glaucoma: observation only, treatment with generic topical prostaglandin analogs (PGAs), or treatment with laser trabeculoplasty (LTP). Methods: Using a Markov model with a 25-year horizon, we compared the incremental cost-effectiveness of treating newly diagnosed mild open-angle glaucoma with PGAs, LTP, or observation only. Results: The incremental cost-effectiveness of LTP over no treatment is $16 824 per quality-adjusted life year. By comparison, the incremental cost-effectiveness of PGAs over no treatment is $14 179 per quality-adjusted life year, and they provide greater health-related quality of life relative to LTP. If PGAs are 25% less effective owing to poor patient adherence, LTP can confer greater value. Conclusions: Prostaglandin analogs and LTP are both cost-effective options for the management of newly diagnosed mild open-angle glaucoma. Assuming optimal medication adherence, PGAs confer greater value compared with LTP. However, when assuming more realistic levels of medication adherence (making them 25% less effective than the documented effectiveness reported in clinical trials), at current prices for PGAs, LTP may be a more cost-effective alternative. ©2012 American Medical Association. All rights reserved. AD - J.D. Stein, Department of Ophthalmology and Visual Sciences, University of Michigan, 1000 Wall St, Ann Arbor, MI 48105, United States AU - Stein, J. D. AU - Kim, D. D. AU - Peck, W. W. AU - Giannetti, S. M. AU - Hutton, D. W. DB - Embase Medline DO - 10.1001/archophthalmol.2011.2727 IS - 4 KW - generic drug prostaglandin derivative adult article controlled study cost effectiveness analysis human laser surgery medical documentation observational study open angle glaucoma patient compliance priority journal probability quality adjusted life year trabeculoplasty LA - English M3 - Article N1 - L364660055 2012-05-07 PY - 2012 SN - 0003-9950 1538-3601 SP - 497-505 ST - Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma T2 - Archives of Ophthalmology TI - Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364660055&from=export http://dx.doi.org/10.1001/archophthalmol.2011.2727 http://archopht.ama-assn.org/cgi/reprint/130/4/497 VL - 130 ID - 3095 ER - TY - JOUR AB - Objective To describe what information is or is not included in health care claims data, provide an overview of the main advantages and limitations of performing analyses using health care claims data, and offer general guidance on how to report and interpret findings of ophthalmology-related claims data analyses. Design Systematic review. Participants Not applicable. Methods A literature review and synthesis of methods for claims-based data analyses. Main Outcome Measures Not applicable. Results Some advantages of using claims data for analyses include large, diverse sample sizes, longitudinal follow-up, lack of selection bias, and potential for complex, multivariable modeling. The disadvantages include (a) the inherent limitations of claims data, such as incomplete, inaccurate, or missing data, or the lack of specific billing codes for some conditions; and (b) the inability, in some circumstances, to adequately evaluate the appropriateness of care. In general, reports of claims data analyses should include clear descriptions of the following methodological elements: the data source, the inclusion and exclusion criteria, the specific billing codes used, and the potential confounding factors incorporated in the multivariable models. Conclusions The use of claims data for research is expected to increase with the enhanced availability of data from Medicare and other sources. The use of claims data to evaluate resource use and efficiency and to determine the basis for supplementary payment methods for physicians is anticipated. Thus, it will be increasingly important for eye care providers to use accurate and descriptive codes for billing. Adherence to general guidance on the reporting of claims data analyses, as outlined in this article, is important to enhance the credibility and applicability of findings. Guidance on optimal ways to conduct and report ophthalmology-related investigations using claims data will likely continue to evolve as health services researchers refine the metrics to analyze large administrative data sets. © 2014 by the American Academy of Ophthalmology. AD - W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, United States H. Dunbar Hoskins, Jr., M.D. Center for Quality Eye Care, American Academy of Ophthalmology, San Francisco, CA, United States Northern Virginia Ophthalmology Associates, Falls Church, VA, United States Jules Stein Eye Institute, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, United States AU - Stein, J. D. AU - Lum, F. AU - Lee, P. P. AU - Rich Iii, W. L. AU - Coleman, A. L. DB - Scopus DO - 10.1016/j.ophtha.2013.11.038 IS - 5 M3 - Article N1 - Cited By :39 Export Date: 19 July 2021 PY - 2014 SP - 1134-1141 ST - Use of health care claims data to study patients with ophthalmologic conditions T2 - Ophthalmology TI - Use of health care claims data to study patients with ophthalmologic conditions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899942338&doi=10.1016%2fj.ophtha.2013.11.038&partnerID=40&md5=eb10f20c605bd4054d308349ec8ad75c VL - 121 ID - 5022 ER - TY - JOUR AB - Objective: To describe what information is or is not included in health care claims data, provide an overview of the main advantages and limitations of performing analyses using health care claims data, and offer general guidance on how to report and interpret findings of ophthalmology-related claims data analyses. Design: Systematic review. Participants: Not applicable. Methods: A literature review and synthesis of methods for claims-based data analyses. Main Outcome Measures: Not applicable. Results: Some advantages of using claims data for analyses include large, diverse sample sizes, longitudinal follow-up, lack of selection bias, and potential for complex, multivariable modeling. The disadvantages include (a) the inherent limitations of claims data, such as incomplete, inaccurate, or missing data, or the lack of specific billing codes for some conditions; and (b) the inability, in some circumstances, to adequately evaluate the appropriateness of care. In general, reports of claims data analyses should include clear descriptions of the following methodological elements: the data source, the inclusion and exclusion criteria, the specific billing codes used, and the potential confounding factors incorporated in the multivariable models. Conclusions: The use of claims data for research is expected to increase with the enhanced availability of data from Medicare and other sources. The use of claims data to evaluate resource use and efficiency and to determine the basis for supplementary payment methods for physicians is anticipated. Thus, it will be increasingly important for eye care providers to use accurate and descriptive codes for billing. Adherence to general guidance on the reporting of claims data analyses, as outlined in this article, is important to enhance the credibility and applicability of findings. Guidance on optimal ways to conduct and report ophthalmology-related investigations using claims data will likely continue to evolve as health services researchers refine the metrics to analyze large administrative data sets. (C) 2014 by the American Academy of Ophthalmology. AN - WOS:000335504200028 AU - Stein, J. D. AU - Lum, F. AU - Lee, P. P. AU - Rich, W. L. AU - Coleman, A. L. DA - MAY DO - 10.1016/j.ophtha.2013.11.038 IS - 5 PY - 2014 SN - 0161-6420 1549-4713 SP - 1134-1141 ST - Use of Health Care Claims Data to Study Patients with Ophthalmologic Conditions T2 - OPHTHALMOLOGY TI - Use of Health Care Claims Data to Study Patients with Ophthalmologic Conditions VL - 121 ID - 6336 ER - TY - JOUR AB - Purpose To assess possible changes in medication adherence to prostaglandin analog (PGA) regimens among patients with open-angle glaucoma (OAG) after the initial introduction of generic PGAs. Design Longitudinal cohort analysis. Participants Patients older than 40 years with OAG continuously enrolled in a nationwide managed-care network during 2009-2012 who used PGAs. Methods Mean adherence rates were calculated for topical PGA use during the 18 months before the introduction of generic latanoprost (September 2009-February 2011) and the 18 months after generic latanoprost became available (July 2011-December 2012). The rates were compared between persons who continued to use brand-name PGAs once generic latanoprost became available and others who switched to generic latanoprost. Multivariable logistic regression identified variables associated with an improvement or worsening of adherence of ≥25%. Main Outcome Measures Mean adherence rates and odds of 25% or more improved or worsened adherence (with 95% confidence intervals [CIs]). Results A total of 8427 patients met the study eligibility criteria. Compared with persons switching to generic latanoprost, patients who continued taking brand name PGAs were 28% less likely to have improved adherence (odds ratio [OR], 0.72; 95% CI, 0.55-0.94) and 39% more likely to have reduced adherence (OR, 1.39; 1.04-1.86) of ≥25%. Improved adherence after the generic drug's introduction was also associated with higher monthly medication copay in the pregeneric period (P = 0.02), lower copay after introduction of the generic drug (P < 0.0001), and black race (OR, 1.25; 95% CI, 1.04-1.50). Six-hundred twelve patients (7.3%) discontinued all antiglaucoma interventions when generic latanoprost became available. Conclusions Given that cost can significantly deter adherence, switching patients to generic medications may help improve patients' drug-regimen adherence. A considerable number of patients discontinued glaucoma drug use altogether when generic latanoprost became available. Ophthalmologists should work with insurers and pharmacists to prevent such discontinuation of use as generic forms of other PGA agents become available. © 2015 American Academy of Ophthalmology. AD - Department of Ophthalmology and Visual Sciences, University of Michigan, W. K. Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI 48105, United States Department of Clinical, Social, and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, United States AU - Stein, J. D. AU - Shekhawat, N. AU - Talwar, N. AU - Balkrishnan, R. DB - Scopus DO - 10.1016/j.ophtha.2014.11.022 IS - 4 M3 - Article N1 - Cited By :27 Export Date: 19 July 2021 PY - 2015 SP - 738-747 ST - Impact of the introduction of generic latanoprost on glaucoma medication adherence T2 - Ophthalmology TI - Impact of the introduction of generic latanoprost on glaucoma medication adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925348975&doi=10.1016%2fj.ophtha.2014.11.022&partnerID=40&md5=cff7f014fdf0f4b53d88f9ae3d7529f3 VL - 122 ID - 5078 ER - TY - JOUR AB - Open-angle glaucoma is a non-curable, blinding disease which has its best prognosis when management begins at its earliest onset. Recent studies, such as those demonstrating axonal loss before functional or physical changes occur, will have an effect on the current standard of management. This includes indications for initiating treatment as well as what constitutes controlled intraocular pressure. Pharmacological management is often difficult due to drug tolerance and compliance problems. Some types of secondary open angle glaucomas respond very poorly to treatment. Hence, an accurate diagnosis is imperative to proper management. Principles underlying pharmacological management are discussed. When pharmacological management fails, laser and/or surgical intervention is required to prevent further vision loss. AD - T.R. Stelmack, VA Medical Center, Chicago, IL 60612. AU - Stelmack, T. R. DB - Medline IS - 9 KW - beta adrenergic receptor blocking agent miotic agent article human laser surgery open angle glaucoma pathophysiology patient compliance trabeculectomy LA - English M3 - Article N1 - L18729870 1988-05-19 PY - 1987 SN - 0003-0244 SP - 716-721 ST - Management of open-angle glaucoma T2 - Journal of the American Optometric Association TI - Management of open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L18729870&from=export VL - 58 ID - 4063 ER - TY - JOUR AB - Objective: Combine and evaluate data from four clinical practice studies investigating the intraocular pressure (IOP)-lowering ability, tolerability of and patient adherence to bimatoprost 0.01% therapy in patients with primary open-angle glaucoma or ocular hypertension. Methods: Data were combined from four multicenter, prospective, observational studies. Patients (n=2,593) were recruited from 328 sites in Austria, Belgium, Switzerland, and the Netherlands. Assessments were at study entry (baseline) and after 10–14 weeks. Results: Bimatoprost 0.01% lowered mean IOP by 5.0 mmHg from baseline to final visit (P<0.0001). Individual IOP goals were achieved in 75.5% of patients. Results were similar in right and left eyes; right-eye data are presented here for brevity. The greatest mean IOP reduction was 6.7±4.7 mmHg (28.8% reduction from baseline to final visit, P<0.0001) in treatment-naïve patients. Switching to bimatoprost 0.01% monotherapy from previous monotherapy reduced mean IOP by a further 3.2±3.6 mmHg (17.2%, P<0.0001). Switching to bimatoprost 0.01% from previous prostaglandin monotherapy reduced mean IOP by 2.9±3.5 mmHg (15.5%), including by 3.1±3.4 mmHg (15.8%) and 3.3±4.1 mmHg (16.9%) for previous latanoprost and travoprost treatment, respectively (all P<0.0001). IOP reduction in patients previously treated with a fixed combination was 2.7±4.0 mmHg (14.2%, P<0.0001). The most commonly reported adverse events were conjunctival hyperemia (5.2%) and eye irritation (4.7%). Tolerability was rated as “very good” or “good” by 90.1% of patients. Adherence was rated by physicians as “better than” or “equal to” previous treatment in 97.2% of patients. Conclusion: The combined studies demonstrated in a clinical practice setting, bimatoprost 0.01% lowered IOP effectively in treatment-naïve and previously treated ocular hypertension and primary open-angle glaucoma patients, and was associated with good tolerability and patient adherence over 12 weeks. AD - A. Stevens, Department of Ophthalmology, Ghent University Hospital, De Pintelaan 185, Ghent, Belgium AU - Stevens, A. AU - Iliev, M. E. AU - de Jong, L. AU - Grobeiu, I. AU - Hommer, A. DB - Embase DO - 10.2147/OPTH.S89904 KW - beta adrenergic receptor blocking agent bimatoprost carbonate dehydratase inhibitor latanoprost prostaglandin travoprost aged article Austria Belgium blepharal pigmentation clinical practice combination chemotherapy conjunctival hyperemia drug safety drug tolerability dry eye eye disease eye irritation eye pain female headache human intraocular hypertension intraocular pressure major clinical study male medication compliance monotherapy multicenter study (topic) Netherlands observational study ocular pruritus open angle glaucoma outcome assessment patient compliance pigment disorder prospective study Switzerland LA - English M3 - Article N1 - L609631610 2016-04-15 2016-04-25 PY - 2016 SN - 1177-5483 1177-5467 SP - 635-641 ST - A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension T2 - Clinical Ophthalmology TI - A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609631610&from=export http://dx.doi.org/10.2147/OPTH.S89904 VL - 10 ID - 2746 ER - TY - JOUR AB - Objective: Combine and evaluate data from four clinical practice studies investigating the intraocular pressure (IOP)-lowering ability, tolerability of and patient adherence to bimatoprost 0.01% therapy in patients with primary open-angle glaucoma or ocular hypertension. Methods: Data were combined from four multicenter, prospective, observational studies. Patients (n=2,593) were recruited from 328 sites in Austria, Belgium, Switzerland, and the Netherlands. Assessments were at study entry (baseline) and after 10–14 weeks. Results: Bimatoprost 0.01% lowered mean IOP by 5.0 mmHg from baseline to final visit (P<0.0001). Individual IOP goals were achieved in 75.5% of patients. Results were similar in right and left eyes; right-eye data are presented here for brevity. The greatest mean IOP reduction was 6.7±4.7 mmHg (28.8% reduction from baseline to final visit, P<0.0001) in treatment-naïve patients. Switching to bimatoprost 0.01% monotherapy from previous monotherapy reduced mean IOP by a further 3.2±3.6 mmHg (17.2%, P<0.0001). Switching to bimatoprost 0.01% from previous prostaglandin monotherapy reduced mean IOP by 2.9±3.5 mmHg (15.5%), including by 3.1±3.4 mmHg (15.8%) and 3.3±4.1 mmHg (16.9%) for previous latanoprost and travoprost treatment, respectively (all P<0.0001). IOP reduction in patients previously treated with a fixed combination was 2.7±4.0 mmHg (14.2%, P<0.0001). The most commonly reported adverse events were conjunctival hyperemia (5.2%) and eye irritation (4.7%). Tolerability was rated as “very good” or “good” by 90.1% of patients. Adherence was rated by physicians as “better than” or “equal to” previous treatment in 97.2% of patients. Conclusion: The combined studies demonstrated in a clinical practice setting, bimatoprost 0.01% lowered IOP effectively in treatment-naïve and previously treated ocular hypertension and primary open-angle glaucoma patients, and was associated with good tolerability and patient adherence over 12 weeks. © 2016 Stevens et al. AD - Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium Department of Ophthalmology, University of Bern, Bern, Switzerland Department of Ophthalmology, Academic Medical Centre, Amsterdam, Netherlands Allergan Holdings Ltd, Marlow, United Kingdom Private Office, Vienna, Austria AU - Stevens, A. AU - Iliev, M. E. AU - de Jong, L. AU - Grobeiu, I. AU - Hommer, A. DB - Scopus DO - 10.2147/OPTH.S89904 KW - Bimatoprost Bimatoprost 0.01% Glaucoma treatment Intraocular pressure Prostaglandin Switch therapy M3 - Article N1 - Cited By :3 Export Date: 19 July 2021 PY - 2016 SP - 635-641 ST - A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension T2 - Clinical Ophthalmology TI - A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964030190&doi=10.2147%2fOPTH.S89904&partnerID=40&md5=f17d3ad4992170ef2dc09ced892d2c4f VL - 10 ID - 5513 ER - TY - JOUR AB - Objective: Combine and evaluate data from four clinical practice studies investigating the intraocular pressure (IOP)-lowering ability, tolerability of and patient adherence to bimatoprost 0.01% therapy in patients with primary open-angle glaucoma or ocular hypertension. Methods: Data were combined from four multicenter, prospective, observational studies. Patients (n=2,593) were recruited from 328 sites in Austria, Belgium, Switzerland, and the Netherlands. Assessments were at study entry (baseline) and after 10-14 weeks. Results: Bimatoprost 0.01% lowered mean IOP by 5.0 mmHg from baseline to final visit (P<0.0001). Individual IOP goals were achieved in 75.5% of patients. Results were similar in right and left eyes; right-eye data are presented here for brevity. The greatest mean IOP reduction was 6.7 +/- 4.7 mmHg (28.8% reduction from baseline to final visit, P<0.0001) in treatment-naive patients. Switching to bimatoprost 0.01% monotherapy from previous monotherapy reduced mean IOP by a further 3.2 +/- 3.6 mmHg (17.2%, P<0.0001). Switching to bimatoprost 0.01% from previous prostaglandin monotherapy reduced mean IOP by 2.9 +/- 3.5 mmHg (15.5%), including by 3.1 +/- 3.4 mmHg (15.8%) and 3.3 +/- 4.1 mmHg (16.9%) for previous latanoprost and travoprost treatment, respectively (all P<0.0001). IOP reduction in patients previously treated with a fixed combination was 2.7 +/- 4.0 mmHg (14.2%, P<0.0001). The most commonly reported adverse events were conjunctival hyperemia (5.2%) and eye irritation (4.7%). Tolerability was rated as "very good" or "good" by 90.1% of patients. Adherence was rated by physicians as "better than" or "equal to" previous treatment in 97.2% of patients. Conclusion: The combined studies demonstrated in a clinical practice setting, bimatoprost 0.01% lowered IOP effectively in treatment-naive and previously treated ocular hypertension and primary open-angle glaucoma patients, and was associated with good tolerability and patient adherence over 12 weeks. AN - WOS:000374283500001 AU - Stevens, A. AU - Iliev, M. E. AU - de Jong, L. AU - Grobeiu, I. AU - Hommer, A. DO - 10.2147/OPTH.S89904 PY - 2016 SN - 1177-5483 SP - 635-641 ST - A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension T2 - CLINICAL OPHTHALMOLOGY TI - A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension VL - 10 ID - 6104 ER - TY - JOUR AB - We evaluated factors associated with decreased or stable visual function in 72 patients with primary open-angle glaucoma and complete cupping of the optic disk who were followed up five years or more. We found a significantly lower mean (15.4 ± 2.7 mm Hg) and peak (24.5 ± 6.9 mm Hg) intraocular pressure in those patients whose vision remained stable vs those whose vision decreased (21.3 ± 3.2 and 39.2 ± 11.0 mm Hg, respectively) (t-test, P < .001). Additionally, the variance of each patient's individual intraocular pressure readings measured during the follow-up period was lower in the group with stable vision (4.5 mm Hg) than in those in whom vision decreased (9.0 mm Hg) (F test, P < .001). Stepwise discriminant analysis disclosed that mean intraocular pressure, variance of an individual's intraocular pressure measurements over time, history of argon laser trabeculoplasty, and compliance with therapy discriminated 92.9% of patients (52 of 56) whose vision remained stable and 87.5% of patients (14 of 16) whose vision decreased. Reduction of intraocular pressure and compliance with therapy are important in patients with complete glaucomatous cupping of the optic disk. AD - Storm Eye Institute, Medical University of South Carolina, 171 Ashley Ave., Charleston, SC 29425-2236, United States AU - Stewart, W. C. AU - Chorak, R. P. AU - Hunt, H. H. AU - Sethuraman, G. DB - Scopus DO - 10.1016/S0002-9394(14)71282-6 IS - 2 M3 - Article N1 - Cited By :131 Export Date: 19 July 2021 PY - 1993 SP - 176-181 ST - Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head T2 - American Journal of Ophthalmology TI - Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027305447&doi=10.1016%2fS0002-9394%2814%2971282-6&partnerID=40&md5=2bfa7970224557e28ae0a15f401732cb VL - 116 ID - 4916 ER - TY - JOUR AB - We evaluated factors associated with decreased or stable visual function in 72 patients with primary open-angle glaucoma and complete cupping of the optic disk who were followed up five years or more. We found a significantly lower mean (15.4 +/- 2.7 mm Hg) and peak (24.5 +/- 6.9 mm Hg) intraocular pressure in those patients whose vision remained stable vs those whose vision decreased (21.3 +/- 3.2 and 39.2 +/- 11.0 mm Hg, respectively) (t-test, P < .001). Additionally, the variance of each patient's individual intraocular pressure readings measured during the follow-up period was lower in the group with stable vision (4.5 mm Hg) than in those in whom vision decreased (9.0 mm Hg) (F test, P < .001). Stepwise discriminant analysis disclosed that mean intraocular pressure, variance of an individual's intraocular pressure measurements over time, history of argon laser trabeculoplasty, and compliance with therapy discriminated 92.9% of patients (52 of 56) whose vision remained stable and 87.5% of patients (14 of 16) whose vision decreased. Reduction of intraocular pressure and compliance with therapy are important in patients with complete glaucomatous cupping of the optic disk. AN - WOS:A1993LR27700007 AU - Stewart, W. C. AU - Chorak, R. P. AU - Hunt, H. H. AU - Sethuraman, G. DA - AUG 15 DO - 10.1016/S0002-9394(14)71282-6 IS - 2 PY - 1993 SN - 0002-9394 SP - 176-181 ST - FACTORS ASSOCIATED WITH VISUAL-LOSS IN PATIENTS WITH ADVANCED GLAUCOMATOUS CHANGES IN THE OPTIC-NERVE HEAD T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - FACTORS ASSOCIATED WITH VISUAL-LOSS IN PATIENTS WITH ADVANCED GLAUCOMATOUS CHANGES IN THE OPTIC-NERVE HEAD VL - 116 ID - 6132 ER - TY - JOUR AB - Aim: The aim of this study was to identify research avenues that might improve patient compliance with glaucoma therapy. Methods: 500 patients and physicians were interviewed by telephone in 5 European countries, and the results were compiled and evaluated by 2 independent physicians. Results: Most physicians believed that pressure reduction is useful (UK (96%), France (94%), Spain (80%), Italy (72%), and Germany (70%), p < 0.0001). The majority of physicians believed that noncompliance exists in 0%-25% of patients, whereas 34% of patients admitted to noncompliance. Physicians believed patients would prefer once-daily dosing (92%) and that it would help compliance, whereas 60% of patients preferred once-daily dosing, and 20% of patients believed it would help compliance. Physicians (94%) believed that noncompliance could lead to visual loss and, while this information concerned most physicians, this was less likely in Germany (52%) (p < 0.0001). Most patients received information concerning dosing of their medicines (79%), and, accordingly, waited an average of 10 minutes between doses; but only half of the patients had been told to wait at least 5 minutes between instilling preparations. Approximately 2 of 3 patients knew that missing medicines could cause visual loss. Conclusions: Once-daily dosing to increase patient satisfaction and/or dosing convenience and providing patient education are potential clinical techniques that could be further evaluated as a means to increase compliance. AD - W.C. Stewart, Pharmaceutical Research Network, LLC, 1639 Tatum Street, Charleston, SC 29412-2464, United States AU - Stewart, W. C. AU - Konstas, A. G. P. AU - Pfeiffer, N. DB - Embase Medline DO - 10.1089/jop.2004.20.461 IS - 6 KW - beta adrenergic receptor blocking agent brimonidine carbonate dehydratase inhibitor dorzolamide latanoprost pilocarpine timolol article controlled study doctor patient relationship drug dose regimen glaucoma health survey human interview intraocular pressure major clinical study medical practice monotherapy patient compliance patient education patient satisfaction physician attitude practice guideline treatment outcome visual impairment LA - English M3 - Article N1 - L39628492 2004-12-31 PY - 2004 SN - 1080-7683 SP - 461-469 ST - Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment T2 - Journal of Ocular Pharmacology and Therapeutics TI - Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39628492&from=export http://dx.doi.org/10.1089/jop.2004.20.461 VL - 20 ID - 3714 ER - TY - JOUR AB - ABSTRACT In an observational study 19 eyes with cataract and coexisting primary open angle glaucoma were scheduled to undergo combined procedure with ECCE‐IOL and trabeculectomy. The aim of the present study was to investigate the results and the efficacy of combined surgery, when we extended the indication for surgery. Thus the surgical decision making was not based solely upon IOP readings, but also involved social/psychological factors. Median decrease in IOP (IOPpost ‐ IOPpre) was significant through a 12‐month observation period, p < 0.001. The number of medications dropped from 1.74 to 0.21, p < 0.01. Complication rate during operation and in the postoperative follow‐up period was low. We conclude that it seems justified to extend the indication for combined surgery in cataract patients with coexisting open angle glaucoma in case of uncontrolled IOP, poor compliance, inability of sufficient medical care, or unacceptable medication. We recommend careful monitoring of the early postoperative IOP, even if hypotensive agents are given prophylactically. 1995 Institution Acta Ophthalmologica Scandinavica AD - Department of Ophthalmology, Gentofte Hospital, University of Copenhagen, Denmark AU - Storr‐Paulsen, A. AU - Perriard, A. AU - Vangsted, P. DB - Scopus DO - 10.1111/j.1600-0420.1995.tb00284.x IS - 3 KW - cataract combined procedure ECCE glaucoma trabeculectomy M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 1995 SP - 273-276 ST - Indications and efficacy of combined trabeculectomy and extracapsular cataract extraction with intraocular lens implantation in cataract patients with coexisting open angle glaucoma T2 - Acta Ophthalmologica Scandinavica TI - Indications and efficacy of combined trabeculectomy and extracapsular cataract extraction with intraocular lens implantation in cataract patients with coexisting open angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029018120&doi=10.1111%2fj.1600-0420.1995.tb00284.x&partnerID=40&md5=d6230c71c150abbe462b88d0fec8c02f VL - 73 ID - 5491 ER - TY - JOUR AB - OBJECTIVE: To identify barriers to compliance of medical treatment for glaucoma among veterans. METHODS: Patients with glaucoma from the Miami Veterans Affairs Eye Clinic (n=74) filled out a 63-question survey regarding dry eye symptoms, concurrent systemic disease, and medications. The association between glaucoma medical compliance was defined as self-reported adherence to drop regimens greater than 75% of the time. RESULTS: Eighty percent of veterans (n=59) reported compliance with glaucoma therapy. Dry eye symptoms (as defined by Dry Eye Questionnaire 5 score ≥6) were reported by 39% (n=29), and their presence was associated with decreased compliance (63% vs. 89%, P=0.007). Anxiety and posttraumatic stress syndrome (PTSD) were also associated with significant noncompliance (64% vs. 83%, P=0.05 and 58% vs. 84%, P=0.02, respectively). Other studied factors including demographics, depression (P=0.11), and glaucoma regimens did not play a significant role in glaucoma medication compliance. CONCLUSIONS: Dry eye symptoms, PTSD, and anxiety were associated with decreased compliance to medical treatment of glaucoma. Identifying and treating underlying ocular surface disease and anxiety disorders may lead to increased adherence to glaucoma treatment. AD - Miami Veterans Administration Medical Center (S.R.W., A.G.), FL; Bascom Palmer Eye Institute (S.R.W., A.G., J.S.), University of Miami, FL; University of Miami Miller School of Medicine (N.A.), Miami, FL, United States AU - Stringham, J. AU - Ashkenazy, N. AU - Galor, A. AU - Wellik, S. R. DB - Scopus DO - 10.1097/ICL.0000000000000301 IS - 1 M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2018 SP - 50-54 ST - Barriers to Glaucoma Medication Compliance Among Veterans: Dry Eye Symptoms and Anxiety Disorders T2 - Eye & contact lens TI - Barriers to Glaucoma Medication Compliance Among Veterans: Dry Eye Symptoms and Anxiety Disorders UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040136408&doi=10.1097%2fICL.0000000000000301&partnerID=40&md5=f321e3d62ecd5168a28790ed2c6f963d VL - 44 ID - 5301 ER - TY - JOUR AB - Purpose: To understand the factors that influence glaucoma treatment adherence with medication taking, prescription refills, and appointment keeping to develop an intervention for a specific population. Patients and methods: In-depth interviews were conducted with 80 individuals diagnosed with open-angle glaucoma, glaucoma suspect, or ocular hypertension. Additional eligibility requirements were that all participants were: between the ages of 18 to 80; white or African American; spoke and understood English; and were taking daily doses of topical glaucoma treatments for at least the past year. Cross-tabulations and χ tests were conducted to compare adherent and nonadherent individuals, classified as such based on self-report and medical chart/pharmacy data. Results: Compared with adherent participants, nonadherent participants were less likely to: believe their eye doctors spent sufficient time with them; ask their eye doctor if they had any questions; know of benefits to taking their glaucoma medication regularly; and have someone help them take their glaucoma medications or drive them to eye appointments. Conversely, compared with adherent individuals, nonadherent participants were more likely to have difficulty remembering to take their medications and to believe their glaucoma would affect their eye sight in the future. Conclusions: Nonadherent glaucoma patients struggle with a variety of issues related to consistent use of glaucoma medicine and routine eye care. Interventions are needed to address these modifiable factors related to glaucoma treatment adherence. © 2010 by Lippincott Williams&Wilkins. AD - J. E. Stryker, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA 30322, United States AU - Stryker, J. E. AU - Beck, A. D. AU - Primo, S. A. AU - Echt, K. V. AU - Bundy, L. AU - Pretorius, G. C. AU - Glanz, K. DB - Embase Medline DO - 10.1097/IJG.0b013e31819c4679 IS - 1 KW - antiglaucoma agent adult African American aged article controlled study education European American eye care female human interview intraocular hypertension major clinical study male memory open angle glaucoma patient attitude patient compliance patient education priority journal race difference self concept self report social status social support LA - English M3 - Article N1 - L358219061 2010-02-11 2010-03-02 PY - 2010 SN - 1057-0829 SP - 66-72 ST - An exploratory study of factors influencing glaucoma treatment adherence T2 - Journal of Glaucoma TI - An exploratory study of factors influencing glaucoma treatment adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358219061&from=export http://dx.doi.org/10.1097/IJG.0b013e31819c4679 VL - 19 ID - 3279 ER - TY - JOUR AB - Purpose: To understand the factors that influence glaucoma treatment adherence with medication taking, prescription refills, and appointment keeping to develop an intervention for a specific population. Patients and methods: In-depth interviews were conducted with 80 individuals diagnosed with open-angle glaucoma, glaucoma suspect, or ocular hypertension. Additional eligibility requirements were that all participants were: between the ages of 18 to 80; white or African American; spoke and understood English; and were taking daily doses of topical glaucoma treatments for at least the past year. Cross-tabulations and χ tests were conducted to compare adherent and nonadherent individuals, classified as such based on self-report and medical chart/pharmacy data. Results: Compared with adherent participants, nonadherent participants were less likely to: believe their eye doctors spent sufficient time with them; ask their eye doctor if they had any questions; know of benefits to taking their glaucoma medication regularly; and have someone help them take their glaucoma medications or drive them to eye appointments. Conversely, compared with adherent individuals, nonadherent participants were more likely to have difficulty remembering to take their medications and to believe their glaucoma would affect their eye sight in the future. Conclusions: Nonadherent glaucoma patients struggle with a variety of issues related to consistent use of glaucoma medicine and routine eye care. Interventions are needed to address these modifiable factors related to glaucoma treatment adherence. © 2010 by Lippincott Williams&Wilkins. AD - Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, United States Atlanta VA Rehab. R. and D. Center of Excellence for Aging Veterans with Vision Loss, Department of Medicine, Division of Geriatric Medicine and Gerontology, United States Department of Ophthalmology, Emory University, School of Medicine, United States AU - Stryker, J. E. AU - Beck, A. D. AU - Primo, S. A. AU - Echt, K. V. AU - Bundy, L. AU - Pretorius, G. C. AU - Glanz, K. DB - Scopus DO - 10.1097/IJG.0b013e31819c4679 IS - 1 KW - Adherence Compliance Glaucoma medications Glaucoma suspect Open-angle glaucoma M3 - Article N1 - Cited By :81 Export Date: 19 July 2021 PY - 2010 SP - 66-72 ST - An exploratory study of factors influencing glaucoma treatment adherence T2 - Journal of Glaucoma TI - An exploratory study of factors influencing glaucoma treatment adherence UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-75749105126&doi=10.1097%2fIJG.0b013e31819c4679&partnerID=40&md5=c32a8541479cca77114b652b2113bd92 VL - 19 ID - 4944 ER - TY - JOUR AB - Purpose: To understand the factors that influence glaucoma treatment adherence with medication taking, prescription refills, and appointment keeping to develop an intervention for a specific population. Patients and Methods: In-depth interviews were conducted with 80 individuals diagnosed with open-angle glaucoma, glaucoma suspect, or ocular hypertension. Additional eligibility requirements were that all participants were: between the ages of 18 to 80; white or African American; spoke and understood English, and were taking daily doses of topical glaucoma treatments for at least the past year. Cross-tabulations and chi(2) tests were conducted to compare adherent and nonadherent individuals, classified as such based on self-report and medical chart/pharmacy data. Results: Compared with adherent participants, nonadherent participants were less likely to: believe their eye doctors spent sufficient time, with them: ask their eye doctor if they had any questions: know of benefits to taking their glaucoma medication regularly; and have someone help them take their glaucoma medications or drive them to eye appointments. Conversely, compared with adherent individuals. nonadherent participants were more likely to have difficulty remembering to take their medications and to believe their glaucoma Would affect their eye sight in the future. Conclusions: Nonadherent glaucoma patients struggle with a variety of issues related to consistent use of glaucoma medicine and routine eye care. Interventions are needed to address these modifiable factors related to glaucoma treatment adherence. AN - WOS:000273792200014 AU - Stryker, J. E. AU - Beck, A. D. AU - Primo, S. A. AU - Echt, K. V. AU - Bundy, L. AU - Pretorius, G. C. AU - Glanz, K. DA - JAN DO - 10.1097/IJG.0b013e31819c4679 IS - 1 PY - 2010 SN - 1057-0829 1536-481X SP - 66-72 ST - An Exploratory Study of Factors Influencing Glaucoma Treatment Adherence T2 - JOURNAL OF GLAUCOMA TI - An Exploratory Study of Factors Influencing Glaucoma Treatment Adherence VL - 19 ID - 5823 ER - TY - JOUR AB - Purpose: COVID-19 pandemic has affected the healthcare system worldwide hindering the continuum of treatment of chronic disease patients. The objective of the study is to analyze the barriers encountered by the glaucoma patients for the follow-up visit and medication adherence during the pandemic.Methods: This cross-sectional study included glaucoma patients who did not attend the scheduled appointment from April 1, 2020 to July 31, 2020 in a tertiary eye care center (88.21%). Eligible patients of age >18 years and advised antiglaucoma medication in Madurai Zone were interviewed with validated questionnaire through telephonic call.Results: 363 patients answered the questionnaire through telephonic interview. 57.3% of the patients were found to be non-adherent to medication. The main barriers for glaucoma follow-up visit during the pandemic were lockdown restriction, transport problem, and financial difficulties. The top barriers for medication adherence were non availability of medication (54.81%), financial difficulties (30.29%), did not feel much improvement with eye drops (20.19%). On multiple regression analysis, longer distance to hospital, low socioeconomic status, more than one antiglaucoma medication use, lack of awareness of glaucoma, non-complaint before COVID-19 and stress due to the pandemic were found to be significant factors for medication non adherence.Conclusion: COVID-19 pandemic has emphasized the need for reformation in health care system for accessibility of medical care to patients in rural areas. Decentralization of health system to primary care level and utilization of teleophthalmology should be considered by health care planners in future. AD - Department of Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu Department of Biostatistics, Aravind Eye Hospital, Madurai, Tamil Nadu Lions Aravind Institute of Community Ophthalmology, Madurai, Tamil Nadu Department of Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu, India AN - 150164475. Language: English. Entry Date: 20210712. Revision Date: 20210715. Publication Type: journal article. Journal Subset: Asia AU - Subathra, G. AU - Rajendrababu, Sharmila AU - Senthilkumar, Vijayalakshmi AU - Mani, Iswarya AU - Udayakumar, B. AU - Subathra, G. N. AU - Rajendrababu, Sharmila R. AU - Senthilkumar, Vijayalakshmi A. DB - ccm DO - 10.4103/ijo.IJO_164_21 DP - EBSCOhost IS - 5 N1 - Biomedical; Peer Reviewed. NLM UID: 0405376. PMID: NLM33913874. PY - 2021 SN - 0301-4738 SP - 1264-1270 ST - Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India T2 - Indian Journal of Ophthalmology TI - Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150164475&site=ehost-live&scope=site VL - 68 ID - 4143 ER - TY - JOUR AB - Purpose: COVID-19 pandemic has affected the healthcare system worldwide hindering the continuum of treatment of chronic disease patients. The objective of the study is to analyze the barriers encountered by the glaucoma patients for the follow-up visit and medication adherence during the pandemic. Methods: This cross-sectional study included glaucoma patients who did not attend the scheduled appointment from April 1, 2020 to July 31, 2020 in a tertiary eye care center (88.21%). Eligible patients of age >18 years and advised antiglaucoma medication in Madurai Zone were interviewed with validated questionnaire through telephonic call. Results: 363 patients answered the questionnaire through telephonic interview. 57.3% of the patients were found to be non-adherent to medication. The main barriers for glaucoma follow-up visit during the pandemic were lockdown restriction, transport problem, and financial difficulties. The top barriers for medication adherence were non availability of medication (54.81%), financial difficulties (30.29%), did not feel much improvement with eye drops (20.19%). On multiple regression analysis, longer distance to hospital, low socioeconomic status, more than one antiglaucoma medication use, lack of awareness of glaucoma, non-complaint before COVID-19 and stress due to the pandemic were found to be significant factors for medication non adherence. Conclusion: COVID-19 pandemic has emphasized the need for reformation in health care system for accessibility of medical care to patients in rural areas. Decentralization of health system to primary care level and utilization of teleophthalmology should be considered by health care planners in future. AN - WOS:000647111200053 AU - Subathra, G. AU - Rajendrababu, S. R. AU - Senthilkumar, V. A. AU - Mani, I. AU - Udayakumar, B. DA - MAY DO - 10.4103/ijo.IJO_164_21 IS - 5 PY - 2021 SN - 0301-4738 1998-3689 SP - 1264-1270 ST - Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India T2 - INDIAN JOURNAL OF OPHTHALMOLOGY TI - Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India VL - 69 ID - 5815 ER - TY - JOUR AB - Purpose: COVID-19 pandemic has affected the healthcare system worldwide hindering the continuum of treatment of chronic disease patients. The objective of the study is to analyze the barriers encountered by the glaucoma patients for the follow-up visit and medication adherence during the pandemic. Methods: This cross-sectional study included glaucoma patients who did not attend the scheduled appointment from April 1, 2020 to July 31, 2020 in a tertiary eye care center (88.21%). Eligible patients of age >18 years and advised antiglaucoma medication in Madurai Zone were interviewed with validated questionnaire through telephonic call. Results: 363 patients answered the questionnaire through telephonic interview. 57.3% of the patients were found to be non-adherent to medication. The main barriers for glaucoma follow-up visit during the pandemic were lockdown restriction, transport problem, and financial difficulties. The top barriers for medication adherence were non availability of medication (54.81%), financial difficulties (30.29%), did not feel much improvement with eye drops (20.19%). On multiple regression analysis, longer distance to hospital, low socioeconomic status, more than one antiglaucoma medication use, lack of awareness of glaucoma, non-complaint before COVID-19 and stress due to the pandemic were found to be significant factors for medication non adherence. Conclusion: COVID-19 pandemic has emphasized the need for reformation in health care system for accessibility of medical care to patients in rural areas. Decentralization of health system to primary care level and utilization of teleophthalmology should be considered by health care planners in future. AU - Subathra, G. N. AU - Rajendrababu, S. R. AU - Senthilkumar, V. A. AU - Mani, I. AU - Udayakumar, B. DB - Medline DO - 10.4103/ijo.IJO_164_21 IS - 5 KW - adolescent communicable disease control cross-sectional study follow up glaucoma human India medication compliance ophthalmology pandemic telemedicine LA - English M3 - Article N1 - L634919445 2021-05-10 PY - 2021 SN - 1998-3689 SP - 1264-1270 ST - Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India T2 - Indian journal of ophthalmology TI - Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634919445&from=export http://dx.doi.org/10.4103/ijo.IJO_164_21 VL - 69 ID - 2300 ER - TY - JOUR AB - Purpose: COVID-19 pandemic has affected the healthcare system worldwide hindering the continuum of treatment of chronic disease patients. The objective of the study is to analyze the barriers encountered by the glaucoma patients for the follow-up visit and medication adherence during the pandemic. Methods: This cross-sectional study included glaucoma patients who did not attend the scheduled appointment from April 1, 2020 to July 31, 2020 in a tertiary eye care center (88.21%). Eligible patients of age >18 years and advised antiglaucoma medication in Madurai Zone were interviewed with validated questionnaire through telephonic call. Results: 363 patients answered the questionnaire through telephonic interview. 57.3% of the patients were found to be non-adherent to medication. The main barriers for glaucoma follow-up visit during the pandemic were lockdown restriction, transport problem, and financial difficulties. The top barriers for medication adherence were non availability of medication (54.81%), financial difficulties (30.29%), did not feel much improvement with eye drops (20.19%). On multiple regression analysis, longer distance to hospital, low socioeconomic status, more than one antiglaucoma medication use, lack of awareness of glaucoma, non-complaint before COVID-19 and stress due to the pandemic were found to be significant factors for medication non adherence. Conclusion: COVID-19 pandemic has emphasized the need for reformation in health care system for accessibility of medical care to patients in rural areas. Decentralization of health system to primary care level and utilization of teleophthalmology should be considered by health care planners in future. © 2021 Indian Journal of Ophthalmology Published by Wolters Kluwer-Medknow. AD - Department of Glaucoma, Aravind Eye Hospital, Madurai, Tamil Nadu, India Department of Biostatistics, Aravind Eye Hospital, Madurai, Tamil Nadu, India Lions Aravind Institute of Community Ophthalmology, Madurai Tamil Nadu, India AU - Subathra, G. N. AU - Rajendrababu, S. R. AU - Senthilkumar, V. A. AU - Mani, I. AU - Udayakumar, B. DB - Scopus DO - 10.4103/ijo.IJO_164_21 IS - 5 KW - Adherence antiglaucoma medication COVID-19 pandemic follow-up lockdown M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 1264-1270 ST - Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India T2 - Indian Journal of Ophthalmology TI - Impact of COVID-19 on follow-up and medication adherence in patients with glaucoma in a tertiary eye care centre in south India UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105076147&doi=10.4103%2fijo.IJO_164_21&partnerID=40&md5=f206d4a1b8c656d604aa21842121addf VL - 69 ID - 5659 ER - TY - JOUR AB - Complications associated with contact lenses range from mild to severe and occur with all lens modalities. Contact lens wear can cause a change in corneal physiology, which can lead to epithelial, stromal, and endothelial compromise. Other complications include lens deposition, allergic conjunctivitis, giant papillary conjunctivitis, peripheral infiltrates, microbial keratitis, and neovascularization. Pre-existing conditions can contribute to these complications, or they can occur in association with contact lens wear and care regimens. Patient-related factors, such as alteration of the recommended wearing or replacement schedules and noncompliance with recommended contact lens care regimens for economic reasons, convenience, or in error, contribute to contact lens-related complications and have led to difficulty in accurate determination of complication rates among the various lens wear modalities. Complications may require discontinuation of contact lenses, topical therapy, and changes in contact lens wearing schedules, materials, and care solutions. On initial lens fitting and follow-up evaluations, practitioners should review contact lens replacement and cleaning regimens with patients and discuss complications. To avoid serious complications, patients should be reminded to remove their contact lenses as soon as ocular irritation occurs, and to call their eye care practitioner immediately if symptoms persist. AD - Division of Ophthalmology, Univ. of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, United States AU - Suchecki, J. K. AU - Donshik, P. AU - Ehlers, W. H. DB - Scopus DO - 10.1016/S0896-1549(03)00056-7 IS - 3 M3 - Review N1 - Cited By :47 Export Date: 19 July 2021 PY - 2003 SP - 471-484 ST - Contact lens complications T2 - Ophthalmology Clinics of North America TI - Contact lens complications UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141592382&doi=10.1016%2fS0896-1549%2803%2900056-7&partnerID=40&md5=09d608fd6f653b3ec79426a79355cf73 VL - 16 ID - 5004 ER - TY - JOUR AB - Purpose: To evaluate the intraocular pressure (IOP)-lowering effect of travoprost in normal-tension glaucoma (NTG) over a 12-month follow-up. Methods: Forty-five eyes of 45 patients with unilateral NTG were treated with travoprost (0.004%) once a day for 12 months. Mean IOP and the IOP reduction from baseline were assessed at 0.5, 1, 3, 6, 9, and 12 months after the initiation of the treatment. Adverse ocular event frequency and the frequency of discontinuation of treatment due to adverse events were evaluated. Results: Mean IOP during 12 months of travoprost treatment ranged from 11.17 to 11.82 mmHg, and the mean IOP reduction in relation to baseline IOP from -2.71 to -3.71 mmHg (-18.3% to -25.1%). Mean IOP and IOP changes in the travoprost-treated and control groups were significantly different at every follow-up (P < 0.05 in each case). Both the magnitude (r = 0.6992) and percentage (r = 0.5464) of IOP reductions correlated positively with baseline IOP values. Ocular adverse events were usually mild to moderate and resolved without treatment. Conclusions: Travoprost was well tolerated and significantly reduced IOP in NTG patients. In addition, initial IOP reductions were maintained throughout follow-up. Travoprost was found to be more effective in patients with greater baseline IOP. © 2009 Japanese Ophthalmological Society (JOS). AD - Department of Ophthalmology, Seoul National University, College of Medicine, Seoul, South Korea Seoul Artificial Eye Center, Seoul National University, Hospital Clinical Research Institute, Seoul, South Korea Division of Ophthalmology, College of Medicine, Seoul National University, 28 Yongon-dong, Chongno-gu, Seoul 110-744, South Korea AU - Suh, M. H. AU - Park, K. H. AU - Kim, D. M. DB - Scopus DO - 10.1007/s10384-008-0617-8 IS - 1 KW - Adverse event Intraocular pressure Normal tension glaucoma Travoprost M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2009 SP - 18-23 ST - Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma T2 - Japanese Journal of Ophthalmology TI - Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-59449083872&doi=10.1007%2fs10384-008-0617-8&partnerID=40&md5=39d1ad37b99aa44f67ed44bf458a8e67 VL - 53 ID - 5113 ER - TY - JOUR AB - Aim: The aim of the study was to evaluate patient cooperation in glaucoma treatment. Methods: We evaluated data collected by an anonymous questionnare from 98 glaucoma patients who answered 6 questions regarding their compliance and persistence in glaucoma treatment. Results: Study results revealed 50% of patients to fail taking their antiglaucoma therapy regularly. Patients on monotherapy showed better compliance and higher level of satisfaction with treatment than those on combination antiglaucoma therapy consisting of 2 or 3 eyedrops. Discontinuation of persistence was recorded in 31% of patients, whereas 51% of patients did not present for control visits every six months as suggested by their ophthalmologist. Conclusion: Patients are more compliant and persistent with antiglaucoma monotherapy than with combined therapy. Greater compliance and persistence with ocular hypotensive therapy may improve the outcomes in glaucoma. AD - S. P. Suić, Klinika za Očne Bolesti, Klinički Bolnički Centar Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia AU - Suić, S. P. AU - Cerovski, B. AU - Jukić, T. DB - Embase Medline IS - 1 KW - antiglaucoma agent eye drops article glaucoma human major clinical study monotherapy patient compliance patient satisfaction questionnaire LA - unknown M3 - Article N1 - L351373638 2008-03-26 PY - 2008 SN - 1330-0164 SP - 57-59 ST - The role of patient compliance in the management of glaucoma T2 - Acta Medica Croatica TI - The role of patient compliance in the management of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351373638&from=export VL - 62 ID - 3463 ER - TY - JOUR AB - Individuals with cystic fibrosis have a 1% to 7% incidence of insulin-dependent diabetes mellitus. The occurrence of diabetic microangiopathy in patients with cystic fibrosis has been reported recently. From 1978 to 1987, 19 patients with cystic fibrosis and diabetes mellitus were followed up. Four patients (21%) had evidence of diabetic microangiopathy. In one, peripheral neuropathy developed 5 years after the onset of diabetes mellitus, and the other 3 patients each had complications of retinopathy, nephropathy, and neuropathy which developed 10 years after the onset of diabetes mellitus. All were poorly compliant in their medical care. Significant morbidity was seen in the 3 patients with multisystem involvement - blindness, glaucoma, hypertension, and renal failure. The combination of long-standing diabetes mellitus, poor glycemic control, plus pathophysiologic features associated with cystic fibrosis may have contributed to the development of microangiopathy. The use of steroids in 4 other patients and dextrose infusions (as part of hyperalimentation) in another 4 patients precipitated or exacerbated diabetes. The data indicate that diabetic microangiopathy can occur in the individual with cystic fibrosis. Routine screening for diabetes and its complications in the population with cystic fibrosis, as well as optimal control of hyperglycemia, is warranted. AD - Department of Pediatrics, St Vincent's Hospital, New York, NY 10011, United States AU - Sullivan, M. M. AU - Denning, C. R. DB - Scopus IS - 4 M3 - Article N1 - Cited By :59 Export Date: 19 July 2021 PY - 1989 SP - 642-647 ST - Diabetic microangiopathy in patients with cystic fibrosis T2 - Pediatrics TI - Diabetic microangiopathy in patients with cystic fibrosis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024458969&partnerID=40&md5=b1167399df24fc692228ff4a1e9c9bb6 VL - 84 ID - 4973 ER - TY - JOUR AB - Ocular hypertensions (OHTs) in juvenile are characterized by occurrence in teenage with intraocular pressure (IOP) frequently fluctuated and increased over 30 mm Hg(l mm Hg=0.133 kPa) without any ocular symptoms and disturbance of visual acuity. IOPs are normalized in the majorities of juvenile over adolescence stage with long-term follow up. The medical terminology of 'adolescence IOP fluctuation' or 'adolescence ocular hypertension' is therefore used. The diagnosis and management of juvenile OHT remain difficult clinical challenges. OHTs in juvenile sometimes are incorrectly diagnosed due to inappropriate IOP measurement and thicker central cornea as younger children are non-compliant and resisting the examination. In this paper, we reviewed OHT in juvenile in the light of significant studies in the past and based on our experience of clinical practice in order to provide a better understanding and management of OHTs in juvenile. AD - Myopia Key Laboratory of Health Ministry, Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai 200031, China AU - Sun, X. H. DB - Scopus DO - 10.3760/cma.j.issn.0412-4081.2012.06.001 IS - 6 KW - Child Diagnosis Ocular hypertension M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2012 SP - 481-484 ST - Management of juvenile ocular hypertension T2 - Chinese Journal of Ophthalmology TI - Management of juvenile ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864382810&doi=10.3760%2fcma.j.issn.0412-4081.2012.06.001&partnerID=40&md5=04f6946752a807b52998ef63fad6cd44 VL - 48 ID - 5635 ER - TY - GEN AB - Travoprost is a prostaglandin analog used in the management of glaucoma and ocular hypertension for reducing intraocular pressure (IOP). The IOP-lowering efficacy of travoprost has been shown to be similar to that of other prostaglandins, including latanoprost and bimatoprost. When compared with fixed combinations of timolol and either latanoprost or dorzolamide, travoprost alone can reduce mean IOP in a similar or superior manner. Concomitant therapy of travoprost and timolol can reach even greater IOP reductions than fixed combinations at some time points, but with no difference in the early morning, when IOP is usually higher. In addition, the long duration of action of travoprost can also provide better control of IOP fluctuation, probably due to its stronger prostaglandin F receptor mechanism. The side effects of travoprost do not represent a risk to the vision or health of the patient. The proven efficacy and safety combined with convenient once-daily dosing for travoprost increases patient compliance with treatment for glaucoma. © 2010 Suzuki and Suzuki. AD - E. R. Suzuki, Instituto de Olhos Pampulha, Av Dr Cristiano Guimaraes, 1994 CEP, 31720-300, Belo Horizonte, Minas Gerais, Brazil AU - Suzuki Jr, E. R. AU - Suzuki, C. L. B. C1 - travatan DB - Embase DO - 10.2147/OPTH.S6289 J2 - Clin. Ophthalmol. KW - adrenergic receptor stimulating agent benzalkonium chloride beta adrenergic receptor blocking agent bimatoprost bimatoprost plus timolol brimonidine brinzolamide carbonate dehydratase inhibitor cholinergic receptor stimulating agent dorzolamide dorzolamide plus timolol latanoprost latanoprost plus timolol placebo prostaglandin derivative prostaglandin F timolol timolol maleate timolol plus travoprost travoprost unoprostone isopropyl ester adjuvant therapy article cardiovascular system conjunctival hyperemia drug dose comparison drug efficacy drug mechanism drug safety drug withdrawal evening dosage eye blood flow eyelash glaucoma hematological parameters human hyperemia hyperpigmentation intraocular hypertension intraocular pressure iritis morning dosage open angle glaucoma patient compliance respiratory system macular edema side effect unspecified side effect urine visual acuity travatan L1 - internal-pdf://3211441679/3218-Efficacy and safety of travoprost al-2010.pdf LA - English M1 - (Suzuki Jr. E.R., emilio.suzuki@uol.com.br; Suzuki C.L.B.) Instituto de Olhos Pampulha, Av Dr Cristiano Guimaraes, 1994 CEP, 31720-300, Belo Horizonte, Minas Gerais, Brazil M3 - Article N1 - L361011379 2011-01-12 PY - 2010 SN - 1177-5467 1177-5483 SP - 1165-1171 ST - Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: Patient considerations TI - Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: Patient considerations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361011379&from=export http://dx.doi.org/10.2147/OPTH.S6289 VL - 4 ID - 3218 ER - TY - JOUR AB - Contact lens hygiene has long been recognised as key to the prevention of contact-lens associated infection and inflammation. Microbial keratitis (MK) is the only serious and potentially sight-threatening contact lens adverse event. International studies including recent research in Asia Pacific show that MK is rare but, as the consequences can be severe, it is important to minimise the risk factors. Studies continue to show that one of the key risk factors is lens and lens case hygiene. Therefore, it is also useful to review the behaviour of our patients, to see how closely they follow the recommended hygiene practices. Recent studies in various regions have shown that patients' lens care habits do not meet a required standard. Patients can become complacent and thus non-compliant with lens care instructions. Furthermore, they do not understand the high risk of some behaviour and they are not hearing the practitioner when instructions and reminders are given. Further education is important to improve patient compliance and safety. The Asia Pacific Contact Lens Care Summit held in Singapore urged the industry and practitioners to restore the emphasis of proper lens care, including the 'rub and rinse' technique, and developed a new set of guidelines to help eye-care professionals educate their patients on the importance of proper contact lens care to avoid eye infections. The summit also presented the latest research on how to avoid corneal staining, another important element of contact lens care. This review provides a summary of the summit presentations and the science behind these guidelines. © 2008 Optometrists Association Australia. AD - D. Sweeney, Vision CRC, Rupert Myers Building, University of New South Wales, Sydney, NSW 2052, Australia AU - Sweeney, D. AU - Holden, B. AU - Evans, K. AU - Ng, V. AU - Cho, P. DB - Medline DO - 10.1111/j.1444-0938.2009.00353.x IS - 2 KW - contact lens solution article contact lens eye infection human hygiene keratitis patient compliance patient education practice guideline LA - English M3 - Article N1 - L354258148 2009-07-14 PY - 2009 SN - 0816-4622 1444-0938 SP - 78-89 ST - Best practice contact lens care: A review of the Asia Pacific Contact Lens Care Summit T2 - Clinical and Experimental Optometry TI - Best practice contact lens care: A review of the Asia Pacific Contact Lens Care Summit UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354258148&from=export http://dx.doi.org/10.1111/j.1444-0938.2009.00353.x VL - 92 ID - 3371 ER - TY - JOUR AD - Vision CRC, University of New South Wales, Sydney, NSW, Australia. d.sweeney@ier.org.au AN - 105473796. Language: English. Entry Date: 20090724. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Australia & New Zealand AU - Sweeney, D. AU - Holden, B. AU - Evans, K. AU - Ng, V. AU - Cho, P. DB - ccm DO - 10.1111/j.1444-0938.2009.00353.x DP - EBSCOhost IS - 2 KW - Contact Lenses -- Adverse Effects Hygiene Practice Guidelines Eye Infections -- Etiology Eye Infections -- Prevention and Control Keratitis -- Etiology Keratitis -- Prevention and Control Ophthalmic Solutions Patient Compliance Patient Education N1 - Biomedical. NLM UID: 8703442. PMID: NLM19278458. PY - 2009 SN - 0816-4622 SP - 78-89 ST - Best practice contact lens care: a review of the Asia Pacific Contact Lens Care Summit T2 - Clinical & Experimental Optometry TI - Best practice contact lens care: a review of the Asia Pacific Contact Lens Care Summit UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105473796&site=ehost-live&scope=site VL - 92 ID - 4651 ER - TY - JOUR AB - Glaucoma encompasses a wide clinical spectrum of disease, with the common pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various classes of IOP-lowering medications is generally employed before more aggressive surgical interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least half of patients may require more than one IOP-lowering medication. One option is the fixed combination of brinzolamide 1% and timolol maleate 0.5%, which is commercially available in some countries as Azarga® for treatment of glaucoma not adequately responsive to monotherapy. These agents may also be used in an unfixed fashion, but fixed combination therapy is generally more convenient for patients, which may result in improved compliance, a reduction of the "washout effect" from instilling multiple drops, and a potential reduction in the side effects related to multiple doses of preservatives. © 2011 Syed and Loucks. AD - M. F. Syed, Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch, 700 University Boulevard, Galveston, TX 77555, United States AU - Syed, M. F. AU - Loucks, E. K. R. C1 - azarga(Alcon) C2 - Alcon DB - Embase DO - 10.2147/opth.s13786 IS - 1 KW - brinzolamide brinzolamide plus timolol carbonate dehydratase inhibitor dorzolamide dorzolamide plus timolol polymer preservative prostaglandin derivative timolol allergic reaction bitter taste blood pressure blurred vision bradycardia bronchospasm chemosis chronic obstructive lung disease conjunctival hyperemia conjunctivitis cornea disease depression dermatitis dizziness drug absorption drug effect drug efficacy drug formulation drug induced headache drug mechanism drug safety drug tolerability drug use dry eye dyspnea epiphora exercise tolerance eye burning eye discharge eye discomfort eye irritation eye pain heart arrhythmia heart block heart failure human hydrogel hyperemia impotence intraocular foreign body intraocular hypertension keratitis lacrimal fluid level libido disorder monotherapy nausea nephrolithiasis nonhuman ocular pruritus open angle glaucoma patient compliance photophobia pruritus punctate keratitis review side effect sore throat faintness taste disorder thorax pain treatment response urticaria xerostomia azarga LA - English M3 - Review N1 - L362920763 2011-11-21 2011-12-06 PY - 2011 SN - 1177-5483 1177-5467 SP - 1291-1296 ST - Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension T2 - Clinical Ophthalmology TI - Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362920763&from=export http://dx.doi.org/10.2147/opth.s13786 VL - 5 ID - 3205 ER - TY - JOUR AB - Purpose: Microbial contamination of contact lenses is associated with corneal infection and inflammation. This study determined the microbiological, clinical, and demographic factors that are associated with bacterial contamination of a silicone hydrogel contact lens when worn for continuous wear (CW).Methods: Two hundred five healthy subjects were enrolled in the Longitudinal Analysis of Silicone Hydrogel Contact Lens Study and were fitted with lotrafilcon A lenses for monthly CW and followed for 1 year. Lenses were aseptically removed after 1 week and 4 months of wear and cultured using an agar sandwich technique. Lids and conjunctiva were routinely cultured at baseline and after 1 week and 4 months of CW. Lenses and ocular sites were considered to have substantial microbial bioburden when they harbored pathogenic organisms or high levels of commensal organisms. Univariate and multivariate logistic regression analyses were conducted to examine whether substantial conjunctival or lid bioburden, subject demographics, lens-wearing history, symptoms, and biomicroscopic signs were associated with lens bioburden.Results: About one third (32.4%) of subjects had substantial bacterial bioburden in either eye across multiple visits. Over half (53.2%) and about one tenth (11.7%) of subjects had substantial lid and conjunctival bioburden, respectively, and 11.2% discontinued because of discomfort. The adjusted odds ratios (and 95% confidence intervals) for presence of substantial lens bioburden were 2.49 (1.17-5.30), 4.24 (1.45-12.40), and 4.11 (1.17-14.46) for substantial lid bioburden, substantial conjunctival bioburden, and lens discomfort, respectively.Conclusions: Bacterial contamination of silicone hydrogel contact lenses is common during CW. Substantial lens bioburden is associated with discomfort precluding successful CW. The presence of substantial lid and conjunctival bioburden is associated with a 2.5-fold and more than fourfold greater risk of substantial lens bioburden and is likely the major route of contamination. AD - Department of Ophthalmology & Visual Sciences, Case Western Reserve University, Cleveland, Ohio 44106, USA Department of Ophthalmology & Visual Sciences, Case Western Reserve University, Cleveland, Ohio 44106, USA. loretta.szczotka@uhhospitals.org AN - 105241610. Language: English. Entry Date: 20100205. Revision Date: 20161222. Publication Type: journal article AU - Szczotka-Flynn, L. B. AU - Bajaksouzian, S. AU - Jacobs, M. R. AU - Rimm, A. AU - Szczotka-Flynn, Loretta B. AU - Bajaksouzian, Saralee AU - Jacobs, Michael R. AU - Rimm, Alfred DB - ccm DO - 10.1097/OPX.0b013e3181bbca18 DP - EBSCOhost IS - 11 KW - Bacteria Contact Lenses, Extended-Wear Contact Lenses Equipment Contamination Adolescence Adult Prospective Studies Colony Count, Microbial Conjunctiva -- Microbiology Eyelids -- Microbiology Human Gels Middle Age Multivariate Analysis Office Visits Risk Factors Silicones Young Adult N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: K23 EY015270-04/EY/NEI NIH HHS/United States. NLM UID: 8904931. PMID: NLM19786927. PY - 2009 SN - 1040-5488 SP - 1216-1226 ST - Risk factors for contact lens bacterial contamination during continuous wear T2 - Optometry & Vision Science TI - Risk factors for contact lens bacterial contamination during continuous wear UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105241610&site=ehost-live&scope=site VL - 86 ID - 4622 ER - TY - JOUR AB - Purpose: A contact lens (CL) can act as a vector for microorganisms to adhere to and transfer to the ocular surface. Commensal microorganisms that uneventfully cohabitate on lid margins and conjunctivae and potential pathogens that are found transiently on the ocular surface can inoculate CLs in vivo. In the presence of reduced tissue resistance, these resident microorganisms or transient pathogens can invade and colonize the cornea or conjunctiva to produce inflammation or infection. Methods: The literature was reviewed and used to summarize the findings over the last 30 years on the identification, enumeration, and classification of microorganisms adherent to CLs and their accessories during the course of normal wear and to hypothesize the role that these microorganisms play in CL infection and inflammation. Results: Lens handling greatly increases the incidence of lens contamination, and the ocular surface has a tremendous ability to destroy organisms. However, even when removed aseptically from the eye, more than half of lenses are found to harbor microorganisms, almost exclusively bacteria. Coagulase-negative Staphylococci are most commonly cultured from worn lenses; however, approximately 10% of lenses harbor Gram-negative and highly pathogenic species, even in asymptomatic subjects. In storage cases, the incidence of positive microbial bioburden is also typically greater than 50%. All types of care solutions can become contaminated, including up to 30% of preserved products. Conclusions: The process of CL-related microbial keratitis and inflammation is thought to be preceded by the presence or transfer or both of microorganisms from the lens to the ocular surface. Thus, this detailed understanding of lens-related bioburden is important in the understanding of factors associated with infectious and inflammatory complications. Promising mechanisms to prevent bacterial colonization on lenses and lens cases are forthcoming, which may decrease the incidence of microbially driven CL complications. © 2010 Lippincott Williams & Wilkins. AD - L. B. Szczotka-Flynn, University Hospitals Eye Institute, 11100 Euclid Avenue, Lakeside 4126C, Cleveland, OH 44106, United States AU - Szczotka-Flynn, L. B. AU - Pearlman, E. AU - Ghannoum, M. DB - Embase Medline DO - 10.1097/ICL.0b013e3181d20cae IS - 2 KW - contact lens solution bacterial colonization bacterial transmission bacterium contamination coagulase negative Staphylococcus commensal contact lens Gram negative bacterium human hygiene keratitis nonhuman patient compliance priority journal review storage LA - English M3 - Review N1 - L358460204 2010-03-24 2010-04-14 PY - 2010 SN - 1542-2321 SP - 116-129 ST - Microbial contamination of contact lenses, lens care solutions, and their accessories: A literature review T2 - Eye and Contact Lens TI - Microbial contamination of contact lenses, lens care solutions, and their accessories: A literature review UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358460204&from=export http://dx.doi.org/10.1097/ICL.0b013e3181d20cae VL - 36 ID - 3271 ER - TY - JOUR AB - Significance: Think Tank 2019 affirmed that the rate of infection associated with contact lenses has not changed in several decades. Also, there is a trend toward more serious infections associated with Acanthamoeba and fungi. The growing use of contact lenses in children demands our attention with surveillance and case-control studies.Purpose: The American Academy of Optometry (AAO) gathered researchers and key opinion leaders from around the world to discuss contact lens-associated microbial keratitis at the 2019 AAO Annual Meeting.Methods: Experts presented within four sessions. Session 1 covered the epidemiology of microbial keratitis, pathogenesis of Pseudomonas aeruginosa, and the role of lens care systems and storage cases in corneal disease. Session 2 covered nonbacterial forms of keratitis in contact lens wearers. Session 3 covered future needs, challenges, and research questions in relation to microbial keratitis in youth and myopia control, microbiome, antimicrobial surfaces, and genetic susceptibility. Session 4 covered compliance and communication imperatives.Results: The absolute rate of microbial keratitis has remained very consistent for three decades despite new technologies, and extended wear significantly increases the risk. Improved oxygen delivery afforded by silicone hydrogel lenses has not impacted the rates, and although the introduction of daily disposable lenses has minimized the risk of severe disease, there is no consistent evidence that they have altered the overall rate of microbial keratitis. Overnight orthokeratology lenses may increase the risk of microbial keratitis, especially secondary to Acanthamoeba, in children. Compliance remains a concern and a significant risk factor for disease. New insights into host microbiome and genetic susceptibility may uncover new theories. More studies such as case-control designs suited for rare diseases and registries are needed.Conclusions: The first annual AAO Think Tank acknowledged that the risk of microbial keratitis has not decreased over decades, despite innovation. Important questions and research directions remain. AD - Department of Ophthalmology and Visual Sciences, Case Western Reserve University, and University Hospitals of Cleveland Eye Institute, Cleveland, Ohio Northeastern Eye Institute, Scranton, Pennsylvania C Schnider Insights & More, Brush Prairie, Washington Toronto Eye Care, Toronto, Ontario, Canada Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia Clinical Trial Consultant, Atlanta, Georgia U.S. Centers for Disease Control and Prevention, Atlanta, Georgia Massachusetts Eye and Ear, Cornea Service, Harvard Medical School, Boston, Massachusetts Department of Ophthalmology and Visual Science, College of Medicine, Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois School of Optometry, University of California, Berkeley, Berkeley, California iBiomedical Consulting, Jacksonville, Florida University of Houston College of Optometry, Houston, Texas Departments of Ophthalmology, and Physiology and Biophysics, University of California, Irvine, Irvine, California Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland University of Illinois Eye and Ear Infirmary, Chicago, Illinois AN - 149636788. Language: English. Entry Date: In Process. Revision Date: 20210717. Publication Type: journal article AU - Szczotka-Flynn, Loretta B. AU - Shovlin, Joseph P. AU - Schnider, Cristina M. AU - Caffery, Barbara E. AU - Alfonso, Eduardo C. AU - Carnt, Nicole A. AU - Chalmers, Robin L. AU - Collier, Sarah AU - Jacobs, Deborah S. AU - Joslin, Charlotte E. AU - Kroken, Abby R. AU - Lakkis, Carol AU - Pearlman, Eric AU - Schein, Oliver D. AU - Stapleton, Fiona AU - Tu, Elmer AU - Willcox, Mark D. P. DB - ccm DO - 10.1097/OPX.0000000000001664 DP - EBSCOhost IS - 3 N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: R21 EY029445/EY/NEI NIH HHS/United States. NLM UID: 8904931. PMID: NLM33771951. PY - 2021 SN - 1040-5488 SP - 182-198 ST - American Academy of Optometry Microbial Keratitis Think Tank T2 - Optometry & Vision Science TI - American Academy of Optometry Microbial Keratitis Think Tank UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149636788&site=ehost-live&scope=site VL - 98 ID - 4163 ER - TY - JOUR AB - PURPOSE: Amniotic membrane transplantation has become an important treatment option for corneal surface reconstruction. However, suture fixation of the transplant has various disadvantages like corneal irritation, scarring, graft loss due to membrane shrinkage, and the need for subsequent suture removal. Replacement of sutures by bioadhesives might be an advantageous alternative. This controlled study was designed to evaluate a new sutureless technique for amniotic membrane fixation onto the corneal surface by using fibrin glue. METHODS: Standardized disks of cryopreserved amniotic membranes were transplanted onto the deepithelialized cornea of 12 rabbits using either conventional suture fixation or a new fibrin glue technique. The rabbits were followed-up with slit-lamp examination and fluorescein staining until epithelialization was completed. Consecutively, the rabbits were killed and the eyes processed for histology and immunohistochemistry for cytokeratin-3. RESULTS: All membranes of both groups stayed in place throughout the follow-up time and showed a progressive graft epithelialization that was completed after 12 days. Whereas suture-fixated membranes showed progressive tissue shrinkage, fibrin-glued sheets remained unaltered. In the bioadhesive group, histology revealed a smooth fibrin layer in the graft-host interface and a continuous, stratified layer of cytokeratin-3 expressing corneal epithelial cells on the membrane surface. In contrast, suture-fixated membranes showed contracted and prominent membrane edges with epithelial ingrowth into the submembrane interface. CONCLUSION: Our results demonstrate the general feasibility of reproducible and reliable sutureless amniotic membrane fixation onto the corneal surface in rabbits. Stable adherence is maintained until epithelialization is completed. The sutureless technique gives sufficient manipulation time for the sheet before the final cross-linking process is completed. Furthermore, several advantageous characteristics could be demonstrated as increased biocompatibility, better epithelialization pattern and the lack of membrane shrinkage. © 2006 Lippincott Williams & Wilkins, Inc. AD - Department of Ophthalmology I, University of Tubingen, Tubingen, Germany Center of Ophthalmology, University of Cologne, Cologne, Germany Department of Ophthalmology I, Eberhard-Karls University Tubingen, Schleichstr. 12, 72076 Tubingen, Germany AU - Szurman, P. AU - Warga, M. AU - Grisanti, S. AU - Roters, S. AU - Rohrbach, J. M. AU - Aisenbrey, S. AU - Kaczmarek, R. T. AU - Bartz-Schmidt, K. U. DB - Scopus DO - 10.1097/01.ico.0000183493.00884.8f IS - 4 KW - Amniotic membrane Cornea Fibrin glue Persistent epithelial defect M3 - Article N1 - Cited By :40 Export Date: 19 July 2021 PY - 2006 SP - 460-466 ST - Sutureless amniotic membrane fixation using fibrin glue for ocular surface reconstruction in a rabbit model T2 - Cornea TI - Sutureless amniotic membrane fixation using fibrin glue for ocular surface reconstruction in a rabbit model UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745038962&doi=10.1097%2f01.ico.0000183493.00884.8f&partnerID=40&md5=ab8446675b5c900bee10d5b43cd7a2f3 VL - 25 ID - 5020 ER - TY - JOUR AB - Purpose: Amniotic membrane transplantation has become an important treatment option for corneal surface reconstruction. However, suture fixation of the transplant has various disadvantages like corneal irritation, scarring, graft loss due to membrane shrinkage, and the need for subsequent Suture removal. Replacement of sutures by bioadhesives might be an advantageous alternative. This controlled study was designed to evaluate a new sutureless technique for amniotic membrane fixation onto the corneal Surface by using fibrin glue. Methods: Standardized disks of cryopreserved amniotic membranes were transplanted onto the deepithelialized cornea of 12 rabbits using either conventional Suture fixation or a new fibrin glue technique. The rabbits were followed-up with slit-lamp examination and fluorescein staining until epithelialization was completed. Consecutively, the rabbits were killed and the eyes processed for histology and immunohistochemistry for cytokeratin-3. Results: All membranes of both groups stayed in place throughout the follow-up time and showed a progressive graft epithelialization that was completed after 12 days. Whereas suture-fixated membranes showed progressive tissue shrinkage, fibrin-glued sheets remained unaltered. In the bioadhesive group, histology revealed a smooth fibrin layer in the graft-host interface and a continuous, stratified layer of cytokeratin-3 expressing corneal epithelial cells on the membrane surface. In contrast, suture-fixated membranes showed contracted and prominent membrane edges with epithelial ingrowth into the submembrane interface. Conclusion: Our results demonstrate the general feasibility of reproducible and reliable sutureless amniotic membrane fixation onto the corneal surface in rabbits. Stable adherence is maintained until epithelialization is completed. The sutureless technique gives sufficient manipulation time for the sheet before the final cross-linking process is completed. Furthermore, several advantageous characteristics could be demonstrated as increased biocompatibility, better epithelialization pattern and the lack of membrane shrinkage. AN - WOS:000237498600016 AU - Szurman, P. AU - Warga, M. AU - Grisanti, S. AU - Roters, S. AU - Rohrbach, J. M. AU - Aisenbrey, S. AU - Kaczmarek, R. T. AU - Bartz-Schmidt, K. U. DA - MAY DO - 10.1097/01.ico.0000183493.00884.8f IS - 4 PY - 2006 SN - 0277-3740 1536-4798 SP - 460-466 ST - Sutureless amniotic membrane fixation using fibrin glue for ocular surface reconstruction in a rabbit model T2 - CORNEA TI - Sutureless amniotic membrane fixation using fibrin glue for ocular surface reconstruction in a rabbit model VL - 25 ID - 5873 ER - TY - JOUR AB - Background: Glaucoma is one of the major public health problems. Lowering intraocular pressure has been shown to inhibit the progression of glaucomatous optic nerve damage which depends on compliance with the treatment. Objectives: To determine the extent of noncompliance to treatment among glaucoma patients at Menelik II Hospital. Methods: A hospital based cross sectional study was conducted on patients who were on topical anti glaucoma treatment and follow-up at glaucoma clinic, Menelik Hospital during May 1 to July 30, 2014. Four hundred one eligible patients were interviewed with a pretested structured questionnaire by the principal investigator. Medical charts of each patient were reviewed for specific information like type of previous procedures and visual acuity. Results: Among the 401 patients interviewed, 230 patients (57.4%) were found to be noncompliant. Younger ages, higher educational level, previous history of procedures for glaucoma were associated with better compliance. Factors associated with noncompliance included poor vision, more than one drug therapy, fair or poor understanding of the disease, use of other systemic medications, unavailability of drugs in the market, dependency on others for instilling the drops. Sex, side effects of the drugs, number of years with glaucoma and family history were not found to be predictors of noncompliance. The main reasons given by the participants were forgetfulness, followed by running out of medications before visiting the clinic. Conclusions: The study has indicated the presence of substantial noncompliance of glaucoma patients at a tertiary center. More attention to the issue of noncompliance, including health education and use of memory aids, could result in important benefits in the preservation of sight. AN - WOS:000384720500005 AU - Tadesse, F. AU - Mulugeta, A. IS - 1 PY - 2015 SN - 1021-6790 SP - 31-36 ST - Compliance to topical anti-glaucoma medication among glaucoma patients at Menelik II Tertiary Hospital, Addis Ababa, Ethiopia T2 - ETHIOPIAN JOURNAL OF HEALTH DEVELOPMENT TI - Compliance to topical anti-glaucoma medication among glaucoma patients at Menelik II Tertiary Hospital, Addis Ababa, Ethiopia VL - 29 ID - 5886 ER - TY - JOUR AB - Purpose: Poverty can be a cause and consequence of blindness. Some causes only affect the poorest communities (e.g. trachoma), and poor individuals are less likely to access services. In low income countries, cataract blind adults have been shown to be less economically active, indicating that blindness can exacerbate poverty. This study aims to explore associations between poverty and blindness using national survey data from Nigeria. Methods: Participants ≥40 years were examined in 305 clusters (2005-2007). Sociodemographic information, including literacy and occupation, was obtained by interview. Presenting visual acuity (PVA) was assessed using a reduced tumbling E LogMAR chart. Full ocular examination was undertaken by experienced ophthalmologists on all with PVA <6/12 in either eye. Causes of vision loss were determined using World Health Organization guidelines. Households were categorized into three levels of poverty based on literacy and occupation at household level. Results: A total of 569/13,591 participants were blind (PVA <3/60, better eye; prevalence 4.2%, 95% confidence interval [CI] 3.8-4.6%). Prevalences of blindness were 8.5% (95% CI 7.7-9.5%), 2.5% (95% CI 2.0-3.1%), and 1.5% (95% CI 1.2-2.0%) in poorest, medium and affluent households, respectively (p = 0.001). Cause-specific prevalences of blindness from cataract, glaucoma, uncorrected aphakia and corneal opacities were significantly higher in poorer households. Cataract surgical coverage was low (37.2%), being lowest in females in poor households (25.3%). Spectacle coverage was 3 times lower in poor than affluent households (2.4% vs. 7.5%). Conclusion: In Nigeria, blindness is associated with poverty, in part reflecting lower access to services. Reducing avoidable causes will not be achieved unless access to services improves, particularly for the poor and women. AD - C.E. Gilbert, International Centre for Eye Health, Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom AU - Tafida, A. AU - Kyari, F. AU - Abdull, M. M. AU - Sivasubramaniam, S. AU - Murthy, G. V. S. AU - Kana, I. AU - Gilbert, C. E. AU - Abiose, A. AU - Bankole Olufunmilayo, O. AU - Ezelum, C. AU - Elhassan, E. AU - Entekume, G. AU - Faal, H. AU - Rabiu, M. M. AU - Lee, P. S. DB - Embase Medline DO - 10.3109/09286586.2015.1077259 IS - 5 KW - adult aphakia article blindness cataract cornea opacity demography educational status eye examination female glaucoma health care access health literacy health survey human major clinical study male Nigeria ophthalmologist poverty practice guideline prevalence priority journal sex difference socioeconomics visual acuity World Health Organization LA - English M3 - Article N1 - L606144007 2015-09-30 2019-10-31 PY - 2015 SN - 1744-5086 0928-6586 SP - 333-341 ST - Poverty and Blindness in Nigeria: Results from the National Survey of Blindness and Visual Impairment T2 - Ophthalmic Epidemiology TI - Poverty and Blindness in Nigeria: Results from the National Survey of Blindness and Visual Impairment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606144007&from=export http://dx.doi.org/10.3109/09286586.2015.1077259 VL - 22 ID - 2789 ER - TY - JOUR AB - Purpose: To evaluate the effect of treatment for 3 years with a dorzolamide/timolol (1%/0.5%) fixed combination (DTFC) on visual field progression in patients with open-angle glaucoma. Participants: A total of 14 consecutive patients were enrolled who had been previously treated with monotherapy or any combination of a beta blocker, carbonic anhydrase inhibitor, and/or prostaglandin analog for primary open-angle glaucoma (POAG; n=4) or normal-tension glaucoma (NTG; n=10). Methods: Patients were switched to DTFC from their prior glaucoma therapy. The IOP was measured at intervals of 4-6 weeks, and the visual fields were examined at least twice a year for 3 years. The annual change of mean deviation (MD slope) was used to quantify visual field loss. Results: The mean MD value was -5.9±5.0 dB at baseline; it was -5.6±4.8 dB at 12 months, -5.9±5.0 dB at 24 months, and -5.6±5.1 dB at 36 months after switching. The mean MD slope was -0.2±0.8 dB/year before switching and 0.3±1.3 dB/year from baseline to 1 year, -0.3±1.1 dB/year from 1-2 years, and 0.3±0.9 dB/year from 2-3 years after switching. The mean MD slope from baseline to 36 months was correlated with the IOP reduction rate at 36 months after switching. Visual field progression was associated with the IOP reduction rate at 12 months after switching. Conclusion: Switching to DTFC from prior glaucoma therapy improved the MD slope for at least 3 years. Reduction of the IOP after switching to DTFC was effective for delaying visual field progression. Although our study was not nonrandomized and was small in scale, the findings suggest that DTFC might have a beneficial effect on the visual fields in patients with open-angle glaucoma. © 2014 Takeda et al. AD - Department of Ophthalmology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan Department of Ophthalmology, Nippori Clinic, Medical Center East, Tokyo Women's Medical University, Tokyo, Japan AU - Takeda, S. AU - Mimura, T. AU - Matsubara, M. DB - Scopus DO - 10.2147/OPTH.S71162 KW - Dorzolamide/timolol (1%/0.5%) fixed combination MD slope Switch Visual field M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2014 SP - 1579-1590 ST - Effect of dorzolamide/timolol combination on the visual field in glaucoma T2 - Clinical Ophthalmology TI - Effect of dorzolamide/timolol combination on the visual field in glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84907374387&doi=10.2147%2fOPTH.S71162&partnerID=40&md5=10517de475eb87b2c7b44ec9708b4d76 VL - 8 ID - 5632 ER - TY - JOUR AB - Background: Compliance with medical treatment is a public health problem. It denotes the patient's perception of the disease and the treatment prescribed by doctors. It concerns one out of two patients. It may happen to any patient at one or another. It is secondary for reasons that are numerous and modifiable in time. It results from problems related to the patient as much as to the doctor. It represents an obstacle to paying for chronic diseases such as chronic open-angle glaucoma, hence the importance given to it in the recent years. Aim: To evaluate the compliance of adult patients suffering from early open-angle glaucoma and to determine the influential factors. Methods: We conducted a survey at the ophthalmology department of Ibn El Jazzar Hospital among 132 adults being treated for early open-angle glaucoma. The evaluation was done on the basis of patient's medical files and a questionnaire from January 2007 to June of the same year. It ranges between good, average or bad depending on the frequency of the patient's visits to doctors, regularity of treatment and compliance with the doctor's prescription. Results: 40.15% of the patients have positively complied with the prescriptions. This improvement has mainly been due to the following factors: The patient's good knowledge of the disease and its treatment; use of antiseptic eye lotion with the utmost effectiveness for the least instillation and side effects; patient's mastery of drop usage; doctor's intensive care required for some particular cases. Conclusion: Our results need to be confirmed by other studies. It's very important to consider all the determining factors in order to improve patient's compliance. AD - J. Taktak, Service d'Ophtalmologie, Unité Chirurgicale Les Aghlabites, Kairouan, Tunisia AU - Taktak, J. AU - Ajmi Nabli, T. AU - Ben Othmen, H. AU - Mtiraoui, A. AU - Ben Hadj Hamida, F. DB - Embase Medline IS - 2 KW - antiinfective agent adult ambulatory care article human intensive care knowledge major clinical study medical record review open angle glaucoma patient compliance patient education prescription questionnaire L1 - internal-pdf://1376710097/3190-Therapeutic compliance in primary op-2011.pdf LA - French M3 - Article N1 - L361257933 2011-02-21 2011-02-25 PY - 2011 SN - 0041-4131 SP - 142-146 ST - Therapeutic compliance in primary open angle glaucoma T2 - Tunisie Medicale TI - Therapeutic compliance in primary open angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361257933&from=export VL - 89 ID - 3190 ER - TY - JOUR AB - Shared Medical Appointments (SMAs) are patient-centered care tools designed to administer patient counseling and education, typically delivered individually, in a group setting. SMAs are effective in facilitating peer-learning, resulting in improvement in knowledge and health behavior. This study aimed to implement what we know of as the first ophthalmology SMA done in the United States. We evaluated the implementation feasibility, patient and provider experience, changes in patient knowledge, and provider stress. Five glaucoma patients who expressed issues with adherence during their clinic visit at Boston Medical Center (BMC) who were interested in the SMA were recruited. Patients and staff had a positive experience with the SMA. There was a marked increase in patient glaucoma knowledge and a decrease in average staff member stress level score during the SMA. From all standpoints, including billing and management, we conclude that SMA implementation is feasible in ophthalmology departments in academic settings. AD - E.K. Tam, Department of Ophthalmology, Boston University Medical Center, Boston, United States AU - Tam, E. K. AU - De Arrigunaga, S. AU - Shah, M. AU - Kefella, H. AU - Soriano, S. AU - Rowe, S. DB - Embase Medline DO - 10.1080/08820538.2021.1896758 KW - adult article clinical article controlled study feasibility study female glaucoma human male Massachusetts ophthalmology physiological stress satisfaction shared medical appointment LA - English M3 - Article in Press N1 - L2010794087 2021-03-23 PY - 2021 SN - 1744-5205 0882-0538 ST - Patient and Clinician Satisfaction With Shared Medical Appointments for Glaucoma T2 - Seminars in Ophthalmology TI - Patient and Clinician Satisfaction With Shared Medical Appointments for Glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010794087&from=export http://dx.doi.org/10.1080/08820538.2021.1896758 ID - 2338 ER - TY - JOUR AB - Shared Medical Appointments (SMAs) are patient-centered care tools designed to administer patient counseling and education, typically delivered individually, in a group setting. SMAs are effective in facilitating peer-learning, resulting in improvement in knowledge and health behavior. This study aimed to implement what we know of as the first ophthalmology SMA done in the United States. We evaluated the implementation feasibility, patient and provider experience, changes in patient knowledge, and provider stress. Five glaucoma patients who expressed issues with adherence during their clinic visit at Boston Medical Center (BMC) who were interested in the SMA were recruited. Patients and staff had a positive experience with the SMA. There was a marked increase in patient glaucoma knowledge and a decrease in average staff member stress level score during the SMA. From all standpoints, including billing and management, we conclude that SMA implementation is feasible in ophthalmology departments in academic settings. © 2021 Taylor & Francis. AD - Department of Ophthalmology, Boston University Medical Center, Boston, United States Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, United States Boston University School of Medicine, Boston, United States Department of Family Medicine, Boston University Medical Center, Boston, United States AU - Tam, E. K. AU - De Arrigunaga, S. AU - Shah, M. AU - Kefella, H. AU - Soriano, S. AU - Rowe, S. DB - Scopus DO - 10.1080/08820538.2021.1896758 KW - glaucoma group visit ophthalmology Shared medical appointment M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 ST - Patient and Clinician Satisfaction With Shared Medical Appointments for Glaucoma T2 - Seminars in Ophthalmology TI - Patient and Clinician Satisfaction With Shared Medical Appointments for Glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102703349&doi=10.1080%2f08820538.2021.1896758&partnerID=40&md5=acc2b73cf0755f27d1fa552eabc524c2 ID - 5676 ER - TY - JOUR AB - Shared Medical Appointments (SMAs) are patient-centered care tools designed to administer patient counseling and education, typically delivered individually, in a group setting. SMAs are effective in facilitating peer-learning, resulting in improvement in knowledge and health behavior. This study aimed to implement what we know of as the first ophthalmology SMA done in the United States. We evaluated the implementation feasibility, patient and provider experience, changes in patient knowledge, and provider stress. Five glaucoma patients who expressed issues with adherence during their clinic visit at Boston Medical Center (BMC) who were interested in the SMA were recruited. Patients and staff had a positive experience with the SMA. There was a marked increase in patient glaucoma knowledge and a decrease in average staff member stress level score during the SMA. From all standpoints, including billing and management, we conclude that SMA implementation is feasible in ophthalmology departments in academic settings. AN - WOS:000629062700001 AU - Tam, E. K. AU - De Arrigunaga, S. AU - Shah, M. D. AU - Kefella, H. AU - Soriano, S. AU - Rowe, S. DO - 10.1080/08820538.2021.1896758 SN - 0882-0538 1744-5205 ST - Patient and Clinician Satisfaction With Shared Medical Appointments for Glaucoma T2 - SEMINARS IN OPHTHALMOLOGY TI - Patient and Clinician Satisfaction With Shared Medical Appointments for Glaucoma ID - 5897 ER - TY - JOUR AB - Purpose: Successful outcomes of medical treatment for glaucoma require proper and daily use of medication to prevent disease progression. The aim of this study was to determine the adherence to anti-glaucoma medications and factors associated with non-adherence among patients with ocular hypertension (OHT) or glaucoma at Jimma University Specialized Hospital, Ethiopia. Materials and Methods: A hospital based cross sectional study was conducted on 200 consecutive patients from July to November 2010 at Jimma University Hospital in Southwest Ethiopia. Patients with OHT or glaucoma who were taking topical anti-glaucoma medications for more than six months were included. The study subjects were interviewed and their medical records were reviewed. Non-adherence to glaucoma therapy (NAGT) was defined as self-reported on missed medications or missed appointments, or a physician noting poor adherence. A P < 0.05 was statistically significant. Result: Overall, 135 (67.5%) patients were non adherent to glaucoma therapy. Non adherence was associated with older age (P = 0.04), advanced stage of glaucoma (P = 0.01), longer frequency of follow up (P = 0.00) and financial problem (P = 0.000). Sex (P = 0.53), level of education (P = 0.09), and marital status (P = 0.77) were not statistically significantly associated with non-adherence to anti-glaucoma drug treatment. Conclusion: A relatively high proportion of patients were not adhering to the medications regimen for glaucoma. Older age, advanced glaucoma, lengthier frequency of follow-up and financial hardship were associated with non-adherence. Eye care providers should be aware of the problem of non-adherence to topical medications. AD - G.W. Gessesse, Jimma University, P.O. Box. 378, Jimma, Ethiopia AU - Tamrat, L. AU - Gessesse, G. W. AU - Gelaw, Y. DB - Embase Medline DO - 10.4103/0974-9233.148350 IS - 1 KW - antiglaucoma agent adult aged article clinical practice controlled study cross-sectional study disease severity educational status Ethiopian ethnicity eye care female follow up human intraocular hypertension major clinical study male marriage medical record review medication compliance middle aged patient compliance self report tertiary care center treatment refusal very elderly young adult LA - English M3 - Article N1 - L601433070 2015-01-23 2015-01-27 PY - 2015 SN - 0975-1599 0974-9233 SP - 59-63 ST - Adherence to topical glaucoma medications in Ethiopian patients T2 - Middle East African Journal of Ophthalmology TI - Adherence to topical glaucoma medications in Ethiopian patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L601433070&from=export http://dx.doi.org/10.4103/0974-9233.148350 VL - 22 ID - 2832 ER - TY - JOUR AB - Purpose: Successful outcomes of medical treatment for glaucoma require proper and daily use of medication to prevent disease progression. The aim of this study was to determine the adherence to anti-glaucoma medications and factors associated with non-adherence among patients with ocular hypertension (OHT) or glaucoma at Jimma University Specialized Hospital, Ethiopia. Materials and Methods: A hospital based cross sectional study was conducted on 200 consecutive patients from July to November 2010 at Jimma University Hospital in Southwest Ethiopia. Patients with OHT or glaucoma who were taking topical anti-glaucoma medications for more than six months were included. The study subjects were interviewed and their medical records were reviewed. Non-adherence to glaucoma therapy (NAGT) was defined as self-reported on missed medications or missed appointments, or a physician noting poor adherence. A P < 0.05 was statistically significant. Result: Overall, 135 (67.5%) patients were non adherent to glaucoma therapy. Non adherence was associated with older age (P = 0.04), advanced stage of glaucoma (P = 0.01), longer frequency of follow up (P = 0.00) and financial problem (P = 0.000). Sex (P = 0.53), level of education (P = 0.09), and marital status (P = 0.77) were not statistically significantly associated with non-adherence to anti-glaucoma drug treatment. Conclusion: A relatively high proportion of patients were not adhering to the medications regimen for glaucoma. Older age, advanced glaucoma, lengthier frequency of follow-up and financial hardship were associated with non-adherence. Eye care providers should be aware of the problem of non-adherence to topical medications. AD - Department of Ophthalmology, St. Paul Millennium Medical College, Addis Ababa, Ethiopia Department of Ophthalmology, Jimma University, Jimma, Ethiopia AU - Tamrat, L. AU - Gessesse, G. W. AU - Gelaw, Y. DB - Scopus DO - 10.4103/0974-9233.148350 IS - 1 KW - Adherence Ethiopia Glaucoma Ocular Hypertension Topical Glaucoma Therapy M3 - Article N1 - Cited By :21 Export Date: 19 July 2021 PY - 2015 SP - 59-63 ST - Adherence to topical glaucoma medications in Ethiopian patients T2 - Middle East African Journal of Ophthalmology TI - Adherence to topical glaucoma medications in Ethiopian patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84921033115&doi=10.4103%2f0974-9233.148350&partnerID=40&md5=7c1f0cd60e0a272565c42cd35f3eab23 VL - 22 ID - 5130 ER - TY - JOUR AB - Purpose: Successful outcomes of medical treatment for glaucoma require proper and daily use of medication to prevent disease progression. The aim of this study was to determine the adherence to anti-glaucoma medications and factors associated with non-adherence among patients with ocular hypertension (OHT) or glaucoma at Jimma University Specialized Hospital, Ethiopia. Materials and Methods: A hospital based cross sectional study was conducted on 200 consecutive patients from July to November 2010 at Jimma University Hospital in Southwest Ethiopia. Patients with OHT or glaucoma who were taking topical anti-glaucoma medications for more than six months were included. The study subjects were interviewed and their medical records were reviewed. Non-adherence to glaucoma therapy (NAGT) was defined as self-reported on missed medications or missed appointments, or a physician noting poor adherence. A P < 0.05 was statistically significant. Result: Overall, 135 (67.5%) patients were non adherent to glaucoma therapy. Non adherence was associated with older age (P = 0.04), advanced stage of glaucoma (P = 0.01), longer frequency of follow up (P = 0.00) and financial problem (P = 0.000). Sex (P = 0.53), level of education (P = 0.09), and marital status (P = 0.77) were not statistically significantly associated with non-adherence to anti-glaucoma drug treatment. Conclusion: A relatively high proportion of patients were not adhering to the medications regimen for glaucoma. Older age, advanced glaucoma, lengthier frequency of follow-up and financial hardship were associated with non-adherence. Eye care providers should be aware of the problem of non-adherence to topical medications. AN - WOS:000460762500010 AU - Tamrat, L. AU - Gessesse, G. W. AU - Gelaw, Y. DA - JAN-MAR DO - 10.4103/0974-9233.148350 IS - 1 PY - 2015 SN - 0974-9233 0975-1599 SP - 59-63 ST - Adherence to Topical Glaucoma Medications in Ethiopian Patients T2 - MIDDLE EAST AFRICAN JOURNAL OF OPHTHALMOLOGY TI - Adherence to Topical Glaucoma Medications in Ethiopian Patients VL - 22 ID - 5812 ER - TY - JOUR AB - Tele-ophthalmology has been employed mainly for patients in under-served rural areas in need of specialty care, but other applications such as telementoring have also been used. In certain populations, cost containment is a significant issue and telemedicine is a solution. Tele-ophthalmology can be performed in realtime, by store-and-forward mode, or by hybrid techniques. After appropriate modification, a range of peripherals may be used for tele-ophthalmology, including the direct ophthalmoscope, indirect ophthalmoscope, slit lamp or retinal camera. Tele-ophthalmology applications include: detecting, screening and diagnosing diabetic retinopathy; anterior segment imaging; glaucoma screening; low vision consultation; telementoring. Tele-ophthalmology shows great promise for improving patient care and increasing access to specialty care not available in under-served areas. In developing countries tele-ophthalmology may be a cost-effective method by which richer countries can assist them. AD - UTMB Department of Ophthalmology and Visual Sciences, Galveston, Texas 77555-1106, USA UTMB Department of Ophthalmology and Visual Sciences, 301 University Blvd, Galveston, TX 77555-1106; rtang@utmb.edu AN - 106401514. Language: English. Entry Date: 20060224. Revision Date: 20200708. Publication Type: journal article AU - Tang, R. A. AU - Morales, M. AU - Ricur, G. AU - Schiffman, J. S. AU - Tang, Rosa Ana AU - Morales, Marlene AU - Ricur, Giselle AU - Schiffman, Jade S. DB - ccm DO - 10.1258/135763305775013509 DP - EBSCOhost IS - 8 KW - Eye Care -- Methods Telemedicine Developing Countries Health Services Accessibility Medically Underserved Area Ophthalmology N1 - pictorial; tables/charts. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 9506702. PMID: NLM16356312. PY - 2005 SN - 1357-633X SP - 391-396 ST - Telemedicine for eye care T2 - Journal of Telemedicine & Telecare TI - Telemedicine for eye care UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106401514&site=ehost-live&scope=site VL - 11 ID - 4621 ER - TY - JOUR AB - Glaucoma is the leading cause of irreversible blindness worldwide. The perspective of clinicians who treat the disease is important and may ultimately dictate the adoption of new treatment modalities, such as drug-eluting contact lenses. Recent advances have enabled contact lenses to serve as a sustained-release drug-delivery platform capable of treating glaucoma. This review covers the medical treatment of glaucoma, suboptimal adherence rates to treatment, and factors that may influence the clinical applicability of drug-eluting contact lenses. Ophthalmologists who treat glaucoma were surveyed to determine their perspective on treatment adherence, bandage contact lens use and the use of a drug-eluting contact lens to treat glaucoma. Given the challenge of treating glaucoma and the clinical need for improved drug delivery, drug-eluting contact lenses appear to be a promising treatment option. AD - J.B. Ciolino, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States AU - Taniguchi, E. V. AU - Kalout, P. AU - Pasquale, L. R. AU - Kohane, D. S. AU - Ciolino, J. B. DB - Embase Medline DO - 10.4155/tde.14.76 IS - 10 KW - antiglaucoma agent polymer bandage contact lens contact lens drug delivery system drug eluting contact lens drug release glaucoma human patient compliance physician attitude punctal plug review sustained drug release visual impairment LA - English M3 - Review N1 - L600638259 2014-12-08 2014-12-11 PY - 2014 SN - 2041-6008 2041-5990 SP - 1077-1083 ST - Clinicians' perspectives on the use of drug-eluting contact lenses for the treatment of glaucoma T2 - Therapeutic Delivery TI - Clinicians' perspectives on the use of drug-eluting contact lenses for the treatment of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600638259&from=export http://dx.doi.org/10.4155/tde.14.76 VL - 5 ID - 2939 ER - TY - JOUR AB - Objective: We aimed to compare the demographics, awareness about glaucoma, and adherence to the treatment between the young and old population of primary open angle glaucoma (POAG) patients. Methods: The POAG patients who were under follow-up in Bakirkoy Training and Research Hospital Ophthalmology Clinic and were using medication since at least one year and volunteered for our survey were included this cross-sectional study between April and May 2018. Two surveys which included 13 questions and were used in previous studies were enriched with 6 additional questions and applied to the patients. The patients were divided into two groups according to the World Health Organization's classification in regard to age as <= 65 years (young patients) and >65 years (old patients) and compared in regards to the survey questions. Results: There was not statistically significant between the two groups in regards to gender, general awareness about glaucoma, regular follow-up, regular drug use, family history of glaucoma, disability in hand and arm movements, duration of glaucoma (p>0.05 for all). There was a statistical difference between the two groups in regards to the education level (the patients <= 65 years were more educated, p=0.03), awareness of blindness secondary to the disease (more frequent in the patients <= 65 years old, p=0.02), awareness of drug's brand (more frequent in the patients <= 65 years old, p=0.003), requiring assistance while using the drugs (more frequent in the group of patients >65 years-old, p=0.01), monthly number of forgetting the drug doses (more frequent in the group of patients >65 years-old, p=0.006), living alone (more frequent in the group of patients >65 years-old, p=0.02), and the number of used drugs (more frequent in the group of patients >65 years-old, p=0.03). Conclusion: It is obvious that the patients who are >65 years old will be less adherent to glaucoma treatment as they more frequently require assistance for drug use and live alone. AN - WOS:000503885100007 AU - Tarakcioglu, H. N. AU - Yildiz, A. M. AU - Sonbahar, O. AU - Yigit, U. AU - Ozkaya, A. DA - DEC DO - 10.4274/BTDMJB.galenos.2019.20181025062426 IS - 4 PY - 2019 SN - 1305-9319 1305-9327 SP - 357-361 ST - Awareness and Adherence in Young and Older Glaucoma Patients who Live in European Side of Istanbul T2 - MEDICAL JOURNAL OF BAKIRKOY TI - Awareness and Adherence in Young and Older Glaucoma Patients who Live in European Side of Istanbul VL - 15 ID - 6011 ER - TY - JOUR AB - Objective. The aim of this study was to carry out a safety evaluation of biologic agents in patients with JIA and associated uveitis. Methods. In three tertiary centres in Finland, all adverse events (AEs) in 348 consecutive patients were collected. AEs were classified according to the Common Terminology Criteria for AEs. Results. A total of 1516 patient-years (py) were included: 710 on etanercept, 591 on infliximab, 188 on adalimumab, 8 on rituximab, 5 on anakinra, 6 on tocilizumab, 6 on abatacept and 1 on golimumab. The median follow-up of an individual patient was 51 months (range 1-155). The most common of the 2902 AEs (191/100 py) observed were mild infections, infusion or injection site reactions and alanine aminotransferase elevations. At least one AE occurred in 319 (92%) patients and 121 (35%) had at least one serious AE (SAE). The rate of SAEs was 11.4/100 py on etanercept, 11.8 on infliximab, 10.1 on adalimumab, 15.7 on abatacept, 31.2 on tocilizumab and 87.5 on rituximab, higher than with most anti-TNF agents (P = 0.005). No cases of malignant neoplasms or tuberculosis were detected. New-onset uveitis occurred in 9 patients, psoriasis or psoriasiform lesions in 13 and IBD in 6. Conclusion. Mild and moderate AEs in patients with JIA treated with biologics were more frequent than previously reported. SAEs were observed in one-third of the patients, but SAEs seldom led to drug discontinuation. © The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. AD - Children's Hospital, Helsinki University, Central Hospital, Helsinki, Finland Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland Poison Information Center, Helsinki University, Central Hospital, Helsinki, Finland Medical Research Center Oulu, Oulu, Finland Oulu University Hospital, Oulu, Finland University of Oulu, Oulu, Finland AU - Tarkiainen, M. AU - Tynjälä, P. AU - Vähäsalo, P. AU - Lahdenne, P. C7 - keu457 DB - Scopus DO - 10.1093/rheumatology/keu457 IS - 7 KW - Adverse drug event Anti-rheumatic agent Anti-TNF Biologic therapy Disease-modifying anti-rheumatic drug Juvenile idiopathic arthritis M3 - Article N1 - Cited By :58 Export Date: 19 July 2021 PY - 2015 SP - 1170-1176 ST - Occurrence of adverse events in patients with JIA receiving biologic agents: Long-term follow-up in a real-life setting T2 - Rheumatology (United Kingdom) TI - Occurrence of adverse events in patients with JIA receiving biologic agents: Long-term follow-up in a real-life setting UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84936874929&doi=10.1093%2frheumatology%2fkeu457&partnerID=40&md5=aad333555909980c3c009293cadd848c VL - 54 ID - 4974 ER - TY - JOUR AD - Moorfields Eye Hospital NHS Foundation Trust, London, UK. AN - 104566602. Language: English. Entry Date: 20120803. Revision Date: 20200708. Publication Type: Journal Article AU - Tatham, A. AU - Murdoch, I. DB - ccm DO - 10.1038/eye.2012.22 DP - EBSCOhost IS - 5 KW - Appointments and Schedules Continuity of Patient Care -- Statistics and Numerical Data Glaucoma -- Physiopathology Intraocular Pressure -- Physiology Outpatient Service Patient Compliance Chronic Disease Female Human Male Monitoring, Physiologic Practice Patterns Practice Guidelines Retrospective Design Time Factors N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM22388592. PY - 2012 SN - 0950-222X SP - 729-733 ST - The effect of appointment rescheduling on monitoring interval and patient attendance in the glaucoma outpatient clinic T2 - Eye TI - The effect of appointment rescheduling on monitoring interval and patient attendance in the glaucoma outpatient clinic UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104566602&site=ehost-live&scope=site VL - 26 ID - 4495 ER - TY - JOUR AB - Aim: To assess the effect of appointment rescheduling on monitoring intervals and patient attendance in the glaucoma clinic. Methods: A retrospective review of 100 consecutive patients was conducted. Patients were categorised into groups based on risk of progressive visual loss. The monitoring interval requested by the clinician was compared with the interval recommended by national guidelines. One hundred consecutive patients who had had their appointment rescheduled were also examined to assess the effect of appointment rescheduling on the actual monitoring interval. Patient non-attendance rates and attendances at the emergency department were also examined. Results: After excluding patients with secondary glaucoma, glaucoma suspects, and those with short-term factors affecting monitoring interval, 54 patients with chronic open-angle glaucoma (COAG) were included. Forty-eight (89%) of patients had a monitoring interval requested in accordance with national guidelines (2 had longer intervals by 1-2 months and 4 had shorter time intervals). The monitoring interval was not influenced by disease severity (Kruskal-Wallis test, P=0.16), but was significantly shorter if the intraocular pressure was above target (P=0.0001) or the patient showed structural or functional progression (P=0.0001). Hospital-initiated appointment rescheduling led to significant lengthening of monitoring interval. The mean difference between intended and actual monitoring interval was 5.6 months. Eight percent (8/100) of patients with rescheduled appointments did not attend compared with 15% (39/265) without rescheduled appointments. Conclusion: Clinical staff are selecting appropriate monitoring intervals for patients with COAG; however, hospital-initiated rescheduling of appointments is a major challenge to appropriate follow-up. © 2012 Macmillan Publishers Limited All rights reserved. AD - Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, United Kingdom Institute of Ophthalmology, London, United Kingdom AU - Tatham, A. AU - Murdoch, I. DB - Scopus DO - 10.1038/eye.2012.22 IS - 5 KW - clinical guidelines glaucoma outpatient M3 - Article N1 - Cited By :17 Export Date: 19 July 2021 PY - 2012 SP - 729-733 ST - The effect of appointment rescheduling on monitoring interval and patient attendance in the glaucoma outpatient clinic T2 - Eye (Basingstoke) TI - The effect of appointment rescheduling on monitoring interval and patient attendance in the glaucoma outpatient clinic UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862527505&doi=10.1038%2feye.2012.22&partnerID=40&md5=39e4fc15878a95864b2237292f69f8cc VL - 26 ID - 5168 ER - TY - JOUR AB - Aim To assess the effect of appointment rescheduling on monitoring intervals and patient attendance in the glaucoma clinic. Methods A retrospective review of 100 consecutive patients was conducted. Patients were categorised into groups based on risk of progressive visual loss. The monitoring interval requested by the clinician was compared with the interval recommended by national guidelines. One hundred consecutive patients who had had their appointment rescheduled were also examined to assess the effect of appointment rescheduling on the actual monitoring interval. Patient non-attendance rates and attendances at the emergency department were also examined. Results After excluding patients with secondary glaucoma, glaucoma suspects, and those with short-term factors affecting monitoring interval, 54 patients with chronic open-angle glaucoma (COAG) were included. Forty-eight (89%) of patients had a monitoring interval requested in accordance with national guidelines (2 had longer intervals by 1-2 months and 4 had shorter time intervals). The monitoring interval was not influenced by disease severity (Kruskal-Wallis test, P = 0.16), but was significantly shorter if the intraocular pressure was above target (P < 0.0001) or the patient showed structural or functional progression (P < 0.0001). Hospital-initiated appointment rescheduling led to significant lengthening of monitoring interval. The mean difference between intended and actual monitoring interval was 5.6 months. Eight percent (8/100) of patients with rescheduled appointments did not attend compared with 15% (39/265) without rescheduled appointments. Conclusion Clinical staff are selecting appropriate monitoring intervals for patients with COAG; however, hospital-initiated rescheduling of appointments is a major challenge to appropriate follow-up. Eye (2012) 26, 729-733; doi: 10.1038/eye.2012.22; published online 2 March 2012 AN - WOS:000303937400016 AU - Tatham, A. AU - Murdoch, I. DA - MAY DO - 10.1038/eye.2012.22 IS - 5 PY - 2012 SN - 0950-222X SP - 729-733 ST - The effect of appointment rescheduling on monitoring interval and patient attendance in the glaucoma outpatient clinic T2 - EYE TI - The effect of appointment rescheduling on monitoring interval and patient attendance in the glaucoma outpatient clinic VL - 26 ID - 5868 ER - TY - JOUR AB - The use of generic medicines has grown considerably in recent years providing considerable cost savings. In England, generic items represented 11.7% of prescriptions for glaucoma and ocular hypertension in 2009, increasing to 55.2% of prescriptions in 2018. Generics can be brought to the market quickly and at low cost as manufacturers are not required to repeat animal or clinical research on active ingredients already approved for safety and efficacy. Although there is no regulatory requirement for studies comparing branded and generic eye drops, several randomised crossover studies have been performed comparing branded and generic prostaglandin analogues. While most have shown similar intraocular pressure lowering, studies are of short duration and have not evaluated visual field endpoints. Furthermore, differences in inactive ingredients, pH, viscosity, levels of particulate matter, and degradation over time have been reported. Other potential problems with generic eye drops include differences in bottle design affecting adherence, problems with supply, and the possibility that reduced revenue for innovator companies will lead to reduced investment in new drug development. This article reviews the potential advantages and disadvantages of generic antiglaucoma medications. AD - Princess Alexandra Eye Pavilion, University of Edinburgh, Chalmers Street, Edinburgh EH3 9HA, UK AN - 142613021. Language: English. Entry Date: 20200410. Revision Date: 20200410. Publication Type: Article AU - Tatham, Andrew J. DB - ccm DO - 10.1155/2020/1651265 DP - EBSCOhost KW - Drugs, Generic -- Therapeutic Use Glaucoma -- Drug Therapy Human Systematic Review Ocular Hypertension -- Drug Therapy Cost Savings Drugs, Prescription Ophthalmic Solutions Prostaglandins -- Analogs and Derivatives Hydrogen-Ion Concentration Viscosity Particulate Matter Drug Design Medication Compliance Treatment Outcomes N1 - research; systematic review; tables/charts. Journal Subset: Biomedical; USA. Special Interest: Evidence-Based Practice. NLM UID: 101524199. PY - 2020 SN - 2090-004X SP - 1-8 ST - The Use of Generic Medications for Glaucoma T2 - Journal of Ophthalmology TI - The Use of Generic Medications for Glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142613021&site=ehost-live&scope=site ID - 4186 ER - TY - JOUR AD - Department of Ophthalmology, University Hospital Leicester, Leicester, Leicestershire, UK. AN - 104114409. Language: English. Entry Date: 20140509. Revision Date: 20200708. Publication Type: Journal Article AU - Tatham, A. J. AU - Sarodia, U. AU - Gatrad, F. AU - Awan, A. DB - ccm DO - 10.1038/eye.2013.187 DP - EBSCOhost IS - 11 KW - Antihypertensive Agents -- Administration and Dosage Glaucoma -- Drug Therapy Ophthalmic Solutions -- Administration and Dosage Aged Aged, 80 and Over Analysis of Variance Cross Sectional Studies Female Human Logistic Regression Male Middle Age Ocular Hypertension -- Drug Therapy Patient Compliance Patient Education -- Standards Self Care N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. NLM UID: 8703986. PMID: NLM23970024. PY - 2013 SN - 0950-222X SP - 1293-1298 ST - Eye drop instillation technique in patients with glaucoma T2 - Eye TI - Eye drop instillation technique in patients with glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104114409&site=ehost-live&scope=site VL - 27 ID - 4429 ER - TY - JOUR AD - Eye Clinic, University 'La Sapienza' of Rome, Rome, Italy AU - Taverniti, L. AU - Voccia, L. AU - Amoroso, L. AU - De Stefano, C. AU - Virno, M. DB - Scopus IS - 224 M3 - Conference Paper N1 - Export Date: 19 July 2021 PY - 1997 SP - 55-56 ST - Ocular tension and pupil diameter effects of timolol 0.50% and pilocarpine 2% or 4% in association T2 - Acta Ophthalmologica Scandinavica, Supplement TI - Ocular tension and pupil diameter effects of timolol 0.50% and pilocarpine 2% or 4% in association UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031283550&partnerID=40&md5=923dbe2ff914fc76a066095eec077ef1 VL - 75 ID - 5791 ER - TY - JOUR AB - The purpose of this study was to gain insights into why patients are not compliant with their glaucoma medications. Patients were recruited from lists provided by two ophthalmologists. Each patient had seen a minimum of two ophthalmologists for their glaucoma, and was taking at least two topical medications for glaucoma. Qualitative methodology was utilized, including two focus groups and eleven in-depth interviews in patients' homes. The results showed that forgetfulness was the number one reported reason for non-compliance. Patients did not claim to be non-compliant specifically because of side effects, but they did complain about them. Communication between physicians and patients is a key factor in compliance for glaucoma patients. Specifically, patients would like their physicians to teach them how to instill their eye drops, tell them about new/alternate medications and procedures as they become available, and offer new ways to make their regimen easier. Patients often do not tell their physician if they experience a side effect unless it is intolerable to them, yet they do realize the seriousness of glaucoma, and the consequences of not following their doctor's orders. Finally, while cost was not a reported deterrence to compliance, some patients would prefer less expensive alternatives. AD - S.A. Taylor, 65 Point Fosdick Terrace NW, Gig Harbor, WA 98335, United States AU - Taylor, S. A. AU - Galbraith, S. M. AU - Mills, R. P. C1 - timoptic(Merck and Co,United States) trusopt(Merck and Co,United States) xalatan(Pharmacia,United States) C2 - Merck and Co(United States) Pharmacia(United States) DB - Embase Medline IS - 5 KW - dorzolamide latanoprost pilocarpine timolol timolol maleate article clinical article controlled study doctor patient relationship drug cost drug tolerability eye color eye pain eyelash female glaucoma human interview male patient attitude patient compliance patient education qualitative analysis side effect stinging sensation visual disorder timoptic trusopt xalatan LA - English M3 - Article N1 - L37420249 2003-12-19 PY - 2002 SN - 1080-7683 SP - 401-409 ST - Causes of Non-Compliance with Drug Regimens in Glaucoma Patients: A Qualitative Study T2 - Journal of Ocular Pharmacology and Therapeutics TI - Causes of Non-Compliance with Drug Regimens in Glaucoma Patients: A Qualitative Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37420249&from=export VL - 18 ID - 3844 ER - TY - JOUR AB - To survey patient understanding of primary open-angle glaucoma (POAG) and difficulties associated with medical treatment of POAG patients, to determine patient compliance rates with medical therapy, to study factors influencing compliance rates, and to formulate suggestions to improve patient compliance. Our descriptive prospective study was carried out at the ophthalmology clinic of the Hubert K. Maga national university medical center and in the "La Lumière" ophthalmology clinic in Cotonou, from January 5 through April 25, 2009. The study included all glaucoma patients under medical treatment for at least 1 year with no surgical POAG intervention, seen in consultation during the study period, i.e. 120 patients. The following parameters were studied: whether the patient took or forgot to take his or her medication within the week preceding the survey, the patient's statement of whether or not voluntary interruption of antiglaucoma treatment occurred for more than 1 day, and the regularity of follow-up appointments with the doctor over the preceding 2 years. The median age of the patients was 56.5 ± 11.9years. A percentage of 90.8 of patients understood the chronic nature of POAG. A percentage of 91.7 knew that, in the absence of treatment, POAG can result in irreversible blindness. A percentage of 90 knew that medical treatment is intended to be lifelong. A percentage of 84.2 knew that the dosing schedule must be adhered to. The rate of total compliance was 53.3%. Only regularity of follow-up visits and adherence to dosing schedules were found as significant factors (P<0.05). Compliance is a dynamic variable which ophthalmologists need to evaluate throughout the follow-up of POAG patients, in order to reduce the prevalence of glaucoma blindness in Bénin. Copyright © 2011 Elsevier Masson SAS. All rights reserved. AD - S. Tchabi, Clinique ophtalmologique, centre national hospitalier universitaire Hubert-Koutoukou-Maga, 03, BP 1357, Cotonou, Bénin. AU - Tchabi, S. AU - Abouki, C. AU - Sounouvou, I. AU - Yèhouessi, L. AU - Doutetien, C. AU - Bassabi, S. K. DB - Medline IS - 9 KW - antihypertensive agent adult aged article attitude to health Benin clinical trial evaluation study female health survey human male middle aged multicenter study open angle glaucoma patient compliance socioeconomics statistics treatment withdrawal LA - French M3 - Article N1 - L560050612 2012-03-12 PY - 2011 SN - 1773-0597 SP - 624-628 ST - [Survey of medical treatment in primary open-angle glaucoma] T2 - Journal français d'ophtalmologie TI - [Survey of medical treatment in primary open-angle glaucoma] UR - https://www.embase.com/search/results?subaction=viewrecord&id=L560050612&from=export VL - 34 ID - 3135 ER - TY - JOUR AB - Purpose.-To survey patient understanding of primary open-angle glaucoma (POAG) and difficulties associated with medical treatment of POAG patients, to determine patient compliance rates with medical therapy, to study factors influencing compliance rates, and to formulate suggestions to improve patient compliance. Patients and methods.-Our descriptive prospective study was carried out at the ophthalmology clinic of the Hubert K. Maga national university medical center and in the "La Lumiere" ophthalmology clinic in Cotonou, from January 5 through April 25, 2009. The study included all glaucoma patients under medical treatment for at least 1 year with no surgical POAG intervention, seen in consultation during the study period, i.e. 120 patients. The following parameters were studied: whether the patient took or forgot to take his or her medication within the week preceding the survey, the patient's statement of whether or not voluntary interruption of anti-glaucoma treatment occurred for more than 1 day, and the regularity of follow-up appointments with the doctor over the preceding 2 years. Results.-The median age of the patients was 56.5 +/- 11.9 years. A percentage of 90.8 of patients understood the chronic nature of POAG. A percentage of 91.7 knew that, in the absence of treatment, POAG can result in irreversible blindness. A percentage of 90 knew that medical treatment is intended to be lifelong. A percentage of 84.2 knew that the dosing schedule must be adhered to. The rate of total compliance was 53.3%. Only regularity of follow-up visits and adherence to dosing schedules were found as significant factors (P < 0.05). Conclusion.-Compliance is a dynamic variable which ophthalmologists need to evaluate throughout the follow-up of POAG patients, in order to reduce the prevalence of glaucoma blindness in Benin. (C) 2011 Elsevier Masson SAS. All rights reserved. AN - WOS:000297911000005 AU - Tchabi, S. AU - Abouki, C. AU - Sounouvou, I. AU - Yehouessi, L. AU - Doutetien, C. AU - Bassabi, S. K. DA - NOV DO - 10.1016/j.jfo.2011.07.009 IS - 9 PY - 2011 SN - 0181-5512 SP - 624-628 ST - Survey of medical treatment in primary open-angle glaucoma T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Survey of medical treatment in primary open-angle glaucoma VL - 34 ID - 5870 ER - TY - JOUR AB - Topical atropine has become a mainstream treatment of myopia throughout East and Southeast Asia, but it is uncertain whether long-term topical atropine therapy induces intraocular pressure (IOP) elevation and subsequent development of glaucoma. We then prospectively examined the effects of long-term atropine treatment on IOP.Our case series collected 186 myopic children who were younger than 16 years of age. Complete ocular examination data, IOP and refractive status measurements beginning in 2008 were collected for all participants. Participants were divided into two groups: 121 children who received atropine therapy at various concentrations were classified as the treated group, whereas 65 children who did not receive atropine therapy were classified as the untreated (reference) group. In the treated group, clinicians prescribed different concentrations of atropine eye drops according to their discretion with regard to the severity of myopia on each visit of the patient. We then calculated the cumulative dose of atropine therapy from 2008 to the patients' last follow-up in 2009. Furthermore, the treated group was then further divided into low- and high-refractive-error groups of nearly equal size for further analysis.There were no significant differences for the baseline refractive errors and IOPs between the treated and untreated groups. Both the low- and high-cumulative atropine dosage subgroups showed significantly lower myopic progression than the untreated group, but there was no significant difference between the two subgroups in terms of different cumulative dosages. All groups, including the untreated group, showed an increase of mean IOP at the last follow-up, but both low- and high-cumulative atropine dosage subgroups experienced a smaller increase of IOP. The mean IOP of all atropine-treated groups showed no significant increase in either low- or high-refractive-error eyes.This study revealed that topical atropine eye drops do not induce ocular hypertension and are effective for slowing the progression of myopia. The treatment effects are not correlated with the cumulative atropine dosages. AD - Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei. School of Medicine, Fu Jen Catholic University, New Taipei City. Department of Medicine, School of Medicine, National Yang-Ming University, Taipei. Department of Ophthalmology, School of Medicine, National Taiwan University, Taipei, Taiwan. Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei School of Medicine, Fu Jen Catholic University, New Taipei City Department of Medicine, School of Medicine, National Yang-Ming University, Taipei Department of Ophthalmology, School of Medicine, National Taiwan University, Taipei, Taiwan AN - 147860908. Language: English. Entry Date: 20210103. Revision Date: 20210104. Publication Type: journal article. Journal Subset: Biomedical AU - Teng-Chieh, Yu AU - Tzu-En, Wu AU - Yuan-Shen, Wang AU - Shen-Fu, Cheng AU - Shiow-Wen, Liou AU - Yu, Teng-Chieh AU - Wu, Tzu-En AU - Wang, Yuan-Shen AU - Cheng, Shen-Fu AU - Liou, Shiow-Wen DB - ccm DO - 10.1097/MD.0000000000022745 DP - EBSCOhost IS - 48 KW - Myopia -- Drug Therapy Atropine -- Therapeutic Use Muscarinic Antagonists -- Therapeutic Use Female Atropine -- Administration and Dosage Child Glaucoma Prospective Studies Ophthalmic Solutions Muscarinic Antagonists -- Administration and Dosage Case Control Studies Male Intraocular Pressure Myopia -- Physiopathology Tonometry N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 2985248R. PMID: NLM33235063. PY - 2020 SN - 0025-7974 SP - 1-7 ST - A STROBE-compliant case-control study: Effects of cumulative doses of topical atropine on intraocular pressure and myopia progression T2 - Medicine TI - A STROBE-compliant case-control study: Effects of cumulative doses of topical atropine on intraocular pressure and myopia progression UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147860908&site=ehost-live&scope=site VL - 99 ID - 4168 ER - TY - JOUR AN - 90022179. Language: English. Entry Date: 20130905. Revision Date: 20130905. Publication Type: Article AU - Tertel, Zack DB - ccm DP - EBSCOhost IS - 8 KW - Ganciclovir -- Administration and Dosage Keratitis, Herpetic -- Drug Therapy Algorithms Patient Satisfaction Patient Compliance N1 - algorithm. Journal Subset: Biomedical; USA. NLM UID: 0045361. PY - 2013 SN - 0030-4085 SP - 52-52 ST - A New Treatment Algorithm for EHK...Epithelial Herpetic Keratitis T2 - Optometric Management TI - A New Treatment Algorithm for EHK...Epithelial Herpetic Keratitis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=90022179&site=ehost-live&scope=site VL - 48 ID - 4785 ER - TY - JOUR AB - Glaucoma is a major cause of blindness worldwide and an increasingly significant global health problem. Glaucoma prevention and management efforts have been challenging due to inherent difficulty in developing a simple and cost-effective screening plan, limited access to health care and educational resources, poverty, and inadequate knowledge of the disease, particularly in developing countries. Starting in 2004 the Tilganga Eye Centre in Kathmandu, Nepal has provided targeted glaucoma screening, treatment, and education through a combination of clinical outreach programs and educational activities for patients.~Background~Background~A simple, age-based glaucoma screening algorithm was incorporated into three one-day cataract screening clinics. Using this algorithm, patients who were newly diagnosed with glaucoma were referred to TEC, where medication and surgery were provided free of charge through private donor funding. In addition, we describe two ongoing educational programs for increasing glaucoma awareness: an annual Glaucoma Awareness Week (which includes free screening, treatment, and counseling), and a repeating lecture series which generates new counselors.~Methods~Methods~From 2004 to 2007 screening at the annual Glaucoma Awareness Week resulted in the diagnosis of 120 individuals with glaucoma, or 7.6% of total registrants. Attendance increased annually with a trend toward an increasing number of returning patients but a decreasing percentage of newly diagnosed patients, though the absolute numbers have remained relatively stable (range 21 to 38). Data from the three one-day screening clinics in 2006 show that approximately 2 to 4% of patients 50 years of age or older per clinic were newly diagnosed with POAG.~Results~Results~This multi-faceted approach appears to successfully identify individuals with glaucoma and provide treatment to those who would otherwise not be able to afford it. While more data is needed to validate this model, specifically regarding the effectiveness of educational activities, long-term visual outcomes, and medication compliance, it may serve as a useful framework for other developing countries with similarly limited resources.~Conclusion~Conclusions AD - Nepal Glaucoma Eye Clinic, Tilganga Eye Centre, Kathmandu, Nepal. ssthapa@tilganga.com.np AN - 105219081. Language: English. Entry Date: 20100709. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Thapa, S. S. AU - Kelley, K. H. AU - Rens, G. V. AU - Paudyal, I. AU - Chang, L. DB - ccm DP - EBSCOhost KW - Glaucoma -- Diagnosis Health Education -- Methods Health Screening -- Methods Patient Education -- Methods Algorithms Counseling Glaucoma -- Drug Therapy Glaucoma -- Surgery Health Screening -- Statistics and Numerical Data Middle Age Nepal Referral and Consultation Uncompensated Care N1 - Europe; UK & Ireland. NLM UID: 100967802. PMID: NLM18950530. PY - 2008 SN - 1471-2415 SP - 21-21 ST - A novel approach to glaucoma screening and education in Nepal T2 - BMC Ophthalmology TI - A novel approach to glaucoma screening and education in Nepal UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105219081&site=ehost-live&scope=site VL - 8 ID - 4727 ER - TY - JOUR AU - The, Lancet DB - Scopus DO - 10.1016/S0140-6736(09)60520-1 IS - 9667 M3 - Editorial N1 - Cited By :2 Export Date: 19 July 2021 PY - 2009 SP - 868 ST - Shining a spotlight on glaucoma T2 - The Lancet TI - Shining a spotlight on glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-61849107730&doi=10.1016%2fS0140-6736%2809%2960520-1&partnerID=40&md5=17a7a914157832a82d44533d4ce740b6 VL - 373 ID - 5583 ER - TY - JOUR AB - Background: The aim of this study was to test the non-inferiority of preservative-free (PF) latanoprost 50 μg/mL multi-dose ophthalmic solution versus the marketed benzalkonium chloride (BAK)-preserved latanoprost 50 μg/mL ophthalmic solution in patients with open-angle glaucoma and patients with ocular hypertension. Methods: This was a prospective, national, randomized, multi-center, observer-blind, parallel-group controlled clinical trial. Patients were randomized to receive either PF or BAK-preserved latanoprost once daily for 12 weeks. The primary endpoint was the change in intraocular pressure (IOP) at 8:00 AM in the affected eye between the end of the treatment (week 12) and the baseline (week 0). Secondary measurements were taken at weeks 2 and 6, with IOP being recorded at 8:00 AM, 12:00 PM, and 4:00 PM. Results: A total of 158 patients were included in the per protocol (PP) population (77 in the PF latanoprost treatment arm and 81 patients in the BAK-preserved latanoprost treatment arm). PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP at 8:00 AM in the study eye from the baseline (week 0) to the end of the treatment (week 12). The point estimate of the between-treatment difference was 0.1 mmHg (95% confidence interval: -0.646, 0.847). Mean between-group differences in IOP reduction from the baseline to each of the secondary measurements were also similar between the two treatment arms. The two treatments were well tolerated and had comparable adverse event profiles. Conclusions: PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Both treatments were well tolerated. © 2020, Author(s). AD - Attikon University Hospital, Athens, Greece General University Hospital of Thessaloniki AHEPA, Thessaloniki, Greece Ophthalmiatreio Athens, Athens, Greece General Hospital of Larissa, Larissa, Thessaly, Greece IASO Thessalias, Larissa, Greece General University Hospital of Patra, Patra, Greece General Hospital of Thessaloniki Ippokrateio, Thessaloniki, Greece BECRO, Athens, Greece Pharmathen S.A, Attica, Greece AU - Theodosiadis, P. AU - Konstas, A. AU - Halkiadakis, I. AU - Dimera, V. AU - Koufakis, D. AU - Georgakopoulos, C. D. AU - Kanonidou, E. AU - Zintzaras, E. AU - Soulele, K. AU - Maigaritis, A. AU - Kalantzi, L. DB - Scopus DO - 10.51329/mehdiophthal1413 IS - 4 KW - Benzalkonium chloride Eye drop Glaucoma Intraocular pressure Latanoprost Preservative-free Randomized controlled trial Timolol M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 273-283 ST - Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: A non-inferiority phase iii randomized, multi-center, single-blind, parallel-group controlled trial T2 - Medical Hypothesis, Discovery, and Innovation in Ophthalmology TI - Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: A non-inferiority phase iii randomized, multi-center, single-blind, parallel-group controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102739451&doi=10.51329%2fmehdiophthal1413&partnerID=40&md5=adbe1e018d24c6b3817740fe42d5efce VL - 9 ID - 5707 ER - TY - JOUR AB - Purpose. To assess the effect of an intervention comprising training in optic disc assessment, explicit referral criteria and ophthalmologist feedback on referred patients, on the number of optometrist referrals for suspected glaucoma seen at a referral site and the positive predictive value of those referrals. Methods. Optometric practices routinely referring to the Ealing Hospital Eye Clinic were randomly divided into two groups taking into consideration those practices, which shared an optometrist (a cluster) and the number of optometrist days worked per week. One group of practices acted as controls, while the other practices were invited to receive the intervention. Data on 397 new patients referred and presenting to Ealing Hospital with suspected glaucoma were collected over a 20-month period. The data on patients who had failed to attend their appointment were collected over 7 months of this period. The number of referrals seen, the positive predictive value of those referrals, and the attendance rate were calculated. Optometrist's opinions of the intervention were assessed qualitatively. Data relating to optometrist compliance with the intervention were also collected. Results. The number of glaucoma referrals presenting to Ealing Hospital from the intervention practices was almost double that from the control practices (210 vs 119). When cluster randomisation, the number of optometrist days per cluster and the number of assessed referrals in the preintervention period are taken into consideration, it is estimated that the intervention is associated with a 52% increase in the number of referrals reaching Ealing Hospital. However, the design effect resulting from the cluster randomisation was unexpectedly high (of the order of 13-14) and so the confidence intervals around the estimate of 52% are very wide (95% c.i. 35% decrease to 253% increase, P = 0.34). There was no evidence of an association between optometrist compliance with the intervention and the number of referrals seen at Ealing Hospital. The positive predictive value (PPV) of referrals was similar for the intervention (0.49 (95% c.i. 0.42, 0.55)) and control groups (0.46 (95% c.i. 0.33, 0.60)). Optometrist opinions of the intervention were largely favourable. All expressed a willingness to participate in future programmes. Conclusion. A large difference in the number of referrals between the practice groups was observed. Since the PPV of referral was unchanged, the potential impact of the intervention in terms of numbers of new cases of glaucoma detected in the community is substantial. However, because of its large design effect, this trial does not provide conclusive evidence of an impact of the intervention on referral numbers. A considerably larger trial will be required to produce conclusive evidence of an effect. © 2004 Nature Publishing Group All rights reserved. AD - J. Theodossiades, Institute of Ophthalmology, Bath Street, London EC1V 9EL, United Kingdom AU - Theodossiades, J. AU - Murdoch, I. AU - Cousens, S. DB - Embase Medline DO - 10.1038/sj.eye.6700676 IS - 5 KW - article case finding confidence interval controlled study correlation analysis data analysis glaucoma human information processing major clinical study optic disk optometry patient compliance patient referral prediction professional practice qualitative analysis randomization LA - English M3 - Article N1 - L38765320 2004-06-24 PY - 2004 SN - 0950-222X SP - 483-490 ST - Glaucoma case finding: A cluster-randomised intervention trial T2 - Eye TI - Glaucoma case finding: A cluster-randomised intervention trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38765320&from=export http://dx.doi.org/10.1038/sj.eye.6700676 VL - 18 ID - 3746 ER - TY - JOUR AB - Purpose. To assess the effect of an intervention comprising training in optic disc assessment, explicit referral criteria and ophthalmologist feedback on referred patients, on the number of optometrist referrals for suspected glaucoma seen at a referral site and the positive predictive value of those referrals. Methods. Optometric practices routinely referring to the Ealing Hospital Eye Clinic were randomly divided into two groups taking into consideration those practices, which shared an optometrist (a cluster) and the number of optometrist days worked per week. One group of practices acted as controls, while the other practices were invited to receive the intervention. Data on 397 new patients referred and presenting to Ealing Hospital with suspected glaucoma were collected over a 20-month period. The data on patients who had failed to attend their appointment were collected over 7 months of this period. The number of referrals seen, the positive predictive value of those referrals, and the attendance rate were calculated. Optometrist's opinions of the intervention were assessed qualitatively. Data relating to optometrist compliance with the intervention were also collected. Results. The number of glaucoma referrals presenting to Ealing Hospital from the intervention practices was almost double that from the control practices (210 vs 119). When cluster randomisation, the number of optometrist days per cluster and the number of assessed referrals in the preintervention period are taken into consideration, it is estimated that the intervention is associated with a 52% increase in the number of referrals reaching Ealing Hospital. However, the design effect resulting from the cluster randomisation was unexpectedly high (of the order of 13-14) and so the confidence intervals around the estimate of 52% are very wide (95% c.i. 35% decrease to 253% increase, P = 0.34). There was no evidence of an association between optometrist compliance with the intervention and the number of referrals seen at Ealing Hospital. The positive predictive value (PPV) of referrals was similar for the intervention (0.49 (95% c.i. 0.42, 0.55)) and control groups (0.46 (95% c.i. 0.33, 0.60)). Optometrist opinions of the intervention were largely favourable. All expressed a willingness to participate in future programmes. Conclusion. A large difference in the number of referrals between the practice groups was observed. Since the PPV of referral was unchanged, the potential impact of the intervention in terms of numbers of new cases of glaucoma detected in the community is substantial. However, because of its large design effect, this trial does not provide conclusive evidence of an impact of the intervention on referral numbers. A considerably larger trial will be required to produce conclusive evidence of an effect. © 2004 Nature Publishing Group All rights reserved. AD - Department of Epidemiology, International Eye Health, Institute of Ophthalmology, Bath Street, London EC1V 9EL, United Kingdom Moorfields Eye Hospital, City Road, London, United Kingdom Dept. of Epidemiol./Pop. Sciences, London Sch. of Hygiene/Tropical Med., Keppel Street, London, United Kingdom AU - Theodossiades, J. AU - Murdoch, I. AU - Cousens, S. DB - Scopus DO - 10.1038/sj.eye.6700676 IS - 5 KW - Case-finding Glaucoma Intervention trial Optometrists Positive predictive value M3 - Article N1 - Cited By :21 Export Date: 19 July 2021 PY - 2004 SP - 483-490 ST - Glaucoma case finding: A cluster-randomised intervention trial T2 - Eye TI - Glaucoma case finding: A cluster-randomised intervention trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-2942695876&doi=10.1038%2fsj.eye.6700676&partnerID=40&md5=3e6e1919f778f449c861b9350572d482 VL - 18 ID - 5138 ER - TY - JOUR AB - Purpose To assess the effect of an intervention comprising training in optic disc assessment, explicit referral criteria and ophthalmologist feedback on referred patients, on the number of optometrist referrals for suspected glaucoma seen at a referral site and the positive predictive value of those referrals. Methods Optometric practices routinely referring to the Ealing Hospital Eye Clinic were randomly divided into two groups taking into consideration those practices, which shared an optometrist ( a cluster) and the number of optometrist days worked per week. One group of practices acted as controls, while the other practices were invited to receive the intervention. Data on 397 new patients referred and presenting to Ealing Hospital with suspected glaucoma were collected over a 20-month period. The data on patients who had failed to attend their appointment were collected over 7 months of this period. The number of referrals seen, the positive predictive value of those referrals, and the attendance rate were calculated. Optometrist's opinions of the intervention were assessed qualitatively. Data relating to optometrist compliance with the intervention were also collected. Results The number of glaucoma referrals presenting to Ealing Hospital from the intervention practices was almost double that from the control practices ( 210 vs 119). When cluster randomisation, the number of optometrist days per cluster and the number of assessed referrals in the preintervention period are taken into consideration, it is estimated that the intervention is associated with a 52% increase in the number of referrals reaching Ealing Hospital. However, the design effect resulting from the cluster randomisation was unexpectedly high ( of the order of 13 - 14) and so the confidence intervals around the estimate of 52% are very wide (95% c. i. 35% decrease to 253% increase, P = 0.34). There was no evidence of an association between optometrist compliance with the intervention and the number of referrals seen at Ealing Hospital. The positive predictive value (PPV) of referrals was similar for the intervention (0.49 ( 95% c. i. 0.42, 0.55)) and control groups (0.46 ( 95% c. i. 0.33, 0.60)). Optometrist opinions of the intervention were largely favourable. All expressed a willingness to participate in future programmes. Conclusion A large difference in the number of referrals between the practice groups was observed. Since the PPV of referral was unchanged, the potential impact of the intervention in terms of numbers of new cases of glaucoma detected in the community is substantial. However, because of its large design effect, this trial does not provide conclusive evidence of an impact of the intervention on referral numbers. A considerably larger trial will be required to produce conclusive evidence of an effect. AN - WOS:000221252600008 AU - Theodossiades, J. AU - Murdoch, I. AU - Cousens, S. DA - MAY DO - 10.1038/sj.eye.6700676 IS - 5 PY - 2004 SN - 0950-222X 1476-5454 SP - 483-490 ST - Glaucoma case finding: a cluster-randomised intervention trial T2 - EYE TI - Glaucoma case finding: a cluster-randomised intervention trial VL - 18 ID - 6280 ER - TY - JOUR AB - PURPOSE. To understand factors associated with poor attendance of follow-up appointments for care of glaucoma (GL), AMD, and diabetic retinopathy (DR) in a tertiary referral center, and to identify strategies to improve adherence. METHODS. Cross-sectional study of 240 adults attending follow-up appointments for GL, AMD, or DR. Cases (N = 102) were patients with poor follow-up who missed and failed to reschedule an appointment within 1 month of the recommended follow-up date during the preceding year. Controls (N = 138) were patients who completed the assigned follow-up. Data regarding the factors impacting adherence to appointments were collected via an orally administered questionnaire. Multivariate logistic regression was performed to determine factors associated with poor follow-up. RESULTS. In a multivariate logistic regression model, independent factors significantly associated with poor follow-up included incorrectly answering more than 50% of questions about eye disease (adjusted odds ratio [OR] = 3.24, P = 0.001), legal blindness (adjusted OR 2.64, P = 0.013), the presence of glaucomatous versus retinal disease (adjusted OR 2.06, P = 0.013), and difficulty for the study subject and/or escort taking time away from work for the appointments (adjusted OR 1.80, P = 0.049). Subjects identified the following strategies to improve follow-up: contact with others having the same eye condition (41.3%), greater education regarding eye disease (40.8%), and improved transportation services to the clinic (44.6%). CONCLUSIONS. Low disease knowledge scores, legal blindness, and difficulty getting time away from work for appointments adversely impacted follow-up independent of eye disease diagnosis. Improvements in patient education, transportation services, and clinic efficiency may increase adherence to recommended appointment intervals. AD - A.C. Thompson, 3711 SW Durham Drive #306, Durham, NC, United States AU - Thompson, A. C. AU - Thompson, M. O. AU - Young, D. L. AU - Lin, R. C. AU - Sanislo, S. R. AU - Moshfeghi, D. M. AU - Singh, K. DB - Embase Medline DO - 10.1167/iovs.15-16444 IS - 8 KW - age related macular degeneration aged anthropometry article awareness cross-sectional study diabetic retinopathy disease severity eye care eye disease female follow up glaucoma health care cost human interview knowledge major clinical study male medical information multivariate logistic regression analysis patient assessment patient transport priority journal protocol compliance questionnaire visual acuity LA - English M3 - Article N1 - L605959804 2015-09-17 2015-09-22 PY - 2015 SN - 1552-5783 0146-0404 SP - 4324-4331 ST - Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases T2 - Investigative Ophthalmology and Visual Science TI - Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605959804&from=export http://dx.doi.org/10.1167/iovs.15-16444 VL - 56 ID - 2859 ER - TY - JOUR AB - PURPOSE. To understand factors associated with poor attendance of follow-up appointments for care of glaucoma (GL), AMD, and diabetic retinopathy (DR) in a tertiary referral center, and to identify strategies to improve adherence. METHODS. Cross-sectional study of 240 adults attending follow-up appointments for GL, AMD, or DR. Cases (N = 102) were patients with poor follow-up who missed and failed to reschedule an appointment within 1 month of the recommended follow-up date during the preceding year. Controls (N = 138) were patients who completed the assigned follow-up. Data regarding the factors impacting adherence to appointments were collected via an orally administered questionnaire. Multivariate logistic regression was performed to determine factors associated with poor follow-up. RESULTS. In a multivariate logistic regression model, independent factors significantly associated with poor follow-up included incorrectly answering more than 50% of questions about eye disease (adjusted odds ratio [OR] = 3.24, P = 0.001), legal blindness (adjusted OR 2.64, P = 0.013), the presence of glaucomatous versus retinal disease (adjusted OR 2.06, P = 0.013), and difficulty for the study subject and/or escort taking time away from work for the appointments (adjusted OR 1.80, P = 0.049). Subjects identified the following strategies to improve follow-up: contact with others having the same eye condition (41.3%), greater education regarding eye disease (40.8%), and improved transportation services to the clinic (44.6%). CONCLUSIONS. Low disease knowledge scores, legal blindness, and difficulty getting time away from work for appointments adversely impacted follow-up independent of eye disease diagnosis. Improvements in patient education, transportation services, and clinic efficiency may increase adherence to recommended appointment intervals. ©2015 The Association for Research in Vision and Ophthalmology, Inc. AD - Stanford University School of Medicine, Stanford, CA, United States Protiviti, New York, NY, United States Scripps Clinic, La Jolla, CA, United States Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, United States AU - Thompson, A. C. AU - Thompson, M. O. AU - Young, D. L. AU - Lin, R. C. AU - Sanislo, S. R. AU - Moshfeghi, D. M. AU - Singh, K. DB - Scopus DO - 10.1167/iovs.15-16444 IS - 8 KW - Age-related macular degeneration Appointment adherence Diabetic retinopathy Follow-up Glaucoma M3 - Article N1 - Cited By :50 Export Date: 19 July 2021 PY - 2015 SP - 4324-4331 ST - Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases T2 - Investigative Ophthalmology and Visual Science TI - Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941281210&doi=10.1167%2fiovs.15-16444&partnerID=40&md5=7992625e6ac32ecdd0b67be3ccd69c2f VL - 56 ID - 4995 ER - TY - JOUR AB - PURPOSE. To understand factors associated with poor attendance of follow-up appointments for care of glaucoma (GL), AMD, and diabetic retinopathy (DR) in a tertiary referral center, and to identify strategies to improve adherence. METHODS. Cross-sectional study of 240 adults attending follow-up appointments for GL, AMD, or DR. Cases (N = 102) were patients with poor follow-up who missed and failed to reschedule an appointment within 1 month of the recommended follow-up date during the preceding year. Controls (N = 138) were patients who completed the assigned follow-up. Data regarding the factors impacting adherence to appointments were collected via an orally administered questionnaire. Multivariate logistic regression was performed to determine factors associated with poor follow-up. RESULTS. In a multivariate logistic regression model, independent factors significantly associated with poor follow-up included incorrectly answering more than 50% of questions about eye disease (adjusted odds ratio [OR] = 3.24, P = 0.001), legal blindness (adjusted OR 2.64, P = 0.013), the presence of glaucomatous versus retinal disease (adjusted OR 2.06, P = 0.013), and difficulty for the study subject and/or escort taking time away from work for the appointments (adjusted OR 1.80, P = 0.049). Subjects identified the following strategies to improve follow-up: contact with others having the same eye condition (41.3%), greater education regarding eye disease (40.8%), and improved transportation services to the clinic (44.6%). CONCLUSIONS. Low disease knowledge scores, legal blindness, and difficulty getting time away from work for appointments adversely impacted follow-up independent of eye disease diagnosis. Improvements in patient education, transportation services, and clinic efficiency may increase adherence to recommended appointment intervals. AN - WOS:000362882700017 AU - Thompson, A. C. AU - Thompson, M. O. AU - Young, D. L. AU - Lin, R. C. AU - Sanislo, S. R. AU - Moshfeghi, D. M. AU - Singh, K. DA - JUL DO - 10.1167/iovs.15-16444 IS - 8 PY - 2015 SN - 0146-0404 1552-5783 SP - 4324-4331 ST - Barriers to Follow-Up and Strategies to Improve Adherence to Appointments for Care of Chronic Eye Diseases T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - Barriers to Follow-Up and Strategies to Improve Adherence to Appointments for Care of Chronic Eye Diseases VL - 56 ID - 5821 ER - TY - JOUR AB - Objective To investigate whether electronically measured medication adherence is associated with vision-related quality of life (VRQoL) in patients with open-angle glaucoma. Methods and analysis This is a 3-year prospective cohort study of 79 subjects with open-angle glaucoma at a Veterans Affairs medical centre. Participants returned a medication event monitoring system (MEMS) for their glaucoma eye-drops and had at least two visits with glaucoma during the study period. Those taking less than 80% of prescribed glaucoma medication doses were considered to be non-adherent. Subjects were interviewed using the National Eye Institute's Visual Function Questionnaire-25 (VFQ-25) at baseline and after 3 years. Results Thirty per cent (n=24/79) of participants took less than 80% of prescribed doses of their glaucoma medications at baseline. Patients who did not adhere to their medications at baseline had lower mean composite VFQ-25 scores at baseline (70.66±20.50 vs 75.91±19.12, standardised mean difference=0.27) and after 3 years (71.68±21.93 vs 76.25±21.67, standardised mean difference=0.21). Visual acuity (P=0.03), but not visual field severity (P=0.13) or medication adherence (P=0.30), was significantly associated with composite VFQ-25 score in an adjusted model. Conclusions Subjects who were non-adherent to their glaucoma medications at baseline as assessed by a MEMS device reported lower VRQoL than adherent subjects at baseline and after 3 years. However, visual acuity was significantly associated with VRQoL. Future studies should assess whether improved adherence to eye-drops impacts VRQoL in patients with glaucoma. © 2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article). All rights reserved. No commercial use is permitted unless otherwise expressly granted. AD - Department of Ophthalmology, Duke University, School of Medicine, Durham, NC, United States Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, Durham, NC, United States Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States Department of Medicine, Duke University, School of Medicine, Durham, NC, United States AU - Thompson, A. C. AU - Woolson, S. AU - Olsen, M. K. AU - Danus, S. AU - Bosworth, H. B. AU - Muir, K. W. C7 - e000114 DB - Scopus DO - 10.1136/bmjophth-2017-000114 IS - 1 KW - electronically measured medication adherence open angle glaucoma vision-related quality of life M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2018 ST - Relationship between electronically measured medication adherence and vision-related quality of life in a cohort of patients with open-angle glaucoma T2 - BMJ Open Ophthalmology TI - Relationship between electronically measured medication adherence and vision-related quality of life in a cohort of patients with open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067481094&doi=10.1136%2fbmjophth-2017-000114&partnerID=40&md5=59fc76f619ac4e896ada82c5b7cbbeb9 VL - 3 ID - 5323 ER - TY - JOUR AB - Objective To investigate whether electronically measured medication adherence is associated with vision-related quality of life (VRQoL) in patients with open-angle glaucoma. Methods and analysis This is a 3-year prospective cohort study of 79 subjects with open-angle glaucoma at a Veterans Affairs medical centre. Participants returned a medication event monitoring system (MEMS) for their glaucoma eye-drops and had at least two visits with glaucoma during the study period. Those taking less than 80% of prescribed glaucoma medication doses were considered to be non-adherent. Subjects were interviewed using the National Eye Institute's Visual Function Results Thirty per cent (n=24/79) of participants took less than 80% of prescribed doses of their glaucoma medications at baseline. Patients who did not adhere to their medications at baseline had lower mean composite VFQ-25 scores at baseline (70.66 +/- 20.50 vs 75.91 +/- 19.12, standardised mean difference=0.27) and after 3 years (71.68 +/- 21.93 vs 76.25 +/- 21.67, standardised mean difference=0.21). Visual acuity (P=0.03), but not visual field severity (P=0.13) or medication adherence (P=0.30), was significantly associated with composite VFQ-25 score in an adjusted model. Conclusions Subjects who were non-adherent to their glaucoma medications at baseline as assessed by a MEMS device reported lower VRQoL than adherent subjects at baseline and after 3 years. However, visual acuity was significantly associated with VRQoL. Future studies should assess whether improved adherence to eye-drops impacts VRQoL in patients with glaucoma. AN - WOS:000435917500006 AU - Thompson, A. C. AU - Woolson, S. AU - Olsen, M. K. AU - Danus, S. AU - Bosworth, H. B. AU - Muir, K. W. DA - FEB DO - 10.1136/bmjophth-2017-000114 IS - 1 PY - 2018 SN - 2397-3269 ST - Relationship between electronically measured medication adherence and vision-related quality of life in a cohort of patients with open-angle glaucoma T2 - BMJ OPEN OPHTHALMOLOGY TI - Relationship between electronically measured medication adherence and vision-related quality of life in a cohort of patients with open-angle glaucoma VL - 3 ID - 5885 ER - TY - JOUR AB - Data on the association between hypothyroidism and glaucoma are conflicting. We sought to shed light on this by conducting a critical review and meta-analyses. The meta-analyses were conducted in adherence with the widely accepted MOOSE guidelines. Using the Medical Subject Heading (MeSH) terms: hypothyroidism, myxoedema and glaucoma or intraocular pressure, case–control studies, cohort studies and cross-sectional studies were identified (PubMed) and reviewed. Using meta-analysis, the relative risk (RR) of coexistence of glaucoma and hypothyroidism was calculated. Based on the literature search, thirteen studies fulfilled the inclusion criteria and could be categorized into two groups based on the exposure. The designs of the studies varied considerably, and there was heterogeneity related to lack of power, weak phenotype classifications and length of follow-up. Eight studies had glaucoma (5757 patients) as exposure and hypothyroidism as outcome. Among these, we found a non-significantly increased risk of hypothyroidism associated with glaucoma (RR 1.65; 95% confidence interval [CI]: 0.97–2.82). Based on five studies (168 006 patients) with hypothyroidism as exposure and glaucoma as outcome, we found the risk of glaucoma to be significantly increased (RR 1.33; 95% CI: 1.13–1.58). Based on these meta-analyses, there seems to be an association between hypothyroidism and glaucoma, which does not seem to be the case between glaucoma and hypothyroidism. However, larger scale studies with better phenotype classification, longer follow-up and taking comorbidity and other biases into consideration are needed to address a potential causal relationship. © 2017 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd AD - Department of Endocrinology and Metabolism, Odense University Hospital, Odense C, Denmark Department of Internal Medicine, Hospital of Southern Denmark, Sonderborg, Denmark AU - Thvilum, M. AU - Brandt, F. AU - Brix, T. H. AU - Hegedüs, L. DB - Scopus DO - 10.1111/aos.13412 IS - 8 KW - glaucoma hypothyroidism meta-analysis myxoedema M3 - Review N1 - Cited By :7 Export Date: 19 July 2021 PY - 2017 SP - 759-767 ST - The interrelation between hypothyroidism and glaucoma: a critical review and meta-analyses T2 - Acta Ophthalmologica TI - The interrelation between hypothyroidism and glaucoma: a critical review and meta-analyses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013435820&doi=10.1111%2faos.13412&partnerID=40&md5=9d284424b18db4de587755ade5f515e4 VL - 95 ID - 5347 ER - TY - JOUR AB - Data on the association between hypothyroidism and glaucoma are conflicting. We sought to shed light on this by conducting a critical review and meta-analyses. The meta-analyses were conducted in adherence with the widely accepted MOOSE guidelines. Using the Medical Subject Heading (MeSH) terms: hypothyroidism, myxoedema and glaucoma or intraocular pressure, case-control studies, cohort studies and cross-sectional studies were identified (PubMed) and reviewed. Using meta-analysis, the relative risk (RR) of coexistence of glaucoma and hypothyroidism was calculated. Based on the literature search, thirteen studies fulfilled the inclusion criteria and could be categorized into two groups based on the exposure. The designs of the studies varied considerably, and there was heterogeneity related to lack of power, weak phenotype classifications and length of follow-up. Eight studies had glaucoma (5757 patients) as exposure and hypothyroidism as outcome. Among these, we found a non-significantly increased risk of hypothyroidism associated with glaucoma (RR 1.65; 95% confidence interval [CI]: 0.97-2.82). Based on five studies (168006 patients) with hypothyroidism as exposure and glaucoma as outcome, we found the risk of glaucoma to be significantly increased (RR 1.33; 95% CI: 1.13-1.58). Based on these meta-analyses, there seems to be an association between hypothyroidism and glaucoma, which does not seem to be the case between glaucoma and hypothyroidism. However, larger scale studies with better phenotype classification, longer follow-up and taking comorbidity and other biases into consideration are needed to address a potential causal relationship. AN - WOS:000417645900015 AU - Thvilum, M. AU - Brandt, F. AU - Brix, T. H. AU - Hegedus, L. DA - DEC DO - 10.1111/aos.13412 IS - 8 PY - 2017 SN - 1755-375X 1755-3768 SP - 759-767 ST - The interrelation between hypothyroidism and glaucoma: a critical review and meta-analyses T2 - ACTA OPHTHALMOLOGICA TI - The interrelation between hypothyroidism and glaucoma: a critical review and meta-analyses VL - 95 ID - 6034 ER - TY - JOUR AB - Background:In the clinical management of patients at risk for or diagnosed with primary open-angle glaucoma (POAG), the aim of medical treatment is to reduce intraocular pressure (IOP) and then maintain it over time at a level that preserves both the structure and function of the optic nerve.Objective:The objective of this report was to establish a consensus on the criteria that should be used to determine the characteristics of IOP-lowering medication.Methods:Discussion was held among a panel of 12 physicians considered to be experts in glaucoma to develop a consensus on the criteria used by them to determine the characteristics of the IOP-lowering medication chosen for initial monotherapy and adjunctive treatment of ocular hypertension (OHT) or POAG. Consensus development combined available evidence and the impressions of these physicians regarding the clinical effectiveness of IOP-lowering medication for OHT and POAG. Once the panel identified the criteria, the order of priority and the relative importance of these criteria were then established in the setting of 3 risk categories (low, medium, and high) for a patient to experience significant visual disability from glaucoma over their expected life span.Results:The panel identified 5 criteria to determine the characteristics of IOP-lowering medication for OHT and POAG: IOP-lowering effect, systemic adverse events (AEs), ocular tolerability, compliance/administration, and cost of treatment. IOP-lowering effect was consistently ranked as the highest priority and cost as the lowest. The priority of compliance/administration did not vary by clinical situation. Systemic AEs and ocular tolerability were ranked as higher priorities in initial monotherapy than in adjunctive treatment and ranked lower as the risk for visual disability increased. The priority given to the criteria used to determine clinical effectiveness varied both with the risk for functional vision loss from glaucoma and whether initial monotherapy or adjunctive treatment was being considered.Conclusion:Glaucoma treatment should be assessed with regard to the need not only to lower IOP but also to minimize systemic and ocular AEs, promote patient compliance, and minimize cost. The order of priority and relative importance given to these treatment criteria will vary as part of individualizing patient care. AD - Department of Ophthalmology 2061, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; john.thygesen@rh.hosp.dk AN - 105880499. Language: English. Entry Date: 20080411. Revision Date: 20200708. Publication Type: Journal Article AU - Thygesen, J. AU - Burk, R. AU - Carassa, R. AU - Crichton, A. AU - Goñi, F. J. AU - Menage, M. AU - Miglior, S. AU - Montgomery, D. AU - Nordmann, J. AU - Roberts, T. AU - Singh, K. DB - ccm DO - 10.1016/j.curtheres.2007.06.002 DP - EBSCOhost IS - 3 KW - Decision Making, Clinical Drug Therapy -- Standards Glaucoma -- Drug Therapy Delphi Technique Drug Therapy, Combination -- Standards Funding Source Intraocular Pressure Netherlands Physician Attitudes Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Pfizer Ophthalmics, New York, New York. NLM UID: 0372621. PY - 2007 SN - 0011-393X SP - 127-136 ST - Criteria for choosing clinically effective glaucoma treatment: a discussion panel consensus T2 - Current Therapeutic Research TI - Criteria for choosing clinically effective glaucoma treatment: a discussion panel consensus UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105880499&site=ehost-live&scope=site VL - 68 ID - 4463 ER - TY - JOUR AB - Abstract. Background: In the clinical management of patients at risk for or diagnosed with primary open-angle glaucoma (POAG), the aim of medical treatment is to reduce intraocular pressure (IOP) and then maintain it over time at a level that preserves both the structure and function of the optic nerve. Objective: The objective of this report was to establish a consensus on the criteria that should be used to determine the characteristics of IOP-lowering medication. Methods: Discussion was held among a panel of 12 physicians considered to be experts in glaucoma to develop a consensus on the criteria used by them to determine the characteristics of the IOP-lowering medication chosen for initial monotherapy and adjunctive treatment of ocular hypertension (OHT) or POAG. Consensus development combined available evidence and the impressions of these physicians regarding the clinical effectiveness of IOP-lowering medication for OHT and POAG. Once the panel identified the criteria, the order of priority and the relative importance of these criteria were then established in the setting of 3 risk categories (low, medium, and high) for a patient to experience significant visual disability from glaucoma over their expected life span. Results: The panel identified 5 criteria to determine the characteristics of IOP-lowering medication for OHT and POAG: IOP-lowering effect, systemic adverse events (AEs), ocular tolerability, compliance/administration, and cost of treatment. IOP-lowering effect was consistently ranked as the highest priority and cost as the lowest. The priority of compliance/administration did not vary by clinical situation. Systemic AEs and ocular tolerability were ranked as higher priorities in initial monotherapy than in adjunctive treatment and ranked lower as the risk for visual disability increased. The priority given to the criteria used to determine clinical effectiveness varied both with the risk for functional vision loss from glaucoma and whether initial monotherapy or adjunctive treatment was being considered. Conclusion: Glaucoma treatment should be assessed with regard to the need not only to lower IOP but also to minimize systemic and ocular AEs, promote patient compliance, and minimize cost. The order of priority and relative importance given to these treatment criteria will vary as part of individualizing patient care. © 2007 Excerpta Medica, Inc. All rights reserved. AD - J. Thygesen, Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark AU - Thygesen, J. AU - Burk, R. AU - Carassa, R. AU - Crichton, A. AU - Goñi, F. J. AU - Menage, M. AU - Miglior, S. AU - Montgomery, D. AU - Nordmann, J. P. AU - Roberts, T. AU - Singh, K. DB - Embase DO - 10.1016/j.curtheres.2007.06.002 IS - 3 KW - alpha adrenergic receptor stimulating agent apraclonidine bimatoprost brimonidine brinzolamide carbachol carbonate dehydratase inhibitor clonidine dorzolamide latanoprost pilocarpine prostaglandin derivative travoprost article consensus development drug efficacy drug tolerability glaucoma human intraocular hypertension intraocular pressure open angle glaucoma optic nerve patient compliance priority journal LA - English M3 - Article N1 - L47268441 2007-05-01 PY - 2007 SN - 0011-393X SP - 127-136 ST - Criteria for choosing clinically effective glaucoma treatment: A discussion panel consensus T2 - Current Therapeutic Research - Clinical and Experimental TI - Criteria for choosing clinically effective glaucoma treatment: A discussion panel consensus UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47268441&from=export http://dx.doi.org/10.1016/j.curtheres.2007.06.002 VL - 68 ID - 3530 ER - TY - JOUR AB - Background: The purpose of this study was to characterize current patterns of treatment of glaucoma and ocular hypertension and to examine the effect of those patterns on intraocular pressure (IOP) control and persistence on therapy. Methods: A retrospective chart review was conducted at 3 ophthalmology practices in Alberta. Data were collected for patients who had begun therapy for newly diagnosed primary open-angle glaucoma or ocular hypertension between May 1, 1998, and Sept. 30, 1999 (phase I), and for patients who had begun second-line therapy after initial therapy with a β-blocker had failed (phase 2). Data were collected for a minimum of 24 months for phase I and a minimum of 18 months for phase 2. Results: We included 115 patient charts in phase I and 93 in phase 2. In each phase, the patients for whom latanoprost had been prescribed in unfixed combination with a β-blocker had the greatest mean percentage reduction in IOP at month 24, and the patients for whom latanoprost had been prescribed alone or in combination with a β-blocker were more likely to still be on initial therapy at month 24; the difference in persistence on therapy was statistically significant only in phase I (p = 0.001). The mean number of switches in therapy was smaller in phase I than in phase 2 in all therapy groups. Interpretation: Compared with other first- and second-line forms of therapy, treatment with latanoprost, alone or in combination with a β-blocker, was associated with greater reductions in IOP, better therapeutic persistence, fewer therapy switches and fewer ophthalmologist visits over a 2-year period. AD - L.M. Bernard, Innovus Research Inc., 1016-A Sutton Dr., Burlington, Ont. L7L 6B8, Canada AU - Tingey, D. AU - Bernard, L. M. AU - Grima, D. T. AU - Miller, B. AU - Lam, A. C1 - alphagan betagan betoptic cosopt timoptic xe trusopt xalatan DB - Embase Medline DO - 10.1016/S0008-4182(05)80027-4 IS - 2 KW - beta adrenergic receptor blocking agent betaxolol brimonidine dorzolamide dorzolamide plus timolol latanoprost levobunolol timolol maleate adult aged Canada cardiovascular disease comorbidity controlled study diabetes mellitus drug efficacy female gonioscopy health care utilization human hypertension intraocular hypertension intraocular pressure major clinical study male open angle glaucoma optic nerve perimetry prescription respiratory tract disease retrospective study review slit lamp tonometry visual acuity alphagan betagan betoptic cosopt timoptic xe trusopt xalatan LA - English M3 - Review N1 - L40676436 2005-05-30 PY - 2005 SN - 1715-3360 0008-4182 SP - 161-169 ST - Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension T2 - Canadian Journal of Ophthalmology TI - Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40676436&from=export http://dx.doi.org/10.1016/S0008-4182(05)80027-4 VL - 40 ID - 3707 ER - TY - JOUR AB - This study intended to evaluate the advantages of brimonidine tartrate 0.2% (Alphagan(R)), a selective alpha-2 receptor agonist, relaying a poorly tolerated beta-blocker treatment. Effectiveness, as assessed by intraocular pressure, local and general tolerance of the treatment, and the quality of life of the patients included in the study, was compared for these two eye drops. This multicenter and prospective study, performed by 450 ophthalmologists, included 807 adults presenting with glaucoma or ocular hypertony over 8 months. After a poorly tolerated beta-blocker treatment, which had started at least 6 months before, these patients received brimonidine over 8 weeks. At 3 successive visits, intraocular pressure, biomicroscopic examination results, and visual acuity were recorded. A quality-of-life questionnaire evaluating breathlessness, fatigue, depressive mood, loss of appetite, and satisfaction with the treatment was also given to patients. In the 731 patients observed in the study, the analysis concluded a statistically significant decrease in intraocular pressure (-2.5mmHg) and in the cardiovascular parameters during brimonidine treatment: blood pressure was reduced by 3mmHg and 1.1mmHg for systolic and diastolic pressure, respectively. The heart rate rose by 1.7 beats/min. The quality-of-life questionnaire revealed less breathlessness (-26%), fatigue (-24.9%), depressive mood (-19.3%), and better appetite (+8.2%). The feeling of satisfaction with the brimonidine treatment was significantly improved for 95 patients. However, 12% of all patients stopped their treatment because of adverse effects. Brimonidine improved the glaucomatous patients' quality of life, at least in some areas. Improved intraocular pressure could at least in part result from better compliance with the treatment. Brimonidine is an encouraging alternative after an unsatisfactory beta-blocker treatment. AN - WOS:000177458500001 AU - Titouamane, S. AU - Baudouin, C. DA - JUN IS - 6 PY - 2002 SN - 0181-5512 1773-0597 SP - 568-575 ST - Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment VL - 25 ID - 6295 ER - TY - JOUR AN - WOS:000488628104359 AU - Tiwana, M. S. AU - Kanu, L. AU - Dikopf, M. AU - Edward, D. DA - JUL IS - 9 PY - 2019 SN - 0146-0404 1552-5783 ST - Glaucoma Disease Characteristics and Outpatient Visit Adherence Among Prisoners T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - Glaucoma Disease Characteristics and Outpatient Visit Adherence Among Prisoners VL - 60 ID - 5999 ER - TY - JOUR AB - Purpose: A questionnaire was used to assess patient satisfaction with a switch from 0.5% timolol solution (TM) to 0.5% timolol gel-forming solution (TMXE) and to determine the effects of changing the medication on intraocular pressure (IOP) in patients with glaucoma. Methods: Compliance, convenience, sensation, and overall satisfaction with the new medication were assessed by sending questionnaires to 40 patients (23 males and 17 females) with glaucoma who had been followed at an outpatient glaucoma clinic in Osaka University Hospital. We also measured the patients' IOP during this period. Results: At 3 and 12 months after switching from TM to TMXE, IOP was significantly lower compared to before switching (p< 0.001), by a mean of 1.5±0.61mmHg (3 months) and 2.5±0.37mmHg (12 months). Patients reported improved compliance with and convenience of treatment with TMXE; however, 73% of patients reported that they did not like the sensation of TMXE and preferred the sensation of TM. Conclusions: Although 74.3% of patients reported that they did not like the sensation of TMXE, most patients reported that they would likely continue treatment with TMXE because it was more convenient. AD - Division of Ophthalmol., JR West Osaka Hosp., 1-2-22 Matsuzaki-cho, Abeno, Osaka 545-0002, Japan AU - Tokugawa, H. AU - Otori, Y. AU - Morimura, H. AU - Okada, M. AU - Tano, Y. DB - Scopus IS - 9 KW - Once-a-Day Eye Drop Questionnaire Timolol Timolol Gel-Forming Solution M3 - Article N1 - Export Date: 19 July 2021 PY - 2003 SP - 724-728 ST - Patient Satisfaction and Change in Intraocular Pressure with a Change from Timolol Solution to Timolol in Gel-Forming Solution T2 - Folia Ophthalmologica Japonica TI - Patient Satisfaction and Change in Intraocular Pressure with a Change from Timolol Solution to Timolol in Gel-Forming Solution UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0344873245&partnerID=40&md5=ff563b4d5babb975807ed752cdddc546 VL - 54 ID - 5782 ER - TY - JOUR AB - Purpose of review Despite a decrease in real average growth rates per capita since 2009, healthcare costs continue to rise worldwide. Numerous patient-related and doctor-related factors have contributed to this rise. Glaucoma is the leading cause of irreversible blindness and requires chronic, usually lifelong treatment. As with other chronic diseases, the adherence to prescribed treatment is often low and maybe influenced by the cost of the therapy. The purpose of this review is to seek potential solutions to best control the escalating costs of glaucoma care. Recent findings The studies we selected for this review can be divided into four different categories: costs of diagnostic tests; costs of direct comparisons between drugs or laser and conventional surgery; patient-related factors (such as adherence); and general aspects regarding costs: Theoretical models and calculations. Summary It is challenging to find reliable studies concerning this subject matter. As patients are under the umbrellas of variously organized healthcare systems which span different cultures, the costs between countries are difficult to compare. However, one common aspect to lower costs in glaucoma care is to improve patient adherence. Theoretical models with actual patient studies could enable cost reductions by comparing multiple diagnostic and therapeutic scenarios. AD - F. Meier-Gibbons, Eye Center Rapperswil, Rapperswil, Merkurstrasse 50, Rapperswil, Switzerland AU - Töteberg-Harms, M. AU - Berlin, M. S. AU - Meier-Gibbons, F. DB - Embase Medline DO - 10.1097/ICU.0000000000000343 IS - 2 KW - antiglaucoma agent brimonidine plus timolol dorzolamide plus timolol eye drops generic drug latanoprost plus timolol prescription drug advanced glaucoma calculation Canada cataract extraction childhood disease comparative study cost control cost effectiveness analysis demography diagnostic imaging diagnostic kit diagnostic test evaluation study glaucoma health care cost health care utilization health economics human intraocular hypertension laser surgery medicare medication compliance medication therapy management optical coherence tomography device patient compliance prescription priority journal review screening theoretical model trabeculoplasty treatment refusal United States Heidelberg LA - English M3 - Review N1 - L613159401 2016-11-15 2017-03-02 PY - 2017 SN - 1531-7021 1040-8738 SP - 127-132 ST - Increasing healthcare costs: Can we influence the costs of glaucoma care? T2 - Current Opinion in Ophthalmology TI - Increasing healthcare costs: Can we influence the costs of glaucoma care? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613159401&from=export http://dx.doi.org/10.1097/ICU.0000000000000343 VL - 28 ID - 2662 ER - TY - JOUR AB - Purpose Of Review: Despite a decrease in real average growth rates per capita since 2009, healthcare costs continue to rise worldwide. Numerous patient-related and doctor-related factors have contributed to this rise. Glaucoma is the leading cause of irreversible blindness and requires chronic, usually lifelong treatment. As with other chronic diseases, the adherence to prescribed treatment is often low and maybe influenced by the cost of the therapy. The purpose of this review is to seek potential solutions to best control the escalating costs of glaucoma care.Recent Findings: The studies we selected for this review can be divided into four different categories: costs of diagnostic tests; costs of direct comparisons between drugs or laser and conventional surgery; patient-related factors (such as adherence); and general aspects regarding costs: theoretical models and calculations.Summary: It is challenging to find reliable studies concerning this subject matter. As patients are under the umbrellas of variously organized healthcare systems which span different cultures, the costs between countries are difficult to compare. However, one common aspect to lower costs in glaucoma care is to improve patient adherence. Theoretical models with actual patient studies could enable cost reductions by comparing multiple diagnostic and therapeutic scenarios. VIDEO ABSTRACT: http://links.lww.com/COOP/A22. AD - Department of Ophthalmology, UniversityHospital Zurich, Zurich, Switzerland. Glaucoma Institute of Beverly Hills, West Hollywood, California, USA. University of California Los Angeles Stein Eye Institute, Los Angeles, California, USA. Eye Center Rapperswil, Rapperswil, Switzerland. AN - 121379894. Language: English. Entry Date: 20170320. Revision Date: 20191107. Publication Type: journal article. Journal Subset: Biomedical AU - Töteberg-Harms, Marc AU - Berlin, Michael S. AU - Meier-Gibbons, Frances DB - ccm DO - 10.1097/ICU.0000000000000343 DP - EBSCOhost IS - 2 KW - Health Care Costs Glaucoma -- Economics Economics, Pharmaceutical Health Care Delivery Antihypertensive Agents -- Economics Models, Theoretical Eye Surgery -- Economics Diagnosis, Eye -- Economics Patient Compliance N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM27828895. PY - 2017 SN - 1040-8738 SP - 127-132 ST - Increasing healthcare costs: can we influence the costs of glaucoma care? T2 - Current Opinion in Ophthalmology TI - Increasing healthcare costs: can we influence the costs of glaucoma care? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121379894&site=ehost-live&scope=site VL - 28 ID - 4265 ER - TY - JOUR AB - Purpose Of Review: For decades, laser trabeculoplasty has been a well-proven therapeutic option in glaucoma management, and more recently, it has only gained in popularity. One reason for such popularity is that selective laser trabeculoplasty (SLT) is a therapy independent of patient adherence, which is typically low among glaucoma patients. Consequently, the number of studies on SLT has multiplied throughout the past years. This review provides an overview of studies on SLT from the last 12 months.Recent Findings: The studies on treatment outcome show a wide range of success rates of SLT reaching between 18 and 88%; however, study designs differ and many studies are not directly comparable. The prospective laser trabeculoplasty for open-angle glaucoma and ocular hypertension (LiGHT) trial has demonstrated good efficacy of SLT - 75% of the eyes achieved their target pressure without drops and 58% after a single SLT.Summary: SLT has proven to be effective in lowering IOP with satisfactory success rates even after single SLT. SLT is repeatable independent of patient's adherence. AD - Department of Ophthalmology, University Hospital Zurich, Zurich Eye Center Rapperswil, Rapperswil, Switzerland AN - 148513735. Language: English. Entry Date: 20210223. Revision Date: 20210223. Publication Type: journal article AU - Töteberg-Harms, Marc AU - Meier-Gibbons, Frances DB - ccm DO - 10.1097/ICU.0000000000000732 DP - EBSCOhost IS - 2 KW - Anterior Eye Segment -- Surgery Glaucoma -- Surgery Laser Therapy -- Methods Trabeculectomy -- Methods Lasers -- Therapeutic Use Ocular Hypertension -- Surgery Ocular Hypertension -- Physiopathology Glaucoma -- Physiopathology Intraocular Pressure -- Physiology N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Wide Range Achievement Test (WRAT). NLM UID: 9011108. PMID: NLM33470670. PY - 2021 SN - 1040-8738 SP - 141-147 ST - Is laser trabeculoplasty the new star in glaucoma treatment? T2 - Current Opinion in Ophthalmology TI - Is laser trabeculoplasty the new star in glaucoma treatment? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148513735&site=ehost-live&scope=site VL - 32 ID - 4192 ER - TY - JOUR AN - WOS:000433205505116 AU - Tran, J. AU - Waisbourd, M. AU - Weiss, D. AU - Murchison, A. P. AU - Katz, L. J. AU - Spaeth, G. L. AU - Haller, J. A. AU - Hark, L. A. DA - APR IS - 13 PY - 2014 SN - 0146-0404 1552-5783 ST - The Effectiveness of a Tailored Intervention to Increase Follow-Up Adherence in Patients with Glaucoma T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - The Effectiveness of a Tailored Intervention to Increase Follow-Up Adherence in Patients with Glaucoma VL - 55 ID - 5969 ER - TY - JOUR AB - INTRODUCTION: The aim of this study was to evaluate the incidence of hyperaemia in patients using bimatoprost and to determine if simple interventions result in increased understanding of glaucoma and hyperaemia. METHODS: This was a multicentre, open-label, evaluator-masked clinical trial of 106 patients. Prior to enrolling in the trial, patients were washed out from any ocular hypotensive medications and prescribed bimatoprost daily in the evening for 6 weeks. Patients were randomised to one of two groups: intervention and no intervention. Patients in the intervention group (n=63) were given a fact sheet explaining the importance of reducing intraocular pressure (IOP) and the efficacy of bimatoprost, while patients in the no intervention group (n=43) were instructed only to instil bimatoprost daily and were given no additional instructions. RESULTS: As graded by the masked investigators, conjunctival hyperaemia peaked 1 day after commencing bimatoprost, with a mean of 1.2 (0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe). By day 7, hyperaemia levels were approximately trace (0.79) and continued to decrease throughout the study. There were no significant differences between groups in mean conjunctival hyperaemia at any study visit (P> or =0.215). At every visit, patients in the intervention group were significantly more likely than patients in the no intervention group to report that lowering IOP was very important for preserving vision (P< or =0.001). At week 6, 98% of patients in the intervention group reported that IOP-lowering was very important for preserving vision, compared with 76% of patients who did not receive the intervention (P< or =0.001). Patients in the intervention group were more likely than patients in the no intervention group to be willing to continue to use bimatoprost, despite hyperaemia. This difference was statistically significant at day 1 (P=0.003). CONCLUSION: Patients were not bothered by the trace.mild hyperaemia associated with bimatoprost therapy. Patient education can improve patient acceptance of a prescribed regimen and potentially increase compliance. AD - Center for Excellence in Eye Care, Baptist Medical Arts Building, East Tower, 8940 North Kendall Drive, Suite 400-E, Miami, FL 33176, USA. wtrattler@gmail.com AN - 105160807. Language: English. Entry Date: 20100409. Revision Date: 20200708. Publication Type: Journal Article AU - Trattler, W. AU - Noecker, R. J. AU - Earl, M. L. DB - ccm DO - 10.1007/s12325-008-0029-7 DP - EBSCOhost IS - 3 KW - Bimatoprost -- Therapeutic Use Hyperemia -- Chemically Induced Ocular Hypertension -- Drug Therapy Patient Education -- Methods Aged Bimatoprost -- Administration and Dosage Bimatoprost -- Adverse Effects Clinical Trials Female Glaucoma -- Drug Therapy Human Intraocular Pressure Male Patient Compliance N1 - clinical trial; research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8611864. PMID: NLM18351298. PY - 2008 SN - 0741-238X SP - 179-189 ST - A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension T2 - Advances in Therapy TI - A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105160807&site=ehost-live&scope=site VL - 25 ID - 4447 ER - TY - JOUR AB - Introduction: The aim of this study was to evaluate the incidence of hyperaemia in patients using bimatoprost and to determine if simple interventions result in increased understanding of glaucoma and hyperaemia. Methods: This was a multicentre, open-label, evaluator-masked clinical trial of 106 patients. Prior to enrolling in the trial, patients were washed out from any ocular hypotensive medications and prescribed bimatoprost daily in the evening for 6 weeks. Patients were randomised to one of two groups: intervention and no intervention. Patients in the intervention group (n = 63) were given a fact sheet explaining the importance of reducing intraocular pressure (IOP) and the efficacy of bimatoprost, while patients in the no intervention group (n = 43) were instructed only to instil bimatoprost daily and were given no additional instructions. Results: As graded by the masked investigators, conjunctival hyperaemia peaked 1 day after commencing bimatoprost, with a mean of 1.2 (0 = none, 0.5 = trace, 1 = mild, 2 = moderate, 3 = severe). By day 7, hyperaemia levels were approximately trace (0.79) and continued to decrease throughout the study. There were no significant differences between groups in mean conjunctival hyperaemia at any study visit (P ≥ 0.215). At every visit, patients in the intervention group were significantly more likely than patients in the no intervention group to report that lowering IOP was very important for preserving vision (P ≤ 0.001). At week 6, 98% of patients in the intervention group reported that IOP-lowering was very important for preserving vision, compared with 76% of patients who did not receive the intervention (P ≤ 0.001). Patients in the intervention group were more likely than patients in the no intervention group to be willing to continue to use bimatoprost, despite hyperaemia. This difference was statistically significant at day 1 (P = 0.003). Conclusion: Patients were not bothered by the trace-mild hyperaemia associated with bimatoprost therapy. Patient education can improve patient acceptance of a prescribed regimen and potentially increase compliance. © Springer Healthcare Communications 2008. AD - Center for Excellence in Eye Care, 8940 North Kendall Drive, Miami, FL 33176, United States University of Pittsburgh Medical College, Eye Center, Pittsburgh, PA, United States Innovative Medical and Epidemiologic Data Solutions, Riverside, CA, United States AU - Trattler, W. AU - Noecker, R. J. AU - Earl, M. L. DB - Scopus DO - 10.1007/s12325-008-0029-7 IS - 3 KW - Bimatoprost Compliance Glaucoma Hyperaemia Hypertension Open-angle M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2008 SP - 179-189 ST - A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension T2 - Advances in Therapy TI - A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-59249103750&doi=10.1007%2fs12325-008-0029-7&partnerID=40&md5=75593d151f2fff4bf854153adc7db922 VL - 25 ID - 5261 ER - TY - JOUR AB - Introduction: The aim of this study was to evaluate the incidence of hyperaemia in patients using bimatoprost and to determine if simple interventions result in increased understanding of glaucoma and hyperaemia. Methods: This was a multicentre, open-label, evaluator-masked clinical trial of 106 patients. Prior to enrolling in the trial, patients were washed out from any ocular hypotensive medications and prescribed bimatoprost daily in the evening for 6 weeks. Patients were randomised to one of two groups: intervention and no intervention. Patients in the intervention group (n=63) were given a fact sheet explaining the importance of reducing intraocular pressure (IOP) and the efficacy of bimatoprost, while patients in the no intervention group (n=43) were instructed only to instil bimatoprost daily and were given no additional instructions. Results: As graded by the masked investigators, conjunctival hyperaemia peaked 1 day after commencing bimatoprost, with a mean of 1.2 (0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe). By day 7, hyperaemia levels were approximately trace (0.79) and continued to decrease throughout the study. There were no significant differences between groups in mean conjunctival hyperaemia at any study visit (P=0.215). At every visit, patients in the intervention group were significantly more likely than patients in the no intervention group to report that lowering IOP was very important for preserving vision (P=0.001). At week 6, 98% of patients in the intervention group reported that IOP-lowering was very important for preserving vision, compared with 76% of patients who did not receive the intervention (P=0.001). Patients in the intervention group were more likely than patients in the no intervention group to be willing to continue to use bimatoprost, despite hyperaemia. This difference was statistically significant at day 1 (P=0.003). Conclusion: Patients were not bothered by the trace-mild hyperaemia associated with bimatoprost therapy. Patient education can improve patient acceptance of a prescribed regimen and potentially increase compliance. AN - WOS:000255873600001 AU - Trattler, W. AU - Noecker, R. J. AU - Earl, M. L. DA - MAR DO - 10.1007/s12325-008-0029-7 IS - 3 PY - 2008 SN - 0741-238X SP - 179-189 ST - A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension T2 - ADVANCES IN THERAPY TI - A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension VL - 25 ID - 6173 ER - TY - JOUR AB - Background: Resource utilisation and direct costs associated with glaucoma progression in Europe are unknown. As population progressively ages, the economic impact of the disease will increase. Methods: From a total of 1655 consecutive cases, the records of 194 patients were selected and stratified by disease severity. Record selection was based on diagnoses of primary open angle glaucoma, glaucoma suspect, ocular hypertension, or normal tension glaucoma; 5 years minimum follow up were required. Glaucoma severity was assessed using a six stage glaucoma staging system based on static threshold visual field parameters. Resource utilisation data were abstracted from the charts and unit costs were applied to estimate direct costs to the payer. Resource utilisation and estimated direct cost of treatment, per person year, were calculated. Results: A statistically significant increasing linear trend (p = 0.018) in direct cost as disease severity worsened was demonstrated. The direct cost of treatment increased by an estimated €86 for each incremental step ranging from €455 per person year for stage 0 to €969 per person year for stage 4 disease. Medication costs ranged from 42% to 56% of total direct cost for all stages of disease. Conclusions: These results demonstrate for the first time in Europe that resource utilisation and direct medical costs of glaucoma management increase with worsening disease severity. Based on these findings, managing glaucoma and effectively delaying disease progression would be expected to significantly reduce the economic burden of this disease. These data are relevant to general practitioners and healthcare administrators who have a direct influence on the distribution of resources. AD - C.E. Traverso, Glaucoma Service, Clinica Oculistica, Azienda Ospedale Università San Martino, 16132 Genova, Italy AU - Traverso, C. E. AU - Walt, J. G. AU - Kelly, S. P. AU - Hommer, A. H. AU - Bron, A. M. AU - Denis, P. AU - Nordmann, J. P. AU - Renard, J. P. AU - Bayer, A. AU - Grehn, F. AU - Pfeiffer, N. AU - Cedrone, C. AU - Gandolfi, S. AU - Orzalesi, N. AU - Nucci, C. AU - Rossetti, L. AU - Azuara-Blanco, A. AU - Bagnis, A. AU - Hitchings, R. AU - Salmon, J. F. AU - Bricola, G. AU - Buchholz, P. M. AU - Kotak, S. V. AU - Katz, L. M. AU - Siegartel, L. R. AU - Doyle, J. J. DB - Embase Medline DO - 10.1136/bjo.2005.067355 IS - 10 KW - adult aged article disease course disease severity Europe female follow up general practitioner glaucoma health care cost health care utilization human intraocular hypertension major clinical study male medical record open angle glaucoma priority journal statistical significance visual field LA - English M3 - Article N1 - L41638858 2005-12-27 PY - 2005 SN - 0007-1161 SP - 1245-1249 ST - Direct costs of glaucoma and severity of the disease: A multinational long term study of resource utilisation in Europe T2 - British Journal of Ophthalmology TI - Direct costs of glaucoma and severity of the disease: A multinational long term study of resource utilisation in Europe UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41638858&from=export http://dx.doi.org/10.1136/bjo.2005.067355 VL - 89 ID - 3664 ER - TY - JOUR AB - Purpose: The aim of this study was to compare rates of pharmacotherapy coverage in patients with ocular hypertension (OH) and patients with primary open-angle glaucoma (POAG). Methods: Retrospective cohort study analysis of a nationally representative, multimanaged health plan database (PharMetrics; 1998-2005) which included 4818 medicated OH patients and 52,985 medicated POAG patients with at least 1 year of continuous enrollment and at least one prescription for IOP-lowering medication during the first year of follow-up. Patients selected for the current study were nested within the cohort of OH patients (n = 36,767) and POAG patients (n =72,412) previously reported. Of the previously reported OH cohort, only 13.1% of patients filled at least one prescription, as compared to 73.2% of the previously reported POAG cohort. Medication coverage was defined as the percent of days during which a patient was in possession of IOP-lowering therapy over the first year of follow-up (medication coverage = number of covered days/365). Compliant patients were defined as those with ≥ 75th percentile medication coverage. Results: POAG patients had slightly longer mean length of enrollment in the database (2.5 years, SD = 1.2) than did OH patients (2.4 years, SD = 1.1; P < 0.0001). The mean medication coverage was 50% for the POAG cohort (SD = 0.26) and 40% for the OH cohort (SD = 0.25; P < 0.0001). In multivariate models controlling for key covariates of interest, POAG patients were 1.9 (95% CI: 1.7 to 2.0) times more likely to be compliant with their pharmacotherapy than OH patients. Conclusion: In general, pharmacotherapy coverage was poor. Patients with POAG, a more severe condition, were significantly more covered with pharmacotherapies than patients with OH. It is important to implement strategies to help improve patient coverage prior to occurrence of more severe disease. © Mary Ann Liebert, Inc. 2009. AD - L. S. Stern, Global Health Outcomes, Analytica International, 450 Park Avenue South, New York, NY 10016, United States AU - Traverso, C. E. AU - Walt, J. G. AU - Stern, L. S. AU - Dolgitser, M. DB - Embase Medline DO - 10.1089/jop.2008.0079 IS - 1 KW - adolescent adult aged article cohort analysis comorbidity controlled study female human intraocular hypertension intraocular pressure major clinical study male open angle glaucoma patient care patient compliance LA - English M3 - Article N1 - L354270839 2009-03-26 PY - 2009 SN - 1080-7683 SP - 77-82 ST - Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma T2 - Journal of Ocular Pharmacology and Therapeutics TI - Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354270839&from=export http://dx.doi.org/10.1089/jop.2008.0079 VL - 25 ID - 3379 ER - TY - JOUR AD - Centro di Ricerca Clinica e Laboratorio per il Glaucoma e la Cornea, Clinica Oculistica, Di.N.O.G., University of Genova, Genova, Italy. AN - 105467640. Language: English. Entry Date: 20090515. Revision Date: 20200708. Publication Type: Journal Article AU - Traverso, C. E. AU - Walt, J. G. AU - Stern, L. S. AU - Dolgitser, M. DB - ccm DO - 10.1089/jop.2008.0079 DP - EBSCOhost IS - 1 KW - Antihypertensive Agents -- Therapeutic Use Carbonic Anhydrase Inhibitors -- Therapeutic Use Glaucoma -- Drug Therapy Ocular Hypertension -- Drug Therapy Patient Compliance Aged Aged, 80 and Over Female Glaucoma -- Epidemiology Male Ocular Hypertension -- Epidemiology Prospective Studies Retrospective Design Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM19232009. PY - 2009 SN - 1080-7683 SP - 77-82 ST - Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma T2 - Journal of Ocular Pharmacology & Therapeutics TI - Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105467640&site=ehost-live&scope=site VL - 25 ID - 4468 ER - TY - JOUR AB - Purpose: The aim of this study was to compare rates of pharmacotherapy coverage in patients with ocular hypertension (OH) and patients with primary open-angle glaucoma (POAG). Methods: Retrospective cohort study analysis of a nationally representative, multimanaged health plan database (PharMetrics; 1998-2005) which included 4818 medicated OH patients and 52,985 medicated POAG patients with at least 1 year of continuous enrollment and at least one prescription for IOP-lowering medication during the first year of follow-up. Patients selected for the current study were nested within the cohort of OH patients (n = 36,767) and POAG patients (n =72,412) previously reported. Of the previously reported OH cohort, only 13.1% of patients filled at least one prescription, as compared to 73.2% of the previously reported POAG cohort. Medication coverage was defined as the percent of days during which a patient was in possession of IOP-lowering therapy over the first year of follow-up (medication coverage = number of covered days/365). Compliant patients were defined as those with ≥ 75th percentile medication coverage. Results: POAG patients had slightly longer mean length of enrollment in the database (2.5 years, SD = 1.2) than did OH patients (2.4 years, SD = 1.1; P < 0.0001). The mean medication coverage was 50% for the POAG cohort (SD = 0.26) and 40% for the OH cohort (SD = 0.25; P < 0.0001). In multivariate models controlling for key covariates of interest, POAG patients were 1.9 (95% CI: 1.7 to 2.0) times more likely to be compliant with their pharmacotherapy than OH patients. Conclusion: In general, pharmacotherapy coverage was poor. Patients with POAG, a more severe condition, were significantly more covered with pharmacotherapies than patients with OH. It is important to implement strategies to help improve patient coverage prior to occurrence of more severe disease. © Mary Ann Liebert, Inc. 2009. AD - Centro di Ricerca Clinica e Laboratorio Per Il Glaucoma e la Cornea, Clinica Oculistica, University of Genova, Genova, Italy Global Health Outcomes Strategy and Research, Allergan, Inc., Irvine, CA, United States Analytica International, New York, NY, United States Global Health Outcomes, Analytica International, 450 Park Avenue South, New York, NY 10016, United States AU - Traverso, C. E. AU - Walt, J. G. AU - Stern, L. S. AU - Dolgitser, M. DB - Scopus DO - 10.1089/jop.2008.0079 IS - 1 M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2009 SP - 77-82 ST - Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma T2 - Journal of Ocular Pharmacology and Therapeutics TI - Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-61749085074&doi=10.1089%2fjop.2008.0079&partnerID=40&md5=c90c857525a2c54b66412182664d0a6d VL - 25 ID - 5337 ER - TY - JOUR AB - Purpose: The aim of this study was to compare rates of pharmacotherapy coverage in patients with ocular hypertension (OH) and patients with primary open-angle glaucoma (POAG). Methods: Retrospective cohort study analysis of a nationally representative, multimanaged health plan database (PharMetrics; 1998-2005) which included 4818 medicated OH patients and 52,985 medicated POAG patients with at least 1 year of continuous enrollment and at least one prescription for IOP-lowering medication during the first year of follow-up. Patients selected for the current study were nested within the cohort of OH patients (n = 36,767) and POAG patients (n = 72,412) previously reported. Of the previously reported OH cohort, only 13.1% of patients filled at least one prescription, as compared to 73.2% of the previously reported POAG cohort. Medication coverage was defined as the percent of days during which a patient was in possession of IOP-lowering therapy over the first year of follow-up (medication coverage = number of covered days/365). Compliant patients were defined as those with >= 75th percentile medication coverage. Results: POAG patients had slightly longer mean length of enrollment in the database (2.5 years, SD = 1.2) than did OH patients (2.4 years, SD = 1.1; P < 0.0001). The mean medication coverage was 50% for the POAG cohort (SD = 0.26) and 40% for the OH cohort (SD = 0.25; P < 0.0001). In multivariate models controlling for key covariates of interest, POAG patients were 1.9 (95% CI: 1.7 to 2.0) times more likely to be compliant with their pharmacotherapy than OH patients. Conclusion: In general, pharmacotherapy coverage was poor. Patients with POAG, a more severe condition, were significantly more covered with pharmacotherapies than patients with OH. It is important to implement strategies to help improve patient coverage prior to occurrence of more severe disease. AN - WOS:000264197500010 AU - Traverso, C. E. AU - Walt, J. G. AU - Stern, L. S. AU - Dolgitser, M. DA - FEB DO - 10.1089/jop.2008.0079 IS - 1 PY - 2009 SN - 1080-7683 1557-7732 SP - 77-82 ST - Pharmacotherapy Compliance in Patients with Ocular Hypertension or Primary Open-Angle Glaucoma T2 - JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS TI - Pharmacotherapy Compliance in Patients with Ocular Hypertension or Primary Open-Angle Glaucoma VL - 25 ID - 5937 ER - TY - JOUR AB - Purpose: To determine the frequency and economic impact of changing initial glaucoma therapy for patients with newly diagnosed open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: This retrospective longitudinal cohort study identified individuals within a large managed care network in the United States, who were newly diagnosed with OAG or OHT from 2001 to 2012 and were prescribed either a topical beta blocker (BB) or a prostaglandin analog (PGA). Claims data were analyzed over the 12-month period following their index prescription to determine physician prescribing habits, healthcare resource utilization patterns, and sociodemographic factors which may have contributed to changing the initial treatment strategy. Results: A total of 15,019 beneficiaries were identified with newly diagnosed OAG or OHT and whose index therapy was either a topical BB or PGA. Among these enrollees 80.9% were started on PGAs, while 19.1% were started on BBs. Of these beneficiaries, 29.2% of those started on PGAs and 39.5% of those started on BBs underwent a change in therapy within 12 months of their index prescription. Those in the topical BB treatment group had a 38% increased odds of changing glaucoma therapy relative to those started on PGAs (odds ratio [OR] 0.61, 95% CI:0.56-0.68). Patients who changed therapy required more frequent office visits (P < 0.0001) and incurred higher median eye care related charges (P < 0.0001) compared to those who remained on the index therapy unchanged. Conclusions: Changing initial ocular hypotensive therapy is common. Individuals who undergo a change in therapy required more frequent face-to-face monitoring and incurred higher healthcare related costs. Identifying strategies capable of optimizing the process of initiating ocular hypotensive therapy are appealing and possess the potential to improve patient outcomes and reduce healthcare costs. AD - S.E. Moroi, Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, United States AU - Trese, M. G. J. AU - Lewis, A. W. AU - Blachley, T. S. AU - Stein, J. D. AU - Moroi, S. E. C2 - lpo DB - Embase Medline DO - 10.1089/jop.2017.0051 IS - 8 KW - beta adrenergic receptor blocking agent prostaglandin derivative adult age ambulatory care article Black person Caucasian clinical article cohort analysis drug cost ethnicity eye care female health care cost health care utilization Hispanic human income intraocular hypertension longitudinal study male managed care middle aged open angle glaucoma prescription retrospective study sex difference United States LA - English M3 - Article N1 - L618557683 2017-10-10 2018-06-01 PY - 2017 SN - 1557-7732 1080-7683 SP - 591-597 ST - Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization T2 - Journal of Ocular Pharmacology and Therapeutics TI - Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization UR - https://www.embase.com/search/results?subaction=viewrecord&id=L618557683&from=export http://dx.doi.org/10.1089/jop.2017.0051 VL - 33 ID - 2632 ER - TY - JOUR AB - Purpose: To determine the frequency and economic impact of changing initial glaucoma therapy for patients with newly diagnosed open-angle glaucoma (OAG) or ocular hypertension (OHT).Methods: This retrospective longitudinal cohort study identified individuals within a large managed care network in the United States, who were newly diagnosed with OAG or OHT from 2001 to 2012 and were prescribed either a topical beta blocker (BB) or a prostaglandin analog (PGA). Claims data were analyzed over the 12-month period following their index prescription to determine physician prescribing habits, healthcare resource utilization patterns, and sociodemographic factors which may have contributed to changing the initial treatment strategy.Results: A total of 15,019 beneficiaries were identified with newly diagnosed OAG or OHT and whose index therapy was either a topical BB or PGA. Among these enrollees 80.9% were started on PGAs, while 19.1% were started on BBs. Of these beneficiaries, 29.2% of those started on PGAs and 39.5% of those started on BBs underwent a change in therapy within 12 months of their index prescription. Those in the topical BB treatment group had a 38% increased odds of changing glaucoma therapy relative to those started on PGAs (odds ratio [OR] 0.61, 95% CI:0.56-0.68). Patients who changed therapy required more frequent office visits (P < 0.0001) and incurred higher median eye care related charges (P < 0.0001) compared to those who remained on the index therapy unchanged.Conclusions: Changing initial ocular hypotensive therapy is common. Individuals who undergo a change in therapy required more frequent face-to-face monitoring and incurred higher healthcare related costs. Identifying strategies capable of optimizing the process of initiating ocular hypotensive therapy are appealing and possess the potential to improve patient outcomes and reduce healthcare costs. AD - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan. Department of Ophthalmology, Beaumont Eye Institute, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan. San Antonio Military Health System, Lackland AFB, Texas. Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan. University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, Michigan. AN - 125431680. Language: English. Entry Date: 20180531. Revision Date: 20181001. Publication Type: journal article AU - Trese, Matthew G. J. AU - Lewis, Andrew W. AU - Blachley, Taylor S. AU - Stein, Joshua D. AU - Moroi, Sayoko E. DB - ccm DO - 10.1089/jop.2017.0051 DP - EBSCOhost IS - 8 KW - Adrenergic Beta-Antagonists -- Administration and Dosage Glaucoma -- Drug Therapy Ocular Hypertension -- Drug Therapy Prostaglandins, Synthetic -- Administration and Dosage Female Office Visits -- Statistics and Numerical Data Aged Health Care Costs -- Statistics and Numerical Data Prospective Studies Managed Care Programs -- Statistics and Numerical Data Adrenergic Beta-Antagonists -- Economics Retrospective Design Managed Care Programs -- Economics Prescriptions, Drug -- Statistics and Numerical Data Administration, Topical Glaucoma -- Economics United States Ocular Hypertension -- Economics Human Male Time Factors Prescriptions, Drug -- Economics Middle Age Prostaglandins, Synthetic -- Economics Validation Studies Comparative Studies Evaluation Research Multicenter Studies Impact of Events Scale Scales N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Berg Balance Scale; Impact of Events Scale (IES). NLM UID: 9511091. PMID: NLM28854348. PY - 2017 SN - 1080-7683 SP - 591-597 ST - Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization T2 - Journal of Ocular Pharmacology & Therapeutics TI - Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=125431680&site=ehost-live&scope=site VL - 33 ID - 4257 ER - TY - JOUR AB - Purpose: To determine the frequency and economic impact of changing initial glaucoma therapy for patients with newly diagnosed open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: This retrospective longitudinal cohort study identified individuals within a large managed care network in the United States, who were newly diagnosed with OAG or OHT from 2001 to 2012 and were prescribed either a topical beta blocker (BB) or a prostaglandin analog (PGA). Claims data were analyzed over the 12-month period following their index prescription to determine physician prescribing habits, healthcare resource utilization patterns, and sociodemographic factors which may have contributed to changing the initial treatment strategy. Results: A total of 15,019 beneficiaries were identified with newly diagnosed OAG or OHT and whose index therapy was either a topical BB or PGA. Among these enrollees 80.9% were started on PGAs, while 19.1% were started on BBs. Of these beneficiaries, 29.2% of those started on PGAs and 39.5% of those started on BBs underwent a change in therapy within 12 months of their index prescription. Those in the topical BB treatment group had a 38% increased odds of changing glaucoma therapy relative to those started on PGAs (odds ratio [OR] 0.61, 95% CI:0.56-0.68). Patients who changed therapy required more frequent office visits (P<0.0001) and incurred higher median eye care related charges (P<0.0001) compared to those who remained on the index therapy unchanged. Conclusions: Changing initial ocular hypotensive therapy is common. Individuals who undergo a change in therapy required more frequent face-to-face monitoring and incurred higher healthcare related costs. Identifying strategies capable of optimizing the process of initiating ocular hypotensive therapy are appealing and possess the potential to improve patient outcomes and reduce healthcare costs. AN - WOS:000412014100004 AU - Trese, M. G. J. AU - Lewis, A. W. AU - Blachley, T. S. AU - Stein, J. D. AU - Moroi, S. E. DA - OCT DO - 10.1089/jop.2017.0051 IS - 8 PY - 2017 SN - 1080-7683 1557-7732 SP - 591-597 ST - Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization T2 - JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS TI - Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization VL - 33 ID - 6106 ER - TY - JOUR AB - Purpose of review: To summarize recent literature regarding medication adherence with a focus on the complexities inherent in glaucoma management. Recent findings: Adherence to medications can be enhanced by undertaking the following strategies: enhanced patient education; improved dosing schedules; increased accessibility to healthcare (including longer hours, evening hours, and shorter wait times), and improved provider-patient relationships (e.g. increased trust). Patients may be less likely to forgo medication use due to cost pressures if the physician trust level is high. Recent studies suggest a role for baseline screening for adherence predictors and focused interventions in addressing modifiable risk factors for poor adherence (such as depression, stress, and lower education). Summary: Many factors are associated with the lack of medication adherence in patients. The solution is likely to be multidimensional and employ combination strategy (must be individualized for the patient). Educational interventions involving patients, family members, or both can be effective in improving adherence. © 2006 Lippincott Williams & Wilkins. AD - J.C. Tsai, Harkness Eye Institute, 635 West 165th St, New York, NY 10032, United States AU - Tsai, J. C. DB - Embase Medline DO - 10.1097/01.icu.0000193078.47616.aa IS - 2 KW - eye drops depression doctor patient relationship drug cost drug dose regimen ethnic or racial aspects glaucoma health care human patient compliance patient education prescription priority journal review risk factor screening social aspect social environment socioeconomics physiological stress LA - English M3 - Review N1 - L43790816 2006-06-07 PY - 2006 SN - 1040-8738 SP - 190-195 ST - Medication adherence in glaucoma: Approaches for optimizing patient compliance T2 - Current Opinion in Ophthalmology TI - Medication adherence in glaucoma: Approaches for optimizing patient compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43790816&from=export http://dx.doi.org/10.1097/01.icu.0000193078.47616.aa VL - 17 ID - 3619 ER - TY - JOUR AB - PURPOSE OF REVIEW: To summarize recent literature regarding medication adherence with a focus on the complexities inherent in glaucoma management. RECENT FINDINGS: Adherence to medications can be enhanced by undertaking the following strategies: enhanced patient education; improved dosing schedules; increased accessibility to healthcare (including longer hours, evening hours, and shorter wait times), and improved provider-patient relationships (e.g. increased trust). Patients may be less likely to forgo medication use due to cost pressures if the physician trust level is high. Recent studies suggest a role for baseline screening for adherence predictors and focused interventions in addressing modifiable risk factors for poor adherence (such as depression, stress, and lower education). SUMMARY: Many factors are associated with the lack of medication adherence in patients. The solution is likely to be multi-dimensional and employ combination strategy (must be individualized for the patient). Educational interventions involving patients, family members, or both can be effective in improving adherence. AD - Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA. AN - 104987715. Language: English. Entry Date: 20110218. Revision Date: 20150711. Publication Type: Journal Article AU - Tsai, James C. DB - ccm DP - EBSCOhost IS - 2 KW - Medication Compliance -- Evaluation Patient Compliance -- Evaluation Disease Management -- Methods Drug Administration Schedule Glaucoma -- Therapy Health Services Accessibility -- Evaluation Ophthalmology Patient Education -- Methods Physician-Patient Relations N1 - review. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9011108. PMID: NLM16552255. PY - 2006 SN - 1040-8738 SP - 190-195 ST - Medication adherence in glaucoma: approaches for optimizing patient compliance T2 - Current Opinion in Ophthalmology TI - Medication adherence in glaucoma: approaches for optimizing patient compliance UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104987715&site=ehost-live&scope=site VL - 17 ID - 4631 ER - TY - JOUR AB - TOPIC: Risk factors for poor adherence or nonadherence to topical glaucoma medication regimens. CLINICAL RELEVANCE: Poor adherence to glaucoma medication regimens may be associated with subsequent visual loss and irreversible optic nerve damage. METHODS: A literature search was performed using the words "glaucoma AND adherence AND risk" and "glaucoma AND compliance AND risk," limited to those studies in English and focused on care in the United States. Publications from well-regarded journals in this field were reviewed, and a focused summary of the literature is presented. RESULTS: There are a myriad of adherence barriers inherent to the glaucoma patient population. Although most of these obstacles are common in the elderly (e.g., reduced cognition, musculoskeletal problems, and transportation difficulties), older age has not been shown to be a consistent risk factor for poor adherence to glaucoma medication regimens. Other expected barriers, such as medication cost, limited health insurance, disease severity, and role of complicated dosing regimens, have varied effects based on the patient population studied and the definition of adherence. Poor medication adherence also is associated with decreased adherence to follow-up medical visit schedules. A systematic taxonomy of adherence barriers has been formulated. In addition, subanalyses from the Glaucoma Adherence and Persistency Study identified 8 variables that affect adherence to glaucoma medication regimens as well as several characteristics that support the importance of and associations between doctor-patient communications. CONCLUSIONS: Recent studies have provided valuable insights into the many factors that increase the risk(s) for poor adherence in patients prescribed glaucoma medications. Four major types of barriers to effective patient adherence (medication regimen, patient factors, provider factors, and situational or environmental factors) have been identified. Addressing these specific barriers will require a tailored, patient-centered approach. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. AD - J.C. Tsai, Department of Ophthalmology and Visual Science, Yale University School of Medicine, Yale Eye Center, New Haven, Connecticut 06510, USA. AU - Tsai, J. C. DB - Medline IS - 11 Suppl KW - antihypertensive agent eye drops attitude to health blindness drug administration drug cost economics educational status glaucoma health care delivery health education human patient compliance review risk factor statistics topical drug administration LA - English M3 - Review N1 - L355507626 2009-11-04 PY - 2009 SN - 1549-4713 SP - S30-36 ST - A comprehensive perspective on patient adherence to topical glaucoma therapy T2 - Ophthalmology TI - A comprehensive perspective on patient adherence to topical glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355507626&from=export VL - 116 ID - 3315 ER - TY - JOUR AB - TOPIC: Risk factors for poor adherence or nonadherence to topical glaucoma medication regimens. CLINICAL RELEVANCE: Poor adherence to glaucoma medication regimens may be associated with subsequent visual loss and irreversible optic nerve damage. METHODS: A literature search was performed using the words "glaucoma AND adherence AND risk" and "glaucoma AND compliance AND risk," limited to those studies in English and focused on care in the United States. Publications from well-regarded journals in this field were reviewed, and a focused summary of the literature is presented. RESULTS: There are a myriad of adherence barriers inherent to the glaucoma patient population. Although most of these obstacles are common in the elderly (e.g., reduced cognition, musculoskeletal problems, and transportation difficulties), older age has not been shown to be a consistent risk factor for poor adherence to glaucoma medication regimens. Other expected barriers, such as medication cost, limited health insurance, disease severity, and role of complicated dosing regimens, have varied effects based on the patient population studied and the definition of adherence. Poor medication adherence also is associated with decreased adherence to follow-up medical visit schedules. A systematic taxonomy of adherence barriers has been formulated. In addition, subanalyses from the Glaucoma Adherence and Persistency Study identified 8 variables that affect adherence to glaucoma medication regimens as well as several characteristics that support the importance of and associations between doctor-patient communications. CONCLUSIONS: Recent studies have provided valuable insights into the many factors that increase the risk(s) for poor adherence in patients prescribed glaucoma medications. Four major types of barriers to effective patient adherence (medication regimen, patient factors, provider factors, and situational or environmental factors) have been identified. Addressing these specific barriers will require a tailored, patient-centered approach. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. AD - Department of Ophthalmology and Visual Science, Yale University School of Medicine, Yale Eye Center, New Haven, Connecticut 06510, United States AU - Tsai, J. C. DB - Scopus DO - 10.1016/j.ophtha.2009.06.024 IS - 11 Suppl M3 - Review N1 - Cited By :147 Export Date: 19 July 2021 PY - 2009 SP - S30-36 ST - A comprehensive perspective on patient adherence to topical glaucoma therapy T2 - Ophthalmology TI - A comprehensive perspective on patient adherence to topical glaucoma therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350488938&doi=10.1016%2fj.ophtha.2009.06.024&partnerID=40&md5=3241eb4ba6d016d319b6301df5c368d9 VL - 116 ID - 4912 ER - TY - JOUR AB - Topic: Risk factors for poor adherence or nonadherence to topical glaucoma medication regimens. Clinical Relevance: Poor adherence to glaucoma medication regimens maybe associated with subsequent visual loss and irreversible optic nerve damage. Methods: A literature search was performed using the words "glaucoma AND adherence AND risk" and "glaucoma AND compliance AND risk," limited to those studies in English and focused on care in the United States. Publications from well-regarded journals in this field were reviewed, and a focused summary of the literature is presented. Results: There are a myriad of adherence barriers inherent to the glaucoma patient population. Although most of these obstacles are common in the elderly (e.g., reduced cognition, musculoskeletal problems, and transportation difficulties), older age has not been shown to be a consistent risk factor for poor adherence to glaucoma medication regimens. Other expected barriers, such as medication cost, limited health insurance, disease severity, and role of complicated dosing regimens, have varied effects based on the patient population studied and the definition of adherence. Poor medication adherence also is associated with decreased adherence to follow-up medical visit schedules. A systematic taxonomy of adherence barriers has been formulated. In addition, subanalyses from the Glaucoma Adherence and Persistency Study identified 8 variables that affect adherence to glaucoma medication regimens as well as several characteristics that support the importance of and associations between doctor-patient communications. Conclusions: Recent studies have provided valuable insights into the many factors that increase the risk(s) for poor adherence in patients prescribed glaucoma medications. Four major types of barriers to effective patient adherence (medication regimen, patient factors, provider factors, and situational or environmental factors) have been identified. Addressing these specific barriers will require a tailored, patient-centered approach. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009; 1 16:S30-S36 (C) 2009 by the American Academy of Ophthalmology. AN - WOS:000271291800002 AU - Tsai, J. C. DA - NOV DO - 10.1016/j.ophtha.2009.06.024 IS - 11 PY - 2009 SN - 0161-6420 SP - S30-S36 ST - A Comprehensive Perspective on Patient Adherence to Topical Glaucoma Therapy T2 - OPHTHALMOLOGY TI - A Comprehensive Perspective on Patient Adherence to Topical Glaucoma Therapy VL - 116 ID - 5840 ER - TY - JOUR AU - Tsai, J. C. AU - Flach, A. J. AU - Ing, M. R. AU - Stamper, R. L. AU - Kaufman, P. L. AU - Alvarado, J. A. DB - Scopus M3 - Note N1 - Export Date: 19 July 2021 PY - 2009 SP - 181-183 ST - Peer discussion T2 - Transactions of the American Ophthalmological Society TI - Peer discussion UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77949396890&partnerID=40&md5=54883a1448aefd0ed03dc30b354d1ed6 VL - 107 ID - 5765 ER - TY - JOUR AB - Purpose: To systematically identify and describe common obstacles to medication adherence (i.e., compliance) for patients with glaucoma. Methods: A prospective case series of structured interviews were conducted with 48 patients with glaucoma. The subjects' responses were recorded verbatim on interview forms as well as recorded on audiotapes. Situational obstacles to medication adherence were elicited. Using hierarchical cluster analysis, the situational descriptions were stratified, grouped, and analyzed by frequency distribution. Results: Seventy-one unique situational obstacles were reported. These were then grouped into 4 defined and separate categories: situational/environmental factors (35 of 71 situations; 49%), medication regimen (23 of 71; 32%), patient factors (11 of 71; 16%), and provider factors (2 of 71; 3%). Conclusion: Significant barriers to compliance exist for patients with glaucoma in addition to those cited by previous ophthalmic studies. A systematic classification (i.e., taxonomy) of these barriers was formulated to assist in optimizing patient education and problem-solving regarding prescribed therapeutic regimens. AD - J.C. Tsai, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia Univ. Coll. of Phys./Surgs., 635 West 165th Street, New York, NY 10032, United States AU - Tsai, J. C. AU - McClure, C. A. AU - Ramos, S. E. AU - Schlundt, D. G. AU - Pichert, J. W. DB - Embase Medline DO - 10.1097/00061198-200310000-00001 IS - 5 KW - antiglaucoma agent adult aged article classification clinical article cluster analysis drug dose regimen environmental factor female frequency analyzer glaucoma health care personnel human male medical record patient attitude patient compliance patient education priority journal problem solving process optimization prospective study statistical analysis statistical significance LA - English M3 - Article N1 - L37237370 2003-10-20 PY - 2003 SN - 1057-0829 SP - 393-398 ST - Compliance barriers in glaucoma: A systematic classification T2 - Journal of Glaucoma TI - Compliance barriers in glaucoma: A systematic classification UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37237370&from=export http://dx.doi.org/10.1097/00061198-200310000-00001 VL - 12 ID - 3794 ER - TY - JOUR AB - Purpose: Multiple factors can influence patients' adherence to topical ophthalmic intraocular pressure-lowering medications. An important factor that is often overlooked is the method of eye drop administration, including the handling, storing, and actual administering of eye drops. These aspects of patients' eye drop administration, which may be strongly related to the success of prescribed therapies, are evaluated. Methods: A 2-page questionnaire was distributed to 253 sequential glaucoma patients at the time of their regular clinical visit with one of two geographically distinct glaucoma specialists. In addition to providing demographic data, the patients were asked to complete a 2-page questionnaire about their current use of eye drops. Results: The study participants had a mean age of 71.5 years (SD, 15.1 years) and were predominantly female (59.8%) and white (72.6%). Approximately 17% of them relied on others for the administration of drops and most commonly cited inadequate vision and trouble with manual dexterity leading to this dependency. Of those who self-administered drops, only 16.3% used a mirror. The most common location for administration was the bedroom (46.8%), followed by the bathroom (23.4%) and kitchen (16.1%). Almost 16% reported "rarely" or "never" washing their hands. Conclusions: Although most individuals may have little difficulty with the use, storage, and handling of eye drops, this study demonstrates that broad variation in reported practices exists. This finding suggests a need for better instruction in eye drop administration and illuminates some of the methodological problems that could be overcome to reduce patients' frustration, improve compliance, and increase efficacy. AD - T. Tsai, Department of Ophthalmology, University of California, San Francisco, CA, United States AU - Tsai, T. AU - Robin, A. L. AU - Smith Iii, J. P. DB - Embase Medline KW - eye drops aged article drug efficacy evaluation study female glaucoma human male patient compliance patient education pilot study priority journal questionnaire LA - English M3 - Article N1 - L352031774 2008-09-23 PY - 2007 SN - 1545-6110 SP - 29-33 ST - An evaluation of how glaucoma patients use topical medications: A pilot study T2 - Transactions of the American Ophthalmological Society TI - An evaluation of how glaucoma patients use topical medications: A pilot study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352031774&from=export http://www.aosonline.org/xactions/2007/1545-6110_v105_p029.pdf VL - 105 ID - 3494 ER - TY - JOUR AB - Purpose: Multiple factors can influence patients' adherence to topical ophthalmic intraocular pressure-lowering medications. An important factor that is often overlooked is the method of eye drop administration, including the handling, storing, and actual administering of eye drops. These aspects of patients' eye drop administration, which may be strongly related to the success of prescribed therapies, are evaluated. Methods: A 2-page questionnaire was distributed to 253 sequential glaucoma patients at the time of their regular clinical visit with one of two geographically distinct glaucoma specialists. In addition to providing demographic data, the patients were asked to complete a 2-page questionnaire about their current use of eye drops. Results: The study participants had a mean age of 71.5 years (SD, 15.1 years) and were predominantly female (59.8%) and white (72.6%). Approximately 17% of them relied on others for the administration of drops and most commonly cited inadequate vision and trouble with manual dexterity leading to this dependency. Of those who self-administered drops, only 16.3% used a mirror. The most common location for administration was the bedroom (46.8%), followed by the bathroom (23.4%) and kitchen (16.1%). Almost 16% reported "rarely" or "never" washing their hands. Conclusions: Although most individuals may have little difficulty with the use, storage, and handling of eye drops, this study demonstrates that broad variation in reported practices exists. This finding suggests a need for better instruction in eye drop administration and illuminates some of the methodological problems that could be overcome to reduce patients' frustration, improve compliance, and increase efficacy. AD - Department of Ophthalmology, University of California, San Francisco, CA, United States Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, United States Department of International Health, Bloomberg School of Public Health, Johns Hopkins University AU - Tsai, T. AU - Robin, A. L. AU - Smith Iii, J. P. DB - Scopus M3 - Article N1 - Cited By :56 Export Date: 19 July 2021 PY - 2007 SP - 29-33 ST - An evaluation of how glaucoma patients use topical medications: A pilot study T2 - Transactions of the American Ophthalmological Society TI - An evaluation of how glaucoma patients use topical medications: A pilot study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-47749085042&partnerID=40&md5=4e2d174018caee4e69d0b4f96e688728 VL - 105 ID - 4980 ER - TY - JOUR AB - Purpose To estimate patient adherence with glaucoma therapy and identify factors associated with adherence using computerised patient prescribing records.MethodsIdentification of patients diagnosed with glaucoma, ocular hypertension or suspect glaucoma and/or prescribed topical glaucoma medications registered at a United Kingdom general practice with 13 422 patients. Adherence was defined as the average difference in the actual number of prescriptions collected annually compared to twelve prescriptions required annually (one bottle per month) over the duration of treatment.ResultsOverall, 278 patients were identified of which 139 (50%) were male. The average age was 72 years (range: 22-100). A total of 206 patients (74%) were prescribed glaucoma treatment. Adherence varied significantly between age groups with younger patients demonstrating poorest adherence (P=0.0347). There was no statistical difference when comparing medication class, diagnosis, co-morbidities, or the number of drops being taken.ConclusionsGlaucoma treatment adherence improves with increasing age. Older patients require more prescriptions and may be experiencing drop wastage. Younger patients should be targeted with educational interventions to improve their understanding of glaucoma, and older patients for drop technique review. General practices are well placed to provide such interventions. AD - A. Shaikh, Department of Ophthalmology, Stoke Mandeville Hospital, Mandeville Road, Aylesbury, Buckinghamshire, United Kingdom AU - Tse, A. P. AU - Shah, M. AU - Jamal, N. AU - Shaikh, A. DB - Embase Medline DO - 10.1038/eye.2016.103 IS - 8 KW - alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor eye drops prescription drug prostaglandin derivative adult age distribution aged article comorbidity controlled study female general practice glaucoma human intraocular hypertension major clinical study male medication compliance patient compliance practice guideline prescription Read code topical treatment treatment duration United Kingdom very elderly LA - English M3 - Article N1 - L611709106 2016-08-23 PY - 2016 SN - 1476-5454 0950-222X SP - 1118-1122 ST - Glaucoma treatment adherence at a United Kingdom general practice T2 - Eye (Basingstoke) TI - Glaucoma treatment adherence at a United Kingdom general practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611709106&from=export http://dx.doi.org/10.1038/eye.2016.103 VL - 30 ID - 2719 ER - TY - JOUR AB - Background: Glaucoma is a group of chronic diseases of the optic nerve that, if not managed effectively, could lead to blindness of many people worldwide. Non-adherence to medical treatments typically lead to burdensome consequences such as progressive visual loss and disabilities. Fortunately, literature reveals that with timed appropriate treatment, such blindness can be prevented. Thus, patients’ adherence to follow-up plays an important role in maintaining vision. However, glaucoma patients in Vhembe District still miss their follow-up appointments. Objective: This study sought to explore factors contributing to loss to follow-up as experienced by glaucoma patients in South Africa. Methods: Qualitative, explorative, and descriptive research designs, using qualitative methodology, were adopted. The population consisted of glaucoma patients who had been on antiglaucoma medications for three years and above. The purposive sampling method was used to select 18 participants for the study. Data were collected using a semi-structured interview using an interview guide. Participants were between the ages of 24 and 80 years. Tesch’s eight steps of qualitative data analysis were used. Measures to ensure trustworthiness and ethical issues were observed. Results: The study findings revealed that some of the patients did not understand glaucoma disease and the importance of follow-up. Financial constraints, traditional/religious belief, shortage of medications, and negative staff attitude were the most cited barriers contributing to loss to follow-up. Conclusion: Follow up adherence amongst glaucoma patients was negatively influenced by low disease knowledge. Therefore an improvement in patient education, transportation services, and clinic efficiency may strengthen follow-up visits. © 2020 Tshivhase and Khoza. AD - Department of Public Health, University of Venda, Thohoyandou, South Africa Department of Advanced Nursing, University of Venda, Thohoyandou, South Africa AU - Tshivhase, S. AU - Khoza, L. B. DB - Scopus DO - 10.2174/1874944502013010531 IS - 1 KW - Adherence Appointment follow-up Financial constraints Glaucoma follow-up Glaucoma patients Shortage of medications M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 531-537 ST - Challenges contributing to loss to follow-up as experienced by glaucoma patients in the Vhembe district of Limpopo Province, South Africa T2 - Open Public Health Journal TI - Challenges contributing to loss to follow-up as experienced by glaucoma patients in the Vhembe district of Limpopo Province, South Africa UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097675549&doi=10.2174%2f1874944502013010531&partnerID=40&md5=da0217f51784b16f53915b32a0fc90d8 VL - 13 ID - 5709 ER - TY - JOUR AB - Background: Glaucoma is associated with visual field loss for which elevated intraocular pressure is the primary risk factor. Proper medication adherence requires daily intake of prescribed medication for a lifetime. Non-adherence patients are at greater risk of poor outcome than adherent Aim: To identify behavioural determinants contributing to loss to follow-up amongst glaucoma patients. Setting: The study was conducted in selected hospitals of South Africa. Methods: A hospital-based cross-sectional study was conducted on glaucoma patients with age ranging from 18 years and above. Quantitative methods were used to collect data from purposefully selected glaucoma patients. Structured questionnaires were distributed to collect data from patients attending glaucoma clinics. The patients should have missed an appointment review at least once during the 12-month period. Results: Amongst the 429 glaucoma patients interviewed, the majority (79%, n = 341) of the patients missed their follow-up more than once during the 12-month period. The most cited contributory barriers to poor follow-up were accessibility (26%) followed by lack of escort and financial cost at 22% and 21%, respectively. About 115 of the 429 study respondents were found to be non-adherent. The main reasons given were shortage of medication and forgetfulness at 36% and 29%, respectively. Conclusion: Accessibility and lack of escort were significant barriers to loss to follow-up. Identifying the predictors of poor follow-up can help in improving follow-up care. Therefore, patient education and support may improve adherence to glaucoma therapy. © 2020. All Rights Reserved AD - Department of Public Health, Faculty of Health Science, University of Venda, Thohoyandou, South Africa Department of Advanced Nursing Science, Faculty of Health Science, University of Venda, Thohoyandou, South Africa AU - Tshivhase, S. E. AU - Khoza, L. B. AU - Tshitangano, T. G. DB - Scopus DO - 10.4102/aveh.v79i1.559 IS - 1 KW - glaucoma glaucoma patient intraocular pressure loss to follow-up medication adherence non-adherence. M3 - Article N1 - Export Date: 19 July 2021 PY - 2020 SP - 1-7 ST - Loss to follow-up amongst glaucoma patients in selected hospitals of the Limpopo Province, South Africa T2 - African Vision and Eye Health TI - Loss to follow-up amongst glaucoma patients in selected hospitals of the Limpopo Province, South Africa UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096799561&doi=10.4102%2faveh.v79i1.559&partnerID=40&md5=fecc4a0347b03f592a0da1b8beea6219 VL - 79 ID - 5710 ER - TY - JOUR AB - Background: Glaucoma is associated with visual field loss for which elevated intraocular pressure is the primary risk factor. Proper medication adherence requires daily intake of prescribed medication for a lifetime. Non-adherence patients are at greater risk of poor outcome than adherent patients. Aim: To identify behavioural determinants contributing to loss to follow-up amongst glaucoma patients. Setting: The study was conducted in selected hospitals of South Africa. Methods: A hospital-based cross-sectional study was conducted on glaucoma patients with age ranging from 18 years and above. Quantitative methods were used to collect data from purposefully selected glaucoma patients. Structured questionnaires were distributed to collect data from patients attending glaucoma clinics. The patients should have missed an appointment review at least once during the 12-month period. Results: Amongst the 429 glaucoma patients interviewed, the majority (79%, n = 341) of the patients missed their follow-up more than once during the 12-month period. The most cited contributory barriers to poor follow-up were accessibility (26%) followed by lack of escort and financial cost at 22% and 21%, respectively. About 115 of the 429 study respondents were found to be non-adherent. The main reasons given were shortage of medication and forgetfulness at 36% and 29%, respectively. Conclusion: Accessibility and lack of escort were significant barriers to loss to follow-up. Identifying the predictors of poor follow-up can help in improving follow-up care. Therefore, patient education and support may improve adherence to glaucoma therapy. AN - WOS:000657296700001 AU - Tshivhase, S. E. AU - Khoza, L. B. AU - Tshitangano, T. G. DA - OCT 28 DO - 10.4102/aveh.v79i1.559 IS - 1 PY - 2021 SN - 0378-9411 2410-3039 ST - Loss to follow-up amongst glaucoma patients in selected hospitals of the Limpopo Province, South Africa T2 - AFRICAN VISION AND EYE HEALTH JOURNAL TI - Loss to follow-up amongst glaucoma patients in selected hospitals of the Limpopo Province, South Africa VL - 79 ID - 5813 ER - TY - JOUR AB - Background: Rural populations comprise almost 20% of the US population and face unique barriers in receiving health care. We describe the implementation of a medical student-run free vision-screening clinic as a strategy to overcome barriers in accessing eye care in New Hampshire and Vermont. Methods: Medical students were trained by an ophthalmologist to administer screening eye examinations. Patients from New Hampshire and Vermont were enrolled through a free community clinic. Screening included a questionnaire, distance and near visual acuity, extraocular movements, confrontational visual fields, and Amsler grid. Patients who met predetermined screening criteria were referred to an ophthalmologist or optometrist for further evaluation. Data including patient demographics, appointment attendance, level of education, and diagnoses were recorded and analyzed. Results: Of 103 patients (mean age of 45.5±12.3 years, 63% female), 74/103 (72%) were referred for further evaluation, and 66/74 (89%) attended their referral appointments. Abnormal ophthalmologic examination findings were observed in 58/66 (88%) patients who attended their referral appointment. Uncorrected refractive error was the most common primary diagnosis in 38% of referred patients. Other diagnoses included glaucoma suspect (21%), retinal diseases (8%), amblyopia (8%), cataract (6%), others (6%), and normal examination (12%). Of the 8/74 (11%) referred patients who did not attend their appointments, reasons included patient cancellation of appointment, work conflicts, or forgetfulness. Patients traveled a mean distance of 16.6 miles (range: 0–50 miles) to attend screening examinations. Mean time for patients’ last effort to seek eye care was 7.1 years (range: 1–54 years). Conclusion: This study underscores the high prevalence of unmet eye care needs in a rural population. Furthermore, it demonstrates that using community health centers as a patient base for screening can yield a high referral attendance rate for this at-risk population and facilitate entrance into the eye care system in a rural setting. AD - E. Tsui, Department of Surgery, Dartmouth–Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, United States AU - Tsui, E. AU - Siedlecki, A. N. AU - Deng, J. AU - Pollard, M. C. AU - Cha, S. AU - Pepin, S. M. AU - Salcone, E. M. DB - Embase DO - 10.2147/OPTH.S90321 KW - adolescent adult age related macular degeneration aged amblyopia article cataract demography diabetic retinopathy education eye care eye examination eye movement female glaucoma health care access health program human keratoconus major clinical study male medical student night blindness ophthalmologist optic nerve disease patient referral pterygium questionnaire refraction error retina disease rural area United States vision screening program vision test visual acuity visual field LA - English M3 - Article N1 - L606339333 2015-10-20 2015-10-30 PY - 2015 SN - 1177-5483 1177-5467 SP - 1883-1887 ST - Implementation of a vision-screening program in rural northeastern United States T2 - Clinical Ophthalmology TI - Implementation of a vision-screening program in rural northeastern United States UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606339333&from=export http://dx.doi.org/10.2147/OPTH.S90321 VL - 9 ID - 2783 ER - TY - JOUR AB - Background: Rural populations comprise almost 20% of the US population and face unique barriers in receiving health care. We describe the implementation of a medical student-run free vision-screening clinic as a strategy to overcome barriers in accessing eye care in New Hampshire and Vermont. Methods: Medical students were trained by an ophthalmologist to administer screening eye examinations. Patients from New Hampshire and Vermont were enrolled through a free community clinic. Screening included a questionnaire, distance and near visual acuity, extraocular movements, confrontational visual fields, and Amsler grid. Patients who met predetermined screening criteria were referred to an ophthalmologist or optometrist for further evaluation. Data including patient demographics, appointment attendance, level of education, and diagnoses were recorded and analyzed. Results: Of 103 patients (mean age of 45.5±12.3 years, 63% female), 74/103 (72%) were referred for further evaluation, and 66/74 (89%) attended their referral appointments. Abnormal ophthalmologic examination findings were observed in 58/66 (88%) patients who attended their referral appointment. Uncorrected refractive error was the most common primary diagnosis in 38% of referred patients. Other diagnoses included glaucoma suspect (21%), retinal diseases (8%), amblyopia (8%), cataract (6%), others (6%), and normal examination (12%). Of the 8/74 (11%) referred patients who did not attend their appointments, reasons included patient cancellation of appointment, work conflicts, or forgetfulness. Patients traveled a mean distance of 16.6 miles (range: 0–50 miles) to attend screening examinations. Mean time for patients’ last effort to seek eye care was 7.1 years (range: 1–54 years). Conclusion: This study underscores the high prevalence of unmet eye care needs in a rural population. Furthermore, it demonstrates that using community health centers as a patient base for screening can yield a high referral attendance rate for this at-risk population and facilitate entrance into the eye care system in a rural setting. © 2015 Tsui et al. AD - Department of Surgery, Dartmouth–Hitchcock Medical Center, Lebanon, NH, United States Department of Ophthalmology, New York University School of Medicine, New York, NY, United States Geisel School of Medicine at Dartmouth, Hanover, NH, United States Section of Ophthalmology, Dartmouth–Hitchcock Medical Center, Lebanon, NH, United States AU - Tsui, E. AU - Siedlecki, A. N. AU - Deng, J. AU - Pollard, M. C. AU - Cha, S. AU - Pepin, S. M. AU - Salcone, E. M. DB - Scopus DO - 10.2147/OPTH.S90321 KW - Rural health Uninsured Vision screening M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2015 SP - 1883-1887 ST - Implementation of a vision-screening program in rural northeastern United States T2 - Clinical Ophthalmology TI - Implementation of a vision-screening program in rural northeastern United States UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944097716&doi=10.2147%2fOPTH.S90321&partnerID=40&md5=8509ff91804a22bb43487951fb001720 VL - 9 ID - 5568 ER - TY - JOUR AB - Background: Rural populations comprise almost 20% of the US population and face unique barriers in receiving health care. We describe the implementation of a medical student-run free vision-screening clinic as a strategy to overcome barriers in accessing eye care in New Hampshire and Vermont. Methods: Medical students were trained by an ophthalmologist to administer screening eye examinations. Patients from New Hampshire and Vermont were enrolled through a free community clinic. Screening included a questionnaire, distance and near visual acuity, extraocular movements, confrontational visual fields, and Amsler grid. Patients who met predetermined screening criteria were referred to an ophthalmologist or optometrist for further evaluation. Data including patient demographics, appointment attendance, level of education, and diagnoses were recorded and analyzed. Results: Of 103 patients (mean age of 45.5 +/- 12.3 years, 63% female), 74/103 (72%) were referred for further evaluation, and 66/74 (89%) attended their referral appointments. Abnormal ophthalmologic examination findings were observed in 58/66 (88%) patients who attended their referral appointment. Uncorrected refractive error was the most common primary diagnosis in 38% of referred patients. Other diagnoses included glaucoma suspect (21%), retinal diseases (8%), amblyopia (8%), cataract (6%), others (6%), and normal examination (12%). Of the 8/74 (11%) referred patients who did not attend their appointments, reasons included patient cancellation of appointment, work conflicts, or forgetfulness. Patients traveled a mean distance of 16.6 miles (range: 0-50 miles) to attend screening examinations. Mean time for patients' last effort to seek eye care was 7.1 years (range: 1-54 years). Conclusion: This study underscores the high prevalence of unmet eye care needs in a rural population. Furthermore, it demonstrates that using community health centers as a patient base for screening can yield a high referral attendance rate for this at-risk population and facilitate entrance into the eye care system in a rural setting. AN - WOS:000366370200001 AU - Tsui, E. AU - Siedlecki, A. N. AU - Deng, J. AU - Pollard, M. C. AU - Cha, S. AU - Pepin, S. M. AU - Salcone, E. M. DO - 10.2147/OPTH.S90321 PY - 2015 SN - 1177-5483 SP - 1883-1887 ST - Implementation of a vision-screening program in rural northeastern United States T2 - CLINICAL OPHTHALMOLOGY TI - Implementation of a vision-screening program in rural northeastern United States VL - 9 ID - 6226 ER - TY - JOUR AB - Introduction: Few reports have investigated the status of adherence in Japan on a large scale. We aimed to investigate the status of adherence to topical glaucoma treatment and its associated factors. Methods: A nationwide survey was conducted as a prospective fashion. Participants in this survey were subjects with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension or pseudoexfoliation glaucoma who had been prescribed anti-glaucoma ophthalmic eyedrops and whose ophthalmologist considered prescribing any fixed combination of ocular hypotensive eyedrops for the first time between 2011 and 2012. Subjects and their attending ophthalmologists independently completed a questionnaire by utilizing a fixed combination of ocular hypotensive eyedrops. Results: A total of 1358 ophthalmologists from 1071 medical institutions participated in this survey. We registered 4430 subjects (2049 males and 2381 females). In total, data from 3853 subjects (87.6%) were analyzed after inclusion of subjects based on inclusion and exclusion criteria. Good adherence was defined as not forgetting instillation during the past week. Rates of good adherence reported by subjects and ophthalmologists were 72.4 and 78.5%, respectively (P < 0.0001). The consistency of adherence evaluation between subjects and ophthalmologists was moderate [kappa score 0.5025 (95% confidence interval 0.4740–0.5309)]. Significant factors associated with adherence were size of clinic, age, gender, number of types of ocular hypotensive eyedrops, ease of instillation, preferred number of eyedrops, preferred frequency of instillation of eyedrops, and knowledge of glaucoma. Conclusion: Adherence to ocular hypotensive eyedrops among Japanese subjects was relatively good. Concordance of adherence between subjects’ reports and ophthalmologists’ responses was moderate. Size of clinic, number of types of ocular hypotensive eyedrops, ease of instillation, preferred number of eyedrops, preferred frequency of instillation of eyedrops, and knowledge of glaucoma were associated with adherence among Japanese glaucoma subjects. AD - K. Kashiwagi, Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, Japan AU - Tsumura, T. AU - Kashiwagi, K. AU - Suzuki, Y. AU - Yoshikawa, K. AU - Suzumura, H. AU - Maeda, T. AU - Takeda, R. AU - Saito, H. AU - Araie, M. DB - Embase Medline DO - 10.1007/s10792-018-0820-7 IS - 2 KW - eye drops aged article attitude to health female gender groups by age health survey human intraocular hypertension Japan major clinical study male open angle glaucoma ophthalmologist patient compliance patient preference prescription pseudoexfoliation questionnaire register LA - English M3 - Article N1 - L620667520 2018-02-16 2019-05-14 PY - 2019 SN - 1573-2630 0165-5701 SP - 375-383 ST - A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan T2 - International Ophthalmology TI - A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620667520&from=export http://dx.doi.org/10.1007/s10792-018-0820-7 VL - 39 ID - 2527 ER - TY - JOUR AB - Abstract: The development and implementation of innovation by healthcare providers is understood as a multi‐determinant and multi‐level process. Theories at different analytical levels (i.e. micro and organisational) are needed to capture the processes that influence innovation by providers. This article combines a micro theory of innovation, actor‐network theory, with organisational level processes using the ‘resource based view of the firm’. It examines the influence of, and interplay between, innovation‐seeking teams (micro) and underlying organisational capabilities (meso) during innovation processes. We used ethnographic methods to study service innovations in relation to ophthalmology services run by a specialist English NHS Trust at multiple locations. Operational research techniques were used to support the ethnographic methods by mapping the care process in the existing and redesigned clinics. Deficiencies in organisational capabilities for supporting innovation were identified, including manager‐clinician relations and organisation‐wide resources. The article concludes that actor‐network theory can be combined with the resource‐based view to highlight the influence of organisational capabilities on the management of innovation. Equally, actor‐network theory helps to address the lack of theory in the resource‐based view on the micro practices of implementing change. AD - Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK Centre for Healthcare Innovation & Improvement, School of Management, University of Bath, Bath, UK Clinical Operational Research Unit, University College London, London, UK NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK Department of Applied Health Research, University College London, London, UK AN - 129511930. Language: English. Entry Date: 20180511. Revision Date: 20190501. Publication Type: Article AU - Turner, Simon AU - Vasilakis, Christos AU - Utley, Martin AU - Foster, Paul AU - Kotecha, Aachal AU - Fulop, Naomi J. DB - ccm DO - 10.1111/1467-9566.12670 DP - EBSCOhost IS - 4 KW - Health Services Accessibility Glaucoma -- Therapy Technology, Medical Human Outpatient Service Ethnographic Research Interpersonal Relations N1 - research; tables/charts. Journal Subset: Biomedical; Europe; Peer Reviewed; Public Health; UK & Ireland. NLM UID: 8205036. PY - 2018 SN - 0141-9889 SP - 654-669 ST - Analysing barriers to service improvement using a multi‐level theory of innovation: the case of glaucoma outpatient clinics T2 - Sociology of Health & Illness TI - Analysing barriers to service improvement using a multi‐level theory of innovation: the case of glaucoma outpatient clinics UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129511930&site=ehost-live&scope=site VL - 40 ID - 4252 ER - TY - JOUR AB - The development and implementation of innovation by healthcare providers is understood as a multi-determinant and multi-level process. Theories at different analytical levels (i.e. micro and organisational) are needed to capture the processes that influence innovation by providers. This article combines a micro theory of innovation, actor-network theory, with organisational level processes using the ‘resource based view of the firm’. It examines the influence of, and interplay between, innovation-seeking teams (micro) and underlying organisational capabilities (meso) during innovation processes. We used ethnographic methods to study service innovations in relation to ophthalmology services run by a specialist English NHS Trust at multiple locations. Operational research techniques were used to support the ethnographic methods by mapping the care process in the existing and redesigned clinics. Deficiencies in organisational capabilities for supporting innovation were identified, including manager-clinician relations and organisation-wide resources. The article concludes that actor-network theory can be combined with the resource-based view to highlight the influence of organisational capabilities on the management of innovation. Equally, actor-network theory helps to address the lack of theory in the resource-based view on the micro practices of implementing change. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Turner, Simon, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, Manchester, United Kingdom, M13 9PL AN - 2018-21893-004 AU - Turner, Simon AU - Vasilakis, Christos AU - Utley, Martin AU - Foster, Paul AU - Kotecha, Aachal AU - Fulop, Naomi J. DB - psyh DO - 10.1111/1467-9566.12670 DP - EBSCOhost IS - 4 KW - healthcare innovation actor‐network theory resource-based view organisational ethnography process mapping ophthalmology NHS Ambulatory Care Facilities Anthropology, Cultural Delivery of Health Care Diffusion of Innovation Efficiency, Organizational Glaucoma Health Personnel Health Services Research Humans Organizational Innovation State Medicine United Kingdom Clinics Innovation Outpatient Treatment Quality of Services Optometry N1 - Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom. Other Publishers: Blackwell Publishing. Release Date: 20190627. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishGrant Information: Turner, Simon. Major Descriptor: Clinics; Innovation; Outpatient Treatment; Health Personnel; Quality of Services. Minor Descriptor: Optometry. Classification: Outpatient Services (3371). Population: Human (10); Outpatient (60). Location: England. Methodology: Empirical Study; Field Study; Interview; Qualitative Study. References Available: Y. Page Count: 16. Issue Publication Date: May, 2018. Copyright Statement: Sociology of Health & Illness published by John Wiley & Sons Ltd on behalf of Foundation for SHIL. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. The Authors. 2018. Sponsor: Special Trustees of Moorfields Eye Hospital. Grant: ST 12 09 D. Recipients: No recipient indicated Sponsor: National Institute for Health Research, Collaboration for Leadership in Applied Health Research and Care North Thames. Other Details: Bart’s Health NHS Trust. Recipients: Turner, Simon; Utley, Martin; Fulop, Naomi J. PY - 2018 SN - 0141-9889 1467-9566 SP - 654-669 ST - Analysing barriers to service improvement using a multi‐level theory of innovation: The case of glaucoma outpatient clinics T2 - Sociology of Health & Illness TI - Analysing barriers to service improvement using a multi‐level theory of innovation: The case of glaucoma outpatient clinics UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-21893-004&site=ehost-live&scope=site ORCID: 0000-0001-5306-6140 ORCID: 0000-0002-4755-177X ORCID: 0000-0001-9928-1516 ORCID: 0000-0002-0391-0910 ORCID: 0000-0002-1801-8351 s.turner@manchester.ac.uk VL - 40 ID - 4812 ER - TY - JOUR AU - Tuulonen, A. DB - Scopus DO - 10.1111/aos.12088 IS - 1 M3 - Editorial N1 - Cited By :5 Export Date: 19 July 2021 PY - 2013 SP - 3-5 ST - Challenges of glaucoma care - High volume, high quality, low cost T2 - Acta Ophthalmologica TI - Challenges of glaucoma care - High volume, high quality, low cost UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873041481&doi=10.1111%2faos.12088&partnerID=40&md5=5b2bc8e8cb371d8a20de3f1d6e460868 VL - 91 ID - 5427 ER - TY - JOUR AB - Purpose: The report describes the concepts behind procedures implemented in Tays Eye Centre to enable improved access to care and improved productivity. Methods: The strategy was developed in 2009 after hospital district decided to construct a new eye hospital which was opened in 2012. The following principles were implemented: (i) identification of high-volume patient groups: the ‘big four’ eye diseases accounting for 70% of patient visits and costs: age-related macular degeneration (AMD), glaucoma, retinal diseases and cataract; (ii) stratification and prioritization of patient care based on risk of permanent visual disability; (iii) standardization of services for low-risk patients; (iv) maximization of productivity; and (v) shared care. The impact of the new strategy on access to care and productivity is reported for years 2011–2015. Results: In 2011–2015, the total number of services provided increased 46% while the work contribution increased 15%. The number of referrals increased 76% and the number of outpatient appointments increased 2.5-fold. Simultaneously, the number of delayed follow-up visits decreased to zero. Age-related macular degeneration (AMD) injections increased 1.8-fold. However, after 50% yearly increase in Age-related macular degeneration (AMD) injections, a plateau was reached in 2014 with a 3% decline in 2014–2015 with no changes in treatment indications. In the beginning of 2016, the number of injections has started to increase again (+9% compared to 2015). The total number of surgical procedures increased 98%. The annual number of cataract surgeries increased 64% and bilateral surgeries from 11% to 39%. Conclusion: Revised operational concepts and new facilities together with a 15% increase in work contribution led to a 46% increase in overall productivity, improved access to care and the clearance of delayed services. Efforts continue to further refine cost-effective care and to define the appropriate levels of services. AD - A. Tuulonen, Tays Eye Centre, Tampere University Hospital, Tampere, Finland AU - Tuulonen, A. AU - Kataja, M. AU - Syvänen, U. AU - Miettunen, S. AU - Uusitalo, H. DB - Embase Medline DO - 10.1111/aos.13168 IS - 7 KW - age related macular degeneration article cataract cataract extraction eye disease glaucoma health care access health care cost health care planning human low risk patient patient care priority journal retina disease standardization surgical technique treatment indication visual impairment LA - English M3 - Article N1 - L611282019 2016-07-25 2016-11-10 PY - 2016 SN - 1755-3768 1755-375X SP - 730-735 ST - Right services to right patients at right time in right setting in Tays Eye Centre T2 - Acta Ophthalmologica TI - Right services to right patients at right time in right setting in Tays Eye Centre UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611282019&from=export http://dx.doi.org/10.1111/aos.13168 VL - 94 ID - 2694 ER - TY - JOUR AB - Purpose: The report describes the concepts behind procedures implemented in Tays Eye Centre to enable improved access to care and improved productivity. Methods: The strategy was developed in 2009 after hospital district decided to construct a new eye hospital which was opened in 2012. The following principles were implemented: (i) identification of high-volume patient groups: the ‘big four’ eye diseases accounting for 70% of patient visits and costs: age-related macular degeneration (AMD), glaucoma, retinal diseases and cataract; (ii) stratification and prioritization of patient care based on risk of permanent visual disability; (iii) standardization of services for low-risk patients; (iv) maximization of productivity; and (v) shared care. The impact of the new strategy on access to care and productivity is reported for years 2011–2015. Results: In 2011–2015, the total number of services provided increased 46% while the work contribution increased 15%. The number of referrals increased 76% and the number of outpatient appointments increased 2.5-fold. Simultaneously, the number of delayed follow-up visits decreased to zero. Age-related macular degeneration (AMD) injections increased 1.8-fold. However, after 50% yearly increase in Age-related macular degeneration (AMD) injections, a plateau was reached in 2014 with a 3% decline in 2014–2015 with no changes in treatment indications. In the beginning of 2016, the number of injections has started to increase again (+9% compared to 2015). The total number of surgical procedures increased 98%. The annual number of cataract surgeries increased 64% and bilateral surgeries from 11% to 39%. Conclusion: Revised operational concepts and new facilities together with a 15% increase in work contribution led to a 46% increase in overall productivity, improved access to care and the clearance of delayed services. Efforts continue to further refine cost-effective care and to define the appropriate levels of services. © 2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd AD - Tays Eye Centre, Tampere University Hospital, Tampere, Finland Research and Development Centre for Ophthalmic Innovations (SILK), Department of Ophthalmology, University of Tampere, Tampere, Finland AU - Tuulonen, A. AU - Kataja, M. AU - Syvänen, U. AU - Miettunen, S. AU - Uusitalo, H. DB - Scopus DO - 10.1111/aos.13168 IS - 7 KW - costs efficiency priority setting segmentation shared care standardization M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2016 SP - 730-735 ST - Right services to right patients at right time in right setting in Tays Eye Centre T2 - Acta Ophthalmologica TI - Right services to right patients at right time in right setting in Tays Eye Centre UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978485861&doi=10.1111%2faos.13168&partnerID=40&md5=fcdaba968a9a3e55f6ca2a51a955952b VL - 94 ID - 5247 ER - TY - JOUR AB - Purpose: The aims of this study were: (i) to create a structural simulation model capable of predicting the future need and cost of eyecare services in Finland; and (ii) to test and rank different policy alternatives for access to care and the required physician workforce. Methods: Using the system dynamics approach, the number and cost of patients with cataract, glaucoma, diabetic retinopathy and age-related macular degeneration (AMD) were described with causal-loop diagrams and were then translated into a set of mathematical equations to build a computer simulation model. Mathematically, the problem was formulated as a set of differential equations that were solved numerically with specialized software. The validity of the model was tested against prevalence and administrative historical data. The costs covered by the public sector in Finland were obtained from 2003 from the Finnish Hospital Discharge Register (including outpatient care), the Finnish Social Insurance Institution and a survey of hospital price lists. Different levels of access to public care were then simulated in four eye diseases, for which the model estimated the need for services and resources and their costs in the years 2005-2040. Results: The model forecasted that the adoption of the 2005 national 'access to care' criteria for cataract surgery would shorten waiting lists. If the workload of Finnish ophthalmologists were kept at the 2003 level, the graduation rate of new ophthalmologists would have to increase by 75% from the current level. If all glaucoma patients were followed in the public sector in future, even this increase in training would not meet the demand for physician workforce. The current model indicated that the screening frequency of diabetes can be increased without large sacrifices in terms of costs. AMD therapy has a significant role in the allocation of future resources in eyecare. The modelling study predicted that ageing alone will increase the costs of eyecare during the next four decades in Finland by about 1% per year in real terms (undiscounted and without inflation of unit costs). The increases in total yearly costs were on average 8.6% between 2001 and 2003. Conclusions: The results of this modelling study indicate that policy initiatives, such as defining criteria for access to care, can have substantial implications on the demand for care and waiting times whereas the effect of ageing alone was relatively small. Measures to control several other factors - such as the adoption and price level of new technologies, treatments and practice patterns - will be at least equally important in order to restrain healthcare costs effectively. © 2009 Acta Ophthalmol. AD - A. Tuulonen, Department of Ophthalmology, University of Oulu, PO Box 5000, FI-90014 Oulu, Finland AU - Tuulonen, A. AU - Salminen, H. AU - Linna, M. AU - Perkola, M. DB - Embase Medline DO - 10.1111/j.1755-3768.2009.01532.x IS - 8 KW - aging article cataract cataract extraction software computer simulation diabetes mellitus diabetic retinopathy eye care Finland glaucoma health care access health care cost hospital billing mathematical analysis prediction prevalence priority journal age related macular degeneration LA - English M3 - Article N1 - L358039257 2010-01-28 PY - 2009 SN - 1755-375X SP - 820-829 ST - The need and total cost of Finnish eyecare services: A simulation model for 2005-2040 T2 - Acta Ophthalmologica TI - The need and total cost of Finnish eyecare services: A simulation model for 2005-2040 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358039257&from=export http://dx.doi.org/10.1111/j.1755-3768.2009.01532.x VL - 87 ID - 3300 ER - TY - JOUR AB - Background: Blindness from glaucoma is prevalent in parts of Africa. Lack of awareness, late diagnosis, poor acceptance and compliance to treatment as well as unorthodox care practices are among many contributing factors. Strategies that improve glaucoma awareness and treatment acceptance are required to resolve this trend. Purpose: To evaluate the influence of counselling on glaucoma awareness, willingness to accept glaucoma surgery and eye care practices among primary open-angle glaucoma patients on medical treatment. Methods: A prospective cross-sectional interviewer-administered questionnaire-based study evaluating the demographics, glaucoma awareness, acceptance of operative care and use of traditional eye medications among patients with primary open-angle glaucoma on medical treatment followed up over a 12-month period. Results: A total of 120 eligible participants were recruited. Glaucoma awareness and basic knowledge were 93.3 and 12%, respectively. Educational attainment and positive family history were associated with glaucoma awareness (p = 0.027 and p = 0.042, respectively). Seventy-five (62.5%) participants accepted glaucoma surgery as a treatment option. However, the duration of medical treatment was inversely related to the acceptance of glaucoma surgery (odds ratio = − 0.390, p = 0.009). Twelve (10.5%) participants use traditional eye medication for their current eye problem. Conclusion: Glaucoma counselling should be performed with a content template that delivers all relevant information to patients and caregivers. This will bridge gaps in knowledge and improve the early presentation, acceptance of glaucoma surgery and eye care practices. © 2020, Springer Nature B.V. AD - Department of Ophthalmology, College of Medicine, University of Nigeria, Ituku/Ozalla Campus, Enugu, 400001, Nigeria Department of Ophthalmology, College of Medicine, ESUT, Parklane, Enugu, Nigeria Department of Surgery, College of Medicine, University of Nigeria, Ituku/Ozalla Campus, Enugu, Nigeria AU - Uche, N. J. AU - Udeh, N. N. AU - Chuka-Okosa, C. M. AU - Kizor-Akaraiwe, N. N. AU - Uche, E. O. DB - Scopus DO - 10.1007/s10792-020-01323-6 IS - 6 KW - Counselling practices Glaucoma awareness Glaucoma surgery Treatment acceptance M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - 1539-1546 ST - Glaucoma care and follow-up in sub-Saharan Africa: Is there a need for modification of counselling practices to improve awareness, knowledge and treatment acceptance profiles? A prospective cross-sectional study T2 - International Ophthalmology TI - Glaucoma care and follow-up in sub-Saharan Africa: Is there a need for modification of counselling practices to improve awareness, knowledge and treatment acceptance profiles? A prospective cross-sectional study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079623803&doi=10.1007%2fs10792-020-01323-6&partnerID=40&md5=11fe4cf81276e5428aa8e5eb47c47d0a VL - 40 ID - 5602 ER - TY - JOUR AB - Background Blindness from glaucoma is prevalent in parts of Africa. Lack of awareness, late diagnosis, poor acceptance and compliance to treatment as well as unorthodox care practices are among many contributing factors. Strategies that improve glaucoma awareness and treatment acceptance are required to resolve this trend. Purpose To evaluate the influence of counselling on glaucoma awareness, willingness to accept glaucoma surgery and eye care practices among primary open-angle glaucoma patients on medical treatment. Methods A prospective cross-sectional interviewer-administered questionnaire-based study evaluating the demographics, glaucoma awareness, acceptance of operative care and use of traditional eye medications among patients with primary open-angle glaucoma on medical treatment followed up over a 12-month period. Results A total of 120 eligible participants were recruited. Glaucoma awareness and basic knowledge were 93.3 and 12%, respectively. Educational attainment and positive family history were associated with glaucoma awareness (p = 0.027 and p = 0.042, respectively). Seventy-five (62.5%) participants accepted glaucoma surgery as a treatment option. However, the duration of medical treatment was inversely related to the acceptance of glaucoma surgery (odds ratio = - 0.390, p = 0.009). Twelve (10.5%) participants use traditional eye medication for their current eye problem. Conclusion Glaucoma counselling should be performed with a content template that delivers all relevant information to patients and caregivers. This will bridge gaps in knowledge and improve the early presentation, acceptance of glaucoma surgery and eye care practices. AN - WOS:000516345100002 AU - Uche, N. J. AU - Udeh, N. N. AU - Chuka-Okosa, C. M. AU - Kizor-Akaraiwe, N. N. AU - Uche, E. O. DA - JUN DO - 10.1007/s10792-020-01323-6 IS - 6 PY - 2020 SN - 0165-5701 1573-2630 SP - 1539-1546 ST - Glaucoma care and follow-up in sub-Saharan Africa: Is there a need for modification of counselling practices to improve awareness, knowledge and treatment acceptance profiles? A prospective cross-sectional study T2 - INTERNATIONAL OPHTHALMOLOGY TI - Glaucoma care and follow-up in sub-Saharan Africa: Is there a need for modification of counselling practices to improve awareness, knowledge and treatment acceptance profiles? A prospective cross-sectional study VL - 40 ID - 6027 ER - TY - JOUR AB - Background: The visual prognosis of Behçet's disease with rubeosis iridis is generally very poor and surgical treatment for Behçet's disease is controversial. We report a case of Behçet's disease with rubeosis iridis in which surgery had merit. Case Report: A 40-year-old male presented with vitritis in both eyes as a manifestation of Behçet's disease. Topical steroid and systemic colchicine were administered but the patient's compliance with therapy was poor. Rubeosis iridis, vitreous hemorrhage, and fibrous proliferation developed after several acute exacerbations. Visual acuity in the patient's right eye was hand motion and the intraocular pressure (IOP) in this eye was 10 mmHg. Pars plana vitrectomy, panretinal photocoagulation, and silicone oil tamponade, which was left in place for 6 months postoperatively, were performed. Rubeosis iridis disappeared by 10 days after surgery and best postoperative visual acuity in the right eye was 0.5. Visual acuity in the right eye decreased to 0.08 because of cataract formation. However, there was no serious recurrence or exacerbation of uveitis during 15 months of follow-up after the operation. Conclusion: This case suggests that the surgical treatment for Behçet's disease with rubeosis iridis may help to prevent rubeotic glaucoma and improve the visual prognosis. AD - Dept of Ophthalmol, School of Med, Univ of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan AU - Ueno, F. AU - Sakaguchi, Y. AU - Naito, T. AU - Shiota, H. DB - Scopus IS - 7 KW - Behçet's disease Rubeosis iridis Vitrectomy M3 - Conference Paper N1 - Export Date: 19 July 2021 PY - 2001 SP - 573-576 ST - A case of vitrectomy for Behçet's disease with rubeosis iridis T2 - Folia Ophthalmologica Japonica TI - A case of vitrectomy for Behçet's disease with rubeosis iridis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035204069&partnerID=40&md5=16a1953a898bb5847f60b37a1689022c VL - 52 ID - 5785 ER - TY - JOUR AB - A fuzzy knowledge base encapsulating core expert rules for glaucoma follow up is developed and subsequently refined into a standard of care by reconciling several expert opinions. The Learning from Examples (LFE) [1] technique is used in addition to expert interviews to generate fuzzy rules from numerical data, and soft competition defines a fuzzy consensus metrics for the expert opinions. Web-based extension of this system into a comprehensive set of e-Health services for the glaucoma community enables, besides wide accessibility of the expert knowledge, continuous improvement of the core rule set (standard of care) with the perspectives of several experts. AN - WOS:000226545500010 AU - Ulieru, M. AU - Crichton, A. C. S. AU - Rizzi, M. AU - Karanicolas, C. DA - NOV DO - 10.1007/s00500-003-0336-5 IS - 10 PY - 2004 SN - 1432-7643 1433-7479 SP - 705-716 ST - Using soft computing to define standards of care in glaucoma monitoring T2 - SOFT COMPUTING TI - Using soft computing to define standards of care in glaucoma monitoring VL - 8 ID - 6035 ER - TY - JOUR AB - The elderly population in the United States (age 65 and older) is growing rapidly, estimated by the U.S. Census Department to reach 83.7 million by 2050.1 Visual impairment increases with age among all racial and ethnic groups.2 In the elderly, the most common culprits for vision loss are cataract, glaucoma, and age-related macular degeneration (AMD).2 In the developed world, vision loss from cataract has been dramatically reduced by increased access to cataract surgery. However, AMD and glaucoma lead to irreversible vision loss without early diagnosis and intervention. In the U.S., cases of AMD are expected to double by 2050, reaching 17.8 million among patients age 50 or older.3 Similarly, cases of glaucoma are expected to reach 5.5 million by 2050, an increase of over 90% from 2014.3 The visually impaired elderly face disparities in access to eye care, and subsequent general medical and psychosocial complications. AD - M.A. Brantley, Vanderbilt Eye Institute, 2311 Pierce Avenue, Nashville, TN, United States AU - Umfress, A. C. AU - Brantley, M. A. DB - Embase Medline DO - 10.3109/08820538.2016.1154171 IS - 4 KW - age related macular degeneration aged cataract cataract extraction comorbidity disability eye care eye disease glaucoma health care access health care disparity human mortality priority journal review social psychology visual impairment LA - English M3 - Review N1 - L610792585 2016-06-20 2016-08-10 PY - 2016 SN - 1744-5205 0882-0538 SP - 432-438 ST - Eye Care Disparities and Health-Related Consequences in Elderly Patients with Age-Related Eye Disease T2 - Seminars in Ophthalmology TI - Eye Care Disparities and Health-Related Consequences in Elderly Patients with Age-Related Eye Disease UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610792585&from=export http://dx.doi.org/10.3109/08820538.2016.1154171 VL - 31 ID - 2725 ER - TY - JOUR AB - The elderly population in the United States (age 65 and older) is growing rapidly, estimated by the U.S. Census Department to reach 83.7 million by 2050.(1) Visual impairment increases with age among all racial and ethnic groups.(2) In the elderly, the most common culprits for vision loss are cataract, glaucoma, and age-related macular degeneration (AMD).(2) In the developed world, vision loss from cataract has been dramatically reduced by increased access to cataract surgery. However, AMD and glaucoma lead to irreversible vision loss without early diagnosis and intervention. In the U.S., cases of AMD are expected to double by 2050, reaching 17.8 million among patients age 50 or older.(3) Similarly, cases of glaucoma are expected to reach 5.5 million by 2050, an increase of over 90% from 2014.(3) The visually impaired elderly face disparities in access to eye care, and subsequent general medical and psychosocial complications. AD - Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA AN - 118941203. Language: English. Entry Date: 20170212. Revision Date: 20190516. Publication Type: journal article. Journal Subset: Biomedical AU - Umfress, Allison C. AU - Brantley, Milam A. DB - ccm DO - 10.3109/08820538.2016.1154171 DP - EBSCOhost IS - 4 KW - Eye Diseases -- Epidemiology Aging Vision Disorders -- Epidemiology Health Status Healthcare Disparities -- Statistics and Numerical Data Aged Aged, 80 and Over Disabled -- Statistics and Numerical Data Health Services Accessibility Scales N1 - Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Health-Related Hardiness Scale (HRHS). Grant Information: R01 EY022618/EY/NEI NIH HHS/United States. NLM UID: 8610759. PMID: NLM27116323. PY - 2016 SN - 0882-0538 SP - 432-438 ST - Eye Care Disparities and Health-Related Consequences in Elderly Patients with Age-Related Eye Disease T2 - Seminars in Ophthalmology TI - Eye Care Disparities and Health-Related Consequences in Elderly Patients with Age-Related Eye Disease UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118941203&site=ehost-live&scope=site VL - 31 ID - 4388 ER - TY - JOUR AB - Purpose: To assess the association between insufficient follow-up and clinical parameters such as disease severity and medication use among glaucoma patients at a metropolitan county hospital. Design: Cross-sectional study. Methods: Two-hundred and six patients with established glaucoma were recruited from San Francisco General Hospital. Subjects were classified based on compliance with recommended follow-up examination intervals over the year preceding commencement of the study, as determined by patient medical records. Glaucoma severity was determined based on the American Academy of Ophthalmology Preferred Practice Patterns guidelines. Multivariate logistic regression analysis was used to assess the relationship between adherence with follow-up visits and disease severity. Results: After adjustment for the impact of potential confounding variables, subjects with severe glaucomatous disease were found to have been less adherent to their recommended follow-up than those patients with mild or moderate glaucomatous disease (adjusted OR 1.89, 95% CI 1.21-2.94; P =.01). Subjects who were on glaucoma medications were found to be less adherent to follow-up recommendations (adjusted OR 3.29, 95% CI 1.41-7.65, P =.01). Conclusion: Subjects with poor follow-up adherence were significantly more likely to have severe glaucomatous disease, suggesting that poor follow-up may contribute to disease worsening or, alternatively, those with more severe disease are less inclined to follow up at appropriate intervals. © 2013 Elsevier Inc. All rights reserved. AD - S.C. Lin, 10 Koret Way, San Francisco, CA 94143-0730, United States AU - Ung, C. AU - Murakami, Y. AU - Zhang, E. AU - Alfaro, T. AU - Zhang, M. AU - Seider, M. I. AU - Singh, K. AU - Lin, S. C. DB - Embase Medline DO - 10.1016/j.ajo.2013.03.005 IS - 2 KW - adult article controlled study disease severity drug use female follow up glaucoma human major clinical study male patient compliance priority journal treatment outcome LA - English M3 - Article N1 - L52542169 2013-04-22 2013-08-03 PY - 2013 SN - 0002-9394 1879-1891 SP - 362-369 ST - The association between compliance with recommended follow-up and glaucomatous disease severity in a county hospital population T2 - American Journal of Ophthalmology TI - The association between compliance with recommended follow-up and glaucomatous disease severity in a county hospital population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52542169&from=export http://dx.doi.org/10.1016/j.ajo.2013.03.005 VL - 156 ID - 2980 ER - TY - JOUR AB - Purpose: To assess the association between insufficient follow-up and clinical parameters such as disease severity and medication use among glaucoma patients at a metropolitan county hospital.Design: Cross-sectional study.Methods: Two-hundred and six patients with established glaucoma were recruited from San Francisco General Hospital. Subjects were classified based on compliance with recommended follow-up examination intervals over the year preceding commencement of the study, as determined by patient medical records. Glaucoma severity was determined based on the American Academy of Ophthalmology Preferred Practice Patterns guidelines. Multivariate logistic regression analysis was used to assess the relationship between adherence with follow-up visits and disease severity.Results: After adjustment for the impact of potential confounding variables, subjects with severe glaucomatous disease were found to have been less adherent to their recommended follow-up than those patients with mild or moderate glaucomatous disease (adjusted OR 1.89, 95% CI 1.21-2.94; P = .01). Subjects who were on glaucoma medications were found to be less adherent to follow-up recommendations (adjusted OR 3.29, 95% CI 1.41-7.65, P = .01).Conclusion: Subjects with poor follow-up adherence were significantly more likely to have severe glaucomatous disease, suggesting that poor follow-up may contribute to disease worsening or, alternatively, those with more severe disease are less inclined to follow up at appropriate intervals. AD - Department of Ophthalmology, Stanford University School of Medicine, Stanford, California. AN - 104197104. Language: English. Entry Date: 20131108. Revision Date: 20200708. Publication Type: journal article AU - Ung, Cindy AU - Murakami, Yohko AU - Zhang, Elisa AU - Alfaro, Tatyana AU - Zhang, Monica AU - Seider, Michael I. AU - Singh, Kuldev AU - Lin, Shan C. DB - ccm DO - 10.1016/j.ajo.2013.03.005 DP - EBSCOhost IS - 2 KW - Continuity of Patient Care -- Statistics and Numerical Data Glaucoma -- Diagnosis Glaucoma -- Physiopathology Hospitals, Public -- Statistics and Numerical Data Patient Compliance Antihypertensive Agents -- Therapeutic Use Cross Sectional Studies Health Care Delivery Female Prospective Studies Glaucoma -- Drug Therapy Guideline Adherence Human Intraocular Pressure -- Drug Effects Intraocular Pressure -- Physiology Male Medication Compliance Middle Age Office Visits Questionnaires Severity of Illness Indices N1 - research. Journal Subset: Biomedical; USA. Grant Information: TLI RR025742/RR/NCRR NIH HHS/United States. NLM UID: 0370500. PMID: NLM23601654. PY - 2013 SN - 0002-9394 SP - 362-369 ST - The association between compliance with recommended follow-up and glaucomatous disease severity in a county hospital population T2 - American Journal of Ophthalmology TI - The association between compliance with recommended follow-up and glaucomatous disease severity in a county hospital population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104197104&site=ehost-live&scope=site VL - 156 ID - 4366 ER - TY - JOUR AB - Purpose: To assess the association between insufficient follow-up and clinical parameters such as disease severity and medication use among glaucoma patients at a metropolitan county hospital. Design: Cross-sectional study. Methods: Two-hundred and six patients with established glaucoma were recruited from San Francisco General Hospital. Subjects were classified based on compliance with recommended follow-up examination intervals over the year preceding commencement of the study, as determined by patient medical records. Glaucoma severity was determined based on the American Academy of Ophthalmology Preferred Practice Patterns guidelines. Multivariate logistic regression analysis was used to assess the relationship between adherence with follow-up visits and disease severity. Results: After adjustment for the impact of potential confounding variables, subjects with severe glaucomatous disease were found to have been less adherent to their recommended follow-up than those patients with mild or moderate glaucomatous disease (adjusted OR 1.89, 95% CI 1.21-2.94; P =.01). Subjects who were on glaucoma medications were found to be less adherent to follow-up recommendations (adjusted OR 3.29, 95% CI 1.41-7.65, P =.01). Conclusion: Subjects with poor follow-up adherence were significantly more likely to have severe glaucomatous disease, suggesting that poor follow-up may contribute to disease worsening or, alternatively, those with more severe disease are less inclined to follow up at appropriate intervals. © 2013 Elsevier Inc. All rights reserved. AD - Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, United States Department of Ophthalmology, University of California San Francisco, San Francisco, CA, United States AU - Ung, C. AU - Murakami, Y. AU - Zhang, E. AU - Alfaro, T. AU - Zhang, M. AU - Seider, M. I. AU - Singh, K. AU - Lin, S. C. DB - Scopus DO - 10.1016/j.ajo.2013.03.005 IS - 2 M3 - Article N1 - Cited By :23 Export Date: 19 July 2021 PY - 2013 SP - 362-369 ST - The association between compliance with recommended follow-up and glaucomatous disease severity in a county hospital population T2 - American Journal of Ophthalmology TI - The association between compliance with recommended follow-up and glaucomatous disease severity in a county hospital population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880570764&doi=10.1016%2fj.ajo.2013.03.005&partnerID=40&md5=4a3055797ca207907baf4a7a4dff4698 VL - 156 ID - 5107 ER - TY - JOUR AB - PURPOSE: To assess the association between insufficient follow-up and clinical parameters such as disease severity and medication use among glaucoma patients at a metropolitan county hospital. DESIGN: Cross-sectional study. METHODS: Two-hundred and six patients with established glaucoma were recruited from San Francisco General Hospital. Subjects were classified based on compliance with recommended follow-up examination intervals over the year preceding commencement of the study, as determined by patient medical records. Glaucoma severity was determined based on the American Academy of Ophthalmology Preferred Practice Patterns guidelines. Multivariate logistic regression analysis was used to assess the relationship between adherence with follow-up visits and disease severity. RESULTS: After adjustment for the impact of potential confounding variables, subjects with severe glaucomatous disease were found to have been less adherent to their recommended follow-up than those patients with mild or moderate glaucomatous disease (adjusted OR 1.89, 95% CI 1.21-2.94; P = .01). Subjects who were on glaucoma medications were found to be less adherent to follow-up recommendations (adjusted OR 3.29, 95% CI 1.41-7.65, P = .01). CONCLUSION: Subjects with poor follow-up adherence were significantly more likely to have severe glaucomatous disease, suggesting that poor follow-up may contribute to disease worsening or, alternatively, those with more severe disease are less inclined to follow up at appropriate intervals. Published by Elsevier Inc. AN - WOS:000322748200022 AU - Ung, C. AU - Murakami, Y. AU - Zhang, E. AU - Alfaro, T. AU - Zhang, M. AU - Seider, M. I. AU - Singh, K. AU - Lin, S. C. DA - AUG DO - 10.1016/j.ajo.2013.03.005 IS - 2 PY - 2013 SN - 0002-9394 SP - 362-369 ST - The Association Between Compliance With Recommended Follow-up and Glaucomatous Disease Severity in a County Hospital Population T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - The Association Between Compliance With Recommended Follow-up and Glaucomatous Disease Severity in a County Hospital Population VL - 156 ID - 5825 ER - TY - JOUR AD - K. Singh, Department of Ophthalmology, Stanford University, 2452 Watson Court, Palo Alto, CA, United States AU - Ung, C. AU - Spaeth, G. L. AU - Lin, S. C. AU - Singh, K. DB - Embase Medline DO - 10.1016/j.ajo.2015.08.026 IS - 6 KW - disease course disease severity disease surveillance editorial follow up glaucoma human medication compliance patient education priority journal treatment refusal visual impairment LA - English M3 - Editorial N1 - L606077972 2015-09-24 2016-04-13 PY - 2015 SN - 1879-1891 0002-9394 SP - 1089-1090e1 ST - Failure of Glaucoma Follow-up Compliance T2 - American Journal of Ophthalmology TI - Failure of Glaucoma Follow-up Compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606077972&from=export http://dx.doi.org/10.1016/j.ajo.2015.08.026 VL - 160 ID - 2862 ER - TY - JOUR AD - Department of Ophthalmology, Stanford University, School of Medicine, Stanford, CA, United States Glaucoma Service, Wills Eye Institute, Philadelphia, PA, United States Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, United States AU - Ung, C. AU - Spaeth, G. L. AU - Lin, S. C. AU - Singh, K. DB - Scopus DO - 10.1016/j.ajo.2015.08.026 IS - 6 M3 - Editorial N1 - Cited By :6 Export Date: 19 July 2021 PY - 2015 SP - 1089-1090.e1 ST - Failure of Glaucoma Follow-up Compliance T2 - American Journal of Ophthalmology TI - Failure of Glaucoma Follow-up Compliance UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942062672&doi=10.1016%2fj.ajo.2015.08.026&partnerID=40&md5=2df2a7b8801498fe43e85385cf9272c2 VL - 160 ID - 5383 ER - TY - JOUR AN - WOS:000365243400001 AU - Ung, C. AU - Spaeth, G. L. AU - Lin, S. C. AU - Singh, K. DA - DEC DO - 10.1016/j.ajo.2015.08.026 IS - 6 PY - 2015 SN - 0002-9394 1879-1891 SP - 1089-1090 ST - Failure of Glaucoma Follow-up Compliance T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Failure of Glaucoma Follow-up Compliance VL - 160 ID - 5829 ER - TY - JOUR AB - Objective: To assess the association between disease severity and adherence with glaucoma medications in a county hospital population. Design: Cross-sectional study. Participants: A total of 126 patients diagnosed with glaucoma receiving intraocular pressure (IOP)-lowering medication were recruited from the San Francisco General Hospital Ophthalmology Clinic. Methods: Subjects completed an oral questionnaire to assess demographic information, knowledge of glaucoma, and perceptions of glaucoma medication adherence. Glaucoma disease severity was classified according to the American Academy of Ophthalmology's Preferred Practice Pattern guidelines. Medication adherence was measured for each patient by obtaining pharmacy refill data and calculating medication possession ratio (MPR), that is, the ratio of total days' supply of medication during a 365-day period. Adherence was measured retrospectively over the 18-month period before study entry. Subjects with an MPR >80% were considered adherent. Main Outcome Measure: Medication adherence. Results: Subjects with mild or moderate glaucoma were more likely to be nonadherent to their prescribed glaucoma medications than those with severe disease (adjusted odds ratio [OR], 1.54; 95% confidence interval [CI], 1.03-2.31; P = 0.04). Age, gender, race, education level, years of glaucoma, number of medications, and glaucoma diagnosis were not found to be statistically significantly associated with adherence. Conclusion: Patients with severe glaucoma were more likely to adhere to their topical IOP-lowering medication regimen than those with milder glaucomatous disease. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2013 American Academy of Ophthalmology. AD - S.C. Lin, 10 Koret Way, San Francisco, CA 94143-0730, United States AU - Ung, C. AU - Zhang, E. AU - Alfaro, T. AU - Murakami, Y. AU - Zhang, M. AU - Seider, M. I. AU - Lin, S. C. AU - Singh, K. DB - Embase Medline DO - 10.1016/j.ophtha.2012.11.026 IS - 6 KW - alpha adrenergic receptor stimulating agent antihypertensive agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor prostaglandin adult article closed angle glaucoma cross-sectional study disease severity female glaucoma human intraocular pressure low tension glaucoma major clinical study male medication compliance open angle glaucoma patient compliance prescription priority journal public hospital LA - English M3 - Article N1 - L52466612 2013-03-04 2013-06-14 PY - 2013 SN - 0161-6420 1549-4713 SP - 1150-1157 ST - Glaucoma Severity and Medication Adherence in a County Hospital Population T2 - Ophthalmology TI - Glaucoma Severity and Medication Adherence in a County Hospital Population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52466612&from=export http://dx.doi.org/10.1016/j.ophtha.2012.11.026 VL - 120 ID - 2999 ER - TY - JOUR AB - Ambulatory pharmacotherapy is marked by many deviations, mostly downward, in drug dosing from prescribed instructions. Soundly compiled dosing histories date from 1977, based on electronic time-stamping of medication 'events': package entry times, done first with eyedrop dispensers for glaucoma drugs. Electronically monitored packages for oral dosage forms date from 1988. Since then, expanding data have brought many surprises, as evidence has replaced eminence in clinical views regarding discrepancies between prescription and reality. Key features of electronic monitoring are: automaticity of time-stamping, inviolable data, and high rates of data-sampling (60/hr vs 2-12/yr with older methods), revealing time-of-day, day-of-week, and white coat effects that facilitate medication management, opening new ways to improve care. © 2010 by Verlag Hans Huber, Hogrefe AG, Bern. AD - J. Demonceau, AARDEX Group, Pharmionic Systems Ltd, Rue de Cyclistes Frontière 24, BE-4600 Visé, Belgium AU - Urquhart, J. AU - Demonceau, J. AU - Vrijens, B. DB - Embase Medline DO - 10.1024/0040-5930/a000052 IS - 6 KW - drug packaging glaucoma health care human patient compliance patient monitoring prescription short survey LA - German M3 - Short Survey N1 - L358925587 2010-06-10 2010-06-18 PY - 2010 SN - 0040-5930 SP - 289-292 ST - Compliance, concordance, adherence T2 - Therapeutische Umschau TI - Compliance, concordance, adherence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358925587&from=export http://dx.doi.org/10.1024/0040-5930/a000052 http://www.verlag-hanshuber.com/zeitschriften/servepdf.php?abbrev=TUM&show=fulltext&year=2010&issue=6&file=TUM067060289.pdf VL - 67 ID - 3246 ER - TY - JOUR AB - Background: Refractory non-infectious uveitis is a serious condition that leads to ocular complications and vision loss and requires effective systemic treatment to control disease. The effectiveness of long-term infliximab [IFX] in refractory non-infectious childhood uveitis and the impact of treatment adherence on disease control were evaluated. Methods: Retrospective, single-center study between December 2002 and April 2016 of 27 children with refractory non-infectious uveitis [17 with juvenile idiopathic arthritis, JIA] treated with long-term IFX [9+ months]. Disease activity was assessed prior to and while on IFX using the Standardization of Uveitis Nomenclature [SUN]. Number of visits per year with active uveitis was analyzed by repeated measures logistic regression analysis from 2 years prior to IFX initiation or from onset of uveitis until most recent visit on IFX. Incomplete treatment adherence was assessed for each visit and defined as any deviance in corticosteroid use, prescribed infusion frequency, and/or follow-up examination frequency. Results: Primary outcomes were sustained uveitic and systemic disease control prior to and during IFX treatment and the impact of incomplete adherence on uveitic disease control while on IFX. Secondary outcomes included corticosteroid and glaucoma medication requirement, ocular complications and need for surgical intervention. Mean age at IFX initiation was 10.4 ± 4.5 years; initial mean dose was 6.6 ± 2.2 mg/kg [and given at weeks 0, 2, 4 and q4 weeks thereafter for 93%]. Median duration on IFX was 35 [range 9-128] months. Prior to IFX, 14/27 patients had failed adalimumab ± methotrexate [MTX]; 21/27 failed MTX. IFX led to uveitis control in 89% and arthritis control in 76% (13/17). The odds ratio of having controlled disease after IFX was 4.1 (2.6, 6.4) compared to pre-treatment visits. Topical corticosteroids and glaucoma medications were statistically decreased (p = 0.007 right eye [OD], 0.003 left eye [OS] and p = 0.001 OD, p = 0.028 OS respectively). Incomplete adherence to treatment showed 10.3 times greater odds (7.1, 15.0) of having disease activity than full adherence. Conclusions: This study adds significantly to the IFX literature by documenting outstanding uveitis control with long-term IFX treatment in non-infectious pediatric uveitis patients. Higher dosage and shorter interval were utilized without adverse effects. Importantly, this is the first study, to our knowledge, to document the significant impact of treatment adherence on uveitis control. AD - V.M. Utz, Abrahamson Pediatric Eye Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States AU - Utz, V. M. AU - Bulas, S. AU - Lopper, S. AU - Fenchel, M. AU - Sa, T. AU - Mehta, M. AU - Ash, D. AU - Lovell, D. J. AU - Kaufman, A. H. DB - Embase Medline DO - 10.1186/s12969-019-0383-9 IS - 1 KW - adalimumab antiglaucoma agent difluprednate infliximab methotrexate prednisolone acetate article band keratopathy cataract child clinical article controlled study disease activity disease assessment disease control drug effect female follow up human hypotension juvenile rheumatoid arthritis long term care male medication compliance outcome assessment patient compliance prescription priority journal retina macula cystoid edema retrospective study school child standardization treatment duration treatment outcome uveitis LA - English M3 - Article N1 - L629996385 2019-12-10 2019-12-16 PY - 2019 SN - 1546-0096 ST - Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis T2 - Pediatric Rheumatology TI - Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629996385&from=export http://dx.doi.org/10.1186/s12969-019-0383-9 VL - 17 ID - 2471 ER - TY - JOUR AB - Background: Refractory non-infectious uveitis is a serious condition that leads to ocular complications and vision loss and requires effective systemic treatment to control disease. The effectiveness of long-term infliximab [IFX] in refractory non-infectious childhood uveitis and the impact of treatment adherence on disease control were evaluated. Methods: Retrospective, single-center study between December 2002 and April 2016 of 27 children with refractory non-infectious uveitis [17 with juvenile idiopathic arthritis, JIA] treated with long-term IFX [9+ months]. Disease activity was assessed prior to and while on IFX using the Standardization of Uveitis Nomenclature [SUN]. Number of visits per year with active uveitis was analyzed by repeated measures logistic regression analysis from 2 years prior to IFX initiation or from onset of uveitis until most recent visit on IFX. Incomplete treatment adherence was assessed for each visit and defined as any deviance in corticosteroid use, prescribed infusion frequency, and/or follow-up examination frequency. Results: Primary outcomes were sustained uveitic and systemic disease control prior to and during IFX treatment and the impact of incomplete adherence on uveitic disease control while on IFX. Secondary outcomes included corticosteroid and glaucoma medication requirement, ocular complications and need for surgical intervention. Mean age at IFX initiation was 10.4 ± 4.5 years; initial mean dose was 6.6 ± 2.2 mg/kg [and given at weeks 0, 2, 4 and q4 weeks thereafter for 93%]. Median duration on IFX was 35 [range 9-128] months. Prior to IFX, 14/27 patients had failed adalimumab ± methotrexate [MTX]; 21/27 failed MTX. IFX led to uveitis control in 89% and arthritis control in 76% (13/17). The odds ratio of having controlled disease after IFX was 4.1 (2.6, 6.4) compared to pre-treatment visits. Topical corticosteroids and glaucoma medications were statistically decreased (p = 0.007 right eye [OD], 0.003 left eye [OS] and p = 0.001 OD, p = 0.028 OS respectively). Incomplete adherence to treatment showed 10.3 times greater odds (7.1, 15.0) of having disease activity than full adherence. Conclusions: This study adds significantly to the IFX literature by documenting outstanding uveitis control with long-term IFX treatment in non-infectious pediatric uveitis patients. Higher dosage and shorter interval were utilized without adverse effects. Importantly, this is the first study, to our knowledge, to document the significant impact of treatment adherence on uveitis control. © 2019 The Author(s). AD - Abrahamson Pediatric Eye Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, United States Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States Gavin Herbert Eye Institute, University of California, Irvine, CA, United States Department of Medicine, University of Chicago, Chicago, IL, United States Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States Cincinnati Eye Institute, Cincinnati, OH, United States AU - Utz, V. M. AU - Bulas, S. AU - Lopper, S. AU - Fenchel, M. AU - Sa, T. AU - Mehta, M. AU - Ash, D. AU - Lovell, D. J. AU - Kaufman, A. H. C7 - 79 DB - Scopus DO - 10.1186/s12969-019-0383-9 IS - 1 KW - Biologic response modifier Infliximab Iridocyclitis Iritis Treatment adherence Uveitis M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2019 ST - Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis T2 - Pediatric Rheumatology TI - Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075789549&doi=10.1186%2fs12969-019-0383-9&partnerID=40&md5=8be7f24b16e40906ccb8a1ba2cfc4af5 VL - 17 ID - 5343 ER - TY - JOUR AB - Background Refractory non-infectious uveitis is a serious condition that leads to ocular complications and vision loss and requires effective systemic treatment to control disease. The effectiveness of long-term infliximab [IFX] in refractory non-infectious childhood uveitis and the impact of treatment adherence on disease control were evaluated. Methods Retrospective, single-center study between December 2002 and April 2016 of 27 children with refractory non-infectious uveitis [17 with juvenile idiopathic arthritis, JIA] treated with long-term IFX [9+ months]. Disease activity was assessed prior to and while on IFX using the Standardization of Uveitis Nomenclature [SUN]. Number of visits per year with active uveitis was analyzed by repeated measures logistic regression analysis from 2 years prior to IFX initiation or from onset of uveitis until most recent visit on IFX. Incomplete treatment adherence was assessed for each visit and defined as any deviance in corticosteroid use, prescribed infusion frequency, and/or follow-up examination frequency. Results Primary outcomes were sustained uveitic and systemic disease control prior to and during IFX treatment and the impact of incomplete adherence on uveitic disease control while on IFX. Secondary outcomes included corticosteroid and glaucoma medication requirement, ocular complications and need for surgical intervention. Mean age at IFX initiation was 10.4 +/- 4.5 years; initial mean dose was 6.6 +/- 2.2 mg/kg [and given at weeks 0, 2, 4 and q4 weeks thereafter for 93%]. Median duration on IFX was 35 [range 9-128] months. Prior to IFX, 14/27 patients had failed adalimumab +/- methotrexate [MTX]; 21/27 failed MTX. IFX led to uveitis control in 89% and arthritis control in 76% (13/17). The odds ratio of having controlled disease after IFX was 4.1 (2.6, 6.4) compared to pre-treatment visits. Topical corticosteroids and glaucoma medications were statistically decreased (p = 0.007 right eye [OD], 0.003 left eye [OS] and p = 0.001 OD, p = 0.028 OS respectively). Incomplete adherence to treatment showed 10.3 times greater odds (7.1, 15.0) of having disease activity than full adherence. Conclusions This study adds significantly to the IFX literature by documenting outstanding uveitis control with long-term IFX treatment in non-infectious pediatric uveitis patients. Higher dosage and shorter interval were utilized without adverse effects. Importantly, this is the first study, to our knowledge, to document the significant impact of treatment adherence on uveitis control. AN - WOS:000502044500001 AU - Utz, V. M. AU - Bulas, S. AU - Lopper, S. AU - Fenchel, M. AU - Sa, T. AU - Mehta, M. AU - Ash, D. AU - Lovell, D. J. AU - Kaufman, A. H. DA - NOV 29 DO - 10.1186/s12969-019-0383-9 IS - 1 PY - 2019 SN - 1546-0096 ST - Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis T2 - PEDIATRIC RHEUMATOLOGY TI - Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis VL - 17 ID - 6084 ER - TY - JOUR AB - Purpose: To evaluate whether a tear substitute can improve corneal subepithelial nerve plexus and corneal sensitivity in glaucomatous patients. Methods: This study was prospective, longitudinal, and single arm. Twenty glaucomatous patients were recruited. All the patients were treated with a prostaglandin analog with preservative for at least 1 year. Preservative-free artificial tears (0.5% tamarind seed polysaccharide 0.5® eye drops single-dose preservative free [Oftagen]) were prescribed thrice per day. The participants were subjected to clinical and instrumental evaluation at baseline (T0), after 1 month (T1) and after 3 months (T3) of treatment. All patients were examined with a digital corneal confocal laser-scanning microscope (HRT II Rostock Cornea Module; Heidelberg Engineering GmbH) and Cochet-Bonnet corneal esthesiometer. Results: After the artificial substitute, corneal and conjunctival sensitivity significantly (P<0.001) improved at T1 and T3 compared to the baseline. A significant correlation was found between break-up time and both central corneal sensitivity and the number of fibers. Conclusion: The use of a preservative-free artificial substitute in association with a topical therapy with chronic preservative could increase the compliance of patients. © Copyright 2015, Mary Ann Liebert, Inc. 2015. AD - Clinica Oculistica, DiNOGMI, University of Genoa, Viale Benedetto XV, 5, Genoa, 16132, Italy Azienda Ospedaliera Universitaria San Martino IST, Genova, Italy AU - Vagge, A. AU - Bonino, M. AU - Rolando, M. AU - Macrì, A. AU - Traverso, C. E. AU - Iester, M. DB - Scopus DO - 10.1089/jop.2014.0131 IS - 5 M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2015 SP - 286-290 ST - The utility of an artificial substitute to improve corneal sensitivity in glaucomatous patients on chronic therapy with prostaglandin analogs T2 - Journal of Ocular Pharmacology and Therapeutics TI - The utility of an artificial substitute to improve corneal sensitivity in glaucomatous patients on chronic therapy with prostaglandin analogs UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930590695&doi=10.1089%2fjop.2014.0131&partnerID=40&md5=17ce04ee31622fad0d69312385b154f2 VL - 31 ID - 5629 ER - TY - JOUR AB - Background: We studied the effect of argon laser trabeculoplasty (ALT) on medically controlled, pressure-stable glaucoma patients to verify whether it is possible to reduce ocular hypotensive medication after ALT while keeping intraocular pressure levels similar to those observed before the procedure. Methods: Seventy-one consecutive chronic glaucoma patients, all of whom were taking ocular hypotensive medication and had intraocular pressure at adequate levels, underwent ALT. After the laser procedure, each patient discontinued one hypotensive drug. Mean follow-up was 16.39 +/- 5.39 months. We performed diurnal pressure curves on each patient before and after trabeculoplasty to determine the effect on intraocular pressure. Results: In 39 (54.9%) patients, it was possible to reduce ocular hypotensive medication and still maintain intraocular pressure levels similar to those achieved before ALT. Interpretation: For some medically controlled, chronic glaucoma patients, ALT can reduce the amount of ocular hypotensive medication without significantly altering intraocular pressure. AN - WOS:000235968900007 AU - Vaidergorn, P. G. AU - Susanna, R. DA - FEB DO - 10.1016/S0008-4182(06)80066-9 IS - 1 PY - 2006 SN - 0008-4182 1715-3360 SP - 44-50 ST - Argon laser trabeculoplasty and reduction of ocular hypotensive medication used by glaucoma patients T2 - CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE TI - Argon laser trabeculoplasty and reduction of ocular hypotensive medication used by glaucoma patients VL - 41 ID - 5990 ER - TY - JOUR AB - Many vision threatening ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and proliferative vitreoretinopathy may result in blindness. Ocular drug delivery specifically to the intraocular tissues remains a challenging task due to the presence of various physiological barriers. Nonetheless, recent advancements in the field of nanomicelle-based novel drug delivery system could fulfil these unmet needs. Nanomicelles consists of amphiphilic molecules that self-assemble in aqueous media to form organized supramolecular structures. Micelles can be prepared in various sizes (10-1000nm) and shapes depending on the molecular weights of the core and corona forming blocks. Nanomicelles have been an attractive carrier for their potential to solubilize hydrophobic molecules in aqueous solution. In addition, small size in nanometer range and highly modifiable surface properties have been reported to be advantageous in ocular drug delivery. In this review, various factors influencing rationale design of nanomicelles formulation and disposition are discussed along with case studies. Despite the progress in the field, influence of various properties of nanomicelles such as size, shape, surface charge, rigidity of structure on ocular disposition need to be studied in further details to develop an efficient nanocarrier system. For further resources related to this article, please visit the WIREs website. Conflict of interest: The authors have declared no conflicts of interest for this article. © 2014 Wiley Periodicals, Inc. AD - A.K. Mitra, Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, 64108-2718, United States AU - Vaishya, R. D. AU - Khurana, V. AU - Patel, S. AU - Mitra, A. K. DB - Embase Medline DO - 10.1002/wnan.1272 IS - 5 KW - antisense oligonucleotide chitosan cyclosporine dexamethasone ethoxzolamide hydrogenated castor oil macrogol stearate metipranolol mucin nanocarrier nanomaterial nanomicelle pilocarpine poloxamer rapamycin surfactant unclassified drug voclosporin aqueous solution article case study cell surface critical micelle concentration delayed drug release drug absorption drug bioavailability drug delivery system drug penetration drug release drug uptake encapsulation endocytosis eye disease human hydrogen bond hydrophobicity intraocular pressure macromolecule micellization molecular weight nonhuman osmolarity particle size patient compliance polymerization priority journal rigidity static electricity surface charge vitreous body LA - English M3 - Article N1 - L53178224 2014-06-13 2014-08-13 PY - 2014 SN - 1939-0041 1939-5116 SP - 422-437 ST - Controlled ocular drug delivery with nanomicelles T2 - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology TI - Controlled ocular drug delivery with nanomicelles UR - https://www.embase.com/search/results?subaction=viewrecord&id=L53178224&from=export http://dx.doi.org/10.1002/wnan.1272 VL - 6 ID - 2929 ER - TY - JOUR AB - Many vision threatening ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and proliferative vitreoretinopathy may result in blindness. Ocular drug delivery specifically to the intraocular tissues remains a challenging task due to the presence of various physiological barriers. Nonetheless, recent advancements in the field of nanomicelle-based novel drug delivery system could fulfil these unmet needs. Nanomicelles consists of amphiphilic molecules that self-assemble in aqueous media to form organized supramolecular structures. Micelles can be prepared in various sizes (10-1000nm) and shapes depending on the molecular weights of the core and corona forming blocks. Nanomicelles have been an attractive carrier for their potential to solubilize hydrophobic molecules in aqueous solution. In addition, small size in nanometer range and highly modifiable surface properties have been reported to be advantageous in ocular drug delivery. In this review, various factors influencing rationale design of nanomicelles formulation and disposition are discussed along with case studies. Despite the progress in the field, influence of various properties of nanomicelles such as size, shape, surface charge, rigidity of structure on ocular disposition need to be studied in further details to develop an efficient nanocarrier system. For further resources related to this article, please visit the WIREs website. Conflict of interest: The authors have declared no conflicts of interest for this article. © 2014 Wiley Periodicals, Inc. AD - Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, 64108-2718, United States INSYS Therapeutics Inc, 444 South Ellis Road, Chandler, AZ, 85224, United States AU - Vaishya, R. D. AU - Khurana, V. AU - Patel, S. AU - Mitra, A. K. DB - Scopus DO - 10.1002/wnan.1272 IS - 5 M3 - Article N1 - Cited By :74 Export Date: 19 July 2021 PY - 2014 SP - 422-437 ST - Controlled ocular drug delivery with nanomicelles T2 - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology TI - Controlled ocular drug delivery with nanomicelles UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905001982&doi=10.1002%2fwnan.1272&partnerID=40&md5=978b06ff87e671e2098caba1aa657c9c VL - 6 ID - 4954 ER - TY - JOUR AB - Purpose: This study was designed to study an alternative technique of lamellar separation of corneal layers for therapeutic keratoplasty in place of an en bloc removal of host corneal button in eyes with perforated corneal ulcers with pseudocornea. Methods: Twelve eyes with perforated corneal ulcers with pseudo-cornea in which therapeutic keratoplasty was planned were included in the study. A new technique was used in which the host corneal tissue was removed in layers by lamellar dissection started peripherally and proceeding centripetally with care taken to prevent perforation at the site of iris incarceration. After injection of viscoelastic into the anterior chamber with a 26-gauge needle entered tangentially, the deeper layer of the cornea was then gently dissected and peeled away from the iris tissue, with care not to avulse the fragile iris and the overlying fibrotic membrane. Adjunctive procedures were performed, and the donor tissue was secured over the host bed. Results: A complete separation of the iris tissue from corneal button and the fibrous membrane was achieved in 9 eyes. In 3 eyes, iris was partly trimmed along with the fibrous membrane, because the membrane was totally adherent to the iris tissue. Eight patients required pupilloplasty. Apart from minimal bleeding, no other complication was encountered. At the end of 3 months, 9 of 12 grafts remained clear. Conclusions: Debulking and layer-by-layer removal of host corneal tissue is effective in preservation of iris while performing therapeutic keratoplasty in eyes with perforated corneal ulcers with pseudocornea. Copyright © 2005 by Lippincott Williams & Wilkins. AD - Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India AU - Vajpayee, R. B. AU - Singhvi, A. AU - Sharma, N. AU - Sinha, R. DB - Scopus DO - 10.1097/01.ico.0000177834.85507.28 IS - 1 KW - Corneal debulking Penetrating keratoplasty Perforated corneal ulcers M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2006 SP - 44-46 ST - Penetrating keratoplasty for perforated corneal ulcers: Preservation of Iris by corneal debulking T2 - Cornea TI - Penetrating keratoplasty for perforated corneal ulcers: Preservation of Iris by corneal debulking UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-29744435269&doi=10.1097%2f01.ico.0000177834.85507.28&partnerID=40&md5=b410a3b44afcd796456b01039faf0260 VL - 25 ID - 5395 ER - TY - JOUR AB - To determine if receiving a prescheduled appointment is associated with an increased likelihood of complying with follow-up eye care among individuals identified as at risk for glaucoma during community-based glaucoma screening in an urban underserved population. This study sampled 362 individuals aged ≥30 years without known glaucoma from low-income, predominantly black/Hispanic neighborhoods in New Haven, Connecticut presenting to one of twelve community-based glaucoma screening events from May 2010 to October 2012. A quasi-experimental design systematically assigned 63 individuals identified as at risk for glaucoma into either intervention or control group with a 1:2 ratio. Individuals in the control group ( n = 41) received counseling on glaucoma and a recommendation for obtaining a follow-up appointment at the eye department of a local community health center, which offers affordable health services with income-adjusted fee discounts to uninsured, low-income patients. Those in the intervention group ( n = 22) received the same counseling and a prescheduled appointment at the community health center. The overall rate of follow-up compliance within 3 months of screening was 30 % (41 % in the intervention group; 24 % in the control group). Multivariate logistic regression analysis adjusting for sex, age, ethnicity, health insurance status, car access, living situation, and smoking status found that follow-up compliance was significantly associated with intervention (adjusted odds ratio 4.8; 95 % confidence interval 1.1-20.9). Providing prescheduled appointments can improve follow-up compliance after community-based glaucoma screening. This finding may be potentially applicable to community-based health screening for other preventable diseases. AD - Department of Ophthalmology and Visual Science, Yale School of Medicine, 40 Temple Street New Haven 06510 USA Perelman School of Medicine, University of Pennsylvania, Philadelphia USA Jules Stein Eye Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles USA Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami USA Humboldt Medical Eye Associates, Eureka USA AN - 103880352. Language: English. Entry Date: 20150121. Revision Date: 20200708. Publication Type: Journal Article AU - van Zyl, Tavé AU - Su, Zhuo AU - Zhou, Elaine AU - Wong, Ryan AU - Mohsenin, Amir AU - Rogers, Spencer AU - Tsai, James AU - Forster, Susan DB - ccm DO - 10.1007/s10900-014-9890-2 DP - EBSCOhost IS - 1 KW - Vision Screening -- Evaluation Appointments and Schedules -- Evaluation Patient Compliance -- Evaluation Medically Underserved Urban Areas Glaucoma -- Diagnosis Human Adult Middle Age Aged Aged, 80 and Over Male Female Connecticut Quasi-Experimental Studies Descriptive Statistics Odds Ratio Confidence Intervals Multiple Logistic Regression Questionnaires Surveys Self Report Data Analysis, Statistical Data Analysis Software P-Value Funding Source N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Special Interest: Public Health. Grant Information: This study was supported in part by grants from the Friends of the Congressional Glaucoma Caucus Foundation and the Dwight Hall of Yale University.. NLM UID: 7600747. PMID: NLM24880821. PY - 2015 SN - 0094-5145 SP - 27-33 ST - Providing Prescheduled Appointments as a Strategy for Improving Follow-Up Compliance After Community-Based Glaucoma Screening: Results from an Urban Underserved Population T2 - Journal of Community Health TI - Providing Prescheduled Appointments as a Strategy for Improving Follow-Up Compliance After Community-Based Glaucoma Screening: Results from an Urban Underserved Population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103880352&site=ehost-live&scope=site VL - 40 ID - 4198 ER - TY - JOUR AB - To determine if receiving a prescheduled appointment is associated with an increased likelihood of complying with follow-up eye care among individuals identified as at risk for glaucoma during community-based glaucoma screening in an urban underserved population. This study sampled 362 individuals aged ≥30 years without known glaucoma from low-income, predominantly black/Hispanic neighborhoods in New Haven, Connecticut presenting to one of twelve community-based glaucoma screening events from May 2010 to October 2012. A quasi-experimental design systematically assigned 63 individuals identified as at risk for glaucoma into either intervention or control group with a 1:2 ratio. Individuals in the control group (n = 41) received counseling on glaucoma and a recommendation for obtaining a follow-up appointment at the eye department of a local community health center, which offers affordable health services with income-adjusted fee discounts to uninsured, low-income patients. Those in the intervention group (n = 22) received the same counseling and a prescheduled appointment at the community health center. The overall rate of follow-up compliance within 3 months of screening was 30 % (41 % in the intervention group; 24 % in the control group). Multivariate logistic regression analysis adjusting for sex, age, ethnicity, health insurance status, car access, living situation, and smoking status found that follow-up compliance was significantly associated with intervention (adjusted odds ratio 4.8; 95 % confidence interval 1.1-20.9). Providing prescheduled appointments can improve follow-up compliance after community-based glaucoma screening. This finding may be potentially applicable to community-based health screening for other preventable diseases. AU - van Zyl, T. AU - Su, Z. AU - Zhou, E. AU - Wong, R. K. AU - Mohsenin, A. AU - Rogers, S. AU - Tsai, J. C. AU - Forster, S. H. DB - Medline DO - 10.1007/s10900-014-9890-2 IS - 1 KW - adult African American counseling epidemiology ethnology female glaucoma health care delivery health center Hispanic hospital management human male middle aged organization and management patient compliance risk factor United States vision test vulnerable population LA - English M3 - Article N1 - L606351717 2015-10-14 PY - 2015 SN - 1573-3610 SP - 27-33 ST - Providing prescheduled appointments as a strategy for improving follow-up compliance after community-based glaucoma screening: results from an urban underserved population T2 - Journal of community health TI - Providing prescheduled appointments as a strategy for improving follow-up compliance after community-based glaucoma screening: results from an urban underserved population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606351717&from=export http://dx.doi.org/10.1007/s10900-014-9890-2 VL - 40 ID - 2823 ER - TY - JOUR AB - To determine if receiving a prescheduled appointment is associated with an increased likelihood of complying with follow-up eye care among individuals identified as at risk for glaucoma during community-based glaucoma screening in an urban underserved population. This study sampled 362 individuals aged ≥30 years without known glaucoma from low-income, predominantly black/Hispanic neighborhoods in New Haven, Connecticut presenting to one of twelve community-based glaucoma screening events from May 2010 to October 2012. A quasi-experimental design systematically assigned 63 individuals identified as at risk for glaucoma into either intervention or control group with a 1:2 ratio. Individuals in the control group (n = 41) received counseling on glaucoma and a recommendation for obtaining a follow-up appointment at the eye department of a local community health center, which offers affordable health services with income-adjusted fee discounts to uninsured, low-income patients. Those in the intervention group (n = 22) received the same counseling and a prescheduled appointment at the community health center. The overall rate of follow-up compliance within 3 months of screening was 30 % (41 % in the intervention group; 24 % in the control group). Multivariate logistic regression analysis adjusting for sex, age, ethnicity, health insurance status, car access, living situation, and smoking status found that follow-up compliance was significantly associated with intervention (adjusted odds ratio 4.8; 95 % confidence interval 1.1–20.9). Providing prescheduled appointments can improve follow-up compliance after community-based glaucoma screening. This finding may be potentially applicable to community-based health screening for other preventable diseases. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Forster, Susan H., Department of Ophthalmology and Visual Science, Yale School of Medicine, 40 Temple Street, New Haven, CT, US, 06510 AN - 2015-02747-004 AU - van Zyl, Tavé AU - Su, Zhuo AU - Zhou, Elaine AU - Wong, Ryan K. AU - Mohsenin, Amir AU - Rogers, Spencer AU - Tsai, James C. AU - Forster, Susan H. DB - psyh DO - 10.1007/s10900-014-9890-2 DP - EBSCOhost IS - 1 KW - Vision screening Access to health care Glaucoma Underserved populations Preventive health services Adult African Americans Appointments and Schedules Community Health Centers Connecticut Counseling Female Health Services Accessibility Hispanic Americans Humans Male Middle Aged Patient Compliance Risk Factors Vulnerable Populations Health Care Utilization Health Screening Treatment Compliance Health Disparities At Risk Populations Community Services N1 - Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, US. Release Date: 20150406. Correction Date: 20200713. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Glaucoma; Health Care Utilization; Health Screening; Treatment Compliance; Health Disparities. Minor Descriptor: At Risk Populations; Community Services; Preventive Health Services. Classification: Health & Mental Health Services (3370). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Feb, 2015. Publication History: First Posted Date: Jun 1, 2014. Copyright Statement: Springer Science+Business Media New York. 2014. Sponsor: Friends of the Congressional Glaucoma Caucus Foundation. Recipients: No recipient indicated Sponsor: Dwight Hall of Yale University. Recipients: No recipient indicated PY - 2015 SN - 0094-5145 1573-3610 SP - 27-33 ST - Providing prescheduled appointments as a strategy for improving follow-up compliance after community-based glaucoma screening: Results from an urban underserved population T2 - Journal of Community Health: The Publication for Health Promotion and Disease Prevention TI - Providing prescheduled appointments as a strategy for improving follow-up compliance after community-based glaucoma screening: Results from an urban underserved population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-02747-004&site=ehost-live&scope=site ORCID: 0000-0003-2982-9894 susan.forster@yale.edu VL - 40 ID - 4827 ER - TY - JOUR AB - To determine if receiving a prescheduled appointment is associated with an increased likelihood of complying with follow-up eye care among individuals identified as at risk for glaucoma during community-based glaucoma screening in an urban underserved population. This study sampled 362 individuals aged ≥30 years without known glaucoma from low-income, predominantly black/Hispanic neighborhoods in New Haven, Connecticut presenting to one of twelve community-based glaucoma screening events from May 2010 to October 2012. A quasi-experimental design systematically assigned 63 individuals identified as at risk for glaucoma into either intervention or control group with a 1:2 ratio. Individuals in the control group (n = 41) received counseling on glaucoma and a recommendation for obtaining a follow-up appointment at the eye department of a local community health center, which offers affordable health services with income-adjusted fee discounts to uninsured, low-income patients. Those in the intervention group (n = 22) received the same counseling and a prescheduled appointment at the community health center. The overall rate of follow-up compliance within 3 months of screening was 30 % (41 % in the intervention group; 24 % in the control group). Multivariate logistic regression analysis adjusting for sex, age, ethnicity, health insurance status, car access, living situation, and smoking status found that follow-up compliance was significantly associated with intervention (adjusted odds ratio 4.8; 95 % confidence interval 1.1–20.9). Providing prescheduled appointments can improve follow-up compliance after community-based glaucoma screening. This finding may be potentially applicable to community-based health screening for other preventable diseases. © 2014, Springer Science+Business Media New York. AD - Department of Ophthalmology and Visual Science, Yale School of Medicine, 40 Temple Street, New Haven, CT 06510, United States Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States Jules Stein Eye Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, United States Humboldt Medical Eye Associates, Eureka, CA, United States AU - van Zyl, T. AU - Su, Z. AU - Zhou, E. AU - Wong, R. K. AU - Mohsenin, A. AU - Rogers, S. AU - Tsai, J. C. AU - Forster, S. H. DB - Scopus DO - 10.1007/s10900-014-9890-2 IS - 1 KW - Access to health care Glaucoma Preventive health services Underserved populations Vision screening M3 - Article N1 - Cited By :8 Export Date: 19 July 2021 PY - 2015 SP - 27-33 ST - Providing Prescheduled Appointments as a Strategy for Improving Follow-Up Compliance After Community-Based Glaucoma Screening: Results from an Urban Underserved Population T2 - Journal of Community Health TI - Providing Prescheduled Appointments as a Strategy for Improving Follow-Up Compliance After Community-Based Glaucoma Screening: Results from an Urban Underserved Population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939872780&doi=10.1007%2fs10900-014-9890-2&partnerID=40&md5=832a5c6fba8d27bb8dd365775dabeef7 VL - 40 ID - 5327 ER - TY - JOUR AB - To determine if receiving a prescheduled appointment is associated with an increased likelihood of complying with follow-up eye care among individuals identified as at risk for glaucoma during community-based glaucoma screening in an urban underserved population. This study sampled 362 individuals aged a parts per thousand yen30 years without known glaucoma from low-income, predominantly black/Hispanic neighborhoods in New Haven, Connecticut presenting to one of twelve community-based glaucoma screening events from May 2010 to October 2012. A quasi-experimental design systematically assigned 63 individuals identified as at risk for glaucoma into either intervention or control group with a 1:2 ratio. Individuals in the control group (n = 41) received counseling on glaucoma and a recommendation for obtaining a follow-up appointment at the eye department of a local community health center, which offers affordable health services with income-adjusted fee discounts to uninsured, low-income patients. Those in the intervention group (n = 22) received the same counseling and a prescheduled appointment at the community health center. The overall rate of follow-up compliance within 3 months of screening was 30 % (41 % in the intervention group; 24 % in the control group). Multivariate logistic regression analysis adjusting for sex, age, ethnicity, health insurance status, car access, living situation, and smoking status found that follow-up compliance was significantly associated with intervention (adjusted odds ratio 4.8; 95 % confidence interval 1.1-20.9). Providing prescheduled appointments can improve follow-up compliance after community-based glaucoma screening. This finding may be potentially applicable to community-based health screening for other preventable diseases. AN - WOS:000348190400004 AU - van Zyl, T. AU - Su, Z. AU - Zhou, E. AU - Wong, R. K. AU - Mohsenin, A. AU - Rogers, S. AU - Tsai, J. C. AU - Forster, S. H. DA - FEB DO - 10.1007/s10900-014-9890-2 IS - 1 PY - 2015 SN - 0094-5145 1573-3610 SP - 27-33 ST - Providing Prescheduled Appointments as a Strategy for Improving Follow-Up Compliance After Community-Based Glaucoma Screening: Results from an Urban Underserved Population T2 - JOURNAL OF COMMUNITY HEALTH TI - Providing Prescheduled Appointments as a Strategy for Improving Follow-Up Compliance After Community-Based Glaucoma Screening: Results from an Urban Underserved Population VL - 40 ID - 5832 ER - TY - JOUR AB - PURPOSE: This study aimed to investigate (1) the prevalence of nonadherence with eye drop treatment; (2) selected correlates of nonadherence at the patient and health-care organization level; and (3) the diagnostic value of the ophthalmologists? ratings, using patients? self-reports as standard. METHODS: This cross-sectional multicenter survey used questionnaires for ophthalmologists and their patients to assess self-reported nonadherence and its correlates. One item, using a 4-point scale [never (ie, adherent) to daily], asked the patients whether they had forgotten to administer eye drops during the past 2 weeks. Ophthalmologists rated their patients as adherent or nonadherent. Nonadherence was also determined by combined methods, whereby either could indicate nonadherence. Given the nested structure of the data, multilevel modeling was used to investigate self-reported nonadherence-correlates. Diagnostic values of ophthalmologists? report were calculated. RESULTS: Of 663 patients (48% female, 44% >69 years), nonadherence was indicated in 39.2% (n=260) through self-reporting, 2.1% (n=14) through ophthalmologists? ratings, and 40% (n=266) through combined measures. The multivariable, multilevel model showed following significant nonadherence-correlates: Male sex (P=0.01), younger age (P=0.027), and higher-dose frequency (P=0.001). No significant correlation with treating ophthalmologist (P=0.21) could be seen. Yet, the patients visiting their ophthalmologists at least every 3 months were less nonadherent than patients with fewer consultations (P=0.01). The ophthalmologists? report showed a sensitivity and specificity of 3% and 98.5%, respectively. CONCLUSIONS: The prevalence of self-reported nonadherence was congruent with literature. The patients visiting their ophthalmologists at least every 3 months have a lower risk of nonadherence. Ophthalmologist report is an insensitive method for detecting nonadherence. © 2011 by Lippincott Williams & Wilkins. AD - T. Zeyen, Department of Ophthalmology, University Hospitals of Leuven, Kapucijnenvoer 33 Blok C, 3000 Leuven, Belgium AU - Vandenbroeck, S. AU - De Geest, S. AU - Dobbels, F. AU - Fieuws, S. AU - Stalmans, I. AU - Zeyen, T. DB - Embase Medline DO - 10.1097/IJG.0b013e3181f7b10e IS - 7 KW - eye drops adult age aged article controlled study cross-sectional study diagnostic value eye care female follow up health survey human intraocular hypertension major clinical study male open angle glaucoma patient compliance predictive value priority journal questionnaire self report sex difference treatment refusal LA - English M3 - Article N1 - L51135558 2010-11-09 2011-09-23 PY - 2011 SN - 1057-0829 1536-481X SP - 414-421 ST - Prevalence and correlates of self-reported nonadherence with eye drop treatment: The belgian compliance study in ophthalmology (BCSO) T2 - Journal of Glaucoma TI - Prevalence and correlates of self-reported nonadherence with eye drop treatment: The belgian compliance study in ophthalmology (BCSO) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51135558&from=export http://dx.doi.org/10.1097/IJG.0b013e3181f7b10e VL - 20 ID - 3153 ER - TY - JOUR AB - PURPOSE: This study aimed to investigate (1) the prevalence of nonadherence with eye drop treatment; (2) selected correlates of nonadherence at the patient and health-care organization level; and (3) the diagnostic value of the ophthalmologists? ratings, using patients? self-reports as standard. METHODS: This cross-sectional multicenter survey used questionnaires for ophthalmologists and their patients to assess self-reported nonadherence and its correlates. One item, using a 4-point scale [never (ie, adherent) to daily], asked the patients whether they had forgotten to administer eye drops during the past 2 weeks. Ophthalmologists rated their patients as adherent or nonadherent. Nonadherence was also determined by combined methods, whereby either could indicate nonadherence. Given the nested structure of the data, multilevel modeling was used to investigate self-reported nonadherence-correlates. Diagnostic values of ophthalmologists? report were calculated. RESULTS: Of 663 patients (48% female, 44% >69 years), nonadherence was indicated in 39.2% (n=260) through self-reporting, 2.1% (n=14) through ophthalmologists? ratings, and 40% (n=266) through combined measures. The multivariable, multilevel model showed following significant nonadherence-correlates: Male sex (P=0.01), younger age (P=0.027), and higher-dose frequency (P=0.001). No significant correlation with treating ophthalmologist (P=0.21) could be seen. Yet, the patients visiting their ophthalmologists at least every 3 months were less nonadherent than patients with fewer consultations (P=0.01). The ophthalmologists? report showed a sensitivity and specificity of 3% and 98.5%, respectively. CONCLUSIONS: The prevalence of self-reported nonadherence was congruent with literature. The patients visiting their ophthalmologists at least every 3 months have a lower risk of nonadherence. Ophthalmologist report is an insensitive method for detecting nonadherence. © 2011 by Lippincott Williams & Wilkins. AD - Centre for Health Services and Nursing Research, Katholieke Universiteit Leuven, Belgium FWO Flanders, Belgium I-Biostat, Katholieke Universiteit Leuven, Belgium Department of Ophthalmology, University Hospitals of Leuven, Belgium Institute of Nursing Science, University of Basel, Switzerland Department of Ophthalmology, University Hospitals of Leuven, Kapucijnenvoer 33 Blok C, 3000 Leuven, Belgium AU - Vandenbroeck, S. AU - De Geest, S. AU - Dobbels, F. AU - Fieuws, S. AU - Stalmans, I. AU - Zeyen, T. DB - Scopus DO - 10.1097/IJG.0b013e3181f7b10e IS - 7 KW - Eye drop treatment Glaucoma Nonadherence M3 - Article N1 - Cited By :17 Export Date: 19 July 2021 PY - 2011 SP - 414-421 ST - Prevalence and correlates of self-reported nonadherence with eye drop treatment: The belgian compliance study in ophthalmology (BCSO) T2 - Journal of Glaucoma TI - Prevalence and correlates of self-reported nonadherence with eye drop treatment: The belgian compliance study in ophthalmology (BCSO) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052680399&doi=10.1097%2fIJG.0b013e3181f7b10e&partnerID=40&md5=6471982729f84a8a7f44976786369fa4 VL - 20 ID - 5169 ER - TY - JOUR AB - Purpose: This study aimed to investigate (1) the prevalence of nonadherence with eye drop treatment; (2) selected correlates of nonadherence at the patient and health-care organization level; and (3) the diagnostic value of the ophthalmologists' ratings, using patients' self-reports as standard. Methods: This cross-sectional multicenter survey used questionnaires for ophthalmologists and their patients to assess self-reported nonadherence and its correlates. One item, using a 4-point scale [never (ie, adherent) to daily], asked the patients whether they had forgotten to administer eye drops during the past 2 weeks. Ophthalmologists rated their patients as adherent or nonadherent. Nonadherence was also determined by combined methods, whereby either could indicate nonadherence. Given the nested structure of the data, multilevel modeling was used to investigate self-reported nonadherence-correlates. Diagnostic values of ophthalmologists' report were calculated. Results: Of 663 patients (48% female, 44% >69 years), nonadherence was indicated in 39.2% (n=260) through self-reporting, 2.1% (n=14) through ophthalmologists' ratings, and 40% (n= 266) through combined measures. The multivariable, multilevel model showed following significant nonadherence-correlates: Male sex (P=0.01), younger age (P=0.027), and higher-dose frequency (P=0.001). No significant correlation with treating ophthalmologist (P=0.21) could be seen. Yet, the patients visiting their ophthalmologists at least every 3 months were less nonadherent than patients with fewer consultations (P=0.01). The ophthalmologists' report showed a sensitivity and specificity of 3% and 98.5%, respectively. Conclusions: The prevalence of self-reported nonadherence was congruent with literature. The patients visiting their ophthalmologists at least every 3 months have a lower risk of nonadherence. Ophthalmologist report is an insensitive method for detecting nonadherence. AN - WOS:000294675700004 AU - Vandenbroeck, S. AU - De Geest, S. AU - Dobbels, F. AU - Fieuws, S. AU - Stalmans, I. AU - Zeyen, T. DA - SEP DO - 10.1097/IJG.0b013e3181f7b10e IS - 7 PY - 2011 SN - 1057-0829 1536-481X SP - 414-421 ST - Prevalence and Correlates of Self-reported Nonadherence With Eye Drop Treatment: The Belgian Compliance Study in Ophthalmology (BCSO) T2 - JOURNAL OF GLAUCOMA TI - Prevalence and Correlates of Self-reported Nonadherence With Eye Drop Treatment: The Belgian Compliance Study in Ophthalmology (BCSO) VL - 20 ID - 5894 ER - TY - JOUR AB - Background: Previous studies have reported that patients who are medication naive in some medication classes have a higher risk of medication discontinuation during the first 30 days of treatment and shorter median times to discontinuation than do medication-experienced patients. Objectives: This study compared the risk of discontinuation during the first 30 days after the index fill and the median time to discontinuation for medication-naive and medication-experienced patients who were prescribed drugs for asthma, diabetes mellitus, high cholesterol, cardiovascular disease, breast cancer, glaucoma, or osteoporosis. Methods: Deidentified outpatient pharmacy records from 4 large US retail chains were searched for patients who had obtained a prescription for one of the index medications between January 1, 2007, and January 31, 2007. Included medication classes were asthma inhalers, asthma pills, oral breast-cancer agents, cardiovascular medications, oral antidiabetic medications, insulin, glaucoma drops, osteoporosis medications, and statins. Patients were divided into 2 groups: those for whom an in-class medication was not dispensed in the previous 180 days were identified as medication naive, and those for whom an in-class medication was dispensed during this period were identified as medication experienced. Discontinuation was defined as being >30 days late for a scheduled refill. Time to discontinuation was measured using Kaplan-Meier analysis during a 360-day follow-up period. Results: Data for 2.17 million patients who received prescriptions from 3821 pharmacies were analyzed. During the first 30 days of therapy, rates of discontinuation for medication-naive patients were 17.4% to 42.6% higher than for medication-experienced patients, and their median times to discontinuation were 14.2% to 28.9% as long. The difference in persistence between medication-naive and medication-experienced patients emerged during the first 30 days of medication use, after which rates of discontinuation were relatively consistent. Patients prescribed nonoral medications for diabetes mellitus (insulin), asthma (inhalers), and glaucoma (drops) had an especially high risk of discontinuation during the first month of treatment. Conclusion: This study found that medicationnaive patients had a higher risk of discontinuation during the first 30 days of therapy than did medicationexperienced patients, regardless of the medication class prescribed, leading to shorter median times to discontinuation. © 2009 Excerpta Medica Inc. All rights reserved. AD - M. Vanelli, Adheris, Inc., Burlington, MA, United States AU - Vanelli, M. AU - Pedan, A. AU - Liu, N. AU - Hoar, J. AU - Messier, D. AU - Kiarsis, K. DB - Embase Medline DO - 10.1016/j.clinthera.2009.11.028 IS - 11 KW - 2,4 thiazolidinedione derivative alpha adrenergic receptor stimulating agent angiotensin receptor antagonist antiestrogen aromatase inhibitor beta adrenergic receptor blocking agent beta adrenergic receptor stimulating agent biguanide derivative bisphosphonic acid derivative calcitonin calcium channel blocking agent carbonate dehydratase inhibitor cholesterol corticosteroid dipeptidyl carboxypeptidase inhibitor diuretic agent hydroxymethylglutaryl coenzyme A reductase inhibitor insulin leukotriene receptor blocking agent meglitinide parathyroid hormone prostaglandin receptor stimulating agent selective estrogen receptor modulator sulfonylurea derivative adult aged article asthma breast cancer cardiovascular disease controlled study diabetes mellitus drug utilization drug withdrawal female financial management glaucoma human hypercholesterolemia income Kaplan Meier method major clinical study male osteoporosis patient compliance personal experience pharmacy (shop) prescription risk assessment treatment duration LA - English M3 - Article N1 - L358128921 2010-03-05 PY - 2009 SN - 0149-2918 1879-114X SP - 2628-2652 ST - The role of patient inexperience in medication discontinuation: A retrospective analysis of medication nonpersistence in seven chronic illnesses T2 - Clinical Therapeutics TI - The role of patient inexperience in medication discontinuation: A retrospective analysis of medication nonpersistence in seven chronic illnesses UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358128921&from=export http://dx.doi.org/10.1016/j.clinthera.2009.11.028 VL - 31 ID - 3318 ER - TY - JOUR AB - Background: Previous studies have reported that patients who are medication naive in some medication classes have a higher risk of medication discontinuation during the first 30 days of treatment and shorter median times to discontinuation than do medication-experienced patients. Objectives: This study compared the risk of discontinuation during the first 30 days after the index fill and the median time to discontinuation for medication-naive and medication-experienced patients who were prescribed drugs for asthma, diabetes mellitus, high cholesterol, cardiovascular disease, breast cancer, glaucoma, or osteoporosis. Methods: Deidentified outpatient pharmacy records from 4 large US retail chains were searched for patients who had obtained a prescription for one of the index medications between January 1, 2007, and January 31, 2007. Included medication classes were asthma inhalers, asthma pills, oral breast-cancer agents, cardiovascular medications, oral antidiabetic medications, insulin, glaucoma drops, osteoporosis medications, and statins. Patients were divided into 2 groups: those for whom an in-class medication was not dispensed in the previous 180 days were identified as medication naive, and those for whom an in-class medication was dispensed during this period were identified as medication experienced. Discontinuation was defined as being >30 days late for a scheduled refill. Time to discontinuation was measured using Kaplan-Meier analysis during a 360-day follow-up period. Results: Data for 2.17 million patients who received prescriptions from 3821 pharmacies were analyzed. During the first 30 days of therapy, rates of discontinuation for medication-naive patients were 17.4% to 42.6% higher than for medication-experienced patients, and their median times to discontinuation were 14.2% to 28.9% as long. The difference in persistence between medication-naive and medication-experienced patients emerged during the first 30 days of medication use, after which rates of discontinuation were relatively consistent. Patients prescribed nonoral medications for diabetes mellitus (insulin), asthma (inhalers), and glaucoma (drops) had an especially high risk of discontinuation during the first month of treatment. Conclusion: This study found that medicationnaive patients had a higher risk of discontinuation during the first 30 days of therapy than did medicationexperienced patients, regardless of the medication class prescribed, leading to shorter median times to discontinuation. © 2009 Excerpta Medica Inc. All rights reserved. AD - Adheris, Inc., Burlington, MA, United States Department of Psychiatry, Beth-Israel Medical Center, Harvard Medical School, Boston, MA, United States AU - Vanelli, M. AU - Pedan, A. AU - Liu, N. AU - Hoar, J. AU - Messier, D. AU - Kiarsis, K. DB - Scopus DO - 10.1016/j.clinthera.2009.11.028 IS - 11 KW - medication discontinuation medication persistence quality of health care M3 - Article N1 - Cited By :49 Export Date: 19 July 2021 PY - 2009 SP - 2628-2652 ST - The role of patient inexperience in medication discontinuation: A retrospective analysis of medication nonpersistence in seven chronic illnesses T2 - Clinical Therapeutics TI - The role of patient inexperience in medication discontinuation: A retrospective analysis of medication nonpersistence in seven chronic illnesses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-74549197186&doi=10.1016%2fj.clinthera.2009.11.028&partnerID=40&md5=7c893ae6efc598514f8cf14289a96810 VL - 31 ID - 4999 ER - TY - JOUR AB - Background: Previous studies have reported that patients who are medication naive In some medication classes have a higher risk of medication discontinuation during the first 30 days of treatment and shorter median times to discontinuation than do medication-experienced patients. Objectives: This study compared the risk of discontinuation during the first 30 days after the index fill and the median time to discontinuation for medication-naive and medication-experienced patients who were prescribed drugs for asthma, diabetes mellitus, high cholesterol, cardiovascular disease, breast cancer, glaucoma, or osteoporosis. Methods: Deidentified outpatient pharmacy records from 4 large US retail chains were searched for patients who had obtained a prescription for one of the index medications between January 1, 2007, and January 31, 2007. Included medication classes were asthma inhalers, asthma pills, oral breast-cancer agents, cardiovascular medications, oral antidiabetic medications, insulin, glaucoma drops, osteoporosis medications, and statins. Patients were divided into 2 groups: those for whom an in-class medication was not dispensed in the previous 180 days were identified as medication naive, and those for whom an in-class medication was dispensed during this period were identified as medication experienced. Discontinuation was defined as being > 30 days late for a scheduled refill. Time to discontinuation was measured using Kaplan-Meier analysis during a 360-day follow-up period. Results: Data for 2.17 million patients who received prescriptions from 3821 pharmacies were analyzed. During the first 30 days of therapy, rates of discontinuation for medication-naive patients were 17.4% to 42.6% higher than for medication-experienced patients, and their median times to discontinuation were 14.2% to 28.9% as long. The difference in persistence between medication-naive and medication-experienced patients emerged during the first 30 days of medication use, after which rates of discontinuation were relatively consistent. Patients prescribed nonoral medications for diabetes mellitus (insulin), asthma (inhalers), and glaucoma (drops) had an especially high risk of discontinuation during the first month of treatment. Conclusion: This study found that medication-naive patients had a higher risk of discontinuation during the first 30 days of therapy than did medication-experienced patients, regardless of the medication class prescribed, leading to shorter median times to discontinuation. (Clin Ther. 2009;31:2628-2652) (C) 2009 Excerpta Medica Inc. AN - WOS:000273160600015 AU - Vanelli, M. AU - Pedan, A. AU - Liu, N. AU - Hoar, J. AU - Messier, D. AU - Kiarsis, K. DA - NOV DO - 10.1016/j.clinthera.2009.11.028 IS - 11 PY - 2009 SN - 0149-2918 1879-114X SP - 2628-2652 ST - The Role of Patient Inexperience in Medication Discontinuation: A Retrospective Analysis of Medication Nonpersistence in Seven Chronic Illnesses T2 - CLINICAL THERAPEUTICS TI - The Role of Patient Inexperience in Medication Discontinuation: A Retrospective Analysis of Medication Nonpersistence in Seven Chronic Illnesses VL - 31 ID - 6315 ER - TY - JOUR AB - Importance: While dosing reminders for glaucoma medications have been shown to increase drug adherence, an outstanding limitation preventing broad adoption is difficulty linking reminders to medication in each patient's electronic health record (EHR).Objective: To examine the feasibility of implementing an EHR-linked, automated reminder system for glaucoma medications and assess patient satisfaction with it.Design, Setting, and Participants: In this prospective, cross-sectional study, patients receiving glaucoma medications were recruited from a university-based glaucoma clinic from April 2017 to January 2018. Analysis began in February 2018.Exposures: A web-based application was added to the EHR patient portal, allowing patients to configure telecommunication-based reminders for their glaucoma medications. For all potential participants, basic information was collected to determine risk of nonadherence with glaucoma medications. Those consenting to participate then answered questions on medication adherence, reminders, and their likelihood of using EHR-linked reminders. They then configured reminders using the EHR patient portal. After 3 months, they answered questions about their satisfaction with the system.Main Outcomes and Measures: Proportions of patients and high-risk patients willing to use the reminders, and patient satisfaction with the system.Results: Of 147 patients approached, 100 (68%) agreed to participate, of whom the majority were men (54 [54%]) and white (51 [51%]), with a mean (SD) age of 65 (12.4) years. There were no differences between those willing and unwilling to participate, except for a slightly lower self-reported medication adherence rate among those who participated (mean [SD], 91% [13.6%] vs 97% [6.0%]). Based on a previously validated risk assessment score, 9% (9 of 100) of participants were categorized as being at high risk for poor adherence (≥50% probability of nonadherence) compared with 11% (5 of 47) of nonparticipants. Of 100 participants, 94 ultimately configured reminders, of whom 89 (95%) completed follow-up. On follow-up, 74% (n = 66; 95% CI, 65-83) of participants found the reminders to be useful, 15% (n = 13) were neutral, and 11% (n = 10) found them not useful. Most participants (72 [81%]; 95% CI, 77-85) had help configuring reminders.Conclusions and Relevance: Electronic health records-linked reminders had good uptake and were well received among patients at a tertiary glaucoma clinic. These portals may represent a new and convenient method of allowing patients to link their glaucoma medications to automated reminders, although the generalizability of these results and the effect on glaucoma outcomes remains unknown. AD - Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland AN - 135358722. Language: English. Entry Date: 20191121. Revision Date: 20200311. Publication Type: journal article. Journal Subset: Biomedical AU - Varadaraj, Varshini AU - Friedman, David S. AU - Boland, Michael V. DB - ccm DO - 10.1001/jamaophthalmol.2018.6066 DP - EBSCOhost IS - 3 KW - Reminder Systems -- Standards Glaucoma -- Drug Therapy Female Prospective Studies Middle Age Aged Adult Cross Sectional Studies Patient Satisfaction Medication Compliance Male Clinical Assessment Tools N1 - USA. Instrumentation: Basic Knowledge Assessment Tool (BKAT). NLM UID: 101589539. PMID: NLM30543342. PY - 2019 SN - 2168-6165 SP - 240-245 ST - Association of an Electronic Health Record-Linked Glaucoma Medical Reminder With Patient Satisfaction T2 - JAMA Ophthalmology TI - Association of an Electronic Health Record-Linked Glaucoma Medical Reminder With Patient Satisfaction UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135358722&site=ehost-live&scope=site VL - 137 ID - 4201 ER - TY - JOUR AB - Importance: While dosing reminders for glaucoma medications have been shown to increase drug adherence, an outstanding limitation preventing broad adoption is difficulty linking reminders to medication in each patient's electronic health record (EHR). Objective: To examine the feasibility of implementing an EHR-linked, automated reminder system for glaucoma medications and assess patient satisfaction with it. Design, Setting, and Participants: In this prospective, cross-sectional study, patients receiving glaucoma medications were recruited from a university-based glaucoma clinic from April 2017 to January 2018. Analysis began in February 2018. Exposures: A web-based application was added to the EHR patient portal, allowing patients to configure telecommunication-based reminders for their glaucoma medications. For all potential participants, basic information was collected to determine risk of nonadherence with glaucoma medications. Those consenting to participate then answered questions on medication adherence, reminders, and their likelihood of using EHR-linked reminders. They then configured reminders using the EHR patient portal. After 3 months, they answered questions about their satisfaction with the system. Main Outcomes and Measures: Proportions of patients and high-risk patients willing to use the reminders, and patient satisfaction with the system. Results: Of 147 patients approached, 100 (68%) agreed to participate, of whom the majority were men (54 [54%]) and white (51 [51%]), with a mean (SD) age of 65 (12.4) years. There were no differences between those willing and unwilling to participate, except for a slightly lower self-reported medication adherence rate among those who participated (mean [SD], 91% [13.6%] vs 97% [6.0%]). Based on a previously validated risk assessment score, 9% (9 of 100) of participants were categorized as being at high risk for poor adherence (≥50% probability of nonadherence) compared with 11% (5 of 47) of nonparticipants. Of 100 participants, 94 ultimately configured reminders, of whom 89 (95%) completed follow-up. On follow-up, 74% (n = 66; 95% CI, 65-83) of participants found the reminders to be useful, 15% (n = 13) were neutral, and 11% (n = 10) found them not useful. Most participants (72 [81%]; 95% CI, 77-85) had help configuring reminders. Conclusions and Relevance: Electronic health records-linked reminders had good uptake and were well received among patients at a tertiary glaucoma clinic. These portals may represent a new and convenient method of allowing patients to link their glaucoma medications to automated reminders, although the generalizability of these results and the effect on glaucoma outcomes remains unknown. © 2018 American Medical Association. All rights reserved. AD - Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 NWolfe St, Wilmer 131, Baltimore, MD 21287, United States Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States AU - Varadaraj, V. AU - Friedman, D. S. AU - Boland, M. V. DB - Scopus DO - 10.1001/jamaophthalmol.2018.6066 IS - 3 M3 - Article N1 - Cited By :5 Export Date: 19 July 2021 PY - 2019 SP - 240-245 ST - Association of an Electronic Health Record-Linked Glaucoma Medical Reminder with Patient Satisfaction T2 - JAMA Ophthalmology TI - Association of an Electronic Health Record-Linked Glaucoma Medical Reminder with Patient Satisfaction UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058577279&doi=10.1001%2fjamaophthalmol.2018.6066&partnerID=40&md5=327a790ba0b88ecd47c1537e944fcda9 VL - 137 ID - 5406 ER - TY - JOUR AB - IMPORTANCE While dosing reminders for glaucoma medications have been shown to increase drug adherence, an outstanding limitation preventing broad adoption is difficulty linking reminders to medication in each patient's electronic health record (EHR). OBJECTIVE To examine the feasibility of implementing an EHR-linked, automated reminder system for glaucoma medications and assess patient satisfaction with it. DESIGN, SETTING. AND PARTICIPANTS In this prospective, cross-sectional study, patients receiving glaucoma medications were recruited from a university-based glaucoma clinic from April 2017 to January 2018. Analysis began in February 2018. EXPOSURES A web-based application was added to the EHR patient portal, allowing patients to configure telecommunication-based reminders for their glaucoma medications. For all potential participants, basic information was collected to determine risk of nonadherence with glaucoma medications. Those consenting to participate then answered questions on medication adherence, reminders, and their likelihood of using EHR-linked reminders. They then configured reminders using the EHR patient portal. After 3 months, they answered questions about their satisfaction with the system. MAIN OUTCOMES AND MEASURES Proportions of patients and high-risk patients willing to use the reminders, and patient satisfaction with the system. RESULTS Of 147 patients approached, 100 (68%) agreed to participate, of whom the majority were men (54 [54%]) and white (51 [51%]), with a mean (SD) age of 65 (12.4) years. There were no differences between those willing and unwilling to participate, except for a slightly lower self-reported medication adherence rate among those who participated (mean [SD], 91% [13.6%] vs 97% [6.0%]). Based on a previously validated risk assessment score, 9% (9 of 100) of participants were categorized as being at high risk for poor adherence (>= 50% probability of nonadherence) compared with 11% (5 of 47) of nonparticipants. Of 100 participants, 94 ultimately configured reminders, of whom 89 (95%) completed follow-up. On follow-up, 74% (n = 66; 95% CI, 65-83) of participants found the reminders to be useful, 15% (n = 13) were neutral, and 11% (n = 10) found them not useful. Most participants (72 [81%]; 95% CI, 77-85) had help configuring reminders. CONCLUSIONS AND RELEVANCE Electronic health records-linked reminders had good uptake and were well received among patients at a tertiary glaucoma clinic. These portals may represent a new and convenient method of allowing patients to link their glaucoma medications to automated reminders, although the generalizability of these results and the effect on glaucoma outcomes remains unknown. AN - WOS:000461203100007 AU - Varadaraj, V. AU - Friedman, D. S. AU - Boland, M. V. DA - MAR DO - 10.1001/jamaophthalmol.2018.6066 IS - 3 PY - 2019 SN - 2168-6165 2168-6173 SP - 240-245 ST - Association of an Electronic Health Record-Linked Glaucoma Medical Reminder With Patient Satisfaction T2 - JAMA OPHTHALMOLOGY TI - Association of an Electronic Health Record-Linked Glaucoma Medical Reminder With Patient Satisfaction VL - 137 ID - 5943 ER - TY - JOUR AB - Background: Latinos have one of the highest rates of visual impairment associated with eye disease in the United States. Although little is known about the prevalence and risk of undetected eye disease (UED) in this population, it is known that Latinos encounter disproportionate barriers in accessing health care, which may influence the burden of UED.Objective: To estimate the burden and to evaluate factors associated with UED among Latinos, a majority of whom were Mexican-American.Research Design: Population-based, cross-sectional study. A detailed interview and eye examination were performed on participants.Subjects: A sample of 6,357 Latinos (95% of whom had Mexican ancestry), aged >or=40, in 6 census tracts in Los Angeles, California.Main Outcome Measure: UED (macular degeneration, glaucoma, diabetic retinopathy, cataract, and refractive error) was defined as those persons with eye disease and no reported history of that eye disease.Results: Fifty-three percent (3,349 of 6,357) of the participants had eye disease. Sixty-three percent (2,095 of 3,349) of them had UED. Major risk factors for UED included older age [odds ratio (OR): 4.7 (age >or=80)], having diabetes mellitus (OR: 3.3), never having had an eye examination (OR: 2.4), being uninsured (OR: 1.6), lower educational attainment (OR: 1.4), and low acculturation (OR: 1.3).Conclusions: These findings provide evidence of the burden of UED among Latinos. Interventions that address the modifiable risk factors (lack of insurance, never having had an eye examination, etc.) may improve detection of eye disease and decrease the burden of visual impairment in this high-risk minority population. AD - Doheny Eye Institute, Suite 4900, 1450 San Pablo Street, Los Angeles, CA 90033, USA Doheny Eye Insitute, Suite 4900, 1450 San Pablo Street, Los Angeles, CA 90033; rvarma@usc.edu AN - 105787697. Corporate Author: LALES Group. Language: English. Entry Date: 20080815. Revision Date: 20171209. Publication Type: journal article AU - Varma, R. AU - Mohanty, S. A. AU - Deneen, J. AU - Wu, J. AU - Azen, S. P. AU - Varma, Rohit AU - Mohanty, Sarita A. AU - Deneen, Jennifer AU - Wu, Joanne AU - Azen, Stanley P. DB - ccm DO - 10.1097/MLR.0b013e31816080fe DP - EBSCOhost IS - 5 KW - Eye Diseases -- Epidemiology -- California Hispanic Americans Acculturation Adult Aged Aged, 80 and Over California Chi Square Test Confidence Intervals Cross Sectional Studies Data Analysis Software Data Analysis, Statistical Descriptive Statistics Eye Diseases -- Risk Factors Female Funding Source Interviews Male Mexico Middle Age Odds Ratio P-Value Scales Socioeconomic Factors Step-Wise Multiple Regression Vision Screening Human N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Acculturation Rating Scale (Cuellar). Grant Information: P30 EY003040/EY/NEI NIH HHS/United States. NLM UID: 0230027. PMID: NLM18438198. PY - 2008 SN - 0025-7079 SP - 497-506 ST - Burden and predictors of undetected eye disease in Mexican-Americans: the Los Angeles Latino Eye Study T2 - Medical Care TI - Burden and predictors of undetected eye disease in Mexican-Americans: the Los Angeles Latino Eye Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105787697&site=ehost-live&scope=site VL - 46 ID - 4597 ER - TY - JOUR AB - Purpose: To report 6-month and 1 year outcomes of eyes treated for neovascular glaucoma (NVG) with intravitreal bevacizumab injection and panretinal laser (PRP) compared to those receiving PRP alone. Design: retrospective, consecutive case series. Methods: Charts of patients with NVG from retinal ischemia and at least 6 months of follow-up were reviewed. Patients were treated with one injection of 1.25 mg intravitreal bevacizumab followed by PRP or with PRP alone. The primary outcome was the long-term angle anatomy. Secondary measures included intraocular pressure (IOP), visual acuity, patient compliance, and control of systemic diseases. Results: Fourteen eyes of 12 patients treated with bevacizumab and PRP and 15 eyes of 11 patients treated with PRP alone were included in the study. Mean sectors of open angle at baseline was 1.31 in the bevacizumab group and 1.47 in the retinal ablation group (P = 0.73). Mean sectors of open angle was 2.14 and 1.18 in the bevacizumab and retinal ablation groups, respectively (P < 0.05) at 6-month follow-up, and 2.27 and 1.18, respectively (P < 0.05) at 1-year follow-up. Mean baseline IOP was 32.3 mmHg (±14.8) in the bevacizumab group and 31.8 mmHg (±13) in the PRP group (P = 0.75). At 6-month follow-up, the mean IOP was 18.28 mmHg (±10) in the bevacizumab group and 23.33 mmHg (±14.6) in the PRP group (P = 0.05), and 19.12 mmHg (±6.8) and 26.2 mmHg (±18) (P = 0.1), respectively at 1-year follow-up. Nineteen patients were judged to be noncompliant, 10 had uncontrolled diabetes and 7 had uncontrolled hypertension. Conclusions: This study documents better long-term preservation of open angle and IOP control in eyes receiving bevacizumab along with PRP. We stress that NVG is still associated with poor visual acuity outcomes. © © Mary Ann Liebert, Inc. 2009. AD - M. P. Blair, University of Illinois, Eye and Ear Infi Rmary, 1855 W Taylor Street, Chicago, IL 60612, United States AU - Vasudev, D. AU - Blair, M. P. AU - Galasso, J. AU - Kapur, R. AU - Vajaranant, T. C1 - alphagan(Allergan,United States) detantol(Santen,Japan) pivalephrine(Santen,Japan) sanpilo(Santen,Japan) timoptol(Santen,Japan) trusopt(Banyu,Japan) xalatan(Pfizer,United States) C2 - Allergan(United States) Banyu(Japan) Pfizer(United States) Santen(Japan) DB - Embase Medline DO - 10.1089/jop.2009.0036 IS - 5 KW - bevacizumab brimonidine bunazosin dipivefrine dorzolamide latanoprost pilocarpine timolol maleate unclassified drug adult article clinical article controlled study diabetes mellitus follow up human hypertension intraocular pressure laser neovascular glaucoma panretinal laser patient attitude patient compliance retina detachment retina ischemia treatment outcome visual acuity alphagan detantol pivalephrine sanpilo timoptol trusopt xalatan LA - English M3 - Article N1 - L355511342 2009-12-23 PY - 2009 SN - 1080-7683 SP - 453-458 ST - Intravitreal bevacizumab for neovascular glaucoma T2 - Journal of Ocular Pharmacology and Therapeutics TI - Intravitreal bevacizumab for neovascular glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355511342&from=export http://dx.doi.org/10.1089/jop.2009.0036 VL - 25 ID - 3331 ER - TY - JOUR AB - Purpose: To report 6-month and 1 year outcomes of eyes treated for neovascular glaucoma (NVG) with intravitreal bevacizumab injection and panretinal laser (PRP) compared to those receiving PRP alone. Design: retrospective, consecutive case series. Methods: Charts of patients with NVG from retinal ischemia and at least 6 months of follow-up were reviewed. Patients were treated with one injection of 1.25 mg intravitreal bevacizumab followed by PRP or with PRP alone. The primary outcome was the long-term angle anatomy. Secondary measures included intraocular pressure (IOP), visual acuity, patient compliance, and control of systemic diseases. Results: Fourteen eyes of 12 patients treated with bevacizumab and PRP and 15 eyes of 11 patients treated with PRP alone were included in the study. Mean sectors of open angle at baseline was 1.31 in the bevacizumab group and 1.47 in the retinal ablation group (P = 0.73). Mean sectors of open angle was 2.14 and 1.18 in the bevacizumab and retinal ablation groups, respectively (P < 0.05) at 6-month follow-up, and 2.27 and 1.18, respectively (P < 0.05) at 1-year follow-up. Mean baseline IOP was 32.3 mmHg (±14.8) in the bevacizumab group and 31.8 mmHg (±13) in the PRP group (P = 0.75). At 6-month follow-up, the mean IOP was 18.28 mmHg (±10) in the bevacizumab group and 23.33 mmHg (±14.6) in the PRP group (P = 0.05), and 19.12 mmHg (±6.8) and 26.2 mmHg (±18) (P = 0.1), respectively at 1-year follow-up. Nineteen patients were judged to be noncompliant, 10 had uncontrolled diabetes and 7 had uncontrolled hypertension. Conclusions: This study documents better long-term preservation of open angle and IOP control in eyes receiving bevacizumab along with PRP. We stress that NVG is still associated with poor visual acuity outcomes. © © Mary Ann Liebert, Inc. 2009. AD - University of Illinois, Eye and Ear Infi Rmary, 1855 W Taylor Street, Chicago, IL 60612, United States AU - Vasudev, D. AU - Blair, M. P. AU - Galasso, J. AU - Kapur, R. AU - Vajaranant, T. DB - Scopus DO - 10.1089/jop.2009.0036 IS - 5 M3 - Article N1 - Cited By :21 Export Date: 19 July 2021 PY - 2009 SP - 453-458 ST - Intravitreal bevacizumab for neovascular glaucoma T2 - Journal of Ocular Pharmacology and Therapeutics TI - Intravitreal bevacizumab for neovascular glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350434088&doi=10.1089%2fjop.2009.0036&partnerID=40&md5=7e56377820ff8db4d2d15c0fffe88b82 VL - 25 ID - 5135 ER - TY - JOUR AB - Purpose: To report 6-month and 1 year outcomes of eyes treated for neovascular glaucoma (NVG) with intravitreal bevacizumab injection and panretinal laser (PRP) compared to those receiving PRP alone. Design: retrospective, consecutive case series. Methods: Charts of patients with NVG from retinal ischemia and at least 6 months of follow-up were reviewed. Patients were treated with one injection of 1.25 mg intravitreal bevacizumab followed by PRP or with PRP alone. The primary outcome was the long-term angle anatomy. Secondary measures included intraocular pressure (IOP), visual acuity, patient compliance, and control of systemic diseases. Results: Fourteen eyes of 12 patients treated with bevacizumab and PRP and 15 eyes of 11 patients treated with PRP alone were included in the study. Mean sectors of open angle at baseline was 1.31 in the bevacizumab group and 1.47 in the retinal ablation group (P = 0.73). Mean sectors of open angle was 2.14 and 1.18 in the bevacizumab and retinal ablation groups, respectively (P < 0.05) at 6-month follow-up, and 2.27 and 1.18, respectively (P < 0.05) at 1-year follow-up. Mean baseline IOP was 32.3 mmHg (+/- 14.8) in the bevacizumab group and 31.8 mmHg (+/- 13) in the PRP group (P = 0.75). At 6-month follow-up, the mean IOP was 18.28 mmHg (+/- 10) in the bevacizumab group and 23.33 mmHg (+/- 14.6) in the PRP group (P = 0.05), and 19.12 mmHg (+/- 6.8) and 26.2 mmHg (+/- 18) (P = 0.1), respectively at 1-year follow-up. Nineteen patients were judged to be noncompliant, 10 had uncontrolled diabetes and 7 had uncontrolled hypertension. Conclusions: This study documents better long-term preservation of open angle and IOP control in eyes receiving bevacizumab along with PRP. We stress that NVG is still associated with poor visual acuity outcomes. AN - WOS:000271143000010 AU - Vasudev, D. AU - Blair, M. P. AU - Galasso, J. AU - Kapur, R. AU - Vajaranant, T. DA - OCT DO - 10.1089/jop.2009.0036 IS - 5 PY - 2009 SN - 1080-7683 1557-7732 SP - 453-458 ST - Intravitreal Bevacizumab for Neovascular Glaucoma T2 - JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS TI - Intravitreal Bevacizumab for Neovascular Glaucoma VL - 25 ID - 6113 ER - TY - JOUR AB - Purpose: To report 6-month and 1 year outcomes of eyes treated for neovascular glaucoma (NVG) with intravitreal bevacizumab injection and panretinal laser (PRP) compared to those receiving PRP alone.Design: retrospective, consecutive case series.Methods: Charts of patients with NVG from retinal ischemia and at least 6 months of follow-up were reviewed. Patients were treated with one injection of 1.25 mg intravitreal bevacizumab followed by PRP or with PRP alone. The primary outcome was the long-term angle anatomy. Secondary measures included intraocular pressure (IOP), visual acuity, patient compliance, and control of systemic diseases.Results: Fourteen eyes of 12 patients treated with bevacizumab and PRP and 15 eyes of 11 patients treated with PRP alone were included in the study. Mean sectors of open angle at baseline was 1.31 in the bevacizumab group and 1.47 in the retinal ablation group (P = 0.73). Mean sectors of open angle was 2.14 and 1.18 in the bevacizumab and retinal ablation groups, respectively (P < 0.05) at 6-month follow-up, and 2.27 and 1.18, respectively (P < 0.05) at 1-year follow-up. Mean baseline IOP was 32.3 mmHg (+/-14.8) in the bevacizumab group and 31.8 mmHg (+/-13) in the PRP group (P = 0.75). At 6-month follow-up, the mean IOP was 18.28 mmHg (+/-10) in the bevacizumab group and 23.33 mmHg (+/-14.6) in the PRP group (P = 0.05), and 19.12 mmHg (+/-6.8) and 26.2 mmHg (+/-18) (P = 0.1), respectively at 1-year follow-up. Nineteen patients were judged to be noncompliant, 10 had uncontrolled diabetes and 7 had uncontrolled hypertension.Conclusions: This study documents better long-term preservation of open angle and IOP control in eyes receiving bevacizumab along with PRP. We stress that NVG is still associated with poor visual acuity outcomes. AD - Eye and Ear Infirmary, University of Illinois, Chicago, Illinois 60612, USA Eye and Ear Infirmary, University of Illinois, Chicago, Illinois. AN - 105233944. Language: English. Entry Date: 20100129. Revision Date: 20200708. Publication Type: journal article AU - Vasudev, D. AU - Blair, M. P. AU - Galasso, J. AU - Kapur, R. AU - Vajaranant, T. AU - Vasudev, Deepta AU - Blair, Michael P. AU - Galasso, John AU - Kapur, Rashmi AU - Vajaranant, Thasarat DB - ccm DO - 10.1089/jop.2009.0036 DP - EBSCOhost IS - 5 KW - Angiogenesis Inhibitors -- Therapeutic Use Antibodies, Monoclonal -- Therapeutic Use Glaucoma -- Drug Therapy Angiogenesis Inhibitors -- Administration and Dosage Antibodies, Monoclonal -- Administration and Dosage Combined Modality Therapy Glaucoma -- Surgery Human Injections Intraocular Pressure Laser Therapy -- Methods Middle Age Patient Compliance Retina -- Surgery Retrospective Design Visual Acuity Vitreous Body N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: P30EY001792/EY/NEI NIH HHS/United States. NLM UID: 9511091. PMID: NLM19857107. PY - 2009 SN - 1080-7683 SP - 453-458 ST - Intravitreal bevacizumab for neovascular glaucoma T2 - Journal of Ocular Pharmacology & Therapeutics TI - Intravitreal bevacizumab for neovascular glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105233944&site=ehost-live&scope=site VL - 25 ID - 4489 ER - TY - JOUR AB - Objective: To summarize pharmacy database studies of persistence with ocular hypotensives and review the literature of adherence with 2 additional classes of medication - antihypertensives and antihyperlipidemics - comparing methods used to analyze adherence in the 3 treatment areas. Data Sources: A search of MEDLINE (1990-2004) was conducted, using search terms designed to identify English-language articles describing adherence or persistence with any of the 3 drug classes of interest. Study Selection and Data Extraction: All articles identified through MEDLINE were reviewed and screened for use of an automated pharmacy database as an information source, quantitative results provided, and follow-up duration of at least 90 days. Details of methods used to estimate adherence or persistence and estimates of persistence with ocular hypotensive therapy, antihypertensives, and lipid-lowering agents were extracted. Data Synthesis: All studies describing the use of ocular hypotensives, and the majority of studies in the other treatment areas, identified inception cohorts of drug initiators. Use of survival analysis techniques to analyze adherence to medication therapy was less common in the hypertension and hyperlipidemia treatment adherence literature than in literature about glaucoma. In the treatment of hypertension, use of angiotensin II receptor antagonists or angiotensin-converting enzyme inhibitors was associated with higher levels of adherence. Statins in treatment of hyperlipidemia and topical prostaglandins as ocular hypotensive medications were also associated with higher levels of adherence. Conclusions: Findings regarding the relative superiority of specific drug classes were consistent within each therapeutic area, with less consistency in identifying other predictors of adherence. Increased use of survival analysis in future studies of persistence might improve comparability of results across studies. AD - Epidemiology, Ingenix i3 Drug Safety, Waltham, MA, United States Department of Ambulatory Care and Prevention, Harvard Medical School and Hard Pilgrim Health Care, Boston, MA, United States Pfizer US Outcomes Research, New York, NY, United States Baxter Bioscience Medical Outcomes Research and Economics, Westlake Village, CA, United States Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Medford, MA, United States Department of Pharmacy, University of Washington, Seattle, WA, United States Department of Pharmacy, University of Washington, United States Amgen, Seattle, WA, United States Ingenix i3 Drug Safety, United States New York University, New York, NY, United States 950 Winter St., Waltham, MA 02451, United States AU - Velentgas, P. AU - Sheffield, R. AU - Nordstrom, B. L. AU - Johnson, E. AU - Do, T. AU - Mentor, S. M. AU - Seeger, J. D. DB - Scopus DO - 10.1177/875512250702300406 IS - 4 M3 - Review N1 - Export Date: 19 July 2021 PY - 2007 SP - 221-231 ST - Persistence with medications in glaucoma management, hypertension, and dyslipidemia T2 - Journal of Pharmacy Technology TI - Persistence with medications in glaucoma management, hypertension, and dyslipidemia UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548243689&doi=10.1177%2f875512250702300406&partnerID=40&md5=4fe7f7c2c3d4eb44690a49f09d24b903 VL - 23 ID - 5770 ER - TY - JOUR AB - Fuchs' heterochromic iridocyclitis (FHI), an unusual form of uveitis of unknown etiology, is frequently misdiagnosed. Purpose: To report the analysis of 26 patients (27 eyes) with FHI who were diagnosed and observed over a period of 1-7 years (mean: 3.42 ± 2.2 years). Methods: Ocular and systemic examinations were performed on all patients. Results: The most common presenting symptom was visual deterioration (42.3%); one patient was affected bilaterally. Characteristic keratic precipitates (100%), cataracts (77.8%), and heterochromia (70.4%) were the major signs. Eleven eyes (40.7%) required cataract surgery. At the initial examination, four eyes (14.8%) had glaucoma, and no new cases of glaucoma developed during the follow-up period. One eye required filtration surgery. Vitrectomy was performed in two eyes (7.4%) because of vitreous opacities. Most patients (73.0%) did not require active treatment; pre- and postoperative anti-inflammatory treatment for cataract extraction was performed successfully to minimize the risk of inflammation. No severe uveitis was seen in any patient after surgery, but visual acuity did not improve greatly after cataract extraction; 54.5% eyes had visual acuity better than 20/40 before surgery, and 45.4% postoperatively. Conclusion: Posterior capsule opacification, glaucoma, and vitreous opacity were the major obstacles to visual rehabilitation after cataract surgery in patients with this type of uveitis. AD - Inst. Oftalmobiol. Aplicada (IOBA), Fac. de Medicina, University of Valladolid, Ramón y Cajal 7, Valladolid 47005, Spain AU - Velilla, S. AU - Dios, E. AU - Herreras, J. M. AU - Calonge, M. DB - Scopus DO - 10.1076/ocii.9.3.169.3964 IS - 3 KW - Cyclitis Fuchs' heterochromic iridocyclitis Heterochromia Secondary glaucoma Uveitis M3 - Article N1 - Cited By :46 Export Date: 19 July 2021 PY - 2001 SP - 169-175 ST - Fuchs' heterochromic iridocyclitis: A review of 26 cases T2 - Ocular Immunology and Inflammation TI - Fuchs' heterochromic iridocyclitis: A review of 26 cases UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035718363&doi=10.1076%2focii.9.3.169.3964&partnerID=40&md5=b1fd69f906924d13ad515d14a7caeef1 VL - 9 ID - 5006 ER - TY - JOUR AB - Fuchs' heterochromic iridocyclitis (FHI), an unusual form of uveitis of unknown etiology, is frequently misdiagnosed. Purpose: To report the analysis Of 26 patients (27 eyes) with FHI who were diagnosed and observed over a period of 1-7 years (mean: 3.42 +/-2.2 years). Methods: Ocular and systemic examinations were performed on all patients. Results: The most common presenting symptom was visual deterioration (42.3%); one patient was affected bilaterally. Characteristic keratic precipitates (100%), cataracts (77.8%), and heterochromia (70.4%) were the major signs. Eleven eyes (40.7%) required cataract surgery. At the initial examination, four eyes (14.8%) had glaucoma, and no new cases of glaucoma developed during the follow-up period. One eye required filtration surgery. Vitrectomy was performed in two eyes (7.4%) because of vitreous opacities. Most patients (73.0%) did not require active treatment; pre- and postoperative anti-inflammatory treatment for cataract extraction was performed successfully to minimize the risk of inflammation. No severe uveitis was seen in any patient after surgery, but visual acuity did not improve greatly after cataract extraction; 54.5% eyes had visual acuity better than 20/40 before surgery, and 45.4% postoperatively. Conclusion: Posterior capsule opacification, glaucoma, and vitreous opacity were the major obstacles to visual rehabilitation after cataract surgery in patients with this type of uveitis. AN - WOS:000172902500005 AU - Velilla, S. AU - Dios, E. AU - Herreras, J. M. AU - Calonge, M. DA - SEP DO - 10.1076/ocii.9.3.169.3964 IS - 3 PY - 2001 SN - 0927-3948 SP - 169-175 ST - Fuchs' heterochromic iridocyclitis: A review of 26 cases T2 - OCULAR IMMUNOLOGY AND INFLAMMATION TI - Fuchs' heterochromic iridocyclitis: A review of 26 cases VL - 9 ID - 6187 ER - TY - JOUR AB - James Joyce, unanimously considered one of the greatest novelists of the 20th century, suffered from several diseases. A series of adverse circumstances progressively deteriorated his health, already precarious because of his very disorderly life habits. Aim of the present study is to summarize the various organic diseases Joyce suffered during his lifetime, as long as the main diagnostic conclusions found in scientific literature. Severe eye problems, caused by recurrent iritis attacks even complicated by glaucoma and cataracts, led him almost to blindness. Undernourishment and irregular eating, great anxiety and alcohol abuse were the major causes of the peptic ulcer which tortured him for many years, causing his final death. To these conditions should also be added dental caries, venereal diseases and recurrent polyarthritis. The hypothesis according which Joyce suffered from neurosyphilis is still debated and should be sufficiently demonstrated, whereas a spondyloarthropathy, either Reiter's syndrome or ankylosing spondylitis, appears more likely. Therapies against these diseases, easily treated today, did not result efficient because of his poor compliance, as well as the state of the art of medical science during his lifetime. A detailed paleopathologic study of Joyce's human remains could allow to solve the diagnostic doubts concerning his main disease. AD - L. Ventura, UOC di Anatomia Patologica, ASL N 4 L'Aquila, Ospedale San Salvatore, Coppito 67100 L'Aquila, Italy AU - Ventura, L. DB - Embase Medline IS - 2 KW - alcohol abuse ankylosing spondylitis anxiety article cataract dental caries eating habit glaucoma human iritis malnutrition neurosyphilis paleopathology patient compliance peptic ulcer polyarthritis Reiter syndrome rheumatic disease sexually transmitted disease LA - Italian M3 - Article N1 - L352777579 2008-12-22 PY - 2008 SN - 0048-7449 SP - 150-158 ST - Portrait of the artist as a sick man. Rheumatological pathography of James Joyce (1882-1941) T2 - Reumatismo TI - Portrait of the artist as a sick man. Rheumatological pathography of James Joyce (1882-1941) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352777579&from=export http://www.reumatismo.org/admin/filesArticoli/60-2-150.pdf VL - 60 ID - 3402 ER - TY - JOUR AB - Introduction: Adherence to glaucoma medications is essential for successful treatment of the disease but is complex and difficult for many of our patients. Health coaching has been used successfully in the treatment of other chronic diseases. This pilot study explores the use of health coaching for glaucoma care. Methods: A mixed methods study design was used to assess the health coaching intervention for glaucoma patients. The health coaching intervention consisted of four to six health coaching sessions with a certified health coach via telephone. Quantitative measures included demographic and health information, adherence to glaucoma medications (using the visual analog adherence scale and medication event monitoring system), and an exit survey rating the experience. Qualitative measures included a precoaching health questionnaire, notes made by the coach during the intervention, and an exit interview with the subjects at the end of the study. Results: Four glaucoma patients participated in the study; all derived benefits from the health coaching. Study subjects demonstrated increased glaucoma drop adherence in response to the coaching intervention, in both visual analog scale and medication event monitoring system. Study subjects’ qualitative feedback reflected a perceived improvement in both eye and general health self-care. The subjects stated that they would recommend health coaching to friends or family members. Conclusion: Health coaching was helpful to the glaucoma patients in this study; it has the potential to improve glaucoma care and overall health. AD - J.A. Rosdahl, Duke University Medical Center, 2351 Erwin Road, DUMC Box no 3802, Durham, NC, United States AU - Vin, A. AU - Schneider, S. AU - Muir, K. W. AU - Rosdahl, J. A. DB - Embase DO - 10.2147/OPTH.S92935 KW - NCT02090777 antiglaucoma agent aged article case report controlled clinical trial controlled study demography drug surveillance program feasibility study female glaucoma glaucoma surgery health coaching human interview laser surgery male medical information medication compliance patient compliance patient counseling pilot study prospective study questionnaire self care telephone unspecified side effect visual analog scale LA - English M3 - Article N1 - L606619176 2015-11-09 2015-11-13 PY - 2015 SN - 1177-5483 1177-5467 SP - 1931-1943 ST - Health coaching for glaucoma care: A pilot study using mixed methods T2 - Clinical Ophthalmology TI - Health coaching for glaucoma care: A pilot study using mixed methods UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606619176&from=export http://dx.doi.org/10.2147/OPTH.S92935 VL - 9 ID - 2864 ER - TY - JOUR AB - Examined and analyzed variations in the behavior of conforming and nonconforming medically diagnosed individuals, with reference to the sick role construct formulated by Parsons. Data were obtained from interviews of glaucoma patients for whom eye drops were prescribed. Where possible, related studies augmented the testing of hypotheses derived from Parsons' theoretical framework. Findings suggest that the conflicts inherent in the sick role may be compounded by conflicts between this role and the normal social role obligations of the individuals involved. According to the theory, a patient's resolution of these conflicts will be influenced by his definition of the situation in which he is interacting. To increase the probability of compliance, 1 of the responsibilities of nursing would be to contribute to the patient's definition of the situation so that the resolution of the conflict is in the direction of compliance. This may assist patients' attaining the maximal benefits from their prescriptions. This does not imply just 'more information' but a careful evaluation of what kinds of information would be most helpful, most meaningful, and least ambiguous for each patient. The increased numbers of individuals who have had medications prescribed for them on an outpatient basis emphasize the importance of the need for further research in this already apparent problem of noncompliant patient behavior. (22 ref.) (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1972-23590-001 AU - Vincent, Pauline DB - psyh DO - 10.1097/00006199-197111000-00008 DP - EBSCOhost IS - 6 KW - patient noncompliance sick vs. normal social role & information given to patient glaucoma patients Adolescent Adult Aged Attitude to Health Behavior Cooperative Behavior Female Glaucoma Humans Male Middle Aged Physician-Patient Relations Socioeconomic Factors United States Conflict Conformity (Personality) Disorders Nurses Roles N1 - Case Western Reserve U. Release Date: 19720801. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: EnglishMajor Descriptor: Conflict; Conformity (Personality); Disorders; Nurses; Roles. Classification: Psychological & Physical Disorders (3200). Population: Human (10). Page Count: 8. Issue Publication Date: Nov, 1971. PY - 1971 SN - 0029-6562 1538-9847 SP - 509-516 ST - Factors influencing patient noncompliance: A theoretical approach T2 - Nursing Research TI - Factors influencing patient noncompliance: A theoretical approach UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1972-23590-001&site=ehost-live&scope=site VL - 20 ID - 4896 ER - TY - JOUR AB - Post-lingual deafness is a stressful condition which is rendered even more painful by the sudden emotional isolation that the patient suffers. Cogan's syndrome is a rare autoimmune cause for post-lingual deafness characterized by non-syphilitic interstitial keratitis, bilateral audio vestibular deficiencies and systemic vasculitis. World over very few cases of Cogan's syndrome have been reported. Cochlear implant surgery in such a patient is a challenging but highly satisfactory experience due to the multitude of clinical problems the patient faces. This demands a proper work up, meticulous surgery and stringent post-operative follow-up. Here we present a patient with atypical Cogan's syndrome, diabetes mellitus and hypothyroidism. She went into a major depression with suicidal tendency following the complete loss of hearing. We performed cochlear implant surgery in this patient, but not before facing several clinical obstacles, helped by a dedicated team consisting of a rheumatologist, endocrinologist, neurophysician, psychiatrist, anaesthetists and audiologist. The results are extremely satisfying for the patient and all the people involved. This case underlines the prime importance of hearing in maintaining the psychological well being of a human being. © 2007 Springer-Verlag. AD - Department of Otorhinolaryngology and Head and Neck Surgery, B J Medical College, Civil Hospital, Ahmedabad, India 18, Triveni Pk. Soc., Ghatlodia Post, Ahmedabad, Gujarat 380061, India AU - Vishwakarma, R. AU - Shawn, T. J. DB - Scopus DO - 10.1007/s00405-007-0362-5 IS - 10 KW - Autoimmune disease Cochlear implant Cogan's syndrome Keratitis Sensorineural hearing loss M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 2007 SP - 1121-1124 ST - Cochlear implant in Cogan's syndrome T2 - European Archives of Oto-Rhino-Laryngology TI - Cochlear implant in Cogan's syndrome UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-36649031900&doi=10.1007%2fs00405-007-0362-5&partnerID=40&md5=8802fd019d15fdad6d60ef00c096ad15 VL - 264 ID - 5262 ER - TY - JOUR AB - Post-lingual deafness is a stressful condition which is rendered even more painful by the sudden emotional isolation that the patient suffers. Cogan's syndrome is a rare autoimmune cause for post-lingual deafness characterized by non-syphilitic interstitial keratitis, bilateral audio vestibular deficiencies and systemic vasculitis. World over very few cases of Cogan's syndrome have been reported. Cochlear implant surgery in such a patient is a challenging but highly satisfactory experience due to the multitude of clinical problems the patient faces. This demands a proper work up, meticulous surgery and stringent post-operative follow-up. Here we present a patient with atypical Cogan's syndrome, diabetes mellitus and hypothyroidism. She went into a major depression with suicidal tendency following the complete loss of hearing. We performed cochlear implant surgery in this patient, but not before facing several clinical obstacles, helped by a dedicated team consisting of a rheumatologist, endocrinologist, neurophysician, psychiatrist, anaesthetists and audiologist. The results are extremely satisfying for the patient and all the people involved. This case underlines the prime importance of hearing in maintaining the psychological well being of a human being. AN - WOS:000249300600001 AU - Vishwakarma, R. AU - Shawn, T. J. DA - OCT DO - 10.1007/s00405-007-0362-5 IS - 10 PY - 2007 SN - 0937-4477 SP - 1121-1124 ST - Cochlear implant in Cogan's syndrome T2 - EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY TI - Cochlear implant in Cogan's syndrome VL - 264 ID - 6277 ER - TY - JOUR AD - A. Vogel, Universitäts-Augenklinik, Langenbeckstraße 1, 55131 Mainz, Germany AU - Vogel, A. AU - Pfeiffer, N. AU - Schwenn, O. DB - Embase Medline DO - 10.1007/s00347-002-0719-5 IS - 12 KW - antiglaucoma agent glaucoma human patient care patient compliance review treatment outcome LA - German M3 - Review N1 - L35470326 2003-01-02 PY - 2002 SN - 0941-293X SP - 964-972 ST - Patient compliance in glaucoma therapy T2 - Ophthalmologe TI - Patient compliance in glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35470326&from=export http://dx.doi.org/10.1007/s00347-002-0719-5 VL - 99 ID - 3838 ER - TY - JOUR AB - Purpose Of Review: Glaucoma patients commonly suffer from ocular surface disease (OSD). As treatment strategies, medications and devices for the treatment of OSD as well as glaucoma surgical approaches evolve rapidly, it is important to consider their application to these patients.Recent Findings: OSD in glaucoma patients may lead to reduced reliability of diagnostic tests, decreased medication compliance, poor surgical outcomes, and overall decreased quality of life. Chronic use of topical glaucoma medications has been linked to the development of limbal stem cell deficiency, and the role of preservatives in OSD continues to be demonstrated. Preservative free glaucoma medications as well as new anti-inflammatory agents for the treatment of OSD are now available. Omega-3 fatty acid supplementation and punctal plugs have been shown to benefit glaucoma patients with OSD. Drop burden may be reduced through the use of the new sustained-release delivery systems, selective laser trabeculoplasty, and minimally invasive glaucoma surgery.Summary: There are multiple emerging strategies for managing OSD that may be applied to patients with glaucoma. With continued research and clinical experiences, we hope to better understand the multifaceted relationship between glaucoma and OSD and develop evidence-based algorithms for the management of these complex patients. AD - Ophthalmic Consultants of Boston New England Eye Center, Tufts University School of Medicine, Boston, Massachusetts, USA AN - 148513744. Language: English. Entry Date: 20210223. Revision Date: 20210714. Publication Type: journal article AU - Voicu, Laura AU - Salim, Sarwat DB - ccm DO - 10.1097/ICU.0000000000000739 DP - EBSCOhost IS - 2 KW - Eyelid Diseases -- Therapy Corneal Diseases -- Therapy Lacrimal Apparatus Diseases -- Therapy Dry Eye Syndromes -- Therapy Conjunctival Diseases -- Therapy Glaucoma -- Complications Antiinflammatory Agents -- Therapeutic Use Antihypertensive Agents -- Therapeutic Use Glaucoma -- Drug Therapy Quality of Life Human Pharmaceutical Additives -- Therapeutic Use Intraocular Pressure -- Physiology Ferrans and Powers Quality of Life Index Scales N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Longitudinal Interval Follow-Up Evaluation (LIFE); Ferrans and Powers Quality of Life Index. NLM UID: 9011108. PMID: NLM33492867. PY - 2021 SN - 1040-8738 SP - 134-140 ST - New strategies for the management of ocular surface disease in glaucoma patients T2 - Current Opinion in Ophthalmology TI - New strategies for the management of ocular surface disease in glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148513744&site=ehost-live&scope=site VL - 32 ID - 4157 ER - TY - JOUR AB - Purpose: To examine outcomes through 36 months in phakic eyes with newly diagnosed primary open-angle glaucoma (POAG) naïve to therapy randomized to treatment with two trabecular micro-bypass stents or topical prostaglandin. Methods: Subjects with POAG naïve to therapy, with intraocular pressure (IOP) ≥21 and ≤40 mmHg, were randomized to implantation of two stents or travoprost. Additional medication was to be prescribed post-treatment for elevated IOP or glaucomatous optic nerve findings. Of 101 randomized subjects, 100 subjects were followed for 24 months and 73 subjects were followed for 36 months. Follow-up on all subjects is ongoing. Results: In this randomized cohort of 101 POAG subjects, 54 subjects underwent 2-stent surgery and 47 received topical travoprost. Mean pre-treatment IOP was 25.5 ± 2.5 mmHg in stent-treated eyes and 25.1 ± 4.6 mmHg in medication-treated eyes. By 3 years, mean IOP was 14.6 mmHg in stent eyes (with medication added in 6 eyes) and 15.3 mmHg in travoprost eyes (with a second medication added in 11 eyes). In the subset of eyes that did not require additional medical therapy, mean IOP was 14.5 mmHg and 15.7 mmHg in the respective groups. Ninety-one percent of stent eyes had 3-year IOP ≤18 mmHg without additional therapy (62% ≤ 15 mmHg) and 79% of travoprost eyes had 3-year IOP ≤18 mmHg (21% ≤ 15 mmHg). Safety was favorable in both groups. Conclusions: In this prospective, randomized comparison of subjects with newly diagnosed POAG naïve to therapy, substantial IOP reduction with a favorable low complication rate was shown through 3 years after either 2 trabecular stents implanted as the sole procedure or topical travoprost therapy. These data suggest 2-stent implantation may be a viable initial treatment option comparable to topical prostaglandin in newly diagnosed POAG patients. Trial registration: ClinicalTrials.gov identifier, NCT01443988. Funding: Glaukos Corporation, Laguna Hills, CA. © 2016, The Author(s). AD - Vold Vision, PLLC, Fayetteville, AR, United States S.V. Malayan Ophthalmology Centre, Yerevan, Armenia Berlin Eye Research Institute and Augenklinik Spreebogen, Berlin, Germany University Hospital Heidelberg, Heidelberg, Germany Birmingham City Hospital, Birmingham, United Kingdom Manchester Royal Eye Hospital, Manchester, United Kingdom University of Toronto, Toronto, ON, Canada McGill University, Montreal, QC, Canada AU - Vold, S. D. AU - Voskanyan, L. AU - Tetz, M. AU - Auffarth, G. AU - Masood, I. AU - Au, L. AU - Ahmed, I. I. K. AU - Saheb, H. DB - Scopus DO - 10.1007/s40123-016-0065-3 IS - 2 KW - Glaucoma IOP MIGS POAG Prostaglandin Trabecular bypass M3 - Article N1 - Cited By :33 Export Date: 19 July 2021 PY - 2016 SP - 161-172 ST - Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months T2 - Ophthalmology and Therapy TI - Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066351008&doi=10.1007%2fs40123-016-0065-3&partnerID=40&md5=28e69b1ba14b003089aba2198f01f813 VL - 5 ID - 5044 ER - TY - JOUR AB - To examine outcomes through 36 months in phakic eyes with newly diagnosed primary open-angle glaucoma (POAG) na < ve to therapy randomized to treatment with two trabecular micro-bypass stents or topical prostaglandin. Subjects with POAG na < ve to therapy, with intraocular pressure (IOP) ae 21 and ae 40 mmHg, were randomized to implantation of two stents or travoprost. Additional medication was to be prescribed post-treatment for elevated IOP or glaucomatous optic nerve findings. Of 101 randomized subjects, 100 subjects were followed for 24 months and 73 subjects were followed for 36 months. Follow-up on all subjects is ongoing. In this randomized cohort of 101 POAG subjects, 54 subjects underwent 2-stent surgery and 47 received topical travoprost. Mean pre-treatment IOP was 25.5 +/- 2.5 mmHg in stent-treated eyes and 25.1 +/- 4.6 mmHg in medication-treated eyes. By 3 years, mean IOP was 14.6 mmHg in stent eyes (with medication added in 6 eyes) and 15.3 mmHg in travoprost eyes (with a second medication added in 11 eyes). In the subset of eyes that did not require additional medical therapy, mean IOP was 14.5 mmHg and 15.7 mmHg in the respective groups. Ninety-one percent of stent eyes had 3-year IOP ae 18 mmHg without additional therapy (62% ae 15 mmHg) and 79% of travoprost eyes had 3-year IOP ae 18 mmHg (21% ae 15 mmHg). Safety was favorable in both groups. In this prospective, randomized comparison of subjects with newly diagnosed POAG na < ve to therapy, substantial IOP reduction with a favorable low complication rate was shown through 3 years after either 2 trabecular stents implanted as the sole procedure or topical travoprost therapy. These data suggest 2-stent implantation may be a viable initial treatment option comparable to topical prostaglandin in newly diagnosed POAG patients. Trial registration: ClinicalTrials.gov identifier, NCT01443988. Glaukos Corporation, Laguna Hills, CA. AN - WOS:000389469600004 AU - Vold, S. D. AU - Voskanyan, L. AU - Tetz, M. AU - Auffarth, G. AU - Masood, I. AU - Au, L. AU - Ahmed, I. I. K. AU - Saheb, H. DA - DEC DO - 10.1007/s40123-016-0065-3 IS - 2 PY - 2016 SN - 2193-8245 2193-6528 SP - 161-172 ST - Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months T2 - OPHTHALMOLOGY AND THERAPY TI - Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months VL - 5 ID - 6146 ER - TY - JOUR AB - Objective: To assess the degree to which glaucoma treatment guidelines have been incorporated into daily practices and to describe the therapeutic practices chosen for patients with insufficient intraocular pressure (IOP) control. Methods: Ophthalmologists in private practice in Germany were surveyed to obtain information about patients who exhibited unsatisfactory progress with IOP-lowering pharmacotherapy. Using a questionnaire, physicians provided data concerning treatment difficulty, target IOP, number and type of medications used, two most recent IOP readings, and optic nerve head and visual field observations. Results: Of the 853 patients analyzed, primary open-angle glaucoma was the diagnosis for 67.1%, and other diagnoses included ocular hypertension, normal tension glaucoma, and Pseudoexfoliation glaucoma. Target IOP levels had been determined for 95.5% of patients, and not achieving the target pressure was identified as a treatment difficulty for 81.0% of patients. Of patients on monotherapy, β-blockers were prescribed most often (42.3%). Of all patients, 53.3% were treated with two or more agents as either fixed or non-fixed combinations. The non-fixed combination of a prostaglandin and carbonic anhydrase inhibitor was the most frequently prescribed dual therapy (19.2%). Non-fixed prostaglandin plus β-blocker was used by 18.0% of dual therapy patients, whereas the available fixed combination was used by 10.5%. Non-compliance was identified as a cause of unsatisfactory IOP-lowering in 26.8% of all patients. This study is limited by its descriptive, non-interventional design. Conclusions: Treatment alterations are necessary to achieve sufficient IOP control in some patients. If these patients were to take advantage of more aggressive therapies as outlined by treatment guidelines, including newer formulations and fixed combination preparations, both efficacy and compliance may be improved. © 2008 Informa UK Ltd. All rights reserved. AD - F. Kimmich, Eyecons, Woeschbacherstr. 37, D76319 Pfinztal, Germany AU - Vorwerk, C. AU - Thelen, U. AU - Buchholz, P. AU - Kimmich, F. DB - Embase Medline DO - 10.1185/030079908X291976 IS - 5 KW - alpha 2 adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor dorzolamide latanoprost metipranolol miotic agent pilocarpine prostaglandin timolol aged article drug efficacy female glaucoma human intraocular hypertension intraocular pressure major clinical study male monotherapy open angle glaucoma optic nerve patient compliance practice guideline prescription private practice pseudoexfoliation questionnaire visual field LA - English M3 - Article N1 - L351741560 2008-07-10 PY - 2008 SN - 0300-7995 SP - 1295-1301 ST - Treatment of glaucoma patients with insufficient intraocular pressure control: A survey of German ophthalmologists in private practice T2 - Current Medical Research and Opinion TI - Treatment of glaucoma patients with insufficient intraocular pressure control: A survey of German ophthalmologists in private practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351741560&from=export http://dx.doi.org/10.1185/030079908X291976 VL - 24 ID - 3455 ER - TY - JOUR AB - Objective: To assess the degree to which glaucoma treatment guidelines have been incorporated into daily practices and to describe the therapeutic practices chosen for patients with insufficient intraocular pressure (IOP) control.Methods: Ophthalmologists in private practice in Germany were surveyed to obtain information about patients who exhibited unsatisfactory progress with IOP-lowering pharmacotherapy. Using a questionnaire, physicians provided data concerning treatment difficulty, target IOP, number and type of medications used, two most recent IOP readings, and optic nerve head and visual field observations.Results: Of the 853 patients analyzed, primary open-angle glaucoma was the diagnosis for 67.1%, and other diagnoses included ocular hypertension, normal tension glaucoma, and pseudoexfoliation glaucoma. Target IOP levels had been determined for 95.5% of patients, and not achieving the target pressure was identified as a treatment difficulty for 81.0% of patients. Of patients on monotherapy, beta-blockers were prescribed most often (42.3%). Of all patients, 53.3% were treated with two or more agents as either fixed or non-fixed combinations. The non-fixed combination of a prostaglandin and carbonic anhydrase inhibitor was the most frequently prescribed dual therapy (19.2%). Non-fixed prostaglandin plus beta-blocker was used by 18.0% of dual therapy patients, whereas the available fixed combination was used by 10.5%. Non-compliance was identified as a cause of unsatisfactory IOP-lowering in 26.8% of all patients. This study is limited by its descriptive, non-interventional design.Conclusions: Treatment alterations are necessary to achieve sufficient IOP control in some patients. If these patients were to take advantage of more aggressive therapies as outlined by treatment guidelines, including newer formulations and fixed combination preparations, both efficacy and compliance may be improved. AD - Augenklinik der Otto von Guericke Universität Magdeburg, Magdeburg, Germany Augenklinik der Otto von Guericke Universität Magdeburg, Magdeburg, Germany. AN - 105780237. Language: English. Entry Date: 20080801. Revision Date: 20200708. Publication Type: journal article AU - Vorwerk, C. AU - Thelen, U. AU - Buchholz, P. AU - Kimmich, F. AU - Vorwerk, Christian AU - Thelen, Ulrich AU - Buchholz, Patricia AU - Kimmich, Friedemann DB - ccm DO - 10.1185/030079908X291976 DP - EBSCOhost IS - 5 KW - Adrenergic Beta-Antagonists -- Administration and Dosage Glaucoma -- Diagnosis Glaucoma -- Drug Therapy Intraocular Pressure -- Drug Effects Prostaglandins, Synthetic -- Administration and Dosage Aged Aged, 80 and Over Dose-Response Relationship, Drug Drug Therapy, Combination Female Germany Intraocular Pressure -- Physiology Male Middle Age Ophthalmology -- Methods Patient Compliance Practice Guidelines Practice Patterns -- Standards Private Practice Prognosis Questionnaires Risk Assessment Severity of Illness Indices Surveys Tonometry Treatment Failure Human N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 0351014. PMID: NLM18366862. PY - 2008 SN - 0300-7995 SP - 1295-1301 ST - Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice T2 - Current Medical Research & Opinion TI - Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105780237&site=ehost-live&scope=site VL - 24 ID - 4435 ER - TY - JOUR AB - Purpose: To assess the number of infants at risk of delayed primary congenital glaucoma (PCG) evaluation due to long travel times to specialists. Design: Cross-sectional geospatial service coverage analysis. Methods: All American Glaucoma Society (AGS) and American Association for Pediatric Ophthalmology and Strabismus (AAPOS) provider locations were geocoded using each organization's member directory. Sixty-minute drive time regions to providers were generated using ArcGIS Pro (Esri). The geographic intersection of AGS and AAPOS service areas was computed because patients typically require visits to both types of specialists. American Community Survey data were then overlaid to estimate the number of infants within and beyond the AGS/AAPOS service areas. Results: One thousand twenty-nine AGS and 1,040 AAPOS provider locations were geocoded. The analysis yielded 944,047 infants age 0-1 year (23.6%) who live beyond the AGS/AAPOS service areas. Therefore, approximately 14-94 new PCG cases/year may be at risk of delayed diagnosis as a result of living in a potential service desert. Compared with children living within the AGS/AAPOS service areas, children aged <6 years in these potential service deserts were more likely to live in households earning below the US federal poverty level, lack health insurance, and live in a single-parent home. These communities are disproportionately likely to experience other rural health disparities and are more prevalent across the Great Plains. Conclusion: Service coverage analysis is a useful tool for identifying underserved regions for PCG referrals and evaluation. These data may assist in targeting screening programs in low access areas for pediatric glaucoma care. © 2020 Elsevier Inc. AD - Bascom Palmer Eye Institute, University of Miami Health System, Miami, FL, United States Department of Geography and Regional Studies, University of Miami, Coral Gables, FL, United States Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, FL, United States AU - Vu, D. M. AU - Stoler, J. AU - Rothman, A. L. AU - Chang, T. C. DB - Scopus DO - 10.1016/j.ajo.2020.12.009 M3 - Article N1 - Export Date: 19 July 2021 PY - 2021 SP - 112-119 ST - A Service Coverage Analysis of Primary Congenital Glaucoma Care Across the United States T2 - American Journal of Ophthalmology TI - A Service Coverage Analysis of Primary Congenital Glaucoma Care Across the United States UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100237954&doi=10.1016%2fj.ajo.2020.12.009&partnerID=40&md5=a396bf1c2b2807b1be138abf5a6bc931 VL - 224 ID - 5665 ER - TY - JOUR AB - PURPOSE: To assess the number of infants at risk of delayed primary congenital glaucoma (PCG) evaluation due to long travel times to specialists. DESIGN: Cross-sectional geospatial service coverage analysis. METHODS: All American Glaucoma Society (AGS) and American Association for Pediatric Ophthalmology and Strabismus (AAPOS) provider locations were geocoded using each organization's member directory. Sixty-minute drive time regions to providers were generated using ArcGIS Pro (Esri). The geographic intersection of AGS and AAPOS service areas was computed because patients typically require visits to both types of specialists. American Community Survey data were then overlaid to estimate the number of infants within and beyond the AGS/AAPOS service areas. RESULTS: One thousand twenty-nine AGS and 1,040 AAPOS provider locations were geocoded. The analysis yielded 944,047 infants age 0-1 year (23.6%) who live beyond the AGS/AAPOS service areas. Therefore, approximately 14-94 new PCG cases/year may be at risk of delayed diagnosis as a result of living in a potential service desert. Compared with children living within the AGS/AAPOS service areas, children aged <6 years in these potential service deserts were more likely to live in households earning below the US federal poverty level, lack health insurance, and live in a single-parent home. These communities are disproportionately likely to experience other rural health disparities and are more prevalent across the Great Plains. CONCLUSION: Service coverage analysis is a useful tool for identifying underserved regions for PCG referrals and evaluation. These data may assist in targeting screening programs in low access areas for pediatric glaucoma care. (Am J Ophthalmol 2021;224:112-119. (c) 2020 Elsevier Inc. All rights reserved.) AN - WOS:000640559300012 AU - Vu, D. M. AU - Stoler, J. AU - Rothman, A. L. AU - Chang, T. C. DA - APR DO - 10.1016/j.ajo.2020.12.009 PY - 2021 SN - 0002-9394 1879-1891 SP - 112-119 ST - A Service Coverage Analysis of Primary Congenital Glaucoma Care Across the United T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - A Service Coverage Analysis of Primary Congenital Glaucoma Care Across the United VL - 224 ID - 6140 ER - TY - JOUR AB - The presence of preservatives in eye drops, may have, depending on the concentration, cytotoxic influence on the corneal and conjunctival cells, and may cause the patients' subjective inconveniences. The authors compare the benzalconium chloride (BAC) concentrations in individual drug used for glaucoma treating. The daily dose of BAC was calculated according to the drop's size and BAC concentration. The daily dose of BAC differs depending on the selected therapy markedly--doses in the range from 0 to 10 micrograms were found. The BAC concentration is one of important factors affecting the patient's compliance in the treatment of the primary open angle glaucoma. AD - P. Výborný, Ocní oddelení UVN--Ocní klinika 1 LF UK a UVN, Praha. AU - Výborný, P. AU - Sejcková, L. DB - Medline IS - 4 KW - benzalkonium eye drops preservative article chemistry human open angle glaucoma patient compliance LA - Czech M3 - Article N1 - L44471635 2006-10-04 PY - 2006 SN - 1211-9059 SP - 270-272, 274 ST - Antiglaucoma drugs--content of preservatives and the patient's compliance T2 - Ceská a slovenská oftalmologie : casopis Ceské oftalmologické spolecnosti a Slovenské oftalmologické spolecnosti TI - Antiglaucoma drugs--content of preservatives and the patient's compliance UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44471635&from=export VL - 62 ID - 3603 ER - TY - JOUR AB - PURPOSE. Continuous light increment perimetry (CLIP) is an improved testing strategy for automated static perimetry designed to save test time and enhance patient compliance. CLIP uses a modified ramp stimulus where stimulus intensity is continuously increased according to patient reaction time, starting from a subthreshold intensity until recognition. The test is constantly modified according to patient performance. As CLIP showed good results in normal subjects in previous studies, the authors now compared CLIP to the standard 4/2-full threshold (4/2) strategy in glaucoma patients. METHODS. Fifty-two patients with glaucomatous visual field defects (mean sensitivities 2.9 to 18.4 dB), all with perimetric experience, were tested with CLIP (three times) and 4/2 in a randomized fashion. Tests were performed at 55 test locations within the central 30° visual field (24-2 area) using the Twinfield perimeter. RESULTS. Average mean sensitivity was significantly higher for CLIP than for 4/2 (t test, p<0.0001). Absolute scotomas and extension of scotomas were comparable for both strategies, whereas CLIP found less deep relative scotomas in some cases. Mean test time was significantly shorter for CLIP (5.6 min) compared to 4/2 (8.9 min) (Wilcoxon signed rank test, p<0.0001). Patient acceptance was better for CLIP than for 4/2. CONCLUSIONS. CLIP showed comparable results to 4/2 with excellent patient acceptance. Mean sensitivities are 1.8 dB higher than for 4/2; similar results were found previously in normal subjects. CLIP was able to save a mean 38% of test time compared to full threshold strategy with good reproducibility. © Wichtig Editore, 2005. AD - B.K. Wabbels, University of Bonn, Department of Ophthalmology, Abbestr. 2, D-53127 Bonn, Germany AU - Wabbels, B. K. AU - Diehm, S. AU - Kolling, G. DB - Embase Medline DO - 10.1177/112067210501500611 IS - 6 KW - adult aged article continuous light increment perimetry controlled study glaucoma human intermethod comparison major clinical study patient compliance performance perimetry priority journal reproducibility reaction time scotoma sensitivity and specificity visual field defect Twinfield perimeter LA - English M3 - Article N1 - L43074698 2006-01-27 PY - 2005 SN - 1120-6721 SP - 722-729 ST - Continuous light increment perimetry compared to full threshold strategy in glaucoma T2 - European Journal of Ophthalmology TI - Continuous light increment perimetry compared to full threshold strategy in glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43074698&from=export http://dx.doi.org/10.1177/112067210501500611 VL - 15 ID - 3710 ER - TY - JOUR AB - Purpose: To evaluate the interest of glaucoma patients and their caregivers in a smartphone-based and tablet-based glaucoma application (App), developed by the Wills Eye Glaucoma Research Center in collaboration with Drexel University. Materials and Methods: Cross-sectional survey of patients with glaucoma and their caregivers. Main outcome measures are answers to survey questions regarding how receptive participants are to using the Glaucoma App. Results: Fifty subjects completed the survey. The mean age (SD) was 59.5 (±17.3) years. A total of 88.6% of the participants lived in a household with access to a smartphone or tablet. The majority (72.3%) of participants would consider downloading the Glaucoma App, and younger participants (<65 y) were more likely to do so compared with their older (Z65 y) counterparts, P=0.025. Participants were more likely to download the App if it was free of charge, compared with a version that costs $3, P=0.018. Although only about one third (37.8%) of participants used eye drop reminders, nearly 3 of 4 (72.9%) participants were receptive to using the automated reminder feature of the Glaucoma App. Conclusions: Glaucoma patients and their caregivers were very interested in using a Glaucoma App; however, many were not willing to spend $3 for an App they seem to value. The free Wills Eye Glaucoma App currently available on the Apple store, includes educational videos, eye drop and appointment reminders, medical and ocular data storage, visual field tutorial, and intraocular pressure tracker. These features aim to increase patients' level of knowledge about glaucoma and improve their adherence to medication and follow-up appointment recommendations. AD - M. Waisbourd, Glaucoma Research Center, Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA, United States AU - Waisbourd, M. AU - Dhami, H. AU - Zhou, C. AU - Hsieh, M. AU - Abichandani, P. AU - Pro, M. J. AU - Moster, M. R. AU - Katz, L. J. AU - Hark, L. A. AU - Myers, J. S. DB - Embase Medline DO - 10.1097/IJG.0000000000000504 IS - 9 KW - antiglaucoma agent eye drops adult African American aged article caregiver Caucasian clinical article cross-sectional study female follow up glaucoma glaucoma surgery health care cost human low level laser therapy male medication compliance mobile application outcome assessment patient compliance patient education perimetry priority journal smartphone LA - English M3 - Article N1 - L611815284 2016-08-30 2016-09-28 PY - 2016 SN - 1536-481X 1057-0829 SP - e787-e791 ST - The Wills eye glaucoma app: Interest of patients and their caregivers in a smartphone-based and tablet-based glaucoma application T2 - Journal of Glaucoma TI - The Wills eye glaucoma app: Interest of patients and their caregivers in a smartphone-based and tablet-based glaucoma application UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611815284&from=export http://dx.doi.org/10.1097/IJG.0000000000000504 VL - 25 ID - 2772 ER - TY - JOUR AB - Purpose: To evaluate the interest of glaucoma patients and their caregivers in a smartphone-based and tablet-based glaucoma application (App), developed by the Wills Eye Glaucoma Research Center in collaboration with Drexel University. Materials and Methods: Cross-sectional survey of patients with glaucoma and their caregivers. Main outcome measures are answers to survey questions regarding how receptive participants are to using the Glaucoma App. Results: Fifty subjects completed the survey. The mean age (SD) was 59.5 (±17.3) years. A total of 88.6% of the participants lived in a household with access to a smartphone or tablet. The majority (72.3%) of participants would consider downloading the Glaucoma App, and younger participants (<65 y) were more likely to do so compared with their older (Z65 y) counterparts, P=0.025. Participants were more likely to download the App if it was free of charge, compared with a version that costs $3, P=0.018. Although only about one third (37.8%) of participants used eye drop reminders, nearly 3 of 4 (72.9%) participants were receptive to using the automated reminder feature of the Glaucoma App. Conclusions: Glaucoma patients and their caregivers were very interested in using a Glaucoma App; however, many were not willing to spend $3 for an App they seem to value. The free Wills Eye Glaucoma App currently available on the Apple store, includes educational videos, eye drop and appointment reminders, medical and ocular data storage, visual field tutorial, and intraocular pressure tracker. These features aim to increase patients' level of knowledge about glaucoma and improve their adherence to medication and follow-up appointment recommendations. © 2016 Wolters Kluwer Health, Inc. AD - Glaucoma Research Center, Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA 19107, United States Drexel University's ISchool, College of Engineering, Philadelphia, PA, United States AU - Waisbourd, M. AU - Dhami, H. AU - Zhou, C. AU - Hsieh, M. AU - Abichandani, P. AU - Pro, M. J. AU - Moster, M. R. AU - Katz, L. J. AU - Hark, L. A. AU - Myers, J. S. DB - Scopus DO - 10.1097/IJG.0000000000000504 IS - 9 KW - Adherence App Glaucoma application Patient education M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 SP - e787-e791 ST - The Wills eye glaucoma app: Interest of patients and their caregivers in a smartphone-based and tablet-based glaucoma application T2 - Journal of Glaucoma TI - The Wills eye glaucoma app: Interest of patients and their caregivers in a smartphone-based and tablet-based glaucoma application UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983354786&doi=10.1097%2fIJG.0000000000000504&partnerID=40&md5=26a37f4a06987ae21f90d871b98e06e9 VL - 25 ID - 5356 ER - TY - JOUR AB - Purpose: To evaluate the interest of glaucoma patients and their caregivers in a smartphone-based and tablet-based glaucoma application (App), developed by the Wills Eye Glaucoma Research Center in collaboration with Drexel University. Materials and Methods: Cross-sectional survey of patients with glaucoma and their caregivers. Main outcome measures are answers to survey questions regarding how receptive participants are to using the Glaucoma App. Results: Fifty subjects completed the survey. The mean age (SD) was 59.5 (+/- 17.3) years. A total of 88.6% of the participants lived in a household with access to a smartphone or tablet. The majority (72.3%) of participants would consider downloading the Glaucoma App, and younger participants (< 65 y) were more likely to do so compared with their older (>= 65 y) counterparts, P=0.025. Participants were more likely to download the App if it was free of charge, compared with a version that costs $ 3, P=0.018. Although only about one third (37.8%) of participants used eye drop reminders, nearly 3 of 4 (72.9%) participants were receptive to using the automated reminder feature of the Glaucoma App. Conclusions: Glaucoma patients and their caregivers were very interested in using a Glaucoma App; however, many were not willing to spend $ 3 for an App they seem to value. The free Wills Eye Glaucoma App currently available on the Apple store, includes educational videos, eye drop and appointment reminders, medical and ocular data storage, visual field tutorial, and intraocular pressure tracker. These features aim to increase patients' level of knowledge about glaucoma and improve their adherence to medication and follow-up appointment recommendations. AN - WOS:000384521100005 AU - Waisbourd, M. AU - Dhami, H. AU - Zhou, C. AU - Hsieh, M. AU - Abichandani, P. AU - Pro, M. J. AU - Moster, M. R. AU - Katz, L. J. AU - Hark, L. A. AU - Myers, J. S. DA - SEP DO - 10.1097/IJG.0000000000000504 IS - 9 PY - 2016 SN - 1057-0829 1536-481X SP - E787-E791 ST - The Wills Eye Glaucoma App: Interest of Patients and Their Caregivers in a Smartphone-based and Tablet-based Glaucoma Application T2 - JOURNAL OF GLAUCOMA TI - The Wills Eye Glaucoma App: Interest of Patients and Their Caregivers in a Smartphone-based and Tablet-based Glaucoma Application VL - 25 ID - 5928 ER - TY - JOUR AB - Purpose: To report the outcomes of bilateral, same-day laser peripheral iridotomy (LPI) in the Philadelphia Glaucoma Detection and Treatment Project. Methods: The Philadelphia Glaucoma Detection and Treatment Project was a community-based initiative aimed to improve detection, management, treatment, and follow-up care of individuals at high risk for glaucoma. This novel project performed LPI, where 2 eyes received laser therapy on the same day. Of the 1649 patients examined between January 1, 2013 and May 31, 2014, patients who underwent bilateral, same-day LPI were included in our analysis. Main outcome measures were visual acuity, intraocular pressure (IOP), and postoperative complication rates. Results: A total of 132 eyes of 66 patients underwent bilateral, same-day LPI. Mean visual acuity remained unchanged following treatment (P=0.85). Eight patients (12.1%) had IOP spikes >5 mm Hg following treatment, and 4 patients (6.1%) spiked >10 mm Hg. IOP returned to normal in all but 1 patient, who was diagnosed with chronic angle-closure glaucoma. Hyphema was reported in 2 patients (3%) and glare in 1 patient (1.5%). Thirteen patients (19.7%) had repeat LPI treatment. All patients successfully tolerated LPI treatment without serious complications. Conclusions: Performing bilateral, same-day LPI was well tolerated in a large community-based, glaucoma detection and treatment project. Applying this treatment strategy may be considered in similar settings, where patients' access to eye care is limited and it may be a cost-effective strategy. © 2016 Wolters Kluwer Health, Inc. AD - Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA 19107, United States Department of Ophthalmology, Temple University, School of Medicine, Philadelphia, PA, United States Thomas Jefferson University, School of Pharmacy, Philadelphia, PA, United States AU - Waisbourd, M. AU - Shafa, A. AU - Delvadia, R. AU - Sembhi, H. AU - Molineaux, J. AU - Henderer, J. AU - Pizzi, L. T. AU - Myers, J. S. AU - Hark, L. A. AU - Katz, L. J. DB - Scopus DO - 10.1097/IJG.0000000000000409 IS - 10 KW - angle closure bilateral same-day ocular procedures glaucoma detection laser peripheral iridotomy M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2016 SP - e821-e825 ST - Bilateral same-day laser peripheral iridotomy in the philadelphia glaucoma detection and treatment project T2 - Journal of Glaucoma TI - Bilateral same-day laser peripheral iridotomy in the philadelphia glaucoma detection and treatment project UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960123283&doi=10.1097%2fIJG.0000000000000409&partnerID=40&md5=c4b18868ea14120aa3a5547d896f8adc VL - 25 ID - 5378 ER - TY - JOUR AB - Purpose: To study patient characteristics and management profile in advanced glaucoma. Method: A retrospective study of 87 case notes of patients registered blind due to glaucoma, and cross-sectional interview of 29 patients. Results: advanced glaucoma at presentation was documented in 43 cases (49%). Insufficient optometry assessment was significantly associated with advanced disease (p = 0.0339). Normal tension glaucoma patients were significantly more likely to present with advanced disease compared to other types of glaucoma (p = 0.0034). Poor compliance with medication was significantly higher in those with hearing loss (p = 0.0168). Patients with advanced field defect at presentation and those with poor compliance had significantly higher social deprivation scores compared to others on the blind register (p < 0.0001). Nine (10%) patients had partial registration before full registration and 29 (33%) patients had late registration. Of the 29 patients interviewed, 20 (69%) did not demonstrate basic knowledge regarding their disease or its management; nor had they received written information on glaucoma or instructions on drop technique. Conclusion: Special care pathways are required in advanced glaucoma taking into account co-existent morbidity, disease education and compliance. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Wallace, Elizabeth Jane, Department of Ophthalmology, Tayside University Hospitals Trust, Dundee, United Kingdom, DD1 9SY AN - 2007-19969-001 AU - Wallace, Elizabeth Jane AU - Paterson, Helen AU - Miller, Shirley AU - Sinclair, Anne AU - Sanders, Roshini AU - Hinds, Alison DB - psyh DO - 10.1177/0264619607083835 DP - EBSCOhost IS - 1 KW - patient characteristics case management advanced glaucoma blind Client Characteristics Glaucoma N1 - Queen Margaret Hospital, Dunfermline, United Kingdom. Release Date: 20080317. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: EnglishMajor Descriptor: Blind; Case Management; Client Characteristics; Glaucoma. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10). Location: United Kingdom. Age Group: Childhood (birth-12 yrs) (100); School Age (6-12 yrs) (180); Adolescence (13-17 yrs) (200); Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Scottish Index of Multiple Deprivation; Mini Mental State Examination [Appended]. Methodology: Empirical Study; Followup Study; Longitudinal Study; Prospective Study; Retrospective Study; Quantitative Study. References Available: Y. Page Count: 17. Issue Publication Date: Jan, 2008. PY - 2008 SN - 0264-6196 1744-5809 SP - 7-23 ST - Patient profile and management in advanced glaucoma T2 - British Journal of Visual Impairment TI - Patient profile and management in advanced glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2007-19969-001&site=ehost-live&scope=site jwallace3@nhs.net VL - 26 ID - 4861 ER - TY - JOUR AB - PURPOSE: To compare the ocular hypotensive efficacy and safety of a once-daily (pm) fixed-dose combination (FDC) product containing netarsudil 0.02% and latanoprost 0.005% with monotherapy with netarsudil or latanoprost. Netarsudil is a Rho kinase inhibitor that lowers intraocular pressure (IOP) primarily by increasing trabecular (conventional) outflow. Latanoprost is the most frequently prescribed of the prostaglandin analogs, which lower IOP primarily by increasing uveoscleral outflow. DESIGN: Three-month, double-masked, randomized (1:1:1), phase 3, superiority study. PARTICIPANTS: Patients had unmedicated IOP > 20 to <36 mmHg at 8:00 am and met other standard criteria for open-angle glaucoma and ocular hypertension. METHODS: Randomization to once-daily (pm) netarsudil/latanoprost FDC, netarsudil, or latanoprost for 3 months. MAIN OUTCOME MEASURES: Mean IOP at 8:00 am, 10:00 am, and 4:00 pm at week 2, week 6, and month 3 (intent-to-treat). Statistical superiority was concluded if the P value for the comparison of netarsudil/latanoprost FDC with each component was <0.05 and the difference in mean IOP (netarsudil/latanoprost FDC minus comparator) was <0 for all time points at all visits. Safety was recorded throughout the treatment period. RESULTS: A total of 750 patients were enrolled, with 90.2%, 89.4%, and 94.4% completing 3 months of treatment with netarsudil/latanoprost FDC, netarsudil, and latanoprost, respectively. Least-squares mean treated IOP ranged from 15.3 to 16.5 mmHg for netarsudil/latanoprost FDC, 17.4 to 19.8 mmHg for netarsudil, and 17.1 to 18.1 mmHg for latanoprost. Netarsudil/latanoprost FDC met the criteria for superiority to each active component at all 9 time points (all P < 0.0001), lowering IOP by an additional 2.2 to 3.3 mmHg versus netarsudil and an additional 1.5 to 2.4 mmHg versus latanoprost. At month 3, the proportion of patients achieving mean diurnal IOP ≤ 15 mmHg was 42.1% for netarsudil/latanoprost FDC, 15.8% for netarsudil, and 18.3% for latanoprost. No treatment-related serious adverse event (AE) was observed. Treatment-related systemic AEs were minimal. The most frequent ocular AE was conjunctival hyperemia (netarsudil/latanoprost FDC, 54.5%; netarsudil, 42.7%; latanoprost, 22.3%), which was generally mild. CONCLUSIONS: Once-daily netarsudil/latanoprost FDC demonstrated IOP reductions that were statistically and clinically superior to its individual components at all 9 time points over 3 months, with tolerable ocular safety. This FDC offers a reduced treatment burden that may improve adherence and clinical outcomes. Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. AD - Austin, TX, United States University of Toronto, Mississauga, ON, Canada Aerie Pharmaceuticals, Inc., Irvine, California; Bedminster, New Jersey; and Durham, North Carolina; Sacramento Eye Consultants, Sacramento, California Statistics & Data Corporation, Tempe, AZ, Italy Aerie Pharmaceuticals, Inc., Irvine, California; Bedminster, New Jersey; and Durham, North Carolina AU - Walters, T. R. AU - Ahmed, I. I. K. AU - Lewis, R. A. AU - Usner, D. W. AU - Lopez, J. AU - Kopczynski, C. C. AU - Heah, T. AU - Group, Mercury- Study DB - Scopus DO - 10.1016/j.ogla.2019.03.007 IS - 5 M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 2019 SP - 280-289 ST - Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study T2 - Ophthalmology. Glaucoma TI - Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070212628&doi=10.1016%2fj.ogla.2019.03.007&partnerID=40&md5=0a58b01f645aaeaa385b63b1bf156b32 VL - 2 ID - 5175 ER - TY - JOUR AB - Purpose: To compare the ocular hypotensive efficacy and safety of a once-daily (PM) fixed-dose combination (FDC) product containing netarsudil 0.02% and latanoprost 0.005% with monotherapy with netarsudil or latanoprost. Netarsudil is a Rho kinase inhibitor that lowers intraocular pressure (IOP) primarily by increasing trabecular (conventional) outflow. Latanoprost is the most frequently prescribed of the prostaglandin analogs, which lower IOP primarily by increasing uveoscleral outflow. Design: Three-month, double-masked, randomized (1:1:1), phase 3, superiority study. Participants: Patients had unmedicated IOP > 20 to <36 mmHg at 8:00 AM and met other standard criteria for open-angle glaucoma and ocular hypertension. Methods: Randomization to once-daily (PM) netarsudil/latanoprost FDC, netarsudil, or latanoprost for 3 months. Main Outcome Measures: Mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and month 3 (intent-to-treat). Statistical superiority was concluded if the P value for the comparison of netarsudil/latanoprost FDC with each component was <0.05 and the difference in mean IOP (netarsudil/latanoprost FDC minus comparator) was <0 for all time points at all visits. Safety was recorded throughout the treatment period. Results: A total of 750 patients were enrolled, with 90.2%, 89.4%, and 94.4% completing 3 months of treatment with netarsudil/latanoprost FDC, netarsudil, and latanoprost, respectively. Least-squares mean treated IOP ranged from 15.3 to 16.5 mmHg for netarsudil/latanoprost FDC, 17.4 to 19.8 mmHg for netarsudil, and 17.1 to 18.1 mmHg for latanoprost. Netarsudil/latanoprost FDC met the criteria for superiority to each active component at all 9 time points (all P < 0.0001), lowering IOP by an additional 2.2 to 3.3 mmHg versus netarsudil and an additional 1.5 to 2.4 mmHg versus latanoprost. At month 3, the proportion of patients achieving mean diurnal IOP <= 15 mmHg was 42.1% for netarsudil/latanoprost FDC, 15.8% for netarsudil, and 18.3% for latanoprost. No treatment-related serious adverse event (AE) was observed. Treatment-related systemic AEs were minimal. The most frequent ocular AE was conjunctival hyperemia (netarsudil/latanoprost FDC, 54.5%; netarsudil, 42.7%; latanoprost, 22.3%), which was generally mild. Conclusions: Once-daily netarsudil/latanoprost FDC demonstrated IOP reductions that were statistically and clinically superior to its individual components at all 9 time points over 3 months, with tolerable ocular safety. This FDC offers a reduced treatment burden that may improve adherence and clinical outcomes. (C) 2019 by the American Academy of Ophthalmology. AN - WOS:000660581700002 AU - Walters, T. R. AU - Ahmed, I. I. K. AU - Lewis, R. A. AU - Usner, D. W. AU - Lopez, J. AU - Kopczynski, C. C. AU - Heah, T. AU - Grp, Mercury- Study DA - SEP-OCT DO - 10.1016/j.ogla.2019.03.007 IS - 5 PY - 2019 SN - 2589-4234 2589-4196 SP - 280-289 ST - Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study T2 - OPHTHALMOLOGY GLAUCOMA TI - Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study VL - 2 ID - 6355 ER - TY - JOUR AB - Hyphema (blood in the anterior chamber) can occur after blunt or lacerating trauma, after intraocular surgery, spontaneously (e.g., in conditions such as rubeosis iridis, juvenile xanthogranuloma, iris melanoma, myotonic dystrophy, keratouveitis (e.g., herpes zoster), leukemia, hemophilia, von Willebrand disease, and in association with the use of substances that alter platelet or thrombin function (e.g., ethanol, aspirin, warfarin). The purpose of this review is to consider the management of hyphemas that occur after closed globe trauma. Complications of traumatic hyphema include increased intraocular pressure, peripheral anterior synechiae, optic atrophy, corneal bloodstaining, secondary hemorrhage, and accommodative impairment. The reported incidence of secondary anterior chamber hemorrhage, that is, rebleeding, in the setting of traumatic hyphema ranges from 0% to 38%. The risk of secondary hemorrhage may be higher in African-Americans than in whites. Secondary hemorrhage is generally thought to convey a worse visual prognosis, although the outcome may depend more directly on the size of the hyphema and the severity of associated ocular injuries. Some issues involved in managing a patient with hyphema are: use of various medications (e.g., cycloplegics, systemic or topical steroids, antifibrinolytic agents, analgesics, and antiglaucoma medications); the patient's activity level; use of a patch and shield; outpatient vs. inpatient management; and medical vs. surgical management. Special considerations obtain in managing children, patients with hemoglobin S, and patients with hemophilia. It is important to identify and treat associated ocular injuries, which often accompany traumatic hyphema. We consider each of these management issues and refer to the pertinent literature in formulating the following recommendations. We advise routine use of topical cycloplegics and corticosteroids, systemic antifibrinolytic agents or corticosteroids, and a rigid shield. We recommend activity restriction (quiet ambulation) and interdiction of non-steroidal anti-inflammatory agents. If there is no concern regarding compliance (with medication use or activity restrictions), follow-up, or increased risk for complications (e.g., history of sickle cell disease, hemophilia), outpatient management can be offered. Indications for surgical intervention include the presence of corneal blood staining or dangerously increased intraocular pressure despite maximum tolerated medical therapy, among others. © 2002 by Elsevier Science Inc. All rights reserved. AD - M. Zarbin, Inst. of Ophthalmol. and Visual Sci., New Jersey Medical School, Univ. of Med./Dent. of New Jersey, 90 Bergen Street, Newark, NJ 01701-1709, United States AU - Walton, W. AU - Von Hagen, S. AU - Grigorian, R. AU - Zarbin, M. C1 - amicar aspirin cyclokapron(Pharmacia) decadron premarin(Wyeth Ayerst) C2 - Pharmacia Wyeth Ayerst DB - Embase Medline DO - 10.1016/S0039-6257(02)00317-X IS - 4 KW - acetylsalicylic acid alcohol aminocaproic acid analgesic agent antifibrinolytic agent antiglaucoma agent atropine carbomer conjugated estrogen cycloplegic agent dexamethasone nonsteroid antiinflammatory agent placebo prednisone prochlorperazine steroid tranexamic acid warfarin accommodation paralysis adhesion bleeding blood stain blunt trauma clinical trial disease association disease severity eye surgery follow up glaucoma hemophilia human hyphema iris iris rubeosis juvenile xanthogranuloma laceration leukemia melanoma mobilization nausea optic nerve atrophy orthostatic hypotension patient compliance priority journal review sickle cell anemia side effect treatment outcome uveitis Varicella zoster virus vertigo vomiting von Willebrand disease amicar aspirin cyclokapron decadron premarin LA - English M3 - Review N1 - L34879924 2002-08-25 PY - 2002 SN - 0039-6257 SP - 297-334 ST - Management of traumatic hyphema T2 - Survey of Ophthalmology TI - Management of traumatic hyphema UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34879924&from=export http://dx.doi.org/10.1016/S0039-6257(02)00317-X VL - 47 ID - 3854 ER - TY - JOUR AB - Hyphema (blood in the anterior chamber) can occur after blunt or lacerating trauma, after intraocular surgery, spontaneously (e.g., in conditions such as rubeosis iridis, juvenile xanthogranuloma, iris melanoma, myotonic dystrophy, keratouveitis (e.g., herpes zoster), leukemia, hemophilia, von Willebrand disease, and in association with the use of substances that alter platelet or thrombin function (e.g., ethanol, aspirin, warfarin). The purpose of this review is to consider the management of hyphemas that occur after closed globe trauma. Complications of traumatic hyphema include increased intraocular pressure, peripheral anterior synechiae, optic atrophy, corneal bloodstaining, secondary hemorrhage, and accommodative impairment. The reported incidence of secondary anterior chamber hemorrhage, that is, rebleeding, in the setting of traumatic hyphema ranges from 0% to 38%. The risk of secondary hemorrhage may be higher in African-Americans than in whites. Secondary hemorrhage is generally thought to convey a worse visual prognosis, although the outcome may depend more directly on the size of the hyphema and the severity of associated ocular injuries. Some issues involved in managing a patient with hyphema are: use of various medications (e.g., cycloplegics, systemic or topical steroids, antifibrinolytic agents, analgesics, and antiglaucoma medications); the patient's activity level; use of a patch and shield; outpatient vs. inpatient management; and medical vs. surgical management. Special considerations obtain in managing children, patients with hemoglobin S, and patients with hemophilia. It is important to identify and treat associated ocular injuries, which often accompany traumatic hyphema. We consider each of these management issues and refer to the pertinent literature in formulating the following recommendations. We advise routine use of topical cycloplegics and corticosteroids, systemic antifibrinolytic agents or corticosteroids, and a rigid shield. We recommend activity restriction (quiet ambulation) and interdiction of non-steroidal anti-inflammatory agents. If there is no concern regarding compliance (with medication use or activity restrictions), follow-up, or increased risk for complications (e.g., history of sickle cell disease, hemophilia), outpatient management can be offered. Indications for surgical intervention include the presence of corneal blood staining or dangerously increased intraocular pressure despite maximum tolerated medical therapy, among others. © 2002 by Elsevier Science Inc. All rights reserved. AD - Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark, NJ, United States Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, 90 Bergen Street, Newark, NJ 01701-1709, United States AU - Walton, W. AU - Von Hagen, S. AU - Grigorian, R. AU - Zarbin, M. DB - Scopus DO - 10.1016/S0039-6257(02)00317-X IS - 4 KW - Amicar Aminocaproic acid Corneal blood staining Cyclokapron Eye trauma Glaucoma Hyphema Optic atrophy Prednisone Sickle cell disease Tranexamic acid M3 - Review N1 - Cited By :127 Export Date: 19 July 2021 PY - 2002 SP - 297-334 ST - Management of traumatic hyphema T2 - Survey of Ophthalmology TI - Management of traumatic hyphema UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036345775&doi=10.1016%2fS0039-6257%2802%2900317-X&partnerID=40&md5=68eedbe76d730927b09e05d95c2e2a6c VL - 47 ID - 4917 ER - TY - JOUR AB - Hyphema (blood in the anterior chamber) can occur after blunt or lacerating trauma, after intraocular surgery, spontaneously (e.g., in conditions such as rubeosis iridis,juvenile xanthogranuloma, iris melanoma, myotonic dystrophy, keratouveitis (e.g., herpes zoster), leukemia, hemophilia, von Willebrand disease, and in association with the use of Substances that. alter platelet or thrombin function (e.g., ethanol, aspirin, warfarin). The purpose of this review is to consider the management of hyphemas that occur after closed globe trauma. Complications of traumatic hyphema include increased intraocular pressure, peripheral anterior synechiae, optic atrophy, corneal bloodstaining, secondary hemorrhage, and accommodative impairment. The reported incidence of secondary anterior chamber hemorrhage, that is, rebleeding, in the setting of traumatic hyphema ranges from 0% to 38%. The risk of secondary hemorrhage may be higher in African-Americans than in whites. Secondary hemorrhage is generally thought to convey a worse visual prognosis, although the outcome may depend more directly on the size of the hyphema and the severity of associated ocular injuries. Some issues involved in managing a patient with hyphema are: rise of various medications (e.g., cycloplegics, systemic or topical steroids, antifibrinolytic agents, analgesics, and antiglaucoma medications); the patient's activity level; use of a patch and shield; outpatient vs. inpatient management; and medical Vs. surgical management. Special considerations obtain in managing children, patients with hemoglobin S, and patients with hemophilia. It is important to identify and treat associated ocular injuries, which often accompany traumatic hyphema. We consider each of these management issues and refer to the pertinent literature in formulating the following recommendations. We advise routine use of topical cycloplegics and corticosteroids, systemic antifibrinolytic agents or corticosteroids, and a rigid shield. We recommend activity restriction (quiet ambulation) and interdiction of non-steroidal anti-inflammatory agents. If there is no concern regarding compliance (with medication use or activity restrictions), follow-up, or increased risk for complications (e.g., history of sickle cell disease, hemophilia), outpatient management can be offered. Indications for surgical intervention include the presence of corneal blood staining or dangerously increased intraocular pressure despite maximum tolerated medical therapy, among others. (C) 2002 by Elsevier Science Inc. All rights reserved. AN - WOS:000177296300001 AU - Walton, W. AU - Von Hagen, S. AU - Grigorian, R. AU - Zarbin, M. DA - JUL-AUG DO - 10.1016/S0039-6257(02)00317-X IS - 4 PY - 2002 SN - 0039-6257 SP - 297-334 ST - Management of traumatic hyphema T2 - SURVEY OF OPHTHALMOLOGY TI - Management of traumatic hyphema VL - 47 ID - 6351 ER - TY - JOUR AB - Introduction: Compliance to medical treatment expresses the patient's perception of the disease and the treatment prescribed by the doctors. Lack of compliance endangers chronic glaucoma care, which explains the importance it has been given these last years. The objectives of this survey were to evaluate the compliance of adult patients suffering from primary open angle glaucoma to discover the influential factors. Materials and methods: We conducted a survey at the ophthalmology clinic of Le Dantec Hospital from January 1997 to May 1998 among 31 adults being treated for primary open angle glaucoma. An indirect evaluation of the patients' compliance was made on the basis of a questionnaire after examination of their medical files. It was deemed good, average, or bad depending on: regularity of the patient's visits to the doctors, regularity of the treatment, respect of the doctor's prescription and the prescribed times for taking the medicine. The Chi square independence test was used to study the influence of the following factors: age, sex, residence, socioeconomic status, duration of symptom progression, level of instruction, counseling, and treatment. Results: The patients' mean age was 60.5 years. Compliance was deemed good for 29% of the total cases, average for 32.3%, and bad for 38.7%. Only factors such as the regular visits to the doctor, the regularity of the treatment, and respect of the doctor's prescription and the prescribed times for taking the medicine were found to be influential (p<0.05). Conclusion: The medical treatment of primary open angle glaucoma, whether temporary or permanent, with a maximum of efficacy and a minimum of side-effects requires good compliance on the part of the patient. This compliance in turn requires a good doctor-patient relationship based on effective repeated counseling to educate patients, help them understand the disease, and act on the influential factors. AD - A.M. Wane, BP 17225 Dakar Liberté, Dakar, Senegal AU - Wane, A. M. AU - Ndiaye, M. R. AU - Wade, A. AU - Ndiaye, P. A. AU - Ba, E. A. AU - De Medeiros, M. E. AU - Ndoye, P. A. AU - Ndiaye, C. S. AU - Kameni, A. DB - Embase Medline IS - 10 KW - acetazolamide beta adrenergic receptor blocking agent dipivefrine pilocarpine adult aged article chronic disease clinical article doctor patient relationship drug efficacy female human male open angle glaucoma patient compliance patient counseling patient education socioeconomics LA - French M3 - Article N1 - L38089664 2004-02-03 PY - 2003 SN - 0181-5512 SP - 1039-1044 ST - Compliance of medical treatment in primitive glaucoma open angle T2 - Journal Francais d'Ophtalmologie TI - Compliance of medical treatment in primitive glaucoma open angle UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38089664&from=export VL - 26 ID - 3783 ER - TY - JOUR AB - Introduction: Compliance to medical treatment expresses the patient's perception of the disease and the treatment prescribed by the doctors. Lack of compliance endangers chronic glaucoma care, which explains the importance it has been given these last years. The objectives 14 of this survey were to evaluate the compliance of adult patients suffering from primary open angle glaucoma to discover the influential factors. Materials and methods: We conducted a survey at the ophthalmology clinic of Le Dantec Hospital from January 1997 to May 1998 among 31 adults being treated for primary open angle glaucoma. An indirect evaluation of the patients' compliance was made on the basis of a questionnaire after examination of their medical files. It was deemed good, average, or bad depending on: regularity of the patient's visits to the doctors, regularity of the treatment, respect of the doctor's prescription and the prescribed times for taking the medicine. The Chi square independence test was used to study the influence of the following factors: age, sex, residence, socioeconomic status, duration of symptom progression, level of instruction, counseling, and treatment. Results: The patients' mean age was 60.5 years. Compliance was deemed good for 29% of the total cases, average for 32.3%, and bad for 38.7%. Only factors such as the regular visits to the doctor, the regularity of the treatment, and respect of the doctor's prescription and the prescribed times for taking the medicine were found to be influential (p<0.05). Conclusion: The medical treatment of-primary open angle glaucoma, whether temporary or permanent, with a maximum of efficacy and a minimum of side-effects requires good compliance on the part of the patient. This compliance in turn requires a good doctor-patient relationship based on effective repeated counseling to educate patients, help them understand the disease, and act on the influential factors. AN - WOS:000188428000006 AU - Wane, A. M. AU - Ndiaye, M. R. AU - Wade, A. AU - Ndiaye, P. A. AU - Ba, E. A. AU - de Medeiros, M. E. AU - Ndoye, P. A. AU - Ndiaye, C. S. AU - Kameni, A. DA - DEC IS - 10 PY - 2003 SN - 0181-5512 SP - 1039-1044 ST - Compliance of medical treatment in primitive glaucoma open angle T2 - JOURNAL FRANCAIS D OPHTALMOLOGIE TI - Compliance of medical treatment in primitive glaucoma open angle VL - 26 ID - 6142 ER - TY - JOUR AB - Purpose--Understanding patients' attitudes toward novel therapeutic options can help guide providers in personalizing treatment regimens for glaucoma patients. This study aimed to determine factors associated with acceptance of new drug delivery options among glaucoma patients. Methods--A total of 199 patient volunteers participated in an interviewer-administered survey from June to August 2016 at the Glaucoma Service of Massachusetts Eye and Ear. The questionnaire was designed to determine acceptance of 6 drug delivery approaches: (1) triple combination eye drop, (2) microdose eye spray, (3) drug-eluting contact lens, (4) drug-eluting periocular ring insert, (5) injectable subconjunctival drug insert, and (6) injectable anterior chamber implant. Other factors analyzed included self-reported demographics, disease severity, and prior ocular history. Results--The average respondent age was 63.2 ± 15.1 years; 48% were female. For approaches 1-6 listed above, overall acceptance rates were, respectively, 85%, 54%, 31%, 43%, 32%, and 30%. Patients with greater disease severity and prior incisional glaucoma surgery were more likely to pursue alternatives to traditional eye drops. Conclusions--There is limited acceptance of alternatives to traditional eye drop medications among glaucoma patients. Understanding motivating factors and potential barriers to patient acceptance of novel drug delivery approaches is important in how providers will incorporate these glaucoma treatment options into practice. AD - Tufts University School of Medicine, Boston, Massachusetts Massachusetts Eye and Ear, Boston, Massachusetts University of Massachusetts Medical School, Worcester, Massachusetts AN - 134817512. Language: English. Entry Date: 20190222. Revision Date: 20190222. Publication Type: Article AU - Wang, Benjamin B. AU - Lin, Michael M. AU - Nguyen, Thuan AU - Turalba, Angela V. DB - ccm DO - 10.5693/djo.01.2018.07.001 DP - EBSCOhost IS - 3 KW - Glaucoma -- Therapy Patient Attitudes Drug Delivery Systems Human Surveys Questionnaires Ophthalmic Solutions Drug Combinations Contact Lenses Self Report Severity of Illness Male Female Middle Age Aged Eye, Artificial Glaucoma -- Surgery N1 - questionnaire/scale; research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; USA. NLM UID: 9605355. PY - 2018 SN - 1542-8958 SP - 16-23 ST - Patient attitudes toward novel glaucoma drug delivery approaches T2 - Digital Journal of Ophthalmology TI - Patient attitudes toward novel glaucoma drug delivery approaches UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134817512&site=ehost-live&scope=site VL - 24 ID - 4241 ER - TY - JOUR AB - Purpose: To identify the location of barriers to treatment for glaucoma and cataract among African-American Medicare beneficiaries. Methods: We examined the receipt of eye care in general and care for glaucoma and cataract in particular among black and white Medicare beneficiaries using 1991 Medicare physician claims data. Racial differences in treatment for glaucoma and cataract were examined both for the Medicare population as a whole and for identified eye care users. The results were compared to the expected value of black-white difference based on population prevalence data for each specific condition. Results: Thirty percent of black beneficiaries and 45% of white Medicare beneficiaries used eye care services in 1991. After adjusting for the expected difference in prevalence, black beneficiaries were half as likely to be surgically treated for glaucoma compared to white beneficiaries, and 80% as likely for cataract. When the analysis was restricted to those using eye care services, blacks continued to have lower than expected rates of treatment for glaucoma (observed RR = 3.2, 95% confidence interval = 3.1-3.4 vs an expected RR of 4.3, 95% confidence interval = 3.5-5.4), but a higher rate of treatment for cataract (RR = 1.2, 95% confidence interval = 1.2-1.3). Among those with physician diagnosed glaucoma and cataract, blacks were more likely to undergo surgical treatment for these conditions than whites (RR = 1.5 for glaucoma, 95% confidence interval = 1.4-1.5; RR = 1.2 for cataract, 95% confidence interval = 1.2-1.3). Medicare population as a whole and for identified eye care users. The results were compared to the expected value of black-white difference based on population prevalence data for each specific condition. Conclusion: Barriers to treatment for glaucoma and cataract among black Medicare beneficiaries involve primarily limitations in access to the eye care system. The undertreatment for glaucoma among black beneficiaries was reduced, but not eliminated, after removing the effect of unequal access to the eye care system. AD - J.C. Javitt, Center for Sight, 3800 Reservoir Rd. NW, Washington, DC 20007, United States AU - Wang, F. AU - Javitt, J. C. AU - Tielsch, J. M. DB - Embase Medline DO - 10.3109/09286589709057101 IS - 2 KW - aged article cataract Caucasian female glaucoma health care access human male medicare Black person priority journal race difference statistical analysis LA - English M3 - Article N1 - L27331118 1997-08-19 PY - 1997 SN - 0928-6586 SP - 89-100 ST - Racial variations in treatment for glaucoma and cataract among Medicare recipients T2 - Ophthalmic Epidemiology TI - Racial variations in treatment for glaucoma and cataract among Medicare recipients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L27331118&from=export http://dx.doi.org/10.3109/09286589709057101 VL - 4 ID - 3958 ER - TY - JOUR AB - Medication is one of the important methods in treatment of glaucoma, but misunderstandings of some problems during glaucoma medication still exist, such as how to use and evaluate the drugs and when to use the drugs etc. These are reviewed and discussed in this paper. AD - Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital University of Medical Sciences, Beijing 100730, China AU - Wang, N. L. AU - Li, S. N. DB - Scopus IS - 2 KW - Glaucoma/drug therapy M3 - Editorial N1 - Export Date: 19 July 2021 PY - 2006 SP - 85-88 ST - Misunderstandings of some problems in glaucoma medications T2 - Ophthalmology in China TI - Misunderstandings of some problems in glaucoma medications UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33744496326&partnerID=40&md5=698d2713f19bcd7514f1c714efab4d50 VL - 15 ID - 5773 ER - TY - JOUR AB - Importance: The iStent Trabecular Micro-Bypass (Glaukos Corporation) is a minimally invasive glaucoma implant used in conjunction with cataract surgery to lower intraocular pressure.Objective: To determine whether implantation of the iStent concurrent with cataract surgery is associated with reduced use of ocular antihypertensive medications in a US health care claims database.Design, Setting, and Participants: Retrospective, observational longitudinal cohort study of individuals enrolled in a US managed care network who underwent iStent implantation with cataract surgery (iStent/CEIOL) from 2012 to 2016 (n = 1509 bilateral and n = 1462 unilateral surgery). A control group of individuals who underwent bilateral cataract surgery only (CEIOL) were matched 1:1 to patients undergoing bilateral iStent/CEIOL on baseline demographic and clinical factors. Data were analyzed between November 1, 2017, and January 31, 2018.Main Outcomes and Measures: The number of topical ocular antihypertensive agents used postoperatively by patients undergoing iStent/CEIOL compared with baseline and with matched CEIOL control individuals, and hazard ratios with 95% confidence intervals for sustained reduced use of at least 1 topical ocular antihypertensive agent postoperatively.Results: Of the 2971 eligible enrollees, mean age at first surgery was 74.3 years, and 1659 (55.8%) were women. Patients undergoing iStent/CEIOL had diagnoses that included primary open-angle glaucoma (n = 2329; 78.4%), narrow angles (n = 381; 12.8%), and secondary glaucomas (n = 261; 8.8%). At baseline, 1223 (41.2%) were receiving no topical glaucoma agents; 876 (29.5%), 437 (14.7%), and 435 (14.6%) were receiving 1, 2, or at least 3 agents, respectively. Although only 678 persons (22.8%) completed at least 2 years of postoperative follow-up, the proportion of patients receiving no drops increased postoperatively (64.7%, 20-24 months, P < .001, χ2). Patients receiving at least 1 topical agent at baseline had mean reduction of 1.01 and 0.61 medications used at 20 to 24 months with bilateral or unilateral surgery, respectively (both P < .001, paired t). Sustained reduction in glaucoma medication use was more likely in patients receiving at least 3 vs 1 medication at baseline (hazard ratio, 1.68; 95% CI, 1.36-2.09). Compared with matched control individuals undergoing CEIOL, patients undergoing bilateral iStent/CEIOL had a greater mean reduction in drops used (0.99 vs 0.49; postoperative month 20-24; P < .001; paired t) and a higher proportion receiving no drops postoperatively (73.5% vs 55.3%, postoperative month 20-24; P < .001; χ2).Conclusions and Relevance: Implantation of the iStent trabecular micro-bypass stent concurrent with cataract surgery was associated with moderately reduced use of topical ocular antihypertensive medication. Reduction in the use of glaucoma medications may lessen the burden of medication adverse effects and promote better adherence. AD - Byers Eye Institute, Stanford University, Palo Alto, California Department of Ophthalmology and Visual Sciences, Center for Eye Policy and Innovation, University of Michigan, Ann Arbor Department of Health Management and Policy, University of Michigan, Ann Arbor AN - 134087706. Language: English. Entry Date: 20191121. Revision Date: 20200311. Publication Type: journal article AU - Wang, Sophia Y. AU - Singh, Kuldev AU - Stein, Joshua D. AU - Chang, Robert T. DB - ccm DO - 10.1001/jamaophthalmol.2018.4461 DP - EBSCOhost IS - 1 KW - Stents Antihypertensive Agents -- Administration and Dosage Prostheses and Implants -- Methods Prostheses and Implants Cataract Extraction -- Methods Glaucoma -- Drug Therapy Aged, 80 and Over Lenses, Intraocular Visual Acuity -- Physiology Male Retrospective Design Aged Female United States Administration, Intraocular Glaucoma -- Physiopathology Insurance, Health -- Statistics and Numerical Data Human Prospective Studies Resource Databases Ophthalmic Solutions Tonometry Intraocular Pressure -- Physiology Glaucoma -- Surgery Validation Studies Comparative Studies Evaluation Research Multicenter Studies Scales N1 - research. Journal Subset: Biomedical; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). Grant Information: R01 EY026641/EY/NEI NIH HHS/United States. NLM UID: 101589539. PMID: NLM30267072. PY - 2019 SN - 2168-6165 SP - 21-27 ST - Ocular Antihypertensive Medication Use After iStent Implantation Concurrent With Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database T2 - JAMA Ophthalmology TI - Ocular Antihypertensive Medication Use After iStent Implantation Concurrent With Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134087706&site=ehost-live&scope=site VL - 137 ID - 4270 ER - TY - JOUR AB - Importance: The iStent Trabecular Micro-Bypass (Glaukos Corporation) is a minimally invasive glaucoma implant used in conjunction with cataract surgery to lower intraocular pressure. Objective: To determine whether implantation of the iStent concurrent with cataract surgery is associated with reduced use of ocular antihypertensive medications in a US health care claims database. Design, Setting, and Participants: Retrospective, observational longitudinal cohort study of individuals enrolled in a US managed care network who underwent iStent implantation with cataract surgery (iStent/CEIOL) from 2012 to 2016 (n = 1509 bilateral and n = 1462 unilateral surgery). A control group of individuals who underwent bilateral cataract surgery only (CEIOL) were matched 1:1 to patients undergoing bilateral iStent/CEIOL on baseline demographic and clinical factors. Data were analyzed between November 1, 2017, and January 31, 2018. Main Outcomes and Measures: The number of topical ocular antihypertensive agents used postoperatively by patients undergoing iStent/CEIOL compared with baseline and with matched CEIOL control individuals, and hazard ratios with 95% confidence intervals for sustained reduced use of at least 1 topical ocular antihypertensive agent postoperatively. Results: Of the 2971 eligible enrollees, mean age at first surgery was 74.3 years, and 1659 (55.8%) were women. Patients undergoing iStent/CEIOL had diagnoses that included primary open-angle glaucoma (n = 2329; 78.4%), narrow angles (n = 381; 12.8%), and secondary glaucomas (n = 261; 8.8%). At baseline, 1223 (41.2%) were receiving no topical glaucoma agents; 876 (29.5%), 437 (14.7%), and 435 (14.6%) were receiving 1, 2, or at least 3 agents, respectively. Although only 678 persons (22.8%) completed at least 2 years of postoperative follow-up, the proportion of patients receiving no drops increased postoperatively (64.7%, 20-24 months, P <.001, χ 2 ). Patients receiving at least 1 topical agent at baseline had mean reduction of 1.01 and 0.61 medications used at 20 to 24 months with bilateral or unilateral surgery, respectively (both P <.001, paired t). Sustained reduction in glaucoma medication use was more likely in patients receiving at least 3 vs 1 medication at baseline (hazard ratio, 1.68; 95% CI, 1.36-2.09). Compared with matched control individuals undergoing CEIOL, patients undergoing bilateral iStent/CEIOL had a greater mean reduction in drops used (0.99 vs 0.49; postoperative month 20-24; P <.001; paired t) and a higher proportion receiving no drops postoperatively (73.5% vs 55.3%, postoperative month 20-24; P <.001; χ 2 ). Conclusions and Relevance: Implantation of the iStent trabecular micro-bypass stent concurrent with cataract surgery was associated with moderately reduced use of topical ocular antihypertensive medication. Reduction in the use of glaucoma medications may lessen the burden of medication adverse effects and promote better adherence. © 2018 American Medical Association. All rights reserved. AD - Byers Eye Institute, Stanford University, 2452 Watson Ct, Palo Alto, CA 94303, United States Department of Ophthalmology and Visual Sciences, Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, United States Department of Health Management and Policy, University of Michigan, Ann Arbor, United States AU - Wang, S. Y. AU - Singh, K. AU - Stein, J. D. AU - Chang, R. T. DB - Scopus DO - 10.1001/jamaophthalmol.2018.4461 IS - 1 M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2019 SP - 21-27 ST - Ocular Antihypertensive Medication Use after iStent Implantation Concurrent with Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database T2 - JAMA Ophthalmology TI - Ocular Antihypertensive Medication Use after iStent Implantation Concurrent with Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054186672&doi=10.1001%2fjamaophthalmol.2018.4461&partnerID=40&md5=100055716ed2b9425c52b9732f6c3678 VL - 137 ID - 5300 ER - TY - JOUR AB - IMPORTANCE The iStent Trabecular Micro-Bypass (Glaukos Corporation) is a minimally invasive glaucoma implant used in conjunction with cataract surgery to lower intraocular pressure. OBJECTIVE To determine whether implantation of the iStent concurrent with cataract surgery is associated with reduced use of ocular antihypertensive medications in a US health care claims database. DESIGN, SETTING, AND PARTICIPANTS Retrospective, observational longitudinal cohort study of individuals enrolled in a US managed care network who underwent iStent implantation with cataract surgery (iStent/CEIOL) from 2012 to 2016 (n = 1509 bilateral and n = 1462 unilateral surgery). A control group of individuals who underwent bilateral cataract surgery only (CEIOL) were matched 1:1 to patients undergoing bilateral iStent/CEIOL on baseline demographic and clinical factors. Data were analyzed between November 1, 2017, and January 31, 2018. MAIN OUTCOMES AND MEASURES The number of topical ocular antihypertensive agents used postoperatively by patients undergoing iStent/CEIOL compared with baseline and with matched CEIOL control individuals, and hazard ratios with 95% confidence intervals for sustained reduced use of at least 1 topical ocular antihypertensive agent postoperatively. RESULTS Of the 2971 eligible enrollees, mean age at first surgery was 74.3 years, and 1659 (55.8%) were women. Patients undergoing iStent/CEIOL had diagnoses that included primary open-angle glaucoma (n = 2329; 78.4%), narrow angles (n = 381; 12.8%), and secondary glaucomas (n = 261; 8.8%). At baseline, 1223 (41.2%) were receiving no topical glaucoma agents; 876 (29.5%), 437 (14.7%), and 435 (14.6%) were receiving 1, 2, or at least 3 agents, respectively. Although only 678 persons (22.8%) completed at least 2 years of postoperative follow-up, the proportion of patients receiving no drops increased postoperatively (64.7%, 20-24 months, P < .001, chi(2)). Patients receiving at least 1 topical agent at baseline had mean reduction of 1.01 and 0.61 medications used at 20 to 24 months with bilateral or unilateral surgery, respectively (both P < .001, paired t). Sustained reduction in glaucoma medication use was more likely in patients receiving at least 3 vs 1 medication at baseline (hazard ratio, 1.68; 95% CI, 1.36-2.09). Compared with matched control individuals undergoing CEIOL, patients undergoing bilateral iStent/CEIOL had a greater mean reduction in drops used (0.99 vs 0.49; postoperative month 20-24; P < .001; paired t) and a higher proportion receiving no drops postoperatively (73.5% vs 55.3%, postoperative month 20-24; P < .001; chi(2)). CONCLUSIONS AND RELEVANCE Implantation of the iStent trabecular micro-bypass stent concurrent with cataract surgery was associated with moderately reduced use of topical ocular antihypertensive medication. Reduction in the use of glaucoma medications may lessen the burden of medication adverse effects and promote better adherence. AN - WOS:000455657000008 AU - Wang, S. Y. AU - Singh, K. AU - Stein, J. D. AU - Chang, R. T. DA - JAN DO - 10.1001/jamaophthalmol.2018.4461 IS - 1 PY - 2019 SN - 2168-6165 2168-6173 SP - 21-27 ST - Ocular Antihypertensive Medication Use After iStent Implantation Concurrent With Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database T2 - JAMA OPHTHALMOLOGY TI - Ocular Antihypertensive Medication Use After iStent Implantation Concurrent With Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database VL - 137 ID - 6283 ER - TY - JOUR AB - Purpose: We investigated both the incidence and types of corneal epithelial complications associated with extended wear of the Acuvue disposable soft contact lens, in particular with respect to risk factors for the typical pattern of superficial punctate keratopathy (SPK). Methods: We conducted s retrospective study of 5,478 eyes. Clinical characteristics of the corneal epithelial complications, tear volumes, and patient compliance were analyzed. Results: A total of 3.6% (197 eyes/5,478 eyes) were observed to have a corneal epithelial complication on at least one examination during the entire follow-up period. Among the 197 eyes, 112 eyes were observed to have e complication during the initial 2 weeks of trial lens use. This included nine eyes that developed SPK with only daily wear use of the lenses. Sixty-eight eyes were beginners with no previous contact lens experience. SPK was observed in 193 eyes and corneal infiltrates in four eyes, although there were no cases of corneal epithelial erosion or corneal ulcer. With respect to type of SPK, a 'smile mark' pattern confined to the area below the pupil was observed in 179 eyes (3.3%). Conclusions: The typical pattern of SPK was observed in 3.3% of users of extended wear disposable soft contact lenses, although the condition usually improved with the use of artificial tears. AD - Department of Ophthalmology, Osaka University Medical School, Osaka, Japan Department of Ophthalmology, Osaka University Medical School, 2-2 Yamadaoka, Suita 565, Japan AU - Watanabe, K. AU - Hamano, H. DB - Scopus IS - 2 M3 - Article N1 - Cited By :11 Export Date: 19 July 2021 PY - 1997 SP - 134-137 ST - The typical pattern of superficial punctate keratopathy in wearers of extended wear disposable contact lenses T2 - CLAO Journal TI - The typical pattern of superficial punctate keratopathy in wearers of extended wear disposable contact lenses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030909619&partnerID=40&md5=b8e6d9e768732cee3f9f635240c41eaa VL - 23 ID - 5269 ER - TY - JOUR AB - Background: In this study the authors sought both to understand the health education needs of patients with glaucoma, with particular regard to adherence to glaucoma treatment, and to examine these patients' views of group education. Methods: Using a health promotion approach to health education, 27 qualitative interviews with new and established patients receiving glaucoma treatment were conducted. Health promotion is defined as a way of strengthening people's capacities to control and optimize their own health. The interviews were transcribed and were then analyzed thematically. Results: Nine categories of health education needs were identified from the transcripts: (1) to understand glaucoma; (2) to understand their diagnosis or understand the difficulties in giving a diagnosis; (3) to understand the implications of eye drops, their side effects, and how to renew the eye drops; (4) to feel confident to put in eye drops; (5) to put the condition into perspective - to know how to manage their risk; (6) to be able to ask questions of clinicians; (7) to be able to navigate the health care system; (8) to understand and be able to manage own adherence behavior; and (9) to know where to access other sources of information. The majority of patients had something positive to say about group education, and about half of the patients said they would attend group education if they were offered the opportunity. Conclusion: A health promotion approach identified a wide range of patient-centered health education needs regarding adherence to glaucoma treatment. Group education will be attractive to some patients. Clinicians could use the health education needs identified in this study to guide the development of either individual or group-based educational intervention to improve adherence to glaucoma treatment. However, clinicians need to be aware that when developing a group intervention, attention will need to be given to making the education relevant to the circumstances of each patient. © 2013 Waterman et al, publisher and licensee Dove Medical Press Ltd. AD - H. Waterman, School of Nursing, Midwifery and Social Work, University of Manchester, Jean McFarlane Building, Manchester M13 9PT, United Kingdom AU - Waterman, H. AU - Brunton, L. AU - Fenerty, C. AU - Mottershead, J. AU - Richardson, C. AU - Spencer, F. DB - Embase DO - 10.2147/ppa.s37535 KW - eye drops adult aged article clinical article education eye redness female glaucoma group education health care system health promotion human interview male medical information patient attitude patient compliance patient education risk management thematic analysis LA - English M3 - Article N1 - L368176263 2013-01-31 2013-02-20 PY - 2013 SN - 1177-889X SP - 55-63 ST - Adherence to ocular hypotensive therapy: Patient health education needs and views on group education T2 - Patient Preference and Adherence TI - Adherence to ocular hypotensive therapy: Patient health education needs and views on group education UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368176263&from=export http://dx.doi.org/10.2147/ppa.s37535 VL - 7 ID - 3030 ER - TY - JOUR AB - Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open-angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information, teaching drop instillation technique and ongoing support according to the patient need may have a positive effect on improving adherence. To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma. We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 6), MEDLINE (June 1946 to June 2012), EMBASE (June 1980 to June 2012), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (June 1937 to June 2012), PsycINFO (1806 to June 2012), PsycEXTRA (1908 to June 2012), Web of Science (1970 to June 2012), ZETOC (1993 to June 2012), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 June 2012. We did not search the National Research Register (NNR) as this resource has now been now archived. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision and Ophthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). We included randomised controlled trials (RCTs) and quasi-RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma. At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We did not pool data due to clinical and methodological heterogeneity. Sixteen trials (1565 participants) met the inclusion criteria. Seven studies investigated some form of patient education. In six of these studies this education was combined with other behavioural change interventions including tailoring daily routines to promote adherence to eye drops. Eight studies compared different drug regimens (one of these trials also compared open and masked monitoring) and one study investigated a reminder device. The studies were of variable quality and some were at considerable risk of bias; in general, the length of follow-up was short at less than six months with only two studies following up to 12 months. Different interventions and outcomes were reported and so it was not possible to produce an overall estimate of effect. There was some evidence from three studies that education combined with personalised interventions, that is, more complex interventions, improved adherence to ocular hypotensive therapy. There was less information on other outcomes such as persistence and intraocular pressure, and no information on visual field defects, quality of life and cost. There was weak evidence as to whether people on simpler drug regimens were more likely to adhere and persist with their ocular hypotensive therapy. A particular problem was the interpretation of cross-over studies, which in general were not reported correctly. One study investigated a reminder device and monitoring but the study was small and inconclusive. Although complex interventions consisting of patient education combined with personalised behavioural change interventions, including tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medication, overall there is insufficient evidence to recommend a particular intervention. The interventions varied between studies and none of the included studies reported on the cost of the intervention. Simplified drug regimens also could be of benefit but again the current published studies do not provide conclusive evidence. Future studies should follow up for at least one year, and could benefit from standardised outcomes.[CINAHL Note: The Cochrane Collaboration systematic reviews contain interactive software that allows various calculations in the MetaView.] AN - 105523389. Language: English. Entry Date: 20101029. Revision Date: 20150711. Publication Type: Journal Article AU - Waterman, H. AU - Evans, J. R. AU - Gray, T. A. AU - Henson, D. AU - Harper, R. DB - ccm DO - 10.1002/14651858.CD006132.pub2 DP - EBSCOhost IS - 4 KW - Glaucoma -- Drug Therapy Medication Compliance Clinical Trials Meta Analysis Ocular Hypertension -- Drug Therapy Relative Risk Human N1 - research; systematic review. Journal Subset: Europe; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. NLM UID: 100909747. Cochrane AN: CD006132. PMID: NLM23633333. PY - 2013 SN - 1469-493X SP - N.PAG-N.PAG ST - Interventions for improving adherence to ocular hypotensive therapy T2 - Cochrane Database of Systematic Reviews TI - Interventions for improving adherence to ocular hypotensive therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105523389&site=ehost-live&scope=site ID - 4752 ER - TY - JOUR AB - Background: Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open-angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information, teaching drop instillation technique and ongoing support according to the patient need may have a positive effect on improving adherence. Objectives: To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma. Search methods: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 6), MEDLINE (June 1946 to June 2012), EMBASE (June 1980 to June 2012), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (June 1937 to June 2012), PsycINFO (1806 to June 2012), PsycEXTRA (1908 to June 2012), Web of Science (1970 to June 2012), ZETOC (1993 to June 2012), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 June 2012. We did not search the National Research Register (NNR) as this resource has now been now archived. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision and Ophthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). Selection criteria: We included randomised controlled trials (RCTs) and quasi-RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma. Data collection and analysis: At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We did not pool data due to clinical and methodological heterogeneity. Main results: Sixteen trials (1565 participants) met the inclusion criteria. Seven studies investigated some form of patient education. In six of these studies this education was combined with other behavioural change interventions including tailoring daily routines to promote adherence to eye drops. Eight studies compared different drug regimens (one of these trials also compared open and masked monitoring) and one study investigated a reminder device. The studies were of variable quality and some were at considerable risk of bias; in general, the length of follow-up was short at less than six months with only two studies following up to 12 months. Different interventions and outcomes were reported and so it was not possible to produce an overall estimate of effect. There was some evidence from three studies that education combined with personalised interventions, that is, more complex interventions, improved adherence to ocular hypotensive therapy. There was less information on other outcomes such as persistence and intraocular pressure, and no information on visual field defects, quality of life and cost. There was weak evidence as to whether people on simpler drug regimens were more likely to adhere and persist with their ocular hypotensive therapy. A particular problem was the interpretation of cross-over studies, which in general were not reported correctly. One study investigated a reminder device and monitoring but the study was small and inconclusive. Authors' conclusions: Although complex interventions consisting of patient education combined with personalised behavioural change interventions, including tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medicatio , overall there is insufficient evidence to recommend a particular intervention. The interventions varied between studies and none of the included studies reported on the cost of the intervention. Simplified drug regimens also could be of benefit but again the current published studies do not provide conclusive evidence. Future studies should follow up for at least one year, and could benefit from standardised outcomes. © 2013 The Cochrane Collaboration. AD - University of Manchester, School of Nursing, Midwifery and Social Work, University Place, Oxford Road, Manchester, M13 9PL, United Kingdom London School of Hygiene and Tropical Medicine, Cochrane Eyes and Vision Group, ICEH, Keppel Street, London, WC1E 7HT, United Kingdom Manchester Royal Eye Hospital, Academic Department of Ophthalmology, Oxford Road, Manchester, M13 9WH, United Kingdom Central Manchester and Manchester Children's NHS Trust, Optometry Department, Manchester Royal Eye Hospital, Oxford Road, Manchester, M13 9WH, United Kingdom AU - Waterman, H. AU - Evans, J. R. AU - Gray, T. A. AU - Henson, D. AU - Harper, R. C7 - Cd006132 DB - Scopus DO - 10.1002/14651858.CD006132.pub3 IS - 4 M3 - Review N1 - Cited By :54 Export Date: 19 July 2021 PY - 2013 ST - Interventions for improving adherence to ocular hypotensive therapy T2 - Cochrane Database of Systematic Reviews TI - Interventions for improving adherence to ocular hypotensive therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886821218&doi=10.1002%2f14651858.CD006132.pub3&partnerID=40&md5=5e82bb22d2f48152d97f68513322912d VL - 2013 ID - 4982 ER - TY - JOUR AB - Background Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open-angle glaucoma. Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if surgical intervention is required. Simplifying eye drop regimes, providing adequate information, teaching drop instillation technique and ongoing support according to the patient need may have a positive effect on improving adherence. Objectives To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension (OHT) or glaucoma. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 6), MEDLINE (June 1946 to June 2012), EMBASE (June 1980 to June 2012), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (June 1937 to June 2012), PsycINFO (1806 to June 2012), PsycEXTRA (1908 to June 2012), Web of Science (1970 to June 2012), ZETOC (1993 to June 2012), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform(ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 June 2012. We did not search the National Research Register (NNR) as this resource has now been now archived. We contacted pharmaceutical manufacturers to request unpublished data and searched conference proceedings for the Association for Research in Vision and Ophthalmology (ARVO), and the Annual Congress for the Royal College of Ophthalmologists (RCO). Selection criteria We included randomised controlled trials (RCTs) and quasi-RCTs that compared interventions to improve adherence to ocular hypotensive therapy for patients with OHT or glaucoma. Data collection and analysis At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically designed forms. We did not pool data due to clinical and methodological heterogeneity. Main results Sixteen trials (1565 participants) met the inclusion criteria. Seven studies investigated some form of patient education. In six of these studies this education was combined with other behavioural change interventions including tailoring daily routines to promote adherence to eye drops. Eight studies compared different drug regimens (one of these trials also compared open and masked monitoring) and one study investigated a reminder device. The studies were of variable quality and some were at considerable risk of bias; in general, the length of follow-up was short at less than six months with only two studies following up to 12 months. Different interventions and outcomes were reported and so it was not possible to produce an overall estimate of effect. There was some evidence from three studies that education combined with personalised interventions, that is, more complex interventions, improved adherence to ocular hypotensive therapy. There was less information on other outcomes such as persistence and intraocular pressure, and no information on visual field defects, quality of life and cost. There was weak evidence as to whether people on simpler drug regimens were more likely to adhere and persist with their ocular hypotensive therapy. A particular problem was the interpretation of cross-over studies, which in general were not reported correctly. One study investigated a reminder device and monitoring but the study was small and inconclusive. Authors' conclusions Although complex interventions consisting of patient education combined with personalised behavioural change interventions, including tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medication, overall there is insufficient evidence to recommend a particular intervention. The interventions varied between studies and none of the included studies reported on the cost of the intervention. Simplified drug regimens also could be of benefit but again the current published studies do not provide conclusive evidence. Future studies should follow up for at least one year, and could benefit from standardised outcomes. AN - WOS:000320654400029 AU - Waterman, H. AU - Evans, J. R. AU - Gray, T. A. AU - Henson, D. AU - Harper, R. DO - 10.1002/14651858.CD006132.pub3 IS - 4 PY - 2013 SN - 1469-493X 1361-6137 ST - Interventions for improving adherence to ocular hypotensive therapy T2 - COCHRANE DATABASE OF SYSTEMATIC REVIEWS TI - Interventions for improving adherence to ocular hypotensive therapy ID - 6047 ER - TY - JOUR AB - BACKGROUND/AIMS: Assess whether a new clinical pathway for glaucoma was acceptable to patients and healthcare professionals and whether it provided useful clinical information on non-responsiveness and non-adherence to the treatment of elevated intraocular pressure with latanoprost eye drops., METHODS: A single arm non-randomised prospective observational study incorporating new glaucoma/ocular hypertension patients. To assess issues of acceptability, qualitative observation and interviews were conducted with patients and healthcare professionals. To determine clinical responsiveness, intraocular pressures were measured before and 4 hours after a clinician-instilled eye drop over two distinct appointments. Adherence data were collected using a Medicine Event Monitoring System. Economic analyses compared the costs between novel and standard care pathways., RESULTS: Of 72 patients approached, 53 entered the study (74.3%) and 50 completed all procedures (94.3%). Intraocular pressure was reduced more than 15% in 83 out of 92 study eyes by final visit (90.2%). The non-response rate was 5.1% once the effect of low adherence was minimised. For the 1376 drop instillation days under observation, eye drops were instilled as prescribed on 1004 days (73.0%), over-instilled on 137 days (9.9%) and not instilled on 235 days (17.1%). The Cardiff Model of Glaucoma Care involved negligible cost, although acceptance for healthcare professionals showed variation., CONCLUSIONS: The Cardiff Model of Glaucoma Care offers novel clinical and adherence insights at marginal costs while acceptable to patients. Healthcare professionals felt that 4 hour and 4 week follow-up appointments could cause administrative problems. A streamlined version of the pathway has therefore been developed to facilitate clinical adoption., TRIAL REGISTRATION NUMBER: ISRCTNID:ISRCTN75888393. Copyright © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. AU - Waterman, Heather AU - Read, Simon AU - Morgan, James Edwards AU - Gillespie, David AU - Nollett, Claire AU - Allen, Davina AU - Weiss, Marjorie AU - Anderson, Pippa DO - https://dx.doi.org/10.1136/bjophthalmol-2019-315436 IS - 12 KW - Aged Aged, 80 and over Antihypertensive Agents/ad [Administration & Dosage] Antihypertensive Agents/ec [Economics] *Critical Pathways *Drug Costs Female Follow-Up Studies *Glaucoma/dt [Drug Therapy] Glaucoma/ec [Economics] Glaucoma/pp [Physiopathology] Humans *Intraocular Pressure/de [Drug Effects] *Latanoprost/ad [Administration & Dosage] Latanoprost/ec [Economics] Male *Medication Adherence Middle Aged Ophthalmic Solutions/ec [Economics] Prospective Studies Tonometry, Ocular PY - 2020 SE - Waterman, Heather. School of Healthcare Sciences, Cardiff University, Cardiff, UK. Read, Simon. School of Healthcare Sciences, Cardiff University, Cardiff, UK readsm@cardiff.ac.uk. Morgan, James Edwards. School of Optometry and Vision Sciences, Cardiff University, Cardiff, UK. Gillespie, David. Centre for Trials Research, Cardiff University, Cardiff, South Glamorgan, UK. Nollett, Claire. Centre for Trials Research, Cardiff University, Cardiff, South Glamorgan, UK. Allen, Davina. School of Healthcare Sciences, Cardiff University, Cardiff, UK. Weiss, Marjorie. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK. Anderson, Pippa. Swansea Centre for Health Economics, Swansea University College of Human and Health Sciences, Swansea, UK. SN - 1468-2079 0007-1161 SP - 1704-1709 ST - Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study T2 - The British journal of ophthalmology TI - Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=32139500 VL - 104 Y2 - 20200304// ID - 229 ER - TY - JOUR AB - Background/aims Assess whether a new clinical pathway for glaucoma was acceptable to patients and healthcare professionals and whether it provided useful clinical information on non-responsiveness and non-adherence to the treatment of elevated intraocular pressure with latanoprost eye drops. Methods A single arm non-randomised prospective observational study incorporating new glaucoma/ocular hypertension patients. To assess issues of acceptability, qualitative observation and interviews were conducted with patients and healthcare professionals. To determine clinical responsiveness, intraocular pressures were measured before and 4 hours after a clinician-instilled eye drop over two distinct appointments. Adherence data were collected using a Medicine Event Monitoring System. Economic analyses compared the costs between novel and standard care pathways. Results Of 72 patients approached, 53 entered the study (74.3%) and 50 completed all procedures (94.3%). Intraocular pressure was reduced more than 15% in 83 out of 92 study eyes by final visit (90.2%). The non-response rate was 5.1% once the effect of low adherence was minimised. For the 1376 drop instillation days under observation, eye drops were instilled as prescribed on 1004 days (73.0%), over-instilled on 137 days (9.9%) and not instilled on 235 days (17.1%). The Cardiff Model of Glaucoma Care involved negligible cost, although acceptance for healthcare professionals showed variation. Conclusions The Cardiff Model of Glaucoma Care offers novel clinical and adherence insights at marginal costs while acceptable to patients. Healthcare professionals felt that 4 hour and 4 week follow-up appointments could cause administrative problems. A streamlined version of the pathway has therefore been developed to facilitate clinical adoption. Trial registration number ISRCTNID:ISRCTN75888393 AD - S. Read, School of Healthcare Sciences, Cardiff University, Cardiff, United Kingdom AU - Waterman, H. AU - Read, S. AU - Morgan, J. E. AU - Gillespie, D. AU - Nollett, C. AU - Allen, D. AU - Weiss, M. AU - Anderson, P. DB - Embase Medline DO - 10.1136/bjophthalmol-2019-315436 IS - 12 KW - ISRCTN75888393 latanoprost adult aged article blepharitis blurred vision clinician economic aspect female glaucoma health care personnel human information processing interview intraocular hypertension intraocular pressure major clinical study male observational study patient care patient compliance pressure measurement priority journal program acceptability prospective study qualitative research treatment response LA - English M3 - Article N1 - L631226448 2020-03-20 2020-12-08 PY - 2020 SN - 1468-2079 0007-1161 SP - 1704-1709 ST - Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: A prospective observational study T2 - British Journal of Ophthalmology TI - Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: A prospective observational study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631226448&from=export http://dx.doi.org/10.1136/bjophthalmol-2019-315436 VL - 104 ID - 2364 ER - TY - JOUR AB - Background/aims Assess whether a new clinical pathway for glaucoma was acceptable to patients and healthcare professionals and whether it provided useful clinical information on non-responsiveness and non-adherence to the treatment of elevated intraocular pressure with latanoprost eye drops. Methods A single arm non-randomised prospective observational study incorporating new glaucoma/ocular hypertension patients. To assess issues of acceptability, qualitative observation and interviews were conducted with patients and healthcare professionals. To determine clinical responsiveness, intraocular pressures were measured before and 4 hours after a clinician-instilled eye drop over two distinct appointments. Adherence data were collected using a Medicine Event Monitoring System. Economic analyses compared the costs between novel and standard care pathways. Results Of 72 patients approached, 53 entered the study (74.3%) and 50 completed all procedures (94.3%). Intraocular pressure was reduced more than 15% in 83 out of 92 study eyes by final visit (90.2%). The non-response rate was 5.1% once the effect of low adherence was minimised. For the 1376 drop instillation days under observation, eye drops were instilled as prescribed on 1004 days (73.0%), over-instilled on 137 days (9.9%) and not instilled on 235 days (17.1%). The Cardiff Model of Glaucoma Care involved negligible cost, although acceptance for healthcare professionals showed variation. Conclusions The Cardiff Model of Glaucoma Care offers novel clinical and adherence insights at marginal costs while acceptable to patients. Healthcare professionals felt that 4 hour and 4 week follow-up appointments could cause administrative problems. A streamlined version of the pathway has therefore been developed to facilitate clinical adoption. Trial registration number ISRCTNID:ISRCTN75888393 © 2020 BMJ Publishing Group. All rights reserved. AD - School of Healthcare Sciences, Cardiff University, Cardiff, United Kingdom School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom Centre for Trials Research, Cardiff University, Cardiff, South Glamorgan, United Kingdom School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom Swansea Centre for Health Economics, Swansea University, College of Human and Health Sciences, Swansea, United Kingdom AU - Waterman, H. AU - Read, S. AU - Morgan, J. E. AU - Gillespie, D. AU - Nollett, C. AU - Allen, D. AU - Weiss, M. AU - Anderson, P. DB - Scopus DO - 10.1136/bjophthalmol-2019-315436 IS - 12 KW - drugs epidemiology glaucoma intraocular pressure pharmacology M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2020 SP - 1704-1709 ST - Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: A prospective observational study T2 - British Journal of Ophthalmology TI - Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: A prospective observational study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081566442&doi=10.1136%2fbjophthalmol-2019-315436&partnerID=40&md5=7bfea0bd819d131b21fb5b2e4b224288 VL - 104 ID - 5597 ER - TY - JOUR AB - Background/aims Assess whether a new clinical pathway for glaucoma was acceptable to patients and healthcare professionals and whether it provided useful clinical information on non-responsiveness and non-adherence to the treatment of elevated intraocular pressure with latanoprost eye drops. Methods A single arm non-randomised prospective observational study incorporating new glaucoma/ocular hypertension patients. To assess issues of acceptability, qualitative observation and interviews were conducted with patients and healthcare professionals. To determine clinical responsiveness, intraocular pressures were measured before and 4 hours after a clinician-instilled eye drop over two distinct appointments. Adherence data were collected using a Medicine Event Monitoring System. Economic analyses compared the costs between novel and standard care pathways. Results Of 72 patients approached, 53 entered the study (74.3%) and 50 completed all procedures (94.3%). Intraocular pressure was reduced more than 15% in 83 out of 92 study eyes by final visit (90.2%). The non-response rate was 5.1% once the effect of low adherence was minimised. For the 1376 drop instillation days under observation, eye drops were instilled as prescribed on 1004 days (73.0%), over-instilled on 137 days (9.9%) and not instilled on 235 days (17.1%). The Cardiff Model of Glaucoma Care involved negligible cost, although acceptance for healthcare professionals showed variation. Conclusions The Cardiff Model of Glaucoma Care offers novel clinical and adherence insights at marginal costs while acceptable to patients. Healthcare professionals felt that 4 hour and 4 week follow-up appointments could cause administrative problems. A streamlined version of the pathway has therefore been developed to facilitate clinical adoption. AN - WOS:000604324100012 AU - Waterman, H. AU - Read, S. AU - Morgan, J. E. AU - Gillespie, D. AU - Nollett, C. AU - Allen, D. AU - Weiss, M. AU - Anderson, P. DA - DEC DO - 10.1136/bjophthalmol-2019-315436 IS - 12 PY - 2020 SN - 0007-1161 1468-2079 SP - 1704-1709 ST - Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study T2 - BRITISH JOURNAL OF OPHTHALMOLOGY TI - Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study VL - 104 ID - 5864 ER - TY - JOUR AB - This article focuses on the nursing care and management of older people with chronic open angle glaucoma (COAG). It provides an overview of the condition, its pathogenesis, clinical features, aetiology, diagnosis and approaches to care and treatment. Patient education and promotion of adherence to medical therapy are paramount in establishing the confidence and independence required for the long-term self-management of COAG because the majority of older people with this condition are based in the community. AD - Associate lecturer, Faculty of Health and Human Sciences, Thames Valley University AN - 105114223. Language: English. Entry Date: 20101022. Revision Date: 20200708. Publication Type: Journal Article AU - Watkinson, S. DB - ccm DO - 10.7748/nop2010.10.22.8.18.c7993 DP - EBSCOhost IS - 8 KW - Glaucoma -- Nursing Gerontologic Nursing Nursing Practice Glaucoma Chronic Disease Glaucoma -- Etiology Glaucoma -- Symptoms Glaucoma -- Diagnosis Glaucoma -- Drug Therapy Glaucoma -- Physiopathology Eye -- Anatomy and Histology Glaucoma -- Complications Intraocular Pressure -- Drug Effects Glaucoma -- Risk Factors Middle Age Glaucoma -- Surgery Medication Compliance Laser Therapy Patient Education Aged Ophthalmic Solutions -- Administration and Dosage Timolol -- Administration and Dosage Carbonic Anhydrase Inhibitors -- Administration and Dosage Prostaglandins, Synthetic -- Administration and Dosage Quality of Life Glaucoma -- Psychosocial Factors Nursing Assessment Support, Psychosocial Support Groups Information Resources World Wide Web United Kingdom N1 - pictorial. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Europe; Nursing; Peer Reviewed; UK & Ireland. NLM UID: 101084156. PMID: NLM21049865. PY - 2010 SN - 1472-0795 SP - 18-23 ST - Improving care of chronic open angle glaucoma T2 - Nursing Older People TI - Improving care of chronic open angle glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105114223&site=ehost-live&scope=site VL - 22 ID - 4459 ER - TY - JOUR AB - Purpose. Despite growing evidence for clinical efficacy of orthokeratology (OK) for the temporary reduction of myopic refractive error, there has been an increasing number of reports of microbial keratitis (MK) in association with overnight wear of OK lenses. This article analyzes the first 50 cases of MK reported in overnight OK, in order to define the spectrum of the disease and to identify possible risk factors. Methods. All reported cases of presumed MK in overnight OK from 2001 onwards were included in the analysis. Demographic data of patients affected and lenses worn, and details of the disease process and possible risk factors were extracted from these reports. Results. Most cases of MK in OK were reported from East Asia (80%) and most affected patients were Asian (88%). The peak age range was from 9 to 15 years (61%). Although Pseudomonas aeruginosa was the predominant organism implicated in this series of cases (52%), an alarmingly high frequency of Acanthamoeba infection (30%) was found. Inappropriate lens care procedures, patient noncompliance with practitioner instructions, and persisting in lens wear despite discomfort emerged as potential risk factors. Conclusions. The high frequency of MK in overnight OK in young Asian patients is likely to reflect the demographics of the OK lens-wearing population. The high frequency of Acanthamoeba infection strongly suggests that tap water rinsing should be eliminated from the lens care regimen for overnight OK. This study does not reveal the absolute incidence or relative risk of MK in overnight OK, and it is therefore premature to ascribe increased risk to this lens-wearing modality compared with other contact lens modalities. © 2005 Contact Lens Association of Ophthalmologists, Inc. AD - H.A. Swarbrick, School of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia AU - Watt, K. AU - Swarbrick, H. A. DB - Embase Medline DO - 10.1097/01.icl.0000179705.23313.7e IS - 5 KW - aminoglycoside antibiotic agent antibiotic agent antifungal agent antiprotozoal agent cephalosporin quinoline derived antiinfective agent steroid tap water Acanthamoeba keratitis adolescent adult article Asia clinical article conservative treatment contact lens demography device infection disease association disease classification doctor patient relationship female human keratitis male monotherapy morbidity myopia orthokeratology lens patient compliance priority journal Pseudomonas aeruginosa refraction error risk factor school child LA - English M3 - Article N1 - L43197006 2006-02-20 PY - 2005 SN - 1542-2321 SP - 201-208 ST - Microbial keratitis in overnight orthokeratology: Review of the first 50 cases T2 - Eye and Contact Lens TI - Microbial keratitis in overnight orthokeratology: Review of the first 50 cases UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43197006&from=export http://dx.doi.org/10.1097/01.icl.0000179705.23313.7e VL - 31 ID - 3670 ER - TY - JOUR AB - Background: This study was conducted to investigate the demographics of orthokeratology (OK) practice in Australia, to uncover any previously undocumented cases of serious adverse responses in OK, including microbial keratitis (MK), and to review the demographics of MK in OK in Australia. Methods: A questionnaire was sent to the 62 members of the Orthokeratology Society of Australia (OSA). Questions related to aspects of their OK practice, demographics of their OK patient base and any adverse responses to OK lens wear that they had encountered. Results: Thirty-three questionnaires (53 per cent) were returned. OSA members have been fitting OK lenses for a median of 7.5 years. OK patients were predominantly female, Caucasian, aged between 15 and 39 years and wearing lenses in an overnight modality. In addition to two cases reported previously, the survey uncovered seven further cases of MK in OK patients over an eight-year period. The infecting organism was Pseudomonas aeruginosa in four cases, Acanthamoeba spp. in two cases and unknown in three cases. There was no loss of visual acuity in seven cases. One case resulted in vision of counting fingers at one metre and another case resolved with 6/12 visual acuity. Non-compliance with instructions on lens care and after-care was reported in seven of nine cases of MK. Conclusion: Overall, OSA members who responded to the survey have many years of experience in OK. The typical Australian OK patient is in young adulthood, female and Caucasian. A total of nine cases of presumed MK associated with OK have been reported in Australia over an eight-year period and seven of these were new cases uncovered by this survey. Our analysis suggests that the demographics of MK cases in OK reflect the demographics of the OK lens-wearing population. © 2007 Optometrists Association Australia. AD - H.A. Swarbrick, School of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia AU - Watt, K. G. AU - Boneham, G. C. AU - Swarbrick, H. A. DB - Medline DO - 10.1111/j.1444-0938.2006.00105.x IS - 3 KW - contact lens solution Acanthamoeba keratitis adolescent adult aged article Australia bacterial infection contact lens demography female Gram negative infection human incidence keratitis male methodology microbiology middle aged myopia optometry patient compliance Pseudomonas aeruginosa LA - English M3 - Article N1 - L46537729 2007-06-14 PY - 2007 SN - 0816-4622 1444-0938 SP - 182-189 ST - Microbial keratitis in orthokeratology: The Australian experience T2 - Clinical and Experimental Optometry TI - Microbial keratitis in orthokeratology: The Australian experience UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46537729&from=export http://dx.doi.org/10.1111/j.1444-0938.2006.00105.x VL - 90 ID - 3525 ER - TY - JOUR AB - Glaucoma in multi-morbid patients is frequently treated by specialists non-ophthalmologists. The growing number of elderly patients with glaucoma and comparatively small knowledge on this disease among the medical workers brought us to review recent findings on the aetiology, pathogenesis, risks of development and namely the problems of glaucoma treatment, possible drug interactions and their side effects. Considering the growing incidence of glaucoma with age, general practitioners, internists, geriatrists and other specialists will face the problems of drug interactions and global or ophthalmological side effects during the polypharmacological treatment of their multi-morbid seniors. The article gives basic information on the problems of using antiglaucoma drugs and their effects on the organism and eyes. Effects of some foodstuff and medicaments used in therapy of other diseases on the intraocular pressure and glaucoma are also summarise. AD - P. Weber, Geriatrické oddelení kliniky geriatrie, osetrovatelství a praktického lékarství LF MU a FN, Brno-Bohunice. AU - Weber, P. AU - Svacinová, J. DB - Medline IS - 14 KW - aged aging article chronic disease drug interaction glaucoma human metabolism patient compliance pharmacokinetics LA - Czech M3 - Article N1 - L33516289 2001-08-14 PY - 2001 SN - 0008-7335 SP - 419-422 ST - Glaucoma and pitfalls in therapy in the elderly with multiple morbidity from the viewpoint of the geriatrician T2 - Casopís lékarů ceských TI - Glaucoma and pitfalls in therapy in the elderly with multiple morbidity from the viewpoint of the geriatrician UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33516289&from=export VL - 140 ID - 3892 ER - TY - JOUR AB - Importance: Glaucoma is a worldwide leading cause of irreversible vision loss. Because it may be asymptomatic until a relatively late stage, diagnosis is frequently delayed. A general understanding of the disease pathophysiology, diagnosis, and treatment may assist primary care physicians in referring high-risk patients for comprehensive ophthalmologic examination and in more actively participating in the care of patients affected by this condition.Objective: To describe current evidence regarding the pathophysiology and treatment of open-angle glaucoma and angle-closure glaucoma.Evidence Review: A literature search was conducted using MEDLINE, the Cochrane Library, and manuscript references for studies published in English between January 2000 and September 2013 on the topics open-angle glaucoma and angle-closure glaucoma. From the 4334 abstracts screened, 210 articles were selected that contained information on pathophysiology and treatment with relevance to primary care physicians.Findings: The glaucomas are a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and resulting changes in the optic nerve head. Loss of ganglion cells is related to the level of intraocular pressure, but other factors may also play a role. Reduction of intraocular pressure is the only proven method to treat the disease. Although treatment is usually initiated with ocular hypotensive drops, laser trabeculoplasty and surgery may also be used to slow disease progression.Conclusions and Relevance: Primary care physicians can play an important role in the diagnosis of glaucoma by referring patients with positive family history or with suspicious optic nerve head findings for complete ophthalmologic examination. They can improve treatment outcomes by reinforcing the importance of medication adherence and persistence and by recognizing adverse reactions from glaucoma medications and surgeries. AD - Hamilton Glaucoma Center, Shiley Eye Center and Department of Ophthalmology, University of California, San Diego, La Jolla. Singapore National Eye Center, Singapore, Singapore3Yong Loo Lin School of Medicine, National University of Singapore, Singapore. AN - 103943226. Language: English. Entry Date: 20140606. Revision Date: 20161117. Publication Type: journal article AU - Weinreb, Robert N. AU - Aung, Tin AU - Medeiros, Felipe A. DB - ccm DO - 10.1001/jama.2014.3192 DP - EBSCOhost IS - 18 KW - Glaucoma -- Complications Glaucoma -- Diagnosis Glaucoma -- Pathology Glaucoma -- Therapy Human Primary Health Care N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: R01 EY021818/EY/NEI NIH HHS/United States. NLM UID: 7501160. PMID: NLM24825645. PY - 2014 SN - 0098-7484 SP - 1901-1911 ST - The pathophysiology and treatment of glaucoma: a review T2 - JAMA: Journal of the American Medical Association TI - The pathophysiology and treatment of glaucoma: a review UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103943226&site=ehost-live&scope=site VL - 311 ID - 4359 ER - TY - JOUR AB - Background: Comorbid depression may play an important role in non-compliance with medical treatment among patients with chronic illnesses. Glaucoma is a potentially blinding chronic disease requiring life-long commitment to medical therapy. failure to adhere to anti-glaucoma treatment may lead to disease progression and visual loss. Objectives: To assess the prevalence of depressive symptoms in glaucoma patients and the association between these symptoms and non-compliance with anti-glaucoma therapy. Methods: In this cross-sectional observational study, compliance with pharmacotherapy was assessed with the Morisky Medication Adherence questionnaire (eight items). Screening for depression was performed by means of the CES-D (Center for Epidemiologic Studies Depression scale). The association between depression and compliance rates was analyzed. Results: The study group comprised 76 glaucoma patients; 19.7% of the subjects were classified as non-compliant (Morisky cutoff < 10) and 21.1% suffered from depression (CES-D cutoff ≥ 16). We found a similar level of non-compliance when comparing depressed with non-depressed glaucoma patients. However, a correlation was observed between the level of depression and the level of non-compliance (P = 0.04). Conclusions: Our study revealed a similar rate of depression in glaucoma patients and the general Israeli population. The presence of depression was not associated with the presence of non-compliance, yet the level of depression was associated with the level of non-compliance. AD - Z. Burgansky-Eliash, Dept. of Ophthalmology, Wolfson Medical Center, P.O. Box 5, Holon 58100, Israel AU - Weiss, G. A. AU - Goldich, G. AU - Bartov, E. AU - Burgansky-Eliash, Z. DB - Embase Medline IS - 12 KW - alpha adrenergic receptor stimulating agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor prostaglandin derivative adult aged article Center for Epidemiological Studies Depression Scale comorbidity cross-sectional study depression disease association eye care female follow up glaucoma human Israel major clinical study male observational study patient compliance perimetry prevalence questionnaire screening LA - English M3 - Article N1 - L364438268 2012-03-22 2012-03-28 PY - 2011 SN - 1565-1088 SP - 730-733 ST - Compliance with eye care in glaucoma patients with comorbid depression T2 - Israel Medical Association Journal TI - Compliance with eye care in glaucoma patients with comorbid depression UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364438268&from=export http://www.ima.org.il/imaj/ar11Dec-03.pdf VL - 13 ID - 3128 ER - TY - JOUR AB - Background: Comorbid depression may play an important role in non-compliance with medical treatment among patients with chronic illnesses. Glaucoma is a potentially blinding chronic disease requiring life-long commitment to medical therapy. failure to adhere to anti-glaucoma treatment may lead to disease progression and visual loss. Objectives: To assess the prevalence of depressive symptoms in glaucoma patients and the association between these symptoms and non-compliance with anti-glaucoma therapy. Methods: In this cross-sectional observational study, compliance with pharmacotherapy was assessed with the Morisky Medication Adherence questionnaire (eight items). Screening for depression was performed by means of the CES-D (Center for Epidemiologic Studies Depression scale). The association between depression and compliance rates was analyzed. Results: The study group comprised 76 glaucoma patients; 19.7% of the subjects were classified as non-compliant (Morisky cutoff < 10) and 21.1% suffered from depression (CES-D cutoff ≥ 16). We found a similar level of non-compliance when comparing depressed with non-depressed glaucoma patients. However, a correlation was observed between the level of depression and the level of non-compliance (P = 0.04). Conclusions: Our study revealed a similar rate of depression in glaucoma patients and the general Israeli population. The presence of depression was not associated with the presence of non-compliance, yet the level of depression was associated with the level of non-compliance. AD - Department of Medicine, University at Buffalo, Buffalo, NY, United States Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel Dept. of Ophthalmology, Wolfson Medical Center, P.O. Box 5, Holon 58100, Israel Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel AU - Weiss, G. A. AU - Goldich, G. AU - Bartov, E. AU - Burgansky-Eliash, Z. DB - Scopus IS - 12 KW - Compliance with glaucoma therapy Depression Glaucoma Glaucoma medical therapy M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 2011 SP - 730-733 ST - Compliance with eye care in glaucoma patients with comorbid depression T2 - Israel Medical Association Journal TI - Compliance with eye care in glaucoma patients with comorbid depression UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858046325&partnerID=40&md5=a1135261b20ebf08c0d8d994aab5a82c VL - 13 ID - 5181 ER - TY - JOUR AB - Background. Corneal abrasion is a frequently encountered complication of contact lens wear, but we are not aware of any previous study of relative frequency comparing keratoconic to nonkeratoconic patients. Methods. We retrospectively studied the incidence of corneal abrasion during 2 months of contact lens practice. Results. 784 contact lens-related patient visits (494 total patients); patients were assessed by 3 optometrists and 13 abrasions (11 patients) were diagnosed. Only the total number of individual patients and the first abrasion for each patient were statistically considered; the overall frequency of abrasion was therefore 11/494 (2.3%)/2 months. The frequency of abrasion was 5/68 (7.4%)/2 months for keratoconic patients and 6/426 (1.4%)/2 months for nonkeratoconic patients and this difference was significant (chi2 test: p < 0.01). Among nonkeratoconic patients, the frequency of abrasion was 2/246 (0.8%)/2 months with hydrogel contact lens wear and 4/178 (2.2%)/2 months with rigid gas permeable (RGP) contact lens wear, but this difference did not achieve significance (chi2 test: p = 0.10). Identified risk factors included: Contact lens wear; a torn lens and chemical keratitis for hydrogel lens wearers; an adherent ''bound'' lens and keratoconus for rigid lens wearers. Conclusion. Keratoconus appears to be a statistically significant risk factor for corneal abrasion among contact lens wearers. AN - WOS:A1994PW54400001 AU - Weissman, B. AU - Chun, M. W. AU - Barnhart, L. A. DA - NOV DO - 10.1097/00006324-199411000-00001 IS - 11 PY - 1994 SN - 1040-5488 SP - 677-681 ST - CORNEAL ABRASION ASSOCIATED WITH CONTACT-LENS CORRECTION OF KERATOCONUS - A RETROSPECTIVE STUDY T2 - OPTOMETRY AND VISION SCIENCE TI - CORNEAL ABRASION ASSOCIATED WITH CONTACT-LENS CORRECTION OF KERATOCONUS - A RETROSPECTIVE STUDY VL - 71 ID - 6356 ER - TY - JOUR AB - Although the risk of developing contact lens associated microbial keratitis is small, the potential consequences of this condition, such as vision loss, are serious. This paper presents an analysis of the risk factors that have been identified for contact lens induced microbial keratitis, which include extended wear, hypoxia, non-compliance, blepharitis, diabetes mellitus, epithelial trauma, steroid use, therapeutic lens use, tobacco use, and possibly travel to warm climates. By remaining mindful of these risk factors, practitioners can take action and offer advice to patients so as to optimize the safety of contact lens wear. © 2002 British Contact Lens Association. Published by Elsevier Science Ltd. All rights reserved. AD - B.A. Weissman, Jules Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, CA 90095-7003, United States AU - Weissman, B. A. AU - Mondino, B. J. DB - Embase DO - 10.1016/S1367-0484(01)00002-9 IS - 1 KW - steroid article blepharitis cigarette smoking contact lens cornea epithelium Corynebacterium diphtheriae diabetes mellitus disease association drug use extended wear contact lens general practitioner Haemophilus human hypoxia keratitis Listeria Neisseria gonorrhoeae patient compliance patient counseling priority journal risk assessment risk factor safety Staphylococcus tissue injury travel tropic climate visual impairment LA - English M3 - Article N1 - L34414012 2002-05-01 PY - 2002 SN - 1367-0484 SP - 3-9 ST - Risk factors for contact lens associated microbial keratitis T2 - Contact Lens and Anterior Eye TI - Risk factors for contact lens associated microbial keratitis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34414012&from=export http://dx.doi.org/10.1016/S1367-0484(01)00002-9 VL - 25 ID - 3869 ER - TY - JOUR AB - Results: There was a good correlation among all the three adherence measures at T1 and T2. The mean values of ARMS2 were in the lower range, with 3.38 at T1 and 2.8 at T2. The VAS-AD detected that 18.5% of patients always took their eye drops correctly, and 77.9% of patients reported not to have missed a single dose in the past 14 days. There was no significant correlation between the patients’ demographic data or knowledge about glaucoma and the adherence measures ARMS2 or VAS-AD. Among the clinical characteristics, only single-eye blindness showed a significant correlation with VAS-AD. Conclusion: In this study, no general relationships were found between medication adherence and the patients’ demographic data, clinical characteristics, or knowledge about glaucoma. It may be assumed that more individualized strategies are required to optimize adherence behavior. Purpose: The goal of this study was to determine the adherence of glaucoma patients to their topical glaucoma medication. Furthermore, the relationships between the adherence behavior and the patients’ demographic data, clinical characteristics, and their knowledge about glaucoma were evaluated. Methods: This was a prospective study of 123 patients with primary open-angle glaucoma who were given two standardized questionnaires. The first questionnaire at time point T1 comprised a knowledge assessment and the self-reported adherence measures Adherence to Refills and Medication Scale 2 (ARMS2), visual analogue scale for adherence (VAS-AD), and missed doses in the past 14 days. Two months later at time point T2, a second questionnaire reevaluated the adherence measures ARMS2, VAS-AD, and missed doses in the past 14 days. AD - A. Lyu, Department of Ophthalmology, Ludwig-Maximilians University, Mathildenstrasse 8, Munich, Germany AU - Welge-Lussen, U. AU - Weise, S. AU - Lyu, A. DB - Embase DO - 10.2147/PPA.S69943 KW - eye drops Adherence to Refills and Medication Scale 2 adult aged article assessment of humans attitude to health clinical feature female follow up human intraocular pressure major clinical study male medication compliance open angle glaucoma patient assessment patient compliance patient decision making questionnaire scoring system self report treatment outcome visual acuity visual analog scale visual field defect LA - English M3 - Article N1 - L600798651 2014-12-26 2015-01-09 PY - 2015 SN - 1177-889X SP - 17-23 ST - Assessing the adherence behavior of glaucoma patients to topical eye drops T2 - Patient Preference and Adherence TI - Assessing the adherence behavior of glaucoma patients to topical eye drops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600798651&from=export http://dx.doi.org/10.2147/PPA.S69943 VL - 9 ID - 2829 ER - TY - JOUR AB - Results: There was a good correlation among all the three adherence measures at T1 and T2. The mean values of ARMS2 were in the lower range, with 3.38 at T1 and 2.8 at T2. The VAS-AD detected that 18.5% of patients always took their eye drops correctly, and 77.9% of patients reported not to have missed a single dose in the past 14 days. There was no significant correlation between the patients’ demographic data or knowledge about glaucoma and the adherence measures ARMS2 or VAS-AD. Among the clinical characteristics, only single-eye blindness showed a significant correlation with VAS-AD. Conclusion: In this study, no general relationships were found between medication adherence and the patients’ demographic data, clinical characteristics, or knowledge about glaucoma. It may be assumed that more individualized strategies are required to optimize adherence behavior. Purpose: The goal of this study was to determine the adherence of glaucoma patients to their topical glaucoma medication. Furthermore, the relationships between the adherence behavior and the patients’ demographic data, clinical characteristics, and their knowledge about glaucoma were evaluated. Methods: This was a prospective study of 123 patients with primary open-angle glaucoma who were given two standardized questionnaires. The first questionnaire at time point T1 comprised a knowledge assessment and the self-reported adherence measures Adherence to Refills and Medication Scale 2 (ARMS2), visual analogue scale for adherence (VAS-AD), and missed doses in the past 14 days. Two months later at time point T2, a second questionnaire reevaluated the adherence measures ARMS2, VAS-AD, and missed doses in the past 14 days. © 2015 Welge-Lussen et al. AD - Department of Ophthalmology, Friedrich-Alexander University, Erlangen, Germany Department of Ophthalmology, University of Cologne, Cologne, Germany Department of Ophthalmology, Ludwig Maximilian University, Munich, Germany AU - Welge-Lussen, U. AU - Weise, S. AU - Lyu, A. DB - Scopus DO - 10.2147/PPA.S69943 KW - Adherence Eye drops Glaucoma Medication M3 - Article N1 - Cited By :9 Export Date: 19 July 2021 PY - 2015 SP - 17-23 ST - Assessing the adherence behavior of glaucoma patients to topical eye drops T2 - Patient Preference and Adherence TI - Assessing the adherence behavior of glaucoma patients to topical eye drops UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84919444482&doi=10.2147%2fPPA.S69943&partnerID=40&md5=81382f55be53cfef39f597ab85a74c29 VL - 9 ID - 5304 ER - TY - JOUR AB - Background: It has been demonstrated that HRT which was administered directly after the onset of the menopause had vascularprotective and neuroprotective effects. It has therefore hypothesised that eye function could benefit from such treatment. Material and methods: Visual acuity, intraocular pressure, patient's gynaecological and ophthalmological history, especially HRT were obtained from women visiting the gynaecological and ophthalmological ambulance. Measuring the visus and the intraocular pressure of women with HRT from the gynaecological ambulance was easily undertaken in the neighbouring ophthalmological department. Unfortunately, due to absence of compliance a control group without HRT could not be recruited. Of 514 women, 402 without having had hysterectomy and adnexectomy could be included in the study from which data were received about the menopausal age. Results: In the group of women with cataract HRT over 5 years was administered less often (two times) than in the group of women with glaucoma. Women mainly aged over 70 suffering from age-related conditions such as glaucoma and cataract almost never had HRT. Thus in the following only women aged up to 60 have been of interest. 7 of 10 women being in the menopause for over 10 years with a visus higher than 0.7 received HRT. Only 1 of 10 women had a visual acuity less than 0.4. There was also a correlation between receiving HRT and intraocular pressure. In the group aged up to 60 without taking HRT 19% had an intraocular pressure above 19. In women with HRT over 5 years this occurred in only 7%. Conclusions: Initiating HRT in healthy women shortly after the onset of the menopause may have vascularprotective and neuroprotective effects for the eye. This is supported by the fact that HRT administered for more than 5 years to healthy women aged up to 60 years was associated with better visual acuity and normal inUniversitätsfrauenklink Ulm traocular pressure. This is further highlighted by ultrasound scan studies in the literature. Thus an ophthalmoprophylaxis could be expected, which has to be confirmed in prospective studies using suitable control groups. AD - J.M. Wenderlein, Universitätsfrauenklinik, Prittwitzstraße 41, 89075 Ulm, Germany AU - Wenderlein, J. M. AU - Hensinger, E. DB - Embase Medline DO - 10.1055/s-2003-43134 IS - 10 KW - sex hormone salpingooophorectomy adult aged ambulance anamnesis article cataract controlled study correlation analysis echography eye protection female glaucoma gynecologic surgery hormonal therapy human hysterectomy intraocular pressure literature major clinical study measurement menopausal syndrome menopause patient compliance postmenopause prophylaxis risk factor visual acuity LA - German M3 - Article N1 - L37408884 2003-12-09 PY - 2003 SN - 0023-2165 SP - 704-709 ST - Hormone Therapy for Ophthalmoprophylaxis T2 - Klinische Monatsblatter fur Augenheilkunde TI - Hormone Therapy for Ophthalmoprophylaxis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37408884&from=export http://dx.doi.org/10.1055/s-2003-43134 VL - 220 ID - 3798 ER - TY - JOUR AB - Background: It has been demonstrated that HRT which was administered directly after the onset of the menopause had vascular-protective and neuroprotective effects. It has therefore hypothesised that eye function could benefit from such treatment. Material and methods: Visual acuity, intraocular pressure, patient's gynaecological and ophthalmological history, especially HRT were obtained from women visiting the gynaecological and ophthalmological ambulance. Measuring the visus and the intraocular pressure of women with HRT from the gynaecological ambulance was easily undertaken in the neighbouring ophthalmological department. Unfortunately, due to absence of compliance a control group without HRT could not be recruited. Of 514 women, 402 without having had hysterectomy and adnexectomy could be included in the study from which data were received about the menopausal age. Results: In the group of women with cataract HRT over 5 years was administered less often (two times) than in the group of women with glaucoma. Women mainly aged over 70 suffering from age-related conditions such as glaucoma and cataract almost never had HRT. Thus in the following only women aged up to 60 have been of interest. 7 of 10 women being in the menopause for over 10 years with a visus higher than 0.7 received HRT. Only 1 of 10 women had a visual acuity less than 0.4. There was also a correlation between receiving HRT and intraocular pressure. In the group aged up to 60 without taking HRT 19% had an intraocular pressure above 19. In women with HRT over 5 years this occurred in only 7 %. Conclusions: Initiating HRT in healthy women shortly after the onset of the menopause may have vascularprotective and neuroprotective effects for the eye. This is supported by the fact that HRT administered for more than 5 years to healthy women aged up to 60 years was associated with better visual acuity and normal intraocular pressure. This is further highlighted by ultrasound scan studies in the literature. Thus an ophthalmoprophylaxis could be expected, which has to be confirmed in prospective studies using suitable control groups. AN - WOS:000186457700008 AU - Wenderlein, J. M. AU - Hensinger, E. DA - OCT IS - 10 PY - 2003 SN - 0023-2165 SP - 704-709 ST - Hormone therapy for ophthalmoprophylaxis T2 - KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE TI - Hormone therapy for ophthalmoprophylaxis VL - 220 ID - 6321 ER - TY - JOUR AB - A new approach to fistulating glaucoma surgery, laser sclerostomy ab externo, was investigated in a clinical study. A pulsed (200 microseconds) erbium-YAG laser was used, as its wavelength (2940 nm) is very well absorbed by tissue water. The laser energy was transmitted via a fiber to an application probe with a cannula particularly designed to guide another fiber into the subconjunctival space. Nine patients with advanced open-angle or neovascular glaucoma were treated. In all cases a functioning fistula with a prominent filtering bleb and a reduction of the intraocular pressure (from up to 50 mmHg to 8-18 mmHg) could be achieved. The total energy was 60 mJ on average. No complication occurred intraoperatively. Postoperatively, all fistulas in patients with neovascular glaucoma (n = 6) were impatent after approx. 7 days due to iris adherence to the internal ostium and episcleral scarring. In cases of open-angle glaucoma (n = 3) a patent fistula persisted for several months. Variation of the exposure parameters, the use of antiproliferative drugs, and a less restrictive selection of patients could further improve the success rate. AD - University Eye Hospital Kiel, Clinic for Ophthalmology, Germany AU - Wetzel, W. AU - Häring, G. AU - Brinkmann, R. AU - Birngruber, R. DB - Scopus IS - 2 M3 - Article N1 - Cited By :16 Export Date: 19 July 2021 PY - 1994 SP - 112-115 ST - Laser sclerostomy ab externo using the erbium: YAG laser. First results of a clinical study T2 - German journal of ophthalmology TI - Laser sclerostomy ab externo using the erbium: YAG laser. First results of a clinical study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028398556&partnerID=40&md5=df0e59095df4345648bc576a26e296a9 VL - 3 ID - 5185 ER - TY - JOUR AB - This study was designed to compare the clinical results of an ab externo approach to laser sclerostomy using two different laser sources under identical conditions. A pulsed (200 microseconds) erbium-YAG laser (lambda = 2940 nm) and a pulsed (200 microseconds) holmium:YAG laser (lambda = 2120 nm) were used. The energy of each laser was transmitted via a fiber (300 microns in diameter) and applied near the limbus, with the fiber tip remaining in steady contact with the sclera. According to the higher tissue absorption coefficient, a shorter penetration depth and, therefore, fewer complications were expected for the Er:YAG laser. A total of 26 patients with advanced open-angle glaucoma were treated and followed for up to 6 months. In all cases a functioning fistula with a prominent filtering bleb and a marked reduction in the intraocular pressure (from up to 35 mm Hg to < 10 mm Hg) could be achieved primarily. The total energy required was about 4 times lower for erbium:YAG laser was compared with holmium:YAG laser sclerostomies. No complication occurred intraoperatively. Postoperatively, reversible adherence of the iris to the internal ostium was more frequently observed in Ho:YAG laser sclerostomies (60%) and small hyphemas were more often seen in Er:YAG laser sclerostomies (30%). After 6 months of follow-up, about 40% of the fistula remained patent in both groups. In principle, both lasers are suited to serve as energy sources for the described approach. Under the conditions of the present study, different levels of thermal effects did not cause any significant difference in the clinical success rate.(ABSTRACT TRUNCATED AT 250 WORDS) AD - Eye Surgery Center of Weinheim, Germany AU - Wetzel, W. AU - Schmidt-Erfurth, U. AU - Häring, G. AU - Roider, J. AU - Dröge, G. AU - Birngruber, R. DB - Scopus IS - 1 M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 1995 SP - 1-6 ST - Laser sclerostomy ab externo using two different infrared lasers: a clinical comparison T2 - German journal of ophthalmology TI - Laser sclerostomy ab externo using two different infrared lasers: a clinical comparison UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029192263&partnerID=40&md5=85e43a94c4dbd3adc2850ef762371dd4 VL - 4 ID - 5210 ER - TY - JOUR AB - Purpose: Most ophthalmologists are unaware of the therapeutic applications of gas-permeable scleral contact lenses for the prevention and treatment of ocular complications in patients with facial nerve palsy and concomitant neuroparalysis. Methods: The case reports refer to 3 patients who developed unilateral lagophthalmos and corneal anesthesia after an acoustic neuroma or intracranial tumor resection. Two patients explicitly requested a tarsorrhaphy to be opened because they were incapacitated by the limited visual acuity and visual field. Tarsorrhaphy was not an acceptable aesthetic solution for the third patient. Fluid-ventilated scleral lenses were fitted because they protect the cornea by creating a precorneal fluid reservoir while optimizing visual acuity. Results: The follow-up periods were 3, 17, and 18 years. Two patients wear the contact lenses full time, but the wearing time is limited to 10 hours per day for the third patient. All patients were instructed not to wear their lenses while sleeping. Two eyes required a corneal transplant, but lens wear could be resumed 4 to 6 weeks after transplantation. The learning curve for the insertion and removal of this large-diameter lens is the main obstacle for a patient, especially when there is loss of corneal sensation. Conclusion: Scleral lens wear is a valid long-term alternative to standard treatment options such as tarsorrhaphy for patients with corneal exposure and corneal anesthesia as a consequence of postsurgery facial nerve paralysis. Scleral contact lenses provide these patients with effective protection of the ocular surface in an aesthetically acceptable way while optimizing visual function. AN - WOS:000314818700023 AU - Weyns, M. AU - Koppen, C. AU - Tassignon, M. J. DA - MAR DO - 10.1097/ICO.0b013e31825fed01 IS - 3 PY - 2013 SN - 0277-3740 SP - 359-361 ST - Scleral Contact Lenses as an Alternative to Tarsorrhaphy for the Long-Term Management of Combined Exposure and Neurotrophic Keratopathy T2 - CORNEA TI - Scleral Contact Lenses as an Alternative to Tarsorrhaphy for the Long-Term Management of Combined Exposure and Neurotrophic Keratopathy VL - 32 ID - 6346 ER - TY - JOUR AD - A. White, Save Sight Institute and Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead, NSW, Australia AU - White, A. AU - Goldberg, I. DB - Embase Medline DO - 10.1111/ceo.12042 IS - 1 KW - alpha adrenergic receptor stimulating agent antiglaucoma agent beta adrenergic receptor blocking agent carbonate dehydratase inhibitor eye drops prostaglandin derivative awareness drug information drug labeling drug tolerability editorial glaucoma human monotherapy patient compliance patient education patient participation patient preference patient satisfaction quality of life questionnaire rating scale Treatment Impact Patient Satisfaction Scale treatment outcome unspecified side effect vision LA - English M3 - Editorial N1 - L368229352 2013-02-07 2013-02-15 PY - 2013 SN - 1442-6404 1442-9071 SP - 1-2 ST - Patient satisfaction: The name of the game? T2 - Clinical and Experimental Ophthalmology TI - Patient satisfaction: The name of the game? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368229352&from=export http://dx.doi.org/10.1111/ceo.12042 VL - 41 ID - 3031 ER - TY - JOUR AB - • PURPOSE: Determine persistence and adherence of glaucoma patients to therapeutic regimens of prostaglandin/prostamide-class IOP-lowering medications. • DESIGN: Retrospective, population-based study. • METHODS: Glaucoma patients in the IMS Health LifeLink database with a pharmacy claim for latanoprost (n = 1567), travoprost (n = 381), or bimatoprost (n = 476) between September, 2001 and March, 2002 who had no claims for IOP-lowering medication in the previous 180 days, and who were persistent during the first 90 days of therapy. Values reported in the quantity dispensed and days supply fields of the database were used in an algorithm that corrected anomalous data and adjusted days supply to calculate the main outcome measures, persistence, and adherence to therapy. • RESULTS: The percentage of patients persistent for the 12-month observation period was 69.4% (1087/1567) for those prescribed latanoprost, 70.6% (269/381) for those prescribed travoprost, and 68.1% (324/467) for those prescribed bimatoprost. Mean adherence for patients prescribed latanoprost was 75.4% of the year, for those prescribed travoprost, 77.1% of the year, and for those prescribed bimatoprost, 78.2% of the year. The mean number of days adherent for bimatoprost-treated patients (291.2 days) was significantly greater than for latanoprost-treated patients (281.0 days), and not remarkably different from travoprost-treated patients (287.0 days). • CONCLUSIONS: Overall, patients in this study who were taking IOP-lowering prostaglandin/prostamide medications had a mean adherence rate of 76% on average, suggesting that opportunities remain for improvement of adherence to therapeutic regimens for glaucoma treatment with prostamides and prostaglandins. © 2006 by Elsevier Inc. All rights reserved. AD - J. Wilensky, University of Illinois at Chicago, 1855 West Taylor, Chicago, IL 60612, United States AU - Wilensky, J. AU - Fiscella, R. G. AU - Carlson, A. M. AU - Morris, L. S. AU - Walt, J. DB - Embase Medline DO - 10.1016/j.ajo.2005.09.011 IS - 1 SUPPL. KW - antiglaucoma agent bimatoprost latanoprost travoprost algorithm article controlled study data base glaucoma human major clinical study outcomes research patient compliance pharmacy (shop) population research priority journal quantitative study retrospective study LA - English M3 - Article N1 - L43028477 2006-01-30 PY - 2006 SN - 0002-9394 SP - S28-S33 ST - Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data T2 - American Journal of Ophthalmology TI - Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43028477&from=export http://dx.doi.org/10.1016/j.ajo.2005.09.011 VL - 141 ID - 3637 ER - TY - JOUR AB - Purpose: Epithelial keratitis is the most common presentation of ocular infection by herpes simplex virus (HSV). Quantitative assessment of available therapy is needed to guide evidence-based ophthalmology. This study aimed to compare the efficacy of various treatments for dendritic or geographic HSV epithelial keratitis and to evaluate the role of various clinical characteristics on epithelial healing. Methods: Following a systematic review of the literature, information from clinical trials of HSV dendritic or geographic epithelial keratitis was extracted, and the methodological quality of each study was scored. Methods of epithelial cauterization and curettage were grouped as relatively equivalent physicochemical therapy, and solution and ointment formulations of a given topical antiviral agent were combined. The proportion healed with 1 week of therapy, a scheduled follow-up day that approximated the average time of resolution with antiviral therapy, was selected as the primary outcome based on a masked evaluation of maximum treatment differences in published healing curves. The proportion healed at 14 days was recorded as supplemental information. Fixed-effects and random-effects meta-analysis models were used to obtain summary estimates by pooling results from comparative treatment trials. Hypotheses about which prognostic factors might affect epithelial healing during antiviral therapy were developed by multivariate analysis of the Herpetic Eye Disease Study dataset. Results: After excluding 48 duplicate reports, 14 nonrandomized studies, 15 studies with outdated or similar treatments, and 29 trials lacking sufficient data on healing or accessibility, 76 primary reports were identified. These reports involved 4,251 patients allocated to 93 treatment comparisons of dendritic epithelial keratitis in 28 categories and 9 comparisons of geographic epithelial keratitis in 6 categories. For dendritic keratitis, idoxuridine was better than placebo at 7 days (combined odds ratio [OR], 3.59; 95% confidence interval [CI], 1.92-6.70), and at 14 days (OR, 4.17; 95% CI, 1.33-13.04), but pooling was limited by lack of homogeneity and low study quality. Direct comparisons at 1 week of treatment showed that trifluridine or acyclovir was significantly better than idoxuridine (OR, 3.12 and 4.56; 95% CI, 1.55-6.29 and 2.76-7.52, respectively), and indirect comparisons were also consistent with a clinically significant benefit. Vidarabine was not significantly better than idoxuridine in pooled treatment comparisons at 1 week (OR, 1.20; 95% CI, 0.72-2.00) but was better in 2 indirect comparisons (OR, 4.22 and 4.78; 95% CI, 1.69-10.54 and 2.15-10.65, respectively). At 14 days, trifluridine (OR, 6.05; 95% CI, 2.50-14.66), acyclovir (OR, 2.88; 95% CI, 1.39-4.78), and vidarabine (OR, 1.24; 95% CI, 0.65-2.37) were each better than idoxuridine. Trials of geographic epithelial keratitis also suggested that trifluridine, acyclovir, and vidarabine were more effective that idoxuridine. Other topical antiviral agents, such as bromovinyldeoxuridine, ganciclovir, and foscarnet, appeared equivalent to trifluridine or acyclovir. Oral acyclovir was equivalent to topical antiviral therapy and did not hasten healing when used in combination with topical treatment. Antiviral agents did not increase the speed of healing when compared to debridement but reduced the risk of recrudescent epithelial keratitis. The combination of physicochemical treatment with an antiviral agent seemed to be better than either physicochemical or antiviral treatment alone, but the heterogeneous cauterization and curettage techniques and the various treatment combinations limited valid quantitative summary effect measures. The combination of topical interferon with an antiviral agent was significantly better than antiviral therapy at 7 days (OR, 13.49; 95% CI, 7.39-24.61) but not at 14 days (OR, 2.36; 95% CI, 0.82-6.79). Finding apparent heterogeneity for some pooled estimates suggested that dissimilarities in patients, interventions, outcomes, or other logistical aspects f clinical trials occur across studies. Conclusions: The available evidence on the acute treatment of presumed HSV epithelial keratitis demonstrates the effectiveness of antiviral treatment and shows the log-logistic healing curve of treated dendritic epithelial keratitis. Topical trifluridine, acyclovir, and vidarabine were significantly more effective than idoxuridine but similar in relative effectiveness for dendritic epithelial keratitis. Physicochemical methods of removing infected corneal epithelium are effective, but adjunctive virucidal agents are needed to avert recrudescent epithelial keratitis. Whether debridement in combination with antiviral therapy is more beneficial than antiviral chemotherapy alone appears likely but remains inconclusive. The combination of topical interferon with an antiviral agent significantly speeds epithelial healing. Future trials of the acute treatment of HSV epithelial keratitis must aim to achieve adequate statistical power for assessing the primary outcome and should consider the effect of lesion size and other characteristics on treatment response. AD - Department of Ophthalmology, Baylor College of Medicine, Houston, TX, United States AU - Wilhelmus, K. R. DB - Scopus M3 - Conference Paper N1 - Cited By :54 Export Date: 19 July 2021 PY - 2000 SP - 505-532 ST - The treatment of herpes simplex virus epithelial keratitis T2 - Transactions of the American Ophthalmological Society TI - The treatment of herpes simplex virus epithelial keratitis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034530630&partnerID=40&md5=72db01ed7f66239b73738ffdf7c4d82d VL - 98 ID - 4985 ER - TY - JOUR AB - The provision of eye care services for competitors and support teams is integral to the modern Olympic Games. The eye clinic for the London 2012 Paralympic Games employed a multidisciplinary team of eye care professionals using state-of-the-art instrumentation to provide the highest level of eye care. The detailed organisation of the eye care clinic at London 2012 is described in a companion paper which summarises the eye care clinic during the London 2012 Olympic Games. These two reports will aid in planning eye care clinics at future Games. This paper summarises the organisation of the eye clinic and provides outline audit data relating to eye conditions encountered during the Paralympic Games. A total of 870 patients representing 102 countries attended the eye clinic. 274 (31.5%) were competitors; the remainder were trainers and support staff. No serious ocular injuries resulted from competitor injury in the field of play during the Paralympic Games, although seven patients were referred urgently to hospital eye services for conditions including orbital cellulitis, retinal detachment, exudative macular degeneration, corneal ulcer, Stevens-Johnson syndrome and macular oedema. A total of 749 spectacles, 14 pairs of contact lenses and 7 low vision aids were dispensed. By combining excellent facilities and equipment with a multidisciplinary team of eye care professionals, we feel we provided the highest level of eye care, providing a legacy for future Games. AD - C.M. Wilson, Department of Visual Neuroscience, UCL Institute of Ophthalmology, London, UK. AU - Wilson, C. M. AU - Thomson, W. D. AU - D'Ath, P. J. DB - Medline IS - 13 KW - adolescent adult ambulatory care article disabled sport eye disease eye injury female human male clinical audit middle aged Olympics optometry patient attitude spectacles sport injury statistics United Kingdom utilization review visual disorder young adult LA - English M3 - Article N1 - L563044208 2014-03-24 PY - 2013 SN - 1473-0480 SP - 869-872 ST - Seeing you through London 2012: eye care at the Paralympics T2 - British journal of sports medicine TI - Seeing you through London 2012: eye care at the Paralympics UR - https://www.embase.com/search/results?subaction=viewrecord&id=L563044208&from=export VL - 47 ID - 2976 ER - TY - JOUR AB - BACKGROUND: The provision of eye care services for competitors and support teams is integral to the modern Olympic Games. The eye clinic for the London 2012 Paralympic Games employed a multidisciplinary team of eye care professionals using state-of-the-art instrumentation to provide the highest level of eye care. The detailed organisation of the eye care clinic at London 2012 is described in a companion paper which summarises the eye care clinic during the London 2012 Olympic Games. These two reports will aid in planning eye care clinics at future Games. AIM: This paper summarises the organisation of the eye clinic and provides outline audit data relating to eye conditions encountered during the Paralympic Games. RESULTS: A total of 870 patients representing 102 countries attended the eye clinic. 274 (31.5%) were competitors; the remainder were trainers and support staff. No serious ocular injuries resulted from competitor injury in the field of play during the Paralympic Games, although seven patients were referred urgently to hospital eye services for conditions including orbital cellulitis, retinal detachment, exudative macular degeneration, corneal ulcer, Stevens-Johnson syndrome and macular oedema. A total of 749 spectacles, 14 pairs of contact lenses and 7 low vision aids were dispensed. CONCLUSIONS: By combining excellent facilities and equipment with a multidisciplinary team of eye care professionals, we feel we provided the highest level of eye care, providing a legacy for future Games. AU - Wilson, C. M. AU - Thomson, W. D. AU - D'Ath, P. J. DB - Medline DO - 10.1136/bjsports-2013-092614 IS - 13 KW - adolescent adult ambulatory care sport injury disabled sport eye disease eye injury female human male clinical audit middle aged patient attitude spectacles statistics and numerical data United Kingdom utilization visual disorder young adult LA - English M3 - Article N1 - L603118063 2015-03-24 PY - 2013 SN - 1473-0480 SP - 869-872 ST - Seeing you through London 2012: eye care at the Paralympics T2 - British journal of sports medicine TI - Seeing you through London 2012: eye care at the Paralympics UR - https://www.embase.com/search/results?subaction=viewrecord&id=L603118063&from=export http://dx.doi.org/10.1136/bjsports-2013-092614 VL - 47 ID - 2977 ER - TY - JOUR AD - R.P. Wilson, Wills Eye Hospital, Philadelphia, Pennsylvania, USA. AU - Wilson, R. P. DB - Medline IS - 4 KW - aged article case report female glaucoma health care quality human methodology nursing organization and management patient compliance patient education psychological aspect LA - English M3 - Article N1 - L129380632 1999-11-04 PY - 1998 SN - 0744-7132 SP - 145-146 ST - Improving the care of glaucoma patients T2 - Journal of ophthalmic nursing & technology TI - Improving the care of glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L129380632&from=export VL - 17 ID - 3941 ER - TY - JOUR AB - The most common reason for a glaucoma medication to be ineffective is that the patient does not take the medicine reliably. Instead of general questions, it is much more effective to try to elicit compliance by asking specific questions. If instruction as to how to instill topical medications is not effective, then the patient should be asked to use a drop guide. AD - Glaucoma Service, Wills Eye Hospital, Philadelphia, Pennsylvania AN - 107295358. Language: English. Entry Date: 19981101. Revision Date: 20150711. Publication Type: Journal Article AU - Wilson, R. P. DB - ccm DP - EBSCOhost IS - 4 KW - Glaucoma -- Drug Therapy Patient Compliance Aged Female N1 - case study. Journal Subset: Nursing; Peer Reviewed; USA. NLM UID: 8219658. PMID: NLM9883134. PY - 1998 SN - 0744-7132 SP - 145-146 ST - Improving the care of glaucoma patients T2 - Journal of Ophthalmic Nursing & Technology TI - Improving the care of glaucoma patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107295358&site=ehost-live&scope=site VL - 17 ID - 4695 ER - TY - JOUR AB - Background: The gold standard of surgical interventions in medically uncontrolled glaucoma is trabeculectomy. Cyclophotocoagulation is often performed only as a secondary/tertiary surgery. Since trabeculectomy demands a high degree of postsurgical compliance to achieve satisfying results, some patients do not qualify for trabeculectomy. Patients and Methods: During cyclophotocoagulation, the ciliary processes were coagulated using a transscleral diode laser. 49 eyes of 47 patients (25 women and 22 men) were included in our study. Patients were regularly followed up for 24 months. During follow-up, IOP, best corrected visual acuity and number of antiglaucoma drugs were recorded. Results: The mean age was 69.27 +/- 14.45 years. The diagnosis was open-angle glaucoma in 15 eyes, pseudoexfoliative glaucoma in 12 eyes, secondary rubeotic glaucoma in 7 eyes and secondary glaucoma without further specification in 15 eyes. On average, cyclophotocoagulation reduced intraocular pressure by 14.45 +/- 11.77 mmHg (-42.7%, p < 0.001). Medication could be reduced by 1.31 +/- 1.27 (-52%, p < 0.001). On average, visual acuity deteriorated by 0.383 LogMAR (+/- 0.848, p = 0.004). Conclusion: For selected glaucoma patients, cyclophotocoagulation could be an option as primary surgical intervention to lower intraocular pressure. AN - WOS:000318222000012 AU - Winkler, N. F. K. AU - Funk, J. DA - APR DO - 10.1055/s-0032-1328359 IS - 4 PY - 2013 SN - 0023-2165 SP - 353-357 ST - Transscleral Cyclophotocoagulation as Primary Surgical Intervention in Glaucoma T2 - KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE TI - Transscleral Cyclophotocoagulation as Primary Surgical Intervention in Glaucoma VL - 230 ID - 6009 ER - TY - JOUR AB - Purpose: Effective glaucoma therapy relies to a great extent on the patients' ability to regularly self-administer eye drops. This study aimed to assess self-reported nonadherence and to identify potential barriers to adherence in glaucoma patients. Methods: Participants completed a 16-item questionnaire, designed to examine nonadherence rate and assess the therapy experience. Inclusion criteria stipulated treatment duration of at least 1 year. Nonadherence was defined as missing ≥5% of the prescribed pressure-lowering eye drops doses. Results: In total, 201 glaucoma patients aged 24-88 years were included. Mean treatment duration was 9.4 years. Nonadherence was reported by 30.3% of participants and 69.7% were reported to be adherent. Individuals who experienced side effects reported higher levels of nonadherence than those who did not (37.6% vs. 18.4%; P = 0.004). Eye drops with preservatives were used by 84.1% of participants, 11.9% were on combined preservative and preservative-free treatment, and 4.0% on preservative-free medication only. Self-reported nonadherence levels were 32.0%, 25.0%, and 12.5%, respectively, for each of these groups. Men reported higher rates of nonadherence than women (36.8% vs. 24.5%; P = 0.066). Age, social status, history of migration, severity of disease, and fear of blindness were not associated with significant differences in nonadherence levels. Conclusions: Nonadherence with glaucoma therapy is a significant barrier to therapeutic success for approximately one-third of patients. Nonadherence may be reduced if side effects are avoided. Preservative-free products may provide adherence benefits. The patient experience should be a key consideration when selecting appropriate treatments, to reduce nonadherence and optimize outcomes. AD - C. Wolfram, Department of Ophthalmology, University Medical Center Mainz, Langenbeckstrasse 1, Mainz, Germany AU - Wolfram, C. AU - Stahlberg, E. AU - Pfeiffer, N. DB - Embase Medline DO - 10.1089/jop.2018.0134 IS - 4 KW - antiglaucoma agent adult aged article blindness blurred vision clinical assessment clinical evaluation controlled study disease duration disease severity dizziness drug self administration female glaucoma headache human major clinical study male migration patient compliance patient-reported outcome social status treatment duration treatment refusal vision xerostomia LA - English M3 - Article N1 - L627684511 2019-05-21 2019-05-22 PY - 2019 SN - 1557-7732 1080-7683 SP - 223-228 ST - Patient-reported nonadherence with glaucoma therapy T2 - Journal of Ocular Pharmacology and Therapeutics TI - Patient-reported nonadherence with glaucoma therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627684511&from=export http://dx.doi.org/10.1089/jop.2018.0134 VL - 35 ID - 2507 ER - TY - JOUR AB - Purpose: Effective glaucoma therapy relies to a great extent on the patients' ability to regularly self-administer eye drops. This study aimed to assess self-reported nonadherence and to identify potential barriers to adherence in glaucoma patients. Methods: Participants completed a 16-item questionnaire, designed to examine nonadherence rate and assess the therapy experience. Inclusion criteria stipulated treatment duration of at least 1 year. Nonadherence was defined as missing ≥5% of the prescribed pressure-lowering eye drops doses. Results: In total, 201 glaucoma patients aged 24-88 years were included. Mean treatment duration was 9.4 years. Nonadherence was reported by 30.3% of participants and 69.7% were reported to be adherent. Individuals who experienced side effects reported higher levels of nonadherence than those who did not (37.6% vs. 18.4%; P = 0.004). Eye drops with preservatives were used by 84.1% of participants, 11.9% were on combined preservative and preservative-free treatment, and 4.0% on preservative-free medication only. Self-reported nonadherence levels were 32.0%, 25.0%, and 12.5%, respectively, for each of these groups. Men reported higher rates of nonadherence than women (36.8% vs. 24.5%; P = 0.066). Age, social status, history of migration, severity of disease, and fear of blindness were not associated with significant differences in nonadherence levels. Conclusions: Nonadherence with glaucoma therapy is a significant barrier to therapeutic success for approximately one-third of patients. Nonadherence may be reduced if side effects are avoided. Preservative-free products may provide adherence benefits. The patient experience should be a key consideration when selecting appropriate treatments, to reduce nonadherence and optimize outcomes. AD - Department of Ophthalmology, University Medical Center Mainz, Mainz, Germany. Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Mainz, Germany. Department for Radiology and Nuclear Medicine, University Hospital of Schleswig Holstein, Campus Luebeck, Mainz, Germany. AN - 136368645. Language: English. Entry Date: 20200926. Revision Date: 20210608. Publication Type: journal article AU - Wolfram, Christian AU - Stahlberg, Erik AU - Pfeiffer, Norbert DB - ccm DO - 10.1089/jop.2018.0134 DP - EBSCOhost IS - 4 KW - Glaucoma -- Drug Therapy Antihypertensive Agents -- Therapeutic Use Pharmaceutical Additives -- Therapeutic Use Patient Compliance Ophthalmic Solutions -- Therapeutic Use Aged, 80 and Over Male Aged Injections Ophthalmic Solutions -- Administration and Dosage Young Adult Antihypertensive Agents -- Administration and Dosage Adult Human Female Germany Pharmaceutical Additives -- Administration and Dosage Middle Age Validation Studies Comparative Studies Evaluation Research Multicenter Studies Social Readjustment Rating Scale N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM30897019. PY - 2019 SN - 1080-7683 SP - 223-228 ST - Patient-Reported Nonadherence with Glaucoma Therapy T2 - Journal of Ocular Pharmacology & Therapeutics TI - Patient-Reported Nonadherence with Glaucoma Therapy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136368645&site=ehost-live&scope=site VL - 35 ID - 4174 ER - TY - JOUR AD - Wolmark AU - Wolmark DB - Medline KW - adolescent adult aged ambulatory care article blindness child cost economics female France glaucoma health care cost health service hospitalization human infant male middle aged newborn preschool child visual disorder LA - French M3 - Article N1 - L15624176 1985-01-09 PY - 1983 SN - 0246-0831 SP - 127-142 ST - The socioeconomic cost of glaucoma T2 - Revue internationale du trachome et de pathologie oculaire tropicale et subtropicale et de santé publique : organe de la Ligue contre le trachome avec la collaboration de l'International Organization against Trachoma et des organisations nationales et internationales de santé publique TI - The socioeconomic cost of glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L15624176&from=export ID - 4085 ER - TY - JOUR AB - We report surgical removal of a droplet of intraocular chloramphenicol ointment in a 70-year-old man who had routine small-incision phacoemulsification. A spherical droplet of ointment adherent to the intraocular lens was noted 2 months postoperatively. The source was considered to be the immediate postoperative conjunctival fornix chloramphenicol ointment. Gonioscopy revealed tiny droplets adherent to the peripheral iris and angle. The droplet was surgically explanted using a minimally traumatic technique with a lens glide and ophthalmic viscosurgical device through an enlarged clear corneal incision and sent intact for laboratory biochemical analysis. The patient maintained good vision without evidence of uveitis or secondary glaucoma at 1 year of follow-up. This uncommon case also raises issues about the need for immediate postoperative antibiotic ointment for endophthalmitis prophylaxis and phacoemulsification thermal wound effects on the integrity of self-sealing clear corneal incisions. © 2006 ASCRS and ESCRS. AD - Department of Ophthalmology (Wong, Bank), Bankstown Hospital, Sydney Eye Hospital (Wong), Sydney, Australia AU - Wong, J. G. AU - Bank, A. DB - Scopus DO - 10.1016/j.jcrs.2006.01.071 IS - 5 M3 - Article N1 - Cited By :14 Export Date: 19 July 2021 PY - 2006 SP - 890-892 ST - Surgical removal of intraocular antibiotic ointment after routine cataract phacoemulsification T2 - Journal of Cataract and Refractive Surgery TI - Surgical removal of intraocular antibiotic ointment after routine cataract phacoemulsification UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33744795432&doi=10.1016%2fj.jcrs.2006.01.071&partnerID=40&md5=9487830e5cd10f177f92e91e1d72dc9f VL - 32 ID - 5206 ER - TY - JOUR AB - We report surgical removal of a droplet of intraocular chloramphenicol ointment in a 70-year-old man who had routine small-incision phacoemulsification. A spherical droplet of ointment adherent to the intraocular lens was noted 2 months postoperatively. The source was considered to be the immediate postoperative conjunctival fornix chloramphenicol ointment. Gonioscopy revealed tiny droplets adherent to the peripheral iris and angle. The droplet was surgically explanted using a minimally traumatic technique with a lens glide and ophthalmic viscosurgical device through an enlarged clear corneal incision and sent intact for laboratory biochemical analysis. The patient maintained good vision without evidence of uveitis or secondary glaucoma at I year of follow-up. This uncommon case also raises issues about the need for immediate postoperative antibiotic ointment for endophthalmitis prophylaxis and phacoemulsification thermal wound effects on the integrity of self-sealing clear corneal incisions. AN - WOS:000238413000042 AU - Wong, J. G. AU - Bank, A. DA - MAY DO - 10.1016/j.jcrs.2006.01.071 IS - 5 PY - 2006 SN - 0886-3350 1873-4502 SP - 890-892 ST - Surgical removal of intraocular antibiotic ointment after routine cataract phacoemulsification T2 - JOURNAL OF CATARACT AND REFRACTIVE SURGERY TI - Surgical removal of intraocular antibiotic ointment after routine cataract phacoemulsification VL - 32 ID - 6119 ER - TY - JOUR AB - Glaucoma is a chronic progressive optic neuropathy that is characterized by optic nerve changes and visual field loss. Elevated intraocular pressure (IOP) is the main modifiable risk factor. Chronic instillation of daily eyedrops to lower IOP is the primary treatment of choice, although it requires patient adherence and correct performance. We have developed a nanoliposome drug delivery system for the longer term delivery of latanoprost. In the present open-label, pilot study, the safety and efficacy of a single subconjunctival injection of liposomal latanoprost was evaluated in six subjects with a diagnosis of either ocular hypertension (OHT) or primary open-angle glaucoma (POAG). Subconjunctival injection of liposomal latanoprost was well tolerated by all six subjects. From a baseline IOP of 27.55 ± 3.25 mmHg, the mean IOP decreased within 1 h to 14.52 ± 3.31 mmHg (range 10-18 mmHg). This represented a mean decrease of 13.03 ± 2.88 mmHg (range 9-17 mmHg), or 47.43 ± 10.05 % (range 37-63 %). A clinically and statistically significant IOP reduction (≥20 % IOP reduction, P = 0.001 to 0.049) was observed through 3 months after injection. The nanomedicine reported here is the first nanocarrier formulation that has an extended duration of action in humans, beyond a couple of weeks. The findings in this study open up a new treatment modality, which will greatly enhance patient compliance and improve treatment outcomes. The current study provides the evidence and support for further clinical studies of liposomal latanoprost in the treatment of glaucoma. © 2014 Controlled Release Society. AD - T. T. Wong, School of Materials Science and Engineering, Nanyang Technological University, Blk N4.1, Nanyang Avenue, Singapore, 639798, Singapore AU - Wong, T. T. AU - Novack, G. D. AU - Natarajan, J. V. AU - Ho, C. L. AU - Htoon, H. M. AU - Venkatraman, S. S. C1 - xalatan DB - Embase DO - 10.1007/s13346-014-0196-9 IS - 4 KW - eye drops latanoprost nanocarrier nanoliposome unclassified drug adult aged article blurred vision clinical article drug delivery system drug efficacy drug safety drug tolerability eye discomfort female glaucoma human intraocular hypertension intraocular pressure liposomal delivery male nanomedicine open angle glaucoma patient compliance priority journal sustained release formulation treatment outcome xalatan LA - English M3 - Article N1 - L373569841 2014-07-29 2014-08-04 PY - 2014 SN - 2190-3948 2190-393X SP - 303-309 ST - Nanomedicine for glaucoma: Sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops T2 - Drug Delivery and Translational Research TI - Nanomedicine for glaucoma: Sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373569841&from=export http://dx.doi.org/10.1007/s13346-014-0196-9 VL - 4 ID - 2912 ER - TY - JOUR AB - Objectives: Estimate the long-term direct medical costs and clinical consequences of improved adherence with bimatoprost 0.01% compared to bimatoprost 0.03% in the treatment of glaucoma. Methods: A cost-consequence model was constructed from the perspective of a US healthcare payer. The model structure included three adherence levels (high, moderate, low) and four mean deviation (MD) defined health states (mild, moderate, severe glaucoma, blindness) for each adherence level. Clinical efficacy in terms of IOP reduction was obtained from the randomized controlled trial comparing bimatoprost 0.01% with bimatoprost 0.03%. Medication adherence was based on observed 12 month rates from an analysis of a nationally representative pharmacy claims database. Patients with high, moderate and low adherence were assumed to receive 100%, 50% and 0% of the IOP reduction observed in the clinical trial, respectively. Each 1 mmHg reduction in IOP was assumed to result in a 10% reduction in the risk of glaucoma progression. Worse glaucoma severity health states were associated with higher medical resource costs. Outcome measures were total costs, proportion of patients who progress and who become blind, and years of blindness. Deterministic sensitivity analyses were performed on uncertain model parameters. Results: The percentage of patients progressing, becoming blind, and the time spent blind slightly favored bimatoprost 0.01%. Improved adherence with bimatoprost 0.01% led to higher costs in the first 2 years; however, starting in year 3 bimatoprost 0.01% became less costly compared to bimatoprost 0.03% with a total reduction in costs reaching US$3433 over a lifetime time horizon. Deterministic sensitivity analyses demonstrated that results were robust, with the majority of analyses favoring bimatoprost 0.01%. Application of 1 year adherence and efficacy over the long term are limitations. Conclusions: Modeling the effect of greater medication adherence with bimatoprost 0.01% compared with bimatoprost 0.03% suggests that differences may result in improved economic and patient outcomes. AD - Allergan Inc. , Irvine, CA , USA. AN - 107910050. Language: English. Entry Date: 20140418. Revision Date: 20150819. Publication Type: Journal Article. Journal Subset: Biomedical AU - Wong, William B. AU - Patel, Vaishali D. AU - Kowalski, Jonathan W. AU - Schwartz, Gail DB - ccm DO - 10.1185/03007995.2013.815159 DP - EBSCOhost IS - 9 KW - Amides -- Administration and Dosage Amides -- Economics Bimatoprost -- Administration and Dosage Bimatoprost -- Economics Models, Biological Ophthalmic Solutions -- Administration and Dosage Ophthalmic Solutions -- Economics Optic Nerve Diseases -- Drug Therapy Optic Nerve Diseases -- Economics Optic Nerve Diseases -- Physiopathology Optic Nerve Diseases -- Therapy Patient Compliance Administration, Topical N1 - Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. NLM UID: 0351014. PMID: NLM23865609. PY - 2013 SN - 0300-7995 SP - 1191-1200 ST - An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03% T2 - Current Medical Research & Opinion TI - An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03% UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107910050&site=ehost-live&scope=site VL - 29 ID - 4397 ER - TY - JOUR AB - The practical value of any therapy depends upon a combination of effectiveness of the agent (or procedure) and the extent to which the patient complies in its proper administration. Thus, it might be said that the multiple of effectiveness times compliance equals the 'usefulness product'. Among the various glaucoma therapies, this product seems to range from about 30%-90%. Timolol's effectiveness in lowering intracular pressure combined with its low incidence of side effects yields a high usefulness product, and this may decrease the incidence of surgery required for the treatment of the open-angle glaucomas. AD - Dept. Ophthalmol., VA Hosp., San Diego, Calif. 92161 AU - Worthen, D. M. DB - Embase Medline DO - 10.1016/0039-6257(79)90236-4 IS - 6 KW - epinephrine pilocarpine propranolol timolol drug efficacy drug therapy glaucoma human cell intraocular pressure major clinical study patient compliance therapy topical drug administration visual system LA - English M3 - Article N1 - L9199798 1979-10-14 PY - 1979 SN - 0039-6257 SP - 403-406 ST - Patient compliance and the 'usefulness product' of timolol T2 - Survey of Ophthalmology TI - Patient compliance and the 'usefulness product' of timolol UR - https://www.embase.com/search/results?subaction=viewrecord&id=L9199798&from=export http://dx.doi.org/10.1016/0039-6257(79)90236-4 VL - 23 ID - 4107 ER - TY - JOUR AB - The purpose of this study was to document attitudes and practices of Australian optometrists in their management of diabetic retinopathy prior to the release of the National Health and Medical Research Council (NHMRC) Clinical Practice Guidelines for the Management of Diabetic Retinopathy and at two time points following their release. A self- administered questionnaire was mailed to a stratified random sample of 500 Australian optometrists at the three time points. The same sample was used for the first two surveys and a new random sample was drawn for the second follow-up survey. The response to the three questionnaires was 86%, 80% and 84%, respectively. More than 90% of optometrists reported receiving a copy of the guidelines and 82% reported receiving the supplementary Retinopathy Chart. Fifty-seven per cent reported having read the guidelines at least once in entirety and 65% reported that they refer to the Retinopathy Chart at least monthly in their clinical practice. There was a significant decrease in the number of optometrists who reported that patient unwillingness to be dilated and their fear of precipitating angle closure glaucoma were moderate or major barriers to performing dilated ophthalmoscopy. Concomitantly, the percentage of optometrists who reported that they often or always perform dilated ophthalmoscopy on new patients with diabetes increased significantly from 74.5% (95% confidence limit = 70.2, 78.8) to 81.5% (95% confidence limit = 77.5, 85.5). There have been some significant changes in the self-reported management practices of optometrists in relation to diabetic retinopathy since the release of the NHMRC guidelines and Retinopathy Chart. AN - WOS:000169886900006 AU - Wright, S. E. AU - McKay, R. AU - Taylor, K. I. AU - Keeffe, J. E. AU - McCarty, C. A. AU - Working Grp Evaluation, Nhmrc R. DA - JUN DO - 10.1046/j.1442-9071.2001.00390.x IS - 3 PY - 2001 SN - 1442-6404 SP - 121-124 ST - Changes in attitudes and practices of optometrists in their management of diabetic retinopathy after the release of NHMRC guidelines T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Changes in attitudes and practices of optometrists in their management of diabetic retinopathy after the release of NHMRC guidelines VL - 29 ID - 6333 ER - TY - JOUR AD - E.I. Wu, New York, NY, United States AU - Wu, E. I. AU - Ritterband, D. C. AU - Yu, G. AU - Shields, R. A. AU - Seedor, J. A. DB - Embase DO - 10.1016/j.ajo.2012.03.005 IS - 1 KW - difluprednate fluorometholone loteprednol prednisolone acetate steroid clinical feature hereditary corneal dystrophy cornea neovascularization Descemet stripping endothelial keratoplasty drug substitution drug withdrawal eye synechia glaucoma graft failure graft rejection high risk patient human inflammation intraocular pressure keratopathy letter maintenance therapy patient compliance penetrating keratoplasty postoperative care priority journal race treatment duration treatment failure treatment indication treatment response LA - English M3 - Letter N1 - L365089124 2012-07-04 PY - 2012 SN - 0002-9394 1879-1891 SP - 211-212 ST - Reply T2 - American Journal of Ophthalmology TI - Reply UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365089124&from=export http://dx.doi.org/10.1016/j.ajo.2012.03.005 VL - 154 ID - 3075 ER - TY - JOUR AB - Objective: To investigate the feasibility and clinical effects of non-Descemet stripping endothelial keratoplasty (nDSEK) on treating iridocorneal endothelial (ICE) syndrome in phakic eyes. Methods: Retrospective noncomparative interventional case series. 7 patients (7 eyes) with ICE syndrome at the Affiliated Xiamen Eye Center of Xiamen University from January 2008 to December 2009 underwent non-Descemet stripping endothelial keratoplasty. All patients were followed up for 3-12 months, pre- and postoperative best corrected visual acuity (BCVA) were compared, the adherence of the donor disc to the recipient endothelium and postoperative donor disc dislocation were monitored during the follow-up period. Graft clearance and endothelial cell density(ECD) were observed, too. Results: After nDSEK, no primary graft failures dislocation and decentered graft occurred during the follow-up period. Study group intraoperative complications included 3 case with elevated intraocular pressure 2 day postoperatively. Subepithelial haze, donor-recipient interface haze, and interface particles were observed in all measurable cases by in vivo laser confocal microscopy. Anteriorsegment optical coherence tomography and ultrasound biomicroscopy showed the adherence of the donor disc to the recipient endothelium and peripheral anterior synechiae were separated. All corneas remained clear during the follow-up. 6 patients had improved BCVA while 1 patient had the same BCVA. The reason for poor VA was optic atrophy due to glaucoma. Postoperative mean EDC was (2176.6±267.6) cells/mm 2. Conclusions: nDSEK for iridocorneal endothelial(ICE) syndrome is feasible, technically easy, safe and effective. It can be one of the surgical treatment option for bullous keratopathy. © 2011 by the Chinese Medical Association. AD - Ocular Surface and Corneal Disease Department, The Affiliated Xiamen Eye Center of Xiamen University, Xiamen 361001, China AU - Wu, H. P. AU - Dong, N. AU - Xie, S. Z. AU - Li, C. AU - Li, X. Z. AU - Liu, Z. S. DB - Scopus DO - 10.3760/cma.j.issn.0412-4081.2011.05.006 IS - 5 KW - Corneal diseases Corneal transplantation Descemet membrane Endothelium, corneal Iris diseases M3 - Article N1 - Cited By :1 Export Date: 19 July 2021 PY - 2011 SP - 410-415 ST - Non-Descemet stripping endothelial keratoplasty for treating iridocorneal endothelial syndrome in phakic eyes T2 - Chinese Journal of Ophthalmology TI - Non-Descemet stripping endothelial keratoplasty for treating iridocorneal endothelial syndrome in phakic eyes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859248468&doi=10.3760%2fcma.j.issn.0412-4081.2011.05.006&partnerID=40&md5=6f5edcb71df01842eda981c0acb7f9f2 VL - 47 ID - 5638 ER - TY - JOUR AB - Objective To investigate the medication adherence and modulation factors of medication adherence in long-term treated glaucoma patients. Methods It was a cross-sectional study. One hundred glaucoma patients who have been followed-up for more than 6 month in the Second Hospital affiliated to Medical College of Zhejiang University were investigated with questionnaires and interview. The data was analyzed by binary logistic regression and χ2 test. Results In the 100 glaucoma patients being ivestigated, the medication compliance of patients is 61 (61.0%) , the medication non-compliance of patients is 39 (39.0%). Age, gender, habitat, glaucoma types, surgical history, inquesting patient before writing out a prescription and informing them the methods for application of eyedrops were not significantly co-related with medication adherence ( χ2 = 0.718, 0.537, 0.338, 3.797, 0.338, 0.297, 0.157 ; P > 0.05 ) . Intraocular pressure before treatment, types of eyedrops, instillation of eye-drops to the eyelids, request for help during application of eyedrops, rechecking regularly and confidence in glaucoma treatment were found significantly related to medication adherence ( P = 0.013, 0.005, 0.005, 0.012, 0.011, 0.004). However, drug side effect, forgetting application of eyedrops and inconvenience to see a doctor was considered the most important factors by patients in the interview. Conclusions Glaucoma physicians should discuss with patients about the methods for the application of glaucoma medication. This can improve the medication adherence of glaucoma patients and promote the therapeutic effect. AD - J.-F. Yin, Department of Ophthalmology, People's Hospital of Dongyang, Dongyang, Zhejiang 322100, China AU - Wu, H. Y. AU - Yin, J. F. DB - Medline DO - 10.3760/cma.j.issn.0412-4081.2010.06.005 IS - 6 KW - adolescent adult aged article child cross-sectional study female glaucoma human male middle aged patient compliance psychological aspect questionnaire LA - Chinese M3 - Article N1 - L359524862 2012-01-18 PY - 2010 SN - 0412-4081 SP - 494-498 ST - Clinical investigation of medication adherence of glaucoma patients T2 - Chinese Journal of Ophthalmology TI - Clinical investigation of medication adherence of glaucoma patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359524862&from=export http://dx.doi.org/10.3760/cma.j.issn.0412-4081.2010.06.005 VL - 46 ID - 3247 ER - TY - JOUR AB - Significance: Access to digital text is increasingly widespread, but its impact on low-vision reading is not well understood.Purpose: We conducted an online survey of people with low vision to determine what assistive technologies they use for visual reading, their preferred text characteristics, and the time they devote to reading digital and hard-copy text.Methods: One hundred thirty-three low-vision participants completed an online survey. Participants reported the nature and history of their low vision, their usage of different assistive technologies, and time devoted to five visual reading activities.Results: The three largest diagnostic categories were albinism (n = 36), retinitis pigmentosa (n = 20), and glaucoma (n = 15). Mean self-reported acuity was 0.93 logMAR (range, 0.1 to 1.6 logMAR). Mean age was 46 years (range, 18 to 98 years). Participants reported on percentage time spent reading using vision, audio, or touch (braille). Seventy-five percent of our participants did more than 50% of their reading visually. Across five categories of reading activities-work or education, news, pleasure, spot reading, and social networking-participants reported more time spent on digital reading than hard-copy reading. Eighty-nine percent of our participants used at least one technology from each of our two major categories of assistive technologies (digital content magnifiers and hard-copy content magnifiers) for visual reading.Conclusions: Despite the growing availability of digital text in audio or braille formats, our findings from an online sample of people with low vision indicate the continuing importance of visual reading. Our participants continue to use technology to access both hard-copy and digital text, but more time is devoted to digital reading. Our findings highlight the need for continued research and development of technology to enhance visual reading accessibility. AD - Department of Psychology, University of Minnesota, Minneapolis, Minnesota Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom AN - 142870579. Language: English. Entry Date: 20200504. Revision Date: 20210715. Publication Type: journal article AU - Wu, Yueh-Hsun AU - Granquist, Christina AU - Gage, Rachel AU - Crossland, Michael D. AU - Legge, Gordon E. DB - ccm DO - 10.1097/OPX.0000000000001503 DP - EBSCOhost IS - 4 KW - Assistive Technology Devices Reading Vision, Subnormal -- Physiopathology Communications Media Young Adult Male Mobile Applications Human Surveys Eyeglasses Female Visual Acuity -- Physiology Middle Age Aged, 80 and Over Diagnostic Tests, Routine Adult Adolescence Aged Comparative Studies Multicenter Studies Evaluation Research Validation Studies Impact of Events Scale Scales Social Readjustment Rating Scale N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Work Environment Scale (WES) (Moos et al); Impact of Events Scale (IES); Social Readjustment Rating Scale (SRRS) (Holmes and Rahe). Grant Information: R01 EY002934/EY/NEI NIH HHS/United States. NLM UID: 8904931. PMID: NLM32304534. PY - 2020 SN - 1040-5488 SP - 249-256 ST - Online Survey of Digital Reading by Adults with Low Vision T2 - Optometry & Vision Science TI - Online Survey of Digital Reading by Adults with Low Vision UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142870579&site=ehost-live&scope=site VL - 97 ID - 4214 ER - TY - JOUR AB - Purpose.: Lens case contamination is a risk factor for microbial keratitis. The effectiveness of manufacturers' lens case cleaning guidelines in limiting microbial contamination has not been evaluated in vivo. This study compared the effectiveness of manufacturers' guidelines and an alternative cleaning regimen. Methods.: A randomized cross-over clinical trial with two phases (n = 40) was performed. Participants used the lens types of their choice in conjunction with the provided multipurpose solution (containing polyhexamethylene biguanide) for daily wear. In the manufacturers' guideline phase, cases were rinsed with multipurpose solution and air dried. In the alternative regimen phase, cases were rubbed, rinsed with solution, tissue wiped, and air-dried face down. The duration of each phase was 1 month. Lens cases were collected at the end of each phase for microbiological investigation. The levels of microbial contamination were compared, and compliance to both regimens was assessed. Results.: The case contamination rate was 82% (32/39) in the manufacturers' guideline group, compared with 72% (28/39) in the alternative regimen group. There were significantly fewer (p = 0.004) colony forming units (CFU) of bacteria from cases used by following the alternative regimen (CFU range of 0 to 10, and median of 12 CFU per well) compared with that of the manufacturer's guidelines (CFU range of 0 to 10, and median of 28 CFU per well). The compliance level between both guidelines was not significantly different (p > 0.05). Conclusions.: The alternative guidelines are more effective in eliminating microbial contamination from lens cases than that of the current manufacturer's guideline. Simply incorporating rubbing and tissue-wiping steps in daily case hygiene reduces viable organism contamination. Copyright © 2011 American Academy of Optometry. AD - School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia Brien Holden Vision Institute, Rupert Myers Building, University of New South Wales, Level 4, North Wing, Gate 14, Barker St., Sydney, NSW 2052, Australia AU - Wu, Y. T. AU - Teng, Y. J. AU - Nicholas, M. AU - Harmis, N. AU - Zhu, H. AU - Willcox, M. D. P. AU - Stapleton, F. DB - Scopus DO - 10.1097/OPX.0b013e3182282f28 IS - 10 KW - Contact lens guidelines hygiene practices microbial contamination M3 - Article N1 - Cited By :27 Export Date: 19 July 2021 PY - 2011 SP - E1180-E1187 ST - Impact of lens case hygiene guidelines on contact lens case contamination T2 - Optometry and Vision Science TI - Impact of lens case hygiene guidelines on contact lens case contamination UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053380736&doi=10.1097%2fOPX.0b013e3182282f28&partnerID=40&md5=5062d25d78f988ae17e2ff2393980da1 VL - 88 ID - 5081 ER - TY - JOUR AB - Purpose: To illustrate that patients with diabetic retinopathy who are treated exclusively with anti–vascular endothelial growth factor (VEGF) therapy and have an interruption in treatment may experience marked progression of disease with potentially devastating visual consequences. Design: Retrospective, multicenter, case series. Methods: Retrospective review of patients treated exclusively with anti-VEGF therapy for proliferative diabetic retinopathy (PDR) or nonproliferative diabetic retinopathy (NPDR), with or without diabetic macular edema (DME), and temporarily lost to follow-up. Baseline disease characteristics, cause and duration of the treatment interruption, and resulting disease progression, complications, and outcomes were assessed. Results: Thirteen eyes of 12 patients with type 2 diabetes were identified. The mean age was 57 ± 10 years, and 50% were women. Anti-VEGF therapy was indicated for PDR with DME in 7 (54%) eyes, PDR without DME in 3 (23%) eyes, and moderate to severe NPDR with DME in 3 (23%) eyes. Eight eyes had visual acuity (VA) of 20/80 or better before treatment interruption. The median duration of treatment hiatus was 12 months. Reasons for treatment interruption included intercurrent illness (31%), noncompliance (31%), and financial issues (15%). Complications upon follow-up included vitreous hemorrhage (9 eyes), neovascular glaucoma (5 eyes), and traction retinal detachment (4 eyes). Despite treatment of these complications, 77% of eyes lost ≥3 lines of VA, with 46% of eyes having a final VA of hand motion or worse. Conclusions: Diabetic patients are subject to significant lapses in follow-up because of illness, financial hardship, or noncompliance. In patients with diabetic retinopathy, especially PDR, who are managed with anti-VEGF therapy alone, unintentional treatment interruptions can result in irreversible blindness. © 2019 Elsevier Inc. AD - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, United States AU - Wubben, T. J. AU - Johnson, M. W. AU - Sohn, E. H. AU - Peairs, J. J. AU - Kay, C. N. AU - Kim, S. J. AU - Gardner, T. W. AU - Paulus, Y. M. AU - Zacks, D. N. AU - Steinle, N. C. AU - Avery, R. L. AU - Berrocal, M. H. AU - Anti, Vegf Treatment Interruption Study Group DB - Scopus DO - 10.1016/j.ajo.2019.03.005 M3 - Article N1 - Cited By :22 Export Date: 19 July 2021 PY - 2019 SP - 13-18 ST - Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions T2 - American Journal of Ophthalmology TI - Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067401201&doi=10.1016%2fj.ajo.2019.03.005&partnerID=40&md5=ad0d83ab078f82af44ab7706287a544f VL - 204 ID - 5119 ER - TY - JOUR AB - PURPOSE: To illustrate that patients with diabetic retinopathy who are treated exclusively with anti-vascular endothelial growth factor (VEGF) therapy and have an interruption in treatment may experience marked progression of disease with potentially devastating visual consequences. DESIGN: Retrospective, multicenter, case series. METHODS: Retrospective review of patients treated exclusively with anti-VEGF therapy for proliferative diabetic retinopathy (PDR) or nonproliferative diabetic retinopathy (NPDR), with or without diabetic macular edema (DME), and temporarily lost to follow-up. Baseline disease characteristics, cause and duration of the treatment interruption, and resulting disease progression, complications, and outcomes were assessed. RESULTS: Thirteen eyes of 12 patients with type 2 diabetes were identified. The mean age was 57 +/- 10 years, and 50% were women. Anti-VEGF therapy was indicated for PDR with DME in 7 (54%) eyes, PDR without DME in 3 (23%) eyes, and moderate to severe NPDR with DME in 3 (23%) eyes. Eight eyes had visual acuity (VA) of 20/80 or better before treatment interruption. The median duration of treatment hiatus was 12 months. Reasons for treatment interruption included intercurrent illness (31%), noncompliance (31%), and financial issues (15%). Complications upon follow-up included vitreous hemorrhage (9 eyes), neovascular glaucoma (5 eyes), and traction retinal detachment (4 eyes). Despite treatment of these complications, 77% of eyes lost >= 3 lines of VA, with 46 /o of eyes having a final VA of hand motion or worse. CONCLUSIONS: Diabetic patients are subject to significant lapses in follow-up because of illness, financial hardship, or noncompliance. In patients with diabetic retinopathy, especially PDR, who are managed with anti-VEGF therapy alone, unintentional treatment interruptions can result in irreversible blindness. (Am J Ophthalmol 2019;204:13-18. (C) 2019 Elsevier Inc. All rights reserved.) AN - WOS:000478859400003 AU - Wubben, T. J. AU - Johnson, M. W. AU - Sohn, E. H. AU - Peairs, J. J. AU - Kay, C. N. AU - Kim, S. J. AU - Gardner, T. W. AU - Paulus, Y. M. AU - Zacks, D. N. AU - Steinle, N. C. AU - Avery, R. L. AU - Berrocal, M. H. AU - Anti-Vegf Treatment, Interruption DA - AUG DO - 10.1016/j.ajo.2019.03.005 PY - 2019 SN - 0002-9394 1879-1891 SP - 13-18 ST - Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions VL - 204 ID - 6161 ER - TY - JOUR AB - Background: Population-based screening was essential for glaucoma management. Although various studies have investigated the cost-effectiveness of glaucoma screening, policymakers facing with uncontrollably growing total health expenses were deeply concerned about the potential financial consequences of glaucoma screening. This present study was aimed to explore the impact of glaucoma screening with artificial intelligence (AI) automated diagnosis from a budgetary standpoint in Changjiang county, China.Methods: A Markov model based on health care system's perspective was adapted from previously published studies to predict disease progression and healthcare costs. A cohort of 19,395 individuals aged 65 and above were simulated over a 15-year timeframe. Fur illustrative purpose, we only considered primary angle-closure glaucoma (PACG) in this study. Prevalence, disease progression risks between stages, compliance rates were obtained from publish studies. We did a meta-analysis to estimate diagnostic performance of AI automated diagnosis system from fundus image. Screening costs were provided by the Changjiang screening programme, whereas treatment costs were derived from electronic medical records from two county hospitals. Main outcomes included the number of PACG patients and health care costs. Cost-offset analysis was employed to compare projected health outcomes and medical care costs under the screening with what they would have been without screening. One-way sensitivity analysis was conducted to quantify uncertainties around model results.Results: Among people aged 65 and above in Changjiang county, it was predicted that there were 1940 PACG patients under the AI-assisted screening scenario, compared with 2104 patients without screening in 15 years' time. Specifically, the screening would reduce patients with primary angle closure suspect by 7.7%, primary angle closure by 8.8%, PACG by 16.7%, and visual blindness by 33.3%. Due to early diagnosis and treatment under the screening, healthcare costs surged dramatically to $107,761.4 dollar in the first year and then were constantly declining over time, while without screening costs grew from $14,759.8 in the second year until peaking at $17,900.9 in the 9th year. However, cost-offset analysis revealed that additional healthcare costs resulted from the screening could not be offset by decreased disease progression. The 5-, 10-, and 15-year accumulated incremental costs of screening versus no screening were estimated to be $396,362.8, $424,907.9, and $434,903.2, respectively. As a result, the incremental cost per PACG of any stages prevented was $1464.3.Conclusions: This study represented the first attempt to address decision-maker's budgetary concerns when adopting glaucoma screening by developing a Markov prediction model to project health outcomes and costs. Population screening combined with AI automated diagnosis for PACG in China were able to reduce disease progression risks. However, the excess costs of screening could never be offset by reduction in disease progression. Further studies examining the cost-effectiveness or cost-utility of AI-assisted glaucoma screening were needed. AD - Eye Center, Renmin Hospital of Wuhan University, 430060, Wuhan, China School of Public Health, Fudan University, 200433, Shanghai, China Department of Eye Plastic and Lacrimal Disease, Shenzhen Eye Hospital of Jinan University, 518040, Shenzhen, China AN - 150691340. Language: English. Entry Date: In Process. Revision Date: 20210717. Publication Type: journal article AU - Xiao, Xuan AU - Xue, Long AU - Ye, Lin AU - Li, Hongzheng AU - He, Yunzhen DB - ccm DO - 10.1186/s12889-021-11097-w DP - EBSCOhost IS - 1 KW - Glaucoma, Angle-Closure Glaucoma -- Diagnosis Aged Cost Benefit Analysis China Health Care Costs Artificial Intelligence Human Comparative Studies Multicenter Studies Evaluation Research Validation Studies Impact of Events Scale N1 - research. Journal Subset: Biomedical; Europe; Public Health; UK & Ireland. Instrumentation: Impact of Events Scale (IES). NLM UID: 100968562. PMID: NLM34088286. PY - 2021 SN - 1471-2458 SP - 1-12 ST - Health care cost and benefits of artificial intelligence-assisted population-based glaucoma screening for the elderly in remote areas of China: a cost-offset analysis T2 - BMC Public Health TI - Health care cost and benefits of artificial intelligence-assisted population-based glaucoma screening for the elderly in remote areas of China: a cost-offset analysis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150691340&site=ehost-live&scope=site VL - 21 ID - 4152 ER - TY - JOUR AB - Aim To evaluate the cost-effectiveness (CE) and budget impact (BI) of introducing a patient visit support system (ACT Pack) along with standard of care (SoC), in glaucoma treatment in Japan. Methods A Markov model was designed to estimate the CE and BI of introducing the support system from Japanese payer and governmental perspective, respectively. Inputted data for CE and BI analysis were referred from published literature and based on medical specialists' inputs. Base case scenario for CE considered the support system cost of 30,000 yen per patient per year and a time horizon of 45 years. BI analysis compared the financial impact due to introduction of support system with SoC compared to SoC alone scenario on Japanese healthcare system with a time horizon of 20 years. Results The base case of CE analysis showed the incremental cost per quality-adjusted life years (QALYs) gained with the support system was 3,241,729 yen/QALY (29,470 USD/QALY). The sensitivity analysis showed that the probability of this support system being cost-effective at a threshold of 5 million yen/QALY (45,455 USD/QALY) was 53.26%. Blindness reduction after introduction of this support system was 8.68%. The BI analysis showed that the introduction of support system will lead to a cumulative cost savings of 1,132 billion yen (10 billion US dollars) for Japanese healthcare system over 20 years of time horizon. Limitation Due to paucity of similar comparative studies, some assumptions were made based on medical specialists' inputs. Death status was not considered in the analysis. Conclusion Introduction of this support system with SoC is cost-effective and will lead to blindness reduction in Japanese patients with glaucoma. Over a 20 year period, it will lead to an overall cost savings of 1,132 billion yen (10 billion US dollars) for the Japanese healthcare system. AN - WOS:000563348500001 AU - Yamada, M. AU - Nakano, T. AU - Matsuda, H. AU - Kim, S. W. AU - Takagi, Y. DA - NOV 1 DO - 10.1080/13696998.2020.1804392 IS - 11 PY - 2020 SN - 1369-6998 1941-837X SP - 1293-1301 ST - Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma T2 - JOURNAL OF MEDICAL ECONOMICS TI - Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma VL - 23 ID - 6195 ER - TY - JOUR AB - Purpose: Contact lens (CL) wear is a risk factor for the acquisition of microbial keratitis. Accordingly, compliance to manufacturers' recommended hygiene and disinfection procedures are vital to safe (CL) use. In this study we evaluated a novel povidone-iodine (PI) (CL) disinfection system (cleadew, Ophtecs Corporation, Japan) against a range of bacterial, fungal and Acanthamoeba.Methods: Antimicrobial assays were conducted according to ISO 14729 using the recommended strains of bacteria and fungi, with and without the presence of organic soil. Regrowth of bacteria and fungi in the disinfection system was also examined. The activity on biofilms formed from Stenotrophomonas maltophilia and Achromobacter sp. was evaluated. Efficacy against A. castellanii trophozoites and cysts was also investigated.Results: The PI system gave >4 log10 kill of all bacteria and fungi following the manufacturer's recommended disinfection and cleaning time of 4h, with or without the presence of organic soil. No regrowth of organisms was found after 14days in the neutralized solution. In the biofilm studies the system resulted in at least a 7 log10 reduction in viability of bacteria. For Acanthamoeba, >3 log10 kill of trophozoites and 1.1-2.8 log10 kill for the cyst stage was obtained.Conclusions: The PI system effective against a variety of pathogenic microorganisms under a range of test conditions. Strict compliance to recommended CL hygiene procedures is essential for safe CL wear. The use of care systems such as PI, with broad spectrum antimicrobial activity, may aid in the prevention of potentially sight threatening microbial keratitis. AD - Ophtecs Corporation. 5-2-4 Minatojima-Minami-Machi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan AN - 129754021. Language: English. Entry Date: 20190530. Revision Date: 20190726. Publication Type: journal article AU - Yamasaki, Katsuhide AU - Saito, Fumio AU - Ota, Ritsue AU - Kilvington, Simon DB - ccm DO - 10.1016/j.clae.2017.12.001 DP - EBSCOhost IS - 3 KW - Ophthalmic Solutions -- Pharmacodynamics Sterilization and Disinfection -- Methods Povidone-Iodine -- Pharmacodynamics Bacteria Contact Lenses Eye Infections, Bacterial -- Prevention and Control Keratitis -- Prevention and Control Antiinfective Agents, Local -- Pharmacodynamics Bacteria -- Drug Effects Eye Infections, Bacterial -- Microbiology Keratitis -- Microbiology Biofilms N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 9712714. PMID: NLM29233457. PY - 2018 SN - 1367-0484 SP - 277-281 ST - Antimicrobial efficacy of a novel povidone iodine contact lens disinfection system T2 - Contact Lens & Anterior Eye TI - Antimicrobial efficacy of a novel povidone iodine contact lens disinfection system UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129754021&site=ehost-live&scope=site VL - 41 ID - 4313 ER - TY - JOUR AB - Objective: To understand the knowledge and attitudes of rural Chinese physicians, patients, and village health workers (VHWs) toward diabetic eye disease and glaucoma. Methods: Focus groups for each of the 3 stakeholders were conducted in 3 counties (9 groups). The focus groups were recorded, transcribed, and coded using specialized software. Responses to questions about barriers to compliance and interventions to remove these barriers were also ranked and scored. Results: Among 22 physicians, 23 patients, and 25 VHWs, knowledge about diabetic eye disease was generally good, but physicians and patients understood glaucoma only as an acutely symptomatic disease of relatively low prevalence. Physicians did not favor routine pupillary dilation to detect asymptomatic disease, expressing concerns about workflow and danger and inconvenience to patients. Providers believed that cost was the main barrier to patient compliance, whereas patients ranked poorly trained physicians as more important. All 3 stakeholder groups ranked financial interventions to improve compliance (eg, direct payment, lotteries, and contracts) low and preferred patient education and telephone contact by nurses. All the groups somewhat doubted the ability of VHWs to screen for eye disease accurately, but patients were generally willing to pay for VHW screening. The VHWs were uncertain about the value of eye care training but might accept it if accompanied by equipment. They did not rank payment for screening services as important. Conclusions: Misconceptions about glaucoma's asymptomatic nature and an unwillingness to routinely examine asymptomatic patients must be addressed in training programs. Home contact by nurses and patient education may be the most appropriate interventions to improve compliance. AD - N. Congdon, Zhongshan Ophthalmic Center, Division of Preventive Ophthalmology, Sun Yat Sen University, Guangzhou, China AU - Yan, X. AU - Liu, T. AU - Gruber, L. AU - He, M. AU - Congdon, N. DB - Embase Medline DO - 10.1001/archophthalmol.2012.145 IS - 6 KW - glucose adult aged article China diabetic retinopathy diet educational status eye care female financial management glaucoma glucose blood level health care cost health care personnel human major clinical study male medical education mydriasis optical coherence tomography patient attitude patient compliance patient education physician attitude priority journal rural area vitrectomy work experience LA - English M3 - Article N1 - L364990438 2012-06-21 2012-06-22 PY - 2012 SN - 0003-9950 1538-3601 SP - 761-770 ST - Attitudes of physicians, patients, and village health workers toward glaucoma and diabetic retinopathy in rural China: A focus group study T2 - Archives of Ophthalmology TI - Attitudes of physicians, patients, and village health workers toward glaucoma and diabetic retinopathy in rural China: A focus group study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364990438&from=export http://dx.doi.org/10.1001/archophthalmol.2012.145 http://archopht.jamanetwork.com/pdfaccess.ashx?ResourceID=3450431&PDFSource=13 VL - 130 ID - 3080 ER - TY - JOUR AN - 104501106. Language: English. Entry Date: 20121012. Revision Date: 20150711. Publication Type: Journal Article AU - Yan, X. AU - Liu, T. AU - Gruber, L. AU - He, M. AU - Congdon, N. DB - ccm DP - EBSCOhost IS - 6 KW - Community Health Workers -- Psychosocial Factors Diabetic Retinopathy -- Psychosocial Factors Glaucoma -- Psychosocial Factors Attitude to Health Patients -- Psychosocial Factors Physicians -- Psychosocial Factors Rural Population Adult Aged Attitude of Health Personnel China Diabetic Retinopathy -- Diagnosis Diabetic Retinopathy -- Therapy Female Focus Groups Glaucoma -- Diagnosis Glaucoma -- Therapy Human Male Middle Age Patient Attitudes Patient Compliance N1 - research. Journal Subset: Biomedical; USA. NLM UID: 7706534. PMID: NLM22801838. PY - 2012 SN - 0003-9950 SP - 761-770 ST - Attitudes of physicians, patients, and village health workers toward glaucoma and diabetic retinopathy in rural china: a focus group study T2 - Archives of Ophthalmology TI - Attitudes of physicians, patients, and village health workers toward glaucoma and diabetic retinopathy in rural china: a focus group study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104501106&site=ehost-live&scope=site VL - 130 ID - 4494 ER - TY - JOUR AB - Glaucoma therapy typically begins with topical medications, of which there are 4 major classes in common use in the United States: beta-Adrenergic antagonists, alpha-Agonists, carbonic anhydrase inhibitors, and prostaglandin analogs. Unfortunately, all 4 classes require at least daily dosing, and 3 of the 4 classes are approved to be administered 2 or 3 times daily. This need for frequent dosing with multiple medications makes compliance difficult. Longer-Acting formulations and combinations that require less frequent administration might improve compliance and therefore medication effectiveness. Recently, we developed an ocular drug delivery system, a hybrid dendrimer hydrogel/poly(lactic-co-glycolic acid) nanoparticle platform for delivering glaucoma therapeutics topically. This platform is designed to deliver glaucoma drugs to the eye efficiently and release the drug in a slow fashion. Furthermore, this delivery platform is designed to be compatible with many of the glaucoma drugs that are currently approved for use. In this article, we review this new delivery system with in-depth discussion of its structural features, properties, and preclinical application in glaucoma treatment. In addition, future directions and translational efforts for marketing this technology are elaborated. © 2013, Mary Ann Liebert, Inc. AD - H. Yang, Department of Biomedical Engineering, Virginia Commonwealth University, 401 West Main Street, Richmond, VA 23284, United States AU - Yang, H. AU - Leffler, C. T. DB - Embase Medline DO - 10.1089/jop.2012.0197 IS - 2 KW - brimonidine dendrimer drug vehicle hybrid dendrimer hydrogel/poly(lactic co glycolic acid) nanoparticle platform macrogol nanoparticle polyamidoamine polyglactin timolol unclassified drug cross linking drug delivery system drug release drug solution glaucoma human hydrogel patient compliance review LA - English M3 - Review N1 - L368533023 2013-03-22 2013-03-27 PY - 2013 SN - 1080-7683 1557-7732 SP - 166-172 ST - Hybrid dendrimer hydrogel/poly(lactic-Co-glycolic acid) nanoparticle platform: An advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management T2 - Journal of Ocular Pharmacology and Therapeutics TI - Hybrid dendrimer hydrogel/poly(lactic-Co-glycolic acid) nanoparticle platform: An advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368533023&from=export http://dx.doi.org/10.1089/jop.2012.0197 VL - 29 ID - 3018 ER - TY - JOUR AB - Purpose To evaluate preoperative characteristics and follow-up in rural China after trabeculectomy, the primary treatment for glaucoma there. Methods Patients undergoing trabeculectomy at 14 rural hospitals in Guangdong and Guangxi Provinces and their doctors completed questionnaires concerning clinical and sociodemographic information, transportation, and knowledge and attitudes about glaucoma. Follow-up after surgery was assessed as cumulative score (1 week: 10 points, 2 weeks: 7 points, 1 month: 5 points). Results Among 212 eligible patients, mean preoperative presenting acuity in the operative eye was 6/120, with 61.3% (n=130) blind (≤6/60). Follow-up rates were 60.8% (129/212), 75.9% (161/212) and 26.9% (57/212) at 1 week, 2 weeks and 1 month, respectively. Patient predictors of poor follow-up included elementary education or less (OR=0.37, 95% CI 0.20 to 0.70, p=0.002), believing follow-up was not important (OR=0.62, 95% CI 0.41 to 0.94, p=0.02), lack of an accompanying person (OR=0.14, 95% CI 0.07 to 0.29, p<0.001), family annual income 20% from baseline. A sample size calculation suggested that 8 patients in each arm would be sufficient to detect a difference of 3.2mm Hg with a power of 80%. Results: Nineteen consecutive consenting patients completed the study - 9 in the steroid arm and 10 in the placebo arm. There were no statistically significant differences between groups in baseline characteristics, IOP at each study visit, or change in IOP from baseline at any time point. At 6 weeks, the change in mean IOP from baseline was +0.50±1.52 versus +0.70±1.44 mm Hg in the steroid and saline nasal spray groups, respectively (P=0.77). Conclusions: Patients with ocular hypertension and primary openangle glaucoma showed no evidence of IOP elevation after 6 weeks use of beclomethasone nasal spray. Copyright © 2013 by Lippincott Williams & Wilkins. AD - G.E. Trope, Department of Ophthalmology and Visual Sciences, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada AU - Yuen, D. AU - Buys, Y. M. AU - Jin, Y. P. AU - Alasbali, T. AU - Trope, G. E. DB - Embase Medline DO - 10.1097/IJG.0b013e3182254811 IS - 2 KW - NCT00775489 beclometasone placebo sodium chloride adult anterior eye segment article clinical article controlled study double blind procedure drug effect female human intraocular hypertension intraocular pressure male open angle glaucoma patient compliance priority journal randomized controlled trial treatment outcome visual acuity LA - English M3 - Article N1 - L51503938 2011-07-06 2013-07-18 PY - 2013 SN - 1057-0829 1536-481X SP - 84-87 ST - Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma T2 - Journal of Glaucoma TI - Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51503938&from=export http://dx.doi.org/10.1097/IJG.0b013e3182254811 VL - 22 ID - 3024 ER - TY - JOUR AB - Purpose: To evaluate the effect of 6 weeks administration of beclomethasone nasal spray on intraocular pressure (IOP) in patients with ocular hypertension or controlled primary open-angle glaucoma. Patients and Methods: Randomized double-masked controlled trial. Patients were randomized to twice daily beclomethasone versus placebo saline nasal spray. There were a total of 4 study visits: baseline and weeks 2, 4, 6 after starting the spray. Each study visit was at the same time within a 1-hour time window. Primary outcome measure was IOP. Secondary measures included visual acuity, anterior segment changes, patient reported side effects, and compliance. Study endpoint was 6 weeks from the start of treatment or an IOP increase of >20% from baseline. A sample size calculation suggested that 8 patients in each arm would be sufficient to detect a difference of 3.2mm Hg with a power of 80%. Results: Nineteen consecutive consenting patients completed the study - 9 in the steroid arm and 10 in the placebo arm. There were no statistically significant differences between groups in baseline characteristics, IOP at each study visit, or change in IOP from baseline at any time point. At 6 weeks, the change in mean IOP from baseline was +0.50±1.52 versus +0.70±1.44 mm Hg in the steroid and saline nasal spray groups, respectively (P=0.77). Conclusions: Patients with ocular hypertension and primary openangle glaucoma showed no evidence of IOP elevation after 6 weeks use of beclomethasone nasal spray. Copyright © 2013 by Lippincott Williams & Wilkins. AD - Department of Ophthalmology and Visual Sciences, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada King Faisal University, Dammam, Saudi Arabia AU - Yuen, D. AU - Buys, Y. M. AU - Jin, Y. P. AU - Alasbali, T. AU - Trope, G. E. DB - Scopus DO - 10.1097/IJG.0b013e3182254811 IS - 2 KW - Glaucoma Intraocular pressure Nasal steroids Ocular hypertension M3 - Article N1 - Cited By :12 Export Date: 19 July 2021 PY - 2013 SP - 84-87 ST - Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma T2 - Journal of Glaucoma TI - Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879453991&doi=10.1097%2fIJG.0b013e3182254811&partnerID=40&md5=0809a12c9f75a026c784a206876404fd VL - 22 ID - 5240 ER - TY - JOUR AB - Purpose: To evaluate the effect of 6 weeks administration of beclomethasone nasal spray on intraocular pressure (IOP) in patients with ocular hypertension or controlled primary open-angle glaucoma. Patients and Methods: Randomized double-masked controlled trial. Patients were randomized to twice daily beclomethasone versus placebo saline nasal spray. There were a total of 4 study visits: baseline and weeks 2, 4, 6 after starting the spray. Each study visit was at the same time within a 1-hour time window. Primary outcome measure was IOP. Secondary measures included visual acuity, anterior segment changes, patient reported side effects, and compliance. Study endpoint was 6 weeks from the start of treatment or an IOP increase of > 20% from baseline. A sample size calculation suggested that 8 patients in each arm would be sufficient to detect a difference of 3.2mm Hg with a power of 80%. Results: Nineteen consecutive consenting patients completed the study-9 in the steroid arm and 10 in the placebo arm. There were no statistically significant differences between groups in baseline characteristics, IOP at each study visit, or change in IOP from baseline at any time point. At 6 weeks, the change in mean IOP from baseline was + 0.50 +/- 1.52 versus + 0.70 +/- 1.44 mm Hg in the steroid and saline nasal spray groups, respectively (P=0.77). Conclusions: Patients with ocular hypertension and primary open-angle glaucoma showed no evidence of IOP elevation after 6 weeks use of beclomethasone nasal spray. AN - WOS:000314184300004 AU - Yuen, D. AU - Buys, Y. M. AU - Jin, Y. P. AU - Alasbali, T. AU - Trope, G. E. DA - FEB DO - 10.1097/IJG.0b013e3182254811 IS - 2 PY - 2013 SN - 1057-0829 SP - 84-87 ST - Effect of Beclomethasone Nasal Spray on Intraocular Pressure in Ocular Hypertension or Controlled Glaucoma T2 - JOURNAL OF GLAUCOMA TI - Effect of Beclomethasone Nasal Spray on Intraocular Pressure in Ocular Hypertension or Controlled Glaucoma VL - 22 ID - 5983 ER - TY - JOUR AN - 104388692. Language: English. Entry Date: 20130215. Revision Date: 20200708. Publication Type: Journal Article AU - Zambelli-Weiner, A. AU - Crews, J. E. AU - Friedman, D. S. DB - ccm DO - 10.1016/j.ajo.2012.03.018 DP - EBSCOhost IS - 6 KW - Eye Diseases -- Epidemiology Health Services Accessibility -- Trends Health Services Accessibility -- Statistics and Numerical Data Ophthalmology -- Trends Disabled -- Statistics and Numerical Data Adult Cataract -- Epidemiology Diabetic Retinopathy -- Epidemiology Female Glaucoma -- Epidemiology Surveys Human Macular Degeneration -- Epidemiology Male Population Surveillance Refractive Errors -- Epidemiology United States N1 - research. Supplement Title: Dec2012 Supplement. Journal Subset: Biomedical; USA. NLM UID: 0370500. PMID: NLM22633355. PY - 2012 SN - 0002-9394 SP - S23-S30.e1 ST - Disparities in adult vision health in the United States T2 - American Journal of Ophthalmology TI - Disparities in adult vision health in the United States UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104388692&site=ehost-live&scope=site VL - 154 ID - 4763 ER - TY - JOUR AD - T. Zarnowski, Department of Ophthalmology, Medical University, Chmielna 1, Lublin, Poland AU - Zarnowski, T. AU - Wyszynska, A. AU - Rekas, M. C1 - duotrav travatan DB - Embase Medline DO - 10.1089/jop.2016.0052 IS - 7 KW - timolol plus travoprost travoprost aged comparative study controlled study drug instillation electronic device female glaucoma Glaucoma Quality of Life 15 questionnaire Glaucoma Symptom Scale human letter major clinical study male medication compliance outcome assessment patient compliance quality of life questionnaire rating scale self report duotrav travatan Travalert DA LA - English M3 - Letter N1 - L612002676 2016-09-09 2018-09-17 PY - 2016 SN - 1557-7732 1080-7683 SP - 403-404 ST - Comparison of Self-Reported and Objective Adherence to Antiglaucoma Medications T2 - Journal of Ocular Pharmacology and Therapeutics TI - Comparison of Self-Reported and Objective Adherence to Antiglaucoma Medications UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612002676&from=export http://dx.doi.org/10.1089/jop.2016.0052 VL - 32 ID - 2707 ER - TY - GEN AD - Department of Ophthalmology, Medical University, Lublin, Poland. Department of Ophthalmology, Military Institute of Medicine, Warsaw, Poland. AU - Zarnowski, Tomasz AU - Wyszynska, Anna AU - Rekas, Marek CY - New Rochelle, New York DB - ccm DO - 10.1089/jop.2016.0052 DP - EBSCOhost J2 - Journal of Ocular Pharmacology & Therapeutics KW - Glaucoma -- Drug Therapy Medication Compliance Self Report Intraocular Pressure N1 - Accession Number: 117760478. Language: English. Entry Date: 20171104. Revision Date: 20180922. Publication Type: letter. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM27429097. PB - Mary Ann Liebert, Inc. PY - 2016 SN - 1080-7683 SP - 403-404 ST - Comparison of Self-Reported and Objective Adherence to Antiglaucoma Medications TI - Comparison of Self-Reported and Objective Adherence to Antiglaucoma Medications UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=117760478&site=ehost-live&scope=site VL - 32 ID - 4573 ER - TY - JOUR AB - Background: Previous studies suggest there are large variations in adherence of ophthalmologists with the American Academy of Ophthalmology's Preferred Practice Patterns (PPPs). The purpose of this study was to compare rates of compliance with glaucoma care guidelines between resident and glaucoma faculty physicians at a single institution.Methods: Charts of resident continuity clinic or glaucoma faculty patients with primary open angle glaucoma (POAG), ocular hypertension (OHTN), or suspicion of glaucoma were reviewed during the 2005-6 academic year. Performance within care measures specified by the 2005 PPP guidelines was compared between resident and faculty physicians using univariate and multivariable logistic regression models.Results: 112 resident and 100 faculty charts were reviewed. The mean compliance rate for all 7 care measures for resident physicians was significantly lower than that of faculty physicians (78% vs. 96%, p < 0.001). As compared to glaucoma faculty, resident physicians were less likely to have documented 6 of the 7 individual care measures (p ≤ 0.001 for all); the exception was optic nerve (ON) description. In multivariable analyses, resident patients were more likely to have at least one undocumented care measure than faculty patients (OR = 10.1, 95% CI = 5.1 to 20.0, p < 0.001). Among resident patients, undocumented care measures were more common among patients with poorer visual acuity (VA) in the better eye.Conclusions: Though unmeasured differences in clinic structure and patient characteristics may have partially contributed to poorer resident performance, residents were more likely than faculty to omit PPP care measures and significantly underperformed faculty in global assessment of glaucoma care. Resident education should focus on integration of PPPs into residency training and monitoring of resident compliance with evidence-based guidelines. AN - 109610499. Language: English. Entry Date: 20150923. Revision Date: 20190223. Publication Type: journal article AU - Zebardast, Nazlee AU - Solus, Jason F. AU - Quigley, Harry A. AU - Srikumaran, Divya AU - Ramulu, Pradeep Y. DB - ccm DO - 10.1186/s12886-015-0027-x DP - EBSCOhost IS - 1 N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: EY018595/EY/NEI NIH HHS/United States. NLM UID: 100967802. PMID: NLM25879212. PY - 2015 SN - 1471-2415 SP - 41-41 ST - Comparison of resident and glaucoma faculty practice patterns in the care of open-angle glaucoma T2 - BMC Ophthalmology TI - Comparison of resident and glaucoma faculty practice patterns in the care of open-angle glaucoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109610499&site=ehost-live&scope=site VL - 15 ID - 4552 ER - TY - JOUR AN - WOS:000394210601256 AU - Zeng, L. AU - Waisbourd, M. AU - Dai, Y. AU - Johnson, D. M. AU - Patel, N. AU - Molineaux, J. AU - Divers, M. AU - Burns, C. AU - Spaeth, G. L. AU - Katz, L. L. DA - SEP IS - 12 PY - 2016 SN - 0146-0404 1552-5783 ST - A Randomized, Controlled Trial to Test the Effectiveness of Patient Navigation in a Community versus Office-Based Setting to Improve Follow-up Appointment Adherence in Patients with Glaucoma T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - A Randomized, Controlled Trial to Test the Effectiveness of Patient Navigation in a Community versus Office-Based Setting to Improve Follow-up Appointment Adherence in Patients with Glaucoma VL - 57 ID - 5857 ER - TY - JOUR AB - Purpose: To assess vision health disparities in the United States by race/ethnicity, education, and economic status.Design: Cross-sectional, nationally representative samples.Methods: We used national survey data from the National Health and Nutrition Examination Survey (NHANES) and the National Health Interview Survey (NHIS). Main outcome measures included, from NHANES, age-related eye diseases (ie, age-related macular degeneration [AMD], cataract, diabetic retinopathy [DR], glaucoma) and from NHIS, eye care use (ie, eye doctor visits and cannot afford eyeglasses when needed) among those with self-reported visual impairment. The estimates were age- and sex-standardized to the 2000 US Census population. Linear trends in the estimates were assessed by weighted least squares regression.Results: Non-Hispanic whites had a higher prevalence of AMD and cataract surgery than non-Hispanic blacks, but a lower prevalence of DR and glaucoma (all P < .001 in NHANES 2005-2008). From 1999 to 2008, individuals with less education (ie, high school) and lower income (poverty income ratio [PIR] <1.00 vs ≥ 4.00) were consistently less likely to have had an eye care visit in the past 12 months compared with their counterparts (all P < .05). During this period, inability to afford needed eyeglasses increased among non-Hispanic whites and Hispanics (trend P = .004 and P = .007; respectively), those with high school education (trend P = .036), and those with PIR 1.00-1.99 (trend P < .001).Conclusions: Observed vision health disparities suggest a need for educational and innovative interventions among socioeconomically disadvantaged groups. AD - Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3727, USA AN - 104388686. Language: English. Entry Date: 20130215. Revision Date: 20210110. Publication Type: journal article AU - Zhang, X. AU - Cotch, M. F. AU - Ryskulova, A. AU - Primo, S. A. AU - Nair, P. AU - Chou, C. F. AU - Geiss, L. S. AU - Barker, L. E. AU - Elliott, A. F. AU - Crews, J. E. AU - Saaddine, J. B. AU - Zhang, Xinzhi AU - Cotch, Mary Frances AU - Ryskulova, Asel AU - Primo, Susan A. AU - Nair, Parvathy AU - Chou, Chiu-Fang AU - Geiss, Linda S. AU - Barker, Lawrence E. AU - Elliott, Amanda F. DB - ccm DO - 10.1016/j.ajo.2011.08.045 DP - EBSCOhost IS - 6 KW - Educational Status Ethnic Groups Eye Diseases -- Ethnology Health Services Accessibility Health Services -- Utilization Population Socioeconomic Factors Adult Cataract -- Ethnology Cross Sectional Studies Diabetic Retinopathy -- Ethnology Glaucoma -- Ethnology Human Interview Guides Macular Degeneration -- Ethnology Resource Databases Surveys United States N1 - research. Supplement Title: Dec2012 Supplement. Journal Subset: Biomedical; USA. Grant Information: Z99 EY999999/ImNIH/Intramural NIH HHS/United States. NLM UID: 0370500. PMID: NLM23158224. PY - 2012 SN - 0002-9394 SP - S53-S62.e1 ST - Vision health disparities in the United States by race/ethnicity, education, and economic status: findings from two nationally representative surveys T2 - American Journal of Ophthalmology TI - Vision health disparities in the United States by race/ethnicity, education, and economic status: findings from two nationally representative surveys UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104388686&site=ehost-live&scope=site VL - 154 ID - 4740 ER - TY - JOUR AB - Objective: To evaluate the long-term outcomes of three surgical procedures for the treatment of primary congenital glaucoma (PCG). Introduction: PCG is one of the main causes of blindness in children. There is a paucity of contemporary data on PCG in China. Methods: A retrospective study of 48 patients (81 eyes) with PCG who underwent primary trabeculectomy, trabeculotomy, or combined trabeculotomy and trabeculectomy (CTT). Results: All patients were less than 4 years (yrs) of age, with a mean age of 2.08 ± 1.23 yrs. The mean duration of follow-up was 5.49 ± 3.09 yrs. The difference in success rates among the three surgical procedures at 1, 3, 6 and 9 yrs was not statistically significant (p = 0.492). However, in patients with over 4 yrs of follow-up, Kaplan-Meier survival analysis revealed that the success rates of trabeculectomy and CTT declined more slowly than that of trabeculotomy. Among the patients, 66.22% acquired good vision (VA ≥ 0.4), 17.57% acquired fair vision (VA = 0.1 - 0.3), and 16.22% acquired poor vision (VA < 0.1). The patients with good vision were mostly in the successful surgery group. Myopia was more prevalent postoperatively (p = 0.009). Reductions in the cup-disc ratio and corneal diameter were only seen in the successful surgery group (p = 0.000). In addition, the successful surgery group contained more patients that complied with a regular follow-up routine (p = 0.002). Discussion: Our cases were all primary surgeries. Primary trabeculectomy was performed in many cases because no treatment was sought until an advanced stage of disease had been reached. Conclusions: In contrast to most reports, in the present study, trabeculectomy and CTT achieved higher long-term success rates than trabeculotomy. The patients with successful surgical results had better vision. Compliance with a routine of regular follow-up may increase the chances of a successful surgical outcome. AD - Glaucoma Department, Zhongshan Ophthalmic Centre, State Key Laboratory of Ophthalmology, Sun Yat-sen University, Guangzhou, China Sun Yat-sen University, Tungwah Hospital, Dongguan, China AU - Zhang, X. AU - Du, S. AU - Fan, Q. AU - Peng, S. AU - Yu, M. AU - Ge, J. DB - Scopus DO - 10.1590/S1807-59322009000600009 IS - 6 KW - China Combined trabeculotomy and trabeculectomy (CTT) Primary congenital glaucoma (PCG) Trabeculectomy Trabeculotomy M3 - Article N1 - Cited By :25 Export Date: 19 July 2021 PY - 2009 SP - 543-551 ST - Long-term surgical outcomes of primary congenital glaucoma in China T2 - Clinics TI - Long-term surgical outcomes of primary congenital glaucoma in China UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-68949105351&doi=10.1590%2fS1807-59322009000600009&partnerID=40&md5=abb9e2725bbac130e12bac4831dd58b6 VL - 64 ID - 5091 ER - TY - JOUR AB - OBJECTIVE: To evaluate the long-term outcomes of three surgical procedures for the treatment of primary congenital glaucoma (PCG). INTRODUCTION: PCG is one of the main causes of blindness in children. There is a paucity of contemporary data on PCG in China. METHODS: A retrospective study of 48 patients (81 eyes) with PCG who underwent primary trabeculectomy, trabeculotomy, or combined trabeculotomy and trabeculectomy (CTT). RESULTS: All patients were less than 4 years (yrs) of age, with a mean age of 2.08 +/- 1.23 yrs. The mean duration of follow-up was 5.49 +/- 3.09 yrs. The difference in success rates among the three surgical procedures at 1, 3, 6 and 9 yrs was not statistically significant (p = 0.492). However, in patients with over 4 yrs of follow-up, Kaplan-Meier survival analysis revealed that the success rates of trabeculectomy and CTT declined more slowly than that of trabeculotomy. Among the patients, 66.22% acquired good vision (VA >= 0.4), 17.57% acquired fair vision (VA = 0.1 - 0.3), and 16.22% acquired poor vision (VA < 0.1). The patients with good vision were mostly in the successful surgery group. Myopia was more prevalent postoperatively (p = 0.009). Reductions in the cup-disc ratio and corneal diameter were only seen in the successful surgery group (p = 0.000). In addition, the successful surgery group contained more patients that complied with a regular follow-up routine (p = 0.002). DISCUSSION: Our cases were all primary surgeries. Primary trabeculectomy was performed in many cases because no treatment was sought until an advanced stage of disease had been reached. CONCLUSIONS: In contrast to most reports, in the present study, trabeculectomy and CTT achieved higher long-term success rates than trabeculotomy. The patients with successful surgical results had better vision. Compliance with a routine of regular follow-up may increase the chances of a successful surgical outcome. AN - WOS:000267705200008 AU - Zhang, X. L. AU - Du, S. L. AU - Fan, Q. AU - Peng, S. X. AU - Yu, M. B. AU - Ge, J. DO - 10.1590/S1807-59322009000600009 IS - 6 PY - 2009 SN - 1807-5932 1980-5322 SP - 543-551 ST - LONG-TERM SURGICAL OUTCOMES OF PRIMARY CONGENITAL GLAUCOMA IN CHINA T2 - CLINICS TI - LONG-TERM SURGICAL OUTCOMES OF PRIMARY CONGENITAL GLAUCOMA IN CHINA VL - 64 ID - 6016 ER - TY - JOUR AB - Purpose: To evaluate factors associated with attendance to follow-up ophthalmic care, and to assess the impact of strategies to improve follow-up. Design: Cross-sectional study. Methods: This is an ongoing study to develop an eye screening paradigm, focusing on African Americans ≥50 years of age at multiple urban community sites in Baltimore, Maryland. Several strategies were employed aiming to increase follow-up attendance rates. Multivariable logistic regression was used to evaluate the associations between demographic, medical, and ocular factors with follow-up rate. Results: The total number of referred patients presenting for a free eye examination (attendance rate) during the first phase, during the second phase, and overall was 686 (55.0%), 199 (63.8%), and 885 (57.0%), respectively. In fully adjusted models, the odds ratio (95% confidence intervals) for attending the follow-up visit was 1.82 (1.19, 2.79) for screening in second phase vs first phase, 0.62 (0.39, 0.99) for screening sites that were 3 to <5 miles vs <1 mile from the hospital, 1.70 (1.12, 2.59) in patients with body mass index ≥ 30 vs < 25 kg/m2, 2.03 (1.28, 3.21) in patients with presenting visual acuity < 20/40 vs ≥ 20/40, and 2.32 (1.24, 4.34) for patients with an abnormal vs normal macula. Conclusions: Obesity, short distance between screening sites and hospital, poor presenting visual acuity in the better eye, and an abnormal macula on fundus photography were associated with increased follow-up rate. Implementation of a combination of strategies effectively increased the follow-up rate. Wider adoption of these strategies in other screening programs has the potential to reduce the burden of visual impairment. AD - D.S. Friedman, Department of Ophthalmology, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Wilmer 120, Baltimore, MD, United States AU - Zhao, D. AU - Guallar, E. AU - Bowie, J. V. AU - Swenor, B. AU - Gajwani, P. AU - Kanwar, N. AU - Friedman, D. S. DB - Embase Medline DO - 10.1016/j.ajo.2018.01.008 KW - adult African American aged article body mass clinical assessment clinical evaluation controlled study cross-sectional study demography disease association female follow up glaucoma human major clinical study male obesity ophthalmoscopy priority journal retina macula lutea urban area visual acuity LA - English M3 - Article N1 - L620589035 2018-02-14 2018-02-20 PY - 2018 SN - 1879-1891 0002-9394 SP - 19-28 ST - Improving Follow-up and Reducing Barriers for Eye Screenings in Communities: The SToP Glaucoma Study T2 - American Journal of Ophthalmology TI - Improving Follow-up and Reducing Barriers for Eye Screenings in Communities: The SToP Glaucoma Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620589035&from=export http://dx.doi.org/10.1016/j.ajo.2018.01.008 VL - 188 ID - 2596 ER - TY - JOUR AB - Purpose: To evaluate factors associated with attendance to follow-up ophthalmic care, and to assess the impact of strategies to improve follow-up. Design: Cross-sectional study. Methods: This is an ongoing study to develop an eye screening paradigm, focusing on African Americans ≥50 years of age at multiple urban community sites in Baltimore, Maryland. Several strategies were employed aiming to increase follow-up attendance rates. Multivariable logistic regression was used to evaluate the associations between demographic, medical, and ocular factors with follow-up rate. Results: The total number of referred patients presenting for a free eye examination (attendance rate) during the first phase, during the second phase, and overall was 686 (55.0%), 199 (63.8%), and 885 (57.0%), respectively. In fully adjusted models, the odds ratio (95% confidence intervals) for attending the follow-up visit was 1.82 (1.19, 2.79) for screening in second phase vs first phase, 0.62 (0.39, 0.99) for screening sites that were 3 to <5 miles vs <1 mile from the hospital, 1.70 (1.12, 2.59) in patients with body mass index ≥ 30 vs < 25 kg/m2, 2.03 (1.28, 3.21) in patients with presenting visual acuity < 20/40 vs ≥ 20/40, and 2.32 (1.24, 4.34) for patients with an abnormal vs normal macula. Conclusions: Obesity, short distance between screening sites and hospital, poor presenting visual acuity in the better eye, and an abnormal macula on fundus photography were associated with increased follow-up rate. Implementation of a combination of strategies effectively increased the follow-up rate. Wider adoption of these strategies in other screening programs has the potential to reduce the burden of visual impairment. © 2018 Elsevier Inc. AD - Dana Center for Preventive Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States Departments of Epidemiology and Medicine, Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, United States Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States AU - Zhao, D. AU - Guallar, E. AU - Bowie, J. V. AU - Swenor, B. AU - Gajwani, P. AU - Kanwar, N. AU - Friedman, D. S. DB - Scopus DO - 10.1016/j.ajo.2018.01.008 M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 2018 SP - 19-28 ST - Improving Follow-up and Reducing Barriers for Eye Screenings in Communities: The SToP Glaucoma Study T2 - American Journal of Ophthalmology TI - Improving Follow-up and Reducing Barriers for Eye Screenings in Communities: The SToP Glaucoma Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041527168&doi=10.1016%2fj.ajo.2018.01.008&partnerID=40&md5=7e7a19f36348a27fe0fad80b67a4ee21 VL - 188 ID - 5373 ER - TY - JOUR AB - PURPOSE: To evaluate factors associated with attendance to follow-up ophthalmic care, and to assess the impact of strategies to improve follow-up. DESIGN: Cross-sectional study. METHODS: This is an ongoing study to develop an eye screening paradigm, focusing on African Americans >= 50 years of age at multiple urban community sites in Baltimore, Maryland. Several strategies were employed aiming to increase follow-up attendance rates. Multivariable logistic regression was used to evaluate the associations between demographic, medical, and ocular factors with follow-up rate. RESULTS: The total number of referred patients presenting for a free eye examination (attendance rate) during the first phase, during the second phase, and overall was 686 (55.0%), 199 (63.8%), and 885 (57.0%), respectively. In fully adjusted models, the odds ratio (95% confidence intervals) for attending the follow-up visit was 1.82 (1.19, 2.79) for screening in second phase vs first phase, 0.62 (0.39, 0.99) for screening sites that were 3 to < 5 miles vs < 1 mile from the hospital, 1.70 (1.12, 2.59) in patients with body mass index >= 30 vs < 25 kg/m(2), 2.03 (1.28, 3.21) in patients with presenting visual acuity < 20/40 vs >= 20/40, and 2.32 (1.24, 4.34) for patients with an abnormal vs normal macula. CONCLUSIONS: Obesity, short distance between screening sites and hospital, poor presenting visual acuity in the better eye, and an abnormal macula on fundus photography were associated with increased follow-up rate. Implementation of a combination of strategies effectively increased the follow-up rate. Wider adoption of these strategies in other screening programs has the potential to reduce the burden of visual impairment. ((c) 2018 Elsevier Inc. All rights reserved.) AN - WOS:000429396200007 AU - Zhao, D. AU - Guallar, E. AU - Bowie, J. V. AU - Swenor, B. AU - Gajwani, P. AU - Kanwar, N. AU - Friedman, D. S. DA - APR DO - 10.1016/j.ajo.2018.01.008 PY - 2018 SN - 0002-9394 1879-1891 SP - 19-28 ST - Improving Follow-up and Reducing Barriers for Eye Screenings in Communities: The SToP Glaucoma Study T2 - AMERICAN JOURNAL OF OPHTHALMOLOGY TI - Improving Follow-up and Reducing Barriers for Eye Screenings in Communities: The SToP Glaucoma Study VL - 188 ID - 5914 ER - TY - JOUR AN - WOS:000394210200113 AU - Zhao, D. AU - Guallar, E. AU - Swenor, B. K. AU - Gajwani, P. AU - Mude, L. AU - Friedman, D. S. DA - SEP IS - 12 PY - 2016 SN - 0146-0404 1552-5783 ST - Compliance and barriers for follow-up care in community eye screening: the SToP Glaucoma Study T2 - INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE TI - Compliance and barriers for follow-up care in community eye screening: the SToP Glaucoma Study VL - 57 ID - 5881 ER - TY - JOUR AB - Importance: Medical and surgical interventions for glaucoma are effective only if they are affordable to patients. Little is known about how affordable glaucoma interventions are in developing and developed countries.Objective: To compare the prices of topical glaucoma medications, laser trabeculoplasty, and trabeculectomy relative with median annual household income (MA-HHI) for countries worldwide.Design, Setting and Participants: Cross-sectional observational study. For each country, we obtained prices for glaucoma medications, laser trabeculoplasty, and trabeculectomy using government pricing data, drug databases, physician fee schedules, academic publications, and communications with local ophthalmologists. Prices were adjusted for purchasing power parity and inflation to 2016 US dollars, and annual therapy prices were examined relative to the MA-HHI. Interventions costing less than 2.5% of the MA-HHI were considered affordable.Main Outcomes and Measures: Daily cost for topical glaucoma medications, cost of annual therapy with glaucoma medications, laser trabeculoplasty, and trabeculectomy relative to MA-HHI in each country.Results: Data were obtained from 38 countries, including 17 developed countries and 21 developing countries, as classified by the World Economic Outlook. We observed considerable variability in intervention prices compared with MA-HHI across the countries and across interventions, ranging from 0.1% to 5% of MA-HHI for timolol, 0.1% to 27% for latanoprost, 0.2% to 17% for laser trabeculoplasty, and 0.3% to 42% for trabeculectomy. Timolol was the most affordable medication in all countries studied and was 2.5% or more of MA-HHI in only 2 countries (5%). The annual cost of latanoprost was 2.5% or more of MA-HHI in 15 countries (41%) (15 developing countries [75%] and no developed countries). The cost of laser trabeculoplasty was 2.5% or more of the MA-HHI in 15 countries (44%) (11 developing countries [65%] and 4 developed countries [24%]). The cost of trabeculectomy was 2.5% or more of the MA-HHI in 28 countries (78%) (18 developing countries [95%] and 10 developed countries [59%]). In 18 countries (53%), laser trabeculoplasty cost less than a 3-year latanoprost supply.Conclusions and Relevance: For many patients worldwide, the costs of medical, laser, and incisional surgical interventions were 2.5% or more of the MA-HHI. Successfully reducing global blindness from glaucoma requires addressing multiple contributing factors, including making glaucoma interventions more affordable. AD - Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor International Eye Foundation, Kensington, Maryland National Clinician Scholars Program, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor Center for Eye Policy and Innovation, University of Michigan, Ann Arbor King Saud University, Riyadh, Saudi Arabia King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia Department of Ophthalmology, University of Illinois Eye and Ear Infirmary, Chicago Department of Ophthalmology and School of International Health, Johns Hopkins University, Baltimore, Maryland Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor AN - 132918782. Language: English. Entry Date: 20191002. Revision Date: 20201207. Publication Type: journal article AU - Zhao, Peter Y. AU - Rahmathullah, Raheem AU - Stagg, Brian C. AU - Almobarak, Faisal AU - Edward, Deepak P. AU - Robin, Alan L. AU - Stein, Joshua D. DB - ccm DO - 10.1001/jamaophthalmol.2018.3672 DP - EBSCOhost IS - 11 KW - Antihypertensive Agents -- Economics Laser Therapy -- Economics Glaucoma -- Economics Glaucoma -- Therapy Trabeculectomy -- Economics Glaucoma -- Surgery Health Services Accessibility -- Economics Health Care Costs Human Male Administration, Intraocular Costs and Cost Analysis Cross Sectional Studies Intraocular Pressure Income Female Glaucoma -- Drug Therapy Middle Age World Health Timolol -- Economics Validation Studies Comparative Studies Evaluation Research Multicenter Studies Funding Source N1 - research; tables/charts. Journal Subset: Biomedical; USA. Grant Information: R01 EY026641/EY/NEI NIH HHS/United States. NLM UID: 101589539. PMID: NLM30178000. PY - 2018 SN - 2168-6165 SP - 1271-1279 ST - A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery T2 - JAMA Ophthalmology TI - A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132918782&site=ehost-live&scope=site VL - 136 ID - 4231 ER - TY - JOUR AB - This cross-sectional study aimed to evaluate adherence rates and identify barriers to receiving follow-up eye care in participants diagnosed with significant non-glaucomatous eye pathology in the Philadelphia Glaucoma Detection and Treatment Project. This community-based project aimed to improve detection, management, treatment, and follow-up eye care of individuals at high risk for glaucoma in community-based settings. Participants throughout Philadelphia, Pennsylvania, USA were enrolled. After a comprehensive eye examination, follow-up recommendations were given to each participant. A telephone survey was administered to individuals diagnosed with non-glaucomatous ocular pathology 3 months after initial eye examination to assess rates of follow-up and to evaluate potential barriers to follow-up. Of the 1649 participants enrolled in this project, 249 (15 %) were diagnosed with significant non-glaucomatous ocular pathology requiring follow-up care. There were 143 (57 %) who responded to the telephone survey. Respondents had a median age of 72 years, and were predominately female (69 %) and African-American (64 %). Of the respondents, 36 (25 %) attended a follow-up appointment. Participants who did not remember the results of their examinations, did not remember their recommendations, and had not seen an eye doctor within the past year were less likely to make a follow-up appointment ( P = 0.04, 0.001 and 0.005, respectively). The Philadelphia Glaucoma Detection and Treatment Program was able to detect a significant amount of non-glaucomatous ocular pathology requiring follow-up care. Actual follow-up rates were sub-optimal. Further research is needed to determine interventions to overcome barriers and increase adherence with follow-up recommendations. AD - Wills Eye Hospital Glaucoma Research Center, 840 Walnut Street, Suite 1110 Philadelphia 19107 USA AN - 113486733. Language: English. Entry Date: 20160310. Revision Date: 20170403. Publication Type: Article AU - Zheng, Cindy AU - Hu, Wanda AU - Tran, Judie AU - Siam, Linda AU - Berardi, Giuliana AU - Sembhi, Harjeet AU - Hark, Lisa AU - Katz, L. AU - Waisbourd, Michael DB - ccm DO - 10.1007/s10900-015-0104-3 DP - EBSCOhost IS - 2 KW - After Care Health Services Accessibility Glaucoma -- Diagnosis Eye -- Pathology Program Evaluation Cross Sectional Studies Patient Compliance Minority Groups Descriptive Statistics Data Analysis Software Human Questionnaires Adult Middle Age Aged Aged, 80 and Over Male Female Funding Source N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Grant Information: The Philadelphia Glaucoma Detection andTreatment Project was supported by a grant from the Centers forDisease Control and Prevention (# 1U58DP004060-01).. NLM UID: 7600747. PY - 2016 SN - 0094-5145 SP - 359-367 ST - Barriers to Receiving Follow-Up Eye Care and Detection of Non-Glaucomatous Ocular Pathology in the Philadelphia Glaucoma Detection and Treatment Project T2 - Journal of Community Health TI - Barriers to Receiving Follow-Up Eye Care and Detection of Non-Glaucomatous Ocular Pathology in the Philadelphia Glaucoma Detection and Treatment Project UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113486733&site=ehost-live&scope=site VL - 41 ID - 4182 ER - TY - JOUR AB - This cross-sectional study aimed to evaluate adherence rates and identify barriers to receiving follow-up eye care in participants diagnosed with significant non-glaucomatous eye pathology in the Philadelphia Glaucoma Detection and Treatment Project. This community-based project aimed to improve detection, management, treatment, and follow-up eye care of individuals at high risk for glaucoma in community-based settings. Participants throughout Philadelphia, Pennsylvania, USA were enrolled. After a comprehensive eye examination, follow-up recommendations were given to each participant. A telephone survey was administered to individuals diagnosed with non-glaucomatous ocular pathology 3 months after initial eye examination to assess rates of follow-up and to evaluate potential barriers to follow-up. Of the 1649 participants enrolled in this project, 249 (15 %) were diagnosed with significant non-glaucomatous ocular pathology requiring follow-up care. There were 143 (57 %) who responded to the telephone survey. Respondents had a median age of 72 years, and were predominately female (69 %) and African-American (64 %). Of the respondents, 36 (25 %) attended a follow-up appointment. Participants who did not remember the results of their examinations, did not remember their recommendations, and had not seen an eye doctor within the past year were less likely to make a follow-up appointment (P = 0.04, 0.001 and 0.005, respectively). The Philadelphia Glaucoma Detection and Treatment Program was able to detect a significant amount of non-glaucomatous ocular pathology requiring follow-up care. Actual follow-up rates were sub-optimal. Further research is needed to determine interventions to overcome barriers and increase adherence with follow-up recommendations. AU - Zheng, C. X. AU - Hu, W. D. AU - Tran, J. AU - Siam, L. AU - Berardi, G. G. AU - Sembhi, H. AU - Hark, L. A. AU - Katz, L. J. AU - Waisbourd, M. DB - Medline DO - 10.1007/s10900-015-0104-3 IS - 2 KW - adult aftercare aged cross-sectional study eye disease female health care delivery health care survey human male middle aged Pennsylvania utilization very elderly LA - English M3 - Article N1 - L616370240 2017-05-29 PY - 2016 SN - 1573-3610 SP - 359-367 ST - Barriers to Receiving Follow-Up Eye Care and Detection of Non-Glaucomatous Ocular Pathology in the Philadelphia Glaucoma Detection and Treatment Project T2 - Journal of community health TI - Barriers to Receiving Follow-Up Eye Care and Detection of Non-Glaucomatous Ocular Pathology in the Philadelphia Glaucoma Detection and Treatment Project UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616370240&from=export http://dx.doi.org/10.1007/s10900-015-0104-3 VL - 41 ID - 2750 ER - TY - JOUR AB - This cross-sectional study aimed to evaluate adherence rates and identify barriers to receiving follow-up eye care in participants diagnosed with significant non-glaucomatous eye pathology in the Philadelphia Glaucoma Detection and Treatment Project. This community-based project aimed to improve detection, management, treatment, and follow-up eye care of individuals at high risk for glaucoma in community-based settings. Participants throughout Philadelphia, Pennsylvania, USA were enrolled. After a comprehensive eye examination, follow-up recommendations were given to each participant. A telephone survey was administered to individuals diagnosed with non-glaucomatous ocular pathology 3 months after initial eye examination to assess rates of follow-up and to evaluate potential barriers to follow-up. Of the 1649 participants enrolled in this project, 249 (15 %) were diagnosed with significant non-glaucomatous ocular pathology requiring follow-up care. There were 143 (57 %) who responded to the telephone survey. Respondents had a median age of 72 years, and were predominately female (69 %) and African-American (64 %). Of the respondents, 36 (25 %) attended a follow-up appointment. Participants who did not remember the results of their examinations, did not remember their recommendations, and had not seen an eye doctor within the past year were less likely to make a follow-up appointment (P = 0.04, 0.001 and 0.005, respectively). The Philadelphia Glaucoma Detection and Treatment Program was able to detect a significant amount of non-glaucomatous ocular pathology requiring follow-up care. Actual follow-up rates were sub-optimal. Further research is needed to determine interventions to overcome barriers and increase adherence with follow-up recommendations. © 2015, Springer Science+Business Media New York. AD - Wills Eye Hospital Glaucoma Research Center, 840 Walnut Street, Suite 1110, Philadelphia, PA 19107, United States AU - Zheng, C. X. AU - Hu, W. D. AU - Tran, J. AU - Siam, L. AU - Berardi, G. G. AU - Sembhi, H. AU - Hark, L. A. AU - Katz, L. J. AU - Waisbourd, M. DB - Scopus DO - 10.1007/s10900-015-0104-3 IS - 2 KW - Access to eye care Barriers Community eye screening Detection of eye disease Underserved population M3 - Article N1 - Cited By :7 Export Date: 19 July 2021 PY - 2016 SP - 359-367 ST - Barriers to Receiving Follow-Up Eye Care and Detection of Non-Glaucomatous Ocular Pathology in the Philadelphia Glaucoma Detection and Treatment Project T2 - Journal of Community Health TI - Barriers to Receiving Follow-Up Eye Care and Detection of Non-Glaucomatous Ocular Pathology in the Philadelphia Glaucoma Detection and Treatment Project UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959555131&doi=10.1007%2fs10900-015-0104-3&partnerID=40&md5=d3fb075a76eb0d2f2399e9cd65c63818 VL - 41 ID - 5353 ER - TY - JOUR AB - This cross-sectional study aimed to evaluate adherence rates and identify barriers to receiving follow-up eye care in participants diagnosed with significant non-glaucomatous eye pathology in the Philadelphia Glaucoma Detection and Treatment Project. This community-based project aimed to improve detection, management, treatment, and follow-up eye care of individuals at high risk for glaucoma in community-based settings. Participants throughout Philadelphia, Pennsylvania, USA were enrolled. After a comprehensive eye examination, follow-up recommendations were given to each participant. A telephone survey was administered to individuals diagnosed with non-glaucomatous ocular pathology 3 months after initial eye examination to assess rates of follow-up and to evaluate potential barriers to follow-up. Of the 1649 participants enrolled in this project, 249 (15 %) were diagnosed with significant non-glaucomatous ocular pathology requiring follow-up care. There were 143 (57 %) who responded to the telephone survey. Respondents had a median age of 72 years, and were predominately female (69 %) and African-American (64 %). Of the respondents, 36 (25 %) attended a follow-up appointment. Participants who did not remember the results of their examinations, did not remember their recommendations, and had not seen an eye doctor within the past year were less likely to make a follow-up appointment (P = 0.04, 0.001 and 0.005, respectively). The Philadelphia Glaucoma Detection and Treatment Program was able to detect a significant amount of non-glaucomatous ocular pathology requiring follow-up care. Actual follow-up rates were sub-optimal. Further research is needed to determine interventions to overcome barriers and increase adherence with follow-up recommendations. AN - WOS:000371793700020 AU - Zheng, C. X. AU - Hu, W. D. AU - Tran, J. AU - Siam, L. AU - Berardi, G. G. AU - Sembhi, H. AU - Hark, L. A. AU - Katz, L. J. AU - Waisbourd, M. DA - APR DO - 10.1007/s10900-015-0104-3 IS - 2 PY - 2016 SN - 0094-5145 1573-3610 SP - 359-367 ST - Barriers to Receiving Follow-Up Eye Care and Detection of Non-Glaucomatous Ocular Pathology in the Philadelphia Glaucoma Detection and Treatment Project T2 - JOURNAL OF COMMUNITY HEALTH TI - Barriers to Receiving Follow-Up Eye Care and Detection of Non-Glaucomatous Ocular Pathology in the Philadelphia Glaucoma Detection and Treatment Project VL - 41 ID - 5856 ER - TY - JOUR AB - Background Ahmed Glaucoma Valve implantation (AGVI) is used to treat refractory glaucoma. Breakdown of the blood-aqueous barrier (BAB) has been noted after some surgical techniques. The current study was designed to assess BAB disruption after AGVI. Methods Anterior chamber protein content was measured by the laser flare cell photometry in 22 eyes of 22 patients with refractory glaucoma before AGVI and at each postoperative visit up to 1 month. Results Before AGVI the mean aqueous flare values in all eyes were (15.17 +/- 9.84) photon counts/ms. After AGVI, the values significantly increased at day 1, day 3, and week 1 compared to those before AGVI (all P <0.05) with a peak at day 3. They returned to pre-operative levels at week 2, and were lower than preoperative level at month 1. Eyes with previous intraocular surgery history had greater aqueous flare values than those without previous intraocular surgery history, but there were no significant differences at all time points postoperatively (all P >0.05). Furthermore, eyes with shallow anterior chambers had greater aqueous flare values at day 3 and week 1 (all P <0.05). When comparing eyes with other refractory glaucoma conditions, neovascular glaucoma combined with intravitreal bevacizumab injection resulted in lower aqueous flare values after AGVI, but no significant differences were observed at all time points, postoperatively (all P >0.05). Conclusions The BAB was impaired and inflammation was present in the anterior chamber in refractory glaucomatous eyes following AGVI. However, such conditions were resolved within 1 month postoperatively. Intravitreal bevacizunnab treatment in neovascular glaucoma eyes before AGVI may prevent BAB breakdown. AN - WOS:000319783700023 AU - Zhou, M. W. AU - Wang, W. AU - Chen, S. D. AU - Huang, W. B. AU - Zhang, X. L. DA - MAR 20 DO - 10.3760/cma.j.issn.0366-6999.20123158 IS - 6 PY - 2013 SN - 0366-6999 SP - 1119-1124 ST - Disorder of blood-aqueous barrier following Ahmed Glaucoma Valve implantation T2 - CHINESE MEDICAL JOURNAL TI - Disorder of blood-aqueous barrier following Ahmed Glaucoma Valve implantation VL - 126 ID - 6201 ER - TY - JOUR AB - Objective:The aim of this study was to determine the characteristics of infectious keratitis in patients wearing bandage contact lenses (BCLs).Methods:The BCL-related infectious keratitis cases were reviewed at the eye center of the Second Affiliated Hospital at the Zhejiang University School of Medicine from January 2015 to August 2018. Detailed information about the patients with infectious keratitis was collected, including the age, gender, clinical characteristics, culture results, and other measures. All the data analyses were performed using IBM SPSS Statistics for Windows version 24.0.Results:From January 2015 until August 2018, 6,385 eyes of 6,188 patients, including 3,410 males and 2,778 females, received BCLs at our hospital. The mean age of these patients was 48.10±20.81 years (range=15-78 years). The mean BCL wearing time was 18.98±23.72 days (range=1-58 days). Eight patients (0.13%) with infectious keratitis were identified, and the mean age of these patients was 54.33±28.14 years (range=16-75 years). Seven of the infectious keratitis patients were older than 50 years, and one patient was 16 years old. The infectious keratitis incidence rate of the older patients (≥50 years) was significantly higher than that of the young patients (<50 years) (χ2=9.647, P=0.002). There was a higher postkeratoplasty risk of BCL-related infectious keratitis than that in the corneal epithelial defect (χ2=21.371, P=0.000) and pterygium surgery (χ2=16.037, P=0.000) cases, but not in the corneal collagen cross-linking cases (χ2=1.792, P=0.181). The mean onset time of BCL-related infectious keratitis was 22.63±18.72 days (range=3-58 days) after wearing the BCLs. Among these 8 infected patients, 3 were noncompliant with their eye drop use and 2 extended their BCL wearing time past 30 days.Conclusion:Bandage CL-related infectious keratitis is more likely to occur in older patients. The most common risk factor for BCL-related infectious keratitis was postkeratoplasty use. Overall, appropriate indications, good compliance, and close follow-up attention are required for BCL wearers. AD - X. Jin, Eye Center, Affiliated Second Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, China AU - Zhu, B. AU - Liu, Y. AU - Lin, L. AU - Huang, X. AU - Zhang, Y. AU - Zheng, J. AU - Jin, X. DB - Embase Medline DO - 10.1097/ICL.0000000000000593 IS - 6 KW - autorefractor bandage contact lens corneal collagen cross-linking device soft contact lens eye drops levofloxacin adolescent adult age aged article clinical feature controlled study cornea disease corneal epithelial defect female gender human infection risk keratoplasty major clinical study male medical device complication microbial keratitis patient compliance patient identification postoperative complication postoperative infection priority journal pterygium retrospective study PureVision SureSight LA - English M3 - Article N1 - L630951200 2020-02-20 2020-02-27 PY - 2019 SN - 1542-233X 1542-2321 SP - 356-359 ST - Characteristics of Infectious Keratitis in Bandage Contact Lens Wear Patients T2 - Eye and Contact Lens TI - Characteristics of Infectious Keratitis in Bandage Contact Lens Wear Patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630951200&from=export http://dx.doi.org/10.1097/ICL.0000000000000593 VL - 45 ID - 2475 ER - TY - JOUR AB - Objective:The aim of this study was to determine the characteristics of infectious keratitis in patients wearing bandage contact lenses (BCLs).Methods:The BCL-related infectious keratitis cases were reviewed at the eye center of the Second Affiliated Hospital at the Zhejiang University School of Medicine from January 2015 to August 2018. Detailed information about the patients with infectious keratitis was collected, including the age, gender, clinical characteristics, culture results, and other measures. All the data analyses were performed using IBM SPSS Statistics for Windows version 24.0.Results:From January 2015 until August 2018, 6,385 eyes of 6,188 patients, including 3,410 males and 2,778 females, received BCLs at our hospital. The mean age of these patients was 48.10±20.81 years (range=15-78 years). The mean BCL wearing time was 18.98±23.72 days (range=1-58 days). Eight patients (0.13%) with infectious keratitis were identified, and the mean age of these patients was 54.33±28.14 years (range=16-75 years). Seven of the infectious keratitis patients were older than 50 years, and one patient was 16 years old. The infectious keratitis incidence rate of the older patients (≥50 years) was significantly higher than that of the young patients (<50 years) (χ2=9.647, P=0.002). There was a higher postkeratoplasty risk of BCL-related infectious keratitis than that in the corneal epithelial defect (χ2=21.371, P=0.000) and pterygium surgery (χ2=16.037, P=0.000) cases, but not in the corneal collagen cross-linking cases (χ2=1.792, P=0.181). The mean onset time of BCL-related infectious keratitis was 22.63±18.72 days (range=3-58 days) after wearing the BCLs. Among these 8 infected patients, 3 were noncompliant with their eye drop use and 2 extended their BCL wearing time past 30 days.Conclusion:Bandage CL-related infectious keratitis is more likely to occur in older patients. The most common risk factor for BCL-related infectious keratitis was postkeratoplasty use. Overall, appropriate indications, good compliance, and close follow-up attention are required for BCL wearers. © 2019 Contact Lens Association of Ophthalmologists, Inc. AD - Eye Center, Affiliated Second Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, China AU - Zhu, B. AU - Liu, Y. AU - Lin, L. AU - Huang, X. AU - Zhang, Y. AU - Zheng, J. AU - Jin, X. DB - Scopus DO - 10.1097/ICL.0000000000000593 IS - 6 KW - Bandage contact lens Corneal cross-linking Incidence Infectious keratitis Keratoplasty M3 - Article N1 - Cited By :4 Export Date: 19 July 2021 PY - 2019 SP - 356-359 ST - Characteristics of Infectious Keratitis in Bandage Contact Lens Wear Patients T2 - Eye and Contact Lens TI - Characteristics of Infectious Keratitis in Bandage Contact Lens Wear Patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074308238&doi=10.1097%2fICL.0000000000000593&partnerID=40&md5=1c2da5c28a6601101dd8f04bf8af7bd0 VL - 45 ID - 5444 ER - TY - JOUR AB - Objective: The aim of this study was to determine the characteristics of infectious keratitis in patients wearing bandage contact lenses (BCLs). Methods: The BCL-related infectious keratitis cases were reviewed at the eye center of the Second Affiliated Hospital at the Zhejiang University School of Medicine from January 2015 to August 2018. Detailed information about the patients with infectious keratitis was collected, including the age, gender, clinical characteristics, culture results, and other measures. All the data analyses were performed using IBM SPSS Statistics for Windows version 24.0. Results: From January 2015 until August 2018, 6,385 eyes of 6,188 patients, including 3,410 males and 2,778 females, received BCLs at our hospital. The mean age of these patients was 48.10 +/- 20.81 years (range=15-78 years). The mean BCL wearing time was 18.98 +/- 23.72 days (range=1-58 days). Eight patients (0.13%) with infectious keratitis were identified, and the mean age of these patients was 54.33 +/- 28.14 years (range=16-75 years). Seven of the infectious keratitis patients were older than 50 years, and one patient was 16 years old. The infectious keratitis incidence rate of the older patients (>= 50 years) was significantly higher than that of the young patients (<50 years) (chi(2)=9.647, P=0.002). There was a higher postkeratoplasty risk of BCL-related infectious keratitis than that in the corneal epithelial defect (chi(2)=21.371, P=0.000) and pterygium surgery (chi(2)=16.037, P=0.000) cases, but not in the corneal collagen cross-linking cases (chi(2)=1.792, P=0.181). The mean onset time of BCL-related infectious keratitis was 22.63 +/- 18.72 days (range=3-58 days) after wearing the BCLs. Among these 8 infected patients, 3 were noncompliant with their eye drop use and 2 extended their BCL wearing time past 30 days. Conclusion: Bandage CL-related infectious keratitis is more likely to occur in older patients. The most common risk factor for BCL-related infectious keratitis was postkeratoplasty use. Overall, appropriate indications, good compliance, and close follow-up attention are required for BCL wearers. AN - WOS:000511858800002 AU - Zhu, B. B. AU - Fliu, Y. F. AU - Lin, L. AU - Huang, X. D. AU - Zhang, Y. AU - Zheng, J. AU - Jin, X. M. DA - NOV DO - 10.1097/ICL.0000000000000593 IS - 6 PY - 2019 SN - 1542-2321 1542-233X SP - 356-359 ST - Characteristics of Infectious Keratitis in Bandage Contact Lens Wear Patients T2 - EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE TI - Characteristics of Infectious Keratitis in Bandage Contact Lens Wear Patients VL - 45 ID - 6302 ER - TY - JOUR AB - Importance: The rate and determinants of persistence to topical glaucoma medications are important for identifying patients at high risk of discontinuing medications and designing targeted approaches to improve persistence. Background: To evaluate the rate and determinants of persistence to topical glaucoma medications among middle-aged and older Australian adults. Design: Population-based cohort study. Participants: Participants in need of persistent topical glaucoma medications in the 45 and Up Study. Methods: The 45 and Up Study is a large-scale population-based cohort study. Participants were classified as needing persistent topical glaucoma medications if at least three claims with related prescriptions were recorded. Persistence was defined as topical glaucoma medications were filled within 90 days. Main Outcome Measures: The rates and determinants of medication persistence at 2-year follow-up. Results: A total of 12 899 patients requiring persistent topical glaucoma medications were identified. Among them, 9019 (69.9%) had persisted with their glaucoma medications for at least 2 years. Multiple logistic regression analysis documented significant effects of patient-related factors (gender, socioeconomic status, language spoken at home, lifestyle and comorbidities) and drug-related factors (total number and drug class) on the persistence rate. Those most at risk groups of non-persistence were those patients living in remote areas (odds ratio, OR: 0.59, 95% confidence interval, CI: 0.37-0.92), having family income over 70 000 AUD/year (OR: 0.53, 95% CI: 0.45-0.62), speaking other languages at home (OR: 0.61, 95% CI: 0.53-0.68), and using cholinergic classes of medications (OR: 0.55, 95% CI: 0.38-0.79). Conclusions and Relevance: Our data has shown a medium level of persistence to topical glaucoma medication among middle-aged and older Australian adults. However, efforts are still needed to improve the rate of persistence. AD - L. Zhang, Department of Ophthalmology and Surgery, Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia AU - Zhu, Z. AU - Jiang, Y. AU - Wang, W. AU - Scheetz, J. AU - Shang, X. AU - Zhang, L. AU - He, M. DB - Embase Medline DO - 10.1111/ceo.13524 IS - 7 KW - antiglaucoma agent cholinergic receptor stimulating agent adult aged article Australia Australian clinical assessment cohort analysis comorbidity controlled study drug industry family income female follow up gender glaucoma health insurance human lifestyle linguistics major clinical study male medication compliance middle aged patient compliance population research prescription prospective study questionnaire randomized controlled trial residential area risk assessment social status LA - English M3 - Article N1 - L627810778 2019-05-29 2019-11-01 PY - 2019 SN - 1442-9071 1442-6404 SP - 881-891 ST - Real-world assessment of topical glaucoma medication persistence rates based on national pharmaceutical claim data in a defined population T2 - Clinical and Experimental Ophthalmology TI - Real-world assessment of topical glaucoma medication persistence rates based on national pharmaceutical claim data in a defined population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627810778&from=export http://dx.doi.org/10.1111/ceo.13524 VL - 47 ID - 2484 ER - TY - JOUR AB - Importance: The rate and determinants of persistence to topical glaucoma medications are important for identifying patients at high risk of discontinuing medications and designing targeted approaches to improve persistence. Background: To evaluate the rate and determinants of persistence to topical glaucoma medications among middle-aged and older Australian adults. Design: Population-based cohort study. Participants: Participants in need of persistent topical glaucoma medications in the 45 and Up Study. Methods: The 45 and Up Study is a large-scale population-based cohort study. Participants were classified as needing persistent topical glaucoma medications if at least three claims with related prescriptions were recorded. Persistence was defined as topical glaucoma medications were filled within 90 days. Main Outcome Measures: The rates and determinants of medication persistence at 2-year follow-up. Results: A total of 12 899 patients requiring persistent topical glaucoma medications were identified. Among them, 9019 (69.9%) had persisted with their glaucoma medications for at least 2 years. Multiple logistic regression analysis documented significant effects of patient-related factors (gender, socioeconomic status, language spoken at home, lifestyle and comorbidities) and drug-related factors (total number and drug class) on the persistence rate. Those most at risk groups of non-persistence were those patients living in remote areas (odds ratio, OR: 0.59, 95% confidence interval, CI: 0.37-0.92), having family income over 70 000 AUD/year (OR: 0.53, 95% CI: 0.45-0.62), speaking other languages at home (OR: 0.61, 95% CI: 0.53-0.68), and using cholinergic classes of medications (OR: 0.55, 95% CI: 0.38-0.79). Conclusions and Relevance: Our data has shown a medium level of persistence to topical glaucoma medication among middle-aged and older Australian adults. However, efforts are still needed to improve the rate of persistence. © 2019 Royal Australian and New Zealand College of Ophthalmologists AD - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China Department of Ophthalmology and Surgery, Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia Ophthalmology, Department of Surgery, Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia Melbourne Sexual Health Centre, Alfred Health, Melbourne, VIC, Australia Central Clinical School, Faculty of Medicine, Monash University, Melbourne, VIC, Australia Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China AU - Zhu, Z. AU - Jiang, Y. AU - Wang, W. AU - Scheetz, J. AU - Shang, X. AU - Zhang, L. AU - He, M. DB - Scopus DO - 10.1111/ceo.13524 IS - 7 KW - glaucoma topical medication persistence rate M3 - Article N1 - Cited By :2 Export Date: 19 July 2021 PY - 2019 SP - 881-891 ST - Real-world assessment of topical glaucoma medication persistence rates based on national pharmaceutical claim data in a defined population T2 - Clinical and Experimental Ophthalmology TI - Real-world assessment of topical glaucoma medication persistence rates based on national pharmaceutical claim data in a defined population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066025577&doi=10.1111%2fceo.13524&partnerID=40&md5=f5a57a348aa57c73faf6972958c8b9d7 VL - 47 ID - 5551 ER - TY - JOUR AB - Importance The rate and determinants of persistence to topical glaucoma medications are important for identifying patients at high risk of discontinuing medications and designing targeted approaches to improve persistence. Background To evaluate the rate and determinants of persistence to topical glaucoma medications among middle-aged and older Australian adults. Design Population-based cohort study. Participants Participants in need of persistent topical glaucoma medications in the 45 and Up Study. Methods The 45 and Up Study is a large-scale population-based cohort study. Participants were classified as needing persistent topical glaucoma medications if at least three claims with related prescriptions were recorded. Persistence was defined as topical glaucoma medications were filled within 90 days. Main Outcome Measures The rates and determinants of medication persistence at 2-year follow-up. Results A total of 12 899 patients requiring persistent topical glaucoma medications were identified. Among them, 9019 (69.9%) had persisted with their glaucoma medications for at least 2 years. Multiple logistic regression analysis documented significant effects of patient-related factors (gender, socioeconomic status, language spoken at home, lifestyle and comorbidities) and drug-related factors (total number and drug class) on the persistence rate. Those most at risk groups of non-persistence were those patients living in remote areas (odds ratio, OR: 0.59, 95% confidence interval, CI: 0.37-0.92), having family income over 70 000 AUD/year (OR: 0.53, 95% CI: 0.45-0.62), speaking other languages at home (OR: 0.61, 95% CI: 0.53-0.68), and using cholinergic classes of medications (OR: 0.55, 95% CI: 0.38-0.79). Conclusions and Relevance Our data has shown a medium level of persistence to topical glaucoma medication among middle-aged and older Australian adults. However, efforts are still needed to improve the rate of persistence. AN - WOS:000491479000007 AU - Zhu, Z. T. AU - Jiang, Y. AU - Wang, W. AU - Scheetz, J. AU - Shang, X. W. AU - Zhang, L. AU - He, M. G. DA - SEP DO - 10.1111/ceo.13524 IS - 7 PY - 2019 SN - 1442-6404 1442-9071 SP - 881-891 ST - Real-world assessment of topical glaucoma medication persistence rates based on national pharmaceutical claim data in a defined population T2 - CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY TI - Real-world assessment of topical glaucoma medication persistence rates based on national pharmaceutical claim data in a defined population VL - 47 ID - 6085 ER - TY - JOUR AB - PURPOSE: To report a case of neurotrophic keratitis in which scleral contact lenses improved vision from 20/100 to 20/20, however, due to poor lens care, an incident of microbial keratitis developed. METHODS: A 64-year-old man with an ocular history of neurotrophic keratitis secondary to herpes simplex in each eye was successfully fit with scleral lenses. He subsequently developed microbial keratitis due to a number of risk factors. RESULTS: The lesion was culture negative, yet was very responsive to treatment with moxifloxacin. The lesion fully healed, and the patient did not suffer additional vision loss. CONCLUSIONS: This case demonstrates the ability of scleral lenses to correct visual impairments secondary to poor epithelial integrity and illustrates the importance of the practitioner providing detailed lens care instruction. © 2013 Contact Lens Association of Ophthalmologists. AD - A.B. Zimmerman, Ohio State University, College of Optometry, Columbus, OH, United States AU - Zimmerman, A. B. AU - Marks, A. DB - Embase Medline DO - 10.1097/ICL.0b013e318273420f IS - 1 KW - aciclovir artificial tear moxifloxacin adult article case report contact lens cornea endothelium eye pain Fusarium gas permeable contact lens herpes simplex keratitis Herpes simplex virus human infection risk keratomycosis male middle aged patient compliance priority journal risk factor scleral contact lens slit lamp telephone interview visual acuity visual impairment LA - English M3 - Article N1 - L52443694 2013-02-20 2014-01-24 PY - 2014 SN - 1542-2321 1542-233X SP - e1-e4 ST - Microbial keratitis secondary to unintended poor compliance with scleral gas-permeable contact lenses T2 - Eye and Contact Lens TI - Microbial keratitis secondary to unintended poor compliance with scleral gas-permeable contact lenses UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52443694&from=export http://dx.doi.org/10.1097/ICL.0b013e318273420f VL - 40 ID - 2921 ER - TY - JOUR AD - Dept. of Ophthalmology/Visual Sci., University of Louisville, Louisville, KY, United States AU - Zimmerman, T. DB - Scopus IS - 2 M3 - Conference Paper N1 - Export Date: 19 July 2021 PY - 2003 SP - 15-16 ST - Switching to latanoprost from other monotherapy T2 - Asian Journal of Ophthalmology TI - Switching to latanoprost from other monotherapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0347599251&partnerID=40&md5=d6b5a31c7620caacfc064cdd45ff440b VL - 5 ID - 5781 ER - TY - JOUR AB - Purpose: To document patient/physician perceptions of adverse effects and their relationship to medication changes among patients prescribed prostaglandin analogs. Methods: Medical/pharmacy claims (private U.S. health network) identified patients filling initial topical ocular hypotensive prescriptions from 2001 to 2004; 300 open-angle glaucoma patients prescribed a prostaglandin analog and 103 ophthalmologists were selected by algorithm for telephone interviews. Medical charts for 225/300 interviewed and 75 non-interviewed patients were abstracted. Medication patterns were assessed in pharmacy claims data. Frequency of adverse effects noted by physicians and associations with medication change decisions were examined in charted data. Patients' experiences with adverse effects were compiled from surveys. Results: In patients treated with latanoprost (N = 4,071), bimatoprost (N = 1,199), or travoprost (N = 1,001), continuous refill of medication through 1 year was seen in 11%, 9%, and 5% of patients, respectively (P = 0.0001; retrospective pharmacy claims). Adverse effects were the second most common reasons noted by physicians for switching medications after lack of efficacy (19% vs. 43%, respectively). Adverse effects were noted in 65% of patient charts. Hyperemia was the most common adverse effect occurring with at least one other adverse effect in 48% of patients with the condition. Conclusions: Ocular adverse effects, particularly hyperemia, negatively affect patient continuation with therapy and switching. © Mary Ann Liebert, Inc. 2009. AD - T. J. Zimmerman, Department of Ophthalmology and Visual Sciences, University of Louisville, 389 Mockingbird Valley Road, Louisville, KY 40207, United States AU - Zimmerman, T. J. AU - Hahn, S. R. AU - Gelb, L. AU - Tan, H. AU - Kim, E. E. DB - Embase Medline DO - 10.1089/jop.2008.0072 IS - 2 KW - bimatoprost latanoprost travoprost adult article billing and claims controlled study drug efficacy drug substitution drug utilization drug withdrawal eye burning eye color eye discomfort eye disease eye pain eyelid disease frequency analysis health survey human hyperemia interview major clinical study medical decision making medical record review monotherapy ocular pruritus open angle glaucoma patient compliance personal experience pharmacy (shop) prescription side effect telephone topical treatment utilization review LA - English M3 - Article N1 - L355148450 2009-10-08 PY - 2009 SN - 1080-7683 SP - 145-152 ST - The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: Changes in prescription patterns and patient persistence T2 - Journal of Ocular Pharmacology and Therapeutics TI - The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: Changes in prescription patterns and patient persistence UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355148450&from=export http://dx.doi.org/10.1089/jop.2008.0072 VL - 25 ID - 3366 ER - TY - JOUR AD - Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, Kentucky 40207, USA. tjzimm01@louisville.edu AN - 105499225. Language: English. Entry Date: 20090821. Revision Date: 20200708. Publication Type: Journal Article AU - Zimmerman, T. J. AU - Hahn, S. R. AU - Gelb, L. AU - Tan, H. AU - Kim, E. E. DB - ccm DO - 10.1089/jop.2008.0072 DP - EBSCOhost IS - 2 KW - Antihypertensive Agents -- Adverse Effects Patient Compliance Practice Patterns -- Statistics and Numerical Data Prostaglandins, Synthetic -- Adverse Effects Administration, Topical Adult Amides -- Adverse Effects Amides -- Therapeutic Use Antihypertensive Agents -- Therapeutic Use Drugs, Prescription Glaucoma -- Drug Therapy Hyperemia -- Chemically Induced Ophthalmic Solutions Pharmacy Service Prostaglandins, Synthetic -- Analogs and Derivatives Prostaglandins, Synthetic -- Therapeutic Use Resource Databases Retrospective Design Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 9511091. PMID: NLM19284321. PY - 2009 SN - 1080-7683 SP - 145-152 ST - The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence T2 - Journal of Ocular Pharmacology & Therapeutics TI - The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105499225&site=ehost-live&scope=site VL - 25 ID - 4650 ER - TY - JOUR AB - Purpose: To evaluate the efficacy, safety and quality of life in ocular hypertensive or open-angle glaucoma patients who required alteration in previous therapy and were changed to latanoprost. Methods: A prospective, multicenter, active, historical controlled trial in which qualified patients had previous therapy substituted with latanoprost 0.005% and were followed for up to 6 months. Results: 3179 patients were included in the intent-to-treat analysis. In all patients latanoprost reduced the intraocular pressure (IOP) from 20.1 ± 3.9 to 17.1 ± 3.5 mm Hg (p < 0.0001) and when compared to previous monotherapies: beta-blockers (-3.0 ± 3.5, n = 1976), alpha-agonists (-3.6 ± 3.7, n = 581), miotics (-2.8 ± 3.0, n = 21), carbonic anhydrase inhibitors (-3.2 ± 3.5, n = 198), and other prostaglandin analogs (-1.6 ± 3.7, n = 402). The most common ocular adverse event with latanoprost was conjunctival hyperemia (n = 66, 2.0% incidence) and the most common systemic adverse event was headache (n = 9, 0.2%). Over the 6-month treatment interval 89.8% of patients were maintained on latanoprost. On the solicited symptom survey patients showed a preference for latanoprost compared to previous therapy for several reasons: (depending on the product) dryness, blurred vision, tearing, stinging on instillation, crusting, itching, fatigue, dizziness, despondency and dry mouth (p < 0.005). Conclusion: Latanoprost generally provides reduced IOP, limited side-effects, improvement in many quality of life measures and is maintained in patients who required a substitution from previous monotherapy. AD - W.C. Stewart, Pharmaceutical Research Network, L.L.C., 1639 Tatum Street, Charleston, SC 29412-2464, United States AU - Zimmerman, T. J. AU - Stewart, W. C. DB - Embase Medline DO - 10.1089/108076803322472971 IS - 5 KW - alpha adrenergic receptor stimulating agent apraclonidine beta adrenergic receptor blocking agent betaxolol bimatoprost brimonidine carbonate dehydratase inhibitor carteolol dipivefrine dorzolamide latanoprost levobunolol metipranolol pilocarpine prostaglandin derivative timolol travoprost unoprostone isopropyl ester adult allergic conjunctivitis allergic reaction article backache clinical trial conjunctival hyperemia drug efficacy drug safety dry eye eye burn eye irritation eye pain fatigue female headache human hyperemia hyperpigmentation intraocular foreign body intraocular pressure iritis keratitis major clinical study male monotherapy multicenter study open angle glaucoma patient compliance prospective study pruritus quality of life retina macula cystoid edema side effect vertigo visual impairment xerostomia LA - English M3 - Article N1 - L37321343 2003-11-07 PY - 2003 SN - 1080-7683 SP - 405-415 ST - Intraocular Pressure, Safety, and Quality of Life in Glaucoma Patients Switching to Latanoprost from Monotherapy Treatments T2 - Journal of Ocular Pharmacology and Therapeutics TI - Intraocular Pressure, Safety, and Quality of Life in Glaucoma Patients Switching to Latanoprost from Monotherapy Treatments UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37321343&from=export http://dx.doi.org/10.1089/108076803322472971 VL - 19 ID - 3795 ER - TY - JOUR AB - Purpose: Neovascular glaucoma (NVG) is a severe secondary glaucoma with uncontrolled intraocular pressure that leads to serious eye pain and vision loss. Presently, the therapeutic strategies for NVG are diverse, but the therapeutic effects are still not ideal. We performed a network analysis to assess the effect of multiple therapeutic strategies on the treatment of NVG patients.Methods: We searched public electronic databases through April 2017 using the following keywords "neovascular glaucoma," "iris neovascularization," "hemorrhagic glaucoma," and "random" without language restrictions. The outcome considered in the present analysis was treatment success rate. A network meta-analysis and multilevel mixed-effects logistic regression were used to compare regimens.Results: We included 27 articles assessing a total of 1884 NVG patients in our analysis. According to the network analysis, interferon and mitomycin plus trabeculectomy (94.9%), glaucoma valve implantation (86.9%), and iris photocoagulation plus trabeculectomy (81.9%) were the most likely to improve treatment success rate in NVG patients. The multilevel logistic regression analysis showed that glaucoma valve, bevacizumab, interferon, cyclophotocoagulation, trabeculectomy, iris photocoagulation, ranibizumab, and mitomycin had advantages in terms of improving treatment success rate in NVG patients. However, the application of retinal photocoagulation and vitrectomy reduced patient treatment success rate.Conclusion: The regimen including mitomycin, interferon, and trabeculectomy was the most likely to improve the treatment success rate in NVG patients. The application of glaucoma valve and bevacizumab were more beneficial for improving patient treatment success rate as a surgery and as an agent, respectively. AD - Department of Ophthalmology, the First Affiliated Hospital of Anhui Medical University, Hefei, China. School of Public Health, Anhui Medical University, Hefei, China. Department of Ophthalmology, the First Affiliated Hospital of Anhui Medical University School of Public Health, Anhui Medical University, Hefei, China AN - 128953312. Language: English. Entry Date: 20180420. Revision Date: 20210111. Publication Type: journal article AU - Zixian, Dong AU - Jianyang, Gong AU - Rongfeng, Liao AU - Shaojun, Xu AU - Dong, Zixian AU - Gong, Jianyang AU - Liao, Rongfeng AU - Xu, Shaojun DB - ccm DO - 10.1097/MD.0000000000009897 DP - EBSCOhost IS - 14 KW - Glaucoma -- Therapy Angiogenesis Inhibitors -- Therapeutic Use Trabeculectomy -- Methods Antiinfective Agents -- Therapeutic Use Eye Surgery -- Methods Human Combined Modality Therapy -- Methods Iris -- Surgery Retina -- Surgery Mitomycins -- Therapeutic Use Treatment Outcomes Interferons -- Therapeutic Use Meta Analysis Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - meta analysis; research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. NLM UID: 2985248R. PMID: NLM29620670. PY - 2018 SN - 0025-7974 SP - 1-8 ST - Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis T2 - Medicine TI - Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128953312&site=ehost-live&scope=site VL - 97 ID - 4232 ER - TY - JOUR AB - BACKGROUND AND OBJECTIVE: To study the results of combined intraocular and strabismus surgery. PATIENTS AND METHODS: Combined surgery was done in 14 patients. In 10 of these patients, cataract and strabismus surgery were combined. One had a penetrating keratoplasty, and another required placement of a glaucoma valve implant. In one patient trabeculectomy, pupilloplasty, and lensectomy were done, and one patient needed repair of a leaking bleb. RESULTS: The strabismus of most patients was significantly improved. Eleven patients (79%) were orthophoric ± 10 prism diopters (PD). Visual outcome was good in patients with no structural abnormalities who were compliant with occlusion therapy, if applicable. CONCLUSIONS: Combined intraocular and strabismus surgery has a success rate comparable with that of standard strabismus surgery. AD - Physicians' Plaza I, Wurzbach 8038, San Antonio, TX 78229, United States AU - Zwaan, J. AU - Al-Sadhan, Y. DB - Scopus IS - 6 M3 - Article N1 - Cited By :6 Export Date: 19 July 2021 PY - 1998 SP - 456-461 ST - Combined intraocular and strabismus surgery T2 - Ophthalmic Surgery and Lasers TI - Combined intraocular and strabismus surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031776881&partnerID=40&md5=d3d628c7adfe3df3e2471c662a23de2a VL - 29 ID - 5398 ER -